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### AW-001. COG AALL0434: A Randomized Trial Testing Nelarabine in Newly Diagnosed T‐cell Malignancy {#pbc27455-sec-0030}

[K. Dunsmore]{.ul} ^1^, S. Winter^2^, M. Devidas^3^, B. Wood^4^, N. Esaishvili^5^, N. Eisenberg^6^, N. Briegel^7^, R. Hayashi^8^, J. Gastier‐Foster^9^, A. Carroll^10^, N. Heerema^11^, B. Asselin^12^, K. Rabin^13^, P. Zweidler‐Mckay^14^, E. Raetz^15^, M. Loh^16^, N. Winick^17^, W. Carroll^18^, S. Hunger^19^

*^1^Carilion Clinic, Pediatrics, Roanoke, USA; ^2^Children\'s Minnesota Research Institute, Pediatric Hematology/Oncology, Minneapolis, USA; ^3^University of Florida, Biostatistics, Gainesville, USA; ^4^University of Washington Seattle, Hematopathology, Seattle, USA; ^5^Emory University, Radiation Oncology, Atlanta, USA; ^6^University of New Mexico, Pediatric Hematology/Oncology, Albuquerque, USA; ^7^Princess Margaret Hospital for Children, Pharmacy, Subiaco, Australia; ^8^Washington University School of Medicine, Pediatric Hematology/Oncology, St. Lous, USA; ^9^Nationwide Children\'s Hospital, Pathology, Colombus, USA; ^10^University of Alabama at Birmingham, Genetics, Birmingham, USA; ^11^The Ohio State University, Pathology, Colombus, USA; ^12^University of Rochester Medical Center, Pediatric Oncology, Rochester, USA; ^13^Baylor College of Medicine, Pediatric Hematology/Oncology, Houston, USA; ^14^Immunogen‐ Inc., Hematologic Malignancies, Waltham, USA; ^15^New York University Medical Center, Pediatric Hematology/Oncology, New York, USA; ^16^University of California‐ San Franciso, Pediatric Hematology/Oncology, San Francisco, USA; ^17^University of Texas Southwestern Medical Center, Pediatric Hematology/Oncology, Dallas, USA; ^18^New York University Medical Center, Pediatrics, New York, USA; ^19^Children\'s Hospital of Pennsylvania, Pediatric Oncology, Philadelphia, USA*

**Background/Objectives**: Nelarabine (Nel) is a T‐cell specific agent, FDA approved for patients who have failed at least two regimens. COG AALL0434 evaluated the safety and efficacy of Nel when incorporated into COG augmented BFM (ABFM) chemotherapy in newly diagnosed patients with T‐ALL.

**Design/Methods**: AALL0434 enrolled 1,895 patients (2007‐2014) and included a 2 x 2 pseudo‐factorial randomization using the ABFM regimen. Patients were randomized to receive escalating dose methotrexate with pegaspargase (CMTX) or High Dose MTX (HDMTX). Intermediate and high‐risk patients with T‐ALL were randomized to +/‐ six 5‐day courses of Nel 650 mg/m^2^/day during Consolidation (2), Delayed Intensification (1) and Maintenance (3). The intermediate and high risk patients received prophylactic (1200 cGy) or therapeutic (1800 cGy, CNS3) cranial irradiation. Patients with induction failure were non‐randomly assigned to HDMTX+Nel.

**Results**: For all randomized patients, the 4‐year disease‐free survival (DFS) and overall survival (OS) rates were 84.3 +/‐ 1.1% and 90.2 +/‐ 0.9%. The 4‐year DFS rate for patients with T‐ALL randomized to Nel (N=323) vs no Nel (N=336) was 88.9 +/‐ 2.2% vs 83.3 +/‐ 2.5%, (p=0.0332). Among patients with T‐ALL randomized to CMTX the 4‐year DFS for Nel (N=147) vs no Nel (N=151) was 92.2 +/‐ 2.8% vs 89.8 +/‐ 3.0%, p=0.3825. For those randomized to HDMTX, 4‐year DFS was 86.2 +/‐ 3.2% with Nel (N=176) vs 78.0 +/‐ 3.7% without Nel (N=185), p=0.024. Differences between DFS in a 4‐arm comparison were highly significant (P = 0.002), with no significant interactions between MTX and Nel randomizations (p=0.41). Patients with induction failure (N=43) assigned to HDMTX/Nel had a 4‐year DFS of 54.8 +/‐ 8.9%. Overall toxicity and neurotoxicity were acceptable and not significantly different between all four arms.

**Conclusions**: COG AALL0434 showed outstanding overall outcomes for patients with T‐cell malignancy with Nel improving DFS for children and young adults with T‐ALL.

### AW-002. Indeterminate Pulmonary Nodules at Diagnosis in Pediatric Rhabdomyosarcoma: Are We Undertreating Patients? A Report from the European Paediatric Soft Tissue Sarcoma Study Group‐RMS‐2005 Study {#pbc27455-sec-0040}

[B. Vaarwerk]{.ul} ^1^, I. Zanetti^2^, G.L. De Salvo^3^, N. Corradini^4^, M. Jenney^5^, D. Orbach^6^, J. Chisholm^7^, A. Ferrari^8^, C. Morosi^9^, H. Brisse^10^, K. McHugh^11^, G. Bisogno^2^, R. van Rijn^12^, H. Merks^13^

*^1^Emma Children\'s Hospital/Academic Medical Centre, Department of Paediatric Oncology, Amsterdam, The Netherlands; ^2^Padova University Hospital, Pediatric Hematology and Oncology Division‐ Department of Woman and Child Health, Padova, Italy; ^3^IRCCS Istituto Oncologico Veneto, Clinical Trials and Biostatistics Unit, Padova, Italy; ^4^Centre Léon Bérard, Department of Pediatric Oncology, Lyon, France; ^5^Children\'s Hospital for Wales, Department of Pediatric Oncology, Cardiff, United Kingdom; ^6^Institut Curie, SIREDO Oncology Center‐ PSL University, Paris, France; ^7^Royal Marsden Hospital, Children and Young People\'s Department, Sutton, United Kingdom; ^8^Fondazione IRCCS Istituto Nazionale Tumori Milano, Pediatric Oncology Unit, Milano, Italy; ^9^Fondazione IRCCS Istituto Nazionale Tumori Milano, Department of Radiology, Milano, Italy; ^10^Institut Curie, Imaging Department, Paris, France; ^11^Great Ormond Street Hospital for Children, Department of Radiology, London, United Kingdom; ^12^Emma Children\'s Hospital/Academic Medical Center, Pediatric Radiology, Amsterdam, The Netherlands; ^13^Princess Máxima Center for Pediatric Oncology, Solid tumor department, Utrecht, The Netherlands*

**Background/Objectives**: Finding indeterminate pulmonary nodules in patients with newly diagnosed rhabdomyosarcoma can pose a diagnostic dilemma, since differentiation between malignant and benign nodules can be very difficult. We aimed to assess the clinical significance of these indeterminate pulmonary nodules (defined as 4 or less nodules \<5 mm or 1 nodule of 5‐10 mm) at diagnosis in patients with pediatric rhabdomyosarcoma (RMS).

**Design/Methods**: We selected patients with supposed non‐metastatic RMS treated in large oncology centers in the United Kingdom, France, Italy and the Netherlands and enrolled in the E*p*SSG‐RMS‐2005 study. Patients who were diagnosed between September 2005 and December 2013, in whom chest CT\'s at diagnosis were available for review were included. Local radiologists were asked to review chest CT\'s for the presence of pulmonary nodules, by using a standardized case report form. In the E*p*SSG‐RMS‐2005 study, patients with indeterminate pulmonary nodules were treated identically to patients without pulmonary nodules, enabling to compare event‐free survival (EFS) and overall survival (OS) by log‐rank test between both groups.

**Results**: In total, 316 patients were included; 67 patients showed indeterminate pulmonary nodules (21.2%), 249 patients showed no pulmonary nodules at diagnosis (78.8%). Median follow‐up for survivors (n=258) was 75.1 months; 5‐year EFS and OS rates \[95% CI\] were 77.0% \[64.8‐85.5%\] and 82.0% \[69.7‐89.6%\] for patients with indeterminate nodules and 73.2% \[67.1‐78.3%\] and 80.8 \[75.1‐85.3%\] for patients without nodules at diagnosis (*p*=0.68, *p*=0.76) respectively. In the group of patients with indeterminate pulmonary nodules 2/67 (3.0%) developed lung metastases, compared to 4/249 patients (1.6%) in the group without nodules (*p*=0.46).

**Conclusions**: These analyses indicate that indeterminate pulmonary nodules at diagnosis do not affect outcome in patients with localized RMS. There is no need to biopsy or upstage patients with indeterminate pulmonary nodules at diagnosis in future rhabdomyosarcoma protocols.

### AW-003. Predictors of Hospitals' Non‐Achievement of Baseline Nursing Standards for Pediatric Oncology {#pbc27455-sec-0050}

[C. Sullivan]{.ul} ^1,2,3^, L. Morissey^2,4^, S. Day^2,3,5^, W. Landier^1^

*^1^University of Alabama at Birmingham, School of Nursing, Birmingham, USA; ^2^SIOP Baseline Nursing Standards Taskforce, PODC Nursing, Geneva, Switzerland; ^3^St. Jude Children\'s Research Hospital, Dept. of Global Pediatric Medicine, Memphis, USA; ^4^Boston Children\'s Hospital, Hematology/Oncology, Boston, USA; ^5^University of Tennessee Health Science Center, College of Nursing, Memphis, USA*

**Background/Objectives**: Nurses caring for children and adolescents with cancer in limited‐resource settings face barriers to delivering quality care. To better understand barriers across resource‐settings, a web‐based survey was conducted to evaluate the ability of hospitals to meet the International Society of Pediatric Oncology (SIOP) recommended baseline nursing standards. An analysis of SIOP baseline nursing standards survey data was conducted to: 1) Determine the proportion of hospitals that met, partially met, or did not meet the baseline nursing standards; and 2) Determine predictors of non‐achievement of each baseline nursing standard.

**Design/Methods**: Between August 2016 and January 2017, nurses from 101 centers in 52 countries were surveyed via RedCAP in English, Mandarin, French or Spanish. Criteria for having met, partially met or not met the standards were determined by expert consensus. Descriptive statistics were calculated; multivariate logistic regression analyses were conducted to determine predictors of non‐achievement of the standards.

**Results**: The proportion of hospitals that met, partially met or did not meet the standards, respectively, were: Standard 1 (staffing plans): 11.9%; 43.6%; 44.6%. Standard 2 (orientation): 29.7%; 46.5%; 23.8%. Standard 3 (continuing education): 49.5%; 0.0%; 50.5%. Standard 4 (multidisciplinary teamwork): 62.4%; 32.7%; 5.0%. Standard 5 (resources for safe care): 37.6%; 45.5%;16.8%. Standard 6 (oncology nursing policies): 66.3%; 9.9%; 23.8%. In multivariable analysis, compared to hospitals with bone marrow transplant (BMT) units, hospitals without BMT units were at increased risk of not achieving Standard 2 (Odds Ratio (OR)=3.8; 95% Confidence Interval (CI), 1.4‐10.2; p=0.007), Standard 5 (OR=2.7; 95% CI, 1.1‐6.6; p=0.035) and Standard 6 (OR=4.0; 95% CI, 1.4‐11.7; p=0.011).

**Conclusions**: Hospitals without a BMT unit are at increased risk of non‐achievement of SIOP baseline nursing standards and will likely require greater capacity‐building support. Much work is needed toward raising the standard of pediatric oncology nursing practice, globally.

### AW-004. Hospital Volume Predicts the Risk of Death for Children and Adolescents with Osteosarcoma in São Paulo State, Brazil {#pbc27455-sec-0060}

[K. Ribeiro]{.ul} ^1^, D. Bivanco de Lima^1^, C. Luizaga^2^

*^1^Faculdade de Ciências Médicas da Santa Casa de São Paulo, Department of Collective Health, São Paulo, Brazil; ^2^Fundação Oncocentro de São Paulo, Department of Epidemiology, São Paulo, Brazil*

**Background/Objectives**: The treatment of osteosarcoma (OS) is complex, requiring a multidisciplinary approach for optimal results. This study analyzed the effect of hospital specialization and volume on the prognosis of patients with OS in a middle‐income country.

**Design/Methods**: We conducted a retrospective cohort study, including all patients with OS aged \<20 years diagnosed and submitted to chemotherapy during the period 2000‐2010. Cases were retrieved from the Hospital‐based Cancer Registry, state of São Paulo, Brazil. Study variables included age, gender, stage, socioeconomic status (SES), tumor site, diagnostic delay, hospital volume and specialization. Five‐year overall survival was calculated using Kaplan‐Meier method and curves were compared using log‐rank test. Cox regression model was employed to estimate adjusted hazard ratios (plus 95% confidence intervals (95% CI)).

**Results**: A total of 577 patients (56.5% males, 43.5% females) was evaluated. Median age at diagnosis was 14 years. Approximately 76% of all individuals lived in areas of high SES and 41.7% presented with metastatic disease. The vast majority (66.5%) was treated in hospitals managing \< 100 new pediatric cancer cases/year. Five‐year overall survival (5y‐OS) was 49.8% (95% CI 45.6‐53.8). In the univariate analysis, survival was affected by surgery (p\<0.001), radiation therapy (p=0.012), hospital specialization (p=0.004), staging (p\<0.001), tumor site (p\<0.001), and hospital volume (p=0.024). In the multiple analysis, after adjustment by SES and hospital specialization, tumor site (axial vs. extremities, HR=2.31, 95% CI 1.36‐3.90), staging (II, HR=1.70, 95% CI 1.09‐2.66, III, HR=1.79, 95% CI 0.81‐3.92, IV, HR=4.17, 95% CI 2.64.6.57), and hospital volume (cases/year) (51‐99, HR=0.86, 95% CI 0.57‐1.28, 100‐199, HR=0.57, 95% CI 0.33‐0.99, 200+, HR=0.43, 95% CI 0.21‐0.88) were identified as independent prognostic factors.

**Conclusions**: Our results support the effect of hospital volume on the outcomes for patients with OS in Brazil, possibly reflecting association with physicians experience, adherence to guidelines and higher enrollment in clinical trials.

### AW-005. Non‐Coding RNA ThymoD Transcription Modulates Nuclear Architecture to Orchestrate T‐Cell Fate and Block T‐Cell Malignancies {#pbc27455-sec-0070}

[T. Isoda]{.ul} ^1^, A. Nishimura^1^, S. Miyamoto^1^, T. Morio^1^, M. Takagi^1^, C. Murre^2^

*^1^Tokyo Medical and Dental University, Department of Pediatrics‐ Developmental Biology, Tokyo, Japan; ^2^UC San Diego, Division of biological sciences, La Jolla, USA*

**Background/Objectives**: It is now well established that the transcriptional regulator Bcl11b specifies T cell fate. However, it has remained an enigma as to how distally located BCL11b enhancers, while separated by vast genomic distances, selectively target their cognate promoters. To explore the mechanism that underpins this precision‐directed targeting, we have examined the nuclear architecture of a super‐enhancer that regulates the expression of Bcl11b.

**Design/Methods**: To identify the position of transcribed long non‐coding RNA before T‐cell commitment, we used that ATAC‐seq and published RNAseq data. For generating ThymoD p(A)/p(A) mouse, hGH poly‐A sequence was inserted into target region at down‐stream of a promoter located on locus control region 2. For locus repositioning, DNA‐FISH and in‐situ Hi‐C were employed for double negative 2 stage cells. GRO‐seq, ChIP‐seq, and whole genome bisulfite sequencing were used for determining enhancer activity.

**Results**: We found that during T cell commitment the super‐enhancer repositioned from the lamina to the transcriptionally permissive compartment. In the search for candidate factors that repositioned the Bcl11b control region, we identified long non‐coding RNA *ThymoD* (Thymocyte Differentiation Factor). ThymoD expression pattern in T cell progenitors immediately precedes that of Bcl11b. ThymoD‐deficient mice displayed a block in T cell development as leaky SCID phenotype and rapidly developed T‐cell malignancies. We found that ThymoD transcription acted in cis to promote demethylation at CTCF bound sites and activated cohesin‐dependent looping to reposition the Bcl11b enhancer from the lamina to the nuclear interior and to juxtapose the Bcl11b enhancer and promoter into a single‐loop domain. These large‐scale changes in nuclear architecture were associated with the deposition of activating epigenetic marks across the loop domain, plausibly facilitating phase separation.

**Conclusions**: These data indicate how, during developmental progression and tumor suppression, non‐coding transcription orchestrates chromatin folding and compartmentalization to direct with high precision enhancer‐promoter communication.

### AW-006. Detection of BRCAness in Osteosarcoma Using a DNA Methylation‐Based Classifier Coupled with Gene Expression Profiling {#pbc27455-sec-0080}

[M. Barenboim]{.ul} ^1^, M. Kovac^2^, B. Ameline^2^, D.T.W. Jones^3^, O. Witt^3,4^, S. Bielack^5^, S. Burdach^1^, D. Baumhoer^2^, M. Nathrath^1,6^

*^1^Hospital rechts der Isar of the Technical University of Munich, Pediatric Oncology Center at the Department of Pediatrics, Munich, Germany; ^2^University Hospital Basel and University of Basel, Bone Tumour Reference Centre at the Institute of Pathology, Basel, Switzerland; ^3^NCT Heidelberg KiTZ, Hopp Children\'s Cancer Center, Heidelberg, Germany; ^4^University Hospital Heidelberg, Hematology and Immunology at the Department of Pediatric Oncology, Heidelberg, Germany; ^5^Olgahospital Stuttgart, Centre for Child Youth and Women\'s Medicine at the Department of Pediatric Hematology‐Oncology, Stuttgart, Germany; ^6^Klinikum Kassel, Department of Pediatric Oncology, Kassel, Germany*

**Background/Objectives**: Osteosarcoma (OS) is the most common primary malignant bone tumour. It shows complex patterns of genomic variations, including structural and single nucleotide variations. BRCAness is a phenotypical trait resembling tumors with BRCA1 and BRCA2 mutations characterized by homologous recombination (HR) deficiency that has been shown to occur in the majority of OS and that might render these tumors susceptible to inhibitors of poly ADP ribose polymerase (PARP). We analyzed RNA‐Seq and DNA methylation data of BRCAness‐positive and ‐negative OS samples to search for patterns correlating with BRCAness.

**Design/Methods**: Methylation and RNA‐Seq data of 23 patients with relapsed OS were obtained within the scope of INFORM project. Illumina Human Methylation450k and EPIC arrays were used to determine the DNA methylation sample profiles. We selected 8 BRCAness‐positive and 7 ‐negative samples based on Myriad Genetics MyChoice scoring system to train classifier algorithm Random Forest (RF). Probes were ranked according to minimum variability within group and maximum variability between groups. The top 1,000 probes were selected for RF training. The importance of predictors was assessed as a mean decrease in accuracy (MDA). Probes with zero MDA were removed from the training set after each iteration.

**Results**: Samples were clustered unambiguously into BRCAness‐positive and ‐negative groups with unsupervised hierarchical clustering. All 7 validation samples were accurately classified. In the independent OS set 10/15 samples exhibited BRCAness. Differential expression analysis of BRCAness‐positive and ‐negative RNA‐Seq samples resulted into 1,458 differentially expressed genes. Only up‐regulated genes in the BRCAness‐positive samples showed highly significant homologous recombination, nucleotide excision and mismatch repair signatures.

**Conclusions**: We established and validated a DNA methylation‐based classifier that differentiates BRCAness‐negative from BRCAness‐positive OS samples with high accuracy. Differential expression and enrichment analyses identified genome instability signatures. Both methylation classifier and gene expression signatures could provide a useful aid in clinical decision making on administering PARP inhibitors.

FPS 01: ALL: Clinical {#pbc27455-sec-0090}
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### O-001. Persistent Disparities in Adolescent and Young Adult Lymphoblastic Leukemia Outcomes Between Pediatric and Adult Centres: A Population‐Based Impact Cohort Study {#pbc27455-sec-0100}

[S. Gupta]{.ul} ^1^, J. Pole^2^, C. Lau^3^, C. Nagamuthu^3^, S. Rinku^3^, N. Baxter^4^, P. Nathan^1^

*^1^Hospital for Sick Children, Division of Haematology/Oncology, Toronto, Canada; ^2^Pediatric Oncology Group of Ontario, Scientific Research Office, Toronto, Canada; ^3^Institute for Clinical Evaluative Sciences, Cancer Research Program, Toronto, Canada; ^4^St. Michael\'s Hospital, Department of General Surgery, Toronto, Canada*

**Background/Objectives**: Retrospective studies have shown that adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have superior survival when treated in pediatric versus adult centers (locus of care; LOC). Clinical studies showing superior survival in AYA treated with pediatric protocols have led to their adoption by some adult centers. Whether this has narrowed LOC disparities in real world settings is unknown.

**Design/Methods**: The IMPACT Cohort is an Ontario population‐based cohort that has captured demographic, disease and treatment (treatment protocol, chemotherapy doses) data for all 15‐21 year olds diagnosed with ALL between 1992‐2011. Cancer outcomes were determined by chart abstraction and linkage to provincial administrative health care databases. Treatment protocols were classified as either pediatric‐ or adult‐based. We examined predictors of outcome, including disease biology, LOC, protocol type, and time period.

**Results**: Of 271 patients, 152 (56%) received therapy at an adult center. 5‐year event‐free survival (EFS ± standard error) among AYA treated at a pediatric vs. adult center was 72%±4% vs. 56%±4% (p=0.03); 5‐year overall survival (OS) was 82%±4% vs. 64%±4% (p\<0.001). In the most recent time period (2006‐2011), 39/59 (66%) AYA treated at an adult center received a pediatric protocol. These 39 AYA had superior outcomes than the 20 AYA treated on an adult protocol, but inferior to the 44 AYA treated at a pediatric center (EFS 72%±5% vs. 60%±9% vs. 81%±6%; p=0.02; OS 77%±7% vs. 65%±11% vs. 91%±4%; p=0.004). Induction deaths, treatment‐related mortality, and dose reductions did not vary by LOC.

**Conclusions**: Survival disparities between AYA treated in pediatric vs. ALL centers have persisted over time, partially attributable to incomplete adoption of pediatric protocols by adult centers. Although use of pediatric protocols has improved survival, residual disparities remain and do not seem to be due to excessive toxicity or dose reductions.

### O-002. Poor Outcome for Children, Adolescents and Young Adults with Hypodiploid ALL is Not Improved by Stem Cell Transplant: A Report from Children\'s Oncology Group (COG) {#pbc27455-sec-0110}

[J. Mcneer]{.ul} ^1^, E. Larsen^2^, K. Maloney^3^, L. Mattano^4^, K. Schultz^5^, A. Carroll^6^, N. Heerema^7^, J. Gastier‐Foster^8^, S. Kahwash^8^, M. Borowitz^9^, B. Wood^10^, N. Winick^11^, W. Carroll^12^, Y. Dai^13^, M. Devidas^13^, S. Hunger^14^, E. Raetz^12^, M. Loh^15^

*^1^University of Chicago Comprehensive Cancer Center, Pediatric Hematology/Oncology, Chicago, USA; ^2^Maine Children\'s Cancer Program, Pediatric Hematology/Oncology, Scarborough, USA; ^3^Children\'s Hospital Colorado, Pediatric Hematology/Oncology, Aurora, USA; ^4^HARP Pharma Consulting, Hematology/Oncology, Mystic, USA; ^5^British Columbia Children\'s Hospital, Pediatric Hematology/Oncology, Vancouver, Canada; ^6^Children\'s Hospital of Alabama, Genetics, Birmingham, USA; ^7^The Ohio State University, Pathology, Columbus, USA; ^8^Nationwide Children\'s Hospital, Pathology and Laboratory Medicine, Columbus, USA; ^9^Johns Hopkins University/Sidney Kimmel Cancer Center, Pathology, Baltimore, USA; ^10^Seattle Children\'s Hospital, Laboratory Medicine, Seattle, USA; ^11^UT Southwestern/Simmons Cancer Center‐Dallas, Pediatric Hematology/Oncology, Dallas, USA; ^12^Laura and Isaac Perlmutter Cancer Center at NYU Langone, Pediatric Hematology/Oncology, New York, USA; ^13^Colleges of Medicine‐ Public Health & Health Professions‐ University of Florida., Biostatistics, Gainesville, USA; ^14^Children\'s Hospital of Philadelphia, Oncology, Philadelphia, USA; ^15^Benioff Children\'s Hospital‐ and the Helen Diller Comprehensive Cancer Center‐ University of California, Pediatrics, San Francisco, USA*

**Background/Objectives**: Due to poor outcomes, hypodiploid ALL is often considered an indication for hematopoietic stem cell transplant (HSCT) in first remission (CR1).We describe event‐free (EFS) and overall survival (OS) rates of these patients and the impact of CR1 HSCT.

**Design/Methods**: Outcomes of patients with hypodiploid ALL (\<44 chromosomes or DI \<0.81) enrolled on AALL03B1 (2003‐2011) were estimated using Kaplan‐Meier, standard errors calculated per Peto, and curves compared using the log‐rank test.

**Results**: Hypodiploid ALL was identified in 131 patients (1.6% of all patients), who were removed from study after induction. Five‐year EFS and OS were 52.1%±4.9% and 58.9%±4.8%. Transplant status was available for 113, 61 (54%) of whom underwent CR1 HSCT. EFS with HSCT was 57.4%±7.0% vs. 47.8%±7.5% without (p=0.48). OS with HSCT was 66.2%±6.6% vs. 53.8%±7.6% without (p =0.34). When corrected for the median time to HSCT (137 days) there were no significant differences in EFS or OS rates with and without HSCT: 53.1%±7.3% and 64.2%±6.9% vs. 48.8%±7.8% and 53.8%±7.8%, respectively. No NCI risk group or MRD subset benefitted significantly from CR1 HSCT. Standard‐risk patients (n=42) had EFS and OS of 68.8±10.3% and 77.3%±9.2% with HSCT (n=27) vs. 57.1%±13.2% and 64.3%±12.8% without. High‐risk patients (n=71) had EFS and OS of 48.3%±9.0% and 57.6%±8.8% with HSCT (n=34) vs. 44.4%±9.2% and 49.9%±9.4% without. For patients with end‐induction MRD \<0.01% (n=74), EFS and OS were 66.3%±7.9% and 79.5%±6.7% with HSCT (n=39) vs. 60.3%±9.2% and 66.7%±8.8% without. End‐induction MRD ≥0.01% patients (n=30) fared poorly with both EFS and OS of 29.4%±14.3% with HSCT (n=18) vs. 16.7%±10.8% and 22.2%±13.9% without. Multivariate regression analysis showed only MRD negativity was significantly associated with EFS (HR 0.256, p\<0.0001) and OS (HR 0.216, p\<0.0001).

**Conclusions**: Patients with hypodiploid ALL fare poorly, particularly with end‐induction MRD ≥0.01%; CR1 HSCT does not confer significant benefit. New strategies are urgently needed for these patients.

### O-003. Day 15 Bone Marrow Minimal Residual Disease (MRD) Predicts Response to Blinatumomab in Relapsed/Refractory Pediatric B‐Precursor Acute Lymphoblastic Leukemia (B‐ALL) {#pbc27455-sec-0120}

[P. Brown]{.ul} ^1^, G. Zugmaier^2^, L. Gore^3^, C.A. Tuglus^4^, A. von Stackelberg^5^

*^1^Johns Hopkins University, Department of Oncology, Baltimore, USA; ^2^Amgen Research Munich GmbH, Clinical Development, Munich, Germany; ^3^University of Colorado Anschutz Medical Campus, Division of Medical Oncology and Hematology, Aurora, USA; ^4^Amgen Inc., Clinical Development, Thousand Oaks, USA; ^5^Charité‐ POH, Department of Pediatric Oncology/Hematology, Berlin, Germany*

**Background/Objectives**: Blinatumomab is an established treatment for relapsed/refractory B‐ALL based on the pivotal MT103‐205 trial (EudraCT 2010‐024264‐18). Early predictive biomarkers of response would allow for more personalized and effective therapy.

**Design/Methods**: Sixty‐four patients in the single‐arm, phase 2 study MT103‐205 (von Stackelberg et al *JCO* 2016;34:4381‐89) treated at the recommended blinatumomab dose (15 μg/m²/day stepped up from 5 μg/m²/day) had a response assessment. Best responses within 2 cycles were: complete MRD response in complete remission (CR; as previously defined in von Stackelberg et al *JCO* 2016;34:4381‐89), n=14; MRD‐positive CR, n=13; blast‐free aplasia, n=2; no response/progressive disease/partial response, n=35. We defined "success" as complete MRD response in CR (n=14), and "failure" as anything other than success (n=50). Blood morphology at day 8 and bone marrow morphology and molecular MRD at day 15 and day 29 were analyzed as potential early predictive biomarkers of complete MRD response.

**Results**: A total of 59 patients had day 15 bone marrow MRD results. Categorizing the day 15 bone marrow as positive (MRD≥1e--4) or negative (MRD\<1e--4), n=46 patients were MRD positive and n=13 were MRD negative. For MRD‐positive patients, the success rate (complete MRD response in CR) was 2/46, accurately predicting failure in 96% of patients. For MRD‐negative patients, the success rate was 12/13, accurately predicting success in 92% of patients. Overall, day 15 MRD results predicted best response after 2 cycles with 95% accuracy (correctly in 56 of 59 patients). The other parameters analyzed were less accurate predictors (accuracy range: 49--90%).

**Conclusions**: Day 15 bone marrow MRD predicts best response to blinatumomab after 2 cycles. As patients with MRD≥1e--4 at day 15 could potentially pursue alternative therapies, such as dose escalation or combination therapies, day 15 MRD results may allow personalized treatment and improve outcomes in pediatric patients with relapsed/refractory B‐ALL.

### O-004. The First Nationwide Clinical Study for the First Relapsed Acute Lymphoblastic Leukemia in Japanese Children: JPLSG‐ALL‐R08 {#pbc27455-sec-0130}

[C. Ogawa]{.ul} ^1,2^, H. Ueki^2^, M. Nishi^2^, J. Yamanaka^2^, S. Mochizuki^2^, T. Nishikawa^2^, H. Toyoda^2^, A. Iguchi^2^, K. Koh^2^, S. Ota^2^, T. Kitoh^2^, K. Okada^2^, T. Asano^2^, T. Deguchi^3^, N. Kiyokawa^4^, T. Hori^5^, Y. Komada^3^, A. Moriya Saito^6^, T. Watanabe^7^, H. Goto^2^

*^1^National Cancer Center Hospital, Department of Pediatric Oncology, Tokyo, Japan; ^2^Japan Children\'s Cancer Group, Relapsed ALL committee, Nagoya, Japan; ^3^Mie University Hospital, Department of Pediatrics, Tsu, Japan; ^4^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^5^Aichi Medical University School of Medicine, Department of Pediatrics, Nagakute, Japan; ^6^Nagoya Medical Center, Clinical Research Center, Nagoya, Japan; ^7^Aichi Gakuin University, Department of Nutritional Science‐ Faculty of Psychological and Physical Science, Nisshin, Japan*

**Background/Objectives**: BFM‐S classification is a leading indicator for the prognosis of children with the first relapsed acute lymphoblastic leukemia (1^st^‐rel‐ALL). We planned a prospective observational study to assess the treatment and prognosis in 1^st^‐rel‐ALL in Japan, Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)‐ALL‐R08‐I. For pediatric patients with 1^st^‐rel‐non‐T‐ALL in the intermediate (S2)‐risk group, we conducted a multicenter phase II clinical trial, JPLSG‐ALL‐R08‐II, to estimate the efficacy and safety of the modified ALL‐REZ BFM 95/96 in Japan.

**Design/Methods**: JPLSG‐ALL‐R08 comprises ALL‐R08‐I and II. In R08‐II, patients with positive minimal residual disease (MRD) after induction therapy underwent allogeneic hematopoietic stem cell transplantation (HCT). The primary endpoint was 3‐year event‐free survival (3y‐EFS), and secondary endpoints were 3y‐EFS, 3y‐overall survival (3y‐OS), remission rate in each risk group, and incidence rates of adverse effects. We assessed survival using the Kaplan--Meier method.

**Results**: In total, 163 patients were enrolled in JPLSG‐ALL‐R08, and 6/19/32/22/3 in S1/S2/S3/S4/post‐HCT(PT) in R08‐I and 81 in R08‐II S2. In R08‐II, four patients were ineligible after enrollment. The 3y‐EFS and 3y‐OS were 83%/37%/65%/28%/13%/0% and 100%/83%/73%/53%/27%/0% in S1/S2(R08‐I)/S2(R08‐II)/S3/S4/PT, respectively. In R‐08‐II, 3y‐EFS and 3y‐OS in the MRD‐negative/positive group at BMA3 were 69%/64% and 90%/86%, respectively, and the differences were not statistically significant. Second complete remission rates were 83%/95%/89%/59%/55%/67% in S1/S2(R08‐I)/S2(R08‐II)/S3/S4/PT, respectively. Notably, one patient died of the progression of CNS infiltration during the trial. Although adverse events were reported in all patients, no other appreciable adverse event was present.

**Conclusions**: BFM‐S classification is a good predictor for the prognosis of children with t1st‐rel‐ALL who were initially treated as per Japanese protocols. According to the stratification based on MRD for S2 patients in R08‐II, MRD‐positive patients underwent HCT, and the prognosis was similar to that of MRD‐negative patients.

### O-005. Extramedullary Relapses Other Than CNS/Testis in Childhood ALL: Update of the ALL‐REZ BFM Registry Data {#pbc27455-sec-0140}

[C. Chen‐Santel]{.ul} ^1^

*^1^Charité, Department of Pediatric Hematology/Oncology/BMT, Berlin, Germany*

**Background/Objectives**: In childhood acute lymphoblastic leukemia (ALL) about 15% of patients suffer a relapse after frontline therapy. Other extramedullary relapses (OEM) besides CNS and testis are a rare, but heterogeneous subgroup. We retrospectively analyzed data of children with first OEM relapse with respect to clinical and prognostic features.

**Design/Methods**: Patients with OEM relapses treated according to the ALL relapse Berlin‐Frankfurt‐Muenster (ALL‐REZ BFM) studies from March 1983 until December 2017 were analyzed for their outcome. They were diagnosed by imaging (MRI, CT scan, scintigraphy) and/or histology.

**Results**: Among the 3050 patients treated within the ALL‐REZ BFM studies, 173 patients had an OEM relapse (5.8%) ‐ 100 combined OEM/bone marrow (BM) relapse, 73 isolated OEM relapse with/without CNS or testis involvement. OEM relapses were associated with unfavourable factors such as T‐cell immunophenotype (n=90) and age \> 10 years (n=84). Relapses were very early or early in 52.8% of patients, late in 47.2%. Lymphatic organs were the most frequent sites of OEM relapses (n=65), followed by mediastinum/thymus (n=41), skin/glands (n=17) and bones (n=17). Other organs such as eye/orbita, kidney, colon, serosae, pancreas and lung were infrequently involved (n=33). The probability of event‐free survival (pEFS) at 5 years for OEM patients (0.29±0.04) was significantly worse than that of patients with non‐OEM relapse (0.47±0.02, p\<0.0001) and similar to those with isolated BM relapse (0.33±0.01, p=0.09). Five‐year pEFS of patients with mediastinal/thymic involvement was the poorest (0.03±0.03), followed by involvement of bones (0.18±0.09, p=0.04). Patients with involvement of skin/glands (0.33±0.12, p\<0.0001, p=0.09), lymphatic organs (0.43±0.06, p\<0.0001, p=0.03) and other organs (0.33±0.08, p\<0.0001, p=0.19) had better pEFS. Subsequent relapses occurred in 63 patients, 23 of them as OEM.

**Conclusions**: The prognosis of patients with OEM relapses was poor. Patients with combined, but especially with isolated OEM might need more intensive therapy including allogeneic hematopoetic stem cell transplantation (HSCT) to prevent relapses.

### O-006. Quinapril Reduces Osteonecrosis in a Murine Model of Acute Lymphoblastic Leukemia Therapy {#pbc27455-sec-0150}

L. Janke^1^, M. Portera^2^, C. Cheng^3^, H. Inaba^4^, S. Kaste^5^, S. Jeha^4^, C.H. Pui^4^, M. Relling^2^, [S. Karol]{.ul} ^4^

*^1^St. Jude Children\'s Research Hospital, Pathology, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Pharmaceutical Sciences, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Biostatistics, Memphis, USA; ^4^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA; ^5^St. Jude Children\'s Research Hospital, Diagnostic Imaging, Memphis, USA*

**Background/Objectives**: Osteonecrosis is a significant toxicity associated with modern therapy for acute lymphoblastic leukemia (ALL). Children aged 10 years and older at diagnosis have the greatest risk of developing osteonecrosis, with 25‐50% developing symptoms. Glucocorticoids and asparaginase are the key drivers of osteonecrosis, with arteriopathy as the preceding pathology in its development. We therefore tested the ability of quinapril to prevent arteriopathy and osteonecrosis in a murine model system.

**Design/Methods**: Male Balb/cJ mice aged 26‐28 post‐natal days were treated with 6 weeks of dexamethasone (2mg/L in drinking water) and weekly injections of PEGylated‐asparaginase (1200IU/kg intraperitoneal). Mice were randomized to receive quinapril 60mg/L in drinking water or control. Osteonecrosis and arteriopathy was evaluated histologically in the distal femur after 6 weeks of therapy. Blood pressures were measured using the CODA tail cuff system.

**Results**: Mice who received quinapril had lower rates of osteonecrosis (20% vs. 65%; P=0.0004) and arteriopathy (26% vs. 47% of knees; P=0.02) than control mice. Chemotherapy for ALL results in systolic hypertension (median, 139 mmHg vs 119 mmHg in no‐chemotherapy mice; P=1.4x10‐5) which was attenuated in mice treated with quinapril in addition to chemotherapy (median 127 mmHg; P=0.03 vs. chemotherapy treated mice). Because antihypertensive therapy decreased osteonecrosis in mice, we evaluated the association of hypertension with osteonecrosis in children with ALL treated on the St. Jude Total XV study. Children 10 years and older at diagnosis who were hypertensive either during induction or reinduction were more likely to have osteonecrosis (55%) than normotensive children (24%; P=0.004).

**Conclusions**: Quinapril decreases osteonecrosis in the murine model. A prospective clinical trial evaluating its utility in older children with ALL is warranted.

FPS 02: PPO I {#pbc27455-sec-0160}
-------------

### O-007. Mapping Psychosocial Screening to Resources: A Pilot Intervention Study {#pbc27455-sec-0170}

[L. Desjardins]{.ul} ^1^, K. Hancock^1^, S. Alexander^1^, D. Mills^1^, W. Shama^1^, C. De Souza^1^, A. Gupta^1^, P. Szatmari^1^

*^1^The Hospital for Sick Children, Psychology, Toronto, Canada*

**Background/Objectives**: Children recently diagnosed with cancer and their caregivers are at high risk for emotional distress (Compas et al., 2015). Psychosocial screening is an evidence‐based practice that has been established as a core standard of psychosocial care in pediatric oncology (Kazak, et al., 2015). However, limited information is available on pathways of care based on psychosocial screening results. This study aimed to evaluate the feasibility of a pilot intervention study mapping comprehensive screening for psychosocial risk and mental health to psychosocial resources over time.

**Design/Methods**: Participants included parent and child (aged 10‐17) dyads enrolled within the first 4 weeks from a cancer diagnosis at a large oncology center in Canada. Parents completed the Psychosocial Assessment Tool. Parents and children completed the Distress Thermometer and the PROMIS measures of anxiety and depression at enrolment (T1) and a year later (T2). Dyads were randomly assigned to an intervention or treatment as usual control group. The intervention group completed monthly psychosocial and distress screenings and a Psychosocial Navigator provided the treating team and family with initial and monthly screening result summaries and recommended resources tailored to the screening.

**Results**: To date. twenty‐three participant families were approached, and 14 families enrolled (n = 6 Intervention; n = 8 Control). Eight families declined to participate, 1 family withdrew after enrollment. Retention for monthly follow‐up screenings in the experimental group is 95%. Reason for non‐participation was predominantly families feeling 'too overwhelmed' by emotional and logistical aspects of new diagnosis and treatment demands.

**Conclusions**: Feasibility results are similar to other intervention studies recruiting pediatric oncology patients near diagnosis (Kazak et al., 2005). Retention rates indicate good acceptability. Results from this study offer novel insights into avenues towards implementing evidence‐based psychosocial screening practice for linking families with psychosocial services early and throughout a child\'s cancer journey.

### O-008. When the Going Gets Tough: Psychiatric Diagnoses in Children with Haematological and Oncology Conditions Referred to Paediatric Psycho‐Oncology Services {#pbc27455-sec-0180}

[R. Daruvala]{.ul} ^1^, S.S. Datta^2^, A. Melavarige Venkatagiri^1^, S. Chakraborty^1^, L. Chandershekhar Rajole^1^, P. P Mallya^1^, S. Badiger^1^, V. Kailasnath^1^, S. Bhat^1^

*^1^Mazumdar Shaw Medical Center, Department of Paediatric Haematology and Oncology, Bangalore, India; ^2^Tata Medical Center, Department of Palliative Care and Psycho‐oncology, kolkata, India*

**Background/Objectives**: Treatment for paediatric haematological and oncology conditions has progressed, however, with prolonged life these illnesses continue to be associated with death, incurability, loss and suffering (Malta, Schall, & Modena, 2008). A review by Satapathy et.al in 2018 showed that culture specific psycho‐oncology interventions and research are necessary to provide better psychological care to paediatric patients with cancer.

**Design/Methods**: Retrospective data analysis from two centres was analysed to understand the psychological relationship to various haematological and oncology conditions. Socio‐demographic data, disease related data and psychological diagnosis were analysed for paediatric patients referred from 2017‐2018.

**Results**: In 109 children referred to paediatric psycho‐oncology services, adjustment disorders were most prominent (20.2%) followed by mood disorders (16.5%) and anxiety disorders (14.7%). 69% percent of referred children had acute lymphoblastic leukaemia(ALL), 22.2% of whom were found to have adjustment disorders, 16.7% anxiety disorders and 13.9% mood disorders. Thus majority of children seen by mental health professionals were diagnosed with leukaemia\'s reflecting the proportion of patients seen by paediatric teams. Acute Myeloid Leukaemia\'s (AML) constituted 15.4% of referrals and 50% of those referred with AML were diagnosed with adjustment disorders. Children referred with solid tumours were commonly diagnosed with adjustment disorders (37.5%), 18.8% with mood disorders and 18.8% with anxiety disorders which could be explained by the psychological impact solid tumours have concerning body image and possible disability. Benign conditions such as thalassemia, aplastic anaemia etc. were found to have least psychological comorbidity in the referred sample with majority being referred for pre‐transplant assessments (41.2%). A minority (9.2%) of all children referred presented with behavioural problems, not specific to any particular disease condition. Besides psychological support for the children, several families irrespective of diagnosis required support through the child\'s treatment.

**Conclusions**: Understanding disease specific psychological manifestations helps in tailoring interventions that may provide better psychological services for paediatric patients.

### O-009. Daily Mood Profiles Predict Psychosocial Adjustment in Children with Newly Diagnosed Cancer {#pbc27455-sec-0190}

[S. Schepers]{.ul} ^1^, K. Russel^1^, K. Berlin^2^, F. Wang^3^, H. Zhang^3^, S. Phipps^1^

*^1^St. Jude Children\'s Research Hospital, Psychology, Memphis, USA; ^2^University of Memphis, Psychology, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Biostatistics, Memphis, USA*

**Background/Objectives**: Daily changes in individuals' mood across time plays a key role in mental health. A new cancer diagnosis leads to many daily changes in the lives of youth. We aimed to identify daily mood profiles during treatment for childhood cancer and to understand how this predicts overall psychosocial adjustment over time.

**Design/Methods**: Youth with cancer (*n*=73, weeks since diagnosis: *M*=6.56, *SD*=1.94) and age‐matched controls (*n*=64), aged 8‐17 years, reported on their positive and negative mood during seven consecutive days. Two to four months later (T2), youth reported on their psychosocial adjustment by completing measures on perceived parental care and overprotection, anxiety, physical and psychosocial quality of life (QOL). Their primary caregiver completed measures on parental distress, and on their child\'s externalizing and internalizing problems. Latent Profile Analysis (LPA) was conducted to identify individual profiles of daily mood. These profiles were used to predict overall psychosocial adjustment at T2, while controlling for sociodemographic factors (age, gender, SES) and health status (cancer vs. control).

**Results**: LPA revealed four daily mood profiles, labeled "stable positive mood" (SPM, 61.6%), "stable negative mood" (SNM, 4.8%), "intermediate mood" (IM, 27.6%), and "fluctuating negative mood" (FNM, 6%). No sociodemographic or health status differences were found across mood profiles. Results showed several relations between mood profiles across the week and self‐ and parent‐reported adjustment outcomes at T2. Overall, a SPM profile during treatment related to most favorable adjustment outcomes, whereas a SNM and FNM profile related to least favorable adjustment at T2. Compared to a FNM, SNM related to less youth‐reported perceived parental care (*p*=.02) and higher youth anxiety (*p*=.05).

**Conclusions**: Most children show healthy mood patterns during treatment for cancer. Close monitoring of QOL and mood during treatment is important to identify youth at risk for worse psychosocial adjustment outcomes over time.

### O-010. Effects of Group‐Based Physical Activity Intervention for Children with Cancer {#pbc27455-sec-0200}

[N. Ouyang]{.ul} ^1^, K. Liu^1^, X. Bu^1^, R. Cai^2^, M. Liu^2^

*^1^Sun Yat‐Sen University, School of Nursing, Guangzhou, China; ^2^Sun Yat‐sen University Cancer Center, Pediatric Oncology Department, Guangzhou, China*

**Background/Objectives**: Physical activity (PA) is becoming an important part of childhood cancer care. However, scarce evidence are available with regard to the effectiveness of group‐based physical activity intervention in China. The purpose of this study was to examine the effects of group‐based physical activity intervention in mitigation of symptom distress and improvement of quality of life (QOL).

**Design/Methods**: A quasi‐experimental study was conducted. Based on convenient sampling, fifty‐seven childhood cancer patients (4‐17 years old) who were admitted in the cancer center included in the intervention group (IG). And 57 childhood cancer patients in other two hospitals who were matched to IG by age, gender and diagnosis included in the control group (CG). A 3‐month group‐based PA intervention (including one PA health education session and 12 group‐based PA intervention sessions) was implemented for children in IG, whereas children in CG received standard care. Symptom distress and QOL were measured using Memorial Symptom Assessment Scale (MSAS) and the Pediatric Quality of Life Inventory Generic Core Scales (PedsQLTM4.0) at baseline and post‐intervention.

**Results**: Significant differences between the IG and CG were identified in the change of the scores of MSAS (‐0.09±0.29 vs 0.04±0.21, *P*\<0.001), physical symptom(‐0.19±0.29 vs 0.13±0.28, *P*\<0.001), psychological symptom(‐0.05±0.23 vs 0.11±0.34, *P*\<0.01), global distress index (‐0.09±0.25 vs 0.14±0.31, *P*\<0.001), social psychology QOL (6.32±9.05 vs ‐0.12±4.64, *P*\<0.001), physical function QOL (13.10±13.01 vs ‐0.93±9.57, *P*\<0.001), physiological function QOL (8.07±12.91 vs ‐1.67±9.70, *P*\<0.001) and social function QOL (6.40±10.89 vs ‐0.18±5.09, *P*\<0.001) from baseline to post‐intervention. However, the change of the number of symptoms and role function quality of life in both groups had no significant.

**Conclusions**: The findings suggest that group‐based PA intervention can release the symptom distress and improve quality of life for childhood cancer patients during hospitalization.

### O-011. A Pilot Randomized Controlled Trial of Using Musical Training in Promoting Psychological Well‐being and Quality of Life in Childhood Brain Tumours Survivors {#pbc27455-sec-0210}

[H.C.W. Li]{.ul} ^1^, T. Cheung^1^

*^1^University of Hong Kong, School of Nursing, Hong Kong, China*

**Background/Objectives**: Evidence suggests that survivors of paediatric brain tumours have more negative psychological sequelae than do survivors of other childhood cancers. Previous studies indicate that damage to neural cells as a result of a brain tumour or its treatment, potentially interacting with psychological adjustments, leads to long‐term and lasting neuropsychiatric conditions in survivors. Increasing evidence suggests the use of musical training to improve psychosocial well‐being in children with autism. Nevertheless, its' effectiveness in enhancing psychological well‐being and quality of life among childhood brain tumours survivors remains relatively unknown. This study aims to examine the effectiveness of musical training in promoting psychological well‐being and quality of life in survivors of paediatric brain tumours

**Design/Methods**: A pilot randomized controlled trial was conducted. Fifty‐eight children surviving from brain tumours having medical follow‐ups at the outpatient clinic of an acute‐care hospital were invited to participate in the study and randomly allocated to the experimental (n=30) and control groups (n=28). Subjects in the experimental group received a weekly 45‐minutes lesson on musical training for 52 weeks, whereas the control group received usual care. Subjects' depressive symptoms, level of self‐esteem and quality of life were assessed at the time of recruitment, 6‐ and 12‐month after starting the intervention.

**Results**: Subjects in the experimental group reported statistically significant fewer depressive symptoms, higher level of self‐esteem and quality of life than children in the control group who received usual care at 6‐ and 12‐month follow up.

**Conclusions**: The musical training was investigated to be effective in reducing the depressive symptoms, improving self‐esteem and quality of life in childhood brain tumours survivors. In addition, it demonstrated the feasibility of implementing musical training in the Hong Kong Chinese context, with their content and nature shown to be acceptable to children surviving brain tumours and their parents.

### O-012. Improving Sleep in Parents of Children with Cancer: Development and Evaluation of a Hospital‐Based Cognitive Behavioral Therapy Intervention {#pbc27455-sec-0220}

[S. Ellis]{.ul} ^1,2,3^, U. Sansom‐Daly^1,3^, R. Cohn^1,3^, L. Juraskova^2^, P. Butow^2^, C. Wakefield^1,3^

*^1^Sydney Children\'s Hospital, Kids Cancer Centre, Sydney, Australia; ^2^The University of Sydney, School of Psychology, Sydney, Australia; ^3^University of New South Wales, School of Women\'s and Children\'s Health‐ UNSW Medicine, Sydney, Australia*

**Background/Objectives**: Parents of children hospitalized for cancer treatment are at increased risk of poor sleep outcomes. Impaired sleep may negatively impact parent\'s physical and psychological health, quality of life and capacity to care for their unwell child. The aims of this study were to: (1) qualitatively assess barriers and facilitators to parent sleep, and unmet needs/preferences for intervention; and (2) develop and evaluate an ecologically valid sleep intervention in the hospital setting.

**Design/Methods**: We conducted semi‐structured interviews with parents and healthcare professionals (HCPs) recruited from Sydney Children\'s Hospital. Interviews were transcribed verbatim and analyzed using an inductive thematic approach. Qualitative findings, in conjunction with a systematic review of the literature and expert advisory panel informed the development of 'CAT NAP', a non‐pharmacological, multi‐component intervention based on cognitive behavioral therapy. We also conducted a pilot feasibility/acceptability trial of the CAT NAP intervention.

**Results**: Parents (n=10) and HCPs (n=11) identified significant difficulties for parents sleeping on the hospital ward and cited a need for personalized intervention. Barriers to sleep were categorized into five themes: environmental; child‐related; psychological; unhelpful thoughts/beliefs; and unhelpful sleep‐related behaviors. Participants also identified parental guilt (needing to be on "constant alert" for their child) and difficulty prioritizing self‐care as contributing to poor sleep and overall wellbeing. Ten parents (age M=28.6 years; 100% mothers) participated in the pilot. The response rate was 52.6% with no withdrawals. Qualitatively, parents identified different intervention components as helpful, highlighting the importance of a multimodal framework. All parents reported benefiting from the intervention, with 90% stating that they would recommend it to others.

**Conclusions**: Parents and HCPs identified a complex combination of factors, which impact sleep outcomes in the hospital setting. The CAT NAP intervention was designed to target aspects of sleep, which are amenable to change, and appeared feasible and acceptable to parents at risk of poor sleep.

FPS 03: High Impact Clinical Trials {#pbc27455-sec-0230}
-----------------------------------

### O-013. The Randomised Induction for High‐Risk Neuroblastoma Comparing COJEC and N5‐MSKCC Regimens. Early Results from the HR‐NBL1.5/SIOPEN Trial {#pbc27455-sec-0240}

[R. Ladenstein]{.ul} ^1,2^, U. Poetschger^3^, D. Valteau‐Couanet^4^, V. Castel^5^, M. Elliott^6^, S. Ash^7^, G. Chan^8^, G. Laureys^9^, M. Beck‐Popovic^10^, K. Vettenranta^11^, W. Balwierz^12^, H. Schroeder^13^, C. Owens^14^, M. Cesen^15^, V. Papadakis^16^, T. Trahair^17^, R. Luksch^18^, G. Schleiermacher^19^, P. Ambros^20^, A. Garaventa^21^

*^1^St. Anna Kinderkrebsforschung e.V., S2IRP Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^2^St. Anna Children's Hospital Vienna, Department of Paediatrics‐ Medical University, Vienna, Austria; ^3^Children\'s Cancer Research Institute, Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^4^Gustave Roussy, Paediatric Oncology and Haematology, Villejuif‐ Paris, France; ^5^Hospital Universitari i Politecnic La Fe, Paediatric Oncology Unit, Valencia, Spain; ^6^Leeds Teaching Hospitals NHS Trust, Paediatric Oncology and Haematology, Leeds, United Kingdom; ^7^Schneider Children's Medical Center of Israel, Paediatric Oncology and Haematology, Petach Tikvah, Israel; ^8^University of Hong Kong& Queen MaryHospital, Paediatric Oncology and Haematology, Hong Kong, Hong Kong S.A.R.; ^9^University Hospital Ghent, Paediatric Oncology and Haematology, Ghent, Belgium; ^10^University Hospital Lausanne, Paediatric Oncology and Haematology, Lausanne, Switzerland; ^11^University of Helsinki, Dept of Pediatrics, Helsinki, Finland; ^12^Jagiellonian University Medical College, Paediatric Oncology and Haematology, Krakow, Poland; ^13^University Hospital of Aarhus, Department of Paediatrics, Aarhus, Denmark; ^14^University of Dublin, Paediatric Oncology and Haematology, Dublin, Ireland; ^15^Paediatric Clinic, Paediatric Oncology and Haematology, Ljubljana, Slovenia; ^16^Agia Sofia Children\'s Hospital Athens, Paediatric Oncology and Haematology, Athens, Greece; ^17^Sydney Children\'s Hospital, Paediatric Oncology and Haematology, Randwick, Australia; ^18^Fondazione IRCCS Istituto Nazionale dei Tumori, Paediatric Oncology and Haematology, Milan, Italy; ^19^Institut Curie, Paediatric Oncology and Haematology, Paris, France; ^20^St. Anna Kinderkrebsforschung e.V., Tumour Biology, Vienna, Austria; ^21^Istituto Giannina Gaslini, Paediatric Oncology and Haematology, Genoa, Italy*

**Background/Objectives**: From 2013‐2017 the HRNBL1.5/SIOPEN trial tested the hypothesis that the N5‐MSKCC induction regimen (*Kushner, JCO 2004*) increases metastatic complete response (mCR) or event‐free survival (EFS) compared to COJEC (*Ladenstein, JCO 2010*).

**Design/Methods**: Eligible patients had stage 4 or 4s with MYCN amplification (MNA) aged \<21 years, or without MNA aged 12‐18 months with segmental chromosomal alterations, and \>18 months with any genomic profile. Patients were stratified for national groups and metastatic sites. Further treatments included addition of 2 TVD (Amoroso, Cancer Res Treat 2018)if \<mCR, primary tumour resection, BuMel megatherapy, primary site irradiation (21Gy), ch14.18/CHO antibody ± IL2 plus 13‐cis‐RA. Primary endpoints aimed with N5‐MSKCC for an increase of mCR rate to 45% (33% for COJEC) and a 2‐year EFS of 52.5% (increase by 12.5 %).

**Results**: 630 patients were randomised (313 for COJEC, 317 for N5‐MSKCC). 56% were female. 99% had stage 4. Median age was 3.2 years (0.2‐20.4) with 16 infants and 56 aged 12‐18 mos. Median follow‐up was 1.7 years. The primary endpoint showed no difference:: 2‐year EFS was 53%±4 for COJEC *vs*. 51%±4 for N5‐MSKCC. mCR rate after induction was 33% for COJEC *vs*. 37% for N5‐MSKCC. Secondary endpoints neither showed a difference: overall survival was 72%±3 for COJEC *vs* 69%±3 for N5‐MSKCC. Relapse‐unrelated mortality (2‐year NRM) was 8%±2 with COJEC *vs*. 6%±2 with N5‐MSKCC. Cumulative incidence of relapse/progression was 39%±3 for COJEC *vs* 43%±4 for N5‐MSKCC. A comparison of CTC Grade 3‐4 toxicities showed significant differences favouring COJEC overN5‐MSKCC: non‐haematological 47%/68% (*P*=.000), compromise of general conditions 12%/19% (*P*=.055); neutropenia 94%/98% (*P*=.020); low platelet count 91%/96% (*P*=.031); infections 24%/35% (*P*=.005); stomatitis 3%/26% (*P*=.000); nausea/vomiting 7%/16% (*P*=.001); diarrhoea 3%/7% (*P*=.033); hypertension 10%/6% (*P*=.050); central neurotoxicity 0%/1% (*P*=.049).

**Conclusions**: As COJEC was less toxic it is maintained as induction standard for SIOPEN studies.

### O-014. Does Quality of Radiation Therapy Affect Clinical Outcomes in Pediatric Multicenter Cooperative Group Trials? A Systemic Review {#pbc27455-sec-0250}

A. Lim^1^, A. Fairchild^1^, [S. Patel]{.ul} ^2^

*^1^University of Alberta/Cross Cancer Institute, Department of Oncology, Edmonton, Canada; ^2^University of Alberta/Stollery Children\'s Hospital, Department of Oncology, Edmonton, Canada*

**Background/Objectives**: Radiotherapy (RT) quality assurance (QA) programs aim to standardize RT delivered on multicenter clinical trials to minimize variables that may confound the validity of results. Our objective was to review available evidence for reported correlation of RT quality with clinical outcomes within pediatric multicenter clinical trials.

**Design/Methods**: Literature search encompassing Medline, Embase, Cochrane Central Register of Controlled Trials, and Quality Assurance Review Center bibliography was performed restricted to English but with no date limits. Candidate studies accrued children age ≤21 years or median age ≤15, were led by any cooperative group, published in full, and described central subjective and/or objective assessment of RT protocol compliance (quality). Data abstracted included assignment of violations in relation to clinical outcomes (loco‐regional and/or distant failure, progression‐free survival \[PFS\], overall survival \[OS\], and adverse events).

**Results**: Thirty‐three multicenter clinical trials reported on rhabdomyosarcoma (RMS; 10 trials), medulloblastoma (MBL; 9), Ewing\'s sarcoma (EWS; 6), classical Hodgkin\'s lymphoma (cHL; 4), supratentorial primitive neuroectodermal tumors (sPNET; 3), and acute lymphocytic leukemia (ALL; 1). Deviations were found in up to 83% of RT plans reviewed. 12/33 from various primary sites reported that RT protocol deviations (eg dose, field placement) significantly affected clinical outcomes in the form of inferior OS (N=1 trial), PFS (N=5), local control (N=3), or any recurrence (N=2). One study suggested improved PFS with local field RT deviations versus without.

**Conclusions**: Suboptimal RT negatively impacts clinical outcomes in pediatric multicenter cooperative group trials.

### O-015. Radiotherapy in Choroid Plexus Carcinoma: An Analysis of the SIOP‐CPT‐2000/2009‐Study and the CPT‐Register {#pbc27455-sec-0260}

C. Ricken^1^, S. Frisch^1^, S. Hartung^2^, R.D. Kortmann^3^, J. Wolff^4^, [B. Timmermann]{.ul} ^1^

*^1^University Hospital Essen ‐ West German Proton Therapy Center, Department of Particle Therapy, Essen, Germany; ^2^University Medical Center Hamburg--Eppendorf, Department of Pediatric Haematology and Oncology, Hamburg, Germany; ^3^University of Leipzig Medical Center, Department of Radiation Therapy, Leipzig, Germany; ^4^Alberta Children\'s Hospital, Department of Pediatric Oncology, Calgary, Canada*

**Background/Objectives**: Choroid plexus tumors are rare pediatric brain tumors diagnosed mainly in infants. Little is known about the role of radiotherapy (RT). The aim of this retrospective study was to evaluate the impact of RT in patients with choroid plexus carcinoma (CPC).

**Design/Methods**: We analyzed the data from the SIOP‐CPT‐2000/2009‐Study and CPT‐registry study on 103 patients with CPC. 99 patients (55 m/44 f; median age 2.21 years (y) (range, 0‐48.87 y)) were evaluable. Complete resection was achieved in 44 cases (44.4%), subtotal in 40 (40.4%). Extent of resection was not further specified in 15 patients (15.2%). In 86 patients (86.9%) chemotherapy was applied before RT.

55 patients (55.6%) received RT (RT group), from whom 33 received local (median dose 54Gy, range 25.2‐61.4Gy) and 20 craniospinal irradiation with local boost (median dose 55Gy, range 36‐60Gy) (in 2 cases, details on RT were missing). In 44 patients (44.4%), no RT was applied (non‐RT group). The median age at diagnosis in the RT‐group was 5.31 y (range, 0.4‐48.9 y) and in the non‐RT‐group 1.1 y (range, 0‐12.7 y). Survival data was estimated using the Kaplan Meier method and the Cox\'s Model.

**Results**: The median follow‐up was 3.67 y (range 0.09‐13.12 y). 5y‐overall survival (OS) was 74.0% vs. 51.4% in the RT vs. non‐RT group (p=0.004). 5y‐progression‐free survival (PFS) was 63.6% vs. 44.8% in the RT vs. non‐RT group (p=0.049). When RT was not applied, the relative risk for failure and death was 1.8 and 2.6 times higher, respectively (p=0.052; p=0.005).

**Conclusions**: Our analysis indicates that RT plays an important role in the cure of CPC. OS und PFS rates were significantly higher in patients receiving RT. The Role of RT in CPC needs to be considered in future concepts. More knowledge is still needed on optimal dose‐volume concepts and timing of RT.

### O-016. Detection of Relapse by Tumor Markers Versus Radiological Imaging in Children and Adolescents with Malignant Germ Cell Tumors: A Report from the Children\'s Oncology Group {#pbc27455-sec-0270}

[A. Fonseca]{.ul} ^1^, C.H. XIa^2^, A. Lorenzo^3^, M. Krailo^4^, T. Olson^5^, F. Pashankar^6^, M. Malogolowkin^7^, J. Amatruda^8^, D.F. Billmire^9^, C. Rodriguez‐Galindo^10^, L. Frazier^11^, F. Shaikh^1^

*^1^The Hospital for Sick Children, Haematology Oncology, Toronto, Canada; ^2^Children\'s Oncology Group, Statistics and Data Center, Monrovia, USA; ^3^The Hospital for Sick Children, Urology, Toronto, Canada; ^4^University of Southern California, Preventive Medicine, Los Angeles, USA; ^5^Children\'s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, USA; ^6^Yale University School of Medicine, Hematology Oncology, New Haven, USA; ^7^University of California, Davis Comprehensive Cancer Center, Sacramento, USA; ^8^University of Texas Southwestern Medical Center and Children\'s Medical Center, Hematology Oncology, Dallas, USA; ^9^Riley Hospital for Children, Surgery, Indianapolis, USA; ^10^St. Jude Children\'s Research Hospital, Global Pediatric Medicine, Memphis, USA; ^11^Dana‐Farber Cancer Institute‐ Harvard Medical School, Haematology Oncology, Boston, USA*

**Background/Objectives**: To investigate relapse detection methods among children and adolescents with malignant germ cell tumors (MGCTs) and to determine if tumor markers alone are sufficient for surveillance.

**Design/Methods**: We retrospectively reviewed all patients enrolled in a phase III, single arm trial for low‐risk (LR) and intermediate‐risk (IR) MGCT. The detection method at relapse was assessed based on case report forms, tumor markers, imaging, and pathology reports. Relapses were classified into one of three categories based on whether they were associated with: elevated tumor markers alone, elevated tumor markers and imaging findings or imaging findings alone. The first two categories were considered "detectable by tumor marker elevation." We determined the proportion of relapses detectable by tumor marker elevation.

**Results**: Three Hundred and two patients were enrolled, and 285 patients had complete data for review. Six patients had normal tumor markers at initial diagnosis, and none experienced a relapse. At a median follow‐up of 5.3 years, 49 patients (17%) had experienced a relapse; 55% were males with testicular tumors, and 43% were less than 11 years of age. By institutional report, 16 relapses (32%) were detected by tumor markers alone, 28 relapses (56%) by tumor markers and imaging, and 5 relapses (12%) by imaging alone. However, upon central review, 4 of the 5 patients reported to be detected by imaging alone had concurrent tumor marker elevation. The fifth patient did not have tumor marker information available.

**Conclusions**: Overall, 48/49 relapses (98%) in children with MGCTs were detected by tumor marker elevation, with the last patient having unknown tumor marker levels at relapse. This result suggests that tumor marker elevation may be a highly sensitive method of relapse surveillance, at least among children and adolescents with tumor marker elevation at initial diagnosis, avoiding exposure to imaging studies with ionizing radiation.

### O-017. Liver Transplant in Upfront Unresectable, Non‐Metastatic Hepatoblastoma {#pbc27455-sec-0280}

[S. Dunn]{.ul} ^1^, G. Tiao^2^, M. Langham^3^, E. McGahren^4^, C. Weldon^5^, A. Towbin^6^, B. McCarville^7^, F. Laurie^8^, M. Finegold^9^, M. Krailo^10^, C. Xia^10^, J. Piao^10^, H. Katzenstein^11^, R. Meyers^12^

*^1^Nemours / Alfred I duPont Hospital for Children, Pediatric Surgery and Solid OrganTransplantation, Wilmington Delaware, USA; ^2^Cincinnati Children\'s Hospital and Medical Center, Pediatric Surgery and Solid Organ Transplantation, Cincinnati Ohio, USA; ^3^Le Bonheur Children\'s Hospital‐ University of Tennessee, Pediatric Surgery, Memphis TN, USA; ^4^University of Virginia Children\'s Hospital, Pediatric Surgery, Charlottesville VA, USA; ^5^Boston Children\'s Hospital, Pediatric Surgery, Boston Massachusetts, USA; ^6^Cincinnati Children\'sHospital and Medical Center, Pediatric Radiology, Cincinnati OH, USA; ^7^St Jude Children\'s Research Hospital, Pediatric Radiology, Memphis TN, USA; ^8^Imaging and Radiation Oncology Core, Department Radiation Oncology Univ of Massachusetts, Lincoln RI, USA; ^9^Baylor College of Medicine‐ Texas Children\'s Hospital, Pathology, Houston TX, USA; ^10^Children\'s Oncology Group, COG Statistics and Data Center, Monrovia CA, USA; ^11^Nemours‐ Center for Childhood Cancer Research, Pediatric Hematology Oncology, Jacksonville FL, USA; ^12^Primary Children\'s Hospital‐ University of Utah, Pediatric Surgery, Salt Lake City, USA*

**Background/Objectives**: The intermediate‐risk stratum of Children\'s Oncology Group AHEP‐0731 (9/2009‐2/2012) included children with non‐metastatic, unresectable at diagnosis, hepatoblastoma. Preoperative chemotherapy was a combination of cisplatin/5FU/vincristine/doxorubicin. We review the patients who underwent liver transplant on this prospective multicenter trial.

**Design/Methods**: Surgical guidelines recommended early referral to a transplant‐capable surgical team between the second and fourth courses of chemotherapy for POST‐TEXT III with concomitant V+(venous), P+(portal), and/or F+(multifocal); and for all POST‐TEXT IV. Radiographic imaging, PRETEXT and POST‐TEXT, and pathology was centrally reviewed. Liver transplantation procedural details and complications were obtained from participating institutions. Patient and graft survival were determined for the cohort and sub‐analyzed according to whole‐organ versus technical‐variant grafts.

**Results**: 34 children received a liver transplant on the intermediate‐risk stratum of this study. All were alive at the time of last follow‐up (mean 59 months, range 37‐89). Patient age at diagnosis: \<1yo=16, 1‐3yo=12; 3‐8yo=3; \>8yo=3. Operative details are available for 26 patients. For these 26 patients, donor was cadaveric=23 and live‐donor=3. Graft type and caval reconstruction were: whole‐organ bicaval 9/26; whole‐organ piggyback 3/26; left lobe bicaval 2/26; and left‐lateral segment piggyback 12/26. Two patients underwent rescue liver transplantation: one for local‐liver relapse two years after a left hemi‐hepatectomy; and one following a failed conventional resection two weeks before transplant. Early complications included: hepatic artery thrombosis (n=1, required retransplantation); portal vein thrombosis (n=1); major postoperative bleeding (n=3); biliary stricture (n=1). Late complications included: lung relapse (n=1 at two years successfully treated by resection); retransplantation (n=1 at six years for chronic cholangitis); and secondary malignancy (n=1, Askin tumor at five years).

**Conclusions**: Long‐term outcomes for non‐metastatic patients receiving liver transplantation on the intermediate‐risk arm of the AHEP‐0731 trial were excellent. Thrombotic complications were uncommon. Most children underwent cadaveric transplantation. The type of graft and the approach to reconstruct the inferior vena cava did not impact outcome.

### O-018. Intravenous Fosaprepitant, Neurokinin 1 (NK‐1) Receptor Inhibitor for Prevention of Chemotherapy Induced Nausea and Vomiting in Children: A Randomized, Double‐Blind, Placebo‐Controlled Study {#pbc27455-sec-0290}

[V. Radhakrishnan]{.ul} ^1^, A. Joshi^1^, J. Ramamoorthy^1^, S. Rajaram^1^, P. Ganesan^1^, T. Sagar^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Fosaprepitant, is a Neurokinin‐1 (NK‐1) receptor antagonist, approved in adults for the prevention of vomiting associated with administration of moderate to highly emetogenic chemotherapy drugs. The efficacy and safety of fosaprepitant in children is not known. Therefore, we conducted a phase 3 randomized trial to assess the safety and efficacy of fosaprepitant in children.

**Design/Methods**: The study was a phase 3, single centre, double blind, randomized placebo controlled trial. Children aged 1‐12 years with documented malignancy, who were scheduled to receive moderate to highly emetogenic chemotherapy, were randomly assigned to arm A (Fosaprepitant) or arm B (Placebo). Arm A received intravenous ondansetron (0.15 mg/kg) plus dexamethasone (0.075 mg/kg) followed by fosaprepitant (3 mg/kg) short infusion. Arm B received intravenous ondansetron (0.15 mg/kg) plus dexamethasone (0.15 mg/kg) followed by normal saline as placebo. Ondansetron and dexamethasone were continued for 48 hours after completion of chemotherapy. Primary end‐point of the study was the proportion of patients who achieved a complete response (defined as no vomiting, no retching) during the 25--120 hours (delayed phase) after administration of fosaprepitant. Secondary end‐point was proportion of patients who achieved complete response during the acute (0--24 hours) and overall phases after administration of fosaprepitant.

**Results**: 135 patients were analyzed (68 in fosaprepitant arm and 67 in placebo arm). Complete response rates were significantly higher in fosaprepitant arm compared to placebo arm during acute phase (84% vs. 57%, p\<0.001), delayed phase (79% vs. 51 %, p\<0.001) and overall phases (69% vs. 42%, p=0.0014). Three (4%) patients in fosaprepitant arm and fourteen (21%) patients in the placebo arm required rescue anti‐emetics (p=0.004). No fosaprepitant related grade 3‐4 adverse events were observed.

**Conclusions**: Addition of fosaprepitant to ondansetron with dexamethasone is safe and effective for the prevention of chemotherapy induced vomiting in children being treated with moderately or highly emetogenic chemotherapy.
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### O-019. Pitfalls in the Management of Ewing Sarcoma in a Developing Country {#pbc27455-sec-0310}

[S. Totadri]{.ul} ^1^, A. Trehan^1^, D. Bansal^1^, A.K. Saxena^2^, R. Kapoor^3^, R. Samujh^4^

*^1^Post Graduate Institute of Medical Education and Research, Pediatric Hematology Oncology unit‐ Department of Pediatrics, Chandigarh, India; ^2^Post Graduate Institute of Medical Education and Research, Department of Radiodiagnosis & Imaging, Chandigarh, India; ^3^Post Graduate Institute of Medical Education and Research, Department of Radiotherapy, Chandigarh, India; ^4^Post Graduate Institute of Medical Education and Research, Department of Pediatric Surgery, Chandigarh, India*

**Background/Objectives**: The study evaluated the outcome of patients with non‐metastatic Ewing sarcoma (ES) on therapy in a low and middle‐income country (LMIC).

**Design/Methods**: This was a retrospective case review of children with ES from January 2011 till December 2017. Neoadjuvant chemotherapy with VDC (vincristine, doxorubicin, cyclophosphamide) and IE (ifosfamide, etoposide) was administered 3‐weekly for 48 weeks. Reassessment was planned at week 12, followed by local therapy (surgery/radiotherapy or both).

**Results**: Forty‐one patients with mean age 8 years (range:0.7‐14); received therapy. The primary site was axial, appendicular and extra‐skeletal in 26 (63%), 13 (32%) and 2 (5%) patients. Median time from start of chemotherapy till local therapy (surgery/radiotherapy) was 16 weeks (IQR: 14;18.8). Local therapy included surgery, radiotherapy or both modalities in 5 (12%), 16 (39%) and 16 (39%) patients. Two patients abandoned therapy and two succumbed to neutropenic sepsis prior to local therapy. Median duration of follow up was 18 months (IQR: 12;27). Event‐free survival (EFS) and disease‐free survival were 43.5±11.7% and 52.3±12.0%. Thirteen patients (32%) had relapse/progression. Delay in local therapy beyond 16 weeks emerged as an independent predictor of relapse/progression on multivariate analysis \[HR:5.3, 95%CI: 1.1‐24.9, P=0.033\]. The median time to radiological reassessment, surgery and radiotherapy was 13, 16 and 19.5 weeks. Patients with delay in local therapy (18 patients) had a greater median interval from the start of chemotherapy to radiological reassessment (14 vs. 12 weeks, P=0.001), surgery (18 vs. 15 weeks, P\<0.001) and radiotherapy (20 vs. 16 weeks, P\<0.011). Paucity of beds contributed to delay in neoadjuvant chemotherapy. The interval between the first and the cycle prior to local therapy was greater in patients with delayed local therapy (14 vs. 10 weeks, P\<0.001).

**Conclusions**: Coordinated efforts to ensure well‐timed admission for chemotherapy, radiological reassessment and local therapy are essential for improving outcome of these tumours in LMICs.

### O-020. Treatment and Outcome of Patients with Thoracic Soft Tissue Ewing Tumors: A Report from the Cooperative Weichteilsarkom Studiengruppe Trials {#pbc27455-sec-0320}

[G. Seitz]{.ul} ^1^, I.C. Urla^2^, M. Sparber‐Sauer^3^, A. Schuck^4^, C. Vokuhl^5^, B. Blank^3^, T. Klingebiel^6^, J. Fuchs^2^, E. Koscielniak^3^

*^1^University Hospital Marburg, Department of Pediatric Surgery, Marburg, Germany; ^2^University Children\'s Hospital, Department of Pediatric Surgery, Tuebingen, Germany; ^3^Klinikum Stuttgart ‐ Olgahospital, Pediatrics 5 ‐ Oncology‐ Hematology‐ Immunology, Stuttgart, Germany; ^4^University Hospital, Department of Radiation Therapy, Münster, Germany; ^5^University Hospital Schleswig‐Holstein, Department of Paidopathology, Kiel, Germany; ^6^University Hospital, Department of Pediatric Hematology / Oncology, Frankfurt / Main, Germany*

**Background/Objectives**: Soft tissue Ewing tumors (STET) including primitive neuroectodermal tumors (PNET) and extraosseous Ewing sarcoma are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. The aim of the study was to analyze patients treated within five different Cooperative Weichteilsarkom Studiengruppe (CWS) trials suffering from intrathoracic and chest wall STET regarding treatment, outcome and surgical procedures.

**Design/Methods**: 62 patients from 0 to 21 years suffering from intra‐thoracic or chest wall STET were enrolled into five different CWS trials from 1981 to 2014. There were 31 males and 31 females. A retrospective chart analysis was carried out. Institutional review board approval was obtained for all trials.

**Results**: The median age of the patients was 7 years. The 5‐years overall (OS) and event free (ES) survival rates were 58.7% \[52.7‐64.7\] and 52.8% \[46.8‐58.8\]. Patients with intra‐thoracic tumor localization (n=24) had a worse outcome (ES: 37.5% \[27.5‐37.5\]) compared to those with chest wall tumors (n=38; ES: 62.3% \[54.3‐70.3\], p=0.008). Patients ≤10 years (n=38) had a better survival compared to those \>10 years (ES: 65.7% \[57.7‐73.7\] vs. 31.3% \[21.3‐41.3\], p=0.01). Tumor size ≤5 cm (n=15) was associated with significantly better survival compared to a size \>5cm (n=47, ES:93.3% \[87.3‐99.3\] vs. 40% \[33‐47\], p=0.002). Primary resections were carried out in 36 patients, of which 75% were incomplete resulting in inferior ES (p=0.006). Incomplete secondary resections were performed in 19/40 with no impact on the ES. Radiotherapy did not improve the survival of the patients.

**Conclusions**: Thoracic STET are rare and aggressive tumors with an inferior outcome. Positive predictive factors for outcome are age ≤10 years, size ≤5cm, and localization at the thoracic wall.

### O-021. Activating Mutations in the MAP‐Kinase Pathway Define Non‐Ossifying Fibroma of Bone {#pbc27455-sec-0330}

[D. Baumhoer]{.ul} ^1^, M. Kovac^1^, A. Flanagan^2^, W. Hartmann^3^

*^1^University Hospital Basel, Bone Tumour Reference Centre at the Institute of Pathology, Basel, Switzerland; ^2^RNOH, Histopathology Department, Stanmore, United Kingdom; ^3^University Hospital Münster, Gerhard‐Domagk‐Institute of Pathology, Münster, Germany*

**Background/Objectives**: Non‐ossifying fibroma (NOF) is considered the most common benign and self‐limiting lesion of bone and it has been estimated that 30‐40% of children develop one or more of those lesions during skeletal growth. The true incidence is, however, unknown, and it seems likely that many lesions stay undetected due to lack of symptoms and spontaneous resolution. Due to the high frequency and clinical course, NOF has been regarded by many authors to represent a developmental abnormality rather than an actual neoplasm but the molecular pathogenesis has not been elucidated so far.

**Design/Methods**: We analysed 61 tumour samples from 59 patients with histologically confirmed NOF using whole exome sequencing and customized Illumina gene panels.

**Results**: We detected pathogenic hotspot mutations in *KRAS* in 38/59 (64.4%) individuals with p.G12A/D/V and p.G13D mutations accounting for two thirds of cases. Further we identified *FGFR1* mutations in 8/59 (13.6%) individuals and *NF1* mutations in two patients with clinically diagnosed neurofibromatosis type 1. All mutations were mutually exclusive and did not affect the germ line except for both *NF1* mutations. All mutations recorded cause active MAP‐kinase signalling and taken together, *KRAS*, *FGFR1* or *NF1* mutations were found in 48/59 patients (81.4%).

**Conclusions**: The pathogenicity of the *KRAS* and *FGFR1* mutations identified in this study has been established in a variety of carcinomas, sarcomas and haematological cancers but has only recently been described also in vascular malformations and benign endometriosis. Our findings therefore add another clearly benign tumour to the spectrum of *KRAS*‐ and MAP‐kinase signalling‐driven lesions. Although activated MAP‐kinase signalling seems to represent the driving force in the majority of NOF, the self‐limiting and uniformaly benign clinical course suggests that altered MAP‐kinase signalling either diminishes over time or at least is not sufficient to prevent autonomous regression and resolution.

### O-022. Effect of Timing of Pulmonary Metastasis Occurrence on the Outcome of Metastasectomy in Osteosarcoma Patients {#pbc27455-sec-0340}

[G. Ahmed]{.ul} ^1^, M. Zamzam^2^, A. Kamel^3^, S. Ahmed^2^, A. Salama^4^, I. zaki^5^, N. kamal^6^, M. Elshafiry^7^

*^1^Faculty Of Medicine Helwan University &Children Cancer Hospital Egypt 5735, Surgery, cairo, Egypt; ^2^Children Cancer Hospital Egypt 57357, pediatric oncology, cairo, Egypt; ^3^National Cancer Institute‐ Cairo University‐ &Children\'s Cancer Hospital 57357‐ Egypt, Pediatric oncology, cairo, Egypt; ^4^National Cancer Institute‐ Cairo University‐ &Children\'s Cancer Hospital 57357‐ Egypt, pathology, cairo, Egypt; ^5^National Cancer Institute‐ Cairo University‐ &Children\'s Cancer Hospital 57357‐ Egypt, radiology, cairo, Egypt; ^6^Children Cancer Hospital Egypt 57357, Research, cairo, Egypt; ^7^National Cancer Institute‐ Cairo University‐ &Children\'s Cancer Hospital 57357‐ Egypt, surgical oncology, cairo, Egypt*

**Background/Objectives**: Complete metastasectomy is the best predictor of survival in osteosarcoma patients with pulmonary metastases. Controversy existed in the literature about the prognostic significance of the timing of occurrence of lung metastasis.

**Design/Methods**: The study included all osteosarcoma patients with pulmonary metastases treated by metastasectomy in our hospital from Jan. 2008 to end of Dec. 2016. All patients that had metastasectomy were categorized into 3 groups: Group 1: patients with lung metastases at initial presentation; Group 2: patients with lung metastases developed during chemotherapy; Group 3: patients with lung metastases developed after completion of chemotherapy. Data were obtained retrospectively and follow‐up was obtained until the end of June 2017.

**Results**: The study included 170 patients with identified pulmonary nodules of whom 99 patients had metastasectomy with (149 thoracotomies). Eleven patients had non‐malignant pulmonary nodules and were excluded. The other 88 patients were Group 1n=37, Group 2n=18 and Group 3n=33. The mean follow‐up duration was 35 months (range 8 to 99 months). Post metastasis 5 years overall survival (OS) and event‐free survival (EFS) were 41% a 21% respectively. Post metastasis 5‐year OS and EFS in the 3 groups were 34.3%, 18% in(Group 1), 8% 6.5% in(Group 2) and 52 %, 25% in (Group 3) with P \< 0.001. The timing of lung metastasis and number of lung nodules were the only significant factors associated with survival in univariate analysis

**Conclusions**: The timing of occurrence of lung metastasis is an important prognostic factor among osteosarcoma patients eligible for metastasectomy. Patients who had metastasis during chemotherapy had the worst survival
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### O-023. Global Retinoblastoma Presentation 2017 {#pbc27455-sec-0360}
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**Background/Objectives**: Retinoblastoma (Rb) outcomes have improved in recent years in high‐income countries, however this improvement has not been seen in most low‐ and middle‐income countries (LMICs). The main reasons are late presentation and limited specialized treatment services. We aimed to investigate the global Rb presentation mode in a single year according to national income level.

**Design/Methods**: A 1‐year cross‐sectional analysis of the presentation of treatment‐naïve Rb patients that presented to participating centers during 2017. Associations between clinical parameters at presentation and national income levels were investigated.

**Results**: The cohort included 2,106 children from 100 countries from 6 continents. Of these, 304 (14%) were from low‐income, 1,385 (66%) from middle‐income and 417 (20%) from high‐income countries. Mean presentation age was 27.0±24.4 months. A significant correlation was found, with higher national income level being associated with younger presentation age (p\<0.001). Familial Rb was reported in 108 (5%) children with a significant trend for higher proportions of patients with familial disease in higher income nations (p\<0.001). On ophthalmic examination, 262 (12%) children presented with extraocular Rb, 98% from LMICs. Of the children from LMICs who presented with intraocular Rb, 904 (54%) had the most advanced form (cT4). Distant metastases were detected at presentation in 172 (8%) children, 98% of which were from LMICs, and 18 (\<1%) died at presentation, all from LMICs.

**Conclusions**: According to this study, which represents approximately 1/4 of the estimated global incidence of Rb during a calendar year, children from LMICs (80% of the cohort), present at a later age, with more advanced disease, and are at higher risk of death from metastatic disease. There was significantly less familial disease in LMICs probably due to late presentation resulting in death. Given that Rb is a curable disease, these data are alarming, necessitating immediate intervention at local and global levels.

### O-024. Extra‐Appendicular Neuroendocrine Tumors: A Report from the TREP Project (2000‐2018) {#pbc27455-sec-0370}

[C. Virgone]{.ul} ^1^, F. De Corti^1^, A. Crocoli^2^, R. Alaggio^3^, L. Tonegatti^4^, S. Chiaravalli^5^, M. Ogunleye^1^, F. Destro^6^, G. Bisogno^7^, A. Ferrari^5^, P. Dall\'Igna^1^

*^1^University‐Hospital of Padua, Pediatric Surgery‐ Department of Women\'s and Child\'s Health, Padua, Italy; ^2^Bambino Gesù Pediatric Hospital, Pediatric Surgery, Rome, Italy; ^3^Children\'s Hospital of Pittsburgh, Department of Pathology, Pittsburgh, USA; ^4^Spedali Civili di Brescia, Pediatric Surgery, Brescia, Italy; ^5^Istituto Nazionale Tumori, Pediatric Oncology, MIlan, Italy; ^6^Vittore Buzzi Children\'s Hospital, Pediatric Surgery, Milan, Italy; ^7^University‐Hospital of Padua, Pediatric Oncology ‐ Department of Women\'s and Child\'s Health, Padua, Italy*

**Background/Objectives**: Extra‐appendicular neuroendocrine tumours (NETs) are very rare tumors, arising from chromaffin cells. Pancreas and bronchi are the most common site of onset. Prognosis may vary widely depending mainly on site and stage at presentation. A complete surgical resection is still the cornerstone of treatment.

**Design/Methods**: A total of 25 patients younger than 18 years with a diagnosis of extra‐appendicular NETs were prospectively registered from January 2000 to March 2018, within the TREP project (Rare Tumors in Pediatric Age). Complete data about tumor\'s features, diagnosis, treatment and follow‐up were available for 24/25 patients.

**Results**: Among 25 patients, 13 were males, 12 females. Age ranged from 70 to 222 months (mean 161 mo). Localization of NET was bronchi in 9 cases, pancreas in 11, liver, Meckel diverticulum and the thymus in 1 each. In 2 patients the primary site remained undetermined (mediastinum and gastrointestinal tract). 10/25 had metastasis at diagnosis (5 pancreatic, 1 bronchi, 1 thymus, 1 liver and 2 of undetermined origin) and died of disease or were lost at follow‐up with stable/progressive disease. Among the localized tumors, none experienced relapse and 14/15 are in complete remission (1 missing data) after surgical treatment only.

**Conclusions**: Reported data and our experience showed that a wide heterogeneity of presentation and outcome affects this group of tumors. A complete surgical resection, when available, was the main prognostic factor of good outcome. Other therapies may have a role in prolonging survival in metastatic disease. International cooperative networks are necessary to better define epidemiology, prognostic factors and overall survival.

### O-025. Congenital Anomalies and Risk of Childhood Leukemia: A Pooled Analysis from the Childhood Leukemia International Consortium (CLIC) {#pbc27455-sec-0380}
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**Background/Objectives**: The association between Down syndrome and childhood leukemia is well established. Less is known about the possible relationships of other chromosomal and non‐chromosomal anomalies with childhood leukemia risk. Due to the rarity of these conditions, it is difficult to assess associations. We pooled data from multiple studies to investigate the associations of different congenital anomaly categories with childhood leukemia subtypes.

**Design/Methods**: We pooled data from the Childhood Leukemia International Consortium on 20 case‐control studies (including 3 registry‐based studies) conducted in 13 countries. Anomalies were categorized as: 1) Down syndrome; 2) other chromosomal anomalies; and 3) non‐chromosomal anomalies. We used multivariable logistic regression to estimate the adjusted odds ratio (aOR) and 95% confidence interval (CI) for each anomaly category and the risk of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), adjusting for infant sex, gestational age, birthweight, maternal age, paternal age, and study center.

**Results**: Analyses included 15,148 childhood leukemia cases and 193,427 controls. The presence of Down syndrome was associated with increased risk of ALL (aOR=24.0, 95%CI: 16.0‐35.9) and AML (aOR=94.2, 95%CI: 57.3‐154.9). These associations were not observed among children with other chromosomal anomalies (ALL aOR=1.57, 95%CI 0.46‐5.37 and AML aOR=3.26, 95%CI: 0.44‐24.26). There was a slightly increased risk of ALL associated with presence of non‐chromosomal anomalies (aOR=1.22, 95%CI: 1.10‐1.37) that was stronger when analyses were restricted to data from the registry‐based studies (aOR=1.55, 95%CI: 1.29‐1.85). An association of AML with non‐chromosomal anomalies was observed only in registry‐based studies (aOR=1.80, 95%CI: 1.20‐2.71).

**Conclusions**: Our results suggest children with non‐chromosomal anomalies have an increased risk of ALL. Additional work is needed to identify specific anomalies underlying this association. This information could be utilized for improved cancer surveillance in affected children and will provide insight into ALL susceptibility.

### O-026. Towards Improved Cancer Care for the 15 to 39 Year Age Group in Canada: Achievements of the Canadian AYA Cancer Task Force {#pbc27455-sec-0390}
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**Background/Objectives**: Adolescents and young adults (AYA) aged 15‐39 years of age have unique needs which are not met by the dichotomous pediatric‐adult healthcare system in Canada.

**Design/Methods**: The Canadian AYA Task Force on cancer was formed in 2008 to address this gap in care. Three working groups were formed in the final 2 year mandate of the Task Force to address: METRICS, ONCOFERTILITY and SUSTAINABILITY. Various methods were undertaken by the working groups including: an international workshop, literature reviews, administrative data analysis (last two decades), and surveys. Groups were tasked with producing a final report in each of these areas.

**Results**: METRICS: *Incidence*: There has been an 18.2% increase in cancer cases in 15‐29 year olds. Survival: 5 year survival rates increased by 6.2% and 9.8%, in 15‐29 and 30‐39 year age groups respectively. *Palliation*: Most AYA cancer deaths occur in hospital (73%). Psychosocial issues: Emotional support was rated negatively by both AYA males (24.1%) and females (26.2%). *Survivorship*: Cancer survivors had similar achievement of post‐secondary education and higher unemployment compared to the general population. *Research*: AYA‐specific cancer research represented 0.4% of cancer research in Canada. *Available clinical trials*: 32.9% of trials were for a cancer prevalent among AYAs. ONCOFERTILITY: A toolkit and knowledge to action plan has been developedto support clinical fertility discussions. SUSTAINABILITY: Task Force funding was ended in 2016 in favour of a systems‐integrated approach. The new AYA National Network consists of representatives from all provincial cancer agencies and Health Ministries, interdisciplinary healthcare providers and AYA survivors. Charged with remedying systemic gaps in care, they will focus initially on education, capacity building, quality care, metrics, and oncofertility.

**Conclusions**: Canada has taken a cancer control perspective in establishing the needs for and barriers to cancer AYA health care and the metrics necessary for implementing change.
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### O-027. Mutational Landscape in Pediatric Patients with Myelodysplastic Syndromes {#pbc27455-sec-0410}

[W. An]{.ul} ^1^, L. Chao^1^, W. Yang^1^, Z. Xiaofan^1^

*^1^Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences & Peking Union Medical College, Pediatric blood diseases center, Tianjin, China*

**Background/Objectives**: Myelodysplastic syndromes (MDS) are uncommon in children. There are limited known on the gene mutations landscape in pediatric patients with MDS.

**Design/Methods**: We performed both whole exome sequencing and targeted sequencing on 30 pediatric MDS patients and targeted sequencing on 57 pediatric cases. The diagnosis was according to the 2016 revised criteria of the WHO for childhood MDS. DNA was obtained from bone marrow. Germline status was analyzed by CD3+ T‐cell or oral epithelial cells.

**Results**: We found 23 germline mutations in 10 distinct genes, and 176 somatic mutations in 52 distinct genes with mutation loads varying from 2% to 99%. Of patients, 76% had at least 1 gene mutation. Nine genes were mutated in greater than 5% of patients, including *PTPN11* 12.6%, *SETBP111*.5%, *ASXL1* 10.3%, *WT1* 9.2%, *RUNX1* 8%, *NRAS* 8%, *NF1* 6.9%, *GATA1* 4.6%, *FLT3* 4.6%. Germline mutation of *GATA2* and *SAMD9*/*SAMD9L* were detected in 8% and 5% of the patients. Mutation of *DNMT3A*, *TP53*, *SF3B1*, *SRSF2* were rare (1.1%, 2.3%, 0%, 1.1%,). genes associated with chromatin modification, RAS and transcriptional regulation, (27.8 %, 25.2%, and 19.1%, respectively). The multivariate analysis showed *SEBP11* and isolated deletion of chromosome 7 was significantly enriched in GATA2 mutated subjects, and NRAS and NF1 were significantly associated with WT1 and PTPN11 subjects, respectively (P\<0.05). Using copy number‐adjusted VAF, we reconstructed the clonal architecture to explore ancestral and subclonal mutations. ASXL1, RUNX1, and PTPN11 were more likely to be an ancestral mutation. The 5‐year overall survival (OS) was 57%. For patients with and without HSCT, the 5‐year OS was 92% and 40% (P\<0.001). Patients with deletion of chromosome 7, mutation of PTPN11 had worse OS. However, for patients accepted HSCT, there was no significant association between the genetic mutation and OS.

**Conclusions**: Collectively, our results help define the mutational landscape in MDS in children.

### O-028. Prognosis of Pediatric AML Patients with FLT3‐ITD is Predicted by DNA Methylation Pattern: JCCG Study JPLSG AML--05 {#pbc27455-sec-0420}
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**Background/Objectives**: Acute myeloid leukemia (AML) is a complicated disease characterized by various genetic alterations. Reportedly, DNA methylation patterns were associated with molecular features and clinical outcome, implying that the definition of DNA methylation patterns of AML was expected to reveal clinical and molecular features and survival in patients with AML. However, there are few reports of DNA methylation in pediatric patients with AML. Thus, we analyzed genome‐wide DNA methylation in pediatric patients with AML.

**Design/Methods**: We performed comprehensive DNA methylation analysis using Infinium MethylationEPIC BeadChip (Illumina, Inc., San Diego, CA, USA) in 64 pediatric patients with *de novo* AML (0--17 years) who participated in the Japanese AML‐05 trial conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group.

**Results**: Unsupervised hierarchical clustering based on methylation values of the 567 CpG sites, which showed most variable methylation values between 64 individuals, generated four clusters (clusters 1--4). These four clusters harbored their molecular features as follows: cluster 1, *RUNX1/RUNX1T1* and *KMT2A* rearrangement; cluster 2 and 4, *FLT3‐ITD* and high *PRDM16* expression; cluster 3, *CEBPA* biallelic mutations. In addition, we focused on CpG sites with significant difference in their methylation values between patients with and without FLT3‐ITD. Consequently, 15 *FLT3*‐ITD patients were divided into 8 and 7 patients (group A and B). Remarkably, 8 *FLT3*‐ITD positive patients classified group A showed significant worse overall survival (OS) and event‐free survival (EFS) when compared with 7 *FLT3*‐ITD patients classified group B (5‐year OS, 13% vs. 100%, *P* = 0.002; 5‐year EFS 0% vs. 86%, *P* \< 0.001).

**Conclusions**: We investigated DNA methylation patterns in pediatric AML patients, and prognosis of *FLT3*‐ITD patient was predicted by DNA methylation pattern. These finding implied that DNA methylation pattern was useful for risk stratification in pediatric AML.

### O-029. Preemptive Treatment with Recombinant Thrombomodulin for Children Who Developed Veno‐Occlusive Disease After Hematopoietic Stem Cell Transplantation: A Single Center Experience in Japan {#pbc27455-sec-0430}

[S. Yoshimura]{.ul} ^1^, C. Kiyotani^1^, T. Osumi^1,2^, Y. Shioda^1^, K. Terashima^3^, M. Kato^2,4^, D. Tomizawa^1^, K. Matsumoto^1,3,4^

*^1^National Center for Child Health and Development, Division of Leukemia and Lymphoma/Solid tumor‐ Children\'s Cancer Center, Tokyo, Japan; ^2^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^3^National Center for Child Health and Development, Division of Neuro‐Oncology‐ Children\'s Cancer Center, Tokyo, Japan; ^4^National Center for Child Health and Development, Division of Stem Cell Transplantation and Cellular Therapy‐ Children\'s Cancer Center, Tokyo, Japan*

**Background/Objectives**: Veno‐occlusive disease (VOD) is a life‐threatening complication after hematopoietic stem cell transplantation (HSCT). Because defibrotide is unavailable in Japan, recombinant thrombomodulin (rTM) is often used for the treatment of VOD. Although several reports on its effectiveness exist in adults, reports in children are limited. Here we report our experiences of preemptive therapy with rTM for children with VOD after HSCT.

**Design/Methods**: Case records of the 103 consecutive patients who received HSCT at our institution between 2013 and 2017 were reviewed.

**Results**: Eighteen patients (17%) were clinically diagnosed as VOD and were treated with rTM. Eleven (61%) were male and the median age at diagnosis was 3.5 years. Thirteen (72%) received myeloablative conditioning regimen, 10 (56%) received busulfan‐based regimen, and 3 (17%) received total body irradiation‐based regimen. Among all, 12 (67%) underwent allogeneic HSCT. All the patients received danaparoid and ursodeoxycholic acid for VOD prophylaxis. The median days from HSCT and the rTM initiation was 14.5 and the median administration period was 12 days. Only two patients met the modified Seattle or Baltimore diagnostic criteria at rTM administration, but 5 patients, including the two with severe VOD, eventually met the criteria. The reasons for early rTM administration before meeting the criteria in the 16 patients were coagulopathy such as transfusion‐refractory thromobocytopenia or elevated D‐dimer level (81%, n=13), mild elevation of total bilirubin or liver enzymes (38%, n=6), abnormal abdominal ultrasonographic findings (31%, n=5), hepatomegaly (13%, n=2), and mild weight gain (13%, n=2). Two patients with severe VOD required additional therapy with corticosteroid. There were no hemorrhagic events, respiratory failure or death due to VOD.

**Conclusions**: Preemptive treatment with rTM in early phase of VOD development, taking notice of laboratory abnormalities and abdominal ultrasonographic findings in addition to coagulopathy in children is feasible and may prevent the progression of life‐threatening VOD.

### O-030. Adult Sexual Function After Childhood Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study {#pbc27455-sec-0440}
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**Background/Objectives**: With a growing number of pediatric allogeneic hematopoietic stem cell transplantation (HSCT) recipients surviving, research is now focusing on their long‐term quality of life. This retrospective multicenter study focused on sexual functions at adult age.

**Design/Methods**: A total of 97 adult males treated by allogeneic HSCT in Denmark or Finland 1980‐2010 before the age of 17, completed the Derogatis Interview for Sexual Functioning self‐report. They were on average 28.7 (range 18.5‐47.0) years at the time of assessment with a mean follow‐up time of 19.0 (range 7.7‐34.6) years. An age‐matched control group was recruited with 56 men without a history of HSCT.

**Results**: Significantly fewer HSCT recipients lived in a relationship (35%) compared to the healthy controls (80%, p\<0.001). HSCT recipients reported significantly poorer sexual functions compared to the healthy control group, F(5,144)=4.08, P=0.002, Wilk\'s Λ=0.876, ηp2 =0.124. A significant interaction between group and relationship status indicated that HSCT recipients living in relationship had comparable sexual functioning to their healthy peers, F(5,144)=3.57, P=0.005, Wilk\'s Λ=0.890, ηp2=0.110. However, HSCT recipients who were not in a relationship had significantly poorer quality of orgasms (P\<0.001), less sexual behaviour (P\<0.001), sexual fantasies (P=0.001) and sexual drive (P=0.004) compared to the control group. In 2‐step regression analyses, cancer treatment pre‐HSCT, total body irradiation and smaller testicular size were related to poorer sexual functions, but significantly more of the variation in outcome was explained by self‐reported depressive symptoms, older age and by HSCT recipients who were currently not sexually active.

**Conclusions**: Among men who have undergone childhood allogeneic HSCT, self‐reported problems with orgasms, drive, sexual fantasies and experiences were common in patients who were not living in a relationship at adult age. The causes seem multifactorial. Increasing age, the absence of sexual experiences, depressive symptoms as well as cancer treatment pre‐HSCT, total body irradiation and gonadal damage were risk factors.
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### O-031. Tumor Volume and Under‐Nutrition at Diagnosis Adversely Affect the Outcome of Children with Wilms Tumor: A Study of 200 Patients {#pbc27455-sec-0460}
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**Background/Objectives**: Prognostic factors affecting the outcome of children with Wilms tumor (WT) from developing countries are infrequently reported.

**Design/Methods**: Design: Retrospective, case‐record analysis. Setting: University, Government‐hospital. Period: 11‐years (2005‐2016). The tumor‐volume at diagnosis was calculated as: V= length x width x thickness x 0.523 ml. Dimensions were obtained from CT‐scan. Weight‐for‐age z‐scores at diagnosis were derived. WHO criteria was utilized for assessment of nutritional status.

**Results**: Two‐hundred children were diagnosed with WT. The median‐age was 33.5 months (IQR: 18, 58). The distribution of stage was I, II, III, IV and V in 29.8%, 35.6%, 14.3%, 16.7% and 3% patients, respectively. Intermediate‐risk category was observed in majority (83.8%). The protocol administered to majority (88%) was SIOP‐2001‐WT. Radiotherapy was administered to 32 (20.2%). Treatment refusal/abandonment was observed in 20.5%. Therapy was completed in 158. The treatment‐related mortality was 13/179 (7.2%). The mean follow‐up duration was 39±36 months. At diagnosis, 68/190 (35.7%) patients were under‐weight, of whom 42.6% were severely under‐weight. The tumor‐volume at diagnosis was 481.7 ml (n=152, IQR: 306.9, 686.8), that reduced to 109.8 ml (n=77, IQR: 151.2, 222) following neo‐adjuvant chemotherapy. A positive‐correlation was observed between tumor‐volume and symptom‐diagnosis‐interval (p\<0.001). The reduction in tumor‐volume was comparable among patients across histology risk‐groups and stage. Twenty‐six (16.5%) patients relapsed. The 3‐year OS and EFS of patients who completed therapy was 83.5±4.9% and 78.5±5.3%, respectively. OS for patients with stage I‐V disease were 92.3±5.2%, 77.4±6.4%, 88±11.7%, 76±12.9% and 50±21.2%, respectively (p=0.017). The OS of patients with low, intermediate and high‐risk histology was 91.7±9.6%, 85.1±4.3% and 57.1±19.6%, respectively (p=0.018). A larger tumor‐volume \[OR: 0.998, (95% CI: 0.997‐0.999)\] and a lower weight‐for‐age z‐score \[OR: 1.7, (95% CI: 1.19‐2.45)\] predicted death/relapse.

**Conclusions**: Under‐nutrition and a larger tumor‐volume at diagnosis adversely affect survival of patients with WT. Treatment refusal/abandonment observed in 1/5th patients is concerning and necessitates improvement in supportive infrastructure.

### O-032. The Diagnostic Accuracy and Clinical Utility of Paediatric Renal Tumour Biopsy: Report of the UK Experience in The SIOP WT 2001 Trial {#pbc27455-sec-0470}
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**Background/Objectives**: The International Society of Paediatric Oncology (SIOP) protocols recommend pre‐operative chemotherapy appropriate for Wilms tumours (WT) in children with renal tumours aged ≥6 months, reserving biopsy for 'atypical' cases. The Children\'s Cancer and Leukaemia Group (CCLG) joined the SIOP WT 2001 study but continued the national practice of biopsy at presentation.

**Design/Methods**: Retrospective study of concordance between locally reported renal tumour biopsies and pathology panel nephrectomy diagnoses of children enrolled by CCLG centres in SIOP WT 2001 Study.

**Results**: Biopsy reports were available for 552/787 children with unilateral tumours. 36/552 (6.5%) were non--diagnostic: 2 normal tissue, 12 necrotic, 9 insufficient sample and 13 indeterminate results (disproportionately non‐WTs). The sensitivity and specificity of biopsy to identify tumours that did not require SIOP empirical pre‐operative chemotherapy were 86.0% and 99.6%, respectively. 13/548 (2.4%) biopsy results were discordant with nephrectomy; non‐WTs other than renal cell carcinoma and clear cell sarcoma (CCSK) were poorly recognised. In children aged 6‐119 months, 480/518 (91.6%) had WT or nephroblastomatosis. 5/518 (1%) had benign tumours, only one diagnosed on biopsy. Biopsy results correctly changed clinical management in 25/518 (4.8%), including identifying 19/20 CCSKs, but would have led to overtreatment in 5/518 (1%) or undertreatment in 4/518 (0.8%). In children aged ≥10 years, biopsy correctly changed management in 5/19 (26%) cases with no discordance.

**Conclusions**: Biopsy is less effective at identifying non‐WTs than WTs and rarely changes management in younger children. Biopsy should be reserved for children ≥10 years and in younger children with clinical or radiological features inconsistent with WT.

### O-033. Nephroblastoma with Intravenous Thrombosis: Analysis of the Key Elements of Surgical Management: A Bicentric Series of 34 Patients Over 20 Years {#pbc27455-sec-0480}
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**Background/Objectives**: About 5% of nephroblastomas are complicated by thrombosis of the renal vein and vena cava, which sometimes extends to the right atrium. If the oncological prognosis does not seem to be compromised by this complication, the surgical management is complex and not standardized. The aim of this work was to try to identify key elements of surgical management through the analysis of a series of patients.

**Design/Methods**: A retrospective study was performed on 356 patients with nephroblastoma operated in two pediatric surgery departments from January 1996 to June 2016. The inclusion criteria were the presence of a renal vein and/or vena cava thrombus at the time of diagnosis.

Tumor stage, pre‐ and post‐operative treatment, preoperative imaging, operative report, pathology, per and postoperative complications, long‐term follow‐up were collected.

**Results**: Thirty‐four patients had inclusion criteria (9.5%) with 12 patients (35%) with right atrial extension. One patient had Budd Chiari syndrome at diagnosis. All patients received neoadjuvant chemotherapy according to SIOP 1993 and then SIOP 2001 protocols.

A regression of the tumor thrombus was observed in 14 cases (33%). Sixteen patients with persistent intra‐ auricular thrombus were operated by sterno‐laparotomy with cardiopulmonary bypass.

The thrombus could be removed in one piece with nephrectomy in 25 cases and after fragmentation in 6 cases. Two massive bleeding occurred during surgical intervention and eight cava vein thrombosis with azygos drainage were observed.

Except for a death at diagnosis on pulmonary embolism, survival was 100% with a mean follow‐up of 6 years (1 year‐11 years).

**Conclusions**: An extensive surgery is feasible with a low complication rate. A neoadjuvant chemotherapy join to a proper combined surgical strategy (pediatric cardiosurgeons and pediatric surgical oncologist) proved to be effective in terms of surgical outcomes, resulting in a comparable survival with children with nephroblastoma without intravascular extension.

### O-034. Chemotherapy‐Induced Changes at the Resection Margins as Only Reason for Stage III Has a Significantly Lower Risk for Local Failure: The SIOP2001/GPOH Experience {#pbc27455-sec-0490}
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**Background/Objectives**: The SIOP Working classification includes a number of reasons for stage III, including necrotic lymph nodes (LN) or chemotherapy‐induced changes (CIC) at resection margins (RM). However, CIC are ignored in certain cases in other classifications. We thus hypothesized that CIC at RM as the only reason for stage III is not a risk denominator for local failure (local or combined relapse).

**Design/Methods**: Retrospective analysis of unilateral nephroblastoma patients registered on SIOP2001/GPOH Nephroblastoma study (2001‐2017, in Austria, Switzerland, Germany) with respect to their reason for stage III, viability and type of relapse. Median follow up was 5.2 years.

**Results**: Local stage distribution of 1384 unilateral tumours was: stage I 856 (62%), stage II 253 (18%), stage III 266 (19%). Relapse‐free‐survival (RFS) and overall‐survival (OS) for stage III was 78% and 84%, respectively. Reasons for stage III were: 35 (13%) CIC at RM, 32 (12%) nLN, 6 (2%) nLN & CIC at RM, 33 (12%) viable (v) RM, 72 (27%) vLN, 52 (19%) rupture or biopsy (RB) and 36 (13%) combinations of these. CIC at RM as compared to other local stage III had 5yrs‐RFS of 100% vs. 74% (p\<0.01) for any relapse, and 100% vs. 88% (p=0.07) for local failure. Similarly, 5yrs‐RFS for CIC at RM and/or nLN (n=69) vs. other local stage III was 86% vs. 74% (p=0.029) for any relapse, and 100% vs. 86% (p\<0.01) for local relapse. Comparison of 59 non‐irradiated (23 CIC at RM/nLN) patients showed similar results (100% vs. 81%, p=0.1).

**Conclusions**: Our results indicate that the current stage III criteria should be modified and CIC at RM (and to lesser extent nLN) could be ignored since local relapses are extremely rare despite lack of irradiation in 1/3 of the patients. In contrast, patients with rupture/open‐biopsy, viable LN metastasis or combinations have a significantly increased risk for local relapse.

### O-035. Outcomes Based on Histopathologic Response to Pre‐Operative Chemotherapy in Children With Bilateral Wilms Tumor: A Prospective Study (COG AREN0534) {#pbc27455-sec-0500}
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**Background/Objectives**: On NWTS‐5, 4‐year event‐free survival (EFS) estimates for patients with bilateral Wilms tumor (BWT) were 65% for favorable histology and 25% for diffuse anaplastic histology. The objective of AREN0534 was to improve outcomes using preoperative chemotherapy of limited duration and by modifying postoperative chemotherapy based on histopathologic response.

**Design/Methods**: Enrolled children were treated with vincristine (V), dactinomycin (A), and doxorubicin (D) for 6 or 12 weeks followed by surgery. Postoperative therapy was prescribed according to histopathologic response and stage using the SIOP system. Patients were treated with either regimen EE4A (VA), regimen DD4A (VDA), regimen I (vincristine, doxorubicin, cyclophosphamide (C) and etoposide (E), or regimen UH‐1 (VDCE and carboplatin) based on risk. The highest risk kidney classification determined the treatment group. Appropriate stage‐based radiation therapy was prescribed.

**Results**: There were 208 BWT of which 189 underwent pre‐nephrectomy chemotherapy and were evaluable. The 4‐year EFS and overall survival (OS) were 83% and 96%, respectively. Eighty‐four percent (163/189) of patients had definitive surgery by week 6 or week 12. There were 8 patients with completely necrotic "low‐risk" tumors and 26 patients with "high‐risk" post induction histology (9 blastemal‐type and 17diffuse anaplasia). One hundred and fifty‐five had "intermediate risk" histology (including 8 focal anaplasia). The most common histopathology within the intermediate‐risk group was mixed, followed by predominantly epithelial subtype. EFS and OS estimates were, respectively, 88% and 100% for completely necrotic tumors, 83% and 97% for intermediate risk, 89% and 100% for blastemal‐type, and 58% and 68% for diffuse anaplasia.

**Conclusions**: A risk‐adapted treatment approach for BWT based on prenephrectomy chemotherapy and postoperative histopathology results in excellent outcomes. Patients with BWT and diffuse anaplasia had the worst prognosis among the histologic subgroups.

### O-036. Treatment and Outcome of Children with Stage IV Nephroblastoma Identifying New Risk Categories; Results of SIOP 2001 Protocol {#pbc27455-sec-0510}
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**Background/Objectives**: To determine the outcome of children with metastatic Wilms tumor (mWT) treated according to SIOP 2001 protocol. To identify adverse prognostic factors.

**Design/Methods**: Patients were treated with 6w preoperative vincristine, dactinomycin and doxorubicin. Patients in complete remission (CR) remained on 3‐drug VAD; patients with remaining metastasis and/or high risk (HR) histology had 4‐drugs (cyclophosphamide/doxorubicin and VP16/carboplatin) with RT to the persisting and/or HR metastases. Central pathology review included a calculation of blastemal residual volume on the renal tumor. Kaplan‐Meier survival curves with log rank testing were performed as well as univariable/multivariable analyses.

**Results**: Between 2001‐2016, 645 patients with mWT were treated. Patients with mWT were older (53 vs 36 months, p\<0.0001) and had larger tumor volume (649 vs 389 ml, p\< 0.0001) compared to patients with localized WT. Local stage distribution in mWT was 26/19/54% for stage I/II/III, respectively (5y‐EFS of 84/74/69%) and 12/74/14% had low, intermediate or high risk histology (5y‐EFS of 92/79/29%). Sixty‐three percent were in CR postoperatively with 14% having metastasectomy. Patients in CR after chemotherapy ± metastasectomy had a better outcome than patients with multiple unresectable metastases (5‐year OS 91%, 87% and 66%, resp. p \< 0.0001). After a median follow‐up of 61 months 75% of the patients were event‐free and 84% alive. Combined metastases had a 5y‐OS of 74% vs 84% for either pulmonary or extra‐pulmonary metastases (p=0.05). Boys had a significantly better 5y‐OS than girls (86% vs 77%, p=0.02). Residual blastemal volume \>10 ml (5y‐EFS 41% vs 86%, p\<0.0001) and \>150 ml of tumour volume at surgery (63% vs 79%, p\<0.0001) influenced adversely. In the multivariable analysis only high‐risk histology and blastemal residual volume correlated with inferior EFS.

**Conclusions**: Patients with mWT have a relative good outcome although subgroups with inferior outcome are identified.
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### O-037. Role of Radiotherapy in Atypical Teratoid/Rhabdoid Tumours (AT/RT): An Analysis of The EU‐RHAB Registry, HIT/HIT‐SKK, AT/RT‐ZNS‐2004, and RHABDOID 2007 {#pbc27455-sec-0530}
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**Background/Objectives**: An atypical teratoid/rhabdoid tumour (AT/RT) is a rare malignancy in childhood originating from the central nervous system. The aim of this analysis was to evaluate the role of radiotherapy (RT) in patients with AT/RT.

**Design/Methods**: We retrospectively analyzed data of patients registered in the EU‐RHAB registry or its precursors HIT/HIT‐SKK, AT/RT‐ZNS‐2004, and RHABDOID 2007. Survival data was analyzed using the Kaplan Meier method. In a multivariate Cox\'s regression RT was used as time‐dependent covariate.

**Results**: Data from 189 patients (119 m/70 f; median age 1.6 years (y) (range, 0‐26.7 y)) was evaluable. 47 patients underwent gross total resection, 108 subtotal, and 23 biopsy only. Chemotherapy was applied in 180 patients. 131 patients received RT (RT group), 58 did not (non‐RT group). The median total local or spinal doses were 54 Gy (range, 19.8‐66.0 Gy) and 35.1 Gy (range, 17.6‐48.6 Gy), respectively. The median follow‐up time was 1.9 y (range, 0.01‐20.1 y). The use of RT was an independent prognostic factor for overall survival (OS) and event‐free survival (EFS) with a hazard ratio of 0.52 (p=0.02) and 0.78 (p=0.038). 1y and 3y OS rates were 88.5% and 52.0% in the RT group vs. 26.5% and 10.5% in the non‐RT group (p\<0.001). 1y and 3y EFS rates were 63.7% and 40.7% in the RT group vs. 21.0% and 14.4% in the non‐RT group (p=0.009; p\<0.001). This advantage of RT was observed independent of age. OS and EFS were superior with protocol‐compliant treatment compared to protocol deviations (p=0.029; p=0.016). Regardless of M‐Stage, craniospinal RT could not prove any positive impact on OS or EFS when compared to local RT.

**Conclusions**: Our analysis reveals RT as an independent positive prognostic factor for OS and EFS in children with AT/RT. However, optimal combined treatment strategies have to aim for further reduction of late effects in future.

### O-038. Sonic Hedgehog Methylation Subgrouping is a Prognostic Factor for Young Children with Nodular Desmoplastic Medulloblastoma: A Report of Children\'s Oncology Group Study ACNS1221 {#pbc27455-sec-0540}
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**Background/Objectives**: ACNS1221 was a single‐arm multicenter trial of conventional chemotherapy for children\<4y with localized nodular desmoplastic medulloblastoma and medulloblastoma with extensive nodularity (ND/MBEN), based on a modified HIT SKK2000 regimen that excluded intraventricular methotrexate. The trial closed prematurely for an excess of relapses. In this report we describe the methylation profile and the final survival outcome of the enrolled cohort.

**Design/Methods**: DNA methylation was performed on prospectively collected tumor samples using Infinium MethylationEPIC BeadChip and profiled on DKFZ molecular neuropathology 2.0 classifier. DNA copy‐number variants were inferred from DNA methylation arrays using Conumee. Methylation profiles were added to a founder cohort of 87 infant SHH‐MB and analyzed by t‐distributed stochastic neighbor embedding (t‐SNE) to delineate SHH‐I and SHH‐II subtypes

**Results**: The cohort included 25 eligible patients (18 ND, 7 MBEN; median age 18.7 months \[7.1‐42.9\] at diagnosis). All tumors clustered within the SHH group and separated into 2 subtypes: 11 SHH‐I (44%) and 14 SHH‐II (56%). SHH‐I patients were significantly older at diagnosis than SHH‐II patients (26.9 vs. 14.2 months). Most MBEN were SHH‐II (86%) but no significant association was found between histology and subgrouping. Chromosome 2 gain was exclusively described in SHH‐I tumors. Twelve patients relapsed (8 SHH‐I and 4 SHH‐II) at a median time of 9.8 months (range, 8.9‐13.7). While the 2y PFS for entire cohort was 52% (±10%), the 2y PFS according to molecular subgroup was 27.3% (±13.4%) for SHH‐I versus 71.4% (±11.5%) SHH‐II (p=0.038). Age \<12 mos, MBEN histology and female sex were also associated with better PFS.

**Conclusions**: In the ACNS1221 cohort, we prospectively validated the existence of 2 SHH subgroups in young children. SHH‐I patients fared significantly worse compared to SHH‐II patients on this regimen of conventional systemic chemotherapy without serial intraventricular methotrexate injections.

### O-039. Preliminary Experience with Whole Exome Sequencing and Transcriptome Analysis of Pediatric Central Nervous System Tumors {#pbc27455-sec-0550}
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**Background/Objectives**: Tumor whole exome sequencing (WES) with transcriptome analysis of pediatric central nervous system (CNS) tumors is increasingly used in clinical practice to guide medical management. We reviewed our combined experience in 2 pediatric oncology centers.

**Design/Methods**: After obtaining informed consent, CNS tumor samples and peripheral blood were subjected to whole exome sequencing and transcriptome analysis in the Laboratory of Personalized Genomic Medicine at Columbia University Irving Medical Center. Results were classified as Tier 1 (actionable somatic mutation associated with specific tumor type), Tier 2 (somatic mutation in targeted pathway or well established cancer gene, or actionable in other tumors), Tier 3 (other somatic cancer gene mutation), or Tier 4 (somatic mutation of unknown significance).

**Results**: We accessioned 90 brain tumor samples, of which 77 were fully evaluable and 13 were partially evaluable. Tier 1, 2, 3, and 4 mutations were found in 1, 36, 1, and 22 patients, respectively, while in 41 patients no Tier 1‐4 mutations were found. Germ‐line variants were detected in 11 patients. Copy number changes were detected in 59 patients. By transcriptome analysis, 39 patients had significantly over‐expressed genes. Fusions were detected in 16 patients. We found potentially actionable mutations in more than half of the cases, and initiated targeted therapy in 10 patients. Best responses were in low or high‐grade gliomas harboring BRAF mutations or fusions. Mean treatment duration was 5.4 months (3 weeks‐12 months), with complete clinical response in 1, partial response or stable disease in 5 (ongoing in 4), pseudo progression/progression in 2 and progressive disease in 2.

**Conclusions**: Routine application of tumor whole exome sequencing with transcriptome analysis provided clinically impactful results for the majority of pediatric CNS tumor patients, including confirmation of diagnosis, refinement of prognosis, and identification of clinically relevant targetable mutations.

### O-040. Epigenetic/Genetic/Morphologic Analyses Reveal Clinical/Prognostic Insight of Pediatric Low Grade Gliomas {#pbc27455-sec-0560}
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**Background/Objectives**: Methylation analysis provides insight into the diagnosis and prognosis of pediatric brain tumors. However, the role of the methylome on pediatric low grade gliomas (PLGG) is still unclear.

**Design/Methods**: We performed methylome analysis using the Illumina EPIC array combined with pathologic, molecular and outcome data on 153 well annotated PLGG from both St‐Jude and SickKids. For BRAFV600E gliomas, high grade gliomas were also included.

**Results**: Hierarchical clustering and t‐Distributed Stochastic Neighbor Embedding (tSNE) plots uncovered multiple factors that influence methylation‐based clustering of PLGG. Importantly, tumor location and lymphocyte infiltration influence the cluster more than molecular status or pathology. Methylation data results in helpful information to change the clinical management in 2.2% of tumors but classified tumors incorrectly 4.3%. For BRAF‐V600E gliomas (n=81), all tumors with *CDKN2A* deletion were included in a PXA cluster regardless of the pathology. Gene‐ontology analysis shows that the genes with highly methylated promoter regions in the PXA cluster are relevant to central nervous system/cell/tissue differentiation/development. Tumors clustering as PXA (DKFZ classifier) had 78% 5‐year overall survival (OS). However, this group could be further stratified into 100% OS for those with low grade histology versus 30% for HGG (p\<0.003).

**Conclusions**: The PLGG methylome is affected by multiple non‐neoplastic factors and provides information on rare subtypes. Combined molecular and pathological and methylation classification is required to implement this analysis in a clinical setting.

### O-041. Whole Exome Sequencing of Circulating Tumor DNA Extracted from the Cerebrospinal Fluid Allows a Pangenomic Characteristisation of the Primary Tumor {#pbc27455-sec-0570}
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**Background/Objectives**: Liquid biopsies are revolutionary tools to detect tumour‐specific genetic alterations in body fluids. Here, we assess whether the circulating tumor DNA (ctDNA) in Cerebral Spinal Fluid (CSF) could be used for tumor genetic profiling of Medulloblastomas (MB).

**Design/Methods**: We extracted the ctDNA of 4‐5 CSF droplets after lumbar puncture from patients with Medulloblastoma (12), or ETMR (1). ctDNA (quantity mean 30ng ; range 8‐177ng) and matched genomic DNA from primary tumors were sequenced by Whole Exome Sequencing (WES) (Illumina 100PE) using Nimblegen Medexome Capture. SNVs/mutations were called using GATK‐UnifiedGenotyper, GATK‐HaplotypeCaller and Samtools, and filtered on constitutional DNA from public databases. Copy Number profiles were generated with CNVkits.

**Results**: 10/13 cfDNA WES yielded satisfactory depth (\>10x). A mean of 466 (range 93‐945) SNVs were detected in the primary tumor and 474 (range 18‐922) in the CSF. A mean of 416 (range 18‐872) commons SNVs were observed between the cfDNA and the primary tumor, comprising classical Medulloblastoma genes such as *SMO* or *MLL2*. Interestingly, several SNVs were observed either in the tumor only (mean 50 ; range 3‐115) or in CSF only (mean 58 ; range 0‐148) suggesting a clonal heterogeneity. For 5 cases, Copy Number profiles were also available, allowing the detection of *MYCN* amplification in 1 MB or 19q13 miRNA cluster amplification in the ETMR

**Conclusions**: Altogether, we demonstrate the feasibility of WES on CSF with a low input of ctDNA. These results will allow innovative diagnostic methods and may pave the way for new tumor monitoring tools.

### O-042. Constitutional Mismatch Repair Deficiency (CMMRD)‐Associated Brain Tumors: Report from the European C4CMMRD Consortium {#pbc27455-sec-0580}
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**Background/Objectives**: Constitutional mismatch repair deficiency (CMMRD) is a rare childhood cancer predisposition syndrome (OMIM\#276300) due to biallelic germline mutations in MMR genes, leading to a broad spectrum of childhood malignancies including brain, hematologic and colorectal cancers associated with café‐au‐lait macules (CALM).

**Design/Methods**: Malignant brain tumors were reported in 48/78 patients (10 countries), registered in the C4MMRD database.

**Results**: Overall, 55 malignant brain tumors (47 high‐grade gliomas (HGG) and 8 embryonal tumors) were diagnosed in 48 patients between 1988 and 2017. Median age at the first brain tumor was 9.1y (1.1‐40.6) with 8 patients over 18y. Twenty‐eight patients developed multiple malignancies (including 17 before the brain tumor). Twenty/37 families were consanguineous. All patients had biallelic germline mutations in MMR genes: *PMS2* (26pts), *MSH6* (10pts), *MSH2* (7pts) and *MLH1* (5pts). All patients with available cutaneous data but one had CALM. In addition several patients presented developmental brain anomalies. Most patients received standard treatment before immunotherapy era, without unusual treatment‐related toxicity. Median survival after the first brain tumor was 2y. Five‐year overall‐survival was 23% (95%CI 12‐41) and 45% (95%CI 17‐76) for HGG and embryonal tumors respectively. Ten patients are alive (7 HGG and 3 medulloblastomas) at last follow‐up. Among the 38 deaths, 33 patients died because of their brain tumors (first brain tumor =28, second brain tumor =5) and 5 of other cancers.

**Conclusions**: Despite a high risk of multiple malignancies, this series suggests that some patients may be long‐term survivors. Prognosis could be improved by early recognition of this rare condition leading to more specific treatments including immunotherapy and screening for second malignancies.
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### O-043. Association Between Antiretroviral Therapy Initiation and Malignancies Among Children Living with HIV in Sub‐Saharan Africa: A Multicenter Case‐Control Study {#pbc27455-sec-0600}
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**Background/Objectives**: Currently only 43% of children living with HIV worldwide receive antiretroviral therapy (ART). Among adults, ART has been shown to decrease risk of HIV‐related malignancies; however, few studies have described the association among children living with HIV, especially in resource‐limited settings. Our objective is to determinethe association between age at ART initiation and the incidence of malignancies in children with HIV infection.

**Design/Methods**: We conducted a multicenter case‐control study at five pediatric HIV centers in Botswana, Malawi, Tanzania, and Uganda from 2003‐2016. Cases were defined as children living with HIV ages 0‐21 years with a cancer diagnosis. Controls were defined as children with HIV but no cancer with 5:1 matching based on sex, country, and age of enrollment in HIV care. We conducted a longitudinal cohort analysis for a subset of incident cancer cases, defined as malignancy diagnosis \>3 months after enrollment in care.

**Results**: There were 451 total cases of malignancies (of which 136 were incident cases) among children living with HIV and 2,175 controls. Cases were 41% female, with a median age of 7 years (IQR 3‐11) at time of HIV diagnosis. Of the 451 cancer diagnoses, 83.8% were Kaposi sarcoma, 10.7% were non‐Hodgkin lymphoma, 2.0% were Hodgkin lymphoma, and 3.6% were other malignancies. Histopathological diagnosis was obtained for 69.9% of incident cases. There was no significant increased cancer risk for males (OR 1.12, p=0.55). Compared to children that initiated ART at under 2 years of age, there were increased odds of developing incident cancer in children who began ART between ages 2‐6 years (OR 3.85, p=0.001) and over 7 years (OR 4.98, p=0.001).

**Conclusions**: Early diagnosis of HIV and prompt initiation of ART may decrease the incidence of some malignancies. Efforts to improve early infant diagnosis and prompt initiation of ART may reduce malignancies among children living with HIV.
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**Background/Objectives**: Gram‐negative bacteria susceptible only to colistin (COS) are emerging causes of complicated infections especially in the immunocompromised patients, reviving interest in the use of colistin. The purpose of this study was to test the renal toxicity of colistin in a cohort of pediatric cancer patients with gram‐negative blood stream infections.

**Design/Methods**: A prospective, observational, cohort study was performed from May 2017 to October 2017 in Children\'s cancer hospital Egypt 57357. All patients who had Blood Stream Infections due to COS gram‐negative bacteria and received intravenous Colistin were prospectively enrolled. A standardized case form was used to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism and in vitro susceptibility, daily doses and duration of colistin therapy, cumulative dose of colistin, co‐administered antibiotics, nephrotoxic agents (aminoglycosides, vancomycin) and clinical and microbiological responses to therapy. The dosing schedule was based on a loading dose of 5 MU and a 5‐MU twice‐daily divided maintenance dose, titrated on renal function. For each Colistin course, clinical cure, bacteriological clearance, daily serum creatinine clearance, and estimated creatinine clearance were recorded.

**Results**: Blood Stream infectious episodes was detected in 134 patients with Klebsiella (32%), and E.Coli (68%). All strains were susceptible to colistin, with MICs of 0.19--1.5 mg/L. Patients were predominantly females (69%), with a mean age of 7 years. It was employed as combination therapy with carbapenems (69.2%) or aminoglycosides (30.8%). Acute kidney injury developed during 5 treatment courses (4%). used in combination with Amikacin. No renal replacement therapy was required and subsided within 7 days from Colistin discontinuation. No correlation was found between variation in serum creatinine level (from base‐ line to peak) and daily and cumulative doses of CMS.

**Conclusions**: Our study shows that in severe infections due to COS gram‐negative bacteria, Colistin had a high efficacy, without significant renal toxicity.
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**Background/Objectives**: Children, adolescents and young adults (CAYA) with Hodgkin lymphoma (HL) in South Africa were treated on a variety of management regimens based largely on institutional preference until 2016. A multicentre retrospective analysis of all children and adolescents treated for HL over a ten year period demonstrated uneven survival rates across the country, ranging from 20% in under‐resourced settings to 80% in established centres. Harmonisation of management protocols in a research setting has been identified as a strategy to improve survival rates of CAYA with cancer.

**Design/Methods**: An email audit was conducted of existing services in 2016. Clinician‐researchers in each centre completed a spreadsheet with parameters including number of patients with HL, number of oncologists, teaching hours and access to specific services (radiation, chemotherapy, intensive care). Funding was sourced to run national meetings and further meetings were conducted online. Potential solutions were explored and discussed.

**Results**: Clinicians from all ten paediatric oncology units responded and all questions were answered. The identified challenges included inequitable access to resources, under‐staffing, inadequate radiation services, lack of research infrastructure and competing demands on the time of clinician‐researchers. Supervision of post‐graduate degrees by external researchers was identified as a potential motivating mechanism to facilitate harmonisation of protocols. An online data‐capturing tool using REDCap was suggested as a means to offer clinical support in a research framework. Specific features, new in this context, include body surface area calculators, International Classification of Disease codes, morphology codes and chemotherapy dose calculators

**Conclusions**: Harmonisationof HL treatment is feasible in South Africa as there is a well identified group of treating clinicians with a common purpose. There is enthusiasm for improving research infrastructure and collaborative work. It is anticipated that survival rates of CAYA with HL will improve with this strategy and this approach, if successful, will be applied to other childhood malignancies.

### O-046. The Results of AHOPCA GCT 2: Risk‐Adapted Therapy for Germ Cell Tumors in Central America {#pbc27455-sec-0630}
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**Background/Objectives**: To evaluate risk‐stratified approach to treat pediatric germ cell tumors in low‐middle income countries.

**Design/Methods**: All patients under age 18 diagnosed with a germ cell tumor (GCT) who were treated at one of the participating AHOPCA centers in Central America were eligible. Low risk patients (mature/immature teratoma, stage I gonadal malignant GCT) were treated with surgery and active surveillance. Intermediate risk patients (stage II gonadal tumors, stage I -- II extragonadal tumors, stage III‐IV gonadal under age 14y) were treated with "JEb" X 4 cycles (carboplatin 600 mg/m2, etoposide 150mg/m2, and bleomycin 15 units/m2). High risk patients (stage III/IV gonadal over age 14y and all stage III‐IV extragonadal tumors) were treated with "PEb" X 4 cycles (cisplatin 20mg/m2, etoposide 100mg/m2 and bleomycin 15 units/m2). Any patient not in CR after 4 cycles could receive an additional 2 cycles. "Event" was defined as progressive disease, relapse and/or abandonment. EFS and OS were calculated.

**Results**: The protocol was open in 5 Central American countries between 2009‐16 and enrolled 322 eligible patients (Guatemala: 140, San Salvador: 42, Dominican Republic: 26 and Nicaragua: 114 patients). Due to ineligible histological type, age at diagnosis or missing data, 37 patients were exclude. Overall EFS and OS at 7 years was 84.9% and 89.0%. EFS and OS by risk group was low risk (n=159): 88.6% and 94.1%; intermediate risk (n=115) 88.7% 90.5% ; high risk (n=48) 63.8% and 69.7%. Abandonment was 1.9%, 1.7% and 2.1% for low, intermediate and high risk group respectively.

**Conclusions**: High rates of EFS and OS are possible for children with GCT in resource‐limited settings with upfront risk assessment and therapy allocation, and low rates of abandonment.

### O-047. Assessment of Nutritional Capacity in Pediatric Oncology Units in India: A Survey Report Based on the Framework Established by SIOP PODC Nutrition Working Group {#pbc27455-sec-0640}
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**Background/Objectives**: Survival rates in pediatric oncology approach 85% in high income countries, but are as low as 20% in low‐ and middle ‐ income ountries (LMICs). Efforts to improve treatment outcomes include nutritional interventions in LMIC\'s, where malnutrition is strikingly high, using a framework developed by the SIOP PODC Nutrition Working Group (WG) for levels of nutritional care among Pediatric Cancer Units (PCUs).

**Design/Methods**: An online survey based upon the WG framework was employed to evaluate nutritional care in India. It was sent through Survey Monkey to assess medical setting, access to nutritional products, capacity in personnel and training, and nutritional assessment and intervention. Institutions were identified from the national list of PCUs. Responses were scored by levels zero (little to no resources) to four (resources reflective of a well‐resourced setting).

**Results**: Forty‐five teaching hospitals participated from 17 states, a union territory, and the capital. Thirty‐one percent, 22%, 20%, 20%, and 7% of participating PCUs were from south, north, central, west, and east, respectively. Overall, 7% scored level 0‐1, 23% level 1‐2, 51% level 2‐3, and only 4% level 3‐4. For access to nutritional products, 73% overall scored level 1‐2; PCUs from north (80%), south (71%), central (67%) and west (67%) showed the most need. For capacity in personnel and training, 78% overall scored less than level 2, while more than 90% from central and north scored less than level 2. For nutritional assessment and intervention, more than 90% overall scored less than level 2, but 100% of PCUs from north and central scored less than level 2.

**Conclusions**: Varying levels of care exist across India, exhibiting unmet needs in nutritional assessment and intervention, and in human capacity; mostly in central and northern states. This assessment is important for addressing regional gaps and directing educational and programmatic development in nutritional care.

### O-048. A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphoma {#pbc27455-sec-0650}
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**Background/Objectives**: Despite excellent outcomes for Burkitt lymphoma (BL) in high‐income settings, the delivery of intensive multi‐agent chemo‐immunotherapy is prevented in low‐income countries by high costs and insufficient access to supportive care facilities. Consequently, patient outcome remains unsatisfactory and new therapeutic approaches are urgently needed to improve survival. Using genomic profiling we aim to identify abnormalities that stratify patients based on response to current protocols and define potential therapeutic targets.

**Design/Methods**: We collected 113 diagnostic samples from the Queen Elizabeth Central Hospital, Malawi and Children\'s Cancer and Leukaemia Group (CCLG), UK. High‐resolution copy number profiling data was generated using Affymetrix Oncoscan and Cytoscan arrays. Survival analysis examined the association of clinico‐molecular factors with risk of relapse. Multivariate Cox regression modelling was applied to develop a risk stratification model.

**Results**: Thirty recurrent focal copy number abnormalities were detected in 63 endemic BL cases using GISTIC2.0. Regions of gain contained known cancer‐related genes, *MCL1, EBF1, BCL6, BACH2, MAP3K7, BTG4, MDM2* and *FOXO1*. Large genomic alterations included gain of 1q, 7q and 12q. Survival analysis identified abnormalities involving chromosomes 1 and 13 to be associated with an increased risk of relapse. Gain of either abnormality identified one third of patients with a high‐risk of relapse (77%) compared to the low‐risk group (25%) (hazard ratio 4.32 (CI 95% 1.46‐12.83), *p*=0.008). Despite differences in treatment intensity, there was no difference in outcome for endemic and sporadic patients identified as low‐risk by this model. However, outcome for high‐risk patients was significantly different (relapse risk 77% versus 13%, *p*=0.0007 for endemic and sporadic BL respectively).

**Conclusions**: We have developed the first risk stratification model for endemic BL which identifies patients at a high‐risk of relapse who may benefit from stratified increase in treatment intensity. In contrast, low‐risk patients may be candidates for treatment de‐intensification to reduce toxicity‐related side‐effects in other healthcare settings.

FPS 10: Infectious Complications {#pbc27455-sec-0660}
--------------------------------

### O-049. Alterations in Gut Microbiome are Associated with Infectious Complications in Patients with Acute Lymphoblastic Leukemia {#pbc27455-sec-0670}
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**Background/Objectives**: The association between the gut microbiome and infectious complications in children with acute lymphoblastic leukemia (ALL) is not clear. This study is aimed to assess these relationships.

**Design/Methods**: After ethics approval, this prospective study examined the gut microbiome of newly‐diagnosed pediatric ALL patients managed at the IWK Health Centre from 2016‐2018. Stool samples were collected prior to chemotherapy and throughout the first 7 months of treatment and were sequenced using 16S rRNA gene and whole metagenome approaches. Virulence factors were determined within assembled metagenomic reads. Patients had an infectious complication (IC) if they had any clinically defined infections, microbially defined infections or febrile neutropenia over the study period. All other patients were classified as non‐infectious complication (NIC) patients.

**Results**: Seventeen patients with ALL were recruited. The mean age was 40.78 months and the sex ratio (M:F) was 2.4:1. Patients who faced IC had significantly lower microbial alpha diversity (p=0.004) and significantly different microbial community structures (p=0.003). In total 14 genera were found to have significant differences greater than 1% in relative abundance between patients with IC and those without. Notable genera increased in NIC patients include *Bacteroides, Parabacteroides*, and *Clostridium*. A few notable genera increased in IC patients include *Streptococcus, Enterococcus*, and *Enterobacter*. Metagenomic data revealed significant differences in gene pathways. Some of these pathways include those that feed into the production of vitamin K, fatty acid oxidation, and heme biosynthesis. Furthermore, metagenomic data showed that there was an increase in the abundance of microbial genes annotated as virulence factors in IC patients when compared to NIC patients.

**Conclusions**: This study indicates that the gut microbiome of pediatric ALL patients who experience infectious complications is compositionally and functionally altered. Further investigation is warranted to determine how these gut microbiome features contribute to risk of infectious complications in pediatric ALL patients.

### O-050. Management of Adenovirus Infections After Hematopoietic Stem Cell Transplantation: State‐of‐the‐Art {#pbc27455-sec-0680}
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**Background/Objectives**: Human adenoviruses (HAdV) are a major cause of morbidity and mortality in pediatric stem cell transplant (HSCT) recipients, mostly resulting from reactivation of persistent viruses (*Lion T. Clin Microbiol Rev. 2014, 27(3):441‐62*). Our previous studies identified the gastrointestinal tract as the main site of HAdV persistence and post‐transplant reactivation in children (*Kosulin et al. Clin Microbiol Infect. 2016, 22(4):381*). Since HAdV expansion in the gastrointestinal tract almost invariably precedes invasive infection, frequent molecular HAdV monitoring of serial stool samples, at least until day 100 post‐HSCT, has become the standard of diagnostic surveillance in the pediatric transplant setting.

**Design/Methods**: We have recently analyzed more than 300 allogeneic HSCT recipients treated at the St.Anna Children\'s Hospital, Vienna, Austria, by serial molecular testing of stool and peripheral blood specimens for the presence and quantity of adenoviruses, to assess the occurrence of invasive infections in relation to currently known risk factors.

**Results**: The analysis revealed a significantly more common occurrence of invasive infection in patients with HAdV persistence and intestinal shedding before HSCT (33% vs 7%; p\<0.0001), thereby unveiling a novel risk factor for ensuing invasive infection and disseminated disease (*Kosulin et al. EBioMedicine. 2018, 28:114‐119*). These observations highlight the need for timely HAdV monitoring and pre‐emptive therapeutic considerations in HSCT recipients.

**Conclusions**: The important insights gained over the past years in diagnosis and treatment of invasive adenoviral infections provide new paradigms for the monitoring and clinical management of these life‐threatening complications. The advances in our understanding of the etiology/pathogenesis and future treatment options have resulted in novel recommendations for diagnostic approaches and pre‐emptive therapy reflecting the present state of knowledge (*Hiwarkar et al. Rev Med Virol 2018‐in press*). The recently emerging diagnostic and therapeutic options will expectedly facilitate effective control or prevention of adenovirus‐related diseases in the pediatric HSCT setting.

### O-051. Prognostic Impact of Neutropenia Period in Patients with Acute Myeloid Leukemia (AML) Enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 study {#pbc27455-sec-0690}
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**Background/Objectives**: Intensified multi‐drug chemotherapy for acute myeloid leukemia (AML) is accompanied by profound myelosuppression, however, the degree of myelosuppression is not equal among the patients. While the Children\'s Oncology Group revealed that longer duration of neutropenia was associated with a reduced risk of relapse in their AAML0531 study, it may be different among the protocols or races. Herein, we analyzed the prognostic impact of prolonged neutropenia in our AML‐05 study.

**Design/Methods**: This analysis was conducted using the prospectively collected data of JPLSG AML‐05 study, which recruited 443 eligible children (age \<18 years) with *de novo* AML between November 2006 and December 2010. For this analysis, we focused on the patients who completed protocol treatment without recurrence or withdrawal. Among the 372 risk‐stratified patients \[low risk (LR), N=126; intermediate risk (IR), N=159; high risk (HR), N=45\], we excluded 43 patients; those who did not complete the protocol treatment for any reasons (N=34), who violated the protocol and received transplantation at first complete remission (N=2), and whose average relative dose intensity were below 0.85 (N=7) to aline the received treatment. Prolonged neutropenia was defined as longer than the median neutropenia periods after the second and third courses in each risk group.

**Results**: At a median follow‐up from the end of treatment (28.2 months), longer duration of neutropenia was associated with better overall survival rate (OS) (88.6% vs 76.7%, p=0.0323, log‐rank). In each risk group, HR patients with prolonged neutropenia showed significantly better OS (p=0.0068). The influence on relapse risk differed among the risk groups (p=0.010, Fine‐Gray proportional hazards model). Hazard ratios of cumulative incidence of relapse in prolonged neutropenia were 1.60 in LR, 0.563 in IR, and 0.409 in HR (p=0.15, 0.024, and 0.087, respectively).

**Conclusions**: In higher risk patients, prolonged neutropenia after the second and third courses was associated with better outcome.

### O-052. Burden of Chemotherapy Induced Febrile Neutropenia and Role of G‐CSF in Febrile Neutropenia in a Low‐Income Country: The Children\'s Hospital Lahore Pakistan Experience {#pbc27455-sec-0700}

[A. Ahmad]{.ul} ^1^, F.S. Khan^2^, M. Sadiq^3^

*^1^The Children\'Hospital&the Institute of Child Health Lahore, Paediatric Haematology/Oncology, Lahore, Pakistan; ^2^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Paediatric Haematology, Lahore, Pakistan; ^3^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Dean, Lahore, Pakistan*

**Background/Objectives**: Febrile neutropenia (FN) is one of most common and potentially lethal complications in patients with cancer during chemotherapy, being inadequately managed in Low‐Income countries. The objective of this study is to evaluate the burden of FN and role of G‐CSF in resource limited settings like a public sector hospital in Pakistan.

**Design/Methods**: A prospective review of data of patients treated for febrile neutropenia from October to December 2017 in the Haematology/Oncology Department of The Children\'s Hospital Lahore after IRB approval.

**Results**: 250 patients were treated for FN during these three months 59% of them male. 58% Acute Lymphoblastic Leukaemia, 16% sarcomas, 10% Lymphoma and 16% other solid malignancies on different chemotherapy regimens. 53% received their chemo during last 3 days and 35% in the last week prior to FN admission. 84% of them were receiving either induction or intensive phase protocols.48% had respiratory tract infection followed by AGE 25%, fever alone in 20%, 82% cases had mucositis. 52% cases had symptoms of more than 24 hours before seek treatment for FN. ANC was \<100 in 60% and platelets \<50000 in 56% cases on arrival.57% cases stayed 1‐3 hours drive from the hospital and only 44% parents had adequate awareness of FN management. 81% discharged home, 16% expired (mainly FN and progressive disease) and 3% abandoned treatment. G‐CSF was used in 30% (0.026 for RX cost and 0.043 Hospital Stay) and blood products in 75%, inotropes in 16% with mean estimated cost of 15000 Rupees/ patient (total 3.8 Million Rs) with 95% staying \>48 hrs. 92% of cultures showed G Positive organisms among positive 60 cultures.

**Conclusions**: This study showed that FN has been a profound burden in childhood cancer care in public sector hospital in resource limited settings and G‐CSF use helps in early discharges in solid tumors.

### O-053. Higher Incidence but Better Outcome of Infections in Children vs Adults After Hematopoietic Stem Cell Transplantation: Results of a Nationwide Multicenter Cross‐Sectional Study {#pbc27455-sec-0710}
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**Background/Objectives**: Comparison of the incidence and outcome of infections in pediatric and adult HSCT centers in Poland in cross‐sectional study over a period 2012‐2015.

**Design/Methods**: All consecutive patients transplanted in 5/5 pediatric and 11/13 adult TC were included in the retrospective study. Only reports with known etiology of infections were analyzed in the study.

**Results**: Data on follow‐up of 650 pediatric and 3200 adult HSCT recipients were analyzed. Bacterial infections: The incidence was 36.0% for children and 27.6% for adult patients (p\<0.0001), including allo‐HSCTs (36.9% vs 41.1%, ns), and auto‐HSCTs (32.9% vs 20.8%; p\<0.0001). The incidence was comparable in patients with ALL, AML/MDS, NHL/HD, and SAA. Infection‐related mortality (IRM) from bacterial infections was lower in pediatric patients (4.5% vs 8.6%; p=0.006). Invasive fungal disease (IFD): The incidence was 25.3% for children and 6.3% for adults (p\<0.001), including allo‐HSCTs (28.3% vs 14.0%; p\<0.0001) and auto‐HSCTs (14.7% vs 2.5%; p\<0.0001), patients with ALL (29.4% vs 11.3%; p\<0.0001) or AML/MDS (41.2% vs 13.2%; p\<0.0001). IRM from IFD was lower in pediatric patients (12.0% vs 25.1%; p\<0.0001). Viral infections: The incidence was 56.3% for children and 29.3% for adults (p\<0.0001) after allo‐HSCT, and 6.6% vs 0.8% (p\<0.0001) after auto‐HSCT. The incidence was higher for: CMV (28.9% vs 24.7%; p\<0.05), BKV (21.0% vs 5.9%; p\<0.0001), EBV (19.4% vs 1.9%; p\<0.0001), ADV (7.4% vs 2.9%; p\<0.0001), and influenza (2.2% vs 0.5%; p=0.0038). Viral infections contributed to mortality usually when coexisted with other infections. IRM from viral infections was similar for children and adults, both for all viral infections (5.7% vs 5.4%, ns), and for each specific infection: CMV (4.9% vs 5.8%, ns), BKV (2.9% vs 0%, ns), EBV (4.0% vs 11.7%, ns), ADV (5.6% vs 8.7%, ns), and influenza (0% vs 30%, ns).

**Conclusions**: Pediatric patients after HSCT have higher incidence but better outcome of infections than adults.

### O-054. Risk Factors for Infectious Morbidity and Mortality During a Prednisone Versus Dexamethasone Induction on Childrens Oncology Group High Risk Acute Lymphoblastic Leukemia Protocol AALL0232 {#pbc27455-sec-0720}
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**Background/Objectives**: AALL0232 randomized patients with acute lymphoblastic leukemia (ALL) to dexamethasone or prednisone in Induction starting in 2004; after 2008 patients ≥10 years received prednisone due to osteonecrosis. In 2006 enhanced infection reporting was instituted. We examined risk factors associated with infectious morbidity and mortality during Induction.

**Design/Methods**: We reviewed grade 3‐5 infection‐related toxicities reported from a sterile site that listed a specific organism. All bacteremias were included, viruses excluded. Grade 5 toxicities deemed infectious by the primary study team were included.

**Results**: Grades 3‐5 infections occurred in 309/3081 (10%) of patients during Induction, 43 (1.4%) were Grade 5. Infections accounted for 80% of Induction deaths. By univariate analysis among all patients infection‐related mortality was significantly higher in patients ≥10 years (1.7% vs 0.7%, p=0.018) despite having significantly less infections overall (8.6% vs 12.9%, p= 0.0002). Caucasians had more infections than Black patients (10.8% vs 4.6%, p=0.0045). Patients randomized to dexamethasone had more infections than those randomized to prednisone (11.7% vs 7.2%, p=0.0005), but no increased infectious mortality. Of 315 infectious toxicities noted in 309 patients, 275 were bacteremia, followed distantly by lung (n=15), soft tissue (n=9), gastrointestinal (n=8) and other (n=8). Staphylococcus species accounted for 41% of bacteremias, followed by Pseudomonas species (12%), viridans group streptococci (10%) and E.coli (8%). Except for Clostridium and Bacillus, Gram‐positive organisms were rarely fatal. Fungi accounted for 9% of all infections; molds were more prevelant than yeast. Fungi caused 18.6% of deaths, all in patients ≥12 years.

**Conclusions**: Older patients with ALL have a higher risk of infectious mortality during Induction; although patients \<10 years, Caucasians and those randomized to dexamethasone had more infections overall. Bacteremia was the most common reported infection with gram‐positive organisms being the most frequent, but least morbid. Having fungal, invasive clostridial, CNS or polymicrobial infections trended to higher mortality rates.

FPS 11: Toxicity and supportive care {#pbc27455-sec-0730}
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### O-055. Potential Factors Influencing the Incidence of Chemotherapy‐Induced Vomiting (CIV) in Children Receiving Emetogenic Chemotherapy: A Pooled Analysis {#pbc27455-sec-0740}
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**Background/Objectives**: Data from a large pediatric drug development program were used to identify factors associated with CIV in pediatric patients receiving emetogenic chemotherapy.

**Design/Methods**: An individual patient‐level pooled analysis was performed using data from 5 prospective clinical trials of aprepitant/fosaprepitant in subjects 0.3‐17 years of age receiving emetogenic chemotherapy. The primary end point of the analysis was the absence of vomiting in children receiving highly emetogenic chemotherapy (HEC) during the acute phase (period from initiation of the first chemotherapy dose until 24 hours after administration of the last chemotherapy dose). Logistic regression was used to identify factors (patient age, sex, race, and puberty status; cancer type, duration of acute phase, and antiemetic regimen) influencing CIV. Relative risks (RR) with 95% confidence intervals (CI) were calculated.

**Results**: A total of 637 subjects (mean age, 8.9 years; range, 0.3‐17.9 years) received at least 1 dose of study medication and HEC (median acute phase duration, 3 days; range, 1‐5 days). Absence of vomiting was less likely with increasing year of age (RR \[95% CI\] = 0.92 \[0.90‐0.95\] and days of acute phase duration \[RR \[95% CI\] = 0.98 \[0.98‐0.99\]). Subjects received 1 of 4 antiemetic regimens: ondansetron alone (n = 240), ondansetron + dexamethasone (n = 103), ondansetron + aprepitant/fosaprepitant (n = 188), and ondansetron + aprepitant/fosaprepitant + dexamethasone (n = 99). Seven patients had missing efficacy data. Antiemetic regimen significantly influenced CIV. Absence of vomiting was more frequent in those receiving ondansetron + aprepitant/fosaprepitant compared with ondansetron alone (57.5% vs 42.5%; RR \[95% CI\] = 1.14 \[1.04‐1.24\]).

**Conclusions**: Younger age, shorter acute phase duration, and antiemetic regimen were significantly associated with a higher likelihood of no acute phase vomiting in children receiving HEC.

### O-056. A Randomised Open Label Non Inferiority Study to Compare Efficacy and Cost of Palonosetron and Ondansetron in Prevention of Acute Chemotherapy Induced Vomiting in Children {#pbc27455-sec-0750}

[S. Jain]{.ul} ^1^, S. Koneru^1^, G. Kapoor^1^, G. Vishwakarma^2^

*^1^Rajiv Gandhi Cancer Institute and Research Centre, Pediatric Hematology‐Oncology, Delhi, India; ^2^Rajiv Gandhi Cancer Institute and Research Centre, Research, Delhi, India*

**Background/Objectives**: Chemotherapy induced vomiting (CIV) is a common and distressing adverse effect of cancer treatment. With the emergence of second generation 5‐HT3 receptor antagonists, which have greater receptor selectivity and longer half life we compared the efficacy and cost of palonosetron and ondansetron.

**Design/Methods**: In this single centre, open label, randomized study, children receiving moderate and high emetogenic chemotherapy were assigned to get either ondansetron or palonosetron in addition to other anti‐emetic prophylaxis. The primary efficacy endpoint was proportion of children with complete response during the acute phase of the first on‐study chemotherapy cycle. Non‐inferiority of palonosetron against ondansetron was assessed using statistical tools. Risk factors for suboptimal response and cost of administration of two drugs were also analysed.

**Results**: 108 children were analysed and various factors likely to influence CIV were equally distributed in two arms. These 108 patients received 412 blocks of chemotherapy. Sixty nine (63.8%) patients received HEC as the first on‐study cycle. The HEC comprised of 262 (63.5%) of all the chemotherapy blocks and 120 (45%) of these were administered as a single day chemotherapy. During the acute phase, complete responses were recorded in 72.2% (39/54) and 83.3% (45/54) receiving ondansetron and palonosetron respectively (p value 0.17) (ΔCR +11.1%). The lower limit of 97.5% confidence interval (‐6.95‐28.39) for ΔCR was greater than ‐15% in palonosetron arm. Only statistically significant risk factor that predisposed response, was use of dexamethasone (p \<0.01). Cost associated with palonosaetron administration was significantly lower compared to ondansetron \[279 (range:169--499) and 395 (range:76--1395) Indian Rupee respectively (p 0.002)\].

**Conclusions**: A single dose of palonosetron is equally efficacious ondansetron in the prevention of acute CIV in children receiving moderate and high emetogenic chemotherapy. Pharmacoeconomic implications and reduced nursing line handling are crucial secondary gains in a resource limited setting.

### O-057. Change of Nutritional Status During Chemotherapy and Factors Predicting Nutritional Status at 6 Month Interval {#pbc27455-sec-0760}

[M. Kashyap]{.ul} ^1^, A. Mishra^1^, A. Tiwari^1^, S. Bakhshi^1^

*^1^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India*

**Background/Objectives**: Children with cancer are vulnerable to malnutrition, because of increased catabolism due to disease and/or its treatment. There is limited data regarding impact of treatment on the same. This study aimed to assess nutritional status of children with cancer and effect of treatment on the same.

**Design/Methods**: In this prospective observational study, data regarding height/length, weight and mid upper arm circumference (MUAC) was collected for all patients at baseline, 3 and 6 months. Information regarding literacy status of caretaker and place of residence (rural/urban) was collected. Children with age ≤ 5 years were defined to be undernourished if MUAC for age and weight for age was \< ‐2SD. Those with age 6‐10 years and 11‐18 years were classified as undernourished if weight for age and BMI for age was \<‐2SD respectively. Nutritional intervention in the form of counseling and provision of high protein supplements from baseline by two dedicated nutritionists.

**Results**: We included 343 patients whose data was available at all endpoints, of which 215 (62.7%) had hematologic malignancy and 128 (37.3%) solid tumors. At baseline, 37% (127) patients were undernourished, which decreased to 34% (117) and to 25% (86) at 3 and 6 months respectively. In the subgroup with hematological malignancies there were 36.7% (79), 31.6% (68) and 22.3% (48) undernourished children at baseline, 3 and 6 months respectively. In the subgroup with solid tumors there were 37.5% (48), 38.2% (49) and 29.6% (38) undernourished children at baseline, 3 and 6 months respectively. At 6‐month interval both haematological (p\<0.001) and solid malignancies (p\<0.001) showed significant reduction in proportion of malnutrition. Malnutrition at 6‐month interval was significantly associated with illiteracy (p\<0.001) and rural background (p=0.004).

**Conclusions**: Nutritional status of children with cancer improved with adequate dietry intervention even during chemotherapy. Literacy status and place of residence had effect on nutrition of these patients.

### O-058. Nutritional Status and Outcomes in Children with Cancer on Admission of Intensive Care Units {#pbc27455-sec-0770}

[L. Cheng]{.ul} ^1^, S. Feng^2^, H. Lu^2^, N. Shen^3^

*^1^Fudan University, School of Nursing, Shanghai, China; ^2^Shanghai Children\'s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, pediatric intensive care unit, Shanghai, China; ^3^Shanghai Children\'s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, nursing department hematology & oncology, Shanghai, China*

**Background/Objectives**: The aim of this study was to describe the nutritional status and determine its impact for pediatric oncology patients on admission of pediatric intensive care unit (PICU).

**Design/Methods**: This was a secondary data analysis of 160 pediatric oncology patients from a single‐center, prospective cohort study. The subset of database recorded the demographic and clinical characteristics, and nutritional status of children (ages 1 month to 18 year) with cancer admitted to a PICU. Data was obtained from the medical record. Patients were followed until hospital discharge. Anthropometric parameters were used to evaluate nutritional status. Malnutrition was considered if the Z‐scores for the anthropometric parameters were \<2. Adjusted Cox\'s regression (adjusted for sex, age, and pediatric critical illness score) and Cross Tabulation were used to examine the association between nutritional status and outcomes.

**Results**: The prevalence of malnutrition was 11.3% according to weight‐for‐height Z‐score, 16.3% according to height‐for‐age Z‐score, 21.3% according to body mass index‐for‐age Z‐score, 14.4% according to weight‐for‐height Z‐score, 34.4% according to mid‐upper arm circumference‐for‐age Z‐score. Serum albumin and pre‐albumin levels were below the normal range in a majority of the cohort (52.5% and 76.3%, respectively). Anthropometrical parameters that predicted the duration of mechanical ventilation were weight‐for‐age (hazard ratio \[HR\], 2.727; 95% confidence interval \[CI\], 1.729‐4.302); height‐for‐age (HR, 1.969; 95% CI, 1.440--2.693); weight‐for‐height (HR, 2.645; 95% CI, 1.575‐4.441); and upper arm muscle area‐for‐age (HR, 2.098; 95% CI, 1.430--3.077). Length of PICU stay was predicted by weight‐for‐age (HR, 1.207; 95% CI, 1.014--1.436). Low level of serum albumin was associated with mortality (risk ratio \[RR\] 2.426, 95% CI 1.200,4.907).

**Conclusions**: Malnutrition is prevalent among pediatric oncology patients admitted to the PICU. Malnutrition on admission of PICU was associated with length of PICU stay, the duration of mechanical ventilation. Nutritional status assessment followed with targeted intervention should be performed for these children.

### O-059. Characteristics and Mortality of Clinical Deterioration Events in Pediatric Oncology Patients Hospitalized in Resource‐Limited Settings: A Multicenter Study {#pbc27455-sec-0780}

[A. Agulnik]{.ul} ^1^, A. Cardenas^2^, A. Carrillo^1^, L. Faughnan^1^, C. Rodriguez‐Galindo^1^

*^1^St. Jude Children\'s Research Hospital, Global Pediatric Medicine, Memphis, USA; ^2^Hospital Infantil Teleton de Oncologia, Critical Care, Queretaro, Mexico*

**Background/Objectives**: Hospitalized pediatric oncology patients are at high‐risk for clinical deterioration requiring pediatric intensive care unit (PICU) transfer and resulting in high inpatient mortality rates, particularly in resource‐limited settings. This study describes the frequency, clinical characteristics, and outcomes of clinical deterioration events among pediatric oncology patients hospitalized in 17 resource‐limited centers across Latin America.

**Design/Methods**: In April, 2017, we implemented a uniform prospective system to track clinical deterioration events (defined as unplanned PICU transfer, vasopressors, mechanical ventilation, CPR, or non‐palliative death on the floor) in 17 collaborating centers in Latin America as a quality improvement measure. Monthly hospital admissions and hospital‐patient‐days were also reported at each site. This is a preliminary analysis of data collected through November, 2017.

**Results**: Three hundred and twenty five deterioration events were reported in hospitalized pediatric oncology patients among 7866 hospital admission (4.1%) and 65,417 hospital‐patient‐days (4.97/1000‐inpatient‐days). At time of preliminary analysis, 197 events had completed case report forms. The majority of patients with clinical deterioration events had ALL (51.3%), AML (15.7%), or solid tumors (21.3%). Of clinical deterioration events, 59 (29.9%) patients required intensive intervention on the floor, 168 (85.3%) were transferred to a higher level of care (intensive care unit or similar), and 93 (47.2%) died prior to hospital discharge. Patients who required mechanical ventilation (46.2%), vasopressors (59.4%), or CPR (21.3%) had significantly higher mortality (p\<0.001). Sixty seven (34%) patients experienced delays in identification of clinical deterioration or PICU transfer, resulting in higher mortality (p=0.02).

**Conclusions**: Hospitalized pediatric oncology patients with clinical deterioration in resource‐limited settings have high mortality. Critical interventions in these settings are frequently initiated on hospital floors and not all patients have access to PICU admission. Delays in identification of deterioration and PICU transfer may contribute to these poor outcomes.

### O-060. Executive Functioning in Children and Adolescents Treated for High‐Risk Acute Lymphoblastic Leukemia (HR‐ALL): A Report from The Children\'s Oncology Group (COG) {#pbc27455-sec-0790}

[K. Hardy]{.ul} ^1^, A. Gioia^2^, J. Kairalla^3^, N. Winick^4^, R. Noll^5^, S. Patel^6^, S. Sands^7^, L. Embry^8^

*^1^Children\'s National Medical Center, Neuropsychology, Washington, USA; ^2^Children\'s National Medical Center, Neurology, Washington, USA; ^3^University of Florida at Gainesville, Biostatistics, Gainesville, USA; ^4^University of Texas Southwestern, Hematology‐Oncology, Dallas, USA; ^5^University of Pittsburgh Medical Center, Pediatric Psychiatry and Psychology, Pittsburgh, USA; ^6^City of Hope, Population Sciences and Supportive Care Medicine, Duarte, USA; ^7^Memorial Sloan Kettering, Pediatric Neuropsychology, New York, USA; ^8^University of Texas Health Sciences Center at San Antonio, Pediatric Hematology‐Oncology, San Antonio, USA*

**Background/Objectives**: Survivors of childhood HR‐ALL may experience cognitive difficulties including attention and executive functioning (EF) problems. EF is a collection of interrelated capacities responsible for purposeful, goal‐directed, problem‐solving behavior, which impact school and occupational performance. We aimed to identify demographic and treatment‐related factors associated with risk for executive dysfunction in this population.

**Design/Methods**: Children with HR‐ALL treated on protocol AALL0232 entered two randomizations to either high‐dose (HD‐MTX) or escalating‐dose methotrexate (Capizzi), and to dexamethasone or prednisone. Neuropsychological functioning was evaluated via protocol AALL06N1 for 179 participants (56% female, 82% white) 8‐24 months following treatment completion. Mean age at diagnosis was 8.4 years (SD=5.0). EF was evaluated with both performance‐based assessments and parent‐report measures.

**Results**: Mean scores for all measures were within the average range, and there were virtually no significant differences in outcomes as a function of MTX delivery or steroid treatment. However, in multivariable models, participants with U.S. public insurance exhibited significantly greater parent‐reported EF difficulties than those with U.S. private or Non‐U.S. insurance (BRIEF Metacognition p=.006; Behavioral Regulation p\<.001). In addition, participants diagnosed under 10 years of age performed more poorly on measures of attention (CPT commissions p=.05; omissions p=.05; response variability p\<.001) and EF (DKEFS category fluency p=.04; letter fluency p=.02; TOL Total Moves p=.02).

**Conclusions**: Consistent with published data on intellectual outcomes in this sample, attention and EF did not differ based on methotrexate delivery or type of corticosteroid received. However, several outcomes varied with demographic characteristics. For example, performance‐based outcomes were significantly worse for children who were under age 10 at diagnosis compared to older children. In addition, parent‐reported EF was worse for children with US public insurance, an indicator of economic hardship. Future research should continue to investigate the contribution of socioeconomic status and other demographics to cognitive outcomes for survivors of pediatric cancers.
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### O-061. Laparoscopic Resection of Adrenal Area Tumor without Image‐Defined Risk Factors: A Single Center Prospective Study on 56 Pediatric Patients {#pbc27455-sec-0810}

[J. Wang]{.ul} ^1^, Z. Zhihui^1^, L. Minju^1^, G. Zhonghai^1^, S. Qiang^1^

*^1^Children\'s Hospital Zhejiang University School Medicine, Surgical Oncology Department, hangzhou, China*

**Background/Objectives**: Over the last 20 years Minimally Invasive Surgery (MIS) has been well‐accepted surgical approach in pediatric surgery. However, MIS is not popular in children with adrenal area tumor. This study aimed at evaluating the safety and effectiveness of MIS resection in a series of children with adrenal area tumor without Image‐Defined Risk Factors (IDRFs).

**Design/Methods**: Since 2014, an institutional protocol for MIS resection of adrenal area tumor in pediatric patients without IDRFs has been applied. Absence of IDRFs was considered as the main indication for MIS approach, regardless of tumor size. Cases underwent preoperative chemotherapy were excluded in this protocol. All patients who underwent MIS for adrenal area tumor between September 2014 and December 2016 were included. Specific technical considerations, demographic data, and follow‐up dada have been recorded.

**Results**: Fifty‐six patients underwent MIS resection for IDRFs‐negative adrenal area tumor. Median age was 2y3m (range 1m‐13y). Median diameter of the mass was 47mm (range 15--95 mm). Median operative time was 63 min (range 45‐85min). Median hospital stay was 5 days. Neuroblastic tumor was the main postoperative pathological diagnosis, including 39 cases of neuroblastoma, 8 cases of ganglioneuroma. Other diagnosis included 4 cases of adrenal cortical tumor, 4 cases of pheochromocytoma, and 1 case of adrenal hematoma. Five patients converted to open surgery, 3 cases caused by intraoperative hemorrhage, 1 case was found extremely easy to rupture, and in 1 case of pheochromocytoma ventricular fibrillation occurred. MIS approach was successful in other 51 patients. All patients were treated successfully, no serious postoperative complications, including port‐site or peritoneal metastases were experienced.

**Conclusions**: This study demonstrated the safety and effectiveness of MIS for the resection of adrenal area tumor without IDRFs in children. Open surgery should be considered as alternative approach if serious complication occurred. Blood pressure control should be intensively performed in the cases of pheochromocytoma.

### O-062. The Influence of Surgical Excision on Survival in High‐Risk Neuroblastoma Revisited After Introduction of ch14.18/CHO Immunotherapy in the HR‐NBL1/SIOPEN Trial {#pbc27455-sec-0820}

[R. Ladenstein]{.ul} ^1,2^, U. Poetschger^3^, S. Sarnacki^4^, T. Monclair^5^, G. Cecchetto^6^, J. Gomez‐Chacon^7^, J. Stenman^8^, J.M. Joseph^9^, R. Luksch^10^, V. Castel^7^, S. Ash^11^, V. Papadakis^12^, J. Malis^13^, W. Balwierz^14^, C. Owens^15^, H. Lode^16^, T. Boterberg^17^, D. Valteau‐Couanet^18^, A.D. Pearson^19^, K. Holmes^20^

*^1^St. Anna Kinderkrebsforschung e.V., S2IRP Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^2^St. Anna Children's Hospital, Department of Paediatrics‐ Medical University, Vienna, Austria; ^3^St. Anna Kinderkrebsforschung‐ Children\'s Cancer Research Institute, Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^4^Necker Enfants -- Malades Hospital‐ Paris Descartes University, Department of Pediatric Surgery, Paris, France; ^5^Oslo University Hospital, Paediatric Surgery, Olso, Norway; ^6^University Hospital of Padua, Paediatric Surgery, Padua, Italy; ^7^Hospital Universitario La FE, Paediatric Oncology, Valencia, Spain; ^8^Karolinska Institutet‐ Astrid Lindgren Children\'s Hospital, Paediatric Oncology, Stockholm, Sweden; ^9^University Hospital Lausanne, Paediatric Oncology, Lausanne, Switzerland; ^10^Fondazione IRCCS‐ Isituto Nazionale dei Tumori, Paediatric Oncology, Milan, Italy; ^11^Schneider Children's Medical Center of Israel, Paediatric Oncology and Haematology, Petach‐ Tikvah, Israel; ^12^Agia Sofia Children\'s Hospital, Department of Paediatric Oncology and Haematology, Athens, Greece; ^13^University Hospital Motol, Department of Paediatric Oncology and Haematology, Prague, Czech Republic; ^14^Jagiellonian University Medical College, Department of Paediatric Oncology and Haematology, Krakow, Poland; ^15^University of Dublin, Department of Paediatric Oncology and Haematology, Dublin, Ireland; ^16^University of Greifswald, Department of Paediatric Oncology and Haematology, Greifswald, Germany; ^17^University Hospital Ghent, Department of Paediatric Oncology and Haematology, Ghent, Belgium; ^18^Institut Gustave Roussy, Department of Paediatric Oncology and Haematology, Villejuif‐ Paris, France; ^19^Institute of Cancer Research and Royal Marsden NHS Trust, Department of Paediatric Oncology and Haematology, Sutton, United Kingdom; ^20^St George\'s Hospital, Paediatric Surgery, London, United Kingdom*

**Background/Objectives**: HR‐NBL1/SIOPEN Trial: The influence of Complete Macroscopic Excision (CME) in the pre‐ and post immunotherapy era.

**Design/Methods**: Eligibility criteria: enrolment between 2002‐2015, stage 4 disease; completion of Rapid COJEC induction ±two courses of TVD; no progression/relapse/death; no prior attempt at resection and complete operation data. Intended therapy following operation comprised: HDT/SCT (BuMel or CEM, after 2011 BuMel), 21Gy radiotherapy to the primary site followed by 13‐cis RA and after 2009 ch14.18/CHO antibody (short term infusion) ± IL2. 1504 patients fulfilled these criteria; 737 were treated prior to ch14.18/CHO availability (2002‐2009) and 767 in the immunotherapy era. Median observation time was 4.9 years (0.1‐14 years).

**Results**: CME was achieved in 77%, Incomplete Macroscopic Excision (IME) in 21% and 2% were inoperable (0E). Surgical mortality was 0.46%. Five year event‐free survival (5y‐EFS ± standard error) was 39%±2% following CME vs. 30%±3% following IME or 0E (p=0.002). The cumulative incidence of local relapse (CILR) was 17%±1 (CME); 31%±3 (IME) and 42%±10 (0E) (p\<0.001). 88% had radiotherapy (78% CME; 21% IME and 1% 0E). In some very young patients and patients with very large primary tumours radiotherapy was omitted. 5y‐EFS for patients with CME and radiotherapy was 44±2%, compared to 31±6% without (p=0.013) and 35±3% with less than CME compared to 20±1% without radiotherapy (NS). CILR was 14%±1 in patients with CME &radiotherapy vs. 28%±6 without radiotherapy (p=0.005). 5y‐EFS was significantly higher (42±2%) for patients enrolled after 2009 compared to before (32±2%) (p=0.000). 5‐y EFS for patients after 2009 who achieved CME was 45±2% vs. 36±2% after IME and 26±13% after 0E respectively (p=0.034); compared to 33±2% vs. 26±4% (IME) and 17±11% (0E) (p=0.059) prior to 2009.

**Conclusions**: In the immunotherapy era, CME in Stage 4 patients who received local radiotherapy resulted in improved 5‐EFS.

### O-063. Preoperative CT Scan for Abdominal Neuroblastomas is Superior to MRI for Safe Surgical Planning {#pbc27455-sec-0830}

[K. Burnand]{.ul} ^1^, G. Barone^2^, K. McHugh^3^, K. Cross^1^

*^1^Great Ormond Street Hospital, Specialists in Paediatric and Neonatal Surgery, London, United Kingdom; ^2^Great Ormond Street Hospital, Paediatric oncology, London, United Kingdom; ^3^Great Ormond Street Hospital, Paediatric radiology, London, United Kingdom*

**Background/Objectives**: Imaging is required to assess disease prior to surgery in all neuroblastoma (NBL) European protocols, however, MRI and CT scans are both accepted. We routinely utilize MRI for diagnosis of NBL but concerns regarding MRI underestimating extent of disease at follow‐up changed practice. Since 2016 we have used MRI and CT before all abdominal neuroblastoma resections. The aim of this retrospective study was to establish which imaging modality is superior in terms of preoperative planning.

**Design/Methods**: Abdominal MRI and CT scans all abdominal/pelvic NBLs referred for surgery from January 2016 to February 2018 were retrospectively reviewed to evaluate the extent of disease and the presence of imaging‐defined risk factors (IDRFs).

**Results**: 31 patients were eligible for consideration of surgery post MRI/MIBG at our MDT meeting. Seven patients were excluded (two did not adhere to SIOPEN treatment protocol, two had no CT and three patients were excluded as their preoperative CT and MRI were during different treatment stages). 17/24 patients underwent surgery. CT was performed a mean of 13 (range 1‐47) days after MRI. MRI unrepresented IDRFs in 13/24 patients. Notably there were fundamental changes in management post CT in 6/24 patients (25%); three patients the decision went from 'surgery' to 'no surgery' due to newly recognised unresectable disease, one postponed surgery for high dose therapy (previously considered for minimally invasive surgery) and two had alterations in surgical approach (bilateral disease noted needed more extensive approach, change of lead surgeon). CT did not underestimate disease compared to MRI in any patient.

**Conclusions**: Due to tumor fibrosis and calcification post‐chemotherapy MRI underestimated the extent of the disease in half of our patients considered for neuroblastoma resection. Preoperative CT scan is necessary to identify all IDRFs to ensure safe surgery. Future protocols should take this limitation of MRI into consideration to avoid underestimating pre‐operative tumor extent.

### O-064. Radiological Description and Impact on Outcome of Postoperative Residue After High‐Risk Neuroblastoma Surgery {#pbc27455-sec-0840}

[S. Irtan]{.ul} ^1^, H. Ducou Le Pointe^2^, C. Fayard^3^, H. Gabra^4^, C. Granata^5^, S. Avanzini^6^, L. Pio^6^, J. Gomez‐Chacon^7^, S. Braungart^8^, J. Stenman^9^, F. Sundquist^9^, J. Strömgren^10^, D. Plantaz^11^, L. Matthyssens^12^, N. Jauquier^13^, K. Bjornland^14^, A. Ingegerd^15^, K. Cross^16^, K. McHugh^17^, S. Sarnacki^18^

*^1^Hôpital Tousseau ‐ Assistance Publique Hôpitaux de Paris, Pediatric Surgery, Paris, France; ^2^Hôpital Trousseau ‐ Assistance Publique Hôpitaux de Paris, Pediatric Radiology, Paris, France; ^3^Curie Institute, Pediatric Radiology, Paris, France; ^4^The Newcastle upon Tyne Hospitals NHS Foundation Trust, Pediatric Surgery, Newcastle, United Kingdom; ^5^Giannina Gaslini Institute, Pediatric Radiology, Genoa, Italy; ^6^Giannina Gaslini Institute, Pediatric Surgery, Genoa, Italy; ^7^Hospital La Fe, Pediatric Surgery, Valencia, Spain; ^8^Royal Manchester Children\'s Hospital, Pediatric Surgery, Manchester, United Kingdom; ^9^Karolinska University Hospital, Pediatric Surgery and Urology, Stockholm, Sweden; ^10^Karolinska University Hospital, Pediatric Radiology, Stockholm, Sweden; ^11^CHU Grenoble, Service Immuno‐Hémato‐Oncologie pédiatrique, Grenoble, France; ^12^Princess Elisabeth Children\'s Hospital, Neonatal and Paediatric Surgery, Ghent, Belgium; ^13^CHUV Lausanne, Service de Chirurgie pédiatrique, Lausanne, Switzerland; ^14^Oslo University Hospital, Pediatric Surgery, Oslo, Norway; ^15^Oslo University Hospital, Pediatric Radiology, Oslo, Norway; ^16^Great Ormond Street for Children, Pediatric Surgery, London, United Kingdom; ^17^Great Ormond Street Hospital for Children, Pediatric Radiology, London, United Kingdom; ^18^Hôpital Necker Enfants‐malades ‐ Assistance Publique Hôpitaux de Paris, Pediatric Surgery, Paris, France*

**Background/Objectives**: Controversial issues regarding the impact of post‐operative residue of high‐risk neuroblastoma (HRNBL) still remain, partly because the tumoral residue was based on the surgeon\'s report. In the view of the future European HRNBL protocol (where radiotherapy will be planned on radiological‐based residue), the volume of residue in patients operated for HRNBL was analysed and associated to risk factors and outcome.

**Design/Methods**: A retrospectivereviewof images at diagnosis, preoperative and postoperative time of children under 18 years diagnosed with HRNBL, treated according to HRNBL01 protocol and operated on for the primary location in 8 participating countries (13 centres) was conducted.

**Results**: A total of 341 patients (128F/213M) with a median age at diagnosis of 33.5 months \[0‐249.5\] were analysed: 310 metastatic (129 MYCN amplification), 26 localized and 5 Ms with MYCN amplification. The tumour originated from the adrenal gland (n=285) and the sympathetic chains, 31 paravertebral (16 thorax, 14 abdomen and one thorax‐abdomen) and 23 perivascular (all but one abdominal) (2 unknown). A residue was noted in 169/334 patients with reviewed postoperative images (50.6%) at a median delay after surgery of 64 days \[1‐933\]. It was linked to the presence of IDRF in 111 patients (65%). The median volume of the residue was 0.6 ml \[0‐201.8\] and 1.4 ml \[0‐201.8\] when patients with residue restricted to micro calcifications were omitted (n=28, 16.6%). Residue volume was over 5 ml in 33 patients (19.5%). Presence of a residue was associated with the number of preoperative IDRF, diagnosis and preoperative tumour volume but not with the number of IDRF at diagnosis, location and morbidity. It does not seem to impact overall survival.

**Conclusions**: The volume of a postoperative residue after HRNBL surgery was low in expert centres. Its impact on outcome will be further studied based on radiotherapy control data.

### O-065. Detection of Minimal Residual Disease (MRD) in High Risk Neuroblastoma Correlates with Outcome: Final Results of International GPOH‐DCOG Prospective Validation Study {#pbc27455-sec-0850}

[L. Van Zogchel]{.ul} ^1^, B. De Carolis^2^, E. van Wezel^3^, J. Stutterheim^1^, L. Zappeij‐Kannegieter^4^, M. van Doornum^4^, R. Schumacher‐Kuckelkorn^2^, J. Gecht^2^, T. Simon^2^, H. Caron^5^, M. Fiocco^6^, E. van der Schoot^3^, B. Hero^2^, F. Berthold^2^, G. Tytgat^1^

*^1^Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands; ^2^Children\'s Hospital ‐ University of Cologne, Department of Pediatric Hematology and Oncology, Cologne, Germany; ^3^Sanquin Research and Landsteiner Laboratory of the AMC‐ University of Amsterdam, Department of Experimental Immunohematology, Amsterdam, The Netherlands; ^4^Sanquin Research and Landsteiner Laboratory of the AMC‐ University of Amsterdam, Department of Immunocytology, Amsterdam, The Netherlands; ^5^Emma Childrens Hospital‐ Academical Medical Center, Department of Pediatric Oncology, Amsterdam, The Netherlands; ^6^Leiden University, Mathematical Institute, Leiden, The Netherlands*

**Background/Objectives**: In a relatively small retrospective study we previously described that MRD detected by real‐time quantitative PCR (qPCR) correlates with survival. We now prospectively studied, in 280 high‐risk neuroblastoma (NB) patients, treated in NBL2004 (GPOH) and NBL2009 (DCOG), the prognostic value of diagnostic levels of NB‐specific mRNA, the clinical significance of BM clearance after 2 courses and at the end of induction‐therapy.

**Design/Methods**: Serial BM samples from 280 high‐risk NB patients at diagnosis and set time points during treatment were prospectively collected (GPOH and DCOG) between 2009 and 2017. qPCR was performed using five NB‐markers: paired‐like homeobox 2b (PHOX2B), tyrosine hydroxylase (TH), dopa decarboxylase (DDC), cholinergic receptor alpha 3 (CHRNA3) and growth‐associated protein 43 (GAP43). BM infiltration was defined as described previously (Stutterheim 2009; van Wezel 2016) and compared to GD2‐immunocytology (IC). Event‐free survival (EFS) and overall survival (OS) were studied by Kaplan‐Meier and a multivariable Cox regression model (including age, MNA and infiltration level).

**Results**: At diagnosis, BM‐infiltration level correlated with EFS (p\<0.001) and OS (p\<0.001). The adjusted hazard ratio for patients with BM infiltration \>10% at diagnosis was 2.23\[95% CI1.39‐3.57\] and 2.41\[95% CI1.38‐4.21\] for EFS and OS, respectively. BM infiltration \<0.1% vs \>0.1% after 2 courses differed significantly for EFS. A significant poorer outcome was seen for post‐induction BM positivity, 5 years EFS and OS for negative, \<0.1% and 0.1‐10% was 55%(95%CI:40‐70), 26%(13‐38) and 20%(1‐45); 66%(50‐81), 47%(33‐62) and 30%(16‐58), respectively. qPCR was overall more sensitive and a better predictor of outcome than IC, especially end of induction IC‐negative/PCR‐positive vs IC‐negative/PCR‐negative patients had a poorer outcome.

**Conclusions**: High BM infiltration levels at diagnosis correlate with poor outcome. BM clearance/low infiltration after 2 cycles of induction therapy is associated with better EFS. qPCR BM clearance at the end of induction therapy is significantly associated with better EFS and OS.

### O-066. Generations of Neuroblastoma Organoid as Personalized Models {#pbc27455-sec-0860}

[J. Molenaar]{.ul} ^1^, W. Hassan^1^, M. Ebus^1^, J. Koster^2^, M. vd Wetering^1^, P. Lijnzaad^1^, F. Holstege^1^, A. Essing^1^, B. Koopmans^1^, E. Dolman^1^

*^1^Princess Maxima Center for pediatric oncology, translational reserach, Utrecht, The Netherlands; ^2^Academic Medical Center Amsterdam, Oncogenomics, Amsterdam, The Netherlands*

**Background/Objectives**: In an attempt to improve the treatment of relapse neuroblastoma and other pediatric cancer, precision medicine programs aim at identifying genomic and/or epigenetic aberrations that could serve as biomarkers for targeted therapies. However, several studies have now shown, that on average, actionable events can be identified in about 50% of the patients. To identify potential treatment options for the remaining 50% of patients we are developing personalized models that can be used in automated compound screening.

**Design/Methods**: We have used 3D serum free culturing conditions to generate neuroblastoma organoids. We used the R2 bioinformatic platform to identify additional growth factors to improve growth rates and single cell tumor take. Genomic profiling and single cell RNA sequencing was used to study the maintenance of tumor heterogeneity in these models. To identify potential new interventions, we have developed a robotics platform to systematically screen a library of 180 compounds. As a reference, the same compound library will additionally be tested on organoids from non‐malignant tissues, including colon, duodenum, kidney and liver.

**Results**: Using our optimized 3D culturing protocol, we could grow neuroblastoma organoids in 23 out of 35 primary tumor materials. Failure of growth mainly related to low tumor content of the biopsy material. Genomic profiling confirmed maintenance the genomic aberrations of the primary tumor material. Heterogeneity was retained as shown by single cell RNAseq analysis. The compound screening identified targeted compounds interfering in DNA damage signalling and epigenetic modifiers with increased sensitivity in neuroblastoma organoids. The compound screening data is now correlated to the genomic profiling of these samples to identify potential new biomarkers.

**Conclusions**: We conclude that neuroblastoma organoid are a valid system to further develop as personalized tumor models.
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### O-067. Academic Achievement Prediction and Outcomes in Children with Brain Tumor {#pbc27455-sec-0880}

[M. Sato]{.ul} ^1^, H. McAtee^2^, A. Grafft^3^, T. Ginader^4^, C. Lynch^5^, S. Barron^6^

*^1^University of Iowa Stead Family Children\'s Hospital, Pediatric Hematology Oncology, Iowa CIty, USA; ^2^University of Iowa, Carver College of Medicine, Iowa City, USA; ^3^University of Iowa Stead Family Children\'s Hospital, Center for Disabilities and Development, Iowa City, USA; ^4^University of Iowa, Biostatistics, Iowa City, USA; ^5^University of Iowa College of Public Health, Epidemiology, Iowa City, USA; ^6^University of Iowa College of Education, Department of Psychological and Quantitative Foundations‐, Iowa City, USA*

**Background/Objectives**: Academic achievement of children with brain tumor has not been addressed. A population‐based cohort was created via a linkage involving the Iowa Cancer Registry (ICR) and the Iowa Testing Programs (ITP). ICR had records of patients with brain tumor diagnosis since 1973, while ITP had a set of standardized academic achievement measures, obtained from students in kindergarten through high school for last 70 years. Measurement domains included vocabulary, reading, language, math, social studies, and science. Purpose of this study is to identify patterns of academic achievement in children before diagnosis of brain tumor and after diagnosis and treatment.

**Design/Methods**: Academic achievement data were analyzed in the form of national percentile rank scores by grade and content domains. Trajectory of academic achievement prior and post diagnosis, statistical analyses between benign and malignant tumors, male and females, right and left tumors, were analyzed.

**Results**: 593 children (median age at nine‐year‐old) with brain tumors diagnosed between 1985 and 2015 were identified. Total of 3536 academic achievement testing results were analyzed. 37% (n=219) of children had malignant and 62% (n=370) of children had benign tumors. There was no significant difference in academic achievement before diagnosis between benign and malignant groups. When compared between genders, female group showed better trajectory in science prior to diagnosis than the male group. After diagnosis, there was a significant decline in academic achievement in all domains in both benign and malignant groups, suggesting surgery intervention only had impacted on academic achievement. Laterality comparison showed significant decline in math and math computation in the right‐sided tumor group.

**Conclusions**: Academic achievement testing is helpful to measure the degree of brain function decline after brain tumor diagnosis. Academic achievement testing at school can be utilized to evelop an intervention for patients with neurocognitive decline.

### O-068. Long Term Effects on Ventromedial Hypothalamus (VMH) and Anterior Pituitary Function in German Patients with CNS Germinoma Treated According to SIOP CNS GCT 96 {#pbc27455-sec-0890}

[G. Calaminus]{.ul} ^1^, C. Kuhrt^1^, U. Göbel^2^, J.E. Müller^1^, S. Klagges^3^, T. Czech^4^, R.D. Kortmann^3^

*^1^University Children\'s Hospital, Department of Paediatric Oncology, Bonn, Germany; ^2^Children\'s Hospital‐ University of Duesseldorf, Department of Paediatric Oncology, Duesseldorf, Germany; ^3^University of Leipzig, Department of Radiation Therapy and Radio‐Oncology, Leipzig, Germany; ^4^University of Vienna, Department of Neurosurgery, Vienna, Austria*

**Background/Objectives**: CNS Germinoma achieve a five years EFS by craniospinal irradiation alone (88%) or by combined chemo and radiotherapy (89%). They occur suprasellar (30 %), pineal (50 %) or bifocal (20%). Radiotherapy (RT) to the pituitary area can cause total panhypopituitarism (PAN) or partial anterior pituitary failures (APF) and VMH damage. VMH damage can also result in body mass index (BMI) elevation. Thus, we examined the effect of treatment on the anterior pituitary function and the BMI‐elevation (cut off \>26kg/m^2^).

**Design/Methods**: We evaluated 86 patients treated between 01/10/1996 and 31/12/2005, who were alive and without recurrence (01/03/2018). Sixty‐four were male, 22 were female (median age, 15 years; median observation time 9,77 years). APF, PAN and BMI were examined before treatment and at least 4 years after (11/2009).

**Results**: Of 86 patients 46 had bifocal/suprasellar primary tumors, 16/46 suprasellar/bifocal showed PAN, 30 had partial or no APF before therapy. Of 86 patients 44 showed APF after treatment of whom 32 showed PAN. After treatment 16/30 patients developed new PAN, 3/16 caused by operation, 7/16 by irradiation and 6/16 were unclear. Only 2/40 pineal germinoma developed partial APF after treatment. Patients with suprasellar/bifocal tumors received 40 Gy radiotherapy (RT) dose to the pituitary area, patients with pineal tumors received 24Gy or less RT dose to the pituitary area. Of the 86 patients 23 developed BMI‐elevation in follow‐up. Riskfactors for developing BMI‐elevation were suprasellar/bifocal localisation (p=0.021), APF (p=0.0028), and radiation dose of 40 Gy (p=0.03016) to PA which also includes VMH.

**Conclusions**: Patients with 40Gy RT dose to the pituitary area had a significant higher risk to develop partial APF or PAN. Our results show that lower RT doses to the pituitary area are needed to prevent APF and VMH damage and the development of BMI‐elevation as an additional health risk.

### O-069. Breast Cancer Risk and Detection in Female Childhood Cancer Survivors in the St. Jude Lifetime Cohort Study (SJLIFE) {#pbc27455-sec-0900}

[M. Ehrhardt]{.ul} ^1^, C. Howell^2^, K. Hale^2^, M. Baassiri^3^, C. Rodriguez^4^, C. Wilson^2^, S. Joshi^5^, T. Lemond^5^, S. Shope^2^, R. Howell^6^, Z. Wang^7^, D. Mulrooney^1^, J. Zhang^7^, L. Robison^2^, K. Ness^2^, M. Hudson^1^

*^1^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^3^Hammoud Hospital University Medical Center, Oncology, Saida, Lebanon; ^4^Wayne State University, Obstetrics and Gynecology, Detroit, USA; ^5^University of Tennessee, Radiology, Memphis, USA; ^6^MD Anderson Cancer Center, Radiation Physics, Houston, USA; ^7^St. Jude Children\'s Research Hospital, Computational Biology, Memphis, USA*

**Background/Objectives**: Female childhood cancer survivors are at risk for subsequent breast cancers. We characterized breast cancer risk and screening outcomes in female SJLIFE participants.

**Design/Methods**: Female SJLIFE participants (n=1,467, mean±SD age of 31.6±8.3 years) underwent clinical assessment, validation of prior health events, risk‐based screening, chest radiation dosimetry estimation, and whole genome sequencing (n=1,343). Biopsy reports of suspected breast cancers were reviewed. A subgroup of women (n=139) underwent both breast magnetic resonance imaging (MRI) and mammography (n=157 paired images) that were retrospectively interpreted by radiologists blinded to clinical outcomes. Proportional hazard models were used to investigate associations \[hazard ratios (HR), 95% confidence intervals (CI)\] between patient characteristics, childhood cancer treatments, and breast cancer occurrence.

**Results**: Fifty‐six women developed 72 breast cancers (28 in situ carcinomas, 40 invasive ductal carcinoma, 4 other) at a mean±SD age of 38.8±7.1 years. Cumulative incidences at ages 35 and 50 years were 1% and 14% (no chest radiation), and 9% and 38% (≥1000 cGy chest radiation), respectively. In a multivariable model, breast cancer was associated with increasing age at diagnosis (HR=1.2 per year, CI:1.1‐1.3), chest radiation dose (≥1000 cGy, HR=7.0, CI:3.1‐15.7), cumulative anthracycline dose (100‐199 mg/m2, HR=5.1, CI:1.9‐13.3; 200‐299 mg/m2, HR=5.4, CI:1.8‐16.6; \>300 mg/m2, HR=15.0, CI:6.4‐35.3), and having a pathogenic/likely pathogenic mutation in one of nine autosomal dominant genes (*BRCA1, BRCA2, ATM, CDH1, CHEK2, PALB2, PTEN, STK11, TP53*) with high penetrance that have been linked to breast cancer (HR=9.2, CI:3.3‐26.0).

Women with paired images were a mean±SD age of 37.3±7.6 years and had a mean chest radiation dose 2,644±979 cGy. Sensitivity and specificity were 53.8% and 94.9% for mammography, 76.9% and 88.9% for MRI, and 89.3% (either image positive) and 99.4% (both images negative) for parallel dual imaging.

**Conclusions**: Treatment and genetic risk factors identify survivors at highest risk for breast cancer and who may benefit most from parallel mammography/MRI screening.

### O-070. Cost Effectiveness of Early Colorectal Cancer Screening in Childhood Cancer Survivors {#pbc27455-sec-0910}

[D. Hodgson]{.ul} ^1^, H. Keshavarz^1^, A. Gini^2^, R. Meester^2^, I. Lansdorp ‐ Vogelaar^2^

*^1^Princess Margaret Cancer Centre, Radiation Oncology, Toronto, Canada; ^2^Erasmus MC, Department of Public Health, Rotterdam, The Netherlands*

**Background/Objectives**: Some Childhood Cancer Survivors (CCS) are at high risk of colorectal cancer (CRC) compared to the general population. The potential benefits, costs and cost‐effectiveness of early CRC screening are unclear, however, and consequently the recommendations of opinion‐based guidelines vary with respect to when screening should be initiated.

**Design/Methods**: We modified an established model of CRC screening (Microsimulation Screening Analysis‐Colon, MISCAN‐Colon) to reflect the CRC risk and other‐cause mortality among CCS. CRC risks and competing causes of death were based on epidemiologic studies of CRC in CCS and data from Surveillance, Epidemiology, and End Results (SEER). We evaluated 75 colonoscopy screening strategies varying in screening intervals, age to start, and age to stop in CCS. We computed the risk of CRC death, CRC deaths prevented, and incremental cost‐effectiveness ratios (ICERs) assuming a willingness‐to‐pay threshold of \$100,000 per life‐year gained (LYG).

**Results**: Among all CCS, 37 survivors per 1,000 at risk were predicted to die of CRC without screening, while this number was 63 per 1,000 among those treated with abdominal/pelvic radiation therapy (APRT). Screening with colonoscopy every 10 years from age 40 was optimal among all CCS (ICER = \$67,000 per LYG), avoiding 79% of CRC deaths. For those treated with APRT, the optimal strategy was 10‐yearly colonoscopy starting at age 35 (ICER = \$92,000 per LYG), preventing up to 82% of CRC mortality. Repeating colonoscopy screening every 3 and 10 years was optimal, respectively, among WT (from age 35, \$73,000/LYG; 86% lower CRC mortality) and HL survivors (from age 40, \$51,000/LYG; 80% reduction in CRC mortality). Age at primary cancer diagnosis and additional all‐cause mortality data did not affect optimal ages to start screening.

**Conclusions**: To our knowledge, this is the first quantitative evidence to indicate that early initiation of CRC screening would be cost effective among CCS, particularly those treated with APRT.

### O-071. Income of Adult Survivors of Childhood and Adolescent Cancer: Findings from the Three Nordic Country‐Wide Population Based SALiCCS Study {#pbc27455-sec-0920}

[A. Tolkkinen]{.ul} ^1,2^, L. Madanat‐Harjuoja^1,2^, M. Taskinen^3^, N. Malila^1,4^, F. Erdmann^5^, J. Pitkäniemi^1,6^

*^1^Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland; ^2^Children\'s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ^3^Helsinki University Hospital, Division of Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Helsinki, Finland; ^4^University of Tampere, Faculty of Social Sciences, Tampere, Finland; ^5^Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark; ^6^University of Helsinki, Department of Public Health, Helsinki, Finland*

**Background/Objectives**: Survivors of childhood cancer may face a broad spectrum of somatic late‐effects following cancer diagnosis. In addition to increased risk of somatic morbidity, survivors may face socioeconomic difficulties in adulthood. The SALiCCS (Socioeconomic Consequences of Adult Life After Childhood Cancer in Scandinavia) research program is a unique three county‐wide registry‐based population based cohort of childhood cancer survivors from Denmark, Finland and Sweden. The aim of this study was to find out how childhood cancer diagnosis affects income of survivors in their adult life and the preliminary results presented describe the Finnish sub‐cohort.

**Design/Methods**: 4027 five‐year survivors diagnosed with cancer under the age of 20 from 1971 to 2009, being 20 years of age or older and alive in 2014 were identified from the Finnish Cancer Registry. Annual disposable income in 2014 was retrieved from Statistics Finland. Survivors' median disposable income in 2014 was compared to a matched population comparison (matched by sex and birth year), testing for significance using the Wilcoxon Signed‐Rank Test. Median disposable income was also calculated for specific diagnostic groups.

**Results**: The median disposable income in 2014 was 20,926 EUR for childhood cancer survivors versus 22,607 EUR for population comparisons. The difference in disposable income between cancer survivors and population comparisons was statistically significant (p=\<0.001). In survivors, median disposable income was 17,716 EUR for survivors of CNS tumors, 19,501 EUR for survivors of leukemia, 21,565 EUR for survivors of lymphoma and 22,659 EUR for survivors of other malignant neoplasms.

**Conclusions**: Our preliminary results indicate that survivors of childhood cancer have lower average median disposable income compared to the general population. Survivors of CNS tumors had the lowest income of all cancer survivors. Both somatic morbidity and psychosocial challenges such as barriers to employment may have contributed to the low income observed among survivors.

### O-072. Genome‐Wide Association Study to Identify Obesity Susceptibility Loci in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study (CCSS) {#pbc27455-sec-0930}

[P. Lupo]{.ul} ^1^, A. Brown^1^, V. Arroyo^1^, J. Belmont^2^, M. Scheurer^1^, K. Foster^3^, D. Kern^3^, W. Leisenring^4^, F. Okcu^1^, Y. Yasui^5^, L. Morton^6^, S. Chanock^6^, L. Robison^5^, G. Armstrong^5^, S. Bhatia^7^, K. Oeffinger^8^, K. Kamdar^1^

*^1^Baylor College of Medicine, Pediatrics, Houston, USA; ^2^Baylor College of Medicine, Molecular and Human Genetics, Houston, USA; ^3^Baylor College of Medicine, Medicine and Pediatrics, Houston, USA; ^4^Fred Hutchinson Cancer Research Center, Clinical Research, Seattle, USA; ^5^St. Jude Children\'s Research Hospital, Epidemiology & Cancer Control, Memphis, USA; ^6^National Cancer Institute, Division of Cancer Epidemiology & Genetics, Bethesda, USA; ^7^University of Alabama at Birmingham, Pediatrics, Birmingham, USA; ^8^Duke University, Medicine, Durham, USA*

**Background/Objectives**: Obesity is an important late effect among survivors of childhood ALL. Although numerous body mass index (BMI) susceptibility variants have been identified in the general population, genetic predisposition for obesity in ALL survivors remains poorly understood. We conducted a GWAS of BMI among ≥5‐year survivors of ALL from the CCSS and Texas Children\'s Cancer Center (TCCC).

**Design/Methods**: The discovery GWAS included 1,114 adult survivors of ALL participating in the CCSS, genotyped on the HumanOmni5Exome array and imputed using the 1000 Genomes Project. Independent replication sets from TCCC, genotyped on the Illumina OmniExpress array, included: 1) 148 adult survivors and 2) 312 survivors \<20 years of age with BMI z‐scores calculated from age‐ and sex‐specific growth charts. In separate models for each population, BMI or BMI z‐score was regressed on age at diagnosis, age at follow‐up, cranial radiotherapy (CRT), sex, and age at diagnosis‐CRT interaction. Resulting residuals were included as the dependent variable in linear regression models to estimate the beta and *P*‐value for each SNP, adjusting for genotype‐derived principal components. For SNPs associated with BMI (*P*\<10^‐6^) in the discovery set, meta‐analyses were conducted across the three populations using an inverse‐variance‐based approach.

**Results**: We first evaluated ∼100 BMI‐associated SNPs identified from GWAS in the general population. None were associated with BMI among ALL survivors after correcting for multiple comparisons. In the meta‐analysis, we identified a putative locus on 16p13.3 that reached genome‐wide significance (*P*=8.5x10‐9) with consistent beta estimates across the three populations: 0.20 (CCSS); 0.16 (TCCC 1); and 0.27 (TCCC 2). In GTEx, SNPs in this locus are associated with *DECR2* expression across multiple tissues, which has been implicated in lipoprotein metabolism.

**Conclusions**: We identified a potentially novel BMI‐associated locus on chromosome 16 in ALL survivors. Additional analyses are underway, including further replication, estimation of polygenic risk scores, and investigation in high‐risk treatment groups.
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### O-073. Independent Validation of the Children\'s Hepatic Tumors International Collaboration (CHIC) Risk Stratification for Hepatoblastoma {#pbc27455-sec-0950}

[L. Mascarenhas]{.ul} ^1^, J. Malvar^2^, J. Stein^3^, L. Wang^4^, Y. Genyk^5^, R. Sposto^1^, S. Zhou^4^

*^1^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Pediatrics‐ Hematology‐ Oncology and‐ Blood and Marrow Transplantation, Los Angeles, USA; ^2^Children\'s Hospital Los Angeles, Pediatrics‐Hematology‐ Oncology and‐ Blood and Marrow Transplantation, Los Angeles, USA; ^3^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Surgery‐ General Pediatric Surgery, Los Angeles, USA; ^4^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Pathology‐ Pediatric Surgical, Los Angeles, USA; ^5^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Surgery‐ Transplant Surgery, Los Angeles, USA*

**Background/Objectives**: The CHIC group recently developed a new international risk stratification system for hepatoblastoma (HB). This risk stratification includes age, PRETEXT stage, PRETEXT annotation factors, metastases, serum alpha‐fetoprotein level and tumor resectability and categorizes patients into four risk groups: very low, low, intermediate, and high. However, it\'s performance has not been evaluated in an independent group of patients.

**Design/Methods**: We analyzed retrospectively collected data on all newly diagnosed patients with HB that were treated at Children\'s Hospital Los Angeles between 2000 and 2016. Using the CHIC risk stratification trees, each patient was assigned to a risk group.

**Results**: There were 98 consecutive patients (62 males, age ranges from 5 months to 18 years) diagnosed with HB in the time period. 16, 29, 23 and 30 patients fell in to the very low, low, intermediate, and high risk groups, respectively. After a median follow‐up of 3.1 years, there were 13 total cancer specific deaths. The estimated 5‐year overall survival rates by the CHIC risk classification trees were 100%, 95.0 ± 4.8%, 89.2 ± 7.2% and 57.9 ± 10.7% in patients in very low, low, intermediate, and high risk groups respectively. Compared to the very low/low risk group, the hazard ratio (HR) for death in patients with high risk and intermediate hepatoblastoma were 15.82 (95% CI 2.02 to 123.8) and 4.36 (95% CI 0.40 to 48.15), respectively (p=0.0011). The Kaplan Meier survival curve for the cohort followed the predicted trend and showed significant difference for both event--free survival (p\< 0.0001) and overall survival (p= 0.0063).

**Conclusions**: The CHIC risk stratification for HB performed well in our cohort. This is the first independent validation of the CHIC risk stratification for HB.

### O-074. Does Histology Add to the Performance of the Childrens Hepatic Tumors International Collaboration (CHIC) Risk Stratification for Hepatoblastoma? {#pbc27455-sec-0960}

S. Zhou^1^, J. Malvar^2^, J. Stein^3^, L. Wang^1^, Y. Genyk^4^, R. Sposto^5^, [L. Mascarenhas]{.ul} ^6^

*^1^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Pathology‐ Pediatric Surgical, Los Angeles, USA; ^2^Children\'s Hospital Los Angeles, Hematology‐ Oncology and‐ Blood and Marrow Transplantation, Los Angeles, USA; ^3^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Surgery‐ General Pediatric, Los Angeles, USA; ^4^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Surgery‐ Transplant, Los Angeles, USA; ^5^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Preventive Medicine and Pediatrics‐ Hematology‐ Oncology and‐ Blood and Marrow Transplantation, Los Angeles, USA; ^6^Children\'s Hospital Los Angeles‐ Keck School of Medicine‐ University of Southern California, Pediatrics‐ Hematology‐ Oncology and‐ Blood and Marrow Transplantation, Los Angeles, USA*

**Background/Objectives**: The CHIC risk stratification for hepatoblastoma (HB) categorizes patients into 4 risk groups based on several prognostic factors but omits histology.

**Design/Methods**: We retrospectively analyzed data of HB patients that were diagnosed at our institution between 2000‐2016. Using CHIC risk stratification, each patient was assigned a risk group. Next, based on the International Pediatric Liver Tumor Consensus Classification, each tumor was first assigned broadly to either epithelial or mixed epithelial‐mesenchymal type, and further to one of the following subtypes: fetal only, embryonal only, embryonal and fetal, hepatic malignant neoplasm not otherwise specified (HEMNOS) and others including small cell undifferentiated (SCU).

**Results**: 98 HB patients (62 males, age 0.42‐18 years) were categorized as very low (n=16), low (n=29), intermediate (n=23), and high (n=30) risk. 72% had PRETEXT stage III/IV tumors. All patients with metastases (n=19) and those \> 8 years (n=8) were high‐risk. 5 patients had AFP levels ≤100 ng/ml; 3 very low‐risk and 2 high‐risk. 85% of tumors had epithelial type histology. In the subtype classification, embryonal and fetal epithelial subtype predominated (44%), followed by embryonal only epithelial subtype (20%). SCU (n=8, INI‐1 retained) was not grouped separately since that group had insufficient events. All 10 patients with HEMNOS (9 high‐risk) survived. After a median follow‐up of 3.1 years, there were 13 total cancer specific deaths. The 5‐year OS rates by CHIC risk group were 100%, 95 ± 4.8%, 89.2 ± 7.2% and 57.9 ± 10.7% for patients with very low, low, intermediate and high‐risk disease respectively. In a multivariate analysis CHIC risk group and histology subtype were independently significant for OS (p = 0.0001, p = 0.0047, respectively). High‐risk patients with embryonal only epithelial subtype had the highest risk of death. Similar results were observed for EFS.

**Conclusions**: Histology subtype is prognostic and may add to the CHIC risk stratification for HB.

### O-075. Decline in Serum α‐Fetoprotein Level before Tumor Resection as a Prognostic Factor for Hepatoblastoma {#pbc27455-sec-0970}

[E. Hiyama]{.ul} ^1^, Y. Ueda^1^, S. Kurihara^1^, Y. Aoki^2^, T. Iehara^2^, K. Ida^2^, T. Kazama^2^, K. Kentaro^2^, Y. Takama^2^, T. Taguchi^2^, T. HIshiki^2^, J. Fujimura^2^, K. Hoshino^2^, S. Honda^2^, K. Matsumoto^2^, M. Mori^2^, M. Yano^2^, A. Yokoi^2^, K. Watanabe^2^, Y. Tanaka^2^
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**Background/Objectives**: We aimed to clarify whether the α‐fetoprotein (AFP) concentration and a decline in the AFP concentration before tumor resection represented prognostic factors for patients with hepatoblastoma (HBL) treated in the JPLT‐2 study (1999‐2012).

**Design/Methods**: In the JPLT‐2 study except 40 initial resected cases (course 1), 320 patients with HBL who underwent preoperative chemotherapy (CTx) were eligible. These patients underwent three different treatment strata (course 2‐4) with the main frame of CITA (cisplatin and pirarubicin) regimen according to the PRETEXT classification. The serum concentrations of AFP at diagnosis and before tumor resection were assessed for their association with event‐free survival (EFS) and overall survival (OS).

**Results**: Distribution of PRETEXT classifications was as follows: 4 patients had PRETEXT I tumors, 98 II, 134 III, and 84 IV, including 61 metastatic HBLs. AFP levels were 104‐7,653,000 ng/ml at diagnosis and 4.8‐3,132,839 ng/ml before resection. Decreases in AFP levels from diagnosis to before resection were 0.0000034‐2.24. Before resection, 12 PRETEXT II, 42 III, and 58 IV patients were down‐staged. But the down‐staging and did not significantly correlate with decline of AFP. The 5‐year EFS/OS of 80 course 2, 184 course 3, and 56 course 4 HBLs were 86%/91%, 76%/87%, and 36%/56%, respectively. Among them, 16 patients did not receive curative surgery due to refractory or progressive and died of disease. AFP levels at diagnosis showed no significant associations with disease‐progression before surgery and with EFS and OS in all cases. On the other hand, the \> 2 log decline in AFP levels was significant between EFS (P = 0.002) and OS (P \< 0.001). This difference was more significant in course 2 and 3 patients.

**Conclusions**: A decline in serum AFP level is useful for prognosis in HBLs. Monitoring AFP levels might aid in determining optimal surgical timing in patients with HBLs, especially localized HBLs.

### O-076. AFP Decline in Upfront Unresectable, Non‐Metastatic Hepatoblastoma {#pbc27455-sec-0980}
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**Background/Objectives**: Hepatoblastoma (HB) is the most common pediatric liver neoplasm. The majority of newly diagnosed patients present with an elevated serum alpha feto‐protein (AFP) level. The exact relationship between AFP decline during treatment and outcome is not well established.

**Design/Methods**: Children\'s Oncology Group (COG) protocol AHEP0731 for children with newly diagnosed HB included a stratum for "intermediate‐risk" patients who had unresectable, non‐metastatic disease or resected disease with small cell undifferentiated (SCU) histology and were anticipated to receive 6 cycles of cisplatin, 5‐fluorouracil, vincristine, and doxorubicin (C5VD). Resection by conventional surgery or transplant was intended to occur prior to cycle \#5. AFP levels were obtained at diagnosis, during therapy, and at off‐therapy visits. We analyzed AFP levels in response to therapy until normal as per institutional standards.

**Results**: One hundred and four eligible subjects were enrolled on this stratum. Mean AFP at diagnosis was 377,408 ng/ml (median: 156,648, range: 363‐3,338,000 ng/mL). AFP values normalized in 93 subjects (89%) as follows: 42 patients during or by the conclusion of protocol therapy; 15, 23, 10 and 3 patients at six, twelve, eighteen, and greater than twenty‐four months off‐therapy. Eleven subjects failed to normalize; 8 of these relapsed. Of the 51 patients who normalized AFP after the conclusion of therapy, none relapsed. All 10 patients who relapsed had progressive increases in their AFP, however, 47 additional patients had a rise in AFP either on therapy (median: 63, range: 4‐292,859 ng/mL) or during follow‐up (median: 32, range: 6‐4,357ng/mL) that normalized without disease recurrence.

**Conclusions**: C5VD, in combination with local control, was effective at promoting normalization of AFP. Rate of AFP decline (time‐to‐normalization or 90% decline) was not associated with relapse. Increases in AFP do not necessarily indicate relapse.

### O-077. Long Term Outcomes After Living Donor Liver Transplantation for Unresectable Hepatoblastoma: A Single Center Experience {#pbc27455-sec-0990}

[A. Pire]{.ul} ^1^, C. De Magnee^1^, M. Janssen^1^, R. Reding^1^

*^1^Saint‐Luc University Clinics, Pediatric surgery and transplant Unit, bruxelles, Belgium*

**Background/Objectives**: While chemotherapy associated with curative surgery is the only potentially curative treatment for hepatoblastoma (HB), total hepatectomy is indicated for children with unresectable HB. The present study aims to review a single center experience of living donor liver transplantation (LDLT) for HB in children.

**Design/Methods**: Between 1993 and 2015, 31 children received a living donor liver graft for unresectable HB (PRETEXT IV) or HB requiring extreme resection (PRETEXT II and III) with major vascular involvement after SIOPEL chemotherapy protocol.

**Results**: Median age at LDLT was 2 years (range: 0.6‐14). Donor underwent a majority of left lobectomy without mortality after donors' procedures. PRETEXT IV was observed in 17 children, PRETEXT III in 5, PRETEXT II in 6, and 3 were "rescue" HB (tumor recurrence in the remaining liver after a partial hepatic resection at a median delay of 1.3 years before LDLT). Caval replacement was performed in 87% of cases, was a prognostic factor of long‐term survival (p=0.0048) and was associated with a decreased HB recurrence\'s risk (p= 0.0057, HR=0.16 (0.035‐0.71)). Postoperative severe morbidity was 22.6%, including biliary leaks (n=3), hemorrhage (n=1), sushepatic thrombosis (n=1), hematoma (n=2) and peripheral venous thrombosis (n=3). Among the 7 cases of tumor recurrence, 3 children died (9.7%), including 2 who were rescue HB. Tumor recurrence after LDLT and LDLT after rescue HB were associated with a prognostic factor of poor survival (p = 0.00067 and p=0.00054 respectively). All tumors recurrences occurred during the first year after LDLT (p=0.00067). Survival at 5 years from LDLT reached 89.6% of children with 76.6% of long‐term disease‐free survivors.

**Conclusions**: Prognosis of patients with LDLT for HB was better in children who did not undergo previous hepatic resection, with good overall and disease‐free survival after 5 years. Caval replacement during LDLT was associated with an improvement of long‐term survival.

### O-078. Genomic Landscape of Pediatric Hepatocellular Carcinoma {#pbc27455-sec-1000}

[T. Pietsch]{.ul} ^1^, A. Carmichael^2^, V. Dreschmann^1^, I. Leuschner^2^, C. Vokuhl^2^

*^1^University of Bonn, Department of Neuropathology, Bonn, Germany; ^2^University Medical Center Schleswig‐Holstein ‐ Campus Kiel, Department of Pathology, Kiel, Germany*

**Background/Objectives**: Hepatocellular carcinomas (HCC) of childhood are rare neoplams. Their pathogenesis is believed to be different from HCC in adulthood. The differential diagnosis from hepatoblastoma (HBL) is important because of worse prognosis of pediatric HCC (pHCC) and different treatment approaches. The aim of this study was to identify recurrent chromosomal aberrations, mRNA expression and epigenetic signatures in a larger cohort of pHCC and compare it to HBL to identify characteristic (epi)genomic alterations and signatures of pHCC.

**Design/Methods**: Genomic DNA was extracted from FFPE samples of a cohort of pHCC identified in the archives of the German Pediatric Tumor Registry (University of Kiel), 1991 -- 2011. Samples from 44 patients with HCC, age range 1 year -- 15 years, median 11 years, were collected. Genome‐wide copy analysis was performed by molecular inversion profiling. GISTIC analysis was done to identify significant large and focal aberrations. Fresh frozen HCC samples (n=9) and HBL (n=44) were used for RNA expression and methylation studies.

**Results**: Most frequent copy number alterations were gains of chromosome 1q (68%), 2q (34%), 20 (34%),6p (30%), 19q (27%) and 8q (27%) and losses of chromosomal regions 1p (52%) and 4q (41%). Alterations of 1p, 1q and 19q were signaificantly more frequent in pHCC compared to HBL. 6/44 pHCC lacked any larger chromosomal imbalances. Of note, 5 of these 6 genomically stable tumors showed fibrolamellar differentiation and carried DNAJB1‐PRKACA fusions. Cluster analysis of mRNA expression and methylation data did not separate pHCC from HBL. GSEA analysis showed enrichment of WNT‐ and ribosome‐assoziated signatures in pedHCC compared to fetal liver.

**Conclusions**: In this genome‐wide copy number analysis, mRNA expression and methylation analysis of a large cohort of pediatric HCC we identified characteristic genetic alterations and signatures indicating a possible specific pathogenesis of these neoplasms which may help to subclassify pHCC and to differentiate these tumors from HBL.
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### O-079. Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Project: Half of Pediatric Cancers Have Their Own "Driver" Genes {#pbc27455-sec-1020}

[D.S. Gerhard]{.ul} ^1^, S. Hunger^2^, C. Lau^3^, J. Maris^2^, P. Meltzer^4^, S. Meshinchi^5^, E. Perlman^6^, J. Zhang^7^, J. Guidry‐Auvil^1^, M. Smith^8^

*^1^National Cancer Institute, Office of Cancer Genomics, Bethesda‐ MD 20852, USA; ^2^Children\'s Hospital of Philadelphia, Pediatrics, Philadelphia, USA; ^3^Connecticut Children\'s Medical Center, Pediatrics, Hartford, USA; ^4^National Cancer Institute, Center for Cancer Research, Bethesda, USA; ^5^Fred Hutchinson Cancer Research Center, Pediatric Hematology/Oncology, Seattle, USA; ^6^Ann & Robert H. Lurie Children\'s Hospital of Chicago, Pathology, Chicago, USA; ^7^St. Jude Children\'s Research Hospital, Computational Biology, Memphis, USA; ^8^National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda‐ MD 20852, USA*

**Background/Objectives**: New therapeutic targets and prognostic markers are needed for high‐risk pediatric cancers.

**Design/Methods**: The TARGET project performed comprehensive molecular characterization (whole genome, whole exome and transcriptome sequencing) of 1,699 tumor/normal pairs of six histotypes to determine genetic changes that drive the initiation and progression of high‐risk pediatric cancers.

**Results**: The median somatic mutation rates in these pediatric cancers were 10‐20 fold lower than observed in common adult cancers. About 10% of cases had germline variants associated with cancer predisposition. Somatic copy number alternations and structural variations comprised the majority (62%) of observed events; single nucleotide mutations or small indels were less frequent. In many patients these genomic alterations are the driver events. In total, 142 genes had population mutation frequencies high enough\[LC1\] to declare them "driver". Only 45% matched potential cancer drivers found in adult tumors, providing strong support that pediatric cancers have different initiation and progression processes than adult cancers. A large number of low frequency drivers are present within and among disease cohorts. Twenty‐one biologic pathways were disrupted by driver alterations (e.g. cell cycle, epigenetic regulation) and may be targetable with existing treatments. Certain signaling pathways show distinctive somatic alterations between solid tumors and leukemias. Over half of the observed pediatric driver genes were specific to a single histotype (e.g., TAL1 for T‐ALL and ALK for neuroblastoma). These trans‐TARGET analyses found some known and novel statistically significant co‐occurrences (e.g., USP7, TAL1 in T‐ALL; ETV6, IKZF1 in AML, and CREBBP, EP300 in B‐ALL and Wilms Tumor) or mutual exclusivities (e.g., MYCN, ATRX or SHANK2 in neuroblastoma; PAX5, TP53 in B‐ALL) among more than 300 gene‐pairs.

**Conclusions**: Pediatric cancers can have different initiation and progression processes than adult cancers, highlighting the need for new therapies to target high‐risk pediatric cancers. TARGET data are available to the research community (<http://www.ocg.cancer.gov>).

### O-080. Dissection of Cancer Cell Diversity in Childhood Tumors by Single Cell Whole Genome Sequencing {#pbc27455-sec-1030}

[D. Gisselsson]{.ul} ^1^, J. Karlsson^2^, A. Valind^2^

*^1^Lund University, Departments of Clinical Genetics and Pathology, Lund, Sweden; ^2^Lund University, Clinical Genetics and Pathology, Lund, Sweden*

**Background/Objectives**: Recent studies of childhood cancer have revealed genetic diversity among cells inhabiting different parts of the same tumor. This causes problems for consistent detection of treatment‐stratifying genetic biomarkers. Here we aimed toassess to what extent DNA sequencing and copy number analysis of (1) multiple samples from a single tumours and (2) multiple cells from a single biopsy reveal distinct patterns of intratumor variation.

**Design/Methods**: A total of 254 samples from 56 tumours consisting of neuroblastomas, Wilms tumors and rhabdomyosarcomas were subjected to whole exome sequencing and array‐based copy number analyses of. For 10 tumours, this was followed by single cell low pass whole genome sequencing of 48 cells per sample.

**Results**: Phylogenetic analyses based on multiregional sampling indicated that neuroblastomas and rhabdomyosarcomas had more (p\<0.02) truncal mutations (mean 16 and 15 allelic imbalances) than Wilms tumors (mean 3.9), while branch lengths did not show any overall differences among the three tumour types (mean 2.4‐4.7). High‐risk Wilms tumours with diffuse anaplasia and *TP53* mutation showed more branch anomalies (mean 5.8) than intermediate risk Wilms tumours (mean 0.7). Truncal aberrations in high‐risk neuroblastomas and rhabdomyosarcomas primarily encompassed structural chromosomal rearrangements in contrast to whole‐chromosome anomalies in more favorable subtypes. Single cell whole genome sequencing revealed a staggering diversity in high‐risk tumours, with a scale‐free accumulation of subclones with fractal characteristics. In specific cases, single cell profiling revealed significant migration of cells between clonal territories.

**Conclusions**: Our data suggest that neuroblastomas and rhabdomyosarcomas already before their latest clonal expansion are endowed with a high‐ or low‐risk genomic profile. In contrast, the complex genome of anaplastic Wilms tumours typically develop during their latest clonal expansion. Intratumoral migration over cm‐scale distances of cancer cells belonging to different genetic lineages may occur in some high‐risk tumours, further complicating the clonal geography of childhood cancer.

### O-081. Integrated DNA and RNA Panel Sequencing Reveals Frequent Targetable Alterations in Metastatic and Treatment‐Refractory Papillary Thyroid Carcinomas of Childhood {#pbc27455-sec-1040}

[S. Potter]{.ul} ^1^, J. Reuther^2^, R. Chandramohan^3^, I. Gandhi^2^, F. Hollingsworth^2^, H. Sayeed^2^, H. Voicu^2^, N. Kakkar^1^, K. Sen Baksi^1^, S.F. Sarabia^2^, M.E. Lopez^4^, D.C. Chelius^5^, I.D. Athannasaki^6^, R. Venkatramani^1^, N.M. Quintanilla^2^, D. Lopez‐Terrada^2^, A. Roy^2^, D.W. Parsons^1^

*^1^Texas Children\'s Cancer Center/Baylor College of Medicine, Pediatric Hematology/Oncology, Houston, USA; ^2^Baylor College of Medicine/Texas Children\'s Hospital, Department of Pathology and Immunology, Houston, USA; ^3^Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA; ^4^Baylor College of Medicine/Texas Children\'s Hospital, Department of Surgery, Houston, USA; ^5^Baylor College of Medicine/Texas Children\'s Hospital, Department of Otolaryngology, Houston, USA; ^6^Baylor College of Medicine/Texas Children\'s Hospital, Pediatric Endocrinology, Houston, USA*

**Background/Objectives**: Pediatric papillary thyroid carcinoma (PTC) is clinically and biologically different than adult PTC. We performed integrated DNA and RNA‐based sequencing of a cohort of clinically‐annotated tumors to identify genetic alterations that might inform improved diagnostic and therapeutic approaches.

**Design/Methods**: Cases were identified from TCH Pathology archives from 2005‐2016. Tumor DNA was captured using a custom‐designed next‐generation mutation panel that includes the entire coding regions and select non‐coding regions of 124 genes implicated in pediatric solid tumors. Tumor RNA was analyzed using a commercially available multiplex gene fusion panel (Archer Oncology Research panel) targeting 75 pediatric solid tumor genes.

**Results**: In total, 41 pediatric PTC cases with high‐risk features were prioritized for analysis. The majority of patients were metastatic to cervical lymph nodes (34/41, 83%), with one third also found to have pulmonary metastases (13/34, 32%). Relapsed/refractory disease occurred in 22 patients (22/41, 54%). DNA sequencing was successfully performed for 31 cases, revealing potentially targetable mutations in 8 tumors (26%): *BRAF* p.V600E x 6, *PIK3R1* p.Y29fs, and *PTPN11* p.S502T. RNA sequencing was accomplished for 26 cases, identifying potentially targetable fusions in 13 tumors (50%): *RET* x 8, *NTRK3* x 4, and *BRAF*. A total of 20 cases had both DNA and RNA analyzed, with mutually‐exclusive potentially‐targetable alterations discovered in 15 (75%).

**Conclusions**: Frequent alterations were identified in known cancer genes in pediatric PTC cases, many of which are currently targetable with FDA‐approved or investigational. Inclusion of RNA sequencing for detection of fusion genes is critical for evaluation of these tumors.

### O-082. Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B‐Cell Non‐Hodgkin Lymphoma (B‐NHL) {#pbc27455-sec-1050}

A.M. Newman^1^, M. Zaka^1^, P. Zhou^1^, A. Erhorn^1^, A. Barnard^1^, R.E. Crossland^1^, S. Wilkinson^1^, K. Wood^2^, D. Televantou^2^, C.J. Harrison^1^, S. Bomken^1^, C.M. Bacon^1^, [V. Rand]{.ul} ^1^

*^1^Northern Institute for Cancer Research, Wolfson Childhood Cancer Research Centre, Newcastle upon Tyne, United Kingdom; ^2^Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Cellular Pathology, Newcastle upon Tyne, United Kingdom*

**Background/Objectives**: Current frontline therapies for paediatric B‐cell non‐Hodgkin lymphoma (B‐NHL) are very effective, achieving \>90% survival. However, for those children who relapse treatment options are limited and outcome remains poor. Little is currently known about the biology of relapsed disease and there are no markers which identify children who will relapse. We performed genome‐wide copy number analysis to identify the abnormalities associated with relapsed disease.

**Design/Methods**: We included 162 paediatric B‐NHL cases in this study; 110 pre‐treatment diagnostic samples were obtained from the Children\'s Cancer and Leukaemia Group (CCLG) Tumour bank and 52 cases were identified from the literature. Matched relapse samples were obtained for 9/18 relapse cases. High‐resolution copy number data was generated using Affymetrix Cytoscan HD or Oncoscan arrays. *TP53* mutations were detected using next‐generation and Sanger sequencing. Univariate and multivariate analyses examined the association of abnormalities with risk of relapse, event‐free and overall survival.

**Results**: Twenty‐six recurrent copy number abnormalities (CNAs) and regions of copy number neutral loss of heterozygosity were detected by GISTIC2.0. Recurrent CNAs involved known cancer genes including *MCL1, REL, BCL11A, MSH6, FBXO11, CDKN2A/B, MIR17HG* and *TP53*. *TP53*mutations were identified in 46% (37/80) of cases, and 68% (25/37) had biallelic inactivation. Multivariate analysis identified *TP53* biallelic inactivation as an independent prognostic factor identifying children with an increased risk of relapse (hazard ratio 3.51, 95% CI 1.22‐10.14, *p*=0.02) and shorter event‐free survival (hazard ratio 3.97, 95% CI 1.04‐15.07, *p*=0.043). Of the matched relapse samples, 6/9 (67%) cases had *TP53* biallelic inactivation at relapse; 5 maintained the abnormalities from diagnosis and one acquired *TP53* inactivation at relapse.

**Conclusions**: Genome‐wide analysis revealed that *TP53* biallelic inactivation is associated with an increased risk of relapse and shorter event‐free survival in paediatric B‐NHL. Further work is essential to understand the biology and exploitation of genomic abnormalities to improve survival for relapsed B‐NHL.

### O-083. Mechanisms of Hepatoblastoma and Development of Novel Therapy {#pbc27455-sec-1060}

[N. Timchenko]{.ul} ^1^, A. Cast^1^, L. Valanejad^1^, A. D\'Souza^2^, M. Wright^1^, K. Lewis^1^, M. Kumbadji^1^, A. Gupta^3^, L. Zhu^4^, R. Karns^5^, S. Shin^1^, K.D. Bissig^6^, M. Weirauch^7^, L. Timchenko^8^, J. Geller^2^

*^1^Cincinnati Children\'s Hospital Medical Center, Surgery, Cincinnati, USA; ^2^Cincinnati Children\'s Hospital Medical Center, Oncology, Cincinnati, USA; ^3^Cincinnati Children\'s Hospital Medical Center, Pathology, Cincinnati, USA; ^4^St. Jude Children\'s Hospital, Pharmaceutiical‐ Sciences, Memphis, USA; ^5^Cincinnati Children\'s Hospital Medical Center, Gastroenterology, Cincinnati, USA; ^6^Baylor College of Medicine, Cell Biology, Houston, USA; ^7^Cincinnati Children\'s Hospital Medical Center, Biomedical Informatics, Cincinnati, USA; ^8^Cincinnati Children\'s Hospital Medical Center, Neurology, Cincinnati, USA*

**Background/Objectives**: Hepatoblastoma (HBL) is the most common type of liver cancer in children. Unfortunately, mechanisms behind the development of HBL are not well understood. The goal of this work was to determine the mechanisms of HBL and develop new therapeutic approaches.

**Design/Methods**: We analyzed a large Biobank of HBL samples at CCHMC and investigated four animal models that recapitulate different molecular features of HBL. Global transcriptome profiling, epigenetic regulation, protein‐protein complexes and post‐translational modifications of tumor suppressor proteins (TSPs) and oncogenes were examined using state‐of the art techniques.

**Results**: We found that classic HBL is characterized by reduction of TSPs. This reduction is mediated both by down‐regulation of TSP mRNAs and by degradation of proteins by the FXR‐Gankyrin‐UPS system. We surprisingly found a subset of patients with chemo‐resistant HBL who had an elevation of TSPs that had undergone post‐translational modifications (PTM). Specifically, there was a modification of C/EBPalpha which converted this protein into oncogene. In searching for the mechanism behind elevated levels of these newfound oncogenes in chemo‐resistant HBL, we identified unique Aggressive Liver Cancer Domains (ALCDs) that are activated by PARP1‐mediated chromatin remodeling. Through activation of ALCDs, there is not only increased expression of oncogenic forms of TSPs, but also activation of many other cancer‐related pathways, including Nfr2, WNT signaling and b‐catenin. Inhibition of PARP1 in liver cancer cells blocks activation of ALCDs and normalizes expression of the oncogenes, resulting in inhibition of proliferation of cancer cells.

**Conclusions**: Our studies identified two types of HBL: 1) classic HBL with Gank‐UPS‐mediated degradation of TSPs; and 2) aggressive HBL with elevation of oncogenic forms of TSPs and additional cancer related pathways. We are currently working with the development of targeted therapy using inhibitors of Gankyrin and PARP1 for treatment of patients with classic and aggressive HBL, respectively.

### O-084. The Impact of the Type of Constitutional RB1 Mutation on Incidence of Second Primary Malignancy Depends on Previous Radiotherapy {#pbc27455-sec-1070}

[P. Temming]{.ul} ^1^, I. Hülsenbeck^2^, M. Reschke^1^, D. Lohmann^2^

*^1^University Hospital Essen, Department of Pediatrics III, Essen, Germany; ^2^University Hospital Essen, Institute of Human Genetics, Essen, Germany*

**Background/Objectives**: Survivors of heritable retinoblastoma carry a high risk to develop second primary malignancies (SPM). The incidence of SPM is significantly raised after external beam radiotherapy (EBRT). We aimed to analyze the impact of the type of constitutional *RB1* mutation on the incidence of SPM with and without previous irradiation.

**Design/Methods**: From 1940 to 2008, 655 national patients were treated for heritable retinoblastoma at the German referral center. Complete information on second primary malignancies until 2012 and data on constitutional *RB1* mutation were available for 318 patients (48.5%).

**Results**: SPM occurred in 51 of 318 survivors of heritable retinoblastoma. After irradiation, the cumulative incidence ratio (per 1,000 person years) of SPM was 10.2 (95% confidence interval 7.3‐13.9) and was not influenced by type of constitutional RB1 mutations. In non‐irradiated retinoblastoma survivors, the cumulative incidence ratio of SPM was lower compared to the irradiated patients (IR 3.6 \[1.7‐6.7\]; p\< 0.005). Without previous irradiation, SPM were only observed in patients with heterozygous nonsense mutations (IR 4.1 \[1.9‐7.5\]). No SPM was reported in survivors with somatic mosaicm of *RB1* gene (IR 0.0 \[‐12.9\]) or in survivors with heterozygous constitutional missense mutations, large deletions or promotor mutations in *RB1* (IR 0.0 \[‐6.2\]). The type of tumors in non‐irradiated heritable retinoblastoma survivors were diverse and comprised of three soft tissue sarcoma, one hematological malignancy, three mamma carcinoma, one bronchial carcinoma, one melanoma and one brain tumor.

**Conclusions**: The influence of the type of constitutional *RB1* mutation on the incidence of SPM in our cohort was only evident without previous radiotherapy treatment. After external beam radiotherapy, all survivors of heritable retinoblastoma were at risk for second cancers regardless of the constitutional *RB1* genotype.
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### O-085. The Role of Irradiated Heart and Left Ventricle Volumes in Heart Failure Occurrence After Childhood Cancer {#pbc27455-sec-1090}

[I. Mansouri]{.ul} ^1^

*^1^CESP‐ Univ. Paris‐Sud‐ UVSQ‐ INSERM‐ Université Paris‐Saclay‐ Cancer and Radiation Team‐ Gustave Roussy‐ Villejuif‐ France, INSERM 1018‐ team cancer and radiation, villejuif, France*

**Background/Objectives**: More than 7% of childhood cancer survivors (CCS) will develop heart failure (HF) within 30 years of their primary cancer diagnosis. The role of irradiated heart volumes in HF occurrence in this population remains unclear, and the consequences of irradiating large parts of the heart with a lower dose versus irradiating smaller parts of the heart with a high dose should be further investigated. The aims of this study were to determine the doses and irradiated volumes of the heart and left ventricle (LV) related to the risk of HF in CCS and to investigate the impact of anthracycline exposure on this risk.

**Design/Methods**: A case--control study nested in the French Childhood Cancer Survivors Study cohort. The mean heart and LV doses and volumes indicators were estimated by reconstruction of individual treatments.

**Results**: A total of 239 HF cases and 1042 matched controls were included. The median age of HF diagnosis was 25.1 years. The interactions between anthracycline administration and the mean heart dose and mean LV dose were significant. In patients who did not receive anthracycline, the risk of HF was increased 3.6‐fold when less than 10% of the LV received at least 30 Gy when compared to patients who were not exposed to any cardiac radiation and anthracycline. These risks were much higher among patients treated with anthracycline and were increased 28.3‐fold (CI 95% 9.4--85.2) in patients receiving at least 30 Gy to more than 50% of the heart volume.

**Conclusions**: Small irradiated volumes of the heart or LV were significantly associated with HF risk. To the author\'s knowledge, this is the first study to report a dose--response relationship based on dose--volume indicators in CCS which can be translated efficiently into current clinical practice.

### O-086. Breast Hypoplasia and Decreased Lactation from Radiotherapy (RT) in Survivors of Pediatric Malignancy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative {#pbc27455-sec-1100}

A. Lo^1^, C. Ronckers^2^, I. van Dijk^3^, T. Rancati^4^, M. Avanzo^5^, G. Gagliardi^6^, L. Kremer^7^, L. Constine^8^, [K. Marcus]{.ul} ^9^

*^1^BC Cancer, Radiation Oncology, Vancouver, Canada; ^2^Academisch Medisch Centrum Universiteit van Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands; ^3^Academisch Medisch Centrum Universiteit van Amsterdam, Radiation Oncology, Amsterdam, The Netherlands; ^4^Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Prostate Cancer Program, Milan, Italy; ^5^Centro di Riferimento Oncologico Aviano IRCCS, Division of Medical Physics, Aviano, Italy; ^6^Karolinska University Hospital, Oncology‐Pathology, Stockholm, Sweden; ^7^Academisch Medisch Centrum Universiteit van Amsterdam, Pediatrics, Amsterdam, The Netherlands; ^8^University of Rochester Medical Center, Radiation Oncology, Rochester, USA; ^9^Dana‐Farber/Boston Children\'s Cancer and Blood Disorders' Center‐ Harvard Medical School, Radiation Oncology, Boston, USA*

**Background/Objectives**: Breast hypoplasia and impaired lactation are poorly studied morbid consequences of chest RT in children. The PENTEC female breast task force aimed to quantitate the radiation dose‐volume effects on these endpoints.

**Design/Methods**: PubMed searches were conducted of peer‐reviewed manuscripts evaluating breast hypoplasia and lactation after chest RT in children, yielding 789 abstracts. Only two studies on children irradiated at \<4 years of age for angioma provided dosimetric data correlated with breast hypoplasia. We calculated relative risks (RR) and 95% confidence intervals (95%CI) based on this data. One study in which patients were given RT for Hodgkin lymphoma at age 14‐40 years was relevant to the lactation endpoint.

**Results**: The three studies involved 206 subjects in total. The risk of patient‐perceived breast hypoplasia was 38% (RR 2.5; 95%CI 1.3‐4.6) after \<1.0Gy, 61% (RR 4.0; 95%CI 2.1‐7.4) after 1.0‐2.5Gy, and 97% (RR 6.3; 95%CI 3.6‐10.8) after ≥2.5Gy to the breast anlage in a single RT fraction. A simple linear regression model (r=0.72; p\<0.001) showed that the irradiated breast was smaller than the unirradiated breast by 10% after 1.0Gy, 20% after 2.5Gy, 36% after 5Gy, and 70% after 10Gy. There was suggestion of lesser severity of breast hypoplasia when total doses of \>5Gy were given over multiple versus single fractions; 2 patients who received 5.7‐5.8 Gy and 2 patients who received 9.6‐10.3 Gy in multiple fractions experienced a breast volume reduction of \<33% and 33‐50%, respectively. The risk of unsuccessful breastfeeding was 39% after a median mediastinal dose of 41Gy, compared to 21% in a sibling control group (*P*=0.044). RT dose of ≥42Gy was not associated with less breastfeeding success.

**Conclusions**: Young adults exposed to thoracic RT as children are at significant risk of breast hypoplasia and impaired lactation. The prevalence and severity of breast hypoplasia increases with increasing dose to the breast bud.

### O-087. Increased Risk for Breast Cancer in Childhood Solid Cancer Survivors {#pbc27455-sec-1110}

[F. De Vathaire]{.ul} ^1^, D. Charlotte^2^, R. Allodji^1^, C. Veres^1^, G. Debiche^1^, A. Mazal^3^, H. Pacquement^4^, S. Bolle^5^, N. Journy^2^, G. Vu‐Bezin^2^, D. Lefkopoulos^5^, C. El Fayech^6^, B. Fresneau^6^, F. Doz^4^, E. Deutsch^5^, P. Poortmans^3^, D. Valteau^6^, I. Diallo^2^, N. Haddy^2^

*^1^INSERM, Unit 1018‐ Cancer and Radiation team, Villejuif, France; ^2^INSERM, Unit1018‐ Cancer and Radiation Team, Villejuif, France; ^3^Institut Curie, Department of Radiotherapy, Paris, France; ^4^Institut Curie, Department of Pediatry, Paris, France; ^5^Gustave Roussy, Departement of Radiotherapy, Villejuif, France; ^6^Gustave Roussy, Department of Pediatry, Villejuif, France*

**Background/Objectives**: Although breast cancer risk is the highest secondary cancer risk in women after cancer during childhood, the International Late Effects of Childhood Cancer Guideline Harmonization Group did not recommend screening if less than 20 Gy of radiation was delivered to the region of the chest. The evidence for an increased breast cancer risk after 10 to 19 Gy was considered moderate or low and even very low after radiation doses between 1 to 9 Gy.

**Design/Methods**: We studied 3,965 women treated before 2001 for a childhood cancer in France. Radiation dose received to the region of the breasts and others organ were estimated for each patient.

**Results**: One hundred sixteen women, of whom 50 only 10 years or less after childhood cancer diagnosis, developed at least one breast cancer. All but 17 breast cancers occurred after the age of 30. The risk of breast cancer increased linearly with increasing radiation doses to the breast region. Of the 162 women who had received 20 Gy or more to at least one of their breast nipple, 27 developed breast cancer (cumulative incidence at age 50y: 34% (95%CI: 25%‐44%). Lower radiation doses also increased breast cancer risk: when adjusting for other risk factors, including chemotherapy, the women who received 1 to 9 Gy, and 10 to 19 Gy as maximal dose to one of their breast nipple had a relative risk of 2.9 (95%CI: 1.5‐5.7) and 4.0 (95%CI:1.8‐8.6) compared to those we did receive no radiation, respectively. Ovaries and pituitary gland irradiation significantly reduced breast cancer risk.

**Conclusions**: Radiation doses lower than 20 Gy received during childhood cancer treatment strongly increase breast cancer risk. Guidelines for follow‐up of survivors should be adapted to take into account this result.

### O-088. Projected Improvement in Life Expectancy Across Three Treatment Decades: Insights from the Childhood Cancer Survivor Study (CCSS) {#pbc27455-sec-1120}

[J. Yeh]{.ul} ^1^, Z.J. Ward^2^, Q. Liu^3^, Y. Yasui^4^, A. Chaudhry^5^, W.M. Leisenring^6^, K.C. Oeffinger^7^, M.M. Hudson^8^, K.R. Krull^4^, T.M. Gibson^4^, R. Howell^9^, G.T. Armstrong^4^, L. Diller^10^

*^1^Boston Children\'s Hospital/Harvard Medical School, General Pediatrics, Boston, USA; ^2^Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, USA; ^3^University of Alberta, Public Health Services, Edmonton, Canada; ^4^St. Jude Children\'s Research Hospital, Epidemiology & Cancer Control, Memphis, USA; ^5^Boston Children\'s Hospital, General Pediatrics, Boston, USA; ^6^Fred Hutchinson Cancer Research Center, Clinical Research, Seattle, USA; ^7^Duke University School of Medicine, Medicine, Durham, USA; ^8^St. Jude Children\'s Research Hospital, Oncology and Epidemiology & Cancer Control, Memphis, USA; ^9^MD Anderson Cancer Center, Radiation Physics, Houston, USA; ^10^Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center, Pediatric Oncology, Boston, USA*

**Background/Objectives**: Late mortality among 5‐year survivors of childhood cancer from more recent eras has declined, yet how this translates into improved life expectancy is unclear. We estimated life expectancy among survivors diagnosed between 1970 and 1999 and assessed whether reduced therapeutic exposures have led to improvements over time.

**Design/Methods**: We developed a microsimulation model of the lifetime course of survivors of childhood cancer. Competing risks included 1) disease‐ and treatment‐related mortality (late recurrence, secondary cancers, cardiac, pulmonary, other causes) based on data of CCSS participants (n=24,355), and 2) U.S. background mortality rates. Model outcomes included conditional life expectancy (LE) (defined as the number of years a 5‐year survivor can expect to live) and loss in LE (defined as the difference in LE between survivors and individuals without a cancer history).

**Results**: Conditional LE for 5‐year survivors diagnosed in 1970‐79, 1980‐89 and 1990‐99 (mean ages 12.5 to 13.1 years) was 48.5, 52.9 and 56.9 years. Compared to individuals without a cancer history, this represented a loss in LE of 16.5 (25.4%), 12.8 (19.5%), and 8.7 years (13.3%), respectively. The loss in LE varied by treatment subgroup and was highest among those treated with radiation alone or radiation with chemotherapy. Between 1970‐79 and 1990‐99, loss in LE remained largely unchanged for survivors treated with radiation alone (21.9 years \[35%\] to 21.4 years \[34%\]) and moderately improved for those who received radiation and chemotherapy (18.0 years \[27%\] to 13.5 years \[21%\]). In contrast, the loss in LE among survivors treated with chemotherapy alone declined from 11.7 years (18%) in 1970‐79 to 4.8 years (7%) in 1990‐99.

**Conclusions**: Evolving treatment approaches are projected to lead to improved LE after treatment for pediatric cancer. Among survivors, radiation therapy exposure remains associated with considerable loss in projected LE, even in more recent decades.

### O-089. High Prevalence of Sleep Problems in Survivors of Brain Tumors with Subjective Cognitive Problems: The Role of Hyperactivity/Inattention and Emotional Difficulties {#pbc27455-sec-1130}

[J. Van Kooten]{.ul} ^1^, H. Maurice‐Stam^2^, A. Schouten^3^, D. van Vuurden^1^, B. Granzen^4^, C. Gidding^5^, M. de Ruiter^2^, R. van Litsenburg^6^, M. Grootenhuis^6^

*^1^VU University Medical Center, Department of Pediatrics, Amsterdam, The Netherlands; ^2^Emma Children\'s Hospital/Academic Medical Center AMC, Psychosocial Department, Amsterdam, The Netherlands; ^3^Emma Children\'s Hospital/Academic Medical Center AMC, Department of Pediatric Oncology, Amsterdam, The Netherlands; ^4^Maastricht University Medical Center, Department of Pediatrics, Maastricht, The Netherlands; ^5^Radboud University Medical Center, Department of Pediatric Oncology/Hematology, Nijmegen, The Netherlands; ^6^Princess Maxima Center for pediatric oncology, Psychosocial Department, Utrecht, The Netherlands*

**Background/Objectives**: Sleep problems are common in survivors of brain tumors. As sleep can negatively affect neurocognitive functioning and quality of life (QoL), it is important to better understand sleep problems in this vulnerable group. This study aimed to determine: 1) the prevalence of sleep problems, and 2) risk factors for sleep problems in survivors of brain tumors with neurocognitive complaints.

**Design/Methods**: Baseline data of a RCT on the effectiveness of neurofeedback are reported here. Survivors 8‐18 years, ≥2 years after brain tumor treatment, without ADHD were eligible. Parents completed the Sleep Disturbance Scale for Children (SDSC). SDSC scores \>1SD above the norm were considered clinically relevant sleep problems. SDSC scores of survivors were compared with the norm using one‐sample t‐tests. Risk factors for sleep problems were assessed with multiple linear regression analyses, predicting SDSC scores by sociodemographic characteristics, tumor location, time since treatment, emotional problems and hyperactivity/inattention (Strength and Difficulties Questionnaire).

**Results**: In total 82 survivors participated (7.0±3.6 years after treatment, age 13.8±3.2 years, 48.8% male). Survivors had a high prevalence of sleep problems on the total scale (34.1%), disorders of initiating and maintaining sleep (DIMS, 36.6%), sleep‐wake transition disorders (22.0%) and disorders of excessive somnolence (30.5%). Mean scores of survivors were significantly higher than the norm (P \<0.02, effect size 0.32 -- 0.92) on these scales. No differences were found on sleep breathing disorders (SBD) and sleep hyperhidrosis (SHY). More emotional symptoms and/or hyperactivity/inattention were associated with higher scale scores (betas 0.27‐0.39) except SBD and SHY. Higher age was associated with a higher score for DIMS (beta 0.24).

**Conclusions**: Survivors of brain tumors with subjective cognitive problems have a high prevalence of sleep problems in different domains. Emotional problems and hyperactivity/inattention are most important risk factors. Addressing sleep problems is important since this could improve cognitive functioning and QoL.

### O-090. Neurocognitive Function in Survivors of Osteosarcoma {#pbc27455-sec-1140}

[S. Sato]{.ul} ^1^, H. Shima^2^, M. Sakai^2^, N. Hashida^2^, T. Takimoto^1^, S. Takahashi^1^, K. Isshiki^2^, H. Dairoku^3^, H. Shimada^2^

*^1^National Center for Child Health and Development, Department of Data Management, Tokyo, Japan; ^2^Keio University School of Medicine, Department of Pediatrics, Tokyo, Japan; ^3^NPO LD/Dyslexia Center, Department of LD/Dyslexia, Chiba, Japan*

**Background/Objectives**: The survival rate for children with osteosarcoma has improved due to advances in treatment, including intravenous high‐dose methotrexate (HD‐MTX). Although HD‐MTX has been associated with neurotoxic effects among survivors of childhood acute lymphoblastic leukemia (ALL) and osteosarcoma survivors received HD‐MTX at cumulative dosages 4‐ to 5‐fold greater than the children with ALL, the impact of osteosarcoma treatment on neurocognitive functioning has not been well‐studied in Japan.

**Design/Methods**: We evaluated the neurocognitive status of 12 children (median age at diagnosis, 8.5 years; median age at baseline, 13.2 years) using the *Wechsler Intelligence Scale for Children 4^th^ Edition* at baseline and annually during a 2‐year follow‐up period. Of the 12 children, 3 underwent the first testing one month after diagnosis and the remaining children after completion of therapy (median years post‐diagnosis, 3.7 years, range 0.8‐9.3). Here, we present the preliminary results including data at baseline and at one‐year follow‐up. At testing, cognitive function, attention, memory, and medical and demographic information were obtained. Three children received 1 cycle of HD‐MTX (dose 12 gm/m^2^) before the baseline testing and additional HD‐MTX (median total dose 40 gm/m^2^, range 35.6‐40) before the second testing. Nine children completed HD‐MTX treatment prior to baseline (median total dose 39 gm/m^2^, range 24‐72).

**Results**: Results from cognitive measures were converted to z‐scores using age‐adjusted normative data. At baseline, 11 of 12 children performed within average range across all cognitive domains (median FSIQ= 102, range 90‐133), and 1 child was below average (FSIQ= 63). At the second testing, the result was similar to the baseline data (median FSIQ= 105, range 76‐139); the same one child was below average (FSIQ=62).

**Conclusions**: The final study is expected to confirm if cognitive functioning remains stable over time.
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### O-091. Germline Cancer Susceptibility in Children and Adolescents with Colorectal Cancer {#pbc27455-sec-1160}
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**Background/Objectives**: Colorectal cancer (CRC) is a rare condition in children and adolescents. CRC syndromes causing such an early onset are familial adenomatous polyposis, Lynch syndrome and constitutional mismatch‐repair deficiency (CMMRD). However, the majority of CRCs in patients ≤25 years are microsatellite‐stable, are not associated with polyposis, show more often mucinous histology and have a worse prognosis compared to adult‐onset CRC. These differences suggest that CRC ≤25 years represents a distinct clinical CRC entity.

Our objective was to unravel the underlying genetics of CRC in children and adolescents.

**Design/Methods**: We performed whole‐exome sequencing on germline DNA from patients with CRC ≤25 years of age (*n*=40). Paired tumour samples were included for 19 patients and for 15 patients trio‐based (child and parents) sequencing was performed. This enabled us to specifically search for *de novo* mutations or mutations that follow recessive inheritance.

**Results**: Six patients carried a pathogenic mutation in a known cancer predisposing gene: *BRCA2, NF1, POLD1, PALB2* (*n*=1 each), and *TP53* (*n*=2). One 15 year old boy carried a *de novo* mutation in the RAS‐MAPK gene *SOS2*. *In vitro* expression of this mutant revealed an increase in ERK phosphorylation, suggesting a gain‐of‐function effect. In addition, three patients presented with potentially pathogenic mutations in genes involved in the extracellular matrix.

**Conclusions**: Sequencing of tumour and paired germline samples and selective screening for *de novo* mutations provides a powerful strategy to investigate known and novel genes that predispose to early onset CRC. Our findings indicate that a genetic predisposition is frequent and heterogeneous in these patients.

### O-092. Retinoblastoma Molecular Diagnostics, Phenotype in Low Penetrance Disease {#pbc27455-sec-1170}

[T. Kazubskaya]{.ul} ^1^, V. Kozlova^1,2^, T. Ushakova^3,4^, O. Gorovtsova^3^, Y. Serov^3^, E. Alekseyeva^5^, V. Strelnikov^5^, S. Mikhaylova^2^, V. Polyakov^3,4^
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**Background/Objectives**: The aim was to analyze the association between germline RB1 mutations and different clinical presentations in RB patients.

**Design/Methods**: From 2010 to 2016 genetic tests for RB1 mutations were performed on peripheral blood samples from 85 patients and 156 their relatives. Analysis of the RB1 gene was conducted first using Next Generation Sequencing (NGS), and Multiplex Ligation‐dependent Probe Amplification (MLPA) was performed for patients in whom no mutations were found by sequencing.

**Results**: Germline RB1 mutations (point mutations, gross deletions) were identified in 39 children (45,8%) including 96,4% (27/28) of patients with the bilateral RB and 21% (12/57) -- with the unilateral RB. The exons 12‐18 and 19‐23 harbored 41% (16/39) of all point mutations. Five cases of mosaic RB1 mutations were detected in children with unilateral RB. A relationship between different types of RB1 germline mutations and clinical presentations was analyzed. Mainly, hereditary RB in carriers of nonsense and frameshift mutations developed into severe clinical form with high penetrance. In the five families harboring mutations at splice sites: с.607 + 1G\>T (intron 6); c.1422‐8delT (exon 16); g.61807 G\>A (exon 9); and 2 missense mutations: p. 1364 G\>C (14 exon); с.1981 C\>T (20 exon) we detected asymptomatic family members carrying low penetrance mutations. Interestingly, all these germline mutations were inherited from not affected fathers. Besides, in the patients with hereditary RB we detected a second cancer in 3.1% cases., all these germline mutations were inherited from not affected fathers. Besides, in the patients with hereditary RB detected of developing a second cancer in 3.1% cases.

**Conclusions**: The patients with germline RB1 mutations showed genotype‐phenotype correlations. A specific RB1 mutation can be associated with incomplete penetrance depending upon the sex of the transmitting parent. State‐of‐the‐art molecular methods in genetic diagnostics of RB are of importance in supporting individualized disease management plans for patients.

### O-093. Report of First National Collaborative Treatment Protocol of Retinoblastoma in South Africa: An Interim Analysis {#pbc27455-sec-1180}
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**Background/Objectives**: Introduction: Collaborative treatment protocols improve the overall survival of children with cancer.

Aim: To determine the outcome of children treated with a standard national treatment protocol for retinoblastoma in South Africa.

**Design/Methods**: All specialists, involved in retinoblastoma care, participated in the development of a national treatment protocol (2009‐2011), based on the SIOP‐PODC retinoblastoma guideline for high income countries (HIC). Treatment involved local therapy for intraocular disease, chemotherapy and/or surgery and/or radiotherapy for more extensive disease. Five of nine existing pediatric oncology units (POUs) initiated treatment in January 2012.

**Results**: One hundred and eighty‐seven patients were included in the interim data analyses. The median age was 28.0 months (range 0‐159.0 months; IQR 16.0‐40.0). Male/female ratio was 1.4:1. Fifty‐two patients (29%) had bilateral disease. Nearly half (61 patients; 49%) had advanced disease. For the interim analysis with 1 year post treatment survival data overall survival was 71%, but 75% if excluding absconding patients (6%). Children with limited disease had overall survival (OS) of 81% versus advanced disease 51%.

**Conclusions**: In comparison to a previous published single South African unit study mean age was younger (28 months versus 35 months) and OS improved from 43% to 71%. A national retinoblastoma treatment protocol was feasible in South Africa with improved overall survival.

### O-094. Prospective Study of Ophthalmic Artery Chemosurgery as Alternative to Enucleation in Retinoblastoma {#pbc27455-sec-1190}
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**Background/Objectives**: Over the past twenty‐five years, the introduction of systemic chemotherapy combined to local treatments has enabled to dramatically increase globe retention for retinoblastoma patients without using external beam radiation (EBR). Ophthalmic artery chemosurgery has more recently emerged as a primary conservative treatment of retinoblastoma. We conducted a prospective phase II non randomized study to determine (i) the efficacy of Melphalan ophthalmic artery chemosurgery in terms of globe salvage rates, without EBR 18 months after inclusion, (ii) patient survival and (iii) adverse events.

**Design/Methods**: Patients with unilateral retinoblastoma group B, C or D without diffuse vitreous seeding or very asymetric bilateral retinoblastoma including one group D eye were eligible. Patients were nationally referred to Institut Curie and treated by ophthalmic artery chemosurgery at the Interventional Neuroradiology Department of the Fondation Rothschild

**Results**: Between February 2012 and December 2016, 39 patients with unilateral retinoblastoma classified by the IRC Classification as Group B (10.3%), Group C (33.3%), Group D (56.4%), were included. Two patients did not receive ophthalmic artery chemosurgery, one due to initial catheterization failure, the second to prolonged general anesthesia contra‐indication. Median age at ophthalmic artery chemosurgery was 19.3 months (3.2‐61.6). Median number of ophthalmic artery chemosurgery cycles was 4 (range 1‐6). For 31 patients, ophthalmic artery chemosurgery was associated to ophthalmological local treatment, starting after the second cycle, by diode laser (31) or cryotherapy (10). All patients are alive, with a median follow‐up of 27.1 months from inclusion (2.9 ‐60.2).Twelve serious adverse events were declared including 4 vascular retinal occlusions. Eight patients presented leucopenia. No extraocular retinoblastoma, second cancer or life‐threatening complication occurred. As follow‐up of the last patients is actually under 18 months, enucleation rate cannot be yet assessed.

**Conclusions**: For advanced RB focal OAC is feasible and generally well tolerated but may expose to some systemic and retinal vascular toxicity.

### O-095. Does Radiology Reliably Predict Clinically Significant Tumour Rupture in Children with Renal Tumours? {#pbc27455-sec-1200}
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**Background/Objectives**: Our aim was to retrospectively determine diagnostic significance of CT and MRI in assessing presumed pre‐operative tumour rupture in children with renal tumours. Diagnosis of rupture results in stage 3 disease and may lead to intensification of treatment. Pre‐operative suspicion of rupture may, in some cases, influence surgical planning.

**Design/Methods**: We reviewed all patients registered on the IMPORT (Improving Population Outcomes for Renal Tumours of childhood) study in the UK and Republic of Ireland between November 2012 and November 2017 (497 patients). Those with suspected tumour rupture at central review by an expert radiologist were selected and their surgical and pathology forms were reviewed to confirm the diagnosis. Patients with rupture seen at surgery were also selected to see if this correlated with findings at central radiology review.

**Results**: Of the 335 cases with central radiology review, 53 (16%) had possible rupture on diagnostic and/or pre‐operative scans. MRI was used to evaluate abdominal disease status in 70% of patients. Imaging quality was variable with 20 adequate, 18 suboptimal, 6 inadequate and 9 unknown quality scans. A surgical form was available for 38/53 cases (72%) and 26 cases had a pathology form (49%). Rupture was confirmed at surgery in 9 patients (24%) and at pathology review in 3 patients (12%).

Surgical information was available for 337 patients. In 34 patients (10%) rupture was found at surgery. Only 4 of these (1 major rupture, 3 fissures) occurred per‐operatively. Twenty four of the patients with surgical rupture also had a corresponding radiology form. Rupture had previously been identified at central radiology review in 9 of these patients (38%).

**Conclusions**: We conclude that features of rupture found at radiology review are not always confirmed at surgery and/or pathology review. Suggested rupture at radiology should therefore not be used for definitive staging and treatment.

### O-096. How Many Lymph Nodes are Enough? Assessing the Adequacy of Lymph Node Yield for Staging in Favorable Histology Wilms Tumor {#pbc27455-sec-1210}
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**Background/Objectives**: Current investigational priorities in the treatment of favorable histology Wilms tumor (FHWT) center on accurate staging and risk‐stratification. The extent of lymphadenectomy has not been clearly defined; however, the importance of accurate lymph node (LN) staging cannot be overstated as it guides adjuvant therapy. The identification of a minimum LN yield that should be sampled to ensure accurate staging could help direct development of surgical guidelines. We present statistical models to describe the risk of occult metastatic disease in patients with FHWT as a function of the number of LNs examined.

**Design/Methods**: The National Cancer Database was queried for patients with unilateral FHWT from 2004‐2013. Demographic and clinical data were abstracted for those who underwent surgical resection and had at least one positive LN and 2 or more LNs examined. For a given number of LNs sampled, the probability of a false negative LN sampling was estimated using a beta‐binomial model and empirically.

**Results**: We identified 422 patients meeting study criteria. Median age was 3 yrs (range 0‐86). The median number of LNs sampled was 4 (range 2‐49) and the median number of LNs positive was 1 (range 1‐24). To achieve ≤10% probability of a false‐negative LN sampling, the beta‐binomial model estimated that 10 LNs needed to be sampled, while empirically it was estimated that 6 LNs would need to be sampled.

**Conclusions**: Using 2 separate approaches, it appears that the desired LN yield to reduce the risk of a false‐negative LN sampling to ≤10% is between 6 and 10. This is an objective attempt to determine the desired LN yield to accurately stage patients with FHWT. These data may be used to standardize surgical guidelines and as a quality metric to measure surgeon performance.
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### O-097. Immunotherapy with Anti‐GD2 Antibody ch14.18/CHO±IL2 within the HR‐NBL1/SIOPEN Trial Improves Outcome of High‐Risk Neuroblastoma Patients Compared to Historical Controls {#pbc27455-sec-1230}
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**Background/Objectives**: Randomization of immunotherapy versus standard was not possible in the HR‐NBL1/SIOPEN trial. In order to explore an impact of immunotherapy on outcome, we used trial patients prior to availability of ch14.18/CHO as internal control.

**Design/Methods**: Trial patients received rapid COJEC, two courses of TVD if needed, surgery, HDT/SCT (BuMel or CEM) and radiotherapy. MRD treatment (MRDT) consisted of isoretinoin alone from 2002 ‐ 2009 (control population, CP) and from 2009 ‐ 2013 with ch14.18/CHO (5 cycles ch14.18/CHO, ± IL2) (immunotherapy population, IP).Patients (844) were ≤9 months between diagnosis and HDT/SCT, PR or better prior to HDT/SCT and had no progression after HDT/SCT until start MRDT (median time 109 days) (CP 466, IP 378). Sex, age groups, stage 4 MycN amplified (MNA) and response prior HDT/SCT were balanced between cohorts. Median follow up was 5.8y (0.05‐13.8y).

**Results**: The 5y‐EFS was 57%±3% for the IP and 42%±2% for the CP (p\<0.001). Univariate risk factors analysis showed a significant impact for age, stage, metastatic compartment (MC)\>1, delayed surgery, response pre HDT/SCT and type of HDT. Multi‐variate analysis identified an independent higher risk for patients without immunotherapy (p=0.0002, HR 1.573), treated with CEM (p=0.0029; HR 1.431), response \<CR prior MRD (p=0.0043, HR 1.494) and \>1MC at diagnosis (\<0.001 HR 2.665). After adjustment for age, stage, MC, TVD and pre‐MRD response, a benefit for immunotherapy was confirmed in BuMel‐ (p=0.0066; HR 1,439) with 5yEFS of, 56±3% vs 48±3% (IP vs CP) and in CEM‐treated patients (p=0.0107; HR 2.334) with 5yEFS of 67±9% vs 35±3% (IP vs. CP).

**Conclusions**: Introduction of ch14.18/CHO immunotherapy achieved a major improvement in outcomes for patients on the HR‐NBL1 trial.

### O-098. Potent Anti‐Tumor Effect Using T Cells Armed with Recombinant Anti‐GD2 Bispecific Antibodies Against GD2 Positive Tumor {#pbc27455-sec-1240}
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**Background/Objectives**: Ex vivo, polyclonal T cells can be armed using chimeric antigen receptor or CD3xGD2 bispecific antibody (BsAb) for infusional cytotherapy. Anti‐GD2 Naxitamab‐BsAb using the IgG(L)‐scFv format, where the anti‐CD3 huOKT3 scFv is linked to the carboxyl end of the Naxitamab light chain has shown promising anti‐tumor properties against GD2(+) tumors. The Phase I study of T cells armed with chemically conjugated Naxitamab x OKT3 (BiAb) was safe with suggestions of clinical response. We now report the safety and efficacy of T cells armed with recombinant Naxitamab‐BsAb in preclinical models.

**Design/Methods**: T cells from normal volunteers were expanded and activated using CD3/CD28 beads at 37^o^C to form ATCs. 7‐9 days later, ATCs were harvested and co‐incubated with a GMP grade Naxitamab‐BsAb at room temperature for 20 minutes. These armed ATCs were tested for cytotoxicity in vitro and in vivo against human GD2(+) cell lines and PDXs xenografted in BALB‐*Rag2* ^‐/‐^IL‐2R‐gc‐KO \[DKO\] mice.

**Results**: Naxitamab‐BsAb armed ATCs showed robust antigen‐specific tumor cytotoxicity against GD2(+) tumors in vitro over a range of antibody dose (0.5‐0.005 ug/106 cells). Optimal arming occurred at 3‐30 zeptomoles (10‐21 moles), 1500‐5000 molecules of BsAb per cell without evidence of activation induced cell death when confronted by target cells. In vivo Naxitamab‐BsAb armed ATCs showed potent anti‐tumor effect in both neuroblastoma and melanoma over a range of cell doses (10, 20, 40 x 106 per injection, twice a week for 3 weeks), without significant side effects in DKO mice. By immunohistochemistry, the frequency of tumor infiltrating CD3(+) T cells were strongly correlated with tumor response.

**Conclusions**: Naxitamab‐BsAb armed ATCs may provide a viable immunotherapy platform against GD2(+) tumors in both adult and pediatrics. Compared to virus‐based gene modification, BsAb uses standard manufacture methods and distribution networks, and has the potential for much higher cell doses without cytokine storm.

### O-099. Prior CD19‐Targeted Therapy is Associated with Increased Non‐Response and Relapse after CAR T Cell Therapy {#pbc27455-sec-1250}

[V. Pillai]{.ul} ^1^, K. Muralidharan^2^, J. Rosenthal^2^, G. Wertheim^1^, M. Paessler^1^, S. Maude^3^, S. Grupp^3^, S. Rheingold^3^

*^1^The Children\'s Hospital of Philadelphia, Pathology and Laboratory medicine, Philadelphia, USA; ^2^University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA; ^3^The Children\'s Hospital of Philadelphia, Oncology, Philadelphia, USA*

**Background/Objectives**: Chimeric antigen receptor T cells targeting CD19 (Tisagenlecleucel, CART‐19) have shown excellent responses in patients with relapsed/refractory B‐ALL and was recently approved by the FDA. The relationship between pre‐treatment CD19 expression and response is not clear. We assessed whether baseline blast CD19 expression level or prior CD19 targeted therapy impacts response to CART‐19 therapy.

**Design/Methods**: Cases of B‐lymphoblastic leukemia (B‐ALL) treated with CART‐19 from 2012‐2017 at Children\'s Hospital of Philadelphia were assessed. Flow cytometric expression of CD19 in blasts was classified as dim, normal or bright compared to normal B cells. CD19 expression and immunophenotype of blasts pre and post‐CART‐19 therapy were correlated with responses to CART‐19 therapy. Failure to reach a MRD‐negative remission was considered as non‐response. Presence of aberrant blasts \>0.01% at any time point after remission was considered as relapsed disease.

**Results**: One hundred and fifty cases were identified of which 10 were classified as non‐responses, 20 were CD19‐positive relapses and 33 were CD19‐negative relapses. Immunophenotype of CD19‐positive relapses were identical to that of pre‐therapy disease in 85% of cases, consistent with loss of CAR T cells as the etiology of those relapses. Non‐responses and CD19‐negative relapses are likely related to disease parameters. Rate of responses and relapses in CD19‐dim B‐ALL were not significantly different from the CD19‐normal/bright group. Fifteen patients received prior CD19‐targeted therapy such as blinatumomab and/or a different CART cell therapy. Prior CD19‐targeted therapy was associated with a significantly higher rate (60%; p=0.014) of non‐response and CD19‐negative relapse compared to 25% in patients who did not receive any prior CD19 targeted therapy.

**Conclusions**: CART‐19 cell therapy is effective in B‐ALL across all levels of CD19 expression. However, prior targeted therapy is associated with increased non‐response and relapse. Hence, using blinatumomab or other CAR T cell therapy may impact curative treatment with FDA approved CAR T cell therapy.

### O-100. Preclinical Efficacy of CD33 Chimeric Antigen Receptor T Cell Immunotherapy in Childhood Acute Myeloid Leukemia {#pbc27455-sec-1260}

L. Yang^1^, S. Tarun^1^, F. Shen^2^, H. Qin^1^, C.D. Chien^1^, M.E. Kohler^1^, T.J. Fry^3^, [S. Tasian]{.ul} ^2^

*^1^National Cancer Institute, Pediatric Oncology Branch, Bethesda, USA; ^2^Children\'s Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, Philadelphia, USA; ^3^University of Colorado Denver, Pediatric Hematology and Immunology, Aurora, USA*

**Background/Objectives**: Antibody‐based and cellular immunotherapies have major potential to overcome chemoresistance in acute myeloid leukemia (AML). CD33 is expressed on \>85% of pediatric AML, and improved efficacy of gemtuzumab ozogamicin addition to chemotherapy has been demonstrated in children with AML (Gamis JCO 2014). We hypothesized that CD33‐redirected chimeric antigen receptor T‐cells (CD33CART) would have potent anti‐AML activity and sought in this study to identify an optimal CD33CART product for clinical development.

**Design/Methods**: We created six CD33CARTs using gemtuzumab, lintuzumab, or M195 single‐chain variable fragments with CD28/CD3ζ or 4‐1BB/CD3ζ co‐stimulatory domains as described (Tarun Blood 2017). Cytokine production and cytoxicity of CD33CARTs incubated with CD33+ AML cell lines were quantified by enzyme‐linked immunoabsorbent and IncuCyte assays, respectively. CD33CARTs were administered to immunocompromised mice engrafted with luciferase‐transduced human AML cell lines or primary childhood AML cells (patient‐derived xenograft \[PDX\] models). Inhibition of leukemia proliferation and CD33CART expansion were measured via bioluminescent imaging or flow cytometric quantification of human CD45+/CD33+ AML and CD3+ T‐cells in murine blood and in spleens and bone marrow at study termination.

**Results**: *In vitro* incubation of CD33CARTs with CD33+ AML cell lines induced similarly high IFN‐γ and IL‐2 levels and robust leukemia cell killing. All six CD33CARTs inhibited *in vivo* leukemia proliferationin luciferase+ MOLM14 and THP‐1 xenograft models. Mice treated with 4‐1BB/CD3ζ CD33CARTs demonstrated significant anti‐leukemia responses, but eventually died of progressive disease. Conversely, mice given CD28/CD3ζ CD33CARTs had no evidence of disease at ≥6 months post‐treatment. All CD33CARTs similarly markedly inhibited leukemia proliferation in childhood AML PDX models (n=3) versus saline and mock‐transduced control T‐cells. Complete leukemia eradication and superior T‐cell expansion was observed in lintuzumab‐CD28/CD3ζ‐CD33CART‐treated PDX animals (p\<0.0001, ANOVA/Tukey post‐test).

**Conclusions**: Based on these preclinical results, our first‐in‐child multi‐institutional Pediatric Bone Marrow Transplant Consortium‐sponsored phase 1 trial will evaluate the safety of lintuzumab‐CD28/CD3ζ CD33CART in children with relapsed/refractory AML.

### O-101. Hypermutant Pediatric Cancers are Enriched for Replication Repair Deficiency and Demonstrate Responses to Immune Checkpoint Inhibition: An Update from the International BMMRD Consortium {#pbc27455-sec-1270}

[B. Campbell]{.ul} ^1^, D. Morgenstern^2^, M. Edwards^1^, N. Light^3^, D. Fabrizio^4^, D. Malkin^2^, A. Shlien^5^, C. Hawkins^6^, E. Bouffet^2^, U. Tabori^2^

*^1^The Arthur and Sonia Labatt Brain Tumour Research Centre‐ The Hospital for Sick Children‐ Toronto‐ Ontario‐ Canada., Department of Haematology/Oncology, Toronto, Canada; ^2^The Hospital for Sick Children, Department of Hematology/Oncology, Toronto, Canada; ^3^The Hospital for Sick Children, Genetics and Genome Biology, Toronto, Canada; ^4^Foundation Medicine Inc., Department of Cancer Immunotherapy, Boston, USA; ^5^The Hospital for Sick Children, Department of Genetics and Genome Biology, Toronto, Canada; ^6^The Hospital for Sick Children, Department of Pathology, Toronto, Canada*

**Background/Objectives**: Hypermutation constitutes an important subgroup of cancers and confers sensitivity to immune checkpoint inhibition (ICI). Hypermutant tumors can arise either due to therapy or germline mutations in the Replication Repair genes (RRD). Our objective was to quantify the frequency of hypermutant tumors in children, determine whether mutational signatures can predict germline mutations, and treat hypermutant tumors with ICIs.

**Design/Methods**: Deep panel sequencing (750x) of 2984 pediatric tumors and 79842 adult tumors was performed. An algorithm was devised to determine mutation burden, mutational signatures, and driver alterations to uncover treatment and germline induced hypermutation. Data on 40 patients with hypermutant tumors identified by sequencing were enrolled on an ICI registry trial

**Results**: Hypermutant tumors (\>10 mut/MB) comprised 5% of all pediatric tumors (n=143). These were highly enriched for RRD mutations (p\<0.0001) and mutation loads correlated with hypermutant adult tumors that have shown demonstrable clinical response to ICI. Analysis of tumors for mutational burden, signatures and other parameters was able to uncover germline mutations in replication repair genes and past history of treatment causing hypermutation in all patients. Of the 40 children with hypermutant cancers treated with ICI, 62% of tumors had objective response including 92% in metastatic recurrent non‐brain tumors. Overall survival at 1 and 2 years is 65+/‐8 and 46+/‐13 % respectively. Survival for brain and non‐brain tumors are 25+/‐12 and 88+/‐8 % respectively (p=0.005)

**Conclusions**: High mutation burden is a sensitive predictor of germline mutations in replication repair genes, leading to cancer predisposition. Hypermutant tumors are more common in the pediatric setting than previously appreciated and can be induced by prior chemotherapies or germline mutations, necessitating novel therapeutic avenues. Encouraging responses for ICI are observed especially in non‐brain recurrent/progressive metastatic hypermutant cancers. Prospective clinical trials are required for hypermutant cancers.

### O-102. Interaction of Immune Checkpoints in Tumor‐Stromal Microenvironment of Primary and Chemoreduced Retinoblastoma {#pbc27455-sec-1280}

[L. Singh]{.ul} ^1^, M.K. Singh^2^, S. Kashyap^2^, S. Sen^2^, M.A. Rizvi^1^

*^1^Jamia Millia Islamia, Biosciences, New Delhi, India; ^2^All India Institute of Medical Sciences, Ocular Pathology, New Delhi, India*

**Background/Objectives**: Interactions between malignant and non‐malignant cells create the tumor microenvironment (TME). The non‐malignant cells of the TME have a dynamic and tumor‐promoting function at all stages of carcinogenesis. Cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are key components of immune checkpoint pathway. They play a role in the regulation of T‐cell activation and their expression in TME constitutes a predictive biomarker in cancers. It has recently been shown that chemotherapeutic agents could modify tumor microenvironment. Therefore, we investigated the expression of PD‐1, PD‐L1 and CTLA‐4 in primary and chemoreduced retinoblastoma to define their significance in tumor microenvironment with patient prognosis.

**Design/Methods**: Expression of immune markers (PD‐1, PD‐L1 and CTLA‐4 protein) was evaluated in 75 prospective cases of primary (Group I) and 25 cases of chemoreduced (Group II) retinoblastoma specimens by immunohistochemistry. mRNA expression of genes of interest were investigated by quantitative real time PCR (qPCR) and results were correlated with clinicopathological parameters and patient outcome by statistical analysis.

**Results**: Differential expression pattern of PD‐1, PD‐L1 and CTLA‐4 proteins was found in both group I (primary retinoblastoma) and group II (chemoreduced retinoblastoma) cases. Immunohistochemistry showed cytoplasmic/membranous staining of these immune markers using their respective antibodies. Increased expression of PD‐1, PD‐L1 and CTLA‐4 was found in stromal/immune cells of group II as compared to Group I. Expression of these immune markers showed significant correlation with poor tumor differentiation, tumor invasion and patient outcome (p\<0.05).

**Conclusions**: This is the first of its kind study investigating the role of immune markers in primary retinoblastoma and their alteration in expression after chemotherapy. Tumor microenvironment of retinoblastoma showed expression of PD‐L1 in primary patients and increased expression in PD‐L1, CTLA‐4 and PD‐1 after chemotherapy. This paves the way for development of immunotherapy as a new strategy for treatment of chemoreduced retinoblastoma.
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### O-103. Clinical and Genetic Risk Factors Define Two Risk Groups of Extracranial Rhabdoid Tumors: A Plea for High Risk Tailored Therapies {#pbc27455-sec-1300}

K. Nemes^1^, D. Kachanov^2^, T. Simon^3^, P. Hauser^4^, S. Tippelt^5^, W. Woessmann^6^, C. Flotho^7^, L. Grigull^8^, P. Hernaiz‐Driever^9^, P.G. Schlegel^10^, F. Abbink^11^, M.J. Gil‐da‐Costa^12^, S. Lowis^13^, C. Hernandes Marquez^14^, N. Graf^15^, K. Nysom^16^, S. Bens^17^, T. Kroencke^18^, R. Furtwängler^19^, [M. Frühwald]{.ul} ^20^

*^1^Children\'s Hospital, Swabian Children\'s Cancer Center, Augsburg, Germany; ^2^National Scientific and Practical Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Heme/Onc, Moscow, Russia; ^3^University CHildren\'s Hosptal Cologne, Pediatric Hem/Onc, Cologne, Germany; ^4^University Children\'s Hospital Budapest, Pediatric Heme/Onc, Budapest, Hungary; ^5^University Children\'s Hospital Essen, Pediatric Heme/Onc, Essen, Germany; ^6^University Children\'s Hospital Giessen, Pediatric Heme/Onc, Giessen, Germany; ^7^University Children\'s Hospital Freiburg, Pediatric Heme/Onc, Freiburg, Germany; ^8^MHH Hannover, Pediatric Heme/Onc, Hannover, Germany; ^9^University Children\'s Hospital Berlin Charite, Pediatric Heme/Onc, Berlin, Germany; ^10^University Children\'s Hospital Würzburg, Pediatric Heme/Onc, Würzburg, Germany; ^11^Vu medisch centrum, oncoloog/hematoloog, Amsterdam, The Netherlands; ^12^Pediatric Hospital‐ Hospital São João, Hematology and Oncology Unit‐, Porto, Portugal; ^13^University Hospital of Bristol, Pediatric Heme/Onc, Bristol, United Kingdom; ^14^Hospital Infantil Universitario Niño Jesús, Pediatric Heme/Onc, Madrid, Spain; ^15^Saarland University Hospital, Department of Pediatric Oncology and Hematology, Augsburg, Germany; ^16^Rigshospitalet Copenhagen, Sect. of Paeditric Haematology & Oncology‐ Dept. of Paediatrics & Adolescent Medicine, Copenhagen, Denmark; ^17^University of Ulm & University Hospital of Ulm, Institute of Human Genetics‐, ulm, Germany; ^18^Klinikum Augsburg, Klinik für Diagnostische und Interventionelle Radiologie, Augsburg, Germany; ^19^Saarland University Hospital, Department of Pediatric Oncology and Hematology, Homburg, Germany; ^20^Klinikum Augsburg / Children\'s Hospital, Swabian Children\'s Cancer Center, Augsburg, Germany*

**Background/Objectives**: Malignant rhabdoid tumors (MRT) are highly aggressive malignancies affecting young children (\<1 year -- 5 per million). The EU‐RHAB registry prospectively collected data on uniformly treated patients with any rhabdoid tumor to lay the foundation for clinical trials across Europe.

**Design/Methods**: Clinical data of 100 patients with extracranial MRT registered to EU‐RHAB from 2009 ‐ 2017 were evaluated. Tumor tissues were investigated for *SMARCB1/SMARCA4* mutations (FISH, MLPA and sequencing). Blood (n=81) was examined for germline mutations.

**Results**: 70 Patients presented with extracranial, extrarenal rhabdoid tumors (eMRT), 30 with renal MRT. Nine demonstrated synchronous tumors. Median age at diagnosis was 11.5 months (range 0‐206). Distant metastases at diagnosis were present in 33%, regional lymph node involvement in 13%. IRS‐stages for eMRT were: IRSI=14, IRSSII=12, IRSSIII=22, IRSSIV=16; 6 had synchronous tumors. SIOP‐stages for renal MRT were: 3/7/20 for stages I/II/III. A germline mutation (GLM) was detected in 21% (17/81). A gross total resection (GTR) was obtained in 53% (53/100). Radiotherapy (RTx) was applied to 56% (56/100). Complete remission (CR) was achieved in 54% (54/100). 5‐yearOS‐ and ‐EFS rates were 45.8±5.4% and 35.2±5.1%. Age (\<12 vs. \>12 months; 36.7±7.2% vs. 53.5±8.2%), distant metastases (21.6±8% vs. 69.2±7%), synchronous tumors (0% vs. 51.2±5.7%), presence of a GLM (6.3±6.1% vs. 55.6±7%), achievement of a GTR (59.2±7.4% vs. 31.4±7.4%), RTx (56.6±6.9% vs. 22.5±7.7%) and CR (53.9±6.8% vs. 21.4±7.5%) were significant prognostic factors for OS (p\<0.05). On multivariate analysis no GTR, presence of a GLM and distant metastases at diagnosis independently prognosticated lower OS.

**Conclusions**: Our data suggest a link of outcome to clinical but also genetic factors. We propose a stratification scheme defining a standard (SR) and high risk (HR) group. Patients with a GLM, distant metastases, stage III/IV and/or lack of a GTR are at high risk for progression. HR‐patients need novel therapies.

*Supported by "Deutsche Kinderkrebsstiftung" (DKKS 2010.03)*

### O-104. Ovarian Juvenile Granulosa Cell Tumors: Report of the German MAKEI and Step Registries {#pbc27455-sec-1310}

[D. Schneider]{.ul} ^1^, F. Puscz^1^, F. Hippert^1^, I.B. Brecht^2^, B. Bernbeck^1^, S. Schönberger^3^, G. Calaminus^3^, U. Göbel^4^

*^1^Klinikum Dortmund, Clinic of Pediatrics, Dortmund, Germany; ^2^University Hospital Tübingen, Clinic of Pediatric Hematology and Oncology, Tübingen, Germany; ^3^University Hospital Bonn, Clinic of Pediatrics, Bonn, Germany; ^4^University Hospital Düsseldorf, ESPED Research Group, Düsseldorf, Germany*

**Background/Objectives**: Juvenile granulosa cell tumors (juvGCT) are rare sex cord stromal tumors. Previous analyses have shown an association of spontaneous preoperative tumor rupture, malignant ascites or peritoneal metastases with poor outcome of approx. 50% in these groups.

**Design/Methods**: Between 2001 and 2015, 69 patients (median age 9.3 (0‐30) years) have been registered prospectively; the largest pediatric series collected to date. A therapeutic risk stratification based on tumor stage has been evaluated: Standard recommendation included PEI chemotherapy for patients with malignant ascites, preoperative rupture and/or metastases; for all other patients watch&wait was recommended.

**Results**: Symptoms included abdominal pain or distension or endocrinological symptoms such as isosexual precocity. Median tumor diameter was 12 cm (3‐30 cm). Stage according to FIGO was: Ia 38 pts., Ic 29 pts., IIa 1 pt., incomplete data. 1 pt.. All patients underwent ovarectomy or adnectomy. Stage Ia patients were followed expectantly. 2/11 pts. with intraoperative spillage and 11/12 pts. with preoperative spontaneous rupture or malignant ascites as well as the stage II pt. received cisplatin‐based chemotherapy. After a median follow‐up of 5.6 years, two events have been reported, both in patients initially presenting with stage Ia tumors: One patient developed a metachronous contralateral juvGCT with several subsequent, ultimately fatal relapses. The other presented with highly anaplastic histology (mitotic count 67/10 HPF) and vascular invasion; after intensive salvage treatment including high‐dose chemotherapy and irradiation, a second continuous remission was achieved. In this interim analysis, estimated event‐free survival is 0.96±0.26 and overall survival 0.98±0.23.

**Conclusions**: Compared to historic cohorts, the central registration of patients including the access to reference pathological evaluation and the introduction of risk‐stratified cisplatin‐based chemotherapy to stage Ic patients with preoperative rupture or malignant ascites have resulted in an improvement of prognosis of patients with juvenile granulosa cell tumors.

*Supported by the German Childhood Cancer Foundation and the Barbara‐und‐Hubertus‐Trettner Foundation*.

### O-105. Laparoscopic Ovary Conservative Neoplasm Resection in Pediatric Population: A Single Center Prospective Study on 236 Patients {#pbc27455-sec-1320}

[J. Wang]{.ul} ^1^, L. Sun^2^, C. Lai^3^, J. Xiong^1^, M. Li^1^, Q. Shu^1^

*^1^Children\'s Hospital Zhejiang University School Medicine, Surgical Oncology Department, hangzhou, China; ^2^Children\'s Hospital Zhejiang University School Medicine, Department of PAG, hangzhou, China; ^3^Children\'s Hospital Zhejiang University School Medicine, Department of Radiology, hangzhou, China*

**Background/Objectives**: Minimally Invasive Surgery (MIS) has been well‐accepted surgical approach in pediatric surgery. However, MIS is not popular in children with ovarian neoplasm. This study aimed at evaluating the safety and effectiveness of MIS resection in a series of children with ovarian neoplasm.

**Design/Methods**: Since 2015, an institutional protocol for MIS resection of ovarian neoplasm has been applied. Neoplasm with clear border line in MR or CT scan was considered as the main indication for MIS approach, ovary conservative neoplasm resection was the standard method. All patients who underwent MIS for ovarian neoplasm between January 2015 and December 2017 were included. Specific technical considerations, demographic data, and follow‐up dada have been recorded.

**Results**: Two hundred and thirty‐six patients underwent MIS resection for ovarian neoplasm. Aged from 1D to 15Y2M. Left Median ovarian neoplasm 85 cases, right side 127 cases and bilateral neoplasms 24 cases. MIS was performed successfully in 232 cases, 4 cases converted to open surgery because of serious adhesion. Median hospital stay was 4 days. 39 cases were prenatally diagnosed. In 9 cases who underwent MIS before 1M, ovary conservation was successful in 4 cases. In other 30 cases who underwent MIS older than 1M, ovary conservation was successful in 4 cases. 6 cases of malignant tumor was found in all patients, 1 case of grade II Immature teratoma (no postoperative chemotherapy), 2 cases with endodermal sinus tumor after chemotherapy (adnexectomy), 1 case of juvenile granulosa cell tumor, 1 case of gonadoblastoma and 1 case of mixed germ cell tumor (redo MIS and adnexectomy). No serious intra‐ or post‐operative complication was observed.

**Conclusions**: This study demonstrated the safety and effectiveness of laparoscopic ovary conservative neoplasm resection in pediatric population. Early laparoscopic surgery should be considered in prenatal diagnosed patients to improve the ovary conservation rate.

### O-106. Differences in Treatment -- Induced Facial Growth Deformity in Head and Neck Rhabdomyosarcoma Survivors {#pbc27455-sec-1330}

[M. Hol]{.ul} ^1^, O. Slater^2^, M. de Win^3^, B. Pieters^4^, S. Strackee^5^, M. Gaze^6^, J. Chisholm^7^, H. Mandeville^8^, T. Maal^9^, J. Merks^10^, L. Smeele^1^

*^1^Academic Medical Center, Department of Oral and Maxillofacial surgery, Amsterdam, The Netherlands; ^2^Great Ormond Street Hospital, Department of Pediatric Oncology, London, United Kingdom; ^3^Academic Medical Center, Department of Radiology, Amsterdam, The Netherlands; ^4^Academic Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands; ^5^Academic Medical Center, Department of Plastic Surgery, Amsterdam, The Netherlands; ^6^University College Hospital, Department of Radiation Oncology, London, United Kingdom; ^7^Royal Marsden Hospital, Department of Pediatric Oncology, Sutton, United Kingdom; ^8^Royal Marsden Hospital, Department of Radiotherapy, Sutton, United Kingdom; ^9^RadboudUMC, Department of Maxillofacial Surgery, Nijmegen, The Netherlands; ^10^Academic Medical Center, Department of Pediatric Oncology, Amsterdam, The Netherlands*

**Background/Objectives**: Facial growth deformity following treatment for head and neck cancer in pediatric patients is a common and severe late adverse effect occurring in about 60% of the patient population. However, the differences in growth deformity for different treatment modalities in head and neck rhabdomyosarcoma (HNRMS) have not been analyzed yet. The purpose of this study was to quantify and compare facial growth deformities in children with HNRMS following different treatment modalities with inherently different radiation dose distributions.

**Design/Methods**: This cross‐sectional study consisted of 68 children treated for HNRMS at least 5 years ago with either External Beam Radiation Therapy (photon) (EBRT) (n=26) or a multidisciplinary approach; consisting of Ablative surgery, MOld technique with afterloading brachytherapy and REconstructive surgery (AMORE) (n=42). Of all survivors a 3D‐stereophotograph was taken and analyzed for curvature, surface area, and volume depletion using a healthy average matched face (matched based on age, sex and ethnicity). Finally, the quantified growth deformity indicators found for the two treatment groups were compared.

**Results**: The mean follow‐up was 11 years; therefore, most patients were post their growth spurt. Growth deformity in the radiated side was present in both AMORE‐patients and EBRT‐patients. However, significantly less curvature and significantly more volume depletion was found in EBRT‐patients (*p*\<0.05). Furthermore, significant growth deformity (\>2SD in comparison to the healthy population) was found in the non‐irradiated side of EBRT‐patients (*p*=0.002). Clinical significant mid‐face hypoplasia was present in the 76% of the EBRT treatment group, resulting in both esthetical and functional problems.

**Conclusions**: We found significant differences in facial growth deformity between the two treatment modalities, favoring patients treated with AMORE. Especially lack of curvature and surface area in the healthy side of the face as well as clinical significant mid‐face hypoplasia is profound in EBRT‐patients. In the future these potential adverse effects should be considered at therapy planning.

### O-107. The Value of Circulating Cell‐Free BRAFV600E Detection in Children with Langerhans Cell Histiocytosis {#pbc27455-sec-1340}

[L. Cui]{.ul} ^1^, D. Wang^2^, Q. Zhang^1^, H.H. Ma^2^, T.Y. Wang^2^, Z.G. Li^1^, R. Zhang^2^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Hematology and Oncology Laboratory‐ Beijing Pediatric Research Institute, Beijing, China; ^2^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Hematology Oncology Center, Beijing, China*

**Background/Objectives**: Langerhans cell histiocytosis (LCH) is the most common histiocytosis. 38‐64% of LCH cases have been reported to harbour the BRAFV600E mutation. The aim of this study was to investigate the clinical value of BRAFV600E mutation detection in circulating cell‐free (ccf) DNA in a paediatric LCH cohort.

**Design/Methods**: A droplet‐digital PCR assay was applied for quantitative detection of the ccf BRAFV600E at diagnosis in plasma of 57 Children with BRAFV600E‐mutated LCH. Eight wild‐type *BRAF* LCH patients were also included as negative controls.

**Results**: At diagnosis, ccf BRAFV600E was detected in 44 (77.2%) of 57 BRAFV600E‐mutated LCH patients. ccf BRAFV600E was positive in 24/25(96.0%) of patients with risk‐organ positive multisystem (RO+ MS) LCH, 9/11 (81.8%) of patients with RO‐ MS LCH and 11/21 (52.4%) of patients with single‐system (SS) LCH (P=0.001). Positive ccf BRAFV600E load was significantly higher for the 24 RO+ children (median, 2.1%; range, 0.1%‐24.0%) than for the 9 RO‐ children (median, 0.3%; range, 0.1%‐1.6%) or 11 SS patients (median, 0.4%; range, 0.1%‐8.9%) (P=0.001). The clinical characteristics of the 44 children with positive ccf BRAFV600E detection ≥ 0.1% were compared to the 13 children with negative ccf BRAFV600E detection according to this threshold. Of the patients with positivity ccf BRAFV600E, 54.5% had a RO+ MS LCH, 20.4% had a RO‐MS LCH, and 25.0% had a SS LCH(P=0.001). The age of patients with positivity ccf BRAFV600E was significantly lower than that of negative detection. The median age was 1.5 years and 4 years, respectively (P=0.033). liver and spleen involvement were also associated with positivity ccf BRAFV600E (liver: 52.3% vs.7.7%, P=0.004; spleen 34.1% vs.7.7%, P = 0.084).

**Conclusions**: These results indicated that ccf BRAFV600E was associated with the clinical classification and the characteristics of patients with LCH, and could be served as a promising biomarker in childhood LCH.

### O-108. GAIA‐102: A Novel Natural Killer Cell Phenotype that Can Eliminate Solid Tumors {#pbc27455-sec-1350}

[M. Ishii]{.ul} ^1^, Y. Harada^2^, N. Kawakubo^3^, R. Sozaki^1^, Y. Kinoshita^4^, T. Taguchi^1^, Y. Yonemitsu^2^

*^1^Kyushu University, Department of Pediatric Surgery‐ Faculty of Medical Sciences, Fukuoka, Japan; ^2^Kyushu University, R&D Laboratory for Innovative Biotherapeutics‐ Graduate School of Pharmaceutical Sciences, Fukuoka, Japan; ^3^National Cancer Center, Department of Pediatric Surgical Oncology, Tokyo, Japan; ^4^Niigata University School of Medicine, Department of Pediatric Surgery, Niigata, Japan*

**Background/Objectives**: Advanced neuroblastoma has poor long‐term survival despite intensive multimodal treatments include anti‐disialoganglioside (GD2) antibody. Thus, we established a novel modality: GAIA‐102, which is the new class natural killer (NK) cells, having high cytotoxicity against neuroblastoma and other various tumor cell lines. GAIA‐102 shows CD56bright/ CD16high and low/ CD57neg phenotype, indicating that the new NK cells might be not exhausted. In addition, GAIA‐102 is also characterized by high expression of adhesion molecules and chemokine receptors that are similar expression patterns of tumor‐infiltrating lymphocytes, unlike to those seen in circulating primary and activated NK cells. Herein, we investigated killing and invasion activity of GAIA‐102 in three‐dimensional (3D) assay and in vivo study.

**Design/Methods**: GAIA‐102 was generated as previously described by our laboratory (Saito S et al, 2013). IMR‐32 (neuroblastoma cell line) spheroid was co‐cultured with fluorescently labeled GAIA‐102. Time‐lapse imaging of invasion of effector cells into spheroid was performed. Spheroids were subjected to counting the number of live/dead tumor cells by flow cytometry. For the murine peritoneal metastasis model, 2x10e6 cells/head of GAIA‐102 were injected to tumor bearing NOG mouse intraperitoneally. Two‐weeks after GAIA‐102 injection, the peritoneae were excised and examined using fluorescence microscopy.

**Results**: In 3D cytotoxic assay, GAIA‐102 efficiently killed IMR‐32 spheroid as compared to IL‐2‐activated primary NK cells, anti‐GD2 antibody, or combination of both. Surprisingly, cytotoxicity of GAIA‐102 alone was nearly equal to that seen in combination with anti‐GD2 antibody. Time‐lapse imaging demonstrated that GAIA‐102 migrated, infiltrated and destroyed via efficient tumor cell killing even in spheroid. In contrast, primary NK cells could not infiltrate into the spheroid. Furthermore, intraperitoneal GAIA‐102 infusion in NOG mice dramatically reduced tumor progression.

**Conclusions**: GAIA‐102 exhibits high cytotoxicity and invasive activity against human neuroblastoma spheroid. GAIA‐102 offers a highly promising modality for the treatment of solid, bulky lesion of advanced neuroblastoma.
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### O-109. Priority Symptoms Identified by Adolescents and Young Adults Receiving Chemotherapy Using an iPad‐Based Symptom Heuristics App {#pbc27455-sec-1370}
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**Background/Objectives**: Adolescents and young adults (AYAs) with cancer experience multiple symptoms due to disease and treatment; however, little is known about which symptoms they identify as priority symptoms. This study describes the occurrence, severity, and associated distress of priority symptoms identified by AYAsand the relationship of severity and distress to designation of priority status.

**Design/Methods**: AYAs used the Computerized Symptom Capture Tool (C‐SCAT) to report their symptoms. The C‐SCAT is an investigator‐developed iPad‐based symptom heuristics app that allows users to identify, from their own perspective: symptoms, relationships between symptoms, symptom clusters, priority symptoms within each cluster, and priority clusters.

**Results**: Participants were 86 AYAs (median 19 years; range 15‐29 years; 52% males; 71% White) receiving chemotherapy at 5 sites in the United States. Participants reported a median of 4 symptoms at each of two timepoints (T1, T2) immediately prior to courses of chemotherapy with a range of 0‐15 symptoms at T1 and 0‐18 symptoms at T2. The number of symptoms reported did not differ based on age (adolescent vs. young adult) or gender. Severity (t=‐3.22; p \<.01) and distress (t=‐3.92; p\<.01) were greater among priority symptoms versus those not identified as priority. The most prevalent priority symptoms were: lack of energy (n=19); nausea (n=18); difficulty sleeping (n=15); and pain (n=13). For these symptoms, severity and distress did not differ based on priority designation. Regardless of priority designation, mean severity and distress ratings for these four symptoms, were greater than those for other symptoms across the study sample.

**Conclusions**: Fatigue, nausea, difficulty sleeping, and pain are among the most severe and distressing symptoms regardless of whether identified as priority symptoms. Identification of priority symptoms can provide clinicians with a starting point to develop patient‐centered plans for symptom management interventions.

**Funding**: University of Utah; St. Baldrick\'s Foundation; Clinical & Translational Science Institute of Southeast Wisconsin

### O-110. Risk of First Prescription of Psychotropic Medication in Parents of Children Diagnosed with Cancer {#pbc27455-sec-1380}

[H. Salem]{.ul} ^1^, E. Wreford Andersen^1^, S.O. Dalton^1^, K. Schmiegelow^2^, J. Falck Winther^1^, W.G. Lichtenthal^3^, C. Johansen^1,4^, P.E. Bidstrup^1^

*^1^Unit of Survivorship, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark; ^2^University Hospital Rigshospitalet, Institute of Clinical Medicine, Medical Faculty, University of Copenhagen, Copenhagen, Denmark; ^3^Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, USA; ^4^Department of Oncology, Finsen Centre, University Hospital Rigshospitalet, Denmark*

**Background/Objectives**: To investigate the risk for first prescription of psychotropic medicine among parents of children with cancer compared with parents of cancer‐free children

**Design/Methods**: We conducted a population‐based registry study of all parents of children in whom cancer was diagnosed when they were under the age of 20 in 1998--2014 and a cohort of parents of cancer‐free children matched individually 1:10 on birth year and sex. In Cox proportional hazard models, we estimated hazard ratios (HRs) for a first prescription of psychotropic medication (antidepressants, anxiolytics, or hypnotics) according to our exposure the child cancer status, with adjustment for age and calendar period. We examined effect modification according to parent\'s sex, family type and size, and parental education and income.

**Results**: We identified 6,744 parents (3,406 fathers and 3,338 mothers) of children with cancer and 65,421 parents (33,185 fathers and 32,236 mothers) of cancer‐free children. The parents of children with cancer were at increased risk for a first prescription of psychotropic medication in the first three years after the diagnosis, the risk being highest in the first year (HR, 1.83; 95% CI, 1.66 ‐ 2.01). The increase in risk was seen particularly for anxiolytics (HR, 2.99; 95% CI, 2.54‐3.52) and hypnotics (HR, 2.64; 95% CI, 2.26‐3.09); no significant increase was seen for antidepressants (HR, 1.02; 95% CI, 0.87‐1.20).

**Conclusions**: This is the only population‐based registry study to document that parents of children with cancer are at greater risk for psychiatric morbidity so severe as to require medical treatment than parents of cancer‐free children. Pediatric oncologists and nurses should identify potentially vulnerable families and monitor early symptoms of anxiety and sleep problems.

### O-111. Positive Emotions, Hope, and Social Support Facilitate the Coping of Pediatric Cancer Patients and their Parents {#pbc27455-sec-1390}

[I. Schwartz Atias]{.ul} ^1^, T. Ronen^2^, T. Krulik^3^

*^1^Schneider Children\'s Medical Center of Israel, Hematology Oncology, Petah‐ Tikva, Israel; ^2^Tel Aviv University, The Gershon Gordon Faculty of Social Sciences, Tel Aviv, Israel; ^3^Tel Aviv University, Nursing‐ Steyer School of Health Professions, Tel Aviv, Israel*

**Background/Objectives**: The current study investigates aspects of positive psychology involved in the coping of pediatric cancer patients and their parents.

In order to explore the resources utilized for coping by this population, the concepts of illness perception, social support, hope, and subjective well‐being were chosen.

**Design/Methods**: The participants recruited for this study consisted of 216 respondents (parent and child). The pediatric patients were six months from diagnosis to one year after the completion of intensive treatment.

The research tool included two types of questionnaires -- for parents and for children. Their reliability was found to be good.

Data was analyzed using the SPSS and AMOS programs to examine the research hypotheses.

**Results**: The findings revealed that while coping with a life‐threatening illness, pediatric cancer patients, and their parents experience twice as many positive emotions than negative ones. In the parents\' group, a significant correlation (p=.005) was found between parents\' perception of their child\'s illness and their subjective well‐being -- the less parents are emotionally controlled by their children\'s illness, the more positive emotions they display. With regards to coping resources, in the children\'s group a direct correlation was found between hope and positive attitude (p=.005) and between hope and life satisfaction (p=.005). A direct correlation was found between social support and hope (p=.003) and between hope and positive attitude (p=.01). Similar findings were found in the parents\' group.

**Conclusions**: The study presents the significance of hope and social support as the variables that affect subjective well‐being. Practitioners must be familiar with the factors that contribute to well‐being and help families by constructing a treatment plan that will guide them to the factors found to have a positive influence on coping with a life threatening illness.

### O-112. Feasibility, Acceptability, and Usefulness of the Resilience Enhancement for Adolescents and Young Adults with Cancer and Healthcare Providers (REACH) Intervention {#pbc27455-sec-1400}

[C. Phillips]{.ul} ^1^, J. Haase^2^

*^1^Indiana Univesity, School of Nursing, Indianapolis, USA; ^2^Indiana University, School of Nursing, Indianapolis, USA*

**Background/Objectives**: Adolescents/young adults with cancer (AYA) experience poorer quality of life (QoL) outcomes than healthy peers or older cancer survivors. The Haase Resilience in Illness Model identifies two risk factors that negatively influence AYA QoL and five protective factors that may minimize risks factors, when used by AYA. However, there are no systematic approaches to assess and address AYA risk and protective factors. Our team developed the Resilience Enhancement for AYA with Cancer and Healthcare Providers (REACH) intervention to foster AYA use of *protective factors* and minimize *risk factors*. Our presentation will describe REACH intervention development, feasibility, acceptability and usefulness.

**Design/Methods**: We developed a web‐based site for AYA to complete the reliable and valid measures for each RIM factor. Then, factor scores were summarized into the AYA\'s RIM profile by depicting the AYA\'s avatar positioned on a soccer field in relation to other AYA of the same age and gender. An AYA/parent advisory board (N=3 dyads) provided iterative feedback on layout, wording, and interpretation of the summarized factor displays. We then evaluated the REACH\'s feasibility, acceptability, and usefulness. Using Motivational Interviewing strategies interveners foster AYA/parent (N=6) conversations regarding RIM factors. Dyads then provided feedback on the REACH profile and conversations.

**Results**: 100% of approached dyads agreed to participate and completed all measures within the timeframe and with no missing data. AYAs and parents actively engaged in the focused conversations. They were highly satisfied with REACH content, the time commitment required and helpfulness for gaining insight into their protective strengths to build on and identifying areas where they needed additional support.

**Conclusions**: With high feasibility, acceptability and usefulness, our next steps are to conduct a pilot study to estimate effect sizes of REACH on QoL outcomes and develop feasible strategies for providers use of the REACH profile for routine assessment and care planning.

### O-113. Families' and Healthcare Professionals' Hopes and Expectations Participating in a Precision Medicine Trial for Children with High‐Risk Cancer: The PRISM‐Impact Study {#pbc27455-sec-1410}

[C.E. Wakefield]{.ul} ^1,2^, J. Vetsch^1,2^, K.M. Tucker^3^, M. Warby^3^, T. O' Brien^2,4^, P. Techakesari^1,2^, M. Glenn^2,4^, T.N. Trahair^2,4^, J.M. Marron^5^, L. Lau^2,4^, V. Tyrell^6^, D. Ziegler^2,4^

*^1^Behavioural Sciences Unit‐ Kids Cancer Centre, Sydney Children\'s Hospital, Randwick‐ NSW, Australia; ^2^School of Women\'s and Children\'s Health, UNSW Sydney, Sydney, Australia; ^3^Hereditary Cancer Centre, Prince of Wales Hospital, Sydney, Australia; ^4^Kids Cancer Centre, Sydney Children\'s Hospital, Randwick‐ NSW, Australia; ^5^Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center, Department of Pediatric Oncology, Boston‐ MA 02215, USA; ^6^Children\'s Cancer Institute, UNSW Sydney, Syndey‐ NSW, Australia*

**Background/Objectives**: The PRISM precision medicine trial uses novel technologies (e.g. genomic, in‐vitro/in‐vivo drug testing) to make personalized therapeutic recommendations for children with high‐risk cancer. Despite great optimism surrounding precision medicine, it will not be possible to find cures for all children. Precision medicine trials are very complex, meaning that families', and even healthcare professionals', understanding about the trial might be limited.'PRISM‐Impact' prospectively assesses parents', patients' and healthcare professionals' hopes and expectations regarding PRISM.

**Design/Methods**: Patients aged \<21 years with a high‐risk cancer (anticipated chance of survival \<30%) are eligible for PRISM. Parents, adolescent patients (\>12years), and healthcare professionals opt‐in to PRISM‐Impact and complete surveys at enrolment, after results delivery, and then annually for five years. We interview healthcare professionals annually.

**Results**: Thirty‐four families and 39 healthcare professionals have opted into PRISM‐Impact (62% of parents, 43% of adolescent patients). Twenty‐four parents (16 mothers; child\'s mean age: 9.04years \[*SD*=4.95\]) and 6 patients (mean age: 13.67years \[*SD*=1.51\]) have returned surveys. We have interviewed 28 healthcare professionals (93% oncologists). At enrolment, most parents (96%) and all adolescents expected that the patient\'s chance of being cured would increase through participation in PRISM. While most parents recognized that this was 'somewhat/very unlikely' (82%), most adolescents believed this was 'very/extremely likely' (67%). Many parents (82%) and adolescents (50%) indicated that they understood what PRISM involved. When ranking groups of people who would benefit, 45% of healthcare professionals ranked *future* patients as benefiting most, while 27% ranked *current* patients, and 23% ranked scientists as those who would benefit most.

**Conclusions**: At enrolment, families felt they had understood PRISM, however they concurrently held hopes of a personal benefit to the patient. Through PRISM‐Impact, we will identify barriers to, and predictors of, implementing precision medicine into clinical practice. Our results are important for future trials across illnesses and age groups.

### O-114. How Can We Help You? Identifying and Addressing Parents' Concerns in Paediatric Cancer Genetic Counselling {#pbc27455-sec-1420}

[M. Warby]{.ul} ^1^

*^1^Prince of Wales Hospital POWH, Hereditary Cancer Clinic, Sydney‐ New South Wales, Australia*

**Background/Objectives**: Over the past five years, an increasing number of children have been referred to hereditary cancer centres worldwide. Prompt identification of the concerns emerging during counselling is needed to better service this growing population. Improved understanding about how clinical factors relate to parents' concerns raised during counselling will facilitate provision of tailored support to families.

**Design/Methods**: We reviewed medical records of all paediatric patients referred to a hereditary cancer clinic in Sydney Australia from 2013‐2017. A geneticist and genetic counsellor involved in each case coded records based on the reason for referral, recommendation of genetic testing, type of testing and their result, primary concerns and emerging counselling themes raised during genetic counselling.

**Results**: 155 new paediatric referrals were received and, of these, 68 underwent genetic testing (43.9%). Reasons for referral included: child affected by cancer (49.3%), predictive testing in an asymptomatic child (26.7%), predictive testing in a symptomatic child (2.7%) and referral for clinical opinion (21.2%). Eight key concerns that families raised during counselling emerged: parental distress, coping with uncertainty, planning for screening, coping with a genetic diagnosis, considering risk to other offspring, considering risk to other family members, considering risk of potential future cancer to the child and child distress. Parents of children with a cancer diagnosis were more likely to be concerned with risk to other family members (*p*=.003) and risk to other offspring (*p*=.046) than families of unaffected children. Of children who had testing, parents of children undergoing initial genetic testing were more likely to discuss risk to other family members than families undergoing predictive testing (*p*=.033).

**Conclusions**: This study identified concerns of families they wish discussed during counselling related to the clinical factors and may help staff to identify areas of psychological distress promptly.
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### O-115. Maternal Diabetes and Risk of Childhood Cancer in Offspring {#pbc27455-sec-1440}

[L. Seppälä]{.ul} ^1^, K. Vettenranta^2^, H. Ryynänen^3^, J. Pitkäniemi^3^, L.M. Madanat‐Harjuoja^4^

*^1^University of Helsinki /Helsinki Children\'s hospital, Faculty of Medicine/Doctoral Programme in Clinical Research, Helsinki, Finland; ^2^University of Helsinki/ Helsinki Children\'s Hospital, Department of Pediatrics, Helsinki, Finland; ^3^Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland; ^4^Finnish Cancer Registry/University of Helsinki/Helsinki Children\'s hospital, Department of Pediatrics, Helsinki, Finland*

**Background/Objectives**: Several studies have demonstrated an association between high birth weight of the neonate and childhood ALL. Incidence of maternal diabetes is on the rise as is the fraction of mothers requiring pharmacological intervention with metformin and insulin therapy. The association between maternal diabetes, medication and early onset cancer has not been previously explored in a registry‐based setting.

**Design/Methods**: Using a case‐control design, our aim was to explore whether maternal diabetes overall and insulin and/or metformin medication for maternal diabetes, is associated with an increased risk of early onset cancer.

Combining data from three population based registries, we identified a total of 2,037 cases, ie. persons diagnosed with early onset cancer, defined as a malignant neoplasm under the age of 40, in years 1996‐2014and a total of 10,185sex‐ and birth year‐ matched population controls. Mothers with a diagnosis of diabetes mellitus before and /or during pregnancy, and mothers who had used insulin and /or metformin during pregnancy were identified through Drugs and pregnancy‐database.

**Results**: Conditional logistic regression modelling was used to analyze the risk of early onset cancer in exposed vs. unexposed. DM prevalence in our data was 6,2%. The OR for early onset cancer in those exposed to maternal diabetes(n=756) was 1.28 (95% CI 1.06‐1.55) compared to the unexposed offspring. In the group exposed to maternal insulin/metformin(n=187) the OR was 1.07(95% CI 0.73‐1.57, not statistically significant) compared to the unexposed offspring.

**Conclusions**: Maternal diabetes appears be associated with an increased risk of early onset cancer in the offspring. Possible underlying mechanisms could involve insulin like growth factor which has been implicated as a promotor of cell growth. The possible association between in‐utero exposure to diabetes medication and risk of cancer warrants further research.

### O-116. Renal Tumours in Australian Children: Thirty Years of Incidence, Outcome, and Second Primary Malignancy Data from the Australian Childhood Cancer Registry {#pbc27455-sec-1450}

[B. Jones]{.ul} ^1,2^, D. Youlden^3,4^, T. Cundy^5,6^, M. O\'Callaghan^7^, J. Karpelowsky^8,9,10^, J. Aitken^3^, C. McBride^1,2^

*^1^Children\'s Health Queensland, Department of Paediatric Surgery, South Brisbane, Australia; ^2^University of Queensland, Department of Paediatrics and Child Health, Brisbane, Australia; ^3^Cancer Council Queensland, Australian Childhood Cancer Registry, Fortitude Valley, Australia; ^4^Griffith University, Menzies Health Institute, Gold Coast, Australia; ^5^Women\'s and Children\'s Hospital, Department of Paediatric Surgery, Adelaide, Australia; ^6^University of Adelaide, Discipline of Surgery, Adelaide, Australia; ^7^Flinders Medical Centre, Department of Urology, Adelaide, Australia; ^8^Kids Research Institute, Children\'s Cancer Research Unit, Sydney, Australia; ^9^University of Sydney, Division of Child and Adolescent Health, Sydney, Australia; ^10^Children\'s Hospital at Westmead, Department of Paediatric Surgery, Sydney, Australia*

**Background/Objectives**: To describe the incidence and outcomes of childhood renal malignancies in Australia using whole‐country population data from the Australian Childhood Cancer Registry (ACCR). To describe the occurrence of second primary malignancy (SPM) in children treated for renal cancers.

**Design/Methods**: All children (0‐14 years) diagnosed with renal malignancies from 1983‐2014 inclusive were identified in the ACCR. Demographic, tumour characteristic, incidence, mortality and treatment data were extracted from the Registry. Cause‐specific (CS) and event‐free (EFS) survival up to 20 years from diagnosis were estimated using the cohort method. Adjusted excess mortality hazard ratios (HR) were calculated using a multivariate flexible parametric survival model. Cumulative incidence, standardised incidence ratios (SIR), absolute excess risk (AER), and mortality relating to SPMs were calculated.

**Results**: There were 1,007 children diagnosed with renal malignancies between 1983‐2014 (91% nephroblastoma), generating an annual age‐standardised incidence rate of 8 per million children. This incidence did not change over the study period. Cause‐specific survival was 89% and 88% at 5 and 20 years, respectively. Five‐year EFS was 82%. Five‐year CS did not change over the study period. Five‐year CS was highest in nephroblastoma (91%) and poorest for rhabdoid renal tumours (36%, HR=8.2 in comparison to nephroblastoma, p\<0.001). All deaths from rhabdoid tumours occurred within 12 months of diagnosis. Of patients achieving remission, 15% relapsed and subsequent 5‐year CS was 49%. Ten children were diagnosed with a SPM (cumulative incidence at 20 years = 2.8%), giving a SIR of 3.05, AER 5.1/10,000 person‐years. Half of those with a SPM died within 5 years of second diagnosis.

**Conclusions**: Children treated for renal malignancies in Australia have excellent long‐term survival, unchanged since 1983. SPMs are uncommon following treatment for childhood renal cancer, but carry a poor prognosis. Relapse carries a similarly poor prognosis. These data are comparable to registry outcomes in similarly developed nations.

### O-117. Thrombo‐Embolism Incidence and Risk Factors in Children with Cancer: A Population‐Based Cohort Study {#pbc27455-sec-1460}

[M.C. Pelland‐Marcotte]{.ul} ^1^, J.D. Pole^2,3^, K. Kulkarni^4^, U.H. Athale^5^, D. Stammers^6^, C.A. Sabapathy^7^, J. Halparin^8^, L.R. Brandão^1^, L. Sung^1,3^

*^1^The Hospital for Sick Children, Department of Paediatrics‐ Division of Haematology/Oncology, Toronto, Canada; ^2^Pediatric Oncology Group of Ontario, Not applicable, Toronto, Canada; ^3^The Hospital for Sick Children, Program in Child Health Evaluative Sciences‐, Toronto, Canada; ^4^IWK, Division of Hematology‐Oncology‐ Department of Pediatrics, Halifax, Canada; ^5^McMaster Children\'s Hospital, Department of Pediatrics‐ Division of Hematology/Oncology, Hamilton, Canada; ^6^Royal University Hospital, Paediatrics, Saskatoon, Canada; ^7^Division of Pediatric Hematology/Oncology‐ Department of Pediatrics, McGill University, Montréal, Canada; ^8^BC Children\'s Hospital, Division of Hematology / Oncology / BMT, Vancouver, Canada*

**Background/Objectives**: Thrombo‐embolism (TE) is a well‐recognized complication of cancer and lead to mortality and excess morbidity. There is conflicting information about the epidemiology of TE in pediatric oncology. Objectives were to describe the incidence and risk factors of TE in children with cancer.

**Design/Methods**: We included all children with cancer less than 15 years of age diagnosed 2001‐2016, treated at one of 12 Canadian pediatric centers outside of Ontario and entered into the Cancer in Young People‐Canada (CYP‐C) database. Outcome was TE requiring medical intervention. Potential risk factors for TE were evaluated using Cox proportional hazards regression stratified by hematological malignancy vs. solid tumors. Factors associated with vascular‐access and non vascular‐access related TE were compared using Chi‐square or Fisher\'s exact tests.

**Results**: Of the 7471 children included, 283 experienced TE requiring medical intervention, of which 152 (53.7%) were vascular‐access related. The cumulative incidence of TE at 5 years was 3.8±0.2% and 0.36% ±0.07% for life‐threatening or fatal TE. For hematological malignancies, the following factors were associated with TE in multivariable regression: age \<1 year, 5‐9.99 years and 10‐14.99 years (relative to age 1‐4.99 years), hematopoietic stem cell transplant (HSCT) (HR=1.49, 95% CI 1.00‐2.32), anthracyclines (HR=2.21, 95% CI 1.12‐4.37) and asparaginase (HR=1.68, 95% CI 1.15‐2.44). For solid tumors, obesity (HR=1.92, 95% CI 1.01‐3.68), surgery (HR=2.70, 95% CI 1.44‐5.08), radiation (HR=47.51, 95% CI 24.01‐94.01), anthracyclines (HR=2.74, 95% CI 1.29‐5.82) and platinum agents (HR=2.26, 95% CI 1.19‐4.28) were associated with TE.

Life‐threatening and fatal TEs were more common among non‐vascular access TEs (14.5% vs 3.3% p=0.001). Recent surgery was also associated with non‐vascular access related TEs (20.6% vs 7.2%, p=0.001).

**Conclusions**: In a population‐based cohort, 4% of children with cancer developed a clinically significant TE. Accurate risk stratification tools are needed specific to malignancy type.

### O-118. Subspecialty Oncology Care and Association with Survival Among Adolescents and Young Adults {#pbc27455-sec-1470}

[C. Collins]{.ul} ^1^, J. Lords^1^, D. Estevez^2^, D. Freyer^3^

*^1^Loma Linda University School of Medicine, Pediatrics, Loma Linda‐ CA, USA; ^2^Loma Linda University, Research Consulting Group, Loma Linda‐ CA, USA; ^3^Children\'s Hospital Los Angeles, Pediatrics, Los Angeles‐ CA, USA*

**Background/Objectives**: The rate of improvement in survival for adolescents and young adults (AYAs) with cancer has lagged behind that of younger children and older adults. The reasons for this trend appear to be multifactorial. AYAs may have the opportunity to access either pediatric or adult subspecialty oncology care. We explored whether provider subspecialty affects survival outcomes in the AYA population.

**Design/Methods**: Using data from the California Cancer Registry, which collects data on all incident cases of cancer in the state, we performed a retrospective cohort study on patients age 15‐24 diagnosed with a malignancy over a 10‐year period, January 1999‐December 2008. Excluded were cases of Kaposi\'s sarcoma, melanoma, skin, thyroid, ovarian, endometrial and cervical carcinoma, relapses, secondary malignancies and cases diagnosed at autopsy only. Patients were assigned as receiving pediatric care if they were treated at a Children\'s Oncology Group‐affiliated center and the treating physician had pediatric training designated in the California state medical license database. Multivariate models were built for each diagnosis using Cox regression with provider subspecialty (pediatric or adult) as the primary variable of interest.

**Results**: The study included 9,749 patients (1,242 pediatric, 8,507 adult). For patients with a diagnosis of germ cell tumor, Hodgkin or non‐Hodgkin lymphoma, carcinoma, sarcoma, acute lymphoblastic or acute myeloid leukemia there was no significant difference in survival between those treated by pediatric versus adult providers. Patients with CNS malignancies had significantly better survival when treated by pediatric providers (HR, adult vs. pediatric, 1.71, p\<0.01).

**Conclusions**: For the most common cancers in the AYA population there does not appear to be a significant difference in survival between patients treated by pediatric and adult providers. However, AYA patients with CNS malignancies may benefit from targeted referral to pediatric oncology providers

### O-119. Mental Healthcare Use and Severe Psychiatric Diagnoses in Mothers of Children with Cancer: A Population‐Based Study {#pbc27455-sec-1480}

[J. Van Warmerdam]{.ul} ^1,2^, C. Lau^3^, J. Pole^4^, P. Kurdyak^5,6^, R. Sutradhar^3,7^, P. Nathan^1,7,8^, S. Gupta^1,7,8^

*^1^The Hospital for Sick Children Research Institute, Child Health and Evaluative Sciences, Toronto, Canada; ^2^University of Toronto, Institute of Medical Sciences, Toronto, Canada; ^3^Institute of Clinical and Evaluative Sciences ICES, Cancer, Toronto, Canada; ^4^Pediatric Oncology Group of Ontario POGO, Epidemiology, Toronto, Canada; ^5^Centre for Addiction and Mental Health CAMH, Mental Health Policy Research, Toronto, Canada; ^6^Institute of Clinical and Evaluative Sciences ICES, Mental Health and Addiction, Toronto, Canada; ^7^University of Toronto, Institute of Health Policy‐ Management‐ and Evaluation, Toronto, Canada; ^8^The Hospital for Sick Children, Hematology/Oncology, Toronto, Canada*

**Background/Objectives**: The impact of a child\'s cancer diagnosis on their mother\'s long‐term mental health is unclear. Health services data offers an objective measure of population‐based mental health outcomes.

**Design/Methods**: We assembled a retrospective population‐based cohort of Ontario mothers of children diagnosed with cancer between 1988‐2016 using a provincial pediatric cancer registry and birth records. Linkage to healthcare data captured all mental health‐related outpatient visits, emergency department (ED) visits, hospitalizations, and suicides. The primary outcome assessed rate of mental health outpatient visits after cancer diagnosis. Secondaryoutcomes included risk of severe mental health event (ED visit, hospitalization, suicide), and risk of specific severe psychiatric diagnoses. Recurrent event and time to event regression models compared cancer mothers to matched population controls, and assessed predictors of adverse outcomes.

**Results**: Median follow‐up was 9 years (range 1‐28). When compared to 26,950 controls, 5,418 childhood cancer mothers had higher rates of outpatient mental health visits \[rate ratio (RR) 1.4, 95% confidence intervals (CI) 1.3‐1.6; p\<0.0001\]. Higher visit rates were associated with prior mental healthcare use (RR 1.1 per additional visit/year, CI 1.1‐1.1; p\<0.0001), low income (RR 1.4 lowest versus highest income quintile, CI 1.1‐1.5; p=0.01), and large family size (RR 1.5 per additional child, CI 1.3‐1.6; p\<0.0001). No cancer, treatment, or outcome‐related factors were significant predictors of maternal outcomes. Though risk of overall severe psychiatric events did not differ between cohorts, cancer mothers had an increased risk of anxiety‐related ED visits and hospitalizations \[hazard ratio 1.3, CI 1.2‐1.5; p\<0.0001\]. Predictors for severe events were similar as those for outpatient visits.

**Conclusions**: Mothers of children with cancer experience significantly higher rates of mental health outpatient visits than controls, and are at increased risk of an anxiety‐related severe event. Maternal risk was predicted by sociodemographic factors rather than cancer‐related factors. Mothers of children with cancer require targeted psychosocial support.

### O-120. Fertility Treatment and Risk of Cancer in Children: A Nationwide Danish Cohort Study {#pbc27455-sec-1490}

[M. Hargreave]{.ul} ^1^, A. Jensen^1^, K. Schmiegelow^2^, S. Kjaer^1^

*^1^Danish Cancer Society Research Center, Virus‐ Lifestyle and genes, Copenhagen, Denmark; ^2^Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark*

**Background/Objectives**: Fertility treatment has been suspected to be linked to increased childhood cancer risk.

**Design/Methods**: We followed a nationwide cohort of 1,084,184 live born children between 1 January 1996 and 31 December 2012 with individual linkage to the Danish Infertility Cohort, in order to identify children born to women with fertility problems and/or conceived after fertility treatment. The study population was followed from date of birth until first diagnosis of cancer (\< 20 years) as registered in the Danish Cancer Registry, date of 20^th^ birthday, date of emigration, date of death or end of follow‐up (31 December 2014), whichever occurred first. We analysed data using Cox proportional‐hazards models, with hazards rates (HRs) as the measure of association and corresponding 95% confidence intervals (CIs).

**Results**: During follow‐up, 2,019 children were diagnosed with cancer. Any type of fertility treatment (HR 1.04; 95% CI 0.89‐1.23), fertility drug use (HR 1.02; 95% CI 0.87‐1.20), any assisted reproduction technology (HR 1.19; 95% CI 0.95‐1.50), in vitro fertilization (HR 0.94; 95% CI 0.67‐1.32), or intracytoplasmic sperm injection (HR 1.32; 95% CI 0.91‐1.90) did not statistically significantly affect the risk of any type of cancer in children, nor affect the risk of specific cancer types, when compared to children born to fertile women. In contrast, frozen embryo transfer markedly increased the risk of any type of cancer (HR 2.49; 95% CI 1.44‐4.30), mainly due to an increased risk of leukaemia (HR 3.08; 95% CI 1.28‐7.45), sympathetic nervous system tumours (HR 8.00; 95% CI 2.53‐25.29) and lymphomas (HR 4.18; 95% CI 1.03‐16.89). Sensitivity analyses, using children born to women with fertility problems as reference, instead of fertile women, showed similar results.

**Conclusions**: The use of frozen embryo transfer in fertility treatment may increase the risk of cancer in children, especially for leukaemia, lymphomas and sympathetic nervous system tumours.
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### O-121. Characterization of PAX5‐Driven Subtypes in B‐Progenitor Acute Lymphoblastic Leukemia {#pbc27455-sec-1510}
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**Background/Objectives**: B‐progenitor acute lymphoblastic leukemia (B‐ALL) remains a leading cause of childhood cancer death. Many chimeric genes have been identified and led to refined classification of B‐ALL and tailored therapies. Still, up to 30% of B‐ALL cannot be classified into established subtypes, and the outcome for many is poor. In this study, we aim to identify novel subtypes of B‐ALL caused by recurrent genetic alterations or commonly disturbed pathways.

**Design/Methods**: We performed transcriptome sequencing (RNA‐seq) of 1,915 cases and analyzed chromosomal rearrangements, gene expression profiles (GEP), somatic mutations and chromosome‐level copy‐number alterations. Cases lacking known or putative subtype‐defining alterations are subjected to whole genome sequencing to screen driver lesions. Effects on proliferation and transformation of novel lesions were assessed by retroviral expression in cell lines and point‐mutation knockin mice using CRISPR/Cas9 genome editing.

**Results**: Using integrated genetic alterations and gene expression profiling, we observed 15 B‐ALL subgroups. Four canonical subgroups included cases with similar GEP but alternative or unknown drivers (e.g., *ETV6‐RUNX1‐*like, n=45). Notably, we identified two groups characterized by *PAX5* alterations. One comprised 2.9% (n=55) of cases with *PAX5* rearranged to diverse partners. A second group of 43 (2.2%) cases, 42 of which had *PAX5* P80R missense mutations. The mutations were either hemizygous due to the deletion of second PAX5 allele (n=28), or compound heterozygous with frameshift/nonsense *PAX5* mutations (n=13), indicating homozygous P80R is the driver lesion of this new subtype. Consistent with this, mice heterozygous or homozygous for P80R developed pre‐B‐ALL with a median latency of 166 and 92 days, respectively, with heterozygous mice acquiring alterations on the second allele. In contrast, *Pax5*+/‐ mice, and those harboring G183S mutation observed in familial leukemia, do not spontaneously develop B‐ALL.

**Conclusions**: This study demonstrates the power of RNA‐seq in refining B‐ALL classification, and reinforces the central role of *PAX5* as a checkpoint in leukemogenesis.

### O-122. Integrated Genetic Analysis Elucidated Expression and Methylation Profiles of Acute Lymphoblastic Leukemia in Down Syndrome {#pbc27455-sec-1520}

[Y. Kubota]{.ul} ^1^, K. Uryu^1^, T. Ito^2^, T. Kawai^3^, M. Seki^1^, T. Isobe^1^, T. Toki^2^, K. Yoshida^4^, K. Kataoka^4^, K. Oki^5^, N. Kiyokawa^5^, S. Miyano^6^, A. Oka^1^, Y. Hayashi^7^, S. Ogawa^4^, K. Terui^2^, A. Sato^8^, K. Hata^3^, E. Ito^2^, J. Takita^1^

*^1^The University of Tokyo, Department of Pediatrics, Tokyo, Japan; ^2^Hirosaki University, Department of Pediatrics, Hirosaki, Japan; ^3^National Research Institute for Child Health and Development, Department of Maternal‐Fetal Biology, Tokyo, Japan; ^4^Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan; ^5^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^6^The University of Tokyo, Laboratory of DNA Information Analysis‐ Human Genome Center‐ Institute of Medical Science, Tokyo, Japan; ^7^Gunma Children\'s Medical Center, Department of Hematology and Oncology, Takasaki, Japan; ^8^Miyagi Children\'s Hospital, Department of Hematology and Oncology, Sendai, Japan*

**Background/Objectives**: Children with Down syndrome (DS) are predisposed to develop acute lymphoblastic leukemia (ALL). DS‐ALL displays unique genetic alterations; however, molecular basis of DS‐ALL is still incomplete.

**Design/Methods**: Our cohort included 179 pediatric B‐cell precursor ALL samples (61 DS‐ALL and 118 non‐DS‐ALL). We performed whole transcriptome sequencing, DNA methylation array analysis, mutation analysis, and copy number analysis.

**Results**: Expression profiling stratified 143 samples into 6 clusters (E1‐E6 clusters), which were well correlated with biological subtypes of ALL. Intriguingly, DS‐ALL cases were clustered into 4 clusters, suggesting the heterogeneity of DS‐ALL. One DS‐ALL was classified into cluster E3, which was characterized by *PAX5*‐abnormalities. Indeed, SNP array analysis revealed that this case had focal amplification of *PAX5*. All DS‐ALL cases with ETV6‐RUNX1 fusion were classified into cluster E4, which also included all *ETV6‐RUNX1* fusion cases of non‐DS‐ALL. This cluster also included one DS‐ALL case with *ETV6‐RUNX1*‐like signature. DS‐ALL with high hyperdiploidy (HeH) were classified into cluster E5, which also included most of HeH samples of non‐DS‐ALL. Cluster E6 was characterized by *BCR‐ABL1* fusion and Ph‐like expression profiles. In our cohort, 9 DS‐ALL cases with Ph‐like signature showing *JAK2* mutation were identified. Similar to the expression analysis, DNA methylation analysis revealed DS‐ALL samples were clustered corresponding to each subtype same as non‐DS‐ALL. In addition, DNA methylation array analysis revealed unique hypermethylation of promoter regions of *RUNX1* in DS‐ALL. Hypermethylation of this region was confirmed in normal B‐cell of DS without ALL, but not in non‐DS‐ALL.

**Conclusions**: We confirmed DS‐ALL was highly heterogeneous due to inclusion of many subtypes, and each subtype had similar expression and methylation profiles as non‐DS‐ALL. Hypermethylation of *RUNX1* located on chromosome 21 was a unique characteristic in DS patients and may be associated with an increasing incidence of ALL in DS patients.

### O-123. Metabolomic Profiling Improves Prediction of Minimal Residual Disease and Reveals Potential Metabolic Vulnerabilities in Pediatric Acute Lymphoblastic Leukemia {#pbc27455-sec-1530}

[J. Schraw]{.ul} ^1^, J. Junco^2^, M. Scheurer^2^, K. Rabin^2^, P. Lupo^2^

*^1^Baylor College of Medicine, Department of Medicine‐ Section of Epidemiology and Population Sciences, Houston, USA; ^2^Baylor College of Medicine, Department of Pediatrics‐ Section of Hematology‐Oncology, Houston, USA*

**Background/Objectives**: End‐induction minimal residual disease (MRD) is the most important predictor of relapse in pediatric acute lymphoblastic leukemia (ALL). However, many relapses occur in MRD‐negative patients. We hypothesized that global metabolomic profiling of diagnostic bone marrow plasma could improve prediction of MRD and provide insights into the biology of relapse.

**Design/Methods**: We retrospectively identified 99 patients diagnosed and treated at Texas Children\'s Hospital from 2007‐2015, of whom 39 were MRD positive and 60 were MRD‐negative at end induction, using a cut‐off of 0.01%. Diagnostic bone marrow plasma was subjected to metabolomic profiling via UPLC‐MS/MS. We used the nonparametric Kruskal‐Wallis test to compute univariate p‐values comparing MRD‐positive vs. negative plasma, and metabolite set enrichment analysis (MSEA) to identify pathways enriched for differentially abundant metabolites with KEGG as the reference. Metabolites with univariate p‐values ≤0.001 were evaluated in logistic regression models for MRD, and the best predictors were obtained by backward elimination. We assessed the performance of models for MRD using clinical features alone and clinical features + metabolites via DeLong\'s test for correlated receiver operating characteristics curves. We measured the *in vitro* cytotoxicity of drugs targeting top‐scoring pathways in ALL cell lines using flow cytometric staining for Annexin‐V/propidium iodide.

**Results**: MSEA revealed central carbon metabolism to be the pathway most enriched for differentially abundant metabolites (p=4.00E‐06). The constituent metabolites pyruvate, succinate, fumarate, and malate were each significantly increased in MRD positive patients (p≤0.001). A predictive model for MRD incorporating these metabolites outperformed clinical features alone (AUC of 0.86 vs 0.73, p=0.001). FK866, an NAMPT inhibitor which depletes these metabolites, demonstrated significant cytotoxicity in 5 of 6 ALL cell lines (IC50s 1‐10 nM).

**Conclusions**: Metabolomic profiling improved prediction of subsequent MRD and identified potentially druggable metabolic alterations. If validated, these biomarkers may improve risk prediction and our understanding of disease biology.

### O-124. Single‐Cell Developmental Classification of B‐Cell Precursor Acute Lymphoblastic Leukemia at Diagnosis Reveals Predictors of Relapse {#pbc27455-sec-1540}

J. Sarno^1^, Z. Good^2^, A. Jager^1^, N. Samusik^3^, N. Aghaeepour^3^, E. Simonds^4^, L. White^5^, N. Lacayo^5^, W. Fantl^6^, G. Fazio^7^, G. Gaipa^7^, A. Biondi^7^, R. Tibshirani^8^, S. Bendall^9^, G. Nolan^3^, [K. Davis]{.ul} ^1^

*^1^Bass Center for Childhood Cancer ‐ Stanford University, Pediatrics, Stanford, USA; ^2^Baxter Laboratory in Stem Cell Biology‐ Stanford University, Department of Microbiology and Immunology, Stanford, USA; ^3^Baxter Laboratory in Stem Cell Biology ‐ Stanford University, Department of Microbiology and Immunology, Stanford, USA; ^4^Helen Diller Family Comprehensive Cancer Center‐ University of California San Francisco, Department of Neurology, San Francisco, USA; ^5^Division of Hematology/Oncology‐ Stanford University, Department of Pediatrics, Stanford, USA; ^6^Stanford University, Departments of Obstetrics and Gynecology, Stanford, USA; ^7^M. Tettamanti Research Center‐ University of Milano Bicocca, Department of Pediatrics, Monza, Italy; ^8^Stanford University, Department of Statistics, Stanford, USA; ^9^Stanford Blood Center‐ Stanford University, Department of Pathology, Stanford, USA*

**Background/Objectives**: Despite high rates of initial response to frontline treatment, cancer mortality largely results from relapse or metastasis. Improved insight into cancer cell populations responsible for relapsed disease will lead to better outcomes for patients. Such resistant cells can be rare and not accurately represented in animal models. Hence, their study will require high‐throughput single‐cell analyses of primary human tissues and new analytical tools to align these rare populations with clinical outcomes. Here, we report a single‐cell study of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) at diagnosisthat revealed hidden developmentally dependent cell signaling states uniquely associated with relapse.

**Design/Methods**: With mass cytometry, we simultaneously quantified 35 B‐cell developmental proteins in 60 primary diagnostic BCP‐ALL samples with known outcome and 5 healthy donor samples. Each leukemia cell was then matched to its nearest healthy B‐cell population by a developmental classifier that operated at the single‐cell level. A machine learning approach was then used to identify features portending relapse at the time of diagnosis.

**Results**: We identified six features of expanded leukemic populations sufficient to predict patient relapse at diagnosis. These features implicated pro‐BII cells with activated mTOR signaling, and pre‐BI cells with activated and unresponsive pre‐B‐cell receptor signaling, to be associated with relapse. This model, termed Developmentally Dependent Predictor of Relapse (DDPR), significantly improves currently established risk stratification methods. Furthermore, analysis of matched diagnosis‐relapse samples from seven BCP‐ALL patients confirmed the persistence and enrichment of DDPR features at the time of relapse.

**Conclusions**: Leveraging a data‐driven approach, we demonstrated the predictive value of single‐cell 'omics' for patient stratification. More broadly, this study highlights the translational value of understanding cancer at the single‐cell level and applying machine learning to guide treatment paradigms for patients with cancer.
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### O-125. Development of an In Vitro Drug Profiling Platform with Primary Rhabdomyosarcoma Cells for Tailoring Patient‐Specific Treatments {#pbc27455-sec-1560}

[B. Schaefer]{.ul} ^1^, M. Wachtel^1^, G. Manzella^1^, M. Roemmele^1^, L. Schreck^1^, L. Zhang^1^, J. Tchinda^1^, F. Niggli^1^
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**Background/Objectives**: The paradigm of cancer therapy currently shifts from broadly used cytotoxic drug cocktails to patient specific precision therapies. These are directed towards tumor specific driver oncogenes, identified mostly by genomic mutational analysis in individual tumors. In case of tumors with a very low mutational burden or undruggable targets however, this approach is less suitable. There, direct drug profiling of *in vitro* cultured tumor cells represents a promising alternative. Conditions maintaining tumor heterogeneity in culture however are, for most tumor entities, ill defined.

**Design/Methods**: Here, we established an *in vitro* drug profiling platform for Rhabdomyosarcoma (RMS). We isolated cells from seven alveolar and eight embryonal RMS patient derived xenografts (PDX) and systematically tested 18 different culture conditions to find suitable conditions for efficient *in vitro* propagation of primary RMS cells without overgrowth of normal fibroblasts.

**Results**: Our approach revealed that cells from most tumors survive and proliferate only in serum‐free medium, whereas tumor cells in serum containing medium are progressively lost over time. Importantly, cells preserve the clonal composition and phenotypic characteristics of the primary PDX, as assessed by genomic and copy number analysis. Moreover, these conditions also allow growth as 3D organoids. Drug profiles established with a library of 204 drugs revealed subgroup and patient‐specific individual vulnerabilities, as well as an unrecognized sensitivity towards AKT inhibitors in a subgroup of patients. Furthermore, screening for resensitization of resistant fusion‐negative relapse samples identified the BCL‐2 family inhibitor ABT‐263 as most potent resensitizer towards standard‐of‐care chemotherapy. Detailed molecular analysis revealed that this effect is based on blockade of the BCL‐XL‐MCL‐1 axis.

**Conclusions**: Our proof of concept study highlights the feasibility of *in vitro* drug profiling of primary RMS cells for patient‐specific treatment selection as an alternative or addition to molecular profiling in a co‐clinical setting.

### O-126. Hypermutant Pediatric High Grade Gliomas are Driven by RAS/MAPK Mutations and Respond to MEK Inhibition {#pbc27455-sec-1570}

[B. Campbell]{.ul} ^1^, D. Morgenstern^2^, T. Lipman^3^, D. Fabrizio^4^, E. Bouffet^2^, C. Hawkins^5^, U. Tabori^2^

*^1^The Arthur and Sonia Labatt Brain Tumour Research Centre‐ The Hospital for Sick Children‐ Toronto‐ Ontario‐ Canada., Department of Haematology/Oncology, Toronto, Canada; ^2^The Hospital for Sick Children, Department of Hematology/Oncology, Toronto, Canada; ^3^The Hospital for Sick Children, Genetics and Genome Biology, Toronto, Canada; ^4^Foundation Medicine Inc., Department of cancer immunotherapy, Boston, USA; ^5^The Hospital for Sick Children, Department of Pathology, Toronto, Canada*

**Background/Objectives**: Hypermutant pediatric high grade gliomas (pHGG) constitute 5‐10% of total PHGG and are almost invariantly caused by replication repair deficiency (RRD). Constitutive activation of the RAS/MAPK pathway via oncogenic mutations can be targeted with MEK inhibitors (MEKi). We hypothesized that hypermutant RRD PHGG would harbor mutations in NF1 and other MAPK pathway regulators, making their tumors susceptible to targeted MEKi.

**Design/Methods**: Tumor sequencing data from \>1200 pediatric tumors was extracted from our foundation‐medicine cohort. Exome sequencing and RNA‐seq was performed on tumors from our international RRD consortium. Xenografts from patient derived brain and GI tumors were established in NOD‐SCID mice and treated with MEK inhibitors Trametinib and Selumetinib. Functional experiments were performed to demonstrate deregulation of the MAPK pathway in the tumors.

**Results**: Screening of 1215 childhood cancers revealed that mutations in RAS/MAPK are the second most common mutation in pediatric tumors. Exome data from patients revealed 95% of PHGG and 60% CRC of GI tumors were found to harbor mutations in key RAS/MAPK pathway regulators. Subclonal analysis reveals mutations in the pathway in each subclone and enrichment of these mutations over time. In‐vitro and in‐vivo treatment of patient derived RRD hypermutant PHGG and colon cancers with MEKi revealed significant tumor suppression with 50% decrease in tumor volume and improved survival (p \<0.001). Finally, two CMMRD patients with progressive/recurrent PHGG treated with Selumetinib and trametinib exhibited \>90% objective tumor response and prolonged survival.

**Conclusions**: These preclinical and clinical observations suggest a novel therapeutic option for children with hypermutant RRD PHGG based on possible oncogenic addiction to RAS/MAPK alterations. These observations are the basis of the upcoming SU2C international clinical trial.

### O-127. Societal Values and Child Health Priorities: Empirical Evidence for Paediatric Cancer Drug Policy {#pbc27455-sec-1580}

[A. Denburg]{.ul} ^1^, S. Chen^2^, J. Abelson^3^, J. Hurley^3^, W. Ungar^4^

*^1^The Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^2^The Hospital for Sick Children, Paediatrics, Toronto, Canada; ^3^McMaster University, Health Research Methods‐ Evidence and Impact, Hamilton, Canada; ^4^The Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Canada*

**Background/Objectives**: As cancer drugs consume increasing proportions of health system budgets, the need to prioritize scarce health system resources has come into acute focus in many countries. The importance of societal values in setting health system priorities is well‐established, but little knowledge exists of public preferences regarding health care funding for children. We assessed societal preferences for health resource allocation to children, to generate evidence to inform priority setting on cancer drugs within publicly funded health systems.

**Design/Methods**: We conducted a population‐based, randomized experimental stated preference survey of societal views on the prioritization of health resources among children and adults. Participants in the intervention group were subjected to a moral reasoning exercise prior to each choice task. We constructed a multiple regression mixed model to evaluate the direction and strength of societal preferences for health resource allocation between children and adults, and identify sociodemographic factors that significantly impacted the expression of societal preferences.

**Results**: Our final study sample was comprised of 1556 participants (n=773 intervention, n=783 control) and was representative of the Canadian population. Multiple regression analyses demonstrated a consistent aggregate preference for allocation to children across most scenarios in both experimental groups. Exposure to the moral reasoning exercise weakened allocative preference for children. Younger respondent age and parenthood were associated with greater preference for children. The three moral principles that most influenced participant preferences were equal treatment, relief of suffering, and rule of rescue.

**Conclusions**: Our study affirms the relevance of age in public preferences for the allocation of scarce health care resources in trade‐offs involving children. Despite fairly consistent priority attached to children, our results suggest the expression of societal values attached to children differ by circumstance and social context. These findings have direct relevance to public policy decisions about cancer drug funding for children in Canada and internationally.
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### O-128. The (mis)Measure of Posttraumatic Stress Disorder in Pediatric Medical Settings {#pbc27455-sec-1600}

[S. Phipps]{.ul} ^1^, S. Schepers^1^, K. Russell^1^, A. Long^1^

*^1^St. Jude Children\'s Research Hospital, Psychology, Memphis, USA*

**Background/Objectives**: Although the diagnostic interview is considered the gold standard for diagnosis of PTSD, most researchers in medical settings rely on survey measures, using established cutoffs. The relationship of prevalence estimates of PTSD based on surveys to those from diagnostic interviews has not been examined in pediatric settings, and reliance on surveys in the absence of appropriate comparison groups may lead to inflated estimates of PTSD.

**Design/Methods**: Children and adolescents with cancer (N = 304), and demographically similar children without history of serious illness (N = 260), along with one parent per child were assessed for PTSD. Youth completed the UCLA PTSD Inventory for DSM‐IV (UCLA) and the Clinician Administered PTSD Scale for Children and Adolescents (CAPS‐CA). Parents completed the Impact of Events Scale (IES‐R) and the CAPS. Established approaches to identify cases were applied to the questionnaires, and these were compared to the diagnostic interviews (CAPS/CAPS‐CA).

**Results**: On the UCLA, 11.6% of youth with cancer exceeded the established cutoffs compared to 11.7% of healthy comparisons (*ns*). A more stringent, specific symptom approach reduced rates to 6.3% in the cancer group and 5.4% in comparisons (*ns*). In contrast, by diagnostic interview with the CAPS‐CA, rates of those meeting full criteria for current PTSD were less than 1% in both groups. Rates of PTSD with survey measures were significantly higher than those from diagnostic interviews in both groups (all p\'s \<.001). Similar findings were obtained for parents, with an absence of any cancer‐control differences, but with rates from questionnaires significantly higher than those from diagnostic interviews (all p\'s \<.001).

**Conclusions**: Survey measures overestimate the rates of PTSD in both youth and their parents. This phenomenon has been demonstrated in military contexts, and appears the same in medical settings. This highlights important methodological considerations for study of medical traumatic stress.

### O-129. Profiles of Mother and Father General and Cancer‐Specific Family Communication following Diagnosis of Pediatric Cancer {#pbc27455-sec-1610}
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**Background/Objectives**: Objective: Parent‐child communication has been linked with children\'s adjustment to pediatric cancer. Parent stress is one family factor found to influence such communication; however, research has generally examined parent‐child interactions independently with mothers without examining overall patterns of communication across mothers and fathers. Moreover, little research has examined general and cancer‐related communication concurrently. The present study identified patterns of mothers' and fathers' general and cancer‐specific parent‐child communication at diagnosis and examined how stress and cancer perceptions predicted families' membership in these profiles.

**Design/Methods**: Method: Participants were 182 families recruited from 2 pediatric hospitals in the United States after children\'s (ages 10‐17) initial diagnosis/relapse. Mothers and fathers each reported their general stress, cancer‐specific stress, children\'s cancer‐specific stress, and frequency of cancer‐related communication with children (illness‐related, emotion‐related, future‐related). Children reported regarding openness and problematic communication with each parent. Profiles of general and cancer‐related communication were derived using Latent Profile Analysis in MPlus, and logistic regression (r3step) examined whether parent stress, child stress, and prediction of treatment success predicted families' profile membership.

**Results**: Three profiles emerged (entropy=.71; BLRT p\<.0001): Open Communication (25%); Limited/Problematic Communication (30%); and Mother Dominant Communication (45%). Parent stress did not differentiate profile membership; however, mothers' perception of children\'s stress (OR=1.11, *p*=.005) and chance of treatment success (OR=1.06, *p*=.05) predicted that families were more likely to belong in the Mother Dominant profile compared to the Limited/Problematic profile.

**Conclusions**: Discussion: Families were generally characterized by open parent‐child communication, particularly with mothers. Mothers' perception that their child experiences more cancer‐related stress may prompt mothers to initiate more cancer‐related communication, with confidence in treatment success perhaps yielding more comfort in communicating regarding cancer topics. Parent stress did not differentiate patterns of communication. Instead, perhaps one parent may compensate for the other. Findings suggest screening for parental perception of children\'s cancer stressors and treatment experience.

### O-130. Social Adjustment in Adolescent Survivors of Pediatric CNS Tumors: A Report from the Childhood Cancer Survivor Study {#pbc27455-sec-1620}
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**Background/Objectives**: Pediatric CNS tumor survivors experience problems with social adjustment. We examined tumor, treatment and demographic factors associated with social adjustment deficits in adolescent long‐term survivors of pediatric CNS tumors.

**Design/Methods**: Survivors of CNS tumors (n=665; 53.8% male; median \[range\] 15.0 \[12.0‐17.0\] years old; 12.1 \[8.0‐17.7\] years from diagnosis; 51.7% treated with cranial radiation) were compared to solid tumor survivors (neuroblastoma, Wilms tumor; n=1377; 50.4% male; 15.0 \[12.0‐17.0\] years old; 13.2 \[8.3‐17.9\] years from diagnosis) and sibling controls (n=726; 52.2% male; 15.0 \[12.0‐17.0\] years old). Social adjustment was measured with items examining the quality and quantity of peer interactions from the Behavior Problems Inventory. Latent profile analysis identified social adjustment classes. Multinomial logistic regression determined predictors of class membership. Path analysis was used to determine whether social problems were mediated by sensory, physical and/or cognitive limitations.

**Results**: A well‐adjusted class was identified in 53.4% of CNS tumor survivors, 86.2% of solid tumor survivors and 91.1% of siblings. Nearly seven times as many CNS tumor survivors (15.3%) reported zero friends compared to solid tumor survivors (2.9%) and siblings (2.3%). More CNS tumor survivors reported interacting with friends less than once per week (41.0%) compared to solid tumor survivors (13.6%) and siblings (8.7%) Among CNS survivors, cranial radiation dose was associated with poor quality (OR=1.16 per 10Gy; 95%CI 1.08‐1.25) and limited interactions (OR=1.14; 95%CI 1.04‐1.25), adjusting for age, sex and age at diagnosis. Limitation in cognitive function was a stronger mediator of number of friends (β=0.380, p\<0.001) and time with friends (β=0.266, p\<0.001) compared to sensory (β=0.110, p\<0.047; β=0.136, p\<0.026) or physical (β=0.096, p\<0.007; β=0.123, p\<0.002) limitations.

**Conclusions**: Cranial radiation therapy and cognitive impairment are associated with increased risk of social adjustment problems among CNS tumor survivors. Interventions to facilitate development of cognitive and social skills in this high‐risk population are needed.

### O-131. Children Treated for Posterior Fossa Brain Tumours have Difficultly Recognizing Facial Emotions: Insights from Viewing Patterns and White Matter Structure {#pbc27455-sec-1630}

[I. Moxon‐Emre]{.ul} ^1,2,3^, E. Bouffet^4^, S. Laughlin^5^, J. Skocic^1^, C. de Medeiros^1^, D.J. Mabbott^1,3^
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**Background/Objectives**: Paediatric patients treated for brain tumours have previously been shown to display deficits in facial emotion recognition, and eye‐movement monitoring might help explain why. Identifying facial emotions is thought to rely on white matter (WM) that connects posterior, limbic and frontal brain regions (e.g., the inferior fronto‐occipital fasciculus (IFOF)). Thus, we examined if WM in the IFOF is related to emotion recognition and social functioning.

**Design/Methods**: Children treated for posterior fossa (PF) brain tumours and healthy controls (N=54) participated at The Hospital for Sick Children (Toronto, Canada). Participants completed the Diagnostic Analysis of Nonverbal Accuracy (DANVA‐2), a computerized task that measures facial emotion recognition using photographs, while their eye‐movements were recorded. Diffusion tensor imaging (DTI) was used to assess fractional anisotropy (FA) and radial diffusivity (RD) of the IFOF. Social functioning was assessed with the Child Behavior Checklist (CBCL). The relations between WM microstructure of the IFOF, emotion recognition, and social functioning were evaluated with partial least squares (PLS) path modeling.

**Results**: Patients made more emotion recognition errors than controls (P=0.01). However, patients and controls did not differ in the number of fixations made (P=0.21), or in the time spent looking at the photographs (P=0.10). Patients had lower social functioning than controls (P=0.04). Treatment for PF brain tumours did not predict WM microstructure in the IFOF (P=0.43); however, WM in the IFOF predicted emotion recognition (P=0.04) across all participants. Social functioning was not predicted by WM in the IFOF or emotion recognition (all P\>0.05).

**Conclusions**: The emotion recognition deficits experienced by children treated for PF brain tumours do not appear to result from inattention to the photographs, or to differences in visual processing of the photographs. The IFOF appears to be related to emotion recognition abilities across all participants, and not in a manner that is unique to treatment for PF brain tumours.
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### O-132. Does Quality of Radiation Therapy Affect Clinical Outcomes in Pediatric Multicenter Cooperative Group Trials? A Systemic Review {#pbc27455-sec-1660}

A. Lim^1^, A. Fairchild^1^, [S. Patel]{.ul} ^2^

*^1^University of Alberta/Cross Cancer Institute, Department of Oncology, Edmonton, Canada; ^2^University of Alberta/Stollery Children\'s Hospital, Department of Oncology, Edmonton, Canada*

**Background/Objectives**: Radiotherapy (RT) quality assurance (QA) programs aim to standardize RT delivered on multicenter clinical trials to minimize variables that may confound the validity of results. Our objective was to review available evidence for reported correlation of RT quality with clinical outcomes within pediatric multicenter clinical trials.

**Design/Methods**: Literature search encompassing Medline, Embase, Cochrane Central Register of Controlled Trials, and Quality Assurance Review Center bibliography was performed restricted to English but with no date limits. Candidate studies accrued children age ≤21 years or median age ≤15, were led by any cooperative group, published in full, and described central subjective and/or objective assessment of RT protocol compliance (quality). Data abstracted included assignment of violations in relation to clinical outcomes (loco‐regional and/or distant failure, progression‐free survival \[PFS\], overall survival \[OS\], and adverse events).

**Results**: Thirty‐three multicenter clinical trials reported on rhabdomyosarcoma (RMS; 10 trials), medulloblastoma (MBL; 9), Ewing\'s sarcoma (EWS; 6), classical Hodgkin\'s lymphoma (cHL; 4), supratentorial primitive neuroectodermal tumors (sPNET; 3), and acute lymphocytic leukemia (ALL; 1). Deviations were found in up to 83% of RT plans reviewed. 12/33 from various primary sites reported that RT protocol deviations (eg dose, field placement) significantly affected clinical outcomes in the form of inferior OS (N=1 trial), PFS (N=5), local control (N=3), or any recurrence (N=2). One study suggested improved PFS with local field RT deviations versus without.

**Conclusions**: Suboptimal RT negatively impacts clinical outcomes in pediatric multicenter cooperative group trials.

### O-133. Radiotherapy in Choroid Plexus Carcinoma: An Analysis of the SIOP‐CPT‐2000/2009‐Study and the CPT‐Register {#pbc27455-sec-1670}

C. Ricken^1^, S. Frisch^1^, S. Hartung^2^, R.D. Kortmann^3^, J. Wolff^4^, [B. Timmermann]{.ul} ^1^
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**Background/Objectives**: Choroid plexus tumors are rare pediatric brain tumors diagnosed mainly in infants. Little is known about the role of radiotherapy (RT). The aim of this retrospective study was to evaluate the impact of RT in patients with choroid plexus carcinoma (CPC).

**Design/Methods**: We analyzed the data from the SIOP‐CPT‐2000/2009‐Study and CPT‐registry study on 103 patients with CPC. 99 patients (55 m/44 f; median age 2.21 years (y) (range, 0‐48.87 y)) were evaluable. Complete resection was achieved in 44 cases (44.4%), subtotal in 40 (40.4%). Extent of resection was not further specified in 15 patients (15.2%). In 86 patients (86.9%) chemotherapy was applied before RT.

55 patients (55.6%) received RT (RT group), from whom 33 received local (median dose 54Gy, range 25.2‐61.4Gy) and 20 craniospinal irradiation with local boost (median dose 55Gy, range 36‐60Gy) (in 2 cases, details on RT were missing). In 44 patients (44.4%), no RT was applied (non‐RT group). The median age at diagnosis in the RT‐group was 5.31 y (range, 0.4‐48.9 y) and in the non‐RT‐group 1.1 y (range, 0‐12.7 y). Survival data was estimated using the Kaplan Meier method and the Cox\'s Model.

**Results**: The median follow‐up was 3.67 y (range 0.09‐13.12 y). 5y‐overall survival (OS) was 74.0% vs. 51.4% in the RT vs. non‐RT group (p=0.004). 5y‐progression‐free survival (PFS) was 63.6% vs. 44.8% in the RT vs. non‐RT group (p=0.049). When RT was not applied, the relative risk for failure and death was 1.8 and 2.6 times higher, respectively (p=0.052; p=0.005).

**Conclusions**: Our analysis indicates that RT plays an important role in the cure of CPC. OS und PFS rates were significantly higher in patients receiving RT. The Role of RT in CPC needs to be considered in future concepts. More knowledge is still needed on optimal dose‐volume concepts and timing of RT.

### O-134. Comparison of Height and Weight After Chemotherapy with and Without 12 Gy Cranial Radiation Therapy in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-1680}

[N. Waheed]{.ul} ^1^, Q. Buck^1^, M.F. Okcu^2^, E. Jo^3^, Z. Dreyer^2^, K. Kamdar^2^, R. Sonabend^4^, A. Yoder^1^, A. Paulino^5^

*^1^Baylor College of Medicine, Radiation Oncology, Houston, USA; ^2^Baylor College of Medicine, Pediatrics‐ Hematology/Oncology, Houston, USA; ^3^Baylor College of Medicine, Biostatistics, Houston, USA; ^4^Baylor College of Medicine, Pediatrics‐ Endocrinology, Houston, USA; ^5^MD Anderson Cancer Center, Radiation Oncology, Houston, USA*

**Background/Objectives**: To compare height and weight indices among patients with acute lymphoblastic leukemia (ALL) receiving chemotherapy with and without 12 Gy cranial radiotherapy (RT)

**Design/Methods**: Records of children with ALL who were treated at a single institution between 2000 and 2011 were reviewed. Patients\' height, weight, and body mass index (BMI) were converted into z‐scores using the Centers for Disease Control growth charts to normalize the values to number of standard deviations from the mean. These values were measured at time of diagnosis (pretreatment) and at the follow up clinic. The z‐scores of the growth indices were fitted into a generalizing estimating equations model and analyzed by various clinical factors.

**Results**: 65 patients (32 boys) with a median age of 7 years (range, 2‐14 years) at initial diagnosis were the subject of the study. Patients were categorized according to 12 Gy cranial RT (Group A, n=30) or no RT (Group B, n = 35). Median follow‐up was 4.9 years and 5.0 years for Groups A and B respectively. There was no statistically significant difference in height, weight and BMI z‐scores at initial diagnosis and last follow‐up among the patients in Groups A and B. On multivariate analysis, females had 0.4 more in weight z‐score (p = 0.048) and 0.62 more in BMI z‐score (p = 0.02) difference than male patients. Similarly, patients ages 3‐5 years had 0.82 less in weight z‐score (p = 0.006) and 1.0 less in BMI z‐score (p = 0.01) difference compared to age \< 3 years.

**Conclusions**: There was no difference in height, weight and BMI z‐scores at initial diagnosis and last follow‐up among patients who received 12 Gy RT or chemotherapy alone, suggesting no impact on growth hormone with 12 Gy. Female patients and children ages 3 to 5 years were more susceptible to changes in weight and BMI.

### O-135. Outcomes Following Proton Therapy for Pediatric Nasopharyngeal Carcinoma {#pbc27455-sec-1690}

[H. Uezono]{.ul} ^1^, D. Indelicato^1^, J. Bradley^1^, R. Rotondo^1^, E. Sandler^2^, S. Andreoli^3^, R. Dagan^1^, W. Mendenhall^1^

*^1^University of Florida, Department of Radiation Oncology, Jacksonville, USA; ^2^Nemours Children\'s Specialty Clinic, Division of Pediatric Oncology, Jacksonville, USA; ^3^Nemours Children\'s Specialty Clinic, Department of Pediatric Otolaryngology, Jacksonville, USA*

**Background/Objectives**: Proton therapy can be used to reduce the dose of radiation to developing tissue in the brain and skull base region of children treated for nasopharyngeal carcinoma. The purpose of this study is to report the outcomes of children treated using a pediatric regimen of induction chemotherapy followed by moderate‐dose proton therapy.

**Design/Methods**: Seventeen patients with non‐metastatic non‐keratinizing undifferentiated/poorly differentiated nasopharyngeal carcinoma were treated with double‐scattered proton therapy at a single institution between February 2011 and July 2017. Median age was 15.3 years (range, 7 to 21). Sixty‐five percent of the patients were male. Eleven and 11 patients had AJCC (7^th^ edition) T3/T4 and N2/3 tumors, respectively. Median radiation dose to the primary target volume and positive lymph nodes was 61.2 Gy(RBE) (range, 59.4 to 61.2). Elective neck radiation was delivered to uninvolved cervical nodes to 45 Gy(RBE) (range, 45 to 46.8). All radiation was delivered at 1.8 Gy(RBE)/fx daily using sequential plans. Photon‐based IMRT was used for the elective neck irradiation phase in 11 patients to optimize dose homogeneity and improve target conformity. All patients received induction chemotherapy and all but one received concurrent chemotherapy. Three patients received adjuvant beta‐interferon therapy.

**Results**: Median follow‐up was 2 years (range, 0.8 to 7). No patients were lost to follow‐up. Overall survival, progression‐free survival, and local control rates were 100%. Fifteen patients developed mucositis requiring enteral feeding (n= 14) or total parenteral nutrition (n= 1) during radiation therapy. Serious late toxicity includes cataract (n=1), esophageal stenosis requiring dilation (n=1), sensorineural hearing loss requiring aids (n= 1), and hormone deficiency (n= 5, including 3 with isolated hypothyroidism).

**Conclusions**: Following induction chemotherapy, moderate‐dose proton therapy can reduce the low/intermediate radiation exposure to developing tissue in the brain and skull base region without compromising disease control or producing unexpected major toxicity.

### O-136. Particle Versus Photon Radiotherapy in Children. What Evidence for and Against it in 2018? {#pbc27455-sec-1700}

[J.L. Habrand]{.ul} ^1^, D. Stefan^1^, S. Bolle^2^, D. Lecomte^1^, J. Datchary^1^, C. Alapetite^3^, S. Helfre^3^, J. Thariat^1^, R. Dendale^3^

*^1^Centre François Baclesse, radiation oncology, Caen, France; ^2^Gustave Roussy Cancer Campus, radiation oncology, Villejuif, France; ^3^Institut Curie, radiation oncology, Paris, France*

**Background/Objectives**: Evaluating the place of particle therapy (mainly protons) in children/adolescents, from an extensive review of literature, with acute and long‐term toxicity/sequelae endpoints.

**Design/Methods**: We performed a review of published articles, from 1997 through 2017, based on Medline, according to the following keywords: English, toxicity, novel technologies. Only comparative studies between both technologies were taken into consideration. Dosimetric studies (group 1), secondary cancers (K2) predictive models (group 2), and clinical series (group 3) were evaluated separately, with best authors' recommendations quoted "P" or "XR", for particles or for 3D/IMRT photons respectively, along with the degree of significance (*pS* if \>.05).

**Results**: 166 articles were selected, from which 49 comparative P vs XR studies represented the core of the project. Anatomical sites for toxicity concerned CNS (29 pub on necrosis, cognition, vision, hearing, pituitary, brain sub‐structures such as hippocampus), Head and Neck (HN: 5 pub on pituitary, auditory, eyes, facial bones), thorax (3 pub on cardiac, pulmonary, thyroid, breast), abdomen/pelvis (3 pub on liver, stomach, bowel, pancreas), total body (1 pub), mixed sites (8 pub).

‐Group 1: CNS: 11/11 "P" (*pS*: 6/11); HN: 2/2 "P" (*pS*: 2/2); thorax: 4/4 "P" (*pS*:4/4); abdomen: 1/2 "P" (*pS*), and 1/2 "X" (pNS).

‐Group 2: 10/10 "P" (*pS*: 3/10).

‐Group 3: CNS: 4/4 "P" (*pS*: 3/4); HN: 1/1 "P" (*pS*:1/1). Endocrine: 3/3 "P" (*pS*: 2/3). Lung: 1/1 "XR" (*pS*: 1/1). Acute toxicity: 3/3 "P" (*pS*: 2/3); K2: 2/2 "P" (*pS*:1/2).

**Conclusions**: The vast majority of published series dealing with dosimetry and K2 modeling are in favor of particle therapy when prevention/limitation of toxicity is concerned, although *pS* value is not systematically mentioned. Similar findings concern clinical evaluations, but the data remain scarce and mainly related with CNS. If particle therapy is becoming popular, it remains essentially based on dosimetrical CNS investigations, so more extra cranial clinical studies are warranted.

### O-137. Patterns of Failure After Total Body Irradiation With or Without CNS Boosts Prior to Bone Marrow Transplant {#pbc27455-sec-1710}

[S. Mcgovern]{.ul} ^1^, S. Naik^2^, S. Curry^3^, M.F. McAleer^1^, A. Paulino^1^, A. Mahajan^4^, R. Krance^2^

*^1^MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA; ^2^Texas Children\'s Hospital, Bone Marrow Transplant/Stem Cell Transplant Program, Houston, USA; ^3^University of Texas at Houston, Medical School, Houston, USA; ^4^Mayo Clinic, Department of Radiation Oncology, Rochester, USA*

**Background/Objectives**: Historically, cranial boosts were included in conditioning regimens with total body irradiation (TBI) for patients with acute lymphocytic leukemia (ALL) undergoing bone marrow transplant (BMT). Currently, only patients with central nervous system (CNS) leukemic involvement prior to BMT receive cranial or craniospinal boosts. This study was undertaken to examine contemporary patterns of failure after TBI with or without cranial or craniospinal boost prior to BMT.

**Design/Methods**: The medical records of 62 pediatric patients with ALL treated with TBI for BMT at a single center from 2001 -- 2014 were retrospectively reviewed.

**Results**: Median follow up for all patients was 28 months. There were 38 patients that received either cranial or craniospinal boost prior to TBI. Of these 38 patients, 10 failed after BMT: 6 in the bone marrow, 1 in cerebrospinal fluid (CSF), 1 in the testicles, 1 in bone, and 1 in both bone marrow and CSF. There were 24 patients that did not have CNS involvement prior to BMT and did not receive cranial or craniospinal boosts with TBI. Of these 24 patients, 5 failed after BMT: 4 in the bone marrow and 1 in the testicles. No patient that did not receive a boost failed in the CNS. There was no difference in the crude rate of failure after BMT between the group that received a boost and the group that did not, 26% vs. 21% (p = 0.76).

**Conclusions**: Bone marrow remains the most common site of failure after BMT with TBI conditioning. Of 38 patients with CNS involvement prior to transplant, only 1 failed in the CNS alone after cranial or craniospinal boost, suggesting that boost improves the likelihood of CNS control. Of 24 patients without CNS involvement prior to transplant, none failed in the CNS, suggesting that a cranial or craniospinal boost was not required.

### O-138. Deformable Image Registration as a Tool for Quantifying the Effect of Radiotherapy on Vertebral Body Growth {#pbc27455-sec-1720}

E. Scher^1^, K. Huang^1^, [R. Vatner]{.ul} ^2^

*^1^University of Cincinnati College of Medicine, Department of Radiation Oncology, Cincinnati, USA; ^2^University of Cincinnati and Cincinnati Children\'s Hospital Medical Center, Department of Radiation Oncology, Cincinnati, USA*

**Background/Objectives**: The effect of spinal radiation during childhood is dependent upon patient age, gender, and radiation dose. However, the radiation dose response on spinal growth is unknown. We apply feature‐based deformable registration as a tool for quantitative analysis of vertebral body growth in pediatric patients after abdominal radiotherapy.

**Design/Methods**: A retrospective study of all pediatric patients treated with abdominal radiotherapy in our department from 2012‐2016 was performed (n=16). Of these, 3 had pre‐ and post‐treatment CT imaging available for analysis. Dosimetric data was obtained from the treatment plans. Automated feature‐based deformable registration was performed on CT images from simulation and follow‐up for each patient with alignment focused on the spine. Growth of each vertebral body was quantified using displacement vectors derived from maps of relative volumetric voxel‐based axial growth using in‐house software. This was compared using an unpaired *t*‐test to published expected normal growth of thoracic and vertebral bodies values for age and gender.

**Results**: The 3 analyzed patients (ages 1 month, 6 years, and 13 years) received median thoracic radiation doses of 4.3, 7.6, and 26.3 Gy, respectively. The observed in‐field thoracic relative growth rate per year was 0.020±0.013, 0.007±0.011, 0.009±0.006 mm, compared with the age matched expected growth rates of 0.183±0.005, 0.028±0.001, and 0.046±0.001 mm, respectively (*p* \< 0.0001). Similar results demonstrating impaired growth at low doses of radiation were obtained from analysis of lumbar growth. Impaired spinal growth was observed even after low doses of radiotherapy (\< 4 Gy).

**Conclusions**: We present a novel application of deformable image registration for measurement of axial vertebral body growth in pediatric patients exposed to low dose spinal radiation during abdominal radiotherapy. This technique allows for precise growth analysis of individual vertebral bodies and provides an unbiased, quantitative, and rapid method for determining the magnitude of spinal growth impairment as a function radiation dose.

### O-139. Outcomes Following Proton Therapy for Pediatric Low Grade Glioma {#pbc27455-sec-1730}

[D. Indelicato]{.ul} ^1^, J. Bradley^1^, R. Rotondo^1^, H. Uezono^1^, E. Sandler^2^, P. Aldana^3^, N. Ranalli^3^, A. Beier^3^, C. Morris^1^, N. Mendenhall^1^

*^1^University of Florida, Department of Radiation Oncology, Jacksonville, USA; ^2^Nemours Children\'s Specialty Clinic, Division of Pediatric Oncology, Jacksonville, USA; ^3^University of Florida, Department of Neurosurgery, Jacksonville, USA*

**Background/Objectives**: Dosimetric studies show that proton therapy can reduce the low/intermediate radiation dose delivered to uninvolved tissue in children with low grade glioma (LGG). Based on this rationale, LGG has become the 4th most common pediatric tumor treated with proton therapy worldwide, yet clinical outcome data on efficacy and toxicity are limited.

**Design/Methods**: Between March 2007 and June 2017, 152 children (≤ 21 years old) with non‐metastatic LGG were treated with proton therapy at a single institution. The median age was 9 years (range, 2‐21) and 52% were male. 2% had neurofibromatosis. Fifty‐five percent of tumors were WHO I and 32% WHO grade II; 13% of children were diagnosed based on imaging characteristics alone. The most common histology was pilocytic astrocytoma (44%). The top tumor subsites were diencephalon/optic pathway (53%), caudal brainstem (16%), and cerebellum (13%). Forty‐three percent of patients received chemotherapy as initial treatment.

**Results**: The median follow‐up was 4 years. Four patients were lost to follow‐up. The 5‐year actuarial rates of local control, progression‐free survival, and overall survival were 85% (CI 77‐90%), 84% (CI 76‐89%), and 92% (CI 85‐96%), respectively. On univariate analysis, brainstem/spinal cord tumor location (62% vs. 88% for other subsites) and radiation dose \<54 Gy(RBE) (69% vs. 89% for 54 Gy(RBE)) was associated with inferior progression free survival (p \<0.05 for both). Strong site/dose correlation prohibited multivariate analysis. Pseudoprogression was observed in 22% of patients. Serious toxicity included vasculopathy (n =1), radiation retinopathy (n =1), brainstem toxicity requiring steroids (n =2), and death from radiation‐induced high grade glioma (n =1).

**Conclusions**: This study suggests that 54 Gy(RBE) may be associated with improved disease control in LGG when not limited by critical adjacent CNS tissue. Compared to modern series using xrays, proton therapy may reduce the radiation dose to developing brain tissue without compromising disease control or producing unexpected toxicity.

### O-140. Association Between Hippocampal Radiation Dose and Short‐Term Memory in Pediatric Low‐Grade Gliomas Treated with Radiation Therapy {#pbc27455-sec-1740}

[S. Acharya]{.ul} ^1^, S. Wu^2^, J. Ashford^3^, C. Tinkle^1^, J. Lucas^1^, H. Conklin^3^, T. Merchant^1^

*^1^St Jude Children\'s Research Hospital, Department of Radiation Oncology, Memphis, USA; ^2^St Jude Children\'s Research Hospital, Department of Biostatistics, Memphis, USA; ^3^St Jude Children\'s Research Hospital, Department of Psychology, Memphis, USA*

**Background/Objectives**: Hippocampal avoidance has been suggested as a strategy to reduce short‐term memory decline in adults receiving whole brain radiation therapy (RT). The purpose of this study is to determine whether hippocampal dose in pediatric patients undergoing focal radiation for low‐grade glioma (LGG) is associated with short‐term memory performance.

**Design/Methods**: Eighty pediatric patients above the age of five with LGGs were treated with conformal RT to 54 Gy with a 0.5 cm clinical target volume on a phase II protocol (NCT00187226). Patients were administered the California Verbal Learning Test (CVLT) at baseline, six months, yearly through five years and at year 7 or 8 and year 10. Patients who participated in at least two memory assessments were included in the analysis. Linear mixed models were used to estimate the longitudinal trends in cognitive assessment scores and to estimate the effects of clinical variables on these trends.

**Results**: Seventy‐three patients had at least two CVLT assessments with a median age at RT of 9.2 years and median neurocognitive follow up of 7.8 years. On multivariate analysis, decline in CVLT‐Short Delay (SD) was associated with hydrocephalus (p=0.02), greater left hippocampal V40Gy (p=0.03) and greater right hippocampal V30Gy (p=0.04). Treating the entire left hippocampus to 40 Gy was associated with a reduction in CVLT‐SD at five years of 1 standard deviation (SD) and 0.5 SD for patients with and without hydrocephalus, respectively. Treating the entire right hippocampus to 30 Gy was associated with a reduction in CVLT‐SD at five years of 1 SD and 0.46 SD for patients with and without hydrocephalus, respectively.

**Conclusions**: Greater hippocampal dose is associated with a greater decline in short‐term memory, as measured by CVLT‐SD. Such findings might be informative for radiation therapy planning in children with brain tumors.
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### O-141. Role of Radiotherapy in Atypical Teratoid/Rhabdoid Tumours (AT/RT): An Analysis of the EU‐RHAB Registry, HIT/HIT‐SKK, AT/RT‐ZNS‐2004, and RHABDOID 2007 {#pbc27455-sec-1760}

H. Libuschewski^1,2^, S. Frisch^2^, J. Gerss^3^, K. von Hoff^4^, R.D. Kortmann^5^, M. Frühwald^6^, [B. Timmermann]{.ul} ^1,2^

*^1^University Hospital Essen, Department of Particle Therapy, Essen, Germany; ^2^West German Proton Therapy Centre Essen, West German Cancer Center, Essen, Germany; ^3^University of Münster, Institute of Biostatistics and Clinical Research, Münster, Germany; ^4^Charité Universitätsmedizin Berlin, Department of Paediatric Oncology and Hematology, Berlin, Germany; ^5^University of Leipzig Medical Center, Department of Radiation Therapy, Leipzig, Germany; ^6^Klinikum Augsburg, Children\'s Hospital, Augsburg, Germany*

**Background/Objectives**: An atypical teratoid/rhabdoid tumour (AT/RT) is a rare malignancy in childhood originating from the central nervous system. The aim of this analysis was to evaluate the role of radiotherapy (RT) in patients with AT/RT.

**Design/Methods**: We retrospectively analyzed data of patients registered in the EU‐RHAB registry or its precursors HIT/HIT‐SKK, AT/RT‐ZNS‐2004, and RHABDOID 2007. Survival data was analyzed using the Kaplan Meier method. In a multivariate Cox\'s regression RT was used as time‐dependent covariate.

**Results**: Data from 189 patients (119 m/70 f; median age 1.6 years (y) (range, 0‐26.7 y)) was evaluable. 47 patients underwent gross total resection, 108 subtotal, and 23 biopsy only. Chemotherapy was applied in 180 patients. 131 patients received RT (RT group), 58 did not (non‐RT group). The median total local or spinal doses were 54 Gy (range, 19.8‐66.0 Gy) and 35.1 Gy (range, 17.6‐48.6 Gy), respectively. The median follow‐up time was 1.9 y (range, 0.01‐20.1 y). The use of RT was an independent prognostic factor for overall survival (OS) and event‐free survival (EFS) with a hazard ratio of 0.52 (p=0.02) and 0.78 (p=0.038). 1y and 3y OS rates were 88.5% and 52.0% in the RT group vs. 26.5% and 10.5% in the non‐RT group (p\<0.001). 1y and 3y EFS rates were 63.7% and 40.7% in the RT group vs. 21.0% and 14.4% in the non‐RT group (p=0.009; p\<0.001). This advantage of RT was observed independent of age. OS and EFS were superior with protocol‐compliant treatment compared to protocol deviations (p=0.029; p=0.016). Regardless of M‐Stage, craniospinal RT could not prove any positive impact on OS or EFS when compared to local RT.

**Conclusions**: Our analysis reveals RT as an independent positive prognostic factor for OS and EFS in children with AT/RT. However, optimal combined treatment strategies have to aim for further reduction of late effects in future.

### O-142. Secondary Malignant Neoplasms in Patients with Medulloblastoma {#pbc27455-sec-1770}

[C. Nantavithya]{.ul} ^1,2^, D. Yeboa^1^, K. Liao^3^, S. McGovern^1^, D. Grosshans^1^, M. McAleer^1^, K. Woodhouse^1^, S. Khatua^4^, M. Chintagumpala^5,6^, A. Paulino^1^

*^1^The University of Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA; ^2^King Chulalongkorn Memorial Hospital, Division of Radiation Oncology‐ Department of Radiology, Bangkok, Thailand; ^3^The University of Texas MD Anderson Cancer Center, Health Services Research, Houston, USA; ^4^The University of Texas MD Anderson Cancer Center, Pediatrics, Houston, USA; ^5^Texas Children\'s Cancer Center, Pediatrics, Houston, USA; ^6^Baylor College of Medicine, Pediatrics, Houston, USA*

**Background/Objectives**: To analyze the incidence and types of second malignant neoplasms (SMN) in patients treated for medulloblastoma.

**Design/Methods**: Using the multiple primary‐standardized incidence ratio (*MP‐SIR*) session from SEER 9 registry data (1973‐2014), we compared the incidence of SMN in patients with medulloblastoma treated with radiotherapy (RT) to the general population. Observed‐to‐expected incidence ratios (O/E ratios) and 95%CI were reported for the overall cohort and classified by disease sites according to age, era treated and use of chemotherapy (CT). P‐values \< 0.05 were reported as statistical significance.

**Results**: Of 1294 patients with medulloblastoma who received RT, 68 developed a SMN. A total of 75 SMN was reported, with 4 patients having 2 SMN and 1 having 4 SMN. The O/E ratio for SMN was 4.49 (95%CI 3.53‐5.62) for all patients diagnosed with medulloblastoma (p\<0.05). The highest risk for developing a SMN was in the CNS (O/E 40.62; 95%CI 25.46 --61.51), followed by endocrine (O/E 15.95; 95%CI 9.12‐25.91), bone (O/E 14.45; 95%CI 1.75‐52.21), soft tissues (O/E 9.01; 95%CI 1.09‐32.56), digestive (O/E 5.03; 95%CI 2.51‐9.00) and lymphatic/hematopoietic (O/E 3.37; 95%CI 1.35‐6.94) systems. Patients receiving chemotherapy had a higher O/E compared to RT alone (O/E 5.52, 95%CI 3.75‐7.83 vs. 3.96, 95%CI 2.88‐5.32); chemotherapy patients also had a higher O/E for SMN in the CNS, salivary gland, and acute non‐lymphocytic leukemia compared to RT alone patients. After accounting for differences in length of follow‐up with standardized incidence ratios, patients treated before 1995 and younger age at diagnosis were associated with a higher O/E for SMN.

**Conclusions**: Medulloblastoma patients have an elevated risk for SMN compared to the general population. Variations by organ systems most at risk were observed based on treatment modality, age at diagnosis and time period. The CNS is the most common site of SMN and is seen more frequently in younger patients and those receiving chemotherapy.

### O-143. A Report from the PENTEC (Pediatric Normal Tissue Effects in the Clinic) Initiative on Acute and Late Effects after Pulmonary Radiation for Childhood Cancer {#pbc27455-sec-1780}

[M.F. Mcaleer]{.ul} ^1^, J. Agrusa^2^, C. Ronckers^3^, L. Kremer^4^, L. Constine^5^, T.M. Briere^6^

*^1^The University of Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA; ^2^Texas Children\'s Hospital, Pediatric Oncology, Houston, USA; ^3^Emma Children\'s Hospital/Academic Medical Center University of Amsterdam, Public Health and Epidemiology, Amsterdam, The Netherlands; ^4^Emma Children\'s Hospital/Academic Medical Center University of Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands; ^5^University of Rochester Medical Center, Radiation Oncology, Rochester, USA; ^6^The University of Texas MD Anderson Cancer Center, Medical Physics, Houston, USA*

**Background/Objectives**: The aim of the PENTEC pulmonary task force is to quantify dosimetric factors and the development of acute and late pulmonary toxicities among children treated for cancer.

**Design/Methods**: A comprehensive search of PubMed from 1965‐2017 was conducted to develop a predictive model of lung injury following radiation in the pediatric cancer population (\< 21 y). Radiation pneumonitis (RP) grade was based on Common Terminology Criteria for Adverse Events (CTCAE) and Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) criteria, and other clinical outcomes were reported using CTCAE and questionnaire response. Lung dose used for RP analysis was calculated from dose‐volume histogram (DVH) data.

**Results**: More than 2,300 abstracts were identified, and 432 papers with detailed treatment and toxicity data were selected for further review. Nine papers with DVH data were used for modeling. The pooled acute and late RP cohorts treated from 2000‐2013 included 139 and 254 patients, respectively, aged 0.04‐22.7y. Grade 2 RP in patients receiving thoracic RT was 4% acute (range, 0‐4%) and 4% late (range, 1.6‐17.4%). Clinical outcomes data included 14,985 patients treated from 1970‐2009, aged 0‐21.9y. Although patients were often asymptomatic, abnormal PFTs correlated with dose. At ≥ 10‐y follow‐up, large multi‐institutional studies suggested a relationship between doses \> 10 Gy and abnormal lung function, clinical outcomes and pulmonary deaths. Bleomycin at doses used in contemporary treatment regimens does not appear to contribute to adverse pulmonary outcomes.

**Conclusions**: Acute and late pulmonary toxicity in pediatric patients treated with thoracic radiation appears to be low in frequency and severity for the contemporary pediatric population. Multivariate analysis of DVH and other contributing factors would be greatly improved by multi‐institutional trials and registries with long‐term follow‐up. Continued follow‐up of pulmonary function late into adulthood is required.

### O-144. Cranial Spinal Irradiation with Proton Therapy: Risk of Early Radionecrosis in Paediatric Patients with High Risk Medulloblastoma {#pbc27455-sec-1790}

[S. Vennarini]{.ul} ^1^, S. Lorentini^1^, B. Rombi^1^, D. Amelio^1^, I.P. Voicu^2^, A. Carai^3^, A. Cacchione^2^, A. Mastronuzzi^2^, M. Amichetti^1^, G.S. Colafati^4^

*^1^APSS, Protontherapy, Trento, Italy; ^2^IRCCS Bambino Gesù Children\'s Hospital, Department of Pediatric Hematology and Oncology, Rome, Italy; ^3^IRCCS Bambino Gesù Children\'s Hospital, Department of Neuroscience and Neurorehabilitation‐ Neurosurgery Unit, Rome, Italy; ^4^IRCCS Bambino Gesù Children\'s Hospital, Neuroradiology Unit‐ Imaging Department, Rome, Italy*

**Background/Objectives**: Proton Therapy (PT) has been used extensively in treating paediatric cerebral tumours such as medulloblastoma. Current publications include limited cases of radionecrosis from the use of PT in paediatric patients. This study has compared our findings to that of published data where the median insurgence equal to 5 months (range 3‐11) has been stated \[*see* S.F. Kralik er al. Am J Neuroradiol 36:1572‐78 Aug 2015\].

**Design/Methods**: A retrospective analysis of 10 paediatric patients with high risk medulloblastoma treated with PT to the cranio‐spinal axis with a dose of 36 Gy RBE followed by a higher dose to the posterior cranial fossa of 18 Gy RBE. All paediatric patients underwent post surgery PT on primary tumour with intensive myeloblative chemotherapy which are potential risk factors for premature radionecrosis.

Patients with high risk medulloblastoma also underwent brain and spine MRI prior and post PT. MRI images were carried out with an RM 3T MAGNETOM Skyra (Siemens Healthcare, Erlangen, Germany) for the axial and sagittal T1‐weighted TSE, axial and coronal T2‐weighted TSE, axial FLAIR, axial DWI with ADC mapping and after intravenous administering of a paramagnetic contrast 3D‐space.

**Results**: This study demonstrates via a median follow up of 15.3 months (range 3.1 ‐20.6) no recorded cases of radionecrosis as per the criteria stated in current publications. Two patients demonstrated diverse areas of constrast enhancement, in the follow up, but were not considered pathologically significant.

**Conclusions**: The paediatric patients with high risk medulloblastoma that underwent PT treatment presented a lower risk of premature radionecrosis in respect to the data currently available in official publications. The study is ongoing with the objective to continuously confirm the emergent data from this preliminary analysis.

### O-145. Pediatric Nasopharyngeal Carcinoma: A Single Institute Experience from a Developing Country {#pbc27455-sec-1800}

[P. Khullar]{.ul} ^1^, A. Thakwani^1^, I. Bansal^2^

*^1^Batra hospital and research institute, Radiation Oncology, New Delhi, India; ^2^Artemis hospital, Radiation Oncology, Gurugram, India*

**Background/Objectives**: Pediatric nasopharyngeal carcinomas (NPCs) accounts \< 1% of all pediatric tumors. There is limited data on clinical features, treatment results, prognostic factors, outcome and late toxicities of pediatric NPC from India

**Design/Methods**: This analysis was carried out in consecutive 71 patients of pediatric NPCs, who were registered at our center in between 1^st^ May 2006 to 30^th^ April 2017 (11 years). Patients were treated with Neoadjuvant chemoradiotherapy (CTRT) with cisplatin and followed by cisplatin and 5‐fluorouracil (5‐FU) or concurrent CTRT with cisplatin.

**Results**: The median age was 15 years (range 10‐18 years) and male: female ratio was 1.5:1 The median duration of symptoms was 6 months (range 0.5‐2 years). AJCC stage distribution was stage II‐ 15%, stage III‐ 40%, and stage IV‐ 45%. Distant metastasis at presentation was seen in 9 patients. Complete response was seen in 65% and overall response was observed in 90% of cases. With a median follow‐up time of 36 months, the 3‐year overall survival (OS) rate, local‐regional control rate and distant metastasis‐free survival rate were 42%, 56% and 38% respectively. There were 9 local‐regional recurrences and 31 distant metastases. In multivariate analysis, T4 (*p* = 0.01) and stage IV (*p* = 0.001) were the independent adverse prognostic factors for OS. Significant reduction in trismus (30% *vs* 5%, *p* = 0.01) and xerostomia (40% *v* 21.2%, *p* = 0.001) was observed in patients treated by intense modulated radiotherapy (IMRT).

**Conclusions**: Most of patients with pediatric NPC present with advanced stage disease at our center. No difference in response rate and outcomes was seen with the two schedules of CTRT (Neoadjuvant *vs* concurrent). Local control could be achieved in majority of patients; however, distant metastasis was the most common reason for relapse. Late toxicities are less with IMRT.

### O-146. Combined Modality Management of Esthesioneuroblastoma in Paediatric and Adolescent Patients: Clinical Experience from a Regional Cancer Centre in North India {#pbc27455-sec-1810}

[A. Biswas]{.ul} ^1^, R. Sahoo^2^, R. Kumar^3^, S. Mallick^1^, K. Sikka^3^, S. Bakhshi^2^, S. Bhasker^1^, A. Sharma^2^, A. Thakar^3^

*^1^All India Institute of Medical Sciences, Radiotherapy & Oncology, New Delhi, India; ^2^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; ^3^All India Institute of Medical Sciences, Otorhinolaryngology, New Delhi, India*

**Background/Objectives**: Esthesioneuroblastoma is a rare cancer arising from the neuroendocrine cells of the olfactory epithelium and constitutes 5% of all sinonasal tumours.

**Design/Methods**: Data pertaining to paediatric and adolescent patients with esthesioneuroblastoma attending our institute from 2002‐17 was abstracted by retrospective chart review.

**Results**: We identified 20 patients with esthesioneuroblastoma. The median age at presentation was 16.5 years(range 3‐24 years). The male to female ratio was 14:6. Common symptoms included nasal obstruction in 55%, epistaxis and proptosis in 50%, visual symptoms in 45% and headache in 25% patients. On clinicoradiological examination 5(25%),11(55%) and 4(20%) patients had modified Kadish B, C and D stage. Chemotherapy was administered in 18(90%) patients. Neoadjuvant chemotherapy was given in 13(65%) patients‐EP (Cisplatin, Etoposide) regimen in 7 and Neuroblastoma protocol (Cyclophosphamide, Doxorubicin, Cisplatin, Etoposide) in 6. Surgery was done in 6(30%) patients‐lateral rhinotomy and excision of tumour in 5 and craniofacial resection in 1. Radiotherapy(RT) was delivered in all, the intent being curative and palliative in 17(85%) and 3(15%) patients respectively. The median definitive/post‐operative RT dose was 60 Gy/30 fractions/6 weeks. Weekly concurrent Cisplatin was added in 7(35%) patients. After a mean follow‐up of 31.4 months, 8 patients had disease progression, leading to death in 6. The common patterns of failure were in the neck(3), brain(2) and spinal drop metastases(3). At last follow‐up, 10(50%) and 3(15%) patients had complete and partial response, 1(5%) and 6(30%) patients had stable and progressive disease. The median overall survival(OS) had not been reached and the estimated median progression free survival(PFS) was 60 months. The 3 year actuarial rates of OS and PFS were 67.3% and 53.4% respectively.

**Conclusions**: Majority of paediatric and adolescent patients with esthesioneuroblastoma present in advanced stage in developing nations. Multimodality management in the form of surgery followed by radiotherapy is recommended in Kadish B tumour. Chemotherapy assumes an important role in Kadish C and D tumour.
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### PD-001. Age and NRAS Mutation Status are Possible Prognostic Markers in Pediatric Acute Myeloid Leukemia with CBFB‐MYH11 Fusion Gene {#pbc27455-sec-1840}

[Y. Hara]{.ul} ^1^, N. Shiba^2^, K. Ohki^3^, G. Yamato^4^, M. Sotomatsu^4^, D. Tomizawa^5^, T. Taki^6^, A. Kinoshita^7^, N. Kiyokawa^3^, H. Arakawa^1^, A. Tawa^8^, K. Horibe^9^, T. Taga^10^, S. Adachi^11^, Y. Hayashi^4^

*^1^Gunma University Graduate School of Medicine, Pediatrics, Maebashi, Japan; ^2^Yokohama City University Hospital, Pediatrics, Yokohama, Japan; ^3^National Research Institute for Child Health and Development, Pediatric Hematology and Oncology Research, Tokyo, Japan; ^4^Gunma Children\'s Medical Center, Hematology and Oncology, Shibukawa, Japan; ^5^National Center for Child Health and Development, Children\'s Cancer Center‐, Tokyo, Japan; ^6^Kyoto Prefectural University of Medicine, Molecular Diagnostics and Therapeutics, Kyoto, Japan; ^7^St Marianna University School of Medicine, Pediatrics, Kawasaki, Japan; ^8^National Hospital Organization Osaka National Hospital, Pediatrics, Osaka, Japan; ^9^National Hospital Organization‐ Nagoya Medical Center, Clinical Research Center, Nagoya, Japan; ^10^Shiga University of Medical Science, Pediatrics, Otsu, Japan; ^11^Kyoto University Graduate School of Medicine, Human Health Sciences, Kyoto, Japan*

**Background/Objectives**: Prognostic markers in pediatric acute myeloid leukemia (AML) with inv(16)(p13q22)/*CBFB‐MYH11* have not been identified yet.

**Design/Methods**: We analyzed molecular and clinical characteristics of 39 pediatric AML patients with *CBFB‐MYH11* enrolled in the Japanese AML99 and AML‐05 trials. Survival analyses revealed the excellent overall survival (OS) of patients with *CBFB‐MYH11* (97.4%), however, their event‐free survival (EFS) remains unsatisfactory (73.8%). Thus, we compared their characteristics between patients with or without events during treatment and follow‐up (n = 10 and 29, respectively). Events in this study included death, relapse, and second malignancy.

**Results**: Median age and the frequency of *NRAS* mutations significantly differed between these two groups (1.5 years vs 10.0 years, *p* = 0.005, and 0% vs 44.8%, *p* = 0.016, respectively). Consequently, we performed survival analyses in patients with *CBFB‐MYH11* according to age and *NRAS* mutation status. When we defined 3 years old as a cutoff (12 patients aged \<3 years and 27 patients aged 3 to \<18years), survival analyses revealed significantly worse 5‐year EFS and cumulative incidence of relapse (CIR) in patients aged \<3 years than in those aged 3 to \<18 years (41.7% vs 88.4%, *p* \<0.001, and 58.3% vs 7.9%, *p* \<0.001, respectively). Conversely, *NRAS*‐mutated patients (n = 13) had significantly better EFS and CIR than *NRAS*‐wildtype patients (n = 26) (100% vs 60.5%, *p* = 0.012, and 0% vs 35.7%, respectively). Accordingly, *NRAS*‐wildtype patients aged \<3 years (n = 9) had the worst outcomes (EFS = 22.2% and CIR = 77.8%).

**Conclusions**: Age and *NRAS*‐mutation status may be useful prognostic markers in pediatric AML with *CBFB‐MYH11*. The utility of these markers should be further investigated to prevent relapse and stem cell transplantation in them.

### PD-002. MLL‐Rearranged Leukaemia Carrying Reciprocal Translocations Indicates Relatively Favourable Prognosis {#pbc27455-sec-1850}

[Y. Liu]{.ul} ^1^, D. Lixia^1^, L. Jianwei^1^, C. Jing^1^, T. Yanjing^1^, X. Huiliang^1^, G. Longjun^1^, S. Shuhong^1^, L. Benshang^1^, C. Jing^1^

*^1^Shanghai Jiaotong University, Shanghai children\'s Medical Center, Shanghai, China*

**Background/Objectives**: The mixed‐lineage leukemia (MLL) with multifarious partner genes leads to aggressive leukemia with dismal outcomes.

**Design/Methods**: Using panel‐based targeted sequencing, we examined a total of 90 MLL‐rearranged(MLL‐r) childhood acute leukemia cases, including 55 patients with acute lymphoblastic leukemia (ALL) and 35 patients with acute myeloid leukemia (AML).

**Results**: All the precise MLL breakpoints, complete rearrangements characterization and 24 novel MLL fusions were identified. A total of 37.8% (34/90) of all the patients displayed a single direct MLL fusion gene, 15.6% (14/90) carried a single reciprocal fusion, and 27.8% (25/90) had both reciprocal MLL fusion alleles. The remaining 17 MLL‐r cases had complex translocations with homozygous disruptions on chromosome 11 or two breakpoints on the same MLL allele with a deletion of functional regions. A total of 77 patients (45 ALL and 32 AML) received chemotherapy with a median follow‐up of 2.5 years. Unexpectedly, we found children with reciprocal MLL fusions that exhibited relatively favorable outcomes compared with those in children with complex translocations or single direct MLL fusion allele (66.1% versus 24.6% and 27.6%, P = 0.001). Functional features of the truncated MLL fusion protein may give an explanation for the favourable clinical prognosis of reciprocal MLL translocations.

**Conclusions**: In conclusion, comprehensive MLL‐r analysis by targeted next‐generation sequencing (NGS) can provide detailed molecular information and is helpful for the precise stratified treatment and clinical prognosis determination.

### PD-003. Downstream Pathway of AML1‐ETO Targeted ARHGEF12 Might be Targetable for Rock Inhibitor to Improve Therapy Outcome {#pbc27455-sec-1860}

[S. Shen]{.ul} ^1^, Y. Xie^2^, R. Wu^1^, L. Gao^1^, Y. Tang^1^, J. Tang^1^

*^1^Shanghai Children\'s Medical Center, pediatric hematology oncology, Shanghai, China; ^2^Shanghai Children\'s Medical Center, Hematology Oncology, Shanghai, China*

**Background/Objectives**: As a transcription factor AML1‐ETO modulate gene expression of its targets. Scanning our ChIP‐seq data we found AML1‐ETO bind to an AML1 binding motif in the promotor region of *ARHGEF12*. Exploring acute myeloid leukemia (AML) microarray databases we confirmed that the expression of *ARHGEF12* was up‐regulated consistently in AML1‐ETO‐positive AML patient samples. To confirmed this finding, we quantitated expression of *ARHGEF12* in pediatric AML samples from Shanghai children\'s medical center. Not out of expectation, all AML1‐ETO‐positive cases have higher *ARHGEF12*. Moreover, the *ARHGEF12* expression was an independent poor prognostic factor for overall survival comparing between patients with higher and lower expressed *ARHGEF12*. (P=0.0258).

**Design/Methods**: To understand the role of *ARHGEF12* in leukemogenic function of AML1‐ETO fusion gene, we knocked down *ARHGEF12 expression in* kasumi‐1 cells by shRNA. Growth of kasumi‐1 cells in vitro was significantly inhibited with cell cycle exit and more apoptosis. Further, we transformed fetal liver cells of *Arhgef12* conditional knockout mice to leukemia model by retrovirus conducted AML1‐ETO9a(AE9a) expression. Induced *Arhgef12* deletion delayed full blown of leukemia in vivo.

**Results**: The overall survival prolonged 15.5 days (median 83.5 vs. 68 days, P=0.0072). ARHGEF12 is a well‐known guanine nucleotide exchange factor for RhoA GTPase, *Arhgef12* deletion decreased activated GTP‐RhoA expression and MYPT1 phosphorylation, which is one of ROCK kinase substrates. Spleen cells from leukemic mice were cultured in vitro, the ROCK inhibitor Y‐27632 significantly decreased the cell proliferation, which mimic the tamoxifen‐induced Arhgef12 knockout phenotype. Y‐27632 combined with tamoxifen treated cells almost eradicate alive leukemia cells on the ninth day and delay leukemogenesis in vivo.

**Conclusions**: These findings suggest that ARHGEF12 as a transcriptional target of the AML1‐ETO fusion protein and plays an essential role in leukemogenesis. The ARHGEF12‐RHOA‐ROCK pathway may serve as a new therapeutic target for AML1‐ETO+ AML.

### PD-004. Analysis of the Distribution and Clinical Features of Alterations Activating NOTCH1 Signaling in Pediatric T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) {#pbc27455-sec-1870}

[S. Kimura]{.ul} ^1,2^, M. Seki^1^, K. Yoshida^3^, H. Ueno^3^, K. Ohki^4^, K. Koh^5^, R. Kobayashi^6^, T. Deguchi^7^, Y. Hashii^8^, T. Imamura^9^, A. Sato^10^, N. Kiyokawa^4^, A. Manabe^11^, K. Horibe^12^, A. Ohara^13^, M. Sanada^12^, M. Kobayashi^2^, S. Miyano^14^, S. Ogawa^3^, J. Takita^1^

*^1^The University of Tokyo, Department of Pediatrics, Tokyo, Japan; ^2^Hiroshima University, Department of Pediatrics, Hiroshima, Japan; ^3^Graduate School of Medicine‐ Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan; ^4^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^5^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^6^Sapporo Hokuyu Hospital, Department of Pediatrics, Sapporo, Japan; ^7^Mie University Hospital, Department of Pediatrics, Tsu, Japan; ^8^Osaka University Graduate School of Medicine, Department of Pediatrics, Suita, Japan; ^9^Kyoto Prefectural University of Medicine‐ Graduate School of Medical Science, Department of Pediatrics, Kyoto, Japan; ^10^Department of Hematology and Oncology, Miyagi Children\'s Hospital, Sendai, Japan; ^11^St. Luke\'s International Hospital, Department of Pediatrics, Tokyo, Japan; ^12^National Hospital Organization Nagoya Medical Center, Clinical Research Center, Nagoya, Japan; ^13^Toho University, Department of Pediatrics, Tokyo, Japan; ^14^Institute of Medical Science‐ The University of Tokyo, Human Genome Center, Tokyo, Japan*

**Background/Objectives**: Aberrant constitutive activation of NOTCH1 signaling (*NOTCH1* and *FBXW7*) is a major oncogenic event in T‐cell acute lymphoblastic leukemia (T‐ALL), classified into two patterns; ligand‐independent activation (LIA) and impaired degradation (ID). Several types of aberration were reported in each activation pattern, so far. In this study, we explored the clinicopathological relevance of *NOTCH1*/*FBXW7* aberrations.

**Design/Methods**: We reanalyzed our previously published data of targeted‐capture sequencing (n=176) and whole transcriptome sequencing (WTS; n=123). We defined as subclonal when variant allele frequency was below 0.15.

**Results**: In total, we detected aberrations activating NOTCH1 signaling in 80.7% (142/176) of cases. Subclonal mutations were observed in 26.1% (n=46). Single nucleotide variations in the heterodimerization domain (HD‐SNV) were the most frequent (42.6%; n=75), followed by PEST domain mutations (32.4%; n=57). Both LIA and ID patterns were detected in 43.2% (n=76). Most mutations were mutually exclusive within each LIA and ID pattern. We detected three cases (1.7%) of SNV at 3' UTR, four (2.3%) intragenic *NOTCH1* deletion (DEL; missing exon 3--27), and two (1.1%) *SEC16A*‐*NOTCH1* fusions. We confirmed that DEL activates NOTCH1 signaling by luciferase reporter assay. Analysis of frequency in each WTS‐based cluster (ETP, SPI1, TLX, TAL1‐RA, and TAL1‐RB) revealed that alterations were frequently detected in TLX (100%; n=24) and TAL1‐RB (95.1%; n=41), whereas less frequent in TAL1‐RA (61.1%; n=18). In TAL1‐RA, all *SEC16A*‐*NOTCH1* fusions were observed despite low rate of HD‐SNV (11.1%). Importantly, cases harboring subclonal *NOTCH1*/*FBXW7* mutations showed significantly worse outcome (log‐rank *P* =0.01). There was no prognostic difference between cases with and without *NOTCH1*/*FBXW7* mutations.

**Conclusions**: We observed *NOTCH1*/*FBXW7* alterations in 80.7%, and detected rare intragenic NOTCH1 deletion and *SEC16A*‐*NOTCH1* fusions recurrently in T‐ALL. Additionally, subclonal *NOTCH1*/*FBXW7* aberrations might be relevant to unfavorable outcome. Our results might be useful for development of a new anti‐NOTCH1 therapeutic strategy for pediatric T‐ALL patients.

### PD-005. miR‐155 Targets Gene ZNF238 Expression and Predicts Childhood Acute Lymphoblastic Leukemia Poor Prognosis {#pbc27455-sec-1880}

[C. Liang]{.ul} ^1^, Y. tang^1^, X. liu^1^, C. peng^1^, W. tang^1^, Y. li^1^, L. wang^1^, L. huang^1^, X. luo^1^

*^1^The First Affiliated Hospital of Sun Yat‐sen University, Pediatrics, guangzhou, China*

**Background/Objectives**: As a significant number of childhood ALL present dismal prognosis, this study evaluated the impact of microRNA on the outcome of childhood ALL in the context of other clinical and molecular prognosticators and explored its mechanism of action.

**Design/Methods**: MicroRNA expression profiles of childhood ALL were investigated from GEO. MiR‐155 expression in bone marrow of forty‐two paired ALL cases at two different time points (initial diagnosis and first relapse status) was detected by qRT‐PCR. Bioinformatics software and dual luciferase reporter assay were applied to predict and verify the target of miR‐155. Furthermore, four human ALL cell lines were transfected with miR‐155 mimics, miR‐155 inhibitor, si‐ZNF238, and corresponding controls. Cell viability and cell apoptosis were analyzed using CCK‐8 and flow cytometry assay. The protein expression were analyzed using Western blotting.

**Results**: A total of 30 differentially expressed miRNAs were identified in ALL patients compared with healthy subject. Patients with higher expression of miR‐155 had shorter overall survival (P=0.0043), shorter leukemia‐free survival (P=0.0017) and higher cumulative incidence of relapse (P=0.0004). Interestingly, there are no statistically significant on overall survival and leukemia‐free survival between our traditional standard‐risk and middle‐risk(P\>0.05).miR‐155 expression was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in ALL (eg, PI3K‐Akt, mTOR, and AMPK), We demonstrate that higher expression levels of MiR‐155 and lower expression levels of ZNF238 both significantly promoted proliferation and inhibited apoptosis in ALL cell lines(CEM‐C1, Jurket, MOLT‐3, MOLT‐4). Dual luciferase reporter system confirmed that ZNF238 was a potential target of miR‐155.

**Conclusions**: MiR‐155 expression may well contribute to an improved prognostic stratification of children with ALL and may play a role in the pathogenesis of this disorder by targeting ZNF238.

### PD-006. Pattern of MTDNA (D‐LOOP) Variations and their Relation with Mitochondrial Encoded Gene in AML {#pbc27455-sec-1890}

[R. Bakhshi]{.ul} ^1^, A. Tyagi^2^, R. Pramanik^2^, V. Sreenivas^3^, S. Ali^1^, S. Bakhshi^2^

*^1^Shaheed Rajguru College of Applied Sciences‐ University of Delhi, Biomedical Sciences, New Delhi, India; ^2^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; ^3^All India Institute of Medical Sciences, Biostatistics, New Delhi, India*

**Background/Objectives**: Role of variation in mitochondrial DNA, particularly those in D‐loop region, in acute myeloid leukemia (AML) remains investigational. The study aimed to assess pattern of variations in mitochondrial D‐loop region in AML patients and to evaluate their association with expression of mitochondrial‐encoded genes.

**Design/Methods**: For denovo AML patient\'s ≤18 years of age, between June 2013‐August 2016, bone marrow sample, buccal swab sample and mother\'s blood sample were collected at baseline. DNA extraction, PCR for D loop region and subsequent Sangers sequencing were performed. RNA extracted from these patients was analyzed using real time PCR for relative gene expression of four mitochondrial DNA encoded genes viz. Nicotinamide adenine dineucleotide dehydrogenase subunit 3 (ND3), Cytochrome B (CytB), Cytochrome c oxidase I (COX1) and ATP synthetase F~0~ subunit 6 (ATP6).

**Results**: 151 patients were included; gene expression was analyzable in 116 patients. Total 1490 variations were found at 237 positions in D‐Loop. Of these, 1206 (80.9%) variations were germline and 284 (15.9%) somatic. Positions 73‐263 was identified as probable hotspot region in D‐loop (11.9 variations per positions). T‐C change was commonest variation in germline (428/1206) (35.5%) as well as somatic (88/284) (30.9%) variations. G bases appeared to be most stable nucleotide (least number of single base substitution) whereas T appeared to be most prone to variations with germline T‐C being commonest. CytB gene expression was significantly higher for variations at position 16192 and 16327. Expression of CytB was significantly lower for variation at position 16051 and 207. Variation at position 152, 207, 513 significantly decreased expression of COX1 while those at position 16051, 152 attenuated expression of ATP6.

**Conclusions**: This first study evaluated type and overall pattern of variation in D‐loop region and segregated them into somatic and germline variation. Effect of these variations on mitochondrial encoded genes is a novel information in AML genomics.

Poster Discussion Session 02: PODC {#pbc27455-sec-1900}
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### PD-007. Optimising Outcomes of Acute Lymphoblastic Leukemias with Supportive Care and Risk‐Stratification Measures at a Tertiary Cancer Care Centre in India {#pbc27455-sec-1910}

[G. Narula]{.ul} ^1^, M. Prasad^1^, S. Jatia^2^, S. Banavali^1^

*^1^Tata Memorial Center, Pediatric Oncology, Mumbai, India; ^2^Tata Memorial Center, ImPaCCT Foundation‐ Pediatric Oncology, Mumbai, India*

**Background/Objectives**: Since 2010, our group put in place comprehensive supportive‐care measures including financial, accommodation, transfusion and nutrition support to ensure no patient was denied treatment on these grounds. By 2013 these measures covered all new registrations. For Acute Lymphoblastic Leukemia(ALL), a risk‐stratified Minimal Residual Disease (MRD) based protocol was implemented from 2013 onwards. We retrospectively audited the impact of these measures on ALL outcomes.

**Design/Methods**: Records of children below 15‐years with ALL registered at our centre from Jan 2010 through Dec 2015 were retrospectively reviewed. Patients with incomplete data, prior treatment, and referred for treatment to other institutions were excluded. To assess the impact of supportive care, we divided this period into two eras‐ Incomplete coverage:2010‐12 (Era‐A), and complete coverage:2013‐15 (Era‐B). Era‐B also had a risk‐stratified protocol for B‐ALL. For financial/ other support, patients were categorised into Completely Supported(CS), Need‐based(NBS), and No Support(NS).

**Results**: Of 1729 patients eligible for analysis, 990(57.2%) were CS, 471(27.2%)‐NBS and 268(15.5%) with 711(41.1%) in Era‐A, and 1018(58.9%) in Era‐B. Treatment Refusal & Abandonment (TR&A) rates fell from Era‐A (Mean‐10.9%) to Era‐B (Mean‐4.93%). Five‐year Overall Survival (OS) for all patients was 75±0.01%. This showed significant improvement over eras‐ 69.1±0.01% and 79.4±0.01% (p\<0.001) for Era‐A and Era‐B respectively. Disease‐wise 5‐yr OS for the entire cohort was B‐ALL‐80.9±0.01%, and T‐ALL‐70.9±0.03%, while era‐wise it was T‐ALL‐68.2±0.05% and 71.9±0.04%, and B‐ALL‐70.6±0.02% and 89±0.01% for Era‐A & Era‐B respectively. Outcomes based on support needs of patients improved across categories, and differences also narrowed. In Era‐A, 5‐year OS was CS‐70.2±0.02%, NBS‐68.6±0.04%, and NS‐76.9±0.04%, while for Era‐B, it was CS‐83.3±0.01%, NBS‐85.7±0.02%, and NS‐89.7±0.03%.

**Conclusions**: Holistic supportive‐care measures that could address needs of all registered patients improved overall outcomes of ALL in a equitable manner by diminishing impact of socio‐economic status, while adoption of risk‐stratification improved B‐ALL outcomes in a tertiary cancer centre in India.

### PD-008. Long‐Term Results of Childhood Acute Lymphoblastic Leukemia: A Single Center Review of the CCLG‐ALL2008 Study in China {#pbc27455-sec-1920}

[X. Chen]{.ul} ^1^, X. Liu^1^, Y. Guo^1^, Y. Zou^1^, B. Zhao^1^, W. Yang^1^, M. Wang^1^, M. Ruan^1^, X. Zhu^1^

*^1^Institute of Hematology‐ Blood Disease Hospital, Chinese Academy of Medical Sciences CAMS, Department of Paediatric Haematology, tianjin, China*

**Background/Objectives**: From 2008, the China Children Leukemia Group (CCLG) conducted a risk‐oriented study of acute lymphoblastic leukemia(ALL), CCLG‐ALL2008.

**Design/Methods**: We analyzed the long‐term outcome of 938 ALL patients treated according to a CCLG‐ALL2008 platform between 2008 and 2015 in our center.

**Results**: The complete remission rate of all patients was 97.3%, death in remission 1.3%.The 10‐year event‐free and overall survival (OS) rates for all children were 71.9 ±1.8% and 79.0 ± 1.6%, respectively. The OS rate for standard risk, middle risk and high risk group were 92.8 ±1.7%, 76.9 ±2.9% and 61.8 ±3.9%, respectively (p \< 0.001). By the last follow up, the development of a second neoplasm was 0.5%, with 25.1% of patients was relapsed. In high risk group, 9.5% of patients received stem cell transplant during the first complete remission stage. In this protocol, Tyrosine Kinase Inhibitor(TKI) wasn\'t regularly combined with chemotherapy for patients with BCR/ABL, 10 out of 44 patients treated with TKI, the 10‐year OS was 47.1 ±11.2%.

**Conclusions**: The survival rate of children with ALL has increased to approximately 90% after substantial progress in risk‐oriented treatment strategies in some study group. It seems lower survival rate in developing countries. Patients with BCR/ABL had poor outcome because of lower rate of TKI used. Increase the number of transplantation may further increase cure rates and reducing the relapse for the high risk group of patients.

### PD-009. Treatment of Relapse/Refractory Hodgkin Lymphoma (HL): A Report from de Association of Central American Pediatric Hematology Oncology (AHOPCA) {#pbc27455-sec-1930}

[P. De Alarcon]{.ul} ^1^, E.M. Castellanos^2^, P. Calderon^3^, S. Fuentes‐Alabi^4^, F. Antillon‐Klussmann^2^, C. Garrido^2^, P. Valverde^2^, P. Obando^2^, J. Blanco^2^, M. Metzger^5^

*^1^University of Illinois College of Medicine and St Jude Children\'s Research Hospital, Department of Pediatrics, Peoria, USA; ^2^UNOP, Oncology, Guatemala, Guatemala; ^3^Hospital Manuel de Jesus Rivera, Oncology, Managua, Nicaragua; ^4^Hospital Nacional de Niños Benjamin Bloom, Oncology, San Salvador, El Salvador; ^5^St Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: The event‐free survival (EFS) and overall survival (OS) for HL in middle and low‐income countries (LMIC) have improved but still many fails therapy. High‐dose chemotherapy followed by stem cell rescue can cure 50‐70% of these patients. This therapy is not always available in LMIC. To rescue these children, AHOPCA designed a rescue regimen of ifosphamide, carboplatin and etoposide (ICE). We report preliminary results in one of the AHOPCA centers.

**Design/Methods**: Children with refractory/resistant (RR) or relapse HL were treated. We defined RR as subjects who did not achieve a response (≥ 80% of disease‐bulk at presentation) or who relapse within three months of completion of therapy, early relapse (ER) between three and 12 months after completion of therapy, and late relapse (LR) those who recurred after one year of completing therapy. ICE regimen consisted of etoposide 100 mg/m^2^ days 1 to 3, carboplatin 600 mg/m^2^ day 1 and ifosfamide 1.8 gm/m^2^ days 1 to 3 with involved field radiotherapy 35 cGY without G‐CSF. Cycles repeated every 21 days for four to six cycles if a response achieved.

**Results**: From 1/1/2004 to 1/26/2018, 3 AHOPCA centers treated 625 with HL. Of these, 82 had RR or relapse (31 RR, 28 ER,23 LR) disease. At the time of analysis, 27 children were alive, 48 dead, 2 abandoned therapy and 5 were lost to follow‐up. The EFS for the cohort at 5‐years was 17%±5.2 and the OS 31%±6.1. The EFS and OS for ER were 12%±7.8 and 41%±8.5 and for LR 32%±10.4 and 48.8%±12.4% respectively. The EFS between RR and relapse HL different (P=0.02).

**Conclusions**: From these limited data, we conclude that some children with late relapse of HL can be rescued with an ICE based regimen in the setting of a LMIC but children with RR are less likely to be rescued.

### PD-010. Effectiveness of Ready‐to‐Use Therapeutic Food (RUTF) in the Management of Malignancy Related Undernutrition in Children: Results of a Prospective Open‐Labeled Randomized Control Trial {#pbc27455-sec-1940}

[M. Prasad]{.ul} ^1^, S. Tandon^1^, G. Narula^1^, G. Chinnaswamy^1^, T. Vora^1^, S. Nikam^1^, R. Gala^1^, A. Paradkar^1^, D. Jagiasibava^2^, A. Jadhav^3^, S. Kannan^4^, S. Banavali^1^, B. Arora^1^

*^1^Tata Memorial hospital, Paediatric Oncology, Mumbai, India; ^2^Bone enterprises, Clinical densitometry, Mumbai, India; ^3^Lokmanya Tilak Municipal Medical College and General Hospital, Paediatrics, Mumbai, India; ^4^Tata Memorial hospital, Biostatistics, Mumbai, India*

**Background/Objectives**: Over half of children with malignancy in Low‐middle‐income countries(LMICs) are malnourished, leading to poor treatment tolerance, higher toxicity and lower survival. Early nutritional intervention may obviate this effect. RUTF is an established medical nutrition therapy, however efficacy data in children with malignancy is lacking.

**Design/Methods**: Severely and moderately malnourished(SAM/MAM) children with cancer aged 5‐15 years underwent stratified randomization to receive either RUTF or standard nutritional therapy(SNT) for 6 weeks. Dietary intake, nutritional status(weight, height, body mass index for age), body composition using dual energy X‐ray absorptiometry(DEXA) scan, health related quality of life(HRQOL) (Health Utilities Index‐HUI2 and 3), and treatment tolerance were compared at baseline and 6‐weeks. Clinical monitoring was done weekly for 6 weeks, then monthly for 6 months.

**Results**: 260 children (130‐each arm) were enrolled between July‐2015 and March‐2018, of whom 237(120‐RUTF, 117‐SNT) are evaluable. Median age 9‐years and M:F 2.3:1. Children on RUTF‐arm compared to SNT‐arm, had greater weight‐increment at 6 weeks (mean‐5.7% of baseline weight vs 3.5%; p‐0.019) and were more likely to achieve normal nutritional status (RUTF‐arm:39.6% and 55%, SNT‐arm:22.5% and 38% at 6 weeks(p‐0.02) and 3 months(p‐0.05%) respectively). RUTF enabled increase in protein and energy consumption by 54%(p‐0.038) and 18%(p‐0.1) and increased HRQOL scores (p‐0.05) at 6 weeks. Children on RUTF‐arm had less treatment delays both during intervention period(10.4% vs 22.7%, p\<0.01) and on follow‐up(10% vs 24%, p\<0.01), as well as fewer episodes of febrile neutropenia(1.34 vs 1.82, p‐0.02), with shorter admission periods per episode(4.7days vs 6.7days, p‐0.2).

**Conclusions**: RUTF is an effective and well tolerated nutritional intervention in SAM/MAM children with malignancy, and improves nutritional status, quality of life, and reduces toxicities of chemotherapy compared to SNT. These benefits are maintained over time. RUTF has immense potential to improve treatment outcomes, and supplementation should be strongly considered during the intensive phase of treatment.

### PD-011. A Comparitive Study of Various Generic Brands of L‐Asparaginase Available in India {#pbc27455-sec-1950}

[V. Gota]{.ul} ^1^, V. Purohit^1^, R. Deshpande^1^, S. Sengupta^1^, K.C. Anand^2^, H. Sankaran^2^, S. Banavali^3^

*^1^Advanced Centre for Treatment‐ Research and Education in Cancer ACTREC‐ Tata Memorial Centre, Clinical Pharmacology, Navi Mumbai, India; ^2^Tata Memorial Centre, Medical Oncology, Mumbai, India; ^3^Tata Memorial Centre, Medical Ondology, Mumbai, India*

**Background/Objectives**: L‐asparaginase (L‐Asp) is an essential medicine in ALL and quality of generic brands is a matter of concern. We compared the quality of L‐asparaginase of various brands available in India.

**Design/Methods**: Nine commonly used generic brands were identified. Quality was assessed by (i) testing the formulations for asparaginase activity using a microplate based colorimetric method and (ii) comparison of trough asparaginase activity in children with ALL receiving induction chemotherapy. L‐Asp was administered at a dose of 10,000 IU/m^2^ i.m. every 3 days per protocol. A 72 hour trough blood sample from each patient was drawn just before the next dose.

**Results**: One Hundred and eighty nine patients were enrolled between March, 2015 and May, 2017 \[M/F=119/70; Age (Median/range) = 4.9(0.8‐15) years; Standard/intermediate/high risk = 55/66/68 cases; BSA=0.64(0.35‐1.7)m2; Dose=6,300 (3,000‐17,000) IU)\]. Two hundred and thirty four blood samples were analyzed for asparaginase activity. Number of samples analyzed for each brand ranged from 7--66 with a median of 18. Average asparaginase activity of brands ranged from 31.66 U/L (n=33 samples) in the lowest activity brand to 525.58 U/L (n=12) in the highest activity brand. Median asparaginase activity corresponded to 86.6 U/L. Proportion of patients who failed to achieve a predefined threshold activity of 50 U/L ranged from 16.7% (2/12) in the highest activity brand to 84.9% (28/33) in the lowest activity brand (Median of all brands=50%). Direct analysis of three formulations and comparison with Medac asparaginase (innovator) showed that asparaginase activity in the generics ranged from 77‐80% of the innovator.

**Conclusions**: There is a wide variation in asparaginase activity between brands. Six out of nine brands tested were markedly inferior with 50% or more patients failing to achieve the trough activity of 50 U/L. This raises serious concerns about the quality of generics of this essential medicine and the need for pharmacovigilance in this area.

### PD-012. Availability and Price of Essential Medicines for Treating Childhood Cancers in India {#pbc27455-sec-1960}

[N. Faruqui]{.ul} ^1^, A. Martiniuk^2^, A. Sharma^3^, B. Rathore^4^, C. Sharma^5^, R. Arora^6^, R. Joshi^7^

*^1^University of Sydney, School of Public Health, Sydney, Australia; ^2^University of Sydney, Faculty of Medicine, Sydney, Australia; ^3^Boston University School of Public Health, Global Health, Boston, USA; ^4^Cankids NGO, Medical Projects, Delhi, India; ^5^Independent Researcher, Independent Researcher, Delhi, India; ^6^Max Super Speciality Hospital, Paediatric Oncology, Delhi, India; ^7^The George Institute for Global Health, Office of the Chief Scientist, Sydney, Australia*

**Background/Objectives**: Limited access to essential medicines (EMs) for treating chronic diseases is a major challenge, particularly in low‐ and middle‐income countries. Although India is the largest manufacturer of generic medicines, availability and affordable prices is not guaranteed. We assessed availability and prices of EMs for treating childhood cancers in Delhi, India.

**Design/Methods**: Using a modified WHO and Health Action International methodology, we collected data on availability and price of 24 anti‐neoplastic EMs (33 specific dosages) and 4 non‐cancer EMs as study control. Data were collected from pharmacies of 8 tertiary‐care 'survey anchor' hospitals (4 public and 4 private) that treat childhood cancers, and from a random sample of 32 retail pharmacies located near the survey anchors. Median Price Ratios (MPRs) were calculated by comparing consumer prices to 2015 International Reference Prices (IRPs).

**Results**: On average, 84% of 'survey anchor areas' (hospital plus retail pharmacies) had anti‐neoplastic EMs available in at least one dosage form, and 67% and 100% availability for dosage‐specific anti‐neoplastic EMs and control EMs, respectively. Vincristine‐5mg injection and Ifosfamide‐500mg injection were unavailable. Mean availability by facility type of dosage‐specific anti‐neoplastic EMs was 33% in retail pharmacies, 40% in public hospital‐pharmacies and 68% in private hospital‐pharmacies. All MPRs, except for Paclitaxel‐6mg/ml injection, were in line with WHO target that no consumer should pay more than 4 times IRPs. Estimated chemotherapy cost, based on consumer prices, for treating a 30kg child with standard‐risk leukaemia \[INR 27,577 (USD 438)\] and Hodgkin disease \[INR 17,500 (USD 278)\] is 26% and 16% of India\'s 2016 per‐capita income, respectively.

**Conclusions**: Most anti‐neoplastic EMs are found in survey anchor areas, however mean availability was less than control medicines; not meeting WHO target of 80% availability across all facilities. In local context, cost of chemotherapy medicines appear to be affordable however greater burden of costs may lie elsewhere.

Poster Discussion Session 03: Leukemia/Lymphoma: Clinical {#pbc27455-sec-1970}
---------------------------------------------------------

### PD-013. A Single Center Experience of Blinatumomab in 27 Pediatric Patients with Heavily Pretreated Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-1980}

[M. Queudeville]{.ul} ^1^, T. Lenz^1^, M. Döring^1^, U. Holzer^1^, A. Heinz^1^, H.M. Teltschik^2^, H. Kreyenberg^3^, A. von Stackelberg^4^, M. Schrappe^5^, T. Feuchtinger^6^, P. Schlegel^1^, P. Lang^1^, R. Handgretinger^1^, M. Ebinger^1^

*^1^University Hospital Tübingen‐ Children\'s Hospital, General Pediatrics‐ Hematology/Oncology, Tübingen, Germany; ^2^Klinikum Stuttgart ‐ Olgahospital, Pediatric Oncology‐ Hematology and Immunology, Stuttgart, Germany; ^3^University Hospital Frankfurt, Department for Children and Adolescents, Frankfurt, Germany; ^4^Humboldt University Berlin‐ Charité Medical Center, Department of Pediatric Oncology/Hematology, Berlin, Germany; ^5^University Medical Center Schleswig‐Holstein‐ Christian‐Albrechts‐University of Kiel, Department of General Pediatrics, Kiel, Germany; ^6^Dr. von Hauner University Children\'s Hospital‐ LMU, Department of Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Munich, Germany*

**Background/Objectives**: Pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have an extremely poor prognosis. Blinatumomab is a bispecific T‐cell engager antibody construct which simultaneously binds CD3‐positive cytotoxic T‐cells and CD19‐positive B‐cells leading to T‐cell‐mediated lysis of normal and malignant B‐cells.

**Design/Methods**: We report a retrospective analysis of our single‐center experience with blinatumomab in 27 patients with relapsed or refractory pediatric B‐cell precursor ALL.

**Results**: The median age at onset of therapy was 8 years (1 to 20 years). Eighty percent of patients had undergone at least one hematopoietic stem cell transplantation (HSCT) prior to therapy with blinatumomab. All but 4 patients received the antibody therapy in a state of open relapse. Despite the high tumor load in most of our patients when starting immunotherapy a total of 8 patients (30%) showed a primary response to blinatumomab, additional 4 of 16 patients (25%) responded after the second cycle. The predominant side effect consisted of febrile reactions in almost all of the patients, nearly half of which were defined as cytokine release syndrome (CRS). The majority of CRS was of low grade and easily manageable. Neurotoxicity was seen in 5 patients (19%) during/after the first and in 4 patients (16%) during the second cycle. To date seven patients (26%) are alive and in remission. Their mean survival is of 48 months (10‐104 months). Blinatumomab enabled transition to HSCT in three of the long‐term survivors. One patient with low blast counts at start of blinatumomab is in remission without HSCT.

**Conclusions**: Despite heavy pretreatment of our patients severe adverse events were rare and response rates encouraging (12/27 patients, 44%). A significant proportion of patients responded to the second treatment cycle. Blinatumomab is a promising new agent for front line treatment and is currently under investigation in pediatric randomized controlled clinical trials.

### PD-014. Rituximab is Highly Effective in Children and Adolescents with Intermediate‐ and High‐Risk Burkitt Lymphoma {#pbc27455-sec-1990}

[Z. Zhen]{.ul} ^1^, J. Zhu^1^, J. Wang^1^, S. Lu^1^, F. Sun^1^, J. Huang^1^, X. Sun^1^

*^1^Sun Yat‐sen University Cancer Center, Pediatric Oncology, Guangzhou, China*

**Background/Objectives**: Data regarding the use of rituximab in children and adolescents with Burkitt lymphoma (BL) is limited. This study retrospectively analyzed the effect of rituximab on children and adolescents with intermediate‐ or high‐risk BL.

**Design/Methods**: Patients underwent chemotherapy according to the revised NHL‐BFM‐95 protocol. Rituximab was administered at the dose of 375 mg/m^2^ on day 0 of each cycle.

**Results**: A total of 106 patients were included. Stratified by the number of doses of rituximab, there were 49, 16, and 41 patients in group 1 (no rituximab), group 2 (1‐3 doses of rituximab) and group 3 (≥4 doses of rituximab), respectively. The 3‐year event‐free survival (EFS) rates were 83.2% ± 5.4%, 81.2% ± 9.8%, and 96.8% ± 3.2% in group 1, group 2 and group 3, respectively. In patients with intermediate‐risk disease, the 3‐year EFS rates were 100% in patients treated with rituximab and 88.2% ± 7.8% in those treated without rituximab. In patients with high‐risk disease, the relapse rates were 18.8%, 21.4% and 3.0% in group 1, group 2 and group 3, respectively (*P* = 0.048).

**Conclusions**: Rituximab is highly effective in children and adolescents with intermediate‐ and high‐risk BL. The optimal number of doses was 4‐6 in patients with high‐risk BL.

### PD-015. PRES in Pediatric ALL Patients Treated According to the Nordic NOPHO ALL‐2008 Protocol {#pbc27455-sec-2000}

[S. Anastasopoulou]{.ul} ^1^, M. Heyman^1^, M.A. Eriksson^1^, R. Niinimäki^2^, I.M. Johansdottir^3^, T. Frandsen^4^, G. Vaitkeviciene^5^, S. Mikkel^6^, Ó.G. Jónsson^7^, A.H. Harila‐Saari^8^, S. Ranta^1^

*^1^Karolinska Institute, Department of Women\'s and Children\'s Health, Stockholm, Sweden; ^2^Oulu University, Department of Children and Adolescents, Oulu, Finland; ^3^Oslo University Hospital, Deparment of Pediatric Hematology/Oncology, Oslo, Norway; ^4^University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^5^Vilnius University Hospital, Department of Pediatrics, Vilnius, Lithuania; ^6^University of Tartu, Department of Hematology and Oncology, Tartu, Estonia; ^7^University of Iceland, Department of Pediatrics, Reykjavík, Iceland; ^8^University of Uppsala, Department of Women\'s and Children\'s Health, Uppsala, Sweden*

**Background/Objectives**: Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity that is increasingly recognized among pediatric patients with acute lymphoblastic leukemia (ALL) and is hypothesized to be triggered by ALL treatments. We aimed to explore the clinical course of PRES in pediatric patients treated according to the Nordic ALL protocol NOPHO ALL‐2008 and identify risk factors for PRES.

**Design/Methods**: Our study group included patients between 1 and 18 years of age at diagnosis of B cell‐precursor (BCP) and T‐cell ALL, between 2008 and 2015 in five Nordic and two Baltic countries. All patients were treated according to NOPHO ALL‐2008. The patients were identified through a unique on‐line registration system and information regarding the detailed phenotype of PRES was collected through a questionnaire focusing on central nervous system toxicities during ALL treatment.

**Results**: PRES was diagnosed in 52/1436 (3,6%) of the patients. The cumulative incidence of PRES at one month was 1,55% (CI 0,5%:1,02 ‐ 95%:2,34) and 3,54% (CI 0,5%:2,69 ‐ 95%:4,64) at one year. Cox regression identified age significant predictor of PRES (HR for a one‐year increase in age 1.09, 95% CI 1,03‐1,15, p=0,001). The risk for T‐cell ALL was higher than BCP ALL (T‐cell HR for T‐cell vs BCP2.869, 95%CI 1.575 -- 5.228, p=0,001). Seizures occured in 44/52 (84,6%) of the patients, hypertension was present in 41/52 (78,8%) patients; encephalopathy was the third most common symptom (33/51, 64.7% of the patients).

**Conclusions**: Seizures, hypertension and encephalopathy are the most common symptoms of PRES in ALL patients treated with the NOPHO ALL‐2008 protocol, which includes high doses methotrexate, vincristine and steroids during the first year of treatment when the incidense of PRES is highest. Further studies are needed to identify the underlying mechanism of PRES in ALL patients as well as the neurocognitive outcome.

### PD-016. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia and High‐Risk Cytogenetics {#pbc27455-sec-2010}

[D. Tomizawa]{.ul} ^1^, M. Yoshida^2^, T. Kondo^3^, T. Miyamura^4^, T. Taga^5^, S. Adachi^6^, K. Koh^7^, M. Noguchi^8^, H. Kakuda^9^, N. Shiba^10^, K. Watanabe^11^, M. Inoue^12^, Y. Hashii^4^, Y. Atsuta^13^, H. Ishida^14^

*^1^National Center for Child Health and Development, Division of Leukemia and Lymphoma‐ Children\'s Cancer Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^3^Kyoto University, Department of Hematology and Oncology, Kyoto, Japan; ^4^Osaka University Graduate School of Medicine, Department of Pediatrics, Osaka, Japan; ^5^Shiga University of Medical Science, Department of Pediatrics, Otsu, Japan; ^6^Kyoto University, Department of Human Health Sciences, Kyoto, Japan; ^7^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^8^National Kyushu Cancer Center, Department of Pediatrics, Fukuoka, Japan; ^9^Chiba Children\'s Hospital, Department of Hematology and Oncology, Chiba, Japan; ^10^Yokohama City University Hospital, Department of Pediatrics, Tokyo, Japan; ^11^Shizuoka Children\'s Hospital, Department of Hematology and Oncology, Shizuoka, Japan; ^12^Osaka Women\'s and Children\'s Hospital, Department of Hematology/Oncology, Osaka, Japan; ^13^Japanese Data Center for Hematopoietic Cell Transplantation, Data center, Nagoya, Japan; ^14^Kyoto City Hospital, Department of Pediatrics, Kyoto, Japan*

**Background/Objectives**: Cytogenetic abnormalities are the most significant prognostic factors in acute myeloid leukemia (AML). It is a standard of care to allocate patients with AML and high‐risk cytogenetic abnormalities (HR‐AML) to allogeneic hematopoietic stem cell transplantation (allo‐HSCT), however, there is a controversy whether allo‐HSCT truly improves outcome of these patients.

**Design/Methods**: Data of 169 children and adolescents (age, 0‐19 years) with HR‐AML who received their first allo‐HSCT in first or second remission between 2000‐2015 were extracted from the nationwide HSCT registry of the Japan Society of Hematopoietic Cell Transplantation. Patients with congenital abnormalities (e.g. Down syndrome), secondary or therapy‐related AML, and/or those lacking cytogenetic data were excluded. HR‐AML was defined as AML with ‐7/7q‐, ‐5/5q‐, complex karyotype, inv(3) or t(3;3), t(6;9)/*DEK‐NUP214*, t(7;12)/*MNX1‐ETV6*, t(4;11)/*KMT2A‐AFF1*, t(6;11)/*KMT2A‐AFDN*, t(10;11)/*KMT2A‐MLLT10*, t(5;11)/*NUP98‐NSD1*, t(9;22)/*BCR‐ABL*, t(16;21)/*FUS‐ERG*, and/or *FLT3*‐ITD. Patients with t(8;21)/*RUNX1‐RUNX1T1* and inv(16) or t(16;16)/*CBFB‐MYH11* were ineligible. Outcome of these patients was retrospectively evaluated.

**Results**: Three‐year event‐free survival (EFS) and overall survival (OS) rates were 55.2% (95%CI, 46.8‐62.9%) and 69.6% (61.4‐76.3%), respectively, for all the 169 HR‐AML patients. In univariate analysis, cytogenetic subgroups had significant impact on both EFS (P=0.011) and OS (P\<0.001) rates. Especially, fourteen patients with t(16;21) showed extremely poor outcome with 3‐year‐ EFS of 26.8% (7.3‐51.5%) and OS of 34.3% (11.6‐58.7%). Additionally, older age at allo‐HSCT (10‐19 years old, P=0.025), myeloablative conditioning with total‐body irradiation (P=0.019), and grade II‐IV acute graft‐versus‐host disease (GVHD, P=0.049) were associated with inferior OS. Donor type and occurrence of chronic GVHD did not affect the outcome. Multivariate analysis revealed t(16;21) to be associated with increased overall mortality (hazard ratio=4.416, P\<0.001).

**Conclusions**: There is heterogeneity on outcome of HR‐AML among cytogenetic subgroups. Because outcome of patients with certain HR‐AML subgroup, such as t(16;21)‐positive cases, is extremely poor even with allo‐HSCT in remission, development of novel therapy is urgently required.

### PD-017. Gemcitabine and Vinorelbine as 3rd Line Chemotherapy for Primary Refractory/Relapsing Hodgkin Lymphoma: Outcome and Toxicity Profile {#pbc27455-sec-2020}

[H. Abdel Rahman Sayed]{.ul} ^1^, A. Hamoda^2^, R. Abdel Aziz^2^, N. El Kinaaie^3^, I. Zaki^4^, E. Mohamed^5^

*^1^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^2^National Cancer Institute‐ Cairo University‐ children Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^3^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Pathology, Cairo, Egypt; ^4^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Radiodiagnosis, Cairo, Egypt; ^5^Chidren Cancer Hospital Egypt, Research, Cairo, Egypt*

**Background/Objectives**: The aim of our study is to report the response rate and toxicity profile of the 3^rd^ line chemotherapy Gemcitabine and Vinorelbine (Gem/Vin) in primary refractory/relapsing HL during 10 years period

**Design/Methods**: A retrospective analysis including all patients who received salvage Gem/Vin following ABVD +/‐ radiotherapy as 1^st^ line, followed by ICE as 2^nd^ line chemotherapy. Patient were diagnosed and treated at the Children Cancer Hospital Egypt.

**Results**: Out of 1145 patients registered, 116 (10.1%) relapsed or had a progressive disease. Ninety‐eight (8.5%) received ICE as second line chemotherapy. Thirty‐six (3.1%) failed second line and received third line. Four patients were excluded from analysis as they received other type of chemotherapy, while 32 (2.7%) patients received Gem/Vin, and were included in our study. They were 21 (65.6%) males, and 11 (34.4%) females. Mean age was 10.71 years, The most common pathologic subtype was nodular sclerosis (62.5%). One (3.1%) patient was stage I, while 6 (18.7%) were stage II, 10 (31.3%) stage III, and 15 (46.9%) stage IV. The majority 21 (65.6%) were high risk patients. Sixteen patients (50%) had late relapse (\> 1 year), 8 (25%) early relapse (3 months‐1 year), and 8 (25%) were progressive/refractory (less than 3 months). Chemotherapy cycles ranged from 1 to 6 with a mean of 3. Thirteen patients (40.6%) were responders to Gem/Vin and underwent autologous hematopoietic stem cell transplantation, while (59.4%) progressed and continued treatment on palliative basis. Eight (25%) patients died, 5 (15.6%) due to disease progression, and 3 (9.3%) out of chemotherapy toxicity. The 2 years overall survival for responding patients was 87.5%, for non‐responders it was 72%. Multivariate analysis included sex, stage, risk stratification, type of relapse, and showed no statistical significant.

**Conclusions**: Gemcitabine and Vinorelbine is safe to be given as 3rd line chemotherapy for relapsing or primary refractory HL.

### PD-018. EBV Infection, Reactivation and Post‐Transplant Lymphoproliferative Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplant {#pbc27455-sec-2030}

[M. Finkbeiner]{.ul} ^1^, V. Lewis^1^, K. Peterson^1^, G. Guilcher^1^, T. Truong^1^

*^1^Alberta Children\'s Hospital, Pediatric Hematology/Oncology/Transplant, Calgary, Canada*

**Background/Objectives**: Epstein Barr Virus (EBV) infection and reactivation are common occurrences after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to determine the overall incidence of EBV reactivation and Post‐Transplant Lymphoproliferative Disease (PTLD) in children.

**Design/Methods**: Retrospective chart review of children who underwent allogeneic HSCT at Alberta Children\'s Hospital in Calgary, Alberta between January 2007 and January 2017.

**Results**: Over a 10‐year period, 162 allogeneic HSCTs in 153 patients were performed for malignant and non‐malignant conditions. The overall incidence of any non‐zero EBV level was 44%. The overall incidence of EBV greater than 20,000 IU/ml was 24% with an incidence of PTLD of 7%. The use of anti‐thymocyte globulin (ATG) in conditioning was significantly associated with high EBV titres. EBV reactivation was associated with the presence of an EBV positive donor but neither the recipient\'s EBV status or the presence of a mismatch in EBV status the donor and the recipient were significant. Patients who received peripheral blood stem cells (PBSCs) had a higher risk of EBV reactivation compared to cord blood or bone marrow but the use of cord blood was protective. On multivariate analysis, the use of ATG and the presence of an EBV positive donor remained significant factors. Of the 10 patients who received treatment for EBV, all had levels greater than 100,000 IU/ml and all received rituximab as part of their therapy. There was no association between EBV reactivation and the development of graft versus host disease (GVHD), graft failure or death.

**Conclusions**: EBV reactivation is common in children who have undergone allogeneic HSCT with an overall incidence of greater than 20,000 IU/ml of 24%. It was statistically associated with the use of ATG, an EBV positive donor and the use of PBSCs. The development of features of PTLD was uncommon and treatment was initiated at the onset of symptoms.

Poster Discussion Session 04: Solid and CNS Tumours: Clinical {#pbc27455-sec-2040}
-------------------------------------------------------------

### PD-019. New Insights into Diagnosis and Therapeutic Options for Proliferative Hepatoblastoma {#pbc27455-sec-2050}

[C. Grosset]{.ul} ^1^

*^1^Université de Bordeaux Inserm‐, BMGIC‐ U1035, Bordeaux, France*

**Background/Objectives**: Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70‐80% of patients. However, some important challenges remain in diagnosing high risk tumors and identifying relevant targetable pathways offering new therapeutic avenues. Previously, two molecular subclasses of hepatoblastoma tumors have been described, namely C1 and C2; C2 being the subgroup with the poorest prognosis, a more advanced tumor stage and the worst overall survival rate. An associated 16‐gene signature to discriminate the two tumoral subgroups was proposed but it has not been transferred into clinical routine.

**Design/Methods**: To address these issues we performed RNA sequencing of 25 tumors and matched normal liver samples from patients.

**Results**: The transcript profiling separated HB into three distinct subgroups named C1, C2A and C2B, identifiable by a concise four‐gene signature: HSD17B6, ITGA6, TOP2A and VIM, with TOP2A being characteristic for the proliferative C2A tumors. Differential expression of these genes was confirmed by RT‐qPCR on an expanded cohort and by immunohistochemistry. We also revealed significant overexpression of genes involved in Fanconi Anemia (FA) pathway in the C2A subgroup. We then investigated the ability of several described FA inhibitors to block grow of HB cells in vitro and in vivo. We demonstrated that bortezomib, an FDA‐approved proteasome inhibitor, strongly impairs the proliferation and survival of HB cell lines in vitro, blocks FA pathway associated double‐strand DNA repair and significantly impedes HB growth in vivo.

**Conclusions**: In conclusion, the highly proliferating C2A subtype is characterized by TOP2A gene up‐regulation and FA pathway activation and HB therapeutic arsenal could include Bortezomib for the treatment of patients with the most aggressive tumors.

### PD-020. Impact of Radiological Caracteristic of Lung Nodules on Survival in Children With Metastatic Hepatoblastoma {#pbc27455-sec-2060}

[F. Neumann]{.ul} ^1^, D. Pariente^2^, L. Brugieres^3^, B. Fresneau^3^, M. Fabre^4^, C. Guettier^5^, S. Branchereau^6^, B. Mallon^3^, V. Laithier^1^

*^1^University Hospital Besançon, Pediatric Oncology Departement, Besançon, France; ^2^AP‐HP Kremlin Bicêtre Hospital, Pediatric radiology departement, Le Kremelin Bicêtre, France; ^3^Gustave Roussy Cancer Campus, Department of Oncology for Children and Adolescents‐, Villejuif, France; ^4^Hôpital Necker, Departement of pathology, Paris, France; ^5^AP‐HP Kremlin Bicêtre Hospital, Departement of Pathology, Le Kremelin Bicêtre, France; ^6^AP‐HP Kremlin Bicêtre Hospital, Pediatric surgery departement, Le Kremelin Bicêtre, France*

**Background/Objectives**: The aim of the study was to assess the prognostic of the radiological characteristic of lung nodules in children with metastatic hepatoblastoma (HB).

**Design/Methods**: Between 2000 and 2015, patients who were treated in France and included in a central database « HEPATOBIO » were eligible for this study. Pulmonary tomography scans and were centrally reviewed at diagnostic and information about number, size, laterality and evolution under treatment were collected. Data about histopathology, chemotherapy regimen were recorded. Overall survival (OS) and 3‐years event free survival (EFS) were analyzed in univariate analysis.

**Results**: During the period, 26 patients with metastatic HB were included. Patients were treated in SIOPEL‐3 (42.3%) and SIOPEL‐4 studies(57.7%). Overall survival (OS) and 3‐years event free survival (EFS) were 76.4% and 67.8% respectively. Patients with less than 5 nodules had increased 3‐years EFS of 85.3% (CI 95% 52.3‐96.1%) and OS of 90.0 % (CI 95%; 47.3‐98.5%) vs 50.0% (CI 95% 20.5‐73.6%) and 47,3% (CI 17.6‐71.,8%) in patients with 5 or more nodules (p=0.017 and p=0.006 for EFS and OS respectively). Patients with nodules \<5mm had a 3‐year EFS and OS of 100% vs 3‐years EFS of 47.9% (CI 95% 21.1‐70.7%) and OS of 50.7% (CI 95% 20.6‐74.7%) (p= 0.01 and p=0.02 for EFS and OS respectively). Patients with bilateral nodules had EFS of 61.4% (CI 95% 37.0‐79.4%) and OS of 64.8% (IC95 % 39.0‐81.8%) whereas patients with unilateral lesions had a 3‐year EFS and OS of 100%.

**Conclusions**: Children with metastatic HB have a poor prognosis but various presentations of diseases seems to exist among them. Patients with light metastatic diseases had a better prognosis. Treatment intensity could be adapted regarding to the burden of metastatic disease to limit the toxity and long term side‐effects. Multivariate analysis must be performed to confirm these results.

The authors thanks HEPATOBIO database scientific committee.

### PD-021. A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma {#pbc27455-sec-2070}

[S. Ackermann]{.ul} ^1^, M. Cartolano^2^, B. Hero^3^, A. Roderwieser^1^, C. Bartenhagen^1^, C. Rosswog^1^, F. Hertwig^4^, T. Simon^3^, A. Eggert^4^, F. Speleman^5^, R. Buettner^6^, R. O\'Sullivan^7^, R. Thomas^2^, F. Berthold^3^, J. Vandesompele^5^, A. Schramm^8^, F. Westermann^9^, J. Schulte^4^, M. Peifer^2^, M. Fischer^1^

*^1^University Hospital of Cologne, Experimental Pediatric Oncology, Cologne, Germany; ^2^University of Cologne, Translational Genomics, Cologne, Germany; ^3^University Hospital of Cologne, Pediatric Oncology and Hematology, Cologne, Germany; ^4^Charité, Pediatric Oncology and Hematology, Berlin, Germany; ^5^Ghent University, Center for Medical Genetics, Ghent, Belgium; ^6^University of Cologne, Department of Pathology, Cologne, Germany; ^7^University of Pittsburgh Cancer Institute UPCI, Pharmacology and Chemical Biology, Pittsburgh, USA; ^8^University of Duisburg‐Essen, Department of Medical Oncology, Essen, Germany; ^9^German Cancer Research Center, Neuroblastoma Genomics B087, Heidelberg, Germany*

**Background/Objectives**: Recent genomic and transcriptomic profiling studies of neuroblastoma have shed light on cancer gene mutations frequencies, structural genomic rearrangements and copy number alterations in this tumor type. However, none of these had been able to convert the data into a coherent model that explains the pathogenesis of the divergent subtypes and can separate those cases in which spontaneous regression occurs from those whose disease progresses.

**Design/Methods**: To determine the molecular basis of favorable and adverse disease courses, we performed massively parallel sequencing of 416 untreated neuroblastomas (whole‐genome or whole‐exome sequencing, n=218; targeted sequencing, n=198) and determined telomere maintenance mechanisms in 208/416 cases. In addition, we performed targeted sequencing of 63 neuroblastoma relapse samples.

**Results**: We detected genomic alterations of 17 genes related to the RAS and p53 pathways in 74/416 patients (17.8%). The presence of these mutations was strongly associated with dismal outcome in the entire cohort, as well as in the high‐risk and non‐high‐risk subgroups. In relapsed neuroblastoma, the frequency of such mutations increased to 36.5% (23/63 samples). We noticed, however, that the prognostic effect of RAS/p53 pathway mutations was strictly dependent on the occurrence of telomere maintenance mechanisms. Survival of patients whose tumors were telomere maintenance‐positive was dramatically inferior when additional RAS/p53 pathway mutations were present as compared to those without such alterations. By contrast, patients whose tumors lacked telomere maintenance mechanisms had excellent outcome, and spontaneous regression or differentiation occurred both in the presence and absence of RAS/p53 pathway mutations.

**Conclusions**: Together, our data suggest a precise mechanistic definition of clinical neuroblastoma phenotypes that is based on the presence or absence of telomere maintenance and RAS or p53 pathway mutations, and provide a starting point for improving diagnostic and therapeutic management of neuroblastoma patients.

### PD-022. Neonatal Suprarenal Masses: An Observational Approach {#pbc27455-sec-2080}

V. Papadakis^1^, M. Conte^2^, D. Plantaz^3^, V. Segura^4^, S. Ash^5^, B. Brichard^6^, R. Ladenstein^7^, V. Combaret^8^, A. Di Cataldo^9^, G. Schleiermacher^10^, K. Wheeler^11^, J. Bermúdez^12^, [A. Cañete]{.ul} ^4^

*^1^Aghia Sophia Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^2^Giannina Gaslini Children\'s Hospital, Department of Hematology‐Oncology, Genoa, Italy; ^3^Hôpital Michallon, Département de pédiatrie, Grenoble, France; ^4^University and Polytechnic la Fe Hospital, Pediatric Oncology Department, Valencia, Spain; ^5^Schneider Children\'s Medical Center, Hematology‐Oncology Department, Tel‐Aviv, Israel; ^6^Cliniques Universitaires Saint Luc, Hématologie et Oncologie Pédiatrique, Bruxelles, Belgium; ^7^Children\'s Cancer Research Institute/ St Anna Children\'s Hospital, Unit S2IRP Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^8^Centre Léon Bérard, Laboratoire de Recherche translationnelle, Lyon Cedex, France; ^9^University of Catania, Pediatric Hematology and Oncology, Catania, Italy; ^10^Institute Curie, Laboratoire de Génétique et Biologie des Cancer, Paris, France; ^11^Oxford Children\'s Hospital, Department of Paediatric Haematology and Oncology, Oxford, United Kingdom; ^12^University of Valencia, Department of Statistics, Valencia, Spain*

**Background/Objectives**: The differential diagnosis of neonatal suprarenal masses ranges from benign (adrenal haemorrhage) to malignant (neuroblastoma, adrenal carcinoma). The optimal management is not clearly defined. Neuroblastoma at this age is an intriguing entity, carrying very good prognosis in most cases. SIOPEN (International Society of Paediatric Oncology European Neuroblastoma), launched this study (Low‐Intermediate Risk Neuroblastoma Study, <http://www.ClinicalTrials.org>:NCT01728155). Primary aim was to maintain 3‐year EFS over 80%, with a non‐operative initial approach for infants with small localized suprarenal masses.

**Design/Methods**: A single multicenter prospective study of infants \<90 days with mass \<5cm, and no regional or metastatic involvement was undertaken. Initial work up included urinary catecholamines, imaging (US and/or MRI), MIGB scintigraphy and MYCN analysis in sera. Infants were monitored during the first year. If the mass increased in volume or/and catecholamine excretion increased, observation stopped and surgery was performed. If a mass persisted after 12 months, an excision of the mass was recommended.

**Results**: A cohort of 128 infants was registered: median age 3 days (range 0‐87), 38.6% female. Masses were described as cystic (29.1%), solid (34.2%) or mixed (32.9%). Antenatal diagnosis had been made in 55 cases. Thirty‐seven patients underwent resection: 17 during observation and 20 at the end of the observation period, 26 proved to be neuroblastoma. Two surgical complications included hemorrhage and renal ischemia, without fatality. MIGB was done to 70 patients and only 55 received thyroid protection despite protocol guidelines. The 1 and 3‐year EFS was 89.5% and 88% respectively and OS was 100%, with a median follow‐up of 30.4 months. Fifteen events were observed: progression to MS (n=5) or L1/L2 tumors (n=10).

**Conclusions**: An observational approach for infants with localized suprarenal masses \<5cm discovered antenatally or neonatally (suspected neuroblastoma) proved safe and most patients avoided surgery. Close monitoring was effective and did not jeopardize overall outcome.

### PD-023. Low Concordance Between Surgical and Radiological Assessment of Degree of Resection and Treatment‐Related Hypothalamic Damage: Results of KRANIOPHARYNGEOM 2007 {#pbc27455-sec-2090}

[H.L. Müller]{.ul} ^1^, J. Reichel^1^, S. Boekhoff^1^, M. Warmuth‐Metz^2^, M. Eveslage^3^, J. Peng^4^, J. Flitsch^5^

*^1^Klinikum Oldenburg AöR‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^2^Universitätsklinikum Würzburg, Department of Neuroradiology, Würzburg, Germany; ^3^University of Münster, Institute of Biostatistics and Clinical Research, Muenster, Germany; ^4^Nanfang Hospital‐ Southern Medical University, Department of Neurosurgery, Guangzhou, China; ^5^University Hospital Hamburg‐Eppendorf UKE, Department of Neurosurgery, Hamburg, Germany*

**Background/Objectives**: Assessment of presurgical hypothalamic involvement (psHI) and treatment‐related hypothalamic damage (trHD) is relevant for the decision on risk‐adapted treatment and rehabilitation strategies in craniopharyngioma.

**Design/Methods**: 129 surgical reports of childhood‐onset craniopharyngioma patients recruited 2007‐2014 in KRANIOPHARYNGEOM 2007 were analyzed. Data on psHI were available based on surgeon\'s (63%), reference neuroradiologist\'s (95%), and local radiologist\'s (23%) assessment. The surgical degree of resection (DoR) was assessed by neurosurgeon (95%), reference neuroradiologist (73%), and local radiologist (61%). TrHD was assessed by neurosurgeon (33%), by reference neuroradiologist (95%), and by local radiologist (2%). Neurosurgical center size was categorized based on patient load.

**Results**: Surgical assessments on psHI (n=78), DoR (n=89) and trHD (n=42) as documented in surgical reports could be compared with the assessment of respective parameters by reference neuroradiologist. Differences with regard to DoR (p=0.0001) and trHD (p\<0.0001) were detectable between surgeon\'s and reference neuroradiologist\'s assessment, whereas psHI was assessed similarly. Concordance for DoR and trHD was observed in 48% and 62%, respectively. Surgeons estimated a higher rate of complete resections and a lower rate of trHD. Neuroradiological reference assessment of trHD had higher predictive value for hypothalamic sequelae then surgical assessment. Observed differences were not related to neurosurgical center size.

**Conclusions**: Observed differences between surgical and neuroradiological estimation of risk factors in craniopharyngioma support the necessity of neuroradiological reference review to assure standards of quality. This could be established by central internet‐based neuroradiological review in KRANIOPHARYNGEOM 2007. Standardization of surgical reports including specific assessment of tumor/damage location is recommended.

### PD-024. Intracranial Growing Teratoma Syndrome: An International Retrospective Study {#pbc27455-sec-2100}

[G. Michaiel]{.ul} ^1^, N. Gottardo^2^, U. Bartels^3^, H. Coltin^4^, J. Hukin^5^, B. Wilson^6^, S. Zelcer^7^, J.R. Hansford^8^, M.S. AbdelBaki^9^, K.A. Cole^10^, G. Dhall^11^, L. Hoffman^12^, N.P. Smiley^13^, A. Smith^14^, A. Vinitsky^15^, N.A. Vitanza^16^, A. Wright^17^, K.K. Yeo^18^, E. Bouffet^3^, L. Lafay‐Cousin^1^

*^1^Alberta Children\'s Hospital, Section of Pediatric Hematology‐ Oncology‐ and BMT, Calgary‐ AB, Canada; ^2^Princess Margaret Hospital for Children, Pediatric Oncology and Hematology, Perth, Australia; ^3^The Hospital for Sick Children, Division of Hematology/Oncology, Toronto‐ ON, Canada; ^4^Children\'s Hospital of Eastern Ontario, Division of Hematology/Oncology, Ottawa‐ ON, Canada; ^5^British Columbia Children\'s Hospital, Division of Neurology and Oncology, Vancouver‐ BC, Canada; ^6^Stollery Children\'s Hospital, Division of Immunology‐ Hematology‐ Oncology & Palliative Care, Edmonton‐ AB, Canada; ^7^London Health Sciences Centre, Pediatric Oncology, London‐ ON, Canada; ^8^Royal Children\'s Hospital‐ Murdoch Children\'s Research Institute, Solid and Brain Tumour Division, Melbourne, Australia; ^9^Nationwide Children\'s Hospital, Hematology/Oncology & BMT, Columbus‐ OH, USA; ^10^Children\'s Hospital of Philadelphia, Pediatric Neuro‐Oncology Program, Philadelphia‐ PA, USA; ^11^Children\'s Hospital Los Angeles, Children\'s Center for Cancer and Blood Diseases, Los Angeles‐ CA, USA; ^12^Children\'s Hospital Colorado, Pediatric Hematology‐Oncology, Aurora‐ CO, USA; ^13^Ann & Robert H. Lurie Children\'s Hospital of Chicago, Hematology‐ Oncology‐ and Stem Cell Transplantation, Chicago‐ IL, USA; ^14^Arnold Palmer Hospital for Children, Pediatric Hematology‐Oncology, Orlando‐ FL, USA; ^15^St. Jude Children\'s Research Hospital, Department of Oncology, Memphis‐ TN, USA; ^16^Seattle Children\'s Hospital, Division of Hematology/Oncology, Seattle‐ WA, USA; ^17^Lucile Packard Children\'s Hospital Stanford, Pediatric Hematology & Oncology, Stanford‐ CA, USA; ^18^Children\'s Hospital Los Angeles, Children\'s Center for Cancer and Blood Diseases, Los Angeles‐ CA, USA*

**Background/Objectives**: Intracranial growing teratoma syndrome (IGTS) is a rare phenomenon of paradoxical germ cell tumor (GCT) growth during or following treatment despite normalization of tumor markers. We sought to evaluate the frequency, clinical characteristics and outcome of IGTS in patients in 21 North‐American and Australian institutions.

**Design/Methods**: Patients with IGTS diagnosed from 2000‐2017 were retrospectively evaluated.

**Results**: Out of 739 GCT diagnoses, IGTS was identified in 33 patients (4.5%). IGTS occurred in 9/191 (4.7%) mixed‐malignant GCTs, 4/22 (18.2%) immature teratomas (ITs), 3/472 (0.6%) germinomas/germinomas with mature teratoma, and in 17 secreting non‐biopsied tumours. Median age at GCT diagnosis was 10.9 years (range 1.8‐19.4). Male gender (84%) and pineal location (88%) predominated. Of 27 patients with elevated markers, median serum AFP and ßHCG were 70 ng/mL (range 9.2‐932) and 44 IU/L (range 4.2‐493), respectively. IGTS occurred at a median time of 2 months (range 0.5‐32) from diagnosis, during chemotherapy in 85%, radiation in 3%, and after treatment completion in 12%. Surgical resection was attempted in all, leading to gross total resection in 76%. Most patients (79%) resumed GCT chemotherapy/radiation after surgery. At a median follow‐up of 5.3 years (range 0.3‐12), all but 2 patients are alive (1 succumbed to progressive disease, 1 to malignant transformation of GCT).

**Conclusions**: IGTS occurred in less than 5% of patients with GCT and most commonly after initiation of chemotherapy. IGTS was more common in patients with IT‐only on biopsy than with mixed‐malignant GCT. Surgical resection is a principal treatment modality. Survival outcomes for patients who developed IGTS are favourable.
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### PD-025. Prognostic Significance of Chromosome Abnormalities in Wilms Tumor may be Causally Related to Upregulation or Downregulation of Genes on Extra Chromosomes or Lost Chromosome Arms {#pbc27455-sec-2120}

[Y. Kaneko]{.ul} ^1^, M. Haruta^1^, Y. Arai^2^, R.P. Sugino^1^, T. Kamijo^1^, H. Okita^3^, Y. Tanaka^4^, T. Takimoto^5^, T. Oue^6^, M. Nozaki^7^, M. Chin^8^, M. Fukuzawa^9^, T. Koshinaga^10^

*^1^Saitama Cancer Center, Research Institute for Clinical Oncology, Ina, Japan; ^2^National Cancer Center Research Institute, Cancer Genomics Division, Tokyo, Japan; ^3^Keio University, Department of Pathology, Tokyo, Japan; ^4^Kanagawa Children\'s Medical Center, Department of Pathology, Yokohama, Japan; ^5^National Center for Child Health and Development, Research Institute, Tokyo, Japan; ^6^Hyogo College of Medicine, Department of Pediatric Surgery, Nishinomiya, Japan; ^7^Dokkyo Medical University, Department of Radiology, Koshigaya, Japan; ^8^Nihon University School of Medicine, Department of Pediatrics, Tokyo, Japan; ^9^Osaka Medical Center and Research Institute for Maternal and Child Health, Department of Pediatric Surgery, Izumi, Japan; ^10^Nihon University School of Medicine, Department of Pediatric Surgery, Tokyo, Japan*

**Background/Objectives**: Overall survival (OS) rates of patients with Wilms tumor (WT) have reached to 90%. Biomarkers which predict favorable or unfavorable outcomes are needed to improve OS rates further and to avoid adverse late effects,

**Design/Methods**: We analyzed array CGH (aCGH) pattern and mutations of *WT1* and 7 other genes in 129 unilateral WTs. Patients were classified according to aCGH or genetic alterations, and each alteration was correlated with relapse‐free survival (RFS) and OS rates. Expression microarray analysis was performed in 27 WTs. Upregulated genes on a specific chromosome, which is duplicated in some WTs, and downregulated genes on a specific chromosome arm, which is lost in some other WTs were determined. Correlation between overexpression of each upregulated gene or under‐expression of each downregulated gene and favorable or unfavorable OS was determined using r2 database.

**Results**: Thirty‐one patients had *WT1* alterations in tumors (RFS 83%; *WT1* type), 20 had no aCGH aberrations (RFS 95%; silent type), and 78 had aCGH changes without *WT1* alterations (non‐*WT1*/non‐silent type). When 78 patients were classified into those with presence or absence of +12, 11q‐, 16q‐, or *HACE1* loss, RFS was better for those with +12 than those without (RFS: *P*=.027), and worse for those with 11q‐, 16q‐, or *HACE1* loss than those without (RFS: *P*=.008, .038, or 3.7E‐04). Of 27 WTs examined, 146 genes on chromosome 12 were upregulated in +12 tumors compared to no +12 tumors, and 10 genes on 16q were downregulated in 16q‐ tumors compared to no 16q‐ tumors. Overexpression in 75 of the 146 upregulated genes and under‐expression in 4 of the 10 downregulated genes were correlated with better and worse OS in patients with WT, respectively.

**Conclusions**: Prognostic significance of chromosome abnormalities may be causally related to upregulation of genes on extra chromosomes, and downregulation of genes on deleted chromosome arm regions.

### PD-026. Tumor Marker Surveillance Alone without Radiographic Imaging for Early Detection of Relapse in Extracranial Solid Tumors of Children, Adolescents and Young Adults {#pbc27455-sec-2130}

[R. Shah]{.ul} ^1^, A. Senerchia^2^, K. Mascarenhas^2^, J. Malvar^2^, R. Sposto^3^, A. Sapra^4^, L. Mascarenhas^1^

*^1^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation‐ Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Department of Pediatrics‐ Keck School of Medicine‐ University of Southern California, Los Angeles, USA; ^2^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation, Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Los Angeles, USA; ^3^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation‐ Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Department of Research‐ Preventive Medicine and Pediatrics‐ Keck School of Medicine‐ University of Southern California, Los Angeles, USA; ^4^Children\'s Hospital Los Angeles, Department of Radiology, Los Angeles, USA*

**Background/Objectives**: Standard surveillance for early detection of relapse in extracranial solid tumors (EST), with elevated tumor markers (TMs) at diagnosis, includes TM monitoring and serial radiographic imaging. Given the high sensitivity of TMs for detection of relapse, the role of radiographic imaging is debated in patients with EST.

**Design/Methods**: Retrospective chart review of newly diagnosed patients with EST and elevated pre‐treatment TMs between 2002‐2012.

**Results**: Ninety‐four patients (62 males, age range 0.25‐19 years) were included with a median follow‐up of 6.2 years; Hepatoblastoma (HB)=49, Hepatocellular Carcinoma (HCC)=7, Malignant Germ Cell Tumor (GCT)=38. Median serum alpha‐fetoprotein (AFP) at diagnosis was 198,000 ng/mL, 9270 ng/mL and 283 ng/mL for HB, HCC and GCT respectively. Median beta‐human chorionic gonadotropin (β‐hCG) at diagnosis in GCT was 65.46mIU/L. Fourteen patients experienced a confirmed relapse. In 13 patients, the TM elevation preceded radiographic detection of relapse. In one patient with HCC, TMs never normalized and disease progression was detected on radiographic imaging prior to a rise in serum AFP. The mean time from TM elevation to radiographic detection of relapse was 125.7 days. The total number of radiographic imaging studies performed were 2858; chest X‐ray=1386, computed tomography (CT) chest with contrast=694, CT abdomen/pelvis with contrast=666, magnetic resonance imaging abdomen/pelvis=73 and radionuclide bone scan=39. The total number of AFP and β‐hCG assays performed were 2392 and 771 respectively. Based on the 2017 Medicare fee schedule, the total TM costs were \$238,050 and the radiographic imaging costs were \$5,963,126. Thus, the omission of routine radiographic surveillance in our patient cohort could have potentially resulted in a mean costs savings of \$61,560.

**Conclusions**: TM assessment, without radiographic imaging, is adequate for disease surveillance in patients with EST and elevated TMs at diagnosis that normalize at the end of primary treatment. Surveillance with TMs alone will reduce both radiation exposure and health care costs.

### PD-027. Somatic TP53 Mutations Are Detectable in Circulating Tumour DNA from Children with Anaplastic Wilms Tumours {#pbc27455-sec-2140}

[T. Treger]{.ul} ^1^, T. Chagtai^2^, R. Butcher^3^, G. Cresswell^4^, R. Al‐Saadi^2^, C. Roberts^3^, R. Williams^2^, J. Brok^5^, N. Luscombe^4^, K. Pritchard Jones^5^, W. Mifsud^6^

*^1^UCL Great Ormond Street Institute of Child Health‐ The Francis Crick Institute, Developmental Biology and Cancer‐ Bioinformatics and Computational Biology Laboratory, London, United Kingdom; ^2^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer, London, United Kingdom; ^3^London School of Hygiene & Tropical Medicine, Clinical Research Department‐ Faculty of Infectious and Tropical Diseases, London, United Kingdom; ^4^The Francis Crick Institute, Bioinformatics and Computational Biology Laboratory, London, United Kingdom; ^5^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer‐ Department of Paediatric Haematology and Oncology, London, United Kingdom; ^6^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer‐ Department of Histopathology, London, United Kingdom*

**Background/Objectives**: Diffuse anaplastic Wilms tumour (DAWT) is a rare, high‐risk subtype that is often missed on needle biopsy. Somatic *TP53* mutations are found in approximately 60% of cases and have been associated with poorer survival, particularly in advanced stage disease. Detection of circulating *TP53* could aid earlier diagnosis of anaplastic tumours when pre‐operative chemotherapy is commenced without histological confirmation, the standard management for childhood renal tumours in countries that follow SIOP guidelines.

**Design/Methods**: All patients with a diagnosis of WT were enrolled in the UK‐wide IMPORT study. Patients were treated according to SIOP WT 2001. Normal kidney and multi‐sampled tumour tissue were collected at surgery, whilst blood and urine were collected at up to five treatment time points. We assessed *TP53* status in frozen tumour, matched germline DNA and circulating tumour DNA (ctDNA) from plasma, serum and urine. In 10 patients with DAWT, *TP53* status was determined with Sanger and targeted sequencing. Droplet digital Polymerase Chain Reaction (ddPCR) was then employed to evaluate 21 ctDNA samples from 4 patients with DAWT and variant *TP53*.

**Results**: Mutant *TP53* was detectable in ctDNA from plasma and serum in all patients. We did not detect variant *TP53* in the same volume (200 μL) of urine. One patient displayed heterogeneity of *TP53* in the tumour, despite both sections displaying anaplastic histology. Concentration of ctDNA from plasma/serum taken pre‐nephrectomy varied significantly between patients, ranging from 0.44 (0.05‐0.90) to 125.25 (109.75 -- 140.25) copies/μL. We observed variation in ctDNA throughout treatment and in all but one patient, who relapsed 339 days post‐operatively, ctDNA levels fell following nephrectomy.

**Conclusions**: Our results are the first to demonstrate that ddPCR is an effective method for detection of mutant *TP53* in ctDNA from children with WT, even when there is intra‐tumoral somatic heterogeneity or low burden disease.

### PD-028. Novel STAT3 Inhibitors from the In‐House Library Targeted to Retinoblastoma {#pbc27455-sec-2150}
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**Background/Objectives**: STAT3 is known to be highly expressed in retinoblastoma tumors. We previously reported that STAT3 inhibition could be a treatment option for retinoblastoma via down‐regulation of the miR‐17‐92 cluster. In this study, we investigated the therapeutic potential of STAT3 inhibitors from a library of 27 different derivatives with a Michael acceptor for the treatment of retinoblastoma.

**Design/Methods**: SNUOT‐Rb1 and Y79 cells from 2 different retinoblastoma cell lines were treated with STAT3 inhibitors from a library of 27 derivates to screen the cellular toxicity. The level of STAT3 phosphorylation was estimated by the enzyme‐linked immunosorbent assay and the expression levels of target genes of STAT3 was measured by quantitative real‐time polymerase chain reaction upon the treatment with STAT3 inhibitors. From a library of 27 STAT3 inhibitors, the 2 most potent STAT3 inhibitors were selected from aforementioned assays. Then, using the mouse orthotopic transplantation model, *in vivo* therapeutic efficacy of them was evaluated. The toxicity of STAT3 inhibitors on normal retinal tissues was estimated with histologic evaluation and the terminal deoxynucleotidyl transferase dUTP nick end labeling assay.

**Results**: 27 different derivatives demonstrated differential cellular toxicity, STAT3 phosphorylation, and expression of target genes. The 2 most potent STAT3 inhibitors effectively inhibited the formation of retinoblastoma tumors in the mouse orthotopic transplantation model. Despite their therapeutic efficacy, these STAT3 inhibitors did not significantly affect the cellular viability and histologic integrity of the retina even at 10 times the therapeutic concentration.

**Conclusions**: Novel STAT3 inhibitors identified from screening of an in‐house library of chemicals demonstrated potent *in vitro* and *in vivo* therapeutic efficacy without definite toxicity on normal tissues. We expect that these STAT3 inhibitors can be utilized for the treatment of retinoblastoma.

### PD-029. Targeting RRM2 in 3D Tumor Organoid Models of High Risk Hepatoblastoma {#pbc27455-sec-2160}

[L. Zhu]{.ul} ^1^, L. Li^1^, M. Qian^1^, L. Hamel^1^, D. Lopez‐Terrada^2^
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**Background/Objectives**: Hepatoblastoma (HB) is the most common liver cancer and the fastest‐growing cancer in children. Prognosis for children with metastatic and recurrent HB remains dismal over the past few decades. Previous studies have demonstrated that metastasis‐ or relapse‐initiating cells often hijack normal stem cell pathways to gain survival and growth advantages. Recent advances in 3D stem cell culture provide a means to rapidly select and propagate cancer cells with strong stemness properties for in‐depth biological analysis and therapeutic testing.

**Design/Methods**: HB organoid models were established from mouse and human tumors via 3D stem cell culture and their in vivo tumorigenicity was determined via liver orthotopic transplantation in mice. We then conduced a large comparative RNA‐seq profiling to identify genes commonly dysregulated in metastatic HB tumors and organoids compared to their non‐aggressive counterparts. The biological functions and therapeutic values of the top candidate genes are being determined via the impact of their molecular manipulation on HB cell growth, invasion, metastasis and drug response in vitro and in vivo.

**Results**: Multiple HB organoid models displayed potent in vivo tumorigenicity, driving rapid invasion and multi‐organ metastasis upon orthotopic transplantation. RNA‐seq profiling identified a small number of genes significantly upregulated in aggressive HB tumors and organoids. Among them is RRM2, an enzyme catalyzing the formation of deoxyribonucleotides from ribonucleotides that is essential to DNA replication and repair. Further analysis revealed a significant association between *RRM2* expression and the prognosis of HB patients, making it a promising therapeutic target for high risk HB. Studies are currently ongoing to reveal the effects of biological and pharmacological inhibition of RRM2 on HB growth and metastasis both in vitro and in vivo.

**Conclusions**: 3D organoid‐based approach represents a unique strategy to model high risk HB and a powerful research platform for the identification of novel disease mechanisms and drug targets.

### PD-030. ATM/Chk2/p53 Pathway Inactivation is Required for ATRX‐Mutation‐Related Tumorigenesis {#pbc27455-sec-2170}

[J. Akter]{.ul} ^1^, Y. Katai^1^, S. Parvin^1^, H. Takenobu^1^, R. Okada^1^, M. Haruta^1^, R. Sugino^1^, M. Ohira^1^, T. Kamijo^1^

*^1^Research Institute for Clinical Oncology‐ Saitama Cancer Center, Clinical Oncology, Saitama, Japan*

**Background/Objectives**: Neuroblastoma (NB) is the most common pediatric tumor and accounts for 9‐15 % cancer‐related deaths in children. The chromatin remodeling factor *ATRX* is a tumor suppressor gene, and its recurrent somatic mutations associated with stage 4 NB patients. But the precise mechanisms by which *ATRX* mutation related with the NB tumorigenesis and aggressiveness remain to be elucidated. Here, we demonstrate that ATRX‐knockout (KO) induces ATM/p53 dependent DNA damage response in NB cells.

**Design/Methods**: *ATRX* KO *clones established* in *MYCN* amplified (NGP) and single copy (NB‐69) NB cells using CRISPR‐Cas9 technology. Cell proliferation was detected by WST assay. Microarray‐based expression analysis of *ATRX* KO clones was performed by Agilent 8x60K oligonucleotide microarrays. Gene Set Enrichment Analysis (GSEA) was used to analyze the differential‐expression data. p53 inactivation was done by lentiviral mutant p53 transduction. ATM signaling pathway was studied by western‐blot analysis.

**Results**: Herein, several *ATRX* KO clones were established in both NB cell lines. Interestingly, the clones proliferate slowly compared to control and become differentiated. Our, GSEA analysis of microarray data indicated that gene‐set related to DNA double‐strand break repair, DNA damage response, negative cell cycle regulation, G2M checkpoint and, p53 pathway activation were induced in *ATRX* KO cells. By *in vitro* analysis, ATRX loss results in increased expression of phosphorylated histone variant H2AX (gamma‐H2AX), a canonical marker for double‐stranded breaks, indicating the accumulation of endogenous DNA damage in *ATRX* KO cells. Furthermore, accumulation of DNA damage results in activation of the ATM/Chk2/p53 pathway, leading to cell cycle arrest. Moreover, lentiviral‐mediated inactivation of p53 rescued the decreased cell growth levels in *ATRX* KO cells. We also studied the correlation between *ATRX*‐mutation and ATM/p53 pathway inactivation by multiomics database analysis.

**Conclusions**: Taken together, these findings suggest that ATRX plays a role in maintaining DNA integrity and ATM/Chk2/p53 pathway inactivation is required for NB tumorigenesis.
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### PD-031. Pediatric Cancer Families\' Participation in Whole Genome Sequencing Research in Denmark: Parent Perspectives {#pbc27455-sec-2190}
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**Background/Objectives**: We examined parent perspectives on participating in Whole Genome Sequencing (WGS) research in the weeks following a cancer diagnosis.

**Design/Methods**: As an embedded part of the project STAGING (Sequencing of Tumor And Germline DNA -- Implications for National Guidelines), a qualitative parent perspective study was conducted by a physician and an anthropologist to document the pragmatic, social, and ethical dilemmas faced by families when deciding on participation in pediatric WGS research. Following genetic counselling, systematic debriefings were held between the anthropologist and the physician. The anthropologist subsequently carried out semi‐structured, in‐depth parent interviews (N=30 parents to 15 patients). Interviews were transcribed verbatim. Debriefings and interviews were read and thematically analyzed by the anthropologist and physician separately, followed by meetings for consensus on key themes.

**Results**: Parents were approached 2‐28 days after diagnosis. The majority reported that an early approach had been acceptable for them, although one family stated it was too early. Participation in STAGING was explained in terms of altruism and a desire to learn why their child had developed cancer. Most parents requested full feedback on genomic findings, although some described being torn between wanting to receive cancer and other disease predisposition findings and worrying that they would become patients‐in‐waiting. A small minority wanted as little information returned as possible. Some parents openly disagreed about the amount of information they wanted reported back, but following family deliberations reached a consensus (a precondition for participation in STAGING).

**Conclusions**: Parents of newly diagnosed childhood cancer patients articulated numerous dilemmas arising from participation in WGS research. Enrollment at diagnosis is feasible however flexibility from researchers is essential. Notwithstanding high participation rates and a tendency to choose full disclosure, caution regarding parental views on participating in WGS research is warranted. Follow‐up studies after families have received WGS findings are necessary.

### PD-032. Associations Between Fitness and Neurocognitve Outcomes in Adult Survivors of Childhood Acute Lymphoblastic Leukemia in the St. Jude Lifetime Cohort Study {#pbc27455-sec-2200}

[N. Phillips]{.ul} ^1^, C. Howell^1^, M. Hudson^2^, L. Robison^1^, K. Krull^1^, K. Ness^1^

*^1^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for both exercise intolerance and neurocognitive deficits. Exercise capacity is associated with cognitive performance, and interventions to improve exercise capacity are associated with improved cognitive performance in other populations. Thus, the aim of this analysis was to determine if exercise intolerance is associated with neurocognitive impairment in ALL survivors.

**Design/Methods**: Submaximal (85% of predicted heart rate) cardiopulmonary exercise testing and neurocognitive performance were compared between 341 survivors of ALL (49% female; mean \[range\] age at diagnosis 5.1 \[0.6‐18.8\] years; age at evaluation 28.5 \[18.4‐44.6\] years) and 288 controls (49.3% female; age at evaluation 32.4 \[18.3‐44.8\] years). Within survivors, multivariable modeling tested associations between peak oxygen uptake (pkV0~2~) and neurocognitive domains, adjusted for sex, age at diagnosis, cranial radiation, anthracycline exposure and tobacco smoking status.

**Results**: Survivors had worse peak oxygen uptake (pkV02) (24.1 vs. 32.3 milliliters/kilogram/minute (ml/kg/min), p\<0.001), and performance (z‐scores) on verbal intelligence (‐0.35 vs. 0.92), verbal fluency (‐0.24 vs. 0.11), working memory (‐0.26 vs. 0.04), dominant/non‐dominant motor speed (‐0.92 vs. ‐0.11/‐0.81 vs. ‐0.04), visual ‐motor speed (‐0.22 vs 0.43), memory span (‐0.16 vs. 0.18), reading (‐0.30 vs. 0.002) and math (‐0.41 vs. ‐0.14) measures (all p\'s \< 0.001) than controls. In adjusted models, a 1 metabolic equivalent increase in exercise tolerance was associated with increases (in standard deviations) in performance of verbal intelligence (0.11, p=0.02), \[PN1\] verbal fluency (0.14, p\<0.001), working memory (0.07, p=0.03), dominant motor speed (0.14, p\<0.001), non‐dominant motor speed (0.18, p\<0.001), visual‐motor speed (0.98, p\<0.01), memory span (0.11, p\<0.01), reading academics (0.11, p\<0.01) and math academics (0.11, p\<0.01) in survivors.

**Conclusions**: This study demonstrates that fitness levels are significantly lower in survivors of childhood ALL than peers, with clear associations between fitness levels and neurocognitive outcomes in intelligence, executive function, processing speed, memory, and academic performance.

### PD-033. Things that Matter: Adolescent and Young Adult Patients\' Priorities during Cancer Care {#pbc27455-sec-2210}

[D. Graetz]{.ul} ^1^, K. Fasciano^2^, S. Block^3^, J. Mack^4^

*^1^St. Jude Children\'s Research Hospital, Hematology/Oncology, Memphis, USA; ^2^Dana Farber Cancer Institute, Psychology, Boston, USA; ^3^Dana Farber Cancer Institute, Psychiatry, Boston, USA; ^4^Dana Farber Cancer Institute, Oncology, Boston, USA*

**Background/Objectives**: Adolescents and young adults (AYAs) experience cancer in the midst of emerging identity and life goals. We investigated AYAs' priorities during cancer treatment and the balance between psychosocial concerns, cure‐directed therapy, and potential late effects.

**Design/Methods**: We surveyed 203 AYA cancer patients (response rate 74%) aged 15‐29 treated at Dana‐Farber Cancer Institute, Boston, Massachusetts, and their oncologists. Patients were approached within 6 weeks of diagnosis and asked to rate the importance of aspects of cancer treatment, cancer outcomes, and life during treatment; 193 patients completed all relevant questions. For each attribute, response options were "extremely," "very," "somewhat," "a little important," or "not at all important". Ratings of "extremely" or "very important" were used as indicators of strong priorities.

**Results**: Patients' 3 most frequent priorities were cure (97%), being good to the people they care about (95%), and having supportive people around them (94%). Most also prioritized being with family (90%), returning to school/work (89%), maintaining relationships with friends (88%), and feeling normal (85%). While still important to many patients, fewer prioritized minimizing long term (78%) and acute side effects (68%) and fertility (59%). Older AYAs (\>22) were more likely to prioritize cure (P=0.02, Chi‐square), having romantic relationships (P\<0.001), and being around those who support them (P=0.01). Patients with poorer prognoses (\<50% chance of cure as reported by oncologists) were less likely to prioritize school or work during treatment (P=0.04) but no less likely to prioritize cure (P=0.38) when compared to patients with more favorable prognoses.

**Conclusions**: Nearly all AYA cancer patients prioritize having the best chance of cure, while maintaining relationships and a sense of normalcy. These priorities may influence decisions they make about medical aspects of treatment. Providers can help support AYA patients by recognizing and acknowledging these priorities from diagnosis.

### PD-034. The Child Chooses Medical Support During Invasive Procedures: Analysis of the Results {#pbc27455-sec-2220}

[K. Maslak]{.ul} ^1^, C. Favara‐Scacco^1^, M. Barchitta^2^, A. Agodi^2^, M. Astuto^3^, R. Scalisi^3^, S. Italia^1^, F. Bellia^1^, G. Bertuna^1^, S. D\'Amico^1^, M. La Spina^1^, M. Licciardello^1^, L. Lo Nigro^1^, P. Samperi^1^, V. Miraglia^1^, E. Cannata^1^, M. Meli^1^, F. Puglisi^1^, G. Russo^4^, A. Di Cataldo^4^

*^1^University Hospital Policlinico Vittorio‐Emanuele, Department of Pediatric Hematology and Oncology, Catania, Italy; ^2^University of Catania, Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", Catania, Italy; ^3^University Hospital Policlinico Vittorio‐Emanuele, Section of Anesthesia‐ Department of General Surgery and Medical Specialties, Catania, Italy; ^4^University of Catania, Department of Pediatric Hematology and Oncology‐ Department of Clinical and Experimental Medicine, Catania, Italy*

**Background/Objectives**: When cancer intrudes children\'s life, everyday equilibrium is destroyed. They suddenly find themselves in a totally new world where adults make all the important decisions. Children undergoing diagnostic and therapeutic treatment, experience an increasing level of anxiety with repeated invasive procedures and do not adapt to the discomfort. Bone marrow aspiration and lumbar puncture remain one of the most vivid memories even years after the treatment is finished. Professionals agree that children must receive developmentally appropriate preparatory information about invasive procedures, along with an adequate psychological support. Literature describes different support modalities, e.g. pharmacological, behavioural, sedative etc; however, there is no report on the possibility of asking children themselves about their preference for the medical support.

**Design/Methods**: The day of the procedure, each child was offered to choose the type of medical support among general anesthesia (GA), conscious sedation (CS) or nothing. Each child received also a psychological support, i.e. given by the psychologist before, during and after the procedure. An 'ad hoc' assessment tool was prepared in order to measure child discomfort before, during and after each procedure; also the caregiver adequacy was measured, based on a 4‐dimension evaluation. Both forms were filled in at every procedure by the attending psychologist.

**Results**: We monitored 247 consecutive invasive procedures in 85 children. We found that the choice of the type of medical support was different in the various age groups; elementary‐school age group showed significantly higher distress level than others; distress level diminished at succeeding procedures; caregiver behaviour influenced children\'s experience.

**Conclusions**: Offering children an opportunity to choose the medical support, during invasive procedures, is an effective modality to return active control to them; it is a way to truly strengthen the children\'s capacity to face the invasive procedures, limiting their emotionally traumatic content.

### PD-035. Health‐Related Quality of Life in Adolescents with Cancer {#pbc27455-sec-2230}

[M.N. Sitaresmi]{.ul} ^1^, B.W. Indraswari^1^

*^1^Faculty of Medicine‐ Public Health and Nursing‐ Universitas Gadjah Mada/ DR. Sardjito Hospital, Paediatric Department, Yogyakarta, Indonesia*

**Background/Objectives**: Health‐related quality of life (HRQOL) of adolescents with cancer may be affected by the disease and treatment. The aims of this study are to assess profile HRQOL of adolescents with cancer and to assess the influence of demographic and medical characteristics on HRQOL score.

**Design/Methods**: Method: We conducted a cross sectional study of HRQOL in Dr. Sardjito General Hospital Yogyakarta, Indonesia from June to November 2017. Adolescent cancer patients (10‐18 years old) and their guardians in various phase of treatment were recruited. HRQOL was assessed using PedsQL ™ 4.0 generic module and PedsQL™ 3.0 cancer module Indonesian validated versions.

**Results**: Fifty‐eight adolescents and their guardians were recruited. The internal validity of both scales were good (Cronbach\'s Alpha Coefficient ranged from 0,81 to 0,98) as well as the internal correlation between self‐reports and proxy‐ reports (ICC was 0.84 to 0,95). Both patients and their guardians reported low scores on school function subscale (36 and 37). Compared to boys, female adolescent patients reported lower score in emotional function subscale (87 vs 76, p\<0.01). Late adolescents reported lower score than early adolescents especially in total score of both scales, emotional subscale and worry subscale. Guardians of non‐hematology malignancy patients reported lower score than hematology malignancies patients in physical function (83 vs 72, p 0.04), social function (94 vs 88, p 0.02) and pain‐hurt function (89 vs 77, p\<0.00).

**Conclusions**: Late adolescents had more problems both in generic and cancer scale. Psychosocial support should be provided by their families and peer group to facilitate their coping with the disease and treatment. School substitution should be offered to adolescents during their treatment.
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### PO-001. Hospital Admission Time for Newly Diagnosed Children and Adolescents with Acute Lymphoblastic Leukemia. Experience of One Spanish Unit {#pbc27455-sec-2260}

N. Bilbao^1^, J.M. De Pedro^1^, [R. Adán]{.ul} ^1^, N. Larrinaga^2^, A. Ricondo^1^, I. Ojinaga^1^, A. Espinosa^3^, A. Echebarria‐barona^1^, M. Garcia‐Ariza^1^, I. Astigarraga^1^, R. Lopez‐Almaraz^1^

*^1^Cruces University Hospital, Pediatric Oncology and Hematology Department, Barakaldo, Spain; ^2^Araba University Hospital, Pediatric Department, Vitoria‐Gasteiz, Spain; ^3^Basurto University Hospital, Pediatric Department, Barakaldo, Spain*

**Background/Objectives**: In our country, patients with acute lymphoblastic leukemia (ALL) are treated according to our national protocol. There is no consensus on the support management of these patients during this first phase of treatment (induction). The objective of the study is to describe the\"conservative management\" carried out during this first month in our Unit.

**Design/Methods**: Retrospective descriptive study of the clinical characteristics and evolution during the IA induction of patients between 1‐18 years diagnosed with ALL from 2013 to 2018 in a tertiary hospital.

**Results**: 50 patients were diagnosed with ALL. The average stay of admission was 13 days. 22% presented complications during the first admission; especially due to treatment toxicity. At discharge 51% had neutropenia and 4% neutropenia plus thrombocytopenia. 10% were discharged with infectious prophylaxis, unrelated to the risk of ALL and the absolute neutrophil count (ANC) at discharge. The first control consultation was made after 3 days on average. 49% of patients were re‐admitted during the induction phase; although only one within the first 48 hours after discharge (mean admission day +23). Febrile neutropenia was the main cause of admission (43%), obtaining microbiological confirmation in 69% of the cases (most cultures isolating bacteria). The second admission cause was infections related to the catheter, 30%. Negative coagulase Staphylococcus was the most frequent microorganism. The remaining patients were re‐admitted due to deep vein thrombosis (6%) and toxicities secondary to chemotherapy. No patients died during induction

**Conclusions**: Half of our patients were re‐admitted after the first discharge; however we don\'t believe that by extending the hospital stay we could have prevented any of the causes. The risk of re‐admission was not associated with the risk of ALL and the ANC at discharge. Our more conservative management didn\'t imply a higher rate of complications

### PO-002. Gene Copy Number Alterations and Association with Prognostic Factors in Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-2270}

[M. Agarwal]{.ul} ^1^, S. Rashmi^1^, S. Bakhshi^2^, D. Sadanand^3^, K. Madhulika^1^, S. Rachna^1^

*^1^All India Institute of Medical Sciences, Paediatrics, Delhi, India; ^2^IRCH‐ All India Institute of Medical Sciences, Paediatrics, Delhi, India; ^3^All India Institute of Medical Sciences, Biostatistics, Delhi, India*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL), commonest leukemia in children with survival upto 80‐85% with higher mortality (30‐35%) in Indian children with ALL. ALL is found to be associated with copy number alterations in various coexisting genes representing varying mechanisms of carcinogenesis including genes involved with progression of cell division as wells as inhibition of cell differentiation. We conducted the study with the objective of finding copy number variations in some of the genes implicated in prognosis in childhood ALL

**Design/Methods**: 104 newly diagnosed and confirmed children with ALL, age 1‐14 years, were included in the study. All the children were investigated for hematological and cytogenetic prognostic factors. In addition, the children were also monitored for response to prednisolone (D‐8), complete morphological remission and minimal residual disease post induction. All the children were followed up for minimum 6 months. These children were analyzed for copy number alterations in *CDKN2A/B, IKZF1, PAX5, RB1, ETV6, BTG1, EBF1*, and *PAR1*genes using multiplex ligation‐dependent probe amplification (MLPA) assays with SALSA MLPA P335 ALL‐*IKZF1*kit, MRC‐ Holland, Amsterdam, The Netherlands.

**Results**: Copy number alterations were seen in 59 (56.7%) of individuals. CDKN2A/B, PAX5 and IKZF1 gene deletions were commonly deleted. Alterations in genes located in Pseudo autosomal regions are also frequently deleted, including deletion of IL3RA and CSF2RA genes and duplications of CRLF2, IL3RA, CSF2RA, P2RY8 genes.

**Conclusions**: CDKN2A/B genes were significantly associated with higher age, leukocyte count at presentation and higher incidence of adverse events while IKZF1 gene was associated with higher MRD. IKZF1, ETV6, RB1 and BTG1 gene deletions were associated with poor cytogenetics in children with ALL

### PO-003. Challenges During Induction Phase Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: A Tertiary Centre Experience from North India {#pbc27455-sec-2280}

[P. Aggarwal]{.ul} ^1^, T.B. Singh^2^, V. Gupta^1^

*^1^Institute of Medical Sciences‐ Banaras Hindu University, Division of Pediatric Hematology Oncology‐ Department of Pediatrics, Varanasi, India; ^2^Institute of Medical Sciences‐ Banaras Hindu University, Division of Biostatistics‐ Department of Community Medicine, Varanasi, India*

**Background/Objectives**: The aim of this study was to assess the effect of socio‐demographic profile along with nutritional status of patients with pediatric ALL on the duration of Induction phase chemotherapy.

**Design/Methods**: One hundred ten patients aged 1.5 to 14 years who underwent induction of remission from June 2015 to February 2018 were included in the study. The weight, immunization status of the child, type of house, sanitary facilities and source of drinking water were noted at the start of treatment. Weight age percentile of the child was determined using WHO growth charts. Kuppuswami Scale was used to assess the socioeconomic status (SES). The duration of Induction phase chemotherapy was considered delayed, if the patient received chemotherapy for more than 29 days.

**Results**: Our patients belonged to lower (n=50) and middle (n=60) socioeconomic status which had no significant effect on the duration of induction phase chemotherapy (p = 0.832). Among the other parameters, the duration was significantly delayed in patients who were not immunized (p = 0.000), were residing in mud house (p=0.000) with no sanitary facility (p=0.013) and no access to filtered drinking water (p=0.005). Although the duration was delayed in patients with weight \>10 percentile, it was not statistically significant (p=0.079).

**Conclusions**: The duration of Induction phase chemotherapy is affected significantly with the immunization status of the child, the type of house, presence/ absence of sanitary facility and the source of drinking water.

### PO-004. Impact of the National Medical Access Childhood Cancer Program on the Survival of Acute Lymphoblastic Leukemia (ALL) in the Philippines {#pbc27455-sec-2290}

[V. Aguilar]{.ul} ^1^, A.P. Alcasabas^2^, J. Lecciones^3^, C. Ngelangel^4^, O. Sison^4^

*^1^Bicol Regional Training and Teaching Hospital, Department of Pediatrics, Albay, Philippines; ^2^University of the Philippines ‐ Philippine General Hospital, Department of Pediatrics, Manila, Philippines; ^3^Philippine Children\'s Medical Center, Department of Pediatrics, Quezon City, Philippines; ^4^University of the Philippines ‐ Philippine General Hospital, Department of Clinical Epidemiology, Manila, Philippines*

**Background/Objectives**: Acute Lymphoblastic Leukemia (ALL) survival in the Philippines remains poor due to low detection rates, late referrals and incomplete treatment. Financial constraints for chemotherapy drugs are a main barrier. In 2012, a program for free ALL chemotherapy was implemented in the 3 pediatric cancer units and 13 hospitals nationwide. We review the program\'s impact on ALL outcomes.

**Design/Methods**: Multi‐center, retrospective chart review of newly diagnosed ALL patients (0‐18 years) using standardized data sheet, from January 1, 2012 to December 31, 2015. Study end‐point was December 31, 2017.

**Results**: Out of 1359 patients reached by the program only 1340 were evaluable. Diagnosis was based on immunophenotyping in 52% (n=697) patients and morphology in 48% (n=643). Mean age at diagnosis was 6.8 years old (0.8‐18). M:F Ratio 1.5:1. NCI risk stratification: low 53% (n=709) and high 47% (n=631). Treatment protocols (n=7) varied across centers. At end of study period, 43% were alive (n=570), of which 22% completed treatment (n=225), 24 % died (n=325), and 33 % abandoned treatment (n=445). Most common causes of death were sepsis and bleeding. There were 163 relapses (12%) including 7% (n=16) who completed treatment. The sites were bone marrow in 63% (n=103), CNS 32% (n=52) and combined 5% (n=8). The 2 and 5 year overall survival (OS) and abandonment‐sensitive OS were 70/64% and 48/19%, respectively. Multivariate analysis of patient characteristics showed mortality was strongly correlated with NCI high risk, initial levels of hemoglobin \<7g/dL and platelet counts ≤100X109/L.

**Conclusions**: The major causes of treatment failure are abandonment and toxic death. An expanded and more wholistic national leukemia program is urgently needed and should include initiatives on patient navigation, infection control, safe blood products, standard clinical practice guidelines and creation of hospital registries.

### PO-005. Is it Ethical in Low and Middle‐Income Countries to Continue the use of E. coli L‐Asparaginase in Patients with Acute Lymphoblastic Leukemia? Analysis made in Mexico {#pbc27455-sec-2300}

[E.G. Aguillen Jimenez]{.ul} ^1^, M.M. Dr.^1^, A.M.A. Dr.^1^, A.M.F. Dr.^1^

*^1^Instituto Nacional De Pediatria, Pediatric Oncology, Mexico City, Mexico*

**Background/Objectives**: Recent acute lymphoblastic leukemia (ALL) protocols in high income countries include only PEG asparaginase as front ‐line treatment since 2013. Due to its cost in low and middle‐income countries it is unlikely to implement it systematically. Our objective was to review the frequency of adverse events associated to E Coli L‐Asparaginase (ELA) and the rate ofthe central nervous system relapse in our institution. In addition, we elaborate a systematic review searching for this information in Latin‐American countries in order to have elements to discuss the ethic issue of this current problem.

**Design/Methods**: We made a prospective, observational study including all pediatric patients with ALL registering adverse events associated to ELA, the time and treatment phase of presentation and its association with nutritional status. We reviewed the rate of CNS relapse in the cohort of patients treated with St Jude XIIIB from 2010‐2016.

**Results**: We included 534 ELA administrations. We registered thrombosis (0 %), pancreatitis 1.6 %), anaphylaxis (1.8 %), Drug induced skin disorders (3.5 %), hypertriglyceridemia (2%). 1 patient developed in the first application,6 in the 2‐5 application, 33 in \>5 applications. 5 in induction therapy, 9 consolidation and 26 in maintenance. The CNS relapse rate was 8%.

The adverse events of PEG‐asp is are barely lower than E.Coli. The rate of CNS relapse has decrease 3 % from the start of using PEG‐asp. It is difficult to demonstrate that this decrease is due only to the use of one drug, however it is a safer first line treatment drug. Is it ethic to use ELA?

**Conclusions**: Despite of adverse events of ELA and the higher risk of CNS relapse, in our reality the use of this drug is still the most cost‐effective choice and we consider a correct ethical decision.

### PO-006. Screening of Candidate Prognostic Biomarker Genes in Pediatric BCP‐ALL {#pbc27455-sec-2310}

[D.F. Akin Bali]{.ul} ^1^, D. Aslar Oner^2^, A.E. Kurekci^3^, N. Akar^4^, H. Ozdag^5^

*^1^Niğde Ömer Halisdemir University‐ Faculty of Medicine, Medical Biology, Niğde, Turkey; ^2^Gazi University, Molecular Biology, Ankara, Turkey; ^3^LOSANTE Children\'s and Adult Hospital, Pediatric Hematology, Ankara, Turkey; ^4^TOBB‐ETU Hospital, Pediatric Disease, Ankara, Turkey; ^5^Ankara University‐ Biotechnology Institute, Biotechnology, Ankara, Turkey*

**Background/Objectives**: BCP‐ALL (B‐cell precursor acute lymphoblastic leukemia) is characterized by recurring cytogenetic and molecular genetic abnormalities. We aimed to investigate recently identified genomic risk factors that affect the pathogenesis of BCP‐ALL, with effects on their molecular mechanism and prognostic significance by Next Generation Sequence (NGS) and gene expression analyses in childhood BCP‐ALL. The secondary aim of this study was to correlate the data obtained from study with some biological and clinical features as characteristic of pediatric BCP‐ALL patients, genetic aberrations and prognosis based on treatment protocol criteria.

**Design/Methods**: Blood samples were obtained from 45 pediatric patients with BCP‐ALL. We used NGS method to study the ZAP70, TSLP, JAK2, CRFL2, IKZF1, PAX5, EBF1, CREBBP, FOXO3, RB1, ZNRF1, NR3C1, NF1 and ERG genes. Known mutational hot spot regions of these genes were sequenced and gene expression levels were performed using qRT‐PCR.

**Results**: Among the 14 gene analyses of the 45 pediatric BCP‐ALL patients, we identified 328 gene variants including 104 deletions, 28 insertions, 75 duplications, 47 indels, 74 single nucleotide mutations and polymorphisms by NGS in the hot spot regions of genes. 15 of the identified mutations were novel mutations in present study. Among them, the most commonly mutated gene was CRFL2 (14.3%), followed by NR3C1 (12.8%) RB1 (9.7%), IKZF1 (9.1%), PAX5 (8. 8%), EBF1 (7.9%), JAK2 (6.0%), CREBBP (5.45) We detected that ERG and JAK2 gene expressions were associated with different pathophysiological and clinical features, such as peripheral blood cell count and treatment protocols in our study groups.

**Conclusions**: The detected variants are likely to lead to ending of the products of genes, the different splicing of the possible transcripts and transformation of the amino acids. Our data suggest a prognostic role of studying genes expression levels and mutation profiles in pediatric BCP‐ALL

### PO-007. Comprehensive Genetic Analysis of Iraqi Childhood Acute Leukemia in Japan using FTA Filter Cards {#pbc27455-sec-2320}

[L. Al‐Kzayer]{.ul} ^1^, Y. Okuno^2^, M. Al‐Jadiry^3^, S. Al‐Hadad^3^, H. Salih^4^, Y. Nakazawa^1^

*^1^Shinshu University School of Medicine, Department of Pediatrics, Matsumoto‐ Nagano, Japan; ^2^Nagoya University Graduate School of Medicine, Center for Advanced Medicine and Clinical Research, Nagoya, Japan; ^3^Children Welfare Teaching Hospital‐ Baghdad College of Medicine, Department of Pediatrics, Baghdad, Iraq; ^4^Basra Children\'s Specialty Hospital, Department of Pediatric‐oncology, Basra, Iraq*

**Background/Objectives**: Molecular diagnosis of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), helps to define the prognosis and to select the appropriate treatment protocol. Our successful previous genetic analysis of pediatric Iraqi ALL/AML samples in Japan, using Flinders Technology Associates (FTA) cards, and further implementation of results in management of enrolled patients, have motivated us to perform a more comprehensive analysis to detect genetic prognostic markers for ALL/AML, using the next‐generation sequencing (NGS) technology.

**Design/Methods**: FTA filter cards were used to transfer the dried‐blood‐spot samples of bone marrow aspirated at days: 0, 30 and 60 of therapy, from children with acute leukemia aged ≤15‐year‐old, from 2 main pediatric‐oncology centers in Iraq. Since October 2016 (planned until 2020), 36 patients' samples (30 ALL, 3 AML, and 3 acute undifferentiated leukemia), were shipped to Shinshu University/Japan, for DNA extraction, and NGS was done at Nagoya University/Japan. We performed a whole‐exome sequencing (WXS) of samples at the time of diagnosis and remission to identify somatic/germline mutations including copy number aberrations. Minimal residual disease (MRD) detection was also performed based on complementarity‐determining region‐3 (CDR3) of immunoglobulin heavy‐chain (IgH) and T‐cell receptor‐gamma‐chain (TCR‐G).

**Results**: WXS using FTA‐derived DNA was satisfactory in terms of sequencing coverage, sensitivity, and error rate. The spectrum of somatic mutations among Iraqi childhood ALL/AML, was comparable to other countries, with slightly higher *RAS*‐mutations frequency: (3/20, ALL). MRD markers were detectable; however, the sensitivity was limited due to insufficient amount of DNA delivered by FTA cards.

**Conclusions**: Molecular markers of Iraqi childhood ALL/AML were successfully detectable, using FTA‐derived DNA samples, by NGS. MRD detection was also possible using IgH and TCR‐G. Our study will contribute to better management of patients with acute leukemia in Iraq.

Acknowledgments: We appreciated the 50th‐Annual SIOP acceptance for our abstract to be published in the official congress publications.

### PO-008. Assessment of Patient with Poor Response During Induction of Acute Lymphoblastic Leukemia in Children in a National Cancer Center in Peru {#pbc27455-sec-2330}

[S. Alarcon]{.ul} ^1^, R. Diaz^1^, J. Garcia^1^, L. Vasquez^2^

*^1^Instituto Nacional de Enfermedades Neoplásicas, Pediatría Oncológica, Lima, Peru; ^2^Hospital Edgardo Rebagliati Martins, Pediatría Oncológica, Lima, Peru*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common cause of pediatric cancer at the Instituto Nacional de Enfermedades Neoplasicas. The mayority of them are stratified as High risk patients (age more than 10 years, white blood count more than 49, 999, M3 those more than 25% of blast in marrow on day 7 of Induction, Minimal Residual Disease post Induction or involve leptomeningeal or testicular). The aim is to determine if patients with M3 marrow on day 7 had a worse outcome for High Risk ALL.

**Design/Methods**: This is a retrospective study. Between January 2015 and December 2016, 390 patients less than 15 years of age were diagnosed having ALL, 165 patients met high risk criteria (42.3%) and they were separated in: Group I, classified only by white blood count more than 49,999 y/o age more 10 years (120 patients), and Group II, by M3 Marrow on day 7 of Induction (45 patients) without any other criteria. Survival analysis was performed using Kaplan‐Meier method.

**Results**: The median age was 7.4 years (range 1 to 14 years), M/F ratio 1.09. One hundred fifteen patients (94.5%) had complete remission, 15 (9 %) relapse, 22 patients abandon treatment and 25 died (15.2 %): 3 died during induction (1.8%) and 5 patients have progressive disease (3%). The median time to follow up was 22.3 months. The 4 years overall survival (OS) with the abandonment included as an event was 64% (+/‐ 4.6%) and the event free survival (EFS) was 59% (+/‐ 4.6%). In group I, 114 (95%)had complete remission and group II, 42 (93.3%).

**Conclusions**: Our amount of High risk ALL exceeds the international reports. Complete remission in High Risk ALL patients at end of induction are the same as international reports. Those with M3 marrows on day 7 had not a worse outcome than I group.

### PO-009. Single Center Experience on Incidence of Venous Thromboembolism in Childhood Acute Leukemia Patients -- Indicative of a Regional VTE Registry for Childhood Malignancies {#pbc27455-sec-2340}

[M. Alsaleh]{.ul} ^1^, A. AlJefri^1^, A. AlAhmari^1^, H. AlSaedi^1^, A. AlSeraihy^1^, N. Farhan^2^, S. Jose^2^, B. Safi^2^, S. Jafri^1^, V. Mohammed^1^, S. AlSweedan^1^

*^1^King Faisal Specilaist Hospital & Research Centre, Pediatric Hematology / Oncology, Riyadh, Saudi Arabia; ^2^King Faisal Specilaist Hospital & Research Centre, Pediatric Nursing, Riyadh, Saudi Arabia*

**Background/Objectives**: Incidence of venous thromboembolism (VTE) in patients with cancers is known to be associated with solid tumors, studies suggests a similar incidence rate in Acute leukemia (AL) more common in children and VTE may have a negative prognostic impact. Pediatric Hematology section of King Faisal Specialist Hospital and Research Centre, Riyadh manages several cases of childhood AL with VTE.

**Design/Methods**: Retrospective chart review of newly diagnosed patients with AL from 2012 to 2016 was conducted.

**Results**: Total of 372 patients identified as 291 (78%) ALL and 81 (22%) AML cases, mean follow‐up period of 2.7 years; VTE observed in 47 patients (ALL,37 and AML, 10) representing an overall incidence of 13 %. Majority (83%) of children((male,28 and female, 19) developed VTE within 12 months of diagnosis, 64% (30) occurring in Non‐Central Nervous System (CNS) defined by central venous catheter (CVC)‐ associated upper or lower --extremity deep venous thrombosis(DVT); while 36% (17) occurred in CNS defined by Dexamethsone and / or Asparginase ‐associated cerebral venous thrombosis. Two‐Third (67%) of patients were thrombocytopenic secondary to chemotherapy‐related bone marrow failure during the VTE course. Upper extremity DVT (87%) was most common amongst Non‐CNS cases ; while one (6%) developed cerebral emboli and rest experienced cerebral sinus thrombosis (94%) amongst CNS cases. Five‐Year overall survival (OS) of the cohort was 78%, comparison of Non‐VTE to the VTE leukemia cases a Five‐Year OS of 77% and 87% respectively observed, statistically not‐significant (P‐value \> 0.05)

**Conclusions**: Five‐year VTE incidence of 13% is comparable to published thrombosis risk of 1% ‐ 37% in pediatric cases; risk factors remained CVC and Asparginase therapy, a higher incidence of upper extremity DVT is observed due to our practice. However, regional pediatric VTE registry accurately estimating risk of thrombosis, treatment delays and survival in childhood malignancies is warranted.

### PO-010. PRES in Pediatric ALL Patients Treated According to the Nordic NOPHO ALL‐2008 Protocol {#pbc27455-sec-2350}

[S. Anastasopoulou]{.ul} ^1^, M. Heyman^1^, M.A. Eriksson^1^, R. Niinimäki^2^, I.M. Johansdottir^3^, T. Frandsen^4^, G. Vaitkeviciene^5^, S. Mikkel^6^, Ó.G. Jónsson^7^, A.H. Harila‐Saari^8^, S. Ranta^1^

*^1^Karolinska Institute, Department of Women\'s and Children\'s Health, Stockholm, Sweden; ^2^Oulu University, Department of Children and Adolescents, Oulu, Finland; ^3^Oslo University Hospital, Deparment of Pediatric Hematology/Oncology, Oslo, Norway; ^4^University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^5^Vilnius University Hospital, Department of Pediatrics, Vilnius, Lithuania; ^6^University of Tartu, Department of Hematology and Oncology, Tartu, Estonia; ^7^University of Iceland, Department of Pediatrics, Reykjavík, Iceland; ^8^University of Uppsala, Department of Women\'s and Children\'s Health, Uppsala, Sweden*

**Background/Objectives**: Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity that is increasingly recognized among pediatric patients with acute lymphoblastic leukemia (ALL) and is hypothesized to be triggered by ALL treatments. We aimed to explore the clinical course of PRES in pediatric patients treated according to the Nordic ALL protocol NOPHO ALL‐2008 and identify risk factors for PRES.

**Design/Methods**: Our study group included patients between 1 and 18 years of age at diagnosis of B cell‐precursor (BCP) and T‐cell ALL, between 2008 and 2015 in five Nordic and two Baltic countries. All patients were treated according to NOPHO ALL‐2008. The patients were identified through a unique on‐line registration system and information regarding the detailed phenotype of PRES was collected through a questionnaire focusing on central nervous system toxicities during ALL treatment.

**Results**: PRES was diagnosed in 52/1436 (3,6%) of the patients. The cumulative incidence of PRES at one month was 1,55% (CI 0,5%:1,02 ‐ 95%:2,34) and 3,54% (CI 0,5%:2,69 ‐ 95%:4,64) at one year. Cox regression identified age significant predictor of PRES (HR for a one‐year increase in age 1.09, 95% CI 1,03‐1,15, p=0,001). The risk for T‐cell ALL was higher than BCP ALL (T‐cell HR for T‐cell vs BCP2.869, 95%CI 1.575 -- 5.228, p=0,001). Seizures occured in 44/52 (84,6%) of the patients, hypertension was present in 41/52 (78,8%) patients; encephalopathy was the third most common symptom (33/51, 64.7% of the patients).

**Conclusions**: Seizures, hypertension and encephalopathy are the most common symptoms of PRES in ALL patients treated with the NOPHO ALL‐2008 protocol, which includes high doses methotrexate, vincristine and steroids during the first year of treatment when the incidense of PRES is highest. Further studies are needed to identify the underlying mechanism of PRES in ALL patients as well as the neurocognitive outcome.

### PO-011. Outpatient Parenteral Antimicrobial Therapy in Children and Young Adolescents Diagnosed with Cancer {#pbc27455-sec-2360}

A. Espinosa Pousa^1^, [I. Astigarraga Aguirre]{.ul} ^2^, N. Larrinaga Dañobeitia^3^, R. Lopez Almaraz^2^, J. De Pedro Olabarri^2^, R. Adan Pedroso^2^, A. Echebarria Barona^2^, M. Garcia Ariza^2^, M.C. Pinedo Gago^4^, J. Sanchez Echaniz^4^

*^1^Basurto University Hospital, Pediatrics, Bilbao, Spain; ^2^Cruces University Hospital, Pediatric Oncology and Hematology, Barakaldo, Spain; ^3^Arava University Hospital, Pediatrics, Vitoria, Spain; ^4^Cruces University Hospital, Pediatric Domiciliary Hospitalization Unit, Barakaldo, Spain*

**Background/Objectives**: Traditionally intravenous antimicrobial treatment has been administered entirely in an inpatient setting. Pediatric Domiciliary Hospitalization Units have become a safe alternative care, especially for patients with chronical or malignant diseases. The objective of this study is to present our experience with outpatient parental antimicrobial therapy in a Pediatric Domiciliary Hospitalization Unit in patients diagnosed with cancer.

**Design/Methods**: We conducted a retrospectivedescriptive study by medical record review of pediatric patients diagnosed with cancer who received outpatient parenteral antimicrobial therapy between October 2012 and December 2017.

**Results**: Over this period a total of 52 episodes were treated in 38 patients, 22 male and 16 female, age 1 to 17 years. Fifty percent of the patients were diagnosed of Acute Lymphoblastic Leukemia. The main indication of antimicrobial therapy was catheter‐related bacteremia (82%). The most common organism isolated was *Staphylococcus epidermidis* (44%). Teicoplanin was used in 67% of the episodes. The treatment was given through: port‐a‐cath (88%), central venous catheter (9%) and peripheral line (3%). The antibiotics were administered by direct infusion in 77% and a programmable infusion device was used in 23% of the episodes. Two patients were treated with parental antifungal agents (caspofungin and voriconazole). Mean duration of outpatient antimicrobial treatment was 7 days. We registered two cases of catheter occlusion that were resolved at home. There were no complications and no patient required inpatient treatment. Analysis of health costs showed differences between the daily cost of inpatient (593€/day) and outpatient management (147€/day).

**Conclusions**: Outpatient parenteral antimicrobial therapy provided with the support of a Pediatric Domiciliary Hospitalization Unit is a feasible and safe option for patients with cancer. This strategy reduces health care costs and improves the quality of life of children and their families.

### PO-012. Exploring the Communication Experience in Caring of Children with Cancer: An Ethnographic Multiple Case Study Approach from Palestine {#pbc27455-sec-2370}

[M. Atout]{.ul} ^1^, I. Bashayreh^2^, B. Carter^3^

*^1^Philadelphia university, Faculty of Nursing, Amman, Jordan; ^2^Philadelphia University, nursing, Amman, Jordan; ^3^Edge Hill University, Faculty of Health and Social care, Edge Hill, United Kingdom*

**Background/Objectives**: There has been little research in the Middle East regarding the experience of communicating with children with cancer from the perspectives of physicians, family carers and nurses. This study explores the experience of communicating regarding the care of children with cancer, from the perspective of physicians, nurses, mothers and children in Palestine.

**Design/Methods**: This study employed an ethnographic collective qualitative case study approach. It was conducted in one oncology unit in a Palestinian hospital. Two data collection methods were employed: participant observation and semi‐structured interviews.

**Results**: Thirty two interviews have been collected to date: physicians (n=5), nurses (n=10), children aged 6--18 (n=6), mothers (n=6) and grandmothers (n=5). A total of 65 observational hours have been completed. Findings reveal that while a few parents completely hid the diagnosis of leukaemia from their children, others tried to relieve the situation by informing their children of their having different diagnoses, such as a blood infection. The term cancer, a taboo term in Arab culture, was avoided in the discussion of the disease by health care providers and parents to ameliorate the negative effect of this term. Generally, children were not involved in discussions related to their disease and most communications about their illness were with their parents and physicians.

**Conclusions**: The study findings reveal the challenges that physicians, nurses and mothers face when they communicate with children with cancer. They also reported their need for improving their communication skills with children with cancer. Finally, strategies are needed to involve children in the communication regarding their disease and their prognosis on the hospital level.

### PO-013. The Experience of Having a Second Child with Leukemia: The Case of Palestinian Mothers {#pbc27455-sec-2380}

[M. Atout]{.ul} ^1^

*^1^Philadelphia university, Faculty of Nursing, Amman, Jordan*

**Background/Objectives**: The aim of this study was to explore the experience of having a second child with leukemia from the perspective of Palestinian mothers

**Design/Methods**: This study employed a hermeneutic phenomenological approach informed by the philosophy of Heidegger. The study was conducted in two academic paediatric oncology centers in Palestine. The data was collected using semi‐structured interviews.

**Results**: Thirteen interviews have been collected with mothers of children with leukemia. The findings indicate that some mothers who had a second child with the same disease were stronger because the experience increased their ability to adapt themselves to the second situation. However, these mothers reported enormously painful experiences if they were admitted to the same room in which their previous child had been cared for. In addition, the second child was often treated by the same health professionals who had treated the deceased child. The mothers who had more than one child with the same illness had a tendency to dredge up unhappy memories, and some of them refused to talk with students who they expected to ask them to review the family history. The mothers avoided these kinds of discussions because of these painful memories, and also as a means of maintaining their strength in the face of the current situation.

**Conclusions**: The clinical practice could benefit from these findings by avoiding stimulating the painful memories of parents who had deceased children. This could help the parents to adapt to their children\'s illness. However, it is important to assess parental preferences before such intervention to account for individual differences among parents. Therefore, a clear discussion with parents who have a second child with the same illness, in order to understand their preferences regarding the medical environment and the medical teams they would like to treat their second child could significantly improve parental satisfaction with hospitalization.

### PO-014. The Effect of Single Dose and Increased Cumulative Anthracycline Dose on Cardiac Repolarization Changes in Children with Cancer: A Prospective Follow‐Up Study {#pbc27455-sec-2390}

[S. Aydin Köker]{.ul} ^1^, Y. Oymak^1^, T. Meşe^2^, M.M. Yılmazer^2^, B. Demirağ^1^, R. Özdemir^2^, T.H. Karapınar^1^, D. İnce^3^, R.C. Vergin^1^

*^1^Dr. Behçet Uz Children\'s Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey; ^2^Dr. Behçet Uz Children\'s Hospital, Department of Pediatric Cardiology, Izmir, Turkey; ^3^Dokuz Eylül University School of Medicine, Department of Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Although anthracycline treatment‐related chronic cardiotoxicity has been well recognized, importance of subclinical anthracycline acute cardiotoxicity has not yet been unknown.

We aimed to prospectively evaluate the acute cardiotoxicity effect of single dose and increased cumulative anthracycline dose on cardiac repolarization changes with 12‐lead electrocardiograpic (ECG) in children with cancer.

**Design/Methods**: A total of 53 patients with cancer who treated with anthracycline were enrolled into the study. During 6 months follow‐up, the standard 12‐lead electrocardiograpic was performed at basale, first, fourth and twenty‐fourth hour at the first dose of anthracycline treatment, at the time of 120 mg/m^2^ cumulative anthracycline dose and 240 mg/m^2^ of cumulative anthracycline dose in the same patients. P wave dispersion (PWd), QT dispersion (QTd), corrected QT dispersion (QTcd), Tp‐e interval, Tp‐e/ QT and Tp‐e/ QTc ratio were obtained from 12‐lead electrocardiograpic. The patients were classified into three groups according to increasing cumulative anthracycline doses: Group 1: the first dose (n=53), Group 2: 120 mg/m^2^ (n=42), Group 3: 240 mg/m^2^ (n=19).

**Results**: The median age for patients was 48 months (range 9‐192 months). While PWd, QTd, QTcd and Tp‐e interval were significantly increased during first 24 hours after first dose of anthracycline treatment (p\<0.001, p=0.005, p=0.041, p=0.016, respectively), Tp‐e/ QT and Tp‐e/ QTc ratio were significantly altered during first 24 hours after 120 mg/m2 cumulative dose of anthracycline treatment (p\<0.001). However, changes of 12‐lead electrocardiograpic (ECG) parametres were not significantly higher at 240 mg/m2 cumulative dose of anthracycline treatment. Therewithal, our results showed that each increased administration anthracycline cumulative dose is associated with changes in all ECG parameters, especially some parametre such as PWd, Tp‐e/ QT and Tp‐e/ QTc ratio were good correlation statistically among Group 1, Group 2 and Group 3.

**Conclusions**: ECG parametres are useful for detecting subclinical cardiac abnormality and acute anthracycline toxicity.

### PO-015. Assesment of Heart Rate Variability in Children with Cancer after Increased Cumulative Anthracycline Dose: A Prospective Follow‐Up Study {#pbc27455-sec-2400}

[S. Aydin Köker]{.ul} ^1^, B. Demirağ^1^, T. Meşe^2^, M.M. Yılmazer^2^, Y. Oymak^1^, R. Özdemir^2^, T.H. Karapınar^1^, D. İnce^3^, R.C. Vergin^1^

*^1^Dr. Behçet Uz Children\'s Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey; ^2^Dr. Behçet Uz Children\'s Hospital, Department of Pediatric Cardiology, Izmir, Turkey; ^3^Dokuz Eylül University School of Medicine, Department of Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Anthracyclines are an effective group of chemotherapeutic drugs commonly used in childhood cancers.

We aimed to prospectively evaluate the heart rate variability after increasing cumulative dose with 24‐hour Holter electrocardiography (ECG) in children with cancer who treated with anthracycline drugs.

**Design/Methods**: The 24‐hour Holter electrocardiography (ECG) was performed at the diagnosis time, at the time of 120 mg/m^2^ of cumulative anthracycline dose and 240 mg/m^2^ of cumulative anthracycline dose in the 51 patients with cancer who treated with anthracycline, respectively. The heart rate variability such us SDNN, SDANN, SDNN index, rMSSD, pNN50, LF, HF, VLF, Total power, LF/HF ration and heart rate parametres such as mean average heart rate, mean minimum heart rate, mean maximum heart rate and mean RR were obtained from 24‐hour Holter ECG. The patients were classified into three groups according to increasing cumulative anthracycline doses: Group 1: at diagnosis (n=51), Group 2: 120 mg/m^2^ (n=20), Group 3: 240 mg/m^2^ (n=26). Group 1 was taken as control group.

**Results**: The median age for patients was 48 months (range 9‐192 months). All type of cancer were distributed for 36 patient (68%) of acute lymphoblastic leukemia, 2 patients (4%) of T lymphoblastic lymphoma and 15 patients (28%) of other childhood cancer who treated with anthracycline during chemotherapy protocols. However, all heart rate variability parametres were decreased after each increased cumulative dose, especially SDNN index, rMSSD, pNN50, LF, HF, Total power were significantly altered among Group 1 and Group 3. LF/HF ration was also increased as statistically significant in Group 3. According the heart rate parameters, mean average heart rate, mean minimum heart rate and mean RR were statistically significantly prolonged, especially between Group 1 and Group 3.

**Conclusions**: Heart rate variability parametres is a noninvasive technique to demonstrate cardiac autonomic neural dysfunction and the early myocardial injury.

### PO-016. The Prophylactic Use of Granulocytic‐Colony Stimulating Factor During Post Remission Induction is Associated with Increased Leukemia‐Free Survival of Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-2410}

[G. Bahoush Mehdiabadi]{.ul} ^1^, K. Arjmandi Rafsanjani^2^

*^1^Associated Professor in Pediatric Hematology and Oncology‐ Ali‐Asghar Children Hospital‐ Iran University of Medical Sciences, Pediatrics, Tehran, Iran; ^2^IUMS, Pediatrics, Tehran, Iran*

**Background/Objectives**: Granulocyte‐colony stimulating factor (G‐CSF) is used to prevent febrile neutropenia and support intense chemotherapy. However, its impact on long‐term outcome in oncological patients including children with acute lymphoblastic leukemia (ALL) has not been determined so far.

**Design/Methods**: In the current study follow‐up data from individual patients recruited in Ali‐Asghar Children hospital, prospective, randomized study were pooled to perform a joint analysis. Among 63 children with B‐precursor ALL treated by IC‐BFM 2002 protocol, 32 patients were assigned to receive prophylactically G‐CSF along with post‐induction chemotherapy while 31 patients were treated without G‐CSF support.

**Results**: With the median follow‐up of 7.9 years, there was a tendency towards increased 10 year probability of the leukemia‐free survival for the G‐CSF arm compared to the controls (93.9% ± 4.2% versus 80.4% ± 7.2%, P = .09); This is despite the fact that the number of high‐risk patients in the G‐CSF arm was almost twice as high as the controls. There was no early relapse in the G‐CSF arm while two cases were in the controls. There were two cases of late relapse in the G‐CSF arm compared with four cases in the controls.

**Conclusions**: The prophylactic use of G‐CSF during post‐induction chemotherapy of childhood ALL is associated with improved long‐term outcome and should be recommended especially in a setting of childhood ALL. Our analysis provides direct evidence coming from prospective studies for the impact of primary G‐CSF prophylaxis on disease‐free survival of oncological patients.

### PO-017. Elucidating and Targeting Epigenetic Metabolic Stress Response Signatures in Acute Lymphoblastic Leukemia (ALL) {#pbc27455-sec-2420}

[J. Barredo]{.ul} ^1^, G. Sun^2^, A. Shavab^3^, B. Li^3^

*^1^Univiersity of Miami Miller School of Medicine, Pediatrics‐ Medicine and Biochmeistry And Molecular Biology, Miami, USA; ^2^Univeriity of Miami Miller School of Medicine, Pediatrics, Miami, USA; ^3^Univiersity of Miami Miller School of Medicine, Pediatrics, Miami, USA*

**Background/Objectives**: Cure rates for relapsed/refractory ALL patients are poor and as a result it remains the most common cause of cancer‐related death in children and adolescents. ALL cells exhibit significant vulnerability to energy/metabolic stress and strategies targeting these pathways are viable therapeutic options.

**Design/Methods**: We treated Nalm6 cells (Bp‐ALL) with AICAR (an AMP mimetic known to disrupt cellular AMP/ATP balance that mimics energy stress and activates 5′ AMP activated protein kinase ‐ AMPK), and analyzed its mRNA transcript profile using RNAseq. Quantitative RT‐PCR and chromatin immunoprecipitation (ChIP) assays were employed to validate the RNASeq data using other Bp‐ and T‐ALL cell models.

**Results**: We found that AICAR treatment, which mimics energy stress, triggered rapid epigenetic reprogramming within an hour in all the ALL cell models. Through bioinformatics profiling, gene signatures related to mitogen activated protein kinase (MAPK) and immediate early genes (IEGs) were identified which overlapped with the known integrator (INT) transcriptional complex signature. Top hits were extensively analyzed and validated using dedicated gene expression assays. We found a dose/time dependent correlation between AICAR treatment and IEGs' repression, and upregulation of TRIM6 (inhibitor of MYC\'s transcription activation activity). Consistent with above results, ChIP assays revealed that RNA Pol‐II occupancy on the repressed gene\'s loci was also diminished/abolished following AICAR treatment. Notably, the repression of some IEGs reverted overtime, suggesting a compensatory signaling was also activated, and AMPK knock‐down experiments partially reversed AICAR‐induced DUSP1 (dual specificity phosphatase 1) gene reprogramming, suggesting a role for AMPK in its transcriptional regulation.

**Conclusions**: We conclude that AICAR treatment triggered a transient yet significant energy stress response, which led to shutting off IEGs' expression in a MAPK‐like manner, likely as a pro‐survival response. Delineating AICAR\'s AMPK‐dependent and jndependent mechanism(s) of epigenetic reprograming and responsible molecular pathways will allow us to exploit synthetic lethality in relapse/refractory ALL.

### PO-018. Comparison of Biological Characteristics and Outcomes of T‐Acute Lymphoblastic Leukemia and T‐Lymphoblastic No Hodgkin Lymphoma in Patients who Received High Dose Methotrexate {#pbc27455-sec-2430}

[M.C. Bertone]{.ul} ^1^, A. Bernasconi^1^, M.L. Galluzo^1^, V. Solernou^1^, M. Guitter^1^, C. Sánchez La Rosa^1^, N. Millan^1^, E. Alfaro^1^, J. Rossi^1^, M.S. Felice^1^

*^1^Hospital Nacional de Pediatría Prof. Dr. Juan P. Garrahan, Hematology and Oncology, Buenos Aires, Argentina*

**Background/Objectives**: T‐Acute‐Lymphoblastic‐Leukemia (T‐ALL) and T‐Lymphoblastic‐Non‐Hodgkin‐Lymphoma (T‐LNHL) usually receive similar treatment. However, it is not totally clear if they have different biological characteristics, behavior and outcomes.

Our aims were to compare biological characteristics of T‐ALL and T‐LNHL, response to treatment, events and outcome of both groups of patients.

**Design/Methods**: We analyzed data‐bases and records between January‐1996 and October‐2017 of 183 eligible T‐ALL patients accrued in 3 ALL studies and 44 T‐LNHL in 1 NHL protocol who received Methotrexate at 5g/m2 during treatment. Characteristics were compared through Chi‐square and Wilcoxon‐Sum‐Rank tests and Kaplan‐Meier and long‐rank‐test were used for estimating and comparing survival.

**Results**: There were not differences in median age and sex distribution; however, 4 infants were diagnosed in T‐ALL group. Mediastinal‐mass was detected in 56% of T‐ALL and 86% of T‐LNHL(p=0.0004). Pleural and pericardial involvement were observed in 3% and 1.6% in T‐ALL and 47% and 20% in T‐LNHL respectively(p\<0.00001). Early‐T‐precursor phenotype was detected in 17 cases of T‐ALL and in 2 T‐LNHL. Risk‐group distribution of T‐ALL was: Intermediate‐risk in 109 patients and High‐risk in 74. Stage‐groups of T‐LNHL was: I/II in 2 patients and III/IV in 42. Complete Remission (CR) was achieved in 97% of T‐ALL and 95% of T‐LNHL. Among patients who achieved CR, 35 T‐ALL and 12 T‐LNHL relapsed. Within the T‐ALL group, 15 patients died in CR and 7 developed second malignancies. DFS(SE) probability was 70(4)% for T‐ALL and 73(7)% for T‐LNHL. There were no differences in mean time for presenting relapses, and in T‐ ALL the latency for developing second malignancies was longer than relapses(p=0.0037).

**Conclusions**: Extra‐medullar compromise occurred more frequently in T‐LNHL than in T‐ALL. Even when T‐ALL is a more advanced disease, there was not a difference in survival and in mean time of relapses between both groups. Second neoplasms were observed only in T‐ALL with longer latency period.

### PO-019. Side‐Effects and Symptoms in Children and Adolescents with Down Syndrome and Acute Lymphoblastic Leukemia During Maintenance Therapy: A Qualitative Study of Parents\' Experiences {#pbc27455-sec-2440}

[C. Bohnstedt]{.ul} ^1^, L. Olersbacken^2^, K. Schmiegelow^3^, M. Stenmarker^4^, H. Baekgaard Larsen^5^, L. Schmidt^6^, E.H. Hansson^7^

*^1^Pediatrics and Adolescent Medicine, The Juliane Marie Centre‐ The University Hospital Rigshospitalet, Copenhagen‐, Denmark; ^2^The University Hospital Rigshospitalet, Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^3^University hospital Rigshospitalet, Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^4^Länssjukhuset Ryhov, Barn‐och Ungdommedicinska Klinik, Jönköping, Sweden; ^5^the Juliane Marie Centre‐ The University Hospital Rigshospitalet, Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^6^The Faculty of Health Sciences‐ The University of Copenhagen, Institute of Clinical Medicine, Copenhagen, Denmark; ^7^The University Hospital Rigshospitalet, Pediatrics and Adolescent Medicine‐ The Juliane Marie Centre, Copenhagen, Denmark*

**Background/Objectives**: Purpose: The purpose of this study was to explore the experiences from parents of patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) in relation to the background for the lower treatment intensity of maintenance treatment in patients with DS‐ALL.

**Design/Methods**: A criterion sampling of 14 parents to 10 DS‐ALL patients treated on NOPHO ALL2008 from Sweden (n=7) and Denmark (n=3) were selected to capture a wide range of experiences. The interviews were conducted in their native language and an interpreter was used in one case. The interview‐guide was structured with the topics: parents' experiences with their child\'s side‐effects and symptoms, adherence to treatment, and collaboration with physician in regulating doses to be able to address their special needs, and to provide sufficient treatment and care for this population.

The interviews were audio‐recorded with parents' permission and transcribed verbatim. The transcribed text was analyzed by the research group using qualitative content analysis.

**Results**: Main theme: Being the child\'s spokesperson to safeguard the child and it\'s specific needs (in interpreting symptoms, adhere to treatment, communication with physicians, balancing side‐effects and sufficient treatment). Sub themes: 1) Varying side‐effects and reactions to treatment, 2) Challenges in interpreting symptoms and communication, 3) Importance of adapting to the child\'s behavior, 4) Dealing with the child\'s sensitivity and dosage regulation

**Conclusions**: Parents of DS‐ALL patients experience a great variety in the degree of side‐effects and all parents' report of no difficulties in adherence to therapy. Parents experience challenges in interaction and interpretation of children with DS and ALL. However, parents possess valuable knowledge about their children\'s health condition leaving them with a great responsibility to act as a spokesperson for their children. Involving parents during treatment of ALL in children with DS enables a more accurate interpretation of symptoms which may improve the outcome.

### PO-020. Myelotoxicity Following High‐Dose Methotrexate in Children with Down Syndrome and Acute Lymphoblastic Leukemia {#pbc27455-sec-2450}

[C. Bohnstedt]{.ul} ^1^, M. Levinsen^2^, S. Rosthøj^3^, B. Zeller^4^, M. Taskinen^5^, S. Hafsteinsdottir^6^, H. Björgvinsdóttir^7^, M. Heyman^8^, K. Schmiegelow^9^

*^1^Pediatrics and Adolescent Medicine, The Juliane Marie Centre‐ The University Hospital Rigshospitalet, Copenhagen‐, Denmark; ^2^The Juliane Marie Centre‐ The University Hospital Rigshospitalet, Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^3^University of Copenhagen, Department of Biostatistics‐, copenhagen, Denmark; ^4^University Hospital Oslo, Department of Pediatrics‐, Oslo, Norway; ^5^Children\'s Hospital‐ Helsinki University Hospital, Childeren\'s Hospital, Helsinki, Finland; ^6^University Hospital Reykjavik, Department of Pediatrics‐, Reykjavik, Iceland; ^7^Karolinska Institute‐, Childhood Cancer Research Unit Department of Women\'s and Children\'s Health, Stockholm, Sweden; ^8^Karolinska Institute, Childhood Cancer Research Unit Department of Women\'s and Children\'s Health‐, Stockholm, Sweden; ^9^The University Hospital Rigshospitalet, Pediatrics and Adolescent Medicine‐ The Juliane Marie Centre, Copenhagen, Denmark*

**Background/Objectives**: Children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) have an inferior prognosis compared to non‐DS ALL patients. High‐dose methotrexate (HD‐MTX) given concurrently with oral 6‐mercaptopurine (6MP) is frequently followed by myelotoxicity causing treatment interruption. HD‐MTX may enhance incorporation of the cytotoxic 6MP metabolites into DNA. The increased dosage of chromosome 21 genes in DS‐ALL may increase the cellular MTX uptake by the reduced folate carrier.

**Design/Methods**: We reviewed the courses of white blood cell (WBC) and absolute neutrophil counts (ANC) for 3 weeks following HD‐MTX during MTX/6MP maintenance therapy for children in the Nordic countries. We compared DS‐ALL diagnosed 1992‐2008 to non‐DS‐ALL diagnosed 1992‐1996.

**Results**: We had a total of 7238 blood samples following HD‐MTX courses. Non‐DS ALL received reduced doses in 6.0% of the HDM treatment (110 of 1727), whereas DS‐ALL received reduced doses in 32% of the courses (29 of 91), p\<0.0001).Models describing levels of WBC and ANC following HD‐MTX, the courses were significantly different between groups defined by their 6MP dose and for DS‐ALL vs. non‐DS ALL (p\<0.001 and p\<0.001 respectively) However, there were no differences in the time to nadir from HD‐MTX administration. Similarly, there were no differences for DS and non‐DS patients receiving full dose 6MP in the absolute reduction of ANC or WBC levels. The HD‐MTX clearance, measured as s‐MTX at 24, 36 and 42 hours after the HDM‐MTX infusion started, was similar for the DS‐ALL and non‐DS ALL on full‐dose HD‐MTX (p=0.06). For those DS‐ALL and non‐DS ALL with reduced HD‐MTX dose, the s‐MTX levels were different for non‐DS‐ALL a nd DS‐ALL (p \<0.0001).

**Conclusions**: In conclusion, myelotoxicity is similar in frequency and intensity in DS vs non‐DS ALL. Thus, HD‐MTX dose reduction should not be recommended. Prospective studies are needed to determine if 6MP dose reduction necessary to avoid myelotoxicity in DS.

### PO-021. The Toys Sewing School for Mothers During the Long‐Term Hospital Stay {#pbc27455-sec-2460}

A. Solovyeva^1^, [I. Borovova]{.ul} ^2^

*^1^Russian Association of oncological patients "Zdravstvuy!", Russian Association of oncological patients "Zdravstvuy!", Moscow, Russia; ^2^Russian Association of oncological patients "Zdravstvuy!", Russian Association of oncological patients "Zdravstvuy!", Moscow, Russia*

**Background/Objectives**: In 2016, in children under the age of 15, malignant neoplasms were diagnosed for the first time in 3,335 cases, which is 33.4% higher than in 2006 (2,425 cases). 3,803 cases of malignant neoplasms were detected in children under the age of 18 years. The diagnosis of "cancer" changes not only the patient\'s life, but also the lives of his loved ones. Cancer occurs in children and young people increasingly. Having a child with cancer has a great impact on families' psychological health. Creativity and love help to face any ailment.

Parents, whose children are fighting against cancer, need the assistance to get distracted from heavy thoughts, find their business during hospital stay and become happier.

**Design/Methods**: Conference Theme: Advancing cure, transforming care. We submit the abstract to the session: 1) Understanding Impact of Having A Child with Cancer on Family Dynamics

**Results**: "Very skillful hands" is a weekly free master‐class on sewing for moms with children on long‐term treatment. Each participant of the project gets a starter kit with threads and needles, patterns, cloth flaps and, of course, sewing skills, a new hobby and things sewn by hand. From each shred a toy was born, a new character which the mothers of courageous patients create according to the ideas of their children. Moms‐masters give smiles, warmth and joy, and cute little friends help the children to recover faster. Participants are granted a certificate of completion of the course after the complete production of three toys.

**Conclusions**: mothers support their children and each other on the way to recovery. The participants receive a certificate at the end of the course and many of them, having already stepped outside the walls of oncological centers, even open their small sewing business.

*Disclosures*: No relevant conflicts of interest to declare.

### PO-022. Long‐Term Results of the Risk‐Stratified Treatment of Childhood Acute Lymphoblastic Leukemia in China: A Retrospective Study of the SCMC‐ALL‐2005 Protocol {#pbc27455-sec-2470}

[J. Cai]{.ul} ^1^, S. Shen^1^, J. Chen^1^, H. Xue^1^, C. Pan^1^, Y. Gao^1^, Y. Tang^1^, J. Wang^1^, B. Li^1^, X. Wang^1^, J. Chen^1^, L. Gu^1^, J. Tang^1^

*^1^Shanghai Children\'s Medical Center‐ Shanghai Jiao Tong University school of Medicine‐ Key Lab of Pediatric Hematology & Oncology of China Ministry of Health, Hematology/Oncology, Shanghai, China*

**Background/Objectives**: This retrospective study, conducted at Shanghai\'s Children\'s Medical Center in China (SCMC), investigated the long‐term results of risk‐stratified treatment of childhood acute lymphoblastic leukemia (ALL) in order to improve the outcomes of childhood ALL and to identify prognostic factors.

**Design/Methods**: From 2005 to 2014, patients with ALL aged 1 to 18 years old were enrolled and treated using the risk‐stratified SCMC‐ALL‐2005 protocol.

**Results**: From 2005 to 2014, patients with ALL aged 1 to 18 years old were enrolled and treated using the risk‐stratified SCMC‐ALL‐2005 protocol. The analysis included 1085 evaluable patients. Treatment intensity was based on the patients' presenting features, genetic abnormalities, early response to treatment, and level of minimal residual disease (MRD). Complete remission (CR) was achieved in 96.6% of patients. At 10 years, the event‐free survival (EFS) rate was 65±2.0%, and the overall survival rate was 77±1.0%. The 10‐year EFS rates were 76.6%, 64.0%, and 14.3% for patients in low‐risk (LR), intermediate‐risk (IR), and high‐risk (HR) groups, respectively. Induction failure conferred worse prognosis. Patients younger than 1 year of age at diagnosis, T‐cell immunophenotype, and male gender were associated with significantly worse prognosis (*P*=0.000). MRD‐positive status (\>0.01%) on day 55 was associated with significantly reduced EFS (10‐year EFS of 72.7% vs. 44.2%, *P*=0.000), especially in patients who achieved CR.

**Conclusions**: The overall outcomes for LR and IR patients treated with protocol SCMC‐ALL‐2005 in SCMC were reasonable. MRD‐negative status on day 55 of induction therapy had important predictive and therapeutic implications.

### PO-023. Successful Stepwise Treatment Intensification of the SIOP PODC Graduated Intensity Regimen for Acute Lymphoblastic Leukemia in a Resource Limited Tertiary Referral Center in the Philippines {#pbc27455-sec-2480}

[J.P. Caneba]{.ul} ^1^, J. Estanislao^1^, P. Fajardo^1^, C. Lam^2^, A.P. Alcasabas^1^

*^1^Philippine General Hospital, Pediatrics‐ Hematology & Oncology, Manila, Philippines; ^2^St. Jude Children\'s Research Hospital, Department of Global Pediatric Medicine‐ Department of Oncology, Memphis, USA*

**Background/Objectives**: At the Philippine General Hospital, the adoption of the International Society of Pediatric Oncology (SIOP) Pediatric Oncology in Developing Countries (PODC) Graduated intensity regimen 1 for acute lymphoblastic leukemia (ALL) improved outcomes compared to baseline, with reported 5‐year overall survival (OS) at 39%, and both toxic death rate and treatment abandonment rates at 17%. In 2012, we proceeded with stepwise protocol intensification to regimen 2. We report our outcome.

**Design/Methods**: Prospective data collection with retrospective analysis for newly‐diagnosed ALL patients (0‐18 yrs.) seen from January 1, 2012 through December 31, 2016. Patients were stratified to standard risk (SR), high risk (HR) and very high risk (VHR), based on NCI criteria, CNS status, immunophenotype, day 8 prednisone response and post induction bone marrow morphology. Treatment outcome was analyzed at endpoint March 2018.

**Results**: There were 311 patients evaluable. Risk classification: SR:138 (44%), HR:105 (34%) and VHR 68 (22%). Remission induction was 81% (253) as 6% (19) died, 10% (30) abandoned and 3% (9) had resistant ALL. Deaths in first remission was 4%. Relapse occurred in 18% (55) patients (SR:12%, HR:19%, VHR:28%) and 40% achieved second remission. With a median follow‐up of 25.4 months (range 0.1-- 75.6), 61% (154) of complete responders are in continuous complete remission. Five‐year EFS and overall survival (OS) with abandonment as event were 48% and 51%, respectively. EFS/OS were 52%/64%, 46%/49% and 29%/34% for SR, HR and VHR, respectively.

**Conclusions**: Stepwise treatment intensification to Regimen 2, coupled with improvements in supportive care, was associated with better overall survival. Although abandonment and relapse are major causes of treatment failure, the role of institutional delays and protocol non‐adherence should be evaluated particularly for SR patients. Further treatment stratification of HR and VHR patients to regimen 3 could further improve outcome.

### PO-024. Improved Treatment Outcome of Adolescents with Acute Lymphoblastic Leukemia by Minimal Residual Disease‐Based Therapy in Taiwan: A Single Center Report {#pbc27455-sec-2490}

[S.H. Chen]{.ul} ^1^, T.H. Jaing^1^, C.P. Yang^1^, I.J. Hung^1^, T.Y. Chang^1^, Y.J. Huang^2^, L.Y. Shih^2^

*^1^Linkou Chang Gung Memorial Hospital, Pediatric Hematology/Oncology, Taoyuan, Taiwan R.O.C.; ^2^Linkou Chang Gung Memorial Hospital, Hematology/Oncology, Taoyuan, Taiwan R.O.C*.

**Background/Objectives**: Adolescents with acute lymphoblastic leukemia (ALL) have been reported as having a poorer prognosis compared to younger patients. Recent studies have demonstrated that personalized treatment based on minimal residual disease (MRD) can improve outcome by identifying patients who can be successfully managed with low‐intensity regimens as well as those who require intensified treatment to avert relapse. The aim of our study was to evaluate the impact of MRD‐based therapy on treatment outcome of adolescents with ALL in a single center in Taiwan.

**Design/Methods**: Between 1996 and 2016, 411 pediatric ALL patients, including 63 adolescents aged 12 to 18 years, had complete genetic/cytogenetic analysis at diagnosis and were treated with consecutive Taiwan Pediatric Oncology Group (TPOG)‐ALL protocols at Linkou Chang Gung Memorial Hospital, Taiwan. In earlier TPOG‐ALL protocols, risk stratification was based on presenting clinical features and leukemic cell genetics. In the latest TPOG‐ALL‐2013 protocol, we started to determine MRD by multiparameter flow cytometry, PCR analysis or both, and the MRD level was used to guide further treatment intensity.

**Results**: The 63 adolescents were significantly more likely to have T‐cell ALL, the t(9;22)(*BCR‐ABL1*), and the t(1;19)(*TCF3‐PBX1*); they were less likely to have the t(12;21)(*ETV6‐RUNX1*) and hyperdiploidy compared with younger patients. Forty‐eight adolescent patients were treated with earlier TPOG‐ALL protocols. Fifteen adolescent patients underwent chemotherapy with TPOG‐ALL‐2013 protocol. There was no significant difference in definitive risk group allocation compared to earlier TPOG‐ALL protocols. Three patients in the provisional HR group with MRD \> 0.01% at the end of induction were assigned to the definitive VHR group. The overall treatment outcome was better in patients treated with TPOG‐ALL‐2013 protocol: 4‐year event‐free survival rates 86.7% vs. 59.6% (*P* = 0.12).

**Conclusions**: Although the case number was small and the follow‐up duration was short, more adolescents with ALL are cured with MRD‐based risk‐adjusted intensive chemotherapy.

### PO-025. Long‐Term Results of Childhood Acute Lymphoblastic Leukemia: A Single Center Review of the CCLG‐ALL2008 Study in China {#pbc27455-sec-2500}

[X. Chen]{.ul} ^1^, X. Liu^1^, Y. Guo^1^, Y. Zou^1^, B. Zhao^1^, W. Yang^1^, M. Wang^1^, M. Ruan^1^, X. Zhu^1^

*^1^Institute of Hematology‐ Blood Disease Hospital, Chinese Academy of Medical Sciences CAMS, Department of Paediatric Haematology, tianjin, China*

**Background/Objectives**: From 2008, the China Children Leukemia Group (CCLG) conducted a risk‐oriented study of acute lymphoblastic leukemia(ALL), CCLG‐ALL2008.

**Design/Methods**: We analyzed the long‐term outcome of 938 ALL patients treated according to a CCLG‐ALL2008 platform between 2008 and 2015 in our center.

**Results**: The complete remission rate of all patients was 97.3%, death in remission 1.3%.The 10‐year event‐free and overall survival (OS) rates for all children were 71.9 ±1.8% and 79.0 ± 1.6%, respectively. The OS rate for standard risk, middle risk and high risk group were 92.8 ±1.7%, 76.9 ±2.9% and 61.8 ±3.9%, respectively (p \< 0.001). By the last follow up, the development of a second neoplasm was 0.5%, with 25.1% of patients was relapsed. In high risk group, 9.5% of patients received stem cell transplant during the first complete remission stage. In this protocol, Tyrosine Kinase Inhibitor(TKI) wasn\'t regularly combined with chemotherapy for patients with BCR/ABL, 10 out of 44 patients treated with TKI, the 10‐year OS was 47.1 ±11.2%.

**Conclusions**: The survival rate of children with ALL has increased to approximately 90% after substantial progress in risk‐oriented treatment strategies in some study group. It seems lower survival rate in developing countries. Patients with BCR/ABL had poor outcome because of lower rate of TKI used. Increase the number of transplantation may further increase cure rates and reducing the relapse for the high risk group of patients.

### PO-026. High Dose Methotrexate in Acute Lymphoblastic Leukaemia without Monitoring Drug Levels: Experience from a Rural Cancer Centre in India {#pbc27455-sec-2510}

[P. Chitalkar]{.ul} ^1^, C.D. Yadlapalli^2^, A. Punia^3^, V. Gumdal^3^, R. Mishra^3^, N. Gupta^3^, P. Kumbhaj^3^, A. Bs^3^, R. Sharma^3^

*^1^Director SAIMS Cancer Centre, Department of Medical & Pediatric Oncology, Indore, India; ^2^SAIMS‐ Indore‐ India, Medical Oncology, Indore, India; ^3^SAIMS, Medical Oncology, Indore, India*

**Background/Objectives**: High‐dose methotrexate (HDMTX), ≥500mg/m2, delivered over 4‐36 h infusion with leucovorin(LV) rescue is a therapeutic strategy in acute lymphoblastic leukemia (ALL). Methotrexate level estimation has logistical issues in rural, underserved areas. We report the experience of HDMTX use with leucovorin rescue without monitoring of MTX levels.

**Design/Methods**: In a retrospective study 24 patients from Jan‐2015‐ Feb 2018, were treated on BFM‐2002 protocol, after risk stratification. HDMTX(2‐5 g/m2) was given over 18 hours after 2 consecutive urine pH \> 7.5, with hydration, sodium bicarbonate and urinary alkalinization. Leucovorin rescue(15mg/m2) started 10 hours after completion, for total of 6 doses every 4th hourly. Toxicities were recorded based on Common Terminology Criteria for Adverse Events(CTCAE) Version 4.03.

**Results**: There were 24 patients(M:F 15:9), median age 7 y (2‐29y).Median distance from hospital 150 km. Eight (33%) were supported by the Teenage & Young Adult Cancer(TYAcan) Foundation. Thirteen were standard risk (SR),7 intermediate(IR) and 4 high risk(HR). Four cycles of HDMTX given for SR and IR; whereas HR patients received 2 cycles of HDMTX. Eighty‐eight cyles of HDMTX were administered. Elevation in ALT (2‐3 times ULN) occurred in 19(22%); serum bilirubin elevation upto 2.4mg% in 2(3%). Nausea and vomiting occurred in 3(4%); oral mucositis in 12(14%).Transient elevation in serum creatinine noted in 2(2%). Hematological toxicity occurred in 7(8%); subacute encephalopathy occured in 1(0.8%).Morbilliform rash in 6(7%).Most toxicities were grade 2‐3 and managed conservatively. Two patients relapsed: one in IR with isolated testicular relapse and one in HR with marrow, testicular & CNS relapse.

**Conclusions**: The unavailability of MTX levels and delayed turn‐around time of outsourced samples, maintaining cold chain are challenges. The use of HDMTX with careful pretreatment evaluation, with adequate hydration, alkalanization and leucovorin appears feasible with manageable toxicities even in patients coming from long distances and pemits risk‐adapted therapy, in rural patients with limited resources.

### PO-027. Survival of Filipino Children with Acute Lymphoblastic Leukemia Diagnosed in a Tertiary Referral Center for Childhood Cancer: A Retrospective Cohort Study {#pbc27455-sec-2520}

[T. Chu]{.ul} ^1^, A.M. Shiu^1^, M.C. Leongson‐Cruz^1^, M.B. Gepte^1^

*^1^Philippine Children\'s Medical Center, Cancer and Hematology Center, Quezon City, Philippines*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) represents the largest group of pediatric malignancies. The high cure rate of childhood ALL represents one of the most remarkable success stories in the war on cancer. In a lower middle income country (LMIC) like the Philippines, we reviewed the five year survival in a tertiary referral center. This retrospective cohort study aims to determine the survival of children 1‐18 years old with ALL treated at a tertiary referral center for childhood cancer from January 2012 to December 2016.

**Design/Methods**: Research design employed a retrospective cohort study. Medical Charts of newly diagnosed ALL ages 1 to 18 years old from January 2012 to December 2016 were reviewed.

**Results**: A total of 435 subjects were included in the study. The 5 year overall survival (OS) and event free survival (EFS) were 65.3% and 62.8%, respectively. The 5 year OS for standard risk ALL was 68.8% and for high risk patients was 50%. The 5 year OS for the patients on remission was 83.7% and for those who relapsed was 21.1%. Univariate and multivariate by Cox proportional hazards regression revealed WBC count at diagnosis, risk classification, immunophenotyping, and relapse showed significant prognostic impact for mortality. Age and gender were reported with no prognostic significance.

**Conclusions**: The 5‐year OS and EFS were lower compared to the developed countries but are comparable with other LMICs. The prognostic factors identified were compatible with the literature. Prognosis after relapse is poor. Overall, the adopted treatment protocols for childhood ALL in this institution showed acceptable results.

### PO-028. Improving Quality of Care: Desires of Mothers Caring for Children Newly Diagnosed with Acute Lymphocytic Leukemia {#pbc27455-sec-2530}

[C. Chun Fei]{.ul} ^1^, H. Yu‐Ping^2^, C. Yueh‐Chih^3^, H. Fang‐Liang^4^

*^1^9F.‐1‐ No.40‐ Ln. 22‐ Baoning Rd.‐ Shalu Dist.‐ Taichung City 433‐ Taiwan R.O.C. Daytime and evening phone number:+886 919 066 803, RN‐ Master degree‐ Department of Nursing‐ and Preceptor ‐ Hung Kuang University, Taichung City 433, Taiwan R.O.C.; ^2^National Quemoy University School of Nursing, RN‐ PhD‐ Associate Professor, Kinmen County 89250, Taiwan R.O.C.; ^3^College of Medicine National Taiwan University, RN‐ PhD ‐Professor Emeritus School of Nursing, Taipei County100, Taiwan R.O.C.; ^4^Hung kuang University, Assistant Professor‐Hung kuang University‐ Director of hemotolgical section and Attending doctor of infectious disease section‐ department of pediatrics‐ Taichung Veterans General Hospital‐ Taichung Veterans General Hospital, Taichung City 433, Taiwan R.O.C*.

**Background/Objectives**: Mothers feel shock, fear, anxiety, and sadness upon learning that their child has been diagnosed with acute lymphocytic leukemia (ALL). Following a child\'s cancer diagnosis, mothers must assume new roles and responsibilities, especially in the first year following the diagnosis. This study examined the desires of mothers caring for children within 1 year of an initial ALL diagnosis.

**Design/Methods**: This research adopted a qualitative model and involved semi‐structured guided interviews of 12 mothers aged from 34 to 43 years with children aged from 1 year and 9 months to 16 years who had been diagnosed with ALL to explore maternal desires when caring for children with cancer. All interview transcripts were verbatim, and data analysis was performed using content analysis.

**Results**: Findings revealed that the mothers' desires were as follows: not wanting to feel alone in terms of availability of emotional support and understanding from their family and health professionals; wanting to learn appropriate knowledge and skills from health professionals, the Internet, and other parents of children with cancer; wanting health professionals to take the time to discuss their children\'s condition; wanting extra support so they can care for their other healthy children; wanting God to protect their sick children from the danger posed by the cancer and treatment; wanting spiritual support to provide the family with the willpower to overcome this difficult period; and wanting financial security because they have had to resign from their job and pay for the cancer treatment.

**Conclusions**: Health professionals should not only provide emotional, informational, and practical support but also use various resources to assist mothers in overcoming the challenges faced when caring for a child with cancer, such as by holding family, social welfare, and interdisciplinary meetings, to enhance the quality of care provided to children and their families.

### PO-029. Copy Number Alterations in Oncogenic Pathways Associated with Immunophenotypic Profiles in Pediatric T‐Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-2540}

[L. Codeço‐Marques]{.ul} ^1^, E. Terra‐Granado^1^, F. Gomes de Andrade^1^, I. Sardou‐Cezar^1^, E. Pereira Noronha^1^, M.S. Pombo‐de‐Oliveira^1^

*^1^Instituto Nacional de Câncer, Pediatric Hematology Oncology Program, Rio de Janeiro, Brazil*

**Background/Objectives**: T‐cell acute lymphoblastic leukemia (T‐ALL) is a heterogeneous disease regarding immunophenotypic profile and molecular alterations. In contrast with precursor B‐cell ALL, the immunophenotype‐genotype and outcome associations are not completely understood.

**Design/Methods**: We investigated somatic alterations (*IL7R, FLT3, FBXW7, NOTCH1, N/KRAS* mutations, *STIL‐TAL1*, *TLX3* and *KMT2A* gene rearrangements and copy number alteration \[CNA\]) and evaluated their correlation with clinical, laboratory features and maturative profile. The immunophenotype was evaluated in 139 T‐ALL cases (\<19 years old). Mutations and fusion genes were identified according to standard molecular techniques (PCR, direct sequencing and RT‐PCR and multiplex ligation dependent probe amplification \[MLPA, kit MC Holland P383‐A1\]).

**Results**: *TLX3*pos cases was associated with alterations in epigenetic regulators (*EZH2*, *SUZ12* and *PHF6*) (p=0.028), while *STIL‐TAL1*pos was negatively correlated with alterations in signalling pathways (*N/KRAS*, *FLT3*, *IL7R*, *NUP214‐ABL1*, *PTEN*, *NF1*, *PTPN2*) (p=0.025). Regarding the immunophenotype‐genotype association, alterations in epigenetic regulators were associated with ETP‐ALL (p=0.001), as was *FLT3*mut (p\<0.0001) while *CDKN2A/B*del was rarely found in this subtype (p\<0.0001). When analysing TCR cellular expression, TCRαβpos cases had a higher frequency of *STIL‐TAL1*pos, *PTEN*del and *LEF1*del (p=0.001, p=0.009 and p=0.034), while TCRγδpos were *TLX3*pos and *SUZ12*del (p\<0.0001 and p=0.019 respectively). *IL7R*mut, *FLT3*mut and *NF1*del were also found in this group of T‐ALL cases. Analysing T‐ALL survival, the probability of overall survival (pOS) was 62.5% and ETP‐ALL had no impact on pOS. Regarding molecular alterations, *STIL‐TAL1*pos cases had lower pOS (38.0%) than *STIL‐TAL1*neg (pOS 66.1%) (p=0.001), while *NOTCH1/FBXW7*mut cases (pOS 68.8%) and *N/KRAS*mut cases (pOS 92.9%) had a higher pOS (p=0.005 and p=0.028 respectively).

**Conclusions**: TCRγδpos T‐ALL had an association with alterations in genes that were enriched in the immature phenotype subtype, such as epigenetic regulators and signaling pathway regulators. *STIL‐TAL1*, *NOTCH1/FBXW7* and *N/KRAS* genomic alteration had an association with T‐ALL outcome in this cohort.

### PO-030. Neurocogntive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-2550}

[V. Cr]{.ul} ^1^, R. Seth^1^, S. Sapra^1^

*^1^All India Institute of Medical Sciences, Paediatrics, New Delhi, India*

**Background/Objectives**: With improving survival in acute lymphoblastic leukemia (ALL), now the focus is on late effects of therapy. Among these neurocognitive deficits are the most worrisome. The objective of the study was to determine prevalence, spectrum and the various factors associated with neurocognitive deficits in survivors of ALL aged 6 to 17 years.

**Design/Methods**: It was an observational, cross‐sectional study. 70 children were enrolled in the study. The neurocognitive functions were assessed by using the Indian adaptation of Wechsler intelligence scale for children‐IV (WISC‐IV). Full scale intelligence quotient (FSIQ) and the 4 primary index scores were determined.

**Results**: The prevalence (95% confidence interval) of neurocognitive deficits in the sample population was 50% (38% ‐ 62%). The prevalence (95% confidence interval) of deficits in the sample population in verbal comprehension was 49% (37% ‐ 60%), in perceptual reasoning was 50% (38% ‐ 62%), in working memory was 47% (35% ‐ 59%) and in processing speed was 44% (32% ‐ 56%). Among the various risk factors assessed, lower socioeconomic status, poorer maternal & paternal education and higher birth order were associated with increased prevalence of neurocognitive deficits in the sample population. Other factors including gender, age at assessment, age at initiation of treatment, number of siblings, family type, presence of CNS disease at diagnosis and type of chemotherapy protocol used were not statistically significant. Children with neurocognitive deficits had poorer nutrition status at the time of initiation of therapy and at the time of assessment.

**Conclusions**: The prevalence of neurocognitive deficits in the survivors of childhood ALL was high (50%) as hypothesized. Only 26% children had normal scores in all the 4 domains. The prevalence of deficits was higher in perceptual reasoning as compared to the other 3 primary index scores.

### PO-031. Health Insurance Scheme Positively Impacts Outcomes of Childhood Acute Lymphocytic Leukemia in the Philippines {#pbc27455-sec-2560}

[M.C. Cruz]{.ul} ^1^, J. Lecciones^1^, T. Chu^1^, M.F. Sisteberio^1^

*^1^Philippine Children\'s Medical Center, Cancer and Hematology Center, Quezon City, Philippines*

**Background/Objectives**: Disparities in survival outcomes of pediatric acute lymphocytic leukemia (ALL) are largely due to the high out of pocket cost in low income countries like the Philippines. In 2012, Philhealth, the government insurance system, launched the Z benefit package for standard risk (SR), treatment naive childhood ALL. We determined the outcomes of patients who were enrolled in the Z benefit from 2013 to 2017 at the Philippine Children\'s Medical Center.

**Design/Methods**: Patients were enrolled consecutively. Demographic and clinical data were gathered, which included age, gender, initial white blood cell count, initial CSF analysis with cytospin, testicular involvement for males, and bone marrow morphology with immunophenotyping. The National Cancer Institute (NCI) clinical criteria for risk stratification was used. Only SR patients with Philhealth eligibility were able to avail of the Z benefit. The modified BFM‐Hong Kong ALL protocol was used to treat the patients.

**Results**: A total of 470 patients were newly diagnosed to have ALL. There were slightly more males (n=263, 56%) than females. SR patients comprise 51.5% (n=242). Overall, 159 (65.7%) patients were enrolled in Z benefit. Eligibility and availment had a dramatic increasing trend: 2013 -- 28.3%; 2014 -- 48.9%; 2015 -- 73.5%; 2016 -- 90.9%; 2017 -- 93.6%. More patients (n=12, 14.4%) abandoned treatment among those who did not have Z benefit compared to the patients (n=6; 3.8%) who availed. Likewise, more patients relapsed from those without the Z benefit, 17 of 83 (20.5%) versus 12 of 159 (7.5%) patients with Z benefit. EFS and OS for those with Z benefit were 93.9% and 91.2% respectively while those without Z benefit, had an EFS and OS of 92.4% and 84.3%.

**Conclusions**: Our data suggest that establishment of a financing scheme is effective in dismantling economic barriers to care and translates to improved outcomes for children with ALL.

### PO-032. A Cost Analysis of Childhood Acute Lymphoblastic Leukemic Randomised to Treatment with PEG‐Asparaginase Administered at Either 2‐ or 6‐Week Intervals {#pbc27455-sec-2570}

H. Vogt^1^, [T. Davidson]{.ul} ^2^, M. Heyman^3^, J. Malmros^3^, N. Mogensen^3^, M. Stenmarker^4^, A. Harila‐Saari^5^

*^1^Linköping University, Department of Clinical and Experimental Medicine‐ and Crown Princess Victoria Children\'s Hospital‐ Linköping University Hospital, Linköping, Sweden; ^2^Linköping University, Department of Medical and Health Sciences‐ Division of Health Care Analysis, Linköping, Sweden; ^3^Karolinska Institutet, Department of Women\'s and Children\'s Health‐ Division of Pediatric Oncology, Stockholm, Sweden; ^4^Futurum Academy for Health and Care‐ Jönköping County Council, and Department of Paediatrics‐ Institution for Clinical Sciences‐ Sahlgrenska Academy‐ University of Gothenburg, Jönköping, Sweden; ^5^Uppsala University, Department of Women\'s and Children\'s Health, Uppsala, Sweden*

**Background/Objectives**: Treatment with pegylated asparaginase (PEG‐asparaginase) for childhood acute lymphoblastic leukaemia (ALL) is a crucial part of most paediatric ALL treatment protocols. However, information about optimal treatment intensity is unclear, causing uncertainty regarding efficacy and toxicity of the treatment as well as its impact on health care costs.

The current paediatric ALL treatment protocol of the Nordic countries NOPHO ALL‐2008 randomised patients to PEG‐asparaginase during delayed intensification and early maintenance at two‐ versus six‐week intervals and a total of 15 vs 8 doses with two‐week intervals and 15 doses as the standard treatment. The purpose of our study was to compare resource use and costs of childhood ALL treatment according to NOPHO ALL‐2008 between the randomised groups.

**Design/Methods**: A retrospective study design was used based on patient files of two consecutive years (2009‐2010) from two Swedish University Hospitals. A total of 45 patients with ALL treatment according to NOPHO‐ALL 2008 protocol was investigated. Costs were calculated in Euro (€) based on all health care consumption due to ALL up to 2.5 years after diagnosis.

**Results**: The total cost of patients treated with PEG‐asparaginase administered in the standard arm was €213,617 while the corresponding cost of patients treated with the experimental arm (8 doses, 6‐week intervals) was €172,230. This difference in costs was not significant (p=0.344).For patients not included in the randomization (n=23) costs were higher than for patients included in the study (n=22) (€311,774 vs €195,032, p=0.009).

**Conclusions**: We have found that total treatment costs did not differ between patients treated with PEG‐asparaginase administered at two‐ or six‐week intervals. Since the higher frequency and total dose of PEG‐asparaginase did not seem to influence survival but had a clear impact on toxicity (Klug‐Albertsen et al., Blood 2017 130:1275), PEG‐asparaginase administered at six‐week intervals and a lower total dose is to be preferred in this treatment context.

### PO-033. The Use of Bovine Colostrum Against Chemotherapy‐Induced Gastrointestinal Toxicity in Children with Acute Lymphoblastic Leukemia: A Double‐Blind Placebo‐Controlled Randomized Trial {#pbc27455-sec-2580}

M. Rathe^1^, [S. De Pietri]{.ul} ^2^, P.T. Sangild^3^, S. Husby^1^, T.L. Frandsen^2^, S.W. Wehner^1^, K. Schmiegelow^2,4^, K. Müller^2,4^

*^1^Hans Christian Andersen Children\'s Hospital‐ Odense University Hospital, Department of pediatric hematology and oncology, Odense, Denmark; ^2^Rigshospitalet‐ University of Copenhagen, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^3^University of Copenhagen, Department of Clinical Veterinary and Animal Science‐ Section of Comparative Pediatrics and Nutrition, Copenhagen, Denmark; ^4^University of Copenhagen, Institute of Clinical Medicine‐ The Faculty of Health and Medicine, Copenhagen, Denmark*

**Background/Objectives**: Gastrointestinal toxicity is a common adverse effect of chemotherapy in childhood acute lymphoblastic leukemia (ALL). It presents with oral mucositis, diarrhea, abdominal pain and increased risk of infections. Bovine colostrum (BC) is rich in trophic and immune‐modulating factors and it has shown a protective effect against chemotherapy‐induced gastrointestinal toxicity in piglets. A randomized double‐blind placebo‐controlled trial was established to investigate if BC affects gastrointestinal toxicity, systemic inflammation and infectious morbidity chemotherapy for childhood ALL.

**Design/Methods**: A total of 62 children (1‐18 years) with ALL treated according to the NOPHO‐ALL2008 protocol at Odense University Hospital and University Hospital Rigshospitalet, Denmark (2013‐2016), were randomized at diagnosis to daily nutritional supplement with BC or a placebo product during induction therapy. Families registered daily compliance, body temperature, and gastrointestinal toxicity through the pediatric Oral Mucositis Daily Questionnaire (OMDQ). Gastrointestinal toxicity was scored weekly by the investigators using the NCI‐CTCAE 4.0 criteria. Plasma CRP was measured weekly. Blood cultures and intravenous antibiotics were registered throughout induction treatment. Outcomes were investigated by intention‐to‐treat analysis.

**Results**: Out of 62 patients, 32 (52%) were randomized to placebo and 30 (48%) to BC with similar overall compliance (49.1% and 53.1%, respectively, p=0.19). The two groups did not differ in gender, age, ALL phenotype, risk group, or treating center. Overall, BC did not influence the incidence (p=0.44) or severity (p=0.19) of OMDQ‐assessed mucositis over the four weeks of induction. Nevertheless, the severity of oral mucositis by NCI‐CTCAE in the first two weeks was significantly lower in the BC group compared to the placebo group (OR=0.22, 95% CI 0.05‐0.88, p=0.03). Patients receiving placebo and BC did not differ in number of days with fever, number of bacteremia episodes, days on intravenous antibiotics or CRP levels.

**Conclusions**: Despite low compliance, these preliminary results show a protective effect of BC against chemotherapy‐induced oral mucositis.

### PO-034. Safe Administration of High Dose Methotrexate with Minimal Drug Level Monitoring: Experience from a Center in North India {#pbc27455-sec-2590}

[H. Dhingra]{.ul} ^1^, M. Kalra^1^, A. Mahajan^1^

*^1^Indraprastha Apollo Hospital, Pediatric hematology and oncology, delhi, India*

**Background/Objectives**: High dose methotrexate (HDMTX) is an integral part of management of children with Acute Lymphoblastic leukemia (ALL) and Non Hodgkin lymphoma (NHL). HDMTX can cause significant toxicity and hence needs stringent monitoring of plasma drug levels. Through this study we aim to investigate the toxicity profile of HDMTX, correlate the plasma drug levels with toxicity and also share our experience with drug level monitoring in this cohort.

**Design/Methods**: A 5 year (2011‐2015) retrospective analysis was performed for clinical and laboratory data of 184 patients, aged 0‐18 years, with ALL (168), T‐NHL (16) who underwent 598 cycles of HDMTX (3‐5 gm/m^2^). Based on our experience prior to this time (when inhouse methotrexate level estimation was not available), it was the unit policy to send the first level for monitoring after the third dose of leucovorin at 54 hours.

**Results**: Only three episodes (0.5%) developed severe toxicity in the form of severe mucositis or severe myelosupression requiring prolonged hospitalization. No patient had renal failure or life threatening toxicity. On monitoring the drug levels at 54 hours, it was seen that 11% (68 cycles) had drug levels in the range of 0.5‐1 micromol/Land 8% (50 cycles) had levels \>1 micomol/L. However, 531 cycles of HDMTX were managed with monitoring only single plasma drug level at 54 hours from the start of 24 hour infusion.

**Conclusions**: Though imperative, dynamic monitoring of plasma drug level may not always predict toxicity. The strategy of monitoring drug concentration at 54 hours was safe in our cohort.

### PO-035. Traumatic Lumbar Puncture at Diagnosis in Children with Acute Lymphoblastic Leukemia: Risk Factors and Impact on Outcome {#pbc27455-sec-2600}

[N. Dhingra]{.ul} ^1^, T. Seth^1^, P. Mishra^2^, H. Pati^1^, V. Iyer^3^, M. Mahapatra^1^, S. Tyagi^1^, R. Saxena^1^

*^1^All India Institute of Medical Sciences, Hematology, New Delhi, India; ^2^Max Super Speciality Hospital‐ Patparganj, Haematology and Bone marrow transplant, New Delhi, India; ^3^All India Institute of Medical Sciences, Pathology, New Delhi, India*

**Background/Objectives**: Traumatic lumbar puncture (TLP) at diagnosis in acute lymphoblastic leukemia (ALL) adversely impacts event‐free survival especially if blasts are also present. A platelet count of 50000/μl is recommended for diagnostic LP. In a resource‐constrained set‐up with scarcity of platelets, achieving this target is difficult. We analyzed risk factors for TLP and its impact on central nervous system (CNS) relapse in pediatric ALL.

**Design/Methods**: Medical records of children treated for ALL between 2011‐2017 were retrospectively analyzed. Putative risk factors for TLP were age, sex, body mass index, total leucocyte count and platelet count, day of protocol at LP and prior chemotherapy administered. All patients with CNS2, CNS3 and TLP (\>10 erythrocytes/μl of CSF) received additional intrathecal therapy during induction. Patients achieving remission were followed‐up and disease relapse noted.

**Results**: 129 children with a median age of 13 years (range 0.5‐18 years) and a male preponderance (M:F=3.6) were identified. 99 children (76.7%) had CNS1, 1 (0.8%) had CNS2 and 6 (4.7%) were CNS3 at baseline. TLP was seen in 23 cases (17.8%). The median day of LP was 4 (range 1‐22). None of the risk factors analyzed for TLP were found significant except hyperleukocytosis (OR 2.85, 95% CI 1.083‐7.536, *p*=0.034). The median platelet count in patients with atraumatic LP was 39000/cumm vs 25500/cumm in for TLP (*p*=0.7). The median duration of follow‐up was 19 months (range, 0‐142 months) for 113 patients in remission. CNS relapse occurred in 22 patients (19.4%). Using Kaplan‐Meier Survival estimates, the CNS relapse‐free survival (RFS) for patients with TLP was 68.3% (95% CI CI 28.5‐89.1%) and 68.6% (95% CI 45.9‐83.3%) for CNS1 at 24 months (*p*=0.59).

**Conclusions**: Hyperleucocytosis was found to be a risk ‐factor for TLP with an insignificant trend for TLP at lower platelet counts. In this cohort TLP was not found to be a risk‐factor for CNS relapse.

### PO-036. Therapy Interruption During Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia and the Risk of Relapse {#pbc27455-sec-2610}

[N. Dhingra]{.ul} ^1^, N. Gupta^1^, T. Seth^1^, M. Mahapatra^1^, S. Tyagi^1^, H. Pati^1^, R. Saxena^1^

*^1^All India Institute of Medical Sciences, Hematology, New Delhi, India*

**Background/Objectives**: Survival rates of pediatric acute lymphoblastic leukemia (ALL) in India vary between 45‐80%. Treatment abandonment, infections and disease relapse are the major causes for inferior outcomes compared to first world countries. We identified that therapy interruption during induction chemotherapy in ALL is a major impediment to long‐term relapse‐free survival (RFS).

**Design/Methods**: Medical records of children with ALL who underwent treatment between 2011‐2017 were retrospectively reviewed. All children were planned for a uniform 4‐drug induction followed by risk‐adapted post remission therapy. Therapy interruption was defined as any deviation from the protocol other than pre‐specified hepatic or renal dose modifications. Details of follow‐up were recorded till last visit.

**Results**: 129 children with median age of 13 years (range 0.5‐18 years) and male:female ratio of 3.6:1 underwent ALL induction during the study period. The median duration of follow‐up for the 113 cases that went into remission was 19 months (range 1‐142 months). Twenty‐six cases (20.1%) had therapy interruption during induction on account of severe infections in 16, jaundice in 5, l‐asparaginase induced pancreatitis in 2, seizures in 2 and hypersensitivity reaction in 1 case. Amongst the infectious causes, fungal pneumonia was observed in 11 of the 17 cases (64.7%). At end of induction morphologic remission was attained in 25 of 26 cases with therapy interruptions (96.3%). 12 of these cases (46.2%) had relapse (medullary, extramedullary or combined) as compared to 20.61% relapses in the group without therapy interruption (p\<0.01). Kaplan‐Meier survival estimates at 24 months for RFS in patients with therapy interruptions was 49.9% (95% CI 26.1‐69.7%) vs 73%(95%CI 60.1‐82.3%) for patients with no interruptions (p=0.02).

**Conclusions**: Infectious complications were the most common cause for treatment interruption. Despite achievement of morphological remission at end of induction, patients with therapy interruptions had adverse outcomes with inferior RFS.

### PO-037. Improving Treatment Compliance Increases Chances for Cure for Pediatric ALL Patients in Low Middle Income Settings {#pbc27455-sec-2620}

[C.L. Diez]{.ul} ^1^, A.J. Peralta^1^, D.V. Bautista^1^, B.J. Zainal^1^, G.A. Pecson^1^, J. Ong^1^, C. Lam^2^, M.C. Dolendo^1^

*^1^Southern Philippines Medical Center, Department of Pediatrics‐ Children\'s Cancer Institute, Davao City, Philippines; ^2^St Jude Children\'s Research Hospital, Global Pediatric Medicine Department, Memphis, USA*

**Background/Objectives**: Southern Philippines Medical Center is the largest tertiary government referral center for pediatric cancer in Mindanao, Philippines. ALL is the most common diagnosis of 200 new patients seen annually. Baseline data for ALL (2004‐2007) showed an event free time of 53.9 weeks with 43% abandonment on modified BFM protocol. Treatment regimen was shifted to COG backbone in 2008 (ALL2008). We report our outcome.

**Design/Methods**: Newly diagnosed pediatric patients with ALL (0‐18 years old) on ALL2008 treatment protocol were included in the study. A retrospective review of demographic data and treatment outcomes was conducted from hospital medical records and Pediatric Oncology Network Database during the study period (January 2008‐December 2017).

**Results**: Only 354 were eligible for analysis from 409 patients diagnosed (n=23 refused treatment upfront, n=15 on other regimens, n=17 died prior to treatment). Mean age at diagnosis is 5 years old. Male: Female ratio is 1.3:1 NCI risk classification showed SR n=171(48.3%); and HR n= 183(51.7%). Only 44 (12.4%) had immunophenotyping (B cell n=32,9%; T cell n=12, 3.4%). Remission induction was 77.7%. At study endpoint, 147 (41.5%) were alive, 35 (9.9%) relapsed, 109(30.8%) died and 88 (24.8%) abandoned treatment. Infection and bleeding were major causes of death. The 5‐year event free survival and overall survival, considering abandonment as an event were 25.6% /43.3% respectively.

**Conclusions**: The decrease in treatment abandonment reflects better compliance to the current treatment regimen allowing higher chances for cure. Improvements in supportive care addressing infection prevention and bleeding may further improve survival as well as strategies promoting enhanced access to care.

### PO-038. Low Level Central Nervous System (CNS) Disease in Acute Lymphoid Leukemia (ALL): Does it Impact Outcome? {#pbc27455-sec-2630}

[Z. Dreyer]{.ul} ^1^, A. Marcogliese^1^, S. Hashmi^1^, J. Margolin^1^, K. Kamdar^1^, J. Brackett^1^, K. rabin^1^, A. stevens^1^, T. Horton^1^, R. Redell^1^, R. Rouce^1^, J. Yi^1^, E. Schafer^1^, T. Armstrong^1^, D. Kollar^1^, L. Sealy^1^, M. Gramatges^1^, C. Steuber^1^

*^1^Baylor College of Medicine, Pediatrics, Houston, USA*

**Background/Objectives**: Historically, CNS2 disease (\< 5 WBC with blasts) twice within four weeks met the definition of CNS relapse (CNS R) in ALL. Currently, the dx of CNS R (CNS3) is ≥ 5 WBC with blasts. To assess the role of CNS2 disease on outcome, we reviewed our patients diagnosed with CNS2 disease post induction between January 2010‐March 2018.

**Design/Methods**: Twenty eight patients CNS2 CSF as a first event post induction were included with a median age of 10 yrs. At diagnosis, 20 were CNS1 (CNS1‐dx) and 8 were CNS2 (CNS2‐dx). CNS2 first events occurred in Consolidation (6); Interim Maintenance (2); Delayed Intensification (2); Maintenance (14); End of Treatment (2); \> 1 year off treatment (2). All patients were treated on /or according to COG protocols with the current Berlin/Frankfort /Munster (BFM) or augmented BFM schemas.

**Results**: Patients were categorized as: *Category 1* ‐ CNS2 x 1 with no subsequent event (CNS1‐dx 6; CNS2‐dx 1); *Category 2* ‐ CNS2 x 1 with a subsequent non CNS2 event (CNS1‐dx 7; CNS2‐dx 3); *Category 3* ‐ CNS2 x ≥ two events (CNS1‐dx 7; CNS2‐dx 4). Fourteen events occurred in CNS1‐dx: CNS3 (6), marrow relapse (5), combined CNS/BM (3) with median time to second event 2 months. Seven events occurred in CNS2‐dx: CNS3 (3), multiple CNS2 (2), marrow relapse (1); combined CNS/BM (1) with median time to second event 6 months. All patients in Category 1 remain in first remission. Six patients in Category 2 and five in Category 3 are alive with disease control on / off treatment. Ten pts died of disease or infection.

**Conclusions**: Patients with a single CNS2 event did well without further events (Category 1). No Category 2 / 3 patients remained disease free though with early recognition/intervention 11/21 (52%) remain alive and in remission.

### PO-039. Fever at Diagnosis of Acute Lymphoblastic Leukemia: Is it Always Necessary to Indicate or Maintain Empirical Antibiotherapy? {#pbc27455-sec-2640}

N. Bilbao^1^, J.M. De Pedro^1^, [A. Echebarria‐Barona]{.ul} ^1^, R. Amaia^1^, O. Itziar^1^, E. Alexandra^1^, N. Larrinaga^1^, A. Rosa^1^, A. Itziar^1^, M. Garcia‐Ariza^1^, R. López‐Almaraz^1^

*^1^Cruces University Hospital, Pediatric Oncology and Hematology Department, Barakaldo, Spain*

**Background/Objectives**: The need for empirical antibiotic therapy is well established in febrile neutropenia but remains unclear what the ideal management in patients with ALL and fever at diagnosis is. The objective of this study is to describe the prevalence and management of patients with fever and ALL at diagnosis in our unit.

**Design/Methods**: Retrospective descriptive study of children between 1‐18 years diagnosed with ALL in our center between June 2013 and January 2018. We analyzed: fever at onset (T≥38ºC axillary), days of fever, presence of severe neutropenia (absolute neutrophil count ≤ 0.5 x 109/mcl), blood cultures, and administration and duration of empirical antibiotherapy

**Results**: 50 children were diagnosed with ALL, 68% (n = 34) had fever at diagnosis. Half with Tª \<38.5ºC. In any case sepsis was suspected; although one of them was admitted to the PICU due to a fulminant hepatic failure that required an emergency liver transplant prior to ALL diagnosis. Three had a confirmed infection (8%): pneumonia (2) and digital cellulitis (1). Blood cultures were obtained in 85% of the febrile patients: 90% was negative and one was contaminated (S.capitis). The 70.5% (n = 24) of patients with fever received empirical antibiotic therapy. Median duration of fever was one day, usually disappearing within the first 12 hours after the onset of prednisone. We didn\'t find an association between neutrophil count at diagnosis and risk of fever (57% vs 81%, p = 0.076) or blast count in peripheral blood and risk of fever (p = 0.892).

**Conclusions**: Bacteremia is very rare in children with ALL and fever at diagnosis; which strengthens the theory of the possible neoplasic origin of fever. We believe that antibiotic therapy should be discontinued in patients who, at 48h, have negative cultures, remain afebrile and clinically stable; although they do remain with neutropenia.

### PO-040. Cost‐Utility of Protocols of BFM‐ALL and UK‐ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran {#pbc27455-sec-2650}

[M. Ehsani]{.ul} ^1^, H. Hayati^2^, E. Shahgholi^1^, A. Kebriaeezadeh^3^, A. Mehrvar^4^, M. Tashvighi^4^, S. Nikfar^3^

*^1^Tehran University of Medical Sciences, Pediatric Hemaiology Oncology, Tehran, Iran; ^2^Lorestan University of Medical Sciences, Faculty of Pharmacy, KhorramAbad, Iran; ^3^Faculty of Pharmacy Tehran University of Medical Sciences, Pharmacoeconomics and Pharmaceutical Departartment, Tehran, Iran; ^4^Mahak Charity Hospital, Pediatric Oncology, Tehran, Iran*

**Background/Objectives**: There is a requirement to assess the effectiveness and resources used in two protocols United Kingdom (UK‐ALL) and Berlin‐Frankfurt‐Munster (BFM‐ALL) that are most commonly used to treatment of ALL patients by oncologists in Iran. Accordingly, we analyzed the cost of treatment and utility of children treated with two protocols in Iran.

**Design/Methods**: The entire medical direct costs of patients in "BFM ALL" protocol and "UK ALL" protocol in mul‐ti‐centers calculated from Apr 2010 to Jun 2015. For calculating utility and Quality Adjusted Life Year (QALY) of the patients, we used standard questionnaire Health Utilities Index 3 (HUI3). The patients and their parents were interviewed. Data were analyzed using software SPSS18 and EXCEL.

**Results**: The average direct medical cost for each patient for BFM‐ALL was 15026 USD and UK‐ALL was 8282 USD which showed a significant difference in the total cost of the treatment in the two protocols (P≤0.02). Finally, there was a significant difference in the utility score of the maintenance phase of these two methods (P≤0.003).

**Conclusions**: UK‐ALL is dominant and BFM protocol is dominated by both sides total costs and utility and QALY. Mainly, more hospital stay in "BFM ALL" protocol is the cause of raised costs in this protocol. Conse‐quently, by considering different QALYs in the methods and low costs in "UK ALL" protocol, "UK ALL" protocol is more preferred.

### PO-041. Cost‐Analysis of Treatment of Pediatrics Acute Lymphoblastic Leukemia Based on ALL‐BFM Protocol {#pbc27455-sec-2660}

[M. Ehsani]{.ul} ^1^, E. shahgholi^1^, H. Hayati^2^, A. kebriaeezadeh^3^, S. Nikfar^3^, A. Mehrvar^4^, M. Tashvighi^4^

*^1^Tehran University of Medical Sciences, Pediatric Hemaiology Oncology, Tehran, Iran; ^2^Lorestan university of Medical sciences, Pharmacy College, Khorramabad, Iran; ^3^Tehran University of Medical Sciences, Pharmacoeconomics and Pharmaceutical Administration, Tehran, Iran; ^4^Mahak Charity Hospital, Pediatric Oncology, Tehran, Iran*

**Background/Objectives**: Among all pediatric cancers acute lymphoblastic leukemia (ALL) is highly prevalent, but the overall cost of ALL management is not well‐known, there is a need to assess the Berlin‐Frankfurt‐Munster (BFM) protocol commonly used in ALL management in Iran. So, the aim of this study was to estimate direct and indirect costs of ALL treatment among children based on the ALL‐BFM protocol from the societal perspective in Iran.

**Design/Methods**: A retrospective study was conducted. All pediatric patients newly diagnosed with ALL and managed by the BFM protocol from 2010‐2015 were included. Finally, total costs, including direct medical costs, direct non‐medical costs and indirect costs were calculated.

**Results**: The total direct medical cost per patient for a complete treatment period was 15,026.6 US dollars, the direct non‐medical cost incurred was 1,688.9 USD and the indirect cost due to productivity loss was 932.3 USD.

**Conclusions**: Treatment of pediatrics ALL is less costly in Iran comparing other countries. So, physicians and policy makers and health care system administrators should devise an appropriate strategy to reduce the direct medical costs which have more economic burden special for hospitalization days and chemotherapy costs based on the findings.

### PO-042. Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries {#pbc27455-sec-2670}

[M. Ehsani]{.ul} ^1^, S. Elham^1^, H. Hayati^2^, A. Kebriaee^3^, S. Nikfar^3^, A. Mehrvar^4^, T. Maryam^4^

*^1^Tehran University of Medical Sciences, Pediatric Hemaiology Oncology, Tehran, Iran; ^2^Lorestan University of Medical Sciences, Pharmacy Faculty, KhorramAbad, Iran; ^3^Tehran University of Medical Sciences, Pharmacoeconomics and Pharmaceutical Administration, Tehran, Iran; ^4^Mahak Charity Hospital, Pediatric Oncology, Tehran, Iran*

**Background/Objectives**: Pediatric acute lymphoblastic leukemia (ALL) is the most common, yet curable childhood malignancy within the pediatric cancers; but in most developed and developing countries cost of cancer treatment in children with ALL is high. So, we specified the range of expenses for the treatment of pediatric cancer and compared the results in developed and developing countries.

**Design/Methods**: To evaluate treatment costs in childhood ALL, a review was taken place through published papers during the years 2000 to 2015. We searched multiple well known databases such as Medline, Scopus, ISI Web of Science and Google Scholar on January 2015 with "cost effectiveness", "cost utility", "cost minimization", "cost analysis", "economic evaluation", "childhood", "acute lymphoblastic leukemia", and "ALL" as our keywords.

**Results**: Regarding the reviewed evidence the essential result was that the total costs for treatment of pediatrics ALL in developing countries such as Asian countries were considerably lower than the costs reported from high income countries in Europe and North America. So different protocols were performed to treat ALL and this matter was significant due to the different durations of hospitalization.

**Conclusions**: According to the results, the total costs for treatment of pediatrics ALL in developing countries were considerably lower than the costs reported from high income countries.

### PO-043. Minimal Residual Disease ‐ Preliminary Experience and its Correlation with Outcome of Children with Acute Lymphoblastic Leukemia Treated at a Tertiary Care Facility in Pakistan {#pbc27455-sec-2680}

[Z. Fadoo]{.ul} ^1^, F. Raza^2^, I. Nisar^3^

*^1^Aga Khan University, oncology, KARACHI, Pakistan; ^2^Aga Khan university, Medical college, Karachi, Pakistan; ^3^Aga Khan university, Pediatrics and Child Health, karachi, Pakistan*

**Background/Objectives**: Minimal Residual Disease (MRD) detects the presence of leukemic cells even when not morphologically evident in the bone marrow by conventional methods. MRD has been established as a prognostic marker with the risk of relapse generally proportional to the level of MRD. All major centers in the world treating childhood ALL use MRD as predictor of response and adjust treatment accordingly. Our study aimed to validate our MRD results and establish a correlation between post induction MRD and the event free survival rate in children with Acute Lymphoblastic leukemia (ALL) treated at the Aga Khan University Hospital.

**Design/Methods**: This was a retrospective study done at the Aga Khan University, Karachi Pakistan. Our patients were children under the age of 18 years with newly diagnosed ALL between September 2009 and 2012, who completed therapy. The flow cytometry based MRD values, when available, for day 28 were obtained for these patients from the Patient Care Inquiry (PCI) system, which has medical records of all patients coming to AKUH.

**Results**: From 2009‐2012 there were a total of 72 patients who completed the entire chemotherapy. Out of these 45 patients had Day 28 MRD values available. The mean age was 5.96 years, with 32 patients (71.11%) in the age group between 1 and 10 years. There were 33 males (73.33%). Majority 35 patients (77.78%) were diagnosed as B precursor ALL and 10 patients with T‐cell ALL. The 5 year EFS was 87.2% for all 45 patients. The 5 year EFS was significantly lower in those with an MRD lymphoblast value of ≥0.1 i.e. 64.8% (95% CI 25.3‐87.2) versus 93.5% (95% CI 76.3‐98.3) for those with MRD \<0.1.

**Conclusions**: Our study validates the MRD results and technique at our institute and shows MRD positivity (\>0.1% blasts) to be associated with a significant lower EFS rate.

### PO-044. Genotype and Phenotype of Polymorphisms in 6‐MP Metabolism in Retrospective Cases {#pbc27455-sec-2690}

[O.L. Fan]{.ul} ^1^, K. Chan^1^, F. Cheng^1^, G. Lam^1^, K.T. Leung^1^, C.K. Li^1^

*^1^The Chinese University of Hong Kong, Department of Paediatric, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Mercaptopurine (MP) is essential for treating paediatric Acute Lymphoblastic Leukaemia (ALL). Thiopurine methyltransferase (TPMT) mutation is associated with 6‐MP toxicity but has low incidence in Asians. Polymorphisms on nudix hydrolase 15 (NUDT15), inosine triphosphatase (ITPA) and ATP‐binding cassette sub‐family C member 4 (ABCC4) are also potential predictors of toxicity. We aim to explore the correlation between 6‐MP dosage and incidence of different variants of genes including TPMT, NUDT15, ITPA, ABCC4 etc. in HK patients and to identify novel gene interactions and SNPs.

**Design/Methods**: Patients with ALL treated in Prince of Wales Hospital from 1993 to 2015 were recruited. Clinical data including maximal tolerated 6MP and MTX dosage during maintenance phase, leukopenia and neutropenia episodes are retrieved. Blood samples from consented patients were analyzed by genotyping.

**Results**: Clinical data from 180 survivors was retrieved, the recommended dose of 6MP was 50mg/m2/day. The mean 6‐MP tolerance is 86%, 12% of patients had poor tolerance (\<50%). 95 DNA samples were analysed, gene mutation frequency is as follows: TMPT (460G\>A) 0%, NUDT15 (593 C\>T, 52G\>A, delGGAGTC, 101G\>A & 101 G\>C) 18.3%, ITPA (94 C\>A; 124+21A\>C; 138G\>A; 211G\>C; IVS3+101G\>A) 73.0% and ABCC4 (99666G\>T & 2044G\>A) 36.17%. Genotypes of 58 samples with 6‐MP dosage data were correlated with the dose. NUDT15 595C\>T (rs116855232) significantly correlated with 6‐MP intolerance (p=0.003), mean tolerance is 90.1% and 54.4% for patients with wild type(wt) and heterozygous alleles respectively. Potential gene interaction is found between ABCC4 99666G\>T (rs2274407) and ITPA 94 C\>A (rs41320251), mean tolerance is 94.5% and 56.0% for patients with wt ABCC4 and ITPA alleles and double heterozygous genotype respectively, with significant correlation with tolerance (p=0.008).

**Conclusions**: These results indicate association of genetic polymorphism of NUDT15, ITPA and ABCC4 with 6‐MP toxicity in HK patients. More samples and SNPs will be analysed to formulate a more comprehensive pharmacogenetic model to guide treatment.

### PO-045. Function of SLC7A7 in T‐Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-2700}

X. Ji^1,2^, X. Yang^1,2^, N. Wang^1,2^, M. Kang^1,2^, Y. Wang^1,2^, L. Rong^1,2^, Y. Xue^1,2^, [Y. Fang]{.ul} ^1,2^

*^1^Children\'s Hospital of Nanjing Medical University, Depatment of Hematology and Oncology, Nanjing, China; ^2^Nanjing Medical University, Key Laboratory of Hematology, Nanjing, China*

**Background/Objectives**: Y+LAT1 protein encoded by SLC7A7 (a member of SLC7 family) gene, consists the cation amino acid transport system y+L (system y+L). This transport system transports cationic amino acids out of the cell, such as arginine, lysine. Arginine is critical for T cell activation and function in the process of immune response.

**Design/Methods**: This study analyses cell proliferation, apoptosis rate, the cell cycle and the ability of migration and invasion to explore the role of SLC7A7 gene in Jurkat cells.

**Results**: In our study, the proliferation ability of Jurkat cell did not change significantly after being transfected with SLC7A7 over‐expression vectors. However, the percentage of apoptosis Jurkat cells did decrease significantly when SLC7A7 was over‐expressed (P = 0.007), while the proportion of G1 phase cell (P = 0.029), the migration (P \< 0.001) and invasion (P \< 0.001) ability were all obviously increased in SLC7A7 over‐expressed cells. After the knockdown of SLC7A7, cell apoptosis ratio increased (P = 0.006), G1 phase ratio (P = 0.002), migration (P \< 0.001) and invasion (P \< 0.001) ability of Jurkat cell all decreased.

**Conclusions**: Our result demonstrated that the SLC7A7 has a significant role in the pathogenesis of T‐cell acute lymphoblastic leukemia.

### PO-046. The Relationship Between Sleep Problems and Fatigue in Children with Acute Lymphoblastic Leukemia During One Cycle of Chemotherapy on Induction Phase {#pbc27455-sec-2710}

[A. Fernandes]{.ul} ^1^, A. Allenidekania^1^, F.T. Waluyanti^1^

*^1^Faculty of Nursing Universitas Indonesia., Pediatric Nursing Department, Depok, Indonesia*

**Background/Objectives**: Chemotherapy has an impact of disruption in sleep patterns and fatigue in children who suffer from acute lymphoblastic leukemia. Fatigue in children can be exacerbated by sleep problems experienced. This study aimed to analyze the relationship between sleep problems and fatigue in children with acute lymphoblastic leukemia whom undergoing one cycle of induction phase chemotherapy.

**Design/Methods**: Using descriptive analytic with repeated measurements to 62 children aged 7‐18 years, the data were taken for 7 days, consist of T0 ‐ one day before chemotherapy, T1‐T5 five days during chemotherapy, and T6 one day after chemotherapy.

**Results**: The majority of patient characteristics were male (51.6%), school‐age children (72.6%), and standard‐risk acute lymphoblastic leukemia (62.9%).Sleep problems prevalence is 98% and fatigue prevalence 98%. Using Pearson correlation test with significance level 95% shown significant relationship (p \<0.001) between sleep problems with fatigue. Moreover, combinations of chemotherapy agent contribute to sleep problems and fatigue such as Methotrexate, Dexamethasone, and L Asparaginase.

**Conclusions**: Children with cancer who suffered from sleep problems would experience severe fatigue. Nurse need to screen the sleep problem as well as fatigue regularly during chemotherapy.

### PO-047. De Novo T‐Cell Acute Lymphoblastic Leukemia Following Therapy for Acute Myeloid Leukemia is Sensitive to Agents Targeting Growth Factor Signaling and Apoptosis Pathways {#pbc27455-sec-2720}

[M. Finkbeiner]{.ul} ^1^, V. Meier‐Stephenson^2^, A. Narendran^1^, F. Kolvear^3^, T. Truong^1^

*^1^Alberta Children\'s Hospital, Pediatric Hematology/Oncology/Transplant, Calgary, Canada; ^2^University of Calgary, Cumming School of Medicine, Calgary, Canada; ^3^University of Calgary, Department of Pathology, Calgary, Canada*

**Background/Objectives**: Following therapy for acute leukemia, there is increased risk of secondary leukemia, commonly acute myeloid leukemia (AML). We describe a patient with an initial diagnosis of AML who later developed a T‐cell acute lymphoblastic leukemia (T‐ALL).

**Design/Methods**: Case report with exploratory precision therapeutic approach.

**Results**: A 10‐year‐old boy was diagnosed with FAB M1 AML and normal cytogenetic/molecular assessments. Treatment was as per Children\'s Oncology Group study AAML1031, arm A, including standard induction I with cytarabine, daunorubicin and etoposide. At the end of induction, he was MRD negative and was stratified into the low risk arm. He received 3 more cycles and remained in remission. Fifteen months after completion of AML therapy, he was diagnosed with T‐ALL with no evidence of AML. Cytogenetics at that time showed trisomy 19, which was not previously present and is associated with de novo myeloid malignancies. This data suggested that it was a de novo leukemia with no evidence of therapy‐related or lineage transformation. He began induction as per the UKALL 2003 protocol with vincristine, dexamethasone, PEG asparaginase and daunorubicin and went into remission. He is currently on maintenance chemotherapy and remains in remission from both leukemias. A cell line was established from the T‐ALL. Screening of a panel of approved small molecule inhibitors identified a number of agents with significant *in vitro* activity. These include the PARP inhibitor, Veliparib, IGF‐1R/InsR inhibitor BMS‐754807, the active metabolite of irinotecan SN38 and the MAPK inhibitor VX‐702.

**Conclusions**: Secondary ALL following AML therapy is highly unusual. Here, we describe a novel case of de novo T‐ALL following AML therapy, without any evidence of lineage transformation or a therapy‐related leukemia. Continuously growing cells from the relapsed specimen provide an opportunity to study a rare leukemogenic event as well as to gain molecular insights into actionable pathways.

### PO-048. Epidemiological Profile of Leukemias Children and Adolescents in the South of Brazil {#pbc27455-sec-2730}

[C. Fiori]{.ul} ^1^, S. Miglioranza^2^, A. Rosa^1^

*^1^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric Oncology, Cascavel, Brazil; ^2^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric, Cascavel, Brazil*

**Background/Objectives**: Introducion ‐ In Brazil, according to the National Cancer Institute, 12,500 new cases of cancer occur in children and adolescents (up to 19 years) per year. This represents 1 to 3% of all new cases of cancer. Leukemia is the most common childhood and childhood cancer, comprising 25% to 35%

Objective ‐ To evaluate the epidemiological profile of leukemias in children and adolescents in the western region of Paraná, Brazil.

**Design/Methods**: The descriptive statistics of the data obtained through electronic medical records analysis and the physical records provided by the Medical Archive Service in patients younger than 19 years with diagnosis of leukemia attended from January 2009 to December 2016.

**Results**: 114 medical records were analyzed, 104 (91.23%) cases of ALL, 9 (7.89%) AML and one (0.88%) cases of chronic myeloid leukemia (CML), 70 (61.4%) were male and 44 (38.6%) were female. The age group with the highest prevalence was school age with 41 (36.0%) patients, followed by the preschool age with 32 (28.1%) patients, and these two groups were responsible for 73 (64.1%) of the cases. 92 (80.7%) were of the white subgroup and 22 (19.3%) were non‐white. The most frequent clinical manifestations observed at the time of diagnosis were: fever, pallor and bone pain, splenomegaly, lymph node enlargement and hepatomegaly.

**Conclusions**: In southern Brazil the epidemiological characteristics are similar to those found in developed countries, however still frequent the late diagnosis of this disease. We like to alert health professionals to the possibility of diagnosing leukemia when two or more of these signs and symptoms do not go away within the first week. In the persistence of symptoms should request a blood count that can help in the early diagnosis of leukemia in our country.

### PO-049. Involvement of miRNA Polymorphisms in Treatment‐Related Liver Toxicity in Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-2740}

M. Umerez^1^, A. Gutierrez‐Camino^1^, B. Santos‐Zorrozua^1^, I. Martin‐Guerrero^1^, E. Lopez Lopez^1^, N. Garcia de Andoin^2^, A. Sastre^3^, A. Navajas^4^, I. Astigarraga^4^, [A. Garcia‐Orad]{.ul} ^1^

*^1^University of the Basque Country‐ UPV/EHU, Department of Genetics‐ Physical Anthropology and Animal Physiology, Leioa, Spain; ^2^University Hospital Donostia, Department of Pediatrics, San Sebastian, Spain; ^3^University Hospital La Paz, Department of Oncohematology‐, Madrid, Spain; ^4^University Hospital Cruces, Department of Pediatrics, Barakaldo, Spain*

**Background/Objectives**: Hepatic toxicity is one of the most common drug‐related toxicity during the treatment of childhood acute lymphoblastic leukemia (ALL). Many genes involved in liver‐specific signaling pathways are tightly controlled by miRNAs, and miRNA function could be modulated by SNPs. In consequence, we hypothesized that variants in miRNAs could be associated with drug‐induced hepatotoxicity.

**Design/Methods**: We analyzed 213 SNPs in 206 miRNAs in a cohort of 179 children with ALL homogeneously treated.

**Results**: rs2648841 in miR‐1208 was the most significant SNP during consolidation phase after FDR correction, probably through an effect of its target genes *DHFR*, *MTR* and *MTHFR*.

**Conclusions**: These results point out the possible involvement of SNPs in miRNAs in toxicity to chemotherapy in children with ALL.

### PO-050. miRNA Polymorphism as Predictive Markers of Mucositis in Pediatric Acute Lymphoblastic Leukemia Treatment {#pbc27455-sec-2750}

A. Gutierrez‐Camino^1^, M. Umerez^1^, E. Lopez Lopez^1^, B. Santos‐Zorrozua^1^, I. Martin‐Guerrero^1^, N. García de Andoin^2^, A. Sastre^3^, A. Navajas^4^, I. Astigarraga^4^, [A. Garcia‐Orad]{.ul} ^1^

*^1^University of the Basque Country‐ UPV/EHU, Department of Genetics‐ Physical Anthropology and Animal Physiology, Leioa, Spain; ^2^University Hospital Donostia, Department of Pediatrics, San Sebastian, Spain; ^3^University Hospital La Paz, Department of Oncohematology, Madrid, Spain; ^4^University Hospital Cruces, Department of Pediatrics, Barakaldo, Spain*

**Background/Objectives**: Mucositis, one of the most debilitating and frequent side effect of childhood acute lymphoblastic leukemia (ALL) therapy, is characterized by a breakdown of the gastrointestinal mucosa, frequently accompanied of vomits and diarrhea. As a consequence, treatment could be delayed or even discontinued, which may impair survival. Mucositis can be linked to a several antileukemic agents such as methotrexate (MTX), daunorubicin (DNR) or cyclophosphamide (CPA). Nowadays it is known that miRNAs regulate the expression of genes involved in pharmacokinetic (PK) and pharmacodynamic (PD) pathways of these drugs. SNPs in miRNAs could affect their levels of function, and then, affect their target genes in these pathways. Therefore, the aim of the study was to determine the association between miRNA genetic variants targeting mucositis‐related genes and the risk to develop this toxicity.

**Design/Methods**: To achieve this aim, we analyzed 213 SNPs in 206 miRNAs in a cohort of 179 Spanish children with B‐cell precursor ALL (B‐ALL) homogeneously treated with LAL/SHOP protocols.

**Results**: We identified three SNPs in miR‐4268, miR‐4751 and miR‐3117 associated with mucositis, diarrhea and vomits, respectively, which could be explained through the effect on genes related to drug PK and PD, as well as other mucosal injury‐related genes.

**Conclusions**: These results point out the possible involvement of SNPs in miRNAs in treatment‐related digestive toxicity in children with ALL.

### PO-051. MicroRNAs as a New Tool for Diagnosis, Classification and Prognosis in Pediatric Acute Lymphoblastic Leukemia: A Systematic Review {#pbc27455-sec-2760}

A. Gutierrez Camino^1^, S. Garcia Obregon^2^, E. Lopez Lopez^1^, I. Astigarraga^3^, [A. Garcia‐Orad]{.ul} ^1^
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**Background/Objectives**: Although acute lymphoblastic leukemia (ALL) has been defined as a single disease, its etiology, diagnosis, clinical behavior and response to treatment are heterogeneous. Although group risks have been defined, additional markers are needed. In this line, microRNAs (miRNAS) have emerged as a new tool for diagnosis, classification and prognosis prediction in different malignancies. In the case of ALL, several studies have been performed but miRNA signatures have not been defined. Our aim was to perform a systematic review of the literature to determine which miRNAs are the most involved in ALL diagnosis, classification, prognosis and response.

**Design/Methods**: We used the keywords "acute lymphoblastic leukemia" AND ("microRNA" OR "noncoding") in Pubmed until September‐30‐2017.

**Results**: We obtained 276 records, identifying 49 which analyzed miRNA expression in pediatric ALL, 22 for diagnosis, 25 for classification, 18 for prognosis and 12 for treatment. We found 34 microRNAs that were significant in at least 2 studies, 13 being the strongest candidates for ALL signatures.

**Conclusions**: MiRNAs could be a useful tool as markers for diagnosis, classification, prognosis and response in B‐ALL. Validation of the published miRNAs and a deep search for new miRNAs is needed in order to establish a signature of use for the clinical management of children diagnosed with ALL.

### PO-052. Genetic Polymorphisms in Candidate Genes Including CEP72 are not Associated with Increased Vincristine‐Related Peripheral Neuropathy in Arab Children Treated for Acute Childhood Leukemia {#pbc27455-sec-2770}

[K. Ghanem]{.ul} ^1^, N. Khoueiry‐Zgheib^2^, C. Al‐Aridi^1^, H. El‐Khoury^3^, H. Tamim^4^, R. Shahine^1^, N. Tarek^1^, R. Saab^1^, M. Abboud^1^, H. El‐Solh^1^, S. Muwakkit^1^

*^1^American University of Beirut, Pediatrics, Beirut, Lebanon; ^2^American University of Beirut, Pharmacology and toxicology, Beirut, Lebanon; ^3^American University of Beirut, Faculty of Medicine, Beirut, Lebanon; ^4^American University of Beirut, Medicine, Beirut, Lebanon*

**Background/Objectives**: The aim of this study was to evaluate the potential association between candidate genetic polymorphisms and vincristine‐related peripheral neuropathy in Arab children with acute lymphoblastic leukemia (ALL)

**Design/Methods**: This is a retrospective evaluation of 133 Arab children treated for ALL at the Children\'s Cancer Center of Lebanon, with a protocol adopted from St Jude Total XV Therapy. Incidence and severity of, as well as the timing (in weeks) at which grade 2 or higher peripheral neuropathy occurred were recorded. Genotyping for ABCB1 (rs1045642), ABCB1 (rs1128503), ABCC2(rs717620), CEP72 (rs924607), ETAA1 (rs17032980), and MTNR1B (rs12786200) was performed using light SNP^®^ assays on a Roche^®^ Lightcycler.

**Results**: The sample included 133 children with mean ± SD age in years of 6.71 ± 5.01 with 76 (57.1%) males and 57 (42.9%) females. Fifteen were non‐Lebanese: 7 Palestinians, 5 Syrians and 3 Iraqis. Sixty six (50.4%) were allocated to the low risk treatment protocol arm, while 65 (49.6%) were allocated to the intermediate/high risk arm. Twenty‐six (19.5%) subjects developed peripheral neuropathy, three of which occurred during the induction phase. No statistically significant associations were revealed for any of the polymorphisms with neither incidence of vincristine‐related toxicity, toxicity severity, nor time to the first episode of grade 2 or higher vincristine‐related peripheral neuropathy.

**Conclusions**: This study presents the first pharmacogenetic analysis of vincristine‐related peripheral neuropathy in children with ALL in an Arab country. Our results showed lack of a previously‐proven association with variants such as CEP72 in two US cohorts of children treated for ALL and another cohort of adults treated for ALL. It also showed no associations with ABCB1 and ABCC2 candidate genetic variants. Larger high‐throughput genetic analyses may be warranted to evaluate variants in other candidate genes such as CYP3A4, and reveal new non‐previously reported alleles that may be peculiar to this region of the world.

### PO-053. A Comparitive Study of Various Generic Brands of L‐Asparaginase Available in India {#pbc27455-sec-2780}

[V. Gota]{.ul} ^1^, V. Purohit^1^, R. Deshpande^1^, S. Sengupta^1^, K.C. Anand^2^, H. Sankaran^2^, S. Banavali^3^

*^1^Advanced Centre for Treatment‐ Research and Education in Cancer ACTREC‐ Tata Memorial Centre, Clinical Pharmacology, Navi Mumbai, India; ^2^Tata Memorial Centre, Medical Oncology, Mumbai, India; ^3^Tata Memorial Centre, Medical Ondology, Mumbai, India*

**Background/Objectives**: L‐asparaginase (L‐Asp) is an essential medicine in ALL and quality of generic brands is a matter of concern. We compared the quality of L‐asparaginase of various brands available in India.

**Design/Methods**: Nine commonly used generic brands were identified. Quality was assessed by (i) testing the formulations for asparaginase activity using a microplate based colorimetric method and (ii) comparison of trough asparaginase activity in children with ALL receiving induction chemotherapy. L‐Asp was administered at a dose of 10,000 IU/m^2^ i.m. every 3 days per protocol. A 72 hour trough blood sample from each patient was drawn just before the next dose.

**Results**: One Hundred and eighty nine patients were enrolled between March, 2015 and May, 2017 \[M/F=119/70; Age (Median/range) = 4.9(0.8‐15) years; Standard/intermediate/high risk = 55/66/68 cases; BSA=0.64(0.35‐1.7)m2; Dose=6,300 (3,000‐17,000) IU)\]. Two hundred and thirty four blood samples were analyzed for asparaginase activity. Number of samples analyzed for each brand ranged from 7--66 with a median of 18. Average asparaginase activity of brands ranged from 31.66 U/L (n=33 samples) in the lowest activity brand to 525.58 U/L (n=12) in the highest activity brand. Median asparaginase activity corresponded to 86.6 U/L. Proportion of patients who failed to achieve a predefined threshold activity of 50 U/L ranged from 16.7% (2/12) in the highest activity brand to 84.9% (28/33) in the lowest activity brand (Median of all brands=50%). Direct analysis of three formulations and comparison with Medac asparaginase (innovator) showed that asparaginase activity in the generics ranged from 77‐80% of the innovator.

**Conclusions**: There is a wide variation in asparaginase activity between brands. Six out of nine brands tested were markedly inferior with 50% or more patients failing to achieve the trough activity of 50 U/L. This raises serious concerns about the quality of generics of this essential medicine and the need for pharmacovigilance in this area.

### PO-054. IgG Antibodies Cannot Explain Silent Inactivation in PEG‐Asparaginase Treatment {#pbc27455-sec-2790}

[S. Gottschalk Højfeldt]{.ul} ^1^, A. Harila‐Saari^2^, B. Lund^3^, J. Abrahamsson^4^, P. Lähteenmäki^5^, L. Tram Henriksen^1^, G. Vaitkeviciene^6^, K. Pruunsild^7^, Ò. G. Jónsson^8^, M. Heyman^9^, K. Schmiegelow^10^, B. Klug Albertsen^1^, J. Nersting^11^

*^1^Aarhus University Hospital, Department of pediatrics and adolescent medicine, Aarhus, Denmark; ^2^Uppsala University, Department of Women\'s and Children\'s health, Uppsala, Sweden; ^3^St. Olavs Hospital, Department of Pediatrics, Trondheim, Norway; ^4^Sahlgrenska Academy‐ University of Gothenburg, Department of Paediatrics and Institution for Clinical Sciences, Gothenburg, Sweden; ^5^Turku University Hospital, Department of Pediatric and Adolescent Medicine, Turku, Finland; ^6^Vilnius University, Clinic of Children\'s Diseases‐ Faculty of Medicine, Vilnius, Lithuania; ^7^University Children\'s Hospital, Department of Oncology and Haematology, Tallinn, Estonia; ^8^Landspitali University Hospital, Children\'s Hospital, Reykjavik, Iceland; ^9^Karolinska University Hospital and Karolinska Institute, Department of Women\'s and Children\'s health‐ Childhood Cancer Research Unit, Stockholm, Sweden; ^10^University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^11^University Hospital Rigshospitalet, Pediatric Oncology Research Laboratory‐ Rigshospitalet, Copenhagen, Denmark*

**Background/Objectives**: PEG‐asparaginase represents a key element in the treatment of acute lymphoblastic leukemia (ALL), however allergic reactions and lack of asparaginase enzyme activity shortly after administration (silent inactivation) constitutes a significant challenge. Anti‐PEG antibodies formed prior to PEG‐asparaginase exposure are suggested to cause the latter accelerated clearance phenomenon.

We investigated anti‐PEG antibody responses before and during PEG‐asparaginase therapy, in children treated according to NOPHO ALL2008 protocol, with and without silent inactivation and hypersensitivity.

**Design/Methods**: PEG‐asparaginase enzyme activity was determined in patients aged 1‐17.9 years as part of the NOPHO ALL2008 protocol. These measurements were used to categorize patients with or without enzyme activity. In this case control study, recovery of spiked PEG‐asparaginase activity after IgG complex depletion with protein G affinity chromatography was used to evaluate IgG antibodies to PEG‐asparaginase. 359 samples were analyzed from 40 patients with: i) no adverse phenotype (n=10), ii) silent inactivation (n=10), iii) allergy and asparaginase enzyme inactivation (n=10), iv) allergy and asparaginase enzyme activity (n=10)

**Results**: No patients with PEG‐asparaginase enzyme activity had or developed anti‐PEG antibodies during treatment. Thus children with and without clinical allergy and enzyme activity could not be distinguished serologically. In contrast, IgG antibodies were detected in 19 of 20 of children without enzyme activity, regardless of allergy status. The lack of *in vivo* asparaginase enzyme activity was always displaying from the first PEG‐asparaginase administration, but anti‐PEG antibodies were only detected in pre‐exposure samples in 2 of 38 patients (5%). 2 patients had missing pre‐exposure samples.

**Conclusions**: IgG responses to repeated PEG‐asparaginase administrations are not the primary driver of PEG‐asparaginase inactivation. However these antibodies may accelerate the drug clearance. Further validation and investigation of IgM antibodies is warranted in order to gain more knowledge about the inactivation of PEG‐asparaginase.

### PO-055. Impact of Loss‐of‐Function and Dominant‐Negative IKZF1 Deletions on Outcome in BCR‐ABL1 Negative Pediatric B‐Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-2800}

[S. Gupta]{.ul} ^1^, S. Bakhshi^2^, V. Kamal^3^

*^1^All India Institute of Medical Sciences AIIMS‐ New Delhi, Lab Oncology‐ IRCH, New Delhi, India; ^2^All India Institute of Medical Sciences AIIMS‐ New Delhi, Medical Oncology‐ IRCH, New Delhi, India; ^3^National Institute of Epidemiology, Division of Epidemiology & Biostatistics, Chennai, India*

**Background/Objectives**: *IKZF1* deletions are seen in 15‐20% of pediatric B‐cell Acute Lymphoblastic Leukemia (B‐ALL) and associated with poor outcome. Recently, it was shown that only loss‐of‐function but not dominant‐negative type of *IKZF1* deletions are associated with adverse prognosis in adult *BCR‐ABL1* negative B‐ALL (Kobitzsch et al, 2017). We undertook this study to assess the distribution and clinical impact of these functional subtypes of *IKZF1* deletions in *BCR‐ABL1* negative pediatric B‐ALL.

**Design/Methods**: The genomic DNA of new cases of pediatric B‐ALL, enrolled over 24 months was analyzed for *IKZF1* deletions using multiplex ligation dependent probe amplification. The deletions were divided into functional subgroups‐A) Loss‐of‐function (whole gene deletions or those involving exon2), B) Dominant negative (exon4‐7 deletions), C)others. Event free survival (EFS) and overall survival (OS) were noted.

**Results**: Overall 35 (19.6%) of 179 pediatric B‐ALL, with median age 6 years (2 months‐18 years), had *IKZF1* deletions. Nine (75%) of 12 *BCR‐ABL1* positive cases had *IKZF1* deletions. The remaining 167 *BCR‐ABL1* negative cases, with 26 (15.6%) having *IKZF1* deletions, were analyzed further. Twenty‐two (85%) of 26 *IKZF1* deletions in this group were loss‐of‐function deletions, 2 (8%)‐dominant negative, 1(4%)‐others and 1 (4%) case had a combination of loss‐of‐function and dominant‐negative deletions. The post‐induction remission rates in cases with loss‐of‐function deletions were lower compared to those without deletions (72.2% vs86.6%;p=0.111). The cases with loss‐of‐function *IKZF1* deletions had significantly worse EFS (p=0.011) and OS (p=0.004) compared to cases without *IKZF1* deletions. The cases with dominant negative deletions were very few for statistical analysis.

**Conclusions**: The *IKZF1* deletions were seen in 15.6% of *BCR‐ABL1* negative pediatric B‐ALL. Most of the *IKZF1* deletions in these patients were loss‐of‐function type. The cases with loss‐of‐function *IKZF1* deletions had lower remission rates, and significantly worse EFS (p=0.011) and OS (p=0.004) compared to cases without *IKZF1* deletions and may be investigated for novel alternative therapies.

### PO-056. Alterations in Bone Turnover in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia During Chemotherapy {#pbc27455-sec-2810}

[V. Gupta]{.ul} ^1^, S. Dash^1^, R. Sonowal^1^, S.K. Singh^2^

*^1^Institute of Medical Sciences‐ Banaras Hindu University, Division of Hematology Oncology‐ Department of Pediatrics, Varanasi, India; ^2^Institute of Medical Sciences‐ Banaras Hindu University, Department of Endocrinology, Varanasi, India*

**Background/Objectives**: Disturbances of bone metabolism frequently occur in patients with acute lymphoblastic leukemia (ALL) leading to increased risk of osteopenia and osteoporosis at diagnosis and during chemotherapy. Caboxyl‐terminal telopeptide of human type 1 collagen (ICTP) is one of the resorptive markers indicating bone turnover. Present study was conducted to evaluate the levels of ICTP in newly diagnosed patients with ALL during chemotherapy.

**Design/Methods**: Forty four newly diagnosed patients with ALL in the age group of 2‐14 years, admitted in the Department of Pediatrics were included. Relapsed and refractory cases were excluded. Risk stratification was done according to NCI criteria. Quantitative analysis of bone resorptive marker, caboxyl‐terminal telopeptide of human type 1 collagen (ICTP) was evaluated at baseline and 3 months after chemotherapy. Levels were compared in relation to age, gender, body mass index (BMI), risk stratification and cell lineage (B or T cell).

**Results**: Mean age of patients was 7.75 ± 4 years (median age 8) with male:female ratio of 3.5:1. Thirty seven (84%) patients had significant increase in mean serum ICTP levels at 3 months. Levels at diagnosis and after 3 months of chemotherapy were 1.78 ± 1.39 ng/ml and 3.55 ± 1.40 ng/ml respectively (p=0.000). Male patients and those with T cell disease had significantly higher mean ICTP levels at 3 months (1.71 ± 1.29 vs 3.53 ± 1.45; 1.66 ± 1.30 vs 3.45 ± 1.38) as compared to female (2.04 ± 1.77 vs 2.66 ± 0.94) and B cell disease patients (2.04 ± 0.89 vs 2.99 ± 1.18). Both high and standard risk patients, those with BMI \<5 or ≥5 and age \<6 years or ≥ 6 years had significantly increased levels at 3 months.

**Conclusions**: There is significant increase in bone resorption in patients with ALL. It can be because of the disease itself or intensive chemotherapy or both.

### PO-057. Lenalidomide, a Potent IKZF1 Degrader, Effectively Induces Apoptosis of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells with IKZF1 Alterations in Synergy with Other Anti‐Leukemic Agents {#pbc27455-sec-2820}
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**Background/Objectives**: IKZF1 is a transcription factor primarily involving survival and differentiation of B cell precursor (BCP), and alterations of *IKZF1* gene have been shown to confer a poor prognosis in BCP acute lymphoblastic leukemia (ALL) particularly with Philadelphia chromosome positive (Ph+). We have been reported that treatment with lenalidomide (LEN), a thalidomide derivative, completely abrogates IKZF1 activity by a selective degradation of normal allele‐derived IKZF1 isoforms in Ph+ALL cells which commonly express a dominant negative Ik6 isoform, and effectively induces their apoptosis in synergy with a tyrosine kinase inhibitor (TKI) imatinib (IM). In the present study, we addressed the effect of other TKIs such as dasatinib (DA) and ponatinib (PO), and the mechanism of induction of apoptosis, and the effect of LEN+TKI in the xenograft mice model of Ph+ALL. Finally, the additional effect of dexamethasone (DEX) to LEN+TKI was examined.

**Design/Methods**: 3 Ph+ALL cell lines expressing Ik6 were used. The synergic effects of LEN, TKI and DEX were also examined. The *ex vivo* studies using NOG mice model were performed.

**Results**: 1. DA+LEN effectively induced apoptosis of Ph+ALL cells. PO+LEN was effective in the induction of apoptosis of the IM‐resistant Ph+ALL cell line with T315I mutation. 2. The expression of pro‐apoptotic protein BAX was markedly up‐regulated on Western blot analysis 48‐72h after LEN+IM treatment, with a gradual increase in the p18 cleaved form. 3. LEN+IM significantly elongated the survival of NOG mice transplanted with Ph+ALL cells. 4. Addition of DEX to LEN+IM was very effective for further induction of apoptosis, and almost of Ph+ALL cells even with T315I mutation were killed after 3 drugs treatment.

**Conclusions**: LEN functions as a potent co‐inducer of apoptosis in Ph+ALL together with other anti‐leukemic agents, and thus 3 drugs treatment (LEN+TKI+DEX) should be clinically effective for the treatment of Ph+ALL even in the case with T315I mutation.

### PO-058. Polymorphisms in Folate Pathway Genes Influence the Susceptibility to Acute Lymphoblastic Leukemia in Children {#pbc27455-sec-2830}

[T. Hassan]{.ul} ^1^, U. El Safy^1^, N. Raafat^2^, A. Gharib^3^

*^1^Zagazig University, Pediatrics, Zagazig, Egypt; ^2^Zagazig, Medical Biochemistry, Zagazig, Egypt; ^3^Zagazig University, Medical Biochemistry, Zagazig, Egypt*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing more than a quarter of all pediatric cancers. The past decade has been marked by extraordinary advances into the genetic basis of leukemogenesis and treatment responsiveness in ALL. The assertion that ALL may have a genetic basis has long been pursued through association studies based on candidate genes as folate metabolism. Polymorphisms in folate pathway genes may influence the susceptibility to acute lymphoblastic leukemia. We aimed to evaluate the contribution of MTHFR C677T and RFC1 80GA gene polymorphism to the risk of acute lymphoblastic leukemia in children.

**Design/Methods**: DNA was isolated from 200 children, divided into 2 groups, group I included 100 pediatric ALL patients and group II included 100 healthy donors as controls. Genotyping of MTHFR C677T and RFC1 G80A was performed by polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) using Hinf I and HhaI restriction endonuclease respectively

**Results**: MTHFR 677T allele carriers were significantly lower in ALL cases (46%) than healthy controls (56%). Reduction in ALL risk was observed for heterozygous (CT) or homozygous (TT) carriers of the MTHFR 677T allele (OR 0.8; 95% CI, 0.9‐1.5; P \< 0.002). RFC1 80A allelic carriers have an increased susceptibility to ALL. Risk was increased 2.0 times (OR 3.5; 95% CI, 1.5‐4.8 ; P .02) for A‐allelic carriers.

**Conclusions**: MTHFR gene variants are associated with decreased ALL rate and risk. the reduced risk associated with the MTHFR C677T polymorphisms may be the result of changed intracellular folate redistribution. the results of our study also supported the suggestion that RFC1 G80A RFC1 G80A single nucleotide polymorphism contributed to increase the susceptibility and the development of pediatric ALL.

### PO-059. Comparing Morphology and Flow Cytometry to Molecular Genetics in the Assessment of Minimal Residual Disease in Paediatric B‐Acute Lymphoblastic Leukaemia (B‐ALL) {#pbc27455-sec-2840}

[C. Hendricks]{.ul} ^1^, S. Buldeo^2^, D. Pillay^2^, R. Thejpal^1^, N. Rapiti^2^, A. Naidoo^2^, Y. Goga^1^, B. Neethling^1^, H. Van Staaden^1^
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**Background/Objectives**: Minimal residual disease (MRD) detection has been shown to be the best prognostic factor in B‐Acute lymphoblastic leukaemia (B‐ALL). Multicolour flow cytometry (FCM) and specific molecular aberrations (MOL) are the classic techniques used to assess MRD. The former is faster and less costly. This study compares morphology and flow cytometry to molecular methods in detecting MRD in a resource limited setting.

**Design/Methods**: This was a retrospective review of children with B‐ALL managed at Inkosi Albert Luthuli Central Hospital (IALCH) from January 2013 ‐ January 2018. FCM was performed using Euroflow^®^ panels. MOL looked at common cytogenetic markers. Presentation and post‐induction morphology (May Grunwald Giemsa stain), FCM and MOL data for MRD were analysed.

**Results**: Eleven patients were excluded (6‐demised, 5‐incomplete records), leaving 64 to be analysed (54% female, median age 5 years). All had post‐induction bone marrow aspirates. Five aspirates were unsuitable (hypocellular/dilute) but the rest (92%) were in morphological remission. At diagnosis and post‐induction, 62 (95%) and 61 (94%) children respectively had FCM performed. A positive MOL result was found in 39 (60%) patients at diagnosis and in 36 the assay was repeated post induction. MOL TATs averaged 14 days compared to FCM average of 3 days. MRD was found in 9 patients on FCM and 6 patients on molecular testing. Of these patients 4/9 had a good correlation between the two. The remaining 5 patients with FCM MRD did not have positive molecular to compare with. Only 2/6 patients with negative FCM had positive MOL MRD post‐induction.

**Conclusions**: Morphology is insensitive and unnecessary in MRD assessment. FCM correlated well with molecular MRD in our setting and has the shortest turn‐around time. FCM has major benefit in the 40% of patients with negative MOL. It can also be safely used to guide treatment escalation in those patients awaiting molecular results.

### PO-060. A Phase 1B Study of Blinatumomab in Japanese Children with Relapsed/Refractory (R/R) B‐Precursor Acute Lymphoblastic Leukemia (ALL) {#pbc27455-sec-2850}
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**Background/Objectives**: Outcomes of children with R/R ALL are poor. Blinatumomab is an anti‐CD3/CD19 bispecific T‐cell engager antibody construct that demonstrated antileukemic activity in a phase 1/2 study of children with R/R ALL (von Stackelberg. *JCO*. 2016;34:381‐4389). We evaluated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics of blinatumomab in Japanese children with R/R ALL.

**Design/Methods**: Eligible patients were \<18 years old with R/R B‐precursor ALL (≥2 bone marrow relapses, marrow relapses after alloHSCT, refractory to other treatments), \>5% bone marrow blasts, Karnofsky/Lansky performance status ≥50% for patients ≥16/\<16 years old, and no CNS pathology. Primary endpoint was incidence of dose‐limiting toxicities (DLTs). Cohort 1 received induction blinatumomab for 4 weeks by continuous intravenous infusion (cycle 1/week 1: 5μg/m^2^/day; cycle 1/weeks 2--4: 15μg/m^2^/day; subsequent cycles/weeks 1--4: 15μg/m^2^/day) followed by a 2‐week treatment‐free interval (each cycle). Responders (M1 bone marrow, ≤5% blasts, within 2 induction cycles) could receive additional consolidation cycles (≤5 induction/consolidation).

**Results**: Nine patients (4 male/5 female, median \[range\] age 11 \[7--17\], 6 with prior alloHSCT) received blinatumomab 5--15μg/m^2^/day (median 2 \[1--5\] cycles). Since no patients experienced DLTs, the MTD was 5--15μg/m^2^/day. Five patients (55.6%) had grade \<3 cytokine release syndrome. All patients had grade ≥3 AEs, most commonly febrile neutropenia (5/9, 55.6%) and neutropenia, pyrexia, or lymphopenia (4/9, 44.4% each). One patient had fatal hemorrhagic shock (not treatment‐related). Five patients (55.6%) had M1 remission within the first 2 cycles (4/5 full hematologic recovery); one achieved complete MRD response. Mean (SD) steady‐state blinatumomab concentrations were 107 (42.7) pg/mL and 361 (137) pg/mL at 5 and 15μg/m^2^/day; mean (SD) clearance, t1/2, and Vd were 1.83 (0.801) L/hour/m^2^, 2.62 (1.67) hours, and 6.38 (3.95) L/m^2^. No anti‐blinatumomab antibodies were detected.

**Conclusions**: The safety and pharmacokinetics of blinatumomab in Japanese children with R/R B‐precursor ALL were consistent with previous global studies.

### PO-061. Disruption of CTCF Boundary Remodels Chromatin Domain and Reprograms HOX Gene Transcription in AML {#pbc27455-sec-2860}

[S. Huang]{.ul} ^1^

*^1^Pennsylvania State University Hershey College of Medicine, Department of Pediatrics, Hershey, USA*

**Background/Objectives**: CTCF insulator constrains the temporal *HOX* gene expression patterns within the confined chromatin domain for normal development. However, dysregulation of *HOX* genes is also a common feature of AML. The molecular mechanisms of aberrant *HOX* expression and associated AML pathogenesis remain unclear.

**Design/Methods**: To systematically investigate *HOX* gene regulation in AML, we employed a pooled CRISPR‐Cas9 genetic knockout library screening to interrogate intergenic regulatory and chromatin boundary elements in all 4 *HOX* gene loci. Through this screening, we identified the CBS7/9 chromatin boundary located between HOXA7 and HOXA9 genes that is critical for maintaining aberrant expression of posterior *HOXA* genes in MLL‐rearranged AML. To further delineate the role of CBS7/9, we then carried out genome wide ChIP‐seq, ATAC‐seq, 4C, and RNA‐seq analysis to examine the changes in chromatin domain organization and corresponding gene expression patterns compared wild‐type and the CBS7/9 KO AML cells.

**Results**: CBS7/9 disruption resulted in a spreading of repressive H3K27me3 domain into the *HOXA9‐A13* domain that subsequently altered enhancer/promoter chromatin accessibility and reducing ectopic interactions among the posterior *HOXA* genes. Impairment of CBS7/9‐boundary reduced posterior *HOXA* gene expression and altered myeloid specific transcriptome profiles important for pathogenesis of myeloid malignancies. Furthermore, the CBS 7/9 boundary was deleted in both MLL rearranged AML cells and primary patient samples by the CRISPR‐Cas9‐mediated genome editing and the edited cells were transplanted into NSG mice for the development of human AML in mice. Disruption of CBS7/9 in the *HOXA* locus reduced human leukemic blast development and invasion as well as enhanced survival of both transplanted AML cell xenograft and patient derived xenograft (PDX) mouse models.

**Conclusions**: Thus, we demonstrated that CTCF boundary not only constrains normal gene expression program, but also maintains oncogenic transcription program for leukemic transformation. Alteration of CTCF mediated topological boundaries in the oncogene loci provides therapeutic approaches for targeting AML.

### PO-062. Obstructive Jaundice: A Rare Presentation of Chidhood Acute Lymphoblastic Leukemia {#pbc27455-sec-2870}

[P. Huong]{.ul} ^1^

*^1^Viet Nam National Cancer Hospital, Pediatric Oncology, Ha Noi, Vietnam*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Cholestatic jaundice is an unusual presentation of ALL. It is even rarer to be caused by involvment of the pancreas resulting in obstructive jaundice. *Purpose*: Describing obstructive jaundice secondary to a pancreatic involvment in childhood mature B cell ALL. *Object*: A four years old girl who had been diagnosed as mature B cell ALL in Pediatric oncology department, Viet Nam National Cancer Hospital.

**Design/Methods**: Describing a clinical case.

**Results**: Pancreatic involvement in ALL is rare and obstructive jaundice secondary to a pancreatic mass as a primary presentation of ALL has not been reported in the literature, only in some case reports. Primary result of treatment by FAB LMB 96 portocol is excellent.

**Conclusions**: This is a rare clinical case of mature B cell ALL in children with very severe conditions. Exact diagnosis results in successful treatment.

### PO-063. Rate of Infections and the Development of Childhood Acute Lymphoblastic Leukemia: A Population‐based Case‐control Study {#pbc27455-sec-2880}

[J. Hwee]{.ul} ^1^, R. Sutradhar^2^, J.C. Kwong^3^, L. Sung^4^, S. Cheng^2^, J.D. Pole^5^

*^1^University of Toronto, Dalla Lana School of Public Health‐ Epidemiology, Toronto, Canada; ^2^Institute for Clinical Evaluative Sciences, Cancer Research Program, Toronto, Canada; ^3^Institute for Clinical Evaluative Sciences, Primary Care & Population Health Research Program, Toronto, Canada; ^4^The Hospital for Sick Children, Department of Haematology/Oncology, Toronto, Canada; ^5^Pediatric Oncology Group of Ontario, Research, Toronto, Canada*

**Background/Objectives**: An infectious trigger for the etiology of childhood acute lymphoblastic leukemia (ALL) is hypothesized. We assessed whether the rate of infections, critical exposure periods, type and severity of infections are associated with ALL.

**Design/Methods**: We conducted a matched case‐control study using administrative databases. We matched 10 cancer‐free controls to each ALL case on date of birth, sex and place of residence. We used a validated approach for infections to determine the rate of infections. We examined critical exposure periods to an infection (yes or no) between the ages of 0‐4 years in the development of ALL. Odds ratios were estimated using adjusted conditional logistic regression models. The mean number of infections over time was calculated using the mean cumulative function.

**Results**: In 1,600 cases of ALL, and 16,000 matched cancer‐free controls aged 2‐14 years, having \>2 infections/year increased the odds of childhood ALL by 43% (OR=1.43, 95% CI 1.13‐1.81) compared to children with ≤0.25 infections/year. Having \>2 respiratory infections/year increased odds of ALL by 28% (OR=1.28, 95% CI 1.05‐1.57) compared to children with ≤0.25 respiratory infections/year. Having an invasive infection increased the odds of ALL by 72% (OR=1.72, 95% CI: 1.31‐2.26). Having an infection between the age of 1 to 1.5 years increased the odds of ALL by 20% (OR=1.20, 95% CI 1.04‐1.39). The cumulative incidence of infections was slightly higher for children with ALL compared to cancer‐free controls.

**Conclusions**: While we can not rule out confounding, children with ALL had more physician visits for infections compared to controls. This may be due to a dysregulated immune function in early life causing a greater propensity to need clinical care when contracting infections, however, we can not confirm this relationship. The study also provides insight into the timing and type of infection that may have a role in the development of ALL.

### PO-064. Baseline Evaluation of Cardiac Functions in Childhood Cancer Patients: Experience at a Tertiary Care Hospital {#pbc27455-sec-2890}

[U. Imam]{.ul} ^1^, H. Ul Haq^1^, M. Hayat^1^, F. Mumtaz^1^, F. G. Ali^1^, S. Bibi^2^

*^1^CHILDREN CANCER CENTRE Caa ‐NATIONAL INSTITUTE OF CHILD HEALTH, PEDIATRIC ONCOLOGY, KARACHI, Pakistan; ^2^National Institute of Child Health, PHRC Specialized Research Centre for Child Health, Karachi, Pakistan*

**Background/Objectives**: One of the most significant complications of pediatric cancer treatment is the occurrence of Cardiotoxicity as a result of anthracycline based chemotherapy. Clinical examination and screening echocardiogram is therefore mandatory before initiation of chemotherapy. As limited data is available on cardiac status of childhood cancer patients in our country, this study aims to find out cardiac abnormalities in patients to help establish optimal use of these tools in identification of risk factors and patient stabilization before starting chemotherapy.

**Design/Methods**: This was a cross‐sectional study conducted from January 2017 to December 2017 at Pediatric Oncology department of National Institute of Child Health Karachi, Pakistan. Medical record including clinical presentation, primary diagnosis, cardiac manifestations and echocardiography results were noted. Children with relapsed disease were excluded. Cardiovascular events before initiation of chemotherapy were defined as heart failure, left ventricular dysfunction, arrhythmia, hypertension and murmur. Echocardiogram abnormalities were defined as ejection fraction (EF) \<55%, valvular lesion, left ventricular dysfunction, left ventricular hypertrophy and Pericardial effusion.

**Results**: Among 340 eligible patients, abnormal cardiac events and Echocardiography results were observed in 8.2% cases (n = 28).Mean age of children was 6.6± 3.8 Years, M: F ratio was 1:1.8. Congestive cardiac failure and low Ejection fraction on echocardiography followed by hypertension and pericardial effusion were found to be the common cardiac manifestations. Baseline Low ejection fraction is significantly common (P=0.001) in children with hematologic malignancies. Severe anemia with mean Hemoglobin of 6.73± 1.96 is a risk factor for Left ventricular dysfunction, P =0.001.

**Conclusions**: Baseline assessment of cardiac functions and screening Echocardiography in childhood cancer patients prior to chemotherapy can unveil an abnormality that prompts better supportive care and hence better treatment outcomes

### PO-065. Delay in Diagnostic Lumbar Puncture to Day 8 of Prednisolone Prophase in Childhood Acute Lymphoblastic Leukemia: An Analysis with Comparison to Conventional Historical Approach {#pbc27455-sec-2900}

[N. Jabbar]{.ul} ^1^, S. Ashraf^1^

*^1^The Indus Hospital, Pediatric Hematology Oncology, Karachi, Pakistan*

**Background/Objectives**: Central Nervous System (CNS) involvement of Childhood Acute Lymphoblastic Leukemia (ALL) is associated with poor outcome. In developing countries, delayed presentation of malnourished patients with high count is common; therefore, modified approach in terms of one week prednisolone prophase with delaying of diagnostic lumbar puncture (LP) at day 8 was followed. The objective was to stabilize the patient with less intensive course and to minimize peripheral absolute blast count before 1^st^ intrathecal therapy (IT) to avoid the iatrogenic introduction of CNS disease.

**Design/Methods**: It is a retrospective observational study, done at pediatric oncology department of The Indus Hospital. Total 435 cases of ALL (Age 1‐17 years) were analyzed for day 8 LP from June 2015 till October 2017. The results were compared with day 1 diagnostic LP of previous data of 600 patients recorded from January 2010 to December 2014. Patients left or died before day 8 were excluded.

**Results**: Among total 435 cases, incidence of CNS 2, CNS 3 and TLP + are 33 (7.5%), 42 (9.6%) and 7 (1.6%) respectively. This incidence for CNS 2 and CNS 3 is significantly higher than previous institutional data which shows (5%) and (3%) respectively. However TLP prevalence in this cohort is less than previous (4%). CNS positive cases are further analyzed with respect to age, white cell count, and phenotype and prophase response.

**Conclusions**: Although, incidence of TLP + cases is decreased with this modified approach (day 8 IT) but higher prevalence of CNS 2 and 3 in this cohort is an unusual finding. There can be different hypothetical explanations for this including delayed presentation with high burden of disease, different disease biology and delay of CNS directed therapy for a week. Thus, before continuing this modified approach as a protocol, incidence of higher CNS disease warrants further relevant studies.

### PO-066. Frequency, Risk Factors, Underlying Causes and Outcome of Seizures in Children During Induction Remission Chemotherapy for Acute Lymphoblastic Leukemia {#pbc27455-sec-2910}

[C.Y. Jamal]{.ul} ^1^, S.A. Soma^1^

*^1^Bangabandhu Sheikh Mujib Medical University, Pediatric Hematology and Oncology, Dhaka, Bangladesh*

**Background/Objectives**: Seizure is one of the most common CNS complication among patients receiving chemotherapy for ALL. Seizures are seen in 8‐13% of patients with acute lymphoblastic leukemia. Most seizure occurs during the induction and consolidation phases of treatment. Not much is known about the etiology, the risk factors and natural history of these seizure. A data regarding the same from Bangladeshi population is lacking.

**Design/Methods**: It was a prospective observational study, conducted at Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka. All children between the age of 1‐17.9years, with no pre‐existing neurological abnormality developing first episode of seizure during the period of induction remission ALL chemotherapy were included. All relevant clinical, treatment related and investigational data were collected prospectively and analyzed.

**Results**: Thirteen patients (14.4%) developed seizures out of 90 patients with ALL getting induction remission chemotherapy during the study period. Majority of seizures occurred in the 1‐10 (84.6 %) years age group and OR is 1.33. Majority of seizures occurred in the B‐ALL immunophenotype and OR is 2.06. No significant increased risk was found by sex, initial WBC count and type of chemotherapy regimen received. The underlying causes identified included CNS leukemic infiltrate (3), meningitis (2), brain abscess (1), CNS infarction (1), tumor lysis syndrome (1). In the remaining 5 patient exact cause was not identified but intracranial hemorrhage was suspected. Among the 13 patients who developed seizure 9 patients (69.2%) died.

**Conclusions**: In our study we found a slightly higher frequency of seizure than previous studies. Lower age group and B‐ALL immunophenotype was found to be significant risk factor for development of seizure. Etiology could be detected in 61.5% of seizure episodes in our study. Outcome was found very poor in patients who developed seizure.

### PO-067. GSTM1 Deletion Variant is Involved in Busulfan Response using Human Lymphoblastoid Cell Lines {#pbc27455-sec-2920}

[S. Jurkovic Mlakar]{.ul} ^1^, C.R. S Uppugunduri^1^, V. Mlakar^1^, P. Huezo‐Diaz Curtis^1^, T. Nava^1^, L. Lesne^1^, D. Marino^1^, M. Boudal‐Khoshbeen^1^, M. Aziz Rezgui^2^, H. Bittencourt^3^, M. Krajinovic^2^, A. Ansari Djaberi^4^

*^1^CANSEARCH research laboratory‐ University of Geneva‐ Faculty of Medicine, Pediatric Oncology and Hematology Unit, Geneva, Switzerland; ^2^Charles‐Bruneau Cancer Center‐ CHU Sainte‐Justine Research Centre‐ University of Montreal, Department of Pediatrics and Pharmacology, Montreal, Canada; ^3^Faculty of Medicine‐ University of Montreal, Department of Pediatrics, Montreal, Canada; ^4^Hopital Universitaire de Geneve, Unite d\"Oncologie et Hematologie Pediatrique‐ Departement de l\"Enfant et Adolescent, Geneva, Switzerland*

**Background/Objectives**: Busulfan (BU) is a bifunctional alkylating agent commonly used in hematopoietic stem‐cell transplantation. However, its efficacy varies greatly among treated patients, and is influenced by the individuals\' genetic background, particularly by its main metabolizing enzyme GSTA1. In order to explore other potential associated genes we chose to use Lymphoblast Cell Lines (LCL) that already have fully sequenced data online, and additionally have negligible expression of GSTA1, allowing the opportunity to evaluate *GSTA1* ‐independent metabolism genes involved in BU‐related cellular toxicity.

**Design/Methods**: We explored the role of functional gene variants: *GSTM5 (rs3754446), CTH (rs648743), GSTP1 (rs1138272, rs1695), GSTM1 (deletion), GSTT1 (deletion)* and *FMO3 (rs2266782, rs1736557);* in determining half‐maximal inhibitory concentration for BU (BU‐IC50) in 56 different LCLs. BU‐induced activation of cellular apoptosis, necrosis and levels of oxidized and reduced form of GSH \[GSHox/GSHred\] were screened in 20 LCLs, stratified according to the presence of significant variants with IC50. Involvement of GSH in resistance against BU was investigated by co‐treatments with inhibitor of GSH synthesis (BSO).

**Results**: We observed an increase of BU‐IC50 values in LCLs carrying *GSTM1‐null/null* alleles compared to *GSTM1*‐*non null* (p=0.019, N=56). No significant differences between other genotype subgroups were observed. Ratios between necrosis and early apoptosis after the induction with BU were significantly lower in *GSTM1*‐*null/null LCLs* (p = 0.019), suggesting a slower progression rate of apoptosis for *GSTM ‐null* LCLs. \[GSHox/GSHred\] ratios were higher in *GSTM1‐*non‐null LCLs (p \< 0.01) suggesting that depletion of the reduced form of GSH might be the main mechanism for the decreased cell survival under BU‐oxidizing conditions.

**Conclusions**: Our results indicate that the *GSTM1*‐null variant is associated with increased BU‐IC50 in LCLs treated with BU possibly through GSH‐related cellular survival. Results provide additional mechanistic explanation of previous reports that demonstrate significant associations of GSTM1 gene deletions with event‐free survival among patients treated with BU.

### PO-068. Current Outcomes of Acute Lymphoblastic Leukemia (ALL) Among Children in Gulf Counties (GC): A Systematic Analysis {#pbc27455-sec-2930}

[Z.A. Kanakkande Kandy]{.ul} ^1^

*^1^Burjeel Hospital, Pediatric oncology, Abu Dhabi, United Arab Emirates*

**Background/Objectives**: Objectives

Published literature from GC on ALL in children is scant. This comprehensive review of published literature was conducted to understand the current outcome of childhood ALL in GC.

**Design/Methods**: A search of Medline and EMBASE using keywords leukemia, child, and Gulf Countries was carried out. All studies, which reported outcomes on survival, related to ALL published up to, 2017, are included. The results of the searches were compared and merged. The reference list of all included studies was searched to identify any other eligible studies.

**Results**: The number of studies published is scarce. Of the 8 studies identified, 7 single centre studies and 1 multicentre study from 4 out of 7 GC met the inclusion criteria. There were a total of 2,780 children with ALL (32‐698 children/study). The median age at presentation was 0---4.37 years in majority of the studies. Minimum Residual Disease (MRD) was not used in majority of cases. Treatment consisted of chemotherapy but there was considerable variation in chemotherapy use among different canters. Different chemotherapies were used; most commonly often without (Minimal Residual Disease) MRD based risk stratification. There was only one multicenter study published yet. Median overall survival (OS) was range 72‐86.9% and Event Free Survival (EFS) Range 30.6‐73%. Reported rate of abandonment were limited. Data on long‐term side effects was also very limited.

**Conclusions**: Survival outcomes of ALL in children in GC are encouraging. Lack of publication from many centers makes it difficult to understand current practices and outcome from many centers. We recommend co ordinated multicentre approach in collaboration with western centers in treating and analyzing experiences to address several questions. Role of children cancer registry for entire Gulf Countries and its effective use is highly recommended.

### PO-069. A Rare Finding in a Case with Sickle Cell Anemia Carriage and Acute Leukemia: Dactilitis {#pbc27455-sec-2940}

[S. Karaman]{.ul} ^1^, A.Ö. Karagenc^1^, S. Aydogdu^1^, D. Tugcu^1^, A. Turkmen^1^, Z. Bayramoglu^2^, E. Caliskan^2^, S. Ocak^1^, R. Tuna^1^, Z. Karakas^1^

*^1^Istanbul University‐ Istanbul Faculty of Medicine, Pediatric Hematology Oncology, İstanbul, Turkey; ^2^Istanbul University‐ Istanbul Faculty of Medicine, Radiology, İstanbul, Turkey*

**Background/Objectives**: Sickle cell anemia (SCA) is a hemoglobinopathy that can result in hemolysis, life threatening acute complications, and chronic damage to various organs. Acute vascular occlusion is the most common cause of hospital admission. In sickle cell anemia carriers, the clinic is usually normal. Here we report a case of acute leukemia with dactilitis known to be a carrier of sickle cell anemia. We thought that deep anemia may cause sickle cell crisis leading to tissue hypoxia, or leukemic blasts may also have triggered this condition

**Design/Methods**: A5‐and‐a‐half‐year‐old girl presented swelling of her fingers and toes. Two days before admission, right food\'s first metatarsophalangeal(MTP)joint;after 1 day, right hand 4thand 5thMKP joints developed swelling, redness and pain were also added. She dropped from the bike 1 month ago, and at that timeMRI examinations revealed a fracture in the right distal fibula, and her foot was plastered., we learned that while her mother, grandmother and grandfather, uncle and aunt were diagnosed with SCA, our patient with 6 month was diagnosed SCA carrier. Physical examination was normal, except right hand 2nd‐5th joints of MKF, right foot 1st MTF joint were swelling, painful, hyperemic. In the laboratory tests revealed pancytopenia. Bone marrow aspiration was performed, acute lymphoblastic leukemia was diagnosed. Medullary infarcts were observed on her hand MRI. The patient was given red blood cell transfusion and effective hydration. Significant improvement of symptoms was observed. Our patient is in remissionand she follows up by our hematology‐oncology department.

**Results**: Patients with SCA carriers are clinically normal. However, it has been reported that hypoxia, dehydration, exercise and after travel with pressurized airplanes in very high regions, may develop infarcts in the literature. Our case was clinically normal before diagnosis of leukemia, and had no painful crisis. At the diagnosis, it\'s the first painful crisis for her, due to profound anemia or blastic infiltration

**Conclusions**: Clinical signs are not expected in carriers of sickle cell anemia. However, it should be kept in mind that accompanying diseases, such as infections, may manifest anemia in these patients and hypoxia may trigger painful crisis.

### PO-070. Central Nervous System Fungal Infections in Children with Leukemia: Risk Factors and Outcome: A Multicentric Study {#pbc27455-sec-2950}

[S. Karaman]{.ul} ^1^, R. Kebudi^2^, H. Kizilocak^2^, Z. Karakas^1^, M. Sezgin Evim^3^, Z. Kaya^4^, N. Yarali^5^, U. Caliskan^6^, B. Karagün Şahin^7^, S. Yilmaz^8^, D. Yilmaz Karapinar^9^, E. Unal^10^, A. Meral Gunes^3^, Z. Guzelkucuk^5^, U. Kocak^4^, T. Celkan^2^

*^1^Istanbul University‐ Istanbul Faculty of Medicine, Pediatric Hematology‐Oncology, İstanbul, Turkey; ^2^Istanbul University‐ Cerrahpasa Faculty of Medicine, Pediatric Hematology‐Oncology, İstanbul, Turkey; ^3^Uludag University Faculty of Medicine, Pediatric Hematology‐Oncology‐ and Bone Marrow Transplantation Unit, Bursa, Turkey; ^4^Gazi University Faculty of Medicine, Pediatric Hematology‐Oncology and Bone Marrow Transplantation Unit, Ankara, Turkey; ^5^University of Health Sciences Ankara Pediatric‐Hematology‐Oncology Education and Research Hospital, Pediatric Hematology‐Oncology and Bone Marrow Transplantation Unit, Ankara, Turkey; ^6^Meram University Faculty of Medicine, Pediatric Hematology‐Oncology, Konya, Turkey; ^7^Adana Acıbadem Hospital, Pediatric Hematology‐Oncology‐ and Bone Marrow Transplantation Unit, Adana, Turkey; ^8^Dokuz Eylul University Faculty of Medicine, Pediatric Hematology‐Oncology and Bone Marrow Transplantation Unit, Izmir, Turkey; ^9^Ege University Faculty of Medicine, Pediatric Hematology‐Oncology and Bone Marrow Transplantation Unit, Izmir, Turkey; ^10^Erciyes University Faculty of Medicine, Pediatric Hematology‐Oncology‐ and Bone Marrow Transplantation Unit, Kayseri, Turkey*

**Background/Objectives**: Invasive fungal infections, including central nervous system (CNSFI), cause significant morbidity and mortality in children with leukemia, necessitating early diagnosis and treatment. There is limited data regarding CNSFI in children.

**Design/Methods**: In this retrospective study, the demographic features, diagnostic approach, treatment and outcome of CNSFI in 23 children with leukemia treated in 10 center in Turkey were evaluated.

**Results**: Twenty three children (8 female, 15 male) with acute lymphoblastic leukemia and CNSFI were evaluated. All recieved broad‐spectrum antibiotics for prolonged neutropenic fever. Fourteen had seizures. Four patient had a headace. Radiologic imaging was performed in patients with febrile neutropenia after median 7 days (1‐22). Seventeen had multiple and 6 single brain lesions in magnetic resonance imaging. Concurrent to CNSFI, 17 (74 %) had pulmonary (15) and/or hepatosplenic fungal infection (2). One patient had geotrichum capitatum fungemia and one had candida albicans fungemia. Galactomannan was positive in 13 (57%) patients. Ten patients underwent surgery, in nine microbiological evidence of fungi was confirmed; four aspergillus flavus, one aspergillus niger, one mucormycosis and one trichoderme longibrachiatum. Hemophagocytosis was observed in 2 patients. Nine received granulocyte transfusions. Eleven were transferred to the ICU. Seven patients (30 %) died due to CNSFI at a median of 30 (15‐42) days from the beginning of the episode. Out of 16 survivors, six have permanent neurological sequela. Before CNSFI diagnosis, antifungal prophylaxis was performed in 15 patients. Five patients received a single antifungal agent, 18 were treated with a combination of antifungals. Liposomal amphoterisin‐B and voriconazole were the two mostly used agents.

**Conclusions**: CNSFI is a major cause of mortality and morbidity in children with leukemia and prolonged neutropenic fever. A cranial imaging is recommended in these children even in the absence of local sign and symptoms. The antifungal spectrum should cover mucor and other rare fungi.

### PO-071. Immunophenotyping Pattern and Treatment Outcome After Completion of Induction Remission in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-2960}

[M.A. Karim]{.ul} ^1^, F. Diba^1^

*^1^Bangabandhu Sheikh Mujib Medical University, Pediatric Hematology and Oncology, Dhaka, Bangladesh*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. It displays characteristic patterns of surface antigen expression (CD antigens), detected by flowcytometry which facilitate their identification and proper classification. To evaluate the immunophenotypic pattern of ALL. And also, to recognize the frequency of different ALL subtypes and treatment outcome after induction remission therapy.

**Design/Methods**: It was a prospective cohort study. The study was done from July 2017 to March 2018 in the dept of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University. Eighty seven newly diagnosed admitted cases of ALL aged 1‐17.9 years were included. Bone marrow examination with both morphology and immunophenotyping and other relevant investigations were done. Immunophenoytping was performed on CYTOMICS FC‐500 flowcytometer. Patients were stratified according to risk and treated with modified UKALL‐2003 protocol A or B according to risk stratification. Outcome was determined by recording the events during the induction period and determining the bone marrow status on D28.

**Results**: Among 87 patients, 73 patients(83.9%) were B‐cell ALL,8 patients(8%) were T‐cell ALL and rest (8%) were mixed phenotype ALL. After completion of induction remission most of the patients were undergone complete remission (B cell ALL‐79.3% and T‐cell ALL 85.7%, p value‐0.256) and 29 patients died(B cell ALL ‐27, T cell ALL‐2).Most common cause of death was septicemia(90% in B cell ALL and 4% in T cell ALL, p value‐1). Complications (septicemia, bleeding, dyselectrolytemia, tumor lysis syndrome and hyperglycemia) were developed in 52 patients during induction therapy. Complications were more in patients who received regimen B (Reg A 48.1% and Reg B 78.8%, p value 0.005). Death rate was also higher in patients with regimen B (Reg A‐25.%, Reg B‐45.5%, p value o.061).

**Conclusions**: B cell phenotype was the commonest pattern observed and in most of the cases, both B cell and T cell ALL had undergone complete remission.

### PO-072. Chromothripsis‐like Single Nucleotide Polymorphism Array Pattern in Pediatric and Adolescent Acute Leukemia {#pbc27455-sec-2970}

[M. Kawamura]{.ul} ^1^, Y. Kaneko^1^, N. Fujita^2^, S. Tashiro^3^

*^1^Saitama Cancer Center, Hematology, Saitama, Japan; ^2^Hiroshima Red Cross Hospital & Atomic‐bomb Survivors Hospital, Pediatrics, Hiroshima, Japan; ^3^Research Institute for Radiation Biology and Medicine, Cellular Biology, Hiroshima, Japan*

**Background/Objectives**: Complex karyotypes are related to poor prognosis in acute leukemia. Chromothripsis, a one‐step catastrophic mechanism of genomic instability, was identified by whole genome sequencing, and could represent a driving force in the development and progression of acute leukemia as well as other cancers. We tried to identify chromothripsis using more practical methods, including Single Nucleotide Polymorphism (SNP) array CGH (aCGH) and PNA‐FISH.

**Design/Methods**: We performed cytogenetic and aCGH analyses in 12 children/adolescents and young adults with hematological malignancies, and selected 3 cases for further analysis. Case 1: a 9‐yr‐old girl with a normal karyotype in B‐ALL. Case 2: an 18‐yr‐old girl had secondary AML with complex karyotypes 10 years after she was diagnosed as having B‐ALL with a normal karyotype. Case 3: an 18‐yr‐old girl had T‐ALL with complex karyotypes. We performed aCGH to detect genomic aberrations, and PNA‐FISH to detect dicentric/ring chromosomes. *TP53* gene was analyzed by aCGH and sequencing after PCR.

**Results**: cCGH showed Chromothripsis‐like SNP array pattern (CSAP), and FISH using TEL (12p13) and AML1 (21q22) probes demonstrated 2 and 5 copies in leukemic cells, respectively, indicating intrachromosomal amplification of chromosome 21 (iAMP21) in Case 1. Breakage‐fusion‐bridge cycles, which are typically an initiating event of chromothripsis, were detected by aCGH. Chromothripsis was suggested by CASP and confirmed by whole genome and RNA sequencing in Case 2. This case also showed a *NUP98* fusion and complex chromosome abnormalities, and *TP53* mutation. A novel *BCL11B* fusion and complex chromosome abnormalities, but not *TP53* mutation, were found in case 3. Numerous dicentric/ring chromosomes were identified by PNA‐FISH in this case.

**Conclusions**: aCGH and PNA‐FISH were useful to screen chromothripsis. The mechanisms underlying chromothripsis are poorly understood, and establishment of clinical detection method, and development of treatment strategy are needed for the improvement of outcomes in patients with chromothripsis‐associated leukemia.

### PO-073. Haploidentical Transplantation with Post‐Transplantation Cyclophosphamide for High‐Risk Acute Pediatric Leukemia: Single Center Experience from India {#pbc27455-sec-2980}

[V. Khandelwal]{.ul} ^1^, D. Doval^1^, D. Choudhary^1^, S. Sharma^1^, M. Kumar^1^, A. Handoo^2^, T. Dadu^2^, R. Setia^3^

*^1^BLK Superspeciality hospital, Haematooncology and BMT, Delhi, India; ^2^BLK Superspeciality hospital, Haematology, Delhi, India; ^3^BLK Superspeciality hospital, Transfusion medicine, Delhi, India*

**Background/Objectives**: Haploidentical transplantation performed with post‐transplantation cyclophosphamide (PTCy)--based graft‐versus‐host disease (GVHD) prophylaxis has been associated with favorable outcomes for adult patients with acute leukemia and lymphomas. However, it remains unclear if such approach is effective for children with High Risk Acute Leukemia. Aim of the study is to analyze retrospectively the outcome of 13 children with high risk leukemia aged between 5 to 21 years.

**Design/Methods**: Retrospective data was analyzed for patient who underwent Haploidentical HSCT at our center from Jan 2014 to Feb 2018. Median age was 12 years (range 5‐21). The diagnosis was: acute lymphoblastic leukemia in 9(69%) patients and acute myeloid leukemia in 4(31%).Out of 13 patients 38% were in first remission (CR1), 38% in second (CR2), and 24 % in third (CR3). Conditioning regimen: Reduced Intensity Conditioning (RIC) ‐ Flu/Cy/TBI in 7 patients; Myeloablative conditioning (MAC) Bu/flu/Cy in 6. GVHD prophylaxis was PTCy with Tacrolimus/MMF

**Results**: All 13 patients received G‐ CSF mobilized peripheral blood stem cells. A median 7.6 million of CD34+ cells/kg was infused. A total of 11 patients (85%) engrafted. Median time for Neutrophil and platelet engraftment was 15 days and 25 days respectively. Four patient developed hemorrhagic cystitis. Acute graft GVHD (GR II -- IV) was seen in 3(29%) and chronic GVHD in 1 patient. CMV reactivation was seen in 5 patients and was treated with Gancyclovir. Primary rejection was seen in 2 patients. Eight patients (60 %) have died, the causes were‐ relapse of leukemia (n: 5), Primary rejection and Infection (n: 2), grade IV gut GVHD (n: 1).Median follow up period was 180 days with overall survival (OS) for the whole group 40 %.

**Conclusions**: Haploidentical HSCT with PTCy is a cheaper and suitable option in pediatric high risk leukemia with encouraging results.

### PO-074. Inhibition of Acute Leukemia by Small Molecules (KYA1797K, Midostaurin, Quizartinib): Simultaneous Downregulation of β‐Catenin and RAS by KYA1797K {#pbc27455-sec-2990}

[M.K. Kim]{.ul} ^1^, M.R. Lee^2^, S.M. Hahn^1,2^, J.W. Han^1,2^, H.S. Kim^3^, C.J. Lyu^1,2^
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**Background/Objectives**: FLT3 mutation is related to poor prognosis and RAS mutation frequently occurs in subclones which have a high chance to relapse. Small molecule therapy opened a new window for cancer treatment. KYA1797K binds directly to RGS domain of Axin and enhances the β‐catenin destruction complex which activates GSK3β and results in degradation of β‐catenin and RAS. In the current study, the effects of Midostaurin, Quizartinib and KYA1797K were studied in leukemic cell lines and in patient\'s BM samples.

**Design/Methods**: MOLT‐4, THP‐1, MV4‐11, RS4‐11 were cultured under various concentration for 48h. Cell proliferation assay and Immunoblotting for β‐catenin, GSK3β, Pan‐RAS, N‐RAS was checked. Downstream targets of Wnt pathway were studied by Immunoblotting. MOLT‐4 was stimulated with Wnt3a and changes in Wnt pathway was observed. BM of ALL patients were evaluated for β‐catenin, RAS. Two went through MACS for CD34+ selection and were treated with KYA1797K.

**Results**: IC50 for Midostaurin and Quizartinib were higher in RS4‐11 compared to MV4‐11 while KYA1797K showed same IC50. β‐catenin was downregulated in most of the cell lines by KYA1797K. N‐RAS downregulation was prominent by KYA1797K. All the downstream targets evaluated were downregulated by KYA1797K in MOLT‐4 at the concentration of 5 μM. Wnt3a activated the Wnt pathway in MOLT‐4 and KYA1797K effectively downregulated β‐catenin, N‐RAS and c‐Myc. BM samples from ALL patients showed various status of β‐catenin and RAS expression. KYA1797K inhibited β‐cateinin and N‐RAS in the ALL patient with hyerleukocytosis, and the effect was weaker in the ALL patient with BCR‐ABL.

**Conclusions**: Effects of Midostaurin and Quizartinib were cell‐dependent while KYA1797K showed effect in a constant narrow range of IC50. KYA1797K effectively destabilized β‐catenin and RAS in acute leukemia even under Wnt pathway activation. Further in vivo study is needed to build up a strategy in small molecule therapy in acute leukemia whether to target FLT3 or RAS.

### PO-075. Analysis of the Distribution and Clinical Features of Alterations Activating NOTCH1 Signaling in Pediatric T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) {#pbc27455-sec-3000}
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**Background/Objectives**: Aberrant constitutive activation of NOTCH1 signaling (*NOTCH1* and *FBXW7*) is a major oncogenic event in T‐cell acute lymphoblastic leukemia (T‐ALL), classified into two patterns; ligand‐independent activation (LIA) and impaired degradation (ID). Several types of aberration were reported in each activation pattern, so far. In this study, we explored the clinicopathological relevance of *NOTCH1*/*FBXW7* aberrations.

**Design/Methods**: We reanalyzed our previously published data of targeted‐capture sequencing (n=176) and whole transcriptome sequencing (WTS; n=123). We defined as subclonal when variant allele frequency was below 0.15.

**Results**: In total, we detected aberrations activating NOTCH1 signaling in 80.7% (142/176) of cases. Subclonal mutations were observed in 26.1% (n=46). Single nucleotide variations in the heterodimerization domain (HD‐SNV) were the most frequent (42.6%; n=75), followed by PEST domain mutations (32.4%; n=57). Both LIA and ID patterns were detected in 43.2% (n=76). Most mutations were mutually exclusive within each LIA and ID pattern. We detected three cases (1.7%) of SNV at 3' UTR, four (2.3%) intragenic *NOTCH1* deletion (DEL; missing exon 3--27), and two (1.1%) *SEC16A*‐*NOTCH1* fusions. We confirmed that DEL activates NOTCH1 signaling by luciferase reporter assay. Analysis of frequency in each WTS‐based cluster (ETP, SPI1, TLX, TAL1‐RA, and TAL1‐RB) revealed that alterations were frequently detected in TLX (100%; n=24) and TAL1‐RB (95.1%; n=41), whereas less frequent in TAL1‐RA (61.1%; n=18). In TAL1‐RA, all *SEC16A*‐*NOTCH1* fusions were observed despite low rate of HD‐SNV (11.1%). Importantly, cases harboring subclonal *NOTCH1*/*FBXW7* mutations showed significantly worse outcome (log‐rank *P* =0.01). There was no prognostic difference between cases with and without *NOTCH1*/*FBXW7* mutations.

**Conclusions**: We observed *NOTCH1*/*FBXW7* alterations in 80.7%, and detected rare intragenic NOTCH1 deletion and *SEC16A*‐*NOTCH1* fusions recurrently in T‐ALL. Additionally, subclonal *NOTCH1*/*FBXW7* aberrations might be relevant to unfavorable outcome. Our results might be useful for development of a new anti‐NOTCH1 therapeutic strategy for pediatric T‐ALL patients.

### PO-076. Paraneoplastic Hypereosinophilic Syndrome Associated with IL3/IgH Positive Acute Lymphoblastic Leukemia {#pbc27455-sec-3010}
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**Background/Objectives**: Hypereosinophilia in hematological malignancies can either be a neoplastic or a reactive condition. Neopslastic eosinophilia has been well documented in myeloid neoplasms with particular chromosomal translocations *i.e., PDGFR, FGFR‐1, JAK2*, and inversion chromosome 16. Chromosomal translocations involving IgH locus are hallmarks of B‐cell malignancies comprising 5 % of B‐cell malignancies with young adult predominance. *IL3/IgH* translocation positive acute lymphoblastic leukemia (ALL) with eosinopnilia has been well documented for the accompanying life threatening thromboembolic complications in lugs, heart, and brain, but little is known about the exact molecular mechanism of the concurrent hypereosinophila.

**Design/Methods**: We encountered an 11‐year‐old boy with *IL3/IgH* positive ALL with hypereosinophilia. He developed eosinophil‐induced organ damages such as left ventricular thrombosis and cardioembolic brain infarction. We verified the genomic signature, including *IL3/IgH* translocation, in ALL fractions and growing eosinophils, respectively.

**Results**: A recurrent translocation t(5;14) developed fusion gene between the *IgH* enhancer to the promoter region of *IL3*, which drives constitutive expression of IL‐3. We confirmed a complete concordance among three parameters, such as bone marrow *IL3* mRNA expression, *IL3/IgH* fusion genomes, and eosinophil counts. The fusion genome was identified in the ALL cells but not in the proliferating eosinophils. We confirmed the absence of driver mutations in the proliferating eosinophils by the whole‐exome sequencing analysis. We confirmed that both ALL blast cells and growing eosinophils expressed IL3 receptor expression of CD123, indicating that IL3 mediation from the clonal ALL cells accounts for this type of hypereosinophilia. In fact, he showed refractory to conventional therapy but successfully treated matched‐sibling allogenic bone marrow transplantation. The subsequent clinical course was uneventful with a complete molecular remission coincident with the resolution of hypereosinophila.

**Conclusions**: Concurrent hypereosinophila in *IL3/IgH* translocation positive ALL is a paraneoplastic phenomenon driven by the leukemic cells.

### PO-077. Treatment Outcome of ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia in Yeungnam Region: A Multicenter Retrospective Study in Korea {#pbc27455-sec-3020}
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**Background/Objectives**: ETV6/RUNX1 gene rearrangement in pediatric acute lymphoblastic leukemia (ALL) has been known as a good prognostic factor, but several studies have reported that it may not be an independent prognostic factor. Therefore, this study evaluates the clinical characteristics and prognosis of ETV6/RUNX1 positive childhood ALL in Yeungnam, South Korea.

**Design/Methods**: The study included 319 patients with pediatric B‐precursor ALL diagnosed at 11 hospitals in the Yeungnam area from January 2004 to December 2013. ETV6/RUNX1 was positive in 49 patients (15.4%) and 50 patients showed hyperdiploidy.

**Results**: The mean age of the ETV6/RUNX1 positive group was 5.25±3.23 years and the negative group was 6.58±4.13 years (*p*=0.013). The mean leukocyte count was 36,678/μL in the positive group and 46,278/μL in the negative group (*p*=0.529). Platelet (55,000 versus 86,000/μL, *p*=0.005), lactate dehydrogenase (1,458 versus 2,181 IU/L, *p*=0.002), and hemoglobin (6.5±1.61 versus 7.42±2.32 g/dL, *p*=0.009) counts were significantly lower in the positive group than in the negative group. The complete remission rates were 97.9% and 99.2% (*p*=0.397), and the recurrence rates were 8.5% and 14.7% in the positive and negative groups, respectively (*p*=0.423). There was no recurrence of the central nervous system (CNS) in the positive group, but recurrence of the CNS occurred in 4.9% of the negative group (*p*=0.032). The 5‐year event‐free survival rates were 88.3% in the positive group, and 78.2% in the negative group (*p*=0.073). The 8‐year overall survival (OS) rates were 92.5% in the positive group and 85.8% in the negative group, but were not statistically significant (*p*=0.091). When accounting for the 50 patients that displayed hyperdiploidy, the 8‐year OS rate was 92.5% in the positive group, 90.1% in the hyperdiploidy group, and 84.7% in the negative group without hyperdiploidy (*p*=0.036) and showed to be statistically significant.

**Conclusions**: ETV6/RUNX1 positive ALL showed a higher survival rate than the negative group without hyperdiploidy.

### PO-078. Human Adipose Tissue Stem Cells Promote the Growth of Acute Lymphoblastic Leukemia Cells in NOD/SCID Mice {#pbc27455-sec-3030}
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**Background/Objectives**: Human mesenchymal stem cells, including adipose tissue stem cells (ASCs), have the potential to support or supress tumor growth. However little is known about the relationship between ASCs and hematologic malignancy including leukemia, and whether ASCs support leukemia cell survival remains unclear. In this study, the effect of ASCs on the growth of acute lymphoblastic leukemia(ALL) cells was examined in an *in vivo* model.

**Design/Methods**: We established ALL cell lines expressing firefly luciferase (ALL/fLuc) by lentiviral infection that were injected intraperitoneally to NOD/SCID mice.

**Results**: The luciferase activities were significantly higher in mice co‐injected with 105 ALL/fLuc cells and ASCs than in those injected with ALL/fLuc cells alone. Co‐injection of 105 ALL/fLuc cells and ASCs in differing ratios into mice gradually increased the bioluminescence intensity in all groups, and mice co‐injected with 1 or 2 × 106 ASCs showed higher bioluminescence intensity than those receiving lower numbers. Interestingly, in the mice injected with 105 or 107 ALL/fLuc cells alone, the formation of tumor masses was not observed for at least five weeks. Moreover, co‐injection of 107 ALL/fLuc cells and 5 × 105 ASCs into mice increased the bioluminescence intensity in all groups, and showed significantly higher bioluminescence intensity compared to mice co‐injected with human normal fibroblast HS68 cells.

**Conclusions**: Overall, ASCs promote the growth of ALL cells *in vivo*, suggesting that ASCs negatively influence hematologic malignancy, which should be taken into account before developing cell therapy products based on ASCs.

### PO-079. Characteristics and Outcome of Acute Leukemia of Ambiguous Lineage in Children: Comparison of EGIL Criteria and WHO 2017 Classification {#pbc27455-sec-3040}

[H. Kook]{.ul} ^1^, H.G. Lee^1^, H.S. Kim^1^, S.M. Park^1^, H.J. Baek^1^, T.J. Hwang^1^
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**Background/Objectives**: Acute leukemias of ambiguous lineage (ALAU) are leukemias showing no clear evidence of differentiation along a single lineage. They include acute undifferentiated leukemias (AUL) and mixed phenotype acute leukemias (MPALs) which can contain acute bilineage leukemia and acute biphenotypic leukemia. The terminology and definitions are confusing, and they pose many diagnostic and therapeutic challenges. The MPAL accounts for 3‐4% of all acute leukemias according to the EGIL criteria, whereas the incidence was 1.5‐2% by WHO criteria. Clinical characteristics and therapeutic outcomes of children with ALAU were described with respect to EGIL or WHO 2017 criteria.

**Design/Methods**: This study was retrospective the review of medical documents on patients who were diagnosed at the Department of Pediatrics, Chonnam National University Hwasun Hospital, Korea from 2001 and 2016.

**Results**: Among 330 acute leukemia patients 12 patients were found to have ALAU (3.6%) by EGIL criteria: AUL, 2; B/myeloid, 6; T/myeloid, 3; and T/B/myeloid, 1. However, 6 patients remained to have ALAU by WHO 2017: AUL, 2; B/myeloid, 2; MPAL with t(9;22)(q34.1;q11.2), 1; and MPAL with t(v;11q23.3), 1. The median age at diagnosis was 10.8 years, with male predominance (67%). Remission induction was achieved in 8 patients (67%) after initial induction therapy. AML‐type induction therapy resulted in remission in 3/7 (43%), whereas ALL‐type therapy in 5/5 (100%) (P\<.05). Two more patients achieved a remission after switching to ALL‐type therapy. HSCT was done in 10 patients. At a median follow‐up of 5 years, the 5‐year probability of OS was 58.3% +/‐ 18.7%. No clinical and laboratory variables was associated with survival outcome.

**Conclusions**: This study demonstrated the rarity of ALAU in children, but the outcome seemed to be better than adult counterpart when ALL‐type induction chemotherapy was used. HSCT may salvage some patients with ALAU, but the best management plan should be sought with multicenter collaborative studies.

### PO-080. Osteoedema and Osteonecrosis of the Ankle in Adolescents with ALL: Findings of Systematic MRI Screening within the OPAL Trial {#pbc27455-sec-3050}
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**Background/Objectives**: Therapy success in acute lymphoblastic leukemia (ALL) is counterbalanced by the burden of long‐term sequelae including osteonecrosis (ON), which severely impacts quality of life. However, little is known about ON of the ankles.

**Design/Methods**: MRIs of adolescents (≥ 10 years) diagnosed with ALL, who were enrolled in the prospective multicenter OPAL trial, were analyzed.

**Results**: Between 03/2013‐12/2017, 47 patients were enrolled and underwent standardized MRI screening of the ankles; median age was 14 years (range 10‐17), median time under evaluation 337 days. 23 (48.9%) were female, 11 (23.4%) dropped out, in 6 (12.8%) screening was terminated according to protocol because of symptomatic ON involving other joints. At initial diagnosis, MRI showed osteoedema (OE) of the upper ankle in 1 of 47 patients (2.1%), ON with \<30% joint surface involvement in 2 of 30 (6.7%) at 6 months, OE in 1 of 20 (5%) and ON in 4 (20%) at 9 months, OE in 3 of 18 (16.7%), ON in 4 (22.2%) at 12 months, OE in 1 of 15 (6.7%) and ON in 3 (20%) at 15 months, ON in 1 of 10 (10%) at 18 months, and neither OE nor ON in 3 patients at the end of treatment. In the lower ankle, OE was present in 4 (8.5%), 5 (16.7%), 6 (30%), 7 (38.9%), 7 (46.7%), 4 (40%) and 3 (100%) patients at the same time points. ON was detectable in 2 (6.7%), 4 (20%), 3 (16.7%) and 2 (13.3%) patients at 6, 9, 12, and 15 months, respectively. In two patients, ON \>30% were present in the ankles. Noteworthy, no patient reported persisting symptoms of ON of the ankles until last follow‐up.

**Conclusions**: OE and ON of the ankles are frequent in adolescents with ALL. These findings should be confirmed in larger patient cohorts and with longer follow‐up times.

### PO-081. PCLO is Overexpressed in ETV6‐RUNX1‐Positive B‐Cell Precursor Acute Lymphoblastic Leukemia {#pbc27455-sec-3060}
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**Background/Objectives**: The genetic translocation ETV6‐RUNX1 (E/R) characterizes the second most common oncogenic subtype (25%) in children with pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) (Lilljebjör and Fioretos, 2017; Blood). Although this oncogenic subtype has cure rates of \> 90% with contemporary treatment protocols (Pui et al., 2017; Leukemia), some patients will suffer from relapsed disease. Further understanding of the molecular biology of this group is necessary for the development of effective targeted therapies that will increase cure rates and reduce long‐term side effects.

**Design/Methods**: The *PCLO* transcript levels in samples from BCP‐ALL cell lines and from pediatric patients were processed and analysed by total RNA sequencing and/or RT‐qPCR. Furthermore, the mRNA expression levels of *PCLO* were evaluated "*in silico*" (Leukemia Gene Atlas "dataset Haferlach et al., 2010").

**Results**: Total RNA sequencing from BCP‐ALL cell lines (n=14) evidenced that the *PCLO* transcript was highly expressed within the E/R‐positive REH cell line (n=1), while absent in other molecular groups. To further validate the initial findings, "*in silico"* gene expression analysis was performed using the mRNA expression profiles of *PCLO* in patients with BCP‐ALL. In addition, mRNA expression levels of *PCLO* from E/R‐positive and --negative BCP‐ALL pediatric samples (n=64) and cell lines (n=12) were evaluated by RT‐qPCR. Both results, "*in silico*" as well as RT‐qPCR expression analysis, confirmed that the *PCLO* transcript is significantly overexpressed in the group of patients ("*in silico*" dataset as well as from the pediatric samples, n=25) and the cell lines (n=3) carrying the translocation.

**Conclusions**: The current findings show that *PCLO* is overexpressed in E/R‐positive BCP‐ALL. Further functional studies are needed to unveil the key mechanisms of PCLO in cells carrying the E/R translocation. Inhibitors of the aberrantly activated PCLO pathway may represent an interesting targeted therapy for patients with E/R‐positive BCP‐ALL.

### PO-082. Tailored Exercise Improves Physical Function in Children with Hematological Malignancies. The SPORT THERAPY Research Project {#pbc27455-sec-3070}
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**Background/Objectives**: Hematological malignancies (HM) in childhood are characterized by the progressive loss of physical function along treatment, which leads to a reduction in muscle mass, strength, and exercise capacity. Although "Sport as Therapy" is accepted for many diseases, the role of tailored training in patients with HM (pHM) is still debated. The aim of this study was to evaluate the effects of a combined (aerobic, strength, balance, flexibility) exercise program on physical function and quality of life (QoL) in pMH.

**Design/Methods**: This Italian based prospective longitudinal cohort study recruited 37 pHM (54% females), after the elective discontinuation of treatment (n.19) or in maintenance therapy (n.18), divided in cohorts of ages (6‐11; 12‐17 yrs). The individually‐tailored exercise training took place 3 times a week for 12 weeks, inside the hospital. The "up and down stairs" test (TUDS), the "6 min walking" test (6MWT), as well as the 1 Repetition Maximum leg extension (1RM‐LE) were evaluated before and after 12 weeks. A child self‐report and a parent proxy‐report inventory (PedsQL 4.0) were used to measure the participants' QoL. The visual analog scale (VAS) method evaluated the satisfaction of both participants and their parents after the training intervention.

**Results**: There were 5 drop‐out. The adherence to training was 85±6%. The TUDS, the 6MWT as well as the 1RM‐LE showed an improved performance (*P*\<0.005; from 6.54±1.37 to 5.76±0.99 sec, from 586.6±74.7 to 613.8±74.1 m, from 35.4±8.57 to 40.2±9.2 kg, respectively). There was a significant increase in the QoL (P\<0.005; from 70.3±17.0 to 85.5±9.0 for pHM and from 72.9±17.6 to 81.8±6.8 for parents). The VAS scores were 9.3 for pHM and 9.7/10 for parents.

**Conclusions**: This study showed that pHM, who trained for 12 weeks, presented an improvement in physical function and in QoL. A tailored exercise program is perceived as fully satisfactory by pHM and their families.

### PO-083. Analysis of Poor Treatment Outcome of Older Children with Acute Lymphoblastic Leukemia: Multi‐Center Retrospective Study of Yeungnam Region {#pbc27455-sec-3080}
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**Background/Objectives**: Recently, treatment outcomes have significantly improved for children with acute lymphoblastic leukemia (ALL), with 5‐year survival rates over 85%. However, survival rates for adolescents with ALL are lower than that for their younger counterparts.

**Design/Methods**: A total of 374 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled in this study from January 2003 to December 2013 at Yeungnam region of Korea. We divided patients into two groups: younger children group aged 1 to 10 years (n=272), adolescents group aged 10 to 18 years (n=102).

**Results**: The 5‐year event‐free survival (EFS) and overall survival (OS) for adolescents group was 79.6% and 81.5% respectively, compared with 89.4% and 96.5% for younger children group. This was not due to an increased cumulative incidence of relapse (CIR) (5‐year CIR: 14.6±3.8% vs. 8.8±1.8%; P = 0.723), but due to an increased incidence of treatment‐related death \[5‐year cumulative incidence of death (CID): 13.2±3.4% vs. 2.7±1%; P = 0.001\]. Adolescents were more likely to present with T‐cell phenotype (*P* = 0.011) and less likely to have the ETV6‐RUNX1 fusion and hyperdiploid karyotype (P=0.002 and P=0.012, respectively)

**Conclusions**: Adolescents were more likely to present at diagnosis with biologically higher risk disease and more likely to experience treatment‐related complications than younger children. Therefore, this specific age group may need particular vigilance when receiving intense chemotherapy, as relapse‐free survival is similar to younger children.

### PO-084. A Simple Method to Distinguish Poor Outcome Children with Non‐High Risk Acute Lymphoblastic Leukemia {#pbc27455-sec-3090}

[H. Li‐Bin]{.ul} ^1^, T. Hui‐Zhen^1^, Z. Xiao‐Li^1^, K. Zhi‐Yong^1^, L. Xue‐Qun^1^

*^1^the first affiliated hospital‐ Sun Yat‐sen University, pediatric, Guangzhou, China*

**Background/Objectives**: Current treatment strategies result in long‐term remission in up to 90% of children with acute lymphoblastic leukemia (ALL). However, the protocols recommend quantitative minimal residual disase (MRD) monitoring by qRT‐PCR and flow cytometry analysis, and these methods are inaccessible especially in developing countries.

**Design/Methods**: In a non‐randomize study, bone marrow samples were collected from the newly diagnosed children with non‐high risk ALL who agreed to monitor MRD in our department. Ig and TCR gene rearrangements were amplified by multiplex PCR (a kind of qualitive PCR). The clonality of PCR production was analyzed by automated fragment analysis using GENEMAPPERID softwares. Those carried monoclonal Ig/TCR at diagnosis were arranged to monitor MRD at the end of VDLD induction (D33). Detectable clonality of Ig/TCR at D33 was defined as MRD positive. All patients were treated with GD2008 ALL protocol. The last follow‐up was December 31, 2017. Relapse free survival (RFS) were estimated by the Kaplan‐Meier, and compared by using the log‐rank test.

**Results**: From August 1, 2008 to December 31, 2015, there were 162 of 254 cases children with non‐high risk ALL treated in our department agreed to receive MRD monitored. 152 (93.8%) patients were found at least one marker positive. 5 case refused the further test. So there were 147 cases had D33 MRD to analyze. There were no significantly difference in gender, age, initial WBC, immunophenotyping, clinical prognostic classification, and the 5‐year RFS between the MRD group (n=147) and no‐MRD group (n=107). For the 147 cases with D33 MRD, there were 129 cases with MRD negative and 18 cases with MRD positive, and the 5‐year RFS was 88.9%± 3.6% and 52.5%±12.5%, respectively, P=0.000.

**Conclusions**: Using multiplex PCR with automated fragment analysis for monoclonal Ig/TCR gene rearrangements is a simple and feasible method to monitor MRD in non high risk childhood ALL.

### PO-085. A Single Center Clinical Analysis of 314 Cases of Children with Acute Lymphoblastic Leukemia for 10 Years {#pbc27455-sec-3100}

[H. Li]{.ul} ^1^, H. Jiang^1^, Z. Lu^1^, J. Yang^1^, J. Shao^1^, N. Zhang^1^, K. Chen^1^

*^1^Shanghai Children\'s Hospital, Hematology/Oncology, Shanghai, China*

**Background/Objectives**: This study is aimed to assess the efficacy and the prognosis of children with acute lymphoblastic leukemia, so as to improve the efficacy of childhood ALL.

**Design/Methods**: Retrospective study on 314 patients with newly diagnosed ALL in our hospital between January 1, 2006 to January 1, 2017. 37 cases were treated by ALL protocol‐2005, 197 cases by protocol‐2009, 80 cases by protocol‐2015.We analyzed retrospectively the clinical and biological characteristics and EFS of the 314 cases. SPSS20.0 statistical software was used to analyze all the datas.

**Results**: 1. According to the risk stratification, we divided 127 cases into low‐risk (LR) group, 105 cases into intermediate‐risk (IR) group, and 82 cases into high‐risk (HR) group.

2\. The complete remission rate of patients was 96.5% after induction therapy.

3\. 5‐years EFS in LR group was 88.1±3.3%, and 68.0±5.2% in IR group, and 56.1±6.0% in HR group(P=0.000). Compare to the different treatment protocols, the 2‐year EFS rate of ALL‐2005, 2009, 2015 were75.7±7.1%, 83.2±2.7%, 82.2±5.3% (P\>0.05).

4\. The result of the COX regression multivariate analysis showed that risk group was effective prognostic factor for childhood ALL(P=0.002).

5\. The death rate out of relapse was 6.5%, and different protocols were 8.11%, 7.11%, 1.78%, ALL‐2015 protocol had a low death rate out of relapse compared with other protocols(P=0.027,0.031).

**Conclusions**: 1. The rate of induction remission with ALL in our center was high. And risk group was effective prognostic factors for cases with childhood ALL. The prognosis of IR/ HR group of childhood ALL remains to be improved.

2\. Childhood ALL using protocol 2005, 2009, and 2015 had no significant difference of survival rates. But protocol 2015 had a lower death rate out of relapse compared with other protocols.

### PO-086. Mir‐155 Targets Gene ZNF238 Expression and Predicts Childhood Acute Lymphoblastic Leukemia Poor Prognosis {#pbc27455-sec-3110}

[C. Liang]{.ul} ^1^, Y. tang^1^, X. liu^1^, C. peng^1^, W. tang^1^, Y. li^1^, L. wang^1^, L. huang^1^, X. luo^1^

*^1^The First Affiliated Hospital of Sun Yat‐sen University, Pediatrics, guangzhou, China*

**Background/Objectives**: As a significant number of childhood ALL present dismal prognosis, this study evaluated the impact of microRNA on the outcome of childhood ALL in the context of other clinical and molecular prognosticators and explored its mechanism of action.

**Design/Methods**: MicroRNA expression profiles of childhood ALL were investigated from GEO. MiR‐155 expression in bone marrow of forty‐two paired ALL cases at two different time points (initial diagnosis and first relapse status) was detected by qRT‐PCR. Bioinformatics software and dual luciferase reporter assay were applied to predict and verify the target of miR‐155. Furthermore, four human ALL cell lines were transfected with miR‐155 mimics, miR‐155 inhibitor, si‐ZNF238, and corresponding controls. Cell viability and cell apoptosis were analyzed using CCK‐8 and flow cytometry assay. The protein expression were analyzed using Western blotting.

**Results**: A total of 30 differentially expressed miRNAs were identified in ALL patients compared with healthy subject. Patients with higher expression of miR‐155 had shorter overall survival (P=0.0043), shorter leukemia‐free survival (P=0.0017) and higher cumulative incidence of relapse (P=0.0004). Interestingly, there are no statistically significant on overall survival and leukemia‐free survival between our traditional standard‐risk and middle‐risk(P\>0.05).miR‐155 expression was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in ALL (eg, PI3K‐Akt, mTOR, and AMPK), We demonstrate that higher expression levels of MiR‐155 and lower expression levels of ZNF238 both significantly promoted proliferation and inhibited apoptosis in ALL cell lines(CEM‐C1, Jurket, MOLT‐3, MOLT‐4). Dual luciferase reporter system confirmed that ZNF238 was a potential target of miR‐155.

**Conclusions**: MiR‐155 expression may well contribute to an improved prognostic stratification of children with ALL and may play a role in the pathogenesis of this disorder by targeting ZNF238.

### PO-087. Clinical Features and Current Treatment Status of Pediatric Acute Lymphoblastic Leukemia with ETV6‐RUNX1 Fusion Gene in China {#pbc27455-sec-3120}

[F. Liu]{.ul} ^1^, Y. Gao^2^, S. Hu^3^, Y. Zhu^4^, Q. Hu^5^, J. Yu^6^, X. Zhu^1^

*^1^The Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences, Division of Pediatrics‐ Department of Clinical Hematology, Tianjin, China; ^2^Shanghai Children\'s Medical Center, Hematology and Oncology, Shanghai, China; ^3^Children\'s Hospital of Soochow University, Hematology, Suzhou, China; ^4^West China Second University Hospital/ West China Women\'s and Children\'s Hospital, Pediatric Hematology and Oncology, Chengdu, China; ^5^TONGJI Medical College‐ TONGJI Hospital, Department of Pediatrics, Wuhan, China; ^6^Children\'s Hospital of Chongqing Medical University, Hematology and Oncology, Chongqing, China*

**Background/Objectives**: A fusion gene of ETV6‐RUNX1, is thought to be the most common rearrangement and an independent good prognostic factor in pediatric acute lymphoblastic leukemia (ALL). However, the situation of this subgroup in the Chinese population has not been thoroughly studied. Our study is going to investigate the clinical features and efficacy of these Chinese children through a large cohort.

**Design/Methods**: 378 children and adolescents who were newly diagnosed at 6 different pediatric hematology centers all over the China from January 2008 to December 2012, were enrolled in this study. Patients received their chemotherapy including induction, consolidation, reinduction and maintenance therapy accompanying with regular intrathecal chemotherapy. Clinical characteristics were collected at diagnosis, and December 31, 2014 was chosen as the reference date for the end of data collection and survival assessment.

**Results**: All 378 cases ranged in age between 1 and 16 years, with a median 4.3 years. The median leukocyte count was 8.76 × 10\^9/L. Almost all cases (99.2%) showed a B‐cell precursor phenotype. Abnormal karyotypes were demonstrated in 17.8% of the children, and only 3 children were noted as cryptic t(12;21) translocation. Only one case suffered central nervous system leukemia at diagnosis. 91.0% of cases had a good response to prednisone. 97.9% of the patients achieved hematologic complete remission (CR) after induction. 9.4% of the patients suffered relapse, in which late relapse and isolated BM relapse were more common. The probability of the events free survival at five years was 84.9±2.4%, and there were no statistically significant differences among 6 different oncology centers.

**Conclusions**: Lower age and leukocyte count, mostly B‐cell precursor phenotype, higher CR rate and survival, all above showed basically the same clinical features and outcomes between Chinese patients and other countries population.

### PO-088. The Clinical Features and Treatment Outcomes of Childhood B‐Precursor Acute Lymphoblastic Leukemia with TCF3‐PBX1 in Asians {#pbc27455-sec-3130}

[H.C. Liu]{.ul} ^1^, K. Koh^2^, Y. Arakawa^2^, T. Imamura^3^, A.E.J. Yeoh^4^, C. Imai^5^, Y. Okamoto^6^, C.K. Li^7^, T.C. Yeh^1^, E.K.H. Chiew^4^, H.J. Yen^8^, D.T. Lin^9^

*^1^Mackay Memorial Hospital and Mackay Medical College, Division of Pediatric Hematology/Oncology‐Department of Pediatrics, Taipei, Taiwan R.O.C.; ^2^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^3^Kyoto Prefectural University of Medicine Graduate School of Medical Science, Department of Pediatrics, Kyoto, Japan; ^4^National University of Singapore, Department of Paediatrics, Singapore, Singapore; ^5^Niigata University Graduate School of Medical and Dental Sciences, Department of Pediatrics, Niigata, Japan; ^6^Kagoshima University Graduate School of Medical and Dental Science, Department of Pediatrics, Kagoshima, Japan; ^7^Prince of Wales Hospital The Chinese University of Hong Kong, Department of Paediatrics, Hong Kong, Hong Kong S.A.R.; ^8^Taipei Veterans General Hospital and National Yang‐Ming University, Department of Pediatrics, Taipei, Taiwan R.O.C.; ^9^National Taiwan University Hospital, Department of Pediatrics, Taipei, Taiwan R.O.C*.

**Background/Objectives**: We sought to determine clinical features and treatment outcomes of childhood B‐precursor acute lymphoblastic leukemia (ALL) with *TCF3‐PBX1* in Asians.

**Design/Methods**: We collected 7 cooperative study groups enrolled 6,366 patients age 1 to 19 years old with newly diagnosed B‐precursor ALL (B‐ALL) treated between 1996 and 2012 in Asia. They were further categorized into 4 major groups: Japan (CCLSG, JACLS, KYCCSG, and TCCSG), Malaysia/Singapore (Ma‐Spore), Hong Kong (HKPHOSG) and Taiwan (TPOG). Altogether, 366 patients were positive for *TCF3‐PBX1*. Aggregate data on clinical features, treatment regimens and survival outcomes could be obtained in 355 patients.

**Results**: The incidence of this genetic subtype is 5.7%, ranged from 4.5% to 6.1% in 4 groups. Among 355 evaluable patients, 85.1% were treated with high‐risk or very high‐risk regimens. In CNS‐directed therapy, 84.8% did not have cranial radiation (CrRT) and 89.4% received ≤20 doses of intrathecal therapy (IT), if IT was given alone. High‐dose (HD) Ara‐C (≥1 g/m2/dose) or HD MTX (5 g/m2/dose) were administered in 33.5% and 23.9% of patients. As a whole group, the 5‐year event‐free survival, overall survival (OS) and cumulative risk of any CNS relapse were 86.2 ± 1.8%, 92.1 ± 1.5% and 2.1 ± 0.8%, respectively. There were no statistically differences between the 4 groups. Using multivariate analysis, only patients with age ≥10 years and CNS disease at diagnosis had inferior OS (P \<0.05). B‐ALLs with *TCF3‐PBX1* (N =355) in Asian groups tend to have age ≥10 years, WBC \>10,000/μL and NCI high‐risk as compared with those without *TCF3‐PBX1* (N =1,024) in TPOG (P \<0.001).

**Conclusions**: The incidence of B‐ALL with *TCF3‐PBX1* is higher in Asians than those reported in Caucasians (1.8‐3.6%).The survival outcomes are similar in the 4 Asian groups treated with higher‐risk arms of contemporary protocols. CrRT does not have an impact on the outcomes of B‐ALL with *TCF3‐PBX1*.

### PO-089. Prognostic Analysis of Pediatric T‐Lineage Acute Lymphoblastic Leukemia with CCLG‐ALL2008 Protocol {#pbc27455-sec-3140}

[X. Liu]{.ul} ^1^, X. chen^1^, Y. zou^1^, Y. chen^1^, M. wang^1^, S. wang^1^, W. yang^1^, Y. guo^1^, X. zhu^1^

*^1^Institute of Hematology‐ Blood Disease Hospital, Chinese Academy of Medical Sciences CAMS, Department of Paediatric Haematology, Tianjin, China*

**Background/Objectives**: To evaluate the clinical efficacy and prognostic factors of childhood T‐ lineage acute lymphocytic leukemia (T‐All) using CCLG‐ALL2008 protocol.

**Design/Methods**: We retrospectively analyzed 84 pediatric T‐ALL patients using CCLG‐ALL2008 platform from 2008.4 to 2015.4, we collected the clinical characteristics, treatment effect and prognostic factors.

**Results**: Among these 84 patients, 63 cases (75.0%) were boys and 21 cases (25%) were girls. The median age was 7.8 (1.5‐15). The median of WBC count at diagnosis was 109.98 (1.57‐820.91)×109/L. Fifty‐eight point three percent (49/84) patients had normal karyotype, 9.5% (8/84) had abnormal karyotype in number 11, 8.3% (7/84) had abnormal karyotype in number 9, 2.4% (2/84) had abnormal karyotype with number 9 and 11, 8.3% (7/84) with other complex chromosomal. The proportion of patients with SIL/TAL1 was 33.3% (28/84). Thirty‐four percent cases (40.5%) were belong to median‐risk group, 50 cases (59.5%) were belong to high‐risk group. Of all the 84 cases, the prednisone reaction rate was 56.0% (47/84); the remission rate was 94.0% (79/84); 23.8% (20/84) patients relapsed. 10‐Year overall survival (OS) and event‐free survival (EFS) were 63.0%±5.6% and 60.0%±5.6%, respectively. The 10‐year OS in medium risk group (77.1%±7.6%) was significantly higher than that in high risk group (52.5%±7.5%) (*P*\<0.05), The 10‐year EFS in medium risk group (75.0%±7.7%) was significantly higher than that in high risk group (49.2%±7.5%) (*P*\<0.05). Cox multivariate regression analysis showed that partition risk group according to CCLG‐ALL2008 protocol was important factor for patients' OS and EFS (*P*\<0.05).

**Conclusions**: Childhood ALL with T phenotype often had high WBC count and worse outcome. Disease recurrence remains the main cause of death. Partition risk group according to CCLG‐ALL2008 protocol was important factor for the long‐term prognosis.

### PO-090. MLL‐Rearranged Leukaemia Carrying Reciprocal Translocations Indicates Relatively Favourable Prognosis {#pbc27455-sec-3150}

[Y. Liu]{.ul} ^1^, D. Lixia^1^, L. Jianwei^1^, C. Jing^1^, T. Yanjing^1^, X. Huiliang^1^, G. Longjun^1^, S. Shuhong^1^, L. Benshang^1^, C. Jing^1^

*^1^Shanghai Jiaotong University, Shanghai children\'s Medical Center, Shanghai, China*

**Background/Objectives**: The mixed‐lineage leukemia (MLL) with multifarious partner genes leads to aggressive leukemia with dismal outcomes.

**Design/Methods**: Using panel‐based targeted sequencing, we examined a total of 90 MLL‐rearranged(MLL‐r) childhood acute leukemia cases, including 55 patients with acute lymphoblastic leukemia (ALL) and 35 patients with acute myeloid leukemia (AML).

**Results**: All the precise MLL breakpoints, complete rearrangements characterization and 24 novel MLL fusions were identified. A total of 37.8% (34/90) of all the patients displayed a single direct MLL fusion gene, 15.6% (14/90) carried a single reciprocal fusion, and 27.8% (25/90) had both reciprocal MLL fusion alleles. The remaining 17 MLL‐r cases had complex translocations with homozygous disruptions on chromosome 11 or two breakpoints on the same MLL allele with a deletion of functional regions. A total of 77 patients (45 ALL and 32 AML) received chemotherapy with a median follow‐up of 2.5 years. Unexpectedly, we found children with reciprocal MLL fusions that exhibited relatively favorable outcomes compared with those in children with complex translocations or single direct MLL fusion allele (66.1% versus 24.6% and 27.6%, P = 0.001). Functional features of the truncated MLL fusion protein may give an explanation for the favourable clinical prognosis of reciprocal MLL translocations.

**Conclusions**: In conclusion, comprehensive MLL‐r analysis by targeted next‐generation sequencing (NGS) can provide detailed molecular information and is helpful for the precise stratified treatment and clinical prognosis determination.

### PO-091. The Interplay Between IKZF1 and COBL Deletions in Acute Lymphoblastic Leukemia {#pbc27455-sec-3160}

[B. Lopes]{.ul} ^1^, C. Meyer^2^, T. Barbosa^1^, C. Poubel^1^, M. Mansur^1^, N. Duployez^3^, C. Palmi^4^, G. Cazzaniga^4^, M. Bashton^5^, C. Harrison^5^, C. Alonso^6^, G. Tsaur^7^, S. Gupta^8^, U. zur Stadt^9^, N. Venn^10^, R. Sutton^10^, M.S. Pombo‐de‐Oliveira^11^, R. Marschalek^2^, M. Emerenciano^1^

*^1^Instituto Nacional de Câncer, Molecular Cancer Study Group‐ Division of Clinical Research, Rio de Janeiro, Brazil; ^2^Goethe‐University of Frankfurt, Diagnostic Center of Acute Leukemia‐ Institute of Pharmaceutical Biology, Frankfurt/Main, Germany; ^3^University Lille Nord de France, Laboratory of Hematology and Tumor Bank‐ Cancer Research Institute of Lille, Lille, France; ^4^Università degli Studi di Milano‐Bicocca, Centro Ricerca Tettamanti‐ Dipartimento di Medicina e Chirurgia, Monza, Italy; ^5^Northern Institute for Cancer Research‐ Newcastle University, Leukaemia Research Cytogenetics Group‐ Wolfson Childhood Cancer Research Centre, Newcastle, United Kingdom; ^6^Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Hematology and Oncology Department, Buenos Aires, Argentina; ^7^Research Institute of Medical Cell Technologies, Regional Children\'s Hospital No. 1, Yekaterinburg, Russia; ^8^All India Institute of Medical Sciences, Laboratory Oncology Unit‐ Dr BRA IRCH, New Delhi, India; ^9^University Medical Center Hamburg Eppendorf, Center for Diagnostic, Hamburg, Germany; ^10^University of New South Wales, Children\'s Cancer Institute‐ Lowy Cancer Research Centre, Sydney, Australia; ^11^Instituto Nacional de Câncer, Pediatric Hematology‐Oncology Program, Rio de Janeiro, Brazil*

**Background/Objectives**: *IKZF1* deletions (Δ*IKZF1*) are predictive for relapses in B‐cell acute lymphoblastic leukemia (BCP‐ALL). We previously revealed that *Cordon‐Bleu* rearrangements (*COBL*‐r) could promote Δ*IKZF1*. Here, we aim at characterizing *COBL*‐r at the genomic level and to unravel its clinical importance.

**Design/Methods**: First, a cohort of 146 patients with BCP‐ALL was prescreened for Δ*IKZF1* with either single‐nucleotide--polymorphism microarray or SALSA MLPA P355/P202. Considering that *COBL* is located ∼600 Kb downstream of *IKZF1*, *COBL*/*IKZF1* co‐deletions encompass the 3' region of *IKZF1*. Therefore, Δ*IKZF1* groups were defined as either Δ1‐8 (complete deletions) or Δn‐8 (partial deletions). Then, recurrent Δ*IKZF1* (Δ2‐8, Δ4‐8) were confirmed by multiplex (M)‐PCR, and the remaining samples were further evaluated by a customized MLPA for chromosome 7, which could identify any potential *COBL*‐r. In order to confirm this alteration, we also performed M‐PCR or long‐distance‐inverse (LDI)‐PCR to characterize the breakpoint of the rearrangements at nucleotide level.

**Results**: The patients enrolled in this study comprised two groups of Δ*IKZF1*: Δ1‐8 (n=109) or Δn‐8 (n=37). *IKZF1* Δ1‐8 were associated with several chromosome 7 alterations, including monosomy 7 (18%), i(7q) (10%), 7p loss (19%), 7p interstitial deletions (41%), and Δ*IKZF1* with *COBL*‐r (12%). On the other hand, most *IKZF1* Δn‐8 were recurrent deletions (86%; Δ2‐8, Δ4‐8), while 8% of the patients presented larger 7p deletions and 6% *COBL*‐r. Overall, the so‐called *COBL*‐r were found in 10% of our cohort, and its breakpoints located close to the *COBL* promoter (15%) or within the gene‐body (85%), mainly within *COBL* intron 5 (55%) and intron 7 (15%), which are DNase hypersensitive sites.

**Conclusions**: Diverse alterations characterize the molecular deletions within the *IKZF1* gene in the investigated cohort of BCP‐ALL patients, including a subgroup of patients (10%) that carry larger deletions comprising the *IKZF1* and *COBL* genes, respectively.

### PO-092. Mirnome Analysis of Brazilian Childhood Acute Lymphoblastic Leukemia Reveals an Association of 10 miRNAs with Increased Soluble HLA‐G Levels {#pbc27455-sec-3170}

R. S Almeida^1^, F. S Araújo^2^, S. A V Oliveira^3^, L. L Coutinho^4^, E. A Donadi^5^, [N. Lucena‐Silva]{.ul} ^6^

*^1^Aggeu Magalhães Institute‐ Oswaldo Cruz Foundation ‐ FIOCRUZ, Department of Immunology, Recife, Brazil; ^2^Aggeu Magalhães Institute‐ Oswaldo Cruz Foundation ‐ FIOCRUZ‐ and Federal University of Pernambuco, Department of Immunology and Medicine Program, Recife, Brazil; ^3^Aggeu Magalhães Institute‐ Oswaldo Cruz Foundation ‐ FIOCRUZ‐ and Federal University of Pernambuco, Department of Immunology, Recife, Brazil; ^4^University of São Paulo USP, Department of Animal Biotechnology, Piracicaba, Brazil; ^5^University of São Paulo USP, Division of Clinical Immunology‐ Department of Medicine, Ribeirão Preto, Brazil; ^6^Aggeu Magalhães Institute‐ Oswaldo Cruz Foundation ‐ FIOCRUZ‐ and Instituto de Medicina Integral Professor Fernando Figueira IMIP Hospital, Department of Immunology and Pediatric Oncology Service, Recife, Brazil*

**Background/Objectives**: Acute Lymphoblastic Leukemia (ALL) is an aggressive disease and the most frequent cancer in children. Immunological and genetic factors, such as soluble HLA‐G (sHLA‐G) and microRNAs (miRNAs), influence tumor proliferation and dissemination, and can be used in disease prognosis. In this study, we aimed to investigate miRNA differential expression (DE) in childhood ALL according to their sHLA‐G levels (low versus high producers).

**Design/Methods**: Patients with ALL (n=15) were attended at IMIP Hospital, Recife, Brazil, and bone marrow aspirates were used for total RNA extraction (Trizol). miRNA library construction (TruSeq Small RNA Kit) and sequencing (HiSeq 2500 platform, Illumina) were performed, and data analyzed using FastQC, Cutadapt, miRDeep2, edgeR (False Discovery Rate ≤ 0.05), miRWalk 2.0, and RNAhybrid 2.2. DE analysis was conducted based on sHLA‐G levels determined by ELISA (EXBIO): low producers (\<150 U/mL; median age= 9.0y; 7M, 2F) versus high producers (\>250 U/mL; median age= 8.5y; 6M) patients.

**Results**: Bioinformatic analysis revealed 10 miRNAs (miR‐1248, miR‐205‐5p, miR‐3196, miR‐4485‐3p, miR‐4488, miR‐4516, miR‐451a, miR‐4532, miR‐486‐5p, and miR‐5096) upregulated in high producers group. miR‐5096 was previously studied by our group, so we focused on the remaining miRNAs. *HLA‐G* mRNA exhibited binding sites for all nine miRNAs, and interactions presented minimum free energy below ‐20 kcal/mol. RNAhybrid analysis revealed putative interactions of all miRNAs with *HLA‐G* exons 2, 3, 4 and 5, and only 5 miRNAs targeting exon 6. The exons 1, 7 and 8 were targeted by one miRNA exclusively, that is miR‐205‐5p, miR‐1248, and miR‐4516, and interestingly, the miR‐4516 binding site mapped within exon 8, recognized as *HLA‐G* 3'UTR, overlapping with +3035 C/T polymorphic site.

**Conclusions**: These data suggest a non‐canonical mechanism of action (namely translation induction) to the above miRNAs in *HLA‐G* mRNA. These findings must be replicated in more samples for confirmation. Acknowledgements: FIOCRUZ‐PE, CAPES‐PROCAD2013, FACEPE‐APQ‐0040‐4.00/13, and FACEPE‐APQ‐1044‐4.01/15.

### PO-093. Infection Related Complications During Maintainnce Phase Treatment for Children with Acute Lymphoblastic Leukemia in Developing Countries: Single Center Experience, Egypt {#pbc27455-sec-3180}

[Y. Madney]{.ul} ^1^, W. elkady^2^, H. elmahalawy^3^, E. ebeid^2^

*^1^consultant pedeatric oncology CCHE / lecturer of pediatric oncology NTIONA‐ CANCER INSTITUTE CAIRO UNIVERSITY, Pediatric oncology, cairo, Egypt; ^2^National cancer institute, Pediatric oncology, cairo, Egypt; ^3^National cancer institute, clinical microbiology, cairo, Egypt*

**Background/Objectives**: The improvement in overall survival in children with acute lymphoblastic leukemia (ALL) over the last 5 decades has been considerable, with around 90% now surviving long term. Despite the recent advances in supportive care, infection related morbidity and mortality comprise a major challenge for successful treatment. Limited number of studies were done to analyze the type and the incidence of infections encountered during different phases of treatment. Type and frequency of infection vary according to the phase of treatment. To evaluate epidemiology and outcome of infectious complications during maintenance phase of chemotherapy.

**Design/Methods**: Retrospective study for ALL pediatric patients who treated on maintenance phase (30 month) St. Jude total XV protocol at National cancer institute, Egypt, period from 2011 to 2014. According to treatment phases of maintenance chemotherapy and degree of neutropenia, each febrile and infectious episodes recorded, analyzed then categorized as a bacteremia, viral, fungal, clinically documented infection or FUO. Finally, the outcomes of the infectious complications and infections related mortality were analyzed.

**Results**: A total of 1052 infectious episode recorded in 146 ALL pediatric patients during maintenance chemotherapy ;(42.1%) in low risk, (50.3%) in standard risk and (7.6%) in high risk group. Most of infectious episodes (39.16%) occurred during early phase of maintenance chemotherapy. FUO was the most common infectious episodes (36.8%) followed by clinically documented infections (26%), viral (17%), bacterial (16.8%) and fungal infections (3.6%). The majority of the infection episodes (53%) reported during neutropenia. Statistically significant relation between relapse and number of patients who had infections during course of maintenance therapy (P=0.046). Mortality was 15/152 (8%) during the whole course of maintenance chemotherapy. Most of deaths were infection related 12 /15 (80%).

**Conclusions**: The incidence of infection‐related death was high. Infectious complications still a major morbidity and mortality challenge for children with Acute lymphoblastic leukemia in developing countries.

### PO-094. HCMV Among Pediatrics Acute Lymphoblastic Leukemia Patients in South Egypt Cancer Institute {#pbc27455-sec-3190}

[M. Maher]{.ul} ^1^, A.R. Zekri^2^, M. El‐Rouby^2^, L. Shalaby^3^, R. Bakry^4^, K. Riad^5^

*^1^South Egypt Cancer Institute, Cancer Biology Department, Assiut, Egypt; ^2^National Cancer Institute, Cancer Biology Department, Cairo, Egypt; ^3^National Cancer Institute, Pediatric Oncology Department, Cairo, Egypt; ^4^South Egypt Cancer Institute, Clinical Pathology Department, Assiut, Egypt; ^5^South Egypt Cancer Institute, Pediatrics Oncology Department, Assiut, Egypt*

**Background/Objectives**: Human Cytomegalovirus (HCMV) is one of the causes of morbidity and mortality in pediatric cancer patients.

**Design/Methods: Patients and methods**: Out of 48 newly diagnosed ALL pediatric cancer patients (age range 2 to 13 years); treated with Total XIII Chemotherapy protocol in SECI were studied for HCMV Seropositivity(IgM/IgG) and viremia in blood plasma via PCR at diagnosis (day 0) and on the end of Chemotherapy Induction phase (day 36).

**Results**: Shown that at diagnosis (Day 0) IgG was positive in 21/48 (43.8%), equivocal in 10/48 (20.8%) and Negative in 17/48 (35.4%) of patients while IgM and plasma PCR were negative in 48/48 (100%) of cases and upon repeating same panel at the end of Induction phase (day 36) we observed complete Seroconversion with 48/48 (100%) of patients to negative IgG, IgM and PCR were also Negative and when reviewing the BMA results at the end of induction we have found that only 2/21 (9.5%) of patients failed to reach Bone Marrow Remission; both were HCMV IgG positive.

**Conclusions**: No observation of Acute CMV Infection either recent before cancer diagnosis, Hospital Acquired or even reactivation through chemotherapy induction phase treatment; further studies are to be made to assure HCMV impact on cancer treatment outcome in south Egypt Cancer Institute

### PO-095. NK Cells Survey Among Pediatrics ALL Induction Phase in South Egypt Cancer Institute {#pbc27455-sec-3200}

[M. Maher]{.ul} ^1^, A.R.N. Zekri^2^, M.N. El‐Rouby^2^, L. Shalaby^3^, R. Bakry^4^, K.F. Riad^5^

*^1^South Egypt Cancer Institute, Cancer Biology Department, Assiut, Egypt; ^2^National Cancer Institute, Cancer Biology Department, Cairo, Egypt; ^3^National Cancer Institute, Pediatrics Oncology Department, Cairo, Egypt; ^4^South Egypt Cancer Institute, Clinical Pathology Department, Assiut, Egypt; ^5^South Egypt Cancer Institute, Pediatrics Oncology Department, Assiut, Egypt*

**Background/Objectives**: Innate host defenses include mucocutaneous barriers, phagocytic cells, natural killer cells (NK), and nonclonal T and B cells. NK cell is in Peripheral Blood Mononuclear Cells (PBMC) with a range of 5--20 % acting as innate effector cells that play an important role in the defense against cancer and viral infections.

**Design/Methods**: Peripheral blood samples were collected out of 48 newly diagnosed ALL pediatric cancer patients (age range 2 to 13 years); treated with Total XIII Chemotherapy protocol in SECI were studied via Flowcytometry using antibody CD3 FITC / CD16+CD56 PE designed for enumeration of mature human natural killer (NK) using flowcytometry and on the end of Chemotherapy Induction phase (day 36).

**Results**: The NK percent at diagnosis (Day 0) was ranged from 0.55‐ 27% with median 5.6% and Interquartile range (IQR) 7.96% and the absolute circulating NK cells ranged from 2 -- 18860 with median 582 cells/mm3 and with IQR 1023 cells/mm3 and upon repeating the same panel at the end of Induction phase (day 36) the NK percent was ranged from 0.3‐31.3% with median 8.8% and interquartile range (IQR) 6.38% and the absolute circulating NK cells ranges from 1‐ 1256 cells/mm3 with median 282.15 cells/mm3 and with IQR 363.85 cells/mm3.

**Conclusions**: Following the initiation of leukemia therapy an increase in the percent NK cells in PBMC was noted while a decrease in the absolute number of circulating cells in ALL pediatrics patients in South Egypt Cancer Institute

### PO-096. NK Cells and CMV Infection in Pediatric ALL Patients: Simple Cross Talk Study {#pbc27455-sec-3210}

[M. Maher]{.ul} ^1^, A.R.N. Zekri^2^, M.N. El‐Rouby^2^, L. Shalaby^3^, R.M. Bakry^4^, K.F. Riad^5^

*^1^South Egypt Cancer Institute, Cancer Biology Department, Assiut, Egypt; ^2^National Cancer Institute, Cancer Biology Department, Cairo, Egypt; ^3^National Cancer Institute, Pediatrics Oncology Department, Cairo, Egypt; ^4^South Egypt Cancer Institute, Clinical Pathology Department, Assiut, Egypt; ^5^South Egypt Cancer Institute, Pediatrics Oncology Department, Assiut, Egypt*

**Background/Objectives**: The repertoire of NK cells differs greatly from one person, or patient, to another after CMV infection, and that in some peculiar situations, the dramatic expansion of CMV‐specific "clonal" NK cells could bias the diversity of the NK‐cell repertoire, and consequently subvert the NK‐cell recognition of other pathological situations, as neoplastic cells

**Design/Methods**: Among 48 newly diagnosed ALL pediatric cancer patients treated with Total XIII Chemotherapy protocol HCMV Seropositivity(IgM/IgG) and viremia in blood plasma via PCR and NK cells was enumerated via Flowcytometry using antibody CD3 FITC / CD16+CD56 PE were studied at diagnosis (day 0) and at the end of Chemotherapy Induction phase (day 36).

**Results**: Patients showing NK percent in normal range was 9/20 (45%) of positive HCMV IgG at diagnosis and only 3/20 (15%) of negative HCMV IgG in a significant relation (*P*‐*Value* = 0.003). While the NK percent on (D36) was significantly below normal range episodes with 8/9 (88.9%) in HCMV seropositive patients compared to 1/9 (11.1%) was in seronegative patients (*P*‐*Value* = 0.012)

**Conclusions**: At ALL diagnosis, the seropositive HCMV patient showed significantly higher NK percent in normal range compared to HCMV seronegative patients in SECI but after the end of Induction, the speed of recovery on NK cells was less in HCMV positive patients when compared to HCMV negative ones.

### PO-097. Long Term Results for Childhood Acute Lymphoblastic Leukemia: An Institutional Review {#pbc27455-sec-3220}

[H. Mai]{.ul} ^1^, X. Fang^1^, X. Yuan^1^, X. Wang^1^, S. Liu^1^, Y. Wang^1^, C. Li^1^, F. Wen^1^

*^1^Shenzhen Children\'s Hospital, Heamatology and Oncology, Shenzhen, China*

**Background/Objectives**: To exam the outcomes of children with acute lymphoblastic leukemia (ALL) treated on Berlin‐Frankfürt‐Münster (BFM) International ALL‐ based protocol, GD 2008ALL protocol.

**Design/Methods**: In total, 274 patients with newly diagnosed ALL age 1 to 16 years were enrolled onto GD2008ALL protocol from July 1, 2008 to June 30, 2016. Five‐year overall survival (OS) rates and even‐free survival (EFS) rates were examined with additional analyses of causes of relapse and death.

**Results**: The 5‐year probabilities of OS and EFS were 90.8% and 86.9%. The 5‐year EFS was 91.7% in SR group, 86.5% in IR group and 82.6% in HR group, respectively. Twenty‐five patients were died. Reasons for mortality included 8 cases due to relapse of leukemia, seven cases due to severe infection, one case due to hepatic failure, one case due to intracranial hemorrhage from accident, eight cases abandoned after relapse. There were 29 cases relapsed, including 22 cases (75%) relapsed of the bone marrow alone, 1 case (3.6%) CNS relapsed alone, 2 cases (7.1%) testicular relapsed, and 4 cases (14.3%) relapsed of bone marrow and extramedullary. Eleven patients survived after therapy for relapse, of which 7 had received HSCT, two out of the 7 had relapsed after HSCT, and continued on CART therapy. Four out of the 11 relapsed patients received relapsed ALLR3 protocol for treatment. All 11 patients remained in remission status.

**Conclusions**: Our single institutional review of pediatric ALL treated on GD 2008ALL Protocol was tolerated and has good long term outcomes. Although relapse is a major factor affecting long term survival, there are still have options such as HSCT or immunotherapy available for these patients.

### PO-098. Epidemiology of Acute Lymphoblastic Leukemia Among Childhood Population in Kyrgyzstan {#pbc27455-sec-3230}

[E. Makimbetov]{.ul} ^1^, A. Usenova^1^

*^1^National center of oncology and hematology, Pediatric oncology and hematology department, Bishkek, Kyrgyzstan\\r*

**Background/Objectives**: Background. Acute lymphoblastic leukemia (ALL) is a first most common childhood malignancy in developed and developing countries.

Objectives. To study childhood ALL incidence, age, sex, geographical, and ethnic differences in the Kyrgyz Republic.

**Design/Methods**: Materials and methods. ALL incidence rate counted on hospital based statistics: the study covers the period from 2006 to 2016. There were collected forms submitted from morphological (cytology and immunophenotyping) findings and death certificates. The population figures and ALL incidence rates were provided for age (0‐4, 5‐9, 10‐14), ethnic, sex groups, and calendar years. There were counted crude, age‐standardized rates (ASR) per 1,000,000. Also there was estimated population relative risk in the urban and rural areas.

**Results**: There were registered 310 cases of ALL in children (46.8% in 0‐4 years, 29.3% in 5‐9 years, and 23.9% in 10‐14 years. The highest incidence rate was registered at the youngest age group with ASR 22.4 per 1,000,000 populations. The moderate incidence rates were in the 5‐9 and 10‐14 age groups with ASR 16.6 and 13.9, respectively. Total crude incidence rate of ALL was 17.9 per 1,000,000 populations. Male / female proportion was 1:0.6, with 196 cases in boys and 113 cases in girls. ASR by sex was 16.8 in males and 14.3 in females. If there is no cause of death from other diseases, the risk of death from ALL was 0.01. ALL incidence rates at the urban areas (18.8) were slightly higher than rural regions (17.5), p\>0.05. Incidence rate was significantly higher in Russians (ASR 21.8), compared with native Kyrgyzs (15.7) or Uzbeks (16.4).

**Conclusions**: The incidence rate in ALL among children in Kyrgyzstan was low and similar to those reported from some Asian developing countries, with a peak of incidence in the youngest age group. Incidence rate was significant high in European than native Asian nationalities.

### PO-099. Evolution of CNS Relapse (CNS‐R) in Pediatric Acute Lymphoblastic (P‐ALL) Leukemia Treated with BFM‐Type Protocols in Argentine Acute Leukemia Group (GATLA) {#pbc27455-sec-3240}

[M. Makiya Dibar]{.ul} ^1^, J. Bietti^2^, C. Murray^3^, G. Arbezu^4^, D. Altuna^5^, G. Elena^6^, S. Zirone^7^, A. Cedola^8^, F. Cuello^9^, P. Negri^10^, E. Dibar^11^

*^1^Hospital Italiano de Buenos Aires, Pediatric Hematology Oncology and BMT Unit, CABA, Argentina; ^2^Hospital Iturraspe. Santa Fe, Pediatric Hematology, Santa Fe, Argentina; ^3^Materno Infantil. Mar del Plata, Pediatric Hematology, Mar delPlata, Argentina; ^4^Hospital Notti, Pediatric hematology, Mendoza, Argentina; ^5^Hospital Italiano de Buenos Aires, Pediatric Hematology, Buenos Aires, Argentina; ^6^Casa Cuna‐ P. Elizalde, Pediatric hematology, Buenos Aires, Argentina; ^7^Hospital de Niños de Rosario, Pediatric Hematology, Rosario, Argentina; ^8^Clinica San Lucas, Pediatric Hematology, Neuquen, Argentina; ^9^Hospital Sor María Ludovica, Pediatric Hematology, La Plata, Argentina; ^10^Hospital de Niños, Pediatric Hematology, Paraná, Argentina; ^11^Hospital Italiano de Buenos Aires, Pediatric Hematology Oncology and BMT Unit, Buenos Aires, Argentina*

**Background/Objectives**: To associate the implementation of some therapeutics elements with pattern of relapse in P‐ALL, focusing in CNS‐R.

**Design/Methods**: Prospective observational pattern of relapse has been analyzed over three decades in the GATLA.

**Results**: Between 1982 and 2012, 6442 children were treated, 5174 were evaluable in five consecutive trials ('84, '87, '90, '96 and '02). Event‐free survival (EFS) and overall survival (OS) at 8 years improved from 53.7% and 56.4% of '82 study to 76.5 % and 81.7% of '02 study. The cumulative incidence of recurrences (CIR) was 43% in the first study and 24% in '02 study. Complete remission (CR) increased from 87% to 96%, deaths in induction decreased from 8.2% to 4.9%. In the '84 study, CIR was 43%, CNS‐R was high: 15.4%. The CIR of '87 study was 40%; introducing methotrexate (MTX) at 1 gr. decreasing CNS‐R to 8.7%, despite only High Risk (HR) received radiotherapy. The CIR of '90 study was 32.7%, HR received 9 blocks, withdrawing prot‐II. HR OS and EFS were unexpectedly bad (25% and 36%); despite HR‐CIR was 38%, the cumulative incidence of events in this group was 70% (6.8% death in CR, 4.6 % in blocks phase) CNS‐R: 7%. In the '96 study, HR reintroduced prot‐II, it improved OS from 25% in previous study to 44%; CNS‐R was 5%, decreasing in all risks but specially in HR. The '02 study: implemented 5 g MTX in T‐ALL. Very early relapses decreased in all risks, CIR: 24% and CNS‐R was similar to international protocols.

**Conclusions**: GATLA standardized treatments of P‐ALL, improved the results, CNS protection were comparable with international studies; reducing radiotherapy, or even eliminating with intensive systemic and intrathecal chemotherapy.

### PO-100. Change in Nutritional Status of Children During Treatment of Acute Lymphoblastic Leukaemia {#pbc27455-sec-3250}

[L. Mathew]{.ul} ^1^, M. Robert^1^, R. John^1^, L. Jeyaseelan^2^

*^1^Christian Medical College, Paediatric Haematology‐Oncology, Vellore, India; ^2^Christian Medical College, Biostatistics, Vellore, India*

**Background/Objectives**: Assessment of nutritional status (NS) of children during treatment of acute lymphoblastic leukaemia (ALL) is essential for appropriate nutritional intervention, as it may affect the overall outcome. We conducted a retrospective study to assess the change in NS of a cohort of children during treatment of ALL

**Design/Methods**: 191 children (129 boys and 62 girls, aged 2‐16 years at diagnosis) treated for ALL from 2007‐12 were included in this analysis. Data was collected from medical records. All of them had weight and height recorded at every visit. For the purpose of this analysis, NS was assessed using BMI centiles at diagnosis, twice during treatment ‐ at the beginning of delayed intensification (DI) and maintenance phase (M) and at end of treatment (EOT).

**Results**: 42% were undernourished (UN), 50% were well nourished (WN) and 8%were overweight‐obese (OW‐O) at diagnosis. At the three time points their NS was assessed, the prevalence of under nutrition decreased 29%, 18% and 12% respectively while that of OW‐O gradually increased from 12%, 17% and 30%. The prevalence of WN was 59%, 65% and 58%. Of the 81 children who were UN at diagnosis, 53% continued to be UN at DI, 28% at M and 25% remained malnourished at EOT. 60% in this group moved from UN to WN and 15% became OW‐O at completion of treatment. The transition in nutritional status of those who were WN at diagnosis showed that 13% became UN at DI and 3% remained UN at the end of treatment. The incidence of obesity increased from 10% at the beginning of delayed intensification to 35% by end of treatment. Those who were OW/O to start with, largely remained in the same nutritional group throughout treatment.

**Conclusions**: Nutritional status of children during treatment of ALL is dynamic and periodic assessment is required for appropriate intervention.

### PO-101. Combination Antifungals as an Effective Means of Salvage in Pediatric Leukemia Patients with Invasive Fungal Infections {#pbc27455-sec-3260}

A. Gupta^1^, [J.P. Meena]{.ul} ^1^, R. Seth^1^

*^1^All India Institute of Medical Sciences, Pediatric Oncology, New Delhi, India*

**Background/Objectives**: Invasive fungal infections (IFI\'s) are an important cause of morbidity and mortality in children with a haematological malignancy. The use of combination antifungals as a modality for treatment of these infections has not been explored much.

**Design/Methods**: The case records of 14 patients who were admitted to our centre between January 2016 and July 2017 with a diagnosis of a hematological malignancy and had received an antifungal combinations were reviewed retrospectively

**Results**: A total of 14 children with IFI who fulfilled the criteria were enrolled in the study. The median age of the patients was 8.5 (range 2.4 to 14.4) years out of which 3 had proven IFI, 7 had probable IFI and 4 had possible IFI. Aspergillus species was the commonest organism suspected and pneumonia was the underlying diagnosis in most of the children. Thirteen patients were treated empirically with amphotericin‐B monotherapy and one patient with voriconazole. In two the amphotericin‐B was changed to caspofungin. In view of no improvement and clinical deterioration, in nine patientsvoriconazole was added to amphotericin‐B and in four patients caspofungin was added to amphotericin‐B. All patients completed four to six weeks of antifungal therapy. The overall mortality attributable to IFI for the cohort was 4 out of 14 (28%).

**Conclusions**: IFI\'s are an important cause of mortality and morbidity in pediatric leukemia patient and Aspergillus species are the predominant cause. Invasive fungal pneumonias are the most common manifestation in these children. Combining antifungal drugs are a feasible and effective way to salvage these patients in case of non --responders to antifungal monotherapy. More trials and studies are needed to determine whether these drug combinations could be used upfront in IFI\'s

### PO-102. Malignancies in Pediatric Patients Less Than Six Months Old: A Report from a Single Center Study from Iran {#pbc27455-sec-3270}

[A. Mehrvar]{.ul} ^1^, M. Faranoush^1^, A. Naderi^1^, A.A. Hedayati Asl^1^, V. Fallah Azad^1^, M. Alebouyeh^1^, H. Nikfarjam^1^, M. Tashvighi^1^

*^1^MAHAK Hematology and Oncology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran*

**Background/Objectives**: Infants' malignancies often have special clinical and biological properties. The distribution of these types of malignancies is different from other cancers in patients more than 6 months old. This project designed to evaluate the pediatric patients less than 6 months old with malignancy in MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran.

**Design/Methods**: All of the pediatric patients less than 6 months old with approved diagnosis of malignancy who referred to MPCTRC during Apr 2007 to Sep 2017 enrolled in this study. Patients' characteristics gathered from individuals' documents. Data analyzed by SPSS software version 22. Overall survival (OS) rate and Progression Free Survival (PFS) rate calculated according to Kaplan Meyer.

**Results**: Totally 153 child enrolled in this study, the age range of patients were from 2 days to 6 months (Median: 105 days; M/F ratio: 1.3). The diagnosed malignancies were respectively as: retinoblastoma (73; 47.7%), neuroblastoma (23; 15%), brain tumors (20; 13.1%), leukemia (18; 11.8%), sarcoma (8), wilms' tumor (4) and rare cancers (7). The rates of recurrences were as: first relapse: 27.4%; second relapse: 26.2% and third relapse: 27.3%. The median times of relapses were as: first relapse: 9.5 months; second relapse: 13 months; third relapse: 4 months. The rate of recurrence was as: retinoblastoma (51%), neuroblastoma (13%), and brain tumors (10%). The 5‐years OS was 68.5 ± 0.05% and also the 2‐years PFS was 13.2 ± 0.04%. The 5‐years OS for categorized malignancies were: Neuroblastoma: 94.7 ± 0.05%, retinoblastoma: 77.3 ± 0.08%; and brain tumors: 73.2 ± 0.11%.

**Conclusions**: At this single center study the most common malignancies in patients less than 6 months were retinoblastoma, neuroblastoma and brain tumors. The low PFS rate means that there are high risk factors to precede the recurrence, and there should be multidisciplinary decisions to decrease these factors.

### PO-103. Upfront Cytogenetic Intrachromosomal Amplification of Chromosome 21 Testing: Need of the Hour {#pbc27455-sec-3280}

[P. Mehta]{.ul} ^1^

*^1^S.L.Raheja Hospital, Pediatric Hematology‐Oncology, Mumbai, India*

**Background/Objectives**: Childhood cancer is treatable and curable provided each child receives the correct treatment. Cytogenetic techniques in childhood acute lymphoblastic leukemia (ALL) have helped in risk stratifying children into different treatment arms. Among them are the high risk ones such as t(9;22), those that are hypodiplod with \< 44 chromosomes and 11q23 MLL gene rearrangement. A rare high risk chromosomal abnormality, intrachromosomal amplification of chromosome 21(i AMP 21) occurs in approximately 2‐5% of pediatric patients with B‐cell precursor ALL.

**Design/Methods**: --- S.L.Raheja Hospital is a private tertiary care hospital treating 12‐ 15 children with ALL per year. In the year 2015, two children with precursor B‐ALL were treated on BFM 95 standard risk arm.

**Results**: Five year old female child, case of precursor B ALL with no high risk cytogenetic features was treated on standard risk arm of BFM 95 protocol. She was MRD negative post induction but relapsed 2 months post completion of maintainence therapy. Eleven year old male child with precursor B ALL with no high risk cytogenetic features treated on standard risk arm of BFM 95 was MRD positive post induction. Both had turned out to be i AMP positive with amplification of RUNX1 allelle on cytogenetic testing before retreatment. This chromosomal abnormality was specifically asked for to be done on relapse and failure of remission respectively. Both children succumbed on relapse treatment.

**Conclusions**: Intrachromosomal amplification of chromosome 21 (i AMP 21) should be included upfront in risk stratifying children with precursor B ALL to upstage their treatment and prevent a relapse as treatment on a standard protocol leads to a poor outcome in these children.

### PO-104. The Micro RNA‐497∼195 Cluster has Tumor Suppressive Functions in Pediatric Acute Lymphoblastic Leukemia Associated with Delayed Leukemia Development and Favorable Outcome {#pbc27455-sec-3290}

E. Boldrin^1^, E. Gaffo^2^, S. Demir^1^, K.M. Debatin^1^, G. te Kronnie^3^, S. Bortoluzzi^2^, [L.H. Meyer]{.ul} ^1^

*^1^Ulm University Medical Center, Dept. of Pediatrics and Adolescent Medicine, Ulm, Germany; ^2^Padova University, Dept. of Molecular Medicine, Padova, Italy; ^3^Padova University, Dept. of Women\'s and Children\'s Health, Padova, Italy*

**Background/Objectives**: MicroRNAs (miRNAs) are short non‐coding RNAs involved in regulation of different cellular processes. Here, we addressed miRNAs in pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) and analyzed the impact of specific miRNAs on leukemia development and patient outcome.

**Design/Methods**: We investigated miRNA expression (small RNA sequencing, qRT‐PCR) in patient‐derived xenograft (pdx) BCP‐ALL samples and corresponding clinical outcome data. MiRNAs were stably overexpressed in BCP‐ALL cell line and pdx samples and compared to empty vector controls. Cell proliferation and death were analyzed by flow cytometry and *in vivo* leukemia growth upon transplantation onto immune‐deficient mice.

**Results**: We identified significant up‐regulation of the miR‐497∼195 cluster in pdx BCP‐ALL (N=13) with long engraftment/good outcome. Significantly higher miR‐497 levels were also identified in good outcome ALL in a larger cohort (N=57) validating these findings. Moreover, increasing miR‐497 expression correlated significantly with longer remission duration (N=11), pointing to an association of high miR‐497 expression and favorable outcome. Analysis of putative targets and functions identified cellular proliferation as the most enriched process, further pointing to tumor suppressive functions of miR‐497∼195 in ALL. To investigate the functional impact on ALL development and growth, we stably overexpressed miR‐497∼195. In EU‐3 cells, overexpression had no effect on proliferation and cell death *in vitro*. However, upon transplantation of miR‐497∼195 overexpressing EU‐3 cells, lower splenic loads were observed. We also investigated a primary pdx‐leukemia (short engraftment/poor outcome/low miR‐497∼195 expression) *in vivo*. Importantly, miR‐497∼195 overexpression resulted in delayed leukemia manifestation and significantly lower leukemia loads (spleen, bone marrow; 2 experiments). In addition, we addressed leukemia‐free survival and observed longer survival (3 weeks) in mice transplanted with miR‐497∼195 overexpressing pdx‐ALL cells.

**Conclusions**: Taken together, high miR‐497∼195 expression is associated with favorable outcome and delayed leukemia development and prolonged survival upon miR‐497∼195 overexpression. Thus, miR‐497∼195 is a negative regulator of leukemia growth acting as tumor‐suppressor in BCP‐ALL.

### PO-105. Lineage Switch from Early T‐Cell Precursor Acute Lymphoblastic Leukemia to Acute Monoblastic Leukemia Following Treatment with Nelarabine and a Cord Blood Stem Cell Transplantation {#pbc27455-sec-3300}

[S. Mizuta]{.ul} ^1^, N. Yamane^1^, K. Kobayashi^2^, M. Suehiro^2^, T. Maihara^3^, I. Usami^2^, T. Komai^1^, T. Heike^3^

*^1^Hyogo Prefectural Amagasaki General Medical Center, Clinical Laboratory, Amagasaki, Japan; ^2^Hyogo Prefectural Amagasaki General Medical Center, Pediatric Hematology and Oncology, Amagasaki, Japan; ^3^Hyogo Prefectural Amagasaki General Medical Center, Pediatrics, Amagasaki, Japan*

**Background/Objectives**: There is a growing concern about lineage switch associated with the molecular target therapy in refractory hematological diseases. Nelarabine, a prodrug of arabinosylguanine nucleotide triphosphate, is currently being incorporated into the frontline therapy in refractory T‐cell malignancy such as early T‐cell precursor acute lymphoblastic leukemia (ETP‐ALL), but little is known for the lineage switch phenomenon in ETP‐ALL.

**Design/Methods**: We encountered a 14‐year‐old boy with ETP‐ALL, which underwent a lineage switch to acute monoblastic leukemia following treatment with nelarabine and a cord blood stem cell transplantation (CBSCT). We serially analyzed cell surface antigen expression, cytogenic changes, and T‐cell receptor (TCR) rearrangement.

**Results**: At the time of admission, leukemic cells were positively stained for both cytoplasmic (cyt) CD3 and aberrant antigens *i.e*. CD11b, CD33, and CD34. While achieving a complete remission with the induction therapy, he developed an early relapse after the first round of the intensification therapy. The second complete remission was attained with nelarabine and CBSCT, however, at 5 weeks after the transplantation, we found the emergence of recipient‐derived monoblastic leukemic cells in peripheral blood that were positively stained for CD11b, CD11c, CD33, CD36, CD56. The leukemic cells were negative for cytCD3, but harbor TCR rearrangement and chromosomal aberrations that were mostly identical to those of the initial diagnostic specimen. The second nelarabine after relapse was no more effective.

**Conclusions**: It is possible that lineage targeting therapy, *i.e*. nelarabine was associated with the lineage switch from ETP to monocytic leukemic cells. We speculate that epigenetic shuttling might an early sign of treatment refractoriness in ETP‐ALL, suggesting the importance of serial cell surface analysis in ETP‐ALL.

### PO-106. Association Between Body Mass Index and Pancreatitis in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-3310}

[P.R. Mogensen]{.ul} ^1^, B.O. Wolthers^2^, K. Grell^3^, L.R. Helt^2^, R.A. Raja^4^, M. Taskinen^5^, G.E. Vaitkevičienė^6^, B.K. Albertsen^7^, L.T. Kõrgvee^8^, B. Lund^9^, O.G. Jonsson^10^, A. Harila‐Saari^11^, M. Heyman^12^, K. Schmiegelow^4^, T.L. Frandsen^13^

*^1^University Hospital Rigshospitalet, Diabetes and Bone‐Metabolic Research Unit & Paediatric Oncology Laboratory, Copenhagen, Denmark; ^2^University Hospital Rigshospitalet, Paediatric Oncology Laboratory, Copenhagen, Denmark; ^3^University of Copenhagen, Section of Biostatistics‐ Department of Public Health, Copenhagen, Denmark; ^4^University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^5^Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; ^6^Vilnius University‐ faculty of Medicine, Clinic of Children\'s diseases, Vilnius, Lithuania; ^7^Aarhus University Hospital Skejby, Department of Paediatrics, Aarhus, Denmark; ^8^Tartu University Hospital, Tartu University Hospital, Tartu, Estonia; ^9^St Olavs University Hospital, Department of Paediatrics, Trondheim, Norway; ^10^Landspitali University Hospital, Children\'s Hospital, Reykjavik, Iceland; ^11^Uppsala University, Uppsala University, Uppsala, Sweden; ^12^Astrid Lindgrens Hospital, Department of Paediatrics, Stockholm, Sweden; ^13^University Hospital Rigshospitalet, Department of Paediatrics and adolescent medicine, Copenhagen, Denmark*

**Background/Objectives**: Pancreatitis is a frequent and severe toxicity to childhood acute lymphoblastic leukemia (ALL) treatment. Asparaginase exposure and older age are known risk factors for pancreatitis in childhood ALL. However, recent data suggest obesity to elevate the risk of pancreatitis. Since obesity is an increasing global health issue and hypertriglyceridemia is a risk factor for pancreatitis in non‐ALL adults, and obesity is correlated to triglyceride levels, an association seems plausible. Accordingly, we investigated the association between body mass index (BMI) and pancreatitis.

**Design/Methods**: Children (1--17 years) diagnosed with ALL receiving asparaginase according to the NOPHO‐2008ALL protocol from July 2008 to December 2015 were included in the study. Pancreatitis was defined according to the Ponte di Legno criteria. Patients were followed from day 30 until pancreatitis, death of any cause, relapse, or day 300 from ALL diagnosis, whichever came first. BMI was calculated at time of diagnosis as z‐scores reflecting individual difference from the median of a sex‐ and age‐ matched reference group.

**Results**: Among 1273 children included, pancreatitis was diagnosed in 85 patients (300‐day cumulative incidence= 6.7%; 95% CI 5.4--8.1) and 44 patients were identified with relapse or death (300‐day cumulative incidence=3.5%; 95% CI 2.6--4.6). Pancreatitis incidence was significantly higher for adolescents ≥10 years compared to children \<10 years (9.5% vs 5.9%, P=0.037). BMI z‐score was not associated with risk of pancreatitis (pancreatitis‐specific HR=1.09 per 1‐unit increase; 95% CI 0.92--1.28, P=0.33). There was no significant interaction between age group and BMI group (obese vs. non‐obese), and the adjustment of age group did not change the non‐significance of BMI group (P=0.93).

**Conclusions**: Increased BMI and obesity at diagnosis were not associated with the risk of pancreatitis. Future studies are needed to clarify the exact mechanisms between BMI, hypertriglyceridemia, asparaginase, and pancreatitis in children and adolescents with ALL.

### PO-107. Acute Lymphoblastic Leukemia Influences Lipid Metabolism at Time of Diagnosis {#pbc27455-sec-3320}

[P.R. Mogensen]{.ul} ^1^, K. Schmiegelow^2^, K. Grell^3^, B.O. Wolthers^4^, S.S. Mogensen^4^, T.L. Frandsen^5^

*^1^University Hospital Rigshospitalet, Diabetes and Bone‐Metabolic Research Unit & Paediatric Oncology Laboratory, Copenhagen, Denmark; ^2^University Hospital Rigshospitalet, Department of Pediatrics and adolescent medicine, Copenhagen, Denmark; ^3^University of Copenhagen, Section of Biostatistics‐ Department of Public Health, Copenhagen, Denmark; ^4^University Hospital Rigshospitalet, Paediatric Oncology Laboratory, Copenhagen, Denmark; ^5^University Hospital Rigshospitalet, Department of Paediatrics and adolescent medicine, Copenhagen, Denmark*

**Background/Objectives**: Increased lipid levels during childhood ALL therapy have been associated to severe toxicities such as thrombosis and osteonecrosis, and hypertriglyceridemia has been associated to pancreatitis risk in non‐ALL adults. Anti‐leukemic therapy attributes to elevated lipid levels in childhood ALL; however, the leukemic influence remains unclear. Accordingly, we studied lipids at ALL diagnosis in children and explored the association with therapy‐related hyperlipidaemia, thrombosis, osteonecrosis, and pancreatitis.

**Design/Methods**: Children (1--17.9 years) diagnosed and treated according to the NOPHO ALL2008 protocol at University Hospital Rigshospitalet, Copenhagen, Denmark, were included. Hyperlipidemia (hypertriglyceridemia and hypercholesterolemia) was defined according to the Ponte di Legno criteria. BMI was calculated as z‐scores reflecting individual difference from the median of a sex‐ and age‐ matched reference group. Patients were followed from ALL diagnosis until thrombosis/osteonecrosis/pancreatitis, death of any cause, relapse, or end of treatment at 2.5 years from ALL diagnosis.

**Results**: Hypertriglyceridemia (triglycerides \> 2.69 mmol/L) was present in 58% of study patients (N=127, missing data N=15) at diagnosis of ALL. Children with hypertriglyceridemia were significantly younger than children without hypertriglyceridemia (median age (IQR) 4.2 years (2.8--7.5) vs. 6.1 (2.9--12.0), P=0.04) and had borderline higher tumour burden (median (IQR) WBC 16.1x10\^9/L (7.2--68.0) vs. 8.5 (3.4--35.0), P=0.08; and low platelets 32x10\^9/L (15--88) vs. 54 (20--128), P=0.09). There was no difference in BMI between the two groups (P=0.18). Triglycerides were correlated with BMI Z‐scores (Spearman rho=0.58, P=0.05). Baseline hypertriglyceridemia and BMI were not associated with the risk of thrombosis, osteonecrosis and pancreatitis during therapy (P\>0.28 for all.

**Conclusions**: ALL influences lipid metabolism prior to anti‐leukemic therapy, but larger studies are needed to clarify the exact biological links between lipid levels, BMI, and toxicities in childhood ALL.

### PO-108. Nutritional Assessment in Children with Acute Lympmphoblastic Leukemia at Diagnosis in the Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, 2016 {#pbc27455-sec-3330}

[J.E. Montoya Vasquez]{.ul} ^1^, C. Ugaz Olivares^1^, R. Morales Rivas^1^, S. Alarcon Leon^1^

*^1^Instituto Nacional de Enfermedades Neoplásicas, Lima, Lima, Peru*

**Background/Objectives**: Cancer‐related malnutrition cause morbidity and reduced survival. Until now there is not previous background in our country about nutritional status in children with leukemia unlike other countries in South America. The aim of this study was to evaluate the nutritional status of children with acute lymphoblastic leukemia (ALL) at diagnosis.

**Design/Methods**: Retrospective, descriptive study. All infants and children younger than 14 years with acute lymphoblastic leukemia diagnosed at the Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 2016 and December 2016 were included. We had a sample size of 175 patients, STATA 14 was used for the statistical analysis.

**Results**: A total of 175 children were identified, 101 patients (42.3%) were male and 74 (57.7%) female. The median age was 5 years (range, 1 month ‐ 14 years). The most frequent diagnosed was B‐cell ALL (90.9%). Fifty‐one (29.1%) patients were from Lima, the capital. One hundred and nineteen (69.6%) patients were eutrophic, 15 (8.8%) malnourished, 22 (12.9%) were overweight, and 15 (8.8%) obese. Only 13 (7.4%) patients had normal hemoglobin values at diagnosis, 65 (37.1%) had mild anemia, 89 (50.9%) had moderate anemia and 8 (4.6%) severe anemia. One hundred twelve (70%) had normal albumin value, and 93 (54.7%) patients did not have parasites, Giardia Lamblia was found in 33 (19.4%) of the children

**Conclusions**: Most of the children diagnosed with acute lymphoblastic leukemia during 2016 were eutrophic in all age groups, they had a normal nutritional status, but we have a significant percentage of overweight and other malnourished patients. This study encourages us to follow up this patients after chemotherapy treatment and determine the complications associated with each nutritional state.

### PO-109. Risk of Relapse in Pediatric Acute Lypmhoblastic Leukemia in Dr. Sardjito Hospital During 1999‐2016 {#pbc27455-sec-3340}

[S. Mulatsih]{.ul} ^1^, S. Sutaryo^1^, P.H. Widjajanto^1^, E. Supriyadi^1^, I. Purwanto^1^, D.A. Tandiono^1^

*^1^Dr. Sardjito General Hospital, Pediatric ‐ Hemato‐Oncology Subdivision, Yogyakarta Special Province, Indonesia*

**Background/Objectives: Background**. Based on the Yogyakarta Pediatric Cancer Registry (YPCR), there are a significant increase of pediatric acute lymphoblastic leukemia (ALL) cases being handled in Dr. Sardjito Hospital (DSH), during the time more novel protocol was developed, to further increase the outcome of said protocol.

**Objective**. Comparing the possibility of relapse in pediatric patients with ALL, during the period of 1999 to 2016.

**Design/Methods: Methods**. Retrospective case‐control study, data was taken from YPCR. Patients grouped into relapse and survive, with comparison of risk positive and negative in regards of leukocyte count (≥100.000 and \<100.000), age (≤1 year old + ≥10 years old and between 1 to 10 years old) and sex (male and female).

**Results**: A total of 419 patients are included in the study. In regards of leukocyte count, the odds ratio of relapse is 2.73 (95% CI 1.47‐5.07, p value=0.001), age is 2.43 (95% CI 1.46‐4.04, p value=0.001) and sex is 0.98 (95% CI 0.65‐1.47, p value=0.929).

**Conclusions**: Positive risk on leukocyte count and age increases the possibility of relapse, while sex gives no apparent risk.

### PO-110. Mortality Review of Childhood Malignancies {#pbc27455-sec-3350}

[H.H. Myint]{.ul} ^1^, K.T. Aung^1^, Y.Y. Kyaw^1^

*^1^consultant, Pediatric Hemato‐Oncology, Mandalay, Myanmar Burma*

**Background/Objectives**: Malignancies are one of the leading causes of death in childhood. This study reviewed the mortality of childhood malignancies and analyzed the causes of death in a Pediatric oncology center.

**Design/Methods**: This is the retrospective study by reviewing the records of mortality cases from Jan‐2016 to Dec‐2017. All the newly registered cases under 13 years were included. Mortality data was collected and analyzed regarding with age, sex, diagnosis, cause of death and timing of death from diagnosis.

**Results**: Among 455 newly diagnosed malignancies, overall mortality was 95 (21%). In these cases, median age at diagnosis was 6 years (range:4/12‐12) with M:F ratio 1.2:1. Median survival time was 103 days (range:1‐460). Mortality rate was higher in leukemias (67%) than solid tumors and lymphomas (33%). Mortality in newly diagnosed leukemias was 35% (64/182) while in solid tumors and lymphomas was 11.3% (31/273).

According to the diseases, Acute Lymphoblastic Leukemia had the highest mortality (41/95‐43%) followed by Acute Myeloid Leukemia (23/95--24%), Lymphomas (8/95‐8.2%), Brain tumors and Neuroblastomas (4/95--4.2% each), Rhabdomyosarcomas (3/95--3.2%) and other solid tumors such as Hepatoblastomas, Retinoblastomas, Nephroblastomas, Ewings Sarcomas, Germ cell tumors and Sinonasal squamous cell carcinomas (2/95--2.2% each).

By analyzing the causes of death, infection was the commonest (39%). Septicaemia, febrile neutropenia, severe pneumonia, fungal infection, H1N1 infection and encephalitis were documented causes for infection. Then, 23% died due to disease progression. Advanced/metastatic disease at the time of diagnosis and bleeding were other leading cause (11.5% each). Organs failure was responsible for death in 7.5%. Five (5.3%) were due to toxic death. The remaining 2.2% of death was due to choking.

**Conclusions**: Leukemias had higher mortality rate than solid tumors and lymphomas. Infection was the major cause of death. Supportive care especially infection control is very important to improve the survival in our center.

Key words: Mortality, Leukemias, Infection

### PO-111. Optimising Outcomes of Acute Lymphoblastic Leukemias with Supportive Care and Risk‐Stratification Measures at a Tertiary Cancer Care Centre in India {#pbc27455-sec-3360}

[G. Narula]{.ul} ^1^, M. Prasad^1^, S. Jatia^2^, S. Banavali^1^

*^1^Tata Memorial Center, Pediatric Oncology, Mumbai, India; ^2^Tata Memorial Center, ImPaCCT Foundation‐ Pediatric Oncology, Mumbai, India*

**Background/Objectives**: Since 2010, our group put in place comprehensive supportive‐care measures including financial, accommodation, transfusion and nutrition support to ensure no patient was denied treatment on these grounds. By 2013 these measures covered all new registrations. For Acute Lymphoblastic Leukemia(ALL), a risk‐stratified Minimal Residual Disease (MRD) based protocol was implemented from 2013 onwards. We retrospectively audited the impact of these measures on ALL outcomes.

**Design/Methods**: Records of children below 15‐years with ALL registered at our centre from Jan 2010 through Dec 2015 were retrospectively reviewed. Patients with incomplete data, prior treatment, and referred for treatment to other institutions were excluded. To assess the impact of supportive care, we divided this period into two eras‐ Incomplete coverage:2010‐12 (Era‐A), and complete coverage:2013‐15 (Era‐B). Era‐B also had a risk‐stratified protocol for B‐ALL. For financial/ other support, patients were categorised into Completely Supported(CS), Need‐based(NBS), and No Support(NS).

**Results**: Of 1729 patients eligible for analysis, 990(57.2%) were CS, 471(27.2%)‐NBS and 268(15.5%) with 711(41.1%) in Era‐A, and 1018(58.9%) in Era‐B. Treatment Refusal & Abandonment (TR&A) rates fell from Era‐A (Mean‐10.9%) to Era‐B (Mean‐4.93%). Five‐year Overall Survival (OS) for all patients was 75±0.01%. This showed significant improvement over eras‐ 69.1±0.01% and 79.4±0.01% (p\<0.001) for Era‐A and Era‐B respectively. Disease‐wise 5‐yr OS for the entire cohort was B‐ALL‐80.9±0.01%, and T‐ALL‐70.9±0.03%, while era‐wise it was T‐ALL‐68.2±0.05% and 71.9±0.04%, and B‐ALL‐70.6±0.02% and 89±0.01% for Era‐A & Era‐B respectively. Outcomes based on support needs of patients improved across categories, and differences also narrowed. In Era‐A, 5‐year OS was CS‐70.2±0.02%, NBS‐68.6±0.04%, and NS‐76.9±0.04%, while for Era‐B, it was CS‐83.3±0.01%, NBS‐85.7±0.02%, and NS‐89.7±0.03%.

**Conclusions**: Holistic supportive‐care measures that could address needs of all registered patients improved overall outcomes of ALL in a equitable manner by diminishing impact of socio‐economic status, while adoption of risk‐stratification improved B‐ALL outcomes in a tertiary cancer centre in India.

### PO-112. Characterization of Pediatric Patients with Acute Lymphoblastic Leukemia and Hepatotoxicity during Induction and Consolidation {#pbc27455-sec-3370}

[S. Navai]{.ul} ^1^, S. Hashmi^1^, R. Rau^1^, M. Gramatges^1^

*^1^Baylor College of Medicine, Pediatrics, Houston, USA*

**Background/Objectives**: The incidence of and risk factors for hepatotoxicity in children with acute lymphoblastic leukemia (ALL) are not well understood. Contributing factors may include disease burden, chemotherapeutic exposures, and underlying genetic risk. Our objective was to define the incidence of hepatotoxicity in a local pediatric ALL cohort and to identify characteristics suggestive of need for closer monitoring during the early phases of ALL treatment.

**Design/Methods**: We performed a retrospective chart review of children treated for non‐infant, non‐Ph+, non‐Down syndrome‐associated ALL diagnosed at Texas Children\'s Hospital from 2011‐2016. Patients with hepatotoxicity during Induction or Consolidation treatment phases were included if they had an AST or ALT \>10x the upper limit of normal or conjugated bilirubin \> 1.0 mg/dl, based on recommended thresholds for dose modification. Differences in age, gender, ethnicity, and BMI were compared by t‐test or Chi square analysis as appropriate.

**Results**: Out of 385 eligible cases, 43 (11.1%) had the above‐mentioned hepatic abnormalities. The median age was 11.3 years, compared with 7.0 years for the entire cohort (p=0.002), and 34 (79%) were of self‐described Hispanic ethnicity, compared with 213 (55%) of the larger cohort (p=0.003). Gender distribution was equivalent between the groups (46.5% vs. 40% female, p = 0.41). Two patterns of hepatotoxicity were identified: isolated elevation of transaminases (n=26, 60.5%), and transaminase elevation in combination with conjugated hyerbilirubinemia (n=17, 39.5%). All patients with conjugated hyperbilirubinemia presented during Induction, were older (average 13.7 years vs. 9.2 years, *p*=0.003), and were more likely to have a BMI \> 85th percentile (92.3% vs. 46.7%, *p*=0.006).

**Conclusions**: Hepatotoxicity can be a dose‐limiting side effect of early therapy for pediatric ALL. Older, overweight children of Hispanic ethnicity may be at higher risk for hepatoxicity that includes conjugated hyperbilirubinemia and may benefit from closer monitoring of liver function tests during Induction and Consolidation phases of ALL therapy.

### PO-113. Relapse Analysis of Childhood Acute Lymphoblastic Leukaemia at Hue Central Hospital in Vietnam {#pbc27455-sec-3380}

[H. Nguyen]{.ul} ^1^, K.H. Tran^1^, V.H. Chau^1^, W. Kazuyo^2^

*^1^Hue Central Hospital, Hue Pediatric Center, Hue, Vietnam; ^2^Asian Children\'s Care League, Founder, Tokyo, Japan*

**Background/Objectives**: Outcome in acute lymphoblastic leukaemia in children has shown an improvement. However, relapse of disease is still a big issue in developing countries. This study aims to analyze the incidence and survival rate of relapse in patients with childhood acute lymphoblastic leukemia treated at Hue Central Hospital, Vietnam, during the period of 2012‐2018.

**Design/Methods**: It is a retrospective and prospective descriptive study. Data were analyzed according to age, gender, relapse type, relapse time.

**Results**: There were 156 new patients admitted hospital, in which, there were 26 relapse cases, accounted for 16.67%. Of 26 relapse cases, the ratio of male to female was 2.71:1. High risk group was 1.6 times higher than standard group (61.5% vs 38.5%). 85.5% patients achieved remission after induction phase. The median time from diagnosis to relapse was 28.3 ± 18.2 months, in which the rate of very early, early and late relapse were 38.5%, 26.9% and 34.6% respectively. Based on relapse timing, 53.8% relapsed during maintenance phase, 23.1% relapsed after finishing therapy, 15.4% relapsed at delayed intensification phase and 7.7% relapsed after induction phase due to abandonment treatment. Based on relapse type, bone marrow relapse occupied 38.5%, followed by isolated CNS, bone marrow combined CNS relapse (23.1% and 23.1% respectively), while the rest had relapse in testes, combination of testis and bone marrow, and combination of bone marrow, testis and CNS. The median time from relapse to death were 7.5 ± 8.3 months. Until April 2018, 73.1% relapse cases passed away and 26.9% cases are alive.

**Conclusions**: Most relapse cases occurred at maintenance phase and after finishing treatment. Bone marrow and CNS were the main sites of relapse. To tackle these facts, modifying the protocol to use escalated methotrexate dose and providing further new therapies such as stem cell transplantation need to be applied.

### PO-114. Monitoring Minimal Residual Disease for Fusion Gene Transcript in ETV6‐ABL1 Positive Acute Lymphoblastic Leukemia: A Case Report {#pbc27455-sec-3390}

[S. Nodomi]{.ul} ^1^, T. Tomii^2^, K. Waki^1^, T. Imamura^2^, T. Imai^1^

*^1^Kurashiki Central Hospital, Pediatrics, Okayama, Japan; ^2^Graduate School of Medical Science‐ Kyoto Prefectural University of Medicine, Pediatrics, Kyoto, Japan*

**Background/Objectives**: A subgroup of acute lymphoblastic leukemia (ALL) called BCR‐ABL1−like (Ph‐like) ALL has been recognized to be associated with poor prognosis. Minimal residual disease (MRD) is the significant prognostic factor in ALL; however, there is a discordancy of results shown in several techniques for MRD. In a recent study of pediatric patients with ALL, some patients with *ETV6‐ABL1* fusion positive ALL, a subgroup of Ph‐like ALL, relapsed after chemotherapy despite of MRD negativity.

**Design/Methods**: In the case of an *ETV6‐ABL1* positive ALL, we monitored MRD in the *ETV6‐ABL1* transcript level sequentially and compared it with MRD in T‐cell receptor (TCR) gene rearrangement.

**Results**: A 10‐year‐old male with B‐cell precursor ALL (BCP‐ALL). Bone marrow showed 91% lymphoblasts. Leukemic cells expressed CD10, CD 19, CD 22, CD79a, TdT and CD66c, but did not express cytoplasmic μ chain. Cytogenetic study showed normal karyotype by G‐banding and abnormal signal for *ABL1* FISH probe. We detected *ETV6‐ABL1* fusion transcript by RT‐PCR and *ETV6* exon 5 fused to *ABL1* exon 2 by Sanger sequencing. He was treated according to the chemotherapy for childhood BCP‐ALL based on Japanese pediatric leukemia/lymphoma study group protocol. He was a prednisone good responder and in a complete remission after the induction therapy. He has been treated with chemotherapy only without relapse. Although *ETV6‐ABL1* transcript level in bone marrow by RT‐PCT showed 3.87 × 10^5^ copy/μg RNA at the initial diagnosis, it did not detect the transcript after the induction therapy and the early‐intensification therapy. MRD for TCR was performed following standardized EuroMRD recommendations showed also negativity after the early‐intensification therapy.

**Conclusions**: Our observations suggest that both fusion gene‐based MRD and TCR‐based MRD is detected in the patient with *ETV6‐ABL1* fusion positive ALL. Furthermore, we must analyze the relationship between discordancy of MRD in the two methods and relapse in Ph‐like ALL.

### PO-115. Double Hit B‐Acute Lymphoblastic Leukemia Presenting with an Extensive Extranodal Disease in an Adolesecent {#pbc27455-sec-3400}

[S. Oberoi]{.ul} ^1^, A. Dawson^2^, D. Marko^3^, M. Almiski^3^, R. Higgins^4^, S. Israels^1^

*^1^CancerCare Manitoba, Paediatric Haematology Oncology, Winnipeg, Canada; ^2^Health Sciences Centre, Section of Genetics and Metabolism, Winnipeg, Canada; ^3^Health Sciences Centre, Department of Pathology, Winnipeg, Canada; ^4^Health Sciences Centre, Department of Radiology, Winnipeg, Canada*

**Background/Objectives**: Combined rearrangements in MYC and BCL2 seen most commonly in mature B‐cell lymphomas (referred to as "double‐hit"), are rare in precursor B‐ALL (acute lymphoblastic leukemia), particularly in pediatric patients. We describe the presentation and outcome of an adolescent diagnosed with double‐hit B‐ALL.

**Design/Methods**: A retrospective review of the patient\'s chart was done to retrieve clinical and laboratory data.

**Results**: A 14‐year‐old adolescent boy presented with a one‐month history of painful swelling of the right knee and upper eyelids associated with fever, weight loss and elevated LDH. X‐ray of the femur demonstrated a destructive lesion associated with joint effusion. CT imaging revealed soft enhancing masses involving the lacrimal glands, orbits, and diffuse infiltration of parotid glands and facial and neck muscles without any involvement of lymph nodes, liver and spleen. An extensive epidural disease was demonstrated throughout the thoracic and lumber spine on MRI. Morphology of knee joint aspirate showed numerous small round blue cells with immuno‐phenotype consistent with B‐ALL. Biopsy of a sub mental lymph node showed very minimal involvement by disease. Bone marrow aspirate confirmed a diagnosis of B‐ALL. Bone marrow cytogenetics and FISH identified a karyotype and rearrangements of MYC and BCL2 consistent with a diagnosis of double‐hit B‐ALL: 46,XY,t(8;14)(q24;q32),t(14;18)(q32;q21)\[16\]/46,XY\[4\]. Treatment was initiated using the COG protocol AALL1131 for high risk B‐ALL, but because of early poor response, was changed to the COG ANHL1131 protocol for mature B cell leukemia, including rituximab. There was a transient partial response and he was subsequently treated with blinatumumab, with no clear evidence of response. He died of refractory and progressive disease three months after diagnosis.

**Conclusions**: Double‐hit B‐ALL is rare, but is characterized by aggressive clinical behavior and poor response to intensive therapy. This case is remarkable for the extent of extranodal disease and the young age of the patient.

### PO-116. A Study of Teenagers Diagnosed with Acute Lymphoblastic Leukemia: Exploring the Impact of Cancer on Growing up in Singapore and the Region {#pbc27455-sec-3410}

[B. Oh]{.ul} ^1^, S. Lee^1^, A. Yeoh^1^

*^1^National University Hospital Singapore, Paediatrics, Singapore, Singapore*

**Background/Objectives**: Cure rates for Acute Lymphoblastic Leukemia (ALL) have increased rapidly with recent advances, giving birth to a new generation of long term survivors. In Singapore, the Ma‐Spore‐ALL protocol (Yeoh at al, JCO 2012) has been highly successful, achieving cure rates of more than 80%. Teenagers and adolescents are usually treated on a more intensive protocol and have a unique set of challenges to manage. Hence, we aimed to study the impact of an ALL diagnosis on adolescent health and outcomes in early adulthood.

**Design/Methods**: A retrospective case note review was performed at the National University Hospital Singapore, of patients diagnosed with ALL between the ages of 10 to 20 from January 2002‐December 2015.

**Results**: 47 patients were evaluated in this study. Mean duration of follow‐up was 7.6years and mean age at time of analysis was 21.4years. 46.8% of the study population was treated on the high‐risk protocol and 21.3% of patients required bone marrow transplantation. Obesity rates increased significantly from 12.8% at diagnosis to 40.4% at most recent follow‐up (p=0.002). Specifically, there was a 2.3‐fold increase in morbid‐obesity (BMI≥30kg/m2) from 2.13% at diagnosis to 14.9% at most recent follow‐up (p=0.027). Neurological complications (Sagittal‐sinus thrombosis, leukoencephalopathy) occurred as commonly as septicemia (27.66%) during treatment. Commonest late effects were psychosocial issues and endocrinopathies such as hypogonadism and thyroid problems, including a case of secondary thyroid carcinoma. 65% of survivors achieved a university degree and 89% completed at least tertiary education (Diploma or GCE 'A' level certification). Unemployment rate was 2.7% in our study population which is comparable to the national rate of 2.1%.

**Conclusions**: Overall outcomes are excellent for ALL adolescent survivors despite more intensive treatment. Obesity, psychosocial issues and endocrinopathies are major issues and care needs to be tailored towards effective screening and early treatment of these problems in young adult survivors.

### PO-117. Use of Blinatumomab to Achieve Remission and Consolidation with Haploidentical Transplant with Cyclophosphamide for the Treatment of Children with Acute Lymphoblastic Leukemia (ALL) Refractory {#pbc27455-sec-3420}

[A. Olaya‐Vargas]{.ul} ^1^, R. Rivera‐Luna^2^, Y. Melchor‐Vidal^3^, H. Salazar‐Rosales^1^, G. Lopez‐Hernandez^1^, N. Ramirez‐Uribe^1^

*^1^Instituto Nacional de Pediatria, Hematopoietic Cell Trasplant and Cell Therapy Department, México, Mexico; ^2^Instituto Nacional de Pediatria, Under Director of Hem/Oncology National Institute of Pediatrics and Program Director of Pediatric Hem/Oncology at the Medical Center ABC at Mexico City., México, Mexico; ^3^Medical Center ABC, Bone Marrow Transplant Unit, México, Mexico*

**Background/Objectives**: Most of patients with ALL in relapse or refractory to conventional treatment have only 30% possibilities to achieve long term remission. This report refers to the therapeutic efficacy and adverse events from the blinatumomab to achieve molecular remission in patients with pre‐B CD19+ which lead to haploidentical transplant as consolidation

**Design/Methods**: A pilot study was conducted in children with refractory ALL preB‐CD19 +. As a strategy to achieve remission blinatumomab was usedat a dose 10 μg/m2 for continous infusion of 48 hours, increasing the dose to 15 μg/m2 during 28 days, patients with a MRD of \< 0.002 Log, after 2 cycles received an haploidentical bone marrow transplant as consolidation, the conditioning regimen was with total body irradiation scheme at 200 cGy/day/3 days, cyclophosphamide and etoposide. Receiving prophylaxis for GVHD with cyclophosphamide.

**Results**: A total of 10 patients were included, 8 of them achieved complete remission after 2 cycles of blinatumomab, these 8 patients received a haploidentic transplant. achieving graft in 8 of the transplanted patients. Two patients had a bone marrow relapse in the first 6 months of the follow‐up and 6 patients are free of disease with a follow‐up to 18 months. As a acute complication 3 patients presented cytokine release syndrome. During the infusion of blinatumumab 10 patients presented tachycardia and 4 patients presented aGVHD (2 grade II and 2 grade IV).

**Conclusions**: Allogeneic bone marrow transplant constitutes a treatment option on those patients that relapse or become refractory to treatment, one of the major problem is basically to identify a HLA‐identical donor, the alternative is a haploidentical donor. The most important factor to get these results is the disease status before the transplant. The use of blinatumomab has proven to be effective in achieving remission in relapse Acute Linfoblastic Leukemia pre‐B CD 19+ or refractory to treatment.

### PO-118. Maternal Diet and Childhood Cancer: Should we Open the Nordic National Birt Cohort Databases, or Should we Wait Until Data from Other Cohorts Become Available? {#pbc27455-sec-3430}

[S. Olsen]{.ul} ^1^

*^1^Statens Serum Institut, Centre for Fetal Programming‐ Department of Epidemiology Research, Copenhagen, Denmark*

**Background/Objectives**: Retrospective case‐control studies have suggested that dietary intake in pregnancy may play a role in the aetiology of some childhood cancers. Thus, a high maternal intake of phytoestrogens may increase and vegetables may reduce offspring risk of acute lymphoblastic leukaemia; and maternal intake of nitrosamides and cured meat may increase offspring risk of brain tumour. The Danish and Norwegian national birth cohorts will be the first databases where these hypotheses can be challenged in prospective analyses. The two databases were recently brought together and are available to us, but data have not been opened yet for this purpose. The objective of this presentation is to discuss strategies for opening the pooled data from these cohorts for the purpose of examining impact of specific dietary factors on offspring cancer risk. The main question is whether this might be too early, or whether we should wait until data from other large cohorts will be available.

**Design/Methods**: During 1996--2002, 101,042 pregnancies were recruited for the Danish National Birth Cohort (DNBC). During 1999--2008, 108,000 pregnancies were recruited for the Norwegian Mother and Child Cohort Study (MoBa). In both cohorts, diet in pregnancy was assessed using similar 300+ food item FFQs.

**Results**: For a continuous dietary variable categorized into quintiles, an analysis comparing the highest and lowest quintiles in the combined DNBC and MoBa databases would have an 80% chance of detecting a relative risk (RR) of 1.5 at 5% significance level. To achieve, under same conditions, a similar power for leukaemia, RR would have to be 2.

**Conclusions**: Based on these and more advanced power calculations, pros and cons will be discussed for the two possibilities: 1) Data from the combined Nordic cohorts shall be opened and specific dietary hypotheses addressed; and 2) This shall wait until data from other large prospective cohorts become available for pooling.

### PO-119. Changes in Intracellular Folate Metabolism During High‐Dose Methotrexate and Leucovorin Rescue Therapy in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-3440}

[N. Oosterom]{.ul} ^1^, R. de Jonge^2^, D.E. Smith^2^, R. Pieters^1^, W.J. Tissing^3^, B.D. van Zelst^4^, M.M. van den Heuvel‐Eibrink^1^, S.G. Heil^4^

*^1^Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands; ^2^VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands; ^3^Beatrix Children\'s Hospital‐ University of Groningen‐ University Medical Center Groningen, Department of Pediatric Oncology, Groningen, The Netherlands; ^4^Erasmus Medical Center, Department of Clinical Chemistry, Rotterdam, The Netherlands*

**Background/Objectives**: Methotrexate (MTX) is an important cytotoxic agent in pediatric acute lymphoblastic leukemia (ALL) treatment. MTX depletes intracellular folate levels and thereby inhibits DNA‐ and RNA synthesis. After high‐dose MTX infusions, folate rescue therapy (Leucovorin) is administered to reduce toxicity. Previous studies showed that MTX‐induced oral mucositis predominantly occurs during the first out of four MTX courses. Leucovorin is a structural analogue of MTX, possibly competing for cellular transport mechanisms, leading to decreased intracellular MTX levels and neutralization of the anti‐metabolic effects of MTX and decreased treatment efficacy. The aim of this study is to determine whether intracellular folate levels increase during consecutive high‐dose MTX courses and therefore "overrescue" the MTX effect.

**Design/Methods**: We prospectively assessed erythrocyte folate vitamers (5‐methyltetrahydrofolate (THF) and non‐methyl THF) and serum folate levels in 67 children with ALL before start (T0) and after stop (T1) of 4x 5g/m2 HD‐MTX courses with a 2‐week interval.

**Results**: The total sum of erythrocyte folate vitamers increased between T0 (mean 416.7 ± 145.5 nmol/L) and T1 (mean 641.2 ± 196.3 nmol/L, p\<0.0001). This was mainly due to an increase in erythrocyte 5‐methyl THF levels (mean increase T0‐T1 217.7 ± 209.5 nmol/L, p\<0.0001), whereas non‐methyl THF levels did not change (median increase T0‐T1 0.6 nmol/L \[‐9.9 -- 11.1\], p=0.676). Serum folate increased during HD‐MTX therapy (median increase T0‐T1 29.2 nmol/L \[19.3 -- 57.4\], p\<0.0001). The changes from T0 to T1 were not significantly affected by age, gender, ALL immunophenotype, MTHFR c.677C\>T genotype and hospital of inclusion.

**Conclusions**: Serum and intracellular folate levels accumulate after 4 courses of 2‐weekly HD‐MTX and Leucovorin therapy in children with ALL, showing that Leucovorin is able to restore the intracellular folate pool. Future studies, that determine whether this results into decreased intracellular MTX levels or neutralization of the anti‐metabolic effects of MTX are necessary to prove "overrescue".

### PO-120. Flow Cytometry Based Initial Therapy in Mixed Phenotypic Acute Leukemia in Children: Fifteen Year Follow up Study from a Single Center in India {#pbc27455-sec-3450}

[S. Patel]{.ul} ^1^, R. Raj^1^, R. Uppuluri^1^, V. Swaminathan^1^, M. Sivasankaran^1^, D. Jayaraman^1^

*^1^Apollo Cancer Institute, Department of Pediatric hematology‐oncology and blood and marrow transplantation, Chennai, India*

**Background/Objectives**: Mixed Phenotypic Acute Leukemia (MPAL) is a rare subgroup of acute leukemia which is seen in less than 3% of pediatric leukemia cases. Data regarding standard therapy regimen and outcomes in these children is scant.

**Design/Methods**: We have performed a retrospective analysis of all children who were diagnosed to have MPAL at our center from March 2002 to March 2017 by immunophenotyping by flow cytometry as per EGIL criteria. The children were assigned to a four drug induction therapy for Acute Lymphoblastic Leukemia (ALL) or standard Acute Myeloid leukemia (AML) induction initially based on the predominant marker. Response was assessed at the end of induction and a second induction of ALL or AML chemotherapy was administered. HSCT was offered to all the patients after initial therapy and ALL maintenance chemotherapy for 2 years was continued in those who declined HSCT.

**Results**: Nineteen children were included in study with a median age at diagnosis of eight years (1 year to 18 years). The median total leukocyte count at presentation was 10,200 (4500 to 500,000). B‐myeloid in fifteen, T‐myeloid in two and B/T lymphoid in two children were the immunophenotype documented. Eleven patients received AML induction therapy and 8 patients received ALL induction therapy. Eight out of thirteen children who underwent allogeneic hematopoietic stem cell transplantation from the best available donor and two of the five patients who did not undergo HSCT are alive. The overall survival in our cohort was 42.1%. The most common cause of mortality was relapse (66%) followed by regimen related toxicity (33%).

**Conclusions**: Children who had received ALL induction followed by AML induction had a trend toward improved survival in our series with an overall survival of 42%. Relapse was the most common cause of mortality and MRD based individualized therapy would help optimize outcomes.

### PO-121. Clinical Profile of Patients with Relapsed Acute Lymphoblastic Leukemia: A Single Centre Experience {#pbc27455-sec-3460}

[S. Patel]{.ul} ^1^, K. Vp^1^, P. Kanvinde^1^, Z. Golwala^1^, A. Swami^1^, N. Shah^1^, M. Desai^1^, B. Agarwal^1^, S. Mudaliar^1^

*^1^Bai Jerbai Wadia Hospital for Children, Department of Pediatric Hematology‐Oncology, Mumbai, India*

**Background/Objectives**: Despite vast improvement in the outcome of pediatric Acute Lymphoblastic Leukemia(ALL), relapsed ALL remains a major cancer subgroup. This study evaluated the clinical profile of patients with relapsed ALL.

**Design/Methods**: A retrospective data analysis of patients with relapsed ALL, registered at BJ Wadia Children\'s Hospital, Mumbai between 2012 and 2017 was done and the parameters at initial diagnosis were evaluated in patients who later had a relapse.

**Results**: A total of 34 out of 301 patients with Precursor B‐cell ALL(Pre‐B ALL) and 11 out of 74 patients with T‐ALL relapsed. In Pre‐B ALL relapses, 52.9% were very early relapses, 35.2% early and 8.8% late relapses. The same data for T ALL was 63%, 27% and 9% respectively. Most common sites of relapse were medullary(50%) and CNS(26.4%) in Pre‐B ALL whereas in T‐ALL it was medullary(55%) followed by combined medullary and CNS(36%). At initial diagnosis, 8.8% Pre‐B ALL and 63% T‐ALL had bulky disease, 32% Pre‐B ALL and 72% T‐ALL had total leukocyte count\>50,000, 2.9% Pre B ALL and 18% T‐ALL had CNS disease while none had testicular disease. 5.8% Pre‐B ALL and 18% T‐ALL had poor day‐8 prednisone response. High‐risk cytogenetics were found in 11.7% patients with Pre‐B ALL. All patients achieved morphological remission, however, minimal residual disease(MRD) was\>10‐3 in 5 out of 19 Pre‐B ALL(26.3%) and 2 out of 4 patients with T‐ALL(50%). 26% patients with Pre‐B ALL and 81% patients with T‐ALL had major breaks in treatment. During maintenance chemotherapy in Pre‐B ALL and T‐ALL, absolute neutrophil count(ANC) between 1000‐2000 was maintained only on 37.5% follow‐up visits. Only 17% Pre‐B ALL and 18% T‐ALL had ANC(1000‐2000) on more than 50% visits.

**Conclusions**: MRD is the most important predictor for relapse in pediatric ALL. Major breaks in upfront treatment and compliance to maintenance can be assessed as added risk factors for relapse.

### PO-122. Silencing of Cyclin Dependent Kinase Interacting Protein (CIP)/Kinase Inhibitory Protein (KIP) Family of Genes by Hypermethylation in Pediatric Patients with Acute Lymphoblastic Leukemia {#pbc27455-sec-3470}

[N. Pathak]{.ul} ^1^, R. Seth^1^

*^1^All India Institute of Medical Sciences, Pediatrics, New Delhi, India*

**Background/Objectives**: Dysregulation of cell cycle by promoter methylation of cell cycle controlling genes is a frequent event in Acute Lymphoblastic Leukemia (ALL) and is recognized as a critical event in the disease pathogenesis and progression. Cell cycle is negatively regulated by CDK interacting protein/Kinase inhibitory protein (Cip/Kip) family of genes. Epigenetic inactivation of these genes has been reported with discrepant frequencies. We aimed to investigate the methylation status of CDK interacting protein/Kinase inhibitory protein family of genes: p21 (CIP1) and p27 (KIP1) in our pediatric patients with ALL to find its correlation with treatment outcome.

**Design/Methods**: Bisulphite modification of the extracted total genomic DNA (from bone marrow /peripheral blood mononuclear cells) of pediatric patients with ALL was done and this followed by the amplification of the modified DNA, using methylation specific PCR.

**Results**: A total of 70 pediatric patients (median age 9 yrs, range 1‐17 yrs; M: F 4:1; median TLC‐17.5x109/l, range 1.1‐405x109/l) were studied. Hypermethylation of p21 CIP1 (21 %) and p27 KIP1 (7%) genes was observed in our patients. The frequency of hypermethylation was significantly associated with higher age group (age\>9 years). Hypermethylation of p21 (CIP 1) was also found to be predictor of poorer Disease Free Survival (DFS) (hazard ratio 5.73; \[95% CI: 2.49‐ 13.19\], p=0.0001).

**Conclusions**: Frequency of hypermethylation of cell cycle controlling genes was found to be higher in our patients with ALL and correlated significantly with poorer DFS. This should be explored further in the Indian scenario. It might provide an insight regarding the poorer outcome in our patients as compare to the West.

### PO-123. Early Residual Disease Assessment by Flow Cytometry Determines Relapse Risk in Children with Acute Lymphoblastic Leukemia: Single Center Experience {#pbc27455-sec-3480}

[K. Pawinska‐Wasikowska]{.ul} ^1^, K. Bukowska‐Strakova^2^, M. Surman^2^, M. Siedlar^2^, W. Balwierz^1^

*^1^Institute of Pediatrics Jagiellonian University Medical College, Department of Children\'s Oncology and Hematology, Krakow, Poland;*

*^2^Institute of Pediatrics Jagiellonian University Medical College, Department of Clinical Immunology and Transplantology, Krakow, Poland*

**Background/Objectives**: Blast clearance is a strong indicator of outcome in childhood acute lymphoblastic leukemia (ALL). According to many therapeutic protocols achievement of minimal residual disease (MRD) below 0.1% on day 15 of induction evaluated by flow cytometry (FC) is used for a risk directed therapy in children with ALL.

We assessed prognostic impact of MRD measured by FC at day 15 and 33 of induction therapy, as well as availability of MRD detection at both time points, considering therapy related antigen modulation and bone marrow hypocellularity.

**Design/Methods**: Since November 2009 and March 2018, bone marrow from 272 children, age 1 to younger than 18 years, with newly diagnosed ALL, treated in Department of Children\'s Oncology and Hematology, Institute of Pediatrics Jagiellonian University, Krakow, Poland according to ALL IC‐BFM‐ protocols were taken for FC MRD analysis at day 15 and 33 of induction therapy. We used a 6 and 10 color FC for detection of leukemia‐associated immunophenotypes.

**Results**: Of the 272 enrolled patients we assessed samples for FC MRD at day 15 from 185 (68%) children and at both time points from 125 (46%). Leukemia‐associated immunophenotypes were recognized in all study patients. According to FC MRD at day 15 three risk groups were identified: standard (\<0.1% blast cells; 24% of the total), intermediate (0.1 to \< 10%; 63%), and high (≥10%; 13%). Their 5‐year cumulative incidences of relapse were 5.1% (SE, 1.0), 14.3% (SE, 2.3), and 25.3% (SE, 4.2), respectively. In multivariative analysis MRD at day 15 was the strongest prognostic factor among others (age, leukocyte number, blast genetic rearrangements).

**Conclusions**: Since early blast clearance kinetics still has the strongest prognostic value, MRD detection during early phases of induction treatment becomes a mandatory tool for childhood ALL therapy. FC MRD evaluation is fast, highly sensitive and applicable, becoming a useful strategy for residual cells assessment.

### PO-124. Childhood Leukemia International Consortium (CLIC) Studies Report Diffrential Associations of Advanced Parental Age with Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-3490}

[E. Petridou]{.ul} ^1,2^, M. Georgakis^1^, F. Erdmann^3,4^, S. Ezzat^5^, A.M. Mora^6^, N. Dessypris^1^, J. Schüz^3^, C. Infante‐Rivard^7^, A. Skalkidou^8^, C.S.G. CLIC Studies Group^9^

*^1^National and Kapodistrian University of Athens Medical School, Dept. of Hygiene‐ Epidemiology and Medical Statistics, Athens, Greece; ^2^Karolinska Institute, Clinical Epidemiology Unit‐ Department of Medicine, Stockholm, Sweden; ^3^International Agency for Research on Cancer, Section of Environment and Radiation, Lyon, France; ^4^Danish Cancer Society Research Center, Childhood Cancer Survivorship Research Group‐ Unit of Survivorship, Copenhagen, Denmark; ^5^National Liver Institute‐ Menoufia University, Department of Epidemiology and Preventive Medicine‐ NLI‐SSI Collaborative Research Center, Caire, Egypt; ^6^Universidad Nacional Heredia, Central American Institute for Studies on Toxic Substances IRET, Heredia, Costa Rica; ^7^McGill University, Department of Epidemiology‐ Biostatistics and Occupational Health Faculty of Medicine, Montreal‐ Québec, Canada; ^8^Uppsala University, Department of Women\'s and Children\'s Health, Uppsala, Sweden; ^9^Anssi Auvinen‐ John D Dockerty‐ David R Doody‐ Johnni Hansen‐ Julia E Heck‐ Eleanor Kane‐ Alice Y Kang‐ Xiaomei Ma‐ Corrado Magnani‐ Catherine Metayer‐ Beth A Mueller‐ Maria S Pombo‐de‐Oliveira‐ Waffa M Rashed‐ Eve Roman‐ Michael E Scheurer‐ Logan G Spector‐ Rong Wang, CLIC Studies Group, Athens, Greece*

**Background/Objectives**: Advanced parental age has been associated with adverse health effects in the offspring including childhood (0‐14 years) acute lymphoblastic leukemia (ALL), as reported in our meta‐analysis of published studies. Primary data from 16 studies participating in the Childhood Leukemia International Consortium provide a unique methodological opportunity to further explore this association.

**Design/Methods**: Data from 11 case‐control (CC) studies (7919 cases; 12942 interviewed controls) and five nested case‐control (NCC) studies (8801 cases; 29690 controls record linked via population‐based registries) with enrollment periods ranging from 1968 to 2015 were used. Adjusted odds ratios (OR) were derived from each study using five‐year paternal and maternal age increments and introduded in two meta‐analyses by CC or NCC study design.

**Results**: Advancement of paternal age was associated with statistically significant higher risk for ALL in the offspring (ORCC:1.05; ORNCC:1.04) and advanced maternal age only in the NCC (ORNCC:1.05). By contrast, the results were heterogeneous in CC studies (ORCC:0.99, 95% CI:0.91‐1.07, heterogeneity *I2*=58%, *p*=0.002). The positive association between parental age and risk of ALL was more evident in the age group among 1‐5 years and remained unchanged after mutual adjustment for the collinear effect of the paternal and maternal age variables. We further performed analyses of the relatively small numbers of discordant paternal and maternal age pairs to explore the collinear effect of parental age but the results were not fully enlightening.

**Conclusions**: The results of this larger ever dataset of primary data allowing for separate analysis by study design and better control of selection bias in CC studies strengthen the evidence that advanced parental age is associated with increased childhood ALL risk. The observational study design and ollinearity of maternal with paternal age complicate causal interpretation. Employing datasets with cytogenetic information may further elucidate involvement of each parental component and clarify underlying mechanisms.

### PO-125. Supratherapeutic Levels of Asparaginase: Therapeutic Drug Monitoring Experience from the Maritimes, Canada {#pbc27455-sec-3500}

[M. Pike]{.ul} ^1^, K. Kulkarni^2^, T. MacDonald^3^

*^1^Dalhousie University‐ IWK Health Centre, Department of Pediatrics, Halifax, Canada; ^2^Dalhousie University‐ IWK Health Centre, Department of Pediatrics‐ Division of Pediatric Hematology/Oncology, Halifax, Canada; ^3^Dalhousie University‐ IWK Health Centre, Department of Pharmacy‐ Division of Pediatric Hematology/Oncology, Halifax, Canada*

**Background/Objectives**: Asparaginase therapeutic drug monitoring (TDM) detects silent inactivation (SI) of asparaginase in up to one‐third of patients with acute lymphoblastic leukemia. Asparaginase levels are measured as a surrogate for asparagine depletion and resultant leukemic cell death. There is a paucity of information on the clinical implications of asparaginase levels that are above the therapeutic minimum. This study describes an asparaginase TDM experience in The Maritimes, Canada.

**Design/Methods**: This prospective cohort study included newly diagnosed leukemia/lymphoma patients managed at the IWK Health Centre from 2016‐2018. All patients were treated according to Children\'s Oncology Group protocols using pegylated asparaginase. After Research Ethics Board approval and informed consent, blood samples were taken from each patient approximately 7 days after each dose to allow for switching products in the event of SI. Levels were analyzed at NEXT Molecular Analytics^©^, a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Levels ≥0.1 IU/mL were considered therapeutic.

**Results**: Fifty‐eight levels were measured in 19 patients (mean age: 8.2±4.6 years). All levels were supratherapeutic (mean: 1.47±0.49 IU/mL, range: 0.66‐2.77). The mean levels were significantly (p=0.018) higher in standard risk (1.80±0.55 IU/mL) than in high‐risk patients (1.36±0.41 IU/mL). Asparaginase levels did not vary significantly based on age, sex, disease type or Minimal Residual Disease status. Three patients (16%) experienced toxicity reactions (hives or pancreatitis).

**Conclusions**: The average asparaginase level was approximately 15 times higher than the therapeutic minimum. No patients showed signs of SI. Standard risk patients had significantly higher asparaginase levels, perhaps because they received a lower number of doses. Previous studies have demonstrated that lower doses of asparaginase maintain levels above 0.1 IU/mL for the same length of time as higher doses. Further studies should consider reviewing the minimum asparaginase dose required for adequate asparagine depletion, as lower doses may reduce toxicity and cost of therapy while maintaining survival outcomes.

### PO-126. Sixty Years of Therapy in Acute Lymphoblastic Leukemia: Pediatric Single‐Center Study in Poland {#pbc27455-sec-3510}

[M. Pogorzala]{.ul} ^1^, J. Styczynski^1^, R. Debski^1^, A. Koltan^1^, S. Koltan^1^, A. Jatczak‐Gaca^1^, A. Krenska^1^, E. Grzesk^1^, B. Tejza^1^, E. Demidowicz^1^, N. Bartoszewicz^1^, K. Czyzewski^1^, M. Richert‐Przygonska^1^, A. Dabrowska^1^, A. Urbanczyk^1^, P. Ksiezniakiewicz^1^, A. Marjanska^1^, M. Dziedzic^1^, P. Galazka^2^, M. Wysocki^1^

*^1^Jurasz University Hospital Collegium Medicum UMK, Department of Pediatric Hematology and Oncology, Bydgoszcz, Poland; ^2^Jurasz University Hospital Collegium Medicum UMK, Department of Pediatric Surgery, Bydgoszcz, Poland*

**Background/Objectives**: The first report on children treated for acute lymphoblastic leukemia (ALL) in Bydgoszcz (Poland) comes from 1958: eleven children were treated with steroids and blood transfusions. The objective of the study is the analysis of results of treatment of children with ALL between 1958‐2018 in single‐center study in Poland.

**Design/Methods**: Total number of 688 children were included into the study: 215 children treated with various drugs between 1958‐1972; 56 children treated with Total Therapy protocols V‐VII (St Jude, Memphis) between 1976‐1983; 33 children treated according to BFM83; 81 children treated according to NOPHO86 between 1988‐1995; 115 children treated with BFM90 or New York I/II protocols between 1995‐2002; 113 children treated with ALL‐IC‐2002 between 2002‐2011 and 75 children treated with ALL‐IC‐2009 between 2011‐2018.

**Results**: (A) In respective periods following 10‐years probability of overall survival (pOS) were obtained: p=0.012±0.008 (1958‐1972); p=0.143±0.047 (1976‐1983); p=0.485±0.087 (1983‐1988); p=0.543±0.055 (1988‐1995); p=0.731±0.042 (1995‐2002); p=0.767±0.047 (2002‐2011); and p=0.968±0.022 (2011‐2018) (p\<0.0001). (B) After adjustment to time period, in univariate Cox analysis, in comparison to 2011‐2018, the hazard risk (HR) of death was: HR=5.2 for patients treated between 2002‐2011; and respectively 8.6 in 1995‐2002; 13.8 in 1988‐1995; 16.5 in 1983‐1988; 35.5 in 1976‐1983 and 85.6 in 1958‐1972 (p\<0.0001). The hazard risk of leukemic relapse was: HR=2.6 for patients treated between 2002‐2011; and respectively 2.4 in 1995‐2002; 4.6 in 1988‐1995; 6.3 in 1983‐1988; 24.6 in 1976‐1983 (p\<0.0001). The hazard risk of any event was: HR=4.1 for patients treated between 2002‐2011; and respectively 4.9 in 1995‐2002; 8.3 in 1988‐1995; 9.2 in 1983‐1988; 27.1 in 1976‐1983 and 85.6 in 1958‐1972 (p\<0.0001).

**Conclusions**: Complex management of children with ALL based on therapy of international strategy of multidrug chemotherapy and multidirectional supportive therapy has enabled to increase long‐term survival from 1% in 1960s to over 90% in 2018.

### PO-127. Outcome in Childhood T‐Lineage ALL is Highly Predictable by Flow Cytometric Investigation of CD1A and T‐Cell Receptors Expression {#pbc27455-sec-3520}

[A. Popov]{.ul} ^1^, O. Illarionova^1^, A. Chervova^1^, T. Verzhbitskaya^2^, L. Fechina^2^, J. Roumiantseva^3^, G. Henze^4^, A. Karachunskiy^3^

*^1^National Research Center for Pediatric Hematology‐ Oncology and Immunology, Laboratory Department, Moscow, Russia; ^2^Regional Children Hospital / Research Institute of Medical Cell Technologies, Pediatric Oncology/Hematology Department, Ekaterinburg, Russia; ^3^National Research Center for Pediatric Hematology‐ Oncology and Immunology, Institute of Oncology Radiology and Nuclear Medicine, Moscow, Russia; ^4^Charité CVK‐ Universitätsmedizin, Pediatric Oncology and Hematology, Berlin, Germany*

**Background/Objectives**: Despite significant improvement of childhood acute lymphoblastic leukemia (ALL) treatment results, T‐lineage ALL (T‐ALL) management is still a challenge. Additional prognostic factors in this ALL type are required. Objective of the study was to investigate the prognostic significance of tumor blasts immunophenotype in childhood T‐ALL.

**Design/Methods**: In total 110 consecutive children with T‐ALL (71 boys and 31 girls with median age of 8 years) were prospectively studied in two reference flow cytometric laboratories of "Moscow‐Berlin" ALL MB‐2015 trial. According to the protocol stratification system patients were distributed into T‐low risk (T‐LR, n=70), T‐intermediate risk (T‐ImR, n=29) and T‐high risk (n=11) groups. Event‐free survival (EFS) with standard error (SE) was used as the outcome parameter.

**Results**: Among all studied single markers CD1a and T‐cell receptors (TCR) expression was found to influence on treatment outcome. 78 CD1a‐positive patients had significantly better EFS (0.83 SE 0.06) compared to 32 CD1a‐negative ones (0.52 SE 0.12, p=0.043). In 16 cases CD1a and TCR were coexpressed. Outcome of these patients was worse as opposed to 62 CD1a(+)TCR(‐)‐ones: EFS 0.57 SE 0.18 and EFS 0.92 SE 0.04 respectively, p=0.045. Similarly in CD1a‐negative group TCR expression was associated with poor prognosis. 24 CD1a(‐)TCR(‐) children had EFS 0.62 SE 0.13 while in 8 CD1a(‐)TCR(+) cases EFS was 0.21 SE 0.18, p=0.030. Taken together CD1a and TCR expression allowed distinguishing of three groups: favorable (CD1a(+)TCR(‐), n=62, EFS 0.92 SE 0.04), intermediate (CD1a(+)TCR(+) and CD1a(‐)TCR(‐), n=40, EFS 0.60 SE 0.11) and unfavorable (CD1a(‐)TCR(+), n=8, EFS 0.21 SE 0.18, p=0.003). This definition of patients with different outcome retained its' significance also in T‐LR and T‐ImR groups analyzed separately (p=0.033 and p=0.047 respectively).

**Conclusions**: Results of present studies indicate the significant prognostic role of CD1a and TCR expression in childhood T‐ALL. Flow cytometric data could be successfully applied in patients' stratification together with conventional risk criteria.

### PO-128. Correlation of Absolute Lymphocyte Count and Peripheral Blood Lymphocyte Subset with Minimal Residual Disease at End of Induction in Pediatric B Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-3530}

[D. Pushpam]{.ul} ^1^, N. Rajpoot^2^, A. Chopra^2^, V. Sreenivas^3^, R. Kumar^2^, S. Bakhshi^1^

*^1^All India Institute of Medical Sciences, Medical Oncology, Delhi, India; ^2^All India Institute of Medical Sciences, Laboratory Oncology, Delhi, India; ^3^All India Institute of Medical Sciences, Department of Biostatistics, Delhi, India*

**Background/Objectives**: Correlation of absolute lymphocyte count (ALC) with minimal residual disease (MRD) and whether it can be used as surrogate marker for MRD in resource limited settings is not known. Data is lacking regarding immunological differences between MRD positive and negative patients in B ALL. This study correlated ALC with MRD, steroid response and complete remission (CR).

**Design/Methods**: This was a prospective study done from July 2015 to June 2017. ALC was done at baseline, day 8, and day 15 and at the end of induction (day 35). MRD and peripheral blood lymphocyte subsets were assessed on day 35. ALC was calculated as percentage of lymphocyte determined manually multiplied by total leucocyte count. MRD assessment was done by 10‐color flow cytometry. MRD positivity cut off was ≥ 0.01%. Peripheral blood lymphocyte analysis was done by flow cytometry. Association was evaluated by Mann--Whitney U‐test.

**Results**: Total 183 patients with de novo B ALL upto 18 years were enrolled, median age 5 year(Range: 1‐18). Out of 175 patients who achieved CR, 116 patients were MRD positive, 34 were negative and 25 were not evaluable. Peripheral lymphocyte subset was available for 58 patients, 43 MRD positive and 15 MRD negative. ALC at baseline, day 8, day 15 and day 35 did not correlate with MRD. ALC at day 8 was greater for poor steroid responders (Mdn=2.45) than for good steroid responders (Mdn =1.06), P \< 0.0001. ALC at baseline, day 15 and day 35 did not correlate with steroid response. ALC at any point did not correlate with CR. CD4‐CD8+ T cells were higher in patients who were MRD positive (Mdn = 10.36) compared to MRD negative (Mdn = 4.28), P = 0.01.

**Conclusions**: ALC cannot be used as surrogate marker for MRD. Immunologically MRD positive and MRD negative patients differ in CD4‐CD8+ T cells.

### PO-129. Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T Acute Lymphoblastic Leukemia: A Pilot Study {#pbc27455-sec-3540}

[D. Pushpam]{.ul} ^1^, A. Chopra^2^, M. Kumari^1^, V. Sreenivas^3^, R. Kumar^2^, S. Bakhshi^1^

*^1^All India Institute of Medical Sciences, Medical Oncology, Delhi, India; ^2^All India Institute of Medical Sciences, Laboratory Oncology, Delhi, India; ^3^All India Institute of Medical Sciences, Biostatistics, Delhi, India*

**Background/Objectives**: Absolute lymphocyte count (ALC) is a readily available prognostic marker. Its correlation with minimal residual disease (MRD) in T cell acute lymphoblastic leukemia (TALL) is not known. This study evaluated the correlation of ALC with MRD and explored whether it can be used as surrogate marker in resource limited settings. ALC was also correlated with induction outcomes i.e steroid response and complete remission (CR).

**Design/Methods**: It was prospective study conducted from July 2015 to June 2017. Newly diagnosed patients with T ALL, age 1 to 18 years were included. ALC was done at baseline, day 8, day 15 and at the end of induction (day 35), calculated as percentage of lymphocytes (manually examined on peripheral smear) multiplied by total leucocyte count. MRD assessment was done by 10‐color flow cytometry. The cut‐off levels used for MRD positivity was \>0.01%. Association between continuous and categorical data was examined by Mann--Whitney U‐test.

**Results**: Total of 43 patients were enrolled, median age 5 years (range: 1‐18). Out of 43 patients 39 (90.7%) achieved CR. MRD was available for 28 patients which were analyzed. ALC at baseline, day 8 and day 15 did not correlate with MRD. ALC at day 35 was greater for MRD negative patients (Mdn = 1.24) than MRD positive patients (Mdn = 0.618), P = 0.03. ALC at any point did not correlate with steroid response and CR.

**Conclusions**: ALC at day 35 correlates with MRD. Higher ALC is a favourable factor and it is possible that ALC may act as surrogate marker of MRD at the end of induction. These findings need to be validated in further studies.

### PO-130. A Single Center Experience of Blinatumomab in 27 Pediatric Patients with Heavily Pretreated Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-3550}

[M. Queudeville]{.ul} ^1^, T. Lenz^1^, M. Döring^1^, U. Holzer^1^, A. Heinz^1^, H.M. Teltschik^2^, H. Kreyenberg^3^, A. von Stackelberg^4^, M. Schrappe^5^, T. Feuchtinger^6^, P. Schlegel^1^, P. Lang^1^, R. Handgretinger^1^, M. Ebinger^1^

*^1^University Hospital Tübingen‐ Children\'s Hospital, General Pediatrics‐ Hematology/Oncology, Tübingen, Germany; ^2^Klinikum Stuttgart ‐ Olgahospital, Pediatric Oncology‐ Hematology and Immunology, Stuttgart, Germany; ^3^University Hospital Frankfurt, Department for Children and Adolescents, Frankfurt, Germany; ^4^Humboldt University Berlin‐ Charité Medical Center, Department of Pediatric Oncology/Hematology, Berlin, Germany; ^5^University Medical Center Schleswig‐Holstein‐ Christian‐Albrechts‐University of Kiel, Department of General Pediatrics, Kiel, Germany; ^6^Dr. von Hauner University Children\'s Hospital‐ LMU, Department of Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Munich, Germany*

**Background/Objectives**: Pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have an extremely poor prognosis. Blinatumomab is a bispecific T‐cell engager antibody construct which simultaneously binds CD3‐positive cytotoxic T‐cells and CD19‐positive B‐cells leading to T‐cell‐mediated lysis of normal and malignant B‐cells.

**Design/Methods**: We report a retrospective analysis of our single‐center experience with blinatumomab in 27 patients with relapsed or refractory pediatric B‐cell precursor ALL.

**Results**: The median age at onset of therapy was 8 years (1 to 20 years). Eighty percent of patients had undergone at least one hematopoietic stem cell transplantation (HSCT) prior to therapy with blinatumomab. All but 4 patients received the antibody therapy in a state of open relapse. Despite the high tumor load in most of our patients when starting immunotherapy a total of 8 patients (30%) showed a primary response to blinatumomab, additional 4 of 16 patients (25%) responded after the second cycle. The predominant side effect consisted of febrile reactions in almost all of the patients, nearly half of which were defined as cytokine release syndrome (CRS). The majority of CRS was of low grade and easily manageable. Neurotoxicity was seen in 5 patients (19%) during/after the first and in 4 patients (16%) during the second cycle. To date seven patients (26%) are alive and in remission. Their mean survival is of 48 months (10‐104 months). Blinatumomab enabled transition to HSCT in three of the long‐term survivors. One patient with low blast counts at start of blinatumomab is in remission without HSCT.

**Conclusions**: Despite heavy pretreatment of our patients severe adverse events were rare and response rates encouraging (12/27 patients, 44%). A significant proportion of patients responded to the second treatment cycle. Blinatumomab is a promising new agent for front line treatment and is currently under investigation in pediatric randomized controlled clinical trials.

### PO-131. Temporal Trends in Nutritional Status of Children with Acute Lymphoblastic Leukemia During Intensive Phase of Treatment {#pbc27455-sec-3560}

[V. RADHAKRISHNAN]{.ul} ^1^, J. Ramamoorthy^1^, P. Ganesan^1^, S. Tenali^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Patients nutritional status has shown to impact the outcome in acute lymphoblastic leukemia (ALL). The present study was conducted to analyse the trends in change of nutritional status in children with ALL during the intensive phase of treatment.

**Design/Methods**: The study included newly diagnosed patients with ALL less than 18 years of age treated with a uniform risk‐stratified protocol between January 2014‐December 2016. Patients height and weight were collected prospectively at diagnosis and at end of induction, consolidation, interim maintenance, and delayed intensification (before starting maintenance). The WHO weight for age (WA) and body mass index (BMI) reference standards were used to classify the nutritional status and values \< ‐2 standard deviation (SD) and \> 2 SD were considered undernourished and obese respectively.

**Results**: The study included 241 patients with a median age of 7 years and 59% patients were males. Undernutrition, normal nutrition, and obesity was observed in 29%, 69% and 2% of patients at diagnosis and 14%, 77% and 9% at the end of delayed intensification respectively (P\<0.001). Significant weight change in patients was observed during the induction phase of treatment (P=0.02) and not between other phases of treatment. NCI high‐risk category was the only parameter predictive of undernutrition at presentation. Patients whose BMI/WA was \<‐1SD or \>1SD at diagnosis were not at risk of obesity or undernutrition later respectively. Maximum variation in nutritional status occurred in patients with WA/BMI between ‐1SD and 1SD. Changes in BMI/WA by 2SD during induction and 1SD between induction and start of maintenance was significantly associated with inferior event free survival (EFS) (P=0.049 and 0.013 respectively).

**Conclusions**: Weight changes during intensive phase of ALL treatment is associated with inferior EFS and predictor of future obesity. Strategies to optimize nutrition during treatment can help in improving outcomes in patients with ALL treated in developing countries.

### PO-132. Preliminary Experience at a Single Centre in India with a Collaborative Multicentre Risk Stratified and Response Adapted Protocol for Treating Pediatric Acute Lymphoblastic Leukemia {#pbc27455-sec-3570}

[V. RADHAKRISHNAN]{.ul} ^1^, J. Ramamoorthy^1^, P. Ganesan^1^, S. Sundersingh^2^, S. Tenali^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India; ^2^Cancer Institute W.I.A, Pathology, Chennai, India*

**Background/Objectives**: The use of risk and response adapted protocol in developing countries has been hampered by lack of access to cytogenetic and minimal residual disease (MRD) testing. We share our experience with the first pan‐India multi‐centric risk and response adapted protocol for treating pediatric ALL.

**Design/Methods**: The study included newly diagnosed patients with ALL between 1‐18 years of age prospectively enrolled between January 2014‐December 2016. Pre‐B group patients were stratified as Standard Risk (SR), Intermediate Risk (IR) and High Risk (HR) based on NCI criteria, disease bulk, cytogenetics, day 8 prednisolone response and post induction bone‐marrow MRD. T‐cell patients were treated as HR. Event Free Survival (EFS) and Overall Survival (OS) were analysed using Kaplan‐Meier method and log‐rank test was used to compare variables.

**Results**: A total of 245 consecutive patients were eligible for analysis. The median age was 7 years and 60% patients were male. Pre‐B cell phenotype was observed in 191/245 (78%) patients and T‐cell in 55/245 (22%). The baseline and post‐induction risk‐stratification for the pre‐B group was 22% SR, 63% IR, 15% HR and 12% SR, 28% IR and 59% HR respectively. Blast clearance on day 8 was observed in 179/245 (73%) patients. At a median follow‐up of 22 months the overall EFS and OS was 70% and 79% respectively. The EFS and OS for pre‐B SR, IR and HR cohort was 77%, 84%, 67% (P=0.1) and 85%, 94% and 76% (P=0.05) respectively. The EFS and OS for T‐cell 62% and 70% respectively. NCI risk stratification predicted EFS. Day 8 prednisolone response, immunophenotype and MRD did not significantly predict EFS and OS

**Conclusions**: In contrast to data from developed countries majority of patients with ALL in our cohort had high‐risk disease. The survival outcome is comparable to similar results reported from other centres in India and better than our historical cohort.

### PO-133. Clinical Profile of Acute Lymphoblastic Leukemia: Indian Experience {#pbc27455-sec-3580}

[S. Ranjani]{.ul} ^1^, I. Mehdi^1^, R. Cp^2^, P. Mallya^3^, C. Sreenath^4^

*^1^Health Care Global, Department of Paediatric Haematology Oncology and BMT, Bengaluru, India; ^2^Rainbow Children s Hospital, Department of Paediatric Oncology, Bengaluru, India; ^3^Narayana Health, Bengaluru, India; ^4^Bengaluru, India*

**Background/Objectives**: Background: Leukemia constitutes 34% of childhood malignancies and acute lymphoblastic leukemia (ALL) accounts for 25% of pediatric leukemia. More than 10,000 cases have been reported in India annually. The survival rates of children with ALL have increased over the last few years. Worldwide, the 5‐year survival rates in pediatric ALL are 80 -- 90 % but the survival rates in India are still reported at \>70%.

Objectives: To study the clinical, hematological and cytogenetic profile of children with Acute Lymphoblastic Leukemia

**Design/Methods**: Design: Retrospective study from January 2011 to December 2015 at a tertiary center for pediatric oncology in southern India with a sample size of 105 children with ALL.

Methods: All children below 18 years diagnosed with ALL were included. Children with relapse were excluded. Risk stratification was according to UK ALL protocol. The presenting features were recorded from case files. Flowcytometry was used to classify the type of ALL. Bone marrow evaluation and MRD by flowcytometry was done to ascertain remission.

**Results**: They mean age of presentation was 7.96 years. Male preponderance (67.6%) was observed. Majority (37.1%) were between 5‐ 10 years. 38.1% of children presented with splenomegaly while 55.2% presented with Hepatomegaly and 48.6% with lymphadenopathy. The mean HB of our children was 8.3g%. Hyper leukocytosis was observed in 29.5% of children. Karyotyping was done in 77.1% of children. Out of which 49.5% had normal karyotype, 3.8% had hyper diploid and 3.8% had hypo diploid. BCR ABL was positive in 8.4% of children and MLL in 13.1%. The 3‐year disease free survival in our study was 95.1%.

**Conclusions**: As the incidence of childhood leukemia is increasing more data required to understand the clinical profile of children with ALL in developing countries. The importance of cytogenetic in risk classification has to be stressed to help risk adopted therapy.

### PO-134. Risk Stratification, Success Outcomes and Induction Phase Related Morbidity and Mortality of Paediatric Leukemic Patients in the Caribbean {#pbc27455-sec-3590}

[M. Reece‐Mills]{.ul} ^1^, G. Wharfe^2^, A. Martin^2^

*^1^University Hospital of the West Indies, Department of Paediatrics, Kingston, Jamaica; ^2^University Hospital of the West Indies, Department of Hematology, Kingston, Jamaica*

**Background/Objectives**: Current treatment of Acute Lymphoblastic Leukaemia (ALL) has produced survival rates greater than 80% in high‐income countries. These regimens are also associated with mortality and morbidity particularly during induction. Initial risk stratification is generally based on age and white cell count at diagnosis, and the presence or absence of extra‐medullary disease. Due to limited local resources to facilitate cytogenetic studies and evaluation of Minimal Residual Disease for risk stratification, all paediatric patients diagnosed with ALL were treated at UWHI with the augmented arm of the CCG1991 protocol reserved for high‐risk patients. The success of this strategy during induction was evaluated.

**Design/Methods**: Patients were retrospectively risk stratified using the Children\'s Oncology Group (COG) criteria. Induction phase related morbidity / mortality were assessed in association with the use of the high‐risk protocol. The population included paediatric patients between 1 ‐ 10 years diagnosed with ALL treated at UHWI, Jamaica between 2007‐2012.

**Results**: Seven patients were eligible for analysis. Four (57%) were classified as standard risk and three (47%) were high risk. All received combination chemotherapy including 4 doses of doxorubicin. All went into remission post induction. There were no deaths, cases of tumor lysis syndrome or treatment abandonment. Three (47%) had febrile neutropenia while one (14%) had chemotherapy induced hyperglycemia.

**Conclusions**: The augmented arm of the CCG 1991 protocol was able to achieve a post induction remission rate of 100 percent. There was no mortality and low morbidity. Having additional information to properly risk stratify patients would have allowed patients known to be standard risk to be treated with less chemotherapy. This regimen proved tolerable in a low to middle income setting but long‐term effects may be an issue in this population.

### PO-135. Glucocorticoids Exert a Dual Role in B‐Cell Acute Lymphoblastic Leukemia: Apoptosis and Differentiation of Early B‐Cell Populations {#pbc27455-sec-3600}

[J. Sarno]{.ul} ^1^, C. Pedersen^2^, A. Jager^1^, T. Burns^3^, G. Gaipa^4^, G. Nolan^3^, A. Bava^5^, K. Davis^1^

*^1^Bass Center for Childhood Cancer ‐ Stanford University, Pediatrics, Stanford, USA; ^2^Technical University of Denmark, Department of Bio and Health Informatics, Kongens Lyngby, Denmark; ^3^Baxter Laboratory in Stem Cell Biology‐ Stanford University, Department of Microbiology and Immunology, Stanford, USA; ^4^M. Tettamanti Research Center‐ University of Milano Bicocca, Department of Pediatrics, Monza, Italy; ^5^Institut Curie, PSL Research University, Orsay, France*

**Background/Objectives**: Glucocorticoids (GCs) have a crucial role in the treatment of B‐cell acute lymphoblastic leukemia (BCP‐ALL) and the response to glucocorticoids is considered a strong prognostic marker of relapse risk. Despite this, their mechanism of action and resistance are still poorly understood.

**Design/Methods**: Through RNA sequencing analysis on healthy B‐cell developmental populations we identified genes related to the GC pathway to be upregulated together with B‐cell receptor (BCR) signaling genes in the transition from pro‐B cells to pre‐B cells. To better understand the impact of GCs on leukemic B‐cells, we performed ex‐vivo experiments on 20 BCP‐ALL primary cells treated with dexamethasone and then profiled by using high‐dimensional single‐cell mass cytometry. Proteomic data have been also confirmed by evaluating BCR and glucocorticoid receptor (GCR) pathway genes by real‐time PCR

**Results**: Analyzing these BCP‐ALL patients we found that GCR is highly expressed in proB/pre‐BI cells. GC treatment mostly affected cells in S‐phase of cell cycle and pro‐B cells. Interestingly, although we observed GC‐induced cell death, we also identified a phenotypic change of the resistant cells compatible with a more mature B‐cell phenotype and an activated pre‐BCR signaling. This phenotypic change could be reverted by the treatment with the SCR/ABL inhibitor, dasatinib that results also in an increased cell death in combination with dexamethasone. Moreover these cells present also an upregulation of B‐cell genes and transcription factors associated with a more mature B‐cell status.

**Conclusions**: These data suggest a dual role of glucocorticoids on B‐cells: apoptosis, preferentially in cycling cells, as well as a differentiation process of B‐cell from the pro‐B/pre‐BI stage to the pre‐BII/immature‐B stage. Furthermore, when, under the pressure of GCs treatment, these cells are pushed to the next developmental stage, they become more sensitive to the combined treatment with dasatinib, opening new insights for the treatment of glucocorticoid‐poor responder patients

### PO-136. Comparative Study of Inhaled Anesthesia vs Intravenous as a Risk Factor for No Early Remission in Pediatric Patients with Acute Lymphoblastic Leukemia {#pbc27455-sec-3610}

[R. Segura]{.ul} ^1^, S. Sanchez^2^

*^1^membership, Pediatrics Hematology and oncology, GUADALAJARA, Mexico; ^2^hospital civil guadalajara, Anestesiology, Guadalajara, Mexico*

**Background/Objectives**: There were studied inhaled anesthetics vs intravenous that had an effect for no early remission in patients with acute lymphoblastic leukemia (ALL). Comparing the anesthetics used as a predisponent factor for a late remission with minimal residual disease (MRD) at day 14.

**Design/Methods**: Transversal, analytical study, between June 2017 and February 2018, new diagnosis with ALL (ages 1‐10 years), two groups were conformed: inhaled anesthesia vs intravenous. Pediatric Oncology‐hematology service, Hospital Civil Nuevo from Guadalajara, Mexico.

**Results**: Twenty patients, inhaled anesthesia (9), intravenous (11). Twelve gender male (60%) and 8 (40%) female. The average age 5.5 ± 3.6 years, it was found that patients from the inhaled anesthesia group were older with average 7.77 vs 3.72, p=0.023, the weight, was 22.19 ± 15.6 kilograms, p=0.019. Duration of anesthesia 25.36 ± 5.15 minutes, the anesthesia was longer in the inhaled anesthesia group with 28.8 vs 11.9 minutes, p=0.010.Fifteen (75%) patients got into remission at day 14 with MRD, vs 5 (25%) who did not get into remission. The remission was bigger in the intravenous anesthesia group with a median of 0.00 vs 0.001. Eighteen (90%) were lineage B vs 2(10%) lineage T. L1 Blasts were 14(70%), L2 6(30%) y L3 0(0%). White blood cell at diagnosis: \>100,000 4(20%), 50,000 ‐ 99,000 1(5%) and 10,000‐ 49,000 15(75%)

**Conclusions**: There were identified potentials impressionable variables that determine therapeutic difficulties: long time duration of inhaled anesthesia could be a fact to can\'t get into early remission for MRD at day 14, other factors as older age + inhaled anesthesia, overweight or obesity + inhaled anesthesia. With inflated anesthesia not many patients could wet into early remission at day 14 in comparison with intravenous anesthesia, more aleatory studies should be realized to confirm these findings.

### PO-137. Acute Lymphoblastic Leukemia (ALL) Presenting as Severe Osteoporosis {#pbc27455-sec-3620}

P. Ahirwar^1^, S. Sivadasan^1^, K. Mullanfiroze^1^, N. Niraj^1^, [S. Sen]{.ul} ^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India*

**Background/Objectives**: Presentation of Acute Lymphoblastic Leukemia(ALL) with acute bone pain is well known, however it is rare for patients to present with osteoporosis. We present the case of a young boy who presented with severe osteoporosis which was precipitated by his leukemia.

**Design/Methods**: A 6 year old boy presented with severe back pain and difficulty in walking. MRI showed small linear undisplaced fracture along superior margin of L1 vertebral body with a normal blood count. Patient was advised bed rest for 3 weeks.

A repeat x ray after 3 weeks showed multiple compression fractures with severe osteoporotic changes in all the bones. Patient was evaluated with routine blood work up and a DEXA scan. The CBC at this stage showed leukemic blasts which were found to be of B cell origin on further investigation.

**Results**: Patient was bedridden by the severe osteoporosis and induction therapy was started along with bisphosphonates which was repeated after 3 months.

Patient was followed up with PINP(procollagen Intact N‐terminal) levels, a marker for osteoporosis, along with chemotherapy and subsequently became mobile after 3 months of therapy with rise in bone density seen on X‐Rays.

Calcium supplements and vitamin D was given and he did not have any other complications related to ALL which responded well to therapy.

Repeat x rays and PINP levels significantly improved along with clinical improvement.

**Conclusions**: One third of the leukemic patients present bone pain with which at times may be misdiagnosed as rheumatoid or septic arthritis. Steroid induced osteoporosis is at times seen after initiation of ALL therapy but is is almost unknown for the disease to present with severe osteoporosis. Clinicians need to be aware of the diverse presentations of ALL.

### PO-138. Intrathecal Methylprednisolone in CNS‐Directed Triple Therapy of Pediatric ALL {#pbc27455-sec-3630}

[G. Sezgin]{.ul} ^1^, I. Bayram^1^, S. Küpeli^1^, A. Tanyeli^2^

*^1^Cukurova University Medical School, Division of Pediatric Oncology/SCT Unit, Adana, Turkey; ^2^Sisli Memorial Hospital, Division of Pediatric Hematology/Oncology and SCT Unit, İstanbul, Turkey*

**Background/Objectives**: One of the reasons for improved cure rates in pediatric ALL is the central nervous system (CNS) directed‐chemotherapy consisting of intrathecal methotrexate, cytarabine and steroids (dexamethasone, hydrocortisone, prednisolone). Intrathecal methylprednisolone has been shown to be effective in postherpetic neuralgia but not used in CNS directed treatment of leukemia.

**Design/Methods**: A total of 73 patients with acute lymphoblastic leukemia diagnosed in our hospital between January 2008, and November 2015 were included in the study. Patients with ALL were treated BFM‐95 based (BFM TR‐ALL 2000) chemotherapy protocol. Steroid treatment was initiated at a daily doses of 2 mg/kg (60 mg/m^2^ methylprednisolone), and on the 8. day of the treatment the patients were divided into risk groups \[standard (SRG), moderate (MRG), and high (HRG)\] based on their response to methylprednisolone treatment. Patients received intrathecal methylprednisolone (20mg/m²), methotrexate (12mg/m²) and cytarabine (20mg/m²) in the maintenace phase every 8 weeks.

**Results**: There were fifty boys and twenty three girls in the group. Mean age of 73 ALL patients was 79.68± 53.31 months (median 65; range 7‐239 months). Overall survival rates (OS) of patients evaluated using Kaplan‐Meier test at various time points were as follows: 2 year, 77% and 5 year, 62%. Two and five year event‐free survival rates were 73% and 64%, respectively. Relapses deveped in twenty one patients (28.8%). Ten patients (13.7%) had isolated CNS relapse and seven patients (9.6%) had both CNS and systemic relapse. Four patients (5.5%) had systemic relapse. Patients with relapse ALL were in the SRG (n=8, 38.1%), MRG (n=11; 52.4%), and HRG (n=2; 9.5%) risk groups. Patients with CNS involvement 3‐, and 5‐year --survival rates were 42, and 21 %. Patients tolerated intrathecal methylprednisolone well. No complications were seen.

**Conclusions**: Intrathecal Methylprednisolone is well tolerated, no complications were seen and CNS relapse rates correlates with the literature.

### PO-139. Study of Hedgehog‐GLI1 Signal Pathway in the Pathogenesis of T‐ALL in Children {#pbc27455-sec-3640}

[J. Shao]{.ul} ^1^, H. Jiang^1^, H. Li^1^, J. Yang^1^, L. Chen^1^

*^1^Shanghai Children\'s Hospital, Hematology/Oncology, Shanghai, China*

**Background/Objectives**: The occurrence of T‐ALL is due to abnormal changes in the T cell precursor cells. The Hedgehog/GLI signaling pathway plays an important role on tumor development. We aim to study on the role of Hedgehog‐GLI1 signal pathway in the pathogenesis of T‐ALL in children.

**Design/Methods**: We detected the expression of transcription factor GLI1 in bone marrow of newly diagnosed T‐ALL patients and human T‐ALL cell line Jurkat cells. Investigated the change of gene expression after knocking out transcription factor GLI1 in Jurkat cells. Analyzed the differential gene with GEO database.

**Results**: The expression of transcription factor Gli1 was significantly higher in the bone marrow of newly diagnosed T‐ALLthan that in the control group. The expression of transcription factor Gli1 was detected in human T‐ALL cell line Jurkat cells. The transcription factor GLI1 was knock out after lentivirus have been transferred to Jurkat cells. In total 2524 genes with significant difference were obtained by the analysis of the whole gene expression profiles. The intersection analysis was carried out between the 2524 differential gene and the T‐ALL differential gene expression data set (GSE66638) in the GEO database, while the data set included 8 samples of bone marrow cells in children diagnosed with T‐ALL and 2 samples of surgical excised thymocyte cells. The results showed that the common differentially expressed genes included 11 up‐regulated genes and 4 down‐regulated genes. We have analyzed the common differentially expressed genes with reported from the literature. The results showed that the intersections genes included 3 up‐regulated genes and 2 down regulated genes. We detected the 5 intersecting genes in bone marrow samples of 5 children diagnosed with T‐ALL. The expression levels of IL1B and LTBP1mRNA were significantly decreased.

**Conclusions**: The Hedgehog‐Gli1 pathway is activated in T‐ALL. The abnormal increase of transcription factor Gli1 participates in the pathogenesis of T‐ALL

### PO-140. Influnce of Vitamin D Receptor Gene Polymorphism and Plasminogen Activitor Gene Polymorphism on Osteonecrosis During Treatment of Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-3650}

[L. Sherief]{.ul} ^1^, M. Beshiar^1^, E. Abdel Khalek^1^, R. Nermin^2^, K. Elgerby^3^, H. Elsayed^1^

*^1^Zagazig University, Pediatric, Zagazig, Egypt; ^2^Zagazig University, Medical Biochemistry, Zagazig, Egypt; ^3^Zagazig University, radiodiagnosis, Zagazig, Egypt*

**Background/Objectives**: Osteonecrosis (ON) is one of the major complications of childhood acute lymphoblastic leukemia treatment (ALL) and can adversely affect long‐term quality of life.

This study was conducted to assess the frequency of ON after consolidation therapy in children with ALL and to detect whether polymorphisms in vitamin D receptor gene (VDR) and plasminogen activator inhibitor‐1(PAI‐1) gene may affect the risk of osteonecrosis in childhood ALL.

**Design/Methods**: We included 48 children with newly diagnosed ALL (aged 3‐15 years) who were treated with the ST. Jude total XV protocol. They were investigated for serum calcium, phosphorus, magnesium, and alkaline phosphatase in addition to detection of polymorphism in PAI‐1 (rs6092) and vitamin D receptor FOKI gene by restriction fragment length polymorphism, polymerase chain reaction Screening for ON was done at diagnosis and after consolidation therapy by MRI and X‐ray on hip and knee. Cases with ON were classified according to modified Ficat and Alert system for knee ON and ARCO classification system for hip ON.

**Results**: Five of 48 patients (9.6%) developed osteonecrosis after consolidation therapy. All patients were older than 10 years (2 male and 3 female) and had an insufficient level of 25(OH) vitamin D. PAI‐1 polymorphism was associated with ON in 60% of all ON cases. A total of 13.04% GA genotype developed ON compared to 8% of GG genotype group. The genotype frequencies of VDR gene in children with ALL were CT 56.3%, TT4.2%, and CC 39.6%. The frequency of VDR polymorphism in ON cases was 4 patients have CC and one CT genotype.

**Conclusions**: Osteonecrosis can develop early during therapy of ALL. Age older than 10 years and insufficient Vitamin D were detected as important risk factors. Inherited variation in PAT‐1 and VDR may contribute to the risk of ON.

### PO-141. Iron Overload in the Survivors of Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-3660}

[L. Sherief]{.ul} ^1^, M. Beshiar^1^, S. Saleem^2^, E. Abdel khalek^1^, W. El Mozy^2^, A. Fawzy^3^

*^1^Faculty of Medicine‐Zagazig University, Pediatric, Zagazig, Egypt; ^2^Kaser Al Ainy School of Medicine‐Cairo University, Radiology, Cairo, Egypt; ^3^Benha Children Specialized Hospital, Pediatric, Benha, Egypt*

**Background/Objectives**: Childhood acute lymphoblastic leukemia survivors receiving multiple packed red blood transfusion (PRBC) may be at risk of vital organ iron deposition causing serious late effects. This study was undertaken to assess the frequency, anatomical pattern, and severity of iron overload in liver and heart by magnetic resonance imaging (MRI).

**Design/Methods**: This cross‐sectional study was conducted on 60 childhood ALL survivor (aged 6‐18 years) and 30 apparently healthy age and sex‐matching children as a control group. All participants were subjected to history taking, physical assessment, and laboratory investigations including complete blood picture, liver function and kidney function tests, C‐reactive protein, serum ferritin and hepatitis markers in addition to quantification of the iron content of liver and heart by MRI.

**Results**: Twenty‐six (43.3%) of ALL Survivors showed evidence of increased liver iron concentration (LIC) by MRI(T2\*7.2 ±5.2msec), While only 2 (3.3%) children showed moderate cardiac iron overload (T2\* 11.5msec&13 msec). The statistics showed a significantly positive correlation between liver T2\* and serum ferritin, the total volume of blood transfused, the frequency of transfusions and HCV infection. There was no significant correlation between myocardial T2\* values, serum ferritin, and transfusion therapy

**Conclusions**: liver iron overload was detected in children and adolescent after therapy of ALL. The risk of iron overload was related mainly to the transfusion burden during therapy

### PO-142. Prognostic Significance of Absolute Lymphocytic Count Recovery in Pediatric Patients with Acute Lymphoblastic Leukemia at South Egypt Cancer Institute {#pbc27455-sec-3670}

[A. Shibl]{.ul} ^1^, H. sayed^1^, N. gaber^2^, N. alieldin^3^

*^1^South Egypt Cancer Institute‐ Assiut Univeristy, pediatric oncology, Assiut, Egypt; ^2^South Egypt Cancer Institute‐ Assiut Univeristy, clinical pathology, Assiut, Egypt; ^3^National Cancer Institute, cancer epidemiology, cairo, Egypt*

**Background/Objectives**: Leukemia is the most common cause of disease‐related death in childhood despite significant improvement in survival and modern risk stratification. Prognostic significance of absolute lymphocytic count (ALC) recovery was studied in pediatric patients with acute lymphoblastic leukemia (ALL).

**Design/Methods**: one hundreds twenty one patients newly diagnosed as ALL ≤18 years were enrolled. Age, sex, initial total leucocytic count, immunophenotyping, CNS involvement, mediastinal mass, BM response at day fifteen and after finishing induction remission were compared to ALC recovery at day 15(ALC‐15) and day 29(ALC‐29) of induction response. Also, prognostic impact of ALC recovery on event free survival (EFS) and overall survival (OS) was evaluated.

**Results**: ALC didn\'t show any significant relation to known prognostic patients factors. Patients with low ALC didn\'t show significant lower response on day 15 and post induction evaluation from those with high ALC (p= 0.74, 0.6 respectively). ALC‐15 ≥500 cells/uL showed a prognostic significance as patients with ALC‐15 \<500cells/uL had a poorer outcome (4‐ EFS 47.8%±0.12) than patients with ALC‐15 ≥500 cells/uL who carried a better outcome (4‐EFS 66.3%±0.05). In multivariate analysis, ALC‐15\<500 cells/uL still had a poor impact on outcome (OR 2.56, 95% CI 1.27‐ 5.14) with d15‐ BM response (OR 2.99, 95% CI 1.35‐ 6.61) and age \<10 (OR 1.96, 95% CI 1.01‐3.69).

**Conclusions**: ALC‐15 has an independent prognostic impact on outcome together with d15‐ BM response and age. so, It can be used as a simple predictor for the outcome.

### PO-143. Flowcytometric CD135 Expression and its Impact on Pediatric Acute Lymphoblastic Leukemia at South Egypt Cancer Institute {#pbc27455-sec-3680}

[A. Shibl]{.ul} ^1^, A. zahran^2^, H. sayed^1^

*^1^South Egypt Cancer Institute‐ Assiut Univeristy, pediatric oncology, Assiut, Egypt; ^2^South Egypt Cancer Institute‐ Assiut Univeristy, clinical pathology, Assiut, Egypt*

**Background/Objectives**: In acute lymphoblastic leukemia(ALL), rare reports are available studying Fms Like Tyrosine Kinase 3(FLT3) expression and its relation to patient characteristics. Also, there is barely any information about the prognostic significance of FLT3 expression of ALL. We aimed at evaluating flowcytometric FLT3(CD 135)expression in relation to patients clinical and laboratory features and its impact on patients outcome.

**Design/Methods**: A prospective study included 101 newly diagnosed pediatric patients with ALL. CD 135 expression at diagnosis was evaluated in relation to patients clinical and laboratory features and its impact on survival outcomes was followed up.

**Results**: The median CD 135 expression mean fluorescence intensity (MFI) was 14.5. There is no statistical significant difference between high (≥14.5) and low (\< 14.5) CD135 expression in relation to age, sex and CNS involvement (p= 0.4, 0.2& 0.3 respectively). High CD135 was more prevalent in patients with precursor B‐ALL (P=0.01), no mediastinal mass (P=0.008) or lymphomatous features (P=0.05) at presentation. There is no statistical significant relation of CD135 expression with myeloid expression (p=0.5) and DNA index (p=0.35). There was a significant positive correlation between CD135 expression and CD 34 & HLADR expression (r value 0.29& 0.3) (P= 0.004& 0.002) respectively and there is significant negative correlation between CD135 expression and CD1a and CD5 (r‐value = ‐0.4) (p= \<0.001). CD135 expression didn\'t show impact on early response or induction response (p= 0.6). CD135 expression didn\'t show prognostic impact on survival outcomes (overall survival, disease free survival& event free survival (P= 0.17, 0.14 & 0.19 respectively).

**Conclusions**: High CD135 expression is more prevalent in patients with precursor B‐ALL and in patients with favourable initial features but doesn\'t have prognostic impact on survival outcome.

### PO-144. Analysis of Long Term Outcome of Pediatric Acute Lymphoblastic Leukemia at South Egypt Cancer Institute {#pbc27455-sec-3690}

[A. Shibl]{.ul} ^1^, H. sayed^1^, A. ali^1^, O. abdelhamid^1^, D. sayed^2^, A. zahran^2^

*^1^South Egypt Cancer Institute‐ Assiut Univeristy, pediatric oncology, Assiut, Egypt; ^2^South Egypt Cancer Institute‐ Assiut Univeristy, clinical pathology, Assiut, Egypt*

**Background/Objectives**: The survival for children with acute lymphoblastic leukemia (ALL) has shown remarkable improvement in the past decades. We aimed at evaluating prognostic factors and outcome of children with ALL.

**Design/Methods**: retrospective study included two hundreds newly diagnosed children with ALL from January 2009 to January 2017. All patients were treated according to modified total therapy study XIIIB for higher risk ALL adopted from St. Jude Children\'s Research hospital (SJCRH). Outcome and prognostic factors were analyzed.

**Results**: patients with favorable age (\<10y) occurred in 75%. Unfavourable intial total leucocytic count ≥50x109/L encountered in 31% (52.3% of them had hyperleukocytosis). B‐ALL represented 82.5%.Central nervous system (CNS) involvement occurred in 4.5%. According to NCI/ Rome criteria for risk classification, high risk patients represented 47% (80% of T‐ALL, 40% of B‐ALL). Induction remission occurred in 92.5%. Slow early response (SER) occurred in 12.7% (10% of them didn\'t achieve induction remission while 1.5% for those with rapid ER). 7‐ year overall survival, disease free survival and event free survival were 77±3%, 70±4% and 66±3% respectively. Adverse events included 9 (4.5%) induction deaths, 6(3%) refractory leukemia, 43(23.2%) ALL relapses, 2ry AML occurred in one patient, 8(4.3%) patients died in continuous complete remission and 16 deaths after relapse due to disease progression. By multivariate analysis, we found that unfavourable age group ≥ 10 years; hyperleukocytosis and patients with SER were associated with unfavourable impact on outcome. T‐ALL and high risk group were poor prognostic factors onlyin univariate analysis while CNS leukemia and sex hadn\'t prognostic significance. There was statistical significant difference between standard and high risk for B‐ALL but not for T‐ALL.

**Conclusions**: survival of patients with ALL has improved at our institute than previous but still lower than that in developed countries. so, More risk stratification should be used to intensify treatment for higher risk patients.

### PO-145. PEG‐Asparaginase Related Hypersensitivity Reactions in Children with Acute Lymphoblastic Leukaemia {#pbc27455-sec-3700}

[A. Sills]{.ul} ^1^, S. Kelliher^2^, L. Storey^3^, A. Malone^1^, A. O Marcaigh^4^, O. Smith^1^

*^1^University College Dublin Ireland School of Medicine‐ Our Lady\'s Children\'s Hospital Dublin, Haematology, Dublin, Ireland; ^2^University College Dublin, School of Medicine, Dublin, Ireland; ^3^Our Lady\'s Children\'s Hospital‐ Dublin, Haematology, Dublin, Ireland; ^4^Royal College of Surgeons‐ Dublin‐ Our Lady\'s Children\'s Hospital Dublin, Haematology, Dublin, Ireland*

**Background/Objectives**: Intravenous (IV) PEG‐asparaginase has been proven to be similarly efficacious to intramuscular native Ecoli L‐asparaginase without long term increased toxicity. With the increased frequency of its use, adverse reactions to IV PEG asparaginase such as hypersensitivity and its associated asparaginase inactivation are being reported.

**Design/Methods**: A retrospective patient chart review was performed to ascertain the spectrum of IV PEG‐asparaginase hypersensitivity reactions that occurred in our cohort of patients with B‐cell precursor acute lymphoblastic leukaemia (ALL).

**Results**: There were 15 events of IV PEG‐asparaginase related hypersensitivity in 13 patients. In total 30% of all patients receiving IV PEG‐asparaginase during our study period had a reaction. Seventy‐three per cent of reactions occurred during the consolidation phase of treatment. Nine (69%) patients had grade 2 reactions, two patients and grade 1 and 3 reactions respectively (15%,15%). Seven patients (47%) required treatment with corticosteroids in the initial period. Eleven patients received Erwinia asparaginase as an alternative in subsequent cycles of therapy and tolerated it well.

**Conclusions**: Asparaginase has long been established as an integral drug in paediatric ALL. With its efficacy, however, comes not insignificant toxicity that includes the development of hypersensitivity ‐ its causation believed to be multifactorial.

### PO-146. NK Cells and T Cells as Possible Prognostic Factors in Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-3710}

[G. Sobol‐Milejska]{.ul} ^1^, A. Mizia‐Malarz^1^

*^1^Medical University of Silesia‐ Upper Silesia Children\'s Care Heatlh Centre, Department of Pediatric Oncology‐ Haematology and Chemotherapy, Katowice, Poland*

**Background/Objectives**: T cells (T lymphocytes) and NK (natural killer) cells are the immune system components. Their deficiency or impaired function might result in the development of serious infections and promote the development of malignancies, including acute lymphoblastic leukaemia (ALL). The purpose of our research was to assess the prognostic role of NK+T cell percentage in bone marrow evaluated on the day of ALL diagnosis.

**Design/Methods**: Procedure: 84 children (49 males = 58%; mean age 5 yrs) newly diagnosed with ALL were enrolled. The NK+T percentage was assessed using flow cytometry. The patients were divided into two subsets: group l (NK+T (+ve)) ‐ patients with NK and T cells detected in bone marrow n=75 (89%) and group ll (NK+T (‐ve)) ‐ patients with NK and T cells undetectable in the bone marrow n=9 (11%). 71 patients (84.5%) survived, whereas 13 patients (15.5%), including all 9 from the NK+T(‐ve) subset, died.

**Results**: In patients with NK and T cells detected in bone marrow upon diagnosis, a prednisone good response was observed significantly more often on day 8. of treatment (*p* = 0.01). Similarly, the remission on day 15. of treatment was observed significantly more often in this group (*p* =0.03). The analysis demonstrated significantly better survival in children from the NK+T(+ve) subset as compared to those from the NK+T(‐ve) subset (*p* = 0.02) (HR 2.59; 95%CI: 1.38 ‐ 4.85).

**Conclusions**: The presence of NK and T cells in bone marrow at diagnosis can be an independent prognostic factor in children with acute lymphoblastic leukemia.

### PO-147. Aberrant RNA Expression and Splicing in Childhood ETV6/RUNX1 Acute Lymphoblastic Leukemia {#pbc27455-sec-3720}

[C. Sun]{.ul} ^1^, T. Zhang^2^, L. Chang^3^, F. Liu^4^, L. Zhang^4^, C. Liu^4^, X. Chen^4^, Y. Lan^4^, Y. Cai^4^, Y. Zhang^4^, B. Sun^4^, X. Zhu^4^

*^1^State Key Laboratory of Experimental Hematology‐ Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences‐ and Peking Union Medical College, Center for Pediatric Blood Disease‐, Ti, China; ^2^Key Laboratory of Genomic and Precision Medicine‐ Collaborative Innovation Center of Genetics and Development‐ CAS Center for Excellence in Molecular Cell Science‐ Beijing Institute of Genomics‐ Chinese Academy of Sciences, Key Laboratory of Genomic and Precision Medicine, Beijing, China; ^3^Center for Pediatric Blood Disease‐ State Key Laboratory of Experimental Hematology‐ Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences‐ and Peking Union Medical College, Center for Pediatric Blood Disease‐ State Key Laboratory of Experimental Hematology‐ Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences‐ and Peking Union Medical College, Tianjin, China; ^4^Center for Pediatric Blood Disease‐ State Key Laboratory of Experimental Hematology‐ Institute of Hematology and Blood Diseases Hospital‐ Chinese Academy of Medical Sciences‐ and Peking Union Medical College, Center for Pediatric Blood Disease, Tianjin, China*

**Background/Objectives**: ETV6/RUNX1(E/R) ‐positive acute lymphoblastic leukemia (ALL), as one of the most common childhood malignancies, its pathogenesis and mechanism remain to be elucidated comprehensively.

**Design/Methods**: In this study, we investigated the whole bone marrow transcriptional profiles of E/R‐positive ALL patients and compared them with the transcriptional profiles of healthy control children. Bioinformatic and statistical methods, including differential expression analysis, lncRNA analysis, alternative splicing analysis and metabolic network analysis were used.

**Results**: We found thousands of differentially expressed genes (DEGs) between ALL patients and normal controls. The functional enrichment analysis indicated that cell proliferation, cell division and cell cycle especially associated with G1/S and G2/M transition were significantly enriched in up‐regulated genes, while inflammatory response, immune response, defense response for down‐regulated genes. In addition, we identified 606 novel lncRNAs with functions related to regulation of immune cell proliferation, differentiation and apoptosis in ALL samples. Furthermore, the splicing analysis indicated 2926 exon skipping events in E/R‐positive ALL samples and many genes among them were potential associated with ALL.

**Conclusions**: Thus, our results characterized the whole transcriptome changes of childhood E/R‐positive ALL patients and elucidated the gene expression, signaling pathways, novel lncRNA transcripts and RNA splicing alterations that may play important roles in the pathogenesis of ALL.

### PO-148. Acute Lymphoblastic Leukemia: 20 Years\' Experience {#pbc27455-sec-3730}

E. Sunamak^1^, N. Özdemir^2^, A. Koka^1^, G. Dikme^3^, H. Kızılocak^3^, B. Koç^3^, H. Apak^3^, A. Özkan^3^, L. Yüksel^3^, İ. Yıldız^3^, [T. Celkan]{.ul} ^3^

*^1^Cerrahpaşa Faculty of Medicine, Pediatrics, İstanbul, Turkey; ^2^Kanuni Sultan Süleyman Training and Research Hospital, Pediatric Hematology‐Oncology, İstanbul, Turkey; ^3^Cerrahpaşa Faculty of Medicine, Pediatric Hematology‐Oncology, İstanbul, Turkey*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common malignancy of children. Today, the patients' chance of survival without sequela is high. We aimed to determine the characteristics of our patients with ALL.

**Design/Methods**: We investigated files of 421 patients with ALL. One hundred and seventeen patients didn\'t meet the inclusion criteria. Remaining 304 newly diagnosed patients treated by BFM (Berlin‐Frankfurt‐Münster) protocols between 1995‐2015 are included in the analysis. The patients are divided into two groups as diagnosed in the first and the second 10 years.

**Results**: Mean age was 6.55 ± 3.97 years; 54.3% of the patients were aged between 1‐5 years, 59.2% were male. The most common complaint was weakness. Hepatomegaly, splenomegaly, lymphadenopathy were observed in 47.5%, 39.6%, 24.1% of the cases, respectively. On admission, median leukocyte count was 10,600/mm3. Common B, T cell, pre B, pro B and undifferentiated ALL were 74.8%, 17.7%, 5.4%, 1.7% and 0.3% of the patients, respectively. At diagnosis, 23 patients had traumatic lumbar puncture and 58 had extramedullary involvement. Involvement of CNS (central nervous system) increased from 5.2% to 11.4%. Translocation t(12;21), t(9;22), t(4;11), hypodiploidy and hyperdiploidy were in 12.6%, 3.9%, 0.9%, 41.7% and 16.7% of the cases, respectively. The patients were in standard (22.7%), medium (59.9%) and high (17.4%) risk groups. Relapse rate was 12.8%. Five year EFS (event‐free survival) of standard, medium, high risk patients were 92.5% ± 6.3, 83.2% ± 5.5, 48.7% ± 14.7 and OS (overall survival) were 92.7% ± 6.0, 87.9% ± 4.7, 54.7% ± 13.3, respectively. For the cohort 5 year OS and EFS were 83.2% ± 4.1 and 79.9% ± 4.7, respectively.

**Conclusions**: The 5‐year EFS and OS of our patients were satisfactory compared to other studies. Decreasing death rates and CNS relapses are promising.

### PO-149. Acute Complications Encountered in Children with ALL Treated by BFM Protocols {#pbc27455-sec-3740}

[E. Sunamak]{.ul} ^1^, N. Özdemir^2^, A. Koka^1^, G. Dikme^3^, H. Kızılocak^3^, B. Koç^3^, H. Apak^3^, A. Özkan^3^, L. Yüksel^3^, İ. Yıldız^3^, T. Celkan^3^

*^1^Cerrahpaşa Faculty of Medicine, Pediatrics, İstanbul, Turkey; ^2^Kanuni Sultan Süleyman Training and Research Hospital, Pediatric Hematology‐Oncology, İstanbul, Turkey; ^3^Cerrahpaşa Faculty of Medicine, Pediatric Hematology‐Oncology, İstanbul, Turkey*

**Background/Objectives**: Five‐year survival of children with ALL is over 90%. Complications seen during and after the treatment have increased. The aim of this study was to report the results of a single‐centre using BFM (Berlin‐Frankfurt‐Münster) protocols.

**Design/Methods**: Between 1995‐2015, 304 patients treated by BFM protocols at our hospital were included in statistical analysis. The patients were divided into 2 groups as diagnosed in the first and the second 10 years.

**Results**: Early complications were tumor lysis syndrome in 1.6%, hypercalcemia in 2.0%, central airway compression syndrome in 1.0%, superior vena cava syndrome in 0.3%, thrombosis in 0.3%, bleeding in 3.0%, central nervous system leukemia in 8.3%, isolated facial nerve palsy in 0.7%, brain mass and optic nerve involvement in 0.3% of the cases. On‐therapy complications were thrombosis in 4.6%, bleeding in 8.9%, central venous catheter complications in 14.6%, intussusception in 0.7%, acute appendicitis and postoperative ileus in 0.3%, paralytic ileus in 0.7%, severe oral mucositis in 22.4%, esophagitis‐gastritis in 17.1%, typhlitis in 3.0%, grade 3‐4 hepatic toxicity in 71.6%, venoocclusive disease in 1.3%, pancreatitis in 2.0%, brain abscess in 0.3%, seizures in 13.5%, spinal cord lipoma in 0.3%, epidural hematoma in 0.3%, acute flaccid paralysis in 0.3%, osteonecrosis in 2.0%, hyperthyroidism in 0.3%, hyperglycemia in 19.1% and hypoglycemia in 2.3% of the cases. Death rates for all patients, the first 10 years and the second 10 years were 17.1%, 18.7% and 15.4%, respectively.

**Conclusions**: Despite rises in rate of the high risk patients and treatment intensity, decline in complications encountered were satisfactory. Except for hypoglycemia, which was more frequent in patients younger than 6 years, all treatment complications were more often in patients older than 10 years.

### PO-150. Coexistence of PRES and SIADH in Children with ALL {#pbc27455-sec-3750}

[E. Sunamak]{.ul} ^1^, G. Dikme^2^, B. Koç^2^, H. Kızılocak^2^, N. Özdemir^3^, İ. Adaletli^4^, S. Kuruğoğlu^4^, T. Celkan^2^

*^1^Cerrahpasa Faculty of Medicine, Pediatrics, İstanbul, Turkey; ^2^Cerrahpasa Faculty of Medicine, Pediatric Hematology and Oncology, İstanbul, Turkey; ^3^Kanuni Sultan Süleyman Training and Research Hospital, Pediatric Hematology and Oncology, İstanbul, Turkey; ^4^Cerrahpasa Faculty of Medicine, Radiology, İstanbul, Turkey*

**Background/Objectives**: The incidence of posterior reversible encephalopathy syndrome (PRES) in children with acute lymphoblastic leukemia (ALL) has been reported as 1.6‐4.5%. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a known complication of chemotherapeutics. The aim of this study was to detect incidences of PRES, SIADH and emphasize rarely reported co‐occurrence of these two syndromes in our patients with ALL.

**Design/Methods**: Files of 308 patients treated by BFM protocols between 1995‐2015 at our hospital analyzed retrospectively to determine the characteristics of PRES, SIADH and their coexistence. All patients had a new diagnosis of ALL.

**Results**: Fourteen (4.5%, n: 308) patients had a diagnosis of PRES. Of these patients, 8 were male, 10 were between 6‐12 years old age, 11 had a diagnosis of B‐cell ALL, 12 were classified into medium risk group. Ten patients were diagnosed on protocol 1 phase of the treatment. Recurrence of PRES was observed in 2 patients. Two patients had epilepsy sequela. Six (1.9%, n: 308) patients had a diagnosis of SIADH. Of these patients, 3 were male, 3 were between 6‐12 years old age, 3 had a diagnosis of B‐cell ALL. All of them were classified into medium risk group. Two patients had central nervous system ALL involvement. Four patients were diagnosed on protocol 1 phase of the treatment. Serum sodium concentrations of the patients were between 110‐126 mEq/L. Four patients had seizures during hyponatremia. Two patients are treated in the intensive care unit. All of the patients underwent fluid restriction treatment. Four of the patients with SIADH also had a diagnosis of PRES.

**Conclusions**: We wanted to emphasize that a diagnosis of PRES can be added to the clinical situation in patients with SIADH during the treatment of ALL in children.

### PO-151. Long‐Term Outcomes of Modified SJCRH Total Therapy XIIIB and XV Protocols for Thai Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-3760}

[P. Surapolchai]{.ul} ^1^, U. Anurathapan^2^, A. Sermcheep^2^, S. Pakakasama^2^, N. Sirachainan^2^, D. Songdej^2^, A. Chuansumrit^2^, S. Hongeng^2^

*^1^Faculty of Medicine‐ Thammasat University, Department of Pediatrics, Pathumthani, Thailand; ^2^Faculty of Medicine‐ Ramathibodi Hospital‐ Mahidol University, Department of Pediatrics, Bangkok, Thailand*

**Background/Objectives**: We aimed to study the long‐term outcomes and prognostic features of Thai children with acute lymphoblastic leukemia (ALL) treated with modified St Jude Children\'s Research Hospital (SJCRH) Total therapy IIIB and XV protocols.

**Design/Methods**: This retrospective cohort study included the patients with newly diagnosed ALL. From 1997 to 2003, this former group was treated with the modified Total XIIIB protocol; "previous protocol". From 2004 to 2014, this latter group was treated with the modified Total XV protocol; "current protocol".

**Results**: Two hundred and fifty‐three patients; 145 males and 108 females, were included in the study. The mean age at diagnosis was 5.9 years (range; 0.5 to 15). The event‐free survival (EFS) rates of the previous protocol (n=94) were 83.7±3.8, 82.6±4.0 and 82.6±4.0% and the EFS rates of the current protocol (n=159) were 87.4±2.7, 84.2±3.2 and 84.2±3.2% at 5, 10 and 15 years, respectively. The overall survival (OS) rates of the previous protocol were 90.2±3.1, 85.7±3.7 and 85.7±3.7% and the OS rates of the current protocol were 90.1±2.4, 87.1±3.2 and 83.8±4.4% at 5, 10 and 15 years, respectively. The relapse rate of the previous protocol was 11.7% (11 patients); 8 isolated hematologic relapses (8.5%) and 3 isolated or combined CNS relapses (3.2%). The relapse rate of the current protocol was 9.4% (15 patients); 7 isolated hematologic relapses (4.4%), 6 isolated or combined CNS relapses (3.8%) and 2 extramedullary relapses (1.2%). Age at diagnosis \>10 years conferred inferior EFS rate of patients in the previous protocol. MRD positivity was not shown to be a prognostic factor for the survival since the treatments were modified depending on the levels of MRD.

**Conclusions**: We demonstrated the favorable outcomes of childhood ALL in Thailand by using adopted protocols from SJCRH. These might be due to the multidisciplinary supportive care team and parent advocacy regarding pediatric cancer treatments.

### PO-152. Outcome of Childhood Acute Lymphoblastic Leukaemia in a Resource Poor Country: A Comparative Study {#pbc27455-sec-3770}

[L.G. Tagoe]{.ul} ^1^, L.A. Renner^1,2^, C.I. Segbefia^1,2^

*^1^Korle‐bu Teaching Hospital, Child Health, Accra, Ghana; ^2^School of Medicine and Dentistry‐ University of Ghana, Child Health, Accra, Ghana*

**Background/Objectives**: Treatment outcomes in childhood acute lymphoblastic leukaemia (ALL) remain sub‐optimal in developing countries. In Ghana, the Paediatric Oncology Unit at Korle Bu Teaching Hospital (KBTH), Accra serves as the major referral centre. In 2010, a twinning programme was established with the Royal Hospital for Sick Children, Edinburgh. Objectives included awareness creation and funding to subsidize treatment costs. The present study determined the outcomes of childhood ALL in KBTH over the successive 5‐year period (2011‐2015) since inception of the twinning programme.

**Design/Methods**: Retrospective review of patient records (age \<13 years) with confirmed ALL from 1 January 2011 to 31 December 2015, compared with previously published data from the same Unit (2006‐2010; Segbefia et al, 2014)

**Results**: Between 2011 and 2015, there were 109 cases of ALL. Of these, 8 cases of Burkitt Leukaemia and 36 inactive clinic patients with incomplete data were excluded. Data analysis was performed for 65 patients. Majority (88%) were between 1 and 9 years, 69% were male and 35 (54%) were classified as high‐risk (NCI/ Rome criteria). Out of 65 patients, 14 (22%) did not complete induction, mainly from treatment abandonment (9/14; 64%). Induction‐related mortality was 3%, compared to 18% in previous study. Of the 51 who completed induction, 34 (67%) had post‐induction events, mainly abandonment of therapy (16/34; 47%), relapse (9/34; 26%) and induction failure (6/34; 18%). In previous study, post‐induction abandonment, relapse and induction failure were 45%, 30% and 15%, respectively. Overall, 27/65 (42%) abandoned treatment, as a primary event or following relapse, similar to previous (50%). Only 22/65 (34%) are alive and in continuing remission as at last follow‐up: median 48.5 months (range: 13‐79 months) vs. 29% from previous study (p=0.65).

**Conclusions**: Abandonment rates remain high in childhood ALL at KBTH despite the twinning programme. Efforts must be directed towards identifying and addressing causes of abandonment.

### PO-153. Melatonin Inhibits MLL‐Rearranged Leukemia Via RBFOX3/HTERT and NF‐ΚB/COX‐2 Signaling Pathways {#pbc27455-sec-3780}

[Y.L. Tang]{.ul} ^1^, L.B. Huang^1^

*^1^The First Affiliated Hospital‐ Sun Yat‐sen University, Department of Pediatrics, Guangzhou, China*

**Background/Objectives**: MLL‐rearranged leukemia is an aggressive malignancy associated with poor outcome, which is refractory to conventional treatment. Melatonin has been proven to exert anti‐tumor activity, but the effect of melatonin on MLL‐r leukemia and the underlying mechanism remain poorly understood.

**Design/Methods**: Firstly, the cell viability was determined by the CCK‐8 assay and the apoptosis was examined by a FACS analysis. Secondly, qRT‐PCR and Western blot were used to examine the expression of RBFOX3, hTERT, NF‐κB and COX‐2. Furthermore, streptavidin‐agarose pulldown assays and ChIP assay were used to test the RBFOX3 binding to hTERT promoter and NF‐κB p65 subunit binding to COX‐2 promoter. Moreover, We investigated the effect of melatonin on the growth in a MLL‐r ALL xenograft mouse model.

**Results**: In this study, we showed that melatonin inhibited cell proliferation and induced apoptosis by activating the caspase‐ dependent apoptotic pathway in MLL‐r leukemia cells. Mechanistic investigations revealed that melatonin suppressed the expression of hTERT by abrogating the binding activity of RBFOX3 to the hTERT promoter. Melatonin also blocked NF‐κB nuclear translocation and suppressed NF‐κB binding to the COX‐2 promoter, thereby suppressing the expression of COX‐2. In addition, clinical samples revealed that melatonin exerts anti‐leukemic activity in primary MLL‐r leukemia blasts ex vivo. In vivo, the mice treated with melatonin experienced a larger reduction in leukemic burden than the control group in a MLL‐r leukemia xenograft mouse model.

**Conclusions**: These results suggested that melatonin inhibited MLL‐rearranged leukemia through suppressing the RBFOX3/hTERT and NF‐κB/COX‐2 signaling pathways. Our findings provide new insights into the role of melatonin for MLL‐r leukemia treatment.

### PO-154. Detection of Bacteria, Fungi, and Viruses by a Real‐Time PCR Assay using Universal Primers and Probes from Blood in Patients with Febrile Neutropenia {#pbc27455-sec-3790}

[H. Teranishi]{.ul} ^1^, W. Shoko^1^, K. Mina^1^, O. Sahoko^1^, K. Atsushi^1^, S. Aki^1^, K. Eisuke^1^, T. Yuuhei^1^, M. Ippei^1^, O. Tomohiro^1^, O. Naoki^1^, O. Kazunobu^1^

*^1^Kawasaki Medical School, Department of Pediatrics, Okayama, Japan*

**Background/Objectives**: Febrile neutropenia episodes (FNEs) are one of the most common adverse event by chemotherapy. When fever occurs in neutropenia patients, they are more likely to develop a serious infectious disease with various microbes. We administer empirical antibiotic therapy for FN patients, after we undertook blood culture. However, the sensitivity of blood culture remains low, and also it takes time to identify causative microorganism. We set up the microbes detecting system by the real‐time PCR method that we can detect bacteria, fungi, and viruses from a blood sample in a short time.

**Design/Methods**: During June 2012 to March 2015, 97 blood culture samples from patients with FNEs were examined for the presence of bacteria and fungi based on 16S rRNA gene and 18S rRNA combined with real‐time PCR amplification and sequencing. Furthermore, we used a real‐time PCR assay for the detection of HSV‐1,2, VZV, EBV, CMV and HHV‐6,7, BKV, B19.

**Results**: Of these samples, bacteria were identified in 20 of 97 FNEs (20.6%) by a real‐time PCR assay and in 10 of 97 (10.3%) by blood culture. In 6 blood culture‐positive samples, real‐time PCR assay detected the same type of bacteria. No fungus was detected both real‐time PCR assay and blood culture. Viruses were identified in 16 of 97 FNE (16.5%). Blood culture took 33 hours 59 min to identify causative bacteria, but the real‐time PCR assay was 8 hours.

**Conclusions**: We conclude a real‐time PCR assay could be given higher microbe\'s detection rate, and need shorter turnaround time, and smaller blood sample than blood culture. We may choose early optimal antibiotics to patients with FNEs by a real‐time PCR assay.

### PO-155. Hematopoietic Cell Transplantation with Unified Conditioning Based on Minimal Residual Disease for Intermediate‐Risk Relapse of Childhood Acute Lymphoblastic Leukemia: Results from the JPLSG R08‐II Study {#pbc27455-sec-3800}

[H. Ueki]{.ul} ^1,2^, C. Ogawa^2^, H. Toyoda^2^, M. Nishi^2^, J. Yamanaka^2^, S. Mochizuki^2^, T. Nishikawa^2^, K. Sakaguchi^2^, S. Kobayashi^2^, A. Arakawa^2^, R. Nishiuchi^2^, S. Yoshida^2^, K. Nakamura^2^, S. Yamamoto^2^, T. Kumamoto^2^, A. Kikuta^2^, T. Hori^3^, A.M. Saito^4^, T. Watanabe^5^, H. Goto^2^

*^1^Japanese Red Cross Narita Hospital, Department of Pediatric Hematlology/Oncology, Narita, Japan; ^2^Japan Children\'s Cancer Group, Relapsed ALL Committee, Nagoya, Japan; ^3^Aichi Medical University School of Medicine, Department of Pediatrics, Nagakute, Japan; ^4^Nagoya Medical Center, Clinical Research Center, Nagoya, Japan; ^5^Aichi Gakuin University, Department of Nutritional Science‐ Faculty of Psycological and Physical Science, Nisshin, Japan*

**Background/Objectives**: In children with intermediate‐risk relapsed acute lymphoblastic leukemia (ALL), the efficacy of allo‐hematopoietic cell transplantation (HCT) as per the minimal residual disease (MRD) has been recognized. We hypothesized that HCT conditioned by etoposide‐intensified regimen would enhance the survival of MRD‐positive children after reinduction.

**Design/Methods**: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) R08‐II study comprised 81 patients at intermediate risk of the first relapsed ALL. The therapy was based on the Acute Lymphoblastic Leukemia--Relapse Study of the Berlin‐Frankfurt‐Münster Group (ALL‐REZ BFM) 95. Patients with MRD ≥ 10e‐3 at the end of the induction (n = 31) were assigned to the transplantation arm. The conditioning regimen comprised total body irradiation (TBI; 12 Gy), etoposide (ETP; 60 mg/kg for patients \<30 kg or 1,800 mg/m² for patients ≥30 kg; maximum dose, 3,000 mg/day), and cyclophosphamide (CY; 60 mg/kg, 2 days) for all patients.

**Results**: In all, 22 patients, including 20 with MRD ≥ 10e‐3 and 2 with unevaluable MRD assigned to the HCT arm at a physician\'s discretion, were transplanted. Unrelated bone marrow and unrelated cord blood were used in 14 and 8 patients, respectively. Engraftment was confirmed in all the patients, and acute and chronic graft‐versus‐host disease were observed in 17 and 7 patients, respectively. Thrombotic microangiopathy, sinusoidal obstruction syndrome, and post‐HCT lung disease were reported in 1, 0, and 0 patients, respectively. Grade 4 allergy and grade 3 mucositis were observed in 1 and 1 patients, respectively. Notably, neither other grade 4 nonhematological toxicity nor transplantation‐related mortality were observed. Three patients developed ALL relapse and died eventually. The 3‐year event‐free survival and overall survival post‐transplantation were 86.4% ± 7.3% and 95.5% ± 4.4%, respectively.

**Conclusions**: Allo‐HCT with the ETP+CY+TBI regimen was feasible and effective for patients with an unsatisfactory reduction of MRD in the JPLSG R08‐II cohort.

### PO-156. Effect of a New Immunomodulator Composed of Muramyl Dipeptide and Anti‐CD10 Monoclonal Antibody on Activation of Memory T Lymphocytes In Vitro and In Vivo {#pbc27455-sec-3810}

[L. Wang]{.ul} ^1^, L. sun^1^

*^1^the affiliated hospital of Qingdao University, pediatrics hematology, Qingdao, China*

**Background/Objectives**: Memory T lymphocytes have the capacity of long‐term self‐renewal and survival in comparison with effector T lymphocytes. We aimed to explore the effect of a new immunomodulatory (MDP‐Ab), composing muramyl dipeptide (MDP) and anti‐CD10 monoclonal antibody (Mab), which was intended for the treatment of leukemia by activating the specific memory T lymphocytes.

**Design/Methods**: PBMC were isolated and cultured with indicated reagent, respectively. The supernatants were collected to measure IFN‐γ level at the time points of 0, 12, 24, 48 and 72 hours. The expressions of CD3, CD4, CD45RA, CD69 and IFN‐γ level were analyzed. The xenograft with leukemia mouse model was established to study whether MDP‐Ab could target with tumor cells and MDP‐Ab could stimulate the immune cells activation.

**Results**: The cells in MDP‐Ab group and BCG group showed aggregation after 24 hours. As the time went on, the number of cell clusters increased, which was the most obvious in BCG group. The levels of IFN‐γ in MDP‐Ab group and BCG group were significantly higher than those in control group at the indicated time point. After 48 hours, the percentage of CD3+CD4+CD45RA‐IFN‐γ+ cells and CD3+CD4+CD45RA‐CD69+ cells in MDP‐Ab group and BCG group were higher, compared to the control group. The xenograft with leukemia mouse model was established to show that MDP‐Ab could target with the tumor cells, especially most obviously 6 hours after injection. The tumor growth curve showed that the tumor growth in MDP‐Ab group was lower than PBS group. Through flow cytometry, CD4+CD8+ and CD4+CD8‐ cell increased in MDP‐Ab group, and IFN‐γ level was also higher.

**Conclusions**: MDP‐Ab can induce CD69 expression on CD4+CD45RA‐T lymphocyte, and stimulate the secretion of IFN‐γ. It is indicated that MDP‐Ab can induce specific memory T lymphocyte activation in vitro and in vivo, which provides further theoretical support for application of the MDP‐Ab in leukemia immunotherapy.

### PO-157. Association of Allele Specific Methylation of ASNS Gene with Prognostic Significance of Chromosomal Abnormalities in Childhood BCP‐ALL {#pbc27455-sec-3820}

[A. Watanabe]{.ul} ^1^, K. Miyake^2^, J. Nordlund^3^, L. Van Der Weyden^4^, H. Hiroaki^5^, K. Urayama^6^, N. Kiyokawa^7^, O. Akira^8^, K. Shunsuke^9^, K. Yasuo^9^, T. Junko^9^, G. Hiroaki^10^, K. Sakaguchi^11^, S. Iwamoto^12^, M. Masayoshi^13^, S. Tamao^1^, K. Akahane^1^, K. Goi^1^, K. Sugita^1^, T. Inukai^1^

*^1^University of Yamanashi, Department of Pediatrics, Yamanashi, Japan; ^2^University of Yamanashi, Department of Health Sciences, Yamanashi, Japan; ^3^Uppsala University, Department of Medical Sciences‐ Molecular Medicine and Science for Life Laboratories, Uppsala, Sweden; ^4^Wellcome Trust Sanger Institute, Experimental Cancer Genetics‐ Wellcome Trust Genome Campus, Cambridge, United Kingdom; ^5^Hiroshima university, Department of Disease Model‐ Research Institute of Radiation Biology and Medicine, Hiroshima, Japan; ^6^National Research Institute for Child Health and Development, Department of Social Medicine, Tokyo, Japan; ^7^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^8^Toho University School of Medicine, Department of Pediatrics, Tokyo, Japan; ^9^Tokyo University, Department of Pediatrics, Tokyo, Japan; ^10^Kanagawa Children\'s Medical Center, Hematology/Oncology and Regenerative Medicine, Kanagawa, Japan; ^11^Hamamatsu University School of Medicine, Department of Pediatrics, Shizuoka, Japan; ^12^Department of Pediatrics, Mie University, Mie, Japan; ^13^Japanese Red Cross, Fukushima Blood Center, Fukushima, Japan*

**Background/Objectives**: Karyotype is an important risk factor for treatment stratification in the current chemotherapy of childhood BCP‐ALL. Asparaginase is one of the most important components for chemotherapy in BCP‐ALL. ALL cells are unable to synthesize adequate amounts of asparagine, while normal hematopoietic cells can produce asparagine by asparagine synthetase (ASNS). Since *ASNS* gene has a CpG island, we comprehensively investigated an association of *ASNS* gene methylation with asparaginase sensitivity and karyotypes in childhood BCP‐ALL.

**Design/Methods**: *ASNS* gene methylation in 83 cell lines and 41 primary samples of BCP‐ALL as well as normal hematopoietic cells and *Asns* gene methylation in mice leukemia samples were quantified by NGS analysis of bisulfite PCR. IC50 of l‐asparaginase (l‐asp) and level of *ASNS* gene expression were determined using alamar blue assay and real time RT‐PCR, respectively. Association between karyotype and *ASNS* gene methylation was analyzed in 663 NOPHO (GSE49031), 206 CCCS (GSE56599), and 93 TCCSG samples.

**Results**: *ASNS* gene in BCP ALL cell lines was frequently methylated in an allele specific manner, while it was almost unmethylated in normal hematopoietic cells. *ASNS* gene methylation status was significantly associated with *ASNS* gene expression level and l‐asp sensitivity in BCP‐ALL cell lines and primary samples at diagnosis but not in primary samples at relapse. In NOPHO cohort, *ETV6‐RUNX1* and hyperdiploidy represented higher methylation, while *TCF3‐PBX1*, *MLLr*, low hypodiploidy, and *BCR‐ABL1* represented lower methylation. Identical pattern was validated in CCCS and TCCSG cohorts. Similar pattern of *Asns* gene methylation was confirmed in mouse leukemia samples from knock‐in mice of *ETV6‐RUNX1* and *TCF3‐PBX1* and transgenic mice of *BCR‐ABL1*.

**Conclusions**: Associations of *ASNS* gene methylation status with l‐asp sensitivity and karyotypes in BCP‐ALL could be one of pharmacogenetic background for an association of karyotypes with chemosensitivity in BCP‐ALL. *ASNS* gene methylation status might be a useful biomarker for precision medicine in childhood BCP‐ALL.

### PO-158. Evaluation of the Indonesian Childhood Acute Lymphoblastic Leukemia Treatment During 2000‐2018 {#pbc27455-sec-3830}

[P.H. Widjajanto]{.ul} ^1^, E. Supriyadi^1^, S. Mulatsih^1^, I. Purwanto^1^, S. Sutaryo^1^, A.J.P. Veerman^2^

*^1^Dr. Sardjito Hospital, Pediatric Hematology and Oncology, Yogyakarta, Indonesia; ^2^VU University Medical Center, Pediatric Oncology, Amsterdam, The Netherlands*

**Background/Objectives**: Childhood Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in our clinic. During the last 18 years, 3 protocols were applied in the Estella Clinic for children with cancer and hematologic diseases in the Dr. Sardjito Hospital supported through twinning program with VU Medical Center, Amsterdam and in cooperation with the Indonesian Pediatrician Association. This study is aimed to measure the outcome of the protocols to design the optimal version that meets the setting of Indonesia as the low‐medium‐income country

**Design/Methods**: This was an observation and retrospective study. Subject were children with ALL who were diagnosed and treated in Dr. Sardjito Hospital during 2000‐2016.The inclusion criteria were age \< 15 years, previously untreated with steroid or chemotherapies, L1 or L2 morphology. We compared the outcomes of patients treated using WK‐ALL 2000 (2000‐2006), Indonesian‐ALL 2006 (2006‐2013), and Indonesian‐ALL 2013 (2013‐2016) protocols. Survival analysis of Kaplan‐Meier method for event‐free survival (EFS) and overall survival (OS) was conducted using SPSS 22 program

**Results**: There were 744 patients in this study. The induction phase remission rate of WK‐ALL 2000 (n=171), Indonesian‐ALL 2006 (n=412), and Indonesian‐ALL 2013 (n=161) were subsequently 66.6%, 68.0% and 79.6%; while the estimated 3‐years EFS were subsequently, 26.8%±3.4%, 32.9%±2.4%, and 36.9%±4.5% (P=0.03); and 3‐years OS were 46.4%±4.3%, 56.2%±2.7%, 55.2%±4.9% (P=0.42). Abandonment and death during induction were lower in Indonesian‐ALL 2013 protocol than the others

**Conclusions**: The Indonesian childhood ALL protocols outcome showed some improvement during the last 18 years. The better support of government insurance, NGOs, experienced medical staffs play important role for this outcome. However, drop‐out and death remained important events. Relapse rates might have been influenced by frequent interruptions of therapy, often by unavailability of essential drugs

### PO-159. Cytokine Profiles at Birth and Risk of Pediatric Acute Lymphoblastic Leukemia {#pbc27455-sec-3840}

[J. Wiemels]{.ul} ^1^, M. Zhou^2^, R. Wang^3^, A. de Smith^4^, L. McCoy^5^, A.B. Nielsen^2^, P. Bracci^2^, A. Kang^6^, T. Whitehead^6^, S. Francis^7^, S. Kogan^8^, C. Metayer^9^, X. Ma^3^

*^1^University of Southern California, Preventative Medicine, Los Angeles, USA; ^2^UCSF, Epidemiology, San Francisco, USA; ^3^Yale U, Epidemiology, New Haven, USA; ^4^USC, Preventative Medicine, Los Angeles, USA; ^5^UCSF, Neurosurgery, San Francisco, USA; ^6^UCB, Epidemiology, Berkeley, USA; ^7^UNR, Epidemiology, Reno, USA; ^8^UCSF, Laboratory Medicine, San Francisco, USA; ^9^UCB, Epidemiology, San Francisco, USA*

**Background/Objectives**: Immune system function is clearly related to risk of childhood acute lymphoblastic leukemia (ALL), given established associations with childhood contacts via daycare and infectious disease history in case‐control studies. Less clear is whether immune development itself, including during the prenatal period, impacts ALL risk.

**Design/Methods**: We assessed whether cytokine levels at birth differed between 137 cases of childhood acute lymphoblastic leukemia (ALL) and 499 control subjects matched to the cases on month and year of birth, sex, and race/ethnicity. Luminex multiplex cytokine screening was performed on protein extracts from neonatal blood spots. The cytokines included IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12p70, GM‐CSF, INF‐γ, TNF‐ α, and VEGF.

**Results**: After an initial evaluation, three of the cytokines (IL‐2, IL‐5, and INF‐γ) were removed from further analyses, because more than 50% of study subjects had levels that were non‐detectable. Case‐control comparisons were made between individual cytokines following categorization (low versus high in controls, or tertiles). Significantly higher levels of IL‐1β, IL‐8, and GM‐CSF were found in cases compared to controls, but not for the remainder of the cytokines. Due to a significant collinearity of many cytokines, we used a principle component approach to derive independent components among the cytokines. The first 3 components described 72% of the cytokine variance. Both component 1 (dominated by IL‐6 and IL‐8) and 3 (GM‐CSF and VEGF) were significantly and positively associated with leukemia risk.

**Conclusions**: The data suggests that proinflammatory (IL‐6, IL‐8, VEGF), or T‐helper‐1 type pathways at birth may enhance risk of leukemia. Whether this immune phenotype influences leukemia risk directly, is a consequence of other prenatal events, and/or sets a stage where an infant will react differently to further infectious stimulants to enhance leukemogenesis will require further research. Funded by National Institutes of Health and EPA: R01CA175737, R01ES009137, P50ES018172, and RD83615901.

### PO-160. Asparaginase with Thrombotic Complication in Childhood Hematologic Malignancies {#pbc27455-sec-3850}

[P. Wongmast]{.ul} ^1^, A. Jetsrisuparb^1^, P. Komvilaisak^1^

*^1^Khon Kaen university, Pediatrics, Khon Kaen, Thailand*

**Background/Objectives**: Thromboembotic event(TEE) is a serious complication of childhood cancers. Asparaginase is a standard chemotherapy which is successful agent against childhood acute lymphoblastic leukemia(ALL) and lymphoblastic lymphoma. However, Asparaginase increased risk of thromboembolism. This study determines to describe characteristics, treatment and outcomes of childhood with Asparaginase related thrombosis in Srinagarind hospital, Thailand.

**Design/Methods**: A retrospective study, pediatric ALL and lymphoblastic lymphoma patients, aged below 18 years of age, treated between 1997‐2017, were included in this study. Evaluations included basic characteristics, dosage of Asparaginase, clinical presentation, imaging, prothrombotic studies, treatment and outcomes by imaging and modified Rankin scale for CNS thrombosis.

**Results**: 14 patients with symptomatic TEE were included with median follow up time 12.5 months (range 0‐158 months). The median age of patient was 11.5 years (range 3‐15 years). 11 patients were ALL and 3 patients were T‐lymphoblastic lymphoma. 13 patients (92.9%) received Asparaginase with dosage ≥ 10000U/m2/dose. There were CNS thrombosis(12), pulmonary embolism(1) and multiple sites of TEE (CNS and DVT left leg)(1). Venous site was more common than arterial site (60% VS 40%). One patient developed central line related TEE. Common presentation was seizure with median time of onset 16.5 days from first exposure (range 1‐25 days). Most common thrombotic state was acquired Protein S deficiency followed by acquired Antithrombin and acquired Protein C deficiency. Most of patients were treated with Low‐molecular weight heparin(75%). 7 patients having outcome assessed by imaging were complete responses (5) and partial responses(2). 8/13 patients (61.5%) with CNS TEE had favorable outcomes (modified Rankin scale 0‐1). 10 patients (71.4%) were alive, 2 patients died from advanced cancer and 1 patient died from brain herniation after cerebral infarction.

**Conclusions**: Asparaginase related TEE increased morbidity and mortality in ALL and lymphoblastic lymphoma patients. Further studies with TEE prophylaxis in Asparaginase use should be done to improve outcomes.

### PO-161. Kidney Involvement in Childhood Leukemia and Lymphoma {#pbc27455-sec-3860}

[P. Wongmast]{.ul} ^1^, P. Komvilaisak^1^, A. Jetsrisuparb^1^

*^1^Khon Kaen university, Pediatrics, Khon Kaen, Thailand*

**Background/Objectives**: Kidney involvement in childhood hematologic malignancy effects clinical outcome during treatment. It has not been widely reported.

**Design/Methods**: We reported 2 cases of acute lymphoblastic leukemia(ALL) and Diffuse large B cell lymphoma(DLBCL) with renal involvement at diagnosis.

**Results**: The first case was 5‐year‐old girl presenting with prolong fever, headache and fatique. She had hypertension, bilateral periorbital edema, generalized lymphadenopathy, bilateral nephromegaly and hepatosplenomegaly. Her CBC revealed anemia with blast cells seen. Serum biochemistry showed that BUN was 23.7 mg/dL, creatinine 1 mg/dL, normal electrolyte. Urinalysis was normal. Ultrasound abdomen revealed bilateral kidney enlargement. Bone marrow aspiration was compatible with pre‐B ALL. Patient was commenced with standard risk ALL protocol with rising of Creatinine. After induction her renal function and kidney sizes were normal. The second case was 10 year‐old boy presenting with hypertensive emergency. He was oliguric with progressive renal failure and very high of uric acid level. There was proteinuria and hematuria. Hematological data showed mild anemia with no blast cells seen. He was initially diagnosed rapid progressive glomerulonephritis, treated with pulse methylprednisolone and hemodialysis. His clinical status was not improved. Kidney biopsy subsequently performed with the result revealed medium to large size lymphoid cells infiltrate in renal tissue compatible with DLBCL. MRI whole abdomen revealed diffuse infiltrative masses of both kidneys with multiple bone and liver metastases. He was treated with high risk mature B‐cell non‐Hodgkin lymphoma protocol. After first cycle of chemotherapy, his creatinine became normal. However, He developed hematological toxicity grade IV from chemotherapy. Renal scintigraphy revealed moderately impaired function of bilateral kidney with total GFR of 43 ml/min. Chemotherapy dosage was adjusted according to GFR. His clinical status was improved with less toxicity from chemotherapy.

**Conclusions**: Regarding to severe complications, Chemotherapy dosage should be adjusted according to renal function to improve outcome and decrease toxicity.

### PO-162. The Aggressive End‐of‐Life Care in Pediatric Cancer Patients in Taiwan {#pbc27455-sec-3870}

[L.M. Wu]{.ul} ^1^

*^1^Kaohsiung Medical University, Nursing, Kaohsiung City, Taiwan R.O.C*.

**Background/Objectives**: Despite the dramatically improved outcomes for pediatric cancer patients, cancer is the leading cause of death in Taiwan, accounting for 21.8% of death in 2014. The pediatric end‐of‐life (EOF) care has not been extensively explored in the pediatric cancer patients. The study was to evaluate the trends in pediatric cancer EOF care in a medical center from 2008‐2016 in Taiwan.

**Design/Methods**: A retrospective chart review was conducted. All participants were diagnosed with cancer, and died between 2008 and 2016 in the southern medical center in Taiwan. 74 participants were included.

**Results**: The average age at diagnosis, and death were 7.6±5.3 year olds, and 11.3±6.1 year olds, respectively. These patients in their last month of life spent greater than 14 days (79.1%) in the hospital, completed Do‐Not‐Resuscitate (DNR) (79.7%), dying in the intensive care unit (70.3%), received related chemotherapy (63.5%), underwent intubation (39.2%), or received cardiopulmonary resuscitation (5.4%). Only 35.1% patents received hospice care or hospice share‐care in their last month of life, of these patents 25 % stared such service within the last 3 days. The care of the pediatric cancer EOF did not change over the study period except for significantly increasing DNR permits, and related chemotherapy in the last month of life.

**Conclusions**: Overly aggressive treatment was reported in the last month of pediatric cancer patients in Taiwan. A quality of EOF care in pediatric cancer patients should be developed to meet the individuals and family\'s needs and preferences.

### PO-163. Parents with a Child Throughout the End‐of‐Course: A Qualitative Study {#pbc27455-sec-3880}

[L.M. Wu]{.ul} ^1^

*^1^Kaohsiung Medical University, Nursing, Kaohsiung City, Taiwan R.O.C*.

**Background/Objectives**: The purpose of the current study was to describe the lived experience of parents with a child with incurable cancer at the end of life (EOL).

**Design/Methods**: A qualitative study was conducted following a phenomenological approach. Ten parents of children with incurable cancer were recruited from a medical center in southern Taiwan from May 2014 to June 2015. Data were collected through in‐depth interviews and analyzed using Giorgi\'s four‐step procedure.

**Results**: Two major themes emerged: keep fighting and acceptance of death. Keep fighting was divided into three sub‐themes: trying as hope, being alive as hope, and waiting for a miracle. Acceptance of death included four sub‐themes: an end to suffering, living in the moment, discussion of death, and letting go. Love was the core value used for making decisions regardless of whether aggressive treatment or palliative care was chosen.

**Conclusions**: Parents had difficulty adapting to a palliative care perspective due to a misconception that this meant giving up on their child. It is critical, however that parents move towards an acceptance of impending death. Religion and belief systems play a varied and important role in the lived experience of parents of a child with incurable cancer.

### PO-164. Treatment Outcome of Children with Acute Lymphoblastic Leukemia: 10‐Year Follow up in a Single Institution in East China {#pbc27455-sec-3890}

[X. Xu]{.ul} ^1^, Y. Tang^1^, H. Song^1^, W. Xu^1^, S. Yang^1^, S. Shi^1^

*^1^Children\'s Hospital of Zhejiang University School of Medicine, Department of Hematology/Oncology, Hangzhou, China*

**Background/Objectives**: The survival rate of children with acute lymphoblastic leukemia (ALL) has increased significantly in the recent decade.

**Design/Methods**: Between January 2008 and October 2016, 834 patients with newly diagnosed ALL were treated with National Protocol of Childhood ALL in China 2006 (NPCAC06).

**Results**: The male to female ratio was1.66, with a median age of 4.7 years. TEL/AML1 fusion gene were found in 20.0% of patients. The 5‐year overall survival (OS) and event‐free survival (EFS) rates for this cohort were 87.2±1.3% and 82.2±1.5%, respectively, with their 5‐year EFS rates of 0.3±1.8%, 83.8±2.7% and 66.7±3.7% in low, intermediate and high risk groups. The minimal residual disease (MRD) turned to be negative (\<0.01%) in 37.2% of patients on the mid‐course of induction and in 51.2% at the end of induction. Seventy‐seven patients underwent disease relapse including 11 with CNS relapse, while 49 patients underwent non‐relapse related mortality. The 5‐year cumulative incidence of relapse (CIR) was 12.1±1.3%. In univariate analysis, age, initial WBC count, immunophenotype, TEL/AML1 fusion gene, risk group, MRD level on the mid‐course of induction and at the end of induction were all associated with EFS and disease relapse. While in multivariate analysis, only TEL/AML1 fusion gene and MRD level at the end of induction were independent prognostic factors, with 4.39 (95%CI, 1.04‐18.56) and 3.85 (95%CI, 1.83‐8.09) folds of relapse for patients negative for TEL/AML1 and with MRD equal to 0.01% or higher when compared with patients positive for TEL/AML1(5‐year CIR 1.5±1.5%) and with MRD less than 0.01% (5‐year CIR 3.4±1.2%).

**Conclusions**: Patients treated with the NPCAC06 protocol achieved relatively high rate of disease cure with quite low rate of CNS relapse. TEL/AML1 fusion gene and MRD level at the end of induction were very important biomarkers for prognosis evaluation.

### PO-165. Promoting Role of PIP4K2A in Acute Lymphoblastic Leukemia and its Dependence on PIP2 {#pbc27455-sec-3900}

[Y. Xue]{.ul} ^1^, X. Ji^1^, M. Kang^1^, Y. Wang^1^, L. Rong^1^, Y. Fang^1^

*^1^Children\'s Hospital of Nanjing Medical University, Depatment of Hematology and Oncology, Nanjing, China*

**Background/Objectives**: Phosphatidylinositol‐5‐phosphate 4‐kinase type 2 alpha (PIP4K2A) is an enzyme catalyzing the phosphorylation of phosphatidylinositol‐5‐phosphate (PI5P) to form phosphatidylinositol‐5,4‐bisphosphate (PIP2). Genomic studies have reported association between genetic polymorphisms of PIP4K2A and pediatric acute lymphoblastic leukemia (ALL). However, the molecular mechanism of PIP4K2A in pathogenesis of ALL has not been revealed.

**Design/Methods**: We conducted RT‐PCR, CCK‐8 assay, cell cycle and cell apoptosis detection to explore the role of PIP4K2A in Jurkat and 6T‐CEM cells. Then we blocked the effect of PIP2 to further investigate whether biological function of PIP4K2A was dependent on PIP2.

**Results**: We found that proportion of G2/M phase cell was increased significantly after over‐expression of PIP4K2A in leukemia cells (P = 0.014 for Jurkat cell and P = 0.001 for 6T‐CEM cell), while the proportion was decreased when Jurkat or 6T‐CEM cells was treated with sh‐PIP4K2A (P = 0.039 and P = 0.022, respectively). Furthermore, the percentage of apoptosis lymphocyte leukemia cells was decreased significantly when PIP4K2A was over‐expressed (P = 0.006 for Jurkat cell and P = 0.001 for 6T‐CEM cell), while apoptosis cell was notable increased after knock‐down of PIP4K2A by sh‐PIP4K2A (P = 0.002 and P = 0.001, respectively). We subsequently inhibit biological function of PIP2 by LY294002, and found that the effect of PIP4K2A was attenuated.

**Conclusions**: The present study demonstrated that PIP4K2A is a promoting factor in the pathogenesis of ALL. Its biological function may be mediated by PIP2.

### PO-166. Prognostic Value of Neuropilin‐1/CD304 in Children with B‐Lineage Acute Lymphoblastic Leukemia {#pbc27455-sec-3910}

[M. Zakaria]{.ul} ^1^, M. Hesham^2^, D. Elnemer^3^, M. Hashem^4^

*^1^lecturer of pediatric hematology and oncology, pediatric departement‐faculty of medicine‐zagazig university, zagazig, Egypt; ^2^Professor of pediatric hematology and oncology, pediatric departement‐faculty of medicine‐zagazig university, zagazig, Egypt; ^3^Professor of clinical pathology, clinical pathology departement‐faculty of medicine‐zagazig university, zagazig, Egypt; ^4^lecturer of clinical pathology, clinical pathology departement‐faculty of medicine‐zagazig university, zagazig, Egypt*

**Background/Objectives**: Neuropilin‐1 (NRP‐1) is a novel receptor for vascular endothelial growth factor (VEGF) which expressed in endothelial and tumor cells and promotes proliferation and chemotaxis of leukemic cells in response to VEGF. Inhibition of NRP‐1 functions may provide a new therapeutic strategy for treatment of ALL.

We aimed to study the neuropilin1/CD304 expression profile of normal B lineage and the leukemic lymphoblast, its prognostic value and its role in Minimal Residual Disease detection.

**Design/Methods**: A prospective case‐controlstudy was conducted on forty newly diagnosed patients with acute B‐lymphoblastic leukemia (22males and 18 females) with a mean age of 6.68±4.70 years and forty age and sex matched subjects as a control group. Expression of NRP‐1 (CD304) by flow cytometry was done at diagnosis and at the end of induction therapy.

**Results**: Fourty five % of the cases were +ve for CD304 expression and fifty five % were --ve. There were no statistically significant differences between cases with +ve and--ve expression of CD304 regarding clinical presentation, morphology, immunophenotyping and CNS infiltration. But there were statistical significance differences between them as regards to relapse (77.7% relapsed cases were CD304 positive) and prognosis (55% of cases with positiveCD304 expression died). There were +ve significant correlation with CD 304% and age, bone marrow blast cells and LDH level and --ve significant correlation with WBCs count and Hb level. There was no significant difference between CD304 positive and negative cases regarding overall Survival rate, while Disease‐freesurvival at 12 months was 75.4% in CD304 positive cases and 33.3% in negative cases with a high significant difference.

**Conclusions**: Neuropilin‐1(CD304) with a high expression on bone marrow blasts can be considered as a marker for bad prognosis in children with B‐lineage ALL and could be used during follow‐up and disease monitoring.

### PO-167. Presepsin a Novel Diagnostic Marker of Bacterial Infections in Febrile Neutropenic Pediatric Patients with Hematological Malignancies {#pbc27455-sec-3920}

[M. Zakaria]{.ul} ^1^, A. Baraka^2^

*^1^lecturer of pediatric hematology and oncology, pediatric departement‐faculty of medicine‐zagazig university, zagazig, Egypt; ^2^associate professor of clinical pathology‐faculty of medicine‐zagazig university, clinical pathology, zagazig, Egypt*

**Background/Objectives**: Febrile Neutropenia(FN) is often observed in children with hematological malignancies C‐reactive protein and procalcitonin have been used as diagnostic markers of bacterial infections but they have some limitations. Recently, Presepsin a glycoprotein derived from monocytes and macrophages, also known as soluble CD14 was reported as a novel and promising biomarker for the diagnosis of sepsis. However, its usefulness in identifying infections in patients with hematological malignancies during episodes of fever and neutropenia remains unclear.

We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with hematological malignancies.

**Design/Methods**: Sixty Pediatric patients with hematological malignancies (Acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non‐Hodgkin lymphoma 10 and Hodgkin disease 2).Thirty age and sex matched healthy children serving as controls were enrolled in this study. Estimation of Presepsin, Procalcitonin and C reactive protein during episode of FN in addition to absolute neutrophil count and blood culture were performed for all the participants.

**Results**: A significant elevation of presepsin level in the patients than in control with high increment in the positive blood culture patients than in sterile cases. Presepsin concentration was significantly higher in bacteremia than clinically proved infection and fever of unknown origin. Presepsin was also superior to C reactive protein and Procalcitonin in identification of bacterial infections either in the form of bacteremia or clinically proved infections with sensitivity (100%, 100%, and 68.8% respectively) and specificity (100%, 64.3%, and 85.7% respectively). A statistically significant positive correlation between Persepsin and C reactive protein and procalcitonin levels but negative correlation with absolute neutrophile count was observed in the patient\'s subgroups.

**Conclusions**: Presepsin is a useful marker for detection of bacteremia with high sensitivity and specificity. This finding supported that Presepsin is superior to Procalcitonin and C reactive protein in identifying bacterial infection in patients with cancer who develop fever and neutropenia.

### PO-168. Phosphorylation of Serine/Arginine‐Rich Splicing Factor 1 at TYR‐19 Promotes Cell Proliferation in Pediatric Acute Lymphoblastic Leukemia {#pbc27455-sec-3930}

L. Xu^1^, [H. Zhang]{.ul} ^1,2^, M. Mei^3^, C. Du^3,4^, X. Huang^3^, T. Li^3^, J. Li^1^, Y. Wang^3^, S. Bao^3^, H. Zheng^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University, Hematology Oncology Center, Beijing, China; ^2^Institute of Medical Biology‐ Chinese Academy of Medicine Sciences and Peking Union Medical College, Institute of Medical Biology, kunming, China; ^3^Institute of Genetics and Developmental Biology‐ Chinese Academy of Sciences, Institute of Genetics and Developmental Biology, Beijing, China; ^4^College of Life Science‐ Leshan Normal University, College of Life Science, Leshan, China*

**Background/Objectives**: Despite improved therapeutic responses with polychemotherapy strategies, pediatric acute lymphoblastic leukemia (ALL) remains fatal in about 10%∼15% of cases. Serine/arginine‐rich splicing factor 1 (SRSF1, also termed SF2/ASF) has been linked to various human cancers including pediatric ALL. Our previous study showed that SRSF1 serves as an anti‐apoptotic factor; however post‐translational modifications such as phosphorylation of SRSF1 in the pathogenesis of pediatric ALL remains unclear

**Design/Methods**: Leukemic cells were isolated from primary pediatric ALL bone marrow samples, followed by immune‐precipitation (IP) assays and mass spectrum analysis specific to SRSF1. Subcellular localization of the SRSF1 protein and its mutants were analyzed by Immunofluorescence staining. Cell proliferation, colony formation, cell apoptosis and cell cycle were also investigated using stable leukemic cell lines generated with lentivirus‐mediated overexpressed wild‐type or mutant plasmids with/without treatment of Tie2 kinase inhibitor

**Results**: The phosphorylation of SRSF1 at tyrosine 19 (Tyr‐19) residue was identified in newly diagnosed ALL samples, but not in complete remission samples. Compared to the SRSF1‐wide type cells, the missense mutants of the Tyr‐19 phosphorylation of SRSF1 affect the subcellular localization of SRSF1. In addition, the Tyr‐19 phosphorylation of SRSF1 also leads to increased cell proliferation, and enhanced colony‐forming properties by promoting cells into differentiation phase. Tie2 was predicted with a strong possibility to phosphorylate the Tyr‐19 residue using the online tools. Our further results showed that Tyr‐19 phosphorylation of SRSF1 markedly increased the proliferation of Nalm‐6 cells, which could be suppressed by application with Tie2 kinase inhibitor

**Conclusions**: We identify that the phosphorylation state of SRSF1 is linked to different phases in pediatric ALL. The Tyr‐19 phosphorylation of SRSF1 disrupts its subcellular localization and promotes proliferation in leukemia cells by driving cell‐cycle progression. Inhibitor targeting Tie2 kinase that may catalyze Tyr‐19 phosphorylation of SRSF1 offer a promising therapeutic target for the treatment of pediatric ALL

### PO-169. Aberrant FLT3 Pathway Arisen from PRC2 Inactivation is a Potential Therapy Target for T Cell Acute Lymphoblastic Leukemia {#pbc27455-sec-3940}

[J. Zhang]{.ul} ^1^

*^1^Institute of Hematology and Blood Disease Hospital‐ Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Pediatrics, Tianjin, China*

**Background/Objectives**: Pediatric T cell acute lymphoblastic leukemia (T‐ALL) is an aggressive subtype of pediatric ALL characterized by recurring genetic and epigenetic alterations. Loss‐of‐function mutations of Polycomb repressive complex 2 (PRC2) core components, including *EED*, *EZH2* and *SUZ12*, have been identified extensively in T‐ALL and are associated with poor prognosis. However, the detailed mechanism of pediatric T‐ALL tumorigenesis driven by PRC2 remains to be further clarified.

**Design/Methods**: Patients were treated in Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), according to CCLG‐2008 protocol. The patients and carriers involved in our study signed an informed consent form approved by the IRB of CAMS/PUMC. Target sequence of EZH2, EED and SUZ12 was performed on bone marrow nucleic cells of 60 pediatric T‐ALL patients. RNA sequence was performed on sorted leukemia cells and normal T cells (CD3 positive) from bone marrow nucleic cells of 12 PRC2 mutated T‐ALL patients and pediatric donor for transplantation, respectively.

**Results**: In our study, RNA‐seq analysis on primary T‐ALL cell with mutations of EED, EZH2 or SUZ12 revealed aberrant expression of FLT3. Increased expression of FLT3 and activation of downstream pathway were also observed in EZH2 knock‐out Jurkat cells. ChIP‐qPCR assay revealed that loss of H3K27me3 modification caused by PRC2 disruption closely coupled to enhanced transcription of FLT3. Furthermore, Inhibitors of FLT3, Sorafenib and Quzartinib, significant prolong the survival of recipient NOD/SCID mice transplanted with EZH2 mutated T‐ALL cells.

**Conclusions**: Pediatric T‐ALL patients suffer a poor outcome partially due to lack of prognostic markers to direct the risk stratification therapy. In our study, we found the aberrant expression of FLT3 in PRC2 deficient T‐ALL patient cells and T‐ALL cell line. Patients‐derived xenograft model revealed that inhibition of FLT3 significantly prolonged the survival of PRC2 deficient T‐ALL xenografts, which suggests aberrant FLT3 pathway is a potent target for the PRC2 deficient T‐ALL patients.

### PO-170. Multiple Clinical Research of Acute Lymphoblastic Leukemia in Older Children and Adolescents {#pbc27455-sec-3950}

[N. Zhang]{.ul} ^1^, H. Jiang^1^, J. Tang^2^, S. Shen^2^, N. Wang^3^, H. Li^1^, J. Yang^1^, J. Shao^1^

*^1^Shanghai Children\'s Hospital, Hematology/Oncology, Shanghai, China; ^2^Shanghai Children\'s Medical Center, Hematology/Oncology, Shanghai, China; ^3^Anhui Medical University Second affiliated Hospital, Hematology, Shanghai, China*

**Background/Objectives**: To analyze the clinical characteristics and long‐term outcomes with multiple centers protocol for acute lymphoblastic leukemia (ALL) over 10 years old and adolescents.

**Design/Methods**: Newly diagnosed ALL patients aged from 10 to 18 years old in three hospitals were included from May 2005 to April 2015. They were received ALL‐2005/2009 protocol following up to December 31^st^ 2016. The clinical characteristics, outcomes and the prognostic analysis were evaluated comparing two protocols.

**Results**: Totally, 237 patients were involved in the study. 76 cases were treated with ALL‐2005 protocol. While 161 cases were in ALL‐2009 protocol. Complete remission (CR) after induction therapy was 94.5%. 64(28.6%) patients relapsed with a median time of 14.5 months and 70 (29.5%) patients passed away during the following time. The 5‐year event‐free survival (EFS) and overall survival (OS) of ALL patients were (63.1±3.3)% and (68.4±3.2)%. The 7‐year EFS and OS were (61.0±3.5)% and (67.6±3.3)%.The 5‐year EFS of intermediate risk group in ALL‐2005 protocol and ALL‐2009 protocol were (73.6±6.1)% and (71.7±4.3)% (*P*=0.801). The 5‐year EFS of high risk group in two protocols were (27.6±9.6)% and (33.9±9.3)% (*P*=0.586). Five years relapsed rate of two protocols were (33.8±5.7)% and (32.6±4.1)% (*P*=0.815).The mortalities were 36.8% and 29.8% separately (*P*=0.090). Single prognosis analysis indicated that age, male, risk, BCR/ABL translocation / t(9;22) and resistant to induction were risk prognostic factors in long‐term survival (*P* \< 0.05). COX multivariate analysis showed male, risk and resistant to induction were independent risk prognostic factors (*P* \< 0.05)

**Conclusions**: Protocol ALL‐2009 enhanced the chemotherapy intensity in intermediate risk group with no benefit of survival. BCR‐ABL fusion or t(9,22) translocation was still the risk factor of prognosis. TKI inhibitor used in these patients could improve survival. EFS rate was lifted a little and death rate was pushed down in ALL‐2009 protocol with no significant lower relapsed rate comparing with ALL‐2005 protocol.

### PO-171. Huaier Extract Enhances the Treatment Efficacy of Imatinib in Ph+ Acute Lymphoblastic Leukemia {#pbc27455-sec-3960}

[F. Zhou]{.ul} ^1^, Q. Ping^1^, H. Juan^1^, J. Runming^1^

*^1^Union Hospital of Huazhong University of Science and Technology, Department of Paediatrics, Wuhan, China*

**Background/Objectives**: Philadelphia chromosome‐positive is considered as a high risk of acute lymphoblastic leukemia children. Imatinib is a tailored drug for Ph+‐ALL, whereas traditional Chinese medicine Huaier extract has been found to have antitumor activity. In the present study, we aimed to investigate the potential benefit of combination therapy with imatinib and Huaier extract.

**Design/Methods**: The Sup‐B15 and BV173 cells were treated with Huaier extract (0.3 umol/L) and imatinib (2.5 mg/ml) for 48h. The proliferation and apoptosis of Ph+‐ALL cells were detected by CCK‐8 and FCM, respectively. The expression levels of apoptosis‐related protein Bcl‐2, Bax and cleaved‐caspase 3, BCR‐ABL protein, p‐STAT5, p‐ERK and p‐Lyn were detected by Western blotting. The BCR‐ABL activity was measured by ELISA. The CD19^+^ cells in bone marrow, liver and spleen of mouse models of Ph+‐ALL were detected by FCM.

**Results**: Analysis of cell proliferation showed that imatinib and Huaier extract exerted synergistic effects on both Sup‐B15 cells and BV173 cells. Using flow cytometry and western blot, the synergistic effects were revealed on induction of cell apoptosis. The two drugs also exhibited a synergistic effect in decreasing protein/enzymatic activity levels of BCR‐ABL. Furthermore, the results of western blotting revealed that the two drugs had a synergistic inhibition effect in p‐STAT5, p‐ERK and p‐Lyn expression. Consistent with the in vitro results, combined Huaier extract with imatinib exerted the most marked inhibitory effect on xenografted tumor growth.

**Conclusions**: Our finding suggests a potential clinical application of imatinib and Huaier extract combination on Ph+‐ALL.

### PO-172. Treatment Outcome of Adolescent Acute Lymphoblastic Leukemia: The CCLG‐ALL2008 Study in a Single Center {#pbc27455-sec-3970}

X. Chen^1^, [Y. Zou]{.ul} ^1^, X. Liu^1^, Y. Guo^1^, W. Yang^1^, B. Zhao^1^, M. Wang^1^, M. Ruan^1^, X. Zhu^1^

*^1^Institute of Hematology‐ Blood Disease Hospital, Chinese Academy of Medical Sciences CAMS, Department of Paediatric Haematology, tianjin, China*

**Background/Objectives**: There were no data of adolescent acute lymphoblastic leukemia in China, to know the outcome of this age group of patients, we retrospectively analysed the patients treated with CCLG‐ALL2008 protocol in a single center.

**Design/Methods**: We analyzed the long‐term outcome of 154 patients newly diagnosed of adolescent acute lymphoblastic leukemia (ALL) treated with CCLG‐ALL2008 protocol between 2008 and 2015 in our center.

**Results**: Among them, 88 (57.1%) patients were male,66 (42.9%) patients were female, 125(81.2%) patients were B‐ALL, and 29(18.8%) patients were T‐ALL. Tweleve of 154 patients(7.8%) with BCR/ABL infusion genes, 6.5% and 5.2% patients were with TEL/AML1 and E2A/PBX1 infusion genes respectively. Of the 154 patients, 77.9% of them had no known gene abnormalities. The 10‐year event‐free survival (EFS) and overall survival (OS) rates for this study were 70.3±4.3% and 75.5± 4.3%, respectively. The 10‐year EFS and OS rates for children younger than 10 years were 70.1 ±0.2% and 77.8±1.7%, respectively. There were no significant differences between these two age groups(*P*=0.625). The complete remission rate was 96.1%, death in remission 3.9%, and 21.6% of patients was relapsed in the older age patients(older than 10 years).

**Conclusions**: Our study indicate that CCLG‐ALL2008 protocol was effective in newly diagnosed adolescent ALL patients than those treated with adult ALL studies. Mostly patients had no known genes infusion, mutation and rearrangement, further study of genes detection in this group patients is urgently needed.
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### PO-173. Predictive Relevance of Clinical Characteristics in Pediatric Patients with Relapsed Acute Myeloid Leukemia Treated at Single Institution: Report of an Outcome Analysis {#pbc27455-sec-3990}

[S. Al‐Sweedan]{.ul} ^1^

*^1^jordan university of science & Technology, Pediatrics, Irbid, Jordan*

**Background/Objectives**: Intensified regimens of chemotherapy and risk classification attributed to improvement of survival.

**Design/Methods**: A medical record of 155 patients with AML were reviewed, 2005 ‐2015, to assess the outcome.

**Results**: 56% were boys with median age of 5.5 years (0.11‐ 13.8).Most commonly observed FAB classification was M‐5 (24%) followed by M‐2 (19%). 27% were Low Risk, 43% Intermediate and 30% High Risk. 43% received HSCT. Our CR‐1 rate was 93.7%, with 100% in Low Risk, 95.2% Intermediate Risk and 85.7% in High Risk patients (P‐Value: 0.023), requiring 1‐3 cycles of chemotherapy. Treatment Failure was observed in 6.3%. Relapse rates was 38.8% (52 of 134). Most common site of relapse was bone marrow (75%, 39 of 52). PML/RAR (P‐Value: 0.044), Post‐Induction BM Classification M‐3 (P‐Value: 0.034) and AML High Risk (P‐Value: 0.003) were found to be significantly associated with Relapse. Age at diagnosis, or Time to CR‐1 were not found to have any association with relapse. 51.9% (27 of 52) who relapsed, went for HSCT. With a median follow‐up of 68.8 months, five year overall survival for our cohort of patients was (0.567±0.046); significantly poor (P‐Value: 0.001) in relapsed (n=52, 0.137±0.051) compared to non‐relapsed (n=82, 0.863±0.041); resulting in a five year event free survival of 0.472±0.044. Among relapsed group (n=52), five year overall survival was significantly better (0.160±0.073) for those who received HSCT (27) than who did not (n=25, 0.114±0.073, P‐Value: 0.029). Five year overall survival was also significantly better for Non‐Relapse group (n=31, 0.828±0.070) compared to relapsed patients (n=27, 0.160±0.073, P‐Value = 0.001) for whom HSCT was administered (n=58).

**Conclusions**: The results of our treatment efforts are in conformity with the western literature. Precise risk classification can be a vital predictor in planning for first line and salvage therapies including HSCT for pediatric patients with AML.

### PO-174. Relationship Between Prophylactic Antibiotics and Blood Stream Infections in Children with Acute Myeloid Leukemia {#pbc27455-sec-4000}

[R. Ando]{.ul} ^1^, T. Osumi^1^, M. Kato^1^, Y. Shioda^1^, C. Kiyotani^1^, K. Terashima^1^, K. Matsumoto^1^, D. Tomizawa^1^

*^1^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan*

**Background/Objectives**: High‐dose cytarabine (HDCA) is associated with profound neutropenia and high‐risk of developing severe bacterial infections. Therefore, prophylactic antibiotics are used in certain occasions for patients who undergo HDCA, but controversies exist especially concerning an emergence of antibiotic‐resistant strains.

**Design/Methods**: We retrospectively analyzed the relationship between prophylactic antibiotics and blood stream infections (BSI) in children (\< 18 years old) with newly diagnosed acute myeloid leukemia (AML; excluding acute promyelocytic leukemia or Down syndrome cases) treated at the National Center for Child Health and Development from January, 2013 to March, 2018.

**Results**: Among the 15 patients with AML, 53 HDCA‐courses with prophylactic antibiotics and 8 HDCA‐courses without were evaluated. Ampicillin(N=31), cefepime(N=18), piperacillin tazobactam(N=1), cefazolin(N=2), levofloxacin(N=1) were used as prophylactic antibiotics. In the prophylaxis group, seven BSI (13%) were detected; 3 cases with Gram‐negative rods of which 2 developed sepsis, and 4 cases with ampicillin‐resistant Staphylococcus. In the no prophylaxis group, two BSI (25%) were documented.

**Conclusions**: There was a trend of lower incidence of BSI with prophylactic antibiotic use at HDCA treatment, but development of severe Gram‐negative rod infections and ampicillin‐resistant Staphylococcus were issues. Further investigation on a role of prophylactic antibiotic use should be explored.

### PO-175. Location of Treatment is Associated with Outcome of Acute Myeloid Leukemia in Early Childhood {#pbc27455-sec-4010}

[F. Andrade]{.ul} ^1^, I. Sardou‐Cezar^1^, F.V.D.S. Bueno^1^, E.P. Noronha^1^, E. Terra‐Granado^1^, M.S. Pombo‐de‐Oliveira^1^, T. Brazilian Study Group of Childhood Acute Leukemia^1^

*^1^National Cancer Institute, Pediatric Hematology‐Oncology Program, Rio de Janeiro, Brazil*

**Background/Objectives**: Acute leukemias that arise in early age are assumed to be initiated during fetal life and accumulate additional genomic lesions in the first years of life, when it is possible that hematopoietic progenitors are more sensitive to genotoxic events. Here, we described the frequency of recurrent molecular abnormalities in infants, toddlers and young children (≤5 years of age) with acute myeloid leukemia (AML), and investigated the association of demographic and molecular features with the outcome.

**Design/Methods**: Two hundred and twenty‐one patients (≤5 years‐old) diagnosed with *de novo* AML were assessed throughout a multicentric network study in Brazil (2009‐2017). Mutations in hotspot regions of RAS pathway affecting genes (*FLT3*, *NRAS*, *KRAS*, and *PTPN11*) were analyzed, as well as fusion genes \[*KMT2A* and *NUP98* rearrangements (*KMT2A*‐r and *NUP98*‐r, respectively), *RUNX1‐RUNX1T1*, *CBFβ‐MYH11*, *PML‐RARα, CBFA2T3‐GLIS2*, *RBM15‐MKL1*, and*MYST3‐CREBBP*\] associated with AML. Patients were treated according to BFM‐AML2004 guidelines, not formally enrolled in treatment protocols. Patients with acute promyelocytic leukemia (APL) were excluded from the survival analysis.

**Results**: All phenotypes were associated with low white blood cell (WBC) count (≤50x109/L) at diagnosis. AML associated with Down syndrome (DS‐AML) represented 32.1% (71/221) of cases. Molecular abnormalities were found in 61.0% of non‐DS‐AML, represented by *KMT2A‐*r (29.8%), followed by APL/*PML‐RARα* (9.1%), *RUNX1*‐*RUNX1T1* (7.6%),*CBFβ‐MYH11* (5.4%), *NUP98*‐r (7.4%), *MYST3‐CREBBP* (2.0%)*, CBFA2T3‐GLIS2* (1.7%), and *RBM15‐MKL1* (1.3%). Mutations in genes of the RAS pathway were observed in 29.0% of cases and were associated with high WBC count (\>50x109/L) at diagnosis (52.9%; p=0.003). The cumulative 5‐year probability of overall survival (pOS) was 34.2±7.0%. The location of treatment was associated with adverse outcomes apart from tumor genetic abnormalities presented at diagnosis (18.5±8.1%; p=0.010).

**Conclusions**: Collaborative efforts allowed the establishment of a network of diagnosis to characterize molecular subtypes AML. Differences in outcome were observed between Brazilian geographic regions, with the Midwest associated with low pOS.

### PO-176. Outcome of Acute Myelogenous Leukemia Treated with a Modified AHOPCA Regimen Combined with Oral Metronomics: Experience in a Tertiary Hospital in the Philippines {#pbc27455-sec-4020}

[A. Ausa]{.ul} ^1^, J. Estanislao^1^, P. Fajardo^1^, A.P. Alcasabas^1^

*^1^University of the Philippines ‐ Philippine General Hospital, Department of Pediatrics, Manila, Philippines*

**Background/Objectives**: The Philippine General Hospital sees 30‐40 new acute myelogeous leukemia (AML) per year. Up until 2015, only palliative care was offered due to limitations in supportive care; with mean patient survival time of only 4.7 months. However with the opening of a dedicated pediatric cancer unit, an in‐house AML protocol, adapted from the AHOPCA regimen, was implemented. This consisted of 5 courses of chemotherapy with reduced anthracyclines and followed by a 6 month oral metronomic therapy with Prednisone, Etoposide and Mercaptopurine. Antibiotic and antifungal prophylaxis was given in between chemotherapy courses. We report our patient profiles and outcome.

**Design/Methods**: Retrospective chart review of newly diagnosed AML (except APML) seen from January 2015 to December 2017. Patient outcomes were evaluated at end of study period, March 2018.

**Results**: There were a total of 87 patients. Diagnosis was by immunophenotyping. Mean age was 9.8 years (0.3--18). M:F1.4:1. Only 45 patients (51%) was started on the in‐house AML regimen, as 23 (26%) refused treatment, 16 (18%) chose palliation, and 5 (6%) received other protocols. Thirty patients (67%) went into remission. At study endpoint, 15 patients (33%) were alive, including 4 with active disease, 9 (20%) abandoned treatment and 21 (46.7%) died. Six patients (24%) had bone marrow relapse at a mean of 13 months from diagnosis. The causes of death were progressive disease in 17 patients (81 %), infection in 3 (14 %), and bleeding in 1 patient (5%). The 2 year overall survival and event free survival were 31.7% and 26.8% respectively. Mean patient survival time was 9.1 months (0.467‐36.13mos).

**Conclusions**: The combination of a low intensity AML regimen combined with oral metronomic therapy was associated with dismal outcomes. Future plans include identification of favorable AML subgroups through routine cytogenetics and protocol intensification with escalation in the anthracycline dose.

### PO-177. Pattern of mtDNA (D‐Loop) Variations and their Relation with Mitochondrial Encoded Gene in AML {#pbc27455-sec-4030}

[R. Bakhshi]{.ul} ^1^, A. Tyagi^2^, R. Pramanik^2^, V. Sreenivas^3^, S. Ali^1^, S. Bakhshi^2^

*^1^Shaheed Rajguru College of Applied Sciences‐ University of Delhi, Biomedical Sciences, New Delhi, India; ^2^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; ^3^All India Institute of Medical Sciences, Biostatistics, New Delhi, India*

**Background/Objectives**: Role of variation in mitochondrial DNA, particularly those in D‐loop region, in acute myeloid leukemia (AML) remains investigational. The study aimed to assess pattern of variations in mitochondrial D‐loop region in AML patients and to evaluate their association with expression of mitochondrial‐encoded genes.

**Design/Methods**: For denovo AML patient\'s ≤18 years of age, between June 2013‐August 2016, bone marrow sample, buccal swab sample and mother\'s blood sample were collected at baseline. DNA extraction, PCR for D loop region and subsequent Sangers sequencing were performed. RNA extracted from these patients was analyzed using real time PCR for relative gene expression of four mitochondrial DNA encoded genes viz. Nicotinamide adenine dineucleotide dehydrogenase subunit 3 (ND3), Cytochrome B (CytB), Cytochrome c oxidase I (COX1) and ATP synthetase F~0~ subunit 6 (ATP6).

**Results**: 151 patients were included; gene expression was analyzable in 116 patients. Total 1490 variations were found at 237 positions in D‐Loop. Of these, 1206 (80.9%) variations were germline and 284 (15.9%) somatic. Positions 73‐263 was identified as probable hotspot region in D‐loop (11.9 variations per positions). T‐C change was commonest variation in germline (428/1206) (35.5%) as well as somatic (88/284) (30.9%) variations. G bases appeared to be most stable nucleotide (least number of single base substitution) whereas T appeared to be most prone to variations with germline T‐C being commonest. CytB gene expression was significantly higher for variations at position 16192 and 16327. Expression of CytB was significantly lower for variation at position 16051 and 207. Variation at position 152, 207, 513 significantly decreased expression of COX1 while those at position 16051, 152 attenuated expression of ATP6.

**Conclusions**: This first study evaluated type and overall pattern of variation in D‐loop region and segregated them into somatic and germline variation. Effect of these variations on mitochondrial encoded genes is a novel information in AML genomics.

### PO-178. Drug Level of Imatinib and its Correlation with Dose and Molecular Remission in Children with Chronic Myeloid Leukemia (CML) {#pbc27455-sec-4040}

T. Shankar^1^, S.V. Attri^2^, A. Patial^2^, S. Naseem^3^, R. Jain^1^, A. Trehan^1^, P. Malhotra^4^, N. Varma^3^, [D. Bansal]{.ul} ^1^

*^1^Postgraduate Institute of Medical Education and Research, Hematology/Oncology unit‐ Dept. of Pediatrics‐ Advanced Pediatrics Center, Chandigarh, India; ^2^Postgraduate Institute of Medical Education and Research, Pediatric Biochemistry‐ Dept. of Pediatrics‐ Advanced Pediatrics Center, Chandigarh, India; ^3^Postgraduate Institute of Medical Education and Research, Hematology, Chandigarh, India; ^4^Postgraduate Institute of Medical Education and Research, Clinical Hematology, Chandigarh, India*

**Background/Objectives**: Role of monitoring drug‐level of imatinib in children with CML is uncertain. A trough plasma level of 1000 ng/ml has been proposed in adults for optimal response.

**Design/Methods**: Design: Cross‐sectional, observational study. Setting: University‐Government‐hospital. Study‐period: July‐2015 to March‐2017. Patient\'s ≤18 years at diagnosis, with chronic‐phase CML, receiving imatinib for ≥6 months were enrolled. Compliance was ensured by dispensing imatinib in exchange for empty blister packs. Patients with poor‐compliance were excluded. Blood was collected prior to the next dose of imatinib for measuring imatinib level by high‐performance‐liquid‐chromatography. Quantitative‐PCR for BCR‐ABL (GeneXpert^®^) and renal/liver biochemistry were assessed. Investigations were performed at a single time‐point.

**Results**: Thirty‐patients were enrolled. The median age at enrolment was 16.4 years (IQR: 12.5, 20). The median duration of imatinib‐therapy was 6‐years (IQR: 6, 10.2). Twenty‐seven were receiving Glivec^®^ through the Glivec^®^‐International‐Patient‐Assistance‐Program and remaining 4 were receiving generic‐imatinib. The median dose was 287 mg/m2 (IQR: 267, 345). No patient had evidence of renal/liver dysfunction.

qPCR was available in 28 patients; median qPCR was 0.0017% (IQR: 0.0006, 0.023) (range: 0.0‐3.0%). Twenty‐four (85.7%) patients were in major molecular remission, of whom 20 had a deep molecular response (DMR). The median trough level of imatinib was 10,820 ng/ml (IQR: 5750, 19,342) (range: 1083‐29,170). No patients had a sub‐therapeutic drug‐level (\<1000 ng/ml). The dose of imatinib correlated with the plasma level of imatinib (rho=0.616, p\<0.001). The median imatinib level in patients with and lacking a DMR was 10,200 ng/ml (IQR: 5720, 19,150) and 15,760 ng/dl (IQR: 6040, 24,580), respectively (p=0.189). The imatinib‐level did not correlate with age (rho=‐0.078, p=0.684), sex (p=0.49) or body surface area (rho=‐0.115, p=0.062).

**Conclusions**: The trough levels of imatinib had a wide range in children/adolescents with chronic‐phase CML and correlated with the dose of imatinib. A single time‐point assessment of imatinib‐level was not found to be useful for clinical management of CML.

### PO-179. Molecular Alterations in Pediatric Acute Megakaryoblastic Leukemia {#pbc27455-sec-4050}

[I. Cezar]{.ul} ^1^, F. Andrade^1^, F. Bueno^1^, L. Marques^1^, E. Terra‐Granado^1^, E. Noronha^1^, M.S. Pombo‐de‐Oliveira^1^

*^1^National Cancer Institute, Pediatric Hematology‐Oncology Program, Rio de Janeiro, Brazil*

**Background/Objectives**: Acute megakaryoblastic leukemia (AMKL) represents about 15% *de novo* acute myeloid leukemia (AML). This subtype is divided into two distinct entities: *i)* AMKL arising in the context of Down syndrome (DS‐AMKL) and *ii)* de novo AMKL (AMKL‐nonDS). Our aim was to compare biological features of pediatric AMKL with and without Down syndrome (DS) and evaluate the outcome according to leukemia subtype.

**Design/Methods**: We have analyzed 324 cases of *de novo* AML (excluding acute promyelocytic leukemia), with age ≤21 years‐old. The most frequent genetic alterations in AMKL \[*KMT2A* rearrangements (*KMT2A*‐r), *NUP98* rearrangements (*NUP98*‐r), *CBF2AT3‐GLIS2*, and *RBM15‐MKL1*\] were identified by FISH, RT‐PCR, and RT‐PCR multiplex. Mutations in *GATA1* were identified by Sanger sequencing in cases with DS. The overall survival (OS) was analyzed by Kaplan Meier method, and differences between groups were compared by log rank test.

**Results**: AMKL subtype represented 21.8% of AML, mostly with \<25 months of age (67.1%; p\<0.001) and white blood cell (WBC) count at diagnosis ≤50x109 cell/ml (88.4%; p\<0.001). The median of WBC count and age at diagnosis in patients with AMKL‐nonDS was 9.2x109cell/ml and 18 months, respectively. In patients with AMKL‐DS the median of WBC count and age was 12x109cell/ml and 19 months, respectively. *RBM14‐MKL1* was analyzed in cases ≤24 months of age and was found in 13% of them (2/15). We also found*KMT2A‐MLLT3* in 3.8% of patients, *NUP98‐*r and *CBF2AT3‐GLIS2* each in 7.7% of patients, and *MYST3‐CREBBP* in 3.8%, corresponding to 32% AMKL‐nonDS presenting some alteration. AMKL‐SD was associated with *GATA1* mutations, with a frequency of 68.8% (22/32) cases with mutation in this gene. Patients with AMKL‐DS presented higher probability of OS compared to patients with AMKL‐nonDS (78.6%±11% and 23.7%±11.1%, respectively; p=0.042).

**Conclusions**: Fusion genes are frequent in AMKL‐nonDS, which is genetically heterogeneous and associated with poor prognosis.

### PO-180. A 10‐Year Retrospective Review on Clinical Presentations, Pathological Features, Treatment and Outcomes on Paediatric Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN) in Hong Kong {#pbc27455-sec-4060}

[W. Chan]{.ul} ^1^, J. Chiu^2^, G. Lam^3^, C.W. Luk^2^, C.K. Li^3^, S.Y. Ha^1^

*^1^Queen Mary Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R.; ^2^Queen Elizabeth Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R.; ^3^Prince of Wales Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: BPDCN is an uncommon haematologic malignancy derived from type 2 dendritic cells (DC). It was first classified as a distinct entity under acute myeloid leukemia (AML) and related precursor neoplasms in the 2008 WHO classification. This neoplasm typically follows a highly aggressive clinical course in adults and elderly, whereas experience in children with this disease is very limited.

**Design/Methods**: This is a territory‐wide multi‐centred retrospective review on the clinical and pathological findings of local paediatric cases of BPDCN presented under the age of 18 years over past 10 years from 1 January 2008 to 31 December 2017 registered under the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG). Additional well‐documented paediatric BPDCN cases from literatures using PubMed search under keyword BPDCN were incorporated for combined statistical analyses using Statistical Package of Social Sciences Version 22.0 (SPSS Inc., Chicago, IL). Probabilities of overall survival (OS) and event free survival (EFS) were calculated using Kaplan‐Meier estimation. Log rank test was used to compare survival of different groups. P‐values \<0.05 were deemed significant.

**Results**: Total 3 cases were identified locally and 43 cases were identified from literature. Median duration of follow up was 22.5 months (range 2 month to 13 years) among the 40 patients with available follow up. Nine patients were alive 5 years after diagnosis. 5‐year OS and 5‐year EFS were 70.1±8.4% and 65.7±10.2% respectively. Statistically significant better OS and EFS were observed in patients treated with ALL verses other protocols (OS 95.7±4.3% for ALL, 41.6±14.1% for AML and others, p = 0.003; 5‐year EFS 82.0±13.2% for ALL, 50.0±13.1% for AML and others, p = 0.006). These results concur with conclusions published in literatures.

**Conclusions**: BPDCN in children are clinically less aggressive compared to adults. High index of suspicion is crucial to early diagnosis. Treatment with ALL‐type chemotherapy appears to be superior outcomes.

### PO-181. Acute Promyelocytic Leukemia Treated with Arsenic Trioxide and Chemotherapy: A Single Center Experience from India {#pbc27455-sec-4070}

[P. Chhabra]{.ul} ^1^, D. Thakkar^1^, A. Sharma^1^, S. Nivargi^1^, N. Rastogi^1^, S.P. Yadav^1^

*^1^Medanta‐ The Medicity, Pediatric Hemato‐oncology and BMT, Gurugram, India*

**Background/Objectives**: Conventional treatment of acute promyelocytic leukemia (APML) with chemotherapy is costly and has high morbidity and mortality. Arsenic Trioxide (ATO) alone is a low cost therapy for APML but associated with significant relapse risk. A combination of low dose chemotherapy and ATO might be an effective therapy. Here we describe our experience of treating children with APML by combination therapy

**Design/Methods**: We retrospectively analyzed data of five children (Male‐4; Female‐1) diagnosed with APML in our unit. All were started on All‐trans retinoic acid (ATRA) at 25 mg/m^2^ soon after diagnosis. Four high‐risk patients received a course of induction chemotherapy (Daunorubicin 45 mg/m^2^ x 3 days and Cytarabine 200 mg/m^2^ x 7 days in 3 children and Idarubicin alone 12 mg/m2 x 4 days in 1 child). The only standard‐risk child developed steroid resistant differentiation syndrome on day 13 of induction with ATRA and ATO and so both were stopped and Daunorubicin (45mg/m^2^ for 3 days) was given. All five patients subsequently received ATO for 28 days as consolidation therapy and 6 maintenance ATO cycles (10 days per month), followed by maintenance oral chemotherapy (6‐Mercaptopurine and Methotrexate) and ATRA (10 days every 3 monthly) for a total duration of 1 year

**Results**: All 4 high‐risk children achieved morphologic remission at the end of induction chemotherapy and molecular remission after ATO consolidation. One child developed differentiation syndrome in induction, another developed gut perforation during induction requiring surgery and a third developed splenic and pulmonary infarcts along with right atrial thrombosis in induction requiring anticoagulation. The standard‐risk child achieved morphologic and molecular remission after receiving further ATO consolidation. All five children are alive and in complete molecular remission at the median follow‐up of 9 months (4‐61 months)

**Conclusions**: It\'s feasible and safe to treat children with APML by combination of low dose chemotherapy and ATO

### PO-182. Incidence and Mortality Among Children, Adolescents and Young Adults with Non‐Lymphocytic Leukemia in Brazil: A Population‐Based Study {#pbc27455-sec-4080}

[S.V.M. Feliciano]{.ul} ^1^, M.D.O. Santos^2^, M.S. Pombo‐de‐Oliveira^1^

*^1^Instituto Nacional de Câncer José Alencar Gomes da Silva, Programa de Hematologia‐Oncologia Pediátrico ‐ PHOP, Rio de Janeiro, Brazil; ^2^Instituto Nacional de Câncer José Alencar Gomes da Silva, Divisão de Vigilância e Análise de Situação‐ Coordenação de Prevenção e Vigilância, Rio de Janeiro, Brazil*

**Background/Objectives**: Non‐lymphocytic leukemia (NLL) is heterogeneous with varied pathogenesis. Recently the Brazilian Population‐Based Cancer Registries (PBCR) demonstrated the differences in incidence rates of childhood leukemia in Brazil. The objective of this study was to evaluate trends in incidence and mortality rate of NLL among children, adolescents and young adults (cAYA) in Brazil.

**Design/Methods**: Incidence data are extracted from dataset of 16 (PBCR) cities located in five geographical regions (1988 to 2014), and mortality from the databases of the Brazilian Health Mortality Information System (1979 to 2014) for the same Brazilian cities. Age‐specific incidence (ASIR), Age‐specific mortality (ASMR), Age‐adjusted incidence (AAIR) and mortality (AAMR) and crude incidence and mortality rates were calculated, according to PBCR and age strata. A *joinpoint* regression analyses were performed for trends evaluations regionally. The Annual Percent Change (APC) and Average Annual Percent Change (AAPC) were also estimated.

**Results**: The median AAIR of NLL was 13.45 per million. The highest ASIR were observed in children \<1 year (18.77 per million) and in young adults (20‐29 years old: 15.13 per million). The lowest ASIR were observed in children into age strata 5‐9 years‐old (9.89 per million). The analysis of incidence trends (AAPC) showed a significant decline in Cuiabá (‐13.9%), Manaus (‐5.5%) and São Paulo (‐4.9%) while an increased rate was observed in Fortaleza (+9.3%), João Pessoa (+7.6%) and Grande Vitória (+2.9%). Mortality rates demonstrated significant decline in Belo Horizonte (‐2.4%), Campinas (‐1.4%), Curitiba (‐5.0), Fortaleza (‐1.5%), Goiânia (‐1.5%), Grande Vitória (‐0.9%), João Pessoa (‐1.8%), Porto Alegre (‐3.9%), Recife (‐2.2%), Salvador (‐2.4%) and São Paulo (‐2.8%).

**Conclusions**: Our data analysis demonstrated a decline of incidence rates when compared with the historical series. A substantial decrease mortality rate observed and interpreted as a an improvement in NLL recognition and therapeutically approach of myeloid malignancies.

### PO-183. Inferior Outomes in Children Having t(8; 21) Translocation in Pediatric AML: A Prospective Analysis from South India {#pbc27455-sec-4090}

[K.G. Gopakumar]{.ul} ^1^, T. Priyakumari^1^, S. Hariharan^2^, S. Seetharam^1^, N. Manjusha^1^, R. Binitha^1^, C.S. Guruprasad^1^

*^1^Regional Cancer Centre, Pediatric Oncology, Trivandrum, India; ^2^Regional Cancer Centre, Cancer Research, Trivandrum, India*

**Background/Objectives**: Children with core binding factor (CBF) acute myeloid leukemia (AML) have high survival with the current standard chemotherapy protocols. However, upcoming data from various parts of the world points to ethnic variations in the survival of children with t (8; 21) translocation

**Design/Methods**: A prospective study to assess the socio‐demographic and clinical profile of children (\<14 years of age) with AML was conducted in the Department of pediatric oncology in a Regional Cancer Centre in South India Children were treated with two cycles of standard "7+3" induction chemotherapy constituting daunorubicin and cytosine arabinoside followed by 3 consolidation courses with high dose cytosine arabinoside (3g/m2/day). An event was described as any induction failure after two induction courses or any disease recurrence after treatment completion. The clinical outcomes were estimated using Kaplan Meier analysis

**Results**: A total of 55 children with de novo AML were enrolled over a period of 1.5 years. Children with t (8; 21) translocation constituted 24% (n=13) of study population. Complete remission after 1st induction was achieved in 69% (n=9). Two children (15.3%) did not attain remission following 2 courses of induction chemotherapy. The 1 year‐RFS and EFS in the 13 patients with t(8;21) translocation was 62.7% (SE 15.5) and 57% (SE 15.1) respectively, which is inferior compared to outcomes in high income countries. Five children (38.4%) in this group had aberrations in sex chromosomes. This was not significantly associated with inferior survival compared to children without these aberrations (60% v/s 53.5%, p=0.82).

**Conclusions**: Our data is consistent with recent emerging literature indicating ethnic heterogeneity in survival outcomes in children with AML having t (8; 21) translocation. A multicenter trial incorporating cytogenetic and molecular analysis would help in identifying additional factors, if any, associated with these ethnic variations in treatment outcomes

### PO-184. Infections and Infection Related Mortality During Induction Chemotherapy in Children with Acute Myeloid Leukemia: A Prospective Analysis from South India {#pbc27455-sec-4100}

[K.G. Gopakumar]{.ul} ^1^, T. Priyakumari^1^, R.N. Swapna^2^, S. Seetharam^1^, N. Manjusha^1^, R. Binitha^1^, C.S. Guruprasad^1^

*^1^Regional Cancer Centre, Pediatric Oncology, Trivandrum, India; ^2^Regional Cancer Centre, Microbiology, Trivandrum, India*

**Background/Objectives**: Infections are an important cause of morbidity and mortality in children with acute myeloid leukemia (AML). Identification and characterization of these infections are often challenging in resource limited settings, the impact of which plays a crucial role in determining the survival of this vulnerable group.

**Design/Methods**: A prospective study was conducted in the Department of Pediatric Oncology in a Regional Cancer Centre in South India to assess the infections and infection related mortality during induction chemotherapy in children having de novo AML treated with the "7+3" standard induction protocol.

**Results**: A total of 50 children with de novo AML (APML excluded) were enrolled over a period of 1.5 years. A total of 93 induction courses were analysed. There were 1.56 infectious episodes per induction course (146 documented infectious episodes). Out of the 356 microbiological cultures taken, 73 (21%) were positive. Thirty seven (50.6%) gram negative, 28 (38.3%) gram positive and 8(11%) fungal organisms were isolated. Multi drug resistant (MDR) organisms constituted 40% (n=31) of all positive cultures. Of the 243 (68.2%) blood cultures taken, Blood stream infections were detected in 36 cases (14.8%). Fever without focus was seen in 9 instances. There were 41 cases of X‐ray proven pneumonitis and 39 cases with skin infections. Septic shock developed in 8.9 % cases with clinically documented infections. There were seven infection related deaths accounting for an induction mortality of 14% (7/50). Three of them did not have any culture proven sepsis. The other four cases had MDR infections

**Conclusions**: Infections during induction were predominantly gram negative. MDR organisms contributed significantly to infection related mortality. With vigilant microbiological surveillance, rational antibiotic use and intensive supportive care, it is possible to limit infection related mortality in resource limited settings to a low level as achieved in high income countries.

### PO-185. Congenital Myeloid Leukaemia: A Tertiary Single Centre Experience {#pbc27455-sec-4110}

[K. Green]{.ul} ^1^, A. Rao^1^

*^1^Great Ormond Street Hospital, Paediatric Haematology, London, United Kingdom*

**Background/Objectives**: Congenital acute myeloid leukaemia is a rare leukaemia, presenting within the first month of life. It is clinically and biologically distinct from leukaemia of infancy and childhood. The overall prognosis is poor; with a high reported mortality. Treatment remains challenging; balancing disease remission with treatment‐related morbidity and mortality. We present the first UK single centre experience of patients with congenital acute myeloid leukaemia, aiding an overview of the characteristics of congenital leukaemia and better evaluation of optimal treatment strategies.

**Design/Methods**: Data was collected for all infants diagnosed with congenital leukaemia between 2004 and 2017 at a UK tertiary paediatric haematology centre. Parameters recorded included demographics, antenatal history, disease morphology and karyotyping, treatment and overall outcomes.

**Results**: 11 newborn infants were diagnosed with congenital myeloid leukaemia; 6 (55%) females and 5 (45%) males. Average gestational age was 39+1 weeks (35‐42). No newborns had family history of paediatric malignancies, antenatal or postnatal TORCH infections, congenital malformations or consanguinity. Average age at diagnosis was 17 days (2‐46). 9 (82%) newborns had acute myeloid leukaemia, and 2 (18%) myeloid sarcoma. 7 (64%) newborns displayed typical MLL rearrangement, 1 (9%) KMT2a rearrangement, and 1 (9%) t(8;16)(q11;p13) translocation. At presentation, 10 (91%) newborns displayed cutaneous blue nodules, 4 (36%) splenomegaly, 5 (45 %) hepatomegaly, and 2 (19%) lymphadenopathy. 2 (19%) children presented with life‐threatening leukostasis. Average white cell count at diagnosis was 80 (6‐271). 1 patient presented in DIC. 10 (91%) newborn infants received chemotherapy treatment; with 1 not due to t(8;16)(q11;p13) translocation and spontaneously remitting disease. 6 (55%) newborns died and 5 (45%) survived.

**Conclusions**: Newborns with congenital acute myeloid leukaemia have overall dismal outcomes; primarily due to treatment related toxicity and increased risk of relapse. Larger studies with international cohorts of patients are needed to aid achieving a balance between cure and minimising treatment related toxicity.

### PO-186. Age and NRAS Mutation Status are Possible Prognostic Markers in Pediatric Acute Myeloid Leukemia with CBFB‐MYH11 Fusion Gene {#pbc27455-sec-4120}

[Y. Hara]{.ul} ^1^, N. Shiba^2^, K. Ohki^3^, G. Yamato^4^, M. Sotomatsu^4^, D. Tomizawa^5^, T. Taki^6^, A. Kinoshita^7^, N. Kiyokawa^3^, H. Arakawa^1^, A. Tawa^8^, K. Horibe^9^, T. Taga^10^, S. Adachi^11^, Y. Hayashi^4^

*^1^Gunma University Graduate School of Medicine, Pediatrics, Maebashi, Japan; ^2^Yokohama City University Hospital, Pediatrics, Yokohama, Japan; ^3^National Research Institute for Child Health and Development, Pediatric Hematology and Oncology Research, Tokyo, Japan; ^4^Gunma Children\'s Medical Center, Hematology and Oncology, Shibukawa, Japan; ^5^National Center for Child Health and Development, Children\'s Cancer Center‐, Tokyo, Japan; ^6^Kyoto Prefectural University of Medicine, Molecular Diagnostics and Therapeutics, Kyoto, Japan; ^7^St Marianna University School of Medicine, Pediatrics, Kawasaki, Japan; ^8^National Hospital Organization Osaka National Hospital, Pediatrics, Osaka, Japan; ^9^National Hospital Organization‐ Nagoya Medical Center, Clinical Research Center, Nagoya, Japan; ^10^Shiga University of Medical Science, Pediatrics, Otsu, Japan; ^11^Kyoto University Graduate School of Medicine, Human Health Sciences, Kyoto, Japan*

**Background/Objectives**: Prognostic markers in pediatric acute myeloid leukemia (AML) with inv(16)(p13q22)/*CBFB‐MYH11* have not been identified yet.

**Design/Methods**: We analyzed molecular and clinical characteristics of 39 pediatric AML patients with *CBFB‐MYH11* enrolled in the Japanese AML99 and AML‐05 trials. Survival analyses revealed the excellent overall survival (OS) of patients with *CBFB‐MYH11* (97.4%), however, their event‐free survival (EFS) remains unsatisfactory (73.8%). Thus, we compared their characteristics between patients with or without events during treatment and follow‐up (n = 10 and 29, respectively). Events in this study included death, relapse, and second malignancy.

**Results**: Median age and the frequency of *NRAS* mutations significantly differed between these two groups (1.5 years vs 10.0 years, *p* = 0.005, and 0% vs 44.8%, *p* = 0.016, respectively). Consequently, we performed survival analyses in patients with *CBFB‐MYH11* according to age and *NRAS* mutation status. When we defined 3 years old as a cutoff (12 patients aged \<3 years and 27 patients aged 3 to \<18years), survival analyses revealed significantly worse 5‐year EFS and cumulative incidence of relapse (CIR) in patients aged \<3 years than in those aged 3 to \<18 years (41.7% vs 88.4%, *p* \<0.001, and 58.3% vs 7.9%, *p* \<0.001, respectively). Conversely, *NRAS*‐mutated patients (n = 13) had significantly better EFS and CIR than *NRAS*‐wildtype patients (n = 26) (100% vs 60.5%, *p* = 0.012, and 0% vs 35.7%, respectively). Accordingly, *NRAS*‐wildtype patients aged \<3 years (n = 9) had the worst outcomes (EFS = 22.2% and CIR = 77.8%).

**Conclusions**: Age and *NRAS*‐mutation status may be useful prognostic markers in pediatric AML with *CBFB‐MYH11*. The utility of these markers should be further investigated to prevent relapse and stem cell transplantation in them.

### PO-187. Extramedullary Myeloid Sarcoma in Children {#pbc27455-sec-4130}

[P. Huong]{.ul} ^1^

*^1^Viet Nam National Cancer Hospital, Pediatric Oncology, Ha Noi, Vietnam*

**Background/Objectives: Background**: Myeloid sarcoma (MS) is a tumor composed of granulocytic precursor cells occurring in an extramedullary location. MS are rare neoplasms whose knowledge is largely based on case reports. MS is often initially misdiagnosed, the most common alternative diagnoses being lymphoma, undifferentiated cancer, malignant melanoma, extramedullary hematopoiesis and inflammation. Immunohistochemistry and immunophenotying are crucial for the accurate diagnosis of MS. **Purpose**: Introduction of a very rare clinical case of MS in the diagnosis of myelodysplastic syndrome. **Object**: A 9 year old boy with MS has been treated in Pediatric Oncology Department, K hospital from May, 2016 to August, 2016.

**Design/Methods**: Retrospectively describe a clinical case.

**Results**: The patient is described smilar to some other cases in literature. He was treated with an Acute Myeloicytic Leukemia conventional chemotherapeutic protocol and discharged.

**Conclusions**: The case is rare in clinical practice. The exact diagnosis was made by immunohistochemistry and immunophenotying. Treatment with systemic chemotherapy was associated with his primary favorable survival outcome.

### PO-188. Аpplication of the Modified Protocol AML‐BFM‐2004 in Uzbekistan {#pbc27455-sec-4140}

[S. Ibragimova]{.ul} ^1^, N. Babakhanova^1^, F. Rizaeva^1^, K. Nigmatov^1^

*^1^Scientific Research institute hematology and blood transfusion, Children, Tashkent, Uzbekistan*

**Background/Objectives**: Evaluating the effectiveness and reproducibility of the modified protocol AML‐BFM‐2004 in Uzbekistan in the treatment of acute myeloid leukemia in children

**Design/Methods**: 130 patients with acute myeloid leukemia (AML) who received treatment in the children\'s department of the Scientific Research Institute of Hematology and Blood transfusion in the period from 2010 to 2015. The mean age of the patients was 6.2 ± 2.1, the median follow‐up was 5 years. Among the patients were 62 girls and 68 boys. The modified protocol AML‐BFM‐2004 provides for stratification of patients into two prognostic risk groups: standard (SRG) (n = 42), including children with AML FAB M0, AML FAB M1/M2 and high‐risk group (HRG) (n = 88)), which included all other patients. The dose of cytarabine is reduced to 2 g/m^2^. Not performed allogeneic bone marrow transplantation in patients at high risk in first remission, in the absence of this therapy in Uzbekistan.

**Results**: Out of 130 patients treated with AML BFM‐2004 (m), 42 (32.3%) patients were referred to SRG, the remaining 88 (67.7%) to HRG. Of these, 13 patients (10.0%) were resistant to the therapy, clinic‐hematologic remission was achieved in 105 (80.7%). Death in induction was noted in 12 patients (9.2%), death in remission ‐ 9 (6.9%). One of the reasons for the high mortality in the initial period of treatment was an increased risk of severe hemorrhagic complications, due to the initial thrombocytopenia. In the period of post‐remission therapy (death in remission), the main cause of mortality was infectious complications, more often fungal etiology. Of the 96 patients who achieved remission, a relapse occurred in 52 (54.1%). 5‐year event‐free survival rate was 45.8% (44 patients).

**Conclusions**: Despite the modification of the AML BFM‐2004 protocol, in general, the AML BFM‐2004 (m) protocol is an effective treatment program and reproduced in hematological clinics in Uzbekistan.

### PO-189. An Outcome Analysis of the Core Binding Factor Childhood Acute Myeloid Leukemia: Rationalized Approach in Resource Limited Settings {#pbc27455-sec-4150}

[N. Jabbar]{.ul} ^1^, S. Ashraf^1^

*^1^The Indus Hospital, Pediatric Hematology Oncology, Karachi, Pakistan*

**Background/Objectives**: Core‐binding factor (CBF) Acute Myeloid Leukemia (AML) is considered as favorable subgroup according to existing classifications such as Medical Research Council (MRC) criteria. It has two major subtypes; t(8;21) (CBFA) and inversion inv. (16) (CBFB). Most of the centers in country do not offer treatment for childhood AML due to limited resources and poor outcome. Therefore, from 2013, a rationalized approach was adapted in our institute to find and treat CBF AML cases. Data is analyzed for prevalence and treatment outcome of this favorable subgroup. This may help in making some strategy of treating AML at national level.

**Design/Methods**: This is retrospective observational study, conducted in pediatric oncology department of The Indus Hospital. Total 244 cases of age group 1‐17 years with AML (excluding Acute Promyelocytic Leukemia and AML with Down syndrome) were registered during a period of July 2013 to June 2017. The cytogenetic study (FISH) performed and CBF positive cases were treated with curative intend and analyzed for outcome.

**Results**: Cytogenetic performed in 206/244 (84%) cases. CBF detected in 68 (33%) including, t(8;21) in 56 (27%) and inv. (16) in 12 (6%) cases. The t(8;21) mainly seen in AML M1 & M2 whereas, inv. (16) in AML M4 subgroups. Abandonment and treatment related mortality seen in 9% and 33%, respectively. Disease relapsed in 25% cases, whereas, event free survival with and without abandonment is noted in 35% and 40% patients respectively. The median follow up is 16 months.

**Conclusions**: The prevalence of CBF AML is comparable with international data. However, in our setting, the anticipated outcome is influenced by variables such as abandonment and high treatment related mortality. As international data advocate high likelihood of response and survival, we suggest broadening this rationalized approach of treatment with strategies to negotiate the limiting factors, especially poor supportive care.

### PO-190. Clinical Significance of Mutations of RAS Pathway Related Genes Including PTPN11, RAS, and CBL Genes in Pediatric AML: JCCG Study JPLSG AML‐05 {#pbc27455-sec-4160}

[T. Kaburagi]{.ul} ^1^, G. Yamato^1,2^, N. Shiba^2,3^, Y. Hara^2,4^, K. Ohki^5^, M. Sotomatsu^1^, H. Arakawa^4^, N. Kiyokawa^5^, D. Tomizawa^6^, S. Adachi^7^, T. Takashi^8^, K. Horibe^2^, Y. Hayashi^1,2,9^

*^1^Department of Hematology/Oncology, Gunma Children\'s Medical Center, Gunma, Japan; ^2^Clinical Research Center, National Hospital Organization Nagoya Medical Center‐, Aichi, Japan; ^3^Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan; ^4^Department of Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan; ^5^Department of Pediatric Hematology and Oncology Research, National Research institute for Child Health and Development, Tokyo, Japan; ^6^Division of Leukemia and Lymphoma, Children\'s Cancer Center‐ National Center for Child Health and Development, Tokyo, Japan; ^7^Department of Human Health Science, Graduate School of Medicine‐ Kyoto University, Kyoto, Japan; ^8^Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan; ^9^Institute of Physiology and Medicine, Jobu University, Gunma, Japan*

**Background/Objectives**: Acute myeloid leukemia (AML) is a complex disease caused by the genetic heterogeneity. Various driver gene mutations in AML were identified owing to massively parallel sequencing technologies. Of these mutations, *RAS* pathway genes were major cause in AML like juvenile myelomonocytic leukemia. However, the characteristics of pediatric AML with mutations of *RAS* pathway genes remain unclear. Thus, to reveal the significance of these mutations, we analyzed *PTPN11*,*CBL, and N and K‐RAS* mutations in pediatric AML patients.

**Design/Methods**: Between 2006 and 2010, 443 pediatric patients with de novo AML (0--17 years) participated in the Japanese AML‐05 trial conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group. Of these, 369 samples were available, and we analyzed *PTPN11* (exons 2‐4, and 13),*CBL* (exon 8‐9)*, and N and K‐RAS* (exons 1‐2) mutations using Sanger sequencing.

**Results**: We found 91 *RAS* pathway mutations as follows: *PTPN11*, 21; *CBL*, 8; *NRAS*, 49; *KRAS*, 13. Five of 8 *CBL* mutations were identified in CBF‐AML. *KRAS* mutations were associated with high frequency of *CSF3R* mutation (6/8, *p* = .029). *NRAS* mutations were frequently observed in inv(16) (20/31, *p* \< .001) and monosomy 7 (5/9, *p* = .021) and were mutually exclusive with *FLT3*‐ITD. *PTPN11* mutations were also frequently observed in monosomy 7 (6/9, *p* = .04). Remarkably, there were significant differences in event‐free survival between patients with or without *PTPN11* mutations (5‐year EFS, 25% vs. 56%; *p* = .007) and overall survival between patients with or without *NRAS* mutations (5‐year OS, 80% vs. 65%; *p* = .010). Interestingly, although*CBL* mutations was not associated with prognosis in pediatric AML, all 3 patients without CBF‐AML relapsed.

**Conclusions**: Pediatric AML patients with *PTPN11, CBL, NRAS* or *KRAS* mutations harbored their own molecular features, respectively. We would like to discuss these data at the annual meeting.

### PO-191. Outcome of Second Hematopoietic Stem Cell Transplantation for Post‐Transplant Relapse of Pediatric Acute Myeloid Leukemia {#pbc27455-sec-4170}

[K. Kawaguchi]{.ul} ^1^, K. Urabe^1^, I. Takahashi^1^, T. Ogura^1^, Y. Horikoshi^1^, K. Watanabe^1^

*^1^Shizuoka Children\'s Hospital, Department of Hematology and Oncology‐ Shizuoka Children\'s Hospital, Shizuoka City, Japan*

**Background/Objectives**: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains the only curative treatment for children with high‐risk acute myeloid leukemia (AML). The prognosis for patients with relapsed AML after allo‐HSCT is dismal. A second allo‐HSCT is a potentially curative option for relapse after allo‐HSCT.

**Design/Methods**: From 2001 to 2017, 9 children with relapsed AML after allo‐HSCT in Shizuoka Children\'s Hospital received second allo‐HSCT. We reviewed their medical records and retrospectively analyzed clinical data and outcome.

**Results**: The median age at the second allo‐HSCT is 6 years old (range:1‐14). Six patients were female. The median interval between transplants was 515 days (range:43‐2367 days). The graft sources of the second allo‐HSCT were as follows: bone marrow, 7; cord blood, 1; peripheral blood stem cell, 1. At the time of the second allo‐HSCT, three patients were in CR, while six were not. Conditioning regimen was myeloabrative in 7 patients and reduced‐intensity in 2. Median follow‐up was 9.5 months (range:3.8‐150.3 months).The cumulative incidence of grade II‐IV acute graft‐versus‐host disease (GVHD) was 66.7 ± 31.4%, and that of chronic GVHD was 28.6 ± 6.8%.The overall survival rate at 5 years was 34.6 ± 18.3%. Non‐relapse mortality rate at 2 years was 28.9 ± 7.3%. Two out of three patients who received second allo‐HSCT in CR are still alive and one died of infection. In contrast, only two out of six who received second allo‐HSCT in non‐CR survived. Two deaths out of seven who received myeloablative conditioning were caused by therapy‐related complications (thrombotic microangiopathy, and infection).

**Conclusions**: Our results suggest that second allo‐HSCT is a promising therapeutic approach for patients especially in CR. Therapy‐related mortality was observed with myeloablative conditioning. Further studies will be required to identify optimal conditioning regimensfor second allo‐HSCT.

### PO-192. Successful Treatment of Pediatric Epstein‐Barr Virus‐Positive Aggressive Natural Killer‐Cell Leukemia {#pbc27455-sec-4180}

[B.K. Kim]{.ul} ^1^, K.T. Hong^1^, H.J. Kang^1^, H.Y. An^1^, J.Y. Choi^1^, H.Y. Shin^1^, H.S. Ahn^1^, K.D. Park^2^, D.S. Lee^3^

*^1^Seoul National University College of Medicine, Pediatrics, Seoul, Republic of Korea; ^2^Chunbuk National University College of Medicine, Pediatrics, Cheongju, Republic of Korea; ^3^Seoul National University College of Medicine, Laboratory medicine, Seoul, Republic of Korea*

**Background/Objectives**: Epstein‐Barr virus (EBV)‐positive aggressive Natural Killer‐cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. There have been less than 100 ANKL cases reported in the literature to date, of which only 12 were in pediatric patients. We report here the first case of a pediatric patient with EBV‐positive ANKL that has been successfully treated and achieved complete remission.

**Design/Methods**: We analyzed retrospectively a 16‐year‐old boy who was diagnosed with EBV‐positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT).

**Results**: A 16‐year‐old boy presented with prolonged fever, night sweating, diarrhea, anorexia, cough and sputum for a week. Hepatosplenomegaly was observed and his laboratory findings showed thrombocytopenia (44x10\^9/L), mild leukopenia (2.970x10\^9/L), mild elevation of alanine aminotransferase (1.57 μkat/L) and aspartate aminotransferase (2.05 μkat/L). His ferritin level was markedly increased (15,981.54 pmol/L ng/mL), while his triglyceride and fibrinogen levels were 2.12 mmol/L and 2.05 g/L, respectively. He was diagnosed with ANKL after bone marrow biopsy and immunohistocytochemical stain.

He was successfully treated using combination chemotherapy and a subsequent alloHSCT. He had no serious side effects after the treatment. He is disease‐free 4 years and 9 months after alloHSCT.

**Conclusions**: This case shows that combination chemotherapy regimen followed by alloHSCT with combination chemotherapy could be a feasible strategy for the treatment of pediatric EBV‐positive ANKL.

### PO-193. Complex Karyotype has Adverse Prognostic Impact in Pediatric De Novo Acute Myeloid Leukemia (AML) {#pbc27455-sec-4190}

[S. Kim]{.ul} ^1^, J.W. Lee^1^, P.S. Jang^1^, N.G. Chung^1^, B. Cho^1^

*^1^College of Medicine‐ The Catholic University of Korea, pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: Karyotypes at diagnosis have important prognostic value in pediatric AML. Our study aimed to determine the prognostic value of complex karyotype in pediatric *de novo* acute myeloid leukemia (AML) except t(15;17).

**Design/Methods**: The present study included 48 patients who were diagnosed and treated for *de novo* AML at The Catholic University of Korea from April 2008 to September 2017, and were found to have abnormal karyotype. Patients with core binding factor AML(n=50), *MLL* rearrangements(n=14) and normal karyotype AML(n=38) were excluded. The median age at diagnosis was 6.6years. Twenty‐four patients had a complex karyotype (CK)(10 female), defined as three or more numerical or structural abnormalities, while the remaining 24 patients had other non‐complex abnormal karyotype. Primary endpoint was event‐free survival (EFS) and overall survival (OS) of CK patients compared with patients with other abnormal karyotypes.

**Results**: Of the 48 CK patients, two were primary refractory (8.3%) and five failed to achieve remission after the first course of induction chemotherapy. The 5‐year EFS of patients with CK and other abnormal karyotypes was 48.5%±11% and 59.0%±12% respectively (p=0.212). The 5‐year OS of CK patients was significantly inferior to that of patients with other abnormal karyotypes(50.0±12% vs. 76.5±11%, p=0.044). All three CK patients treated with chemotherapy alone in first complete remission died of disease progression after relapse. The OS of CK patients was inferior to that of patients with other abnormal karyotypes even after allogeneic hematopoietic cell transplantation in first CR, although without statistical significance (58.0%±14% vs. 75.6%±14%, p=0.251). Overall, 9 of 10 CK who relapsed died, while 3 of 7 patients with other abnormal karyotypes who relapsed died.

**Conclusions**: Patients with CK showed poor outcome with a chemotherapy only‐based treatment strategy. After relapse, response to salvage chemotherapy was inferior in CK patients compared with patients with other abnormal karyotypes, resulting in significantly lower OS for CK patients.

### PO-194. High‐Risk CALM‐AF10 in Myeloid Malignancy: Clinical Outcomes of Four Pediatric Cases in Our Groups {#pbc27455-sec-4200}

[Y. Koga]{.ul} ^1^, K. Nakashima^1^, T. Kobayashi^2^, H. Ono^1^, U. Oba^1^, M. Noguchi^2^, H. Nakayama^2^, S. Ohga^1^

*^1^Graduate School of Medical Sciences‐ Kyushu University, Department of Pediatrics, Fukuoka, Japan; ^2^National Hospital Organization Kyushu Cancer Center, Division of Pediatrics, Fukuoka, Japan*

**Background/Objectives**: t(10;11)(p12‐14;q13‐21) rarely occurs in pediatric leukemias with CALM‐AF10 fusion. This type of AML is not stratified into a high‐risk leukemia that needs hematopoietic stem cell transplantation (HSCT) in the 1^st^ complete remission (CR).

**Design/Methods**: Four cases with t(10;11)(p12‐14;q13‐21) myeloid neoplasia were treated in our hospitals between 2000 and 2016.

**Results**: Case series

Case 1: a 13‐year‐old male with AML showing 44, X, ‐Y, t(10;11)(p12;q14), dic(16;17)(p11.2;q11.2;p11.2), add(22)(q13) \[12/20\]. He died after a matched related bone marrow transplantation (MR‐BMT). Fluorescence *in situ* hybridization analysis revealed CALM‐AF10 in leukemic cells. Case 2: a 14‐year‐old male with AML showing 46, XY, t(10;11)(p12;q14) \[4/20\], 46, idem, add(2)(q31) \[5/20\], 45, idem, t(1;19)(q21;q13), dic(16;17)(p11;p11) \[5/20\], with myeloid antigens and CD7. He died of treatment‐related complications after the 3rd HSCT. Case 3: a 15‐year‐old male with myeloid sarcoma in the mediastinum showing 46, XY, t(10;11)(p12;q14) \[19/20\], 41, idem, t(1;3)(p34;q21), ‐5, ‐7, ‐11, add(12)(q24.1), ‐13, ‐21 \[1/20\], with myeloid antigens and CD7. He obtained CR after chemotherapy, and died of tumor lysis during the re‐induction therapy for regrowth. Case 4: an infant with AML showing 46, XY, t(10;11)(p12;q14) \[18/20\] and myelomonocytic antigens. He received a MR‐BMT after induction failure. It led to the 1st CR that has continued for 8 years.

**Conclusions**: No poor outcome has been reported in pediatric cases with CALM‐AF10 ALL after chemotherapy. However, an early HSCT might be inevitable for the control of CALM‐AF10 AML in pediatric and adult cases.

### PO-195. Exploring Compounds Which have the Potential to be Repurposed into Induction Therapy for Paediatric Patients with Acute Myeloid Leukaemia {#pbc27455-sec-4210}

[K. Lappin]{.ul} ^1^, K. Matchett^1^, K. Mills^1^

*^1^Queen\'s University Belfast, Centre for Cancer Research and Cell Biology, Belfast, United Kingdom*

**Background/Objectives**: Leukaemia is the most frequently (30%) occurring type of paediatric cancer. Of these, approximately 80% are acute lymphoblastic leukaemia (ALL) with acute myeloid leukaemia (AML) cases making up the remaining 20%. Management of ALL has improved dramatically in recent years, but unfortunately, children with AML do not have the same promising outlook with a 60% 5‐year survival, a high risk (20%) of not responding to induction therapy, accompanied by a high rate of relapse. Recent data (Bolouri *et al*., 2017), strongly indicates the need for age‐specific therapies for children with AML.

**Design/Methods**: *In silico* analysis of RNA‐sequencing data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) cohort was performed to generate gene expression changes between different patient subgroups comparing each to patients who survived without relapse following treatment. In addition, high throughput compound screening was performed on cell lines, representative of paediatric AML, with different cytogenetic and mutational backgrounds to identify effective compounds across different patient groups.

**Results**: The*in‐silico* analysis identified a number of key pathways, including those associated with DNA damage response (DDR), were deregulated amongst non‐responder patients who died within 1 year compared to those who survived without relapse. Several DDR genes showed up‐regulation, which has been shown to interfere with a patient\'s response to chemotherapy (Broustas and Lieberman, 2014). Due to the severe side effects of the standard therapy and the percentage of patients who will not respond, we sought to identify possible alternative therapies for the treatment of these patients. Screening of experimental compounds and FDA approved therapies identified several compounds with repurposing potential for age‐specific AML treatment, such as Venetoclax.

**Conclusions**: To improve the outcome for paediatric patients with AML, it is imperative that alternative therapies are identified which when combined with a means of identifying non‐responders will lead to improved outcomes.

### PO-196. Cancer Cytogenetics Including Childhood Cancer: An Experience in a Single Hospital for 34 Years {#pbc27455-sec-4220}

[K. Lee]{.ul} ^1^, J. Kim^1^, J. Kim^1^

*^1^Kyungpook National University School of Medicine, Department of Pediatrics, Daegu, Republic of Korea*

**Background/Objectives**: Chromosome analysis is important diagnostic tool for cancer. We primarily evaluated the type of chromosome abnormalities from the known cancer patient a single hospital for 34 years.

**Design/Methods**: Chromosome study had been done with specimens from peripheral blood, bone marrow and cancer tissue. Cell were cultured short term or long term period with various medium including RPMI without any mitogen. Banding with trypsin EDTA was done.

**Results**: The mean age was 23.8 (1 day‐89 y/o) y/o and male and female ratio was 1:1.1. 3280 (23.9%) were under than 20 years of age.15,921 among total 16,350 (97.4%) samples were successfully cultured for cytogenetic study. Half of them were studied in recent 10 years. For cancer cytogenetics 6,563 cases of peripheral blood, bone marrow cell and tissues were evaluated. Others from peripheral blood for clinical diagnosis of chromosomal abnormality and cancer; 8,323 cases, amniotic fluid and chorionic villi for prenatal diagnosis of chromosomal abnormality; 1035 cases were included. Among 113 translocation observed in peripheral blood Philadelphia chromosome was detected in 22, balanced translocation in 39 and unbalanced translocation in 52. In bone marrow culture numerical abnormalities were observed in 217 samples; hypodiploidy in131, hyperdiploidy in 50, hypotriploidy in 3, hypertriploidy in 5, hypotetraploidy in 5, hypertetraploidy in 23 and trisomy or monosomy of +4, +5, +7, +8, +9, +21, +22, ‐Y, 47, XXY were in 298. Structural abnormalities were observed in 1,092 samples which were included Philadelphia chromosome translocation in 314, t(8:21), t(15:q7) in 103, other translocation t(1:19), t(7:11), t(8:14) in 214. Partial abnormalities including 1p+,1q+,inv(3),7q‐,9p+,9p‐,inv(9),11q+,11q‐,15p+,inv(16),i(17q),der(19),20q‐,mar were in 461. The frequent aberrations were t(8;21), ‐Y, t(15;17), +8 in AML; t(9;22), hyperploidy, ‐19 in ALL; t(9;22) in CML; +8, ‐7, dup(1q), dup(7q), del(20q) in MDS.

**Conclusions**: In this study, the type of cytogenetic abnormalities from known cancer patients were reviewed.

### PO-197. ATRA‐ATO Leads to Proteasomal Degradation of FLT3‐ITD Oncoprotein via Increasing Ubiquitin Conjugate UBCH8 Expression in Leukemia {#pbc27455-sec-4230}

[C. Liang]{.ul} ^1^, X. liu^1^, L. wang^1^, Y. tang^1^, C. peng^1^, W. tang^1^, Y. li^1^, L. huang^1^, X. luo^1^

*^1^The First Affiliated Hospital of Sun Yat‐sen University, Pediatrics, guangzhou, China*

**Background/Objectives**: Our previous research showed that arsenic trioxide (ATO) and all‐trans retinoic acid (ATRA) are selectively targets FLT3‐ITD positive AML cell lines (MV4;11/MOLM‐13). In this study, we investigated the mechanism of ATRA‐ATO mediates the degradation of FLT3‐ITD.

**Design/Methods**: The study was conducted on two FLT3‐ITD positive AML cell lines (MV4;11/MOLM‐13) and two FLT3‐ITD negative AML cell lines (RS4;11/THP1). They were treated with ATRA‐ATO. The interaction between UBE2L6 and FLT3‐ITD were determined by Western blot. The effect of UBE2L6 in the regulation of FLT3‐ITD was detected by cycloheximide (CHX) and Proteasome inhibitor Bortezomib. Cell viability and cell apoptosis were analyzed using cell counting kit‐8 (CCK‐8) and flow cytometry assay. The protein expression were analyzed using Western blotting.

**Results**: Concurrent treatment with ATRA and ATO significantly reduced cell viability and induced cell apoptosis in FLT3‐ITD, but not wild‐type FLT3 (FLT3‐WT), cell lines. Mechanistically, we found FLT3‐ITD oncoprotein was ubiquitinated and degraded during the cotreatment of ATRA and ATO in time‐dependent manners. Moreover, the proteasome inhibitor Bortezomib obviously increased the abundance of ubiquitinated‐FLT3‐ITD (Ub‐FLT3‐ITD), ubiquitin‐conjugating human enzyme 8 (UbcH8), and Ub‐UbcH8, Concerning the potential mechanisms involved in this process, we illustrated that ATRA‐ATO down‐regulated the expression of FLT3‐ITD oncoprotein through the UbcH8 mediated UPS(ubiquitin‐proteasome system).

**Conclusions**: The data support that ATRA‐ATO combination might be a potential candidate therapy for FLT3‐ITD AML treatment by activating apoptotic pathway and degrading FLT3‐ITD oncoprotein via the UbcH8 mediated UPS.

### PO-198. A Follow‐Up Report of Pediatric Acute Myeloid Leukemia from 293 Cases in a Single Center {#pbc27455-sec-4240}

[R. Min]{.ul} ^1^, Q. Benquan^1^, L. Fang^1^, L. Tianfeng^1^, L. Xiaoming^1^, C. Xiaojuan^1^, Y. Wenyu^1^, G. Ye^1^, Z. Li^1^, Z. Yao^1^, C. Yumei^1^, Z. Xiaofan^1^

*^1^Institute of Hematology‐ Blood Disease Hospital‐ Chinese Academy of Medical Sciences‐ Peking Union Medical College, Pediatric, Tianjin, China*

**Background/Objectives**: To investigate the efficacy and the prognostic factors in pediatric acute myeloid leukemia according to the standard diagnostic and therapeutic regimen.

**Design/Methods**: Newly‐diagnosed AML patients, who were treated with CAMS‐2005/2009 regimen from April 2005 to December 2015, were enrolled in this study. Clinical characteristics, therapeutic effect and prognostic factors were retrospectively analyzed. Overall survival (OS) and event free survival (EFS) rates were estimated by the Kaplan‐Meier method.

**Results**: A total of 293 cases were enrolled in this study, included 169 males and 124 females. The median age at diagnosis was 8 years. During the introduction therapy, 24 patients (8.2%) occurred early‐death, while 229 patients (78.2%) achieved CR. After achieved CR, 17 patients (7.4%) accepted hematopoietic stem cell transplantation (HSCT). Sixty‐eight patients (29.7%) relapsed. The 3‐year OS and EFS of all patients were 56.5%±3.0% and 50.7%±3.0%, respectively. The OS and EFS of boys were 50.4%±4.0% and 45.6%±3.9%, while they were 64.8%±4.4%, 58.9%±4.6% in girls (*P* =0.019, 0.019). The OS and EFS of patients with low white blood cell (WBC) count (\<20 ×10\^9/L) were 63.6%±3.9% and 57.0%±4.1%, while they were 48.6%±4.4% and 44.6%±4.3% in patients with high WBC count (≥20×10\^9/L) (*P* =0.027, 0.044). The OS and EFS of patients accepted HSCT were 88.2%±7.8% and 88.2%±7.8%, while they were 70.7%±3.3% and 63.2%±3.4% in other patients who achieved CR (*P* =0.147, 0.050).

**Conclusions**: The early‐death rate, CR rate and relapse rate of AML patients treated with CAMS‐2005/2009 were 8.2%, 78.2% and 29.7%, respectively. The 3‐year OS and EFS of them were 56.5%±3.0% and 50.7%±3.0%, respectively. The sex and WBC count may be important factors for the long‐term prognosis. HSCT may improve the outcome of pediatric AML.

### PO-199. Correlation Analysis of Molecular Biological Characteristics and Prognosis of Pediatric Acute Myeloid Leukemia: Result from a Single Center {#pbc27455-sec-4250}

[R. Min]{.ul} ^1^, Q. Benquan^1^, L. Fang^1^, L. Tianfeng^1^, L. Xiaoming^1^, C. Xiaojuan^1^, Y. Wenyu^1^, G. Ye^1^, Z. Li^1^, Z. Yao^1^, C. Yumei^1^, Z. Xiaofan^1^

*^1^Institute of Hematology‐ Blood Disease Hospital‐ Chinese Academy of Medical Sciences‐ Peking Union Medical College, Pediatric, Tianjin, China*

**Background/Objectives**: To discuss the relationship between molecular biological characteristics and prognosis of pediatric acute myeloid leukemia (AML).

**Design/Methods**: Newly‐diagnosed AML patients, who were treated with CAMS‐2005/2009 regimen from August 2009 to December 2015, were enrolled in this study. The gene analysis was performed. Clinical characteristics, therapeutic effects were retrospectively analyzed. Overall survival (OS) and event free survival (EFS) rates were estimated by the Kaplan‐Meier method. Prognostic factors were evaluated by COX regression analysis.

**Results**: A total of 203 cases were enrolled in this study, included 116 males and 87 females. The median age at diagnosis was 8 years. Of them, 75 patients (36.9%) were positive for RUNX1‐RUNX1T1, 16 (7.9%) were positive for CBFß‐MYH11, 11 (5.4%) were positive for CEBPA double mutations, 5 (2.5%) were positive for NPM1 mutation, 20 (9.9%) were positive for MLL rearrangements and 17 (8.4%) were positive for FLT3‐ITD, and no abnormality was found in 59 (29.1%) cases. The 3‐year OS and EFS of all patients were 61.7%±3.5% and 53.9% ± 3.6 %. The 3‐year OS and EFS of patients with RUNX1‐RUNX1T1 were 73.5%±5.2% and 64.7%±5.8%, while they were 80.8 %±12.2% and 70.7%±14.3% in patients with CBFß‐MYH11, 100%±0.0% and 92.3%±7.4% in patients with CEBPA double mutation, 80.0 %±17.9% and 60.0%±21.9% in patients with NPM1 mutations, 48.8 %±11.4% and 43.6%±11.3% in patients with MLL rearrangements, 45.3%±12.4% and 39.2%±12.2% in patients with FLT3‐ITD mutation, 45.1 %±6.6% and 34.4%±6.4% in other patients (*P*=0.000, 0.000). COX multivariate analysis showed that molecular biological characteristics was an independent prognostic factor.

**Conclusions**: The molecular biological characteristics was an independent factor for the prognosis of pediatric AML.

### PO-200. Free Breath T2\*‐Mapping for Planning and Monitoring of Chelation Therapy in Children {#pbc27455-sec-4260}

[E. Nazarova]{.ul} ^1^, G. Tereschenko^1^, G. Novichkova^2^, N. Smetanina^2^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Radiology, Moscow, Russia; ^2^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Hematology, Moscow, Russia*

**Background/Objectives**: Transfusion‐related patients are required in regular monitoring of iron content in the body due to the iron overload syndrome. Our aim is to introduce the non‐invasive method of MRI‐T2\* mapping instead of liver biopsy for children and to develop the scoring system of T2\* values based on siderosis grades.

**Design/Methods**: MRI investigation was performed in 57 patients aged from 2 to 18. For liver iron overload quantification we have used Cartesian T2\*‐mapping with breath hold technique, and Radial T2\*‐mapping with free breath technique. T2\* values were estimated by special relaxation maps tools and correlated with iron concentration measured by liver biopsy immediately after MRI scan.

**Results**: For non‐invasive assessment of LIC (liver iron concentration) with free breath and breath hold techniques we have received a calibration curves between the biopsy data and the R2\* (R2\*=1/T2\*) values with correlation coefficient 0.95 (R2=0.89; confidence interval of 87% ‐ 97% with CC= 95%) and 0.86 (R2=0.74; confidence interval of 49% ‐ 56% with CC= 95%) respectively. Also we obtained the scoring system of T2\* values based on siderosis grades: 1 ‐ T2\* \> 2.5 ms (LIC 0.1‐2.0mgFe/g dry), 2 ‐ T2\* of 1.5‐2.5ms (LIC 2‐7mgFe/g dry), 3 ‐ T2\* of 1‐1.5ms (LIC 7‐15mg/g dry), 4 ‐ T2\* of 0‐1 ms (LIC \>15mg/g).

**Conclusions**: Therefore, T2\* mapping can replace liver biopsy in all phases of the clinical observation of a patient: the staging of iron overload, the start of chelation therapy, the evaluation of efficacy and the end of therapy. It was established that free breath T2\* mapping is more convenient for iron quantification in children because there is no need for the patients to hold their breath. It also provides much higher in‐plane resolution with thinner slices and whole liver coverage.

### PO-201. Multi‐Organ Thrombosis as a Manifestation of Idiopathic Hypereosinophilic Syndrome in an Adolescent: A Case Report {#pbc27455-sec-4270}

[S. Oberoi]{.ul} ^1^, G. Cuvelier^1^, I. Vanan^1^, J. Wrogemann^2^, S. Veroukis^3^, V. Brule^3^, T. Brown^1^

*^1^CancerCare Manitoba, Paediatric Hematology Oncology, Winnipeg, Canada; ^2^Health Sciences Centre, Paediatric Radiology, Winnipeg, Canada; ^3^Health Sciences Centre, Paediatric Critical Care, Winnipeg, Canada*

**Background/Objectives**: Idiopathic hypereosinophilic syndrome (HES) presenting as multi‐organ thrombosis is rare in children. We here report an adolescent with idiopathic HES who presented with pulmonary embolism and deep venous thrombosis of lower limbs.

**Design/Methods**: A retrospective review of patient\'s electronic chart was conducted to retrieve clinical and laboratory data.

**Results**: A 14‐year‐old boy presented with fever, shortness of breath, chest pain and swelling of the left leg. A Doppler ultrasound of lower limbs revealed thrombosis of the left femoral and popliteal vein. A CT scan of the chest demonstrated segmental pulmonary embolism along with pleural effusion. He was started on Dalteparin and antibiotics. A complete blood count showed an absolute eosinophil count (AEC) of 7770/mm3. His AEC was persistently elevated. He subsequently developed an extensive occlusive clot of right femoral and popliteal vein. Marked eosinophilia was detected in pleural fluid (eosinophils: 21%). A full diagnostic work up for infectious, immunological and rheumatological causes of eosinophilia was negative. Bone marrow aspirate and biopsy were normocellular with marked non‐dysplastic eosinophilia (23%). Bone marrow cytogenetics and flow cytometry were normal. BCR/ABL and JAK2 V617F mutations were negative. FIP1L1, CHIC2, PDGFRA and PDGFRB gene regions were normal by PCR. No evidence of B‐ or T‐cell clonality was seen. He was started on methylprednisolone with the working diagnosis of idiopathic HES. His clinical status improved and AEC normalized within 3 days. Dalteparin was changed to Apixaban due to sub‐therapeutic anti‐Xa levels. Oral prednisolone was started following the pulse dose of methylprednisolone. Assessments done three months in to treatment showed resolving pulmonary emboli with normal pulmonary function and persistence of old thrombus in the lower limbs. Clinically, he continues to do well on Apixaban and minimum doses of prednisolone.

**Conclusions**: HES can present as multiple life‐threatening thromboses in children. One should be aware of the thromboembolic complications of HES.

### PO-202. Serum Zinc Level and Pediatric Acute Myelod Leukemia: A Prospective Observational Study {#pbc27455-sec-4280}

[A. Patel]{.ul} ^1^, B. Biswas^1^, G. Toteja^2^, A. Singh^3^, S. Bakhshi^1^

*^1^Dr BRA IRCH‐ All India Institute of Medical Sciences‐ New Delhi, Department Of Medical Oncology, New Delhi, India; ^2^Indian Council of Medical Research, Center For Nutrition Research and Training ICMR, New Delhi, India; ^3^All India Institute of Medical Sciences‐ New Delhi, Department Of Biochemistry, New Delhi, India*

**Background/Objectives**: Data from our institute (unpublished) on micronutrients in pediatric malignancies showed that decreased serum Zinc(Zn) level was associated with trend toward decreased overall survival in pediatric AML subjects (p=0.09). In view of lacunae of literature on role of Zn in AML and our pilot unpublished data, we planned this study to explore further.

**Design/Methods**: This is a single institute prospective study of consecutively treated pediatric AML patients from Apr 2015‐Jan2018. Infection‐related morbidity data (duration of fever, use of second line antibiotics, probable fungal infection, presence of bacteraemia, death within 30 days) were collected. Serum Zn sample was collected before start of treatment and were analysed by Inductively Coupled Plasma Mass Spectrometry method. From our pilot unpublished data of 39 cases, for 80% power and a error of 0.05, calculated sample size was 90 for low Zn to predict inferior OS at 1 year with hazard of 2.8

**Results**: In 91 AML patients with median age 10 years (range: 1‐18), Zn levels were low in 7(7.7%), normal in 39 (42.8%) and above normal in 45 (49.5%) patients; mean Zn was 1313.24 ug/L. CR rate was 69/89 (78%). At median follow up of 23.83 (range: 0.27‐34), OS was 44±5% (CI 0.33‐0.54) and EFS was 40±5% (CI 0.30‐0.50). Zn deficiency (\<600/ug/L) was associated with increased use of second line antibiotics (p=0.043), increased 30‐day mortality (p=0.01) and also had inferior CR rate (p=0.022). Low Zn level did not predict EFS(p=0.12) and OS(p=0.15). On exploratory analysis, high Zn level (\>1200 ug/L) predicted inferior OS (p=0.05) and EFS (p=0.04)

**Conclusions**: Low Zn level does not predict outcome; however, it is associated with increased death during initial 30 days, more use of second line antibiotics and inferior rate of CR. High levels are associated with inferior outcomes; therefore, whenever supplementing Zn, narrow range needs to be maintained.

### PO-203. Outcomes in Juvenile Myelomonocytic Leukemia: A Single Center Experience from India {#pbc27455-sec-4290}

[S. Patel]{.ul} ^1^, R. Raj^1^, R. Uppuluri^1^, V. Swaminathan^1^, M. Sivasankaran^1^, D. Jayaraman^1^

*^1^Apollo Cancer Institute, Department of Pediatric hematology‐oncology and blood and marrow transplantation, Chennai, India*

**Background/Objectives**: Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy of early childhood, representing 2% to 3% of all pediatric leukemias. Allogeneic hematopoietic stem cells transplantation is the only curative option. In this study we analyze the outcomes of patients with JMML treated at our center.

**Design/Methods**: We have performed a retrospective analysis of all children who were diagnosed to have juvenile myelomonocytic leukemia as per WHO criteria at our centre over a 6 year period from November 2011 to November 2017. The demographic, clinical, laboratory and treatment characteristics were recorded from medical records.

**Results**: Ten children with JMML were included in our study with a male to female ratio of 2.3:1 and a median age at diagnosis of eight months (6 months to 4 years). The median total leukocyte count at presentation was 24,000 (15,000 to 70,000). The most common presenting features were fever and splenomegaly. Two children had clinical evidence of NF‐1 and monosomy 7 was seen in 4 (40%) children. Splenectomy prior to transplantation was performed in 2 children. All children received low dose chemotherapy with 6‐mercaptopurine and cis‐retinoic acid prior to transplantation. Out of the ten children, two children had progressive disease and died prior to HSCT and treatment was abandoned in one child. Seven children underwent allogeneic HSCT of which two needed a second transplant for graft rejection. Myeloablative conditioning with busulfan, cyclophosphamide and melphalan resulted in sustained chimerism in three children with matched sibling donors and treosulfan and fludarabine based conditioning resulted in sustained chimerism in two children after alternate donor HSCT resulting in an overall survival of 50%.

**Conclusions**: Allogeneic HSCT from matched sibling or alternate donor offers a 71% survival rate in children with JMML. The factors determining optimal outcome include adequate disease control prior to HSCT and myeloablative conditioning.

### PO-204. Inherited Genetic Effects and Risk of Langerhans Cell Histiocytosis Relapse {#pbc27455-sec-4300}

[E. Peckham‐Gregory]{.ul} ^1^, R. Chakraborty^1^, M. Scheurer^1^, H. Abhyankar^1^, K. McClain^1^, C. Allen^1^, P. Lupo^1^

*^1^Baylor College of Medicine, Department of Pediatrics‐ Section of Hematology‐Oncology, Houston, USA*

**Background/Objectives**: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia characterized by lesions including pathogenic CD207+ dendritic cells among an inflammatory infiltrate. Children with LCH experience high relapse rates nearing 50%. Recent sequencing studies have found recurrent activating mutations in MAPK pathway genes in ∼85% of LCH lesions, including that carriers of *BRAF*‐V600E experience a 2‐fold increased relapse risk. However, the role of inherited genetic effects in LCH relapse remains unknown. Therefore, we conducted a pilot genome‐wide association study (GWAS) to characterize the role of inherited genetic variants on risk of LCH relapse.

**Design/Methods**: Patients with LCH (n=117) were recruited from Texas Children\'s Hospital, of which 52 patients experienced a relapse event. Genotyping was performed on the Illumina Omni5 Quad BeadChip. We evaluated the role of common variants (minor allele frequency \>5%) on LCH relapse using PLINK. We applied a genome‐wide threshold of *P*‐value\<5.0x10^‐8^, and threshold of suggestive significance at *P*‐value\<1.0x10^‐5^.

**Results**: We identified a variant in high‐linkage disequilibrium with a cluster of loci on Chromosome 9 associated with decreased risk of LCH relapse (non‐coding RNA*LOC100506532* rs2182640; P=6.98x10‐6). While this non‐coding RNA gene is largely uncharacterized, non‐coding RNAs function to regulate gene expression at the transcriptional and post‐transcriptional level.

**Conclusions**: In this genome‐wide assessment of inherited genetic variation and LCH relapse, we identified a genomic region that may be associated with LCH relapse. While this genetic region needs to be validated in an independent replication set, our results provide initial evidence to suggest inherited risk factors influence LCH disease severity.

### PO-205. Acute Myeloid Leukemia: Incremental Improvement in Outcome in a Developing Country {#pbc27455-sec-4310}

[S. Peyam]{.ul} ^1^, A. Trehan^2^, R. Jain^2^, D. Bansal^2^, N. Varma^3^

*^1^Postgraduate institute of Medical Education and Research, Pediatric hematology ‐ oncology unit‐ Department of Pediatrics, Chandigarh, India; ^2^Postgraduate Institute of Medical Education and Research, Pediatric Hematology Oncology unit‐ Department of Pediatrics, Chandigarh, India; ^3^Postgraduate Institute of Medical Education and Research, Department of Hematology, Chandigarh, India*

**Background/Objectives**: Acute Myeloid Leukemia (AML) is reported to have high abandonment and high treatment related mortality (TRM) in low and middle income countries. We have previously presented a TRM of 48% (2004‐2010). This analysis was performed to determine improvement over the years in the outcome of pediatric AML treated in a tertiary centre in India.

**Design/Methods**: One hundred fourteen children treated for AML (Non M3) on AML MRC 15 protocol from January 2011 to December 2017 were analyzed. No patient underwent a transplant.

**Results**: Mean age: 6.96 (1‐12) years (79 boys and 35 girls). FAB subtype: M0: 1; M1: 13; M2: 51; M4: 23; M5: 20; M6: 2; M7: 4. Fourteen patients had gum hypertrophy, 15: chloromas and four patients had central nervous system disease. Cytogenetic profile and molecular response was not available, complete remission (CR) being based on morphology alone. Eighty six patients were evaluated for remission after induction 1: 58 (67.5%) were in CR, 13 having 5‐15% blasts. Eighty were in CR after induction 2, 6 being refractory to therapy. Overall mortality was 30.7% (35/114), 23(65%) being early deaths. Six died after induction 2 and 6 after course 3. Cumulative mortality decreased from 38% (2011‐2014) to 24.5 % (2015‐2017) (p=0.15). Infection related deaths: 85%. Ten defaulted therapy. Twenty six patients relapsed (22.8%), 13 being early relapse (time to relapse: 356 ± 169 days, \[149‐862\]). The 5 year event free survival (EFS) was 31.6%. (EFS being 26% \[2011‐2014\] & 36% \[2015‐2017\] p=0.67)

**Conclusions**: High TRM precludes satisfactory outcomes in AML. Infections are responsible for the majority of TRM. However, a slow improvement is visible, attributable to dedicated fellows in training & enhancement of supportive care facilities. Quality improvement through refining infrastructure and education is a pivotal remedial measure required in LMIC\'s to enable giving demanding and intensive therapy.

### PO-206. Facial Palsy as a Presentation of Relapsed Pediatric AML {#pbc27455-sec-4320}

[H. Poparn]{.ul} ^1^, T. Torchareon^1^, N. Yupensuk^1^, P. Techavichit^1^, K. Chiengthong^1^, S. Lauhasurayotin^1^, D. Sosothikul^1^, P. Seksarn^1^

*^1^Faculty of Medicine, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Facial palsy is a rare manifestation of central nervous system (CNS) involvement of pediatric leukemia, characteristic by infiltration of leukemic cells in peripheral nervous system. We present clinical presentation, treatment, and outcomes of two cases of relapsed AML presented with facial palsy.

**Design/Methods**: Retrospective study

**Results**: Two patient (10‐year‐old girl, a 2‐year‐old boy) were present with facial palsy, lower motor neuron type, after completion of acute myeloid leukemia (AML) treatment. They were initially diagnosed with AML, M 0 and M 5, with no CNS involvement and received four courses of intensive chemotherapy without bone marrow transplantation. They developed facial palsy at 4 and 1 month after treatment competition. Isolated CNS relapsed was revealed by CSF cytology and brain MRI which showed CSF positive for blast cells with 1.5x1.5‐cm high signal intensity in T2W lesion at left globus pallidus on MRI in the first patient and no blast cell in CSF but MRI showed abnormal signal intensity lesion at intracanalicular segment of right facial nerve in the second patient. They received re‐induction with systemic chemotherapy, intrathecal cytarabine, hydrocortisone and methotrexate and cranio‐spinal irradiation. Subsequently, both of them were bone marrow relapsed at 3 months and 2 months after CNS relapsed and died of disease

**Conclusions**: Facial palsy should be considered as a rare manifestation of CNS AML. Children with isolated CNS relapsed remain has a dismal prognosis.

### PO-207. Upfront Addition of Sorafenib and Cladribine Based Chemotherapy in FMS‐Like‐Tyrosine Kinase‐3 Internal Tandem Duplication (FLT3‐ITD) Mutated Pediatric‐Acute Myeloid Leukemia (AML): A Single Centre Experience {#pbc27455-sec-4330}

[N.D. Pradhan]{.ul} ^1^, K. Vijaysekharan^1^, S. Tandon^1^, H. Sankaran^1^, M. Prasad^1^, G. Narula^1^, N. Patkar^2^, P. Tembhare^2^, P.G. Subramanian^2^, S. Banavali^1^

*^1^Tata Memorial Centre, Medical Oncology Pediatric, Mumbai, India; ^2^Tata Memorial Centre, Hematopathology Laboratory, Mumbai, India*

**Background/Objectives**: FLT3‐ITD mutation confers poor prognosis in Acute Myeloid Leukemia (AML). Low remission rates and early relapse with conventional chemotherapy has necessitated alternative treatment approaches such as FLT3‐inhibitors and allogenic‐ Stem Cell Transplant (AlloSCT). We analyzed the outcome of Pediatric FLT3‐ITD mutated AML patients at our centre treated with combination of Sorafenib and chemotherapy.

**Design/Methods**: Pediatric FLT3‐ITD+ AML patients registered from January‐2013 to December‐2017 were included. Patients receieved either standard (3+7) and HDAC chemotherapy, oral metronomic therapy (6TG, Etoposide, Prednisolone), or Cladribine(2CDA)+Cytarabine. Sorafenib was given at dose of 150‐200 mg/m^2^ daily once FLT3‐ITD was found positive. None underwent SCT because of financial and logistic reasons.

**Results**: Of 611 pediatric AML patients registered during this period, 41(6.7%) were FLT3‐ITD+. Median age was 9.5‐years (Range 2‐14.5‐years). Twenty (48%) had high allelic ratio (\>0.4%). Six patients refused treatment. Of the remaining 35, 4 received only conventional chemotherapy without Sorafenib (no survivors); 19 received Sorafenib during induction (post‐induction MRD negative CR in 15; 79%); and 12 during the post‐induction phase (post‐induction MRD negative CR in only 2; 16.6%). Out of 8 post‐induction MRD‐positive patients who received Cladribine based consolidation, 6 (75%) became MRD‐negative; whereas both patients who received HDAC consolidation failed to become MRD‐negative. The Disease Free Survival at 12 and 36 months for 19 patients who received upfront Sorafenib is 85.7% and 39%; as opposed to 38% and 0% for the 12 patients who didn\'t receive upfront Sorafenib.

**Conclusions**: Though allogenic SCT has the best outcomes in FLT3‐ITD+ AML, many patients do not achieve CR and thus cannot be transplanted. Upfront addition of Sorafenib and later Cladribine based consolidation helped us produce deep remissions in most patients treated so and thus this regimen may help more patients to be taken‐up for the curative allogenic SCT.

### PO-208. Neonatal Leukemoid Reaction: Description of Associated Risk Factors and Utility to Predict Morbimortality {#pbc27455-sec-4340}

[J.A. Salinas Sanz]{.ul} ^1^, C.M. Maroto‐García^2^, B. López‐Andrade^3^, M.A. Durán‐Pastor^3^, J. Pons‐De Ves^4^, J. Figuerola‐Mulet^5^

*^1^Pediatric Hemato‐Oncology. Hospital Universitario Son Espases, Pediatrics, Mallorca, Spain; ^2^Neonatology. Hospital Universitario Son Espases, Pediatrics, Mallorca, Spain; ^3^Hematology. Hospital Universitario Son Espases, Hematology, Mallorca, Spain; ^4^Inmunology. Hospital Universitario Son Espases, Inmunology, Mallorca, Spain; ^5^Pediatric. Hospital Universitario Son Espases, Pediatrics, Mallorca, Spain*

**Background/Objectives**: Neonatal leukemoid reaction (LR) is a relatively rare condition in newborns but the incidence in extremely‐low‐birth‐weight infants increases to 17%. It is defined as \>50000/μL leukocytes or \>30000/μL neutrophils without evidence of malignancy.

The etiology is unclear but it is related to an excess of inflammatory cytokines and GM‐CSF. It is associated with prenatal corticosteroids, chorioamnionitis and infections and recently with bronchopulmonar dysplasia, female gender and prematurity. Recently there is a growing evidence suggesting a poor prognosis

**Design/Methods**: We analyze retrospectively newborns with LR and controls matched for gender and gestational age in relation 2:1 admitted to our center between 2012‐2016. We exclude a case with trisomy 21.

We compare maternal and neonatal characteristics, clinical evolution and laboratory findings in both groups.

**Results**: LR was observed in 35 newborns (incidence 7 %), 4 of them with \>100000/μl. The mean gestational age and birth weight of case and control groups were 26+3 vs 26+4 weeks and 950 g vs 873 g. 60% in both groups were women. The severity of leucocytosis is related to less gestational age and lower weight

Chorioamnionitis increases the risk of LR (4‐fold) as well as maternal steroids. LR group have significantly more ventilation needs (4.2‐fold; p=0.003) and surfactant doses (p=0,01)less hospitalization duration (44 vs 79 days; p=0.037) and more mortality (4.1‐fold; p=0.009)

RL began the 2nd day, the peak time was at 4 days and lasted 12 days. The higher value of PCR was 2.8 mg/dl.

Using ROC curves we have chosen 54650/μL leukocytes (p=0.001) as cut‐off value with maximum sensitivity (58,8%) and specificity (81,4%) to predict exitus in our study

**Conclusions**: LR is more frequent in newborns whose mothers had clinical chorioamnionitis and it is associated with more ventilation support, more surfactant and mortality. Number of leukocytes increases significantly with more doses of betametasona, less gestational age and weight.

### PO-209. Dendritic Cell Leukemia: An Uncommon Malignancy in Pediatric Patients {#pbc27455-sec-4350}

[N. Sanclemente‐Lopez]{.ul} ^1^, M.D.R. Alvarez^2^, J.L. Ramirez‐Melo^3^, O. Ramirez^1^

*^1^Centro Medico Imbanaco, Pediatric Oncology Unit, Cali, Colombia; ^2^Hospital Infantil Los Angeles, Pediatric Oncology Unit, Pasto, Colombia; ^3^Universidad Libre, Pediatrics, Cali, Colombia*

**Background/Objectives**: Dendritic cell leukemia (DCL) is \<1% of childhood acute leukemias and \<0.7% of cutaneous lymphomas. Expression of both CD4 and CD56 in the absence of any myeloid, lymphoid or natural killer cell marker, defines the disease. Information about this leukemia in children is scarce. Therefore, we consider the clinical description of cases as valuable to pediatric oncologists.

**Design/Methods**: Direct observation by the authors, medical records, laboratory, and pathology reports were used to obtain demographic and clinical data. We included cases diagnosed at a third level pediatric oncology unit of Pasto, Colombia, from June/01/2017 to March/31/2018.

**Results**: We included three patients. Patient \#1 was the older case (14 years of age), patient \#2 presented with 5 and \#3 with 6 years of age. Patient \#1 and \#3 had skin lesions. Number 1 had a flat plaque on the skin and \#3 had several skin nodules. Patient \#2 had no skin lesions. Patient \#1 and \#2 had elevated plasma lactate dehydrogenase. All had liver and spleen enlargement. None of them had CNS involvement. In other reported cases, the most common findings were hepatosplenomegaly, lymph node enlargement, and medullar infiltration. Not all patients with DCL had skin lesions or CNS involvement. Pulmonary, renal or muscular disease have been described, but none of our cases shows infiltration of any of these organs. All patients showed complete remission after myeloid type induction and had low minimal residual disease. Patient \#1 is \>30 days after allogeneic BMT. The other two are in the process of having a BMT. The three patients are alive.

**Conclusions**: Suspicion of DCL should arouse in patients with skin lesions plus pancytopenia. Nevertheless, it can also occur without skin lesions and only identified by blast immunophenotype. Early allogenic BMT should be considered when the patient is in remission, as is the only curative treatment.

### PO-210. Outcome of FLT3 Gene Mutation in Children with Acute Myloid Leukemia in CCHE Hospita {#pbc27455-sec-4360}

[S. Semary]{.ul} ^1^, S. Mahmoud^2^, M. hamad^2^, S. fahmy^3^, N. hamdy^4^, D. yassin^4^, M. gamal^5^, D. albeltagy^6^

*^1^Faculty of Medicine‐ Beni Sweif University and Children Cancer Hospital Egypt CCHE, Department of Pediatric Oncology, Cairo, Egypt; ^2^national cancer institute and CCHE, pediatric oncology, cairo, Egypt; ^3^national canser institute and CCHE, clinical pathology, cairo, Egypt; ^4^national cancer institute and CCHE, clinical pathology, cairo, Egypt; ^5^CCHE, pharmacy, cairo, Egypt; ^6^CCHE, clinical research, cairo, Egypt*

**Background/Objectives**: The presence of FLT 3 --ITD mutation in pediatric AML is associated with high rates of failure to induction, worse survival and consider as high risk group. The aim of the work is to evaluate pediatric AML patients with mutant FLT3 treated at Children Cancer Hospital Egypt (CCHE) during 10 years period.

**Design/Methods**: A retrospective study to evaluate pediatric AML with mutant FLT3 from July 2007 till July 2017 at CCHE.

**Results**: A total of 71 patients (10.33%) had FLT3 gene mutation out of 687 patients with AML. Sixty five patients (91.6%) had FLT3 gene mutation with allelic ratio \>0.4, 43 patients (66.1%) achieved CR, and 22 patients (33.8%) were refractory and died. BMT was done for 9 patients (13.8%) in 1st CR, 8 of them are alive in CR, and 1 patient (1.5%) relapsed and died. seven patients (10.7%) are alive in CR without BMT. Eight patients (12.3%) died, and 1 patient (1.5%) lost FU, 18 patients (27.6%) relapsed soon after 1stCR, 1 patient (1.5%) is in 2nd CR and alive. The rest of relapsed patients (23%) received salvage chemotherapy and died. Three years OS and EFS for the patients with FLT3 gene mutation with allelic ratio \>0.4 are 26.9%‐22.8% respectively. Three years OS and EFS for patient treated with BMT were 77.8%‐78.8% respectively versus patients were treated and achieve CR without BMT which were 16.3%‐12.8% respectively.

**Conclusions**: FLT 3 --ITD mutation in pediatric AML is associated higher rates of induction failure, survival of relapsing patients is extremely poor, and BMT in first remission if possible is the best option, otherwise significantly worse OS and EFS. Trial of the FLT3 inhibitor sorafenib is mandatory to improve outcomes for this subset of patients.

### PO-211. Downstream Pathway of AML1‐ETO Targeted ARHGEF12 Might be Targetable for Rock Inhibitor to Improve Therapy Outcome {#pbc27455-sec-4370}

[S. Shen]{.ul} ^1^, Y. Xie^2^, R. Wu^1^, L. Gao^1^, Y. Tang^1^, J. Tang^1^

*^1^Shanghai Children\'s Medical Center, pediatric hematology oncology, Shanghai, China; ^2^Shanghai Children\'s Medical Center, Hematology Oncology, Shanghai, China*

**Background/Objectives**: As a transcription factor AML1‐ETO modulate gene expression of its targets. Scanning our ChIP‐seq data we found AML1‐ETO bind to an AML1 binding motif in the promotor region of *ARHGEF12*. Exploring acute myeloid leukemia (AML) microarray databases we confirmed that the expression of *ARHGEF12* was up‐regulated consistently in AML1‐ETO‐positive AML patient samples. To confirmed this finding, we quantitated expression of *ARHGEF12* in pediatric AML samples from Shanghai children\'s medical center. Not out of expectation, all AML1‐ETO‐positive cases have higher *ARHGEF12*. Moreover, the *ARHGEF12* expression was an independent poor prognostic factor for overall survival comparing between patients with higher and lower expressed *ARHGEF12*. (P=0.0258).

**Design/Methods**: To understand the role of *ARHGEF12* in leukemogenic function of AML1‐ETO fusion gene, we knocked down *ARHGEF12 expression in* kasumi‐1 cells by shRNA. Growth of kasumi‐1 cells in vitro was significantly inhibited with cell cycle exit and more apoptosis. Further, we transformed fetal liver cells of *Arhgef12* conditional knockout mice to leukemia model by retrovirus conducted AML1‐ETO9a(AE9a) expression. Induced *Arhgef12* deletion delayed full blown of leukemia in vivo.

**Results**: The overall survival prolonged 15.5 days (median 83.5 vs. 68 days, P=0.0072). ARHGEF12 is a well‐known guanine nucleotide exchange factor for RhoA GTPase, *Arhgef12* deletion decreased activated GTP‐RhoA expression and MYPT1 phosphorylation, which is one of ROCK kinase substrates. Spleen cells from leukemic mice were cultured in vitro, the ROCK inhibitor Y‐27632 significantly decreased the cell proliferation, which mimic the tamoxifen‐induced Arhgef12 knockout phenotype. Y‐27632 combined with tamoxifen treated cells almost eradicate alive leukemia cells on the ninth day and delay leukemogenesis in vivo.

**Conclusions**: These findings suggest that ARHGEF12 as a transcriptional target of the AML1‐ETO fusion protein and plays an essential role in leukemogenesis. The ARHGEF12‐RHOA‐ROCK pathway may serve as a new therapeutic target for AML1‐ETO+ AML.

### PO-212. Pediatric Myeloproliferative Neoplasm: Triple Negative Essential Thrombocytosis {#pbc27455-sec-4380}

[A. Shimada]{.ul} ^1^, H. Ishida^1^, S. Koijima^2^, Y. Hayashi^3^

*^1^Okayama University Hospital, Pediatric Hematology/Oncology, Okayama, Japan; ^2^Nagoya University, Pediatrics, Nagoya, Japan; ^3^Institution of Medical Physiology‐ Jobu University, Medical Physiology, Isezaki, Japan*

**Background/Objectives**: Pediatric patients with myeloproliferative neoplasm (MPN) except for chronic myeloid leukemia or Juvenile myelomonocytic leukemia (JMML) is rarely reported compared with those of adults. It includes polycythemia vera (PV), essential thromobocytosis (ET), and myelofibrosis (MF) etc. There remains unknown the precise incidence of these disorders in pediatric population. Recently, *JAK2*, *CALR*, and *MPL* have a pivotal role in adult PV/ET/MF, especially *JAK2* V617F was found in 90% PV, 40‐50% ET, and 30‐40 % MF, however, our previous study showed that 29.4% of pediatric ET patients had only *JAK2* V617F (Sekiya Y., et al. Int J Hematol 2016). We compared the detection method of *JAK2* V617F by Sanger sequence and Allele specific PCR, but there were no specific difference. Furthermore, the correlation between *JAK2* V617F and 46/1 haplotype was not found in pediatric ET. Therefore, we tried to detect the further variants by Next generation sequence (NGS) in triple‐negative 8 ET pediatric patients.

**Design/Methods**: We established a custermized Haloplex target sequence panel equipped 163 leukemia related genes (Agilent) and analyzed by MiSeq (Ilumina). Informed consent was obtained in each parents and local ethnic committee approved this project.

**Results**: We found the variants of *NFkB1*, *SMARCA2*, *TET2*, *KIT*, *JAK2*, *SH2B3*, *PIK3CG*, etc. Furthermore, all 8 patients did not have a variant in any exons of the three genes (*JAK2*, *CALR*, and *MPL*).

**Conclusions**: From the adult NGS study, triple‐negative ET had heterogenous variants including *ASXL1*, *TET2*, *SH2B3* etc (Lundberg P., et al. Blood 2014). However, the variant frequency was limited from pediatric study (Karow A., et al. Leukemia 2015). Therefore, larger study will be needed to confirm the biological difference between adult and pediatric MPN. Now we had started the nation‐wide study about pediatric MPN in Japan.

### PO-213. Prognostic Factors in Children with AML1‐ETO (+) Acute Myeloid Leukemia {#pbc27455-sec-4390}

J.W. Lee^1^, S. Kim^1^, P.S. Jang^1^, N.G. Chung^1^, B. Cho^1^, K.E. Kim^1^, [J. Shin]{.ul} ^1^

*^1^The Catholic University of Korea, Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: *AML1‐ETO* (+) acute myeloid leukemia (AML), characterized by t(8;21)(q22;q22), comprises 15‐30% of pediatric AML. Our study aimed to determine the most important prognostic variables among an aggregate of clinical, genetic, and treatment response‐based factors in pediatric *AML1‐ETO* (+) AML.

**Design/Methods**: The study cohort included 41 patients (13 female) who were diagnosed with and treated for *AML1‐ETO* (+) AML at the Department of Pediatrics, The Catholic University of Korea from April 2008 to January 2017. Real time quantitative polymerase chain reaction (RQ‐PCR) for the *AML1‐ETO* fusion was done at diagnosis, and after each course of chemotherapy. Whole body magnetic resonance imaging (MRI) was undertaken at diagnosis in all patients to determine the presence of extramedullary involvement (EMI). Patients were also evaluated for possible *KIT* mutation.

**Results**: Median age at diagnosis was 10.1 years (range: 1.9‐17.6), and the median initial white blood cell (WBC) count was 16,050/mm3 (range: 720‐50,210). EMI was diagnosed in 12 patients (29%), and *KIT* mutation was found in 13 patients (32%). The 5‐year event‐free survival (EFS) was 65.9±7.7% (28/41), with 12 relapses and one treatment‐related death during remission induction. Median time to relapse was 15.8 months (range: 7.7‐23.4). A less than ‐2.2log fusion transcript decrement after remission induction, EMI at diagnosis, presence of *KIT* mutation, and higher initial WBC count significantly predicted lower EFS. However, multivariate study showed that only lower fusion transcript decrement after remission induction and EMI at diagnosis were significant predictors of worse outcome. The 5‐year overall survival (OS) was 86.3±5.7% (36/41), with all surviving patients remaining disease‐free.

**Conclusions**: A comprehensive study of risk factors in pediatric *AML1‐ETO* (+) AML showed that fusion transcript decrement after remission induction and the presence of EMI at diagnosis were the most important prognostic variables.

### PO-214. Improving Survival Rates of Acute Myeloid Leukemia in Developing Countries Using AML15 Protocol {#pbc27455-sec-4400}

[S.R. Siddaiahgari]{.ul} ^1^, S. Vaddadi^1^, A. m^2^, B. Jillela^2^

*^1^Rainbow children\'s Hospital‐ Banjara Hills, pediatric Hematology and oncology, Hyderabad, India; ^2^Rainbow children\'s Hospital‐ Banjara Hills, Pediatrics, Hyderabad, India*

**Background/Objectives: Introduction**

Acute Leukemia is most common pediatric malignancies accounting for about 30%. Acute Myeloid Leukemia (AML) accounts to 20% of acute leukemia. There is gap in the survival rates of AML in developed and developing countries. In developed countries the survival rate is about 63 to 65%.In developing countries it is of 25 to 53.8%. APML has higher survival rates.

**Aim**: To look at the outcome of AML in children of developing countries.

**Design/Methods: Period**: 8 years (January 2009‐ December 2017).

**Type of study**‐ Prospective and Retrospective observational study in Rainbow Children\'s tertiary care center.

Methods: Data of patients who have been diagnosed with AML and underwent treatment at Rainbow Children\'s Hospital during the study period was collected and analysed.

**Results**: Total number of cases ‐50. Female 55%, male 45%.3 cases are of Infantile onset. 11 cases are of \> 10 years of age. Both have unfavourable prognosis. Most common AML based on morphology and immunophenotyping -- M5.8 Cases of APML are reported. All 8 cases had t(15,17) positive.

Presenting symptoms: Most common-- Fever with skin and mucosal bleeds in 65.7% cases, 68% of cases had firm organomegaly at the time of presentation. CBP: Severe Anemia --Hb \< 5 g/dl -- 20 cases. WBC count\< 5,000 in 14 cases and \>50,000 in 7 cases. In rest of the cases, WBC count was between 5,000 to 50,000. Platelet count \< 50,000 cells/mm3 -- 28 cases. All cases had Blasts in peripheral smear except 4. All were treated with AML 15 Protocol.

**Conclusions**: The survival rates in our study are at par with the developed countries. Risk adopted chemotherapy with good supportive care improves survival rates even in developing countries.

### PO-215. Pediatric Acute Myeloid Leukemia Outcome in Limited Resource Country Single Institution Brief Report {#pbc27455-sec-4410}

[H.A. Sjakti]{.ul} ^1^

*^1^Division of Hematology‐Oncology, Department of Child Health, Jakarta, Indonesia*

**Background/Objectives**: Pediatric acute myeloid leukemia (AML) still a big problem in limited resource country. During 2007‐2010 we reported 46.2% overall survival (OS) and 6.5% event‐free survival (EFS). Several effort had been done including chemoterapy protocol revision since 2011 and improve supportive care. We doesn\'t have bone marrow transplantation (BMT) until now, and all patient receive same protocol. Aim of this study is to evaluate the result of new revised protocol during 2015‐2018.

**Design/Methods**: This is a retrospective study to pediatric patient in Cipto Mangunkusumo Hospital (CMH). Data gathered from medical record then analysed using statistical program. All patient diagnosed as AML treated by Revised Indonesia National Protocol, consist of 2 blocks induction (3 days daunorubicin, 5 days cytarabine), and 2 blocks of intensification (3 days high dose cytarabin and etoposide). Evaluation after induction chemoterapy done by bone marrow examination, and remission is determined if blast cell less than 5%.

**Results**: We treated 150 patient age 1‐18 years during 2015‐2018. Diagnosis established by morphological staining, less than half used leukemic immunophenotyping. Only 140 of 150 patient received chemotherapy. Only 52 of 140 patient (38.6%) got remission after induction, 35 patient (25.0%) didn\'t get remission, and 53 patient loss to follow up. Relapsed rate is 23 of 52 (44.2%), and time to relapsed range from 6‐36 weeks after remission. Total 63 of 150 patient died, 10 patient died before received chemoterapy, 53 died during chemotherapy. Cause of death mainly due to severe infection as treatment related death (62%). Overall survival is 46 ± 9.8% and EFS is 23 ±4.2%.

**Conclusions**: Our result still poor regardless of protocol modification and improve supportive care. It is obvious that we need more strong chemotherapy and BMT. Risk stratification by more detail patient profiling is a must for risk based treatment to reduce treatment related death.

### PO-216. Pediatric AML in a Resource‐Limited Country: Evaluation of the First Indonesian National AML Protocol {#pbc27455-sec-4420}

[E. Supriyadi]{.ul} ^1^, I. Purwanto^1^, P.H. Widjajanto^1^, S. Sutaryo^1^, S. Mulatsih^1^, G. Kaspers^2^

*^1^Pediatric Hematology Oncology‐ Dr Sardjito Hospital -- Medical‐Public Health and Nursing Faculty Universitas Gadjah Mada, Pediatric, Yogyakarta, Indonesia; ^2^Pediatric Oncology‐ VU University Medical Center‐ Amsterdam, Pediatric, Amsterdam, The Netherlands*

**Background/Objectives**: Survival gap of childhood cancer between developed and developing countries is wide. Treatment‐result of childhood acute myeloid leukemia (AML) in developing countries is estimated to be below 10% while developed countries now achieve cure‐rates of 70%. We developed and implemented a National Protocol for pediatric AML in Indonesia, starting 2011. The aim of this study was to evaluate the results of this protocol

**Design/Methods**: The medical records of children 0--18 years of age, newly diagnosed with AML from October 1995--Dec 2017 were retrospectively reviewed. The diagnosis of AML was confirmed based on morphological and histochemical examinations of marrow samples or peripheral blood. Survival analysis was performed for patients treated on the National AML protocol (doxorubicin, cytarabine and etoposide plus triple drugs intrathecal: methotrexate, hydrocortison and Ara‐C), or other/non‐national AML protocols (NOPHO‐AML, modified‐NOPHO, Maspore, CALGB)

**Results**: Of 383 patients diagnosed with AML, 283(74%) patients received chemotherapy, 22 patients were excluded from the analysis. One hundred and five (40%) patients received national AML protocol and 156(60%) received other AML protocols. Death as first event occurred in 43% of patients who received national protocol, while in other protocols was 57%(p=0.06). Causes of death in national protocol were: infection(50%), bleeding(20%) and AML itself(2%), unknown(28%). In other protocols these causes were infection(11%), bleeding(32%), and AML itself(18%), unknown(40%). The probability of overall survival after 3‐years was 11% in patients who were treated with the National AML protocol whereas it was significantly lower in the other AML protocol group 3%(p=0.04)

**Conclusions**: In national protocol, infection was the major factor causing death. In general, treatment with National AML protocol resulted in a higher survival rate compared to the non‐national AML protocols. However, overall outcome still was very poor. Improved supportive care including blood transfusions, prevention and treatment of infections most likely are key to success in the treatment of AML.

### PO-217. Low‐Dose Azacitidine Maintenance Therapy Post‐Allogeneic Stem Cell Transplantation for High‐Risk Pediatric Acute Myeloid Leukemia {#pbc27455-sec-4430}

[A. Tamura]{.ul} ^1^, T. Ishida^1^, A. Saito^1^, N. Yamamoto^1^, T. Yokoi^2^, S. Uemura^3^, N. Nino^1^, S. Nakamura^1^, A. Kozaki^1^, K. Kishimoto^1^, D. Hasegawa^1^, Y. Kosaka^1^

*^1^Kobe Children\'s Hospital, Department of Hematology and Oncology, Kobe City, Japan; ^2^Osaka University Hospital, Department of Pediatrics, Suita, Japan; ^3^Kobe University Hospital, Department of Pedictrics, Kobe, Japan*

**Background/Objectives**: The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsed after hematopoietic stem cell transplantation (HSCT) requires the exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post‐HSCT. Here, we present the case of 3 children with high‐risk AML post‐HSCT who were treated with low‐dose AZA maintenance therapy.

**Design/Methods**: We retrospectively reviewed the medical records of patients treated with low‐dose AZA post‐HSCT from April 2013 through April 2018 at Kobe Children\'s Hospital. The AZA maintenance therapy regimen comprised 32mg/m^2^ for 5 consecutive days in 1‐month cycles beginning at around day 100 post‐HSCT in patients with high‐risk AML.

**Results**: Patient 1 was a 2‐years‐old girl with AML with *FLT3*‐ITD. After 2 times relapses post‐HSCTs, she underwent the third HSCT. She received 24 cycles of AZA without major adverse events. At 41 months after the HSCT and 14 months after the discontinuation of AZA, she remains in complete remission (CR). Patient 2 was a 4‐years‐old girl with AML with Monosomy 7. After the post‐HSCT relapse, she underwent the second HSCT. Low‐dose AZA were administered post‐HSCT. Although elevated AST/ALT were observed, it was reversible. She received 10 cycles of AZA and remains in CR for 17 months post‐HSCT. Patient 3 was a 15‐years‐old boy with AML with *NUP98*‐*NSD1*. He failed to achieve CR despite two cycles of induction chemotherapies. Subsequently, he underwent HSCT in a non‐remission state. Nine cycles of AZA were given without adverse effects. He is currently on therapy and in CR for 13 months post‐HSCT.

**Conclusions**: Low‐dose AZA maintenance therapy post‐HSCT was feasible. Currently, all three patients are in CR despite their high‐risk characteristics. Our encouraging data warrants larger prospective studies to assess the efficacy and safety of low‐dose AZA maintenance therapy post‐HSCT for pediatric patients with high‐risk AML.

### PO-218. Assessment of Leukemia Fusion Gene, Karyotype, Minimal Residual Disease and Long‐Term Outcome of Children with Acute Myeloid Leukemia: Experience from a Tertial Children\'s Hospital in China {#pbc27455-sec-4440}

C. Liao^1^, [Y. Tang]{.ul} ^1^, D. Shen^1^, S. Yang^1^, W. Xu^1^, X. Xu^1^, F. Zhao^1^, S. Shi^1^, J. Liang^1^, D. Wang^1^

*^1^Children\'s Hospital of Zhejiang University School of Medicine, Department of Hematology‐oncology, Hangzhou, China*

**Background/Objectives**: Acute myeloid leukemia (AML) is less common hematopoietic malignancy in children and poorly defined in terms of fusion genes, karyotypes, minimal residual diseases (MRD) and long‐term outcome assessment in China.

**Design/Methods**: One hundred and sixty‐four children with AML during January 2009 through June 2014 admitted to the Children\'s Hospital of Zhejiang University School of Medicine were treated with NPCLC‐AML2008. The karyotypes, fusion genes, MRD detected by flow cytometry and the long‐term outcomes were analyzed.

**Results**: The fusion genes were detected in 93 (56.7%) patients: 35 (21.3%), 24 (14.6%) and 12 (7.3%) patients were positive for PML/RARα, AML1/ETO and CBFβ/MYH11 fusion genes, respectively. The 5‐year EFS rate of 40 children with APL was 90.5%. One hundred and six of non‐APL patients received the formal protocol, and their 5‐year EFS and OS rates were 59.7% and 68.7%, respectively. The 5‐year EFS rate of patients with AML1/ETO was significantly better than those without (71.1% vs 54.9, P\<0.05), while that of patients with MLL rearrangement was significantly worse than those without (21.0% vs 62.2, P\<0.001). Of the 95 patients who had successful karyotype results, the 5‐year EFS rates were 76.9%, 46.3% and 38.7% for the good, intermediate and bad karyotype groups, respectively (P\<0.05). The 5‐year EFS of patients with MRD\<2.0% after the first cycle of induction therapy was 71.4%, significantly better than those with MRD≥2.0% (40.9%, P\<0.05).

**Conclusions**: Children with AML in China has a much higher proportion of APL than those in western countries. The survial rates of patients with APL and other types of AML with low MRD levels after the first cycle of induction is significantly higher than those of other AML types such as ETO/AML1 positive with the worst survial in patietns with MLL rearrangement, indicating the significant impact of genetic heterogeneity and MRD levels after the first cycle of induction on long‐term outcome.

### PO-219. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia and High‐Risk Cytogenetics {#pbc27455-sec-4450}

[D. Tomizawa]{.ul} ^1^, M. Yoshida^2^, T. Kondo^3^, T. Miyamura^4^, T. Taga^5^, S. Adachi^6^, K. Koh^7^, M. Noguchi^8^, H. Kakuda^9^, N. Shiba^10^, K. Watanabe^11^, M. Inoue^12^, Y. Hashii^4^, Y. Atsuta^13^, H. Ishida^14^

*^1^National Center for Child Health and Development, Division of Leukemia and Lymphoma‐ Children\'s Cancer Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^3^Kyoto University, Department of Hematology and Oncology, Kyoto, Japan; ^4^Osaka University Graduate School of Medicine, Department of Pediatrics, Osaka, Japan; ^5^Shiga University of Medical Science, Department of Pediatrics, Otsu, Japan; ^6^Kyoto University, Department of Human Health Sciences, Kyoto, Japan; ^7^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^8^National Kyushu Cancer Center, Department of Pediatrics, Fukuoka, Japan; ^9^Chiba Children\'s Hospital, Department of Hematology and Oncology, Chiba, Japan; ^10^Yokohama City University Hospital, Department of Pediatrics, Tokyo, Japan; ^11^Shizuoka Children\'s Hospital, Department of Hematology and Oncology, Shizuoka, Japan; ^12^Osaka Women\'s and Children\'s Hospital, Department of Hematology/Oncology, Osaka, Japan; ^13^Japanese Data Center for Hematopoietic Cell Transplantation, Data center, Nagoya, Japan; ^14^Kyoto City Hospital, Department of Pediatrics, Kyoto, Japan*

**Background/Objectives**: Cytogenetic abnormalities are the most significant prognostic factors in acute myeloid leukemia (AML). It is a standard of care to allocate patients with AML and high‐risk cytogenetic abnormalities (HR‐AML) to allogeneic hematopoietic stem cell transplantation (allo‐HSCT), however, there is a controversy whether allo‐HSCT truly improves outcome of these patients.

**Design/Methods**: Data of 169 children and adolescents (age, 0‐19 years) with HR‐AML who received their first allo‐HSCT in first or second remission between 2000‐2015 were extracted from the nationwide HSCT registry of the Japan Society of Hematopoietic Cell Transplantation. Patients with congenital abnormalities (e.g. Down syndrome), secondary or therapy‐related AML, and/or those lacking cytogenetic data were excluded. HR‐AML was defined as AML with ‐7/7q‐, ‐5/5q‐, complex karyotype, inv(3) or t(3;3), t(6;9)/*DEK‐NUP214*, t(7;12)/*MNX1‐ETV6*, t(4;11)/*KMT2A‐AFF1*, t(6;11)/*KMT2A‐AFDN*, t(10;11)/*KMT2A‐MLLT10*, t(5;11)/*NUP98‐NSD1*, t(9;22)/*BCR‐ABL*, t(16;21)/*FUS‐ERG*, and/or *FLT3*‐ITD. Patients with t(8;21)/*RUNX1‐RUNX1T1* and inv(16) or t(16;16)/*CBFB‐MYH11* were ineligible. Outcome of these patients was retrospectively evaluated.

**Results**: Three‐year event‐free survival (EFS) and overall survival (OS) rates were 55.2% (95%CI, 46.8‐62.9%) and 69.6% (61.4‐76.3%), respectively, for all the 169 HR‐AML patients. In univariate analysis, cytogenetic subgroups had significant impact on both EFS (P=0.011) and OS (P\<0.001) rates. Especially, fourteen patients with t(16;21) showed extremely poor outcome with 3‐year‐ EFS of 26.8% (7.3‐51.5%) and OS of 34.3% (11.6‐58.7%). Additionally, older age at allo‐HSCT (10‐19 years old, P=0.025), myeloablative conditioning with total‐body irradiation (P=0.019), and grade II‐IV acute graft‐versus‐host disease (GVHD, P=0.049) were associated with inferior OS. Donor type and occurrence of chronic GVHD did not affect the outcome. Multivariate analysis revealed t(16;21) to be associated with increased overall mortality (hazard ratio=4.416, P\<0.001).

**Conclusions**: There is heterogeneity on outcome of HR‐AML among cytogenetic subgroups. Because outcome of patients with certain HR‐AML subgroup, such as t(16;21)‐positive cases, is extremely poor even with allo‐HSCT in remission, development of novel therapy is urgently required.

### PO-220. The Treatment and Prognosis of 8 Blood Disease Patients with Alveolar Hemorrhage {#pbc27455-sec-4460}

[S. Wang]{.ul} ^1^

*^1^Institute of Hematology‐ Blood Disease Hospital, Chinese Academy of Medical Sciences CAMS, pediatric blood disease dapartment, Tianjin, China*

**Background/Objectives**: To improve the diagnosis and treatment of alveolar hemorrhage.

**Design/Methods**: Retrospectively analyze 8 blood disease patients with alveolar hemorrhage from January 1999 to March 2017 in our hospital pediatric department.

**Results**: CT scan showed pulmonary infection for every patient before alveolar hemorrhage and 3 patients showed diffuse ground ‐glass appearance when alveolar hemorrhage happened and was diagnosed alveolar hemorrhage by CT scan. Two patients suffered from septicemia when bleeding happened and progressed into multiple organ failure. One patient suffered from stenotrophomonas maltophilia and another one suffered from streptococcus mitis. All patients had dyspnea and hyoxemia. Two Patients with over 95% oxyhemoglobin saturation recovered and another two with severe oxyhemoglobin saturation less than 60% were dead. Hemoglobin was reduced for all patients when alveolar hemorrhage happened. Antibiotics were used for all patients and high dose methylprednisolone were used for three patients. High dose methylprednisolone with 500mg/m2.d were used for two patients and one was dead because of multiple organ failure and one was recovery. Another one patient who received 1000mg/m2.d when her oxyhemoglobin saturation decline to 70% was cured at last and then received three courses chemical treatment. For all patients, four patients were cured and four patients were dead.

**Conclusions**: Alveolar hemorrhage was life‐threatening. We should pay high attention to it when patients suffered from pulmonary infections and septicemia, especially for those patients suffered from hemoptysis, dyspea, continues decreasing hemoglobin and CT scan abnormal. High dose methylprednisolone was effective treatment.

### PO-221. Difference Outcome of Pediatric Acute Myeloid Leukemia (AML) Treated with More Intensive Induction Chemotherapy {#pbc27455-sec-4470}

[N. Yupensuk]{.ul} ^1^, T. Torchareon^1^, H. Poparn^1^, K. Chiengthong^1^, P. Techavichit^1^, S. Lauhasurayotin^1^, D. Sosothikul^1^, P. Seksarn^1^

*^1^Faculty of Medicine, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Survival rate of pediatric AML are approximately 50‐60% in developed countries whereas outcome still more inferior in developing and middle to low income country. Treatment related toxicities and disease relapse are the major cause of death. To compare the treatment outcome and toxicities between novel more intensity and less intensive chemotherapy regimen.

**Design/Methods**: A retrospective cohort study in children diagnosed with AML treated with chemotherapy alone at our hospital from 2008 to 2017.

**Results**: Thirty‐eight patients (23male, 15female), median age 5.5 years, were diagnosed with AML. Eighteen patients were treated with less intensive induction ThaiPOG‐AML‐08 protocol which consisted of Idarubicin for 3 days and Cytarabine for 7 days (7+3). Twenty patients were treated with novel more intensive indiction ThaiPOG‐AML‐13 which consisted of Idarubicin for 3 days and Cytarabine for 10 days (10+3). Both group were treated subsequently with three consolidation intensive chemotherapy. The remission rate after induction 1 was higher (65% vs 55%) in ThaiPOG‐AML‐13 group with statistical significant (P =0.03). With the median follow up of 10 months, overall survival was higher (50% vs 44%) in ThaiPOG‐AML‐13 group with no statistical significant (P =0.92). Severe bacterial or fungal infection during induction was not significantly different among 2 groups (80% vs 83.3%, P=0.79).

**Conclusions**: Intensive AML‐induction chemotherapy showed higher remission rate with similar toxicities but not affect disease overall survival. Bone marrow transplantation and good supportive care is crucial for pediatric AML treatment.
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### PO-222. Gemcitabine and Vinorelbine as 3rd Line Chemotherapy for Primary Refractory/Relapsing Hodgkin Lymphoma‐Outcome and Toxicity Profile {#pbc27455-sec-4490}

[H. Abdel Rahman Sayed]{.ul} ^1^, A. Hamoda^2^, R. Abdel Aziz^2^, N. El Kinaaie^3^, I. Zaki^4^, E. Mohamed^5^

*^1^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^2^National Cancer Institute‐ Cairo University‐ children Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^3^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Pathology, Cairo, Egypt; ^4^National Cancer Institute‐ Cairo University‐ Chidren Cancer Hospital Egypt, Radiodiagnosis, Cairo, Egypt; ^5^Chidren Cancer Hospital Egypt, Research, Cairo, Egypt*

**Background/Objectives**: The aim of our study is to report the response rate and toxicity profile of the 3^rd^ line chemotherapy Gemcitabine and Vinorelbine (Gem/Vin) in primary refractory/relapsing HL during 10 years period

**Design/Methods**: A retrospective analysis including all patients who received salvage Gem/Vin following ABVD +/‐ radiotherapy as 1^st^ line, followed by ICE as 2^nd^ line chemotherapy. Patient were diagnosed and treated at the Children Cancer Hospital Egypt.

**Results**: Out of 1145 patients registered, 116 (10.1%) relapsed or had a progressive disease. Ninety‐eight (8.5%) received ICE as second line chemotherapy. Thirty‐six (3.1%) failed second line and received third line. Four patients were excluded from analysis as they received other type of chemotherapy, while 32 (2.7%) patients received Gem/Vin, and were included in our study. They were 21 (65.6%) males, and 11 (34.4%) females. Mean age was 10.71 years, The most common pathologic subtype was nodular sclerosis (62.5%). One (3.1%) patient was stage I, while 6 (18.7%) were stage II, 10 (31.3%) stage III, and 15 (46.9%) stage IV. The majority 21 (65.6%) were high risk patients. Sixteen patients (50%) had late relapse (\> 1 year), 8 (25%) early relapse (3 months‐1 year), and 8 (25%) were progressive/refractory (less than 3 months). Chemotherapy cycles ranged from 1 to 6 with a mean of 3. Thirteen patients (40.6%) were responders to Gem/Vin and underwent autologous hematopoietic stem cell transplantation, while (59.4%) progressed and continued treatment on palliative basis. Eight (25%) patients died, 5 (15.6%) due to disease progression, and 3 (9.3%) out of chemotherapy toxicity. The 2 years overall survival for responding patients was 87.5%, for non‐responders it was 72%. Multivariate analysis included sex, stage, risk stratification, type of relapse, and showed no statistical significant.

**Conclusions**: Gemcitabine and Vinorelbine is safe to be given as 3rd line chemotherapy for relapsing or primary refractory HL.

### PO-223. Prognostic Factors and Treatment Outcome of Pediatric Anaplastic Large Cell Lymphoma Treated at the Children Cancer Hospital Egypt {#pbc27455-sec-4500}

[H. Abdel Rahman Sayed]{.ul} ^1^, S. El Semary^2^, M. Sedky^3^, I. Atteya^1^, N. El Kinaaie^4^, M. El Wakeel^5^, O. Hassanein^6^, R. Mohyy^6^

*^1^National Cancer Institute‐ Cairo University. Children Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^2^Bany Sweif University‐ Children Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^3^National center of research ‐ Children Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^4^National Cancer Institute‐ Cairo University. Children Cancer Hospital Egypt, Pathology, Cairo, Egypt; ^5^National Cancer Institute‐ Cairo University. Children Cancer Hospital Egypt, Radiodiagnosis, Cairo, Egypt; ^6^Children Cancer Hospital Egypt, Research, Cairo, Egypt*

**Background/Objectives**: The aim of the current study is to report the epidemiological data, response rate, treatment outcome, and overall survival (OS) of Anaplastic Large Cell Lymphoma (ALCL) patients during 8 years period.

**Design/Methods**: A retrospective study included all newly diagnosed ALCL patients from July 2007 till December 2015 at the Children Cancer Hospital Egypt \[CCHE\].

**Results**: A total of 48 patients were enrolled. This represented 5.2% of all NHL patients treated at CCHE within this period of time. The majority (66.7%) were males. The mean age was 11.7 years, range 3.3 to 17.2. Twenty‐one patients (43.7%) were low stage I or II, while 27 (56.2%) had advanced stage III or IV. Eighteen patients (41.4%) had extranodal disease. ALK was positive in 42 patients (87.5%), and negative in 6 (12.5%). Following induction chemotherapy, 28 patients (58.3%) achieved complete remission (CR), 17 (35.4%) partial remission (PR), and 1 (2.1%) stable disease (SD). Two patients (4.2%) died during induction chemotherapy, both were stage IV. Disease status at last follow up showed 35 patients (72.9%) in CR, 5 (10.5%) relapse, 5 disease progression (DP), and 1 (2.1%) lost follow up (FU). The median time to relapse was 17.2 months, range 1‐67. Four patients (8.4%) were salvaged by high dose (HD) chemotherapy ICE followed by autologous hematopoietic stem cell transplantation (AHSCT), while 5 (10.5%) died out of DP, and 1 (2.1%) had treatment related mortality (TRM). The 5 years OS was 81.2% while the 5 years EFS 68.6%. Median FU period was 58.7 month, range 0.6 ‐105.8 months. Multivariate analysis included age, sex, stage, response to chemotherapy and showed no statistical significance.

**Conclusions**: Treatment of ALCL according to the Children\'s Oncology Group ANHL 0131 protocol is well tolerated. Relapsing patient could be salvaged by HD chemotherapy and AHSCT.

### PO-224. Surgery in Perforated Pediatric Intestinal Lymphoma {#pbc27455-sec-4510}

A. Younis^1^, [G. Ahmed]{.ul} ^2^, H. Abdelrahman^3^, S. Elsemary^3^, N. Elkinaai^3^, I. Zaki^4^, R. Mohy^5^, M. Elshafiey^1^

*^1^childrens cancer hospital egypt CCHE&National Cancer Institute, surgical oncology, cairo, Egypt; ^2^Faculty Of Medicine Helwan University &Children Cancer Hospital Egypt 5735, Surgery, cairo, Egypt; ^3^childrens cancer hospital egypt CCHE&National Cancer Institute, pediatric oncology, cairo, Egypt; ^4^childrens cancer hospital egypt CCHE, radiology, cairo, Egypt; ^5^childrens cancer hospital egypt CCHE, research, cairo, Egypt*

**Background/Objectives**: Perforation is the most common surgical complication in pediatric intestinal lymphoma. During operation, many surgical decisions are debatable including the extent of resection and feasibility of primary anastomosis

Aim: to assess outcome of surgical management of perforated pediatric intestinal lymphoma.

**Design/Methods**: Retrospective analysis of our data between July 2007 and end of June 2017 of all cases of intestinal lymphoma. Patients presenting with or developing perforation during treatment were then further analysed for risk factors for perforation, type of management and outcome. All patients were ≤18 years old.

**Results**: The study included 240 patients with intestinal lymphoma. Perforation developed in 16 patients (6.7 %). Most of the patients 94.7%(322 of 340) were Burkitt lymphoma with a median age of 5.1(2--15.8) years. The ileum was the most common site of perforation n=10. The timing of perforation was at presentation n=2, during induction n= 10, maintenance n= 2 and relapse n=2. Primary resection anastomosis was done in 12 patients, 3 patients had resection with a stoma and 1 patients hade stoma with no resection. The resected specimen showed a viable tumor in 10 patients, no viable tumor n= 5 and chronic inflammation in 1 patient. Median delay to restart chemotherapy was (16 days) 10‐ 29 days. Wound infection n=4(25%) and dehiscence n=2(12.5%)were the most common complications. The 3‐year OS and EFS of perforated patients were 81.3 ±9.8 %. and 75 ± 10.8 % respectively compared with 88.4 ±2.1 % and 84.4 ±2.4 % in non‐perforated patients. There were no statistically significant difference in OS (P=0.323) and EFS (P=0.22) between the 2 groups.

**Conclusions**: Perforation is not an adverse prognostic factor for survival in pediatric intestinal lymphoma patientss. A primary resection anastomosis is a safe option if complete tumor resection was feasible.

### PO-225. Outcome of Refractory/Relapsing Pediatric Hodgkin Lymphoma at the National Cancer Institute, Egypt {#pbc27455-sec-4520}

[T. Ahmed]{.ul} ^1^, H. Abdel Rahman^2^, H. El Zomor^2^, E. Khorshed^3^

*^1^Faculty Of Medicine‐ Sohag University, Clinical Oncology Department, Sohag, Egypt; ^2^National Cancer Institute‐Cairo University, Pediatric Oncology Department, Cairo, Egypt; ^3^National Cancer Institute‐Cairo University, Pathology Department, Cairo, Egypt*

**Background/Objectives**: Hodgkin lymphoma constitutes approximately 7% of childhood cancers. Children and adolescents with Hodgkin lymphoma achieve long‐term overall survival rates of over 90% with conventional chemotherapy alone or with a combination of chemotherapy and radiotherapy. Nevertheless, up to 10--15% of low stage and 20--25% of children with advanced stage HL will relapse or have primary refractory disease. Our aim is to assess the outcome of children and adolescents with relapsing\\refractory Hodgkin Lymphoma at the National Cancer Institute‐Cairo University.

**Design/Methods**: This is a retrospective analysis over a 7‐year period extending from January 2007 to December 2013, which included all patients with relapsing or primary refractory Hodgkin Lymphoma.

**Results**: Thirty‐eight patients were included in this study. Twenty‐four patients with relapsing HL and 14 with a primary refractory disease. Overall survival rate was worse for primary refractory than relapsing patients (P value = 0.01). Disease stage at relapse was found to be statistically significant for overall survival rate (P value = 0.03). Extranodal involvement have a worse outcome than nodal disease (P value = 0.02). Three year OS rate was 60.7% while 5‐year OS rate was 39.4%. Three year EFS was 58.9%. There was a significant difference between patients who responded to salvage chemotherapy after 2 cycles and who responded later regarding event free survival rates (P value = 0.03). The age, gender, pathological subtypes and presence of B symptoms at initial diagnosis or at relapse was not found to be statistically significant.

**Conclusions**: Patients with primary refractory disease, advanced disease stages at relapse and extranodal involvement have a worse outcome. Early response to salvage chemotherapy is associated with a better outcome.

### PO-226. Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): A Case Series of Consecutive Patients Treated at a Tertiary Care Hospital in Saudi Arabia from 2005‐2015 {#pbc27455-sec-4530}

[S. Al‐Sweedan]{.ul} ^1^, K. Siddiqui^2^, R. Jafri^2^, A. Al‐Kofide^2^

*^1^jordan university of science & Technology, Pediatrics, Irbid, Jordan; ^2^king faisal specialist hospital & research center, pediatric hematology/oncology, riyadh, Saudi Arabia*

**Background/Objectives**: NLPHL is a distinct and rare subtype of Hodgkin\'s Lymphoma which is associated with progressive transformation of germinal centers in concurrence or post diagnosis. We conducted this review to understand the presentation and outcome of this disease at our tertiary care hospital.

**Design/Methods**: Medical records of 22 consecutive patients diagnosed from 2005‐2015 were reviewed through research databases being maintained at the data bio‐bank in a prospective fashion. Survival patterns were evaluated via Kaplan‐Meier survival curves

**Results**: Male preponderance was observed with 72.7%(16) boys. Median age at diagnosis was 11 years (Range 4.8‐13.7). Cervical lymph nodes were most commonly involved (59%). Serology for viral hepatitis (B and C) and HIV were all negative. B‐symptoms were positive for only 9.1%(2). Only one patient had anterior mediastinal mass less than one third of thoracic diameter. Almost half (45.5%, 10) were Stage II, followed by 31.1%(7) Stage I, 18.2%(4) Stage III and 4.5%(1) Stage IV. All were treatment naïve, and were given ABVD as first line chemotherapy with a median of 4 cycles. Radiation therapy was given to 31.8%(7) patients as a part of 1st line treatment. All but two patients (90.9%, 20) achieved remission at the end of 1st line treatment. Median time to first remission recorded was 5.4 months (1.8‐11.0). With a median follow‐up of 39.8 months, all our patient were alive at the last review in February 2018. Relapse rate was 25%(5) while 3 patients had treatment failure. We achieved five year event free survival of (0.622±0.107). All but one with relapse or treatment failure, were successfully salvaged. Three relapsed cases were referred for Stem Cell Transplantation (SCT) and were alive in CR post transplantation. None of our patients experienced transformation of germinal centers

**Conclusions**: Multi‐agent therapy with a choice of SCT as salvage was a reasonable therapeutic option in our cohort of patients

### PO-227. Non Hodgkin Lymphoma: Single Center Experience {#pbc27455-sec-4540}

[E. Ataseven]{.ul} ^1^, B. Tatlı Güneş^1^, Z. Önder Siviş^1^, B. Malbora^1^, M. Türker^1^, B. Atabay^1^, H. Öniz^1^

*^1^Izmir Tepecik Research and Training Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey*

**Background/Objectives**: NHL accounts for 15% of pediatric cancer in children. In this study, our aim is evaluate the clinical characterics and treatment outcomes of NHL cases treated in our institution.

**Design/Methods**: We evaluated the recordings of the patients with NHL retrospectively, between 1987‐2016 in our institution. Demographic and clinical features, treatment results, overall survival(OS) and event free survival (EFS) rates evaluated.

**Results**: A hundred thirty six patients(101 male, 35 female; E/F:2.8/1) were evaluated retrospectively. The median age of patients was 7 years (1 month‐17.5 year).The median duration of complaints was 1.5 months (3 days‐24 month). Most common complaint was abdominal pain (n=47). At diagnosis,40.4% of patients had abdominal involvement (n=55). Pathologic subtypes were Burkitt lymphoma (BL)(n=67), lymphoblastic lymphoma(LL)(n=42), diffuse large B cell lymphoma (DLBL)(n:12), anaplastic large cell lymphoma (ALCL)(n:9).77.4% of patients were advanced stage at diagnosis(stage III n=55, stage IV n=50). 30,9% of patients had bone marrow metastases (n=42). One patient was NF‐1, one was ataxia telangiectasia. Before 1997 patients were treated with POG(n=9), LSA‐L2, COMP protocols. After 1997, patients treated according to BFM protocols (n=82). Eight patients were died before treatment (tumor lysis n:2, post operative period n:1, disseminated illness n:5). Median follow‐up time was 75 months (3day‐30 year). 1,5,10 years EFS were in the order of %76.6;%66,5;%64. OS was %79,5;%70,7;%70,7 respectively. In early stage(stage I‐II) 5 year EFS was %78, OS was %86,3.In advanced stage(III‐IV) 5 year EFS was %62,9;OS was %68,5, there was a significant difference. 5 year EFS according to sex, F/M:%64,7/%66,8; OS, F/M %70/%71,5; no difference detected. According to initial LDH levels; \<500 and \>500; 5 year EFS were %79,5;%61,4 and OS %91,7;%62,6, significant difference. Between BL and LL, no difference between EF and OS;5 year EFS %70;%56,8;OS:%72;%64,9.OS was %100 in ALCL patients. There was no difference between survival rates in patients treated with BFM, COMP, POG protocols, lower in LSA‐L2 protocols.

**Conclusions**: Our patients EFS and OS are similar to other studies. EFS and OS rates in the early stage were significantly higher than the advanced stage. Also initial LDH levels had prominent effect on prognosis. Different from the literature our ALCL patients had an excellent prognosis.

### PO-228. IRF4 Positivity is a Novel Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma {#pbc27455-sec-4550}

[F.B. Çakır]{.ul} ^1^, B. Güler^2^, A. Çay^3^, S. Mirapoğlu^3^, A. Vehaboğlu Türkmen^4^, H. Akı^5^

*^1^Associate Professor, Bezmialem Vakif University Pediatric Hematology Oncology, Istanbul, Turkey; ^2^Bezmialem Vakıf Üniversitesi, Pathology, Istanbul, Turkey; ^3^Bezmialem Vakıf Üniversitesi, Pediatric Surgery, Istanbul, Turkey; ^4^Bezmialem Vakıf Üniversitesi, Pediatrics, Istanbul, Turkey; ^5^Istanbul University Cerrahpaşa Medical Faculty, Pathology, Istanbul, Turkey*

**Background/Objectives**: IRF 4 is a novel oncogen situated next to immunglobulin loci which shows better prognosis among diffuse large B cell lymphomas. Here, a 12 yrs old boy who was diagnosed as diffuse large B cell lymphoma with the presence of IRF4 positivity is presented.

**Design/Methods**: A 12 yrs old boy was hospitalized with the symptoms of acute abdomen after a one month lasting waxing and waning abdominal pain and constipation. An invagination in the colon was detected in magnetic resonance imaging. Right hemicolectomy with ileal resection were carried out. In the differential diagnosis of the pathology, diffuse large B cell lymphoma and follicular lymphoma existed.

**Results**: Follicular pattern B type lymphoma infiltration having CD 20, Bcl 6 and MUM1 positivity was identified. IRF4 (6p25.3) rearrangement detected in atypical lymphoid cells with FISH method confirmed the diagnosis of diffuse large B cell lymphoma. The patient was staged as R2 according to BFM‐Non‐Hodgkin Lymphoma Staging and was found to be tumor free after two cycles of BFM based chemotherapy.

**Conclusions**: IRF4 positivity is a new diagnostic marker for diffuse large B cell lymphoma. It is also reported to be a good prognostic marker and the survival of patients are relatively improved than the other types of diffuse large B cell lymphomas.

### PO-229. Nitrosourea, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplantation for Pediatric Lymphoma Patients: A Single Center Review {#pbc27455-sec-4560}

[J.Y. Choi]{.ul} ^1^, H.Y. An^1^, K.T. Hong^1^, H.J. Kang^1^, H.Y. Shin^1^, H.S. Ahn^1^

*^1^Cancer Research Institute‐ Seoul National University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: Treatment outcome of pediatric lymphoma has improved substantially during the past two decades, but patients with high risk or relapsed disease still show poor prognosis. The role of high dose chemotherapy (HDC) and autologous stem cell transplantation (auto‐SCT) is controversial because there is not so much data about SCT for pediatric lymphoma.

**Design/Methods**: This retrospective study was designed to evaluate the outcome of HDC and auto‐SCT in pediatric patients with high risk or relapsed lymphoma between December 2001 and December 2016. All patients received nitrosourea (51 BCNU; 5 ACNU), etoposide and cyclophosphamide (BEC; AEC) as conditioning regimen.

**Results**: A total of 56 patients (32 male and 24 female) were evaluated. The median age at auto‐SCT was 12 (range 2‐17) year. Forty four patients (77.2%) underwent auto‐SCT because they did not achieve complete remission after induction chemotherapy. Eight patients (14.3%) were treated with auto‐SCT after relapse, and 4 patients (7.1%) with NK/T cell lymphoma were planned to have auto‐SCT. The median number of infused CD34+ cells was 10.15 (Range 0.39‐101.66) x 10\^6/kg and all patients achieved neutrophil and platelet engraftment except 1 patient who died of septic shock. Hepatic veno‐occlusive disease (VOD) developed in 2 patients, and pulmonary VOD occurred in 2 patients who received ACNU. BCNU pneumonitis was suspected in 7 (12.5%) patients, and all of them recovered. Seven (12.5%) patients relapsed after auto‐SCT and 4 of them died of disease progression. Treatment‐related mortality (TRM) occurred in 3 patients (pulmonary VOD in 1, acute respiratory distress syndrome in 1, and septic shock in 1 patient). Overall survival and event‐free survival of all patients were 83.6% (91.7% HD, 81.6% NHL) and 69.5% (83.3% HD; 67.3% NHL), respectively.

**Conclusions**: HDC and auto‐SCT with BEC or AEC regimen for pediatric high risk lymphoma patients showed favorable outcome. However, treatment modifications are warranted to reduceTRM and toxicities.

### PO-230. Treatment of Relapse/Refractory Hodgkin Lymphoma (HL): A Report from De Association of Central American Pediatric Hematology Oncology (AHOPCA) {#pbc27455-sec-4570}

[P. De Alarcon]{.ul} ^1^, E.M. Castellanos^2^, P. Calderon^3^, S. Fuentes‐Alabi^4^, F. Antillon‐Klussmann^2^, C. Garrido^2^, P. Valverde^2^, P. Obando^2^, J. Blanco^2^, M. Metzger^5^

*^1^University of Illinois College of Medicine and St Jude Children\'s Research Hospital, Department of Pediatrics, Peoria, USA; ^2^UNOP, Oncology, Guatemala, Guatemala; ^3^Hospital Manuel de Jesus Rivera, Oncology, Managua, Nicaragua; ^4^Hospital Nacional de Niños Benjamin Bloom, Oncology, San Salvador, El Salvador; ^5^St Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: The event‐free survival (EFS) and overall survival (OS) for HL in middle and low‐income countries (LMIC) have improved but still many fails therapy. High‐dose chemotherapy followed by stem cell rescue can cure 50‐70% of these patients. This therapy is not always available in LMIC. To rescue these children, AHOPCA designed a rescue regimen of ifosphamide, carboplatin and etoposide (ICE). We report preliminary results in one of the AHOPCA centers.

**Design/Methods**: Children with refractory/resistant (RR) or relapse HL were treated. We defined RR as subjects who did not achieve a response (≥ 80% of disease‐bulk at presentation) or who relapse within three months of completion of therapy, early relapse (ER) between three and 12 months after completion of therapy, and late relapse (LR) those who recurred after one year of completing therapy. ICE regimen consisted of etoposide 100 mg/m^2^ days 1 to 3, carboplatin 600 mg/m^2^ day 1 and ifosfamide 1.8 gm/m^2^ days 1 to 3 with involved field radiotherapy 35 cGY without G‐CSF. Cycles repeated every 21 days for four to six cycles if a response achieved.

**Results**: From 1/1/2004 to 1/26/2018, 3 AHOPCA centers treated 625 with HL. Of these, 82 had RR or relapse (31 RR, 28 ER,23 LR) disease. At the time of analysis, 27 children were alive, 48 dead, 2 abandoned therapy and 5 were lost to follow‐up. The EFS for the cohort at 5‐years was 17%±5.2 and the OS 31%±6.1. The EFS and OS for ER were 12%±7.8 and 41%±8.5 and for LR 32%±10.4 and 48.8%±12.4% respectively. The EFS between RR and relapse HL different (P=0.02).

**Conclusions**: From these limited data, we conclude that some children with late relapse of HL can be rescued with an ICE based regimen in the setting of a LMIC but children with RR are less likely to be rescued.

### PO-231. Hodgkin Lymphoma in Marrakesh {#pbc27455-sec-4580}

[J. Elhoudzi]{.ul} ^1^, M. elbaz^2^, E. soufiane^2^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco; ^2^University hospital Mohammed VI, Pediatric hematology and Oncology, Marrakesh, Morocco*

**Background/Objectives**: Hodgkin lymphoma (HL) is a highly curable malignancy. Rare malignancy in the pediatric population, however, it constitutes approximately 40% of all lymphomas that present during childhood and is the most common malignancy in adolescents and young adults. In all age groups, Hodgkin lymphoma is highly sensitive to chemotherapy and irradiation

**Objective**: to carry out an epidemiological analysis, to study the clinical and histological aspects, to evaluate the therapeutic response in Marrakesh.

**Design/Methods**: 22 patients with biopsy proven HL between 2011 and 2017 were retrospectively reviewed in our department

**Results**: The average age was 11.18 years. 73% of the children were male. Cervical lymphadenopathy was the major sign, reaching 90% of cases. The average consultation time was 3 months. 36% of cases was stage II according to Ann‐Arbor\'s classification. Sclera‐nodular HL type was the most common (54.5% of cases). The presence of the general "B" signs was found in 73% of cases. All patients were treated according to the MA‐MDH 2004 protocol. Patients in the favorable group were treated with 4 VAMP courses administered every 28 days. Patients in the adverse group are treated with 2 courses of OPPA followed by 4 courses of COPP given every 28 days followed by radiotherapy. Complete remission is obtained in 73% of cases. 18% of patients were lost following.

**Conclusions**: percentage of CR could be improved with reduce of delay of diagnosis and by raising adherence to treatment.

### PO-232. Primary Subdiaphragmatic Hodgkin Lymphoma in Childhood: Turkish Experience {#pbc27455-sec-4590}

[I. Ergurhan Ilhan]{.ul} ^1^, Z. Yildirim Keskin^2^, G. Sahin^3^, H. Oniz^4^, T. Eren^5^, B. Sevinir^6^, S. Vural Dogan^7^, E.C. Citak^8^, Z. Karakas^9^, R.E. Cecen^10^, N. Sari^11^

*^1^Sağlık Bilimleri University Ankara Oncology Hospital, Pediatric Hematology/Oncology, Ankara, Turkey; ^2^Ataturk Uiversity Faculty of Medicine, Pediatric Hematology/Ocology, Erzurum, Turkey; ^3^Saglik Bilimleri University‐ Dr. Sami Ulus Hastanesi, Pediatric Hematology/Oncology, Ankara, Turkey; ^4^Sağlık Bilimleri University Tepecik Education and Training Hospital, Pediatric Hematology/Ocology, İzmir, Turkey; ^5^Trakya University‐ Faculty of Medicine, Pediatric Hematology/Oncology, Edirne, Turkey; ^6^Uludag University‐ Faculty of Medicine, Pediatric Ocology, Bursa, Turkey; ^7^Saglik Bilimleri University‐ Sisli Hamidiye etfal Hospital, Pediatric Hematology/Ocology, Istabul, Turkey; ^8^Mersin University‐ Faculty of Medicie, Pediatric Hematology/Oncology, Mersin, Turkey; ^9^Istanbul University‐ Faculty of Medicine, Pediatric Hematology/Oncology, Istanbul, Turkey; ^10^Adnan Menderes University‐ Faculty of Medicine, Pediatric Hematology/Oncology, Aydin, Turkey; ^11^Saglik Bilimleri University‐ Ankara Oncology Hospital, Pediatric Hematology Oncology, Ankara, Turkey*

**Background/Objectives**: Primary subdiaphramatic Hodgkin lymphoma (HL) is very rare entity, accounts for 3‐12 % of all HL cases in childhood. Experience with this entity has been limited to retrospective reviews of series or fewer patients, most of them are adult.

**Design/Methods**: Between 1967‐2018, 2915 childhood HL were diagnosed and treated in 33 pediatric hematology and oncology centers in Turkey. Among them 17 patients (0.6 %) with histologically confirmed clinical stage I/II pure subdiaphragmatic HL were included for this study. The medical records of these patients were retrospectively reviewed.

**Results**: The median age was 9.5 years (3.5‐16), and M/F:15/2. The histological subtypes were; nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) in 2, mixed cellularity in 10, nodular sclerosis in 3, lymphocyte predominance in 1 and unclassified in 1. B symptoms were in 6 patients (35 %). Seven patients (41 %) had more than three sites of nodal involvement at presentation and 2 patients had bulky disease. Stage distribution was I in 2, II in 14 and IV in one due to additional hepatic involvement. Median hemoglobin level was 11.3 (5.1‐14)gm/dl, albumin level was 4.2 (2.6‐5.1) gm/dl. All patients were treated with chemotherapy based on ABVD or equivalent regimens (2‐6 cycles). In addition, 8 patients received radiotherapy with 18‐30 Gy to abdomen. Complete response was achieved in all patients except one who developed relaps eight months after initial treatment. The median follow‐up time for all patients was 8.3 years (range, 3 months‐33.6 years). No patients died due to his disease or developed secondary neoplasias.

**Conclusions**: Even this is the largest childhood pure subdiaphramatic Hodgkin lymphoma series in the literature, because of the small number of the patients, hard to estimate any prognostic factor to effect the survival. This study suggests that the outcome of pure infradiaphragmatic HL is not worse than that of its supradiapragmatic counterpart.

### PO-233. Poor Outcome and Prognosis of Hodgkin Lymphoma Treatment in Pakistan {#pbc27455-sec-4600}

[A. Fatima]{.ul} ^1^, S. Zaidi^2^

*^1^SKMC &RC, Pediatric Oncology, Lahore, Pakistan; ^2^Wecare medical centre, Lahore, Pakistan*

**Background/Objectives**: Our study aims to assess the treatment and outcome of children with biopsy proven Hodgkin Lymphoma and discuss various factors which leads to the poor outcome as compared to developed countries.

**Design/Methods**: A retrospective study was done in Shaukat Khanum Research Hospital, Lahore from December 2015 to December 2016. Data regarding age, stage, histopathology, treatment, outcome and impact of delayed presentation were collected and analyzed. Patients were treated ABVD Regimen.

**Results**: Total 150 patients were analyzed with age ranging from 2 to 15 (80% \< 12yrs) were included. M: F Ratio was 8:1. 86% patients presented with advanced stage and only 21/150 (14%) had stage II at presentation. The histopathological examination showed Mixed Cellularity in 76 /150, Nodular Sclerosis in 32/150, Lymphocytic Predominance in 15 (10%) and Lymphocytic Depletion in 4/150 cases. Whereas 23/150 reports did not specify the subtype. Bone marrow was involved in 90 (60%) patients. Total 49/150 have completed treatment, 52/150 are on treatment, 25/150 left against medical advice (LAMA) and 24/150 expired due to sepsis and progressive disease.

**Conclusions**: Survival is not fair as 24/150 expired. Mortality of 36% can be reduced by early diagnosis and aggressive infection‐ control strategies to combat complications. In developing countries, late referrals are strongly associated with metastatic disease. The prognosis can significantly be improved by public awareness to seek early treatment and establishing safe and effective shared care oncology pathways, multidisciplinary team approach. By providing strong social support, intense psychosocial counselling and efficiently run Day Care Oncology, patients compliance can be improved significantly.

### PO-234. Venous Thrombosis in Children, Adolescents and Young Adults with Lymphomas: Incidence, Risk Factors and Prognostic Value {#pbc27455-sec-4610}

[A. Fedorova]{.ul} ^1^, V. Dmitriev^2^, N. Lipay^3^

*^1^Belarusian Research Center for Pediatric Oncology‐ Hematology and Immunology, clinical research, Minsk, Belarus; ^2^Belarusian Research Center for Pediatric Oncology‐ Hematology and Immunology, research, Minsk, Belarus; ^3^Belarusian Research Center for Pediatric Oncology‐ Hematology and Immunology, clinical laboratory, Minsk, Belarus*

**Background/Objectives**: The aim of the study was to define the epidemiology of venous thrombosis (VT) in children, adolescents and young adults with lymphomas, to identify the thrombotic risk factors and VT\'s prognostic value

**Design/Methods**: We reviewed the medical records of 513 lymphoma patients (284 Hodgkin lymphoma (HL) and 229 non‐Hodgkin lymphoma (NHL)) aged from 0,6 to 26 years (median -- 14 years), diagnosed with lymphoma in 2005 -- 2017. Risk thrombotic factors were assessed using binary Cox regression in univariate and multivariate models with calculation of the odds ratio (OR) with 95 % CIs.

**Results**: Twenty‐eight of 513 patients (5.5%, 95% CI, 4.5--6.5%) were diagnosed as having VT with a total of 32 thrombotic events. The incidence of VT in NHL patients (23/229, 10.5%, 95% CI, 8.5--12.5%) was higher than in HL patients (5/284, 1.8%, 95% CI, 1.0--2.6%, P\<0.0001). Age older than 13 years (ОR 2.5, 95% CI, 1.1--6.0, P\<0.05) and lymphoblastic lymphoma (LL) subtype (ОR 5.5, 95% CI; 2.3--13.6, P\<0.01) independently associated with the occurrence of VT patients with NHL. In HL group all cases of VT were detected in patients older than 15 years. The only risk factor predisposing patients with HL to VT was bulky disease (ОR 7.0, 95%; 1.2--42.3, P\<0.05). The presence of VT did not influence OS of NHL patients, but had a negative impact on the OS of HL patients (60.0%, SE 21.9% versus 94.8%, SE 1.5%, P\<0.001).

**Conclusions**: Cumulative incidence of VT in NHL patients was higher than in HL patients. Age older than 13 years and LL were independent thrombotic risk factors for NHL patients. Age older than 15 years and bulky disease increased risk of VT in HL patients. VT occurrence decreased OS of young HL patients. Prophylactic anticoagulation for high thrombotic risk patients might be warranted.

### PO-235. Paediatric Anaplastic Large Cell Lymphoma: A Single Unit Experience in Kwa‐Zulu Natal, South Africa {#pbc27455-sec-4620}

[Y. Goga]{.ul} ^1^, R. Thejpal^1^, B.G. Neethling^1^, C.L. Hendricks^1^

*^1^Inkosi Albert Luthuli Central Hospital‐ Nelson R Mandela School of Medicine‐ University of Kwa‐Zulu Natal, Paediatric Haematology Oncology Unit‐ Dept of Paediatrics and Child Health, Durban, South Africa*

**Background/Objectives**: Anaplastic large cell lymphoma (ALCL) accounts for 10% of paediatric lymphoma. In areas with a high tuberculosis (TB) burden, lymphoma is often misdiagnosed as TB and diagnosis is delayed. We sought to describe patient characteristics, treatment response and survival of patients with ALCL, at a single centre from 2003 -- 2017.

**Design/Methods**: A retrospective review of patients with ALCL from January 2013 -- December 2017.

**Results**: Eighteen patients were diagnosed over a fifteen year period. The male: female distribution was 11:7. All eighteen patients were Black. Patients were aged between two and twelve years. Two patients were human immunodeficiency virus positive. There were two patients each with stage 2 and 3 disease, and 14/18 patients had stage 4 disease. Half of the patients with stage 2 and 3 disease are alive, and the other half have been lost to follow‐up (LTFU). Patients were treated with the NHL -- BFM 90 protocol. Of the ten patients with stage 4 disease, 1 was lost to follow‐up, 3 died within 3 months of diagnosis, 3 had progressive disease, 3 relapsed, and 3 are alive. ALK / t2,5 status was positive in 8 patients (6 alive), negative in 5 patients (4 dead, 1 LTFU) and unknown in 5 patients (4 dead, 1 LTFU). Six patients with stage 4 disease were treated for TB for between 2 and 7 months prior to diagnosis, and in another 5 patients there were delays of between 1‐10 months. Stage 4 disease presented with a wide range of signs including pleural effusions, tender lymphadenopathy, bone lesions, gibbus, ascites and significant abdominal adenopathy.

**Conclusions**: Most patients had stage 4 disease with poor outcomes due to delays in diagnosis and incorrectly being treated for TB. Intensive public awareness on early warning signs and further clinician education enabling earlier diagnosis is needed to improve survival.

### PO-236. Clinical Features and Treatment Outcomes of Non‐Hodgkin Lymphoma in Childhood: A Single Center Experience from Turkey {#pbc27455-sec-4630}
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**Background/Objectives**: To evaluate clinical findings, pathological characteristics, treatment regimens and outcome of Non‐Hodgkin lymphomas (NHL) patients who were treated in our institution.

**Design/Methods**: We retrospectively analyzed the demographic characteristics, clinical features, histopathological findings, disease stage, chemotherapy regimens and outcome of NHL patients who were treated between January 1996 and December 2017.

**Results**: There were 69 males and 27 females with a median age of 9.2 years. Male/female ratio was 2.5:1. The most common presenting symptom was abdominal distension (40.7%). The most common histopathological subtypes were Burkitt lymphoma (n.53) followed by lymphoblastic lymphoma (n: 24), DLBCL (n:8), ALCL (n: 6), and MALT lymphoma (n:1) respectively. Seventeen patients (17.7%) had early stage (stage I and II), 54 (56.3%) patients had stage III and 24 patients (25%) had stage IV disease. Sixteen patients (14.6%) had bone marrow and 8 patients (8.3%) had CNS involvement. Initial primary tumor location sites were abdomen (46%), head and neck region (35%) and thorax (19%). Patients with lymphoblastic lymphoma were treated with LMT89 or ALL BFM 90 regimens. Patients with BL/DLBCL were treated with LMB 89, LMB 96 or BFM NHL 95 regimens. Median follow‐up time was 57 months (0,5‐193). The 5‐year overall survival (OS) and event‐free survival (EFS) for all patients were 70.7% and 68.4% respectively. Twenty‐six patients (2 progressive disease, 5 acute toxicity,19 infection) were lost. Ten patients relapsed; median relapse time was 5.73 months. Survival rates were significantly higher in patients with early stage disease (p\<0.05). EFS were 68%, 65% in stage III and IV respectively. There was no significant relationship between age, gender, histological type, chemotherapy regimens and survival rates.

**Conclusions**: Survival rates are low in advanced disease. Prognosis can be improved by better supportive care and more awareness about early recognition of symptoms of cancer.

### PO-237. Real‐Life Implementation of Novel Trends in the Treatment of Patients with Non‐Hodgkin Lymphoma -- A Single‐Center Overview from the University of Debrecen, Hungary {#pbc27455-sec-4640}

I. Gáspár^1^, [K. Gyurina]{.ul} ^1^, C. Kiss^1^, I. Szegedi^1^

*^1^University of Debrecen, Dept. of Pediatrics, Debrecen, Hungary*

**Background/Objectives**: Application of contemporary combined chemotherapy regimens resulted in excellent treatment outcome measures in the majority of pediatric Non‐Hodgkin lymphomas (NHL). Relapsed and therapy‐resistant (r/r) cases are relatively rare but are associated with poor survival figures. Rituximab was introduced first as targeted therapy within the frames of clinical trials and proved beneficial for pediatric patients with high‐risk (HR) diffuse large B‐cell lymphoma (DLBCL).

**Design/Methods**: We have performed a retrospective analysis of patients with NHL admitted to the Division of Pediatric Hematology‐Oncology, Department of Pediatrics of the University of Debrecen between 2008 and 2017. Data were obtained from institutional electronic database and from the National Pediatric Oncology Register. Treatment regiments of the Hungarian Pediatric Oncology Group were applied. Non‐registered products were used after obtaining approval of the National Pharmaceutical Institute.

**Results**: Fourty‐six patients were diagnosed with lymphoma: 23 with Hodgkin lymphoma and 23 with NHL. Mean age of patients was 11.9 yrs. Nine patients had Burkitt lymphoma (BL), 5 had T‐cell lymphoblastic lymphoma (T‐LL), 3 had DLBCL and 1 case, had 1‐1 anaplastic large‐cell lymphoma, cutaneous T‐cell lymphoma, angioimmunoblastic lymphoma (AL), marginal zone B‐cell lymphoma, and Castleman‐disease (CD). Between 2008 and 2010 patients were treated with BFM‐backbone protocols. Since 2011, LMB protocols have been used. Patients with DLBCL were treated using Rituximab (R)‐CHOP chemo‐immunotherapy. The patient with AL was treated with CHOP cycles. In case of Castleman disease, siltuximab was applied. Two patients with relapsed mature B‐cell NHL received obinutuzumab. Eighteen of 23 patients are alive and in first remission, 5 patients died: 3 BL, 1 T‐LL and 1 DLBCL.

**Conclusions**: Treatment results are approaching the standards of industrialized countries. Targeted treatment modalities were introduced in conjunction with combined chemotherapy regimens and applied successfully in our single‐center pediatric cohort. Large multicentric clinical trials may contribute to further development of the optimal treatment of pediatric NHL.

### PO-238. Prognostic Factors and Treatment Outcome of Relapsing Mature B Cell Non Hodgkin Lymphoma Treated According to LMB96 Protocol at the Children Cancer Hospital Egypt {#pbc27455-sec-4650}

[A. Hamoda]{.ul} ^1^, H. abdelrahman^1^, E. moussa^2^, S. talaat^1^, R. amin^3^, M. elwakeel^4^, N. yasser^5^
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**Background/Objectives**: Non‐Hodgkin\'s lymphoma (NHL) consists of a complex group of cancers arising mainly from B lymphocytes (85% of cases), and occasionally from T lymphocytes. NHL usually develops in lymph nodes (nodal lymphoma), but can arise in other tissues almost anywhere in the body (extranodal lymphoma). The treatment of non‐Hodgkin lymphoma (NHL) is an example of the successful therapy of cancer in children with a cure rate approximating 80%. Unfortunately, relapsed NHL has a dismal prognosis, and the customary treatment is highly toxic chemotherapy followed by hematopoietic stem cell transplantation (HSCT)

Aim of work:to analyze prognostic factors and treatment outcome of relapsing mature B cell NHL treated at the Children Cancer Hospital during according to LMB 96 protocol.

**Design/Methods**: A retrospective study including all patients under age of 18 years or less initially diagnosed as mature B cell NHL who relapsed following initial chemotherapy during 8 years period: July 2007 to July 2014.

**Results**: Thirty patients relapsed out of 500, mean age 8.4 years (range 3‐17), the were 19 males and 11 females. Pathology was Burkitt lymphoma in 53.3%, Burkitt leukemia 33.3%, DLBCL in 6.6%, and PMLBL in 3.4%. Relapsing site was single organ in 76% and multiple organs in 23.3%. Relapsing patients were stage III in 60% and IV un 36.6%. seventy percent of the patients received salvage chemotherapy, while 30% had best supportive care following relapse. Salvage chemotherapy was ICE in 30%, R‐ICE 30%. The 1year OS and EFS was 55.3% and 33.1%, while the 2 years OS and EFS were 31% and 6.9% respectively.

**Conclusions**: Relapsing mature B cell NHL have dismal outcome. Late relapse and single organ at time of relapse offer a better chance for survival following high dose chemotherapy and Hematopoietic Stem cell transplant.

### PO-239. Phosphatase of Regenerating Liver‐3 (PRL‐3) is Overexpressed in Classical Hodgkin Lymphoma and Promotes Survival and Migration {#pbc27455-sec-4660}

[M.A. Hjort]{.ul} ^1^, P. Abdollahi^2^, E.N. Vandsemb^2^, H. Hov^2^, U.M. Fagerli^3^, B. Lund^1^, T.S. Slørdahl^4^, M. Børset^2^, T.B. Rø^2^

*^1^St Olavs hospital‐ Trondheim University Hospital, Children\'s Clinic, Trondheim, Norway; ^2^NTNU, Department of Clinical and Molecular Medicine, Trondheim, Norway; ^3^St Olavs hospital‐ Trondheim University Hospital, Cancer Clinic, Trondheim, Norway; ^4^St Olavs hospital‐ Trondheim University Hospital, Department of Hematology, Trondheim, Norway*

**Background/Objectives**: Phosphatase of regenerating liver ‐3 (PRL‐3) is implicated in oncogenesis of hematological and solid cancers. PRL‐3 expression increases metastatic potential, invasiveness and is associated with poor prognosis. With this study, we aimed to show a possible oncogenic role of PRL‐3 in classical Hodgkin lymphoma (cHL).

**Design/Methods**: PRL‐3 expression was measured in 25 cHL patients by immunohistochemistry and gene expression was analyzed from microdissected malignant cells. We knocked down PRL‐3 in the cHL cell lines L1236 and HDLM2 and used small molecular inhibitors against PRL‐3 to investigate proliferation, migration and cytokine production.

**Results**: PRL‐3 protein was expressed in 16 % of patient samples. In three different gene expression datasets, PRL‐3 was significantly overexpressed compared to normal controls. PRL‐3 knockdown reduced proliferation, viability and Mcl‐1 expression in L1236, but not in HDLM2 cells. Thienopyridone, a small molecule inhibitor of PRL‐3, reduced proliferation of both L1236 and HDLM2. PRL‐3 affected IL‐13 secretion and enhanced STAT6 signaling. IL‐13 stimulation partially rescued proliferation in L1236 cells after knockdown of PRL‐3. PRL‐3 knockdown reduced migration in both L1236 and HDLM2 cells.

**Conclusions**: PRL‐3 was overexpressed in a subset of cHL patients. Inhibition of PRL‐3 increased IL‐13 cytokine production and reduced migration, proliferation and viability. The effects could be mediated through regulation of the anti‐apoptotic molecule Mcl‐1 and a feedback loop of IL‐13 mediated activation of STAT6. This point to a role for PRL‐3 in the pathogenesis of Hodgkin lymphoma, and PRL‐3 could be a possible new drug target.

### PO-240. A Single Center Experience of Pediatric Hodgkin Lymphoma {#pbc27455-sec-4670}

[D. Ince]{.ul} ^1^, M. Erdem^1^, D. Kizmazoglu^1^, E. Cecen^1^, A. Demiral^2^, R. Cetingoz^2^, E. Ozer^3^, H. Guleryuz^4^, O. Ozdogan^5^, M. Olguner^6^, T. Erdag^7^, K. Mutafoglu^8^, F. Sarialioglu^9^, N. Olgun^1^
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**Background/Objectives**: To evaluate the epidemiological, clinical, pathological characteristics and treatment outcomes of Hodgkin Lymphoma(HL) cases treated in our institution.

**Design/Methods**: Between 1988‐2018, patients were reviewed retrospectively. Ann‐Arbor staging and histopathological Rye classification were used. Diagnostic evaluation methods:lymph node biopsy, lung X‐ray, thorax CT or PET‐CT, abdominopelvic USG and CT, in advanced disease bone marrow aspiration/biopsy, bone scintigraphy. Since 1989, we used standard COPP/ABVD based regimens, then in 1997 we started to use the GPOH 90/95 protocols. Low dose radiotherapy was administered in patients with CR after chemo;higher doses of radiotherapy was delivered to patients having residual disease or progressive disease.

**Results**: Eighty patients were eligible out of 99.The median age was 13y(2.75‐19), M/F:1.35(46/34).The major histological subtypes were nodular sclerosis(54%) and mixt cellular(39%). B‐symptoms were present in 39% of cases. Stage distribution was Stage I‐II(n:46), stage III‐IV(n:34).The number of involved lymph node regions were *\<*3 in 50%, and ≥3 in 50% of cases. The most common nodal sites involved were cervical(82.5%), mediastinal(72.5%).Bulky disease was present in 45% of patients,42% of these were mediastinal,47% were peripheral,11% were mediastinal+peripheral. At presentation 16% of children had extranodal disease:lungs(n:10), liver(n:3), epidural(n:1).The number of chemotherapy courses were as follows:2‐4 courses for stage I‐IIA,4‐6 courses for stage IIB‐IIIA,6‐8 courses for stage IIIB‐IV. All patients except 8 cases:stageIB(n:1), stageIIA(n:1), stageIIB(n:1), stageIIISB(n:1), stageIVB(n:2), died before RT(n:1), time has not come (n:1) were irradiated. Median follow‐up time was 7years(1mos‐23years). At 5‐10‐15 years EFS rates were 80%;5‐years OS 95%,10‐15years OS rates 90%.The OS rates were found significantly different between StageI‐II and StageIII‐IV disease;but EFS rates were not found different, also between patients who received GPOH 90/95 and COPP‐ABVD regimens. StageI‐II 5‐10‐15 years OS rates were 100%;stageIII‐IV 5 years OS was 88%,10‐15 years 76%.StageI‐II 5 years EFS 91%,10‐15 years 86%;stageIII‐IV 5‐10‐15 years EFS 72%.

**Conclusions**: Our treatment results were acceptable and same as the literature. Similar OS and EFS rates were obtained with GPOH90/95 and COPP/ABVD based regimens. This finding supports usage of new and safe treatment regimens in HL. No prognostic factor could be determined owing to the limited patient number.

### PO-241. Interim Positron Emission Tomography and Childhood Hodgkin International Prognostic Score Can Predict Survival of Children with Hodgkin Lymphoma in Developing Countries {#pbc27455-sec-4680}
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*^1^National Cancer Institute‐ Cairo University/ Children\'s cancer hospital Egypt 57357, pediatric Oncology, cairo, Egypt*

**Background/Objectives**: Although 'interim' positron emission tomography (PET) may inform therapeutic decisions, Risk stratification at diagnosis allow earlier and potentially better modification during treatment of HL. In this study we aimed to identify the prognostic role of both the IPET and the CHIPS in predicting the prognosis of HL in our center

**Design/Methods**: This is a retrospective, single center study where a total of 140 patients with newly diagnosed Hodgkin lymphoma were enrolled. Only 83 patients were eligible for analysis of both IPET and CHIPS scoring. PET scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. Childhood Hodgkin International Prognostic Score (CHIPS), was evaluated. Log rank testing was used to compare EFS for each CHIPS (0--3)

**Results**: 83 scans out of 140 patients were eligible for analysis of both IPET and CHIPS scoring. 26 patients were scored positive (31.3%) and 57 (68.7%) as negative. The 5‐ years overall survival (OS) was 94%, 83% for patients with interim positive scans and 97% for patients with interim negative scans (P\<0.01). The 5‐year Event‐free survival (EFS) rate was 86.7% for the whole study population, 76% for patients with interim positive scans and 91% for patients with interim negative scans (P\<0.04). 3‐year EFS was 95.7% for patients with CHIPS = 0, 84.2% for patients with CHIPS = 1, 75% for patients with CHIPS = 2, and 80% for patients with CHIPS = 3 (a very limited number of patients).

**Conclusions**: The prognostic role and validity of using the interim PET scan response have been confirmed to be strongly related to treatment outcome by the present study. However the use of CHIPS is a good inexpensive approach to predicting risk in patients with HL that may improve ability to tailor therapy to risk factors known at diagnosis.

### PO-242. Efficiency of Nivolumab in Children with Refractory and Relapsed Hodgkin\'s and Non‐Hodgkin\'s Lymphoma {#pbc27455-sec-4690}
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**Background/Objectives**: Approaches to the management of refractory and relapsed lymphoproliferative disorders (r‐r LD) are changing and become more effective due to the development of immunotherapy. The role of check point inhibitors is extensively investigated in various oncological diseases. The role of nivolumab in children with r‐r LD is only to be elucidated.

**Design/Methods**: Sixteen children with r‐r LD were included in the study. Median age was 16 years (range 6‐17). Hodgkin\'s lymphoma (HL) was diagnosed in 12 children, non‐Hodgkin\'s lymphoma -- 4 patients (2 -- primary mediastinal large B‐cell lymphoma, 1 -- extranodal NK/T‐cell lymphoma, nasal type and 1 -- T‐lymphoblastic lymphoma (T‐LBL)). Median number of previous chemotherapy lines was 4 (range 1‐9). Refractory course of the disease was diagnosed in 9 children (54%) аnd relapses were diagnosed in 7 (44%). Nivolumab was administered 3 mg/kg biweekly with median of 10 cycles (range 1‐28). In 13 (81%) patients nivolumab was used as monotherapy and in 3 (19%) children as a combination with chemotherapy (bendamustine hydrochloride in 2 and gemcitabine in 1).

**Results**: Overall response was demonstrated in 14 patients (87.5%): complete response ‐ 8 (50%), partial response -- 6 (37.5%), stabilization -- 1 (6.25%), progression -- 1 (6.25%). Progression was diagnosed in a patient with T‐LBL. Fifteen children (94%) are alive with median follow‐up of 372 days (range 44 -- 535). Among them 14 children (87.5%) remain in remission. Several clinically significant adverse effects (AE) were registered and included: immune cytopenia (n=2, 12.5%), aseptic meningitis (n=1, 6.25%). All AE were successfully cured. Nivolumab was discontinued in 2 children (12.5%) due to AE.

**Conclusions**: Nivolumab is an effective and relatively safe option in children with refractory and relapsed Hodgkin\'s and Non‐Hodgkin\'s lymphoma.

### PO-243. Malignant Mediastinal Masses in Children and Clinical Factors Associated with Intensive Care Unit Admission {#pbc27455-sec-4700}
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**Background/Objectives**: Majority of mediastinal masses in children are malignant, and they are complex to manage because of risks of compression to surrounding structures causing airway compromise, vascular compression, and effusions. Many of these children have to be managed in the Intensive Care Unit (ICU). Hence, we sought to evaluate the local epidemiology of malignant mediastinal masses in children and the nature of their clinical presentation, and identified factors associated with ICU admission so that at‐risk patients who need intensive care may be identified early.

**Design/Methods**: We retrospectively reviewed case records of children below 18 years of age who presented to National University Hospital Singapore with a malignant mediastinal mass between 2000‐2015. 56 patients were evaluated in this study. We collected data on their presenting symptoms, clinical signs, radiological investigations, need for urgent interventions, and correlated these factors with admission to our Pediatric ICU.

**Results**: Lymphoma was most common diagnosis, comprising 37 children (66.0%). There were 6 patients with neuroblastoma (10.7%), 3 patients with germ‐cell tumor (5.4%), and 10 patients with T‐cell acute lymphoblastic leukemia (17.9%). Overall, 21 patients (37.5%) had to be admitted to the ICU. Factors that are significantly associated with ICU admission are fever (p\<0.01), dyspnea (p\<0.01), stridor (p\<0.01), pleural effusion (p\<0.01), pericardial effusion (p\<0.01), need for pleural tap (p\<0.01) and need for pericardial tap (p\<0.01). Factors that did not reach statistical significance for association are chest pain, lymphadenopathy, night sweats, loss of appetite or weight, neurological symptoms, hepato‐splenomegaly, superior vena‐cava obstruction, and radiological evidence of tracheal compression.

**Conclusions**: Malignant mediastinal masses in children in our institution range from leukemia and lymphomas to germ‐cell tumors and neuroblastomas. These children have a risk of cardiorespiratory collapse and many of them require intensive care. We identified factors that are associated with ICU admission, with the aim of early identification and intervention of at‐risk cases.

### PO-244. Immunodeficiency‐Associated Diffuse Large B‐Cell Lymphoma: Experience of One Polish Center {#pbc27455-sec-4710}
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**Background/Objectives**: Primary and acquired immunodeficiencies promote development of lymphomas.

In overtly immunocompetent patients diagnosed with inflammatory bowel disease (IBD), immunosuppressive treatment, eg. methotrexate, thiopurine, or anti‐tumor necrosis factor (TNF), increases the risk of lymphoproliferative diseases (LD).

Some viral infections, including latent Epstein‐Barr virus (EBV), particularly in patients with immunodeficiencies, have similar risk effects.

**Design/Methods**: There were 2 boys diagnosed in July 2017 with diffuse large B‐cell lymphoma (DLBCL) in the Department of Pediatrics, Hematology and Oncology in Gdansk.

The first (age 16) patient has suffered from Crohn disease (CD) since he was one year old. The clinical course of CD has been at times severe resulting in several surgeries including excision of intestines and ileostomy. He received immunosuppressive drugs (azathioprine, steroids, and methotrexate in the past). One year before the lymphoma was diagnosed he developed severe EBV infection. The DLBCL was localised in the bones, spleen, and mediastinum (stage III).

The second (age 17) patient has had undefined immunodeficiency. He has been suffering from chronic EBV infection. He developed DLBCL, localised in the abdomen, and peripheral lymph nodes (stage III).

**Results**: The first patient was treated according to the protocol Inter‐B‐NHL 2010. He received only COP (induction), since the treatment was interrupted due to excessive neurotoxicity after intrathecal chemotherapy, gastrotoxicity, and the lack of positive response to the treatment. Six cycles of DA‐EPOCH‐R were introduced, he responded with partial remission, and therefore radiotherapy on residual mass is being planned (hip bone and mediastinum). The second patient was treated according to the protocol Inter B‐NHL 2010 with Rituximab and remains in complete remission.

**Conclusions**: Our experience indicates that immunodeficiencies, immunosuppressive treatment, and concomitant EBV infection are risk factors for the development of B‐cell lymphoproliferative disorders.

### PO-245. Initial Report on InPOG‐HL‐15‐01‐ A Risk‐Stratified Response‐based Collaborative Protocol for Newly Diagnosed Childhood Hodgkin Lymphoma Patients in India {#pbc27455-sec-4720}
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**Background/Objectives**: The vast improvements seen in Hodgkin Lymphoma (HL) outcomes worldwide are largely attributable to lessons learnt from collaborative, prospective studies. This has been hitherto difficult to implement in India due to lack of formal funding and health care dynamics leading to large differences in patient treatment. InPOG‐HL‐15‐01 is the first attempt to study prospectively the epidemiology and outcomes of HL in children and adolescents treated uniformly as per a risk‐stratified, response‐based strategy.

**Design/Methods**: ABVD chemotherapy was used in a risk‐stratified fashion. Patients with Early stage (Stage I, IIA) received four cycles ABVD, Advanced stage (Stage IIB, III, IV) six cycles. Response was assessed after two cycles. Radiation was limited to patients with bulky disease or suboptimal response to two cycles. Events were death, progression/relapse, secondary malignancy and treatment abandonment.

**Results**: Recruitment commenced in August 2015 and concluded in February 2018. 407 patients were enrolled from 27 centres (0‐47 patients per centre, median 4 patients). Median age was 8 years and 85% were male. 9% were younger than 5 years. 28% received antituberculosis treatment prior to diagnosis. HL subtype was mixed cellularity 38%, nodular sclerosis 27%, others or unspecified 35%. 65%% patients had advanced stage (Stage distribution was 9% I, 37% II, 35% III, 19% IV with 50% B symptoms). 46% had bulky disease. Till date, there have been 21 events -- deaths 4, progressive disease/relapse 12, abandonment of treatment 5. The 2‐year OS and EFS are 96.9%±1.4% and 87.2%±3.4% respectively at a median follow up of 8.2 months.

**Conclusions**: This study demonstrates the feasibility of conducting a prospective multicenter study in absence of formal funding in childhood cancer in India and provides valuable high quality epidemiological information on childhood HL. Abandonment could be significantly reduced. Ongoing follow‐up will provide more mature data on outcomes and help guide future practice and research.

### PO-246. Clinical Profile and Treatment Outcome of non Hodgkin Lymphoma in Children: A Report from a Tertiary Care Hospital from Developing Country {#pbc27455-sec-4730}

[J.P. Meena]{.ul} ^1^, A.K. Gupta^1^, M.S. Parihar^2^, R. Seth^1^

*^1^All India Institute of Medical Sciences, Department of Pediatrics‐ Division of Pediatric Oncology, New Delhi, India; ^2^All India Institute of Medical Sciences, Department of Pediatrics, New Delhi, India*

**Background/Objectives**: Non‐Hodgkin lymphoma (NHL) is an aggressive malignancy in children. Its outcome has improved over the past decades. Although it accounts for 8‐10% of all childhood cancers but very less information about its clinical presentation and outcomes is available from India. Our objective was to study the clinical presentation, and outcomes in children (\<15 years) with NHL at our centre.

**Design/Methods**: We retrospectively analyzed records of 26 children diagnosed with NHL at our centre from August 2008 to June 2014 and followed them up to May 2017.

**Results**: The median age at the time of diagnosis was 7.7 years (range 2.5‐13). Abdominal distension and an abdominal lump were the commonest presenting features occurring in 75%, followed by fever (73.8%) and weight loss (46.2%). Most patients had advanced stage (stage III/IV, 92.3%) disease at presentation. Primary presentation was extranodal in 57.7%, nodal in 26.9% and combined in 15.4%. Burkitt‐lymphoma (BL) was the most common subtype (46.2%); followed by T‐lymphoblastic lymphoma (T‐LBL), diffuse large B‐cell lymphoma (DLBCL) and anaplastic large‐cell lymphoma (ALCL). Three patients did not take treatment. Median follow‐up of patients was 48 months (36--99 months). Nineteen patients achieved remission and four had progressive disease. The 3‐year event‐free survival (EFS) rate of our study was 82.6%. The 3‐year EFS between the age groups of \<10 years *vs* ≥ 10 years (94.1% *vs* 66.7%, log rank‐test: p‐value =0.008) and between St Jude/Murphy stages were significant (log rank‐test: p‐value =0.000). The EFS did not significantly differ with sex, group of disease, lactate dehydrogenase (LDH) levels and presenting features.

**Conclusions**: Our cohort of patients with NHL showed characteristics similar to those reported from other developing countries. NHL occurred at a younger age, with a higher incidence of BL. The outcome for patients \>10 years was poor. The outcome of NHL was comparable to other centres in the world.

### PO-247. Long‐term Follow‐Up of Successfully Treated Adolescents and Young Adults with Hodgkin Lymphoma. A Single Center Experience {#pbc27455-sec-4740}

[A. Megalakaki]{.ul} ^1^

*^1^METAXA HOSPITAL, HEMATOLOGY, PIRAEUS, Greece*

**Background/Objectives**: Hodgkin lymphoma of adolescents and young adults is considered a curable disease. It is widely recognized however that this particular group of patients (pts) presents several health handicaps, namely late effects in up to 60% of survivors. Of these some are of great importance, e.g. second malignancy, whereas others do not carry mortal risk for the patients but affect their quality of life.

In this paper we present the long‐term follow up of 43 very young patients successfully treated for Hodgkin lymphoma.

**Design/Methods**: Method/Patients

43 patients, age 16‐25 years old, 25 male, 18 female, histology subtypes: classical HL (nodular sclerosing 35, mixed cellularity 6), nodular lymphocyte‐predominant 2, stage I 15pts, stage II 14, III 6, IV 8, were treated with ABVD(33pts), BEACOPPesc (8pts), MOPP (2pts). Eleven pts relapsed and received second‐line chemotherapy (mini BEAM, DHAP) and autologous stem cell transplantation. 22 received radiotherapy.

All patients were successfully treated and remain disease‐free for more than 5 years since the last treatment. Follow‐up extends for 5‐25 (median 11) years. The eldest patient in follow‐up is now 43 years‐old.

**Results**: Patients visit the Haematology Department at least once per year. The following events/situations have been recorded in 25 pts: Infertility and/or sexual dysfunction 10 (7 women, 3 men), metabolic disorder 4, cardiovascular events 4, thyroid dysfunction 7, bone necrosis 3, second primary malignancy 1, respiratory dysfunction 1. Patients heavily treated presented several problems. Moreover 18 pts when asked reported minor psychological problems partly affecting their social behavior. 6 welcomed a referral to the Psychology Department.

**Conclusions**: These results confirm that up to half patients treated for Hodgkin lymphoma suffer either minor or severe long‐term effects. A group of doctors and specialized nurses should be in hospitals treating patients with malignancies to help lymphoma Hodgkin and other malignancies survivors cope with their lives.

### PO-248. Dumbbell‐shaped B Lymphoblastic Lymphoma: A Case Report {#pbc27455-sec-4750}

[M. Minami]{.ul} ^1^, S. Nodomi^1^, S. Hashimoto^2^, S. Katayama^2^, K. Waki^1^, T. Imai^1^

*^1^Pediatrics, Kurashiki Central Hospital, Okayama, Japan; ^2^Pediatric Surgery, Kurashiki Central Hospital, Okayama, Japan*

**Background/Objectives**: Dumbbell tumor is a tumor that connects two or more regions, epidural, intradural, and intramedullary. Although neurogenic tumor is known to tend having the shape of a dumbbell, it is rare in non‐Hodgkin\'s lymphoma in children.

**Design/Methods**: We report a case of dumbbell‐shaped B lymphoblastic lymphoma (B‐LBL).

**Results**: The case was a 4‐year‐old boy with waist back pain and gait disturbance for 19 days. CT imaging revealed a tumor surrounding the Th12‐L1 vertebral body. The tumor is a dumbbell tumor invading from the paravertebral body into the spinal canal with multiple bone metastases. As neuroblastoma was suspected, we prepared open‐ended biopsy and started dexamethasone (DEX) to reduce edema and inflammation associated with spinal cord compression. He could walk immediately 3 days after starting DEX. Before tumor biopsy, MIBG scintigraphyt did not detect abnormal accumulation and both VMA and HVA in urine did not increase. Upon CT imaging again, paravertebral body tumors shrunk markedly and metastatic lesions disappeared. We discontinued DEX and follow the progress of tumor. The tumor increased gradually the volume again and echo‐guided needle biopsy was performed on the 46th day from the first visit. The tumor biopsy demonstrated medium‐sized lymphocytes with fine nuclear chromatin diffusely and numerous histiocytes with phagocytized nuclear dust. Tumor cells stained positive for CD10, CD19 and TdT; however, negative for MPO and CD3. The tumor was finally diagnosed as B‐LBL. In this case, intramedullary invasion was observed in the image and atypical lymphocytes were found in the cerebrospinal fluid. As a stage IV and CNS positive tumor, he was treated according to the modified NHL‐BFM95 protocol.

**Conclusions**: We report a rare case of B‐LBL presenting a dumbbell tumor. B‐LBL should be considered in the differential diagnosis of dumbbell tumor.

### PO-249. Adapted LMB‐96 Protocol in Children with B‐Cell Non‐Hodgkin Lymphoma Treated at the Baghdad Children Welfare Teaching Hospital (CWTH) Between 2006 and 2010 {#pbc27455-sec-4760}

M.F. Al‐Jadiry^1^, M.L. Moleti^2^, W.A. Shateh^3^, A.F. Al‐Darraji^3^, R.M. Al‐Saeed^3^, A.H. Sabhan^3^, S. Mohamed^2^, G. Lapietra^2^, S. Uccini^4^, A. Piciocchi^5^, A.M. Testi^2^, R. Foà^2^, [S.A. Al‐Hadad]{.ul} ^1^

*^1^Children Welfare Teaching Hospital‐ Baghdad College of Medicine‐ Iraq, Department of Pediatrics, Baghdad, Iraq; ^2^Hematology, Department of Cellular Biotechnologies and Hematology‐ Sapienza University, Rome, Italy; ^3^Children Welfare Teaching Hospital, Department of Pediatrics‐, Baghdad, Iraq; ^4^Sapienza University, Department of Experimental Medicine/Pathology‐, Rome, Italy; ^5^Statistic Office, GIMEMA Foundation, Rome, Italy*

**Background/Objectives**: Since January 2000, an adapted LMB96 protocol was implemented at the Children Welfare Teaching Hospital (CWTH) in Baghdad for the treatment of children with B‐cell non‐Hodgkin lymphoma (NHL). The first experience (2000 -- 2005) demonstrated the efficacy and feasibility of this treatment in Iraq (24‐month OS and EFS 66.3% and 53.3%, respectively). In 2006, further adjustments were made, in an attempt to reduce therapy‐related toxicities. We report the outcome in a second cohort of children with B‐cell NHL treated from 2006 to 2010 and compare the results with those obtained in the previous study.

**Design/Methods**: Patients ≤14 years with B‐cell NHL were included. The modifications to the Iraqi LMB‐96 protocol were: steroid pre‐phase, fractionated cyclophosphamide, second COP in critical patients, COPADM1 doxorubicin omission for patients in complete remission (CR) after COP.

**Results**: A total of 190 children were registered: 132 males, 58 females; median age 4.5 years (1.3‐13.6); 27 had stage I‐II disease, 126 stage III and 37 stage IV; 20 (10.5%) had a bone marrow and 22 (11.6%) a CNS involvement; 61 (32.1%) had a WHO‐PS ≥3. Six patients died prior to therapy and 4 refused treatment. The remaining 180 patients were assigned to the three therapeutic risk‐groups (10 A, 116 B, 54 C). One hundred thirty‐eight obtained a CR after COP; 54 died during treatment and 9 abandoned. The 60‐month OS and EFS were 64.7% (95% CI: 58‐72.2) and 56.3% (95% CI: 49.4‐64.1), respectively. No statistically significant differences in terms of 24‐month OS and EFS were observed between the two cohorts (2000‐2005 vs. 2006‐2010): 66.3% vs 65.1% (p=0.89) and 53.3% vs 57.3% (p=0.28), respectively.

**Conclusions**: The Iraqi LMB‐96 adapted protocol has confirmed its efficacy and feasibility for the treatment of B‐NHL children at the CWTH of Baghdad. However, therapy‐related mortality remains high, requiring further protocol adaptations.

### PO-250. Familial Mixed Cellularity Hodgkin Disease (HD): The Same Subtype HD, EBV Negative, with Different Outcome {#pbc27455-sec-4770}

[M. Moschovi]{.ul} ^1^, A. Lagos^1^, C. Tsipou^1^, N. Tourkantoni^1^

*^1^National and Kapodistrian University of Athens, Hematology‐Oncology Unit‐ 1st Department of Pediatrics, Athens, Greece*

**Background/Objectives**: Mixed cellularity Hodgkin disease(HD) is a subtype of classic HD constituting the second most common type and 15‐30% of all cases of HD. It is mostly observed in patients with either Epstein‐Barr virus (EBV) or Human Immunodeficiency Virus (HIV) infection, having less inheritance rate comparing to other subtypes. We present two identical cases among siblings with different outcome.

**Design/Methods**: Two siblings, a girl and a boy, were presented with mixed cellularity Hodgkin disease. Both, had the same histological subtype, the same stage(IIIs), the same location of the disease and both, at the biopsy specimen, where negative for EBV infection.

The only apparent difference between the two cases was the presenting age. The girl was diagnosed at the age of 15 years old and the boy at the age of 25 years old. Both of them received chemotherapy. The girl achieved remission with chemotherapy only. The boy received initially only chemotherapy. Due to the relapsed disease during chemotherapy, radiotherapy was added but he succumbed from refractory disease.

**Results**: The two cases were siblings. They had the same histological subtype of the disease, the same location, different age of onset but eventually different outcome. The girl received chemotherapy according to the SIOP HD protocol, and till now she is in first remission, 10 years after the diagnosis. By contrast, the boy had a poor outcome.

**Conclusions**: Considering that both cases where identical on their anatomical and histological characteristics and also both of them where negative for EBV infection, we conclude that the different age of onset of this subtype of HD, and the different gender, play a crucial role on the outcome. Local genetic predisposing factors may contributed to these familial HD cases.

### PO-251. Third Primary Malignancy After 23 Years from the First Diagnosis of Lymphoma with Good Outcome {#pbc27455-sec-4780}

[M. Moschovi]{.ul} ^1^, A. Lagos^1^, D. Stathaki^1^, A. Zampogiannis^1^

*^1^National and Kapodistrian University of Athens, Hematology‐Oncology Unit‐ 1st Department of Pediatrics, Athens, Greece*

**Background/Objectives**: Childhood Cancer Survivors have increased incidence of development a second cancer. The development of a third cancer is even more uncommon for the survivors' population. This case is a presentation of a third metachronous cancer case with good outcome.

**Design/Methods**: A boy of 6 years old is diagnosed with diffuse small cell non cleaved non Hodgkin lymphoma at the nasopharynx. He received chemotherapy and he achieved remission. Three years after diagnosis, he had a recurrence of non‐Hodgkin lymphoma at the primary site and he achieved a second remission with chemotherapy and local radiotherapy. Seventeen years after the first diagnosis of non‐Hodgkin lymphoma, follicular thyroid cancer was diagnosed followed by total thyroidectomy and radiotherapy with radioactive I^131^. Twenty‐three years later, a third primary cancer appeared on the tongue. Complaining for a persisting ulcer on the tongue, a squamous cell carcinoma was diagnosed. A surgical resection of the lesion was held followed by chemotherapy andIntensity‐Modulated Radiation Therapy (IMRT). The patient achieved again a remission.

**Results**: The patient survived a three metachronous primary tumor development. He is in a long stable remission for Non‐Hodgkin Lymphoma, and thyroid cancer. He is also in remission for the squamous cell carcinoma for 2 years.

**Conclusions**: As the population of Childhood Cancer Survivors increase, there is a possibility of a third cancer, leading of awareness for this. Chemotherapy and radiotherapy increase the risk of a new primary cancer but also genetic predisposition could also interfere a significant risk in such cases.

### PO-252. Epstein--Barr Virus Infection and its Association with Lymphoma: A Polulation‐based Study in South Vietnam {#pbc27455-sec-4790}

[M.T. Nguyen]{.ul} ^1^, T.T. Tran^2^, T.T.T. Ngo^3^, T.H.H. Nguyen^4^

*^1^Children\'s Hospital 1‐ Ho Chi Minh‐ Vietnam, Department of Hematology and Oncology, Ho Chi Minh, Vietnam; ^2^Children\'s Hospital 1‐ Ho Chi Minh‐ Vietnam, Department of Pathology, Ho Chi Minh, Vietnam; ^3^Oncology Hospital, Department of Pediatric Oncology, Ho Chi Minh, Vietnam; ^4^Blood Transfusion and Hematology Hospital, Outpatient Department, Ho Chi Minh, Vietnam*

**Background/Objectives**: The association of Epstein‐Barr virus (EBV) infection with lymphoma has been documented in numerous reports in the literature. In this context, we provide additional support for the role of EBV in lymphoma in order to have a strategy of early diagnosis and appropriate intervention in these patients.

**Design/Methods**: We conducted a population‐based cohort study, using registration databases of children with EBV infection at Children\'s Hospital 1 and other primary and secondary health centers. Diagnosis of lymphoma was obtained from registration databases of all hospitals for children with cancer in South Vietnam. We linked these cases to the EBV database (using a unique personal identification including patients' and parents' full names, date of birth, physical residences) to identify incident cancers, and then to exclude children with previous lymphoma diagnoses. Among 8,646 children with a hospital‐based EBV infection diagnosis, we compared the observed incidence of lymphoma with that expected among children in the general population. We computed absolute lymphoma risk and relative risk which is the standardised incidence ratio.

**Results**: A total of 1,186 children with lymphoma were diagnosed during a follow‐up of 54,469 person‐years. Of all the patients with lymphoma, 61% were boys and the median age was 3.5 years. The 1‐ and 5‐year absolute risk of lymphoma was 3.7% and 10.2% respectively. At any time of follow‐up, more children than expected were diagnosed with lymphomas. The lymphoma standardised incidence ratios were 5.4 (95% CI = 3.1 ‐ 8.3) at 1 year, 4.1 (95% CI = 1.5 ‐ 6.4) at 5 years and 3.3 (95% CI = 1.2 ‐ 5.5) beyond 5 years of follow‐up.

**Conclusions**: These findings emphasize considerable insights into the association of EBV infection to lymphoma as its late consequence. Early diagnosis and management of lymphoma in children at risk can improve patient survival.

### PO-253. Risk‐Adapted, Combined‐ Modality Therapy for Unfavorable Pediatric Hodgkin Lymphoma {#pbc27455-sec-4800}

[A. Osman]{.ul} ^1^, A. M Ali^1^, S. Ahmed^2^

*^1^South Egypt cancer Institute, Pediatric oncology, Assiut, Egypt; ^2^South Egypt cancer Institute, Radiotherapy, Assiut, Egypt*

**Background/Objectives**: Hodgkin\'s lymphoma (HL) is a highly curable malignant disease. Risk‐adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life. We aim To assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality approach, and to detect toxicities and long term complications in the patients.

**Design/Methods**: This prospective study was carried out from January 2010 to January 2018, with median follow up of 74 months (range 8‐103 months). 54 newly diagnosed pediatric patients with unfavorable HL. They were stratified into two risk groups: intermediate risk (IMR) and high risk group (HR). Patients were treated with (4‐6 cycles) and (6‐8 cycles) respectively of alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy followed by response‐based, involved‐field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved partial response.

**Results**: 27 patients were IMR and 27 patients were HR. There were 16 treatment failures, 5 patients had progressive disease and 11 patients had relapse. *9 patients were died from their disease during palliative care*. The 5‐years overall survival (OS) and event free survival (EFS) rates (± SE) were 81.8%± 5.7% and 78.7% ± 5.8% respectively. The only factors affect 5‐years OS are disease bulk, elevated ESR and receiving radiotherapy (p\<0.0001). Regarding 5‐years EFS, the disease stage and radiotherapy are only factors statistically significant. Multivariate analysis revealed that the only independent factor for inferior OS is radiotherapy. Treatment was generally well tolerated and without significant acute or delayed toxicities.

**Conclusions**: Radiotherapy is considered a cornerstone in the treatment of the patients with unfavorable criteria. Also, intensification of treatment is needed for the patients especially HR group to achieve better results.

### PO-254. The Prevalence of Epstein‐Barr Virus Infection in Pediatric Lymphoma at South Egypt Cancer Institute {#pbc27455-sec-4810}

[A. Osman]{.ul} ^1^, A. M Ali^1^, E. Helmy^2^, H. Badrawy^3^

*^1^South Egypt cancer Institute, Pediatric oncology, Assiut, Egypt; ^2^Faculty of medicine, pathology department, Assiut, Egypt; ^3^South Egypt cancer Institute, clinical pathology department, Assiut, Egypt*

**Background/Objectives**: Pediatric lymphoma is known to be associated with Epstein--Barr virus (EBV) infection. The frequency of this linkage varies both between countries as well as within the same country, and is presumed to be related to the socioeconomic status of the population. It also varies within each histologic subtype of lymphoma, gender and age at the time of diagnosis.

This study aims to examine the Prevalence of EBV infection in Pediatric patients with lymphoma at the Pediatric Oncology Department of South Egypt cancer Institute (SECI), Assiut University.

**Design/Methods**: In a retrospective study, we examined 78 consecutive cases of pediatric lymphoma for the presence of EBV in tumor cells By PCR on paraffin blocks for latent membrane protein‐1 (LMP‐1) in a 3‐year period (Janurary2012 to Januray2015). We collected patient data on age, sex and histologic sub type. We reviewed the pathological findings in each case and confirmed diagnosis.

**Results**: HL was diagnosed in 26 of the cases and 38% were positive for EBV LMP‐1. Of the 52 cases of NHL, 28.5% were positive for EBV LMP‐1. The positive cases were significantly related to age, gender and diagnosis.

**Conclusions**: The prevalence of EBV infection in pediatric patients with lymphoma in Pediatric Oncology department of SECI, Assiut University similar to developing countries.

### PO-255. Hodgkin Lymphoma in Childhood: Clinico‐Pathological Features and Treatment Outcomes. Single Center Experience in the Middle‐East {#pbc27455-sec-4820}

[N. Othman]{.ul} ^1^, J. Ali^1^, K. Murad^1^, S. Arif^1^, S. Star^1^, S. Mohammed^1^, K. Mohammed^1^, B. Mhammad^1^, A. Bazaz^1^, L. Mula‐Hussain^2^, A. Gendari^1^

*^1^Zhianawa Cancer Center, Radiation Oncology, Sulaymaniyah, Iraq; ^2^Cross Cancer Institute, Radiation Oncology, Edmonton, Canada*

**Background/Objectives**: Hodgkin lymphoma (HL) accounts for 5% to 6% of all childhood cancer. It displays characteristic epidemiological, clinical, and pathological features according to various geographic areas. We are aiming to assess the epidemiological aspects, clinico‐pathological features, and treatment outcome (overall and event free survival) of pediatric HL who were managed at a single radiotherapy center in the Sulaymaniyah Governorate, Kurdistan region, Iraq, during the period between (March. 2009 -- Dec. 2016).

**Design/Methods**: A retrospective review of the treatment charts of the patients fulfilled the following inclusion criteria: age 18 years and below, HL diagnosis established by both characteristic histopathological findings and immunophenotypic studies and was subclassified according to the WHOclassification. Chart of included patients searched for demographic data, history details, examination findings especially nodal region involvement, investigation results, methods of establishing diagnosis, treatment courses, and follow‐up.

**Results**: Thirty eight children and adolescents with HLwere reviewed. Age of the patients at presentation ranged from 3 to 18 years (median 12 years), the age at diagnosis for the majority (81.6%) of cases was above 5 years. Male: Female ratio was 1.37:1. Cervical lymphadenopathy wasthe most common presentation (50.0%). Nodular sclerosing subtype was dominant (73.7%), followed by mixed cellularity (23.7%), and nodular lymphocyte predominant (2.6%). More than half of patients (60.6%) had advanceddisease (Ann Arbor stage III/IV disease).The duration of follow‐up ranged from 9 to 90 months (median time 49 months). Theoverall survival and relapse‐free survival for patients were 88% and 85%, respectively.

**Conclusions**: in our region, HL occurs in young age group, with a higher incidence of nodular sclerosing subtype and advanced stage of disease. The outcomes of HL treatment in our region were satisfactorily approaching the international percentage.

### PO-256. Outcome and Clinical Predictors of Pediatric Lymphoblastic Lymphoma Treated with a Uniform Protocol: A Single Center Experience of 65 Patients from India {#pbc27455-sec-4830}

[A. Patel]{.ul} ^1^, M.C. Sharma^2^, V. Sreenivas^3^, S. Bakhshi^1^

*^1^Dr BRA IRCH‐ All India Institute of Medical Sciences‐ New Delhi, Department Of Medical Oncology, New Delhi, India; ^2^All India Institute of Medical Sciences‐ New Delhi, Department of Pathology, New Delhi, India; ^3^All India Institute of Medical Sciences‐ New Delhi, Department of Biostatistics, New Delhi, India*

**Background/Objectives**: Pediatric lymphoblastic lymphoma (LBL) are aggressive lymphomas; however, intensive protocols like those for lymphoblastic leukemia have produced good outcomes. There is lack of clinical predictors for prognosticating LBL. In view of this lacuna, we evaluated outcomes and prognostic factors for LBL treated at our center treated with a uniform protocol

**Design/Methods**: This study was conducted at our cancer center of All India Institute of Medical Sciences, New Delhi. All consecutive patients of pediatric LBL aged ≤ 18 years from Jan 2003 till Jan 2018 were enrolled after ethical approval. Patients were staged by St Jude (Murphy) staging system. All patients were treated with ALL like BFM‐90 protocol. Event was defined as death due to any cause, relapse or progressive disease. The data were censored on 31 Jan 2018. Kaplan Meier method used for analysis of survival

**Results**: Sixty‐five patients were studied with median age of 12 years (range:1‐18) and male to female ratio was 2.25:1. Fifty‐four patients presented with mediastinal disease and rest of the patients had various organ involvement like lymph nodes, bone, liver and spleen. Median follow‐up was 54.57 months (range: 0.6‐140.5). EFS at 10 years was 62±6% (CI 0.49‐0.73) and OS was 72±5% (CI‐0.59‐.082). On multivariate analysis, symptom duration ≤ 30 days (p=0.015), WBC \> 12000/uL (0.047) and serum albumin ≤ 3.5 gm/dL (p=0.003) predicted inferior EFS. Similarly, inferior OS was predicted by symptom duration ≤ 30 days (p=0.014), WBC \> 12000/uL (0.013) and serum albumin ≤ 3.5 gm/dL (p=0.004).

**Conclusions**: Our outcomes are 15‐20% lower than the published literature in trial setting. Low albumin, high WBC and symptom duration of less than 30 days emerged as adverse predictors for EFS and OS. These are novel clinical predictors of pediatric LBL; however, the same need to be validated in a prospective cohort as well

### PO-257. Vena Cava Superior Syndrome in Children with Mediastinal Tumors: Single Center Experience {#pbc27455-sec-4840}

[T. Patiroglu]{.ul} ^1^, A. Ozcan^1^, E. Unal^1^, M. Karakukcu^1^, A.H. Coskun^2^

*^1^Pediatric Hematology‐Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; ^2^Pediatric radiology, Erciyes University Medical Faculty, Kayseri, Turkey*

**Background/Objectives**: Vena cava superior syndrome (VCSS) comprises various symptoms of compression of vena cava superior. The resulting increased venous pressure in the upper body may cause edema of the head and neck associated with cyanosis, pletore and distended subcutaneous vessels. VCSS is rare in childhood. Therefore, we planned this retrospective study.

**Design/Methods**: The retrospective study was carried out on the children with mediastinal tumors in the department of pediatric hematology‐oncology, Erciyes University Medical School, from january 2010 to december 2017. Diagnostic procedures included hematological investigations, chest radiography, thoracic computed tomography, echocardiography and lymph node or mediastinal biopsy.

**Results**: 19 (five were female) of 41 patients with mediastinal tumors had VCSS. Mean age of the patients with VCSS was 8.57 years (range:1‐17 years). Diagnosis included Hodgkin\'s disease (HD) in 7, non‐Hodgkin\'s lymphoma (NHL) in 6, acute T‐ lymphoblastic leukemia in 5, neuroblastoma and anaplastic round cell sarcoma in one each respectively. All the 19 patients had dyspnea, venous distention and mediastinal widening. Two patients with NHL had bilateral pleural effusion. All patients received intravenous corticosteroids (0.6 mg/kg dexamethasone). Furthermore, the patient with anaplastic round cell sarcoma recevied emergency radiotherapy. All patients received chemothepy and followed up in our PHO clinic. No patients died because of VCSS.

**Conclusions**: Compression of structures in the superior mediastinum is known as VCSS that it is a medical emergency requiring urgent treatment. In this retrospective study, we found that the most common cause of VCSS was HD as different from literature.

### PO-258. Tumour Lysis Syndrome in Children with Hematologic Malignancies: Single Center Experience {#pbc27455-sec-4850}

[T. Patiroglu]{.ul} ^1^, A. Ozcan^1^, E. Unal^1^, M. Karakukcu^1^, C. Turan^2^

*^1^Pediatric Hematology‐Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; ^2^pediatric surgery, Erciyes University Medical faculty, Kayseri, Turkey*

**Background/Objectives**: Tumour lysis syndrome (TLS) is a life‐threatening oncologic emergency characterized by metabolic abnormalities including hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemia. TLS arises most commonly after the start of initial chemotherapeutic treatment, but spontaneous cases have increasingly been documented in patients with high proliferative rates and tumour burden such as Burkitt\'s lymphoma and acute lymphoblastic leukemia.

In the study, we aimed to examine the incidence, characteristics, and outcome of TLS in children with hematologic malignancies.

**Design/Methods**: In the study, the medical records of the 331 patients with leukemia and lymphoma that were treated at our hospital between january 2010 and december 2017 were examinated and TLS was diagnosed according to procedures including hematological and biochemical investigations, lymph node or tumor biops

**Results**: 255 (77.03%) of 331 patients had leukemia (acute lymphoblastic leukemia:203, acute myelooblastic leukemia:43, biphenotypic leukemia:5, chronic myeloid leukemia:5),76 (22.96 %) lymphoma (Hodgkin lymphoma:43, Non‐Hodgkin lymphoma:33) respectively. 14 (4.22 %) of 331 patients had TLS and all of them (mean age:10±31 years) were male. Lactic dehidrogenase (LDH) level in sera of 10 patients (71.42 %) with TLS was \>1000 IU/L. Mean uric acide level was 12.36±6.11mg/dl, mean calcium level 7.81±1.97 mg/dl, mean potassium level 5.29±1.43 mEq/L, mean phosphor level 6.08±3.47 mg/dl respectively. Seven (50%) of 14 patients had low, 4 (28.57%) intermediate, 3 (21.42%) high grade TLS respectively. The treatment include aggressive hydration and diuresis, control of hyperuricaemia with allopurinol prophylaxis and rasburicase treatment, and vigilant monitoring of electrolyte abnormalities. One patient (7.14%) required leukopheresis, 5 patients also hemodialysis due to renal failure respectively. Four (28.57%) patients died because of TLS.

**Conclusions**: Because tumor lysis syndrome is potentially lethal, the main principles of management are identification of high‐risk patients with initiation of preventive therapy and early recognition of metabolic and renal complications and the prompt administration of supportive care, including hemodialysis.

### PO-259. Rituximab with Reduced Dosage LMB Chemotherapy Schedule in Childhood and Adolescent Mature B Cell Lymphoma/Leukemia: Evaluation of Efficacy and Toxicity Profile in Developing Country Setting {#pbc27455-sec-4860}

[J. Ramamoorthy]{.ul} ^1^, V. Radhakrishnan^2^, T.G. Sagar^3^

*^1^Assistant professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^2^Associate professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^3^professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India*

**Background/Objectives**: In developing country setting survival rates of mature B cell lymphoma is 65‐75%. Survival rates are plagued by higher toxic death rates & poor tolerance of chemotherapy precluding the maintenance of chemotherapy intensity. Reported incidence of grade ¾ toxicity is \>75%. Reducing dosage of chemotherapy and addition of rituximab is expected to improve survival and reduce toxic death.

Objective: To evaluate the efficacy and toxicity profile of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy

**Design/Methods**: A prospective observational study was performed in children (\< 18 years) with CD 20 positive mature B cell lymphoma (Burkitt lymphoma and diffuse large B cell lymphoma only).

Inclusion criteria: Children with risk group B & C as per the LMB protocol LMB 89 protocol with dosage of chemotherapy reduced to 75% along with single dose rituximab at 375 mg/m^2^ in every chemotherapy course (including prophase except maintenance) was administered. Toxicity was graded using CTCAE version 4.0. Toxicity profile and treatment response was evaluated using descriptive statistics

**Results**: Seven children (5 boys and 2 girls) were enrolled between january and october 2017. The median age was 5 (range 3‐15 years). All children belonged to risk group B. Median LDH was 1108 IU/L (532‐2290) and response rate to prophase was 30% (20‐50%). All the chemotherapy schedules could be delivered in 21 days interval. Toxicity profile: grade ¾ neutropenia‐ 66%, ¾ thrombocytopenia‐ 33%, ¾ mucositis‐ none and total 16 grade 2/3 febrile neutropenia developed. There was no toxic death. Survival rate is 84.4% (5 surviving & 1 relapsed) after a median follow‐up of 8 months (3‐ 12).

**Conclusions**: Administration of rituximab with reduced dosage LMB chemotherapy protocol results in improved survival rates & comparable acute toxicity. The intensity of chemotherapy could be maintained without undue treatment delay.

### PO-260. Comparing Survival Rates Between Pediatric and Adult Regimens of Treatment for B‐Cell Non‐Hodgkin Lymphoma in Adolescents and Young Adults {#pbc27455-sec-4870}

[L.E. Rios Lopez]{.ul} ^1^, D. Castro Uriol^2^, L. Vasquez Ponce^1^, J. Geronimo Meza^1^

*^1^Hospital Rebagliati, Pediatric Oncology, Lima, Peru; ^2^Hospital Rebagliati, Medical Oncology, Lima, Peru*

**Background/Objectives**: B‐cell non‐Hodgkin Lymphoma (BcNHL) in adolescents and young adults (AYA) is a rare challenging clinical entity. The AYA population has a special interest due to age‐related differences in clinical presentation, biology, and outcomes. The objective was compare survival rates between pediatric and adult regimens of treatment for AYA patients with BcNHL in Peru.

**Design/Methods**: Retrospective study of patients aged 10‐39, newly diagnosed of BcNHL, who completed at least three cycles of chemotherapy, treated consecutively at Rebagliati Hospital (2010‐2016). Histological subtypes, clinical features and other well‐known prognostic factors were studied. For statistical analyses we used chi2, the overall‐survival (OS) and event‐free survival (EFS) were estimated by Kaplan‐Meier curves and log‐rank test (significance level of 5%).

**Results**: Thirty‐one AYA patients diagnosed with BcNHL were included. Six patients received pediatric regimens (LMB96 with/without Rituximab, BFM95) and 25 patients, adult regimens (R‐CHOP, R‐EPOCH, Methotrexate HD). Median ages in pediatric and adult regimens were 13 and 34 years (p=0.001). Stage of disease, extranodal disease, B symptoms, initial risk category or histology subtype were similar between groups. Relapse rate of the entire cohort was comparable in both groups (17% pediatric vs. 32% adult, p=0.43). Among relapsed cases, only the patient of pediatric regimen achieved second remission with R‐ICE and autologous stem cell transplantation, meanwhile all cases of adult regimen died for progressing disease. For the whole cohort, 3‐year EFS was 67% and OS was 70%. The 3‐year EFS was 83% and 64% for pediatric and adult regimen respectively (p=0.35). The 3‐year OS was 100% for pediatric group and 64% for adult group (p=0.13).

**Conclusions**: In this study, AYA patients with BcNHL treated with a pediatric regimen had a trend toward a higher survival rates than adult regimen, although no significance was reached. These findings should be validated in prospective multicenter studies with a larger number of patients.

### PO-261. Modified BEACOPP Regime: An Effective Alternative for Unfavourable Hodgkin Disease in Developing Countries {#pbc27455-sec-4880}

[D.S. Sharma]{.ul} ^1^, N. Somani^2^

*^1^SMS medical college and attached hospitals Jaipur, Radiotherapy, jaipur, India; ^2^BMCHRC Jaipur, medical oncology, Jaipur, India*

**Background/Objectives**: In early 2000\'s, the BEACOPP regimen, both basic and escalated, has emerged as an acceptable alternative to ABVD for the management of Hodgkin\'s Disease (HD) both in terms of efficacy and cost. In the present study, the cost‐effectiveness of modified escalated BEACOPP regimen was studied in Indian context. The modified escalated BEACOPP regimen differed from the standard one in having higher Doxorubicin at a dose of 30 mg, administration of Bleomycin on day 8 in addition to day 1, and no support of growth factors.

**Design/Methods**: From April 2000 to January 2003, 20 children with biopsy proven HD with clinical stage I to IV and adverse clinical features like B symptoms, extranodal or bulky mediastinal disease were selected for treatment with modified BEACOPP regimen. Ten patients with bulky disease received IFRT with a dose of 30 Gy.

**Results**: The median follow up was 97 (range, 71‐147) months. The median age was 11 (range, 4‐15) years, 14 were male and 6 female. Three patients had stage I, 6 patients stage II and 11 stage III HD, with 0, 2 and 5 having B symptoms respectively. Most common subtype was nodular sclerosis seen in 10 (6 had mediastinal disease) followed by mixed cellular in 6, lymphocyte predominant in 3 and lymphocyte depleted in 1 patient. All patients were compliant to the prescribed treatment. Grade III anemia, neutropenia, and thrombocytopenia were seen in 2, 2, and 1 patient respectively. One patient developed locoregional recurrence while another one developed distant relapse, so the remission rate was 90%. Overall survival was 95 % one patient died at 103 months due to secondary AML.

**Conclusions**: modified BEACOPP regimen has shown excellent results in terms of prolonged clinical remission with acceptable morbidity. lesser treatment cost and duration are desirable for both patients as well as caregivers in Indian scenario.

### PO-262. Hodgkin Lymphoma Treatment Outcomes: Retrospective Analysis from a Low‐Income Setting in Kenya {#pbc27455-sec-4890}

[R. Sharma]{.ul} ^1^, T. Vik^2^, G. Kaspers^3^, S. Langat^4^, G. Olbara^5^, S. Mostert^3^, H. Martijn^3^, S. Martin^6^, J. Skiles^2^, F. Njuguna^7^

*^1^Indiana University School of Medicine, Department of Pediatrics, Indianapolis, USA; ^2^Indiana University School of Medicine, Pediatric Hematology‐Oncology, Indianapolis, USA; ^3^VU University Medical Center, Pediatric Oncology/Hematology, Amsterdam, Netherlands Antilles; ^4^Moi University School of Medicine, Hematology and Oncology, Eldoret, Kenya; ^5^Moi University School of Medicine, Pediatrics, Eldoret, Kenya; ^6^Texas Children\'s Hospital, Pediatric Oncology/Hematology, Houston, USA; ^7^Moi University School of Medicine, Pediatric Hematology and Oncology, Eldoret, Kenya*

**Background/Objectives**: Hodgkin lymphoma (HL) is a common malignancy in sub‐Saharan Africa. Five‐year survival for children in high‐income countries is approaching 95% while survival is largely unknown in developing countries such as Kenya. This study assesses treatment outcome and factors influencing outcome from a cohort of 45 patients recently diagnosed with HL at one academic hospital in Kenya.

**Design/Methods**: Our retrospective study reviewed medical records of patients diagnosed with HL at Moi Teaching and Referral Hospital, in Eldoret, Kenya between 2011‐2016. Data on treatment outcomes and various socio‐demographic and clinical characteristics were collected. All patients received a standard chemotherapy regimen of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 cycles, given on days 1 and 15 of each 28‐day cycle.

**Results**: Forty‐five children were diagnosed with HL over the study period with the median age of 10 years (range 4‐15). The diagnosis was confirmed by core tissue biopsy in 83% of cases. Staging with clinical exam, chest radiograph and abdominal ultrasound was completed. Patients frequently presented with advanced disease: stage I (25%), stage II (11%), stage 3 (48%), stage IV (16%). Only 14% of patients abandoned treatment on the single day, biweekly regimen for 6 months for HL in comparison to 35% abandonment of treatment for children with Non‐Hodgkin lymphoma. Enrollment in the Kenyan National Health Insurance Fund, distance from hospital (\< or \> 100km), duration of symptoms prior to diagnosis (\< or \> 3 months), or gender did not predict outcome. Overall our patients had 80% event free survival at 3 years.

**Conclusions**: Utilizing a standard and well‐tolerated chemotherapy regimen can lead to long‐term survival of the majority of patients with HL in Kenya. Factors affecting outcomes for other tumor types, such as insurance status or travel distance do not predict HL outcome when using the ABVD regimen.

### PO-263. Unusual Presentations with Hodgkin Lymphoma in Children {#pbc27455-sec-4900}

C. Hendricks^1^, [R. Thejpal]{.ul} ^1^, B. Neethling^1^, Y. Goga^1^

*^1^Inkosi Albert Luthuli Central Hospital‐ University of KwaZulu Natal, Paediatric Haematology, Durban, South Africa*

**Background/Objectives**: Most children with Hodgkin lymphoma (HL) present with lymph node enlargement or with systemic symptoms. Presentation with paraneoplastic syndromes and at unusual sites is rare.

**Design/Methods**: Atypical presentations in children with HL managed at Inkosi Albert Luthuli Central Hospital (IALCH) were reviewed. Seven patients were identified -- 2 with proptosis, 2 with nephrotic syndrome, 1 with a recurrent pericardial effusion, 1 with cerebellar atrophy and 1 with hypertrophic pulmonary osteoarthropathy.

**Results**: Patients 1‐6 were African males and patient 7 was an Indian male. 1) Eleven year 5 month old patient with Stage IV B Nodular sclerosing (NS) HL presented with lower limb weakness, headache, proptosis with 3rd and 6th nerve palsies. Imaging confirmed intraconal mass extending to the cavernous sinus. 2) Eight year 6 month old patient with Stage II A Mixed cellularity (MC) HL presented with facial pain and proptosis. Imaging showed intracranial extension. Diagnosis confirmed after enucleation. 3) Nine year old patient with Stage IV A MC HL presented with recurrent pericardial effusions associated with a mediastinal mass. 4) Nine year old patient with Stage IV A MC HL presented with severe cerebellar signs and cerebellar atrophy on imaging. 5) Nine year old patient with Stage II B MC HL and 6) Ten year old patient with Stage II A NS HL both presented with nephrotic syndrome. 7) Nine year old patient with Stage II A NS HL presented with clubbing of the fingers and joint pain for 6 months. This was associated with an asymptomatic mediastinal mass.

**Conclusions**: In the children described the diagnosis of HL was not the first consideration because of the atypical presentation. The paraneoplastic features (nephrotic syndrome, cerebellar atrophy, clubbing) resolved with chemotherapy. Apart from the enucleation the patients with proptosis achieved remission with no neurological deficit.

### PO-264. Endocrinologic Late Effects in Pediatric Hodgkin Lymphoma Patients {#pbc27455-sec-4910}

R. amirov^1^, [G. Tokuc]{.ul} ^2^, N. eker^3^, A. bereket^4^, E. senay^2^

*^1^marmara university, pediatrics, istanbul, Turkey; ^2^marmara university, pediatric oncology‐hematology, istanbul, Turkey; ^3^marmara university, pediatric oncology‐ hematology, istanbul, Turkey; ^4^marmara university, pediatric endocrinology, istanbul, Turkey*

**Background/Objectives**: Survival rate of Hodgkin Lymphoma (HL) has been increased but this resulted an increase of chemotherapy and radiotherapy related late side‐effects. One of the most common long‐term side effects are endocrine‐related side effects. In this study, we searched for long‐term endocrine‐related side effects of our pediatric Hodgkin patients.

**Design/Methods**: HL patients at complete remission at least for 2 years were eligible for this prospective study. Patients whose disease were relapsed or who were at complete remission for less than 2 years or undergone bone marrow transplantation were excluded. For thyroid related side effects, serum TSH, free T3, free T4, anti‐TGB, anti‐TPO, thyroglobulin levels and thyroid gland ultrasound were assessed. For gonadal functions, serum FSH, LH, estradiol (for girls), testesterone (for boys) levels were measured. Sexual development was assessed with Tanner staging and ovary and testis sizes were noted. Glucose metabolism and obesity were evaluated by measuring serum fasting glucose and insulin levels, HBA1C, HOMA and body mass indexes. For bone metabolism related side effects, serum Ca, P and ALP paramethers were detected. All data were analyzed by comparison of variables related to clinical features and treatment.

**Results**: 19 patients (%46) had hypothroidism. Thyroid nodule were detected in 7 patients (%17). 5 patients' (%12) serum FSH levels were above normal. %48 of patients had increased HOMA index while %34 were assessed as overweight or obese according to their BMI. None of the patients had abnormal result for bone metabolism and adrenal axis.

**Conclusions**: In our study population, hypotiroidism, gonadal toxicity, insulin resistance and obesity were detected. It\'s important to follow up these patients for long‐term to prevent morbidity after HL treatment. Although there are many studies on endocrine side‐effects of chemotherapy and radiotherapy in HL patients, detailed randomized controlled trials are needed especially for glucose metabolism and obesity related side effects.

### PO-265. Comparison of Two Periods in Terms of Clinical Findings and Viral Studies in Childhood Hodgkin Disease in a Single Center in Turkey {#pbc27455-sec-4920}

G. Yavuz^1^, [E. Unal Cabi]{.ul} ^1^, N. Tacyildiz^1^, H. Dincaslan^1^, G. Kaygusuz^2^, S. Fitoz^3^, G. Tanyıildiz^1^, S. Gozdasoglu^1^, E. Babacan^1^, A. Cavdar^1^

*^1^Ankara University Faculty of Medicine, Department of Pediatrics ‐ Division of Pediatric Hematology‐Oncology, Ankara, Turkey; ^2^Ankara University Faculty of Medicine, Department of Pathology, Ankara, Turkey; ^3^Ankara University Faculty of Medicine, Department of Radiology ‐, Ankara, Turkey*

**Background/Objectives**: In developing countries the epidemiologic, clinical and histopathologic features of pediatric Hodgkin disease (HD) show considerable differences from those of developed countries.

**Design/Methods**: The charts of 175 children with newly diagnosed HD, treated between 1964‐1994 were retrospectively analyzed and was referred as first period and were compared with the clinico‐epidemiologic findings of 66 HD patients, reated between 1997‐2018, namely the second period..

**Results**: In the first period 80% were in the 1.st decade with male predominance. 15.6% in CSI, 19.1% in CS II,65.3%, CS III (15.6%) IV (49.7%). the male predominance remained the same however, unlike the first period, \>10 yrs at initial presentation and the changes of CS distribution were noted (9.9% in CS I, 19.8% CS II, 25.7% CSIII,43.8% in CS IV). histopathologic subtypes w/o significant changes between two periods MC subtype being the most common, a decrease in LP and an increase in NS histopathology in two groups, respectively. The distribution of histopathological subtypes are as follows: Between 1964‐1994 ‐ LP 18.7%, NS 16.85%, MC 60.6%; Between 1997‐2018 LP 3%, NS 38.5%, MC 52.6% and NLPHL 1.5%. Epstein‐Barr virus studies, which has been carried out in HD patients since 1985, had shown high seropositivity (95%) in those patients. In the second period in 66 cases, in addition to serologic studies EBV related LMP1 was found to be positive in 37.8% of umor tissue samples of the patients

**Conclusions**: Increased CSIII, decreased CSIV might be due to the improvements in health services, changes in the environmental and socioeconomical conditions. Increased frequency of NS histopathology may reflect the characteristics of a more industrialized society. Though there is a high frequency of EBV association with HD by serologic and immunocytochemical methods, we suggest that the association of EBV infection does not have a major impact on the prognosis of children with HD.

### PO-266. Hydroa Vacciniforme--Like Lymphoproliferative Disorder: A Systematic Review {#pbc27455-sec-4930}

[L. Vasquez]{.ul} ^1^, I. Maza^1^, B. Beltran^2^

*^1^Rebagliati Hospital, Pediatric Oncology, Lima, Peru; ^2^Rebagliati Hospital, Clinical Oncology, Lima, Peru*

**Background/Objectives**: Hydroa Vacciniforme‐like lymphoproliferative disorder (HVLPD) is an uncommon Epstein‐Barr Virus (EBV) associated cutaneous lymphoma. Due to multiple small case series and reports, this study aimed to provide a comprehensive systematic review of reported cases of HVLPD, according to PRISMA guidelines.

**Design/Methods**: We performed a systematic electronic search through Pubmed/Medline, Google Scholar and hand searches for relevant references without any language restriction. Inclusion criteria involved all newly diagnosed cases of HVLPD published until March 2018 according to the World Health Organization (WHO) classification. Extracted data included age, gender, patient demographics, presentation, duration of symptoms, systemic compromise, pathology, immunohistochemistry and molecular profile, received therapy, outcome and follow‐up time.

**Results**: A total of 49 studies and 166 reported cases of HVLPD were included for analysis. The majority of cases have been reported exclusively from Latin America (62.7%) and Asia (36.8%). Eighty‐two of cases were male (50.1%) with a median age of 12 years (range,1‐70). Median latency to presentation was 24 months (range, 2‐372). Initial clinical presentation was reported in 77.5% of studies. Facial edema (105/107, 98.1%) and lesions in sun exposed/unexposed skin of trunk and/or extremities (71/107, 66.4%) were common features. EBV‐encoded RNA (EBER)‐positivity in the neoplastic cells was present in all cases. TCR‐γ gene clonal rearrangement was detectable in 31.3% of cases. Systemic symptoms (including fever, hepatosplenomegaly and lymphadenopathy) were described in 101 cases (60.8%) and were associated to higher mortality (p=0.045). Clinical features and prognosis did not vary between pediatric and adult patients. Systemic chemotherapy was the most frequently describe treatment (58,1%), followed by immunomodulatory agents. Death was reported in 41/166 cases (24.7%).

**Conclusions**: HVLPD is a rare entity mainly affecting children from Latin America and Asia, with distinct clinical features. Further research should focus on long term follow‐up studies to give concrete evidence on the prognostic factors and standard treatment of this disease.

### PO-267. The Relationship Between Lympadenopathy and HIf‐1 Alpha Gene Polymorphism in Children {#pbc27455-sec-4940}

[S. Yilmaz]{.ul} ^1^, A. Yoruk^2^, E. Zemheri^3^, O. Suakar^4^, N. Imamova^4^, P. Canizci^5^, A. Kuşkucu^4^

*^1^Yeditepe University, Pediatric Hematology/Oncology, Istanbul, Turkey; ^2^Medeniyet University Goztepe Education and Research Hospital, Pediatric Hematology/Oncology, Istanbul, Turkey; ^3^Health Science University‐ Umraniye Education and Research Hospital, Pathology, Istanbul, Turkey; ^4^Yeditepe University, Medical Genetics, Istanbul, Turkey; ^5^Medeniyet University Goztepe Education and Research Hospital, Pediatrics, Istanbul, Turkey*

**Background/Objectives**: Lymphadenopathy is an abnormality in the size or the character of the lymph node including both reactive and malignant conditions. The assessment of lymphadenopathy in children is a common diagnostic problem in the field of pediatrics. Understanding the wide variety of diseases or conditions that may present as lymphadenopathy is essential to determine the most appropriate workup for an individual patient. Cells develop numerous adaptive responses regulated by hypoxia Hif‐1 alpha against to hypoxic stress. Considering the polymorphism of Hif‐1 α, Hif‐1 α may play a role in the process of carcinogenesis with increasing in the early stage of cancer. Meta‐analysis indicated that both the polymorphisms C1772T and G1790A significantly associated with overall cancer risk. In the present project, we aimed to investigate whether Hif‐1 α gene polymorphisim is availiable or not in lymph nodes with reactive hyperplasia and lymphoma.

**Design/Methods**: Twenty lymphoma (16 Hodgkin, 4 Non‐Hodgkin lymphoma) and 12 reactive hyperplasia preserved through formalin‐fixation and paraffin embedding (FFPE) were investigated. Polymerase chain reaction‐restriction fragment length polymorphism was used to assess the C1772T and G1790A polymorphisms in the Hif‐1α gene, and differences in genotypes between the 2 groups were compared.

**Results**: C1772T polymorphism was not observed in both lymphoma and reactive hyperplasia cases. Particularly, G1790A polymorphism was seen in 3 Hodgkin lymphoma and 5 reactive hyperplasia cases.

**Conclusions**: Reactive hyperplasia and lymphoma should be differentiated in terms of an early diagnosis and treatment of lymph node malignancies. Interestingly Hif‐1α G1790A polymorphism was associated with an increased susceptibility to reactive hyperplasia in our study. In the light of results, it can be emphasized that children diagnosed with reactive hyperplasia should be followed up closely.

### PO-268. Multiple Small Bowel Perforations of Diffuse Large B Cell Lymphoma: A Case Report {#pbc27455-sec-4950}

[X. Zhang]{.ul} ^1^, W. liu^2^, G. Qian^3^

*^1^Children\'s Hospital Affiliated to Zhengzhou University, Department of Pediatric Oncology Surgery, Zhengzhou, China; ^2^Children\'s Hospital Affiliated to Zhengzhou University, Department of Blood and Oncology, Zhengzhou, China; ^3^Children\'s Hospital Affiliated to Zhengzhou University, Department of Dermatology, Zhengzhou, China*

**Background/Objectives**: To present a case of small intestinal lymphoma with severe multiple perforation treatment and therapeutic effect.

**Design/Methods**: The present case study reports the case of a 17‐month‐old girl with intestinal perforation. The patient presented with fever, vomiting and abdominal distention. Acute bowel obstruction was initially diagnosed based on the abdominal radiograph findings, reexamination of abdominal radiograph revealed free air under the diaphragm, prompting a suspicion of intestinal perforation. An emergency laparotomy revealed ten discrete perforations and fifteen ulcerative lesions in the small bowel, starting from duodenojejunal junction to the terminalileum. The closure of perforations was undergone, while severe involved bowel was resected.

**Results**: The pathological results of the lesions showed Epstein‐Barr virus‐positive primary small bowel diffuse large B cell lymphoma. Following surgery, six cycles of chemotherapy(R‐CHOP) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. During the 2 years of follow‐up, the patient\'s indicators were normal, and no obvious recurrence and metastasis of lymphoma was found.

**Conclusions**: Patients with small intestinal lymphoma with severe perforation can achieve good therapeutic effect after careful operation and standardized postoperative chemotherapy.

### PO-269. Multiple Small Bowel Perforations of Diffuse Large B Cell Lymphoma: A Case Report {#pbc27455-sec-4960}

[X. Zhang]{.ul} ^1^, W. liu^2^, G. Qian^3^

*^1^Children\'s Hospital Affiliated to Zhengzhou University, Pediatric Oncology Surgery, Zhengzhou, China; ^2^Children\'s Hospital Affiliated to Zhengzhou University, Blood and Oncology, Zhengzhou, China; ^3^Children\'s Hospital Affiliated to Zhengzhou University, Dermatology, Zhengzhou, China*

**Background/Objectives**: To present a case of small intestinal lymphoma with severe multiple perforation treatment and therapeutic effect.

**Design/Methods**: The present case study reports the case of a 17‐month‐old girl with intestinal perforation. The patient presented with fever, vomiting and abdominal distention. Acute bowel obstruction was initially diagnosed based on the abdominal radiograph findings, reexamination of abdominal radiograph revealed free air under the diaphragm, prompting a suspicion of intestinal perforation. An emergency laparotomy revealed ten discrete perforations and fifteen ulcerative lesions in the small bowel, starting from duodenojejunal junction to the terminalileum. The closure of perforations was undergone, while severe involved bowel was resected.

**Results**: The pathological results of the lesions showed Epstein‐Barr virus‐positive primary small bowel diffuse large B cell lymphoma. Following surgery, six cycles of chemotherapy(R‐CHOP) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. During the 2 years of follow‐up, the patient\'s indicators were normal, and no obvious recurrence and metastasis of lymphoma was found.

**Conclusions**: Patients with small intestinal lymphoma with severe perforation could achieve good therapeutic effect after careful operation and standardized postoperative chemotherapy.

### PO-270. Multiple Small Bowel Perforations of Diffuse Large B Cell Lymphoma: A Case Report {#pbc27455-sec-4970}

[X. Zhang]{.ul} ^1^, W. liu^2^, G. Qian^3^

*^1^Children\'s Hospital Affiliated to Zhengzhou University, Pediatric Oncology Surgery, Zhengzhou, China; ^2^Children\'s Hospital Affiliated to Zhengzhou University, Blood and Oncology, Zhengzhou, China; ^3^Children\'s Hospital Affiliated to Zhengzhou University, Dermatology, Zhengzhou, China*

**Background/Objectives**: To present a case of small intestinal lymphoma with severe multiple perforation treatment and therapeutic effect.

**Design/Methods**: The present case study reports the case of a 17‐month‐old girl with intestinal perforation. The patient presented with fever, vomiting and abdominal distention. Acute bowel obstruction was initially diagnosed based on the abdominal radiograph findings, reexamination of abdominal radiograph revealed free air under the diaphragm, prompting a suspicion of intestinal perforation. An emergency laparotomy revealed ten discrete perforations and fifteen ulcerative lesions in the small bowel, starting from duodenojejunal junction to the terminalileum. The closure of perforations was undergone, while severe involved bowel was resected.

**Results**: The pathological results of the lesions showed Epstein‐Barr virus‐positive primary small bowel diffuse large B cell lymphoma. Following surgery, six cycles of chemotherapy(R‐CHOP) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. During the 2 years of follow‐up, the patient\'s indicators were normal, and no obvious recurrence and metastasis of lymphoma was found.

**Conclusions**: Patients with small intestinal lymphoma with severe perforation could achieve good therapeutic effect after careful operation and standardized postoperative chemotherapy.

### PO-271. Rituximab is Highly Effective in Children and Adolescents with Intermediate‐ and High‐Risk Burkitt Lymphoma {#pbc27455-sec-4980}

[Z. Zhen]{.ul} ^1^, J. Zhu^1^, J. Wang^1^, S. Lu^1^, F. Sun^1^, J. Huang^1^, X. Sun^1^

*^1^Sun Yat‐sen University Cancer Center, Pediatric Oncology, Guangzhou, China*

**Background/Objectives**: Data regarding the use of rituximab in children and adolescents with Burkitt lymphoma (BL) is limited. This study retrospectively analyzed the effect of rituximab on children and adolescents with intermediate‐ or high‐risk BL.

**Design/Methods**: Patients underwent chemotherapy according to the revised NHL‐BFM‐95 protocol. Rituximab was administered at the dose of 375 mg/m^2^ on day 0 of each cycle.

**Results**: A total of 106 patients were included. Stratified by the number of doses of rituximab, there were 49, 16, and 41 patients in group 1 (no rituximab), group 2 (1‐3 doses of rituximab) and group 3 (≥4 doses of rituximab), respectively. The 3‐year event‐free survival (EFS) rates were 83.2% ± 5.4%, 81.2% ± 9.8%, and 96.8% ± 3.2% in group 1, group 2 and group 3, respectively. In patients with intermediate‐risk disease, the 3‐year EFS rates were 100% in patients treated with rituximab and 88.2% ± 7.8% in those treated without rituximab. In patients with high‐risk disease, the relapse rates were 18.8%, 21.4% and 3.0% in group 1, group 2 and group 3, respectively (*P* = 0.048).

**Conclusions**: Rituximab is highly effective in children and adolescents with intermediate‐ and high‐risk BL. The optimal number of doses was 4‐6 in patients with high‐risk BL.

### PO-272. Outcome of Chinese Children Burkitt Lymphoma with Bone Marrow Involvement or Burkitt Leukemia: Single Center Experience in China {#pbc27455-sec-4990}

[J. Zhu]{.ul} ^1^, Z. Zhen^1^, J. Wang^1^, F. Sun^1^, S. Lu^1^, J. Huang^1^, X. Sun^1^

*^1^State Key Laboratory of Oncology in South China‐ Collaborative Innovation Center for Cancer Medicine‐ Sun Yat‐Sen University Cancer Center‐, Pediatric Oncology, Guangzhou, China*

**Background/Objectives**: Burkitt lymphoma usually involves bone marrow(BM). The survival has been improved by using intensive chemotherapy with short pulse, multi‐agents and central nerve system prophylaxis. The present study retrospectively analyzed outcome of Chinese pediatric Burkitt lymphoma patients with BM involvement or Burkitt leukemia treated by using NHL‐BFM‐90/95 protocol± Rituximab.

**Design/Methods**: The data were collected from 189 Burkitt lymphoma patients younger than 18 years old who were treated with NHL‐BFM‐90/95 protocol in Sun Yat‐Sen University Cancer Center from 2001 to 2018. The patients with BM involvement **or Burkitt** leukemia were available for analysis. The patients with more than 25% marrow blasts are classified as having Burkitt leukemia, and those with 5%‐ 25% marrow blasts are classified as having BM involvement of Burkitt lymphoma.

**Results**: A total of 23 cases of Burkitt lymphoma with BM involvement or Burkitt leukemia were analysed. There were 19 males and 4 females with a median age of 8 years old (range 2‐17). Ten cases were BM involvement of Burkitt lymphoma and 13 cases with Burkitt leukemia. Of 13 Burkitt leukemia, eight cases had 25%‐89% marrow blasts and five cases were more than 90% marrow blasts. All patients were designed for high risk group and treated by using BFM‐90/95 protocols± Rituximab. A total of six courses were administered for all patients(v‐AA‐BB‐CC‐AA‐BB‐CC).Rituximab combined with BFM‐90/95 protocols were given to 11 cases (48%). The median follow‐up time was 46.4 months (2.5‐230 months). A total of 3 cases died, two cases died of tumour progression and one abandoned therapy after tumour lysis syndrome was relieved. The estimated 5‐year event‐free survival and overall survival rates were 86.5% and 86.5%, respectively.

**Conclusions**: Pediatric Burkitt lymphoma with BM involvement or Burktt leukemia can achieve better survival treated with protocol NHL‐BFM‐90/95±Rituximab.

Haematology ‐ Stem Cell Transplantation {#pbc27455-sec-5000}
---------------------------------------

### PO-273. Does a Uniformly Applied Initial IV Ciclosporin Dose Achieve Target Trough Concentrations in Children with Malignant and Non‐Malignant Disease Following Allogenic Hematopoietic Stem Cell Transplantation? {#pbc27455-sec-5010}

[S. Abbas]{.ul} ^1^

*^1^Royal Hospital For Children Glasgow, Paediatric Haematology & Oncology ward‐ Royal Hospital for Children Glasgow, Glasgow, United Kingdom*

**Background/Objectives**: A retrospective analysis of ciclosporin A (CsA) data from 53 children aged 9 months to 17 years (median 6.4 years) who underwent allogenic hematopoietic stem cell transplantation (HSCT) was undertaken to determine if an IV CsA dose of 3 mg/kg/day achieves target trough concentrations in patients with malignant (n = 30) and non‐malignant disease (n = 23).

**Design/Methods**: A total of 71 patients were identified during the study period. Patients were divided into two groups, those with an underlying malignant disease and those with a non‐malignant disease. The initial and final daily dose required to reach target trough concentration in varying age, weight and disease type was studied. The ratio between trough and dose for all patients was averaged to determine the relationship between these two variables and the resulting trough concentrations for different alternative dosing regimens was calculated. The number (percentage) of patients who would achieve different concentration ranges for different dosage regimens was then calculated.

**Results**: The initial 3 mg/kg/day CsA dose was increased in 22 malignant patients (73%) and 23 non‐malignant patients (100%). The median final daily dose required to reach target trough concentration was 3.6 mg/kg/day (range 3‐5.4) in malignant patients and 5.2 mg/kg/day (range 3.8‐8.6) in non‐malignant patients. All patients required a dose increase but those with non‐malignant disease, those who were younger and with lower weights required a greater increase in dose. The time to achieve target trough concentrations was longer in non‐malignant patients compared to malignant patients (13 ± 5 days vs 6 ± 4 days, *p* \<0.0001).

**Conclusions**: In conclusion, a starting dose of 3 mg/kg/day is too low to achieve target trough concentrations in malignant and non‐malignant disease in children with varying age and weight. When considering alternate dosage regimens either a cut‐off at age 6 years or weight 20 kg would be appropriate.

### PO-274. Hematopoietic Stem Cell Transplantation in Children with Hemoglobinopathy: A Single‐Centre Experience {#pbc27455-sec-5020}

[M.M. Alam]{.ul} ^1^, M. Bayoumy^1^, H.A. Al‐Trabolsi^1^, I. Abosoudah^1^

*^1^King Faisal Specialist Hospital and Research Center, Department of Oncology‐ Section of Pediatric Hematology/Oncology/BMT, Jeddah, Saudi Arabia*

**Background/Objectives**: Hematopoietic Stem Cell Transplantation (HSCT) has become an accepted therapeutic modality for a wide variety of diseases and is increasingly utilized and considered as a curative treatment for thalassemia major (TM) and sickle cell disease (SCD).

**Design/Methods**: Retrospective analysis of clinical, laboratory and outcome data

**Results**: Total of 32 patients included, out of them 19 (59.4 %) were TM and remaining 13 (40.6%) were SCD. The mean age at transplant was 8.14 +/‐ 4.6 years. Males were 16 (50%) and females were 16 (50%). Conditioning regimen was Bu/Cy/ATG (n=17, 53.1%, Flu/Bu/Cy/ATG (n=14, 43.8%) Italian protocol (n=1, 3.1%). Source of stem cell in all patients were bone marrow. Mean stem cell dose CD 34+ was 6.25 (+/‐ 2.9) x 106/kg. Acute GVHD was observed in 10 (31.25%); out of them skin (n=5) gut (n=2), liver (n=2) and both skin and gut (n=1). Grade I, II, III and IV GVHD were observed in 1 (3.1%), 4 (12.5%) and 4 (12.5%) and 1 (3.1%) patients respectively. Chronic GVHD were noticed in 2 (6.3%) patients and both had skin involvement. Median duration of ANC engraftment was is 22 (Range: 12‐27) and median platelet engraftment was 32 (Range: 18‐ 45) days in 28 patients and remaining 4 patients had delayed platelet engraftment (62‐90 days). CMV reactivation was observed in 18 (56.3%) cases. Majority were asymptomatic (n=17; 53.1%) and remaining (n=1; 3.2%) had clinical manifestation/organ involvement (pneumonia and skin manifestation). OS rate were 93.7% with median duration of follow up 33.72 (+/‐25.3) months.

**Conclusions**: The results of the pediatric BMT program at our institution have nearly comparable to those reported in the literature as far as transplant‐related morbidity and mortality is concerned. However, the duration of follow‐up is short and the long‐term outcome is yet to be determined.

### PO-275. Pre ‐ Stem Cell Transplant Work‐up Tracking System for Patients with Pediatric Non‐Malignant Blood Disorders {#pbc27455-sec-5030}

[M. Alsaleh]{.ul} ^1^, A. AlJefri^1^, A. AlAhmari^1^, M. Ayas^1^, D. Qattan^2^, B. Safi^2^, S. Jose^2^, V. Mohammed^1^

*^1^King Faisal Specilaist Hospital & Research Centre, Pediatric Hematology / Oncology, Riyadh, Saudi Arabia; ^2^King Faisal Specilaist Hospital & Research Centre, Pediatric Nursing, Riyadh, Saudi Arabia*

**Background/Objectives**: Learning Stem Cell Transplant (SCT) could be the only curative option available marks beginning of a journey that takes through a battery of pre‐clearance tests before a patient indicated for SCT is cleared. Thus, Pre‐SCT clearance necessitates an effective follow‐up approach between nursing and hematologists /oncologists to improve transplant outcome, SCT is often offered as a curative option for Inherited Non‐Malignant Blood Disorders (NMBD) and several cases are referred to pediatric hematology section of King Faisal Specialist Hospital and Research Centre, Riyadh.

**Design/Methods**: Hematology Pre‐BMT Screening and Clearance module was developed in January\'2016, as part of the institutions performance improvement initiative to reduce pre‐SCT clearance time. Research Electronic Data Capture (REDCap) software was used to generate disease specific log of medical investigations.

**Results**: A total of 240 cases for SCT were registered,69%(166) with Hemoglobinopathies (sickle cell disease, 64%; thalassemia,33%; sickle cell‐thalassemia,3%) and 31% (74) Bone Marrow failures (Fanconi anemia,33%; Aplastic anemia,24%;Diamond‐Blackfan anemia,19%; Dyserythropoietic anemia,16%, Kostmann syndrome, 4%, Sideroblastic anemia,3% ; Dyskeratosis congenita 1%). Patients were categorized in to virtual reports based on their HLA typing, pre‐SCT workup and clearance status: No‐donor 25% (59), Follow‐up 35% (84) and Cleared 40% (97) respectively. Patients from follow‐up list are weekly reviewed by clearance team to facilitate investigations and an alternate donor search is conducted periodically for patients from No‐ donor list, while 69% (67) of cleared patients were transplanted. A comparison of median pre‐SCT clearance time in patients transplanted during first three quarters of 2016 and 2017 was conducted ; a reduction of 26% (84.5 to 62.5 days) was observed.

**Conclusions**: User‐friendly feature enabled electronic disease‐specific work‐up plans, identification of early‐scheduling areas and real‐time follow‐up; additionally, "no‐donor" patients were catalogued for effective alternate donor search. Preliminary cost ‐analysis indicated transfusion‐related cost saving of up to 38,000 USD with further analysis warranted.

### PO-276. Outcome of Hematopoietic Stem Cell Transplantation as Salvage Therapy for Pediatric Relapsed/Refractory Hodgkin Lymphoma: A Single Center Experience {#pbc27455-sec-5040}

[S.S. Anak]{.ul} ^1^, Y. Yaman^1^, M. Elli^1^, E. Saribeyoglu^1^, V. Hazar^1^, K. Ozdilli^1^

*^1^16996, Medipol University Pediatric Hematology/Oncology/BMT, Istanbul, Turkey*

**Background/Objectives**: Despite the generally excellent prognosis of children with Hodgkin lymphoma (HL), approximately 15% of patients relapse. Salvage therapy with further chemo‐radiotherapy and autologous HSCT following high‐dose chemotherapy (HDC‐SCT) and/or allogeneic haematopoietic SCT (allo‐HSCT), may improve survival up to 40%.

**Design/Methods**: A retrospective analysis of 15 consecutive pediatric patients with relapsed/refractory HL, treated at our institute, from 4/2014 to 3/2017, is conducted to evaluate the effectiveness of this approach.

**Results**: 9 girls, 6 boys with median age of 14 years (7‐19 years) with relapsed/refractory HL were treated with HDC‐SCT. Except for one in PR, 14 patients were in 2nd CR before SCT. BEAM (Busulphan, E toposide, ARA‐C, Melphalan) was the conditioning regimen for 12 patients, while Bendamustine replaced BCNU in 3. PR patient could not achieve CR, 6/15 patients remained in CCR, while 8/15 relapsed after HDC‐SCT. One of the relapsed patients was treated using Nivolumab in a trial and still in CR after one year. For the other 8 relapsed patients, several chemotherapy regimens together with bridging therapy (Brentuximab, 4‐12 courses for 5/14 patients) were used. 6/8 achieved CR, while 2/8 remained in PR. Allo‐SCTs (4 FMDs, 2MUDs, 2 haploSCT with post transplant Cyclophosphamide) with RIC (Melphalan + Busulphan or Fludarabine) were conducted in all 8 patients and full donor chimerism could be achieved in all of them. 2/8 patients, who were in PR before SCT, expired in 6 months with progressive disease. Among 6/8 patients with a a median follow up of 2 years (1‐4 years), 5 are in CR, one is with stable disease.

**Conclusions**: Outcome for patients with chemosensitive relapsed HL who receives HDC‐SCT and allo‐HSCT if needed after a bridging chemotherapy seems acceptable but for chemoresistant patients, the results are not encouraging. This approach must be evaluated in larger patient groups.

### PO-277. Hematopoetic Stem Cell Transplant Using Fludarabine‐ Busulfan Based Conditioning Regimen in Pediatric Acute Myeloid Leukemia {#pbc27455-sec-5050}

S. Bhat^1^, [S. Chakraborty]{.ul} ^1^, A. Venkatagiri^1^, R. Joshi^1^, S. Badiger^1^, V. Kailasnath^1^, N. K Srinivasarao^1^, S. Damodar^1^, P. Mallya^1^

*^1^Mazumdar Shaw Medical Center‐ Narayana Health City, Pediatric Hematology‐ Oncology‐ Blood and Marrow Transplant, Bangalore, India*

**Background/Objectives**: Recent studies have shown that during conditioning for haematopoietic stem cell transplant (HSCT) in acute myeloid leukemia (AML), the use of busulfan along with fludarabine (Flu) in lieu of cyclophosphamide (Cy) leads to a significant decrease in regimen related toxicity and transplant related mortality.

**Design/Methods**: Retrospective analysis of pediatric patients with AML undergoing HSCT at our Center from July 2013 to January 2018.

**Results**: Twenty eight patients with a median age of 85.5 months (range 26 to 204) were included in the study. Eleven patients were in CR1, 16 in CR2 and 1 in CR3. Fludarabine ‐ Busulphan based myeloablative conditioning was used in all the patients.13 (46.4%) of the patients underwent matched sibling donor (MSD) transplant while 15 (53.6%) underwent haploidentical transplant (3 with TCR αβ & CD19 depletion and 12 with post transplant cyclophosphamide \[PTCY\] as GVHD prophylaxis). The median MNC (108 /kg) and CD34 (106 / kg) doses were 4.7 & 6.4, 6.7 & 23.6 and 6.1 & 6.3 in the MSD, TCR αβ depletion and PTCY groups respectively. Twenty six patients achieved hematological recovery with neutrophil and platelet engraftment at a median of 13.5 and 14 days respectively. Grade 3‐4 mucositis was seen in 16 (57.1%) patients while VOD was seen in 4 (14.2%) patients (mild=2, moderate=1 and severe =1).There were a total of 11 (39.2%) deaths (relapse = 6, sepsis = 5). The cumulative incidences of non relapse mortality, acute GVHD grade II‐IV and III‐IV were 25.7 ± 14.9 %, 27.1 ± 30.7% and 13 ± 35.7% at 1 year respectively. The overall survival and disease free survival were 62.6% ± 10.8 and 59.4 ± 10.7 % at 2 years respectively.

**Conclusions**: Flu‐Bu in AML is a well tolerated conditioning regimen with acceptable toxicity and transplant outcome.

### PO-278. Open‐Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Children with Steroid‐Refractory Sclerotic/Fibrotic Type Chronic Graft‐Versus‐Host Disease {#pbc27455-sec-5060}

H.J. Kang^1^, [J.Y. Choi]{.ul} ^1^, H. Kim^2^, H.J. Baek^3^, H. Kook^3^, J.M. Lee^4^, H.Y. An^1^, K.T. Hong^1^, H.Y. Shin^1^, H.S. Ahn^1^

*^1^Cancer Research Institute‐ Seoul National University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^2^Asan Medical Center Children\'s Hospital, Division of Pediatric Hematology/Oncology‐ Department of Pediatrics, Seoul, Republic of Korea; ^3^Chonnam National University Hwasun Hospital‐ Chonnam National University Medical School, Department of Pediatrics, Hwasun, Republic of Korea; ^4^College of Medicine‐ Yeungnam University, Department of Pediatrics, Daegu, Republic of Korea*

**Background/Objectives**: Chronic graft‐versus‐host disease (cGVHD) is the most common late complication following allogeneic stem cell transplantation. There is no standard therapy for those who fail to respond to steroids, and steroid‐refractory cGVHD is associated with high morbidity. In this study, we evaluated the efficacy and safety of imatinib mesylate (Gleevec) and mycophenolate mofetil (MMF) to treat steroid‐refractory sclerotic/fibrotic type cGVHD.

**Design/Methods**: In non‐randomized, open‐label, single‐arm, multi‐center, prospective phase II study, we enrolled patients with steroid‐refractory sclerotic/fibrotic type cGVHD. Participants were treated with MMF at a dose of 15‐20mg/kg (maximum 1g) bid and Gleevec at the initial dose of 260 mg/m^2^/day (maximum 400mg). The primary endpoints was overall (complete and partial) response rate of steroid‐refractory sclerotic/fibrotic cGVHD to Gleevec plus MMF at 1 year. Secondary endpoints included safety, quality of life, discontinuation of steroid and overall survival rate.

**Results**: A total of 13 patients were enrolled between October 2013 and July 2017. The median age was 10.4 years (range 5.0‐20.1 years). Five of the 13 patients had previously experienced acute GVHD. The diagnoses were acute lymphoblastic leukemia in 5, acute myeloid leukemia in 3, chronic granulomatous disease in 3, neuroblastoma in 1 and hemophagocytic lymphohistiocytosis in 1 patient. Nine of the 13 patients achieved partial response (PR), 2 showed stable diseases (SD), and 1 died of pulmonary infection and progression of chronic lung GVHD. The remaining 1 patient died of primary disease progression. The overall response rate was 69.2 %. Nine of the 13 patients were able to reduce or discontinue steroids. Among 13 patients, 6 patients showed improvements in Lee cGVHD symptom scale score to assess quality of life. Common adverse events included grade 1‐2 liver enzyme, creatinine elevations and fever.

**Conclusions**: Although limited by a small sample size, Gleevec plus MMF for cGVHD showed promising results with acceptable toxicity.

### PO-279. Visual‐Motor Integration and Executive Functions State in Patients with Acute Lymphoblastic Leukemia who Underwent Hematopoietic Stem Cell Transplantation and Who Did Not {#pbc27455-sec-5070}

[A. Dreneva]{.ul} ^1^, A. Ryabova^1^, V. Kasatkin^1^, A. Karelin^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Rehabilitation Research Center for Patients in Remission "Russkoye Pole", Moscow, Russia*

**Background/Objectives**: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, which presently has 5‐year survival rates containing up to 60%. This treatment success is the result of current methods of treatment including radiotherapy and chemotherapy. However, in some cases it is necessary to use hematopoietic stem cell transplantation (HSCT) as well. Both the initial disease and HSCT can lead to the deficiency in the domains of motor skills, cognitive functions and visual‐motor integration.

**Design/Methods**: We used Beery™ Visual‐Motor Integration Test for the assessment of motor coordination, visual perception and visual‐motor integration, and Cambridge Neuropsychological Test Automated Battery for the evaluation of executive functions.

The cohort consisted of 79 children and adolescents who survived ALL: 39 patients who underwent HSCT (9 females, mean age was 11.15 ±3.51) and 40 patients who did not (20 females, mean age was 10.49 ±3.4).

**Results**: The comparison between two subgroups of patients reveals that HSCT recipients have demonstrated significantly worse results in such functions as visual‐motor integration, visual perception, motor coordination, working memory, and attention. These findings are coherent with other research indicating the deficiency in executive functioning, visual‐motor integration and fine motor skills in children post‐HSCT.

**Conclusions**: According to this study, the procedure of HSCT is supposed to cause more severe impairment in the domains of working memory, attention, and visual‐motor integration in ALL survivors, comparatively to the condition without HSCT.

### PO-280. Clinico ‐ Epidemiological Profile of Patients Admitted to the Bone Marrow Transplantation Unit: Experience of the Civil Hospital of Guadalajara, Mexico {#pbc27455-sec-5080}

[D.J. Duran Rodriguez]{.ul} ^1^, O. Gonzalez Ramella^2^, R.M. Navarro^2^

*^1^Fundacion Ayudame a vivir pro niños con Cancer de El Salvador, Pediatric oncology, San Salvador, El Salvador; ^2^Nuevo Hospital Civil de Guadalajara, Pediatric Hematology Oncology, Guadalajara, Mexico*

**Background/Objectives**: The pediatric hemato‐oncology department at Civil Hospital of Guadalajara diagnoses an average of 200 new patients with cancer per year. Looking forward to improving outcomes in pediatric cancer a bone marrow transplantation unit(BMTU) was built in 2003. This retrospective study aimed to describe the characteristics of the patients admitted to BMTU.

**Design/Methods**: The study included all patients between the age of six months and 20 years old admitted to BMTU from 2003 to 2017. Patients who were eligible for stem cell transplant presented diagnosis with a malignant, or benign hematologic diseases, or solid tumor. All the information was abstracted from the BMTU census; also, the clinical chart was reviewed to obtain the demographic and clinical variables. The descriptive statistical analysis was done using EPIinfo 7.

**Results**: Children that received stem cell transplant (SCT) were 119; 65 were male (54.62%) and 54 females (45.38%). The type of SCT were 50.42% allogeneic transplants (N = 60), 35.29% umbilical cord (N=42) and 14.29% were autologous (N=17). The mean age was six years 11.76%. The majority of SCT performed were in patients with Leukemia (57.14%). STC in children with benign hematologic diseases represented 36.97%. The acute graft versus host disease (GvHD) was observed in 44 patients (36.97%). Patient Mortality during their sojourn at BMTU was 18.49%.

**Conclusions**: The information provided by this study represents the improvements in rescue therapy, and supportive care to manage the GvHD for children with cancer in Guadalajara. Further research regarding the follow up of the patients seems to be the next step to create strategies to approach patients that relapse after allogenic‐STC.

### PO-281. EBV Infection, Reactivation and Post‐Transplant Lymphoproliferative Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplant {#pbc27455-sec-5090}

[M. Finkbeiner]{.ul} ^1^, V. Lewis^1^, K. Peterson^1^, G. Guilcher^1^, T. Truong^1^

*^1^Alberta Children\'s Hospital, Pediatric Hematology/Oncology/Transplant, Calgary, Canada*

**Background/Objectives**: Epstein Barr Virus (EBV) infection and reactivation are common occurrences after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to determine the overall incidence of EBV reactivation and Post‐Transplant Lymphoproliferative Disease (PTLD) in children.

**Design/Methods**: Retrospective chart review of children who underwent allogeneic HSCT at Alberta Children\'s Hospital in Calgary, Alberta between January 2007 and January 2017.

**Results**: Over a 10‐year period, 162 allogeneic HSCTs in 153 patients were performed for malignant and non‐malignant conditions. The overall incidence of any non‐zero EBV level was 44%. The overall incidence of EBV greater than 20,000 IU/ml was 24% with an incidence of PTLD of 7%. The use of anti‐thymocyte globulin (ATG) in conditioning was significantly associated with high EBV titres. EBV reactivation was associated with the presence of an EBV positive donor but neither the recipient\'s EBV status or the presence of a mismatch in EBV status the donor and the recipient were significant. Patients who received peripheral blood stem cells (PBSCs) had a higher risk of EBV reactivation compared to cord blood or bone marrow but the use of cord blood was protective. On multivariate analysis, the use of ATG and the presence of an EBV positive donor remained significant factors. Of the 10 patients who received treatment for EBV, all had levels greater than 100,000 IU/ml and all received rituximab as part of their therapy. There was no association between EBV reactivation and the development of graft versus host disease (GVHD), graft failure or death.

**Conclusions**: EBV reactivation is common in children who have undergone allogeneic HSCT with an overall incidence of greater than 20,000 IU/ml of 24%. It was statistically associated with the use of ATG, an EBV positive donor and the use of PBSCs. The development of features of PTLD was uncommon and treatment was initiated at the onset of symptoms.

### PO-282. Autologous Peripheral Blood Stem Cell Transplantation in Pediatric Solid Tumors, an Experience from Turkey {#pbc27455-sec-5100}

G. Tuysuz^1^, K. Yalcin^1^, H. Akbas^1^, V. Hazar^2^, A. Kupesiz^1^, [E. Guler]{.ul} ^1^

*^1^Akdeniz University, Pediatric Hematology and Oncology, Antalya, Turkey; ^2^Bahcesehir University Medical Park Hospital, Pediatric Hematology and Oncology, istanbul, Turkey*

**Background/Objectives**: Autologous peripheral blood stem cell transplantation (ABSCT) after high dose chemotherapy is one of the treatment options for aggressive tumors and refractory or relapsed diseases in childhood malignancies.

**Design/Methods**: In this study, we retrospectively analyzed the data of 68 children who received HDT followed by ABSCT from 1998 to 2017 in our center.

**Results**: Forty‐four (%64.7) of the patients were male and median age of transplantation was 76.2 months (22.8‐251.8 months). Indication for transplantation included neuroblastoma (n: 34), Hodgkin lymphoma (n: 8), Ewing Sarcoma (n:6), Non Hodgkin lymphoma (n:4), and others (n:22). While 35 of these patients received this treatment as a part of primary tumor treatment, the rest 33 received HDT followed by ABSCT due to refractory or relapsed disease. Disease status before transplantation was complete remission in 38 and very good partial response in the rest 30 patients. Febrile neutropenia (n:55), mucositis (n:50) and veno‐occlusive diseases (n:4), were the non‐hematological complications. Four patients (5.8%) died due to regimen related toxicities. Thirty‐three patients have relapsed (50%) with a mean time of 15,3 months (1‐66 months) after ABSCT. While 26 of these patients were lost due to progressive disease despite salvage chemotherapy the rest 7 are still in remission. Four patients were lost to follow up. Five year EFS and OS of the group were 34.3% and 47.6% respectively. One patient developed secondary AML and was lost despite the treatment Overall 30 patients (47%) are still in remission with a median follow up of 63 months (3.7‐166 months).

**Conclusions**: We conclude that ABSCT after high dose chemotherapy can be a treatment option for refractory or relapsed solid tumors.

### PO-283. Study of Haploid Peripheral Blood Combined with Umbilical Cord Blood Stem Cell Transplantation with Severe Aplastic Anemia in Children {#pbc27455-sec-5110}

[J. Hui]{.ul} ^1^, K. Chen^1^, B. Zou^1^, N. Zhang^1^, J. Shao^1^, H. Li^1^, J. Yang^1^

*^1^Shanghai children\'s Hoapital, haemotology/oncology, Shanghai, China*

**Background/Objectives**: To observe the effect of haploid peripheral blood(PB) combined with umbilical cord blood(UCB) stem cell transplantation in the treatment of children with severe aplastic anemia (SAA), including implantation, transplantation related complications and overall survival rate (OS), and to explore the prognostic factors of SAA patients after HSCT.

**Design/Methods**: From August 2016 to January 2018, 8 cases of SAA were treated with haplo‐HSCT, in which the proportion of boy and girl was 1:1, and the median age was 4 (2∼13) years. The median time of the interval from diagnosis to transplantation was 150 (92‐550) days. The median number of PB mononuclear cells was 11.02\*10^8^/kg, and the median of CD34+ cells was 4.43\*10^6^/kg. The pretreatment program mainly includes busulfan, fludarabine, cyclophosphamide and antithymocyte globulin. CsA, MMF combined with short course MTX were used to prevent GVHD.

**Results**: The early hematopoietic and megakaryocytic functions of all patients (100%)were recovered. The median time of neutrophils\>0.5\*10\^9/L and platelets\>20\*10\^9/L were 12(10∼15)days and15(12∼19) days after transplantation, respectively. After transplantation, STR showed complete chimerism, without cord blood components. 2 cases had I‐III degree aGVHD, and Chronic GVHD occurred in 1 cases, mainly in the local skin and eyes. Other complications were 1 cases of secondary implants, 1 cases of invasive fungal infection, 3 cases of cytomegalovirus infection, 4 cases of EB virus infection, and 1 cases had organic mental disorder after transplantation. The median follow‐up time was 10 (3∼20) months, and OS was 85.7±13.2%. Only one case died of diffuse alveolar hemorrhage (DAH) occurred at tenth months after the transplantation.

**Conclusions**: (1) Haplo‐HSCT is an effective method for the treatment of SAA without sibbing and unrelated matched donors. (2) Umbilical cord blood assisted infusion can alleviate graft versus host reaction, but may increase the incidence of viral infection. (3) Our data are not significantly different from those by major haploid transplantation centers in the world.

### PO-284. Haploidentical Hematopoietic Stem Cell Transplantation for Thalassemia: A Treatment Option for Patient Lacking a HLA‐Matched Donor {#pbc27455-sec-5120}

[P. Iamsirirak]{.ul} ^1^

*^1^samitivej children hospital, pediatric, bangkok, Thailand*

**Background/Objectives**: Thalassemia is the most common genetic disease in Thailand. In our country, severe thalassemia affecting health, quality of life and life expectancy includes beta thalassemia major (B/B) and beta thalassemia/Hb E disease (B/E). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for this disease at present. Matched related and unrelated donor have been effectively used for HSCT severe thalassemia. However, more than 50% of the patients lack of these suitable donors. To extend opportunity for HSCT in thalassemia, haploidentical donor stem cells for HSCT has been studied. The objective of this study was to demonstrate efficacy and early complications in patients with severe thalassemia recieving haploidentical HSCT at our institute.

**Design/Methods**: We collected demographic and transplant related data of patients with thalassemia underwent haploidentical HSCT at Samitivej Srinakarin hospital between 2014 and 2017

**Results**: There were 28 patients diagnosed with thalassemia (B/B=7, B/E=21) underwent 30 transplants. The median age was 7.6 years (range, 1‐27 years). The conditioning regimen consisted of antithymocyte globulin, fludarabine and IV busulfan. The donors were either father (n=13) or mother (n=17). The peripheral blood stem cells with the median CD34+ cells of 11.04x106 /kg (range, 6.8‐16 x106/kg) were infused. Neutropenia engraftment occurred on day + 14 (range, 12‐24 days). Two patients developed primary graft failure. Both of them underwent second haploidentical HSCT. However, only one engrafted and survived. Median length of hospital stay was 42.4 days (range, 31‐155 days). Infectious complications included bacterial sepsis (n=1), fungal sepsis (n=1) and CMV reactivation (n=2). Acute graft versus host disease (GVHD) was diagnosed in 11 patients (grade I=7, II=3 and IV=1). Four patients required PICU admissions. Three patients were readmitted within 30 days after discharge.

**Conclusions**: We demonstrate that haploidentical HSCT for patient with thalassemia is feasible and may be considered as a choice of curative treatment.

### PO-285. Ex Vivo T Cell‐Depleted Haploidentical Hematopoietic Cell Transplantation for Children with Acute Leukemia after a Reduced‐Intensity Preparative Regimen Containing Low‐Dose TBI {#pbc27455-sec-5130}

[H.J. Im]{.ul} ^1^, H. Kim^1^, K.N. Koh^1^, S.Y. Min^1^, J.J. Seo^1^

*^1^University of Ulsan College of Medicine‐ Asan Medical Center, Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: We evaluated the outcome of haploidentical HCT (HHCT) using ex vivo αβ T cell‐depleted (TCD) grafts after reduced‐intensity conditioning (RIC) containing low‐dose TBI (LD‐TBI) in pediatric patients with acute leukemia (AL).

**Design/Methods**: Of 38 patients with AL, 13 had ALL (5 CR1, 7 CR2, 1 CR3), 25 had AML (10 CR1, 8 CR2, 7 NR). Nine had relapsed after previous allogeneic HCT. All 25 patients with AML underwent a uniform RIC regimen consisting of LD‐TBI (600 cGy, TBI^600^), fludarabine, cyclophosphamide, and rabbit ATG. Of 13 patients with ALL, 8 received same conditioning regimen with AML, the remaining 5 received higher TBI dose of 800 cGy (TBI^800^).

**Results**: All 38 patients achieved a sustained neutrophil engraftment at a median of 10 days (range, 9‐17). The cumulative incidence of acute GVHD grade II‐IV was 20%. As of March 2018, 21 of the 38 patients survive free of disease at a median follow‐up of 34 months (range, 2‐71). The TRM was 4.4% at 1 year. EFS and OS at 2 years for all patients were 42% and 51%, respectively. Among the 13 patients with ALL, 7 out of 8 who received TBI600 relapsed, whereas, none of 5 who received TBI800 relapsed (*P*=0.091). Among the 25 patients with AML, EFS of 15 patients who received their first HHCT in CR was better than that of 10 patients who received HCT at active disease or relapsed after previous allogeneic HCT (85% vs 0%, *P*\<0.001).

**Conclusions**: Ex vivo αβ TCD HHCT using RIC containing LD‐TBI is feasible with a low TRM. The outcome of patients with AML who received their first transplant in CR was excellent. However, the outcome of ALL was poor suggesting that more intensified conditioning regimen may be reasonable. Furthermore, an innovative treatment strategy is warranted for patients with relapsed or refractory AML.

### PO-286. Umbilical Cord Blood Transplantation (UCBT) for the Treatment of Familial Hemophagocytic Syndrome (FHL) with DSA Positive: A Case Report {#pbc27455-sec-5140}

H. Jiang^1^, [C. kai]{.ul} ^1^, B. Zou^1^, N. Zhang^1^, J. Shao^1^, J. Yang^1^, H. Li^1^

*^1^Shanghai children\'s Hoapital, haemotology/oncology, Shanghai, China*

**Background/Objectives**: To explore the feasibility and prognosis of modified umbilical cord blood transplantation (UCBT) for the treatment of familial hemophagocytic syndrome (FHL) with donor specific HLA antibody (DSA) positive.

**Design/Methods**: We summarized the clinical features, treatment plans and short term follow‐up of 1 patients with DSA strongly positive, and reviewed the literature.

**Results**: (1) Case review: a 14‐month old boy who was diagnosed as FHL which was found the UNC13D gene Exon15 had c.1358delC (mother mutation source).There was a relapse after 6 months of HLH‐04 regimen treatment. Meanwhile, the central nervous system was involved. The intrathecal injection was given 4 times, the chemotherapy and anti CD25 monoclonal antibody were strengthened, then the condition was controlled. (2) Transplant selection: We found that the child was DSA positive, mainly existed B 58:01 \> 10000MFI and DQB 06:01 \> 2000 MFI. After the treatment of rituximab and plasma exchange, the reexamination of DSA was not significantly reduced. We finally chose a HLA 7/10 CB (TNC 8.9\*10^7^/kg, CD34+6.24\*10^5^/kg), which was only positive for HLA‐A2 antiprototype antibody positive (7589.58MFI) compared with CB. (3) Transplant scheme: The final improved preconditioning regimen is front ATG 5mg/kg, VP16 300mg/m2, Bu12mg/kg, Flu160mg/m2, CTX120mg/kg and prevention of GVHD by CsA. (4) Curative effect analysis and follow‐up: The time of neutrophils \>0.5\*10\^9/L and platelets \>20\*10\^9/L were 17 days and 38 days after transplantation, respectively. +30d reexamination of UNC13D gene were not mutated, STR showed complete chimerism. I‐II degree aGVHD (skin, 1‐2 grade) were found in +36d and +51d. Cytomegalovirus infection was present in +40d and +70d. (5) Literature review: At home and abroad, it is pointed out that the failure rate of UCBT is high, there are many complications after transplantation. There is no related report about UCBT with DSA positive.

**Conclusions**: (1) Umbilical cord blood transplantation for FHL is difficult and has many complications. (2) Front ATG in preconditioning regimen has some advantages in protecting umbilical cord blood cells and increasing implantation.

### PO-287. Successful Preemptive Therapy with Rituximab for Epstein‐Barr Virus Infection to Prevent Post‐Transplant‐Lymphoproliferative Disease after Pediatric Hematopoietic Stem Cell Transplantation {#pbc27455-sec-5150}

[B.K. Kim]{.ul} ^1^, K.T. Hong^1^, H.J. Kang^1^, H.Y. An^1^, J.Y. Choi^1^, H.Y. Shin^1^, H.S. Ahn^1^, S.S. Park^2^, J.S. Lee^3^

*^1^Seoul National University College of Medicine, Pediatrics, Seoul, Republic of Korea; ^2^Seoul National University College of Medicine, Laboratory Medicine, Seoul, Republic of Korea; ^3^Hallym University Sacred Heart Hospital, Laboratory Medicine, Anyang, Republic of Korea*

**Background/Objectives**: Post‐transplant‐lymphoproliferative disease (PTLD) is one of the most common post‐transplant malignancies. PTLD occurs in 1‐3.5% after hematopoietic stem cell transplantation in pediatric patients. Rituximab (anti‐CD20 monoclonal antibody) is used for prophylaxis and treatment of EBV‐ PTLD, but the efficacy of the preemptive treatment has not yet been fully elucidated. The purpose of this study was to prove the effects of preemptive treatment with rituximab for EBV related PTLD after HSCT in pediatric patients.

**Design/Methods**: We analyzed 14 pediatric patients undergoing allogeneic HSCT at Seoul National University Children\'s Hospital from 2005 to 2017 who developed high EBV DNAemia. We administrated rituximab preemptively to patients with ≥40,000 copies/mL (375 mg/m2, once daily), and followed up weekly until EBV load \<1,000 copies/mL. We investigated EBV titer in whole blood after rituximab infusion and checked PTLD incidence, and side effects.

**Results**: Underlying diseases of patients were 7 acute leukemia (53.8%), 2 aplastic anemia (15.4%), and the other genetic rare diseases (30.8%). Median EBV titer just before rituximab treatment was 178,335 copies/mL (range, 49,605‐267,203 copies/mL). Rituximab was infused on median 51 days (range, 9‐214 days) after EBV DNAemia. In all 14 patients EBV DNAemia were eradicated after median 7 days (range, 1‐12 days) and PTLD did not occur in all patients. There was no patient with severe side effects. HSCT related mortalities occurred in 2 patients not by EBV infection or PTLD but by acute graft versus host disease and hepatic venous occlusive disease. Other 12 patients are still alive without disease after median 50 months (range, 4.8‐111months) after transplantation.

**Conclusions**: Preemptive therapy with rituximab was effective and safe for the treatment EBV DNAemia after pediatrtic HSCT. This preemptive therapy is expected to reduce the incidence of PTLD after HSCT and improve post‐transplantation outcomes. However, large‐scale and long‐term follow up studies are needed.

### PO-288. Hematopoietic Stem Cell Transplantation with Treosulfan‐Based Conditioning in Children of the First Year of Life is Safe and Effective Way of Treatment of Malignant Diseases {#pbc27455-sec-5160}

[K. Kirgizov]{.ul} ^1,2^, E. Pristanskova^2^, A. Burya^2^, N. Sidorova^2^, O. Blagonravova^2^, E. Skorobogatova^2^

*^1^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Institute of Management and Translational Medicine, Moscow, Russia; ^2^The Russian Children\'s Research Hospital, bone marrow transplant, Moscow, Russia*

**Background/Objectives**: Hematopoietic stem cell transplantation (HSCT) is effective method for treatment of children and adults with broad spectrum of diseases. Experience of HSCT for children with malignant diseases under first year of life is limited. Objective of our study was to represent the features of HSCT in children of first year of life.

**Design/Methods**: Sixteen patients transplanted from 2010 to 2017 were included to analysis. Age median -- 9.5 months (7.4 -- 11.8). Males:females=9:7. Diagnoses: NB -- 7, AML -- 6, JMML -- 3. Patients with neuroblastoma received autologous HSCT, children with hematological malignancies -- allogenic HSCT: 5 -- from matched unrelated donor, 4 -- from matched related donor. All patients received treosulfan‐based myeloablative conditioning and standard supportive care.

**Results**: Twelve patients survived, four patients died: 2 patients with AML -- relapse, 2 patients with neuroblastoma -- relapse and transplant‐related mortality. Median follow‐up -- 2.8 years. No other causes of death were registered. Toxicity: no or mild mucositis -- 11 patients, severe mucositis -- 5 patients; mild enterocolitis -- 9, severe enterocolitis -- 7. CMV/HHV6‐viremia was registered in 6 patients and successfully treated. Complications were resolved with adequate supportive care. No severe GvHD was found. Most of the patients (n=10) received breast‐feeding; it was revealed that all patients receiving it have less intensive mucositis. No severe late effects revealed. Development and growth is normal.

**Conclusions**: HSCT in patients of first year of life is effective and safe method of treatment of malignant disorders including both solid tumors and leukemia. Toxicity could be controlled in case of adequate supportive care and nutrition support (breast feeding). Children of first year of life could be transplanted with treosulfan‐based intensive myeloablative conditioning regimens. Future development of these patients is not affected.

### PO-289. Busulfan Level Monitoring and Veno‐Occlusive Disease after Hematopoietic Stem Cell Transplant in Children in Hong Kong {#pbc27455-sec-5170}

[G.K.S. Lam]{.ul} ^1^, F.W.T. Cheng^1^, R.K.T. Kam^2^, M.H.M. Chan^2^, M.K. Shing^1^, V. Lee^1^, C.K. Li^1^

*^1^Prince of Wales Hospital‐ The Chinese University of Hong Kong, Department of Paediatrics, Hong Kong, Hong Kong S.A.R.; ^2^Prince of Wales Hospital‐ The Chinese University of Hong Kong, Department of Chemical Pathology, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Children receiving busulfan based conditioning regimen before haematopoietic stem cell transplantation (HSCT) have marked variability in busulfan pharmacokinetics. This study aimed to review the transplant related toxicities of paediatric HSCT patients who received intravenous busulfan with therapeutic drug monitoring (TDM) in a tertiary hospital in Hong Kong.

**Design/Methods**: Patients below 18 years who underwent HSCT with busulfan conditioning from April 2015 to December 2017 were included. Busulfan pharmacokinetics were analysed after the first dose. The target area under the curve (AUC) was defined as 3600‐6000 umol/L\*min for once daily dose, and 900‐1500 umol/L\*min for q6h (every 6 hours) dose. Clinical outcomes of interest are hepatic veno‐occlusive disease (VOD) and transplant‐related mortality.

**Results**: Twenty‐nine patients were included, 20 (68.9%) had malignant conditions and 9 (31.3%) had non‐malignant conditions. The median age was 7.8 years. Sixteen patients, mainly with malignant conditions, received once daily dose. Thirteen received q6h dose. Four patients (13.8%) had dosage adjusted proportionally based on TDM results (2 increased and 2 reduced). VOD occurred in 7 patients, 5 received once daily dose (31.3%) and 2 received q6h dose (15.3%). Median time of VOD diagnosis was post‐HSCT day 16. One patient with very high AUC (11620 umol/L\*min) developed severe VOD despite dose reduction by 47.3%, and died of multi‐organ failure at 2.6 months post‐transplant. The other 6 patients had AUC within target range after the first dose, and they all recovered from VOD. The overall survival of patients who developed VOD was 71.4% at post‐HSCT day 100.

**Conclusions**: VOD might be more common in children who received daily dose busulfan. Two patients had dose reduced but one still developed severe VOD and died. Two patients had dose increase without severe VOD. Repeating TDM after busulfan dose modification may guide the decision for further adjustment.

### PO-290. Pooled Analysis of Defibrotide Studies in Pediatric Patients Treated for Veno‐Occlusive Disease/Sinusoidal Obstruction Syndrome {#pbc27455-sec-5180}

S. Corbacioglu^1^, S. Aggarwal^2^, O. Topaloglu^2^, [R. Martin]{.ul} ^3^, K. Villa^3^

*^1^University of Regensburg, Department of Pediatric Hematology Oncology and Stem Cell Transplantation, Regensburg, Germany; ^2^Novel Health Strategies, Statistics, Bethesda, USA; ^3^Jazz Pharmaceuticals, Medical, Palo Alto, USA*

**Background/Objectives**: Hepatic veno‐occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life‐threatening complication of hematopoietic stem cell transplant (HSCT); VOD/SOS with multi‐organ dysfunction (MOD) may be associated with \>80% mortality. This analysis assessed Day+100 survival reported in the literature for pediatric patients (≤18 or ≤16 years) treated with defibrotide for VOD/SOS with or without MOD.

**Design/Methods**: A systematic literature review of PubMed, Embase, and specific congress websites searched for "defibrotide" in English‐language reports published up to July 10, 2017. Study types were randomized‐controlled, single‐arm, cohort, case (≥10) series, and retrospective chart reviews. A random effects model was used to pool efficacy data. Interstudy heterogeneity was assessed with Cochran\'s Q‐test. Percentage of total variation across studies due to heterogeneity (*I* ^2^) was evaluated. Adverse events (AEs) were summarized.

**Results**: Six studies provided data for 957 pediatric patients receiving defibrotide ∼25 mg/kg/day. Overall estimated Day+100 survival was 63% (95%CI, 55%--71%). For VOD/SOS with MOD, 3 studies were identified (n=348) with pooled estimated Day+100 survival of 58% (51%--66%). One expanded‐access study identified VOD/SOS without MOD (n=289); Day+100 Kaplan‐Meier estimated survival was 78% (72%--82%). Safety results were not pooled; individual study results were consistent with the phase 3 historically controlled trial in VOD/SOS with MOD (43% pediatric), in which 101/102 defibrotide‐treated patients and all 32 controls had ≥1 AE; hypotension was most frequent (39%, defibrotide; 50%, controls). Common hemorrhagic AEs (ie, pulmonary alveolar and gastrointestinal hemorrhage) occurred in 64% of defibrotide‐treated patients and 75% of controls.

**Conclusions**: In this pooled analysis of pediatric patients with VOD/SOS treated with defibrotide ∼25 mg/kg/day, estimated Day+100 survival was 63% (with MOD, 58%; without MOD, 78%). Safety results were generally consistent with the known defibrotide safety profile. This analysis of published literature provides insight into estimated Day+100 survival of pediatric patients with VOD/SOS treated with defibrotide ∼25 mg/kg/day.

Support: Jazz Pharmaceuticals.

### PO-291. "Dump Freezing" of Stem Cells: An Acceptable Alternative to Controlled Rate Freezing: Evidence from a Tertiary Centre in a Developing Country {#pbc27455-sec-5190}

[K. Mullanfiroze]{.ul} ^1^, S. Gupta^1^, M. Gupta^2^, R. Sawant^2^, S. Tulpule^1^, S. Sen^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Blood And Marrow Transplant, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Transfusion Medicine, Mumbai, India*

**Background/Objectives**: Clinical outcomes especially white cell and platelet engraftment after autologous stem cell transplant (ASCT) depends to a great extent on the viability of stem cells infused into the recipient. The technique of cryopreservation of stem cells is a key determinant of its viability. Of the two methods used for cryopreservation viz controlled and dump freezing/uncontrolled rate freezing, the former is said to be the gold standard. In view of non‐availability of expertise and infrastructure required for controlled rate freeze techniques, "dump‐freezing" has been practiced at our centre. We hereby evaluate the efficacy of this method in terms of engraftment of the recipients who received the uncontrolled‐rate frozen product.

**Design/Methods**: Thirty‐four stem cell products were studied over a period of 2 years. Viability of the stem cells derived from these products, before cryopreservation and after thawing i.e at the time of infusion into the recipient, were measured by flow cytometry. Stem cells were infused at 6.5 months (range 1‐12 months) on an average after cryopreservation. Paired 't' test was used for statistical analysis of the data. All the recipients received identical supportive care measures as per their clinical need.

**Results**: The mean pre‐cryopreservation viability was 96% and post thaw viability was 84.7%. Overall reduction in viability was 11.9%(p value 0.0001). The average white cell and platelet engraftment of the recipients in whom these cryopreserved products were infused for ASCT was 12 (range 7‐16) and 18 (range 14‐23) days respectively.

**Conclusions**: Dump‐freezing is not the optimal method for cryopreservation of stem cells as evidenced by significant loss of viability of stem cells as seen in this study. However, the clinical outcome of engraftment post ASCT is almost identical to that as reported in literature. Hence dump freezing is an acceptable option for cryopreservation, especially in developing countries, where infrastructure for controlled freezing is currently lacking.

### PO-292. "Dump Freezing" of Stem Cells: An Acceptable Alternative to Controlled Rate Freezing: Evidence from a Tertiary Centre in a Developing Country {#pbc27455-sec-5200}

[K. Mullanfiroze]{.ul} ^1^, G. Shweta^1^, M. Gupta^2^, R. Sawant^2^, S. Tulpule^1^, S. Sen^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Blood And Marrow Transplant, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Transfusion Medicine, Mumbai, India*

**Background/Objectives**: Clinical outcomes especially white cell and platelet engraftment after autologous stem cell transplant (ASCT) depends to a great extent on the viability of stem cells infused into the recipient. The technique of cryopreservation of stem cells is a key determinant of its viability. Of the two methods used for cryopreservation viz controlled and dump freezing/uncontrolled rate freezing, the former is said to be the gold standard. In view of non‐availability of expertise and infrastructure required for controlled rate freeze techniques, "dump‐freezing" has been practiced at our centre. We hereby evaluate the efficacy of this method in terms of engraftment of the recipients who received the uncontrolled‐rate frozen product.

**Design/Methods**: Thirty‐four stem cell products were studied over a period of 2 years. Viability of the stem cells derived from these products, before cryopreservation and after thawing i.e at the time of infusion into the recipient, were measured by flow cytometry. Stem cells were infused at 6.5 months (range 1‐12 months) on an average after cryopreservation. Paired 't' test was used for statistical analysis of the data. All the recipients received identical supportive care measures as per their clinical need.

**Results**: The mean pre‐cryopreservation viability was 96% and post thaw viability was 84.7%. Overall reduction in viability was 11.9%(p value 0.0001). The average white cell and platelet engraftment of the recipients in whom these cryopreserved products were infused for ASCT was 12 (range 7‐16) and 18 (range 14‐23) days respectively.

**Conclusions**: Dump‐freezing is not the optimal method for cryopreservation of stem cells as evidenced by significant loss of viability of stem cells as seen in this study. However, the clinical outcome of engraftment post ASCT is almost identical to that as reported in literature. Hence dump freezing is an acceptable option for cryopreservation, especially in developing countries, where infrastructure for controlled freezing is currently lacking.

### PO-293. Prospective Monitoring of BK Virus and Adenovirus Viral Load and Specific T‐Cell Response in Children after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) {#pbc27455-sec-5210}

[M. Ponlakan]{.ul} ^1^, N. Apiwattanakul^1^, S. Pakakasama^1^

*^1^Faculty of Medicine Ramathibodi Hospital‐ Mahidol University, Department of Pediatric, Bangkok, Thailand*

**Background/Objectives**: Hemorrhagic cystitis(HC) is a common complication after allogeneic HSCT. BK virus(BKV) and adenovirus(AdV) are major organisms causing virus‐induced HC. Clinical severity ranges from microscopic hematuria to renal failure. However, kinetics of BKV and AdV viral load in patients after allogeneic HSCT has not been well elucidated. Prospective BKV and AdV‐specific T‐cell response has not been studied in patients after allogeneic HSCT with/without HC. Objectives were to demonstrate kinetics of BKV and AdV viral load and to determine BKV and AdV‐specific T‐cell response in patients after allogeneic HSCT

**Design/Methods**: This was a prospective cohort study. We recruited 33 patients underwent allogeneic HSCT between November 2016 and November 2017. Demographic and transplant related data were collected. Viral load was prospectively regularly measured starting from day 0 to 12 months after transplant. BKV and AdV‐specific T‐cell response was detected using flow cytometry technique. The patients were classified into 3 groups: group1, negative viral load and no HC(n=8); group2, positive viral load but no HC(n=15), and group3, positive viral load and HC(n=10).

**Results**: The median age was 8 years(range, 2.5‐19.5 years). Underlying diseases were both malignant(51.5%) and non‐malignant(48.5%) diseases. Most of the patients received from haploidentical donors stem cells(75.8%). HC occurred in 10 patients, with median onset of 27 days, caused by BKV(n=2), AdV(n=2), and mixed(n=6). The mean of maximal BKV and AdV viral load in serum were 15,246.73+56,892.50, 180.73+259.39 copies/mL in group2 and 26,480.4+58,107.02, 300,251.4+888,809.33 copies/mL in group3. The mean maximal BKV and AdV‐specific T‐cell response were 0.07%, 0.02% in group3 and 0.13%, 0.03% in group2.

**Conclusions**: Serum BKV and AdV viral loads in patients with HC were higher than those without HC. Interestingly, patients with BKV and/or AdV infections but without HC(group2) produced higher viral specific T‐cell responses than patients with HC(group3). Our data support the usage of virus specific T‐cell therapy in this setting.

### PO-294. Standardisation and Validation of PCR‐ Fragment Analysis Based Assay for Post Transplant Chimerism Using Short Tandem Repeat (STR) Markers {#pbc27455-sec-5220}

[M. Pusalkar]{.ul} ^1^, S. Sen^2^, R. Tibrewala^1^, Y. Salunkhe^1^, V. Raman^1^, K. Mullanfiroze^2^, S. Gupta^3^, S. Tulpule^3^, P. Dutta^1^, K. Ghodke^1^, V. Vadera^1^, J. Vyas^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Laboratory Medicine, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India*

**Background/Objectives**: Detection of donor chimerism is used to detect early graft loss or disease recurrence. PCR ‐ fragment analysis based detection using short tandem repeat (STR) markers has been helpful in accurately measuring the percentage of donor cells. The aim of the present study was to standardize and validate the assay for detection of mixed donor chimerism following BMT.

**Design/Methods**: Standardization of the assay was carried out using artificial chimeric blood samples from four healthy volunteers with different grades of donor cell population (1% ‐ 90%). Validation of the assay was done as per standard guidelines and a total of 12 patient donor pairs were screened for base line STR analysis before HSCT. A total of 44 samples of 18 HSCT follow‐up cases were assessed.

Baseline screening for informative STR markers was done by PCR amplification of 9 STR loci viz. D3S3045, D4S2366, D12S1064, D16S539, D17S1290, SE33, FGA, D20S481 and AME, along with GAPDH as an internal control. These products were subjected to capillary electrophoresis using 3500 Genetic Analyser and the data were analysed using GeneMapper software. Further, PCR ‐ fragment analysis was carried out for specific informative markers across all the artificial chimeric samples as well as post‐HSCT samples.

**Results**: Chimeric samples from healthy volunteers showed 99% accuracy for detection of expected donor chimerism values. These results were further independently validated and were in concordance with a Coefficient of Variation of \<5%. Accuracy of estimation of donor status could be achieved at levels down to 1% of donor cells

**Conclusions**: Chimerism data from our standardized samples and real patient samples showed excellent correlation when compared with an independent laboratory, thus confirming the validity of our diagnostic method in analysing post transplant chimerism. Thus the use of our assay will facilitate in early detection of graft loss or disease recurrence in post transplant patients.

### PO-295. Ciprofloxacin Prophylaxis is Associated with Reduce Incidence of BK Virus Reactivation and Associated Severe Hemorrhagic Cystitis in Post Haploidentical Hematopoietic Stem Cell Transplant Recipients {#pbc27455-sec-5230}

[M. Ramzan]{.ul} ^1^, S. Katewa^1^, R. Bairwa^1^, A. Sharma^1^, T. Khan^2^, M. Gupta^3^

*^1^Manipal Hospital, Dept of Pediatrics Hematology Oncology and BMT, Jaipur, India; ^2^Manipal Hospital, Obstetrics and Gynecology, Jaipur, India; ^3^Manipal Hospital, Dept of Hematopathology, Jaipur, India*

**Background/Objectives**: BK virus‐associated hemorrhagic cystitis (BKHC) is a potentially serious complication that occurs in 12% to 40% of allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Ciprofloxacin prophylaxis has shown reduced incidence of severe BKHC in HSCT with matched related and unrelated donor.

**Design/Methods**: We retrospectively analyzed our data of patients who underwent haploidentical HSCT for varied indications between August 2015 to February 2018. We instituted universal ciprofloxacin prophylaxis from starting of conditioning regimen till day+60 post HSCT. Episodes of hemorrhagic cystitis (HC) were graded as follows: grade 1, microscopic hematuria; grade 2, macroscopic hematuria; grade 3, macroscopic hematuria with small blood clots; grade 4, massive macroscopic hematuria requiring instrumentation of the urinary tract or causing urinary retention. We included grades 3 and 4 BKHC as severe BKHC.

**Results**: Thirty six patients underwent haploidentical HSCT. Thirty three were benign (hemoglobinopathy 27, aplastic anemia 2, Diamond Blackfan anemia 1, primary immunodeficiency 3) and 3 malignant (T cell lymphoma 2, acute myeloid leukemia 1). A total of 8/36 (22.222%) had HC (grade 2‐ six and grade 4‐ two). Four of Thirty six (11.11%) had BKV reactivation. Only 2/36 (5.5%) had severe BKHC. Conditioning regimen included thiotepa had more significant symptoms of of HC and BKV reactivation. Mean day of BKV reactivation was day 34 post HSCT. None of patients with BKHC had features of acute graft versus host disease. All patients who had symptoms of HC were initially treated with leflunamide. One treated with cidofovir but had nephropathy and died due to sepsis.

**Conclusions**: Ciprofloxacin prophylaxis is effective in reducing severe BKHC in haploidentical HSCT. Conditioning regimen with thiotepa is associated with more BKV reactivation. More studies are needed to confirm our results.

### PO-296. Incidence of Hemorrhic Cystitis in Patients after Stemm Cel Transplant: Experience at One Center {#pbc27455-sec-5240}

[M. Rivera]{.ul} ^1^, Ó.R. González Ramella^1^, R. Navarro Martin del Campo^1^, A.L. Alvarado Orozco^1^

*^1^Hospital Civil de Guadalajara Juan I. Menchaca, Pediatric Hematology/ Oncology, Guadalajara, Mexico*

**Background/Objectives**: Hemorrhagic cystitis (CH) is characterized by a micro/macroscopic hematuria of variable intensity of at least 7 days duration. It presents in 13‐38% of patients who receive an hematopoietic cell transplant. It is related to: intensive conditioning, high doses of Cyclophosphamide, thrombocytopenia secondary to transplantation or viral infections such as CMV, BK‐virus and polyomavirus. Prevention includes hyperhydration and Mesna and the treatment of late cystitis is supportive. The objective is to know the incidence of HC at the transplant unit of our center and to analyze the used therapies.

**Design/Methods**: This was a systematic and retrospective review of all the patients who were transplanted in the Unit of Hematopoietic Progenitors of the Hospital Civil de Guadalajara Juan I. Menchaca from 2003 to 2017.

HC was classified: grade 1 microscopic hematuria; grade 2 macroscopic hematuria; grade 3, gross hematuria with clots and grade 4 the above and/or urinary obstruction, renal failure and bladder damage. CH was defined as microscopic or macroscopic hematuria and dysuria with a negative urine bacterial culture and no other hemorrhagic conditions.

**Results**: 114 patients were transplanted. 16 of 114 patients developed CH (14%). Average duration was 27.1 days, only in 4 patients a viral infection was determined as etiology. 50% of patients required at least 3 different treatments. All required hyperhydration and 12 patients (75%) blood products. 8 patients (50%) had grade III cystitis. 4 patients(25%) died with active HC.

**Conclusions**: Incidence of HC in our unit is within the world incidence, the non‐determination of viral markers is a disadvantage to determine certainly the etiology and to give an specific treatment or targeted prophylaxis.

### PO-297. Toxic Epidermal Necrosis after an Allogeneic Transplant {#pbc27455-sec-5250}

[K. Rojas]{.ul}, M. Rivera, O. Gonzalez, R. Mallinalli, A. Orozco, C. Carballido, G. Tavare

*Oncología pediátrica, Guadalajara, Mexico*

**Background/Objectives: Objective**: To report the clinical case of a patient who develops toxic epidermal necrolysis (NET) after an allogeneic transplant with good response to treatment.

**Clinical report**: 11‐year‐old female with pure aplasia of red series with allogeneic transplantation of identical family in the presence of anti‐HLA antibodies, compatibility 10/10. History of ferritin iron overload 6.776. It is conditioned with busulfan, CFM, fludarabine, ATG, rituximab and plasmapheresis, during infusion of progenitors, it presents generalized cutaneous rash that achieves self‐limitation, at day + 4 it presents intense erythema and exanthema with flictenas in the neck, anterior thorax and extremities that become sloughing (figure 1), at day +9 on skin biopsy (figure 2) spongiosis is documented in the dermoepidermal junction and incipient subdermal vesicle formation. Receives treatment with surgical debridement, topical colloidal silver, Methylprednisolone 5 mg / kg / day, Immunoglobulin 1 g / kg weekly, MTX 10 mg / m2, as prophylaxis for GVHD, folinic acid 100 mg / m 2 / dose, thus the lesions resolve towards day +20 and the day + 67 is discharged.

**Design/Methods**: descriptive case report

**Results**: NET manifests as a flu‐like syndrome followed by the development of erythema on the skin, subsequently pruritic macules that rapidly evolve into large necrotic blisters, with involvement of the oral, ocular and genital mucosa. Among the triggering agents are sulfonamides, tetracyclines, carbamazepine, allopurinol, barbiturates, antimalarial agents, chemotherapeutic drugs, warfarin and non‐steroidal anti‐inflammatory agents. (2)The onset of NET is usually acute and may occur 1 to 3 weeks after starting therapy, but also during the first 2 months of treatment. (2) The diagnosis is based mainly on clinical signs and histological analysis of a skin biopsyPrognosis is reserved, although appropriate therapy has high mortality (30% to 50% in adults, less in children).5,6

**Conclusions**: The relationship between the 2 pathologies has been suggested by many authors.

### PO-298. Toxic Epidermal Necrosis after an Allogeneic Transplant {#pbc27455-sec-5260}

[K. Rojas, M. Rivera, O. Gonzalez, R. Mallinalli, A. Orozco, C. Carballido, G. Tavares]{.ul} ^1^

*^1^Oncología pediátrica, Guadalajara, Mexico*

**Background/Objectives: Introduction**

**Objective**: To report the clinical case of a patient who develops toxic epidermal necrolysis (NET) after an allogeneic transplant with good response to treatment.

**Clinical report**: Female, 11 years old, diagnosed with pure aplasia of the red series, who underwent an allogeneic transplant of an identical family patient, HLA 10/10. Conditioning with busulfan, CFM, fludarabine, ATG, rituximab (7) and plasmapheresis (2).

At day 6, he presents grade IV skin‐related GVHD, which begins as intense generalized erythema and exanthema with flictenas and evolves to shiny, edematous skin with 8‐10 cm flictenas on the right upper limb and knee with areas of dislocation and skin detachment. figure 1), at day +9 a skin biopsy was performed (Figure 2) in which spongiosis was evidenced in the dermoepidermal junction and incipient formation of subdermal vesicle, without evidence of vasculitis suggesting GVHD.

**Design/Methods**: case report

**Results**: Toxic epidermal necrolysis (TEN, Lyell\'s syndrome) is a febrile reaction with scarce occurrence (1 or 2 / 1,000,000) leads to severe skin involvement (1), affects more the female gender, is characterized by complete loss of the epidermis leaving denuded areas, which involve more than 30% of the body surface. (2) Its appearance after allo‐HSCT has been described only in adults. (3‐4)

**Conclusions**: GVHD during allogeneic transplantation of hematopoietic stem cells may represent an immune trigger that is often difficult to differentiate from NET only by clinical (3,5) given the cutaneous involvement they generate; however, biopsy can help in the differential diagnosis (4), however, these 2 conditions can evolve to each other. (6) The relationship between the 2 pathologies has been suggested by many authors.

### PO-299. Conditioned Medium from Human Tonsil‐Derived Mesenchymal Stem Cells Enhances Bone Marrow Engraftment via Restoration of Endothelial Cells {#pbc27455-sec-5270}

[K.H. Ryu]{.ul} ^1^, E.S. Yoo^1^, E.J. Choi^2^, Y.H. Kim^3^, K.A. Cho^3^, H.M. Kim^4^, J.W. Park^5^, S.Y. Woo^3^

*^1^Ewha Womans University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^2^Catholic University of Daegu School of Medicine, Department of Pediatrics, Daegu, Republic of Korea; ^3^Ewha Womans University College of Medicine, Department of Microbiology, Seoul, Republic of Korea; ^4^Yonsei University College of Medicine, Department of Pediatrics, Wonju, Republic of Korea; ^5^Ewha Womans University College of Medicine, Department of Biochemistry, Seoul, Republic of Korea*

**Background/Objectives**: Administration of mesenchymal stem cells (MSCs) in the procedure of bone marrow transplantation (BMT) has been widely reported to promote BM engraftment. In this study, we assessed the effects of MSC conditioned medium (CM) in BM engraftment. In addition, we investigated whether MSC CM could restore vascular endothelial cells (ECs) is order to enhance BM engraftment.

**Design/Methods**: Partial ablation of mouse bone marrow (BM) was performed by administration of busulfan and cyclophosphamide (Bu‐Cy) conditioning regimen (20 mg/kg Bu for 4 days and 100 mg/kg Cy for 2 days) in BALB/c recipient mice. Donor BM cells were isolated from C57BL/6 mice and transplanted via tail vein with or without tonsil‐derived mesenchymal stem cells conditioned medium (T‐MSC CM). T‐MSC CM was injected once again two days later. BM engraftment was examined on day 10 post‐BMT using H&E staining of femurs and flow cytometry analysis of BM cells. Restoration of endothelial cells (ECs) was examined by measuring CD45‐CD144+ ECs in circulation by flow cytometry and endomucin expression in proximal femurs by immunohistochemistry.

**Results**: CM improved BM engraftment as revealed by microscopic observation of H&E stained femurs and flow cytometric MHC class I haplotyping. Conditioning regimen impairs vascular ECs hence increase in the number of circulating ECs. We identified that increased peripheral ECs by Bu‐Cy treatment was partially restored by BMT and this was further decreased by CM treatment. Expression of endomucin, a marker of BM endothelial cells, were examined and found that endomucin expression was downregulated in BMT group of mice, whereas CM treatment protected BM endothelial cells.

**Conclusions**: In conclusion, T‐MSC CM administration during BMT enhances BM engraftment in part by restoring ECs. Further studies are required to find the molecules secreted from MSC that show the effectiveness in BM engraftment. These findings highlight the potential therapeutic relevance of T‐MSC CM for increasing BMT efficacy.

### PO-300. Acceptable Viability of Peripheral Blood Stem Cells When Stored at 4°C for up to 72 Hours {#pbc27455-sec-5280}

[S. Sen]{.ul} ^1^, S. Tulpule^2^, K. Mullanfiroze^1^, S. Gupta^2^, M. Gupta^3^, R. Ahmed^3^, A. Priyadarshaini^3^, K. Ghodke^3^, P. Dutta^3^, R. Sawant^3^, V. Vadera^3^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Department of Laboratory Medicine, Mumbai, India*

**Background/Objectives**: The optimum mode of storage of non frozen stem cell products is not defined or standardised. Most transplant units would store stem cell in the non frozen state at 4°C if it is meant for infusion within 24‐48 hours. However, viability of such stem cells is not certain and no permissible time for such storage is available. Hence we ascertained the viability of stem cell products when stored for up to 72 hours of collection.

**Design/Methods**: 15 peripheral blood stem cell (PBSC) products were taken for this study and all the samples were kept in the non frozen liquid state at 4°C. Flow cytometry using the 7‐AAD protocol was used to determine viability of the samples at 2 hours after collection and again at 24, 48 and 72 hours. Statistical analysis of the results was done using paired 't' test.

**Results**: Mean volume of the 15 samples tested was 182.08 ml (45‐380 ml), with a mean WBC count of 32.5x10\^9 (4.5‐48.1x10\^9). Average viability at 2 hours was 97.2%. At 24 hours, the average viability was 96.1% which equates to a 1.1% loss. However, viability dropped to 93.6% at 48 hours (3.6%) and to 88.1% at 72 hours (a drop of 9.1%).

**Conclusions**: PBSC integrity was optimally maintained upto 72 hours when stored in the liquid state at 4°C. This can be useful to limit the use of DMSO for cryopreservation and assist in decision making to harvest PBSC early if mobilisation has been rapid. Our study provided conclusive evidence of acceptable viability of PBSC when stored at 4°C for upto 72 hours.

### PO-301. Rescue Haploidentical Stem Cell Transplantation for Aplastic Anaemia Following Primary Graft Failure {#pbc27455-sec-5290}

[S. Sen]{.ul} ^1^, K. Mullanfiroze^1^, S. Gupta^2^, S. Tulpule^2^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India*

**Background/Objectives**: Primary graft failure remains one the important causes of mortality and morbidity in cases of stem cell transplantation. We report on a case of Aplastic Anaemia where an immediate rescue haploidentical stem cell transplantation from a different donor resulted in a successful engraftment.

**Design/Methods**: A 3yr old male child was diagnosed to have Severe Aplastic Anemia. Unfortunately there were no matched sibling donors and hence a haploidentical transplant using his fathers stem cells was undertaken. He was conditioned with Fludarabine, Cyclophosphamide, ATG and TBI and Post Transplant Cyclophosphamide was used for GVHD prophylaxis

Unfortunately he failed to engraft, and at day +21 we undertook a second rescue haploidentical transplant for the primary graft failure. As he had rejected his fathers stem cells, we decided not to use father the second time around as a donor re‐transplant him using his mother stem cells. Though he was profoundly neutropenic with a WBC count of 20, we decided to give him full repeat conditioning with the same protocol as we surmised that he still had a active immune system that had rejected the primary graft. Repeat conditioning using the same protocol was started from Day + 22 and mother\'s stem cells was infused on Day +28.

**Results**: He engrafted successfully by Day +12 of the second transplant and though the transplant was complicated by a cutaneous fungal infection and CMV reactivation, child was discharged home with 100% donor engraftment.

**Conclusions**: A second haploidentical transplant using repeat conditioning can be used successfully in cases of primary graft failure.

### PO-302. Haploidentical Bone Marrow Transplants, Viable Alternative for the Developing World: A Tertiary Centre Experience {#pbc27455-sec-5300}

N. Iyer^1^, K. Mullanfiroze^1^, S. Tulpule^2^, S. Gupta^2^, [S. Sen]{.ul} ^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India*

**Background/Objectives**: Lack of a HLA matched sibling or fully matched unrelated donor can be an impediment for a transplant. Haploidentical transplants are a viable alternative in the developing world in this context. This is especially relevant in the Indian subcontinent due to the lack of any large stem cell registries and costs associated with obtaining cells from overseas registries.

**Design/Methods**: From February 2014 to March 2018, 26 haploidentical bone marrow transplantations(BMT) were done in 19 patients. The age range was 5 months to 27 years with a median of 9 yrs. 18 male and 8 female patients underwent haploidentical BMT for indications ranging from malignant diseases (such as relapsed AML or ALL, CML to benign diseases like Thalassemia Major, Chronic Granulomatous Disease and Aplastic Anaemia. The donors were parents or immediate siblings who were haploidentical to the recipients.

**Results**: 4 of the 26 died due to transplant related toxicity. 1 child with aplastic anaemia had a first transplant from the father had a graft rejection and a second successful haploidentical BMT was done with the mother as the donor. All received T cell replete stem cells with Post Transplant Cyclophosphamide, MMF and a calcineurin inhibitor for GVHD prophylaxis. All but one (who received bone marrow stem cells) were transfused GCSF stimulated peripheral blood stem cells.

**Conclusions**: With a median follow up period of 15 months our data is still young, however, with an overall survival of 84%, haploidentical bone marrow transplant is a promising new option specially in the developing world for those who lack other appropriate donors.

### PO-303. ABO Incompatible Bone Marrow Transplants: A Tertiary Centre Experience {#pbc27455-sec-5310}

[S. Sen]{.ul} ^1^, K. Mullanfiroze^1^, S. Nair^1^, S. Tulpule^2^, S. Gupta^2^, R. Sawant^3^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Department of Laboratory Medicine, Mumbai, India*

**Background/Objectives**: Though ABO incompatibility is not a contraindication for BMT, it can be a factor responsible for graft failure and lower survival. We present our data on ABO incompatible transplants and their outcomes.

**Design/Methods**: We identified 14 transplants that were done with ABO incompatibility between January 2016 to December 2017. The indications for BMT were malignancies like refractory AML or relapsed B ALL and benign haematological conditions like Aplastic Anaemia and Thalassemia Major. Among the ABO incompatible BMTs, 9 were major incompatibility, 5 were minor. For all major and bidirectional blood group incompatibility, we determined the recipient antibody titres, and in all cases where the recipient isoagglutinin titre was more than 1:64, repeated plasma exchange was done till antibody titres were less than 1:16. IVIG in a dose of 0.5 gm/kg was also given to the recipient on Day ‐1. Red cell depletion of the graft by centrifugation was also undertaken in all cases of major ABO incompatibility.

**Results**: One patient with major ABO incompatibility had a severe haemolytic reaction following infusion of bone marrow stem cells and transplant had to be aborted. The baseline isoagglutinin level was 1;64 and repeat plasma depletion of the patient was done to reduce the isoagglutinin levels to below 1:4. Peripheral blood stem cells were harvested from the donor which was red cell depleted by centrifugation and this was infused without incident. None of the other cases had any immediate or delayed haemolytic reaction. However 1 patient subsequently died due to graft failure and 2 from sepsis.

**Conclusions**: In our series, ABO incompatibility did not seem to have been a major factor behind poor outcome. The mortality in our limited series is possibly due to the aggressive nature of the primary disease like refractory AML and patient condition rather than blood group mismatch per se.

### PO-304. Haploidentical Stem Cell Transplantation with Post‐Transplantation Cyclophosphamide in Paediatric Acute Leukemia: A Single Centre Experience from India {#pbc27455-sec-5320}

[A. Sharma]{.ul} ^1^, N. Rastogi^1^, P. Chhabra^1^, D. Thakkar^1^, S. Nivargi^1^, S.P. Yadav^1^

*^1^Medanta The Medicity, Paediatric Haematology ‐ Oncology and BMT, Gurgaon, India*

**Background/Objectives**: Haploidentical family donor is universally available and is fast emerging as an alternative donor choice for children with leukaemia needing hematopoietic stem cell transplant (HSCT). Herein we describe the experience of treating children with leukaemia by haploidentical HSCT with post‐transplant cyclophosphamide (PTCy).

**Design/Methods**: We retrospectively analysed outcome data of 11 children with acute leukaemia (acute lymphoblastic leukemia‐8, acute myeloid leuekmia‐2 and Mixed phenotype acute leukemia‐1) who underwent haploidentical HSCT; median age was 78 months. Ten were in complete remission (CR) prior to HSCT: CR1‐4, CR2‐4 and CR3‐2 and one was in partial remission. Donors were mobilized with GCSF. The conditioning was Non‐myeloablative in 4 (Fludarabine 160 mg/m2, Cyclophosphamide 29 mg/kg, total body irradiation TBI 2Gy) and Myeloablative in 7 (Thiotepa 10 mg/kg, Fludarabine 160 mg/m2, Cyclophosphamide 29 mg/kg, TBI 2Gy in 6 and Fludarabine 160 mg/m2, Busulfan 12.8 mg/kg in 1). All received PTCy 50 mg/kg on day 3 and 4 as graft vs. Host disease (GVHD) prophylaxis along with tacrolimus and mycophenolate mofetil. A median of 12.6 million of CD34cells/kg was infused.

**Results**: The engraftment rate was 100%, median time of neutrophil engraftment was 17 days and platelet engraftment was 16 days. Chimerism at day +30 was fully donor in all 11 children. Four children relapsed (3 died and one child with CD20 positive leukaemia is disease‐free after therapy with Rituximab). Remaining 7 patients are in CR. Acute GVHD (grade‐I) was seen in 1 patient. All four children who developed chronic GVHD (limited‐3 and extensive‐1) are alive and disease‐free. Three out of 4 children receiving non‐myeloablative conditioning have relapsed. Overall survival is 72% and event‐free survival is 63 % at a median follow‐up of 583 days

**Conclusions**: Haploidentical HSCT with PTCy is safe and effective therapy for children with acute leukaemia. Myeloablative conditioning and chronic GVHD lead to improved disease‐free survival.

### PO-305. Donors‐Related Factors Affecting the Outcome of Hematopoietic Stem Cell Transplantations in Children {#pbc27455-sec-5330}

[N. Sidorova]{.ul} ^1^, K. Kirgizov^1^, E. Pristanskova^1^, A. Burya^1^, V. Konstantinova^1^, O. Blagonravova^1^, E. Skorobogatova^1^

*^1^Bone marrow transplatation, Russian children research hospiltal, Moscow, Russia*

**Background/Objectives**: Hematopoietic stem cell transplantation from matched unrelated donor (MUD HSCT) is routine method for oncological and non‐oncological diseases in children. Importance of donor‐related factor is discussed now.

**Design/Methods**: During the period 2003‐2017 we performed 234 MUD HSCT. Diagnosis: Malignant blood diseases -- 58% (n=135), non‐malignant diseases -- 42% (n=99). Gender distribution: male -- 64% (n=150), female -- 36% (n=84). Age median -- 7.35 y.o. (8 months -- 17 y.o.). Stem cell source: bone marrow -- 77% (n=179), peripheral blood stem cells -- 23% (n=55). 184 pts. (79%) received 10/10 MUD HSCT and 50 pts. (21%) -- 9/10 MUD HSCT. Differences in the АВО system: single group 40% (n=94), minor 29% (n=68), major 20% (n=46), mixed 11% (n=26). Age of donor: 18‐25 y.o 30% (n=50), 26‐35 y.o. 40% (n=65), 36‐45 y.o 24% (n=39), 46 and more 6% (n=10). Gender differences in donor/recipient: male/female 21% (n=49), female/male 18% (n=42), one sex 61% (n=142).

**Results**: In the 10/10 group the estimated probability of overall survive (OS) was 67% (n=124) and in the 9/10 group OS was 56% (n=28). Overall incidence of aсute graft versus host disease (a.GvHD) I‐IV st. in the 10/10 group was 67% (n=124) and in the 9/10 -- 76% (n=38). The increase in donor age of 10 years reduces the OS by 5‐6%, however, the OS from donors over 46 years old was 90% (n=9). We have found no difference between transplants from donors that are compatible/incompatible with the ABO or the gender differences in donor/recipient.

**Conclusions**: Our study showed the role of genetic matching on the HLA system between the patient and the unrelated donor, and the donor\'s age value. 10/10 transplants have better outcome and lower incidence of severe a. GvHD. Younger donor increases OS, but there is a significant increase in OS if the donor is over 46 years old.

### PO-306. Donor‐Related Factors Affecting the Outcome of Hematopoietic Stem Cell Transplantations in Children {#pbc27455-sec-5340}

[N. Sidorova]{.ul} ^1^, K. Kirgizov^2^, M. Persiantseva^3^, E. Pristanskova^1^, V. Konstantinova^1^, O. Blagonravova^1^, A. Burya^1^, E. Skorobogatova^1^

*^1^The Russian Children\'s Research Hospital, bone marrow transplant, Moscow, Russia; ^2^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Institute of Management and Translational Medicine, Moscow, Russia; ^3^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Hematopoietic Stem Cell Transplantation, Moscow, Russia*

**Background/Objectives**: Hematopoietic stem cell transplantation from matched unrelated donor (MUD HSCT) is routine method for malignant and non‐malignant diseases in children. Importance of donor‐related factor is discussed now. Objective was to analyze donor‐related factors affecting the outcome of hematopoietic stem cell transplantations in children.

**Design/Methods**: We performed 234 MUD HSCT during 2003‐2017. Diagnoses: malignant blood diseases -- 58% (n=135), non‐malignant diseases -- 42% (n=99). Gender distribution: male -- 64% (n=150), female -- 36% (n=84). Age median -- 7.35 y.o. (8 months -- 17 y.o.). Stem cell source: bone marrow -- 77% (n=179), peripheral blood stem cells -- 23% (n=55). 184 pts. (79%) received 10/10 MUD HSCT and 50 pts. (21%) -- 9/10 MUD HSCT. Differences in the АВО system: single group 40% (n=94), minor 29% (n=68), major 20% (n=46), mixed 11% (n=26). Age of donor: 18‐25 y.o 30% (n=50), 26‐35 y.o. 40% (n=65), 36‐45 y.o 24% (n=39), 46 and more 6% (n=10). Gender differences in donor/recipient: male/female 21% (n=49), female/male 18% (n=42), one sex 61% (n=142).

**Results**: In 10/10 group the estimated probability of overall survive (OS) was 67% (n=124) and in the 9/10 group OS was 56% (n=28). Overall incidence of aсute graft versus host disease (a.GvHD) I‐IV st. in the 10/10 group was 67% (n=124) and in the 9/10 -- 76% (n=38). The increase in donor age of 10 years reduces the OS by 5‐6%, however, the OS from donors over 46 years old was 90% (n=9). No difference between transplants from donors that are compatible/incompatible with the ABO as well as gender differences in donor/recipient.

**Conclusions**: We showed that 10/10 transplants have better outcome and lower incidence of severe a. GvHD. Younger donor increases OS, but there is a significant increase in OS if the donor is over 46 years old.

### PO-307. Stem Cell Collections and the Efficiency of CMNCs {#pbc27455-sec-5350}

[C. Strahlendorf]{.ul} ^1^, K. Douglas^2^, G. Chan^3^

*^1^BC Children\'s Hospital, Division Hem/Onc/BMT, Vancouver, Canada; ^2^BC Children\'sHospital, Vancouver, Canada; ^3^, Vancouver, Canada*

**Background/Objectives**: Peripheral blood mononuclear cells (PBMC) are collected after the administration of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and used for autologous hematopoietic stem cells after myeloablative therapy in many instances in pediatric cancer. In children the ability to time the collection accurately as well as efficiently collect enough stem cells in the shortest possible time is an advantage. The new Continuous Mononuclear Cell Collection (CMNC) protocol on the Spectra Optia Apheresis System for collecting autologous Peripheral Blood Stem Cells (PBSC) has allowed us to evaluate this method in pediatrics.

**Design/Methods**: We evaluated our stem cell collections using CMNC protocol on the Spectra Optia. Children with solid tumours were mobilized with chemotherapy and rhG‐CSF and monitored with peripheral CD34 counts prior to collection. Final products (CP) were evaluated for CD34+ cells.

**Results**: 10 children with weights ranging from 9 -- 77 kg (mean 28.5kg) with solid tumours had stem cells collected using the CMNC protocol. Apheresis duration was 254 minutes. Peripheral CD34+ counts were above 35x106 (range 37‐806). Collection efficiency of 53.4% (range 27‐87%). Median platelet loss was 1%. Median CD34+ count in product was 11x106 with an average of 24.5 × 106CD34+ cells/kg. This equates to a CD34 dose ≥ 3 × 106/kg for 100% of the procedures. Linear correlation between peripheral CD34 count and the final product CD34 dose/kg allowed a prediction model for efficient collection. Procedures were well tolerated with no adverse events. Engraftment data is not yet available.

**Conclusions**: Spectra Optia CMNC protocol successfully collected CD34+ cells with yields sufficient for autologous transplantation in solid tumours in children. The CD34+ cell yield prediction was good, with excellent collection efficiency. PBSC collection with the CMNC protocol has the advantage of predicting final product dose, minimize platelet loss and minimize product volume making stem cell collection in children easier, faster and safe.

### PO-308. Treatment of Long‐Lasting Aggressive GVHD by Donor‐Derived Immune System Reset {#pbc27455-sec-5360}

[N. Subbotina]{.ul} ^1^, V. Daylidite^1^, I. Dolgopolov^1^, V. Boyarshinov^1^, G. Mentkevich^1^

*^1^N.N. Blokhin\'s National Medical Research Oncological center, Institute of Pediatric Oncology and Hematology, Moscow, Russia*

**Background/Objectives**: Because of great problem with resistant cGVHD treatment we suppose that patient\'s immune system reset may have benefit in such cases.

**Design/Methods**: Patient Z. was diagnosed in July 2011 at the age 3 y.o. with JMML 45XY(‐7). He was treated with low‐dose cytarabine with epigenetic agents. In December 2014 on disease progression G‐CSF priming followed by MAC with melphalan 100 mg/m^2^ and treosulfan 42 g/m^2^ and unmanipulated haploidentical PBSCT from mother was performed. In early posttransplant period on top of immunosuppression therapy with CNI and MMF patient had acute GVHD and was also treated with steroids, TNF‐α inhibitor and multiple ECP. The boy stayed in complete remission with full donor chimerism. All attempts of immunosupression reduction caused skin flares of GVHD and the patient was kept on high dose of tacrolimus, MMF, courses of steroids till spring 2016. So we decided to make a kind of immune system reset. In April and May 2016 the patient got two doses of rituximab 375 mg/m^2^ as a part of preparative regimen before naïve immune system restoring. Later in May 2016 first course of CY 2000 mg/m^2^ was performed. On hematological recovery G‐CSF primed PBSCs collection was done. In June 2016 patient underwent NMA regimen with CY 1500 mg/m^2^ on day ‐3 and Flu 10 mg/m^2^, on days ‐3, ‐2, ‐1 followed by auto HSCT.

**Results**: Hematological recovery was fast without significant toxicity. It becomes possible to decline dose of tacrolimus in 6 months and the pt became steroid‐free. Now the patient is in remission on MMF only with no signs of GVHD for 22 months after auto‐HSCT.

**Conclusions**: Thus this approach of naïve donor immune system restoration can be considered as a new treatment option for long lasting aggressive GVHD.

### PO-309. Allogeneic Stem Cell Transplantation in Children: Single Centre Experience from North India {#pbc27455-sec-5370}

[C. Vyas]{.ul} ^1^, F. Ansari^1^, A. Pandit^1^, N. Singh^1^, V. Dua^1^

*^1^Fortis Memorial Research Institute, Pediatric hematology‐oncology and bone marrow transplant, Gurugram, India*

**Background/Objectives**: Allogeneic stem cell transplant (Allo‐SCT) services in children are still far behind in India as compared to the developed countries because of the resource constraints. We present our experience of Allo‐SCT for various benign and malignant paediatric diseases.

**Design/Methods**: A retrospective analysis of total 101 children (61 male and 40 female) who underwent allo‐SCT between January 2014 and May 2017 at our centre was done. The mean age of the patients was 9.2 years (range, 14 months--17 years). The indications for allo‐SCT were hemoglobinopathy \[thalassemia major(TM)‐22, sickle cell disease(SCD)‐6\], aplastic anemia‐16, Fanconi anaemia‐10, Diamond‐Blackfan anemia‐1, immunodeficiency (mucopolysaacharidoisis‐2, one each for Wiskott‐Aldrich syndrome and Chediak‐Higashi syndrome), acute myeloid leukaemia (AML)‐14, acute lymphoblastic leukaemia (ALL)‐20, juvenile myelomocytic leukaemia (JMML)‐1, myelodysplastic syndrome‐1, relapse neuroblastoma‐1 and chronic myeloid leukaemia (CML)‐5. Donors were HLA‐matched sibling‐58, haploidentical‐33, single antigen mismatch‐5 and matched unrelated‐5. The source of stem cells was peripheral blood in 98 patients and bone marrow in 3 patients. We chose a post‐transplant cyclophosphamide based approach in majority of haploidentical transplants.

**Results**: Out of total 101 patients, 70 patients are alive and disease free at a median follow‐up of 223 days (range, 55--1213 days). The median time for neutrophil engraftment was at day 13 (range, 11‐ 18 days). Five patients had rejection (one each with TM, SCD, AML, CML and JMML). Acute graft versus host disease (GVHD) was reported in 31% patients (grade III/IV‐12%) while chronic GVHD in 14% patients (grade III/IV‐4%). Day 100 mortality was 31/101 (30%). Causes of non relapse mortality were infection‐18, GVHD‐5, veno‐occlusive disease‐1. Seven patients died due to relapse and/or progressive disease.

**Conclusions**: Our results are comparable to the reports from developed countries in terms of complications and outcomes of the treatment. This gives hope to many children who need allogeneic stem cell transplant in the developing world.

### PO-310. Burden of Hospitalizations in Long‐Term Survivors of Childhood AML Treated with Allogeneic‐HSCT: An ALiCCs Study {#pbc27455-sec-5380}

[M. Wilhelmsson]{.ul} ^1^, J. Winiarski^2^, J. Falck Winther^3^, T. Gudmundsdottir^4^, L. Madanat‐Harjuoja^5^, J.H. Olsen^4^, K. Jahnukainen^6^, H. Hasle^7^

*^1^Karolinska Institutet&Karolinska University Hospital, Department of Women\'s and Children\'s Health, Stockholm, Sweden; ^2^Karolinska Institutet&Karolinska University Hospital, Department of Clintec, Stcokholm, Sweden; ^3^Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; ^4^Danish Cancer Society Research Center, Danish Cancer Society Research Center, Copenhagen, Denmark; ^5^University of Helsinki and Helsinki University Hospital‐, Department of Paediatrics‐ University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ^6^Karolinska Institutet, Dept of Women\'s and Children\'s Health, Stockholm, Sweden; ^7^Aarhus University Hospital Skejby, Department of Paediatrics, Aarhus, Denmark*

**Background/Objectives**: Long‐term survivors of childhood AML treated with allogeneic hematopoietic stem cell transplantation (alloSCT) may have a significantly higher hospitalization rates than the general population and the survivors treated with chemotherapy only.

**Design/Methods**: A cohort of 282 survivors of childhood AML treated according to the NOPHO‐AML protocols ‐84, ‐88, ‐93, and 2004 in the Nordic countries was identified through the NOPHO‐AML database. Linkage between basic treatment and national hospital registries could be performed for 196 (70%) of the AML survivors and they were included in the study. Ninety‐seven (49%) had been treated with alloSCT and 99 with chemotherapy only. Survivors\' observed numbers of first‐time hospitalizations were compared with the expected numbers in the population. The follow‐up for hospitalizations started at ≥5 years from AML diagnosis and ≥1 year from latest alloSCT. TBI‐based conditioning had been used in 61% of the alloSCTs

**Results**: In total, 35 (36%) of alloSCT survivors had been hospitalized with an observed over expected ratio (O/E) of 2.8 (95% CI 2.04-- 3.96). Main causes for hospitalizations included gastrointestinal (15%), cardiovascular (13%), pulmonary (13%), endocrine (11%) and diseases of the urinary system (6%). Compared to the general population, the O/E was significantly increased for hospitalizations due to cardiovascular 8.7 (95% CI 3.9--19.3), endocrine 12.1 (6.7--21.9), pulmonary 3.0 (1.8--5.2), gastrointestinal 4.0 (2.4--6.7), infectious diseases 3.1 (1.3--7.6), neurological 4.4 (2.1--9.2) and urinary system conditions 2.9 (1.3--6.4). Proportion of hospitalized survivors among the CT survivors was 21%, and their O/E for hospitalizations was comparable with the general population; 1.4 (0.9--2.1). However, CT survivors O/E was significantly increased for hospitalizations due to gastrointestinal disorders 5.9 (1.5--23.8).

**Conclusions**: Long‐term survivors of childhood AML treated with alloSCT have a significantly increased risk of hospitalizations when compared to the general population. Childhood AML survivors treated with alloSCT have a higher burden of hospitalizations than the conventionally treated AML survivors.

### PO-311. Effects of 280 nm Ultraviolet LED on Murine Leukemia Cell L1210 and Hematopoietic Stem Cells In Vitro {#pbc27455-sec-5390}

[D. Xie]{.ul} ^1^

*^1^Affiliated hospital of Qingdao University, hematology pediatrics, Qingdao, China*

**Background/Objectives**: Purification in vitro is critical for autologous hematopoietic stem cell transplantation (AHSCT). Ultraviolet (UV) has historically been considered an apoptosis‐inducing agent, and S‐phase cells are more sensitive to UV‐induced damage than G0/G1‐phase cells. Over the past few decades, UV light‐emitting diode (LED) as an alternative UV source has been recommended to replace traditional UV lamps due to a number of advantages. In the current study, we observed the impact of 280nm UV LED on murine leukemia cell L1210 and hematopoietic stem cells (HSCs) in vitro, to explore the feasibility of UV LED for in vitro purification of AHSCT.

**Design/Methods**: HSCs of DBA/2 mouse were isolated by the immunomagnetic beads sorting using biotin or PE labeled SCA1 antibody. HSCs and L1210 cells were irradiated with 280nm UV LED at various doses and then were incubated for various time. The colony formation, cell proliferation and apoptosis of both cells were observed by automatic colony count, CCK‐8 assay and Annexin V‐FITC/PI double staining, respectively.

**Results**: The purity of HSCs determined by flow cytometry was up to 97.1%. UV LED dose‐dependently inhibited the colony formation of both cells, and the inhibitory effect on L1210 was stronger than that of HSCs, among which 9.6J/m2 was the most significant. Similarly, UV LED significantly inhibited the proliferation and induced apoptosis of both cells in a dose and time‐dependent manner, and the effect on L1210 cells was stronger than that on HSCs, with 224J/m2 for 24h being the most significant.

**Conclusions**: 280nm UV LED can selectively kill L1210 cells in a dose and time dependent manner in vitro. Its mechanisms include inhibition of colony formation, inhibition of cell proliferation and induction of apoptosis, yet it has little effect on HSC.

### PO-312. Cumulus Cell: Is a New Candidate for Cell Therapy? {#pbc27455-sec-5400}

[S. Yilmaz]{.ul} ^1^, E. Aydemir^2^, O. Akcin Alagoz^3^, E.E. Mohammad^4^, A. Ismicoglu^3^, B. Nalbantoglu^4^, C. Ficicioglu^5^

*^1^Yeditepe University Faculty of Medicine, Pediatric Hematology/Oncology, Istanbul, Turkey; ^2^Yeditepe University Faculty of Medicine, Department of Biotechnology, Istanbul, Turkey; ^3^Yeditepe University Faculty of Medicine, Yeditepe University Hospital‐ IVF Center, Istanbul, Turkey; ^4^Yildiz Technical University, Department of Biochemistry, Istanbul, Turkey; ^5^Yeditepe University Faculty of Medicine, Department of Gynecology and Obstetrics, Istanbul, Turkey*

**Background/Objectives**: The cumulus--oocyte complex in a mammalian ovarian follicle is consistent with an oocyte and neighboring follicular cells, known as cumulus cells (CCs). Close interaction between the oocyte and CCs is known. We aimed to investigate whether CCs have a role in the cell therapy beside the important roles in the oocyte development.

**Design/Methods**: During oocyte harvesting, mural cumulus granulosa cells were removed from the follicular fluid two hours before the sperm injection (Figure 1). CCs were digested with hylorunidase at 37^0^C for shortly and then seperated from the occyte with a help of scraper. Cumulus cells digested with hyaluronidase were cultivated with medium containing 10% FBS and 1% PSA and seeded onto collagen coated flasks and incubated at 37°C, % 18 O~2~ and %5 CO~2~ for days. After proliferation cells were characterized by flow cytometry and gene expression analysis for surface markers CD44 and CK19, respectively. Conditional media collected from the cumulus cells were filtered for unwanted cross‐contaminated cells and introduced into pancreatic cancer cell line BXPC3. Pancreas cancer cells treated with conditional cumulus media were incubated in hypoxic (1% O~2~) and normoxic (8 %O2) environment for three days separately. Cellular death in pancreatic cancer cells were monitored and detected by gene expression analysis for caspase dependent pathway related genes. Caspase dependent cell death and early apoptotic markers were investigated by flow cytometry assay and Annexin V staining, respectively.

**Results**: CCs expressed CD44 and CK19. Cumulus cells were different in hypoxic condition (Figure 2). Pancreatic cancer cells were gone apoptosis when co‐cultured with cumulus condition media. Apoptosis was found much more in hypoxic condition. Caspase pathways (Figure 3A) and early biomarkers of apoptosis (Figure 3B) were increased in hypoxic condition.

**Conclusions**: Metabolites secreted by cumulus cells caused to apoptosis of pancreatic cancer cells could be a promising tool on against cancer treatment.

Solid Non Brain Tumours ‐ Neuroblastoma {#pbc27455-sec-5410}
---------------------------------------

### PO-313. Childhood Ganglioneuroma: Experience of the Children Cancer Hospital of Egypt {#pbc27455-sec-5420}

[S. Abdelalim]{.ul} ^1^, M. Fawzy^1^, H. Elzomor^1^, N. Elkinaai^1^, G. Taha^1^, S. Abdelalim^1^, A. Refaat^1^, M. Amr^1^, M. Elshafiey^1^

*^1^clinical research spiciatist, Clinical research department at 57357 hospital, Cairo, Egypt*

**Background/Objectives**:Ganglioneuroma is a benign neuroblastic tumor that arise from neural crest sympathogonia or adrenal medulla. It represents the most differentiated spectrum of neuroblastic tumors with surgery being therapy of choice. ganglioneuroma can be the dominant histology in ganglioneuroblastoma especially on biopsy material. Ganglioneuroma can represent also histologic maturation neuroblastoma/ganglioneuroblastoma that occurs commonly after chemotherapy.

The aim is to study the clinicopathologic features and outcome of ganglioneuromatous tumor, whether confirmed to be ganglioneuroma or underwent maturation to ganglioneuroma after treatment and the clinicopathologic characteristics of ganglioneuroma on core biopsy that turned out to be ganglioneuroblastoma on resection or open biopsy material.

**Design/Methods**: This is a retrospective study and will include patients diagnosed at Children cancer hospital, Egypt, during the period from 2007 to 2017.

**Results**: Twenty‐nine patients out of 1,429 patients were ganglioneuroma.15 patients (65.5%) were extradrenal, 6 patients had intraspinal extension, 51.7% had surgical resection, 13 patients (86.6%) had complete surgical resection, 20 patients did bone marrow biopsy and were all negative.

Twenty four patients changed into GNB after excision/biopsy, 12.5% were adrenal, only one patient (4.1%) proved to be nodular, 10 patients (41.6%) had intraspinal extension. All underwent surgery, 13 patients (54.2%) had complete resection, 22 patients did bone marrow biopsy and were all negative.

Thirty nine cases were diagnosed as neuroblastoma (58.9%) and 16 patients were ganglioneuroblastoma (41%), 58.9% were adrenal, 23.1% patients only had intraspinal extension, 46.1% patients were bone marrow positive, two were NMYC amplified, all underwent surgery with 48.7% undergoing complete resection.

Follow up revealed all ganglioneuromatous patient were alive, the 3‐years overall survical was 95.8% for ganglioneuroblastoma cases and 69.5% for pot therapy maturing ganglioneroma cases.

**Conclusions**: Ganglioneuroma are benign tumors with excellent survival. Complete surgical resection didn\'t differ from incomplete resection. Cases that changed to GNB intermixed Maturing ganglioneuroma is a separate group with differenent biology and survival.

### PO-314. A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma {#pbc27455-sec-5430}

[S. Ackermann]{.ul} ^1^, M. Cartolano^2^, B. Hero^3^, A. Roderwieser^1^, C. Bartenhagen^1^, C. Rosswog^1^, F. Hertwig^4^, T. Simon^3^, A. Eggert^4^, F. Speleman^5^, R. Buettner^6^, R. O\'sullivan^7^, R. Thomas^2^, F. Berthold^3^, J. Vandesompele^5^, A. Schramm^8^, F. Westermann^9^, J. Schulte^4^, M. Peifer^2^, M. Fischer^1^

*^1^University Hospital of Cologne, Experimental Pediatric Oncology, Cologne, Germany; ^2^University of Cologne, Translational Genomics, Cologne, Germany; ^3^University Hospital of Cologne, Pediatric Oncology and Hematology, Cologne, Germany; ^4^Charité, Pediatric Oncology and Hematology, Berlin, Germany; ^5^Ghent University, Center for Medical Genetics, Ghent, Belgium; ^6^University of Cologne, Department of Pathology, Cologne, Germany; ^7^University of Pittsburgh Cancer Institute UPCI, Pharmacology and Chemical Biology, Pittsburgh, USA; ^8^University of Duisburg‐Essen, Department of Medical Oncology, Essen, Germany; ^9^German Cancer Research Center, Neuroblastoma Genomics B087, Heidelberg, Germany*

**Background/Objectives**: Recent genomic and transcriptomic profiling studies of neuroblastoma have shed light on cancer gene mutations frequencies, structural genomic rearrangements and copy number alterations in this tumor type. However, none of these had been able to convert the data into a coherent model that explains the pathogenesis of the divergent subtypes and can separate those cases in which spontaneous regression occurs from those whose disease progresses.

**Design/Methods**: To determine the molecular basis of favorable and adverse disease courses, we performed massively parallel sequencing of 416 untreated neuroblastomas (whole‐genome or whole‐exome sequencing, n=218; targeted sequencing, n=198) and determined telomere maintenance mechanisms in 208/416 cases. In addition, we performed targeted sequencing of 63 neuroblastoma relapse samples.

**Results**: We detected genomic alterations of 17 genes related to the RAS and p53 pathways in 74/416 patients (17.8%). The presence of these mutations was strongly associated with dismal outcome in the entire cohort, as well as in the high‐risk and non‐high‐risk subgroups. In relapsed neuroblastoma, the frequency of such mutations increased to 36.5% (23/63 samples). We noticed, however, that the prognostic effect of RAS/p53 pathway mutations was strictly dependent on the occurrence of telomere maintenance mechanisms. Survival of patients whose tumors were telomere maintenance‐positive was dramatically inferior when additional RAS/p53 pathway mutations were present as compared to those without such alterations. By contrast, patients whose tumors lacked telomere maintenance mechanisms had excellent outcome, and spontaneous regression or differentiation occurred both in the presence and absence of RAS/p53 pathway mutations.

**Conclusions**: Together, our data suggest a precise mechanistic definition of clinical neuroblastoma phenotypes that is based on the presence or absence of telomere maintenance and RAS or p53 pathway mutations, and provide a starting point for improving diagnostic and therapeutic management of neuroblastoma patients.

### PO-315. ATM/Chk2/P53 Pathway Inactivation is Required for ATRX‐Mutation‐Related Tumorigenesis {#pbc27455-sec-5440}

[J. Akter]{.ul} ^1^, Y. Katai^1^, S. Parvin^1^, H. Takenobu^1^, R. Okada^1^, M. Haruta^1^, R. Sugino^1^, M. Ohira^1^, T. Kamijo^1^

*^1^Research Institute for Clinical Oncology‐ Saitama Cancer Center, Clinical Oncology, Saitama, Japan*

**Background/Objectives**: Neuroblastoma (NB) is the most common pediatric tumor and accounts for 9‐15 % cancer‐related deaths in children. The chromatin remodeling factor*ATRX* is a tumor suppressor gene, and its recurrent somatic mutations associated with stage 4 NB patients. But the precise mechanisms by which *ATRX* mutation related with the NB tumorigenesis and aggressiveness remain to be elucidated. Here, we demonstrate that ATRX‐knockout (KO) induces ATM/p53 dependent DNA damage response in NB cells.

**Design/Methods**: *ATRX* KO *clones established* in *MYCN* amplified (NGP) and single copy (NB‐69) NB cells using CRISPR‐Cas9 technology. Cell proliferation was detected by WST assay. Microarray‐based expression analysis of *ATRX* KO clones was performed by Agilent 8x60K oligonucleotide microarrays. Gene Set Enrichment Analysis (GSEA) was used to analyze the differential‐expression data. p53 inactivation was done by lentiviral mutant p53 transduction. ATM signaling pathway was studied by western‐blot analysis.

**Results**: Herein, several *ATRX* KO clones were established in both NB cell lines. Interestingly, the clones proliferate slowly compared to control and become differentiated. Our, GSEA analysis of microarray data indicated that gene‐set related to DNA double‐strand break repair, DNA damage response, negative cell cycle regulation, G2M checkpoint and, p53 pathway activation were induced in *ATRX* KO cells. By *in vitro* analysis, ATRX loss results in increased expression of phosphorylated histone variant H2AX (gamma‐H2AX), a canonical marker for double‐stranded breaks, indicating the accumulation of endogenous DNA damage in *ATRX* KO cells. Furthermore, accumulation of DNA damage results in activation of the ATM/Chk2/p53 pathway, leading to cell cycle arrest. Moreover, lentiviral‐mediated inactivation of p53 rescued the decreased cell growth levels in *ATRX* KO cells. We also studied the correlation between *ATRX*‐mutation and ATM/p53 pathway inactivation by multiomics database analysis.

**Conclusions**: Taken together, these findings suggest that ATRX plays a role in maintaining DNA integrity and ATM/Chk2/p53 pathway inactivation is required for NB tumorigenesis.

### PO-316. Hepatic Outcomes in Survivors of Neuroblastoma {#pbc27455-sec-5450}

[Z. Anan]{.ul} ^1^, P. Ci^1^, W. Xiaoxia^1^, G. Yijin^1^, T. Jingyan^1^

*^1^SHANGHAI Children\'s Medical Center, Hematology &Oncology, Shanghai, China*

**Background/Objectives**: At the time of treatment completion, some patient of neuroblastoma still had abnormal hepatic imaging. We aimed to investigate the hepatic survival of neuroblastoma with stage 4 and 4s.

**Design/Methods**: We retrospectively reviewed the clinicl information and images of 38 survivors of neuroblastoma with hepatic involvement treated between June 1998 to December 2015 in Shanghai Children\'s Medical Center. We divided children into two groups according to hepatic infiltration or not when treatment completed.

**Results**: We identified 21 stage 4 and 17 stage 4s patients. The median age at diagnosis was 7 months(1∼58).Six children had amplified MYCN. Except that one children had primary tumor removal without chemotherapy, the remaining children received a median of 9 (4∼12)cycles of chemotherapy. Two children received radiation, and one children received autologous hemopoietic stem cell transportation. Twenty‐one children had hepatic biopsy in the course of treatment and the postoperative pathology confirmed neuroblastoma metastasis. At the completion of treatment, hepatic imaging of twenty‐four children was abnormal which showed a single or multiple low density shadow. Six cases had tumor recurrence in non‐hepatic location. The imaging abnormities of the remaining 18 cases resolved in the following‐up without intervention. Adverse liver outcome was not detected. Fourteen children still had normal hepatic imaging when treatment completed. six cases had local or systematic relapse. The median follow‐up period was 48 (range 32 to 204) months after diagnosis. The 2 year and 3 year event free survival was 68.4%, 47.8%. According to univariate analysis, high levels of lactic dehydrogenase (\>3 times the nomal value) and age were two significant poor prognostic factors.

**Conclusions**: The onset of neuroblastoma with hepatic involvement was young. At the time of treatment completion, the abnormities of hepatic imaging was frequent, which was not a poor prognostic factor and may resolve over time without invention. Adverse liver outcome was not detected.

### PO-317. Survival and Late Effects of Comprehensive Treatment in Children with Neuroblastoma {#pbc27455-sec-5460}

[Z. Anan]{.ul} ^1^, J. Haoxiao^1^, X. Jianmin^1^, P. Ci^1^, T. Jingyan^1^

*^1^SHANGHAI Children\'s Medical Center, Hematology &Oncology, Shanghai, China*

**Background/Objectives**: To investigate the survival, late effects and secondary malignancy in children with high risk neuroblastoma who received comprehensive treatment including high‐dose chemotherapy or autologous stem cell transplantation or radiation.

**Design/Methods**: A total of 23 children with high risk neuroblastoma who received comprehensive treatment in Shanghai Children\'s Medical Center from 1998 to 2010 were eligible. All tests were formulated according to the Children\'s Oncology Group\'s guidelines with the approval of parents. The late side effects were graded by CTCAE v3.0, and hearing loss related to platinum was graded by Brock and Chang.

**Results**: The median follow‐up was 96(65‐170)months. All the patients had at least one late effect. The occurrence rate of 1‐2 adverse effect was 100%, and 17.4% (4/23 cases) of patients had grade 3‐4 adverse effects. 90.5% (19/21 cases) of children developed hearing loss on both sides. 52.4% (11/21) of children developed dental abnormities, comprising microdontia, missing teeth, root stunting and enamel hypoplasia. 9.5% (2/21) of children had scoliosis. 42.8% (9/21) of children developed hypogonadism or delayed growth. 47.4% (9/19) of children had abnormal respiratory function. 36.8% (7/19) 0f children had abnormal cardiac function. 33.4% (7/21) developed renal damage. 66.7% (14/21) of children had low level of cortisol, but adrenocorticotrophic hormone was normal. All children had normal function of thyroid. Three patients had second malignancy: leukemia, malignant fibroma and liver tumor.

**Conclusions**: The incidence of patients with neuroblastoma treated with high‐dose chemotherapy or ABMT or irradiation was high, including hearing loss, dental abnormality, cardiopulmonary function abnormality, musculoskeletal problems, et al. The upmost importance is to establish long‐tem follow‐up program, to discover the problem early and improve life quality.

We accept the abstract to be published in the official publication.

### PO-318. Influence of the Numbers of Image Defined Risk Factors in Localized Neuroblastoma {#pbc27455-sec-5470}

[Z. Anan]{.ul} ^1^, P. Ci^1^, X. Min^1^, W. Xiaoxia^1^, Y. Qidong^1^, G. Yijin^1^, T. Jingyan^1^

*^1^SHANGHAI Children\'s Medical Center, Hematology & Oncology, Shanghai, China*

**Background/Objectives**: We evaluated the numbers of image defined risk factors (IDRFs) and their correlation with tumor resection, therapy response, and prognostic value. We also evaluated the impact of individual IDRF on tumor resection and survival.

**Design/Methods**: We retrospectively reviewed the images of patients with localized neuroblastoma who were enrolled between June 1998 and December 2012 in Shanghai Children\'s Medical Center. Unequivocal categorization regarding IDRFs was possible in 67 patients. IDRF assessment was made both at diagnosis and after neoadjuvant chemotherapy. The median follow‐up period was 84 (range 48 to 132) months after diagnosis.

**Results**: MRI and CT indicated a total of 177 IDRFs in these 67 patients. Logistic regression analysis revealed a highly significant negative correlation between the number of IDRFs and the possibility of completely removal of neuroblastoma. Multivariate logistic regression analysis detected two independent factors for complete tumor resections: intraspinal tumor extension and vessel involvement. According to univariate analysis, high numbers of IDRFs(≥4), Intraspinal tumor extension were significant poor prognostic factors.

**Conclusions**: High numbers of IDRFs were useful in predicting surgical outcome, and also event free survival.

We accept the abstract to be published in the official publication.

### PO-319. 5‐Hydroxymethylcytosine is an Epigenetic Mark that Serves as a Biomarker for Risk Classification and Outcome in Neuroblastoma {#pbc27455-sec-5480}

[M. Applebaum]{.ul} ^1^, E. Barr^1^, J. Nie^2^, A. Chlenski^1^, H. Salwen^1^, M. Dobratic^1^, B. Stranger^3^, C. He^2^, S. Cohn^1^

*^1^University of Chicago, Pediatrics, Chicago, USA; ^2^University of Chicago, Chemistry, Chicago, USA; ^3^University of Chicago, Medicine, Chicago, USA*

**Background/Objectives**: 5‐hydroxymethylcytosine (5hmC) is an epigenetic modification associated with gene activation. In adult cancers, 5hmC signatures serve as robust biomarkers of cancer and outcome. Recently, Dr. He invented a novel, highly sensitive technology (nano‐hmC‐Seal‐Seq) allowing characterization of genome‐wide 5hmC using small quantities of tumor DNA. We hypothesized 5hmC plays a key role in regulating genes driving neuroblastoma phenotype, and that 5hmC profiles are prognostic of outcome in neuroblastoma.

**Design/Methods**: 5hmC was quantified by nano‐hmC‐Seal‐Seq using 100ng of DNA from locally banked, FFPEdiagnostic neuroblastoma tumors. Fragment counts were called using featureCounts and normalized with DESeq2, which also identified genes with differential 5hmC between risk groups. Gene Ontology (GO) pathway analysis of differential 5hmC genes was performed.

**Results**: We profiled 5hmC in 15 high‐risk, 11 intermediate‐risk, and 27 low‐risk tumors. An elastic net regression model was identified 151 genes that are able to distinctly cluster high‐risk, intermediate‐risk and low‐risk tumors. Compared to the current neuroblastoma risk classification schema, 5hmC profiling enabled more accurate prediction of outcome of one patient with *MYCN*‐amplified disease with unexpectedly good outcome and two patients classified as low‐ or intermediate‐risk who relapsed. Additionally, we identified 997 unique differentially hydroxymethylated genes between high‐ and low‐risk tumors. Similar to expression profiles of tumors from these risk groups, pathways of neuronal differentiation were enriched in low‐risk tumors, whereas 5hmC gains in high‐risk tumors were detected in embryonal maintenance pathways. Because it is currently impossible to predict which patients with high‐risk disease will survive, we performed an exploratory analysis which identified 76 genes that are able to accurately stratify the 15 high‐risk patients by outcome.

**Conclusions**: 5hmC profiles differentiate neuroblastoma risk groups, and may refine risk classification at diagnosis. Because of its stability and ease of isolation, a DNA‐based 5hmC biomarker such as this is more suitable than RNA‐based signatures for translation into the clinical setting.

### PO-320. Autologous Stem‐Cell Transplant (ASCT) for High‐Risk Neuroblastoma: Achieving Cure with Low‐Cost Innovations {#pbc27455-sec-5490}

R. Jain^1^, R. Hans^2^, S. Totadri^1^, A. Trehan^1^, R.R. Sharma^2^, P. Menon^3^, R. Kapoor^4^, A. Saxena^5^, B.R. Mittal^6^, P. Bhatia^1^, N. Kakkar^7^, R. Srinivasan^8^, A. Rajwanshi^8^, N. Varma^9^, R. Samujh^3^, N. Marwaha^2^, [D. Bansal]{.ul} ^1^

*^1^Postgraduate Institute of Medical Education and Research, Hematology/Oncology unit‐ Dept. of Pediatrics‐ Advanced Pediatrics Center, Chandigarh, India; ^2^Postgraduate Institute of Medical Education and Research, Transfusion Medicine, Chandigarh, India; ^3^Postgraduate Institute of Medical Education and Research, Pediatric Surgery‐ Advanced Pediatrics Center, Chandigarh, India; ^4^Postgraduate Institute of Medical Education and Research, Radiotherapy, Chandigarh, India; ^5^Postgraduate Institute of Medical Education and Research, Radiodiagnosis, Chandigarh, India; ^6^Postgraduate Institute of Medical Education and Research, Nuclear Medicine, Chandigarh, India; ^7^Postgraduate Institute of Medical Education and Research, Histopathology, Chandigarh, India; ^8^Postgraduate Institute of Medical Education and Research, Cytology, Chandigarh, India; ^9^Postgraduate Institute of Medical Education and Research, Hematology, Chandigarh, India*

**Background/Objectives**: Outcome of high‐risk neuroblastoma with ASCT is rarely reported from developing countries.

**Design/Methods**: Study design: Retrospective chart review of patients with neuroblastoma. Period: Jan‐2012 to September‐2017. Setting: Government, University‐hospital in India.

The high‐risk patients were treated on backbone of HR‐NBL‐1/SIOPEN protocol with rapid‐COJEC, surgery, ASCT, radiotherapy and cis‐RA. Measures for reducing cost/infections and ensuring rapid engraftment, included: a) Transplants performed in regular, multi‐bedded ward, without HEPA filter, b) No ECHO/GFR/PFT assessment, c) No cryopreservation of stem cells, d) Stem cell apheresis performed on 2 consecutive days, e) Venous access by peripheral cannula, except for apheresis, f) No antibiotic/antifungal/antiviral prophylaxis, g) PEGylated‐G‐CSF on Day+4.

**Results**: During 5‐¾ years, 164 patients with neuroblastoma were diagnosed. The risk‐categorization was: high 100 (61%), intermediate 20 (12%), low 18 (11%) and very‐low‐risk 9 (5.5%). Among 100 high‐risk patients: 35 (35%) did not opt for treatment (limited finances); 30 were treated without ASCT; *data of 35 patients who received ASCT is presented*. The median‐age was 39 months. Twelve (34%) were underweight.

An ASCT was performed at a median‐duration of 124 days from start of COJEC. Conditioning regimen included melphalan (20%), oral busulfan‐melphalan (17%) or parenteral busulfan‐melphalan (63%). The median CD34+ stem cell collection was 5.7x10\*6 cells/kg. The harvested product was stored at 2‐6\*C for 5‐7 days; the median viability was 91% (range: 60‐99%). Median time to neutrophil engraftment was 11 days (range: 9‐46).

A relapse was recorded in 14 (40%) patients, at median duration of 14 months. Treatment related mortality was observed in 2 (6%) patients. The mean follow‐up duration of alive patients is 24 months (range: 8.6‐53). The overall and event‐free‐survival at 45 months was 46±9.5% and 42±9.5%, respectively.

**Conclusions**: Administration of multi‐disciplinary treatment in a disciplined time‐frame and low‐cost innovations for ASCT were successful in achieving cure in selected patients with high‐risk neuroblastoma, in a public hospital in India.

### PO-321. Inhibition of BIRC5/Survivin Protein by S12 Decreases Neuroblastoma Growth While Hemizygosity of BIRC5 in Transgenic Mice Does Not: Implications for Survivin as a Therapeutic Target {#pbc27455-sec-5500}

C. Dorneburg^1^, C. Galiger^1^, V. Rasche^2^, A. Lechel^3^, S.F. Katz^3^, K.M. Debatin^1^, [C. Beltinger]{.ul} ^1^

*^1^University Medical Center Ulm, Pediatrics and Adolescent Medicine, Ulm, Germany; ^2^University Medical Center Ulm, Internal Medicine II, Ulm, Germany; ^3^University Medical Center Ulm, Internal Medicine I, Ulm, Germany*

**Background/Objectives**: Overexpression of survivin, a crucial regulator of the mitotic spindle checkpoint with additional antiapoptotic effects, is associated with poor prognosis in neuroblastoma (NB). Transcriptional inhibitors of survivin have been tested in clinical trials. However, results have been disappointing. We thus investigated the small molecule S12 that inhibits dimerization of the survivin protein and compared its growth‐inhibiting efficacy with that of markedly decreased survivin expression in a novel transgenic NB mouse.

**Design/Methods**: Mice hemizygous for Birc5/survivin were crossed with TH‐MYCN mice to generate Birc5+/‐ MYCN tg/+ mice. NB growth was assessed by serial MRI imaging. Anchorage‐independent growth was determined in soft agar.

**Results**: Mice developed NB where mRNA and protein expression of survivin was markedly decreased. Surprisingly, incidence and latency of the NB that developed in the Birc5+/‐ MYCN tg/+ mice did not differ from the NB in the TH‐MYCN mice, growth of tumors was not decreased and survival of the mice was not increased. Immunohistochemistry of the NB did not show decreased proliferation, increased apoptosis or a change in vascularity. No difference in copy number variations between the two NB mouse models was discernible. To determine whether dysfunctional T cells described in mice hemizygous for Birc5 could have masked any loss of aggressiveness of NB cells hemizygous for Birc5, NB of Birc5+/‐ MYCN tg/+ mice were transplanted into Birc5+/+ MYCN+/+ mice. No difference in tumor incidence, latency and growth was detected. In stark contrast, S12 abolished anchorage‐independent growth of NB cell lines.

**Conclusions**: Despite a marked decrease in the expression of BIRC5/survivin by hemizygosity, NB was not inhibited in the transgenic mice. In contrast, S12 showed marked efficacy *in vitro*. These results support targeting survivin protein in NB to inhibit its interaction with itself and other proteins.

### PO-322. LDHA Predicts Poor Survival in Neuroblastoma and its Depletion Causes Aerobic Glycolysis‐Independent Inhibition of Neuroblastoma Cells {#pbc27455-sec-5510}

C. Dorneburg^1^, M. Fischer^2^, T.F.E. Barth^3^, W. Mueller‐Klieser^4^, B. Hero^2^, J. Gecht^2^, D.R. Carter^5^, K. de Preter^6^, F. Speleman^6^, G.M. Marshall^7^, L. Christner^1^, K.M. Debatin^1^, [C. Beltinger]{.ul} ^1^

*^1^University Medical Center Ulm, Pediatrics and Adolescent Medicine, Ulm, Germany; ^2^Children\'s Hospital‐ University of Cologne, Pediatric Oncology and Hematology, Cologne, Germany; ^3^University Medical Center Ulm, Patholoy, Ulm, Germany; ^4^University Mainz, Pathophysiology, Mainz, Germany; ^5^Lowy Cancer Centre‐ University of New South Wales, Children\'s Cancer Institute Australia, Sydney, Australia; ^6^Ghent University, Center for Medical Genetics CMGG, Ghent, Belgium; ^7^Sydney Children\'s Hospital, Kids Cancer Centre, Sydney, Australia*

**Background/Objectives**: We wanted to know whether lactate dehydrogenase A (LDHA), an important component of the LDH tetramer pivotal for the Warburg effect, is associated with patient survival in neuroblastoma (NB) and can be therapeutically targeted in this tumor.

**Design/Methods**: To this end, expression of LDHA mRNA and protein were determined in 709 and 110 NB patient samples, respectively, and correlated with survival and risk factors. LDHA and LDHB were knocked out and down in human NB cell lines, respectively, and aerobic glycolysis, clonogenicity and tumorigenicity were determined. Expression of LDHA in relation to MYCN was determined in NB cell lines and in the TH‐MYCN NB mouse model.

**Results**: We observed that expression of LDHA mRNA and protein was significantly and independently associated with decreased patient survival. Predominant cytoplasmic localization of LDHA protein was associated with poor outcome. Amplification and expression of *MYCN* did not correlate with expression of LDHA in NB cell lines or TH‐MYCN mice, respectively. Knockout of LDHA inhibited clonogenicity, tumorigenicity and tumor growth without abolishing LDH activity or significantly decreasing aerobic glycolysis. Concomitant depletion of LDHA and the isoform LDHB ablated clonogenicity while not abrogating LDH activity or decreasing aerobic glycolysis. The isoform LDHC was not expressed.

**Conclusions**: We conclude that high expression of LDHA is independently associated with outcome of NB and that NB cells can be inhibited by depletion of LDHA or LDHB. This inhibition appears to be unrelated to LDH activity and aerobic glycolysis. Thus, investigations into inhibitory mechanisms other than attenuation of aerobic glycolysis are warranted, both in NB and normal cells.

### PO-323. Bony Metastasis from Primary Adrenal Neuroblastoma Masquerading as Acute Osteomyelitis {#pbc27455-sec-5520}

[D. Bhat]{.ul} ^1^, S. kakkar^1^

*^1^dayanand medical college.ludhiana, pediatrics, LUDHIANA, India*

**Background/Objectives**: Due to overlapping clinical and radiological features, the differentiation between osteomyelitis and bone tumor can be challenging. We present an eleven month old infant who presented with fever and left thigh swelling, initially manage outside our hospital as acute osteomyelitis but turned out to be bony metastasis from adrenal neuroblastoma.

**Design/Methods**: A case report

**Results**: A 11 month old infant came to our hospital with complaints of fever and swelling left thigh since 15 days, inability to bear weight and irritability since last 10 days. On examination child was having tachycardia with a heart rate of 174/minute, temperature of 10OºF, severe pallor and irritable. On local examination there was a diffuse swelling of 8X6 cm over lower end of left femur, tender to touch but no overlying redness or raised temperature. Xray lower end of femur showed a lytic lesion. Initially child was managed as a case of osteomyelitis. Laboratory investigations revealed a hemoglobin of 6 gm/dl, total leucocyte count of 19,000/dl with neutrophilic predominance. As child had already received 10 days intravenous antibiotics, biopsy was done which revealed round cell tumor. Bone scan suggeste metastasis in lower end of left femur and 6th rib. CT abdomen revealed primary tumor in left suprarenal gland. Bone marrow examination also revealed infiltration by round cell tumor. patient was diagnosed as stage IV neuroblastoma with bony metastasis.

**Conclusions**: In patients with osteomyelitis like symptoms and bone pain refractory to medical treatment, a thorough diagnostic work‐up should be undertaken, and unusual neoplasms such as this haematopoetic malignancy should be considered in differential diagnosis.

### PO-324. Adoption of SIOP‐PODC Risk Stratification and Treatment Guidelines for LMICs {#pbc27455-sec-5530}

[S. Bhatnagar]{.ul} ^1^

*^1^B.J.Wadia Hospital for Children, Pediatric Surgery, Mumbai‐ Maharashtra‐ India, India*

**Background/Objectives**: Neuroblastoma outcomes are dependant on consistent management protocols based on extensive workup for risk stratification and metastatic status. However, in low & middle income countries, suboptimal workup may lead to suboptimal management. Adoption of SIOP‐PODC adapted risk stratification and treatment guidelines recommended in 2015, can provide improved outcomes.

**Design/Methods**: Prospective data collection was done for 3 years between April 2014 to December 2017. As per the SIOP‐PODC recommendations, the resource settings for neuroblastoma diagnosis, staging and risk stratification was identified. Based on the resource setting, the patients were diagnosed, staged and treatment was initiated.

The Institute was identified to have Setting 3, wherein the neuroblastoma staging and risk classification included CT of neck, chest, abdomen, and pelvis with intravenous contrast; MRI of sites with suspected spinal involvement and sites where tumor extent was not well defined by CT; and ^123^I‐ mIBG scans, or ^18^FDG‐PET. Adapted risk stratification and treatment assignment was done after staging in all patients.

**Results**: 21 children were diagnosed with neuroblastoma, staged and risk stratified as per the adapted risk stratification. 2/21 were in low risk group, 10/21 were in intermediate risk group and 9/21 belonged to high risk group. As per the guidelines, modified therapy was given to these risk groups leading to shorter course of treatment, reduction in cumulative doses, reduce toxicities, and maintain survival outcomes to OS of 100% for low risk group, 75% for intermediate group, and 28% for High risk group.

**Conclusions**: Inspite of limitations in resources and infrastructure in LMIC, the adapted recommendations and guidelines had allowed risk assignment for children with neuroblastoma, regardless of their setting, and selection of feasible and appropriate treatment.

### PO-325. Mesenchymal Neuroblastoma Cells Express Less Norepinephrine Transporter (NET), and as a Consequence Show Reduced Uptake of Meta‐Iodobenzylguanidine (MIBG) {#pbc27455-sec-5540}

[T. Blom]{.ul} ^1^, J. Van Wijk^2^, R. Meinsma^3^, R. Leen^3^, J. Van Nes^4^, A. Van Kuilenburg^3^, E. Van der Schoot^2^, G. Tytgat^1^

*^1^Princess Máxima Center for Pediatric Oncology, Research, Utrecht, The Netherlands; ^2^Sanquin Research, Experimental Immunohematology, Amsterdam, The Netherlands; ^3^Academic Medical Center, Laboratory Genetic Metabolic Diseases, Amsterdam, The Netherlands; ^4^Academic Medical Center, Oncogenomics, Amsterdam, The Netherlands*

**Background/Objectives**: Approximately 10% of neuroblastoma tumors are non‐avid on diagnostic meta‐iodobenzylguanidine (MIBG) imaging, leading to false‐negative imaging interpretations. Although Norepinephrine Transporter (NET) protein expression correlates with MIBG avidity, the biological origins of the difference between avid and non‐avid disease are largely unclarified. Recently, the existence of two types of neuroblastoma cells with diverging gene expression profiles was demonstrated. Besides classic adrenergic neuroblastoma cells, undifferentiated mesenchymal cells exist, leading to intratumoral heterogeneity. These mesenchymal cells are enriched in post‐therapy and relapse tumors. The aim of our study was to investigate whether mesenchymal neuroblastoma cells show less NET expression and consequently less MIBG uptake.

**Design/Methods**: Using Real‐time qPCR, 13 human neuroblastoma cell lines (SK‐N‐BE(2)C, SK‐N‐SH, LAN‐6, GIMEN, NGP, N206, IMR32, SJNB‐1, SJNB‐8,) including two isogenic cell line pairs (SH‐SY5Y ‐ SHEP2, and 691‐B ‐ 691‐T) were tested for NET mRNA expression. NET protein expression was determined in these cell lines using Western Blotting. Adrenergic cell lines were generated containing an inducible regulator of mesenchymal transformation: SK‐N‐BE(2)C‐PRRX1, and SH‐SY5Y‐NOTCH3. In a time series, NET mRNA expression was measured after induction using RT qPCR. With a subset of cell lines, \[125‐iodine\]‐labeled MIBG internalization studies were performed.

**Results**: NET mRNA expression in mesenchymal cell lines (691‐T, SHEP2, GIMEN) is very low/undeterminable in comparison with the classic adrenergic cell lines. The mesenchymal cell lines showed no protein expression. Induction of regulators of mesenchymal transformation resulted in a motile, mesenchymal phenotype, accompanied by a decrease in NET expression over time. Internalization studies with MIBG affirmed these findings; after two hours of incubation in medium containing radiolabeled MIBG, the adrenergic cell lines showed high uptake, which could be nearly fully inhibited by desipramine, whereas the mesenchymal cell lines showed no selective uptake of MIBG.

**Conclusions**: The mesenchymal differentiation state of neuroblastoma seems to be accompanied by the absence of NET expression.

### PO-326. Typical Neuroblastoma Complicated by an Atypical Hemolytic Uremic Syndrome {#pbc27455-sec-5550}

[D. Brik Simon]{.ul} ^1^, S. Amar^2^, S. Ash^2^

*^1^Schneider Children\'s Medical Center‐, Pediatric Hematology Oncology‐, Petach Tikva‐, Israel; ^2^Schneider Children\'s Medical Center, Pediatric Hematology Oncology, Petach Tikva, Israel*

**Background/Objectives**: An eight year old patient with a metastatic neuroblastoma developed hypertension, elevated creatinine and hematuria, four weeks after receiving his first Cisplatin treatment.

This was attributed at first to the nephrotoxic effect of the chemotherapy. Simultaneity blood count showed signs of hemolysis and worsening thrombocytopenia. A peripheral blood smears demonstrated schistoctes which contributed to the diagnoses of atypical hemolytic uremic syndrome.

**Design/Methods**: After receiving a negative ADAMTS13 mutation and normal levels of complement, we decided to treat him with ECOLIZUMAB, a complement inhibitor. After 3 doses kidney function test and the blood count started to recover slowly. Results of complement levels and CH50 were low which confirmed the effectiveness of ECOLIZUMAB treatment.

**Results**: Under ECOLIZUMAB treatment, no further signs of hemolysis or worsening kidney function were noted and our patient was able to receive the necessary chemotherapy and proceed to an autologous BMT.

**Conclusions**: Abnormal regulation of complement may be associated with other cases of cisplatin‐induced HUS and treatment with Eculizumab may be appropriate for other affected individuals.

### PO-327. Real Time PCR Detection of Minimal Residual Disease in Patients with Neuroblastoma {#pbc27455-sec-5560}

[V. Brilliantova]{.ul} ^1^, D. Shevtsov^1^, T. Shamanskaya^1^, A. Drui^1^, D. Kachanov^1^, E. Stepovik^1^, E. Raykina^1^

*^1^Dmytry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Russian Ministry of Health, Moscow, Russia*

**Background/Objectives**: The actual problem in patients with neuroblastoma (the most extensive tumor in pediatric solid oncology) is the detection of minimal residual disease (MRD). The most popular method for MRD monitoring is the real time PCR based on detection of gene\'s mRNA that expressed only in neuroblastoma cells. Three specific markers are recommended by SIOPEN group to monitoring MRD in patients with neuroblastoma: tyrosinehydroxylase -- TH, doublecortine -- DCX and PHOX2B gene. The introducing calibrators in real time PCR system will make possible to observe changes of MRD intensity during the treatment.

**Design/Methods**: The group of patients consists of 12 children (age 0‐8 years) with diagnosis of high‐risk neuroblastoma. The bone marrow biopsy was examined for four times during the treatment: before starting therapy, after second and fourth block of chemotherapy and in conclusion of induction treatment. RNA was extract from samples by standard way and after revers transcription reaction was add to the real‐time PCR with primers and probes to target gene and to housekeeper gene.

**Results**: In experiment was observe correlation between MRD calculated by ΔΔCt and number of target gene transcript copies determined by calibrators. The number of target transcript copies changed in patients with neuroblastoma during the treatment. Positive MRD status initially was observe in 9 patients, 3 patients were MRD negative at first time, before treatment and they have a long term remission. 3 patients died in progression, all of them had MRD positive bone marrow. 1 patient died from TRM. 8 patients are alive after two years, 6 of them became MRD negative, and 2 have MRD positive bone marrow.

**Conclusions**: MRD detection in neuroblastoma with real‐time PCR including calibrators system is more suitable in high risk group patients and helps to observe MRD changes during the treatment.

### PO-328. Initial Results of the Treatment for High Risk Neuroblastoma According to the Siopen Protocol in Vietnam National Children\'s Hospital {#pbc27455-sec-5570}

[N.L. Bui]{.ul} ^1^, T.L. Phung^1^, H.A. Nguyen^1^, A.D. Dang^2^, H.S. Pham^2^, M.D. Tran^2^

*^1^Vietnam National Children\'s Hospital, Pediatric Oncology Hematology Center, Hanoi, Vietnam; ^2^Vietnam National Children\'s Hospital, Surgical Intensive Care Unit, Hanoi, Vietnam*

**Background/Objectives**: Children with high‐risk (HR) neuroblastoma have a poor outcome. Conventional therapy is difficult to perform in developing countries because of the high cost. In this study, we assess the feasibility and initial results of HRN1.5/SIOPEN protocol for 5 patients with HR neuroblastoma in VNCH.

**Design/Methods**: 5 patients (2 males, 3 females, and ages from 12.5 months to 5 years) with HR neuroblastoma were treated with the same regimen including intensive induction (Rapid COJEC), tumor resection, myeloablative therapy with BuMel following stem cell rescue, irradiation and maintenance with 13‐cis RA from October 2014 to June 2016. All patients did not have disease progression after Induction phase. The assessment based on bilateral BMA, bone marrow biopsy, bone SPECT‐ Tc 99/± PET CT, CT scan for primary tumor, serum LDH level, and urine VMA/HVA assays. We present the updated results in March 2018.

**Results**: 2 of 5 patients are alive without progressive disease at 22 and 31 months from diagnosis. One patient died of early bone marrow relapse and pneumocystis pneumonia. Two patients had bone marrow relapse after 15 months from diagnosis. One continued treatment with haplo‐HSCT but suffered second relapsed and deceased at 37 months from diagnosis. One is alive and on palliative treatment. All patients received chemotherapy of Rapid COJEC regimen every 10 days as plan. The residual tumor was unable to remove in the one patient. Total CD34 from 3.3x10\^6/kg to 6x10\^6/kg cells had been harvested from peripheral blood in 4 patients and bone marrow in the other. Engraftment occurred from day 15 to day 18 with ANC \> 1G/L and PLT \> 20G/L. Complications after auto‐HSCT were severe infections. Most of the cost was covered by government insurance.

**Conclusions**: Treatment with HRN1.5/SIOPEN protocol is feasible in VNCH for children with HR neuroblastoma and can lead to improvement in survival.

### PO-329. Development of Encephalopathy Secondary to CIS‐Retinoic Acid in a Patient with Neuroblastoma {#pbc27455-sec-5580}

[F.B. Çakır]{.ul} ^1^, N. Aydın^2^, F.D. İçağasıoğlu^2^, A. İşcan^2^

*^1^Associate Professor, Bezmialem Vakif University Pediatric Hematology Oncology, Istanbul, Turkey; ^2^Bezmialem Vakıf Üniversitesi, Pediatric Neurology, Fatih, Turkey*

**Background/Objectives**: 13‐cis retinoic asit (RA) is the agent used in the maintenance treatment of neuroblastoma. Case reports concerning the complications of the central nervous system (CNS) secondary to RA such as bleeding, cranial nerve palsy, or increased intracranial pressure are reported. Encephalopathy development as a result of RA is a very rare complication and this report presents a 3 years old neuroblastoma patient with the development of encephalopathy secondary to RA.

**Design/Methods**: A 3 yrs old boy who was diagnosed with neuroblastoma originating from right sided adrenal gland was under RA treatment since 3 months. The first three‐months period of RA treatment lasted without any complains. However, as the second three‐months set, the boy could not open his eyes and look around with his eyelids closed after 10 days of completion of RA. Sleepiness and unable to walk let the physicians obtained CNS magnetic resonance imaging which resulted normal findings. Viral serology, NSE and spot urine VMA levels, CSF cytopathology and chemistry results revealed no pathological conditions. Electroencephalography established encephalopathy development due to RA.

**Results**: The boy had no use of drugs other than RA. RA medication was stopped and the patient was in close follow‐up without any treatment. The sleepiness of the patient was reduced and the patient become more active around 20 days time. After 3 months time, neurological examination other than bilateral ptosis was within physiological limits.

**Conclusions**: RA treatment rarely causes central nervous system pathologies. Neuroblastoma metastasis and meningoencephalitis were ruled out and the only risk factor to be responsible was RA administration. The patient gradually becomes more active after stopping RA treatment.

### PO-330. Neonatal Suprarenal Masses: An Observational Approach {#pbc27455-sec-5590}

V. Papadakis^1^, M. Conte^2^, D. Plantaz^3^, V. Segura^4^, S. Ash^5^, B. Brichard^6^, R. Ladenstein^7^, V. Combaret^8^, A. Di Cataldo^9^, G. Schleiermacher^10^, K. Wheeler^11^, J. Bermúdez^12^, [A. Cañete]{.ul} ^4^

*^1^Aghia Sophia Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^2^Giannina Gaslini Children\'s Hospital, Department of Hematology‐Oncology, Genoa, Italy; ^3^Hôpital Michallon, Département de pédiatrie, Grenoble, France; ^4^University and Polytechnic la Fe Hospital, Pediatric Oncology Department, Valencia, Spain; ^5^Schneider Children\'s Medical Center, Hematology‐Oncology Department, Tel‐Aviv, Israel; ^6^Cliniques Universitaires Saint Luc, Hématologie et Oncologie Pédiatrique, Bruxelles, Belgium; ^7^Children\'s Cancer Research Institute/ St Anna Children\'s Hospital, Unit S2IRP Studies & Statistics for Integrated Research and Projects, Vienna, Austria; ^8^Centre Léon Bérard, Laboratoire de Recherche translationnelle, Lyon Cedex, France; ^9^University of Catania, Pediatric Hematology and Oncology, Catania, Italy; ^10^Institute Curie, Laboratoire de Génétique et Biologie des Cancer, Paris, France; ^11^Oxford Children\'s Hospital, Department of Paediatric Haematology and Oncology, Oxford, United Kingdom; ^12^University of Valencia, Department of Statistics, Valencia, Spain*

**Background/Objectives**: The differential diagnosis of neonatal suprarenal masses ranges from benign (adrenal haemorrhage) to malignant (neuroblastoma, adrenal carcinoma). The optimal management is not clearly defined. Neuroblastoma at this age is an intriguing entity, carrying very good prognosis in most cases. SIOPEN (International Society of Paediatric Oncology European Neuroblastoma), launched this study (Low‐Intermediate Risk Neuroblastoma Study, <http://www.ClinicalTrials.org>:NCT01728155). Primary aim was to maintain 3‐year EFS over 80%, with a non‐operative initial approach for infants with small localized suprarenal masses.

**Design/Methods**: A single multicenter prospective study of infants \<90 days with mass \<5cm, and no regional or metastatic involvement was undertaken. Initial work up included urinary catecholamines, imaging (US and/or MRI), MIGB scintigraphy and MYCN analysis in sera. Infants were monitored during the first year. If the mass increased in volume or/and catecholamine excretion increased, observation stopped and surgery was performed. If a mass persisted after 12 months, an excision of the mass was recommended.

**Results**: A cohort of 128 infants was registered: median age 3 days (range 0‐87), 38.6% female. Masses were described as cystic (29.1%), solid (34.2%) or mixed (32.9%). Antenatal diagnosis had been made in 55 cases. Thirty‐seven patients underwent resection: 17 during observation and 20 at the end of the observation period, 26 proved to be neuroblastoma. Two surgical complications included hemorrhage and renal ischemia, without fatality. MIGB was done to 70 patients and only 55 received thyroid protection despite protocol guidelines. The 1 and 3‐year EFS was 89.5% and 88% respectively and OS was 100%, with a median follow‐up of 30.4 months. Fifteen events were observed: progression to MS (n=5) or L1/L2 tumors (n=10).

**Conclusions**: An observational approach for infants with localized suprarenal masses \<5cm discovered antenatally or neonatally (suspected neuroblastoma) proved safe and most patients avoided surgery. Close monitoring was effective and did not jeopardize overall outcome.

### PO-331. Plasma Metabolomic Profiling Differentiates High‐ and Low‐Risk Neuroblastoma Patients {#pbc27455-sec-5600}

G. Quintás^1^, Y. Yáñez^2^, P. Gargallo^2^, I. Roche^2^, A. Juan^2^, [A. Cañete]{.ul} ^2^, V. Castel^2^, V. Segura^3^

*^1^Leitat Technological Center, Bio in vitro Division, Barcelona, Spain; ^2^Hospital Universitario y Politécnico La Fe, Pediatric Oncology, Valencia, Spain; ^3^University and Polytechnic la Fe Hospital, Pediatric Oncology, Valencia, Spain*

**Background/Objectives**: Neuroblastoma (NB) accounts for at least 15% of cancer‐related deaths in children. Although the current risk‐based treatment approaches in NB has resulted in improved outcome, there remains a need for new approaches to further stratify High‐risk patients, especially for those who do not respond to conventional therapies or relapse after treatment. This study evaluated the potential of metabolomics profiling for improving current risk‐based stratification system in Neuroblastoma.

**Design/Methods**: Plasma samples from 90 NB patients (52 Low‐risk and 38 High‐risk) were collected at diagnosis. Metabolomic analysis of plasma samples were carried out by ultra‐performance liquid chromatography‐mass spectrometry (UPLC‐MS). Pattern recognition and selection of discriminant metabolic features between groups was performed using supervised partial least squares‐discriminant analysis (PLS‐DA).

**Results**: Plasma metabolomic profiles differentiated Low and High‐risk patients at diagnosis. The validation set of the model correctly predicted 16 out of 19 High‐risk patients and 15 out of 16 Low‐risk patients resulting in a sensitivity of 79% and a specificity of 81.3%. In addition, plasma metabolomic profiling identified key differences at diagnosis between High risk patients with no evidence of disease immediately after treatment and those who progressed during or after treatment. The PLS‐DA model identified in the validation set, 5 out of 6 of subjects who were in complete remission at the end of treatment and 5 out of 5 of subjects who progressed during treatment.

**Conclusions**: The present study showed that metabolomics signatures are able to provide useful information on biomarkers to discriminate low‐risk from high‐risk patients and also distinguish between High‐risk patients with active disease from those in remission. This Omic if prospectively validated, could definitely contribute to refine stratification of High‐risk patients and also monitor response to treatment.

### PO-332. Local Control with Reduced‐Dose Radiation Therapy for High‐Risk Neuroblastoma: 3‐Year Results from a Prospective Trial {#pbc27455-sec-5610}

[D. Casey]{.ul} ^1^, B. Kushner^2^, N.K. Cheung^2^, S. Modak^2^, M. La Quaglia^3^, S. Wolden^1^

*^1^Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York City, USA; ^2^Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York City, USA; ^3^Memorial Sloan Kettering Cancer Center, Department of Surgery, New York City, USA*

**Background/Objectives**: For patients with high‐risk neuroblastoma (HR‐NB), a dose of 21 Gy to the primary tumor site after gross total resection (GTR) provides excellent local control. However, there has never been a clinical trial specifically evaluating the optimal dose of radiation therapy (RT), and recent reports have described an increased risk of late effects after treatment with 21 Gy. We sought to assess local control after a reduction in dose to the primary site from 21 Gy to 18 Gy.

**Design/Methods**: After induction chemotherapy and surgical resection, 25 patients with HR‐NB (ages 1.6‐9.5, median 4.3 years) were enrolled and treated on a RT dose‐reduction prospective trial. As per protocol, all patients underwent GTR followed by 18 Gy hyperfractioned RT with twice‐daily fractions of 1.5 Gy each. All patients also received anti‐GD2 monoclonal antibody as part of consolidative therapy.

**Results**: Of 25 patients, 24 (96%) had stage 4 NB, 8 (32%) had *MYCN*‐amplified disease, 11 (44%) were in complete remission (CR), and 14 (56%) had persistence of bone marrow involvement post‐induction. Three patients (12%) were treated with proton therapy, while the rest were treated with intensity‐modulated photon therapy. After a median follow‐up of 3.1 years from initiation of treatment, there were no local failures observed among the entire cohort. The 3‐year event‐free and overall survival for patients in first CR were 53.0% and 90.9% respectively. For those patients not in metastatic CR prior to RT, 3‐year event‐free and overall survival were 42.9% and 76.2%.

**Conclusions**: Reduced‐dose RT with 18 Gy does not compromise local control in patients with HR‐NB after GTR. The current cohort of patients on protocol are receiving 15 Gy. Given the young patient age and increase in incidence of late toxicities seen with improved survival, it is essential to find the optimal dose of RT that minimizes toxicity without compromising disease outcomes.

### PO-333. Central Nervous System Metastases in Neuroblastoma: Results of Turkish Pediatric Oncology Group Neuroblastoma 2009 (TPOG‐NB‐2009) Protocol {#pbc27455-sec-5620}

[E. Cecen]{.ul} ^1^, D. Ince^1^, B. Sevinir^2^, F.B. Cakir^3^, N. Kurucu^4^, E. Guler^5^, S. Vural^6^, Y. Koksal^7^, H. Oniz^8^, A. Oguz^9^, F. Sarialioglu^10^, N. Olgun^1^

*^1^Dokuz Eylul University Enstitute of Oncology, Department of Pediatric Oncology, Izmir, Turkey; ^2^Uludag University School of Medicine, Department of Pediatric Oncology, Bursa, Turkey; ^3^Bezmiâlem University School of Medicine, Department of Pediatric Oncology, Istanbul, Turkey; ^4^Hacettepe University School of Medicine, Department of Pediatric Oncology, Ankara, Turkey; ^5^Akdeniz University School of Medicine, Department of Pediatric Oncology, Antalya, Turkey; ^6^Sisli Hamidiye Etfal Training Hospital, Department of Pediatric Oncology, Istanbul, Turkey; ^7^Selcuklu University School of Medicine, Department of Pediatric Oncology, Konya, Turkey; ^8^Tepecik Training Hospital, Department of Pediatric Oncology, Izmir, Turkey; ^9^Gazi University School of Medicine, Department of Pediatric Oncology, Ankara, Turkey; ^10^Baskent University School of Medicine, Department of Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Neuroblastoma (NB) is the most common extracranial solid tumor in children and is widely metastatic at the time of diagnosis in about half of the patients. The frequency of central nervous system (CNS) metastases in NB is low. This study aimed to investigate the status of CNS metastases with neuroblastoma in Turkey.

**Design/Methods**: We undertook a review of CNS involvement due to recurrence or disease progression in the 251 children with Stage 4 neuroblastoma who were included the Turkish Pediatric Oncology Group Neuroblastoma 2009 (TPOG‐NB‐2009) Protocol of between June 1, 2009 and December 31, 2016.

**Results**: Eighty‐nine percent of 251 patients with Stage 4 disease were in the high‐risk group while others were in the intermediate‐risk group. Seventy‐nine high‐risk NB patients (31%) underwent CD34+ transplantation with myeloablative chemotherapy. Remaining patients were treated with conventional chemotherapy. Eighteen patients (7.2%) developed documented CNS disease as their site of recurrence or progression. Thirteen patients had isolated CNS recurrences, and the remaining patients developed recurrences concomitantly in other sites. None of them had CNS NB at the time of diagnosis. The median interval from the initial diagnosis to the involvement of CNS was 15 months. All patients died despite several rescue treatments.

**Conclusions**: CNS recurrence in NB is rare and fatal. Multicenter studies with sufficient numbers of patients aming to improve the novel therapeutic management of these patients are needed.

### PO-334. NF‐κB Activated Protein Regulates Neuronal Differentiation and Promotes Apoptosis in Neuroblastoma {#pbc27455-sec-5630}

[H.H. Chang]{.ul} ^1^, W.M. Hsu^2^, M.C. Huang^3^, Y.F. Liao^4^, H. Lee^5^, H.F. Juan^5^, K.H. Lin^1^, D.T. Lin^1^

*^1^National Taiwan University Hospital, Pediatrics, Taipei, Taiwan R.O.C.; ^2^National Taiwan University Hospital, Surgery, Taipei, Taiwan R.O.C.; ^3^National Taiwan University College of Medicine, Institute of Anatomy and Cell Biology, Taipei, Taiwan R.O.C.; ^4^Academia Sinica, Institute of Cellular and Organismic Biology, Taipei, Taiwan R.O.C.; ^5^National Taiwan University, Department of Life Science, Taipei, Taiwan R.O.C*.

**Background/Objectives**: Our previous study revealed NF‐κB activated protein (NKAP) expression correlates with the differentiation of neuroblastoma (NB) and predicts a favorable prognosis for patients with NB. However, the underlying mechanisms by which NKAP regulate the tumorigenesis of NB is unclear.

**Design/Methods**: Oligonucleotide microarray experiments (Agilent system) of 28 primary NB tumors were conducted. Those genes whose expression had similarity (correlation coefficient≧0.7) to NKAP expression in microarray data were selected and mapped to related pathways analysis. The in vitro validated experiments were conducted by retinoid acid (RA)‐induced NB cells differentiation.

**Results**: Thirty‐four genes were found to have similarity in gene expression to NKAP from microarray data. Of which, 18 genes were positively and 16 genes were negatively correlated to NKAP gene expression. Seven pathways were mapped to be related to NKAP gene expression in above genes. We then validated above results with in vitro study by quantitative real‐time PCR. NB cell line, SH‐SY5Y, was treated with RA for 3 days. The mRNA levels of STX6, PRPS1L1, PARN, and OGG1, along with NKAP, were increased in RA‐treated cells. The increases were most significant at day 1 and day 3 of RA treatment. In the parallel controls, the neuronal differentiation markers, GAP43 and NSE, are consistently up‐regulated in RA‐treated cells. When we used lentivirus infection protocol to deliver NKAP into SH‐SY5Y cells, NKAP promoted neuronal differentiation (increased GAP43 expression) of SH‐SY5Y cells that can be further augmented by RA treating in 1 day. In addition, the GAP43 level in NKAP‐infected SH‐SY5Y cells returned to the basal level comparable to mock‐infected control after 2 days, concomitant with an increase in active caspase 3 (cleaved caspase 3).

**Conclusions**: NKAP can speed up the neuronal differentiation of NB cells and promote the differentiated NB cells to undergo apoptosis.

### PO-335. CPEB1 Functions as a Tumor Suppressor by Translational Regulation on MYCN in Neuroblastoma {#pbc27455-sec-5640}

[Y. Chen]{.ul} ^1^, Y.H. Tsai^1^

*^1^Far Eastern Memorial Hospital, Division of Pediatric Surgery‐ Department of Surgery, Banciao‐ New Taipei City, Taiwan R.O.C*.

**Background/Objectives**: Neuroblastoma is one of the most common extracranial malignancy in early childhood, and the prognosis of the patients is still away from satisfying. Finding novel biomarkers and therapeutics for neuroblastoma has been an important task. CPEB1 (cytoplasmic polyadenylation element binding protein‐1) is a RNA binding protein involved in the translational regulation of cytoplasmic polyadenylation element (CPE)‐containing mRNAs. Recently, the expression levels of CPEB1 are found to be decreased in several cancer types; however, there is no CPEB1‐related report in neuroblastomas. Therefore, we aimed to explore the possible role of CPEB1 in human neuroblastoma cells.

**Design/Methods**: Human neuroblastoma cells were used to study the function of CPEB1. The effect of CPEB1 over‐expression on the cell viability was verified by MTT assay and AnnexinV/ PI staining. The molecular mechanism for the tumor suppression was further examined by RNA‐IP, real‐time PCR, luciferase reporter assay, and site‐directed mutagenesis.

**Results**: By western blot analysis, we found the level of endogenous CPEB1 protein very low in the neuroblastoma cells. Ectopic expression of CPEB1 significantly decreased the viabilities of SH‐SY5Y cells (36.2%) and BE(2)‐M17 cells (23.5%). A panel analysis of oncogene levels showed down‐regulation of MYCN and other oncogenes in CPEB1‐expressing cells. By RNA‐IP, we found the association between CPEB1 protein and the mRNA of MYCN. Sequence analysis revealed that there is a CPE sequence in the 3'‐UTR region of the mRNA of MYCN. Insertion of this MYCN mRNA‐derived CPE sequence into the 3′‐UTR of luciferase gene significantly down‐regulated luciferase activity in the context of CPEB1 expression. Furthermore, mutated MYCN mRNA‐derived CPE that no longer associated with CPEB1 rescued CPEB1‐induced inhibition on luciferase activity.

**Conclusions**: CPEB1 exerts strong tumor‐suppressing effect in human neuroblastoma cells, through the CPE‐mediated inhibition on the expression of MYCN. CPEB1 activation or induction would be a potential approach as finding novel therapeutics for neuroblastomas.

### PO-336. ARID1A‐SIN3A is Required for Transcriptional Repression of TERT upon Retinoic Acid‐Induced Neuroblastoma Differentiation {#pbc27455-sec-5650}

[B. Chi Bao]{.ul} ^1^, V. My^2^, C. Allimalima^3^, T. Quang Dinh^4^

*^1^University of medicine and pharmacy at HCMC, Centre for molecular biomedicine, Hochiminh, Vietnam; ^2^Molecular Medicine Group‐ Area Science Park, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy; ^3^Angkor Hospital for Children, Oncology, Siem Reap, Cambodia; ^4^City Children Hospital, Surgery, Hochiminh, Vietnam*

**Background/Objectives**: High‐risk neuroblastoma (NB) associates with and rearrangement of hTERT, but the molecular regulation of hTERT remains poorly understood.

**Design/Methods**: Here based on our NB cohort (N = 88) and other public database, the ChIP analysis and luciferase assay was performed to determine how AT‐Rich Interaction Domain 1A (ARID1A), a subunit of SWI/SNF chromatin remodelers, directly occupies within hTERT proximal promoter region.

**Results**: We showed the occupancy of ARID1A and SIN3A under the 13‐cis retinoic acid (RA) induced differentiation in NB cell lines. We further demonstrate that ARID1A is essential for the recruitment of SIN3A complex to suppress telomerase activity and expression upon 13‐cis Retinoic acid‐induced differentiation. This mechanism is inhibited when inactivated ARID1A by its truncated‐ARID domain and siRNA targeted silencing. Moreover, mutation in ‐124C\>T in hTERT promoter enhances the ARID1A‐ bound by *in vitro* luciferase activities. Finally, our NB cohorts show that lost or low expression of ARID1A is relatively linked to elevated expression of TERT, an eminent feature of aggressive NB.

**Conclusions**: These results indicate ARID1A plays a tumor suppressive role for TERT expression by recruiting SIN3A complex via its modifying chromatin access.

### PO-337. Allogeneic Stem Cell Transplantation for High‐Risk Neuroblastoma Patients {#pbc27455-sec-5660}

[W. Choeyprasert]{.ul} ^1^, S. Hongeng^2^, S. Pakakasama^2^, U. Anurathapan^2^

*^1^Vejthani Hospital, Pediatrics, Bangkok, Thailand; ^2^Ramathibodi Hospital‐ Mahidol University, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: High‐risk neuroblastoma (NBL) has a very poor outcome with a high rate of recurrence despite intensive therapies including chemotherapy, surgery, radiotherapy and autologous stem cell transplantation (auto‐SCT). In previous studies, allogeneic stem cell transplant (allo‐SCT) has not shown any advantage compared to auto‐SCT.

Objectives: This study aims to explore the feasibility and outcomes of allo‐SCT with pre‐transplant ^131^I‐MIBG (meta‐iodobenzylguanidine) treatment in high risk NBL patients.

**Design/Methods**: Children diagnosed with high risk NBL who underwent allo‐HSCT from 2011 to 2017 at Ramathibodi Hospital, Mahidol University were retrospectively analyzed.

**Results**: A total of 18 patients (male 8, female 10) who underwent haploidentical SCT (Haplo; n=11) and match‐related allo‐SCT (MRD; n=7) were enrolled with a median age of 5.04 years (range, 2.0‐9.42 years) at transplant. Three of 18 patients had recurrent diseases. All patients received pre‐transplant 131I‐MIBG treatment with a median dose of 315 mCi (range, 150‐630 mCi). The conditioning regimens for MRD comprised fludarabine + busulfan (n=2), fludarabine + busulfan + anti‐thymocyte globulin (ATG) (n=2), busulfan + melphalan (n=2) and busulfan + melphalan + ATG (n=1) and for haplo‐SCT comprised busulfan + melphalan (n=6) and busulfan + melphalan + ATG (n=5). For haplo group, all patients also received cyclophosphamide post‐transplantation for GVHD prophylaxis. Patients received a median of 10.47 x 106/kg CD34+ stem cells. During a median follow‐up of 44 months (range, 13‐123 months), 3‐year event‐free and overall survival rates were 66.7 ± 12.4% regardless of donor types. Seven patients died of relapsed disease (n=2), bronchiolitis obliterans (n=2), veno‐occlusive disease (n=1) and encephalopathy (n=1). Patients with complete remission (CR) at transplant tended to have lower relapse rate and better DFS and OS compared to those not in CR.

**Conclusions**: This study showed the feasibility and favorable outcome of allo‐SCT with 131I‐MIBG for high risk NBL patients.

### PO-338. Excellent Treatment Outcomes in Children Younger than 18 Months with Stage 4 MYCN Non‐Amplified Neuroblastoma {#pbc27455-sec-5670}

K. Chiwoo^1^, [Y.B. Choi]{.ul} ^2^, L. Ji Won^1^, Y. Keon Hee^1^, J. Hye Lim^3^, S. Ki Woong^1^, K. Hong Hoe^1^

*^1^Samsung Medical Center‐ Sungkyunkwan University School of Medicine, Pediatrics, Seoul, Republic of Korea; ^2^Chungbuk National University Hospital, Pediatrics, Cheongju, Republic of Korea; ^3^Sungkyunkwan University School of Medicine‐ Kangbuk Samsung Hospital, Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: Although the prognosis is generally good in patients with intermediate‐risk neuroblastoma, no consensus has been reached on the ideal treatment regimen. This study analyzed treatment outcomes and toxicities in patients younger than 18 months with stage 4 *MYCN* non‐amplified neuroblastoma.

**Design/Methods**: We retrospectively analyzed 20 patients younger than 18 months newly diagnosed with stage 4 *MYCN* non‐amplified neuroblastoma between January 2009 and December 2015. Patients received 9 cycles of chemotherapy and surgery, with or without local radiotherapy, followed by 12 cycles of differentiation therapy with 13‐cis‐retinoic acid. Chemotherapy consisted of alternating cycles of CEDC (cisplatin, etoposide, doxorubicin, and cyclophosphamide) and ICE (ifosfamide, carboplatin, and etoposide) regimens.

**Results**: The most common primary tumor site was the abdomen (85%), and the most common metastatic sites were the lymph nodes (65%), followed by the bones (60%), liver (55%), skin (45%), and bone marrow (25%). At the end of induction therapy, 14 (70%) patients achieved complete response, with 1 achieving very good partial response, 4 achieving partial response, and 1 showing mixed response. Nine (45%) patients received local radiotherapy. At a median follow‐up of 47 months (range 17--91 months), none of these patients experienced relapse, progression, or secondary malignancy, or died. Three years after chemotherapy completion, none of the patients had experienced grade ≥3 late adverse effects.

**Conclusions**: Patients younger than 18 months with stage 4 *MYCN* non‐amplified neuroblastoma showed excellent outcomes, without significant late adverse effects, when treated with alternating cycles of CEDC and ICE, followed by surgery and differentiation therapy.

### PO-339. MLN8237 Induces Cellular Senescence of Neuroblastoma Cells Through the P53/P21 Signaling Pathway {#pbc27455-sec-5680}

A. Liu^1^, [L. Ding]{.ul} ^1^, Q. Hu^1^, Y. Yang^2^, J. Sun^1^, A. Zhang^1^, Y. Wang^1^, D. Nie^1^, Y. Hu^1^

*^1^Tongji Hospital‐Tongji Medical College‐ Huazhong University of Science & Technology, Department of Pediatrics, Wuhan, China; ^2^Tongji Hospital‐Tongji Medical College‐ Huazhong University of Science & Technology, Department of Experimental MedicineCenter, Wuhan, China*

**Background/Objectives**: The over‐expression of Aurora kinase A (AURKA) is correlated with the prognosis of NB. While, MLN8237, a small molecule AURKA targeting inhibitor, can suppress the activity of AURKA. This research was to explore the effect and mechanism of MLN8237 on NB, and to study the adverse effects of MLN8237 in this process.

**Design/Methods**: We applied western blot, SA‐β‐gal staining, cell cycle and apoptosis analysis, siRNA transfection, immunofluorescence and immunohistochemistry to explore the effect of MLN8237 on NB treatment and the possible underlying mechanisms.

**Results**: 1. In neuroblastoma IMR32 cells, small molecule inhibitor MLN8237 can induce cell cycle arrest at G2/M and cell senescence. Besides, the expression of P21 and P53 were significantly increased with MLN8237 while no significant changes were found in the expression of P16, P27, PTEN and other related proteins. 2. In the NB nude mice xenografts model, we can see that MLN8237 can induce neuroblastoma cells senescence, inhibit tumor growth and prolong the lifetime of the mice with neuroblastoma. 3.MLN8237 could significantly increase the protein expression of AURKA in the NB cell lines of IMR32, SK‐N‐BE2, LAN‐1 and SK‐N‐SH. Morever, immunohistochemistry of tumor tissues from NB nude mice showed that the expression of total AURKA in the MLN8237 treatment group was also up‐regulated. 4.The IMR32 cells were co‐treated with MLN8237 and AURKA small interfering RNA (siAURKA). Compared with the cells treated with MLN8237 alone, the combined group exhibited a synergistic effect on NB treatment.

**Conclusions**: MLN8237 could induce cellular senescence of NB cells through the P53/P21 signaling pathway. In addition, MLN8237 might increase the expression of total AURKA while inhibiting AURKA phosphorylation. However, the combined treatment of MLN8237 and siAURKA transfection exhibited a synergistic effect on NB treatment.

### PO-340. Expression Signature Developed on Consensus Gene List Predicts Outcome in Patients with Neuroblastoma Independently from Clinical Risk Group {#pbc27455-sec-5690}

[A. Druy]{.ul} ^1^, L. Yasko^2^, Y. Olshanskaya^3^, T. Shamanskaya^4^, D. Kachanov^4^, S. Varfolomeeva^5^, A. Rumyantsev^6^

*^1^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology / Research Institute of Medical Cell Technologies, Laboratory of cytogenetics and molecular genetics‐ Molecular oncology group, Moscow / Yekaterinburg, Russia; ^2^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Laboratory of molecular biology‐ Molecular oncology group, Moscow, Russia; ^3^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Laboratory of cytogenetics and molecular genetics, Moscow, Russia; ^4^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Department of clinical oncology, Moscow, Russia; ^5^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Institute of translational medicine, Moscow, Russia; ^6^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Directorate, Moscow, Russia*

**Background/Objectives**: Clinical heterogeneity, which is a hallmark of neuroblastoma, depends on the inequalities in gene expression profile. Different multigene signatures were developed to define prognosis in neuroblastoma patients.

**Design/Methods**: The consensus gene expression panel including 42 genes presented in at least 2 of 4 international classifiers was created by K. De Preter and demonstrated prognostic significance by *in silico* analysis. In the current study expression of these genes was measured by Nanostring in 36 primary and 3 relapse neuroblastoma samples. 22 patients belonged to observation or intermediate risk groups upon to NB2004 protocol criteria, 17 -- to the high‐risk group. Prognostic significance was determined by event‐free survival (EFS) calculation with median of follow‐up time 34 months.

**Results**: In high‐risk patients gain of unfavorable genes expression perfectly predicts outcome (EFS 0.40SE0.22) compared to 0.92SE0.08 in favorable expression group, where one toxic death was the only adverse event (p=0.025). In low and intermediate risk groups gain of *TYMS, CDCA5, BIRC5, MCM2* and *CDKN3* expression was strongly associated with adverse events: EFS 0.09SE0.09 vs. 1.00, p\<0.001, while other unfavorable genes were less significant. In the total cohort of patients expression of *SLC25A5, SNAPC1* and *NCAN* slightly correlated with clinical risk group and did not predict outcome. In contrast, unfavorable signature of 5 genes described above defined dismal prognosis (EFS 0.24SE0.10) while gain of *WSB1, FYN, DPYSL3, EPN2, ULK2, PTPRN2, NTRK1, CAMTA2* and *CLSTN1* expression oppositely ensured against adverse event (EFS 1.00) both independently from clinical risk group, p\<0.001. Enhanced expression of *PAICS, MRPL3, AHCY, MYCN, ODC1, NME1* demonstrated poor prognostic significance only in high‐risk patients. In relapsed patients favorable gene expression signature predicts good secondary EFS also independently from risk group.

**Conclusions**: Consensus gene expression signature created by merging of several classifiers provides robust and clinically relevant prognostic information regardless of conventional risk grouping.

### PO-341. Outcome and Prognostic Factors of High Risk Neuroblastoma at National Cancer Institute, Egypt {#pbc27455-sec-5700}

[A. elhemaly]{.ul} ^1^, M. fawzy^2^, A. fattahallah^3^, M. elhusseny^4^

*^1^national cancer institute‐cairo university and children cancer hospital of egypy, pediatric oncology, cairo, Egypt; ^2^national cancer institute egypt‐ children cancer hospital of egypt, paediatric oncology, cairo, Egypt; ^3^national cancer institute, surgical oncology, cairo, Egypt; ^4^national cancer institute‐ children cancer hospital of egypt, paediatric oncology, cairo, Egypt*

**Background/Objectives**: Children with high‐risk neuroblastoma have poor outcome. There was progress in treatment using myeloablative chemotherapy and radiotherapy plus purged ABMT with significant difference in 3‐year event free survival (EFS) compared with conventional chemotherapy (CC), although overall survival (OS) was not significantly different.

this work aims To find out(OS) and (EFS) of high risk neuroblastoma patients

**Design/Methods**: Retrospective study at the National Cancer Institute, Egypt including 133 patients from 1/01/2008 to 31/12/2015.

**Results**: All patients received induction chemotherapy VP16/CARBO, CADO (6 to 8 cycles), two died from septic shock. Two were in CR, 15 patients were in VGPR, 82 were in PR, 23 had NR& 9 had PD.3 years OS for (CR, VGPR& PR) group was (51.7%) compared with (19%) (NR& PD) group with (P\<0.001). 71 patients needs salvage (ICE), 9 died from septic shock and 13 showed CR, VGPR in 11, PR in 5, 33 patients had progressive disease HSCT was done in 49 patients. Patients who received HSCT showed better 3 years overall survival (66.5%) than who did not (24.4%) with (P\<0.001). median OS was 22.3 months while median EFS was 12.4 months. primary site mediastinum have better 3 years overall survival (71.4%) than abdominal (34.5%, 51.9%)with P=0.022, There was no statistically significant impact of different metastatic sites on the overall survival except liver metastasis that showed inferior 3 years overall survival (12.5%) compared with those without (41.4%) with P =0.003; MYCN amplification showed inferior 3 years overall survival (35.9%) compared with non‐amplified MYCN (40.4%) with P=0.900, At end of treatment, 16 were dead as treatment complication, 26 were in CR, 10 were in VGPR, 6 were in PR and 75 patients had PD.

**Conclusions**: High risk Neuroblastoma still having poor outcome, more insights should be done to tandem transplant and immune therapy to improve outcome

### PO-342. Neuroblastoma in Over Age of 5 Years {#pbc27455-sec-5710}

[J. Elhoudzi]{.ul} ^1^, N. baddouh^2^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco; ^2^University hospital Mohammed Vi, Pediatric hematology and oncology, Marrakesh, Morocco*

**Background/Objectives**: Neuroblastoma (NB) occurs rarely over age of 5 years old, and information is scarce on its characteristics and clinical course in this age group.

To show clinical features and outcomes of neuroblastoma (NB) children aged more 5 years, and to provide a theoretical basis for improving prognosis.

**Design/Methods**: A retrospective analysis was performed for the clinical data of 8 previously untreated NB children, and their clinical features and outcome were analyzed since 2011 till 2017

**Results**: 8 cases, representing 12.1 % of all neuroblastomas in our center. Average age was 7.1 years. Male predominance and adrenal location were frequent. Clinically 5 patients were admitted with poor status and abdominal pain. In 5 cases an abdominal mass was found. There was a predominance of advanced stages, 7 patients had metastases at diagnosis. Bone metastases were the most frequent, followed by bone marrow and in 6 patients multiple sittes. MIBG was positive in 5/8 patients (62%); Ferritinemia and LDH were eleveted in 7 cases, and catecholamines in 5 cases. Histologically one case corresponded to poorly differentiated and one to differentiated NB. Moreover, 6 tumours were considered undifferentiated. Seven cases were stage IV except one stage III. NMYC was not done. Partial primary resection of the tumor was possible for one patient. Chemotherapy was done according to Moroccan protocol. Four of seven patients undergoing chemotherapy required the palliative treatment for progression of the mass and / or metastases, without the possibility of a surgical cure. Death rate in our series was 50%. One patient died during the first course and 3 after 2 years of metronomic protocol. Other patients are still under treatment.

**Conclusions**: At age after 5years, neuroblastoma is associated with a poor prognosis. High dose chemotherapy does not seem to be useful, hence the need for new therapeutic approaches in this age group.

### PO-343. Autologous and Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience {#pbc27455-sec-5720}

[F. Erbey]{.ul} ^1^, D. Atay^1^, A. Akçay^1^, A. Akmuradova^1^, F. Seferkolli^1^, G. Öztürk^1^

*^1^Acıbadem University Scholl of Medicine, Pediatric Hematology/Oncology & BMT Unit, İstanbul, Turkey*

**Background/Objectives**: In recent years, the conditioning regimens were given before hematopoietic stem cell transplantation (HSCT) have been compared in terms of efficacy and toxicity in large studies, in neuroblastoma cases. On the other hand, the experience of allogeneic HSCT in neuroblastoma is increasing. For this reason, we aim to share our clinics experience about autologous and allogeneic HSCT in neuroblastoma.

**Design/Methods**: Eighteen neuroblastoma patients who underwent autologous (16 cases) or allogeneic (2 cases) HSCT between May 2011 and March 2018 were included in this study. Pre‐transplant disease status, conditioning regimen, post‐transplant complications, recurrence and recent status were recorded. Event‐free survival (EFS) and overall survival (OS) were calculated.

**Results**: Ten patients were male and 8 patients were girl. The mean age at diagnosis was 4,3 years. Sixteen cases were metastatic at diagnosis. Ten cases were relapsed or refractory before transplantation. There was complete remission in 12 cases, very good partial response in 5 cases and partial response in 1 case before transplantation.

Sixteen patients with autologous transplant received 12 of them as a conditioning regimen of Carboplatin, Etoposide, Melphalan (CEM), 4 of them Busulfan, Melphalan (BuMel).

Two patients with allogeneic transplant received treosulfan based conditioning regimen. In the first patient, HLA‐matched unrelated donor, in the second patients, HLA‐matched sibling donor were used.

Engraftment occurred in all patients. The most common toxicity was mucositis, esophagitis. There was no significant difference between BuMel and CEM conditioning regimens in toxicity, infections, post‐transplant recurrence, transplant‐related mortality, EFS, and OS.

The mean follow‐up period after transplantation was 38 months. Recurrence developed after transplantation in seven patients. Six (33.3%) patients died. Transplant‐related mortality was 11%. The 6‐year EFS and OS were 50% and 66.7%, respectively.

**Conclusions**: Both conditioning regimens were found to be effective, feasible and acceptable adverse‐ effect profiles. More data are needed in order to be able to ripen allogeneic transplant outcomes.

### PO-344. Anemia and Iron Deficiency in Children with Neuroblastoma at Initial Diagnosis {#pbc27455-sec-5730}

[H. Fan]{.ul} ^1^, C. Duan^1^, Q. Zhao^1^, W. Zhao^1^, X. Wang^1^, S. Zhu^1^, G. Li^1^, X. Zhang^1^, M. Jin^1^, Y. Su^1^, X. Ma^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Hematology Oncology Center, Beijing, China*

**Background/Objectives**: The aim of the present study was to investigate the prevalence of anemia and iron deficiency in newly diagnosed neuroblastoma patients.

**Design/Methods**: The clinical characteristics were retrospectively collected for newly diagnosed neuroblastoma patients in our center between Dec, 2015 to Jan, 2018. Iron deficiency was defined according to NCCN Guidelines for Cancer‐ and Chemotherapy‐Induced Anemia (Version 2.2018).

**Results**: There were 100 (51.3%) male, 31 (15.9%) under 18 months old, 136 (69.8%) originating in abdomen, 120 (61.5%) high‐risk neuroblastoma (HR‐NB) and 94 (48.2%) with bone marrow metastasis in the all 195 patients according to the inclusion criterions. Anemia was observed in 128 (65.6%) of 195 patients and significantly more likely to occur in patients with tumor origin in abdomen, HR‐NB and bone marrow metastasis (*p*\<0.05). The mean values of MCH, total iron binding capacity and serum iron were 24.9 pg, 48.5 μmol/L and 8.4 μmol/L in the anemia group, which were significantly lower than no anemia group (*p*\<0.05). Absolute iron deficiency (AID), functional iron deficiency (FID), possible functional iron deficiency and no iron deficiency occurred in 14 (10.9%), 75 (58.6%), 22 (17.2%) and 17 (13.3%) of the 128 anemia patients. AID and FID were more likely to happen in patients with age under 18 months, tumor origin in abdomen, HR‐NB and bone marrow metastasis (*p*\<0.05). Hemoglobin was significantly higher in AID and FID group (97.2 and 94.4 g/L) than no iron deficiency group (81.9 g/L), while serum ferritin lower in AID and FID group (19.3 and 194.4 ng/ml) than no iron deficiency group (1195.85 ng/ml) (*p*\<0.05).

**Conclusions**: In neuroblastoma patients, there was a high prevalence of anemia and iron deficiency at initial diagnosis. Iron deficiency was more likely to happen in patients under 18 months old. Long‐term effect of iron supplementation in different types of iron deficiency is need to be studied.

### PO-345. Bilateral Suprarenal Neuroblastoma {#pbc27455-sec-5740}

[M. Fawzy]{.ul} ^1^, Y. Gobrial^2^, S. Elmenawi^3^, N. Elkinaai^4^, A. Refaat^5^, M. Amr^6^, F. Said^7^, G. Taha^8^

*^1^Children\'s Cancer Hospital of Egypt and National Cancer Institute, Pediatric oncology, Cairo, Egypt; ^2^Children\'s Cancer Hospital of Egypt, Pediatric oncology, Cairo, Egypt; ^3^Children\'s Cancer Hospital of Egypt, clinical Research, Cairo, Egypt; ^4^Children\'s Cancer Hospital of Egypt, Pathology, Cairo, Egypt; ^5^Children\'s Cancer Hospital of Egypt, Radiology, Cairo, Egypt; ^6^Children\'s Cancer Hospital of Egypt, Nuclear Medicine, Cairo, Egypt; ^7^Children\'s Cancer Hospital of Egypt, Clinical Pathology, Cairo, Egypt; ^8^Children\'s Cancer Hospital of Egypt, Surgical oncology, Cairo, Egypt*

**Background/Objectives**: Bilateral suprarenal Neuroblastoma (BSN) is a rare presentation; it could occur on both sides simultaneously or metachronously, which is less common. Few previously published literature showed patients with BSN to have more favorable biological features and prognosis. This study aim was to evaluate clinical, biological features and outcome of patients with BSN treated at the Children Cancer Hospital‐ Egypt (CCHE).

**Design/Methods**: This retrospective study included patients with BSN presenting to CCHE from 2007 to 2017. A pre‐treatment biopsy of the primary tumor was mandatory. Confirmation by PET‐CT/MIBG was done, if available at time of presentation. Clinical variables including age and INSS stage were used in association with biological features (INPC and MYCN) in determining patients' risk group.

**Results**: Study included 33 patients with BSN (2% of CCHE patients with Neuroblastoma during this period) of 17 males and 16 females; 24 were less than 1 year old and 9 were above 1 year of age (range: 1 month to 3 years). Metachronous disease was present in 1. Ten patients had amplified MYCN, 18 were not amplified and 5 were not done. At diagnosis, most patients had metastatic disease (20/25 stage 4, 5/25 stage 4s), 6 were stage 3 and 2 patients stage 2. Fifteen were treated as high risk (HR), 15 as intermediate risk (IR), 2 as low risk (LR) and 1 was undetermined, due to inadequate tissue biopsy. Total number of deaths were 13 (39%). 3‐year overall survival of HR and IR patients were 37.8% and 78.3%, respectively, event‐free survival was 21.7% for HR and 52.9% for IR patients.

**Conclusions**: Compared to our results for patients with unilateral adrenal disease (of similar stage and risk), patients with bilateral suprarenal neuroblastoma had more worse outcome showing poorer biological features and more advanced disease and consequently, poorer outcomes than previously reported in literature as well.

### PO-346. Survival Outcome of Intermediate Risk Neuroblastoa at Children\'s Cancer Hospital of Egypt {#pbc27455-sec-5750}

[M. Fawzy]{.ul} ^1^, H. Elzomor^1^, G. Ahmed^2^, S. Elmenawi^3^, N. Elkinaai^4^, A. Refaat^5^, S. Soliman^3^, M. Amr^6^, M. Zaghloul^7^

*^1^Children\'s Cancer Hospital of Egypt and National Cancer Institute, Pediatric oncology, Cairo, Egypt; ^2^Children\'s Cancer Hospital of Egypt, Surgical oncology, Cairo, Egypt; ^3^Children\'s Cancer Hospital of Egypt, Clinical Research, Cairo, Egypt; ^4^Children\'s Cancer Hospital of Egypt, Pathology, Cairo, Egypt; ^5^Children\'s Cancer Hospital of Egypt, Radiology, Cairo, Egypt; ^6^Children\'s Cancer Hospital of Egypt, Nuclear Medicine, Cairo, Egypt; ^7^Children\'s Cancer Hospital of Egypt, Radiotherapy, Cairo, Egypt*

**Background/Objectives**: Neuroblastoma is remarkable for its broad spectrum of clinical behavior, ranging from spontaneous regression to inevitable progression and death. Survival of patients with neuroblastoma (NBL) have been markedly improved after development of risk stratification system that favored multimodality tailored treatment.

The present study aimed to evaluate survival outcome in newly diagnosed pediatric intermediate risk patients with NBL treated at the Children Cancer Hospital‐Egypt (CCHE) and their relation to various clinical and pathological factors.

**Design/Methods**: Study included patients \<1.5 years with stage 3 NBL, stage 3 disease above 1.5 years and favorable histopathological features, infants \<1 year with stage 4 disease, stage 4 disease in children 1 to 1.5 years and favorable biology, and infants with stage 4s and unfavorable biological features. Patients received systemic chemotherapy, in the form of etoposide and carboplatin alternating with cyclophosphamide, doxorubicin and vincristine, administered at 3‐week intervals, with a total of 6 or 8 cycles targeting objective response (complete/very good partial/partial response) as end point.

**Results**: Study included 136 patients; 67 males and 69 females. Abdominal primary tumor was present in 101/136 patients, 28/136 had mediastinal mass and 7/136 with mass in the neck. Among all patients, 68% were stage 3 and the remaining (n=44) had metastatic disease.

Three‐year overall and event‐free survival were 94%±2% and 90.9%±2.5%, respectively. Gender, age and pathology were all statistically not significantly different by either overall or event free survival. Overall survival was not significantly different by surgery versus no surgery (inoperable residual) was statistically, (98.4%±1.6% & 88.7%±5.3%, p=0.034).

**Conclusions**: Very high rate of survival is currently achievable in patients with intermediate risk neuroblastoma by chemotherapy or chemotherapy and surgery, biology‐based treatment to reduce treatment‐induced complications and late effects among survivors is highly recommended.

### PO-347. Clinical Characteristics and Treatment Outcomes of Children with Neuroblastoma in Central America: Results of the AHOPCA NB‐2012 Protocol {#pbc27455-sec-5760}

[S. Fuentes‐Alabi]{.ul} ^1^, R. Vasquez Zelaya^1^, C. Arambu Elvir^2^, P. Calderon Sotelo^3^, R. Rosado^4^, K. Quintero Delgado^5^, M. Montero Diaz^6^, K. Braga Ribeiro^7^, C. Rodriguez‐Galindo^8^

*^1^National Children Hospital Benjamin Bloom, Pediatric Hemato‐oncology, San Salvador, El Salvador; ^2^Hospital Escuela Universitario, Pediatric Hemato‐oncology, Tegucigalpa, Honduras; ^3^Hospital Infantil Manuel de Jesus Rivera La Mascota, Pediatric Hemato‐Oncology, Managua, Nicaragua; ^4^Unidad de Oncologia Pediatrica UNOP, Pediatric Hemato‐Oncology, Guatemala City, Guatemala; ^5^Hospital del Niño"Dr. José Renán Esquivel", Pediatric Hemato‐Oncology, Panama, Panama; ^6^Hospital Infantil Dr. Robert Reid Cabral, Pediatric Hemato‐Oncology, Santo Domingo, Dominican Republic; ^7^Santa Casa Medicine School‐ São Paulo, Social Medicine, São Paulo, Brazil; ^8^St. Jude Children\'s Research Hospital, Global Medicine Department, Memphis‐ Tennessee, USA*

**Background/Objectives**: Risk assignment and treatment are major challenges to successful outcomes for children with neuroblastoma (NB) in Central America (CA). This prospective study aimed to implement a resource‐ and risk‐adapted protocol.

**Design/Methods**: AHOPCA NB‐2012 enrolled patients \< 18 years old from January 2012 to December 2016 in El Salvador (39), Guatemala (35), Nicaragua (34), Dominican Republic (25), Panama (12), and Honduras (33). Using the International Neuroblastoma Staging System (INSS), age, and histopathological features, patients were stratified for treatment in low, intermediate, and high‐risk groups, and received a risk‐adapted chemotherapy regimen available in the region, surgery, and radiotherapy. Event‐free Survival (EFS) and Overall Survival (OS) were estimated using Kaplan‐Meier method, and the log‐rank test was employed to compare survival curves. For all statistical analyses, an alpha error=5% was used.

**Results**: Children evaluable were 159 (59% males). Mean age at diagnosis was 2.9 years (sd=2.9). The majority of patients presented with advanced disease (stages 3 and 4 = 75.5%) and 106 children (66.7%) were classified as high‐risk. Abandonment was observed in 4.4% of the patients. Overall, two‐year EFS and OS were 43.3% and 59.1%, respectively. Risk classification significantly correlated with outcomes; the 2y EFS and OS estimates for low, intermediate, and high risk groups were 80.2% and 91.7%; 72.5% and 87.9; and 30.7% and 46.4%, respectively (p\<0.001). Histology also affected 2y‐EFS (Favorable=90%, Unfavorable=36.2%, p=0.009).

**Conclusions**: AHOPCA NB‐2012 successfully implemented a regional resource‐adapted and risk‐stratified protocol for neuroblastoma and was able to achieve high cure rates for patients with low and intermediate risk. Additional capacity building is necessary to optimize diagnosis and risk assignment and to better inform resource allocation.

### PO-348. Survival Outcome of Neuroblastoma: Two Decades of Experience in a Tertiary Referral Centre {#pbc27455-sec-5770}

[C.H. Fung]{.ul} ^1^, F. Yeung^1^, I.H.Y. Chan^1^, K.K.Y. Wong^1^, P.K.H. Tam^1^

*^1^Queen Mary Hospital, Division of Paediatric Surgery‐ Department of Surgery, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Neuroblastoma is the most common pediatric extracranial solid tumor and accounts for 10‐15% of pediatric malignancy‐related mortality. The study aims to evaluate the survival outcome of children with neuroblastoma treated at a tertiary centre and their relationships with various clinical and pathological factors.

**Design/Methods**: A retrospective single‐centre analysis of patients diagnosed with neuroblastoma between 1998 and 2018 was performed. Patients' demographics, site of primary tumor, stage of disease at presentation, extent of tumor excision, presence of N‐MYC amplification, were extracted and analyzed. Overall survival was calculated using the Kaplan‐Meier method comparing survival probability.

**Results**: A total of 92 patients were identified and included in the study. The median age at diagnosis was 2.25 years (range: 1 month to 7 years). 63% of the patient presented with International Neuroblastoma Staging System Stage 4 disease. Three‐year, five‐year and ten‐year overall survivals for the cohort were 86%, 75% and 65% respectively. INSS Stage 4 disease, N‐MYC amplification and extent of tumor resection were found to have statistically significant influence on the five‐year survival, with 55% of Stage 4 disease patients survive at 5 years as compared with 85% and 75% in patients with stage 2 and 3 diseases respectively (p = 0.045). On the other hand, 55% of N‐MYC positive patients survive at 5 years as compared to 90% in N‐MYC negative patients (p = 0.02). For extent of resection, more complete resection (\>90% of tumor resected) was found to have positive influence on survival with 79% five‐year survival verses 40% in patients with subtotal resection (\<90% of tumor resected) (p \<0.05).

**Conclusions**: There was a predominance of advanced stage patients in our cohort. Despite this, the survival outcome of patients treated in our centre is comparable with international centres (75% five‐year survival versus 61.6‐79.6% in European centres).

### PO-349. Risk and Benefits of Diagnostic Ultrasound Guided Cutting Needles Biopsies in Neuroblastoma {#pbc27455-sec-5780}

[K. Georgantzi]{.ul} ^1^, E. Sköldenberg^2^, E. Tiensuu Jansson^3^, Å. Jakobson^1^, R. Christofferson^2^

*^1^Uppsala University, Dept. of Women\'s and Children\'s Health‐ Section of Pediatrics, Uppsala, Sweden; ^2^Uppsala University, Dept. of Women\'s and Children\'s Health‐ Section of Pediatric Surgery, Uppsala, Sweden; ^3^Uppsala University, Dept. of Medical Sciences, Uppsala, Sweden*

**Background/Objectives**: Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Except of the disease stage at diagnosis, many molecular factors are also important in staging the tumor. The diagnosis and the analysis of the molecular profile are based on tumor sample taken either by fine needle biopsy, core needle biopsy, or open biopsy. The method used depends on local tradition and routines. At the Uppsala University Hospital ultrasound guided needle biopsies (UCNBs) have been used for the diagnosis of pediatric solid tumors since 1988. Our aim was to investigate if UCNB is an appropriate method for the diagnosis of NB.

**Design/Methods**: Medical records of 29 patients with NB that underwent pretreatment, diagnostic UCNB at the Uppsala University Hospital were reviewed. The information extracted from the patients records included: age at diagnosis, gender, tumor site, INSS stage, molecular analyses (MYCN status, 1 p deletion, 11q, 17q) and any biopsy complications (bleeding, pain, and complications due to anesthesia).

**Results**: A total of 34 UCNBs were performed in 29 patients. Three patients had to undergo biopsy at more than one occasion to achieve adequate material for diagnosis and for molecular studies. A correct primary diagnosis was obtained in 90%. In 25 out of 29 (86%) patients molecular studies of their tumor were performed. Six percent had a drop of hemoglobin of more than 10%, 6% had a bleeding after the biopsy and 7% needed analgesia after the procedure. Neither infections nor tumor growth in the needle tract were observed. The patients did not experience any complications related to anesthesia.

**Conclusions**: UCNBs are safe in patients with NB and give an adequate amount of tumor tissue to obtain histological diagnosis, as well as for the analysis of the molecular profile of NB.

### PO-350. Novel Neuroendocrine Markers in Neuroblastoma {#pbc27455-sec-5790}

[K. Georgantzi]{.ul} ^1^, A. Tsolakis^2^, Å. Jakobson^1^, R. Christofferson^3^, E. Tiensuu Janson^4^, L. Grimelius^5^

*^1^Uppsala University, Dept. of Women\'s and Children\'s Health‐ Section of Pediatrics, Uppsala, Sweden; ^2^Uppsala University, Dept. of Medical Sciences, Uppsala, Sweden; ^3^Uppsala University, Dept. of Women\'s and Children\'s Health‐ Section of Paediatric Surgery, Uppsala, Sweden; ^4^Uppsala University, Dept. of Medical Sciences, Uppsala, Sweden; ^5^Uppsala University, Dept of Immunology‐ Genetics and Pathology, Uppsala, Sweden*

**Background/Objectives**: Chromogranin A (CgA) and synaptophysin are among the most known general neuroendocrine (NE) markers and also used for the pathology work up of neuroblastomas (NBs). Synaptic vesicle 2 (SV2), similar to synaptophysin, is an integral protein of the vesicular membrane playing an important role in its fusion with the cytoplasmatic membrane. Vesicular monoamine transporter 1 (VMAT 1) and 2 (VMAT 2) are acidic glycoproteins responsible for the uptake and storage of catecholamines. VMAT 1 is more abundantly expressed in the adrenal medulla than VMAT 2.Our aim was to compare the relative incidence of CgA, synaptophysin and SV2 in human NBs in order to identify the best immunohistochemical marker for their identification. Furthermore, to investigate the possible relationship between the expression of VMATs and urinary (u‐) catecholamine excretion in the respective patients.

**Design/Methods**: Thirty‐seven tumor samples from twenty‐one patients with various NB stages were included. The tumor specimens were obtained before and/or after treatment. In some patients both pretreatment and after treatment tumor tissue was available. Consecutive 4 mm sections were immunostained for all the above markers. U‐catecholamine concentrations were measured in 20 patients at diagnosis. Statistics were used to test if there was a correlation between survival and the different catecholamines.

**Results**: CgA and SV2 showed equal relative incidence in the tumours examined, in contradiction to synaptophysin that was less frequently expressed. The relative incidence of VMAT 2 was higher in the vast majority of the specimens examined compared to VMAT 1. Furthermore, VMAT 2 immunoreactivity was correlated to u‐vanillylmandelic acid (VMA) excretion. Finally, u‐homovanillic acid (HVA) and u‐dopamine excretion were correlated to outcome.

**Conclusions**: SV2 can be used as an alternative NE marker in the diagnosis of NBs. VMAT 2 may act as a catecholamine transporter in these tumours. U‐HVA and u‐dopamine could be predictive for outcome.

### PO-351. Feasibility of Outpatient Stem Cell Rescue in High Risk Neuroblastoma Patients {#pbc27455-sec-5800}

[R. Glincher]{.ul} ^1^, S. Modak^1^, E. Basu^1^

*^1^Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA*

**Background/Objectives**: Autologous stem cell rescue (ASCR) is often utilized in high‐risk neuroblastoma (HR‐NB) to reverse myelosuppression or myeloablation after high‐dose chemotherapy (HDC) or MIBG therapy. ASCR has been reported to be associated with acute toxicities and is performed in‐patient in most centers. Using an established procedure that includes fluids, furosemide and vital parameter monitoring for 4 hours post‐ASCR, we preferably perform ASCR in the out‐patient setting.

**Design/Methods**: After receiving approval from IRB, we retrospectively analyzed records of patients with NB receiving ASCR from 2008 through 2017 focusing on toxicities during the first 24 hours post‐ASCR.

**Results**: Of 122 ASCR performed on patients with HR‐NB, 72 infusions were performed in the outpatient setting. Reasons for inpatient ASCR included: neutropenic fever, planned chemotherapy, pain management, seizures, electrolyte imbalances, stem cell infusion, intractable vomiting, hematuria, hypertension, and post‐operative management. Prior chemotherapy included high‐dose Ifosfamide, Carboplatin, Etoposide (n=24), Carboplatin, Irinotecan, Temozolomide, Etoposide, and Cyclophosphamide (n=22), Carboplatin, Irinotecan, Temozolomide (n=6), Thiotepa (n=4), Cyclophosphamide, Topotecan, Vincristine (n=4), or others (n=2). Intravenous radiopharmaceuticals included MIBG therapy (n=8), and I131 3F8 (n=2), Median cell number was 3.24 x10e6 CD34+cells/kg (range: 0.83‐ 21 x10e6 CD34+ cells/kg) and median DMSO (2.5 % for patients collected at MSKCC and 7.5‐10% for patients collected elsewhere) volume was 50 mL (range 10 mL‐140 mL). Acute reactions during/immediately post‐ASCR occurred in 46 patients and included. Nausea (n=33), Vomiting (n=20), Fever (n=6) and, hypertension (n=2). Nine of the 54 patients evaluated the following day, had symptoms: fever (n=4), nausea (n=3), vomiting (n=1), and tachycardia (n=1). Fourteen patients were admitted within 24 hours for neutropenic fever and one was admitted with sinus bradycardia post platelet transfusion.

**Conclusions**: Out‐patient ASCR is well tolerated in patients receiving myeloablative regimens for NB and should be considered over inpatient administration to reduce costs and stress to the patient and caregivers.

### PO-352. Neuroblastoma in North East Egypt: A 5‐Year Multicenter Study {#pbc27455-sec-5810}

[T. Hassan]{.ul} ^1^, M. Badr^1^, Y. Al Tonbary^2^, U. El Safy^1^, S. Shebl^3^, R. Nofal^1^

*^1^Zagazig University, Pediatrics, Zagazig, Egypt; ^2^Mansoura University, Pediatrics, Mansoura, Egypt; ^3^Tanta University, pediatrics, Tanta, Egypt*

**Background/Objectives**: Neuroblastoma is the most common extracranial solid tumor of infancy. It is an embryonal malignancy of the sympathetic nervous system. We aimed to study the epidemiological characteristics of neuroblastoma in Egypt through a multicenter study in four Egyptian centers.

**Design/Methods**: The clinico‐epidemiological features of neuroblastoma in infants and children were retrospectively investigated between January 2005 and January 2010 at the Pediatric Oncology units of Mansoura, Zagazig, and Tanta University Children\'s Hospitals (Egypt).

**Results**: Of 142 cases of neuroblastoma, 10 were omitted from the study due to defective data. The median age of the patients was 30 months, with 75.8% aged ≥1 year and 24.2% aged \<1 year at time of diagnosis. The male‐to‐female ratio was 1.06. Suprarenal glands were the most common primary tumor site (72.7%). The majority of the patients (76.7%) had stage IV disease. Favorable pathology was observed in 43.8% of patients, while 56.2% exhibited unfavorable pathology. The estimated survival rate of patients was 30.7±10.0%, and mean survival time was 24.2±5.2 months. The rate of mortality was 28.6% for patients aged \<1 year, and 81.8% for those aged ≥1 year (P=0.005). For patients with favorable pathology, the rate of mortality was significantly lower (28.6%) compared with that of patients with unfavorable pathology (77.8%; P=0.049). Additionally, an age of ≥1 year was associated with unfavorable pathology (P=0.024), stage IV disease (P=0.026) and a suprarenal primary tumor site (P=0.001).

**Conclusions**: the association between age at presentation, stage and pathology supports the hypothesis that neuroblastoma is a heterogeneous disease. The establishment of an effective, computerized, research‐oriented registration system for neuroblastoma is urgently required in north east Egypt. Furthermore, larger international multicenter studies are required to support the findings of the present study.

### PO-353. The Role of NR4A3, a Prognostic Factor of Neuroblastoma, in the Differentiation of Neuroblastoma Cells {#pbc27455-sec-5820}

[T. Hirano]{.ul} ^1^, K. Fujiwara^2^, E. Nagasaki^1^, S. Uekusa^1^, H. Kawashima^1^, S. Uehara^1^, T. Koshinaga^1^

*^1^Nihon University School of Medicine, Pediatric Surgery, Tokyo, Japan; ^2^Nihon University School of Medicine, General Medicine, Tokyo, Japan*

**Background/Objectives**: Differentiation therapy to convert neuroblastoma (NB) cells into mature ganglioma cells is a promising curative treatment currently under development. However, because of the tremendous clinical heterogeneity of NB, this therapy provides benefit to only a limited number of patients. To elucidate the molecular mechanisms underlying NB cell differentiation and to identify an appropriate therapeutic target, we investigated the role of nuclear receptor subfamily 4 group A member 3 (*NR4A3*), which was identified as a candidate prognostic factor for the differentiation of NB cells (Uekusa S et al. Int J Oncol.2014).

**Design/Methods**: Human NB cell lines with or without *MYCN* amplification were used in this study. siRNA of *NR4A3* was transfected into the cells, or an expression vector of *NR4A3* was transfected to generate cells stably expressing *NR4A3*, followed by the analysis of the cell morphology as well as the expression of differentiation markers and prognostic factors. *MYCN* was silenced using siRNA to determine its direct effect on the *NR4A3* expression. A chromatin immune precipitation (ChIP) assay was performed to examine the binding of the MYCN protein to the regulatory region of the *NR4A3* gene.

**Results**: The clones stably expressing *NR4A3* showed obvious neurite outgrowth along with the up‐regulation of the differentiation markers. The expression of *NR4A3* tended to be higher in the cells without *MYCN* amplification than in those with *MYCN* amplification. In addition, *MYCN* knock‐down cells showed an increased expression of *NR4A3* and similar phenotypes to those of *NR4A3*‐overexpressing cells. The ChIP assay showed that MYCN binds to the promoter region and exon 3 of the *NR4A3* gene.

**Conclusions**: Our data indicated that *NR4A3* promotes the differentiation of NB cells and that the expression of *NR4A3* is negatively regulated by *MYCN*.

### PO-354. Synergistic Activity of ALK and STAT3 Inhibitors for the Treatment of ALK Mutated Neuroblastoma Cells {#pbc27455-sec-5830}

[M. Hiwatari]{.ul} ^1^, K. Watanabe^2^, S. Kimura^2^, J. Takita^2^

*^1^University of Tokyo, Cell Therapy and Transplantation Medicine, Tokyo, Japan; ^2^University of Tokyo, Pediatrics, Tokyo, Japan*

**Background/Objectives**: The presence of ALK aberrations relatively frequently observed in patients with high‐risk neuroblastoma. ALK inhibitors such as crizotinib has provided novel treatment opportunities for malignancies associated with ALK translocations. Neuroblastoma cells harboring F1174L‐mutated ALK were relatively resistant to crizotinib. Inhibition of F1174L‐mutated ALK remains a therapeutic challenge in neuroblastoma.

**Design/Methods**: To identify compounds with the potential of inhibiting oncogenic activity of ALK in neuroblastoma, we implemented a high throughput chemical screen in 23 neuroblastoma ‐derived cell lines with varying ALK statuses, using a curated library of ∼450 compounds. We evaluated the therapeutic effects of crizotinib and its combined treatment with JAK‐STAT inhibitor (cucurbitacin I) in neuroblastoma cell lines. Cultured cells were evaluated for effects of these drugs on proliferation, signaling, and assessment of synergy.

**Results**: In the drug screen, JAK‐STAT kinase inhibitor (cucurbitacin I) was the most discriminatory with regard to sensitivity for ALK‐mutated cell lines. In neuoblastoma cell lines harboring F1174L or R1275Q‐mutated ALK, crizotinib combined with cucurbitacin I enhanced tumor responses and showed synergistic cytotoxicity. The combination therapy in all of 6 cell lines with ALK aberrations and 10 of 13 ALK wild‐type cell lines with MYCN amplification or 11q LOH was more effective than vehicle, crizotinib alone, and cucurbitacin Ialone. Analysis of downstream molecules through MAPK, AKT and STAT3 pathways showed that TGW, a cell line harboring R1275Q‐mutated ALK, expressed lower levels of pERK, pAKT and pSTAT3 in combination therapy compared with cells treated with cucurbitacin I or crizotinib alone.

**Conclusions**: These results may provide a indication that the combination of low‐dose ALK and STAT3 inhibitors may be benefitical for th etratment of neuroblastoma, by enhancing efficacy while reducing toxicity. Our studies suggest that the combination of ALK and JAK‐STAT inhibitors could be a valuable therapeutic optionfor high‐risk neuroblastoma with potential clinical application.

### PO-355. Needle Core vs Open Biopsy for Diagnosis of Neuroblastoma, A UK Survey {#pbc27455-sec-5840}

[S. Hotonu]{.ul} ^1^, M. Elliott^2^, D. Tweddle^3^, P. Losty^4^, H. Gabra^5^

*^1^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Paediatric Surgery, Newcastle Uppon Tyne, United Kingdom; ^2^Leeds General Infirmary‐ Leeds Teaching Hospitals NHS Trust, Paediatric Oncology, Leeds, United Kingdom; ^3^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Paediatric Oncology, Newcastle Uppon Tyne, United Kingdom; ^4^Alder Hey Children\'s Hospital, Paediatric surgery, Liverpool, United Kingdom; ^5^The Great North Children Hospital‐ Newcastle University Teaching Hospitals Foundation Trust, Paediatric Surgery, Newcastle Uppon Tyne, United Kingdom*

**Background/Objectives**: Open (surgical) biopsy has been traditionally utilised for diagnosis of neuroblastoma in the previous UKCCLG protocols. Over the last decade, there has been an increase in the number of centres in the UK and abroad utilising needle core biopsies (NCB). However, there is a lack of knowledge about the current trend for biopsying neuroblastoma in the UK.

**Design/Methods**: An online survey conducted among UK‐CCLG surgeons. The data included the type of biopsy (surgical vs needle core), who performed it (surgeon vs radiologist), when NCB: the number of cores and where it was perfomed. In addition, the outcome of the survey was compared to data obtained by a retrospective audit of the current practice of Neuroblastoma biopsy in 19 UK centres, in which data over 12 months period obtained and analysed.

**Results**: Sixteen centres responded to the survey (74% UK response rate) (UK=14, Netherland=1, France=1), 75% performed NCB under image guidance with 70% reported that \>5 cores are usually obtained to yield adequate tissues and the gauge of the needle utilised was 14‐16 G (74%). 60% are done by the radiologists while 40 % are still done by the paediatric surgeons with the majority (81%) performed at the operating theatre and 20% at the interventional radiology suites. The results of the audit showed that 52% of the biopsies were obtained via NCB vs19% via open surgery with no significant morbidity while in 22% of cases, biopsies were not performed and the diagnosis was achieved via different route (e.g. bone marrow sampling).

**Conclusions**: The current survey reflects the change in practice in the UK regarding the biopsying for neuroblastoma. Both open and NCB appear to yield adequate tissue sampling for diagnosis. Further larger international studies may be useful to provide further guidance for the future neuroblastoma protocols.

### PO-356. Clinical Features and Survival Analysis of Neuroblastoma with Cervical Lymph Node Metastasis in Children {#pbc27455-sec-5850}

[C. Huang]{.ul} ^1^, Y. Su^1^, S. Wang^2^, M. Jin^1^, X. Chai^1^, T. Liu^1^, X. Wang^3^, L. He^4^, H. Qin^5^, H. Wang^5^, X. Ma^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University, National Center for Children\'s Health, Beijing Key Laboratory of Pediatric Hematology Oncology‐ National Discipline of Pediatrics‐ Ministry of Education‐ MOE Key Laboratory of Major Diseases in Children‐ Hematology Oncology Center, Beijing, China; ^2^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Beijing Key Laboratory of Pediatric Hematology Oncology‐ National Discipline of Pediatrics‐ Ministry of Education‐ MOE Key Laboratory of Major Diseases in Children‐ Department of Otorhinolaryngology‐ Head and Neck Surgery, Beijing, China; ^3^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Beijing Key Laboratory of Pediatric Hematology Oncology‐ National Discipline of Pediatrics‐ Ministry of Education‐ MOE Key Laboratory of Major Diseases in Children‐ Department of Ultrasonography, Beijing, China; ^4^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Beijing Key Laboratory of Pediatric Hematology Oncology‐ National Discipline of Pediatrics‐ Ministry of Education‐ MOE Key Laboratory of Major Diseases in Children‐ Department of Pathology, Beijing, China; ^5^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Beijing Key Laboratory of Pediatric Hematology Oncology‐ National Discipline of Pediatrics‐ Ministry of Education‐ MOE Key Laboratory of Major Diseases in Children‐ Department of Surgical Oncology, Beijing, China*

**Background/Objectives**: The presence of distant metastases is one of the most powerful predictors of outcome in patients with neuroblastoma. We summarize the clinical features and analyse the survival situation in order to guide the therapy.

**Design/Methods**: The research analyse the medical records of 225 patients with cervical lymph node metastasis of NB from 2007‐4‐1 to 2017‐5‐31 in our single center. The treatment are divided into two phase: 2007‐4‐1 to 2011‐12‐31 and 2012‐1‐1 to 2017‐5‐31. We analyse the survival situation and treatment effect in each phase. The following up time end at January 31, 2018.

**Results**: Total 225 cases admitted in the research with about 37.3% of all the neuroblastoma patients. There are 33 cases which metastasic site confined to cervical lymph node(4N, 14.7%). 139 cases with bone marrow metastasis. 159 cases with bone metastasis. The number of patients in high‐risk group is 208. A total of 200 cases received systemic treatment. The 5‐year OS of all the patients is 46.5%, and the 5‐year EFS is 39.7%. For the earlier phase of treatment, the 5‐year EFS is 39.5%, and the 5‐year OS is 44.7%. According to the second phase of treatment, the 5‐year EFS is 46.8%, and the 5‐year OS is 48.7%. For the 4N patients, the 5‐year EFS is 61.5%, and the 5‐year OS is 76.7%.

**Conclusions**: Only 14.7% of patients' metastatic disease limited to cervical lymph nodes, higher than 6.5%, which the international have reported. The probable reason is ultrasound has become a routine examination to screening the lymph node metastasis in our center. The 5‐year EFS for 4N patients is 61.5%, lower than another foreign center haver reported(77%). The probable reason is the proportion of the high‐risk patient in our center is higher. The metastastic disease didn\'t receive the surgical and radiotherapy totally in our center.

### PO-357. Treatment of Stage 4S Neuroblastoma: Dokuz Eylul University Experience of the Last 10 Years {#pbc27455-sec-5860}

[D. Ince]{.ul} ^1^, D. Kizmazoglu^1^, B. Baysal^1^, E. Cecen^1^, E. Ozer^2^, S. Aktas^3^, A. Demiral^4^, M. Olguner^5^, H. Guleryuz^6^, K. Mutafoglu^7^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey; ^3^Dokuz Eylul University Institute of Oncology, Basic Oncology, Izmir, Turkey; ^4^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^6^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^7^Dokuz Eylul University Institute of Oncology, Pediatric Oncology‐ current address: İzmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To evaluate our patients diagnosed as stage 4S neuroblastoma (NB) and treated with NB‐TPOG 2009 protocol in our center.

**Design/Methods**: Clinical characteristics and treatment responses of 6 stage 4S NB patients analyzed retrospectively.

**Results**: Stage 4S NB 6 patients were eligible for analysis. M/F ratio was 1.0. Median age at diagnosis was 2.5 mos (1‐6mos). Primary sites: surrenal (n:5), cervical paravertebral (n:1). 2/6 MYCN, 1p‐, 17q+, 11q‐ negative; 2/6 MYCN and 11q‐ negative, 1p‐ and 17q+ positive. Risk groups (RG): low RG (n:3), intermediate risk‐favourable histology (n:2), intermediate risk‐unfavourable histology(n:1). Tumor was heterogen in 1 patient in intermediate risk favourable histology group. Primary surgery with total resection was done in 3/6 patients and with 1/6 delayed surgery. Tumor totally disappeared in 1 patient. One patient died at 5.month with progressive disease before surgery. One patient was asymptomatic and only followed up; 5/6 patients received A7 chemo, treatment changed as A8 (cyclophosphamide, etoposide, cisplatin) + A9 (ifosfamide, vincristine, dacarbazine, adriamycin) in one of them after 2 courses of A7. 2/6 received radiotherapy(RT). One patient received RT to liver because of extensive liver metastasis and clinical symptoms (advanced hepatomegaly, respiratory distress, vena cava inferior syndrome, decreased urine output and hypertension), and in other patient liver metastasis rapidly progressed after A7 chemotherapy, so RT was given to liver. Median follow up time 1 yrs (3mos‐4yrs). 5/6 stage4S patients were disease free. 1/6 patient progressed under chemotherapy at third month, 1/6 at forth month. 1/6 controlled with chemotherapy and RT, but other one died at fifth month with progressive disease despite chemotherapy.

**Conclusions**: The treatment outcomes of children with stage 4S neuroblastoma are satisfactory. Treatment responses of symptomatic patients to carboplatin, etoposide, vincristine based A7 course were good. Quick and effected response provided by addition of RT to chemotherapy in one patient with extensive liver metastasis, Pepper syndrome, respiratory distress.

### PO-358. Localized Neuroblastoma: The 30 Years Experience of Dokuz Eylul University {#pbc27455-sec-5870}

[D. Ince]{.ul} ^1^, D. Kizmazoglu^1^, E. Cecen^1^, M. Erdem^1^, Z. Altun^2^, S. Aktas^2^, M. Olguner^3^, A. Celik^4^, H. Guleryuz^5^, A. Demiral^6^, E. Ozer^7^, O. Ozdogan^8^, K. Mutafoglu^9^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Institute of Oncology, Basic Oncology, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^4^Ege University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^6^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^7^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey; ^8^Dokuz Eylul University Faculty of Medicine, Nuclear Medicine, Izmir, Turkey; ^9^Dokuz Eylul University Institute of Oncology, Pediatric Oncology‐ current address: İzmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To analyze patients diagnosed as localized neuroblastoma(NB).

**Design/Methods**: Clinical characteristics and treatment responses of 43 patients diagnosed as localized neuroblastoma were analyzed retrospectively.

**Results**: Median age at diagnosis was 19mos(1mos‐6.3yrs), M/F ratio was 1.26.Stage distrubution:Stage 1(n:13), stage 2a(n:2), stage 2b(n:4), stage 3(n:24).Risk groups:LRG(n:14), IRG(n:16), HRG(n:8) patients. IPOG protocol(n:5):One stage1 patient followed up for 7 years without disease. Stage 3 patients with paravertebral tumor(n:4):primary total resection in 1, secondary surgery with macroscopic residue in 2, RT in 1.Only one event:death after progression at 86th month after primary relapse at 60th month. TPOG‐NB2003&NB2009: LRG(n:14):Stage 1(n:12):Tumor localization;surrenal 6, paravertebral 5, midline one.9/12 MYCN(‐). Two patients with opsomyoklonus received IVIG,1 patient with ROHHAD syndrome received cyclophosphamide, rituximab and IVIG. One 9mos stage2a patient with paravertebral tumor received chemotherapy(CT)after decompression surgery with macroscopic residue, after complementary surgery, she is disease free for 11years. Stage2b cervical paravertebral NB patient was asymptomathic after surgery, he is on follow up without treatment for 10months. For LRG median follow up time 3yrs(7mos--10 yrs), only 1 event:death of patient with ROHHAD. IRG(n:16)Stages:stage2a(n:1), stage2b(n:3), stage3(n:12).Stage2a patient with paravertebral tumor diagnosed as GNB after primary surgery with macroscopic residue, after two courses CT, tumor resected totaly, disease free for 10 mos. Stage2b,2/3paravertebral,1/3surrenal tumor, all 3 patients are disease free.6/12 IR‐FHG and 6/12 IR‐UHG in stage3.2/12 treated with primary surgery(one cord decompression) and resulted with macroscopic residue. Other 11 patients' induction response was 100%(CR+PR).RT was given to primary tumor in 2patients. For IRG median follow up time 32mos(4mos--12.5 yrs),5‐10yrs OS ve EFS94%.Only one event:stage 3 patient with Pepper syndrome died at 4.month related to surgery. HRG(n:8):4/8 midline,3/8 surrenal,1/8 paravertebral, no primary surgery. Induction response 100%(CR+PR).Two patients had refractory progressive disease, one of them died from progression at 9.mos and other died SCT related at 26.mos. Except patient with ROHHAD syndrome, for all patients with localized NB(n:42) median follow up time 5yrs(3mos--17yrs),5‐10 years EFS 87% and 85%, OS 92% and 85%, respectively.

**Conclusions**: Our treatment responses, overall and event free survival rates of localised neuroblastoma were acceptable and consistent with the literature. There was no toxicity related death.

### PO-359. Treatment of Neuroblastoma in Infants Younger than 18 Months: The 30 Years Experience of Dokuz Eylul University {#pbc27455-sec-5880}

[D. Ince]{.ul} ^1^, D. Kizmazoglu^1^, M. Erdem^1^, S. Aktas^2^, E. Cecen^1^, Z. Altun^2^, A. Demiral^3^, E. Ozer^4^, M. Olguner^5^, O. Altungoz^6^, R. Cetingoz^3^, H. Guleryuz^7^, K. Mutafoglu^8^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Institute of Oncology, Basic Oncology, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^4^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^6^Dokuz Eylul University Faculty of Medicine, Medical Biology and Genetics, Izmir, Turkey; ^7^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^8^Dokuz Eylul University Institute of Oncology, Pediatric Oncology‐ current address: İzmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To evaluate clinical characteristics, treatment responses and survival rates of infants with neuroblastoma (NB).

**Design/Methods**: Clinical characteristics and treatment responses of 46 patients \<18months who diagnosed as neuroblastoma in our center between 1987‐2018 were analyzed retrospectively.

**Results**: Forthyfive patients were eligible for analysis. M/F ratio was 1.8, median age at diagnosis was 7mos(0‐18mos),30 patients were\<12 months. Stage distrubution:Stage 1 11%, stage 2 4%, stage 3 38%, stage 4 31%, stage 4S 16%. Except 2 patients treated with IPOG 92 protocol, risk strafication of other 43 patients:LRG 10, IRG 26, HRG 7. Ten patients were treated with TPOG‐NB‐2003,33 patients with TPOG‐NB‐2009 protocols. LRG(n:10): Five patients were Stage 1, 2 were stage 2, 3 were stage4S. MYCN was negative in 6patients, amplified in one stage1 patient. One stage4S patient died at 5.month with disease progression. One‐5 years EFS and OS were 90%. IRG‐favourable Shimada(n:9):Five patients were Stage3,1 was stage4,3 were stage4S. MYCN was negative in 7 patients. After 2 courses of A7, one stage4S patient received RT and A8‐A9 because of progression of liver metastasis, and CR achieved. Stage3 patient with liver metastasis died related to surgery. One‐5 years EFS were 78% and OS were 89%. IRG‐unfavourable Shimada(n:17): Seven patients were Stage 3, 9 were stage 4, 1 was stage4S. MYCN was negative in 16patients. One‐5 years EFS were 85% and OS 100%. HRG(n:7): Three patients were Stage3,4 were stage 4. MYCN was amplified at 5/7 patients. One of them was stage 3, two of stage 4 three patients had progressive disease and had died. One‐5 years EFS were50% and OS 50%.Ten patients received RT;five of them were\<=12mos infants who received RT to liver metastasis. Median follow up time 18mos(1mos‐16yrs),1‐5‐10yrs EFS 79%, OS 87%. Median event time 5.5 mos(3‐7mos);5 patients progression, one nonprimary relapse, one refracter disease and one surgery related death occured. Causes of death:4/5progression,1/5 surgery related. MYCN performed in 37 patients,16% amplified. For MYCN+/‐ patients 5yrs EFS 40% and 88% (p:0,018), OS 40% and 100%(p:0.00) respectively. For\<12m and 12‐18m patients 5yrs EFS 80% and 77%(p:0,98), OS 92% and 79%(p:0.31) respectively.

**Conclusions**: Survival rates of our infancy neuroblastoma (\<=18m) patients were succesfull and similar to literature. OS and EFS rates were significantly different between MYCN+/‐ patients.

### PO-360. Treatment of Children with Intermediate‐Risk Neuroblastoma: Dokuz Eylul University Experience {#pbc27455-sec-5890}

[D. Ince]{.ul} ^1^, M. Erdem^1^, D. Kizmazoglu^1^, E. Cecen^1^, S. Aktas^2^, Z. Altun^2^, A. Demiral^3^, R. Cetingoz^3^, H. Guleryuz^4^, M. Olguner^5^, A. Celik^6^, E. Ozer^7^, O. Ozdogan^8^, K. Mutafoglu^9^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Institute of Oncology, Basic Oncology, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^4^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^6^Egel University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^7^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey; ^8^Dokuz Eylul University Faculty of Medicine, Nuclear Medicine, Izmir, Turkey; ^9^Dokuz Eylul University Institute of Oncology, Pediatric Oncology. current address: İzmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To evaluate patients diagnosed as intermediate risk group neuroblastoma(IRG‐NB).

**Design/Methods**: There were 31 patients in IRG‐NB treated with TPOG protocol, one of them went to another center,30 were eligible. Clinical characteristics, treatment responses and survival rates were analyzed retrospectively.

**Results**: Median age at diagnosis was 7mos(0‐5yrs), 76%\<18mos, M/F ratio was 4.0.Primary sites:surrenal 37%(n:11), paravertebral 37%(n:11), midline 26%(n:8).25/30 neuroblastoma (NB),5/30 ganglioneuroblastoma(GNB). Stage distrubution:Stage1 3%(n:1), stage2b 10%(n:3), stage3 40%(n:12), stage4 37%(n:11), stage4S 10%(n:3).17/30 patients(57%) were metastatic. Metastasis regions:lymph node 20%, bone 17%, bone marrow 10%, subcutaneous nodule 10%, lung 7%, other 7%.1p del(+) in 8/20(40%) patients.11q del(+) in 1/20 (5%)patient.17q gain(+) in 8/9(42%) patients. MYCN(‐) in 26/30 patients. DNA diploidy analyzed in 14 patients:diploidy(n:5), neardiploidy(n:8), tetraploidy(n:1). Shimada classification:favourable histology 23%(n:7), unfavourable histology 47%(n:14), GNB 17%(n:5).1/30 had no histopathologic diagnosis, in 3/30 further evaluation failed(NOS). Primary surgery:2/7 total resection(one of them had lymph node metastasis so stage2, other had liver metastasis so stage4S),5/7 with macroscopic residue.29/30 patients could be evaluated after induction chemotherapy, response rate was 86%(3CR+8VGPR+14PR). In 2 of them tumor regressed with only CT, in 1 of them delayed surgery time did not come yet. CR achieved in 1/2 patient of total resection with primary surgery, in other one liver metastasis progressed and RT was given to liver. Tumor resected totally with delayed second look surgery in 3/5 patients with macroscopic residue after primary surgery and CR achieved. Complementary surgery not performed in 2/5 patient, RT was given to primary tumor and CR achieved. Delayed surgery was done to 20 patients without primary surgery:11 total resection,9 resection with macroscopic residue. RT was given to 1 patient for progressive liver metastasis. Five patients had received RT to primary tumor. Median follow up time was 32mos(4mos--12.5 yrs), 1‐5 years EFS and OS were 86% and 97%. Four events in this patient group:one progression in liver metastasis, one nonprimary relapse, one refractory disease and one surgery related death.

**Conclusions**: Survival rates of our IRG‐NB were succesfull and treatment responses similar to COG, SIOPEN, GPO and Japan pediatric oncology groups' results. Toxicity was at acceptable levels, no toxicity related death. One patient died related to surgery.

### PO-361. Could the Residuel Tumor Histopathology be a Therapeutic Directing Effect in Intermediate Risk Neuroblastoma? {#pbc27455-sec-5900}

[D. Ince]{.ul} ^1^, M. Erdem^1^, D. Kizmazoglu^1^, E. Cecen^1^, E. Ozer^2^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey*

**Background/Objectives**: Residue tumor after induction chemotherapy effects treatment and prognosis in intermediate risk group neuroblastoma (IRG‐NB).In this preliminary study, role of residue tumor histopathology(HP) on treatment decision has been investigated.

**Design/Methods**: 24/30patients in IRG‐NB were eligible. Medical records analyzed retrospectively. HP classification:tumor tissue changes after induction chemotherapy, regression patern(RP); maturation patern(MP);regression and maturation patern(RP+MP) or no changes despite chemotherapy. RP:defined as intense fibrozis, calcification, necrosis without NB differentiation or schwannian stroma(SS) formation. MP:ganglioneuroblastoma type with SS and differentiated NB without SS(Ped Blood Cancer 2012;58(5):675).

**Results**: M/F ratio was 5,20/24\<18 mos. Tumor localisation: surrenal (n:7), paravertebral (n:9), midline (n:8). 14/24 metastatic disease. Stage distrubution: Stage 2 (n:2), stage 3 (n:9), stage 4 (n:11), stage 4S (n:2).Primary surgery with macroscopic residue in 4/24. Induction response was 83%(CR+PR).Diagnosis histopathology:andifferentiated NB(21%), poor differentiated NB(46%), differentiated NB (8%), not further evaluated(12.5%), GNB(12.5%). MKI can be evaluated:7/24 high,7/24 low. Delayed surgery resulted with total resection 13/24, macroscopic residue 11/24.13/24 patient with total resection not received RT. HP reports evaluated for RP/MP:RP (n:9), MP (n:4), GNB with SS;MP without SS(n:5), differentiated NB subgroup, RP+MP (n:3), no change after chemo (n:3). 1/11 patient with macroscopic residue had died at 4.mos related to surgery. 5/24 received RT to primary tumor, 5/24 not received. RT (+) group: 2/5 tumor HP not changed after CT in 2/5, 2/5 MP (differentiated NB without SS), 1/5 RP (+). RT (‐) group: 3/5 patient RP (+), 2/5 RP+MP (+), maintenance chemotherapy was given to this group. 1/5 patient with macroscopic residue after delayed surgery who received RT had refractory disease at 6.mos; 1/5 RT (‐) patient with familial NB had nonprimary relapse at 6.mos. Both of 2 patient groups are in follow up, no death.

**Conclusions**: Despite few patient number and short follow up times, according to the results of this preliminary study;patients in IRG‐NB with residue tumor after induction chemotherapy and surgery, patients wih regression±maturation HP can be followed by receiving maintanance treatment, differentiating and antiangiogenic agents without additional chemotherapy courses and/or RT as considering the long time side effects and risks.

### PO-362. Immune Checkpoint Inhibition Induce Activated Dendritic Cell Infiltration in PD‐L1 Negative Tumor in Mouse Neuroblastoma Model {#pbc27455-sec-5910}

[S. Inoue]{.ul} ^1^, Y. Setoyama^2^, Y. Takeuchi^1^, T. Mori^2^, A. Odaka^1^, Y. Beck^1^

*^1^Saitama medical center‐ Saitama medical university, Pediatric surgery, Kawagoe city, Japan; ^2^Saitama medical center‐ Saitama medical university, Medical research, Kawagoe city, Japan*

**Background/Objectives**: Antitumor therapy by the immune check point inhibition is the concept of blocking tumor progressing co‐stimulatory signals transferred by the engagement of PD‐L1 molecule on the surface of cancer cell and PD‐1 on T cell in tumor microenvironment. However, in some pediatric cancers, the frequency of the surface expression of PD‐L1 molecule are reported very low. Here we evaluated the anti‐tumor effect of immune checkpoint inhibition to the mouse neuroblastoma cell not expressing PD‐L1 molecule on their surface, followed by analyzing the immunological reaction in the host mouse lymphatic organs and tumor microenvironment.

**Design/Methods**: Expressions of the co‐stimulatory molecule on mouse neuroblastoma cell (neuro‐2a) surface were analyzed by flowcytometry. Neuro‐2a were inoculated subcutaneously in host mouse thigh. Intra‐peritoneal administration of 250mg of anti‐PD‐1 and PD‐L1 antibodies at 5^th^, 7^th^ and 12^th^ days following tumor inoculation in the treated group and PBS in the control (n=5 in each). Mice were sacrificed on 14^th^ day and tumor size were evaluated. Cells from inguinal lymph nodes and spleens were collected and tumor‐infiltrating cells were analyzed using flowcytometry.

**Results**: Co‐stimulatory molecules, especially PD‐1 and PD‐L1, were not expressed on neuro‐2a surface. However, tumor growth was markedly suppressed in antibody treated group compared to control. There were no remarkable differences of immune cell population in inguinal lymph nodes or spleens between groups. However, CD8a‐CD11c+ tumor infiltrating cells were markedly increased compared to control. These CD11c+ cells expressed MHC II, CD80, CD86, CD14 and CD40 but not CD205 on their surface. Moreover, these cells did not express PD‐L1 and CTLA4, however PD‐1 was weakly expressed.

**Conclusions**: Treatment with anti‐PD‐1 and PD‐L1 effectively suppressed the tumors' growth of PD‐1 PD‐L1 negative neuro‐2a cells and increased tumor infiltrating cells of CD11c+ activated immune cells. These cells were PD‐L1 negative, but slightly expressed PD‐1 molecule on their surface.

### PO-363. NRF2 Regulated CSE1L Expression to Inhibits Differentiation of Neuroblastoma via Regulation of the P53 Pathway {#pbc27455-sec-5920}

[Y. Jin]{.ul} ^1^, F. Chen^2^, H. Wang^3^, Y. Yu^1^, L. Fu^4^, S. Han^1^, S. Yang^3^, H. Yang^1^, L. He^4^, X. Ni^1^, Y. Guo^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health‐ China, Beijing Key Laboratory for Pediatric Diseases of Otolaryngology‐ Head and Neck Surgery‐ Beijing Biobank for Diseases in Children, Beijing, China; ^2^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health‐ China, Beijing Key Laboratory for Pediatric Diseases of Otolaryngology‐ Head and Neck Surgery, Beijing, China; ^3^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health‐ China, Department of Surgical Oncology, Beijing, China; ^4^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health‐ China, Department of Pathology, Beijing, China*

**Background/Objectives**: Neuroblastoma is a common pediatric solid tumor of neural crest origin, ranging from tumors with predominantly poorly differentiated neuroblasts to those largely consisting of fully differentiated sympathetic neurons, while the molecular basis for this remains unclear. The chromosome segregation 1‐like protein (CSE1L) was reported regulating cell cycle. Although several studies have reported that CSE1L plays different roles in variety cancers, little is known about its role in neuroblastoma. Here we demonstrated that CSE1L functions as an oncogene in maintaining the highly dedifferentiated stage of this aggressive malignancy neoplasm which regulated by nuclear factor, erythroid 2 like 2 (NFE2L2/NRF2).

**Design/Methods**: Nighty‐nine neuroblastoma clinical specimens were used to investigate the correlation between CSE1L/NRF2 expression and neuroblastoma cell differentiation. In NB cells, proliferation, cell cycle and apoptosis were assessed following the knockdown of CSE1L expression. Then, transcriptome profiling was conducted to explore pathway changes after CSE1L silencing. Affinity purification and mass spectrometry was utilized to explore the interactome of CSE1L protein in NB cells.

**Results**: Among neuroblastoma clinical specimens, a significant positive correlation was documented between CSE1L/NRF2 expression and neuroblastoma cell un‐differentiation. Loss‐of‐function of CSE1L was sufficient to inhibit neuroblastoma cell growth *in vitro* and *in vivo*. Silencing CSE1L also sensitized neuroblastoma cells to retinoic acid and promoted cell differentiation. Transcriptome analysis of neuroblastoma cells lacking CSE1L revealed that induction of neuronal differentiation pathways and p53 signaling pathway, and repression of oncogenic signaling pathways. By affinity purification and mass spectrometry, CSE1L was found to interact with Protein arginine methyltransferase 5 (PRMT5) and positively regulate its expression in neuroblastoma cells.

**Conclusions**: Overall, our findings illuminated a novel NRF2--CSE1L--PRMT5‐p53 molecular axis as a neuroblastoma cells differentiation regulator, with potential implications to improve diagnosis and treatment of this disease.

### PO-364. Lung Metastases in Neuroblastoma {#pbc27455-sec-5930}

T. Shamanskaya^1^, [D. Kachanov]{.ul} ^1^, V. Likhotkina^1^, G. Tereschenko^2^, A. Scherbakov^2^, E. Ternovaya^2^, Y. Likar^3^, A. Kazakova^4^, V. Roschin^5^, S. Varfolomeeva^1^

*^1^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Clinical Oncology, Moscow, Russia; ^2^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Radiology, Moscow, Russia; ^3^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Nuclear Medicine, Moscow, Russia; ^4^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Cytogenetics, Moscow, Russia; ^5^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Pathology, Moscow, Russia*

**Background/Objectives**: The aim of the study was to analyze the clinical, radiologic and biologic characteristics of neuroblastoma presented with lung metastases.

**Design/Methods**: 132 patients with stage 4 neuroblastoma for the period 01.2012‐12.2016 (60 months) were included in analyses. Stage was assign according to INSS. Patients were stratified and treated according to the German NB2004 protocol. Comparative analysis of clinical and biological characteristics was done in patients with and without lung metastases. Overall (OS) and event‐free survival (EFS) was assessed using Kaplan‐Meier method.

**Results**: 132 patients with stage 4 neuroblastoma stratified to high‐risk (n= 111) and intermediate‐risk (n = 21) group were included in the analysis. 10 (7.6%) patients had lung metastases. The median age was 26.4 months (range 4.3‐92.5). The most common site of primary tumor was adrenal gland ‐ 5 (50.0%). 9 (90.0%) patients were stratified to high--risk group, 1 (10%) to intermediate‐risk group. Patients with one and two side involvement were equally distributed. 6 (60%) had multinodular involvement. Calcification was noted only in 1 (10%) case. 2 (20%) patients had tumor‐associated thrombosis. Comparative analyses of patients with and without lung metastases showed no statistically significant difference in terms of gender, age at diagnosis, topography of the primary tumor, MYCN status, sites of metastases. Progression on therapy was observed more often in high‐risk patients with lung metastases (p=0.02). 2‐year EFS for patients with and without lung metastases was 40.0±15.4%and 46.1±4.7% (р=0.37). 2‐year OS was worse in case of lung metastases ‐ 50.0±15.8% versus 75.9±3.9% (р=0.045).

**Conclusions**: Lung metastases are rare in patients with disseminated neuroblastoma. Assessment of initial images by experienced radiologists is very important for correct differential diagnosis if the lung lesions in neuroblastoma patients. Careful implementation of the treatment protocol and timely assessment of response is extremely important. Patients with lung metastases have statistically significantly worse prognosis for the disease.

### PO-365. Combined Chemo‐ and Targeted Therapy in Primary Resistant/Relapsed Neuroblastoma Patients: A Single‐Center Experience {#pbc27455-sec-5940}

[I. Kazantsev]{.ul} ^1^, A. Gevorgyan^1^, T. Jukhta^1^, P. Tolkunova^1^, A. Kozlov^1^, T. Andreeva^1^, E. Morozova^2^, S. Safonova^1^, Y. Punanov^1^, L. Zubarovskaya^3^, B. Afanasyev^4^

*^1^R.M.Gorbacheva Memorial Institute for Pediatric Oncology‐ Hematology and Transplantation, Pediatric Oncology, Saint‐Petersburg, Russia; ^2^R.M.Gorbacheva Memorial Institute for Pediatric Oncology‐ Hematology and Transplantation, Hematology, Saint‐Petersburg, Russia; ^3^R.M.Gorbacheva Memorial Institute for Pediatric Oncology‐ Hematology and Transplantation, Pediatrics, Saint‐Petersburg, Russia; ^4^R.M.Gorbacheva Memorial Institute for Pediatric Oncology‐ Hematology and Transplantation, Transplantation, Saint‐Petersburg, Russia*

**Background/Objectives**: Neuroblastoma (NB) is the most common extracranial pediatric tumor. While overall prognosis is generally good the results in primary resistant/relapsed NB are still dismal. There are no established guidelines for these patients with second‐line therapy not being a curative option in most cases in spite of moderately good initial response rate. There is some data on targeted therapy being able to improve the results in this population.

**Design/Methods**: We review a consecutive cohort of 61 patients with median age of 5 (range 1‐20) years with primary resistant (n=30) or relapsed (n=31) NB receiving a combination of chemotherapy (irinotecan, temozolomide) and targeted therapy (sirolimus, dasatinib) in 2008 to 2017. Most patients (n=53) had disseminated disease at the time of therapy initiation, were exposed to 1‐3 lines of salvage chemotherapy (n=58) achieving clinical response in 26(43%) cases, 43 patients had previous exposure to topoisomerase I inhibitors. A total of 231 courses with a median of 4 (range 1‐12) courses per patient were performed with response routinely evaluated after each 3 courses and therapy stopped at disease progression. Fourteen (23%) patients with clinical response received additional high‐dose chemotherapy, immune therapy or ALK inhibitors.

**Results**: While CR was reached only in 6 patients, 22 patients achieved PR (20 patients becoming MIBG‐negative) with clinical response observed in 51 (84%) patients. The median EFS is 8 months and 13 of 16 patients currently alive received additional therapy. The therapy was characterized by acceptable toxicity (mostly hematological), which allowed using it in outpatient settings.

**Conclusions**: Although the combination used is not curative in the majority of cases it provides a good response rate and median EFS compared to historic cohorts (London W, 2017) in a very high‐risk population and is well tolerated. The factors determining the response and best options for remission consolidations are still to be determined.

### PO-366. Testis Involvement in Neuroblastoma: Report of Three Cases in the Turkish Pediatric Oncology Group Neuroblastoma Study and Review of the Literature {#pbc27455-sec-5950}

[R. Kebudi]{.ul} ^1^, B.S. Koc^2^, F. Akici^3^, F.B. Cakir^4^, O. Gorgun^1^, N. Olgun^5^

*^1^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^Istanbul University Cerrahpasa Medical Faculty, Pediatric Hematology and Oncology, Istanbul, Turkey; ^3^Kanuni Sultan Suleyman Training and Research Hospital, Pediatric Oncology, Istanbul, Turkey; ^4^Bezmi Alem University School of Medicine, Pediatric Hematoogy and Oncology, Istanbul, Turkey; ^5^Dokuz Eylul University Oncology Institute, Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. Primary and secondary testicular involvement is extremely uncommon in neuroblastoma.

**Design/Methods**: All children with neuroblastoma treated with the Turkish Pediatric Oncology Group (TPOG) ‐ Neuroblastoma Study and who had testis involvement either at diagnosis or at relapse were retrospectively evaluated. A review of all cases with neuroblastoma and testis involvement in the literature was done.

**Results**: There were three children with NB documented to have involvement of the testes, two at diagnosis, one at recurrence, within the 559 cases (0.5%) treated with the Turkish Pediatric Oncology Group (TPOG) ‐ Neuroblastoma Protocol. All had advanced stage. Two were infants. The third case had first recurred in the central nervous system, followed by the testis. All cases were histopathologically confirmed. Fifty‐four cases of testicular or paratesticular neuroblastoma have been reported in children, and most cases represent metastases from an adrenal neuroblastoma as in the three cases in our series.

**Conclusions**: In conclusion, testis involvement is extremely uncommon in neuroblastomas. Neuroblastoma should be considered in the differential diagnosis of testicular mass. Scrotal ultrasonography should be used as the first diagnostic tool and an abdominal ultrasonography shall be done additionally. Testis examination should be performed at diagnosis and regularly during follow‐up for boys diagnosed with neuroblastoma. Testes may be sanctuary sites when neuroblastoma is metastatic as is the case in leukemia.

### PO-367. Bone Marrow Infiltration in Neuroblastoma and Associated Hematological Features {#pbc27455-sec-5960}

A. Ahmad^1^, [F.S. Khan]{.ul} ^2^

*^1^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Paediatric Haematology/Oncology, Lahore, Pakistan; ^2^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Paediatric Haematology, Lahore, Pakistan*

**Background/Objectives**: Neuroblastoma is the second commonest solid tumor in children accounting for 8--10% of childhood cancers in Europe & USA and less common in developing countries like Pakistan. Bone marrow infiltration in Neuroblastoma occurs in advanced stage disease & accurate assessment of bone marrow infiltration in newly diagnosed cases is of immense significance.

Objectives: Determining the frequency and pattern of bone marrow infiltration in Neuroblastoma and its correlation with hematological parameters as N‐Myc amplification and cytogenetics and more sophisticated tests are not available in resource limited settings like a public sector hospital in Pakistan.

**Design/Methods**: This study included 83 newly diagnosed cases of Neuroblastoma from January 2016 to December 2017 in the departments of Paediatric Haemtology and Paediatric Haematology/Oncology of the Children\'s Hospital Lahore Pakistan. Clinicohaematological parameters and bone marrow biopsies for metastases were analyzed, cases on chemotherapy were excluded from the study. The data was analyzed using SPSS.

**Results**: Anemia was equally common in cases with and without marrow infiltration while leucopenia & thrombocytopenia were significantly (*p* value 0.009 & 0.002) associated with marrow infiltration. Bone marrow infiltration was present in 42 cases (50.6 %), 20 cases (47.6%) both aspirate and trephine biopsies were positive. There were 28 positive marrow aspirates, 05 showing focal infiltration, diffuse infiltration in 18 while rosettes were seen in 8 cases and 07 had both focal and diffuse infiltrates. Infiltration in 34 trephines was seen with focal infiltration in 20 cases & diffuse infiltration in 07 and both focal and diffuse infiltrates in another seven cases, while Fibrosis was present in seven cases. Bilateral infiltration was present in 6 trephine biopsies.

**Conclusions**: Outcome of high risk disease is usually poor, with long‐term survival being less than 50% in Low‐Income Countries positing thereby necessity of early detection of advanced disease.

### PO-368. Use of Plerixafor in Stem Cell Collection in Autologous Stem Cell Transplant in Paediatric Age Group: A Single Centre Experience from India {#pbc27455-sec-5970}

[V. Khandelwal]{.ul} ^1^, D. Doval^1^, D. Choudhary^1^, S. Sharma^1^, M. Kumar^1^, R. Setia^2^, A. Handoo^3^, B. Sharma^1^

*^1^BLK Superspeciality hospital, Haematooncology and BMT, Delhi, India; ^2^BLK Superspeciality hospital, Transfusion medicine, Delhi, India; ^3^BLK Superspeciality hospital, Haematology, Delhi, India*

**Background/Objectives**: High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) has been recommended in high‐risk neuroblastoma, relapsed or refractory lymphoma, and high risk Ewing\'s sarcoma. Plerixafor has been approved for use in combination with granulocyte‐colony‐stimulating factor for hematopoietic stem cell collection by apheresis in adults with multiple myeloma or non‐Hodgkin lymphoma. However, its use, efficacy and side effects in pediatric patients is not well‐studied or reported. We report our experience with use of Plerixafor in stem cell collection for Autologous HSCT in High risk neuroblastoma in children aged between 3 year to 4 year.

**Design/Methods**: A retrospective observational analysis was performed studying medical records on all pediatric patients who received plerixafor as part of the mobilization regimen between March 2015 and March 2018. The primary outcome was stem cell yield. Secondary outcomes included the ability to undergo autologous HSCT and engraftment status.

**Results**: Four stem cell collections by apheresis after mobilization with GCSF and Plerixafor performed on pediatric patients. Dose of Plerixafor used was 0.24 mg/kg body weight by subcutaneous (SC) injection. No major adverse events with plerixafor administration or apheresis collections were reported. All four case were high risk neuroblastoma and they were heavily pre treated paediatric patients aged between 3 to 4 years. In two patient Plerixafor was used electively with G‐CSF on Day 4 and in two patients it was used when yield of CD34+ stem cell with GCSF was very low. In both the patients Peripheral blood stem cell harvest after plerixafor injection provided adequate dose of stem cells for autologous HSCT. Median dose of of CD34+ cells/kg collected was 3.4 million. All of them engrafted. Median time for Neutrophil and platelet engraftment was 10 days and 15 days respectively.

**Conclusions**: Plerixafor in combination with G‐CSF is a safe and potentially helpful mobilization agent in heavily pre treated paediatric patients.

### PO-369. αβ T‐Cell‐Depleted Haploidentical Hematopoietic Cell Transplantation and Posttransplant Immunotherapy using Zoledronate and Interleukin‐2 in Children with Relapsed, High‐Risk Neuroblastoma {#pbc27455-sec-5980}

[K.N. Koh]{.ul} ^1^, H.J. Im^1^, N. Kim^2^, H. Kim^1^, S.H. Kang^1^, J.W. Yoo^1^, S.Y. Min^1^, Y.S. Kim^1^, E.S. Choi^1^, C.J. Park^3^, S. Jang^3^, H.M. Kim^4^, J.J. Seo^1^

*^1^Asan Medical Center Children\'s Hospital‐ University of Ulsan College of Medicine, Pediatrics, Seoul, Republic of Korea; ^2^Asan Medical Center‐ University of Ulsan College of Medicine, Asan Institute for Life Sciences, Seoul, Republic of Korea; ^3^Asan Medical Center‐ University of Ulsan College of Medicine, Laboratory Medicine, Seoul, Republic of Korea; ^4^Wonju College of Medicine‐ Yonsei University, Pediatrics, Wonju, Republic of Korea*

**Background/Objectives**: We performed a pilot study to evaluate the feasibility and efficacy of high‐dose ^131^I‐metaiodobenzylguanidine (HD‐MIBG) with αβ T‐cell‐depleted haploidentical hematopoietic cell transplantation (haplo‐HCT) and posttransplant immunotherapy using zoledronate and interleukin (IL)‐2 in children with relapsed, high‐risk neuroblastoma.

**Design/Methods**: Patients with relapsed, high‐risk neuroblastoma after high‐dose chemotherapy, who showed at least partial response to salvage treatment were eligible for this study. At 21 days prior to haplo‐HCT, all patients received a single intravenous infusion of ^131^I‐MIBG (10--12 mCi/kg). The reduced‐intensity conditioning regimen comprised fludarabine (40 mg/m^2^/day, days ‐8 to ‐5), thiotepa (10 mg/kg/day, day ‐4), melphalan (70 mg/m^2^/day, days ‐3 to ‐2) and rabbit anti‐thymocyte globulin (2 mg/kg at day ‐9 and 1 mg/kg at day ‐8). The graft underwent αβ T‐cell depletion by negative selection. Zoledronate and IL‐2 was administered after engraftment until 1 year posttransplant.

**Results**: Four patients (two in complete response and two in partial response), who relapsed after tandem high‐dose chemotherapy, were enrolled. HD‐MIBG treatment and conditioning were well‐tolerated. Engraftments were rapid and complete donor chimerism was achieved in all patients. Prior to transplant, αβ T cells were predominant among CD3+ cells (median 96%). At day 14 posttransplant, CD3+ cells predominantly comprised γδ T cells (median 82%). Three patients received 3--7 rounds of zoledronate and IL‐2 to stimulate and expand γδ T cell numbers after haplo‐HCT. Although γδ T cell numbers decreased over time after transplant, administration of zoledronate and IL‐2 transiently reversed the decline after 6 of 12 administrations. Three patients developed acute graft‐versus‐host disease (GVHD) but none developed chronic GVHD. Two patients remained disease‐free without chronic GVHD, while two patients died due to progressive disease.

**Conclusions**: Our results suggest that HD‐MIBG with αβ T‐cell‐depleted haplo‐HCT and posttransplant immunotherapy using zoledronate and IL‐2 is a feasible treatment with possible benefit that warrants further investigation.

### PO-370. Neuroblastoma in Low Middle Income Country: Lesson from Yogyakarta, Indonesia {#pbc27455-sec-5990}

[S.D. Kristian]{.ul} ^1^, S. Sutaryo^1^

*^1^Faculty of Medicine‐ Universitas Gadjah Mada ‐ Dr. Sardjito General Hospital‐ Yogyakarta‐ Indonesia, Department of Child Health, Yogyakarta, Indonesia*

**Background/Objectives**: Factors determining cure rate in children with neuroblastoma (NB) depend on some factors, not only protocol. General health, nutritional state, hospital‐ and house‐related infection, socio‐economic factors, genetic factors, diagnostic and risk stratification, drug availability, expertise of pediatric oncology team, and finally, protocol and protocol adherence.

**Design/Methods**: This is a retrospective review of all children under 18 years old with NB in children ward of Dr. Sardjito General Hospital, Yogyakarta, Indonesia from 2012‐2016. Data were taken from Yogyakarta Pediatric Cancer Registry (YPCR) and medical record.

**Results**: From 2012‐2016, we had 39 patients with NB. They were diagnosed based on histopathology. They were treated with OPEC protocol. Only 6 (15.4%) patients were alive at the end of study. OPEC protocol along with excellent supporting care gave promising result in developed country 20 years ago, around 40% in overall survival, even for high risk patients. But it did not give same result in low middle income country. The problems in low middle income country are most of patients came in stage IV disease (82.1%) and poor nutritional state (92.0%). Most of deaths were caused by sepsis (37.5%), it indicated that infection rate during therapy was high. Most of patients came from low educated family (48.3%) and it might implicate in high number of lost to follow up (43.6%). Biologic and genetic examination for risk stratification also could not be done.

**Conclusions**: From 5 year experience with 39 patients, the main problem is from outside the protocol. Most of the patients came late. Lack of access to biologic risk stratification, poor supporting care during therapy, and abandonment also became a problem.

### PO-371. Advanced Neuroblastoma: Experience with Limited Resources {#pbc27455-sec-6000}

[B. Kumar]{.ul} ^1^, V.D. upadhyaya^1^, R. yadav^2^

*^1^sanjay gandhi post graduate institute of medical sciences, paediatric surgical superspeciality, Lucknow, India; ^2^sanjay gandhi post graduate institute of medical sciences, radiodiagnosis, Lucknow, India*

**Background/Objectives**: Neuroblastoma is the most common extra‐cranial childhood tumour characterised by spectrum of clinical presentations and diverse prognosis. Here, we present our experience with few cases of advanced neuroblastoma (Stage III/IV; INSS) managed with limited resources.

**Design/Methods**: All patients with advance neuroblastoma (stage III/IV) from July 2012 to June 2017; managed at our centre were included. Chemotherapy offered to all patients while Radiotherapy / Tumour Resection was done when feasible. Final outcome was categorised as Complete Response (CR), Partial Response (PR), No Response (NR) and Progressive Disease (PD). Survival analysis for significance of stage and age was done.

**Results**: Ten patients with neuroblastic origin tumours (1 ganglioneuroma, 1 ganglioneuroblastoma, 8 neuroblastoma) were included in the study. 4 patients were female and age ranged from 9 months to 12 years (median age 4 years). By location, one had mediastinal tumor while rest had abdominal tumor (1 pelvis, 4 paraspinal and 4 adrenal). 4 patients detected bony or lung metastasis at time of diagnosis. Chemotherapy was given in 9 patients and surgery was performed in 6 patients while 2 patients received local radiotherapy in addition. 2 patients were referred to higher center due to partial response, disease progression or recurrence within one year. 2 patients were died. Only 6 patients are alive (including patient with ganglioneuroma) but one patient is on palliative care because of multiple bony recurrences after one year. Follow‐up ranged from 8 months to 5 years (median 2 years).

**Conclusions**: Age, stage and response to chemotherapy were major factors for outcome. All patients \<1 year with stage III achieved CR except one patient with ganglioneuroblastoma who developed PD. Only one patient with stage IV showed CR but developed recurrence within year.

### PO-372. Success of the HR‐NBL1/SIOPEN Trial Local Control Strategy in High‐Risk Neuroblastoma Patients Receiving High‐Dose Therapy and Stem Cell Transplantation {#pbc27455-sec-6010}
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**Background/Objectives**: Investigation of the local relapse rate (LRR) and outcomes in high‐risk neuroblastoma.

**Design/Methods**: HR‐NBL1/SIOPEN treatments included Rapid COJEC or N5‐MSKCC induction, plus two TVD courses if unsatisfactory metastatic response, attempted primary tumour gross resection, HDT/SCT (BuMel or CEM) and 21Gy radiotherapy to the primary site followed by 13‐cis‐RA with addition of ch14.18/CHO antibody after 2009. Analysis included patients starting treatment prior to 2016, with HDT/SCT, alive without event 30 days after SCT and information on radiotherapy. The cumulative incidence of local relapse/progression (CILR/P) either isolated or combined with other sites was calculated considering competing risks from other causes including isolated distant relapse/progression (R/P), R/P at unknown sites, death or secondary malignancy without prior R/P

**Results**: Radiotherapy and response data was available in 1297 patients (median follow‐up 4.9 years) with 5‐year EFS (5‐yr EFS) of 46%±2 and 5‐year CILR/P of 17%±1. Isolated CILR was observed in 5%±1 whilst the combined (local and distant) CIR was 12%±1. 963 were in local CR (LCR) and 334 had \<LCR with 5yr‐EFS (5‐yr CILR/P) of 49%±2 (15%±1) and 38%± 3 (23±3), respectively. Radiotherapy was given as planned in 90% of the patients with 5‐yr EFS (5‐yr CILR/P) of 53%±2 (15%±1) versus 43%±5 (22%±4) for patients without radiotherapy. Decision not to irradiate was related to very young age and to large radiotherapy fields based on pre‐operative volumes. Adjusted for stage, age, surgical result, HDT/SCT regimen and remission status, radiotherapy had a significant impact on EFS and CILR/P with hazard ratios of 0.76 (p=0.014) and 0.57 (p=0.003).

**Conclusions**: Local radiotherapy with 21Gy is important for a better local control rate. European historical data previously had shown a 40% LRR. Further research to optimise the use of radiotherapy is needed. Most importantly, local radiotherapy contributed to improved outcomes.

### PO-373. Targeting Folate‐Mediated One‐Carbon Metabolism in MYCN Amplified Neuroblastoma {#pbc27455-sec-6020}

[T. Lammens]{.ul} ^1,2^, K. Vandemeulebroecke^1^, A. Diez‐Fraile^1^, T. Bauters^1,3^, G. Laureys^1,2^
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**Background/Objectives**: Despite remarkable progress in the understanding of neuroblastoma biology during the past decades, high‐risk neuroblastoma remains a devastating disease. Genetic aberrations identified in tumor samples might eventually lead to identification of novel therapeutic targets. Detailed analysis of routine diagnostic array comparative genomic hybridization (CGH) assays might contribute in this process.

**Design/Methods**: Routine diagnostic aCGH was performed as described in Kumps C. et al., 2013. Association of gene expression with clinical and genetic parameters was evaluated *in silico* using the R2 (r2.amc.nl) platform. The impact of methotrexate on apoptosis, cytotoxicity and viability of neuroblastoma cell lines was evaluated *in vitro* (ApoTox‐Glo^TM^ Triplex assay, Promega).

**Results**: During routine aCGH diagnostic work‐up of a neuroblastoma patient, we observed a focal amplification encompassing the *MTHFD1L* gene, involved in folate‐mediated one‐carbon metabolism. Expression of *MTHFD1L* and nine other folate‐dependent one‐carbon metabolism genes (out of 19 known in the process) was found significantly higher in stage 4 disease and significantly correlated with the presence of *MYCN* amplification and older age (dataset GSE16476 and GSE16237). In addition, high expression of *MTHFD1L*, *ATIC*, *TYMS*, *MTHFD2* and *DHFR* was found to be associated with overall survival and event‐free survival. Treatment of neuroblastoma cell lines with methotrexate, a widely used folate antagonist blocking one‐carbon metabolism, revealed that methotrexate provoked significant cell death by apoptosis in those cell lines characterized by *MYCN* amplification.

**Conclusions**: Our data point towards the importance of targeting the folate‐mediated one‐carbon metabolism pathway in *MYCN*‐amplified neuroblastoma. These results further provide a rational base for further investigating the one‐carbon metabolism in neuroblastoma disease. The current results are in line with a previous report illustrating the association of expression of the MTX‐transporter gene reduced folate carrier (*SLC19A1*) with *MYCN* overexpression in neuroblastoma (Lau TD et al., 2015, Oncotarget).

### PO-374. Prospective Germline Next Generation Sequencing Identifies Novel Variants and Frequent DNA‐Damage Response Pathway Alterations in Patients with Neuroblastoma {#pbc27455-sec-6030}

[K. Langenberg‐Ververgaert]{.ul} ^1^, A. Villani^1^, W. Lo^2^, T. Young^3^, S. Davidson^3^, N. Anderson^3^, B. Gallinger^4^, D. Morgenstern^1^, S. Meyn^4^, L. Brunga^3^, D. Malkin^1^, A. Shlien^3^, M. Irwin^1^
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**Background/Objectives**: ALK and PHOX2b are the most commonly mutated genes in patients with familial neuroblastoma (NB). Advances in next‐generation sequencing lead to the identification of novel germline variants with potential roles in patients with and without suspected cancer predisposition syndromes.

**Design/Methods**: Patients with newly diagnosed and relapsed malignancies, including 29 NB patients, were enrolled to sequence germline DNA and tumor DNA and RNA. Rare germline non‐synonymous substitutions and indels were called using GATK. Population allele frequencies were compared to ExAC and internal databases and cross‐referenced to known polymorphisms (dbSNP). Variant pathogenicity was classified at multi‐disciplinary molecular tumor boards. Rare variants of uncertain significance (VUS) with supportive corresponding somatic data, patient phenotype and/or literature or in‐silico functional analyses were termed "Variants of uncertain significance with limited evidence for pathogenicity' (VUS‐LEP)".

**Results**: To date, analyses have been completed on 17/29 NB patients. Patient history was retrospectively categorized as "high genetic risk" (HGR) in 5/17 patients based on ≥1 of the following criteria: (1) family history of NB and/or significant family history of other cancer(s); (2) patient with NB and another primary tumor; or (3) NB plus congenital anomalies. Pathogenic variants in known cancer‐predisposition genes involved in DNA‐repair, including BRCA1, CHEK2, and PALB2, were identified in 2/5 HGR patients. For the 12 non‐HGR patients, ≥ 1 rare likely pathogenic variant or VUS‐LEP in DNA‐repair genes, including BAP1, BRCA2, ERCC2, RAD51, and BLM, were identified in 7 patients (58%). Notably, an additional 3/12 non‐HGR and 2/5 HGR patients harboured VUS‐LEPs in other cancer‐predisposition genes including EZH2, SOS1 and DICER1.

**Conclusions**: Our preliminary results identified frequent DNA‐repair pathway alterations and variants in genes not commonly associated with NB predisposition syndromes, even in the absence of family history. These findings may have implications for therapies (e.g. PARP inhibitors) and genetic counselling for patients and families.

### PO-375. Treatment of High‐Risk Neuroblastoma in a Southeast Asian Hub of Medical Tourism {#pbc27455-sec-6040}

[A. Lee]{.ul} ^1^, C.H. Chui^2^, L. Aung^1^, W. Wong^3^

*^1^Mount Elizabeth Hospital, Children\'s Haematology and Cancer Centre, Singapore, Singapore; ^2^Mount Elizabeth Medical Centre, Surgery Centre for Children, Singapore, Singapore; ^3^The University of Hong Kong, Department of Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Outside Europe and North America, little is known about the outcomes of children suffering from high‐risk neuroblastoma. We aim to contribute our experience from the Southeast Asia.

**Design/Methods**: This is a retrospective study on high‐risk neuroblastoma treated from 2008 to 2014 in a single institution. Both new cases and patients who had been partially treated were accepted for intensive treatment. Survival was measured from the date of autologous transplantation to the day of relapse, death or the end of 2017. Disease status at the time of transplantation, country of residence, conditioning regimen, and timing of transplantation from diagnosis were examined for their impact on survival.

**Results**: Twenty‐four children (16 boys) of mean age 4.6 (1.5‐11.1) years were treated. Three children were diagnosed de novo while the rest had received some treatment elsewhere. Five children were considered "local" (from Singapore, Malaysia and Indonesia). At the time of transplant, nine children were in good partial remission while 15 were in complete remission. Nine children were conditioned with carboplatin‐etoposide‐melphalan and the rest with busulfan‐melphalan. In addition, six received therapeutic 131I‐iodobenzylguanidine and eight received total body irradiation as part of the conditioning. Nine children had a late transplantation (\> 8 months after diagnosis) while 15 were transplanted early. Eleven children relapsed and died from neuroblastoma. Three children died in remission from accident, massive gastrointestinal bleeding, and treatment‐associated myelodysplasia, respectively. The 3‐year event‐free/overall survival was 42%. None of the studied factors had any statistically significant impact on survival, although there was a trend towards better survival if the patient is local as compared with other countries (80% vs 32%, p=0.07).

**Conclusions**: In a real‐life experience where children with high‐risk neuroblastoma are accepted for treatment despite prior suboptimal therapy, an aggressive approach with intensive chemotherapy and surgery results in \>40% of long‐term survivors.

### PO-376. Potential Anti‐Tumor Effect of Calcineurin Inhibitor on Neuroblastoma by Inhibiting its Catalytic Subunit PPP3CB {#pbc27455-sec-6050}

[Y. Li]{.ul} ^1^, I. Shakhova^2^, F. Yu^3^, Y. Kaneko^3^, Y. Nakamura^3^, M. Ohira^4^, H. Izumi^1^, M. Yasunami^1^, T. Mae^1^, S.R. Varfolomeeva^2^, A.G. Rumyantsev^2^, A. Nakagawara^1,5^
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**Background/Objectives**: Calcineurin is a calcium‐dependent serine/threonine phosphatase that is involved in a number of biological processes. Aberrantly activated calcium/calcineurin/NFAT (nuclear factor of activated T‐cells) signaling promotes tumor proliferation, invasion and angiogenesis. We previously identified a gain‐of‐function mutation in the calcineurin catalytic subunit PPP3CB in a neuroblastoma (NB) tissue with MYCN amplification. Additionally, we have found that high expression of PPP3CB significantly predicts a poor outcome in NB, independent of known clinical prognostic factors.

**Design/Methods**: Overexpression and shRNA‐mediated knockdown were conducted in several NB cell lines to investigate the functional roles of PPP3CB and its gain‐of‐function mutant in NB. NB cell lines with or without MYCN amplification were treated with two kinds of calcineurin inhibitor (CaI) cyclosporin A (CsA) and FK506. Cell viability, proliferation and cell death were assessed by the MTT assay, trypan blue exclusion and cell growth curve assay and the FACS analysis, respectively. Expressions of PPP3CB, NFAT and its target genes were detected by Western blot analysis.

**Results**: Overexpression of wildtype or mutated PPP3CB (PPP3CBmut) promoted cell growth, but PPP3CB knockdown decreased cell growth in NB cells. PPP3CB and PPP3CBmut activated NFAT2 and NFAT4 transcription factors and inhibited GSK3β activity, resulting in the increase in the expressions of c‐Myc, MYCN and β‐catenin. Treatment with calcineurin inhibitors suppressed cell proliferation and induced apoptotic cell death in several NB cell lines. Expression of PPP3CB along with those of c‐Myc, MYCN and β‐catenin was decreased in the mRNA and protein levels in response to CaIs.

**Conclusions**: Our findings demonstrate that elevated expression of PPP3CB and the expression of its constitutively active mutant both contribute to the aggressive behavior of NB tumors and calcineurin inhibitors have a strong anti‐tumor activity in vitro by targeting PPP3CB. Our results suggest that inhibition of calcineurin activity might have therapeutic potential for high‐risk NBs.

### PO-377. The Clinical Significance of the Expression of B7H3 and PD‐L1 in Neuroblastoma {#pbc27455-sec-6060}

[R. Liao]{.ul} ^1^, Y. Zhang^2^, J. Wang^1^, Z. Zhen^1^, J. Zhu^1^, S. Lu^1^, F. Sun^1^, J. Huang^1^, X. Sun^1^
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**Background/Objectives**: We investigated the clinical significance of the expression level of B7H3 and PD‐L1 in neuroblastoma(NB).

**Design/Methods**: Clinical data and tumor paraffin tissues of NB were collected at Sun Yat‐Sen University Cancer Center from January 2004 to December 2015. The expression of B7H3, PD‐L1 were detected by immunohistochemical technology. The relationship between the B7H3, PD‐L1 expression and the clinical prognosis of patients with NB was analyzed.

**Results**: A total of one hundred patients with NB, of which, the low risk, intermediate risk and high risk NB were 15%, 18% and 67%, respectively. 79% of the patients were B7H3 positive. 58% were low expression and 42% were high expression. The B7H3 high expression was positively related with risk stratifications, stage, MYCN gene status. Four‐year EFS of patients with low and high expression of B7H3 was 41.8% and 27.1%, respectively, *P*=0.051; 4‐year OS was 58.6% and 63.8%, respectively, *P*=0.739. For the 33 non‐high‐risk patients, 4‐year EFS of patients with low and high expression of B7H3 was 94.7% and 44.2%, respectively, *P*=0.003; 4‐year OS was 100.0% and 90.9%, respectively, *P*=0.157. For the 67 high‐risk patients, 4‐year EFS of patients with low and high expression of B7H3 was 22.1% and 13.9%, respectively, *P*=0.805; 4‐year OS was 57.7% and 36.3%, respectively, *P*=0.151. The positive rate of PD‐L1 in NB tumor tissue was 57.0%, 98% of patients were low expression. The expression of PD‐L1 of NB was not significantly correlated with tumor sizes, age, gender, stage, treatment efficiency, MYCN gene status, risk stratifications and survival. Multivariate analysis showed that B7H3 positive, MYCN amplification were independent adverse prognostic factors for OS. B7H3 positive and advanced stage were independent adverse prognostic factors for EFS (*P* \<0.05).

**Conclusions**: This study showed B7H3 may be used as a new prognostic indicator in NB in the future.

### PO-378. Study on the Role of TGF Beta 1/GLI1 Pathway in the Epithelial‐Mesenchymal Transition of Neuroblastoma {#pbc27455-sec-6070}

J. Shao^1^, [Z. Lu]{.ul} ^2^
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**Background/Objectives**: Metastasis of neuroblastoma has been shown to be associated with the acquisition of epithelial‐mesenchymal transition (EMT) while the molecular mechanisms are uncertain. Transforming growth factor TGF beta 1 involved in the development and progression of EMT in tumor cells. Our previous studies found that TGF beta 1 induced the occurrence of EMT in human neuroblastoma cell line through non Smad signaling pathway. The transcription factors GLI was a key regulator in EMT induced by TGFβ1 in human neuroblastoma cells, and also is a key transcription factor downstream of Hedgehog signaling pathway. Our aim was to investigate the molecular mechanism of TGF beta 1/GLI1 regulating EMT in neuroblastoma.

**Design/Methods**: TGF beta 1 induced EMT phenotype in vitro culture of neuroblastoma cell lines. Study on the molecular mechanism of Hedgehog/GLI signaling pathway in EMT induced by TGF beta 1 in neuroblastoma cells by westernblot, fluorescence quantitative PCR, siRNA interference, lentivirus mediated gene overexpression and knockout.

**Results**: The expression of Smad2 and Smad3 were not increased in EMT induced by TGF‐β1 in neuroblastoma SK‐N‐SH cells.

The expression of transcription factor GLI1 induced by TGF‐β1 increased significantly in neuroblastoma cells. Interference or overexpression of classical Smad pathway did not affect the expression of EMT and GLI induced by TGFβ1.

Our further study showed that the increase of GLI1 expression had not been affected only by the inhibition of the classical Hedgehog pathway.

In neuroblastoma cell lines, TGF beta 1 up regulated the expression of GLI1 protein and phosphorylation of AKT dose‐dependent.

**Conclusions**: It is suggested that there are other signaling pathways together with the Hedgehog pathway, which up‐regulated the expression of CLI1 induced by TGF beta 1 in neuroblastoma, The abnormal activation of PI3K/AKT pathway may involved in the increase of GLI and the expression of EMT, which is closely related to the metastasis of neuroblastoma.

### PO-379. Plasma Cell Free DNA Quantification is Highly Correlated to Tumor Burden in Children with Neuroblastoma {#pbc27455-sec-6080}

[X. Ma]{.ul} ^1^, X. Wang^1^, L. Wang^2^, Y. Su^1^, Z. Yue^1^, T. Xing^1^, W. Zhao^1^, Q. Zhao^1^, C. Duan^1^, C. Huang^1^, D. Zhang^1^, M. Jin^1^, X. Cheng^2^, Y. Liu^2^
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**Background/Objectives**: To evaluate plasma cell‐free DNA (cfDNA) as a promising biomarker for neuroblastoma (NB) tumor burden.

**Design/Methods**: Seventy‐nine eligible patients with newly diagnosed NB were recruited from Beijing Children\'s Hospital between April 2016 and April 2017. Additionally, from September 2011 to June 2017, 79 patients with stable NB were evaluated with a median follow‐up time of 21 months. Approximately 2 ml of peripheral blood was drawn upon enrollment, and plasma cfDNA levels were measured via quantitative polymerase chain reaction (qPCR). Total cfDNA analysis was performed using the long interspersed nuclear element 1 (LINE‐1) 79 bp fragment, and DNA integrity was calculated by the ratio of the LINE‐1 300 bp fragment to the LINE‐1 79 bp fragment.

**Results**: A total of 79 NB patients with a median age of 36 months comprised the group of newly diagnosed NB patients. The main primary tumor site was the retroperitoneal and adrenal region (81%). Three or more metastatic sites were found in 17.7% of patients. Stable NB patients older than 18 months comprised 98.7% of the stable NB patients. Neuron‐specific enolase (NSE), lactate dehydrogenase (LDH) and cfDNA levels were dramatically increased in the newly diagnosed NB patients and significantly different from those in the stable NB patients. Moreover, the concentration of cfDNA was much higher in patients with larger tumors. By analyzing the area under the receiver operator characteristic (ROC) curve (AUC), the areas of total cfDNA, NSE and LDH levels were 0.953, 0.929 and 0.906, respectively.

**Conclusions**: The sensitivity and specificity data clarified that the level of circulating cfDNA in plasma can be considered as a reliable biomarker for describing tumor load in NB. The plasma cfDNA concentration was more accurate than the levels of LDH and NSE to describe the tumor burden in children with NB.

### PO-380. Clinical Significance of the GD2 and CD56 Immunostaining Procedure for Detection of Bone Marrow Metastasis in Neuroblastoma {#pbc27455-sec-6090}
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**Background/Objectives**: Bone marrow (BM) examination is necessary for risk stratification of neuroblastoma (NBL). We have used the immunostaining procedure using GD2 and CD56 antibodies to evaluate BM metastasis and residual BM disease after induction chemotherapy.

**Design/Methods**: We retrospectively reviewed clinical courses of NBL patients with BM metastasis diagnosed in our institution between January 2000 and December 2015. Positive rates of the GD2 and CD56 immunostaining procedure in BM, treatment outcomes, and sites of relapse were evaluated.

**Results**: Twenty eight out of 38 patients with any metastases were proved to have BM metastasis at initial diagnosis. By the INRG classification, 22 were stratified into the high risk (HR) group. Positive rates of the GD2 and CD56 immunostaining procedure at initial BM examination were 100% (28/28) and 96.4% (27/28), respectively. For HR group patients, peripheral blood stem cell (PBSC) harvest was initiated after clearance of GD2 and/or CD56 positive NBL cells from BM. After all, Seventeen HR patients receipt high dose chemo‐radiotherapy followed by auto PBSC rescue. Four patients receipt allograft because of continuous positive detection by immunostaining after induction chemotherapy. One patient did not undergo high‐dose therapy because of early death. In the HR group, 5‐years EFS, OS, and cumulative incidence of relapse were 50.0% (95%CI: 28.2‐68.4), 58.3% (95%CI: 35.0‐75.8), and 41.5% (95%CI: 14.6‐59.9), respectively with the median follow‐up period of 53.5 months (range: 5‐196). Eight patients relapsed in primary site (n=3), primary site and BM (n=3), and central nervous system (n=2). Interestingly, relapsed NBL cells became negative by the GD2 immunostaining procedure after cord blood transplantation in one case, although the CD56‐staining positively detected relapsed tumor cells.

**Conclusions**: The GD2 and CD56 immunostaining procedure is useful in terms of sensitivity and specificity to detect BM metastasis and post‐induction residual disease of NBL.

### PO-381. Liquid Biopsies Provide Exosomal MicroRNAs as Biomarkers of the Response to Induction Chemotherapy in High‐Risk Neuroblastoma Patients {#pbc27455-sec-6100}
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**Background/Objectives**: The response of High‐Risk (HR) neuroblastoma (NB) patients to induction‐chemotherapy lacks prognostic molecular indicators of sensitivity/resistance. Circulating exosomes represent the bioprint of the tumor cell of origin in liquid biopsies. We investigated the modulation of exosomal microRNAs (exo‐miRs) expression in HR‐NB‐patients in response to induction‐chemotherapy.

**Design/Methods**: Exosomes were isolated from plasma samples of 53 HR‐NB patients collected before and after induction‐therapy. Flow cytometry was used to detect GD2 positive vesicles. Exo‐miRs expression was measured by RTqPCR on a 381 miRNA panel. Data analyses included feature selection and pathway analysis.

**Results**: Exosomes isolated from plasma samples were GD2 positive, indicating that the vesicles are specifically secreted by tumor cells. We analysed the whole exosome population and found that the expression of 18 exo‐miRs (fold change\>1.5, P value\<0.05) was significantly modulated in response to chemotherapy, providing evidence that exo‐miRs may serve as biomarkers of the induction‐therapy. Cluster analysis demonstrated that exo‐miR profile can identify two groups of patients potentially reflecting different chemotherapy responses. Pathway analysis results showed that the majority of differentially expressed exo‐miRs are predicted to regulate drug efficacy/resistance. Generalized linear models identified three exo‐miRs that clearly differentiate poor and good responders. *In silico* analysis showed that these exo‐miRs interact with chemotherapeutics employed in the induction‐therapy (Cisplatin/Etoposide). The exo‐miRs profile in the middle phase of the treatment is under investigation to identify exo‐miRs that are early predictors of response and may allow a timely change in the induction protocol.

**Conclusions**: We demonstrated that HR‐NB plasma samples contain GD2 positive exosomes released by tumor cells. We obtained the proof of principle that exo‐miRs can be biomarkers of induction‐chemotherapy and indicators of susceptibility/resistance to specific drugs. These results pave the way for the application of exo‐miRs in liquid biopsies as circulating biomarkers of response and potentially development of NB targeted treatment.

### PO-382. Neuroblastoma in Children Under 12 Months of Age: Anthropometric and Demographic Characteristics {#pbc27455-sec-6110}

[M. Moschovi]{.ul} ^1^, N.M. Tagkou^1^, O. Klavdianou^1^, P. Kourou^1^, D. Stathaki^1^
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**Background/Objectives**: Neuroblastoma is the most common extracranial solid tumor of infancy and the 30% of the malignancies in children under the 12 months of age. The early onset of Neuroblastoma suggests a potential relationship between the age of diagnosis and the biology of the tumor. It is a study of the association between perinatal characteristics and the high incidence of the diagnosis of Neuroblastoma.

**Design/Methods**: 39 children with Neuroblastoma were involved, who diagnosed under 12 months of age and for which, systematic follow‐up or treatment was required. Parameters like residence, gender, birth weight and gestational age were analyzed.

**Results**: The age of diagnosis ranged from birth to 12 months. The 72% of the patients was aged less than 6 months at diagnosis. The patients that lived in urban centers represented 61.5%. We analyzed the age at diagnosis based on the residence. It was observed that in urban centers the ratio of age at diagnosis 0‐6 months vs. 7‐12 months was 3:1, whereas in the province the same ratio was 2:1. Males were 64% of the patients, but considering the residence, the percentage of males increased up to 71% in urban centers and decreased to 53% in the province. The duration of pregnancy was 31‐41 weeks, while gestational age ≤38 weeks had 31% of the cases. Delivery after scheduled cesarean section had the 41.5% of the patients. The birth weight ranged from 1,553gr to 4,775gr, whereas birth weight ≤3,200gr had the 55% of the patients.

**Conclusions**: Neuroblastoma among children under 12 months old appears more frequently during the first six months of life. Male\'s superiority is notable, mainly in urban centers. Gestational age \<38 weeks had 31% of the patients, while birth weight \<3,200gr had 55%. It means that prematurity, or the low birth weight in full term infants may be predisposing factors.

### PO-383. Neonatal Oncology Is a New Scientific Object of Modern Paediatrics: Children of First Year of Life are Unique Population with Increased Risk of Cancer {#pbc27455-sec-6120}
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*^1^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Institute of Management and Translational Medicine, Moscow, Russia; ^2^Dmitry Rogachev National Medical Research Center of Pediatric Hematology‐ Oncology and Immunology, Institute of Oncology‐ Radiology and Nuclear Medicine, Moscow, Russia*

**Background/Objectives**: Neonatal oncology -- is a new scientific object of modern paediatrics. Children of first year of life are unique population with increased risk of cancer. There are some features of diagnostics and treatment of children of this age group. Objective is to analyze the experience of Dmitry Rogachev Center in neonatal oncology.

**Design/Methods**: Three hundred eighty one patients admitted to Dmitry Rogachev Center during 2012‐2017 were analysed. Most of the patients were boys (63,9%). Median of onset of first clinical signs was 1,7 months (0,03 -- 12) and diagnosis -- 4,2 months (0,07 -- 12,6). Most of cases were neuroblastoma (62%), soft tissue sarcomas (11%), Wilms' tumor (11%), hepatoblastoma (10%) and malignant rhabdoid tumor (6%). Modified protocols (NB, SIOPEL, SIOP‐WT, Euro‐Hub and CWS) were used for treatment. In case of different diseases we used innovative approach of escalation or de‐escalation of therapy depending on disease.

**Results**: Most complicated cases of patients with neuroblastoma (NB) were children with 4S stage. Most of them (91,8%) were in obrservation group. Special attention was paid for patients with life‐threating syndromes. Reduced intensity chemo required. For these patients estimated probability of OS was 92,2% and EFS -- 61,3% in the median follow‐up 22,1 months. Events were registered usually after 12 months old. All hepatoblastoma patients of standard risk group survived and OS of all group was 85,7% in the median follow‐up of 25,2 months. OS of rhabdoid tumor group was about 25%. Several predisposition mutations were found (с.669_670del (p. C223\*, c.157 C‐T (p. R53\*, с.843 G‐A (p. W281\*). Predisposition syndroms were found in 16,6% children.

**Conclusions**: Cancer in patients under the first year of life is unique situation requiring individual multidisciplinary approach including rational chemotherapy, high‐tech surgery, radiation and cellular therapy. Predisposition syndromes are very important in these patients. New methods of diagnostics and therapy allow improvement of results.

### PO-384. Experience of Autologous Stem Cell Transplant in High Risk Neuroblastoma Without the Use of Chimeric Anti‐GD2 Antibody: A Single Centre Study from a Developing Country {#pbc27455-sec-6130}

[K. Mullanfiroze]{.ul} ^1^, S. Gupta^1^, S. Tulpule^1^, S. Sen^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Blood And Marrow Transplant, Mumbai, India*

**Background/Objectives**: Standard of care for treatment for high‐risk(HR) neuroblastoma(NB) includes remission induction with chemotherapy followed by surgery and myeloablative conditioning followed by autologous stem cell transplant(ASCT).This is followed by radiotherapy and immunotherapy. Chimeric anti‐GD2 antibody remains the main stay of immune therapy. However, financial constraints and unavailability, limits its use in the developing countries. Overall survival(OS) of 50‐65% has been reported in the developed world. In the PODC setting, OS has been reported at much less than 50%.

**Design/Methods**: Retrospective analysis of children who underwent ASCT for HR‐NB at a tertiary centre in western India, from May2012‐March2018 was conducted. All children were defined as HR based on either age at diagnosis and/or N‐Myc status and/or stage and/or histology.

**Results**: Nine HR‐NB children(4 girls,5 boys) aged 6months‐6years(median age‐36 months)underwent ASCT. ASCT was undertaken only after complete remission(CR), as evidenced by negative PET‐CT scan or MIBG scan and/or bone marrow biopsy tests, was confirmed. Busulfan‐Melphalan conditioning therapy was used for the entire cohort. Average stem cell dose was 5x106/kg. Average white cell and platelet engraftment was on day+11 and +13.5 respectively. Between day +60 to +90, all children underwent local radiotherapy followed by oral 13‐cis‐retinoic acid therapy for 6 months. Two children(22%) relapsed at 6 months from ASCT. With a median follow‐up of 13 months(range=1‐41 months), OS of the cohort, without the use of the chimeric antibody was 78%. Approximate cost of the ASCT was between 1600‐1900 USD at our centre.

**Conclusions**: In developing countries, ASCT should justifiably be offered to those children with HR‐NB who have achieved CR, especially when anti‐GD2 antibody is unavailable and its cost is prohibitory. Although this study\'s follow up is short, we recommend careful patient selection for aggressive therapy in this population as OS comparable to the developed world can then be achieved even without immunotherapy.

### PO-385. Polyethylene Glycol Derivatives Originally Extracted from Filamentous Bacteria Suppress the Proliferation of Neuroblastoma Cells {#pbc27455-sec-6140}

[E. Nagasaki‐Maeoka]{.ul} ^1^, K. Fujiwara^2^, T. Hirano^1^, Y. Ishizuka^1^, Y. Watanabe^1^, R. Hoshi^1^, S. Yoshizawa^1^, S. Uekusa^1^, H. Kawashima^1^, H. Kaneda^1^, T. Furuya^1^, K. Ohashi^1^, S. Uehara^1^, T. Koshinaga^1^

*^1^Nihon University School of Medicine, Pediatric Surgery, Tokyo, Japan; ^2^Nihon University School of Medicine, General Medicine, Tokyo, Japan*

**Background/Objectives**: We recently found that some polyethylene glycol derivatives (PEG‐X) originally extracted from filamentous bacteria strongly suppress the growth of many types of tumor cells, including neuroblastoma (NB). However, how PEG‐X exerts its antitumor effects remains unclear. In the present study, we investigated the molecular mechanisms underlying the cytotoxicity of PEG‐X on NB cells.

**Design/Methods**: The human‐derived NB cell lines NB9 (with *MYCN* amplification) and SK‐N‐AS (without *MYCN* amplification) as well as normal fibroblast cells were used for the study. The cell viability after PEG‐X addition was analyzed by a WST‐8 assay. The cell cycle distribution was determined using a flow cytometer (FACS). The expression of the cell cycle‐related proteins were analyzed by Western blotting.

**Results**: PEG‐X decreased the viability of NB9 and SK‐N‐AS cells in a dose dependent manner, and 1 μM of PEG‐X suppressed NB9 and SK‐N‐AS cell growth completely for at least 3 days. In contrast, more than 50% of normal fibroblast cells survived even at high concentrations of PEG‐X. A FACS analysis showed that the ratios of G0‐G1 phase and G2/M phase were increased by PEG‐X treatment, whereas the ratio of dead cells was hardly changed. Western blotting showed that the expression of the cell cycle‐related protein p21WAF1 was increased by PEG‐X treatment, but activation of p53 was not observed.

**Conclusions**: PEG‐X suppresses the cell viability in NB cells regardless of the presence or absence of *MYCN* amplification through the induction of p21WAF1 in a p53‐independent manner. To elucidate the detailed mechanism underlying the antitumor action of PEG‐X, we are now examining the effects of PEG‐X on the response of cells to several kinds of stress. Since PEG‐X showed limited effects on normal fibroblast cells, it has strong potential to become a new anti‐cancer drug.

### PO-386. Expression Profiles of Seven Minimal Residual Disease Markers in Bone Marrow and Peripheral Blood of Patients with High‐Risk Neuroblastoma {#pbc27455-sec-6150}

[N. Nishimura]{.ul} ^1^, K.K.M. Thwin^1^, T. Ishida^2^, S. Uemura^1^, N. Yamamoto^2^, A. Tamura^2^, A. Kozaki^2^, A. Saito^2^, K. Kishimoto^2^, D. Hasegawa^2^, Y. Kosaka^2^, N. Nino^1^, S. Takafuji^1^, T. Mori^1^, K. Iijima^1^

*^1^Kobe University Graduate School of Medicine, Pediatrics, Kobe, Japan; ^2^Kobe Children\'s Hospital, Hematology and Oncology, Kobe, Japan*

**Background/Objectives**: To determine the expression profiles of 7 minimal residual disease (MRD) markers in bone marrow (BM) and peripheral blood (PB) of patients with high‐risk neuroblastoma.

**Design/Methods**: Total 420 (307 BM and 113 PB) samples with clinical disease evaluations were obtained from 23 patients with high‐risk neuroblastoma treated at Kobe Children\'s Hospital and Kobe University Hospital between January, 2012 and January, 2018. mRNA expression of 7 MRD markers (CRMP1, DBH, DDC, GAP43, ISL1, PHOX2B, TH) was quantified by droplet digital PCR (ddPCR) and expressed as the copy number. Mann‐Whitney\'s U‐test was used to evaluate the difference between two groups.

**Results**: All patients were diagnosed as high‐risk neuroblastoma and treated according to the Japan Children\'s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG) protocol. Their BM and PB samples were obtained as frequently as possible during the entire course of treatment. At initial diagnosis, the total copy number of 7 MRD markers was significantly larger in BM than PB (24 BM samples from 14 patients and 10 PB samples from 10 patients). During follow‐up between the completion of induction therapy and the diagnosis of relapse, it was significantly larger in BM from relapsed patients than non‐relapsed patients (17 samples from 7 relapsed patients and 56 samples from 8 non‐relapsed patients). Although there was no statistical significance, it also tended to be larger in PB from relapsed patients than non‐relapsed patients (4 samples from 2 relapsed patients and 17 samples from 6 non‐relapsed patients).

**Conclusions**: Expression of 7 MRD markers in BM and PB samples may represent disease status and predict relapse in high‐risk neuroblastoma patients.

### PO-387. CD146 is a Potential Therapeutic Target in Neuroblastoma {#pbc27455-sec-6160}

[S. Obu]{.ul} ^1^, K. Umeda^1^, M. Sonoda^2^, I. Kato^1^, H. Hiramatsu^1^, K. Morita^3^, Y. Kamikubo^3^, E. Ogawa^2^, S. Okamoto^2^, H. Okajima^2^, T. Nakahata^4^, S. Yagyu^5^, T. Iehara^5^, H. Hosoi^5^, S. Adachi^3^

*^1^Department of Pediatrics‐ Graduate School of Medicine, Kyoto University, Kyoto, Japan; ^2^Department of Pediatric Surgery‐ Graduate School of Medicine, Kyoto University, Kyoto, Japan; ^3^Department of Human Health Science‐ Graduate School of Medicine, Kyoto University, Kyoto, Japan; ^4^Drug Discovery Technology Development Office‐ Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; ^5^Department of Pediatrics‐ Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan*

**Background/Objectives**: Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, which is thought to arise from neural crest (NC)‐derived immature cells. Since the prognosis of patients with high‐risk NB with recurrent/refractory disease remains poor despite the intensive multimodal therapy, novel therapeutic interventions are required. CD146 (also known as MCAM), a cell adhesion molecule expressed by various neural crest‐derived derivatives, which has been expected to be a therapeutic target for immunotherapy against various CD146‐expressing malignancies.

**Design/Methods**: The expression level of CD146 in six NB cell lines and clinical samples was examined by flow cytometric and immunohistochemical analyses. The anti‐tumor effect of blocking CD146 by rabbit anti‐CD146 polyclonal antibody or shRNA knockdown of CD146 was evaluated both *in vitro* (by WST‐8 assay and sphere forming assay) and *in vivo* (by subcutaneous transplantation into immunodeficient mice).

**Results**: CD146‐positive cells were detected in each NB cell lines and most of clinical samples. Anti‐CD146 polyclonal antibody and knockdown of CD146 significantly inhibited *in vitro* tumor viability. Anti‐CD146 polyclonal antibody also suppressed *in vivo* tumor formation in immunodeficient mice. Details of underlying mechanism are now under investigation.

**Conclusions**: Notable anti‐tumor effect of blocking CD146 will facilitate a novel immunotherapy for NB.

### PO-388. Identification Somatic Variants FOXO3A and FOXK2 in Neuroblastoma Patients that May Affect Doxorubicin and Platin Chemoterapy {#pbc27455-sec-6170}

[V. Odone‐Filho]{.ul} ^1^, N.H. Neves^1^, T.M. Gimenez^1^, A.R. Santos^2^, C.C. Vince^1^, F.A. Marchi^3^, A.C. Krepischi^4^, R.M. Lapa^5^, G. Zamperlini^1^, G. Zamperlini^6^, L.M. Cristofani^1^, E.M. Novak^7^

*^1^São Paulo University Medical School ITACI‐ São Paulo‐ SP‐ Brazil, Pediatric Hematology‐Oncology Department, Sao Paulo, Brazil; ^2^Children\'s Institute‐ Clinical Hospital‐ School of Medicine‐ University of São Paulo‐ São Paulo‐ SP‐ Brazil., Laboratory of Medical Investigation LIM 36, São PAulo, Brazil; ^3^A.C.Camargo Cancer Center‐ São Paulo‐ SP‐ Brazil, laboratory, São Paulo, Brazil; ^4^Institute of Biosciences‐ University of São Paulo‐ São Paulo‐ Brazil., Department of Genetics and Evolutionary Biology‐, Sao Paulo, Brazil; ^5^Faculty of Medicine‐ Sao Paulo State University ‐ UNESP‐ Botucatu‐ SP‐ Brazil., laboratory, Botucatu, Brazil; ^6^São Paulo University Medical School ITACI‐ São Paulo‐ SP‐ Brazil.Hospital Israelita Albert Einstein HIAE‐ Hematology Oncology Division‐ São Paulo‐ SP‐ Brazil., Pediatric Hematology‐Oncology Department, Sao Paulo, Brazil; ^7^Fundação Pró‐Sangue Hemocentro de São Paulo‐ São Paulo., Division of Molecular Genetics. São Paulo‐ Brazil., São Paulo, Brazil*

**Background/Objectives**: Neuroblastoma is an autonomic embryonal tumor, being the most common cancer diagnosed during the first year of life. Several key members of the Transcription Factor Forkhead box (FOX), such as *FOXO* and *FOXK* subfamilies, are strongly implicated in drug resistance in cancer. Variants associated to carbo*platin* plus *doxorubicin* resistance in neuroblastoma are investigated.

**Design/Methods**: Twelve neuroblastoma were obtained from 8 children with neuroblastoma, 4 being 4 and 4 stage 3 (International Neuroblastoma Staging System). All patients were older than 18 months and had non‐amplified *MYCN*. All children were exposed to *platin derivatives* plus *doxorubicin* before delayed surgery (preoperative chemotherapy). RT‐qPCR was assessed in HEK293T cells and SK‐N‐BE(2) cells treated with carboplatin plus doxorubicin and 12 tumor samples from neuroblastoma patients. Tumor and blood were sequenced using targeted resequencing, performed with Nextera^®^XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA), according to the manufacturer\'s instructions and sequenced on a MiSeq sequencing platform (Illumina, San Diego, CA, USA). Polymorphisms were identified using dbSNP138, 1,000 genomes Project Consortium and NHLBI Exome Sequencing Project (ESP) databases with minor allele frequencies recorded from each database and ClinVar database.

**Results**: Three somatic variants not described previously in neuroblastoma were identified in 3 patients. *FOXO3a* variants (c.1445G\>A:p.S482N) and (c707 C\>A:p.P236Q) are likely to induce a conformational change in the protein, which could have considerable repercussions, including effects on cellular events such as DNA binding and nuclear localization.*FOXK2* variant (c.1943 C\>T: p.T648M). The change to threonine to methionine may to affect its binds to the proximal *FOXO3a* promoter region.

**Conclusions**: Evidence from this study argue strongly that *FOXO3a* and *FOXK2* variants can be reliable diagnostic markers as genotoxic drug resistance in neuroblastoma.

### PO-389. Molecular Heterogenity in Neuroblastoma {#pbc27455-sec-6180}

T.C. Aktas^1^, E. Serinan^1^, A.P. Erçetin^1^, M. Aydın^1^, Ö. Gökbayrak^1^, A. Erol^1^, S. Aktas^1^, Z. Altun^1^, [N. Olgun]{.ul} ^1^, on behalf of the Turkish Pediatric Oncology Group

*^1^Dokuz Eylul University, Institute of Oncology, Izmir, Turkey*

**Background/Objectives**: Heterogeneity in cancer is the difference of tumor cells in biological behaviors. Neuroblastoma treatment depends on risk classification including molecular tests. In this study, we searched for heterogeneity in DNA ploidy, MYCN amplification, 1pLOH, 11q deletion and 17q gain in metachronous neuroblastoma samples.

**Design/Methods**: 25 cases among 882 cases from Turkish Pediatric Oncology Group neuroblastoma database had multiple samples. MycN amplification, 1pLOH, 11qdel and 17q gain was evaluated by RT‐PCR and DNA ploidy by flow cytometry for both fresh tumor samples. Statistical analyzes are made using SPSS 22.0 by paired sample T test and frequencies were calculated.

**Results**: The mean age of 25 cases was 41.00 ± 43.76 months. 13 patients were female and 12 patients were male. 25% of patients were in low risk, 25% intermediate risk and 50 % in high risk group. Heterogeneity was observed in 20% cases for MycN, 44% for 1pLOH, 12% for 11qdel, 24% for 17q gain and 28% in DNA ploidy.

**Conclusions**: Molecular heterogeneity is observed in neuroblastoma among different tumor samples of the same patients. Molecular tests are better analysed in tumor tissues in each sample obtained at different times and cases should be evaluated for risk classification possible changes.

### PO-390. Could Manganese‐Superoxide Dismutase be a Biomarker in Neuroblastoma? {#pbc27455-sec-6190}

Z. Altun^1^, S. Aktas^1^, B. Demir^2^, E. Serinan^1^, T. Aktas^1^, [N. Olgun]{.ul} ^3^, on behalf of the Turkish Pediatric Oncology Group

*^1^Dokuz Eylul University Institute of Oncology, Department of Basic Oncology, IZMIR, Turkey; ^2^Dokuz Eylul University‐ Institute of Oncology and Izmir University of Economics‐ Faculty of Medicine, Basic Medical Sciences, Izmir, Turkey; ^3^Dokuz Eylul University Institute of Oncology, Department of Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Neuroblastoma, which is heterogeneous molecular and clinical behavior, still needs to find new biomarkers for treatment and determination of prognosis. The aim of this study was to determine whether the expression level of manganese‐superoxide dismutase(SOD2) protein, which we identified as a candidate for biomarker in the previous proteomic study, is important in neuroblastoma tissues.

**Design/Methods**: 94 neuroblastoma cases were studied by immunohistochemically for SOD2 expression in paraffin tissue samples. SOD2 protein expression was scored as negative, one, two and three positive. N‐MYC expression, 1pLOH, 11q deletion, 17q gain were evaluated with Real‐time PCR and DNA ploidies were detected by Flow cytometry in the tissue samples. SOD2 protein expression levels were correlated with molecular and clinical data including patients'\' N‐MYC expression, 1pLOH, 11q deletion, 17q gain and DNA ploidis. Statistical analysis were performed by using Kruskal‐Wallis and Pearson correlation analysis.

**Results**: The age range was 0‐168 months (average was 30.73±35.25 months) of 94 cases (44 females, 50 males). N‐Myc positivity was found to be 19.1%, 1pLOH 45.7%, 11q del 20.2% and 17q gain 46.8% and 31.7% as a diploid. The SOD2 expression was negative in 37.2%, one positive in 26.6%, two positive in 17.0% and three positive in 19.1% cases. SOD2 expression was found to be association with differentiation. The positivity of SOD2 expression in the ganglioneuron areas, neurofilic and ganglion cells was detected intensely. SOD2 expression did not show any significant correlation with clinical data(*p*\> 0.05).

**Conclusions**: SOD2 protein showed a similar level of expression, which is thought to be related to differentiation. Moreover, SOD2 expression has been not showed correlation with clinical data. The number of patients should be increased to assess whether SOD2 protein expression is important as a biomarker. These results should be assessed with according to neuroblastoma risk groups and clinical observations.

### PO-391. The Effects of Cisplatin and Oleuropein on Neuroblastoma Cells {#pbc27455-sec-6200}

D. Dursun^1^, Z. Altun^1^, S. Aktas^1^, [N. Olgun]{.ul} ^2^

*^1^Dokuz Eylul University Institute of Oncology, Department of Basic Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Institute of Oncology, Department of Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: High‐risk neuroblastoma patients still neeeds new therapautics because of Cisplatin (cis‐diaminedichloroplatinum II; CDDP), the main chemotherapautic of neuroblastoma treatment, has many adverse effects. Oleuropein (OLE), found in an olive leaf, has been shown to reduce cancer cell viability. The aim of this study was to investigate the possible anti‐proliferative and apoptotic effects of OLE and combination with CDDP in good prognostic SH‐SY5Y N‐MYC(‐) and poor prognostic KELLY N‐MYC(+) neuroblastoma and PSI‐ fibroblast cells.

**Design/Methods**: PSI and SH‐SY5Y cells were cultured in DMEM and KELLY cells were cultered in RPMI medium supplemented with 10% FBS, 1% L‐glutamine, 1% penicillin/streptomycin. OLE(50‐800 uM), CDDP(5‐200 μM) and combinations were applied for 24, 48 and 72 hours to PSI, SH‐SY5Y and KELLY cells. LD50 doses were determined by cell viability analysis using WST‐1 test. Apoptotic cell death was determined by flow‐cytometry using Annexin‐V/PI assay after CDDP(50uM), OLE(500uM) and OLE(500uM)‐CDDP(50uM) treatment of cells. Statistical analysis were performed using Kruskal‐Wallis and non‐parametric Mann‐Whithney‐U tests. P value \<0.05 was considered as statistically significant.

**Results**: In SH‐SY5Y and KELLY neuroblastoma cells, OLE(500 uM) decreased the viability and showed apoptotic effect. In contrast, OLE(500 uM)‐CDDP(50 uM) combination induced apoptosis in SH‐SY5Y cells, but not in KELLY cells. Inhibition of cells viability and apoptotic effects of OLE(500 uM) were determined especially at 72 hours in PSI‐fibroblast cells.

**Conclusions**: This study showed the first time that OLE, CDDP and combinations induced cell death in neuroblastoma cells through apoptotic cell death mechanism. OLE was also caused apoptosis in healthy fibroblast cells. Furthermore, OLE‐CDDP did not induced cell death bad prognostic KELLY cells. The mechanisms of anti‐proliferative effect of OLE in neuroblastoma should be studied in further studies *in vitro* and *in vivo*.

### PO-392. Mesenchimal Stem Cell and Cisplatin Interference in Neuroblastoma Experimental Animal Model {#pbc27455-sec-6210}

S. Aktas^1^, P. Ercetin^1^, M. Aydin^1^, M. Calisir^2^, O. Bekcioglu^1^, O. Yilmaz^2^, [N. Olgun]{.ul} ^1^

*^1^Dokuz Eylul University, Institute of Ocnology, Izmir, Turkey; ^2^Dokuz Eylul University, Department of Experimental Animals Sciences, Izmir, Turkey*

**Background/Objectives**: High dose cisplatin induces dose limiting side effects in neuroblastoma (NB). Mesenchymal stem cells (MSC) by multipotential properties, are contemporary research area in cellular therapies. The aim of this study is to evaluate the interference of MSC with cisplatin in NB in nude mice animal model.

**Design/Methods**: Atymic male nude mice (n=28) were be injected subcutaneously by C1300 NB cell line. After tumor formation within 7‐10 days in one cm diameter, experimental groups as control, cisplatin therapy, MSC therapy, cisplatin+MSC therapy were randomly designed with 7 mice in each group. Animals were intraperitoneally injected with cisplatin (16mg/kg) and intravenous injected with 1x10^5^ MSCs once. After 7 days the animals were sacrified. Tumor tissues were evaluated for necrosis and viability, Apoptosis was evaluated by annexin V+PI by flow cytometer. The MSC ratio within tumor was evaluated by flow cytometer with triple CD34+, CD44+, CD117‐ expression. Statistical evaluation was performed by nonparametric Kruscal Wallis and Mann Whitney U test at p\<0.05 level.

**Results**: The viability of tumor tissues were higher in MCS treated groups. Necrosis in tumor tissues were statistically significant in cisplatin group, cisplatin+MSC group compared with control and MSC groups (p=0,001, p=0,006). Although cisplatin+MSC group seems to have lower tumor necrosis ratio than cisplatin group, statisticaly significance is not observed (p=0.05). MSC did not change tumor dimension decrease (p=0.557). The MSCs is found more than control and cisplatin groups in treated groups by CD34+, CD44+, CD117‐ triple expression.

**Conclusions**: By this study, MSC as candidate side effect preventing agent of cellular therapy, is found to somehow interfere with antitumoral effect of cisplatin in NB by decreasing apoptosis, necrosis, although it did not stop tumor dimention decrease caused by cisplatin. It is role in side effect should carefully considered on the point of view of tumor therapy.

### PO-393. Artificial Intelligence Methods for Risk Assessment of Neuroblastoma {#pbc27455-sec-6220}

A. Leblebici^1^, B. Uncu^1^, A. Onan^2^, Y. Baskın^3^, [N. Olgun]{.ul} ^4^

*^1^Dokuz Eylul University, Institute of Health Sciences‐ Department of Translational Oncology, Izmir, Turkey; ^2^Manisa Celal Bayar University, Hasan Ferdi Turgutlu Faculty of Technology‐ Department of Software Engineering, Manisa, Turkey; ^3^Dokuz Eylul University, Institute of Oncology‐ Department of Basic Oncology, Izmir, Turkey; ^4^Dokuz Eylul University, Institute of Oncology‐ Department of Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Neuroblastoma is the most common solid tumor among childhood cancers except the skull. About fifty percent of neuroblastoma cases are children under two years of age. Neuroblastoma is a type of cancer of the nervous system originating from the brain that carries messages to the whole body. Neuroblastoma is divided into three risk groups; low, moderate, and high level depend on COG (Chidren\'s Oncology Group) Risk Group. Each group has different treatments and survival rates. This study aimed to improve the decision support system by using machine learning algorithms for better decision making by adding different variables to the existing acceptance class.

**Design/Methods**: In order to identify risk groups for neuroblastoma patient dataset from GDC (Genomic Data Commons) the feature sets were divided into two groups, as the base feature sets and the individual features. In this way, 16 different feature sets were obtained by combining the base feature sets with the individual features. To analyze the predictive performance, six learning algorithms (Naive Bayes, logistic regression, multilayer perceptron, support vector machines, K‐star and C4.5 algorithm) and three ensemble methods (AdaBoost, Bagging and Random Forest) were considered.

**Results**: Random forests and C4.5 decision tree classifier outperform the other learning algorithms with a classification accuracy of 97.62%. For Random forest algorithm, the use of grade and diagnostic category as the feature sets with the base feature set and the use of first event as the feature set with the base feature set yield the highest predictive performance. C4.5 algorithm obtained better predictive performance on combined feature sets.

**Conclusions**: The identification of risk groups for neuroblastoma is of great importance for proper treatment. We believed that supporting this decision will help the clinician to give better results. In this study, an empirical analysis of machine learning based methods is presented with a relatively high predictive performance.

### PO-394. Neuroblastoma in Southern and Eastern Europe: Effect of Human Development Index on Incidence and Survival {#pbc27455-sec-6230}

P. Panagopoulou^1^, M. Georgakis^1^, V. Papadakis^2^, M. Baka^3^, M. Moschovi^4^, S. Polychronopoulou^2^, M. Kourti^5^, E. Hatzipantelis^6^, E. Stiakaki^7^, H. Dana^8^, K. Strantzia^9^, K. Stefanaki^10^, N. Dessypris^1^, S.E.E.G. Southern‐ Eastern European Group^11^, [E. Petridou]{.ul} ^1,12^

*^1^National and Kapodistrian University of Athens Medical School, Dept. of Hygiene‐ Epidemiology and Medical Statistics, Athens, Greece; ^2^"Agia Sofia" Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^3^"Pan. & Agl. Kyriakou" Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^4^"Agia Sofia" Children\'s Hospital, Pediatric Hematology/Oncology Unit‐ First Department of Pediatrics‐ University of Athens, Athens, Greece; ^5^Hippokration Hospital, Department of Pediatric Hematology and Oncology, Thessaloniki, Greece; ^6^Aristotle University of Thessaloniki‐ AHEPA Hospital, Hematology‐Oncology Unit‐ 2nd Pediatric Department, Thessaloniki, Greece; ^7^University of Crete, Department of Pediatric Hematology‐Oncology, Heraklion, Greece; ^8^"Mitera" Children\'s Hospital, Pediatric Hematology‐Oncology Department, Athens, Greece; ^9^"P & A. Kyriakou" Children\'s Hospital, Pathology Laboratory, Athens, Greece; ^10^"Agia Sofia" Children\'s Hospital, Pathology Laboratory, Athens, Greece; ^11^Luis Antunes‐ Joana Bastos‐ Daniela Coza‐ Anna Demetriou‐ Domenic Agius‐ Sultan Eser‐ Raluca Gheorghiu‐ Mario Šekerija‐ Maciej Trojanowski‐ Tina Žagar‐ Anna Zborovskaya‐ Anton Ryzhov, Southern‐ Eastern European Group, Southern‐ Eastern Europe, Greece; ^12^Karolinska Institute, Unit of Clinical Epidemiology‐ Department of Medicine, Stockholm, Sweden*

**Background/Objectives**: Neuroblastoma, a tumor of infancy/early childhood, has variable clinical behavior and outcome. We aimed to explore whether socioeconomic indicators were associated with neuroblastoma incidence (IR) and survival in Southern‐Eastern European (SEE) countries.

**Design/Methods**: Age‐adjusted incidence rates (AIR) were calculated and correlated with HDI for 1,859 incident neuroblastoma cases diagnosed among children (0--14 years) reported by 13 registries in 11 SEE countries (1990--2016). Temporal trends were assessed using Poisson regression and Joinpoint analyses. Kaplan‐Meier curves and multivariable Cox proportional hazard models were used to assess the effect of age, gender, primary tumor site, HDI and urbanization on overall survival (OS).

**Results**: Overall AIR was 10.1/million (range: 4.0‐16.5/million) and one--third of cases were diagnosed in infancy with IR reaching 43.7/million. IRs were positively associated with HDI, especially at ages \<1 and 1--4 years. Lower median age at diagnosis correlated with higher AIR. Two‐thirds of primaries were located in the abdomen. Neuroblastoma was slightly more common in males (M/F: 1.1), especially among infants. IR among infants decreased overtime in Slovenia and Cyprus and increased in Ukraine and Belarus. OS5‐yearwas 59% in SEE and varied widely from 54% (Ukraine) to 81% (Poland). Age \>18 months (HR:2.5), diagnostic period (HR5‐year increment:0.82), rural residence (HR: 1.3), living inhigh(HR:1.9) or medium (HR:2.2) HDI country and specific primary locations (HRabdomen: 1.9, HRCNS: 2.1) weresignificantly associated with worse outcome.

**Conclusions**: Neuroblastoma incidence varies significantly in SEE and was lower in infants from low HDI countries possibly indicating less over‐diagnosis. Incidence surges in infancy should be carefully examined to avoid unnecessary interventions for tumours that could spontaneously regress. Survival is worse in children from rural areas and lower HDI countries; this may be attributed to potentially modifiable socio‐economic and healthcare system performance characteristics.

### PO-395. Characteristics and Outcome of Neuroblastoma in Greece: Data from the Clinical Nationwide Registry of Childhood Hematological Malignancies/Solid Tumors (NARECHEM‐ST) 2009‐2017 {#pbc27455-sec-6240}

V. Papadakis^1,2^, M. Baka^3^, S. Polychronopoulou^2^, M. Moschovi^4^, M. Kourti^5^, E. Stiakaki^6^, H. Dana^7^, E. Hatzipantelis^8^, P. Panagopoulou^1^, N. Dessypris^1^, [E. Petridou]{.ul} ^1^

*^1^National and Kapodistrian University of Athens Medical School, Dept. of Hygiene‐ Epidemiology and Medical Statistics, Athens, Greece; ^2^"Agia Sofia" Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^3^"Pan. & Agl. Kyriakou" Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^4^"Agia Sofia" Children\'s Hospital, Pediatric Hematology/Oncology Unit‐ First Department of Pediatrics‐ University of Athens, Athens, Greece; ^5^Hippokration Hospital, Department of Pediatric Hematology and Oncology, Thessaloniki, Greece; ^6^University of Crete, Department of Pediatric Hematology‐Oncology, Heraklion, Greece; ^7^"Mitera" Children\'s Hospital, Pediatric Hematology‐Oncology Department, Athens, Greece; ^8^Aristotle University of Thessaloniki‐ AHEPA Hospital, Hematology‐Oncology Unit‐ 2nd Pediatric Department, Thessaloniki, Greece*

**Background/Objectives**: The clinical Nationwide Registry of Childhood Haematological Malignancies and Solid Tumours (NARECHEM‐ST) in Greece is functioning since 2009. We aimed to present the characteristics and outcomes of neuroblastoma cases.

**Design/Methods**: Data of all incident neuroblastoma cases (2009‐2017) aged 0‐14 years were extracted and analysed using standard descriptive analyses and Cox regression models.

**Results**: In total 186 patients were registered (58.6% males) resulting in a relatively high 15.0/106 age‐standardized incidence; no seasonal peak or significant temporal trend was observed. Age‐wise 51.6% were \<18 months and 7% \>60 months, (median age: 1.43 years; mean age: 1.97±2.08 years), whereas 58.6% were males. International Neuroblastoma Risk Group (INRG) staging was 52.2% localized (L1/L2) and 47.8% metastatic (M/Ms); *MYC‐N*amplification of evaluated patients: 22.3% (infants\<6 months:7.7%; children\>60 months: 36.4%); primary site: adrenal=45.7%, abdominal=32.3%, thoracic=15.6%, other=6.4% with 54.0%, 43.3% and 34.9% of those being metastatic respectively. Opsoclonus/myoclonus was present in 5.6%. Up to 75% of patients were managed following SIOPEN protocols. Event‐free (EFS) was 74.2% and overall survival (OS) 79% (mean follow‐up time: 49.5 and 49.8 months, respectively); specifically localised: 93.8% and 95.9%; metastatic: 52.8% and 60.1%; \<18 months: 88.5% and 91.7%; \>18 months: 58.9% and 65.6%, respectively. Multivariate analysis derived hazard ratios (HR) for ≥18 months associated with worse outcome were: HREFS=3.44, 95%CI (1.54,7.67); HROS=3.39, 95%CI (1.40,8.21); stage M: HREFS=9.87, 95%CI:4.10,23.76; HROS=12.43, 95%CI:4.33,35.69; stage MS: HREFS=8.57, 95%CI:2.55,28.82; HROS=7.78, 95%CI:1.82,32.28; *MYC‐N*amplified HREFS=3.00, 95%CI: 1.51,5.96; HROS= 3.89, 95%CI:1.81,8.36.

**Conclusions**: Νeuroblastoma incidence is relatively higher is Greece compared to other European countries and the US. Survival is comparable to other developed countries and varies significantly by age, stage and *MYC‐N*amplification. Clinical registration data are important in also showing that the recent financial crisis has not affected the provision of high quality specialized care for childhood neuroblastoma in Greece.

### PO-396. Clinical Outcome and Prognostic Factors to Predict Induction Response in High‐Risked Neuroblastoma Patients Receiving Topotecan‐Based Regimen: Multicenter Study {#pbc27455-sec-6250}

[A. Photi‐A]{.ul} ^1^, P. Rujkijyanont^1^, C. Traivaree^1^, C. Monsereenusorn^1^, S. Wiangnon^2^, T. Chotsampancharoen^3^, S.O. Chainansamit^4^, K. Sanpakit^5^, D. Sosothikul^6^, S. Kanjanapongkul^7^, S. Hongeng^8^

*^1^Phramongkutklao Hospital, Pediatric, Bangkok, Thailand; ^2^Khon Kaen University, Pediatric, Khon Kaen, Thailand; ^3^Prince of Songkla University, Pediatric, Songkla, Thailand; ^4^Khon Kaen Hospital, Pediatric, Khon Kaen, Thailand; ^5^Siriraj Hospital, Pediatric, Bangkok, Thailand; ^6^King Chulalongkorn Memorial Hospital, Pediatric, Bangkok, Thailand; ^7^Queen Sirikit National Institute of Child Health, Pediatric, Bangkok, Thailand; ^8^Ramathibodi Hospital, Pediatric, Bangkok, Thailand*

**Background/Objectives: Background**: Neuroblastoma is the most common pediatric solid tumor with a wide range of clinical presentations and non‐uniform response to treatment. Despite using a combination of chemotherapy, surgery and radiation, high‐risk patients respond very poorly. Topotecan has been widely used in treating relapsed pediatric solid tumor including neuroblastoma. Herein, we have introduced Topotecan as a first line therapy during induction regimen in those high‐risk patients.

**Objective**: To determine the clinical outcome and identify the prognostic factors to predict induction response in high‐risk neuroblastoma patients receiving Topotecan‐based regimen in Thailand between 2016‐2017.

**Design/Methods: Method**: High‐risk neuroblastoma patients undergone ThaiPOG high‐risk neuroblastoma protocol were enrolled. The induction regimen consisted of 6 cycles of chemotherapy in which Topotecan was introduced in the first 2 cycles of treatment. Clinical data, laboratory results and imaging studies at the initial diagnosis and after 5^th^ cycles prior to surgery were collected and analyzed. In addition, potential prognostic factors were studied and identified in order to predict the treatment response in those high‐risk patients.

**Results**: One hundred and seven patients diagnosed with high‐risk neuroblastoma were enrolled in the study. The majority of the patients were diagnosed and treated in the university hospital. After undergoing Topotecan‐based induction regimen, almost all patients achieved satisfied or reasonable treatment responses. None of the patients had no response and progressive disease. Interestingly, high‐risk features such as N‐myc, tumor histology and Shimada histology were not the predictive factors of induction response. However, supportive care seemed to have significant impact on induction response. The most common treatment‐related toxicity was febrile neutropenia. Other toxicities such as mucositis and diarrhea were minimal.

**Conclusions**: Topotecan‐based induction regimen could provide satisfied treatment response with minimal toxicities in high‐risk neuroblastoma patients in Thailand.

### PO-397. Treatment Outcome of Neuroblastoma in Thailand: A Lesson from Center with Limited Resources {#pbc27455-sec-6260}

[K. Phuakpet]{.ul} ^1^, N. Suwantarat^1^, K. Sanpakit^1^, N. Vathana^1^, J. Buaboonnam^1^, N. Narkbunnam^1^, C. Takpradit^1^, G. Veerakul^1^

*^1^Hematology/Oncology division, Department of Pediatrics‐ Siriraj hospital Mahidol university, Bangkok, Thailand*

**Background/Objectives**: Treatment of neuroblastoma depends on various factors including tumor staging and MYCN amplification. However, the test for MYCN amplification is not available in most centers in Thailand including our institute. The treatment stratification in our institute depends mainly on staging and Shimada histology. To avoid under‐treatment in such patients, most of them were shifted to a higher risk group.

Objective: To assess the treatment outcome and survival of children with neuroblastoma treated in our institute.

**Design/Methods**: The retrospective chart reviews of neuroblastoma patients were conducted and results were analyzed.

**Results**: Eighty‐four patients were enrolled to the study. Median age at diagnosis was 2.8 years. According to the INSS classification and COG risk stratification without using MYCN amplification, majority of the patients were in INSS stage IV (66.7%) and high risk (HR) group (72.6%). Most patients received combination treatment of surgery and chemotherapy. Sixty‐one patients (75.3%) had grade III & IV hematologic toxicity; HR group patients had more grade IV hematologic toxicity than the low‐risk (LR) and intermediate‐risk (IR) groups (53% vs 13.5%). Five‐years overall survival (OS) for the whole group, LR, IR and HR group were 44.8 %, 87.5%, 86.2% and 27.8% respectively. Twenty‐eight patients (42.4%) relapsed at the median time of 1.8 years. The median follow‐up time was 2.6 years (5 month‐15 years).

**Conclusions**: Although some LR and IR patients were falsely classified into HR group, the survival rate of the HR group remained unsatisfied whereas LR and IR groups had excellent outcome. Moreover, HR patients experienced more treatment toxicities due to a more intensive treatment. The accurate tumor stratification method including the use of MYCN amplification can identify the patients\' true risk group. Treatment reduction in those who were falsely classified into HR group will prevent unnecessary intensive chemotherapy resulting in less treatment toxicities without compromising the treatment result.

### PO-398. Serum Neuron‐Specific Enolase Level for Diagnosis in Children with Neuroblastoma {#pbc27455-sec-6270}

[B. Pongtanakul]{.ul} ^1^, C. Takpradit^1^

*^1^Faculty of Medicine Siriraj Hospital‐ Mahidol University, Division of Hematology and Oncology‐ Department of Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Neuroblastoma is the second most common solid tumor in children. Various tumor markers have been used for diagnosis in this disease. However, vanillymandelic acid (VMA) and homovanillic acid (HAV) in urine are the tumor marker of choice in neuroblastoma but it is difficult to properly collect especially in young children. We evaluated the significance of serum neuron‐specific enolase (NSE) level for diagnosis in neuroblastoma.

**Design/Methods**: Serum samples for NSE analysis in our hospital were included. NSE level, clinical data and final diagnosis were recorded and analyzed for correlation between NSE level and diagnosis.

**Results**: One hundred and ninety five patients were enrolled. Sixty seven (34.4%) and 128 (65.6%) patients were diagnosed with neuroblastoma (NB) and non‐neuroblastoma (NNB). Mean NSE level for NB and NNB group were 278.5 and 41.15 ng/ml (P\<0.01). The top three highest NSE level in NNB group were leukemia (209.64 ng/ml), Wilm\'s tumor (79.04 ng/ml) and gonadal germ cell tumor (47.43 ng/ml). For NB group, mean NSE for stage I, II, III, IV and IVs were 191.3, 60.15, 350.48, 653 and 137.5 ng/ml, respectively. When we used NSE level above normal value (\>15.2 ng/ml), the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 98.5%, 27.34%,41.5% and 97.2%, respectively. However, we used NSE level \> 100 ng/ml, the sensitivity, specificity, PPV and NPV were 85.07%, 92.96%, 86.40% and 92.24%. When we combined NSE level \> 100 ng/ml and patients presented with abdominal mass, the sensitivity, specificity, PPV and NPV were 88.24%, 91.67%, 88.24% and 91.67%, respectively.

**Conclusions**: Serum NSE is a useful tumor marker for neuroblastoma. However, serum NSE can rise in many childhood malignancies. The cut off NSE level \>100 ng/ml can increase specificity and positive predictive value in diagnosis of neuroblastoma especially in advanced stages and patients presented with abdominal mass.

### PO-399. Infant Neuroblastoma: 10 Year Experience from a Tertiary Cancer Centre in a Low and Middle Income Country {#pbc27455-sec-6280}

[V.R. Prasanth]{.ul} ^1^, T. Priyakumari^1^, N. Manjusha^1^, R. Binitha^1^, C.S. Guruprasad^1^, S. Shwetha^1^, N. Sindhu^2^

*^1^Regional Cancer Centre, Paediatric Oncology, Trivandrum, India; ^2^Regional Cancer Centre, Pathology, Trivandrum, India*

**Background/Objectives**: To evaluate the clinical profile and treatment outcome of Infant neuroblastoma (NB) from a tertiary cancer centre in India.

**Design/Methods**: All Infant NB patients treated between January 2007 and December 2016 were retrospectively analysed for patient demographics, INSS staging, treatment modalities including chemotherapy, surgery and radiation. Survival was calculated using Kaplan‐Meier method.

**Results**: Of the 72 infants, the median age was 193 days (1‐363 days).M:F ratio was1.3:1. Asymptomatic abdominal mass (60%) was the commonest presentation and adrenals were (61%) the most common primary. INSS stages 1‐4 and 4s were seen in 10%, 6%, 18%, 44% and 22% infants respectively. N‐Myc estimation was not available and hence not done as part of routine diagnostic work up.77% infants received chemotherapy. Surgery including delayed primary was done in 34% infants. 8 infants received radiation, of which 2 received radiation alone for massive hepatomegaly. Median follow ‐up was 49 months (range 3‐122 months). 3 infants had recurrence after 12‐15 months from diagnosis. 23 infants had disease progression and died. 3 year overall (OS) was 65.8% +/‐ 6%. INSS stage 1 and stage 2 tumours had a 3 year OS of 100%. Three year OS was 58.7% +/‐ 14% and 56.6% +/‐9% for stage 3 and 4 respectively. Stage 4s infants had a 3 year OS of 73.7% +/‐11.%. High lactate dehydrogenase was significant in univariate analysis for OS (P=0.05).

**Conclusions**: Most infant NB patients (62%) had advanced disease at diagnosis. Even with the limited resources available in the low and middle income country (LMIC), 3 year OS of 65.8% could be achieved. Incorporation of biological risk stratified tailored therapy is essential in LMIC to further improve the treatment outcome of infant NB.

### PO-400. Real World Experience of Treating Neuroblastoma in a Low‐Middle Income Country (LMIC) {#pbc27455-sec-6290}

[V. RADHAKRISHNAN]{.ul} ^1^, J. Ramamoorthy^2^, P. Ganesn^1^, T. Sagar^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India; ^2^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Management of neuroblastoma especially high‐risk (HR) disease is difficult in resource limited setting. There is paucity of literature on outcomes of patients treated in LMIC. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at our centre.

**Design/Methods**: The study included newly diagnosed patients with neuroblastoma treated at our centre between the years 2000 to 2016. The International Neuroblastoma Staging System and risk grouping was used to classify patients as Standard‐Risk (SR), Intermediate‐Risk (IR) and High‐Risk (HR). SR patients underwent only surgery, IR patients received 4‐8 cycles of chemotherapy and if feasible surgical resection of primary and HR patients received 5‐cycles of induction chemotherapy followed by surgical resection of primary, autologous stem cell transplantation (ASCT), radiotherapy to primary and 13‐CRA maintenance. Kaplan‐Meier method was used to calculate the overall survival (OS).

**Results**: The study included 86 patients with a median age of 4‐years and 66% were males. Malnutrition was observed in 55% patients. Adrenal was the most common site in 76% patients followed by mediastinum in 12%. SR was observed in 8/86 (15%) patients, IR 20/86 (23%) and HR in 58/86 (67%) patients. CCG‐3891 protocol was used in 80% patients. ASCT could be performed in 32% of HR patients. The median follow‐up was 30 months and the median OS for all patients was 30.6 months. The 3‐year OS for SR, IR and HR patients was 100%, 78% and 34% respectively (P=0.001). Factors predictive of OS in HR patients on univariate analysis included ASCT, surgical resection of primary, radiotherapy to primary, hemoglobin and more than 5 cycles of chemotherapy. On multivariate analysis more than 5‐cycles of chemotherapy was predictive of better OS.

**Conclusions**: Outcomes in HR neuroblastoma in LMIC remain dismal due to treatment abandonments and lack of access to ASCT, surgical expertise and radiotherapy.

### PO-401. Multiplex Ligation‐Dependent Probe Amplification (MLPA): An Effective Tool for Testing Multiple Segmental Chromosomal Aberrations in Children with Neuroblastoma {#pbc27455-sec-6300}

[M. Ramadwar]{.ul} ^1^, O.S. shetty^2^, G. Chinnaswammy^3^, M. Gurav^2^, T. Vora^3^, S. Medhi^4^, S. Qureshi^5^, N. Khanna^6^

*^1^Tata Memorial Hospital, 8th floor‐ Annexe building‐ Pathology, MUMBAI, India; ^2^Tata Memorial Hospital, Molecular Pathology, Mumbai, India; ^3^Tata Memorial Hospital, Medical Oncology, Mumbai, India; ^4^Tata Memorial Hospital, Radiology, Mumbai, India; ^5^Tata Memorial Hospital, Surgical Oncology, Mumbai, India; ^6^Tata Memorial Hospital, Radiation Oncology, mumbai, India*

**Background/Objectives**: Apart from MYCN gene amplification (MNA) and 11q aberration, other segmental chromosomal aberrations (SCAs) are now known to be of adverse prognostic significance in patients with NB. MLPA is a PCR‐based technique which enables testing for gains, losses and amplifications of multiple genes.

**Design/Methods**: Study was performed on 54 patients with NB between 2014‐2018. MLPA kits with 3 panels P251, P252 and P253 (MRC Holland, Amsterdam) were used to test SCA at 7 chromosomes including MYC‐N testing. Coffalyser software was used for data analysis. SIOPEN guidelines were used for nomenclature.

**Results**: Age range was from 0 to 60 months, with 25/54 patients were below 18 months old. MLPA yielded meaningful results in 49 samples. 2 yielded ambiguous values since they did not fall into any of the defined categories. Amplifiable template DNA was inadequate in 3 samples. MNA was found in 8 /49 patients. Number of SCAs ranged from 2 to 10. 17q gains and amplification were most common (37/54), followed by 2p gains and amplifications (25/54 inclusive of MNA), 11q loss (18/54), 3p loss (14/54), and 17p gains (13/54). 1p aberration was seen in 20/ 54. None of the tumours showed 12p aberrations. 1 of 25 infantile NB samples showed MNA. Rest showed SCA in 1p, 11q and 17q respectively. Alk amplification was seen in two patients.

**Conclusions**: Going beyond MYC‐n amplification, detection of more number of SCAs is emerging as adverse biologic prognostic factor in patient with NB. Short of next generation sequencing platforms, we found MLPA an effective tool for multiplex gene testing for SCA including myc‐N in a single assay. Thus it is easier and cost effective to conform to International Neuroblastoma Risk Group (INRG) and SIOP‐EN recommendations. This technique will enable us to determine clinical significance of each of the SCAs detected which are beyond current guidelines.

### PO-402. Prognostic Factors for Survival in Paediatric Patients with Ewing Sarcoma in Low‐Middle‐Income Setting: A Multicentre Study {#pbc27455-sec-6310}

[S. Resham]{.ul} ^1^, M. Raza^2^, A. Muneeb^3^, B. Qureshi^4^, M. Umer^5^, S. Ashraf^2^, F. Shaheen^1^, S. Altaf^4^

*^1^Aga Khan University Hospital, Paediatric and Child health, Karachi, Pakistan; ^2^The Indus Children Cancer Hospital, Paediatric Oncology, Karachi, Pakistan; ^3^Aga Khan University Hospital, Aga Khan University Hospital, Karachi, Pakistan; ^4^Aga Khan University Hospital, Oncology, Karachi, Pakistan; ^5^Aga Khan University Hospital, Orthopaedic surgery, Karachi, Pakistan*

**Background/Objectives**: To evaluate prognostic factors and treatment outcomes in paediatric Ewing Sarcoma (EWS) at two major paediatric oncology centres in Pakistan.

**Design/Methods**: All patients 1‐16 years from 2005 to 2015 at Aga Khan University Hospital and Indus Children Cancer Hospital. Factors relevant to survival and relapse were analysed.

**Results**: One hundred‐thirty‐four patients were identified. Thirty‐five (26%) left before treatment. Ninety‐seven (72%), median age 11, were analysed. Fifty‐eight (60%) were male. Extremity (n=55, 57%) was the commonest site. Ninety‐one (94%) were bone EWS. Tumour size was \> 8cm in 40 (41%). EWSR1 translocation was performed in 16(16%). Sixty‐seven (69%) had localised disease, 27(29%) were metastatic. Lung (n=12, 44%) was the most common site of metastasis. Majority received EURO‐E.W.I.N.G.99 (n=53, 55%), 16(17%) received AEWS0031 protocol, 13 patients (13%) were given different regimens. Twenty‐eight (29%) were treated with surgery + radiation, 26 (27%) each received surgery and radiation. The median follow‐up period was 13 months. Improved 2‐years overall survival (OS) in localised disease was associated with surgery (n=26, 66%, P=0.55), \<8cm tumour size 64% (n=15, 60%, P=0.95) and clear surgical margins (n=16, 60%, P=0.86). Fifty‐eight events occurred; 19 relapses (19%), 14 (14 %) treatment abandonments and 25 (26%) died. The 5‐year OS and EFS for localised and metastatic EWS was 58% (95% CI 8%‐40%) and 42% (95% CI: 11%‐90%). The 2‐year OS for localised EWS was 70% (95% CI: 5%‐57%). The 5‐year EFS for localised and metastatic EWS with relapse+ treatment abandonment + death was 20% (95% CI: 8%‐70%).

**Conclusions**: Our study demonstrates excellent survival for localised disease. Fifty percent of our patients did not get any treatment because of insufficient resources, one‐third had metastasis at presentation because of delayed presentation and lack of access to medical care. Tumour size (\<8cm) and clear surgical margins correlated well with outcomes, not statistically significant due to small sample size.

### PO-403. Survival Outcomes in Paediatric Patients with Osteosarcoma in Low Middle‐Income Setting; A Ten‐Year Multicentre Study {#pbc27455-sec-6320}

[S. Resham]{.ul} ^1^, R. Raza^2^, S. Ashraf^2^, M. Umer^3^, F. Shaheen^1^, S. Altaf^4^

*^1^Aga Khan University Hospital, Paediatric and Child Health, Karachi, Pakistan; ^2^The Indus Children Cancer Hopsital, Paediatric Oncology, Karachi, Pakistan; ^3^Aga Khan University Hospital, Orthopaedic Surgery, Karachi, Pakistan; ^4^Aga Khan University Hospital, Oncology, Karachi, Pakistan*

**Background/Objectives**: To evaluate significant prognostic factors and treatment outcomes in Osteosarcoma at two major paediatric oncology centres in Pakistan.

**Design/Methods**: All patients 1‐16 years, from 2005 to 2015 at Aga Khan University Hospital and Indus Children Cancer Hospital. Patient characteristics, treatment, outcomes and factors influential to survival and relapse were analysed.

**Results**: One hundred‐thirty‐four were identified. Forty‐six (47%) left before treatment. Ninety‐seven (72%) with median age of 14 were included. Fifty‐two (64%) were female. Extremity (n=87, 92%) was the commonest site. Thirty‐six (37%) had metastatic disease. Lung (n=24, 66%) was the most frequent site of metastasis. AOST0331 protocol was given in 47(48%), 29 (30%) received Cisplatin/Adriamycin, 3 (3%) were treated on different regimens, 18 (18%) did not receive any chemotherapy. Improved 3‐years overall survival (OS) in localised disease was associated with limb salvage (n=34, 56%, P=0.091), clear surgical margins (n=25, 88%, P=0.006), and post‐operative tissue necrosis (n=22, 88%, P=0.011). Age 6‐10 years (n=21, 75%, P=0.12) and limb amputation (n=29, 64%, P=0.99) showed relatively inferior event free survival (EFS). The median follow up was 8 months (IQR 3--20 months). Seventy‐three events occurred; 14 experienced relapse (14%), 28 (29%) were treatment abandonments and mortality in 31 (40%). The 5‐year OS for both localised and metastatic osteosarcoma was 30.8 %(95% CI: 19%‐44%). The 5‐year OS for localised osteosarcoma was 44% (95% CI: 26%‐61%). The 5‐year EFS for localised osteosarcoma with relapse as an event was 69 %(95% CI: 47 %‐83%) and the 5‐years EFS for localised and both localised and metastatic disease with relapse, death and treatment abandonment as an event was 42 %(95% CI: 24%‐59%) and 29% (95% CI: 17%‐43%).

**Conclusions**: Limb salvage surgery with good response to chemotherapy were favourable prognostic factors. Poor outcome was associated with treatment abandonment and metastatic disease at presentation.

### PO-404. Prognostic Factors, Multidisciplinary Treatment and Survival Outcomes of Paediatric Rhabdomyosarcoma in Low‐Middle‐Income Setting: A Ten‐Year Multicenter Study {#pbc27455-sec-6330}

[S. Resham]{.ul} ^1^, R. Raza^2^, B. Qureshi^3^, S. Ashraf^2^, M. Umer^4^, S. Altaf^3^

*^1^Aga Khan University Hospital, Paediatric and Child health, Karachi, Pakistan; ^2^The Indus Children Cancer Hospital, Paediatric Oncology, Karachi, Pakistan; ^3^Aga Khan University Hospital, Oncology, Karachi, Pakistan; ^4^Aga Khan University Hospital, Orthopaedic Surgery, Karachi, Pakistan*

**Background/Objectives**: Evaluate prognostic factors and outcomes in Paediatric Rhabdomyosarcoma at two centres in Pakistan.

**Design/Methods**: Patients 1‐16 years from 2005 to 2015 at Aga Khan University Hospital and Indus Children Cancer Hospital. Factors relevant to survival and relapse were analysed.

**Results**: One hundred fifty‐three patients were identified. Forty‐one (27%) left before treatment. Data was analysed from 112, median age five years. Sixty‐five (58%) were male. Parameningeal (n=33, 29%) was the commonest site. Ninety‐one were group III (81%), 41 were stage 3 (36%), 20 were stage 2 (18%) and 21(19%) stage 1 and 4 each. Ninety‐four (84%) were embryonal. Tumour size was \> 5cm in 58 (52%). Eighty‐two (73%) had localised disease, 21 (19%) metastatic with lung (n=8, 38%) the commonest site. 96 (86%) were treated. Majority (n=84, 75%) received ARST0531, 3 (3%) received high‐risk protocol. 36 (32%) received radiation, 15 (13%) surgery whereas 23 (21%) surgery + radiation. Median follow‐up period was 11 months. Improved 5‐year overall survival (OS) was associated with age 1‐9 years (60%, P=0.029), dose of radiation 50Gy (85%, P=0.004), and local control with surgery + radiation (90%, P=0.001). 70 events occurred; 12 relapsed (11%) and 27 (24%) died; 1 (4%) had progressive disease and 10 (37%) died during treatment, cause remained unknown in 16 (59%) and 31 (28 %) abandoned treatment. Five‐year (OS) in both localised and metastatic disease was 58% (95% CI:51.6‐70.83) and event free survival (EFS) with relapse was 70% (95% CI:62.93‐83.06). Five‐year (OS) in patients treated with curative intent was 60% (95% CI:54.71‐74.72) and EFS with relapse was 73%(95% CI:63.10‐83.66). EFS with relapse + death and treatment abandonment was 35% (95% CI:27.38‐44.32).

**Conclusions**: Favourable site of presentation, effective local control with appropriate doses of radiation correlated well with positive outcomes. 50% of diagnosed patients either did not start or abandoned therapy, a serious concern in our setting.

### PO-405. Comparing Peripheral Stem Cell Collection Following Mobilisation Therapies in Paediatric High Risk Neuroblastoma Patients {#pbc27455-sec-6340}

[M. Ronghe]{.ul} ^1^, R. Graham^1^, D. Murphy^2^, J. Sastry^2^, C. Betts^3^, K. Douglas^3^

*^1^Royal Hospital for Children, Paediatric Haematology Oncology, GLASGOW, United Kingdom; ^2^Royal Hospital for Children, Paediatric Oncology, Glasgow, United Kingdom; ^3^Beatson West of Scotland Cancer Centre, Clinical Apheresis Unit‐, Glasgow, United Kingdom*

**Background/Objectives**: To audit the effectiveness of recommended changes to the peripheral blood stem cell (PBSC) collection protocol in paediatric high‐risk neuroblastoma patients. Treatment is currently dictated by the SIOPEN study. The effectiveness of stem cell mobilisation in the current SIOPEN protocol was questioned following a comparison with PBSC stem cell yields in Ewing\'s sarcoma mobilisation regimes.

**Design/Methods**: This was a retrospective audit of paediatric patients with neuroblastoma treated at the Royal Hospital for Children, Glasgow. Data collection sheets were completed from patient paper notes documenting 16 episodes of PBSC transplants. Episodes were arranged into 4 categories according to the variations on mobilisation chemotherapy; 'G‐CSF + plerixafor', 'Rapid COJEC', 'Rapid COJEC + G‐CSF hot on heels' and 'N7'. The mobilisation chemotherapy was defined as the last myelotropic medication given before a collection attempt. In the 'Rapid COJEC + GCSF hot on heels' regime patients were given G‐CSF for 4 or more days following Rapid COJEC, facilitating neutrophil count recovery over 1.0x10^9^/mcL prior to apheresis collection.

**Results**: Mobilisations are still being attempted following Rapid COJEC and N7, and second attempts are being carried out using G‐CSF + plerixafor as 'rescue therapy'. G‐CSF + plerixafor is the most effective mobilising regime, however promising results were seen when collection following Rapid COJEC was delayed to allow neutrophil count recovery of \>1.0x109 n=1.

**Conclusions**: Mobilisation following Rapid COJEC is able to produce the highest CD34+ total cell dose and peripheral cell count. However, the rate of successful transplantable product is 57% with Rapid COJEC and 100% for GCSF + Plerixafor. Results suggest that collections may be most successful using a 'GCSF + plerixafor hot on heels' approach, allowing greater neutrophil recovery by increasing the number of days between mobilisation and collection whilst administering G‐CSF.

### PO-406. Reconstructing the Evolution of Complex Genomic Amplification Patterns at Chromosome 12q in Neuroblastoma {#pbc27455-sec-6350}

[C. Rosswog]{.ul} ^1^, C. Bartenhagen^1^, A. Engesser^1^, Y. Kahlert^1^, F. Hertwig^2^, A. Roderwieser^1^, B. Hero^3^, M. Peifer^4^, R. Thomas^4^, M. Fischer^1^

*^1^University Children\'s Hospital of Cologne, Department of Experimental Pediatric Oncology, Cologne, Germany; ^2^Charité -- Universitätsmedizin Berlin, Department of Pediatric Oncology and Hematology, Berlin, Germany; ^3^University Children\'s Hospital of Cologne, Department of Pediatric Oncology and Hematology, Cologne, Germany; ^4^Center of Integrated Oncology Cologne--Bonn‐ University of Cologne‐, Department of Translational Genomics, Cologne, Germany*

**Background/Objectives**: Amplification of genomic regions at chromosome 12q13‐15 occurs in several cancer entities as extrachromosomal double minutes (DM) or intrachromosomal homogeneously staining regions (HSR). The amplicons cover proto‐oncogenes, such as *MDM2* and *CDK4*, and are associated with poor prognosis. The evolutionary process leading to these amplifications has remained elusive so far.

**Design/Methods**: We examined seven primary neuroblastoma cases and three cell lines harboring complex genomic amplification patterns along with multiple rearrangements on chromosome 12q. To gain insights to tumor evolutionary processes of amplification and rearrangement events we fully characterized these samples using whole genome sequencing and multicolor FISH analyses. Additionally, large genome maps of the cell lines were generated using Bionano\'s optical mapping, and tumor samples were further characterized by linked‐read sequencing. Rearrangements and copy numbers were integrated and modeled *in silico* to reconstruct amplification patterns and to infer the order of events and mechanisms behind them.

**Results**: Amplification of 12q regions occurred as HSR or DM, involving *MDM2* and *CDK4*, and was occasionally linked to *MYCN* amplification. Two cell lines harbored neochromosome structures. In HSRs and neochromosomes, the amplified regions were composed of highly fluctuating copy numbers ("firestorms") intertwined with numerous rearrangements. DMs appeared more uniformly, with fewer rearrangements connected as a loop in a walkable manner. Our results suggest an initial catastrophic event leading to disruption of one or more chromosomes, followed by rejoining of separated fragments to generate stable loop structures. After further amplification by breakage fusion bridge cycles, loop structures may linearize and acquire telomeres, thus resulting in neochromosomes, or integrate into a normal chromosome as HSR.

**Conclusions**: Amplification of the 12q region shows complex patterns of copy number changes and rearrangements, and is highly variable among patients and cell lines. Comprehensive structural analyzes allow to reconstruct modules and chronology of these complex events.

### PO-407. Outcomes of Low and Intermediate Risk Neuroblastoma: Results of a Risk‐Stratified Approach from India {#pbc27455-sec-6360}

[M. Saroha]{.ul} ^1^, V. Bhat^1^, H. Sankaran^1^, G. Chinnaswamy^1^, M. Prasad^1^, T. Vora^1^, S. Qureshi^2^, M. Ramadwar^3^, S. Shah^4^, S. Laskar^5^, N. Khanna^5^, N. Salins^6^, O. Shetty^3^, S. Desai^3^, S. Banavali^1^

*^1^Tata Memoral Hospital, Pediatric Oncology, Mumbai, India; ^2^Tata Memoral Hospital, Pediatric Surgery, Mumbai, India; ^3^Tata Memoral Hospital, Pathology, Mumbai, India; ^4^Tata Memoral Hospital, Nuclear Medicine, Mumbai, India; ^5^Tata Memoral Hospital, Radiation Oncology, Mumbai, India; ^6^Tata Memoral Hospital, Palliative Medicine, Mumbai, India*

**Background/Objectives**: Risk stratified treatment of neuroblastoma has been shown to optimise outcomes and reduce long‐term toxicities. However, this requires advanced diagnostics, appropriate infrastructure and careful surveillance which could be challenging in a Low middle income (LMIC) setting. We analyzed the outcomes of patients with neuroblastoma treated with a risk stratified approach at our centre.

**Design/Methods**: All children with histologically proven low risk(LR) and intermediate risk (IR) neuroblastoma treated from January 2011 to December 2015 underwent a retrospective review of charts and database for clinical, demographic details and outcomes. Staging included bilateral bone marrow biopsies, PET/CT and MIBG, and N‐MYC amplification, and risk stratification was according to International Neuroblastoma Staging System (INSS)/International Neuroblastoma Risk Grouping (INRG). LR patients were treated with observation only or surgery;chemotherapy in life‐threatening situations, and IR patients with surgery and 4‐8 cycles of chemotherapy.

**Results**: Of 190 children with neuroblastoma,37(19.5%) were LR and 48 (25%) were IR. Histology was neuroblastoma (n=68), ganglioneuroma (n=11), and ganglioneuroblastoma (n=5) ;54 children had favourable histology (FH) and 31 had unfavourable histology (UH) by INPC classification. Staging as per INRG categorized children as L1 (n=28), L2 (n=46), M (n=9) and MS (n=2). At a median follow‐up of 30.1 months, patients with LR had a 3 year OS of 94.0% (95% CI: 77.9‐98.5%) and 3 year EFS of 82.3% (95% CI: 60.7‐ 92.7%), while those with IR had a 3 year OS of 77.5% (95% CI: 62.2‐87.2%) and 3 year EFS was 63.7% (95% CI: 47.5‐76.1%). 3 year EFS for observation alone LR was 76.0% (95% CI: 48.0‐90.3%) and OS was 83% (95% CI: 60.7%‐93.3%).

**Conclusions**: Risk stratified approach to neuroblastoma is feasible in LMIC setting with excellent outcomes in low and intermediate risk neuroblastoma. Centres treating neuroblastoma in LMICs need to acquire the basic minimum infrastructure in order to optimise outcomes.

### PO-408. Flow Cytometry of Bone Marrow Aspirates in Neuroblastoma Patients is a Highly Sensitive Technique for Detection of Low Level Neuroblastoma in Routine Care {#pbc27455-sec-6370}

[S. Sattar]{.ul} ^1^, S. Inglott^2^, A. Serban^3^, R. Thomas^2^, C. Connor^2^, N. Ghara^4^, G. Barone^1^, J. Anderson^5^

*^1^Great Ormond Street Hospital London, Paediatric Oncology, London, United Kingdom; ^2^Great Ormond Street Hospital London, Specialist Integrated Haematological Malignancy Diagnostic, London, United Kingdom; ^3^Great Ormond Street Hospital London, Paediatric Surgery, London, United Kingdom; ^4^Great Ormond Street Hospital London, Paediatric Haematology, London, United Kingdom; ^5^Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health, Paediatric Oncology, London, United Kingdom*

**Background/Objectives**: Identification of neuroblastoma metastasis to bone marrow by examination of aspirate and trephine samples is not only a requisite in staging, but is used to follow treatment response and to detect relapse.

**Design/Methods**: We analysed 675 consecutive bone marrow samples from 70 patients with neuroblastoma. These comprised 367 aspirates and 308 trephines. In 59 procedures, no trephine was taken. All samples underwent prospective examination by flow cytometry of disaggregated cells by enumerating CD45 negative and CD56/GD2 positive cells following live/dead gating. We then compared these results with standard morphology and trephine histopathology.

**Results**: Out of 367 aspirates 31 (8.4%) samples showed a clear population of CD56/GD2 positive cells on flow cytometry whilst the morphology was negative for neuroblastic infiltration. Two out of these 31 samples were taken at diagnosis, whilst 29 samples were taken following the start of treatment. Nineteen out of 308 trephine samples (6.1%) were similarly positive on flow cytometry whilst negative by standard analysis. Four of the 19 were at diagnosis whilst 15 were post treatment.

**Conclusions**: Flow cytometry appears to have increased sensitivity compared with both aspirate and trephine morphology and may be an additional quick and cost effective tool for detection of minimal residual disease in patients with neuroblastoma.

### PO-409. Preliminary Study of Yes‐Associated Protein 1 Expression in Neuroblastoma and Relationship with Drug Sensitivity {#pbc27455-sec-6380}

[W. Shan]{.ul} ^1^

*^1^Children\'s Hospital of Chongqing Medical University, Department of Pediatric Surgical Oncology, Chingqing, China*

**Background/Objectives**: To investigate the expression of Yes‐associated protein 1 (YAP1) in tissue from children with neuroblastoma. Further to analyze the relationship between the expression of YAP1 and clinicopathological parameters and the sensitivity to chemotherapeutic agents.

**Design/Methods**: Quantitative Real‐Time PCR (RT‐qPCR) and immunohistochemical (IHC) staining were performed to detect the expression of mRNA and protein in 25 neuroblastoma (NB), 7 ganglioneuroblastomas (GNB) and 8 ganglioneuroma (GN). Immunohistochemical staining, polymerase chain reaction amplification and sequencing were employed to examined expression or mutation of drug‐related genomic markers in 11 NB/GNB.

**Results**: The RNA levels of YAP1 in NB/GNB were significantly higher than those in GN (2.369±1.420 VS 0.829±0.122, P\<0.05). In NB/GNB, YAP1 mRNA expression was associated with tumor staging, risk stratification, Shimada classification, differentiation, size and metastasis (P\<0.05), but had nothing to do with age and sex (P\>0.05). The protein level of YAP1 was consistent with the mRNA level: Strongly positive YAP1 protein expression in the stage III and IV tumors, weakly positive in the stage I and II tumors and negative in GN by IHC. Five genomic markers of anti‐neoplastic agents were examined, including excision repair cross‐complementing 1 (ERCC1), topoisomerase I (TOPO I), topoisomerase II A (TOPO IIA), O6‐methylguanine‐DNA methyltransferase (MGMT), CYP2C19\*2. It showed that 36.4% (4/11) tumor samples had highly sensitivity to platinum; 27.3% (3/11) had highly sensitivity to irinotecan/topotecan, anthracycline/etoposide and cyclophosphamide, respectively; 63.6%(7 / 11)had highly sensitivity to temozolomide/carmustine/semustine. YAP1 mRNA expression significantly higher in poorly sensitivity to cyclophosphamide group than highly sensitivity group (3.251±1.349 VS 1.307±0.298, P\<0.05), while no significant correlation with sensitivity to platinum, irinotecan/topotecan, anthracycline/etoposide and temozolomide/carmustine/semustine (P\>0.05).

**Conclusions**: YAP1 expression was associated with tumor staging, risk stratification, Shimada classification, differentiation, size and metastasis. It may identify YAP1 promote tumorigenesis and progression. Furthermore, YAP1 expression is related to cyclophosphamide resistance, it may be a potential therapeutic target for cyclophosphamide‐resistant NB/GNB.

### PO-410. Characterizing Treatment for Relapsed and Refractory High Risk Neuroblastoma and the Resultant Impact on Survival {#pbc27455-sec-6390}

[V. Smith]{.ul} ^1^, S. Cheng^2^, J. Foster^1^

*^1^Baylor College of Medicine / Texas Childrens Hospital, Pediatrics / Cancer Center, Houston, USA; ^2^Benedictine University, Public Health, Lisle, USA*

**Background/Objectives**: Most patients with relapsed/refractory high risk neuroblastoma (HRNBL) die of disease despite numerous salvage regimines. While the response rate of each regimen is known, it is unknown how the totality of treatment effects survival. Here we describe treatment of relapsed and refractory high risk neuroblastoma patients from time of first relapse or progression to time of death, no disease or consistently stable disease.

**Design/Methods**: Data from electronic medical records were abstracted on patients with HRNBL treated at Texas Children\'s Hospital from 2002‐2013. Kaplan‐Meier survival analysis was used to explore time to death and time to relapse, and the Log‐Rank (Mantel‐Cox) p‐value was reported. Analysis was performed with SPSS vs 24.

**Results**: Thirty‐six patients with relapsed/refractory neuroblastoma who had records available for their entire treatment course were identified. 15.4% of patients are alive with no disease or stable disease for at least 24 months. Phase 1 therapy was the most frequently utilized regimen at 31%. The mean number of days from time of diagnosis to 1st relapse was 347.1 days and 357.2 days between 1st relapse and death. The mean number of progressions and/or relapses was 3. Those who participated in Phase 1 trials had significantly higher mean number of days from relapse to death than those not on Phase 1 trials (606.25 d vs 207.80 d; p=0.004). There was no significant difference in time to death between patients who took a break from treatment (defined as \>21 days without therapy) and those who did not (p=0.52). However, those who took a break reported 439.88 mean days from relapse to death compared to 327.14 for those not taking a break.

**Conclusions**: Patients who participated in Phase 1 trials had a greater number of days between relapse and death. Taking a break from therapy does not appear to impact time to death.

### PO-411. Risk Stratification with Surgical Intervention in Children with Neuroblastoma {#pbc27455-sec-6400}

[S. Sokolov]{.ul} ^1^, M. Suchov^1^, A. Narbutov^1^, I. Lyvina^1^, E. Andreev^1^, N. Ponomaryova^2^

*^1^Russian Children\'s Clinical Hospital of the Russian Ministry of Health, department of microsurgery, Moscow, Russia; ^2^Russian Children\'s Clinical Hospital of the Russian Ministry of Health, department of hematology, Moscow, Russia*

**Background/Objectives**: The greatest difficulties in the surgical treatment of neuroblastoma occur when the tumor is intimately connected with large vessels and internal organs. For successful treatment of this category of patients, a thorough stratification of oncological and surgical risk is necessary.

**Design/Methods**: An analysis of the results of diagnosis and treatment of neuroblastoma of abdominal and thoracoabdominal localization in 9 children aged from 9 to 55 months was implemented. Five children were classified as high risk, intermediate risk was detected in three patients, low ‐ in one. All of them received treatment according to the NB‐2004 protocol. Preoperative assessment of surgical risk was based on visual diagnostic methods, the number of factors was, on average, 5.

**Results**: Injuries of the renal vein in 4 patients, the aorta in 1 child, inferior vena cava in 2 cases and the celiac trunk in 1 patient were sutured without subsequent complications. After injury and suturing of the inferior vena cava, 1 patient had a parietal thrombus without clinically significant hemodynamic disturbances. In 1 observation, postoperative thrombosis of the left renal artery caused blood flow disorders requiring nephrectomy. Damage to the pancreas in 1 child was accompanied by a long drainage. Subsequently, anastomosis between the pancreas and small intestine was performed. The volume of tumor resection was, on average, 93%. The duration of postoperative follow‐up was 18 months. Overall survival was 100%, the event‐free survival rate ‐ 78%. The continued growth of the tumor was registered in 2 patients in the high‐risk group.

**Conclusions**: Radical removal of the neuroblastoma is acceptable in the absence of invasive growth in the adjacent vessels and internal organs, otherwise, the resection should be performed for cytoreduction and elimination of disorders caused by compression of the neoplasm.

### PO-412. Clinical Presentation and Diagnosis of Adrenal Tumor During the Perinatal Period {#pbc27455-sec-6410}

[M. Sugawa]{.ul} ^1^, Y. Arakawa^1^, H. Chikai^1^, T. Takaki^1^, J. Noguchi^1^, M. Yanagi^1^, K. Isobe^1^, M. Mori^1^, H. Kawashima^2^, E. Oguma^3^, A. Nakazawa^4^, H. Kishimoto^5^, K. Koh^1^

*^1^Saitama Children\'s Medical Center, Hematology and Oncology, Saitama, Japan; ^2^Saitama Children\'s Medical Center, Pediatric Surgery, Saitama, Japan; ^3^Saitama Children\'s Medical Center, Radiology, Saitama, Japan; ^4^Saitama Children\'s Medical Center, Clinical Research, Saitama, Japan; ^5^Saitama Children\'s Medical Center, Pathology, Saitama, Japan*

**Background/Objectives**: Recently, ultrasonography has progressed, and the number of neonates diagnosed as having adrenal tumor/masses without symptoms has been increasing. Most of these masses are neuroblastomas or adrenal hemorrhages. The optimal strategies for diagnosis and treatment of these masses remain a challenge for clinicians.

**Design/Methods**: The medical records of 32 neonates without symptoms who were diagnosed as having adrenal tumor/masses in the Department of Radiology, Saitama Children\'s Medical Center, between April 1, 2004, and March 31, 2018, were reviewed.

**Results**: Nine patients were diagnosed antenatally and 23 after birth. The initial diagnosis was adrenal hemorrhage in 19 patients (group A) and adrenal tumor in 13 patients (group B). In group A, 18 patients were finally diagnosed as having adrenal hemorrhage after follow‐up with ultrasonography and urine vanillylmandelic acid (VMA)/homovanillic acid (HVA) test, which had regressed in the final follow‐up. However, one patient was found with a growing neuroblastoma. In group B, complete surgical resection, biopsy, and observation were performed in 8, 2, and 3 patients, respectively. Among the 13 patients with adrenal tumors, 1, 2, and 10 patients were finally diagnosed as having adrenal hemorrhage, teratoma, and neuroblastoma, respectively. Among the patients with neuroblastoma, 8 were in stage 1, 1 was in stage 2, and 1 was in stage 4s. MYCN amplification was not detected in all the tumor cases. All the patients were alive at the last follow‐up.

**Conclusions**: In our cases, by using initial imaging, clinical information, and urine VMA/HVA test, we performed a differential diagnosis between neuroblastoma and suprarenal hemorrhage with high accuracy. However, the diagnosis was changed during follow‐up in a few cases. Follow‐up ultrasonography and urine VMA/HVA test are important until the mass achieves regression or is surgically removed. Less‐invasive diagnostic and treatment strategies should be considered for these masses.

### PO-413. Development of a Novel Therapeutic Strategy Targeting High Copy Number Amplification of Oncogenes in Neuroblastoma {#pbc27455-sec-6420}

[A. Takatori]{.ul} ^1^, H. Yoda^1^, Y. Ota^1^, T. Inoue^2^, K. Hiraoka^2^, S. Krishnamurthy^1^, T. Watanabe^1^, Y. Shinozaki^2^, H. Nagase^2^

*^1^Chiba Cancer Center Research Institute, Division of Innovative Cancer Therapeutics, Chiba, Japan; ^2^Chiba Cancer Center Research Institute, Division of Cancer Genetics, Chiba, Japan*

**Background/Objectives**: High copy number amplification of oncogenes is involved in the development of various types of tumors. In neuroblastoma, gene amplification of *MYCN* and/or *ALK* is involved in its tumorigenesis, although targeting amplified genomic regions has been a therapeutic challenge. We have previously developed a DNA‐alkylating Pyrrole‐Imidazole (PI) polyamide, CCC‐002, to target the *MYCN* gene in neuroblastoma. In this study, we confirmed its anti‐tumor activity of CCC‐002 in xenograft mouse models and investigated the mode of action of CCC‐002 in highly amplified *MYCN* regions. We also employed CRISPR/Cas9 system targeting *MYCN* as a site‐specific DNA damage agent to investigate whether *MYCN* amplification is a potentially druggable target for neuroblastoma.

**Design/Methods**: Since *ALK* gene includes potential binding sequences of CCC‐002, we tested CCC‐002 for its growth inhibition effect in neuroblastoma cells with not only MYCN but also *ALK* amplification. CCC‐002 was synthesized by an automated peptide synthesizer PSSM‐8. CRISPRs targeting *MYCN* gene were designed according to The Broad Institute′s CRISPR Design tool (<http://www.crispr.mit.edu/>).

**Results**: CRISPR/Cas9 system targeting MYCN significantly increased the number of apoptotic cells compared to control crRNA in *MYCN*‐amplified neuroblastoma cells, while no induction of apoptosis was observed in *MYCN* non‐amplified cells. In *MYCN*‐amplified neuroblastoma cells, CCC‐002 significantly suppressed MYCN gene expression and cell proliferation. In xenograft mouse models using *MYCN*‐amplified neuroblastoma cells, CCC‐002 administration at 0.3 mg/kg significantly inhibited tumor growth without affecting weight gain of mice. In *ALK*‐amplified neuroblastoma cells, CCC‐002 treatment demonstrated anti‐proliferative potency over conventional ALK inhibitors, such as crizotinib and alectinib. Intriguingly, CCC‐002 diminished probe hybridizations at *MYCN* and *ALK* loci by FISH analyses, suggesting that it reduced the copy number gain of amplified genes both *in vitro* and *in vivo*.

**Conclusions**: Site‐specific DNA damage induction by CRISPR/Cas9 and CCC‐002 within the amplified region of oncogenes is potential therapeutic strategy in neuroblastoma.

### PO-414. Treatment of High Risk Neuroblastoma with Topotecan Containing Chemotherapy, MIBG Treatment, High Dose Chemotherapy with Autologous Stem Cell Rescue and Maintenance Cis‐Retinoic Acid {#pbc27455-sec-6430}

[P. Techavichit]{.ul} ^1^, S. Lauhasurayotin^1^, K. Chiengthong^1^, D. Sosothikul^1^

*^1^Faculty of Medicine, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Neuroblastoma is the most common extracranial malignancy in children, usually presents with high risk disease with poor treatment outcome. Topotecan containing regimen shows to be effective and feasible for the treatment of high risk neuroblastoma (HR‐NB).

**Design/Methods**: Retrospective study from 2013 to 2018 at Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

**Results**: Fourteen patients (6 females, 8 males), median age of 3.8 years, were diagnosed with HR‐NB according to COG risk‐classification at our institute during the study period. All patients received six cycles induction chemotherapy consisted of initial two cycles of topotecan/cyclophosphamide with subsequent four cycles of cisplatin, etoposide, cyclophosphamide, vincristine and doxorubicin. All patients tolerated treatment well and showed at least partial response post‐induction. Post‐induction, local control with surgery was attempted in all patients. Six patients received consolidation treatment with 18 mCi/kg MIBG treatment followed by busulflex/melphalan and autologous stem cell rescue (auto‐BMT), the rest eight patients underwent four cycles of ifosfamide/carboplatin/etoposide (ICE‐regimen) without stem cell rescue. The maintenance treatment was continued for 12 months with cis‐retinoic acid for all patients. At the median follow‐up of 34 months, event free survival in auto‐BMT and ICE‐regimen groups were 44.44% and 33.33% respectively with no statistical significant (P=0.24). The median time to progression in auto‐BMT and ICE‐regimen groups were 30 and 19 months respectively. Eight patients (3 in auto‐BMT, 5 in ICE‐regimen group) died of disease.

**Conclusions**: Topotecan containing chemotherapy is effective and well tolerate for high risk neuroblastoma treatment. MIBG treatment with high dose chemotherapy autologous stem cell rescue prolongs time to progression with no significant survival benefit.

### PO-415. Utility of Flow Cytometric Detection of Circulating Tumor Cells (CTC) in the Prediction of BM Metastasis in Children with Neuroblastoma {#pbc27455-sec-6440}

[P. Tembhare]{.ul} ^1^, K. Khirwal^2^, K. Girase^1^, I. Sanyal^1^, Y. Badrinath^1^, S. Ghogale^1^, N. Deshpande^1^, G. Chinnaswamy^3^, S. Qureshi^4^, M. Ramadwar^2^, G. Chatterjee^1^, N. Patkar^1^, T. Vora^3^, M. Prasad^3^, P.G. Subramanian^1^, S. Gujral^2^

*^1^Tata Memorial Centre, Hematopathology Laboratory, Mumbai, India; ^2^Tata Memorial Centre, Department of Pathology, Mumbai, India; ^3^Tata Memorial Centre, Department of Medical Oncology, Mumbai, India; ^4^Tata Memorial Centre, Department of Surgical Oncology, Mumbai, India*

**Background/Objectives**: Bone marrow (BM) metastasis is a well‐established prognostic‐factor in Neuroblastoma. Ideally bilateral BM‐aspirate/biopsy, a costly and painful procedure performed under anesthesia, is required to adequately assess BM‐metastasis. Presence of circulating tumor cells (CTC) has potentially similar prognostic impact. Detection of CTC by flow‐cytometric immunophenotyping (FCI) is readily available, safe and relatively cost‐effective method. Hence, this study was aimed to determine the utility of detection of CTC by FCI for prediction of BM‐metastasis in Neuroblastoma.

**Design/Methods**: We compared presence of CTC by FCI with both morphology alone and combination of morphology and FCI of bilateral BM aspirate/biopsy for presence of metastasis in 47 children with Neuroblastoma. FCI was done with ten‐color antibody‐panel that included GD2, CD3+CD19, CD36, CD13, CD45, CD56, CD81, CD90, CD99, and CD271.

**Results**: Of 47 children with Neuroblastoma (age range, 0.6‐13 years), thirty‐one (66%) children showed FCI BM involvement \[bilateral ‐26(55%), unilateral ‐5(11%)\] with median levels 2.1% (range, 0.001‐66.55%). Notably, 5/31 children were negative for BM‐metastasis by aspirate/biopsy morphology indicating FCI had higher sensitivity than morphology alone. In these 31 patients, CTC were detected in 18(58%) patients with median tumor level of 0.005% (range, 0.0006‐0.61%). Median number‐of‐cells studied for FCI‐CTC analysis was 5,61,935 (range 2,01,620--60,24,038). CTC were not detected in any child without BM metastasis (n=16). Specificity and sensitivity of CTC in prediction of BM‐metastasis was 100% and 58% respectively (positive‐predictive‐value, 100%; negative‐predictive‐value, 55%). Majority of patients with BM‐metastasis with non‐detectable CTC (n=13) had lower number of cells studied (cells \<5,00,000, n=9/13) and minimal levels of BM‐tumor burden (tumor levels\<0.5%, n=11/13).

**Conclusions**: The presence of CTC by a sensitive FCI is highly predictive of underlying BM metastasis in Neuroblastoma. Our data indicate that detection of CTC by sensitive FCI can avoid invasive BM procedure in approximately 40% of children with Neuroblastoma and can be further improved by studying higher number‐of‐cells (\>5,00,000).

### PO-416. Cross‐Talk Between Neuroblastoma Cells and their Microenvironment at the Metastatic Bone Marrow Niche {#pbc27455-sec-6450}

[I. Timmerman]{.ul} ^1^, L. Zogchel^2,3^, C. Kuijk^1^, M. Kleijer^1^, C.E. van der Schoot^2^, G. Tytgat^3^, C. Voermans^1^

*^1^Sanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam, The Netherlands; ^2^Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Amsterdam, The Netherlands; ^3^Princess Máxima center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands*

**Background/Objectives**: Neuroblastoma (NB), the second most common cancer in childhood, shows a strong tendency to metastasize to bone marrow (BM). Once settled in the BM, tumor cells can acquire chemoresistance, become dormant and hide until they are triggered to proliferate again. This is a likely key factor in disease relapse, which is unacceptably high for NB. Therefore, better understanding of dormancy control is essential to improve NB therapy. In some cancer types, bone metastatic tumor cells create a tumor‐protective microenvironment by recruiting and affecting mesenchymal stromal cells (MSCs) that, in turn, have been shown to induce tumor cell dormancy. We aimed to study whether NB‐cells influence MSC in the BM‐metastatic niche.

**Design/Methods**: Diagnostic BM aspirates from patients with metastatic‐NB (stage 4) were compared to patients with localized‐NB (stage 1‐3). We also examined follow‐up BM samples of metastatic‐NB patients with relapsed disease. MSCs were counted by flow cytometry using the classical CD34^‐^, CD45^‐^, CD90^+^, CD105^+^ phenotype. To get insight in phenotypical changes within the heterogeneous MSC population, we also analyzed the distribution of subtypes, characterized by surface markers such as CD271 and CD146.

**Results**: Immunophenotypical analyses revealed that NB patients with BM metastases have a higher frequency of MSCs in their BM than patients without BM metastases, at diagnosis as well as at relapse. Of particular interest is a distinctive CD271‐ CD146+ MSC subtype, which appears to be unique for patients with metastatic‐NB. Of note, these cells did not express NB‐markers, hence are not NB‐derived.

**Conclusions**: Together, these findings suggest that metastasized NB‐cells affect MSC in their microenvironment. Further characterization of MSC subtypes within the BM‐metastatic niche is ongoing and may uncover tumor‐supporting subsets. Ultimately, increasing our understanding of MSC‐NB cross‐talk could provide targets for potential combination therapies that act on the BM microenvironment to enhance NB chemo‐sensitivity.

### PO-417. Short Stature Among High‐Risk Neuroblastoma Survivors Treated with Non‐TBI Regimen {#pbc27455-sec-6460}

[Y. Tsumura]{.ul} ^1^, C. Kiyotani^1^, Y. Shioda^1^, T. Osumi^1^, M. Kato^1^, D. Tomizawa^1^, K. Terashima^1^, T. Hishiki^2^, H. Fuji^3^, R. Horikawa^4^, K. Matsumoto^1^

*^1^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Division of Surgery, Tokyo, Japan; ^3^National Center for Child Health and Development, Department of Radiology, Tokyo, Japan; ^4^National Center for Child Health and Development, Division of Endocrinology and Metabolism, Tokyo, Japan*

**Background/Objectives**: Short stature due to growth hormone deficiency (GHD) is frequently recognized among child cancer survivors treated with TBI. To avoid the radiation induced late effect, non‐TBI regimen was introduced to high‐risk neuroblastoma (HR‐NB) treatment as standard therapy since late 1990s. We retrospectively investigated the growth pattern of 5‐year HR‐NB survivors treated with non‐TBI regimen in our institution.

**Design/Methods**: Serial twenty‐two HR‐NB survivor\'s clinical data diagnosed between December 2002 and February 2013 were reviewed. All the patients received chemotherapy, surgery, local radiation therapy and HD‐chemotherapy (non‐TBI regimen) followed by autologous PBSCT. Follow‐up was performed on a regular basis. If the patients were found to have some late sequelae, they were treated accordingly.

**Results**: Nineteen of 22 were 5‐year survivors. At diagnosis, their median age was 2.8 years old and median height was 0.6SD. No one had any other basic disease affecting his or her heights. There was no follow‐up loss. Median follow up period is 9.0 years. The survivors' median age is 11.4 years old. At last follow‐up, 42% of all the survivors and 80% of 5 post‐pubertal survivors had short stature (\<‐2SD). Median Z‐score of the post‐pubertal survivors is ‐4.3SD (‐0.6SD∼‐ 5.1SD). GHD was recognized in only one patient who had skull base tumor. Six patients required replacement therapy for thyroid dysfunction and five for gonadotropin dysfunction. No one has Fanconi syndrome or severe renal failure during the follow‐up.

**Conclusions**: Multidisciplinary treatment for HR‐NB significantly impacts the height in spite of sparing TBI. No apparent growth spurt was recognized even under the careful replacement therapy. Their short stature might be caused by some other factors than the endocrine levels.

### PO-418. Strategic Dietetic Intervention for Children Following the High Risk Neuroblastoma Treatment Protocol (HR‐NBL 1/SIOPEN) {#pbc27455-sec-6470}

[L. Upton]{.ul} ^1^

*^1^Birmingham Children\'s and Women\'s Hospital Foundation Trust, Nutrition and Dietetics, Birmingham, United Kingdom*

**Background/Objectives**: The importance of preserving growth and nutritional status in children with cancer is well acknowledged throughout the literature. In practice, achieving this in children diagnosed with high risk Neuroblastoma (NB) presents a significant dietetic challenge, with studies suggest between 25‐50% of children present as underweight at diagnosis (Small *et al*, 2015). Children typically then follow a multimodal, intensive treatment protocol (HR‐NBL 1/SIOPEN). Each treatment stage elicits side effects affecting the suitability and efficiency of nutrition support intervention and may contraindicate the ability to maintain a child\'s nutritional status.

**Design/Methods: Aim**: Develop a dietetic treatment pathway which tracks alongside the HR‐NBL 1/SIOPEN protocol identifying treatment specific and strategic dietetic interventions to optimise nutritional outcomes.

**Results**: Methods: A treatment pathway was produced by the BWCH Oncology Dietitian with the support of the Specialist Oncology ANP. Collaboration allowed for detailed understanding of the anticipated side effects for each stage of the protocol, with a focus on nutritional and growth implications and/or management.

**Conclusions**: Implications for practice: It is anticipated this pathway will encourage proactive and appropriate dietetic intervention in children following HR‐NBL 1/SIOPEN, aiming to improve quality of care by preventing malnutrition and weight loss. The pathway includes identification of; timeframes to optimise weight gain, consideration of enteral nutrition parameters (regimen, feed formulation) and pertinent use of parenteral nutrition. It is also hoped that it will support families with an understanding of their child\'s nutritional needs at each stage of treatment and manage their expectations surrounding growth or tolerance of nutritional interventions.

### PO-419. Neuroblastoma Survival in a Middle Income Country: A Report of VIGICANCER Pediatric Cancer Surveillance System from Cali, Colombia {#pbc27455-sec-6480}

[L.A. Urcuqui]{.ul} ^1^, M.X. Castro^1^, D. Medina^2^, P. Aristizabal^3^, L.E. Bravo^4^, O. Ramirez^5^

*^1^POHEMA Foundation. Fundación Valle del Lili, Pediatric Oncology, Cali, Colombia; ^2^POHEMA Foundation. Fundación Valle del Lili, Bone Marrow Transplantation Unit, Cali, Colombia; ^3^University of California/Peckham Center for Cancer and Blood Disorders‐ Rady Children\'s Hospital‐ San Diego‐ and University of California San Diego Moores Cancer Center‐ La Jolla‐ CA, Pediatric Oncology, San Diego, USA; ^4^Universidad del Valle, Cali\'s Population Based Cancer Registry‐ Pathology Department, Cali, Colombia; ^5^POHEMA Foundation. Centro Médico Imbanaco de Cali‐ Colombia, VIGICANCER Childhood Cancer Surveillance System Medical Coordinator‐ On Behalf of VIGICANCER Working Group, Cali, Colombia*

**Background/Objectives**: In high‐income countries, neuroblastoma(NB) is the most common extracranial solid tumor with a 70% 5‐year survival. In Cali, the third largest city in Colombia, the annual incidence of NB is 3.8 per million children, being the 6^th^ most common extracranial solid tumor. Outcome data in low and middle‐income countries are scarce. We describe the survival of children with NB in Cali.

**Design/Methods**: VIGICANCER was established in 2009 ‐ with the support of Sanofi‐Espoir Foundation\'s "My Child matters program" ‐within Cali\'s cancer registry to collect data on outcomes of patients \<19 years old with a new diagnosis of cancer treated at pediatric oncology units. Baseline and follow‐up data were collected from medical records, hospital discharge logs, pathology reports, death certificates, and the National Public Health Insurance database. Survival analyses were performed using Kaplan‐Meier.

**Results**: From 2009‐2017, we identified 52 NB within 1711 children (\<15 years of age) registered. Median age was 1.8 years (range: 0.02 to 12), 44% male, 21% afro‐descendants, 21% stage 3, 68% stage 4, 76% high‐risk, and 27% achieved complete response. 47% of high‐risk patients underwent autologous BMT. Treatment‐related deaths and abandonment were 18% and 10%, respectively. Five‐year overall survival (OS5y) and event‐free survival (EFS5y) was 37% (95%CI:22, 52) and 30% (95%CI: 16, 46), respectively. In patients \<1 year of age, EFS5y was 61% (95%CI: 29, 82). EFS5y for stage 3 and 4 was 42% (95%CI: 7, 75) and 21% (95%CI: 7, 42%), respectively. All stage 1 and 2 patients are alive. For stage 4 patients, EFS5y was higher in patients with semi‐private insurance compared to those with public health insurance (42% vs. 9%;P=0.06).

**Conclusions**: NB survival in Cali is 30% lower than in high‐income countries. We found a survival disparity between health insurance types. High treatment‐related death, abandonment and limited access to autologous stem‐cell transplant contribute to this survival gap.

### PO-420. Neuroblastoma with Opsoclonus Myoclonus Ataxia Syndrome: Case Series from Tertiary Care Center {#pbc27455-sec-6490}

[S. Vaddadi]{.ul} ^1^, S.R. Siddaiahgari^2^, L. Lingappa^3^, H. Jayaram^4^, M. Deb^4^

*^1^Rainbow Children\'s hospital‐ Banjara hills, Pediatric hematology and oncology, Hyderabad, India; ^2^Rainbow children\'s Hospital‐ Banjara Hills, Pediatric Hematology and oncology, Hyderabad, India; ^3^Rainbow children\'s Hospital‐ Banjara Hills, Pediatric Neurology, Hyderabad, India; ^4^Rainbow children\'s Hospital‐ Banjara Hills, Pediatric surgery, Hyderabad, India*

**Background/Objectives**: The Opsoclonus‐Myoclonus Ataxia Syndrome (OMAS) has Opsoclonus, Myoclonus and Ataxia as its components with changes like irritability & behavioral problems. In children with OMAS, 20 to 50% may have underlying Neuroblastoma, however incidence of OMAS in Neuroblastoma is 3 to 4%. Data is scanty in literature about its outcomes.

**Aims**: To determine outcomes of children with Neuroblastoma with OMAS association and OMAS outcomes in Neuroblastoma.

**Design/Methods: Type of study**‐ Retrospective observational study in Rainbow Children\'s tertiary care center.

**Materials & methods**‐ Medical records of children with Neuroblastoma and OMAS and records of children attending neurology out‐patient clinic with OMAS reviewed from 2010 to 2016.

**Results**: Total 31 children diagnosed as OMAS in neurology outpatients. Out of 31, 9 had underlying neuroblastoma. Median age 23 months.

Various neurological manifestations‐ Opsoclonus myoclonus in 7, Ataxia in 2. Stage of neuroblastoma ‐ stage I in one child, stage II in 5, stage III in 2 and one had stage IV disease. Except 2, remaining 7 underwent upfront surgical resection. In two, tumor resolved with neoadjuvant chemotherapy without need for surgery.

OMAS was treated with steroids, ACTH and Rituximab.

All are off treatment with no neuroblastoma recurrence with 3months to 6 years follow up. Three had prolonged OMAS for 2 to 2.6 years and subsequently recovered, rest recovered in 2 to 5 months' time.

**Conclusions**: Screening for underlying neuroblastoma is mandatory in all children with OMAS. A Multidisciplinary team approach with Neurology, Pediatric Oncology and Pediatric surgery team, results in excellent outcomes.

### PO-421. Urinary 3‐Methoxytyamine (3MT) -- a Non‐Invasive Biomarker for MYC‐Activity in Neuroblastoma Patients {#pbc27455-sec-6500}

[I. Verly]{.ul} ^1,2,3^, G. Tytgat^2^, R. Leen^3^, R. Meinsma^3^, F. Haneveld^4^, N. Hasselt^4^, J. Koster^4^, R. Volckmann^4^, R. Versteeg^4^, L. Valentijn^4^, A. van Kuilenburg^3^

*^1^Academic Medical Center, Department of Pediatric Oncology, Amsterdam, The Netherlands; ^2^Princess Máxima Center for Pediatric Oncology, for Pediatric Oncology, Utrecht, The Netherlands; ^3^Academic Medical Center, Laboratory for Genetic Metabolic Diseases, Amsterdam, The Netherlands; ^4^Academic Medical Center, Department of Oncogenomics, Amsterdam, The Netherlands*

**Background/Objectives**: Prognosis in neuroblastoma is determined by risk factors such as stage and *MYCN* amplification (MNA). Recently, we identified elevated urinary 3‐methoxytyramine (3MT) as an independent risk factor for poor clinical outcome in patients with neuroblastoma (Verly *et al*. Eur J Cancer 2018). We now sought a biological explanation for the correlation between elevated urinary 3MT and poor prognosis, which led us to the discovery that MYC‐activity can regulate 3MT levels and thus might explain the poor prognosis.

**Design/Methods**: Bioinformatic analyses were conducted using the R2 platform. A gene signature corresponding to elevated 3MT was generated in a test cohort and validated in a second cohort (DCOG‐set). Correlation between the 3MT gene signature and clinical outcome was tested in international cohorts (non‐DCOG sets) and compared to other cancer‐related gene signatures. Finally, the effect of MYC‐activity on catecholamine biosynthesis was investigated by overexpressing *MYCN* in *MYCN* single copy neuroblastoma cell lines. RT‐PCR and Western blot were used to detect the catecholamine biosynthetic enzymes, while HPLC was used to measure 3MT.

**Results**: The 3MT signature corresponded to urinary 3MT with an accuracy of 88%. High 3MT signature was associated with poor clinical outcome (GPOH‐set, n = 498, 5‐year EFS of 25% vs 80%, p = 7.2E‐32). The 3MT signature mainly correlated with MYC‐related signatures (R = 82%, p = 6.3E‐121). MYC‐activity was predicted by MNA and the 3MT signature with a sensitivity of 59% and 87%, respectively. *In‐vitro* overexpressing *MYCN* caused downregulation of dopamine beta‐hydroxylase, which subsequently shifted catecholamine metabolism towards 3MT.

**Conclusions**: Increased MYC‐activity in neuroblastoma causes a biochemical blockage in catecholamine biosynthesis, which forces catecholamine metabolism towards 3MT. Therefore, elevated urinary 3MT is a highly sensitive, non‐invasive biomarker for MYC‐activity, correlating better than MNA with MYC‐activity and might improve future risk‐assessment of patients with neuroblastoma.

### PO-422. Molecular Basis Underlying Targeting Metabolism for Cancer Therapy in Neuroblastoma {#pbc27455-sec-6510}

[K. Watanabe]{.ul} ^1^, S. Kimura^1,2^, M. Seki^1^, I. Tomoya^1^, T. Kawai^3^, M. Hiwatari^1,4^, K. Yoshida^5^, K. Kataoka^5^, Y. Sato^5^, Y. Fujii^5^, Y. Shiraishi^6^, K. Chiba^6^, H. Tanaka^6^, A. Oka^1^, K. Koh^7^, S. Miyano^6^, S. Ogawa^5^, J. Takita^1^

*^1^The University of Tokyo, Department of Pediatrics, Tokyo, Japan; ^2^Hiroshima University, Department of Pediatrics, Hiroshima, Japan; ^3^National Research Institute for Child Health and Development, Department of Maternal‐Fetal Biology, Tokyo, Japan; ^4^The University of Tokyo Hospital, Department of Cell Therapy and Transplantation Medicine, Tokyo, Japan; ^5^Graduate School of Medicine‐ Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan; ^6^The Institute of Medical Science‐ The University of Tokyo, Laboratory of DNA Information Analysis‐ Human Genome Centre, Tokyo, Japan; ^7^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan*

**Background/Objectives**: The prognosis of high‐risk neuroblastoma (NBL) remains poor, and novel treatments are demanded. Tumor metabolism is a promising research field for many kinds of cancer, but in NBL, it is not fully explored.

**Design/Methods**: To unravel genetic and epigenetic basis associated with metabolic alterations, RNA sequencing and DNA methylation analysis were performed in 34 NBL specimens. The open data of "TARGET NBL" was also analyzed. We extracted *PHGDH*, coding phosphoglycerate dehydrogenase (PHGDH, essential enzyme in serine biosynthesis), and *ASS1*, responsible for arginine synthesis, as the candidate targets to conduct further functional analysis. The effects of si‐RNA mediated knock down of *PHGDH* and its inhibitor, CBR‐5884, on NBL cell lines were assessed. We also analyzed the effect of arginine depletion by recombinant arginine deiminase (rADI) to the sensitivity to CBR‐5884. Metabolome analysis in 2 NBL cell lines was performed to study the effects of these treatments.

**Results**: In both cohorts, high expression with hypermethylation of gene body regions of *PHGDH* were observed in all samples with *MYCN* amplification and a part of samples with 11q deletion. High expression of *PHGDH* was significantly associated with worse prognosis in cases with 11q deletion. Expression levels of *ASS1* and *PHGDH* were positively correlated. Inhibition of *PHGDH* suppressed cell growth in NBL cells with high expression of *PHGDH*. Administration of rADI enhanced the cytotoxic effect of CBR‐5884 on NBL cells with low expression of *PHGDH* and *ASS1*. Metabolome analysis showed distinct effects of rADI and CBR‐5884 in each 2 cell lines. When rADI was administered in advance, cells with low expression of *PHGDH* and *ASS1* showed distinct metabolic reactions to CBR‐5884.

**Conclusions**: Our results suggest that *PHGDH* is a promising target for high‐risk NBL. In addition, rADI might change tumor metabolism and expand application of PHGDH inhibitor to include NBL with low expression of *PHGDH*.

### PO-423. Targeting Cysteine Metabolism as a Novel Therapeutic Concept for MYCN/MYC‐Driven Childhood Cancers {#pbc27455-sec-6520}

[F. Westermann]{.ul} ^1^

*^1^German Cancer Research Center, Neuroblastoma Genomics, Heidelberg, Germany*

**Background/Objectives**: Aberrant expression of MYC family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance.

**Design/Methods**: A global MYCN synthetic lethal screen and metabolic amino acid profiling were performed in high‐MYCN versus low‐MYCN backgrounds. Global proteomes from primary neuroblastomas were analyzed using mass spectrometry and compared to global transcriptome data. Small molecule inhibitor treatment and shRNA‐mediated knockdown were used to validate functional hits and the in vivo relevance was tested in neuroblastoma xenograft models.

**Results**: Here we show that MYCN induces massive lipid peroxidation upon depletion of cysteine, the rate‐limiting amino acid for glutathione biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non‐apoptotic and iron‐dependent type of cell death. The high cysteine demand of *MYCN*‐amplified childhood neuroblastoma is met by uptake and MYCN‐induced transsulfuration of methionine to cysteine. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of glutathione, thus creating an Achilles' heel. Inhibiting cysteine uptake or transsulfuration strongly reduces neuroblastoma growth in vivo, and inactivity of transsulfuration may contribute to spontaneous tumor regression in low‐risk neuroblastomas.

**Conclusions**: We identified several proteins and mechanisms crucial to ferroptotic escape, providing multiple previously unknown sites that may be acted on therapeutically.

### PO-424. Circulating Cell Free DNA as a Tumor Specific Biomarker of Tumor Lysis Syndrome in Advanced Stage Neuroblastoma {#pbc27455-sec-6530}

[N. Yamane]{.ul} ^1^, S. Mizuta^1^, K. Kobayashi^2^, M. Suehiro^2^, T. Maihara^3^, I. Usami^2^, T. Komai^1^, T. Heike^3^

*^1^Hyogo Prefectural Amagasaki General Medical Center, Department of Clinical Laboratory, Amagasaki, Japan; ^2^Hyogo Prefectural Amagasaki General Medical Center, Department of Pediatric Hematology and Oncology, Amagasaki, Japan; ^3^Hyogo Prefectural Amagasaki General Medical Center, Department of Pediatrics, Amagasaki, Japan*

**Background/Objectives**: Circulating cell free DNA (cfDNA) is a novel tumor specific biomarker in clinical oncology. The noninvasive analysis of tumor genomics, namely liquid biopsy, promises a future invention of individualized therapy, but the clinical significance of serial cfDNA analysis, especially during tumor lysis syndrome, is largely unknown.

**Design/Methods**: We established a standard operation procedure to isolate cfDNA from 1 ml plasma. We serially analyzed *MYCN/NAGK* in cfDNA with quantitative polymerase chain reaction (q‐PCR) of a 6‐month‐old boy with advanced stage neuroblastoma (NB). He developed several episodes of laboratory tumor lysis syndrome during the treatment period, for which we analyzed the association between serum tumor marker levels and *MYCN*/*NAGK* in cfDNA.

**Results**: The quantified *MYCN*/*NAGK* in cfDNA were identical to those in the tumor biopsy specimen. The q‐PCR based cfDNA analysis allows us to analyze *MYCN*/*NAGK* within 2 hours. We found that the serial *MYCN*/*NAGK* alteration was significantly correlated with the disease activity. Pearson correlation coefficient between *MYCN*/*NAGK* alteration and serum tumor markers, *i.e*. neuron specific enolase and lactate dehydrogenase were statistically significant (*P* value \< 0.05). The amount of cfDNA was finally normalized following by the completion of the high dose chemotherapy.

**Conclusions**: We found that q‐PCR based cfDNA analysis with liquid biopsies is a rapid and inexpensive method to evaluate tumor dynamics, even in tumor lysis syndrome. Our observation suggests that cfDNA can be included within reliable supplementary techniques that might provide clinicians with additional data on clonal evolution during the treatment.

### PO-425. Familial Neuroblastoma in Three Siblings of a Turkish Family with PHOX2B Gene Mutation {#pbc27455-sec-6540}

[G. Yavuz]{.ul} ^1^, E. Ünal Cabi^1^, N. Tacyildiz^1^, H. Dincaslan^1^, D. Ozyoruk^1^

*^1^Ankara University Faculty of Medicine, Department of Pediatrics‐ Division of Pedİatric Hematology‐Oncology, Ankara, Turkey*

**Background/Objectives**: Neuroblastoma is one of the most common malignant neoplasms in childhood. These tumours represent a heterogeneous group both in terms of clinical course and histological appearance, ranging from benign, slowly growing, often asymptomatic ganglioneuromas to malignant, highly aggressive neuroblastomas. Most cases occur sporadically, but in rare cases several individuals in the same family present with ganglioneuroblastomatous tumours. Germline mutations in a small proportion of neuroblastoma patients have been reported in the paired‐like homeobox2B (PHOX2B) gene. We report a case of familial neuroblastoma, occurring in three siblings.

**Design/Methods**: A 5‐year‐old boy, was diagnosed as ganglioneuroblastoma originated from thoracal and abdominal paravertebral ganglions. On his medical history, it was learned that his male sibling died of neuroblastoma in another hospital. Our patient received combined chemotherapy and than his shrunk tumor mass was taken out with gross total surgery. After autologous stem cell transplantation, he is followed with stable sized thoracal residuel mass for 7 years. During his treatment, his mother had a new baby. Bilateral adrenal mass was detected while the baby was 5‐month‐old and he was diagnosed as neuroblastoma. After chemotherapy and surgery, he is free of disease.

**Results**: We obtained peripheral blood samples from two siblings and sent for genetic analysis. PHOX2B gen mutations were detected in our male siblings.

**Conclusions**: Neuroblastoma is an embryonal tumor originating from neural crest cells and is one of the most common solid tumors of childhood. Recently, constitutional mutations in PHOX2B have been shown to confer an increased risk of neuroblastoma. Missense, nonsense and polylalanin repeat expansion mutations in PHOX2B were shown to be responsible for these heritable disorders, account for 5%of hereditary neuroblastomas. Patients with hereditary neuroblastoma differ from those with sporadic disease, they are diagnosed at an earlier age and/or with more than one primary tumor, reflecting cancer predisposition syndromes.

### PO-426. Infant Neuroblastoma Mimicking Stage MS but Metastasis to Skeletal Muscle and Pancreas {#pbc27455-sec-6550}

[Y. Yoshimoto]{.ul} ^1^, Y. Suenaga^1^, M. Tanaka^1^, H. Uryu^1^, J. Yamanaka^1^, N. Sato^1^, H. Shichino^1^

*^1^National center for global health and medicine, Pediatrics, Tokyo, Japan*

**Background/Objectives**: Locations of metastasis of neuroblastoma stage MS are limited to skin, liver and bone marrow. The therapy for infant neuroblastoma varies from observation to high‐intensity chemotherapy. We experienced a unique case having a feature of stage MS, but atypical metastasis to skeletal muscle and pancreas. His neuroblastoma was characterized by 11q aberration.

**Design/Methods**: \[Case\] An asymptomatic 4‐month‐old boy presented with abdominal distension by hepatomegaly and multiple subcutaneous nodules. On laboratory findings, the serum neuron‐specific enolase (NSE), the urinary creatinine (Cre) adjusted vanillymandelic acid (VMA) and homovanillic acid (HVA) elevated to 110 ng/ml, 1150μg/ mg Cre and 314 μg/ mg Cre, respectively. Metaiodobenzylguanidine (MIBG) scintigraphy showed abnormal uptake in nodules in skeletal muscle and a mass located in pancreas, in addition to left adrenal mass and liver. Biopsy from subcutaneous nodule revealed poorly differentiated neuroblastoma with MYCN non‐amplified but 11q loss of heterozygosity (LOH). DNA index was 1.93.

**Results**: Hepatomegaly and the level of tumor markers were improving without treatment, however undefined metastasis for stage MS and the presence of 11q aberration were the key to initiate chemotherapy at age 6 months.

**Conclusions**: \[Discussion\] Metastasis to muscle and pancreas is uncommon for neuroblastoma and might be special, suggesting that MS might allow other metastatic locations. In contrast, 11q aberration in MS patients is considered to be associated with poor prognosis, indicating this population might share different clinical characteristics from typical MS patients, like this case. Optimal intensity of chemotherapy for infant neuroblastoma is heterogeneous and still under construction.

### PO-427. Study on the Survival Outcome of Intermediate‐, and High‐Risk Neuroblastoma from 2006 to 2015 {#pbc27455-sec-6560}

[Y. Zhang]{.ul} ^1^, W. zhang^1^, D. Huang^1^

*^1^Beijing Tongren Hospital‐ Capital Medical University, Pediatrics, Beijing, China*

**Background/Objectives**: Neuroblastoma (NB) is one of the most common malignant solid tumors in infant and have high mortality, special high‐risk NB. Our aim was to study on the survival outcome of the intermediate‐risk and high‐risk of 147 NB children we collected from the last nine years in our pediatrics.

**Design/Methods**: We collected 147 NB patients with the pathological diagnosis. NB was classified into low‐, intermediate‐, or high‐risk categories based on clinical and biological features according to INRGSS. All of NB patients were followed up to 31 March 2016 from the date of diagnosis. We analyzed the clinical data using SPSS 20.0 software for studying on the survival outcome of NB children and the relationship between the outcome of NB and risk factors.

**Results**: 80 NB patients survived, account for 54.4% (80/147), and 67 NB Patients were dead (only 3 patients of IR), account for 45.6% (67/147) until to the last time of follow up. The follow‐up time of 81 NB patients was ≥24 months in 147 cases. The 2‐year, and 5‐year OS of 81 NB patients were 79%, and 34%. The 2‐year, and 5‐year EFS of 81 NB patients were 77% and 11%. The medium survival time of 81 NB patients was 60 months, and the 95% confidence interval (CI) was (50.4∼69.6) months. The medium OS of 61 NB patients with HR group was 53.0months. In 35 NB patients of HR group, 25 patients were dead and only 10 patients survived.

**Conclusions**: Relapse was one of the risk factors in NB. The prognosis of NB with HR group was more poor, special recurrence NB. Therefore, it was very important to diagnosis early and reduce relapse rate for improving the survival outcome of NB.

### PO-428. GD2 Chimeric Antigen Receptor T Cells in Treatment of 5 Cases of Childhood Neuroblastoma {#pbc27455-sec-6570}

[Z. Zhang]{.ul} ^1^, X. Shi^1^

*^1^capital institute of pediatrics, hematology/oncology, Beijing, China*

**Background/Objectives**: To evaluate the efficacy and safety of GD2 chimeric antigen receptor T cell in childhood neuroblastoma.

**Design/Methods**: From July 2015 to March 2016, 5 cases of childhood neuroblastoma were adopted GD2 chimeric antigen receptor T cells. We analyzed the clinical features, evaluated treatment effects, and observed the adverse effects.

**Results**: Among the 5 patients, 2 were male and 3 were female, with the median age of 2 years and 4 months old. All of the pathological types were nodular ganglioneuroblastoma. Before the infusion of GD2 chimeric antigen receptor T cells, 1 case was in the status of disease progression, and 4 cases in complete remission. The median number of GD2 chimeric antigen receptor T cells is 6×106 /kg. After the infusion, 1 case got continuously complete response, 1 case getting worse before got improved shortly and recurrent after 6 months, and the other 3 cases got recurrent after 2, 6 and 12 months respectively. Adverse effects mainly were fever, headache, and bone pain, which could be tolerated.

**Conclusions**: GD2 chimeric antigen receptor T cells are effective for a short time and safe in the treatment of some neuroblastoma cases and can be used as one of the treatments in children with high‐risk neuroblastoma, especially those who are not sensitive with chemotherapy. Large‐scale clinical trials are needed to confirm it.

### PO-429. Analysis the Causes of Recurrence and Death in Children with N‐MYC Amplified Neuroblastoma {#pbc27455-sec-6580}

[Q. Zhao]{.ul} ^1^, Y. Zhixia^1^, H. Cheng^1^, Z. Wen^1^, W. Xisi^1^, J. Mei^1^, S. Yan^1^, Z. Dawei^1^, H. Lejian^2^, M. Xiaoli^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University, National Center for Children\'s Health‐ Beijing, Hematology Oncology Center, Beijing, China; ^2^Beijing Children\'s Hospital‐ Capital Medical University, National Center for Children\'s Health‐ Beijing, Pathology department, Beijing, China*

**Background/Objectives**: We summarize the clinical characteristics, therapeutic effect and prognosis in N‐myc--amplified neuroblastoma (NB) patients.

**Design/Methods**: The clinical information and therapeutic effect of 16 NB patients were analyzed retrospectively. N‐myc gene status was evaluated by FISH. All patients were treated with BCH‐HR‐NB‐2007 protocol, and followed up to death.

**Results**: 16 NB patients, with median age 30.8±3.2 months, were defined as stage IV, high risk with N‐myc amplification, got recurrence and finally dead. All the primary tumors were located at retroperitoneal and with at least two sites of metastases, tumor \>10cm and chromosomal abnormalities were existed in 11 and 9 patients. All patients' NSE were \>370ng/ml at first diagnosis, and LDH\>3000 U/L in 10 patients. After 4 cycles of chemotherapy, NSE and LDH decreased 84% and 92%, and 5 patients got VGPR, 7 PR and 4 SD; Surgery were given after 4 or 5 chemotherapy. After 6 cycles of chemotherapy, 10 patients got CR, 1 VGPR and 1 PR, and 4 patients got PD. All patients got recurrence between 4.5‐16 months (median 8.7±3.2s), mainly at abdominal (31%), BM (25%), liver (19%), lymph nodes(13%), central(6%) and lung(6%). 3 patients got palliative treatment, 8 got chemotherapy and 5 patients got chemo, MIBG, CAR‐T and radiotherapy. Time from diagnosis to first relapse were 0.58, 1.68 and 3.87 months in those 3 groups, P\<0.05;The overall survival time was between 5.5‐23 months (average 11.3±4.7). Time from first recurrence to death was between 0.25‐7 months (average 2.5±1.5).

**Conclusions**: N‐myc‐amplified NB often got huge tumor and multi‐organ involvement, recurrence most took place while consolidation therapy, indicate that induction chemotherapy and local control, and clinical monitoring still need further investigate. Treatment after recurrence, including chemotherapy, MIBG, CAR‐T and radiotherapy, might be effective in prolong the overall survival time.

### PO-430. Diagnosis and Treatment of Childhood Neuroblastoma with CCCG‐NB‐2015 in Multicenter of China {#pbc27455-sec-6590}

[Q. Zhao]{.ul} ^1^, J. Yan^1^, Y. Jin^1^

*^1^Tianjin Medical University Cancer Institute and Hospital, Pediatric Oncology, Tianjin, China*

**Background/Objectives**: The CCCG‐NB‐2015 program is formulated by the Pediatric Oncology Committee of China Anti‐Cancer Association based on the CCCG‐NB‐2009 program. This study aimed to summarize the recent clinical status of the application of CCCG‐NB‐2015 in the treatment of neuroblastoma in multicenter of China.

**Design/Methods**: The clinical data of children diagnosed and treated with neuroblastoma by CCCG‐NB‐2015 were collected from January 2014 to August 2016 in our hospital.

**Results**: A total of 128 cases were identified, with 27 patients give up treatment, ultimately, 101 cases were included in this study, of which only 89 cases received regular treatment. In 32 children of low‐risk group, a total of 30 cases underwent radical surgery, 2 cases of partial resection, CR or VGPR rate was 96.9%, survival time 11∼39 months (median 24.5 months), all survived. In the median‐risk group, the CR or VGPR rate was 86.1%, 19 patients survived, 3 patients died and the survival time was 9∼51 months (median 26 months). As for the 47 cases of high‐risk group, CR or VGPR rate 85.1%, 14 cases accepted autologous peripheral blood stem cell transplantation (including two sequential transplants in 7 cases), 19 cases received radiotherapy. Finally, 36 cases survived and 14 cases relapsed, 1 case progressed, 11 patients died, the survival time range from 8 to 46 months (median 23 months). There were significant differences (both P \<0.001) between the median‐risk group and the high‐risk group; regular and irregular treatment group. The higher the risk, the worse the prognosis (P = 0.04).

**Conclusions**: The results show that CCCG‐NB‐2015 is reasonable in the risk sub‐group assignment, and risk level is closely related with patients' prognosis. Regular treatment can significantly improve the survival rate of children, indicating that the current treatment program has great potential value, which still needs to be further clinical validated.

### PO-431. The Relationship Between Cytokine Level and Bone Metastasis of Neuroblastoma in Children {#pbc27455-sec-6600}

[W. Zhao]{.ul} ^1^, X. Ma^1^, Y. Liu^1^, R. Zhang^1^, M. Jin^1^, D. Zhang^1^, X. Wang^1^

*^1^Beijing Key Laboratory of Pediatric Hematology Oncology‐National Discipline of Pediatrics Ministry of Education‐MOE Key Laboratory of Major Diseases in Children‐Capital Medical University, Hematology Oncology Center, Beijing, China*

**Background/Objectives**: To summarize the cytokine levels with bone metastasis of neuroblastoma at first‐hospitalization in children. To further understand the correlatioin between cytokines and bone metastasis in children with NB in order to seek more effective treatment and improve survival rate.

**Design/Methods**: The retrospective research was carried out analyzing the medical records of patients with bone metastasis of NB from 1 Dec 2011 to 30 April 2017 in Hematology Oncology Center, Beijing Children\'s Hospital, Capital Medical University. The diagnosis, staging and treatment are based on BCH‐2007‐NB. All the stage IV NB patients with no bone metastases and were treated as control group. Peripheral blood cytokine levels were measured by flow cytometry. The levels of expression of IL‐2, IL‐4, IL‐6, IL‐10, IFN‐γ, TNF‐α were retrospectively analysed. The relationship between cytokine and general clinical data, were analyzed and summarized.

**Results**: 216 children of NB with bone metastasis were admitted for this research. The expression of IFN‐γ was lower in bone metastases group than in the nonbone metastases group, P value was 0.047. The expression of TNF‐α in bone metastases was higher than that in nonbone metastases, P value was 0.045. The expression of IFN‐γ in bone marrow metastases was lower than non‐bone marrow metastases. The expression of TNF‐α in bone marrow metastases was higher than non‐bone marrow metastases, P=0.030 and 0.006.

**Conclusions**: The study of peripheral blood cytokine level is related to the occurrence and development of NB, and can indirectly reflect the bone metastases in children with NB. Determination of the level of expression of cytokines may be used as an adjunct to the assessment of bone metastases and the monitoring of efficacy. In NB children with bone metastases, fever, bone pain and bone marrow metastases were associated with IFN‐γ and TNF‐α levels.

### PO-432. The Clinical Characteristics and Prognosis of Neuroblastoma with Liver Involvement in Children {#pbc27455-sec-6610}

[S. Zhu]{.ul} ^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University, National Center for Children\'s Health, Pathology department, Beijing, China*

**Background/Objectives**: To analyze the clinical characteristics and prognosis of neuroblastoma with liver involvement in children.

**Design/Methods**: 77 cases of neuroblastoma with liver involvement in children from 2007 to 2017 in the Beijing Children Hospital were Analyzed retrospectively. The follow‐up ended on December 31^st^, 2017. The clinical characteristics were analyzed using χ^2^ test, the cumulative survival was estimated by the Kaplan‐Meier method.

**Results**: The median age of the patients is 31months (2‐132 months), male 41 and female 36, the primary sites involve retroperitoneum (67, 87.0%), mediastinum (6, 7.8%), others (4, 5.2%). Risk group: HR (63, 81.8%), MR (5, 6.5%), LR (9, 11.7%). The incidence of liver involvement is 12.8%, the imaging manifests as metastasis (63.6%) or invasion (36.4%). The rate of bone metastasis is 70.1%, bone marrow metastasis is 62.3%, and adjacent organs involvement is 51.9%, 29.4% patients with MYC testing had MYC amplification, 16.9% patients had alanine transaminase elevation and 18.2% patients had γ‐glutamine transaminase elevation at diagnosis. Among the 77 cases, 59 cases (76.6%) received BCH‐NB Stratified therapy based on risk groups regularly and only one patient receive liver radiotherapy, the median follow‐up is 19months (6‐122months). Six‐year cumulative survival of the 59 cases is 43.3%. Univariate analysis suggests there is no significant difference between patients \< 18 months and ≥18 months (57.1% vs 36.8%, χ2=2.211, P=0.137). There is a significant difference between patients with or without MYC amplification(9.2% vs 58.2%, χ2=14.306, P=0.000), and in low‐median or high risk group(90% vs 35.7%, χ2=4.347, P=0.037) in the Six‐year cumulative survival.

**Conclusions**: The clinical features between liver metastasis and invasion were similar, the neuroblastoma with liver invasion prefer to infiltrate the adjacent organs. Neither ALT nor GGT could be regarded as liver involvement marker. Patients with liver involvement have a higher rate of MYC amplification. MYC amplification and high‐risk group are associate with a significant wore outcome.

Solid non Brain Tumours ‐ Renal Tumours {#pbc27455-sec-6620}
---------------------------------------

### PO-433. Outcome of Wilms Tumor in Children: A 10‐Year Multi‐Center Experience from the Saudi Arabian Pediatric Hematology Oncology Society (SAPHOS) {#pbc27455-sec-6630}

[I. Abosoudah]{.ul} ^1^, I. AlFawaz^2^, M. Viqaruddin^2^, A. Mohammad^2^, D. Bushnak^2^, N. Alkhayat^3^, A. Al Omari^4^, M. Eltawel^4^, A. Abbas^5^, Q. Alharbi^6^, H. Omar^6^, O. Kashari^7^, A. Ali^2^

*^1^King Faisal Specialist Hospital & Research Centre, Department of Oncology, Jeddah, Saudi Arabia; ^2^King Faisal Specialist Hospital & Research Centre, Department of Pediatric Hematology/Oncology, Riyadh, Saudi Arabia; ^3^Prince Sultan Military Medical City, Department of Pediatrics Hematology Oncology, Riyadh, Saudi Arabia; ^4^King Abdullah Specialized Children Hospital, Department of Pediatric Hematology Oncology, Riyadh, Saudi Arabia; ^5^King Abdul Aziz Medical City, Pediatric Hematology and Oncology Section, Jeddah, Saudi Arabia; ^6^King Fahd Specialist Hospital, Department of Pediatric Hematology/Oncology & SCT, Dammam, Saudi Arabia; ^7^East Jeddah General Hospital, Pediatric Department, Jeddah, Saudi Arabia*

**Background/Objectives**: Wilms tumor (WT) regional outcome data is scarce. Therefore, SAPHOS performed a nationwide study to evaluate the clinical outcome of patients with WT.

**Design/Methods**: Information of patients aged 0‐14 years was retrospectively reviewed from all referral centers in Saudi‐Arabia in‐between 2001‐2011.

**Results**: Six out of Seven centers submitted their data. Out of 283 cases identified, 266 cases were analyzable. The median age at diagnosis was 37.6 months (0.3‐184.7), 56 %(150) were females. Unilateral disease occurred in 91 %(241) and 9%(25) were bilateral. Patients presented with combination of the following: abdominal distension (84%), abdominal pain (36%), hematuria (15%), and vascular thrombosis (6%). Over half the patients were considered stage III or IV at diagnosis (34%, 20% respectively), 89% of the patients had favorable histopathology. A relapse incidence of 23%(61) was observed of which the majority were stage III, IV, and V. The five‐year OS for all stages was 89.6%; (Stage I,94.8%; II, 93.1%; III, 89.6%; IV, 84.4%; and V, 82.3%). The five‐year EFS for all stages was 72.9%; (Stage I, 85.9%; II, 84.3%; III,75.1%; IV,59.3%; V, 43.2%). Although there is a difference in OS and EFS, statistical significance (p‐value \<0.05) was observed in EFS when compared based on the staging.

**Conclusions**: Our result demonstrates that the overall survival of WT in Saudi Arabia is similar to the reported from other countries. However, we observed that over half the patients are stage III or IV at diagnosis. The advanced disease at diagnosis is not explained by delay in presentation. Further data on upfront surgery vs. upfront chemotherapy is being collected after which a definitive analysis will be completed.

### PO-434. Exploring Global Methylation Patterns in Wilms Tumor: A Pilot Study {#pbc27455-sec-6640}

[R.A.R.T. Ahmad]{.ul} ^1^, S. Agarwala^2^, A. Chopra^3^

*^1^All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; ^2^All India Institute of Medical Sciences, Pediatric Surgery, New Delhi, India; ^3^All India Institute of Medical Sciences, Laboratory Oncology, New Delhi, India*

**Background/Objectives**: Background: Cancer development not only depends on genetic alterations but on epigenetic changes (the cancer epigenome), which produce heritable gene expression patterns critical for neoplastic initiation and progression. Next‐generation sequencing (NGS) provides a means for visualizing the human epigenome and how it is altered in cancer. The epigenomics in wilms tumor has not been studied extensively.

Aim: Evaluation of global methylation patterns in Wilms tumor to identify its epigenetic profile

**Design/Methods**: Prospective study utilizing specimens, following upfront surgical resection, from 4 untreated cases of Wilms tumour. Adjoining normal renal tissue from the resected specimens were used as controls. Cell samples and DNA isolation followed by NGS (using MeDip‐Seq) and PCR enrichment was done using standard protocol. The methylated regions in cases were compared with controls.

**Results**: 1365 methylation variable positions (MVPs) of genome‐wide significance (p \< 5 X 10‐10) were identified in the wilms tumors specimens. Among these, 13 DMRs (differential methylated regions in Wilms tumor samples with genome wide significance were identified. As these DMRs were hypermethylated with respect to normal kidney, we predict that levels of methylated DNA in the circulation may increase with increasing tumor burden. Charlton et al found 309 MVPs in their initial analysis. In contrast, the current analysis demonstrated 1365 MVPs MeDIP‐seq technique was utilized. This is more extensive and sensitive, for the study of global methylation.

**Conclusions**: The study defines the global epigenetic profile of the Wilms tumor patients in India. As these DMRs were hypermethylated with respect to normal kidney, we predict that levels of methylated DNA in the circulation may increase with increasing tumor burden. The current study is significant as it gives broader spectrum of the methylation pattern. These DMRs identified would provide areas of interest for further analysis.

### PO-435. Management of Wilms Tumor in Post‐War Iraq (2004‐2013) {#pbc27455-sec-6650}

[M.F. Al‐Jadiry]{.ul} ^1^, H.H. Ghali^1^, S.A. Faraj^2^, R.M. Al‐Saeed^3^, A.A. Hassan^3^, K.J. Al‐Tuwaijeri^3^, R. Al‐Saadi^4^, J.S. Brok^5^, S.A. Fadhil^3^, A.H. Sabhan^3^, A.F. Al‐Darraji^3^, A.R. Alsaadawi^6^, S.A. Al‐Hadad^1^

*^1^Children\'s Welfare Teaching Hospital‐ Medical City‐ Baghdad College of Medicine, Pediatrics‐ Oncology Unit, Baghdad, Iraq; ^2^Children\'s Welfare Teaching Hospital‐ Medical City‐ Wasit College of Medicine, Pediatrics‐ Oncology Unit, Baghdad, Iraq; ^3^Children\'s Welfare Teaching Hospital‐ Medical City, Pediatrics‐ Oncology Unit, Baghdad, Iraq; ^4^University College London Great Ormond Street Institute of Child Health‐ London‐ United Kingdom, Developmental Biology and Cancer, London, United Kingdom; ^5^University College London Great Ormond Street Institute of Child Health‐ London‐ United Kingdom, Haematology and Oncology, London, United Kingdom; ^6^Central Teaching Laboratory‐ Medical City, Pathology, Baghdad, Iraq*

**Background/Objectives**: Wilms tumor (WT) has an excellent survival rate in developed countries but similar outcomes can be challenging to achieve in limited‐resource countries. In Iraq, acknowledging damaged health care services, lack of multidisciplinary approaches and security challenges, survival is jeopardized. We studied the management and outcome of WT patients hospitalized at the largest institution in Iraq.

**Design/Methods**: Retrospective analysis of 198 children treated for WT over a 10‐year period (2004‐2013) at Children\'s Welfare Teaching Hospital/Medical City/Baghdad was performed. Chi‐squared test was used to compare survival between 2 time periods.

**Results**: To determine WT, 21 patients had a biopsy, 89 had up‐front nephrectomy, and 88 had radiological evidence of WT, of whom 27 had a nephrectomy and 44 a biopsy. The median age at diagnosis was 33 months (range, 2‐139), 95 females, 159 (80%) patients were \< 5 years. Forty one were treated according to COG and 151 to SIOP adapted protocols. All had abdominal US, 138/87 CT abdomen/chest. Staging for 162 patients; I‐II 58 (36%), III 65 (40%), IV 39 (24%), V 19, delayed referral (1.5‐40 months) of 15 patients post nephrectomy resulted in local recurrence or metastasis. With a median follow up of 26 months (3 days to 14 years), 107 (54%) patients were alive, 36 (18%) died and 55 (28%) abandoned treatment. Comparing OS of 2 subsequent periods; 2004‐2008 (71) and 2009‐2013 (127). The second period has better survival rate; \[82(65%) alive, 21 (16%) died and 24(19%) abandoned\] vs first period \[25(35%) alive,15 (21%) died and 31 (44%) abandoned\].

**Conclusions**: Optimal treatment and registration of WT is a challenge in Iraq. Survival seems to improve in the last 5 years of the study. This might reflect better health services and improved management by the oncology team. Collaboration with major institutions would likely increase survival further

### PO-436. Treatment Outcomes of Wilms Tumor: Ten‐Year Single Institution Experience from Iraq {#pbc27455-sec-6660}

[J. Ali]{.ul} ^1^, N. Khoshnaw^2^, K. Murad^1^, S. Star^1^, N. Othman^1^, S. Othman^1^, K. Mohammed^1^, A. Bazaz^1^, S. Mohammed^1^, A. Gendari^1^, B. Mhammad^1^, L. Mula‐Hussain^3^

*^1^Zhianawa Cancer Center, Radiation Oncology, Sulaymaniyah, Iraq; ^2^Hiwa Cancer Hospital, Hemotology, Sulaymaniyah, Iraq; ^3^Cross Cancer Institute, Radiation Oncology, Edmonton, Canada*

**Background/Objectives**: Wilms tumor (WT) is the most common primary renal tumor in children with a rate of around 6% among all other childhood cancers. Current treatment guidelines include nephrectomy, chemotherapy, and in some cases, radiotherapy. The aim of the study is to identify the mode of the clinical presentations, staging distribution and the survival outcomes of WT patients in our institution.

**Design/Methods**: Retrospective study on 50 WT patients who had been managed at our oncology complex in Northern Iraq in ten years (from January 2007 to January 2017). Comparison with other relevant published literature was accomplished. Statistical Package for Social Science (SPSS) software (version 20.0) is used while the survival outcomes were analyzed by Kaplan‐Meier method.

**Results**: Fifty children (29 females and 21 males) were analysed. Median age at time of diagnosis was 2.7 years (ranged 0.7‐10.1). The distributions of stages were as follows; stage I 40%, stage II 2%, stage III 44%, stage IV 6% and stage V 8%. Favorable histology was identified in 96% of patients and the remaining 4% were unfavorable histology. The National Wilms Tumor Study strategies were applied in the treatment of these cases. Neoadjuvant chemotherapy was administered in 34% and all of them received adjuvant chemotherapy. Sixty‐two of patients received radiation postoperatively. The 4‐year overall survival and Event‐free survival were 80% and 60%, respectively.

**Conclusions**: As a limited‐resource country, our obtained survival outcome showed an improvement outcomes in comparison to other local results reported in the last decade, but still lower than the treatment outcomes of WT gained in developed nations. We need more effort to improve our oncology care to get better results.

### PO-437. Papillary Renal Cell Carcinoma: A Rare Manifestation in Pediatric Patients {#pbc27455-sec-6670}

[O. Beck]{.ul} ^1^, A. Russo^1^, M. Brandt^2^, M. Neu^1^, A. Wingerter^1^, A. Haferkamp^2^, A. Schröder^2^, J. Faber^1^

*^1^University Medical Center‐ Johannes Gutenberg‐ University Mainz, Children\'s Hospital‐Pediatric Hematology and Oncology, Mainz, Germany; ^2^University Medical Center‐ Johannes Gutenberg‐University Mainz, Department of Urology and Pediatric Urology, Mainz, Germany*

**Background/Objectives**: Renal cell carcinoma (RCC) is rare in children and adolescents.

**Design/Methods**: We present the unusual cases of two children, both with a severe primary disease, who were treated at the Department of Pediatric Hematology and Oncology at Mainz University Medical Center, as well as a review of the literature.

**Results**: Patient 1:

An eight‐year‐old boy with a history of tetralogy of fallot, severe developmental delay, and seizure disorder, presented at our institution for evaluation of precocious virilisation. Ultrasound and magnetic resonance imaging (MRI) revealed a tumor in the right kidney that was not considered a Wilms tumor or neuroblastoma. The patient underwent nephron sparing tumor resection by robotic‐assisted laparoscopic surgery. Histopathology revealed a papillary RCC, Type1 (pT1bN0M0).

Patient 2:

An eleven‐year‐old boy, suffering from (hereditary) leiomyomatosis and undergoing treatment with the mTOR inhibitor rapamycin, was admitted due to urinary tract infection. Imaging studies revealed a tumor in the left kidney and multiple stones. The tumor was not entirely typical for a nephroblastoma, however, as a Wilms tumor could not be ruled out, neoadjuvant chemotherapy was initiated, according to the protocol of International Society of Pediatric Oncology (SIOP) 2001. Reassessment after 4 weeks of treatment showed no change in tumor size and the patient was subjected to open tumor resection. The histopathological report confirmed a papillary RCC, Type1 (pT1bN0M0).

Both patients recovered fully and were disease free at follow‐up after 9 and 12 months, respectively.

**Conclusions**: RCC is a rare entity in pediatric patients. Our patients underwent successful nephron‐sparing surgery with a favorable short‐term outcome.

### PO-438. Minimally Invasive Surgery for Wilms Tumours: Can We Safely Expand the SIOP Umbrella Protocol Criteria? {#pbc27455-sec-6680}

[A. Bouty]{.ul} ^1^, T. Blanc^2^, A. Scalabre^3^, M.D. Leclair^4^, F. Lavrand^5^, A. Faure^6^, A. Binet^7^, M. O\'Brien^1^, S. Sarnacki^2^, M. Nightingale^8^, Y. Heloury^1^, F. Varlet^3^

*^1^Royal Children\'s Hospital, Paediatric Urology, Parkville, Australia; ^2^APHP‐ Hopital Necker Enfants Malades, Paediatric Surgery, Paris, France; ^3^Centre Hospitalier Universitaire de Saint‐Etienne, Paediatric Surgery, Saint‐Etienne, France; ^4^Centre Hospitalier Universitaire de Nantes, Paediatric Surgery, Nantes, France; ^5^Centre Hospitalier Universitaire de Bordeaux, Paediatric Surgery, Bordeaux, France; ^6^APHM, Paediatric Surgery, Marseille, France; ^7^Centre Hospitalier Universitaire de Tours, Paediatric Surgery, Tours, France; ^8^Royal Children\'s Hospital, Paediatric Surgery, Parkville, Australia*

**Background/Objectives**: To determine if the SIOP criteria for Minimally Invasive Surgery (MIS) in Wilms Tumours (WT) could be safely expanded.

**Design/Methods**: We conducted an international multicentre review of MIS resection for WT between 2006‐2017. Electronic or paper medical records were retrospectively assessed. Demographic, imaging, treatment, pathologic and oncological outcome data were analysed. Only WT were included. All sites received local institutional ethics board approval.

**Results**: Fifty patients from 9 centres were included. Median age at diagnosis was 38 months (6‐181). Twenty‐eight tumours were left‐sided, 7 were metastatic at diagnosis and three had pre‐operative radiological evidence of rupture. Twenty‐one patients underwent percutaneous biopsy prior to treatment and all received neoadjuvant chemotherapy, according to SIOP protocol. Location of the tumour was upper pole in 18, lower pole in 15 and interpolar region of the kidney in 17. Median tumour volume post‐chemotherapy was 673 ml (18‐2,480), 16 were crossing the lateral border of the spine and three were crossing the midline. There were 6 conversions (median volume 1,560 ml (299‐2,480), three crossing the lateral border of the spine) but no intraoperative rupture. A median of 4 lymph nodes (1‐10) was sampled in 42 cases. Tumour was Stage I in 29, II in 16 and III in 5 and histology was reported as Low in three, Intermediate in 42 and High risk in five. Three patients had positive tumour margins. After a median follow‐up of 35 months (2‐138), there were two local recurrences (both Stage I, Intermediate risk, 7 and 9 months post‐surgery) and one metastatic relapse (Stage III, High risk, 4 months post‐surgery).

**Conclusions**: For surgeons experienced in both MIS and oncologic surgery, SIOP criteria can be safely expanded to tumours abutting the midline. A low threshold for conversion should however remain in the event of surgical difficulty.

### PO-439. The Clinical Case of Secretory Adenocarcinoma of Small Salivary Glands of the Palate in a 14 Year Old Patient {#pbc27455-sec-6690}

[D. Buletov]{.ul} ^1^, V. Polyakov^1^, O. Merkulov^1^, T. Gorbunova^1^, A. Yushina^2^

*^1^Institute of Pediatric Oncology and Hematology N.N. Blokhin, Head and neck tumors in children, Moscow, Russia; ^2^Pirogov Russian National Research Medical University, pediatrics department, Moscow, Russia*

**Background/Objectives**: Tumors of the salivary glands are rare neoplasms which differ in their morphological structure. Benign and malignant neoplasms of small and large salivary glands represent 6% of all tumors of head and neck area. Only 3‐5% of patients with salivary glands tumors are in their childhood or adolescence. This paper presents a rare clinical case of the secretory adenocarcinoma of small salivary glands of the hard palate in a 14 year old patient. The aim of the current publication is to reflect the features of the treatment and response to therapy in a patient of this age group.

**Design/Methods**: In the region of the seventh tooth, a rounded defect of the mucous membrane, with an inflammatory roller along the periphery was found. Histological analysis confirmed the growth of secretory adenocarcinoma of small salivary glands. According to the immunohistochemical analysis. B. Given the histological, immunohistochemical findings and instrumental methods, it was decided to start a special treatment, according to the following scheme: cisplatin (40 mg/м2 1 day), doxorubicin (60 mg/м2 1 day).

**Results**: In total, three courses of neoadjuvant polychemotherapy were conducted, without any apparent dynamics. After the control analyses, it was decided to start an operative treatment of the tumor in the volume of resection of the upper jaw to the left, replacing the defect with a musculocutaneous flap displaced from the medial surface of the forearm. Based on the results of the treatment, the patient was discharged under observation in a satisfactory condition. The post‐surgical period was uneventful.

**Conclusions**: Secretory adenocarcinoma of small salivary glands of the palate is a rare type of tumor in children. It poses difficulty in both diagnostics and treatment of the patients. In this work a successful case of a treatment of an adenocarcinoma of small salivary glands of the palate is presented.

### PO-440. Bilateral Wilms Tumor: Surgical Management and Outcome Retrospective Analysis of One Single Brazilian Institute {#pbc27455-sec-6700}

[R. Carvalho]{.ul} ^1^, P. Oliveira^2^, F.N. Gutierrez^1^, F. Da Silva Lima^3^, M.F. Grabois^4^, S.E. Ferman^4^, P.A. Silvestre de Faria^5^, V. Nascimento Santos^1^, H.R. Gouveia^6^, A.D.O. Moura Junior^7^, S.O. Coelho^1^

*^1^Cancer National Institute INCA of Brazil, Pediatric Oncology Surgery, Rio de Janeiro, Brazil; ^2^Cancer National Institute INCA of Brazil, Pediatric Oncology Surgery Fellowship, Rio de Janeiro, Brazil; ^3^Cancer National Institute INCA of Brazil, Pediatric Research, Rio de Janeiro, Brazil; ^4^Cancer National Institute INCA of Brazil, Oncology Pediatric, Rio de Janeiro, Brazil; ^5^Cancer National Institute INCA of Brazil, Patology, Rio de Janeiro, Brazil; ^6^Cancer National Institute INCA of Brazil, Radiology Intervention, Rio de Janeiro, Brazil; ^7^Cancer National Institute INCA of Brazil, Pediatric Surgery, Rio de Janeiro, Brazil*

**Background/Objectives**: Wilms tumor is the most commom solid renal cancer in children under 15 years old, representing approximately 6% of all cancer diagnosis in this age group and still stand as a therapeutic challenge. The aim of this study was to evaluate all bilateral Wilms tumor submitted to surgical procedure using SIOP (International Society of Pediatric Oncology) protocol in the last 18 years of a Brazilian institution.

**Design/Methods**: The records of patients treated for bilateral tumor, suspected by radiological ultrasound, CT or MR in our hospital for the last 18 years following SIOP protocol. Retrospectively, data collected were composed of age at the surgery, associated conditions, neoadjuvant and adjuvant chemotherapy, radiation therapy, surgical details, pathology results and patient survival.

**Results**: This study were composed by 5 males and 8 females with mean age of 2,5 years. There were one patient with ambiguous genitalia, one with Beckwith‐Wiedmann syndrome and one with Von Willebrand disease. Metastasis were detected in lungs of 2 patients. Three patients received radiotherapy for pulmonary metastasis, positive surgical margins or local recurrences. All childrens were submitted to neoadjuvant chemotherapy and three female did not need adjuvant chemotherapy. Nephron sparring surgery (NSS) were performed in four patients. In only one case occour tumor breakdown. The pathological results showed 6 kidneys with unfavorable histology and 20 with favorable histology. The global survive rate were 76%, one patient still in the treatment with chemotherapy, one changed the city and one is out of therapy possible.

**Conclusions**: Bilateral Willms tumor stills a big challenge for pediatric surgeons, even in large cancer treatment centers. NSS could be considered in selected cases with good outcomes and nephron preservation should be the aim while taking positive surgical margin risk on NSS side relying on postoperative chemotherapy and carefully planned radiotherapy to avoid recurrence.

### PO-441. A Conclusion in the Surgical Management of Wilms Tumor According to the NWTS‐5 Protocol in Hong Kong {#pbc27455-sec-6710}

[K.W.E. Chan]{.ul} ^1^, H.Y.V. Wong^1^, S.Y.B. Tsui^1^, J.W.C. Mou^1^, K.H. Lee^1^

*^1^The Prince of Wales Hospital‐ The Chinese University of Hong Kong, Division of Paediatric Surgery and Paediatric Urology‐ Department of Surgery, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: The Hong Kong Children Hospital (HKCH) will be established in late 2018 and all the pediatric oncology services will be centralized In HKCH. The HKCH will adopt the SIOP umbrella protocol in the management of Wilms tumor. The aim of this study is to conclude our surgical experience in the management of Wilms tumor using NWTSG‐5 protocol.

**Design/Methods**: A retrospective study was conducted to review all patients with Wilms tumor and underwent nephrectomy according to NWTS‐5 protocol in a University teaching hospital in Hong Kong from January 1996 to January 2018.

**Results**: Fourteen boys and eleven girls with Wilms tumor underwent nephrectomy in the study period. The mean age was 2.6 years (range 0.9 to 10 years). Four children had stage I disease, 12 had stage II disease, 5 had stage III disease, 1 had stage IV and 3 had stage V disease. Pre‐operative chemotherapy was given to children with stage III or above disease. The mean tumour size was 10.7 cm (range, 3 to 17 cm). Unilateral radical nephrectomy was performed in children with unilateral disease via a transperitoneal laparotomy. Children with bilateral disease underwent nephron‐sparing surgery (NSS). Lymph node biopsies were performed in 20 cases while 1 had positive lymph node involvement. There was no intraoperative tumour rupture in patients underwent nephrectomy. Intraoperative complications including small bowel injury (n=1), diaphragmatic injury (n=1), and major bleeding that required transfusion (n=2). One patient had post‐operative urinary leakage after NSS. At a median follow‐up of 7 years, there is no local recurrence. Two patients had distant tumor recurrence. The OS is 100% and EFS is 84%.

**Conclusions**: Upfront nephrectomy can be safely performed with no intra‐operative rupture. With collaboration with SIOP in future, we believe the EFS can be further improved.

### PO-442. Evaluation of Renal Tumors in Children: A Single Center Experience {#pbc27455-sec-6720}

[C. Citak]{.ul} ^1^, G. Bozlu^2^

*^1^Mersin University Faculty of Medicine, Pediatric Oncology, Mersin, Turkey; ^2^Mersin University Faculty of Medicine, Pediatrics, Mersin, Turkey*

**Background/Objectives**: Childhood renal tumors account for around 7% of all childhood cancers. The majority of cases are Wilms' tumor. In this study, we aimed to evaluate the clinical and pathological features of renal tumors in children.

**Design/Methods**: Between 2008 and 2017, the records of children with renal tumors in our institution were retrospectively analyzed. Data collected were composed of demographic and clinical characteristics including gender, age at time of diagnosis, symptoms, side of tumor and pathological evaluation.

**Results**: A total of 48 children with renal tumor (28 males and 20 females) were included in the study. They were diagnosed at mean age of 53.26 ± 46.64 months (range: 1‐192) and the mean follow‐up was 73.45 ± 48.92 months (range:6‐120).The most common symptom was a lump or mass in the area of the kidneys (45.8%), abdominal pain and hematuria (14.6%). Four patients (8.3%) were diagnosed at antenatal period. Wilms' tumor was found in 68.8% of the children and the major histological groups of non‐Wilms' renal tumors were renal cell carcinoma (12.5%), congenital mesoblastic nephroma (10.4%) and angiomyolipoma (4.2%). Bilateral tumors were detected in 10.4% of the children and one patient had Wilms' tumor with horse shoe kidney. Surgical treatment was performed in 87.5% of the patients. The patients had chemotherapy and radiotherapy (83.3% and 41.7%, respectively). Seven patients (14.6%) died during follow‐up.

**Conclusions**: Wilms' tumor is the most common pediatric renal neoplasm. On the other hand, we showed that considerable number of children with renal tumors had non‐Wilms' tumors including renal cell carcinoma, congenital mesoblastic nephroma and angiomyolipoma.

### PO-443. Glomerular Filtration Rate in Patients with Wilms Tumor Before and after Treatment: Experience in a Single Institution {#pbc27455-sec-6730}

[W. Espinal]{.ul} ^1^, R.M. Navarro‐Martín del Campo^1^, A.L. Orozco‐Alvarado^1^, H.A. Romo‐Rubio^1^, O.R. González‐Ramella^1^

*^1^Hospital Civil de Guadalajara "Juan I Menchaca", Service of pediatric hematology and oncology, Guadalajara‐ Jalisco, Mexico*

**Background/Objectives**: Wilms tumor is the most common kidney tumor in childhood; with overall 5‐year survival of 88%; preservation of renal function has become a fundamental goal of treatment. Normal value for glomerular filtration rate (GFR) is greater than 90 ml/min, slight decrease of GFR is 60‐89 ml/min, moderate decrease of GFR is 30 ‐59 ml/min, severe decrease GFR 15‐29 ml/min, acute failure or dialysis means GFR less 15 ml/min. Rate of chronic renal failure in Wilms tumor survivors is 3.1%.

**Objetive**: To assess the GFR of patients with Wilms tumor before and after end of treatment.

**Design/Methods**: A retrospective transversal analytic cohort study was designed, all patients diagnosed in our hospital with Wilms tumor from 2007 to 2017 were included, the GFR was measured by the modified Schwartz method and urine tests were evaluated pre and post‐treatment.

**Results**: GFR of 52 patients was evaluated. Female‐male ratio was 1.2:1; 5.9% of patients presented Stage I, 37.3% stage II, 37.3 % stage III, 11.8 % stage IV and 7.8% stage V. At the start of treatment 62.7% patients had normal GFR; 33.3% had slight decrease in GFR; 3.9% had moderate decreased GFR and none of them showed lower GFR. After treatment GFR of 52 % patients remained normal; 25% patients had slight decreased GFR; and 21.1% patients had moderate decreased GFR. Only two patients (1.9%) presented chronic renal failure and kidney transplantation, remarkably she owned horseshoe kidney. Urinary tract infection was associated in 21.6% patients and 25.5% of patients presented proteinuria but not in nephrotic range.

**Conclusions**: We detected an important reduction in GFR values after treatment in children with Wilms tumor, patients with proteinuria during treatment showed decrease in GFR at the end of the study and one patient required end renal stage treatment.

### PO-444. Trisomy 4 and Tetrasomy 4 Cells Detected in Renal Tumors of Childhood {#pbc27455-sec-6740}

[W. Guan]{.ul} ^1^, W. Lifeng^1^, W. Ruifen^1^, L. Yi^1^

*^1^Xinhua hospital affiliated to Shanghai jiaotong university medical school, pathology, Shanghai, China*

**Background/Objectives**: To observe the changes in the 4 chromosome ploidy in these renal tumors of children.

**Design/Methods**: Detect 18 cases of renal tumors in our research were diagnosed at Xinhua Hospital, Shanghai Jiaotong University School of Medicine from 2013 to 2015, by FISH, to observe the changes in the 4 chromosome ploidy in these renal tumors of children.

**Results**: The 18 cases of renal tumors in our research, the patients were aged 2 months ‐5 years (average age 2.4 years), 12 male and 6 female. Histologically, 8 cases of nephroblastoma were mixed type and all contained blastemal, epithelial and stromal components. 4 cases of CMN, 2 were classic type, 1 cellular variant and 1 mixed. 4 cases of CCSK were classic patten. And the other 2 cases were ORIT. The percentage of trisomy 4 cells of WT was 0.12%‐2.2% (average 1.85%), and tetrasomy 4 cells 0.25%‐3.1% (average 1.32%).The percentage of trisomy 4 cells of CMN was 6.5%‐8.88% (average 7.02%), and tetrasomy 4 cells 1.35%‐2.35% (avergae1.65%). The percentage of trisomy 4 cells of CCSK was 2.43%‐4.3% (average 3.365%), tetrasomy 4 cells 12.25%‐18.34% (average 16.47%).The percentage of trisomy 4 cells of ORTI was 10.6%, and tetrasomy 4 cells 0%‐0.1% (average 0.05%).Meanwhile , The percentage of trisomy 4 cells of the other 2 case of nonneoplasitc kiney tissue was 0.12‐0.28%(average 0.2%), with tetrasomy 4 cells 0%.

**Conclusions**: The percentage of trisomy 4 cells of CMN and ORTI is much higher than other tumors and nonneoplasitc kiney tissue. Meanwhile, The percentage of tetrasomy 4 cells of CCSK is the highest in the cases. trisomy 4 in CMN or ORTI and tetrasomy 4 in CCSK seem to be a cytogenetic alteration characteristic of the tumor. Detection of chromosome 4 in the renal tumors of childhood may be helpful in differentiation among these tumors

### PO-445. Stable Long‐Term Remission of Aggressive Fibromatosis of the Right Maxilla with Weekly Vinblastine and Valproate in Pediatric Patient {#pbc27455-sec-6750}

[S. Heine]{.ul} ^1^, D. Lothschuetz^1^, G. Schneider^2^, N. Graf^1^

*^1^Pediatric oncology, Pediatric oncology of the University Children\'s Hospital of the Saarland, Homburg, Germany; ^2^University hospital of the Saarland, Department of MRI and radiology, Homburg, Germany*

**Background/Objectives**: Aggressive fibromatosis poses many therapeutic dilemmas as it is often not susceptible to chemotherapy and often requires also surgical and radiation approaches to try to affect a cure.

**Design/Methods**: We report on a girl diagnosed with aggressive fibromatosis of the right maxilla aged one, now thirteen yrs of age. Multiple local recurrences required surgical interventions, seven operations with hemimaxillektomy and consecutive radiotherapy in 2013. Chemotherapy was tried with four cycles of vincristine, cyclophosphamide, actinomycin D, followed by liposomale doxorubicin, followed by tamoxifen and diclofenac, followed by vinblastine and methotrexate. All combinations never stopped progression or local recurrence. even after the extensive operation in 2013 local multifocal recurrence was observed. Sorafenib was initiated, to no avail, the side‐effects with cutaneous bullae and paronchia were pronounced. We implemented vinblastine 5 mg/sqm body surface area and valproate 20 mg/kg/day as a palliative measure to make life less burdensome for the patient and the family.

**Results**: This therapy was adopted in 2014, a gastrostomy was put in, as we feared that feeding would become more difficult in the course of the disease. Chemotherapy was given via the Port‐a‐cath. We felt to be at the end of all options. But the disease hasn\'t come back, the MRI in February 2018 could not depict any sites with vital tumor. The gastrostomy was removed in 2016 as the child eats sufficiently. The therapy was well tolerated, no severe infectious complications were observed. The blood counts only showed mild lymphopenia. MRI scans are demonstrated to show the course of the disease.

**Conclusions**: We feel that vinblastine in addition with valproate might be an option in the treatment of aggressive fibromatosis in pediatric patients though it is not clear whether all the chemotherapy cycles and the surgical measures and the radiotherapy have not had an additive effect and thus caused the disease remission.

### PO-446. Blastemal Predominant Histology Type in Wilms Tumor has a Poor Prognosis: Survival Analysis of 113 Wilms Tumor with Favorable Histology {#pbc27455-sec-6760}

[J. Huang]{.ul} ^1^, Z. Yu^2^, Z. Zijun^1^, L. Suying^1^, S. Feifei^1^, Z. Jia^1^, W. Juan^1^, S. Xiaofei^1^

*^1^Sun Yat‐sen University Cancer Center, Department of Pediatric Oncology, Guangzhou, China; ^2^Sun Yat‐sen University Cancer Center, Department of Pathology, Guangzhou, China*

**Background/Objectives**: To retrospectively analyze the survival outcome of different subtypes of favorable‐histology (FH) Wilms\' tumor in Chinese children.

**Design/Methods**: From October 2006 to May 2016, the clinical data of FH Wilms\' tumor patients under 15 years old treated in Sun Yat‐Sen University Cancer Center were collected and analyzed. The tumor specimens of biopsy or surgery were collected before chemotherapy. FH Wilms\' tumors were divided into stromal type, epithelial type, blastemal predominant type and mixed type. The patients were treated based on NWTS‐5 protocol (some stage Ⅲ patients received a modified NWTS‐5 protocol).

**Results**: A total of 113 patients with FH Wilms' tumor were enrolled. There were 57 males and 56 females with a median age of 2 years old (range 2 months to 10 years). There were 31 cases in stage I‐II and 82 cases in stage III‐IV. Histopathological types included mixed type(n=46), epithelial type(n=17), stromal type(n=21), and blastemal predominant type(n=29). The median follow‐up time was 36 months (range: 4 months to 11 years). 2 cases had second cancer.16 patients had recurrences, including 10 blastemal predominant type, 3 mixed type, 2 epithelial type and 1 stromal type. The recurrence rates of different subtypes were blastemal predominant type 34.48%; mixed type 6.52%; epithelial type 11.76%; stromal type 4.76%, P=0.015. The 3 year event‐free survival rates (EFS) and overall survival rates (OS) were as follows: blastemal predominant type (65.3%, 80.9%), mixed type (88.9%,97.8%), epithelial type(87.4%, 86.3%), stromal type (94.4 %; 100%).. The survival analysis showed blastemal predominant type were independent prognostic factors of EFS(P=0.001) and OS (P=0.031).

**Conclusions**: This study showed that the patients with blastemal predominant type in Wilms' tumor had a higher recurrence rate and a lower EFS and OS. The treatment of Wilms\' tumor with blastemal predominant type should be intensified to further improve the survival.

### PO-447. Metastatic Wilms Tumor Recurrence Presenting as Cerebellar Mass {#pbc27455-sec-6770}

[R. Ismail]{.ul} ^1^, U. Uparkar, E. Ross

*^1^Locum Registrar, Pediatric Oncology, Leicester, United Kingdom*

**Background/Objectives**: Introduction

Recurrence with metastasis in the central nervous system (CNS) in children with Wilms tumour (WT) is very rare, accounting in less than 1%.^1,2^ The development of CNS metastasis is commonly associated with concurrent or prior lung metastasis.^2‐4^

**Design/Methods**: Case Report

June 2016, 15 year old boy presented with few months history of worsening back pain and signs of spinal cord compression. These findings were confirmed on MRI, which revealed Left renal mass with multiple pulmonary nodes and Left para spinal extradural mass compressing T12‐L2 nerve roots.

Biopsy of the mass confirmed triphasic WT, after which he was commenced on 3 drug neoadjuvant as per SIOPWT2001, after 6 weeks of therapy partial response(PR) in both local and metastatic site was noted. He was given further 3 weeks of therapy post national WT consensus prior attempting local control. In Sept 2016 he underwent left radical nephrectomy followed by radiation to whole abdomen and Para spinal vertebral area. He received 5 drug, high risk adjuvant chemotherapy for further 32 weeks. Aug 2017, end of therapy assessment showed complete response (CR) at local site but stable disease (SD‐ Paravertebral mass, CR Lungs)

Oct 2017, he presented with very short history of headache, MRI revealed cerebellar tumor with mass effect. Same day he succumbed to the disease after a seizure activity followed by coning of brain.

**Results**: Limited postmortem findings were consistent with Metastatic WT in the cerebellum.

**Conclusions**: Whenever there is clinical suspicion, cranial surveillance should be added to the routine follow‐up to detect intracranial tumors in timely fashion. In such cases there is need for separate prognostic subgroup after understanding the biology of these tumors.

1\. Coppes MJ et al Med Ped Onc.2000;267:1852.

2\. Lowis SP et al Cancer 1998;83:2023‐20293.

3\. Kebudi R et al J Neuro Oncol. 2005;71(1):43‐484.

4\. Bouffett E et al Cancer 1997;79(2):403‐410

### PO-448. Causes of Mortality Among Children with Wilms Tumour {#pbc27455-sec-6780}

[L. Joseph]{.ul} ^1^, R. John^1^, H. Ns^1^, D. Boddu^1^, N. Chaudhary^1^, L.G. Mathew^1^

*^1^Christian Medical College‐ Vellore, Department of Paediatric Haematology‐Oncology, Vellore, India*

**Background/Objectives**: The overall and event free survival of Wilm\'s tumour (WT) has improved remarkably even in low and middle income countries. However, a significant proportion of children still die of the disease or complications. We looked at the cause of death in children with WT registered in our department, which caters largely to low and middle income population.

**Design/Methods**: Clinical data was collected from medical records of children with WT diagnosed from 2004‐ 2017. Families were contacted to get additional information, as required.

**Results**: 29/ 162 children with WT died. There were 15 boys and 14 girls. The median age was 4 years (range 8 months ‐ 14 years). Five were \<2 years and four were \>5 years at diagnosis. 13 had metastatic disease at presentation. One child had stage 1 disease, 5‐ stage II, 6‐III, 13‐IV and 4 had stage V disease. The child with stage 1 disease had local recurrence and died of infection during relapse treatment. Among the five with stage II disease, three died of liver toxicity, one died of respiratory infection and the fifth patient had relapsed disease 10 months post treatment. One except all with stage III tumour died of disease; three of them had inoperable tumours and 2 developed metastatic disease post treatment. The 6th patient died of varicella infection. All with stage IV tumour died of progressive disease. The cause of death in those with bilateral disease were cardiac dysfunction and road traffic accident in one each and progressive inoperable disease in the remaining two. Overall, 21/29 children died of refractory or relapsed disease, four had treatment related liver or cardiac toxicity, three died of infection and one of unrelated cause.

**Conclusions**: 18% of children with Wilm\'s tumour registered in our system died. Progressive primary disease or relapse accounted for 72% of deaths.

### PO-449. Clinical Analysis of 13 Cases of Chinese Children with Localized Clear Cell Sarcoma of Kidney {#pbc27455-sec-6790}

[W. Juan]{.ul} ^1^, S. Xiaofei^1^, Z. Zijun^1^, Z. Jia^1^, L. suying^1^, S. Feifei^1^, H. Junting^1^, Z. Yu^2^, G. Yuanhong^3^

*^1^Sun Yat‐Sen University Cancer Center, Department of Pediatric Oncology, Guangzhou, China; ^2^Sun Yat‐Sen University Cancer Center, Pathology department, Guangzhou, China; ^3^Sun Yat‐Sen University Cancer Center, Department of Radiotherapy, Guangzhou, China*

**Background/Objectives**: To analyzed the survival and prognosis of paediatric primary CCSK from January 2012 to May 2017 in Sun Yat‐sen University Cancer Center.

**Design/Methods**: The primary treatment of renal clear cell sarcoma in children from January 2012 to May 2017 in Sun Yat‐sen University Cancer Center was collected. The patients received the combined treatment of surgery+chemotherapy+radiotherapy. The chemotherapy regimens included: CAV/CE (CTX+THP+VCR /CBP+VP‐16), CAV/IE (CTX+THP+VCR/IFO+VP‐16).

**Results**: A total of 13 patients were enrolled, including 10 males and 3 females, with a median age of 25.4 months (8.0 to 171.6 months). There were 7 cases in stage I, 1 case in stage II, and 5 cases in stage III. 11 patients underwent direct radical nephrectomy, and 2 patients received preoperative neoadjuvant chemotherapy (Because preoperative biopsy were nephroblastoma, these 2 patients received 2 courses neoadjuvant chemotherapy with Act‐D+THP+VCR, 1 SD, 1 PD). Except for one patient with stage III who did not receive radiotherapy, the remaining 12 patients received radiotherapy with a median dose of 21.6 Gy (21.6 to 28.8 Gy). All of the 13 patients received adjuvant chemotherapy (9 cases used CAV/CE regimens and 4 cases used CAV/IE regimens) with a median course of 8 cycles (2 to 10). All 13 patients achieved CR after comprehensive treatment with a median follow‐up duration of 29.8 months (10.3 to 70.6 months). One case of stage III patients occurred brain metastasis 17.5 months after first CR. One patient who received chemotherapy with the CAV/IE regimen developed tubulointerstitial nephritis 3 months after discontinuation of treatment. The 3‐year EFS rate and 3‐year OS rate of the whole group were 85.7%±13.2% and 100%.

**Conclusions**: Pediatric localized CCSK has a good prognosis after comprehensive treatment. Reducing treatment intensity in patients with stageⅠ/Ⅱ is worth further study.

### PO-450. Prognostic Significance of Chromosome Abnormalities in Wilms Tumor may be Causally Related to Upregulation or Downregulation of Genes on Extra Chromosomes or Lost Chromosome Arms {#pbc27455-sec-6800}

[Y. Kaneko]{.ul} ^1^, M. Haruta^1^, Y. Arai^2^, R.P. Sugino^1^, T. Kamijo^1^, H. Okita^3^, Y. Tanaka^4^, T. Takimoto^5^, T. Oue^6^, M. Nozaki^7^, M. Chin^8^, M. Fukuzawa^9^, T. Koshinaga^10^

*^1^Saitama Cancer Center, Research Institute for Clinical Oncology, Ina, Japan; ^2^National Cancer Center Research Institute, Cancer Genomics Division, Tokyo, Japan; ^3^Keio University, Department of Pathology, Tokyo, Japan; ^4^Kanagawa Children\'s Medical Center, Department of Pathology, Yokohama, Japan; ^5^National Center for Child Health and Development, Research Institute, Tokyo, Japan; ^6^Hyogo College of Medicine, Department of Pediatric Surgery, Nishinomiya, Japan; ^7^Dokkyo Medical University, Department of Radiology, Koshigaya, Japan; ^8^Nihon University School of Medicine, Department of Pediatrics, Tokyo, Japan; ^9^Osaka Medical Center and Research Institute for Maternal and Child Health, Department of Pediatric Surgery, Izumi, Japan; ^10^Nihon University School of Medicine, Department of Pediatric Surgery, Tokyo, Japan*

**Background/Objectives**: Overall survival (OS) rates of patients with Wilms tumor (WT) have reached to 90%. Biomarkers which predict favorable or unfavorable outcomes are needed to improve OS rates further and to avoid adverse late effects,

**Design/Methods**: We analyzed array CGH (aCGH) pattern and mutations of *WT1* and 7 other genes in 129 unilateral WTs. Patients were classified according to aCGH or genetic alterations, and each alteration was correlated with relapse‐free survival (RFS) and OS rates. Expression microarray analysis was performed in 27 WTs. Upregulated genes on a specific chromosome, which is duplicated in some WTs, and downregulated genes on a specific chromosome arm, which is lost in some other WTs were determined. Correlation between overexpression of each upregulated gene or under‐expression of each downregulated gene and favorable or unfavorable OS was determined using r2 database.

**Results**: Thirty‐one patients had *WT1* alterations in tumors (RFS 83%; *WT1* type), 20 had no aCGH aberrations (RFS 95%; silent type), and 78 had aCGH changes without *WT1* alterations (non‐*WT1*/non‐silent type). When 78 patients were classified into those with presence or absence of +12, 11q‐, 16q‐, or *HACE1* loss, RFS was better for those with +12 than those without (RFS: *P*=.027), and worse for those with 11q‐, 16q‐, or *HACE1* loss than those without (RFS: *P*=.008, .038, or 3.7E‐04). Of 27 WTs examined, 146 genes on chromosome 12 were upregulated in +12 tumors compared to no +12 tumors, and 10 genes on 16q were downregulated in 16q‐ tumors compared to no 16q‐ tumors. Overexpression in 75 of the 146 upregulated genes and under‐expression in 4 of the 10 downregulated genes were correlated with better and worse OS in patients with WT, respectively.

**Conclusions**: Prognostic significance of chromosome abnormalities may be causally related to upregulation of genes on extra chromosomes, and downregulation of genes on deleted chromosome arm regions.

### PO-451. Rare Pediatric Renal Tumors: The Mayo Clinic Experience {#pbc27455-sec-6810}

[M. Kohorst]{.ul} ^1^, P. Galardy^1^, C. Arndt^1^, S. Khan^1^

*^1^Mayo Clinic, Department of Pediatric and Adolescent Medicine/Division of Hematology and Oncology, Rochester, USA*

**Background/Objectives**: Renal cancers account for 6% to 7% of all childhood tumors, with Wilms tumor being the most common. Other rare renal malignancies account for approximately 10% of renal tumors, and are under‐reported to date. These tumors have unique clinical presentations, genetic underpinnings, pathologic findings, imaging characteristics, and treatment courses. The objective of this study was to report the incidence, clinical presentation and treatment outcomes for pediatric non‐Wilms renal malignancies.

**Design/Methods**: A retrospective review was conducted on the clinical features for all pediatric renal tumors over an 18‐year period.

**Results**: From January 2000 to January 2018, 69 patients aged 0‐21 years were diagnosed with renal tumors. Of those, 88.4% (n=61) had Wilms tumors and 11.6% (n=8) had other rare renal tumors including renal cell carcinoma (RCC, n=3), mesoblastic nephroma (n=1), rhabdoid tumor (n=1), Ewing sarcoma (n=1), malignant peripheral nerve sheath tumor (n=1), and an unclassified non‐Wilms renal tumor (n=1). Of the rare renal malignancies, 6/8 were female. Median age at diagnosis was 13.6 years (range 0‐20 years). Clinical presentation was variable: 3/8 presented asymptomatically; 5/8 had symptoms including pain (n=2), hematuria (n=1), palpable mass (n=1), and irritability (n=1). At diagnosis, 3/8 had metastatic disease to regional lymph nodes (2 RCC, 1 rhabdoid). Initial management included up front total or partial nephrectomy (n=8), chemotherapy (n=5), and radiation (n=2). At a median follow up time of 3.8 years (range 0.4‐13.2 years), 2 patients developed recurrence (1 RCC, 1 mesoblastic nephroma) and 1 patient died of disease (recurrent RCC), with the remaining 7 alive at last follow up.

**Conclusions**: Non‐Wilms renal tumors comprise a clinically significant percentage of renal malignancies in children. These tumors are treated differently from Wilms tumors and therefore are important to distinguish. Continued attention to these tumors is necessary for meaningful advances in treatment and patient outcomes.

### PO-452. Comparison of Serum Micro‐RNA Profiles in Patients with Wilms Tumors and Patients with Other Renal Cancers Identifies Potential Micro‐RNA Biomarkers {#pbc27455-sec-6820}

[N. Ludwig]{.ul} ^1^, L. Groeger^1^, R. Furtwängler^2^, M. Kahraman^3^, N. Graf^2^, A. Keller^3^, E. Meese^1^

*^1^Saarland University, Human Genetics, Homburg, Germany; ^2^Saarland University, Pediatric Hematology and Oncology, Homburg, Germany; ^3^Saarland University, Chair for Clinical Bioinformatics, Saarbrücken, Germany*

**Background/Objectives**: Wilms Tumor (WT) is the most common childhood kidney cancer. As treatment according to SIOP includes preoperative chemotherapy without histological confirmation of WT by biopsy, minimal‐invasive diagnostic markers confirming WT diagnosis are highly warranted. To date, there is only limited knowledge on serum micro‐RNA (miRNA) profiles in patients with WT with only two studies analyzing serum levels of a selected number of miRNAs.

**Design/Methods**: In our study, we analyzed serum profiles of 2459 miRNAs in 72 individuals, including 42 patients with different subtypes of WT and 30 patients with other renal cancers or non‐cancer diseases before treatment using microarrays. We identified miRNAs with differential abundance in WT compared to controls using t‐test and in different subtypes using ANOVA.

**Results**: We identified 69 miRNAs with significantly higher and 53 miRNAs with significantly lower levels in serum of WT patients compared to controls. Amongst others, miR‐34a‐5p, miR‐483‐3p and miR‐205‐3p levels were higher, and miR‐371a‐5p, miR‐1287‐5p levels were lower in serum of patients with WT compared to patients with other renal tumors. ANOVA comparison of abundance levels revealed 348 miRNAs with significant differences between WT subtypes and controls. In detail, we found miRNAs with differential expression in serum of patients with WT subtypes with different blastemal cell content, including miR‐320a with higher and miR‐26b‐5p with lower expression in patients with blastemal subtype or regressive/mixed subtype with high residual blastem compared to patients with other WT subtypes.

**Conclusions**: We identified a set of miRNAs with differential expression in serum of patients with WT that is significantly different from patients with other renal malignancies and non‐cancer diseases. Furthermore, some of these miRNAs show also a differential expression between different subtypes of WT. These miRNAs show promise as minimal‐invasive biomarkers to differentiate WT patients from controls at time of diagnosis.

### PO-453. Results of Treatment of Children with a Mesoblastic Nephroma {#pbc27455-sec-6830}

[N. Merkulov]{.ul} ^1^, D. Akhaladze^1^, D. Kachanov^1^, S. Talypov^1^, S. Varfolomeeva^2^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Surgery, Moscow, Russia; ^2^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Oncology, Moscow, Russia*

**Background/Objectives**: The analysis of experience of the center in surgical treatment of patients with the congenital mesoblastic nephroma (CMN).

**Design/Methods**: The research included 11 patients with the established diagnosis of VMN which received treatment from October, 2014 till January, 2018. Assessment of abundance of process and tactics of treatment were defined within the recommendations of SIOP. At all children the main method of treatment was the surgical oncotomy.

**Results**: In total in our center it was operated 12o children with tumors of kidneys. Among them 15 children were younger than 6 months. Are initially operated 9 (81,8%) children. 2 (18,2%) the patient are operated after carrying out a preoperative chemotherapy. Medians of an age of patients at the time of detection of a tumor of a kidney made 1,9 months (0,2‐5,6 months). At the same time the median of an age of realization of operation made 2,2 months (0,2‐5,6 months). At 3 (27,3%) children the new growth of a kidney is diagnosed in the prenatal period. At others 8 (72%) patients the tumor is revealed at screening ultrasonic investigation antenatal. All patient carried out a nephrectomy. Radical operation is executed in 8 (73%) observations. The intraoperative rupture of a tumor is revealed in one (9%) a case. The median of overseeing by patients made 15,3 (0,3 -- 32,3) months. The common survival was 82%. the 2nd ‐ the summer survival was 90%. The local recurrence is diagnosed at 2 (18%) patients. Two patients died.

**Conclusions**: Keyest in treatment of children with SMN is the radical oncotomy. Violation of a wholeness of the capsule of a tumor leads to development of a recurrence of a disease which progressing of a disease follows, demanding intensifications of a chemotherapy and repeated surgical interventions.

### PO-454. Comparative Analysis of Childhood Renal Cancer Between the UK and Japan, Using Clinical Trial Datasets {#pbc27455-sec-6840}

[K. Nakata]{.ul} ^1^, R. Williams^2^, Y. Kinoshita^3^, T. Koshinaga^4^, V. Moroz^5^, G. Vujanic^6^, T. Oue^4^, K. Pritchard‐Jones^2^

*^1^Osaka International Cancer Institute, Cancer Control Center, Osaka, Japan; ^2^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer Programme, London, United Kingdom; ^3^Japanese Society of Pediatric Surgeons, Malignant Tumor Committee, Tokyo, Japan; ^4^Japan Children\'s Cancer Group, Renal Tumor Committee, Tokyo, Japan; ^5^University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom; ^6^Sidra Medicine, Department of Pathology, Doha, Qatar*

**Background/Objectives**: Our population‐based analysis (1993‐2010) found a significantly higher annual incidence of childhood renal cancers (aged 0‐14 years) in England than in Japan (8.9 vs 3.5 per million person‐years, respectively). To enhance understanding of these differences, we used clinical trial datasets that enrolled the majority of patients in each country over a 20 year period (1996‐2015) to provide detailed patient and tumour demographics.

**Design/Methods**: Three consecutive clinical trial datasets (UKW3, SIOP2001, IMPORT) from the UK and one prospective observational study from the Japanese Society of Pediatric Surgeons (JSPS) registry were used. We compared distribution of patient sex, age at diagnosis, stage, largest diameter, histology of tumour, and number of treatment hospitals between UK and Japan. Overall survival (OS) and event‐free survival (EFS) during 1996‐2005 were estimated using the Kaplan--Meier method.

**Results**: Total patients: 1,623 (UK) and 777 (Japan). Wilms tumours (WT) was the most common childhood renal cancer in both countries (86%, UK; 69%, Japan). Japanese patients with WT had significantly younger median age at diagnosis compared to those in UK (28m vs 39m). Proportion with metastatic disease (stage IV) was higher in UK (18% vs 11%) as was the proportion with largest tumour diameter \>10cm (62% vs 49%). Proportion of anaplastic tumours was also higher in UK than Japan (8% vs 3%). Seventy‐seven hospitals treated WT in Japan compared to only 22 hospitals in the UK. There were no significant differences in OS and EFS from WT between UK and Japan:5‐year OS was 92% (95%CI: 89‐93%) vs 92%(95%CI:87‐95%) and 5‐year EFS was 81% (95%CI:78‐84%) vs 78% (95%CI:72‐83%), respectively.

**Conclusions**: There are differences in age distribution, proportion with metastatic disease, tumour size and anaplastic tumours between UK and Japan. Most WT patients were cured in both countries.

### PO-455. Diffusion‐Weighted Magnetic Resonance Imaging for the Evaluation of Wilms Tumors: Radiological‐Pathological Correlation {#pbc27455-sec-6850}

[E. Nazarova]{.ul} ^1^, G. Tereschenko^1^, E. Ternovaya^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Radiology, Moscow, Russia*

**Background/Objectives**: Wilms tumor (WT), or nephroblastoma is one of the most common extracranial tumors in pediatric population. Different histological types of nephroblastoma impact staging, treatment options and outcome. The aim of the study was to analyze possible correlation between diffusion‐weighted imaging (DWI) data and different histological types of WT.

**Design/Methods**: The study was based on data of 25 pediatric patients with histopathologicaly verified WT. Median age at the time of diagnosis was 5 years (from 1 to 8 years old), male to female ratio was 1:1,3. Imaging data was obtained with 1.5T MRI (magnetic resonance imaging) scanner. The apparent diffusion coefficient (ADC) value for each tumor was calculated using region‐of interest measurements. The mean ADC values and histological types of WT were compared using regression analysis method.

**Results**: Out of 25 patient 4 (16%) were low risk, 14/25 (56%) intermediate and 7/25 (28%) high risk. The mean ADC values were 1.82±0.068 ×10‐3 mm²/s for low grade WT, 1.005±0.093 ×10‐3 mm² /s for medium grade WT, and 0.56±0.13 ×10‐3 mm² /s for high grade WT. Intraclass correlation coefficient was 0.81.

**Conclusions**: In our study we have found a significant correlation between ADC values and histological types of WT. MRI DWI can be a useful tool in the initial assessment and differential diagnosis in patients with nephroblastoma.

### PO-456. Synchronous Bilateral Wilms Tumor in a Two Year Old Male Child {#pbc27455-sec-6860}

[R. Nerli]{.ul} ^1^

*^1^KLES Kidney Foundation, Division Paed Urology ‐, Belgaum, India*

**Background/Objectives**: Approximately 5% of children with Wilms tumor present with bilateral disease. The treatment challenge is to achieve a high cure rate while maintaining adequate long‐term renal function. We report the feasibility and outcome of nephron‐sparing surgery in a child with bilateral Wilms tumor who was treated at our institution.

**Design/Methods**: Due to the rarity of BWT, NSS has been less commonly used in pediatric renal tumors, but has been shown to provide excellent oncologic control and at the same time preserve renal function. In this article we describe the operative steps of NSS in a child with BWT.

**Results**: A 2 year old male child presented to the Paediatric urological services of the hospital with complaints of distension of the abdomen. The child had normal mile stones and was vaccinated as per the schedule. The child was anemic (Hb -- 9.2 gm%) and weighed 10.5 kgs. Serum creatinine was 0.24 mg%. Ultrasonographic examination revealed bilateral renal masses. Computed tomography (CT) showed a heterogeneously enhancing lobulated mass 2.83.14.2 cm in the upper pole of the right kidney and a hypo‐enhancing solid mass 6 cm upper and mid polar mass in the left kidney.

**Conclusions**: The focus of treatment in children with BWT is survival, and the preservation of good long term renal function. Nephron‐sparing surgery for children with bilateral Wilms tumors is nearly always technically feasible, with acceptable complications. This approach, when combined with adjuvant therapy, provides an opportunity to preserve renal function while maintaining a high probability of cure and should be considered strongly for all patients who have synchronous, bilateral Wilms tumors, despite the radiographic appearance of the kidneys and associated tumors.

### PO-457. Congenital Mesoblastic Nephroma and Congenital Infantile Fibrosarcoma a Case Series Review of Histopathology, Genetics and Outcomes {#pbc27455-sec-6870}

[K. O\'shea]{.ul} ^1^, R. Craigie^1^, E. Cheesman^1^, P. Farrelly^1^

*^1^Royal Manchester Children\'s Hospital, Paediatric Surgery, Manchester, United Kingdom*

**Background/Objectives**: Congenital Mesoblastic Nephroma (CMN), comprising 5% of childhood renal tumours, is considered benign. However, certain subtypes demonstrate a propensity for recurrence and mortality. Cellular CMN is histologically and cytogenetically identical to Congenital Infantile Fibrosarcoma (CIFS), with both demonstrating a high frequency of ETV6‐NTRK3 gene fusion.

We present our case series to inform understanding of adverse prognostic factors that influence clinical outcomes in CMN and CIFS.

**Design/Methods**: We retrospectively reviewed all cases of CMN and CIFS at our institution between 1994‐2016. Data was collected regarding; age at presentation, operative intervention, tumour rupture, stage, histology, molecular genetics, recurrence, morbidity, and mortality. Outcomes were noted in relation to molecular genetics, immunohistological staining, and ETV6:NTRK3 translocation.

**Results**: 16 cases were identified, n=8 CMN n=8 CIFS.

All patients in the CMN group had primary nephrectomy. There were 2 pre‐operative and 2 intraoperative tumour ruptures. Histology identified 4 cellular, 3 classic and 2 mixed type tumours. The ETV6:NTRK3 translocation was identified in 1 CMN. In the CMN group we identified 3 recurrences, all were ruptured, of a cellular subtype; none demonstrated the translocation. All cases of recurrence were managed by chemotherapy and resection. For one child this was curative, 2 children died. Overall mortality 25%. Median follow‐up 45 months.

In the CIFS group 3 cases were managed with primary resection, 4 cases were biopsied prior to resection. 5 demonstrated the ETV6:NTRK3 translocation. There is no mortality in this group. Median follow‐up 48.5 months.

**Conclusions**: CMN, whilst considered a benign disease can be aggressive, associated with a mortality of 25% in our series. Cellular subtype, tumour rupture and lack of the ETV6:NTRK3 translocation appear to be associated with poor prognosis. We propose these translocation negative CMN\'s may represent a different, undescribed tumour entity. More advanced molecular testing, such as whole genome or RNA sequencing, is required to investigate this.

### PO-458. Botryoid Wilms Tumor: A Rare Presentation of a Well‐known Childhood Cancer {#pbc27455-sec-6880}

[S. Ocak]{.ul} ^1^, R. Tuna^1^, B. Çetin^2^, D. Tugcu^1^, S. Karaman^1^, T.M. Oktar^2^, Z. Karakas^1^

*^1^Istanbul University‐ Istanbul Medical Faculty, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^Istanbul University‐ Istanbul Medical Faculty, Pediatric Urology, Istanbul, Turkey*

**Background/Objectives**: Wilms tumor usually originates from renal parenchyma. Rarely the tumor arises from renal pelvis with an appearance similar to botryoid sarcoma. Due to it\'s atypical localisation and extension, diagnosis and staging is difficult.

**Design/Methods**: A 4‐year‐old boy was admitted to pediatric urology department with dysuria. Physical examination revealed a right‐sided abdominal mass with regular borders. Abdominal USG and MRI showed a solid, lobulated mass filling the right renal pelvis and extending into the ureter. Right sided nefroureterectomy was performed and pathologic examination was consistent with Wilms\' tumor, with significant necrosis but without anaplasia and ureteral wall infiltration. A few days after the operation, dysuria and urgency developed and repeated cystoscopy revealed a necrotic mass in the bladder cavity free form the bladder wall. This mass was also full of "ghost cells" and necrosis. Thorax CT was reported to be normal. Together with the ureteral extension and necrotic bladder mass. The patient was accepted as Stage 2, favorable disease. NWTS‐5 study protocol was started and he is still on chemotherapy and free of disease.

**Results**: Botryoid Wilms tumor is rare in response to its origin and local extension pattern. In literature only 25 cases was reported to date. Differently from classical Wilms tumor, dysuria, urgency and hematuria are the most common symptoms. It is thought to arise from an intralobar nephrogenic rest in renal pelvis. Despite its atypical localisation and extensions, prognosis was reported to be similar to parenchymal Wilms tumor.

**Conclusions**: The ureteral extension and necrotic mass in the baldder cavity were posed a diffuculty in staging and treatment of this case. In the light of present evidence in literature we evaluated the patient as classical Wİlms\' tumor. But we think in addition to standart treatment and follow‐up, need for regular cystoscopic examination for bladder involvement should be discussed for each case.

### PO-459. Synchronous Occurrence of Wilms Tumor and Alveolar Soft Part Sarcoma in a Child ‐ A Case Report {#pbc27455-sec-6890}

[R. Palassery]{.ul} ^1^, K. Sharma^2^, J. M Gururajachar^3^, N. Kilara^1^

*^1^MS Ramaiah Medical College, Medical Oncology, Bengaluru, India; ^2^Core Diagnostics, Oncopathology, Gurgaon, India; ^3^MS Ramaiah Medical College, Radiation Oncology, Bengaluru, India*

**Background/Objectives**: Multiple primary malignancies (MPM) are extremely rare in pediatrics and often associated with cancer predisposition syndromes. Their treatment is challenging due to varying drug sensitivities and therapy related adverse effects. We report the case of a 9 year old female with synchronous Wilms tumor (WT) and Alveolar Soft Part Sarcoma (ASPS).

**Design/Methods**: Case report.

**Results**: A 9 year old female with stomach pain was found to have an abdominal mass. A CT scan showed bilateral pulmonary nodules, a large left renal mass and another mass within the left psoas muscle behind the renal mass. Renal mass biopsy showed triphasic WT. She received chemotherapy with Vincristine, Actinomycin‐D and Doxorubicin for 6 weeks, following which she had a left nephrectomy and removal of the psoas mass. Histopathology of the kidney showed WT with focal anaplasia while the psoas mass was consistent with ASPS. The patient underwent genetic screening for cancer predisposition syndromes, which was negative. She received adjuvant chemotherapy for high risk WT along with lung and abdomen radiation and a radiation boost to the ASPS tumor bed. She had a pulmonary relapse of WT 5 months post therapy. There was no evidence of disease in the nephrectomy bed, opposite kidney or the psoas muscle. She is currently undergoing salvage chemotherapy for the WT relapse.

**Conclusions**: MPMs including sarcomas and WT have been described before in children with Fanconi anemia (BRCA2 or PALB2 mutations) and Li‐Fraumeni syndrome (TP53 or CHEK2 mutations). Our patient tested negative for all of these mutations. We chose to treat our patient with WT directed therapy since ASPS has poor sensitivity to chemotherapy. This case highlights the rarity of MPMs in children, our limited understanding of cancer predisposition syndromes and the need for individualized treatment plans for such patients.

### PO-460. Characterization of the Immune Microenvironment of Pediatric Nephroblastoma Using a Transcriptomic Approach {#pbc27455-sec-6900}

[M. Penel‐Page]{.ul} ^1^, M. Robert^2^, F. Dijoud^3^, V. Attignon^2^, P. Saintigny^2^, C. Bergeron^1^

*^1^Centre Léon Bérard, Institut d\'Hématologie et d\'Oncologie Pédiatrique, Lyon, France; ^2^Centre Léon Bérard, Translational Research Laboratory, Lyon, France; ^3^Hospices Civils de Lyon, Pathology, Lyon, France*

**Background/Objectives**: Nephroblastoma, or Wilms tumor (WT) is a heterogeneous embryonic tumor composed of three main subtypes: blastema, stroma and epithelium. With pre‐operative chemotherapy, according to SIOP classification, only 9% of WT are blastemal, and associated with poor prognosis. On the other hand, with first‐line surgery, 30% of WT are blastemal without prognostic impact. The immune microenvironment of WT is barely known. This work aims to characterize the microenvironment of WT, taking into account intra‐tumoral heterogeneity and using a transcriptomic approach.

**Design/Methods**: Ninety‐six specific area from formalin‐fixed paraffin‐embedded (FFPE) samples, from 37 patients treated at IHOPE (Centre Léon Bérard, Lyon, France) according to SIOP2001 protocol were retrospectively selected by one of the two French Referent Pathologists for WT, in order to analyze every tissue component of WT. Targeted‐sequencing of 2,559 transcripts involved in tumorigenesis and immune response (Oncology Biomarker Panel) was performed using the HTG EdgeSeq system.

**Results**: Ninety‐five areas passed the quality control: 46 blastema, 13 epithelium, 11 stroma, 14 mixt, and 11 nephrogenic rests. We identified 1,012 and 310 genes differentially expressed (p\< 0.05) in blastemal versus stromal areas, and in blastemal versus epithelial areas respectively. In particular, SIX1 and CCN2 (genes with recurrent mutations in WT) were strongly upregulated in blastemal areas compared to stroma and epithelium. Unsupervised hierarchical cluster analysis using the 100 most variant genes identified 3 groups. Blastemal samples clustered in either one of the groups. Blastemal samples from intermediate‐risk WT were enriched in inflammatory response genes compared to those from unfavorable‐risk WT.

**Conclusions**: Gene expression differs in each component of WT. Our results may help to identify new prognostic factors and therapeutic targets.

### PO-461. Wilms Tumor in Southern and Eastern Europe: Incidence and Survival Rates by Human Development Index {#pbc27455-sec-6910}

D. Doganis^1,2^, P. Panagopoulou^1^, A. Tragiannidis^3^, M. Georgakis^1^, T. Vichos^1^, M. Moschovi^4^, S. Polychronopoulou^5^, E. Rigatou^5^, E. Papakonstantinou^6^, E. Stiakaki^7^, H. Dana^8^, K. Strantzia^9^, K. Stefanaki^10^, T. Psaltopoulou^1^, N. Dessypris^1^, S.E.E.G. Southern‐ Eastern European Group^11^, [E. Petridou]{.ul} ^1,12^

*^1^National and Kapodistrian University of Athens Medical School, Dept. of Hygiene‐ Epidemiology and Medical Statistics, Athens, Greece; ^2^"P & A Kyriakou" Children\'s Hospital, Oncology Department, Athens, Greece; ^3^Aristotle University of Thessaloniki‐ AHEPA Hospital, Hematology‐Oncology Unit‐ 2nd Pediatric Department, Thessaloniki, Greece; ^4^University of Athens‐ "Agia Sofia" Children\'s Hospital, Pediatric Hematology‐Oncology Unit‐ First Department of Pediatrics, Athens, Greece; ^5^"Agia Sofia" Children\'s Hospital, Department of Pediatric Hematology‐Oncology‐, Athens, Greece; ^6^Hippokration Hospital‐, Department of Pediatric Hematology and Oncology, Thessaloniki, Greece; ^7^University of Crete, Department of Pediatric Hematology‐Oncology, Heraklion, Greece; ^8^"Mitera" Children\'s Hospital, Pediatric Hematology‐Oncology Department, Athens, Greece; ^9^"P & A. Kyriakou" Children\'s Hospital, Pathology Laboratory, Athens, Greece; ^10^"Agia Sofia" Children\'s Hospital, Pathology Laboratory, Athens, Greece; ^11^Luis Antunes‐ Joana Bastos‐ Daniela Coza‐ Anna Demetriou‐ Domenic Agius‐ Sultan Eser‐ Snezana Zivkovic Perisic‐ Mario Šekerija‐ Maciej Trojanowski‐ Tina Žagar‐ Anna Zborovskaya‐ Anton Ryzhov, Southern‐ Eastern European Group, Southern‐ Eastern Europe, Greece; ^12^Karolinska Institute, Clinical Epidemiology Unit‐ Department of Medicine, Stockholm, Sweden*

**Background/Objectives**: Wilms (WT) is a tumor of largely obscureetiology with remarkably variable survival. We aimed to compare incidence and survival rates among children (0‐14 years) in 12 South‐Eastern European (SEE) countries in relation to Human Development Index (HDI).

**Design/Methods**: Age‐standardized incidence rates (AIR; 1990‐2016) were calculated and correlated with HDI in 12 SEE collaborating countries entailing 13 registries. Kaplan--Meier curves and Cox Proportional Hazards analyses were used to assess the role of age, gender, urbanization and HDI on overall survival (OS) in 11 countries entailing 12 registries.

**Results**: The median age at diagnosis was 3.1 years with steadily declining rates after the fifth year of life and a transition from a slightly male (1.1) to a slightly female (0.7) preponderance with advancement of age. The overall SEE‐AIR was 9.2/106with significant differences among registries and a statistically significant positive association of higher HDI with increasing incidence (regression coefficient:+3.25, 95% CI:+1.35,+5.15). Persisting regional variations shaped an overall 78% OS5‐yearwith a remarkable gradually escalating OS (HR5‐year increment:0.67, 95% CI:0.60, 0.75). Results reported for the first time from Greece, show a high 90% OS3‐year during the total registration period and 97% during the last five years. Boys (HR:1.24), children aged 10‐14 years (HR:1.75), those living in rural areas (HR:1.37) and other than very high HDI countries (HRhigh HDI:2.17;HRmedium HDI:3.40) had a significantly higher death risk.

**Conclusions**: Variations in incidence described for the first time across SEE countries, changing male to female patterns with advancement of age and positive associations with the HDI imply a plausible interplay of environmental with genetic factors in disease etiology. Likewise, children residing in this area do not equally enjoy the substantial gains in WT survival, pointing to strong socioeconomic differentials despite recent therapeutic improvements.

### PO-462. Characteristics and Outcomes Among Children Suffering Wilms Tumor: Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM‐ST) Greek Data {#pbc27455-sec-6920}

D. Doganis^1,2^, P. Panagopoulou^1^, A. Tragiannidis^3^, M. Moschovi^4^, S. Polychronopoulou^5^, E. Rigatou^5^, E. Papakonstantinou^6^, E. Stiakaki^7^, H. Dana^8^, P. Bouka^1^, K. Strantzia^9^, K. Stefanaki^10^, N. Dessypris^1^, [E. Petridou]{.ul} ^1^

*^1^National and Kapodistrian University of Athens Medical School, Dept. of Hygiene‐ Epidemiology and Medical Statistics, Athens, Greece; ^2^"P & A Kyriakou" Children\'s Hospital, Oncology Department, Athens, Greece; ^3^2nd Pediatric Department‐ Aristotle University of Thessaloniki‐ AHEPA Hospital, Hematology‐Oncology Unit, Thessaloniki, Greece; ^4^First Department of Pediatrics‐ University of Athens‐ "Agia Sofia" Children\'s Hospital, Pediatric Hematology‐Oncology Unit, Athens, Greece; ^5^"Agia Sofia" Children\'s Hospital, Department of Pediatric Hematology‐Oncology, Athens, Greece; ^6^Hippokration Hospital, Department of Pediatric Hematology and Oncology, Thessaloniki, Greece; ^7^University of Crete, Department of Pediatric Hematology‐Oncology, Heraklion, Greece; ^8^"Mitera" Children\'s Hospital, Pediatric Hematology‐Oncology Department, Athens, Greece; ^9^"P & A. Kyriakou" Children\'s Hospital, Pathology Laboratory, Athens, Greece; ^10^"Agia Sofia" Children\'s Hospital, Pathology Laboratory, Athens, Greece*

**Background/Objectives**: To present, for the first time, characteristics and outcomes of children suffering Wilms tumor (WT) derived from a childhood cancer registry entailing also clinical data and developed during the period of financial crisis in Greece.

**Design/Methods**: Followingintensive collaboration of NARECHEM‐ST personnel with attending physicians aiming to increase quality and harmonize childhood cancer registration demographic and clinical data of WT patients(2009‐2017)were analyzedaccording to standard methodologies.

**Results**: A total of 115 patients (0‐14 years) were registered with median age 3.29 years (75%\<5 years) out of whom 46 (40%) were males. The annual age standardized incidence rate was 9.0/106children; the event‐free survival (EFS5‐year) was 83% and the overall (OS5‐year) 88%. Specifically, an increasing by time majority (68%) received SIOP‐2001 protocol with pre‐operative chemotherapy. Neither the relapse rate (14.8%) or the death rate (10.4%) showed statistically significant difference among boys (17.4%, 10.9%, respectively) compared to girls (13%, 10.1%, respectively). One girl (stV, high risk histology) died due to refractory disease, whereas no death was attributed to toxicity. The relapse rate increased significantly by anatomical stage (stI:1/30, stII:2/31, stIII:8/36, stIV:5/11, stV:1/7); likewise, the death rate (stI:0/30, stII:1/31, stIII:6/36, stIV:3/11, stV:2/7). The relapse rates among patients with high‐risk/unfavorable histology were 5.5 times higher compared to those of intermediate risk/favorable histology, whereas the death rate was 9 times higher. No significant differences regarding the relapse/death rates among different age groups or patients with pre‐operative chemotherapy vs. immediate surgery were observed.

**Conclusions**: NARECHEM‐ST data indicate that provision of specialized care for childhood cancer seems not to lag behind. Indeed, EFS and OSin Greece were comparable, albeit somehow lower, than those of the two large, cooperative, international groups (NWTSG and SIOP‐RTSG). Higherenrolment rates into clinical trials may have facilitated the process for the development of the clinical NARECHEM‐ST component.

### PO-463. Photodynamic Therapy in the Multimodal Treatment of Wilms Tumor in Children {#pbc27455-sec-6930}

[N. Rostovtsev]{.ul} ^1^, V. Polyakov^2^, E. Neizvestnykh^3^, S. Kovalenko^4^

*^1^Chelyabinsk Regional Children Hospital, Surgery, Chelyabinsk, Russia; ^2^N.N. Blokhin Russian Cancer Research Center, Institute of Pediatric Oncology and Hematology, Moscow, Russia; ^3^South Ural State Medical University, Pediatric Surgery, Chelyabinsk, Russia; ^4^Chelyabinsk Regional Children Hospital, Pediatric oncology and haematology, Chelyabinsk, Russia*

**Background/Objectives**: Photodynamic therapy (PDT) use has recently been of great importance for Wilms tumor (WT) treatment at advanced stage of the disease. The aim of our study was to determine optimal PDT regimens with radochlorine photosensibilizator during intraoperative radiation of nephroblastoma in children.

**Design/Methods**: 24 patients with the diagnosis of III‐IV stage WT received PDT treatment in our clinic.

Median age of the whole group was 1,8 years. PDT was performed intrasurgically after tumor removal. Laser output was 2,5 W. During treatment laser power density was from 0,1 to 0,8 W/cm^2^. Different doses of light energy were used -- from 150 to 400 J/cm^2^, radiation dose was increased (300‐500 J/cm^2^) for tumors with deep infiltrative growth.

Injected photosensibilizator amount was 0,6‐0,8 mg/kg. Exposure time depended on tumor size and changed from 10 to 30 min. The lightguide with microlens at the end was used for tumor irradiation.

**Results**: PDT effectiveness evaluation was performed according to the following criteria: complete local tumor recurrence absence; no visual (according to ultrasound examination) and palpation signs of tumor growth; local recurrence in 6 months; without effect -- tumor growth extension during early postoperative period according ultrasound measures. PDT direct results evaluation was performed for 6 months. This period was sufficient for tumor recurrence revealing. There was no tumor recurrence in 21 (87,5%) patients, the recurrence was revealed in 3 (12,5%) children. There were 3 recurrences in patients with generalized WT. In such cases repeated PDT courses were not performed because of tumor extension. There were 14 patients with the recurrence of the disease from 6 months to 3 years that had no follow‐up examination for this period.

**Conclusions**: Our study shows PDT high therapeutic efficiency in children with Wilms tumor at the advanced stage. However in 87,5% of children there was no tumor recurrence for 3 years.

### PO-464. Simple Renal Cysts in a Patient of Ambiguous Genitalia: Precursor to Wilms Tumor!! {#pbc27455-sec-6940}

[R. Samujh]{.ul} ^1^, N. Peters^1^, S. Pattanshetti^1^, M.A. Malik^1^

*^1^Post Graduate Institute of Medical Education and Research‐ Chandigarh, Pediatric Surgery, Chandigarh, India*

**Background/Objectives**: Wilms' tumour (WT) is the commonest paediatric renal tumour and occurs in association with various predisposing syndromes, genetic abnormalities and clinical malformations. Renal cysts are rarely seen in the paediatric population, with a frequency of 0.22% and rarely have neoplastic potential.

**Design/Methods**: Case report

**Results**: A 6 months old infant presented with a small phallus with peno‐scrotal hypospadias and bilateral undescended testes for which laparoscopic orchiopexy was done at the age of one year after androgen stimulation. Post up follow up was uneventful. At age of 2 years child presented with painless hematuria, fever and abdominal lump. On evaluation there was Wilms\' tumor arising from lower pole of right kidney. Retrospective evaluation of previous MRI showed small simple renal cysts in lower pole of right kidney. Subsequently the patient had developed tumor at the same site. Patient was managed with modified SIOP protocol and a radical nephro‐ureterectomy was performed after preoperative chemotherapy. Histopathology showed triphasic Wilms\' tumor, predominantly mesenchymal component. The patient is doing well at 1.5 year of follow up.

**Conclusions**: We suspect cortical renal cystic lesions are associated with Wilms\' tumor and may be regarded as tumor precursor specially when associated with risk factors like genitourinary malformations. Patients should be followed up with frequent ultrasonography imaging atleast till the age of 5 years. There should be a high index of suspicion in such clinical settings.

### PO-465. Wilms Tumor Misdiagnosed Initially as Metanephric Adenofibroma {#pbc27455-sec-6950}

[Y. Sarin]{.ul} ^1^

*^1^Maulana Azad Medical College‐ New Delhi‐ India, Pediatric Surgery, New DElhi, India*

**Background/Objectives**: *Metanephric adenofibroma* (MAF) is a rare renal neoplasm which was thought to represent a well‐differentiated, mature form of *Wilms*\' *tumor (WT)*.

**Design/Methods**: A 5‐year‐old girl presented with a right‐sided abdominal mass of 7‐month duration. CECT showed right renal mass and sub‐centrimetric peripheral left pulmonary metastases. Tru‐cut biopsy gave differential diagnoses of mesenchymal variant of WT and cellular mesoblastic nephroma. Considering it to be Stage IV WT, she received 6 cycles of AVD chemotherapy. Post chemotherapy CECT showed complete resolution of lung nodules with no significant change in size of renal mass. She underwent right nephroureterectomy (R~0~ resection) with lymph node sampling. Final histopathology (HPE) was reported as MAF. Keeping benign nature of tumor in mind, no postoperative chemotherapy was administered, and she was kept on close follow‐up. Two years after the initial presentation, she presented with a large local recurrence. CECT revealed 10.8cX8.2X7cm hypodense mass lesion in the right renal fossa, abutting right psoas, inferior border of liver and gall bladder, with loss of fat planes and encasement of aorta; there were no lung metastases. The pathologists maintained that it to be MAF on review of previous HPE slides. Trucut biopsy of recurrent mass showed features of WT with chemotherapy‐induced changes. She was administered 3 cycles of 3‐weekly ICE chemotherapy. Follow‐up CECT revealed the mass having reduced dramatically to 3.1X2.1X1cm size. She underwent excision of residual mass that was totally necrotic; no lymph nodes were found. She was administered flank radiation along with a boost to the local recurrence site and 2 more cycles of IE.

**Results**: She is disease‐free for 3 weeks now and is under close surveillance.

**Conclusions**: Review of literature revealed renal tumors containing areas of MAF and WT. She should have received adjuvant therapy initially for WT regardless of the tumor\'s histology.

### PO-466. Antenatally Diagnosed Congenital Mesoblastic Nephroma that Recurred {#pbc27455-sec-6960}

[Y. Sarin]{.ul} ^1^

*^1^Maulana Azad Medical College‐ New Delhi‐ India, Pediatric Surgery, New DElhi, India*

**Background/Objectives**: Congenital mesonephric nephroma (CMN) is commonest renal tumor of early infancy. It is usually dealt with surgical excision. The management of cellular CMN, especially adjunct chemotherapy, has not been standardized yet.

**Design/Methods**: Here reported is a case of antenatal detection of a right renal mass with polypoidal and peripheral cystic components on ultrasonography at 32‐week gestation; it was associated with retroperitoneal perirenal collection ?hemorrhagic. Post‐natal CECT performed at 3 weeks of age revealed a 6.5X5.2X.4.1cm right renal mass with solid and cystic components and associated localized peri‐renal collection. He underwent right nephro‐ureterectomy at Day 26 of life elsewhere. Histopathological examination (HPE) revealed cellular atypical mesoblastic nephroma, with foci of tumors showing classical CMN features and definite diffuse infiltration of renal sinus. The tumor cells showed brisk mitosis and expressed Vimentin and cyclin D1; immunonegative for WT‐1 and CD34. He received 13 cycles of Actinomycin D and vincristine‐based chemotherapy, starting from 40^th^ post‐operative day. At the age of 4.5 months (while on chemotherapy), he developed recurrence that grew to larger than original tumor in coming 6 weeks. At 6 months of age, he was first seen at our center. Exploration revealed a large friable mass infiltrating adrenal gland, along with peri‐nephric fat and Gerota\'s fascia; R~1~ resection was done. HPE showed tumor composed of round by spindled out cells present in sheet, entrapping adrenal gland, clear to eosinophilic cytoplasm, showing brisk mitosis and cystic degeneration, suggestive of cellular CMN. He received whole abdomen radiation 10.8 Gy over 6 fractions in view of intra‐op tumor rupture and adjuvant ICE chemotherapy 6 cycles at a third center.

**Results**: He has been disease‐free for last 8 months.

**Conclusions**: AV therapy used for Wilms tumor is not an ideal chemotherapy for cellular CMN and chemotherapy used for sarcomas should be administered to infants with cellular CMN.

### PO-467. Adult Nephroblastoma in a Pediatric Oncology Unit {#pbc27455-sec-6970}

[A. Schiavetti]{.ul} ^1^, D. Cozzi^1^, C. Cappelli^1^, M.G. Mollace^1^, E. Ferrara^1^

*^1^University "Sapienza", Pediatrics, Rome, Italy*

**Background/Objectives**: Wilms tumor (WT) is extremely rare in adults and the diagnosis is usually unexpected after surgery.

**Design/Methods**: In a retrospective review of WT treated in a single center from 1990 to 2017, we selected adult patients with WT.

**Results**: Two patients (2,9%) out of 69 were adults. They were referred to our pediatric oncology unit for the management of relapse tumor.

Case 1: a 31‐year old man was referred to our pediatric oncology unit for management of an abdominal relapse two months after robotic nephron‐sparing surgery for kidney cancer, eventually turned out to be Wilms tumor. The patient was treated with preoperative chemotherapy, aggressive surgery including completion nephrectomy and removal of metastatic deposits in the omentum and parietal peritoneum, whole abdomen radiotherapy and postoperative chemotherapy. The patient is off‐ therapy, alive without disease at 3‐year follow‐up.

Case 2: a 28‐year old woman underwent open radical right nephrectomy; a diagnosis of renal cell carcinoma was made. After six years the patient presented with a lung nodule, which was resected. The histology showed an epithelial nephroblastoma. The histology revision of primary renal tumor confirmed the diagnosis of nephroblastoma. After further seven months a new lung nodule was detected and lobectomy was performed. Then, the patient was referred to our pediatric oncology unit. At present, she is well without disease seven months after surgery, under chemotherapy yet.

**Conclusions**: The need to consult a pediatric oncology center and to start postoperative treatment has to be emphasized if a nephroblastoma diagnosis was made in the urology center. Adult WT may be successfully rescued by multimodal therapy according to the pediatric guidelines also in cases with relapse.

### PO-468. Oncological and Renal Function Outcome in Children with Unilateral Wilms Tumors Treated with Nephron Sparing Surgery or Ablative Nephrectomy {#pbc27455-sec-6980}

[M. Sharma]{.ul} ^1^, R. Nerli^1^, S. Ghagane^2^, M. Hiremath^3^

*^1^Department of Urology‐ JN Medical College‐ KLE Academy of Higher Education & Research Deemed‐to‐be‐University‐ JNMC Campus‐ Belagavi‐590010‐ Karnataka‐ India., Department of Urology, Belagavi, India; ^2^Department of Urology‐ KLES Kidney Foundation‐ KLES Dr. Prabhakar Kore Hospital & M.R.C‐ Belagavi‐590010‐ Karnataka‐ India., Department of Urology, Belagavi, India; ^3^Department of Biotechnology and Microbiology‐ Karnatak University‐ Dharwad‐580003‐ Karnataka‐ India., Department of Biotechnology and Microbiology, Dharwad, India*

**Background/Objectives**: In this present study we have prospectively assessed the oncological outcome as well as the renal functional outcome in children with unilateral localized Wilms tumor (WT) treated with either nephron sparing surgery (NSS) or ablative nephrectomy.

**Design/Methods**: Children presenting with unilateral Wilms tumor during the period Jan 2006 to Dec 2015 were prospectively randomized to undergo either ablative (simple/radical) nephrectomy or nephron sparing surgery. Treatment was administered to children according to the SIOP protocol 2001.

**Results**: During the study period thirteen children underwent ablative nephrectomy, whereas the remaining 15 underwent nephron sparing surgery. The opposite kidneys were normal on USG and CT. The mean age at intervention was 44.8±16.7months. Eight children had stage I disease and the remaining had stage II disease. The mean follow‐up period was 53.6823.82 months and all children were alive at the last follow‐up. Event free survival was 100% in children undergoing NSS, whereas it was 92.3% in children undergoing ablative nephrectomy. All children were alive with clinically no evidence of the disease at the last follow‐up. The children undergoing ablative nephrectomy had significantly higher mean systolic and diastolic blood pressure, as well as significantly higher mean value of serum creatinine compared to children undergoing NSS.

**Conclusions**: In children with unilateral Wilms tumors, the oncological outcome of nephron sparing surgery was as good as ablative nephrectomy. NSS minimizes the loss of renal function.

### PO-469. Wilms Tumor: A Single Center Experience {#pbc27455-sec-6990}

[H.G. Tanyıldız]{.ul} ^1^, N. Tacyildiz^1^, H. Dincaslan^1^, E. Unal^1^, G. Yavuz^1^, T. Soygur^2^, M. Cakmak^3^, D. Kankaya^4^, S. Fitoz^5^, S. Akyürek^6^

*^1^Ankara University Medical Faculty, Pediatric Oncology, Ankara, Turkey; ^2^Ankara University Medical Faculty, Pediatric Urology, Ankara, Turkey; ^3^Ankara University Medical Faculty, Pediatric Surgery, Ankara, Turkey; ^4^Ankara University Medical Faculty, Pathology, Ankara, Turkey; ^5^Ankara University Medical Faculty, Radiology, Ankara, Turkey; ^6^Ankara University Medical Faculty, Radiation Oncology, Ankara, Turke*y

**Background/Objectives**: Recently, successful treatment approaches have reached 95% in early stages of Wilms tumor.

**Design/Methods**: A total of 32 Wilms tumor patients who were followed up Pediatric Oncology at Ankara University between 2002‐2018 were retrospectively evaluated.

**Results**: Male and female ratio was 19 / 7 and the age median age was 4 years. Bilateral Wilms tumor was seen in three patients. One patient had bilateral cryptorchidism, one patient had bilateral aniridia, without any kidney anomaly. Abdominal mass (n=18,56%), abdominal pain (n=10,32%), hematuria (n=3,9%) and hypertension (n=1,3%) were seen at diagnosis. Patients were evaluated according to the SIOP staging system (stage, I‐II (n=9), III‐IV (n=20), V (n=3)). Doxorubicin was added to patients with lung metastases. In three patients, there was a tumor thrombus in the VCI and the thrombus was found to extend to the right atrium and was resorbed by chemotherapy. Three of the cases had spontaneous rupture during the diagnosis. Unilateral patients underwent radical nephroureterectomy while total nephrectomy with unilateral conservative surgery performed to bilateral patients. For surgical staging, sampling of paracaval, paraaortic, and renal hilus lymph nodes was performed. Tissue specimens were evaluated for anaplasia and was seen in four patients. 1080 cGy was applied to the tumor site and 1050 cGy was applied to the lung metastases. The follow‐up period was 1‐16 years (median = 5 years). Six patients with advanced clinical stage died due to refractory disease. One of them died although he received İCE combined with tyrosine kinase inhibitors and anti‐VEGF. In other refractory cases, carboplatin and paclitaxel chemotherapies were also added. One case was lost because of progression during the autologous transplant preparation regimen. Our survival rate was 82%

**Conclusions**: Developing countries still diagnose Wilms tumor cases in advanced stage. It is very important to follow up Wilms tumor in experienced clinics to obtain successful and long‐term results.

### PO-470. Somatic TP53 Mutations are Detectable in Circulating Tumour DNA from Children with Anaplastic Wilms Tumours {#pbc27455-sec-7000}

[T. Treger]{.ul} ^1^, T. Chagtai^2^, R. Butcher^3^, G. Cresswell^4^, R. Al‐Saadi^2^, C. Roberts^3^, R. Williams^2^, J. Brok^5^, N. Luscombe^4^, K. Pritchard Jones^5^, W. Mifsud^6^

*^1^UCL Great Ormond Street Institute of Child Health‐ The Francis Crick Institute, Developmental Biology and Cancer‐ Bioinformatics and Computational Biology Laboratory, London, United Kingdom; ^2^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer, London, United Kingdom; ^3^London School of Hygiene & Tropical Medicine, Clinical Research Department‐ Faculty of Infectious and Tropical Diseases, London, United Kingdom; ^4^The Francis Crick Institute, Bioinformatics and Computational Biology Laboratory, London, United Kingdom; ^5^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer‐ Department of Paediatric Haematology and Oncology, London, United Kingdom; ^6^UCL Great Ormond Street Institute of Child Health, Developmental Biology and Cancer‐ Department of Histopathology, London, United Kingdom*

**Background/Objectives**: Diffuse anaplastic Wilms tumour (DAWT) is a rare, high‐risk subtype that is often missed on needle biopsy. Somatic *TP53* mutations are found in approximately 60% of cases and have been associated with poorer survival, particularly in advanced stage disease. Detection of circulating *TP53* could aid earlier diagnosis of anaplastic tumours when pre‐operative chemotherapy is commenced without histological confirmation, the standard management for childhood renal tumours in countries that follow SIOP guidelines.

**Design/Methods**: All patients with a diagnosis of WT were enrolled in the UK‐wide IMPORT study. Patients were treated according to SIOP WT 2001. Normal kidney and multi‐sampled tumour tissue were collected at surgery, whilst blood and urine were collected at up to five treatment time points. We assessed *TP53* status in frozen tumour, matched germline DNA and circulating tumour DNA (ctDNA) from plasma, serum and urine. In 10 patients with DAWT, *TP53* status was determined with Sanger and targeted sequencing. Droplet digital Polymerase Chain Reaction (ddPCR) was then employed to evaluate 21 ctDNA samples from 4 patients with DAWT and variant *TP53*.

**Results**: Mutant *TP53* was detectable in ctDNA from plasma and serum in all patients. We did not detect variant *TP53* in the same volume (200 μL) of urine. One patient displayed heterogeneity of *TP53* in the tumour, despite both sections displaying anaplastic histology. Concentration of ctDNA from plasma/serum taken pre‐nephrectomy varied significantly between patients, ranging from 0.44 (0.05‐0.90) to 125.25 (109.75 -- 140.25) copies/μL. We observed variation in ctDNA throughout treatment and in all but one patient, who relapsed 339 days post‐operatively, ctDNA levels fell following nephrectomy.

**Conclusions**: Our results are the first to demonstrate that ddPCR is an effective method for detection of mutant *TP53* in ctDNA from children with WT, even when there is intra‐tumoral somatic heterogeneity or low burden disease.

### PO-471. Identification of BCOR Internal Tandem Duplication in Circulating Tumor DNA from Children with Renal Tumors {#pbc27455-sec-7010}
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**Background/Objectives**: Optimized multimodal therapy based on pathological subgroup is essential to improve outcome of pediatric renal tumors. However, biopsy of tumor to obtain diagnostic samples is not routinely performed, considering a risk of spillage of tumor cells. On the other hand, recent studies revealed that internal tandem duplication (ITD) of *BCOR* is a genetic hallmark of clear cell sarcoma of the kidney (CCSK), for which intensive chemotherapy and radiotherapy is indicated. Here we show "liquid biopsy" can make a diagnosis of CCSK by identification of *BCOR*‐ITD from cell free DNA (cfDNA) from plasma of children with renal tumor.

**Design/Methods**: We extracted cfDNA from plasma of three children with renal tumors before treatment. Two cases with CCSK (one was stage I and the other was stage II), and one case with nephroblastoma. We performed PCR using ITD‐specific primers to detect *BCOR*‐ITD from cfDNA.

**Results**: *BCOR*‐ITD was detected in both of the CCSK cases, while it was negative in the nephroblastoma case as well as normal control. The duplicated sequences amplified from cfDNA contained the consensus sequence as previously reported in CCSK.

**Conclusions**: The liquid biopsy method could provide preoperative diagnosis of CCSK by identification of *BCOR*‐ITD in cfDNA, even though the cases were non‐metastatic early stage. This less‐invasive approach enables diagnosis of CCSK without a risk of tumor rapture. Furthermore, the detection of *BCOR*‐ITD in cfDNA might be useful for other *BCOR*‐ITD positive tumors.

Solid non Brain Tumours ‐ Bone Tumours {#pbc27455-sec-7020}
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**Background/Objectives**: Despite advances in multimodal management, survival rates for patients with Osteosarcoma (OS) presenting metastases at diagnosis remain at 20%. Dysregulation of the developmental regulators Homeobox (HOX) has been associated with tumor growth and progression. Unanimously, upregulated HOX genes found in cancer are canonically expressed during development and/or in undifferentiated cells, whereas those that are downregulated are normally expressed in differentiated tissues. Interestingly, HOXA and HOXD gene clusters are responsible for the development of bone tissue and specifically, altered HOXD10 expression results in defects in the hind limbs of mice. Herein, we aimed to investigate the expression levels of HOXD10 in pediatric OS and their association with clinical parameters.

**Design/Methods**: HOXD10 mRNA levels were studied through Taqman^®^‐based RT‐qPCR (\# Hs00157974_m1) in 25 consecutive primary OS samples and compared with normal bone (n=12) and primary osteoblast cultures (n=9). Immunohistochemical reactions were performed on 48 OS samples with Abcam^®^ antibody and detection kit (ab172865 and ab80436, respectively) and analyzed through the IHC Image Analysis Toolbox for ImageJ^®^.

**Results**: HOXD10 mRNA is scarcely expressed in non‐neoplastic tissue while highly expressed in tumor samples (fold change 41.8; P=0.00018). Highly positive immunostaining was verified in all tumor samples though in 65% positivity was focal. Paradoxically, lower HOXD10 expression and focal staining were associated with higher tumor volume (P=0.0388 and P=0.0164, respectively), while lower expression among samples with diffuse immunostaining was associated with death (P= 0.0194) and global survival (P=0.02). No correlations with tumor relapse, HUVOS grade, or metastasis were found.

**Conclusions**: High levels of HOXD10 suggest that its dysregulation is a common feature of OS and might contribute for tumor establishment. However, as seen by others, its expression may fluctuate and influence tumor prognosis. Considering HOXD10 pleiotropic nature, the identification of its targets may reveal useful biomarkers or novel therapeutic targets.
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**Background/Objectives**: In low and middle‐income countries (LMIC), Osteosarcoma and Ewing sarcoma (O&E) survival is dismal. High frequency of advanced disease at diagnosis is a major contributing factor on poor survival in LMIC. However, literature is scarce on all contributing factors in LMIC. Herein we describe outcomes of children with metastatic and non‐metastatic O&E in Cali, Colombia.

**Design/Methods**: VIGICANCER was established in 2009 ‐ with the support of Sanofi‐Espoir Foundation\'s "My Child matters program" ‐ within Cali\'s cancer registry to collect data on outcomes of patients \<19 years old with a new diagnosis of cancer treated at pediatric oncology units. Baseline and follow‐up data were collected from medical records, hospital discharge logs, pathology reports, death certificates, and the National Public Health Insurance database. Survival analyses were performed using Kaplan‐Meier. We included only O&E for analyses. Kaplan‐Meier method was used for survival analyses and Cox regression for adjusted hazards rates (HR~a~).

**Results**: From 2009 to 2017, we identified 101 Osteosarcomas and 46 Ewing from 2115 patients. Mean age was 13.1 (SD: 3.6) years old. 55% were males, 7% were afro‐descendants, and 55% had public insurance (PI). Metastatic O&E (mO&E) was 69% in the PI patients compared to 34% in the semi‐private insurance (SPI);P=0.001. Osteosarcoma and Ewing 5‐year overall survival (OS5y) was 25%(95%CI:14, 38) and 36%(95%CI:19, 53), respectively. OS5y for mO&E was 9% (95%CI:2,24), compared with 32%(95%CI:15, 60) for non‐mO&E. Treatment related mortality and abandonment was 3% and 5%, respectively. mO&E was not associated with increased mortality (HRa=0.97 (95%CI:0.89, 1.08). PI HRa was of 2.81(95%CI: 1.54, 5.1) and Afro‐descendants 3.06(95%CI:1.24, 7.53).

**Conclusions**: We found that the role of disease extension as a prognostic factor was inconsistent in our patient population, similar to data from the pre‐chemoterapy era. More research is needed to identify all contributing factors to dismal outcomes in LMIC to implement more effective treatments.
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**Background/Objectives**: The aim of this study is to evaluate patients with osteosarcoma treated at a single center and see the effect of mifamurtide treatment and compare with historic results.

**Design/Methods**: All cases of high‐grade osteosarcoma recorded between January 2012 and 2018 were reviewed. Clinical information was obtained from clinical charts during this period; 14 patients with osteosarcoma were treated according to a protocol of neoadjuvant chemotherapy with cisplatine, epirubicine and ifosfamide 3 times before and additional 3 after operation. Mifamurtide is usually used in combination with post‐operative multi‐agent chemotherapy or after chemotherapy cycles finished following resection in 8 patients.

**Results**: The median age at diagnosis was 11 years (range 5 ‐ 16). Primary tumors were located in extremity (12 leg; 8 right, 1 humerus and 1 in the axial skeleton). Surgery was limb salvage in all except axial localization and amputation was done only in 2 after relapse. A good histopathological response (\>90% tumour necrosis) was found only in 6 (6/13= %46). Seven patients relapsed (2 only from lung, 2 lung and local and 3 local). The 8 patients whom were treated with mifamurfide, 2 relapsed locally. Two patients with isolated lung recurrence were free of disease after surgical resection of metastasis whom were not treated with mifamurtide. Three cases were lost with disease.

**Conclusions**: The physician treating a patient with osteosarcoma will occasionally be faced with the dilemma of dealing with locally recurrent disease. We have a suspicion if mifamurfide usage decreasing lung relapses will increase local relapses. Analysis of this patient group is important to guide management decisions. Our historical cohort had 5‐year OS (overall survival) 57.52%. Our new cohort has 5‐year event‐free survival and OS 37.5 ± 28.8% and 68.2 ± 30.2%, respectively. Although follow‐up period was too short, addition of mifamurtide treatment to our protocol improved our OS results.

### PO-475. Pediatric Patients Diagnosed with Bone Sarcomas: A Descriptive Study of 37 Cases {#pbc27455-sec-7060}
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**Background/Objectives**: Bone sarcomas represent about 6% of all new pediatric cancer cases being osteosarcoma (OS) and Ewing sarcoma (ES) the most common ones. Patients need a multidisciplinary approach and new therapies to improve the prognosis.

Objective: Description of the characteristics of patients diagnosed with bone sarcoma in a Pediatric Oncology Unit at a tertiary hospital and enrolled in Spanish protocols.

**Design/Methods**: Retrospective analysis of the clinical, biological and radiological data of the pediatric patients diagnosed with OS and ES by SPSS.

**Results**: Thirty‐seven patients were diagnosed with bone sarcoma from January 2001 to January 2018: 16 patients with OS and 21 with ES. Median age: 11 years‐old (Range: 7.5‐13). Sex distribution: 60% boys and 40% girls. The OS and ES most common location was femur and pelvis respectively. Ten patients showed metastasis at the moment of diagnosis: 4 patients with OS and 6 with ES. Lung metastases were the most frequent. Fifty percent of patients with metastasis died. Patients were treated with chemotherapy and conservative surgery. Radiotherapy and mifarmutide were also used in some cases. Thirteen patients (35%) relapsed in less than 3 years after the diagnosis (7 with OS and 6 with ES). Nine of them had more than one relapse. Eleven patients died (5 with OS and 6 with ES). Only 2 OS patients who relapsed were alive. One of them had no evidence of disease during 11 years; the other was included in a clinical trial with lenvatinib. Thirteen patients with ES (62%) and 8 with OS (50%) were alive with no evidence of disease.

**Conclusions**: The multidisciplinary approach and conservative surgery have improved the quality of life of patients with bone tumors. However the survival rate still remains low. Therefore, the development of new targets for personalized medicine and the introduction of new drugs are needed to enhance outcome.

### PO-476. Efficacy Sulbactamcefoperazone as Empirilcal Monotherapy for Febrile Neutropenic Children with Solid Tomors and Lymphoma {#pbc27455-sec-7070}
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**Background/Objectives**: Febrile neutropenia (FEN) is one of the major causes of morbidity and mortality in patients with cancer. The clinical effectiveness of sulbactam‐ cefoperazone (SC) was demonstrated in adult FEN.. With this retrospective study, we aimed to assess the efficacy of SC as emprical monotherapy for FEN in pediatric cancer patients.

**Design/Methods**: Children with neutropenic fever (age≤18years) hospitalized at our center for lymphomas or solid tomors between 2004‐2016 were included in the study. Patients were assigned to receive SC (80 mg/kg/day, every 8 hours), reevaluated at 72 hours and in case of persistent fever, an aminoglycoside and/or a glycopeptide was added. Treatment responses was defined as success without modification, overall success or failure.

**Results**: There were 350 episodes of FEN in 157 patients (F:73, M:84, median age:11.8 years (0.6‐18)) evaluated. The most common diagnosis were osteosarcom (%35), Ewing\'s sarcoma (%30) non‐Hodgkin\'s Iymphoma (13)rhabdomyosarcoma (%7). Absolute neutrophil count and duration of neutropenia were 60/mm³ (0‐800) and 7 days (3‐60). The median time of therapy was 7 days (3‐30). Of the 350 episodes, 113 (32%) developed during induction therapy, 114(33%)in partial remission, 87 (%25) in treatment for relapsed disease, and 36 (10%) in remmission.. The origin of fever could not be detected (FUO) in 220 (63%) episodes, microbiologically documented infection (MDI) was present in 81 (23%) episodes, and infection was clinically documented (CDI) in 60 (17%). The success rate without treatment modification was 70% (244) the failure rate was 30% (106). Overall success rate was 100% as none of the patients died of infection. SC monotherapy failed in 60% of episodes with MDI, 43% of episodes with CDI. SC monotherapy was successful in 84% of episodes in which fever of origin could not be detected

**Conclusions**: Empiric SC monotherapy was found to be effective in FENepisodes with FUO, but episodes with MDI or CDI may reguire modification.

### PO-477. PARP Inhibitors are Feasible in Patients with Refractory Osteosarcoma. A Case Series of Four Patients {#pbc27455-sec-7080}
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**Background/Objectives**: Improving the antitumor activity of DNA‐damaging drugs is a captivating strategy to ameliorate current treatment options. Trabectedin binds to minor grooves of DNA inducing single‐ and double‐strand breaks that result in activation of PARP1, a first‐line enzyme in DNA‐damage response pathways. The combination of olaparib and trabectedin leads to deregulation of the DNA damage repair machinery that was shown to elicit antitumor activity in preclinical models. Additionally, osteosarcoma cells with BRCAness were found to be susceptible to PARP inhibition in combination with chemotherapy. Based on the high frequency of BRCAness in osteosarcomas we hypothesized that therapy with olaparib (PARP1/2 inhibitor) followed by trabectedin could be effective in patients with refractory osteosarcoma.

**Design/Methods**: 4 patients with refractory osteosarcoma were treated with olaparib monotherapy, followed by trabectedin or temozolomide.

Patients 1 and 2, BRCAness +, suffered from bulky disease and were treated with 2 cycles of olaparib. Patient 1 was treated with olaparib and additionally trabectedin. Patients 3 and 4, BRCAness ‐, suffered from refractory pulmonary metastases and received 2 cycles of olaparib, followed by combinations with trabectedin and temozolomide, respectively.

Olaparib was given at 400 mg/d day 1‐ 7, trabectedin at 0,5 mg/m^2^/ 3h on day 8. Temozolomide was given day 1‐5 in a dosage of 75 mg/m^2^ during first cycle and escalated if feasable.

**Results**: Therapy was tolerated well, toxicity were aplasia (grade IV) and nausea III‐IV (one patient). All patients showed progressive disease.

**Conclusions**: Therapy with PARP inhibitors in combination with chemotherapy is feasible but showed no efficacy in this very limited cohort of patients with refractory osteosarcoma including BRCAness positive tumors. The mechanism of therapy failure including the elucidation of resistence mechanisms needs to be better understood to employ this synthetic lethality approach. For further clinical application it should be considered to adapt the treatment schedule.

### PO-478. Destructive Telangiectatic Osteosarcoma with Secondary Aneurysmal Bone Cyst of Cervical and Thoracic Vertebra in a Mexican Boy: Case Report {#pbc27455-sec-7090}
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**Background/Objectives**: To report a rare case of a destructive telangiectatic osteosarcoma with secondary aneurysmal bone cyst of cervical vertebra in a Mexican child, and discuss the pathogenesis of this disease. The combination of telangiectatic osteosarcoma and aneurysmal bone cyst in the cervical and thoracic spine is rare in primary bone neoplasm. We report for their rarity and diagnostic difficulty. There is no report of this kind in our country.

**Design/Methods: Study Design**: A case report and review of previous literature are presented.

**Method**: Plain X‐rays, CT scan and MRI indicated and expansile, destructive lesion of the C6 ‐ C7 involving the body of the vertebra causing spinal cord compression.

**Results**: After operation the tumor was removed completely but he relapsed in a T1 vertebra, while they gave us the pathology report, he received treatment with chemotherapy and reduce the tumor and he had another surgery to remove completely. Actually has been no sign of tumor recurrence.

**Conclusions**: We report a rare case of destructive telangiectatic osteosarcoma with secondary aneurysmal bone cyst of the cervical and thoracic vertebra in a child in Mexico, a full investigation indicated that complete resection of the tumor and chemotherapy can prevent recurrence. Long--term follow‐up is needed to declare a lifelong cure of the disease.

### PO-479. Single‐Agent Expansion Cohort of Lenvatinib and Combination Dose‐Finding Cohort of Lenvatinib + Etoposide + Ifosfamide in Patients Aged 2 to ≤25 Years with Relapsed/Refractory Osteosarcoma {#pbc27455-sec-7100}
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**Background/Objectives**: Lenvatinib is a multikinase inhibitor of VEGFR1--3 and other targets. We report emerging data from a phase 2 single‐agent lenvatinib expansion and a phase 1b dose‐finding cohort of lenvatinib + etoposide + ifosfamide in relapsed/refractory osteosarcoma.

**Design/Methods**: Patients age 2--25 years with relapsed osteosarcoma and \<2 prior VEGF‐targeted therapies received lenvatinib 14 mg/m^2^ (phase 2) or a phase 1b combination regimen (starting dose: lenvatinib 11 mg/m^2^/day + ifosfamide 3000 mg/m^2^ + etoposide 100 mg/m^2^ daily/3 days). Primary endpoints: phase 2, progression‐free survival at 4 months (PFS‐4) per RECIST v1.1; phase 1b, recommended dose. Data cutoff: October 6, 2017.

**Results**: In the phase 2 cohort (n=16), median number of cycles received was 3.0 (range, 1--9). Most common treatment‐emergent adverse events (TEAEs) were diarrhea, hypothyroidism, and proteinuria (43.8% each). Most common Grade 3/4 TEAEs were back pain and dyspnea (12.5% each). One patient discontinued due to TEAEs (myelodysplastic syndrome). 5/15 evaluable patients achieved PFS‐4; best overall rate (BOR): partial response (PR; n=1); stable disease (SD; n=7). In the phase 1b combination cohort, 7 patients received lenvatinib 11 (lenvatinib 11 mg/m2 + chemotherapy); 6 received lenvatinib 14 (lenvatinib 14 mg/m2 + chemotherapy). DLTs were: lenvatinib 11, n=1 (Grade 3 thrombocytopenia); lenvatinib 14, n=2 (Grade 4 thrombocytopenia, Grade 3 bleeding in 1 patient; Grade 2 oral dysesthesia, Grade 2 back pain, Grade 1 muscle spasms in 1 patient). Grade ≥3 TEAEs incidences were 85.7% and 66.7% in lenvatinib 11 and lenvatinib 14, respectively. No patients discontinued due to TEAEs. BOR: PR (n=1) and SD (n=5). Lenvatinib steady‐state AUC and clearance were comparable between single‐agent lenvatinib and the combination.

**Conclusions**: In the single‐agent phase 2 cohort, 5 patients on lenvatinib at 14 mg/m2 achieved PFS‐4. In phase 1b, lenvatinib + chemotherapy had a manageable safety profile. The study is ongoing.
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**Background/Objectives**: Outcome of pediatric osteosarcoma has dramatically improved over the past few decades, with an overall survival rate of 70% and 30% for patients with localized and metastatic disease, respectively.

**Design/Methods**: We retrospectively reviewed the clinical characteristics and outcome of 38 patients treated between 2001 and 2012 at a single institution in Lebanon. All patients received a uniform 3‐drug chemotherapy regimen consisting of cisplatin, doxorubicin, and methotrexate. Ifosfamide and etoposide were added to the adjuvant treatment regimen in case of metastatic disease and/or poor degree of tumor necrosis (\<90%).

**Results**: After a median follow‐up of 61 months (range: 8--142 months), patients with localized disease had a 5‐year overall and event‐free survival rates of approximately 81% and 68%, respectively, while for metastatic disease they were approximately 42%. The most common primary site was the long bones around the knee (n=34, 89.5%). Six patients (15.8%) had metastatic disease to lungs, and three (7.9%) had synchronous multifocal bone disease with lung metastases. Adverse prognostic factors included non‐lower extremity sites, metastases, poor degree of necrosis, and delay of more than 4 weeks in local control. In bivariate analysis, only the degree of necrosis was a prognostic predictor for survival and disease recurrence.

**Conclusions**: Treatment of pediatric osteosarcoma in a multidisciplinary cancer center in Lebanon results in similar survival to that in developed countries. Delays in local control were associated with worse outcome. The only statistically significant inferior outcome predictor was the poor degree of necrosis at the time of local control.

### PO-481. PBI‐ShRNA EWS/FLI1 Lipoplex: Targeting EWS‐FLI1 Preliminary Data {#pbc27455-sec-7120}
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**Background/Objectives**: EWS is an aggressive tumor affecting AYA. Treatments combine compressed chemotherapy with surgery and/or radiation. Prognosis is poorer for patients with metastatic disease. Survival within two years of diagnosis is \<10%. The EWS‐FLI1 fusion gene t(11; 22) is the EWS cancer‐driver‐gene. Type 1 variant (60% cases) is between EWS exon 7 with FLI1 exon. We designed a pbi‐shRNA™ EWS/FLI1 Type 1 LPX which has demonstrated, preclinical safety/efficacy. The pbi‐shRNA strategy silences target gene expression.

**Design/Methods**: Phase I Study 3x3 escalation to determine the safety and MTD. Testing pbi‐shRNA™ EWS/FLI1 LPX (starting at 0.04 mg/kg) on patients (≥age 8) with advanced EWS Type 1 translocation. Intravenous infusion was given twice a week for four weeks with the following escalation schema: 50%→33%→25%→25%→25%. Required KPS \> 80% and adequate organ function. Cytokines induction pre and post infusion was analyzed (IL‐12, IL‐6, TNF‐alpha, IL1Ra).

**Results**: First cohort has been enrolled (17‐35 y.o.). Three patients had \>3 lines of therapy and 1 patient had refractory disease, 3 patients received a complete cycle of pbi‐shRNA™ EWS/FLI1 LPX (twice a week infusions). A total of 69 doses were given. The most prominent related toxicity has been hematological, 1 patient developed G3 neutropenia, another developed G3 anemia (required PRBC transfusion), this patient had significant bone and BM involvement. One patient received a single LPX infusion; she developed a fatal RSV pneumonia. Other reported G2 toxicities includes fatigue and headache. Evaluable patients (n3) had stable disease between 4 and 12 month before progression. One patient had sustained response (12 month), two patients are alive 13 and 11 months from last dose.

**Conclusions**: Preliminary experience supports the safety and potential efficacy of pbi‐shRNA™ EWS/FLI1 Type 1 LPX with limited toxicity. IL‐6 increase correlates with higher bi‐shRNAi EWS/FLI1 LPX infusion rate and symptoms. Two patients are alive, despite multiple previous progression.

### PO-482. Improvements in Osteosarcoma Outcomes in Sri Lanka: Lessions Learned {#pbc27455-sec-7130}

[S. Gunasekera]{.ul} ^1^, M. Somathilake^2^, P. Abeysinghe^3^

*^1^National Cancer Institute‐ Sri Lanka, Paediatric Oncology, Colombo, Sri Lanka; ^2^National Cancer Institute‐ Sri Lanka, Paedoatric Oncology, Colombo, Sri Lanka; ^3^National Cancer Institute‐ Sri Lanka, Clinical Oncology, Colombo, Sri Lanka*

**Background/Objectives**: Three year Event Free Survival (EFS) for patients with osteosarcoma in High Income Countries (HIC) exceeds 70%. In Low Income Countries (LICs) like in Sri Lanka (SL) it is much less. To improve outcomes in osteosarcoma in children 3 main initiatives were launched. Adaptation of standard high dose Methotrexate based chemotherapy protocol to treat all childhood osteosarcoma patients (2007), establishment of tumour boards (2011) to decide on treatment and adapting a febrile neutropenia treatment protocol (2011). The aim of the study was to describe the impact of the above initiatives on the outcome in the past 10 years.

**Design/Methods**: This is a cohort study where we analysed prospectively collected data of all patients treated with osteosarcoma in SL from 2011‐2014 and compared that with data extracted from clinic records of 2 periods (2007‐2011 and 2003‐2007.) Significance between differences of survival were analysed using Analysis of Variance (ANOVA)

**Results**: During periods of 2003‐06, 2007‐2010, 2011‐14, 34, 42 children 18 years or less respectively were treated for osteosarcoma in Sri Lanka. Three year EFS were 18.5%, 37%, 42% (P\<0.036). Metastatic disease at presentation were 24%, 26%, 22%. Treatment abandonment rate were 27%, 25%, 15%. Limb salvage surgery was the local treatment in 5%, 17%, 18%. Mean duration of treatment delays were 24, 18 and 12 weeks during chemotherapy and 10, 8 and 3 weeks due to surgery.

**Conclusions**: Relatively simple interventions like adaptation of standard treatment protocols, establishing tumour boards and adaptation infection control methods can improve outcomes in osteosarcoma in LICs like SL. In Sri Lanka limb salvage rate continues to be low over a decade.

### PO-483. High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with High Risk or Relapsed Ewing Sarcoma Family of Tumors: A Single Institute Experience {#pbc27455-sec-7140}

[C.R. Hong]{.ul} ^1^, I.H. Kim^2^, S.H. Park^3^, J.E. Cheon^4^, H.S. Kim^5^, S.K. Kim^6^, H.Y. Kim^7^, C.H. Kang^8^, H.J. Kang^1^, K.D. Park^9^, H.Y. Shin^1^, H.S. Ahn^1^

*^1^Seoul National University College of Medicine, Division of Hematology/Oncology‐ Department of Pediatrics‐ Cancer Research Institute, Seoul, Republic of Korea; ^2^Seoul National University College of Medicine, Department of Radiation Oncology, Seoul, Republic of Korea; ^3^Seoul National University College of Medicine, Department of Pathology, Seoul, Republic of Korea; ^4^Seoul National University College of Medicine, Department of Radiology, Seoul, Republic of Korea; ^5^Seoul National University College of Medicine, Department of Orthopedic Surgery, Seoul, Republic of Korea; ^6^Seoul National University College of Medicine, Division of Pediatric Neurosurgery, Seoul, Republic of Korea; ^7^Seoul National University College of Medicine, Department of Pediatric Surgery, Seoul, Republic of Korea; ^8^Seoul National University College of Medicine, Department of Thoracic and Cardiovascular Surgery, Seoul, Republic of Korea; ^9^Chonbuk National University Hospital, Department of Pediatrics, Chonbuk, Republic of Korea*

**Background/Objectives**: Prognosis of patients with newly diagnosed Ewing\'s sarcoma family of tumors (ESFT) has improved significantly over the last few decades. Nonetheless, long‐term survival is still below 35% in patients with high risk features. The role of high dose chemotherapy and autologous stem cell transplantation (HDCT & ASCT) for high risk and relapsed ESFT needs to be evaluated.

**Design/Methods**: A retrospective medical chart review was done on EFST patients who underwent HDCT & ASCT between September 1998 and January 2015 at Seoul National University Children\'s Hospital for metastasis at diagnosis, bulky primary tumor (\>100mL), axial/central primary site, and relapsed disease. Single transplantation was performed in earlier period with regimens MEC (melphalan, etoposide, carboplatin), TTC (topotecan, thiotepa, carboplatin), and BuMel (busulfan, melphalan). Tandem transplantations were performed in recent period with BuMel followed by modified MEC.

**Results**: Twenty‐one patients diagnosed at median age of 8.7 years underwent conventional chemotherapy, radiation and/or surgery and HDCT & ASCT in complete response (n=14) or partial response (n=7). Overall survival was 70.0% at median 3.6 years and event free survival (EFS) was 55.0% at median 2.9 years from off‐treatment. EFS of recipients of single transplantation with MEC (n=11), TTC (n=1), and BuMel (n=4) was 54.5%, 0.0% and 75% respectively. EFS of recipients of tandem transplantations (n=5) was 50.0%. Seven patients relapsed at median 6.6 months from off‐treatment; after further chemotherapy, 5 died of disease and 2 are alive without disease. One patient developed acute myeloid leukemia at 17.8 months from off‐treatment and is alive without disease after chemotherapy, haploidentical stem cell transplantation, and donor lymphocyte infusions. One patient died of transplantation related mortality.

**Conclusions**: HDCT & ASCT may be a promising treatment option for high risk or relapsed ESFT. Further refinements may be needed to identify the optimal regimens for HDCT & ASCT.

### PO-484. Ewings Sarcoma of Proximal Phalanx of Last Digit in a Six Year Old Boy {#pbc27455-sec-7150}

[R. Ismail]{.ul} ^1^, H. Salleh^2^, U. Uparkar^2^, E. Ross^2^

*^1^Pediatric Oncology, Leicester, United Kingdom; ^2^Leicester Royal Infirmary, Paediatric, Leicester, United Kingdom*

**Background/Objectives**: Ewings sarcoma, mesenchymal cell tumour is the second most commonest malignant primary bone tumour of childhood and adolescent.^1^ The tumour is extremely rare in hand accounting less than 1% ^2^, when affected metacarpals are the commonest. There are around 15 cases reported in literature past 7 decades.^3^ The most affected finger being thumb and most affected phalanx is proximal phalanx. Most of these patients have received multimodal therapy with most of them being alive with median follow‐up of 10 months. The median time from symptomatology to diagnosis reported is 2‐5 months. In unusual site this duration is up to 3 years.^4^

**Design/Methods**: Six year old boy, right handed presented with swelling in his proximal phalanx of his little finger for around 18 months. Initially he was under regular surveillance of dermatology for a presumed diagnosis of hemangioma. There was swelling noted later last year which warranted further investigation. He underwent excision biopsy, histology reveled Ewings sarcoma with EWI‐FLI gene mutation. He underwent staging work up. He was found to have localized disease which was completely excised. He has started adjuvant chemotherapy as per EUROEWINGS‐99. He is planned for ray amputation post Induction.

**Results**: Patient had post‐operative MRI revealed no involvement of bone or any extra axial soft tissue lesion. PET scan revealed local metabolic activity only. He is currently still in induction and has received 5 cycles of VIDE.

**Conclusions**: The five year survival for localized Ewings sarcoma is almost in the tune of 80%5 but to achieve that we have to diagnose patient in timely manner and institute multimodal therapy. Although finger is very rare site for Ewings sarcoma, it should be considered in differential diagnosis.

1\. Jerome J Eur J hand Surg Eur

2\. Mohan J Radiol Imaging.

3\. S Baccari J. OTSR.

4\. MA Gokalp J Clin Imaging Sci

5\. MA Smith Cancer

### PO-485. High‐Dose Chemotherapy (HDCT) with Autologous Hemopoietic Stem Cell Transplantation (auto‐HSCT) in Children and Young Adults with Ewing Sarcoma Family Tumors (ESFT), a Single Center Experience {#pbc27455-sec-7160}

[T. Iukhta]{.ul} ^1^, I. Kazantsev^1^, P. Tolkunova^1^, A. Gevorgian^1^, A. Kozlov^1^, T. Andreeva^1^, E. Morozova^1^, Y. Punanov^1^, L. Zubarovskaya^1^, B. Afanasyev^1^

*^1^High‐dose chemotherapy HDCT with autologous hemopoietic stem cell transplantation auto‐HSCT in children and young adults with Ewing sarcoma family tumors ESFT‐ a single center experience, Bone Marrow Transplantation Department for Pediatric Solid Tumors, Saint‐Petersburg, Russia*

**Background/Objectives**: While current dose‐intense treatment protocols allow achieving 70‐80% survival in localized ESFT patients, the long‐term survival in high‐risk cases is still unsatisfactory. Although there is a considerable body of data on high‐dose consolidation the real effectiveness and optimal indications for this option are still not completely clarified. Therefore, a large prospective cohort analysis is still necessary.

**Design/Methods**: The whole cohort includes 70 consecutive high‐risk ESFT patients with median age of 12 (range 1‐23) years receiving HDCT with auto‐HSCT in 2007 to 2017 after obtaining 1^st^ (n=26) or 2^nd^ (n=3) CR, PR (n=34), or stable disease (n=7). The high‐risk features included lung (n=50), bone (n=23) or bone marrow (n=10) involvement, inadequate local control in primary axial tumors (n=50), large lesions volume or poor treatment response (n=51), and chemosensitive relapse (n=8). Most patients had several risk factors. Disseminated disease patients were also evaluated according to prognostic score by R.Ladenstein et al. In most cases Bu‐Mel HDCT was used, 3 relapsed patients received tandem HSCT with second thiotepa‐based regimen.

**Results**: The median observation time was 36 (range 3‐122) months. The 3‐year overall (OS) and event‐free (EFS) survival were 57.3% and 54%, accordingly. At present, 41.2% of patients are alive and 39.3% of them remain in remission. Therapy toxicity was acceptable with CTC Gr III‐IV tocivity observed in 35.7% of cases and one toxic death. Most important outcome predictors were inadequate local control in chemoresistant cases, high prognostic score value and initial bone marrow involvement in patients with disseminated disease (р\<0.01) with all but one very high‐risk patients dying within 18 months post‐HSCT.

**Conclusions**: While Bu‐Mel HDCT with auto‐HSCT may still be a feasible option with acceptable toxicity for chemosensitive patients with inadequate local control and some primarily disseminated cases it is ineffective in primary resistant or very high‐risk metastatic patients.

### PO-486. Osteosarcoma with Central Nervous System (CNS) Metastases: 64 Cases from the Cooperative Osteosarcoma Study Group (COSS) {#pbc27455-sec-7170}

[E. Koustenis]{.ul} ^1^, C.O.S.S. Cooperative Osteo Sarcoma Study^1^

*^1^Stuttgart Cancer Center‐ Klinikum Stuttgart‐ Olgahospital, Pediatrics 5 Oncology‐ Hematology‐ Immunology, Stuttgart, Germany*

**Background/Objectives**: In osteosarcoma (OS), CNS‐involvement is considered rare and associated with widely disseminated disease. Literature is limited to case reports or small series.

We sought to evaluate presentation, treatment and prognosis of OS CNS‐metastases.

**Design/Methods**: CNS‐metastases of primary high‐grade OS from the COSS Registry (4,038 OS, 1977‐10/2017) arising at any time during the disease course were analyzed for patient‐, tumor‐ and treatment related factors and outcomes.

**Results**: While COSS protocols never included routine CNS imaging, we identified 64/4,038 OS to have caused CNS‐metastases (1.6%). Median patient‐age was 15.8/18.5yrs at OS diagnosis/CNS involvement, respectively. 62/64 OS (97%) were located in an extremity, 20/64 (31%) had primary metastases, mostly pulmonary. At initial OS‐presentation, all 64 patients received chemotherapy, 58/64 (91%) achieved a complete surgical remission.

Three/64 CNS‐metastases (5%) were detected at initial OS‐diagnosis, 61/64 (95%) at 1st or subsequent progression/recurrence. 47/64 were noticed because of symptoms, 3/64 (5%) were chance findings upon imaging, 14 unknown. Metastases were limited to CNS in 19/64 (30%), combined with extra‐CNS sites in 45/64 (70%). CNS‐metastases themselves were solitary in 34/64 (53%), multiple in 30/64 (47%). Treatment included CNS‐metastasectomy in 26/64 (41%, 20 complete, 6 incomplete), irradiation (dose‐range 4‐60Gy) in 29/64 (45%; 14 with surgery, 15 radiotherapy only), chemotherapy in 20/64 (31%). Twenty/64 patients achieved a surgical remission in the CNS, 14/64 of all involved sites.

After a median follow‐up from first CNS‐involvement of 18.3 months (range: 0‐88), only 2/64 were alive (0.2, 6.6 yrs), 62/64 had died (59 OS, 1 suicide, 2 unknown). 1/2/5 year actuarial overall‐survival was 19%/8%/5%. Number of CNS‐metastases, surgical remission status, chemotherapy, and radiotherapy correlated with prognosis in uni‐ and multivariate analyses.

**Conclusions**: CNS‐metastases of OS can arise at any time during the disease course. While this largest reported series found treatment to correlate with survival expectancies, overall outcome remained dismal.

### PO-487. Osteosarcoma Animal Model Using Humanized NOD‐SCID IL‐2R Null (NSG) Mice {#pbc27455-sec-7180}

[J.A. Lee]{.ul} ^1^, Y. Ko^2^, H.M. Kim^3^

*^1^Korea Cancer Center Hospital, Department of Pediatrics, Seoul, Republic of Korea; ^2^Korea Cancer Center Hospital, Division of Radiological Science and Clinical Study, Seoul, Republic of Korea; ^3^Yonsei University Wonju College of Medicine, Department of Pediatrics, Wonju, Republic of Korea*

**Background/Objectives**: The humanized mice represent a powerful *in vivo* model to study the human hematopoiesis, the interaction between human immune system and cancer. In this study, we aimed to establish a humanized osteosarcoma model using NSG mice.

**Design/Methods**: A 3 to 4‐week‐old NSG mice (Jackson Laboratory, USA) were conditioned with 25mg/kg busulfan (*Korea Otsuka* Pharmaceutical, Korea), and human umbilical cord blood (UCB)‐derived CD34^+^ cells (1x10^5^ cells/mice) were injected into the retro‐orbital sinus. Seven or 17 weeks after human UCB‐derived CD34^+^ cell transplantation, KHOS‐NP osteosarcoma cells expressing luciferase (KHOS/NP‐*luc*) were injected into the knee joint (orthotopic, 1x10^5^ cells) or thigh (heterotopic, 1x10^6^ cells) of the humanized NSG mice. Tumor growth was monitored by size measurement and luminescence imaging.

**Results**: The bone marrow and spleen of the NSG mice were analyzed for hCD45+ expression 9‐, 11‐ and 21 weeks after human UCB‐derived CD34+ cell transplantation. The engraftment rate of hCD45+ were 83.7% (9th week), 74.2% (11th week) and 78% (21th week) in the bone marrow, and 23.4% (9th week), and 53.9% (21th week) in the spleen, respectively. The expression level of hCD3+ was 0.11% (21th week) in the bone marrow, and 2.92% in the spleen. The hCD19+ level was 0.06% (9th week) and 1.03% (11th week) in the bone marrow. The growth of KHOS/NP‐*luc* tumor was monitored for 30 days after tumor implantation, using *in‐vivo* Xtreme imaging (Brunker, USA). We observed that NSG mice implanted with KHOS/NP‐*luc* cells at 7th week after CD34+ cell transplantation showed faster tumor growth and metastatic tumor spread to the liver and lung, than mice implanted with KHOS/NP‐*luc* cells at 17th week.

**Conclusions**: This was a pilot study to establish a humanized osteosarcoma mice model, and more sophisticated modifications are necessary to enhance the human cell engraftment and to detect early tumorigenesis.

### PO-488. Lymphocyte‐Monocyte Ratio at Day 14 of First Cisplatin‐Doxorubicin Chemotherapy is Associated with Treatment Outcome of Pediatric Patients with Osteosarcoma {#pbc27455-sec-7190}

[J.A. Lee]{.ul} ^1^, S.K. Kim^2^, H.M. Kim^3^

*^1^Korea Cancer Center Hospital, Department of Pediatrics, Seoul, Republic of Korea; ^2^Inha University Hospital, Department of Pediatrics, Incheon, Republic of Korea; ^3^Yonsei University Wonju College of Medicine, Department of Pediatrics, Wonju, Republic of Korea*

**Background/Objectives**: Leukocyte count in peripheral blood is associated with survival in adult patients with cancer. We aimed to determine its prognostic significance in pediatric patients with osteosarcoma.

**Design/Methods**: We retrospectively reviewed the medical records of 27 pediatric osteosarcoma patients treated at Korea Cancer Center Hospital between May 2002 and March 2016. Pretreatment and day 14 of first cisplatin‐doxorubicin chemotherapy leukocyte counts (lymphocyte, neutrophil, and monocyte) and lymphocyte‐monocyte ratio (LMR) were evaluated. Patients were divided into 2 groups using the median value of these parameters, and survival rates were compared.

**Results**: The median age of the 27 patients (9 female and 18 male) was 9.9 years (range, 3.2‐14.1 years). The tumor sites were distal femur (n=14), proximal humerus (n=7), proximal tibia (n=2), proximal fibula (n=2), and elsewhere (n=2). The median pretreatment neutrophil, lymphocyte, and monocyte counts were 3,610/μL (range, 1,510‐11,020/μL), 2,320/μL (range, 1,430‐4,590/μL), and 370/μL (range, 200‐1,011/μL), respectively. The pretreatment LMR was 6.3 (range, 2.3‐21.5). The median day 14 neutrophil, lymphocyte, and monocyte counts were 580/μL (range, 40‐5,470/μL), 1,540/μL (range, 650‐2,610/μL), and 300/μL (range, 70‐890/μL), respectively. The day 14 LMR (LMR14) was 5.0 (range, 1.8‐24.9). Patients were followed for a median of 76.4 months (range, 4.5‐174.7 months), and 5‐year overall (OS) and event‐free survival (EFS) rates were 66.0±9.8% and 60.9±9.7%, respectively. Patients with a higher pretreatment lymphocyte count had better OS (90.9% vs. 46.2%, *P*=0.04) and EFS (83.9% vs. 38.5%, *P*=0.02). However, day 14 lymphocyte count was not associated with survival. While no survival difference was observed between patients grouped according to pretreatment LMR, patients with a higher LMR14 fared better than those with lower LMR14 (5‐year OS, 83.3% *vs*. 46.3%, *P*=0.04).

**Conclusions**: In addition to pretreatment lymphocyte count, LMR during chemotherapy had prognostic significance in pediatric osteosarcoma patients. Further studies involving larger cohorts are necessary to validate our findings.

### PO-489. Anthracycline‐Related Cardiotoxicity in Ewing and Osteosarcoma Patients {#pbc27455-sec-7200}

[N. Osifodunrin]{.ul} ^1^, J. Sastry^1^

*^1^Royal Hospital for Children, Oncology, Glasgow, United Kingdom*

**Background/Objectives**: Anthracyclines are included in the multi‐modal chemotherapy regimens described in the current protocols used across the UK and Europe: Euro Ewings 2012 and EURAMOS‐1 for the treatment of Ewing\'s sarcoma and osteosarcoma. Although anthracycline chemotherapy has been shown to improve the outcome of bone sarcomas they are also associated with cardiotoxicity. Cardiovascular complications are the leading non‐oncological related causes of morbidity and mortality in childhood cancer survivors. Certain risk factors associated with cardiotoxicity have been found including higher cumulative anthracycline dose, female sex, younger age at diagnosis and the presence of pre‐existing cardiovascular disease.

**Design/Methods**: A retrospective review of all patients \<18yrs diagnosed with Ewing\'s Sarcoma and osteosarcoma between 2012‐2017 was undertaken. Echocardiograms performed pre‐treatment, during treatment and after treatment were reviewed. Cardiotoxicity was graded using Common Terminology Criteria for Adverse Events v 3.0.

**Results**: 23 patients were identified, 5 patients with osteosarcoma and 18 patients with Ewing\'s sarcoma. 2 patients that died during treatment were excluded.11 were female and 10 were male. The median cumulative dose of anthracycline was 380mg/m2. The median age at diagnosis was 11.5 years. There were 2/21 patients with ejection fraction (EF) \<50% during treatment (CTCAE Grade 2). The remaining 19 patients had an EF \>60% during and post‐treatment. The range of percentage decline in EF was 5‐11% with an average of 7.7%. No patients required a dose reduction of anthracycline. No patients required treatment for cardiotoxicity.

**Conclusions**: In this small cohort, no patients treated with anthracyclines as per EURAMOS and Euro‐Ewings protocols had significant problems with cardiotoxicity. Long term follow up however, is necessary to pick up late toxicity.

### PO-490. Comparison of Response and Toxicity Between the Neoadjuvant Chemotherapy Using Methotrexate, Doxorubicin, and Cisplatin With or Without Ifosfamide in Osteosarcoma Patients {#pbc27455-sec-7210}

[M. Park]{.ul} ^1^, J.M. Kang^2^, H.Y. Ju^2^, S.Y. Park^3^, J.H. Kim^4^, H.G. Kang^4^, M. Kwon^2^, H.J. Park^2^, B.K. Park^2^

*^1^Center for Pediatric Cancer‐ National Cancer Center, Pediatric Cancer, Goyang‐si, Republic of Korea; ^2^National Cancer Center, Center for pediatric cancer, Goyang‐si, Republic of Korea; ^3^National Cancer Center, Department of Pathology, Goyang‐si, Republic of Korea; ^4^National Cancer Center, Orthopedic Oncology Clinic, Goyang‐si, Republic of Korea*

**Background/Objectives**: Histologic response to chemotherapy is an important prognostic factor in osteosarcoma. Thus we tried to develop an effective neoadjuvant regimen to obtain a better histoloigic response.

**Design/Methods**: Patients who had been treated with a high‐grade osteosarcoma at the National Cancer Center of Korea between Jan 2002 and Dec 2015 were registered. Patients received two courses of neoadjuvant chemotherapy with MAP regimen (methotrexate (M) 12 g/m², cisplatin (P) 120 mg/m², and doxorubicin (A) 75 mg/m²) or MAPI regimen (MAP plus ifosfamide (I) 9g/m²). We applied interval‐compression strategy to MAPI without lengthening a preoperative period as compared with MAP. Adjuvant chemotherapy was tailored according to the necrosis rate of resected tumor specimens. Necrosis rate and toxicity were assessed between the two groups, and a difference in outcome was also compared.

**Results**: Total of 29 patients were included; 17 patients in the MAPI group and 12 patients in the MAP group. The interval between the first day of neoadjuvant chemotherapy and surgery was 97 days in the MAPI group and 90.5 days in the MAP group (*P* = 0.19). The good histologic response (\> 90% of necrosis) was observed in 71% of the MAPI group and in 42% of the MAP group (*P*=0.04 by multivariate logistic regression analysis). Major toxicities of grade 3 or worse were not different between the two groups. Probability of progression‐free survival and 5‐year overall survival of the MAPI group were 74% and 83% (*P*= 0.64) and those in the MAP group were 50% and 75% (*P*= 0.89).

**Conclusions**: This study suggests that the addition of ifosfamide to conventional MAP therapy given in a similar duration of preoperative phase could achieve a better histologic response without a significant increase in major toxicities. Further study in a larger scale is warranted to reach a solid conclusion.

### PO-491. Development of Novel Chimeric Antigen Receptor for Osteosarcoma {#pbc27455-sec-7220}

[C. Shin]{.ul} ^1^

*^1^Niigata University, Department of Pediatrics, Niigata, Japan*

**Background/Objectives**: Survival of osteosarcoma (OS) patients is still unsatisfactory, mainly due to uncontrollable and refractory lung metastases. Immunotherapy may offer new perspectives for such high‐risk patients. Several studies have reported tremendous efficacy of chimeric antigen receptor (CAR) engineered T cells for CD19‐positive malignancies. However, targeting solid tumors by CAR have been difficult because of lack of suitable antigens and various mechanisms of immune escape including expression of immune checkpoint molecules. PD‐1 ligands are critical for cancer to evade host immunity and survive. We aimed to develop a novel CAR construct to kill OS cells by targeting PD‐1 ligands.

**Design/Methods**: We tested several OS cell lines for expression of PD‐1 ligands. We constructed several CAR constructs targeting PDL1/L2 (PD1‐CAR) by using extracellular domain of the PD‐1 from human T cell as a ligand binding domain. We investigated whether cell surface expression of PD‐1 ligands can be upregulated and then targeted by CAR‐T cells.

**Results**: T cells retrovirally transduced with PD1‐CAR were successfully expanded in the presence of anti PD‐1 blocking antibody added in the early phase of expansion culture. OS cell lines tested (SaOS2, U2OS and NOS10) expressed moderate amount of PD‐L1, and U2OS also expressed PD‐L2. PD1‐CAR‐T cells showed potent cytotoxicity against OS cell lines. To mimic and reproduce PD‐1 ligands upregulation after CAR‐T cell attack, we stimulated OS cell lines with cytokines or supernatant from co‐culture of CD19‐CAR‐T cells and Raji Burkitt lymphoma cells. This treatment induced PD‐1 ligands upregulation in all OS cell lines tested. In SaOS2 cells, expression of PD‐1 ligands was increased to 28‐fold (PD‐L1) and 6‐fold (PD‐L2), thereby enhancing cytotoxicity exerted by PD1‐CAR‐T cells.

**Conclusions**: PD1‐CAR may be a candidate of a novel therapy for OS and/or other solid tumors, as secondary CAR‐T therapy for cancer that evade after first CAR‐T cells targeting another molecule.

### PO-492. Long Term Surgical Outcome of Paediatric Vertebral Haemangiomas Presenting with Myelopathy {#pbc27455-sec-7230}

[P. SINGH]{.ul} ^1^, P.S. Chandra^2^, S. Kale^2^, D. Sawarkar^2^, A. Kumar^2^, S. Verma^2^

*^1^All India institute of medical scieces, Neurosurgery, NEW DELHI, India; ^2^All india institute of medical sciences, Neurosurgery, New Delhi, India*

**Background/Objectives**: Paediatric vertebral haemangiomas (VH) are exceedingly rare benign and highly vascular tumours of spine.. Purpose of study was to evaluate long term outcome (\> 5 years) of patients with vertebral haemangioma presenting with myelopathy treated surgically.

**Design/Methods**: Seven patients (Mean age 14.57 years, range: 12‐ 18 years,(3 females and 4 male)were treated surgically may 2007 to june 2016. Clinical/Neurological outcome was assessed using American Spinal Injury Association (ASIA) scale. Surgery consisted of intra operative bilateral transpedicular absolute alcohol injection and laminectomy at the level of pathology followed by instrumented fusion using pedicle screws and rod in 4, laminectomy with alcohol injection in 1, laminectomy with alcohol an bone cement injection in 1 and corpectomy with instrumentation in 1. Demographical, clinical, radiological, operative details and postoperative events were retrieved from hospital records.

**Results**: Myelopathy was present in all patients. The pre‐operative ASIA score was A in 5, C in 1 and D in 1 patient. All were in thoracic region on imaging study.. Post‐surgery, at mean follow up of 73.43 (range 63 to 90 months) months all patients showed improvement in power. ASIA score was E in all at last follow up.

**Conclusions**: Present study is largest series of paediatric symptomatic VH with more than 5 years follow up. Surgery tailored according to needs of patient is having good long term outcome.

### PO-493. Treatment Outcomes of Paediatrics Ewing Sarcoma Patients in a War‐Torn Country: Single Institute Experience from Iraq {#pbc27455-sec-7240}

[S. Star]{.ul} ^1^, J. Ali^2^, N. Othman^1^, S. Mohammed^1^, B. Muhsin^1^, S. Othman^1^, K. Murad^1^, K. Mohammed^1^, A. Kamal^1^, A. Gendari^1^, L. Hussain^3^

*^1^Zhianawa Cancer Center, RadiationOncology, SUlaimaniyah, Iraq; ^2^Zhianawa Cancer Center, Radiation Oncology, Sulaimaniyah, Iraq; ^3^Cross Cancer Institute, Radiation Oncology, Edmonton‐ Alberta, Canada*

**Background/Objectives**: Ewing sarcoma (ES) is a rare malignant neoplasm tumour of musculoskeletal system. It is the second most common malignant bone tumour in children and adolescent age groups. The ideal management of ES includes multimodality approaches of neoadjuvant chemotherapy, surgical resection and/or radiotherapy followed by adjuvant chemotherapy. The aim of this study is to evaluate the treatment outcomes of paediatric ES patients in our institute.

**Design/Methods**: This is a cross‐sectional descriptive study by retrospectively chart reviewing of paediatric patients (1 -- 18 years old) with proven diagnosis of ES who were managed at Zhianawa Cancer Center (ZCC) and Hiwa cancer Hospital (HCH) between 2009 through 2015. SPSS software was used for data analysis.

**Results**: A total of 31 paediatric ES patients were enrolled in this study. All of the patients received chemotherapy and radiotherapy and 14 of them (45.2%) underwent tumour resection and free surgical margins were obtained only in 8 patients (25.8%). The median age of diagnosis was 13 years. The study showed a lower survival among female patients (*p* value 0.047) and also there was poor survival between patients with tumour recurrences (*p* value ≤0.001). Furthermore, there was a significant difference between disease recurrence and mean survival time for those patients with recurrences which was 22.3 (95% CI; 16.4 ‐ 28.1) months and for those with no recurrence was 90.8 (95%CI; 60.4 ‐ 121.3) months. The 5‐year overall survival (OS) was 19%, while, 5‐year recurrent‐free survival was 34%.

**Conclusions**: The survival rate of ES in our region is much lower compared to survivals from developed countries in spite of using multimodal treatment approaches including chemotherapy, surgery and radiotherapy. The lack of multidisciplinary decision and shortage of adequate oncology facilities in our regions may partially attributed to this lower outcomes.

### PO-494. Leg Length Discrepancy in Pediatric Osteosarcoma: Impact of Surgery and Surgical Procedures {#pbc27455-sec-7250}

[Y. Taniguchi]{.ul} ^1^, N. Yamamoto^1^, K. Hayashi^1^, A. Takeuchi^1^, S. Miwa^1^, K. Igarashi^1^, H. Yonezawa^1^, Y. Araki^1^, H. Tsuchiya^1^

*^1^Kanazawa University Hospital, Orthopaedics, Kanazawa, Japan*

**Background/Objectives**: In patients with pediatric osteosarcoma, postoperative leg length discrepancy is a clinical problem. However, the impact of surgery on leg length is still unclear. The purpose of this study was to evaluate postoperative leg length discrepancy in patients with pediatric osteosarcoma and to assess the difference among the surgical procedures.

**Design/Methods**: Patients with primary osteosarcoma of the lower extremities treated at our department between 2006 and 2015 were examined; 21 patients (10 males and 11 females) aged 6--15 years were enrolled. The locations of the tumor were proximal femur (n = 2), distal femur (n = 9), and proximal tibia (n = 10). The patients were divided into femur and tibia groups based on the tumor location. Postoperative discrepancy in femur and tibia length was assessed using frontal view radiographs. Untreated bone was defined as ipsilateral femur or tibia not affected by the tumor. The differences in untreated bone length discrepancy associated with the use of frozen autograft and prosthesis were evaluated and statistically analyzed.

**Results**: The average follow‐up period was 56 (range: 15--126) months. In the femur group, the average femur length discrepancy was 4.68 (range: 0.07--20.1) cm; in the tibia group, the average tibia length discrepancy was 0.78 (range: 0.09--1.78) cm. In the femur group, the average untreated bone length discrepancy associated with the use of frozen autograft and prosthesis was 0.32 cm and 1.89 cm, respectively, and the difference was found to be significant (P \< 0.05). In the tibia group, the average untreated bone length discrepancy associated with use of frozen autograft and prosthesis was 0.62 cm and 1.36 cm, respectively, and the difference was found not to be significant.

**Conclusions**: Patients with osteosarcoma of femur may experience severe postoperative leg length discrepancy (average: approximately 4 cm). Use of prosthesis in distal femur causes shortening of the tibial length.

### PO-495. Mutational Profiling and Copy Number Analysis Suggest Homologous Recombination Deficiency in Osteosarcoma {#pbc27455-sec-7260}

[F. Yamazaki]{.ul} ^1,2^, N. Asano^3^, M. Sekimizu^1^, S. Mitani^1^, T. Kubo^1^, C. Ogawa^4^, A. Kawai^5^, A. Yoshida^6^, H. Ichikawa^1^

*^1^National Cancer Center Research Institute, Department of Clinical Genomics, Tokyo, Japan; ^2^Keio University, Graduate School of Medicine, Tokyo, Japan; ^3^National Cancer Center Research Institute, Divison of Rare Cancer Research, Tokyo, Japan; ^4^National Cancer Center Central Hospital, Department of Pediatric Oncology, Tokyo, Japan; ^5^National Cancer Center Central Hospital, Department of Musculoskeletal Oncology, Tokyo, Japan; ^6^National Cancer Center Central Hospital, Department of Pathology, Tokyo, Japan*

**Background/Objectives**: Homologous recombination deficiency (HRD), mainly due to inactivation of *BRCA1*/2, causes many structural variations (SVs) and copy number alterations (CNAs) in breast and ovarian cancer genomes. Several scoring systems of SVs and/or CNAs to estimate HRD have been developed, and these scores are now recognized as useful predictive biomarkers. Recently, a specific signature (signature 3) in base‐substitution signature analysis was found to correlate with HRD. Osteosarcoma (OS) is known to exhibit an exceptionally high number of SVs and CNAs. Thus, we assessed genomic alterations in OS from the viewpoint of HRD.

**Design/Methods**: We performed whole‐exome sequencing (WES) analysis of 53 sarcoma samples from adolescent and young adult (AYA) patients, including 5 OSs, and analyzed mutational profiles based on signatures listed in the COSMIC database using the package "Signature Estimation." Furthermore, we conducted SNP array analysis of additional 17 OSs from pediatric and AYA patients to determine the loss of heterozygosity (LOH) score (one scoring system for HRD).

**Results**: A significantly higher contribution of signature 3 was observed in 5 OSs than in the other 48 AYA sarcomas (*P* \< 0.01). LOH scores calculated from the WES data were also higher in OSs (11.0 vs. 3.0, *P* \< 0.01). The signature 3 contributions and the LOH scores were correlated in OS (*R* = 0.64). LOH scores calculated from the SNP array data were mostly high (median, 19) in 17 OSs, and were similar to those reported in breast and ovarian cancers. When these tumors were separated by response to neoadjuvant chemotherapy including a platinum agent, the LOH scores were significantly higher in good responders (at least 90% necrosis) than in poor responders (20.1 vs. 12.0, *P* \< 0.05).

**Conclusions**: Our results suggest that HRD underlies high genomic alterations in OS and that HRD scores may become predictive biomarkers for OS treatment.

### PO-496. Clinical Outcomes of Cannulation by Using a Short Hydroxyapatite Pin for Simple Bone Cysts in Long Bones {#pbc27455-sec-7270}

[H. Yonezawa]{.ul} ^1^, N. Yamamoto^1^, K. Hayashi^1^, A. Takeuchi^1^, S. Miwa^1^, K. Igarashi^1^, Y. Taniguchi^1^, Y. Araki^1^

*^1^Graduate School of Medical Science‐ Kanazawa University, Department of Orthopaedic Surgery, Kanazawa, Japan*

**Background/Objectives**: Simple bone cysts (SBCs) are benign bone tumors. However, the treatment of SBCs remains controversial because of their healing rate and the invasiveness of surgery. We defined "short" hydroxyapatite (HA) pin as a pin with a length shorter than half of the bone diameter. The purpose of this study was to evaluate the treatment of SBCs using a short HA pin.

**Design/Methods**: Between 1998 and 2017, 8 patients (6 men and 2 women; mean age, 9.6 years; age range, 4--15 years) with SBCs were treated with continuous decompression by inserting ceramic HA pins. The SBCs were located in the humerus in 6 and the femur in 2. In all the patients, minimal fenestration of the cyst wall, and curettage and multiple drilling in the cyst wall were performed, followed by insertion of the HA pin. The mean follow‐up period was 37.9 months. Radiographically, we defined two types of recurrence. One is that the recurrence cyst is in contact with the pin (central type \[C type\]), and the other is that the recurrence cyst is apart from the pin (peripheral type \[P type\]). Operating time, healing period, risk factors for recurrence, and the cure rate were evaluated.

**Results**: Five cases were in the active phase; and three, in the latent phase. Two patients had recurrences but were cured by curettage and artificial bone grafting. The final healing rate by cannulation only using a short HA pin was 75%. No reoperation was performed for a P‐type recurrence cyst. The recurrence interval of the C‐type cases was shorter than that of the P‐type cases.

**Conclusions**: In the present study, cannulation using a short HA pin for SBC in long bones was found to be a useful technique and was associated with a low rate of recurrence.

### PO-497. (A)VCP/IEV for Pediatric Ewing Sarcoma Family of Tumors -- Report of 46 Cases {#pbc27455-sec-7280}

[J. Zhang]{.ul} ^1^, J. Tang^1^, C. Pan^1^, Y. Gao^1^, J. Chen^1^, S. Shen^1^, Q. Ye^1^, M. Zhou^1^, W. Hu^1^

*^1^Shanghai Children\'s Medical Center, Department of Hematology and Oncology, Shanghai, China*

**Background/Objectives**: The Ewing\'s sarcoma family of tumors (ESFT) are high‐grade malignancy that most often occurs in children. This study aims to evaluate the efficacy of (A)VCP/IEV protocol for pediatric ESFT, and to analyze the possible prognostic factors.

**Design/Methods**: From September 1997 to November 2015, a total of 46 patients with ESFT diagnosed at our hospital were enrolled. The protocol (A)VCP/IEV which included vincristine, cis‐diaminedichloroplatinum, cyclophosphamide, etoposide, ifosfamide, adriamycin, and dactinomycin, is almost the same as for rhabdomyosarcoma. All the patients have been successfully followed up. Kaplan‐Meier methods were used to analyze survival.

**Results**: There are 26 males and 20 females, with a median age of 95 months (range, 13 to 170 months). The 3‐year and 5‐year EFS estimates were 70.1%±7.2% and 62.9%±7.6%, respectively. Patients in LR and MR group reached much better result than those in HR group, and the difference was significant. 5‐year EFS of LR and MR group is 79.4%, but HR group is only 41.9%(P=0.043). 5‐year EFS was better in patients with localized diseases than those with metastatic diseases at primary diagnosis, and the difference was also significant (77.1% vs 42.1%; P=0.016.). Declining trend with the larger size of tumor (\<8cm vs ≥8cm) was also found in 5‐year EFS, and the difference was significant (81.2% vs 40.6%; P=0.023). One patient developed second malignancy. No therapy related death was documented.

**Conclusions**: The (A)VCP/IEV protocol for ESFT is safe and efficient. High risk group, metastatic disease and larger tumor size can predict poor prognosis.

### PO-498. Treatment Results of Patients with Osteosarcoma by Implementing Modular Endoprosthesis in the Republic of Kazakhstan {#pbc27455-sec-7290}

[B. Zhumadullaev]{.ul} ^1^, B. Baizakova^1^, G. Nurzhanova^1^, Y. Krivenko^1^, K. Bertaeva^1^, G. Algazieva^1^, S. Sargelov^2^, A. Makhneva^3^, E. Kurakbaev^4^

*^1^Scientific Center of Pediatrics and Pediatric Surgery, Oncology, Almaty, Kazakhstan; ^2^Scientific Center of Pediatrics and Pediatric Surgery, Radiology, Almaty, Kazakhstan; ^3^Scientific Center of Pediatrics and Pediatric Surgery, Pathology, Almaty, Kazakhstan; ^4^Scientific Center of Pediatrics and Pediatric Surgery, Intensive Care, Almaty, Kazakhstan*

**Background/Objectives**: Proportion of osteosarcoma in children under the age of 18 in the Republic of Kazakhstan is 6‐7%. Endoprosthetic reconstruction following resection of bone has improved the quality of life of children with osteosarcoma and performed in 90% of sick children and adolescents with malignant bone tumors. The purpose of this study is to show results of using endoprosthesis in patients with osteosarcoma.

**Design/Methods**: Retrospective review of 29 patients with osteosarcoma treated in Scientific Centre of Pediatrics and Pediatric surgery between February 2013 and February 2018 was done. There were 11 (37.9%) boys and 18 (62.1%) girls, median age of patients was 11.7 years. Metastatic disease was revealed in 5 (17.2%) patients. Proximal localization of tumor was in 13 (44.8%) cases, while 16 (55.2%) patients had distal localization. Patients were treated according to Euramoss Protocol, MAP arm. For local surgical control as a method of limb salvage treatment modular invasive endoprosthesis with hydroxylapatite coating used for cement‐free fixation was performed. Limb function was assessed according to the scale of Muscular‐Skeletal Society Tumor Score.

**Results**: Types of performed limb salvage surgery: endoprosthetics of shoulder joint in 5 patients and knee joint in 24 cases. Evaluation of limb function assessed as "satisfactory" in 9 (31.0%) patients and "good and excellent" in 20 (69.0%) patients. Local relapse occurred in 1 (3.4%) patient with tumor of proximal metaphysis of humerus 5 months after therapy completion. Infection complication was observed in 1(3.4%) case, 11 months after surgery, caused by Candida famata. After successful antimycotic treatment reendoprosthetics was performed. Overall survival is 75.8%, median follow‐up 28 months (ranging from 4 to 60 months).

**Conclusions**: Endoprosthetics improved the functionality of the limb with an increase in the quality of life. At the same time, the number of infectious complications and relapses were minimal.

Solid non Brain Tumours ‐ Soft Tissue Sarcomas {#pbc27455-sec-7300}
----------------------------------------------

### PO-499. Sarcomas of the Head and Neck: About 6 Cases, Experience of the Medical Oncology Department of HASSAN II Hospital University in Fez {#pbc27455-sec-7310}

[N. Acharfi]{.ul} ^1^

*^1^M. Benhami ‐R.Boujarnija‐ L. Amaadour ‐ K. Oualla‐ Z. Benbrahim ‐ FZ Elmrabet‐ S. Arifi‐ N. Mellas, Oncology Department Hassan II University Hospital, Fez, Morocco*

**Background/Objectives**: Sarcomas of the head and neck are rare and very heterogeneous malignant tumors. The difficulty of their management requires the intervention of a multidisciplinary team to improve the prognosis. The objective of this study is to report their epidemiological, clinical, histological, therapeutic and evolutionary peculiarities.

**Design/Methods**: This is a retrospective study conducted in the medical oncology department of the HASSAN II hospital university in Fez, including patients with head and neck sarcoma stretching between January 2013 and December 2017.

**Results**: 6 cases were reported, 5 men and 1 woman, the mean age was 39 years. In order to evaluate the tumor extension, a facial CT was performed in 4 patients and MRI in 2 patients. The seat of sarcomas in 2 patients, the nasal cavity in 3 patients and the cheek in one patient. The histological types were rhabdomyosarcoma in 3 patients, leiomyosarcoma in one patient, pleomorphic sarcoma in one patient, and myxofibrosarcoma in one patient. patient. Tumor stage was localized in 4 patients and metastatic in 2 patients. Pulmonary metastases were evidenced in 2 patients. Four patients were treated surgically. Radiotherapy was performed in 4 adjuvant patients. Chemotherapy was administered in 5 patients including 3 in the neoadjuvant setting and 2 in metastatic patients. The chemotherapy protocols used were MAI in 2 patients including 1 patient in neoadjuvant situation and 1 patient in metastatic situation and VAC in 3 patients including 2 neoadjuvant patients and 1 metastatic patient. After a median follow‐up of 22 months, 4 patients remained under good control, one patient was lost to follow‐up and one patient died.

**Conclusions**: Sarcomas of the head and neck represent a relatively rare but histologically diverse group. The treatment is essentially based on the combination of surgery and radiotherapy and chemotherapy to optimize the therapeutic results.

### PO-500. Paclitaxel, Carboplatin, and Cyclophosphamide for Relapsed or Refractory Childhood Tumors {#pbc27455-sec-7320}

[B. Aydin]{.ul} ^1^, C. Akyuz^1^, M. Cemaloglu^1^, A. Varan^1^, N. Kurucu^1^, B. Yalcin^1^, T. Kutluk^1^

*^1^Hacettepe University, Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Treatment options for children with relapsed/refractory tumors are few. There are limited number of chemotherapeutic agents left after the first line regimens, and response rates are usually low. We present the outcome results of paclitaxel, carboplatin and cyclophosphamide (PaxCC) as salvage regimen for patients with relapsed/refractory tumors.

**Design/Methods**: The medical records of 38 patients who received PaxCC either alone or alternated with low‐dose VAC (vincristine, actinomycin, cyclophosphamide) regimen as 28‐day cycles were retrospectively reviewed for their demographic characteristics, responses to treatment and outcome.

**Results**: The median age was 8.5 years (ranged between 0.68‐17.4) and M:F ratio was 1.1. Histopathological diagnoses were: rabdomyosarcoma (29%), Ewing sarcoma (29%), Wilms tumor (16%), osteosarcoma (10%), other soft tissue sarcomas (8%) and yolk sac tumors (8%). PaxCC or PaxCC‐VAC was used as second, third, fourth or fifth line regimen in 29%, 60%, 8% and 3% of patients. Tumor resection was performed and/or radiotherapy to primary or metastatic sites was given as adjuvant treatment in 21 patients (55%). Patients received median 4 courses (1‐10). Objective response rate was 47% in 18 patients with best responses of CR in 5 (13%), VGPR in 5 (13%), PR in 4 (11%) and SD in 4 (11%) patients. Twenty patients (53%) had progressive disease. The median follow‐up time was 7.3 months. Overall and event‐free survival rates at first year was 49% and 29%. Patients who received PaxCC‐VAC fared better than others who received only PaxCC. Their 1‐year EFS rates were 54% and 14% (p=0.03), and 1‐year OS rates were 64% and 25% (p=0.05). The 1‐year EFS rates were 28% and 27% for patients with rhabdomyosarcoma and Ewing sarcoma.

**Conclusions**: PaxCC seems to have an impact on relapsed/refractory tumors and might be an option for salvage regimen. Paclitaxel might be more effective with VAC as alternated PaxCC‐VAC regimen.

### PO-501. Up‐to‐Date Surgical Strategy in Treatment of Soft Tissue Sarcomas {#pbc27455-sec-7330}

[I. Beder]{.ul} ^1^, M. Mikeskova^2^, P. Omanik^1^, M. Funakova^1^, R. Pechanova^1^, A. Kolenova^2^, J. Trnka^1^

*^1^National Institute of Child Diseases, Department of pediatric surgery, Bratislava, Slovak Republic; ^2^National Institute of Child Diseases, Department of pediatric hematology and oncology, Bratislava, Slovak Republic*

**Background/Objectives**: Sarcomas in children are relatively rare. It is heterogeneous group of malignancies originating from mesenchymal cells, divided into soft tissue sarcomas (STS) and bone sarcomas. STS are extrasceletal malignant tumors, classified as rhabdomyosarcoma (RMS) and non‐rhabdomyosarcoma soft tissue sarcomas (NRSTS), with multiple histological variations. The aim of our report is to present treatment strategy and outcome of our cohort with soft tissue sarcomas.

**Design/Methods**: Retrospective single centre analysis of patients treated for STS in period 2005‐2017 and a summary of the latest strategy of surgical treatment recommended by EpSSG (European pediatric Soft tissue sarcoma Study Group) was performed. Authors collected 41 patients during reviewed period. RMS group (56%) consisted of 11 males/12 females, with median age 5.5 years at diagnosis.

**Results**: Complete remission was achieved in 16 patients (5‐ years overall survival rate 69%). NRSTS group (44%) presented 8 males/10 females, with median age 16 years at diagnosis, showing 15 different histological findings. 5‐years overall survival rate was 61% with complete remission in 11 patients. 15 patients with NRSTS underwent surgery for local control. Pulmonary metastases were confirmed in 75% of patients with relapse (n=6). In 3 cases unilateral metastasectomy, in 1 patient one‐step bilateral metastasectomy was performed.

**Conclusions**: Outcome and prognosis of STS depends on time of diagnosis, presence of metastases, tumor size and extent of resection. Sarcomas, in particular NRSTS, are generally weakly sensitive to radio and chemotherapy. Therefore complete resection (R0) is the main curative therapy. Metastasectomy is indicated in all patients with pulmonary metastases even in recurrence cases. Slovakia has got approximately 5, 5 million inhabitants with pediatric population of 1,2 million children which limited the number of presented study. Thanks to participation in European Study Groups the results can contribute to evaluation of patients with such uncommon diagnosis.

### PO-502. Patterns of Failure in Paramenigneal Alveolar Rhabdomyosarcoma {#pbc27455-sec-7340}

[J. Bradley]{.ul} ^1^, R. Rotondo^1^, H. Uezono^1^, C. Morris^1^, E. Sandler^2^, D. Indelicato^1^

*^1^University of Florida, Radiation Oncology, Jacksonville‐ FL, USA; ^2^Nemours Childrens\' Specialty Clinic, Pediatric Oncology, Jacksonville‐ FL, USA*

**Background/Objectives**: The purpose of this study is to determine patterns of failure, clinical outcomes, and prognostic factors in pediatric patients with parameningeal alveolar rhabdomyosarcoma (ARMS).

**Design/Methods**: Clinical and treatment planning records of children age ≤ 21 years with parameningeal ARMS treated with definitive or adjuvant RT enrolled on an institutional prospective registry were evaluated. Nodal regions were not irradiated in N0 disease. For N1 disease, involved nodal levels were treated to 36 Gy(RBE) and involved nodes to 50.4 Gy(RBE) in sequential plans. Kaplan‐Meier product limit method assessed local and regional control, progression‐free survival (PFS), and overall survival (OS); log‐rank test was used to evaluate prognostic impact.

**Results**: Between 2009 and 2016, 24 patients with a median age of 4 years (range, 1‐20) were identified. Median follow‐up was 2 years for all patients (range, 0.3‐5.6) and 3.1 years for living patients (range, 1.3‐5.6). Most patients had Group III (96%), node negative (67%) positive FOX fusion status (54%) disease. Infratemporal fossa was the most common subsite (25%). Intracranial extension (ICE) was present in 54%. Lumbar puncture was performed in 75% and negative in all. 42% had staging PET.

All patients were treated with concurrent chemotherapy and proton RT with a median dose of 50.4 Gy(RBE) (range, 41.4‐59.4Gy(RBE)) at median week 14 (range, 3‐27). 3 year local control was 66% (all recurrences in‐field) and regional control 94%. 3 year PFS was 40% and OS 57%. Median time to any failure was 0.5 years (range, 0.2‐2.1). N1 disease and ICE were associated with inferior OS (p=0.02 and 0.03, respectively). No variables had a significant association with local control. 7 patients developed distant metastases as first site of recurrence, all leptomeningeal.

**Conclusions**: While regional failures were rare, in‐field local recurrences and leptomeningeal progression in those with ICE suggest the need for intensification of both local and CNS therapies.

### PO-503. Experience of Endoscopic Transnasal Removal of Tumors of the Nasal Cavity, Paranasal Sinuses and the Base of the Skull in Children {#pbc27455-sec-7350}

[D. Buletov]{.ul} ^1^, O. Merkulov^1^, T. Gorbunova^1^, V. Polyakov^1^

*^1^nstitute of Pediatric Oncology and Hematology N.N. Blokhin, Head and neck tumors in children, Moscow, Russia*

**Background/Objectives**: The method of endonasal surgery (ES) is used for the treatment of inflammatory diseases and for the removal of benign neoplasms of the nasal cavity, paranasal sinuses and skull base in adult patients. In pediatric onoclogy practice these method is not so common.

**Design/Methods**: From 2015 to 2017 68 endoscopic transnasal surgeries were performed in 57 patients aged 1 month to 17 years. With malignant tumors ‐ 32, with benign tumors ‐ 25. In the first group more common Rhabdomyosarcoma and estheioneuroblastoma were morphologically verified. In the second group, there was a significant variety of morphological variants of neoplasms. In the first group, 14 biopsies and 24 tumor removals (including 8 previously biopsies) were performed. In 3 cases, delayed reconstructive‐plastic surgery was performed. In the second group 27 formations were removed.

**Results**: The main complication in the removal of the tumor were intraoperative liquorrhea in 6 cases, which required the plastication of the dura mater. The follow‐up period ranged from 1 year to 4.2 years. In the first group, 26 patients were alive, 2 lost of observation, 6 died, including 5 from the progression of the underlying disease, 1 from the causes of non‐tumor and toxicity treatment. Relapses arose in 8 patients, of them alive ‐ 2. In the second group, all patients are alive, relapses occurred in 2 cases. The patients were operated again, the observation period was 9 and 14 months.

**Conclusions**: The use of ES in the complex treatment of children with malignant tumors is possible for obtaining histological material and as a method of local control. Endoscopic transnasal removal of benign tumors in children is an independent and sufficient method of treatment. The technique is safe, as it allows for improved visual control in the wound, low traumatism, shortens the recovery time of the patient.

### PO-504. Results of Surgical Treatment of Medullary Thyroid Cancer in Children and Preventive Thyroidectomy in Children with MEN2 Syndrome {#pbc27455-sec-7360}

[D. Buletov]{.ul} ^1^, R. Shishkov^1^, N. Ivanova^1^, V. Polyakov^1^, N. Koshechkina^1^, N. Kalinichenko^1^, V. Kozlova^2^, T. Kazubskaya^3^, A. Pavlovskaya^4^, O. Blisnukov^4^

*^1^Institute of Pediatric Oncology and Hematology N.N. Blokhin, Head and neck tumors in children, Moscow, Russia; ^2^National Institute of Oncology named after N.N. Blokhin, Genetics Laboratory department, Moscow, Russia; ^3^National Institute of Oncology named after N.N. Blokhin, Laboratory department, Moscow, Russia; ^4^National Institute of Oncology named after N.N. Blokhin, Patology department, Moscow, Russia*

**Background/Objectives**: Find the optimal surgical tactics for medullary thyroid carcinoma in children and the risk of developing medullary cancer as part of the MEN2 syndrome.

**Design/Methods**: From 1971 to 2018 21 patients were operated at the age of 5 to 15 years and 8 children from 2 to 15 years of age underwent surgical treatment, in connection with the risk of MTC, as part of the MEN2A syndrome, after detection of a mutation in the RET gene. Of 21 patients diagnosed before the operation of the MTC, 7 patients had MEN type 2B syndrome, 3 had MEH type 2A, and 3 familial MTC cases, in 8 ‐ sporadic cases of the disease.

**Results**: Of the 21 patients, 8 had metastases to the lymph nodes of the neck. Out of 8 patients with metastases, 4 died, 3 patients were monitored, and 1 patient disappeared from the observation. A total of 17 patients were alive, one patient disappeared from the observation, four died as a result of the progression of the disease. In 8 children ‐ prophylactic thyroidectomy, in connection with a 100% risk of MTC, as part of the MEN2A syndrome, after detection of a mutation in the RET gene. In 5 out of 8 cases, a mutation of r.C634R in 11 exon was detected, in 1 mutation of r.C634G in 11 exon, in 1 case, a germinal compound‐heterozygous mutation was found with 2556C \<G, p.I852M in 14 exon and c.2372A \< T, p.Y791F in 13 exon, in 1 case a mutation of del632‐636ins6 in 11 exon was revealed.

**Conclusions**: Treatment of MTC should be only aggressive. If a mutation in the RET gene is detected and the risk of developing the MEN 2A syndrome, preventive TE and the operation should be performed as early as possible.

### PO-505. Clinical Outcomes of Pediatric Patients with Newly Diagnosed Rhabdomyosarcoma Treated By Two Consecutive Protocols: A Single Institution Report in Taiwan {#pbc27455-sec-7370}

[S.W. Chou]{.ul} ^1^, H.H. Chang^1^, M.Y. Lu^1^, Y.L. Yang^2^, D.T. Lin^2^, K.H. Lin^1^, S.T. Jou^1^

*^1^National Taiwan University Children Hospital, Pediatrics, Taipei City, Taiwan R.O.C.; ^2^National Taiwan University Hospital, Laboratory Medicine, Taipei City, Taiwan R.O.C*.

**Background/Objectives**: Taiwan Pediatric Oncology Group (TPOG) initiated two consecutive protocols for treating pediatric patients with rhabdomyosarcoma since 1995. However, the results have not been analyzed and reported yet. The aim of this study is to investigate the treatment results of these two protocols in our hospital and to assess whether the results are comparable to other large‐scaled studies.

**Design/Methods**: Treatment of pediatric patients with rhabdomyosarcoma according to TPOG protocols at National Taiwan University Hospital began in 1995. Between 1995 and 2006, patients were treated by TPOG RMS 95 protocol, which was based on IRS‐III/IV. After 2007, patients were treated by TPOG RMS 2007 protocol which was adapted from IRS‐V study. The clinical data of patients were obtained retrospectively by reviewing medical records. The date of the latest follow‐up was December 31, 2016.

**Results**: Thirty‐seven patients were enrolled in this study. The 5‐year overall survival (OS) and event‐free survival rates of them were 54.7±8.8% and 48.5±8.6%, respectively. The 5‐year OS rates for patients treated by TPOG RMS 95 and TPOG RMS 2007 protocols were 55.0±11.1% and 55.9±14.0%, respectively. Age at diagnosis of less than ten years old and receiving operation with gross total or subtotal tumor resection were identified as independent prognostic factors that predicted better outcomes in the multivariate analysis.

**Conclusions**: The clinical outcomes of pediatric patients with rhabdomyosarcoma in Taiwan improved dramatically after incorporating two consecutive protocols from TPOG. In addition, the treatment results of these two protocols were comparable to large‐scale studies of other countries.

### PO-506. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial {#pbc27455-sec-7380}

A. Hayes‐Jordan^1^, [B. Coakley]{.ul} ^2^, H. Green^3^, L. Xiao^4^, K. Fournier^1^, J. Ludwig^5^, C. Herzog^6^, M. McAleer^7^, P. Anderson^8^, W. Huh^6^

*^1^MD Anderson Cancer Center, Department of Surgical Oncology, Houston, USA; ^2^The Mount Sinai Health System, Department of Surgery‐ Division of Pediatric Surgery, New York, USA; ^3^Children\'s Hospital of Los Angeles, Department of Pediatric Surgery, Los Angeles, USA; ^4^MD Anderson Cancer Center, Department of Biostatistics, Houston, USA; ^5^MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Houston, USA; ^6^MD Anderson Cancer Center, Department of Pediatrics, Houston, USA; ^7^MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA; ^8^The Cleveland Clinic, Pediatric Hematology Oncology and Blood and Marrow Transplantation, Houston, USA*

**Background/Objectives**: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that primarily affects adolescents and young adults. Patients can present with many peritoneal implants. We conducted a phase 2 clinical trial utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS‐HIPEC) with cisplatin for patients with DSRCT and pediatric‐type abdominal sarcomas.

**Design/Methods**: A prospective cohort study was performed on 20 patients, who underwent CRS‐HIPEC procedures, with cisplatin from 2012 to 2013. All patients were enrolled in the phase 2 clinical trial. Patients with extra‐abdominal disease and in whom complete cytoreduction (CCR0‐1) could not be achieved were excluded. All outcomes were recorded.

**Results**: Fourteen patients had DSRCT, while five patients had other sarcomas. One patient had repeat HIPEC. Patients with DSRCT had significantly longer median overall survival after surgery than patients with other tumors (44.3 vs. 12.5 months, p = 0.0013). The 3‐year overall survival from time of diagnosis for DSRCT patients was 79%. Estimated median recurrence‐free survival (RFS) was 14.0 months. However, RFS for patients with DSRCT was significantly longer than for non‐DSRCT patients (14.9 vs. 4.5 months, p = 0.0012). Among patients with DSRCT, those without hepatic or portal metastases had longer median RFS than those with tumors at these sites (37.9 vs. 14.3 months, p = 0.02). In 100% of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS‐HIPEC.

**Conclusions**: Complete CRS‐HIPEC with cisplatin is effective in select patients with DSRCT. Patients with DSRCT with hepatic or portal metastasis have poorer outcomes.

### PO-507. Role of Surgery in Diagnosis and Treatment of Inflammatory Myofibroblastic Tumors: The Bambino Gesù Children Hospital Experience {#pbc27455-sec-7390}

[A. Crocoli]{.ul} ^1^, C. Martucci^1^, C. Grimaldi^1^, A. Narciso^1^, G.M. Milano^2^, I. Russo^2^, R. Boldrini^3^, A. Di Giannatale^2^, M.D. De Pasquale^2^, A. Inserra^1^

*^1^Bambino Gesù Childrens\' Hospital IRCCS, Surgery, Rome, Italy; ^2^Bambino Gesù Childrens\' Hospital IRCCS, Oncohematology, Rome, Italy; ^3^Bambino Gesù Childrens\' Hospital IRCCS, Pathology, Rome, Italy*

**Background/Objectives**: Inflammatory myofibroblastic tumors (IMTs) are rare pediatric neoplasms, with unpredictable biologic behavior, that occur at a young age. Complete resection is the treatment of choice. Since the development of targeted therapies, the study of anaplastic lymphoma kinase (ALK) expression in these tumors, triggered by ALK gene rearrangement at chromosome 2p23, could have a potential role in disease management.

**Design/Methods**: Data of patients diagnosed and treated for IMT at Bambino Gesù Children\'s Hospital were retrospectively evaluated. Primary site of tumor, dimensions, surgical intervention and ALK expression were considered.

**Results**: Eleven patients (8 boys, median age 6.9 years: range 0.7 -- 15.1) were diagnosed with IMT, from January 2003 to December 2017. Primary neoplasm site was lung (6), omentum (3), paratesticular (1), and limb (1). Tumor\'s diameter was \< 5 cm (5 patients), \> 5 cm (4 patients), not evaluable (two patients). ALK expression was evaluated in 7 out of 11 patients, resulting positive in one case of omental IMT. All patients underwent tumor radical resection: demolitive in 6 cases (pneumonectomy n=2; omentectomy n=3, orchiectomy n=1). Three patients underwent adjuvant chemotherapy (methotrexate plus vinorelbine in 2 cases; COX‐2 inhibitors in 1 case). At a median follow up of 28.6 months (range 4‐440 months) all patients are alive and ten are disease free.

**Conclusions**: Data from this long‐term series emphasize the role of surgery as the cornerstone of treatment for pediatric IMTs. The role of targeted therapies, in ALK+ IMTs, is controversial and should be further investigated. However, in unresectable tumors, in the attempt to reduce surgical morbidity, biopsy should be performed and ALK expression evaluated.

### PO-508. Rhabdomyosarcomas in Infants Younger than 1 Year of Age. A 30 Years Experience in a Single Pediatric Institution {#pbc27455-sec-7400}

[R. Dugo]{.ul} ^1^, M.F. Gutierrez^1^, M. Cores^1^, M. Nana^1^, M. Urbieta^1^, E. De Matteo^2^, S. Colli^2^, M. Garcia Lombardi^1^

*^1^Hospital de Niños Ricardo Gutierrez, Oncology Unit, Buenos Aires, Argentina; ^2^Hospital de Niños Ricardo Gutierrez, Pathology Unit, Buenos Aires, Argentina*

**Background/Objectives**: Rhabdomyosarcoma (RMS) is the most frequent malignant subtype of Soft Tissue Sarcomas (STS). Prognosis is variable according to age, anatomopathology and staging.

To report clinical, histological and/or molecular characteristics, event‐free survival and overall survival in infants younger than 1 year with RMS treated in an institution

**Design/Methods**: We reviewed medical records of patients (p) with RMS younger than 1 year admitted to Hospital de Niños Ricardo Gutiérrez between January 1987 and December 2017.

**Results**: Of 3269 patients with solid tumors admitted, 326 (10%) were STS, 36 (11%) younger than 12 months. Twenty (6%) RMS. Three neonatal. Male / female 1.1:1. Median age 9 months (1‐12 months). Median follow‐up 2 years. Histology: 60% embryonal (1 botroid), 10% alveolar and 30% NOS. Molecular analysis: 3p, 1 with presence of FOXO 13q14 rearrangement. Staging: I 6p (26%), II 4p (17%), III 13p (56%), IV 2p (1%). Location sites: 7 head and neck, 5 limbs, 3 prostate, 2 parameningeal, 1 paratesticular, 1 retroperitoneal, 1 perineal, 1 vagina, 1 thorax and 1 bladder. Treatment: initial complete resection 7p (35%), neoadjuvant chemotherapy according to SIOP schemes 13p (65%). Local control: surgery alone 10p, radiotherapy alone 5p and surgery + radiotherapy 1p. All received adjuvant chemotherapy. Outcome: 20/23 evaluable for survival. Nine died of progressive disease and 1 for toxicity (sepsis). Relapse: 11p (7 local, 2 CNS, 2 pulmonary). Two were rescued with chemotherapy, surgery and radiotherapy, and remain disease free at 1 and 8 years of follow‐up. Ten alive, with a median follow‐up of 3 years. OS: 50%. EFS: 40%

**Conclusions**: Patients younger than one year with RMS were uncommon in our STS population. Head and neck location and embryonal subtype were the most frecuent. Molecular analisis helped us to better cathegorize our patients, allowing us to choose the best treatment for them (3p).

### PO-509. Successfully Treated Synchronous Double Malignancy of Rhabdomyosarcoma and Wilms Tumor in an Infant {#pbc27455-sec-7410}

[I. El Nady]{.ul} ^1^

*^1^children cancer hospital of egypt, pediatric oncology, CAIRO, Egypt*

**Background/Objectives**: RMS cases arise mostly as sporadic tumors with small fraction are associated with heritable genetic syndromes. We describe an infant who presented with 2 synchronous solid tumors (Wilms tumor and Rhabdomyosarcoma) who cured from both

**Design/Methods**: Patient initially presented at 20/11/2011 surgically resectd tongue swelling, pathology was embryonal rhabdomyosarcoma Investigations RMS was done

**Results**: Initial CT chest lower cuts showed accidental discovery of a well defined solid mass is seen at the RT suprarenal region ?nature. PET, CT showed Intense focal FDG uptake is seen corresponding to large right renal mass involving the upper half of the right kidney sarcoma She started protocol based on COG (ARST‐0331)‐ LOW RISK at 12‐2011 She was schedueled for biopsy from right renal mass pathology was wilms tumor patient had radical nephrectomy and was up staged to satge III (1‐2011) Surgery was followed by radiotherapy at renal bed. He received right flank conformal radiotherapy 1080 Cgy/1.8GY/f Patient continued on IR‐RMS PROTOCOL with replacing ActinomycinD‐ with Adriamycin every other cycle so she received alternative courses of VAC and VAD Radiotherapy to tongue was omitted because of age and complete resection of lesion (inspite that margin was not confirmed to be clear)

At 4‐2014 patient developed tongue mass recurrence. Biopsy Showed Recurrent Embryonal Rhabdomyosarcoma. She received salvage chemotherapy in the form of 6 cycles of CCE with local radiotherapy to tongue Patient is under follow up since then. Last visit was 02/2018 patient was in complete remission

**Conclusions**: the infant showed negative family history and negative consanguinity. Maternal age was 18 years with unremarkable pregnancy. Genetic analysis of the child did not show any abnormality, p53 was negative. Inspite cancers in infants represent less than 0.05% of all malignant neoplasms, but form a particulary interesting group for study.

### PO-510. Rhabdomyosarcoma of the Head and Neck in Children: Review and Update {#pbc27455-sec-7420}

[J. Elhoudzi]{.ul} ^1^, M. elbaz^2^, N. mansouri^3^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco; ^2^University hospital Mohammed Vi, Pediatric hematology and oncology, Marrakesh, Morocco; ^3^University hospital Mohammed Vi, Maxillar surgery department, Marrakesh, Morocco*

**Background/Objectives**: rhabdomyosarcoma (RMS) remains one of the most common pediatric soft tissue sarcomas of pediatric cancers (4,5%) and also the most common sarcoma of the head and neck (35%), but the paucity of cases in the pediatric population makes it a difficult disease to study at a single institution.

**Objective**: to review the clinical presentation, histology, staging, treatment modalities and survival for pediatric head and neck rhabdomyosarcoma (non‐orbital).

**Design/Methods**: retrospective study at pediatric hematology and oncology department, treated over 7 years (2011‐2018) for primary head and neck non‐orbital RMS.

**Results**: our study concern 8 children with RMS in median age of 5 years. Majority of tumors were parameningeal location (5 /8) with embroyal histology. Primary surgical exicision was performed in no patient. All patient received chemotherapy and 3/ 8 received radiotherapy. The overall survival was 75% for the duration of the study. 3 patients had a relapse confirmed by histology, 2 patients with temporal RMS had stable evolution with a persistant tumor and no possibility of complete surgery.

**Conclusions**: pediatric head and neck RMS is challenging to study given its low incidence and evolving diagnosis and treatment plans. Although surgery is considered critical to treatment of sarcomas, it may not be feasible for many head and neck RMS. That\'s why multimodal approach remains the ultimate treatment plan

### PO-511. Rhabdomyosarcoma in Marrakesh {#pbc27455-sec-7430}

[J. Elhoudzi]{.ul} ^1^, H. Laila^1^, E. meriem^1^, O. mohamed^2^, K. fouraiji^2^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco; ^2^University Hospital Mohammed VI‐, Pediatric surgery department, Marrakesh, Morocco*

**Background/Objectives**: Childhood rhabdomyosarcoma (RMS) is the most common malignant soft‐tissue tumor of childhood. It accounts for approximately 3.5% of the cases of cancer among children aged 0 to 14 years. it present with localized disease but need a multimodal therapy.

**Objective**: the aim of the study is to discuss the different therapeutic protocols and analyze the different prognostic elements in terms of global survival and event‐free survival

**Design/Methods**: Retrospective descriptive study of 34 cases of rhabdomyosarcoma (RMS) collected in the pediatric hematology and oncology department of Mohammed VI Medical Center of Marrakech,

**Results**: RMS represents 4.13% of all admissions. Median age is 4 years with a male predominance: sex ratio 1.26. Diagnosed was done before 3months in 67%. Tumoral syndrome and pain especially of the head and neck area were frequent. Embryonic form is the most common histological type. Head and neck location is the most common followed by the urogenital tract. 59% of patients presented with advanced disease (III and IV). 58.81% of patients received first‐line chemotherapy, followed in 23.52% of surgery and in 26.47% of radiotherapy. 41.1% received VAC / VAD protocol and 50% MMT‐2005 protocol. Radiotherapy is carried out in 35.29% of patients, and average dose administered is 50.25Gy. At the date of the latest news: 05 patients died, 29 were alive, 32.35% were in complete remission(CR)and 26.47% progressing and 14.7 relapsed.

**Conclusions**: It was difficult to compare our results with others studies because of use of 2 different protocols, and specially of loss of follow up related to luck of financial and social support.

However, overall survival is relatively good.

### PO-512. A Rare Case of Paraneoplastic Optic Neuritis Presenting in a Teenage Patient with Localised Paratesticular Alveolar Rhabdomyosarcoma {#pbc27455-sec-7440}

[K. Gordon]{.ul} ^1^, G. Taylor^1^, P. Brown^2^, H. Bishop^1^, N. Ahmad^1^

*^1^Royal Aberdeen Children\'s Hospital, Department of Paediatric Haematology and Oncology, Aberdeen, United Kingdom; ^2^Aberdeen Royal Infirmary, Department of Pathology, Aberdeen, United Kingdom*

**Background/Objectives**: Paraneoplastic neurological syndromes (PNS) are rare, resulting from an immune‐mediated attack on the nervous system, in response to developing cancer. In children, the most common PNS are opsoclonus myoclonus syndrome, limbic encephalitis, and Anti‐N‐methyl‐D‐aspartate receptor encephalitis. Paraneoplastic optic neuritis has been reported in adult patients with lung cancer, particularly small cell lung cancer. However, we have found no published reports of this phenomenon occurring in children.

**Design/Methods**: We present the case of a 13 year old boy, who developed unilateral visual loss, prior to commencing chemotherapy for alveolar rhabdomyosarcoma.

**Results**: Our patient, a teenage boy with non‐metastatic left paratesticular rhabdomyosarcoma, had undergone orchidectomy, and was preparing for first chemotherapy cycle. The patient reported a 48‐hour history of decreased vision and pain on movement of the right eye. Neurological examination and routine observations were otherwise normal. There was no personal or family history of ophthalmological, neurological or autoimmune disease. Examination revealed markedly decreased visual acuity and swollen optic disc in the right eye. Left eye was normal. Magnetic resonance imaging (MRI) showed inflammation of the right optic nerve, consistent with optic neuritis, there was no evidence of space occupying lesion or metastatic disease. Serum virology screen and autoantibody screen was negative. CSF bacterial and virology testing was negative. No malignant cells were identified. CSF lactate, protein, albumin and IgG were normal. Paired serum and CSF oligoclonal bands were consistent with inflammation/infection. Treatment consisted of 3 days of IV methylprednisolone and immunoglobulins, then 6 weeks of oral prednisolone. Chemotherapy was commenced as per standard protocol. There was good recovery following treatment, with resolution of optic disc oedema and normal visual acuity in the affected eye.

**Conclusions**: Our case highlights that paraneoplastic optic neuritis can occur in children. An occult or underlying tumour should be considered in children presenting with optic neuritis.

### PO-513. Infant Malignant Ectomesenchymoma Mimicking Inguinal Hernia: Two Cases Repotrs {#pbc27455-sec-7450}

Y. Hsiao^1^, [C. Hsiao]{.ul} ^2^

*^1^Kaohsiung Chang Gung Memorial Hospital, Medical education, Kaohsiung, Taiwan R.O.C.; ^2^Kaohsiung Chang Gung Memorial Hospital, Department of Pediatric Hematology and Oncology, Kaohsiung, Taiwan R.O.C*.

**Background/Objectives**: Malignant ectomesenchymoma is a rare and potentially aggressive biphasic tumor consisted of mesenchymal and neuroectodermal elements. The neoplastic cells are believed to arise from pluripotent embryologic neural creast cells. It also has at least one malignant mesenchymal element, generally rhabdomyosarcoma. This tumor occurs mostly in children and adolescents.

**Design/Methods**: Two pediatric patients were identified and data pertaining to tumor size, histology with Immunohistochemical(IHC) study, treatment and outcome were reported.

**Results**: The case 1 patient was a 4‐month‐old male infant who presented with left inguinal mass, the size around 6 x 4cm, incidentally found during left inguinal herniorrhaphy. Initial pathology showed rhabdomyosarcoma. Following total tumor excision and orchiedectomy, the IHC stain showed positive synaptophysin, S100, S0X10, myogenin, desmin and myo D1, the result is consistent with malignant ectomesenchymoma consisted of schwann cells and rhabdomyosarcomatous elements, stage I. He was treated with TPOG RMS 2007 low risk A chemotherapy protocol of vincristine and actinomycin. After finishing chemotherapy, the PET scan and MRI showed no residual tumor. The patient is 2 years from diagnosis, without evidence of disease. The case 2 patient was a 6‐month‐old female infant noted to have a mass, about 1.8 x 1.8 cm, over right inguinal. Excision pathology showed ganglion cells and rhabdomyosarcomatous elements, the result of IHC stain was the same as Case 1, but resection margin involved by sarcoma, stage II. After finishing TPOG RMS 2007 low risk B chemotherapy protocol with cyclophosphamide, vincristine and actinomycin, no residual tumor was found by PET scan. The patient was found to be without recurrence or metastatic disease at 13 months.

**Conclusions**: This report highlights that inguinal malignant ectomesenchymoma may masquerade as inguinal hernia. An early and detailed IHC stain is required to establish an accurate diagnosis. Chemotherapy with rhabdomyosarcoma protocols, or combined with radiotherapy, could be applied for patients with malignant ectomesenchymoma.

### PO-514. Leptomeningeal Recurrence in Pediatric Patients with Non‐Central Nervous System Primary Tumors: A Single Institution Experience {#pbc27455-sec-7460}

W. Throckmorton^1^, D. Harrison^1^, J. Gill^1^, [W. Huh]{.ul} ^1^

*^1^University of Texas MD Anderson Cancer Center, Pediatrics, Houston, USA*

**Background/Objectives**: The development of leptomeningeal disease (LMD) in pediatric patients with non‐central nervous system (CNS) based primary tumors while uncommon portends a grim prognosis. There are a lack of data in the literature regarding patient characteristics and duration of response to conventional treatment methods. The objective of this study is to describe the clinical characteristics and treatment of patients with LMD at a single institution. The goal of this study is to obtain data regarding duration of survival and response towards the development of novel therapeutic trials for LMD.

**Design/Methods**: Retrospective review of medical records of pediatric patients treated at the University of Texas MD Anderson Cancer Center from January 1, 2008 to December 31, 2016 for a non‐CNS based primary tumor who subsequently recurred with LMD.

**Results**: Fourteen evaluable patients were identified. Median age at initial diagnosis was 11.5 years (range 8 months to 20 years); 8 patients were male. Alveolar rhabdomyosarcoma (RMS) was the most common histology identified (n=5) followed by embryonal RMS (n=3). The head/neck was the presenting primary tumor site for 9 patients including one with intracranial sarcoma. Seven patients had metastasis at initial diagnosis. One patient with embryonal RMS was noted to have leptomeningeal involvement at initial diagnosis. Median time from last treatment without LMD to LMD recurrence was 1 month (range 0‐10 months), including 7 patients who progressed on frontline chemotherapy. Despite aggressive multimodal therapy, the median time to death for 13 patients after LMD diagnosis was 3 months (range 0.5 -- 10 months). One patient is currently alive with disease 1 month following LMD diagnosis.

**Conclusions**: The development of LMD conveys an extremely poor prognosis, and current multimodal therapies do not provide significant durable response. The results of this study provide a historical control for duration of survival for comparison when developing novel therapies for LMD.

### PO-515. Dokuz Eylul University Pediatric Oncology Group: Ewing Sarcoma Family of Tumors Experience {#pbc27455-sec-7470}

[D. Ince]{.ul} ^1^, D. Kizmazoglu^1^, M. Erdem^1^, E. Cecen^1^, B. Baysal^1^, R. Cetingoz^2^, A. Demiral^2^, H. Guleryuz^3^, M. Olguner^4^, H. Havitcioglu^5^, E. Ozer^6^, K. Mutafoglu^7^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^4^Dokuz Eylul University Faculty of Medicine, Pediatric Surgery, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Orthopedics, Izmir, Turkey; ^6^Dokuz Eylul University Faculty of Medicine, Pathology, Izmir, Turkey; ^7^Dokuz Eylul University Institute of Oncology, Pediatric Oncologyy Institute of Oncology‐ current address: Izmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To evaluate clinical features and treatment results of the children with the diagnosis of Ewing sarcoma family of tumors(ESFTs) in our center.

**Design/Methods**: Medical records of children with ESFTs treated between 1995--2018 were analyzed retrospectively. Clinical characteristics, treatments and survival rates were analyzed.

**Results**: 55/62 cases were eligible and analyzed. Median age at diagnosis was 12.5yrs(7mos‐20yrs), M/F ratio was 1.6.Primary tumor site:extremity 35%(n:19), paravertebral 20%(n:11), pelvic 20%(n:11), extrapulmonary intrathoracic 16%(n:9), skull bones 3.5%(n:2), parapharyngeal 1.8%(n:1), cheek 1.8%(n:1), abdominal retroperitoneal 1.8%(n:1). Histopathologic examination revealed Ewing sarcoma in 82%(extraosseous27, osseous18) and PNET in 18%(n:10) of cases. The rate of metastatic cases was 31%(lung11, bone9, bone marrow4).In the median 3yrs follow‐up time(3mos‐15.5years),5years EFS 46%,10‐15yrs 33%;5yrs OS 53%,10‐15 yrs38%.I. Primary surgery performed in 16 cases:These cases were admitted to our center after they had been operated at another center. Different chemotherapy(CT) regimens were given to these patients, and radiotherapy(RT) to the primary tumor site was applied to 12cases. Of these 6 have been alive without disease,3 have been alive with disease,2 lost to follow‐up and 5/16 cases died. II. Neoadjuvan chemotherapy was given in 39cases:Primary chemotherapy was IECESS 92 protocol in 21 cases, AEWS0031 in 12cases, others received CYC/IFO and anthracyclin based different regimens. Induction chemotherapy response was 74%(5CR+24PR). IIa. Surgery performed after neoadjuvant CT in 19 cases:Induction response was 89%(2CR+15PR) in this group. Relapse occured in 6cases(at 11,18,18,22,45and47months), refractory disease in one,7of them died. Secondary leukemia occured in one case at 67 months and he died related to this. IIb. Surgery wasn\'t performed after neoadjuvant CT in 20 cases:Induction response was 60%(3CR+9PR).One case with metastatic Ewing sarcoma died early, and other lost to follow‐up. Among cases who received CT and RT:6 cases had refractory disease,2cases had early and 1 case late relapse occured.

**Conclusions**: Although metastatic disease rate was 31% in our ESFT group, high survival rates approaching 50% by multiagent chemotherapy, nonmutilating surgery and radiotherapy were promising. Despite high dose alkylating agents/anthracyclin containing regimens toxic death wasn\'t occur, however secondary leukemia developed in one case which was remarkable for late effects.

### PO-516. Clinical Effect of Arterial Scleroembolization in Treatment of Hemangioma Combined with Kasabach‐Merritt Phenomenon in Infants {#pbc27455-sec-7480}

[Y. Jie]{.ul} ^1^

*^1^Beijing children\'s hospital, Radiology department, BEI JING, China*

**Background/Objectives**: To observe and investigate the clinical effect of artery embolization intervention for Kasabach‐Merritt phenomenon (KMP) patients and to provide experience and reference for the diagnosis and treatment of such diseases.

**Design/Methods**: 15 patients with hemangioma in children with KMP, of which 13 cases of arteriosclerosis after embolization, choice of bleomycin + lipiodol + dexamethasone + contrast agent and the formation of emulsion microspheres or bleomycin mixed microspheres embolization before and after operation, clinical observation, laboratory examination and imaging check the treatment effect comparison. SPSS software was used to analyze the preoperative and postoperative indexes.

**Results**: All the 13 patients who were treated with arterial embolization were cured or improved. The average of platelet count, fibrinogen and tumor size before and after operation were respectively changed from(34.62±29.97)×109/L to (212.08±70.10)×109/L, (1.06±0.45) g/L to (2.10±0.66) g/L, (74.04±57.51) cm³ to (46.94±42.52) cm³, and the differences were significant. Two cases reached the standard of surgery and completed the tumor resection.

**Conclusions**: Arterial embolization therapy is a significant, safe and reproducible therapeutic effect on hemangioma and coagulation dysfunction. Based on experiences from operations, we suggest to improve the success rate and treatment effect by preoperative enhanced CT careful evaluation, attention soft puncture and used ultrasound guidance, appropriate selection of embolic materials and technology, aspects sclerotherapy.

### PO-517. Parameningeal Rhabdomyosarcoma in Children: Single Center Experience in Russia {#pbc27455-sec-7490}

T. Sergeeva^1^, [D. Kachanov]{.ul} ^1^, A. Nechesnyuk^2^, N. Grachev^3^, M. Teleshova^1^, V. Roschin^4^, G. Tereschenko^5^, T. Shamanskaya^1^, S. Varfolomeeva^1^

*^1^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Clinical Oncology, Moscow, Russia; ^2^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Radiation Therapy, Moscow, Russia; ^3^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Pediatric Surgery, Moscow, Russia; ^4^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Pathology, Moscow, Russia; ^5^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Radiology, Moscow, Russia*

**Background/Objectives**: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood. Parameningeal (PM) site has proven an unfavorable prognostic factor. The aim of the study was to analyze the results of therapy of PM RMS in children treated in federal center in Russian Federation.

**Design/Methods**: All prospectively registered patients with PM RMS in the age group \< 10 years treated during the period 02.2012 ‐ 12.2017 were included. Diagnosis was confirmed by histology. All patients were examined and stratified according to the GPOH Cooperative Weichteilsarkom Study (CWS) Group guidance 2009.

**Results**: 13 patients with a median age at diagnosis of 52.6 months (range 6.7--107.1) have been included. Male to female ratio was 1.1:1. The initial location of RMS was infratemporal and pterygoid palatine fossa (n=4; 31%), nasopharynx (n=3; 23%), middle ear (n=2; 15%), paranasal sinuses (n=1; 8%), simultaneous spread of the tumor into the nasopharynx, oropharynx, paranasal sinuses (n=3; 23%). Seven (54%) patients had stage III, while 6 (46%) ‐ stage IV. Local control was provided to 12/13 patients: only radiotherapy in 9/12 (75%), radiotherapy and surgery in 3/12 (25%). The median radiation dose was 50.4 Gy (range 46.8 ‐ 59.4). Median age at the beginning of radiotherapy was 61.6 months (range 13.3 ‐ 123.27). Median follow‐up time was 27.1 months (range 3.2‐51.0). 4 events were observed: 1 patient ‐ early death because of multiple organ failure, 2 patients had experienced recurrence, 1 patient ‐ progression after 3 cycles of chemotherapy. 10 patients are alive (1/10 received palliative treatment), 3 died. 3‐year overall survival (OS) was 82.0% ± 11.6%, 3‐year event‐free survival (EFS) ‐ 74.0%±13.2%.

**Conclusions**: Multidisciplinary approach including systemic chemotherapy, radiation therapy and in selected cases surgical treatment improves the prognosis of PM RMS in terms of EFS and OS.

### PO-518. Non‐Rhabdomyosarcoma Soft‐Tissue Sarcomas in Children: Experience from a Single Centre {#pbc27455-sec-7500}

[S. Karamercan]{.ul} ^1^, A. Okur^1^, C. Karadeniz^1^, F.G. Pinarli^1^, A. Poyraz^2^, H. Bora^3^, A. Oguz^1^

*^1^Gazi University Medical School, Pediatric Oncology and Hematology Department, Ankara, Turkey; ^2^Gazi University Medical School, Department of Pathology, Ankara, Turkey; ^3^Gazi University Medical School, Department of Radiation Oncology, Ankara, Turkey*

**Background/Objectives**: In this study, we aimed to investigate the clinical and epidemiological properties of non‐rhabdomyosarcoma soft tissue sarcomas (NRSTS) in our center.

**Design/Methods**: A total of 30 patients with NRSTS who were followed‐up between the years 1995‐2018 at the Department of Pediatric Oncology are included in the research.

**Results**: The male/female ratio was 1/1. The mean age of the cases was found to be 100 months (1.5‐192 months). The most common complaint was painless swelling (50%) and was diagnosed at a mean of 3.6 months (1‐13 months) from the first admission. The most common histopathologic diagnoses were fibrosarcoma (33%), malign mesenchymal tumor (16.7%) and hemangioperistoma (10%). Patients were followed for 1‐152 months (median: 43.5 months). Most of the encountered tumors were located in the head and neck region (40%). Regional lymph node involvement was 2%. Localized disease rate was found to be 86.7%. The surgical margin was clear in 56.7% of patients with wide excision (63.3%). Neoadjuvant chemotherapy was administered to only 4 (13.3%) patients, whereas 19 patients (63.3%) received adjuvant chemotherapy. Only 50% of patients received radiotherapy with dose of 3000‐5400 cGy (median: 5400 cGy); 43.3% of them received radiotherapy in the primary site. Five patients relapsed within 3 to 36 months (median 13 months) from the diagnosis. Seven patients died (23.3%) and the most frequent causes of death were progression (16.7%) and neutropenic sepsis (6.7%). Sixteen patients (53.4%) were in remission. 5‐year overall and event‐free survivals (OS/EFS) were 52% and 35%, respectively.

**Conclusions**: The NRSTS were a rare and heterogeneous group of tumors of children. The NRSTS were relatively insensitive to chemotherapy and the main treatment modalities are surgery and radiotherapy. In our series, half of the patients were cured of their disease, and the OS/EFS were acceptable in the current management. This study was consistent with the other series reported.

### PO-519. Ewings Sarcoma of the Head and Neck Region: Long Term Outcomes of Multimodality Treatment {#pbc27455-sec-7510}

[N. Khanna]{.ul} ^1^, B. Visariya^1^, C. Hotwani^1^, G. Chinnaswamy^2^, T. Vora^2^, M. Prasad^2^, M. Ramadwar^3^, B. Rekhi^3^, S. Kembhavi^4^, S. Shah^5^, S. Laskar^1^

*^1^Tata Memorial Hospital, Radiation Oncology, Mumbai, India; ^2^Tata Memorial Hospital, Medical Oncology, Mumbai, India; ^3^Tata Memorial Hospital, Surgical Pathology, Mumbai, India; ^4^Tata Memorial Hospital, Radiology, Mumbai, India; ^5^Tata Memorial Hospital, Nuclear Medicine, Mumbai, India*

**Background/Objectives**: To evaluate treatment response and prognostic factors for patients of non‐metastatic Ewings sarcoma (ES) of the head and neck region treated with curative intent at the Tata Memorial Hospital (TMH).

**Design/Methods**: From January 2009 to December 2014, 40 patients with histologically proven ES in the age group of 2 months -- 50 Yrs (Median 17 Yrs) were retrospectively evaluated. Prognostic factors like age at diagnosis, sex, skeletal/ extra‐skeletal origin, primary site (PNS/non PNS), tumor size, nodes, performance status, hematological & biochemical parameters (hemoglobin, total count, lactate dehydrogenase, alkaline phosphatase and albumin), response to chemotherapy (CTh) and type of local treatment were evaluated.

**Results**: Out of total 40, 26 (65%) were males and 21 (52.5%) patients had extra‐skeletal disease with a mean tumor size of 6cms. All patients received multimodal treatment in the form of EFT 2001 systemic CTh and local treatment comprising of surgery (Sx) or radiation therapy (RTh) or both. RTh alone was offered in cases where Sx was either not feasible or was deemed to be associated with significant morbidity. After a median follow‐up of 51 months, the 5‐year local control (LC), disease free survival (DFS) and overall survival (OS) were 72%, 79% and 74% respectively. At last follow up, 26 (65%) patients were alive & disease free. Three patients had local relapse only, 3 had distant metastases only, while 4 had both local relapse & distant metastases. Three patients died of treatment related toxicities. On uni‐variate analysis patients undergoing Sx+RTh had similar LC, DFS & OS compared to RTh alone. None of the prognostic factors were statistically significant.

**Conclusions**: Multimodality treatment using a combination of CTh, Sx & RTh results in optimal disease control with acceptable toxicities. Radiotherapy alone gives outcome similar to combined surgery and adjuvant radiotherapy.

### PO-520. Tumor Expression of Hypoxic Markers Predict the Response to Neo‐Adjuvant Chemotherapy in Children with Inoperable Rhabdomyosarcoma {#pbc27455-sec-7520}

[M. Krawczyk]{.ul} ^1^, E. Izycka‐Swieszewska^2^, B. Kazanowska^3^, M. Styczewska^4^, E.M. Sokolewicz^4^, A. Gabrych^5^, M. Kunc^6^, A. Fatyga^5^, A. Plenis^7^, E. Adamkiewicz‐Drozynska^1^, E. Bien^1^

*^1^Medical University of Gdansk, Department of Pediatrics‐ Hematology and Oncology, Gdansk, Poland; ^2^Medical University of Gdansk, Department of Pathology and Neuropathology, Gdansk, Poland; ^3^Wroclaw Medical University, Department of Pediatric Bone Marrow Transplantation‐ Oncology and Hematology, Wroclaw, Poland; ^4^Medical University of Gdansk, The English Division Pediatric Oncology Scientific Circle, Gdansk, Poland; ^5^University Clinical Centre, Department of Pediatrics‐ Hematology and Oncology, Gdansk, Poland; ^6^Medical University of Gdansk, Department of Pathomorphology, Gdansk, Poland; ^7^Medical University of Gdansk, Department of Pharmaceutical Chemistry, Gdansk, Poland*

**Background/Objectives**: To assess the role of tumor expressions of hypoxia‐inducible factor (HIF)‐1α, glucose transporter (GLUT)‐1, carbonic anhydrase (CA) IX and vascular endothelial growth factor (VEGF) in predicting the response to neo‐adjuvant chemotherapy (naCHT) in children with advanced inoperable rhabdomyosarcoma (RMS).

**Design/Methods**: The study included 46 patients with embryonal RMS (RME) and 20 with alveolar (RMA), treated with CWS protocols (1992‐2013). Immunohistochemical expressions of hypoxia markers were determined semi‐quantitatively in tumor tissue microarray, evaluating the staining intensity and percentage of immunopositive cells.

**Results**: In patients with RME, response to naCHT was influenced by the expression of CA IX (p=0.023F and p=0.032F, respectively) and GLUT‐1 (p=0.078 and p=0.086, respectively). RMA subgroup was too small for statistical analyses, however, patients with low expressions of analyzed markers responded well to naCHT, while all poor‐responders had high tumor markers' expressions. Only 5% of RMA and 22% of RME tumors did not display high expressions of any of the analyzed proteins. All hypoxia markers correlated positively with each other. Not surprisingly, in both RME and RMA, most poor‐responders demonstrated simultaneous high expression of ≥3 markers, while most patients with high expressions of ≤2 markers responded well to naCHT. In the whole cohort, co‐expression of ≥3 markers of hypoxia was the only independent factor included in the multivariable logistic regression model predicting poor‐response to chemotherapy (odds ratio 14.706; 95% confidence interval 1.72‐125.75; p=0.014).

**Conclusions**: HIF‐1α‐related processes of adaptation to hypoxia influence the chemo‐sensitivity of childhood RMS. Immunohistochemical expression pattern of 4 endogenous markers of hypoxia, in the tumor at diagnosis, emerges as a promising tool to predict response to neo‐adjuvant CHT in children with RMS. Basing on different frequencies of hypoxia‐related proteins in RME and RMA, the histology may also be of importance, but larger group of RMA patients has to be enrolled to prove this hypothesis.

### PO-521. Color Doppler Ultrasound‐Guided Photoelectric Therapy for Hemangioma {#pbc27455-sec-7530}

[Y. Lou]{.ul} ^1^, L. weiguang^2^

*^1^Academic leader, Surgery Department of Hangzhou children\'sHospital, hangzhou, China; ^2^vice‐president, Surgery Department of Hangzhou children\'sHospital, hangzhou, China*

**Background/Objectives: Objective**: To assist in the determination of different types of skin hemangiomas with the help of color Doppler ultrasound, and to develop individualized and relatively accurate optoelectronic technology treatment plans.

**Design/Methods: Methods**: A total of 131 patients with hemangiomas were collected, aged 45 days to 6 years old; 57 males and 74 females.The scope of hemangiomas infiltration, the type and nature of the tumors were measured, PSV and other related blood flow parameters were measured, and the ultrasound imaging features of various types of skin hemangiomas was counted. According to the color Doppler ultrasound guidance, 131 patients were divided into two groups; Group A is subdivided into three groups. A1 group (the depth of skin hemangiomas \<1.2mm), Selection of intense pulsed light (IPL) treatment; group A2 (hemangioma depth 1.2‐3 mm), single pulse long pulse width 1064 nm Nd:YAG laser treatment; A3 group (rapist 3‐5 mm depth or blood flow velocity \>15cm/s), IPL combined with single pulse long pulse width 1064nm Nd:YAG laser‐treatment. Treatment group B: The skin lesions of children were not subjected to color Doppler ultrasonography. Single pulse long pulse width 1064 nm Nd:YAG laser treatment was selected based on the experience of clinicians. Both groups of patients were treated for 5 times and their efficacy was compared.

**Results**: The overall efficiency of group A treatment was 84%; A1 group was 85.6%; A2 group was 83.6%; A3 group was 84.9%. The effective rate in group B was 73.3%. The difference in total effective rate between group A and group B was statistically significant (P\<0.05).

**Conclusions**: Color Doppler ultrasound can help determine the type of skin hemangiomas and show different imaging features of skin hemangiomas. Under the guidance of color Doppler ultrasound, reasonable choice of optoelectronic technology for the treatment of skin hemangioma can enhance the efficacy and reduce adverse reactions.

### PO-522. Clinical Analysis of Multi‐Center 64 Cases of Chinese Children and Adolescents with Fibrosarcoma {#pbc27455-sec-7540}

[S. Lu]{.ul} ^1^, X. Sun^1^, J. Tang^2^, X. Ma^3^, S. Wang^4^, Z. Zhen^1^, J. Zhu^1^, J. Wang^1^, F. Sun^1^, J. Huang^1^

*^1^Sun Yat‐sen University Cancer Center, Pediatric Oncology, Guangzhou, China; ^2^Shanghai Children\'s Medical Center, Hematology and Oncology, Shanghai, China; ^3^Beijing Children\'s Hospital‐ Capital Medical University, Hematology Oncology Center, Beijing, China; ^4^Children\'s Hospital of Chongqing Medical University, Surgical Oncology, Chongqing, China*

**Background/Objectives**: To analyze the clinical characteristics, treatment and prognosis of children and adolescents with fibrosarcoma (FS).

**Design/Methods**: We reviewed the medical records of patients with FS younger than 18 years old treated at four hospitals including Sun Yat‐sen University Cancer Center (SYSUCC), Shanghai Children\'s Medical Center (SCMC), Beijing Children\'s Hospital, Capital Medical University (BCH, CMU), Children\'s Hospital of Chongqing Medical University (CHCMU) from January 2000 to January 2014. Patients' clinical characteristics, treatment effects and prognostic factors were analyzed.

**Results**: A total of 64 patients were included in this study, including 24 patients from SYSUCC, 15 patients from SCMC, 16 patients from BCH, CMU, and nine patients from CHCMU. The median age was 3.3 years old (0.03 ∼ 18 years old). There were 40 males and 24 females. The most common sites were lower limbs (14/64). The pathological types were classified as follows: infantile fibrosarcoma (n = 26), FS (n = 20), dermatofibrosarcoma (n = 16), sclerosing epithelioid fibrosarcoma (n = 2). Forty‐four patients were treated with surgery alone, eighteen patients received surgery combined with chemotherapy, and two patients received surgery combined with radio‐chemotherapy. With a median follow‐up time of 36.8 months (1.8∼222.4months), the follow‐up rate was 75.0%. A total of 28 patients had local recurrence. Among of this, 23 patients (88.5%) were treated with surgery alone, and five patients received surgery combined with chemotherapy. Until the last follow‐up time, the 3‐years overall survival rate was 86.7%. The 3‐years recurrence‐free survival rates of patients treated with surgery alone or combined with chemotherapy were 30.0% and 71.2%, respectively (P = 0.034). There were no recurrences in the two patients who had received surgery combined with radio‐chemotherapy.

**Conclusions**: Children and adolescents with FS treated with surgery alone had a higher local recurrence rate. Surgery combined with chemotherapy can help to reduce the local recurrence rate.

### PO-523. Relationship Between the Toxicity of Chemotherapy and Genomic DNA Polymorphism in Children with RMS {#pbc27455-sec-7550}

[X. Ma]{.ul} ^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University, National Center for Children\'s Health, Hematology Oncology Center, Beijing, China*

**Background/Objectives**: Analyse relationship between the toxicity of first‐line chemotherapy and genomic DNA polymorphism in children with rhabdomyosarcoma (RMS).

**Design/Methods**: Retrospective analysis of RMS children admitted in our center from January 2016 to December 2017. All patients were treated bases on VAC (vincristine, doxorubicin, and cyclophosphamide). From 2017 on, VI (vincristine, irinotecan) were as the standard for MR. Analysis clinical features, major organ functions, and the relationship between toxicity and drug genomic DNA test.

**Results**: Total 61 cases, median age for 60 months (5‐180 months). 27 cases of head and neck, 9 case of urogenital tract,, 6 cases of limbs, 19 cases of truncus. 39 cases of embryonic type, 22 cases of alveolar. IRS‐II in 4 cases, IRS‐Ⅲ in 39 cases, IRS‐Ⅳ in 18 cases. There are 3 cases only detect UGT1A1\*6, 18 for GA, 42 for GG, 1 for AA type; ABCB1 gene 24 cases of CT, 28 cases of TT, 6 cases of CC type; CYP3A5 gene GA type 11 cases, GG type 18 cases, AA type 1 case, AG type 28 cases. Organ functions were primitively normal. 4 cases of grade 3 neutropenia, 57 cases of grade 4. 26 patients used irinotecan, 24 cases of grade 4 neutropenia, 5 patients with grade 4. Toxicity and above drug genomic DNA weren\'t statistically different.

**Conclusions**: Our study showed that there is no relationship between the toxicity of chemotherapy and genomic DNA polymorphism in children with RMS. We need to further study to verify this result.

### PO-524. Soft Tissue Sarcomas (STS) in the First Year of Life. A 15‐Year Experience at a Single Pediatric Institution in Argentina {#pbc27455-sec-7560}

[M.D. Mathey]{.ul} ^1^, L. Peruzzo^1^, N. Cabero^1^, A. Montanari^1^, D. Fortunati^1^, G. Felizzia^1^, M. Viso^1^, W. Cacciavillano^1^, J. Lopez Martí^2^, P. Barriga Cano^2^, A.B. Cervini^3^, A. Lanoel^3^, P. Zubizarreta^1^, A. Rose^1^, A. Pollono^4^

*^1^Hospital de Pediatría "Juan P. Garrahan", Hematology and Oncology, Capital Federal, Argentina; ^2^Hospital de Pediatría "Juan P. Garrahan", Pathology, Capital Federal, Argentina; ^3^Hospital de Pediatría "Juan P. Garrahan", Dermatology, Capital Federal, Argentina; ^4^Hospital de Niños "Sor María Ludovica", Oncology, La Plata, Argentina*

**Background/Objectives**: STS in infants are a heterogeneous group of tumors that represent \<10% of overall STS, and differ in many aspects from older children, with respect to histology, biology, behavior and prognosis, and the difficulty to manage.

To report clinical features and outcome of patients ≤1 year with histological diagnosis of STS.

**Design/Methods**: We retrospective analyzed 42 infants with STS admitted to our Institution from January 2002 to December 2017.

**Results**: STS in children ≤1year represent 11% of the total STS admitted during the study period. The most common symptom was tumor (83.3%). Nineteen patients (45.2%) presented symptoms during the neonatal period, and 16/19 at time of birth. Median age at diagnosis was 5.7 months (0.6‐12). Female/Male 1.3/1.

The histologies were Rhabdomyosarcoma (38.1%), Infantile Fibrosarcoma (IFS) (30.9%), Malignant Extra‐craneal Rhabdoid Tumor (MRT) (14.3%), Fibroblastic/Myofibroblastic Tumors (11.9%), Ewing Sarcoma (2.4%) and NOS Sarcoma (2.4%).

Most common primary sites were trunk (33.3%) and extremities (31%), followed by head&neck and genitourinary (16.7% respectively) and multiple (2.3%). Tumor size was \>5cm in 27 patients (64.3%). Eleven patients (26%) had metastatic disease.

Surgery was the only treatment in 6 patients, (4 IFS, 2 fibroblastic/myofibroblastic tumors), chemotherapy was administered to 32 patients (dosages according to age and weight), "wait&see" in 3 patients (1 IF, 2 fibroblastic/myofibroblastic tumors) and 1 MRT didn\'t receive any treatment. Two patients received Radiotherapy in first‐line of treatment.

With a median follow‐up of 42 months (6‐186), the 5‐year OS, and EFS was 60%, and 52% respectively. The 5‐y OS vs EFS was 43% vs 40%, 92% vs 85%, 100% vs 61% for Rhabdomyosarcoma, IFS, and Fibrobastic/myofibroblastic tumor, respectively and MRT 0%.

**Conclusions**: STS in infants represents a rare and heterogeneous entity. The most common histological types were RMS and FSI. RMS and MRT showed a high prevalence of unfavorable features that may impact in poor outcome. FSI had an excellent survival.

### PO-525. Prevalence and Clinical Impact of Anaplasia in Pediatric Rhabdomyosarcoma: Results in a Middle‐Income Country Under a Public Health Insurance Program {#pbc27455-sec-7570}

[L. Mendez]{.ul} ^1^, R. Cardenas Cardos^1^, R. Rodriguez Jurado^1^

*^1^Instituto Nacional de Pediatria, Pediatric Oncology, Mexico City, Mexico*

**Background/Objectives**: According to recent reviews of cases from the Soft Tissue Sarcoma Committee of the Children\'s Oncology Group, anaplasia suggests to be more common than previously reported and may impact clinical outcome. Nonetheless of the high suspicion that anaplastic characteristics are envolved in the efficacy of therapy and prognosis, its rareness represents a difficulty to be considered among the morphologic criteria by the International Classification of Rhabdomyosarcoma.

**Design/Methods**: The prevalence of anaplasia (focal or diffuse) was assessed among a group of 59 elegible patients classified according to de International Classification of Rhabdomyosarcoma criteria and treated from January 01, 2007 to December 31, 2017. An evaluation of morphological features and histological subtypes was determined with a clinical correlation between treatment response and failure‐free survival.

**Results**: A sample of 59 patients from the National Institute of Pediatrics (Instituto Nacional de Pediatría) with diagnosis of rhabdomyosarcoma and anaplasia was analyzed. Median age at diagnosis was 7.4 years. Anaplasia was more common in patients with tumors in favorable sites but with embrional histology (83%), and was commonly seen in patients with stages 2, 3 or clinical group lll disease. Regardless of its distribution (focal or diffuse), on univariate analysis the presence of anaplasia had a significant negative impact for both failure‐free survival (66% vs 75% at 5 years) and survival (68% vs 82% at 5 years) (p= \<0.03) in patients with embryonal rhabdomyosarcoma. This effect was clearly pronounced in children with intermediate risk disease. There was no impact for alveolar rhabdomyosarcoma.

**Conclusions**: The prevalence of anaplasia in rhabdomyosarcoma is higher than previously described and may be of prognostic significance in children with intermediate risk embryonal rhabdomyosarcoma.

### PO-526. Soft Tissue Sarcoma: 18 Years Single Center Experience {#pbc27455-sec-7580}

[M. Mikeskova]{.ul} ^1^, I. Beder^2^, A. Kolenova^1^, S. Jakesova^3^

*^1^National Institute of Children Diseases, Department of Paediatric Haemathology and Oncology, Bratislava, Slovak Republic; ^2^National Institute of Children Diseases, Department of Paediatric Surgery, Bratislava, Slovak Republic; ^3^National Institute of Children Diseases, Department of Radiology, Bratislava, Slovak Republic*

**Background/Objectives**: Soft tissue sarcoma (STS) is very heterogeneous group of tumors. In the Slovak Republic, approximately 2‐6 new cases of childhood STS are diagnosed per year. These children are treated according EpSSG strategy at one of three Slovak centers of pediatric hematology and oncology. STS are separated in two basic groups as rhabdomyosarcoma (RMS) and non‐rhabdomyosarcoma (nonRMS). The clinical presentation can vary and depends on tumor type and location. The objective of our study was to analyze the outcome of patients with STS from single center in Slovakia.

**Design/Methods**: Our study is retrospective analysis, during period from January 2005 up to January 2018, focused on treatment strategies according the EpSSG study criteria, event free (EFS) and overall survival OS. The cohort consisted of 41 patients with STS, in group of RMS we analyzed 23 patients, with age 1,5year‐ 16,5years, median 5,5 years. Group of non‐RMS consisted of 18 patients, with age 2,5months‐ 17years, median 16 years.

**Results**: The most common histological type was embryonal RMS in 16 children. Initially 7 children in RMS group were metastatic. In a group of non‐RMS there were 5 children with metastases. In our study 5 years EFS in RMS resp. non‐RMS cohort was 58% resp. 44% and 5‐years OS was 66% resp.‐ 60%.

**Conclusions**: Multimodal therapeutic approach is the mainstay in treatment of STS. In a case of initially metastatic disease EFS and OS rapidly descend. For the outcome of patients in smaller centers it is crucial to be part of international collaboration.

### PO-527. Clinical Characteristics and Overall Survival in Children with Sarcomas Non Rhabdomysarcomas Between 2013 and 2017 in the Instituto Nacional De Enfermedades Neoplásicas Lima‐Peru {#pbc27455-sec-7590}

[J.E. Montoya Vasquez]{.ul} ^1^, C. Ugaz Olivares^1^, J. García León^1^, E. Maradiegue Chirinos^1^, L. Vasquez Ponce^2^

*^1^Instituto Nacional de Enfermedades Neoplásicas, Lima, lima, Peru; ^2^Hospital Edgardo Rebagliati Martins, Lima, Lima, Peru*

**Background/Objectives**: Sarcomas non rhabdomyosarcomas tumors represent 3‐5 % of all pediatric cancer, in our country we receive this patients with advanced disease and until now there is not previous studies in this field. The main objectives were to know the clinical features of this group of patients and evaluate the overall survival.

**Design/Methods**: Retrospective, descriptive study. All infants and children younger than 14 years with sarcomas non rhabdomyosarma diagnosed at the Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 2014 and December 2017 were included. We had a sample size of 21 patients, STATA 14 was used for the statistical analysis.

**Results**: A total of 21 children were identified, 13patients (61.9%) were female and 8 (38%) male. The median age was 11 years (range, 3 month ‐ 14 years). The most frequent diagnosis was synovial sarcoma (33.3).Eight (38%) were sarcomas located in the extremities. Six (28.5%) patients were from Lima, the capital. In this study was found an overall survival of 45% to 3 years. Five (23.8%) patients abandoned treatment.

**Conclusions**: In this study we found an overall survival of 45 % to 3 years and a high percentage of patients that did not complete treatment, this results encourage us to look for the causes of treatment abandonment, evaluate the surgical management and response to chemotherapy and radiotherapy if it was used.

### PO-528. Insulin‐Like Growth Factors and Pediatric Rhabdomyosarcoma: A Gene‐Based and Mendelian Randomization Approach {#pbc27455-sec-7600}

[L. Morimoto]{.ul} ^1^, X. Shao^1^, C. Kennedy^1^, X. Ma^2^, S.S. Ma^2^, J. Wiemels^3^, C. Metayer^1^

*^1^University of California Berkeley, School of Public Health, Berkeley, USA; ^2^Yale University, School of Public Health, New Haven, USA; ^3^University of Southern California, Keck School of Medicine, Los Angeles, USA*

**Background/Objectives: Background**: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and is comprised of embryonal (eRMS) and alveolar (aRMS) subtypes. Positive associations have been observed between accelerated fetal growth and risk of both eRMS and aRMS. Alterations in insulin‐like growth factors (IGFs) may mediate these associations. Using candidate gene and Mendelian Randomization approaches, we evaluated the role of genetic variation in IGFs and pediatric RMS risk.

**Design/Methods: Methods**: Archived newborn dried blood spots from 207 Caucasian RMS cases diagnosed between ages 0‐19 years during 1988‐2011 and identified from the California Cancer Registry were genotyped using the Illumina OmniExpress array. Publicly available control genotypes generated from the same array were matched 4:1 to cases based on genetic ancestry. Genotypes were imputed based on the Haplotype Reference Consortium panel. Genes in the IGF/insulin pathway were selected (*IGF1, IGF2, IGF1R, IGF2R, IGFBP1‐6, GH, GHR, GHRH, INS, INSR, IRS1*), and their association to RMS was assessed using the minP test based upon 1,000 permutations. To assess the role of circulating IGF1 and IGFBP3, an instrumental variable was constructed using genetic variants.

**Results**: *IRS1* and *IGFBP4* were associated with both total and eRMS (p=0.02‐0.04), while only *IRS1* was associated with rarer subtype aRMS (p=0.02). Estimated circulating IGF1 was inversely associated with total RMS risk; results for eRMS and aRMS were not statistically significant. IGFBP1 and the molar ratio of IGF1:IGFBP3 were unrelated to risk.

**Conclusions**: There was evidence that *IRS1*, which codes a protein that plays a key role in transmitting insulin growth factor signals to intracellular pathways, was associated with RMS risk in Caucasian children. Circulating IGF1 was inversely associated with RMS risk, a result paradoxical to the current hypotheses of accelerated fetal growth and RMS risk. Separate analyses are underway in an independent set of RMS cases to replicate these findings.

### PO-529. High Incidence of Local and Regional Failure in Pediatric Rhabdomyosarcoma of the Nasal Ala {#pbc27455-sec-7610}

[M. Nelson]{.ul} ^1^, T. Yock^2^, S. Wolden^3^, J. Wang^1^, Y. Cheng^1^, C. Hess^2^, A. Kim^1^, H. Meany^1^, R. Schulte^4^, M. Stavas^5^, S. Terezakis^6^, M. Ladra^6^

*^1^Children\'s National Medical Center, Center for Cancer and Blood Disorders, Washington‐ District of Columbia, USA; ^2^Massachusetts General Hospital, Department of Radiation Oncology, Boston, USA; ^3^Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, USA; ^4^Vanderbilt University Medical Center, Division of Pediatric Hematology‐Oncology, Nashville, USA; ^5^Vanderbilt University Medical Center, Department of Radiation Oncology, Nashville, USA; ^6^Johns Hopkins School of Medicine, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, USA*

**Background/Objectives**: Primary site impacts treatment and outcome in pediatric rhabdomyosarcoma (RMS). It has been our clinical observation that children with nasal ala RMS have more frequent local recurrences and regional nodal failures compared to other favorable head and neck sites, which may indicate a need to evaluate the current treatment paradigm for this subset of patients.

**Design/Methods**: We retrospectively identified 17 pediatric patients with RMS of the nasal ala and buccal/nasal region (nasal cavity primaries were excluded) treated between September 1997 and February 2017 at 5 different pediatric cancer centers within the United States. Primary endpoints were local control (LC), failure‐free survival (FFS), and overall survival (OS). Survival analysis was used to generate survival curves for each outcome. Cox regression was applied to model the hazard of event occurrence with bootstrap methods.

**Results**: Median age at diagnosis was 1 year. The majority were alveolar histology (n=15). Four patients had regional nodal disease and no patients had metastasis at diagnosis. Surgery was either biopsy alone (n=7), upfront resection (n=4) or delayed primary excision (n=6). All patients received intermediate risk VAC‐based chemotherapy and radiation therapy (RT) (range 36 Gy‐50.4 Gy) to the primary disease site and any involved lymph nodes if present. Mean follow up was 4.7 years. Twelve patients experienced recurrence (local=4, local+regional=4, regional=2, local+distant=1, distant=1). Median time to recurrence was 13 months. Five year LC rate was 47%, FFS was 24% and OS was 71%. Recurrence was significantly associated with nodal disease at presentation and there was a trend toward improved outcomes with a higher cyclophosphamide dose. RT dose and surgery type did not appear to influence recurrence rates.

**Conclusions**: In our experience, pediatric RMS of the nasal alar region fare poorly with current treatment algorithms. Re‐evaluation of risk stratification and treatment strategy for these patients should be considered.

### PO-530. Infantile Fibrosarcoma (IFS). A 10‐Year Experience at a Single Pediatric Institution in Argentina {#pbc27455-sec-7620}

[L.B. Peruzzo]{.ul} ^1^, M. Mathey^1^, G. Felizzia^1^, M. Viso^1^, W. Cacciavillano^1^, J. Lopez Martí^2^, A. Bosaleh^2^, A.B. Cervini^3^, P. Zubizarreta^1^, A. Rose^1^

*^1^Hospital de Pediatria "Juan P. Garrahan", Hematology and Oncology, Buenos Aires, Argentina; ^2^Hospital de Pediatria "Juan P. Garrahan", Pathology, Buenos Aires, Argentina; ^3^Hospital de Pediatria "Juan P. Garrahan", Dermatology, Buenos Aires, Argentina*

**Background/Objectives**: IFS is the most common soft tissue sarcoma non rhabdomyosarcoma in children under 1 year, with local aggressiveness, but high curability rate with conservative therapy.

To report the experience of our Institution with IFS analyzing clinical features, response to treatment and outcome.

**Design/Methods**: A retrospective, descriptive study of 11 patients with histological diagnosis of IFS treated at our Institution from January 2008 to December 2017 according to EpSSGnonRMS 2005 Protocol.

**Results**: Median age at diagnosis was 4.34 months (0‐36). Male/Female 2.6/1. The delay between the onset of symptoms and diagnosis was 66 days (5‐283). Extremity was the most common site 81% (n=9). Tumor diameter was \>5cm in 8 patients. IFS was misdiagnosed as a vascular tumor by clinical and imaging findings in 6 patients. Only 1 patient had metastatic disease (lung). Molecular techniques were performed in all cases (FISH and/or RT‐PCR), being positive in 8/11 patients. Initial non‐mutilating surgery was performed in 5 patients with post‐operative staging IRS I (n=2), IRS II (n=3). The remaining patients (n=6) received chemotherapy with Vincristine/Actinomycin (VA) post‐biopsy, and 1 patient with Progressive Disease after surgery received VA. A delayed surgery could be performed in 5/6 patients (IRS II n=3, IRS III, n=2). Rate response to chemotherapy was Very Good Partial Response/Partial Response 57%, and Stable Disease 43%. The most common toxicity was hematological. No febrile neutropenia was observed. With a median follow up of 38 months (9‐105) all the patients (except metastatic one), are alive. The 5‐year Overall Survival vs Event Free Survival of the series was 89% and 81.5% respectively.

**Conclusions**: IFS is often a challenging problem due to similarities with vascular tumors. Although FSI is locally aggressive it has high rate overall survival similar to other series, due to its good response to chemotherapy (VA) and non‐mutilating surgery even with involved margins.

### PO-531. Clinical Profile and Outcome of Treatment of Pediatric Rhabdomyosarcoma in a Tertiary Care Hospital, Dhaka, Bangladesh {#pbc27455-sec-7630}

[A.T.M.A. Rahman]{.ul} ^1^, M. Akter^2^, M. Begum^1^, S.F. Noor^3^, C.S.H. Kibria^1^, A. Islam^1^, C.Y. Jamal^1^

*^1^BSMMU, Pediatric Hematology and Oncology, Dhaka, Bangladesh; ^2^Dhaka Dental College Hospital, Emergency, Dhaka, Bangladesh; ^3^BSMMU, Dermatology and venereology, Dhaka, Bangladesh*

**Background/Objectives**: To evaluate the clinical characteristics and treatment outcome of children with rhabdomyosarcoma among a series of 39 children, at BSMMU Hospital, with emphasis on age, gender, clinical presentation, site, histological subtype, TNM stage, treatment modalities and survival.

**Design/Methods**: A retrospective study carried out analyzing the medical records of 39 patients with rhabdomyosarcoma from the BSMMU tumor registry. Medical records of children with rhabdomyosarcoma were reviewed over a period of 6 years, from June 2011 to May 2017.

**Results**: There were males 56% and females 46%. M: F ratio 1.2:1. The age at diagnosis ranged from 7 months to 12 years. Most of the cases presented with a mass at varying sites. The primary site of disease was the head and neck in 46% followed by pelvis 40%. The most frequent histological subtype was in 46% embryonal rhabdomyosarcoma followed by alveolar rhabdomyosarcoma 23%, botryoid type 5%, spindle cell type 5% and unspecified 21%. At the time of diagnosis, 64% of patients were TNM stage 3, next frequency is stage IV 23%. Most patients 56% received multimodality therapy (radiotherapy, chemotherapy and surgery). The overall 5‐year survival rate in stage III is 41% and stage IV is 11%, there is significant relationship between overall survival and stage of the disease.

**Conclusions**: The data regarding clinical characteristics, histology and stage of rhabdomyosarcoma at BSMMU Hospital are similar to the data of worldwide countries. The majority of presentations were in the advanced stages of disease but sensitive to multimodality therapy. Poor survival rate is correlated with the advanced stage of the disease.

### PO-532. Outcomes and Prognostic Variables in Pediatric Rhabdomyosarcoma: A Study from a Tertiary Referral Cancer Center in India {#pbc27455-sec-7640}

[S. Ramanathan]{.ul} ^1^, V. Bhat^1^, K.C. Anand^1^, M. Ramadwar^2^, O. Shetty^2^, S. Kembhavi^3^, S. Qureshi^4^, S. Laskar^5^, N. Khanna^5^, N. Salins^6^, M. Prasad^1^, T. Vora^1^, G. Chinnaswamy^1^, S. Banavali^1^

*^1^Tata Memorial Centre, Pediatric Oncology, Mumbai, India; ^2^Tata Memorial Centre, Pathology, Mumbai, India; ^3^Tata Memorial Centre, Radiodiagnosis, Mumbai, India; ^4^Tata Memorial Centre, Surgical Oncology, Mumbai, India; ^5^Tata Memorial Centre, Radiation Oncology, Mumbai, India; ^6^Tata Memorial Centre, Palliative Care, Mumbai, India*

**Background/Objectives**: While factors influencing outcome of Rhabdomyosarcoma(RMS) in developed countries have evolved from clinical characteristics to molecular profiling, prognostic data on outcomes from developing countries is scarce. This is an analysis of pediatric RMS treated on a multimodality regimen with IRS‐4 based chemotherapy comprising of Vincrisitine, Ifosfamide, Etoposide(VIE) and Vincristine, Actinomycin‐D, Cyclophosphamide(VAC).

**Design/Methods**: Retrospective study of all children with histopathologically proven RMS treated from Jan'2010 to Dec'2015(6 years). All patients received chemotherapy(8\# VIE and 4\# VAC) with definitive therapy in the form of radiotherapy or surgery or both.

**Results**: A total of 258 patients were diagnosed with RMS, of whom 156 took treatment in our hospital. Amongst the rest, 52 were palliated, 30 were pre‐treated, 9 children abandoned treatment and 11 patients were referred outside. The median age of the analyzable cohort was 5.35 years(range:0.53‐17.56)with a boy:girl ratio of 1.8:1. Embryonal and Alveolar variants were seen in 117(75%) and 35(22.4%) patients respectively, and inconclusive in 4 patients(2.5%). Molecular studies done on 58 patients showed PAX‐3/FKHR positive disease in 13(22.4%) patients and PAX‐7/FKHR positive in 4(7%) patients. Low(LR), Intermediate(IR) and High Risk(HR) tumors were seen in 37(23.7%), 98(62.8%)and 21(13.4%)patients respectively. Seventeen patients(11%) progressed, 39(25%) relapsed(median time to relapse‐16.36 months) and 3(2%) developed second cancers. Mortality due to treatment related toxicity was noted in 14 patients(LR‐1, IR‐12, HR‐1). At a median follow‐up of 33 months, the 5‐year OS and PFS was 60.7% (LR‐89.9%;IR‐59.8%;HR‐13.8%) and 54.5% (LR‐88.7%;IR‐49.8%;HR‐13.8%) respectively. While low risk disease (p\<0.01) and favorable site(p\<0.01) emerged as good prognostic variables on both univariate and multivariate analysis, fusion status, histological variant and gender had no bearing on survival.

**Conclusions**: Encouraging outcomes in low and intermediate risk groups ask for a decrease in therapy to avoid toxic deaths in LMICs. Molecular studies need to be incorporated in frontline work‐up in order to better risk stratify these patients.

### PO-533. Peritoneal Involvement in Rhabdomyosarcoma: A Single Centre Experience from UK {#pbc27455-sec-7650}

[N. Roy Moulik]{.ul} ^1^, S. Vaidya^2^, H. Mandeville^2^, S. Gatz^2^, J.C. Chisholm^2^

*^1^Clinical Fellow, Children and Young People\'s Unit‐ Royal Marsden Hospital, Sutton, United Kingdom; ^2^Royal Marsden Hospital‐ Sutton‐ UK, Children and Young People\'s Unit, Sutton, United Kingdom*

**Background/Objectives**: Paediatric sarcomas involve the peritoneum in about 10% of patients either as primary site of disease or metastatic involvement at diagnosis/relapse and occasionally following surgical tumour spillage. The optimum management of this potentially life‐threatening condition is not clear due to scarcity of reported data. In this retrospective study we present our experience with peritoneal rhabdomyosarcoma (RMS).

**Design/Methods**: The electronic medical records of patients aged 1 ‐24 years registered with our unit from July 2007 through June 2017 with a diagnosis of RMS with ascites/ peritoneal involvement at presentation/relapse were reviewed and data on modes of presentation, imaging, histopathology, molecular markers, treatment received and outcome were recorded.

**Results**: Nine patients (median age 16.8 (2.0‐20.5) years, male: female 1:2, histology‐alveolar (5), embryonal (3), biphasic(1)) had ascites at presentation (n=4) or at relapse (n=5). Intra‐abdominal primary was seen in all except 1.Signs of potential peritoneal involvement were heterogenous ranging from small volume ascites to nodular deposits, plaques, caking and stranding of peritoneum. Two of 4 patients with baseline ascites had embryonal histology and abdominal tumours but no documented peritoneal disease. Initial treatment comprised of standard systemic chemotherapy in all and local therapy with surgery (n=3) and radiotherapy (n=8). Two patients were disease free \>3 years, 1 was on treatment and the rest 6 relapsed/progressed before last analysis. Five of 6 patients with progressive/relapsed disease died at median 5(3‐7) months from relapse despite second line chemotherapy. Both of the long term survivors (one with only small volume ascites and no peritoneal disease at baseline) had non‐alveolar histology, near complete resection of residual disease and focussed abdomino‐pelvic radiotherapy.

**Conclusions**: Peritoneal involvement was seen mostly in patients with primary abdominal RMS. The pattern of peritoneal involvement was heterogenous. Overall outcome of peritoneal disease was dismal. However, 2 patients with non‐alveolar histology undergoing adequate local therapy have survived long term.

### PO-534. Recalcitrant Desmoid Tumors: Does Cryoablation Help? {#pbc27455-sec-7660}

[R. Shaikh]{.ul} ^1^

*^1^Boston Children\'s Hospital and Dana Farber Cancer Center, Interventional Radiology, Boston, USA*

**Background/Objectives**: Desmoid tumors are highly aggressive rare musculoaponeurotic tumors which often recur after treatment. Conventional treatments include surgical resection, radiation, systemic therapy, and neoadjuvant radiation with or without chemotherapy. Reported mean local failure rates of 22%, 35%, and 28% for radiation alone, surgery alone, and radiation plus surgery, respectively. Reported mean stable disease rates of 91% and 52% for cytotoxic and noncytotoxic chemotherapy, respectively. Cryoablation can be used in isolation or as adjuvant to chemotherapy/radiotherapy in large, recalcitrant desmoids to promote faster tumor necrosis and shrinkage from critical structures. It also helps in long term control of tumor progression. We present our experience with percutaneous cryoablation of desmoid tumors with the objective of showing the safety and efficacy of this treatment.

**Design/Methods**: Eight patients (2‐26 years; mean 16.6 yr) who had ten symptomatic, recurrent and resistant progressive extra‐abdominal desmoid tumors post resection and chemotherapy underwent percutaneous image guided cryoablation, from September 2012 to March 2018. The desmoids were in anatomically challenging locations. Patients were evaluated in an interdisciplinary tumor conference before being referred for cryoablation. Percutaneous image guided cryoablation was performed using Argon and Helium gases in a single or staged sessions. Pre procedure and follow up clinical and imaging evaluation was done to assess outcome.

**Results**: Following cryoablation, there was significant improvement in symptoms and tumor size regression followed over 1 to 3 years. Technical success was 100%.Tumor shrinkage seen in 100% of tumors. There were no major complications.

**Conclusions**: Percutaneous cryoablation as local control in resistant desmoids is safe and effective. This modality should be considered as a primary or adjuvant in management of desmoid tumors.

### PO-535. Proton Beam Radiotherapy for Pediatric Soft Tissue Sarcomas: A Single‐Institutional Experience on Acute Toxicity and Short‐Term Outcomes {#pbc27455-sec-7670}

[J. Shin]{.ul} ^1^, W. Hartsell^2^, J.H.C. Chang^3^

*^1^Rush University Medical Center, Radiation Oncology, Chicago, USA; ^2^Northwestern Medicine Chicago Proton Center, Radiation Oncology, Warrenville, USA; ^3^Vanderbilt University Medical Center, Radiation Oncology, Nashville, USA*

**Background/Objectives**: The objective of our study is to assess the short‐term efficacy and acute toxicity of proton beam radiotherapy (PBT) as part of definitive management in pediatric patients diagnosed with soft tissue sarcomas.

**Design/Methods**: We identified 40 pediatric patients treated between 2011 and 2016 with soft tissue sarcoma. The endpoints analyzed were treatment‐related acute toxicity, progression‐free survival (PFS), and overall survival (OS). Acute treatment‐related toxicities were assessed according to the CTCAE v4.0. All data analyses were performed using SPSS 22.0. Kaplan‐Meier estimates were used to analyze OS rates.

**Results**: Median follow‐up was 17.2 months (7.8‐68.8). Rhabdomyosarcoma was the most common histology (52.5%) followed by Ewing\'s sarcoma (30.0%). Most patients (67.5%) underwent primary surgery, and 95% of patients received chemotherapy. The most common proton radiation technique used was three‐dimensional uniform scanning (82.5%) while the remaining patients received pencil beam scanning. The median proton radiation prescription was 50.4 Cobalt Gray Equivalents (CGyE) in 28 CGyE fractions. The most commonly reported acute toxicity was grade 2 dermatitis in 23 patients (57.5%). Four patients (10.0%) had grade 3 dermatitis. One patient (2.5%) experienced grade 3 nausea. Other grade 2 acute toxicities included pain in 11 patients (27.5%), weight loss in 5 (12.5%), fatigue in 4 (10.0%) and nausea in 3 patients (7.5%). Twenty‐nine patients (72.5%) were alive without local failure or distant disease at last follow‐up, corresponding to a 2‐year OS of 94.4%. The 1‐ and 2‐year local control rates were 91.6% and 81.4%. The 1‐ and 2‐year PFS rates were 88.9% and 67.5%, respectively.

**Conclusions**: Proton beam therapy for pediatric sarcomas appears to be effective and was delivered with acceptable acute treatment‐related toxicity in the setting of definitive or adjuvant irradiation. Further long‐term follow‐up is warranted.

### PO-536. Expanded Access of Larotrectenib to Manage Pediatric TRK Fusion Sarcomas {#pbc27455-sec-7680}

[Y. Suehara]{.ul} ^1^, T. Trahair^2^, M. Kirby^3^, S. Saito^4^, M. Capra^5^, T. Ghosh^6^, M. Cox^7^, N. Ku^7^, D. Henry^7^, S. Kato^8^, D. Zeigler^2^

*^1^Juntendo university, Orthopedic surgery, Tokyo, Japan; ^2^Children\'s Cancer Institute‐ University of New South Wales, Pediatrics, New South Wales, Australia; ^3^Women\'s and Children\'s Hospital, Pediatrics, Adelaide, Australia; ^4^Nagano Children\'s Hospital, Pediatrics, Nagano, Japan; ^5^Our lady\'s Children\'s Hospital, Pediatrics, Crumlin, Iran; ^6^University of Minnesota Medical School, Department of Pediatrics‐ Minneapolis, Minneapolis‐ MN, USA; ^7^Loxo Oncology‐ Inc, None, South San Francisco‐ CA‐, USA; ^8^Juntendo university, Medical oncology, Tokyo, Japan*

**Background/Objectives**: TRK fusions (involving genes *NTRK1*, *NTRK2*, and *NTRK3*) occur in a broad range of malignancies. Larotrectinib, the first selective TRK inhibitor, has demonstrated an overall response rate of 75% in TRK fusion solid tumors (93% in children) with a favorable safety profile (Drilon et al., *NEJM*, 378:731‐739, Laetsch et al., Lancet Oncology 2018, in press). Larotrectinib was provided worldwide according to local regulations via an expanded access to patients with TRK fusion cancers (NCT03025360). The efficacy and safety results of the pediatric sarcoma subset of this experience are presented here.

**Design/Methods**: Pediatric patients with TRK fusion sarcomas who were unable to access larotrectinib through a clinical trial were eligible. Patients received larotrectinib 100mg/m^2^/dose orally BID (max 100mg/dose) continuously. Disease response was assessed by investigators. Surgery for local control was allowed at investigator\'s discretion.

**Results**: As of Feb 28, 2018, six patients \[infantile fibrosarcoma (4), soft‐tissue sarcoma NOS (1) and retroperitoneal congenital sarcoma (1)\], age of 4 months‐8 years, from Japan (2), Australia (2), Ireland (1) and USA (1) were enrolled. Four patients had fusions involving *NTRK3* and 2 had fusions involving *NTRK1*. Previous therapies included chemotherapy and surgery (2), chemotherapy only (2) or surgery only (1). One patient was treatment‐naïve. One patient had grade 2 nausea and grade 1 vomiting, another had grade 2 increase in liver transaminases. There were no dose modifications or discontinuations due to adverse events. The investigator‐assessed objective response rate was 100% (1 CR and 5 PR) with ongoing duration of treatment ranging from 1.6 to 6 months. One patient underwent limb‐sparing surgery with negative margins (R0 surgery) upon significant tumor reduction following 3 months of treatment.

**Conclusions**: In the real‐world setting, larotrectinib is an effective, and safe treatment for pediatric patients with TRK fusion sarcomas, and can prevent disfiguring surgery.

### PO-537. Topotecan and Ifosfamide Therapy for Pediatric Patients with Relapsed Solid Tumors {#pbc27455-sec-7690}

[M. Sugiyama]{.ul} ^1^, A. Arakawa^1^, N. Shirakawa^1^, S. Tomoko^1^, M. Nakajima^1^, S. Ishimaru^1^, T. Kumamoto^1^, N. Kawakubo^2^, T. Hishiki^2^, A. Kawai^3^, C. Ogawa^1^

*^1^National Cancer Center Hospital, Department of Pediatric Oncology, Tokyo, Japan; ^2^National Cancer Center Hospital, Department of Pediatric Surgical Oncology, Tokyo, Japan; ^3^National Cancer Center Hospital, Department of Musculoskeletal Oncology and Rehabilitation, Tokyo, Japan*

**Background/Objectives**: The prognosis of pediatric relapsed solid tumors remains poor, necessitating new treatment strategies. We treated pediatric patients with relapsed solid tumors using topotecan and ifosfamide (TI) therapy (topotecan, 0.6 mg/m^2^/dose and ifosfamide, 1.2 g/m^2^/dose every 5 days) and retrospectively analyzed the treatment outcomes and adverse events to clarify the efficacy and safety of TI therapy.

**Design/Methods**: We reviewed the electronic medical records of patients who received TI therapy in the Department of Pediatric Oncology (National Cancer Center Hospital) between March 2013 and December 2017.

**Results**: Twenty patients \[5 males and 15 females; median age, 14.5 (range, 3--34) years\] received TI therapy. Tumor histology comprised Ewing\'s sarcoma family tumor (10 patients), rhabdomyosarcoma (4 patients), osteosarcoma (3 patients), retinoblastoma (2 patients), and desmoplastic small round cell tumor (1 patient). The median number of treatment courses was 6 (1--7), and 9 patients received additional therapy, including radiotherapy, surgery, and autologous peripheral stem cell transplantation. Adverse events (AEs) were mainly limited to hematological toxicity; common non‐hematological AEs included nausea, constipation, aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, and proteinuria. Grade 3 non‐hematological AEs were infrequent and included febrile neutropenia (2 patients), elevated AST (1 patient), elevated ALT (1 patient), and proteinuria (1 patient). Grade 4 non‐hematological AE was not reported. Except for 1 patient who did not have an evaluable lesion, 10 (52.6%) patients achieved complete or partial response within four courses, and the median relapse‐free survival was 195 days (95% confidence interval, 130--382 days).

**Conclusions**: TI therapy is effective in relapsed pediatric solid tumors and can be tolerable to heavily treated patients. Although it does not frequently achieve the complete response, a particular span of survival could be attained during and after the treatment. Thus, TI therapy is useful against relapsed pediatric solid tumors.

### PO-538. Programmed Cell Death 1 (PD‐1) and Programmed Cell Death Ligand 1 (PD‐L1) Expression Patterns in Ewing and Ewing‐Like Sarcoma {#pbc27455-sec-7700}

[A. Tamura]{.ul} ^1^, M. Yoshida^2^, N. Yamamoto^1^, S. Nakamura^1^, T. Fujiwara^1^, T. Tahara^1^, A. Saito^1^, A. Kozaki^1^, K. Kishimoto^1^, T. Ishida^1^, D. Hasegawa^1^, Y. Kosaka^1^

*^1^Kobe Children\'s Hospital, Department of Hematology and Oncology, Kobe City, Japan; ^2^Kobe Children\'s Hospital, Department of Diagnostic Pathology, Kobe City, Japan*

**Background/Objectives**: The prognosis of patients with metastatic Ewing and Ewing‐like sarcoma is dismal. Therefore, there is a clear need for novel therapeutic strategies. Immune checkpoint inhibitors have become emerging therapeutic strategy for various kinds of cancers. However, there is almost no data regarding the use of these drugs for Ewing and Ewing‐like sarcoma. PD‐1 and PD‐L1 expression may be a surrogate marker of response to immune checkpoint inhibitors. We investigated the expression patterns of PD‐1 and PD‐L1 in Ewing and Ewing‐like sarcoma by immunohistochemistry analysis of tumor samples at diagnosis.

**Design/Methods**: Immunohistochemistry analysis was performed on paraffin‐embedded pretherapeutic tumor biopsies from newly diagnosed patients with Ewing sarcoma (n=11) and Ewing‐like sarcoma (n=6). For the assessment of staining, a semiquantitative scoring system; (−) as negative, (+) as weak, (++) as intermediate, and (+++) as high, were used.

**Results**: PD‐L1 expression was not detected on tumor cells in any of the 17 samples (0%) with Ewing and Ewing‐like sarcoma. PD‐1 expression was detected weakly (+) on tumor infiltrating lymphocytes in 3 out of 11 (27.2%) Ewing sarcoma and 4 out of 6 (66.6%) Ewing‐like sarcoma samples. PD‐1 was expressed on 4 out of 11 (36.3%) Ewing tumor cells, either strongly (+++, n=3), or intermediately (++, n=1). In contrast, none of 6 Ewing‐like tumor cells (0%) expressed PD‐1. Two out of 4 (50%) patients with PD‐1 expressing Ewing sarcoma presented with distant metastases. In contrast, 2 out of 7 (28.6%) patients with Ewing sarcoma without PD‐1 expression on tumor cells presented with distant metastases.

**Conclusions**: Ewing and Ewing‐like sarcoma tumor cells do not usually express PD‐L1. PD‐1 expressing tumor infiltrating lymphocytes are not predominant in Ewing and Ewing‐like sarcoma. However, PD‐1 is strongly expressed in a subset of Ewing sarcoma tumor cells. In contrast, Ewing‐like sarcoma tumor cells did not express PD‐1.

### PO-539. Sirolimus for the Treatment of Children with Complex Vascular Anomalies {#pbc27455-sec-7710}

[D. Tugcu]{.ul} ^1^, S. Ocak^1^, Z. Bayramoglu^2^, A. Ozkan Karagenc^1^, R. Tuna^1^, S. Karaman^1^, I. Adaletli^2^, A. Aydin^3^, Z. Karakas^1^

*^1^Istanbul University‐ Istanbul Faculty of Medicine, Pediatric Hematology‐Oncology, Istanbul, Turkey; ^2^Istanbul University‐ Istanbul Faculty of Medicine, Radiology, Istanbul, Turkey; ^3^Istanbul University‐ Istanbul Faculty of Medicine, Plastic and Reconstructive Surgery, Istanbul, Turkey*

**Background/Objectives**: Local treatment of complex vascular anomalies is often difficult. In recent years, there are reports the use of sirolimus in symptomatic cases where surgical and local sclerotherapy can not be applied. In this study, we aimed to report of treatment results of ten patients, who underwent sirolimus treatment.

**Design/Methods**: Ten patients(6 boys,4 girls) were treated with sirolimus between january 2016 and february 2018. There were cystic complex lymphangiomatous malformation in six cases, complex venous malformation in four cases. Median age at diagnosis was 5 years(8months‐13 years). Lesions were located in head, neck and trunck in 6 patients, extremity in 4 patients. All cases were diagnosed by radiologically and clinical evaluation. Ultrasonography or MRI and follow‐up imaging were performed according to the lesion location. Sirolimus was initiated in cases of growth or pain in the lesions from birth, in the presence of loss of function, and in cases not suitable for local treatment. Therapy results were evaluated.

**Results**: Sirolimus was used 0.8 mg/m2/dose, two doses per day, 6‐12 months, according to the response. During the treatment, cases were evaluated monthly for clinical response, infection, lymphopenia, hyperlipidemia and 3‐month intervals in terms of radiological response. Clinical and radiological complete or near complete response was achieved in cases with lymphangioma. However, in two of the four complex venous malformation cases, there was minimal decrease in clinical complaints and lesion sizes. Stable findings were seen in other 2 cases and no significant response was obtained. Sirolimus was well tolerated with insignificant side effects.

**Conclusions**: Sirolimus was found to be effective in the treatment of vascular anomalies, especially lymphangiomas. However, it was determined that the efficacy of treatment in venous malformations, was not as good as lymphangiomas, further studies with larger sample size are warranted. The optimum length of treatment and possible long‐term side effects have to be evaluated with a longer term results.

### PO-540. Rhabdomyosarcoma in Infants: A Single Center Experience {#pbc27455-sec-7720}

[C. Ugaz Olivares]{.ul} ^1^, J. Montoya Vasquez^1^, J. Garcia Leon^1^, L. Vasquez Ponce^2^

*^1^Instituto Nacional de Enfermedades Neoplasicas, Lima, Lima, Peru; ^2^Hospital Nacional Edgardo Rebagliati, Lima, Lima, Peru*

**Background/Objectives**: Rhabdomyosarcoma (RMS) in infants younger than 1 year represent a subset of patients with a challenging treatment. In this study, we report a 28‐year single center experience at the National Institute of Neoplastic Diseases (INEN).

**Design/Methods**: We collected retrospectively the clinical and outcome data of all children younger than 1 year diagnosed with RMS.

**Results**: Twenty‐three patients younger than 1 year with definitive diagnosis of RMS were included. Median age was 5 months (range, 0.5‐11), with a female predominance (65%). Nineteen patients (82.6%) had a non‐alveolar histological subtype and 12 patients (52.2%) had a non‐favorable primary location. Nine patients (39.1%) had metastatic disease at onset. With a median follow‐up of 20 months, 5‐year event‐free survival (EFS) and overall survival (OS) rates were 23% (Standard Error, SE 10%) and 60% (Standard Error, SE 12.7%), respectively. Metastatic disease was the most significant prognostic factor for OS and EFS.

**Conclusions**: In this study, we confirm that RMS in infants has a dismal prognosis. Multicenter studies should be encouraged to analyze prognosis factors in these patients.

### PO-541. AMORE Treatment as Salvage Treatment in Children with Relapsed Head‐Neck Rhabdomyosarcoma {#pbc27455-sec-7730}

[B. Vaarwerk]{.ul} ^1^, M. Hol^2^, R. Schoot^3^, W. Breunis^1^, M. de Win^4^, H. Westerveld^5^, R. Davila Fajardo^6^, P. Saeed^7^, M. van den Brekel^8^, B. Pieters^5^, S. Strackee^9^, L. Smeele^2^, H. Merks^10^

*^1^Emma Children\'s Hospital/Academic Medical Centre, Department of Paediatric Oncology, Amsterdam, The Netherlands; ^2^Academic Medical Center, Department of Oral and Maxillofacial surgery, Amsterdam, The Netherlands; ^3^Emma Children\'s Hospital‐ Academic Medical Center, Department of Paediatric Oncology, Amsterdam, The Netherlands; ^4^Academic Medical Center, Department of Radiology, Amsterdam, The Netherlands; ^5^Academic Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands; ^6^University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands; ^7^Academic Medical Center, Orbital Centre‐ Department of Ophthalmology, Amsterdam, The Netherlands; ^8^The Netherlands Cancer Institute, Department of Head and Neck Oncology and Surgery, Amsterdam, The Netherlands; ^9^Academic Medical Center, Department of Plastic‐ Reconstructive and Hand Surgery, Amsterdam, The Netherlands; ^10^Princess Máxima Centre for Paediatric Oncology, Solid tumour department, Amsterdam, The Netherlands*

**Background/Objectives**: Survival after relapse of rhabdomyosarcoma in the head and neck area (HNRMS) after prior external beam radiotherapy (EBRT) is poor, since options for adequate local treatment are often lacking. In this study we describe our experience with salvage AMORE in patients with relapsed HNRMS after prior EBRT.

**Design/Methods**: Patients with relapsed HNRMS after prior EBRT in which salvage AMORE treatment was considered feasible were analysed; this includes patients with parameningeal, head and neck non‐parameningeal and orbital localisation. AMORE treatment consisted of Ablative surgery, MOuld technique brachytherapy and surgical REconstruction.

**Results**: In total 18 patients received salvage AMORE treatment; nine patients had relapsed parameningeal (PM) RMS, two patients had relapsed head and neck non‐parameningeal RMS (HN‐nonPM) and seven patients had relapsed orbital RMS. The local control rate was 67% and 5‐year overall survival was 54% (95% confidence interval: 31‐78%); 3/9 patients with PM RMS, 0/2 patients with HN‐nonPM RMS and 6/7 patients with orbital RMS were alive after a median follow‐up of 8.6 years. One patient with PM RMS survived more than 5 years after which he died from a secondary cancer. Six patients developed a local relapse (of which one patient also developed a distant metastasis) and two patients developed distant metastases. Most reported adverse events in surviving patients with PM located tumours were musculoskeletal deformities and growth hormone deficiency. Most reported adverse events for surviving patients with orbital located tumours this were musculoskeletal deformities caused by the orbital exenteration.

**Conclusions**: Salvage AMORE treatment is a safe and effective local therapy approach even after prior EBRT. Since salvage AMORE treatment is sometimes the only curative option in patient with relapsed HNRMS, we encourage physicians to consider salvage AMORE treatment for patients with relapsed HNRMS after prior EBRT.

### PO-542. Combined Immunotherapy Treatment to Prevent Pediatric Sarcoma Metastasis {#pbc27455-sec-7740}

[M. Vela]{.ul} ^1^, P. González‐Navarro^1^, A. Brito^1^, J. Valentín^1^, D. Bueno^2^, A. Escudero^3^, L. Fernández^4^, P.M. Antonio^2^

*^1^Hospital La Paz Institute for Health Research IdiPAZ, Translational Research in Pediatric Oncology‐ Hematopoietic Transplantation & Cell Therapy, Madrid, Spain; ^2^La Paz University Hopsital, Pediatric Hemato‐Oncology Unit, Madrid, Spain; ^3^Institute of Medical and Molecular Genetics INGEMM‐ La Paz University Hopsital, Molecular Pediatric Oncology Unit, Madrid, Spain; ^4^Spanish National Cancer Research Centre CNIO, H12O‐CNIO Hematological Malignancies Clinical Research Unit, Madrid, Spain*

**Background/Objectives**: Metastasis occurs in 20‐55% of sarcoma patients and remains the main cause of death. We propose a novel immunotherapeutic approach based in anti CXCR4 antibody MDX1338 (Bristol Myers Squibb) in combination with Activated and Expanded Natural Killer (NKAE) cells therapy. CXCR4 is upregulated in 33.3‐73.3% sarcomas. Its signaling blockade by MDX1338 may reduce tumor growth and metastatic burden. NKAE cells have shown cytotoxicity against osteosarcoma and Ewing sarcoma.

**Design/Methods**: Expression of CXCR4 by different sarcoma cell lines was analyzed by flow cytometry. Its migration and invasion capacity towards CXCL12 was tested using Transwell plates and Matrigel. NKAE cells were obtained coculturing healthy donors' peripheral blood mononuclear cells with K562‐mb15‐41BBL cells and IL‐2. Rhabdomyosarcoma cells were inoculated intravenously in immunodeficient NSG mice to generate an *in vivo* model of metastatic sarcoma. Four treatment arms were established: MDX1338; NKAE; MDX1338+NKAE; vehicle. Luminiscent tumors were monitored and subsequently micrometastasis were identified and quantified: by qRT‐PCR; by immunohistochemistry; and by fluorescence *in situ* hybridization.

**Results**: Alveolar rhabdomyosarcoma RH30 cell line showed the highest CXCR4 expression, concomitant with highest migration and invasion index. Both MDX1338 and NKAE efficiently reduced *in vitro* RH30 cells migration and invasion, but only the combination of both agents completely abrogated it. In *in vivo* assays, NKAE treatment was enough to completely prevent RH30 tumor implant. Nontheless, qRT‐PCR analysis found RH30 lung micrometastasis in NKAE‐treated mice group. Again, the combination of both MDX1338 and NKAE was necessary to completely eliminate it. Immunohistochemical and *in situ* hybridization analysis further confirmed these results.

**Conclusions**: Our *in vitro* and *in vivo* studies show a complementary role of anti CXCR4 antibody MDX1338 and NKAE cell therapy to prevent rhabdomyosarcoma cells migration, invasion, tumor implant and lung metastasis formation. These preclinical results constitute a first evidence of the efficacy of this combined immunotherapy to prevent sarcoma disease dissemination.

### PO-543. External Irradiation Combined with Brachytherapy in Treatment of Invasive Maxillofacial Rhabdomyosarcoma: A Case Report {#pbc27455-sec-7750}

[Y. Wang]{.ul} ^1^, J. Chang^2^, L. Wang^3^, L. Wang^4^

*^1^first hospital of jilin university, department of pediatric, changchun, China; ^2^first hospital of jilin university, department of pediatric oncology, Changchun, China; ^3^first hospital of jilin university, department of prdiatric oncology, changchun, China; ^4^First hospital of jilin university, depatrment of pediatric ultrasound, Changchun, China*

**Background/Objectives**: Here we report external irradiation combined with brachytherapy for a 12‐year‐old female with invasive maxillofacial rhabdomyosarcoma.

**Design/Methods**: A 12‐year‐old female presented to our department with a complaint of swelling of the right face. A small mass was noted on the right cheek. The opening of mouth was restricted, appoxamately 2cm. Intraroral examination revealed just a small mass about 1X1cm. After needle biopsy, the tumor was diagnosed as Spindle cell rhabdomyosarcoma. After needle biopsy, the mass enlarged very quickly. Just three days, we could saw a huge tumor growing outside the mouth. We gave the first cycle of chemotherapy with vincristine, ifosfamide and etoposide. Even during the chemotherapy, the tumor continued growing. Then, we gave the patient intratumor injection with carboplatin. In the first week after intratumor injection, the mass in mouth kept growing. So the chemotherapy region switched to vincristine, topotecan and cyclophosphamide. During the second cycle of chemotherapy, the mass in the mouth came off by itself. Then, this patient received concurrent radiochemotherapy, the dose of gross target volume was 5940cGY. The follow‐up MRI showed the mass was still 4.8X7X7cm. After that, the girl received brachytherapy. After the surgery, the girl received 4 cycles of chemotherapy. During the eighth chemotherapy, serious bleeding was happened on the sufface of tumor in mouth, and the opening of mouth was more restricted. After symptomatic support treament, this patient received additional 7cycles of chemotherapy.

**Results**: After the whole treatment procoss, we took PET‐CT scan. It showed that the residual fraction of tumor was inactive. But now, it is hard for the girl to open mouth freely, and the facial skin pigmentation caused by radiation therapy increases the mental burden of the young girl.

**Conclusions**: There is no consensus on radiotherapy in children with maxillofacial rhabdomyosarcoma. Although the patient\'s tumor was well controlled, there was a serious adverse reaction associated with radiotherapy. The pattern and dosage of radiotherapy should be further studied.

### PO-544. Clinical Outcomes of 71 Chinese Children with Rhabdomyosarcoma Under Multidisciplinary Treatment {#pbc27455-sec-7760}

X. Yuan^1^, [X. Yanli]{.ul} ^1^

*^1^Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Pediatric Hematology/Oncology, Shanghai, China*

**Background/Objectives**: To explore the effectiveness and feasibility of multidisciplinary treatment (MDT) based on CQ‐RMS‐2009 protocol, and analyze prognostic factors on long‐term survival of children with rhabdomyosarcoma (RMS).

**Design/Methods**: Medical records of patients with newly diagnosed RMS under 14 years old at Xinhua Hospital Affilated to Shanghai Jiao tong University School of Medicine, from May 2006 till April 2016.The clinical data of age, gender, primary site, histology type, FOXO1 fusion gene, tumor size, lymph nodes involved, pre‐treatment stages, postsurgical grouping, risk, patterns of treatment according to different years were retrospectively analyzed.

**Results**: A total of 77 new cases of children with RMS were treated in our hospital, 6 patients (7.8%) were excluded from the analysis for abandoning treatment after diagnosis. Hence, 71 patients with complete follow‐up data were eligible for this study. The male to female ratio was 1.84:1, median age at diagnosis was 47 (2‐166) months, and median follow‐up time was 29 (10‐126) months. During 2006‐2009 years and 2009‐2016 years the 3y‐OS was 59.6±11.9% and 77.5±7.5% respectively, and 3y‐EFS were 53.5±12.1% and 71.1±9.1%(P=0.064).Univariate analysis showed that pathological subtypes (P=0.031), postoperative clinical group (P=0.043), treatment patterns (P=0.040) were significantly associated with overall survival. Multivariate analysis showed that the postsurgical grouping (P=0.014), recurrence/ progressive disease (P=0.029) and treatment patterns (P=0.032) were independent prognostic factors. Twenty‐nine cases (40.8%) developed recurrence/ progressive disease, median relapsed/ progressive time was 17 months after diagnosis (5‐55 months) and 2y‐OS was 39.9±11.7%. The number of patients with relapse/ progressive disease during 2006‐2009 accounted for 61.1%(11/18), while the rate was only11.9% (18/53) during 2009‐2016, there was significant differences(ⅹ2=7.017, P=0.008).

**Conclusions**: The main cause of high recurrence/ progressive disease during 2006‐2009 was lack of multidisciplinary treatment. It suggested that CQ‐RMS‐2009 protocol with MDT modality could effectively improve the prognosis of children with RMS.

### PO-545. MYOG Promoter Controlled Oncolytic Adenovirus Selectively Kills Rhabdomyosarcoma Cells {#pbc27455-sec-7770}

[H. Yoshida]{.ul} ^1^, M. Sato‐Dahlman^1^, P. Hajeri^1^, K. Jacobsen^1^, M. Yamamoto^1^

*^1^University of Minnesota, Department of Surgery, Minneapolis, USA*

**Background/Objectives**: Oncolytic adenovirus (OAd) infects, replicates and kills the target cancer cell selectively. MYOG is one of muscle differentiation markers, and its expression is restricted to muscle system cells. Previous report indicated that PAX3‐FOXO1 activated mutant MYOG promoter (MYOGp, with mutations in MEF2‐binding region) approximately ten times compared to parental MYOD1 without mutation. Therefore, we developed an OAd that can attack RMS cells but not normal cell by exploiting the differences of MYOG expression between normal and RMS cells, and also developed another OAd with mMEF2 that can attack RMS with PAX3‐FOXO1 more specifically.

**Design/Methods**: Two RMS cell lines, RH30 (PAX3‐FOXO1 positive) and RD (PAX3‐FOXO1 negative) were used followed experiment. Three different of length of MYOGp (about 0.3, 1 and 2.7kbp; MYODp(S), MYODp(M), MYODp(L)) were cloned, and then pShuttle‐MYOGp‐luc and AdEasy‐MYOGp‐luc were established. We evaluated which length of MYOGp was the most powerful and specific for RMS. Subsequently, to evaluate for their cell killing ability, we also made AdMG‐MYOGp‐E1 viruses, fully competent OAd.

**Results**: Luciferase assay revealed that MYOGp(S) with MEF2 mutation showed highest activity closest to the wild type promoter (WT) in Rh30 among three length of MYOGp. Next, in luciferase assay using AdEasy‐MYOGp‐luc, MYOGp(S) controlled AdV showed higher activity in not RD but Rh30, and the difference between WT and mMEF2 was significant. Based on these results, we made AdMG‐MYOGp(S)‐E1 and evaluated its killing ability. AdMG‐MYOGp(S)‐E1 needed 100 times as high virus titer as AdMG‐CMV‐E1 in not‐muscular cell lines. Additionally, it needed 10 times as high virus titer to kill normal differentiated muscle cell compared to RMS cell. The difference of cell killing ability between WT and mMEF2 was not clear in RH30 and RD using AdMG‐MYOGp(S)‐E1.

**Conclusions**: MYOGp controlled OAd specifically killed RMS. To enhance its specificity, we are developing a virus fiber recognizing RMS specific cell surface antigen.

### PO-546. Therapeutic Targeting of Hypercitrullination Following PADI2 Overexpression in Ewing Sarcoma {#pbc27455-sec-7780}

[S. Zöllner]{.ul} ^1^, S. Horibata^2^, S.P. Selvanathan^3^, M. Hotfilder^1^, G.T. Graham^3^, A. Albers^1^, D. Clemens^1^, S.A. Coonrod^2^, U. Dirksen^4^, T.G. Grünewald^5^, W. Hartmann^6^, J. Rehkämper^6^, C. Rössig^1^, P.R. Thompson^7^, A. Üren^3^, J.A. Toretsky^3^

*^1^University Hospital Muenster, Department of Pediatric Hematology and Oncology, Muenster, Germany; ^2^Cornell University‐ College of Veterinary Medicine, Baker Institute for Animal Health, Ithaca, USA; ^3^Georgetown University, Department of Oncology and Pediatrics, Washington, USA; ^4^University Hospital Essen, West German Cancer Centre‐ Pediatrics III‐ Hematology/Oncology, Essen, Germany; ^5^Ludwig‐maximilians‐universität, Max‐Eder Research Group for Pediatric Sarcoma Biology‐ Institute of Pathology, München, Germany; ^6^University Hospital Muenster, Institute of Pathology, Muenster, Germany; ^7^University of Massachusetts Medical School, Department of Biochemistry and Molecular Pharmacology, Worcester, USA*

**Background/Objectives**: Chromatin modifications are increasingly recognized as a key mechanism in cancer. Ewing sarcoma (ES) is driven by EWS‐FLI1 which has been shown to mediate global and gene specific epigenetic alterations in ES biology. The peptidylarginine deiminase (PADI) enzymes catalyze a definitive structural remodeling of chromatin called citrullination to modulate gene regulation. Hypercitrullination occurs following PADI overexpression in some cancers. We discovered *PADI2* as a novel gene target in ES and dissected its oncogenic role and potential therapeutic targeting.

**Design/Methods**: Using different *in vitro* and *in vivo* models we analyzed PADI2 expression in response to the oncogenic driver EWS‐FLI1. Further, we studied the effect of PADI2 downregulation via shRNA in ES cell lines and the effect of pharmacological reduction of PADI2.

**Results**: We found isoform specific PADI2 overexpression in ES cell lines which was confirmed in ES patient cohorts. PADI2 upregulation is specifically found in ES clinical samples compared to other sarcoma types including Ewing‐like sarcomas harboring different translocations. Both PADI2 expression and histone citrullination are features of ES patients. Knockdown of EWS‐FLI1 via shRNA decreased PADI2 expression both *in vitro* and *in vivo*. Using YK‐4‐279 as a probe to disrupt protein‐protein interactions of EWS‐FLI1, we found that treatment with YK‐4‐279 significantly reduced PADI2 expression in ES cell lines. *Vice versa*, reduction of PADI2 in ES cells abrogated the oncogenic phenotype. Aberrant PADI2 expression and/or hypercitrullination can be targeted therapeutically in ES through pan‐PADI‐inhibitor BB‐Cl‐amidine at IC50 of 5 μM. BB‐Cl‐amidine significantly induced apoptosis and reduced colony formation compared to MCF7 cells in ES cell lines *in vitro*.

**Conclusions**: Increased *PADI2* expression and hypercitrullination following EWS‐FLI1‐induction is a hallmark of ES. Therapeutic abrogation of citrullination through PADI‐inhibitors is cytotoxic for ES warranting further validation of PADI2 inhibitors both to target this novel epigenetic regulator in ES and more deeply understand the pathobiology of EWS‐FLI1.

Solid Non Brain Tumours ‐ Retinoblastoma {#pbc27455-sec-7790}
----------------------------------------

### PO-547. To Save Eye or Save Life: Retinoblastoma in Low‐Income Countries {#pbc27455-sec-7800}

[A. Ahmad]{.ul} ^1^, S. Qayyum^2^

*^1^The Children\'Hospital&the Institute of Child Health Lahore, Paediatric Haematology/Oncology, Lahore, Pakistan; ^2^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Paediatric Ophthalmology, Lahore, Pakistan*

**Background/Objectives**: While Retinoblastoma is highly curable in developed countries, the outcome is still dismal in Pakistan with low ocular and patient survival. RB is one of the more common malignancies in paediatric oncology in developing countries. The objective of this study is to analyzes the challenges of Rx abandonment and enucleation refusal and advanced staging faced in managing RB in public sector hospital in Pakistan.

**Design/Methods**: Retrospective review of 150 patients enrolled with diagnosis of RB from January 2014 to December 2017 in the department of Paediatric Ophthalmology and Paediatric Oncology of the Children\'s Hospital Lahore Pakistan. The data analyzed using SpSS 20.

**Results**: A total of 150 children with 57% of males and 25% \<1 year and 69% 1‐5 Years age. Bilateral RB was present in 34%, unilateral in 64% and trilateral in two cases. Optic nerve was involved in 53% and Brain metastasis in 22%. Neoadjuvant chemotherapy was given 51% and enucleations done in 68%. Chemotherapy started late in 40% and 41% cases refused enucleation and 44% defaulted Treatment course after initiation of therapy. Local therapy and radiotherapy given in 22%.The treatment completed in 53% cases (p‐value: 0.000 for outcome and defaulted Rx), 22% absconded, 10% expired 8% relapsed and 7% put on palliation.--

**Conclusions**: Retinoblastoma is one of the most challenging childhood cancers to manage in resource limited settings with immense sociocultural barriers. A more focus on how to improve acceptance of families for life saving procedure of enucleation and compliance of treatment emphasized requiring strong multidisciplinary team management and intense Psychosocial support.

### PO-548. Implementation of a Retinoblastoma Program in Philippine Pediatric Cancer Units: Quality Measures and Survival for Unilateral, International Retinoblastoma Staging System (IRSS) Stage 1 Patients {#pbc27455-sec-7810}

[A.P. Alcasabas]{.ul} ^1^, J.P. Caneba^2^, C.L. Diez^3^, C. Rodriguez‐Galindo^4^, C. Lam^4^, J. Estanislao^2^, P. Fajardo^2^, M. Dolendo^3^

*^1^University of the Philippines ‐ Philippine General Hospital, Department of Pediatrics, Manila, Philippines; ^2^University of the Philippines ‐ Philippine General Hospital, Pediatrics, Manila, Philippines; ^3^Southern Philippines Medical Center, Pediatrics, Davao, Philippines; ^4^St. Jude Children\'s Research Hospital, Global Pediatric Medicine, Memphis, USA*

**Background/Objectives**: A multi‐faceted retinoblastoma program has been systematically developed in 3 pediatric cancer units (PCUs) in the Philippines. Stage based treatment protocols were implemented and for unilateral, intra‐ocular retinoblastoma, includes upfront enucleation, identification of pathology high risk features, complete staging work‐up and timely administration of risk‐adapted chemotherapy. Compliance with these key treatment components measures the quality of healthcare delivery. We report on the protocol adherence of 2 PCUs and their patient survival outcomes.

**Design/Methods**: Prospective data collection with retrospective analysis of consecutive, newly‐diagnosed, unilateral, intra‐ocular patients from January 2014 to December 2017. Study end‐point was March 2018.

**Results**: A total of 49 patients were seen. Mean age was 18.7 months (1 -- 51); M: F 1.4:1. Symptom to diagnosis interval was 5.5 months (0‐24) and median distance of patients' residence to treatment center was 98 km (1.5 ‐ 778). Forty five (92%) patients underwent upfront enucleation, 1 refused treatment, and 3 had neo‐adjuvant chemotherapy. Median time from diagnosis to enucleation was 15 days (1 -- 58). Pathological high risk features were determined in 48 patients, and were present in 34 (76%) of patients who received upfront enucleation. Five patients (10 %) had incomplete staging work‐up. Chemotherapy started at a median of 26 days (3 ‐ 198) after enucleation in 37 patients, including 3 without high risk features. Sixteen percent of chemotherapy cycles were delayed. At study end‐point, 90% (44) were alive, 2% (n=1) died (infection), 8% refused (2%; n=1) or abandoned (6%; n=3) treatment; 4% developed new tumors in the contralateral eye (n=2). The 2‐year abandonment sensitive overall and event free survival was 89%/83.

**Conclusions**: Systematic evaluation and development of standardized measures of healthcare delivery for retinoblastoma fosters patient safety, timely treatment; and potentially may decrease abandonment and improve survival, especially for complex clinical scenarios requiring multidisciplinary care coordination and decision making.

### PO-549. Results of Multidicsiplinary Treatment Approach of Retinoblastoma in Kazakhstan {#pbc27455-sec-7820}

[B. Baizakova]{.ul} ^1^, R. Boranbayeva^1^, B. Zhumadullayev^1^, O. Pankova^1^, B. Elibayev^1^, M. Remkulova^1^, M. Ensepbaev^2^, A. Bekisheva^3^, Y. Tyan^4^, D. Karimov^5^, A. Aubakirova^6^

*^1^Scientific Center of Pediatrics and Pediatric Surgery, Oncology, Almaty, Kazakhstan; ^2^Scientific Center of Pediatrics and Pediatric Surgery, Radiology, Almaty, Kazakhstan; ^3^Scientific Center of Pediatrics and Pediatric Surgery, Pathology, Almaty, Kazakhstan; ^4^Scientific Center of Pediatrics and Pediatric Surgery, Ophthalmology, Almaty, Kazakhstan; ^5^Scientific Center of Pediatrics and Pediatric Surgery, Intensive Care, Almaty, Kazakhstan; ^6^Scientific Center of Eye Diseases, Pediatric ophthalmology, Almaty, Kazakhstan*

**Background/Objectives**: Retinoblastoma is the most frequent intraocular tumor in children. Annually 600 cases treated in 2 tertiary cancer centers in Kazakhstan. Since 2015 patients with retinoblastoma from around the country has been focused in a one center which reveals 15‐25 patients with retinoblastoma per year. The aim of this study was to analyze the results of a multidisciplinary approach in the treatment of retinoblastoma.

**Design/Methods**: Cases of 53 patients treated at the Scientific Center for Pediatrics and Pediatric Surgery between 2015‐2017 were analyzed. Data included their age, sex, duration of diagnosis, stage, and the results of therapy. Patients were treated according to RBA‐2003 protocol.

**Results**: Total 53 patients (68 eyes) were enrolled with M:F ratio 1.3:1. Bilateral retinoblastoma occured in 15/53 (28%) cases. The average age is 13.6 months, for unilateral 16.2 months and 9.1 months for bilateral. The average time from the onset of the first symptom to hospitalization was 5.1 months. Classification according to the ICRB system: A‐3 (4.5%), B‐4 (6%), C‐4 (6%), D‐18 (26.5%), E‐39 (57%). Primary enucleation was performed in 14/53 (26.4%) patients, secondary enucleation ‐ 23/53 (43%), including one bilateral enucleation. Exenteration was conducted for 1 patient. Histological classification of removed eyes according to IRSS: I stage 29 (76%), II stage 7 (19%) and III stage 2 (5%). Forty (75.4%) children completed treatment, mean follow‐up time is 12.9 months. Overall survival rate is 90%. Thirteen patients refused treatment at different stages of therapy, 12 continued eye‐salvage treatment in foreign clinics, most of them 7(58%) with bilateral form. One complete rejection with fatal outcome within 15 months.

**Conclusions**: Multidisciplinary approach with the focus of specialists and patients in one center has made it possible to improve the management of the retinoblastoma and reduce mortality. Limited capacity of eye‐salvage local therapy is the main reason for refusing treatment.

### PO-550. Establishment of Carboplatin‐Resistant Retinoblastoma Cell Lines with Multidrug Resistance {#pbc27455-sec-7830}

[C.S. Cho]{.ul} ^1^, J. Dong Hyun^1,2^, J. Hyoung Oh^1^, K. Jin Hyoung^1^, K. Jeong Hun^1,2^

*^1^Fight against Angiogenesis‐Related Blindness FARB Laboratory, Clinical Research Institute‐ Seoul National University Hospital, seoul, Republic of Korea; ^2^Department of Ophthalmology, Seoul National University College of Medicine, seoul, Republic of Korea*

**Background/Objectives**: Many patients responded to the initial treatment of chemotherapy, but some patients were resistant to chemotherapy. Multidrug resistance is known as one of the causes. The purpose of this study was to establish carboplatin resistant retinoblastoma cell lines to study the treatment of chemotherapy of retinoblastoma.

**Design/Methods**: Y79 and SNUOT‐Rb1 based carboplatin‐resistant human retinoblastoma cell lines (Y79/CBP and SNUOT‐Rb1/CBP) were established by stepwise dose‐escalation method. The resistance of Y79/CBP and SNUOT‐Rb1/CBP cells against carboplatin induced cell death were validated using MTT assay, DNA fragmentation assay and immunocytochemistry for cleaved caspase‐3. In order to investigate the mechanism of carboplatin resistance in these cells, expression of multidrug resistance genes, growth curve, cell cycle distribution and cell cycle protein expression were observed. In order to compare the therapeutic effects of carboplatin, intraocular injections were performed on in vivo xenogeneic animal models made of parental and resistant cells.

**Results**: Resistant cell lines were developed by stepwise increasing the concentration of carboplatin in human retinoblastoma cell lines. Cell viability analysis, DNA fragmentation and cleaved caspase‐3 expression assay showed that resistance to carboplatin was increased in resistant cells compared to the parent cells. In addition, resistant cells increased the expression of multidrug resistance related genes as compared to parental cells. Interestingly, the growth rate of resistant cells was slower than that of parental cells. Cell cycle distribution showed an increase in G1 phase in resistant cells. Expression levels of cyclins D1 and D3 were decreased in resistant cells and expression levels of p18 and p27 were increased. It was confirmed that resistant cells formed in vivo intraocular tumors more effectively even with intravitreal injection of carboplatin than their parental cells.

**Conclusions**: This study suggests that carboplatin resistant retinoblastoma cell lines by multidrug resistanc can be used for further study of chemotherapy of retinoblastoma.

### PO-551. A Social Network Analysis of Global Retinoblastoma Care {#pbc27455-sec-7840}

[H. Dimaras]{.ul} ^1^, H. Girdler^1^, K. Hougham^1^, J. Prochaska^2^

*^1^The Hospital for Sick Children, Ophthalmology & Vision Sciences, Toronto, Canada; ^2^University of Texas Medical Branch, Preventive Medicine & Community Health, Galveston, USA*

**Background/Objectives**: We explored the nature and type of partnerships within the One Retinoblastoma World (<http://www.1rbw.org>) network.

**Design/Methods**: We conducted a mixed‐methods egocentric social network analysis to identify the prevalence and type of partnerships in the One Retinoblastoma World network. Participants completed an e‐survey to identify collaborations between their retinoblastoma treatment center (nodes), and partners (alters). The survey collected details of interactions (e.g. patient consultation, joint planning, resource sharing), and duration, frequency and nature of partnerships (e.g. formal or informal). Network maps were generated to visualize connectivity. Key informants participated in follow‐up semi‐structured interviews to provide further partnership details.

**Results**: Of 170 network members, 56 submitted survey responses (33% participation rate), representing 6 continents. Collectively, they identified 183 alters; 150 were treatment centers, while 33 were organizations outside of the network. North American and European nodes identified the most alters (mean 7 and 5, respectively), while Middle Eastern and North African nodes identified the fewest (mean 1). Most partnerships were related to patient referrals, with most of these operating within a single geographical region. Four research networks were identified; each had 1 node acting as a central 'hub'. Four twinning networks were identified; 3 dyads, and 1 with a central 'hub' connected to 5 nodes. Key informants revealed 4 main concepts: (1) the definition of 'partnership' varies; (2) the main motivation behind partnership is to improve patient outcomes; (3) developing strong partnerships is challenging; and (4) partnership activities are limited by the capacity of partners.

**Conclusions**: The One Retinoblastoma Network is highly connected, with distinct patterns of partnership following regional lines, with few exceptions. Partnership activities centred on retinoblastoma referral appear to mitigate local resource and capacity constraints. Capacity‐building partnerships improve availability of retinoblastoma treatment and enhance survival. Monitoring the evolution of these networks over time may reveal key influencers of capacity and improve survival.

### PO-552. Risk Stratification of Unilateral Retinoblastoma Patients with the RB1 Genetic Testing {#pbc27455-sec-7850}

[H. Hattori]{.ul} ^1,2^, I. Taguchi^1^, M. Morikawa^1^, T. Kubota^3^, N. Akita^2^, M. Sekimizu^2^, M. Ichikawa^2^, N. Maeda^2^, M. Ushiama^4^, T. Yoshida^4^, K. Sugano^5^, K. Horibe^2^

*^1^National Hospital Organization Nagoya Medical Center, Department of Clinical Genetics, Nagoya, Japan; ^2^National Hospital Organization Nagoya Medical Center, Department of Pediatrics, Nagoya, Japan; ^3^National Hospital Organization Nagoya Medical Center, Department of Ophthalmology, Nagoya, Japan; ^4^National Cancer Center Hospital, Department of Genetic Medicine and Services, Tokyo, Japan; ^5^Tochigi Cancer Center Research Institute, Oncogene Research Unit/Cancer Prevention Unit, Utsunomiya, Japan*

**Background/Objectives**: Retinoblastoma (RB) is a representative of inheritable childhood cancer, and even unilateral RB exhibits *RB1* germ‐line mutation in about 15% of cases, compared to 100% in bilateral RB. The purpose of genetic testing for the unilateral RB is to screen high risk cases for relapse, trilateral RB, and/or secondary cancer. *RB1* genetic testing into clinical practice was introduced in 2018 in Japan since health insurance coverage was initiated.

**Design/Methods**: We started the *RB1* genetic testing in our RB practice in 2016. In principle, all the parents whose child was newly diagnosed after 2014 were informed about the genetic testing.

**Results**: Out of 26 patients, 16 received the genetic counselling and 15 had the tests. Fourteen analysis were completed as of Apr. 2018. The patterns of mutation included exon skipping in 2, one splicing alteration, and one nonsense mutation. Germline mosaicism was suggested in two patients. We informed the parents whose child had the mutations about the importance of follow‐ups and possible risks of the secondary cancer. We continued to follow‐up using brain MRI imaging and ophthalmoscopy in the mutation positive patients at the same frequency as the bilateral cases, but discontinued the MRI for the mutation negative patients.

**Conclusions**: *RB1* genetic testing provided medical benefits that enabled us to follow‐up the higher risk patients more closely. In addition, the *RB1* genetic testing for the unilateral RB should be performed to support individualized disease management plan, which can also consider the psychological impact on the affected families. Further observation is needed to elucidate the impact of mosaicism and/or low‐penetrance mutation upon the relapse, trilateral RB development, and secondary cancer.

### PO-553. Serum Urea Nitrogen and Creatinine Changes and its Clinical Analysis in Children with Retinoblastoma Before and after Chemotherapy {#pbc27455-sec-7860}

[H. Hong]{.ul} ^1^, M. Jin^1^, J. Zhao^2^, C. zhang^3^, W. Zhao wen^1^, X. Wang^1^, Q. Zhao^1^, C. Duan^1^, Y. Su^1^, X. Ma^1^

*^1^Beijing Children\'s Hospital, Capital Medical University, National Center of Children\'s Health, Hematology Oncology Center, Beijing, China; ^2^Beijing Children\'s Hospital, Capital Medical University, National Center of Children\'s Health, Department of Ophthalmology, Beijing, China; ^3^Beijing Children\'s Hospital, Capital Medical University, National Center of Children\'s Health, Department of Ophthalmology, Beijing, China*

**Background/Objectives**: To analyze alterations of blood urea nitrogen(BUN) and serum creatinine(Scr) in children with retinoblastoma(Rb) before and after chemotherapy and its clinical significance of the chemotherapy effect, and to provide the reference for the further improvement of the safety of treatment.

**Design/Methods**: 280 children with retinoblastoma were enrolled in the study, each of them was treated with CEV(carboplatin+ etoposide+ vincristine) methods combined with local ophthalmic therapy and enucleation, BUN and Scr were detected before the initial chemotherapy and after the last chemotherapy. Eligible eyes were classified according to the International Intraocular Retinoblastoma Classification(IIRC).

**Results**: There were 280 patients, including 153 males and 127 females, with a mean treatment of 4.5 cycles and a mean age of 21.5 months. 149 cases were Clinical diagnosed, 131 cases were pathological diagnosed. 8 cases were in extraocular stage, 3 cases in glaucoma and 269 cases in intraocular period. Among 269 Intraocular Rb, the tumor occurred unilaterally in 101 children and bilaterally in 168 children. BUN was 3.05 mmol /L before chemotherapy and 3.46 mmol /L after chemotherapy in the group aging from 4 months to less than 12 months, BUN after chemotherapy is higher, and only in this group the change was statistically different(t=‐2.829, p=0.006), but all BUN values in this group were not beyond the highest reference value. Before initial chemotherapy, 149 patients have Scr below the reference range, 20 cases have the BUN below the reference value.

**Conclusions**: Renal function of 280 Rb children before treatment are normal. 7 percent of these patients have BUN under the reference range and 53 percent have Scr under the reference range, it suggested that reference values of BUN and Scr need to be adjusted. BUN of Infant Rb increased significantly after chemotherapy, but not met the current diagnostic criteria of mild nephrotoxicity. Still, the early renal damage needs to be noticed.

### PO-554. Analysis of the Short‐Term Curative Effect of 356 Cases of Intraocular Retinoblastoma in Children in Beijing Children\'s Hospital {#pbc27455-sec-7870}

[M. Jin]{.ul} ^1^, J. Zhao^2^, D. Zhang^1^, C. Zhang^2^, W. Zhao^1^, X. Wang^1^, Q. Zhao^1^, C. Duan^1^, Y. Su^1^, H. Hong^1^, X. Ma^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Hematology Oncology Center, Beijing, China; ^2^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Department of Ophthalmology, Beijing, China*

**Background/Objectives**: To assess a multidisciplinary approach to intraocular retinoblastomas(RB) by systemic and local chemotherapy, to evaluate preservation of eyes, eye sight, safety and the survival rate.

**Design/Methods**: 356 patients with intraocular RB (486 eyes) treated in Beijing children\'s hospital with at least 1 course of chemotherapy from December 2009 to April 2017 were retrospectively reviewed. All patients were treated with carboplatin, vincristine and etoposide(VEC). Survival probability, cause of death, and chemotherapy‐related toxicity were measured. All patients were followed up to Nov. 30, 2017.

**Results**: There were 193 male and 163 female. The median age was 18.5 months (1‐84 months). unilateral RB were 226; bilateral RB were 130 patients(260 eyes). 72 patients with advanced intraoeular disease were enucleated at the time of presentation. Enucleation were recommended for 80 eyes (45.7%) after chemotherapy. In group D was 59.6%; in group E was 33.8%. In 110 bilateral patients(220 eyes), 35 eyes were enucleated after chemotherapy. In group D was 79.1%, in group E was 52.1%, in group C was 91.7%. All patients had grade 2‐4 hematologic toxicities after chemotherapy, of which 18 cases (5%) were received packed RBC transfusions or platelet transfusions. 14 cases (3.9%) children were died. The major cause of death was central nervous system relapse (n=7). Median follow‐up time was 47 months (1‐96 months).The 5‐year Overall Survival rate was 95.3 %, including the 5‐year OS was 96.7% in unilateral RB and the 5‐year OS was 92.9% in bilateral RB, no significant difference (P=0.074).

**Conclusions**: VEC chemotherapy combined with local therapy for intraocular RB was safe and effective. Intracranial metastasis is still the major cause of death of RB. The longest follow‐up of children in this group was 8 years, no second tumor occurred.

### PO-555. Novel STAT3 Inhibitors from the In‐House Library Targeted to Retinoblastoma {#pbc27455-sec-7880}

[D.H. Jo]{.ul} ^1^, E. Bak^1^, J.H. Kim^2^, S. Lee^3^, Y.G. Suh^3^, J.H. Kim^1^

^1^Seoul National University Hospital, Department of Ophthalmology, Seoul, Republic of Korea; ^2^Seoul National University Hospital, Department of OphthalmologyFight against Angiogenesis‐Related Blindness FARB Laboratory‐ Clinical Research Institute, Seoul, Republic of Korea; ^3^Cha University, College of Pharmacy, Seongnam, Republic of Korea

**Background/Objectives**: STAT3 is known to be highly expressed in retinoblastoma tumors. We previously reported that STAT3 inhibition could be a treatment option for retinoblastoma via down‐regulation of the miR‐17‐92 cluster. In this study, we investigated the therapeutic potential of STAT3 inhibitors from a library of 27 different derivatives with a Michael acceptor for the treatment of retinoblastoma.

**Design/Methods**: SNUOT‐Rb1 and Y79 cells from 2 different retinoblastoma cell lines were treated with STAT3 inhibitors from a library of 27 derivates to screen the cellular toxicity. The level of STAT3 phosphorylation was estimated by the enzyme‐linked immunosorbent assay and the expression levels of target genes of STAT3 was measured by quantitative real‐time polymerase chain reaction upon the treatment with STAT3 inhibitors. From a library of 27 STAT3 inhibitors, the 2 most potent STAT3 inhibitors were selected from aforementioned assays. Then, using the mouse orthotopic transplantation model, *in vivo* therapeutic efficacy of them was evaluated. The toxicity of STAT3 inhibitors on normal retinal tissues was estimated with histologic evaluation and the terminal deoxynucleotidyl transferase dUTP nick end labeling assay.

**Results**: 27 different derivatives demonstrated differential cellular toxicity, STAT3 phosphorylation, and expression of target genes. The 2 most potent STAT3 inhibitors effectively inhibited the formation of retinoblastoma tumors in the mouse orthotopic transplantation model. Despite their therapeutic efficacy, these STAT3 inhibitors did not significantly affect the cellular viability and histologic integrity of the retina even at 10 times the therapeutic concentration.

**Conclusions**: Novel STAT3 inhibitors identified from screening of an in‐house library of chemicals demonstrated potent *in vitro* and *in vivo* therapeutic efficacy without definite toxicity on normal tissues. We expect that these STAT3 inhibitors can be utilized for the treatment of retinoblastoma.

### PO-556. Meta‐Analysis of Mutational Spectrum of *RB1* Gene in Retinoblastoma {#pbc27455-sec-7890}

[D.H. Jo]{.ul} ^1^, S. Im^2^, H.B. Lee^2^, S.J. Lee^3^, S. Cho^4^, J.H. Kim^3^, J.H. Kim^1^

*^1^Seoul National University Hospital, Department of Ophthalmology, Seoul, Republic of Korea; ^2^Seoul National University College of Medicine, Department of Medicine, Seoul, Republic of Korea; ^3^Seoul National University Hospital, Fight against Angiogenesis‐Related Blindness FARB Laboratory‐ Clinical Research Institute, Seoul, Republic of Korea; ^4^University of Toronto, Faculty of Arts and Science, Toronto, Canada*

**Background/Objectives**: It is well‐known that retinoblastoma, the most common intraocular malignant tumor in children, is mainly related to *RB1* gene mutation. The lack of functional retinoblastoma protein is linked to the uncontrolled growth of tumor cells. To address the functional consequence of *RB1* gene mutation, it is important to figure out the mutational spectrum among patients with retinoblastoma. In this study, we investigated the mutational spectrum of *RB1* gene in the patients with retinoblastoma through meta‐analysis of data in the open database.

**Design/Methods**: From the NCBI PubMed database, articles were identified using the search words, 'retinoblastoma' and 'mutation' on February 28, 2018. From the relevant papers with the information on *RB1* gene mutation, the information was obtained regarding the mutational patterns. The types of mutations, substitutions, and the consequences of substitutions were identified by manual verification.

**Results**: In total, 4,093 papers were identified using the search words, 'retinoblastoma' and 'mutation'. Substitution, the change of one nucleotide, was the most common mutation type identified from the reported germline and somatic mutations. Also, we identified that transition from cytidine to thymidine (C to T mutation) was the most common substitution pattern. It is also remarkable that the nonsense mutation was the most evident (60‐70%) in both reported germline and somatic mutations.

**Conclusions**: In this study, we successfully identified the mutational spectrum of *RB1* gene in patients with retinoblastoma. We expect that these data will help us to investigate the therapeutic approaches addressing the consequences of *RB1* gene mutation for the treatment of retinoblastoma.

### PO-557. Expression of Transcriptional Target of p53 Protein in Human Retinoblastoma {#pbc27455-sec-7900}

[S. Kashyap]{.ul} ^1^, L. Singh^1^, M.K. Singh^1^, S. Sen^1^, B. Chawla^2^, S. Bakhshi^3^

*^1^All India Institute of Medical Sciences, Ocular Pathology, New Delhi, India; ^2^All India Institute of Medical Sciences, Ophthalmology, New Delhi, India; ^3^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India*

**Background/Objectives**: Deregulation of apoptotic pathway leads to cancer development, proliferation, and treatment resistance. Bcl‐2 protein family play a key role in the control of apoptosis and in the initiation of the apoptotic pathways. Noxa and Puma are transcriptional targets of p53 which play an active role in p53‐induced apoptosis. The aim of our study was to evaluate the expression of PUMA, p53 and NOXA and its prognostic significance in human retinoblastoma (Rb).

**Design/Methods**: Prospective analyses of 60 primary enucleated retinoblastoma specimens were imunohistochemically assessed for PUMA, p53 and NOXA expression and then confirmed by western blotting. RT‐PCR was also performed to amplify these genes. Cytoplasmic staining was considered as positive and the expression was correlated with clinical parameters, tumor differentiation and histopathological high risk factors like massive choroidal invasion, scleral invasion, optic nerve invasions etc.

**Results**: There were total of 45 (75%) cases with poorly differentiatedretinoblastoma. Necrosis and calcification was found to be present in 37 and 17 cases respectively. Of the 60 eyes, 20 (33.3%) had massive choroidal invasion, 17 (28.3%) had retrolaminar and cut end optic nerve invasion, 9 (15%) had iris & ciliary body invasion and 5 (8.33%) had anterior chamber invasion. Expression of PUMA was observed in 26/60 (43.33%) cases, p53 expressed in 22/55 (40%) casesand NOXA was positive in 28/60 (46.66%) cases. These were confirmed by western blotting and RT‐PCR technique. p53 alone significantly correlated with poor tumor differentiation. Similarly, PUMA and NOXA correlated with tumor differentiation and various histopathological high risk factors.

**Conclusions**: Expression of PUMA and NOXA may be regulated by p53 tumor suppressor protein. Therefore, these proteins may be used as a future therapeutic target in combating retinoblastoma. Future investigation of Bcl‐2 pathway might be helpful for developing biomarkers in the management of retinoblastoma patients.

### PO-558. Deletion of RB1, DLEU1 and PCDH8 Genes in an Infant with Bilateral Retinoblastoma, Dysmorphic Features and Developmental Delay {#pbc27455-sec-7910}

Ö. Şükrüoğlu^1^, Ş.B. Tunçer^1^, B. Çelik^1^, S. Kılıç^1^, D. Akdeniz^1^, S. Büyükkapu Bay^2^, S. Tuncer^3^, [R. Kebudi]{.ul} ^4^, H. Yazici^1^

*^1^Istanbul University Oncology Institute, Cancer Genetics, Istanbul, Turkey; ^2^Istanbul University Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^3^Istanbul University Istanbul Medical Faculty, Ophthalmology, Istanbul, Turkey; ^4^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey*

**Background/Objectives**: Retinoblastoma is the malignant tumor of the embryonic neural retina observed in young children. Mutations in the *RB1* gene, which is a tumor suppressor gene, are responsible for most cases of retinoblastoma. However, other genetic changes may be involved. In this study, we report the genetic changes observed in an infant with bilateral retinoblastoma, who had dysmorphic features and developmental delay.

**Design/Methods**: The peripheral blood of the patient and his parents were investigated for both small indels and rearrangements of *RB1* gene using Next Generation Sequencing(NGS) and multiplex ligation‐dependent probe amplification (MLPA) analysis.

**Results**: A three month old baby boy was diagnosed with bilateral retinoblastoma (ICRB right group B, left group A). He was born as a second child of healthy unrelated parents. The family history was unremarkable. He was treated by six courses of chemotherapy (vincristine, carboplatinum) and local ophtalmic treatment. He had a high and broad forehead, deeply grooved philtrum and had developmental delay. He is thirteen months old at present. Genetic analysis revealed complete deletion of the *RB1* gene, in addition *DLEU1* and *PCDH8* genes were partially deleted. There was no mutation in the parents. The mutation in the child with bilateral retinoblastoma is a de novo mutation.

**Conclusions**: This case with bilateral retinoblastoma has a unique genetic alteration in which three genes *RB1, DLEU1* and *PCDH8* are deleted. *PCDH8 may be responsible for the neurological phenotype*. The genes that flank the *RB1* gene, namely *PCDH8* and *DLEU1*, also encode for candidate tumor suppressors, and these additional genetic alterations could play a role in retinoblastoma.

This study was funded by the Istanbul University Research Fund (Grant BYP‐2016‐20546).

### PO-559. Retinoblastoma and Outcomes with Local Salvage {#pbc27455-sec-7920}

[S. Khan]{.ul} ^1^, P. Rehman^1^

*^1^Shaukat Khanum Memorial Cancer Hospital & Research Center, Pediatric Oncology, Lahore, Pakistan*

**Background/Objectives**: Retinoblastoma (RB) is one of the most common malignancies of childhood; it can present either as bilateral, hereditary form because of the presence of the RB1 gene or can be unilateral sporadic‐non hereditary. This review was conducted to determine the stage of disease in children presenting with retinoblastoma and the type of local control offered for eye salvage in our setting.

**Design/Methods**: A retrospective audit was done for all patients presenting to the Shaukat Khanum Memorial Cancer Hospital from September 2014 to September 2017 with retinoblastoma who received local therapy for disease salvage as well as chemotherapy.

**Results**: A total of 15 patient charts were reviewed. Bilateral disease was seen 11 (73.3%) patients whereas 4 (26.7%) had unilateral findings. All of them received Carboplatin, Vincristine and Etoposide (JOE) chemotherapy at diagnosis. The median number of cycles given were 8 (range: 4‐10). Majority (n=8, 53%) of patients had Group‐D/E disease. Salvage therapy for preserving the globe was attempted for all patients. Eleven (73.3%) patients were treated with laser therapy. Peri‐ocular Topotecan was used in 5 (33.3%) patients. Four patients (26.7%) went on to get second line Ifosphamide, Vincristine and Doxorubicin (IVAD) chemotherapy along with efforts at local salvage. Five patients progressed despite efforts at local salvage. The rest of the 10 (66.7%) patients are still under observation.

**Conclusions**: Despite systemic chemotherapy attempts at local salvage were unsuccessful. Upfront enucleation and chemotherapy if high‐risk features are present can save patients from prolonged course of treatment and associated anxiety.

### PO-560. Superselective Ophthalmic Artery Chemoinfusion (SOAC): A Novel Therapy in Intraocular Retinoblastoma {#pbc27455-sec-7930}

[S. Kulkarni]{.ul} ^1^, N. Shetty^1^, K. Gala^1^, S. Panbude^1^, S. Qureshi^2^, G. Chinnaswamy^3^, N. Shetye^2^

*^1^Tata Memorial Hospital, Radiodiagnosis, Mumbai, India; ^2^Tata Memorial Hospital, Surgical Oncology, Mumbai, India; ^3^Tata Memorial Hospital, Medical Oncology Pediatric, Mumbai, India*

**Background/Objectives**: To assess safety and efficacy of Superselective Ophthalmic Artery Chemoinfusion (SOAC) in intraocular retinoblastoma.

**Design/Methods**: Retrospective analysis of 40 eyes in 34 patients with intraocular retinoblastoma who received Superselective Ophthalmic Artery Chemoinfusion with either Melphalan alone or Melphalan+Carboplatin \[Melphalan 0.3‐0.4mg/kg (max.7.5mg), Carboplatin‐15‐30mg\]. Cycle repeated after 3weeks as per tumor response. Investigations done pre and post procedure were CBC, coagulation profile, biochemistry, B‐Scan, MRI, evaluation under anesthesia, electroretinogram.

**Results**: We have treated 40 eyes in 34 patients with 154 separate sessions of SOAC. Twenty eyes (50%) received SOAC as a primary treatment and 20 eyes (50%) received SOAC as secondary treatment. According to the International Classification of Retinoblastoma (ICRB), 4 eyes had group B disease (10%), 1 eye with group C disease (2.5%), 20 eyes with group D disease (50%) and 15 eyes had group E disease (37.5%). Technical success rate was 96.25% (catheterization successful in 154/160 sessions). Mean sessions of SOAC per eye was 3.85 (range was 1‐ 8 sessions per eye) with median follow up period of 57 months (Range 1‐ 58 months). Out of these, complete response was seen in 21 eyes (52.5%), partial response in 12 eyes (30%), progression in 5 eyes (12.5%) and stable disease in 2 eyes (5%). Globe survival was 82.4% at 12 months and 71.1% at 24 months which was stable upto 28.95 months. Median progression free survival was 56 months. No major complications of the procedure noted.

**Conclusions**: Superselective Ophthalmic Artery Chemoinfusion in intraocular retinoblastoma is safe and effective novel technique for achieving good tumor response. It offers means to salvage globe while preserving useful vision in patients with intraocular retinoblastoma. It can be offered as a primary as well as secondary treatment. Even in advanced retinoblastoma and in the persistent/recurrent disease after systemic chemotherapy, it is very effective.

### PO-561. Chronic Myeloid Leukemia as a Second Primary Malignancy in a Patient with Retinoblastoma {#pbc27455-sec-7940}

[K. Pawinska‐Wasikowska]{.ul} ^1^, W. Balwierz^1^

*^1^Institute of Pediatrics Jagiellonian University Medical College, Department of Children\'s Oncology and Hematology, Krakow, Poland*

**Background/Objectives**: In the last decades magnificent progress has been made in the diagnosis and treatment of retinoblastoma (RB) leading to improvement of survival rates, thus most RB patients survive the disease and live into adulthood. Although second primary tumors are extremely rare cases in RB patients, they may occur months or years after primary malignancy was diagnosed, are consider now the leading cause of death in patients with heritable RB.

**Design/Methods**: We report a case of a 2‐year‐old boy with bilateral RB, who developed chronic myeloid leukemia (CML) 12 months after treatment of RB.

**Results**: The boy was diagnosed with RBL of both eyes at the age of 5 months. The patient started on VEC chemotherapy (vincristine, etoposide, and carboplatin), along with local treatment (brachytherapy, photocoagulation and cryoapplication of both eyes). There were only partial response observed, thus enucleation of left eye was performed, and two more cycle of VEC were given. The treatment was finished and patient started careful monitoring towards relapse and side effects of therapy. 12 months later during regular follow up visit a complete blood count revealed a white blood cell count of 53,000 cells/mm3 and a platelet count of 665,000 cells/mm3. In physical examination patient had neither hepato nor splenomegaly or lymphadenopathy. Bone marrow examination revealed presence of bcr/abl translocation, which confirmed the diagnosis of CML. The child received therapy with hydroksyurea, imatinib, finally underwent stem cell transplantation form unrelated donor. At 13‐year follow‐up, the child is doing well with complete remission of leukemia. The RB in one left eye is regressed and stable, with preserved vision.

**Conclusions**: Screening for second primary malignancy is an important part of pediatric oncological follow‐up in patients with heritable retinoblastoma. Screening for second primary malignancy is an important part of pediatric oncological follow‐up in patients with heritable retinoblastoma.

### PO-562. Clinical Features and Treatment Outcome of Retinoblastoma at Kanti Children\'s Hospital, Kathmandu, Nepal {#pbc27455-sec-7950}

[K. Sah]{.ul} ^1^

*^1^Kanti Children\'s Hospital, Hemato‐Oncology, Kathmandu, Nepal*

**Background/Objectives**: Retinoblastoma is a malignant tumor of the embryonic neural retina. It is the most common intraocular tumor of childhood. It is a disease of early childhood with 80% cases diagnosed before the age of 4 years. The median age at diagnosis is 2 years. Bilateral cases are diagnosed earlier (median at 12 months and unilateral median age at 24 months). The incidence of retinoblastoma is approximately 1 in 15000‐18000 live births in developed countries. The aim is to study the clinical pathological features, treatment and survival of children with retinoblastoma over eighteen years.

**Design/Methods**: A retrospective hospital based study was conducted from March 1998 to March 2016, Gender, age, clinical presentation, pathology reports, treatment, follow --up and outcome were recorded at time of diagnosis.

**Results**: A total of 75 children with retinoblastoma 55 unilateral (73.4%) and 20 bilateral (26.6%). There were 52 male and 23 female (Ratio 2.26:1). 85% children came from rural areas and among of them 80% children had advance disease. The most common presenting signs were extra ocular (28.6%), proptosis (23.8%), leukoria (23.8%), phthisis bulbi (16.7%), and strabismus (7.1%). The age at presentation ranged from 6‐120 months with mean age of 46.6 months. The male to female ratio was 1.1:1.Two‐thirds presented between 2‐5 yrs, followed by 12‐24 months (23.8%). Majority of children had poorly differentiated retinoblastoma (62 %), followed by well differentiated (28.6%), and moderately differentiated (9.5%). Out of this (40%) having optic nerve involvement was studied. CEV based protocol used to treat after enucleation, and over‐all 18 yrs survival was 30 (40%), death 15 (20 %), and abandon 30 (40%.)

**Conclusions**: Despite severe resource limitation, pediatric oncology unit has been successfully treating retinoblastoma with the success rate of 40%.

### PO-563. Clinical Features and Treatment Outcome of Retinoblastoma at Kanti Children\'s Hospital, Kathmandu, Nepal {#pbc27455-sec-7960}

[K. Sah]{.ul} ^1^

*^1^Kanti Children\'s Hospital, Hemato‐Oncology, Kathmandu, Nepal*

**Background/Objectives**: Retinoblastoma is a malignant tumor of the embryonic neural retina. It is the most common intraocular tumor of childhood. It is a disease of early childhood with 80% cases diagnosed before the age of 4 years. The median age at diagnosis is 2 years. Bilateral cases are diagnosed earlier (median at 12 months and unilateral median age at 24 months). The incidence of retinoblastoma is approximately 1 in 15000‐18000 live births in developed countries. The aim is to study the clinical pathological features, treatment and survival of children with retinoblastoma over eighteen years.

**Design/Methods**: A retrospective hospital based study was conducted from March 1998 to March 2016, Gender, age, clinical presentation, pathology reports, treatment, follow --up and outcome were recorded at time of diagnosis.

**Results**: A total of 75 children with retinoblastoma 55 unilateral (73.4%) and 20 bilateral (26.6%). There were 52 male and 23 female (Ratio 2.26:1). 85% children came from rural areas and among of them 80% children had advance disease. The most common presenting signs were extra ocular (28.6%), proptosis (23.8%), leukoria (23.8%), phthisis bulbi (16.7%), and strabismus (7.1%). The age at presentation ranged from 6‐120 months with mean age of 46.6 months. Two‐thirds presented between 2‐5 yrs, followed by 12‐24 months (23.8%). Majority of children had poorly differentiated retinoblastoma (62 %), followed by well differentiated (28.6%), and moderately differentiated (9.5%). Out of this (40%) having optic nerve involvement was studied. CEV based protocol used to treat after enucleation, and over‐all 18 yrs survival was 30 (40%), death 15 (20 %), and abandon 30 (40%.)

**Conclusions**: Despite severe resource limitation in Nepal, pediatric oncology unit has been successfully treating retinoblastoma with the success rate of 40%.

### PO-564. Minimal Disseminated Disease in Trilateral Retinoblastoma as a Marker of Tumor Dissemination and Clinical Outcome {#pbc27455-sec-7970}

[C. Sampor]{.ul} ^1^, A. Torbidoni^2^, V. Laurent^3^, R. Aschero^4^, S. Iyer^3^, J. Rossi^5^, D. Alonso^6^, I. Szijan^7^, D. Alderete^3^, G. Chantada^3^

*^1^Hospital de Pediatria JP Garrahan, Hematology and Oncology, Buenos Aires, Argentina; ^2^Hospital de Pediatra JP Garrahan, Buenos Aires, Argentina; ^3^, Buenos Aires, Argentina; ^4^, Pathology Service, Buenos Aires, Argentina; ^5^, Immunology Service, Buenos Aires, Argentina; ^6^Quilmes National University, Molecular Oncology Laboratory, Buenos Aires, Argentina; ^7^University of Buenos Aires, Genetic and Molecular Biology, Buenos Aires, Argentina*

**Background/Objectives**: Trilateral retinoblastoma (TRb) is a rare manifestation in hereditary retinoblastoma that presents intracranial tumors, in the pineal or in supra/parasellar region. It is considered almost invariably fatal since intracranial tumors are seldom times resectable and quickly disseminate. Currently, there are no risk factors to predict the evolution and final outcome in each patient. The aim of this study was to evaluate minimal dissemination (MD) in the bone marrow (BM) and the cerebrospinal fluid (CSF) at diagnosis and during follow‐up and reviewing its potential impact in the outcome of TRb patients.

**Design/Methods**: This retrospective study included 5 patients with TRb. We evaluated MD detecting the cone‐rod homebox mRNA (CRX) by RT‐qPCR and/or GD2 by immunocitology, in samples from BM and CSF, obtained at diagnosis, follow‐up and relapse. Treatment involved systemic chemotherapy in 4 patients (according COG‐ARET 0321 protocol in 3 patients and moderate dose chemotherapy in one) and one did not receive treatment.

**Results**: Three patients receive high dose chemotherapy and two of them underwent stem cell rescue after it. The patient who did not receive treatment died of progression of the disease. Three patients had leptomeningeal relapse and died. One patient remains disease‐free for 84 months. At diagnosis, one patient had tumor cells in the CSF, and none had the BM involved. Only one case of four presented MD in the CSF during follow‐up without concomitant detection in the BM. Upon leptomeningeal relapse, no case had MD in the BM.

**Conclusions**: The presence of MD in the CSF without systemic circulation involvement could indicate a forthcoming relapse. Positive tumor dissemination in the CSF concluded in the death of all patients. This result denotes the importance of being more aggressive with chemotherapy directed to the CSF compartment.

### PO-565. Post Enucleation Adjuvant Chemotherapy for the Treatment of High Risk Retinoblastoma: A Single Centre Experience {#pbc27455-sec-7980}

[M.S. Sedky]{.ul} ^1^, H. ElZomor^2^, H. Taha^3^, A. Alyeldine^4^, A. Refaat^5^, E. Moussa^6^, F. Abdelhameed^7^, D. ElGalaly^7^, W. Zekry^2^

*^1^Children Cancer Hospital Egypt 57357 @, Pediatric Oncology, Cairo, Egypt; ^2^Children Cancer Hospital Egypt 57357 \@and National Cancer Institute Cairo University, Pediatric Oncology, Cairo, Egypt; ^3^Children Cancer Hospital Egypt 57357 \@and National Cancer Institute Cairo University, Pathology, Cairo, Egypt; ^4^Children Cancer Hospital Egypt 57357 @, Ophtalmology, Cairo, Egypt; ^5^Children Cancer Hospital Egypt 57357 @, Radiology, Cairo, Egypt; ^6^Children Cancer Hospital Egypt 57357 \@and Cancer Hospital Menoufiah University, Pediatric Oncology, Cairo, Egypt; ^7^Children Cancer Hospital Egypt 57357 @, Clinical Research, Cairo, Egypt*

**Background/Objectives**: Extensive intraocular unilateral non germ line retinoblastoma, carries a higher risk for local recurrence and metastasis despite upfront enucleation. For High risk histopathological factors, adjuvant chemotherapy has been suggested to prevent treatment failure. We aim to assess the outcome of extensive intraocular unilateral retinoblastoma with high risk histopathologic features in patients receiving adjuvant chemotherapy.

**Design/Methods**: We retrospectively analyzed newly diagnosed non germ cell unilateral retinoblastoma patients, undergoing enucleation. Those put under follow up without adjuvant chemotherapy were patients with no features, only invasion optic disc at lamina or focal choroid. While those with independent high risk features optic nerve posterior to the lamina cribrosa or massive choroid invasion or any other 2 risk features combination, received adjuvant Vincristine Etoposide Carboplatine (VEC) chemotherapy.

**Results**: Between 2010 and 2016, 160 patients M/F 86/74, mean age 31 months +/−20.5 underwent enucleation. Fifty one patients (32%) lacking high risk features were kept under follow up only. Of them, one patient with focal choroid showed local recurrence. While 109 patients (68%) with high risk features; massive choroid invasion n=40, optic nerve invasion post lamina n=33 or other combination n=36 received adjuvant (VEC). Of them, one with focal choroid and optic disc invasion at lamina showed metastasis and the other with ciliary body invasion and rupture globe showed metastasis and died. The 5 years Overall Survival (OS) for patients without high risk features and those with and receiving adjuvant VEC is 100% and 98.9% respectively p0.5 and the event free survival (EFS) is 94 % and 95% respectively p0.96.

**Conclusions**: Adjuvant chemotherapy has a role in disease control post enucleation in patients with high risk features. Prompt histopathologic examination is crucial for proper stratification.

### PO-566. Micro‐RNA Profiling in Retinoblastoma by Next Generation Sequencing {#pbc27455-sec-7990}

[M. Sharma]{.ul} ^1^, D. Bansal^2^, U. Singh^3^, J. Advani^4^, T.S.K. Prasad^5^, N. Kakkar^6^, R. Aggarwal^7^

*^1^PGIMER, Hematology‐Oncology Unit‐ Departmemt of Pediatrics, Chandigarh, India; ^2^PGIMER, Hematology‐Oncology Unit‐ Department of Pediatrics, Chandigarh, India; ^3^PGIMER, Department of Ophthalmology, Chandigarh, India; ^4^Institute of Bioinformatics‐ International Technology Park‐ Bangalore‐ India, Bioinformatics, Bangalore, India; ^5^Institute of Bionformatics‐ International Technology Park‐ Bangalore 560066‐ India. Center for Systems Biology and Molecular Medicine‐ Yenepoya Deemed to be University‐ Mangalore 575018‐ India, Bioinformatics, Bangalore, India; ^6^PGIMER, Departmemt of Histopathology, Chandigarh, India; ^7^PGIMER, Department of Immunopathology, Chandigarh, India*

**Background/Objectives**: MicroRNA (miRNA) are increasingly being explored for therapeutic potential in oncology. A limited number of miRNAs have been reported earlier in retinoblastoma, typically utilizing microarray or real‐time polymerase chain reaction (PCR). We report miRNome profiling in retinoblastoma tumor tissue using high‐throughput next generation sequencing (NGS).

**Design/Methods**: Setting: University hospital. Study duration: January'15 to December'17. Tumor tissue was obtained from patients with unilateral, intra‐ocular retinoblastoma (Group D or E) undergoing an enucleation. Normal retinal tissue was obtained from the institute\'s eye bank. RNA was extracted and quality assessed by determining RNA integrity number (RIN) using Bioanlayzer. Quantitation was performed using Qubit^®^3.0 fluorometer. Libraries for the samples with satisfactory RNA criteria were generated using Illumina\'s small‐RNA library preparation kit and sequenced on Illumina MiSeq platform. The miRNA expression profile was estimated using MiSeq reporter. The differentially expressed miRNAs were identified using DESeq. Targets were fetched for the differentially expressed miRNAs using TargetScan and Diana Tools. Probe‐base real‐time PCR was performed to validate the expression of target genes.

**Results**: Six normal retina, and retinoblastoma tissues, each, were enrolled. Four samples from each group satisfying the recommended criteria (RIN ≥ 8, RNA concentration: 200 ng/μl) were sequenced with 50‐bp single‐end reads. Thirty‐three significantly upregulated miRNAs were identified in retinoblastoma (p≤0.05). Among these, three miRNAs (miR‐145, miR‐16 and miR‐200a) have been reported previously in retinoblastoma. *In‐silico* target analysis revealed putative miRNA targets in hallmark pathways of cancer \[cell signaling (PI3/Akt, NFκB, Wnt), apoptosis, tumor invasion and cell cycle proteins\]. The expression of selected target genes revealed downregulation of *CDK4, CDK6, Cyclin E*, and*RB1*, which corroborated with miRNA expression profile.

**Conclusions**: We report the upregulation of 30 novel miRNAs in retinoblastoma utilizing NGS platform. *In‐silico* target analysis of miRNAs revealed their participation in oncogenic pathways. The miRNAs could be further explored for therapeutic application in patients with retinoblastoma

### PO-567. Efficacy of Conservative Management for Unilateral Retinoblastoma in the National Cancer Center Hospital: A Retrospective Analysis {#pbc27455-sec-8000}

[N. Shirakawa]{.ul} ^1^, T. Kumamoto^1^, S. Ishimaru^1^, T. Sonoda^1^, M. Sugiyama^1^, A. Arakawa^1^, C. Ogawa^1^, S. Suzuki^2^

*^1^National Cancer Center Hospital, Pediatric Oncology, Tokyo, Japan; ^2^National Cancer Center Hospital, Ophthalmic Oncology, Tokyo, Japan*

**Background/Objectives**: Patients with advanced unilateral retinoblastoma often require initial enucleation at diagnosis. Conservative management, such as local control and systemic chemotherapy, is aimed at preserving the eye and optimizing the visual function. This retrospective chart review aimed to investigate the efficacy of combined systemic chemotherapy and/or local ophthalmic treatment for unilateral retinoblastoma, used to avoid enucleation and external beam radiation therapy (EBRT).

**Design/Methods**: We reviewed the electronic medical records of newly diagnosed patients with unilateral retinoblastoma treated at the National Cancer Center Hospital between January 1, 2016 and December 31, 2015. We defined events as either enucleation or EBRT and analyzed the 3‐year event‐free survival (EFS) among the patients.

**Results**: We examined 156 patients \[median age, 19 (range, 0--85) months\]. The median follow‐up period was 82 (1 ‐ 139) months. Among the patients, 71 (45.5%) received initial enucleation or EBRT. Eighty‐five patients (54.5%) classified as per the International Classification of Retinoblastoma (ICRB) into groups B (n = 20, 23.5%), C (n = 16, 18.8%), D (n = 39, 45.8%), and E (n = 11.7%) were initially treated with systemic chemotherapy and/or local therapy. Among these, 42 (49.4%) patients subsequently required enucleation and 2 (2.4%) required EBRT. The 3‐year EFS was 0.488 (95% CI, 0.375--0.591), and the 3‐year EFS for ICRB B/C and ICRB D/E was 0.620 (95% CI, 0.436--0.760) and 0.394 (95% CI, 0.256--0.530; P = 0.0432), respectively. One patient in the group D died because of central nervous system invasion by retinoblastoma. No patient experienced second malignancy.

**Conclusions**: More than half of our patients were treated with combined systemic chemotherapy and/or local ophthalmic treatment as the initial treatment. Conservative management is a safe and feasible strategy for unilateral patients with retinoblastoma to avoid initial enucleation.

### PO-568. P53/HMGB1 Complex Protein as a Target for Apoptosis and Tumorigenesis in Retinoblastoma {#pbc27455-sec-8010}

[M.K. Singh]{.ul} ^1^, L. Singh^2^, S. Kashyap^1^, S. Sen^1^, N. Pushker^3^, J. Kaur^4^

*^1^Dr.R.P.Centre for Ophthalmic Sciences‐ All India Institute of Medical Sciences, Ocular Pathology, New Delhi, India; ^2^Jamia Millia Islamia, Biosciences, New Delhi, India; ^3^Dr.R.P.Centre for Ophthalmic Sciences‐ All India Institute of Medical Sciences, Ophthalmology, New Delhi, India; ^4^Dr.R.P.Centre for Ophthalmic Sciences‐ All India Institute of Medical Sciences, Ocular Biochemistry, New Delhi, India*

**Background/Objectives**: High mobility group box 1 (HMGB1) and p53 forms protein complex regulates the balance between tumor cell death and survival. They plays a role in suppressing or promoting tumorigenesis, apoptosis and autophagy which contributes to the resistance of tumors to various therapies. Interaction of p53 with HMGB1 in response to DNA damage promotes binding of HMGB1 to damaged DNA and thereby provides a molecular platform for subsequent p53‐mediated DNA repair. Interactions of these proteins regulates tumorigenesis and tumor invasion. The aim of the study is to detect p53/HMGB1 protein complex in retinoblastoma patients.

**Design/Methods**: Immunohistochemistry using p53/HMGB1 protein complex was performed in 65 formalin fixed retinoblastoma tissues and RT‐PCR was done on 40 fresh primary enucleated retinoblastoma samples. Immunoexpression of p53 and HMGB1 were together considered as a protein complex called (p53/HMGB1). Immunopositive expression of both proteins were taken as positive expression (p53^+^/HMGB1^+^) and immunonegative of both proteins taken as (p53^‐^/HMGB1^‐)^ negative expression. Results were then correlated with clinicopathological parameters. Western blotting was performed on 10 fresh primary enucleated retinoblastoma samples to confirm the immunohistochemical expression.

**Results**: Immunoexpression of p53+/HMGB1+ protein complex found in 38.46% of retinoblastoma cases. Immunoexpression of p53+/HMGB1+ is localized to nucleus in normal retina whereas both cytoplasmic and nuclear expression was seen in tumour cells. At transcriptional level, p53+/HMGB1+ complex expression was found to be 40%. Immunoexpression of p53+/HMGB1+ complex was significantly correlated with poor tumor differentiation, choroidal invasion and optic nerve invasion but did not correlate with any of the clinical parameters.

**Conclusions**: This preliminary data suggests that p53/HMGB1 protein complex may contribute to tumorigenesis of retinoblastoma. Further translational studies are required to explore the nature of HMGB1/p53 interactions in the cytoplasm and identify how it induces the progression of retinoblastoma.

### PO-569. Correlation Between Calcification on Ultrasound and Histopathology Finding in Children with Bilateral Retinoblastoma {#pbc27455-sec-8020}

[S. Susanah]{.ul} ^1^, A. Susanty^2^, M. Sari^3^

*^1^Hasan Sadikin General Hospital, Pediatric, Bandung, Indonesia; ^2^Cicendo Eye Hospital, Pediatric, Bandung, Indonesia; ^3^Cicendo Eye Hospital, Pediatric ophthalmology, Bandung, Indonesia*

**Background/Objectives**: Retinoblastoma is the most common intraocular tumour in children and the second most frequent children malignancy in Indonesia. Most of the cases came to the hospital with very late stage. Calcification of the ultrasound and histopathology finding in tumour mass would confirm the diagnosis. Most of chemotherapy delayed because of the requirement of histopathology result. The aim of this study is to standardize the policy in Indonesia, whether bilateral retinoblastoma doesn\'t need histopathology result prior chemotherapy.

**Design/Methods**: Retrospective, medical record children with Retinoblastoma in Child Health Department Hasan Sadikin Hospital and Cicendo Eye Hospital, Bandung, Indonesia.

**Results**: There were 248 cases examined between 2012‐2017, 4 cases excluded because uncompleted medical record. The first presentation from less than 1 year until 15 year. Unilateral Retinoblastoma 169 cases (69%) and bilateral retinoblastoma 75 cases (31%), in bilateral retinoblastoma calcification was present on ultrasound and invasion on histopathology 53 cases, 15 cases with calcification in ultrasound without invasion on histopathology, 1 case with calcification without histopathology result (grade D), 4 patients loss to follow up, no calcification and no invasion 1 case, no calcification and refuse to enucleation 1 case. From 69 patients who performed both USG and histopathology showed 53 cases with calcifications on ultrasound and histopathology (77%). Eighty six cases with unilateral retinoblastoma performed both ultrasound and histopathology showed 65 cases with calcifications on ultrasound and histopathology (76%). Analysis showed a significant correlation between the presence of calcification on ultrasound and histopathology finding.

**Conclusions**: In patient with bilateral retinoblastoma, chemotherapy could have performed soon after enucleation without histopathology result.

### PO-570. White Pupil in Children: What to Consider? {#pbc27455-sec-8030}

[A. Susanty]{.ul} ^1^, S. Susanah^2^, M. Sari^3^, P. Oktarima^3^

*^1^Cicendo Eye Hospital, Pediatric, Bandung, Indonesia; ^2^Hasan Sadikin General Hospital, Pediatric, Bandung, Indonesia; ^3^Cicendo Eye Hospital, Pediatric ophthalmology, Bandung, Indonesia*

**Background/Objectives**: Primary symptom of white pupil could be a clinical challenge. Many ocular conditions in children might mimic retinoblastoma, either by similar primary sign like white pupil, and similar physical examination. Any child presenting with white pupil should be considered to have retinoblastoma unless proven otherwise. Less common type of presentation occurs include redness, squinting, extrude of the eye, decrease in visual acuity, painful, and orbital cellulitis. However, we have to consider of differential diagnosis such as Coats disease, congenital cataract, retinopathy of prematurity, toxocariasis, toxoplasmosis, choroidal coloboma, tuberculosis, uveitis anterior, vitreous hemorrhage, retinal capillary hemangioma, medulloepithelioma, and intracerebral tumor. The aim of this study is to distinguish diagnosis of white pupil in children, whether retinoblastoma or not.

**Design/Methods**: Retrospective, medical record children with working diagnosis retinoblastoma in Cicendo Eye Hospital, Bandung, Indonesia.

**Results**: There were 95 cases examined in 2017 with working diagnosis is retinoblastoma, 4 cases excluded because uncompleted medical record. All cases did history taking, physical examination and imaging techniques like ultrasound and computed tomography scan or magnetic resonance imaging. Seventy‐eight cases with retinoblastoma (86%), consist of 52 cases with unilateral retinoblastoma and 26 cases with bilateral retinoblastoma. Thirteen cases were not retinoblastoma (14%), although signs and symptoms mimicking retinoblastoma. They consist of 8 boys and 5 girls who were 3 cases with exudative retinal ablation, 2 cases with persistent hyperplastic primary vitreous, 2 cases with Coats disease, and 1 case of each group with: endogen endophtalmitis, retinopathy of prematurity, coloboma, glioma, acute lymphoblastic leukemia, and adult orbital xantogranuloma.

**Conclusions**: In patient with white pupil, careful history taking include family history, physical examination and perform imaging techniques are critical to proper diagnosis.

### PO-571. Effect of Delay and Abandonment in Retinoblastoma on Stage at Diagnosis and Survival: A Single‐Center Experience {#pbc27455-sec-8040}

[F. Tarrillo]{.ul} ^1^

*^1^HOSPITAL EDGARDO REBAGLIATI MARTINS, PEDIATRIC ONCOLOGY, LIMA, Peru*

**Background/Objectives**: Retinoblastoma (RB) is the most frequent primary intraocular tumor in children. Previous studies in low‐ and middle‐income countries (LMIC) suggest that delayed presentation and treatment abandonment are associated with higher rates of extraocular spread and metastasis. In this study, we aimed to determine the effect of diagnostic and treatment delay and abandonment in children diagnosed with RB in Peru.

**Design/Methods**: We retrospectively analyzed data from medical records of children diagnosed with RB in Rebagliati Hospital between 2008 and 2016. Clinical characteristics, time to diagnosis(TD) (defined as the length of time between noticing the first RB‐related symptoms and diagnosis), time to treatment(TT) (defined as the length of time between diagnosis and treatment), abandonment of treatment(TxAb) and overall(OS) and event‐free survival(EFS).

**Results**: A total of 28 children diagnosed with RB were included; 64,3% of the cases were unilateral and 35,7% were bilateral. Median TD was 9 (range,2‐52) and 14 weeks (range,4‐70) in unilateral and bilateral RB, respectively. After diagnosis, median TT was 1.5 weeks (range, 0.4‐16). According to the International RB staging system, 96.4% presented with at least D or E eye. TxAb occurred in 2 children(7.1%). Five‐year OS was 93.1%+/‐6.6 and 57.1%+/‐2.3 in unilateral and bilateral RB, respectively. Five‐year EFS was 88.5%+/‐7.6 and 45%+/‐17.4 in unilateral and bilateral RB, respectively. TD longer than 12 weeks was associated with higher rates of extraocular disease(p=0.01) and death rate(p=0.04) and TT longer than 4 weeks was significantly higher in patients with extraocular disease(p=0.02). After multivariate analyses, TxAb(HR=2.09, p=0.04) and metastasis (HR= 3.0, p=0.04) were independent factors for worse OS. Similarly, TxAb (HR=29.3, p=0.005) and extraocular disease (HR=8.3, p=0.001) were independent factors for worse EFS. Median follow‐up time was 33 months(range,8‐110).

**Conclusions**: In Peru, survival rates for children with RB generally are very similar to the survival rates in other LMIC. Delayed diagnosis and TxAb rates are high and significantly affected outcomes.

### PO-572. Retinoblastoma in Infants Less Than 3 Months of Age: Retrospective Study of a Single Center Experience {#pbc27455-sec-8050}

[M. Tashvighi]{.ul} ^1^, A.A. Hedayati Asl^1^, M. Faranoush^1^, A. Naderi^1^, M. Alebouyeh^1^, H. Nikfarjam^1^, N. Anousha^1^, V. Fallah Azad^1^, A. Mehrvar^1^

*^1^MAHAK Hematology and Oncology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran*

**Background/Objectives**: Children diagnosed with retinoblastoma in early stages of life are at more risk of bilateral tumors and advanced disease. The aim of our study was to evaluate epidemiological characteristics and clinical features of retinoblastoma in infants less than 3 months of age at MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC) in Iran.

**Design/Methods**: This was a retrospective study of infants before the age of 3 months diagnosed with retinoblastoma at MPCTRC from May 2007 to May 2017. The epidemiological characteristics were analyzed using SPSS software version 22.0. Survival analyses of patients were performed using Kaplan‐Meier test.

**Results**: Fifty‐two eyes of 30 infants were included in this study with 53.3% of being female. The frequency of bilateral tumors was 73.3%. Family history of cancer was found among 43.4% of children and retinoblastoma in first degree relatives were 23.3% with 16.7% of paternal retinoblastoma. Consanguineous marriage was defined in 13.3% of parents. The mean age at diagnosis was 58 days. The most frequent symptom was leukocoria (77.6%). Almost 27 eyes had International Classification of retinoblastoma group D or E. Enucleation was performed in 43% of patients. In two patients (6.6%) both eyes were enucleated. The most often used protocols for systemic chemoreduction were vincristine, etoposide, and carboplatin (VEC) and high‐dose VEC. Bilateral retinoblastoma was associated with lower overall survival compared with unilateral (74%±0.1 vs. 100%, 3‐year overall survival). Three year enucleation free survival rate for bilateral and unilateral tumors were 100%. One patient had second malignancy (osteosarcoma) by the age of 9 years. Four patients (13.3 %) died due to complication of therapy or metastasis.

**Conclusions**: Since there are challenges in the treatment of retinoblastoma in infants less than 3 months further multicenter studies and a national registry of retinoblastoma are required to improve diagnosis and treatment of the disease.

### PO-573. National Retinoblastoma (RB) Registry in India March 2009‐2014 {#pbc27455-sec-8060}

[V. Thavaraj]{.ul} ^1^

*^1^INDIAN COUNCIL OF MEDICAL RESEARCH, CHILD HEALTH, NEW DELHI, India*

**Background/Objectives**: National retinoblastoma registry was set up in India.

**Design/Methods**: All the new cases of the retinoblastoma from 11 centers in India using a common core proforma along with SOP, data entered into excel sheet, both internal/external Quality control done. Duplications removed. Stata 11 was used to analyze data. The survival analysis was done using Kaplan Meier curves.

**Results**: 2823 confirmed cases enrolled into the registry from Jan 1, 2009 to March 2014 (the total cases were 2955 patients‐132 patients removed --date of diagnosis before 2009/duplicate entry/non analytical) The median age was 20 months. There are 1573 boys and 1250 girls enrolled in the study. The first sign noticed was Leucocoria in 77%. The family history of retinoblastoma was seen in 4.0 % of the cases. 51 % of the cases of retinoblastoma occur before 2 years (SEER data 63% before 2 Years) and 94 % of the cases occur before 5 years (SEER data 95 %). Unilateral retinoblastoma was seen in 1861 (65.9 %) cases and bilateral in 941 (33.3%) cases. In less than 1 year old bilateral was seen in 51.1% and unilateral in 47.7%. 0.4% had trilateral Retinoblastoma and 0.8% converted from Uni to Bilateral disease. (SEER data 42 % bilateral disease). The IIRC grouping showed 75 % of the cases were in Group D and E (total no of intraocular eyes were 2966). 26. 6 % were extraocular by Chantada Staging (no data in 43 cases). The multy modality treatment will be discussed. The median follow up of 13.1 months. The median survival time not reached. Both overall and disease free survival studies were done with respect to the age, sex, stage, extra ocular status, risk pathology, laterality and type of therapy.

**Conclusions**: The survival of 2823 cases of RB enrolled in the RB registry in India is reported

### PO-574. Six‐Year Practice of Intra‐Arterial and Intravitreal Chemotherapy in the Organ‐Preserving Treatment of Patients with Retinoblastoma {#pbc27455-sec-8070}

[T. Ushakova]{.ul} ^1,2^, I. Pogrebnyakov^3^, O. Gorovtsova^1^, Y. Serov^1^, O. Yugay^4^, I. Trofimov^3^, A. Кukushkin^3^, E. Virshke^3^, A. Yarovoy^5^, S. Saakyan^6^, B. Dolgushin^3^, V. Polyakov^1,2^

*^1^Institute of pediatric oncology and hematology of N. N. Blokhin Science Medical Research Center of Oncology, head and neck tumors, Moscow, Russia; ^2^Russian Medical Academy of Postgraduate Education, pediatric oncology, Moscow, Russia; ^3^Institute of clinical and experimental radiology of N. N. Blokhin Science Medical Research Center of Oncology, interventional radiology, Moscow, Russia; ^4^Institute of pediatric oncology and hematology of N. N. Blokhin Science Medical Research Center of Oncology, scientific advisory outpatient, Moscow, Russia; ^5^S. Fyodorov Eye Microsurgery Federal State Institution, eye oncology, Moscow, Russia; ^6^Moscow Helmholtz Research Institute of Eye Diseases, eye oncology, Moscow, Russia*

**Background/Objectives**: The aim was to improve of organ‐preserving treatment results of the children with retinoblastoma (RB) with selective intra‐arterial (IAC) and intravitreal (IViC) chemotherapy.

**Design/Methods**: The research included treatment results of 110 children (129 eyes) with retinoblastoma in N. N. Blokhin Science Medical Research Center of Oncology from 2011 to 2017. All patients/eyes were divided into 2 groups. The first group included 99 children/116 eyes where IAC±IViC were carried out due to insufficient efficiency of earlier treatment of RB refractory forms in 32 eyes and according to the multicenter protocol of retinoblastoma «C» and « D» groups treatment in 84 eyes. The second group included 11 patients/13 eyes where the local chemotherapy (IAC±IViC) was the first line of the treatment.

**Results**: 108 of 110 patients are alive. The cause of death in one case was acute leukemia and in the second ‐ metastasis in connection with the parents\' refusal to observe. One patient (2 eyes) of the first group (116 eyes) was lost from the study. In the first group 95 of 114 eyes (83,3%) were retained. The salvage of eyes by Kaplan‐Meier was reached in 94,5% in 1 year, 88,5% in 2 years, 86,5% in 3 years, 82,9% in 4 years and 75,0% from 4 to 6 years. Patients were followed up to 30,3±16,81 months. One of 11 patients was lost from the study in group of primary local chemotherapy. In group of primary local chemotherapy 11 of 12 eyes (91,7%) were retained in 10 paitients. The salvage of eyes by Kaplan‐Meier was reached in 92,3% in 1 and 2 years. Patients were followed up to 13,5±5,3 months.

**Conclusions**: Local chemotherapy is an effective and perspective organ‐preserving method. It can be used as a complex therapy part of advanced and refractory RB forms and as a primary therapy of the identified RB.

### PO-575. Study on the Correlation Between Retinoblastoma Imaging and Pathology of Optic Nerve Invasion {#pbc27455-sec-8080}

[Y. Wang]{.ul} ^1^, D. Huang^1^, Y. zhang^1^, Y. zhou^1^

*^1^Beijing Tongren Hospital‐ Capital Medical University, Pediatrics, Beijing, China*

**Background/Objectives**: To investigate the relationship between radiographically enhanced or enhanced RB and postoperative pathology and prognosis, and to evaluate the diagnostic value of imaging and the clinical guiding value of early‐warning pathological grade.

**Design/Methods**: Preoperative MRI examination of the eyelid was performed to record whether the optic nerve was thickened and/or intensified. Postoperative optic nerve invasion was divided into 4 groups (invading the optic disc Invasion of the septum plate; infringement of the posterior optic nerve of the ethmoidal plate; infringement of the optic nerve stenosis), treatment according to pathological results to be treated accordingly, analysis of the correlation between radiographic findings and postoperative pathological findings and prognosis.

**Results**: Clinical data characteristics: 65 males and 39 females, male to female ratio 1.67:1. There were 26 eyes in the eyes, 78 eyes in the monocular eye, and a ratio of 3:1 eyes and eyes. Clinical staging: 16 eyes (13.3%) in the AC phase, 40 eyes (30%) in the D phase, 46 eyes (38.3%) in the E phase, and 2 cases in the extraocular phase. In addition to surgery, chemotherapy was combined with local treatment, intramuscular injection And radiotherapy and other comprehensive treatment. Imaging characteristics analysis: Postoperative pathological grading: Grade I 66 cases accounted for 63.5%, II cases 18 cases accounted for 17.3%, grade III 16 cases accounted for 15.4%, IV grade 4 cases accounted for 3.8%. The 1‐year cumulative survival rate of the overall survival rate was 94%. Cox regression survival analysis suggested that the degree of optic nerve involvement (P=0.049) and pathological grade (P=0.034) were risk factors affecting survival time. The degree of optic nerve invasion was different in imaging. There is a difference in the survival rate among the groups.

**Conclusions**: The degree of tumor involvement in orbital MRI is positively correlated with pathological grade.

### PO-576. A Five Year Review of the Presentation, Treatment and Outcome of Retinoblastoma in a Developing Country {#pbc27455-sec-8090}

[N. Zia]{.ul} ^1^

*^1^The Indus Hospital, Department of Paeds hematology and oncology, Karachi, Pakistan*

**Background/Objectives**: Retinoblastoma is the most‐frequent neoplasm of the eye in childhood, representing 2.5% to 4% of all neoplasm. In developing countries it may comprise of about10‐15% of all diagnosed paediatric cancers(hospital based retrospective study).Two third are diagnosed before 2 years & 95% before 5 years of age. We will analyze the clinical features & outcome of children with retinoblastoma & highlight areas where improvements required.

**Design/Methods**: Medical records of patients diagnosed with Retinoblastoma at our regional centers were retrospectively chart reviewed from June 2013 to July 2017 after IRB approval.

**Results**: A total of 140 (100%) patients charts were reviewed. More male n=81 (57%) patients were seen than females n= 59 (42%). Most patients were diagnosed before the age of 5 years. Positive family history observed in 2 patients. Total number of bilateral disease were 63(45%), 4(3%) were Trilateral and 73 (52%) were unilateral disease. Patients presented after upfront enucleation were 35(21%). Patients with Stage IV metastatic disease were 34(24%).Median age of presentation is 24months for bilateral disease and 36monthsfor unilateral disease. The patients on active treatment 82(59%), on palliation 34(24%), left before treatment 25 (17%).The patients on active treatment survived were 61(74%).

**Conclusions**: A significant percentage presented with advance and metastatic disease lead to the over all poor outcome. Significant numbers presented after enucleation with recurrence to our centre with no referral to peads oncologist which needs awareness among ophthalmologists. The rate of abandonment is higher due to poor socio‐economics, low literacy rate, false myths, limited peadiatric oncology treatment centres in Pakistan. We also need to educate histopathologist to report retinoblastoma according to standard guidelines so that we may not miss intermediate and high risk histopathological features. We have limited expertise in local control modalities due to which we are unable to salvage advanced group eyes with retinoblastoma.

Solid Non Brain Tumours ‐ Liver Tumours {#pbc27455-sec-8100}
---------------------------------------

### PO-577. Genomic Studies of Brazilian Patients with Hepatoblastoma: Insight Into Somatic Mutations Using Whole‐Exome Sequencing {#pbc27455-sec-8110}

[T. Aguiar]{.ul} ^1^, T. Rodrigues^2^, M. Rivas^2^, F. Aparecida^3^, G. Fernandes^2^, R. Valieris^4^, C.M. Lima da Costa^3^, I. Werneck^5^, M. Cypriano^6^, S. Caminada de Toledo^6^, V. Odone^7^, I. Tojal^4^, D. Carraro^4^, C. Rosenberg^2^, A. Krepischi^2^

*^1^AC CAMARGO CANCER CENTER, MOLECULAR ONCOLOGY, SAO PAULO, Brazil; ^2^University of Sao Paulo, Genetics, Sao Paulo, Brazil; ^3^AC Camargo Cancer Center, Pediatrics, Sao Paulo, Brazil; ^4^AC Camargo Cancer Center, Cipe, Sao Paulo, Brazil; ^5^AC Camargo Cancer Center, Pathology, Sao Paulo, Brazil; ^6^Graacc, Oncology Pediatric, Sao Paulo, Brazil; ^7^Itaci, Oncology Pediatric, Sao Paulo, Brazil*

**Background/Objectives**: Hepatoblastomas (HB) are embryonal tumors of the liver with histological features that resemble different stages of liver differentiation. The identification of molecular pathways involved in HB development can expand the understanding of the connections between disruption of normal differentiation and cancer.

**Design/Methods**: Exome sequencing (*244K Agilent SureSelect Target Enrichment)* analysis was performed for 10 hepatoblastomas matched with their non tumoral liver tissues (fresh frozen tissues). Bioinformatic analysis using Varseq Software (Golden Helix, Inc., Bozeman, Montana, US) of exome data identified somatic variants in 104 genes which were chosen for validation using a target sequencing panel (*SureSelectXT Target Enrichment System for Illumina Paired‐End Sequencing Library*) in this group of HB and more 12 cases.

**Results**: A total of 112 somatic rare coding mutations (missense and loss‐of‐function) were validated considering the entire HB group. The somatic analysis reveals pathogenic mutations in the *CTNNB1* gene and a recurrent missense mutation in the *CX3CL1* gene; the role of these mutations was explored by IHQ studies of their proteins as well as by gene expression analysis by RT‐PCR. We also used results from Illumina 450k to evaluated the methylation levels of *CX3CL1* and *CX3CR1* genes.

**Conclusions**: Most investigated HBs carry few pathogenic genetic mutations. This observed low frequency of somatic mutations is a result similar to previous studies. The proposed explanation is based on the fact that pediatric tumors would originate from precursor cells with pluripotent characteristics; therefore, such tumors may require fewer mutations than adult solid tumors to develop. The congenital HB case of our cohort is discrepant from this scenario since a relatively high number of mutations were found compared to the HB group. To our knowledge, this is the first comprehensive genomic characterization of Brazilian HBs. Next steps include expanding the casuistry of exome sequenced tumors, including two cases of HB associated with Hirschprung disease.

### PO-578. Treatment Outcomes of Hepatoblastoma in Kazakhstan {#pbc27455-sec-8120}

[G. Algazieva]{.ul} ^1^, K. Khairov^2^, B. Zhumadullaev^1^, G. Nurzhanova^1^, E. Iseeva^1^, U. Ibragimov^3^, A. Bekisheva^4^, D. Karimov^5^

*^1^Scientific Center of Pediatrics and Pediatric Surgery, Oncology, Almaty, Kazakhstan; ^2^Scientific Center of Pediatrics and Pediatric Surgery, Surgery, Almaty, Kazakhstan; ^3^Scientific Center of Pediatrics and Pediatric Surgery, Radilogy, Almaty, Kazakhstan; ^4^Scientific Center of Pediatrics and Pediatric Surgery, Pathology, Almaty, Kazakhstan; ^5^Scientific Center of Pediatrics and Pediatric Surgery, Intensive Care, Almaty, Kazakhstan*

**Background/Objectives**: Every year 6‐8 primary patients with hepatoblastoma are detected in the Republic of Kazakhstan, it is about 1.0 -- 1.3% in the structure of all malignant tumors of childhood. The goal of this study was to analyze outcome of hepatoblastoma treatment.

**Design/Methods**: Retrospective review of 26 patients with hepatoblastoma enrolled between February 2013 -- December 2017 was done. Data regarding patients age, sex, stage, treatment course, surgical treatment and outcome. Treatment was given according to SIOPEL protocol.

**Results**: Total number of patients is 26; the average age is 30.8 months. M:F ratio was 2.25:1. Staging according to the PRETEXT system: stage II ‐ 2 (7.7%), stage III ‐16 (61.5%), stage IV ‐ 8 (30.8%). Initial average tumor volume was 720,5сm3. The initial mean level of alpha fetoprotein was 265,884 ng /ml. Before treatment 1 patient died. Neoadjuvant therapy was given in 25/26 cases included combined adriamycin / cisplatin cycle for 21/25 (84%) cases. Monotherapy by cisplatin received 4/25 (16%) patients. Partial regression was observed in 24/25 (96%) cases. Progression under chemotherapy was reported in 1 patient. In 4/25 (16%) cases patients refused surgical treatment. The control volume of the tumor decreased by more than 70% (from 54 to 89%) and amounted to 197,8 cm3. Operative treatment had 20/25 (80%) patients: right‐side hemihepatectomy ‐ 11 (55%), left hemihepatectomy 2 (10%), atypical liver resection ‐ 5 (25%), extended left hemihepatectomy‐1 (5%), extended right‐sided hemihepatectomy ‐ 1 (5%). Early postoperative mortality occurred in 2 (10%) patients. Adjuvant chemotherapy was performed for 18/20 (90%) patients. The overall survival rate is 90.0% with median follow‐up of 21.8 months.

**Conclusions**: Neoadjuvant therapy leads to partial tumor regression in more than 2/3 of patients, which in turn improves the results of surgical treatment and prognosis. However, the risk of fatal complications associated with the operation remains high.

### PO-579. Establishment of Two Pre‐Clinical Models of Childhood Liver Cancer as Tools for Drug Screening {#pbc27455-sec-8130}

L. Royo^1^, B. Aguilar^2^, J. Carrillo‐Reixach^1^, M. Domingo‐Sabat^1^, M. Garrido^3^, L. Guerra^4^, Y. Mozo^5^, C. Sábado^6^, G. Guillén^7^, J.A. Molino^7^, F. Hernandez^8^, M.E. Mateos^8^, D. Plaza^5^, M. Lopez‐Santamaria^7^, P. Sancho‐Bru^2^, A. Villanueva^10^, [C. Armengol]{.ul} ^1,11^

*^1^Health Sciences Research Institute Germans Trias i Pujol IGTP, Childhood Liver Oncology Group, Badalona, Spain; ^2^Institut d\'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS‐ Hospital Clínic‐ University of Barcelona, Liver Unit, Barcelona, Spain; ^3^Hospital Vall d\'Hebron, Pathology department, Barcelona, Spain; ^4^University Hospital La Paz, Pathology Department, Madrid, Spain; ^5^University Hospital La Paz, Pediatric Oncology department, Madrid, Spain; ^6^Hospital Vall d\'Hebron, Pediatric Oncology department, Barcelona, Spain; ^7^Hospital Vall d\'Hebron, Pediatric Surgery department, Barcelona, Spain; ^8^University Hospital La Paz, Pediatric Surgery department, Madrid, Spain; ^9^University Hospital Reina Sofía, Pediatric Oncology department, Córdoba, Spain; ^10^Catalan Institute of Oncology ICO, Translational Research Laboratory, Bellvitge, Spain; ^11^CIBER, Hepatic and Digestive Diseases, Barcelona, Spain;*

**Background/Objectives**: At the precision medicine decade, the establishment of highly‐reproducibility pre‐clinical models for rare diseases, such as childhood cancer, are necessary as tools for assessing new anti‐tumor drugs based from molecular characterization.

We aim at developing new pre‐clinical models of hepatoblastoma (HB), the main childhood liver cancer, based on 1) the establishment of orthotopic PDX and 2) organoid cultures.

**Design/Methods**: PDX establishment: Fresh tumor (T) pieces from 16 HB patients were grafted into the liver of nude mice. Organoid establishment: Fresh T and non‐tumour (NT) pieces from 6 HBs were minced, digested and single cell suspension was seeded in Matrigel and grown in a growth factor‐enriched culture media. Pathological and molecular characterization was performed by examining HE slides and studying CTNNB1 gene (PCR‐Sanger sequencing) and gene expression profiling (RT‐qPCR). Finally, we used the established PDXs as tools to test the anti‐tumoral effect of a new agent.

**Results**: Orthotopic PDXs and organoids were successfully established from 43% (7/16) and 50% (3/6) of the cases, respectively. Pathological examination of PDXs showed a more immature phenotype compared to the primary Ts, mainly characterized by a loss of the foetal epithelial component and an increase of embryonal and SCU patterns. CTNNB1 gene mutations found in the primary Ts were also present in the T pre‐clinical models, but not in organoids isolated from NT tissue. Both T pre‐clinical models showed a gene expression profile similar to the corresponding primary Ts. In contrast, T AFP expression was preserved in PDXs but lost in the organoids. Finally, a significant inhibition of PDX growth was observed by using molecular profile‐based therapies (p=0.028).

**Conclusions**: We have been able to develop pre‐clinical models from almost 50% HBs that could be used to test innovative therapies in a near future. Acknowledgements: This study is supported by AGAUR 2017‐SGR‐490 and ChiLTERN project (GA‐668596).

### PO-580. Activation of Hedgehog Signaling in Aggressive Infantile Hemangioendothelioma {#pbc27455-sec-8140}

D. Wendling‐Keim^1^, L. Wanie^2^, R. Grantzow^1^, D. von Schweinitz^1^, R. Kappler^1^, [M. Berger]{.ul} ^1^

*^1^Dr. von Hauner Childrens\' Hospital, Pediatric Surgery, Munich, Germany; ^2^Klinik Memmingen, Surgery, Memmingen, Germany*

**Background/Objectives**: Infantile Hemangioendotheliomas (HE) are vascular tumors of the liver. These tumors are typically harmless but can show an aggressive course with significant complications. Prognostic markers that identify an aggressive course are entirely absent. Previously, we have shown that Hedgehog signaling is overexpressed in infantile hemangiomas of the skin with aggressive courses. Here, we hypothesize that Hedgehog signaling is overactivated in aggressive HE.

**Design/Methods**: Patient records and specimen of 6 patients with previously diagnosed and surgically treated aggressive HE were selected from our tumor bank and analyzed. Quantitative PCR of all specimen were performed to investigate the expression of the markers *FGF2* and *GLUT1* as well as the Hedgehog signaling components *SHH* and *GLI2* and its target gene *FOXA2*. For comparison, we additionally analyzed 3 cases of kaposiform hemangioendothelioma (KHE) and compared our results to previously analyzed expression levels in aggressive hemangiomas of the skin.

**Results**: All cases of HE expressed the hemangioma markers *FGF2* and *GLUT1*. Notably, upregulation of the Hedgehog signaling component *SHH* as well as its transcription factor *GLI2* and its target gene *FOXA2* were detected in all cases. Further, we found a positive correlation between expression levels of *SHH* and *FOXA2* (r = 0.857; p = 0.0107). For KHE, we found expression of *FGF2* but not *GLUT1* as well as a similar overexpression of the Hedgehog signaling components *GLI2*, *FOXA2* and *SHH* as in HE (p = 0.2172; p=0.4100; p=0.2230, respectively). Hedgehog signaling in HE was similar to expression in aggressive hemangioma of the skin (p = 0.3560; p=0.1314; p=0.1418, respectively).

**Conclusions**: The study demonstrated an overexpression of Hedgehog components *SHH* and *GLI2* and its target gene *FOXA2* in aggressive HE. This finding can help efforts to understand and identify aggressive growth in HE, possibly making it an independent biomarker and allowing early for intervention.

### PO-581. Clinical Characteristics and Treatment Outcome of Paediatric Hepatoblastoma in Hong Kong: A Population‐based Cohort Study {#pbc27455-sec-8150}

[A. Chiang]{.ul} ^1^, A.P. Liu^1^, A.W. Leung^2^, C.W. Luk^3^, C.H. Li^4^, K.K. Ho^5^, R. Lo^1^, E.K. Chan^6^, A.C. Chan^7^, P.H. Chung^7^, J.J. Ip^8^

*^1^The University of Hong Kong, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R.; ^2^Prince of Wales Hospital, Paediatrics, Hong Kong, Hong Kong S.A.R.; ^3^Queen Elizabeth Hospital, Paediatrics, Hong Kong, Hong Kong S.A.R.; ^4^Tuen Mun Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R.; ^5^Princess Margaret Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R.; ^6^Prince of Wales Hospital, Surgery, Hong Kong, Hong Kong S.A.R.; ^7^The University of Hong Kong, Surgery, Hong Kong, Hong Kong S.A.R.; ^8^Queen Mary Hospital, Radiology, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: We reviewed the outcome of the consensus HB/HCC 1996 treatment protocol for paediatric hepatoblastoma (HB) and investigated the role of PRETEXT staging and risk stratification.

**Design/Methods**: Overall survival (OS), event‐free survival (EFS) and predictors of outcome were determined for HB patients (\<18 years) treated between July 1996 and June 2014. Retrospective assignment of PRETEXT staging and SIOPEL risk group were performed.

**Results**: Sixty patients were enrolled. Median age at diagnosis was 1.1 year (range, 0.08‐14.82) and median follow‐up time was 6.8 years (range, 0.002‐19.6). Eight (13%) patients had tumour rupture. Alpha‐fetoprotein (AFP) was raised (\>100ng/ml) in 58 (97%) patients. Five (8%) had lung metastases at presentation. Twelve pateints (20%) had upfront surgical resection. Twenty‐nine patients (48%) received treatment with first‐line chemotherapy (5‐Fluorouracil, cisplatin and vincristine); 23 (38%) required alternative agents. Surgical resection could be performed in 48 (80%) patients whilst 8 patients had unresectable or metastatic disease among which 3 (5%) underwent upfront liver transplantation. There were 14 deaths (23%) and 11 relapses (18%). Five‐year OS and EFS rates were 77.6% (±5.5%) and 69.2% (± 6.1%), respectively. Predictors of inferior outcome included advanced Evans staging, unresectable or bilobar disease, tumour rupture, low AFP and suboptimal response to first‐line chemotherapy. PRETEXT staging was performed in 44 patients retrospectively. Staging with PRETEXT was I in 5, II in 13, III in 22 and IV in 4. Thirty‐five patients belonged to standard risk (SR) and 9 to high risk (HR) according to the SIOPEL risk criteria. 5y OS and EFS rates were significantly better in the SR than HR patients (89.9%±6.8% vs 42.2%±15.6% \[p=0.017\]; 84.7%±8.2% vs 13.6%±11.7% \[p\<0.001\]).

**Conclusions**: Although the consensus HB/HCC 1996 protocol could achieve cure of about three‐quarters of HB patients, a robust risk stratification system is required to identify high risk patients to improve their treatment outcome.

### PO-582. Perioperative Complications after Partial Hepatectomy for Hepatoblastoma {#pbc27455-sec-8160}

[M. Cornet]{.ul} ^1^, F. Guérin^1^, F. Virginie^1^, C. Baujard^2^, P. Tissieres^3^, V. Laithier^4^, S. Taque^5^, S. Branchereau^1^

*^1^Hopital CHU Bicêtre, Pediatric Surgery, PARIS, France; ^2^Hopital CHU Bicêtre, Anesthesiology, Paris, France; ^3^Hopital CHU Bicêtre, Pediatric intensive care unit, Paris, France; ^4^CHU Besancon, Pediatric Oncology, Besancon, France; ^5^CHU de Rennes ‐ hopital sud, Pediatric Oncology, Rennes, France*

**Background/Objectives**: Surgery is one of the cornerstones in the treatment of hepatoblastoma. Partial hepatectomy (PH) is a demanding procedure and perioperative complications are common. The objective of this study is to assess perioperative complications after PH for hepatoblastoma.

**Design/Methods**: All patients that had a PH for hepatoblastoma after chemotherapy according the SIOPEL protocols in our institution, a pediatric liver disease and transplantation center, between January 1996 and January 2015 were included in this study. Examined variables were patient characteristics, tumour characteristics, perioperative complications, and impact on post‐operative chemotherapy.

**Results**: 116 patients underwent a PH for hepatoblastoma, 78 standard‐risk hepatoblastoma (SR‐HB) and 38 high‐risk hepatoblastoma (HR‐HB). There was 55 Pretext I/II and 61 Pretext III/IV. Neighty‐five procedures were undergone under hepatic vascular exclusion, with a median duration of 35 minutes (range: 10‐104 minutes). Eighty‐seven major hepatectomy were performed. Eleven intra‐operative complications occurred in 10 patients including 8 severe hemorrhages, rupture of the tumour in 2 patients, air embolism in one case. One patient died due to a severe hemorrhage and air embolism. Postoperative complications occurred in 26 patients (22,4%), consisting in 14 complications grade 2 and 12 complications grade 3 according to Dindo‐Clavien classification. Seven patients required a second operation during the first 10 days after partial hepatectomy, one for hemorrhage, 5 for biliary peritonitis and one for diaphragmatic rupture. Five patients presented a biliary leakage managed with drainage. No irreversible acute liver failure was observed. The rate of complications was higher in the HR‐group (49%) compared to the SR‐group (27%) (p=0,04). Perioperative complications resulted in a delayed post‐operative chemotherapy (p=0,001), with no impact on 3 years overall survival.

**Conclusions**: Perioperative complications after partial hepatectomy are relatively frequent and resulted in a significant delay in postoperative chemotherapy, but with no impact on 3 years overall survival in this report.

### PO-583. Evaluation of the Impact of Liver Regeneration after Partial Hepatectomy on Hepatoblastoma Intrahepatic and Distant Growth by Using Patient‐Derived Xenografts in Nude Mice {#pbc27455-sec-8170}

[M. Cornet]{.ul} ^1^, A. Delaitre^2^, L. Brulle Soumare^2^, S. Cairo^2^, S. Branchereau^1^

*^1^Hopital CHU Bicêtre, Pediatric Surgery, Paris, France; ^2^Xentech, research and development, Evry, France*

**Background/Objectives**: We made the assumption that the release of partial hepatectomy‐induced regenerating factors might help the proliferation of intrahepatic or distant hepatoblastoma (HB) tumor cells. The aim of this study was to evaluate the impact of partial hepatectomy (PH) on extrahepatic and intrahepatic tumor growth of HB in an animal model.

**Design/Methods**: We took advantage of a panel of HB patient‐derived xenograft. Firstly, HB fragments were implanted subcutaneously in athymic nude mice. Partial hepatectomy (PH) was performed 5 days after implantation. For the control group, only a sham laparotomy (SL) was done. Tumor growth was assessed weekly until the tumor volume reached 1770mm^3^. In a second time, an orthotopic model of luminescent HB in athymic nude mice was developed. A PH was performed during the same procedure than the HB cells injection into the liver. Tumor growth was evaluated weekly by monitoring serum Alfa Foeto Protein (AFP) and bioluminescence.

**Results**: For the subcutaneous model, the median time to reach 1000mm3 was 64,8 days (59,2‐72,8) in the SL group and 61,8 days (53,7‐67,5) in the PH group. The difference was not statistically significant (p=0,6). For the orthotopic model, the average AFP three weeks after HB cells injection was 2101 (± 1100) for the SL group and 8336 (± 2350) for PH group (p=0,008) and bioluminescence was measured at 168,9 (± 90) for the SL group and 449,7 (± 440) for PH group (p=0,048).

**Conclusions**: These results suggest that increased tumor growth induced by hepatectomy can occur in intrahepatic model of HB in athymic nude mice.

### PO-584. Inhibition of Gankyrin as a Therapeutic Approach for Pediatric Liver Cancer {#pbc27455-sec-8180}

[A. D\'souza]{.ul} ^1^, A. Cast^2^, M. Kumbaji^2^, L.V. Kiefer^2^, K. Glaser^2^, S. Sheeniza^3^, D. Smithrud^3^, A. Bondoc^2^, N. Timchenko^2^

*^1^Cincinnati Children\'s Hospital Medical Center, Hematology & Oncology, Cincinnati, USA; ^2^Cincinnati Children\'s Hospital Medical Center, Pediatric Surgery, Cincinnati, USA; ^3^University of Cincinnati, Chemistry, Cincinnati, USA*

**Background/Objectives**: Relapsed hepatoblastoma (HBL) and upfront hepatocellular carcinoma (HCC) are notoriously chemoresistant tumors associated with poor outcomes. Gankyrin, a small subunit of the 26S proteasome, is a known oncogene that is overexpressed in pediatric liver cancer and implicated in chemoresistance. The objective of this work was to study the role of cjoc42, a small molecule inhibitor of Gankyrin, in the treatment of pediatric liver cancer.

**Design/Methods**: Initial work was done in tissue culture, using Huh6 (human HBL) and Hepa1c1c7 (mouse HCC) cell lines. Cells were treated with cjoc42 alone or in combination with cisplatin or doxorubicin. Analysis included proliferation and cytotoxicity assays, QRT‐PCR, and Western blot. In vivo work was done in wild type mice treated with different doses of cjoc42 to assess tolerability and toxicity. Clinical, pathologic, and radiographic data was collected on 8 fresh samples of pediatric HBL and histological examination was done after staining for Gankyrin to determine presence of overexpression.

**Results**: Treatment of cancer cells with cjoc42 was not cytotoxic, but lead to reduced proliferation and rescue of tumor suppressor proteins. In combination with cisplatin or doxorubicin, there was a significant increase in cytotoxicity seen, more so than chemotherapy alone. Cjoc42 was well tolerated in mice based on gross examination, serum analysis, and histology. Treatment with cjoc42 alone and in combination with chemotherapy in patient derived xenografts is undergoing. Analysis of pediatric tumor samples show that Gankyrin is heavily expressed, especially in patients with minimal necrosis after chemotherapy and relapsed disease.

**Conclusions**: Gankyrin inhibition blocks proliferation of cancer cells and enhances the cytotoxicity of traditional chemotherapeutic agents used in pediatric liver cancer. In HBL samples, Gankyrin overexpression is widely seen, which supports its use as a targeted approach in pediatric patients. Cjoc42 appears to be safe and tolerable in mice and further experiments in patient derived xenografts are underway.

### PO-585. Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma {#pbc27455-sec-8190}

[R. Dong]{.ul} ^1^, D. Kuiran^2^

*^1^Children\'s Hospital of Fudan University‐ Key Laboratory of Neonatal Disease, Department of Pediatric Hepatobiliary Surgery, Shanghai, China; ^2^Children\'s Hospital of Fudan University, Department of Pediatric Surgery, Shanghai, China*

**Background/Objectives**: Hepatoblastoma is the most common liver tumor in early childhood. Recently, Circular RNAs (circRNAs) have been identified as novel regulators and prognostic markers in several cancers. However, the expression profile and clinical significance of circRNAs in hepatoblastoma is still unknown.

**Design/Methods**: Circular RNA Microarray was conducted to identify hepatoblastoma‐related circRNAs. GO analysis, pathway analysis, and miRNA response elements analysis was conducted to predict the potential functions of dysregulated circRNAs in hepatoblastoma. MTT assays, Ki67 staining, and Transwell assays were conducted to detect the effect of circRNA silencing on hepatoblastoma cell function. Bioinformatics and *in vitro* experiments were conducted to investigate the mechanism of circRNA‐mediated hepatoblastoma cell function.

**Results**: We identified 869 differentially expressed circRNAs, including 421 up‐regulated circRNAs and 448 down‐regulated circRNAs, between hepatoblastoma and non‐hepatoblastoma samples. The significant enriched GO term of hepatoblastoma‐related circRNAs in biological process, cellular component, and molecular function were "chromosome organization", "cytoplasm", and "organic cyclic compound binding". Tight junction signaling pathway was ranked the Top 1 potentially affected by circRNA‐mediated regulatory network. circ_0015756 was significantly up‐regulated in human hepatoblastoma specimens and metastatic hepatoblastoma cell lines. circ_0015756 silencing decreased hepatoblastoma cell viability, proliferation, and invasion *in vitro*. circ_0015756 acted as miR‐1250‐3p sponge to regulate hepatoblastoma cell function *in vitro*.

**Conclusions**: Our findings indicate that circRNAs are involved in the pathogenesis of hepatoblastoma. circ_0015756 is a promising therapeutic target for the prognosis, diagnosis, and treatment of hepatoblastoma.

### PO-586. Hepatoblastoma in Marrakesh {#pbc27455-sec-8200}

[J. Elhoudzi]{.ul} ^1^, E. meriem^2^, O. mohamed^3^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco; ^2^University hospital Mohammed Vi, Pediatric hematology and oncology, Marrakesh, Morocco; ^3^University hospital Mohammed Vi, pediatric surgery department, Marrakesh, Morocco*

**Background/Objectives**: Liver tumors account for 1% of all pediatric solid tumors dominated by hepatoblastoma. Annual incidence is 1 per million children, usually occurring before the age of 3 years. This study sought to identify clinical presentation, histology, staging, treatment modalities and survival for pediatric hepatoblastoma in Marrakesh.

**Design/Methods**: retrospective study, included 7 cases collected over nine years (June 2009‐December 2017) in Pediatric hematology‐oncology department of university hospital Mohammed VI, Marrakesh.

**Results**: Hepatoblastoma is rare: 1 case per 2 years, average age was 12 months, abdominal distension was a constant reason for consultation (100%), diagnosis was evident in 5 cases, 2 cases needed biopsy to confirm it. 4 infants were stage IV of PRETEXT. Chemotherapy was administered in 4 infants (cisplatin, doxorubucin), a curative surgery performed in 4 patients with complete remission, 2 deaths were registered before any treatment and 1 death was caused by sepsis after a week post chemotherapy

**Conclusions**: management of hepatic tumors in children should be done in a specialized center. The work done over the past ten years has led to an improvement in the classification, the description of histo‐prognostic factors. The prognosis is satisfactory reaching nearly 80% overall survival. Difficulty lies in surgical technique to prevent liver function. In our center, we need to develop supportive care to improve survival.

### PO-587. Treatment and Prognosis of Persistent Postoperative Bile Leakage in Pediatric Patients with Hepatoblastoma {#pbc27455-sec-8210}

[J. Feng]{.ul} ^1^

*^1^Beijing children\'s hospital, Surgical oncology, Beijing, China*

**Background/Objectives**: Bile leakage is a common postoperative complication in pediatric patients receiving hepatectomy for hepatoblastoma. However, persistent bile leakage is uncommon. This article aims to summarize and discuss the treatment and prognosis of this rare condition.

**Design/Methods**: Between 2013 and 2017, persistent postoperative bile leakage occurred in three patients with hepatoblastoma. Their medical records were reviewed and summarized.

**Results**: 2 boys and 1 girl underwent hepatectomy for hepatoblastoma. The median age was 13 (5‐29) months. All received 5‐cycle preoperative chemotherapy. Bile leakage occurred within 2 weeks after surgery and the duration was 1.5 month, 6 months and 19 months respectively. 2 cases were complicated with severe bacterial infections. Bile leakage was cured in 2 cases by cholangiojejunostomy and 1 by liver transplantation. 1 patient received 3‐cycle chemotherapy afterwards and the others no further treatment. The median follow‐up period was 12 (8‐19) months. All have survived without signs of bile leakage or tumors.

**Conclusions**: Persistent bile leakage may induce severe infection and liver injuries. Intervention should start on the time of diagnosis. Surgery may be recommended as an effective way of treatment. Even without adjuvant chemotherapy after operation, the outcomes were not bad, maybe related to local infection and immunization.

### PO-588. Liver Tumors in Children: 12‐Year Experience of a Reference Center in Southern Brazil {#pbc27455-sec-8220}

[C. Fiori]{.ul} ^1^, F. Bredt^1^, A. Rosa^1^, L.C. Bredt^2^

*^1^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric Oncology, Cascavel, Brazil; ^2^Cancer Hospital of Cascavel‐UOPECCAN, Surgery Oncology, Cascavel, Brazil*

**Background/Objectives: Introduction**: Liver tumors are rare in the childhood and adolescence, and the tumor origin varies with age.

**Objective**: Report a series of cases of childhood and adolescence hepatic tumors treated at a referral center for pediatric cancer in Brazil, describing the clinical findings, diagnosis, treatment and clinical evolution of cases.

**Design/Methods**: Retrospective, descriptive and cross ‐sectional study of 21 patients treated at Cancer Hospital UOPECCAN, Cascavel, Parana, from 2004 to 2016.

**Results**: Of the total number of patients (n = 21), six presented a diagnosis of benign tumor and fifteen of malignancy, with hepatoblastoma (n = 6) being the most common malignant tumor. The most common clinical signs were abdominal tumor (95.2%), abdominal pain (38%), and fever (19%). Abdominal ultrasound was the first complementary exam performed in 95.2% of patients and alpha‐fetoprotein (AFP) was elevated in seven cases, all cases of hepatoblastoma (HB) and in one patient with hepatocarcinoma (HCC). Four cases (19%) were treated with exclusive chemotherapy, six cases (28.5%) with exclusive surgery, all of which were benign, and eleven cases (52.5%) with chemotherapy combined with surgical resection. Five‐year survival rates for malignant tumors were 32%, 52% for primary liver tumors (n = 10) and 20% for liver metastases (n = 5) (p \<0.001).

**Conclusions**: Abdominal tumor is the most common clinical manifestation of hepatic tumors in childhood and adolescence, and abdominal ultrasound was the main complementary examination at initial investigation. Hepatoblastoma was the most common malignant liver tumor and AFP was increased in these cases. Benign tumors have exclusive surgical treatment, and chemotherapy combined to surgical resection presented better results in the treatment of primary liver tumors compared to liver metastases.

### PO-589. Outcome of HCC on Chronic Liver Disease in Children: A Multicenter Series {#pbc27455-sec-8230}

[C. Grimaldi]{.ul} ^1^, C. Guettier^2^, E. Gonzales^2^, R. Angelico^1^, M.C. Saffioti^1^, F. Guerin^2^, M. Spada^1^, S. Branchereau^2^

*^1^Ospedale Pediatrico Bambino Gesu\', Pediatric Surgery and Transplantation, Roma, Italy; ^2^Hôpitaux Universitaires Paris Sud APHP Bicetre, Pediatric Surgery, Le Kremlin Bicetre, France*

**Background/Objectives**: Background. Even if HCC is rare in children, treatment options have been improving over the last decades. Surgery is the mainstay of treatment with primary target to obtain complete resection. However, resectability can be compromised by different conditions. In such cases, LT may be indicated for the theoretical advantage of removing not only the tumor but also the entire diseased pre‐neoplastic liver.

**Design/Methods**: From 2008 to present, 35 HCC were diagnosed at Bambino Gesu' Children Hospital, Rome, Italy and CHU Bicetre, France. 4 patients were excluded from this analysis because they did not receive surgery (1 tumoral rupture, one metastatic disease and two patients currently on pre‐operative chemotherapy) and 1 because she received a post mortem diagnosis of HCC on neonatal hemochromatosis.

**Results**: Out of the 31 cases, 19 were on chronic liver disease (7 tyrosinemia, 2 criptogenic cirrhosis, 3 biliary atresia, 5 PFIC, 2 mytocondrial disease). All patients underwent a cadaveric LT with median time on the waiting list of 33 days (2‐270). None received chemotherapy before or after surgery. Except for one patient who died for unrelated causes, all patients are alive and disease free at a median follow up of 6.2 years (4,5 months‐ 9 years)

**Conclusions**: In this long‐term series, no patient received chemotherapy. LT proves to be a good option for treatment of HCC in chronic liver disease. Accurate surgical evaluation by experienced liver surgeons is mandatory to assess the correct management.

### PO-590. New Insights into Diagnosis and Therapeutic Options for Proliferative Hepatoblastoma {#pbc27455-sec-8240}

[C. Grosset]{.ul} ^1^

*^1^Université de Bordeaux Inserm‐, BMGIC‐ U1035, Bordeaux, France*

**Background/Objectives**: Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70‐80% of patients. However, some important challenges remain in diagnosing high risk tumors and identifying relevant targetable pathways offering new therapeutic avenues. Previously, two molecular subclasses of hepatoblastoma tumors have been described, namely C1 and C2; C2 being the subgroup with the poorest prognosis, a more advanced tumor stage and the worst overall survival rate. An associated 16‐gene signature to discriminate the two tumoral subgroups was proposed but it has not been transferred into clinical routine.

**Design/Methods**: To address these issues we performed RNA sequencing of 25 tumors and matched normal liver samples from patients.

**Results**: The transcript profiling separated HB into three distinct subgroups named C1, C2A and C2B, identifiable by a concise four‐gene signature: HSD17B6, ITGA6, TOP2A and VIM, with TOP2A being characteristic for the proliferative C2A tumors. Differential expression of these genes was confirmed by RT‐qPCR on an expanded cohort and by immunohistochemistry. We also revealed significant overexpression of genes involved in Fanconi Anemia (FA) pathway in the C2A subgroup. We then investigated the ability of several described FA inhibitors to block grow of HB cells in vitro and in vivo. We demonstrated that bortezomib, an FDA‐approved proteasome inhibitor, strongly impairs the proliferation and survival of HB cell lines in vitro, blocks FA pathway associated double‐strand DNA repair and significantly impedes HB growth in vivo.

**Conclusions**: In conclusion, the highly proliferating C2A subtype is characterized by TOP2A gene up‐regulation and FA pathway activation and HB therapeutic arsenal could include Bortezomib for the treatment of patients with the most aggressive tumors.

### PO-591. Surgical Treatment for Large Solitary Focal Nodular Hyperplasia of Liver in Children: An Analysis of Twelve Years of Experience {#pbc27455-sec-8250}

[J. Hu]{.ul} ^1^, H. Wang^1^, W. Han^1^

*^1^National Center for Children\'s Health Beijing‐ Beijing Children\'s Hospital‐ Capital Medical University, surgical oncology, Beijing, China*

**Background/Objectives**: Focal Nodular Hyperplasia(FNH) is an uncommon nonmalignant epithelial liver tumor with an annual incidence as high as 2.25 cases per million children. Mostly, the lesions with a diameter less than 5 cm are not removed, data on experience in surgical treatment of large pediatric FNH are limited. Thus, this paper aimed to furtherly verify the effect of operation in \> 5 cm FNH lesions.

**Design/Methods**: This study evaluated the pediatric patients who were pathologically diagnosed with FNH between January 2006 and January 2018 at our institution. Data were collected on age at diagnosis, size of lesion, presenting symptoms, history of past illness, radiographic findings, pathological findings, and clinical outcomes.

**Results**: A total of 729 children with liver tumor was treated at our institution during this period. Meanwhile, nine males and thirteen females aging from 15 to 136 months old were diagnosed as FNH (mean, 59.3 months). None of them had history of malignancy treatment, hepatitis virus or using contraceptive drugs. All the patients had different degree of symptoms including abdominal pain (12/22), abdominal distention and palpable mass (8/22), nausea (1/22), or occasionally found by radiological examination (1/22). The diagnostic accuracy is respectively as followed: 45.5% by ultrasound (10/22), 55% by CT enhanced scan (11/20) and 33% by MRI (1/3). Complete resection of all the 22 solitary masses was achieved. The diameters were above 5 cm, and the largest one was 14.5 cm. The main factors affecting postoperative hospitalization days included body temperature, abdominal drainage and diet status. Central fibrovascular scars were found in 11 cases (50%), which were approximately consistent with preoperative imaging findings. After 4 to 66 months follow‐up, these 22 cases all survived without recurrence or disease progression.

**Conclusions**: Simple resection plays a vital role in the treatment of pediatric liver FNH. The overall prognosis was favorable.

### PO-592. In Vitro Radiosensitivity of Hepatoblastoma Cell Line Huh‐6 {#pbc27455-sec-8260}

[M. Jiang]{.ul} ^1^

*^1^Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, radiotherapy, shanghai, China*

**Background/Objectives**: Hepatoblastoma (HB) is the most common malignant embryonal liver tumor in the pediatric population and the incidence is increasing. Radiation therapy may be a potential option of adjuvant therapy for HB cases could not be managed with surgery or chemotherapy, but our experience and knowledge of radiation therapy on HB treatment is limited. In order to evaluate the feasibility of utilizing radiation therapy on HB remedy, here we conducted a vitro experiment to detect the radiosensitivity of a HB cell line Huh‐6.

**Design/Methods**: The proliferation, morphology change, cell apoptosis and cell cycle of Huh‐6 cells received gradient X‐ray irradiation were systemically studied with CCK‐8 assay, microscopy, Annexin V/7‐ADD and PI single staining respectively.

**Results**: The proliferation of Huh‐6 cells were significantly inhibited and the inhibition efficiency was positively correlated with the irradiation dose. Cells received higher irradiation dose showed higher percentage of deformed cells characterized by plenty of bubbles in the cytosol at the early stage post irradiation and debris in the cytosol of the non‐regular shaped dead cells at the later stage. Cell apoptosis was enhanced with the increment of irradiation dose. The percentage of cells arrested in G2/M phase increased and meanwhile the proportion of cells in G0/G1 phase decreased with the rising dose gradient.

**Conclusions**: This Huh‐6 cell line is radiosensitive in vitro and the efficiency of inhibition is positively correlated with the irradiation dose received, indicated the potential of radiation therapy on the treatment of HB.

### PO-593. A First Glimpse of the Genomic Landscape of Metastatic Hepatoblastoma {#pbc27455-sec-8270}

[R. Kappler]{.ul} ^1^, C. Vokuhl^2^, D. von Schweinitz^1^

*^1^University of Munich, Department of Pediatric Surgery, Munich, Germany; ^2^Institute of Paidopathology, Pediatric Tumor Registry, Kiel, Germany*

**Background/Objectives**: Hepatoblastoma (HB) is the most common malignant liver tumor in childhood and mainly driven by mutations in either the β*‐catenin* (*CTNNB1*) or *adenomatosis polyposis coli* (*APC*) gene. However, the molecular mechanisms underlying tumor progression remain elusive. Here, we aimed at identifying genes that cause metastatic spread of HB.

**Design/Methods**: Genomic DNA was isolated from unaffected liver tissue, primary tumor and metastasis of three patients with HB. DNA was analyzed by whole exome sequencing. Functional annotation of mutated genes was performed with DAVID v6.7.

**Results**: We found that the mean mutation rate was heavily increased in metastases (84 per tumor) compared to primary tumors (18 per tumor). The reported mutation rate in the literature for HB is 3.8 per tumor. Metastases showed significant enrichment of mutations in genes involved in covalent chromatin modification (*ATRX, CHD8, CHD7, ARID1A, NR3C1, KDM4E*) and canonical Wnt signaling (*DVL3, CHD8, WNT7A, UBE2B*). Mutations in the driver genes *CTNNB1* and*APC* as well as in the genomic caretaker genes *XRCC1* and *ATRX* were stable and occurred in both the primary tumor and the metastases.

**Conclusions**: The genetic alterations found in metastases of patients with HB pinpoint to a role of genomic instability and epigenetic derailment in the process of tumor spread.

### PO-594. Demographics and Clinical Outcome of Pediatric Liverr Tumors: Experience from a Tertiary Care Centre of Pakistan {#pbc27455-sec-8280}

[A. Khalid]{.ul} ^1^

*^1^The Children\'s Hospital And Institute Of Child Health, Pediatric Hematology/Oncology, Lahore, Pakistan*

**Background/Objectives**: Primary pediatric hepatic malignancies account for 0.5 ‐2% of all the childhood solid tumors. Hepatoblastoma (HB) and Hepatocellular carcinomas (HCC) are the most common, making upto 27.6% and 16.5% respectively. The objective of this studt was to analyze the clinical data and outcome of pediatric liver tumors in a developing country with limited resources.

**Design/Methods**: The data of 49 patients diagnosed with HB and HCC who reported from January, 2015 to December 2017 in Children\'s hospital, lahore was analyzed retrospectively. Patients demographics, extent if tumor, surgical procedures performed, complications of treatment and outcome were compiled.

**Results**: Data of forty nine patients with malignant liver tumors was analyzed retrospectively. Hepatoblastoma accounts for majority of the cases 44 presenting between 6 months to 3 years of age, while all the 5 cases of HCC were more than 10 years old. There was a male predisposition accounting for 64% cases. All the patients presented with a palpable lump in abdomen and the alpha fetoprotein (AFP)was \>30,000ng/ml in 86%. Liver biopsy was performed in 13 cases. Staging was done by PRETEXT syatem and most were of stage III, 42%. Patients with HB were started on treatment according to SIOPEL protocol and 29 cases received standard risk chemotherapy. Surgical resection was done in 29 cases and 14 were unresectable. Treatment completed in 20 cases and are on follow up, 11 patients expired on treatment however there was no death due to post operative complications. Twelve patientswere counselled regarding palliation and 6 lost follow up on treatment.

**Conclusions**: The certaininty of diagnosis of HB without biopst in children between age 6 months to 3 years with elevated AFP is high. Moreover, the multidisciplinary approach involving the combination of chemotherapy and surgery has a better outcome in pediatric liver tumors.

### PO-595. Accuracy of CT Scan Diagnosis Comparing with Pathological Findings in Small Lung Metastases of Hepatoblastoma {#pbc27455-sec-8290}

[N. Kitagawa]{.ul} ^1^, M. Shinkai^2^, K. Mochizuki^2^, H. Usui^2^, F. Asano^2^, E. Osawa^2^, T. Kondo^2^, K. Nozawa^3^, M. Yoshida^4^, M. Tanaka^4^, Y. Tanaka^4^

*^1^Kanagawa Children\'s Medical Center, Children\'s Cancer Center, Yokohama, Japan; ^2^Kanagawa Children\'s Medical Center, Department of Surgery, Yokohama, Japan; ^3^Kanagawa Children\'s Medical Center, Department of Radiology, Yokohama, Japan; ^4^Kanagawa Children\'s Medical Center, Department of Pathology, Yokohama, Japan*

**Background/Objectives**: We have performed thorough lung metastasecromy of hepatoblastoma. No limitation of tumor number and size were set for operative indication. Even lesions under 2mm were extirpated using indocyanine green fluorescent method (ICGF). This strategy resulted a 3‐years survival rate of 87% for stage IV hepatoblastoma with conventional chemotherapy. The aim of this study is to confirm accuracy of preoperative CT scan findings.

**Design/Methods**: Retrospective review of CT findings, pathological findings and operation records were performed. All operations included thoracotomy and wedge resection of tumors. ICGF was done by intravenous administration of 0.5mg/kg of ICG one day before operations and fluorescence was detected by a detector within an infrared ray radiator (PDE neo^R^).

**Results**: Two hundred and sixty‐one nodules were extirpated in 38 operations for 6 patients between 2013 and 2016 at our institute. Among them, 193 nodules were proved as metastases pathologically, and 107 were confirmed by preoperative CT. As for the size of tumors, 57 were 5mm or more, 30 were 2‐4mm, 106 were 1mm or less, respectively. The positive rate of CT was 97% for 5mm or more, 43% for 2‐4mm, 37% for 1mm or less, respectively. False positives were found in 4 nodules in CT. On the other hand, 79 false positives were found in intraoperative ICGF, which were caused by bleedings, granulation by suture strings or atelectasis. The minimum size of ICGF‐positive tumor was 0.053mm.

**Conclusions**: The sensitivity of preoperative CT was estimated as 55%, while false positive rate was 3%. From these results, very small lesions of CT findings are reliable.

### PO-596. Retrospective Analysis of Hepatoblastoma Treatment in Lviv Region: SIOPEL Guidelines Strategy Adapted to Low‐Income Country Healthcare Realms {#pbc27455-sec-8300}

[R. Kizyma]{.ul} ^1^, Z. Kizyma^1^, I. Lukavetskyi^1^, B. Romanyshyn^1^, B. Kotsay^2^, A. Synyuta^1^, M. Zakharus^1^, A. Kuzyk^3^, I. Shchurovska^4^, I. Andrejczuk^4^, R. Sobko^4^

*^1^Western Ukrainian Specialized Pediatric Medical Centre, Pediatric Surgery/Oncology, Lviv, Ukraine; ^2^Lviv National Medical University, Pediatrics, Lviv, Ukraine; ^3^Lviv National Medical University, Pediatric Surgery, Lviv, Ukraine; ^4^Western Ukrainian Specialized Pediatric Medical Centre, Intensive Care Department, Lviv, Ukraine*

**Background/Objectives**: The objectives of the analysis were to review the clinical presentation and management of children with hepatoblastoma and the factors influencing the outcome in Lviv region. Despite the good overall prognosis in patients with this tumour, most children in the developing country present with late stage of disease at diagnosis and require careful risk group stratification decision.

**Design/Methods**: A retrospective chart review was performed of 14 children with hepatoblastoma that received protocol chemotherapy in our institution from 2003 to 2017. Diagnosis was confirmed histologically and with conventional CT, MRI and sonography, that were performed accordingly at the initial diagnosis, preoperatively and after adjuvant treatment. The treatment protocol was based on SIOPEL recommendations. The patients risk group was identified due to pretreatment extent of disease (PRETEXT) grouping guidelines.

**Results**: The age range at diagnosis was from 1 months to 6 years (median 25 months). The main presenting symptom was abdominal mass and the median Alpha Fetoprotein (AFP) level at the time of diagnosis was above 50,000 ng/ml. PRETEXT stage I or II was documented in 3 patients and III in 7 patients. Four patients had high risk disease (PRETEXT IV or metastatic disease involving lungs). All patients received neoadjuvant platinum‐based chemotherapy and postoperative chemotherapy. Surgery was performed after 4 or 7 cycles of chemotherapy. Trisectionectomy or hemihepatectomy was performed, basing on tumour initial extent and chemotherapy response. The median follow‐up was 32 months and the 3‐year overall survival was 79.6 % (for high‐risk patients was 50%).

**Conclusions**: The approach of SIOPEL risk stratification and platinum‐based neoadjuvant chemotherapy of hepatoblastoma with strict timing of surgery is the decent strategy in the realms of developing country, considering statistically larger amount of advanced stage tumours at presentation.

### PO-597. Identification of the DNA Methylated RASAL3 Gene as a Potential Molecular Marker Predicting Metastasis of Hepatoblastoma {#pbc27455-sec-8310}

[L. Lu]{.ul} ^1^, Z. Lv^1^

*^1^Shanghai Children\'s Hospital‐ Shanghai Jiao Tong University, Department of General Surgery, Shanghai, China*

**Background/Objectives**: Hepatoblastoma (HB) is the most common pediatric liver malignancy. Chemotherapy is effective to improve tumor resectablity and overall survival. However, the patients with metastatic HB often fail to respond to the standard treatment. It is critical to identify a novel molecular marker for metastasis prediction and investigate new therapeutic stagey for patients with metastatic HB.

**Design/Methods**: Tumor tissues from metastatic HB patients were used to identify RASAL3 as a potential molecular marker which was regulated by DNA methylation and related to tumor metastasis. Suppressing and reconstituting RASAL3 in tumor cell lines were used to explore its role in metastatic HB. Meanwhile RNA‐Seq assay was conducted to analyze the transcriptome alternation result from RASAL3 silencing and reveal the mechanism of RASAL3 regulating tumor metastasis.

**Results**: Frequent CpG methylation of RASAL3 was found in metastatic tumor tissues in HB but not in normal liver and primary tumor tissues. Expression of RASAL3 was observed significantly downregulated in the metastatic HB. Further study revealed that RASAL3 descent could be reversed by methyltransferase inhibitor, and the methylation of two critical regions in the CpG Island around the transcription start site resulted in the RASAL3 silencing. RASAL3 deficiency increased the invasion and migration ability of tumor cells. As evidenced by RNA‐seq analysis that RASAL3 silencing altered the genes involved in cell adhesion and cellular cytoskeleton, RASAL3 knockdown upregulated the protein level of SNAIL1/2 and phosphorylation level of MLC, which indicated that RASAL3 was a potential epithelial‐mesenchymal transition (EMT) suppressor. Mechanically, RASAL3 exerted its effect via its inhibition on the RAS protein activity and subsequently the RAS/RAF/ERK pathway.

**Conclusions**: Our study indicates that RASAL3 methylation level is a promising biomarker for metastatic HB diagnosis. These data further reveal that RASAL3 suppresses EMT process during HB development through regulating RAS/RAF/ERK pathway, and supply new therapeutic target for patients with metastatic HB.

### PO-598. Clinical Characteristics and Treatment Outcome of Hepatoblastoma with Lung Metastases: A Single‐Center Experience {#pbc27455-sec-8320}

[S.Y. Min]{.ul} ^1^, J.W. Yoo^1^, H. Kim^1^, K.N. Kim^1^, H.J. Im^1^, J.J. Seo^1^, D.Y. Kim^2^, J.M. Namgung^2^, S.H. Choi^3^, D.K. Kim^3^

*^1^Asan Medical Center Children\'s Hospital‐ University of Ulsan College of Medicine, Division of Pediatric Hematology/Oncology‐ Department of Pediatrics, Seoul, Republic of Korea; ^2^Asan Medical Center Children\'s Hospital‐ University of Ulsan College of Medicine, Department of Pediatric Surgery, Seoul, Republic of Korea; ^3^Asan Medical Center Children\'s Hospital‐ University of Ulsan College of Medicine, Department of Thoracic and Cardiovascular Surgery, Seoul, Republic of Korea*

**Background/Objectives**: The most common metastatic site of hepatoblastoma is the lung. Patients with hepatoblastoma who have lung metastases are considered very high‐risk patients. The aim of this study is to investigate the clinical characteristics and treatment outcome of hepatoblastoma with lung metastases.

**Design/Methods**: The medical records of 87 patients who were newly diagnosed with hepatoblastoma at Asan Medical Center Children\'s Hospital between January 1991 and August 2017 were reviewed retrospectively. Among them, 29 patients had lung metastases at diagnosis.

**Results**: Of the 29 patients diagnosed with lung metastases, 0, 12, 7, 10 were PRETEXT I, II, III, and IV respectively. PRETEXT did not affect the survival outcome of patients with lung metastasis. Among 29 patients, 20 had lung metastases only and other 9 had metastases in lung and other organs. Pulmonary metastasectomy was done in 18 patients. There was no significant difference in survival outcome between who underwent pulmonary metastasectomy and who did not. Four patients underwent liver transplantation (LT), and all of them were alive without disease. The 5‐year overall survival (OS) rate of patients without lung metastasis was significantly better than those with lung metastasis (84.9% vs 56.9%, *p* = 0.014). The OS rate of patients with lung metastasis who were diagnosed after 2006 were better than those diagnosed before 2006 with modest significance (80.4% vs 40.0%, *p* = 0.069). Twenty patients had complete radiographic resolution of all pulmonary metastatic lesions. There was a strong statistical significance between survival outcome and complete resolution of lung metastases (*p* \< 0.001).

**Conclusions**: Patients with pulmonary metastatic hepatoblastoma had unfavorable prognosis. However, recent outcomes have been improving, probably due to effective chemotherapy and LT. The resolution of pulmonary metastatic lesions was an important prognostic factor. A larger, multi‐center study is required to investigate treatment strategies to improve the outcomes of hepatoblastoma with lung metastasis.

### PO-599. Impact of Radiological Caracteristic of Lung Nodules on Survival in Children with Metastatic Hepatoblastoma {#pbc27455-sec-8330}

[F. Neumann]{.ul} ^1^, D. Pariente^2^, L. Brugieres^3^, B. Fresneau^3^, M. Fabre^4^, C. Guettier^5^, S. Branchereau^6^, B. Mallon^3^, V. Laithier^1^

*^1^University Hospital Besançon, Pediatric Oncology Departement, Besançon, France; ^2^AP‐HP Kremlin Bicêtre Hospital, Pediatric radiology departement, Le Kremelin Bicêtre, France; ^3^Gustave Roussy Cancer Campus, Department of Oncology for Children and Adolescents‐, Villejuif, France; ^4^Hôpital Necker, Departement of pathology, Paris, France; ^5^AP‐HP Kremlin Bicêtre Hospital, Departement of Pathology, Le Kremelin Bicêtre, France; ^6^AP‐HP Kremlin Bicêtre Hospital, Pediatric surgery departement, Le Kremelin Bicêtre, France*

**Background/Objectives**: The aim of the study was to assess the prognostic of the radiological characteristic of lung nodules in children with metastatic hepatoblastoma (HB).

**Design/Methods**: Between 2000 and 2015, patients who were treated in France and included in a central database « HEPATOBIO » were eligible for this study. Pulmonary tomography scans and were centrally reviewed at diagnostic and information about number, size, laterality and evolution under treatment were collected. Data about histopathology, chemotherapy regimen were recorded. Overall survival (OS) and 3‐years event free survival (EFS) were analyzed in univariate analysis.

**Results**: During the period, 26 patients with metastatic HB were included. Patients were treated in SIOPEL‐3 (42.3%) and SIOPEL‐4 studies(57.7%). Overall survival (OS) and 3‐years event free survival (EFS) were 76.4% and 67.8% respectively. Patients with less than 5 nodules had increased 3‐years EFS of 85.3% (CI 95% 52.3‐96.1%) and OS of 90.0 % (CI 95%; 47.3‐98.5%) vs 50.0% (CI 95% 20.5‐73.6%) and 47,3% (CI 17.6‐71.,8%) in patients with 5 or more nodules (p=0.017 and p=0.006 for EFS and OS respectively). Patients with nodules \<5mm had a 3‐year EFS and OS of 100% vs 3‐years EFS of 47.9% (CI 95% 21.1‐70.7%) and OS of 50.7% (CI 95% 20.6‐74.7%) (p= 0.01 and p=0.02 for EFS and OS respectively). Patients with bilateral nodules had EFS of 61.4% (CI 95% 37.0‐79.4%) and OS of 64.8% (IC95 % 39.0‐81.8%) whereas patients with unilateral lesions had a 3‐year EFS and OS of 100%.

**Conclusions**: Children with metastatic HB have a poor prognosis but various presentations of diseases seems to exist among them. Patients with light metastatic diseases had a better prognosis. Treatment intensity could be adapted regarding to the burden of metastatic disease to limit the toxity and long term side‐effects. Multivariate analysis must be performed to confirm these results.

The authors thanks HEPATOBIO database scientific committee.

### PO-600. Eight Surgery Cases for Pulmonary Metastasis of Hepatoblastoma by Indocyanine Green Fluorescence Navigation {#pbc27455-sec-8340}

[M. Ohno]{.ul} ^1^, T. Hishiki^2^, K. Tomonaga^1^, K. Tahara^1^, T. Watanabe^1^, A. Fujino^1^, Y. Kanamori^1^, K. Matsumoto^3^, M. Kasahara^4^, T. Yoshioka^5^

*^1^National Center for Child Health and Development, Division of Surgery‐ Department of Surgical Specialties, Tokyo, Japan; ^2^National Center for Child Health and Development, Division of Surgical Oncology, Tokyo, Japan; ^3^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^4^National Center for Child Health and Development, Center for Organ Transplantation, Tokyo, Japan; ^5^National Center for Child Health and Development, Department of Pathology, Tokyo, Japan*

**Background/Objectives**: Complete resection is an important tool for the cure of hepatoblastoma (HB) with pulmonary metastases. Recently, navigation surgery using indocyanine green (ICG) has been reported as a useful technique to detect minimal pulmonary metastatic lesions. We performed ICG navigation surgery for eight cases with metastatic HB in our center, and discussed its efficacy and drawback.

**Design/Methods**: We retrospectively analyzed eight cases (six males and two females) with hepatoblastoma who underwent ICG‐navigated metastasectomy from August 2010 to December 2017. Intravenous injection of 0.5mg/kg of ICG was administered 24‐72 hours prior to the surgery. ICG accumulation was intraoperatively detected through an infrared camera dedicated for the procedure. Age at operation ranged from 6 months to 12 years old. Two recurrent cases underwent the procedure twice. Procedures were performed through right thoracotomy in three cases, left in one case, and bilateral in four cases. ICG‐positive lesions and palpable nodules detected by preoperative computed tomography (CT) scans were removed by wedge resections.

**Results**: A total of 51 lesions were resected. Ultimately, thirty‐one were pathologically proven to be metastatic tumors (61%). Forty‐six lesions were ICG‐positive (90%), and 29 were viable tumors (sensitivity=93.5%), whereas 17 were non‐malignant lesions (specificity=15%). Among the 51 resected lesions, 33 were detectable by preoperative CT. Twenty‐five of these were metastatic tumors (sensitivity=81%), while 8 were not (specificity=60%). There were four metastatic nodules that were not detectable by CT but were ICG‐positive.

**Conclusions**: ICG navigation could demonstrate minimum lesions that were undetectable by CT scans. The procedure is extremely sensitive, although the false positive rate was also high. Further investigation is warranted to decrease the number of false‐positive nodules and avoid unnecessary resections.

### PO-601. Epidemiological and Prognostic Characteristics of Hepatocarcinoma in Children and Teenagers of Three Centers: Rebagliati and Almenara Hospitals and Clinic Oncosalud in Lima Peru 1999‐2018 {#pbc27455-sec-8350}

[A.M.G. Paredes Guerra]{.ul} ^1^

*^1^Essalud Rebagliati Hospital, Paediatric oncology, Lima, Peru*

**Background/Objectives**: Evaluate the impact of the latest surgical advances and evolution of treatment of childhood Hepatocarcinoma (HCC) in major centers of Peru with a prognostic significance.

**Design/Methods**: Descriptive, retrospective, longitudinal study, 25 patients with Hepatocarcinoma from 0 to 18 years in 3 centers for 19 years.

**Results**: Of 78 cases of cancer\'s liver: 25 (32%) Hepatocarcinoma. Average age 8 years, school 68%, male/female 3/1; hepatomegaly, abdominal mass and weight loss 100%. Immunized Hepatitis B vaccine 52%; 6 with chronic active Hepatitis B, all received lamiduvudine. One HCC by tyrosinemia and another secondary to everolimus. Alphafetoprotein average debut 93,064 ng/ml (300 to \>400,000). SIOPEL Stadium: PreText I: 4%, II: 12%, III: 56% and PreText IV: 28%; twelve (48%) metastases and 4 (16%) cirrhosis. Percutaneous biopsy\'s diagnostic 75%. Epithelial hepatocarcinoma 100%. Five debut\'s resection (4 tumor and 1 liver transplant for tyrosinemia), after 1 received adjuvant chemotherapy (qt) + sorafenib and 2 qt + thalidomide; 4 remission and one died after surgery by hepatic vein involment. Twenty unresectable at debut: 3 received SIOPEL protocol, 6 SIOPEL + intrarterial hepatic doxorubicin, 6 received SIOPEL + sorafenib and 5 SIOPEL + thalidomide. After treatment 16 (64%) became resectable, one after packing by rupture at onset. Four with chronic active HepatitisB + cirrhosis died. One of six with cronic active Hepatitis B in remission. Of the 25 patients: 13 (52%) alive: 11 (44%) in remission and 2 in second line chemotherapy by relapse. Disease‐free survival of 11 patients in remission 96 months.

**Conclusions**: Higher incidence of mortality in patients not immunized with Hepatitis B more cirrhosis, pretext III‐IV, alpha‐fetoprotein greater than 100 ng / ml, portal vein or hepatic involvement, spontaneous rupture at onset, metastasis and epithelial histology. Liver transplantation, intra‐arterial chemotherapy and white therapy favored the good response of HCC together with surgical advances and updated multicentre protocols.

### PO-602. Hepatoblastoma: 16‐Years Experience from a Tertiary Cancer Centre in India {#pbc27455-sec-8360}

[V. RADHAKRISHNAN]{.ul} ^1^, M. Avronan^1^, J. Ramamoorthy^2^, P. Ganesan^1^, T. Sagar^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India; ^2^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Hepatoblastoma is a rare paediatric tumour arising from the liver. The present study was conducted to ascertain the clinical profile and survival outcomes of patients with hepatoblastoma treated at our centre.

**Design/Methods**: We collected the case records of patients with hepatoblastoma treated between January 2000 to December 2016 and analysed the baseline characteristics, treatment details and outcomes. Survival was analysed using Kaplan Meier method.

**Results**: Twenty‐seven patients with hepatoblastoma received treatment at our centre during the study period. Median age of the patients was 12 months and 76 % were males. The commonest presenting symptom was abdominal mass and the median Alpha Fetoprotein (AFP) level at the time of diagnosis was 40,000 ng/ml. PRETEXT stage II was documented in 11 and III in 11 patients. High risk disease (PRETEXT IV or metastatic disease or portal venous invasion or AFP \< 100 ng/ml) was documented in 8/27 (30%) patients. Neoadjuvant chemotherapy (NACT) was given to 23/27 patients and complete surgical resection was possible in 15/23 (65%) after NACT. Infusional cisplatin and doxorubicin (PLADO) was given in 24/27 patients. Liver transplantation was done in 1 patient. The median follow‐up was 51 months and the 5‐year overall survival for standard risk and high‐risk patients was 78.8% and 40% respectively.

**Conclusions**: Patients with standard risk hepatoblastoma have survival outcomes comparable to Western countries, however, outcomes in patients with high risk non‐metastatic inoperable disease remains low due to financial constraints in performing liver transplantation. Multimodality treatment including NACT with PLADO based regimens followed by resection is a feasible strategy.

### PO-603. Sarcopenia as a Nutritional Biomarker in Children with Hepatoblastoma {#pbc27455-sec-8370}

[A. Ritz]{.ul} ^1^, R. Kappler^1^, J. Hubertus^1^, D. von Schweinitz^1^, M. Berger^1^, E. Lurz^2^

*^1^Dr. von Hauner Childrens' Hospital, Department of Pediatric Surgery, Munich, Germany; ^2^Dr. von Hauner Childrens' Hospital, Department of Pediatric Gastroenterology and Hepatology, Munich, Germany*

**Background/Objectives**: Sarcopenia, reflected by a decreased psoas muscle surface area (PMSA), is associated with poor post‐surgical outcome. Children with hepatoblastoma (HB) have a high risk of sarcopenia due to immobility, malnutrition and systemic inflammation. Hence, we hypothesized that children with HB would have a smaller PMSA than healthy controls and that PMSA would correlate with clinical parameters.

**Design/Methods**: Children (ages 0 to 10 years) with HB treated at our institution from 2009 to 2018 were included in this pilot study. Pre‐surgical CT or MRI images were retrieved from the hospital imaging database. PMSA was measured at 2 intervertebral disc (L3/4; L4/5) levels. *Z* scores were calculated using age and gender specific reference values from a large cohort of pediatric trauma victims. PMSA *z* scores were correlated with clinical variables and outcome.

**Results**: A total of 43 children with HB were included. On both lumbar levels, PMSA was significantly smaller in HB subjects compared with healthy controls (L3/4 mean ‐2.17, SD 0.91; L4/5 mean ‐2.13, SD 0.87; *P* \<0.0001). PMSA *z* scores correlated poorly with weight *z* scores (L3/4: r\^2 = 0.291; L4/5: r\^2 = 0.297) and BMI (L3/4: r =0.463; L4/5: r = 0.455). PMSA in HB did not correlate with age at diagnosis, length of hospital stay, PRETEXT, CTNNB1 mutation, C1/C2 gene signature, metastasis, AFP levels, tumor type/histology or focality.

**Conclusions**: In this retrospective pilot study, PMSA was significantly lower in children with HB compared with healthy age‐ and gender‐matched controls. Although PMSA did not correlate with clinical markers, this result has to be interpreted carefully as all children had severe sarcopenia. Importantly, PMSA correlated poorly with participants' weight *z* scores and BMI. Thus, sarcopenia might be a novel and independent nutritional biomarker in children with liver cancer.

### PO-604. Human Palatine Tonsil‐Derived Mesenchymal Stem Cells Attenuates TGF‐β‐Induced Epithelial to Mesenchymal Transition and Stemness of Hepatocellular Carcinoma Cells {#pbc27455-sec-8380}

[K.H. Ryu]{.ul} ^1^, E.S. Yoo^1^, E.J. Choi^2^, K.A. Cho^3^, Y.H. Kim^3^, J.W. Park^4^, S.Y. Woo^3^

*^1^Ewha Womans University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^2^Catholic University of Daegu School of Medicine, Department of Pediatrics, Daegu, Republic of Korea; ^3^Ewha Womans University College of Medicine, Department of Microbiology, Seoul, Republic of Korea; ^4^Ewha Womans University College of Medicine, Department of Biochemistry, Seoul, Republic of Korea*

**Background/Objectives**: In carcinoma progression, epithelial to mesenchymal transition (EMT) plays a crucial role in early steps of metastasis when cells lose cell‐cell contacts and acquire increased motility to spread into surrounding or distant tissues. Epithelial plasticity has become a hot issue in hepatocellular carcinoma (HCC), as strong inducers of EMT such as transforming growth factor‐β (TGF‐β) are able to orchestrate both fibrogenesis and carcinogenesis, showing rising cytokine levels in cirrhosis and late stage HCC. Thus, there has been intense interest in targeting the TGF‐β signaling pathway for anti‐metastatic therapies. Here we show whether human palatine tonsil‐derived mesenchymal stem cells (T‐MSCs) regulate the TGF‐β --induced EMT phenotype of human hepatocellular carcinoma cell line, HepG2 cells.

**Design/Methods**: HepG2 cells were cultured in the presence of TGF‐β at a concentration of 20 ng/ml to observe the extent of proliferation and expression of EMT markers and cancer stem cell markers. To investigate the effect of T‐MSCs on the proliferation and gene expression of HepG2 cells, conditioned medium from T‐MSCs were added separately. After 72hrs, cells were harvested and proliferation rate was compared by performing Carboxyfluorescein succinimidyl ester (CFSE) assay. Also, the expression of CD44, CD133, CD151, EPCAM, P53, and K19 was detected by RT‐PCR.

**Results**: HepG2 cells rapidly proliferate that accompanied with increase of EMT markers and cancer stem cell markers upon TGF‐β stimulation for 72 hrs. However, T‐MSCs‐conditioned medium effectively decreased the TGF‐β‐induced proliferation on HepG2 cells. Importantly, T‐MSCs‐conditioned medium markedly suppressed markers of EMT and hepatocellular stemness.

**Conclusions**: Our findings indicate that T‐MSCs inhibit the carcinoma progressive trait of HepG2 cells by a paracrine effect via released factors and the effect of T‐MSCs is at least in part due to disturbance of TGF‐ β signaling.

### PO-605. miR‐492 Regulates Metastatic Properties of Hepatoblastoma via CD44 {#pbc27455-sec-8390}

J. von Frowein^1^, S.M. Hauck^2^, R. Kappler^3^, P. Pagel^4^, K.K. Fleischmann^1^, T. Magg^1^, S. Cairo^5^, A. Roscher^6^, D. von Schweinitz^3^, [I. Schmid]{.ul} ^1^

*^1^Dr. von Hauner Children\'s Hospital‐ Ludwig‐Maximilians‐University Munich, Department of Pediatric Hematology and Oncology‐ Children\'s Research Center, Munich, Germany; ^2^Helmholtz Zentrum Munich GmbH‐ German Research Center for Environmental Health, Research Unit Protein Science, Munich, Germany; ^3^Dr. von Hauner Children\'s Hospital‐ Ludwig‐Maximilians‐University Munich, Department of Pediatric Surgery, Munich, Germany; ^4^Technische Universität München‐ Freising and Numares AG‐ Regensburg, Lehrstuhl für Genomorientierte Bioinformatik, Freising, Germany; ^5^University of Ferrara and XenTech‐ Evry‐ France, Department of Morphology‐ Surgery and Experimental Medicine, Ferrara, Italy; ^6^Dr. von Hauner Children\'s Hospital‐ Ludwig‐Maximilians‐University, Children\'s Research Center, Munich, Germany*

**Background/Objectives**: MicroRNAs are important genetic regulators of physiological and pathophysiological processes including cancer initiation and progression of hepatoblastoma, the most common liver tumour in childhood. We aimed to identify malignant and metastasis promoting effects of miR‐492, a miRNA, previously reported to be overexpressed in metastatic hepatoblastoma. Furthermore, we intended to evaluate its diagnostic and prognostic potential.

**Design/Methods**: Stable and transient overexpression of miR‐492 in two liver tumour cell lines HepT1 and HUH7 was used to analyse features of metastatic tumour progression such as proliferation, anchorage‐independent growth, migration and invasion. Via a mass spectrometry based proteomic screen, we investigated miRNA‐492‐dependent effects on proteome level and explored the underlying biology. One of the predicted target genes, CD44, was experimentally validated via luciferase assays. Diagnostic and prognostic properties of miR‐492 were studied in hepatoblastoma tumour samples.

**Results**: We show that miR‐492 significantly enhances cell proliferation, anchorage‐independent growth, migration and invasion of hepatoblastoma cells. We also identified and validated CD44, a transmembrane adhesion receptor for hyaluronan, as direct and functional target of miR‐492. This miRNA has a strong direct impact on two CD44 isoforms (standard and v10). High miR‐492 expression correlates with high‐risk or aggressive tumours and further bears potential for predicting reduced event‐free survival.

**Conclusions**: We identified miR‐492 and its target CD44 as regulators of a number of biological features important for malignancy and metastasis. Furthermore, we demonstrated the diagnostic and prognostic potential of miR‐492, a promising novel therapeutic target and biomarker for hepatoblastoma.

### PO-606. High Expression of NQO1 with Promoter Hypomethylation in High‐Risk Hepatoblastoma is Related to Increased Cell Proliferation and Drug Resistance {#pbc27455-sec-8400}

[M. Sekiguchi]{.ul} ^1^, M. Seki^1^, T. Kawai^2^, T. Isobe^1^, K. Yoshida^3^, M. Yoshida^1^, R. Shirai^4^, R. Souzaki^5^, Y. Shiraishi^6^, N. Hoshino^7^, K. Watanabe^1^, Y. Arakawa^8^, K. Koh^8^, T. Taguchi^5^, M. Kato^4^, Y. Tanaka^9^, S. Miyano^6^, K. Hata^2^, S. Ogawa^3^, J. Takita^1^

*^1^The University of Tokyo, Department of Pediatrics, Tokyo, Japan; ^2^National Center for Child Health and Development, Department of Maternal‐Fetal Biology, Tokyo, Japan; ^3^Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan; ^4^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^5^Kyushu University, Department of Pediatric Surgery, Fukuoka, Japan; ^6^The University of Tokyo, Human Genome Center‐ The Institute of Medical Science, Tokyo, Japan; ^7^Saitama Children\'s Medical Center, Department of Pediatric Surgery, Saitama, Japan; ^8^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^9^Kanagawa Children\'s Medical Center, Department of Pathology, Kanagawa, Japan*

**Background/Objectives**: Although hepatoblastoma (HBL) is the most common pediatric liver tumor, genetic heterogeneity that defines clinical variety of HBL is yet to be clarified.

**Design/Methods**: To investigate the genetic and epigenetic diversity of HBL and identify therapeutic targets, we performed targeted capture sequencing (TCS) on 384 cancer‐associated genes, RNA sequencing, DNA methylation array analysis, and SNP array analysis on 42 samples of HBL. Since *NQO1*, a detoxification enzyme critical for protecting cells from oxidative stress and cytotoxicity, was identified as a promising target of high‐risk HBL, we further performed inhibition experiments using *NQO1* siRNA and dicoumarol (an *NQO1* inhibitor) on HBL cell lines HepG2 and HuH‐6. Subsequently, the effects of *NQO1* inhibition on cell proliferation and anti‐cancer drug resistance were assessed.

**Results**: We identified mutations/deletions of *CTNNB1/APC* in all 42 samples in TCS. Consensus clustering of methylation data revealed the presence of three clusters with distinct clinical and biological features. We found the most essential biological difference among these subgroups was differentiation stages, based on differential methylation of the binding sites of HNF4A/CEBPA, master regulators of hepatocyte differentiation. By comparing these subgroups, we identified high expression of *NQO1* with promoter hypomethylation as a key marker in high‐risk groups. In knockdown and inhibition experiments using HepG2 (high *NQO1* expression), both siRNA and dicoumarol induced significant growth inhibition. In addition, they also sensitized the HepG2 cells to anti‐cancer drugs cisplatin and doxorubicin. These effects were not observed in HuH‐6 with low expression of *NQO1*.

**Conclusions**: Comprehensive genetic and epigenetic analyses defined three distinct subgroups of HBL, and we identified *NQO1* as a promising target in high‐risk groups. The results of siRNA knockdown and dicoumarol inhibition suggested the effectiveness of *NQO1* suppression for growth inhibition and chemosensitization in aggressive HBL cells. Thus, *NQO1* can be a therapeutic target in poor prognostic HBL cases with high *NQO1* expression.

### PO-607. Feasibility of Image‐Guided Minimally Invasive Therapies in Pediatric Liver Tumors {#pbc27455-sec-8410}

[R. Shaikh]{.ul} ^1^

*^1^Boston Children\'s Hospital and Dana Farber Cancer Center, Interventional Radiology, Boston, USA*

**Background/Objectives**: To demonstrate the safety and feasibility of image guided interventional radiology therapies in pediatric liver tumors.

**Design/Methods**: We present our initial experience of treating 5 patients with liver tumors in interventional radiology. These were as follows: Transarterial Chemo embolization (TACE) for primary hepatocellular carcinoma (n=1) in a 2 year old patient; Radiofrequency ablation (RFA) for metastatic gastrointestinal liver tumor (n=1) in a 13 year old patient; Transarterial embolization (TAE) for metastatic gastrointestinal liver tumor in a 15 year old patient; Microwave ablation (MW) for metastatic renal cell carcinoma in a 21 year old patient, Yttrium‐90 radio‐embolization for metastatic hepatocellular carcinoma in a 15 year old patient and Transarterial embolization and Cryoablation for Enzinger\'s hemangioma in a 6 year old patient. These patients were discussed at the multidisciplinary tumor conference prior. The techniques and challenges and utility of these modalities in management of pediatric liver tumors will be discussed.

**Results**: Patients underwent successful interventional radiology treatments as palliation or bridge to transplant without any major complications.

**Conclusions**: Minimally invasive interventional radiology therapies are feasible and safe in treatment of pediatric liver tumors and should be considered as adjuvant or in combination with other treatment modalities.

### PO-608. Fluorescent Patterns of Indocyanine Green (ICG) of Hepatoblastoma {#pbc27455-sec-8420}

[T. Shinkai]{.ul} ^1^, K. Mausumoto^1^, T. Aiyoshi^1^, N. Tanaka^1^, A. Kawami^1^, F. Chiba^1^, K. Ono^1^, Y. Urita^1^, H. Takayasu^1^, S. Hosaka^2^, R. Suzuki^2^, T. Fukushima^2^

*^1^Faculty of Medicine‐ University of Tsukuba, Pediatric Surgery, Tsukuba, Japan; ^2^Faculty of Medicine‐ University of Tsukuba, Pediatrics, Tsukuba, Japan*

**Background/Objectives**: Real time fluorescent imaging using indocyanine green (ICG) is applied widely in oncologic surgery in order to detect sentinel lymph node metastasis, surgical margins, and metastatic lesions. Several fluorescent patterns of hepatocellular carcinoma have been reported. We investigated the fluorescent patterns of the primary site and peritoneal metastatic lesions of hepatoblastoma.

**Design/Methods**: Three hepatoblastoma patients were analyzed during the hepatectomy. ICG (0.5mg/kg) was injected intravenously 72 hours before surgery. Detection of ICG was performed using a portable handy camera (pde‐neo^®^, Hamamatsu Photonics, JAPAN) and an endoscopic system (1588 AIM, Stryker).

**Results**: Case 1: a 7‐month‐old girl had a PRETEXT III tumor in S5 with peritoneal dissemination and bilateral lung metastasis. Case 2: a 27‐month‐old boy had a PETEXT I tumor in S2, without distant metastasis. Case 3: a 16‐month‐old boy had a PRETEXT II tumor in S5 without distant metastasis. All of these cases were treated with neoadjuvant chemotherapy before the hepatectomy. In case 1, there was a false negative fluorescence in omental dissemination, and a false positive in the residual resected liver surface. The primary site of the tumor in case 2 showed florescence positive (whole‐type). In case 3, the florescence was positive in the surrounding tissues of the primary site of the tumor (ring‐type).

**Conclusions**: ICG navigation surgery has been reported to be very useful in detecting lung metastasis of hepatoblastoma. In our cases, several florescence patterns of the primary site were seen in hepatoblastoma. Moreover, there are false positives and false negatives were confirmed in the ICG florescent patterns in hepatoblastoma. We need to further investigate the relationship between florescence patterns of hepatoblastoma and tumor biology.

### PO-609. Overcoming Recurrent Hepatoblastoma after Liver Transplantation in Adolescent Generation with the Novel Technology of Fluorescence Imaging System Utilizing Indocyanine Green (ICG) {#pbc27455-sec-8430}

[Y. Yamada]{.ul} ^1^, T. Fujimura^2^, T. Mori^2^, K. Abe^2^, H. Shimada^3^, H. Shima^3^, K. Hoshino^2^, K. Tatsuo^2^

*^1^Keio University School of Medicine‐ National Center for Child Health and Development, Pediatric Surgery, Tokyo, Japan; ^2^Keio University School of Medicine, Pediatric Surgery, Tokyo, Japan; ^3^Keio University School of Medicine, Pediatrics, Tokyo, Japan*

**Background/Objectives**: The curability of heaptoblastoma(HB) largely depends on the achievement of radical surgical resection. The advancement in imaging technology contributes to a precise resection of tumors.

Here, we report three patients aged 15‐19 years old, who underwent liver transplantation(LTx) followed by resections for metastatic HB utilizing Indocyanine green(ICG) navigation technique.

**Design/Methods**: ICG 0.5mg/kg was given intravenously between 24 hours to 72 hours prior to the operations. Fluorescence imaging system (Photodynamic eye, Hamamatsu photonics or Pinpoint system, Novadaq) was utilized to visualize lesions that had taken up ICG.

**Results**: Case 1: 17‐year‐old female, who underwent LTx for unresectable HB following the preoperative chemotherapy of SIOPEL‐4 protocol. Partial lung resections for metastatic HBs were performed with ICG navigation two and three years after the LTx. She has been disease free for 10 months with normal values of AFP. Case 2: 15‐year‐old male, initially presented with ruptured HB at the age of 8, underwent rescue LTx following multiple sessions of chemotherapy when he was 11. Recurrent HBs were observed in the transplanted liver and the peritoneum 4 years after the LTx. Then he underwent the second LTx with ICG navigation, which helped us to clear extrahepatic HBs at the time of the second LTx. He has been recurrence free for 2 years since then. Case 3: 19‐year‐old female underwent rescue LTx along with the SIOPEL‐4 chemotherapy. CT showed recurrent HBs on the chest wall and the diaphragm two years after the LTx. Thoracoscopy loaded with PINPOINT system was utilized to visualize the recurrent tumors. The recurrent tumor, which was well demarcated in the near infrared mode, was resected en‐block. The patient has been tumor free for a year since the metastasectomy.

**Conclusions**: The advancement in ICG imaging technology provides more precise and sensitive resections for metastatic HBs and can lead to the cure even in high‐risk patients.

### PO-610. Analysis of Related Factors of Recurrent Hepatoblastoma in Children {#pbc27455-sec-8440}

[W. Yang]{.ul} ^1^, W. Huanmin^1^

*^1^Beijing Children\'s Hospital, Oncology Surgery, Beijing, China*

**Background/Objectives**: To analyze the factors associated with the recurrence of hepatoblastoma in children. In order to make development of treatment modalities for patients with recurrent hepatoblastoma and to assess prognosis.

**Design/Methods**: A total of 28 patients with recurrent hepatoblastoma were reviewed. Summarize the clinical stage, pathological type, alpha fetoprotein (AFP) levels, the change trend of the tumor volume and AFP level of the patients after received chemotherapy, and the decreased AFP level after surgical resection.

**Results**: In this group, 3 cases of clinical stage I, 6 cases of stage II, 18 cases of stage Ⅲ, 1 case of stage IV. 5 cases were of embryonal pathological type, 1 case of fetal type, 16 cases of mixed type, 2 cases of giant trabecular type and small cell undifferentiated type in 1 case. At onset, serum AFP values ranged from 1080000ng/ml to 1778 ng/ml. After preoperative chemotherapy, the tumor volume decreased by more than 50% in 12 cases, and AFP level dropped to normal range in 1 case. The AFP level of one patient dropped to normal within one month after operation. A random selection of 28 cases of non recurrent hepatoblastoma in the same period was compared with the recurrence group. The results showed that the patients with recurrence in the clinical stage was higher than that in the non recurrence group. In recurrence patients, the proportion of tumor reduction, the extent of AFP decrease and the proportion of AFP dropped to normal range within one month after chemotherapy were significantly lower than those in the patients without recurrence. There was no significant difference between the two groups in other factors.

**Conclusions**: The main factors affecting the recurrence of hepatoblastoma include preoperative staging, tumor volume reduction and AFP level decrease after preoperative chemotherapy, and the rate of AFP level decrease to normal after tumor resection.

### PO-611. Modified Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Extensive Hepatoblastoma: Case Report and Short‐Term Outcome {#pbc27455-sec-8450}

[W. Yao]{.ul} ^1^, K. Dong^1^, K. Li^1^, X. Xiao^1^, S. Zheng^1^

*^1^Children\'s Hospital of Fudan University, Pediatric Surgery, Shanghai, China*

**Background/Objectives**: To investigate the feasibility and safety of modified associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for hepatoblastoma.

**Design/Methods**: A 3‐year‐old boy presented with heterogeneously mass that still involved Couinaud hepatic segments VII, VIII, IVa and small disseminating foci involved in segments II, III was sent to our hospital after 7 cycle chemotherapy. So, the left hemihepatectomy and segments VII/VIII resection need be performed and a large short hepatic vein also need to be retained to drain the venous of the residual liver. As such, a modified ALPPS procedure was performed. The first stage operation was to ligate the left and middle branch of Glission. Irregular in‐situ liver split was performed and a large short hepatic vein was preserved to drain venous of segments V, VI. The second stage operation was performed to remove the left liver, S VII and S VIII 9 days later. After 16 days of operation, laparotomy and hepatic duct jejunum Roux‐Y anastomosis was performed because of obstructive jaundice.

**Results**: The remnant liver volume was 149.6ml before the first step of operation, which was increased by 163.8% to 394.7ml on day 7 after operation. The future liver remnant accounted for 32.2 and 85.2% of liver total volume before the first and second step of operation. The operative time for the first and second step of operation was 300 min and 180 min, respectively. Jaundice was gradually subsided and liver function was normal after operation. 2 weeks after the last operation, the liver function and blood coagulation function of the patients were normal. Currently, the patient had finished 4 cycles of adjuvant chemotherapy and no tumor recurrence was found 1 year after operation.

**Conclusions**: Although ALPPS has some complications, the procedure provides a new treatment option for hepatoblastoma patients with residual liver insufficiency.

### PO-612. Liver Resectional Surgery (LRS) in Children: Who Should Do it, and Where Should it Be Done? {#pbc27455-sec-8460}

[H. Zaidan]{.ul} ^1^, M. Corbally^1^, A. mortell^2^, A. al shaafi^3^, F. breatnach^4^, M. McDermott^5^, A. O\'Meara^6^

*^1^King Hamad University Hospital, Paediatric Surgery, Manama, Bahrain; ^2^Childrens Hospital Crumlin‐ Dublin, Surgery, Dublin, Ireland; ^3^Children\'s Hospital Crumlin, Surgery, dublin, Ireland; ^4^Children\'s Hospital Crumlin, Oncology, dublin, Ireland; ^5^Childrens Hospital Crumlin‐ Dublin, pathology, Dublin, Ireland; ^6^Childrens Hospital Crumlin‐ Dublin, Oncology, Dublin, Ireland*

**Background/Objectives**: To demonstrate the effect of specific training in liver surgery, multi‐disciplinary decisions, neo‐adjuvant therapy, and adjuvant care on outcome.

**Design/Methods**: This study compares the outcomes of LRS in two separate eras, 1964‐1990 (Group 1, G1, n=21, previously published), and 1994‐2011 (Group 2, G2, n=33), all operated liver tumours. Patient files, histology/radiology records (HIPE) and clinical follow up were used for Group 2 patients. Results for age at presentation, diagnosis, type of surgery, morbidity and mortality were analyzed by descriptive statistics and survival by Kaplan Meier and log rank regression (Mantle‐Cox).

**Results**: Malignant disease comprised 20 patients in G1 and 25 patients in G2. All patients in G2 were discussed at an MDT Tumour Board and underwent complete tumour resection with negative margins performed by a trained Paed HB surgeon. All G2 patients received neo‐adjuvant and adjuvant chemotherapy whereas 8 G1 patients received neo‐adjuvant and 5 adjuvant therapy. Six G1 patients had incomplete resection or biopsy and 13 underwent attempted complete resection. Overall survival was 15% in G1 and 88 %in G2. Serious morbidity was noted in 65% (n=13) of patients in G1 but only 3.6% (2) in G2.

**Conclusions**: This study confirms the essential benefits of specific HB training, MDT and neo‐adjuvant/adjuvant chemotherapy in paediatric patients with malignant liver disease. Improved outcomes with minimal morbidity and long term survival were seen in Group 2 patients as compared with Group 1. This has potential impact on delivery of care in other jurisdictions (as in the ROI) and also on the delivery of training in Paediatric Surgery.

### PO-613. Oxaliplatin/Vincristine/Topotecan Combined with Radiofrequency Ablation in Treatment of Refractory/Recurrent Pulmonary Hepatoblastoma {#pbc27455-sec-8470}

[Y. Zhang]{.ul} ^1^, J. Chang^1^

*^1^The first hospital of Jilin university, pediatric oncology, Changchun, China*

**Background/Objectives**: Among our institution, we hypothesized a treatment with a combination of Oxaliplatin/Vincristine/Topotecan(OVT) paired with radiofrequency ablation (RFA) of twelve patients with multiple refractory/recurrent pulmonary hepatoblastoma(HB). Due to lack of standard treatment, combination was used as compassionate treatment.

**Design/Methods**: Oxaliplatin (130mg/m^2^/day, 3.47 mg/kg in patients 12 months of age or younger) was administrated over 2‐hours infusion on day 1. Vincristine (1.5mg/m^2^/day ×1 day) was administered over 15 minutes intravenously on D1. Topotecan (0.7mg/m^2^/day) was administrated as 1‐hour infusion on day 1‐5. Treatment cycles were repeated every 3 weeks up to a maximum of six cycles. RFA was performed seven to fourteen days after the last cycle of chemotherapy, A 15‐gauge multitined expandable radiofrequency (RF) needle electrodes was used in all patients. The goal of each RFA session attempted to treat all metastases located in one lung during a single session. While impossible, a second session targeting the same lung was re‐scheduled 4 weeks later.

**Results**: A total of 14 patients were included into this study: five patients achieved CR, two patients had PR, two patients had PD, three patients had SD. The 2‐year EFS was 33% (95%CI, 20.5% to 64.6%), and 2‐year OS for the study group was 41.7% (95%CI, 8.9% to 74.4%). All toxicity events were handled satisfactorily and no toxic related death were observed.

**Conclusions**: Our report shows that OVT combined with RFA can be a successful treatment modality for previously heavily treated refractory/recurrent pulmonary metastatic lesions from hepatoblastoma.

### PO-614. microRNA‐26A‐5P Functions as a New Inhibitor of Hepatoblastoma by Repressing LIN28B and AURKA Expression {#pbc27455-sec-8480}

[Y. Zhang]{.ul} ^1^, L. Wang^2^, Y. Zhao^2^

*^1^The first hospital of Jilin university, pediatric oncology, Changchun, China; ^2^The Institute for Systems Genomics‐ University of Connecticut, Department of Physiology and Neurobiology, Storrs, USA*

**Background/Objectives**: Hepatoblastoma (HB) is the most common liver tumor in children. Somatic mutations in genes encoding components of the Wnt/β‐catenin are prevalent in sporadic HB cases. The interplay of Wnt/β‐catenin and Myc signaling has been shown to play a critical role in poorly differentiated aggressive HB. However, MYC does not harbor any cavities into which small molecules can easily bind.

**Design/Methods**: Our work was motivated by report that LIN28B and AURKA expression was upregulated in a transcriptomic and genomic analysis of human HB. In addition, neuroblastoma tumorigenesis can be promoted by the LIN28B‐RAN‐AURKA signaling network. We propose a central regulatory role for LIN28B in HB by its effect on RAN and AURKA.

**Results**: Our results show that malignant tissues have higher LIN28B, RNA and AURKA expression than normal liver samples. LIN28B, RNA and AURKA are also upregulated in a panel of malignant HB cells. We demonstrate RAN to be a key downstream component of LIN28B signaling, AURKA is a key downstream component of RAN signaling. We further show that inhibiting LIN28B by siRNAs significantly decreases HB cell proliferation and colony formation, suggesting that the LIN28B‐RAN‐AURKA pathway may play a critical role in HB development. We also elucidated miR‐26a‐5p‐mediated translational inhibition of LIN28B and AURKA in HB. Overexpression of miR‐26a‐5p markedly decreased LIN28B and AURKA 3'UTR activities and protein expression, and repressed HB cell proliferation and colony formation. In contrast, re‐expression of LIN28B and AURKA rescued miR‐26a‐5p‐mediated suppression of HB cell growth and clonality. Importantly, a decreased miR‐26a‐5p expression correlated with the poor outcome of HB patients.

**Conclusions**: Our results revealed miR‐26a‐5p as a new repressor of HB growth via its inhibition of the oncogenic LIN28B‐RAN‐AURKA pathway.

### PO-615. Targeting RRM2 in 3D Tumor Organoid Models of High Risk Hepatoblastoma {#pbc27455-sec-8490}

[L. Zhu]{.ul} ^1^, L. Li^1^, M. Qian^1^, L. Hamel^1^, D. Lopez‐Terrada^2^

*^1^St. Jude Children\'s Research Hospital, Pharmaceutical Sciences, Memphis, USA; ^2^Texas Children\'s Hospital, Pathology, Houston, USA*

**Background/Objectives**: Hepatoblastoma (HB) is the most common liver cancer and the fastest‐growing cancer in children. Prognosis for children with metastatic and recurrent HB remains dismal over the past few decades. Previous studies have demonstrated that metastasis‐ or relapse‐initiating cells often hijack normal stem cell pathways to gain survival and growth advantages. Recent advances in 3D stem cell culture provide a means to rapidly select and propagate cancer cells with strong stemness properties for in‐depth biological analysis and therapeutic testing.

**Design/Methods**: HB organoid models were established from mouse and human tumors via 3D stem cell culture and their in vivo tumorigenicity was determined via liver orthotopic transplantation in mice. We then conduced a large comparative RNA‐seq profiling to identify genes commonly dysregulated in metastatic HB tumors and organoids compared to their non‐aggressive counterparts. The biological functions and therapeutic values of the top candidate genes are being determined via the impact of their molecular manipulation on HB cell growth, invasion, metastasis and drug response in vitro and in vivo.

**Results**: Multiple HB organoid models displayed potent in vivo tumorigenicity, driving rapid invasion and multi‐organ metastasis upon orthotopic transplantation. RNA‐seq profiling identified a small number of genes significantly upregulated in aggressive HB tumors and organoids. Among them is RRM2, an enzyme catalyzing the formation of deoxyribonucleotides from ribonucleotides that is essential to DNA replication and repair. Further analysis revealed a significant association between *RRM2* expression and the prognosis of HB patients, making it a promising therapeutic target for high risk HB. Studies are currently ongoing to reveal the effects of biological and pharmacological inhibition of RRM2 on HB growth and metastasis both in vitro and in vivo.

**Conclusions**: 3D organoid‐based approach represents a unique strategy to model high risk HB and a powerful research platform for the identification of novel disease mechanisms and drug targets.

Solid Non Brain Tumours ‐ Germ Cell Tumours {#pbc27455-sec-8500}
-------------------------------------------

### PO-616. Clinical and Histological Analysis of Children and Adolescents with Ovarian Germ Cell Tumours in Poland {#pbc27455-sec-8510}

[E. Adamkiewicz‐Drozynska]{.ul} ^1^, K. Polczynska^2^, J. Stefanowicz^2^, M. Jezierska^1^, E. Izycka‐Swieszewska^1^, M. Rapała^3^, K. Bilska^4^, L. Chelmecka‐Hanusiewicz^5^, R. Debski^6^, G. Karolczyk^7^, E. Leszczynska^8^, A. Mizia‐Malarz^9^, J. Nurzynska‐Flak^10^, B. Rosinska^11^, K. Wachowiak‐Szajdak^12^, I. Malinowska^13^, J. Trelinska^14^, P. Wawrykow^15^, M. Woszczyk^16^, A. Pobudejska^17^, J. Wieckowska^18^, W. Balwierz^5^, B. Dembowska‐Baginska^18^, J. Kowalczyk^10^, M. Krawczuk‐Rybak^8^, M. Matysiak^19^, W. Mlynarski^20^, G. Sobol‐Milejska^21^, T. Szczepanski^22^, J. Peregud‐Pogorzelski^23^, T. Urasinski^24^, J. Wachowiak^12^, M. Wysocki^25^, A. Chybicka^26^, E. Bien^1^

*^1^Medical University of Gdansk, Dep Paediatrics‐Hematology and Oncology, Gdansk, Poland; ^2^Medical University of Gdansk, Dep Paediatrics‐ Hematology and Oncology, Gdansk, Poland; ^3^Regional Specialistic Hospital in Wroclaw, Dep Paediatric Surgery, Wroclaw, Poland; ^4^Mother and Child Institute in Warsaw, Dep Oncological Surgery for Children and Adolescents, Warsaw, Poland; ^5^Jagiellonian Collegium Medicum in Cracow, Dep Paediatric Oncology and Hematology, Cracow, Poland; ^6^Collegium Medicum in Bydgoszcz, Dep. Pediatrics‐ Hematology and Oncology, Bydgoszcz, Poland; ^7^Regional Specialistic Hospital in Kielce, Dep. Paediatric Oncology and Hematology, Kielce, Poland; ^8^Medical Uniwersity of Bialystok, DepPaediatric Oncology and Hematology, Bialystok, Poland; ^9^Silesian Medical University, Dep. Paediatrics, Katowice, Poland; ^10^University Children Hospital in Lublin, Dep.Hematology‐ Oncology and Children Transplantology, Lublin, Poland; ^11^Medical University in Wroclaw, Dep Children Bone Marrow Transplantation‐ Oncology and Hematology, Wroclaw, Poland; ^12^Medical University in Poznan, Dep. Oncology‐ Hematology and Paediatric Transplantology, Poznan, Poland; ^13^Medical University of Warsaw, Dep. Paediatrics‐ Hematology and Oncology, Warsaw, Poland; ^14^Medical University of Lodz, Dep. Paediatrics‐ Oncology‐ Hematology and Diabetology, Lodz, Poland; ^15^pomeranian Medical University, Dep Paediatrics and Children Oncology, Szczecin, Poland; ^16^Specialistic Hospital in Chorzow, Dep. Children Hematology and Oncology, Chorzow, Poland; ^17^Public Clinical Hospital No 1 in Katowice, Dep. Paediatrics‐ Hematology and Oncology, Katowice, Poland; ^18^Hospital Children\'s Memorial Health in Warsaw, Dep. Oncology, Warsaw, Poland; ^19^Medical University of Warsaw, Dep Paediatrics‐ Hematology and Oncology, Warsaw, Poland; ^20^Medical University of Lodz, Dep Paediatrics‐ Oncology‐ Hematology and Diabetology, Lodz, Poland; ^21^Silesian Medical University, Dep Paediatrics, Katowice, Poland; ^22^Silesian Medical University, Dep Paediatrics‐ Hematology and Children Oncology, Zabrze, Poland; ^23^Medical University in Szczecin, Dep. Paediatrics and Children Oncology, Szczecin, Poland; ^24^Medical University in Szczecin, Dep Paediatrics‐ Hematooncology and Gastroenterology, Szczecin, Poland; ^25^CollegiumMedicum in Bydgoszcz, Dep.Paediatrics‐ Hematology and Oncology, Bydgoszcz, Poland; ^26^Medical University in Wroclaw, Dep. Bone Marrow Transplantation‐ Children Oncology and Hematology, Wroclaw, Poland*

**Background/Objectives**: To analyse the clinical and histological features of ovarian germ cell tumours (GCT) in children and adolescents treated in Polish oncological centres according to TGM‐95 protocol.

**Design/Methods**: Analysis of the girls 0‐18 years of age with ovarian GCT was performed. Clinical and histological data from multicentre Polish database from 2008‐2017 were evaluated.

**Results**: Fifty nine from 310 patients with GCT presented ovarian location of primary tumour. Median age at diagnosis was 14. Seven girls was under 10 years old. In 30 patients the tumour developed in the right ovary, in 18 in the left one and in 11 the tumours were revealed bilaterally. Lower clinical stages were found in 29 girls, more advanced stages in 30. Metastases appeared mainly in retroperitoneal and mediastinal lymph nodes, peritoneum and liver. GCT markers were assessed at diagnosis in 43 patients. Alfafetoprotein (AFP) was increased in 34, βchoriogonadotropin (βHCG) in 19. AFP \>10000ng/ml appeared in 11, βHCG \>50000mIU/l in 19 patients. Histological examination of tumours was performed in 49 cases: 29 were monomorphic ‐ mostly yolk sac tumours, dysgerminomas and teratomas, 20 tumours were mixed. Nonmutilating surgical procedures at the start of treatment were performed in 47 patients. In 9 the tumour was radically resected without chemotherapy used. Chemotherapy was performed in 49. Second surgery to remove the rests was needed in 16 girls. Recurrence was observed in 4 patients, all of them achieved the second complete remission. Poor outcome was seen in one girl at diagnosis, before starting chemotherapy. Fifty eight survivors are now in complete remission. Long term side effects as hearing disturbances and nephrotoxicity were noted in 5 patients.

**Conclusions**: Ovarian GCT are recognised mostly over 10 years of age. Most tumours are diagnosed in advanced stages. The prognosis is excellent. The girls with stage I, treated only by surgery can survive.

### PO-617. Expression Analysis of SHH Signaling Pathway Genes in Paediatric Germ Cell Tumours {#pbc27455-sec-8520}

E. Izycka‐Swieszewska^1^, D. Kuleszo^2^, B. Lipska‐Zietkiewicz^2^, K. Czarnota^3^, W. Grajkowska^4^, B. Dembowska‐Baginska^5^, R. Cosanrovici^6^, J. Stefanowicz^7^, [E. Adamkiewicz‐Drozynska]{.ul} ^7^

*^1^Medical University of Gdansk, Dep Pathology and Neuropathology, Gdansk, Poland; ^2^Medical University of Gdansk, Dep Biology and Genetics, Gdansk, Poland; ^3^Copernicus hospital in Gdansk, Dep. Pathomorphology, Gdansk, Poland; ^4^Children\'s Health Memorial Institute in Warsaw, Dep Pathology, Warsaw, Poland; ^5^Children\'s Health Memorial Institute in Warsaw, Dep Ocology, Warsaw, Poland; ^6^Medical University of Cluj, Dep Children Oncology, Cluj, Romania; ^7^Medical University of Gdansk, Dep Paediatrics‐ Hematology and Oncology, Gdansk, Poland*

**Background/Objectives**: Germ cell tumors (GCTs) are a group of neoplasms with different levels and directions of differentiation. They can be gonadal or extragonadal localized on the embryonal cells migration ways. Several signaling pathways participate in migration and specification of cell lines in embryogenesis, such as WNT‐beta catenin, TGFB and Sonic Hedgehog (SHH) pathway. The role of SHH signaling in GCTs has not been analyzed in details. The abnormal activation of this signaling is observed in many type of cancer‐ gastric, lung, breast, pancreatic, prostate, also in gliomas and medulloblastoma. The main elements of this pathway are encoded by: *SHH, PTCH1, SMO, SUFU, GLI1, GLI2, GLI*3, but SHH signaling interacts also with many other systems.

**Design/Methods**: Analysis of expression of SHH pathway related genes in pediatric GCTs was performed on 30 cases of tumors of different histological categories (*mature teratoma, immature teratoma, mixed GCT, yolk sac tumor, dysgerminoma/seminoma, embryonal carcinoma)* and control tissues. Paraffin‐embedded tissue sections underwent DNA and RNA isolation. Expression analysis was performed with 3 repeats qPCR in each case with Quiagen kits (Hedgehog Signaling Pathway RT^2^ Profiler PCR Array) including 84 genes engaged in SHH signal transduction. The next step was analysis with dedicated software Geneglobe (Quiagen).

**Results**: The results were available for 24 tumors. The significant differences in expression between control and tumor samples were observed concerning some key genes: *SMO, GLI1, HHIP, GLI3*. In addition*PTCHD1, ERBB4, FGFR3, WNT3, FGF9*, *ZIC1, ZIC2, LRP2*, and*WIF1* were overexpressed in different tumors. Some significant differences in expression between various GCTs histological categories were also found.

**Conclusions**: The results show that some SHH pathway‐ related proteins are involved in GCTs biology in context of level and direction of differentiation.

Work financed by Polish National Science Centre grant 2014/15/B/NZ4/04855 (head: E. Iżycka‐Swieszewska).

### PO-618. Outcome of Prepubertal Gonadal Tumors in Resource Limited Settings {#pbc27455-sec-8530}

[A. Ahmad]{.ul} ^1^, M. Saleem^2^

*^1^The Children\'Hospital&the Institute of Child Health Lahore, Paediatric Haematology/Oncology, Lahore, Pakistan; ^2^The Children\'s Hospital & the Institute of Child Health Lahore Pakistan, Paediatric Surgery, Lahore, Pakistan*

**Background/Objectives**: The Children\'s Hospital Lahore is a 1050 bedded tertiary hospital with 60 bedded paediatric Oncology Unit providing free cancer treatments to over 1000 new cases each year referred from all over Punjab and across border. The objective of this to present the clinical and histological features of prepubertal testicular and ovarian tumors, 5‐year experience of a single institution with resource limited settings was reviewed

**Design/Methods**: A total of 90 prepubertal children who were treated for gonadal tumors at the Children\'s Hospital Lahore Pakistan from January 2013 to December 2017 were retrospectively reviewed. Histopathological findings, risk stratification, clinical stage, and outcomes were analyzed. They were treated using UKCCSG protocol of JEB Chemotherapy.

**Results**: Among 90 primary ovarian and testicular tumors, 65% cases were females and 68% were less than 5 years of age. 78% had tumor size more than 5 CM. 62% were high risk. The histopathology revealed 53% yolk sac tumor,8% mixed malignant GCT, 13% Dysgerminoma,8% Teratomas, 6% JGCTO, 3% Sertoli and Leydig cell Tumors and rest unspecified. 14% had stage II, 41% stage III and 45% stage IV. Surgery in the form of orchidectomies and Oosalpingectomies were done in 83 % cases. MDT was utilized in 73% cases. 74% have completed Rx and are well, 8% abandoned Rx, 15% expired mainly due to infections, progression of disease and advanced stage with delayed onset of Rx. Febrile Neutropenia was most common event during RX (31%), obstructive uropathy(10%) and recurrence of tumor after surgery as not referred for chemotherapy timely (9%). Only 7 % tumors were benign.

**Conclusions**: Most of the prepubertal gonadal tumors were malignant, and the most common histologic sub‐type was Yolk Sac Tumor followed by dysgerminoma. High mortality and abandonment can be reduced by timely diagnosis and effective multidisciplinary team management to achieve the excellent cure rates as obtained in developed countries.

### PO-619. A Case of Yolk Sac Tumor in a Patient with Turner Syndrome Without Y Chromosomal Material {#pbc27455-sec-8540}

[H.W. Chueh]{.ul} ^1^, S.Y. Lee^2^, J.Y. Han^1^

*^1^Dong‐A University College of Medicine, Department of Laboratory medicine, Busan, Republic of Korea; ^2^Dong‐A University College of Medicine, Department of Pediatrics, Busan, Republic of Korea*

**Background/Objectives**: Gonadoblastoma and malignant transformations have well‐known to occur frequently in females with Turner syndrome (TS) and Y chromosomal material. These gonadoblastoma usually occur in bilaterally, mostly in patients of late adolescent or early 20s. However, gonadoblastoma or germ cell‐origin tumors with malignant transformation in patients with Turner Syndrome without any Y material have been reported rarely.

**Design/Methods**: Here, we report 15‐months‐old girl diagnosed as yolk sac tumor with Turner syndrome without T chromosomal material.

**Results**: Case: 15‐months‐old girl came to pediatric department for the evaluation of the mass in sacral area. She had received resection surgery in same area when she was 1month‐old, and the biopsy was revealed as benign teratoma of sacrum. Ultrasonography and serum AFP level were checked every 3 month, regularly after the surgery. Studies on visit showed rising of serum AFP upto 19,792.02 ng/mL, with newly found mass lesion size of 6X 4.4 X 4.5 cm in sacral area. Resection was done, and the biopsy result revealed as yolk sac tumor. Metastatic work up showed no evidence of mestastasis. Sacral tumor was big and attached firmly to the sacral area, bladder, and rectum, she suffered from neurogenic bladder and incontinence after the surgery. Karyotyping result was reported after the surgery, which showed that she had abnormal female chromosome (46,X,der(X)del(Xp?)del(Xq?)\[19\]/45,X\[11\]) with negative DUZ1‐B and SRY genes. She received 6 cycles of chemotherapy, and the treatment was over. She is currently well and without signs of relapse, and receiving rehabilitation therapy of bladder training and hearing.

**Conclusions**: Gonadoblastoma or germ‐cell origin malignancy can be occur in Turner Syndrome without Y chromosomal material. We need to evaluate to find out whether this germ cell tumor occured in the same process of gonadoblastoma, or just occured incidentally.

### PO-620. Salvage Treatment for Children with Relapsed/Resistant Germ Cell Tumors: The Italian Association of Pediatric Hematology and Oncology Experience {#pbc27455-sec-8550}

[M.D. De Pasquale]{.ul} ^1^, P. D\'Angelo^2^, A. Crocoli^3^, R. Boldrini^4^, M. Conte^5^, G. Bisogno^6^, F. Spreafico^7^, A. Inserra^3^, D. Biasoni^8^, P. Dall\'Igna^9^, F. Siracusa^10^, F. Locatelli^1^, M. Terenziani^7^

*^1^Bambino Gesù Children Hospital IRCCS, Oncohematology, Rome, Italy; ^2^A.R.N.A.S. Civico Di Cristina e Benfratelli‐ Palermo‐ Italy, Pediatric Hematology/Oncology Unit, Palermo, Italy; ^3^Bambino Gesù Children Hospital IRCCS, Surgery, Rome, Italy; ^4^Bambino Gesù Children Hospital IRCCS, Pathology, Rome, Italy; ^5^IRCCS Istituto G. Gaslini, Oncology, Genova, Italy; ^6^University of Padua, Pediatric Oncology‐ Women\'s and Children\'s Health Department, Padova, Italy; ^7^Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pediatrics, Milano, Italy; ^8^Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Surget, Milano, Italy; ^9^University of Padua, Pediatric Surgery ‐ Women\'s and Children\'s Health Department, Padova, Italy; ^10^University of Palermo, Pediatric Surgery, Palermo, Italy*

**Background/Objectives**: Due to the rarity of the disease and the high cure rate of newly diagnosed patients, there are limited data on salvage treatment in children with relapsed/resistant germ cell tumors (GCTs).

**Design/Methods**: Prospectively collected data regarding patients enrolled in the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) TCGM 2004 protocol for treatment of GCTs were analyzed. Patients with relapsed/progressing malignant GCT after first‐line, platinum‐based chemotherapy were included.

**Results**: Twenty‐one patients (6 males, 15 females; median age 131 months, range 20‐332) were included in the study; primary tumor site was extragonadic (14 patients), ovary (3 patients) and testis (4 patients). At diagnosis, 11 patients presented with metastatic disease, while 10 patients had localized disease. All patients had non seminomatous GCTs. Twelve patients relapsed, while 9 had progressive/resistant disease. All patients received second‐line chemotherapy (SLCT) based on the combination of carboplatin, etoposide and ifosfamide; in 6 patients, surgery on residual disease after SLCT was also performed. Subsequently, 16 patients underwent high dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue. One patient is lost at follow up in complete remission (CR) after HDCT. At a median time of 77 months from relapse (range 18‐161), 14 patients are alive (2, in CR after SLCT, did not receive HDCT), while 6 patients died due to disease progression (three did not receive HDCT for progressive disease after SLCT). The 18‐month overall survival and event‐free survival are 65% and 60%, respectively. There were no treatment--related deaths.

**Conclusions**: SLCT followed or not by HDCT is an effective salvage treatment for children with relapsed/resistant GCTs. However, the role of HDCT following second‐line treatment needs to be further investigated, especially regarding the identification of specific patient subgroups which can beneficiate of this more intensive treatment.

### PO-621. Outcomes of Child Ovarian Germ‐Cell Tumors Treated Over Seven‐Year Period: Experience from 106 Cases in a Single Institution {#pbc27455-sec-8560}

[L. Fan]{.ul} ^1^

*^1^Shanghai Xinhua Hospital affiliated to Shanghai Jiaotong University School Of Medicine, Department of Pediatric Surgery, Shanghai, China*

**Background/Objectives**: This study aimed to review the clinical characteristics and the treatment outcomes of children with ovarian germ cell tumors (OGCT).

**Design/Methods**: The clinical data of 106 cases of histologically proven ovarian germ cell tumors treated at our department between June 2010 and June 2017 were retrospectively analyzed.

**Results**: One hundred and six patients were recruited from this period with the mean age of 6.5 years, and 97 of them were before menstruation. There were 65 cases of right side and 41 cases of left side ovarian tumor in this group. The most common symptoms were pelvic mass and acute abdominal pain (29 cases had ovarian torsion). Sixty‐three patients underwent an emergency exploratory surgery and forty‐three patients underwent elective exploratory surgery. Sixty‐seven patients underwent unilateral salpingo‐oophorectomy, thirty‐nine received tumor dissection. The histologic subtypes included 82 mature teratoma, 9 immature teratoma, 5 dysgerminomas, 5 yolk sac tumors, 2 embryonal carcinomas, and 3 cases of young granular cell tumor. Postoperatively, 18 patients received chemotherapy according to the pathological findings. Follow‐up time was 8 months to 59 months. One patients had recurrent disease, and underwent secondary surgery. During the follow‐up period, 32 girls were admitted to puberty with normal menstruation and normal FSH/LH level.

**Conclusions**: Ovarian germ cell tumors are rare in childhood, but girls with abdominal pain, abdominal mass should be highly vigilant. Treatment with fertility sparing operations showed a good outcome. Dissection of unilateral ovaries and attachments does not affect adolescent menstruation and FSH/LH levels to our data.

### PO-622. Laparoscopy‐Assisted Abdomino‐Posterior Approach for En Bloc Resection of Sacrococcygeal Germ Cell Tumors in Children {#pbc27455-sec-8570}

[S. Fumino]{.ul} ^1^, K. Sakai^1^, M. Higashi^1^, S. Aoi^1^, T. Furukawa^1^, H. Tonomura^2^, T. Shirai^2^, T. Iehara^3^, H. Hajime^3^, T. Tajiri^1^

*^1^Kyoto Prefectural University of Medicine, Department of Pediatric Surgery, Kyoto, Japan; ^2^Kyoto Prefectural University of Medicine, Department of Orthopedics, Kyoto, Japan; ^3^Kyoto Prefectural University of Medicine, Department of Pediatrics, Kyoto, Japan*

**Background/Objectives**: Sacrococcygeal germ cell tumors (SC‐MGCTs) in children are consisted of teratoma and malignancy. The standard surgical goal for SC‐MGCTs with intrapelvic lesion is en bloc resection of the tumor with coccygectomy via abdomino‐posterior approach. Since 2017, we have introduced laparoscopy to abdominal approach, and we reported our experience of using laparoscopy‐assisted abdomino‐posterior approach for en bloc resection of SC‐MGCTs in this paper.

**Design/Methods**: From April 2017 to March 2018, three children with SC‐MGCTs (cystic teratoma; n=2, yolk sac tumor; n=1) underwent laparoscopic approach. Laparoscopic procedure was through 4 ports using coagulating shears.

**Results**: Regarding teratoma, two infants with Altman II ‐ III underwent surgical treatment. The indication of laparoscopy was; 1) tumor consisted mainly of multilocular cyst; 2) the patient\'s cardiac function was tolerable to pneumoperitoneum. The surgical strategy for teratoma was as follows; 1) laparoscopic mobilization of the pelvic part of the tumor, 2) preservation of the intrapelvic structure (hypogastric nerve and so on), 3) constant observation of intraabdomen during posterior approach. For this purpose, manipulation of the posterior sacral part was performed with lower limbs retracted upward with keeping supine position. The postoperative course of both patients was satisfactory with good cosmetics.

Regarding malignancy, a 1.5‐year‐old girl with yolk sac tumor had large intrapelvic mass with intraspiral extension (below S3). After 6 cycle of neoadjuvant chemotherapy, laparoscopic combined approach with sacrectomy was performed. This time, laparoscopic maneuver was performed in order to only tumor margin marking with metal clip for en bloc sacretomy with prone position, because of small tumor size and severe adhesion with surrounding organs. The postoperative course was satisfactory and no other neurological deficit developed.

**Conclusions**: Use of laparoscopy provides good surgical view in the pelvis and allow minimal manipulation for the intrapelvic tumor. This abdominal approach for SC‐GCTs is feasible and safty procedure.

### PO-623. Molecular Profiling in Sacrococcygeal Teratomas {#pbc27455-sec-8580}

[M. Hambraeus]{.ul} ^1^, J. Karlsson^2^, I. Kasselaki^3^, L. Hagander^1^, D. Gisselsson^3^

*^1^Skåne University Hospital, Pediatric Surgery, Lund, Sweden; ^2^Lund University, Laboratory Medicine, Lund, Sweden; ^3^Lund University, Clinical Sciences, Lund, Sweden*

**Background/Objectives**: Sacrococcygeal teratomas (SCT) are rare congenital tumors with a birth prevalence of 1:10.000‐1:40.000. Their pathogenetic background remains unclear. This study aimed to evaluate the presence of genomic alterations and gene expression signatures in SCTs.

**Design/Methods**: To screen for allelic imbalances, SNP‐array analysis was performed on 12 samples from 3 sacrococcygeal teratomas. Gene expression was analyzed by RNA sequencing in 4 cases of mature SCTs and 6 cases of immature SCTs. RNA was extracted from 1‐4 samples of representative mature, immature and neuronal areas from each teratoma, generating 31 samples. The global gene expression pattern was compared to a reference group consisting of malignant pediatric tumors, and between morphologically different areas within each SCT.

**Results**: SNP‐array analysis did not detect any allelic imbalances in any of the analyzed SCT samples. Compared to the reference group, SCT had a unique transcriptional profile. A diverse set of genes were highly expressed in SCT, including signaling pathways of neuronal synapses, neurotransmitters, EGF and DNA‐binding molecules. Pathways of early germ cells and states of pluripotency were also highly expressed in SCT. When comparing the morphologically different areas within SCTs, immature regions showed a high expression of histone genes compared to neuronal areas. In addition, genes of the two transcription factors *NEUROG2* and *NHLH1* showed high expression in immature areas. We currently evaluate the corresponding proteins as markers for immature SCT components.

**Conclusions**: Non‐malignant sacrococcygeal teratomas are genetically stable tumors, but are highly diverse with respect to gene expression. SCTs share a common activation of pathways involved in neuronal development, DNA‐binding and endodermal growth, as well as pathways of early germ cells and pluripotency.

### PO-624. BEP Chemotherapy with or Without Surgery are Both Effective in Treatment of Endodermal Sinus Tumor (EST) of Vagina {#pbc27455-sec-8590}

[J.Y. Han]{.ul} ^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University., Surgical Oncology, Beijing, China*

**Background/Objectives**: To analyze the treatment and outcomes of endodermal sinus tumor (EST) of Vagina in children.

**Design/Methods**: A retrospective review was conducted of medical records and pathologic materials of patients with EST of the vagina treated in Beijing Children\'s Hospital between 2008 and 2018. Ultrasonography, CT scan, detection of serum AFP level and biopsy were performed before and after treatment to evaluate the tumor status. The diagnoses were confirmed by pathological and imaging findings. All patients were treated with bleomycin, etoposide and cisplatin (BEP) combination chemotherapy with or without surgery.

**Results**: 12 patients (median age 14.5 months, range 9--21) were identified. The average tumor size was 4.1 cm. One patient has iliac fossa lymph node metastasis. Serum AFP level was markedly elevated before treatment and decreased dramatically after chemotherapy and drop to the normal level after two to three cycles of chemotherapy (average 2.7 cycles). Seven patients (58.3%) obtained complete remission(CR) with averagely four cycles of chemotherapy. Five patients (41.7%) obtained partial remission(PR) whose serum AFP turned to normal levels but residual tumor nodule remained. Three of them received surgery with postoperative pathology confirmed necrotic tumor cells, while two patients refused surgery received more cycles of BEP chemotherapy without serum AFP increased in the long‐term follow‐up. The mean follow‐up time of 12 patients is 77 months and no one has recurrence.

**Conclusions**: BEP chemotherapy as the first‐line treatment for EST of the vagina can achieve excellent results. Children with lymph node metastasis may require more chemotherapy than non‐metastatic children. For patients with residual tumor nodule after repeated chemotherapy, there is no recurrence of subsequent surgery or chemotherapy. Our findings confirm the good prognosis of vaginal EST.

### PO-625. Treatment Results of Childhood Extracranial Malignant Germ Cell Tumors and Salvage Approach for Recurrent and Refractory Cases: A Single Center Report {#pbc27455-sec-8600}

[K. He]{.ul} ^1^, X. Yuan^1^, Z. Tan^1^

*^1^Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Pediatric Hematology/Oncology, Shanghai, China*

**Background/Objectives**: Pediatric germ cell tumors have good outcomes with multimodality treatment including surgery and platinum based chemotherapy. More than 10% of the pediatric malignant germ‐cell tumors are refractory or recurrent cases that need for salvage therapy. This report has two aims: (1) To study the result of current treatment with surgery and JEB regimen chemotherapy for extracranial MGCTs in Chinese children; (2) To investigate the safety and efficacy of multimodality salvage approach for recurrent and refractory MGCT cases in our center.

**Design/Methods**: 58 patients diagnosed with extracranial malignant germ cell tumor from 2007 to 2015 were enrolled. During this period, another 14 recurrent and refractory cases referred were added to the study for salvage approach. Treatment included surgery and JEB (carboplatin, etoposide, and bleomycin) regimen chemotherapy for most cases. Salvage approach, including multi‐drug second‐line chemotherapy, radiotherapy and second‐look surgery was tried for recurrent and refractory cases.

**Results**: We evaluated the treatment results with a median follow‐up of 47.5 months. The 5‐year event‐free survival and overall survival for primary cases was 74.1±5.7% and 86.2±4.5%, respectively. 25 recurrent or refractory cases entered the salvage approach study. Seventeen patients were alive till the end of follow‐up, and 5‐year event‐free survival, overall survival for cases in this series was 48.0±10.0%, 67.8±9.4%, respectively. In the univariate analyses of prognostic factors, we found significant difference in OS between patients treated with or without local irradiation (77.4±10.0% versus 42.9±18.7%, P=0.045) and treated with or without second surgery (80.8±10.0% versus 44.4±16.6%, P=0.025). Cox regression model revealed that no second‐look surgery could be considered as individual factor contributing to shorter survival.

**Conclusions**: With the combination of surgical resection and JEB chemotherapy, GCTs in children have good outcome. We demonstrated superior survival outcome for recurrent and refractory cases with successful local control through pre‐operative and post‐operative radiotherapy, second‐look surgery and multi‐drug second‐line chemotherapies.

### PO-626. Long Term Oncological Outcome of Testicular Tumours in Prepubertal Children and Adolescents {#pbc27455-sec-8610}

[L. Leung]{.ul} ^1^, I.H.Y. Chan^1^, P.H.Y. Chung^1^, K.K.Y. Wong^1^, P.K.H. Tam^1^

*^1^Division of Paediatric Surgery‐ The University of Hong Kong, Department of Surgery‐ Queen Mary Hospital, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: We aim to study the disease spectrum and long term survival of paediatric testicular tumours.

**Design/Methods**: We retrospectively reviewed the records of patients with testicular tumours from 1992 and 2018. Patient demographics, histological characteristics, surgical approach, treatment modalities, event‐free survival (EFS), time‐to‐relapse, 5‐year and 10‐year survivals were analyzed. Variables evaluated for correlation with survival included staging, age at operation, tumour size, tumour markers level, resection margins and adjuvant therapies.

**Results**: We identified 13 patients (12 prepubertal, 1 adolescent) with a median age of 23 months (range 7 to 192 months) at diagnosis. Eighty‐five percent were non seminomatous germ cell tumours (6 yolk sac tumours, 1 embryonal carcinoma, 1 mixed embryonal carcinoma and yolk sac tumour, 3 mature teratomas). The remaining two were large cell calcifying Sertoli cell tumor and testicular angiomyxoma respectively. Ten (77%) patients were diagnosed at stage I, one stage III (8%) three and two stage IV (23%). Twelve (92%) patients underwent radical inguinal orchidectomy, one underwent scrotal orchidectomy prior to referral to our center. Resection margins were clear in 10 (77%) patients. Four (31%) received adjuvant chemotherapy and none had radiotherapy. The median follow up duration was 120 months (range 20 -- 240 months). The 5‐year overall survival was 90% and the 5‐year EFS was 70%. The 10‐year overall survival was 89%. Relapse occurred in 3 (23%) patients, median time‐to‐relapse was 5 months (range 3 -- 12 months). Univariate and multivariate analysis did not identify any positive predictive factors for EFS and overall survival.

**Conclusions**: Our series showed a predominance of malignant pathologies in prepubertal patients. The overall long term survival was favourable. Prompt referral to a specialized center and vigilant surveillance for relapse is recommended.

### PO-627. National Studies for Childhood Germ Cell: 1073 Patients. Intermediate Risk with Cisplatin/Etoposide (PE) and no Bleomycin. High Risk Good Responders (HR‐GR) with Excellent Results {#pbc27455-sec-8620}

[L.F. Lopes]{.ul} ^1^, C.R. Donato Macedo^2^, G. Eiras Martins^3^, S.R. Brandalise^4^, V. Sonaglio^5^, M. Milone Silva^6^, M.T. de Assis Almeida^7^, F. Watusi^8^, M. Albonei Pianovski^9^, R. Melaragno^10^, C.A. Scridelli^11^

*^1^Barretos Cancer Center, Children Cancer Hospital, Barretos, Brazil; ^2^Instituto de Oncologia Pediatrica‐GRAACC‐ Universidade Federal de Sao Paulo, 'Pediatric Oncolgy, Sao Paulo, Brazil; ^3^Barretos Cancer Center, Children Cancer Center, Barretos, Brazil; ^4^Centro Infantil Boldrini, Pediatric Oncolgy, Campinas, Brazil; ^5^A.C.Camargo Cancer Center, Pediatric Oncolgy, Sao Paulo, Brazil; ^6^Centro de Tratamento Fabiana Macedo de Moraes/GACC, Pediatric Oncolgy, Sao jose dos campos, Brazil; ^7^Universidade de Sao Paulo‐FMUSP, Itaci‐Pediatric Oncology, sao paulo, Brazil; ^8^Hospital da Criança de Brasilia Jose de Alencar, Pediatric Oncology, Brasilia, Brazil; ^9^Hospital Erasto Gaertner, Pediatric Oncolgy, Curitiba, Brazil; ^10^Hospital Santa Marcelina, Pediatric Oncolgy, Sao Paulo, Brazil; ^11^Faculdade de Medicina da USP‐Ribeirao Preto, Pediatric Oncolgy, Ribeirao Preto, Brazil*

**Background/Objectives: Introduction**‐ Germ Cell tumours in childhood are rare; 1073 patients referred to one of the 3 National protocols from 1991 to 2017.

**Design/Methods: Methods**: Low Risk (LR) did not receive chemotherapy. Protocol GCT‐91 treated the IR‐Good Responders with standard dose PE and the HR‐GR with HD PE. IR‐GR from GCT‐99 and GCT‐2008 PE and for HR‐GR received PEI (addition of Ifosfamide)

**Results**: Available for analysis were 913 pts, excluding SNC and violations. Ovarian (42.5%‐388), Testicular (26.6%‐243), Sacrococcygeal (15.6%‐142), Mediastinal (5.8%‐53), Retroperitoneal (4.1%‐37), Head/Neck (2.3%‐21), Vagina (1.4%‐12) and others (1.8%‐16 were 2 from parotid, 2 heart, 1 penis). E I‐430 pts (47.1%), E II 84 (9.2%), E III 213 (23.3%), E IV 179 (19.6%). Histology 25.6% YST, 24.9 % Pure Teratoma, 18.3% Mixed tumours, 13.3% Dysgerminoma, 12.4% Immature Teratoma, 4.3% Embrionary Ca, 0.8% Coriocarcinoma. Survival Analysis LR 422 (no chemo‐ 5 years Overall Survival 98.9%‐); 168 IR (152 GR with PE‐ 5y‐OS 89.6%/ 16 PR treated PE+ IVB‐Ifo/Vb/Bleo‐ 5y‐OS 73.7%), and 297 HR (219 GR with 5y‐OS 77.9%/81 PR with 5y‐OS 69.2%). From the total HR 297 pts: 50 were treated with TCG‐91 (E III and IV gonadal and extra gonadal 35 GR treated with HDPE with 5yOS 94.1% and 15 PR treated with HDPE+IVB with 60.0% 5yOS; from 129 HR pts from GCT‐99 protocol (E III and IV extra gonadal and IV gonadal) 84 GR (received 4 cycles PEI) with 5yOS‐ 67.4% and 45 PR received 6 cycles PEI with 5yOS‐73.9%; from 118 HR from GCT‐2008 protocol (extra gonadal III, IV and gonadal IV) 100 pts GR received 5 cycles PEI with 5yOS 83.0% and 18 PR pts with 5yOS 70.0%.

**Conclusions**: Response‐based therapy produced excellent outcomes for patients with GCTs who were at IR. Challenges remain in our approach to patients with HR disease.

### PO-628. Rare Location Germ Cell Tumor: 53 Cases of the National Multicentric Protocols {#pbc27455-sec-8630}

[G. Martins]{.ul} ^1^, L.F. Lopes^1^, A.G. Vieira^1^, C. Macedo^2^, R. Melaragno^3^, F. Watusi^4^, L. Cristofani^5^, S. Brandalise^6^

*^1^Barretos Cancer Hospital, pediatric department, Barretos, Brazil; ^2^IOP‐GRAACC, Pediatric, São Paulo, Brazil; ^3^Santa Marcelina, pediatric, São Paulo, Brazil; ^4^Hospital da Criança de Brasília, pediatric, Brasília, Brazil; ^5^Itaci‐ICR‐HCFM USP, Pediatric, São Paulo, Brazil; ^6^Centro Infantil de Investigações HematológicasDr Domingos A Boldrini, pediatric, Campinas, Brazil*

**Background/Objectives**: The incidence of gonadal tumors increases with the puberty, and prior to 15 years of age they are predominantly extragonadal. There are few studies describing Germ CellTumor (GCT) of rare regions such as head and neck, and vagina among others.

**Design/Methods**: The National Multicentric protocols GCT ‐91, GCT ‐99 and GCT ‐2008, identified 53 cases of rare regions.

**Results**: The rare sites have been registered into consecutive protocols (1991, 1999 and 2008) for GCT tumors the following numbers: 4 patients, 34 patients and 15patients, respectively. The series showed the following locations: kidney, dorsal region, pericardial sac, midline between stomach and esophagus, uterus, liver, vagina, and head and neck. Vagina GCT accounted for 22.6% of the cases, head and neck 41.5%, and others 35.8%. The 22 cases of head and neck tumors (11cervical area, 6 face, 2 parotid, 2 rhinopharynx and 1 ephignatus) had, predominantly, pure teratoma and immature teratoma histology, followed by yolk sac, embryonal carcinoma and, less often, mixed GCTs. The most common histological subtypes of vaginal GCT were yolk sac and, less often, mixed GCTs. Most vaginal tumors (10/12 patients) were high risk, in contrast with Head and Neck tumors, which were, in their majority (16/22 patients), low risk. Overall survival at 5 years was 80.8%, 93.8% and 84.6% for vagina, head and neck, and other rare primary sites, respectively.

**Conclusions**: Rare location tumors with malignant histology could be treated, and the patients had excellent rates of survival, including the ones who presented with vaginal tumors, which usually lead to worse rates of survival in relation to the other sites. This may have happened probably due to resection and/or staging, since 83% of these tumors were high risk. Regarding the tumors that presented benign histology, it could be observed that the survival rate was related exclusively to resection.

### PO-629. Outcome of Paediatric Mediastinal Germ Cell Tumour in Asian Single Institution {#pbc27455-sec-8640}

[M.S. Nwe]{.ul} ^1^, S.G. Liew^1^, C.M.J. Lam^1^, S.Y. Soh^1^, M.Y. Chan^1^, A.M. Tan^1^

*^1^KK Women\'s and Children\'s Hospital, Paediatric Haematology/Oncology Subspecialties, Singapore, Singapore*

**Background/Objectives**: Mediastinal Germ Cell Tumour (MGCT) in Paediatric group is rare and often a challenge to manage. We described our experiences in a single paediatric center in Asian population.

**Design/Methods**: Data within 2004‐2017 were collected from Singapore Children Cancer Registry and epidemiology aspects, clinical presentation, treatment and outcomes were reviewed.

**Results**: The incidence was 15.4% (12/78) among extra‐cranial GCT during 13 years period. Two patients were excluded as they moved to other centres. The median age was 14 years (2 to 17.3 years) and all are male. One was associated with multiple congenital abnormalities and Klinefelter syndrome was found in 2. The most common presentation was cough more than 2 weeks in 9 patients. Two patients were stage 4 and the rest were stage 3 at diagnosis. Four had significant raised AFP and both AFP/bHCG were raised in 5 patients. All had curative chemotherapy except for the child with multiple congenital abnormalities with global retardation. Six had neoadjuvant chemotherapy followed by surgery. The upfront surgery was performed in 2 and complicated with residual tumors and phrenic nerve damage, needed second surgery. Both received adjuvant chemotherapy. One patient received chemotherapy alone, relapsed one year after off treatment and salvaged with surgery, myeloablative chemotherapy. None received radiotherapy. The 5 years OS and DFS were 68.6% and 50% respectively with median follow‐up 39 months (13‐155 months). There were two deaths from second cancer and two deaths from disease(one with no treatment and one with Choriocarcinoma). Second cancer happened in 3 patients and one who had leiomyosarcoma in lungs, bone and bone marrow 20 months after first malignancy survived with salvage chemotherapy. Two developed haematologic malignancy; systemic mastocytosis with myeloproliferative marrow and MDS/AML at 21 months and 8 years after first diagnosis respectively.

**Conclusions**: MGCT is seen mainly in adolescents and prognosis was poor with second haematologic malignancy.

### PO-630. Extracranial Germ Cell Tumours in Sarawak: An 18‐Year Experience {#pbc27455-sec-8650}

[S.W. Quah]{.ul} ^1^, S.H. teh^1^, G.B. ong^1^

*^1^Sarawak General Hospital, Paediatric Haematology‐Oncology Unit‐ Department of Paediatrics, Kuching‐ Sarawak, Malaysia*

**Background/Objectives**: Paediatric Germ Cell Tumours (GCTs) account for approximately 3% of childhood cancer in the Western population.

**Design/Methods**: A retrospective review of 76 children with extracranial GCTs that had been treated at the Sarawak paediatric oncology centre from the year 2000 to 2017. The patient characteristics, treatment modalities and outcomes were analyzed.

**Results**: Extracranial GCTs comprised 7% out of a total of 1097 paediatric cancers treated in Sarawak. The incidence rate was 8.2 cases per 100,000 children in Sarawak. The majority of extracranial GCT patients (66%) were in the youngest age group of 0‐4 years, with 16% in 5‐9 year group, another 16% in the 10‐14 year group and 3% in the 15‐19 years. The male to female ratio was 1: 2.8. Malays were the predominant ethnic group affected (38%), followed by Ibans (29%) and Chinese (26%).Gonadal and extragonadal tumours had an almost equal distribution. The majority of extragonadal tumours were sacrococcygeal (46%), followed by retroperitoneal (38%), thoracic (8%) and others (8%). For children under 5 years of age, common sites were the sacrococcygeal region(36%), retroperitoneum (28%) and testis (22%) while the ovary (80%) was the commonest site for children older than 5 years old. Extracranial GCTs in Sarawak commonly presented with a mass (86%), abdominal distension (36%), constitutional symptoms (26%), pain (18%), and obstructive symptoms (13%). Only 6% were diagnosed antenatally. Mature teratomas made up 42% of extracranial GCTs, with the rest were yolk sac tumours (29%), immature teratomas (13%), mixed malignant germ cell tumours (13%) and dysgerminomas(1%). 52% were treated with surgery and chemotherapy while 46% required only surgery. In terms of outcome, 70 patients are still alive, 4 patients died and 2 were lost to follow up.

**Conclusions**: The incidence of extracranial GCTs in Sarawak is higher than in Western populations with an excellent overall survival rate of 89%.

### PO-631. Degree of Response to Chemotherapy May Determine Need for Second Look Surgery in Pediatric Extra‐Cranial Malignant Germ Cell Tumors {#pbc27455-sec-8660}

[H. Saeed]{.ul} ^1^, A. Rashid^2^, A.U.R. Maaz^3^

*^1^Shaukat Khanum Memorial Cancer Hospital and Research Center, Pediatric Oncology, Lahore, Pakistan; ^2^Great North Children Hospital, Pediatric Oncology, Newcastle upon Tyne, United Kingdom; ^3^Noah\'s Ark Children\'s Hospital for Wales, Pediatric Oncology, Cardiff, United Kingdom*

**Background/Objectives**: Residual masses are present in upto 35% of patients of malignant germ cell tumors (MGCT) after chemotherapy. These are in a variety of sites, many of which, require mutilating surgery to achieve complete resection. The incidence of viable tumor varies from 7% to 52%. We conducted this study to review the management and outcome of residual masses in extra‐cranial MGCT at our institution.

**Design/Methods**: Retrospective review of electronic medical records of all pediatric MGCT patients with residual mass at end of chemotherapy during study period (2008‐2010). Partial response (PR) was defined as \>50% reduction in size on imaging.

**Results**: Twenty‐three (37%) of all treated patients had residuum. Most common histologic type was YST (43%). All patients were stage III (48%) or IV (52%). The most common location was abdomino‐pelvic or retroperitoneal (61%). PR was seen in 74%, stable disease (SD) in 22% and progression (PD) in 4%. Fifteen patients (65%) underwent surgical resection or biopsy of residual mass. Surgical procedure was hysterectomy/oophorectomy for five patients (33%) while the remaining had biopsies. Residual tumor was only identified in two patients (13%). Both these patients did not achieve PR. Some patients (n=5) received chemo/radiation for residual masses that were not resected while the rest were follow expectantly. Progression free survival and Overall survival of entire cohort is 70% and 86% respectively at 5 years with median follow up of 39 month. Analyzing by degree of response we found a statistically significant difference in OS and PFS between PR (OS 100%, PFS 81%) and SD (OS 53%, PFS 24%) (p\<0.001). Survival was slightly worse for patients that received chemotherapy/radiation for residual masses.

**Conclusions**: Residual masses are a frequent finding at end of treatment in MGCT tumors. Greater than 50% radiologic response predicts excellent outcome and so careful follow‐up instead of aggressive therapy may be considered.

### PO-632. Tumor Marker Surveillance Alone Without Radiographic Imaging for Early Detection of Relapse in Extracranial Solid Tumors of Children, Adolescents and Young Adults {#pbc27455-sec-8670}

[R. Shah]{.ul} ^1^, A. Senerchia^2^, K. Mascarenhas^2^, J. Malvar^2^, R. Sposto^3^, A. Sapra^4^, L. Mascarenhas^1^

*^1^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation‐ Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Department of Pediatrics‐ Keck School of Medicine‐ University of Southern California, Los Angeles, USA; ^2^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation, Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Los Angeles, USA; ^3^Division of Hematology‐ Oncology‐ and Blood and Marrow Transplantation‐ Children\'s Center for Cancer and Blood Diseases‐ Children\'s Hospital Los Angeles, Department of Research‐ Preventive Medicine and Pediatrics‐ Keck School of Medicine‐ University of Southern California, Los Angeles, USA; ^4^Children\'s Hospital Los Angeles, Department of Radiology, Los Angeles, USA*

**Background/Objectives**: Standard surveillance for early detection of relapse in extracranial solid tumors (EST), with elevated tumor markers (TMs) at diagnosis, includes TM monitoring and serial radiographic imaging. Given the high sensitivity of TMs for detection of relapse, the role of radiographic imaging is debated in patients with EST.

**Design/Methods**: Retrospective chart review of newly diagnosed patients with EST and elevated pre‐treatment TMs between 2002‐2012.

**Results**: Ninety‐four patients (62 males, age range 0.25‐19 years) were included with a median follow‐up of 6.2 years; Hepatoblastoma (HB)=49, Hepatocellular Carcinoma (HCC)=7, Malignant Germ Cell Tumor (GCT)=38. Median serum alpha‐fetoprotein (AFP) at diagnosis was 198,000 ng/mL, 9270 ng/mL and 283 ng/mL for HB, HCC and GCT respectively. Median beta‐human chorionic gonadotropin (β‐hCG) at diagnosis in GCT was 65.46mIU/L. Fourteen patients experienced a confirmed relapse. In 13 patients, the TM elevation preceded radiographic detection of relapse. In one patient with HCC, TMs never normalized and disease progression was detected on radiographic imaging prior to a rise in serum AFP. The mean time from TM elevation to radiographic detection of relapse was 125.7 days. The total number of radiographic imaging studies performed were 2858; chest X‐ray=1386, computed tomography (CT) chest with contrast=694, CT abdomen/pelvis with contrast=666, magnetic resonance imaging abdomen/pelvis=73 and radionuclide bone scan=39. The total number of AFP and β‐hCG assays performed were 2392 and 771 respectively. Based on the 2017 Medicare fee schedule, the total TM costs were \$238,050 and the radiographic imaging costs were \$5,963,126. Thus, the omission of routine radiographic surveillance in our patient cohort could have potentially resulted in a mean costs savings of \$61,560.

**Conclusions**: TM assessment, without radiographic imaging, is adequate for disease surveillance in patients with EST and elevated TMs at diagnosis that normalize at the end of primary treatment. Surveillance with TMs alone will reduce both radiation exposure and health care costs.

Solid Non Brain Tumours ‐ Rare Tumours and Histiocytosis {#pbc27455-sec-8680}
--------------------------------------------------------

### PO-633. An Iraqi Girl with a Slowly Growing Jaw Mass Diagnosed in Japan as a Case of DOCK8 Deficiency {#pbc27455-sec-8690}

[L. Al‐Kzayer]{.ul} ^1^, Y. Okuno^2^, H. Al‐Aradi^3^, K. Sano^4^, T. Shigemura^1^, Y. Nakazawa^1^

*^1^Shinshu University School of Medicine, Department of Pediatrics, Matsumoto‐ Nagano, Japan; ^2^Nagoya University Graduate School of Medicine, Center for Advanced Medicine and Clinical Research, Nagoya, Japan; ^3^Al‐Hussein Teaching Hospital, Department of Pediatrics, Samawah‐ Muthanna, Iraq; ^4^Iida Municipal Hospital, Department of Pathology, Iida‐ Nagano, Japan*

**Background/Objectives**: Dedicator of cytokinesis 8 (*DOCK8*) deficiency is a rare disease of combined immunodeficiency, that exemplifies the broad clinical features of primary immunodeficiency diseases (PID), and accounts for the autosomal recessive hyper IgE syndrome, extending beyond recurrent infections to include atopy, autoimmunity, and cancer. Lymphoproliferative disease (LPD) complicating PID is difficult to diagnose.

**Design/Methods**: Case report: A 10‐year‐old Iraqi girl, for first‐cousins‐parents, had a history of severe eczema since early childhood, repeated chest infection, autoimmune enteropathy, and a relatively retarded growth. She presented a year ago, with a slowly growing right jaw mass, progressing over several months, with bilateral cervical and axillary lymphadenopathy. Laboratory evaluations showed an immunoglobulin (Ig) assay of 14, 3.6, and 1.6, folds above normal levels of IgE, IgA and IgG, respectively, but low IgM. In addition to eosinophilia, lymphopenia, and elevated LDH. Bone marrow aspirate (BMA) was hypercellular, with eosinophilia. In Iraq, two biopsies from the mass suggested B‐cell‐lymphoma, one was re‐evaluated in Japan, and revealed a polyclonal‐reactive‐proliferation spectrum of LPD/plasmacytic hyperplasia, complicating PID. Though, Epstein‐Barr virus was negative by *in situ* hybridization in Japan. BMA was transferred to Japan using Flinders Technology Associates (FTA) card.

**Results**: *DOCK8* truncating‐mutation was detected by whole‐exome sequencing in Japan, using FTA‐derived DNA. The patient was treated conservatively, with neither steroid nor chemotherapy, and started gluten‐free diet. Gradually, the jaw mass regressed and eczema was relatively improved.

**Conclusions**: Although lymphoma could occur in *DOCK8*, our case asserted that careful pathogenetic evaluation, in the advanced setting, was crucial to rule out the neoplastic process and to avoid exposing the patient to unnecessary and risky therapy. In addition, the disclosure of *DOCK8* mutation was by itself a diagnostic entity, which can be cured by hematopoietic stem cell transplantation.

Acknowledgments: We appreciated the 50th‐Annual SIOP acceptance for our abstract to be published in the official congress publications.

### PO-634. A Syrian Girl Diagnosed with IL12RB1 Deficiency in Japan {#pbc27455-sec-8700}

[L. Al‐Kzayer]{.ul} ^1^, Y. Okuno^2^, K. Sharif^3^, K. Sano^4^, T. Shigemura^1^, Y. Nakazawa^1^

*^1^Shinshu University School of Medicine, Department of Pediatrics, Matsumoto‐ Nagano, Japan; ^2^Nagoya University Graduate School of Medicine, Center for Advanced Medicine and Clinical Research, Nagoya, Japan; ^3^Sulaymaniyah University‐ College of Medicine‐ Sulaymaniyah Pediatric Teaching Hospital, Department of Pediatrics, Sulaymaniyah, Iraq; ^4^Iida Municipal Hospital, Department of Pathology, Iida‐ Nagano, Japan*

**Background/Objectives**: Mendelian susceptibility to mycobacterial diseases (MSMD) is caused by genetic defects in the mononuclear phagocyte/T‐helper‐cell type 1 pathway. Patients with MSMD have increased susceptibility to systemic infections with weakly virulent nontuberculous mycobacteria (NTM) including the *Bacillus Calmette‐Guerin* (BCG) vaccine strain. Mutations in the gene encoding interleukin‐12 receptor beta1 (IL12RB1) have been identified in patients with disseminated Salmonella, and NTM infections or disseminated BCG infection following inoculation with the vaccine in the setting of IL‐12 unresponsiveness.

**Design/Methods: Case Report**: An 8‐year‐old Syrian girl, for first‐cousins‐parents living as refugees in Iraq, received BCG vaccine at 7^th^ day‐old, developed a progressive axillary swelling at 2 months‐old, on the same side of BCG vaccine. After repeated non‐conclusive biopsies from the axillary mass, anti‐tuberculous (anti‐TB) regimen was given in accordance with clinical bases, persistent very high ESR, and a local TB‐prevalence setting. She had on/off different systematic infections, including meningitis, in addition to relapsing/remitting skin rash, lymphadenopathy, and fever necessitated the intensive care in one occasion. She received frequent anti‐TB courses with doubtful responses. Bone marrow aspirate (BMA) in Iraq was normal. BMA sample was transferred to Japan using Flinders Technology Associates (FTA) card

**Results**: *IL12RB1* mutation was detected by performing whole‐exome sequencing in Japan, using genomic DNA extracted from FTA sample

**Conclusions**: The diagnosis of MSMD due to *IL12RB1* deficiency was possible through transferring FTA sample for genetic evaluation in Japan.

Acknowledgments: We appreciated the 50th‐Annual SIOP acceptance for our abstract to be published in the official congress publications.

### PO-635. Extra Renal Wilm\'s Tumor: Case Report from a Saudi Tertiary Care Center {#pbc27455-sec-8710}

[A. Alkhamisy]{.ul} ^1^, Z. Habib^1^, A. Ali^2^, A. Mouhab^2^, Y. Khafaga^3^, V. Mohammed^2^, D. Bushnak^2^

*^1^King Faisal Specialized Hospital and Research centre, Pediatric Surgery, Riyadh, Saudi Arabia; ^2^King Faisal Specialized Hospital and Research centre, Pediatric Hematology and Oncology, Riyadh, Saudi Arabia; ^3^King Faisal Specialized Hospital and Research centre, Radiation Oncology, Riyadh, Saudi Arabia*

**Background/Objectives**: Wilms' Tumor (WT) is the most common childhood malignancy of the kidneys but may also arise from outside the renal parenchyma. Extrarenal Wilms' (EWT) tumor, which is very rare is often reported as a sporadic and isolated case report in the literature.

**Design/Methods**: We present case of a 2‐year old girl with EWT at King Faisal Specialist Hospital & Research Center, Riyadh.

**Results**: A two‐year old girl with EWT who was referred with an abdominal distension. She had a 2‐ month history of abdominal distension with a big palpable mass in the abdomen starting from the left flank, crossing the midline. An abdominal ultrasound revealed a large solid mass in the left side of the abdomen. A CT of the abdomen performed revealed a soft tissue mass occupying the left abdomen and midline measuring approximately 13.3 x 15.8 x 16.9 cm. She underwent an open biopsy, a frozen section was sent for histopathology which confirmed the diagnosis of WT. There was no evidence of anaplasia. She was staged as stage III and started on neo‐adjuvant chemotherapy. CT abdomen was repeated after 8 weeks of chemotherapy, it showed mild reduction in tumor size. At laparotomy, the tumor was very mobile and separated from left kidney, so the excision of the tumor with safe margin was done. Post‐operatively, the patient was given radiotherapy to the left abdominal flank.

**Conclusions**: EWT is very rare and little information is known about prognosis, response to therapy and outcome. Also, no defined management guidelines have been established for this entity. While still early in her management, our patient is post‐week 16 and has thus far shown good response to the standard management for WT. We will continue to follow her in terms of response to therapy and also long term survival.

### PO-636. Doxorubicin Eluting Embolization Therapy for Pediatric Desmoid Fibromatosis: A Promising Approach to a Perplexing Disease {#pbc27455-sec-8720}

[S. Ash]{.ul} ^1,2^, E. Atar^2,3^, S. Amar^1^, E. Bruckheimer^2,4^, M. Knizhnik^5^, T. Dujovny^6^, M. Feinmesser^2,7^, E. Elnekave^2,3,8^

*^1^Schneider Children\'s Medical Center of Israel., The Rina Zaizov Hematology‐Oncology Division, Rosh Haain, Israel; ^2^Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ^3^Rabin Medical Center, Dept. of Diagnostic Radiology, Petach Tikva, Israel; ^4^Schneider Children\'s Medical, Section of Pediatric Cardiology, Petach Tikva, Israel; ^5^Schneider Children\'s Medical Center of Israel, Dept. of Diagnostic Radiology, Petach Tikva, Israel; ^6^Haemek Medical Center, Pediatric Oncology Unit, Afula, Israel; ^7^Rabin Medical Center ‐ Beilinson Hospital, Dept. of Pathology, Petach Tikva, Israel; ^8^Davidoff Center‐ Rabin Medical Center, Institute of Oncology, Petach Tikva, Israel*

**Background/Objectives**: Desmoid fibromatoses are rare and clinically enigmatic soft tissue tumors with high propensity for local invasion but no metastatic potential. Surgery remains the cornerstone of primary treatment, but postoperative recurrence is common and tends to behave more aggressively than the primary tumor. Systemic options are widely varied and overall show marginal benefit, with the exception of doxorubicin. Doxorubicin has proven clinical benefit, but its use is limited by dose‐dependent toxicities.

**Design/Methods**: To maximize the local efficacy of doxorubicin while minimizing systemic toxicity we developed a protocol for super‐selective intra‐arterial doxorubicin delivery via drug eluting beads. Here we present the results of selective doxorubicin eluting beads in four children with recurrent or refractory Desmoid fibromatoses using cumulative bead‐loaded doses of 27, 45 and 133 mg/m2. We assessed efficacy by tumor response on Magnetic Resonance Imaging (MRI) and by symptomatic improvement.

**Results**: Tumor volumes were reduced by 54% ‐ 97% within three to twelve months. Treatment was accompanied by reduction or complete elimination of MRI T2 signal in all patients with Desmoid fibromatoses. Symptomatic relief was accomplished within three months for all patients. A single patient experienced transient lower extremity paresthesia (Grade I) which resolved within two months. No other adverse effects were encountered over a post treatment follow up of 6‐32 months.

**Conclusions**: We present the first use of intra‐arterial doxorubicin delivery via drug eluting beads for patients with Desmoid fibromatoses to achieve controlled local drug delivery, achieving promising clinical and disease responses quickly while using a fraction of the standard systemic dose and encountering no significant toxicity.

### PO-637. Diffuse Ganglioneuromatosis and Malignant Peripheral Nerve Sheath Tumor Associated with Neurofibromatosis Type 1 {#pbc27455-sec-8730}

[E. Ataseven]{.ul} ^1^, Ö. Üzüm^2^, Z. Önder Siviş^1^, M. Karakoyun^3^, M. Baran^3^, B. Malbora^1^, M. Türker^1^, B. Atabay^1^, H. Öniz^1^

*^1^Izmir Tepecik Research and Training Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey; ^2^Izmir Tepecik Research and Training Hospital, Department of Pediatrics, Izmir, Turkey; ^3^Izmir Tepecik Research and Training Hospital, Department of Pediatric Gastroenterology and Hepatology, Izmir, Turkey*

**Background/Objectives**: Intestinal ganglioneuromatosis in gastrointestinal system is extremely rare. It is often associated with neurofibromatosis type‐1(NF‐1) and multiple endocrine neoplasia type‐2b but, more rarely, it can present in a sporadic form. Here, we report a patient with diffuse ganglioneuromatosis, diagnosed as NF‐1 and malign peripheral nerve sheath tumor(MPNST) detected during surgery.

**Design/Methods**: A 16‐year‐old boy applied with diarrhea‐constipation attacks for 3 months, severe abdominal pain,diminished oral intake and 10 kg weight loss. Abdominal USG and tomography revealed diffuse ileal wall thickening and mesenteric lymphadenopathy. He was hospitalized with preliminary diagnosis of inflammatory bowel disease. Physical examination revealed diffuse cafe‐au‐lait skin lesions and axillary freckling. On eye examination Lisch nodules detected. From his family history we learned that his father had same brownish macules in his skin so he was diagnosed as NF‐1.Endoscopy and colonoscopy revealed diffuse inflammation. MRI enterography performed and revealed ileal wall thickening,diffuse polypoid lesions(plexiform neurofibroma?) in ileum and in mesentery,diffuse nodular lesions infiltrating the superior vascular formations. Double balloon entheroscopy revealed diffuse polypoid lesions in 70 cm segment of ileum,mucosal biopsies taken from mucosa revealed diffuse ganglioneuromatosis. We decided to surgery,because of patients severe abdominal pain,diminished oral intake and uncontrolled diarrhea attacks. At surgery ileal segment with polypoid lesions and nodular formation in mesentery resected. The resected ileal segment contained plexiform neurofibromatosis without malignant transformation. On the other hand,mesenteric nodular lesion contained MPNST. After surgery, because of residual lesion in mesentery CEVAIA(Carboplatinum,Epirubicin,Vincristin,Ifosfamide,Etoposide,Actinomycin) chemotherapy started. After 28 weeks treatment,patient achieved remission. For 4 months followed up without disease.

**Results**: Diffuse ganglioneuromatosis,in which the large intestine is usually affected,is a rare condition. Malignant transformation of a neurofibroma occurs in 3‐5% of patients with NF1. MPNST are the most common tumors. Our case is important because of age,dıffuse ganglioneuromatosis of small intestine which is very rare and coexisting MPNST.

**Conclusions**: In NF‐1,malignancy should be kept in mind in all ages and patients should be followed closely in terms of malignancy.

### PO-638. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in a 14 Year Old Patient with Poorly Differntiated Nasopharyngeal Carcinoma: JRRMMC Experience of the ARAR0331 Protocol {#pbc27455-sec-8740}

[M.V. Barcelona]{.ul} ^1^, J.A. Flores^1^, M.J. Go^1^, J. Estanislao^2^, M.J. Calaguas^1^

*^1^Jose R. Reyes Memorial Medical Center, Department of Radiotherapy, Manila, Philippines; ^2^Jose R. Reyes Memorial Medical Center, Department of Pediatrics‐ Section of Pediatric Hematology‐Oncology, Manila, Philippines*

**Background/Objectives**: A major consideration in giving radiotherapy to children is the acute and long‐term toxicity. Standard treatment of nasopharyngeal carcinoma (NPCA) in adults consists of concurrent chemoradiotherapy with or without adjuvant chemotherapy;^1‐4^ however, the rarity of pediatric patients with NPCA makes the sequence and dosages of both modalities less clear‐cut. The ARAR0331 protocol published by the Children\'s Oncology Group noted good overall and event‐free survival.^5^ This paper aims to show the outcomes of a pediatric patient with NPCA treated at our institution utilizing this protocol.

**Design/Methods**: This is a case report of a 14 year old Filipino male who presented with a right‐sided neck mass around 2x2 cm noted 1 year prior to consult without accompanying symptoms. Five months prior to consult, the mass increased to 5x5 cm. Punch biopsy revealed squamous cell carcinoma, poorly differentiated. Head and neck CT scan showed lobulated right nasopharyngeal mass, extending to the right temporal lobe and an enlarged level II lymph node (T4N1M0, Stage IVA). ARAR0331 protocol was adopted and 4 cycles of induction chemotherapy (5‐FU 1 g/m^2^/d CI x 5 days + Cisplatin 80 mg/m^2^) was initiated. CT scan post‐chemotherapy revealed absence of mass and lymphadenopathy. Patient was given concurrent chemoradiotherapy (tri‐weekly cisplatin 100 mg/m^2^). Radiotherapy included opposed lateral faciocervical fields prescribed 61.2 Gy/1.8 Gy/34 fractions and low anterior neck area (anteroposterior field) prescribed 50.4 Gy/1.8 Gy/28 fractions.

**Results**: Patient tolerated treatment for 7 weeks without complications or delays. RTOG grade 1 toxicities to the skin, saliva, and mucous membranes were noted. Follow‐up imaging up to 1 year post treatment revealed complete absence of the mass. Follow‐up metastatic work‐ups and cognitive tests revealed normal findings.

**Conclusions**: This is the first reported use of the ARAR0331 protocol for a case of pediatric nasopharyngeal carcinoma in the country and illustrates its feasibility and short‐term effectiveness in our setting.

### PO-639. Nasopharyngeal Carcinoma in Children: Beyond Five Year Survival {#pbc27455-sec-8750}

[T. Ben‐Ami]{.ul} ^1^, S. Ash^2^, M. Ben‐Harosh^3^, H. Gavriel^4^, S. Revel‐Vilk^5^, M. Weintraub^6^, M. Ben‐Arush^7^

*^1^Kaplan Medical Center, Pediatric Hematology‐Oncology Unit, Rehovot, Israel; ^2^Schneider Children\'s Medical Center of Israel, Pediatric Hematology‐Oncology Department, Petah‐Tikva, Israel; ^3^Soroka University Medical Center, Pediatric Hematology‐Oncology Department, Beer‐Sheva, Israel; ^4^Haemek Medical Center, Pediatric Hematology‐Oncology Unit, Afula, Israel; ^5^Shaare Zedek Medical Center, Pediatric Gaucher and Hematology Unit, Jerusalem, Israel; ^6^Alyn Rehabilitation Center for Children and Adolescents, Department of Rehabilitation, Jerusalem, Israel; ^7^Ruth Rappaport Children\'s Hospital‐ Rambam Health Care Campus, Pediatric Hematology‐Oncology Department, Haifa, Israel*

**Background/Objectives**: Nasopharyngeal carcinoma (NPC) is a rare childhood cancer. Information regarding the clinical characteristics, biology and long term follow up of childhood NPC is scarce. We present our data on very late follow up on NPC in children.

**Design/Methods**: Retrospective data was collected from medical files and electronic data. This study was approved by local IRB committees.

**Results**: Between 1989‐2017, 43 children with NPC were treated in 5 Pediatric Hematology‐Oncology centers in Israel. Thirty four patients (79%) were males. Median age at diagnosis was 14 years (6‐18 years). Sixty three percent (22 of 35) of the children were Jewish, 34% (12 patients) were Arabs. Four patients (11%) were diagnosed with stage 2 disease, 23 patients (64%) were diagnosed with stage 3 disease. None of the children had distant metastases at presentation. All patients received radiotherapy at an average dose of 65.6 Gy (60.0‐74 Gy). All children were treated with cisplatinum‐based chemotherapy according to the regimens used during these years. Median time of follow‐up was 12.6 years (5.2 months to 26 years). During long term follow up, ten children (23%) had an event. Five patients had local (1 child) and distant (4 patients) disease recurrence. Median time to recurrence was 44 months (4‐48 moths). Four children developed secondary malignancy. Median time to secondary malignancy diagnosis was 105 months (53‐163 months). One child developed intracranial bleeding from a cavernoma in the radiation field margins. Median time to first event was 57.5 months (4‐163 months). Six children died during follow‐up. Four children succumbed to their disease, and 2 children died from secondary malignancy. Twenty five year overall survival and event free survival were 86.8 ±5.5% and 84.3±5.9% respectively.

**Conclusions**: Nasopharyngeal carcinoma is rare in children. Continued long term follow up is necessary in order to consider novel treatment approaches for this highly curable neoplasm.

### PO-640. Malignant Rhabdoid Tumour in an Adolescent with Coffin‐Siris Syndrome and a Germline ARID1B Mutation: A Case Report and Review of the Literature {#pbc27455-sec-8760}

J. Calley^1^, P.A.J. Brown^2^, D. Morgan^3^, [H. Bishop]{.ul} ^1^

*^1^Royal Aberdeen Children\'s Hospital, Department of Paediatric Oncology, Aberdeen, United Kingdom; ^2^Aberdeen Royal Infirmary, Department of Pathology, Aberdeen, United Kingdom; ^3^Royal Aberdeen Children\'s Hospital, Department of Radiology, Aberdeen, United Kingdom*

**Background/Objectives**: Mutations affecting key subunits of the SWItch/Sucrose Non‐Fermenting (SWI/SNF) chromatin remodelling complex have recently been identified as the cause of Coffin‐Siris syndrome (CSS; OMIM \#135900), a rare autosomal dominant syndrome with heterogenous phenotype typically involving intellectual disability, characteristic facial features, aplasia/hypoplasia of the distal phalanx or nail of the fifth digit, hirsutism, and sparse scalp hair. The SWI/SNF complex also functions as a tumour suppressor (TS), of importance in the aetiology of paediatric malignant rhabdoid tumour (MRT) with mutations predominantly involving the *SMARCB1* subunit or *SMARCA4*. Despite the TS function of the SWI/SNF complex, neoplastic disorders are sparsely reported amongst patients with CSS and MRT has not previously been described in CSS.

**Design/Methods**: We report a case of a 15 year old female with MRT, recently diagnosed with CSS due to an *ARID1B* mutation through whole exome sequencing as part of the deciphering developmental disorders study, and with absent *SMARCB1* expression on tumour analysis. A literature search of Ovid MEDLINE and EMBASE was performed to review existing evidence for risk of MRT in CSS.

**Results**: No reports were identified of co‐occurrence of MRT and CSS. There are single case reports of hepatoblastoma, schwannomatosis and astrocytoma in CSS. There is currently limited understanding of any link between SWI/SNF related neurodevelopmental disorders and neoplastic disease, although all of the causative proteins in CSS have been reported in association with tumour development.

**Conclusions**: CSS is a rare disorder for which the genetic basis has only recently been identified. Multiple subunits of the SWI/SNF complex may be affected by heterogenous mutations in this disorder. We report a novel case of MRT in the context of germline *ARID1B* mutation. Further research is warranted into whether germline mutations in components of the SWI/SNF complex impact risk of disease development or severity in related tumours such as MRT.

### PO-641. Pediatric Malignant Melanoma Patients; Demographic, Clinical, Therapeutical Characteristics and Long Term Outcome in a Single Center {#pbc27455-sec-8770}

[S. Büyükkapu Bay]{.ul} ^1^, R. Kebudi^2^, O. Görgün^2^, S. Kurul^3^

*^1^Istanbul University Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^3^Istanbul University Oncology Institute, Surgical Oncology, Istanbul, Turkey*

**Background/Objectives**: Malignant Melanoma (MM) comprises 1‐3% of all malignancies in children and adolescents. In this study, we aim to evaluate the clinical aspects, histopathologic features and treatment outcome of our MM patients.

**Design/Methods**: Retrospective review.

**Results**: Between 2003‐2018, 19 (10 female, 6 male) patients with a median age of 7.5 years (6‐166 mo) diagnosed in the Istanbul University Oncology Institute were evaluated. Three patients were only consulted, thus 16 patients were assessed. All had cutaneous melanoma except one with mucosal (conjunctival) melanoma. The most frequent localization was the lower extremities in six; the upper extremities in 4, the head and neck in 4, and the abdomen in two. Sentinel lymposcintigraphy + sentinel node biopsy and PET/CT were performed as the staging procedures at initial diagnosis. Localized disease was present in seven patients; nine had regional lymph node metastasis. three developed distant metastasis (bone, lung, ‐brain) at a median of 9 months. The median Breslow width of the tumor was 3.5 mm (1.5‐19 mm). The only treatment was surgery in localized disease; surgery and adjuvant interferon in patients with regional lymph node metastasis. One patient with regional lymph node and bone metastasis at recurrence recieved vemurafenib and immunotherapy (pembrolizumab) for three months, he died. Another died with metastatic recurrence. The patient with conjunctival melanoma and distant metastasis did not respond to treatment with temozolamide, BRAFV600E mutation was negative, immunotherapy with ipilumumab was initiated, palliative radiotherapy was administered to bone and brain metastasis. The median follow‐up for all patients was 28 months (3‐149 mo.). The 5 year overall survival was 76%.

**Conclusions**: Although MM is rare in children, prognosis is good if diagnosed early. Clinicians should be aware of skin lesions and full layer biopsy should be obtained in suspicious skin lesions. Patients with congenital melanocytic nevus or dysplastic nevus should also be followed cautiously.

### PO-642. Hypertrophic Pulmonary Osteoartropathy Secondary to Thymic Carcinoma {#pbc27455-sec-8780}

[F.B. Çakır]{.ul} ^1^, F. Ustabaş Kahraman^2^, M. Yazıcı^3^

*^1^Associate Professor, Bezmialem Vakif University Pediatric Hematology Oncology, Istanbul, Turkey; ^2^Bezmialem Vakıf Üniversitesi, Pediatrics, Fatih, Turkey; ^3^Bezmialem Vakıf Üniversitesi, Pediatrics, Istanbul, Turkey*

**Background/Objectives**: Thymic carcinoma is a very rare neoplasm in children identified as a large mass in the anterior mediastinum. Hypertrophic pulmonary osteoartropathy (HPO) occurs as a paraneoplastic syndrome defined by the development of clubbing of fingers and toes, proliferative periostitis in the long bones and painful symmetric arthropathy. Intrathoracic neoplasms like thymic carcinomas are the major causes of HPO. A 11 yrs old boy with the development of HPO diagnosed with thymic carcinoma is presented.

**Design/Methods**: A 11 yrs old boy with a one yr lasting malaise and tenderness in the body, development of changes in the fingers and toes had chest pain in the last three months. At presentation, he was not tachypneic and tachycardic. His physical examination was unremarkable other than clubbing in the fingers and toes and swelling in the ankles. In his chest X‐ray, there was a mass lesion in the anterior mediastinum.

**Results**: Magnetic Resonance imaging showed a 105x83x65mm mass with cystic and solid components. FDG‐PET‐CT showed the same mass having dense FDG involvement and hypermetabolic state. Tru‐cut biyopsy revealed primary lymphoepitelioma like carcinoma of the thymus. Since the mass was unresectable with clear margins, cisplatin and etoposid combination chemoterapy was initiated. The symptoms of malaise and pain wained just after the first cycle. The mass was gross totally resected after four cycles.

**Conclusions**: Thymic carcinoma is a rare neoplasm in the childhood. However, paraneoplastic syndrome like HPO should alert the physician with the suspicion of a mediastinal mass.

### PO-643. Two Very Rare Pancreatic Tumors in a Single Center {#pbc27455-sec-8790}

[S. cakmakci]{.ul} ^1^, T. Bayhan^1^, N. Karaman^2^, B. Aksel^2^, A. Erol^3^, I. Ergurhan İlhan^1^

*^1^Saglik Bilimleri University‐ Ankara Oncology Hospital, Pediatric Hematology Oncology, Ankara, Turkey; ^2^Saglik Bilimleri University‐ Ankara Oncology Hospital, Surgery, Ankara, Turkey; ^3^Saglik Bilimleri University‐ Ankara Oncology Hospital, Pathology, Ankara, Turkey*

**Background/Objectives**: Solid pseudopapillary tumor of the pancreas (SPT) is a rare, low‐grade, malign tumor of the exocrine pancreas.. It accounts for 0.2‐2.7 % of all pancreatic tumors mainly seen in young women. We aimed to present two cases with SPT of the pancreas.

**Design/Methods**: Case 1

A 13‐year‐old girl admitted with trauma history, there was a firm mass on the right upper side of the abdomen. Carcinoembryonic antigen (CEA) levels were 19.9, CA‐125 was elevated (55, N: 0‐35). Abdominal ultrasound (USG) and computed tomography (CT) revealed a large mass of the pancreatic body and tail (12 x 11 cm) with left renal vascular structures extending to the midline of the stomach. The capsular tumor totally was excised. Microscopically, tumor cells with eosinophilic cytoplasm, in which pseudopapillary structures, mostly composed of solid areas,the diagnosis was consistent with SPT. Postoperatively, a residual lesion of 4 x 2 cm was observed and subtotal pancreatectomy, splenectomy and left hemicolectomy were performed. She is fin remission for 17 months since diagnosis.

**Results**: Case 2

A 16‐year‐old girl was evaluated with stomach pain lasting for 9 months and referred to our clinic with an abdominal mass. A large firm mass was palpated in the right upper quadrant. Alpha‐feto protein (AFP), human chorionic gonadotropic hormone (BHCG), CA19.9, CEA, CA‐125 levels were normal. The CT of the abdomen revealed a large mass (14 x 12 cm) arising from the right lobe of the liver and extending to the right kidney with cystic and solid areas. Subtotal resection of pancreatic head, subtotal gastrectomy, cholecystectomy were performed by Whipple procedure. On pathological examination SPT was diagnosed with negative surgical margins. No recurrence was observed at the 12‐month follow‐up.

**Conclusions**: Pancreatic SPT is rare tumors. The gold standard for treatment is surgery with negative margins and protection of pancreatic tissue should be targeted as much as possible.

### PO-644. Two Case Reports: Gastric Adenocarcinoma in Children at the Instituto Nacional De Enfermedades Neoplasicas (INEN), Peru {#pbc27455-sec-8800}

[S. Chavez]{.ul} ^1^, R. Morales^1^, R. Diaz^2^, J. Garcia^1^, A. wachtel^1^
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**Background/Objectives: Background**: Gastric adenocarcinoma (GAC) is an extremely rare type of cancer in children, it represents 0.05% of all childhood cancer with very limited information on the clinical presentation and outcome

**Objective**: To report two pediatric patients less than 15 years of age with GAC treated between 2012 and 2017 at our Institution.

**Design/Methods: Case Reports**

**Results**: CASE 01: 11‐year‐old male with a history of 6 months of weight loss, dysphagia and anemia, after many consults, an endoscopy showed a suspicious lesion of neoplasia. Referred to INEN in March 2012, thin, pale, brownish‐milk patches of diffuse distribution, pain at the epigastrium, no masses, endoscopy concludes type III stenosing gastric malignant neoplasm and type I lesion in gastric body, probable synchronous, the CT scans describes thickening of the distal portion of the esophagus, gastric esophageal junction and the stomach partially,it extends to the adjacent fat, surrounding the aorta and celiac trunk. No metastatic disease. Anatomical Pathology was INFILTRATIVE ADENOCARCINOMA WITH SOLID PATTERN OF SIGNET RING CELL. Unresectable tumor. Genetics evaluates the possibility of neurofibromatosis or Legius syndrome. He received chemotherapy with a FOLFOX regimen (5‐fluoracil, leucovorin, oxaliplatin) up to 4 courses; he died 12 months after the diagnosis with progressive disease. CASE 02: A 14‐year‐old girl with a history of 8 months characterized by abdominal pain, dysphagia; CT scans showed thickened gastric wall and liver metastasis. She was referred to INEN in January 2017 where an endoscopy described an involvement of anterior wall, posterior and greater curvature and an ulcerated lesion that infiltrated the edges, findings related to BORMANN III. Pathology report: INFILTRATIVE TUBULAR ADENOCARCINOMA MODERATELY DIFFERENTIATED. Unresectable, no lung metastasis, she started chemotherapy FOLFOX scheme, completed 5 courses with progressive disease, and died 8 months after diagnosis.

**Conclusions**: Gastric adenocarcinoma (GAC) is rare type of cancer in children, with poor prognosis.

### PO-645. Clinical and Prognostic Characteristics of 61 Patients with Malignant Rhabdoid Tumor in Children: A Single Institute Experience 2007‐2017 {#pbc27455-sec-8810}

[H. Cheng]{.ul} ^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Surgical Oncology, Beijing, China*

**Background/Objectives**: Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that commonly occurs in infancy and young children. To add the curremt knowledge of this disease, we reviewed the MRT patients treated in our institute.

**Design/Methods**: A retrospective medical record review was conducted on 61 patients with pathologically confirmed MRT at Beijing Children\'s Hospital between January 2007 and October 2017.

**Results**: Sixty‐one patients were diagnosed with MRT at a median age of 17 months, including 35 cases of malignant rhabdoid tumor of the kidney (MRTK), five cases of atypical teratoid rhabdoid tumor (ATRT) involving the central nervous system and 21 cases of extrarenal extracranial rhabdoid tumor (EERT). Fifteen (15/35, 42.86%) patients of MRTK and five (5/21, 23.81%) patients of EERT had distant stage according to the Surveillance, Epidemiology, and End Results (SEER) staging system at diagnosis, whereas all patients of ATRT had localized or regional tumors. Among the 61 patients in this study, 47 (77.05%) patients died, 10 (16.39%) patients survived and four patients (6.56%) lost to follow‐up. Among the 47 dead patients, 44 patients died of disease rapid progression or tumor recurrence. Forty‐five patients (45/47) died within 10 months after the diagnosis and the overall survival rates of three years and five years for the entire cohort were 19.64% and 15.28%, respectively. Those patients of male, younger age at diagnosis, and distant SEER stage had poor outcomes. Statistically significant differences in survival were noted among patients treated with regular chemotherapy and radiotherapy.

**Conclusions**: MRT is still a highly aggressive tumor in children. Patients of male, younger age and metastatic disease were most likely to have a poor outcome due to the rapid progression or recurrence of tumor. Multimodal therapy that combined with surgery, chemotherapy, and radiotherapy was recommended. Consolidation with radiotherapy may benefit patients.

### PO-646. Langerhans Cell Histiocytosis: Response to Cladribine‐ Cytosine Arabinoside in a Rural Cancer Centre: A Case Report {#pbc27455-sec-8820}

[P. Chitalkar]{.ul} ^1^, C.D. Yadlapalli^2^, A. Punia^2^, A. Varma^2^

*^1^Director SAIMS Cancer Centre, Department of Medical & Pediatric Oncology, Indore, India; ^2^SAIMS, Medical Oncology, Indore, India*

**Background/Objectives**: Langerhans cell histiocytosis(LCH) presents a spectrum of clinical manifestations from single bone lesion or skin rash to an explosive disseminated disease. Evaluation of pathologic dendritic cells in blood and bone marrow has proven that LCH is caused by myeloid dendritic cells with activation of the RAS pathway. There is evidence to suggest that cladribine in combination with cytosar has activity in advanced LCH. Other agents which have shown activity are bortezomib with lenalidomide. However evidence is lacking for safety and efficacy of proteosome inhibitors and immunomodulators in children. We report the case of a child from rural Western Madhya Pradesh (India).

**Design/Methods**: We describe an eight year old child who presented with advanced multisystem LCH after a 3‐year loss to follow up, and achieved a major response to cladribine‐cytosar induction.

**Results**: DK residing in village 200 km away, developed nail changes and itching and rash at age 3 years, diagnosed as LCH, and treated with induction phase vinblastine, prednisone, 6‐MP for 6 months. Lost to follow‐up for 3 years and presented with bulging of right eyeball with vision loss in December 2016. MRI was suggestive of diffuse expansion of cranio‐facial bones with soft tissue along posterio‐lateral wall of right orbit causing axial proptosis. On further work‐up, found to be having hepatic and skin (multisystem) LCH. Treated with 4 cycles of cladribine(5mg/m2) and cytosar(100mg/m2) for 5 days every 28 days as induction, he achieved significant relief of proptosis and healing of cranial bone lesions. This was followed by maintainance: three‐weekly vinblastine(6mg/m2), five days of prednisone(40mg/m2) and six days of purinethol per week. The child remains in major partial response with good quality of life, seventeen months into his treatment.

**Conclusions**: This case represents multisystem involvement by Langerhans cell histiocytosis. In advanced cases with CNS involvement, Cladribine ‐cytosar is an active combination.

### PO-647. Lung Carcinoma in Children and Adolescents: Role of Genetic Analysis {#pbc27455-sec-8830}

[C.F. Classen]{.ul} ^1^

*^1^Oncology Hematology, University Childrens Hospital, Rostock, Germany*

**Background/Objectives**: Lung carcinoma is extremely rare in children and adolescents. Both therapy and prognosis depend on histological subtype and stage but in the era of targeted therapy, molecular understanding is essential.

**Design/Methods**: Between 2008 and 2018, 3 pediatric patients with lung carcinomas were diagnosed at the University Childrens Hospital, Rostock. In each, an inoperable primary tumor and metastases were found. However, treatments and outcomes were completely different, depending on disease subtype.

**Results**: The first patient was a 16‐year‐old caucasian male with squamous cell non‐small cell lung carcinoma T4N2M1c, without EGFR overexpression or k‐ras mutation. He presented with paraplegia due to spinal metastases. Treatment following adult protocols included first‐line cisplatinum/gemcitabine, irradiation and second‐line docetaxel. After transient response the patient experienced progression and died after 6 months. The second patient was a 17‐year‐old caucasian male with papillary lung adenocarcinoma T4N2M1a, presenting with pain and hematothorax, and pulmonary metastases. Biopsy showed no specific genetic marker or mutation. A palliative therapy was initiated with cisplatinum/pemetrexed/bevacizumab, leading to tumor reduction. After gross tumor resection and multiple further chemotherapy, the patient has prolonged stable disease with good quality of life, now 3 years after diagnosis. The third patient, an 11‐year‐old caucasian male, presented with a large tumor of the upper pulmonary lobe, T4N3M1c, with numerous sceletal metastases. Lymph node biopsy showed a NUT carcinoma. Polychemotherapy was initiated, following recently published observations; yet it is too early to comment on outcome. None of our patients showed an established drugable molecular target; the first patient had been treated before the checkpoint inhibition era.

**Conclusions**: Lung carcinomas are very rare in children and adolescents, however, may manifest with extended stages. Therapy should follow recommendations for adults, depending on molecular genetics. However, subtypes like NUT carcinoma that are rare in adults, should be considered, requiring specifical treatment approaches.

### PO-648. Comprehensive Molecular Analyses Reveal SMARCB1‐ and SMARC4‐Deficient Rhabdoid Tumors as a Single and Homogenous Entity {#pbc27455-sec-8840}
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**Background/Objectives**: Rhabdoid tumors (RTs) exhibit biallelic inactivation of *SMARCB1*, a core member of the SWI/SNF complex, with no other genetic abnormality. Rare RTs present a retained expression of SMARCB1, but a loss of SMARCA4, another core subunit of this complex. Whether SMARCB1‐ and SMARCA4‐deficient RTs are a homogenous entity has never been deeply addressed so far. We aimed to answer this question by a comprehensive analysis of the biological features of SMARCA4‐deficient RTs.

**Design/Methods**: We identified 5 patients with extra‐cranial SMARCA4‐deficient rhabdoid tumors. Biological features were assessed by Whole Exome Sequencing, RNAseq and methylome arrays (Illumina 850 K). SMARCA4‐deficient RT were compared with a cohort of SMARCB1‐deficient RTs (n=16), SMARCB1‐deficient non RTs (n=24) and other pediatric cancers (n= 132). Several clustering methods were applied to determine the biological homogeneity of RTs.

**Results**: Median age at diagnosis was 11.5 months (range 11‐36 months); no familial history of cancer was reported. Tumors were located in the kidney (n=2), the bladder, the soft tissues and the thorax, and showed no regional or metastatic extension. All patients were refractory to treatment or relapsed within the 2 years after diagnosis and died within 3 years. Constitutional DNA was available for 3 patients and all had germline alterations of *SMARCA4*. Genomic analysis showed that SMARCA4‐deficient RTs have no copy number variation apart from chromosome 19; we also noticed a very low mutation rate, comparable to SMARCB1‐deficient RTs, with no recurrent mutation other than *SMARCA4*. Clustering methods using RNAseq and methylome profiling across all pediatric cancer showed that SMARCA4‐deficient RT didn\'t clusterize separately from SMARCB1‐deficient RTs.

**Conclusions**: SMARCA4‐deficient RTs are equally aggressive as SMARCB1‐deficient RTs. Consistently, our multi‐omic approach reveals that SMARCA4‐ and SMARCB1‐deficient RTs have highly similar features. Functional analyses on cell lines are ongoing to address the extent of redundancy of SMARCB1 and SMARCA4 loss in the rhabdoid context.

### PO-649. Colorectal Carcinoma in Children and Adolescents Leading LMIC Experience from Children Cancer Hospital of Egypt {#pbc27455-sec-8850}

A. Hamoda^1^, [A. elhemaly]{.ul} ^1^, W. zekri^1^, S. ahmed^2^, G. ahmed^3^, A. younes^4^, I. zaky^5^, A. elnashar^6^, M. adly^6^

*^1^national cancer institute‐cairo university and children cancer hospital of egypy, pediatric oncology, cairo, Egypt; ^2^aswan university and children cancer hospital of egypt, radiotherapy, cairo, Egypt; ^3^national canser institute‐cairo university and childrean canser hospital of egypt, surgical oncology, cairo, Egypt; ^4^national cancer institute‐cairo university and children cancer hospital of egypy, surgical oncology, cairo, Egypt; ^5^national cancer institute‐cairo university and children cancer hospital of egypy, radiodiagnosis, cairo, Egypt; ^6^children cancer hospital of egypt, clinical research, cairo, Egypt*

**Background/Objectives**: Colorectal carcinoma (CRC) is common in adults, but extremely rare in children and presents with a poor prognosis. Surgical management and long‐term follow‐up of this entity are still obscure because of lack of data. The study aimed to evaluate the clinical characteristics of childhood CRC and determining the predictors of poor outcome.

**Design/Methods**: This study was retrospectively done on a group of 15 cases less than 18 years of age with median age of 15 years treated in Children\'s Cancer Hospital of Egypt in the period between, 2007‐2016. All patients had unfavorable CRC histopathology types (mucinous adenocarcinoma) and 10 cases had metastatic disease at presentation. Initial surgical resection was complete in 8/15 cases, and all patients received adjuvant chemotherapy. Four patients were diagnosed with rectal adenocarcinoma and all were treated with upfront chemo‐radiotherapy. Patient\'s informations included age, sex, predisposing factors, positive family history, clinical characteristics, diagnostic procedures, extent of disease, treatment methods, histological types, and outcome were collected from files after patients approval.

**Results**: 10/15 patients had tumor progression or relapse, and 12/15 died of their tumor: overall survival (OS) and event free survival (EFS) for all cases was 17.8 % and 16.5 % respectively at 3 years. Two cases out of 4 rectal cases had progressive disease and died. Family history was positive in 3 cases; 2 cases had both predisposing syndrome (Adenomatous Familial polyposis) and Neurofibromatosis type 1 (NF1) and one case had NF1 syndrome only.

**Conclusions**: Delayed diagnosis, advanced stages of disease, and, most importantly, mucinous type of histology are the major determinants of poor outcome in childhood colorectal carcinoma. Surgery remains the mainstay of treatment of pediatric CRC as in adults. Preoperative radiotherapy for rectal adenocarcinoma, offers better prognosis. Chemotherapy plays role in the metastatic disease and is able to down stage the primary tumor for better local control.

### PO-650. Needs Assessment of Histiocytosis Physicians in Asia and the Middle East: Results of An "AME‐ Histio Network" Questionnaire {#pbc27455-sec-8860}

[R. Farah]{.ul} ^1^, A. Naqvi^2^, Z. Wang^3^, W. Lai^3^, R. Dalu^4^, J. Zhang^3^, M. Ashraf^5^, I. Kventsil^6^, J. Cao^7^, Y. Zhao^8^, D. Urang^8^, S. Shamji^9^, A. Morimato^10^, F. Al Anzi^11^, M. Weintraub^12^, X. Shi^7^, A. Tojo^13^, M. Kobayashi^13^, E. Ishii^14^, J. Yacobovich^15^, M. Golan^6^, Y. Sun^8^, J. Li^7^, Y. Shioda^16^, I. Morakani^17^, P. Zhao^3^, R. Zhang^8^, D. Luo^7^, J.J. Seo^18^, G. Bahoush^19^, T. Al‐Harbi^20^, A. Ahmad^21^, R. Raza^26^, Z. Fadoo^27^, Y.J. Gao^28^, S.Y. Soh^22^, C. Rodriguez‐Galindo^23^, S. Ladisch^24^, G. Janka^25^, Oussama Abla on behalf of the Asian and Middle Eastern ‐ AME ‐ Histiocytosis Network^2^

*^1^Saint George Hospital University Medical Center, Department of Pediatrics, Beirut, Lebanon; ^2^Hospital for Sick Children, Division of Hematology/Oncology‐ Department of Pediatrics, Toronta, Canada; ^3^Beijing Friendship Hospital, Beijing, China; ^4^Bombay Hospital Institute of Medical Sciences, Mumbai, India; ^5^Indus Medical Center, Karachi, Pakistan; ^6^Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel; ^7^Capital Institute of Pediatrics, Beijing, China; ^8^Beijing Children\'s Hospital, Beijing, China; ^9^Shahid Behesho Medical University, Iran; ^10^Jichi Medical University, Japan; ^11^Prince Faisal Cancer Center, Kingdom of Saudi Arabia; ^12^Hadassah Medical Center, Israel; ^13^Institute of Medical Science, University of Tokyo, Tokyo, Japan; ^14^Ehime University, Tokyo, Japan; ^15^Schneider Childrens\' Medical Center, Israel; ^16^National Center for Child Health and Development, Tokyo, Japan; ^17^Kochi University, Japan; ^18^Asan Medical Center, Seoul, Korea; ^19^Ali‐Asghar Children\'s Hospital, Iran University of Medical Sciences, Tehran, Iran; ^20^King Abdulaziz Medical City, Kingdom of Saudi Arabia; ^21^The Children\'s Hospital & the Institute of Child Health, Lahore, Pakistan; ^22^KK Women\'s and Children\'s Hospital, Singapore; ^23^St Jude Children\'s Research Hospital, Tennessee, United States of America; ^24^Children\'s National Medical Center, District of Columbia, United States of America; ^25^Children\'s University Hospital, Germany; ^26^The Indus Cancer Children Hospital, Karachi, Pakistan; ^27^Aga Khan Hospital, Karachi, Pakistan; ^28^Shanghai Children\'s Medical Center, Shanghai, China*

**Background/Objectives: Background**: Histiocytic disorders can present with a wide range of clinical manifestations and severity. Data on the needs of physicians looking after such patients in Asia and the Middle East (AME) is lacking. A group of experts from these regions convened during the 2016 Histiocyte Society meeting, and created the "AME Histio Network".

**Objectives**: To assess the challenges that physicians from AME encounter when treating patients with histiocytic disorders, with regards to diagnosis and treatment, availability of molecular/genetic testing, and to assess the existence of national consensus guidelines.

**Design/Methods: Methods**: A 15‐item questionnaire was distributed. Questions included: the presence of national registries and patient support groups, availability of specialized diagnostic testing, and existence of treatment guidelines.

**Results**: Thirty‐five participants from ten countries responded. Most did not have a national histiocytosis association, a parent support group, or a histiocytosis registry. Specialized imaging studies were available in almost all centers, while sophisticated genetic/molecular testing such as *BRAF‐V600E* and HLH genetic testing were lacking in many institutions. Most centers have adopted the International LCH and HLH treatment protocols, and most did not have difficulty finding the most common histiocytosis chemotherapy drugs. Novel drugs such as cladribine, clofarabine and BRAF‐inhibitors were not readily available in many centers. There was a great interest in participating in national registries, clinical trials, genetic/molecular studies and in exchanging information and resources. Due to the heterogeneity of participating countries, priorities and expectations varied depending on the country and its available resources.

**Conclusions**: The lack of national histiocytosis associations, parent organizations, and treatment guidelines were noted by most participants. The diagnostic and treatment challenges varied among different countries due to economic, rather than geographic, reasons. Establishing international training scholarships to support physicians from countries with limited resources, and partnerships between centers could be the first steps in facing these challenges.

### PO-651. Prognostic Value of Plasma Epstein‐Barr Viral Deoxyribonucleic Acid in Children and Adolescents with Nasopharyngeal Carcinoma in a Non‐Endemic Region {#pbc27455-sec-8870}

[A. Farrag]{.ul} ^1,2^, W. Puppe^3^, C. Schmitt^3^, S. Franzen^1^, U. Kontny^1^

*^1^Medical Faculty‐ RWTH Aachen University Hospital, Division of Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Aachen, Germany; ^2^South Egypt Cancer Institute‐ Assiut University, Pediatric Oncology Department, Assiut, Egypt; ^3^Medical School Hannover, Institute of Virology, Hannover, Germany*

**Background/Objectives**: In endemic areas, almost all cases of nasopharyngeal carcinoma (NPC) are linked to infection with Epstein‐Barr virus (EBV). Here, we aimed to investigate the relationship between plasma EBV‐DNA and anti‐EBV‐VCA IgA antibodies with clinical parameters in children and adolescents with NPC in a non‐endemic area.

**Design/Methods**: Data of all patients with NPC registered between 1984 and 2017 at the NPC study center of the German Society of Pediatric Oncology and Hematology (GPOH) at Aachen University Hospital were analyzed retrospectively. Parameters analyzed included: patient\'s age, gender, stage of disease, status and level of plasma EBV‐DNA and anti‐EBV‐VCA IgA at time of diagnosis and at end of therapy, duration of follow up and outcome.

**Results**: One hundred sixty‐five patients were included in this study. Median age at diagnosis was 14.4 years. Male: female=1.5:1.0. Median duration of follow up was 5.4 years. About 81% (n=134), and 13% (n=22) of patients had stage IV, and III at time of diagnosis, respectively. At the time of the analysis, 143 (87%) patients were alive. Pretreatment plasma EBV‐DNA levels were available in 74 patients, and were positive in 41 patients (55.4%), while anti‐EBV‐VCA IgA was done in 78 patients, and was positive in 62 patients (79.5%). Median plasma EBV‐DNA level at diagnosis was 1,600 copies/ml in EBV‐positive patients with stage IV disease vs. 314 copies/ml for patients with other stages, and was 23,555 copies/ml in patients with relapse/disease progression vs. 1,600 copies/ml in others. Detection of EBV‐DNA at the end of treatment was associated with a higher incidence of relapse (50%) (p= 0.003) and mortality (40%) (p= 0.005).

**Conclusions**: Levels of plasma EBV‐DNA at diagnosis in children and adolescents with NPC correlate with disease stage. High levels of plasma EBV‐DNA at diagnosis and continuous detection at the end of treatment are both predictors of relapse and poor outcome.

### PO-652. Desmoid Type Fibromatosis (DF): A 15‐Years Experience at a Single Pediatric Institution in Argentina {#pbc27455-sec-8880}

[D. Fortunati]{.ul} ^1^, J. Kaplan^2^, A. Ponzone^3^, Y. Lenz^4^, J. López Martí^5^, S. Innocenti^3^, S. Fiscina^3^, W. Cacciavillano^1^, G. Felizzia^1^, P. Zubizarreta^1^, A. Rose^1^

*^1^Hospital Nacional de Pediatría J. P. Garrahan, Hematology and Oncology, Buenos Aires, Argentina; ^2^Hospital Nacional de Pediatría J. P. Garrahan, Radiology, Buenos Aires, Argentina; ^3^Hospital Nacional de Pediatría J. P. Garrahan, Orthopedics and Traumatology, Buenos Aires, Argentina; ^4^Hospital Nacional de Pediatría J. P. Garrahan, Surgery, Buenos Aires, Argentina; ^5^Hospital Nacional de Pediatría J. P. Garrahan, Pathology, Buenos Aires, Argentina*

**Background/Objectives**: DF is a rare tumor of intermediate malignancy, locally invasive, with a high rate of local relapse (LR), and 10‐year survival rate \>90%. Although surgery has been considered the mainstay of treatment, current recommendations include a front‐line conservative approach in stable tumors. Our aim was to describe the clinical features and outcome of patients with DF.

**Design/Methods**: Retrospective study of 16 patients with 18 tumors with DF admitted to our Institution between January\'02 and January\'17, treated since 2005 according to EpSSGnonRMS2005 Protocol.

**Results**: Median age at diagnosis was 11.5 years (0.25‐16), median time to diagnosis was 216 days (28‐2487).The most frequent symptom was tumor (75%).Two patients had Gardner\'s syndrome. The tumor sites were trunk and limbs (37.5% respectively), abdomen and pelvis and head&neck (12.5% respectively). Tumors were multifocal in 2 patients. Primary surgery was performed in 13/18 tumors (72%), with complete resection in 6 (46%) being 1 IRS I and 5 IRS II. LR occurred in 10/13 (including IRS I). Median time to recurrence was 4.5 months (4‐9). Low Dose Chemotherapy (LDC) with Metotrexate/Vinblastine was given to 11 patients with 13 tumors. At least partial response was evident in 6 tumors, 3 tumors had stable disease, 2 tumors showed progressive disease; (2 tumors had complete remission with initial surgery). No major toxicity was observed. All patients are alive, except one who had lost follow‐up and died due to progressive disease. Eleven of 15 patients (73%) presented sequelae; the most frequent were mobilitylimitation and keloid scars. The 10‐year progression‐free survival and overall survival were 40% and 93.7%, respectively.

**Conclusions**: DF is a locally aggressive disease, with high LR rate, regardless of surgical margins, with an excellent survival rate in our series. The LDC allows to achieve stability and even remission with low toxicity and could decrease the risk of surgical sequelae.

### PO-653. Results of Chemoradiotherapy of Nasopharyngeal Cancer in Young Patients {#pbc27455-sec-8890}

[T. Gorbunova]{.ul} ^1^

*^1^N.N. Blokhin National Medical Research Center of Oncology, sergery of head and neak, Moscow, Russia*

**Background/Objectives**: Nasopharyngeal cancer (NC) is a rare malignant epithelial tumor in children. The disease is more often registered in boys 10‐17 years. The undifferentiated histological variant of NC predominates. Overall 5‐year survival rate is 70‐90% for young patients with localized stages and with disseminated ones does not exceed 10‐25%.

**Objective**: to report the results of treatment of nasopharyngeal cancer in pediatric patients

**Design/Methods**: The study included 47 patients with a follow‐up period from 2001 to 2017. Among the sick, boys predominated ‐ 28 (59.6%). The average age of boys is 13.1 g, girls ‐ 14.4 g. The undifferentiated version of NC is verified in 81.9% of cases. Common stages of NC (III‐IV) were detected in 87.1% of patients, among them distant metastases were detected in 19.2%. The study of antibodies to antigens of the Epstein‐Barr virus was carried out in 42.6% of patients. Chemotherapy included drugs: bleomycin, cyclophosphamide, doxorubicin, vinblastine, fluorouracil, cisplatin, dactinomycin. An average of 8 courses of HT. Radiation therapy in SOD 50‐60 Gy on the nasopharynx and lymph nodes of the neck, in 7 (14.9%) areas of distant metastasis were irradiated. On a background of special treatment, immunotherapy was performed in 31.9%.

**Results**: The median follow‐up after treatment was 32 months. Relapses arose in 17.0% as a localized tumor, dissemination of the process in 4.3%. Anti‐relapse therapy was carried out in 12.8% of them for 1 patient with local and disseminated relapse NC. Live without signs of a tumor, 80.1%, including 2 with disseminated NC. Eliminated 8.5%, died of a progression of 17.0%, from the causes not related to the underlying disease 2.1%.

**Conclusions**: Carrying out of further researches will allow establishing the most rational combination of chemotherapy, radiation and immune therapy for yang patients with NC.

### PO-654. Treatment for Abdominal Inflammatory Myofibroblastic Tumor in Children: An Analysis of Twelve Years of Experience {#pbc27455-sec-8900}

[J. Hu]{.ul} ^1^, H. Wang^1^, X. Chang^1^, J. Xu^2^

*^1^National Center for Children\'s Health Beijing‐ Beijing Children\'s Hospital‐ Capital Medical University, surgical oncology, Beijing, China; ^2^National Center for Children\'s Health Beijing‐ Beijing Children\'s Hospital‐ Capital Medical University, pathology department, Beijing, China*

**Background/Objectives**: Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm with low incidence. This paper aims at studying the clinical characteristics and treatment of abdominal inflammatory myofibroblastic tumor (AIMT) in children.

**Design/Methods**: This study evaluated the pediatric patients who were diagnosed with AIMT between January 2006 and January 2018, by reviewing the medical records and follow‐up data.

**Results**: The study population are 17 males and 13 females with onset ages ranging from 1 to 156 months, median 51.5 months. 2 cases had diffused abdominal lesions, the remaining tumors were solitary. There were 12 tumors occurring in the urinary system including bladder (n=9), kidney (n=2), ureter (n=1), accompanied by symptoms like hematuria, frequent urination, painful urination. There were 11 tumors occurring in mesentery (n=7), greater omentum (n=3) and mesorectum (n=1), which initially led to fever, anemia, intussusception, dysuria and difficulty in defecation. 2 tumors occurred in retroperitoneal space, representing as obstructive jaundice and abdominal enlargement. One tumor from the head of the pancreas also led to jaundice, while the other two from the liver led to abdominal distention and fever. All cases were examined by ultrasound and CT. Most of them were rich in blood flow and enhanced during the intensive phase. 28 cases underwent resections and open surgeries including a nephrectomy, a pancreatoduodenectomy and five enterectomies. The two children with diffused abdominal lesions respectively underwent 4 operations and 6∼10 courses of postoperative chemotherapy. The tumor cells were fusiform with inflammatory cell infiltrate. Finally, three cases were lost to follow‐up, an infant died of infections in 4 months after surgery, 26 cases were followed up for 4 to 29 months and survived, including one with diffused abdominal lesions.

**Conclusions**: IMT can occur in any abdominal region with diverse symptoms. Solitary lesions can be removed by operation. Further study for treating the diffused abdominal lesions is wanted.

### PO-655. Rapid Response to Crizotinib in 3‐Year‐Old Boy with ROS1‐Rearranged Inflammatory Myofibroblastic Tumor of the Stomach {#pbc27455-sec-8910}

A. Suleymanova^1^, E. Imyanitov^2^, V. Roschin^3^, T. Shamanskaya^1^, Y. Olshanskaya^4^, A. Kazakova^4^, N. Mitiushkina^2^, E. Preobrazhenskaya^2^, [D. Kachanov]{.ul} ^1^, S. Varfolomeeva^1^

*^1^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Clinical Oncology, Moscow, Russia; ^2^National Research Center of Oncology named after N.N Petrov, Cancer Biology, St.‐Petersburg, Russia; ^3^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Pathology, Moscow, Russia; ^4^National Research Center of Pediatric Hematology‐ Oncology and Immunology named after Dmitry Rogachev, Cytogenetics, Moscow, Russia*

**Background/Objectives**: Inflammatory myofibroblastic tumor (IMT) is a rare type of neoplasm in pediatric age group with intermediate biologic behavior.*ALK* gene rearrangements occur in 50% of ITM. In a large study (Lovly C.M., 2014) activation of *ROS1* gene was detected in 4/11 patients with *ALK*‐negative tumors. These findings serve as a basis to implement crizotinib in the group of *ROS1*‐rearranged IMT.

**Design/Methods**: 3‐year‐old boy presented with 2‐year history of chronic anemia. At the time of diagnosis growth retardation was noted as well as transfusion‐dependency. The laboratory tests showed elevation of inflammatory markers (CRP ‐ 233 mg/L, IL‐6 -- 202 pg/mL). Imaging findings demonstrated the presence of a large stomach mass (size 5,3х6,0х4,3 cm, V= 71 cm3). Biopsy was done and histopathology revealed IMT. There were negative ALK expression by immunohistochemistry (IHC) and no *ALK* rearrangements by fluorescence *in situ* hybridization (FISH). Real‐time polymerase chain reaction (RT‐PCR) revealed unbalanced expression of *ROS1* gene and detected *TFG‐ROS1* fusion. The tumor was deemed unresectable, that allowed us to start treatment with ALK/ROS1 inhibitor -- crizotinib. Crizotinib was given in dose 250 mg twice daily orally.

**Results**: Rapid response was detected during the first month of therapy, the volume of tumor decreased by 45% as well as inflammatory markers (CRP‐13,4 mg/L, IL‐6 -- 8,6 pg/mL). Also the patient\'s transfusion requirement progressively decreased. The body weight at the time of diagnosis was 11 kg, increase of the weight after 1 month of therapy was 2 kg. Inflammatory markers have reached the normal values after 3 month of therapy. No significant side effects were observed during therapy. The patient has now been on treatment for 5 months.

**Conclusions**: We present the patient with*ROS1*‐rearranged IMT with dramatic response to *ALK*/*ROS1* inhibitor crizotinib. This case demonstrates the necessity of more detailed analyses of ALK‐ negative IMT\'s to find additional druggable targets.

### PO-656. Single System‐Single Lesions of Langerhans Cell Histiocytosis in the Craniofacial Bones: Hacettepe Experience with 46 Children {#pbc27455-sec-8920}

[N. Kalkan]{.ul} ^1^, B. Yalcin^1^, İ. Bajin^1^, B. Aydin^1^, İ. Altan^1^, N. Kurucu^1^, A. Varan^1^, T. Kutluk^1^, C. Akyuz^1^

*^1^Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Involvement of craniofacial bones is common in Langerhans cell histiocytosis (LCH) and LCH in some particular craniofacial bones is regarded as "CNS‐risk lesions" and chemotherapy is commonly indicated. In this study, we aimed to review our institutional experience with children having isolated craniofacial LCH bone lesions.

**Design/Methods**: Hospital charts of children \<18 years of age diagnosed to have single‐isolated craniofacial bone LCH at our hospital were reviewed retrospectively. Data for demographic characteristics, presenting symptoms, diagnostic interventions, treatment approaches, follow‐up events and final outcome were collected and analyzed.

**Results**: Forty‐six cases were identified who were diagnosed at our department between January 1990 and December 2017 \[median age 9.2 years (1.2‐18), male/female 29/17\]. Most common symptoms were pain (24/46), swelling (21/46) and ptosis (1). Plain X‐rays were the most commonly utilized imaging modality followed by computerized tomography and magnetic resonance imaging. Primary sites of involvement were parietal (16), frontal (10), occipital (7), orbital (6), mandibular (6), temporal (1) bones. Surgical resection‐curettage was performed in 37/46 cases (80%), 7/46 patients received systemic chemotherapy and two required radiotherapy. Surgical resection‐curettage was performed mostly to cranial bones (parietal, occipital, frontal) (p=0.05); most other bone lesions underwent biopsy only. Among 8/46 cases considered to have "CNS risk lesions", all but one underwent surgery and none received chemotherapy. At a median of 52 months, 22/46 patients were lost to follow‐up and 24 were under regular follow‐up. Only one patient had recurrence of LCH in the tibia and was in second remission after chemotherapy. None of the cases experienced significant LCH related sequela.

**Conclusions**: Local control with surgical resection is mostly sufficient for single‐isolated bone lesions of craniofacial LCH, even with dura involvement. Eight cases with "CNS‐risk lesions" experienced no problems in the follow‐up despite no chemotherapy. The concept of "CNS‐risk lesions", especially for LCH orbital bone involvement should be revisited.

### PO-657. Extrarenal Rhabdoid Tumor Presented with Brachial Plexus Palsy in a Two‐Year‐Old Boy {#pbc27455-sec-8930}

[Z. Karakas]{.ul} ^1^, S. Ocak^1^, R. Tuna^1^, D. Tugcu^1^, S. Karaman^1^

*^1^Istanbul University‐ Istanbul Medical Faculty, Department of Pediatric Hematology‐Oncology, Istanbul, Turkey*

**Background/Objectives**: Extrarenal rhabdoid tumor (ERRT) is a very rare and aggressive tumor that mainly occurs in infants and children and may manifest with neurological symptoms when it involves peripheral nerves. Herein we report a boy with ERRT and brachial plexus palsy

**Design/Methods**: A two‐year‐old boy was admitted with new onset immobility of the left arm. Physical examination was consistent with brachial plexus palsy and axillary mass. Contrast enhanced MRI revealed a solid infiltrative mass arising from left axillary fossa reaching to supraclavicular fossa, encircling vascular and neural bundle. Pathologic examination of biopsy was reported to be Ewing sarcoma. Thorax CT and PET‐CT was negative for any metastases. Alternative courses of IE and VAC was scheduled. During the fourth course, MRI was repeated due to left shoulder pain and swelling. Progression of the residual mass was documented. A subtotal resection of the mass was performed and pathologic examination was reported as malignant rhabdoid tumor. With changing diagnosis, local radiotherapy and second line chemotherapy was started. He is still on chemotherapy with partial regression in the mass.

**Results**: ERRT is a rare aggressive soft tissue sarcoma with a great diagnostic and therapeutic challenge. The tumor was usually located in head‐neck region, and total resection is not possible in most cases due to local infiltrative pattern. In literature, similar to our patient, two more cases with brachial plexus involvement of ERRT was reported.

**Conclusions**: In small children malignant rhabdoid tumor should be placed in the differential diagnosis of soft tissue sarcoma of the head‐neck region. Correct diagnosis and scheduling the aggressive local attempts are very important to increase the success of the treatment.

### PO-658. A Rare Neoplastic Disease of Childhood: Multifocal Epithelioid Hemangioendothelioma {#pbc27455-sec-8940}

[S. Karaman]{.ul} ^1^, Ö. Bayrak Demirel^2^, A. Özkan Karagenç^1^, S. Aydoğdu^1^, İ. Adaletli^3^, D. Tuğcu^1^, Z. Karakaş^1^

*^1^Istanbul University‐ Istanbul Faculty of Medicine, Pediatric Hematology, İstanbul, Turkey; ^2^Istanbul University‐ Istanbul Faculty of Medicine, Pediatrics, İstanbul, Turkey; ^3^Istanbul University‐ Cerrahpaşa Faculty of Medicine, Radiology, İstanbul, Turkey*

**Background/Objectives**: The management of epithelioid hemangioendothelioma (EHE) consists of surgical treatment, drug administration such as bevacizumab or follow‐up without treatment. We aimed to present a case of EHE who was managed by follow‐up without treatment.

**Design/Methods**: We, herein, introduced a 17‐year‐old girl in whom the diagnosis of epithelioid hemangioendothelioma was established incidentally. Immunohistochemical investigation revealed some endothelial specific markers including CD34 and CD31. Further detailed examination showed multiple metastatic lesions in the brain and both lungs. Regardless of the extent of metastatic lesions, follow‐up without treatment was preferred based on the patient\'s asymptomatic clinical status.

**Results**: At the third month, sixth month and first year control visits, the radiologic examination indicated stable multifocal epithelioid hemangioendothelioma with no new metastatic lesion.

**Conclusions**: Physicians should be aware of that follow‐up without treatment can be rendered for patients with EHE who have asymptomatic clinical status.

### PO-659. A Rare Case of Diaphragmatic Congenital Hemangioma with Massive Pleural Effusion {#pbc27455-sec-8950}

[M. Kawasaki]{.ul} ^1^, M. Kanno^1^, N. Kawasaki^1^, Y. Uemura^1^, T. Meguro^1^, H. Sato^1^, R. Ishigaki^1^, T. Otagiri^1^, M. Abiko^1^, T. Takahashi^1^, K. Suzuki^1^, T. Fujii^1^, T. Mitsui^1^, T. Abe^2^, M. Nakamura^2^, H. Ohizumi^2^, M. Sadahiro^2^, Y. Toyoguchi^3^, F. Watarai^3^, N. Kenji^3^, R. Ohe^4^, M. Yamakawa^4^, Y. Hori^5^, E. Mori^5^

*^1^Yamagata university, Pediatrics, Yamagata, Japan; ^2^Yamagata university, Second Department of Surgery, Yamagata, Japan; ^3^Yamagata university, Radiology, Yamagata, Japan; ^4^Yamagata university, Pathological Diagnostics, Yamagata, Japan; ^5^Osaka University Graduate School of Medicine, Pathology, Osaka, Japan*

**Background/Objectives**: Congenital hemangioma (CH) are rare benign vascular tumors that proliferate in utero. Most of them occur at cutaneous, diaphragmatic lesion is very rare. Although pathological examination is important to exclude aggressive tumor, biopsy for diaphragmatic lesion is difficult for abundance of blood flow.

**Design/Methods**: We here describe a case of neonate presenting with diaphragmatic CH accompanied by massive pleural effusion. He received biopsy safely with prior embolization of feeder vessels.

**Results**: A five‐day‐old newborn male was admitted to a local hospital due to cyanosis. Truncal CT scan revealed massive pleural effusion with large tumor along with right diaphragm. The tumor extended to liver to epicardium. Continuous drainage of plural effusion was required to enough breathing. Thoracic MRI showed slight T2 hypo intensity mass that was contrasted well. An open chest biopsy after embolization of tumor feeder vessels was done. The lesion was consisted of nodular or lobular capillary vessels with negative for GLUT‐1. The diagnosis of CH was made. His pleural effusion subsided after one month. The tumor shows reduction in size and he is now in six−month‐old infant with no particular symptom.

**Conclusions**: There are only six neonatal diaphragmatic CH described in the literature. This case is the first case diagnosed pathologically by biopsy with tumor feeding vessel embolization. Prior feeding vessel embolization is efficacious for safe biopsy for accurate diagnosis.

### PO-660. Nasopharengeal Carcinoma in Children and Adolescents 1990‐2018: Demographic, Clinical, Therapeutical Characteristics and Long Term Outcome of 97 Patients in a Single Institution {#pbc27455-sec-8960}

[R. Kebudi]{.ul} ^1^, M. Altun^2^, S. Büyükkapu Bay^3^, O. Görgün^1^, I. Ayan^3^, R. Meral^2^, B. Zulfikar^1^, F.Y. Agaoglu^2^, E. Darendeliler^2^

*^1^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^Istanbul University Oncology Institute, Radiation Oncology, Istanbul, Turkey; ^3^Istanbul University Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey*

**Background/Objectives**: The aim of this study is to evaluate the demographic, clinical and therapeutic characteristics and long‐term outcome in childhood and adolescent nasopharyngeal carcinoma (NPC) in a single center.

**Design/Methods**: From January 1990 to January 2018 the files of 97 patients \< 18 years with NPC, treated in Istanbul University Oncology Institute were evaluated retrospectively. All patients received three courses of neoadjuvant chemotherapy (1990‐1994; cisplatinum‐based regimens; 1995‐2008: Bleomycin, epirubicin and cisplatinum‐ BEP; since 2008‐:EP) followed by radiotherapy given both to the primary tumor and to the metastatic cervical lymph nodes

**Results**: Sixty‐nine boys and 28 girls (M:F = 2.5) with a median age of 14 yrs (6‐18), presented mostly with a lump in the neck, headache, and ear and nose problems. Median follow‐up was 83 months (1month‐26.6 years). Ninety % of the biopsies of NPC were WHO type III tumors. Most patients had advanced stage tumors, 5 had distant metastatis. Chemotherapy was followed with radiotherapy 60‐66 Gy to the primary tumor and involved lymph nodes, and 50‐54Gy to the cervical nodal region. The 10‐year overall survival (OS) was 78.9 %. There was no significant difference in survival in patients who received BEP or EP. Seventeen patients died, 2 with accident/suicide, 3 with second primary cancer, 12 with progressive disease. Seven second malignancies developed in six patients. Late effects included hypothyroidism, neck fibrosis, xerostomia, bony hypoplasia, skin problems and hearing loss.

**Conclusions**: Children and adolescents with advanced NPC treated with neoadjuvant chemotherapy and radiotherapy have a high locoregional control rate and much higher long‐term survival (OS 78 % vs 46‐58 %) than the OS reported in our center before 1990\'s when most recieved only radiotherapy or radiotherapy and adjuvant chemotherapy. Neoadjuvant therapy with EP chemotherapy seems to be as effective as BEP. Survivors should be followed for long‐term morbidities.

### PO-661. Pleuropulmonary Blastoma: A Retrospective Single Institution Experience of a Rare Malignancy {#pbc27455-sec-8970}

[N. Khanna]{.ul} ^1^, J. Bhatia^1^, M. Prasad^2^, G. Chinnaswamy^2^, T. Vora^2^, A. Shah^3^, M. Ramadwar^3^, B. Rekhi^3^, S. Qureshi^4^, S. Kembhavi^5^, S. Shah^6^, S. Laskar^1^

*^1^Tata Memorial Hospital, Radiation Oncology, Mumbai, India; ^2^Tata Memorial Hospital, Medical Oncology, Mumbai, India; ^3^Tata Memorial Hospital, Surgical Pathology, Mumbai, India; ^4^Tata Memorial Hospital, Surgical Oncology, Mumbai, India; ^5^Tata Memorial Hospital, Diagnostic Radiology, Mumbai, India; ^6^Tata Memorial Hospital, Nuclear Medicine, Mumbai, India*

**Background/Objectives**: Pleuropulmonary blastoma (PPB) is a rare and aggressive neoplasm of childhood arising from the pleuropulmonary mesenchyme. We evaluate the clinico‐patho‐radiological profile, treatment response and over‐all outcome for patients with PPB treated at the Tata Memorial Hospital (TMH).

**Design/Methods**: All patients with histologically confirmed PPB were retrospectively analyzed.

**Results**: Between December 2004 & March 2017, 19 patients (11 males) with histologically proven PPB in the age group of 2 to 22 years (Median 4 years) were evaluated at TMH. Clinico‐radiological and treatment details were available for 14 patients. Mean tumor size in this cohort was 8.3cm (Range 5.3--17.7cm). Presence of pleural effusion and intrathoracic nodes was observed in 5 (42%) and 2 (17%) patients, respectively. All of them presented with locally extensive and type II/III disease. Curative intent treatment was offered to 11 patients and all of them received intensive multi‐agent chemotherapy. Six (55%) patients progressed on induction chemotherapy and hence, did not undergo local treatment. Local treatment was offered to only 5 (45%) patients in the form of surgery followed by adjuvant radiotherapy to 3 patients, whereas 2 patients received definitive radiotherapy alone. At the time of last follow up only 4 (36%) patients were alive and disease free. All patients with progressive disease on chemotherapy and not receiving local treatment died of disease progression. Of the 5 patients receiving local treatment, only 1 died of early local relapse. The 2‐year and 3‐year over‐all survival of the entire cohort was 45% and 30%, respectively. The choice of local treatment did not have an impact on the outcome.

**Conclusions**: PPB is associated with dismal outcome. Patients responding to induction chemotherapy and receiving local treatment have better survival. These findings warrant development of new and aggressive strategies in the management of this rare neoplasm.

### PO-662. Pregnancy Associated Breast Cancer in Young Adolescent: An Institutional Analysis from Developing Country {#pbc27455-sec-8980}

[P. Khullar]{.ul} ^1^, A. Thakwani^2^

*^1^Batra hospital and research institute, Radiation Oncology, New Delhi, India; ^2^Batra hospital and research institute, Radiation Oncology, New Delhi, India*

**Background/Objectives**: Pregnancy‐associated breast cancer (PABC) has been defined as breast cancer diagnosed during pregnancy or within 1 year of delivery. There is a paucity of data on PABC from India. The aim of our study was to assess the clinical‐pathological parameters and outcome of PABC at our centre

**Design/Methods**: We screened 4900 breast cancer cases registered from January 2006 to December 2016 and found 41 cases of PABC.

**Results**: The median age was 21 years (range 18‐25). The median duration of symptoms was 6 months and median tumor size was 5.5 c.m. The American Joint Committee on Cancer stage distribution was Stage I ‐ 1, Stage II ‐ 3, Stage III ‐ 26 and in Stage IV ‐ 11 patients. Seven patients were presented with the inflammatory breast cancer. Positive family history was elicited in fifteen patients and BRCA 1 & 2 mutation were found in 7 cases. Twenty‐one patients were diagnosed after delivery, 4 patients in the first trimester, 6 patients in the second trimester and 10 patients in the third trimester. Estrogen receptor (ER), progesterone receptor (PR) positivity and human epidermal growth factor receptor 2 (HER2/neu) positivity was 45% and 38% and 40%, respectively. Triple negativity was found in 38% of cases. Thirty patients had a high‐grade tumor and 80% had pathological node positivity. With a median follow‐up of 33 months, 3 years relapse free survival and overall survival was 35% and 50% respectively. Brain was the most common site for systemic relapse.

**Conclusions**: PABC constituted 0.8% of all breast cancer patients. It is associated with advanced stage at presentation. Outcome is poor in this group probably because of bad tumor biology. Triple negativity and HER2/neu positivity were found in 38% and 40% respectively.

### PO-663. Genetic Alterations and Their Clinical Implications in Langerhans Cell Histiocytosis {#pbc27455-sec-8990}

[K.N. Koh]{.ul} ^1^, S.M. Chun^2^, J.J. Kim^2^, S.Y. Min^1^, J.W. Yoo^1^, H. Kim^1^, H.J. Im^1^, H.M. Kim^3^, J.J. Seo^1^

*^1^Asan Medical Center Children\'s Hospital‐ University of Ulsan College of Medicine, Pediatrics, Seoul, Republic of Korea; ^2^Asan Medical Center‐ University of Ulsan College of Medicine, Pathology, Seoul, Republic of Korea; ^3^Wonju College of Medicine‐ Yonsei University, Pediatrics, Wonju, Republic of Korea*

**Background/Objectives**: MAPK pathway activation is known to be associated with oncogenesis of Langerhans cell histiocytosis (LCH). The purpose of this study was to investigate the frequency of genetic mutations and their correlation with clinical features and prognosis in Korean patients with LCH.

**Design/Methods**: Genomic DNA was extracted from formaldehyde‐fixed and paraffin‐embedded samples from patients who were pathologically confirmed with LCH and treated at Asan Medical Center. Profiling of somatic mutations for 41 critical genes related to tumor development was performed using OncoMap version 4.4‐Core under the MassARRAY technology platform (Sequenom, San Diego, CA).

**Results**: A total of 51 LCH cases were evaluated. A median age at diagnosis was 4.3 years (range, 0.1‐55.8 years), and male‐to‐female ratio was 0.8:1. Forty‐two patients had single system disease (23 with unifocal bone disease, 15 multifocal bone disease, 4 with skin disease), and 9 had multisystem disease (6 without risk organ involvement, and 6 with risk organ involvement. OncoMap assay revealed that 24 patients (47.1%) harbored *BRAF* mutation, and 16 (31.4%) *MAP2K1* mutation. One patient had both *BRAF* and *MAP2K1* mutations. Other recurrent mutations included *CHEK2* (n = 7), *ARID1B* (n = 6), and *NTRK1* (n = 2) mutations. The age at diagnosis and the presence of multisystem involvement did not differ according to genetic mutations. Patients with *BRAF* or *MAP2K1* mutations seemed to have more unifocal bone disease than patients without those mutations (*P* = 0.075). The 5‐year overall survival and relapse‐free survival (RFS) rates of all patients were 100% and 65.8%, respectively. RFS was not different according to genetic mutations.

**Conclusions**: Our study showed that *BRAF and MAP2K1* mutations can be frequently demonstrated in Korean patients with LCH. Our results suggest that mutation profiles were associated with organ involvement but did not predict the severity of the disease.

### PO-664. Interferon‐ß and Anti‐PD1/PD‐L1 Checkpoint Blocakde Cooperate in NK Cell‐Mediated Killing of Nasopharyngeal Carcinoma Cells {#pbc27455-sec-9000}

[U. Kontny]{.ul} ^1^, A. Makowska^1^, T. Braunschweig^2^, L. Shen^1^, B. Denecke^3^

*^1^RWTH University Medical Center, Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Aachen, Germany; ^2^RWTH University Medical Center, Pathology, Aachen, Germany; ^3^RWTH University Medical Center, Interdisciplinary Center for Clinical Research, Aachen, Germany*

**Background/Objectives**: Nasopharyngeal carcinoma (NPC) is a highly malignant epithelial cancer linked to EBV infection. Addition of interferon‐ß (IFNß) to chemo‐ and radiochemotherapy has led to survival rates \>90% in children and adolescents. As NPC cells are sensitive to apoptosis via tumor necrosis factor‐related apoptosis inducing ligand (TRAIL), we explored the role of the TRAIL pathway and IFNß in the killing of NPC cells by natural killer (NK) cells.

**Design/Methods**: Cells of different NPC cell lines and a nasoepithelial cell line used as control were exposed to NK cells of healthy donors in the presence or absence of IFNß. Cytotoxicity was measured by calcein assay, the role of different killing pathways of NK cells by using respective inhibitors, and regulation of death ligands and checkpoint modulators by RNAseq and flow cytometry.

**Results**: NK cells killed NPC‐ but not nasoepithelial cells and killing was predominately mediated via the TRAIL pathway. Incubation of NK cells with IFNß increased cytotoxicity against NPC cells. Concomitant incubation of NK‐ and NPC cells with IFNß before coculture reduced cytotoxicity and could be overcome by blocking the PD1/PD‐L1 axis.

**Conclusions**: The combination of IFNß and anti‐PD1, augmenting cytotoxicity of NK cells against NPC cells *in vitro*, could be a strategy to improve NPC‐directed therapy requiring further evaluation *in vivo*.

### PO-665. Clinical and Prognostic Course of Mexican Pediatric Patients with Rare Malignant Tumors. Report of the Cooperative Research Group on Pediatric Oncology. Sociedad Mexicana De Oncología {#pbc27455-sec-9010}

[N.A. Lopez‐Facundo]{.ul} ^1^, F. Arreguín^2^, M. Zapata^3^, L. Velasco^3^, D. Covarrubias^4^, E. Baños^2^, M. López^5^, D. Ortiz^6^, M. Aguilar^3^, L. Vega^7^, C. Simon^8^, I. Tejocote^9^, L. Garcia^10^, S. Cruz^11^

*^1^Hospital Materno Infantil del Instituto de Seguridad Social del Estado de México y Municipios, Pediatric Oncology, Toluca, Mexico; ^2^Instituto de Seguridad Social al Servicio de los Trabajadores del Estado, Pediatric Oncology, Ciudad de México, Mexico; ^3^Instituto Nacional de Pediatría, Pediatric Oncology, Ciudad de Mexico, Mexico; ^4^Centro Estatal de Oncología Dr Luis Gonzalez F, Pediatric Oncology, Campeche, Mexico; ^5^Hospital de Especialidades Pediatricas, Pediatric Oncology, Tuxtla Gutierrez, Mexico; ^6^Hospital General de Mexico, Pediatric Oncology, Ciudad de Mexico, Mexico; ^7^Hospital Infantil Teleton Oncologia, Pediatric Oncology, Queretaro, Mexico; ^8^Hospital Para el niño, Pediatric Oncology, Tabasco, Mexico; ^9^Hospital Para el Niño del Instituto Materno Infantil del Estado Mexico, Pediatric Oncology, Toluca, Mexico; ^10^hospital general de celaya, pediatric oncology, Celaya, Mexico; ^11^Hospital Para el Niño Poblano, pediatric oncology, Puebla, Mexico*

**Background/Objectives**: Rare malignant tumors make up 10% of all cancer in the pediatric age. The national and international cooperative projects will allow to understand their biology and improve the treatment results.

**Objective**: Know the clinical course and prognosis of Mexican pediatric patients with rare malignant tumors

**Design/Methods**: We designed a multicentric case series that included patients with rare malignant tumors in childhood according to sub‐group 11 of the international cancer classification in children. We evaluated clinical‐demographic characteristics: age, gender, main symptom and duration of this, histopathological diagnosis, stage, mortality by the received treatment and survival time. Descriptive statistics was performed. Survival was analyzed by the Kaplan‐Meier method

**Results**: 164 patients were evaluated, age 3 months to 17 years, 58% over 10 years. The time of evolution of symptoms prior to diagnosis from 7 days to 2 years, median of 6 months. The most frequent symptoms were pain and palpable mass. The predominant histological type was thyroid carcinoma (29%) followed by non‐germ gonadal tumors 9%, pancreatic exocrine tumors 10 (6%). 27% of our patients with metastatic disease at diagnosis. The basic treatment was surgery in 88%, 5% received only palliative treatment. 26 patients died due to progression and 10 due to toxicity. The follow‐up of 18.9% of the patients was lost due to abandonment or transfer to the adult hospital. The overall survival for all rare tumors was 63% at 90 months. Overall survival for thyroid carcinomas was 68% to 109 months

**Conclusions**: The systematic study of these patients is usually not possible. It is difficult to know the real incidence. They are staged and treated with protocols designed for adults. The majority of our patients are diagnosed in advanced stages. In our series, surgery is the cornerstone of treatment. Age constitutes an organizational barrier for the treatment and follow‐up of these patients in our country

### PO-666. The North American Pediatric Rare Tumor Registry: A Report on the First 70 Patients {#pbc27455-sec-9020}

[P. Mahajan]{.ul} ^1^, A. Roy^2^, J. Randall^1^, U. Ramamurthy^3^, R. Thiruvenkatam^1^, D.W. Parsons^1^, M. Chintagumpala^1^, R. Venkatramani^1^

*^1^Baylor College of Medicine‐ Texas Children\'s Cancer Center, Pediatrics‐ Hematology/Oncology, Texas, USA; ^2^Baylor College of Medicine, Pathology, Houston, USA; ^3^Baylor College of Medicine, Pediatrics, Houston, USA*

**Background/Objectives**: The outcomes for children with rare cancers has lagged behind other cancers due to the lack of clinical trials, standardized treatment protocols, and disease expertise. The North American Pediatric Rare Tumor Registry was established at Texas Children\'s Hospital to advance the care of children with rare cancers.

**Design/Methods**: Patients less than 21 years of age with a diagnosis of a rare cancer (incidence \< 2 per million) are consented in person or via telephone. Clinical information is abstracted from medical records. Tumor tissue, blood or saliva sample are obtained from the patient. Saliva samples are collected from biological parents.

**Results**: Between February 2017 and March 2018, 70 patients were enrolled from ten different states in USA and Canada. The median age at diagnosis of enrolled patients was 13.41 years (range two months ‐ 19 years). Twenty‐six patients were male. Patients identified as White (50), Black (4), Asian (5), American Indian (4), Pacific Islander (1), mixed race (2) and four declined. Thirty‐six patients were Hispanic. Diagnoses included thyroid cancer (20), germ cell tumors (8), neuroendocrine tumors (5), clear cell sarcoma of the kidney (4), carcinoma (4), desmoplastic small round cell tumor (3), melanoma (3), sex cord stromal tumors (2), borderline tumor of ovary (2), mammary analogue secretory cancer (2), pancreatoblastoma (1), inflammatory myofibroblastic tumor (1), malignant mesenchymal tumor (1), and non‐rhabdomyosarcoma soft tissue sarcomas (15), such as synovial sarcoma, angiomatoid fibrous histiocytoma, epithelioid sarcoma, dermatofibrosarcoma protuberans, MPNST, liposarcoma, and undifferentiated sarcoma. Fifty tumor samples and 53 blood/saliva samples have been collected from patients. Seventy‐two saliva samples have been collected from parents.

**Conclusions**: Large numbers of children with rare cancers have been enrolled and their biological samples have been collected in the inaugural year of the registry. This registry will serve as a resource for clinical and basic science investigators interested in pediatric rare cancers.

### PO-667. Preclinical Effect of Selinexor (KPT‐330), a Selective Inhibitor of Nuclear Export, in Pediatric Rhabdoid Tumors {#pbc27455-sec-9030}

[L. Marks]{.ul} ^1^, D. Diolaiti^2^, P. Mundi^3^, E. Gaviria^2^, A. Rainey^4^, F. Dela Cruz^1^, C. Andrea^5^, A. Kung^1^

*^1^Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA; ^2^Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, USA; ^3^Columbia University Medical Center, Internal Medicine, New York, USA; ^4^Columbia University Medical Center, Irving Cancer Center Core, New York, USA; ^5^Columbia University Cancer Center, Systems Biology, New York, USA*

**Background/Objectives**: Malignant rhabdoid tumors (MRTs) are rare, aggressive pediatric solid tumors characterized by a 22q11 chromosome rearrangement that inactivates the SMARCB1 gene. Outcomes remain poor despite multimodality treatment. MRTs are among the most genomically stable cancers and lack therapeutically targetable genetic mutations. We used the Virtual Inference of Protein‐activity by Enriched Regulon (VIPER) algorithm to computationally infer protein activity from MRT whole transcriptomic data available in the TARGET database to identify candidate non‐genetically encoded vulnerabilities. This approach identified markedly aberrant activation of the nuclear export protein Exportin‐1 (XPO1) in MRTs compared to other tumor types. We hypothesized that MRTs may be dependent on high XPO1 activity and this dependence can be co‐opted as a novel non‐oncogene directed therapeutic approach using the XPO1 inhibitor selinexor.

**Design/Methods**: A panel of 6 MRT and 3 atypical teratoid/rhabdoid tumor (ATRT) cell lines were used for *in vitro* studies. Two patient‐derived xenograft (PDX) mouse models of MRT were treated with selinexor to determine anti‐tumor effects.

**Results**: All MRT cell lines demonstrated marked baseline activation of XPO1. The median IC50 following 72 hour selinexor treatment was 200 nM (IQR 175‐435 nM) for MRT, 460 nM (IQR 400 nM‐1.4 uM) for ATRT and 1.1 uM (IQR 580 nM‐1.4 uM) for 5 non‐MRT cell lines. There was a correlation between inferred XPO1 activity and IC50 with cell lines with the highest inferred activity being the most sensitive to selinexor. Treatment with selinexor *in vitro* led to cell cycle arrest and induction of apoptosis in MRT cell lines. *In vivo* treatment of two MRT PDXs with oral selinexor for 15 days significantly inhibited tumor growth in both models (p\<0.0001 and p=0.0002).

**Conclusions**: Selinexor demonstrates efficacy in preclinical models of MRT. These results support further investigation of selinexor in a phase II study in children with MRT.

### PO-668. Rituximab Therapy for Patients with Langerhans Cell Histiocytosis Neurologic Dysfunction Syndrome {#pbc27455-sec-9040}

O. Eckstein^1^, [C. Mcatee]{.ul} ^1^, J. Greenberg^2^, A. Kumar^3^, C. Fein Levy^4^, T. Smith^5^, B. Tran^6^, C. Allen^1^, M. Kenneth^1^

*^1^Texas Children\'s Cancer Center, Pediatrics, Houston, USA; ^2^Children\'s National Medical Center, Pediatrics, Washington D.C., USA; ^3^Cincinnati Children\'s Medical Center, Pediatrics, Cincinnati, USA; ^4^The Steven and Alexandra Cohen Children\'s Medical Center of New York, Pediatrics, New York, USA; ^5^The Children\'s Hospital, Pediatrics, Denver, USA; ^6^Texas Children\'s Hospital, Radiology, Houston, USA*

**Background/Objectives**: Patients with Langerhans Cell Histiocytosis with neurologic dysfunction (LCH‐ND) may fail standard therapy. Because of biologic and clinical parallels with the neurodegeneration of multiple sclerosis (MS), we evaluated the role of rituximab for treating LCH‐ND.

**Design/Methods**: Charts of 7 patients with LCH‐ND treated with rituximab after failing other therapies were reviewed including 4 males and 3 females diagnosed between ages 1.8‐21 years. Central Nervous System risk bone lesions occurred in 3/7 and pituitary involvement with diabetes insipidus (DI) in 5/7. Onset of LCH‐ND ranged from 0‐10 years after diagnosis of LCH and 3‐11 years after diagnosis of DI. Following treatment failure with regimens including cytarabine, clofarabine, alemtuzumab, and IVIG, rituximab was generally given at a dose of 375 mg/m^2^ weekly for 4 weeks with planned repeat dosing at 3 month intervals. However, after the initial 4 week period completed and the dose frequency was decreased, some patients developed worsening symptoms. Frequency was increased to 3‐4 week intervals. Four patients had worsening symptoms and were "re‐induced" with 555 mg/m^2^ of rituximab weekly for 4 weeks repeated at 3‐4 week intervals. This is our current initial protocol for patients receiving rituximab for LCH‐ND. Time between LCH‐ND onset and rituximab therapy ranged from 1‐15 years with a median of 7.5 years. Responses of motor and neuropsychological signs/symptoms were assessed.

**Results**: Six of 7 patients experienced clinical improvement after rituximab therapy. Motor symptoms which improved were ataxia and tremors in 3 children, proprioceptive deficits in 2, and dysarthria/dysphasia in 1. Five of 7 patients demonstrated improvement in intellectual, behavioral, or psychological symptoms. Improvements tended to be sustained with monthly infusions of rituximab.

**Conclusions**: Rituximab treatment results in improved motor, behavioral, intellectual, and psychological symptoms in a select group of patients with LCH‐ND who have not responded to other therapies. Monthly infusions may provide the optimal response.

### PO-669. Limited Radiotherapy for Langerhans Cell Histiocytosis with Complete Paraplegia: A Rare Oncologic Emergency in Infancy {#pbc27455-sec-9050}

[K. Nakashima]{.ul} ^1^, Y. Koga^1^, Y. Sakai^1^, H. Takada^1^, K. Harimaya^2^, S. Ohga^3^, T. Taguchi^4^, Y. Oda^5^, H. Honda^3^, S. Ohga^1^

*^1^Graduate School of Medical Sciences‐ Kyushu University, Department of Pediatrics, Fukuoka, Japan; ^2^Kyushu University, Department of Orthopedic Surgery, Fukuoka, Japan; ^3^Graduate School of Medical Sciences‐ Kyushu University, Department of Radiology, Fukuoka, Japan; ^4^Graduate School of Medical Sciences‐ Kyushu University, Department of Pediatric Surgery, Fukuoka, Japan; ^5^Graduate School of Medical Sciences‐ Kyushu University, Department of Pathology, Fukuoka, Japan*

**Background/Objectives**: Langerhans cell histiocytosis (LCH) is a clonal disease with focal or disseminated lesions that may compress the surrounding tissues, including the spinal cord. Because few reports have described the spinal symptoms as the first manifestation of pediatric LCH, the long‐term neurological outcomes remain unclear.

**Design/Methods**: A 21‐month‐old boy who had no history of developmental or growth delay was transferred to our hospital for the further study of his leg weakness. On admission, seven days after the onset of paralysis, his vital signs were normal. Neurological examinations revealed complete paralysis of the lower legs. Computed tomography (CT) revealed multiple osteolytic lesions in the parieto‐temporal regions of the skull, vertebrae and mass lesions in the lungs. Magnetic resonance imaging (MRI) of the whole spine showed compressed fracture of T6 and T8 by T2‐weighted images and an epidural tumor at the T7‐9 levels compressing the spinal cord.

**Results**: Twelve days after he developed leg weakness, emergency radiotherapy was started after a tumor biopsy. During the course of radiotherapy, paralysis steadily ameliorated. After we excluded infections and determined the pathological diagnosis of LCH, multi‐drug chemotherapy was started. Apparent improvement in his complete paraplegia was observed after a total 15 Gy of radiotherapy and subsequent chemotherapy, leaving no neurological sequelae at 4 years of age. Through a literature search of studies published from 1980 to 2017, we found that children with LCH showed a generally favorable recovery from neurological dysfunction after the acute phase of spinal symptoms.

**Conclusions**: This report underscores the utility of emergency radiotherapy for the neurological recovery of spinal LCH in infants. Our long‐term observation further denotes the value of this treatment in terms of the intact survival with preserved motor functions and physical growth.

### PO-670. Langerhans Cell Histiocytosis: Retrospective Analysis of 57 Cases at Hospital Infantil De México Federico Gómez {#pbc27455-sec-9060}

M. Arzola Medrano^1^, C.E. Cicero Oneto^1^, [M.A. Palomo Colli]{.ul} ^1^, S. Sadowinski Pine^2^, L.E. Juárez Villegas^1^, J.F. Gaytán Morales^1^, A. Medina Sanson^1^, M. Murillo Maldonado^1^, I. Castorena Villa^1^

*^1^Hospital Infantil de México Federico Gómez, Oncology, México City, Mexico; ^2^Hospital Infantil de México Federico Gómez, Department of Clinical and Experimental Pathology, México City, Mexico*

**Background/Objectives**: Langerhans cell histiocytosis (LCH) is a rare (about 3‐5 cases per million children aged 0‐14 years), non‐malignant disease characterized by proliferation and accumulation of clonal dendritic cells, extreme clinical heterogeneity, and an unpredictable course.

**Objective**: To analyze the clinical characteristics and treatment outcome of children with LCH.

**Design/Methods**: From January 2010 to December 2016, newly diagnosed patients with histopathologically‐confirmed LCH were enrolled in this retrospective study. Medical records were analyzed retrospectively for the 67 patients diagnosed. All patients were treated at Hospital Infantil de México Federico Gómez with LCH III protocol. Survival was determined using the Kaplan‐Meier method with differences between different groups compared using the Log‐Rank test.

**Results**: Of the 67 included patients, only 54 were evaluated (34 boys and 20 girls). Twenty‐seven patients (50%) had disease in clinical group (CG) 1, seven had disease in CG 2 and 20 patients had disease in CG 3. The most frequent site of involvement was the bone 26 (48%), bone marrow involvement ocurred in three patients, 19 had hepatic enlargement, 6 had spleen enlargement. Response at week 6 was achieved in 81.4% (44/54) evaluable patients. Twenty‐three patients (43%) relapsed, they received a second course of the same induction protocol. During the years of study five children died due to the progression of the disease. The overall survival (OS) was 82% with a median follow‐up period of 5 years.

**Conclusions**: In this study all children were treated with the LCH protocol, in our institution we do not have other drugs for the treatment of relapses. As described in the original protocol, response rates and second reinductions are effective in this disease. Second initial treatment for patients without response at week 6 and effective salvage therapy need to be taken into account in our future studies. A new strategy to decrease the incidence of relapse is needed.

### PO-671. Liver Sarcoma: Clinical‐Pathological and Immunohistochemical Study and its Differential Diagnosis with Intrabdominal Tumors in Children of Edgardo Rebagliati Hospital Lima Peru 1999‐2018 {#pbc27455-sec-9070}

[A.M.G. Paredes Guerra]{.ul} ^1^, R. rivera^1^, C. alvarez^1^, C. machado^1^, E. guzman^1^

*^1^Essalud Rebagliati Hospital, Paediatric oncology, Lima, Peru*

**Background/Objectives**: Liver sarcoma is an infrequent mesenchymal neoplasm, difficult to diagnose by imaging and histology. Objective: to emphasize the early, differential diagnosis and its management.

**Design/Methods**: Descriptive Study, Longitudinal Retrospective of liver sarcoma children from 0 to 14 years in Rebagliati Hospital during 19 years.

**Results**: Of 78 cases hepatic cancer: 4 (5.12%) Sarcoma, average age 9 years, female 100%. Sickness time 2 weeks; abdominal pain, palpable mass and low weight 100%, alpha‐fetoprotein normal 100%. Ultrasound and tomography: large cystic mass partitioned \>15cm (15.1 to 30 cm) in right hepatic lobe 100%. One case (25%) pulmonary metastasis. Case 1 and 2 biopsy: undifferentiated embryonic sarcoma, desmin and vimentin (+) received cyclophosphamide+doxorubicin/ifosfamide+etoposide. First case chemotherapy pre and postsurgery in remission 6 months; relapsed and died after surgery. Second case stage IV received 50% doses of chemotherapy presenting massive hepatic hemorrhage and died. Case 3 by images: echo and tomography diagnosed hydatid cyst, received albendazole 15 days, complicating with tumor rupture, performing tamponade and drainage of disseminated vesicles in the liver, pathology: undifferentiated embryonic hepatic sarcoma desmin and vimentin (+) and ki67: 50‐ 60% post 2 courses of chemotherapy: radical surgery for an abscessed tumor + hepatocutaneous fistula received chemoadjuvant. Case 4: biopsy: epithelial hepatoblastoma after 3 courses of cisplatin, tumor of 19.3cm increased to 30cm+portal vein thrombus, review of pathology: hepatic leiomyosarcoma, vimentin+desmin+alpha‐actin positive. He started imatinib+ifosfamide+doxorubicin, then radical surgery plus chemoadjuvant. Global survival 50%: one undifferentiated embryonic sarcoma and one leiomyosarcoma. Disease free survival 20.2 months.

**Conclusions**: Sarcomas are uncommon hepatic tumors, clinical and imaging are challenging to diagnose. They are easily complicated with abscess and/or hemorrhage due to tumor rupture. Histological diagnosis is difficult due to over morphological position with other hepatic tumors and non‐specific immunohistochemistry. Radical surgery plus chemotherapy and white therapy has increased their survival.

### PO-672. Cytokine Serum Expression in Patients with Infantile Hemangioma Treated with Oral Propranolol: A Multi‐Institutional Study on Behalf of Korean Pediatric Hematology Oncology Group (K‐PHOG) Study {#pbc27455-sec-9080}

[M. Park]{.ul} ^1^, H.L. Jung^2^, Y.J. Shim^3^, H.S. Kim^3^, H.S. Yun^4^, S.K. Park^5^, H.W. Cheuh^6^, M.J. Lee^7^, J.M. Lee^8^, E.S. Park^9^, J.H. Lee^10^, Y.J. Lim^11^, E.J. Choi^12^

*^1^Center for Pediatric Cancer‐ National Cancer Center, Pediatric Cancer, Goyang‐si, Republic of Korea; ^2^Kangbuk Samsung Hospital‐ Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^3^Keimyung University Dongsan Medical Center, Department of Pediatrics, Daegu, Republic of Korea; ^4^Kyung Hee University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^5^Ulsan University Hospital‐ University of Ulsan College of Medicine, Department of Pediatrics, Ulsan, Republic of Korea; ^6^Dong‐A University College of Medicine, Department of Pediatrics, Busan, Republic of Korea; ^7^Dankook University College of Medicine, Department of Pediatrics, Cheonan, Republic of Korea; ^8^Yeungnam University College of Medicine, Department of Pediatrics, Daegu, Republic of Korea; ^9^Gyeonsang National University College of Medicine, Department of Pediatrics, Jinju, Republic of Korea; ^10^Chosun University Schoool of Medicine, Department of Pediatrics, Gwangju, Republic of Korea; ^11^Chungnam National University College of Medicine, Department of Pediatrics, Daejon, Republic of Korea; ^12^Daegu Catholic University Hospital, Department of Pediatrics, Daegu, Republic of Korea*

**Background/Objectives**: Oral propranolol has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first‐line treatment of IHs. The present prospective study aimed to identify possible therapeutic mechanisms of propranolol and early regression indicators with hematological parameters.

**Design/Methods**: Seventy‐five blood samples were obtained from 30 babies (median age of 80 days, range between 36 days and 265 days) who were treated with propranolol in 11 medical centers in Korea. Twelve different serum cytokines involving angiogenesis, vasculogenesis and/or chronic inflammation were analyzed at 0, 1 and/or 12 months after propranolol treatment using Luminex Multiplex Assays.

**Results**: Seventeen patients completed the study with 3 blood samples at 0, 1 and 12 months and 10 patients showed excellent regression with visual analogue score (VAS) of \>7 (maximum score of 9). Seven patients were lost their follow‐up or withdrew their consent to the study after \>1 month of propranolol treatment and 6 patients are still under the study. Patients with larger size of hemangioma showed significantly higher platelet‐derived growth factor‐BB (PDGF‐BB) (*r*=0.40, *p*=0.03) and vascular endothelial growth factor‐alpha (VEGF‐α) (*r*=0.45, *p*\<0.01). Serum VEGF and matrix metalloproteinase‐2 (MMP‐2) showed steady decrease over treatment period with statistical significance. Patients with greater improvement of IH at 1 year showed significantly less decrease of MMP‐2 over 1 year. Patients with lower pre‐treatment matrix metalloproteinase‐9 (MMP‐9) showed greater volume reduction at 1 year after treatment.

**Conclusions**: In this study, we showed for the first time the significant change of several blood parametes involving angiogenesis as serum indicators of IH regression with propranolol and potentially useful signs to monitor vascular proliferation.

### PO-673. Chest Wall Tumors in Children: Surgical Challenges and Short Term Outcomes {#pbc27455-sec-9090}

[N. Peters]{.ul} ^1^, R. Samujh^1^, M.A. Malik^1^, J.K. Mahajan^1^, N. Bharadwaj^2^

*^1^Post Graduate Institute of Medical Education and Research‐ Chandigarh, Pediatric Surgery, Chandigarh, India; ^2^Post Graduate Institute of Medical Education and Research‐ Chandigarh, Anesthesia and Critical Care, Chandigarh, India*

**Background/Objectives: Background/Aim**: Chest wall tumors (CWT) constitute 1.8% of all childhood cancers and ∼45% include sarcomas. We studied the challenges, surgical approach and peri‐operative events in resection of CWT in children.

**Design/Methods: Materials and Methods**: A retrospective analysis of patients operated for chest wall malignancies, from September 2016 to December 2017 was done. Data on presentation, radiological and histological diagnosis, neoadjuvant therapy, surgery, and immediate post operative events was analyzed.

**Results**: A total of 8 patients, 6 boys and 2 girls were operated. Age ranged from 1 to 12 years(Median: 5 years). Five patients presented with respiratory distress and chest pain. Two were evaluated for fever. Two presented with upper back swellings. Preoperative FNAC was done in all, 7 cases were of Ewing\'s sarcoma and 2 of posterior chest wall Rabhdomyosarcoma (RMS). All patients underwent neoadjuvant chemotherapy followed by surgical excision. Surgically none of the patients required chest wall reconstruction using meshes or artificial support. Important structures like brachial plexus, diaphragm and spinal canal were in close proximity of resected margins. Two patient required excision of a part of lung parenchyma to achieve en‐bloc resection. Six patients required peri‐operative blood transfusion. One patients required post operative ventilation. No patients had significant problems with pulmonary toilet in the post operative period. Biopsy reports showed negative margins in 7 patients. One patient has had recurrence after 8 months and all others are disease free over a period 3 months to 1.5 years.

**Conclusions**: Rib and chest wall resections, with adequate margins is very important the treatment of CWT. Surgical planning includes accurate preoperative radiology, approach, number of rib resections, proximity to important structures and reconstruction keeping in mind adequate pulmonary toilet and pain relief.

### PO-674. Crizotinib Therapy in Anaplastic Lymphoma Kinase‐Positive Inflammatory Myofibroblastic Tumour: When to Stop? {#pbc27455-sec-9100}

[S. Ray]{.ul} ^1^, C. Willis^1^, D. Murphy^1^

*^1^Royal Hospital for Sick Children, Paediatric Haematology and Oncology, Glasgow, United Kingdom*

**Background/Objectives**: Inflammatory myofibroblastic tumours (IMTs) are rare mesenchymal malignancies. Peak incidence is within the first 2 decades of life. Complete excision is fundamental to cure.

Crizotinib is a promising novel therapy.

Anaplastic lymphoma kinases (ALK) play a key role in oncogenesis. ALK mutations in IMTs are well described in the literature.

A recent trial suggests ALK inhibition is very effective and crizotininb should be considered as first line^(1)^.

Evidence on discontinuation is currently lacking.

**Design/Methods**: A 3 year old girl presented with progressive right lid swelling, ptosis and downward displacement of her globe necessitating urgent ophthalmology review.

MRI and CT revealed a non metastatic 6cmx2cmx2.3cm mass within the right superior orbit. Biopsy confirmed IMT (wild type ALK mutation).

**Results**: She was initially commenced on prednisolone but long term effect wasn\'t sustained. Ibuprofen was started, and despite initial stable disease, her tumour progressed after 3 months. A trial of celecoxib was unsuccessful. 18 months post‐diagnosis, crizotinib was commenced. The response was dramatic with no detectable disease on MRI post 6 months of therapy.

**Conclusions**: Our patient suffered profound myelosuppression with a persistent prolonged neutropaenia \<0.2x10\^9/L. As a result, she required a significant dose reduction. Our patient has been on crizotinib for 2 years and has had no disease recurrence. There is no evidence to guide cessation of therapy.

Reference

Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\'s oncology group study. Yael P. Mosse et al. <https://doi.org/10.1200/JCO.2017.73.4830> Journal of clinical oncology 35, no. 28 (October 2017)

### PO-675. A Case Series of Pancreatic Tumours in Paediatric and Adolescent Patients {#pbc27455-sec-9110}

[S. Rhead]{.ul} ^1^, S. Wilson^1^, E. Blanco^1^, D. Fowler^2^, K. Lakhoo^3^

*^1^John Radcliffe Hospital‐ Oxford University Hospitals, Paediatric Oncology, Oxford, United Kingdom; ^2^John Radcliffe Hospital‐ Oxford University Hospitals, Pathology, Oxford, United Kingdom; ^3^John Radcliffe Hospital‐ Oxford University Hospitals, Paediatric Surgery, Oxford, United Kingdom*

**Background/Objectives**: Primary pancreatic tumours are rare in childhood and adolescence and can present a diagnostic and therapeutic challenge for clinicians. We present our single institution experience of these tumours.

**Design/Methods**: A 10 year retrospective analysis of primary pancreatic tumours in paediatric and adolescent patients was carried out between January 2008 and March 2018. Data collected included patient demographics, clinical presentation, diagnosis, treatment and outcomes.

**Results**: Six patients were identified with primary pancreatic tumours, 5 of whom were female. The age range at diagnosis was 11 to 18 years. In 5 of these cases histological diagnosis was confirmed after imaging and biopsy or resection of the primary mass. Diagnosis was confirmed in 1 patient by liver biopsy. Tumour types were solid pseudopapillary neoplasm (n = 3), metastatic pancreatic neuroendocrine tumour (NET, n = 2) and tumour of indeterminate type (n = 1). Four patients underwent complete surgical resection. One patient with metastatic pancreatic NET is undergoing DOTATATE therapy and the second patient is starting cold octreotide treatment. Multiple endocrine neoplasia type 1 (MEN1) has been genetically confirmed in 1 patient with NET. All patients are currently alive with a median follow up of 5 years and 2 months (follow up range from 1 month up to 10 years and 2 months).

**Conclusions**: Pancreatic tumours are extremely rare in paediatric and adolescent patients, with an incidence of 0.46 per million in under 30 year olds (National Cancer Institute SEER (Surveillance, Epidemiology, and End Results) Public‐use Database from 1973 to 2004).These tumours account for less than 0.2% of paediatric cancer‐related deaths. Clinical symptoms are often non‐specific and presentation may be delayed. For localised tumours, complete surgical resection is the optimal treatment and offers the best outcomes. Management of metastatic tumours is dependent on histological diagnosis. Non--surgical options for metastatic NET can provide prolonged symptom control.

### PO-676. Severe Hyponatremia Induced by Intravenous Fluids in Children with High Grade Esthesioneuroblastoma: Case Series {#pbc27455-sec-9120}

[M. Rojas]{.ul} ^1^, B. Wilson^2^, S. Desai^2^, P. Grundy^2^, S. McKillop^2,3^

*^1^Stollery Children\'s Hospital‐ Alberta Health Services, Pediatric Oncology, Edmonton, Canada; ^2^Stollery Children\'s Hospital‐ University of Alberta, Pediatric Oncology, Edmonton, Canada; ^3^Cross Cancer Institute, Pediatric Oncology, Edmonton, Canada*

**Background/Objectives**: Esthesioneuroblastoma (ESN) is a tumor arising from nasal neuroepithelium associated with vasopressin production. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and cerebral salt wasting (CSW) presenting with hyponatremia has been described in case reports in adults.

We aim to report a cohort of children diagnosed with ESN presenting with hyponatremia triggered by intravenous fluids (IVF).

**Design/Methods**: Case series in pediatric patients with ages of 0 -- 18 years with ESN and hyponatremia induced by IVF, treated in two centers.

**Results**: Three patients presented with high grade ESN (biopsy proven) arising from paranasal sinuses with intracranial/orbits extension, cervical lymph nodes (patients 2 and 3) and bone metastases (patient 2). All received Cisplatin 50mg/m2 days 1‐4 and Etoposide 200mg/m2 days 1‐3 (cycle 1) with hydration (125ml/m2/hour, 6 hours pre‐hydration and 18 hours post‐hydration).

All patients had normal baseline Sodium (Na) and developed severe hyponatremia requiring IVF titration with Normal Saline and 3% saline, strict fluid balance and electrolyte monitoring. All patients had hyponatremia work‐up (Serum osmolality, Urine osmolality, Specific gravity and Urinary sodium). Na became normal, post‐cycle 1 (Patient 1 and 3) and post‐cycle 3 and tumor resection (patient 2).

Patient 1: 18‐year‐old male had initial decompression of intracranial tumor extension with satisfactory recovery. A month later, on day 1, during pre‐hydration, Na was 126mmol/L. Patient 2, 13‐year‐old male received IVF prior to central line insertion, presented with lethargy and Na 124mmol/L requiring 3% saline. Both cases presented with SIADH based on fluid retention, euvolemia and hyponatremia work‐up. Patient 3, 9‐year‐old female, on day 1, during post‐hydration, Na 122mmol/L. CSW was confirmed by hypovolemia and hyponatremia work‐up. She later complicated with proximal tubulopathy.

**Conclusions**: ESN can present with SIADH and salt wasting resulting in hyponatremia unmasked by IVF in children. Careful electrolyte monitoring is recommended in this population. Prospective studies are required to further confirm this association.

### PO-677. Follicular Carcinoma of the Thyroid in a Four Year Old Girl: Importance of Testing for DICER1 Syndrome {#pbc27455-sec-9130}

[M. Ronghe]{.ul} ^1^, C. Willis^1^, G. Shaikh^2^, D. Wynne^3^, O. Hilmi^3^, R. Davidson^4^, N. Reed^5^

*^1^Royal Hospital for Children, Paediatric Oncology, Glasgow, United Kingdom; ^2^Royal Hospital for Children, Paediatric Endocrinology, Glasgow, United Kingdom; ^3^Royal Hospital for Children, Paediatric ENT Department, Glasgow, United Kingdom; ^4^Royal Hospital for Children, Genetics, Glasgow, United Kingdom; ^5^Beatson West Of Scotland Cancer Centre, Clinical Oncologist, Glasgow, United Kingdom*

**Background/Objectives**: The familial tumour susceptibility syndrome, associated with*DICER1* mutation, was first described in 2009. *DICER1* syndrome is characterised by autosomal dominant pattern of inheritance. It\'s associated with rare tumours, including pleuropulmonary blastoma, cystic nephroma, pineoblastoma and multinodular goitre. We present a case of minimally invasive follicular thyroid carcinoma in a four‐year‐old girl with a *DICER 1* syndrome.

**Design/Methods**: Our patient was being followed up for a stable renal cyst. At the age of 3 years a thyroid swelling was noted. She was clinically euthyroid. There was a significant family history of benign multi‐nodular goitre on the maternal side, with all females requiring thyroidectomy post pregnancy.

Thyroid function tests, parathyroid hormone and thyroid antibodies were normal. Ultrasound scan demonstrated a large vascular mass within the left lobe of the thyroid. MRI confirmed a 2.5x2.5x3.2cm mass with local mass effect (tracheal deviation) with no evidence of metastatic disease.

Following MDT discussion, a hemi‐thyroidectomy was performed. Molecular and immunohistochemical profiles were consistent with minimally invasive follicular carcinoma. Excision was complete.

We discussed her management at both national and international level. As excision was complete, total thyroidectomy was not deemed necessary. Radio‐iodine therapy was also not felt to be in her best interests, given her young age, complete excision and late adverse effects associated with its use.

**Results**: She is 1 year post hemi‐thyroidectomy and remains clinically well. Given the family history, and the rarity of the tumour, genetic testing was performed. *DICER1* gene mutation was identified.

**Conclusions**: This case highlights the importance of considering *DICER1* testing in the presence of a positive family history of multi‐nodular goitre or any of the other associated features of*DICER1* syndrome. Genetic counselling should be offered to affected families. We recognise the need for long‐term surveillance with chest x‐ray, abdominal ultrasound scans and cranial MRI although evidence based screening is lacking.

### PO-678. Two Cases of Rare Salivary Gland Tumours in Children: Complexity of Management and Outcomes {#pbc27455-sec-9140}

C. Willis^1^, H. Kubba^2^, R. Jones^3^, F. Cowie^3^, D. Indelicato^4^, [M. Ronghe]{.ul} ^1^

*^1^Royal Hospital for Children, Paediatric Oncology, Glasgow, United Kingdom; ^2^Royal Hospital for Children, Paediatric ENT, Glasgow, United Kingdom; ^3^Beatson West Of Scotland Cancer Centre, Clinical Oncology, Glasgow, United Kingdom; ^4^Proton Therapy Institute, Clinical Oncology, Jacksonville‐ Florida, USA*

**Background/Objectives**: The differential diagnosis of parotid swellings in children is expansive. The presentation for benign or malignant lesions may be identical. Parotid / salivary gland tumours are exceedingly rare. We present two cases of salivary gland tumours and discuss their management and outcomes.

**Design/Methods**: Patient 1, a twelve‐year‐old girl, and patient 2, a five‐year‐old boy, both presented with long‐standing histories of parotid gland swelling. For both patients, onward referral for imaging was instigated when the lesions increased in size.

Investigations

Patient 1\'s initial USS revealed a well circumscribed lesion within the left parotid gland, which was confirmed on MRI.

Patient 2\'s USS demonstrated a solid mass of the superficial lobe of the parotid gland, associated with low vascularity.

**Results**: Patient 1 underwent a left superficial parotidectomy. The mass was adherent to the facial nerve. Pathology was consistent with a low grade mucoepidermoid carcinoma, with positive margins near the facial nerve. We elected to treat her with proton therapy, given the high risk of recurrence of her tumour, and the difficulties that further surgery would involve, i.e. sacrificing the facial nerve. She is now 3 years post treatment with no disease recurrence.

Patient 2 underwent a left parotidectomy. The tumour was locally extensive below the mandibular branch of the facial nerve. Histology was consistent with a sialoblastoma, with a close excision margin. We acknowledged the significant risk associated with post‐operative radiotherapy and elected to observe, with the appreciation that should disease recur, then surgical excision will prove very difficult. He is now six years post resection and remains well with no evidence of recurrence.

**Conclusions**: Parotid gland tumours are exceedingly rare and management is complex, requiring a multi disciplinary approach. We have reported successful outcomes for our two patients, who remain disease free more than three years post therapy.

### PO-679. Management and Long‐Term Outcomes of Paediatric Thyroid Cancer: West of Scotland Experience Over Two Decades {#pbc27455-sec-9150}

[D. Sarode]{.ul} ^1^, M. Ronghe^2^, D. Wynne^3^, F. MacGregor^4^, O. Hilmi^4^, G. Shaikh^5^, T. Kunanandanum^3^, N. Reed^6^

*^1^NHS Greater Glasgow and Clyde, Surgery/General Medicine, Glasgow, United Kingdom; ^2^NHS Greater Glasgow and Clyde, Paediatric Oncology, Glasgow, United Kingdom; ^3^NHS Greater Glasgow and Clyde, Paediatric Otorhinolaryngology, Glasgow, United Kingdom; ^4^NHS Greater Glasgow and Clyde, Otorhinolaryngology, Glasgow, United Kingdom; ^5^NHS Greater Glasgow and Clyde, Paediatric Endocrinologist, Glasgow, United Kingdom; ^6^NHS Greater Glasgow and Clyde, Clinical Oncology, Glasgow, United Kingdom*

**Background/Objectives**: Although thyroid cancer comprises the commonest paediatric endocrine malignancy the absolute incidence remains low. Consequently, there remains a paucity of evidence surrounding the optimal treatment strategy of this condition. Here, we aim to summarise our experience of managing paediatric thyroid cancer in the West of Scotland. In doing so, we hope to expand the evidence base to inform clinicians dealing with this uncommon but clinically significant condition.

**Design/Methods**: Patients with malignant thyroid disease were identified from a prospective database of thyroid operations performed in the West of Scotland from 2000‐2017. Data was extracted using a retrospective case‐review approach. Extracted data included the following dates: GP referral, first ENT outpatient review, ultrasound and fine needle aspiration (USS‐FNA), surgery, and radio‐iodine treatment(s) (if performed).

**Results**: Our analysis identified five relevant patients. The average age at time of surgery was 9.48 years. Management of all patients was highly multi‐disciplinary, involving the following members: ENT surgeon; endocrinologist; paediatrician; clinical oncologist. All patients underwent USS‐FNA prior to surgery but in two cases the pre‐operative pathology was not unequivocal for thyroid carcinoma. Post‐operative pathology revealed three patients had papillary carcinoma and the remaining two had follicular carcinoma. The average time from first ENT outpatient review to USS‐FNA was 20.5±12.0 days and that from USS‐FNA to surgery was 38.4±29.7 days. Three patients underwent post‐operative radio‐iodine therapy; two had 1 cycle and the third had 3 cycles. No patients developed secondary malignancies by the time of our analysis.

**Conclusions**: Our analysis confirms that the incidence of paediatric thyroid cancer remains low in the West of Scotland. In our experience, such patients are managed using a similar strategy to adult patients with this condition due to the lack of age‐specific evidence‐based guidelines. We hope to build upon the data presented here to further inform clinical practice.

### PO-680. Role of MIR‐483‐3P in Pediatric Adrenocortical Tumors {#pbc27455-sec-9160}

C.A.P. Corrêa^1^, A.F. Andrade^2^, R.C.P. Lira^3^, J.A. Yunes^4^, M.J. Mastellaro^4^, S.R. Brandalise^4^, L.G. Tone^5^, [C. Scrideli]{.ul} ^5^

*^1^Ribeirão Preto Medicine School ‐ University of São Paulo, Genetics Department, Ribeirão Preto, Brazil; ^2^Institut de Recherche en Cancérologie de Montpellier‐ INSERM, Oncology, Montpellier, France; ^3^Ribeirão Preto Medicine School ‐ University of São Paulo‐ Centro Universitário CESMAC‐ Maceió‐AL, Pediatrics Department, Ribeirão Preto, Brazil; ^4^Centro Infantil Bondrini‐ State University of Campinas UNICAMP, Pediatrics, Campinas, Brazil; ^5^Ribeirão Preto Medicine School ‐ University of São Paulo, Pediatrics Department, Ribeirão Preto, Brazil*

**Background/Objectives**: Although childhood adrenocortical tumors (ACT) are rare neoplasms, its incidence in Brazil is particularly higher. Currently, there are no reliable biomarkers able to predict diagnosis or prognosis of ACT in children. Aiming to find potential biomarkers of ACT prognosis, we validated the expression of miR‐483‐3p that was found differentially expressed in a microarray‐based microRNA profiling, conducted with 37 pediatric ACT samples.

**Design/Methods**: The validation was performed by RT‐qPCR in 45 ACT pediatric tumors and 8 non‐neoplastic adrenal pediatric samples. Association between miRNA profiles and clinical/biological features were analyzed by Mann‐Whitney test. It was knocked‐down the expression of miR‐483‐3p in the adrenocortical carcinoma cell line H295, using lentiviral vectors, and evaluated cell viability (24‐96h) and gene expression of potential miR‐483‐3p target genes *IGF1R, TGFβ1* e *SMAD3*.

**Results**: The miR‐483‐3p was overexpressed in tumor samples compared to non‐neoplastic adrenal (P\<0.000022). And its higher levels were found in tumors with TP53 mutation p.R337H (P=0.042) and in patients classified as stage II in relation to those classified as stage IV according to Sandrini\'s classification (P=0.047). The silencing of miR‐483‐3p increased cell viability compared to control (P\<0.05) and also increased mRNA levels of *IGF1R, TGFβ1 e SMAD3* (P\<0.05).

**Conclusions**: Taken together, our data show that the expression profile of miR‐483‐3p may be indicative of prognosis and biological/clinical parameters of pediatric ACTs. This data suggests a possible relationship between this miRNA and the regulation of genes belonging to pathways important for adrenal development, such as TGFβ1 and IGF, which when deregulated contribute to the process of tumorigenesis.

### PO-681. MIR‐149‐3P is Indicative of Poor Prognosis and Increased Cell Viability of Adrenocortical Tumors {#pbc27455-sec-9170}

R.C.P. Lira^1^, C.A.P. Corrêa^2^, J.A. Yunes^3^, M.J. Mastellaro^3^, S.R. Brandalise^3^, S.R.R. Antonini^4^, L.G. Tone^4^, [C. Scrideli]{.ul} ^4^

*^1^Ribeirão Preto Medicine School ‐ University of São Paulo‐ Centro Universitário CESMAC -- Maceió/AL‐ Brazil, Pediatrics Department, Ribeirão Preto, Brazil; ^2^Ribeirão Preto Medicine School ‐ University of São Paulo, Genetics Department, Ribeirão Preto, Brazil; ^3^Centro Infantil Boldrini/ State University of Campinas UNiCAMP, Pediatrics, Campinas, Brazil; ^4^Ribeirão Preto Medicine School ‐ University of São Paulo, Pediatrics Department, Ribeirão Preto, Brazil*

**Background/Objectives**: Many efforts have been done to understand the molecular biology of pediatric adrenocortical tumors (ACT), a rare neoplasm with incidence 15X higher in Brazil. Although miRNA signatures have been evaluated in different cohorts, none reliable biomarker was assumed for ACT prognosis in children. Our previews data from microarray‐based miRNA and its validation by RT‐PCR showed that higher levels of miR‐149‐3p are associated with lower 5‐years Event‐free Survival (EFS) rates, being an independent prognostic factor (P = 0.042) when analyzed with tumor size and advanced stage in 47 pediatric patients. We aimed to investigate the role of miR‐149‐3p in NCI‐H295 cells viability.

**Design/Methods**: Since NCI‐H295 cells presented none expression of miR‐149‐3p by RT‐PCR, we induced the miR‐149‐3p expression with lentiviral vectors for the miRNA (Mir_149) or the negative control (Neg_Ctrl) (HLMIR0241;NCLMIR001;Sigma‐Aldrich) and selected the transduced cells with puromycin. Cell viability assays were conducted with Resazurin salt after Cisplatin (0‐10 uM), and the IGF1R inhibitor OSI‐906 (0‐2 uM) or without drug treatments. One‐way Anova test was performed using SPSS software.

**Results**: Transduction with MOI=10 increased more than 300x miR‐149 expression in the cells, which acquired a different growing profile when compared to the Neg_Ctrl. Cell viability assay confirmed that Mir‐149 cells show significant higher viability rates than Neg_Ctrl, mainly 48h (P=0.001) and 72h (P=0.004) after seeded. Mir_149 cells were more resistant to Cisplatin treatment (5 uM for 48 hours; P=0.01). However, we noticed resistant profile of Mir_149 cells for most of the OSI‐906 concentrations used for 24h, 48h (P\<0.0001) and 72 hours (1 uM; P=0.004), except for the highest dose (2 uM).

**Conclusions**: Patients\' EFS data and the higher viability rates observed *in vitro* suggest that overexpression of miR‐149‐3p can drive malignant profiles in ACT cells, which may be associated with IGF signaling. Other assays must be performed to identify the roads behind these observations.

### PO-682. Outcome of High Risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children. Does Intermediate Dose Methotrexate Improve the Outcome? {#pbc27455-sec-9180}

[M.S. Sedky]{.ul} ^1^, A. Hamouda^1^, H. Taha^2^, I. Zaky^3^, O. Hassanain^4^, A. Elhemaly^1^, A. ElHaddad^1^

*^1^Children Cancer Hospital Egypt 57357 @, Pediatric Oncology, Cairo, Egypt; ^2^Children Cancer Hospital Egypt 57357 @, Pathology, Cairo, Egypt; ^3^Children Cancer Hospital Egypt 57357 @, Radiology, Cairo, Egypt; ^4^Children Cancer Hospital Egypt 57357 @, Clinical research, Cairo, Egypt*

**Background/Objectives**: High risk multi‐system organs (RO+) Langerhans cell histiocytosis (LCH) has the least survival. We present the outcome of RO+ LCH in a pediatric single centre.

**Design/Methods**: Fifty RO+ LCH patients, treated between 07/ 2007 and 07/2015 were retrospectively analyzed. A 1st¤ line induction Vinblastine (VBL), Prednisone (PRED) with intermediate dose methotrexate (idMTX) was adopted till 2012 (n=20) where idMTX was omitted afterwards (n=30).

**Results**: The 3 year overall survival (OS) of idMTX and non idMTX groups is 75 % and 63% respectively p0.537. While the event free survival (EFS) is 36,9% and 13,2% respectively p0.005. At week 12 of induction, better status' was obtained in 80% of those receiving MTX, and 55% of those not. The statistically significant factors associated with poor both OS and EFS were tri‐hemopoietic cytopenias, hepatic dysfunction, tri high risk organ combination and single induction. The factors associated with disease progression (DP) post induction were tri‐hemopoietic cytopenias, hepatic dysfunction and lack of idMTX. While those for disease reactivation (REA) were seasonal autumn winter, lung disease, male gender and idMTX.

**Conclusions**: IdMTX is associated with better response and survival. Risk stratification should highlight the role of tri hemopoietic cytopenias, hepatic dysfunction, tri high risk organs, CNS risk site, lung association and double induction. Seasonal autumn winter might carry a viral agent for reactivation.

### PO-683. High Risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children: The Role of Salvage in Improving the Outcome {#pbc27455-sec-9190}

[M.S. Sedky]{.ul} ^1^, A. Hamoda^2^, H. Taha^3^, Z. Iman^4^, O. Hassanain^5^, A. Elhaddad^2^

*^1^children cancer hospital Egypt 57357 and national research centre, Pediatric Oncology, Cairo, Egypt; ^2^children cancer hospital Egypt 57357 and national cancer institute cairo university, Pediatric Oncology, Cairo, Egypt; ^3^children cancer hospital Egypt 57357 and national cancer institute cairo university, pathology, Cairo, Egypt; ^4^children cancer hospital Egypt 57357 and national cancer institute cairo university, radiology, Cairo, Egypt; ^5^children cancer hospital Egypt 57357, clinical research, Cairo, Egypt*

**Background/Objectives**: Failing 1^st^ line treatment in multi‐system high risk organs (RO+) pediatric Langerhans cell histiocytosis (LCH) has the highest mortality. We aim to present the outcome of failing 1^st^ line in RO+ LCH and to show the impact of salvage by 2‐chlorodeoxyadenosine/ aracytine (2‐cda/arac).

**Design/Methods**: Fifty four RO+ LCH patients, treated between 08/ 2007 and 06/2016 were retrospectively analyzed. Patients failing 1^st^ line were due to either Disease Progression (DP) at end of induction or Reactivation (REA) after having achieved better status. They received salvage with or without 2‐cda/arac.

**Results**: Thirty four patients failed 1st line and were divided in 2 groups. Group I DP n=19 and Group II REA n=15. In Group I, 7 patients received 2‐cda/arac where 5 died. The 12 patients who did not receive 2‐cda/arac died except one. In Group II (REA), 3 patients received 2‐cda/arac where one died. The 12 patients who did not receive 2‐cda/arac survived except two. Overall survival (OS) for patients showing no failure, DP and REA is 95 %(CI±9.6), 17.8 % CI±18.0 and 79.4 % CI±20.8 respectively p\< 0.001. OS for DP patients is 28.6 % CI±33.5 and 12.5 % CI±21.2 in 2‐cda versus none respectively p0.037. OS for REA patients is 66.7 % CI±53.3 and 83.3 % CI±21.16 in 2cda versus none respectively p0.43.

**Conclusions**: 2‐cda/aracytine rescued DP RO+LCH in relation to regimen without. Moreover, the impact of 2‐cda/aracytine on REA remains controversial in relation to repetition of 1st line treatment.

### PO-684. Clinical Summary of Comprehensive Treatmentsrelated to Oral Propranolol of Vascular Anomaliesin Children {#pbc27455-sec-9200}

[W. Shan]{.ul} ^1^

*^1^Children\'s Hospital of Chongqing Medical University, Department of Pediatric Surgical Oncology, Chingqing, China*

**Background/Objectives**: To analyze the efficacy and safety of the different treatmentsrelated to oral Propranolol of vascular anomalies in children.

**Design/Methods**: 126patients confirmed as vascular anomalies included in the Children\'s Hospital of Chongqing Medical University from July 2016 to March 2018. 65 of them were divide into three treatment groups: group 1 are treated with oral Propranolol only, group 2 are treated with oral propranolol united topical injection of bleomycin,group 3 are treated with oral propranolol united other comprehensive treatment. All the treatment groups take oral Propranolol by the initiation dosage of 0.5mg/kg each time, twice one day, and gradually add to 1mg/kg each time, twice one day in three days. Observe and record the changes of lesion size, color, texture, associated symptoms and other adverse reactions in each group.

**Results**: Among the 65 cases, there are 25 males and 40 females, the median age is seven months and eleven days old, the clinical responses are6% complete remission(lesions disappeared), 23% very good partial remission(lesions reduce by 76%‐99%), 35% partial remission(lesions reduce by 51%‐75%), 31% micro remission(lesions reduce by 26%‐50%), 5% stable disease(lesions reduce less than 25%). The overall treatment efficiency(lesions reduce more than 25%) of the vascular anomalies achieves 95%.The adverse effectrate of abnormal liver function is 7% and there are no sever adverse effects such as hypotendion, bradycardia, convulsion, vomiting and so on. There are 37 cases of  hemangioma ,18 cases of  vascularmalformations and 10 cases of coexist lesions. The overall treatment efficiency of them is respectively 100%, 94%, 80%. The therapeutic effect of different treatment groups is various. The overall treatment efficiency of group 1 is 96% (with total case of 27), group 2 is 95% (with total case of 22) and group 3 is 94% (with total case of 16).

**Conclusions**: The different comprehensive treatmengs centred on oral Propranolol are effective and safe for the treatment ofvascular anomalies in children.

### PO-685. A 4‐Year‐Old Girl with Pleuropulmonary Blastoma and Unusual Histologic Appearance: A Case Report {#pbc27455-sec-9210}
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*^1^University Children\'s Hospital, Division of Hematology and Oncology, Belgrade, Serbia; ^2^University Children\'s Hospital, Surgery Department, Belgrade, Serbia; ^3^Children\'s Hospitals and Clinics of Minnesota, Cancer and Blood Disorders, Minneapolis, USA; ^4^Children\'s Hospitals and Clinics of Minnesota, International PPB Registry, Minneapolis, USA; ^5^Barnes‐Jewish and St. Louis Children\'s Hospitals‐ Washington University Medical Center, Lauren V. Ackerman Laboratory of Surgical Pathology, St.Louis‐ MO, USA; ^6^Children\'s National Medical Center, Department of Pathology‐ Center for Cancer and Immunology Research, Washington DC, USA*

**Background/Objectives**: Pleuropulmonary blastoma (PPB) is a rare malignancy, which may occur sporadically or in the context of a pathogenic variant in the *DICER1* gene. Pathogenic variants in *DICER1* increase the risk of PPB, ovarian, renal, thyroid and brain tumors, intestinal polyps and lung cysts.

**Design/Methods**: We report the case of a patient diagnosed with Type III PPB.

**Results**: A 4.3‐year‐old girl was admitted to our hospital because of dyspnea. Radiological examinations revealed left pneumothorax and pleural effusion on both sides. Necrotic pneumonia with pleural empyema was suspected. After pleural drainage, CT scan revealed the tumor mass on the left side and a contralateral cystic lesion. Soon after percutaneous biopsy, she developed superior vena cava syndrome. She underwent left thoracotomy with gross total resection of the tumor. Histopathological analysis at the treating institution showed Type III PPB. Central pathology review provided by the International PPB Registry showed undifferentiated sarcoma with blastemal‐like features. Genetic analysis of the tumor revealed biallelic pathogenic mutations in *DICER1*. After surgery, she was treated with ifosfamide, vincristine, doxorubicin and dactinomycin. After completing primary treatment, she was released from the hospital in complete remission. Four months after finishing the primary treatment, a local recurrence was detected. She underwent gross total resection. Recurrent PPB was histologically confirmed. She is currently receiving second‐line treatment with ifosfamide, carboplatin and etoposide. Radiation therapy to the site of recurrence is planned.

**Conclusions**: The contralateral cystic lesion and age of our patient were classic for PPB, despite the histologic appearance being less classic. *DICER1* testing should be considered in young children with undifferentiated malignant thoracic tumors initially presenting with pneumonia, pneumothorax and solid, cystic or mixed lung lesions.

### PO-686. Successful Vemurafenib Re‐Challenge at Disease Reactivation in Refractory Multi‐System Langerhans Cell Histiocytosis {#pbc27455-sec-9220}

[S.Y. Soh]{.ul} ^1^, L.L. Htet^2^, D. Lian^3^

*^1^KK Women\'s and Children\'s Hospital, Haematology/Oncology, Singapore, Singapore; ^2^KK Women\'s and Children\'s Hospital, Pharmacy, Singapore, Singapore; ^3^KK Women\'s and Children\'s Hospital, Pathology and Laboratory Medicine, Singapore, Singapore*

**Background/Objectives**: The role of BRAF inhibitors in histiocytic disorders is increasingly being explored.

**Design/Methods**: We report a case of successful re‐challenge with vemurafenib at disease reactivation in a young infant with refractory multi‐system Langerhans cell histiocytosis (LCH).

**Results**: An infant presented at 4 months of age with multi‐system LCH with risk organ involvement. She showed partial response to prednisolone and vinblastine, but at week 19 of continuation developed disease progression (rash, hepatosplenomegaly, fever, malaise, cytopenias) which failed to respond to salvage chemotherapy. Immunohistochemistry for BRAF V600E was performed on a skin biopsy at disease progression which showed equivocal staining. Sequencing with two sets of primers (240bp & 210bp) revealed mutation at EXON14, c1799T\>A, confirming the presence of BRAF V600E mutation. With parental consent, vemurafenib was started at 60mg BID and gradually increased to 120mg BID (12mg/kg/dose) over 8 weeks. Within days, the parents reported improvement in the child\'s well‐being. After 3 weeks, she no longer needed transfusions, and her hepatosplenomegaly was regressing. She was continued on the same absolute dose (120mg BID) for 10 months but developed disease reactivation (fever, malaise, progressive hepatosplenomegaly and cytopenias, rash) within one week of stopping vemurafenib. Vemurafenib was restarted at disease reactivation, with again rapid improvement in her condition. Vemurafenib was then continued at the same dose of 120mg BID (despite the child\'s weight gain) for 12 months and then tapered off gradually over another 6 months. The child remained well months after tapering off vemurafenib.

**Conclusions**: The remarkable response in our patient at disease progression and again at "re‐reactivation" highlights the promising role of BRAF inhibitor in this group of high‐risk LCH patients where disease control can be very challenging and whose prognosis are often poor. Current limitations include the lack of commercially available pediatric formulation, and the inadequate understanding of optimal pediatric dosing and therapy duration.

### PO-687. Macrophage Activation Syndrome as Presentation of a Child with Concomitant Systemic Lupus Erythematosus and HIV Infection: A Case Report {#pbc27455-sec-9230}

[P. Sowithayasakul]{.ul} ^1^, C. Takpradit^2^, J. Buaboonnam^2^, P. Pruangprasert^1^, P. Takkinsatian^1^

*^1^Srinakharinwirot university, Pediatric, Bangkok, Thailand; ^2^Siriraj hospital‐ Mahidol university, Pediatric, Bangkok, Thailand*

**Background/Objectives**: Macrophage activation syndrome (MAS) is a life threatening complication of several autoimmune diseases. Systemic lupus erythematosus (SLE) is rarely reported in association with HIV infection but MAS in coexistence of SLE and HIV has never been reported in the literature. Herein, we report a case of SLE coexisting with HIV infection in a child manifesting as MAS.

**Design/Methods**: Case report

**Results**: A 13‐year‐old girl presented with fever for 2 weeks. Physical examination revealed body temperature of 39.5°C, puffy eyelids and splenomegaly. Her complete blood count showed hemoglobin 10.8 g/dL, WBC count 1,600 /mm3 (ANC count 660/mm3) and platelet count 57,000/mm3. She had been diagnosed as congenital HIV infection with good adherence to ARV therapy; her viral load was less than 20 copies/mL and CD4 count was 285 cells/mm3. Further investigations revealed hyperferritinemia (31,132.3 ng/mL), hypofibrinogenemia (130.6 mg/dL), fasting triglyceride was 537 mg/dL and increased hemophagocytic activity in bone marrow. Her blood urea nitrogen and creatinine were 61.4 and 2.58 mg/dL, respectively. Immunological screening was positive for ANA (≥ 1: 5,120 homogenous) and anti‐dsDNA (≥1:640). Serum C3 and C4 were low (0.27 g/L and 0.09 g/L, respectively). Her kidney biopsy report was compatible with lupus glomerulonephritis. She was diagnosed as MAS and was subsequently treated with HLH‐2004 treatment protocol consisting of IVIG, dexamethasone and etoposide. She did not respond to treatment and die of multi organ failure 10 days after initiation of treatment.

**Conclusions**: Macrophage activation syndrome in concomitant systemic lupus erythematosus and HIV infection is fatal. Physicians taking care children with HIV infection should be aware of such condition particularly in those presenting with prolonged fever and pancytopenia.

### PO-688. Descriptive Epidemiology of the Rare Pediatric Cancers of the Head and Neck Region in São Paulo State, Brazil {#pbc27455-sec-9240}

[L. Stangler]{.ul} ^1^, R. Hidalgo^1^, F. Moryama^1^, K. Ribeiro^1^

*^1^Faculdade de Ciências Médicas da Santa Casa de São Paulo, Department of Collective Health, São Paulo, Brazil*

**Background/Objectives**: Among children, all cancers are uncommon, but there is a mixture of neoplasms with particular biological and clinical characteristics, called rare tumors (RT). This study aimed to describe the epidemiology of RT in the head and neck region (H&N) among children and adolescents (0‐19 years old) in São Paulo state (SP), Brazil.

**Design/Methods**: This is a descriptive study, including all cases of RT in H&N, retrieved from the Hospital‐based Cancer Registry of SP, diagnosed between 2000 and 2013, and classified according to the definition of the Rarecare project. Descriptive statistics was used to characterize malignancies according to attributes of person (gender, age group, tumor type, previous diagnosis), place (home state), and time (year of diagnosis).

**Results**: We have identified 2,400 tumors (2,394 patients), corresponding to 22.9% of all RT in the pediatric group. Gender was equally distributed (50.8% males and 49.2% females), and most cases were diagnosed in young children (0‐4 years) (35.1%) and adolescents (15‐19 years, 33.9%). Approximately 62% of all cases arrived at the hospitals without a diagnosis, but this percentage was lower for those living outside SP (45.9% vs. 66.7% for individuals living in SP, p\<0.001). The majority of the cases lived in SP (79.4%), but all states were represented, with frequencies ranging from 0.2% (Paraíba) to 6.4% (Minas Gerais). Most frequent malignancies were: Hodgkin lymphoma (28.7%), retinoblastoma (28.7%), thyroid (13.7%), and nasopharyngeal carcinomas (5.5%). The number of cases has increased during the study period: from 147 (2000) to 205 (2013). Cases were managed in 60 hospitals, but seven were responsible for treating 74.4% of all cases.

**Conclusions**: The epidemiological profile of rare pediatric cancers of H&N in São Paulo state, Brazil, is similar to that reported in the literature. Treatment appears to be centralized in specialized centers. However, public policies to warrant faster diagnosis and referral are still required.

### PO-689. Denosumab Treatment of Giant‐Cell Tumors {#pbc27455-sec-9250}

G. Yavuz^1^, E. Unal^1^, N. Tacyildiz^1^, H. Dincaslan^1^, [H.G. Tanyıldız]{.ul} ^1^, B.A. Aksoy^1^, M. Berberoglu^2^, Z. Sıklar^2^, Z. Gordu^1^, F. Asarcikli^1^

*^1^Ankara University Medical Faculty, Pediatric Oncology, Ankara, Turkey; ^2^Ankara University Medical Faculty, Pediatric Endocrinology, Ankara, Turkey*

**Background/Objectives**: Giant‐cell tumor of bone (GCTB) is primarily seen in young adults. It is usually a benign tumor but frequently recurs locally after surgical resection.

**Design/Methods**: Here, we would like to present two pediatric patients successfully treated with denosumab.

**Results**: A 9‐year‐old girl presented with a facial mass causing a swelling on her left side. Family history revealed her father and brother being diagnosed as GCTB. The patient was treated with intralesionar steroids and calcitonin, developed cellulitis, was hospitalized with broad spectrum antibiotics, surgical drainage and curettage. After she was discharged, she was lost to follow up for 3 years, finally she admitted with a left maxillary huge mass. She was put on subcutaneous IFN‐Alpha2A 3million U/m2/d every other day and imatinib mesylate 400mg/day orally. Two months later maxillofacial surgeons performed intralesionar steroids/ weekly, for a month then every other month. Denosumab treatment was planned because there was no satisfactory regression of the tumor. She was started on denosumab with induction dosing of 120 mg subcutaneously/ weekly for 3 weeks, followed by 120 mg subcutaenously per month. She is currently 2 years into treatment. The patient has required 4,000 IU/ day of oral vitamin D and 40mg/kg/day elementary calcium supplementation because of developing hypocalcemia. The tumor showed shrinkage, the reconstructive surgery is planned. A four year old another female patient diagnosed with GCBT used b‐IFN‐Alfa2a and imatinib mesylate at first. When the patient had clinical and radiological progression, denosumab was started. The patient responded dramatically to denosumab.

**Conclusions**: Denosumab is a monoclonal antibody and is used in targeted therapies. GCTB is frequently seen in adults so our experinces are important for pediatricians.

### PO-690. Complete Control of a Post‐Transplant Monomorphic Lymphoproliferative Disorder (PTMLD) with the Sole Use of Hydroxyurea (HY) {#pbc27455-sec-9260}

V. Odone‐Filho^1^, [R.A. Teixeira]{.ul} ^1^, L.M. Cristofani^2^, C. Vince^1^, A.L. Cornacchioni^2^, L.R. Ricardi^2^, P. Maluf^2^, M.T. Almeida^2^, C. França^2^, P. Pereira^1^, A. Azambuja^1^

*^1^Sao Paulo University Medical School FMUSP‐ Sao Paulo‐ SP‐ Brazil and Albert Einstein Hospital HIAE‐ São Paulo‐ SP‐ Brazil, Pediatric Hematology‐Oncology Department at FMUSP ITACI and Hematology Division at HIAE, Sao Paulo, Brazil; ^2^Sao Paulo University Medical School FMUSP‐ Sao Paulo‐ SP‐ Brazil, Pediatric Hematology‐Oncology Department at FMUSP ITACI and Hematology Division at HIAE, Sao Paulo, Brazil*

**Background/Objectives**: HY is capable of interfering with Epstein‐Barr virus (EBV) replication by inhibiting ribonucleotide reductase. Low‐dose HY was shown to eliminate EBV episomes in EBV‐positive Burkitt\'s lymphoma, suggesting its value in EBV‐associated neoplasias (Chodosh J, 1998). Also, possible anti‐viral effects achieved with non‐toxic doses is attractive. Complete resolution(CR) of EBV‐associated PTMLD with HY, in a child without conditions for regular chemotherapy, is described.

**Design/Methods**: A 3‐year‐old girl, liver transplanted 13 months earlier due to an unspecific hepatitis, developed a plasmoblastic lymphoma involving multiple supradiaphragmatic nodal areas. Tumor cells were CD20+, with positive EBV *in situ* hybridization (EBVISH). Real‐time PCR (RTPCR) for EBV revealed 96,234 copies. She was treated as per the COG‐ANHL022 protocol, including Cyclophosphamide(CYCLO), Prednisone(PRED) and RITUXIMAB(six 375 mg/m^2^ weekly doses) with CR and disappearance of the viral load. 2 months later an aggressive recurrence was seen, with huge abdominal mass, documented by PET‐CT and bone marrow(BM) involvement. Biopsy revealed the same pattern of tumor, positive EBVISH, however without CD20+ cells. Only 4,026 copies of circulating EBV were found. Alternative aggressive chemotherapy (Etoposide + Doxorubicin + Vincristine + CYCLO and PRED), without Rituximab, determined tumor lysis syndrome but provided only a partial response. Biopsy of the remaining mass showed the same features, including negative CD20 and positive EBVISH. The decision of adding Hydroxyurea (30 mg/kg/day/X45 days) was done considering the child\'s precarious conditions and based upon the presence of tumor EBV.

**Results**: CR was achieved (negative PET‐CT and BM), without signs of tumor relapse as of 30 March, 2018 (follow‐up: 3 months). EBV RTPCR remains negative but the child now experiences signs of graft rejection (she had been out of immunosuppression ever since the diagnosis of PTMLD).

**Conclusions**: Hydroxyurea may be an useful and safe therapeutic approach for EBV‐related lymphroliferative disorders and an efficient preventive tool for viral replications and their potential consequences.

### PO-691. Pediatrics Nasopharyngeal Carcinoma: A Single Intuitional Experience {#pbc27455-sec-9270}

[T. Torchareon]{.ul} ^1^, H. Poparn^1^, N. Yupensuk^1^, K. Chiengthong^1^, P. Techavichit^1^, S. Lauhasurayotin^1^, D. Sosothikul^1^, P. Seksarn^1^

*^1^Faculty of Medicine, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Nasopharyngeal carcinoma (NPC) is rare in children. It is relatively common in Asian population compare to others.

**Design/Methods**: Retrospective review.

**Results**: Seven patients (6 males and 1 female), median age 13.8 years old, were diagnosed with NPC at out hospital during 2012 and 2017. Palpable mass with or without epistaxis are presentation in all cases. Only one case has Epstein‐Barr Viral (EBV) Load positive. Disease staging were III in four patients and IVA in two patients and IVB in one patient. Histology subtype consisted of non‐keratinizing in three and undifferentiated in four patients. All patients received neoadjuvant chemotherapy consisted of cisplatin and 5‐fluorouracil (5‐FU) for 3 cycles with subsequent 70 Gy irradiation with 2 cycles of adjuvant cisplatin. None of them underwent surgical tumor removal. Median time to recurrent event is 14 months. At the median follow up time of 21 months, four patients alive with no disease, one alive with disease and one loss to follow up.

**Conclusions**: NPC is rare among pediatric malignancies, predominant in male adolescent and EBV negative. Neoadjuvant chemotherapy with cisplatin and 5FU with irradiation reveled good disease response and outcome.

### PO-692. Clinical Profile and Outcomes of Langerhans Cell Histiocytosis in Children Requiring Systemic Chemotherapy: A Single Center Experience {#pbc27455-sec-9280}

[K. V P]{.ul} ^1^, S. Patel^1^, P. Kanvinde^1^, S. Mudaliar^1^, A. Swami^1^, Z. Golwala^1^, B. Agarwal^1^

*^1^Bai Jerbai Wadia Hospital for Children, Department of Pediatric Haemato‐Oncology, Mumbai, India*

**Background/Objectives**: Langerhans cell Histiocytosis(LCH) is a rare disease. Limited data has been published from India about LCH needing systemic chemotherapy.

**Design/Methods**: Retrospective analysis of patients requiring systemic chemotherapy for LCH‐SS(single system) with multifocal bone and MS(multisystem) with/without risk organ(RO) involvement in BJ Wadia Children\'s hospital,Mumbai was done from the period of 2010‐2017.

**Results**: 24 patients were treated during the period of 2010‐2017.Age at presentation varied from 1‐84 months with median age‐18 months and M:F ratio‐1.4:1.Bone(70%) and liver(66%) were most commonly involved followed by spleen(41%),hematopoietic system(37%),skin(50%),lung(45%),nodes(25%),CNS(16%),ear(12%),dental(4%). All children were started with LCH III/IV(referred as Standard protocol(SP)) protocol. Children with disease progression were treated with salvage protocols/JLSGP(Japanese LCH study group protocol)/targeted therapy. Response assessment was done at 6,12 weeks and completion.3 children with SS+multifocal bone involvement responded to SP;are in remission. Among 4 children with MS with RO‐,2 responded to SP.1 had disease progression;in remission with JLSGP and 1 relapsed 3 years post therapy,in remission with SP. All 4(100%)are presently in remission. Of the 17 children with MS and RO+,7(35%) are in remission with SP.6(35%) had disease progression‐1 had BRAF mutation;started on Vemurafinib;achieved remission.2(11%) started on Stratum III‐LCH IV‐both expired due to treatment toxicity. Among 3 on JLSGP,1 is in remission,2 progressed;opted for palliation.3 had worsening of liver disease during initial courses;expired. In total,9(52%) children with MS and RO+ are in remission. Mortality in our study was 35%(n‐6).Mortality following salvage therapy in our study is 100%.Comparitively,our results were better with targeted therapy(100%,n‐1) and JLSGP(50%,n‐4).Increased mortality in our study is probably due to extensive disease involvement at presentation.3 patients had Diabetes Insipidus in follow up;2‐MS/RO+ and 1‐MS/RO‐ at diagnosis.

**Conclusions**: LCH requires high index of suspicion for early diagnosis. Since our center is tertiary hospital in Western India,many of our patients were in an advance stage at diagnosis,which could be one of the reasons for our increased mortality. SS/MF bone involvement and MS/RO‐ have excellent prognosis with therapy.

### PO-693. Small Cell Carcinoma of the Ovary Presenting with Hypercalcaemia in Association with a SMARCA4 Mutation: Complexities of Management and Importance of Genetic Screening {#pbc27455-sec-9290}

[C. Willis]{.ul} ^1^, D. Murphy^1^, J. Sastry^1^, M. Ronghe^1^, D. McIntosh^1^

*^1^Royal Hospital for Children, Paediatric oncology, Glasgow, United Kingdom*

**Background/Objectives**: Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is an extremely rare ovarian tumour. Peak incidence is in the third decade. One year survival rates of fifty percent and five year survival rates of ten percent have been reported. SCCOHT are characterised by germline and somatic SMARCA4 mutations, sharing the same malignant features as malignant rhabdoid tumour groups.

**Design/Methods**: Our patient, a fourteen year old girl, presented with a six week history of abdominal pain, nausea and vomiting. Examination demonstrated a grossly distended abdomen with a large palpable pelvic mass. Initial bloods revealed hypercalcaemia (4.8). AFP and HCG were normal. Ca125 was elevated at 1113.

**Results**: MRI confirmed a large pelvic mass (12x17x27cm). Staging investigations revealed local regional spread and lung metastasis. Histologically, the tumour was composed of undifferentiated small round blue cells with oval vesicular nuclei and numerous mitosis. Immunohistochemistry was positive for vimentin, CD56 and EMA. Genetic testing revealed a heterozygous pathogenic variant in SMARCA4 (c.2502C.A). Mum also has a SMARCA4 mutation.

Hypercalcaemia was managed with IV fluids and pamidronate. Her management was discussed extensively at MDT. She was treated with cisplatin and etoposide chemotherapy. Dramatic initial symptom relief corresponded with a fall in calcium levels. Recurrence of symptoms during the second cycle corresponded with disease progression. Alongside symptomatic management, she underwent palliative laparotomy (ovarian mass resection and omentectomy) during the later stages of her disease, making her much more comfortable. With palliative care input, our patient passed away peacefully 4 months following diagnosis.

**Conclusions**: Management of patients with SCCOHT is complex. When metastatic, they are inevitably fatal. As with this case, the implications of the SMARCA4 mutation on other family members must be considered. The mother of this child subsequently had a bilateral oophorectomy. This is one of the youngest patients with SCCOHT reported in the literature.

### PO-694. A 10‐Year Retrospective Review of Lipoblastoma in a Single Tertiary Center {#pbc27455-sec-9300}

[H.Y. Wong]{.ul} ^1^, Y.K. Ng^1^, K.W.E. Chan^1^, K.H. Lee^1^

*^1^Division of Paediatric Surgery and Paediatric Urology‐ Department of Surgery‐ Prince of Wales Hospital‐ The Chinese University of Hong Kong, Department of Surgery, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Lipoblastoma is a rare childhood tumor originates from embryonal adipose tissue. The aim of this review is to study the surgical outcome of lipoblastoma in Chinese pediatric population.

**Design/Methods**: In this retrospective study, the surgical outcome in the management of lipoblastoma in a tertiary center in Hong Kong was studied.

**Results**: A total of 6 cases of lipoblastoma were treated at our unit from 2007 to 2017. Four boys and two girls (M to F ratio: 2:1) underwent surgical resection. All patients presented with asymptomatic and slow growing subcutaneous tissue mass. The median age of presentation was 13 months (range from 0.5month to 24 months) while the median age of diagnosis was 18 months (range from 18 months to 72 months). The median tumor volume was 35 cm3 as documented from imaging. Location were trunk (3), intra‐scrotal (1), scalp (1) and omentum (1). Cytogenetic study was performed in the most recent 2 cases and only 1 showed *PLAG‐1* gene alteration. At a median follow‐up of 19.5 months, no local recurrence was found.

**Conclusions**: This study concluded our experience in the surgical aspect in the management of lipoblastoma. A good long term outcome was expected in complete surgical excision but a high awareness is essential for timely diagnosis of this rare but benign tumor.

### PO-695. Clinical Features and Treatment of Thyroid Carcinoma in Children {#pbc27455-sec-9310}

[Y. Wu]{.ul} ^1^, Y. Wang^1^

*^1^Xinhua Hospital, Pediatric Surgery, Shanghai, China*

**Background/Objectives**: This article intends to summarize the clinical features of children with thyroid carcinoma treated in Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine in recent years, analyze the treatment methods and prognosis, and discuss the diagnosis and treatment experience.

**Design/Methods**: Nineteen children with thyroid cancer (≤14 years old) who were admitted to our hospital from January 2008 to December 2017 were reviewed. Clinical characteristics, pathological features, treatment methods, and their prognosis were carefully analyzed.

**Results**: Of the 19 patients, the youngest was 19 months and the largest was 12.6‐year‐old. All the patients were treated with surgery. The surgical methods included total thyroidectomy in 2 cases and subtotal thyroidectomy in 17 cases. Lymph node dissection was performed in 14 patients. Preoperative CT and postoperative 131I scan confirmed pulmonary metastases in 5 patients. Postoperative complications occurred in 4 patients: 2 cases suffered with hypocalcemia, and 2 patients developed sonar, which were all recovered after symptomatic treatment. Postoperative pathological results showed: papillary thyroid carcinoma (PTC) in 16 cases, and follicular thyroid cancer (FTC) in the other 3cases. All of the patients received 131I isotope therapy with a total dose of 30 to 150 mCi. In the follow‐up with 0.5 to 9.7 years, the overall survival rate was 89.5%. 7 cases (36.8%) had postoperative local recurrence or pulmonary metastasis, and two patients died.

**Conclusions**: Most of thyroid carcinoma in children are PTCs. These cancer is highly invasive. The recurrence rate of thyroid carcinoma in children is high, but overall prognosis is good. For high‐risk patients, total thyroidectomy or subtotal resection combined with cervical lymph node dissection is the very important. Besides that, postoperative long‐term follow‐up is necessary. 131I isotope therapy plays an important role in supporting treatment, and it need to performed with strictly indications.

### PO-696. Single System/Single Site Langerhans Cell Histiocytosis of Bone: Hacettepe Experience with 74 Children {#pbc27455-sec-9320}

[I. Yaman Bajin]{.ul} ^1^, B. Yalcin^1^, N. Kalkan^1^, I. Altan^1^, B. Aydin^1^, N. Kurucu^1^, A. Varan^1^, T. Kutluk^1^, C. Akyuz^1^

*^1^Hacettepe University, Department of Pediatrics‐ Division of Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Langerhans cell histiocytosis (LCH) is a rare disease that usually affects the bones. Single system/single site bone lesions are usually managed with surgical excision‐curettage (with or without intralesional steroid injections); chemotherapy and radiotherapy are other treatment options. In this study, we aimed to review our institutional experience with children having single system/single site LCH bone lesions.

**Design/Methods**: Hospital charts of children \<18 years of age diagnosed to have single system/single site LCH bone lesions at our hospital were reviewed retrospectively. Data for demographic characteristics, presenting symptoms, diagnostic interventions, treatment approaches, follow‐up events and final outcome were collected and analyzed.

**Results**: Seventy‐four LCH cases with single system/single site bone lesions were diagnosed between January 1990 and December 2017 \[male/female 43/31; median age 8 years (1‐18)\]. Initial presenting symptoms were swelling and pain for 96% of patients. Most frequent sites of involvement were skull in 46 patients (62%), trunk in 18 (24%) and extremities in 10 (13%). All cases had histopathological diagnosis with incisional biopsies in 20 and excisional biopsies‐curettage in 54. Fifty‐three (71%) and 2 patients were followed without any treatment after excision‐curettage and incisional biposies, respectively; 13 were treated with 'vinblastin+prednisolone' chemotherapy, six patients received radiotherapy (600‐2000 cGy) to sacroiliac region (n=1) and to vertebrae (n=5). At a median follow‐up of 57 months, 41 cases were lost to follow‐up, 33 were under regular follow‐up. The disease relapsed in 4 patients. All relapses were in distant bones and were treated with surgery, chemotherapy and/or radiotherapy with complete remissions. Seven (%9) patients had long‐term problems like tooth disruption, arm numbness and T12 vertebra compression.

**Conclusions**: Local control with surgical excision‐curettage was curative in most cases with single system/single site LCH bone lesions. Low dose radiotherapy can be used for selected cases, especially with vertebra involvement. Aggressive treatment should be avoided to prevent long term morbidity.

### PO-697. Kasabach‐Merritt Phenomenon Lessons and Outcomes: A Single Center 10‐Year Experience from China {#pbc27455-sec-9330}

[X. Yuan]{.ul} ^1^, S. Huang^1^

*^1^Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Pediatric Hematology/Oncology, Shanghai, China*

**Background/Objectives**: Kasabach‐Merritt phenomenon (KMP) is rare in patients with hemangioma, but has a rapid progress and poor prognosis. There is not a recognized optimal therapeutic schedule. The aim of this study was to analyze the characteristics of massive hemangioma with KMP, compare the different efficacy with multiple modalities, calculate the cost of treatment, and reduce the misdiagnosis to this disease.

**Design/Methods**: We retrospectively collected the archives of 6120 infants who diagnosed with hemangioma between April 1st 2006 and December 31th 2017 at Xinhua Hospital, 31 cases developed to KMP. They were treated with combined therapy or monotherapy. The median followed‐up time was 4 years. The main observing indexes included variations of lump size, platelet counts and coagulation disorders at pre‐ and post‐treatment.

**Results**: The KMP incidence rate of infants with hemangioma in our center was 0.5%. Male to female ratio was 1.4:1. The median age at diagnosis was 90 days. The average interval before diagnosis was 56 days after the onset of KMP. The average total cost of treatment was about 21,863 (from 3,152 US\$ to 78,817 US\$). Twenty (64.5%) infants received combined therapy, all of them got complete remission (CR) and were still alive. Eleven cases received monotherapy. Among them, three infants got CR, three got partial remission (PR), three showed no response (including one lost follow‐up, two died finally). One patient only underwent surgery due to localized primary lump, who got CR after operation. Another infant just received supportive care and then abandoned any treatment due to deteriorative coagulation disorder.

**Conclusions**: The misdiagnosis and delayed diagnosis were two risk factors of poor prognosis of KMP and increased the treatment cost. In this study, combined therapy was superior to monotherapy, which could greatly improve the prognosis of KMP.

### PO-698. Quality of Life and Social Features Among Long‐Term Survivors of Childhood Thyroid Cancer in Belarus {#pbc27455-sec-9340}

[H. Zbarouskaya]{.ul} ^1^

*^1^Belarusian Research Center for Pediatric Oncology‐ Hematology and Immunology, Childhood Cancer SubRegistry of Belarus, Minsk reg, Belarus*

**Background/Objectives**: The quality of life of the long‐term survivors of childhood cancer and their social functioning are of unquestionable importance in the era of pediatric oncology success.

**Design/Methods**: We used WHOQOl‐Bref survey among 96 long‐term survivors of pediatric thyroid cancer cured in 1990‐2000 years in Belarus. Four domains (physical health, psychological, social relationships and environment) were scored and transformed to a 0 to 100 scale and presented as mean±s.e. We added additional questions to the survey: the level of education, employment, marital status, children, diseases other than thyroid carcinoma, disability. The majority of patients were from Gomel (44.8%) and Brest (28.1%) regions of Belarus. Median age at the moment of Chernobyl disaster was 2.1 years, median age at the time of illness was 12.7 years, at the time of filling the questionnaire ‐ 32.8 years. M/F ratio was 0.55.

**Results**: Distribution of respondents by level of education: higher ‐ 30 people (31.3%); secondary (secondary special, secondary technical) ‐ 61 people (63.5%); basic (9 classes) ‐ 5 (5.2%). Unemployed 10 from 34 men (29.4%) and only 6 from 62 women (9.7%). Sixty five (67.7%) respondents were married. The level of marriage was higher among those having higher education ‐ 26 (86.7%). There were no children in 29 participants (30.2%), 1 child in 32 participants (33.3%), 2 children ‐ in 30 cases (31.3%), 3 or more children in 5 families (5.2%). Sixty people (62.5%) indicated illness and 76 (79.2%) had a disability. According the surveys respondents, mean overall perception of quality of life was 3.3; quality of health ‐ 2.8; domain 1 (phisical health) 57.1±1.68; psychological 58.1±1.64; social relationships 62.2±2.13; environment 50.0±1.51.

**Conclusions**: Knowledge of the factors, affected the quality of life in the long‐term survivors of childhood thyroid cancer is extremly necessary for the planning of their rehabilitation activities and adequate social functioning in society.

### PO-699. Expression and Clinical Significance of Vascular Endothelial Growth Factor in 66 Children with Malignant Solid Tumors {#pbc27455-sec-9350}

[W. Zhang]{.ul} ^1^, Y. Zhang^1^, D. Huang^2^

*^1^Beijing Tongren Hospital, Pediatrics, Beijing, China; ^2^Beijing Tongren Hospital‐Capital Medical University, Pediatrics, Beijing, China*

**Background/Objectives**: With analysis of vascular endothelial growth factor (VEGF) expression characteristics in tumor tissue of malignant solid tumors cases, to explore its correlation with tumor types, metastasis and prognosis.

**Design/Methods**: Clinical data of 66 patients those VEGF gene expression in tumor tissue were detected were collected in our hospital, the correlation among the VEGF expression and metastasis and different tumor types and prognosis were analyzed with application of statistics.

**Results**: Classification of malignant solid tumor. Neuroblastoma in 21 cases, hepatoblastoma in 17 cases, Wilms' tumor in 12 cases, rhabdomyosarcoma in 8 cases, primitive neuroectodermal tumor in 4 cases, other tumors in 4 cases. The expression of VEGF gene and distant metastasis. Tumor distant metastasis rate in low expression group, middle expression group and high expression group were 50% (11/22), 66.67% (14/21) and 91.30% (21/23), respectively. P value of Fisher exact test of three groups was P=0.008, and the difference was statistically significant Characteristics of VEGF mRNA expression and distant metastasis In 21 cases of neuroblastoma showed that 7 cases with metastasis in low expression group, 4 cases with metastasis in middle expression group and 6 cases with metastasis in high expression group. There was no significant difference of Fisher exact test (P=1.00). VEGF gene mRNA expression and prognosis. Survival time in low expression group of VEGF mRNA was (61.82± 12.00) months, while the survival time of the middle expression group was (40.37 ±6.28) months, the survival time of the high expression group was (37.19 ± 4.71) months. Three group test showed no significant difference (P=0.482).

**Conclusions**: The expression level of VEGF gene mRNA in tumor tissues is closely related to tumor distant metastasis. The proportion of middle and high VEGF mRNA expression in hepatoblastoma and Wilms' tumor tissue is significantly higher than that in neuroblastoma tissure.

Treatment and Care ‐ Radiation Oncology (PROS) {#pbc27455-sec-9360}
----------------------------------------------

### PO-700. Telemedicine for Case Conferencing in Australia and New Zealand (ANZ) ‐ Improving Paediatric Radiation Therapy Quality and Preparing for Protons {#pbc27455-sec-9370}

[V. Ahern]{.ul} ^1^, J. Chard^2^, R. Cheuk^3^, P. Daly^4^, M. Dwyer^5^, C. Harrington^6^, B. Hindson^7^, L. Murphy^2^, A. Salkeld^2^, J. cantwell^2^, G. Wheeler^5^

*^1^Crown Princess Mary Cancer Centre‐ Westmead Hospital. Sydney Medical School‐ University of Sydney, Radiation Oncology, Westmead Sydney, Australia; ^2^Crown Princess Mary Cancer Centre‐ Westmead Hospital, Radiation Oncology, Westmead Sydney, Australia; ^3^Royal Brisbane and Womens\' Hospital, Radiation Oncology, Brisbane, Australia; ^4^St Luke\'s Radiation Oncology Network, Radiation Oncology, Dublin, Ireland; ^5^Peter MacCallum Cancer Centre, Radiation Oncology, Melbourne, Australia; ^6^Christchurch Hospital, Radiation Oncology, Christchurch, New Zealand; ^7^Christchurch Hospital, Radiation Oncology, Christchurch, New Caledonia*

**Background/Objectives**: Fewer than 20 radiation oncologists in ANZ manage children. They are scattered over a vast geographic area and 4 time zones. A fortnightly paediatric radiation therapy (RT) videoconference began in August 2013 as an initiative of the Paediatric Radiation Oncology Special Interest Group of the Royal Australian and New Zealand College of Radiologists. The purpose was to ensure children receive high quality RT. There is no proton facility in ANZ currently. The aim of the current audit was to document cases discussed, changes in RT made as a consequence of the conference, and referral of children for more specialised RT including protons.

**Design/Methods**: Minutes of all videoconferences held until January 2018 were reviewed. Information analysed included tumour pathology, presentation purpose and timing (before, during or after commencement of RT), review of RT target volumes and organs at risk, management changes made, and whether there was a recommendation for proton or brachytherapy.

**Results**: Over 200 cases have been presented. Almost all cases were presented for the purpose of discussion about the appropriate use of RT, or the RT target volume and dose. Changes to treatment intent or to the RT plan were made in around 1 in 8 cases. Peer review of RT target volumes was performed for only 10% of cases. Three patients were referred abroad for proton therapy as a result of discussion at the videoconference, and two patients were referred to other cities for brachytherapy.

**Conclusions**: Telemedicine has brought together the small group of paediatric radiation oncologists in ANZ. The case conference has resulted in RT management change for an important proportion of children discussed. The next phase is to implement a Quality Assurance checklist for peer review of RT treatment plans for all children treated with radical intent, prior to the start of RT.

### PO-701. ASTRO/ARRO Global Health Scholar Program: Pediatric Radiation Oncology in Dominican Republic {#pbc27455-sec-9380}

[S.A. Castaneda]{.ul} ^1^, S. Gajjar^2^, L. Quiroz^3^, L.T. Komarnicky^1^, S.E. Romero Zoghbi^4^

*^1^Hahnemann University Hospital -- Drexel University College of Medicine, Department of Radiation Oncology, Philadelphia, USA; ^2^University of Miami, Department of Radiation Oncology, Miami, USA; ^3^Clinica Abreu, Service of Radiotherapy and Radiosurgery, Santo Domingo, Dominican Republic; ^4^Oncoserv Santo Domingo, Service of Radiotherapy, Santo Domingo, Dominican Republic*

**Background/Objectives**: The Dominican Republic (DR) has a robust model for radiotherapy but insufficient data regarding resources for pediatric radiotherapy is available. In contrast, Haiti currently has no working radiotherapy services. We sought to elucidate the model for pediatric oncology, review the pediatric experience at a primary referral site, and identify opportunities in global health in the DR.

**Design/Methods**: Two radiation‐oncology residents participated in the American Society for Radiation Oncology/Association of Residents in Radiation Oncology (ASTRO/ARRO) Global Health Scholar Program aiming to study the radiotherapy services model in DR. Oncoserv Santo Domingo was selected as a primary pediatric radiotherapy referral site to explore global health opportunities.

**Results**: DR has several payment models for healthcare services including contributive regimen (employment based), subsidized regimen (government sponsored), private insurance (national and international policies), and out‐of‐pocket self‐payed (minority of patients). Most pediatric patients were treated in referral cancer centers with modern radiotherapy equipment and expert pediatric staff (hematology, oncology, radiotherapy, surgery, and anesthesiology). One‐hundred‐seventy pediatric patients treated at Oncoserv Santo Domingo (August 2012‐August 2017) were analyzed. Patients included 90 males and 80 females with median age of 10 years (range 3‐17 years). Seventy‐four patients had CNS tumors, 65 hematologic malignancies, 16 Wilms tumors, eight head/neck tumors, six bone/soft‐tissue disorders, and one a gynecological malignancy. Radiotherapy goals were definitive/adjuvant in 112, prophylactic in 48, and palliative in 10 of them. All patients were treated using LINACs employing a 2D technique (3 cases), a 3DCRT technique (152 cases), and an IMRT technique (15 cases). Interestingly, 153 patients were from DR and 17 from Haiti. Patients from both nationalities had similar demographic and oncological characteristics.

**Conclusions**: DR has a well‐developed radiotherapy infrastructure offering modern techniques to pediatric patients from both DR and Haiti. Further studies are warranted to characterize the global health model that allows treating pediatric patients coming from Haiti.

### PO-702. Differential Gene Expression in Thalamic Astrocytes after Cranial Irradiation to the Developing Brain {#pbc27455-sec-9390}

[Y. Eriksson]{.ul} ^1^, M. Boström^2^, T. Björk‐Eriksson^3^, M. Kalm^1^

*^1^University of Gothenburg/Sahlgrenska Academy‐ Institute of Neuroscience and Physiology, Department of Pharmacology, Gothenburg, Sweden; ^2^University of Gothenburg/Sahlgrenska Academy ‐ Institute of Neuroscience and Physiology. University of Gothenburg/Sahlgrenska Academy ‐ Institute of Clinical Sciences, Department of Pharmacology, Gothenburg, Sweden; ^3^University of Gothenburg/Sahlgrenska Academy ‐ Institute of Clinical Sciences, Department of Oncology, Gothenburg, Sweden*

**Background/Objectives**: Brain tumours are one of the most common childhood cancers. Cranial radiotherapy is one treatment, which can lead to permanent brain damage. The late effects after irradiation include perturbed growth, late puberty and cognitive impairment. Understanding the mechanisms in this chronic damage is of major importance to be able to find ways to help childhood cancer survivors. Amyloid precursor protein, which often is associated with Alzheimer\'s disease, accumulates in the thalamus four months after irradiation to the developing brain. Interestingly, the accumulation occur in astrocytes. The aim of this project was to identify genetic alterations in the astrocytes after cranial irradiation that could be used to better understand injury mechanisms.

**Design/Methods**: Male mice received a single dose of 8 Gray to the brain at postnatal day 14. Four months after irradiation thalamus was homogenized followed by fluorescence‐activated cell sorting targeting astrocytes. Next generation sequencing followed by Ingenuity Pathway Analysis was used to analyse differential gene expression (*p* ≤ 0.05) in thalamic astrocytes after irradiation.

**Results**: Cranial irradiation to the young mouse brain increase the number of thalamic astrocytes with 54% compared to controls. Further, genes involved in cognition and immunology showed altered responses four months after cranial irradiation. A consistent downregulation was observed in genes involved in cell structure, cell adhesion and cell motility. Interestingly, genes coding for axonemal dyneins, which are expressed in primary cilia, were also all downregulated.

**Conclusions**: Cranial irradiation to the young mouse brain increases the number of thalamic astrocytes and alter the gene expression four months after the injury was induced. Basic and important functions are negatively affected in thalamic astrocytes after irradiation. The increase of astrocytes in thalamus might therefore be a compensatory mechanism in response to radiation induced‐injury.

### PO-703. Is Respiration of Children Constant During a Radiotherapy Session? {#pbc27455-sec-9400}

[S. Huijskens]{.ul} ^1^, I. van Dijk^1^, J. Visser^1^, B. Balgobind^1^, A. Bel^1^

*^1^Academic Medical Center, Radiation Oncology, Amsterdam, The Netherlands*

**Background/Objectives**: A pre‐treatment four‐dimensional CT scan (4DCT) quantifies respiratory motion in order to optimize safety margins. However, in both children and adults, respiratory motion as measured on 4DCT does not always accurately predict the respiratory motion throughout a treatment course, suggesting that respiratory motion could also be monitored throughout the treatment using pre‐treatment cone‐beam CTs (CBCTs). The aim of this study was to investigate if respiratory‐induced diaphragm motion in children is constant during a radiotherapy session.

**Design/Methods**: This retrospective study is based on 52 abdominal‐thoracic CBCTs of 11 children (\<18 years) treated with radiotherapy for various childhood cancers. According to protocol settings, these patients received pre‐ and post‐treatment CBCTs within one or multiple fractions over their treatment course. For each CBCT, the cranial‐caudal diaphragm dome position was manually detected in the CBCT projection images corresponding to the end‐exhale and end‐inhale phases. The amplitude was quantified as the difference in diaphragm dome positions between end‐exhale and end‐inhale phases. Respiratory motion was also expressed as breathing frequency (breaths/min). We tested the possible differences in amplitude and frequency between the pre‐ and post‐treatment CBCTs (paired t‐test, *p\<0.05*).

**Results**: The mean CBCT acquisition time interval was 19min (range 4‐34 min). Overall, the average amplitude and standard deviation in the pre‐ and post‐treatment CBCT was 11.4±3.4mm and 11.1±3.5mm, respectively (*p=0.46*). For 18/26 fractions (69%) the amplitude was larger on the first CBCT than on the second CBCT. The absolute difference in amplitude between the CBCTs was on average 1.6mm, with a difference \>3mm in 4 fractions of 4 patients. Breathing frequency was also not significantly different between the pre‐ and post‐treatment CBCT (average 21.2 and 21.1 breaths/min, respectively, *p=0.86*), and the average difference was 2 breaths/min.

**Conclusions**: Respiratory‐induced diaphragm motion in children is constant during a radiotherapy session and could thus be reliably predicted from a single pre‐treatment CBCT.

### PO-704. Head and Neck (H&N) Rhabdomyosarcoma: Outcomes of Patients with Low and Intermediate Risk Disease {#pbc27455-sec-9410}

[S. Laskar]{.ul} ^1^, A. Sasidharan^1^, N. Khanna^1^, R. Singh^1^, G. Chinnaswami^2^, T. Vora^2^, S. Qureshi^3^, M. Ramadwar^4^, S. Kembhavi^5^, S. Shah^6^, M. Prasad^2^, A. Baheti^5^, M.A. Muckaden^7^, P. Kurkure^2^

*^1^Tata Memorial Hospital, Radiation Oncology, Mumbai, India; ^2^Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; ^3^Tata Memorial Hospital, Surgical Oncology, Mumbai, India; ^4^Tata Memorial Hospital, Pathology, Mumbai, India; ^5^Tata Memorial Hospital, Radiodiagnosis, Mumbai, India; ^6^Tata Memorial Hospital, Bio Imaging, Mumbai, India; ^7^Tata Memorial Hospital, Palliative Care, Mumbai, India*

**Background/Objectives**: To analyze the outcomes of patients with low and intermediate risk H&N rhabdomyosarcoma treated with IRS IV chemotherapy regimen along with radiotherapy and/or surgery.

**Design/Methods**: Medical records of 102 patients with low and intermediate risk H&N rhabdomyosarcoma treated between 2007 and 2016 in a single institution were analyzed.

**Results**: Median age was 8 years (range: 3 mths -- 50 yrs; 83.3% were less than 20 yrs). The commonest histology was ERMS (59.8%), followed by ARMS (29.4%), Not specified (5.9%), Pleomorphic (2.9%) and Spindle cell (2.0%). The site of disease was parameningeal (69.6%), orbit (16.7%) and other non‐parameningeal sites (13.7%). Mean tumor size was 4.6 cm (range: 1--11 cm). Regional nodes were positive in 30.4%. Majority (73.5%) had intermediate risk disease. Median duration of induction chemotherapy was 6 weeks (range: 0‐36 weeks). Local therapy in the form surgery alone, radiotherapy alone and surgery followed by radiotherapy was received by 1.9%, 74.8% and 22.5% patients respectively. After a median follow up of 30 mths (range: 4--115 mths) the local control (LC), disease free survival (DFS) and overall survival (OS) at 5 yrs were 71.7%, 64.6% and 83.2% respectively. Patients with low risk had superior outcomes compared to intermediate risk disease (LC: 87.4% vs 66%, DFS: 87.9% vs 56.2% and OS: 96% vs 78.3%). Patients with orbital disease had superior DFS compared to other sites (68.2% vs 63.1%). Relapse was seen in 30.4% patients of whom 17.6% had isolated local relapse. Grade 3 acute skin and mucosal toxicities were seen in 2%. Late toxicities included cataract, xerostomia, dental caries and subcutaneous fibrosis in 14.7%, 8.8%, 7.8% and 2% respectively.

**Conclusions**: IRS‐IV chemotherapy along with radiotherapy and/or surgery in patients with H&N rhabdomyosarcoma results in good disease outcome with acceptable toxicities.

### PO-705. Four‐Dimensional Computed Tomography‐Derived Internal Target Volumes Reduce Volume of Normal Tissue in the High Dose Region in Intensity Modulated Radiotherapy Planning for High Risk Neuroblastoma {#pbc27455-sec-9420}

*^1^Institute of Cancer Research, Radiotherapy and Imaging, London, United Kingdom; ^2^Royal Marsden NHS Foundation Trust, Joint Department of Physics, London, United Kingdom; ^3^Royal Marsden NHS Foundation Trust, Children\'s and Young People\'s Unit, London, United Kingdom*

**Background/Objectives**: Upper abdominal organ motion in children may be overestimated by currently applied population‐derived planning target volumes (PTV). A four‐dimensional computed tomography (4DCT) ‐derived internal target volume (ITV) approach is used in adult radiotherapy planning to take respiratory‐related organ motion (RROM) into account but is less well described in paediatric cohorts. In this study, the dosimetric consequences for target coverage and organs at risk from the use of an ITV approach compared to population‐derived PTV margins for high risk neuroblastoma (HR‐NBL) were investigated.

**Design/Methods**: 14 patients (9 midline targets, 5 lateralised) with HR‐NBL each had two dual arc volumetric modulated arc therapy plans (1.5Gy x 14) created on the average 4DCT phase; 1 used an ITV approach using motion information from 4DCT (PTV_itv) with a 5mm ITV to PTV expansion, and 1 used standard PTV (PTV_conv) with a 10mm CTV to PTV expansion. Changes in PTV size and number of vertebral levels irradiated to near prescription dose were compared in addition to differences in D98, D95 for target coverage.

**Results**: PTV volumes generated with the ITV approach were consistently smaller; mean 281.4cc (SD 240.4cc, range 58.2 -- 1030.2cc) compared to 422.9cc (SD 302.7cc, range 107.3 -- 1339.5cc), P \< 0.001. An ITV approach enabled a reduction in vertebral levels irradiated to near prescription dose in 6/14 patients. All PTV_itv plans met clinical dose objectives for PTV and kidney. PTV coverage was compromised in 3 midline PTV_conv plans to meet kidney constraints; PTV_conv mean D98 19.9Gy (1.3Gy) compared 20.4Gy (0.1Gy) for PTV‐itv, p=0.02.

**Conclusions**: An ITV approach to RROM in children significantly reduces absolute PTV volumes. Dosimetric gains in target coverage and kidney dose for midline targets and a reduction in the number of vertebral bodies irradiated to near prescription dose for a proportion of patients is demonstated.

### PO-706. Deformable Image Registration of Four‐Dimensional Computed Tomography Demonstrates Significantly Less Renal Motion in Children Under General Anaesthetic Compared to Children Who Are Not {#pbc27455-sec-9430}

[N. Lavan]{.ul} ^1^, D. McQuaid^2^, G. Smyth^2^, S. Vaidya^3^, F.H. Saran^3^, H. Mandeville^3^

*^1^Institute of Cancer Research, Radiotherapy and Imaging, London, United Kingdom; ^2^Royal Marsden NHS Foundation Trust, Joint Department of Physics, London, United Kingdom; ^3^Royal Marsden NHS Foundation Trust, Children\'s and Young People\'s Unit, London, United Kingdom*

**Background/Objectives**: Optimal use of abdominal intensity‐modulated RT and proton therapy (IMRT, IMPT) requires quantification of internal motion. Common solid tumours requiring upper abdominal RT occur in very young children; the majority of whom require general anaesthesia (GA). 4DCT is commonly used for intrafraction motion assessment in adults. This study uses deformable image registration (DIR) of 4DCT to estimate kidney motion in paediatric patients with and without GA.

**Design/Methods**: 20 patients were included (17 right and 13 left kidneys); 8 GA; median age 3.4 (SD 1.5, range 1.7‐6.1) and 12 without GA; median age 7.3 (SD 4.9, range 4.1‐17.5). Kidneys were contoured on 10 phases of 4DCT by a single clinician. DIR of 4DCT (0% reference phase) was performed in RayStation v6.99 (RaySearch Laboratories AB, Stockholm). Deformation vector field (DVF) displacement of voxels within kidneys quantified motion in superior / inferior (SI), right /left (RL) and anterior / posterior (AP) directions. For each patient, the largest mean DVF displacement RL, AP and SI was determined (a 'worse case' scenario for motion‐encompassing planning) and compared between groups.

**Results**: Median DVF displacement (mm) for patients under GA was 0.1, 0.1, 0.1 and ‐0.1, 0.1 and 0.4 for right and left kidneys in RL, AP and SI compared to patients not under GA; ‐0.1, 0.9, 3.2 and ‐0.5, 0.3, 1.8 respectively and was statistically significantly different between the two groups (p\<0.0007, Wilcoxon signed rank test). Greater individual variation is demonstrated in patients without GA; maximum displacement superiorly of 6.4mm compared to 1.4mm in those under GA.

**Conclusions**: Intrafraction kidney motion in very young anaesthetised children is small and strategies to reduce systematic and random set‐up uncertainties are warranted to optimally maximise normal tissue sparing made possible by IMRT and IMPT. Wide variation in SI motion in children not under GA supports individual motion assessment for these patients.

### PO-707. Total Body Irradiation by Volumetric Modulated ARC Therapy for a Pediatric Patient with Acute Lymphoid Leukemia {#pbc27455-sec-9440}

[V. Lee]{.ul} ^1,2^, T. Hui^2^, E. Lee^2^, J. Chan^2^, D.L.W. Kwong^1,2^, Z.J. Chen^2^, K. Lai^2^, A.W.M. Lee^1,2^

*^1^The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong S.A.R.; ^2^The University of Hong Kong‐Shenzhen Hospital, Clinical Oncology Center, Shenzhen, China*

**Background/Objectives**: Volumetric modulated arc therapy (VMAT) delivering total body irradiation (TBI) for pediatric patients has not been reported since prolonged anesthesia/sedation is necessitated during planning and treatment. We report the feasibility of VMAT in delivering TBI for our first pediatric patient.

**Design/Methods**: An eight‐year‐old boy diagnosed to have T‐lymphocyte acute lymphoid leukemia was referred for TBI before autologous stem cell rescue in February 2018. After intravenous sedation and immobilization by vacuum mattress, computed tomography (CT) scan of the whole body was performed with 3mm slice thickness. The CT images were split into 5 segments which were planned with 5 isocenters. Autosegmentation of important organs‐at‐risk including lungs, heart, brain, kidneys as well as the planning target volume (PTV) were performed by Eclipse Treatment Planning System^TM^ version 11.0 with manual adjustment and the treatment plan was generated by RapidArc^TM^ software. VMAT with 3 full arcs to the upper body (3 segments) and 2 full arcs to the lower body (2 segments) were delivered with an overlap of at least 3cm into the neighboring segment to improve dose homogeneity. Twelve Gy in 6 fractions was given to the PTV by a 6MV linear accelerator.

**Results**: The mean doses to the lungs, heart, brain and kidneys were 10.8, 12.4, 12.9, and 12.7 Gy respectively. The percentage of PTV receiving 90%, 95%, 100%, 110% and 120% of prescribed dose were 98.0%, 95.9%, 86.0%, 1.5% and 0% respectively (Dmax 114.0%). The total MU of each segment in each fraction was 536, 558, 516, 426 and 438 MU. The time for contouring, dose calculation and optimization and quality assurance was 5, 40 and 48 hours. The treatment was well tolerated with only self‐limiting acute grade 1 fatigue.

**Conclusions**: VMAT is highly feasible for TBI in our patient, at the expense of long planning, quality assurance, patient setup and treatment delivery time.

### PO-708. Proton Beam Radiation Results in Pediatric Head and Neck Rhabdomyosarcoma {#pbc27455-sec-9450}

[F. Meniai]{.ul} ^1^, S. Bolle^2^, F. Goudjil^3^, R. Dendale^1^, S. Helfre^1^

*^1^Institut curie, Radiation Oncology, Paris, France; ^2^Institut Gustave Roussy, Radiation Oncology, Paris, France; ^3^Institut curie, Department of Physics, Paris, France*

**Background/Objectives**: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric population. In 35% of cases, RMS develops in the head and neck (H&N) region. Proton beam therapy (PBT) may reduce toxicity by limiting exposure of normal tissue to radiation. In this study, we report toxicities and outcomes following PBT for pediatric H&N RMS.

**Design/Methods**: Between May 2006 and February 2015, pediatric patients with localized or metastatic embryonal RMS were treated with PBT. Clincal and dosimetric data were abstracted from the medical record and treatment planning system with institutional review board approval. All patients have recieve chemotherapy and protontherapy. Surgical resection was based on tumor site and accessibility. The toxicities were graded according to Common Terminology Criteria of Adverse Events,Version 4.0.

**Results**: Fifty six consecutive pediatric patients were treated with PBT for H&N RMS. Median follow‐up was 52 months (range, 6 to 118 months).The median dose was 54 (36‐59.4) Gy relative biological effectiveness (RBE). Tumor sub sites included Para meningeal (54%), orbit (41%) and other (5%). Actuarial 5‐years events‐free survival (EFS), overall survival (OS), and local control (LC) were 77%, 81% and 85% respectively, for the entire cohort. Grade 3 acute radiation dermatitis, oral mucositis was reported to be 9% and 2%, respectively. There were no acute toxicities higher than Grade 3. Common late toxicities were facial deformity (n=15, 27%), cataract (n= 10,18%), dental problems (n= 4,7%), chronic otitis (n= 2, 4%), and hearing loss (n= 6, 11%), growth hormone deficit (n= 7,12%). There were tow secondary solid malignancies.

**Conclusions**: In this study, we report low rates of acute and late toxicities in a cohort of pediatric patients with H&N RMS. Late toxicities are common in survivors of pediatric H&N RMS. PBT appears safe to represent effective radiation modality for pediatric H& N RMS. Longer follow‐up will be required to evaluate the quality‐of‐life analyses.

### PO-709. Dosimetric Benefit of Highly‐Conformal Volumetric Modulated ARC Therapy (VMAT) Compared to Two Opposing Photon Beams (AP‐PA) for Flank Irradiation in Pediatric Renal Tumors {#pbc27455-sec-9460}

[J. Mul]{.ul} ^1^, E. Seravalli^2^, M. Bosman^2^, C. van de Ven^1^, M.M. van den Heuvel‐Eibrink^1^, G.O. Janssens^1^

*^1^Princess Maxima Center for Pediatric Oncology, Radiation Oncology, Utrecht, The Netherlands; ^2^University Medical Center Utrecht, Radiation Oncology, Utrecht, The Netherlands*

**Background/Objectives**: In current renal tumor protocols, post‐operative radiotherapy to the flank is administered in ±20% of cases. Over decades, two opposing photon beams (AP‐PA) has been the standard technique for flank irradiation. Recently, a consensus guideline for highly‐conformal delineation of the target volume has been developed by the SIOP‐Renal Tumor Study Group. This guideline combined with Volumetric Modulated Arc Therapy (VMAT) should enable sparing of a large amount of normal tissue and organs at risk (OARs).

The purpose of this study is to analyze the dosimetric benefit of VMAT versus AP‐PA.

**Design/Methods**: Twenty consecutive children with renal tumors (10 right‐ and 10 left‐sided; median age:3.2 years) were selected. For the purpose of this study a therapeutic dose of 14.4Gy in 1.8Gy fractions was used, since this is prescribed in the majority of patients. Of all delineated organs, the contra‐lateral kidney, pancreas and intestines were considered as clinical relevant OARs. Mean doses to the OARs were compared.

**Results**: No significant differences between both techniques in CTV coverage, averaged over all patients, were found (VMAT:99.9%; AP‐PA:99.8%; P=0.23). For the whole group, a reduction in mean dose to the kidney (VMAT:3.6Gy; AP‐PA:4.9Gy; P=0.02), pancreas (VMAT:10.1Gy; AP‐PA:12.7Gy; P=\<0.01) and intestines (VMAT:7.2Gy; AP‐PA:10.2Gy; P=\<0.01) was observed for VMAT. For individual patients dose reductions to the kidney, pancreas, and intestines up to 6.4Gy, 12.5Gy and 5.0Gy, respectively, were obtained with VMAT.

The body volume outside of the CTV receiving 80% of the prescribed dose, averaged over all patients, is 2.2 times higher for the AP‐PA technique (AP‐PA:1,774cm3; VMAT:804cm3; P=\<0.01) while the one receiving 20% of the prescribed dose is comparable for both techniques (AP‐PA:2,286cm3; VMAT:2,444cm3: P=0.06).

**Conclusions**: VMAT applied for highly‐conformal flank delineations of pediatric renal tumors reduces normal tissue dose compared to AP‐PA. For individual patients dose reductions exceeding 5.0Gy are observed when 14.4Gy is prescribed.

### PO-710. Bladder Toxicity and Clinical Outcome in Children with Pelvic Rhabdomyosarcoma {#pbc27455-sec-9470}

[S. Nagaraja]{.ul} ^1,2,3^, T. Steinmeier^2,3^, C. Plass^1,2,3^, S. Plaude^2,3^, S. Peters^1,2,3^, C. Blase^4^, P.H. Kramer^2,3^, D. Geismar^1,2,3^, B. Timmermann^1,2,3^

*^1^Clinic for Particle Therapy‐ University Hospital Essen, Hufelandstraße 55‐ 45147, Essen, Germany; ^2^West German Cancer Center WTZ, Hufelandstraße 55‐ 45147, Essen, Germany; ^3^West German Proton Therapy Center Essen WPE, Hufelandstraße 55‐ 45147, Essen, Germany; ^4^AnästhesieNetz Rhein‐Ruhr, Westenfelder Str. 62/64‐ 44867, Bochum, Germany*

**Background/Objectives**: Proton therapy (PT) has the potential to reduce treatment related morbidity in children with pelvic rhabdomyosarcoma (RMS). In this study we investigate the bladder toxicity and clinical outcome in children with pelvic RMS treated with PT.

**Design/Methods**: Twenty‐six children with pelvic RMS \[median age 4.1 years (range 1.5‐16.1 years); embryonal 84.6%, n=22; IRS group III 61%, n=16\] treated between 2013 and 2017 with a median follow‐up of 18.4 months (range 6.3‐47 months) were included. All children received chemotherapy according to CWS protocol. Median PT dose was 54Gy (range 45‐59.4Gy). Adverse events including bladder toxicity were prospectively documented according to CTCAE v4.0 within the "KiProReg" registry.

**Results**: Three children had undergone cystectomy before PT. One child underwent cystectomy 3 months after PT due to histologically proven progressive disease and another after 1 year due to recurrent urinary tract infection. During PT, 1 patient experienced grade 3 cystitis and 2 had grade 2 cystitis. At last contact, 17 children retained normal bladder function with 2 of them having grade 1‐2 late urinary toxicity. The median of the mean and maximum doses received by the bladder was 29.64Gy (range 13‐42Gy) and 50Gy (range 34‐60Gy), respectively. Eighteen patients had a complete remission, 5 experienced local failure, 2 had stable disease and 1 developed distant metastasis. Overall survival rate was 84.6% with local progression being the cause of death in 3 out of 4 patients. Tumour size more than 5 cm (n=12) was associated with poor local control (p=0.02), whereas total dose \> 54Gy (n=13) resulted in better local control (p=0.01). Surgical resection before PT (n=10) did not appear to add significant benefit (p=0.61).

**Conclusions**: Bladder preservation using proton therapy is associated with favourable toxicity profile and good clinical outcome. Verification of these results with larger cohorts and a longer follow‐up is necessary.

### PO-711. One of the Process of Mothers\' Decision Making to Receive Proton Beam Therapy of Children {#pbc27455-sec-9480}

[N. Ozawa]{.ul} ^1^, F. Kayuri^2^, O. Hisayo^1^, A. Yosiki^1^, F. Rieko^1^

*^1^University of Tsukuba, Department of Health Innovation and Nursing, Ibaraki, Japan; ^2^Saitama Prefectural University, Department of Nursing, Saitama, Japan*

**Background/Objectives**: Proton beam therapy is expected to reduce the late complications. However there are few institutions and there are difficult aspects such as requiring a transfer to receive it. So we have to support for mothers. So far there are suggested the expectation and pressure of mothers are characteristic concepts. To understand them, it is necessary to clarify the process of decision making.

**Design/Methods**: A searcher interviewed mothers and analyzed by the grounded theory approach.

**Results**: 13 mothers participated.

Every children were transferred the hospital.

We derived 8 categories relating to decision making, such as \[Increased fear of radiation therapy\],\[Search for a treatment method so that there is no regret\],\[Expectation for proton beam therapy as one and only treatment\],\[Think that there is no specification and select X rays\],\[Confident choice for receiving proton beam therapy\]...

Mothers with a high degree of \[Increased fear of radiation therapy\] trace the process to \[Search for a treatment method so that there is no regret\]even if they offer only X‐ray options from medical personnel.

Mothers with a high degree of \[Increased fear of radiation therapy\], even if they offer only X‐ray options from a doctor, \[Search for a treatment method so that there is no regret\] And they increase \[Expectation for proton beam therapy as one and only treatment\], and get to \[Confident choice for receiving proton beam therapy\].

Mothers who have low degree of \[Increased fear of radiation therapy\] can sometimes go to \[Think that there is no specification and select X rays\] if the degree of \[Acquire information on proton therapy by proposal from others\] is low.

**Conclusions**: Due to the degree of fear of mothers or providing information from medical personnel, the process is different. We need to provide psychological support for mothers with high fear and expectation and provide information beyond the boundaries of facilities

### PO-712. Precision of Two Low‐Dose Abdomen/Pelvis Cone Beam Computed Tomography Protocols for Alignment to Bone and Soft‐Tissue in Pediatric Patients Reciving Image‐Guided Radiation Therapy {#pbc27455-sec-9490}

[A. Rao]{.ul} ^1^, J. Lee^1^, W. Fu^1^, S. Nicholas^1^, S. Alcorn^1^, J. Moore^1^, M. Ladra^1^, M. Mahadevappa^1^, S. Bartolac^1^, S. Terezakis^1^

*^1^Johns Hopkins University School of Medicine, Radiation Oncology, Baltimore, USA*

**Background/Objectives**: We evaluated the precision of two low‐dose cone beam computed tomography (LD‐CBCT) protocols to align to bone and soft‐tissue for pediatric patients receiving image‐guided radiation therapy (IGRT) to the abdomen and pelvis (A/P).

**Design/Methods**: Image quality evaluation of 858 CBCTs from 46 pediatric patients treated with IGRT from January 2015--December 2017 guided the development of two significantly dose‐reduced protocols, LD‐CBCT1 (180º rotation, 120 kV, 63 mAs total, 315 frames, S20 collimator) and LD‐CBCT2 (180º rotation, 100 kV, 31.5 mAs total, 315 frames, S20 collimator). A representative LD‐CBCT1 and LD‐CBCT2 scan from 8 patients with at least 1 CBCT from both protocols were registered separately to a bone and soft‐tissue landmark on the simulation CT (SIM‐CT). Eighteen identical blinded random offsets were applied to each patient\'s LD‐CBCT1 and LD‐CBCT2 from a starting registration that was then realigned using rigid registration. Differences in the vector magnitude difference (VM=√(x^2^+y^2^+z^2^))between the applied offset and final registration attempt was calculated after adjusting for any systematic error in the initial SIM‐CT↔LD‐CBCT1/2 registration were analyzed to evaluate if LD‐CBCT1, delivering higher dose, was superior to the lower dose LD‐CBCT2 for bone and soft‐tissue alignment.

**Results**: Comparing 288 registrations to a bone landmark across 8 patients, there was no difference in the vector magnitude offsets using LD‐CBCT 1 (mean \[$\overline{x}$\], 0.73 mm; standard deviation \[σ$\overline{x}$\], 0.39 mm) and LD‐CBCT2 ($\overline{x}$, 0.74 mm; σ, 0.40 mm) (p=0.425). Comparing 216 registrations to a soft‐tissue landmark across 6 patients, alignment using LD‐CBCT2 ($\overline{x}$, 1.55 mm; σ, 1.08 mm) resulted in larger differences in the vector magnitude of the offsets compared to LD‐CBCT1 ($\overline{x}$, 1.37 mm; σ, 0.74 mm) (p=0.049).

**Conclusions**: Clinics treating pediatric patients should implement a protocol mirroring LD‐CBCT2 for A/P IGRT aligned to bone and consider further evaluation of LD‐CBCT1 for soft‐tissue alignment.

### PO-713. Cystic Dynamic Evaluation and Early Late Toxicity in Two Pediatric Low Grade Gliomas Treated with Active Scanning Proton Beam Radiotherapy {#pbc27455-sec-9500}

[B. Rombi]{.ul} ^1^, M. Zucchelli^2^, S. Vennarini^1^, L. Ronchi^3^, M. Lipparini^1^, I. Ammendolia^3^, S. Cammelli^3^, D. Zama^4^, A. Prete^4^, D. Scartoni^1^, F. Toni^5^, A.G. Morganti^3^, A. Pession^4^, F. Melchionda^4^, M. Amichetti^1^

*^1^Proton Therapy Center, Santa Chiara Hospital, Trento, Italy; ^2^Pediatric Neurosurgery‐, Bellaria Hospital, Bologna, Italy; ^3^Bologna University‐ S. Orsola Hospital, Radiation Oncology Department, Bologna, Italy; ^4^Bologna University‐ S. Orsola Hospital, Onco‐Hematology Department, Bologna, Italy; ^5^Bellaria Hospital, Neuro Radiology Department, Bologna, Italy*

**Background/Objectives**: To Evaluate cystic dynamics in two pediatric Low grade Gliomas during Proton beam therapy (PBT) by weekly MRI and in the follow up (FU) time. Early late toxicity was also reported.

**Design/Methods**: Both solid and cystic tumor\'s components were drown in weekly MRI performed during proton radiation and in the FU phase. P1 case was a multiple partially resected 5 yo girl with hypothalamic pylocitic Astrocytoma no‐responding after second line of chemotherapy, who acutely lost visual acuity due to cystic tumor\'s progression. P2 case was a 13 yo boy with progressive mesencephalic pylocitic Astrocytoma previously treated with multi‐agents chemotherapy and several surgeries. After cystic drainage both were treated with PBT at 54 Gy GCE.

**Results**: During proton therapy \# 7 MRI for P1 and \# 6 MRI for P2 patient were performed and didn\'t shown cyst growth which required intervention; P1 developed two episodes of severe acute headache and both developed partial alopecia. In P1patient both cystic and solid component progressively reduced (cyst/solid‐1w +2/−15%, cyst/solid‐2w −9/−22%, cyst/solid‐3w −17/−28%, cyst/solid‐4w −18/−38%, cyst/solid‐5w −30/−43%, cyst/solid‐6w −34/−44%, cyst/solid‐1FU −43/−50%, cyst/solid‐2FU −51/−63%). In P2 patient only cyst part progressively increased (cyst/solid‐2w +7/−4%, cyst/solid‐3w +36/−10%, cyst/solid‐4w +58/−12%, cyst/solid‐5w +73/−15%, cyst/solid‐6w +90/−15%, cyst/solid‐7w +94/−16%, cyst/solid‐1FU +126/−37%, cyst/solid‐2FU −18/−45%). P2 had transient cyst growth after PT with significant volume reduction on the second FU. After 10 months of median FU, no late side effects were noted however P1 improved visual acuity.

**Conclusions**: Compliance was excellent and acute side effects related to PT were rare and mild without treatment breaks. No evidence of early late side effects were also noted. These very preliminary data confirm the importance to evaluate any possible cystic dynamic changes in cystic tumors during PT.

### PO-714. Role of Radiotherapy in Paediatric Population: An Institutional Experience {#pbc27455-sec-9510}

[D.S. Sharma]{.ul} ^1^, K. rastogi^1^

*^1^SMS medical college &attached hospitals Jaipur India, Radiotharapy, jaipur, India*

**Background/Objectives**: To evaluate the role of radiotherapy in paediatric patients at a single tertiary care centre.

**Design/Methods**: The present retrospective study was carried at department of Radiotherapy, SMS Medical College, Jaipur, India; over pediatric patients less than 20 years who were treated with radiotherapy during 2013 to 2017.

**Results**: A total of 127 pediatric patients were treated. The median age was 12 (range, 1‐19) years; 79 (62.2%) were boys and 48 (37.8%) were girls. 77.2% children belonged to rural background. The most common malignancy seen in pediatric patients were acute lymphoblastic leukemia (ALL, 52.8%) followed by central nervous system (CNS) tumors (21.3%), bone tumors (12.6%), nasopharyngeal tumors (6.3%), and others (7%). The most common cause for prescribing pediatric radiotherapy was prohylactic (52.8%) followed by curative (37%) and palliative (10.2%). The most common RT prescription was (Gy/fraction) 18/10 (43.3%) followed by 50/25 (17.3%), 54/27 and 12/8 (both 15.7%), and others (8%). Among the children who received curative RT, 8.5% had complete response, 44.7% had partial response, 40.4% had stable disease and 6.4% had progressive disease; and among those who recieved palliative RT, more than 50% symptomatic relief was noted in 77%.

**Conclusions**: There is scarcity of data regarding RT in paediatric patients. Such patients present with different symptomatology and site of disease, requiring different dose fractionations.

### PO-715. A Planning Study to Demonstrate the Feasibility of Re‐Irradiation Plus Hyperthermia for Recurrent Pediatric Sarcoma {#pbc27455-sec-9520}

H. Kok^1^, [I. Van Dijk]{.ul} ^1^, K. Crama^1^, N. Franken^1^, C. Rasch^1^, J. Merks^2^, J. Crezee^1^, B. Balgobind^1^, A. Bel^1^

*^1^Academic Medical Center, Radiation Oncology, Amsterdam, The Netherlands; ^2^Emma Children\'s Hospital/Academic Medical Center‐ Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Amsterdam‐ Utrecht, The Netherlands*

**Background/Objectives**: Re‐irradiation combined with hyperthermia has shown to be a successful treatment for recurrent tumours in adult cancer patients. In children, chemotherapy plus hyperthermia is a favorable treatment strategy for some indications, whereas re‐irradiation plus hyperthermia has not yet been investigated. Our objective was to investigate the feasibility to treat previously irradiated paediatric sarcoma recurrences in the pelvis and in extremities with re‐irradiation plus hyperthermia.

**Design/Methods**: Between 2002 and 2017, 46 children (\<18 years) were diagnosed with recurrent sarcoma at the AMC. Those not previously irradiated (n=5), with outfield recurrences (n=30), locations other than the pelvis and extremities (n=1), pelvic recurrence larger than 15 cm (n=4), or without diagnostic CT scan suitable for treatment planning (n=2) were excluded. Treatment plans combining radiotherapy and hyperthermia for two pelvic recurrent sarcomas, one sarcoma in a foot, and one in a lower leg were generated using realistic low dose treatment schedules(i.e. 46 Gy in 23 fractions) plus weekly hyperthermia. The radiosensitizing effect of hyperthermia was quantified using biological modelling with a temperature‐dependent change in the α and ß parameters of the Linear‐Quadratic model. The possible effectiveness of re‐irradiation plus hyperthermia was estimated by calculating the equivalent radiotherapy dose distribution.

**Results**: Treatment planning showed that it is feasible to effectively heat pelvic locations and extremities in children. Evaluation of the equivalent dose distributions indicated that hyperthermic radiosensitization can be quantified as a target‐selective additional D95% of typically 10 Gy in the PTV, thereby realizing at least an effective biologically equivalent curative dose of 54 Gy, without substantially increasing the equivalent dose to organs at risk (e.g. bladder, rectum).

**Conclusions**: Re‐irradiation plus hyperthermia is theoretically feasible and a promising effective treatment for recurrent paediatric sarcoma in the pelvic region and extremities. Based on these results, we plan to investigate the clinical feasibility.
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### PO-716. Liquid Crystalline Nanoparticles (LCNPS) Based Delivery of an Anticancer Bioactive, Methotrexate {#pbc27455-sec-9540}

[M. Bhargava]{.ul} ^1^, S. Bhargava^2^

*^1^GTB Hospital, R&D, Kanpur, India; ^2^United Institute of Pharmacy, Pharmacy, Kanpur, India*

**Background/Objectives**: Liver cancer is a disease of uncontrolled cell growth, which may invade adjacent tissue and cause infiltration beyond the liver. Most of the potent and effective anticancer drugs used in liver cancer therapy shows poor bioavailability at desired site as well as toxic in nature. The aim of the study was to investigate mannose modified Liquid Crystalline Nanoparticle(LCNPs) carrier for efficient and site specific delivery of potent anticancer drug (Methotrexate) used in hepatic carcinoma therapy.

**Design/Methods**: MTX loaded LCNPs were prepared by lipid cast film method and sonication method. The nanoparticles were characterized *in‐vitro* for their shape, size, percent drug entrapment and stability by Optical Microscopy, Cross Polarized Light Microscpy (CPLM), Transmission Electron Microscopy (TEM), X‐ray diffraction (XRD) and Atomic Force Microscopy (AFM).

**Results**: *In‐vitro* stability studies reveal that LCNPs formulations are stable for 120 days at room temperature. *Ex‐vivo* cell cytotoxicity was performed on Human hepatoma cell line. *In‐vivo* studies included fluorescence microscopy and organ distribution studies which show the Mannose modified LCNPs exhibit better accumulation in liver as compared to unmodified system. The results of the present study indicate, this system is more stable as compared to other system.

**Conclusions**: Eventually it may be concluded that incorporation of MTX in mannose modified LCNPs increases the residing time of drug in the body by altering of pharmacokinetics and biodistribution pattern, and the drug primarily concentrates in the liver. This system showed excellent cytotoxicity towards cancer cells. From the present investigation it is evident that this system may be used for liver cancer and other liver disease.

### PO-717. Mitochondriotropic Carbon Nanotubes for Efficient Tumour Targeting {#pbc27455-sec-9550}

[S. Bhargava]{.ul} ^1^, V. Bhargava^2^

*^1^United Institute of Pharmacy, Pharmacy, Kanpur, India; ^2^GTB Hospital, Pharmacy, Kanpur, India*

**Background/Objectives**: Cancer is the uncontrollable growth of cells which are devoid of apoptosis. The project aimed to develop Ligand mediated tumor targeting via carrier systems. Multiwalled carbon nanotubes(MWCNTs) were selected for mitochondrial targeting as it has Central role in Apoptosis, there are Multiple activation pathways and the tumour growth depends on energy & availability of mitochondriotropics. Rhodamine‐123 is shown to be rapidly taken up by mitochondria in living cells and serves a triple purpose. MWCNTs are the choice of delivery system as it directly enters into the cell without passing through endo‐lysosomes, have large inner volume, have distinct inner and outer surfaces & have ability to enter cell by spontaneous mechanism. Thus, proposed work envisages Rhodamine‐123 conjugated Paclitaxel loaded *functionalized‐*CNTs to provide an enhanced cell permeation and mitochondrial in order to enhance mitochondrial availability of Paclitaxel.

**Design/Methods**: Raw MWCNT were procured and were purified, oxidized & then conjugated with rhodamine‐123 by carbodimide method. MWCNT\'s were characterized *in‐vitro* for shape & size by Scanning(SEM) & Transmission Electron Microscopy(TEM), FTIR analysis, X‐ray diffraction and zeta potential determined. Stability studies were performed at exaggerated conditions along with Hemolytic Toxicity Study. Cell Cytotoxicity Study‐MTT Assay was done using Hela cell lines. Mitochondrial localization was determined by CLSM study. *In‐vivo* study comprised of determining distribution of drug in various organs by fluorescence microscopy.

**Results**: The CNTs showed high paclitaxel loading, sustained release, and excellent biocompatibility as evident by *in‐vitro* drug release and low hemolytic toxicity. MTT assay against HeLa cell lines suggested the potential anticancer activity of developed system. Confocal microscopic study suggested that mitochondrial specific localization of Rhodamine‐123 conjugated MWCNTs in HeLa cells.

**Conclusions**: Thus, we concluded that Rhodamine‐123 conjugated Paclitaxel loaded *f‐*CNTs system have potential to provide an enhanced cell permeation and mitochondrial localization for effective tumour chemotherapy.

### PO-718. Mannosylated Poly (Propylene Imine) Dendrimer Mediated Lung Delivery of Anticancer Bioactive {#pbc27455-sec-9560}

[S. Bhargava]{.ul} ^1^

*^1^United Institute of Pharmacy, Pharmacy, Kanpur, India*

**Background/Objectives**: Tumors originating in lung tissues or in the bronchi invade adjacent tissue and cause infiltration beyond the lung. Lung macrophages express mannose‐specific endocytosis receptor that might binds or internalize mannose terminated dendrimer. Therefore, it is hypothesized that incorporation of anticancer drug into mannose anchored dendrimer will transport drug effectively to tumor cells via receptor mediated endocytosis. The project aimed to investigate the targeting potential of mannose conjugated Poly Propyl Imine (PPI) dendrimer having potent anticancer drug, Gemcitabine in lung cancer cells. The dendrimers were conjugated so as to enhance the therapeutic potential and reduce adverse effect of anticancer drug.

**Design/Methods**: The 5.0 generation dendrimers were synthesized and were characterized by FTIR and Nuclear Magnetic Resonance (NMR). The PPI dendrimers prepared were then conjugated with mannose and drug was loaded. The shape and size were characterized by Transmission Electron Microscopy (TEM), drug loading efficiency, In‐vitro drug release and stability studies. The ex‐vivo studies constituted Hemolytic toxicity study and Cell cytotoxic study by MTT Cytotoxicity Assay on A‐549 (Lung adenocarcinoma epithelial) cell line. The *in‐vivo* studies were performed on albino rats and Pharmakokinetic parameters were studied, also Biodistribution Studies were done to access gemcitabine level attained in different organs.

**Results**: Thus Mannosylated PPI dendrimers showed high gemcitabine loading, sustained release and excellent biocompatibility as evident by low hemolytic toxicity. MTT assay suggested high cytotoxicity of GmcH‐MPPI against A549 cancer cell lines. The Presence of ligand on dendrimer molecule, elevated receptor mediated binding or internalization in AM. The developed ligand conjugated dendritic system targeted higher concentration of GmcH to lung than the free drug.

**Conclusions**: Thus, we concluded that GmcH loaded mannosylated PPI dendritic system could have higher potential to target anticancer drug to lungs for effective chemotherapy of lung tumor.

### PO-719. Inclusion of Adolescents in Adult Early Phase Trials and Young Adults in Paediatric Early Phase Trials: A Reality or a Myth? {#pbc27455-sec-9570}

P. Berlanga^1^, A. Vozy^2^, B. Geoerger^1^, [L. Brugieres]{.ul} ^1^, C. Massard^2^, N. Gaspar^1^

*^1^Gustave Roussy, Department of Child and Adolescent Cancer, Villejuif, France; ^2^Gustave Roussy, Drug Development Department, Villejuif, France*

**Background/Objectives**: There is mounting evidence that supports the inclusion of adolescents (12‐17 years) in adult early phase I/II trials, without requiring prior specific paediatric trials. However, only few adult early phase trials currently include adolescents. On the other hand, the classical arbitrary upper age limit in most paediatric trials (18 or 21 years old), hinders appropriate access to trials to young adults (19‐25 years) with paediatric disease types.

**Design/Methods**: Retrospective review of all phase I/II trials opened at Gustave Roussy for solid tumours/lymphomas, from 01/01/2012 to 31/12/2017. Systematic analysis of each protocol/synopsis by three independent (1 medical, 1 adolescent/young adult, 1 paediatric) oncologists, with the main objective to describe the current inclusion of adolescents in adult trials and young adults in paediatric trials.

**Results**: In the period analysed, there were 465 trials that fulfilled the inclusion criteria. Of them, only 65 (15%) included adolescents (12‐17 years): 61/62 (98%) paediatric trials and 4/403 (1%) adult trials. In 11/403 (3%) adult trials, lower age limit was 15/16 years. Concerning the 389 trials not opened for adolescent recruitment, adolescents could have been included in 212/389 (55%) trials. Of them, 28/389 (7%) trials were open to tumour types frequently found in adolescents (e.g. sarcoma, lymphoma, germ cell tumours). Inclusion of young adults (19‐25 years) was not allowed for accrual in 36/62 (58%) of paediatric trials (upper age limit 18 years in 22 trials, 21 years in 13 trials), while 10/36 (28%) trials had opened cohorts to tumour types also found in this age group.

**Conclusions**: Lower and upper age limit of future (paediatric and adult) early phase trials should be individually discussed taken with both paediatric and medical oncologist into account current evidence and international recommendations.

### PO-720. Social Values and Public Policy on Cancer Drug Funding Decisions for Children in Canada {#pbc27455-sec-9580}

[A. Denburg]{.ul} ^1^, M. Giacomini^2^, W. Ungar^3^, J. Abelson^2^

*^1^The Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^2^McMaster University, Health Research Methods‐ Evidence and Impact, Hamilton, Canada; ^3^The Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Canada*

**Background/Objectives**: As the costs of novel cancer drugs continue to rise and put pressure on health system budgets, public policy approaches to funding paediatric cancer medicines remain understudied. Current approaches to health technology assessment (HTA) present a variety of conceptual, methodological and practical problems in the context of child health. Our study explored the technical, social and political determinants of public funding decisions on paediatric cancer drugs in Canada.

**Design/Methods**: We interviewed a stratified purposive sample (*n*=22) of stakeholders involved with or affected by cancer drug funding decisions for children at the provincial (Ontario) and national levels in Canada. Grounded theory methods were employed to guide data collection and thematic analysis. The themes that emerged informed the development of conceptual and practical insights on social values and system dynamics related to public policymaking on the coverage of novel cancer drugs for children.

**Results**: Participant reflection on the normative and systems dimensions of drug funding for children revealed notable differences related to how child cancer drugs are prioritized and evaluated for public funding. Analysis of these differences revealed a number of substantive and procedural shortcomings of current HTA paradigms in respect of child health, and underscored the need to account for distinguishing features of childhood cancer -- in biological, health system and sociocultural terms -- when assessing paediatric cancer drugs for public coverage.

**Conclusions**: Our study furnishes novel empirical data on the social, political and economic determinants of cancer drug funding for children in Canada. It brings to light a unique range of social values attached to child health technologies, and maps the health system dynamics that condition the assessment of paediatric cancer drugs for public coverage. The insights yield fundamental knowledge about the normative dimensions of HTA for children that are germane to cancer drug policy both in Canada and internationally.

### PO-721. The First Report Related to First‐Line Therapy with Anti‐CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency {#pbc27455-sec-9590}

[H. Dincaslan]{.ul} ^1^, E. Unal^1^, N. Tacyildiz^1^, G. Tanyildiz^1^, Z. Kuloglu^2^, G. Kaygusuz^3^, M. Cakmak^1^, M. Berber^1^

*^1^Ankara University, Pediatric Hematology‐Oncology, Ankara, Turkey; ^2^Ankara University, Pediatric gastroenterology, Ankara, Turkey; ^3^Ankara University, Pathology, Ankara, Turkey*

**Background/Objectives**: The goal of frontline chemotherapy for Hodgkin\'s lymphoma is to cure patients without the need for additional therapy. ABVD is the most widely used regimen for patients with advanced stage Hodgkin\'s lymphoma. Brentuximab vedotin (anti‐CD30) has shown significant clinical activity, with a manageable safety profile, in patients with relapsed or refractory Hodgkin\'s lymphoma.

**Design/Methods**: In this case report, we present a child with advanced HL with hepatic failures and immunodeficiency. The patient received brentuximab vedotin plus dose reduced AVD as first‐line therapy.

**Results**: A 13‐year‐old boy was referred to our hospital for the chronic hepatic failure and CVID. He had an abdominal/pelvic computed tomography which showed hepatosplenomegaly, ascites and multiple paraaortic conglomerate lymphadenopathy suggested that lymphoproliferative disease. Lymph node biopsy was revealed classical mixed cellularity Hodgkin\'s lymphoma (CD30 positive). A bone marrow biopsy showed Hodgkin\'s disease involvement. Intense abnormal focus of fluorodeoxy‐glucose (FDG) uptake in multiple enlarged lymph nodes and multiple focuses in bones and bone marrow in a PET‐CT scan. He was evaluated as stage IV. In his viral studies, EBV‐DNA levels was detected rather high with 50 000 copy/mL. Because of his hepatic failure and immunodeficiency and the fear that he might not tolerate a full course of standard chemotherapy, the decision was made to start him on brentuximab vedotin (1.8 mg/kg/every 2 week, intravenously) and rituximab (375 mg/m2/week for 8 weeks, intravenously). On the second week brentuximab combined with dose reduced AVD. After 3 cycles of chemotherapy a repeat PET‐CT revealed complete resolution of increased FDG uptake. His treatment continues withous any toxicity related to chemotherapy.

**Conclusions**: Brentuximab vedotin plus AVD regimen was well tolerated and resulted as first‐line therapy in a child with newly diagnosed advanced stage Hodgkin\'s lymphoma. This case is the first child patient that used brentuximab vedotin as the first line therapy in the literature.

### PO-722. CRISPR Screen Identifies MAD1L1, CDC27 and CDC42 as Determinants of Sensitivity to Sonic Hedgehog Inhibitor Sonidegib in Medulloblastoma Cell Lines {#pbc27455-sec-9600}

[L. Geron]{.ul} ^1^, K. Borges^2^, K. Salomão^1^, C.A. Scrideli^2^, L.G. Tone^3^

*^1^Ribeirão preto Medical School, Genetics, Ribeirão Preto, Brazil; ^2^Ribeirão Preto Medical School, Pediatrics, Ribeirão Preto, Brazil; ^3^Ribeirão Preto Medical School, Pediatrics and Genetics, Ribeirão Preto, Brazil*

**Background/Objectives**: Medulloblastoma (MB) is the most common malignant brain tumor in childhood and comprises four major subgroups \[Wingless (WNT), Sonic hedgehog (SHH), group 3, and group 4\]. SHH‐driven medulloblastomas represent an intermediate prognosis subgroup, with overall survival rates ranging from ∼60‐80%.Antagonists of SHH signaling, especially those inhibiting the pathway at the level of SMO such is Sonidegib, are in clinical trials for MB. Despite showing a pronounced initial response to treatment with SMO inhibitors, both humans and mice models acquired resistance to the treatment and relapsed within a short period, suggesting that such inhibitors may be ineffective when administered as monotherapy. SHH‐MB displays varying degrees of chromosomal instability and alterations in the expression of the mitotic spindle checkpoint genes are likely to contribute to this phenotype. Interestingly, several mitotic spindle checkpoint genes have been associated with the modulation of the SHH pathway. Thus, in this study, a set of mitotic spindle checkpoint‐wide screens was conducted to interrogate the involvement of these genes in the Sonidegib response.

**Design/Methods**: Cell lines (UW473, DAOY and ONS‐76) stably expressing Cas9 were generated and Cas9 expression confirmed by western blot. Then, we performed a CRISPR knock‐out screen, which contained 25 sgRNAs that target 25 proteins, followed by the Sonidegib treatment for 48h.

**Results**: We identify *MAD1L1*, *CDC27* and *CDC42* as synthetically lethal with Sonidegib treatment. *In silico* analysis revealed that the expression of the theses three genes is associated with SHH subgroup in the MB patients.

**Conclusions**: Together, these observations suggest that *MAD1L1*, *CDC27* and *CDC42* combined with Sonidegib may be potential targets to MB treatment in the Shh subgroup.

### PO-723. Repurposing Old Drugs as SAMHD1 Inhibitors to Improve Efficacy of Cytarabine in Paediatric Acute Myeloid Leukaemia {#pbc27455-sec-9610}

S.G. Rudd^1^, C.B. Paulin^1^, T. Nikolaos^2^, K. Sanjiv^2^, K. Juliane^3^, I. Hed Myrberg^1^, H. Axelsson^4^, A. Rasti^2^, E. Witta^2^, S. Lee^1^, G.Z. Rassidakis^1^, K. Pokrovskaja Tamm^1^, M. Heyman^2^, D. Grandér^1^, T. Lundbäck^4^, S. Lehmann^5^, T. Helleday^1^, J.I. Henter^2^, T. Schaller^3^, [N. Herold]{.ul} ^2^

*^1^Karolinska Institutet, Department of Oncology‐Pathology, Stockholm, Sweden; ^2^Karolinska Institutet, Childhood Cancer Research Unit‐ Department of Women\'s and Children\'s Health, Stockholm, Sweden; ^3^University Hospital Heidelberg, Department of Infectious Diseases, Heidelberg, Germany; ^4^Karolinska Institutet, Chemical Biology Consortium Sweden, Stockholm, Sweden; ^5^Uppsala University, Department of Medical Sciences, Uppsala, Sweden*

**Background/Objectives**: Three out of ten children with acute myelogenous leukaemia (AML) die from their cancer even though AML therapies belong to the most toxic chemotherapy regimens in paediatric oncology. Cytarabine (ara‐C), a deoxycytidine analogue, builds together with anthracyclines the backbone of AML treatment. The clinical efficacy of ara‐C correlates with the propensity of AML blasts to produce and retain its active metabolite ara‐CTP. We have demonstrated that SAM and HD domain‐containing protein 1 (SAMHD1) inactivates ara‐CTP by hydrolysis, leading to ara‐C resistance tin primary paediatric AML blasts and animal models of paediatric of AML. Furthermore, SAMHD1 expression levels significantly correlate negatively with survival in paediatric AML. In addition, we showed that SAMHD1 has no impact on the efficacy of induction therapy, but limits the outcome of consolidation courses containing high‐dose ara‐C.

Combining high‐dose ara‐C with SAMHD1 inhibitors bears the potnetial to greatly improve outcome for children with AML during consolidation chemotherapy.

**Design/Methods**: Several libraries of small molecules were screened in a cell‐based assay to identify compounds that sensitise SAMHD1‐wildtype cells to ara‐C, but not SAMHD1‐knockout cells. Efficacy was validated in AML mouse models. In vitro activity together with cellular thermal shift and cross‐linking assays furthermore deciphered the mode of action of inhibition of SAMHD1 ara‐CTPase activity (allosteric vs catalytic).

**Results**: We identified two FDA‐ and EMA‐approved substances with expired patents and extensive phase‐IV safety data exists in both adults and children. These drugs completely alleviated SAMHD1‐mediated resistance to ara‐C in primary AML samples in a SAMHD1‐dependent manner and resensitised animal models of AML to ara‐C.

**Conclusions**: We advocate clinical studies that prospectively test the ability of these novel SAMHD1‐inhibitors to improve survival when combined with high‐dose ara‐C consolidation courses.

### PO-724. Smoothened Inhibitor, Sonidegib, Induces Apoptosis and Affects the Expression of Hedgehog Pathway Genes in Pediatric Ependymoma RELA Subgroup {#pbc27455-sec-9620}

[T. Magalhaes]{.ul} ^1^, G. Alencastro Veiga Cruzeiro^2^, K. Silva Borges^2^, K. Rodrigues da Silva^1^, G. Ribeiro de Souza^1^, R. Caroline Peixoto Lira^2^

*^1^University of Sao Paulo, Genetics, Ribeirao Preto, Brazil; ^2^University of Sao Paulo, Pediatrics, Ribeirao Preto, Brazil*

**Background/Objectives**: Ependymoma (EPN) is the third most common childhood cancer of the central nervous system. RELA fusion‐positive EPN accounting for approximately 70% of all childhood supratentorial tumors and shows the worst prognosis among the supratentorial EPNs. Due to the low efficacy of the chemotherapy the treatment options for this tumor are limited. Sonidegib is a Hedgehog (HH) pathway inhibitor (via smoothened antagonism) and it is under Phase II study in pediatrics brain tumors. However, the role of HH pathway in EPNs still remain unclear. The aim of this study was to evaluate the HH pathway activation on BXD1425 cell line, classified as RELA subgroup, and examine the effects of the Sonidegib on cell proliferation and apoptosis of this cell line.

**Design/Methods**: Gene expression was evaluated by RT‐qPCR using TaqMan probes. *GUS* and *HPRT* were utilized as endogenous control and normal brain cDNA as calibrator. Protein expression was investigated by western blot. Cell proliferation was assessed by resazurin and cell apoptosis was detected by flow cytometry.

**Results**: Overexpression of *SMO* and *GLI1* and downregulation of *PTCH1* and *SUFU* were observed in untreated BXD cell line compared with normal brain. Moreover, GLI1 protein expression was detected in total protein lysates. These data suggest that the HH pathway signaling is activated in BXD cells. Treatment of the BXD cell line with Sonidegib resulted in decreased mRNA expression of *SMO, GLI1, PTCH1* and *SUFU* as well as the GLI1 and BLC2 protein expression. Sonidegib significantly caused reduction of the cell proliferation and increased cell apoptosis after 48 hours of treatment.

**Conclusions**: Our data showed that HH pathway is activated in the BXD cell line and that Sonidegib exerts antiproliferative and proapoptotic effects on these cells. These findings encourage future investigations to better characterize the role of Hedgehog signaling in EPN RELA subgroup.

### PO-725. Histology Agnostic Drug Development: A Potential Mechanism to Expedite Approvals in Rare Pediatric Cancers {#pbc27455-sec-9630}

[L. Marcus]{.ul} ^1^, G. Reaman^2^, M. Donoghue^3^

*^1^Food and Drug Administration, OHOP/DOP2, Silver Spring‐ MD, USA; ^2^Food and Drug Administration, Office of Cancer Excellence, Silver Spring‐ MD, USA; ^3^Food and Drug Administration, Department of Oncology Products 2, Silver Spring‐ MD, USA*

**Background/Objectives**: Traditionally, oncology drugs are approved for a specific histologically‐defined tumor type. Advances in molecular profiling and biomarker development show that multiple different cancer types can share genetic signatures, yielding opportunities for a tissue‐agnostic approach to drug development targeting abnormalities across multiple cancer types, including rare pediatric tumors. The tissue agnostic drug approval pathway may expedite approvals in cancers with a dual prevalence in adults and pediatrics.

**Design/Methods**: Shared genetic aberrations exist across multiple rare pediatric cancers. Limited patient numbers often preclude randomized trials but large effects on response rate and response duration may provide sufficient evidence of efficacy and clinical benefit. The commonality of some rare molecular abnormalities in pediatric tumors can be leveraged through a tissue agnostic approach to facilitate timely development and approval of certain targeted therapies.

**Results**: FDA approval of pembrolizumab in MSI‐H/dMMR tumors, and breakthrough therapy designation of NTRK‐fusion protein drugs entrectinib and larotrectinib, illustrate the applicability of a tissue‐agnostic approach to evaluation of drugs targeting molecular abnormalities in adult and pediatric cancers. MSI‐H/dMMR is sporadically found in pediatric cancers (glioma, colorectal cancer) and Lynch syndrome tumors. NTRK‐fusions are pathognomonic for rare tumors (infantile fibrosarcoma, congenital mesoblastic nephroma). Data was submitted supporting the underlying biology of these biomarkers across tumor types, the pharmacokinetic profile bridging these data, and clinically meaningful response rates in a blinded central review, resulting in favorable and expedited regulatory decisions.

**Conclusions**: Since evaluation of a targeted therapy in multiple small populations is inefficient and often infeasible, the tissue agnostic approach is valuable in advancing drug development in molecularly‐defined subsets of adult and pediatric rare cancers. The recent tissue agnostic approval for pembrolizumab in MSI‐H/dMMR tumors and development of larotrectinib and entrectinib for NTRK‐fusion cancers demonstrate the promise of this approach in advancing treatment of pediatric cancers.

### PO-726. Effective Response and Good Tolerability to Pembrolizumab in Three Pediatric Patients with Unknown/Negative PDL1 Test: Experience in Hospital de Niños Ricardo Gutierrez {#pbc27455-sec-9640}

[M. nana]{.ul} ^1^, M. Cores^1^, M. García Lombardi^1^

*^1^Hospital de Niños Ricardo Gutierrez, Oncology, Buenos Aires, Argentina*

**Background/Objectives**: Antitumor effects were observed in a variety of malignancies via blockade of immune checkpoints. PDL1 expression in pediatric tumors is still under research. Pembrolizumab is an anti‐PD1 monoclonal antibody, useful for small cell lung carcinoma, urothelial carcinoma, Hodgkin\'s lymphoma (HL) and head and neck tumors. There are few reports of the use of Pembrolizumab in pediatric patients.

We report response and tolerability with pembrolizumab in pediatric patients with unknown/known PDL1 expression testing.

**Design/Methods**: Review records of patients treated with pembrolizumab at Hospital de Niños Ricardo Gutierrez. Dose: 2 mg/kg (HL) and 200 mg/dose (carcinoma), 30 minutes infusions every 21 days on outpatient basis. Toxicity was controlled with endocrinological follow‐up with laboratory and clinic control. PDL1 testing performed in biopsy sample by immunohistochemistry.

**Results**: Three patients: two post‐autoSCT relapsed HL progressed to brentuximab, 1 patient with unresectable squamous cell carcinoma of the conjunctiva (xeroderma pigmentosum). Ages: 19‐16--8 years. Total infusions: 34. One grade II liver toxicity (required temporary suspension). No endocrinological toxicity. Patients with HL received 8 and 6 infusions. PET‐CT with very good objective response after 6th dose, currently on treatment. Patient with carcinoma received total of 12 infusions with pseudoprogression after first course, and complete response after third infusion with necrosis and spontaneous tumor detachment; currently off treatment in complete remission. PDL1 expression testing was performed in the last patient: negative. Result was obtained once patient achieved complete clinical remission.

**Conclusions**: Effective objetive response was achieved in 3 patients despite unknown/negative PDL1 expression. Treatment was safe, easily managed and good tolerated. Very good partial response was achieved in 2 patients with HL with no other known therapeutic option. In patient with irresectable carcinoma, complete response allowed preservation of eye and vision. It is necessary to continue testing PDL1 expression in pediatric tumors and using this antibody in pediatric patients to achieve more conclusions.

### PO-727. Blockade of Beta‐Catenin/ALDH1 Axis Suppresses Progression and Metastasis of Osteosarcoma: Preclinical Study of a Novel WNT/Beta‐Catenin Pathway Inhibitor Tegavivint {#pbc27455-sec-9650}

[M. Nomura]{.ul} ^1,2,3^, N. Rainusso^1^, J. Yustein^1^

*^1^Texas Children\'s Cancer and Hematology Center‐ Baylor College of Medicine, Pediatrics, Houston, USA; ^2^National Institutes of Biomedical Innovation‐ Health and Nutrition, Laboratory of Experimental Animal Models and Experimental Animals Resource Bank, Ibaraki, Japan; ^3^Osaka University, Pediatric Surgery, Suita, Japan*

**Background/Objectives**: Osteosarcoma is the most common bone cancer in children and adolescents, and patients with metastatic disease still have extremely poor prognosis. It has been reported that the activation of Wnt/β‐catenin pathway is closely associated with osteosarcoma development and metastatic progression. Tegavivint, a novel Wnt/β‐catenin pathway inhibitor, is reportedly active against multiple types of cancer cells. In this study, we investigated the antitumor activity of Tegavivint against metastatic osteosarcoma using PDX models.

**Design/Methods**: Antitumor efficacy was evaluated by CCK‐8 assay *in vitro* using established osteosarcoma cell lines and PDX‐derived cells. The*in vivo* activity of Tegavivint was evaluated using a pair of PDX models in immunodeficient mice derived from an inherently chemo‐resistant osteosarcoma patient at different disease stages: TCCC‐OS63 was derived from the pre‐treatment biopsy of the primary tumor, and TCCC‐OS84 was derived from the relapsed metastatic lung lesion after chemotherapy. Gene and protein expression were quantified by qPCR or Western blot analysis. TCCC‐OS84‐derived cells were sorted into ALDH1‐high and ALDH1‐low populations by ALDEFLUOR assay and those cells were intravenously injected to NSG mice.

**Results**: *In vitro*, Tegavivint effectively inhibited cell survival in all types of cells. Subcutaneously engrafted TCCC‐OS63 tumors were significantly suppressed by Tegavivint and the expression of ALDH1, which is a potential marker for cancer stem cells, was significantly downregulated by Tegavivint. Furthermore, a lung metastasis model using TCCC‐OS84 tumor‐dissociated cells intravenously injected in NSG mice demonstrated that Tegavivint markedly suppressed lung metastases. Finally, ALDH1‐high cells showed higher expression of β‐catenin and higher sensitivity to Tegavivint than the ALDH1‐low cells *in vitro*. An intravenous injection model demonstrated significantly more lung lesions in the ALDH1‐high group than the ALDH1‐low group, and Tegavivint significantly suppressed ALDH1‐high derived lung metastases.

**Conclusions**: Our preclinical findings demonstrate that Tegavivint has promising therapeutic potential for primary and metastatic osteosarcoma through the blockade of β‐catenin/ALDH1 axis.

### PO-728. A Review of Outcomes for Paediatric Patients with Solid Tumours Treated with Targeted Therapies in the West of Scotland {#pbc27455-sec-9660}

[C. Willis]{.ul} ^1^, D. Murphy^1^, M. Ronghe^1^, D. McIntosh^1^, J. Sastry^1^

*^1^Royal Hospital for Children, Paediatric oncology, Glasgow, United Kingdom*

**Background/Objectives**: Mortality from childhood cancer has rapidly declined from the 1970\'s. More recently, this trend has not been as steep, especially amongst children with solid tumours. We hope that the development of novel therapies, including targeted therapies (TT), may favourably alter disease outcomes. The objectives of this review were to determine the number of children with solid tumours treated with TT (off trial), to document survival outcomes and to report side effects.

**Design/Methods**: Patients with solid tumours who have received TT in the last three years were identified. Patients enrolled on clinical trials were excluded. Patient electronic records were used to collate information on diagnosis, stage, TT used, side effect profile and disease outcome.

**Results**: Three patients treated with TT off trial were identified (2 males and 1 female). Diagnosis included metastatic TFE3 rearranged renal cell carcinoma treated with sunitinib, relapsed undifferentiated sarcoma treated with pazopanib and inflammatory myofibroblastic tumour (IMT) treated with crizotinib. Age at diagnosis ranged from 3 to 15 years. Patient 1 (treated with sunitinib) has experienced white pigmentation of his hair and eye lashes. He is on his 6th cycle of treatment. Surveillance imaging demonstrates stable disease. Patient 2 was treated with pazopanib. He had his therapy discontinued after 2 cycles due to radiological evidence of disease progression. He is currently two months off treatment, with further clinical progression. Patient 3 was treated with Crizotinib and had an excellent response to therapy within days of starting treatment. In light of profound myelosuppression, she required a significant dose reduction. She has been on therapy for 3 years and remains in complete remission.

**Conclusions**: With limited experience of only three patients, two patients receiving TT had a positive outcome, with minimal side effect profiles. Further research into outcomes and side effect profiles of targeted agents in paediatric oncology is needed.

Brain Tumours {#pbc27455-sec-9670}
-------------

### PO-001. Field‐in‐Field Technique with Intrafractionally Modulated Junction Shifts for Craniospinal Irradiation (CSI) Planning with 3D‐CRT at Ziauddin Hospital {#pbc27455-sec-9680}

[S.H. A. Ali]{.ul} ^1^, H. Nazim^1^, R. Gohar^2^, J. Mallick^1^

*^1^Ziauddin University, Radiotherapy, Karachi, Pakistan; ^2^Aga Khan University, Radiotherapy, Nairobi, Kenya*

**Background/Objectives**: To plan craniospinal irradiation with ''field‐in‐field'' (FIF) homogenization technique in combination with daily, intra‐fractional modulation of the field junctions, to minimize the possibility of spinal cord overdose. Photon‐based techniques for craniospinal irradiation (CSI) may result in dose inhomogeneity within the treatment volume and usually require a weekly manual shift of the field junctions to minimize the possibility of spinal cord overdose. Nowadays field‐in‐field technique is used to feather out the dose inhomogeneity caused by multiple fields. We have started using this technique after acquiring advanced technology machines in recent years.

**Design/Methods**: 16 patients (2 adults, 14 children) treated with 3D‐CRT for craniospinal irradiation were retrospectively chosen for this analysis. These patients were planned and treated during 2016‐2017. Contouring of Brain and Spine Cord and organ at risk were already done and planning done on Eclipse ^TM^ Treatment Planning System (Varian). All of these patients were planned Lateral cranio‐cervical fields and posterior spinal fields were planned using a forward‐planned, FIF technique. Field junctions were automatically modulated and custom‐weighted for maximal homogeneity within each treatment fraction. Dose volume histogram (DVH) was used for analysis of results. A corresponding plan without FIF technique was planned and maximum dose at the junction was noted for each patient with both plans and the readings were evaluated.

**Results**: Plan inhomogeneity improved with FIF technique. Planning with daily modulated junction shifts provided consistent dose delivery during each fraction of treatment across the junctions. The maximum doses calculated at the junction were higher in the CSI plans without FIF compared to those with FIF technique.

**Conclusions**: This paper hence proves that FIF technique is better in planning craniospinal irradiation.

### PO-002. A Weighted Genetic Risk Score of Adult Glioma Susceptability Loci Associated with Pediatric Brain Tumor Risk {#pbc27455-sec-9690}

[M. Adel Fahmideh]{.ul} ^1^, C. Lavebratt^2^, G. Tettamanti^1^, J. Schüz^3^, M. Röösli^4,5^, K. Kjaerheim^6^, M.A. Grotzer^7^, C. Johansen^8,9^, C.E. Kuehni^10,11^, B. Lannering^12^, L.S. Schmidt^13^, H. Darabi^14^, M. Feychting^1^

*^1^Karolinska Institutet, Unit of Epidemiology‐ Institute of Environmental Medicine, Stockholm, Sweden; ^2^Karolinska Institutet, Neurogenetics Unit‐ Department of Molecular Medicine and Surgery, Stockholm, Sweden; ^3^International Agency for Research on Cancer IARC, Section of Environment and Radiation, Lyon, France; ^4^Swiss Tropical and Public Health Institute, Department of Epidemiology and Public Health, Basel, Switzerland; ^5^University of Basel, University of Basel, Basel, Switzerland; ^6^The Cancer Registry of Norway, The Cancer Registry of Norway, Oslo, Norway; ^7^University Children\'s Hospital of Zurich, Department of Oncology, Zurich, Switzerland; ^8^The Danish Cancer Society Research Centre, Unit of Survivorship, Copenhagen, Denmark; ^9^Finsen Centre, Oncology Department, Copenhagen, Denmark; ^10^University of Bern, Swiss Childhood Cancer Registry‐ Institute of Social and Preventive Medicine, Bern, Switzerland; ^11^University of Bern, Children\'s University Hospital of Bern, Bern, Switzerland; ^12^University of Gothenburg, Department of Pediatrics, Gothenburg, Sweden; ^13^University Hospital Herlev, Department of Pediatrics, Copenhagen, Denmark; ^14^Quantify, Quantify, Stockholm, Sweden*

**Background/Objectives**: Genetic risk score (GRS) is used to demonstrate the genetic variants contributing to the polygenic architecture of complex diseases. In the present study, by using a GRS, we have investigated the additive impact of the known adult glioma susceptibility loci on the pediatric brain tumor risk and assessed the proportion of pediatric brain tumor heritability attributable to these susceptibility loci.

**Design/Methods**: We generated the GRS for pediatric brain tumors based on the alleles and associated effect sizes derived from a previously published genome‐wide association study (GWAS) on adult glioma, which in turn was based on the meta‐analysis of two GWAS including 1878 cases and 3670 controls and also three additional independent replication series including 2545 cases and 2953 controls. The GRS was calculated based on 8 SNPs in the CEFALO study. CEFALO is a population‐based case‐control study of brain tumors in children and adolescents aged 7‐19 years conducted in Sweden, Denmark, Norway, and Switzerland and it includes saliva DNA of 245 cases and 489 controls. The unconditional logistic regression model was applied to evaluate whether the standardized GRS is associated with the risk of pediatric brain tumors adjusted for age, sex and country. To measure the variance explained by the effect of GRS, Nagelkerke pseudo‐R^2^ was calculated.

**Results**: The results indicate that genetic risk scores for adult brain tumors were associated with an increased risk of pediatric brain tumors (OR 1.23 \[95% CI 1.04‐1.46\], p = 0.014) and 0.8% of the variance in pediatric brain tumors could be explained by the effect of the genetic risk scores on the liability scale.

**Conclusions**: This study provides evidence that the heritable risks of pediatric brain tumors are in‐part attributable to some common genetic variants associated with adult glioma.

### PO-003. Central Nervous System (CNS) Tumors among Very Young Children (\< 3 Years of Age): Survival Pattern at a Tertiary Care Hospital in Saudi Arabia {#pbc27455-sec-9700}

[A. Al‐Kofide]{.ul} ^1^, M. Ayas^1^, Y. Khafaga^2^, K. Siddiqui^1^, M.G. Barria^1^, E. Al‐Shail^3^

*^1^KFSHRC, Ped Hem Onc, Riyadh, Saudi Arabia; ^2^KFSHRC, Radiation Oncology, Riyadh, Saudi Arabia; ^3^KFSHRC, NeuroScience, Riyadh, Saudi Arabia*

**Background/Objectives**: CNS tumors among very young children (VYC) are associated with a dismal prognosis. We conducted this study to observe the survival pattern among VYC with CNS tumors at our tertiary care hospital.

**Design/Methods**: Medical records of the patients diagnosed and treated from 2005‐2016 were reviewed through research databases being maintained at the data bio‐bank in a prospective fashion. Survival patterns were evaluated via Kaplan‐Meier survival curves.

**Results**: A total of 80 patients were included. Median age was 1.8 years. Primary Diagnostic Related Groups (DRG) included: Medulloblastoma (32, 40%) followed by Atypical Teratoid/Rhabdoid Tumors (ATRT, 21, 26.3%). 57.5% (46) had received some type of treatment at their referring hospitals. Seventeen (21.3%) got radiation therapy in first line treatment regimen. Relapse/Progressive Disease rate was 51.3% (41). Thirty‐three (80.5%) had local, 9.8% (4) had distant and 9.8% (4) had both local+distant relapsed sites. Mortality rate was 41.2% (33) with medulloblastoma (42.4%, n=14) the highest followed by ATRT (33.3%, n=11). With a follow‐up of 68.9 months, five year overall survival of the whole group of our patients was 0.503±0.065 while the same for Ependymoma was observed to be 0.417±152 followed by 0.452±0.119 for ATRT and 0.508±0.098 for medulloblstoma. Among those alive, 12.8% (6) were on palliative care. Of 31 evaluable alive cases, 19.4% (6) were in CR, 38.7% (12) in SD and remaining 41.9% (13) were with PD.

**Conclusions**: VYC with CNS tumors are a distinct group of oncology patients with a poor prognosis. We emphasize that novel therapeutic strategies and biological advances are needed to augment personalize care for this unique group of patients.

### PO-004. Childhood Medulloblastoma and Pineablastoma Treated with SAPHOS Study Protocol at King Fahad Medical City (KFMC): 10 Years Experience at Single Tertiary Center in Saudi Arabia {#pbc27455-sec-9710}

[M. Alharbi]{.ul} ^1^, N.A. Mobark^1^, A. Balbaid. A^2^, A. Abdal Samie Marie^3^, N. Fayea NY^1^, F. Al‐Manjomi^1^, W. Ballourah^1^, M. Rayis^1^, Z. Ullah^1^, A. Bany Hamdan^4^, W.A.R. Aljabarat^1^, Y. Bashawari^5^, S. Santagata^6^, M. Abedalthagafi^7^, E. Bouffet^8^

*^1^Comprehensive Cancer Centre‐ King Fahad Medical City KFMC Saudi Arabia, Pedatric Oncology Department‐, Riyadh, Saudi Arabia; ^2^Comprehensive Cancer Centre‐ King Fahad Medical City KFMC Saudi Arabia, Radaition Oncology Department‐, Riyadh, Saudi Arabia; ^3^Comprehensive Cancer Centre‐ King Fahad Medical City KFMC Saudi Arabia, Radiation Oncology Department‐, Riyadh, Saudi Arabia; ^4^Comprehensive Cancer Centre‐ King Fahad Medical City KFMC Saudi Arabia, Oncology Department‐, Riyadh, Saudi Arabia; ^5^Reserch Centre‐ King Fahad Medical City KFMC Saudi Arabia, Oncology Department‐, Riyadh, Saudi Arabia; ^6^Brigham and Women\'s Hospital‐ Harvard Medical School‐, Department of Pathology‐, Boston‐, USA; ^7^Genomics Research Department‐ Saudi Human Genome Project King Fahad Medical City KFMC, Department of Pathology‐ Brigham and Women\'s Hospital‐ Harvard Medical School‐, Riyadh, Saudi Arabia; ^8^The Hospital for SickChildren‐ Toronto, pediatric neuroncolgy, Toronto, Canada*

**Background/Objectives**: KFMC is the major tertiary care center for children with brain tumors in Saudi Arabia. The aim of this study is to analyze demographic data, treatment strategy and clinical outcome in Saudi children with Medulloblastoma (MB) and pineablastoma treated with Saudi Arabian Pediatric Hematology Oncology Society (SAPHOS) treatment study protocol

**Design/Methods**: A retrospective study of 65 patients newly diagnosed MB and Pineablastoma (\>3 year and \< 16 year) All treated at KFMC between 2009‐2016.All received multimodal therapy consisting of maximal surgical resection followed by Risk adapted craniospinal radiation concurrent with oral VP16 then adjuvant chemotherapy consisting of 3 cycles of Cisplatin Plus Oral VP16 alternating with 3 cycles of cyclophosphamide and vincristine. Post‐chemotherapy, maintenance with oral Isotretinoin was given for 6 months Molecular analysis was done using next generation targeted sequencing (NGS) from FFPE tissue for 560 cancer‐relevant genes Molecular subgroup analysis was done for 36 MB patients: WNT group (11.1%), SHH (19, 4%), group 3 (14%), and group 4 (55.5%).

**Results**: The majority of patients (70.8%) were male, median age at diagnosis 85 months, 46.2% treated as average‐risk (AR) & 53.8% treated as high‐risk(HR). Pineablastoma patients (7.7%) were treated as high --risk. 5years overall survival OS: for AR patients 89.7%and for HR patients 78.6%. Median time to start radiation was 31.00 days. A median follow‐up of 46 months: 5‐years PFS for the entire study patients was 80.7% and 5‐year OS was 84.6% 5‐year OS for the WNT subgroup and SHH subgroup was 100%, 20 % for Group 3, 77.8% for Group 4.

**Conclusions**: Our study protocol results was acceptable compared with international studies although most of our patients had high risk features. Oral VP16 was tolerable and convenient during craniospinal radiation. this study will form baseline to unify treatment protocols for children with brain tumor in Saudi Arabia.

### PO-005. Treating Infantile Brain Tumors without Conventional Radiotherapy: The Experience of a Tertiary Care Center in a Middle‐Income Country {#pbc27455-sec-9720}

[R. Alyoussef]{.ul} ^1^, K. Ghanem^1^, S. Muwakkat^1^, R. Saab^1^, N. Tarek^1^, D. Hamideh^1^, M. Najjar^2^, M. Abboud^1^

*^1^American University of Beirut, Pediatrics, Beirut, Lebanon; ^2^American University of Beirut, Surgery, Beirut, Lebanon*

**Background/Objectives**: Outcome of brain tumors in infants less than 12 months is not well described in middle‐income countries. Brain tumors in this age group have different management approach compared to older children.

**Design/Methods**: Retrospective analysis of disease characteristics, treatment and survival outcomes was done for all children less than 12 months who were diagnosed with brain tumors at the Children\'s Cancer Institute of Lebanon between 2002 and 2016.

**Results**: Sixteen patients (11 males and 5 females) with a median age of 8.3 months (range: 2‐11 months) were identified. There were 12 supratentorial and 4 Infratentorial tumors. The presenting symptoms included increased head circumference (n=3), vomiting (n=1), irritability (n=1), seizures (n=3), abnormal eye movement (n=3), hemiparesis (n=2), developmental delay (n=1) and decreased vision (n=2). Thirteen patients underwent surgical resection, gross total in 5 and subtotal in 8 patients. Three patients did not undergo surgical resection as the diagnosis was clear radiologically (with optic nerve glioma). The histological diagnosis included astrocytoma (n=7), medulloblastoma (n=2), choroid plexus carcinoma (n=2), chroid plexus papiloma (n=1), glioblastoma (n=1), immature teratoma (n=1), atypical teratoid rhabdoid tumor (n=1) and anaplastic ependymoma (n=1). Twelve patients received chemotherapy. One patient with ATRT received proton radiotherapy outside the country; none of the other patients received radiotherapy. After a median follow‐up of 57.6 months (range: 15‐120 months), the 5‐year overall and progression‐free survival rates were 100% and 79.4% (95% CI: ‐48.8‐92.9%), respectively. Tumor progression occurred only in 3 patients with low‐grade glioma. All patients who underwent complete surgical resection had no recurrence.

**Conclusions**: Brain tumors in infants less than 12 months can be well controlled by surgical resection and chemotherapy avoiding the side effects of conventional radiotherapy. Studies with larger number of patients are needed to confirm this finding.

### PO-006. Who Are the High Risk Medulloblastoma Subgroups in Jordan? {#pbc27455-sec-9730}

[N. Amayiri]{.ul} ^1^, M. Swaidan^2^, A. Ibrahimi^3^, N. Hirmas^1^, A. Musharbash^4^, E. Bouffet^5^, M. Al‐Hussaini^6^, V. Ramaswamy^5^

*^1^King Hussein Cancer Center, Department of Pediatrics, Amman, Jordan; ^2^King Hussein Cancer Center, Diagnostic Radiology, Amman, Jordan; ^3^King Hussein Cancer Center, Radiation oncology, Amman, Jordan; ^4^King Hussein Cancer Center, Department of Surgery, Amman, Jordan; ^5^The Hospital for Sick Children, Hematology oncology/Neurooncology, Toronto, Canada; ^6^King Hussein Cancer Center, Department of Pathology, Amman, Jordan*

**Background/Objectives**: Medulloblastoma is comprised of four distinct molecular subgroups (WNT, SHH, Group3, Group4) with unique clinical and prognostic implications. However, this relationship is rarely reported in the Middle East.

**Design/Methods**: We assembled an institutional cohort of children\<18 years diagnosed with medulloblastoma and received radiotherapy at KHCC/Jordan between 2003‐2015 and subgrouped tumours using limited gene expression analysis.

**Results**: Eighty‐one patients were identified (36% females) with median age 7.3years (2.9‐17.6years). Twenty‐six patients (32%) were M1‐M3. Twenty‐eight patients were treated as standard risk (SR, 47%) and 43 as high risk (HR, 53%). Subgrouping revealed 27 Group4 (33%), 20 SHH (25%), 20 Group3 (25%) and 14 Wnt (17%). The median time between craniotomy and radiotherapy was 45 days (17‐155days). Median duration of radiotherapy was 44days (36‐74days). Overall 5year EFS was 70.5± 6% and OS 68.8± 6.1%; statistically not significant between SR and HR (p=0.1). Absence of metastasis had survival advantage (OS 81.3±6.9% for M0 and 43.6±11% for M1‐M3, p=0.001). SHH and Group4 tumors had very good OS (79.7± 10.7% and 81.5± 9.8% respectively). Metastatic Group4 did very well (OS 80± 17.9%) while metastatic Group3 had dismal OS (33.3±13.5%). Unexpectedly, WNT patients had relatively poor OS (67.9± 15.9%).

**Conclusions**: SHH and Group4 medulloblastomas had an excellent survival comparable to developed countries despite treatment delays. Strikingly, we observed lower survival of WNT subgroup, suggesting possible background differences compared to other cohorts. This highlights the importance of validation of molecular stratification in the developing world, and suggests that background genetic differences may underlie differences in therapy response.

### PO-007. Comparative Survival Analysis of Pediatric Central Nervous System Tumors Between Boston and Egypt {#pbc27455-sec-9740}

[E. Auwarter]{.ul} ^1^, D. Shyr^2^, C. Ma^2^, A. Abdel Aziz^3^, I. Maher^3^, M. El Beltagy^4^, K. Marcus^5^, M. Zaghloul^6^, P. Manley^1^

*^1^Dana Farber Cancer Institute, Pediatric Neuro‐Oncology, Boston, USA; ^2^Dana Farber Cancer Institute, Pediatric Oncology, Boston, USA; ^3^Children\'s Cancer Hospital Egypt, Clinical Research, Cairo, Egypt; ^4^Children\'s Cancer Hospital Egypt, Neurosurgery, Cairo, Egypt; ^5^Dana Farber Cancer Institute, Radiation Oncology, Boston, USA; ^6^Children\'s Cancer Hospital Egypt, Radiation Oncology, Cairo, Egypt*

**Background/Objectives**: Pediatric brain tumors affect many children worldwide, attributing to 25% of all diagnosed pediatric cancers annually. More than 85% of those newly diagnosed pediatric brain tumor cases occur in developing, low‐middle income countries (LMICs). There is paucity in overall survival studies that examine 5‐year survival of children in LMICs compared to children in HICs.

**Design/Methods**: A retrospective chart review was conducted of 299 patients diagnosed with medulloblastoma or ependymoma, and treated at either Dana‐Farber Cancer Institute (DFCI), Boston, MA or Children\'s Cancer Hospital Egypt (CCHE), Cairo, Egypt. The study cohort data was extracted from medical records and cancer registries from both hospitals identifying 225 cases from CCHE and 74 cases from DFCI. Patients diagnosed between 2007 to 2012, were abstracted and the follow up period of patients for outcomes took place through 2016. We evaluated demographic and clinical factors of overall survival (OS) using log‐rank test and Kaplan‐Meier curves stratified by tumor type. Overall survival rates were compared between the two cohorts with a median follow up of six years.

**Results**: Five‐year OS for DFCI was 80 ± 6% (medulloblastoma) and 95 ± 5% (ependymoma), and for CCHE was 66 ± 4% (medulloblastoma) and 64 ± 6% (ependymoma). Type of treatment received was associated with significantly improved OS among medulloblastoma patients. Age of diagnosis was associated with significantly improved OS among ependymoma patients.

**Conclusions**: With current treatment protocols, there is still upwards of 20% mortality with medulloblastoma and ependymoma. In LMICs these numbers are even higher. These findings highlight the importance of collaboration between developed countries and LMICs to consolidate therapies to improve overall survival.

### PO-008. Atypical Teratoid Rhabdoid Tumor (ATRT): Hacettepe Results {#pbc27455-sec-9750}

C. Akyuz^1^, [B. Aydin]{.ul} ^1^, N. Kalkan^1^, B. Yalcin^1^, N. Kurucu^1^, A. Varan^1^, T. Kutluk^1^

*^1^Hacettepe University, Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Atypical teratoid rhabdoid tumor (ATRT) is a rare high grade malignant brain tumor with poor prognosis. Most patients are younger than 3 years of age and as the age becomes younger, prognosis gets worse. Because of its rarity, experience regarding chemotherapy recommendation is scarce.

**Design/Methods**: Medical records of the patients who treated with a diagnosis of ATRT were evaluated retrospectively for demographic features, presenting symptoms, treatment approaches, response to treatment and outcome.

**Results**: The median age of 7 girls and 8 boys was 26 months. Three patients were younger than 12 months of age and 3 patients were older than 4 years of age at the time of diagnosis. Nine patients had supratentorial, 3 had infratentorial and 3 had spinal primary tumors. Tumor resections were complete or near complete in 3, partial resection in 10 and biopsy only in 2 patients. Patients were followed‐up for a median 7 months. Two‐year OS for patients who were older than 2 years at diagnosis were 44%. All the patients who were younger than 2 years died within the first year of treatment (p=0.005). Seven patients received etoposide and cisplatin and their 1‐year OS rate was 21%. OS rate was 67% for 8 patients who received more intensive sarcoma‐like chemotherapy at first year (p=0.03). Craniospinal radiotherapy (CSRT) was given to 7 patients at diagnosis. Eight patients had relapsed/refractory disease and received second or third‐line chemotherapy and additional RT. Survival was better in patients who had additional radiotherapy.

**Conclusions**: Younger age at diagnosis is a sign of poor prognosis. Intensive chemotherapy regimens are needed for ATRT and CSRT should be part of first‐line treatment. Also, intensive second line chemotherapy and additional RT might have impact on survival in recurrent disease.

### PO-009. Development of Training in Problem Solving (TIPS) for Caregivers of Young Adult Survivors of Childhood Brain Tumors {#pbc27455-sec-9760}

E. Stevens^1^, [L. Barakat]{.ul} ^1,2^, K. Knafl^3^, W. Hobbie^1^, J. Minturn^1,2^, J. Ginsberg^1,2^, S. Ogle^1^, R. Noll^4^, E. Ver Hoeve^1,5^, D. Leri^2^, J. Deatrick^6^

*^1^Children\'s Hospital of Philadelphia, Division of Oncology, Philadelphia, USA; ^2^University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA; ^3^University of North Carolina at Chapel Hill, School of Nursing, Chapel Hill, USA; ^4^University of Pittsburgh, School of Medicine, Pittsburgh, USA; ^5^University of Arizona, Psychology, Arizona, USA; ^6^University of Pennsylvania, School of Nursing, Philadelphia, USA*

**Background/Objectives**: Young adult survivors of childhood brain tumors (YAS) are the most impacted of all childhood cancer survivors. Caregivers are tasked with family management (FM) (i.e., managing the special needs of the YAS and incorporating those responsibilities into everyday life). Components of FM include the YAS daily life, caregiver\'s effort and ability to manage, impact of condition on family, family life difficulties, and ability to work together. No known evidence based interventions exist to support long‐term FM of YAS. This study describes development of a web‐based intervention, Training in Problem Solving (TIPS), based on Bright IDEAS, to support families' capacity for caregiving for YAS and improving caregiver and YAS health‐related quality of life (HRQOL).

**Design/Methods**: Directed content analysis identified FM challenges in data from semi‐structured interviews with 45 maternal caregivers of AYA survivors. An interdisciplinary team of experts then met biweekly to: (1) develop content--tailoring Bright IDEAS with FM challenges; (2) create informational videos of caregivers\' problem‐solving common FM challenges; and (3) design an engaging website that addressed health literacy issues and multi‐platform access, including videoconferencing technology for live chats with a coach. Mixed methods were used to evaluate acceptability and feasibility of a prototype module among key stakeholders (Community Advisory Board of caregivers of YAS).

**Results**: TIPS was organized into seven modules based on core FM challenges: 1) survivor well‐being; 2) survivor independence; 3) sibling well‐being; 4) family activities; 5) parents as caregivers; 6) survivor late effects; and 7) support and advocacy. Eight caregivers provided feedback on the prototype module. Initial ratings of acceptability and feasibility were high. Caregivers reported TIPS was understandable, informative, user‐friendly and relevant to their experience. Coach interaction was strongly endorsed.

**Conclusions**: Findings support initial acceptability and feasibility. TIPS may be an effective tool for improving FM among caregivers and caregiver and YAS HRQOL.

### PO-010. MST2 Inhibition Promotes Apoptosis and Decreases Cell Viability of Medulloblastoma Cell Lines {#pbc27455-sec-9770}

[M. Baroni Milan]{.ul} ^1^, G.A.V. Cruzeiro^2^, C.A.P. Correa^1^, V.K. Suazo^2^, R.G. de Paula Queiroz^2^, C.A. Scrideli^2^, L.G. Tone^2^

*^1^Ribeirao Preto Medical School ‐ University of Sao Paulo, Genetics, Ribeirão Preto, Brazil; ^2^Ribeirao Preto Medical School ‐ University of Sao Paulo, Pediatrics, Ribeirão Preto, Brazil*

**Background/Objectives**: Medulloblastoma (MB) is the most common type of pediatric malignant primary brain tumor. Despite the new advances, about one third of MB patients die due to recurrence and most survivors suffer from long‐term side effects. In the search for potential targets, we found MST2 a member of MST kinases family (Mammalian Sterile Twenty Like) that belongs to the Hippo Signaling. Several studies have shown the involvement of MST2 and Hippo pathway in carcinogenesis of different tumor types. Therefore, the aim of this study was to analyze the expression of MST2 in MB samples, and investigated the effect of pharmacological inhibition of MST2 on the viability of MB cell lines.

**Design/Methods**: We analyzed the MST2 expression in 48 samples of MB, 4 cell lines of MB and 5 non‐neoplastic human cerebellum by qRT‐PCR. Then we performed pharmacological inhibition of MST2 in DAOY and UW473 cell lines with the drug XMU‐MP‐1 (selective inhibitor of MST2). Cells were treated with different doses of XMU‐MP‐1 (1, 3 and 10μM) and times (24‐96h) and performed Resazurin Cell Viability kit. For clonogenic survival analysis the cells were treated with 0‐1 μM XMU‐MP‐1 for 72 hours and the colonies were counted after staining with giemsa. In the apoptosis assay the annexin/propidium iodide positive cells were counted by flow cytometry after 72 hours of 10μM XMU‐MP treatment. Statistical analysis was performed with SPSS Statistics 20.0.

**Results**: MST2 is upregulated in tumors and cell lines when compared to non‐neoplastic cerebellum. It was observed that the viability of cells decreased after XMU‐MP‐1 treatment. In the clonogenic assay did not form any colonies at the dose 1μM. Apoptosis increased after treatment with 10μM of XMU‐MP‐1.

**Conclusions**: These preliminary data show that MST2 expression is higher in MB samples and MST2 kinase may be involved in pathways that are important for cell survival in MB.

### PO-011. Diagnosis Delay: The Main Adverse Prognosis Factor for Ependymoma in Low‐Middle Income Countries. Analysis of Ten Years in a Mexican Hospital {#pbc27455-sec-9780}

[J.A. Bermudez Lugo]{.ul} ^1^, M. Ramirez Martinez^2^, A. Niembro Zuñiga^3^, M. Zapata Tarres^4^

*^1^Hospital San Angel Inn Universidad, Pediatrics, Mexico city, Mexico; ^2^Instituto Nacional de Pediatria, Pediatrics, Mexico, Mexico; ^3^Instituto Nacional de Pediatria, Pediatric oncology, Mexico city, Mexico; ^4^Instituto Nacional de Pediatria, Pediatric oncology, Mexico, Mexico*

**Background/Objectives**: CNS neoplasms are the second most common childhood tumors. They represent 20% of childhood cancer, of which, ependymomas are 10 to 15%. The purpose of this study was to describe the clinical characteristics and survival in pediatric patients diagnosed with ependymoma in a 10‐year period in a Mexican pediatric oncology reference center.

**Design/Methods**: This was a retrospective, retrolective, descriptive and observational study. Medical files of pediatric patients diagnosed with ependymoma between 2005 and 2015 were analyzed. Clinical characteristics were summarized with measures of central frequency.

**Results**: Thirty patients with this diagnosis were found. Of them, 46.7% were women and 53.3% men with a ratio of 1:1.14. The average age of diagnosis was 3.8 years (0.6‐15 years). The most frequent location was the ventricular region in 40%, hemispheres 26.7%, cerebellum 16.7%, column 6.7%, mesencephalon 3.3% and bridge 3.3%. Regarding histology, 63.3% were classic, 30% anaplastic and 3.3 mixopapillary. The most common symptoms were nausea and vomiting which were present in 80% of patients followed by headache in 73.3%, paresis and hydrocephalus in 60%, ataxia in 43.3%, neurodevelopmental regression in 36.7%, paralysis of some nerve 26.7% and visual changes in 23.3%. Only 20% achieved a complete surgical resection while 73.3% underwent partial resection and surgery was not performed in 6.6%. The 5‐year disease‐free survival was less than 20% for patients with low‐grade lesions while no patient with high‐grade lesions was found alive after one year of diagnosis.

**Conclusions**: The most frequent symptoms at the time of diagnosis are related to intracranial hypertension. We found a lower survival in our population compared to what has been reported due to the delay in diagnosis by first contact physicians. We will carry out actions focused on medical education and a media information campaign will be planned in order to shorten the time of diagnosis.

### PO-012. The Role of Modified C.O.M.B.A.T (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) in High‐Risk and Relapsed Medulloblastoma: A Single Institution Experience {#pbc27455-sec-9790}

[V. Bhat]{.ul} ^1^, G. Chinnaswamy^1^, T. Vora^1^, M. Prasad^1^, H. Sankaran^1^, K.C. Anand^1^, S. Epari^2^, A. jain^2^, T. Gupta^3^, R. Krishnatry^3^, A. Janu^4^, S. Banavali^1^
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**Background/Objectives**: Patients with high risk and relapsed medulloblastoma continue to have poor outcomes compared to average risk disease in low middle income countries (LMIC). C.O.M.B.A.T is an oral metronomic therapy that has shown benefit in progression‐free survival in patients with relapsed embryonal brain tumors. We reviewed the efficacy and feasibility of modified C.O.M.B.A.T in high risk and relapsed medulloblastoma in patients we had treated.

**Design/Methods**: We retrospectively evaluated patients from April 2011 to December 2016 with high risk medulloblastoma or relapsed medulloblastoma who were started on modified C.O.M.B.A.T regimen after completion of conventional therapy were included in this analysis. Modified C.O.M.B.A.T (modified version with sodium valproate replacing celecoxib) regimen consists of low dose temozolomide, etoposide, sodium valproate and 13‐cisretinoic acid administered in 12‐weekly cycles.

**Results**: Thirty nine children (median age, 9 years; median follow‐up, 27.7 months; male:female ratio, 5.5:1) were started on modified C.O.M.B.A.T during the study period, of which 19 (48.7%) were started after completion of conventional therapy and 20 (51.3%) were started at relapse. Molecular data was available for 17 children (WNT n=2; SHH, n=3; Group 3, n=5; Group 4, n =7). 2‐year progression free survival (PFS) after starting modified C.O.M.B.A.T was 83.9% (95%CI: 49.4‐95.7) and 25.8% (95% CI: 6.5‐51.1%) for upfront therapy and relapsed medulloblastoma respectively. 2‐year overall survival was 92.3% (95% CI: 56.6‐98.9%) and 67.4% (95% CI: 41.0‐84.0%) for upfront therapy and relapsed medulloblastoma. Only 1 child developed secondary AML and warranted discontinuation of modified C.O.M.B.A.T therapy.

**Conclusions**: Modified C.O.M.B.A.T regimen is a well‐tolerated and effective treatment option after completion of conventional treatment for children with high risk medulloblastoma especially in LMIC where options of high dose chemotherapy and stem cell transplant is not routinely available. Future studies based on molecular subtypes will further delineate the role of modified C.O.M.B.A.T in patients with high risk medulloblastoma.

### PO-013. Combined Modality Management of Paediatric Primary Central Nervous System Lymphoma: Clinical Experience from a Regional Cancer Centre in North India {#pbc27455-sec-9800}

[A. Biswas]{.ul} ^1^, S. Bakhshi^2^, V. Suri^3^, M. Sharma^3^, P. Julka^1^

*^1^All India Institute of Medical Sciences, Radiotherapy & Oncology, New Delhi, India; ^2^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; ^3^All India Institute of Medical Sciences, Pathology, New Delhi, India*

**Background/Objectives**: Paediatric primary central nervous system lymphoma(PCNSL) is rare and constitutes 1% of all PCNSLs.

**Design/Methods**: Data pertaining to paediatric patients with PCNSL attending our institute from 2016‐18 was abstracted by retrospective chart review.

**Results**: We identified 5 immunocompetent paediatric patients with PCNSL. The median age at presentation was 13 years(range 7‐17 years). The male to female ratio was 3:2. The median ECOG performance status was 2. Common symptoms included headache,vomiting and seizures in 80%, visual symptoms in 60% and motor impairment in 40% patients. On neuro‐imaging, 3 patients had solitary and 2 patients had multiple parenchymal lesions. CSF cytology showed atypical cells in 1 patient. None had ocular involvement. Systemic lymphoma work‐up was negative in all. Biopsy and resection of tumour were done in 2 and 4 patients respectively. Histopathology revealed DLBCL in 4 and B‐cell NHL in 1 patient. All patients underwent induction chemotherapy(median 5 cycles)‐ modified DeAngelis protocol (high‐dose IV Methotrexate‐2.5gm/m2,IT Methotrexate‐12 mg,Vincristine,Procarbazine and Rituximab‐375mg/m2 every 2 weeks) in 4 and single agent high‐dose Methotrexate‐3.5gm/m2 every 3 weeks in 1 patient. During chemotherapy, grade 3 neutropenia and grade 4 mucositis were noted in 1 patient. Radiotherapy(RT) was administered in 4 patients (and due in 1 patient). Whole brain RT(36‐45Gy/20‐25fractions/4‐5weeks) was given in 3 patients. Craniospinal RT(36Gy/18fractions/3.5weeks) followed by whole brain RT(9Gy/5fractions/1week) was given in 1 patient with positive CSF cytology. Subsequently consolidation chemotherapy with 2 cycles of high‐dose Cytarabine(3gm/m2 IV D1‐2 every 3 weeks) was administered in 2 patients (and due in 2 patients). After a median follow‐up of 7.4 months, all patients are in complete radiological remission.

**Conclusions**: Paediatric PCNSL is a rare tumour and multimodality management with high‐dose Methotrexate and Rituximab based chemo‐immunotherapy and cranial radiotherapy leads to excellent early clinical outcome. Awareness of this entity is important to preclude surgical resection of a highly chemosensitive and radiosensitive tumour.

### PO-014. Clinical Applications of Quantitative Three‐Dimensional MRI Analysis for Pediatric Embryonal Brain Tumors {#pbc27455-sec-9810}

J. Hara^1^, A. Wu^1^, J. Villanueva‐Meyer^2^, G. Valdes^1^, V. Daggubati^1^, S. Mueller^3^, T. Solberg^1^, [S. Braunstein]{.ul} ^1^, O. Morin^1^, D. Raleigh^4^

*^1^University of California San Francisco, Radiation Oncology, San Francisco, USA; ^2^University of California San Francisco, Radiology, San Francisco, USA; ^3^University of California San Francisco, Pediatrics‐ Neurology and Neurological Surgery, San Francisco, USA; ^4^University of California San Francisco, Radiation Oncology and Neurological Surgery, San Francisco, USA*

**Background/Objectives**: Physician‐defined, qualitative radiographic features are associated with molecular subgroups of pediatric embryonal brain tumors, and may provide useful information to adapt adjuvant therapy. By utilizing quantitative imaging, radiomics can function as a guide to provide novel information beyond what a physician can consciously observe. The purpose of this study was to investigate the prognostic utility of quantitative three‐dimensional (3D) magnetic resonance imaging (MRI) radiomic analysis for primary pediatric embryonal brain tumors.

**Design/Methods**: Thirty‐four pediatric embryonal brain tumor patients with concurrent pre‐operative T1‐weighted post contrast (T1PG) and T2‐weighted fluid‐attenuated inversion recovery (FLAIR) MR images were identified from an institutional database. The median follow‐up was 5.2 years. Radiomic features were extracted from axial T1PG and FLAIR contours using MATLAB, and 15 features were selected for analysis based on qualitative radiographic features with prognostic significance for pediatric embryonal brain tumors. Logistic regression, linear regression, receiver operating characteristic curve, Harrell\'s C index and Somer\'s D index were used to test the relationships between radiomic features, demographic variables and clinical outcomes.

**Results**: We found that pediatric embryonal brain tumors in older patients had increased normalized mean tumor intensity (P=0.05, T1PG), decreased tumor volume (P=0.02, T1PG) and increased markers of heterogeneity (P≤0.01, T1PG and FLAIR) relative to younger patients. We identified 10 quantitative radiomic features that delineated between medulloblastoma, pineoblastoma and supratentorial primitive neuroectodermal tumor, including size and heterogeneity (P£0.05, T1PG and FLAIR). Decreased markers of tumor heterogeneity were predictive of neuraxis metastases and trended towards significance (P=0.1, FLAIR). Tumors with increased size (AUC=0.7, FLAIR) and decreased heterogeneity (AUC=0.7, FLAIR) at diagnosis were more likely to recur.

**Conclusions**: Quantitative radiomic features are associated with pediatric embryonal brain tumor patient age, histology, neuraxis metastases and recurrence. These data suggest that quantitative 3D MRI radiomic analysis could be used to risk stratify pediatric embryonal brain tumor patients.

### PO-015. Liquid Biopsy Micro‐RNA Profiling in Meduloblastoma {#pbc27455-sec-9820}

Y. Yañez^1^, I. Roche^1^, L. Igual^1^, A.J. Cañada^2^, P. Gargallo^1^, J. Selles^3^, M. Llavador^4^, B. Torres^1^, V. Segura^1^, V. Castel^1^, [A. Cañete]{.ul} ^1^
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**Background/Objectives**: Medulloblastoma (MB) is the most common malignant CNS tumor in children. Molecular mechanisms involved in MB pathogenesis and aggressiveness are still poorly understood. MicroRNA (miRNA), a type of non‐coding short RNA, has been recognized as very important regulators of cancer related signaling pathways. We aim to analyze the miRNA expression profile in liquid biopsy and its correlation with MB specific signaling pathways, histopathology and tumor behavior.

**Design/Methods**: Circulating plasma‐miRNA was obtained from 15 MB patients. Plasma‐miRNA expression was evaluated using GeneChip miRNA 4.0 Platform (Affymetrix). Penalized regression models (Elastic Net) were implemented to evaluate the association between the miRNA expression profile and clinical behavior, histopathology and the major gene‐regulated pathways that are altered in this tumor.

**Results**: Differential plasma‐miRNA expression profile was identified in Wnt MB subgroup (hsa‐miR‐647, OR=1.054; SNORA81, OR=1.151 and hsa‐mir‐6884, OR=1.548). Notably, differential expression levels of: hsa‐mir‐584 (HR=1.312); hsa‐miR‐4676‐5p (HR=1.344); hsa‐miR‐4692 (HR=1.432); SNORD112 (HR=0.507); hsa‐miR‐4763‐5p (HR=0.75) and hsa‐miR‐548as‐3p (HR=0.85) were identified when comparing relapsed and non‐relapsed patients.

**Conclusions**: Liquid biopsy miRNA profiling could represent a promising tool for early detection of relapse and also for improving MB classification. Further validation of plasma‐miRNA signatures will be needed in larger patient cohorts. *MicroRNAs* targeting *pathways* of MB would provide new and potential powerful candidates for *therapeutic* intervention.

### PO-016. Survival Following High Dose Chemotherapy for Infant Medulloblastoma/PNET in Ireland {#pbc27455-sec-9830}

F. Clinton^1^, C. Thompson^1^, A. Stanzelova^1^, K. Gavin^1^, J. Pears^1^, C. Owens^1^, [M. Capra]{.ul} ^1^

*^1^Our Lady\'s Children\'s Hospital, Haematology/Oncology, Dublin, Ireland*

**Background/Objectives**: Survival of young children with medulloblastoma (MB)/primitive neuroectodermal tumour (PNET) is generally poor. Following resection, high dose chemotherapy (HDC) and stem cell rescue (SCR) provides a non‐radiotherapy treatment option, negating significant radiotherapy (RT)‐related toxicity to the immature developing brain. We document the response and toxicity with such treatment.

**Design/Methods**: A retrospective review of all patients \<4 years, diagnosed with MB/PNET, between June 2009 and February 2017 and treated in Ireland was performed. HDC comprised 3 sequential cycles of thiotepa/carboplatin administered after 3 cycles of induction combination chemotherapy following contemporary protocols (99703/ACNS0334/ACNS1221).

**Results**: There were 23 evaluable patients: 13 had MB (Chang staging ‐ M0:6, M1:1, M2:0, M3:6) 10 PNET (metastatic in 5), 17 boys. Four patients were treated with palliative‐intent with no HDC/SCR. Of the remaining 19, 7 (MB=5, PNET=2) had a complete resection, no evidence of disease pre‐chemotherapy, did not receive RT and remain alive with no evidence of disease (NED), 4 in partial remission pre‐chemotherapy remain alive (3 with NED), 8 have died (6 due to disease progression, 2 \[10.5%\] treatment‐related \[adenovirus x1, pulmonary fibrosis x1\]). Three patients received craniospinal RT: for progressive disease in 2 (both fatal), recurrence x 1(alive, NED). Nine of 19 (47.3%) did not receive RT and are alive with NED. Febrile neutropaenia followed 52/55 (94.5%) and 41/52 (78.8%) episodes of induction and consolidation chemotherapy respectively. Five patients required chemotherapy dose reductions (ototoxicity:4, myelotoxicity:1). Three‐year event‐free/overall survival (%) for the total group, and chemotherapy‐receiving, MBL, PNET subgroups respectively are: 43.5/47.8, 52.6/57.9, 46.2/53.8, 40/40. Three‐year overall survival for the patients in complete remission pre‐chemotherapy subgroup is 100%.

**Conclusions**: Surgery and HDC/SCR, with no RT, provides cure in nearly 50% of young children with MB/PNET in Ireland, but is associated with significant toxicity, including fatal treatment‐related outcomes (10%). Complete remission pre‐chemotherapy is a favourable prognostic variable.

### PO-017. Management and Outcomes of Non‐Irradiated Recurrences of Intracranial Non‐Germinomatous Germ Cell Tumors {#pbc27455-sec-9840}

[J. Chan]{.ul} ^1^, B. Imber^2^, C. Cheung^1^, A. Banerjee^3^, T. Tihan^4^, A. Bollen^4^, D. Raleigh^1^, D. Haas‐Kogan^5^, S. Mueller^3^, S. Braunstein^1^
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**Background/Objectives**: Craniospinal irradiation (CSI) historically has been integral for management of intracranial non‐germinomatous germ cell tumors (NGGCT). However, improvements in systemic therapy and concerns for late sequelae of CSI have motivated more limited radiation fields. The goal of this study is to evaluate the failures at non‐irradiated sites and subsequent salvage therapy outcomes.

**Design/Methods**: Patients who received curative‐intent treatment for intracranial NGGCTs between 1986‐2016 at a single institution were retrospectively reviewed. Actuarial estimates of progression‐free survival (PFS) and overall survival (OS) were determined using the Kaplan‐Meier method.

**Results**: 28 patients underwent curative‐intent treatment with combinations of surgery (61%), chemotherapy (68%), and radiation therapy (61%). The median age at diagnosis was 12.2 years (IQR 9.0‐16.8). 61% of patients had primary tumors in the pineal gland alone, 11% had bifocal tumors. There was significant heterogeneity with initial radiation therapy (RT) approach, ranging from no RT (39%), tumor‐directed RT (21%), whole ventricle (WVRT) or whole brain (WBRT) radiotherapy (25%) and CSI (14%). At a median follow‐up of 9.5 years (IQR 1.1‐15.8), the 5‐ and 10‐ year rates of PFS were 64% and 50%, and OS 81% and 75%, respectively. There were 10 recurrences at a median time of 1.1 years (IQR 0.6‐4.2). Four (14%), 3 (11%), 2 (7%), 1 (4%), and 0 recurrences occurred among patients who received no RT, tumor‐directed RT, WVRT or WBRT, and CSI respectively. Among the 17 irradiated patients, none experienced in‐field recurrences. Among all patients, 8 of 10 recurrences were salvaged with CSI (3) or high‐dose chemotherapy (5). Median OS from the time of salvage therapy was 6.7 years (IQR 2.3‐14.4) and OS from diagnosis in patients who underwent salvage therapy was 9.5 years (IQR 3.0‐15.4).

**Conclusions**: Despite high rates of non‐irradiated recurrences among this cohort of patients with NGGCT, long‐term overall survival appeared preserved, potentially due to successful salvage therapies.

### PO-018. Evaluation of Central Retinal Thickness and Macular Volume in Neurofibromatosis Type 1 {#pbc27455-sec-9850}

[C. Citak]{.ul} ^1^, E. Dinc^2^, O. Dursun^3^, O. Tezol^4^, G. Temel^5^

*^1^Mersin University Faculty of Medicine, Pediatric Oncology, Mersin, Turkey; ^2^Mersin University Faculty of Medicine, Department of Opthalmology, Mersin, Turkey; ^3^Mersin State Hospital, Department of Opthalmology, Mersin, Turkey; ^4^Mersin University Faculty of Medicine, Pediatrics, Mersin, Turkey; ^5^Mersin University Faculty of Medicine, Bioistatistics, Mersin, Turkey*

**Background/Objectives**: This study aimed to evaluate central retinal thickness (CRT) and macular volume (MV) in patients with neurofibromatosis type 1 (NF‐1) and compared to healthy subjects.

**Design/Methods**: The study included 35 eyes of NF‐1 patients as well as 37 eyes of healthy subjects with no ocular pathology as a control group. Macular sections were obtained by Heidelberg Retinal Tomography (HRT) after pupillary dilation with tropicamide 1%. CRT and MV measurements were recorded and then analysed. Normality of the data distributions was tested for each group using the Shapiro‐Wilk test. Normally distributed parameters were summarized with the descriptive statistics mean and standard deviation. Categorical variables were expressed using the descriptive statistics number and percentage. Mann Whitney U and Student\'s t‐test was used to compare means of the parameters between the patient and control groups. All data analyses were performed using the SPSS 11.5 package program, and p\<0.05 was considered significant.

**Results**: CRT value was significantly increased in the patient group \[277 μ (266‐283)\] compared to control group \[261 μ (252.5‐271.5)\] (p=0.016). In addition, MV was decreased in the patient group (8.49±0.69) compared to control group (8.71±0.43) but it was insignificant (p=0.092).

**Conclusions**: Present study showed that CRT increased in NF‐1 patients compared to healthy subjects.

### PO-019. A Prospective Study of Neurocognitive Outcomes and Hippocampal Volumes in Pediatric Patients with Primary CNS Malignancies Treated with Proton Therapy {#pbc27455-sec-9860}

[J. Contreras]{.ul} ^1^, A. Srivastava^1^, H. Heimos^1^, P. Stephanie^1^

*^1^Washington University School of Medicine, Radiation Oncology, St. Louis, USA*

**Background/Objectives**: Neurocognitive dysfunction is a known late toxicity of radiotherapy in pediatric patients. In this study we assessed the effects of proton therapy (PT) on volumetric changes in the hippocampus and their association with cognitive function using the National Institutes of Health Toolbox Cognitive Battery (TCB).

**Design/Methods**: This was a prospective cohort study conducted between 2014‐2018 in children ages 4‐21 with a CNS malignancy treated with PT. Patients completed TCB testing at baseline and at scheduled follow‐up visits. Brain magnetic resonance imaging (BMRI) was completed pre‐treatment and at scheduled follow‐up visits within 90 days of testing. Brain substructures were automatically segmented on MPrage MRI using Freesurfer. Linear mixed effects models were used to analyze the effects of age, time since PT, and PT dose on CNS volumes and TCB metrics.

**Results**: Thirteen children (median age 14 years, range 4‐19) with 31 BMRIs were included. Median follow up time was two years (range 0.5‐2.9). Total hippocampal volume (THV) increased over time (p=0.03) with a lower rate of change seen in patients irradiated at a younger age (p=0.02). THV was correlated with the cognitive function composite (p\<0.01), fluid composite (p=0.01), and episodic memory (p=0.04) domains, which were all found to decrease from baseline values over the course of follow up (p\<0.01). An increasing volume of total hippocampus receiving greater than 40 Gy was associated with worse neurocognitive outcomes (p\<0.01).

**Conclusions**: Changes in total hippocampal volume and a higher dose of PT were associated with decreased performance in neurocognitive testing. Our study suggests that hippocampal dose may represent an actionable treatment parameter in the treatment of pediatric CNS malignancies

### PO-020. Genetic Variants in the 9p21.3 Locus Are Associated with Pediatric Glioma Risk {#pbc27455-sec-9870}
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**Background/Objectives**: Genome‐wide association studies (GWAS) have identified germline genetic variants in 25 genetic loci that increase an individual\'s risk of developing glioma in adulthood. The aim of the present study is to investigate if these genetic variants increase the risk of glioma in childhood.

**Design/Methods**: Based on the two most recent GWAS of adult glioma, we selected 41 genetic variants located in 25 different loci for investigation. The association between these genetic variants and risk of pediatric glioma was investigated in 854 cases and 3689 controls from Sweden and Denmark. Recruitment of both cases and controls was population‐based. Genotyping was performed using Illumina BeadChips, and untyped variants were imputed with IMPUTE2 and data from the 1000 genomes project as reference.

**Results**: Three of the investigated variants, all mapping to the 9p21.3 (*CDKN2A*) locus, were associated with pediatric glioma risk (odds ratio=1.21, p=5.8x10‐4). We also found indications of an interaction between variants located in or near three genes involved in the p53 pathway.

**Conclusions**: Our findings line up with the existing evidence that genetic variants in the 9p21.3 (*CDKN2A*) locus increase the risk of pediatric glioma. The interaction between genetic risk‐variants located in genes involved in the p53 pathway warrants further investigation.

### PO-021. Safety and Tolerability of Intra‐Cerebrospinal Fluid (CSF) Chemotherapy in the Treatment of Leptomeningeal Disease in Relapsed/ Refractory Childhood Cancer‐ A Single Centre Feasibility Pilot {#pbc27455-sec-9880}

[M. Dandapani]{.ul} ^1^, M. Chohan^1^, J. Cox^2^, L. Meijer^3^, R. Grundy^4^, S. Wilne^1^, D. Walker^4^

*^1^Nottingham Children\'s Hospital, Paediatric Oncology, Nottingham, United Kingdom; ^2^Nottingham Children\'s Hospital, Paediatrics, Nottingham, United Kingdom; ^3^Beatrix Kinder Ziekenhuis, Paediatric Oncology, Groningen, The Netherlands; ^4^University of Nottingham, Childrens Brain Tumour Research Centre, Nottingham, United Kingdom*

**Background/Objectives**: Leptomeningeal disease provides a treatment challenge due to its disseminated nature and inadequate penetration of chemotherapy to the site of disease. Intra CSF chemotherapy has been used for Central nervous system (CNS) prophylaxis and treatment in leukemia and lymphoma as well as in CNS tumours. Our objective was to assess the safety and tolerability of intra‐CSF etoposide in patients with relapsed /refractory cancer with leptomeningeal disease.

**Design/Methods**: Patients were treated between 2011‐2017 at the Nottingham Childrens Hospital on an individualised basis. Patients received the intraventricular treatment as an adjunct to their systemic treatment via an indwelling device (ommaya reservoir or lumbar port in patients with ventriculoperitoneal shunts). Dosing was based on age and a treatment schedule of 5 days treatment per week for 1‐ 2 weeks per 21‐day cycle was used. Treatment was outpatient based and carried out in designated areas as per protocol.

**Results**: Twenty nine children and young people were treated with Intra CSF etoposide. Sixteen were male and thirteen were female. Twenty five of these patients received treatment with intra‐CSF etoposide (alcohol free).The median age was 4 years (range 0.2 ‐21 years).Twenty of these patients had a relapse of a CNS tumour such as medulloblastoma, ependymoma, primitive neuroectodermal tumour and pineoblastoma. Some patients received intra CSF treatment with multiple lines of systemic therapy with treatment free intervals based on clinical course. The mean number of cycles received was 12.6 (range 1‐48). Median time to progression was 418 days. The treatment was generally well tolerated. The main complications included infection (24%) and mechanical issues (3.5%). One patient in the original cohort is still receiving treatment.

**Conclusions**: Our experience has shown us that intra‐CSF etoposide is well tolerated and is feasible in patients with leptomeningeal disease. The efficacy of the treatment remains to be fully explored.

### PO-022. Thiotepa‐Based Conditioning and Autologous Stem Cell Transplantation in Children with High‐Risk Medulloblastoma {#pbc27455-sec-9890}

[V. Daylidite]{.ul} ^1^, G. Mentkevich^1^, I. Dolgopolov^1^, N. Subbotina^1^, A. Levashov^2^, S. Babelyan^2^

*^1^National Cancer Research Centre, Pediatric stem cell transplantation, Moscow, Russia; ^2^National Cancer Research Centre, Pediatric haematology, Moscow, Russia*

**Background/Objectives**: High‐risk (HR) medulloblasoma characterized by poor long‐term survival. This group of medulloblastoma includes patients with residual tumor, metastasis, unfavorable histology type (anaplastic), poor prognosis molecular biology (C‐myc/N‐myc amplification, iso17q). We suppose using high doses of thiotepa may improve the prognosis in these patients.

**Design/Methods**: Our treatment is based on tandem conditioning with thiotepa 300 mg/m2 (for pts under 36 months -- 10 mg/kg) on days ‐4, ‐3 and carboplatin (Carbo) 510 mg/m2 (for pts under 36 months -- 17 mg/kg) on days ‐4, ‐3 on consolidation stage followed by autologous stem cell transplantation (ASCT). Second course of high‐dose chemotherapy (HDCT) was given 4 weeks later provided blood counts recovered sufficiently without evidence of tumor progression.

**Results**: From 2012 till 2017 22 patients with HR medulloblastoma got tandem HDCT based on TT and Carbo. The median age was 6,8 (2 -- 16) years. All patients got CT and age‐adjusted RT at induction. Regimen toxicity didn\'t strongly increase after second course. Toxic mortality rate of 9% was observed: two patients died of sepsis after second course. One patient died of delayed neurological toxicity (cerebral necrosis) a year after end of treatment. After second course of HDCT 15 patients (63,6%) had no signs of disease, other patients had stable disease without signs of progression. To date 17 patients (77,2%) are alive, one of them relapsed and now is on treatment.

**Conclusions**: Two cycles of high dose thiotepa with ASCT are tolerable. We got 61% 5‐years overall survival with a median follow‐up 42 months and 70,9% 5‐years disease‐free survival with a median follow‐up 39 months in these high‐risk group patients.

### PO-023. Feasibility of Visual‐Motor and Executive Functions Training in Pediatric Posterior Fossa Tumor Survivors: A Quasi‐Experimental Trial {#pbc27455-sec-9900}

[A. Dreneva]{.ul} ^1^, A. Ryabova^1^, V. Kasatkin^1^, A. Karelin^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Rehabilitation Research Center for Patients in Remission "Russkoye Pole", Moscow, Russia*

**Background/Objectives**: Over the past decades the survival rates of patients with posterior fossa tumors have substantially increased. Nevertheless, these patients often demonstrate the deficiency of cognitive and motor skills, which can be caused either by tumor itself or by the treatment. The most frequently observed effects are the impairment of motor skills, visual‐motor integration, and executive functions due to the cerebellum pathology involvement.

The aim of the trial was to determine the potential feasibility of visual‐motor and executive functions training in patients who survived posterior fossa tumors.

**Design/Methods**: The cohort included 51 patients who survived posterior fossa tumors (24 females, 27 males, mean age was 12.02±3.24).

In the first phase of the trial, all the patients completed the assessment using Cambridge Neuropsychological Test Automated Battery, Visual‐Motor Integration Test and Bruininks‐Oseretsky Test. Then the sample was split into two subgroups of equal sex, age, and diagnosis. In the second phase of the trial, one of the patients' subgroups received 6 sessions of visual‐motor and executive functions training during two weeks; and the other subgroup underwent through 'empty' two weeks with no intervention. After this phase, the assessment of cognitive and motor functions was conducted in all patients once again. In the third phase, the subgroups were changed: the first subgroup went through 'empty' two weeks, and the second one completed the training. After this, the whole assessment was carried out in all patients once again.

**Results**: The results indicate significant improvement in the domains of visual‐motor integration, motor skills and working memory in the training condition comparatively to the control condition.

**Conclusions**: The trial has revealed the potential effectiveness of training of such functions as visual‐motor integration, spatial working memory and attention, in the cohort of pediatric posterior fossa tumor survivors.

### PO-024. Health‐Related Quality of Life \[HRQOL\] in Pediatric Brain Tumors: A Review of Literature {#pbc27455-sec-9910}

[I. Eche]{.ul} ^1^, C. Isibor^2^

*^1^Boston Children\'s Hospital, Hematology/Oncology, Boston, USA; ^2^Boston Children\'s Hospital, Neuro‐Surgery Program, Boston, USA*

**Background/Objectives**: Pediatric brain tumors are the second most common cause of cancer in children from ages 0 to 14 years old in the United States. Like other pediatric cancers, children with brain tumors are living long enough to experience impairments in their HRQOL due to substantial improvements in survival rates. These children experience severe neurological, cognitive, and psychosocial impairments that affect their overall HRQOL. HRQOL is well recognized as being negatively impacted by cancer treatment as treatment‐related sequelae can persist throughout trajectory of care. The purpose of this literature review is to describe HRQOL experiences in children with brain tumors.

**Design/Methods**: Four electronic databases were searched for research findings using the terms: *pediatric brain tumors, QOL, children with brain tumors, and HRQOL* for studies published between February 2013 and January 2018 in English language. Exclusion criteria were non‐research articles, literature reviews, and studies that focused on pediatric cancer survivors and/or other types of pediatric cancers. Using formal guidelines from Preferred Reporting Items for Systematic Reviews and Meta‐Analyses, data were extracted from included studies and synthesized.

**Results**: 15 articles met the inclusion criteria. Children with brain tumors experienced multiple impairments in HRQOL dimensions due to treatment and disease‐related variables. Cognitive, emotional, motor or sensory dysfunctions predicted lower HRQOL scores. Children with infratentorial tumors reported lower HRQOL at baseline and long‐term compared to children with supratentorial tumors. Children with brain tumors reported higher scores in the physical functioning dimension of HRQOL (experienced less pain, nausea and pain) compared to children with solid and/or hematologic malignancies. Higher intelligence functioning predicted higher HRQOL scores overtime for children who are on and off active treatments.

**Conclusions**: Future research is needed to examine the impairments in the emotional and psychosocial HRQOL domains with a focus on sub‐groups of pediatric brain tumors at higher risk for lower HRQOL.

### PO-025. Interim Analysis of a Phase I/II Study of Bevacizumab, Irinotecan and Erlotinib in Children with Progressive Diffuse Intrinsic Pontine Glioma {#pbc27455-sec-9920}

[F. El‐Khouly]{.ul} ^1^, S. Veldhuijzen van Zanten^1^, M. Jansen^1^, G. Kaspers^1,2^, D. van Vuurden^1,2^

*^1^VU University Medical Center, Pediatric Oncology/Hematology, Amsterdam, The Netherlands; ^2^Princes Máxima Center for Pediatric Oncology, Pediatric Oncology/Hematology, Utrecht, The Netherlands*

**Background/Objectives**: The purpose of this phase I/II, open‐label, single‐arm trial was to investigate the safety, tolerability, and preliminary efficacy of combining VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse intrinsic pontine glioma (DIPG).

**Design/Methods**: Biweekly bevacizumab (10 mg/kg) and irinotecan (125 mg/m^2^) were administered intravenously, concomitantly with daily oral erlotinib. Two successive cohorts received increasing doses of erlotinib (65 and 85 mg/m^2^) following a 3+3 dose‐escalation schedule indefinitely until disease progression with a maximum of one year. Dose‐limiting toxicities (DLT) were extensively monitored (bi)weekly during treatment. PFS and OS were determined based on clinical and radiological response. Clinical response was assessed using predefined case report forms and radiological response was assessed using the modified RANO criteria. Quality of life (QoL) was assessed using PedsQL questionnaires.

**Results**: Between November 2011 and July 2017, nine patients with disease progression after initial radiotherapy were enrolled. These patients were on average 7.3 months from diagnosis (95%CI 4.4 -- 10.3). Treatment was well tolerated. In the first dose cohort (65 mg/m2 erlotinib), one patient experienced a DLT (acute CTACE 4.0 grade III diarrhea). As a result, three additional patients were enrolled in this cohort. No additional DLTs were observed up to the maximum dose of 85 mg/m2. Patients received a median of 7 cycles (range 3 -- 25). Median time to secondary progression was 3.2 months (95%CI 0.0 -- 6.4), median OS from diagnosis was 13.8 months (95%CI 13.4 -- 14.2). QoL was stable during treatment.

**Conclusions**: Daily erlotinib up to 85 mg/m2 combined with biweekly bevacizumab and irinotecan is safe and well tolerated in children with progressive DIPG. In subsequent patients, MTOR inhibitor everolimus will be added to this 3‐drug combination. Cohorts of three patients will receive escalating doses of everolimus (2 and 3 mg/m2) following a 3+3 dose‐escalation schedule.

### PO-026. A Systematic Review of miRNAs as a New Tool for the Diagnosis of Pediatric Medulloblastoma {#pbc27455-sec-9930}

N. Berastegui‐Zufiaurre^1^, M. Garcia‐Ariza^2^, E. Lopez Lopez^1^, B. Santos‐Zorrozua^1^, I. Martin‐Guerrero^1^, A. Navajas^2^, [A. Garcia‐Orad]{.ul} ^1^

*^1^University of the Basque Country‐ UPV/EHU, Department of Genetics‐ Physical Anthropology and Animal Physiology, Leioa, Spain; ^2^University Hospital Cruces, Department of Pediatrics, Barakaldo, Spain*

**Background/Objectives**: Pediatric medulloblastoma (MB) is the most common malignant tumor of the central nervous system in pediatrics. Although its classification and treatment have been improved in recent years, mortality remains around 30%. For these cases, new markers are needed to improve the diagnosis and management of these patients. In this line, microRNAs (miRNA) have proven their usefulness as markers of diagnosis in different types of cancers. However, until now, a diagnostic signature in pediatric MD has not been defined. The objective of this work is to define a signature of miRNA with utility in the diagnosis of pediatric MB, through a systematic review of the literature.

**Design/Methods**: A systematic search was made in PubMed until March 2018, with the terms \["Non‐coding RNA" AND "Medulloblastoma"\], \["miRNA" AND "Medulloblastoma"\], \["Exosome" AND "Medulloblastoma"\], \["Extracellular vesicle" AND "Medulloblastoma"\] and \["Secretome" AND "Medulloblastoma"\]. The inclusion criteria were that the studies presented original and independent information and that they evaluated the impact of the expression of miRNAs on the diagnosis of MB in human population, using pediatric age (under 18 years) patients and controls.

**Results**: Applying the defined search criteria, 339 articles were obtained. After applying the inclusion criteria, only 6 articles remained. For miRNA selection, we used only those with significant results in at least two studies. Among others, mir‐139‐3p was downregulated and mir‐18a, mir‐34a and mir‐216a were upregulated in the tumor.

**Conclusions**: In our review, despite the few studies carried out so far, some miRNAs have already been identified with possible usefulness in the diagnosis of pediatric MB (mir‐139‐3p, mir‐18a, mir‐21, mir‐34a and mir‐216a). New studies confirming these results are necessary.

### PO-027. Evaluation of the Role of microRNAs for Prognosis in Pediatric Medulloblastoma: A Systematic Review {#pbc27455-sec-9940}

M. Garcia‐Ariza^1^, E. Lopez Lopez^2^, I. Martín‐Guerrero^2^, A. Navajas^1^, [A. Garcia‐Orad]{.ul} ^2^

*^1^University Hospital Cruces, Department of Pediatrics, Barakaldo, Spain; ^2^University of the Basque Country‐ UPV/EHU, Department of Genetics‐ Physical Anthropology and Animal Physiology, Leioa, Spain*

**Background/Objectives**: Pediatric medulloblastoma (MB) is the most common malignant primary brain tumor in children. Recently, microRNAs (miRNAs) have proven their usefulness as markers in different types of cancers, in which diagnostic, classification and prognostic signatures already exist. However, although some studies have already been carried out, a prognostic signature has not been defined for pediatric MB until now. The objective of this work is to determine if a signature of miRNAs with utility for prognosis in pediatric MB can be defined, through a systematic review of the literature.

**Design/Methods**: A systematic search was made in PubMed until March 2018, with the terms \["Non‐coding RNA" AND "Medulloblastoma"\], \["miRNA" AND "Medulloblastoma"\], \["Exosome" AND "Medulloblastoma"\], \["Extracellular vesicle" AND "Medulloblastoma"\] and \["Secretome" AND "Medulloblastoma"\]. The inclusion criteria were that the studies presented original and independent information and that they evaluated the impact of the expression of miRNAs on the prognosis of MB in human population, using pediatric age (under 18 years) patients.

**Results**: With the defined search criteria, 339 articles were obtained. Among them, only 2 studies met the inclusion criteria, with a total of 13 significant miRNAs. However, none of the miRNAs was replicated.

**Conclusions**: In our review, due to the limited number of studies carried out so far in pediatric MB, it has not been possible to identify a signature of miRNAs with utility in the prognosis of pediatric MB. For this reason, new studies are needed to define this prognostic signature.

### PO-028. Identification of Features Associated with Aggressive Behavior in Pediatric Optic Nerve Glioma Using Multiplex Immunofluorescence and Next Generation Sequencing {#pbc27455-sec-9950}

[R. Gartrell]{.ul} ^1^, A.A. Campbell^2^, G. Zanazzi^3^, M. Mansukhani^3^, A.M. Silverman^1^, D. Shan^4^, T.D. Hart^4^, A.T. Turk^3^, Y.M. Saenger^5^, P. Canoll^6^, M. Kazim^7^, J. Garvin^8^

*^1^Columbia University Irving Medical Center, Department of Pediatrics ‐ Division of Pediatric Hematology/Oncology/ Stem Cell Transplant, New York, USA; ^2^Wilmer Eye Institute‐ Johns Hopkins School of Medicine, Department of Ophthalmology, Baltimore, USA; ^3^Columbia University Irving Medical Center, Department of Pathology & Cell Biology, New York, USA; ^4^Columbia University, Columbia College, New York, USA; ^5^Columbia University Irving Medical Center, Department of Medicine ‐ Division of Hematology/Oncology, New York, USA; ^6^Columbia University Irving Medical Center, Department of Pathlogy & Cell Biology, New York, USA; ^7^Columbia University Irving Medical Center, Department of Ophthalmology ‐ Division of Ophthalmic Plastic and Reconstructive, New York, USA; ^8^Columbia University Irving Medical Center, Department of Pediatrics, New York, USA*

**Background/Objectives**: Optic nerve glioma (ONG) in childhood is a rare, sight‐threatening tumor with variable clinical behavior. Available data suggest most pediatric ONG have alterations in the mitogen‐activated protein kinase pathway, and microglia have been implicated in pathogenesis, but the molecular landscape and tumor immune microenvironment in ONG remain understudied.

**Design/Methods**: Cases of pediatric ONG biopsied or resected between 2000 and 2017 at Columbia University Irving Medical Center were identified from medical records, and tumor DNA was sequenced using the Columbia Combined Cancer Panel. Samples were stained using quantitative multiplex immunofluorescence (qmIF) for CD3, CD8, CD68, CD163, HLA‐DR, and Olig2. Multispectral images were acquired using Vectra^TM^ and analyzed using inForm^TM^ software and R studio to evaluate density of immune phenotypes within the tumor microenvironment.

**Results**: Seven patients were identified. Two specimens were insufficient for analysis. Targeted sequencing in 5 evaluable cases identified NF1 mutations in 2, KIAA1549:BRAF fusions in 2, and a novel truncating mutation in histone methyltransferase, SETD2 in 1 (with accompanying KIAA1549:BRAF fusion and clinically aggressive behavior). Cases representing each mutation were characterized by qmIF. Findings were (1) increased CD3+CD8+ cytotoxic T lymphocyte (CTL) infiltration associated with KIAA1549:BRAF fusion compared to NF1 mutation, (2) similar infiltration by microglia/macrophages (CD68+, CD68+CD163+) in KIAA1549:BRAF fusion and NF1 mutated cases, and (3) increased CD68+CD163+HLA‐DR+ macrophage infiltration associated with KIAA1549:BRAF fusion.

**Conclusions**: The finding of distinct patterns of tumor immune cell infiltration in cases of pediatric ONG with differing molecular alterations provides new insight into the variable clinical behavior of this challenging tumor. Next generation sequencing showed mutually exclusive recurrent KIAA1549:BRAF fusions and NF1 mutations, in ONG and 1 novel mutation, SETD2 in an aggressive ONG. QmIF analysis showed higher CTL and CD68+C163+HLA‐DR+ activated macrophage infiltration associated with KIAA1549:BRAF fusion when compared to NF1.

Acknowledgements: This project received funding from Swim Across America (Garvin and Gartrell).

### PO-029. Results of High‐Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Brain Tumors {#pbc27455-sec-9960}

[A. Gevorgian]{.ul} ^1^, P. Tolkunova^1^, E. Morozova^1^, I. Kazantsev^1^, T. Iukhta^1^, A. Kozlov^1^, T. Andreeva^1^, Y. Punanov^1^, L. Zubarovskaya^1^, O. Zheludkova^2^, B. Afanasyev^1^

*^1^Gorbacheva Memorial Institute of Children Oncology‐ Hematology and Transplantation‐ Pavlov First Saint Petersburg State Medical University, Bone Marrow Transplantation Department for Pediatric Solid Tumors, St. Petersburg, Russia; ^2^Scientific Center of Roentgenoradiology, Pediatric cancer multimodality treatment research laboratory, Moscow, Russia*

**Background/Objectives**: Central nervous system (CNS) tumors are the second most common pediatric malignancies with an about 30% 5‐year overall survival rate in high‐risk group. We tried to assess the effectiveness of high‐dose chemotherapy (HDCT) with autologous hematopoietic stem‐cell transplantation (auto‐HSCT) in this patient group.

**Design/Methods**: From 2008 to 2018, 106 pediatric patients with high‐risk or relapsed medulloblastoma (N=69), supratentorial PNET, NOS (N=12), germinoma (N=9), pineoblastoma (N=6), atypical teratoid rhabdoid tumor (N=3), choriocarcinoma (N=1), ETMR (N=6) received single or tandem HDCT with auto‐HSCT after induction chemotherapy, radiotherapy and surgical treatment. At the moment of HDCT 43 patients were in complete remission (CR), 58 patients were in partial remission (PR) and 5 patients had stable disease (SD).

**Results**: The median follow‐up is 48 months (range, 5--203). Twenty‐nine of 101 patients with CR or PR relapsed 1‐24 months after HDCT, the other 72 patients are currently in CR or PR on the maintenance therapy. Cumulative incidence of relapse in 4 years accounted 55% (95% CI 16%‐79%). The conditioning regimens had acceptable toxicity. Complications grade 4 were observed in 14% of cases. Transplant related mortality in 4 years was 7% (95% CI 1%‐33%). Four‐year overall survival (OS) in all patient\'s group was 54% and disease free survival (DFS) was 45%. MB and other embryonal CNS tumors had better survival rate (DFS 57% and 62%, respectively) in compared to germ cell tumors (DFS 16%, p=0,22). DFS was better among patients \>4year in compared to children \<4year: 59% and 49%, accordingly (p=0,015). Patients in CR or PR at the moment of HDCT had better DFS rate than patients in SD: 60%, 45% and 22% (p=0,007), respectively.

**Conclusions**: HDCT with auto‐HSCT in pediatric patients with high‐risk CNS tumors may be a feasible option for patients in CR\\PR after induction chemotherapy. It is ineffective as a salvage therapy in refractory patients.

### PO-030. Theophylline in Vision‐Impaired Children with Optic Pathway Glioma {#pbc27455-sec-9970}

[G. Halliday]{.ul} ^1^, M. Zapotocky^1^, A. Reginald^2^, U. Tabori^1^, E. Bouffet^1^, L. Dupuis^3^, I. Fried^4^, U. Bartels^1^

*^1^The Hospital for Sick Children, The Division of Haematology & Oncology, Toronto, Canada; ^2^The Hospital for Sick Children, The Division of Ophthalmology, Toronto, Canada; ^3^The Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Canada; ^4^Shaare Zedek Hospital, Haematology Oncology, Jerusalem, Israel*

**Background/Objectives**: Preclinical models suggest that phosphodiesterase inhibitors may slow or prevent axonal damage to the optic nerve in NF1 mice with visual pathway glioma likely through elevation of cAMP. We sought to evaluate whether theophylline could stabilize or improve visual outcome in vision impaired children with optic pathway glioma (OPG) who suffered further visual loss despite active chemotherapy or in the absence of radiological progression.

**Design/Methods**: In this case series, OPG patients with moderate to severe visual impairment who experienced further visual decline were treated with theophylline for a planned duration of 12 months. The initial theophylline dose was calculated based on ideal body mass and subsequently adjusted according to trough plasma concentrations. Safety was defined by absence of grade 3‐5 toxicity using the National Cancer Institute Common Toxicity Criteria version 4.0. Visual acuity was assessed at 3 monthly time intervals.

**Results**: Eleven patients, with a median age of 9.2 years (range 3.2 to 16.8) were treated with theophylline at The Hospital for Sick Children, Toronto between 2009 and 2015. After a mean duration of therapy of 10.5 months no grade 3‐5 treatment related toxicities were identified. Of the three patients who discontinued therapy prematurely, two suffered from grade 1 toxicities. Improvements in binocular vision were seen in three of the eleven patients with a further three patients showing stabilization of vision.

**Conclusions**: Theophylline, when given in combination with standard OPG chemotherapies is well tolerated. In a proportion of patients with progressive visual decline despite active chemotherapy, theophylline enabled stabilization or improvement in visual acuity.

### PO-031. Impact of Dedicated Pediatric Neuro‐Oncological Services in a Developing Country: A Single Institution, Pakistani Experience {#pbc27455-sec-9980}

F. Imran^1^, [A. Hamid]{.ul} ^1^

*^1^The Indus Hospital Karachi ‐Pakistan, Paediatric Haematology and Oncology department, Karachi, Pakistan*

**Background/Objectives**: To see the impact of dedicated pediatric neuro‐oncological services in resource limited setting by the comparison of patient turnover and overall abandonment in two distinct periods; 1998‐2013 (15 years) and 2014--2018 (4 years).

**Introduction**: Paediatric brain tumor is the second most common childhood cancer after leukemia and lymphoma and the most common solid tumor in children. The disease outcome is very poor in developing countries due to various challenges specially the lack of trained health care providers in neuro oncology leading to advance diseases at presentation.

**Design/Methods: Material and Methods**: This is retrospective chart review. The study was conducted at department of Peadiatric Oncology, The Indus Hospital Karachi Pakistan. Retrospective data from 1998‐2013 was made a baseline, and compared to the initiation of dedicated neuro‐oncological services from 2014‐2018 via variables including age, gender, patient number, abandonment include patients,referred for opinion and left before treatment (LBT) and overall outcome.

**Results**: There was a massive increase in the number of patients, with an average of 15 patients presenting per year between 1998‐2013, with the same number increasing to 45 from 2014‐2018. Between 1998 -- 2013 the overall majority of patients presented only to seek an opinion (61%) and 29% were LBT. From 2014‐2018, the number of patients seeking just an opinion fell to 7%. The percentage of patients who were LBT also decreased to 13%.

**Conclusions**: The start of neuro‐oncological services has caused an increase in the number of patients almost 3 times. Similarly the abandonment and lost to follow up ratio was also drastically reduced. There was a significant increase in the number of patients receiving active treatment. The importance of multi‐disciplinary approach in paediatric neuro oncology was also an important contributing factor in all the differences achieved. A dedicated paediatric neuro‐oncological expertise in surgery is a need of the hour.

### PO-032. What a Wonderful World: No Cancer, No SIOP {#pbc27455-sec-9990}

[P. Ivanovski]{.ul} ^1^

*^1^Medical Faculty University of Belgrade, Cancer prevention research center, Belgrade, Serbia*

**Background/Objectives**: Achievement a World without cancer and consequently without SIOP.

**Design/Methods**: A comprehensive reading of papers on cancer epidemiology and pathogenesis and exclusively the use of my own cortical neurons.

**Results**: There are no literature data about neoplasms which originate from terminally differentiated cells (TDCs) such as are Purkinje neurons, Betz neurons, and alpha motoneurons. This indicates that carcinogenesis cannot occur in cells not having mitotic potential, and consequently there is no mitotic crossing over (MCO) and no loss of heterozygosity (LOH), a mechanism responsible for the disabling of tumor suppressor genes. All known cancers so far, have been derived from cells possessing mitotic activity. Cancer is just a "privilege" of these cells. Larger body cell burden, longer life, means more mitoses, more MCO, more LOH and greater chances for cancer development. Li--Fraumeni syndrome(LFS) is a rare, autosomal dominant, hereditary disorder that pre‐disposes carriers to cancer development, because of *germline heterozygous* TP53 mutation. This mutation is present in all body cells, including TDCs. Classical and most frequent LFS malignancies are sarcomas, cancers of the breast, brain (especially glioblastomas), adrenocortical carcinoma, leukemias and lymphomas. Despite exaggerated predisposition for cancer development, no cancer originating from TDCs has been seen in LFS persons, so far. In all malignant cells of all tumors in LFS, *homozygous TP53 mutation (LOH at TP53)* is present, which is generated by MCO events during mitoses of the cells.

**Conclusions**: Chemical and biochemical scientists must create an oral MCO inhibitor (the basic substance is salicylic acid) that would be administrated to all humans throughout their lifetime in the form of food supplement for the achievement of the final goal of *A World Without Cancer*.

### PO-033. Utilization of the Eye Tracking Technique for the Evalution of Oculomotor Impairments in Patients with Cerebellar Tumors {#pbc27455-sec-10000}

M. Shurupova^1^, [V. Kasatkin]{.ul} ^1^, V. Anisimov^1^, A. Latanov^2^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Research Rehabilitation Center "Russkoe Pole", Moscow, Russia; ^2^Moscow State University, Neurobiology, Moscow, Russia*

**Background/Objectives**: Cerebellum is mostly involved in all types of eye movements. The cerebellar lesions inevitably provoke oculomotor impairments in patients of different age. Eye tracking technique is widely used as a non‐invasive method for measuring oculomotor parameters in patients with such injuries

**Design/Methods**: In present report, we showed the improvement in functioning of oculomotor system in 32 children and adolescent patients that were recovering from the cerebellar tumor‐removal surgeries and chemotherapy and/or radiotherapy and undergoing course of neurocognitive rehabilitation. Patients were asked to perform two oculomotor tests -- gaze stability test and visual counting test -- both before and after post‐surgery rehabilitation. Eye movements were recorded by eye tracker at the acquisition rate of 60 samples/s.

**Results**: Within the final sessions of both tests we observed significant improvement in tasks performance. The gaze stability was enhanced most likely because of decreased number of intrusive saccades and microsaccades which disrupt the fixation of the gaze on the object. The execution time declined and the visual scanpath got shortened in visual counting test probably because of optimization of visual scanning and visual processing of information.

**Conclusions**: Our findings indicate that there is a positive dynamics in the functioning of the oculomotor system in patients following the cerebellar tumor removal surgeries and subsequent neurocognitive rehabilitation. The experimental data support the effectiveness of the utilization of the eye tracking technique as diagnostic tool in the field of neurooncology.

### PO-034. Incidence of Cavernomatous Lesions on Brain MR of Pediatric Patients Treated with Intraventricular Radioimmunotherapy {#pbc27455-sec-10010}

[G. Kaur]{.ul} ^1^, S. Wolden^1^, M. Donzelli^1^, S. Haque^2^, K. Kramer^1^

*^1^Memorial Sloan Kettering Cancer Center, Neuro‐Oncology, New York, USA; ^2^Memorial Sloan Kettering Cancer Center, Radiology, New York, USA*

**Background/Objectives**: Cerebral cavernomas are encountered in pediatric patients with central nervous system (CNS) tumors, and may cause neurological compromise. The incidence of cavernomatous lesions on brain MR of pediatric patients treated with intraventricular radioimmunotherapy is unknown.

**Design/Methods**: 217 patients were treated on institutional clinical trials with 2‐ 5 serial intraventricular injections ^124^I‐ or ^131^I‐ (2‐ 100 mCi) labeled monoclonal antibodies (cRIT) targeting tumor associated antigens. Pre‐treatment brains MR at baseline and periodically for follow up over several years were obtained. Brain MR with Gradient echo T2\*‐weighted imaging and susceptibility‐weighted imaging was used to identify cavernomatous lesions.

**Results**: Of 217 patients, 175/ (80.645%) identified as Caucasian, 18 (8.29%) African American, 9 (4.15%) Asian and 15 (6.91%) wished not to identify. Median age at the time of cRIT was 7.6 years (9 months‐34.5 years). Median time for MR follow‐up examinations was 38.4 months from the time of first cRIT. Cavernomatous lesions were detected in 22/217 (10 %) patients, and in 17/80 patients (21%) who survived \> 2 years since cRIT. All in patients with prior external beam radiotherapy 22 (99%) Caucasian, 1 (1%) African American. Diagnoses were, metastatic neuroblastoma (N=12), medulloblastoma (N=8), ependymoma (N=1), pineoblastoma(N=1), and rhabdomyosarcoma (N=1). 12 patients had unifocal cavernomas frontal lobes (N=9), temporal lobe (N=2) or parietal (N=1). Multiple supratentorial and infratentorial lesions were detected in 9 patients; Only 1 patient had lesions involving the brainstem. One patient with cavernomas and concurrent vasculitis had neurologic symptoms; remaining patients were asymptomatic.

**Conclusions**: Cavernomatous lesions are found in 10% of all patients and 21% of long term survivors treated with cRIT and external beam radiotherapy. The majority of lesions are multifocal and supratentorial. Despite numerous lesions, patients remain without neurologic compromise.

### PO-035. Intracranial Germ Cell Tumors in Children {#pbc27455-sec-10020}

[R. Kebudi]{.ul} ^1^, S. Büyükkapu Bay^2^, O. Görgün^1^, A. Irıbas^3^, B. Zuifikar^1^, F. Agaoglu^3^, E. Darendeliler^3^

*^1^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^Istanbul University Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^3^Istanbul University Oncology Institute, Radiation Oncology, Istanbul, Turkey*

**Background/Objectives**: Intracranial germ cell tumors (iGCT) constitute 1% of all malignant neoplasms in children. The aim of this study is to evaluate the demographic characteristics, therapy, and long term outcome of children with iGCT in a single institution.

**Design/Methods**: Retrospective review.

**Results**: Twenty‐six children (11 female, 15 male) with a median age of 11 years (10 months‐18 yrs) diagnosed and treated for iGCT between 1990 and 2018 were evaluated. Three were only consulted, thus 23 patients were assessed. They were treated according to our institutional protocol. Patients \> 13 years old with germinomas recieved radiotherapy (RT) alone, patients \<13 yrs old recieved 2 courses of etoposide, cisplatinum followed with cranial radiotherapy. Nongerminoma patients recieved 3 courses of bleomycine, etoposide, cisplatinum followed by RT. Twelve had germinomas and 11 nongerminomatous GCT. Twelve were suprasellar; 10 pineal; 1 suprasellar and pineal. AFP and BHCG were evaluated in serum and CSF at diagnosis and during therapy. Three had seeding in the spinal axis, one had widespead systemic metastasis. Four had a total resection, 18 had a biopsy, 1 was clinically/radiologically diagnosed, 8 had a shunt. Twenty‐one patients are alive at a median follow‐up of 11 years (1--27.5 years) from diagnosis. One patient had a new germ cell tumor in the right testis 7 years after treatment. The patients are also followed up in the endocrinology clinic. Five patients had a recurrence/progression at a median of 13 months. The 10 year event free survival and survival were 76% and 90% respectively.

**Conclusions**: Cisplatin based chemotherapy and radiotherapy is successful and well tolerated in children with iGCT. The possibility of an early clinical diagnosis based on MRI and tumor markers and the use of modern neurosurgical techniques increases the chance of cure, gives a chance to reduce acute morbidity and further decrease late effects.

### PO-036. KRAS Mutation in Pediatric Intracranial Germ Cell Tumors {#pbc27455-sec-10030}

[C. Khaiman]{.ul} ^1^, P. Techavichit^1^, S. Laohasurayothin^1^, K. Chiangthong^1^, D. Sosothikul^1^, P. Seksarn^1^, S. Shuangshoti^2^

*^1^Division of Pediatric Hematology and Oncology‐ Department of Pediatrics‐ Faculty of Medicine‐ Chulalongkorn University, Pediatrics, Bangkok, Thailand; ^2^Chula GenePro center‐ Faculty of Medicine‐ Chulalongkorn University, Department of Pathology, Bangkok, Thailand*

**Background/Objectives**: Intracranial germ cell tumors (IGCTs) are considered rare, highly curable neoplasms. KRAS is a gene in KIT/RAS signaling pathway that plays important role in pathogenesis of many cancers. KRAS mutations were reported in patients diagnosed with IGCTs. Objectives: To describe clinicopathologic, molecular features of KRAS mutation and treatment outcome of children diagnosed with IGCTs.

**Design/Methods**: A retrospective review in patients diagnosed with IGCTs at Department of Pediatrics, King Chulalongkorn Memorial Hospital from 2007 to 2016. For molecular study, DNA was extracted from formalin‐ fixed, paraffin‐embedded (FFPE) tissue in 17 patients. Identifies mutations in codon 12,13 and 61 of the KRAS gene was performed by using real‐time PCR technique of the Cobas test and pyrosequencing method.

**Results**: Eighteen patients were diagnosed with IGCTs (11 males and 7 females). Age ranged from 5 to 14 years (median 10.5 years). Diagnosis was germinoma and non‐germinomatous IGCTs in 9 patients each. Elevated markers were revealed in approximately 25% of patients. Four patients had leptomeningeal involvement. All patients underwent surgical procedure and received adjuvant chemotherapy. Radiotherapy was given in 16 patients and craniospinal radiation (CSI) was given only in leptomeningeal metastasis. With the median follow up of 26 months, overall survival is 88.9% in germinomas and 37% in non‐germinomatous IGCTs. Mutation of KRAS gene was detected by pyrosequencing technique in one patient. The mutation located at codon 61, frequency 38.3% units, nucleotide substitution CAA \> CTA and amino acid substitution was Q61L. The patient who carries mutant gene was diagnosed intracranial germinoma with CSF metastasis and eventually died during treatment.

**Conclusions**: Our study revealed treatment outcomes of IGCTs in Thai children. We describe KRAS codon 61 mutation in metastasis germinoma patient with poor outcome, support KRAS codon 61 mutation (Q61L) may has clinical correlation in IGCTs.

### PO-037. Clinical Analysis of Twenty Children with Ependymoma {#pbc27455-sec-10040}

[Y. Kimura]{.ul} ^1^, M. Yoshida^1^, T. Osumi^1^, Y. Shioda^1^, C. Kiyotani^1^, M. Kato^1^, D. Tomizawa^1^, K. Usami^2^, H. Ogiwara^2^, H. Aoki^3^, Y. Tsutsumi^3^, R. Irie^4^, T. Yoshioka^4^, H. Fuji^5^, K. Matsumoto^1^, K. Terashima^1^

*^1^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Division of Neurosurgery, Tokyo, Japan; ^3^National Center for Child Health and Development, Department of Radiology, Tokyo, Japan; ^4^National Center for Child Health and Development, Department of Pathology, Tokyo, Japan; ^5^National Center for Child Health and Development, Division of Radiation Oncology, Tokyo, Japan*

**Background/Objectives**: The aim of this study is to evaluate clinical features and prognosis of ependymoma.

**Design/Methods**: We conducted a retrospective study on 20 pediatric patients with ependymoma who were treated at our center between April 2002 and February 2018.

**Results**: Fourteen patients were boys and 6 were girls. The median age at diagnosis was 2.9 years (0 ‐ 12.3 years) and the median follow‐up period was 74.5 months (2 ‐ 209 months). The locations of tumor were supratentorial (n= 7), infratentorial (n= 10) and spinal cord (n= 3). Six patients showed anaplastic pathology. Frontline treatment modalities varied. Five patients were dead at the time of analysis. Five‐year event‐free survival (EFS) and overall survival (OS) rates of all the patients were 30.9% (10.3 ‐ 54.5) and 82.6% (54.6 ‐ 94.1), respectively. There was no difference in 5‐year EFS between the patients who achieved gross total resection (GTR) and who did not {40.6% (6.7 ‐ 74.0) vs. 25.0% (4.1 ‐ 54.8)}. Patients who achieved GTR had better 5‐year OS than who did not {100% (100 ‐ 100) vs. 70.1% (32.3 ‐ 89.5), p=0.09}. Frontline radiation therapy was not associated with better EFS or OS. Among the patients who did not achieve GTR, supratentorial location was associated with better OS. Age at diagnosis, anaplastic pathology or treatment modality was not associated with better survival in non‐GTR patients. Neurological sequelae occurred in 9 patients (cranial nerve palsy in 4, motor paralysis in 3, and epilepsy in 3). Two patients had endocrinopathy (growth hormone and gonadotropin deficiency). Cognitive dysfunction was observed in 3 patients.

**Conclusions**: In children with ependymoma, initial GTR was associated with better OS. Tumor location was a prognostic factor in non‐GTR patients. While neurological sequelae were common, endocrinopathy and cognitive dysfunction were uncommon in survivors of pediatric ependymoma.

### PO-038. Intraventricular 131I‐Labeled Monoclonal Antibody 8H9 (Omburtomab) Targeting the Surface Glycoprotein B7‐H3 in Patients with CNS Malignancies {#pbc27455-sec-10050}

[K. Kramer]{.ul} ^1^, B. Kushner^2^, S. Modak^3^, N. Pandit‐Taskar^4^, U. Tomlinson^3^, M. Donzelli^3^, S. Wolden^5^, P. Zanzonico^3^, J. Humm^4^, S. Haque^4^, M. Souweidane^6^, J. Greenfield^7^, E. Basu^3^, S. Roberts^8^, J. Carrasquillo^4^, J. Lewis^4^, S. Lyashchenko^4^, S. Larson^4^, N.K. Cheung^3^

*^1^Memorial Sloan Kettering, Pediatrics, New York, USA; ^2^MSKCC, Peds, New York, USA; ^3^MSK, Peds, New York, USA; ^4^MSK, Radiology, New York, USA; ^5^MSK, Rad Onc, New York, USA; ^6^MSK, Neurosurgery, New York, USA; ^7^MSK, Surgery, New York, USA; ^8^MSK, Peds, New Yrok, USA*

**Background/Objectives**: Tumors metastasizing to the central nervous system (CNS) are associated with significant mortality. Intraventricular ^131^I‐labeled monoclonal antibody targeting tumor associated antigens may eradicate micrometastases.

**Design/Methods**: We tested the toxicity and dosimetry of intraventricular ^131^I‐labeled monoclonal antibody 8H9 (Omburtomab) targeting B7‐H3 in patients with CNS disease on a phase I/II trial. CSF flow was determined by ^111^Indium‐DTPA cisternography through intraventricular devices. 152 patients \[median age 5.4 years (1.2‐ 53.6 years)\]received 450 injections involving 2 mCi ^124^I‐ or ^131^I‐8H9 as a tracer for imaging and a therapeutic injection (10‐80 mCi, dose levels 1‐8 /10 mCi increments for phase I patients; expanded cohort 50 mCi/injection) ^131^I‐8H9. Pharmacokinetics were studied by serial CSF and blood samplings over 48 hours. Dosimetry was based on pharmacokinetics and ROI analyses on serial scans. Toxicity was defined by CTCAE v3.0.Injections were repeated after 1 month in the absence of serious adverse event or progressive disease. Tumor response was determined by clinical, radiographic, cytologic criteria; overall survival was noted.

**Results**: Injections were well tolerated, routinely administered in the outpatient setting. Rare self‐limited adverse events included grade 1 or 2 fever, headache, vomiting, biochemical elevations in AST or ALT \[1 injection with grade 3 ALT elevation (dose level 3)\]. Although not dose limiting, myelosuppression occurred in patients who had received craniospinal radiation. Up to 200 mCi (4 therapy injections/50 mCi 131I ‐8H9) was safely administered to a patient with leptomeningeal neuroblastoma with a positive response. Mean absorbed CSF dose was 104.9 cGy/mCi/ 2.6 cGy/mCi to the blood. Long term survival has been noted in several challenging pediatric CNS malignancies including embryonal tumor with multilayered rosettes, recurrent ependymoma and choroid plexus carcinoma, and metastatic neuroblastoma.

**Conclusions**: Intraventricular 131I‐8H9 (Omburtomab) is safe, has favorable CSF and blood dosimetry, and has curative potential in the treatment of B7‐H3 ‐positive CNS cancers.

### PO-039. Treatment of Central Nervous System Atypical Teratoid/Rhabdoid Tumor with VDC/ICE Protocol, Surgery and Craniospinal Irradiation {#pbc27455-sec-10060}

[S. Lauhasurayotin]{.ul} ^1^, S. Shuangshoti^2^, K. Chiangthong^1^, D. Sosothikul^1^, P. Seksarn^1^, P. Techavichit.^1^

*^1^Chulalongkorn University, Department of Pediatrics, Bangkok, Thailand; ^2^Chulalongkorn University, Department of Pathology, Bangkok, Thailand*

**Background/Objectives**: Central Nervous System (CNS) Atypical Teratoid/Rhabdoid Tumor (ATRT) is rare and clinically aggressive tumor that most often affects young children. Standard treatment for ATRT is not well established.

**Objectives**: To study characteristics and outcomes of ATRA patients treated with non‐CNS malignant rhabdoid tumors (MRT) protocol, surgery and cranio‐spinal irradiation.

**Design/Methods**: A retrospective review in patients diagnosed with ATRT at our department from 2007 to 2017.

**Results**: Eight patients were diagnosed with pathological confirmed ATRT (7 males and 1 females). Age ranged from 5 to 136 months (median 23 months). Tumors were infra‐tentorial in six patients and spinal metastasis in two patients. Presenting symptoms were consisted of increase intracranial pressure in all patients with hemiparesis in three patients. Total tumor removal was performed in four, partial removal in three and biopsy in one patients. Adjuvant chemotherapy consist of ifosfamide, carboplatin and etoposide alternate with vincristine, doxorubicin and cyclophosphamide, total of eight cycles, was given in seven patients. Craniospinal radiation (CSI) was given in five patients with 54 and 36 Gy at tumor bed and spine respectively. With the median follow up of 28 months, overall survival is 37.5%. All survive patients underwent upfront total tumor removal and received CSI immediately after chemotherapy completion with no spinal metastasis. Five patients died of disease with median survival time of 12 months. One patient, age six months, died one month after diagnosis with no further treatment.

**Conclusions**: Treatment outcome of ATRT is unfavorable with intensive adjuvant chemotherapy protocol. The major prognostic factors for survival is respectability, metastatic disease and CSI.

### PO-040. An Analysis of Medulloblastoma: 12 Year Experience of Rebagliati Hospital in Peru {#pbc27455-sec-10070}

[E. León]{.ul} ^1^, V. Liliana^2^, M. Bianca^1^

*^1^Sabogal Hospital, lima, lima, Peru; ^2^Rebagliati Hospital, Lima, Lima, Peru*

**Background/Objectives**: Medulloblastoma is an embryonal tumor with aggressive behavior and more commonly seen in children. Our purpose was to identify epidemiological patterns and to analyze prognosis factors with emphasis on treatment time and outcome.

**Design/Methods**: Study participants were identified from a retrospective cohort of 65 patients less than18 years old who had histologically confirmed with meduloblastoma diagnosed between 2005 and 2017, in our institution. Data were obtained from medical records and phone calls. Time to delay of surgery, radiation and chemotherapy were categorized, as, more than 10, 42 and 21 days, respectively. Statistical analysis was performed. Multimodality treatment included surgery followed by craniospinal irradiation up to 36 Gy followed by posterior fossa boost up to 54 Gy.

**Results**: The mean duration of symptoms 32 days. Median surgery therapy duration was 12 days. 38 patients received radiation post‐surgery (all of them had more than 3 years). 15 patients received delay Radiotherapy more than 42 days. The median follow‐up time was 18.5 months, in patients with High‐Risk disease, 2 and 5‐year overall survival(OS) rates were 71.5% and 58.5%, and Disease Free Survival(DFS) were 53.7% and 33.5%, respectively. In patients with standard‐risk disease, 2 and 5‐year OS and DFS rates were 50.5%, 34.4% and 36.3%, 19.9%, respectively. In multivariate analysis, group risk was an independent prognostic factor for OS along with metastatic disease, risk (HR 2.7;95%CI,1.58‐3.17) and positive CSF (HR2.5;95%CI,1.82‐7.60). A delayed radiation start after surgery(\>42 days) was associated to inferior OS(p=0.0186). There was no significant difference in OS among delayed chemotherapy time or surgery time.

**Conclusions**: In children older than 3 years, a delayed radiation start after surgery was significant factor for unfavorable prognosis. Early treatment, in addition to a quickly diagnosis, is the key to management of medulloblastoma, which still needs to be achieved.

### PO-041. Treatment Results of Medulloblastoma in Children Older Than 3 Years of Age According to Molecular Subgroup‐Specific Risk Stratification and Expression of Drug Resistance Markers {#pbc27455-sec-10080}

[A. Levashov]{.ul} ^1^, D. Khochenkov^2^, M. Ryzhova^3^, A. Stroganova^4^, S. Babelyan^1^, N. Subbotina^1^, V. Daylidite^1^, S. Gorelyshev^5^, S. Zagidullina^1^, G. Seregin^6^, I. Dolgopolov^1^, G. Mentkevich^1^

*^1^N.N. Blokhin National Medical Research Center of Oncology, Pediatric Hematology and Oncology Institution, Moscow, Russia; ^2^N.N. Blokhin National Medical Research Center of Oncology, Experimental Diagnostic and Treatment of Tumor Institution, Moscow, Russia; ^3^N.N. Burdenko National Medical Research Center of Neurosurgery, Department of Neuropathology, Moscow, Russia; ^4^N.N. Blokhin National Medical Research Center of Oncology, Department of pathology, Moscow, Russia; ^5^N.N. Burdenko National Medical Research Center of Neurosurgery, Department of Neurosurgery 1, Moscow, Russia; ^6^Moscow State University of Medicine and Dentistry, Moscow State University of Medicine and Dentistry, Moscow, Russia*

**Background/Objectives**: The aim of this study was to estimate overall survival (OS), event‐free survival (EFS) according to subgroup‐specific risk stratification, MGMT and ERCC1 protein expression.

**Design/Methods**: From 2008 to 2016 forty nine pediatric patients with de novo medulloblastoma were included in trial. Average risk group (ARG) was presented by: R0M0; high risk group (HRG): M+, R1 and large‐cell anaplastic (LCA) histologic variant. SHH subgroup, MGMT, ERCC1 proteins expression were assessed by immunohistochemical method and WNT -- by FISH (del6q). Children underwent like‐SJMB03 therapy.

**Results**: Twenty seven children were included in ARG, 22 in HRG. R1 status was revealed in 13 (26.5%) patients, M+ in 13 (26.5%), LCA variant in 4 (8.2%). Molecular subgroups were assessed in 45 (91.8%) patients. WNT subgroup was determined in 3 cases (6.7%), SHH in 14 (31.1%), non‐WNT/non‐SHH in 28 (62.2%). MGMT protein expression was revealed in 13 (56.5%) cases, ERCC1 in 5 (25%). OS was 92.6 ± 5.1% in ARG, 55.8 ± 12.% in HRG (p = 0.023), EFS was 75.7 ± 10.8% in ARG, 44.1 ± 10.8% in HRG (p = 0.013), a median follow‐up 66.3 ± 4.7 months. 5 events were revealed in ARG, 12 in HRG. Events were presented by: late relapse in 9 cases, early relapse in 4 cases, local relapse in 6 cases, disseminated relapse in 7 cases, progression during high‐dose chemotherapy in 1 case, secondary tumor in 1 case. Treatment related mortality was 4% (2 children) due to septic complications (patients with complete response). EFS was 100% in WNT, 57.3 ± 15.2% in SHH, 54.5 ± 9.9% in non‐WNT/non‐SHH (p = 0.351). EFS was 31.9 ± 16.6% in group with MGMT‐positive tumor, 100% with MGMT‐negative samples (p = 0.008).

**Conclusions**: High‐intensive program of therapy showed good effect in ARG patients. There was also determined negative prognostic significance of MGMT protein expression.

### PO-042. Atypical Teratoid/Rhabdoid Tumor (AT/RT) in Taiwan, 1999--2014: A Nationwide, Population‐Based Study {#pbc27455-sec-10090}

[Y.L. Liu]{.ul} ^1^, Y.C. Yen^2^, C.W. Tsai^2^, M.L. Tsai^3^, S.H. Chen^4^, T.T. Wong^5^, J.S. Miser^6^

*^1^Taipei Medical University and TMU Hospital, Pediatrics, Taipei, Taiwan R.O.C.; ^2^Taipei Medical University, Research Center of Biostatistics, Taipei, Taiwan R.O.C.; ^3^Taipei Medical University Hospital, Pediatrics, Taipei, Taiwan R.O.C.; ^4^Taipei Medical University and Shuang Ho Hospital, Pediatrics, Taipei, Taiwan R.O.C.; ^5^Taipei Medical University Hospital, Pediatric Neurosurgery, Taipei, Taiwan R.O.C.; ^6^Taipei Medical University, College of Medical Science and Technology, Taipei, Taiwan R.O.C*.

**Background/Objectives**: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare but highly aggressive embryonal brain tumor in young children.

**Design/Methods**: We performed a nationwide, population‐based study of AT/RT (ICD‐O‐3 code: 9508/3) in Taiwan using the Taiwan Cancer Registry Database and the National Death Certificate Database.

**Results**: From 1999 to 2014, a total of 47 cases (male:female = 29:18; median age, 1 year) with the pathological diagnosis of AT/RT were registered. The site of the primary tumor included 11 supratentorial (23%), 20 infratentorial (43%), 2 spinal (4%), and 14 unspecified nervous system or others (30%). On survival analysis, infants with AT/RT diagnosed at age \< 1 year (*n* = 11 \[23%\]) all died within 18 months after diagnosis, while cases diagnosed at age 1--2 years (*n* = 15 \[32%\]) had 5‐year overall survival probability (5y‐OS) of 28% and those ≥ 3 years (*n* = 21 \[45%\]) had 5y‐OS of 41% (*P* \< 0.0001). All cases treated with surgery only (*n* = 6 \[13%\]) died within 6 months; all cases treated with chemotherapy without radiotherapy (*n* = 12 \[25%\]) died within 3 years; the other cases treated with radiotherapy ± chemotherapy (*n* = 27 \[62%\]) had 5y‐OS of 45% (*P* \< 0.0001). The surgical extent and radiotherapy fields were not evaluable in this dataset. Univariate Cox proportional hazard modeling identified older age (≥ 1 year), supratentorial sites, and the use of radiotherapy, chemotherapy, or both as predictors of better survival. By contrast, gender or treatment era had no effect on survival. Multivariate analysis of 31 patients with specified primary site data confirmed the impact of age, site, and treatment on survival.

**Conclusions**: Nationwide, population‐based data from Taiwan of 47 cases with AT/RT showed older age, supratentorial site, and radiotherapy as predictors of better survival. The development of more effective therapy for younger children with AT/RT is desperately needed.

### PO-043. Visual Sequelae in Children with Primary Brain Tumors {#pbc27455-sec-10100}

[Y.A. Liu]{.ul} ^1^, C. Abongwa^2^, S. Ashwal^3^, D. Deming^4^, T. Winter^5^

*^1^Loma Linda University Children\'s Hospital, Pediatrics/Child Neurology, Loma Linda, USA; ^2^Loma Linda University Children\'s Hospital, Pediatrics/Hematology and Oncology, Loma Linda, USA; ^3^Loma Linda University Children\'s Hospital, Pediatrics/Child Neurology, Loma Linda, USA; ^4^Loma Linda University Children\'s Hospital, Pediatrics/Neonatology, Loma Linda, USA; ^5^Loma Linda University Medical Center, Ophthalmology/Neuro‐ophthalmology and Pediatric ophthalmology, Loma Linda, USA*

**Background/Objectives**: The prevalence of visual sequelae in children with brain tumors has received limited attention in the literature. We performed a retrospective analysis on long‐term visual outcomes that may affect quality‐of‐life considering significantly improved survival.

**Design/Methods**: We reviewed records of 141 children with primary brain tumors and detailed information of tumor demographics and eye related diagnoses were analyzed.

**Results**: Only 68 patients (48%, Male=32, Female=36) were evaluated by ophthalmology across 222 visits. The most common tumor types included glioma (35%), medulloblastoma (13%), and ependymoma (13%). Tumor locations were on the optic pathway (45%) and in the posterior fossa and brainstem (55%). A total of 54% of patients received chemotherapy and/or radiation. Overall survival was 84% (median follow‐up = 28 months). Median time from tumor diagnosis to initial ophthalmological evaluation was 9 months (0‐94 months). Ten children (15%) presented with visual symptoms at tumor diagnosis while 90% had abnormal ophthalmologic exam findings during treatment---strabismus (60%), visual acuity impairment (54%), amblyopia (38 %), papilledema (35%), visual field defects (19%), optic atrophy (18%), and keratopathy (15%) with 30% requiring tarsorrhaphy or corneal transplant. The presence of unrecognized visual field defects was high in patients with no visual complaints (p=0.007). Strabismus occurred more frequently in patients with posterior fossa tumors (p=0.041). Radiation was associated with amblyopia (p=0.019) and had an increased risk of 4.5.

**Conclusions**: Unrecognized visual sequelae are prominent in children with primary brain tumors. Ophthalmologic evaluation is helpful in identifying such complications and treatment may improve the quality of life of affected individuals.

### PO-044. Impact of Surgery and Radiotherapy in a Serie of Mexican Infants with Choroid Plexus Carcinoma. A Multicentric Study {#pbc27455-sec-10110}

[A.R. Martinez Frias]{.ul} ^1^, D. Perez Gomez^1^, E.G. Aguillen Jimenez^1^, M. Ortiz Azpilcueta^2^, L.E. Juarez Villegas^3^, C. Leal Cavazos^4^, G.E. Ana Cristina^5^, A.M. Niembro Zuñiga^1^, M. Zapata Tarres^1^

*^1^Instituto Nacional de Pediatria, Pediatric Oncology, Mexico City, Mexico; ^2^Centro Medico Nacional Siglo XXI, Pediatric Oncology, Mexico City, Mexico; ^3^Hospital Infantil de Mexico Federico Gomez, Pediatric Oncology, Mexico City, Mexico; ^4^Hospital Universitario Dr. José Eleuterio González, Pediatric Oncology, Monterrey, Mexico; ^5^Hospital Infantil de Chihuahua, Pediatric Oncology, Mexico City, Mexico*

**Background/Objectives**: Choroid plexus carcinoma (CPC) constitutes less than 5% of all Central Nervous System tumors. CPC are usually diagnosed before 2 years of life. There are even reports in newborns assuming CPC as a congenital disease. Clinical presentation is characterized by intracranial hypertension symptoms. Prognosis depends on the grade of surgical resection. Radiotherapy also has increased overall survival; nevertheless the young age of these patients does not allow this mode of treatment; chemotherapy is not a frontline management. There are some reports in which chemotherapy has increased survival.

**Design/Methods**: We made an observational, descriptive, retrospective and longitudinal multicentric study describing age, primary site, treatment and outcome of infants with diagnosis of CPC.

**Results**: We present six cases of infants (4 males) with CPC from 5 different oncological centers. Median age at presentation was 16.3 months; the most frequent site at presentation was the third ventricle; the percentage of surgical resection varied among 50 to 80%. Of those, 3 are currently alive with 36 months of follow up with a lansky performance over 70%.

**Conclusions**: Clinical presentation and primary site observed in our serie are the one reported in international literature. Three patients are alive and radiotherapy was administered to 2 of the 3 patients. Currently, chemotherapy plays a secondary role in management of these patients, however 50% of living patients in reported cases received protocols that include ifosfamide, carboplatin and etoposide. Two‐thirds of patients who did not received chemotherapy are dead. This treatment modality plays an important role in outcome. In our patients surgery and radiotherapy seem to be a good treatment strategy avoiding chemotherapy toxicity in this group of age. We must register CPC cases globally and specifically in Mexico in order to offer a major benefit systematizing treatments with surgery, radiotherapy and chemotherapy.

### PO-045. Pediatric Intracranial Ependymoma: Correlating Signs and Symptoms at Recurrence with Outcome in the Second Prospective AIEOP Protocol Follow‐Up {#pbc27455-sec-10120}
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*^1^Fondazione IRCCS Istituto Nazionale dei Tumori, pediatrics, Milano, Italy; ^2^Fondazione IRCCS Istituto Nazionale dei Tumori, Statistica Med. Biom. E Bioinform., Milano, Italy; ^3^Università Sapienza, Scienze Radiologiche‐ Oncologiche e Anatomo Patologiche, Roma, Italy; ^4^IRCCS Neuromed, Pathology, Pozzilli, Italy; ^5^Fondazione IRCCS Istituto Neurologico Carlo Besta, Neuroradiology, Milano, Italy; ^6^Ospedale S.Anna, SOS‐ID Laboratorio di Genetica‐ Pathology Department, Como, Italy; ^7^Università Sapienza, Dipartimento di Scienze Radiologiche‐ Oncologiche e Anatomo Patologiche, Rome, Italy; ^8^IRCCS Giannina Gaslini, Dipartimento Testa‐Collo e Neuroscienze, Genova, Italy; ^9^AOU Città della Salute e della Scienza, Pediatric Oncology, Torino, Italy; ^10^Ospedale Pediatrico Meyer, Pediatric Oncology, Firenze, Italy; ^11^Azienda Ospedaliera, Pediatric Oncology, Padova, Italy; ^12^Istituto Oncologico del Veneto, Radiotherapy, Padova, Italy; ^13^IRCCS Centro di Riferimento Oncologico, Radiotherapy, Aviano, Italy; ^14^Ospedale Santobono/Pausilipon, Pediatric Oncology, Napoli, Italy; ^15^AOU Città della Salute e della Scienza, Radiotherapy, Torino, Italy; ^16^Ospedale Pediatrico Bambino Gesù, Pediatric Oncology, Roma, Italy; ^17^Policlinico Agostino Gemelli, Pediatric Oncology, Roma, Italy; ^18^Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy, Milano, Italy*

**Background/Objectives**: The aims of patients' radiological surveillance are: to ascertain relapse; to apply second‐line therapy; to accrue patients in phase 1/2 protocols if second‐line therapy is not standardized/curative; to assess/treat iatrogenic effects. Aiming to lessen the emotional and socioeconomic burdens for patients and families, we ideally need to establish whether scheduled radiological surveillance gives patients a better outcome than waiting for symptoms and signs to appear.

**Design/Methods**: We analyzed a prospective series of 160 newly‐diagnosed and treated pediatric/adolescent patients with intracranial ependymoma comparing patients with recurrent disease identified at scheduled examinations (the RECPT group; 34 cases) with patients showing signs/symptoms of recurrent disease (the SYMPPT group; 16 cases). The median follow‐up was 67 months.

**Results**: No significant differences emerged between the two groups in terms of gender, age, tumor grade/site, shunting, residual disease, or type of relapse (local, distant, or concomitant). The time to relapse (median 19 months; range 5‐104) and the re‐treatment possibilities did not differ between the SYMPPT and RECPT groups either. The presence of signs/symptoms was an unfavorable factor for overall survival (OS) from recurrence (5‐year OS: 8% vs. 37%). At multivariable analysis, an adjusted model confirmed as much.

**Conclusions**: To improve OS in symptomatic patients, their early identification ‐ within the first 2‐3 years after their initial diagnosis ‐ would be desirable. This might be achievable by focusing on "heuristically detected" subgroups of patients and not just describing general prognostic variables, but also seeking potential biological differences in the light of patients' signs and symptoms.

### PO-046. Intracranial Growing Teratoma Syndrome: An International Retrospective Study {#pbc27455-sec-10130}

[G. Michaiel]{.ul} ^1^, N. Gottardo^2^, U. Bartels^3^, H. Coltin^4^, J. Hukin^5^, B. Wilson^6^, S. Zelcer^7^, J.R. Hansford^8^, M.S. AbdelBaki^9^, K.A. Cole^10^, G. Dhall^11^, L. Hoffman^12^, N.P. Smiley^13^, A. Smith^14^, A. Vinitsky^15^, N.A. Vitanza^16^, A. Wright^17^, K.K. Yeo^18^, E. Bouffet^3^, L. Lafay‐Cousin^1^

*^1^Alberta Children\'s Hospital, Section of Pediatric Hematology‐ Oncology‐ and BMT, Calgary‐ AB, Canada; ^2^Princess Margaret Hospital for Children, Pediatric Oncology and Hematology, Perth, Australia; ^3^The Hospital for Sick Children, Division of Hematology/Oncology, Toronto‐ ON, Canada; ^4^Children\'s Hospital of Eastern Ontario, Division of Hematology/Oncology, Ottawa‐ ON, Canada; ^5^British Columbia Children\'s Hospital, Division of Neurology and Oncology, Vancouver‐ BC, Canada; ^6^Stollery Children\'s Hospital, Division of Immunology‐ Hematology‐ Oncology & Palliative Care, Edmonton‐ AB, Canada; ^7^London Health Sciences Centre, Pediatric Oncology, London‐ ON, Canada; ^8^Royal Children\'s Hospital‐ Murdoch Children\'s Research Institute, Solid and Brain Tumour Division, Melbourne, Australia; ^9^Nationwide Children\'s Hospital, Hematology/Oncology & BMT, Columbus‐ OH, USA; ^10^Children\'s Hospital of Philadelphia, Pediatric Neuro‐Oncology Program, Philadelphia‐ PA, USA; ^11^Children\'s Hospital Los Angeles, Children\'s Center for Cancer and Blood Diseases, Los Angeles‐ CA, USA; ^12^Children\'s Hospital Colorado, Pediatric Hematology‐Oncology, Aurora‐ CO, USA; ^13^Ann & Robert H. Lurie Children\'s Hospital of Chicago, Hematology‐ Oncology‐ and Stem Cell Transplantation, Chicago‐ IL, USA; ^14^Arnold Palmer Hospital for Children, Pediatric Hematology‐Oncology, Orlando‐ FL, USA; ^15^St. Jude Children\'s Research Hospital, Department of Oncology, Memphis‐ TN, USA; ^16^Seattle Children\'s Hospital, Division of Hematology/Oncology, Seattle‐ WA, USA; ^17^Lucile Packard Children\'s Hospital Stanford, Pediatric Hematology & Oncology, Stanford‐ CA, USA; ^18^Children\'s Hospital Los Angeles, Children\'s Center for Cancer and Blood Diseases, Los Angeles‐ CA, USA*

**Background/Objectives**: Intracranial growing teratoma syndrome (IGTS) is a rare phenomenon of paradoxical germ cell tumor (GCT) growth during or following treatment despite normalization of tumor markers. We sought to evaluate the frequency, clinical characteristics and outcome of IGTS in patients in 21 North‐American and Australian institutions.

**Design/Methods**: Patients with IGTS diagnosed from 2000‐2017 were retrospectively evaluated.

**Results**: Out of 739 GCT diagnoses, IGTS was identified in 33 patients (4.5%). IGTS occurred in 9/191 (4.7%) mixed‐malignant GCTs, 4/22 (18.2%) immature teratomas (ITs), 3/472 (0.6%) germinomas/germinomas with mature teratoma, and in 17 secreting non‐biopsied tumours. Median age at GCT diagnosis was 10.9 years (range 1.8‐19.4). Male gender (84%) and pineal location (88%) predominated. Of 27 patients with elevated markers, median serum AFP and ßHCG were 70 ng/mL (range 9.2‐932) and 44 IU/L (range 4.2‐493), respectively. IGTS occurred at a median time of 2 months (range 0.5‐32) from diagnosis, during chemotherapy in 85%, radiation in 3%, and after treatment completion in 12%. Surgical resection was attempted in all, leading to gross total resection in 76%. Most patients (79%) resumed GCT chemotherapy/radiation after surgery. At a median follow‐up of 5.3 years (range 0.3‐12), all but 2 patients are alive (1 succumbed to progressive disease, 1 to malignant transformation of GCT).

**Conclusions**: IGTS occurred in less than 5% of patients with GCT and most commonly after initiation of chemotherapy. IGTS was more common in patients with IT‐only on biopsy than with mixed‐malignant GCT. Surgical resection is a principal treatment modality. Survival outcomes for patients who developed IGTS are favourable.

### PO-047. Success of Stem Cell Collection and Neutrophil Recovery in Pediatric Patients with Brain Tumours {#pbc27455-sec-10140}

[G. Michaiel]{.ul} ^1^, T. Truong^1^, N. Prokopishyn^2^, H. Luu^3^, L. Lafay‐Cousin^1^, D. Strother^1^, G. Guilcher^1^, V. Lewis^1^

*^1^University of Calgary‐ Alberta Children\'s Hospital, Section of Pediatric Hematology‐ Oncology‐ and BMT, Calgary‐ AB, Canada; ^2^Calgary Laboratory Services, Cellular Therapy Laboratory, Calgary‐ AB, Canada; ^3^Alberta Children\'s Hospital, Department of Pediatrics, Calgary‐ AB, Canada*

**Background/Objectives**: The use of high‐dose chemotherapy (HDC) and autologous hematopoietic stem cell transplant (HSCT) has been used in certain pediatric patients with brain tumours to delay/spare radiotherapy. We aimed to study factors predicting a successful stem cell collection (SCC) and correlate stem cell dose infused with HSCT outcomes.

**Design/Methods**: A retrospective chart review was undertaken for pediatric patients with brain tumours treated at our centre with HDC/HSCT between 2004‐2016.

**Results**: Fifty‐five patients were identified (32 male) with median age of 6.3 years at time of SCC (range 0.4‐18.7). Patients\' diagnoses were medulloblastoma (62%), ATRT (20%), and PNET (18%). Most patients (82%) underwent a single/1‐day SCC, while the remaining required 2 SCC procedures. Peripheral blood stem cells were the source in most collections (95%). Successful SCC (CD34 collected ≥ 2 x10\^6/kg/transplant) and ideal SCC (≥ 5 x10\^6/kg/transplant) was achieved in 85% and 45% of patients, respectively. Use of mobilizing chemotherapy with G‐CSF was the only factor associated with achieving an ideal collection, while gender, age, stem cell source, and pre‐apheresis peripheral blood CD34 count were not significant. Higher CD34/kg infused was associated with faster neutrophil engraftment in the first 3 courses of HDC/HSCT and platelet engraftment in the first course.

**Conclusions**: The majority of SCC for autologous HSCT can be successfully completed with a single apheresis session. Mobilization with both chemotherapy and G‐CSF yields higher CD34 compared to G‐CSF alone. Higher dose of CD34/kg infused was associated with faster neutrophil and to a more limited scale platelet recovery post‐HSCT.

### PO-048. Changes in Height after Craniospinal Irradiation. Retrospective Analysis of Single Institute Experience {#pbc27455-sec-10150}

[M. Mizumoto]{.ul} ^1^, Y. Oshiro^2^, H. Pan^3^, T. Merchant^2^

*^1^University of Tsukuba, Radiation Oncology, Tsukuba, Japan; ^2^St. Jude Children\'s Research Hospital, Radiation Oncology, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Biostatistics, Memphis, USA*

**Background/Objectives**: To investigate the impact of radiation dose and clinical factors on final height after craniospinal irradiation (CSI).

**Design/Methods**: Between 1996 and 2012, 296 pediatric patients were treated with CSI including 178 with medulloblastoma. The investigation cohort was limited to 213 patient that survived more than 5 years. The cohort included 132 male patents and the median age at CSI was 8.4 years old (range: 2.8‐21.7). CSI doses were 18Gy (n=1), 23.4Gy (n=147) and 36.0‐39.6Gy (n=65). Growth hormone replacement was administered to 122, was not necessary for 81, and refused in 10.

**Results**: With a median follow‐up of 8.0 years (range, 5.0--20.4), 4585 height measurements were obtained from clinical records with a median of 22 measurements per patient. Considering patients aged \< 10 years at the time of CSI for male (n=81) and female (n=55) patients, respectively, the following median heights were determined prior to CSI (118.5 cm ± 13.1cm vs. 118.2cm ± 13.0cm), at 12 years of age (142.9cm ± 9.1cm vs. 142.4cm ± 8.0cm), 15 years of age (156.6cm ± 11.1cm vs. 150.7 cm ± 6.6cm), and 18 years of age (161.4 cm ± 11.8cm vs. 152.5 cm ± 7.9cm). The median height was 2.5%ile for male and 8.8%ile for female. Compared to the US population, median height impairment(male vs. female) was 3.3% vs. 7.3% at 12 years old, 7.0% vs. 6.7% at 15 years old, and 7.2 vs. 7.4% at 18 years old. Multivariate analysis showed that younger age, higher CSI dose, and female is significantly associated with short stature.

**Conclusions**: Final height was significantly lower than U.S population for pediatric patients with brain tumors treated with CSI. 7% impairment in final height can be expected for patients exposed to CSI before the age of 10 years. Younger age and higher CSI dose are significant risk factors for height impairment.

### PO-049. Anthropometric Data in Childhood Brain Tumors {#pbc27455-sec-10160}

[M. Moschovi]{.ul} ^1^, A. Pavlopoulos^1^, A. Zampogiannis^1^, A. Lagos^1^, D. Stathaki^1^

*^1^National and Kapodistrian University of Athens, Hematology‐Oncology Unit‐ 1st Department of Pediatrics, Athens, Greece*

**Background/Objectives**: Brain tumors are the most common solid tumors in childhood. The possible association between perinatal characteristics and the occurrence of brain tumor in children was the point of the study.

**Design/Methods**: Children with brain tumors, that diagnosed in our Department, were enrolled in this study. Parameters like gender, birth weight and gestational age were analyzed.

**Results**: Medical records of 56 children were reviewed. The age of diagnosis ranged from 7 days to 16 years, the mean age was 6 years. Males were 59% of the patients. The mother\'s age at pregnancy, ranged from 21 to 44 years, while in 62% of the cases, the mother\'s age was less than 30 years. The duration of the pregnancy ranged from 34 to 41 weeks. It must be pointed out that in 48% of the cases the duration of pregnancy was equal to or less than 38 weeks. Additionally, 48% of the patients were first born. In 44% of the cases, the delivery was performed with a scheduled caesarean section. The birth weight ranged from 2,190gr to 4,250gr, while in 67% of the cases the birth weight was less than 3,200gr.

**Conclusions**: Brain tumors are more common in males and there are no significant differences regarding the gestational age of the mother or the birth order compared with the published data of the general population in Greece. It is notable that in 63% of the cases, the duration of pregnancy was less or equal to 38 weeks, while the 67% had a birth weight less than 3,200g. Thus, this is an indicator that children with brain tumor are possibly born prematurely or with lower birth weight even after a full term pregnancy. Factors affecting intrauterine growth may predispose to the occurrence of brain tumors.

### PO-050. Low Concordance Between Surgical and Radiological Assessment of Degree of Resection and Treatment‐Related Hypothalamic Damage: Results of KRANIOPHARYNGEOM 2007 {#pbc27455-sec-10170}

[H.L. Müller]{.ul} ^1^, J. Reichel^1^, S. Boekhoff^1^, M. Warmuth‐Metz^2^, M. Eveslage^3^, J. Peng^4^, J. Flitsch^5^

*^1^Klinikum Oldenburg AöR‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^2^Universitätsklinikum Würzburg, Department of Neuroradiology, Würzburg, Germany; ^3^University of Münster, Institute of Biostatistics and Clinical Research, Muenster, Germany; ^4^Nanfang Hospital‐ Southern Medical University, Department of Neurosurgery, Guangzhou, China; ^5^University Hospital Hamburg‐Eppendorf UKE, Department of Neurosurgery, Hamburg, Germany*

**Background/Objectives**: Assessment of presurgical hypothalamic involvement (psHI) and treatment‐related hypothalamic damage (trHD) is relevant for the decision on risk‐adapted treatment and rehabilitation strategies in craniopharyngioma.

**Design/Methods**: 129 surgical reports of childhood‐onset craniopharyngioma patients recruited 2007‐2014 in KRANIOPHARYNGEOM 2007 were analyzed. Data on psHI were available based on surgeon\'s (63%), reference neuroradiologist\'s (95%), and local radiologist\'s (23%) assessment. The surgical degree of resection (DoR) was assessed by neurosurgeon (95%), reference neuroradiologist (73%), and local radiologist (61%). TrHD was assessed by neurosurgeon (33%), by reference neuroradiologist (95%), and by local radiologist (2%). Neurosurgical center size was categorized based on patient load.

**Results**: Surgical assessments on psHI (n=78), DoR (n=89) and trHD (n=42) as documented in surgical reports could be compared with the assessment of respective parameters by reference neuroradiologist. Differences with regard to DoR (p=0.0001) and trHD (p\<0.0001) were detectable between surgeon\'s and reference neuroradiologist\'s assessment, whereas psHI was assessed similarly. Concordance for DoR and trHD was observed in 48% and 62%, respectively. Surgeons estimated a higher rate of complete resections and a lower rate of trHD. Neuroradiological reference assessment of trHD had higher predictive value for hypothalamic sequelae then surgical assessment. Observed differences were not related to neurosurgical center size.

**Conclusions**: Observed differences between surgical and neuroradiological estimation of risk factors in craniopharyngioma support the necessity of neuroradiological reference review to assure standards of quality. This could be established by central internet‐based neuroradiological review in KRANIOPHARYNGEOM 2007. Standardization of surgical reports including specific assessment of tumor/damage location is recommended.

### PO-051. Pediatric Prolactinoma: Initial Presentation, Treatment, and Long‐Term Prognosis {#pbc27455-sec-10180}

A. Hoffmann^1^, S. Adelmann^2^, K. Lohle^2^, A. Claviez^3^, [H.L. Müller]{.ul} ^2^

*^1^Klinikum Oldenburg‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^2^Klinikum Oldenburg AöR‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^3^University Hospital‐ Kiel, Department of Pediatric Oncology, Kiel, Germany*

**Background/Objectives**: Prolactinoma is a rare pituitary adenoma secreting prolactin. Studies on diagnostics, treatment and prognosis in pediatric prolactinoma patients are rare.

**Design/Methods**: We analyzed clinical presentation, response to treatment, and prognosis of 27 paediatric prolactinoma patients (10m/17f) based on patients' records.

**Results**: Tumors included 6 microadenomas (tumor volume: median 0.2 cm3, range: 0.01--0.4 cm3; serum prolactin at diagnosis: median 101 ng/ml, range: 33--177 ng/ml) 15 macroadenomas (volume: median 3.3 cm3, range: 0.4--25.8 cm3; prolactin: median 890 ng/ml, range: 87--8624), and 3 giant adenomas (volume: median 44.5 cm3, range: 38.6--93.5 cm3; prolactin: median 4720 ng/ml, range: 317--10400); data for 3 patients were not available. Dopamine agonist treatment (n=22) was safe and effective, leading to reductions in tumor size (p\<0.01) and prolactin levels (p\<0.01). Threat to vision was the indication for decompressing surgery in 3 of 7 operated patients. No patient was irradiated. Long‐term functional capacity was not impaired when compared with other sellar masses (n=235).

**Conclusions**: In pediatric prolactinoma, diagnosis is based on hyperprolactinemia and imaging. Dopamine agonist treatment is effective and safe. Overall‐survival and functional capacity as a measure of quality of survival were not impaired, indicating an optimistic prognosis. Surgery should be considered only in emergency situations of threatened visual function, not presenting a fast response to dopamine agonist treatment. Severe side effects of medication and lack of efficacy should be considered as contraindications.

### PO-052. Periostin Concentrations in Childhood‐Onset Craniopharyngioma Patients {#pbc27455-sec-10190}

K. Heinks^1^, C. De Schutter‐Nüsse^1^, S. Boekhoff^1^, A. Hoffmann^1^, J. Zhu^2^, J. Peng^3^, [H.L. Müller]{.ul} ^1^

*^1^Klinikum Oldenburg AöR‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^2^Zhejiang University, Department of Gastroenterology, Hangzhou, China; ^3^Nanfang Hospital‐ Southern Medical University, Department of Neurosurgery, Guangzhou, China*

**Background/Objectives**: The expression of the extracellular matrix protein periostin has been found to be increased in adamantinomatous craniopharyngioma‐associated fibroblasts. It has been further identified as a novel marker for Non‐Alcoholic Fatty Liver Disease (NAFLD). Half of childhood‐onset craniopharyngioma (CP) patients with hypothalamic involvement develop a NAFLD. We hypothesized that periostin concentration is elevated in CP patients with pathological hepatic parameters.

**Design/Methods**: We analyzed 35 patients with childhood‐onset CP, 3 patients with isolated growth hormone deficiency (GHD), 5 patients with low insulin‐like growth factor (IGF)‐1 (IGF‐1D) and 7 healthy controls. Periostin concentration was determined in serum (34 CP, 3 GHD, 5 IGF‐1D and 7 healthy controls), urine (27 CP, 3 GHD, 5 IGF‐1D and 7 healthy controls) and salvia (18 CP, 3 GHD, 3 IGF‐1D and 7 healthy controls).

**Results**: Periostin serum, urine and salvia concentrations in CP patients were similar to concentrations of the other groups. Hypothalamic involvement as well as hepatic enzymes were not associated with elevated periostin concentrations. However, due to low patients numbers with pathological hepatic parameters (8 of 35 CP showed increased hepatic enzymes) no conclusions can be drawn from measured periostin concentrations in serum. Interestingly, the subgroup of patients with low IGF‐1 levels showed elevated concentrations of serum periostin when compared with other groups.

**Conclusions**: Periostin does not seem to be a suitable marker for NAFLD in childhood‐onset CP. However, the association between low IGF‐1 levels and periostin should be part of further investigations.

### PO-053. Eating Behavior and Oxytocin in Childhood‐Onset Craniopharyngioma Patients {#pbc27455-sec-10200}

A.M. Daubenbüchel^1^, A. Hoffmann^1^, M. Warmuth‐Metz^2^, M. Eveslage^3^, J. Özyurt^4^, [H.L. Müller]{.ul} ^1^

*^1^Klinikum Oldenburg AöR‐ Medical Campus University Oldenburg, Department of Pediatrics and Pediatric Hematology / Oncology, Oldenburg, Germany; ^2^University Hospital Würzburg, Department of Neuroradiology, Würzburg, Germany; ^3^University of Münster, Institute of Biostatistics and Clinical Research, Münster, Germany; ^4^University of Oldenburg, Biological Psychology Lab‐ Department of Psychology, Oldenburg, Germany*

**Background/Objectives**: Severe obesity due to disease and/or treatment‐related hypothalamic lesions (HL) frequently impairs quality of life in childhood‐onset craniopharyngioma patients (CP). CP often show eating restraints or binge eating. Oxytocin, a peptide hormone produced in the hypothalamus and secreted by posterior pituitary gland, plays a major role in the regulation of eating behavior and body composition.

**Design/Methods**: 34 CP and 73 healthy controls participated in a cross‐sectional case‐control study which aimed to investigate the associations between eating behavior/eating disorders, HL and OSC (oxytocin saliva concentrations). OSC were measured before and after standardized breakfast by immunoassay. Eating behavior was assessed using the Inventory for Eating Behavior and Weight Problems and the Inventory for Eating Disorders.

**Results**: CP with anterior plus posterior HL (grade 2) scored more pathological with regard to eating behavior and eating disorders associated with obesity than CP with a lower HL grade and healthy controls. Eating behavior in CP with anterior HL (grade 1) was more similar to that of healthy controls except their tendency for high dietary restraints. Decreases in postprandial compared to fasting OSC were associated with adverse eating behavior in CP and healthy controls and with higher BMI SDS in CP.

**Conclusions**: This is the first study to show that different grades of HL are associated with distinct patterns of eating behavior. In addition, our results suggested that reduced postprandial compared to fasting OSC is associated with weight problems in CP and with adverse eating behavior and eating disorders in both CP and healthy controls.

### PO-054. Clinical Characteristics and Outcome of Glioblastoma Multiforme in Children and Adolescents \< 21 Years at a Single Tertiary Health Care Center, Pakistan: 3 Year\'s Experience {#pbc27455-sec-10210}

[N. Mushtaq]{.ul} ^1^, S. Usman^1^, K. minhas^2^, A. darbar^3^, F. najmuddin^3^

*^1^Aga Khan University Hospital, Department of Oncology, karachi, Pakistan; ^2^Aga Khan University Hospital, department of pathology, karachi, Pakistan; ^3^Aga Khan University Hospital, Department of Neuro‐surgery, karachi, Pakistan*

**Background/Objectives: Introduction**: Glioblastoma Multiforme (GBM) is the most aggressive malignant primary brain tumor. Glioblastoma represent 15% of all primary brain tumors and 3% of all pediatric CNS tumors. Maximum safe surgical resection is the principle of treatment followed by focal radiation with concurrent temozolomide (TMZ) and maintenance TMZ. This is the only study highlighting clinical characteristics and outcome of children and adolescents with GBM, at a single tertiary health care center. It will help in better understanding of disease impact and to design support programs.

**Design/Methods: Methods/Materials**: It was a descriptive, crossectional, retrospective study including all patients \<21 years with diagnosis of GBM, from January 2015‐December 2017 at Aga Khan University Hospital. Relevant information about clinical features at presentation, radiological findings, metastatic workup, histopathology, management and outcome was collected from medical record after approval from ERC.

**Results**: Twenty cases were included in the study. Study was predominated by female patients (55%). Majority of the patients were between 5‐10 years (40%). Most common presenting features were vomiting, hemiparesis and headaches (60%) and the most common site was posterior fossa (60%). Duration of presenting illness was \< 6 months in all patients. Only 1 patient presented with metastatic disease. Family history of cancer was positive in only 2 patients. Subtotal resection 11(55%) was commonly performed. Chemotherapy was given to 7(35%) and radiation therapy was received by 11(55%) patients. Fourteen (70%) of the 20 patients expired, four (20%) had progressive disease, three (15%) had recurrence and only 2(10%) patients are alive with residual disease. Three (15%) patients were lost to follow up.

**Conclusions**: GBM is a rare Pediatric primary malignant brain tumor. majority of our patients died despite getting chemo radiation therapy. Early diagnosis, safe surgical resection, a strong rehabilitation program should be the key factors for the management of GBM in children.

### PO-055. Pediatric Neuro‐Oncology Twinning Program in a Developing Country: Three Years' Experience {#pbc27455-sec-10220}

[N. Mushtaq]{.ul} ^1^, S. usman^1^, K. minhas^2^, B.M. qureshi^3^, F. mubarak^4^, E. bari^5^, S.A. hamid^6^, V. ramaswamy^7^, U. tabori^7^, C. hawkins^8^, U. bartels^9^, E. bouffet^7^

*^1^Aga Khan University Hospital, Department of Oncology, karachi, Pakistan; ^2^Aga Khan University Hospital, department of histopathology, karachi, Pakistan; ^3^Aga Khan University Hospital, department of radiation oncology, karachi, Pakistan; ^4^Aga Khan University Hospital, Department of radiology, karachi, Pakistan; ^5^Aga Khan University Hospital, Department of Neuro‐surgery, karachi, Pakistan; ^6^indus children cancer institute, department of oncology, karachi, Pakistan; ^7^the hospital of sick children, department of neuro‐oncology, toronto, Canada; ^8^the hospital of sick children, department of pathology, toronto, Canada; ^9^the hospital of sick children, department of neru‐oncology, toronto, Canada*

**Background/Objectives**: A neuro‐oncology video‐teleconferencing twinning program was started in June 2014 between Aga Khan University Hospital, Indus Children Cancer Institute (Karachi, Pakistan) and the Hospital for Sick Children (Toronto, Canada) on monthly basis.

**Design/Methods**: We report descriptive analysis of 42 months of video‐teleconferencing for improvement in management of pediatric brain tumors in Pakistan. Minutes of each video teleconference were retrospectively reviewed from June 2014 to March 2018.

**Results**: During 42 months, 232 cases were discussed from two centers of Karachi. There were 53 (23%) Low grade Glioma, 40 (17%) Medulloblastoma, 37 (16%) High grade glioma, 20 (8.6%) Ependymoma, 10 (4.3%) oligodendroglioma, 24 (10%) Craniopharyngioma, others 35(15%). Germinoma 3(1.3%) pineoblastoma 4(1.7%) Choroid plexus carcinoma 4(1.7%) medulloepethelioma2 (0.8%) One hundred and three samples were sent to Sick Kids for medulloblastoma molecular subgrouping and immunohistochemistry. Four out of six families with consanguinity and brain tumors were found to have constitutional biallelic mismatch repair syndrome (CMMRD) while 1 family diagnosed as Li Fraumeni. Compassionate based Dabrafenib was started on one patient who had BRAF V600E immunopositive Optic Glioma. Early referrals, formation of multidisciplinary team, changes in radiation doses, necessity of immediate post‐operative scans and second look surgery were some of the changes due to this twinning. Changes in management plans based on recommendations were initially in 24% of cases, this went down to 5% during the current analysis. Most of the recommendations were followed.

**Conclusions**: The video‐teleconferencing and twinning between AKUH and Sickkids Hospital has improved management of children with brain tumors by having timely referrals from neurosurgeons and radiation oncology. The twinning program helped develop local treatment protocols as well. Such programs are a necessity in the low middle income setting to improve survival outcomes and quality of care provided. Eventually this will allow us to develop more programs within the country and provide local twinning.

### PO-056. High Dose Chemotherapy Followed by Tandem Autologous Hematopoietic Stem Cell Transplantation in Pediatric Patients with Malignant Brain Tumors: Single Institute Experience from India {#pbc27455-sec-10230}

S. Bhat^1^, [A. Mv]{.ul} ^1^, P. Mallya^1^, S. Chakraborty^1^, R. Chaudhary^1^, R. Daruvala^1^, R. Joshi^1^, V. Kailasnath^1^, S. Badiger^1^

*^1^Mazumdar Shaw Medical Center‐ Narayana Health City, Pediatric Hematology‐ Oncology‐ Blood and Marrow Transplant, Bangalore, India*

**Background/Objectives**: Tumors of the CNS may fail to respond to standard‐dose chemotherapy as a result of drug resistance or because of limited drug exposure to the tumor tissue. In order to overcome this high‐dose chemotherapy with autologous stem cell transplant (HDCT‐ASCT) has been explored. It is also appropriate for young children as radiation avoiding or bridging modality.

**Design/Methods**: In this retrospective analysis we investigated demographic data, treatment details and clinical outcome of patients diagnosed to have high risk malignant brain tumour in our institution, treated with HDCT‐ASCT, from March 2014 to March 2018.

**Results**: 15 children (8 males) with a mean age of 74 months (range 19‐168 months) diagnosed with malignant brain tumour were enrolled. Four children were \<3years of age. Nine children had high risk medulloblastomas, 3 recurrent medulloblastoma, 2 metastatic pineoblastoma and 1 Atypical teratoid rhabdoid tumour (ATRT). Five children received pre‐transplant chemotherapy and 12 children received radiotherapy. Eleven patients received 4 tandem transplants each with cisplatin vincristine and cyclophosphamide based conditioning regimen. Four patients received 3 tandem transplants each with carboplatin and thiotepa based conditioning regimen. Median infused CD34 cell dose was 3.2 X 106 /kg (1.9‐21.5 X 106 /kg) and median mononuclear cell count was 3.8 X 108/kg (1.78‐13.3 X 108/kg). Haematological recovery in the form of both neutrophil and platelet engraftment happened at a median of 10 days (6‐24days). All patients are alive at the time of analysis and two years progression free survival is 55.4%. No transplant related mortality was documented in our study.

**Conclusions**: HDCT‐ASCT is a feasible option for high risk CNS tumors along with other modalities. This treatment produces durable and comparable remissions with multimodality standard treatment. Limitation of our study was it being a single institution study with retrospective analysis and relatively small sample size.

### PO-057. Late Toxicity and Survival Outcomes of Pediatric Medulloblastoma Treated with VMAT Cranio‐Spinal Irradiation (VMAT‐CSI): Data from a Tertiary Oncology Centre {#pbc27455-sec-10240}

N. Alsafadi^1^, [V. Nair]{.ul} ^2^, G. Aljawi^2^, K. Abdalla^3^, M. Khan^4^, E. Ismail^4^

*^1^Radiation oncology department‐ Princess Norah oncology center‐ KAMC, Radiation oncology, Jeddah, Saudi Arabia; ^2^Division of Radiation oncology‐ University of Ottawa, Radiation oncology, Ottawa, Canada; ^3^Pediatric oncology department‐ Princess Norah oncology center‐ KAMC, Pediatric oncology, Jeddah, Saudi Arabia; ^4^Medical physics department‐ Princess Norah oncology center‐ KAMC, Medical physics, Jeddah, Saudi Arabia*

**Background/Objectives**: VMAT based Cranio‐Spinal Irradiation (VMAT‐CSI) demonstrates the ability to dosimetrically spare organ at risks in comparison to conventional radiation techniques. However, the clinical data supporting this is still emerging. In this study we present the early and late toxicity data of pediatric medulloblastoma treated with VMAT‐CSI at tertiary oncology center.

**Design/Methods**: Treatment charts of patients aged \<18 years, treated with VMAT IMRT between 2010 and 2015 were selected for this retrospective review. Of the 93 patients identified, 21 patients with diagnosis of medulloblastoma and treated with VMAT‐CSI were selected for this analysis. Treatment and toxicity details were collected and tabulated following the CTCAE 4.0 Toxicity criteria.

**Results**: The median follow‐up was 43.9 months. The mean overall survival of the entire cohort was 74 months. The median OS was not reached. The median age was 7 years (range 2‐13 years). Fifteen were high risk. VMAT‐CSI doses delivered was 23.4 -- 36 Gy delivered in 13‐20 fractions, and tumor boost dose in 18‐30.6 Gy in 10‐17 fractions. Most common acute toxicities included anorexia (100%), mucositis (90.48%), nausea (90.48%), vomiting (76.19%) and neutropenia (76.19%). Most common severe (grade ≥3) toxicities were neutropenia (42.86%), febrile neutropenia (33.33%) and anorexia (14.28%). The most common acute toxicities that became chronic were headache (71.43%) and alopecia (57.14%). The most common late toxicities (\>3months) were skin hyperpigmentation (47.62%), hypothyroidism (19.05%) and endocrinopathies (9.52%). No patient developed secondary malignancies during the follow‐up period.

**Conclusions**: Early follow‐up data suggests that the of high precision radiation techniques like VMAT‐CSI helps in reducing acute toxicity in children. Use of a multidisciplinary approach to managing the long term toxicity is warranted during the follow‐up of these patients.

### PO-058. Nationwide Application of an Integrated Diagnosis System for Pediatric Brain Tumors in Clinical Settings: The Japan Children\'s Cancer Group (JCCG) Brain Tumor Committee Initiative {#pbc27455-sec-10250}

[Y. Nakano]{.ul} ^1^, K. Ichimura^1^, Y. Kanemura^2^, J. Hirato^3^, Y. Takako^4^, S. Nobusawa^3^, M. Kitahara^1^, T. Shofuda^2^, K. Yamasaki^5^, K. Fukuoka^1^, H. Sakamoto^6^, R. Nishikawa^7^, J. Hara^5^

*^1^National Cancer Center Research Institute, Division of Brain Tumor Translational Research, Tokyo, Japan; ^2^Osaka National Hospital, Division of Regenerative Medicine‐ Institute for Clinical Research, Osaka, Japan; ^3^Gunma University Hospital, Department of Pathology, Gunma, Japan; ^4^National Center for Child Health and Development, Department of Pathology, Tokyo, Japan; ^5^Osaka City General Hospital, Department of Pediatric Hematology and Oncology, Osaka, Japan; ^6^Osaka City General Hospital, Department of Pediatric Neurosurgery, Osaka, Japan; ^7^Saitama Medical University International Medical Center, Department of Neuro‐Oncology/Neurosurgery, Saitama, Japan*

**Background/Objectives**: Histopathological diagnosis of brain tumors is sometimes challenging because of their rarity and diversity. To facilitate a biology‐based diagnosis, the latest WHO Classification of CNS Tumours (WHO2016) recommends integrated diagnosis based on histopathology and genetic information. Here we report our recent implementation of an integrated diagnosis system for pediatric brain tumor in JCCG.

**Design/Methods**: Patients were registered to JCCG observational study by participating centers. Samples were collected and managed by the Data Center. All cases underwent central pathology review. A set of genetic analysis using frozen samples were performed according to the pathological diagnoses as follows: for gliomas, detection of *BRAF* fusion by RT‐PCR and analysis of hot spot pathogenic variant (PV) of *BRAF, H3F3A, HIST1H3B, FGFR1*, and *IDH1/2* by pyrosequencing; for medulloblastoma, subgrouping by expression analysis using NanoString, sequencing of *CTNNB1* and *TP53* and copy number analysis; for supratentorial ependymomas, detection of *RELA* fusion by RT‐PCR.; for posterior fossa ependymomas, PFA or PFB classification by analysis of methylation status of three selected genes and/or immunohistochemistry of H3K27me3. For those which showed no diagnostic abnormalities in the above routine analysis or for other types of tumors, targeted DNA sequencing, RNA sequencing, and/or methylation analysis were performed as necessary. The final report was then generated integrating histopathological and molecular findings and sent to the local physicians.

**Results**: Between April 2016 and March 2018, over 450 tumors underwent central pathology review, of which 278 frozen samples were deposited to molecular analysis. In the routine molecular analysis, *BRAF* fusion or PVs were detected in approximately 60% of gliomas. The targeted sequencing identified *KIT* PVs in more than 60% of germinomas. Targetable fusions including *NTRK* fusions were also detected in several gliomas.

**Conclusions**: A nationwide central diagnosis system for pediatric brain tumor in clinical setting has now been established in Japan.

### PO-059. Risk of Developing Second Primary Tumors and Survival Outcomes in Medulloblastoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis {#pbc27455-sec-10260}

[C. Nantavithya]{.ul} ^1,2^, D. Yeboa^1^, K. Liao^3^, S. McGovern^1^, D. Grosshans^1^, M. McAleer^1^, K. Woodhouse^1^, S. Khatua^4^, M. Chintagumpala^5,6^, A. Paulino^1^

*^1^The University of Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA; ^2^King Chulalongkorn Memorial Hospital, Division of Therapeutic Radiation and Oncology‐ Department of Radiology, Bangkok, Thailand; ^3^The University of Texas MD Anderson Cancer Center, Health Services Research, Houston, USA; ^4^The University of Texas MD Anderson Cancer Center, Pediatrics, Houston, USA; ^5^Texas Children\'s Cancer Center, Pediatrics, Houston, USA; ^6^Baylor College of Medicine, Pediatrics, Houston, USA*

**Background/Objectives**: To define factors that increase risk of developing second primary tumor (SPT) and analyze survival outcomes in medulloblastoma patients.

**Design/Methods**: Patients who were diagnosed with medulloblastoma in 1973‐2014 from SEER18 registries were classified according to age (0‐10, 11‐20 and \>20 years), gender (male and female), race (white, black or other), year of diagnosis (1973‐1994, 1995‐2014), adjuvant treatment (no radiation (RT) or chemotherapy (CT), RT + CT, RT alone and CT alone), region (north‐east/middle Atlantic, south, west, mid‐west) and histology (desmoplastic nodular, large cell and not otherwise specified).

**Results**: Of 2771 cases, 146 cases developed SPT of which 42 were benign. The overall incidence rate of SPT at 10 and 15 years was 3.1% and 5.0%. There was no difference in SPT between patients who received only RT and RT+CT, 4.0% and 2.9% (10 years) and 4.8% and 6.0% (15 years), (p=0.33). RT+CT showed better overall survival (OS) compared with RT alone, 66.3% and 55.6% (10 years) and 61.4% and 49.5% (15 years), (p\<0.001). On multiple regression analysis, female gender (p=0.0077) and earlier year of diagnosis (1973‐1994) (p\<0.0001) were associated with a higher risk of developing SPT. The most common for SPT include brain and other nervous system (43.2%), thyroid (12.3%) and reticuloendothelial (10.3%). The OS rates in patients who development second malignancies and benign tumors were 74.1% and 91.4% (10 years) and 59.2% and 91.4% (15 years), (p\<0.001).

**Conclusions**: Female gender and diagnosis before 1995 were showed associated with a higher risk of developing SPT. Patients receiving RT + CT had a better OS without a reduction of SPT when compared to RT alone.

### PO-060. Phase II Study of Reduced‐Dose Craniospinal Irradiation and Combination Chemotherapy for Children with Newly Diagnosed Medulloblastoma: A Report from Japanese Pediatric Brain Tumor Consortium {#pbc27455-sec-10270}

[K. Okada]{.ul} ^1^, T. Soejima^2^, H. Sakamoto^3^, J. Hirato^4^, J. Hara^1^

*^1^Osaka City General Hospital, Department of Pediatric Hematology/Oncology, Osaka, Japan; ^2^Kobe Proton Center, Department of Radiation Oncology, Kobe, Japan; ^3^Osaka City General Hospital, Department of Pediatric Neurosurgery, Osaka, Japan; ^4^Gunma University Hospital, Department of Pathology, Maebashi, Japan*

**Background/Objectives**: We tested whether multidrug chemotherapy with simultaneous irradiation was able to reduce dose of craniospinal irradiation (CSI) for patients with medulloblastoma (MB).

**Design/Methods**: Children of three years and over were eligible. Patients with Stage M1‐4 were classified to high‐risk MB. The others, including M0 patients with \>1.5cm^2^ postoperative residual tumor, were classified average‐risk MB. Patients received chemotherapy consisting of cyclophosphamide, etoposide, cisplatin vincristine, and intrathecal methotrexate. Radiotherapy was started concomitantly with the second course of chemotherapy. Radiation doses were 50 Gy to the primary site and 18 Gy to the craniospinal axis with the exception of average‐risk patients of 12 years and over, who received 24 Gy CSI. Average‐risk patients received five courses of chemotherapy every 4 weeks. High‐risk patients received four courses of chemotherapy every 4 weeks. Five to six weeks after the last chemotherapy start, high‐risk patients received high‐dose chemotherapy consisting of thiotepa and melphalan (thiotepa 200 mg/m^2^/day continuous infusion and melphalan 70 mg/m^2^/day one‐hour infusion on days ‐12, ‐11, ‐5, ‐4) with autologous stem cell rescue.

**Results**: From 2006 to 2014, 57 patients (Average: 42, High: 15) were enrolled. The 5‐year PFS and OS were 83.8 (+/− 6.2) and 92.9 (+/− 4.0) % in average‐risk; 92.9 (+/− 6.9) and 92.9(+/−6.9)% in high‐risk. Seven average‐risk patients of 12 years old and over received 24 Gy CSI. Although expected hematologic and non‐hematologic Grade 4 toxicity were observed, there was no leukoencephalopathy and treatment‐related death. Two patients experienced secondary cancer.

**Conclusions**: These promising results suggest that intensive chemotherapy with simultaneous irradiation and high‐dose chemotherapy might be able to reduce dose of CSI to 18 Gy regardless of risk.

### PO-061. Postoperative Radiation Therapy Using a 5mm Clinical Target Volume Margin for Pediatric Patients with Newly Diagnosed Ependymoma. Treatment Results and Dose Volume Analysis {#pbc27455-sec-10280}

[Y. Oshiro]{.ul} ^1^, M. Mizumoto^2^, J. Lucas^2^, C. Tinkle^2^, S. Upadhyaya^3^, L. Jacola^4^, T. Merchant^2^

*^1^Tsukuba Medical Center Hospital, Radiation Oncology, Tsukuba, Japan; ^2^St. Jude Children\'s Research Hospital, Radiation Oncology, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Neuro‐Oncology, Memphis, USA; ^4^St. Jude Children\'s Research Hospital, Psychology, Memphis, USA*

**Background/Objectives**: We investigated tumor control rates in pediatric patients with localized ependymoma treated with radiation therapy (RT) using a 0.5 cm anatomically‐constrained, clinical target volume (CTV) margin surrounding the post‐operative tumor bed and evaluated the reduction in dose to brain and cochleae compared to treatment using a 1.0 cm CTV margin.

**Design/Methods**: Beginning November 2006, 50 pediatric patients with localized ependymoma received postoperative RT using a 0.5 cm CTV margin. The median age was 6 years (range, 1‐22). Tumor location was infratentorial in 33 patients, gross total resection was performed in 39, and 9 had multiple surgeries. The total prescribed dose was 59.4Gy (n = 45) or 54.0Gy (n = 5) based on age. The clinical plans for 5 patients each with supratentorial and infratentorial tumor location treated with intensity modulated radiotherapy (IMRT) or proton therapy (PT) were randomly selected to evaluate the impact of normal tissue doses by reducing the CTV margin from 1.0 to 0.5 cm.

**Results**: After a median follow‐up of 52.1 months (range, 8.0--132.0 months), 7 patients had died and 14 had experienced progression in the form of local (n = 8), distant (n = 4), or combined local and distant failure (n = 2). The 5‐year local control, event‐free survival, and overall survival rates were 77.9% (95% CI: 63.9%--91.8%), 59.3% (95% CI: 42.3%--76.3%), and 86.4% (95% CI: 75.1%--97.7%), respectively. One case of fatal secondary brain tumor and one case of fatal brain necrosis were observed. The mean brain, ipsilateral and contralateral cochlear doses were reduced by 69%, 60% and 52%, respectively, using a 0.5 cm CTV margin.

**Conclusions**: Tumor control rates and patterns of failure using a 0.5 cm CTV margin are comparable to those observed for pediatric patients treated with a 1.0 cm margin. A CTV margin of 0.5 cm substantially reduces dose to brain and cochleae.

### PO-062. Neuropsychological Outcome of Children with Medulloblastoma/Ependymoma Younger Than 4 Years: 2 & 5 Year Follow‐Up Data from the German HIT2000 & HIT2005Relapse Trials {#pbc27455-sec-10290}

[H. Ottensmeier]{.ul} ^1^, P.G. Schlegel^1^, M. Eyrich^1^, R. Schmidt^2^, A. Faldum^2^, M. Mynarek^3^, B.O. Juhnke^3^, S. Rutkowski^3^

*^1^University Children\'s Hospital‐ University Medical Center Wuerzburg, Department of Pediatric Hematology and Oncology, Wuerzburg, Germany; ^2^University of Muenster, Biostatistik and Clinical Research, Muenster, Germany; ^3^University Medical Centre‐ Hamburg‐Eppndorf, Pediatric Hematology Oncology, Hamburg, Germany*

**Background/Objectives**: Medulloblastoma (MB) and ependymoma (EP) require multimodal treatment which might affect mental outcome. In order to unveil long‐term treatment‐related deficits we used a Cattell‐Horn‐Carroll model of intelligence adapted to the pecularities of children \< 4 years.

**Design/Methods**: Between 2007 and 2017 n=239 neuropsychological examinations were performed in children treated within the HIT2005 and HIT 2005relapse trials. N=55 examinations were performed two and n=184 five years after surgery, with a male:female ratio of 1.4. The following tests were applied: for mental intelligence: Coloured Progressive Matrices, Visual‐Motor Integration, Kaufman Assessment Battery for Children; for psychomotor abilities: Tapping‐Speed; for executive functions: Continuous Performance (hit rate & decision time = CPT‐Power); for participation in daily life the FMH scales. In order to control variables we applied a multivariable analysis. The median age was set to 2.27 years and the time points of analysis adjusted to exactly 2 and 5 years using estimated scores for all tests.

**Results**: There was no significant difference when comparing age‐adapted standard scores (SS) of different treatment groups at 2/5 years. Furthermore, no gender‐specific effects could be detected. In multivariate analysis the main difference existed between different treatments. Patients with MBM0 (n=25) receiving systemic chemotherapy and MTXith were choosen as a reference (SS=88.4). Children with relapsed MBM0 and primary MBM+ (n=21) both receiving systemic chemotherapy and craniospinal irradiation (CSI) performed significantly worse: K‐ABC‐MPC (SS =−23.5), CPM (SS=−15.3), VMI SS=−13,5, WUEP‐KD (SS = ‐13.5), CPT‐Power SS=−21.7), FMH (SS=−6.6) (p\<0.01). A positive effect regarding psychomotor abilities could be observed: patients with supratentorial EP receiving systemic chemotherapy and local radiotherapy (RT) showed a significantly better tapping score (SS=76) than MBM0 (SS=58.1, p\<0.016).

**Conclusions**: MB Patients receiving systemic chemotherapy and CSI showed a significant worse performance in tested scores. In contrast, EP supratentorial tumor location in combination with local RT seems to better preserve psychomotor abilities.

### PO-063. A Family with Constitutional Mismatch Repair Deficiency and Multiple Cancers from Turkey {#pbc27455-sec-10300}

[D. Ozyoruk]{.ul} ^1^, F. Pinarli^2^, A.S. Oğuz Erdogan^3^, S. Hanalioglu^4^

*^1^Ankara Children Hematology and Oncology Hospital, Pediatric Oncology, Ankara, Turkey; ^2^Diskapi Yildirim Beyazit Training and Research Hospital, Genetic diagnostic center, Ankara, Turkey; ^3^Ankara Children Hematology and Oncology Hospital, Pathology, Ankara, Turkey; ^4^Diskapi Yildirim Beyazit Training and Research Hospital, Neurochirurgie, Ankara, Turkey*

**Background/Objectives**: Constitutional mismatch repair deficiency syndrome is a rare childhood cancer predisposition syndrome resulting from biallelic germline mutations of MMR genes and it is poorly recognised by clinicians so far.

**Design/Methods**: Here we present CMMRD sendrom due to germline bi‐allelic MSH 6 mutations with multiple cancers in family members. Index case: A 8 year‐old female presented with intracranial mass on MRI of brain. On family history, the parents were first degree cousins. One of her sisters diagnosed with an aggressive brain tumor at 4 years of age afterthat her brother had been diagnosed in childhood with neurofibromatosis type 1 and a medulloblastoma followed by colorectal cancer at 15 years of age. The mother\'s great uncle diagnosed with colorectal cancer at age 45. The physical examination was unremarcable other than 8 to 10 cafe au lait spots and hipodence macules on her body. After near‐total resection of cerebellar mass, histopathology revealed classic desmoplastic medulloblastoma. The genetic test was done and a novel homozygous single bone insertion mutation in exon 5 of the MSH 6 gene(c.3261dupCp. Phe1088Leufs 5) was detected. NF 1 and NF 2 genes were found to be negative. Blood samples obtained from parents and siblings.

**Results**: Her parents were found to be heterozygous for the mutation. Her two siblings were to be found homozygous, the other two siblings were heterozygous. The one of homozygous siblings diagnosed with medulloblastoma desmoplastic nodullarity subtype and colon adenocarcinoma at 13 years age, 2 years ago. He died with progressive disease. The other homozygous sibling is 9 month‐old. She has multiple cafe au lait spots and hipodence macules on her body. The other heterozygous siblings are 11 and 7 years old age.

**Conclusions**: An international collaboration is required to evaluate guidelines for screening and treatment of malignancies and to explore prevention strategies patients with CMMRD.

### PO-064. Irinotecan, Temozolamide and Bevacizumab in Patients with Relapsed Medulloblastoma: Experience of Two Institutions {#pbc27455-sec-10310}

[R.N. Palomar]{.ul} ^1^, S. Acosta^1^, M. Cores^1^, M. Nana^1^, M. Urbieta^1^, B. Diez^2^, M. Garcia Lombardi^1^

*^1^Hospital de Niños Ricardo Gutierrez, Oncology Unit, Buenos Aires, Argentina; ^2^Hospital Fleni, Oncology Unit, Buenos Aires, Argentina*

**Background/Objectives**: In Argentina CNS tumors represent 18.8% of all pediatric neoplasms. Medulloblastoma (MB) is the most frequent malignant tumor. Treatment is based on surgery, radiotherapy and chemotherapy. The relapse of this disease is always of poor prognosis.

To evaluate the results of treatment with irinotecan, temozolamide and bevacizumab (ITB) in patients (p) with relapsed or refractory medulloblastoma after radiotherapy and chemotherapy: toxicity, objective response and mean time to progression.

**Design/Methods**: Retrospective analysis of medical records of patients with relapsed medulloblastoma treated on outpatient basis with IV irinotecan (125‐150 mg/m2/day every 2 weeks), oral temozolamide (100‐150 mg/m2/day for 5 days every 4 weeks) and IV bevacizumab (10 mg/kg/day every 2 weeks), from 2013 to 2017.

**Results**: Evaluable patients: 11. Median age at diagnosis 6 yo (1‐13). Chang staging: M0 10p and M2 1p. Complete resection surgery: 10p. High risk: 4p (anaplasia). Median time to relapse 16 months (1‐72). Two patients progressed on treatment. M staging at relapse: M1 1p, M2 2p and M3 8p. Treatment at relapse: surgery/radiotherapy/chemotherapy 2p, radiotherapy/chemotherapy 9p. Total cycles performed: 81, median of 6 cycles (3‐18). Toxicity: diarrhea (GII 5p) and haematological toxicity (GI/II 3p, GIII 1p), one patient showed cholinergic symptoms during irinotecan infusion. Evaluable at 12 months (MRI): 10p. Complete response (CR) 4p, partial response (PR) 3p, stable disease (SD) 1p and refractory disease 2p. Objective response: 70%. Mean time to progression: 15 months. Patients currently alive: 5; 1p second relapse with cervical lymph node metastasis (M4) at 13 months of initial relapse; 1p undergoing radiotherapy; and 3p CR (1 after autoSCT), at 12, 20 and 51 months since relapse.

**Conclusions**: ITB treatment was useful, safe and well tolerated. A high objective response was achieved in patients with no other therapeutic option.

### PO-065. Outcome of Malignant Central Nervous System Tumours in Young Children from a Single Institution in Malaysia: 15‐Year Experience with Head Start I and II Protocols {#pbc27455-sec-10320}

[R. Rajagopal]{.ul} ^1^, D. Ganesan^2^, K.T. Wong^3^, A.Z. Bustam Mainudin^4^, T.Y. Yap^1^, L.A. Chong^1^, L.L. Chan^1^, W.A. Abdullah^1^, H. Ariffin^1^

*^1^University Malaya Medical Centre, Haematology‐Oncology Unit‐ Department of Paediatrics, Kuala Lumpur, Malaysia; ^2^University Malaya Medical Centre, Department of Surgery, Kuala Lumpur, Malaysia; ^3^University Malaya Medical Centre, Department of Pathology, Kuala Lumpur, Malaysia; ^4^University Malaya Medical Centre, Department of Radiation Oncology, Kuala Lumpur, Malaysia*

**Background/Objectives**: To determine the outcome of young children (≤ 3 years old) with malignant central nervous system (CNS) tumours treated at University Malaya Medical Centre, Malaysia from January 1998 to December 2012.

**Design/Methods**: Retrospective review of young children with malignant CNS tumours treated with definitive surgery, intensive induction followed by myeloablative chemotherapy and autologous hematopoietic stem cell rescue (ASCR) using Head Start I (1998‐2002) and II (2003‐2012) protocols.

**Results**: Twenty patients were identified with a median follow‐up of 1.9 years (range 0.1‐15.4). The mean age was 1.5 years (range 0.3‐3.0) with male: female ratio of 1:1. Thirteen patients were diagnosed with medulloblastoma, five with posterior fossa ependymoma, one each with left frontal lobe primitive neuroectodermal tumour and posterior fossa atypical teratoid/rhabdoid tumour respectively. Six patients had disseminated disease at presentation. Only twelve patients completed induction and myeloablative chemotherapy with ASCR. Five recurrences occurred with a median duration of 5 months after ASCR; two of them did not respond to subsequent salvage radiotherapy. Another four patients experienced disease progression with a median time of 3.6 months following diagnosis during the induction phase. All five recurrences after ASCR and three patients with progressive disease died with a median duration of 2.3 months from the progression. Four toxic deaths occurred during induction. The 3‐year event‐free survival and overall survival for the whole group was 35±10.7% and 40±11.0% respectively. There are seven long‐term medulloblastoma survivors without any radiation and one patient with ependymoma who is under palliation for progressive disease.

**Conclusions**: This strategy of definitive surgery, intensive induction followed by myeloablative chemotherapy and ASCR using Head Start I and II protocols in young children with malignant CNS tumours eliminated the need for radiation in seven long‐term survivors. Hence, intensive chemotherapy is feasible in middle‐income countries; the rate of toxic death is not different from that in developed countries.

### PO-066. Brain Tumors in Dubai: A Five‐Year Experience {#pbc27455-sec-10330}

[A. Rana]{.ul} ^1^, A. AlJassmi^1^, A. Madasu^2^, H. Humad^1^

*^1^Dubai Hospital, Pediatric Hematology & Oncology, Dubai, United Arab Emirates; ^2^Dubai Hospital, Department of Pediatric Hematology & Oncology, Dubai, United Arab Emirates*

**Background/Objectives**: Dubai hospital is one of three main centers treating childhood cancers in the United Arab Emirates. In the last five years, twenty seven children with Brain tumors presented to our institution. We present details of this rare group of tumors in our region.

**Design/Methods**: All children with a diagnosis of brain tumor seen at Dubai hospital were identified from the hospital electronic record system from the year 2012 to 2017.

**Results**: A total of twenty seven children with brain tumors were managed from end of 2012 to 2017 at the Dubai health authority. Their age at diagnosis ranged from six weeks to eleven years with a median age of five years. The male to female ratio was 1.4:1. Majority of the tumors were Pilocytic astrocytomas (40.7%) and majority of the malignant ones were medulloblastoma and brain stem tumors. We were able to get the genetics in four (15%) tumor specimens and found BRAF mutation positive in two of our pilocytic astrocytomas and H3K27M mutation positive in two of our pontine gliomas. One child was positive for NF‐1. Headache and vomiting was the presenting symptom in 13 (48%) children and 14 (60.8%) had significant long‐term morbidity with 4 (17%) deaths.

**Conclusions**: Majority (70%) of our children with brain tumors have survived, albeit with severe sequel (60.8%). H3K27M mutation and BRAF mutations are the only ones identified in our pontine gliomas and astrocytoma respectively. We need to push for genetic studies in all our tumor specimens to be able to offer targeted therapy and hence improve survival in future.

### PO-067. Mortality in Pediatric Neurooncology: The SickKids Experience from 2000‐2017 {#pbc27455-sec-10340}

[S. Renzi]{.ul} ^1^, O. Michaeli^1^, V. Ramaswamy^1^, A. Huang^1^, U. Tabori^1^, E. Bouffet^1^, U. Bartels^1^

*^1^The Hospital for Sick Children‐ Toronto‐ On‐ Canada., Division of Hematology/ Oncology, Toronto, Canada*

**Background/Objectives**: Primary benign and malignant central nervous system (CNS) tumors are the most frequent solid tumors in pediatric age and represent a significant cause of death in childhood. Mortality in this population has not been extensively studied. Objectives were to investigate mortality in a large cohort of children diagnosed at our institution.

**Design/Methods**: Using our internal database, we identified patients diagnosed with benign or malignant CNS tumor and treated at the Hospital for Sick Children between January 2000 and December 2017. Patients were analyzed according to different variables as tumor diagnosis, location, gender, age at diagnosis, age at death, time elapsed from diagnosis to death and cause of death. All statistics were descriptive.

**Results**: Of 1392 patients, 272 (19.5 %) succumbed to their disease. Mortality rate varies significantly according to tumor subtype, ranging from 2.2% in low grade glioma (LGG) to 80.4% in High grade glioma (HGG). While representing only 12% of total diagnoses, HGG accounted for 49.6 % of total deaths (n=135). Of them, 27.9% were diffuse intrinsic pontine gliomas. 14.7 % of patients died of medulloblastoma, 14.3% of other embryonal tumors and 8.4 % of ependymoma. Male/ female ratio was 1:1. Median age at death was 8.8 years (13 days‐24.4 years). Mean time elapsed from diagnosis to death was 2.05 years (3 days‐ 15 years). Only 16.5 % (n= 45) of patients who died had disseminated disease at diagnosis. Causes of death were: progression of primary disease (n=260, 95.6 %), treatment‐associated complications (sepsis n=1, perioperative death n=1), secondary malignancy (GBM n=4, Lymphoma n=2, MDS=1) and other (n=2).

**Conclusions**: Mortality remains a significant burden in children with brain tumors. In less than 5% of cases, cause of death was unrelated to disease progression. Research should continue to focus on improving treatment strategies for patients whose prognosis remains dismal (i.e High grade glioma).

### PO-068. Visual Function Decline Can Be Independent of Tumor Progression in Low Grade Childhood Optic Pathway Gliomas {#pbc27455-sec-10350}

[R. Riccardi]{.ul} ^1^, A. Ruggiero^1^, C. Colosimo^2^, A. Chiaretti^1^, D. Rizzo^1^, G. Placidi^3^, M. Piccardi^3^, L. Melotti^1^, B. Falsini^3^

*^1^Catholic University of Sacred Hearth, Department of Pediatric Oncology, Rome, Italy; ^2^Catholic University of Sacred Hearth, Department of Neuroradiology, Rome, Italy; ^3^Catholic University of Sacred Hearth, Department of Ophtalmology, Rome, Italy*

**Background/Objectives**: According to current clinical guidelines, in children with Optic Pathway Gliomas (OPGs), a deterioration of the compromised visual function regardless of tumor volume changes should be considered a criteria for local and/or systemic treatment. The aim of this study was to retrospectively evaluate if changes in visual function are associated with tumor progression in low grade childhood OPGs.

**Design/Methods**: Clinical visual function history and brain MRI of 22 children with OPGs, collected over a follow up of at least 5 years, were reviewed.

**Results**: At least two consecutive ophthalmological tests confirmed a significant decline in visual acuity of ≥ 2 lines, as well as a reduction of peripheral visual field (Goldmann V/4e) of ≥ 20 degrees in 6 patients (27%). In the same patients no significant changes (greater than 20%) in tumor volume were observed over the follow up.

**Conclusions**: The present results suggest that a clinically significant visual decline can be found in OPG patients with no detectable tumor progression, and challenge the current guidelines on therapeutic management of OPGs. Given the high percentage of visual impairment in absence of tumor progression and the discovery of new molecular pathways involved in NF‐1 associated OPGs, we suggest that if a decrease of visual function without tumor volume increase occurs, emerging targeted therapeutic treatments (i.e K‐RAS inhibitors, lovastatin, antiapoptotic treatment by Nerve Growth Factor) should be tested in a placebo controlled study avoiding more aggressive treatments including chemotherapy and radiotherapy.

Supported by Fondazione per l\'Oncologia Pediatrica.

### PO-069. Review of Relapsed Medulloblastoma: Experience at Single Institution {#pbc27455-sec-10360}

[M. Rivera]{.ul} ^1^, R. Navarro Martin del Campo^1^, A.L. Alvarado Orozco^1^, Ó.R. González Ramella^1^

*^1^Hospital Civil de Guadalajara Juan I. Menchaca, Pediatric Hematology/ Oncology, Guadalajara, Mexico*

**Background/Objectives**: Medulloblastoma (MB) is the most frequent solid tumor in pediatric age, with an incidence close to 25%. In Mexico, the incidence is 17 cases per million. Up to 40% of children have disseminated disease at diagnosis and up to 20 % experience tumor progression or recurrence, for which no curative therapies exist. Over 30% of patients presents relapse or no response to the treatment.

**Design/Methods**: A retrospective study was designed to identify all children treated with MB who relapsed or had progression during treatment from 2007 to 2017 in the Hospital Civil de Guadalajara Juan I. Menchaca. Pattern of relapse, treatment and survival after relapse were analyzed.

**Results**: Forty three patients received treatment, 5 relapses (11.6 %) were detected, one second neoplasm (4.3%) and two (8.6%) progressive diseases despite treatment. The relapse pattern were: one in the posterior fossa, three extended leptomeningeal relapses, and 2 relapses in frontal lobe. Median time of relapse was 11.4 months. Relapse treatment consisted of combinations of surgery (40 %), focal radiotherapy (RT 20 %), and chemotherapy (87%). After relapse or progression the survival was above 7 months. One patient was treated with palliative care and one still being under treatment. All patients died after relapse.

**Conclusions**: Relapsed MB has a fatal course in our series, it could reflect absence a targeted therapies because we have no molecular subgroups classification. New therapies are urgently needed.

### PO-070. Medulloblastoma in Children: Experience in Treatment and Follow up in a Developing Country Center {#pbc27455-sec-10370}

[M. Rivera]{.ul} ^1^, R. Navarro Martin del Campo^1^, A.L. Alvarado Orozco^1^, Ó.R. González Ramella^1^

*^1^Hospital Civil de Guadalajara Juan I. Menchaca, Pediatric Hematology/Oncology, Guadalajara, Mexico*

**Background/Objectives**: Medullobastoma is the most common malignant brain tumor in children with an incidence of 12‐20%. Highest incidence is at 5 years and is more common in males 2:1. Treatment for the standard risk group includes maximal surgical resection followed by craniospinal irradiation (CSI) and chemotherapy with vincristine (VCR), platinum (CDDP)‐, and nitrosourea‐containing regimens. This approach has resulted in 5‐year overall survival (OS) near 80 % at this group. Highest risk group and has a 10‐year OS of 42‐45%.

**Design/Methods**: This was a transversal, retrospective study which included all patients under the age of 18 years diagnosed with medulloblastoma from 2007 to 2017 in the Hospital Civil de Guadalajara Juan I. Menchaca. Data collected included date of diagnosis, age at diagnosis, sex, stage, pathology, treatment, recurrence, and current status

**Results**: In total, 51 cases were enrolled. Male‐Female ratio was 1.6:1. Median age at diagnosis was 6.6 years, twelve (23.5%) patients were infants. Risk classification was: in high risk 29 patients and 15 patients in standard risk, 6 patients were unclassified because they dead after surgery, 11 (21.5%) patients did not receive any oncological treatment because death, refusing treatment, lost or transfer. Metastasic pattern showed in 30 (71.4%) patients M0/M1 and 12 (28.6%) patients M2/3. ICE with or without Temozolamide were the most used treatment regimen in high risk patients, and CDDP/VCR/Cyclophosphamide in standard risk, and in infants methotrexate based chemotherapy. Overall survival was 57.5%, deaths in order of frequency were due to relapse, infection, progressive disease or abandoning

**Conclusions**: The most frequent cause of death was relapse. Patients younger than 3 years are the group that most abandoned. The mortality rate remains high and is related to high risk staging and the lack of resources for a molecular classification in order to give targeted therapies.

### PO-071. High Risk Factors of Medulloblastomas in Children Under Five Years {#pbc27455-sec-10380}

[E. Salnikova]{.ul} ^1^, S. Ozerov^1^, A. Ektova^2^, M. Ryzhova^3^, A. Korshunov^4^, A. Nechesnyuk^5^, A. Merishavyan^1^, S. Gorbatykh^6^, E. Erega^7^, A. Shapochnik^8^, S. Stambekov^9^, A. Karelin^10^, E. Kumirova^11^, A. Rumyantsev^12^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Neurooncology, Moscow, Russia; ^2^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Pathoanatomical, Moscow, Russia; ^3^N.N. Burdenko Neurosurgical Institute, Pathoanatomical, Moscow, Russia; ^4^German Cancer Research Center DKFZ, Clinical Cooperation Unit Neuropatology, Heidelberg, Germany; ^5^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Radiation Therapy, Moscow, Russia; ^6^Morozov Children\'s Clinical Hospital, Oncology, Moscow, Russia; ^7^Children\'s Regional Clinical Hospital, Hematology, Khabarovsk, Russia; ^8^Regional Oncology Center, Oncology, Orenburg, Russia; ^9^National center of oncology, Children\'s department, Bishkek, Kyrgyzstan\\r; ^10^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Rehabilitation Research Center for patients in remission "Russkoye pole", Moscow, Russia; ^11^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Head of Neurooncology Department, Moscow, Russia; ^12^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, General director, Moscow, Russia*

**Background/Objectives**: The definition of risk groups in patients under 5y with medulloblastomas is still necessary. To evaluate treatment results of 87 patients under 5y (median=41m) with primarily diagnosed medulloblastomas depending on the current risk factors.

**Design/Methods**: We retrospectively analyzed the data of 87 patients, who are observed in Rogachev\'s Center from June 2001 till September 2017. Molecular genetic testing was performed in all cases (DKFZ/Germany): Gr3/Gr4/SHH was diagnosed in 40/16/31 cases. MYC/MYCN amplification/17q gain/17q loss/i17/MGMT/PTCH1 mutation/P53 mutation=7/7/38/26/19/2/ 10/2 cases. HIT 2000/2008 treatment regimes used in 44 patients. Gr3: M0/M+/Mx=14/25/1, R0/R+/Rx=31/7/2, classic/anapl/desmo=25/13/2, without/with‐VPS=28/12, without/with‐ivMTX/no data=29/10/1, with/without‐RT=30/10, PD=18 cases, are alive 19 patients. Gr4: M0/M+/Mx=6/8/2, R0/R+/Rx=13/2/1, classic/anapl=15/1, without/with‐VPS=13/3, without‐ivMTX=16, withRT=16, PD=2 cases, are alive 11. SHH: M0/M+/Mx=18/10/3, R0/R+/Rx=21/5/5, classic/anapl/desmo=2/3/26, without/with‐VPS=25/6, without/with‐ivMTX=20/11, with/without‐RT=14/17, PD=12 cases, are alive 18. Risk groups: SR (SHH М0 no‐TP53 no‐NMYC amplification no‐LCA, Gr3 M0 no‐NMYC amplification, Gr4 M0)‐n=29; HR (SHH M+, Gr4 M+, SHH NMYC, i17)‐n=25; VHR (Gr3 M+, SHH/TP53)‐n=27.

**Results**: 5y‐OS in Gr3/Gr4/SHH=0.56/0.75/0.76 (р=0.1). 5y‐PFS in Gr3/Gr4/SHH=0.54/0.87/0.6 (р=0.07). PFS with/without MYC and MYCN amplification 0.0/0.68 (p=0.00007) and 0.57/0.62 (p=0.77); with/without 17q loss and 17q gain 0.43/0.7 (p=0.00585) and 0.6/0.63 (p=0.47); with/without P53 and PTCH1 mutations 0.5/0.62 (p=0.66) and 0.8/0.59 (p=0.25); with/without i17=0.52/0.64 (p=0.18); with/without MGMT=1.0/0.61 (p=0.26). Gr3‐PFS: 12‐36m/36‐60m=0.42/0.58 (p=0.35); R+/R0=0.44/0.5 (p=0.54); М0/М+=0.71/0.46 (р=0.21); classic/anapl/desmo=0.59/0.44/0.5 (р=0.29); without/with‐VPS=0.6/0.39 (p=0.16); without/with‐ivMTX=0.57/0.5 (p=0.94); without/with‐RT=0.24/0.63 (p=0.04884). Gr4‐PFS: 12‐36m/36‐60m=1.0/0.86 (p=0.69); R+/R0=0.0/1.0 (p=0.00019); М0/М+=1.0/0.87 (р=0.78); classic/anapl=0.86/1.0 (р=0.69); without/with‐VPS=1.0/0.34 (p=0.00243). SHH‐PFS: \<12m/12‐36m/36‐60m=0.0/0.57/0.75 (p=0.62); R+/R0=0.8/0.62 (p=0.55); М0/М+=0.54/0.8 (р=0.14); classic/anapl/desmo=0.5/0.34/0.65 (р=0.76); without/with‐VPS=0.67/0.25 (p=0.19); without/with‐ivMTX=0.57/0.64 (p=0.93); without/with‐RT=0.45/0.78 (p=0.03944). OS SR/HR/VHR=0.8/0.71/0.45 (p=0.04286), PFS SR/HR/VHR=0.74/0.72/0.46 (p=0.08).

**Conclusions**: Factors of high risk were: MYC amplification/17q loss; absence RT in Gr3 and SHH; R+ and VPS in Gr4. Statistically significantly worse OS value was obtained in patients with VHR group.

### PO-072. Incidence and Risk Factors of Posterior Fossa Syndrome in Children with Posterior Fossa Tumors {#pbc27455-sec-10390}

[M. Sato]{.ul} ^1^, D. Eble^2^, B. Zimmerman^3^, A. Menezes^4^, J. Greenlee^4^, S. Wilson^4^, B. Dlouhy^5^, S. O\'Dorisio^1^

*^1^University of Iowa Stead Family Children\'s Hospital, Pediatric Hematology Oncology, Iowa CIty, USA; ^2^University of Iowa, Carvar College of Medicine, Iowa City, USA; ^3^University of Iowa, Biostatistics, Iowa city, USA; ^4^University of Iowa, Neurosurgery, Iowa City, USA; ^5^University of Iowa, Neurosurgery, Neurosurgery, USA*

**Background/Objectives**: The exact cause of posterior fossa syndrome (PFS) is largely unknown, and its unpredictable outcome makes the management of PFS very challenging. This study objective is to investigate the prognostic factor of PFS in children with posterior fossa tumors in Iowa.

**Design/Methods**: The retrospective chart review from 1976 to March 2017 was conducted and medical records of 87 children with posterior fossa tumors were analyzed to look for outcomes, clinical variables such as tumor type, presentation and surgical methods. Pre and post surgical MRI imaging of 64 patients were evaluated for PFS prediction.

**Results**: Of the 87 charts reviewed 48 (55%) had medulloblastoma, 26 (30%) had low grade glioma, 10 (11%) had ependymoma, and 3 (3%) had ATRT. Fifteen patients (17%) developed PFS, 10 (67%) had medulloblastoma, 2 (13%) had low grade glioma, 2 (13%) had ATRT, and 1 (7%) had ependymoma. Ten out of 15 patients (67%) with PFS had severe PFS symptoms. Among observed variables, the intraoperative splitting vermis was the only prognostic factors of PFS (p=0.009). Pre and post operative MRI of 64 patients were available and the damage of bilateral dentate nuclei and superior cerebellar peduncles were detected significantly in PFS (P=0.008 and p=0.012, respectively)

**Conclusions**: This study worked to elucidate the incidence, clinical outcome and prognostic risk factors of PFS in University of Iowa patients with posterior fossa tumors. Symptoms of PFS vary thus retrospective chart review may underestimate the actual incidence. Postoperative MRI findings could be useful to suspect PFS and may lead to deliver early interventions.

### PO-073. Phase II Study with Bevacizumab Irinotecan Association in Relapsed/Progressed Brain Tumors: A Single Institution Experience {#pbc27455-sec-10400}

[A. Schiavetti]{.ul} ^1^, M.G. Mollace^1^, B. Fabrizio^1^, M. Paiano^1^, C. Dominici^1^, G. Varrasso^1^

*^1^University "Sapienza", Pediatrics, Rome, Italy*

**Background/Objectives**: To estimate the rates of major responses (MR) (complete response \[CR\] + partial response \[PR\]), treatment‐related toxicities, progression‐free survival (PFS) and overall survival (OS) in children with relapsed/refractory brain tumors treated with bevacizumab containing regimen in a single center phase II study.

**Design/Methods: P**atients that had received I and II line treatment with or without megatherapy were included. The schedule was as follows: bevacizumab (BVZ) 10 mg/kg i.v. with irinotecan (IRI) 150 mg/m^2^ i.v. every 2 weeks ± temozolamide (TMZ) 200 mg/m^2^ p.o. daily for 5 days every 28 days. TMZ was omitted in heavily pretreated cases.

**Results**: Between 2013 and 2017, 12 patients (3F/ 9M), median age at diagnosis 140 months (range 27‐312), with medulloblastoma (n 7), low grade glioma (n 2), high grade glioma (n 3), were enrolled. All patients received BVZ/IRI (median courses 20, range 4‐67); 3 of them also received maintenance therapy with single‐agent BVZ (median courses 23, range 8‐39). TMZ (median courses 8, range 2‐26) was added in 8 patients, then it was stopped in 3 of these for myelotoxicity or lack of compliance. After 3 months, 2 CR, 2 PR, 7 stable disease, 1 progressive disease were observed at radiological evaluation. The rate of MR was 33.3%. Nine cases (80%) experienced an improvement in neurological symptoms. Median time to progression was 11 months (95 % confidence interval, 4--18 months). The 6‐month and 2‐year PFS rates were 75% and 42%, respectively. Currently, OS is 33.3%; importantly, 2 cases (1 with medulloblastoma and 1 with high grade glioma) are progression‐free and off‐therapy after 20 and 55 months, respectively. Treatment was well tolerated with a good quality of life.

**Conclusions**: Bevacizumab‐irinotecan association ± temozolamide showed encouraging results in relapsed brain tumors, prospective clinical trials are needed to evaluate its efficacy in extended setting.

### PO-074. Biomolecular Analysis of Pediatric Medulloblastoma and Prognostic Relevance of FSTL5 Expression: A Single‐Center Study {#pbc27455-sec-10410}

S. Minasi^1^, M. Paiano^2^, A. Clerico^2^, [A. Schiavetti]{.ul} ^2^, F.R. Buttarelli^1^

*^1^University "Sapienza", Radiological‐ Oncological and Anatomo‐Pathological Sciences, Rome, Italy; ^2^University "Sapienza", Pediatrics, Rome, Italy*

**Background/Objectives**: We retrospectively evaluated the prognostic relevance of molecular subgroups (WNT, SHH, group 3 and 4) in patients with medulloblastoma, treated at a single institution. Additionally, the prognostic relevance of the follistatin‐like 5 (FSTL5) expression was assessed in the same cohort.

**Design/Methods**: From 1998 to 2008, 29 patients (20M/9F), median age 11.2 years, were treated with post‐surgical chemotherapy (2 cycles of carboplatin 1000 mg/m2 with total maximum dose 1000 mg/m2 per patient per course and etoposide 300 mg/m2), followed by radiotherapy (54Gy+23.4Gy Standard‐Risk, 54Gy+36Gy High‐Risk) and post‐radiotherapy chemotherapy (4 cycles of carboplatin 600 mg/m2 and etoposide 200 mg/m2). Formalin‐fixed paraffin embedded (FFPE) samples were analyzed via IHC, FISH, RT‐PCR and Sanger Sequencing, according to WHO classification system; the results were correlated to the outcome by Kaplan‐Meier survival analysis.

**Results**: Twenty‐six of 29 patients, 11 at Standard‐Risk (SR) and 15 at High‐Risk (HG) according to the Chang staging system, completed the treatment. Progression free survival (PFS) at 3‐5‐7 years after diagnosis was 90%‐80%‐75% for SR and 40%‐25%‐19% for HR; overall survival (OS) was 100%‐90%‐85.7% for SR and 62.5%‐62.5%‐56% for HR. According to the molecular subgroups, OS was 100% for WNT, 66% for SHH, 60% for Not Classifiable (NC), \<30% for groups 3 and 4 (WNT vs groups 3 and 4 p\<0.05). The FSTL5 down‐expression was associated with better outcome of patients (OS\>80%) compared to the over‐expression with OS\<30% (p \<0.05). FSTL5 expression was higher in the groups 3 and 4 compared to that in SHH/WNT/NC groups (p =0.02).

**Conclusions**: Our survival rates are comparable to those of contemporary studies, using less nephro‐ototoxic drugs. We confirm that molecular subgroups are relevant for risk stratification. FSTL5 is an independent prognostic marker for medulloblastoma.

### PO-075. Reported Outcome of Recurrent Medulloblastoma Treated with Temozolomide and Irinotecan {#pbc27455-sec-10420}

[N. Sirachainan]{.ul} ^1^, A. Hansasuta^2^, S. Samart Pakakasama^1^, U. Usanarat Auarathapan^1^, M. Montana Dhanachai^3^, S. Hongeng^1^

*^1^Faculty of Medicine‐ Ramathibodi Hospital, Pediatrics, Bangkok, Thailand; ^2^Faculty of Medicine‐ Ramathibodi Hospital, Surgery, Bangkok, Thailand; ^3^Faculty of Medicine‐ Ramathibodi Hospital, Radiology, Bangkok, Thailand*

**Background/Objectives**: Recurrent medulloblastoma accounts for 30% to 40% of patients with medulloblastoma especially in high risk group. Treatment of recurrent medulloblastoma includes surgery, chemotherapy with or without hematopoietic stem cell transplantation (HSCT) and advanced targeted therapy. However, the outcome remains poor with response rate around 10% to 20%. The aim of this study was to demonstrate the outcome of patients with recurrent medulloblastoma treated with temozolomide and irinotecan.

**Design/Methods**: The study enrolled patients who diagnosed with recurrent medulloblastoma which was documented by magnetic resonance imaging (MRI) study. All patients previously received the National high risk medulloblastoma protocol at diagnosis. After documented tumor progression, neurosurgery had been consulted for the possibility of re‐surgery. Then chemotherapy including temozolomide at a dose of 150 mg/m^2^/day on days 1‐5 and irinotecan at a dose of 125 mg/m^2^ /day on days 1, 8 and 15 was given at a 28‐day cycle until the tumor progression.

**Results**: Seven patients, median age 7.6 years old were enrolled. Five of them were male. All patients had tumor recurrence at their primary sites and leptomenigeal involvement. The 2‐year overall survival (OS) was 57.1±19.7% and 4‐year OS was 28.6±17.1%. The median OS was 27.9±5.9 months. Fever with neutropenia was identified in one patient. No treatment related death was observed.

**Conclusions**: The outcome of patients with recurrent medulloblastoma treated with temozolomide and irinotecan was comparable to the previous high dose chemotherapy with HSCT. The side effect was minimal.

Acknowledgement: Ramathibodi Comprehensive Cancer Center, Faculty of Medicine, Ramathibodi Hospital

### PO-076. Survival and Risk Factors in Children with Medulloblastoma {#pbc27455-sec-10430}

[G. Sobol‐Milejska]{.ul} ^1^, P. Sikorska‐Juśko^1^, A. Mizia‐Malarz^1^

*^1^Medical University of Silesia, Department of Pediatric Oncology‐ Haematology and Chemotherapy, Katowice, Poland*

**Background/Objectives**: Medulloblastoma (MB) is the most common malignant brain tumor in children, and although the treatment results have significantly improved, there is a patients group with unsuccessful treatment outcome.

The aim of the study was to assess the survival with determining risk factors in children with medulloblastoma treated in our center in the period 2004‐2014.

**Design/Methods**: The clinical picture of MB was analyzed taking into account location of the tumor, the extent of resection, histopathological form, time from surgery to the beginning of therapy, response to initial treatment, response to the end of treatment.

**Results**: From 2004 to 2014 in our institution 44 children were diagnosed with medulloblastoma, aged 14 months ‐ 18 years old, middle age 8.1 years. Dominat tumor location‐ IV chamber 26pts (59%). Resection: total 11 (25%), almost total (GTR) 10 (22.7%), partial 23 (52.3%). Histopatology:classic type 25 (56.8%), desmoplastic in 10 (22.7%) and anaplastic in 9 (22.5%) patients. Control imaging (MR) after the initial treatment in 19 patients (43.2%) a complete response was obtained, in 22 (50%) partial, and in 3 cases (6.8%) progression of changes was observed. After the end of treatment CR was diagnosed in 30 (68.2%) children, in 9 cases (20.4%) further progression of the disease was observed, while 5 children (11.4%) died. In patients with relapse, recurrence after CR was diagnosed in 6 (20%) children, including 4 patients (66.7%) with local recurrence and 2 (33.3%) children with other than primary tumor location. During the 5‐year follow‐up period in the examined group OS (overall survival) was 73%, while EFS (event free survival) was obtained in 66% of patients.

**Conclusions**: The initially disseminated form and the anaplastic type of MB are the more significant risk factors for treatment failure. For a full assessment of the factors for therapy failure, the assessment of the molecular group MB is recommended.

### PO-077. Rare Tumors of the Central Nervous System in Children {#pbc27455-sec-10440}

[T. Stepanova]{.ul} ^1^, G. Trubnikova^2^, I. Balalaeva^1^, A. Pozdniakov^1^

*^1^N.N.Burdenko State Medical University, Pediatric oncology, Voronezh, Russia; ^2^Regional Children\'s Hospital, Pediatric oncology, Voronezh, Russia*

**Background/Objectives**: Atypical teratoid‐rhabdoid CNS tumor is a rare highly aggressive neoplasm occurs mainly in young children with bad prognosis. The average overall survival of patients after chemotherapy was 7.3 months, and after chemo and radiotherapy ‐17.4 months. The morphological picture is a combination of classic rhabdoid, primitive neuroectodermal and mesenchymal components with co‐expression of Vimentin and Ema, and a chromosomal mutation of 22q11.

**Design/Methods**: Three children with an atypical teratoid‐rhabdomous tumor were observed.

**Results**: Case 1. Boy, age 4. Diagnosis: Atypical teratoid‐rhabdomoid tumor of the third ventricle. M3. Metastasis in the spinal cord. Protocol treatment received within 1 year 5 months. In 1 month the metastasis at level L1. Operative intervention was made, tumour in the spinal cord removed, verified by ATRO. A month later no metastases were found. Progression of the tumor process led to a lethal outcome.

Case 2. Boy, age ‐ 1 year 10 months. Diagnosis: Atypical teratoid ‐ rhabdomous tumor of the pineal region. M0 stage. Complication: Hypertensive‐hydrocephalic syndrome. After therapy (protocol ATRO -- 2006) the child has a stabilization of the disease.

Case 3. Boy, age ‐ 6 months. Only biopsy was made, tumor not removed, diagnosis: ATRO of the bridge‐cerebellar angle with metastasis in the brain stem, spinal cord. ATRO protocol. The child died at the age of 13 months.

**Conclusions**: Atypical mixed teratoid‐rhabdomoid tumors are very rare. All three patients are males. It is possible to assume a chromosome linked to the X chromosome. In all cases, patients entered the department in a serious condition. Stabilization of the disease occurs in a child with a radically removed tumor. Two other patients who only had a tumor biopsy or subtotal removal died from continued tumor growth. The median survival was 7 months. Further research is needed to improve the prognosis

### PO-078. Optic Pathway Glioma: A Single Center\'s Experience {#pbc27455-sec-10450}

H.G. Tanyıldız^1^, [N. Tacyildiz]{.ul} ^1^, H. Dincaslan^1^, E. Unal^1^, S. Teber^2^, O. Bektas^2^, K. Gunduz^3^, G. Yavuz^1^

*^1^Ankara University Medical Faculty, Pediatric Oncology, Ankara, Turkey; ^2^Ankara University Medical Faculty, Pediatric Neurulogy, Ankara, Turkey; ^3^Ankara University Medical Faculty, Ophthalmology, Ankara, Turkey*

**Background/Objectives**: Optic pathway gliomas (OPGs) are the most common CNS tumors seen in neurofibromatosis type 1 (NF1) with a ratio of 15%--20% and represent 3%‐6% of all childhood brain tumors. In this study, our aim was to describe the characteristics, and management of patients with OPG.

**Design/Methods**: A retrospective analysis of clinical and imaging data and treatment history from children with OPG and NF1 seen at a single center between 2008 and 2017 was performed.

**Results**: During the 10‐year period, 55 individuals with NF1 were screene dusing brain/orbital MRI. OPGs were identified in %20 of patients and the a median age at detection was 6,5 years. Sixteen children (9 girls /7 boys) were diagnosed with OPG. Among them, 11 (68 %) had NF1. The medianage of patients without NF1 at detectionwas 8. The main reason for seeking medical advice was decreased vision in 6, decreased vision and proptosis in 1, hemiparesis (Moyamoya disease) in 1, headache due to hydrocephalus in 2, confusion and papillary stasis in 1, incidentally in a brain computed tomography scan after head injury in 1, and café au lait spots in 4.Seven patients showed deterioration of visual acuity and 1 patient in imaging findings. One of them underwent tumor resection, whereas 1 received radiation treatment and 6 (6/8) received chemotherapy. Five patients with non‐NF1 glioma were treated with an average of 4 cycles of vincristine, carboplatin plus 270 mg / m2 oral imatinib therapy. In one patient, systemic chemotherapy and imatinib were used in optic glioma with NF1

**Conclusions**: All children without NF1 required therapeutic interventions, whereas only 3 patients with NF1 received treatment. OPGs in childrenwith NF1 frequently remain indolent. This differs from OPGs in the general population, which are more aggressive. However, when symptomatic, OPGs can lead to vision loss in a subset of children with NF1.

### PO-079. microRNA--mRNA Expression Profiles can Differentiate Medulloblastoma Subgroup 3 and 4 {#pbc27455-sec-10460}

S. Gershanov^1^, [H. Toledano]{.ul} ^2,3^, S. Michowiz^4^, O. Barinfeld^3,5^, A. Pinhasov^1^, N. Goldenberg‐Cohen^5,6,7^, M. Salmon‐Divon^1^

*^1^Ariel University, Molecular Biology, Ariel, Israel; ^2^Schneider Children\'s Medical Center of Israel, Pediatric Oncology, Petach Tikva, Israel; ^3^Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel; ^4^Hadassah University Hospital, Neurosurgery, Jerusalem, Israel; ^5^Felsenstein Medical Research Center‐ Beilinson Hospital, The Krieger Eye Research Laboratory, Petah Tikva, Israel; ^6^Bnai Zion Medical Center, Ophthalmology, Haifa, Israel; ^7^Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel*

**Background/Objectives**: Medulloblastoma (MB), the most common malignant brain tumor in children, is divided into four subgroups: wingless‐type (WNT), sonic hedgehog (SHH), Group 3, and Group 4. Each subgroup has a distinct demographic and genetic profile and outcome. Subgroup based treatment protocols are currently evolving with escalation of therapy for high risk group 3 patients and de‐escalation for some low risk WNT and group 4 patients. While WNT and SHH subgroups have well‐defined biomarkers, distinguishing Group 3 from Group 4 is not so straightforward. MicroRNAs (miRNAs), which regulate posttranscriptional gene expression, are involved in MB tumorigenesis. However, the miRNA--messenger RNA (mRNA) regulatory network in MB is far from being fully understood. Our aims were to investigate miRNA expression regulation in MB subgroups, to assess miRNA target relationships, and to identify miRNAs that can distinguish Group 3 from Group 4.

**Design/Methods**: With these aims, integrated transcriptome mRNA and miRNA expression analysis was performed on primary tumor samples collected from 18 children with MB, using miRNA sequencing (miRNA‐seq), RNA sequencing (RNA‐seq), and quantitative PCR.

**Results**: Of all the expressed miRNAs, 19 appeared to be significantly differentially expressed (DE) between Group 4 and non‐Group 4 subgroups (false discovery rate \[FDR\] \<0.05), including 10 miRNAs, which, for the first time, are reported to be in conjunction with MB. RNA‐seq analysis identified 165 genes that were DE between Group 4 and the other subgroups (FDR \<0.05), among which seven are predicted targets of five DE miRNAs and exhibit inverse expression pattern.

**Conclusions**: This study identified miRNA molecules that may be involved in Group 4 etiology, in general, and can distinguish between Group 3 and Group 4, in particular. In addition, understanding the involvement of miRNAs and their targets in MB may improve diagnosis and advance the development of targeted treatment for MB.

### PO-080. Efficay and Safety of Everolimus Maintenance Therapy for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis: A Single Center, Prospective Intervention "Eminents Study" {#pbc27455-sec-10470}

[J. Trelinska]{.ul} ^1^, I. Dachowska^1^, W. Fendler^1,2^, K. Bobeff^1^, D. Baranska^3^, K. Kotulska^4^, S. Jozwiak^5^, W. Mlynarski^1^

*^1^Medical University of Lodz, Department of Pediatrics‐ Oncology‐ Hematology and Diabetology, Lodz, Poland; ^2^Medical University of Lodz, Department of Biostatistics and Translational Medicine, Lodz, Poland; ^3^Medical University of Lodz, Department of Pediatric Radiology‐ Central Research Hospital, Lodz, Poland; ^4^The Children\'s Memorial Health Institute, Department of Neurology & Epileptology and Pediatric Rehabilitation, Warsaw, Poland; ^5^Medical University of Warsaw, Department of Child Neurology, Warsaw, Poland*

**Background/Objectives**: The aim of the study was to evaluate efficacy and safety of mTOR inhibitor, everolimus (Votubia, Novartis) therapy in standard and reduced dose as a registered clinical trial (EMINENTS, DRKS 00005584), in patients with tuberous sclerosis (TSC) and subependymal giant cell astrocytoma (SEGA) treated between December 2011 and March 2018.

**Design/Methods**: Thirteen patients with TSC‐related SEGA, aged 1.5 -- 18.0 met the inclusion criteria and were treated with everolimus in a daily dose to attain trough concentration of 5 -- 15 ng/ml (standard treatment) for at least 12 months and then in maintenance dose -- EMINENTS study (three times a week with a daily dose as in standard treatment). Tumor volumes were evaluated using magnetic resonance imaging at baseline and after 3, 6, 12 months of standard dose, and then after 3, 6, 12, 24, 48 months of maintenance dose. Adverse events (AEs) of therapy were assessed in the same time‐points.

**Results**: Significant reduction in SEGA volumes were noted after 3, 6, 12 months of standard dose treatment (median tumor volume 1.14 cm3, p=0.0005; 0.86 cm3, p=0.0002; 0.72 cm3, p=0.0001 versus 1.64 cm3 at baseline). Treatment with maintenance dose resulted in slight but not significant increase in SEGA volumes. SEGA volumes measured in maintenance therapy time‐points were significantly lower when compared to baseline volume (median volumes after 3, 6, 12, 24, 48 months of maintenance dose were respectively: 0.87 cm3, p=0.0002; 0.99 cm3, p=0.0003; 0.96 cm3, p=0.0008; 1.02 cm3, p=0.0008; 0.87 cm3, p=0.0008 versus 1.64 cm3 at baseline). No AEs grade 3 or 4 were noted during maintenance therapy.

**Conclusions**: This study confirms efficacy of mTOR inhibitor (everolimus) in treatment of SEGA in patients with TSC. Maintenance dose after 12 months of standard treatment does not influence efficacy, but significantly reduces rates of adverse events.

Funded by the National Science Center grant number 2015/19/B/NZ5/02229.

### PO-081. How Can We Perform the Centralization of Treatment for Pediatric Brain Tumors in Japan? Results from National Questionnaire Findings {#pbc27455-sec-10480}

[Y. Watanabe]{.ul} ^1^, M. Hanihara^2^, R. Nishikawa^3^, T. Kumabe^4^

*^1^Tohoku University Graduate School of Medicine, Pediatrics, Miyagi, Japan; ^2^Yamanashi University School of Medicine, Neurosurgery, Yamanashi, Japan; ^3^Saitama Medical University International Medical Center, Neuro‐Oncology/Neurosurgery, Saitama, Japan; ^4^Kitasato University School of Medicine, Neurosurgery, Kanagawa, Japan*

**Background/Objectives**: The balance between the "centralization" and "standardization" of pediatric cancer treatment has been emphasized since the announcement of core pediatric cancer centers in 2013, but organization of the system has been difficult. We conducted a study to clarify the current state of treatment for pediatric brain tumors.

**Design/Methods**: To investigate the current state for pediatric brain tumors at each hospital, as well as at the national level, a questionnaire survey was conducted at core facilities for neurosurgery across Japan and at the departments of neurosurgery and pediatrics of the member facilities of the Japan Children\'s Cancer Group.

**Results**: Hospitals proudly reported the progress made, such as interdisciplinary cooperation between neurosurgeons and pediatric oncologists as well as among other healthcare professionals, improvements in medical care levels, and provision of high‐quality care. However, this was not attributable to the establishment of core pediatric cancer centers. Most hospitals intend to continue treating new patients. In contrast, approximately one‐fourth of physicians stated that medical care provided at the national level was not the best possible care. The survey data also revealed the inability to provide emergency craniotomy or magnetic resonance imaging as needed and a lack of adequate diagnostic pathology. Because evaluation of the skills of neurosurgeons is difficult without addressing this point, it will not be possible to centralize medical care to a small number of facilities. Furthermore, due to the possible need for emergency surgery, hospitals in metropolitan and rural areas cannot use the same system. An inadequate educational system and low public awareness underscore the need to develop more proactive approaches.

**Conclusions**: The current situation is not favorable for gathering and treating pediatric patients with brain tumors at core pediatric cancer centers. Our findings show that many issues remain to be addressed, such as determining the optimal method to change the treatment system in each lesion.

### PO-082. Trends in Pediatric Central Nervous System Tumor Incidence by Subtype Among Children in the United States, 1998‐2013 {#pbc27455-sec-10490}

[D. Withrow]{.ul} ^1^, A. Berrington de Gonzalez^1^, M.S. Linet^1^, C.J.K. Lam^2^, K.E. Warren^3^, M.S. Shiels^4^

*^1^US National Cancer Institute, Radiation Epidemiology Branch, Rockville, USA; ^2^US National Cancer Institute, Surveillance Research Program, Rockville, USA; ^3^US National Cancer Institute, Pediatric Oncology Branch, Bethesda, USA; ^4^US National Cancer Institute, Immunoepidemiology Branch, Rockville, USA*

**Background/Objectives**: Though rare, brain and other central nervous system (CNS) cancers are now the leading cause of US pediatric cancer mortality. We used 29 high‐quality US cancer registries to estimate recent national trends in rates of pediatric CNS tumors.

**Design/Methods**: Malignant primary CNS cancers and pilocytic astrocytomas (borderline or benign, but routinely and historically registered) were included. Age‐standardized incidence rates and annual percent changes (APCs) in incidence rates during 1998‐2013 were calculated for ages 0‐19 years. Gliomas were further stratified by grade, histology and location. To estimate the absolute change in number of cases diagnosed US‐wide during 2013 due to changes in incidence over time, we calculated the difference between the number of cases estimated based on 2013 and 1998 rates applied to age‐specific 2013 US census population counts.

**Results**: Rates of all malignant CNS cancer combined (n=18,612) did not change between 1998 and 2013 (APC:0.16, 95% confidence interval \[CI\]: ‐0.21,0.53). There were statistically significant changes in several sub‐types, however: glioma incidence (n=10,664) increased by 0.77%/year (95%CI:0.29,1.26), embryonal cancers (n=5,423) decreased by 0.88%/year (95%CI: ‐1.33, ‐0.43) and pilocytic astrocytoma (n=6,858) rates increased by 0.89%/year (95%CI:0.21,1.58). We estimated there were 1,171 malignant tumors and 450 pilocytic astrocytomas diagnosed in US children in 2013, including an additional 120 gliomas, 94 additional pilocytic astrocytomas, and 72 fewer embryonal CNS tumors than would have been expected had 1998 rates remained stable.

**Conclusions**: The relatively slow, gradual changes in incidence that we measured for major types of pediatric CNS cancers are likely due to a combination of changes in classification at both the registry and clinical levels and true CNS cancer risk over time.

### PO-083. High‐Dose Chemotherapy (HDC) with Autologous Haematopoietic Stem Cell Rescue for Recurrent Central Nervous System Germ Cell Tumours (CNS‐GCTS) {#pbc27455-sec-10500}

[M. Yamaoka]{.ul} ^1^, S. Yamamoto^2^, Y. Hashii^3^, J. Hara^4^, S. Adachi^5^, K. Sakashita^6^, M. Inoue^7^, T. Yanagisawa^8^, Y. Atsuta^9^, K. Matsumoto^10^

*^1^Jikei University School of Medicine, Pediatrics, Tokyo, Japan; ^2^Showa University Fujigaoka Hospital, Pediatrics, Kanagawa, Japan; ^3^Osaka University Graduate School of Medicine, Pediatrics, Osaka, Japan; ^4^Osaka City General Hospital, Pediatric Hematology/Oncology, Osaka, Japan; ^5^Kyoto University Hospital, Pediatrics, Kyoto, Japan; ^6^Nagano Children\'s Hospital, Hematology/Oncology, Nagano, Japan; ^7^Osaka Women\'s and Children\'s Hospital, Hematology/Oncology, Osaka, Japan; ^8^Jikei University School of Medicine, Pediatric Neuro‐oncology/Neurosurgery, Tokyo, Japan; ^9^Japanese Data Center of Hematopoietic Cell Transplantation, Committee for Nationwide Survey Data Management, Nagoya, Japan; ^10^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan*

**Background/Objectives**: Central nervous system germ cell tumours (CNS‐GCTs) are highly chemosensitve and their multimodal management still remains controversial in search for higher survival rates and minor morbidity. The evidence of dose‐response relationship in systemic GCTs has facilitated the employment of dose escalation strategy in the treatment for recurrent CNS‐GCTs. This paper is to make clear the effectiveness of high‐dose chemotherapy (HDC) for recurrent CNS‐GCTs in Japan.

**Design/Methods**: Retrospective analysis of patients in the nationwide registry data of the Japan Society for Haematopoietic Cell Transplantation.

**Results**: Ninety‐nine patients (74 males and 25 females) with recurrent CNS‐GCTs treated with HDC between 1984 and 2015 were eligible for this analysis. Median age at HDC was 14 years (range 5‐42 years) and median time of follow‐up from HDC was 75 months (range 4‐255 months). 5‐year Relapse‐free survival (RFS) were 72.0 and 69.9% in germinoma (N=33) and non‐germinomatous germ cell tumour (NGGCT) (N=44) (P=0.63); 5‐year overall survival (OS) were 81.2% and 75.3%, respectively (P=0.26). 5‐year RFS were 78.5% in patients who achieved complete remission (CR) (N=63) before HDC and 53.8% in those who did not achieve CR (non‐CR) (N=26) (P=0.03); 5‐year OS were 87.1% in CR and 62.3% in non‐CR, respectively (P=0.006). Especially in NGGCT, 5‐year RFS were 83.6% in patients with CR (N=25) before HDC and 46.2% in those with non‐CR (N=13) (P=0.003); 5‐year OS were 90.9% in CR and 52.7% in non‐CR, respectively (P=0.009). There are no toxic death associated with HDC. In multivariate analysis, only pre HDC status (CR or non‐CR, hazard ratio 3.25, 95% CI 1.14‐9.30, P=0.028) was favorable prognostic factor.

**Conclusions**: In this large cohort, HDC with stem cell rescue for recurrent CNS‐GCTs was shown to be tolerable and effective to long‐term survival, even those with NGGCTs in CR before HDC. Prospective studied are needed to confirm the optimal HDC regimen in these patients.

### PO-084. Ototoxicity Following Cisplatin and Radiation Therapy in Children with Posterior Fossa Tumors {#pbc27455-sec-10510}

C. Hess^1^, B. Bajaj^1^, M. Lawell^1^, M. Giblin^1^, E. Weyman^1^, S. Gallotto^1^, B. Patteson^1^, D. Ebb^1^, R. Jones^1^, S. MacDonald^1^, N. Tarbell^1^, [T. Yock]{.ul} ^1^

*^1^Massachusetts General Hospital, Radiation Oncology, Boston, USA*

**Background/Objectives**: Hearing loss (HL) is associated with cochlear exposure to both radiotherapy (RT) and cisplatin chemotherapy.

**Design/Methods**: Children treated at MGH between 2002‐2016 with medulloblastoma or posterior fossa (PF) ependymoma and ≥1 year of audiogram follow‐up comprised the study population. HL was graded using the SIOP‐Boston ototoxicity scale (0‐4). We investigated the association of cochlear RT and cisplatin doses with grade 3 or 4 (high‐grade) HL (HGHL) at last audiogram. Cochleae/ears of the same patient were analyzed independently.

**Results**: 139 children with ependymoma (N=25, 18.0%) and medulloblastoma (N=114, 82.0%) were included, representing 44 and 217 ears, respectively. Median audiogram follow‐up was 5.4 years. 16 ears with HGHL prior to RT were excluded from the analysis (6 received pre‐RT chemotherapy). Cumulatively, 20.7% (54/261 ears) developed HGHL, with a higher proportion among children treated for medulloblastoma (23.0%, 50/217 ears) versus ependymoma (9.1%, 4/44 ears, p=0.04). Medulloblastoma patient‐ears had both higher median cochlear doses (30.1 Gy versus 20.0 Gy, p\<0.0001) and higher incidence of cisplatin exposure than ependymoma patient‐ears (98.1% versus 8.0%, p\<0.0001). Ears with HGHL were more likely to be 1) medulloblastoma (OR=2.99, 95%CI: 1.14‐10.3), 2) have higher RT dose (30.6 Gy versus 27.1 Gy, p=0.03), and 3) have received cisplatin (OR=4.4, 95%CI: 1.5 -- 18.7). In a multivariable model including age, diagnosis, radiation dose, and cisplatin exposure, no variables significantly increased the odds of HGHL. Stratifying by diagnosis revealed similar non‐significance with the exception that the rare addition of cisplatin increased the rate of HGHL among ears of children with ependymomas (2/3 \[66.7%\] vs 2/41 \[4.9%\] p=0.02).

**Conclusions**: HGHL occurs more frequently in children treated for medulloblastoma compared to PF ependymoma (23% versus 9%) likely due to the higher rates of exposure to both ototoxic radiation therapy and cisplatin chemotherapy. Cisplatin use may increase HGHL among children with PF ependymoma.

### PO-085. Multiple Intracranial Malignant Meningioma with Hematologic Changes in a 2‐Year‐Old Girl: A Case Report and Literature Review {#pbc27455-sec-10520}

[H. Zeng]{.ul} ^1^, W. Xiaoyu^1^

*^1^Shenzhen Children\'s Hospital, Radiology Department, Shenzhen, China*

**Background/Objectives**: We describe a case of intracranial dural malignant meningioma initially showed hemorrhage spot in the skin and decrease of platelet count.

**Design/Methods**: The clinical information, radiology data, pathology data were analyzed.

**Results**: History: A 10‐month‐old boy with good birth condition, presented with an enlarged head circumference greater than the 95thpercentile with no neurologic signs. His growth and development are in line with the age of the infant. He was hospitalized 3 months ago for the site of hemorrhage spot, who has a limited hunch in the temporal region and a mild enlarged liver. The biochemical tests were characterized by decrease of platelet count (platelets at admission was 5 × 10 \^ 9 / L). The examination of bone marrow cytology and blood smear were performed on the admissions: 8.5% of unclassified cells were found in the whole sample. Most of the cell size is relatively uniform, with a diameter of about 25ul, with irregular edges, cloud‐like protrusions, less cytoplasm, moderate basophilia, and large nuclear chromatin, and nucleolar inconsistencies (Figure 1). Considering that the unclear cell morphology is similar to a megakaryocyte,

One week later, he was hospitalized again. The proportion of abnormal cell immune groups in peripheral blood leukemia immunophenotypes was 11.6%, and CD33, 36, and 41 were expressed. Among them, CD41 supports M7 diagnosis.

Figure 2 ‐ Figure 5). Imaging findings: On MRI T1WI (Fig. 2), there were multiple masses of circular T1WI and other cerebral masses in the cerebral hernia and the cerebellum. The broad basement was connected to the dura mater. T2WI (Figure 3) showed a slightly lower signal, and the enhanced scan (Figure 4, post‐contrast FS‐T1WI) was markedly enhanced. The dural tail sign was seen. DWI (Figure 5) suggested mild diffusion restriction. The mass effect was obvious without brain edema.

**Conclusions**: Be aware of malignant meningioma in young children.

### PO-086. Shotgun Proteomic Profiling in Group 3 and Group 4 Medulloblastoma {#pbc27455-sec-10530}

L. Hernychova^1^, M. Nekulova^1^, M. Kyr^2^, L. Dosedelova^1^, L. Capkova^1^, P. Dvorakova^1^, M. Jezova^3^, O. Slaby^4^, J. Sterba^2^, B. Vojtesek^1^, [K. Zitterbart]{.ul} ^2^

*^1^Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; ^2^University Hospital Brno, Department of Pediatric Oncology, Brno, Czech Republic; ^3^University Hospital Brno, Department of Pathology, Brno, Czech Republic; ^4^Masaryk University, Central European Institute of Technology, Brno, Czech Republic*

**Background/Objectives**: Medulloblastoma (MB) comprises distinct molecular diseases. The consensus based on the epigenetic and transcriptional methods defined four main subgroups of MB (WNT, SHH, Group 3 and Group 4) with divergent biology and clinical outcomes. Recently, quantitative proteomics developed as a robust approach additional to genomics to identify prognostic markers and drugable targets in human cancer. Here, we report proteomic differences between Group 3 and Group 4 MB.

**Design/Methods**: MB tissues were classified by use of transcriptomic analysis of a set of 22 discriminatory genes as Group 3 or Group 4 MB. Shotgun proteomic method was employed for quantitative profiling (n=10). Fifty micrograms of peptides per sample were labeled with TMT labels, according to the manufacturers protocol (TMT 10plex™ Label Reagent Set, Thermo Fisher Scientific) and were analyzed using Orbitrap Elite coupled with UltiMate 3000 RSLCnano chromatograph.

**Results**: A list of quantified proteins from tumor proteome was obtained and subjected to bioinformatical and statistical evaluation. Clustering of the differentially expressed proteins revealed upregulation of cell‐cell adhesion proteins and actin cytoskeleton proteins in Group 4 MB. Targets of interest among 11 significantly upregulated proteins in Group 4 MB are nidogen‐2, netrin receptor DCC and chloride intracellular channel protein 6.

**Conclusions**: To sum, we demonstrate that a mass spectrometry‐based proteomic approach allows to distinguish molecular signatures linked to medulloblastoma subgroups.

The study was supported by Ministry of Health of the Czech Republic grant AZV 15‐30657A and the project MEYS‐NPS I -- LO1413.
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### PO-087. Infections in Long‐Term Venous Access Devices: Should the Catheter Always be Withdrawn? {#pbc27455-sec-10550}

[S. Abib]{.ul} ^1^, M. Gama^2^, F. Carlesse^3^, F. Souza^1^, A. Duarte^1^

*^1^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Surgery, São Paulo, Brazil; ^2^Federal University of São Paulo, Student, São Paulo, Brazil; ^3^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Infectious Disease Control, São Paulo, Brazil*

**Background/Objectives**: CVC‐related infections enhances morbidity and mortality in cancer. Catheter withdrawal is indicated in most protocols, antibiotic treatments are recommended in immunocompetent children for CVCs salvage, but no specific recommendations are given for immunocompromised patients. Benefits of catheter removal must be weighed against the difficulty of obtaining alternative venous access in children.

**Objective**: To assess the impact of catheter maintenance in children with cancer and RC‐BSI.

**Design/Methods**: Single institution study (300 implanted Port‐a‐caths a year). Patients with RC‐BSI from the Pediatric Infectious Disease Control database from 2011 to 2015. Exclusion criteria: CVC associated infections, Complicated CVC related infections and sepsis, fungal infections, polymicrobial infections. **Treatment success**: clinical improvement (fever, astenia) and/or negative blood culture after 72hs of treatment, infection cure. **Treatment failure**: positive blood culture after 72hs of treatment, reincident infection with the same agent, clinical deterioration after 72hs, need for prolonged antibiotic therapy for more than 30 days, death.

**Results**: 95 patients with 107 CVC infections (7% implanted Ports) 51 male (53.7%), 44 female (46.3%), age at CVC infection: 3 mo -- 17 ys (6.1 ys +/‐4.9), solid tumors: 64 (67.4%), hematologic neoplasia:31 (32.6%), neutropenia: 57 (60%). Removed cathaeters: 22 (21.2%), mantained: 74 (77.9%). 54 cure, failure in 20. Clinically there was no difference between the removed and mantained groups (p=0.693). Agents: GRAM positive = 55 (51.4%), GRAM negative = 52 (48.6%), p=0.144 between cure and failure, independent of agent group or mantained catheter (p=0.201). Neutropenia did not interfere in cure rates (p=0.976), neither did the oncological diagnosis (p=0.579). Age \< 2 ys tended to have impact in the univariate analysis (p=0.061). No deaths occured, no need from antibiotics for more than 30 days.

**Conclusions**: Catheter maintenance in children with cancer and CR‐BSI did not impact mortality. Further studies with greater sample can lapidate other possible risk factors for catheter maintenance.

### PO-088. Extended Liver Resections or Liver Transplantation? Single Center Experience {#pbc27455-sec-10560}

[S. Abib]{.ul} ^1^, A. Duarte^1^, F. Souza^1^, M. Cypriano^2^, H. Lederman^3^, M.T. Alves^4^

*^1^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Surgery, São Paulo, Brazil; ^2^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Oncology, São Paulo, Brazil; ^3^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Radiology, São Paulo, Brazil; ^4^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pathology, São Paulo, Brazil*

**Background/Objectives**: Surgery is a milestone in liver tumors treatment. PRETEXT guides the risk groups and also tumor resectability, along with POSTEXT classification.

There is still not a consensus about the indication of extended liver resections or liver transplantation (OLT) in patients with cetral liver POSTEXT III and IV with vascular extension, which have pros and cons, although literature shows similar survival rates. The aim of this study is to describe a series comparing both approaches.

**Design/Methods**: Single center experience of 67 liver tumors, included 30 patients from 2009 to 2018.

**Results**: 21 hepatoblastomas: 6 PRETEXT I/II, 15 PRETEXT III/IV; 4 hepatocarcinomas, 2 hepatic sarcomas, 1 hemangioendotheliomas, 2 mesenchymal hamartomas. Inclusion criteria: POSTEXT hepatoblastomas III/IV submitted to extended resections or liver transplantation. 10 patients were included. One patient had cavo‐atrial extension. 4 patients were submitted to OLT and 6 to extended liver resections. Median survival rate: 57 months. One patient died and one relapsed. Surgical procedures in extended liver resections: 2 right trisegmentectomies, 3 left trisegmentectomies (one with CBP), 2 non anatomical resections. One OLT was indicated as rescue transplant after left trisegmentectomy. Complications post OLT: 1 graft rejection, 1 biliary stenosis, 1 graft portal thrombosis with retransplantation, 1 bleeding. No complications occured in the extended resection group. There was no difference in survival rates between the OLT and extended resection groups (p=0.317).

**Conclusions**: Extended resections are feasible and safe and provide similar survival rates as those observed in liver transplantation groups. Such cases should be treated in reference centers.

### PO-089. Hepatoblastoma with Intracardiac Extension: Surgical Approach {#pbc27455-sec-10570}

[S. Abib]{.ul} ^1^, A. Duarte^1^, M. Amorim^1^, F. Souza^1^, J.C. Guilhen^2^, M. Cypriano^3^, H. Lederman^4^, M.T. Alves^5^

*^1^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Surgery, São Paulo, Brazil; ^2^Federal University of São Paulo, Cardiovascular Surgery, São Paulo, Brazil; ^3^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Oncology, São Paulo, Brazil; ^4^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Radiology, São Paulo, Brazil; ^5^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pathology, São Paulo, Brazil*

**Background/Objectives**: Hepatoblastoma is the most common malignant liver tumor of childhood. The therapeutic management had an important evolution with the advent of neoadjuvant chemotherapy followed by surgical resection or liver transplantation. However, despite advances, some tumors with vascular and cardiac extension are still considered a surgical challenge.

**Objective**: To present a case of hepatic tumor with vascular and cardiac extension and discuss the surgical challenges of the simultaneous thoracic and abdominal approach, with the use of cardiopulmonary bypass (CPB).

**Design/Methods**: Case report.

**Results**: 5‐year‐old male patient with abdominal mass and post‐meal vomiting. Image and initial biopsy revealed hepatoblastoma with tumor extension for suprahepatic veins and atrium, entering the ventriculum through the valve, confirmed in echocardiogram. Although there was a high risk of embolization, treatment was made with preoperative chemotherapy, followed by a surgical approach with cardiopulmonary bypass (CPB) with total circulatory arrest and profund hypothermia, making possible cardiac tumor resection, followed by partial hepatectomy after circulatory return. The patient had an uneventful postoperative period, received chemotherapy, but presented elevated AFP and liver relapse.

**Conclusions**: Hepatoblastomas with vascular extension are very complex and challenging from the surgical perspective. The objective of the case report is to present the surgical approach (cardiopulmonary bypass with cardiac arrest and profund hypothermia) for such cases.

### PO-090. Testicular Metastasis in Wilms Tumor: Case Report {#pbc27455-sec-10580}

[S. Abib]{.ul} ^1^, A. Duarte^1^, F. Souza^1^, M. Cypriano^2^, H. Lederman^3^, M.T. Alves^4^

*^1^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Surgery, São Paulo, Brazil; ^2^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Oncology, São Paulo, Brazil; ^3^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Radiology, São Paulo, Brazil; ^4^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pathology, São Paulo, Brazil*

**Background/Objectives**: Wilms tumor is is the most common malignant renal tumor in childhood. The knowledge of the clinical characteristics and the accomplishment of adequate surgical procedures have an important impact on the prognosis of the disease.

Testicular and paratesticular metastasis due to the tumor have been reported, but their occurrence is extremely rare, with only 10 cases reported in literature.

The aim of this study is to report a Wilms tumor testicular metastasis.

**Design/Methods**: Case report.

**Results**: Male, 3‐year‐old. Left Wilms Tumor, Stage III, intermediate risk, with preoperative rupture. SIOP protocol with preoperative chemotherapy. Submitted to left nephrectomy, left partial colectomy with primary anastomosis, distal pancreatectomy and bilateral inguinal herniorrhaphy. 8 months after the first procedure he had an obstructive acute abdomen and was reoperated. There were no signs of tumor relapse, only adhesions. After 2 months he developed a testicular volume increase, at first treated as orchitis, without success after 14 days, so a right inguinal exploration was indicated and orchiectomy due to macroscopic appearance of the testis was performed. Pathology revealed Wilms tumor.

**Discussion**: The ipsilateral spread can be caused by the spermatic vein or by retrograde transcelomic pathway. The cross‐involvement of the kidney and testis may be owing to the patency of the vaginal conduit. However, the hematogenic pathway may be considered.

**Conclusions**: Although testicular tumor is rare in children, any solid scrotal mass should be considered malignant until proven otherwise, especially when malignant neoplasm is present outside the testicle. Therefore, we recommend routine examination of testicles in patients with Wilms tumor during treatment and follow‐up period.

### PO-091. Primary Liver Germ Cell Tumor: A Rare Entity {#pbc27455-sec-10590}

[S. Abib]{.ul} ^1^, A. Duarte^1^, F. Souza^1^, C. Macedo^2^, M. Amorim^1^, R. Azevedo^3^, H. Lederman^4^, M.T. Alves^5^

*^1^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Surgery, São Paulo, Brazil; ^2^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pediatric Oncology, São Paulo, Brazil; ^3^Federal University of São Paulo, Pediatric Gastroenterology, São Paulo, Brazil; ^4^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Radiology, São Paulo, Brazil; ^5^Pediatric Oncology Institute ‐ GRAACC ‐ Federal University of São Paulo, Pathology, São Paulo, Brazil*

**Background/Objectives**: Germ cell tumors (GCT) can occur in various sites, but there are less than 20 cases of primary liver GCT in the literature. The aim of this paper is to relate a rare case of this entity.

**Design/Methods**: Case report.

**Results**: 13 ys, female presented with nausea, weight loss (4 Kg) and jaundice. Sclerosing cholangitis and ulcerative rectocolitis since 4 ys old. Internal and external biliary drainage with 2 drains for obstructive jaundice. Liver abscesses treated with antibiotics. Persistent liver abscess images despite long‐term antibiotics and was investigated for tumor: negative colonoscopy, CEA 225,1 e AFP 5000, Ca 19.9 304. Image guided biopsy: solid pattern carcinoma in liver, with necrotic areas, suggesting either liver adenocarcinoma or cholangiocarcinoma Tumor was considered unresectable, but due to the previous history, resectability was evaluated intraoperatively. Surgical findings: right lobe tumor and blockage in hilum due to the presence of 2 biliary drains (risk of hilum elements injury). An intraoperative cholangiography was perfomed and it was decided to do a non anatomic resection (right hepatectomy). Uneventful postoperatory period: extubated on 2 day PO, no drugs, discharged from hospital on 8th PO. Cholangiography on 15th PO and Kehr drain withdrawn. AFP levels from 243 to 143 She presented fever due to bile leakage, which was treated with image guided drainage. Pathology revealed Mixed Malignant Germ Cell Tumor (Yolk sac and Embrionary Carcinoma) Re‐staging: no other tumor sites, so the diagnosis was GCT originated from liver She received chemotherapy (TCG 2008 Brazilian Protocol) -- intermediate risk, stage II with Etoposide e Cisplatine (4 Cycles), CDDP:35mg/m2/d x 3, VP‐16:170mg/m2/d x 3 and Image reevaluation after 2nd and 4th cycles Unfortunately she died due to sepsis.

**Conclusions**: Primary liver GCT are extremely rare and should be considered as differential diagnosis for liver and biliary carcinomas.

### PO-092. Ewing Sarcoma of Ribs: Outcome of Surgical Management as a Part of Multimodality Treatment {#pbc27455-sec-10600}

[S. Agarwala]{.ul} ^1^, D. Murli^1^, A. Dhua^1^, V. Jain^1^, K. Sharma^1^, S. Bakhshi^2^, A. Biswas^3^, S. Thulkar^4^, M. Jana^5^, D. Kandasamy^5^, M. Srinivas^1^, V. Bhatnagar^1^

*^1^All India Institute of Medical Sciences, Pediatric Surgery, New Delhi, India; ^2^All India Institute of Medical Sciences, Medical Oncology‐ BRAIRCH, New Delhi, India; ^3^All India Institute of Medical Sciences, Radiotherapy‐ BRAIRCH, New Delhi, India; ^4^All India Institute of Medical Sciences, Radiology‐ BRAIRCH, New Delhi, India; ^5^All India Institute of Medical Sciences, Radiodiagnosis, New Delhi, India*

**Background/Objectives**: To evaluate the surgical treatment and the outcome of children with Ewing sarcoma(EW)/PNET of the ribs and correlate the outcome with presence of metastatic disease and treatment strategy.

**Design/Methods**: EW/PNET of the ribs registered from November 2011 through June 2017 were included. All received neoadjuvant chemotherapy(NACT) \[vincristine+ doxorubicin+cisplatin+ifosphamide+etoposide\] and either radical radiotherapy alone(RRT) or surgical resection(Sx) or both surgery+RT(Sx+RT). Kaplan Meier survival estimates for overall survival(OS) and event free survival(EFS; events being progression/recurrence/death) were done using statistical program STATA 9.

**Results**: Twenty two children with rib involvement in the age group of 21‐156 months (mean 94) were enrolled. 15 (68%) were more than 60 months of age, 12 (54.5%) the tumor size was greater than 8 cm, 5 (22.7%) had pleural effusion and 4 (18.2%) had metastatic disease(3 lung; 1 bone marrow). All received Neoadjuvant chemotherapy (NACT). Ninteen(86.4%) received local treatment in the form of Surgical resection(7), Sx+RT(7), RRT(5). One died and one discontinued treatment during NACT. All 14 patients undergoing surgery achieved clear margins with resection of a single rib and achieved CR, though 5 of these recurred. Of the 5 RRT alone, only 1 achieved CR. Of the 5 with pleural effusion, (4 non‐metastatic; 1 metastatic) 2 had Sx+RT and 3 RRT as local treatment; 3/5 (60%) achieved CR, 1 of whom recurred. Overall 15/22 (68%) achieved CR (14/18 non‐metastatic and 1/4 metastatic) and of these 5 recurred. Overall there was 1 death giving a 3‐year OS of 0.96 (95CI 0.73‐0.99) and there were 7 events (1 death, 1 progression, 5 recurrences) giving a 3‐year EFS of 0.57(95CI 0.24‐0.79).

**Conclusions**: EW/PNET of ribs present as large tumors(54%) and are metastatic in 20%. Resection of the involved rib alone is adequate and gives a CR in all with a recurrence rate of 30% and an OS and EFS of 96% and 57%.

### PO-093. Neuroblastoma with Opsoclonus‐Myoclonus‐Ataxia Syndrome (OMAS): Outcomes of Surgical Management Over Twenty Years {#pbc27455-sec-10610}

[S. Anand]{.ul} ^1^, S. Agarwala^1^, V. Jain^1^, A. Dhua^1^, S. Bakhshi^2^, R. Seth^3^, S. Gulati^3^, M. Jana^4^, D. Kandasamy^4^, M. Srinivas^1^, V. Bhatnagar^1^
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**Background/Objectives**: To evaluate outcome of surgical management of children with neuroblastoma (NB) having opsoclonus‐myoclonus‐ataxia syndrome (OMAS).

**Design/Methods**: Retrospective analysis for children with NB‐OMAS managed at our institution during January 1998 to January 2018 was performed.

**Results**: Eighteen patients of NB‐OMAS with mean age of 25 ± 12 (range 8‐60) months with an equal gender preponderance were included. One patient (5.6%) had metastatic disease in right orbit and sphenoid bone. Thirteen (72%) were abdominal tumors (4 adrenal, 8 extra‐adrenal, 1 pelvic) and five (28%) were thoracic in location (1 being thoraco‐abdominal). MIBG scan showed uptake in the primary tumor in 10 of 15(67%) in whom it was performed. Eleven (61.1%) received chemotherapy (8 Neoadjuvant\[NACT\] + adjuvant\[ACT\]; 3 ACT only). Only 1(5.6%) received adjuvant radiation. Sixteen (88.9%) underwent surgical resection (9\[56%\] upfront surgery without NACT). Other medical interventions including adrenocorticotrophic hormone (8/18; 44.4%), intra‐venous immunoglobulin (3/18; 16.7%) pulse methylprednisolone (1/18; 5.6%) were used in addition in 12/18(66.7%). There were no deaths and all are alive and disease free. Complete remission of OMAS symptoms was achieved in all. Two (11%) who were not resected, also achieved complete remission of tumor and all symptoms on NACT alone. Histology for 16 resected specimens was Ganglioneuroblastoma 9(56%), Neuroblastoma 3(19%) and Ganglioneuroma 2(12.5%), and no identifiable tumor 2(12.5%). Two children (11%) had residual neurologic sequelae (slurring of speech and gait instability) which resolved on subsequent follow‐up visits.

**Conclusions**: Children with neuroblastoma having opsoclonus‐myoclonus‐ataxia syndrome had non‐metastatic disease in 94% cases. Surgery with or without chemotherapy was the mainstay of treatment. Adjuvant treatment in the form of adrenocorticotrophic hormone, pulse methylprednisolone and intra‐venous immunoglobulin aided in resolution of neurologic symptoms in 66% cases. All achieved complete resolution of neurologic symptoms and 100% disease free long term survival. Long term residual neurologic sequelae were not observed.

### PO-094. Surgical Management of Ovarian Tumours: A 25 Year Single Centre Experience {#pbc27455-sec-10620}

P. Losty^1^, I. Hennessey^2^, B. Pizer^3^, [F. Arthur]{.ul} ^2^

*^1^Institute Of Child Health ‐ University Of Liverpool‐ UK, Department Of Paediatric Surgery, Liverpool, United Kingdom; ^2^Alder Hey Children\'s Hospital NHS Foundation Trust, Department Of Paediatric Surgery, Liverpool, United Kingdom; ^3^Alder Hey Children\'s NHS Foundation Trust, Department Oncology, Liverpool, United Kingdom*

**Background/Objectives**: Ovarian neoplasms in children are rare heterogenous lesions with variable biological behaviour and outcome (Von Allmen Sem Pediatr Surg 2005).

**Design/Methods**: All female patients requiring operation for ovarian tumours were identified from a single center during the period 1990 ‐ 2015. Clinical outcomes are reported.

**Results**: Eighty eight patients with 101 ovarian tumours included those with synchronous and metachronous neoplasms. Mean age at diagnosis was 11.8 years. Tumours were equally distributed in left and right ovary(s). Bilateral disease occurred in 11 (10.8%). Eighty six (85%) neoplasms were benign and 15 (14.8%) malignant requiring chemotherapy and / or radiation. There were no significant difference(s) in maximum tumour diameter in benign vs malignant lesions. Tumour marker studies BHCG and AFP were normal in 5 benign neoplasms. Fifteen (15%) lesions were metastatic at presentation including a case of disseminated peritoneal gliomatosis. Two of these cases had mature cystic teratoma(s) with peritoneal deposits. Surgical management included salpingo‐oopherectomy 21 (21%), ovary excision 33 (33%), 'ovary sparing' tumourectomy 34 (34%) and cyto‐reductive extirpation in 2 cases (2%). Lymphadenectomy was performed in 9 patients (9%) together with peritoneal fluid cytology in 18 cases (18%) who had abdominal ascites. Omentectomy was required in 14 patients (14%), multiple peritoneal biopsy(s) ‐ in 11 cases (11%) and biopsy of other suspicious organs -- bowel, mesentery, contralateral ovary in 7 (7%) further patients. Recurrent and metachronous lesions occurred in 10 (10%) cases in those with teratoma (n=9) and adenocarcinoma(s) (n=1). Overall survival was 97% with only 3 deaths: mucinous cystadenocarcinoma (n=1), desmoplastic small round cell tumour of ovarian origin (n=1) and small cell carcinoma ovary / hypercalcaemia (n=1).

**Conclusions**: These data confirm excellent survival (97%) of pediatric ovarian neoplasms. Rare malignant neoplasms have a dismal prognosis. In the modern era all efforts should be made to preserve fertility with 'ovary‐sparing ' operation(s).

### PO-095. Equivalent Outcome with Radiotherapy Only Versus Surgery as Local Treatment Modality in Head and Neck Ewing Sarcoma Family of Tumors {#pbc27455-sec-10630}
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**Background/Objectives**: Treatment of head and neck Ewings sarcoma family tumors (ESFT) is challenging as it may cause disfigurement and morbidity. There is lack of randomized data comparing radiotherapy versus surgery. We analyzed local treatment modality and its impact on overall survival (OS), event free survival (EFS) and local control rate (LCR) and prognostic factors in ESFT of head and neck region treated with uniform chemotherapy protocol.

**Design/Methods**: All patients of ESFT of head and neck treated from June 2003 to November 2015 were analyzed retrospectively. Univariate survival analysis was performed with Kaplan‐Meier graphs and compared with Log‐Rank‐Test. Multivariate survival analysis was conducted with Cox\'s proportional hazards model.

**Results**: Of the 67 patients included for analysis, median age was 12 years (range:1 to 45); 59 patients were non metastatic. Fifty patients received local therapy of which 14 received surgery±radiotherapy whereas 36 patients received radical radiotherapy. Five year OS, EFS and LCR for the whole cohort were 59.65%, 43.15% and 58.29 % respectively. Five year OS, EFS and LCR for the non‐metastatic cohort was 62.93%, 43.97% and 57.38% respectively. In this cohort of 50 patients, where comparison between surgery±radiotherapy vs. radical radiotherapy was done five year EFS, 38% vs. 50.7% (P=0.60), OS 90% vs. 57% (P=0.21) and LCR was 47% vs. 53% (P =0.36).In multivariate analysis, in the non metastatic group those with symptom duration \> two months had better 5 year EFS 50% vs. 20% (P=0.04) and WBC\> 11×109 /l predicted poor EFS, 24.5% vs 57.9% (P=0.03). For OS, only WBC \> 11×109 /l predicted poor OS: 44% vs. 75.9 % (P=0.02).

**Conclusions**: This largest data on head and neck ESFT suggests that surgery may not be mandatory in this site. Baseline WBC is an independent predictor for poor outcome. Perhaps, those patients with symptoms duration \>2 months had a relatively less aggressive biology.

### PO-096. Prospective Study of Systematic Retroperitoneal Lymph Node Sampling for Wilms Tumors and Comparison with Random Lymph Node Sampling {#pbc27455-sec-10640}

[M. Bhagat]{.ul} ^1^, S. Qureshi^1^, S. Kembhavi^2^, G. Chinnaswamy^3^, T. Vora^3^, M. Prasad^3^, L. Sidddhartha^4^, N. Khanna^4^, M. Ramadwar^5^
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**Background/Objectives**: Lymph node (LN) sampling is an indispensable component of staging for Wilms tumor. However, there are no definite guidelines for sampling of retroperitoneal LN and usually the hilar or random enlarged LN\'s are sought. It is also not uncommon to be overlooked entirely. We performed a prospective study of systematic sampling of the retroperitoneal LN as per predefined station and compared the results with our own retrospective data of random LN sampling.

**Design/Methods**: Forty‐four children (Group A) with Wilms tumor were enrolled for this study between May 2015 to January 2018. Lymph node sampling was performed from five stations: the ipsilateral hilar, suprahilar and infrahilar regions and suprahilar and infrahilar interaortocaval region for all tumors. The presence of LN metastases in the interaortocaval region with negative ipsilateral LN was considered as skip metastases. The lymph node yield, incidence of positive LN, skip metastases and disease relapse were analysed and compared with the data of ninety‐five consecutive patients with randomly sampled LN operated at our centre between January 2006 to November 2014 (Group B).

**Results**: The median number of LN sampled was 11.5 (range, 3‐25) in group A versus eight (range, 0‐22) in group B (p=0.05). The overall incidence of LN metastases in the entire cohort was 10.2% and the incidence was 18.8% in Group A as compared to 6.3% in group B (p= 0.06). Skip metastases was present in 37.5% in Group A. The presence of positive LN had a significant risk of disease relapse in the entire cohort. (p=0.0001).

**Conclusions**: The yield and the incidence of positive nodes is better with systematic sampling, though it is not different as compared to random sampling. However, the high incidence of skip metastases justfies disciplined LN sampling. The presence of LN metastases increases the incidence of relapse.

### PO-097. Wilms Tumour: Is Aggressive Surgery Required in Patients with Vena Cava Disease Extension? Impact of Chemotherapy and Radiotherapy on Tumour Thrombus and Viability {#pbc27455-sec-10650}

P. Losty^1^, [T. Boam]{.ul} ^1^

*^1^Institute Of Child Health ‐ University Of Liverpool, Department Of Paediatric Surgery, Liverpool, United Kingdom*

**Background/Objectives**: Patients with Wilms tumour and inferior vena cava (IVC) disease are typically managed with neoadjuvant chemotherapy with the hope that tumour thrombus will regress making operation safer. Excision of tumour thrombus is challenging in some cases involving cavotomy or cavectomy, cardiopulmonary bye pass and reconstructive vascular surgery. This study critically examines the evidence to support or refute whether major surgery is required in all such patients.

**Design/Methods**: English language published literature was searched for ALL studies detailing the surgical management of patients with Wilms tumour and IVC disease extension. All reports citing full histopathological data on these treated patients were then analyzed.

**Results**: Ten eligible studies were identified during 1993‐2018 reporting data on 164 patients with IVC disease extension. 12 children received adjuvant radiotherapy. 98 (60%) patients were found to have viable thrombus after operation excluding cases that had also received pre‐operative radiotherapy. 7 of 12 children (58%) having radiotherapy had no viable tumour thrombus.

**Conclusions**: Based on currently available information tumour thrombectomy is likely necessary to achieve complete oncological clearance in patients with advanced staged Wilms tumour. Radiotherapy plays a vital role in pre and post‐operative care plans showing that tumour shrinkage and obliteration can be achieved obviating heroic surgery for a subset of patients. A surgeon led trial would usefully address the debate.

### PO-098. Cardiac Teratoma {#pbc27455-sec-10660}

[S. Braungart]{.ul} ^1^, A. Penn^2^, S. Nedungadi^3^, P.D. Losty^4^, P. Farrelly^1^, R.J. Craigie^1^
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**Background/Objectives**: Paediatric cardiac tumours are rare, with a reported autopsy rate of 0.0017--0.28 %. \[Uzun et al. Orphanet Journal of Rare Diseases 2007\] They are predominantly lesions characterised by benign histology (90%). However, due to the mass effect they often present with life‐threatening problems such as cardiac outflow tract obstruction, heart failure or arrhythmias. Rhabdomyoma is the most common histological subtype tumour (60%). Other lesions include fibroma, teratoma, haemangioma and myxoma though far less common.

**Design/Methods**: We report successful outcome of a newborn with a large cardiac teratoma and describe the unique presentation, diagnostic studies and definitive management.

**Results**: A baby girl was delivered prematurely by caesarean section due to reduced fetal movements at 33+1 weeks of gestation. Antenatal ultrasound had noted polyhydramnios and fetal hydrops, and a pericardial tumour with an associated pericardial effusion (Fig 1). At birth, APGARS were poor (4 at 1min and 6 at 5 min). The patient was resuscitated and transferred emergently to a regional paediatric cardiac surgical center. Imaging after birth and delivery showed a large cardiac tumour (Fig 2). AFP and bHCG were normal. Complete resection of the tumour under cardiopulmonary bypass was successful, and the infant made an excellent recovery. Pathology showed an immature pericardial teratoma lesion with yolk sac elements microfoci. The infant remains healthy on follow‐up.

**Conclusions**: Cardiac teratomas in the paediatric age group are extremely rare. Echocardiography, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) of the heart are the main diagnostic tools and important in the preoperative work‐up. Prognosis is favourable following complete surgical resection and no further treatment is generally required. Gross total resection can be challenging due to the anatomical lesion location and cases of tumour recurrence and malignant differentiation have been described in the world literature. Aftercare with surveillance imaging notably echocardiography and monitoring of tumour markers is mandatory.

### PO-099. When Lightning Strikes Twice: Management of Familial Neuroblastoma {#pbc27455-sec-10670}

[S. Braungart]{.ul} ^1^, A. Penn^2^, R.J. Craigie^1^, P. Farrelly^1^, P.D. Losty^3^
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**Background/Objectives**: Familial neuroblastoma (NBL) is rare (1‐2% of all NBL). In contrast to sporadic cases, it occurs at a younger age, often with multifocal primary tumours. Inheritance pattern is incomplete autosomal dominant. The two most frequent mutations include ALK mutations (80%) and lesser so, germline mutations of PHOX2B (6‐7%).

**Design/Methods**: We present two siblings with familial neuroblastoma and discuss clinical management.

**Results**: A 3‐year‐old male presented with classical symptoms of NBL (fatigue, bone pain, weight loss). Biopsy confirmed a poorly differentiated NBL (MYCN non‐amplified, 17q gain, segmental chromosomal abnormalities). Staging showed a metastatic tumour (thorax, liver, bone, bone marrow disease). He commenced treatment for stage IV high‐risk NBL, with complete response of metastatic disease following rapid COJEC induction. The thoracic mass remained unchanged and required gross total resection. Unilateral ocular miosis was incidentally detected by the surgeon in an asymptomatic 10‐month‐old sister visiting her brother in hospital. Imaging in the female sibling showed multifocal NBL tumours (left lung apex, thoracic paraspinal, abdominal lesions). Biopsy confirmed neuroblastoma (MYCN non‐amplified, 17q gain, segmental chromosomal abnormalities). The 'asymptomatic' female commenced treatment for intermediate‐risk NBL. Both patients have been referred to clinical genetics and are awaiting whole genome sequencing.

**Conclusions**: Cases of familial neuroblastoma provide great opportunity to advance genetic understanding of NBL. Screening of 'asymptomatic' children with a history of familial NBL has been proposed in an effort to detect the two most common mutations, ALK and PHOX2B. If positive, surveillance with sonography and urinary catecholamines until age 5 years has been recommended \[Bosse et al Cancer 2016\]. No robust clinical data exists to support such practice. Familial NBL can be linked to other genetic polymorphisms. Subtle anomalies notably ocular miosis in siblings of children with NBL therefore require careful investigation. Whole genome sequencing may aid further insight into these families and the overall heritability of NB.

### PO-100. Horner\'s Syndrome in Infants and Children: Should we Routinely Screen for Neuroblastoma? {#pbc27455-sec-10680}

[S. Braungart]{.ul} ^1^, R.J. Craigie^1^, P. Farrelly^1^, P.D. Losty^2^
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**Background/Objectives**: Horner\'s syndrome (HS) -- ocular miosis, ptosis and anhidrosis -- may be a subtle sign of occult pathology in otherwise asymptomatic children, neuroblastoma (NBL) being the commonest associated malignant tumour. Despite such knowledge robust evidence to guide best clinical practice is sparse and the incidence of occult malignancy in children with Horner\'s syndrome remains largely unclear. We performed a systematic review aimed to (1) identify the incidence of neuroblastoma in children with HS of unknown aetiology, and (2) establish if screening for neuroblastoma should be routinely performed in this patient population.

**Design/Methods**: Systematic review of the literature (PubMed and Ovid/Medline database, 1961‐2018).

**Results**: The initial search identified 334 manuscripts; 269 records were screened after duplicate removal. Exclusion criteria: paper not addressing research question, not English language, case reports, review/comment. Six papers were included in the final analysis. All reports were single‐centre retrospective studies without control groups. All studies included patients with unilateral miosis +/‐ associated signs +/‐ positive cocaine test, without previously known diagnosis. Studies included a total of 137 patients (age range 0‐20years; mean age 3.32years). Overall incidence of a lesion detected was 12.4% (17/137). Neuroblastoma was diagnosed in 7.3% (10/137). Seven other patients were diagnosed with: rhabdomyosarcoma (n=1), Ewing\'s Sarcoma (n=1), ganglioneuroma (n=1), astrocytoma (n=1), juvenile xanthogranuloma (n=1), intraorbital hemolymphangioma (n=1) and brain stem vascular malformation (n=1).

**Conclusions**: It is well recognized that HS may be the first sign of occult malignancy, neuroblastoma being the most common one. We report the first systematic review study that comprehensively investigates the incidence of occult malignancy in this unique patient cohort. The study crucially shows that suspicion of HS of unknown aetiology in children should involve further investigation(s) to exclude an underlying space occupying lesion. We strongly recommend CT/MRI imaging of the brain, neck and thorax, plus urinary catecholamines for prompt diagnosis and treatment.

### PO-101. Surgical Management of Pediatric Ovarian Tumors: Classical 'Open' or Minimally Invasive Surgery? {#pbc27455-sec-10690}
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**Background/Objectives**: Ovarian tumors in the pediatric age group are rare. A significant number of children with ovarian mass lesions present "out of hours" as surgical emergencies. Surgical management may involve specialty services notably surgical oncologists or general surgeons. This multi‐center study herein reports how the mode of clinical presentation may influence (i) operation (classical 'open' vs minimally invasive surgery (MIS)) and (ii) examines if young females presenting as surgical emergency(s) are more likely to undergo radical oophorectomy vs ovarian‐sparing surgery.

**Design/Methods**: Nationwide multicenter voluntary data study registry amongst pediatric oncology centers. Females \<16 years with an index diagnosis of ovarian tumor (excluding functional/neonatal ovarian cysts) during 2006 ‐ 2016 were recruited and data analyzed.

**Results**: 271 patients with ovarian pathology were identified. Mean age at surgery was 11 years \[IQR 8--13\]. 68% of cases underwent classical open surgery and 26% had minimally invasive operations. 2.2% surgeries were initially MIS and then converted to open operation(s). 31% of MIS operations were performed as emergency procedures vs 35% as classical open procedures (p=0.65; Fisher\'s Exact Test). Tumor size in MIS operations was smaller: median tumor size was 6.5cm \[IQR 4.5‐10\] vs 11cm \[IQR 7.25‐17.5\] in the classical open group (p\<0.00001, t‐test). Ovary‐sparing surgery was significantly more common with MIS (45% ovary‐sparing, vs 14.1% in the classical open group, (p\<0.00001; Fishers exact test)). Female patients who underwent emergency resection(s) were less likely to have ovarian‐sparing surgery.

**Conclusions**: The majority of female patients reported in this voluntary national study registry underwent open classical surgery for resection of ovarian tumor and had a total oophorectomy. Cases having MIS were more likely to receive ovarian‐sparing surgery. Small tumor size in the MIS group cohort may have facilitated fertility‐preserving outcomes.

### PO-102. Ovarian Tumors in Children: How Common are Lesion Recurrence(s) and Metachronous Disease? Results of a Nationwide Study {#pbc27455-sec-10700}
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**Background/Objectives**: Ovarian tumors in children are rare; incidence depends on tumor biology and patient age. Robust protocol guidelines to aid patient follow‐up after tumor excision are distinctly lacking. Published work shows metachronous tumor recurrence(s) can occur in some 2.5%--23% patients. Nevertheless, there are surgeons who recommend that no patient follow‐up is required after tumor excision as the outlook for many children is considered excellent. Therefore, we performed a nationwide multicenter study to investigate the incidence of (i) recurrence and (ii) metachronous disease in pediatric patients following ovarian tumor resection.

**Design/Methods**: Nationwide multicenter voluntary data study registry amongst pediatric oncology centers. Female patients \<16years with index diagnosis of ovarian tumor from 2006‐2016 were identified. Functional/neonatal ovarian cysts were excluded. 'Tumor recurrence(s)' was defined as tumor occurring in the same ovary following primary resection; 'metachronous disease' as new tumor occurring in the contralateral ovary after primary operation.

**Results**: 271 patients with ovarian tumors from 10 surgical oncology centers were identified. Mean age at surgery was 11years \[IQR8‐13\]. 46% patients presented as surgical emergencies, 51% had elective presentation, unclear history in 3%. 3% children were found to have bilateral tumors at first primary operation. Most common diagnosis were mature teratoma(55%), immature teratoma(12%), serous/mucinous cystadenoma(8.8%) and dysgerminoma(4.1%). 8.5% of females were identified with tumor recurrence(s) or metachronous disease. Majority(78%) of patients with recurrent or metachronous disease were diagnosed from routine clinic follow‐up, 4.3% incidentally ('lesions' on imaging following road traffic accident), 4.3% due to "new symptoms", 8.6% unclear. Mean time to detection of recurrent and/or metachronous disease was 13.5 months \[IQR8.75‐19.75\].

**Conclusions**: This nationwide study clearly shows that ovarian tumor recurrence(s) and metachronous disease occur. The majority of patients with recurrent and/or metachronous disease were detected at routine clinic follow‐up. We strongly advocate ALL female pediatric patients should have robust follow‐up care plans after diagnosis and resection of ovarian tumor(s).

### PO-103. Testicular Germ Cell Tumor: A National Multicentric Study {#pbc27455-sec-10710}

[R. Chaves Ribeiro]{.ul} ^1^, S.D.C. Abib^2^, V. kremer^1^, M. Macedo^3^, L.F. Lopes^4^
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**Background/Objectives**: Germ Cell tumours in childhood are a rare disease. Thus testicular germ cell tumors are rarity in the pediatric population. Adequate information about their clinical course is difficult.

The aim of this study is to present the clinical and histological features of testicular tumors in multicentric protocols.

**Design/Methods**: A retrospective analysis from testicular tumors enrolled to one of the 3 National multicentric protocols from 1991 to 2017. The clinical characters, histopathological findings, management, and outcome of patients were analyzed.

**Results**: Available for analysis were 270 patients from 31 hospitals. The mean patient ages at diagnosis were 105 months. Staging were: 44% I, 11% II, 15% III, 29% IV. Histology: 40,1% yolk sac tumor, 12% pure teratoma, 17% mixed tumours, 4% seminoma, 6% immature teratoma, 9% embrionary carcinoma and 10% mixed teratoma. Risk classification: 122 patients were low risk (LR), 50 were intermediate risk (IR) and 97 were high risk (HR). Primary orchiectomy was done in 94%. Low Risk (LR) patients did not receive chemotherapy. Patients IR received Platiran and Etoposide (PE) and for HR patients had addition of Ifosfamide. Primary orchiectomy was done in 94%. Relapse occurred in 8,7%, 0%, 24% and 15% (stage I,II, III and IV respectively). The 5‐year survival rates were 100% for stage I, 96% for stage II, 85%for stage III and 72% for stage IV.

**Conclusions**: Testicular tumors in children are rare. In our data, yolk sac tumors were the most common tumor. The multicentric experience is important to understand the clinical and the results of this rare tumor. A multidisciplinary approach with surgical, radiological, pathological, and oncological input is the cornerstone of management in order to achieve excellent outcomes.

### PO-104. New Criteria for Laparoscopic Nephrectomies in Pediatric Renal Tumors {#pbc27455-sec-10720}

[R. Chaves Ribeiro]{.ul} ^1^, V. Kremer^1^, W.E. Oliveira Jr^1^, F.M.P. Sousa^2^, C.E.B. Cavalcante^2^
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**Background/Objectives**: Minimally invasive surgery (MIS) is commonly used to perform nephrectomy for nononcological reasons. The MIS approach to renal tumors in children has become a new frontier of studies. However, the literature not defines the criteria for does laparoscopy nephrectomy in pediatric renal tumors. The aim of this study is verify if the distance between the tumor and great vessel (aorta and cava vein) and volume of the tumor are good criteria for do nephrectomy laparoscopic.

**Design/Methods**: A retrospective analysis of all renal tumors was done between the year 2016 and 2017. The patients were divided in two groups: open surgery (OS) and laparoscopy surgery (LS). The two groups were compared in demographic characteristics and in two specific criteria: distance between tumor kidney and great vessel (aorta for right side tumors and vena cava to left side tumors) in the hilum and tumor volume. All patients followed the SIOP protocol.

**Results**: There were 22 patients (15 males and 7 females). The mean age was 43 months (3‐129). There were 9 right sides tumors and 13‐left side, none bilateral. Three patients not received preoperative chemotherapy, because the age (lesser than 6 months) or rupture. The preoperative average tumor volume was 572 cm3. After chemotherapy the volume decrease to 238 cm3. LS group had 7 patients and OS group 15. Mean age were 42 months in OS and 45 in LS. Tumor volume was 304 cm3 in OS group and 143 cm3 in LS (p=0.03). Great vessels distance were 0,41 cm in OS group and 0,65 cm in LS (p=0.13).

**Conclusions**: Laparoscopic nephrectomies are feasible in pediatric renal tumors. Tumor volume could be criteria to laparoscopic surgery. However another criteria are necessary. Further studies are needed to confirm whether tumor distance from large vessels is a criterion for laparoscopy.

### PO-105. Tunneled Non‐Cuffed Centrally Inserted Central Catheters in Pediatric Oncology: Initial Experience {#pbc27455-sec-10730}

[R. Chaves Ribeiro]{.ul} ^1^, V. kremer^1^, W.E. Oliveira Jr^1^, K.A.S. Rodrigues^2^, F.F. Gonçalves^2^
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**Background/Objectives**: A long‐term venous access is essential in children when treating malignant diseases. Tunneling of central lines is a simple tool that allows simultaneously achieving both ideal puncturing site and catheter exit, reducing risks of many complications. When use in centrally inserted central catheters (CICC) this technique is particularly useful in children. There is no study focused on pediatric oncology patients. The aim of this study is evaluate our initial experience with CICCs regarding feasibility, catheter life, complications and reason for removal in children with cancer.

**Design/Methods**: A retrospective analysis of all pediatric oncology patients who underwent tunneling non‐cuffed CICC line insertion by the pediatric surgery team at our institution from May 2016 to December 2017. Demographic features, primary diagnosis, catheter days, reason for removal and complications were reviewed.

**Results**: Thirty‐three CICCs were inserted into 31 children during the 19‐month period. Median catheter life was 50 days, ranging from 2 to 522 days, with a total of 2527 catheter days. Complication rate of 5.54 per catheter days was recorded. 25 lines were removed, 4 elective and 7 due to death. Remaining reasons for catheter removal were infection in 9 patients, occlusion in 3and dislodgement in 2, with rates of 3.56, 1.18, 0.79 per 1,000 catheter days, respectively. When compared to solid tumors, catheter in hematological malignancies had a higher permanence (53 catheter‐days in hematological and 38 in solid tumors) and Lymphomas showed the highest median with 167 catheter‐days.

**Conclusions**: Tunneled CICC lines are feasible and provide reliable long‐term intra‐venous access in children suffering from malignancies, particularly those with hematological malignancies during induction chemotherapy when the infection rate is higher. Although in our developing country setting better care and proper dressings are important to minimize premature removals and suspected infection. Education for both parents and nursing team and guidelines are needed to improve complication rates.

### PO-106. Treatment Effect of Neuroblastoma of Neonates and Small Infants {#pbc27455-sec-10740}

[Y. Chen]{.ul} ^1^, Z. yong^2^

*^1^Beijing children\'s hospital affiliated to capital medical university, Neonatal Surgery, Beijing, China; ^2^Beijing Children's Hospital ‐Neonatal surgery, Beijing Children's Hospital ‐Neonatal surgery, Beijing, China*

**Background/Objectives**: To study the clinical features and treatment effect of neuroblastoma(NB) of neonates and small infants.

**Design/Methods**: The clinical dates of 54 neonates and small infants under the age of 3 month with NB were retrospectively analyzed from July 2006 to December 2017 in neonatal surgery department of Beijing children\'s hospital.

**Results**: Among 54 cases, the tumors were detected prenatally in 38 cases and postnatally in 16 cases. The tumors locatedin the adrenal gland in 44 cases, retroperitoneum in 6 cases, posterior mediastinum in 2 cases and pelvic cavity in 2 cases. NSE was tested in 38 cases. The measured values of NSE were higher than the normal rang in 35 cases and higher than\>100gμ/L in 11 cases. NB were classified according to the INSS. 49 cases underwent tumorectomy, complete removal in 36, in sita tumor resection in 11, one side tumorectomy for bilateral tumor in 2. 1 case underwent tumor biopsy only. 52 cases were followed up and 2 cases lost. The average of follow‐up period was 46.4 months, 48 cases survived and 6 cases died. The causes of death: the parents of 4 cases in IVs stage abandoned operation, one case in III stage underwent tumor biopsy only, one case in IVs stage occurred poly metastasis postoperatively. Survive rate was 92.3%. The survive rate were higher in cases whose tumors were detected prenatally and NEC \<100ng/ml than that of postnatally and NSE\>100ng/m, respectively. All of 31 cases in 1stage and 10 cases in 4s stage survived.

**Conclusions**: For neonates and small infants with NB, most of the tumor can be detected through the prenatal ultrasonography. These patients have better prognosis than diagnosed postnatally. Tumorectomy and in sita tumor resection for patients in 4s stage are essential treatment. NSE values before operation is very important for the prognosis evaluation.

### PO-107. Management of Thoracoabdominal Neuroblastoma: A 13‐Years' Experience {#pbc27455-sec-10750}

[C.H. Chui]{.ul} ^1^, G.H.N. Tan^1^

*^1^Surgery Centre for Children Pte Ltd, Surgical Oncology, Singapore, Singapore*

**Background/Objectives**: Neuroblastoma involving the thorax and abdomen concurrently is a unique surgical challenge. Involving 2 major body compartments, these tumors are usually extensive. We reviewed our experience focusing on the disease patterns and their surgical approaches.

**Design/Methods**: Among 310 patients in our neuroblastoma database, 27(8.7%) had neuroblastoma that involved both thorax and abdomen concurrently. Patients' clinical charts were reviewed and analysed. 2 disease patterns were identified, (Group A) solitary thoracoabdominal tumor(n=12) and (Group B) multifocal tumors in thorax and abdomen(n=15). The operative approaches were categorized based on routes of surgical access. Mean follow‐up was 4.8 years (0.8‐14.2 years).

**Results**: 27 patients, average age 4.1 years (ranged 0.8‐12.8 years), male:female ratio 14:13 were studied. All received pre‐operative chemotherapy. Among 12 Group A patients, 3 were stage 3 intermediate‐risk (IR) and 9 were stage 4 high‐risk (HR). Surgical approaches included single‐incision thoracoabdominal approach(n=8), multi‐incision laparotomy‐cum‐thoracotomy approach(n=2), and laparotomy‐cum‐transdiaphragmatic thoracic approach(n=2). Average duration of operations was 11 hours (ranged 5 to 20 hours). 1 patient had 10% residual disease and the rest achieved gross total resection. Postoperative complications included chylous ascites(n=3), intestinal obstruction(n=3), pneumonia(n=1) and spinal cord infarction (n=1). Among 15 Group B patients, all were stage 4 with 5 IR and 10 HR. Thoracic components included satellite paravertebral tumor(n=4); subcarinal tumor(n=3), superior mediastinal tumor(n=4), peribronchial lymphadenopathy(n=1), parietal pleural tumor(n=3) and pulmonary nodules(n=3). Surgical approaches included multi‐incision laparotomy‐cum‐thoracotomy(n=14) and laparotomy‐cum‐transdiaphragmatic thoracic approach(n=1). Average duration of operations was 11.2 hours (ranged 5 to 17 hours). Gross total resection was achieved in all surgeries. Postoperative complications included chylous ascites (n=3) and Horner\'s syndrome(n=2). Overall, all 8 IR patients survived and 9(47.4%) HR patients relapsed and died of disease. There was no perioperative mortality.

**Conclusions**: Surgical resection of thoracoabdominal neuroblastoma is feasible and safe. Despite its complexity, thoracoabdominal neuroblastoma has comparable treatment outcomes when compared with single‐compartmental disease.

### PO-108. Use of Subcutaneously Anchored Securement Devices in Preventing Central Venous Catheters Dislocation in Children Affected by Cancer {#pbc27455-sec-10760}

[A. Crocoli]{.ul} ^1^, L. Sidro^2^, D. Delle Donne^2^, E. Blessich^2^, V. Alessandri^3^, A. Narciso^1^, I. Russo^4^, M.D. De Pasquale^4^, C. Grimaldi^1^, A. Inserra^1^

*^1^Bambino Gesù Childrens\' Hospital IRCCS, Surgery, Rome, Italy; ^2^Santobono ‐ Pausilipon Children Hospital, Anesthesiology and Intensive Care Unit, Naples, Italy; ^3^Bambino Gesù Childrens\' Hospital IRCCS, Anesthesiology, Rome, Italy; ^4^Bambino Gesù Childrens\' Hospital IRCCS, Oncohematology, Rome, Italy*

**Background/Objectives**: Dislocation of tunnelled central venous catheters (CVCs) is still major complication among pediatric patients, especially for whom affected by cancer. Recently, subcutaneously anchored suturless device (SASD) has been introduced for securing CVCs, but their role in prevention of dislocation is still debated and no data reported among pediatric patients has been reported so far.

**Design/Methods**: we reviewed use of SASD for long‐term tunnelled CVCs in pediatric patients inserted over a period of 2 years in two tertiary care centers. All CVC were inserted according to institutional insertion bundle and managed according institutional policies. Complications during placement and removal, pain/exit site inflammation and rate of dislocation were evaluated.

**Results**: One‐hundred and eleven CVCs (28 Peripherally inserted central catheters/PICCs, 64 centrally inserted central catheters/CICCs and 8 femoral inserted central catheters/FICCs) inserted for hematologic malignancies (n=47), hematologic non‐malignant disorders (n=3) and solid tumors (n=61) were secured with SASD in 99 patients (age range 3 months -- 17 years, median age 6.8 years). Median duration of the CVC was 7.8 months (range 0.6 months -- 2.3 years). No complication occurred during SASD placement. Four patients experienced prolonged pain after SASD placement; 4 patients experienced accidental CVC removal for skin erosion of the exit site after 4 weeks. In one patient kinking of the CVC was determined for wrong SASD placement. SASD removal -- performed by splitting in two halves with scissors ‐ did not require sedation or local anesthesia and was easy and uneventful in all cases.

**Conclusions**: SASD is effective in preventing dislocation in pediatric patients affected by cancer, with negligible complications both at insertion and during maintenance and removal. Considering that SASD saved approximately \$6,00 per week (cost of traditional sutureless devices) and avoided CVC primary dislodgement in this high‐risk patient population, it can be also considered cost‐effective.

### PO-109. Benign Tumors of the Liver in Children and Adolescents: The Experience of a Single Institution {#pbc27455-sec-10770}

[P. Dall\'igna]{.ul} ^1^, A. Sgrò^1^, M. Andreetta^1^, S. Peggion^1^, F. De Corti^1^, M. Zuliani^2^, M. Duci^1^, L. Santoro^3^, M.C. Affinita^4^, C. Virgone^1^, P. Gamba^1^, R. Alaggio^5^

*^1^Department of Women\'s and Children\'s Heath‐ University‐Hospital of Padua, Pediatric Surgery, Padua, Italy; ^2^Dipartimento Diagnostica per Immagini e Radiologia Interventistica‐ University of Padua, Radiology, Padua, Italy; ^3^DIMED, Pathology, Padua, Italy; ^4^Department of Women\'s and Children\'s Heath‐ University‐Hospital of Padua, Pediatric Oncology, Padua, Italy; ^5^Children\'s Hospital of Pittsburgh‐ UPMC, Pathology, Pittsburgh, USA*

**Background/Objectives**: Benign tumors of the liver are very rare, and the diagnostic/therapeutic approaches are not univocal. In children, they represent about one third of primary liver masses. This retrospective study analyzes our experience on epidemiology, diagnosis, therapy and outcome of children affected by these tumors, observed in our Institution. Data were also confronted with other single Institution series.

**Design/Methods**: The medical records of children with infantile hepatic hemangioma (IHH), mesenhymal hamartoma (MH), hepatic adenoma (HA), focal nodular hyperplasia (FNH), nodular regenerative hyperplasia (NRH), and "other lesions", observed between 1991 and 2017 in the Pediatric Surgery Unit of the University of Padua, were analyzed.

**Results**: Forty‐six patients (24 F, 22 M; age 0‐20 years, median 3) were identified: 16 affected by IHH, 15 FNH, 3 MH, 3 HA, 2 NRH and 7 "other". In 45% of cases, the lesion was incidentally discovered. Diagnosis was obtained by imaging in 20% of cases, after biopsy in 50% and after complete resection of the tumor in 30%. A "wait and see" approach was adopted in 21 patients (46%), surgery was necessary in 22 (48%) (1 embolization); 3 patients were treated with propranolol. A biliary fistula was the only surgical complication after resection of FNH. Forty‐four patients are alive (14 with their disease), 2 patients with IHH died (due to Kasabach‐Merrit phenomenon and malignant transformation).

**Conclusions**: Our series confirms the rarity of these tumors, whose incidence, however, may be underestimated. Improvement of radiological techniques in recent years made it possible to limit the number of unnecessary biopsies and surgical resections. Considering the number of cases and the diagnostic/therapeutic approach, our series is comparable with others from the literature. However, these data are not satisfactory, and National/International database are required to improve knowledge, and guarantee a more appropriate approach, still controversial for some lesions.

### PO-110. Treatment of Nephroblastoma with Venous Thrombus: Single‐Center Experience {#pbc27455-sec-10780}

[K. Dong]{.ul} ^1^, H. Weijin^1^, X. Xianmin^1^, L. kai^1^, Y. Min^1^

*^1^Children\'s Hospital of Fudan University, Surgery, Shanghai, China*

**Background/Objectives**: To retrospective analysis cases of nephroblastoma combined with vein tumor thrombosis diagnosed and treated at our department in the last 6 years.

**Design/Methods**: 12 pediatric patients with nephroblastoma combined with vein tumor thrombosis who were diagnosed and treated at our hospital from January 2010 to December 2016 were included in this retrospective analysis. The cohort included 4 boys and 8 girls, and the average age were 3.94±1.79 years. Five and four cases were in clinical phases 2 and 3, respectively, while three cases were in clinical phase 4, of which 2 showed pulmonary metastasis and 1 showed liver and pulmonary metastases. According to Nesbitt typed venous thrombosis of renal malignancies method, the cases were classified as five cases of type I, two cases of type II, two cases of type III, and three cases of type IV. All patients received the standardized treatment regimen recommended by the National Wilms Tumor Study. Tumor resection and vein tumor thrombus removal operation were carried out with or without cardiopulmonary bypass according to the different type of thrombosis.

**Results**: All 12 children recovered well after surgery. Pathology confirmed all of the twelve patients had favorable histology. For those cases with preoperative chemotherapy, tumor cells were not seen in the thrombus,but only fibrous tissue and foam cells. During the operation, Type I thrombi do not adhere to the vein wall, while types II--IV do adhere to the wall or infiltrate the inferior vena cava to different degrees. All patients were followed up at 0.5 --6 years, no tumor recurrence was found. Further, there are five cases have residual tumor thrombosis in the IVC, but no significant changes were found.

**Conclusions**: As for nephroblastoma with venous thrombus, complete resection of the tumor thrombus may not be aggressively pursued. Continuous standardized chemotherapy and radiotherapy after surgery guarantee a good prognosis.

### PO-111. National Survey on the Management of Wilms Tumor {#pbc27455-sec-10790}

[A. Elgendy]{.ul} ^1^, S. Shehata^2^, A. Medhat Zaki^3^, S. Shehata^4^

*^1^Tanta University, Surgical Oncology Unit, Tanta, Egypt; ^2^Tanta University, Pediatric Surgery Department, Tanta, Egypt; ^3^Ain Shams University, Pediatric Surgery Department, Cairo, Egypt; ^4^Alexandria University, Pediatric Surgery Department, Alexandria, Egypt*

**Background/Objectives**: To investigate the current management of Wilms tumor (WT) by the Egyptian pediatric surgical association (EPSA) consultants in order to assess our practice patterns.

**Design/Methods**: After approval of EPSA executive board, a questionnaire was distributed individually to all consultants attending the general assembly of EPSA 2017 annual congress.

**Results**: Out of 88 consultants, responses were received from 61 (response rate 61/88, 69.3%) who are involved in WT management. Diagnosis: palpable abdominal mass was indicated by 72.13% of respondents as most common presenting symptom. Concerning imaging requested, CT was reported by 80.33%. A total of 45.90% never request preoperative tumor biopsy during their practice. Surgery: 62.30% of respondents perform approximately 1‐3 cases annually. Regarding timing of surgery, upfront resection was the most frequent reported by 62.30%. Transverse transperitoneal incision was the commonest in use during surgeries (90.16%). Out of all respondents, 42.62% never encountered intraoperative complications, whereas 57.38% had different complications (mainly tumor rupture). A total of 77.05% perform lymph nodes sampling during tumor resection. Nephron sparing surgery (NSS) was adopted by only 26.23% (mainly for bilateral tumors), while none of the all respondents reported the use of minimal invasive surgery (MIS) for management (not prefer to perform or due to lack of properly selected cases). Follow up: overall, 93.44% of surgeons ask for a visit every 3 months in the first year postoperatively. CT was the most common imaging requested during follow up (54.10%).

**Conclusions**: Upfront nephrectomy is the commonest procedure for WT in current practice of EPSA consultants, whereas there is a consensus against MIS for management. Surgical guidelines for NSS are still incomplete and need to be tabulated. Based on the results of this survey, a national wide retrospective analysis is warranted for establishment of uniform protocol with international reference to be adopted in Egypt.

### PO-112. Postoperative Chylous Ascites after Resection of Pediatric Retroperitoneal Malignancies: Interventions and Impact Upon Adjuvant Therapy {#pbc27455-sec-10800}

[A. Fahy]{.ul} ^1^, M. Irwin^2^, J.T. Gerstle^1^

*^1^The Hospital for Sick Children, Division of General and Thoracic Surgery, Toronto, Canada; ^2^The Hospital for Sick Children, Division of Haematology/Oncology, Toronto, Canada*

**Background/Objectives**: Pediatric patients with retroperitoneal malignancies (in particular, neuroblastomas, Wilms' tumors or retroperitoneal sarcomas) usually undergo surgical resection of the primary mass and associated lymph nodes. Postoperative chylous ascites is a potential complication of the retroperitoneal lymphadenectomy. The purpose of this study was to examine the therapy and duration of postoperative chylous ascites for these patients, as well as review the impact of this complication on adjuvant therapy.

**Design/Methods**: Patients who underwent retroperitoneal resections for neuroblastomas, Wilms' tumors, and sarcomas at the Hospital for Sick Children between 2001 and 2016 were reviewed. Demographics, disease and treatment details as well as the extent, duration and treatment of their chylous ascites were reviewed. Any impact on additional therapy (delay or alteration of planned adjuvant therapy) was documented.

**Results**: Of the 328 retroperitoneal resection patients, 21 had evidence of moderate to marked ascites on postoperative imaging at 4‐6 weeks. These cases included 11 neuroblastoma, 3 retroperitoneal rhabdomyosarcoma and 6 Wilms' tumor patients. Most ascites (15/21, 71%,) resolved in 4‐8 weeks, either without intervention, or with a fat‐free formula/diet or restricted oral intake with parenteral nutrition. Three patients required multiple paracenteses. Three other patients required placement of a Denver shunt. For four of the six patients who required paracenteses or Denver shunts, the chylous ascites had a significant impact on their subsequent adjuvant therapy, leading to a delay in bone marrow transplant (median 8 weeks) or an alteration in previous chemotherapy plan (change in planned agents and/or timing).

**Conclusions**: For patients undergoing resections of retroperitoneal malignancies, postoperative chylous ascites occurs with low frequency but can have a significant impact on adjuvant therapy. Care should be taken intraoperatively to minimize the risk of lymphatic leak and prompt definitive post‐operative management with special fat‐free enteral and parenteral diets or shunts should be considered promptly to minimize delays to adjuvant therapy.

### PO-113. Minimally Invasive Surgery for Neuroblastic Tumours: A SIOPEN International Study {#pbc27455-sec-10810}

[H. Gabra]{.ul} ^1^, L. Pio^2^, S. Irtan^3^, K. Cross^4^, P. Lobos^5^, G. Gabriela Guillén Burrieza^6^, J.G.C. Javier Gómez Chacón Villalba^7^, G. Giovanna Riccipetitoni^8^, F. Florent Guérin^9^, M. Nightingale^10^, C. Calogero Virgone^11^, S. Faraj^12^, S. Warmann^13^, M.D. Leclair.^14^, A. Scalabre^15^, G. Girolamo Mattioli^16^, P. Losty^17^, S. Sarnacki^2^

*^1^The Great North Children Hospital‐ Newcastle University Teaching Hospitals, Paediatric Surgery, Newcastle Uppon Tyne, United Kingdom; ^2^Necker Enfants‐Malades Hospital‐Université Paris Descartes‐ Sorbonne Paris Cite, Department of Pediatric surgery, Paris, France; ^3^Trousseau Hospital‐ ‐ Centre de Recherche St Antoine Inserm‐ Sorbonne Universités, Pediatric Surgery, Paris, France; ^4^Great Ormond Street Hospital, Pediatric surgery, London, United Kingdom; ^5^Hospital Italiano, Pediatric surgery, Buenos Aires, Argentina; ^6^Hospital Universitario Vall d\'Hebron, Servicio de Cirugía Pediátrica, Barcelona, Spain; ^7^Hospital Universitario y Politécnico La Fe, Unidad de Cirugía Oncológica Pediátrica, Valencia, Spain; ^8^V. Buzzi Children\'s Hospital, Pediatric surgery, Milan, Italy; ^9^Hôpitaux universitaires Paris Sud‐ Hôpital Bicêtre Assistance Publique Hôpitaux de Paris‐ Université Paris XI, Pediatric surgery, Paris, France; ^10^The Royal Children\'s Hospital, Paediatric surgery, Melbourne, Australia; ^11^Department of Women\'s and Children\'s Health‐ University of Padu, Pediatric Surgery, Padua, Italy; ^12^University Children Hospital, Pediatric Surgery& Urology, Nantes, France; ^13^Tübingen University Hospital, Pediatric surgery, Tübingen, Germany; ^14^University Children Hospital, Pediatric surgery and Urology, Nantes, France; ^15^CHU‐hôpital Nord, service de chirurgie pédiatrique, Saint‐Etienne, France; ^16^Pediatric Surgery Unit‐ Istituto Giannina Gaslini‐ Genova. DINOGMI University of Genoa, Pediatric Surgery Unit, Genoa, Italy; ^17^Alder Hey Children\'s Hospital NHS Foundation Trust‐ University of Liverpool, Paediatric surgery, Liverpool, United Kingdom*

**Background/Objectives**: Surgery is an important part of treatment of neuroblastic. These are usually challenging tumours where standard operative approach is open surgery. In some cases, mainly in adrenal locations, minimally invasive surgery (MIS) is considered as feasible but the indication, morbidity and efficiency remain undetermined due to small number of reported series. The aim of this study was to report the indication, morbidity, EFS and OS in a large cohort of patients from international expert centres.

**Design/Methods**: The study protocol was approved by the SIOPEN surgical group and the Newcastle\'s ethical committee. Data was collected regarding patients demographics, tumour features, imaging, operative complications, follow up were analysed.

**Results**: A total of 262 patients(M:F=51:49) from 16 centres in 9 countries, with INSS staging: stage I =40%, stage II=8%, stage III=6%, stage IV&4S=18%); INRGSS staging: L1 (47%), L2 (18%), M and MS (31%). IDRFs were present in 30% and the majority of the tumours were adrenals (54%) compared to retroperitoneal and pelvic (16%) and thoracic (30%). The mean operating time was 131 minutes (range= 40‐530). Total and almost total macroscopic resection was achieved in 67% and 15 % respectively. While incomplete resection was recorded in 3% and 12 % had biopsies, 9% had conversion to open surgery. Median Hospital stay was 3 days (range=1‐90). Complications were recorded in 11% with no intra/post operative 30 days mortality. Median follow up was 32 months (range= 1‐156) with overall mortality of 8% (Neuroblastoma=20, Ganglioneuroblastoma=1).

**Conclusions**: This is the largest reported international series of MIS for neuroblastic tumours. The presence of IDRFs was not a contraindication for MIS. The conversion to open surgery and the overall complication rates were low in reflecting the overall expertise in these centres. Based on this study, The SIOPEN surgical group is currently working on identifying standard guidelines for MIS for neuroblastic tumours.

### PO-114. The Role of Pediatric Surgical Services in Optimal Management of Childhood Cancers {#pbc27455-sec-10820}

[H. Halepota]{.ul} ^1^, L. Samad^1^, H. Arbab^1^, S. Dogar^2^

*^1^The Indus Hospital, Pediatric Surgery, Karachi, Pakistan; ^2^The Aga Khan Hospital, Pediatric Surgery, Karachi, Pakistan*

**Background/Objectives**: Role of surgeons in diagnosing, definitive management and management of complications in children cancer patients

*Cancer is emerging as major cause of morbidity and mortality in developing countries. If treated appropriately and in a timely manner, 70% of childhood cancers are curable. However,in low resource settings, mortality rates for many pediatric cancer can approach 100%. Many factors contribute to poor childhood cancer outcomes in these settings*. The purpose of this study is to review all children requiring surgical intervention, either for diagnostic purposes, definitive treatment, or supportive treatment during the course of their management.

**Design/Methods**: A retrospective review of medical records of all children admitted to The Indus Hospital, Karachi, between September 1, 2014 and August 31, 2017, with a primary diagnosis of cancer and requiring surgical intervention was conducted. All children up to 14 years of age were included. Demographics, type and location of tumour, surgical notes, histopathological findings, radiological findings, presence or absence of metastasis, treatment protocols and outcome details were reviewed. Data was analyzed using SPSS22.

**Results**: A total of 164 children required surgical intervention during this period. This included surgical resection of solid tumours (n=60), diagnostic biopsies (n=72), porta cath insertions (n=23), intestinal diversions (n=6) and tube thoracostomies (n=3). The commonest solid tumours operated were malignant germ cell tumours (n=25, 42%), followed by renal tumours (n=21, 35%), soft tissue sarcomas (n=6,10%), neuroblastoma (n=3, 5%) and others (n=4, 6%).

**Conclusions**: A close collaboration between pediatric oncological and surgical services is essential to provide optimal care to children with cancers. The role of the surgeon is not restricted to tumour excision alone; both diagnostic and supportive interventions are required, which contribute greatly to the overall care and outcomes of childhood cancer patients.

### PO-115. Surgical Outcomes in Patients with High Risk Neuroblastoma, the European High Risk Neuroblastoma‐1 Trial: A UK Single Centre Experience {#pbc27455-sec-10830}

[S. Hotonu]{.ul} ^1^, R. Lisseter^1^, Q. Campbell‐Hewson^1^, D. Tweddle^1^, H. Gabra^1^

*^1^The Great North Children\'s Hospital‐ newcastle University Hospitals NHS Foundation Trust, Paediatric Surgery, Newcastle Upon Tyne, United Kingdom*

**Background/Objectives**: High risk neuroblastoma (HRNB) is traditionally associated with higher post‐operative relapse rates than other risk groups. This study aims to examine the surgical outcomes of patients with high risk neuroblastoma since the inception of the European High Risk Neuroblastoma Trial (HR‐NBL‐1) in our centre.

**Design/Methods**: Retrospective study including data between 2003 and 2015. Inclusion criteria: all patients considered high risk by the International Neuroblastoma Risk Group Staging System (INRGSS). Two patient groups were identified: \>90% resection or \<90% resection achieved, based on intra‐operative assessment and post‐operative imaging. Outcome measures: surgical complications, relapse (local or distant), event free and overall survival. Predictor variables: *MYCN* amplification status (‐ve or +ve), presence of residual tumour on post‐operative imaging. Statistical analysis: *X* ^2^ and t‐tests, with p \< 0.05 considered significant. Kaplan‐Meier survival plots were used to estimate survival, with Log‐Rank tests used for comparison.

**Results**: Thirty three patients were identified (26 males, 7 females). Median age was 3.1 (range=1‐23); 50% were *MYCN*+. The majority were INRGSS stage M (n=29, 91%). Over 90% resection was achieved in 84% (n=27), compared to 16 % (n=6) with \<90% resection. Significant post‐operative complications occured in 8 patients (24%). Follow up ranged from 4‐108 months. Overall survival was 58% with no significant difference in survival between \>90% resection vs \<90% resection groups. Relapse occurred in 50% of patients (distant metastases n=14, local n=2).There was no correlation between degree of resection and overall relapse rate or survival. Radiologically detectable tumour on post‐operative imaging was not statistically significant factor for relapse (p=0.6), nor was *MYCN* amplification status.

**Conclusions**: Surgery for HRNB is associated with significant morbidity and the overall mortality. However, there was no observed effect of degree of resection or presence of post‐operative radiologically detectable tumour on recurrence or overall survival in patients in the HR‐NBL‐1 trial.

### PO-116. Cutting it to the Core in Neuroblastoma Biopsy: How Many Cores are Enough? {#pbc27455-sec-10840}

[S. Hotonu]{.ul} ^1^, K. Wood^2^, N. Bown^3^, L. McDonald^4^, P. Losty^5^, Q. Campbell‐Hewson^6^, D. Tweddle^6^, H. Gabra^7^

*^1^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Paediatric Surgery, Newcastle Uppon Tyne, United Kingdom; ^2^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Histopathology, Newcastle Uppon Tyne, United Kingdom; ^3^The Northern Genetics Service‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Cytogenetics, Newcastle Uppon Tyne, United Kingdom; ^4^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Radiology, Newcastle Uppon Tyne, United Kingdom; ^5^Alder Hey Children\'s Hospital‐ NHS Foundation Trust, Paediatric Surgery, Liverpool, United Kingdom; ^6^The Great North Children Hospital‐ Newcastle University Teaching Hospitals NHS Foundation Trust, Paediatric Oncology, Newcastle Uppon Tyne, United Kingdom; ^7^The Great North Children Hospital‐ Newcastle University Teaching Hospitals, Paediatric Surgery, Newcastle Uppon Tyne, United Kingdom*

**Background/Objectives**: Needle core biopsy (NCB) has been increasingly utilised in the diagnosis and biological staging for Neuroblastoma. It has proven to be safe and reliable. However, there is a lack of consensus regarding the gauge of the core needle used and the adequate minimal number of cores which are required to yield adequate tissues for histology and cytogenetics.

The aim is to develop UK guidelines for neuroblastoma core needle biopsy including the needle gauge and number of cores required to yield "an adequate biopsy".

**Design/Methods**: A retrospective audit of the all core biopsies received by the histopathology and cytogenetics laboratories at the Newcastle University hospitals in the period of 2011‐2016. Data included the needle gauge, number of cores received per biopsy, the total length of cores and the final outcome regarding the adequacy of the biopsy for diagnosis of neuroblastoma.

**Results**: A total number of 19 cores per biopsy were received. All cores were performed using 14‐16 G needles. The overall adequacy was 74% (n=14). The mean number and length of NCB that yielded adequate diagnosis was 4 cores (range 1‐9) and 25 mm (range 4‐ 54 mm) respectively. It appeared that the total length on NCB was more reliable indicator of the adequacy than the number of cores. Our impression that a total cores length of 25‐40 mm seemed to be the length of choice.

**Conclusions**: Our study reflects the current practice in a UK Neuroblastoma specialist centre as NCB is the approach of choice. It highlighted that the minimal total length of cores is more important factor that the minimal number of cores. There is a need to have national/International standard guidelines for Neuroblastoma. We propose size 14‐16G needle aiming for 6‐8 cores with a minimal total cores length of 25‐40mm.

### PO-117. "Pneumobladder": A New Mini‐Invasive Approach for the Diagnosis and Treatment of Intravesical Tumors in Children {#pbc27455-sec-10850}

[M. Ilari]{.ul} ^1^, G. Torino^1^, E. Brandigi^1^, G. Cobellis^1^, A. Martino^1^

*^1^"G. Salesi" Children\'s Hospital, Paediatric Surgery, Ancona, Italy*

**Background/Objectives**: In children, the diagnosis and treatment of the intravesical tumors, sometimes are very difficult, mostly if they are perimeatal. The "pneumobladder" is a new mini‐invasive technique utilized for the bladder surgery, but never used for diagnosis and treatment of intravesical tumors in paediatric age. In this study, we have evaluated our results regarding the use of pneumobladder tecnique for the diagnosis and treatment of intravesical tumors of their uncertain "behavior" in children.

**Design/Methods**: From December 2013 to December 2017, we have performed the pneumobladder technique to manage bladder tumors in 3 male patients of 19 months, 7 and 15 years respectively. The procedure starts with cystoscopic examination of the bladder and after a midline small skin incision the first 5 mm trocar is suprapubically introduced into the bladder. The two 5 mm lateral trocars are then introduced through the anterolateral wall of the bladder under cystoscopic or vesicoscopic vision, and the bladder is insufflated with carbondioxide to 8‐10 mmHg pressure.

**Results**: In one case a biopsy of the primary tumor was performed; in the other two cases it was possible the total removal of the papillomas that were "in close" connection with the ureteral meatus. The postoperative pain was controlled by intravenous injection of paracetamolo. Patients from our group had a mean hospital stay of 3 days. No conversion and surgical complication was observed.

**Conclusions**: The pneumobladder seems to be a feasible, safe and mini‐invasive technique for the diagnosis and treatment of intravesical tumors in children. Moreover, the pneumobladder could be an alternative procedure when the transurethral endoscopic technique is not practicable. Additional research studies to evaluate this new approach are anyway necessary.

### PO-118. Liver Transplant as Treatment of the Metastatic Gastrointestinal Stromal Tumors in Children not Responding to Medical Therapy {#pbc27455-sec-10860}

[M. Ilari]{.ul} ^1^, G. Torino^1^, E. Brandigi^1^, F. Mariscoli^1^, G. Cobellis^1^, A. Martino^1^

*^1^"G. Salesi" Children\'s Hospital, Paediatric Surgery, Ancona, Italy*

**Background/Objectives**: Gastrointestinal stromal tumours (GISTs) are neoplasms of mesenchymal smooth muscle. Their incidence during childhood, is about 0.02 cases per 1 million per year. All tumors of mesenchymal origin that express the membrane protein kit (CD117) or which have a mutation in platelet‐derived‐growth factor a (PDGFRA) should be considered as GISTs. Purpose of this study is to define the clinical‐pathological characteristics of GISTs in patients recruited in the Italian study TREP.

**Design/Methods**: All patients enrolled in this study were less than 16 years old at the diagnosis. Staging and follow‐up workup included the following investigations: digestive endoscopy, magnetic resonance imaging, and, in some cases, computed tomography. Samples of tumour tissue were also stained with the antibodies against KIT and PDGFRAa.

**Results**: Nine patients (5 male and 4 female) with GIST were enrolled in this study. Tumour was located in the stomach for 8 patients and in the ileum for 1 patient. All patients underwent sparing surgery. One patient with gastric GIST required afterward a radical gastrectomy because of a local recurrence. Three patients submitted to partial gastric resection have been underwent to following chemotherapy because of hepathic/peritoneal metastases; two of them responded to medical therapy, but one patient with multiple not resectable hepathic metastases, not responding to 4 courses of chemotherapy, has been submitted to liver transplant and at 10 months follow‐up is disease free. All patients are alive up to now.

**Conclusions**: To date there are no concordant international guideline regarding the treatment of GISTs during childhood. However, it is important to remember that for children affected by GISTs the 5‐year probability of survival is 90%, therefore sparing surgery should be considered even in cases of multifocal disease or local nodal metastases. Finally, the liver transplant could be an option to manage children affected by metastatic gastrointestinal stromal tumors not responding to chemotherapy.

### PO-119. Reduction of Complication Rate in Neuroblastoma Surgery after Centralization of Care {#pbc27455-sec-10870}

[M. Jans]{.ul} ^1^, C. Terwisscha van Scheltinga^1^, C. van de Ven^1^, G. Tytgat^2^, M. Wijnen^1^

*^1^Princess Máxima Center for Pediatric Oncology, Pediatric Surgery, Utrecht, The Netherlands; ^2^Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands*

**Background/Objectives**: In a previous study we described peri‐operative complications in Neuroblastoma surgery up to 46%. Since 2015 surgical care for neuroblastoma (NBL) in The Netherlands has been centralized at the Princess Máxima Center for Pediatric Oncology, increasing the number of performed procedures. This study evaluates if centralization of care improves surgical complications and mortality.

**Design/Methods**: A prospective observational cohort study was conducted including all children treated for NBL in the period 2015‐2018 at the Princess Máxima Center. Surgery related complications and mortality were documented. Outcome is compared with results of our previous study from the 1998‐2014 cohort, when surgical treatment for NBL in the Netherlands was performed in five different centers.

**Results**: All children were treated according to the DCOG‐NBL 2009 protocol. Three surgeons performed primary tumor resections for NBL in 54 children. INSS stage I/II was found in 16%, Stage III in 20%, Stage IV in 64%. Sixty‐two percent were high‐risk. The tumor was situated in the abdomen in 91%. IDRFs were present at time of surgery in 63%. The total intra‐operative complication rate was 20% (vs. 46% in cohort 1998‐2014). Major intra‐operative complication rate was 7% (vs. 30%) and major hemorrhage rate was 4% (vs. 28%). Loss of a kidney occurred in 2% of children (vs. 8%). Short‐term post‐operative complications occurred in 30% of children (vs. 41%), 28% concerned Clavien‐Dindo 1‐2 complications (vs. 32%) and 9% Clavien‐Dindo 3‐5 complications (vs. 14%). Postoperative PICU support due to complications was necessary for 2% (vs. 6%), secondary surgery for 9% (vs. 6%). Surgery related mortality did not occur (vs. 2%).

**Conclusions**: Since the start of centralized surgical care for neuroblastoma in The Netherlands, intra‐operative complication rate clearly improved. The postoperative short‐term complication rate did also improve. These findings demonstrate the possible benefits of centralization of complex surgery.

### PO-120. Pediatric Non‐Wilms Renal Tumors: Review of Clinico‐Pathological Behaviour, Treatment and Outcome from a Tertiary Care Center, India: A Single Institution Experience {#pbc27455-sec-10880}

[B. Jindal]{.ul} ^1^, K. Sambadan^1^, B.K. Naredi^1^, K. Govindarajan^1^, B. Dubashi^2^, D. Bhararthi^3^, S. Bh^4^

*^1^Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Department of Pediatric Surgery, Pondicherry, India; ^2^Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Department of Medical Oncology, Pondicherry, India; ^3^Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Department of Radiology, Pondicherry, India; ^4^Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Department of Pathology, Pondicherry, India*

**Background/Objectives**: Renal tumors accounts for 7% of all childhood cancer and of these Wilms tumors (WT) are the most common pediatric renal tumors. Renal tumors other than WT also called as pediatric non‐Wilms renal tumor (NWRT) are infrequent (account for less than 1%) in childhood. They always pose a diagnostic and therapeutic challenge because of their heterogeneity and poor understanding of pathological behavior.

**Design/Methods**: Retrospective review of records of all infant and children treated for Pediatric Non‐Wilms renal tumors from 2009 to 2017 and analyzed in relation to clinical presentation, diagnosis, pathological behavior and outcome.

**Results**: Of the 11 cases of pediatric non‐Wilms renal tumors, the most common tumors included were mesoblastic nephroma (3), followed by clear cell sarcoma (3), cystic nephroma (2), Xp11.2 translocation renal cell carcinoma (TRCC) (1), primary primitive neuro‐ectodermal tumor (PNET) of kidney (1) and a case of cystic partially differentiated neuroblastoma (CPDN) in a bilateral WT. Usual presentation were abdominal mass and hematuria. All the patients had undergone upfront surgery except for three patients that received neo‐adjuvant chemotherapy. Disease relapse was seen in one patient (PNET), who refused further treatment and lost to follow up. All the other children are in follow up with no recurrence.

**Conclusions**: Pediatric NWRTs comprise less than 25% of all renal mass in our study and are to be considered when presented at unusual age (\< 6months or \> 5 years) and the approach (upfront surgery/neoadjuvant chemotherapy followed by surgery) depends age at presentation and imaging. The overall outcome in general is very good and depends upon histology and staging. Of all the NWRT, renal PNET and malignant rhabdoid tumor of kidney have very poor prognosis.

### PO-121. Circulating *MYCN* DNA as a Tumor‐Specific Marker in Neuroblastoma {#pbc27455-sec-10890}

[J. Karpelowsky]{.ul} ^1^, S. Kahana‐Edwin^2^, F. Saletta^2^, G. McCowage^3^, T. Toby^4^, F. Jamie^5^

*^1^University of Sydney, Children\'s Cancer Research Unit‐ Department of Paediatric Surgery, Sydney, Australia; ^2^University of Sydney, Children\'s Cancer Research Unit, Sydney, Australia; ^3^Children\'s Hospital At Westmead, Paediatric Oncology, Sydney, Australia; ^4^Children\'s Cancer Institute, Paediatric Oncology, Sydney, Australia; ^5^Children\'s Cancer Institute, Neuroblastoma Project leader, Sydney, Australia*

**Background/Objectives**: Liquid biopsy approaches for solid paediatric malignancies are lagging, mainly due to the rarity of cancers, overall low mutational burden and the lack of recurrent oncogenic point mutations. *MYCN* oncogene amplification drives the development of about 20% of neuroblastoma, and is routinely assayed for therapy stratification. We suggest using circulating *MYCN* DNA copy number as a liquid biopsy test for *MYCN*‐amplified neuroblastoma (MAN).

**Design/Methods**: Using ddPCR we developed *MYCN* copy number variation assay. We evaluated its limit of detection in cell lines. We tested 5 cell lines (2 MAN, 3 non‐MNA), 1 non‐MAN tumour, tumour and matched plasma samples from n=3 patient derived MAN xenografted mice (PDX), and a plasma sample from one patient with metastatic MAN.

**Results**: Circulating *MYCN* DNA copy number evaluation is very specific and *MYCN* copy number gains / amplifications were found only in n=8 MAN samples (out of 12). the limits of detection for detect *MYCN* amplification was 1 cell per 9 cells of normal diploid background, and *MYCN* gain 1 cell per 99 cells of normal diploid background. All PDX plasma samples were positive for *MYCN* amplification at the same levels as PDX tumours. For the tested patient\'s plasma sample, we were able to detect *MYCN* amplification of 35 copies per haploid genome.

**Conclusions**: Our results show that the sensitivity of the ddPCR‐based *MYCN* copy number determination highly depends on the normal diploid background. Measurement of plasma *MYCN* copy number is a simple, reproducible, and minimally‐invasive assay that may represent a reasonably sensitive and very specific tool. This is a proof of principle for *MYCN* copy number based liquid biopsy test and seems to be a promising method for accurately assessing MAN, although a larger set of patients needs to be examined to confirm this result.

### PO-122. Sacrcoccygeal Teratoma: Long Term Outcomes in Terms of Urological and Bowel Problems, Cosmesis and Gait {#pbc27455-sec-10900}

[K. Khanna]{.ul} ^1^, S. Agarwala^1^, M. Bajpai^1^, S. Maddur^1^, V. Bhatnagar^1^

*^1^All India Institute of Medical Sciences, Pediatric Surgery, New Delhi, India*

**Background/Objectives**: To study the patients with sacrococcygeal teratoma(SCT) for long term outcomes in terms of urological, bowel, cosmetic and gait disturbances.

**Design/Methods**: A prospective cross‐sectional study conducted in the solid tumor clinic of the department to include cases of SCT operated from Jan.‐2002 till June 2015. Data pertaining to the clinical details, Altman type, treatment, histology, and follow‐up in terms of urological, bowel, cosmetic and gait disturbances were analysed.

**Results**: Fifty‐seven patients reported for evaluation. Their mean age at presentation was 16.2+19.7months(8days‐84months), at follow up was 70.8+41.3months(7‐84months) and the period of follow‐up was 54.58+37.45months(4‐133months). Forty‐two(73.7%) were females. Twenty‐two(38.6%) were malignant and 35(61.4%) benign. The common presenting complaints were mass in 51(89.47%), constipation 19(33.33%), urinary retention 11(19.29%), pain 5(8.77%) and local recurrence 2(3.5%). The Altman Type 1,2,3 and 4 were present in 8(14%), 26(45.6%), 19(33.3%) and 4(7%). Thirty‐five patients with benign disease had undergone upfront surgical resection. Of 22 with malignant disease, 9(41%) had undergone surgery after neoadjuvant chemotherapy and 13(59%) upfront surgery followed by adjuvant chemotherapy(PEB regimen). The average tumor size was 8.17+4.45cm. Histopathology (with/without chemotherapy) revealed 39(68.4%) mature teratomas, 7(12.3%) immature teratomas, 6(10.5%) yolk sac tumors, 4(7.0%) mixed pathology and 1(1.8%) with no viable tumor. Seventeen of 31(54.8%) patients \> 6 months of age had malignant disease as compared to 5/26(19.2%) \< 6months (Hazard ratio=3.5,SE=1.8,p=0.008). Twenty‐eight(49.1%) had urological and/or bowel problems, 22(38.6%) had cosmetic issues, 2(3.5%) had gait related problems. However, 50/53(94.3%) had a good quality of life (QLI score \>8). Higher incidence of bladder dysfunction was significantly associated in patients with malignant disease(p=0.05) and those with intra‐operative rectal involvement(p=0.02). However, no significant association was observed with the age, sex, Altman type and the number of surgeries.

**Conclusions**: Operated patients of SCT have long term urological, bowel, cosmetic and gait problems. However, these are mild and do not affect the quality of life.

### PO-123. The Incidence of Associated Abnormalities in Patients with Sacrococcygeal Teratoma {#pbc27455-sec-10910}

[M. Kremer]{.ul} ^1^, J. Altman^1^, J. Derikx^2^, R. van Baren^3^, H. Heij^2^, M. Wijnen^4^, R. Wijnen^5^, D. van der Zee^6^, E. van Heurn^2^

*^1^MUMC, Pediatric Surgery, Maastricht, The Netherlands; ^2^AMC and VU Medical Centre Amsterdam, Pediatric Surgery, Amsterdam, The Netherlands; ^3^UMC Groningen, Pediatric Surgery, Groningen, The Netherlands; ^4^Prinses Maxima Centrum Utrecht, Pediatric Surgery, Utrecht, The Netherlands; ^5^Erasmus MC Rotterdam, Pediatric Surgery, Rotterdam, The Netherlands; ^6^Wilhelmina Kinderziekenhuis Utrecht, Pediatric Surgery, Utrecht, The Netherlands*

**Background/Objectives**: Gross genetic causes for sacrococcygeal teratoma (SCT) are unknown; however, it might be associated with other abnormalities. We assessed the incidence of associated abnormalities in a large national cohort of neonates with SCT and aimed to identify predictive risk factors.

**Design/Methods**: The medical records were reviewed of 235 consecutive neonates with SCT treated at the six pediatric surgical centers in the Netherlands from 1970 to 2010. Potential risk factors for associated abnormalities analyzed included sex, gestational age, tumor‐volume/histology and Altman‐classification.

**Results**: In 76 patients (32.3%) at least one associated abnormality was diagnosed, with hydronephrosis as the most common (16.2%) and hip dysplasia in 4.3%. Multiple abnormalities were documented for 21 (9.0%). Prematurity and Altman type IV SCT were associated with an increased risk of any associated abnormality. No association between increased tumor‐volume and hydronephrosis or hip dysplasia was found. Patients with type IV Altman SCT had a fourfold risk of suffering from hydronephrosis compared to Altman type I SCT. An additional logistic regression analysis was performed distinguishing between potentially acquired abnormalities owing to tumor extension or surgical treatment and true congenital malformations (e.g. esophageal atresia, renal agenesis, Fallot\'s tetralogy, congenital hyperthyreosis or omphalocele). Altman type and tumor histology were not related to the occurrence of congenital malformations in patients with SCTwhile prematurity was associated with a higher risk of the occurrence of true congenital malformations.

**Conclusions**: Sacrococcygeal teratoma was associated with other abnormalities in one‐third of the children. Some were tumor‐related while others were related to prematurity or occurred sporadically. The incidence of congenital abnormalities was slightly higher compared to the general European population. In contrast to clinically obvious anomalies, hip dysplasia or hydronephrosis might be latently present with more subtle clinical presentation. We therefore suggest renal‐ and hip‐ultrasound in all patients, certainly those with Altman type IV SCT.

### PO-124. Complications after Excision of Retroperitoneal Tumours in Children {#pbc27455-sec-10920}

[B. Kumar]{.ul} ^1^, V.D. upadhyaya^1^, N. Mutt^1^, M.K. Gupta^1^, S.K. Rahul^1^

*^1^Sanjay Gandhi Post Graduate Institute of Medical Sciences, Paediatric Surgical Superspeciality, Lucknow, India*

**Background/Objectives**: Peri‐operative complications are well known morbidity in the treatment of patients with malignancy and associated with prolonged hospital stay, even mortality. Aim of this study is to present our peri‐operative problems and morbidity associated with management of retroperitoneal/renal tumours in children.

**Design/Methods**: We included all patients operated (complete or partial excision) between July 2012 to July 2017 for retroperitoneal mass with complete records and followed‐up for minimum 6 months. Peri‐operative complications and morbidity were assessed and correlated with size/stage/type/site of tumour and age of patient.

**Results**: Total 34 patients were included in the study in which 11 were germ cell tumour (3 yolk sac tumour, 2 immature and 6 mature teratoma), 6 wilms tumour, 1 clear cell sarcoma, 1 rhabdoid tumour of kidney, 9 neuroblastoma, 2 primitive neuroectodermal tumour, 2 rhabdomyosarcoma and 2 patient had the diagnosis of pseudotumour. 8 patients were female and age ranged from 2 months to 16 years (median age 8 year). Partial excision/biopsy was done in 4 patients and almost complete excision was performed in rest of patients. Nephrectomy was done in 10 patients. 26 peri‐operative problems encountered in 12 patients which include excessive bleeding (3), excision of part of adjacent organ (2), hypothermia (2) and respiratory problems (6), immunosupression (1), wound infection (4) and adhesive bowel obstructions in 8 patients in which 6 required re‐explorations and adhesiolysis and stoma in one patient. 2 patients were died while 4 were lost in follow‐up. Follow‐up period ranged from 6 -- 48 months.

**Conclusions**: Surgical morbidity depends on size and site of tumour and age of patient. High incidence of adhesive bowel obstruction and morbidity encountered because of excessive dissection and relative large size of tumour with age.

### PO-125. The Surgical Choice for Unilateral Thyroid Carcinoma in Pediatrics: Lobectomy or Total Thyroidectomy? {#pbc27455-sec-10930}

[K. Li]{.ul} ^1^

*^1^Children\'s Hospital of Fudan University, Department of Pediatric Surgery, Shanghai, China*

**Background/Objectives**: Total thyroidectomy is no doubt the standard procedure for patient with bilateral thyroid carcinoma in pediatrics. However, for lesion confined in unilateral thyroid gland, lobectomy or radical total thyroidectomy is still controversial in pediatrics.

**Design/Methods**: Thirty‐five cases of pediatric thyroid carcinoma who were confirmed by pathology were retrospectively analyzed in our hospital from 2005‐2016. In 13 cases of unilateral lesions, 6 received lobectomy while others underwent total thyroidectomy. Recurrence and complications were compared between 2 groups. Also, there were 20 cases of primary total thyroidectomy and 4 cases of supplementary resection of residual gland, the short‐term complications were compared.

**Results**: There were no differences between groups of lobectomy and total thyroidectomy in size, extra‐thyroid extension, stage, cervical lymph nodes metastases, and distant metastases (table 1). There were same in incidence of postoperative hypocalcemia, calcium supplement, recurrent laryngeal nerve damage, recurrence rate and mortality, except that the length of stay in hospital was shorter in group of lobectomy (table 2). Patients in supplementary resection were more likely to present the symptoms of postoperative hypocalcemia, hypokalemia and were difficult to identify parathyroid gland during operation by comparing with patients of primary total thyroidectomy (table 3).

**Conclusions**: Thyroid carcinoma in pediatrics inclines to be multifocal, even a single focus, the volume is large. Total thyroidectomy does not bring much more complications, in contrast, the morbidity increases in staged resection. Endocrine hormone supplement can satisfy the need of growth and development.

### PO-126. Neoadjuvant Regional Intraarterial Chemotherapy in Combination with Systemic Chemotherapy for Treatment of Advanced Pelvic Malignant Tumors in Children {#pbc27455-sec-10940}

[M.J. Li]{.ul} ^1^, D.X. Tang^1^, S. Xu^1^, J.H. Wang^1^, C. Lai^2^, Q. Shu^1^

*^1^The Children\'s Hospital‐ Zhejiang University School of Medicine, Department of Pediatric Surgery, Hangzhou, China; ^2^The Children\'s Hospital‐ Zhejiang University School of Medicine, Department of Radiology, Hangzhou, China*

**Background/Objectives**: We present our experience of neoadjuvant regional intraarterial chemotherapy in combination with systemic chemotherapy for treatment of advanced pelvic malignant tumors in children.

**Design/Methods**: From 1999 to 2013, twenty‐four patients (8 males and 16 females) with advanced pelvic malignant tumors received neoadjuvant alternating intra‐arterial chemotherapy and systemic chemotherapy. The median age at diagnosis for patients was 3 years (range 0.5‐14.4 years). The location and histopathological types of the tumors were: bladder/ prostate in 8 cases (7 rhabdomyosarcoma and 1 Inflammatory myofibroblastic tumor); pelvic retroperitoneum in 6 cases (5 endodermal sinus tumor and 1 rhabdomyosarcoma); ovarian tumor in 4 cases (4 endodermal sinus tumor); and vaginal tumor in 6 cases (3 rhabdomyosarcoma and 3 endodermal sinus tumor). Three of these patients had lung metastasis at admission.

The select artery for arterial infusion chemotherapy were bilateral internal iliac arteries. The infused drugs were cisplatin, pirarubicin, and vindesine. Intravenous chemotherapy consisted of vindesine, ifosfamide and etoposide administered 3 weeks after arterial chemotherapy. Alternating arterial and intravenous chemotherapy were repeated with a 3‐week interval for 1 to 3 courses before operation. After operation, the patients underwent chemotherapy and radiotherapy.

**Results**: The most common side effects were grade Ⅱ‐Ⅲ bone marrow suppression, mild nausea and vomiting. No cardiotoxicity, nephrotoxicity or hepatic dysfunction were observed during neoadjuvant therapy. Tumors were significantly reduced after preoperative treatment. Four patients with vaginal tumor didn\'t need surgery due to tumor necrosis and fall off. Twenty patients received surgery, and 16 patients received radiotherapy after surgery. The duration of follow‐up ranged from 4.8 to 18.1 years (median 9 years). The event‐free survival rate was 79.1% (19/24) and overall survival rate was 83.3% (20/24).

**Conclusions**: Neoadjuvant alternating arterial and intravenous chemotherapy is safe and effective for the treatment of advanced malignant pelvic tumors in children.

### PO-127. Evaluation of a Bony Landmark‐Based Method for Teaching Percutaneous Insertion of Subclavian Venous Catheters in Paediatric Patients {#pbc27455-sec-10950}

Z.J. Lin^1^, Y.T. Lee^2^, J.H.Y. Chua^3^, R. Wang^4^, V. Lee^4^, S.M. Cheah^5^, S.E. Saffari^6^, J.C.M. Lam^7^, [A.H.P. Loh]{.ul} ^2^

*^1^Flinders University, Flinders University School of Medicine, Melbourne, Australia; ^2^KK Women\'s and Children\'s Hospital, Department of Paediatric Surgery, Singapore, Singapore; ^3^Raffles Hospital, Children\'s Centre, Singapore, Singapore; ^4^National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore; ^5^KK Women\'s and Children\'s Hospital, Department of Paediatric Medicine, Singapore, Singapore; ^6^Duke NUS Medical School, Centre for Quantitative Medicine, Singapore, Singapore; ^7^KK Women\'s and Children\'s Hospital, Department of Paediatric Subspecialties Haematology Oncology Service, Singapore, Singapore*

**Background/Objectives**: Learning efficient, safe and accurate placement of central venous access devices (CVAD) is essential in paediatric surgical oncology training. The commonest technical errors in subclavian vein (SCV) cannulation are related to incorrect visualization of anatomical structures and wrong needle trajectory. To improve mental visualization of the venous anatomy and surrounding structures, we designed and taught paediatric surgical trainees a novel method of SCV cannulation which uses the coracoid process and Halsted ligament as bony landmarks, and compared training outcomes with SCV cannulations taught using the classic surface landmark‐based approach.

**Design/Methods**: We prospectively recorded patient, surgeon and operative details on all Hickman line and port‐a‐cath insertions performed over 6 years. During two equal 3‐year periods (2011‐2014 and 2014‐2017), trainees were taught surface‐ and bony‐landmark approaches, respectively. We studied CVAD placements where supervised trainees--as the first surgeon--performed blind percutaneous SCV cannulation, and compared procedural duration, number of cannulation attempts and operative complications in both periods.

**Results**: In total, 271 cases were included in the study. Trainees performed 52 (50.5%) and 92 (54.8%) procedures in the first and second periods, respectively. Patients in both periods did not differ by gender, cancer type, CVAD device, or prior CVAD, chemotherapy or infection status. In the second (bony landmark) period, patients were younger (6.0 vs 8.7 years, P=0.003) but mean procedural duration was shorter (42.5 vs 58.3 minutes, P\<0.001), and the left SCV was used more often (P\<0.001); mean attempts at SCV cannulation and incidence of operative complications did not differ significantly between study periods (P=0.257 and 1.0, respectively).

**Conclusions**: With the new pedagogy, trainees could perform the procedures faster despite operating on younger patients, without impacting complication rates and cannulation attempts. Bony landmarks may better approximate SCV position across a range of body sizes and habituses, thus improving the consistency of SCV cannulation in CVAD placements in children.

### PO-128. Surgical Treatment of Pancreatic Tumors in Children {#pbc27455-sec-10960}

[A. Lukashenko]{.ul} ^1^, O. Kolesnik^2^, G. Klimnyuk^3^, Y. Ostapenko^1^, N. Chorna^1^

*^1^National Cancer Institute, Minimally invasive and endoscopic surgery‐ interventional radiology, Kiev, Ukraine; ^2^National Cancer Institute, Department of Tumors of Abdominal Organs and Retroperitoneal Space, Kiev, Ukraine; ^3^National Cancer Institute, Department of Pediatric Oncology, Kiev, Ukraine*

**Background/Objectives**: Pancreatic tumors in children are uncommon. he knowledge of their presentation accrues principally through institutional case series. The very limited experience, together with the broad histological heterogeneity, has made it difficult to identify possible prognostic factors and develop treatments protocol. The aim of the present paper was perfection treatment of pancreatic tumors in children.

**Design/Methods**: Retrospective review of medical records and pathology reports of children who underwent surgery at National Cancer Institute from 1990 through 2018. From mentioned period 21 patient in age younger then 18 underwent surgical treatment for pancreatic tumors.

**Results**: Radical (R0) surgical resection was achieved in 20 patients (95,2%). In 11 (55%) cases distal pancreatic resection were performed accordingly to localization of the tumor in pancreatic body or tail. Pancreatoduodenectomy (PD) was performed in 7 (33,3%) cases. Organ‐preserving approach was used for 7 patients: enucleations for tumor of pancreatic tail in 1 case (4,7%), spleen preserving distal pancreatectomy in 4 (19%) cases. There was no postoperative mortality, but postoperative complications occurred in 4 patients (q9%) and was treated conservatively. The median follow‐up consist 124 months (range 16‐312 months). No patients had postoperative pancreatic exocrine or endocrine insufficiencies. At the present day all patient are alive.

**Conclusions**: Pancreatic tumors in children has more favorable outcomes in compare to adults. Surgical treatment is the prominent method for pancreatic tumors in children. Pancreatic resection for pancreatic tumors in children should performed in high‐volume surgical center.

### PO-129. One‐Lung Ventilation in Pediatric Thoracic Surgical Oncology {#pbc27455-sec-10970}

[N. Matinyan]{.ul} ^1^, L. Martynov^1^

*^1^N.N. Blokhin Russian Cancer Research Center‐ Pediatric Oncology and Hematology Institute, Anesthesiology, Moscow, Russia*

**Background/Objectives**: In pediatric oncology, the lungs are the most frequent target of metastasis, so diagnostic and therapeutic surgeries are required. To guarantee optimal conditions for surgery, collapse of operated lung is required, thus one lung ventilation (OLV) should be performed. Novel devices for OLV, such as bronchial blockers (BB) Cohen, EZ‐Blocker and Arndt allow to achieve lung collapse avoiding traumatisation of trachea and other complications. Our experience of use of BB is presented. Aim of study is to improve the efficiency and safety of lung ventilation in thoracic surgical oncology in children.

**Design/Methods**: During September 2014 ‐ March 2018 82 surgeries in patients 10‐17 y/o were performed. OLV was achieved and mantained using BB. BB was introduced through the lumen of video endobronchial tube and was placed into the bronchus under continuous video control. Installation of Arndt BB was conducted under endoscopic control. In 37 cases (45%) right and in 45 cases (55%) ‐ left main bronchus was blocked. Time of BB installation, lung collapse score, hemodynamics, frequency of postoperative complications such as sore throat and aphonia were evaluated.

**Results**: The mean time of intubation and BB installation was 122 +/‐ 47seconds. In all cases it was possible to achieve lung collapse. Ensuring the collapse of the right lung presents some difficulties due to the anatomical and physiological features as higher embranchement of the right upper lobe bronchus. In this case the use of EZ‐Blocker BB is preferable as it is designed to provide stability with respect to carina, making it less likely to displace during surgery. In surgeries of the left lung the use of Cohen BB is more preferable.

**Conclusions**: BB in thoracic surgery in pediatric oncology is promising technique to achieve the effective collapse of lung on side of operation with minimal traumatisation, fewer complications postoperatively and rapid rehabilitation after anesthesia.

### PO-130. The Evidence for Cytoreductive Surgery and (Hyperthermic) Intraperitoneal Chemotherapy ((H)IPEC) in Children: A Systematic Review of the Literature {#pbc27455-sec-10980}

[L. Matthyssens]{.ul} ^1^, A. Claeys Bouuaert^2^, D. Van de putte^1^, K. Van Renterghem^1^, W. Willaert^1^, W. Ceelen^1^

*^1^Ghent University Hospital, Dept of Gastrointestinal and Paediatric Surgery, Ghent, Belgium; ^2^Ghent University, Dept of Gastrointestinal and Paediatric Surgery, Ghent, Belgium*

**Background/Objectives**: Cytoreductive surgery (CRS) and (hyperthermic) intraperitoneal chemotherapy ((H)IPEC) are increasingly used in the treatment of several tumours in adult patients. Clinical evidence for the use of (H)IPEC in children remains rare.

We aimed to investigate the evidence in the literature for a survival benefit and under which circumstances CRS+(H)IPEC may be beneficial in children.

**Design/Methods**: Systematic review of the literature according to the PRISMA guidelines. Three different sets of keywords were entered in PubMed, Embase and Web of Science. After duplicate removal, 283 remaining abstracts were screened for eligibility. 114 full‐text articles possibly containing data of a (H)IPEC‐procedure in a child up to the age of 18 years were assessed by two independent researchers. Only full‐text articles meeting the inclusion criteria and containing individual patient data were selected.

**Results**: Seventeen original articles were identified describing 51 children who underwent CRS+(H)IPEC. There were nine case reports or case series, five retrospective observational studies, two articles based upon retrospective surveys and one single‐arm phase‐II trial. Qualitative assessment of survival gain by (H)IPEC was impossible because of methodological limitations or too little data transparency. Indications, pre‐ and postoperative treatments and (H)‐IPEC‐parameters varied in every article. Combining all information, it appears that every patient had a unique treatment trajectory. Lack of standardisation prevented further analysis since no comparison was possible. Purely observational, (H)IPEC possibly has an effect on survival of mesothelioma. For sarcomas, carcinomas and germ cell tumours, this effect remains unclear.

**Conclusions**: Heterogeneity of 51 patients described in the literature prevented a valid analysis about a possible survival gain by (H)IPEC in children. Summarising all articles on (H)IPEC in children, robust evidence is lacking. An international database of children undergoing CRS+(H)IPEC may improve data quality and transparency. The few centers performng (H)IPEC in children should consider working together to study and potentially standardise the procedure.

### PO-131. Radiologic‐Guided Biopsies of Pediatric Tumors: A Systematic Review {#pbc27455-sec-10990}

[V. Montano]{.ul} ^1^, E. Zambaiti^2^, A. Siles Hinojosa^3^, A. Mutanen^4^, M. Glenisson^5^, S. Franchi‐Abella^6^, S. Sarnacky^7^, D. Pariente^6^, L. Pio^7^

*^1^Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Pediatric Surgery, Milan, Italy; ^2^Università degli studi di Padova, Pediatric Surgery, Padova, Italy; ^3^Miguel Servet Univerisity Hospital, Pediatric Surgery, Zaragoza, Spain; ^4^Helsinki University Central Hospital, Section of Pediatric Surgery, Helsinky, Finland; ^5^Robert Debrè Children Univeristy Hospital‐ APHP, Department of Pediatric Surgery and Urology, Paris, France; ^6^Bicetre Hospital ‐ AP‐HP‐ Le Kremlin‐Bicetre‐, Pediatric Radiology, Paris, France; ^7^Hospital Bicetre Assistance Publique Hospital de Paris, Pediatric Surgery Department Hopitaux Universitaires Paris Sud, Paris, France*

**Background/Objectives**: Radiologic‐guided biopsies are widely used in adults but only recently introduced in the evaluation of paediatric tumours. The development of interventional radiologic techniques (especially ultrasonography) changed the approach of the surgeons to the world of biopsy, focusing on the diagnostic utility of non‐open biopsies versus surgical biopsies. The aim of our review is to determine, according to present literature, diagnostic accuracy and safety of radiologic‐guided biopsies in paediatric patients.

**Design/Methods**: We conducted a systematic review of peer‐reviewed articles published between 1980 and 2017. Searching terms were "paediatric oncology", "biopsy" and "interventional radiology". Manual screening of reference in other papers was also performed. Report with less than 10 patient, patients older than 18 years, studies concerning lymphomas/leukemia, retinoblastoma, cerebral and musculoskeletal tumours were excluded. We analysed dichotomous and continuous variables by appropriate statistical methods.

**Results**: Of more than of 158 papers analysed, we included in the review 8 papers, all retrospective. Pathologies biopsied were in 6 papers neuroblastoma, 1 thyroid nodules and 1 soft‐tissues tumours. Mean number of patients included in the studies was 77 (±51). Results are very variable. Regarding the possibility to retrieve sufficient tissue for histological classification, some papers assess adequate tissue for diagnosis while others insufficiency with guided biopsies compared to open, but the advantage of sampling various parts of the tumour. Complications are overall considered to be less with the radiological‐guided technique, by minimizing bleeding. Finally, a multicentric study reported that video‐assisted needle core biopsy can be a better option in that patients who are not candidates to imaging‐guided biopsies.

**Conclusions**: Radiologic‐guided biopsy is a valuable clinical tool for diagnosis of paediatric neoplastic lesions, it can provide real‐time visualization of the needle tip to the targeted area, with lower complications rates compared to surgery. Real efficacy and adequacy of sampling however needs further assessment.

### PO-132. Factors Affecting Perioperative Outcomes in Children Undergoing Neuroblastoma Surgery in a Tertiary Cancer Hospital in India: A Prospective Observational Study {#pbc27455-sec-11000}

[N. Amin]{.ul} ^1^, M. Desai^1^, J. Doctor^1^, B. Trivedi^1^, S. Qureshi^2^

*^1^Tata Memorial Centre, Anaesthesia‐ Critical Care and Pain, Mumbai, India; ^2^Tata Memorial Centre, Department of Pediatric surgical oncology, Mumbai, India*

**Background/Objectives**: Neuroblastoma is the commonest extracranial tumor of childhood. It arises from the neural crest of sympathetic nervous system and encases major vessels like aorta and IVC, hence these surgeries can last for a long duration and may be associated with blood loss and fluid shifts.

The aim of this study was to identify factors predicting morbidity in children undergoing neuroblastoma surgery.

**Design/Methods**: Perioperative outcome data was prospectively collected from children who underwent neuroblastoma surgery between Jan 2013 and Dec 2017. Morbidity was defined as ICU stay more than 48hrs, readmission, resurgery, mechanical ventilation and need for respiratory or cardiovascular interventions in the perioperative period.

**Results**: One hundred and forty‐nine patients (86 males and 63 females) with a median age of 3yrs (3mts‐12 years) underwent surgery for abdominal (79%), thoracic (18%) and cervical (3%) neuroblastoma. Preoperative hypertension seen in 7.4% patients. Median duration of surgery was 5 hours (1:30‐11 hours). Intraoperative hypotension occurred in 37.6% patients and 4.7% needed vasopressors in the perioperative period. There was no association between preoperative hypertension and the need for vasopressors. Median blood loss was 13.6ml/kg (1‐200ml/kg) with 8% patients having loss \>1 blood volume. Median intraoperative fluid administered was 11 ml/kg/hr (2 ml‐61ml/kg/hr). Postoperative ventilation required in 14% patients. One patient had acute renal failure needing dialysis in the post‐operative period. 8.7% were readmitted for respiratory distress. Median ICU stay 38 hours IQR \[21‐50 hours\] and hospital stay 7 days IQR \[5‐9 days\]. 38.3% patients had morbidity. Fluids \> 12 ml/kg/hr (p=0.003) OR 3.4 (CI 1.5‐7.5) and surgical duration\> 5 hours (p=0.03) OR 2.5 (CI 1.1‐5.7) predicted morbidity. ICU and hospital mortality was 1.3% and 2.7% respectively.

**Conclusions**: In our study morbidity following neuroblastoma surgery was unrelated to age, stage or site of the disease but was strongly related to the duration of surgery and intraoperative fluid volume.

### PO-133. Factors Responsible to Stage III Disease in the Patients with Wilms Tumor Treated in the JWiTS‐2 Study {#pbc27455-sec-11010}

[T. Oue]{.ul} ^1^, K. Fukumoto^2^, R. Souzaki^3^, T. Takimoto^4^, T. Koshinaga^5^

*^1^Hyogo College of medicine, Pediatric Surgery, Nishinomiya, Japan; ^2^Shizuoka Children\'s Hospital, Pediatric Surgery, Shizuoka, Japan; ^3^Kyushu University, Pediatric Surgery, Fukuoka, Japan; ^4^National Center for Child Health and Developmemt, Center for Clinical Research and Development, Tokyo, Japan; ^5^Nihon University, Pediatric Surgery, Tokyo, Japan*

**Background/Objectives**: Treatment is more intensive for stage III, than for stages I and II non‐metastatic Wilms tumors (WT). Various factors including tumor spillage, unresectability, and lymph node metastasis are responsible for stage III disease. The present study aimed to determine clinical factors that are associated with the features of stage III WT to establish new treatment strategies.

**Design/Methods**: Among 166 patients with non‐metastatic WT enrolled in the Japan Wilms Tumor Study (JWiTS)‐2, 51 had stage III disease. The treatment protocol of JWiTS‐2 was essentially the same as that in the National Wilms Tumor study (NWTS)‐5. Local hospitals were surveyed to collect details of clinical findings related to stage III disease and data regarding 45 (88%) patients were obtained.

**Results**: 1. Nine patients with massive tumors underwent pre‐operative chemotherapy. Biopsy was performed in 6. Reduction in the tumor size was achieved in 8 of the 9 cases. Nephrectomy was finally performed in all of them.

2\. Thirty‐six patients underwent primary nephrectomy. The reason for the stage III disease was lymph node metastasis (n=9), tumor spillage (n=20), and tumor extension/incomplete resection (n=17). Some patients had more than one of these factors. Tumor spillage significantly correlated with tumor size, vascular compression, and contralateral extension.

3\. Most patients were treated with the DD‐4A regimen and 43 (95.6%) of the 45 patients received abdominal radiation therapy.

4\. Tumors recurred in three patients (local, 1; metastasis, 2) and two patients died. Rates of overall and relapse‐free survival were 95.2% and 90.8%, respectively.

**Conclusions**: The prognosis of stage III WT was good. Therefore, the doses of chemotherapy and radiotherapy should be reduced to avoid late effects. The high rate of tumor spillage after primary resection suggests that a pre‐operative surgical risk classification system should be established to avoid too aggressive tumor resection.

### PO-134. Congenital Mesoblastic Nephroma: A Single Centre Series {#pbc27455-sec-11020}

[M. Pachl]{.ul} ^1^, B. Morland^2^, D. Hobin^2^, G.S. Arul^1^, I. Jester^1^

*^1^Birmingham Children\'s Hospital, Paediatric Surgery and Urology, Birmingham, United Kingdom; ^2^Birmingham Children\'s Hospital, Paediatric Oncology, Birmingham, United Kingdom*

**Background/Objectives**: Congenital mesoblastic nephroma (CMN) is a rare disease that is seen most commonly in children less than 6 months of age. Treatment is surgical in the first instance and chemotherapy is not thought to have a role in management of straightforward disease. Recent literature suggests a 50% mortality rate for recurrent/metastatic disease.

**Design/Methods**: This was a retrospective case note review of prospectively collected data in which patient demographics, histopathology, treatment, outcomes and follow up were reviewed.

**Results**: Nine patients were included(6 male, 3 female). Their age at presentation was a median of 1(range 0‐7) month(s) and follow up was a median of 8(range 0‐88) months. CMN sub‐types were cellular in 5, classical in 2 and mixed in the remaining 2. All patients underwent primary surgical resection with 8 patients having an open procedure and 1 laparoscopic. There were 3 recurrences in the group of which 2 were local and 1 was pulmonary, 2 were of the cellular sub‐type and one was mixed. Of the two local recurrences: one had positive microscopic margins requiring chemotherapy and further surgery; the other had positive macroscopic margins and the recurrent disease was unresectable but subsequently disappeared radiologically following an extended course of chemotherapy. The patient with pulmonary recurrence had a complete initial resection with negative margins. Two other patients with the cellular sub‐type had positive microscopic margins but did not receive chemotherapy and have not exhibited recurrent disease. The patient with the pulmonary recurrence unfortunately died from acute‐on‐chronic respiratory failure secondary to lung irradiation but was disease free. The other 8 patients are disease free, alive and well with no sequelae at latest follow up.

**Conclusions**: Surgery remains the mainstay of management with chemo and radiotherapy reserved for unresectable tumours or adjuvant management of recurrent disease. Microscopically positive resection margins are not an indication for instituting chemotherapy.

### PO-135. Central Venous Catheter Positioning in Pediatric Oncology: Systematic Review and Meta‐Analysis of the Group of Young Pediatric Surgeons of Europe {#pbc27455-sec-11030}

A. Siles Hinojosa^1^, E. Zambaiti^2^, V. Montano^3^, Y. González Ruiz^1^, A. Mutanen^4^, M. Glenisson^5^, S. Franchi‐Abella^6^, D. Pariente^6^, S. Sarnacki^7^, [L. Pio]{.ul} ^8^

*^1^Miguel Servet University Hospital, Department of Pediatric Surgery, Zaragoza, Spain; ^2^UCL Great Ormond Street Institute of Child Health, Pediatric Surgery, London, United Kingdom; ^3^Fondazione IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Department of Pediatric Surgery, Milan, Italy; ^4^University of Helsinki‐ Helsinki University Central Hospital‐ Children\'s Hospital, Section of Pediatric Surgery, Helsinki, Finland; ^5^Robert Debré Children University Hospital‐ APHP, Department of Pediatric Surgery and Urology, Paris, France; ^6^Bicêtre Hospital‐ AP‐HP, Department of Pediatric Radiology, Le Kremlin‐Bicêtre, France; ^7^Paris Descartes University‐ Hôpital Necker Enfants‐Malades‐ Assistance Publique‐Hôpitaux de Paris, Department of Pediatric Surgery, Paris, France; ^8^Hôpitaux universitaires Paris Sud‐ Hôpital Bicêtre Assistance Publique Hôpitaux de Paris, Pediatric Surgery Department, Le Kremlin‐Bicêtre, France*

**Background/Objectives**: The aim of this study is to compare the outcomes of open and ultrasound (US) guided approach for placement central venous catheter (CVC) in pediatric oncology.

**Design/Methods**: Using defined search strategy systematic review and meta‐analysis were performed following "Cochrane Handbook for systematic reviews of intervention" and "preferred reporting item for systematic reviews and meta‐analysis" (PRISMA). Inclusion criteria were defined and data collection included factors related to patient, CVC placement technique and complications. Maneuvers were compared by appropriate statistical methods, and meta‐analysis was conducted using RevMan 5.3.

**Results**: Systematic review: of 1831 abstracts screened, 128 full‐text articles were analyzed. Of these, 8 papers (629 infants) met our inclusion criteria. There were no randomized studies and only one prospective. 4 articles (322 infants) reported CVC placement with ultrasound percutaneous guided approach and 4 articles (307 patients) reported open placement of CVC fitting inclusion criteria. Success and failure definition were not specified in most reports. Meta‐analysis: 8 studies compared CVC placement US guided percutaneous approach (444 procedures) versus open approach (346 procedures) to the occurrence of complications (inmediate and delayed). Forest plot shows a prevalence of immediate complications in the US guided procedures compared, while in open procedures delayed complications are prevalent than immediate (p\<0.001).

**Conclusions**: The meta‐analysis shows a potential to reduce delayed complications when ultrasound is used in CVC placement. However, further randomized control trials are needed to identify risk factors to prevent immediate and delayed complications in both approaches.

### PO-136. Multidisciplinary Surgical Strategy for Dumbbell Neuroblastoma: A Single Center Experience of 33 Cases {#pbc27455-sec-11040}

[L. Pio]{.ul} ^1^, M. Cornet^2^, T. Blanc^1^, D. Valteau Couanet^3^, J. Michon^4^, H. Brisse^5^, S. Puget^6^, M. Zerah^6^, S. Sarnacki^1^

*^1^Hôpital Necker Enfants‐Malades‐ Université Paris‐Descartes, Pediatric Surgery, Paris, France; ^2^Hôpital Necker Enfants‐Malades, Pediatric Surgery, Paris, France; ^3^Institut Gustave Roussy, Department of Child and Adolescent Cancer, Villejuif, France; ^4^Institut Curie, Department of Pediatric Oncology, Paris, France; ^5^Institut Curie, Imaging Department, Paris, France; ^6^Hôpital Necker Enfants‐Malades‐ Université Paris‐Descartes, Department of Neurosurgery, Paris, France*

**Background/Objectives**: Prognosis of dumbbell neuroblastoma (NB) is mainly linked to the sequels induced by the tumor itself and the neurosurgical approach. Primary chemotherapy is the first treatment in symptomatic cases at diagnosis, but there are still debates on the surgical management of the residual tumor, especially the intraspinal component, and the timing and type of surgical resection. The aim of this study was to report a single center experience with dumbbell neuroblastoma with functional and oncological follow‐up.

**Design/Methods**: All NB with extension in the spinal canal treated by the same team over the last 15 years were analyzed regarding timing, type of surgery, complications, functional and oncological follow‐up.

**Results**: Thirty‐three children were collected (8 metastastic and 25 localized). Upfront surgery was performed in 2 patients and neoadjuvant chemotherapy in 31. Combined neurosurgical/extraspinal procedure was performed in 10 cases, neurosurgery as first operation in 5 patients, thoracic surgery and abdominal surgery for the extraspinal component as first procedure in 14 and 3 patients respectively. Three postoperative complications occurred: two transitory sciatic paralysis and one intestinal occlusion that did not required surgical intervention. Functional sequels were observed in 13 patients (9%): scoliosis treated by corset, 3 steppage, 1 paraplegia and 4 neurogenic bladder. Twenty nine patient are in complete remission, two patient had a local recurrence and two patients metastatic at diagnosis deceased with metastatic relapse. Median follow‐up was of 8 years (1 year ‐15 years).

**Conclusions**: An extensive and combined surgical strategy provides good results in terms of survival. An adequate multidisciplinary follow‐up with orthopedics, neurosurgeons and urologists is mandatory to manage properly the functional sequels links to tumor and/or surgical resection.

### PO-137. Robot‐Assisted Laparoscopic Management of Renal Tumors in Children: Preliminary Results {#pbc27455-sec-11050}

T. Blanc^1^, [L. Pio]{.ul} ^1^, P. Clermidi^1^, C. Muller^1^, D. Orbach^2^, V. Minard‐Colin^3^, Y. Heloury^4^, S. Sarnacki^1^

*^1^Hôpital Necker Enfants‐Malades‐ Université Paris Descartes‐ Sorbonne Paris Cité, Pediatric Surgery Department, Peris, France; ^2^Institut Curie, Department of Pediatric‐ Adolescent and Young Adult Oncology, Paris, France; ^3^Institut Gustave‐Roussy, Department of Paediatric and Adolescent Oncology, Villejuif, France; ^4^Royal Children\'s Hospital, Urology Department, Melbourne, Australia*

**Background/Objectives**: We present preliminary results of robot‐assisted laparoscopic (RAL) total and partial nephrectomy for renal malignant tumours.

**Design/Methods**: For total nephrectomy, a four‐trocar transperitoneal approach was used. The tumour was extracted inside a plastic bag without morcellation through a Pfannenstiel incision. Partial nephrectomy was performed using a three‐trocar retroperitoneal approach with renal artery clamping. Renorrhaphy was done with sliding‐clip technique. Patients with Wilms were treated according to SIOP‐2001.

**Results**: Eight children underwent RAL nephrectomy at a mean age of 6 years (3.2‐14.1). Total nephrectomy for Wilms tumour was done in 5 cases; one converted due to renal vein injury, one had a renal vein tumour thrombus misdiagnosed on preoperative imaging that could not be treated robotically and was converted. Staging was I (n=3); II (n=1), III (lymph nodes involvement, n=1). Histology showed regressive type (n=4) and diffuse anaplasia (n=1). Three patients had partial nephrectomy: increasing size of one nodule in a bilateral nephroblastomatosis after Vincristin‐Actinomycin,,onset of right tumour after left nephrectomy for Wilms and tumour ten years after liver transplantation for hepatoblatoma. Warm ischemia time was 40‐29‐26 minutes. Pathology was Wilms in 2 cases (stage I with standard histology) and tubulopapillary renal cell carcinoma (n=1). Tumour was completely removed in all cases (R0). No ruptures occurred. Postoperative course was uneventful and patients were discharged from day 2 to day 7. No recurrence or long‐term complications occurred (1--15 months follow‐up).

**Conclusions**: RAL total and partial nephrectomy for renal tumours in children is feasible and safe in highly selected children.

### PO-138. Postoperative Lymphatic Leakage after Surgery for Advanced Neuroblastoma: Is it a Rare Complication? {#pbc27455-sec-11060}

[A. Pohl]{.ul} ^1^, J. Muehling^1^, D. von Schweinitz^1^

*^1^Dr. von Hauner childrens Hospital‐ Ludwig‐Maximilians‐University, Department of Pediatric Surgery, Munich, Germany*

**Background/Objectives**: Lymphatic leakage (LL) after extensive retroperitoneal surgery is a known complication in patients with abdominal Neuroblastoma (NB). While there are various publications in adult patients about definition and treatment options of LL, there is up to now no clear definition regarding frequency and treatment of LL in pediatric patients.

**Design/Methods**: We evaluated charts of 149 patients with advanced NB (INSS stage 3 or 4), who received surgery in our department for age, MYCN‐Status, extend of surgery, follow‐up, duration of drainage, occurence of LL and treatment options for LL.

**Results**: LL occured in 52% of patients with locally advanced or metastasized NB. LL was defined if Duration of abdominale drainage was more than 7 days or laboratory testing of ascites for chylomicrones was positive. None of the patients needed surgical intervention for closure of LL. Treatment options of LL included watch and wait, total parenteral nutrition, i.v.‐Administration of somatostatine and application and application of Arista, a local hemostypticum. Patients follow‐up and extend of surgery were significantly associated with LL (p= 0.013 vs p= 0.030). There was no significant association between MYCN Status and LL. Furthermore, None of the treatment options showed a clear Advantage regarding Duration of LL.

**Conclusions**: LL is a frequent, but self‐limiting complication after extensive retroperitoneal resection. "Wacht and wait" seems to be a reliable therapeutic Option for treatment of LL.

### PO-139. Duodenum‐Preserving Pancreas Head Resection in the Treatment of Pediatric Benign and Low‐Grade Pancreatic Tumors: A Ten‐Year Single‐Center Review {#pbc27455-sec-11070}

[H. Qin]{.ul} ^1^, S. Yang^1^, H. Wang^1^

*^1^Beijing Children\'s Hospital‐ Capital Medical University‐ National Center for Children\'s Health, Surgical Oncology Department, Beijing, China*

**Background/Objectives**: To investigate the safety, feasibility, short‐term and long‐term complications of the duodenum‐preserving pancreas head resection (DPPHR) in surgical treatment of pediatric benign and low‐grade malignant pancreatic head tumors.

**Design/Methods**: 35 patients with benign or low‐grade malignant pancreatic head tumors underwent tumor resection between 2007 and 2018. Patients were retrospectively divided into 3 groups: DPPHR group, local enucleation group and conventional pancreatoduodenectomy (PD) group. Perioperative factors and postoperative complications were compared between the 3 groups.

**Results**: No statistical significance was found in operation time between the DPPHR and the PD group (P\>0.05). No statistical difference was found in the incidence of postoperative pancreatic fistula and the other short‐term complications between the 3 groups (P\>0.05). The incidence of long‐term complications was markedly lower in both the DPPHR (3/21, 14.29%) and local enucleation (0/7, 0) groups than in the PD group (4/4, 100%) (P\<0.05). Longer drainage time, prolonged use of somatostatin and hospital stays were observed in the DPPHR group and had statistical significance compared to the PD group (P\<0.05).

**Conclusions**: DPPHR may be a safe procedure for treating pediatric patients with benign and low‐grade malignant pancreatic head tumors. The incidence of digestive long‐term complications was significantly lower with DPPHR. However, perioperative management might be challenging for surgeons.

### PO-140. Customize Approach for Upfront or Delayed Resection using Radiological Characteristics in Unilateral, Non‐Metastatic Pediatric Renal Tumors: A Prospective Study {#pbc27455-sec-11080}

[S. Qureshi]{.ul} ^1^, S. Kembhavi^2^, T. Vora^3^, G. Chinnaswamy^3^, L. Sidharth^4^, M. Prasad^3^, N. Khanna^4^, M. Bhagat^1^, M. Ramadwar^5^

*^1^Tata Memorial Hospital, Pedaitric Surgical oncology, Mumbai, India; ^2^Tata Memorial Hospital, Radiology, Mumbai, India; ^3^Tata Memorial Hospital, Pedaitric Medical oncology, Mumbai, India; ^4^Tata Memorial Hospital, Radiation oncology, Mumbai, India; ^5^Tata Memorial Hospital, Pathology, Mumbai, India*

**Background/Objectives**: The availability of robust, compelling data for upfront or delayed surgery invariably, leads to a dilemma in selecting the initial treatment. Imaging criteria\'s associated with the risk of rupture or incomplete resection provides an objective assessment for customization for the timing of surgery.

**Design/Methods**: Eighty children with unilateral, non‐metastatic renal tumours were enrolled for this study between January 2012 to December 2017. Radiological features of perinephric spread or adjacent organ infiltration, tumours crossing midline, intravascular thrombus, and extensive adenopathy were utilized for deciding the initial treatment approach. An upfront nephrectomy was performed in the absence of these high‐risk features and delayed surgery (after a biopsy and chemotherapy) in their absence.

**Results**: Upfront nephrectomy was performed in eighteen and delayed surgery in sixty‐two. There were no complications attributed to biopsy in any patient. The upfront surgery group had predominantly Stage 1/2 diseases (89%) with only one tumour rupture. The histological diagnosis was Wilms tumour in eleven, non‐Wilms tumour in five and a benign tumour in two. In the delayed surgery group, the histological diagnosis was Wilms tumour in fifty‐seven and non‐Wilms tumour in five. Following chemotherapy, 60% had Stage 1/2 diseases. Only one patient in the upfront group and 23 in the delayed group with Wilms tumour received doxorubicin and radiotherapy for stage 3 disease. In addition, five with stage 1/2 blastemal predominant histology also received doxorubicin. The event‐free and overall survival at a median follow‐up of 48 months for the entire cohort is 88% and 89%. The event‐free and overall survival is 100% for the upfront surgery group and 86% and 86.5% in the delayed surgery group.

**Conclusions**: A customized approach based on radiological criteria facilitate the identification of early‐stage Wilms tumour and other non‐Wilms histology in children. The appropriate initial chemotherapy aids in tumour down‐staging and identification of high‐risk pathology.

### PO-141. Surgery Options and Results of Treatment of Children with Solid Pseudopapillary Tumors of the Pancreas {#pbc27455-sec-11090}

[D. Rybakova]{.ul} ^1^, P. Kerimov^1^, A. Kazancev^1^

*^1^Federal State Budgetary Institution "National Medical Research Center of Oncology. N.N. Blokhin" of the Ministry of Health of Russia, Children oncology, Moscow, Russia*

**Background/Objectives**: Development rational surgery for solid pseudopapillary tumor (SPT) of the pancreas and implementation of Endosurgery.

**Design/Methods**: 24 children with SPT were operated since 2007 to 2018. We analyzed clinical data, operation options and results of treatment.

**Results**: All patients were girls age from 9 to 17 years (median 13y.o.). Localization tumors in pancreas: in the tail -- 10, in the body ‐ 7 and in the head ‐ 37. The size: 9.7 -- 2.5 sm (M 5.6 sm). 8 children underwent laparoscopic distal pancreatectomy, 3 ‐ pancreatoduodenal resection; 3 ‐ gastropancreatoduodenal resection, 6 -- central resection of pancreas; 3 ‐ distal subtotal resection and 1 ‐ uncinate process of pancreas resection with resection of duodenal wall. Time of operations: 95 -- 290 min. Bleeding: 100‐ 450ml (median 185ml). Complications occurred in 8 patients: in 4 cases -- pancreatitis with pancreatic fistula, 1 ‐ bleeding from the pancreatic branch of the splenic artery after Whipple operation, 1‐ bleeding from the wound surface, 1 ‐ left‐sided pleurisy and 1 ‐ pneumonia. There were 2 reoperation for complications. The observation period of the patients was from 1 month to 11 years. All patients are alive without evidence of disease recurrence.

**Conclusions**: The main method of treatment is surgery, however there is a moderate risk of complications because of tumor localization. Great attention should be paid to the prevention of postoperative pancreatitis. A promising method is endosurgery providing early rehabilitation and cosmetic effects.

### PO-142. Possibilities of Endosurgery in Diagnosis of Tumor Diseases of Thoracic and Abdominal Localization at Children {#pbc27455-sec-11100}

[D. Rybakova]{.ul} ^1^, P. Kerimov^1^, A. Kazancev^1^

*^1^Federal State Budgetary Institution "National Medical Research Center of Oncology. N.N. Blokhin" of the Ministry of Health of Russia, children oncology, moscow, Russia*

**Background/Objectives**: to define possibilities of endosurgery in diagnosis of tumor of thoracic and abdominal localization at children

**Design/Methods**: in our institute from 2007 to 2012 with the diagnostic purpose it is carried out the 160th operation at 153 children, from which 63 laparoscopic and 44 thoracoscopic biopsies. Except diagnostic biopsies it was executed 53 thoracoscopic resections of lungs at 51 children for the purpose of diagnostics of progressing of a disease, confirmation of metastatic defeat or inflammatory process. The age of patients varied from 2 months to 19 years. The ratio on a floor was approximately equal: boys was -- 76 (49,7%), girls -- 77 (50,3%). And children about one year there were 9,8% (15 children).

**Results**: Duration the thoracoscopic and laparoscopic biopsies made from 20 minutes to 260 minutes, on average 59 minutes. Blood loss during diagnostic operations averaged 78,3 ml. Intraoperative complications are in 5 cases, and postoperative in -- 8. After the endosurgery operations at 59,3% of patients special treatment was carried out, 7,4% had a repeated operation, but already in radical volume and in 33,3% were written out on continuation treatment in a residence or in profile establishment. The average time of the beginning of special treatment made 4 days.

**Conclusions**: Advantages of use of endosurgery in children\'s oncology are: early terms of the beginning of special treatment, small injury, the minimum blood loss, low number of postoperative complications, early activation of the patient and reduction of terms staying in a hospital, good cosmetic effect. Performance the endosurgery of operations at children with malignant tumors it is possible aged from several weeks, thus the oncological principles of performance of surgery aren\'t broken, and also the age of the child isn\'t the limiting factor for performance the endosurgery of operations.

### PO-143. Peripherally Inserted Central Catheters in the Treatment of Children with Cancer: Results of a Multicenter Study {#pbc27455-sec-11110}

[M. Rykov]{.ul} ^1^

*^1^N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia*

**Background/Objectives**: To review our experience with peripherally inserted central catheters in pediatric cancer patients.

**Design/Methods**: The analysis included 353 patients (3 months up to 17 years, mean age 11.2 years) with a variety of cancers diseases, which in 2011--2016, 354 peripherally inserted central catheters were placed. All settings are carried out using ultrasound guidance. In 138 (39%) patients, external anatomical landmarks were used and in 216 (61%) intraoperative fluoroscopy.

**Results**: Maximal duration of the line was 1.3 years, the lowest 1.5 months, and average 6.3 months. Among the technical difficulties during placement, most frequently have been the migration of the distal end of the catheter into the internal jugular vein against blood flow---32 (9%) patients. In one (0.3%) case, we were unable to catheterize the patient\'s vein. Among the most common complications of operation were marked peripherally inserted central catheter clot occlusion of the lumen---26 (7.3%) cases. Symptomatic catheter‐related thrombosis was observed in 16 (4.5%) cases. Catheter‐related blood stream infections were not reported. Removal of peripherally inserted central catheters related to the complications was performed in 30 (8.5%) patients who were later implanted venous ports.

**Conclusions**: Peripherally inserted central catheters are recommend to use in the treatment of children with cancer. There should be trained nursing staff to minimize the risk of complications.

### PO-144. Neuroblastoma: The Association of Anatomical Tumour Site, Molecular Biology and Patient Outcomes {#pbc27455-sec-11120}

P. Losty^1^, [A. Salim]{.ul} ^2^, A. Raitio^2^, B. Pizer^3^, D. Mullassery^2^

*^1^Institute Of Child Health ‐ University Of Liverpool. UK, Department Of Paediatric Surgery, Liverpool, United Kingdom; ^2^Alder Hey Children\'s Hospital NHS Foundation Trust, Department Of Paediatric Surgery, Liverpool, United Kingdom; ^3^Alder Hey Children\'s Hospital NHS Foundation Trust, Department of Oncology, Liverpool, United Kingdom*

**Background/Objectives**: Numerous factors have been identified as carrying prognostic value in neuroblastoma many of which are incorporated in risk stratification of disease. We investigate the association(s) of anatomical site of neuroblastoma with molecular biology and outcomes.

**Design/Methods**: One hundred and twenty four patients with neuroblastoma were studied over a 30 year period. Tumour location was confirmed with CT / MRI imaging. Data on molecular biology was obtained as testing became available. Chi‐square, Fisher\'s exact test and Kaplan‐Meier Log‐Rank Tests were used for statistical / survival analyses.

**Results**: Eighteen patients (15%) had thorax tumours (TNBL), 92 (74%) adrenal gland lesions (ANBL), 14 (11%) abdominal / paravertebral chain neoplasms (PVNBL). ANBL cases had significantly poor outcome(s) vs other anatomical groups (OS 35%; p=0.015). ANBL site favoured Stage IV widespread metastatic disease (68%; p=0.001). No significant association(s) were found with tumour origin and age at diagnosis (p=0.198). MYCN was available in 58 patients ‐ Amplification was noted in 34% ANBL and associated with lower OS (14% vs 59% MYCN Non‐Amplified ANBL; p=0.006). The vast majority of TNBL and PVNBL were non‐MYCN amplified (100% and 88%) and carried better prognosis (OS 89% and 86%). DNA copy data was available in 24 cases ‐ 7/14 (50%) ANBL had diploidly and reduced OS (14% vs 71% Hyperdiploid ANBL; p=0.031). Thorax tumours (TNBL) / Abdominal paravertebral chain lesions (PVNBL) were found to be hyperdiploid (86% and 100%) with better prognosis (OS 83% and 33% for hyperdiploid TNBL and PVNBL respectively). Segmental chromosomal alterations (17q gain, 1p / 11q deletions) detected in 18/34 patients had prognostic significance in those with TNBL (n=6) and PVNBL (n=5) (p=0.014, p=0.025).

**Conclusions**: Thoracic neuroblastoma tumours have better outcomes than adrenal tumours. This may be due to factors such as non‐metastatic disease, non‐amplification of MYCN oncogene and favourable molecular biology.

### PO-145. The Chick Embryo: A New Experimental Model to Study Tumour Biology and Test Cancer Therapies for Neuroblastoma {#pbc27455-sec-11130}

[K. Sampat]{.ul} ^1,2^, A. Herrmann^1^, B. Pizer^3^, V. See^1^, P. Losty^2,4^

*^1^University of Liverpool, Institute of Integrative Biology, Liverpool, United Kingdom; ^2^Alder Hey Children\'s Hospital, Department of Paediatric Surgery, Liverpool, United Kingdom; ^3^Alder Hey Children\'s Hospital, Department of Oncology, Liverpool, United Kingdom; ^4^University of Liverpool, Institute of Child Health, Liverpool, United Kingdom*

**Background/Objectives**: We describe the utility of the chick embryo as a new experimental model to study tumour biology of neuroblastoma (NBL). We have developed this model to observe neuroblastoma metastases in living systems and here present preliminary observations with cancer drug agent screening in the chick.

**Design/Methods**: Neuroblastoma tumours develop from fluorescently labelled tumour cells placed on the chorio‐allantoic membrane of the chick embryo. Potential novel agents, such as cyclin D kinase (CDK) and NFkB inhibitors, have been identified by our lab group through genetic profiling of metastatic neuroblastoma tumours. Drugs are introduced into the chick embryo and we are able to observe in real time the effect of the drug on the developing cancer. Chick survival and weight are used as indicators of drug toxicity. Tumours are harvested and drug efficacy quantified using immunohistochemistry techniques. Volumetric whole tumour imaging with multiphoton and light sheet microscopy allows analysis of an entire NBL tumour without sectioning.

**Results**: Embryos treated with CDK inhibitors ‐ RO3306; p \< 0.001 and Palbociclib; p \< 0.01 showed significant reduction in proliferating cells within tumours demonstrating potent efficacy against neuroblastoma in vivo vs all controls. Advanced microscopy protocols to visualise whole tumours in 3D show dynamic images of NBL tumour organisation and its vascularisation. 3D tumour imaging is currently permitting an unprecedented platform to obtain novel measurements beyond conventional histopathological analysis.

**Conclusions**: The chick embryo is a versatile experimental model to study the biology of neuroblastoma and its treatments. We are using this model to selectively screen and target new chemotherapy agents against neuroblastoma. Alongside conventional tumorigenesis assays, novel use of 3D microscopy imaging allows detailed observation of drug effects on NBL tumour microenvironment, as well as cell invasion and metastasis.

### PO-146. Resection of Presacral Mass in Currarino Syndrome is Mandatory {#pbc27455-sec-11140}

J. Rod^1^, C. Cretolle^2^, L. Faivre^3^, N. Cheynel^4^, [S. Sarnacki]{.ul} ^2^

*^1^CHU Caen, Pediatric Surgery, Caen, France; ^2^Necker Enfants Malades, Pediatric Surgery, Paris, France; ^3^CHU Dijon, Center of Genetics, Dijon, France; ^4^CHU Dijon, Digestive Surgical Oncology, Dijon, France*

**Background/Objectives**: Currarino syndrome was initially described as a triad: sickle‐shaped sacrum, hindgut anomaly and presacral mass. This study considers the optimal management of presacral masses in Currarino syndrome.

**Design/Methods**: This study considers the optimal management of presacral masses in Currarino syndrome by analysing two new malignant cases (one in a child, one in an adult) and reviewing currently published literature regarding the current clinical, imaging, histology and genetic data of CS patients with a malignant presacral mass.

**Results**: Among more than 300 Currarino syndrome patients, 13 cases of malignant presacral mass have been reported to date (4%) with various histological types, and two of the cases were assessed for MNX1 gene mutations. In the two additional cases reported here, malignancy could be directly linked to Currarino syndrome since they all occurred in the presacral mass in childhood and adulthood by identifying a mutation within the MNX1 gene. Although it is a rare event, malignant transformation of presacral mass in Currarino syndrome may occur not only in adulthood but also in infancy.

**Conclusions**: Two messages: first, that systematic removal of presacral masses in Currarino syndrome is mandatory after a spinal cord MRI, particularly when a procedure for anorectal or spinal malformation is performed; second, to investigate the possibility of Currarino syndrome in any patient presenting with a presacral mass, and thus to propose genetic testing for MNX1 mutation, even if all the features of Currarino syndrome are not present and in the absence of a family history.

### PO-147. Human Papillomavirus in Retinoblastoma: Is it Relevant? {#pbc27455-sec-11150}

S. Chauhan^1^, [S. Sen]{.ul} ^1^, A. Sharma^2^, N. Singh^3^, B. Chawla^4^, N. Pushker^5^, S. Kashyap^6^

*^1^All India Institute of Medical Sciences, Department of Ocular Pathology‐ Dr. Rajendra Prasad Centre for Ophthalmic Sciences, New Delhi, India; ^2^All India Institute of Medical Sciences, Department of Microbiology‐ Dr. Rajendra Prasad Centre for Ophthalmic Sciences, New Delhi, India; ^3^All India Institute of Medical Sciences, Department of Biochemistry, New Delhi, India; ^4^All India Institute of Medical Sciences, Ocular Oncology Service‐ Dr. Rajendra Prasad Centre for Ophthalmic Sciences‐, New Delhi, India; ^5^All India Institute of Medical Sciences, Ophthalmoplasty service‐ Dr. Rajendra Prasad Centre for Ophthalmic Sciences, New Delhi, India; ^6^All India Institute of Medical Sciences‐ Ansari Nagar, Department of Ocular Pathology‐ Dr. Rajendra Prasad Centre for Ophthalmic Sciences, New Delhi, India*

**Background/Objectives**: Retinoblastoma is the most common primary intraocular childhoodmalignancy. Earlier studies have suggested an association of HPV with sporadic retinoblastoma, indicating that the virus may have a role in the development of these tumors. Marked variation (0‐40%) of HPV positivity in retinoblastoma has been reportedworldwide. The present study aims to detect the presence of HPV in retinoblastoma in north Indian population.

**Design/Methods**: HPV genome was detected by multiplex PCR using PGMY09/11 primers in 72 ocular malignant tumors. This was followed by genotyping using linear array (reverse hybridization).

**Results**: Of the 72 retinoblastoma cases recruited, (23 unilateral and 49 bilateral, mean age of4.04 ±2.4 years (3 months to 8 years), 57 were poorly differentiated (PD) and 15 well differentiated. Optic nerve and choroidal invasion was seen in 50 cases. All the retinoblastoma cases were negative for HPV by both multiplex PCR as well as reverse hybridization.

**Conclusions**: HPV genome was absent in all retinoblastoma cases. Therefore, HPV may not be associated with the pathogenesis of these tumors in north India.

### PO-148. A Multicenter Study of 33 Cases with Synovial Sarcoma {#pbc27455-sec-11160}

[W. Shan]{.ul} ^1^

*^1^Children\'s Hospital of Chongqing Medical University, Department of Pediatric Surgical Oncology, Chingqing, China*

**Background/Objectives**: To analyze clinical features, outcomes and correlative prognostic factors of pediatric synovial sarcoma.

**Design/Methods**: From January 2008 to November 2014, 33 newly diagnosed children with synovial sarcoma at Children\'s Hospital of Chongqing Medical University, Shanghai Children\'s Medical center, Sun Yat‐sen University cancer center and Beijing Children\'s Hospital were enrolled into this study. The clinical features, surgery, chemotherapy, radiotherapy protocol and prognostic factors were retrospectively analyzed.

**Results**: The tumor was resected at first in 24 patients. The remaining 9 patients had biopsy first and in three of them the tumor was resected after 3∼4 cycles of neoadjuvant chemotherapy. Twenty‐two patients received chemotherapy postoperation and the median cycles were 7 (1∼12). Five to 25 times radiotherapy were received by ten patients postoperation and the total dose was 25∼60Gy. Eight patients gave up treatment after biopsy or after direct surgery with 0∼2 cycles chemotherapy postoperation. All the other 25 fulfilled the comprehensive treatment as planned. Twenty‐one patients achieved complete response, 3 stable disease and 1 progressive disease at the end of treatment. Tumor metastatic or local relapse occurred in 11 patients after 14.5 months (3∼48 months). Except for 8 cases giving up treatment, the median follow‐up period was 36 months (3‐92 months). The estimated 3 year event‐free survival was (61.9 ± 10.1)%. Patients with completely excited tumors after initial surgery had significantly better event‐free survival while significant prognostic factors were not found including age(≤10, \>10), sex, primary site (extremities, axial), size (≤5 cm, \>5 cm), IRS group, distant metastasis on univariate analysis.

**Conclusions**: Pediatric synovial sarcoma arises most commonly in the extremities. Comprehensive treatment advocated in pediatric synovial sarcoma, but it also tends to late local recurrence and metastasis. Completely excited tumor after initial surgery shows an effect on the prognosis. Effective treatment need to be found to improve long‐term outcome.

### PO-149. Hepatoblastoma: Role Diffusion Weighted MRI (DW‐MR) in Detection of Satellite Lesions not Detected with Multi‐Phase CT Scans {#pbc27455-sec-11170}

[K. Sharma]{.ul} ^1^, S. Agarwala^1^, M. Jana^2^, D. Kandasamy^2^, V. Jain^1^, A. Dhua^1^, S. Bakhshi^3^, V. Bhatnagar^1^

*^1^All India Institute of Medical Sciences, Pediatric Surgery, New Delhi, India; ^2^All India Institute of Medical Sciences, Radiodiagnosis, New Delhi, India; ^3^All India Institute of Medical Sciences, Medical Oncology‐ BRAIRCH, New Delhi, India*

**Background/Objectives**: Satellite lesions are known to occur in some patients with hepatoblastoma (HB). If these are missed on initial radiological evaluation then the segments harbouring these satellite lesions may be retained after hepatic resection leading to recurrence. Aim: To evaluate the role of Diffusion weighted MRI (DW‐MR) in fresh cases of hepatoblastoma (HB) for the detection of satellite lesions as compared to multiphase CT (CECT) scans.

**Design/Methods**: CECT scans and DW‐MR were performed before initiation of chemotherapy in newly enrolled cases of hepatoblastoma. Results of interpretation of two separate radiologists was compared for detection satellite lesions. PRETEXT grouping and risk categorization was done according to SIOPEL.

**Results**: Ten fresh cases of HB, in the age range 5‐84months (median 11.5) were included. The αFP ranged from 4000‐\>1200,000 ng/ml. The Pretext grouping was II in 2(20%), III in 8(80%). There was 1(10%) standard risk and 9(90%) high risk tumors. In 2 of the 10(20%) patients additional satellite lesions were detected on DW‐MR. In one patient, CECT had diagnosed a large unifocal tumor involving segments 1,4,5,7 and 8 (PRETEXT III, HR), additional 6 satellite lesions detected up on DW‐MR, upgrading the patient to PRETEXT 4,HR. In another patient CECT detected a large lesion in segments 2,3,4,5,and 8 with a satellite in segment 3 (PRETEXT III, HR), additional 3 satellite lesions were detected in segment 7 on DW‐MR, upgrading the patient to PRETEXT 4,HR.

**Conclusions**: As compared to multiphase CT scans, DW‐MR detected additional satellite lesions in 20% cases. Detection of additional satellite lesions could lead to upgrading of PRETEXT grouping and change in the extent of hepatectomy required in patients with HB. The two upgstaged patients in this study would have required total hepatectomy with liver transplantation. Therefore, DW‐MR should be the investigation of choice for deciding the local extent in HB cases.

### PO-150. How Does Surgery Impact Childhood Cancer Patients? The Lasting Experiences and Needs of Survivors and Their Parents {#pbc27455-sec-11180}

[C. Signorelli]{.ul} ^1^, C. Wakefield^1^, M. Gabriel^1^, J. Vetsch^1^, J. Karpelowsky^2^, A.S. Darlington^3^, C. Richard^1^

*^1^Sydney Children\'s Hospital/UNSW Sydney, Kids Cancer Centre, Sydney, Australia; ^2^Children\'s Hospital Westmead/Kids Research Institute/University of Sydney, Department of Paediatric Surgery/Children\'s Cancer Research Unit, Sydney, Australia; ^3^University of Southampton, Faculty of Health Sciences, Southampton, United Kingdom*

**Background/Objectives**: Surgery in children is especially stressful for both patients and parents. We aimed to understand patients'/parents' experiences and needs during and post‐surgery and the long term impact of surgery for pediatric cancer.

**Design/Methods**: Stage 1: We conducted a systematic review of paediatric patients' and parents' psychosocial experiences and needs during the surgical period for any condition.

Study 2: We conducted semi‐structured interviews with childhood cancer survivors and parents (of survivors \<16 years) to evaluate their experiences and needs across the surgical trajectory.

**Results**: Stage 1: Our review yielded 11 eligible studies, representing over 1,300 children undergoing surgery or their parents. Peri‐operatively, children commonly displayed adverse psychological/behavioural changes (e.g. eating disturbances) and parents mainly reported psychological distress. Patients' needs related primarily to medical/healthcare services. Parents typically had high information needs. Patients with prior hospitalizations/surgeries reported worse experiences, suggesting experiences may be worse in patients with chronic conditions. No studies eligible for our review evaluated the experiences of children undergoing surgery for childhood cancer, prompting our interview study in this population.

*Stage 2*: We interviewed 32 participants (17 survivors, mean surgery age 6.9years; 15 parents, child\'s surgery mean age, 2.1years). Overall, 56% were satisfied with their surgical experience. Yet, participants rated surgery as highly distressing. Survivors recalled fear and pain from pre‐operative procedures, and some experienced immobility or persistent behavioural disturbances. Parents reported pre‐ and intra‐operative stress and some lasting psychological distress post‐operatively. Factors which improved participants' experiences included clear and consistent communication from hospital staff, living near the hospital, and for children, parental support.

**Conclusions**: Surgery during childhood appears to have a lasting impact for some families, with both survivors and parents describing vivid memories and adverse effects. Understand families' surgical experiences and needs is critical to improve the standard of care offered and reduce perioperative stressors.

### PO-151. Usefulness of Navigation Surgery Using Indocyanine Green Fluorescent Imaging for Hepatoblastoma Patients {#pbc27455-sec-11190}

[R. Souzaki]{.ul} ^1^, T. Matsuura^1^, Y. Kinoshita^1^, Y. Koga^2^, J. Takemoto^3^, K. Kohashi^3^, Y. Oda^3^, S. Ohga^2^, T. Taguchi^2^

*^1^Kyushu university, pediatric surgery, FUKUOKA, Japan; ^2^Kyushu university, pediatrics, Fukuoka, Japan; ^3^Kyushu university, Anatomic Pathology, Fukuoka, Japan*

**Background/Objectives**: The detection of liver tumors and identification of the bile ducts during liver surgery using indocyanine green (ICG) has recently been developed. However, the usefulness of ICG navigation surgery for HB has not been fully clarified. We herein report our experiences with surgical navigation using ICG for in HB patients.

**Design/Methods**: In five HB patients, liver tumors and lung metastatic tumors were intraoperatively examined using a 10‐mm infrared fluorescence imaging scope after the administration of ICG preoperatively.

**Results**: Navigation surgery using ICG was performed for primary liver tumors in 4 cases. The extended right hepatectomy was performed for 3 patients and liver transplantation for a patient. All primary tumors exhibited intense fluorescence and no fluorescence was detected in the residual liver. All tumors were proved to be completely resected by pathological examination. ICG navigation for the primary liver tumor was useful for the detecting the residual tumor surrounding IVC and invasion to the diaphragm. Five navigation surgeries using ICG was performed for metastatic lung tumors in two cases. Both cases were performed bilateral lung partial resections and left upper lobectomy for recurrent tumor in one case. All 9 metastatic lung lesions detected by preoperative CT exhibited intense fluorescence and only one lesion not detected by CT exhibited weak fluorescence. All of these fluorescence‐positive lesions except for the one lesion not detected by CT were pathologically proven to be made up of HB cells and one lesion not detected by CT showed no tumor cells. ICG navigation for metastatic lung tumors was useful for the detection of the tumor and the confirmation of the tumor free on the resection stumps.

**Conclusions**: Navigation surgery using ICG for patients with HB was useful for identifying tumors and confirming complete resection.

### PO-152. Intra‐Operative Photographic Imaging for Objective Documentation of the Surgical Resection in Neuroblastoma {#pbc27455-sec-11200}

[J. Stenman]{.ul} ^1^, K. Burnand^2^, F. Sundquist^1^, J. Strömgren^3^, G. Barker^1^, P.J. Svensson^1^, S. Giuliani^2^, K. Cross^2^

*^1^Karolinska University Hospital, Departments of Pediatric Surgery and Pediatric Urology, Stockholm, Sweden; ^2^Great Ormond Street Hospital, Department of Specialist Neonatal and Paediatric Surgery, London, United Kingdom; ^3^Karolinska University Hospital, Department of Pediatric Radiology, Stockholm, Sweden*

**Background/Objectives**: Neuroblastoma surgery is only rarely radical as defined by a microscopically clear resection margin and the completeness of the resection is determined by the surgeons estimation of the amout of residual tumor tissue. We have evaluated Intra‐Operative Photographic Imaging (IOPI) for objective documentation of the extent of the surgical resection and the amount of residual tumor.

**Design/Methods**: 89 intra‐operative photographies from 52 patients, taken during surgery for INRG stage L1, L2 or M neuroblastoma at the Karolinska University Hospital and Great Ormond Street Hospital during 2008‐2017 were retrospectively analyzed. Photographic images taken at the end of resection were analyzed and scored with respect to image quality, correlation with the operation report and to which extent pre‐defined Image‐Defined Risk Factors (IDRFs) were adequately displayed. The analysis was performed by surgeons well aquainted with the field, but who were not the operating surgeons in the specific cases.

**Results**: The image quality was good or adequate with regards to resolution, sharpness, lightning and orientation in 88% (46/52) of cases. In 63% (33/52) of cases all anatomical regions of the pre‐defined IDRFs were clearly displayed. The correlation between photographic images and the operation report was complete in 52% (27/52), partial in 42% (22/52) and absent in 6% (3/52) of cases. In 19 cases available images did not cover all IDRFs and in the 6 cases a poor image quality made judgement of residual disease impossible.

**Conclusions**: Systematically performed IOPI, as a supplement to a standardized surgical case report form, provides a means for objective documentation of the surgical resection. This allows for retrospective validation and central review of the quality of surgery in neuroblastoma. A prospective study to establish imaging criteria and evaluate IOPI in relation to pre‐ and post‐operative radiographic imaging has been initiated.

### PO-153. Minimally Invasive Thoracic and Abdominal Surgery in Pediatric Solid Oncology {#pbc27455-sec-11210}

[S. Talypov]{.ul} ^1^, D. Kachanov^2^, T. Shamanskaya^2^, D. Akhaladze^1^, N. Ivanova^1^, E. Kazantseva^1^, N. Merkulov^1^, N. Uskova^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Pediatric oncology and surgery, Moscow, Russia; ^2^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Pediatric oncology, Moscow, Russia*

**Background/Objectives**: Minimally invasive surgical (MIS) interventions now often displace open operations in children\'s surgical hospitals. All this also contributes to the wide spread of video endoscopic surgery in pediatric Oncology, both for the purpose of biopsy and removal of solid tumors.

**Design/Methods**: In the Department of pediatric surgery from February 2012 to December 2017, 173 minimally invasive operations aimed at removing a solid tumor of thoracic and abdominal localization were performed. 97 laparoscopic surgery was performed, 76 -- thoracoscopic. Laparoscopy was in 69 children with retroperitoneal neurogenic tumors, benign tumors (9), adrenal hemorrhage (3), kidney tumors (3), in other cases (13).

Removal of solid tumors was carried out thoracoscopically in 49 children with neurogenic tumors, lung tumors (13), bronchogenic cysts (3), esophageal cysts (3), thymus tumors (4) and others (4).

The minimum age was 1 month, maximum -- 19 years. The sex ratio (boys:girls) was approximately 1:1.3.

The operation was performed with three‐ or four‐troacar access. Bipolar coagulation was used to mobilize the tumor. In case of vessels diameter to 3 -- 4 mm those were coagulated, vessels of bigger diameter clipped with clips. The isolated tumor was immersed in an endoscopic container, which was extracted through an expanded hole of one of the troacars.

**Results**: The duration of the operation ranged from 20 minutes to 4.5 hours, depending on the location and size of the tumor, involvement of surrounding organs and vessels. Conversion was 20 (11,5%): 7 -- large tumor volume, 6 -- bleeding, 5 -- adhesive process, 2 ‐ not found pathological lesions in the lung. As intraoperative complications were bleeding (6). There were 4 local relapses, which required an open operation.

**Conclusions**: MIS in pediatric Oncology is justified due to less traumatically, promotes faster recovery of patients in the postoperative period and an earlier continuation of the chemotherapy of the underlying oncologically disease.

### PO-154. Surgical Treatment Strategy for Advanced Hepatoblastoma: Resection vs. Transplantation {#pbc27455-sec-11220}

[H. Uchida]{.ul} ^1^, S. Sakamoto^1^, A. Fukuda^1^, T. Hishiki^1^, S. Nosaka^2^, T. Yoshioka^3^, K. Matsumoto^4^, M. Kasahara^1^

*^1^National Center for Child Health and Development, Organ Transplantation Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Division of Radiology, Tokyo, Japan; ^3^National Center for Child Health and Development, Division of Pathology, Tokyo, Japan; ^4^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan*

**Background/Objectives**: Excellent outcomes of the extreme procedure of liver resection (LR) for advanced hepatoblastoma (HB) have been achieved in recent reports. However, liver transplantation (LT) remains the only surgical treatment for patients with unresectable HB. The aim of this study was to evaluate our retrospective data for cases of advanced HB necessitating surgical intervention and analyze the prognostic factors of recurrence by comparing LR and LT patients.

**Design/Methods**: We retrospectively reviewed 24 children with PRETEXT II/III/IV tumors that required consideration for LT between August 2011 and October 2017.

**Results**: The staging at the time of the diagnosis was PRETEXT II/III/IV in 1/13/10 patients, while the preoperative staging after neoadjuvant chemotherapy was POST‐TEXT II/III/IV in 5/17/2 patients. Among those 24 patients, complete resection of the primary tumor was achieved with LT in 12 patients and LR in 12 patients. Two patients underwent rescue LT due to recurrence in the remaining lobe of the liver. No significant decrease rate of alpha‐fetoprotein, a low tumor shrinkage rate, and vascular invasion in the pathological findings were related to a risk of tumor recurrence, and LR patients with those risks had a significantly higher recurrence rate than those without them. The overall survival, recurrence‐free survival, and event‐free survival (EFS) rate were higher in LT patients (100%, 91.7% and 91.7%, respectively) than in LR patients (91.7%, 58.3% and 50%, respectively), and there was a significant difference in EFS (p \< 0.05).

**Conclusions**: Although strengthening the preoperative assessment with advanced imaging tools may aid in the decision‐making process with regard to solid strategies, patients with advanced HB with a poor response to chemotherapy should definitively be prioritized for primary LT, given the possibility of vascular invasion and microscopic residual tumor.

### PO-155. Implementation of an International Standard for Systematic Surgery Report for Neuroblastoma: A SIOPEN, COG and GPOH Initiative {#pbc27455-sec-11230}

[C. Van De Ven]{.ul} ^1^, J.G. Nuchtern^2^, L. Matthyssens^3^, M. Jans^1^, H. Gabra^4^, S. Irtan^5^, J. Stenman^6^, K. Bjørnland^7^, D. Hompes^8^, L. Pio^9^, K.M. Cross^10^, S. Avanzini^11^, J. Gómez^12^, P.D. Losty^13^, J. Fuchs^14^, M.P. LaQuaglia^15^, D. Von Schweinitz^16^, S. Sarnacki^9^

*^1^Princess Máxima Center for Pediatric Oncology, Solid Tumor Unit, Utrecht, The Netherlands; ^2^Texas Children\'s Hospital, Michael E. DeBakey Department of Surgery‐ Baylor College of Medicine, Houston, USA; ^3^University Hospital Gent, Pediatric surgery, Gent, Belgium; ^4^The Newcastle upon Tyne Hospitals, Pediatric surgery, Newcastle upon Tyne, United Kingdom; ^5^Hôpital Armand Trousseau, Pediatric surgery, Paris, France; ^6^Karolinska University Hospital, Pediatric surgery, Stockholm, Sweden; ^7^Oslo University Hospital, Pediatric surgery, Oslo, Norway; ^8^University Hospital Gasthuisberg, Oncological surgery, Leuven, Belgium; ^9^University Hospital Necker, Pediatric surgery, Paris, France; ^10^Great Ormond Street Hospital for Children, Pediatric surgery, London, United Kingdom; ^11^IRCCS G. Gaslini Institute, Pediatric surgery, Genova, Italy; ^12^University Hospital La Fe, Pediatric Surgery, Valencia, Spain; ^13^Alder Hey Children\'s Hospital, Pediatric surgery, Liverpool, United Kingdom; ^14^University Children\'s Hospital, Pediatric surgery, Tübingen, Germany; ^15^Memorial Sloan Kettering Cancer Center, Pediatric surgery, New York, USA; ^16^Hospital of the University Munich, Pediatric surgery, Munich, Germany*

**Background/Objectives**: Treatment of high‐risk neuroblastoma consists of a multidisciplinary approach with induction chemotherapy, surgical resection, high‐dose chemotherapy and radiation therapy, completed by biological therapy. The surgical resection of the tumor is often a demanding procedure because of the tumor\'s tendency to encase vital vessels, risking loss of vital organs. To be able to compare surgical procedures in multicenter studies, it is important to register surgical procedures in a standardized and extensive manner. Additionally, this standardized description will help surgical and radiation planning.

**Design/Methods**: This proposal for an international CRF is the result of intensive discussions between the different international working groups to combine the existing surgical case reports forms (CRF) of SIOPEN, COG and GPOH and introducing lists of possible complications.

**Results**: The first part describes the nature, approach and result of the procedure as well as a description of the anatomical involvement of the tumor. The second part extensively describes the nature of vascular involvement of specific vessels including degree of resection and damage. Organ involvement, resection and macroscopic tumor residue is recorded. These items are concordant with preoperative image‐defined risk factors. Additionally, detailed intraoperative complications are recorded as well as the postoperative complications using Clavien‐Dindo classification. An on‐line form directly filled out by surgeons will resolve the challenge linked to the high variation in anatomical locations.

**Conclusions**: This is the first international CRF for standardization of neuroblastoma surgery. It will improve the collection of surgical data and facilitate their comparison across borders. This CRF also aims to be useful for non‐high‐risk neuroblastomas.

### PO-156. Tunnelled Central Venous Access Devices in Small Children: A Comparison of Open versus Ultrasound‐Guided Percuntaneous Insertion in Children Weighing Ten Kilograms or Less {#pbc27455-sec-11240}

[L. Vierboom]{.ul} ^1^, A. Darani^2^, C. Langusch^2^, S.V. Soundappan^2^, J. Karpelowsky^2^

*^1^Starship Children\'s Health, Department of Paediatric Surgery and Urology, Grafton‐ Auckland, New Zealand; ^2^The Children\'s Hospital at Westmead, Department of Paediatric Surgery, Westmead, Australia*

**Background/Objectives**: Ultrasound‐guided (USG) percutaneous insertion of tunnelled central venous access devices (CVADs) has been shown to be safe and effective in adults. However, there have been concerns over the safety of this technique in small children. This study analyses the safety of USG percutaneous CVAD insertion in the paediatric population weighing ten kilograms or less.

**Design/Methods**: All surgically inserted CVADs for children weighing ten kilograms or less, between January 2010 and December 2015 at the Children\'s Hospital at Westmead were retrospectively reviewed. Open and USG percutaneous techniques were compared with intraoperative complications as the primary outcome variable. Secondary outcome measures included conversion to open technique, post‐operative complications, operating time and catheter longevity.

**Results**: 232 cases were identified: 96 (41.4%) open, 136 (58.6%) USG percutaneous. Age ranged \<1‐48 months; weight 0.7‐10 kilograms. CVADs ranged 2Fr‐9Fr in size. Eleven USG percutaneous cases required conversion to open. There was no significant difference in intraoperative complication rate between open (11/96, 11.5%) and USG percutaneous (19/136, 14.0%) groups (p = 0.574). There was no significant difference in overall post‐operative complications, operative time or catheter longevity. Mechanical blockage was significantly higher in the open group than the USG percutaneous group (21% vs 10%, p=0.015)

**Conclusions**: USG percutaneous CVAD insertion is safe in children weighing ten kilograms or less. Open catheter insertion may be associated with higher rates of post‐operative catheter blockage in small children.

### PO-157. Plasty and Salvage of the Kidney in Treatment of Bilateral Wilms Tumor‐ Experience of 53 Cases in 10 Years at a Single Institution {#pbc27455-sec-11250}

[H. Wang]{.ul} ^1^, H. Qin^1^, X. Chang^1^, J. Hu^1^

*^1^Beijing Children\'s Hospital, Surgical Oncology, Beijing, China*

**Background/Objectives**: Nephron‐sparing surgery has been accepted as the optimal treatment for bilateral Wilms tumor. Experience needs to be accumulated since the limited case data, particularly of complicated disease.

**Design/Methods**: A retrospective review was conducted of all cases enrolled in Beijing Children\'s Hospital for synchronous, bilateral Wilms tumor from Oct. 2006 through Oct. 2016. Patient demographics, Imaging studies, surgical techniques, chemotherapy, and pathology reports were reviewed.

**Results**: Fifty three patients were identified. Nine patients received upfront surgery. Three patients received bilateral nephron‐sparing procedure at one surgery. Totally in the 106 procedures of the 53 cases, 8 procedures of nephrectomy were underwent in the initial period and 98 succeeded with nephron‐sparing in later period. The max diameter of tumor were more than 10cm in 16 kidneys, in which 6 were resected off. For the 98 successful procedures of nephron‐sparing, the largest tumor was measured as 20×18×15cm. In procedures of nephron‐sparing, 11 underwent without temporary vascular occlusion. Interrupted vascular occlusion of the renal pedicle were carried out for more than 30 minutes in 3 procedures. There was no operation related erythrocyte transfusion nor renal vessel thrombogenesis. The multifocal disease was challenging to plasty and salvage of the kidney, which were conducted with polyester or biologic patch. The pathology reviewed favorable in all cases. Upon SIOP staging, there was one case of stage Ⅳ with lung metastasis and the others as stage Ⅱ and Ⅲ. Postoperative complications included one case of intestinal obstruction, one case of renal failure. Long‐term complications included tumor recurrence, 7 patients in local site, 3 patients as implanted nodules of peritoneum and diffusion to retroperitoneal lymphonodus. Seven patients were reported death in the follow up.

**Conclusions**: The nephron‐sparing procedure are feasible in most bilateral Wilms tumor. The multifocal disease was challenging to surgery. Complications were minimal, and long‐term renal function and survival were excellent.

### PO-158. An Interdisciplinary Surgical Approach (Pediatric Surgery/Neurosurgery) Allows Successful Tumor Resection in Specific Complex Conditions of Pediatric Solid Malignancies {#pbc27455-sec-11260}

[S. Warmann]{.ul} ^1^, C. Urla^1^, J. Schäfer^2^, M. Schuhmann^3^, J. Fuchs^1^

*^1^University Children\'s Hospital Tübingen, Pediatric Surgery and Pediatric Urology, Tübingen, Germany; ^2^University Hospital Tübingen, Diagnostic and Interventional Radiology, Tübingen, Germany; ^3^University Hospital Tübingen, Neurosurgery, Tübingen, Germany*

**Background/Objectives**: Success of solid tumor surgery in children is regularly hampered by infiltration of essential organs and structures. Regularly, imaging data suggest a conflict between complete tumor resection and preservation of organ integrity and/or function. Involvement of central and peripheral nerves often seems to make resection of some tumors impossible.

**Design/Methods**: We retrospectively analyzed data Data of 17 children with solid tumors relevantly involving essential neuronal structures. Children underwent surgery simultaneously performed by a pediatric surgeon and a neurosurgeon. Analyses were performed with regard to surgical and oncological outcome.

**Results**: The diagnoses of the 17 children were: Neurofibromatosis type I (n=10), Neuroblastoma (n=4), Ewing Sarcoma (n=2), and Desmoid Tumor (n=1). The sites of tumors were thoracic (n=5), pelvis (n=5), abdominal/retroperitoneal (n=2), legs (n=2), neck (n=2), Ellbow (n=1). Three patients (2x Ewing Sarcoma, 1x Desmoid Tumor) had tumor relapses. The median age at surgery was 13 years (range: 2‐16 years). Macroscopically complete resection was achieved in 14 patients, in the remaining 3 cases a subtotal tumor resection was performed. In the 3 patients with tumors of the limbs, an amputation was planned at outside institutions. However, through simultaneous interdisciplinary surgery, a limb‐salvage procedure could be successfully performed in all affected patients. In 2 children nerve replacement was performed after en bloc resection of tumor and neuronal structures. Postoperative complications occurred on three instances (1 transient foot flexor paresis, 1 Horner‐Syndrome and 1 transient sensorial and motoric deficit C8/Th1). All patients are alive after a median follow‐up of 48 months (3‐132).

**Conclusions**: Simultaneous interdisciplinary surgery combining Pediatric‐ and Neurosurgical techniques is a successful approach to realize local control of tumors with affection of neuronal structures. Although this approach is mainly relevant for a selective cohort of patients, it contains important implications for achieving complete tumor resection in certain conditions of solid tumors.

### PO-159. Hepatic Sinusoidal Obstruction Syndrome Induced by Actinomycin‐D in Right‐Sided Wilms Tumors {#pbc27455-sec-11270}

[H. Wei]{.ul} ^1^, M. De‐guang^2^, Q. hong^3^, W. huanmin^3^

*^1^xi cheng, Beijing Children\'sHospital, bei jing, China; ^2^Baoding Children\'s Hospital, Pediatric surgery Oncology, Baoding, China; ^3^Beijing Children\'s Hospital, Pediatric surgery Oncology, Beijing, China*

**Background/Objectives**: Sinusoidal obstruction syndrome of liver (SOS), also known as veno‐occlusive disease (VOD), is commonly described as a complication of chemotherapy in children with Wilms' tumor. Observations suggest that actinomycin‐D is the most likely cause of HSOS. The outcome of this complication remain disputed.

**Design/Methods**: The present cases of 4 children with right‐sided Wilm\'s tumor who developed SOS after receiving chemotherapy consisting of actinomycin‐D and vincristine, clinical features were summarized.

**Results**: 4 cases with stage II Wilm\'s tumor in right side receiving post‐nephrectomy chemotherapy with dactinomycin and vincristine, developed SOS with hepatomegaly (2 painful), weight gain and palpable ascites, liver dysfunction and bilirubin abnormality, the activated partial thromboplastin time (APTT) prolongation, serum level of D‐dimer elevated. 2 boys and 2 girls. Diffuse hepatomegaly, inhomogeneous liver parenchyma, unclear or thinner hepatic veins, hydrothorax/ascites, or splenomegaly were observed on Doppler sonography. No patients underwent liver biopsy. Treatments were basically symptomatic and supportive with fluid restriction. No N‐acetylcysteine or defibrotide were involved in the treatment. Complete resolution of clinical signs and amelioration of lab abnormalities followed within several months. Prognosis was good in all patients.

**Conclusions**: Children with Wilms' tumor in right side who received chemotherapy consisting of actinomycin‐D should be given greater awareness for SOS, if they present with the minimal signs of hepatomegaly, sudden weight gain, liver dysfunction and coagulation dysfunction. While in most patients this complication resolves uneventfully.

### PO-160. Clinical Presentation and Outcome of Paediatric Non‐Wilms\' Renal Tumours {#pbc27455-sec-11280}

[D.K. Yadav]{.ul} ^1^, S. sharma^1^, D.K. gupta^1^

*^1^All india institute of medical sciences‐ New Delhi, Pediatric Surgery, New Delhi, India*

**Background/Objectives**: To evaluate the clinical presentation and outcome of non‐Wilms renal tumours in children.

**Design/Methods**: Patients registered in Paediatric Surgery Tumour Clinic from Jan 2015 to Jan 2018 who were diagnosed as non‐Wilms tumours were studied prospectively for their clinical presentation and outcome.

**Results**: Out of 41 cases of renal tumors 13 had non‐Wilms Tumors. 03 cases had Congenital Mesoblastic Nephroma(CMN), presented with lump, M;F 1:2 and mean age of presentation was 1.5 Month. All doing well over a follow up period(FUP) of 24 months. 03 patients had Cystic Nephroma(CN), presented with lump, M:F,1:2, mean age of presentation was 21.3 month, All doing well over a FUP of 20 months.02 patients had clear cell sarcoma of kidney (CCSK), presented with lump, both male and mean age of presentation was 48 month. One patient is well and another die (multiple site recurrence) over a FUP of 30 months. 01 patient had Intra Renal Neuroblastoma (NB), presents with lump but die during adjuvant chemotherapy. 01 patient had renal peripheral neuroectodermal tumor (PNET), presented with lump at 9 yrs of age, received adjuvant chemotherapy and doing well over a FUP of 30 month. 03 patients had Xp11 Translocation Renal Cell Carcinoma(RCC), 02 presented with hematuria, 01 with lump, M:F 1:2, mean age of presentation was 100 months. One patient of translocation RCC developed local recurrence and lung metastasis for which metastasectomy was done, doing well over a FUP of 24 months. Second patient of translocation RCC developed local recurrence, vertebral metastasis, B/L multiple lung metastasis and was advised palliative therapy. Third doing well. Nine patients were treated with nephrectomy alone. Four patients required chemotherapy including neo‐adjuvant chemotherapy (CCSK, NB) and adjuvant chemotherapy for PNET.

**Conclusions**: Though the clinical presentation of non‐Wilms tumour is like Wilms tumour, but the outcome varies depending up on the histopathology.

### PO-161. Surveillance for Boys with Localized Testicular Non‐Seminomatous Germ Cell Tumors: Hacettepe Experience {#pbc27455-sec-11290}

[B. Yalcin]{.ul} ^1^, B. Aydin^1^, C. Tanyel^2^, D. Orhan^3^, M. Cemaloğlu^1^, N. Kurucu^1^, A. Varan^1^, T. Kutluk^1^, C. Akyuz^1^

*^1^Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey; ^2^Hacettepe University Faculty of Medicine, Pediatric Surgery, Ankara, Turkey; ^3^Hacettepe University Faculty of Medicine, Pathology, Ankara, Turkey*

**Background/Objectives**: Owing to the high success rate in the salvage of recurrences, surveillance strategy after orchiectomy has been adapted in the management of stage 1 testicular nonseminomatous germ cell tumors (NSGCTs). In this study, we aimed to review our institutional experience with stage 1 testicular NSGCTs and teratomas managed with surveillance after surgery.

**Design/Methods**: We retrospectively reviewed the files of boys diagnosed with localized testicular NSGCTs between 1996 and 2017 at our hospital. Data for demographical characteristics, clinicopathological findings, serum tumor markers, events in the follow‐up, management approaches and final outcome were recorded and analyzed.

**Results**: Forty‐three cases with testicular NSGCTs were identified \[25 malignant NSGCTs (median age 24 months),18 teratomas (median age 15 months)\]. Histopathological diagnoses were: yolk sac tumors (YST) (n=20), mature teratomas (MT) (n=13), immature teratomas (IT) (n=5), mixed GCTs (n=3), embryonal carcinomas (EC) (n=2). Ages of 17 YSTs were ≤30 months; 3 mixed GCTs were 174, 185, 186 months‐old. Alpha feto‐protein (AFP) levels were elevated in 20 YSTs, 3 EC/mixed GCTs, 1 IT; beta‐HCG levels were elevated in 5 EC/mixed GCTs. Postoperatively, patients were under clinical and radiological surveillance with clinical, laboratory and radiological controls. At a median follow‐up of 60 months (2.5‐218), 4 cases experienced recurrences: 1 YST with AFP elevation only at 2.5 months, 1 YST with AFP elevation and pulmonary metastasis at 2.7 months, 1 mixed GCT with beta‐HCG elevation and retroperitoneal metastasis at 4.3 months, 1 EC with mediastinal metastasis only at 22.5 months. All recurrences were treated with BEP chemotherapy (bleomycin/etoposide/cisplatin) with complete remissions. Ten‐year event‐free survival was 88.5%. At a median of 70 months of follow‐up (4.6‐218) 10 cases were lost to follow‐up, 33 were alive and disease free.

**Conclusions**: Surveillance after orchiectomy is a reliable strategy in compliant stage 1 testicular NSGCT cases. Recurrences can be detected early and treated successfully.

### PO-162. Solid Pseudopapillary Neoplasm of the Pancreas in Children: Hacettepe Experience {#pbc27455-sec-11300}

[B. Yalcin]{.ul} ^1^, B. Yagci Kupeli^1^, S. Ekinci^2^, D. Orhan^3^, B. Oguz^4^, A. Varan^1^, B. Aydin^1^, T. Kutluk^1^, C. Akyuz^1^

*^1^Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey; ^2^Hacettepe University Faculty of Medicine, Pediatric Surgery, Ankara, Turkey; ^3^Hacettepe University Faculty of Medicine, Pathology, Ankara, Turkey; ^4^Hacettepe University Faculty of Medicine, Radiology, Ankara, Turkey*

**Background/Objectives**: Solid pseudopapillary neoplasm of the pancreas (SPNP) is mostly seen in young women in the second and third decades of life; it is quite uncommon in children. Complete surgical resection is curative in nearly all patients. We aimed to review our institutional experience with SPNP in children.

**Design/Methods**: Hospital charts of children \<18 years of age diagnosed to have SPNP at our hospital were reviewed retrospectively. Data for demographic characteristics, presenting symptoms, diagnostic interventions, physical examination findings, radiological data, extent of disease, diagnostic and management strategies and final outcome were collected and analyzed.

**Results**: Nineteen cases were diagnosed as SPNP at our hospital between 1992 and 2017 \[female/male, 16:3; median age, 13 years (range, 8.5‐16.5)\]. Most common symptom was abdominal pain. Physical examination was normal in 12/19 cases. Three cases were diagnosed incidentally. Most common tumor localization was the head of the pancreas. Median tumor diameter was 5 cm (1.4‐15). Histopathological diagnosis was confirmed in all cases (with fine needle aspiration biopsy in 6). One patient had abdominal disseminated disease and others had localized disease. Surgical interventions were enucleations in 10, distal pancreatectomies in 4 and total resection in 1 patient; 3 patients were followed with no surgery following diagnosis. Only one patient received adjuvant chemotherapy and radiotherapy. Overall, one patient died, one was lost to follow‐up at 164 months, and 17 were under follow‐up with no events at a median of 60 months (20‐308).

**Conclusions**: In children, SPNP demonstrates different clinical features compared to adults. Complete resection is curative in most patients. For unresectable or recurrent tumors, cisplatin based chemotherapy might be considered. In children, the optimal surgical strategy for SPNP is still debatable. Instead of radical resections, limited pancreatic resections, like enucleations, with negative surgical margins should be attempted to preserve as much pancreatic tissue and spleen as possible.

Treatment and Care ‐ Treatment Toxicity and Supportive Care {#pbc27455-sec-11310}
-----------------------------------------------------------

### PO-163. Possible Pediatric Nephrotoxicity of Cisplatin {#pbc27455-sec-11320}

[S. Abdelrahman]{.ul} ^1^, S. Salah^2^, M. Hamza^2^, H. Zaki^3^, A. Al Haddad^4^, H. Moawad^3^

*^1^Children\'s Cancer Hospital Egypt, Pharmaceutical services & Sciences, Cairo, Egypt; ^2^Children\'s Cancer Hospital Egypt, Clinical Research, Cairo, Egypt; ^3^Faculty of Pharmacy‐ Cairo University, Department of Pharmacology and Toxicology, Cairo, Egypt; ^4^Children\'s Cancer Hospital Egypt, Department of Pediatric Oncology and Stem Cell Transplantation, Cairo, Egypt*

**Background/Objectives**: Risk of Cisplatin nephrotoxicity increases with increased cumulative dose, bolus dosage and associated nephrotoxic drugs. Adverse Events\' Early detection and management improves patient care. Objectives were to identify incidence of Cisplatin nephrotoxicity within paediatrics, as well as associated risk factors, also to identify most sensitive test(s) for early toxicity detection and possibility of using early therapy cycle(s) exposure as predictor of late nephrotoxicity.

**Design/Methods**: Observational prospective study of 51 patients scheduled to receive Cisplatin‐based standard protocols was run. Patients were scored for nephrotoxic events (glomerular filtration rates and renal salt wasting) throughout chemotherapy course, using National Cancer Institute Common Terminology Criteria for Adverse Events. Events\' severity was correlated to patients\' demographics, Cisplatin dosage, associated nephrotoxic drugs and disease risk, using logistic regression analyses. Cramér\'s V was used to test strength of association between late nephrotoxicity relative to earlier cycles\' toxicity. Also between different nephrotoxicity events relative to overall patient exposure.

**Results**: Of 51 patients, 6(12%) developed grades 1,2 events, 14(27%) grade 3 and 31(61%) grade 4. Female gender, rapid Cisplatin dose rate and nephrotoxic drugs were significant predictors of higher toxicity grades upon univariate logistic regression (ODDs ratios \<1, 95% confidence interval \[CI\]). Upon multivariate logistic regression, aminoglycoside therapy was significant predictor of higher nephrotoxicity score (ODDs ratio:0.496, 95% CI). Cramér\'s V between early Cisplatin cycles:1,2,3 toxicity & cycle:4 were 0.394, 0.451, 0.489. Cramér\'s V between chemotherapy cycles:1,2,4 toxicity & late toxicity were \>0.4, while between renal events\' severity & overall patient exposure was \>0.4 for Sodium, Potassium, Phosphorus, Magnesium, creatinine (P‐values \<0.05).

**Conclusions**: Severe nephrotoxicity was observed in 61% of children receiving Cisplatin. Serum Potassium, Sodium and Phosphorus were most sensitive toxicity detectors. Nephrotoxicity during chemotherapy was indicator of late nephrotoxicity. Combination of female gender, rapid Cisplatin dose rate, and nephrotoxic drugs increased nephrotoxicity severity. Aminoglycosides with/without other factors, increased nephrotoxicity risk.

### PO-164. Impact of Discharge Before Noon Planning on Pediatric Hematology Oncology Services: Tertiary Care Centre Experience from Kingdom of Saudi Arabia {#pbc27455-sec-11330}

[A. Al‐Kofide]{.ul} ^1^, M. Ayas^1^, A. AlSeraihy^1^, A. Ali^1^, M. AlSaleh^1^, A. AlAhmari^1^, I. Ghemlas^1^, H. AlSaedi^1^, M. Zulfiqar^1^, M. AlEid^1^, A. AlObaidy^1^, S. Jafri^1^, K. Siddiqui^1^, D. Qattan^2^, D. Bushnak^2^, N. Farhan^2^, A. AlHmouz^2^, M. Hazeem^2^, F. AlShammari^3^, V. Mohammed^1^

*^1^King Faisal Specilaist Hospital & Research Centre, Pediatric Hematology / Oncology, Riyadh, Saudi Arabia; ^2^King Faisal Specilaist Hospital & Research Centre, Pediatric Nursing, Riyadh, Saudi Arabia; ^3^King Faisal Specilaist Hospital & Research Centre, Data Warehouse and Business Intelligence Department, Riyadh, Saudi Arabia*

**Background/Objectives**: Late Afternoon discharges are often associated with admission bottlenecks arising from sub‐optimal discharges, administrators encourage clinicians to adapt Discharge Before Noon (DBN) practice and at King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh an operational trigger of \> 36% DBN rate is set. Pediatric Hematology / Oncology (PHO) department is the national referral center for malignant and non‐malignant cases including but not limited to Hematopoietic Stem Cell Transplant (HSCT) care, an average of 500 new cases and 130 transplants per year.

**Design/Methods**: Weekly interdisciplinary round entitled "Discharge Planning Meeting (DPM)" was introduced in early 2016, pre‐/post‐intervention retrospective analysis to compare DBN rate, average Length of Stay (ALOS), outpatient utilization and re‐admission rate in post‐HSCT patients performed.

**Results**: Interdisciplinary presence by attending physicians, pharmacists, social workers, case managers, clinical Nurse coordinators, nutritionists, charge nurses, clinical research specialist, research data managers and front‐line staff resulted in early identification of sub‐specialized medical issues, OP care evaluation and early pre‐HSCT work‐up started. An increase in DBN rate by 16% (62%, 2016 vs.46%, 2015), while a decrease in ALOS by 5% (14.73, 2016 vs. 15.44, 2015) observed over a 12‐month period of intervention. Post‐HSCT patients known to be at risk of re‐admission within day 100 adds to patient flow; a decrease in day 100 re‐admission rate by 7.5% (39%, 2016 vs. 46.5%, 2015), while an increase of 43% (40 cases, 2015 vs. 28 cases, 2016)) in outpatient utilization observed, eliminating Hickman line related re‐admissions (40% in 2015).

**Conclusions**: In our experience interdisciplinary discharge planning process enabled system of effective communication and prioritization, this practice was awarded the "Annual Performance Award" in 2017 by the institutional Quality Management division. Detailed analysis to understand the effect of DPM on patient outcome and hospital metrics in terms of cost‐effectiveness is underway.

### PO-165. Evaluation of a Nutrition Feeding Algorithm for Children and Adolescents Undergoing Haematopoietic Stem Cell Transplantation {#pbc27455-sec-11340}

[E. Alexander]{.ul} ^1^, J. Bartle^1^, N. Koopmans^1^

*^1^Royal Children\'s Hospital, Dietetics, Melbourne, Australia*

**Background/Objectives**: The important role of nutrition support for paediatric patients undergoing haematopoietic stem cell transplantation (HSCT) is well recognised however international evidence demonstrates inconsistencies in the way nutritional needs are addressed through this acute time. A feeding algorithm for children and adolescents during HSCT has been developed by dietitians at the Royal Children\'s Hospital (RCH), Melbourne; with input from oncology, immunology, gastroenterology and clinical nutrition teams. This algorithm was developed to help clinicians make consistent decisions around appropriate use of enteral nutrition (EN) and parenteral nutrition (PN) during the acute HSCT phase. The purpose of this current project is to evaluate this algorithm to assess its effectiveness and outcomes; and determine barriers to its use.

**Design/Methods**: Standard nutritional practice during HSCT at RCH is for patients to have a nasogastric tube (NGT) placed around day 0 and commencement of enteral nutrition support using a peptide based formula. During this project, standard nutritional practice was followed with the implementation of HSCT feeding algorithm to guide recommendations for EN and PN use based on clinical symptoms.

**Results**: Data has been collected on all children and adolescents who underwent allogenic HSCT over a 6 month period (N=20). Data will be presented on the number of children within different diagnostic groups, anthropometric measures (z‐scores), use of EN and PN, compliance with nutrition feeding algorithm and barriers to its use.

**Conclusions**: A feeding algorithm for children and adolescents undergoing HSCT has been implemented and evaluated. Although the algorithm can aid consistent decision making for nutrition support in this patient group; barriers have been identified which for some patients can lead to inadequate use of EN and/or inappropriate use of PN. A future focus will be directed to addressing these barriers.

### PO-166. Challenges in Undertaking a Multi‐Center Prospective, Observational, Cohort Study in the Pediatric Oncology Population {#pbc27455-sec-11350}

T. Nayiager^1^, J. Halton^2^, L. Brandao^3^, M. Silva^4^, L. Jardine^5^, A. Chan^6^, L. Thabane^7^, [U. Athale]{.ul} ^6^

*^1^McMaster University, Pediatric Oncology, Hamilton, Canada; ^2^The Children\'s Hospital of Eastern Ontario CHEO, Pediatric Oncology, Ottawa, Canada; ^3^The Hospital for Sick Children, Pediatric Oncology, Toronto, Canada; ^4^Cancer Centre of Southeastern Ontario at Kingston General Hospital, Pediatric Oncology, Kingston, Canada; ^5^The Children\'s Hospital at London Health Sciences, Pediatric Oncology, London, Canada; ^6^McMaster University/Hamilton Health Sciences, Pediatric Oncology, Hamilton, Canada; ^7^McMaster University, Department of Health Research Methods‐ Evidence and Impact, Hamilton, Canada*

**Background/Objectives**: Well‐designed, prospective observational cohort studies are important to evaluate therapy‐associated morbidities in children with cancer. These studies provide the same level of evidence as randomized controlled trials, and avoid the disadvantages associated with retrospective studies namely limited insight into the temporal sequence, poor quality or missing data. However, conducting multi‐center prospective cohort studies can be challenging. We examine the obstacles encountered in the initiation and conduct of a multi‐center, prospective analytical cohort study evaluating central venous line dysfunction (CVL‐D), and its impact on outcome of children with cancer.

**Design/Methods**: This study aimed to enroll 510 children (\<18 years) with new diagnoses of non‐CNS cancer from 5 tertiary‐care pediatric oncology centers in Ontario. The study protocol was generated and reviewed in collaboration with site investigators and a statistician. Variables, data collection and management procedures, and timelines were established prior to commencement.

**Results**: The initial challenge was to secure funding for the study. Once support was established, despite pre‐planning, difficulties encountered resulted in delays to study timelines. The anticipated 2‐year start‐up and patient enrollment period was extended to 6 years to enroll the required sample size. Study commencement obstacles included variability in institutional ethics requirements and approval, delays in contracts, and barriers to patient enrollment. Logistical challenges during conduct of the study included staff turnover and managing large volumes of data. These challenges were addressed collaboratively with co‐investigators through monthly teleconferences, responding and adapting to issues strategically, and by engaging research staff at the study sites. Ultimately 486 eligible participants contributed data to the study.

**Conclusions**: Adequate planning, time and resources must be allotted to the execution of prospective observational cohort studies. Centralized or joint ethics approval across regional, national centers may expedite study initiation for multi‐institutional studies. Conducting supportive care studies alongside large therapeutic trials may facilitate high‐quality data collection.

### PO-167. Micronutrients do not Impact Overall Survival, Event Free Survival and Complete Remission in Acute Lymphoblastic Leukemia: A Prospective Observational Study of 155 Patients {#pbc27455-sec-11360}

[S. Bakhshi]{.ul} ^1^, R. Srivastava^1^, D. Pushpam^1^, G. Toteja^2^, D. Dhawan^1^

*^1^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; ^2^Indian Council of Medical Research, Nutrition, Delhi, India*

**Background/Objectives**: It is believed that micronutrients may be affecting various cellular processes and that their deficiency may adversely impact outcome. Data pertaining to the same are lacking. In view of this lacuna, we evaluated the impact of baseline vitamin B12, folic acid, selenium, copper, zinc and iron on overall‐survival (OS), event‐free‐survival (EFS) and complete remission (CR) in acute lymphoblastic leukemia (ALL).

**Design/Methods**: It was a prospective observational study conducted from October 2012‐October 2016 in de novo ALL patients. Serum folic acid was measured by Boil Competitive Immunoassay; vitamin B12 by Solid Phase competitive Chemiluminscent Enzyme Immunoassay; copper, zinc and selenium by mass spectrometry and iron by Ferrozine method without deproteinization. EFS and OS were measured by Kaplan‐Meier method. Comparisons for outcome were made with patients deficient vs. normal values. Another comparison was made by dividing patients based on median values of micronutrient.

**Results**: Total 155 ALL patients werer enrolled. Median age was 7 years (Range: 0.9‐18). Patients deficient in serum folic acid, vitamin B12, zinc, selenium, copper and iron were 68(43.9%), 48(31%), 16(10.3%), 9(5.8%), 53(34.2%) and 48(31%) respectively. There was no statistically significant difference between deficient vs. normal and below median vs above median for baseline micronutrient valueswith respect to OS, EFS and CR. There was a trend towards better EFS in patients with normal serum copper (P=0.09,HR=0.64,%CI:0.39‐1.06) and serum iron (P=0.08,HR=0.63,%CI:0.38‐1.04). On comparing patients by dividing them on basis of median values, there was a trend towards worse EFS in patients whose vitamin B12 was above median (P=0.08, HR=1.58, %CI:0.94‐2.63).

**Conclusions**: This is the largest study evaluating impact of micronutrients on outcome in ALL, and data suggests that baseline serum folic acid, vitamin B12, zinc, selenium, copper and iron do not impact OS, EFS and CR. Perhaps micronutient supplementation is not warranted in patients undergoing chemotherapy for ALL.

### PO-168. Isolation of Multi‐Drug Resistant Organisms in Stool Surveillance Cultures is a Risk Factor for Mortality in Children with Hematological Malignancies {#pbc27455-sec-11370}

S.B. Gundluru^1^, M. Biswal^2^, A. Trehan^1^, K. Jasleen^2^, P. Ray^2^, [D. Bansal]{.ul} ^1^

*^1^Postgraduate Institute of Medical Education and Research, Hematology/Oncology unit‐ Dept. of Pediatrics‐ Advanced Pediatrics Center, Chandigarh, India; ^2^Postgraduate Institute of Medical Education and Research, Medical Microbiology, Chandigarh, India*

**Background/Objectives**: Aim: To study the baseline colonization of gut by multidrug‐resistant organisms (MDRO) by surveillance stool cultures in children with hematological malignancies and its correlation with bacteria isolated from blood culture during episodes of febrile neutropenia during course of treatment.

**Design/Methods**: Design: Prospective‐observational study; Setting: University‐Government‐hospital; Study‐period: July‐2016 to December‐2017. The first and second stool cultures were collected at diagnosis and 2‐months after start of chemotherapy, respectively. Patients were followed for 6‐months for episodes of febrile neutropenia. The positive blood cultures obtained during 6‐months of treatment were compared with stool culture isolates for concordance. A concordance was defined as similar species and sensitivity pattern.

**Results**: Eighty patients were enrolled; the mean age was 5.9±3.2 years. Diagnosis: B‐ALL: 54 (68%), AML: 13 (16%), T‐ALL: 9 (11%), biphenotypic‐leukemia: 3 (4%) and T‐NHL: 1 (1%).

The number of MDROs in first and second stool cultures were 13 (16.4%) and 15 (22.1%), respectively (p=0.45). The stool‐isolates included Escherichia coli (56.1%), *Enterococcus faecium* (14.9%), *Klebsiella pneumoniae* (13.5%), among others. Eleven/80 (13.8%) patients died, from sepsis (54.5%), pneumonia (36.4%) and intra‐cranial bleed (9%). Of 13 patients with MDRO in first stool culture, 4 (30.8%) died within 26.7±13.9 days from start of treatment. Non‐MDROs were isolated in 66 (82.5%) patients from first stool culture. Of these 7 (10.6%) died within 46.3±36.9 days. A positive blood culture was obtained in 22 patients: 2 (8.7%) MDROs were identified. In merely one patient, there was a concordant Escherichia coli (non‐MDRO) in the first stool culture and a blood culture.

An increase in mortality among patients colonized with MDROs (30.8%) was observed, as compared to those colonized with non‐MDROs (10.6%) (p=0.02). However, there was no concordance of MDROs in stool culture with isolates from subsequent blood culture.

**Conclusions**: Isolation of MDROs in stool surveillance cultures is a significant risk factor for mortality in children with hematological malignancies.

### PO-169. Antibacterial Prophylaxis with Fluoroquinolones in Children with Acute Myeloid Leukemia: Impact on Viridans Group Streptococci {#pbc27455-sec-11380}

[T. Bauters]{.ul} ^1,2^, L. Staels^2^, G. Laureys^1^, L. Willems^1^, B. De Moerloose^1^

*^1^Ghent University Hospital, Pediatric Hematology‐ Oncology and Stem Cell Transplantation, Ghent, Belgium; ^2^Ghent University Hospital, Pharmacy, Ghent, Belgium*

**Background/Objectives**: Infections remain an important cause of morbidity and mortality in children with acute myeloid leukemia (AML). In recent years, ciprofloxacin prophylaxis was introduced in our hospital to reduce the risk of infectious complications. Recent reports however, describe breakthroughs of Viridans Group Streptococci (VGS) bacteremia in children with AML receiving fluoroquinolone (FQ) prophylaxis.

The aim of this study is to investigate the impact of FQ‐prophylaxis on bloodstream infections in terms of prevalence and type of isolated species in a pediatric AML population who received FQ prophylaxis and those who did not.

**Design/Methods**: Retrospective study in pediatric patients hospitalized in the period 11/2009‐4/2017 and treated according to subsequent international AML protocols. Pharmaceutical and laboratory records were analyzed to determine the use of FQs (ciprofloxacin) and to identify positive hemocultures (HCs). Statistical analysis was performed by Chi square tests.

**Results**: The study included 26 patients with de novo or relapse AML, representing 195 episodes of hospitalization. FQ prophylaxis was administered in 109/195 episodes (55.9%). HCs were positive in 17 episodes (17/195; 8.7%) and in 13 of these episodes (13/17; 76.5%) FQ prophylaxis was used. When looking at the species isolated from the 17 HC‐positive episodes, a mix of VGS/non‐VGS (1/4) or a non‐VGS species (3/4) was identified in the patients who did not receive prophylaxis. The 13 HC‐positive episodes with FQ (13/17; 76.5%) revealed 11/13 (84.6%) VGS or a mix of VGS/non‐VGS and 2/13 (15.4%) non‐VGS species (p = 0.022).

**Conclusions**: The use of FQ prophylaxis was associated with a significantly higher number of VGS positive HCs. This prompted us to stop FQ prophylaxis in our pediatric patients. A larger retrospective study to validate these findings is currently ongoing.

### PO-170. Thrombotic Events in Pediatric Oncological Patients with Central Venous Access Devices (CVAD) -- Single Center Retrospective Study Over 11 Years {#pbc27455-sec-11390}

[O. Beck]{.ul} ^1^, J. Goedeke^2^, S. Hofmann^1^, A. Russo^1^, A. Wingerter^1^, M. Neu^1^, H. Rossmann^3^, O. Muensterer^2^, J. Faber^1^

*^1^University Medical Center of the Johannes Gutenberg University Mainz, Children\'s Hospital‐ Pediatric Hematology‐ Oncology & Hemostaseology, Mainz, Germany; ^2^University Medical Center of the Johannes Gutenberg University Mainz, Children\'s Hospital‐ Pediatric Surgery, Mainz, Germany; ^3^University Medical Center of the Johannes Gutenberg‐ University Mainz, Institute of Clinical Chemistry and Laboratory Medicine, Mainz, Germany*

**Background/Objectives**: Central venous access devices (CVAD) provide important benefits in the management of oncological pediatric patients. However, these catheters are responsible for severe complications, in particular thrombotic events.

In this context, we aimed to analyze all patients receiving a CVAD in the Department of Pediatric Hematology and Oncology of the University hospital of Mainz over a period of 11 years, focused on CVAD related complications.

**Design/Methods**: From 2005 until 2017, pediatric oncological patients with CVAD were retrospectively included in the study. Data on demographics, as well as intraoperative and postoperative complications were extracted.

**Results**: A total of 309 patients were analyzed. In 87.6% of the patients, CVAD were implanted at the right body side (Cephalic Vein: 35.3%; Jugular Vein: 47.8%; Subclavian Vein: 4.5%). Six patients with severe thrombotic complications were identified. In all involved patients CVAD were implanted at the right side. In 3/6 of patients a thrombosis of the upper extremity was found. 3/6 suffered from a severe pulmonary embolism (PE) diagnosed in the first 50 days of treatment. In 2/3 patients with PE a multi‐lumen tunneled CVAD was implanted. In 5/6 patients at least one mutation in the plasminogen activator‐inhibitor‐1 gene polymorphismand in all analyzed patients 5/5 at least one mutation in the methylene tetrahydrofolate reductase (MTHFR) could be detected. All thrombotic events could be treated successfully, all patients survived and could continue chemotherapy. In all patients, methotrexate was a component of the treatment protocol.

**Conclusions**: In our cohort, thrombotic events are rare. In all analyzed patients, a mutation of PAI‐1 and of MTHFR could be found. Beside genetic evaluation in advance, the measurement of homocysteine could be a possible support to specify the risk under chemotherapy.

### PO-171. Efficacy of Piperacillin Tazobactum as Empiric Treatment of Febrile Neutropenia in Children and Young Adults on Cancer Chemotherapy {#pbc27455-sec-11400}

[A. Borker]{.ul} ^1^, P. Subramanian^1^, A. Chichra^1^

*^1^Asian Cancer Institute‐ Somaiya Ayurvihar‐ Mumbai‐ India, Department of Paediatric Oncology, Mumbai, India*

**Background/Objectives**: Piperacillin‐tazobactam (PTZ) is recommended for the empiric treatment of febrile neutropenia (FN) in patients receiving chemotherapy. We evaluated the efficacy of PTZ for the treatment of FN in our unit.

**Design/Methods**: It was a retrospective study of patients admitted for FN or neutropenic infections from September 2014 to February 2018. All patients received PTZ at 100 mg/kg/dose 8 hourly as first line antibiotic therapy. Second line antibiotics were started if the patient did not respond after 72 hours or if cultures so dictated. Coverage for gram positive organisms and anti fungal therapy was administered as per guidelines. Antibiotics were continued till 24 hours after defervescence, or recovery of neutropenia, or of documented infection or documentation of a negative blood culture whichever was later.

**Results**: There were 51 episodes of FN in 19 patients with age range from 1 to 23 years(mean age 9 years). The male to female ratio was 7.5:1. The mean lowest ANC was 118/cmm (range: 3--486/cmm). Fourteen patients had hematolymphoid malignancies and 5 patients had solid tumours. Thirty‐nine of the 51 episodes (76%) had high risk neutropenia. The response to first line antibiotic was seen in 19 episodes (37 %). Clinically documented infections (CDI) were present in 13 episodes (25 %). Response to first line antibiotics was seen in only 1 case with CDI. Microbiologically documented infection (MDI) was present in 10 episodes (19 %). Nine MDIs were due to gram negative organisms and 1 with Candida. None of the MDIs responded to first line antibiotics. Primary anti fungal prophylaxis was used in 17 episodes. There were 10 episodes of presumptive fungal infection and 2 with proven fungal infection. There was no mortality.

**Conclusions**: Response to PTZ as first line antibiotic was poor. Majority of patients had high risk neutropenia and needed second line antibiotics.

### PO-172. Evaluation of Silibinin Effect on Methotrexate Induced Hepatotoxicity in Rats {#pbc27455-sec-11410}

E. Kürt^1^, A. Çetinkaya^2^, G. Turan^3^, M. Köroğlu^4^, H. Yazar^5^, M.E. Büyükokuroğlu^6^, [M. Büyükavcı]{.ul} ^7^

*^1^Sakarya University Faculty of Medicine, Department of Pediatrics, Sakarya, Turkey; ^2^Abant İzzet Baysal University Faculty of Medicine, Department of Physiology, Bolu, Turkey; ^3^Sakarya University Faculty of Medicine, Department of Peathology, Sakarya, Turkey; ^4^Sakarya University Faculty of Medicine, Department of Microbiology, Sakarya, Turkey; ^5^Sakarya University Faculty of Medicine, Department of Biochemistry, Sakarya, Turkey; ^6^Sakarya University Faculty of Medicine, Department of Pharmacology, Sakarya, Turkey; ^7^Sakarya University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Sakarya, Turkey*

**Background/Objectives**: Methotrexate (MTX) is an efficient anticancer and immune suppressant drug. Hepatotoxicity is one of the major side effects of MTX and limits its use. In this study, we investigated the hepatoprotective effect of silibinin and the role of oxidative stress markers and cytokines on high dose methotrexate induced hepatotoxicity in rats.

**Design/Methods**: Rats were randomly divided into five groups (n:7). MTX (20 mg/kg, intraperitoneally) was administered on first day in all groups except control. Silibinin was injected for five days in MTX‐SLB25, MTX‐SLB50 and MTX‐SLB100 groups at a dose of 25, 50 and 100 mg/kg/day, respectively. On sixth day, blood and liver samples were obtained and rats were sacrificed. Serum total antioxidant capacity, total oxidant status, total thiol, native thiol, alanine aminotransferase (ALT), aspartate transaminase (AST), bilirubin, albumin, TNF‐α and IL‐10 levels were measured. Oxidative stress index and disulphide levels were calculated from these parameters. In addition, histopathological evaluation of liver tissues was peformed.

**Results**: MTX reduced total antioxidant capacity, however, had no effect on total oxidant capacity and oxidative stress index. MTX increased disulphide/total thiol ratios and reduced total thiol, native thiol levels, and native/total thiol ratios by inducing oxidative stress. On the other hand, silibinin reduced disulphide levels. MTX reduced ALT and albumin levels, however, did not affect AST and bilirubin levels. TNF‐α and IL‐10 levels did not change by administration of MTX and/or silibinin. Histopathologic examination revealed that MTX increased hepatic damage and 50 mg/kg/dose of silibinin prevented inflammatory cell infiltration in particular.

**Conclusions**: Silibinin (50 mg/kg/day) reduced the hepatic damage in MTX induced hepatotoxicity in rats. However, this effect did not reflect on biochemical markers. The protective effect of silibinin is made by antioxidant properties, not by cytokines.

### PO-173. False Positivity of Gallium‐68 Dota‐ Octreotid PET/MR Secondary to cis‐Retinoic Asid Treatment in a Patient with Neuroblastoma {#pbc27455-sec-11420}

[F.B. Çakır]{.ul} ^1^, L. Uslu Beşli^2^, T. Kıran^3^

*^1^Associate Professor, Bezmialem Vakif University Pediatric Hematology Oncology, Istanbul, Turkey; ^2^Istanbul University Cerrahpaşa Medical Faculty, Nuclear Medicine, Istanbul, Turkey; ^3^Bezmialem Vakıf Üniversitesi, Pathology, Istanbul, Turkey*

**Background/Objectives**: 13‐cis retinoic asid (RA), is a type of Vitamin A that is used to convert malignant neuroblasts to benign mature cells in neuroblastoma. There are reports stating vitamin A causse hypercalcemia and metastasis like bony changes. Gallium‐68 DOTA‐Octreotid scan is reported to be better than I‐123 MIBG in the diagnosis of the lesions in neuroblastoma. A 5 yrs old neuroblastoma case under RA treatment is reported due to the false positivity of Gallium‐68 DOTA‐Octreotid scan.

**Design/Methods**: A 5 yrs old boy was diagnosed as neuroblastoma originating from right sided adrenal gland. He had no distant metastasis and were free of tumor after gros total resection of the mass lesion. He was started of RA as the maintenance therapy and under follow‐up with magnetic resonance imaging (MRI) obtained in every 3 months.

**Results**: In his last MRI, a 18x10 mm so‐called metastatic lesion in his right femoral proximal diaphysis was detected. He had no complain and his physical examination was unremarkable. His blood chemistry including neuron specific enolase and urine vanilmandelic acid were within normal limits. Ga‐68 DOTATATE PET/MRI was obtained in order to rule out a bony metastasis. However, the lesion was DOTA positive and confirmed metastasis. A tru‐cut biopsy is carried out and the pathology was within normal tissue limits.

**Conclusions**: RA treatment might cause metastasis like changes in the bones. Ga‐68 DOTATATE PET/MRI is reported to be superior in detecting the primary or relapsing lesions. However, this report shows that Ga‐68 DOTATATE PET scan might be false positive and great caution should be undertaken particularly under RA treatment.

### PO-174. Implementation of a New Risk Classification Strategy in Children with Febrile Neutropenia and its Impact on Mortality in a Pediatric Oncology Center in Colombia {#pbc27455-sec-11430}

[A. Castro]{.ul} ^1,2^, W. Coronell^3^, G. Perez^4^, S. Paternina^2^, C. Artega^5^

*^1^Universidad de Cartagena, Pediatric Department, Cartagena, Colombia; ^2^Clinica Blas de Lezo, Oncohematology department, Cartagena, Colombia; ^3^Universidad de Cartagena, Microbiology department, Cartagena, Colombia; ^4^Clinica Blas de Lezo, Pediatric intensive care unit, Cartagena, Colombia; ^5^Universidad Rafael Nuñez, Epidemiology, Cartagena, Colombia*

**Background/Objectives**: Febrile neutropenia (FN) is a frequently complication in pediatric oncology. The therapeutic approach is a challenge for the oncology units in low in‐come countries.

Intensives chemotherapy increase the risk to have FN. Between 48% and 60% of the patients with FN have an infection and 20% present bacteremia. The mortality associate with FN events is near 10% in high in‐come countries.

Determine the impact on mortality of a new risk classification strategy in pediatric patients with FN.

**Design/Methods**: Comparative study of three cohorts. First cohort was retrospective, international management protocols of the patient with FN were applied and C‐reactive protein, procalcitonin and lactate were determined to establish the risk classification of sepsis. Second cohort was prospective, in which the new risk classification was applied, measuring biomarkers at admission, at 24, 48 and 72 hours, generating early interventionist management for high‐risk patients. In the third cohort, the new risk classification was maintained and modifications were added to the use of antimicrobial therapy.

**Results**: We analyzed 293 FN events (2014: 84, 2015:81, 2016: 128), 2014 cohort were treated with international guidelines, 2015 and 2016 cohort were treated with our own protocol. There were no differences in the sex distribution, median age was 8 years. The diagnosis were acute lymphoblastic leukemia 52.9%, acute myeloid leukemia 14.33%, others tumors 25.77%. Neutrophil count were 266.8(2014), 110.5(2015) and 65.8(2016). Positive blood cultives were in 33.7%(2014), 33.33%(2015) and 21.1%(2016). 100% of patients in 2014 and 65.55%(137/209) in 2015 and 2016 cohorts were classifieds high risk. The mortality was 10.7%(2014), 4.9%(2015) and 4.7%(2016).

**Conclusions**: The implementation of this protocol in our institution decreased the mortality in patients with FN in 2 consecutives years. The adequate risk classification offers a diferents treatment strategies getting better final results. The own risk classification strategies are very important for each oncology center.

### PO-175. A Child with Acute Myeloid Leukaemia Complicated by Calcaneal Osteomyelitis due to Atypical Mycobacterial Infection after Induction Chemotherapy with Mitoxantrone, Etoposide, Cytarabine and Daunorubicin {#pbc27455-sec-11440}

[W. Chan]{.ul} ^1^, P. Lee^1^, A. Chiang^1^, D. Cheuk^1^, G. Chan^1^, S.Y. Ha^1^

*^1^Queen Mary Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Tuberculosis (TB) is an important infection in Hong Kong (HK). HK listed by listed by the World Health Organization (WHO) as having an intermediate burden of TB amongst Western Pacific Region\'s areas. Every year there are about 4500 notified cases of TB in HK. About 0.6 out of every 1000 persons in HK develop the disease each year. This rate is about 10 times higher than that of other western developed countries like the United States (US) and the United Kingdom (UK). Myelosuppressive effect of acute myeloid leukaemia (AML) and subsequent cytotoxic chemotherapy further predispose patients to develop TB infection.

**Design/Methods**: Hereby we reported a 4‐year old girl with acute myeloid leukaemia (AML) t(8,21) from our institution who received induction chemotherapy according to NOPHO‐AML 2012 protocol who developed right calcaneal osteomyelitis due to atypical mycobacteria after 2 courses of induction chemotherapy. Literature review and personal communications with collaborators within NOPHO group did not experience similar complications before.

**Results**: Urgent surgical debridement was performed for the patient and intraoperatively confirmed diagnosis of right calcaneal osteomyelitis with extension to form subcutaneous abscess. Drainage was done followed by anti‐tuberculosis chemotherapy with clarithromycin, levofloxacin, amikin and ethambutol. Good clinical response was noted.

**Conclusions**: High index of suspicion for tuberculosis infection is required for AML patients who developed prolonged neutropenia or neutropenic fever after immunosuppresive chemotherapy, espeically in endemic areas such as Hong Kong.

### PO-176. Outcome of Children with Acute Lymphoblastic Leukemia and Successful Experiences in Reducing Abandonment at Hue Central Hospital from 2007 to 2017 {#pbc27455-sec-11450}

[H. Chau Van]{.ul} ^1^, H. Tran Kiem^1^, M. Phan Xuan^1^, T. Phan Huy^1^, L. Nguyen Dac^1^, H. Nguyen Kim^1^, K. Watanabe^2^

*^1^Hue Central Hospital, Pediatric Center, Hue, Vietnam; ^2^Asian Children\'s Care League, Asian Children\'s Care League, Tokyo, Japan*

**Background/Objectives**: Hue Central Hospital (HCH) plays a key role to treat Acute Lymphoblastic Leukemia (ALL) in the central zone of Vietnam which covers geographically wide areas. Before 2007, the survival rate was very low, and abandonment rate was more than 50%.The aims of this study are to determine the outcome of newly diagnosed children with ALL treated at HCH from June 2007 to December 2017 and to report our experiences in reducing the abandonment

**Design/Methods**: This is a retrospective review of 238 children with ALL admitted from June 2007 to December 2017. The diagnosis was confirmed by morphological FAB criteria and cytochemistry. Patients were classified as standard risk (SR) or high risk (HR) according to NCI criteria, using modified CCG‐1881 and CCG‐1882 protocol. Social supports were provided to patients/families

**Results**: A total of 238 children with ALL were analyzed with mean age of 4.7 years ranging from 1 month to 16 years. The male to female ratio was 2:1. SR and HR patients were 139 (59%) and 99 (41%) respectively. The overall complete remission (CR) rate on day 28 of induction were 92.1% (SR) and 84.9% (HR). Induction death were 3.6% (SR) and 10.1% (HR). Patients accounted for 44 (18.5%) had relapses which occurred in isolated BM n=12, isolated CNS n=17, combined BM and CNS n=13, isolated testis n=2. Overall survival (OS) at 10 years were 70.7% (SR) and 51.5% (HR).The event‐free survival (EFS) at 10 years were 66.1%(SR) and 47.3%(HR). Abandonment cases were 9 (3.8%).

**Conclusions**: With less toxic modified protocol, survival rate has been improved and treatment related mortality was minimized though high relapse rate is still an issue. Abandonment has been reduced successfully with holistic strategies such as financial support, managing family group, providing education, early follow‐up of patients who missed appointments and free accommodation near hospital for patients/families.

### PO-177. Dexamethasone Dosing in Children with Brain Tumours: An Unresolved Problem {#pbc27455-sec-11460}

[S. Curry]{.ul} ^1^, J. Dutton^2^, S. Awrey^3^, E. Bouffet^2^, U. Bartels^2^

*^1^University Hospital Southampton, The Department of Paediatric Oncology, Southampton, United Kingdom; ^2^The Hospital for Sick Children, The Division of Haematology & Oncology, Toronto, Canada; ^3^Princess Margaret Cancer Center, The Department of Radiation Medicine, Toronto, Canada*

**Background/Objectives**: Corticosteroids remain the most utilized medication in supportive care for children with brain tumours, but no standardized dosing regimen exists. While dexamethasone is useful, it causes significant side effects especially if given in high doses and for lengthy time periods. We hypothesized that a low dose dexamethasone (LDD) regimen would be non‐inferior to the usual dose (UDD) regimen for symptom control in children undergoing cranial or cranio‐spinal radiation for their brain tumour.

**Design/Methods**: A Pan‐Canadian multi‐centre non‐inferiority RCT aimed to prospectively evaluate the effectiveness of LDD (1mg/m^2^/day) versus UDD (5mg/m^2^/day) for treating radiation induced vomiting and headaches. This study failed to accrue adequately. Subsequently, a survey was distributed to institutions, endeavoring to discover factors hampering recruitment. Respondents specified their local dexamethasone prescribing practices.

**Results**: This study opened from December 2010 to May 2015. Twenty‐five of proposed 64 subjects were recruited, and 4 children were randomised to receive dexamethasone after developing symptoms; 2 in either arm. Only 25% of Canadian institutions enrolled patients. Factors identified as barriers to enrolment included: trial administration work, patient ineligibility due to prior steroid administration, short recruitment window and the time taken on site for trial opening. In 2016, 80% of participating institutions did not have a local standard for dexamethasone prescribing. A wide variation in the dexamethasone dose prescribed for children with radiation induced symptoms was highlighted, ranging from 0.1mg/kg twice daily up to 10mg/m2/day.

**Conclusions**: A prospective trial to prove that a LDD is sufficient therapy for radiation induced symptoms, regrettably failed to accrue. Notably, only 4 of 25 patients developed symptoms of headaches and/or vomiting during cranial radiation while on prophylactic 5 HT‐3 antagonists. Large discrepancies persist in dexamethasone prescribing regimens. There remains a "to be determined" optimal minimal dose of dexamethasone for paediatric patients, who are especially vulnerable to side effects.

### PO-178. Invasive Fungal Infection (IFI) of the Central Nervous System (CNS) in Children with Haematological Malignancy: Aggressive Multidisciplinary Management Improves Outcome {#pbc27455-sec-11470}

[K.T. D]{.ul} ^1^, R. Bhattacharyya^1^, D.C.Y. Low^2^, W.H.N. Tan^3^, A.M. Tan^1^

*^1^KK Women\'s and Children\'s hospital, Paediatric haematology/Oncology, Singapore, Singapore; ^2^KK Women\'s and Children\'s hospital, Neurosurgical Service, Singapore, Singapore; ^3^KK Women\'s and Children\'s hospital, Paediatric Medicine‐ Infectious Disease Service, Singapore, Singapore*

**Background/Objectives**: Patients with haematological malignancy and IFI of the CNS have high mortality rate. We report three children with acute lymphoblastic leukaemia/ lymphoma and IFI of CNS who were successfully salvaged with multidisciplinary management.

**Design/Methods**: This is a retrospective study of children with haematological malignancy and IFI of CNS treated in our institution between January 2013 and December 2017.

**Results**: Case1: Six year old boy with Philadelphia chromosome positive B acute lymphoblastic leukaemia (ALL) presented with paranasal sinusitis during induction therapy. Antral wash out and resection of necrotic tissues was performed and Rhizopus species was identified. Antifungal therapy with ambisome, voriconazole and repeated debridement were done with temporary chemotherapy interruption. He developed intracranial extension with infarcts of left anterior and middle cerebral arteries causing hemiparesis. He underwent bi‐frontal craniotomy and resection of affected brain. Leukaemia therapy was restarted and antifungal therapy continued for 1 year. Although in minimal residual disease (MRD) remission initially his leukaemia relapsed in maintenance and presently planned for stem cell transplant in second remission but without fungal recurrence.

Case 2: Ten year old girl with T cell ALL developed intracranial haemorrhage during induction chemotherapy secondary to CNS aspergillus infection. She was treated with craniotomy and evacuation on 3 occasions with prolonged antifungal therapy. Despite treatment interruption she completed chemotherapy and remains in remission presently 30 months off treatment with persisting right hemiparesis and expressive aphasia.

Case3: Nine year old boy with T lymphoblastic lymphoma during induction chemotherapy developed disseminated aspergillus infection of lungs, brain and spinal cord requiring drainage of spinal intradural abscess and prolonged antifungal therapy with ambisome and voriconazole. He remains in complete remission 28 months from initial diagnosis with persistent monoparesis.

**Conclusions**: These three cases highlight that with aggressive combined medical and neurosurgical management outcome of CNS IFI has improved although with neurological morbidity.

### PO-179. Management of Non‐Neutropenic Fever in Paediatric Oncology Patients: Single Centre Study from Singapore {#pbc27455-sec-11480}

[K.T. D]{.ul} ^1^, A.A. Khaing^2^, R. Bhattacharyya^1^, A.M. Tan^1^, M.Y. Chan^1^

*^1^KK Women\'s and Children\'s hospital, Paediatric haematology/Oncology, Singapore, Singapore; ^2^Yangon Children\'s Hospital, Paediatric Haematology/Oncology, Yangon, Myanmar Burma*

**Background/Objectives**: Children with cancer are known to have increased risk of blood stream infections due to immunosuppression and indwelling central venous catheters. Guidelines for the care of febrile neutropenic episodes are well studied but little evidence is available to direct care of the febrile non‐ neutropenic patients with or without central venous catheters.

Objective is to perform a retrospective review of febrile episodes in non‐ neutropenic paediatric patients with cancer and determine patients who have significant infection (bacteraemia) that could influence decision regarding empirical antibiotics therapy.

**Design/Methods**: This is a single institution, retrospective review of episodes of non‐neutropenic fever (temperature of 38 ˙Cx2 or ≥ 38.5 ˙C and absolute neutrophil count ≥1000/uL) in paediatric oncology patients admitted to KK Women\'s and Children\'s hospital in one year.

**Results**: A total of 113 episodes of non‐neutropenic fever in 67 patients were identified and majority of patients had a diagnosis of acute leukaemia (75%). All patients were admitted for monitoring and intravenous antibiotics. Empirical treatment with ceftrixone was administered to 94% of patients. All patients had central venous catheter. Bacteraemia was found in five (4.4%); Sternotrophomonas maltophilia, Campylobacter jejuni, Coagulase‐negative staphylococcus (CONS) and Acinetobacter baumannii in two. One with CONS bacteraemia required port removal. Hypotension required normal saline bolus was seen in two patients; one had bacteraemia with sternotrophomonas and the other had no positive blood culture. There was no death due to sepsis.

**Conclusions**: This study highlights that even in non neutropaenic paediatric oncology patients with central line have a 4.4% risk of bacterial sepsis and the decision to treat with empiric intravenous antibiotics should be based on clinical suspicion and clinicians should not rely on neutrophil count alone while making antibiotic initiation decision.

### PO-180. Perceptions of Enteral and Parenteral Nutrition in Pediatric Oncology Patients and Parents in a Turkish Pediatrİc Oncology Clinic {#pbc27455-sec-11490}

[U. Demirsoy]{.ul} ^1^, F. Corapcioglu^1^

*^1^Kocaeli University Medical School, Department of Pediatric Oncology, Kocaeli, Turkey*

**Background/Objectives**: Poor nutrition as a consequence of pediatric malignancy is frequently witnessed worldwide. Its' negative effect on the treatment success is well‐known. Medical treatment providers have been hardworking to prevent undernutrition in pediatric cancer but both patients' and parents' views on the issue is not well identified. Herein, we present the nutritional knowledge of our patients with cancer and their parents.

**Design/Methods**: This study was conducted in Kocaeli University Medical School Pediatric Oncology Clinic from November 2017 to March 2018. Patients aged 8‐22 years who have received or were receiving cancer treatment and their parents were included in the study. Two different questionnaires about nutritional beliefs were designed by the investigators. All patients that fulfilled study criteria were asked to complete questionnaires (13 questions for patients and 19 questions for parents) in the outpatient clinic.

**Results**: A total of 87 volunteers (38 patients/49 parents) participated. The majority of patients (median age: 15 years) were patients with Hodgkin disease (34.2%), non‐Hodgkin lymphoma (15.8%) and CNS tumors (13.2%). Twelve patients (31.6%) were receiving cancer treatment during the study. Twenty‐one patients (55.3%) thought they had nutrition problem during cancer treatment and 4 (19%) of them had parenteral nutrition (PN). Twenty‐four patients (63.2%) were advised to use oral nutrition supplements (ONS) but 7 patients (29% of advised group) refused. Most disliked features of ONS were bad taste and nauseous effect. Three parents (6.1%) had no education while 25 parents (51%) graduated from primary school. Twenty‐one parents (43%) stated use of ONS. All of the parents and patients who used ONS believed they had varying but positive effects. In both groups, PN was the most preferred method when needed.

**Conclusions**: Turkish children with cancer and their parents are generally in favor of oral nutrition supplements. But, they are also prone to choose PN when oral intake is not possible.

### PO-181. Risk Factors Associated with Anthracyclines Among Pediatric Patients {#pbc27455-sec-11500}

[A. Fatima]{.ul} ^1^, S. Zaidi^2^

*^1^SKMC & RC, Pediatric Oncology, Lahore, Pakistan; ^2^Wecare medical centre, oncology, Lahore, Pakistan*

**Background/Objectives**: Anthracyclines (i.e., doxorubicin, daunorubicin) are the mainstay treatment and have significant impact on outcome in many pediatric chemotherapy protocols. Our study aims to find out the risk factors for Anthracycline induced cardiac dysfunction in pediatric patients. The study was conducted in Children Hospital and Shaukat Khanum Hospital Lahore. Multiple logistic regression model was applied to assess the risk factors for development of cardiac dysfunction.

**Design/Methods**: 110 pediatric oncology patients were available for final analysis. 75 (66%) children were males and mean age was 74 ± 44 months. ALL (n = 70, 64%) was the most common primary diagnosis followed by lymphoma (n = 19; 17%) and AML (n = 12, 11%). Daunorubicin alone or in combination with doxorubicin was used in (n = 94, 85%) patients and cumulative dose \< 300 mg was used in (n = 95; 86%) children. 24 (22%) children received radiation therapy as per protocol and sepsis were observed in 47 (43%) cases.

**Results**: Post anthracycline, 15 (14%) children had cardiac dysfunction within a month; out of them 10/15 (67%) had isolated diastolic dysfunction, while 28 (25%) developed dysfunction within a year. 19 (17%) had pericardial effusion. 11 expired and out of them, 7 had significant cardiac dysfunction. Cumulative dose \> 300 mg/m2 (p \< 0.001; AOR 2.3), radiation therapy (p = 0.009; AOR 3.5) and sepsis (p = 0.002; AOR 2.6) were found to be independent risk factors associated anthracycline induced cardiac dysfunction. At univariant level use of daunorubicin alone or in combination therapy (p \< 0.001)

**Conclusions**: In conclusion anthracycline induced cardiac dysfunction is mostly related to cumulative dose \> 300 mg/m2, use of Daunorubicin alone or in combination with doxorubicin, mode of delivery, radiation therapy and sepsis. Regular long term follow‐up with cardiologist is the key point for early diagnosis and therapy for a long term survival.

### PO-182. Investigating Malnutrition Among Cancer Patients Receiving Chemotherapy in a Tertiary Care Hospital of Pakistan {#pbc27455-sec-11510}

[A. Fatima]{.ul} ^1^

*^1^SKMC & RC, Pediatric Oncology, Lahore, Pakistan*

**Background/Objectives**: Cancer patients often suffer from Malnutrition which raises the risk of infections. Being immunocompromised, there is a marked reduction on quality of life (QoL) and health outcome. Malnutrition also enhances the incidence of postoperative complications such as delayed wound healing, wound dehiscence, morbidities and mortalities. To investigate malnutrition among cancer patients and to assess the nutritional status of patients receiving chemotherapy.

**Design/Methods**: The study was conducted in Sir Ganga Ram Hospital, Lahore. Simple screening tool (Short screening sheet) for malnutrition was used. Nutritional assessment of 80 patients receiving chemotherapy was done by assessing BMI, mid upper arm circumference MUAC, triceps skin‐fold thickness TST, serum albumin, Total lymphocytes count. Nitrogen Balance and intake of macronutrients were also analysed.

**Results**: According to full nutritional assessment, 42 patients (52.5%) out of 80 were found malnourished. Short screening sheet identified 51 patients as malnourished who were receiving chemotherapy. The SSM had a specificity of 0.88 and sensitivity of 0.72. 62% of the patients exhibited negative nitrogen balance.

**Conclusions**: Nutrition is the most neglected area of clinical care. Early nutritional support and counselling is essential in order to improve patients Quality of Life (QoL). Mass media should be involved so that adequate attention can be given to nutritional issues arising in diagnostic and therapeutic procedures

### PO-183. Epidemiological Profile of Blood Current Infections in Children with Cancer {#pbc27455-sec-11520}

[C. Fiori]{.ul} ^1^, R. Vargas^1^, C. Sakuma^1^, A. Rosa^1^

*^1^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric Oncology, Cascavel, Brazil*

**Background/Objectives: Introduction**: The hospital‐acquired infections (HAI) in patients with malignant and oncological hematological diseases are an important cause of morbidity and mortality. During the period of bloodstream infection, empirical antibiotic therapy should be used immediately, according to the prevalence of microorganisms that most affect each age group with its specific characteristics according to protocols and scientific studies worldwide.

**Objective**: To analyze the epidemiological profile of hospital ‐ acquired bloodstream infections in children aged 0 to 9 years of age in the Cancer Hospital from January 2007 to December of 2015.

**Design/Methods**: The study was performed in the cross‐sectional model, with retrospective analysis of blood cultures reported by the active surveillance method, coordinated by the Hospital Infection Control Commission.

**Results**: 130 episodes of infection contributed to in‐hospital morbidity in the period and site studied, prolonging hospitalization time. The ICS were the main hospital infections (IH) reported by the CCIH. The predominant age group was in children aged ≤ 3 years. The isolated infectious agent was described in 94% of the ICS, being 37,3% classified as gram‐positive and 45,1% gram‐negative and 13% as fungus. The most frequent pathogen was the Coagulase negative Staphylococcus group (19.6%), followed by Pseudomonas aeruginosa (15.2%) and Candida spp. (12.2%). The oncological disease that most presented absolute reporting of ICS was Acute Lymphocytic Leukemia (38.5%), followed by Neuroblastoma (12.2%) and Acute Myeloid Leukemia (9.3%).

**Conclusions**: The result of the study allowed us to know the prevalence of pathogens of hospital may help programs to prevent these infections in this specific group. The number of gramȀnegative microorganisms was higher than that of gram‐positive in all years, so when doing empirical antibiotic therapy broad‐spectrum antibiotics should be used. The prevalence of blood cultures with growth of Candida spp. should increase the prevention of candidemia.

### PO-184. Microbiological Profile of Blood Infections in Adolescents with Cancer in the West of Paraná, Brazil {#pbc27455-sec-11530}

[C. Fiori]{.ul} ^1^, L. Santos^1^, C. Sakuma^1^, A. Rosa^1^

*^1^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric Oncology, Cascavel, Brazil*

**Background/Objectives: Introduction**: Hospital infections (IH) in pediatric patients with oncological diseases are an important cause of morbidity and mortality. HIs are considered to be a relevant public health problem, resulting in high rates of complications to health, prolongation of the hospitalization period, direct increase in the costs of care, and favor the selection and dissemination of multiresistant microorganisms. Adolescents with these oncological diseases initiate antimicrobial treatment empirically and the knowledge of the microbiological profile is fundamental for the effectiveness of this type of treatment.

**Objective**: To analyze the microbiological profile of hospital‐acquired bloodstream infections (ICS) in adolescents (10 to 19 years old) hospitalized in the West Paraná, from January 2007 to December of 2016.

**Design/Methods**: The study was accomplished, with a retrospective analysis of blood cultures reported by the active surveillance method, coordinated by the Hospital Infection Control Commission.

**Results**: The ICS were as major hospital infections (IH) reported. A predominant age group in adolescents aged 12 to 13 years. The isolated infectious agent was described in most ICS, 46.6% as compulsively negative, 31.6% gram‐positive and 21.6% fungi. The most frequent pathogen was Staphylococcus epidermidis (18.3%), followed by Pseudomonas aeruginosa (16.6%) and Candida albicans (15%). The year that presented the most ICS absolute notification was that of 2015, and the age group most available for 12 to 13 years for this sample.

**Conclusions**: The results of the study allowed us to know the prevalence of pathogens of hospital origin that affect portable infectious diseases, which may lead to auxiliary prevention programs in this specific group. The number of gram‐negative microorganisms was higher than that of gram‐positive in most exercises, as well as empirical antibiotics should be used antibiotics with good coverage against gram‐negatives. The prevalence of blood cultures with growth of Candida albicans alert in the prevention of candidemia.

### PO-185. Investigating the Mechanisms of Methotrexate Neurotoxicity in Patients Under Treatment for Childhood Leukemia and Long‐Term Survivors {#pbc27455-sec-11540}

[V. Forster]{.ul} ^1^, J. Carr‐Wilkinson^2^, H. Issa^3^, A. Isa^3^, S. Nakjang^3^, D. Tweddle^3^, S. Choufani^1^, R. Weksberg^1^, F. van Delft^3^

*^1^The Hospital for Sick Children, Genetics and Genome Biology, Toronto, Canada; ^2^University of Sunderland, Faculty of Health Sciences and Wellbeing, Sunderland, United Kingdom; ^3^Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom*

**Background/Objectives**: Adverse neurological events are common (4‐20%) during treatment for pediatric acute lymphoblastic leukemia (ALL) and include seizures, stroke like syndrome and leukoencephalopathy. In addition, chronic neurotoxicity is emerging as a worrying late effect of treatment with long‐term survivors experiencing decreased executive function, processing speed and memory function. Survivors are also at increased risk of experiencing learning difficulties, social withdrawal issues and inattention hyperactivity disorders. Methotrexate, an anti‐folate chemotherapy agent, is a mainstay of pediatric leukemia treatment regimens globally and is widely implicated as a cause of these neurological side effects. We hypothesize that methotrexate disrupts DNA methylation via effects on S‐adenosyl methionine, a key methylation component that has previously been described to regulate genes involved in myelination.

**Design/Methods**: Using both neural cell lines and glial cells derived from iPSC treated with methotrexate, we assayed for changes in DNA methylation and consequential effects on gene expression using whole‐genome methylation arrays and RNAseq, respectively. Genes with corresponding methylation and expression changes were then taken forward for confirmation of expression by real‐time qPCR and assessment of protein levels.

**Results**: We identified methylation and expression changes in genes involved in neurodevelopmental pathways and neurological disorders. Of particular interest was dose‐dependent demethylation and consequential increase in gene expression of IRS1, a vital component of insulin signalling pathways, highly expressed in neural tissue and implicated in regulating cognitive performance. We also detected altered methylation within the PLP1 gene, which encodes the most major protein component of myelin. We identified that increased PLP1 methylation after methotrexate treatment in iPSC‐derived oligodendrocytes resulted in a corresponding reduction in PLP1 transcript levels and PLP1 protein.

**Conclusions**: Our work provides insight as to the biological mechanisms behind methotrexate‐induced neurological side effects for the first time and implicates altered myelination as a potential causative factor in neurotoxicity.

### PO-186. Posterior Reversible Encephalopathy Syndrome: 2 Chemotherapy Related Cases in 10 Years in a Childrens Hospital of Mexico {#pbc27455-sec-11550}

[A.C. Garcia‐Espinosa]{.ul} ^1^, R. Rodriguez‐Navarro^2^, S. Fierro‐Saenz^3^

*^1^Children\'s Hospital of Specialties, Pediatric Oncology, Chihuahua, Mexico; ^2^Children\'s Hospital of Specialties, Pediatric neurology, Chihuahua, Mexico; ^3^Children\'s Hospital of Specialties, Pediatric fellow, Chihuahua, Mexico*

**Background/Objectives**: Posterior reversible encephalopathy syndrome (PRES), is a clinical‐radiological condition caractherized by headache, altered mental functioning, seizures and visual alteration, with the magnetic resonance imagin showing cerebral edema, predominantly in the White matter with posterior distribution. Multiple clinical conditions can act as triggers. In this retrospective analysis, we present 2 cases of children with cáncer, who had undergone chemotherapy in a Children\'s Hospital of Specialities in Mexico.

**Design/Methods**: We identified 2 patients who had radiological and clinical features consistent with PRES in 10 years (JANUARY 2007‐ JANUARY 2017), in the Children Hospital of Specialities in Mexico, both of them had acute lymphoblastic leukemia (ALL), receiving chemotherapy when they presented with this patology. And rewiew of previus literature are presented

Magnetic Resonance imaging, CT scan.

**Results**: (1) female 8 years old with ALL, she was in the remission induction chemotherapy; (2) Female 14 years old with ALL she was in consolidation chemotherapy, when both had PRES, with hypertension, headache, Seizures, altered mental functioning and visual alteration. The 2 patients develop epilepsy and remain on chronic anticonvulsuvant therapy.

**Conclusions**: PRES is an increasingly recognized complication of pediatric cáncer tratment. We report 2 chemotherapy cases in children with ALL in a Children\'s Hospital in Mexico in 10 years. A prompt diagnostic, an appropiate therapy for hipertensión, and a rapid control of the seizures are the keys to avoiding sequelae

### PO-187. The Impact of Febrile Neutropenia Pathway on the Quality of Care Received by Patients with Episodes of Febrile Neutropenia {#pbc27455-sec-11560}

[C. Gardner]{.ul} ^1^, S. Picton^1^, R. Hollis^1^

*^1^Leeds Teaching Hospitals Trust, Children\'s Haematology and Oncology Unit, Leeds, United Kingdom*

**Background/Objectives**: Febrile neutropenia is one of the most common and potentially life threatening side effects of chemotherapy treatment. The Advanced Nurse Practitioner (ANP) role is ideally suited to support structured care and adherence to agreed guidelines. This project was undertaken in order create a pathway proforma that guided the multidisciplinary team to provide efficient, safe care for patients, ensuring adherence to local treatment guidelines, prompt initiation and appropriate 'step down' or escalation of antimicrobial treatment.

Aim: To introduce a pathway proforma to guide the treatment of febrile neutropenic patients within the local guidelines. The tool would support decision making through the identification of risk factors on admission or at the commencement of a febrile neutropenic episodes and on a subsequent daily basis for a duration of seventy‐two hours.

**Design/Methods**: A comprehensive proforma was introduced to ensure data collection from first assessment to completion of antibiotic treatment of febrile neutropaenia. An audit cycle was established over a year with ongoing review, modification and re‐audit. A multidisciplinary agreement on the final tool was reached.

**Results**: The audit cycle demonstrated which aspects of the document were difficult to follow, not completed and subject to non‐adherence of the guidelines. Audit results showed completion compliance between 30% and 100% over the period of audit. Following the cycle of audit and multidisciplinary review, completion rates have improved. Clinical experience suggests audit of compliance with local guidelines will show positive results

**Conclusions**: The use of the structured treatment pathway can improve quality of care. The implementation and on going audit of the pathway is an appropriate role for an ANP. The tool can guide decision making in the management of febrile neutropenia and will improve effective antimicrobial treatment; reducing treatment initiation, time in hospital and reducing use of antibiotics for patients. This will help address current issues with antimicrobial resistance and stewardship.

### PO-188. Treatment of Fever and Neutropenia in Children with Cancer: Outcome of Early Discharge {#pbc27455-sec-11570}

[K. Ghanem]{.ul} ^1^, H. Siblini^2^, N. Badaro^1^, D. El‐Tabesh^1^, D. Hamideh^1^, M. Abboud^1^, S. Muwakkit^1^, R. Saab^1^, R. Hanna‐Wakim^1^, N. Tarek^1^

*^1^American University of Beirut, Pediatrics, Beirut, Lebanon; ^2^American University of Beirut, Faculty of Medicine, Beirut, Lebanon*

**Background/Objectives**: Fever during neutropenia episodes is a common complication of cancer therapy in children and may be life threatening. Initiation of empiric broad spectrum antibiotics within 60 minutes of presentation has been shown to decrease morbidity and mortality associated with infection. The required length of treatment and safety discharge criteria after admission for fever and neutropenia in children with no documented infection have not been extensively evaluated.

**Design/Methods**: This is a retrospective review of all admissions for febrile neutropenia episodes in children treated for cancer at the Children\'s Cancer Institute of Lebanon between 2014 and 2016. Development of new fever, signs of infection and risk of readmission within 72 hours of discharge were reviewed.

**Results**: A total of 294 febrile neutropenia admissions were identified. Only 5 patients (1.7%) were readmitted within 72 hours of discharge. All due to febrile neutropenia. None of the readmitted patients had significant morbidity/mortality during readmission. In 117 admissions (39.8%), patients were discharged with an ANC \< 500. In 43 admissions (14.6%), patients were discharged on daily IV antibiotics administered in the outpatient clinic. Fifty discharges (17%) had an episode of fever within 48 hours from discharge. Eighty‐seven admissions (29.5%) received inpatient care for ≤ 72 hours.

**Conclusions**: Our data shows that the risk of infection and readmission in children with cancer hospitalized for febrile neutropenia and discharged with an ANC \< 500 was low suggesting that patient discharge and discontinuation of antibiotics prior to full neutrophil recovery is safe.

### PO-189. Measurement of Symptoms Using Patient‐Reported Symptom Assessment Scale in Children with Cancer {#pbc27455-sec-11580}

[X.N. Goh]{.ul} ^1^, G.C.Y. Chang^1^, A. Chan^2^

*^1^KK Women\'s and Children\'s Hospital, Pharmacy, Singapore, Singapore; ^2^National University of Singapore, Pharmacy, Singapore, Singapore*

**Background/Objectives**: Self‐reporting of symptoms may be used to supplement clinician‐based reporting. However, the use of symptom assessment scales in paediatric oncology patients is still not routine. Hence, this study aims to describe the prevalence of symptoms in children aged 7 to 18 years who are undergoing chemotherapy in a local paediatric hospital and to evaluate the feasibility of use of a self‐reported symptom assessment scale in this special population.

**Design/Methods**: This study is a prospective, longitudinal study that included children aged 7 to 18 years who were admitted for chemotherapy in the paediatric oncology wards in KK Women\'s and Children\'s Hospital (KKWCH). Eligible patients aged 7 to 9 years were administered the Memorial Symptom Assessment Scale for Children (MSAS) 7‐12 while older patients aged 10 to 18 years were given the MSAS 10‐18 scale. Descriptive statistics, frequency distributions and Pearson\'s Chi‐square test were used to summarize the demographic characteristics, describe the items of MSAS and assess the differences between severity of symptoms reported by healthcare professions and patients respectively.

**Results**: A total of 31 patients were recruited from April 2017 to February 2018, with 6 patients being surveyed using the MSAS 7‐12 and 25 patients surveyed using MSAS 10‐18. Lack of appetite was the most common (71.4%: MSAS 7‐12; 71.1%: MSAS 10‐18 respectively) symptom reported. Majority (\>90%) of the patients encountered little difficulty and took an average (± SD) of 6.6 (± 2.6) and 6.7 (± 3.1) minutes to complete the MSAS 7‐12 and MSAS 10‐18 respectively.

**Conclusions**: This study demonstrated that children, undergoing chemotherapy in a children\'s hospital in Singapore, reported experiencing symptoms from their cancer or chemotherapy. Implementation of MSAS 7‐12 and MSAS 10‐18 is feasible in the local setting and would allow optimization of control of symptoms in paediatric oncology patients.

### PO-190. Risk Based Management Strategies and Outcomes Among Children at Risk of Tumor Lysis Syndrome: Analysis of Children with Leukemia/Lymphoma in Resource Limited Settings {#pbc27455-sec-11590}

[K.G. Gopakumar]{.ul} ^1^, T. Priyakumari^1^, S. Seetharam^1^, K.K. Jagathnath^2^, N. Manjusha^1^, R. Binitha^1^, C.S. Guruprasad^1^, V.R. Prasanth^1^

*^1^Regional Cancer Centre, Pediatric Oncology, Trivandrum, India; ^2^Regional Cancer Centre, Cancer Epidemiology & Biostatistics, Trivandrum, India*

**Background/Objectives**: There is limited data from low and middle income countries regarding the management and outcomes of tumor lysis syndrome (TLS) in children with leukemia/lymphoma.

**Design/Methods**: The clinical and biochemical characteristics of children with intermediate and high risk for developing TLS were retrospectively studied over a three year period in the department of pediatric oncology at a Regional Cancer Centre in South India.

**Results**: The medical records review identified 224 children with acute leukemia/lymphoma having intermediate risk (22.3 %, n=50) and high risk (77.6%, n=174) for developing TLS. TLS developed in 53.6 % (n=120) cases. Ninety children (40.1%) had Laboratory‐TLS alone while 30 children (13.3%) subsequently progressed to develop Clinical TLS. All patients with Clinical TLS had Acute Kidney Injury (AKI). Only one patient developed seizures. A significant reduction in blood urea, potassium and uric acid was observed (p\< 0.05) over a period of 24hrs with hyper hydration alone. Hemodialysis was required only in 0.8% (n=2) of children, one of whom had AKI at presentation. Rasburicase was used in 10.3% (n=18) of children with high risk disease. The mean dose of rasburicase used in our setting was 0.085 mg/kg. With this low dose, the serum uric acid level decreased to less than 8 mg/dl within 24 hours of administration in 83.3 % (n = 15) of cases. Two children (0.8%) expired during the course of TLS management. Multivariate analysis identified hyperuricemia to be associated with significant risk for developing TLS and AKI.

**Conclusions**: Our data underscores the importance of aggressive hydration and judicious use of rasburicase for managing TLS in resource‐limited settings

### PO-191. Steroid‐Induced Hyperglycemia and Hispanic Ethnicity in Childhood Acute Lymphoblastic Leukemia {#pbc27455-sec-11600}

[A. Grimes]{.ul} ^1^, R. Barrera^1^

*^1^University of Texas Health Science Center San Antonio, Pediatrics, San Antonio, USA*

**Background/Objectives**: Glucocorticoids are critical in the treatment of childhood acute lymphoblastic leukemia (ALL). However, they contribute to numerous adverse effects including severe hyperglycemia affecting 20.4% during treatment induction. Steroid‐induced hyperglycemia (SIH) is associated with lower event‐free and overall survival in childhood ALL and increased infectious complications, particularly for those age 10 years or more, or with high risk disease. Additional predisposing factors include non‐white ethnicity. Therefore, we aimed to evaluate the association between SIH and Hispanic ethnicity in childhood ALL across a largely Mexican‐American population.

**Design/Methods**: We evaluated patients with ALL age 0‐25 treated from 2014‐2017 at a minority‐underserved cancer center. Data collected included: cancer diagnosis, age, gender, race/ethnicity, and serum glucose values. SIH was defined as serum glucose ≥ 200 mg/dL during glucocorticoid‐containing therapy.

**Results**: Overall, 10/32 (31.2%) pediatric ALL patients met criteria for SIH. Most patients were Hispanic (84.4%). Among Hispanics, SIH was seen in 33.3% (RR 1.67) but was less frequent in non‐Hispanic patients (20%). Thus, Hispanic ethnicity appears to confer an elevated relative risk of SIH relative to non‐Hispanic ethnicity (RR 1.67). Additionally, when stratified by age, older patients (age 10+ years) also experience a greater SIH compared to younger children, RR 1.93. This effect is amplified when older age and Hispanic ethnicity are combined (RR 1.61). Gender also appears to play a role, with female childhood ALL patients at a slightly greater risk of developing SIH relative to males (RR 1.31).

**Conclusions**: Results suggest that Hispanic ancestry, age 10+ years, and female gender confer increased risk for SIH in childhood ALL. SIH is known to be an independent risk factor for decreased survival in childhood ALL. Aggressive identification and management of SIH may therefore improve survival outcomes in Hispanic children with ALL. Thus, we are currently developing a clinical trial assessing SIH management and impact on patient outcomes.

### PO-192. Study on the Predictive Index of High Dosage Methotrexate Treatment for Children with ALL/Lymphoma {#pbc27455-sec-11610}

[H. Guo]{.ul} ^1^

*^1^Nanfang Hospital‐Southern Medical University, Pediatric Hematology/Oncology, Guangzhou, China*

**Background/Objectives**: In recent years, it is argued that the MTHFR gene polymorphism C677T can be used to predict the adverse reaction index of high‐dose methotrexate (HDMTX) chemotherapy in children with acute lymphoblastic leukemia(ALL) or lymphoma. This study was intended to study the predictive indices of mucosa and renal toxicity after high dose methotrexate in children with ALL /lymphoma.

**Design/Methods**: In 2017, MTHFR gene in 677 C\>T, 1298A\>C were detected in 72 cases with fluorescence in situ hybridization DNA sequence. Among them, renogram were also done in 30 cases, Creatinine Clearance(Ccr) were calculated with 24 hours of urine in 28 patients with coordination at the same time. The dosage of MTX was adjusted according to the results of gene test, and the changes of MTX concentration, liver and kidney function and oral mucosa state were observed after high‐dose methotrexate chemotherapy, and the correlation between three detection methods and the side effects of MTX was analyzed.

**Results**: It is difficult to operate with Ccr because of difficulty to collect 24‐hour urine n children, and there are more factors affecting its accuracy. The correlation with clinical side effects is low. Renogram is more accurate than Ccr, and has high compliance with genetic test. However, it has poor accuracy guiding clinical dose adjustment, and is radioactive. The mutation of 667C and 1298A loci could predict the activity of MTFHR enzyme and better guide the dosage adjustment of MTX

**Conclusions**: The combined detection of gene C667T and A1298C loci mutation is an effective and convenient method for predicting the toxicity of high‐dose methotrexate. It needs further clinical verification whether determination of urinary metabolites can replace gene detection.

### PO-193. Febrile Neutropenia in Hemato‐Oncological Malignancies: Clinical and Microbiological Profile from a Tertiary Care Hospital from War‐Torn Kashmir {#pbc27455-sec-11620}

[F. Guru]{.ul} ^1^, V. toka^1^, J. muzammil^1^, M. gull^1^

*^1^Sher I Kashmir Institute of Medical Sciences, Paediatric and Medical Oncology, Srinagar, India*

**Background/Objectives**: Febrile neutropenia (FN) is the commonest medical oncologic emergency in clinical medicine. This study depicts the clinical profile, microbiological yield and antibiotic sensitivity pattern in FN cancer patients receiving chemotherapy.

**Design/Methods**: The study was conducted at the Department of Medical Oncology, at the Sher‐i‐Kashmir Institute of Medical Sciences, Kashmir, between December 2015 to December 2017.The patients recruited consecutively with hematologic malignancies who received chemotherapy and presented with FN were managed as per IDSA guidelines and evaluated with respect to the underlying status of primary disease, microbial isolates and antibiotic sensitivity pattern and eventual outcome with such treatment.

**Results**: The disease profile of the 200 febrile neutropenic patients is depicted below (Table A).Majority of the patients with FN episodes had Acute Lymphoblastic Leukemia. Overall culture positivity was 17%. The culture isolates are shown below (Table B). The most common organisms isolated were Staphylococcus Aureus, Escherichia Coli, Acinetobacter, Pseudomonas, Stenotrophomonas maltophilia. Patients would be treated as per IDSA guidelines and would be modified on basis of culture sensitivity yields. All Gram negative organisms were sensitive to Imipenem, whereas sensitivity pattern to other antibiotics in order of decreasing sensitivity were Pipercillin‐ Tazoactum, Meropenem, Cefipime, Amikacin, Teicoplanin respectively.

Table A

Acute Lymphoblastic Leukemia 60%

Acute Myeloid Leukemia 20%

Non Hodgkins Lymphoma 10%

Ewings Sarcoma 7%

Hodgkin\'s Disease 3%

Table B

Staphylococcus Aureus 35 %

Escherichia Coli 20%

Acinetobacter 18%

Pseudomonas 12%

Stenotrophomonas maltophilia 10%

**Conclusions**: Hematologic malignancies have a high risk of developing FN. FN if untreated is almost always fatal. Prompt recognition of subtle signs and symptoms of FN and prompt institution of appropriate treatment leads to satisfactory outcome in FN and therapy should be tailored to the most appropriate antibiotics according to the bacterial culture results.

### PO-194. Efficacy and Safety of Varicella Vaccination in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-11630}

[V. Guru]{.ul} ^1^, V. Radhakrishnan^1^, J. Ramamoorthy^1^, P. Ganesan^1^, T. Sagar^1^

*^1^Cancer Institute, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Varicella infection in children with Acute Lymphoblastic Leukemia (ALL) is associated with significant morbidity and mortality. Immunisation against varicella infection is not mandatory as per the national immunization program in India and therefore majority of children with ALL are unimmunized and are at an increased risk of infection.

**Design/Methods**: Patients with ALL who have no previous history of varicella infection or immunization are given a single dose of live attenuated varicella vaccine at our hospital prior to the start of maintenance phase of treatment. The present study retrospectively analysed the case records of patients with ALL who received the varicella vaccine between the years 2014 and 2017.

**Results**: The study included 125 patients with a median age of 6 years and 57% patients were males. Median duration from last dose of chemotherapy to administration of varicella vaccine was 12 days (range: 2‐79 days). Fifty‐two patients (41%) developed vaccine induced varicella and among them 50 required hospitalization. The median time to develop vaccine induced varicella was 21 days (range: 10‐35 days) and the median duration of hospital stay was 4 days (range: 2‐10 days). Sixty‐eight percent of patients had systemic symptoms at presentation the commonest being fever and rash. The median duration of fever was 2 days (range; 1‐8) and 5 patients developed febrile neutropenia. Maintenance chemotherapy was withheld in symptomatic patients for a median duration of 7 days (range: 3‐15 days). Breakthrough varicella infection after vaccination was seen in 2 patients. There was no mortality due to vaccine induced varicella.

**Conclusions**: Varicella immunization is safe and efficacious in children with ALL and should be considered in countries were varicella immunization is not routinely practiced. Vaccine induced varicella is commonly seen, however, it is self‐limiting. The introduction of varicella immunization at our hospital has prevented mortality due to varicella infection.

### PO-195. Efficacy of Low Dose Defibrotide Prevention of Hepatic Veno‐Occlusive Disease after Autologous Hematopoietic Stem Cell Transplantation {#pbc27455-sec-11640}

Y.Y. Roh^1,2^, S.M. Hahn^1,2^, Y.H. Choi^1,2^, J.P. Hong^1,2^, C.J. Lyu^1,2^, [J.W. Han]{.ul} ^1,2^

*^1^Yonsei University College of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^2^Yonsei Cancer Center, Department of Pediatric Hemato‐Oncology, Seoul, Republic of Korea*

**Background/Objectives**: Hepatic veno‐occlusive disease (VOD) is serious systemic endothelial disease posing risk of transplantation related morbidity and mortality. Defibrotide has been used for the treatment of VOD and under investigation for the purpose of prophylaxis. The use of defibrotide for prophylaxis is limited due to the high cost. We evaluated the prevention efficacy of low dose defibrotide for VOD.

**Design/Methods**: Total 93 patients (31 patients with prophylaxis and 62 historical controls) who underwent autologous hematopoietic stem cell transplantation at department of pediatric hemato‐oncology, Yonsei Cancer Center, Seoul Korea from March, 2013 to July, 2017 were reviewed retrospectively. Low dose defibrotide of 12.5 mg/kg/day from D‐3 to D+10 after HSCT were delivered to patients. The incidence of VOD in case and control group were evaluated.

**Results**: The most common diagnosis of the cohort was brain tumor (N=51). Age, diagnosis, treatment procedure were not different between case and control group. In total group, 9/62 (14.5%) developed VOD in control group whereas, only 1 in 31 (3.2%) developed VOD in prophylaxis group (P=0.098). In the second HSCT group, 5.9% (1/17) in prophylaxis group developed VOD but 28% (5/18) developed in non prophylaxis group (P=0.086). VOD severity was more severe in control group than in prophylaxis group in the setting of second HSCT (P=0.044). Total 3 VOD‐related mortality were in the control group whereas there was no death in the prophylaxis group.

**Conclusions**: Thus this study suggests that low dose defibrotide prophylaxis works effectively for preventing hepatic VOD and also cost‐effective.

### PO-196. Ototoxicity in Pediatric Hematopoietic Stem Cell Transplant Patients {#pbc27455-sec-11650}

[R. Hayashi]{.ul} ^1^, K. Gerston^2^, S. Hayashi^3^, K. Trinkaus^4^

*^1^Washington University School of Medicine, Pediatrics, St. Louis, USA; ^2^Washington University School of Medicine, Program in Audiology and Communication Sciences, St. Louis, USA; ^3^St. Louis Children\'s Hospital, Audiology, St. Louis, USA; ^4^Siteman Cancer Center‐ Washington University School of Medicine, Surgery, St. Louis, USA*

**Background/Objectives**: Use of hematopoietic stem cell transplantation (HSCT) is increasing for a variety of diseases. Ototoxicity from this procedure has not been extensively studied.

**Design/Methods**: A retrospective chart review examined 275 patients receiving a HSCT at St. Louis Childrens Hospital from January 1, 2007 to April 30^th^, 2017. Data extracted included therapy before HSCT and the subsequent transplant course. Evaluable patients had complete medical records and interpretable audiograms. Ototoxicity was analyzed as a percent change over baseline using one‐sample tests for difference of proportions. SIOP grades prior to HSCT were compared in patients with and without ototoxicity using an ordinal test for trend (Jonckheere\'s test). Logistic regression, chi‐square and Fisher\'s Exact tests identified associations of ototoxicity to patient characteristics.

**Results**: One hundred and forty seven patients were evaluable. Ototoxicity was observed in 10.2% of patients. Higher SIOP grades prior to HSCT was significantly associated with a higher risk of post‐transplant ototoxicity, (p \<0.01). Prior cisplatin (p \<0.01) but not carboplatin, or radiation, was also associated with ototoxicity from the HSCT. Diagnosis of a solid tumor or brain tumor (p \<0.01), and autologous transplants (p\<0.01) also identified patients at higher risk. No post‐transplant events were significantly associated with ototoxicity.

**Conclusions**: Ototoxicity affects a significant percentage of patients undergoing HSCT. Careful monitoring is needed to identify patients impacted by this procedure.

### PO-197. Morbidity and Mortality During the Induction in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) of the Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru {#pbc27455-sec-11660}

[E. Hernandez Broncano]{.ul} ^1^, J. Garcia^1^, R. Diaz^1^, A. Wachtel^1^

*^1^Instituto Nacional de Enfermedades Neoplasicas, Oncologia Pediatrica, Lima, Peru*

**Background/Objectives**: Acute Lymphoblastic Leukemia is the common diagnosis of Pediatric cancer at Instituto Nacional de Enfermedades Neoplásicas. The mortality during Induction is about 1 ‐ 2% in high income countries, nevertheless, these numbers are higher in developing countries. The aim was to determine the clinical characteristics, morbidity and mortality during induction of ALL treatment, and also if these causes are factors associated with survival.

**Design/Methods**: This is a retrospective and descriptive study. Between January 2009 and December 2012, 466 patients less than 15 years of age were diagnosed having ALL. We include all the patients, evaluated the common causes of mortality and morbidity during Induction as: Infection, chemotherapy toxicity. Survival analysis was performed using Kaplan‐Meier method.

**Results**: We included 466 patients, the median age was 5.9 years (range 1 to 14 years), M/F ratio 1.5/1. The median time to follow up was 52.7 months, 108 patients (22.5%) relapse, 48 patients (10.3%) abandoned treatment and 22 died (4.7%) during induction; the common causes were: septic shock (31.8%), intraparenchymal hemorrhage (18.8%), or both (13.6%). 330 patients (70%) had at least 3 febrile episodes. We found 161 positive blood cultures, 138 bacterial (85.7%) and 23 fungal (14.2%) infections of 917 febrile episodes. The Overall (OS) survival was 77% regarding the risk, there was no significant difference in the OS between the numbers of febrile episodes.

**Conclusions**: The Instituto Nacional de Enfermedades Neoplásicas has high mortality during induction treatment compared to developed countries, while the causes of death did not differ. Febrile episodes were present in 75 patients, with high percentage of positive blood culture.

### PO-198. Clinical Courses and Susceptibility of Pathogenic Fungi Identified from Pediatric Oncology Patients: Single Center Experience {#pbc27455-sec-11670}

[M. Hino]{.ul} ^1^, N. Ishiwada^2^, T. Aoki^1^, R. Okada^1^, T. Okunushi^1^, M. Okusu^2^, A. Watanabe^3^, K. Kamei^3^, N. Shimojo^1^

*^1^Chiba University, Department of Pediatrics‐ Graduate School of Medicine, Chiba, Japan; ^2^Chiba University, Department of Infectious Diseases‐ Medical Mycology Research Center, Chiba, Japan; ^3^Chiba University, Division of Clinical Research‐ Medical Mycology Research Center, Chiba, Japan*

**Background/Objectives**: Echinocandin resistance to Candida has been increasing in the United States. Identification of pathogenic fungi and its susceptibility is difficult in pediatric patients. To clarify the necessity of bacteriological analysis for the treatment of pediatric fungal infections, we retrospectively analyzed clinical courses and susceptibility of bacteriologically confirmed fungal infections who were treated in our institution.

**Design/Methods**: 136 pediatric oncology patients between January 2004 and December 2014 were analyzed. Serum bd‐glucan levels were analyzed using the b‐Glucan test Wako. Drug susceptibility tests were performed using a Yeast‐like Fungus DP Eiken Kit. This study was approved by the Ethical Review Board of our facility.

**Results**: Pseudalleshceria boydii was isolated from a 0‐year‐old boy who suffered from otitis media after stem cell transplantation. Aspergillus terreus was repeatedly isolated from the ear discharge of a patient with otitis externa during neutropenia. In accordance with susceptibility test results, the patient safely received stem cell transplantation with voriconazole combined with micafungin (MCFG). All the yeasts detected in 5 patients with bloodstream infections were Candida species. Patients had Candida colonization, and they were administered antifungal prophylaxis. Although the bd‐glucan titer and clinical manifestation of the splenic abscess worsened, we treated C.tropicalis infection with MCFG only by the susceptibility test results. C. parapsilosis have a high minimum inhibitory concentration (MIC) against MCFG. A 0‐year‐old girl with the diagnosis of an ALL has treated candidemia (C. parapsilosis) with liposomal amphotericin b. Although C. glabrata is known to be sensitive to MCFG, the C. glabrata from a 8‐year‐old girl with the diagnosis of an AML had a high MIC against MCFG. FKS2 S663P mutation was obtained from the C. glabrata.

**Conclusions**: Identification of pathogenic fungi and drug susceptibility test results will be more important to treat pediatric oncology patients. C.glabrata resistance to echinocandins revealed and may increase in pediatric cancer patients.

### PO-199. Nutritional Screening of Patient with Acute Lymphoid Leukemia at Diagnosis, 28th Day of Induction and 8th Week of Therapy {#pbc27455-sec-11680}

[M. Hussaini]{.ul} ^1^

*^1^The Aga Khan University Hospital Karachi, Cancer Care, Karachi, Pakistan*

**Background/Objectives**: Nutritional depletion is a major problem among pediatric oncology patients in the developing world. This is associated with treatment related toxicity and mortality. Studies found that children with malignancies die due to the effects of undernourishment rather than the malignancy itself. Early identification, thorough assessment and management can help prevent complications.

The purpose of this study is to estimate the prevalence of malnutrition that is present at the time of diagnosis.

**Design/Methods**: A sample size of 22 pediatric patients, newly diagnosed with ALL within last 1 year (i‐e October 2016 till December 2017) was taken to estimate the nutritional status of patients at the time of diagnosis, on 28^th^ Day of induction and 8 week post induction. Height, weight, BMI, height for age, weight for age, and BMI for age percentiles of patients were collected. Analysis was done using growth charts for height, weight, and BMI and percentiles were noted for all patients. Written consent was taken from all patients participating in the study.

**Results**: Overall analysis of the data showed that out of 22 patients, 6 children were found to have their height, weight and BMI percentiles below 25th which indicates that they were already undernourished at the time of diagnosis. Furthermore, 9 out of these 22 children were found to have height, weight and BMI percentiles of less than 10 which is a clinically significant finding. In addition to these findings 10 out of 22 patient has a significant weight loss from the 28th Day of induction till the 8th week post induction therapy.

**Conclusions**: The need for adequate nutritional assessment throughout the therapy has a great significance. Therefore, proper growth monitoring, timely reporting and management is required to prevent child from developing further complications. This study will to plan holistic strategies and integrate nutritional therapy as part of cancer therapy.

### PO-200. Symptom Documentation and Intervention Provision for Symptom Control in Children Receiving Cancer Treatments {#pbc27455-sec-11690}

[S. Hyslop]{.ul} ^1^, H. Davis^1^, N. Duong^1^, R. Loves^1^, T. Schechter^2^, T. Deborah^1^, G.A. Tomlinson^3^, L.L. Dupuis^4^, L. Sung^5^

*^1^The Hospital for Sick Children, Program in Child Health Evaluative Sciences, Toronto, Canada; ^2^The Hospital for Sick Children, Division of Haematology/Oncology, Toronto, Canada; ^3^Toronto General Hospital, Department of Medicine, Toronto, Canada; ^4^The Hospital for Sick Children, Department of Pharmacy‐ Program in Child Health Evaluative Sciences, Toronto, Canada; ^5^The Hosptial for Sick Children, Division of Haematology/Oncology‐ Program in Child Health Evaluative Sciences, Toronto, Canada*

**Background/Objectives**: The Symptom Screening in Pediatrics Tool (SSPedi) is a validated, self‐report symptom screening tool for children receiving cancer treatments that assesses degree of bother for 15 symptoms. Objectives were to describe the proportion of bothersome symptoms self‐reported using SSPedi that were documented in the medical records and were associated with an intervention.

**Design/Methods**: Eligible respondents were inpatients 8‐18 years of age who were receiving cancer treatments and expected to be in hospital or clinic three days later. Children self‐reported symptom bother using SSPedi. We evaluated symptom documentation and interventions in the medical records proximal to SSPedi administration.

**Results**: There were 168 children included; median age was 13.1 (range 8.0 to 18.2) years. For 12 of the 15 symptoms measured, symptoms reported using SSPedi as severely bothersome were documented in the medical records less than 60% of the time. The most infrequently documented severely bothersome symptoms were problems with thinking or remembering things (0%), changes in how your body or face look (4.8%), changes in taste (7.7%) and tingly or numb hands or feet (11.1%).

Intervention provision for severely bothersome symptoms occurred less than 60% of the time for 10 of 15 symptoms. The most infrequently treated symptoms were thinking or remembering things (0%), changes in how your body or face look (0%), tingly or numb hands or feet (0%), changes in taste (0%), diarrhea (0%) and feeling tired (1.6%). Even when interventions were provided, they were often not prescribed specifically for that symptom.

**Conclusions**: Documentation of symptoms and provision of interventions to address them were generally infrequent. Severe symptoms that were almost never documented or treated included problems with cognition, body image, changes in taste and peripheral neuropathy. Future efforts should incorporate symptom screening into routine care and facilitate symptom management by improving access to evidence‐based clinical practice guidelines.

### PO-201. Reconstitution of the Immune System and Incidences of Infection after Chemotherapy in Patients with Hematological Malignancies {#pbc27455-sec-11700}

[A. Iguchi]{.ul} ^1^, Y. Terashita^1^, M. Sugiyama^1^, J. Okubo^1^, Y. Cho^1^

*^1^Hokkaido University, Pediatrics, Sapporo, Japan*

**Background/Objectives**: High cure rates in childhood hematological malignancies have been achieved by intensive chemotherapy. In this study, we investigated reconstitution of the immune system and incidences of infection after chemotherapy in patients with hematological malignancies.

**Design/Methods**: We reviewed medical records for 45 patients with children (M/F:30/15, median age:7 years who were treated between January 2007 and March 2018 in Department of Pediatrics, Hokkaido University Hospital. We analyzed CD4‐positive cell counts, serum immunoglobulin G (IgG) levels, and the incidences of infection until 2 years after chemotherapy. Sulfamethoxazole‐Trimethoprim was administered in all patients whose CD4‐positive cell counts were below 500/ul. We excluded patients who received stem cell transplantation.

**Results**: The duration of CD4 positive cell counts \<500/ul after chemotherapy were 4.95±2.1 months in patients with acute lymphoblastic leukemia (ALL), 5.09±2.84 months in patients with acute myelogenous leukemia (AML), 5.0±3.21 months in patients with non‐Hodgkin\'s lymphoma (NHL), 15.25±14.86 months in patients with Hodgkin\'s lymphoma (HL), and 3.43±1.9 months in patients with Langerhans cell histiocytosis (LCH). The durations of IgG \<500mg/dl after chemotherapy was 3.74±4.09 months in ALL, 6.44±4.64 months in AML, 3.5±1.0 months in NHL, 1.33±0.58 months in HL, and 5.0±6.08 months in LCH. There was a significant higher incidence of infection in the period of 6 to 12 months after chemotherapy than other periods (0.32±0.32/month (0‐6 months), 0.41±0.38/month (6‐12 months), 0.34±0.27/month (12‐24 months), respectively, *p*=0.05).

**Conclusions**: In this study, CD4‐positive cell counts and IgG levels were recovered at about 6 months after chemotherapy in most patients. We have achieved a low incidence of infection by education and medication for patients until recovery of CD4‐positive cell counts and IgG levels. However, we found a higher incidence of infection in the period of 6 to 12 months after chemotherapy than other periods. Thus, additional medication against infection might be needed in patients in this period.

### PO-202. Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients with Relapsed Solid Tumors {#pbc27455-sec-11710}

[D. Johnston]{.ul} ^1^, S. Zupanec^2^, D. Nicksy^2^, D. Morgenstern^2^, A. Narendran^3^, R. Deyell^4^, Y. Samson^5^, S. Baruchel^2^

*^1^Children\'s Hospital of Eastern Ontario, Division of Paediatric Hematology/Oncology, Ottawa, Canada; ^2^Hospital for Sick Children, Division of Hematology/Oncology, Toronto, Canada; ^3^Alberta Children\'s Hospital, Division of Hematology/Oncology, Calgary, Canada; ^4^BC Children\'s Hospital, Division of Hematology/Oncology, Vancouver, Canada; ^5^Ste Justine Hospital, Division of Hematology/Oncology, Montreal, Canada*

**Background/Objectives**: Melatonin is a natural health product used for sleep disturbances. In preliminary studies of adults with advanced cancer, 20 mg daily of melatonin (approximately 0.25 mg/kg) was associated with reduction in anorexia and weight loss -- symptoms that also impact pediatric oncology patients. However, high doses of melatonin have not been studied in the pediatric population.

**Design/Methods**: This was a multicentre single arm phase I dose escalation study utilizing a 3+3 design. Primary objective was to determine the safety and tolerability of escalating doses of melatonin in pediatric oncology patients with relapsed solid tumors. Secondary objectives were to: determine the cumulative effect of an 8‐week course of high dose melatonin; establish the pharmacokinetics of melatonin; establish the cytokines associated with melatonin; and, determine if melatonin improved weight gain. Melatonin was given for 8 weeks at 3 dose levels, 0.075 mg/kg (maximum 5 mg), 0.15 mg/kg (maximum 10 mg) and 0.3 mg/kg (maximum 20 mg).

**Results**: Melatonin was well tolerated at all 3 dose levels with no significant adverse events. The only grade 3/4 toxicities were bone marrow suppression which was attributed to the concomitant chemotherapy and occurred at all dose levels. Weight gain occurred in 7 of 9 patients, with a mean increase of 0.79 kg (range ‐3.3 to 4.5) or 1.5% (range ‐10.2 to 8.7), with 2 patients losing weight (one in dose level 1 and one level 3). PK data showed mean Cmax 11.6 ng/mL, elimination t½ 44 min for dose level 1, Cmax 16.4 ng/mL, elimination t½ 37 min for dose level 2, and Cmax 44.9 ng/mL, elimination t½ 78 min for dose level 3.

**Conclusions**: Melatonin is well tolerated at a dose of 0.3 mg/kg (maximum 20 mg), in the pediatric population. This study provides the background for further study of high dose melatonin in pediatric oncology patients.

### PO-203. Nutritional Screening and Intervention in a Turkish Pediatric Oncology Clinic {#pbc27455-sec-11720}

D. Hopanci Bıçaklı^1^, H. Hekimci^2^, A. Sahin^2^, N. Çetingül^2^, [M. Kantar]{.ul} ^2^

*^1^Ege University School of Medicine, Tulay Aktas Oncology Hospital, Izmir, Turkey; ^2^Ege University School of Medicine, Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: Nutrition is one of the major concerns in the treatment of children with cancer as clinical malnutrition becomes more evident with current intensive treatments. In this study we analyzed our current nutritional approach to the children.

**Design/Methods**: During 2017 period, 77 patients with cancer (35 female, 42 male) (mean age 8,8 years) were evaluated in terms of nutrition within 24 hours of admission to the oncology clinic. We used STRONGkids (SK) to screen malnutrition. Anthropometric measures were done using height, weight and upper mid‐arm circumference (UMAC), and daily intake of energy and protein was recorded. Nutritional intervention was given by either enteral (oral supplementation or tube feeding) or parenteral ways during their treatment period.

**Results**: Diagnosis of the patients was bone and soft tissue sarcomas (28.6%), CNS tumors (22%), leukemias (13%), lymphomas (11.7%), neuroblastoma (9.1%), other tumors (15.6%). On hospital admission, 33.8% of the patients have a weight percentile less than 25%, while 26% have a height percentile less than 25. Thirty‐five percent of the patients have weight loss at the time of evaluation. BMI was less than 25% in 39% of the patients whereas UMAC in 67.1%.

According to STRONGkids screening, 63.6% of the patients have medium risk while 36.4% to have high risk. Interestingly, we found that 49.4% of the patients have lower energy intake less than 50% of the recommended while 58.4% have lower protein intake.

As a part of nutritional intervention, 36.4% of the patients were given oral supplementation, 26% tube‐pump feeding and 2.6% total parenteral nutrition.

**Conclusions**: Malnutrition either on admission or in the follow‐up is a common problem that could affect cancer treatment. Children in the oncology clinics should be screened using scales and anthropometric measurements. After evaluating these data, nutritional intervention are needed in the majority of the patients as was documented in our study.

### PO-204. Impact of Tuberculosis Infection in Children with Acute Leukemia {#pbc27455-sec-11730}

[P. Kanvinde]{.ul} ^1^, Z. golwala^1^, S. patel^1^, K. vp^1^, A. swami^1^, N. shah^1^, M. desai^1^, S. mudaliar^1^, B. Agrawal^1^

*^1^Bai Jerbai Wadia Hospital for Children, Pediatric Hemato‐oncology, Mumbai, India*

**Background/Objectives**: Patients with acute leukemia (AL) are immunocompromised and at a high risk of reactivation of latent infections like tuberculosis (TB). We aim to study clinical characteristics of patients diagnosed with TB in AL and its impact on treatment of leukemia.

**Design/Methods**: Retrospective analysis of all AL patients diagnosed with TB from 2012‐2017 at BJ Wadia children\'s hospital, Mumbai was done for characteristics related to AL, site of TB infection, mode of diagnosis and sensitivity pattern and response to antitubercular treatment.

**Results**: A total of 5 patients of AL were also diagnosed with TB. All had acute lymphoblastic leukemia (ALL), 4 were diagnosed during maintenance and 1 during induction. All presented with persistent fever nonresponsive to antibiotics and antifungals, only 1 in induction was neutropenic. Site of involvement was isolated lung in 3 patients (pleural effusion with mediastinal lymphadenopathy(1), persistent patch on chest radiogram(1), mediastinal lymphadenoapthy(1)), lung plus abdominal(miliary shadows and ileoceacal thickening) and ocular involvement in 1 patient each. Median time for diagnosis of TB post symptoms appearance was 4 weeks. The drug sensitivity pattern was proven in 80%, sensitive to all 1st line drugs in 2 patients, multidrug resistant (MDR) and extensively drug resistant (XDR) in 1 patient each. Diagnosis was on clinic‐radiological basis in 10%. Rescheduling of chemotherapy due to delay in diagnosis of TB was required in 80% of patients. Complete cure was seen in 2 patients, 1 patient of XDR TB is on intensive phase and 3 are on continuation phase. Early stoppage of chemotherapy was required for XDR TB patient due to poor clinical condition whereas others did not require any alteration of chemotherapy post diagnosis of TB. No hepatotoxicity was seen.

**Conclusions**: TB requires high index of suspicion for early diagnosis. In our study TB did not cause significant delay or alteration in chemotherapy or additional toxicities.

### PO-205. Clinical and Microbiological Profile of Bloodstream Infections in Pediatric Cancer Patients at a Tertiary Care Center {#pbc27455-sec-11740}

[P. Kanvinde]{.ul} ^1^, Z. Golwala^1^, S. Patel^1^, K. Vp^1^, A. Swami^1^, N. Shah^1^, M. Desai^1^, S. Mudaliar^1^, B. Agrawal^1^

*^1^Bai Jerbai Wadia Hospital for Children, Pediatric Hemato‐oncology, Mumbai, India*

**Background/Objectives**: Bloodstream infections (BSI) in pediatric cancer patients are a leading cause of morbidity and mortality during treatment. We aim to study the prevalence of BSI, their antibiotic sensitivity patterns and outcome in pediatric cancer patients.

**Design/Methods**: Data of all cultures sent from pediatric cancer unit at BJ Wadia children\'s hospital from June 2016 to January 2018 were analyzed for their microbiological profile and sensitivity pattern and clinical features and outcome.

**Results**: A total of 560 blood culture samples were sent for suspected bloodstream infections and (55) 9.8% were culture positive, out of which 27.2% were isolated from central venous lines. 96% of culture proven BSI were isolated from patients of hematolymphoid malignancies. Of the culture positive, 72.7% were Gram negative bacilli (GNB), 20% gram positive cocci (GPC) and 7.3% candida species. Among GNB organisms isolated were Pseudomonas (35%), Kleibseilla pneumonia (32.5%), Escherichia coli (22.5%), Citrobacter (5%) and Non fermenter GNB (5%). Among GPC staphylococcus was isolated in 90% and beta haemolytic streptococci in 10%. Among GNB, 47.5% were resistant to 3rd generation cephalosporins, 27.5% were extended spectrum beta lactamases (ESBL) producers and 19.5% were resistant to carbapenems (CR) and all were sensitive to colistin. Among the staphylococci, methicillin sensitive (MSSA) were 37.5% and resistant (MRSA) were 25% and rest were CONS. Underlying morbid conditions like Downs Syndrome and Granzyme deficiency present in 2 patients. All patients with culture proven BSI had severe neutropenia. Sepsis leading to organ dysfunction was seen in 80% and secondary HLH in 27% of GNB infections. Mortality in culture proven BSI was 18.2%, due to carbapenem resistant Kleibseilla, E.coli and Pseudomonas and MRSA.

**Conclusions**: There is an increasing incidence of antibiotic resistance and complications among GNB. The need of the hour is to implement infection control and follow strict antibiotic policy with regular surveillance of changing microbiological profile.

### PO-206. Differential Diagnosis of Infectious Etiology in Febrile Pediatric Hematology/Oncology Patients using Infrared Spectroscopy of Peripheral Blood {#pbc27455-sec-11750}

[J. Kapelushnik]{.ul} ^1^, G. Beck Rosen^1^, A.H. Agbariaa^2^, A. Salman^3^, H. ‐ Mahmoud^4^, S. Mordrchai^2^

*^1^Sorok Medical and Ben Gurion University, Pediatrics Oncology /Hematology, BeerSheva, Israel; ^2^Ben Gurion University of the Negev, Physics, Beer Sheva, Israel; ^3^Sami Shamoon College of Engineering, Physics, Beer Sheva, Israel; ^4^Ben Gurion University of the Negev, Microbiology‐ Immunology and Genetics, Beer Sheva, Israel*

**Background/Objectives**: In the Pediatric Hematology/Oncology setting, rapid identification of infectious etiology is highly important The current methods are mainly based on microbial cultures and are time consuming. The main objective of this study was to evaluate the potential of the mid infrared spectroscopic method for rapid and reliable identification of bacterial and viral infections based on peripheral blood samples. Fourier transform infrared (FTIR)‐spectroscopy has been found useful for monitoring the effectiveness of antibiotics treatment in cancer patients with bacterial infections and used to distinguish between bacterial and viral etiology, based on an analysis of the blood components

**Design/Methods**: We have evaluated 70 events of pediatric hematology oncology admissions. White blood cells and plasma were isolated from peripheral blood samples of patients with confirmed viral or bacterial infections. Spectroscopy of diagnostic markers (i.e. RNA/DNA ratio and Amide1/Amide2 ratio) was used for monitoring the biochemical changes in WBCs and plasma during treatment. The obtained spectra were analyzed by multivariate analysis: principle component analysis, followed by linear discriminant analysis, in a time span of about one hour after the collection of the blood sample. Each confirmed result was then used to develop and refine an algorithm for prediction of the etiology

**Results**: By employing the (FTIR)‐spectroscopy of feature extraction with Fisher linear discriminant analysis in order to identify the infectious type, a sensitivity of ∼92 % and an accuracy of ∼80 % for an infection type diagnosis was achieved

**Conclusions**: The present study suggests that FTIR spectroscopy of WBCs is a potentially feasible and efficient tool for the diagnosis of the infection etiology type in the pediatric hematology/oncology setting. We plan to empower the algorithm with additional future events and developing a system that could process whole‐blood drops to enable rapid, safe and reliable point‐of‐care test results for clinical decision making in this special population of patients

### PO-207. Treatment Challenges in the Management of BK Virus Infections in Nontransplanted Immunsuppressed Children with Cancer {#pbc27455-sec-11760}

[Z. Karakas]{.ul} ^1^, R. Tuna^1^, S. Ocak^1^, D. Tugcu^1^, M. Onel^2^, S. Aydogdu^1^, S. Karaman^1^

*^1^Istanbul University‐ Istanbul Medical Faculty, Department of Pediatric Hematology‐Oncology, Istanbul, Turkey; ^2^Istanbul University‐ Istanbul Medical Faculty, Department of Virology, Istanbul, Turkey*

**Background/Objectives**: BK virus (BKV) is a double‐stranded DNA virus belongs to polyomavirus family. Primary infection occurs in childhood and viral latency may persist in urogenital tract epithelium. BKV reactivation typically causes nephropathy after kidney or hematopoietic stem cell transplantation. It is rarely seen in non‐transplanted immuncompromised patients and can be associated with systemic complications like encephalitis, pneumonia and pneumonitis. Treatment strategies are controversial. We present 3 children who had BKV infection secondary to solid or hematological malignancy related immunosuppressive state.

**Design/Methods**: Descriptive case report

**Results**: Patients were 5‐year‐old girl, 6‐year‐old boy and 15‐year‐old‐boy whose diagnoses were neuroblastoma, acute myeloid leukemia and Burkitt\'s lymphoma, respectively. Each of 3 patients developed hematuria during their chemotherapy courses and high BKV titer detected in urine and blood. After hematuria and acute renal failure, the first case developed right heart failure and pneumonitis. She treated with ciprofloxacin, intravenous immunoglobulin and 1 course of sidofovir synchronous with hemodiafiltration in addition to other supportive therapies. Despite mild clinical recovery, she died of acute pulmonary hemorrhage. The second case had encephalitis during BK viremia and treated with ciprofloxacin and intravenous immunoglobulin. His clinical condition improved and BKV titer became negative. He is in the 4th year of disease‐free follow up. The 3rd case had underlying cirrhosis and had 2 courses of chemotherapy while he had BKV nephropathy. He was treated with ciprofloxacin and intravenous immunoglobulin. His clinical condition improved with supportive therapy, BK virus titer became negative. He is in remission for Burkitt\'s lymphoma with stable signs of chronic liver failure.

**Conclusions**: BKV infection should be considered for the differential diagnosis of opportunistic infections in immunosuppressed pediatric cancer patients in the presence of renal involvement. Treatment strategies are limited. Due to the lack of effective treatment and fatal consequences, future research on risk factors of BKV infection and targeted therapies are essential.

### PO-208. Cryptosporidium Infections Among Paediatric Oncology Patients with Diarrhoea in a Tertiary Care Hospital Dhaka, Bangladesh {#pbc27455-sec-11770}

[S. Karim]{.ul} ^1^, A. Islam^1^, M.A. Tatafdar^2^, C.Y. Jamal^1^, M. Begum^3^, A.A. Rahman^1^, S. Ahsan^4^, H. Rashid^5^, M.J. Islam^6^, B. Malik^7^

*^1^Bangabandhu Sheikh Mujib Medical University, Paediatric Haematology & Oncology, Dhaka, Bangladesh; ^2^Z H Sikder Womens Medical College, Community Medicine, Dhaka, Bangladesh; ^3^National Institute of Cancer Research & Hospital, Paediatric Oncology, Dhaka, Bangladesh; ^4^Combined Military Hospital‐ Savar, Administration, Dhaka, Bangladesh; ^5^National Centre for Immunisation Research & Surveillance NCIRS‐, The Children\'s Hospital at Westmead‐, Sydney, Australia; ^6^National Institute of Cancer Research & Hospital, Cancer Epidemiology, Dhaka, Bangladesh; ^7^National Centre for Immunisation Research & Surveillance NCIRS, The Children\'s Hospital at Westmead‐, Sydney, Australia*

**Background/Objectives**: Cryptosporidium is a major cause of moderate to severe diarrhoea worldwide. Children with malignancy are at increased risk of serious complications caused by intestinal parasites such as Cryptosporidium. The burden of Cryptosporidium infections in children with malignancy remains understudied in resource‐poor settings due to lack of affordable tests. The aim of the present study was to estimate the proportion of Cryptosporidium infection among pediatric oncology patients with diarrhea at a tertiary teaching hospital in Dhaka, Bangladesh.

**Design/Methods**: A cross sectional study was carried out from March 2016 to February 2017 among children with malignancy at the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Seventy stool samples were collected consecutively from patients who developed diarrhea during hospitalization and investigated for the presence of Cryptosporidium Antigen by ELISA at the microbiology laboratory of BSMMU

**Results**: Seventy diarrheal episodes were recorded in 66 patients, aged 11 to 216 (median 60) months, among them 83% had hematological malignancies and the remaining 17% had solid tumors. Cryptosporidium antigen was detected in 3 (4%) stool samples. About 57% of children had stool frequency of 6‐9 times/day. Over two third (77%) children passed low volume stool, in more than half of the cases the stool was watery in consistency. Diarrhea was more common (61.4%) during induction phase of chemotherapy, 35.7% of children with diarrhea were profoundly neutropenic and 42.2% were severely lymphopenic. All the cryptosporidium positive cases were aged \< 60 months, had prolonged diarrhoea, were malnourished and in induction phase of chemotherapy.

**Conclusions**: These data from a pilot study suggest that cryptosporidium is a non‐negligible cause of diarrhea in pediatric oncology patients but future large scale prospective studies are needed to quantify the burden of cryptosporidium infections in pediatric oncology patients.

### PO-209. Outcome of Intermediate Risk Pediatric Febrile Neutropenia: A Single Center Prospective Study from Pakistan {#pbc27455-sec-11780}

[M. Khan]{.ul} ^1^, M.S. Ashraf^2^, S. Iftikhar^3^

*^1^The Indus Hospital, Pediatric Hematology Oncology, Karachi, Pakistan; ^2^The Indus Hsopital, Pediatric Hematology Oncology, Karachi, Pakistan; ^3^The Indus Hospital, Statistics, Karachi, Pakistan*

**Background/Objectives**: Febrile Neutropenia (FN) is an oncological emergency and a significant cause of morbidity and mortality in low middle‐income countries. Early recognition, prompt antibiotics administration based on risk stratification and good supportive care are the hallmark for better outcome. We aim to determine the outcome and association of demographic, clinical and laboratory data of intermediate risk pediatric febrile neutropenia patients treated on Piperacillin / Tazobactam and amikacin in tertiary care hospital of Pakistan.

**Design/Methods**: All intermediate risk FN(IRFN) patients less than 16 years age being admitted in the pediatric oncology ward of The Indus Hospital from May to July 2016 were enrolled. Outcome analyzed using SPSS 21. Relapsed patients, low and high‐risk FN were excluded. Outcome defined as success if discharged after completion of antibiotics or as failure if antibiotics were changed, antifungal added or need of intensive care due to hemodynamic instability and death.

**Results**: Total 141 episodes occurred. 104 events (74%) were documented in acute leukemia. Induction and consolidation were the major chemotherapy phases for occurrences (71%). Only 3.5% of blood cultures were positive. Success rate was 83% (n=117) and failure 17% (n=24). Major reason of failure was change in antibiotics (79.2%) due to persistent fever \> 72 hrs. 3 deaths occurred due to probable fungal infection. On multivariable analysis, four independent risk factors were found to be significant for failure‐ Absolute Neutrohil Count (ANC) \< 100 at presentation (aOR (95% CI): 11.45 (1.70‐77.19), p= 0.012), C‐Reactive Protein(CRP)≥20mg/dl (aOR (95% CI): 3.94 (1.03‐15.12), p=0.045), respiratory rate (RR) (aOR (95% CI): 1.48 (1.17‐1.88), p=0.001) and heart rate(HR) (aOR (95% CI): 0.96 (0.93‐1.00), p=0.048).

**Conclusions**: ‐ Our approach to treat IRFN proved optimal. Strategy of low and high risk needs investigation. Based on HR, RR, ANC and CRP, scoring model can be formulated for further refinement of our current management

### PO-210. Pediatric Oncology Patient Outcomes in a Developing Country Intensive Care Unit {#pbc27455-sec-11790}

[S. Khan]{.ul} ^1^, G.Z. Khan^1^

*^1^Shaukat Khanum Memorial Cancer Hospital & Research Center, Pediatric Oncology, Lahore, Pakistan*

**Background/Objectives**: Cancer is not a common but an important cause of pediatric morbidity and mortality in the developing world. With improved treatment regimens survival rates are higher. However these chemotherapeutic regimens can also lead to complications requiring transfer to an intensive care unit (ICU). Here we report our experience of reasons for critically ill pediatric oncology patients needing an ICU transfer and their outcomes.

**Design/Methods**: A retrospective cohort study was conducted from December 2015 to June 2017. After IRB approval pediatric oncology patient medical records with ICU admissions were reviewed for data regarding demographics, diagnosis, disease stage, pediatric risk of mortality (PRISM) III score and therapeutic interventions.

**Results**: A total of 60 patient medical records with 66 ICU admissions were reviewed with 36 (60%) boys and 24 (40%) girls. The median age was 4 years (range: 1 to 17). Both Precursor‐B‐acute leukemia 17 (28.3%) and mature B‐cell lymphoma 15 (25%) were the most common diagnosis seen followed by Wilm\'s tumor 10 (16.7%). The mean PRISM‐III score among survivors was lower 8.6 +/‐ 4.3 than that seen in the non‐survivors 16.2 +/‐ 9.7 (p\<0.0001). Overall 27 patients (45%) died. The mortality rate was 57.6 % (n‐19) in patients with PRISM III of \> 10 during an ICU admission as compared to 24.2% (n‐8) in patients with a score of \</= 10.

**Conclusions**: The mortality rate for pediatric oncology patients admitted to the ICU in developing countries is higher than that seen in developed countries. Mostly children with haematology malignancies were referred to the ICU. Mortality rate was significantly related to a high PRISM‐III of more than 10 score on admission to the ICU.

### PO-211. Presentation of Carbapenem‐Resistant Enterobacteriaceae (CRE) in Hospital Acquired Infections of Pediatric Oncology Unit at Indus Hospital {#pbc27455-sec-11800}

[A. Khatoon]{.ul} ^1^, D.F. Saddiqui^1^, K. Qadir^1^

*^1^The Indus Hospital network, Infection Control, Karachi, Pakistan*

**Background/Objectives**: Pediatric Cancer patients are at a higher risk for life threatening hospital acquired infections (HAI) due to their intensive treatments. Carbapenem‐resistant Enterobacteriaceae (CRE) are type of germs that are difficult to treat and manage due to resistance to multiple antibiotics including carbapenem. CRE infections are spread by direct contact with bodily fluids of infected person, as well as by contact touch of contaminated surfaces. By further misusing broad spectrum antibiotics, CRE resistance infections continue to spread, becoming a global health issue in hospital settings. This limits the survival rate amongst the already immunocompromised children due to multidrug resistance. It is estimated that half the children who become infected with CRE die from it.

**Design/Methods**: Over a period of six months from September 2017 to February 2018, data was collected from Microbiology department of the Indus Hospital. Positive blood Culture sensitivity test results were collected. On the basis of drug sensitivity, results were categorized into Carbapenem‐resistant Enterobacteriaceae (CRE). They were further categorized on type of organism. Patients who had the same CRE organisms were counted once and multiple admissions were excluded From the 11 samples, two different CRE organisms were found in the same patient.

**Results**: From the sample of 66 positive blood cultures, 11 (16.7%) samples were CRE positive. More than half of the CRE samples were E Coli (CRE) (6 samples, 54.5%). The remaining samples were divided into klebsiella species (4 samples, 36.4%) and Enterobacter species (1 sample, 9.1%). Out of the 10 patients with CRE organisms, mortality occurred in 8 patients (80%).

**Conclusions**: CRE infections are difficult to treat and in most cases end in mortality. Thus, while treating Immunocompromised children, there is a dire need to have strict hospital policies regarding antibiotic stewardship and infection control to increase survival.

### PO-212. Paranasal Sinusitis at Diagnosis Predicts the Development of Invasive Fungal Disease in Children and Adolescents Receiving Chemotherapy {#pbc27455-sec-11810}

[K. Kishimoto]{.ul} ^1^, R. Kobayashi^2^, D. Hori^2^, H. Sano^2^, D. Suzuki^2^, K. Kobayashi^2^

*^1^Kobe Children\'s Hospital, Hematology & Oncology, Kobe, Japan; ^2^Sapporo Hokuyu Hospital, Hematology/Oncology for Children and Adolescents, Sapporo, Japan*

**Background/Objectives**: The objective of this study was to determine whether paranasal sinusitis at diagnosis affects the development of infectious complications in children and adolescents with cancer receiving chemotherapy.

**Design/Methods**: A total of 130 consecutive patients aged between 0 and 20 years with hematological malignancy (n=98) or solid tumor (n=32) who received chemotherapy in Sapporo Hokuyu Hospital between 2012 and 2016 were enrolled in a retrospective cohort study. High‐dose chemotherapy as part of conditioning regimens for stem cell transplantation was excluded from the analysis. Paranasal sinusitis was defined as the presence of a fluid level or mucosal swelling or total opacity on sinus CT examination. Invasive fungal disease (IFD) were defined according to the European Organization for Research and Treatment of Cancer/Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group consensus.

**Results**: Paranasal sinusitis was observed in 57 (44%) patients at diagnosis of cancer. There were no significant differences in age, sex, and disease distribution between the patients with paranasal sinusitis at diagnosis (sinusitis group) and those without (non‐sinusitis group).The cumulative incidence of IFD at 1 year after treatment initiation was significantly higher in the sinusitis group than in the non‐sinusitis group (22% vs 6%, P=0.007).There was no significant difference in the cumulative incidence of bacteremia or septic shock between the two groups (bacteremia, 33% in the sinusitis group, 35% in the non‐sinusitis group, P=0.65; septic shock, 4% in the sinusitis group, 4% in the non‐sinusitis group, P=0.88).A multivariate analysis showed that paranasal sinusitis at diagnosis was significantly associated with an increased risk of IFD (odds ratio: 4.8, 95% confidence interval: 1.4‐16.8, P=0.016).

**Conclusions**: We found a significantly higher incidence of IFD in the sinusitis group. Paranasal sinusitis at diagnosis should be recognized as an additional potential risk factor for IFD.

### PO-213. Severe Bacterial Infections Causing Muscle Necrosis in Children with Hematologic Malignancy {#pbc27455-sec-11820}

[P. Komvilaisak]{.ul} ^1^, P. Wongmast^1^, A. Jetsrisuparb^1^, P. Tanming^1^

*^1^Srinagarind Hospital, Department of Pediatrics‐ Faculty of Medicine‐ Khon Kaen University‐ Khon Kaen, Khon Kaen, Thailand*

**Background/Objectives**: Infection related mortality in childhood hematologic malignancy could lead to worse outcome in treatment and complications related to infection. Fulminant bacterial infections such as Aeromonas species has been reported in patients with acute lymphoblastic leukemia.

**Design/Methods**: The study is to review and report the three cases with hematologic malignancy having the fulminant bacterial infections.

**Results**: Among of three cases, 2 cases diagnosed with high risk acute lymphoblastic leukemia(ALL) and 1 case diagnosed with high risk acute monoblastic leukemia(AMoL). 2 cases with ALL were started with induction therapy consisting of vincristine, L‐asparaginase, doxorubicin and prednisolone. Two weeks post therapy they developed febrile neutropenia and progressive bilateral leg pain, tenderness and swelling with pulse present. Unfortunately, both legs became discoloration, extensive to both thighs and into bloodstreams. Apart from empirical antibiotics, surgical treatment including above knee amputation(AKA) left leg on one case and initial fasciotomy with subsequent bilateral AKA on another case. The former case passed away from septicemia and the latter case is still alive. Hemoculture demonstrated Aeromonas hydrophila and Aeromonas veronii be sobria. Pathological result showed extensive muscular tissue necrosis with no thrombus in vascular seen. The third case with AMoL developed febrile neutropenia presenting with hypotension and right thigh pain and swelling after consolidation phase. Computerized tomography angiogram performed demonstrated myositis of deep intramuscular posterior compartment below right knee with no evidence of arterial occlusion. Finally he underwent AKA of right leg. He is alive. Muscle culture revealed Plesiomonas shigelloides. Hemoculture revealed staphylococcus coagulase negative which might be from contamination. Two survival cases also developed rhabdomyolysis post amputation which was resolved.

**Conclusions**: Fulminant Aeromonas and Plesiomonas species infections in immunocompromised patients such as hematologic malignancy can lead to serious complications such disability and death. Early detection, empirical antibiotic and emergency surgical management are necessary for proper treatment in order to safe life‐threatening condition.

### PO-214. Invasive Fungal Infections Associated with Childhood Cancer in Srinagarind Hospital, Thailand {#pbc27455-sec-11830}

[P. Komvilaisak]{.ul} ^1^, T. Kanjanapradap^1^, P. Wongmast^1^, A. Jetsrisuparb^1^

*^1^Srinagarind Hospital, Department of Pediatric‐ Faculty of Medicine‐ Khon Kaen University, Khon Kaen, Thailand*

**Background/Objectives**: The more aggressive chemotherapy to improve outcome of cancer treatment, the prevalence of invasive fungal infections (IFIs) in children with cancer is more increasing.

**Objective**: To describe IFIs, including clinical manifestations, risk factors, treatment and outcomes in pediatric patients with cancer.

**Design/Methods**: Retrospective descriptive study in pediatric patients (\< 18 years of age) with cancer, who were diagnosed with IFIs between January 2005 and September 2016.

**Results**: Diagnoses of IFIs in 26 (of 446) patients were regarded as proven in 3 (11.5%), probable in 16 (61.5%), and possible in 7(26.9%). Among these, two had a yeast infection (*Candida tropicalis*) and 24 had mold infections; *Aspergillus* (22), and *Mucor* (2). The underlying diseases were ALL (14), AML (8), lymphoma (3) and osteosarcoma(1). Factors contributed to IFIs, included prolonged antibiotic use, absolute neutrophil count \< 500 cells/ml, absolute lymphocyte count \< 500 cells/μl, steroid use, total parenteral nutrition and central line catheter placement. Sites of IFIs were most common in the lungs, followed by sinuses and nasal cavity, spleen and kidney. All patients with IFIs were empirically treated with antifungal medications with improvement in 23 and death in 2 patients, loss follow‐up (1) and death from other organism sepsis (1).

**Conclusions**: IFIs in pediatric patients with cancer might result in worse outcomes of cancer due to increased mortality rate and delayed chemotherapy. Patients at greater risk of IFIs should be appropriately investigated and treated promptly leading to better outcome.

### PO-215. Use of Tissue Plasminogen Activator for Episodes of Central Venous Catheter Dysfunction is Associated with Inferior Survival Outcome in Pediatric Cancer Patients {#pbc27455-sec-11840}

Z. Forbrigger^1^, S. Kuhle^2^, M.M. Brown^2^, C. Digout^1^, [K. Kulkarni]{.ul} ^1^

*^1^IWK Health Centre, Division of Pediatric Hematology Oncology‐ Department of Pediatrics, Halifax, Canada; ^2^Dalhousie University, Perinatal Epidemiology Research Unit‐ Departments of Pediatrics and Obstetrics & Gynaecology, Halifax, Canada*

**Background/Objectives**: Tissue plasminogen activator (tPA) is commonly used to treat central venous catheter (CVC) dysfunction. Catheter dysfunction is often associated with thrombosis, which has been linked to poorer survival outcomes in adults and more recently in pediatric cancer patients. Our objective, therefore, was to examine the association between tPA administration for episodes of CVC dysfunction and survival in pediatric cancer patients.

**Design/Methods**: The present study is a population‐based retrospective cohort study of pediatric oncology patients from the Canadian Maritimes provinces of Nova Scotia, Prince Edward Island, and New Brunswick; all pediatric oncology patients in the Maritimes are treated at the IWK Health Centre. Data for the current study came from the IWK pharmacy database, pediatric oncology database, and patient charts, as well as the Cancer in Young People in Canada registry. Demographics, diagnosis, date of death or date of last visit, and tPA use for CVC dysfunction were collected from 2000 through 2015. The association between tPA and survival was examined using Cox proportional hazards regression adjusted for sex and age at diagnosis.

**Results**: Out of 933 patients, 190 (20%) received tPA: 93 (10%) patients received one dose of tPA, 48 (5%) received two, and 49 (5%) received ≥3 doses. Patients who received ≥1 doses of tPA had poorer survival than those who did not (HR 1.93, 95% CI 1.36‐2.73). In the adjusted model, patients who received one (HR 1.73, 95% CI 1.08, 2.78) and two or more doses of tPA (HR 2.01, 95% CI 1.30‐3.10) were more likely to die than patients who never received tPA.

**Conclusions**: We demonstrated a significantly poorer survival in pediatric cancer patients who received one or more doses of tPA. Future studies should corroborate these findings in other populations, examine the role of potential confounders, and determine the role of tPA in prognostic models of cancer survival.

### PO-216. The Toxicity of Dexrazoxane as a Cardioprotective Agent in Children with Cancer: A Population‐Based Study {#pbc27455-sec-11850}

D. deWaard^1^, [K. Kulkarni]{.ul} ^1^, A. Warren^2^, T. MacDonald^1^

*^1^IWK Health Centre, Division of Pediatric Hematology Oncology‐ Department of Pediatrics, Halifax, Canada; ^2^IWK Health Centre, Division of Pediatric Cardiology‐ Department of Pediatrics, Halifax, Canada*

**Background/Objectives**: Due to a paucity of available data, the present study was designed to assess the toxicity of dexrazoxane based on treatment delays.

**Design/Methods**: After ethics approval, a retrospective, population‐based cohort study was completed using chart and database information on children treated with anthracycline from 2009‐2015. Since 2012, all patients receiving \>150 mg/m2 cumulative anthracycline dose or ≤5 years old received dexrazoxane. This group was compared with pre‐2012 children who did not receive dexrazoxane. Toxicity was defined as chemotherapy delays (by 3 days or more) from any of: decreased absolute neutrophil count (ANC), decreased platelets, and viral/bacterial episodes. Adjusted incidence rate ratios (IRR) for all outcomes were obtained using count models.

**Results**: 198 patients had toxicity data available (90 treated, 108 untreated), mean age 7.82 years. The average cumulative anthracycline dose was 230 mg/m2 in the treated group and 205 mg/m2 in the untreated group. No difference in gender distribution was seen. The total number of delays in chemotherapy cycles in the treated group was significantly higher (p\<0.001). The adjusted IRR for (i) the total number of episodes of decreased absolute neutrophil count (ANC), decreased platelets, and viral/bacterial infection \[1.73 (95%CI:1.26 to 2.73, p\<0.001)\], and (ii) number of delays due to ANC \[1.52(95%CI:1.11‐2.09, p=0.009)\] were significantly higher in the treated group versus untreated group respectively. The study group had 11.7 (95%CI: 1.79‐235.6, p=0.03) odds of having at least 1 platelet event.

**Conclusions**: Patients who receive dexrazoxane are at significantly increased risk of delays in therapy due to myelosuppression, infection and thrombocytopenia. Since treatment delays may be associated with relapse, the risk versus benefit of dexrazoxane as a cardioprotective agent in children with cancer should be further examined.

### PO-217. The Efficacy of Dexrazoxane to Prevent Early Cardiotoxicity in Children with Cancer: A Population‐Based Study {#pbc27455-sec-11860}

D. DeWaard^1^, [K. Kulkarni]{.ul} ^1^, A. Warren^2^, T. MacDonald^1^

*^1^IWK Health Centre, Division of Pediatric Hematology Oncology‐ Department of Pediatrics, Halifax, Canada; ^2^IWK Health Centre, Division of Pediatric Cardiology‐ Department of Pediatrics, Halifax, Canada*

**Background/Objectives**: The efficacy of dexrazoxane as a cardioprotective agent in children treated with anthracycline has not been well established. The present study was designed to assess the efficacy of dexrazoxane.

**Design/Methods**: After ethics approval, a retrospective, population‐based cohort study was completed using chart and database information on children treated with anthracycline from 2009‐2015. Since 2012, all patients receiving \>150 mg/m2 cumulative anthracycline dose or ≤ 5 y.o. received dexrazoxane. This group was compared with pre‐2012 children who did not receive dexrazoxane. Lack of efficacy was defined as deviations in identified cardiac parameters on echocardiogram (ECHO) associated with anthracycline toxicity, which included: ejection fraction (EF), shortening fraction (FS), z‐scores for left ventricular internal diameter end‐diastole and end‐systole (LVIDd, LVIDs), left ventricular posterior wall thickness end‐diastole (LVPWd), and LV mass.

Statistics

The number of cardiac parameters were reduced to a single value for each individual. For each outcome the largest negative relative difference from baseline was considered with corresponding cumulative anthracycline dose (CAD) adjusting for age, sex, and diagnosis. EF \< 55% and FS \< 30% were cut‐off values and z‐scores were all ‐2 except LVPWd which was ‐1.64 (due to the low number of observations less than ‐2). These values were plotted against the CAD and multiple regression models were performed.

**Results**: 153 patients had efficacy data available (62 treated, 91 untreated). The mean age was 8.74 years. The average CAD in the treated group was 230 mg/m2 and untreated group 200 mg/m2. No difference in gender distribution was seen. There were no significant differences in cardiac parameters between the treated and untreated patients.

**Conclusions**: Over a 3‐year period children who received dexrazoxane did not show a significant deviation from baseline ECHO data. Further studies identifying children who are at risk of significant cardiotoxicity would be helpful to determine who may benefit from dexrazoxane.

### PO-218. Early Stoppage versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with Febrile Neutropenia, Before Recovery of Counts: A Feasibility and Pilot Study {#pbc27455-sec-11870}

[A. Kumar]{.ul} ^1^, R. Pramanik^1^, A. Chopra^2^, A. Kapil^3^, S. Vishnubhatla^4^, S. Bakhshi^1^

*^1^AIIMS, Department of Medical Oncology, New Delhi, India; ^2^AIIMS, Department of Laboratory Oncology, New Delhi, India; ^3^AIIMS, Department of Microbiology, New Delhi, India; ^4^AIIMS, Department of Biostatistics, New Delhi, India*

**Background/Objectives**: Despite a common practice to de‐escalate or stop antibiotics in low risk pediatric febrile neutropenia patients adequately responding to antibiotics, robust evidence has been lacking. We conducted a randomized controlled pilot study to determine if early discontinuation of antimicrobials in low risk febrile neutropenia is as effective as continuing therapy till recovery of counts.

**Design/Methods**: Pediatric cancer patients with low risk febrile neutropenia presenting to the outpatient department were started on empirical intravenous (i.v) antibiotics. After an afebrile period of 24‐48 hrs, patients were randomized between stoppage of antibiotics (ARM‐A) and oral antibiotics (ARM --B). The intervention was considered to be successful if the patient remained afebrile till recovery of absolute neutrophil count (ANC) ≥ 500. Failure was defined as re‐appearance of fever

**Results**: A total of 261 patients were screened. 65 patients, fulfilling the inclusion criteria, were randomized (ARM‐A = 32 patients & ARM‐B = 33 patients). B aseline parameters, like age, sex, disease type, maximum grade of fever, interval between fever onset and presentation, absolute neutrophil count (ANC), and absolute monocyte count (AMC), were equally balanced in between two arms. At the end of the study, 5 patients experienced failure of intervention in each arm, demonstrating a success rate of 84.3% vs 84.8%, respectively. All the patients, who failed, responded optimally to re --initiation of i.v. antibiotics. None had any sign of systemic instability at the time of failure and no one required inpatient care.

**Conclusions**: Low risk febrile neutropenia patients can be managed on outpatient basis. An initial intravenous course of empirical antibiotics for 48‐72hrs, till the child gets afebrile for at least 24hrs appears adequate. Further antibiotics may be stopped, provided adequate close follow‐up can be ensured. Based on this early data, a larger randomized controlled trial is recruiting actively at our centre.

### PO-219. Improving and Preventing Central Line Associated Blood Stream Infection Through CLABSI Bundle {#pbc27455-sec-11880}

[D. Lalani]{.ul} ^1^

*^1^Aga Khan University Hospital, Oncology, Karachi, Pakistan*

**Background/Objectives**: CLABSI (central line associated blood stream infections) are one of the life‐threatening infections that can result in longer hospital stays, increased costs of treatment and increased risk of death.. In oncology patients, especially those who are on chemotherapy are expected to get neutropenic once they receive the therapy making them more prone to infections. Studies have also reported some serious life threatening conditions pertinent to CLABSI. Therefore, keeping a check on the routines of health allied while handling central lines can help improve the statistics of CLABSI in pediatric oncology patients.

**Design/Methods**: The Bundle checklist is filled daily through observation when health allied are handling line for various purposes. The Clinical Nurse Coordinator is responsible to sign off the checklist. Every month the analysis of the bundle is made and lacking factor are identified to be reemphasized. Various sessions over the month are planned for nurses and doctors on hand hygiene, central line handling and blood sampling from central line are done to emphasize the correct practice of handling central lines.

**Results**: This quality improvement initiative has resulted in decreased rates of CLABSI. Moreover, the sessions taken on hand hygiene and central line handling has brought a deeper sense of responsibility in all health allied while handling central lines. Since, the bundle has produced some greater effects in the CLABSI; therefore, this checklist is still in continuation to improve the practices of central line handling.

**Conclusions**: The perks of reducing CLABSI just not only improves patient outcome, but it also reduces mortality and serious life threatening condition i.e. sepsis. Reducing CLABSI also improves satisfaction of physicians, nurses, patients and their families. Lastly, it also provides financial benefits as the line is save for a longer period of time for the completion of therapy.

### PO-220. Diagnostic Value of Procalcitonin, C‐Reactive Protein and Lactate Dehydrogenase in Pediatric Malignant Solid Tumor Concurrently with Infection and Tumor Progress {#pbc27455-sec-11890}

[F. Li]{.ul} ^1^, W. Zhang^1^, H. Hu^1^, Y. Zhang^1^, D. Huang^1^

*^1^Beijing Tongren Hospital‐ Capital Medical University, Pediatrics, Beijing, China*

**Background/Objectives**: Infection is a fatal complication in cancer patients, sometimes it is not prone to be distinguished with tumor progress. We compared the diagnostic value of procalcitonin (PCT), C‐reactive protein (CRP) and lactate dehydrogenase (LDH) in pediatric malignant solid tumor concurrently with infection and tumor progress.

**Design/Methods**: One hundred and fifty‐two children were enrolled and divided into infection group (34 cases) and control group (118 cases). Each group was further divided into stable group and progressive group. An intergroup comparison was made in terms of serum PCT, CRP and LDH of all children.

**Results**: PCT, CRP and LDH levels in infection group were significantly higher than those in control group (P\<0.05); In the control group, PCT, CRP and LDH levels in progressive group were significantly higher than those in stable group (P\<0.05), but there was no significant difference in terms of PCT and CRP in infection group (P\>0.05). LDH had the highest correlation with tumor progress, while PCT was the lowest (LDH: r=0.684; CRP: r=0.570; PCT: r=0.322).

**Conclusions**: PCT has the highest value in diagnosing infection and is less susceptible to tumor progress than CRP. LDH has obvious advantages in judging the tumor progress.

### PO-221. Contribution of the *GSTP1* C.313A\>G Variant to Hearing Loss Risk in Patients Exposed to Platin Chemotherapy During Childhood {#pbc27455-sec-11900}

[P. Liberman]{.ul} ^1^

*^1^Hospital AC Camargo Cancer Center, Audiology, Sao Paulo, Brazil*

**Background/Objectives**: Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children.

Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin.

**Design/Methods**: Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the *GJB2* c.35delG, *GSTP1* c.313A\>G, and *MT‐RNR1* m.1555A\>G polymorphisms.

**Results**: Hearing loss was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (*p* = .002) and carboplatin (*p* = .010). The c.313A\>G variant of *GSTP1* (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (*p* = .020; 10‐fold vs. non‐carriers). No associations with HL were observed for *GJB2* or *MT‐RNR1* gene variants.

**Conclusions**: The *GSTP1* c.313A\>G variant may increase the risk of low‐frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.

### PO-222. Oral Medication Adherence Among Adolescents and Young Adults with Cancer During a Trial of a Smartphone‐Based Medication Reminder App {#pbc27455-sec-11910}

[L. Linder]{.ul} ^1^, Y. Wu^2^, A. Wilson^3^, Y. Jo^1^, C.F. Macpherson^4^, R. Johnson^5^

*^1^University of Utah, College of Nursing, Salt Lake City, USA; ^2^University of Utah, Department of Dermatology, Salt Lake City, USA; ^3^PAREXEL International Corporation & University of Utah, Real World Data Services department, Salt Lake City, USA; ^4^Seattle Children\'s Hospital, Nursing, Seattle, USA; ^5^Mary Bridge Childrens Hospital, Pediatric Hematology‐Oncology, Tacoma, USA*

**Background/Objectives**: Optimizing oral medication adherence is challenging for adolescents and young adults (AYAs) with cancer. mHealth resources, including reminder apps, are proposed strategies to support adherence. This pilot study evaluated oral medication adherence among AYAs during a trial of a smartphone‐based medication reminder app.

**Design/Methods**: Twenty‐three AYAs (median 19 years; range 15‐29 years) receiving at least one prescribed, scheduled oral medication related to their cancer treatment participated in this 12‐week longitudinal single group interrupted time series study. Baseline oral medication adherence was monitored using electronic monitoring caps for four weeks. Participants then used a medication reminder app and had their oral medication adherence monitored for 8 weeks. Paired t‐tests compared adherence before and during the intervention. Multilevel unconditional growth curve models assessed adherence trajectories, accounting for individual variation. Visual graphic analysis techniques were applied to individual profile plots of weekly adherence to evaluate trends and identify adherence phenotypes (patient subgroups with similar adherence patterns).

**Results**: Adherence did not differ during the intervention period compared with baseline (t=‐0.67, p=0.51); however, the variance in adherence narrowed for more highly adherent AYAs. Four adherence phenotypes were identified: 1) high adherence during both pre‐intervention and intervention periods (n=13), 2) high pre‐intervention adherence and low adherence during the intervention period (n=1), 3) low pre‐intervention adherence and improved adherence during the intervention period (n=3) and 4) low adherence during both periods (n=6).

**Conclusions**: Although overall average adherence was unchanged with app use, variance in adherence narrowed for more highly adherent participants. Additional or alternative interventions are needed for AYAs with persistently poor adherence. Formal assessment of adherence patterns may guide interventions to promote adherence.

Funding: Oncology Nursing Society Foundation; Huntsman Cancer Institute; Gamma Rho Chapter, Sigma Theta Tau International; University of Utah, College of Nursing; National Institute of Nursing Research, 1K23NR014874‐01; National Cancer Institute, K07CA196985, National Center for Advancing Translational Sciences UL1TR000105

### PO-223. An Oral Botanical Extract Safely Reduces Fatigue in a Radiation‐Induced Fatigue Mouse Model {#pbc27455-sec-11920}

L.N. Saligan^1^, B. Wolff^1^, B. Patsner^2^, G. Cauwenbergh^2^, W. Pralong^2^, C. Bernier^2^, M. Chretienne^2^, S. Harti^2^, [J. Liu]{.ul} ^2^

*^1^National Institutes Health, National Institute of Nursing Research, Bethesda, USA; ^2^Legacy Healthcare, Research & Development, Epalinges‐ Lausanne, Switzerland*

**Background/Objectives**: Cancer related fatigue (CRF) is a particularly prevalent debilitating condition with multifactorial etiology that can persist even during survivorship. No gold‐standard treatment is approved for CRF due to insufficient understanding of underlying mechanisms.

Sustained inflammation is believed to play a key role in CRF.

We previously observed significant correlations between changes in the expressions of eight mitochondria‐related genes (e.g. BCL2) with worsening of fatigue symptoms in radiation‐treated men. We also observed that Cellium, a safe botanical extract, inhibited inflammation and normalized BCL2 levels in human alopecia models.

Our objective is to investigate the anti‐fatigue effects of the oral Cellium in a radiation‐induced fatigue mouse model.

**Design/Methods**: Two successive placebo‐controlled experiments (N=40, n=20 Cellium, n=20 placebo) were conducted. Oral Cellium/placebo were provided to all mice before, during and following irradiation. Voluntary wheel running activity measuring distance and speed, served as the surrogate objective measure of fatigue‐like behavior in these mice.

**Results**: Average cumulative post‐irradiation running distance in the Cellium‐group was up to 47% greater than the Placebo‐group. The Cellium‐group returned to initial running distance 5‐8 days earlier than the Placebo‐group with no between‐group differences in bodyweight. Average speed improved post‐irradiation in the Cellium‐group by up to 77% compared to the placebo‐group. No adverse event related to the product use was observed.

**Conclusions**: Oral Cellium had anti‐fatigue effects in irradiation‐induced fatigue mice, possibly related to its anti‐inflammatory and BCL2 effects. Based on the safety and efficacy observed in this model, further investigations on the anti‐fatigue effects of Cellium on cancer patients receiving treatment (including pediatric patients) and cancer survivors are warranted.

### PO-224. Evaluation of Vancomycin use in Chinese Pediatric Oncology Patients with Fever and Neutropenia {#pbc27455-sec-11930}

[L.L. Liu]{.ul} ^1^, H. Mai^2^, S. Liu^2^, X. Yuan^2^, F. Wen^2^, C. Li^2^, X. Wang^2^, Z. Chen^1^

*^1^Shenzhen Children\'s Hospital, Pharmacy, Shenzhen, China; ^2^Shenzhen Children\'s Hospital, Hematology Oncology, Shenzhen, China*

**Background/Objectives**: To determine the incidence with which a conventional vancomycin dosing regimen of 10mg/kg per dose every 6 hours achieves target trough concentrations of 10‐15mg/L in Chinese pediatric hematology oncology patients.

**Design/Methods**: This was a retrospective chart review of the vancomycin used for all pediatric patients hospitalized in Hematology Oncology Department within this institution from Jan 1 to Dec 31 of 2017. The patients included were all \<18 years of age and received vancomycin for persistent febrile neutropenia. The vancomycin concentrations were done by immunoassay.

**Results**: There were 134 courses of vancomycin therapy eligible for review, out of which 59 trough concentrations were drawn, with a trough monitoring rate of 44%. 47 vancomycin peak concentrations were drawn, with a peak monitoring rate of 35%. Amongst the trough levels, 53 were HSCT patients, and 6 had hematological malignancy. All vancomycin courses were dosed initially based on the Chinese product monograph of recomended pediatric dose of 10mg/kg per dose every 6 hours. According to the IDSA and literature recommendations of target steady state trough level of 10‐15mg/L, only 12 (20%) out of the 59 initial levels achieved target range, 45 levels (76%) were subtherapeutic (\<10mg/L), and 2 levels (3%) were supratherapeutic (\>15mg/L). 19 (32%) fell below the acceptable level of 5mg/L. There was no dosage adjustment following subtherapeutic levels. None of the patients had developed adverse reactions related to vancomycin.

**Conclusions**: From a single center\'s experience, in Chinese pediatric hematology oncology patients, a vancomycin dose of 10mg/kg/dose every 6 hours is unlikely to achieve a target trough concentration, possibly due to altered pharmacokinetics from febrile neutropenia. The approach of individualized vancomycin therapy titrated to target trough concentrations should be considered instead. Further investigation should help define an appropriate initial vancomycin dose and target trough concentration in this population.

### PO-225. Effectiveness and Safety of Fosaprepitant in the Treatment of Chemotherapy‐Induced Nausea and Vomiting in Mexican Adolescent Girls Treated with Cisplatin {#pbc27455-sec-11940}

[N.A. Lopez‐Facundo]{.ul} ^1^, R. Tejocote^1^, D. Cardenas^1^, M. Laffont^1^, I. CruzM^1^

*^1^Hospital Para el Niño Instituto Materno Infantil del Estado de México, Pediatric Oncology, Toluca, Mexico*

**Background/Objectives**: Chemotherapy‐Induced Nausea and vomiting (CINV) is one of the adverse effects that cause more discomfort in patients with cancer and is an abandonment of treatment cause. in adolescents. Cisplatin is a highly emetic chemotherapy. Fosaprepitant is an NK‐1 blocker that has been shown to be useful in the treatment of in adults with CNVI.

Objective to assess the efficacy and safety of fosaprepitant in adolescent girls treated with cisplatin

**Design/Methods**: Objective to assess the efficacy and safety of fosaprepitant in adolescent girls treated with cisplatin

We designed an open clinical trial that included adolescent girls with some type of cancer who received cisplatin for 5 days. They received randomly: Treatment with or without fosaprepitant 150 mg IV, 1 hour before the start of chemotherapy plus ondansetron and dexamethasone at conventional doses. We evaluated nausea and vomiting according to the WHO scale. number of course of chemotherapy, and age The level of nausea and vomiting less than 2 on the WHO scale during the 5 days was considered effective. Local and systemic adverse reactions were documented

**Results**: Twenty‐eight courses of chemotherapy were administered with fosaprepitant, in 18 patients, 18 of the female gender diagnosed with ovarian germinal tumor, who received cisplatin, etoposide and bleomycin, being their own control. Effectiveness was recorded in 26/28 courses of chemotherapy (90%) vs 22/28, p 0.05 No local or systemic adverse effects were recorded.

**Conclusions**: Fosaprepitant is a effective drug in adult patients and appears to be a safe and effective treatment option for CINV adolescents with cancer who receive cisplatin, can contribute to improve the quality of life. doubleblind studies with larger sample are required to confirm the finding.

### PO-226. Usefulness of the Determination of Procalcitonin as a Predictor of Septic Shock in Children with Febrile Neutropenia in Hospital Materno Infantil Issemym, Toluca, México {#pbc27455-sec-11950}

[N.A. Lopez‐Facundo]{.ul} ^1^, I. Tejocote^1^, A. Marquez^1^, Y. Jaimes^1^, C. Rodriguez^1^

*^1^Hospital Materno Infantil del Instituto de Seguridad Social del Estado de México y Municipios, Pediatric Oncology, Toluca, Mexico*

**Background/Objectives**: Sepsis is cause of death in children with cancer and febrile neutropenia, the biomarkers available in our environment are modified with oncological treatment and steroids. The level of procalcitonin (PCT) \> 0.5 ng / dl is a biomarker that is not modifiable by neutropenia, nor with the use of

Objective: To know the utility of procalcitonin as an early predictor of septic shock in children with cancer and febrile neutropenia

**Design/Methods**: We designed a case‐control study, evaluated patients with febrile neutropenia and cancer, evaluated clinical and paraclinical variables such as PCT, C‐reactive protein, LDH, microbiology, age, gender, type of cancer, fever time, antibiotic adminsitration interval, sensitivity, specificity, positive predictive value, negative predictive value were estimated. bivariate analysis was performed to evaluate the weight of each variable in the outcome of all patients.

**Results**: We included 26 patients with 42 events of febrile neutropenia, Mean age 9 years, 80% with acute lymphoblastic leukemia, 9 of the 16 patients with septic shock had procalcitonin greater than 0.5 and the bivariate analysis showed OR of 7 (95% CI 1.6‐30) "p" = 0.008; sensitivity of 69%, specificity of 76%, 13 of 16 patients presented systemic inflammatory response syndrome (SIRS) and levels of procalcitonin \> .5ng/dl, OR of 9.24 were obtained (CI 95% 2.1‐38.9) "p" = 0.002 with a sensitivity of 69%, specificity of 81% Vpp69% Vpn 81% of procalcitonin in SIRS. 100% of patients with septic shock had severe neutropenia, the most frequent isolated germ was Escherichia coli.

**Conclusions**: Discussion Procalcitonin can be considered a useful biomarker for the timely detection of septic shock in patients with cancer with febrile neutropenia. However, organizational factors such as delay in requesting care and a start interval of the first prolonged antibiotic dose are factors that must be modified in tandem with the detection of sepsis biomarkers.

### PO-227. Suboptimal Piperacillin‐Exposure Following Bolus Administration in Children with Chemotherapy‐Induced Fever {#pbc27455-sec-11960}

[S.F. Maarbjerg]{.ul} ^1^, A.N. Kristoffersson^2^, L.E. Friberg^3^, B. Brock^4^, H. Schrøder^1^

*^1^Aarhus University Hospital, Department of Paediatrics and Adolescent Medicine, Aarhus N, Denmark; ^2^Uppsala University, Department of Pharmaceutical Biosciences, Uppsala, Sweden; ^3^Uppsala University, Department of Pharmaceutical Bioscienses, Uppsala, Sweden; ^4^Steno Diabetes Center Copenhagen, Clinical research, Copenhagen, Denmark*

**Background/Objectives**: Piperacillin‐Tazobactam (Pip/Taz) is frequently prescribed as first line empiric therapy in children with chemotherapy‐induced fever, and standard guidelines recommend bolus administration every 6‐8 hours. The best predictor of antibacterial efficacy is the time the unbound Pip‐concentration stays above a pathogen\'s minimal inhibitory concentration (t\>MIC). Data on Pip/Taz pharmacokinetics and optimal dosing in children with chemotherapy‐induced fever remain limited. Our objective was to investigate the pharmacodynamic (PD) Pip‐exposure following Pip/Taz bolus administration.

**Design/Methods**: A prospective, observational study was conducted between April 2016 -- January 2018. Children aged 6 months -- 17 years requiring empiric Pip/‐Taz due to chemotherapy‐induced fever were included. In accordance with standard guidelines, a 100mg/kg (Pip‐component) Pip/Taz bolus was administered every 8 hours. Each participant contributed 6 blood samples for Pip‐determination, and population pharmacokinetics (popPK) was performed.

The main outcome was t\>MIC. MICs of 4 and 8 mg/L represented threshold values for the pathogens, and optimal PD targets were defined as 100 % t\>MIC or 50 % t\>4 x MIC.

**Results**: 492 Pip‐concentrations were obtained in 43 children from 90 separate fever episodes.13 children (30%) had a weight \<25 kg and 30 children (70%) \>25 kg. Preliminary popPK analysis showed Pip‐exposure (t\>MIC) below the PD targets. Median t\>MIC was 57% for a MIC of 4 mg/L and 48% for a MIC of 8 mg/L. Categorised into weight groups, children \<25 kg displayed lower Pip‐exposure (median of 47% t\>MIC of 4 mg/L and 39% t\>MIC of 8 mg/L).

**Conclusions**: Our data revealed Pip‐exposure below the PD targets in children with chemotherapy‐induced fever. In order to improve the Pip/Taz dosing regimen, we are investigating the hypothesized benefits of continuous infusion in our next study.

Acknowledgements: The authors sincerely thank the Danish Childhood Cancer Foundation for founding the study and study nurses Kamilla Tofting‐Olesen and Karen Møller for their great assistance in collecting the Pip‐concentrations.

### PO-228. Breakthrough Candidemia in Pedeatric Leukemia Patients Under Antifungal Prophylaxis: Clinical, Microbiological Characteristics and Treatment Outcome {#pbc27455-sec-11970}

[Y. Madney]{.ul} ^1^, H. Hafiz^2^, R. Khedr^2^, L. shalaby^2^, M. Gaber^3^, N. adel^4^, K. ELsheshtawy^5^, A. elhadad^4^

*^1^consultant pedeatric oncology CCHE / lecturer of pediatric oncology NTIONA‐ CANCER INSTITUTE CAIRO UNIVERSITY, Pediatric oncology, cairo, Egypt; ^2^consultant pedeatric oncology CCHE /NATIONAL CANCER INSTITUTE CAIRO UNIVERSITY, Pediatric oncology, cairo, Egypt; ^3^children cancer hospital ‐egypt CCHE, Clinical microbiology, cairo, Egypt; ^4^children cancer hospital ‐egypt CCHE, Clinical pharmacology, cairo, Egypt; ^5^children cancer hospital ‐egypt CCHE, research, cairo, Egypt*

**Background/Objectives**: Breakthrough candidaemia was reported to be a major clinical issue, especially in high‐risk patients with hematological malignancies under antifungal prophylaxis. Our study aimed to identifying the clinical and microbiological characteristics and outcome of breakthrough candidemia in pediatric cancer patients under antifungal prophylaxis.

**Design/Methods**: Between June 2012 and june 2017, we retrospectively reviewed the medical records of patients with candidaemia in children cancer hospital Egypt CCHE. Breakthrough candidaemia was defined as candidaemia if it developed during the administration of anti‐fungal agents. Candida spp. were identified using the Vitek and Vitek2 systems.

**Results**: 154 episodes of candidaemia, of which 25 were identified as Breakthrpough Candidemia; C. parapsilosis (8 cases),C. guilliermondii (2 cases), C. tropicalis (6 cases),C. albicans (4 cases), C. lipolytica (1 case), C. krusei (3 case), and C. ciferrii (1 case). The anti‐fungal used as prophylaxis in breakthrough cases: micafungin (14 cases), voriconazole (8 cases), fluconazole (3 cases). All the C. parapsilosis breakthrough isolated that received micafungin for prophylaxis (8 cases) were susceptible to micafungin except one case was resistant. All breakthrough candida was sensitive except 3 isolates, one case candida albicans, candida parapsilosis and candida krusi. Breakthrough candidemia show resistant pattern to fluconazole in 5 cases (3 krusi, 1 lipolytica, 1 c parapsilosis. Resistant pattern to amphotericin B in 3 cases (1 C. albicans, 1 C. krusi, 1 c.tropicalis). Resistant pattern to micafungin in 2 cases (1 C. albicans. c parapsilosis). The overall 30‐day mortality rate was 12% (3 patients) and attributable mortality rate was (2 patients) 8%

**Conclusions**: Breakthrough Candida is a major clinical issue in high risk hematological pediatric cancer patient with high mortality rate. clinicians should pay attention to Breakthrough Candida even patient under antifungal prophylaxis. serum BD glucaln may be helpful for early detection.

### PO-229. Review of Nutritional Assessment and Intervention in Pediatric Oncology Unit {#pbc27455-sec-11980}

[S.Y. Mak]{.ul} ^1^, W.S. Kong^1^, P.L. To^1^

*^1^Queen Mary Hospital, Pediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Nutritional status in children with cancer is an important prognostic factor. Clinical growth chart assessments have commenced in pediatric oncology unit since 2015. Interventions were given according to patients' weight‐for‐height percentile. The objective of this study is to review nutritional status of children with cancer so as to improve existing nutrition interventions.

**Design/Methods**: This is a prospective study of nutritional status and management of active oncology cases diagnosed in January 2015 -- June 2017. Age, gender, body weight, body height, body mass index and nutritional interventions at initial diagnosis, three‐months and six‐months post treatment were recorded. Data were categorized and analyzed.

**Results**: Sixty‐seven patients were reviewed. Patients with leukemia (43.3%), lymphoma (13.4%) and brain tumour (13.4%) accounted for majority of the active oncology cases. Nutritional advice was given by nurses to all patients upon diagnosis. Majority of the patients' (74.6%) growth curves were below or equal to 50th percentile, and 17 patients (25.4%) were underweight initially. Almost half of the patients (40.3%) experienced a drop on growth percentile at third month of treatment. Dietician consultations were offered to 40 patients (59.7%), and 37 patients (55.2%) received milk supplement. Two patients (3%) required ryles' tube feeding. Around one third of the patients (30%) received total parental nutrition. Five patients (7.5%) with three of them having head and neck tumours received extra oromotor training from occupational and speech therapists. Most patients were able to maintain (41.8%) or improve (26.9%) their growth curve at 6 months.

**Conclusions**: Nutritional assessment needs to be done regularly to determine if there were any deterioration in nutritional status. Patients with head and neck tumours are usually at high risk for malnutrition should be prioritized and follow‐up throughout treatment. Nutritional support should be a major part of supportive care to prevent or reverse malnutrition and increase well‐being of children with cancer.

### PO-230. Management of Neutropenic Fever in a Reduced‐Intensity Treatment Regimen for Acute Lymphoblastic Leukemia (ALL) at Butaro Cancer Centre of Excellence, Rwanda {#pbc27455-sec-11990}

G. Dugan^1^, [A. Manirakiza]{.ul} ^1^, A. Fehr^1^, C. Shyirambere^1^, E. Iradukunda^2^, T. Mpunga^2^, L. Lehmann^3^

*^1^Partners In Health/Inshuti Mu Buzima, Butaro Cancer Centre of Excellence, Butaro, Rwanda; ^2^Ministry of Health, Butaro District Hospital, Butaro, Rwanda; ^3^Dana‐Farber Cancer Institute, Paediatric Hematology/Oncology, Boston, USA*

**Background/Objectives**: Outcomes in acute lymphoblastic leukaemia (ALL) in low income countries are poor, with only 20‐50% of patients are successfully treated. Many of the failures are due to recurrent disease but mortality from complications of therapy is also increased. Hunger et al. have proposed regimens of graduated intensity for ALL in resource‐limited centres so that capacity for managing toxicity, particularly neutropenic fever (NF) can be built over time without excessive treatment‐related deaths.

The Butaro Cancer Center of Excellence transitioned in 2016 from the lowest intensity regimen to a more intense regimen (Hunger 2) which incorporates a delayed intensification phase. The centre is in a Rwandan district hospital with limited antibiotics, no microbiology laboratory and no intensive care unit.

The study includes all patients treated for ALL with Hunger 2 regimen at BCCOE from October 2016 to October 2017. The objective was to capture the incidence of NF from diagnosis through the end of the delayed intensification phase and describe its management and outcome.

**Design/Methods**: A retrospective cohort study design was used, with data extraction by manual chart review.

**Results**: Seventeen patients commenced treatment for ALL during the study period. Patients had a median of one episode of NF (range 0‐3). Half of the episodes occurred in the delayed intensification phase. Median time to antibiotics was 10.5 hours. Identified sources of infection included malaria, pyoderma, pneumonia and enterocolitis.. A median of three anti‐infective agents were used per epsisode, with the most common being ceftriaxone and ceftazidime. One patient required oxygen therapy. All episodes of NF resolved with no patient deaths.

**Conclusions**: This study suggests that NF may be less of a limiting factor in ALL treatment in resource‐poor settings than has been supposed. All patients were treated successfully using empiric antibiotics therapy without microbiology or capacity to deliver critical care.

### PO-231. A Novel Ex‐Vivo Human Skin Model for the Study of Invasive Candidiasis in the Presence of a Vascular Access Device {#pbc27455-sec-12000}

[C. Mark]{.ul} ^1^, D. Corzo‐Leon^1^, C. Munro^1^, D. MacCallum^2^

*^1^The University of Aberdeen, Institute of Medical Sciences, Aberdeen, United Kingdom; ^2^University of Aberdeen, Institute of Medical Sciences, Aberdeen, United Kingdom*

**Background/Objectives**: Children and young people with a cancer diagnosis are at risk of invasive fungal disease. The risk of fungal blood stream infections is increased if a long‐term vascular access device is present. We have demonstrated the utility of a human skin explant model for the study of, in the first instance, invasive candidiasis in the presence of a vascular access device.

**Design/Methods**: Human skin was obtained, ethically and from consenting adult donors, and shipped by Tissue Solutions Ltd. Viability of the skin was maintained by incubation in glucose‐rich Dulbecco Modified Eagle Medium. Venous catheters were inserted into 1 cm^2^skin sections. Skin sections were then inoculated with 1 x 10^6^candida cells. 1 cm^2^ sections without a catheter in situ were present as comparators. In addition, select sections were present as 'non‐infected controls'. After 5 days' incubation invasion of the skin by candida species was assessed by light microscopy and scanning electron microscopy (SEM). Host‐fungus interactions were explored using a combination of RNA extraction with quantitative polymerase chain reaction (qPCR) and proteomics. Biofilm formation and the viability of catheter‐adherent fungal cells was determined using XTT assay, and sonication and plating, respectively.

**Results**: SEM and light microscopy images demonstrated clustering of candida cells around the catheter device and the presence of viable candida colonies on the surface of the catheter out‐with the skin tissue. Analysis of qPCR data/proteomics revealed an up to two‐fold decrease in expression of antimicrobial peptides, namely Human Beta‐defensin 4, Psoriasin and RNase7, when a venous catheter was present during candida infection. Between 1,300 and 11,600 candida cells, confirmed metabolically active on XTT testing, were present on catheters removed from the tissue after the 5‐day incubation period.

**Conclusions**: The skin explant model proves a useful, and highly translational, means of studying invasive candidiasis in the presence of a venous access device.

### PO-232. Introducing Complementary Therapies Into Conventional Treatment: Educating Staff on Safety and Effectiveness of Integrative Medicine {#pbc27455-sec-12010}

A. Mccabe^1^, [D. McDaniel]{.ul} ^2^

*^1^Roswell Park Comprehensive Cancer Center, Pediatric Hematology/Oncology, Williamsville, USA; ^2^Roswell Park Comprehensive Cancer Center, Pediatric Hematology/Oncology, Buffalo, USA*

**Background/Objectives**: Many patients and their families seek out a holistic approach to enhance treatment using non‐medical supportive care during therapy. In March 2017, Roswell Park comprehensive Cancer Center\'s Department of Pediatrics Hematology/Oncology introduced complimentary modalities along with the standard medical care for patients to enhance their treatment experience. Integrating evidence based complimentary therapies can benefit the patient without risking the side effects of additional drugs.

**Design/Methods**: Assessing attitudes and educating the medical team about the safety and effectiveness of Integrative Medicine was the first step to achieving a successful program. The integrative medicine program director provided staff education on safety and effectiveness of all the modalities being offered. The local Association of Pediatric Hematology Oncology Nursing chapter supported an outside lecture for all to attend. All treatments were offered and encouraged for staff participation and survey feedback.

**Results**: Fifty four percent surveyed had tried some form of complementary therapy prior to the introduction. Seventy three percent of the team surveyed opted to try acupuncture, acupressure and/or aromatherapy with one hundred percent using it multiple times. One hundred percent surveyed stated there was some benefit from treatment. Only one stated a slight discomfort from the acupuncture needles. All surveyed would refer, support and educate patients on complimentary therapies for pain, nausea, relaxation and/or anxiety.

**Conclusions**: Once the team\'s comfort level was established and patients were identified, a discussion with the patients\' primary oncologist is initiated prior to treatment to define treatment goals and ensure patient safety. Informed consent is obtained along with assent from those eight years and up. Staff understanding and support is extremely important to help educate patients and their families in using complimentary modalities to enhance their care in a safe and effective manner.

### PO-233. Prevalence and Clinical Outcome of Respiratory Viral Infections (RVI) Among Children with Cancer and Febrile Neutropenia {#pbc27455-sec-12020}

[J.P. Meena]{.ul} ^1^, M. Brijwal^2^, J. Jethani^2^, R. Seth^1^, A.K. Gupta^1^, K.R. Jat^3^, A. Choudhary^2^, A. Kapil^2^, S.K. Kabra^3^, S.N. Dwivedi^4^, L. Dar^5^

*^1^All India Institute of Medical Sciences, Deptt. of Pediatrics‐ Division of Pediatric Oncology, New Delhi, India; ^2^All India Institute of Medical Sciences, Deptt. of Microbiology, New Delhi, India; ^3^All India Institute of Medical Sciences, Deptt. of Pediatrics‐ Division of Pediatric Pulmonology, New Delhi, India; ^4^All India Institute of Medical Sciences, Deptt. of Biostatistics, New Delhi, India; ^5^All India Institute of Medical Sciences, Deptt. of Microbiology, New Delhi, India*

**Background/Objectives**: Febrile neutropenia (FN) is a common complication in pediatric oncology. Respiratory viruses (RV) are the most common cause of febrile infections in healthy children, but their role in causation of FN has not been well studied.

**Design/Methods**: Children with cancer and FN having acute respiratory infections (ARI) were considered cases and febrile neutropenic patients without ARI were considered as controls. A throat swab sample was obtained from all patients for the detection of 21‐respiratory pathogens using polymerase chain reaction.

**Results**: A total of 81 episodes of FN in cases and 37 episodes of FN in controls were enrolled. Baseline characterises were similar between cases & controls and among cases with respiratory viral infection (RVI) & without RVI. Prevalence of RVI was seen in 76.5% of cases & 48.6% of controls (p= 0.005). Sole virus was seen in 50.6% and mixed viruses (co‐infections of ≥2 viruses) in 26% of patients in cases. The mixed viruses were seen only in cases (26% vs 0) (p=0.000). Rhinovirus (36.8%) and respiratory syncytial virus (13.6%) were most frequently detected respiratory viruses. The median total duration of fever was 4(1‐25) days in patients with RVI and 3(1‐9) days in patients without RVI (p=0.005). The median duration of neutropenia and median duration of antibiotic days were more in patients with RVI compared to patients without RVI \[8(3‐24) days vs 7(3‐20)\] days (p=0.021) and \[9(4‐31) days vs 7(4‐21)\] days (p=0.046). The delay of chemotherapy was detected in 50% of patients from RVI group and 36.8% from other group. There were three mortalities from RVI group but none from other group.

**Conclusions**: High prevalence of respiratory viral infections suggests a significant role of viral infections in children presenting with febrile neutropenia and it is associated with increased morbidity, mortality, and delay in chemotherapy. Further studies with viral load determination are warranted.

### PO-234. Malnutrition and Associated Factors in Paediatric Cancer Patient at Baseline {#pbc27455-sec-12030}

A. Tiwari^1^, M. Kashyap^1^, [A. Mishra]{.ul} ^1^, S. Bakhshi^1^

*^1^All India Institute of Medical Sciences, Medical Oncology, New Delhi, India*

**Background/Objectives**: Malnutrition in children with cancer is multifactorial and both disease and toxicity related to its treatment contributes to this. These children also have a higher risk of infections, treatment‐related toxicity. To determine the prevalence of malnutrition in children presenting with malignancy and to assess factors related to it.

**Design/Methods**: In this descriptive study we included all pediatric patients (≤ 18 years) with cancer registered at our center from July 2016--July 2017. The information regarding demographics, anthropometry, and type of malignancy were collected for all patients. Undernourishment was defined as MUAC for age \< ‐2 SD (under 5 years). Patients with 6‐10 years and 11‐18 years of age were defined as undernourished if their weight for age and BMI for age were \<‐2SD respectively. Patients \> +2SD were classified as over‐nourished and others were classified as adequately nourished.

**Results**: We included 513 children with cancer of which 306 (59.5%) had hematologic and 207 (40.5%) had other solid pediatric tumors. The children with age \< 5 years formed the majority of the cohort \[195 (38%)\]. There were 377 (73%) males and 136 (26.5%) female. In the whole cohort undernourished children constituted 38.5% (n=198), 1.75 (n=9) were over‐nourished and 59.6% (n=306) were adequately nourished. The patients with undernourishment constituted 38.6% (n=118) and 38.6% (n=80) of patients with hematologic and other pediatric solid malignancy respectively. With regards to socio‐economic status, a majority of children belonged to a rural community (63.84%). There was no difference in undernourishment when compared with gender or place of residence.

**Conclusions**: Malnutrition is common in pediatric patients with malignancy at presentation. The place of residence (urban/rural) or gender is not related to malnutrition in these patients at presentation.

### PO-235. Lethality, Source and Microbiological Profile of Bloodstream Infection in Pediatric Patients: A Cohort Study Comparing Solid and Hematological Neoplasm {#pbc27455-sec-12040}

[M. Monteiro Garrido]{.ul} ^1^, V. Gonçalves^1^, E. Velasco^1^, S. Ferman^2^, S. Superti^3^, I. Souto Martins^1^

*^1^Instituto Nacional de Câncer, Infection Control Section, rio de janeiro, Brazil; ^2^Instituto Nacional de Câncer, Paediatric Oncology Department, rio de janeiro, Brazil; ^3^Instituto Nacional de Câncer, Microbiology Laboratory Department, rio de janeiro, Brazil*

**Background/Objectives**: Bloodstream infections (BSIs) increase the risk of death during cancer treatment. Clinical outcome of patients with cancer complicated by BSI seems to be influenced by the type of neoplasm. However, data about children with cancer are scarce. The aim of this study is to compare epidemiological and microbiological characteristics of BSI episodes between children with haematological malignancies and solid organ neoplasm.

**Design/Methods**: A cohort was performed from October 2012 to November 2015, with inclusion of all patients aged 18 years or younger with cancer and laboratory‐confirmed BSI assisted in a referral hospital for cancer care in Rio de Janeiro, Brazil. Cases were detected by laboratory‐based surveillance. Data were collected throughout 30 days before and 30 days after the date of BSI diagnosis.

**Results**: 210 episodes of BSI were detected among children with solid tumor (n:153) and haematological neoplasm (n:57). The overall 30‐day and 7‐day mortality were 13.8% and 3.8%, respectively, without statistical difference between groups. Indication of intensive care unit admission was more common in children with solid tumors (23.5% vs. 10.5%, P:0.05). BSIs associated with long‐term central lines (66.7%) were the most common source of infection. BSI associated with semi‐implantable central‐line was more frequent in children with haematological disease (22.2% vs 59.6%, P\<0.01), whereas, BSI associated with totally‐implantable (30.7% vs 3.5%, P\<0.01) or peripherally‐inserted central‐line (15.0% vs zero, P\<0.01) was more common in patients with solid tumors. The frequency of polymicrobial infections (5.9% vs 15.8%, P:0.05) and BSI caused by Gram‐negative bacilli (35.9% vs 52.6%, P:0.04) were significantly greater among children with haematological neoplasm.

**Conclusions**: These data about BSI in children with cancer from Brazil, can guide preventive and treatment approach of this population, according to the type of cancer. Studies with larger sample size and other healthcare centers are desirable to better understanding these findings.

### PO-236. Carmustine Induced Non‐Infective Pulmonary Complication in a Child Post‐Autologous Stem Cell Transplant {#pbc27455-sec-12050}

[K. Mullanfiroze]{.ul} ^1^, S. Sivadasan^2^, P. Ahirwar^2^, N. Jha^2^, T. Singhal^3^, S. Sen^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Blood And Marrow Transplant, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Pediatrics, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Pediatric Infectious Diseases, Mumbai, India*

**Background/Objectives**: Pulmonary complications in the post‐autologous stem cell transplant(ASCT) setting are common. Non‐infective pulmonary complication(NIPC) after ASCT in children is under‐reported. We hereby report a case of probable carmustine induced NIPC in a child.

**Design/Methods**: A 10 year‐old boy,case of refractory Stage IV(B) Hodgkins Lymphoma, who had already received 6 cycles of (ABVD) adriamycin, bleomycine, vincristine, dacarbazine chemotherapy underwent salvage chemotherapy followed by ASCT, at our institute. He had attained complete remission as evidenced by normal PET scan prior to BEAM conditioning \[B(Carmustine) 300 mg/m^2^ IV on day ‐6, E (Etoposide) 150 mg/m^2^ IV from day ‐5 to day ‐2, A (Cytarabine) 200 mg/m^2^ IV 12 hourly from day‐5 to day ‐2, M (Melphalan) 140 mg/m^2^ IV on day ‐1\].At Day +35 post ASCT he complained of dry cough with fatigue. His chest examination was non‐contributory. He was given symptomatic treatment and kept under follow‐up. On day +41, he presented with dyspnea and hypoxemia (oxygen saturation in room air‐90%). He was started on supplemental oxygen. CT chest demonstarted centrilobular,ground glass opacities in bilateral lung fields suggestive of interstitial pneumonia probably non‐infectious in etiology. The radiologist,pulmonologist,BMT physician and infectious disease specialist concluded that in view of hypoxemia with history of carmustine administration in recent past,carmustine induced lung injury was probably the cause of his pulmonary complication. He was promptly started on steroids and within 48 hours his hypoxemia resolved.

**Results**: NIPC due to carmustine is reported in adults but under‐reported in children. NIPC must be considered in concurrence with radiological and clinical findings.

**Conclusions**: NIPC must be considered when cough,dyspnea and hypoxemia occur in children post‐ASCT especially if they have received carmustine with or without cyclophospamide, bleomycin,total body irradiation or mediastinal radiation. Carmustine induced lung injury can be reversed by early administration of steroids resulting in a good outcome.

### PO-237. Successful Use of Granulocyte Infusions with Triple Antifungal Therapy in Disseminated Cutaneous Mucormycosis {#pbc27455-sec-12060}

[K. Mullanfiroze]{.ul} ^1^, T. Singhal^2^, S. Tulpule^3^, S. Gupta^3^, S. Sen^1^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatrics, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India*

**Background/Objectives**: Invasive fungal infections (IFI) needs a prompt identification of the fungus and aggressive anti‐fungal treatment along with reversal of neutropenia and immunosuppression. We describe a case of Mucormycosis where granulocyte infusions & aggresive antifungal therapy led to a successful outcome.

**Design/Methods**: 13 year old child with Acute Lymphoblastic Leukaemia presented in week 4 of induction with multiple tender blackish discoloured skin lesions with central ulceration over the body. Parents reported the presence of a damp wall in their residence. He was initially afebrile with CBC ‐ Hb 7.5 g%, TLC 310/mm3 (0% neutrophils), platelet count 62000/mm3. He was empirically started on parenteral antibiotics along with anti‐fungal therapy with liposomal amphotericin‐B and Voriconazole. Skin biopsy revealed a budding yeast with hyphae which was identified as Mucor. With clinical deterioration, Caspofungin was added. Dexamethasone was tapered and stopped and started on growth factors. Granulocyte infusions were given daily until absolute neutrophil count (ANC) was more than 1000/mm3 for 2 days. On day 7 of hospitalisation, he started having restlessness, anxiety, disorientation, hallucinations and urinary and bowel incontinence. MRI brain was normal, but worsening of CNS symptoms, voriconazole induced adverse reaction was suspected and it was withdrawn and Posaconazole was started. He gradually started improving and regained bowel and bladder continence.

Later, his hallucinations and restlessness reappeared and hence posaconazole was stopped and amphotericin‐B and caspofungin were continued. He developed amphoericin‐B induced hypersensitivity and was then re‐challenged with posaconazole and this time, he tolerated it well.

**Results**: Currently, the patient is well and skin lesions have healed completely.

**Conclusions**: Combination anti‐fungals, reducing immunosuppression and rapidly increasing the neutrophil count is useful in treating severe IFI. Use of granulocyte infusions in combination with effective antifungal therapy can be useful while awaiting count recovery.

### PO-238. Worldwide Incidence of Invasive Fungal Infections in Paediatric Oncology Patients; A Systematic Review {#pbc27455-sec-12070}

[L. Naeije‐Overtoom]{.ul} ^1^, C. Pawliuk^2^, S.R. Rassekh^1^

*^1^BC Children\'s hospital, paediatric oncology/hematology/ BMT, Vancouver, Canada; ^2^BC Children\'s hospital, Paediatrics, Vancouver, Canada*

**Background/Objectives**: Invasive fungal infections (IFI) are an important cause of mortality and morbidity in children treated for malignancies. High incidence of IFI is reported in patients treated for AML, relapsed ALL and children who underwent hematopoietic stem cell transplantation. The prolonged neutropenia after intense chemotherapy leave them vulnerable to infections. There is evidence that the incidence rate worldwide is rising. In addition, there appears a large variability in incidence of IFI reported in the literature, which could be due to a several factors including era of treatment, definitions of IFI, treatments delivered, and use of prophylaxis. The primary aim of this study is to investigate the effect of geography on rates of IFI.

**Design/Methods**: We will perform a systematic review to identify all published literature about incidence of fungal infections (proven and probable) in paediatric oncology patients and patients who underwent a bone marrow transplant.

**Results**: We searched Ovid MEDLINE, Embase, CENTRAL, LILACS and conducted a grey literature search by combining controlled vocabulary terms and keywords for "fungal infections" and "cancer" or "bone marrow transplant" and "paediatric population." We did not limit by publication date or by language. We identified 3,502 studies. Title and abstracts of studies were screened independently by two authors and 2,541 studies were excluded. The full‐text of the remaining 961 studies are in process of being reviewed by two authors for final inclusion. Final analysis of the systematic review will be presented at the SIOP meeting and will include a heat map of the world with the incidence rates as found in all the included literature.

**Conclusions**: There has been much literature about IFI in paediatric oncology. This is the first review with a worldwide look at the incidence rates and this can be important when reviewing all studies of IFI in paediatric oncology.

### PO-239. Compliance with Referrals at the Paediatric Oncology Unit in a Teaching Hospital, Ghana {#pbc27455-sec-12080}

[P. Obeng]{.ul} ^1^, V. Paintsil^1^, L. Osei‐Tutu^1^, G. Acquah^1^, C. Asiamah^1^, S.C. Yeboah‐Manu^1^, B. Manlokiya^1^, L. Adu‐Gyamfi^1^, R. Appiah^1^

*^1^Komfo Anokye Teaching Hospital, Child Health‐ Paediatric Oncology Unit, Kumasi, Ghana*

**Background/Objectives**: Caretakers may be faced with a number of barriers before complying with a referral advice. Such barriers can be financial, geographical and cultural. The most complex aspect of referral care is often the caretaker\'s acceptance of and compliance with a referral recommendation. This is determined by factors such as perceived need of referral (disease severity), caretaker or community experience with and impressions of the referral facility (quality) and cost (time and resources).

The objective of this study was to determine caretaker barriers to compliance with referral in order to improve diagnosis, treatment outcomes and guidelines for the Integrated Management of Childhood Illness (IMCI).

**Design/Methods**: The study was cross sectional conducted at the Paediatric Oncology Unit (POU) at the Komfo Anokye Teaching Hospital (KATH), Ghana from October to December 2017. The POU receives about 28 referrals per month. Seven caretakers were recruited weekly for a period of 12 weeks. A sample size of 84 was used for the study. Data on time of arrival at the referral facility and the barriers to compliance with referral were obtained after informed consent. Ethical approval was sought before the commencement of the study.

**Results**: The barriers to compliance with referral from caretakers perspective are lack of financial resources 38 (45.2%), time wasting at the referral facility 30 (35.7%), seeking alternative treatment 23 (27.4%), experience and impression of the referral facility 18 (21.4%) and lack of knowledge on disease severity 16 (19.0%).

**Conclusions**: Lack of financial resources, time wasting, seeking alternative treatment, experience and impression and lack of knowledge on disease severity are the barriers to compliance with referral. A further study on these barriers to compliance with referral will inform outcome improvement interventions.

### PO-240. Influence of Health‐Insurance Status on Childhood Cancer Treatment Outcomes in Kenya {#pbc27455-sec-12090}

[G. Olbara]{.ul} ^1^, H. Martijn^2^, F. Njuguna^1^, S. Langat^1^, S. Martin^3^, J. Skiles^3^, T. Vik^3^, G. Kaspers^2,4^, S. Mostert^2^

*^1^Moi Teaching and Referral Hospital, Child Health and Pediatrics, Eldoret, Kenya; ^2^VU University Medical Center, Pediatric Oncology‐Hematology, Amsterdam, The Netherlands; ^3^Indiana University‐ School of Medicine, Pediatrics‐Division of Haemato ‐Oncology, Indianapolis, USA; ^4^Princes Maxima Center for Pediatric Oncology, Pediatric Oncology ‐Hematology, Utrecht, The Netherlands*

**Background/Objectives**: Survival of childhood cancer in high‐income countries is approximately 80%, whereas in low‐income countries it is less than 10%. Limited access to health‐insurance in low‐income settings may contribute to the poor survival rates. This study evaluates the influence of health‐insurance status on childhood cancer treatment in a Kenyan academic hospital.

**Design/Methods**: This was a retrospective medical records study. All children diagnosed with a malignancy from 2010 until 2012 were included. Data on treatment outcomes and health‐insurance status at diagnosis were abstracted from patient charts.

**Results**: Of 280 patients, 34% abandoned treatment, 19% died, 18% had progressive or relapsed disease resulting in 29% event‐free survival. The majority of patients (65%) did not have health‐insurance at diagnosis. The main cause of treatment failure among patients without health‐insurance at diagnosis was abandonment of treatment (37%), which occurred less often (28%) among patients with health‐insurance at diagnosis. The event‐free survival estimate was significantly higher for patients with health‐insurance at diagnosis compared to those without (P=0.004). Of patients without health‐insurance at diagnosis, 77% enrolled during treatment. Among those patients who later enrolled in health‐insurance, the frequency of progressive or relapsed disease and deaths were significantly lower (P=0.013, P\<0.001 respectively), while the event‐free survival estimate was significantly higher (P\<0.001) compared to those who never enrolled in health‐insurance.

**Conclusions**: Childhood cancer event‐free survival was 29% at a Kenyan academic hospital. The main reason of treatment failure was abandonment of cancer treatment. Children without health‐insurance had a significant lower chance of event‐free survival. Childhood cancer treatment outcomes could be ameliorated by strategies that prevent abandonment of treatment and improve access to health‐insurance.

### PO-241. Evaluation of Ototoxicity in Children with Head and Neck Cancer who Received Cisplatin and/or Carboplatin During Treatment {#pbc27455-sec-12100}

[Y. Olgun]{.ul} ^1^, D. Ince^2^, D. Kizmazoglu^2^, M. Erdem^2^, G. Kirkim^1^, A. Demiral^3^, K. Mutafoglu^4^, R. Cetingoz^3^, E.A. Guneri^1^, N. Olgun^2^

*^1^Dokuz Eylul University Faculty of Medicine, Otorhynolaryngology, Izmir, Turkey; ^2^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Radiation Oncology, Izmir, Turkey; ^4^Dokuz Eylul University Institute of Oncology, Pediatric Oncology‐ current address: İzmir University of Economics, Izmir, Turkey*

**Background/Objectives**: To evaluate hearing impairment in children with head and neck cancer who received platinum compounds.

**Design/Methods**: Medical records of 1095 children with the diagnosis of cancer who treated between 1988‐2017 were evaluated retrospectively for having head/neck cancer and receiving platinum‐based chemotheraphy. Characteristics of patients and details of platinum‐based chemotherapy,head/neck radiotherapy,audiologic records were analyzed. The audiological tests included pure tone audiometry,transient oto‐acoustic emissions,auditory brainstem response. Ototoxicity were graded according to Brock\'s hearing loss criteria.

**Results**: There were 47 patients with head/neck cancer,received platinum. Baseline audiological assessments were available in 41% patients. Diagnosis:CNS tumors(n:22), retinoblastoma(n:8), nasopharynx carcinoma(n:7), Hodgkin lymphoma(n:4), intracranial germ cell tumor(n:2), neuroblastoma(n:1), rhabdomyosarcoma(n:1), fibrohistiocytic sarcoma(n:1), larynx carcinoma(n:1). The median‐age was 8years(3mos‐16.8yrs), M:F ratio was 1.14. There were 18 patients(38%) in group‐1(cisplatin‐only), 7 patients(15%) in group‐2(cisplatin+carboplatin), and 22 patients(47%) in group‐3 (carboplatin‐only). In group 1 39% (n:7), and in group 2 28%(n:2) of patients received cisplatin by divided doses schema; in groups 2 and 3 carboplatin had been administered by single dose schema. In follow‐up,high frequency hearing loss was detected in 32%(n:15) of patients. According to the Brock\'s grading system 5 patients(33%) had grade(1),4 patients (27%) had grade(2), 4 patients (27%) had grade(3), two patients(13%) had grade(4) ototoxicity. Brock\'s grade(1‐4) ototoxicity incidence was 54%(n:8) in group‐1, 33%(n:5) in group‐2, and 13%(n:2) in group‐3.Mean diagnosis age was found significantly different between patients with(n:15) or without (n:32) ototoxicity(p:0.00). Ototoxicity was not different between boys and girls. Ototoxicity was found significantly higher in patients who received cumulative dose of cisplatin≥400mg/m2(p:0.040) and also found significantly higher in patients who received platinum and head/neck radiotherapy (p:0.041). Between group‐1 and ‐2; and between patients who received cisplatin by single‐dose and divided‐doses schema, incidence of ototoxicity wasn\'t different. Cumulative carboplatin doses wasn\'t different between patients with or without ototoxicity. In group‐3 ototoxicity occured in two patients. Ototoxicity occurred in 15/38 patients(39%) who received head/neck radiotherapy.

**Conclusions**: Higher cumulative doses of cisplatin and performing head/neck radiotherapy increase the risk of ototoxicity. Audiologic follow‐up is necessary for early management and improving quality of life.

### PO-242. Review of Antiemetic use for Chemotherapy‐Induced Nausea and Vomiting in Pediatric Oncology Patients at Hospital Infantil de Mèxico Federico Gòmez {#pbc27455-sec-12110}

[M.A. Palomo Colli]{.ul} ^1^, A.V. Guevara Mèndez^1^, L.E. Juàrez Villegas^1^, J.F. Gaytan Morales^1^, C.E. Cicero Oneto^1^, M. Murillo Maldonado^1^

*^1^Hospital Infantil de Mèxico Federico Gomez, Oncology, Mexico City, Mexico*

**Background/Objectives**: Chemotherapy‐induced nausea and vomiting are the most dreaded and distressing side effects for cancer patients undergoing chemotherapy treatment. These side effects have a significant impact on the patients\' quality of life and can interfere with their ability to receive intensive chemotherapy regimens.

**Design/Methods**: This was a retrospective cohort study of pediatric oncology patients who were less than 18 years of age receiving chemotherapy. The data abstracted included the following: age, gender, type of cancer, emetogenic risk and level, prescribed prophylactic antiemetic regimen, incidence of breakthrough emesis. Emetogenic risk was classified based on published guidelines into low, moderate, or high emetogenic chemotherapy. Clinical effectiveness was assessed based on breakthrough emesis.

**Results**: A total of 102 patients were included in the study. High emetogenic chemotherapy was administered in 21/102 (20.5%) and moderate emetogenic chemotherapy was administered in 81/102 (79.5%) patients. Only 9/102 (7.8%) received appropriate antiemetic prophylaxis; 44/102 (43.1%) patients experienced breakthrough emesis. Breakthrough emesis occurred in 18/21 (85.7%) patients receiving high emetogenic chemotherapy versus 26/81 (32%) patients receiving moderate emetogenic chemotherapy. The use of an inadequate antiemetic regimen was found in 44/44 (100%) patients with breakthrough emesis. Thus, inadequate prophylaxis resulted in a 46%(44/94) risk of breakthrough emesis. This risk was higher in patients receiving high emetogenic chemotherapy versus those receiving moderate emetogenic chemotherapy (85.7% versus 32 %). Nausea and vomiting affected the intake of food and recreational activities 56% and 36% in the children evaluated in the seven days after chemotherapy.

**Conclusions**: Standardizing antiemetic prophylaxis based on emetogenic level could reduce breakthrough emesis and improve the quality of life in pediatric oncology patients. Inadequate antiemetic prophylaxis is associated with a high risk of breakthrough emesis.

### PO-243. Neutropenic Sepsis Mortality as a Measure of Childhood Cancer Care Delivery: A Step Towards Positively Impacting the Outcome in Developing Countries {#pbc27455-sec-12120}

[S. Patel]{.ul} ^1^, R. Raj^1^, R. Uppuluri^1^, V. Swaminathan^1^, M. Sivasankaran^1^, D. Jayaraman^1^, I. Jayakumar^2^

*^1^Apollo Cancer Institute, Department of Pediatric hematology‐oncology and blood and marrow transplantation, Chennai, India; ^2^Apollo Cancer Institute, Department of Pediatric intensive and critical care, Chennai, India*

**Background/Objectives**: The trend in mortality due to neutropenic sepsis is an important quality indicator in developing countries where there is an alarming increase in the incidence of multidrug resistant bacterial infections.

**Design/Methods**: We performed a retrospective analysis of all children admitted in the pediatric intensive care unit (PICU) with neutropenic sepsis from January 2014 to December 2017. Neutropenia was defined as an absolute neutrophil count of less than 1000. Sepsis was defined as per surviving sepsis campaign guidelines. Data was analyzed annually and subset analysis was done between two groups: Group 1 -- neutropenia post chemotherapy for malignancies and Group 2‐ neutropenia post hematopoietic stem cell transplantation.

**Results**: A total of 276 patients were admitted to the PICU between 2014 and 2017 of which ninety nine (35.8%) were admitted with neutropenic sepsis. Group 1 included 41% children and group 2 included 58% children. The overall survival was 61%. In 2014 and 2015 the mortality rates were 31% and 38% respectively. As the mortality rate increased to 51% in 2016, aggressive antibiotic stewardship and interventions to decrease rates of multidrug resistant organism sepsis were instituted. The mortality rate decreased to 30% in 2017. On subset analysis, we found the mortality rates to be significantly different between the post chemotherapy and post HSCT cohorts: 55% and 14.6% respectively. In 56% children, cultures were positive with carbapenam resistant Klebsiella pneumoniae in 41% being the most common isolate. Mortality was higher in those with culture positive sepsis (53%) as compared to culture negative (16%).

**Conclusions**: Our data provides evidence for the need for instituting pre‐emptive measures to rationalize the use of antibiotics and team effort with pediatric intensive care units. Survival rates of 85% among post chemotherapy and 44% in the post HSCT group can be achieved if trends quality indicators are watched diligently.

### PO-244. Cancer‐Related Fatigue: What Potential has Physical Activity? {#pbc27455-sec-12130}

[A.M. Platschek]{.ul} ^1^, C. Kukutschka^1^, T. Simon^2^, B. Hero^2^, T. Foitschik^1^, H.K. Strüder^1^

*^1^German Sport University Cologne, Institute of Movement and Neurosciences, Cologne, Germany; ^2^University of Cologne, Children\'s Hospital, Cologne, Germany*

**Background/Objectives**: Cancer‐related fatigue (CrF) is a common symptom of pediatric cancer limiting the patients\' activity and affecting quality of life. CrF is multidimensional, effecting a vicious cycle of decreasing capacity, inactivity, lack of recovery, and helplessness. There is still uncertainness about the potential of physical activity prior and during disease in the context of CrF.

**Design/Methods**: In fifteen pediatric patients with different types of cancer (6 female; mean age = 12.13 ± 2.85 years) PedsQL Multidimensional Fatigue Scale questionnaire was completed during cancer therapy. The standard treatment for the pediatric patients was adjuvant chemotherapy according to national protocols. Daily activity level before disease was retrospectively interrogated with 24 hours division self‐report (active time, sleeping, sitting, lying awake in bed) at the beginning of treatment. Physical activity during treatment was queried with questionnaire about type and duration of activity and was summarized in hours of activity per month. Pearson correlations were used to analyze the data (α = 0.05).

**Results**: Mean time between start of cancer therapy and CrF questionnaire was 111.13 ± 35.82 days. Mean activity level before disease was 6.00 ± 1.93 hours per day. Patients with higher activity level before disease showed a significant higher CrF score during cancer therapy (r = 0.724, P = 0.002), higher scores indicate lower CrF. Mean time of physical activity during treatment was 5.36 ± 5.70 hours per month. Patients with higher activity level during disease also showed a significant higher CrF score (r = 0.587; P = 0.021).

**Conclusions**: Physical activity has the potential to reduce CrF during cancer treatment in pediatric cancer patients and improve quality of life. Exercise represents an effective therapeutic intervention for preparing children to successfully complete treatments, and for reducing acute side effects like CrF. These findings emphasize the importance of physical activity in lessening side effects in cancer therapy.

### PO-245. Changes in Activity Behavior at the Beginning of Cancer Therapy {#pbc27455-sec-12140}

[A.M. Platschek]{.ul} ^1^, T. Simon^2^, B. Hero^2^, T. Foitschik^1^, H.K. Strüder^1^

*^1^German Sport University Cologne, Institute of Movement and Neurosciences, Cologne, Germany; ^2^University of Cologne, Children\'s Hospital, Cologne, Germany*

**Background/Objectives**: Physical activity with its positive influences on physical, mental and psychosocial level can prevent the vicious cycle of lack of exercise and decreasing capacity, and can counteract cancer‐related side effects. However, at the beginning of cancer therapy changes in everday life have to be accepted. In view of the positive impacts of exercise it is important how much the activity behavior is affected.

**Design/Methods**: In fifteen pediatric patients with different types of cancer (6 female; mean age = 12.13 ± 2.85 years) activity behavior before and during disease was queried. Daily activity level before disease was retrospectively interrogated with 24 hours division self‐report (active time, sleeping, sitting, lying awake in bed) at the beginning of treatment. Daily activity level during disease was interrogated with 24 hours division self‐report, too. Exercise before and during treatment was queried with questionnaire about type and duration of exercise and was summarized in hours/month. Pearson correlations were used to analyze the data (α = 0.05).

**Results**: Mean activity level decreased from 6.00 ± 1.93 hours/day before disease to 2.20 ± 1.87 hours/day during disease (P \< 0.001). Mean exercise decreased from 31.72 ± 23.71 hours/month before disease to 5,36 ± 5.70 hours/month during disease (P \< 0.001). Both, patients with higher activity level before disease and patients with higher exercise before disease showed a significant higher activity level during disease (r = 0.615, P = 0.015; r = 0.554, P = 0.032).

**Conclusions**: Activity behavior seems to be significantly reduced at the beginning of cancer therapy. Patients who were active before disease also appear to be more active during cancer therapy. Exercise therapies should be implemented during acute care to increase activity level and prevent cancer related side effects.

### PO-246. Effectiveness of Ready‐to‐Use Therapeutic Food (RUTF) in the Management of Malignancy Related Undernutrition in Children: Results of a Prospective Open‐Labeled Randomized Control Trial {#pbc27455-sec-12150}

[M. Prasad]{.ul} ^1^, S. Tandon^1^, G. Narula^1^, G. Chinnaswamy^1^, T. Vora^1^, S. Nikam^1^, R. Gala^1^, A. Paradkar^1^, D. Jagiasibava^2^, A. Jadhav^3^, S. Kannan^4^, S. Banavali^1^, B. Arora^1^

*^1^Tata Memorial hospital, Paediatric Oncology, Mumbai, India; ^2^Bone enterprises, Clinical densitometry, Mumbai, India; ^3^Lokmanya Tilak Municipal Medical College and General Hospital, Paediatrics, Mumbai, India; ^4^Tata Memorial hospital, Biostatistics, Mumbai, India*

**Background/Objectives**: Over half of children with malignancy in Low‐middle‐income countries(LMICs) are malnourished, leading to poor treatment tolerance, higher toxicity and lower survival. Early nutritional intervention may obviate this effect. RUTF is an established medical nutrition therapy, however efficacy data in children with malignancy is lacking.

**Design/Methods**: Severely and moderately malnourished(SAM/MAM) children with cancer aged 5‐15 years underwent stratified randomization to receive either RUTF or standard nutritional therapy(SNT) for 6 weeks. Dietary intake, nutritional status(weight, height, body mass index for age), body composition using dual energy X‐ray absorptiometry(DEXA) scan, health related quality of life(HRQOL) (Health Utilities Index‐HUI2 and 3), and treatment tolerance were compared at baseline and 6‐weeks. Clinical monitoring was done weekly for 6 weeks, then monthly for 6 months.

**Results**: 260 children (130‐each arm) were enrolled between July‐2015 and March‐2018, of whom 237(120‐RUTF, 117‐SNT) are evaluable. Median age 9‐years and M:F 2.3:1. Children on RUTF‐arm compared to SNT‐arm, had greater weight‐increment at 6 weeks (mean‐5.7% of baseline weight vs 3.5%; p‐0.019) and were more likely to achieve normal nutritional status (RUTF‐arm:39.6% and 55%, SNT‐arm:22.5% and 38% at 6 weeks(p‐0.02) and 3 months(p‐0.05%) respectively). RUTF enabled increase in protein and energy consumption by 54%(p‐0.038) and 18%(p‐0.1)and increased HRQOL scores (p‐0.05) at 6 weeks. Children on RUTF‐arm had less treatment delays both during intervention period(10.4% vs 22.7%, p\<0.01) and on follow‐up(10% vs 24%, p\<0.01), as well as fewer episodes of febrile neutropenia(1.34 vs 1.82, p‐0.02), with shorter admission periods per episode(4.7days vs 6.7days, p‐0.2).

**Conclusions**: RUTF is an effective and well tolerated nutritional intervention in SAM/MAM children with malignancy, and improves nutritional status, quality of life, and reduces toxicities of chemotherapy compared to SNT. These benefits are maintained over time. RUTF has immense potential to improve treatment outcomes, and supplementation should be strongly considered during the intensive phase of treatment.

### PO-247. Loss of Protective Anti HBS Antibodies & Seroconversion to Hepatitis B Vaccination in Children During Chemotherapy for Acute Lymphoblastic Leukemia {#pbc27455-sec-12160}

[V.R. Prasanth]{.ul} ^1^, T. Priyakumari^1^, R. Binitha^1^, C.S. Guruprasad^1^, N. Manjusha^1^, K.G. Gopakumar^1^

*^1^Regional Cancer Centre, Paediatric Oncology, Trivandrum, India*

**Background/Objectives**: This study aimed to evaluate the loss of protective anti Hbs titres and seroconversion to Hepatitis b (HB) immunization during intensive phase of chemotherapy among Paediatric Acute Lymphoblastic Leukaemia (ALL) patients with negative HB serology at diagnosis

**Design/Methods**: Paediatric ALL patients below 14 years treated during Feb 2016‐ Jan 2017 were categorized based on the anti HBs titre at presentation, into Group 1 having protective anti HBs titre (\> 10 miu/ml) who were given a double dose of hepatitis B vaccine and group II having non‐protective titre (\<10 miu/ml) who were given Hepatits B immunoglobulin (HBIG), prior to start of chemotherapy, followed by three double doses of HB vaccine at 0,1, and 6 months, first dose 2 months after HBIG.

**Results**: Of the 125 children,78 % were fully immunized and 88 belonged to group I and 37 to group II. Among group I patients 98%, 93% and 86% retained their protective titres at end of induction, beginning of reinduction and start of maintenance chemotherapy respectively. In group II, only 62 % and 64% of children attained protective titres on evaluation prior to "0" dose of HB vaccine and 2 weeks after third dose of vaccine. Subgroup analysis of group I showed that children with initial anti Hbs titres \> 100 IU/L retained their protective titres better compared to those with titres between 11‐100 IU/L(p=0.0001). No one became HB positive or developed hepatitis.

**Conclusions**: Recombinant HB vaccine at double dose offers protective titres in fully immunized children with initial titre \> 100 IU/L /l during the intensive phase of chemotherapy. The ideal vaccination schedule for those with antiHBs\<10IU/L remains to be established in the LMIC setting due to financial constraints, although in our study more than 50% patients attained protective titres with this vaccination strategy.

### PO-248. Efficacy of Single Dose Rasburicase (1.5 MG) for Prophylaxis and Management of Tumor Lysis Syndrome {#pbc27455-sec-12170}

[V. RADHAKRISHNAN]{.ul} ^1^, A. philips^1^, J. Ramamoorthy^1^, P. Ganesan^1^, T. Sagar^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Rasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of 0.2mg/kg/day for 5 days is expensive and it is not known whether this extended schedule is clinically beneficial compared to a single fixed dose of 1.5 mg. The aim of the present study was to evaluate the efficacy of single dose rasburicase 1.5 mg in prevention and management of TLS.

**Design/Methods**: Rasburicase is available as single use 1.5 mg vial. At our institution a single dose of rasburicase 1.5 mg irrespective of bodyweight has been used in adults and in children a dose of 0.15 mg/kg (maximum 1.5 mg) has been used since 2012 for prevention and management of TLS and subsequent doses are given based on biochemical response and clinical condition. We retrospectively analysed the case records of patients who had received rasburicase from January 2012 to January 2017.

**Results**: The study included 186 patients with hematological malignancies who received rasburicase. Children accounted for 56.4% (n=105) patients and males comprised 73% (n=135). Rasburicase was used prophylactically in 59 (31.7%) patients, for laboratory TLS in 76 patients (40.8%) and for clinical TLS in 51 (27.4%) patients. Single fixed dose rasburicase prevented laboratory/clinical TLS in 87% of the prophylactic group and prevented clinical TLS in 72% of the laboratory TLS group. None of the patients in prophylactic and laboratory TLS group developed clinical TLS. However, majority of the patients with clinical TLS required more than one dose rasburicase.

**Conclusions**: Single dose of 1.5 mg (1 vial) rasburicase is efficient in preventing and managing laboratory TLS and is economically viable in resource constrained settings.

### PO-249. Prevalence of Multi‐Drug Resistant Organisms in Stool of Pediatric Patients with Acute Leukemia and Correlation with Blood Culture Positivity: A Single Institution Experience {#pbc27455-sec-12180}

[V. RADHAKRISHNAN]{.ul} ^1^, K. Shankar^1^, J. Ramamoorthy^1^, P. Ganesan^1^, T. Sagar^1^

*^1^Cancer Institute W.I.A, Medical Oncology and Pediatric Oncology, Chennai, India*

**Background/Objectives**: Multi‐drug resistant (MDR) bacteria are associated with increased morbidity and mortality in children with acute leukemia. The present study was conducted to assess the prevalence of MDR bacteria in stool cultures of patients with acute leukemia at presentation to the hospital. The results were then correlated with blood cultures when patients developed septicemia.

**Design/Methods**: The study involved analysis of case records of patients with newly diagnosed acute leukemia less than 18 years of age treated at our centre from January to December 2015. Stool cultures were sent within 72 hours of hospital admission and blood cultures were sent when clinically indicated. MDR was defined as resistance to at least 1 antibiotic in 3 or more following antimicrobial groups: cephalosporins, β‐lactam/β‐lactamase inhibitor, carbapenems, fluoroquinolones and aminoglycosides.

**Results**: The analysis included 85 patients with acute leukemia, among whom 48/85 (56%) patients had positive stool cultures and 42/85 (50%) patients were positive for MDR bacteria. Blood cultures were positive in 13/48 (27%, 7 MDR and 6 non‐MDR) patients with positive stool cultures and 3/37 (8%, 1 MDR and 2 non‐MDR) patients with negative stool cultures (P=0.01). The concordance between stool and blood culture for similar organism was 61%. There were 7 deaths in 48 stool culture positive patients and 2 deaths in 37 stool culture negative patients.

**Conclusions**: This study shows the high prevalence of MDR bacteria in newly diagnosed children with acute leukemia. Colonisation with MDR bacteria in stools is associated with increased positivity of blood cultures and mortality.

### PO-250. Risk Factors and Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer Patients {#pbc27455-sec-12190}

[I. Ragab]{.ul} ^1^, H. Hafez^2^, M. Shams^1^, A. Youssef^3^, E. Habib^1^

*^1^Ain Shams University, Pediatric Hematology‐Oncology, Cairo, Egypt; ^2^Children\'s Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; ^3^Children\'s Cancer Hospital Egypt, Radiology Department, Cairo, Egypt*

**Background/Objectives**: Posterior reversible encephalopathy syndrome (PRES) is a clinico‐radiological diagnosis characterized by a spectrum of symptoms, including altered mental status, headache, seizures and visual impairment. We aimed to study the risk factors, clinical and radiological patterns of PRES in pediatric cancer patients and their outcomes

**Design/Methods**: This retrospective study included pediatric cancer patients who were developed PRES during the course of their treatment at the Children\'s Cancer Hospital Egypt (CCHE‐57357) from January 2013 to June 2017. The clinical and radiological data of the studied patients were collected and reviewed. All MRI findings were revised by the specialized neuroradiologist for defining different kinds of PRES. The medical records were reviewed to find the underlying medical conditions of the patients included in the study.

**Results**: Among the 50 patients with PRES, 62% were less than 10 years of age; with female: male ratio 1.17:1. Leukemia and lymphoma wee the commonest diagnosis (64%). Forty patients (80%) received chemotherapy or immunosuppression during last 14 days. Hypertension was presented in 86% of patients at the time of PRES. Regarding the MRI findings most of the patients had either occipital affection. Other affected areas like frontal involvement was seen in 16 patients (32%), temporal lobe in 22%, cerebellum in 12%, basal ganglia in 8% and thalamus in 6%. Unilateral PRES was present in 10 patients and atypical findings in 9 patients. Advanced PRES was presented in 8 patients.80 % had complete clinical resolution and 60% complete radiological resolution at 2 weeks evaluation.

**Conclusions**: Although clinical and radiologic reversibility is expected, a small number of patients may develop persistent neurological sequelae and even death may occur. Advanced and atypical sites are of worse prognosis

### PO-251. Incidence and Risk Factors for Recurrent Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia: A Tertiary Centre Experience {#pbc27455-sec-12200}

[J. Ramamoorthy]{.ul} ^1^, V. Radhakrishnan^2^, T.G. Sagar^3^

*^1^Assistant professor, Department of Medical Oncology‐ Cancer Institute Adyar, Chennai, India; ^2^Associate professor, Department of Medical Oncology‐ Cancer Institute Adyar, Chennai, India; ^3^professor, Department of Medical Oncology‐ Cancer Institute Adyar, Chennai, India*

**Background/Objectives**: High risk febrile neutropenic (FN) episodes in children with acute lymphoblastic leukemia (ALL) are treated with antibiotics till counts recovery (CR) irrespective of their fever status. Prolonged hospital stay & escalated treatment expenditure are the necessary evil of this recommendation. Targeting antibiotic administration only to children at risk for recurrent febrile neutropenia (RFN) can curtail this problem. The objective was to estimate the incidence and risk factors of RFN in children with ALL.

**Design/Methods**: FN episodes between January 2016 and June 2017 in children diagnosed with ALL during the year 2016 (N=113; boys‐ 65, girls‐ 48) were analyzed retrospectively. World Health Organization definition was utilized to classify nutritional status.

Definitions: RFN: Febrile episode developing 24 hours after and within 7 days of afebrile period. CR: Absolute neutrophil count \> 500/mm^3^ or absolute monocyte count \> 100/mm^3^ in peripheral blood.

**Results**: 38/256 episodes (14.85%) were RFN. Timing of occurrence: induction‐ 13, consolidation‐ 13, reinduction‐7 and maintenance‐3. Evidence of clinical or microbiological documented infection (COMDI): 26 episodes & absence of CR: 35. Risk factors associated with development of RFN were: non‐ remissional status of marrow (NRSM) (P=0.007; OR‐14.5; 95%CI, 5.1‐40.2), profound neutropenia (PN) (P=0.002; OR‐25.7; 95%CI, 7.7‐87.4), COMDI (P=0.002; OR‐3.9; 95%CI, 1.9‐8.1) & underweight (P=0.037; OR‐2.1; 95%CI, 1.3‐4.7). Multivariate analysis revealed significant association between RFN and NRSM (P=0.002), PN (P=0.001) and underweight status (p=0.031). In FN episodes which were defervescent and not in CR by 72 hours, RFN developed in 31/82 (37.8%). These RFN episodes were associated with COMDI (P=0.02), underweight (P=0.01), stunting (P=0.006) and PN (P=0.002) on univariate analysis; with underweight (P=0.006) and PN (P=0.003) on multivariate analysis.

**Conclusions**: Underweight status, PN and NRSM predisposes children with ALL to develop RFN. Antibiotics need to be continued until counts recovery in underweight children and PN episodes irrespective of their defervescence status

### PO-252. Is Usage of Colistimethate Sodium Rational or Rampant in Our Unit? A Self Audit of Tertiary Care Centre {#pbc27455-sec-12210}

[J. Ramamoorthy]{.ul} ^1^, V. Radhakrishnan^2^, T.G. Sagar^3^

*^1^Assistant professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^2^associate professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^3^Professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India*

**Background/Objectives**: Resistance to beta‐lactam/beta‐lactamase inhibitors and carbapenems was reported in 66% and 50% of gram negative bacterial (GNB) isolates respectively. The only lifeline left during management of multidrug resistant (MDR) GNB isolates was colistimethate sodium (CS). We performed an audit to estimate the frequency, indication and impact on outcome of febrile neutropenia episode (FNE) by CS administration.

**Design/Methods**: FNE in children during the period from January 2016 to July 2017 in our centre were audited retrospectively. MDR was defined as non‐susceptibility (intermediate and resistant) to one agent in atleast 3 different class of antibiotics.

**Results**: Of the 924 FNE, CS was administered in 116 (12.3%) episodes. These FNE were secondary to treatment for acute myeloid leukemia in 62 episodes, acute lymphoblastic leukemia in 42 episodes, lymphoma in 9 episodes and others in 3 episodes. The duration of neutropenia & febrile neutropenia was 19.9±7.4 days & 17.5±7.1 days respectively. The median days of FNE & absolute neutrophil count at the time of CS initiation was 4 (3‐5) and 200 (100‐400)/ mm3. CS therapy was initiated following clinical sepsis in 46 episodes, microbiologically documented infection (MDI) in 39 episodes, previous MDI by MDR isolates in 14 episodes, clinically documented infection in 8 episodes and severe sepsis in 9 episodes. MDR GNB were isolated in 33/39 episodes with MDI (Escherichia coli‐ 19 episodes, Klebsiella pneumonia‐ 12 episodes and pseudomonas aeruginosa 2 episodes). After initiation of CS, deferevescence was achieved in 102 FNE (87.9%) after an interval of 10.9±5.7 days. Defervescence was not achieved in 14 episodes (12.1%) resulting in death

**Conclusions**: CS was administered in 12% of FNE; commonly in children with clinical sepsis or MDI. CS initiation is a necessary evil of pediatric oncology practice. Clinical risk stratification and robust biomarkers for antibiotic escalation and response assessment are needed to avoid its inappropriate utilization

### PO-253. Who Should Be Screened for Thiopurine Toxicity Secondary to NUDT15 Polymorphism in a Developing Country Setting? A Pilot Study {#pbc27455-sec-12220}

[J. Ramamoorthy]{.ul} ^1^, A. philips^2^, V. Radhakrishnan^3^, T.G. Sagar^4^

*^1^Assistant professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^2^Senior resident, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^3^Associate professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India; ^4^Professor, Department of Medical Oncology‐ Cancer Institute WIA Adyar, Chennai, India*

**Background/Objectives**: Germline polymorphisms in genes involved in thiopurine metabolism influences the response rate and toxicity profile following 6‐mercaptopurine exposure. Prevalence of NUDT polymorphism (NUDTP) in children with East Asian ancestry is reported to be 3‐10%. A risk stratified testing strategy is expected to reduce the expenses incurred in testing for NUDTP. The objective of this study was to identify clinico‐laboratorical parameters (CLP) which could predict the existence of NUDTP

**Design/Methods**: Twenty consecutive children with total leukocyte count (TLC) \<4000/mm^3^ by seventh day of thiopurine exposure (SDTPE) during consolidation phase of ALL treatment were enrolled prospectively. Details of treatment interruptions, TLC and febrile neutropenia episodes (FNE) were collected. Receiver operating curve (ROC) was utilized to derive cut‐off points with sensitivity and specificity \>90% in CLP. NUDTP was evaluated using allele specific real time PCR

**Results**: The median age of the cohort was 11(2‐15) years. The median TLC by SDTPE was 1650(300‐3900)/ mm3 with grade 3 & 4 leukopenia seen in 20% and 35% children respectively. The median duration of leukopenia (DOL) was 7(2‐39) days with 35% children requiring \>10 days to recover TLC. Homozygous and heterozygous NUDTP was observed in 15% and 35% of the cohort respectively. NUDTP could be predicted with 90% sensitivity and specificity whenever the TLC was \<1650/mm3 by SDTPE. NUDTP could be predicted with 90% & 95% sensitivity and specificity respectively whenever the duration of leucopenia was \>7.5 days. All 3 children with homozygous NUDTP had \>18(21‐39) days of leucopenia and TLC \<700/mm3 by SDTPE. Children with NUDTP had treatment interruption for 19(12‐35) days and 3 (2‐7) FNE with 1 child succumbing to FNE.

**Conclusions**: TLC \<1650/mm3 by SDTPE and DOL \>7.5 days could be utilized as a threshold to screen for NUDTP. Prospective evaluation in larger sample size is needed to validate these cut‐off points.

### PO-254. High Rates of Cisplatin Induced Hearing Loss in the ABLE Ototoxicity Cohort: A Prospective Pan‐Canadian Pharmacogenomic Study {#pbc27455-sec-12230}

[S.R. Rassekh]{.ul} ^1^, B. Brooks^2^, M. Barker^3^, K. McMahon^4^, B. Drogemoller^5^, F. Kozak^6^, R. Tsuyuki^7^, G. Groeneweg^8^, M. Zappitelli^9^, B.C. Carleton^10^, C.J. Ross^5^

*^1^University of British Columbia, Pediatrics‐ Division of Pediatric Hematology/Oncology/BMT, Vancouver, Canada; ^2^British Columbia\'s Children\'s Hospital, Audiology and Speech Pathology, Vancouver, Canada; ^3^University of British Columbia, Experimental Medicine, Vancouver, Canada; ^4^McGill University, Division of Experimental Medicine, Montreal, Canada; ^5^University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, Canada; ^6^British Columbia\'s Children\'s Hospital, Surgery‐ Division of Pediatric ENT, Vancouver, Canada; ^7^University of Alberta, Department of Medicine, Edmonton, Canada; ^8^British Columbia\'s Children\'s Hospital Research Institute, Pharmaceutical Outcomes Programme, Vancouver, Canada; ^9^Hospital for Sick Children, Department of Pediatrics‐ Division of Pediatric Nephrology, Toronto, Canada; ^10^University of British Columbia, Department of Pediatrics‐ Division of Translational Therapeutics, Vancouver, Canada*

**Background/Objectives**: Cisplatin is a highly effective chemotherapeutic agent used in the treatment of a variety of childhood cancers. However, its use is limited by significant toxicity, specifically hearing loss and nephrotoxicity. We have conducted multiple pharmacogenetic studies of cisplatin‐induced ototoxicity (CIO) and have discovered multiple genes that are associated with toxicity. To further validate these findings a prospective cohort was recruited for further pharmacogenomic studies.

**Design/Methods**: The ABLE team was established to validate predictive markers of late effects of cancer treatment including cisplatin induced toxicity. This 3‐year observational study enrolled any participant under 18 receiving cisplatin treatment at one of 12 Canadian institutions before their first or second cycle of Cisplatin therapy. Subjects were eligible for this particular analysis if they had an end of therapy audiogram that could be graded using the SIOP Boston scale. All audiograms were centrally reviewed by one expert audiologist. The pharmacogenomic analyses was performed using a genome‐wide panel, with previously identified candidate genes included.

**Results**: 159 participants have been enrolled in the ABLE oto‐nephrotoxicity study. 44 are currently non‐evaluable (18 have no post therapy audiogram uploaded, 24 had incomplete audiology assessment to allow for grading as per SIOP Boston Scale, and 2 died prior to end of therapy audiology). Therefore 115 participants met inclusion criteria for this ototoxicity assessment. 37.4% did not have detectable ototoxicity (Grade 0). Toxicity observed included: 29 with Grade 1 ototoxicity (25.2%); 14 Grade 2 (12.2%); 19 Grade 3 (16.5%); 10 Grade 4 (8.7%). Baseline characteristics analysis and pharmacogenomic results are pending.

**Conclusions**: Ototoxicity is common in children treated with cisplatin with over 62% of children having evidence of toxicity. Risk factors for hearing loss, including genetic predictors, are being analysed and will be presented at the meeting.

### PO-255. Can We Achieve the National Standard Door to Needle Time for Children with Febrile Neutropenia? A Paediatric Oncology Shared Care Unit Experience {#pbc27455-sec-12240}

[S. Rhead]{.ul} ^1^, M. Aye^1^, J. Savage^1^, V. Chukwulozie^1^

*^1^Milton Keynes University Hospital, Paediatrics, Milton Keynes, United Kingdom*

**Background/Objectives**: Febrile neutropenia (FN) is a well‐recognised emergency in oncology patients, requiring rapid assessment and treatment. According to 2012 NICE guidelines, children with malignancy and fever should be assessed and receive parental antibiotics within 60 minutes of arrival to hospital. As a Paediatric Oncology Shared Care Unit (POSCU) we aimed to investigate if patients with suspected FN were being given antibiotics within the recommended door to needle (DTN) time, and how we compared nationally.

**Design/Methods**: A retrospective audit was conducted by reviewing medical notes of oncology patients. Any admission for suspected FN during September to December 2014 was included. The results of the audit were presented to the department. We produced a FN pathway poster on the admissions unit and ward. After implementing the changes, this process was repeated for May to August 2015 and January to June 2016.

**Results**: The initial audit included 15 admissions for suspected FN, 73% of admissions received antibiotics within 60 minutes. The first re‐audit included 14 admissions, 93% of admissions received antibiotics within 60 minutes. The second re‐audit in 2016 included 16 admissions, 81% received antibiotics within 60 minutes. After presentation of the initial audit results along with implementation of an admission pathway poster, the percentage of patients that received antibiotics within 60 minutes had increased in both the first and second re‐audit from 73% to 93% and 81% respectively.

**Conclusions**: In a national audit published by Herd et al in 2016 the overall DTN for FN was 62%. We found that staff education on FN and the implementation of an admission pathway, has raised awareness and had a positive outcome on our DTN time. This highlighted the need for continual education and awareness for staff and parents. Our next step is to introduce an information leaflet including a clock as a visual tool to encourage timely presentation.

### PO-256. Use of an Early Warning Score to Evaluate Clinical Deterioration in Pediatric Oncology Patients {#pbc27455-sec-12250}

[J. Rivera]{.ul} ^1^, C. Hernández^2^, S. Espinoza^2^, R. Martínez^2^, M. Nuñez^2^, A. Agulnik^3^, A. Cárdenas^4^, A. Ellis^5^, G. Escamilla^5^, L. Vega^5^

*^1^Hospital Infantil Teleton de Oncología, Pediatric Emergency, Queretaro, Mexico; ^2^Hospital Infantil Teleton de Oncología, Nurse, Queretaro, Mexico; ^3^St. Jude Children\'s Research Hospital, Department of Pediatric Global Medicine, Memphis, USA; ^4^Hospital Infantil Teleton de Oncología, Pediatric Intensive Care Unit, Queretaro, Mexico; ^5^Hospital Infantil Teleton de Oncología, Pediatric Oncology, Queretaro, Mexico*

**Background/Objectives**: Introduction: Early warning scores use clinical parameters to generate scores that allows identifying patients at risk for clinical deterioration.

Objective: Evaluate the use of the PEWS (Pediatric Early Warning Score) score as a marker of early clinical deterioration in pediatric oncology patients that require evaluation by the intensive care team.

**Design/Methods**: 128 events were reviewed, corresponding to 71 patients with a diagnosis of cancer, which required evaluation by the pediatric intensive care unit (PICU) team between December 2013 and October 2015. A PEWS score was assigned in a retrospective manner to each one of the events up to 10 hours before the evaluation by the PICU team. A score of greater than 4 was classified as critical based on vital signs. The events were classified based on the intervention as: PICU consult, medical response team activation and code team activation.

**Results**: Before evaluation by the PICU team, 78% of the patients had critical PEWS. PICU evaluation ranged from 10 hours before the event to the moment of the event. Of the 182 events, 79 patients (85.9%) that were transferred to the PICU had critical PEWS before the event. Of the remaining 90 events that did not require transfer to the PICU, 65 patients (72.2%) require an intervention to improve their critical condition.

**Conclusions**: The use of an early warning score is useful to identify clinical deterioration early. The results suggest that the early warning score would allow for the objective identification of patients at risk for deterioration.

### PO-257. Tuberculosis in Children with Cancer: Experience from a South African Center {#pbc27455-sec-12260}

[B. Rowe‐Potgieter]{.ul} ^1^, G. Naidu^1^, D. Mackinnon^1^, S. Poyiadjis^1^, M. Bassingthwaighte^1^

*^1^University of the Witwatersrand, Paediatric Oncology Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa*

**Background/Objectives**: Tuberculosis(TB) has been reported in children undergoing chemotherapy. The objective of this study is to (i) describe the incidence of latent TB‐infection and TB‐disease in children with cancer, (ii) to compare the Tuberculin Skin Test(TST) with the Interferon Gamma Release Assay(IGRA‐T‐SPOT.TB) for diagnosing latent TB‐infection and (iii) to describe the characteristics and outcome of children with TB‐disease and cancer.

**Design/Methods**: A prospective cohort study was conducted at a tertiary center in South Africa from 1 April 2010 to 31 March 2012. Newly diagnosed children with cancer were enrolled and screened for latent TB‐infection with a TST and T‐SPOT.TB test. Where TB‐disease was suspected during chemotherapy sputum was sent for culture.

**Results**: A total of 169 patients were enrolled. Latent TB‐infection was documented in 5 patients (2.9%). The T‐SPOT.TB assay yielded negative results. Twenty‐four(14.2%) patients were diagnosed with TB‐disease during chemotherapy. The incidence of TB‐disease was 4.7 per 100 child years. Those that developed TB‐disease during chemotherapy had a higher number of high‐dose corticosteroid courses (397.4 per 100 child years) compared to those who did not develop TB (40.7 per 100 child years; p\<0.001). Children who developed TB‐disease had more septic episodes associated with profound neutropenia (319.5 vs 46.6; p\<0.001), profound lymphopenia (264.9 vs 41; p\<0.001) and profound monocytopenia (389.6 vs 63.7; p\<0.001). Children who developed TB had more septic episodes with prolonged neutropenia (350.6 vs 51.1; p\<0.001), prolonged lymphopenia (335.1 vs 59.2; p\<0.001) and prolonged monocytopenia (444.2 vs 70.7; p\<0.001). There were 4/24(16.7%) deaths.

**Conclusions**: The incidence of latent TB‐infection in children with cancer was low. The TST and T‐SPOT.TB tests have limited value in diagnosing TB‐infection in immunocompromised patients. Risk factors for developing active TB‐disease in patients with hematological malignancies are the use of numerous courses of high‐dose corticosteroids and profound, prolonged neutropenia, lymphopenia and monocytopenia. Mortality in patients with TB and cancer are due to complex factors.

### PO-258. Respiratory Virus Infections in Children with Febrile Neutropenia: Experience from a South African Center {#pbc27455-sec-12270}

[B. Rowe‐Potgieter]{.ul} ^1^, G. Naidu^1^, D. Mackinnon^1^, S. Poyiadjis^1^, M. Bassingthwaighte^1^

*^1^University of the Witwatersrand, Paediatric Oncology Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa*

**Background/Objectives**: The role of respiratory viruses(RV) as infecting or co‐infecting pathogens in patients with febrile neutropenia(FN) has not been extensively characterized. The aim was to (i) document the incidence of RV‐infections in children with hematologic malignancies and solid tumours, and to assess whether there was a difference between these groups, (ii) to identify the most common RV\'s occurring in children with FN and (iii) document the incidence of RV‐infections in those children that died.

**Design/Methods**: All children diagnosed with cancer between 01/04/2010 and 31/03/2012 at a paediatric oncology unit at a tertiary center in South Africa were enrolled in a prospective cohort study. A suspected septic episode(SSE) was defined according to the standard definition of FN. During a SSE, blood investigations and nasopharyngeal aspirates were done and various parameters recorded.

**Results**: There were 169 patients, 82/169(48.5%) with hematologic malignancies and 87/169(51.5%) with solid tumours. A total of 528 SSE\'s occurred. The number of SSE\'s associated with RV were 147/330(44.5%) in hematologic malignancies and 64/198(32.3%) in solid tumours(p=0.007). The number of SSE\'s with bacterial‐viral co‐infections were 112/330(33.9%) in hematologic malignancies vs 45/198(22.7%; p=0.01). The overall incidence per 100 child years of RV‐associated SSE\'s was 61.2 with 92.4 in hematologic malignancies vs 35.1 in solid tumours(p\<0.001). Human rhinovirus(HRV) was identified in 96/368(26.1%). Viral‐viral co‐infections occurred in 17.5% and RV‐bacterial co‐infection in 35%. Twelve children (7.1%) died due to sepsis. Eighteen RV\'s were isolated in the 12 deceased patients; Human Coronavirus in 44.4% and HRV in 27.8%.

**Conclusions**: RV‐infections and bacterial‐viral co‐infections in SSE\'s were more common among children with hematologic malignancies compared to those with solid tumours. The most common RV identified was HRV. Viral‐viral co‐infections were lower than bacterial‐viral co‐infections. The patients who died had bacterial and fungal co‐infections in addition to the identified RV\'s. The presence of RV‐infection and its clinical significance and relationship with outcome remains uncertain.

### PO-259. PICCs in the Treatment of Children with Cancer: Results of a Multicenter Study {#pbc27455-sec-12280}

[M. Rykov]{.ul} ^1^, A. Petrash^1^, S. Zaborovskih^2^, A. Shvecov^3^, V. Shukin^4^

*^1^N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia; ^2^Regional Children\'s Clinical Hospital, Anesthesiology, Nizhny Novgorod, Russia; ^3^R.M. Gorbacheva Institute of Pediatric Oncology‐ Hematology and Transplantation, Oncology, Saint‐Petersburg, Russia; ^4^Dmitry Rogachev Federal Research Center of Pediatric Hematology‐ Oncology and Immunology, Anaesthesiology, Moscow, Russia*

**Background/Objectives**: To review our first in the Russian Federation experience with PICCs in pediatric cancer patients.

**Design/Methods**: The analysis included 353 patients (3 months up to 17 years, mean age 11.2 years) with a variety of cancers diseases, which in 2011 ‐ 2017 354 PICCs were established. All settings are carried out using ultrasound navigation. In 138 (39%) patients used external anatomical landmarks, in 216 (61%) -- intraoperative fluoroscopy.

**Results**: Maximum duration of operation ‐ 1.3 years, the lowest ‐ 1.5 months, average ‐ 6.3 months. Among the technical difficulties during installation most frequently have been the migration of the distal end of the catheter into the internal jugular vein against blood flow ‐ 32 (9%) patients. In 1 (0.3%) case we were unable to catheterize the patient\'s vein. Among the most common complications of operation were marked PICCs thrombosis ‐ 26 (7.3%) cases. Venous thrombosis was observed in 16 (4.5%) cases. Catheter‐related bloodstream infections were not reported. Removal of PICCs related to the complications were performed in 30 (8,5%) patients who were later implanted venous ports.

**Conclusions**: PICCs are recommend to use in the treatment of children with cancer. It should be trained nursing staff to minimize the risk of complications.

### PO-260. Half of the Non‐Neutropenic Febrile Episodes in First‐Line Treatment for Cancer Develop Severe Infection in Cali, Colombia {#pbc27455-sec-12290}

[N. Sanclemente‐Lopez]{.ul} ^1^, O. Ramirez^1^, C.A. Portilla^2^, S. Andrade‐Mejia^1^, C. Hernandez^3^, E. Lopez^4^

*^1^Centro Medico Imbanaco, Pediatric Oncology Unit, Cali, Colombia; ^2^Universidad del Valle, School of Medicine, Cali, Colombia; ^3^Centro Medico Imbanaco, Pediatric Infectology, Cali, Colombia; ^4^Universidad del Valle, Pediatric Infectology, Cali, Colombia*

**Background/Objectives**: Febrile neutropenia is a well‐recognized urgency because of its high mortality rate if untreated. Etiology and complications of the febrile non‐neutropenic child under first‐line chemotherapy are not well known in the setting of a middle‐income country. Herein we describe outcomes of non‐neutropenic febrile episodes in children treated in a pediatric oncology unit in Cali, Colombia.

**Design/Methods**: We included all febrile episodes of non‐neutropenic children in first‐line chemotherapy at a third level private pediatric oncology unit, from Jan/01/2014‐Dec/31/2017. Baseline and follow‐up data from each episode were collected from medical records, laboratory, and pathology reports. We define as severe infection any child who required inpatient treatment with a microbiological isolate, localized infection or elevated inflammatory biomarkers in the setting of suspected infection. Descriptive statistics were carried‐out.

**Results**: We identified 89 non‐neutropenic events (46 patients) from 250 febrile episodes (73 patients). Half of the patients had ≤2.5 or ≥13.5 years old, M: F ratio was 1:1.1, afro‐descendant 15%, born in Cali 29% and acute lymphoblastic leukemia (ALL) 52%; of which 63% were in maintenance. Seventy‐nine episodes needed inpatient treatment, 52 with severe infections, 34 with microbiological isolates. The most frequent were gram‐negative bacteria 18, followed by viral 7 (adenovirus 1, cytomegalovirus 1, influenza A 2, parainfluenza 2, Coxsackie 1), and 1 amebiasis. Nineteen foci without isolated organism; pneumonia 3, upper respiratory infecion 7, gastrointestinal 6, skin 2, and cholecystitis 1. Four episodes required PICU; all are alive. Twenty episodes were inpatient with non‐severe infections and 7 episodes of tumoral origin.

**Conclusions**: Severe infection occurs in febrile non‐neutropenic patients and seems to be particularly relevant for ALL in mantainence. With current intensive chemotherapy patients become more immunosuppressed but not always neutropenic. This information should increase awareness of pediatric emergency physicians who usually provide first clinical care to these patients.

### PO-261. Impact of a Multimedia Campaign on Community Knowledge of Pediatric Cancer in a Low Resource Setting {#pbc27455-sec-12300}

K. McHenry^1^, A. Morgan^2^, H. Dhudha^1^, H. Sued^1^, N. Masalu^1^, N. Chao^2^, [K. Schroeder]{.ul} ^1,3^

*^1^Bugando Medical Centre, Oncology, Mwanza, Tanzania; ^2^Duke University, Global Health, Durham, USA; ^3^Duke University Medical Center, Pediatric Oncology and Global Health, Durham, USA*

**Background/Objectives**: In low‐resource settings pediatric cancer often goes unrecognized, creating a barrier to improving childhood cancer survival rates. In Tanzania, fewer than 20% of children with cancer present for treatment. Increased community awareness about pediatric cancer can lead to improved referrals and reduced diagnostic delays. This study evaluates the implementation and impact of a pediatric cancer community awareness campaign in Tanzania.

**Design/Methods**: Key stakeholders agreed on campaign education content. Targeted print and radio media were developed and evaluated by community focus groups. Four communities were randomly selected in the Lake Zone Region of Tanzania for the planned intervention, including 2 urban and 2 rural communities. Pre‐intervention and 2‐week post‐intervention surveys were conducted via random sampling to assess an individual\'s knowledge of pediatric cancer causes, symptoms, and treatment. Post‐intervention surveys also evaluated exposure to, and perceived acceptability of, each component of the multimedia campaign.

**Results**: There was no significant difference in responder age or sex between pre‐ (n=100) and post‐ (n=100) intervention groups (average age 42 years, p=0.4; 78% female, p=32). Post intervention, knowledge score increased from 49% to 59% (p=\<0.001), with increased improvement among rural compared to urban communities (15% vs 7%). Radio programs had the greatest reach, with 44% reported exposure. Media exposure correlated to increased knowledge scores, with Pearson correlation coefficients of 0.73.

**Conclusions**: A targeted multimedia campaign can effectively increase pediatric cancer knowledge in low‐resource settings, with potential for greater impact in rural communities. Future studies are needed to evaluate the impact of awareness campaigns on patient‐related outcomes.

### PO-262. Cumulative Incidence of Blood Stream Infections During Acute Myeloid Leukemia Treatment in the Netherlands: A 15‐Year Overview {#pbc27455-sec-12310}

[E. Schwartz]{.ul} ^1^, K. Klein^1^, V. De Haas^2^, B. Lissenber‐Witte^3^, L. Ball^4^, N. Dors^5^, M. Van den Heuvel‐Eibrink^2^, R. Knops^6^, W. Tissing^7^, B. Versluys^8^, M. Zwaan^9^, R. van Litsenburg^1^, G. Kaspers^1^

*^1^VU University medical center, Pediatric Hematology‐Oncology, Amsterdam, The Netherlands; ^2^Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands; ^3^VU University medical center, Epidemiology and Biostatistics, Amsterdam, The Netherlands; ^4^Leiden University Medical Center, Pediatric Oncology, Leiden, The Netherlands; ^5^Radboud University Medical Center, Pediatric Oncology, Nijmegen, The Netherlands; ^6^Academic Medical Center, Pediatric Oncology, Amsterdam, The Netherlands; ^7^University Medical Center Groningen, Pediatric Oncology, Groningen, The Netherlands; ^8^University Medical Center Utrecht‐Wilhelmina Children\'s Hospital, Pediatric Oncology, Utrecht, The Netherlands; ^9^Erasmus University Medical Center, Pediatric Oncology, Rotterdam, The Netherlands*

**Background/Objectives**: Despite the use of antibiotic prophylaxis, bacterial infections remain the leading cause of treatment‐related morbidity in children with acute myeloid leukemia (AML). The objectives of this study were to: 1) evaluate the cumulative incidence of blood stream infection (BSI) during treatment according to the last three consecutive protocols of the Dutch Childhood Oncology Group (DCOG); 2) determine the most common bacterial pathogens; and 3) determine risk factors.

**Design/Methods**: A retrospective chart review was performed on 246 patients (DCOG treatment protocols ANLL‐97/AML‐12 n=119, AML‐15 n=60, DB‐AML01 n=67) diagnosed with de novo AML (APL and Down syndrome excluded) between 1998‐2013. All patients received prophylaxis with co‐trimoxazole. From AML‐15 onwards, patients also received prophylactic fluoroquinolones. BSIs were defined as a positive blood culture confirmed by the hospital\'s microbiologist. The cumulative incidence of BSIs was determined using competing risk analysis with death, switch to another protocol, or stem cell transplantation as competing events. Age, sex, BMI, white blood cell count (WBC) at diagnosis, cytogenetics, and treatment protocol were evaluated as risk factors.

**Results**: Median age was 6.4 years \[range 17.4\], 58% were male. The cumulative incidence of BSIs was 78.2%. The most common pathogens were Staphylococcus epidermidis (15.6%), Streptococcus mitis (14.9%) and other Staphylococci (11.6%). ANLL‐97/AML‐12 (78%) and AML‐15 (72%) showed a lower BSI incidence than DB‐AML01 (84%; hazard ratio(HR)s 0.69 \[0.50‐0.97\], p=0.033 and 0.59 \[0.40‐0.89\], p=0.012, respectively). WBC \>20x109/l was associated with a lower risk of infections (HR 0.72 \[0.54‐0.96\], p=0.026). The other risk factors were not statistically significant.

**Conclusions**: The most recent DCOG protocol was associated with the highest incidence of BSIs, probably as a result of the high intensity of this protocol. Furthermore, the use of prophylactic antibiotics with gram‐negative coverage may have resulted in a relatively higher incidence in gram‐positive BSI. The high incidence stresses the urge to improve anti‐infective supportive care measures.

### PO-263. Higher Incidence of SIADH During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: An Indian Experience {#pbc27455-sec-12320}

[S. Seetharam]{.ul} ^1^, P. Thankamony^1^, K.G. Gopakumar^1^

*^1^Regional Cancer Centre, Pediatric Oncology, Thiruvananthapuram, India*

**Background/Objectives**: Syndrome of inappropriate anti diuretic hormone secretion (SIADH) is a well‐known adverse effect of vincristine (VCR). Literature suggests that Asians are predisposed to developing SIADH following VCR administration. However data regarding the occurrence of SIADH in pediatric oncology is limited. The aims of this study was to analyze the incidence, clinical picture, risk factors, management and outcome of SIADH in pediatric patients during induction chemotherapy for acute lymphoblastic leukemia (ALL) treated at a tertiary cancer centre in India.

**Design/Methods**: One hundred and sixty six pediatric patients, aged upto 14 years, with newly diagnosed ALL who were treated according to the institutional chemotherapy protocol (a modified BFM ALL 95 protocol) between January 2015 and December 2015, at a tertiary cancer care centre in South India were included.

**Results**: The incidence of SIADH was 10.8% with a mean sodium level of 125mEq/L (114‐129mEq/L). Seventy two percent of episodes were associated with the administration of 2 (n=6) or 3 (n=7) doses of vincristine in the preceding 2 weeks. Only one patient presented with seizures. All the patients were managed with fluid restriction and only two patients required sodium correction with hypertonic saline. A marginally significant correlation was noted in girls \> 10 years of age (P value = 0.059).

**Conclusions**: We report a higher incidence of SIADH (10.8%) in Indian children on induction chemotherapy for ALL. Regular monitoring of sodium levels during induction chemotherapy would help to avert neurological symptoms secondary to SIADH.

### PO-264. Voriconazole Induced Periostitis: A Rare Complication {#pbc27455-sec-12330}

S. Sivadasan^1^, K. Mullanfiroze^2^, T. Singhal^1^, S. Tulpule^3^, [S. Sen]{.ul} ^2^

*^1^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatrics, Mumbai, India; ^2^Kokilaben Dhirubhai Ambani Hospital, Department of Paediatric Oncology & BMT, Mumbai, India; ^3^Kokilaben Dhirubhai Ambani Hospital, Department of Haematology & BMT, Mumbai, India*

**Background/Objectives**: Voriconazole is commonly used antifungal agent used in paediatric oncology patients for prophylaxis and treatment of fungal infections. We report here on one of our post transplant patients who presented with acute bone pain over the tibia.

**Design/Methods**: A 6 year old boy with relapsed B cell ALL had a successful matched sibling donor transplant. Post transplant, patient was given presumptive therapy with liposomal amphotericin as his galactomannan screen was positive. Later his antifungal therapy was switched to voriconazole and he was discharged on the same.

Voriconazole levels were monitored and kept at a therapeutic level. On Day + 45 patient presented with severe leg pain and difficulty in walking. There were no neurological findings and a X Ray of the legs were normal. Suspecting a relapse, a bone marrow aspiration and biopsy was done which showed no evidence of disease recurrence with MRD being negative and 100% donor chimerism.

The pain increased in severity to an extent that the child stopped walking. A MRI scan was done which only showed periosteal thickening suggestive of mild periostitis over the tibia. Differential diagnosis of leukemic infiltration, osteomyelitis and drug induced periostitis was considered. As we had ruled out a relapse with a bone marrow examination and all inflammatory markers were negative, we deduced that drug induced periostitis was the most likely cause for the symptoms. Discontinuation of voriconazole led to complete resolution of pain within 48 hours.

**Results**: At one year post transplant, patient continued to be in remission and pain free.

**Conclusions**: Painful periostitis is a rare complication of long term voriconazole therapy which has only been recently reported in literature. Fluorosis and promotion of bone formation by osteoblast stimulation is the the proposed mechanism for voriconazole induced periostitis. Increased awareness of this rare condition can lead early correct diagnosis.

### PO-265. Outcomes of Children with Leukemia Admitted with Septic Shock and Myocardial Dysfunction: Role of Intravenous Globulins {#pbc27455-sec-12340}

R. Seth^1^, [S. Seth]{.ul} ^2^, J. Meena^3^, A. Gupta^3^

*^1^Professor, Pediatrics, Delhi, India; ^2^AIIMS, Cardiology, New Delhi, India; ^3^AIIMS, Pediatrics, New Delhi, India*

**Background/Objectives**: Myocarditis can be a complication in children with leukemia, not just due to cardiotoxic chemotherapy, but also due to sepsis due to viral or bacterial infection and is often fatal. Intravenous globulins have been found to be useful in children with myocarditis. We report the results in a series of patients presenting with leukemia with septic shock and myocarditis who were treated with intravenous globulins.

**Design/Methods**: Children with leukemia undergoing chemotherapy and presenting with Septic shock and myocarditis are included. All children were treated with antibiotics, diuretics, intravenous inotropes. Myocarditis was defined by an ejection fraction \< 50% with /without elevated blood troponin I levels. Intravenous gamma globulin (IVIG) was given as 2 gm/kg.

**Results**: Five children presenting with a combination of leukemia (acute lymphoblastic leukemia, acute myeloid leukemia and juvenile myelomonocytic leukemia) complicated by sepsis and myocardial dysfunction not responding to supportive care were treated with IVIG started within 24 ‐48 hours of diagnosis. The age range was from 2.5 to 9 years. All were undergoing chemotherapy and had presented with features of sepsis and developed shock. Two had evidence of viral infection (varicella and EBV). Four patients improved with improvement of left ventricular function to normal and they were discharged on enalapril (ACE inhibition) and carvedilol (Beta blockers) and continued to be on follow up. One patient declined therapy after the initial care.

**Conclusions**: IVIG has been found to have both anti‐microbial (Mycoplasma, Chlamydia, etc) and anti‐viral activity (Herpesvirus, varicella zoster, parvovirus, adenovirus). It may also have a scavenging effect on toxins or inflammatory mediators. Mortality for Leukemia with septic shock is high and IVIG could be a potential treatment when myocarditis is demonstrated.

### PO-266. A Clinical Study on Shenmai Injection in Children with Malignant Solid Tumor Treated with Chemotherapy {#pbc27455-sec-12350}

[W. Shan]{.ul} ^1^

*^1^Children\'s Hospital of Chongqing Medical University, Department of Pediatric Surgical Oncology, Chingqing, China*

**Background/Objectives**: To study the effect of Shenmai Injection on the protection of bone marrow, reducing the toxic and side effects of chemotherapy.

**Design/Methods**: 215 children with malignant solid tumor, including Neuroblastoma, lymphoma, hepatoblastoma, rhabdomyosarcoma, synovial sarcoma, primitive neuroectodermal tumor, osteosarcoma, immature or malignant teratoma and yolk sac tumor, were randomly divided into control group and three dose gradient experimental groups, the control group receives standard chemotherapy only, in addition to standard chemotherapy, three experimental groups were treated with a corresponding dose gradient of Shenmai injection. After four courses of treatment, the differences in the blood, liver and kidney function and side effects of chemotherapy, short‐term efficacy and quality of life were evaluated between experimental groups and the control group.

**Results**: There was no significant difference between three experimental groups and the control group in white blood cells, neutrophil, hemoglobin, and platelets (*p*\>0.05); There was no significant difference in liver function and renal function between the three experimental groups and the control group (*p*\>0.05); There was no significant difference in cardiac markers and electrocardiogram between the three experimental groups and the control group (*p*\>0.05); There was no significant difference in nausea, vomiting and other chemotherapy side effects between the three test groups and the control group (*p*\>0.05). Experimental group 1(*P*=0.011)and experimental group 2(*P*=0.004)were significantly different from the control group in short‐term curative effect, but there was no significant difference between experimental group 3 and control group (*P*=0.139). There was a significant difference in life quality between three experimental groups and the control group (*P*=0.000,0.003,0.001, respectively).

**Conclusions**: Shenmai Injection can help to recover the body during chemotherapy, improve the quality of life, make children able to tolerant and complete chemotherapy, improve the prognosis of children with malignant solid tumors.

### PO-267. Non Sino‐Pulmonary Fungal Infections in Children with Immunodeficiency {#pbc27455-sec-12360}

[S.R. Siddaiahgari]{.ul} ^1^, S. Vaddadi^1^

*^1^Rainbow children\'s Hospital‐ Banjara Hills, pediatric Hematology and oncology, Hyderabad, India*

**Background/Objectives**: Fungal infections are becoming the leading cause of mortality and morbidity in children with leukemia. Most of them present in Induction period with low leucocyte and platelet counts. Aspergillus is common among them. We are now discussing the fungal infections that occur in rare sites.

**Design/Methods**: It is an observational study.

Data of children with immuno deficiency (primary or acquired) being treated at Rainbow children\'s hospital, who developed fungal infections in non sinus, non pulmonary sites, was collected.

**Results**: Five cases have been identified, out of which four had Acute leukemia and one had Chediak Higashi Syndrome.

Site of infection was Eye in one case, cannula site in 2 cases, foot in one case and forearm in one case.

Fungus identified include Aspergillus in 2 cases, Rhizopus in two cases and Exserohilum Rostratum in one case.

Four cases recovered with aggressive antifungals and local debridement and one case required limb amputation.

**Conclusions**: Strong clinical suspicion and active interventions are needed to treat such infections. Infections may occur with rare fungi and common fungal infections can occur in rare sites.

### PO-268. Role of Oral Appetite Stimulants in Improving the Nutritional Status of Children Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation: A Systematic Review {#pbc27455-sec-12370}

[G. Singh]{.ul} ^1^, S. Oberoi^2^, G. Cuvelier^2^, T. Truong^3^

*^1^University of Calgary, Pediatric Oncology, Calgary, Canada; ^2^Cancer Care Manitoba, Pediatric Hematology Oncology, Winnipeg, Canada; ^3^University of Calgary, Pediatric Hematology Oncology and Stem Cell Transplant, Calgary, Canada*

**Background/Objectives**: To evaluate the efficacy and safety of oral appetite stimulants in improving the nutritional status of children undergoing treatment for cancer or hematopoietic stem cell transplant (HSCT).

**Design/Methods**: A comprehensive search of MEDLINE, Embase and CINAHL databases was performed to identify prospective, retrospective or randomized controlled studies (RCTs) evaluating the efficacy of oral appetite stimulants in children with cancer undergoing chemotherapy or HSCT. Two authors independently identified eligible studies and abstracted data. The primary outcome was the change in weight post‐intervention.

**Results**: Of the 139 citations screened, 6 studies (4 retrospective, 1 prospective and 1 randomized control trial), conducted on 167 patients were included in the review. Megestrol acetate (MA) was used in 4 studies and Cyproheptadine in 2 studies. The only RCT included in the review, had a low risk of bias and showed a significant weight gain (mean difference in weight gain: +20.9% (95%CI: +11.3% to +30.5%, P‐0.003) with the use of MA. All non‐randomized studies suffered from a high risk of bias and reported different outcomes. Two non‐randomized studies reporting the primary outcome of interest showed significant weight gain with MA (P \< 0.001 & P = 0.0007) and Cyproheptadine (P\<0.05 & P= 0.001). Both MA and Cyproheptadine were associated with a significant increase in appetite in two non‐randomized studies (P \< 0.001 & P\< 0.0028). Low cortisol levels were demonstrated in all studies using MA, with one study reporting grade 4 adrenal suppression. Heterogeneity among the included studies precluded any data synthesis.

**Conclusions**: A meaningful and valid conclusion on the efficacy of oral appetite stimulants in pediatric oncology patients could not be drawn from the available literature. Further studies are needed to determine the effect of oral appetite stimulants in this cohort of patients. Adrenal suppression associated with MA must be considered before its use in clinical trials.

### PO-269. Piloting a Mobile Health Platform to Improve Compliance in Children with Acute Lymphoblastic Leukemia {#pbc27455-sec-12380}

M. Valentine‐King^1^, G. Moore‐Higgs^2^, [W. Slayton]{.ul} ^2^

*^1^University of Florida, Environmental and Global Health, Gainesville, USA; ^2^University of Florida, Pediatrics‐ Division of Hematology and Oncology, Gainesville, USA*

**Background/Objectives**: Poor medication compliance during maintenance therapy is associated with inferior outcomes in children with acute lymphoblastic leukemia (ALL). However, medication nonadherence occurs in 10 to 40% of pediatric patients with ALL and medication errors are common, occurring in up to 30% of cases. To address this, we piloted HealthSteps, a mobile health platform, which displays a synchronized care plan with instructions, reminders and the ability to complete activities, and allows providers to view adherence data. We aimed to determine the usability of HealthSteps via user‐surveys and app‐generated data.

**Design/Methods**: In this pilot, we enrolled up to 20 pediatric patients with ALL receiving maintenance therapy at UF Health in Gainesville, Florida. We administered three surveys: one at enrollment inquiring about demographics and care management, and two follow‐up surveys gauging app usage, benefits and challenges. To measure app usage, we used app‐generated data and defined consistent users as those that completed care plan activities ≥ 75% of the time. We used either a chi‐square or Mann‐Whitney test to compare differences between consistent versus inconsistent app users.

**Results**: Among the ten subjects enrolled thus far, four subjects consistently used the app. No significant differences existed when comparing demographics or smartphone use ability between consistent versus inconsistent app users. In the baseline survey, subjects reported symptom management (50%), medication administration (40%), and coordinating care plan changes (40%) as their greatest challenges. The most prominent issue reported was confusion over reminders.

**Conclusions**: To address this issue with reminders, we amended our study protocol to ensure that subjects receive test reminders in the office, and showed subjects how to make reminders appear permanent. Based on survey data, this population could benefit from symptom tracking. Thus, HealthSteps version 1.2 will add individualized symptom tracking and gamification to increase app usage.

### PO-270. Improved Access to International Society of Paediatric Oncology (SIOP) Paediatric Oncology in Developing Countries (PODC) Adapted Treatment Regimens {#pbc27455-sec-12390}

[J. Slone]{.ul} ^1^, M. Zobeck^1^, J. Libes^2^, R. Kunkel^3^, N. Ranasinghe^4^, J. Geel^5^

*^1^Baylor College of Medicine/Texas Children\'s Hospital, Pediatrics, Houston, USA; ^2^University of Illinois College of Medicine, Pediatrics, Peoria, USA; ^3^Arkansas Children\'s Hospital, Pediatrics, Little Rock, USA; ^4^Thomson Reuters, Product Management, London, United Kingdom; ^5^Wits University, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa*

**Background/Objectives**: The high mortality rates of children with cancer in low‐ and middle‐income countries (LMICs) are due, in part, to lack of resources (including treatment guidelines) and educational opportunities. To promote optimal treatment of pediatric cancers in LMICs, SIOP PODC working groups have published guidelines in Pediatric Blood and Cancer (PBC). Many health care providers in LMICs do not have access to medical journals like PBC and treat pediatric malignancies with limited or no specialized training. The SIOP PODC Education and Training Working Group launched a new website, <http://www.cancerPOINTE.com>, in October 2016 to support clinicians in LMICs.

**Design/Methods**: In July 2017, with assistance from SIOP PODC leadership and permission from PBC, eight guidelines were posted on <http://www.cancerPOINTE.com>: Burkitt lymphoma, Kaposi sarcoma, medulloblastoma, neuroblastoma, nutrition support, retinoblastoma, supportive care and Wilms tumor. Google Analytics was utilized to monitor website traffic. Parameters analyzed included all users, new users, page views and country of origin, though there is not a mechanism to differentiate automated software tasks (bots) from individual users accessing the site.

**Results**: From October 2016 to April 2018, <http://www.cancerPOINTE.com> had 2234 visitors from 119 countries and 10,021 page views. Since posting SIOP PODC adapted treatment guidelines in July 2017, <http://www.cancerPOINTE.com> had 1105 users (87% new users) from 94 countries. The Adapted Treatment Protocols page, where these guidelines are hosted, was visited 214 times in this period.

**Conclusions**: Hosting SIOP PODC guidelines on <http://www.cancerPOINTE.com> has improved access to these guidelines to healthcare providers who typically may not have access to medical journals or cancer treatment protocols. An open source platform with an increasing social media presence, <http://www.cancerPOINTE.com> could be an essential tool in rapidly disseminating resources to health care providers in LMICs who otherwise would not be aware nor have access to the resources.

### PO-271. Comparison Between Manco‐Johnson Score versus Modified Villalta Score to Detect Post‐Thrombotic Syndrome in Childhood Cancer/Hematologic Disease {#pbc27455-sec-12400}

[D. Sosothikul]{.ul} ^1^, N. Yupensuk^1^, P. Seksarn^1^

*^1^Chulalongkron University, Department of Pediatrics, Bangkok, Thailand*

**Background/Objectives**: The incidence of venous thrombotic events in pediatric patients is 5.3/10,000 hospital admissions per year. Post‐thrombotic syndrome (PTS) is one of the potential complications of deep vein thrombosis (DVT). To compare the accuracy of the 2 different score Manco‐Johson and Modified Villalta score to detect PTS in childhood cancer/hematologic disease previously diagnosed as DVT.

**Design/Methods**: A retrospective study in childhood cancer/ hematologic disease with PTS diagnosed as DVT at King Chulalongkorn Memorial Hospital, Thailand from January,2005 to December,2016.

**Results**: A total of 86 patients diagnosed DVT were included. The incidence rate of venous thrombotic events was 6.3/10,000 hospital admissions per year. Sixty patients (69.7%) and 13 patients (15.1%) of total 86 patients had primary diagnose as childhood cancer and hematologic disease, respectively. Median age was 10.6 years. The most common risk factor of venous thrombotic event was catheter‐related thrombosis (62.9%). When comparing 2 score,14 patients (16.3%) were diagnosed with PTS by Manco‐Johnson score and 13 patients (15.1%) by Modified Villalta score. Age ranged from 1 to 14years (median 9 years). Eight patients (57.1%), and 6 patients (42.9%) of 14 patients diagnosed as PTS had primary diagnose as childhood cancer and other hematologic diseases, respectively. Most Modified Villalta score groups were mild severity identified 1 score (76.9%) and 2 score (23.1%) (mean 1.14). Manco‐Johnson score groups were ranged from 1‐4 (mean 1.85) identified in 1 score (42.8%), 2 score (35.7%), 3 score (14.3%) and 4 score (7.2%). Mean of Manco‐Johnson groups was higher than that of Modified Villalta groups (P=0.001).

**Conclusions**: Manco‐Johnson score is better than Modified Villalta score in detecting PTS. Observation and monitoring for PTS in childhood cancer survivors diagnose as DVT are essential and also beneficial in other hematologic diseases.

### PO-272. The Impact on Professionals When Children Develop Central‐Line Infections {#pbc27455-sec-12410}

[C. Soto]{.ul} ^1^, C. Tarrant^2^, M. Dixon‐Woods^3^

*^1^University College Hospital London, Children\'s Hospital, LONDON, United Kingdom; ^2^University of Leicester, Social Science Applied to Healthcare Improvement Research SAPPHIRE Group, Leicester, United Kingdom; ^3^University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom*

**Background/Objectives**: Central‐line associated bloodstream infections (CLABSIs) are a form of healthcare associated infection (HCAI) with potentially devastating consequences for patients. Although the clinical outcomes of CLABSIs are well‐described, the challenges for professionals when a child under their care develops a CLABSI have not been investigated.

**Design/Methods**: Semi‐structured interviews were conducted with 15 multi‐disciplinary professionals who had experience of caring for children who had developed CLABSI. Interviews were digitally recorded and transcribed verbatim. Data analysis was based on the constant comparative method.

**Results**: Although CLABSI were familiar occurrences for healthcare professionals (HCPs) in this study, they were still traumatic events. They reported their experience of children with significant CLABSI becoming more unwell, more dramatically than other children. Further, memories of other children who had died as a result of CLABSI made the HCPs fearful that each subsequent child in their care would also die despite optimal treatment. They described significant emotional turmoil associated with making clinical decisions about the child\'s care. They felt that the severity of CLABSI, compared to other cases of sepsis, was not widely appreciated by colleagues, and they often struggled to explain to their peers how unwell the child was. They believed this contributed to delays in accessing external support such as admissions to PICU or surgical removal of central lines.

**Conclusions**: CLABSI are emotionally traumatic events for HCPs, leaving significant residual emotional impact of each case. HCPS described facing particular challenges in communicating the severity of CLABSI to colleagues, risking delays to the child\'s care. A wider education on the severity and impact of CLABSI amongst allied specialties, coupled with structured protocols for communicating about the severity of CLABSIs, would be valuable in improving the speed of access to potentially life‐saving interventions.

### PO-273. The Impact of Central‐Line Infections on Children and Families {#pbc27455-sec-12420}

[C. Soto]{.ul} ^1^, C. Tarrant^2^, M. Dixon‐Woods^3^

*^1^University College Hospital, Children\'s Hospital, London, United Kingdom; ^2^University of Leicester, Social Science Applied to Healthcare Improvement Research SAPPHIRE Group, Leicester, United Kingdom; ^3^University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom*

**Background/Objectives**: Central‐venous access devices (CVADs; "central‐lines") are used in children with complex medical conditions to deliver life‐saving treatments. Central‐line associated bloodstream infections (CLABSIs), although rare, can result in prolonged hospital admissions, intensive care admissions and even death. As more children are facilitated to live at home, families have to manage the risks of developing CLABSI. The impact of living with these risks on the emotional and mental health of the children at home and their families requires exploration.

**Design/Methods**: As part of a larger study exploring care of invasive devices in the community, semi‐structured interviews were conducted with 11 parents of children and with 20 professionals. Interviews were digitally recorded and transcribed verbatim. Data analysis was based on the constant comparative method.

**Results**: Four families had personal experience of CLABSI, and all were aware of other children who had experienced CLABSI. CLABSIs were unpredictable and children could deteriorate rapidly; some families were aware of children who had died. All parents, irrespective of first‐hand familiarity, experienced unrelenting fear that their child would develop an infection and die. Families described a state of constant vigilance, continually monitoring the child for signs of infection to expedite treatment. This resulted in significant emotional burden on top of the emotional workload inherent in caring for children with complex medical conditions. Parents with first‐hand experience of CLABSI recounted vivid, traumatic memories of their child\'s illness. Hospital admissions for infection disrupted family life, parents' work, school, hobbies and family celebrations.

**Conclusions**: CLABSIs disrupt the lives of children and families. The threat of CLABSI causes significant emotional distress for families in addition to existing burdens. Professionals should be aware of this emotional burden when counselling families about the risk of CLABSI, and work with families to manage their fear. Children and families with experience of CLABSI may benefit from additional psychological support.

### PO-274. Golden Hour: Audit on Timely Administration of Antibiotics in Haemato‐Oncologic Patients Presenting with Febrile Neutropenia {#pbc27455-sec-12430}

[A. Stanzelova]{.ul} ^1^, M. Connell^2^, J. Pears^1^, M. Capra^1^, A. Malone^3^, O. Smith^3^, A. O\'Marcaigh^3^, C. Owens^1^

*^1^Our Lady\'s Children\'s Hospital‐ Crumlin, Oncology, Dublin, Ireland; ^2^UCD School of Medicine and Medical science, Medical School, Dublin, Ireland; ^3^Our Lady\'s Children\'s Hospital‐ Crumlin, Haematology, Dublin, Ireland*

**Background/Objectives**: Febrile Neutropenia (FN) is defined as a single temperature over 38.5C or two temperatures between 38.0C and 38.4C at least an hour apart, within 24 hours, in the presence of neutrophil count below 0.5x10\^9. Because of significant risk of overwhelming sepsis, timely cover with broad spectrum intravenous antibiotics is paramount: a benchmark of 60 minutes is established as a marker of quality of care in oncologic centres. We wanted to determine the length of time between presentation and administration of antibiotics (time‐to‐antibiotics: TTA) in our population.

**Design/Methods**: This is a retrospective audit of medical records of all patients presenting to our haemato‐oncologic unit with FN between July and December 2017. Collected information included TTA, clinical symptoms at presentation, length of admission and treatment and identified pathogens. Data was analysed through Excel spreadsheet.

**Results**: Forty‐one episodes of FN in 26 children were identified. TTA was less than 60 minutes in 14% (6/41). Majority (31/41 ‐ 75%) were treated within 3 hours. Eighty percent (33/40) presented out‐of‐hours. In 41% (17/40) fever was the only symptom. Ninety percent (37/41) of children were well upon presentation (Paediatric Early Warning Score -- PEWS\<4). Twenty percent of peripheral and 30% of central blood cultures were positive. The most commonly identified organisms were coagulase negative staphylococci. Seventeen percent (7/41) received antibiotic locks for infection of Broviac line. Oncologic patients had more events per person (1.7 versus 1.4) but generally shorter stays (4.8 vs 7.3 days). There were no ICU admissions or FN‐associated deaths.

**Conclusions**: TTA was over the 1‐hour benchmark in most cases showing significant room for improvement. We created a proforma to facilitate early identification and treatment of FN. Through PDSA (Plan‐Do‐Study‐Act) cycles with education of nurses, doctors, parents, and implementation of the proforma we hope to decrease our TTA. Re‐audit is planned for July to December 2018.

### PO-275. Phase Angle from Bioelectrical Impedance is Reduced and Related to Muscle Strength in Children and Adolescents with Cancer {#pbc27455-sec-12440}

[S. Stössel]{.ul} ^1^, M.A. Neu^1^, A. Wingerter^1^, C. Paret^1^, K. El Malki^1^, N. Henninger^1^, A. Russo^1^, H. Otto^1^, N. Lehmann^1^, F.T. Baumann^2^, P. Zimmer^3^, W. Bloch^4^, J. Faber^1^

*^1^University Medical Center Mainz‐ Center for Pediatric and Adolescent Medicine, Department of Pediatric Hematology/Oncology/Hemostaseology, Mainz, Germany; ^2^University Hospital of Cologne, Department I of Internal Medicine‐ Center of Integrated Oncology Köln Bonn, Köln Bonn, Germany; ^3^German Sport University Cologne‐ Institute of Cardiovascular Research and Sports Medicine and German Cancer Research Center, Department of Molecular and Cellular Sport Medicine‐ Cologne and Department for physical activity‐ preventive research and cancer, Köln and Heidelberg, Germany; ^4^German Sport University Cologne‐ Institute of Cardiovascular Research and Sports Medicine, Department of Molecular and Cellular Sport Medicine‐ Cologne, Köln, Germany*

**Background/Objectives**: Phase angle (PhA) derived from bioelectrical impedance is a parameter of nutritional status in healthy children and adults as well as in sick persons. Due to multifactorial reasons such as tumor cachexia, malnutrition and low calorie intake, nutritional status is often altered in pediatric cancer patients. PhA is a marker for cellular health. In patients with cancer, low PhA is an indicator for complication risk and inferior prognosis.

**Design/Methods**: In this cross‐sectional study, PhA was assessed in children and adolescents during intensive cancer treatment, prior to the start of a new chemotherapy course. At the same time point, isometric leg muscle strength was measured with a handheld dynamometer.

**Results**: During intensive cancer treatment, 32 patients, aged 11.5 (4.2‐17.7) years, were included. Seventeen patients suffered from a solid tumor, 11 from leukemia or t‐cell‐lymphoma and 4 from a central nervous system tumor. Eleven patients were male. Compared to age and sex matched normal values, PhA was significantly reduced in the present sample of pediatric cancer patients (4.88° vs. 5.62°, p=0.000). PhA showed a moderate statistically significant correlation with leg muscle strength (Pearson r=0.532, p=0.003). Concerning body mass index, there was no statistical difference comparing patients to age and sex matched normal values.

**Conclusions**: Even though body mass index of patients does not differ from normal values, the reduced PhA indicates malnutrition in the present population. As PhA is related to muscle strength, further studies should investigate whether exercise training might improve body composition resulting in a higher PhA. Bioelectrical impedance is an easy‐to‐use tool and a non‐invasive technique to evaluate changes in body composition and nutritional status in children and adolescents suffering from cancer.

### PO-276. Improved Outcome and Differential Incidence of Infectious Complications in Children Treated for Malignancies or Undergoing Hematopoietic Cell Transplantation: Results of Multicenter Nationwide Study in Poland {#pbc27455-sec-12450}

[J. Styczynski]{.ul} ^1^, K. Czyzewski^1^, O. Zajac‐Spychala^2^, J. Fraczkiewicz^3^, M. Salamonowicz^3^, O. Gryniewicz‐Kwiatkowska^4^, A. Szmydki‐Baran^5^, F. Pierlejewski^6^, T. Ociepa^7^, L. Chelmecka‐Wiktorczyk^8^, R. Tomaszewska^9^, M. Plonowski^10^, Z. Gamrot^11^, Z. Malas^12^, A. Urbanek‐Dadela^13^, W. Stolpa^14^, J. Musial^15^, A. Zaucha‐Prazmo^16^, E. Bien^17^, N. Irga‐Jaworska^17^

*^1^Jurasz University Hospital Collegium Medicum UMK, Department of Pediatric Hematology and Oncology, Bydgoszcz, Poland; ^2^Medical University, Department of Pediatric Hematology‐ Oncology and Transplantology, Poznan, Poland; ^3^Medical University, Department of Transplantology‐ Pediatric Hematology and Oncology, Wroclaw, Poland; ^4^CZD, Department of Oncology, Warszawa, Poland; ^5^Medical University, Department of Pediatric Hematology and Oncology, Warszawa, Poland; ^6^Medical University, Department of Pediatric Hematology‐ Oncology and Diabetology, Lodz, Poland; ^7^Medical University, Department of Pediatric Hematology and Oncology, Szczecin, Poland; ^8^University Hospital Collegium Medicum UJ, Department of Pediatric Hematology and Oncology, Krakow, Poland; ^9^Medical University, Department of Pediatric Hematology and Oncology, Zabrze, Poland; ^10^Medical University, Department of Pediatric Hematology and Oncology, Bialystok, Poland; ^11^Pediatric Center, Department of Pediatric Hematology and Oncology, Chorzow, Poland; ^12^Children Hospital‐ UWM, Department of Pediatric Hematology and Oncology, Olsztyn, Poland; ^13^Children Hospital UJK, Department of Pediatric Hematology and Oncology, Kielce, Poland; ^14^Medical University, Department of Pediatrics‐ Division of Hematology and Oncology, Katowice, Poland; ^15^University Hospital UR, Department of Pediatric Hemato‐Oncology, Rzeszow, Poland; ^16^Medical University, Department of Pediatric Hematology and Oncology, Lublin, Poland; ^17^Medical University, Department of Pediatric Hematology and Oncology, Gdansk, Poland*

**Background/Objectives**: Over a decade ago, infection‐related mortality (IRM) exceeded 20% in allogeneic hematopoietic cell transplantation (allo‐HSCT) and 10% in autologous HSCT or children during anticancer chemotherapy. The objective of this study was the analysis of incidence and outcome of infections in children treated for malignancy (PHO, pediatric hematology‐oncology) or undergoing HSCT over a period of 6 consecutive years in 17 centers.

**Design/Methods**: A total number of 5628 patients with newly‐diagnosed malignancies and 971 patients after HSCT (including 741 allo‐HSCT and 230 auto‐HSCT).

**Results**: BACTERIAL INFECTIONS: For PHO patients the incidence of bacterial infections was lower: 34.2% vs 41.5% (p\<0.0001), while survival was better: 97.7% vs 92.6% (p\<0.0001). Rate of MDR bacteria was higher in HSCT setting both for G‐ (55% vs 41%) and G+ (34% vs 19%) bacteria. Auto‐HSCT patients had lower incidence (34.8% vs 43.7%) and lower IRM than allo‐HSCT. INVASIVE FUNGAL DISEASE (IFD): For PHO patients the IFD incidence was lower: 8.8% vs 21.2% (p\<0.0001), and survival after IFD was better: 94.2% vs 84.1% (p\<0.0001). Auto‐HSCT patients had lower incidence (10.9% vs 24.4%) and lower IRM than allo‐HSCT patients. Introduction of national antifungal prophylaxis program in HSCT and acute leukemia patients decreased incidence of IFD in HSCT (23.1% to 13.4%) and AML (36% to 23%) but not in ALL patients. VIRAL INFECTIONS: For PHO patients the incidence of viral infections was lower than for allo‐HSCT patients: 4.9% vs 60.9% (p\<0.0001), and comparable with auto‐HSCT patients: 4.9% vs 5.6% (p=0.3). Survival after viral infections reached: 100% for auto‐HSCT, 98.2% for PHO, and 95.8% for allo‐HSCT (p=0.084).

**Conclusions**: The incidence of infections in allo‐HSCT patients is high, while in auto‐HSCT is comparable to PHO patients. The outcome of infections both in PHO and HSCT patients has largely improved in comparison to historical international data.

### PO-277. Nutritional Status at Diagnosis of Cancer: Are We Underestimating the Problem? {#pbc27455-sec-12460}

[V. Subramani]{.ul} ^1^, B. Anil Kumar^2^, R. Jain^3^, D. Bansal^3^, A. Trehan^4^

*^1^Postgraduate Institute of Medical Education and Research, Department of Pediatrics, Chandigarh, India; ^2^Postgraduate Institute of Medical Education and Research‐, Department of Pediatrics, Chandigarh, India; ^3^Postgraduate Institute of Medical Education and Research, Pediatric Hematology Oncology unit‐ Department of Pediatrics, Chandigarh, India; ^4^Postgraduate institute of Medical Education and Research, Pediatric hematology ‐ oncology unit‐ Department of Pediatrics, Chandigarh, India*

**Background/Objectives**: Undernutrition (UN) has an adverse impact in children on treatment for a malignancy. There is no global standardized tool for the evaluation of the nutritional status of a child. We evaluated patients with complete anthropometric, clinical and biochemical assessment.

**Design/Methods**: Children newly diagnosed with a malignancy were classified as inadequately nourished(IN) with any one of the following 6 parameters: Height for age \< 5^th^ percentile, Weight for height\< 10^th^ percentile, body mass index (BMI) \< 10^th^ percentile for age and gender, triceps skinfold thickness (TSF) \< 5^th^ percentile for age and gender, mid upper arm circumference (MUAC) \< 5^th^ percentile for age and gender, serum albumin under 3.2mg/dl and clinical evidence of UN.

**Results**: Ninety children (60 boys, 30 girls), mean age: 65.27 ± 37.96 months were evaluated. With any of the six parameters‐ 62.2% were IN at diagnosis (73.3% girls & 56.7% boys). Sixty percent (38/63) of children with a haematological malignancy and 18/27 (66.6%) with a solid tumour were IN. Twenty three percent had a weight for age \< ‐2Z scores, 16.6% children had a height for age \< ‐2Z scores (WHO). Twenty percent children had a BMI for age \< ‐2Z scores. Severe depletion was evident by 48% children having a MUAC \< 5th centile for age, 18.3% having a TSF \< 5th centile for their age, and 36% percent children having serum albumin level \< 3.2gram% at diagnosis.

**Conclusions**: All children need a detailed evaluation for nutritional status at the time of diagnosis of cancer. A gold standard for the assessment of nutritional status in children is the need of the hour. The necessity for nutritional rehabilitation for patients is vital to get a child out of his inadequately nourished state in order to reduce the associated morbidity and mortality.

### PO-278. Steroid‐Induced Glaucoma in Paediatric Patients with Acute Leukaemia or Malignant Lymphoma {#pbc27455-sec-12470}

[M. Sugiyama]{.ul} ^1^, Y. Terashita^1^, J. Ohkubo^1^, Y. Cho^1^, A. Iguchi^1^

*^1^Hokkaido University Graduate School of Medicine, Department of Pediatrics, Sapporo, Japan*

**Background/Objectives**: Although steroid‐induced glaucoma has been reported in children, its frequency in paediatric patients with acute leukaemia and malignant lymphoma remains unclear. Typically, such patients are administered a substantial amount of corticosteroid during induction therapy, which requires considerable hydration and may further predispose an increased intraocular pressure.

**Design/Methods**: We enrolled patients with acute leukaemia or malignant lymphoma, who received chemotherapy, including corticosteroid, at our institution from January 2016 to February 2018. Their intraocular pressures were measured by ophthalmologists within 7 days from the initiation of corticosteroid. If patients required some medication, including eye drops or diuretic agents, the intraocular pressure measurement was repeated after induction therapy. Here, we evaluated the frequency of Steroid‐induced glaucoma in paediatric patients with acute leukaemia or malignant lymphoma.

**Results**: During the study period, 15 patients \[seven males and eight females; median age, 9.0 (range, 3--15) years\] with haematological malignancy received induction therapy for 14 months. The intraocular pressure in nine patients \[five males and four females; median age, 9.0 (range, 6--15) years\] who received eye drops was \>20 mmHg. Of these, four needed diuretic agents. Only one patient underwent trabeculotomy between an interval of chemotherapy. The intraocular pressure in two patients increased only during the administration of dexamethasone (10 mg/m2) and not during the administration of prednisolone (60 mg/m2). Notably, only two of the nine patients demonstrated symptoms, including headache or photophobia.

**Conclusions**: In this study, more than half of the patients with haematological malignancy who received corticosteroid had glaucoma. If they have no symptoms, paediatric patients with acute leukaemia or malignant lymphoma perform well in the measurement of intraocular pressure during induction therapy.

### PO-279. Cardiac Late Effects in Pediatric Oncology Patients Treated with Protocols Containing Anthracyclines {#pbc27455-sec-12480}

C.E. tagi^1^, O. dogru^2^, [G. Tokuc]{.ul} ^2^, N. eker^2^, F. akalın^3^, E. senay^2^

*^1^Marmara University, Pediatri, Istanbul, Turkey; ^2^Marmara University, Pediatric Oncology‐Hematology, Istanbul, Turkey; ^3^Marmara University, Pediatric Cardiology, Istanbul, Turkey*

**Background/Objectives**: One of the most commonly used chemotherapeutic agents in childhood malignancies are anthracyclines. Increased survival rate in pediatric cancer requried researchs on side effects of drugs. One of the most important side effects of chemotherapeutics is cardiotoxicity. In our study, we aimed to investigate chronic cardiotoxicity due to anthracyclines by various methods.

**Design/Methods**: Eighty‐two children who were followed up for at least 6 months after treatment with protocols containing anthracyclines were included in the study. Electrocardiographic and echocardiographic examinations were performed following a detailed systemic physical examination of the children in the patient and control groups. Serum NT‐proBNP, troponin I and galectin‐3 levels were studied by ELISA. The results were analyzed by using SPSS‐20.0 for Windows.

**Results**: Electrocardiography revealed two incomplete right bundle branch block, one degree AV block and three sinus tachycardia in two patients. The systolic and diastolic blood pressures of the patients who received high dose anthracycline were significantly higher on physical examination, QTc distance on electrocardiography was sgnificantly longer, EF, EF, E ′, E′ / A 'were lower and MPI, IVR and IVC values were significantly higher on echocardiography. With conventional echocardiographic methods, the number of patients diagnosed with cardiotoxicity was 19. When tissue Doppler echocardiographic methods are also used, the number of patients who developed cardiotoxicity was 33. NT‐proBNP and troponin I values were significantly higher in all 3 patient groups receiving anthracycline treatment than in the control group. There were no significant relationship between mediastinal radiotherapy age and gender with cardiotoxicity

**Conclusions**: 2D and M‐mode echocardiography as well as tissue Doppler echocardiography were found to be useful in the evaluation of subclinical cardiotoxicity in children treated with anthracyclines. Along with a large number of studies on the role of NT‐proBNP and troponin I in assessing cardiotoxicity, more studies are needed for galectin‐3.

### PO-280. Comparison of Interventions and Outcomes in Following a Nutritional Algorithm to Conventional Approaches in Children Undergoing Chemotherapy for Cancer {#pbc27455-sec-12490}

[S. Totadri]{.ul} ^1^, A. Trehan^1^, D. Mahajan^1^, E.J. Ladas^2^, R. Barr^3^, K. Viani^4^

*^1^Post Graduate Institute of Medical Education and Research, Pediatric Hematology Oncology unit‐ Department of Pediatrics, Chandigarh, India; ^2^Columbia University Medical Center, Division of Hematology/Oncology/Stem Cell Transplant‐ Department of Pediatrics, New York, USA; ^3^McMaster Children\'s Hospital, Pediatrics‐ Pathology and Medicine, Hamilton, Canada; ^4^Universidade de São Paulo, Department of Hematology‐Oncology, São Paulo, Brazil*

**Background/Objectives**: There is no standard nutritional clinical practice worldwide, despite nutrition being a modifiable risk factor in the outcome of cancer. As an initial step to standardize nutritional practice in pediatric oncology, we sought to validate a nutritional algorithm with specific application to the low and middle‐income country setting.

**Design/Methods**: Fifty children with cancer were enrolled in this randomised interventional study. Weight, length and mid‐upper arm circumference (MUAC) were measured at diagnosis. Patients were assigned randomly to two groups. The study group was administered nutritional care as per an algorithm and the control group received the institutional standard of care. Weight was monitored regularly and MUAC was repeated after 3 months. Children were classified, based on weight for height if \<2‐years of age or body mass index if ≥2‐years, as normal (+2 \> z \> ‐2), wasted (z = ‐2 to ‐3) and severely wasted (z \< ‐3). The algorithm directing nutritional care was based upon the nutritional status of the patient and the available resources of the institution.

**Results**: Nineteen (76%), four (16%) and two (8%); and 21 (84%), three (12%) and one (4%) were normal, wasted and severely wasted, in the control and study groups. MUAC was \<5th‐percentile in 13 (52%) and 15 (60%) patients in each group. There was significant increase in the MUAC \[15.4±2.0 cm to 16.3±2.7 cm (P\<0.001)\] and weight \[17.2±6.5 Kg to 18.2±7.8 Kg (P=0.020)\] after three months in the study group. No significant changes were observed in the control group. A significantly higher proportion of patients improved MUAC in the study group compared to control group (36%, 8% P =0.019).

**Conclusions**: The application of a nutritional algorithm designed for use in LMICs resulted in significant improvement in MUAC and weight when compared to a conventional approach. Next steps will include its application in a multi‐center setting.

### PO-281. Diffuse Motor and Sensory Neuropathy in a Child with Nasopharynx Carcinoma who Treated with Cisplatin {#pbc27455-sec-12500}

[R. Tuna]{.ul} ^1^, S. Ocak^1^, O. Kipoglu^2^, A. Ozkan Karagenc^1^, D. Tugcu^1^, S. Karaman^1^, M. Calıskan^2^, Z. Karakas^1^

*^1^Istanbul University‐ Istanbul Medical Faculty, Department of Pediatric Hematology‐Oncology, Istanbul, Turkey; ^2^Istanbul University‐ Istanbul Medical Faculty, Department of Pediatric Neurology, Istanbul, Turkey*

**Background/Objectives**: Cisplatin is a platinum analog which has a potential of sensory neuropathy by accumulating in the neurons of dorsal root ganglions. While permanent sensory neuropathy can be seen approximately 1 in 5 patients, motor neuropathy associated with cisplatin is rare.

**Design/Methods**: Descriptive case report

**Results**: A 10‐year‐old girl presented with 1 month history of epistaxis. Rhinoscopy examination revealed an irregular surfaced lesion extending from the coana to the nasal cavity in right side of the nasopharynx. Biopsy confirmed squamous, non‐keratinizing nasopharynx carcinoma. EBV DNA titer was negative. After neccessary evaluation, she was started on chemotherapy with the diagnose of nasopharynx carcinoma, classification T2N2M1, stage IVB. After 3 courses of cisplatin and epirubicin, she received IRMT at prescribed doses of 60 grays/30 fraction. Control images showed that the primary lesion and metastases were regressed but two new millimetric nodules were found in the right lung. The local tumor board favoured chemotherapy continuation. After 3 more courses of cisplatin and epirubicin (cumulative doses were 600 mg/m2 and 540 mg/m2, respectively), she developed febrile neutropenia, severe sepsis, lymphedema at the neck region, and vocal cord paralyses. Imaging studies revealed findings in favor of neck lymphedema due to radiation fibrosis, which was treated with steroids. But respiratory distress progressed, therefore she underwent tracheostomy and was transferred to pediatric intensive care unit for postoperative follow‐up. She could not able to wean from ventilater. Her physical examination revealed depressed deep tendon reflexes and reduced muscle strength on all extremities. Kraniospinal MRI and cerebrospinal fluid examinations were normal. EMG revealed severe sensorimotor polyneuropathy. Supportive therapies are ongoing.

**Conclusions**: Cisplatin neurotoxicity was reported over cumulative doses of 350 mg/m2. Clinical picture mostly involves sensory neuropathy, while motor symptoms are rare. In patients who are receiving cisplatin treatment, careful follow‐up is necessary in terms of neurotoxicity.

### PO-282. Outcome of Sepsis in Pediatric Oncology Patients Admitted in Pediatric Intensive Care Unit: A Developing Country Perspective {#pbc27455-sec-12510}

[S. Usman]{.ul} ^1^, Q. Abbas^2^, A. Afzal^1^, B. Saeed^2^

*^1^Aga Khan University Hospital, Oncology, Karachi, Pakistan; ^2^Aga Khan University Hospital, Pediatric Intensive care Unit, Karachi, Pakistan*

**Background/Objectives**: The outcome of pediatric oncology patients has been improved with current treatment protocols. However, these aggressive therapy protocols cause immunosuppression leading to systemic infections. Sepsis remains a leading cause of death in these patients, especially in developing countries like Pakistan. This study aims to find the outcome of pediatric oncology patients with sepsis admitted in the Pediatric Intensive Care Unit (PICU) of a tertiary care hospital in Karachi and assess factors associated with mortality in these patients.

**Design/Methods**: Retrospective review of medical records of all children (1 month to 16 years) admitted in PICU from January 2008 to December 2016, with underlying oncological diagnosis, fulfilling the criteria of sepsis /severe sepsis/ septic shock was done. The data was collected on a structured proforma, and analyzed using SPSS 20.0. Results are presented as mean with standard deviation and frequency with percentages. Appropriate statistical tests were applied to see factors associated with mortality.

**Results**: Out of the 3150 patients, 63 patients were included in the study. Males were forty two(66.7%) and median age was 93 months. Oncological diagnosis included forty five(71.4%) leukemia, twelve(19%) lymphoma, three (4.7%) solid tumors and brain tumors. Forty two(66.7%) patients were in induction phase of chemotherapy, ten(16%) in consolidation/intensification phase and eleven(17%) were in maintenance phase. Thirty nine(62%) and twenty four(38%) patients were admitted from ward and emergency room respectively. Median of 24hrs was required to shift the patient to PICU. Septic shock was present in twenty two(35%) patients. Median PRISM III score was eleven. Twenty six(41%) patients had enterobacteriaceae in their blood culture. Thirty three (52%) patients survived. Renal failure, hepatic dysfunction, septic shock and mechanical ventilation were associated with mortality (p=0.05).

**Conclusions**: Children in induction phase of chemotherapy were mostly admitted in PICU due to sepsis. Mechanical ventilation,septic shock, and organ dysfunction were associated with mortality in these patients.

### PO-283. PICC Line Fracture and Embolization into Pulmonary Artery‐ A Rare But Potentially Life Threatening Complication: A Case Report {#pbc27455-sec-12520}

[K. V P]{.ul} ^1^, P. Kanvinde^1^, S. Patel^1^, S. Mudaliar^1^, A. Swami^1^, S. Jain^2^, J. Mishra^2^, B. Agarwal^1^

*^1^Bai Jerbai Wadia Hospital for Children, Department of Pediatric Haemato‐Oncology, Mumbai, India; ^2^Bai Jerbai Wadia Hospital for Children, Department of Pediatric Cardiology, Mumbai, India*

**Background/Objectives**: Peripherally inserted central catheter or PICCs are popular means of long term Intravenous access in Oncology patients. PICCs are associated with complications like breakage/leakage,phlebitis,catheter related infections,thrombosis,embolization. Fracture and embolization are very rare but potentially serious complication.

**Design/Methods**: Here we present an unusual fracture of the PICC line with embolization to the Right ventricle (RV) and Right Pulmonary Artery (RPA).

**Results**: A 9 year old boy diagnosed with Left Femur Ewing\'s Sarcoma had a PICC(Bard Groshong 4.5 size)inserted via the Right median cubital vein before chemotherapy. Position of the catheter was confirmed with Chest radiograph. Child received 6 cycles of chemotherapy pre operatively and 7 cycles post operatively via the PICC line with the PICC line in situ for 255 days. For his radiotherapy,child was referred to another hospital. It was found that the PICC line had occlusion. An attempt was made for removal which resulted in fracture of the PICC line and incomplete removal. So the child was referred back to our hospital. The child was asymptomatic at presentation. Chest radiographs and Echocardiogram done showed the embolization of the PICC line fragment in the RV and RPA. The embolised PICC line part was retrieved percutaneously by Trans catheter snare assisted retrieval. The child tolerated the procedure well.

**Conclusions**: Catheter fracture is a rare complication;mainly occurs near the entrance site during removal. Factors leading to catheter fatigue are‐long duration,chemotherauptic agents, weekly dressings, blockages. In our patient the PICC fracture occurred after 255 days which is longer than the reported intervals and/or due to attempted removal at another center. This emphasises the importance of specially trained nursing staff. PICC fracture and embolization can be potentially life threatening situation. It can be removed by either Trans catheter retrieval or open cardiac surgery. The latter can cause considerable morbidity. Hence adequate care and precautions must be taken to prevent such complications.

### PO-284. Antiemetic Efficacy of a Palonosetron‐Dexamethasone Schedule in Pediatric Patients Treated with Moderately or Highly Emetogenic Chemotherapy {#pbc27455-sec-12530}

[G. Varrasso]{.ul} ^1^, A. De Grazia^1^, E. Ferrara^1^, M. Paiano^1^, C. Mattiucci^1^, V. Pedetti^1^, A. Schiavetti^1^

*^1^"Sapienza" University of Rome, Pediatrics, Rome, Italy*

**Background/Objectives**: Chemotherapy‐induced nausea and vomiting (CINV) is the most frequent and distressing side effect of childhood cancer treatment.

To evaluate the efficacy of palonosetron‐dexamethasone association in the prevention of CINV in children receiving moderately (MEC) or highly emetogenic chemotherapy (HEC**)**.

**Design/Methods**: All consecutive patients with solid tumors were enrolled. The antiemetic schedule was as follows: palonosetron 5 mcg/Kg i.v. 30 minutes before chemotherapy on day 1 if chemotherapy duration was less than 3 days, every other day if chemotherapy lasted ≥ 3 days. In the MEC courses dexamethasone at 0.1 mg/kg daily was associated to palonosetron until one day after chemotherapy. In the HEC courses dexamethasone was given at a dosage of 0.2 mg/kg daily during chemotherapy and at 0.1 mg/kg until 2 days after chemotherapy. Complete response (CR) was defined as no vomiting and no rescue therapy, complete control (CC) as CR and no more than mild nausea.

**Results**: 29 patients (14 M, 15 F), median age 7 yrs (range 1‐18) were prospectively enrolled. A total of 160 courses, 105 MEC and 55 HEC were delivered. In the MEC courses a CR was obtained in 95.5% in the acute phase and in 100% in the delayed phase; CC was observed in 87% and 94.5% of acute and delayed phase, respectively. In the HEC courses CR and CC rates in acute and delayed phase were 89%, 98%, 83%, 98%, respectively.

**Conclusions**: Our data show a very high antiemetic efficacy of palonosetron‐dexamethasone association in children receiving MEC or HEC.

### PO-285. Nutritional Status Deterioration of Children with Cancer in the First Week of Intensive Care and Relation to Clinical Outcomes {#pbc27455-sec-12540}

[K. Viani]{.ul} ^1^, M. Neto Rafael^1^, C. Pugliese^2^, G. Bouchabki Miguel^1^, B. Stachissini Manzoli^1^, P. Zamberlan^2^

*^1^ITACI ‐ Serviço de Onco‐Hematologia‐ Instituto da Criança‐ Hospital das Clínicas‐ Faculdade de Medicina‐ Universidade de São Paulo, Nutrition, São Paulo, Brazil; ^2^Instituto da Criança‐ Hospital das Clínicas‐ Faculdade de Medicina‐ Universidade de São Paulo, Nutrition, São Paulo, Brazil*

**Background/Objectives**: Pediatric critical patients with cancer are at high nutritional risk, which may exacerbate morbimortality. The goal of this study was to evaluate whether nutritional status decline in the first week of pediatric intensive care unit (PICU) worsens mortality and length of stay, and compare with a group of non‐oncologic critical patients.

**Design/Methods**: This was a retrospective longitudinal study. Charts of patients who had 2 nutritional assessments contemplating the first week of PICU were reviewed. Z scores based on weight and height were classified by World Health Organization growth charts and mid‐upper arm circumference (MUAC) by Frisancho percentiles. Kruskal‐Wallis rank and chi‐square tests were used for comparisons, Spearman\'s rank for correlation. Receiver operating characteristic (ROC) curves were constructed to evaluate the impact of change in MUAC on overall survival.

**Results**: There were 127 patients and 189 controls (59.8%) comparable by length of stay (p=0.84), death rate in 31 days (p=0.20) and overall survival (p=0.21). The groups diverged by nutritional status at admission on PICU, both as classified by weight and height (p=0.05) and MUAC (p=0.00), the oncologic patients presenting less malnutrition (20.6 versus 12.6% and 54.5 versus 26.8%, respectively). Patients with cancer were also older than non‐oncologic critical patients (median 74.2 versus 36 months, p=0.00). MUAC was significantly reduced in the first week of PICU (median 18 to 17.5 cm, p=0.00). The ROC curve had an area of 0.41 (95%CI 0.22‐0.60) for patients and 0.67 (95%CI 0.49‐0.86) for controls (p=0.05). Change in MUAC wasn\'t correlated to length of stay for patients (rs=0.03, p=0.74) or controls (rs=‐0.09, p=0.22).

**Conclusions**: Despite significant decrease in the first week, MUAC alteration didn\'t correlate to overall mortality -- unlike controls -- or length of stay. Nonetheless, the initial deterioration of nutritional status reinforces the importance of nutritional care during this phase.

### PO-286. Risk Factors for Malnutrition in Pediatric Cancer Patients in Botswana and Impact on Survival {#pbc27455-sec-12550}

[O. Wally]{.ul} ^1^, A. Slone^2^, D. Joel^1^, M. Scheurer^3^, P. Mehta^2,4^, J.S. Slone^3,5^

*^1^University of Botswana/Princess Marina Hospital, Pediatrics, Gaborone, Botswana; ^2^Baylor College of Medicine, Texas Children\'s Hospital, Houston‐ TX, USA; ^3^Baylor College of Medicine, Texas Children\'s Hospital, Houston‐ TX, USA; ^4^Texas Children\'s Cancer and Hematology Centres, Global Hematology‐Oncology Pediatric Excellece, Houston‐ TX, USA; ^5^Texas Children\'s Cancer and Hematology Centers, Global Hematology‐Oncology Pediatric Excellence, Houston‐ TX, USA*

**Background/Objectives**: Malnutrition is common in resource‐limited settings. The impact of malnutrition on pediatric cancer outcomes is unclear. A study performed at the only pediatric cancer program in Botswana investigated the prevalence of malnutrition in newly diagnosed pediatric cancer patients, risk factors associated with malnutrition and the impact on survival

**Design/Methods**: A retrospective cohort study was performed via the Botswana Pediatric Oncology Database (BPOD) evaluating a cohort of patients up to 18 years and diagnosed with cancer between 2008‐2015. Weight, height, and weight for height Z‐scores were used to categorize nutritional status and evaluated in relation to demographics, disease characteristics, and outcome.

**Results**: A total of 84 patients were included with 52.4% meeting criteria for malnutrition. Median age was 6.4 years (standard deviation (STD) 4.8 years) and 51.2% were male. Malnourished patients had lower mean albumin levels at diagnosis at 34.9 g/L (STD 9.0) vs. 39.2 g/L (STD 5.9) \[normal range 35‐55 g/L\]. The risk for malnutrition of children with cancer was increased with positive human immunodeficiency virus (HIV) status (Odds Ratio (OR) 5.76, 95% Confidence Interval (CI) 1.5‐21.9, p‐value=0.01) and decreased if the family had private medical aid (OR 0.13, 95% CI 0.03‐0.61, p=\<0.001). There was no difference in risk for malnutrition based on age, gender, residence or cancer diagnosis in univariate analysis. There was no increased risk in early mortality (\<3 months) or two year‐overall survival based on nutrition status at initial diagnosis

**Conclusions**: Over half of patients in this cohort presented with malnutrition with HIV status increasing the risk while having private medical aid was protective. In this cohort, malnutrition did not impact survival, either at three months or two years. Further prospective study with expanded

### PO-287. No Improvement in Pediatric Intensive Care Outcome of Critically Ill Children with Cancer Over Time. A Meta‐Analysis by the Poker Consortium {#pbc27455-sec-12560}

[R. Wösten‐Van Asperen]{.ul} ^1^, J.P.J. van Gestel^1^, M. van Grotel^2^, E. Tschiedel^3^, C. Dohna‐Schwake^3^, F.V. Valla^4^, J. Willems^5^, J.S. Nielsen^6^, M.F. Krause^7^, J. Potratz^8^, M.M. van den Heuvel‐Eibrink^2^, J. Brierley^9^

*^1^Wilhelmina Children\'s Hospital/University Medical Center Utrecht, Department of Pediatric Intensive Care, Utrecht, The Netherlands; ^2^Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands; ^3^Universitätsklinik Essen, Department of Pediatric Intensive Care, Essen, Germany; ^4^Hôpital Universitaire Femme Mère Enfant‐ Hospices Civils de Lyon, Pediatric Intensive Care Unit, Lyon, France; ^5^Ghent University Hospital, Department of Pediatric Intensive Care, Ghent, Belgium; ^6^Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark; ^7^Universitätsklinikum Schleswig‐Holstein, Department of Pediatrics, Kiel, Germany; ^8^University Children\'s Hospital Münster, Department of General Pediatrics‐Intensive Care Medicine, Münster, Germany; ^9^Great Ormond Street Hospital for Children NHS Trust‐ Great Ormond Street, Department of Critical Care & Bioethics, London, United Kingdom*

**Background/Objectives**: Outcomes for children diagnosed with cancer have improved dramatically over the past 20 years. However, although 40% of pediatric cancer patients require at least one intensive care admission throughout their disease course, PICU outcomes and resource utilization by this population have not been rigorously studied in this specific group.

**Design/Methods**: Using a systematic strategy, we searched Medline, Embase, and CINAHL databases for articles describing PICU mortality of pediatric cancer patients admitted to PICU. Two investigators independently applied eligibility criteria, assessed data quality, and extracted data. We pooled PICU mortality estimates using random‐effects models and examined mortality trends over time using meta‐regression models.

**Results**: Out of 1281 identified manuscripts, 31 studies were included covering 14312 PICU admissions with the majority being retrospective in nature. Overall pooled weighted mortality was 27.8% (95% confidence interval (CI), 23.7 ‐ 31.9%). Mortality decreased slightly over time when post‐operative patients were excluded. The use of mechanical ventilation (odds ratio (OR): 18.49 \[95% CI 13.79‐24.78\], p \<0.001), inotropic support (OR: 14.05 \[95% CI 9.16‐21.57\], p \< 0.001), or continuous renal replacement therapy (OR: 3.24 \[95% CI 1.31‐8.04\], p = 0.01) was significantly associated with PICU mortality.

**Conclusions**: PICU mortality rates of pediatric cancer patients are far higher when compared to current mortality rates of the general PICU population. PICU mortality has remained relatively unchanged over the past decades, a slight decrease was only seen when post‐operative patients were excluded. This compared unfavorably with the improved mortality seen in adults with cancer admitted to ICU, where research‐led improvements have led to the paradigm of unlimited, aggressive ICU management without any limitations on resuscitations status, for a time‐limited trial.

### PO-288. The Effect of Amiloride in Reducing Magnesium Supplementation on Severe Hypomagnesemia in Children with Malignancy {#pbc27455-sec-12570}

[E.J. Yang]{.ul} ^1^, K.M. Park^1^, Y.T. Lim^1^

*^1^Pusan National University Children\'s Hospital, Pediatrics, Yangsan‐si, Republic of Korea*

**Background/Objectives**: Hypomagnesemia is common finding in children with malignancies by various cause; chemotherapy, immunosuppressive and antifungal agents. The oral magnesium supplementation is recommended, excluding patients with diarrhea such as graft‐versus‐host disease in hematopoietic stem cell transplantation (HSCT). Amiloride, a potassium‐sparing diuretics, has been reported to reduce potassium and magnesium‐wasting in patients receiving amphotericin B. The purpose of this study was to evaluate the effect of amiloride in pediatric patients with malignancies to reduce the need for magnesium supplementation.

**Design/Methods**: This study was retrospectively identified in Department of Pediatrics, Pusan National University Children\'s Hospital, from June 2015 to May 2017. Magnesium was supplemented by oral and intravenous route to maintain the serum magnesium level \>1.4 mEq/L. Serum magnesium, potassium, creatinine, and average daily magnesium supplementation were measured in the one week preceding amiloride to that of one and two weeks post‐amiloride.

**Results**: 10 patients (mean age, 9.9±1.8 years) were received concomitant amiloride and magnesium supplement. Two patients were treated cisplatin for hepatoblastoma, eight patients were received tacrolimus after HSCT. In 16 patients of the control group, four patients had hepatoblastoma, 12 patients underwent HSCT. Compared to the week 1 pre‐amiloride period: 1) total magnesium supplement decreased by 727.71±163.38 mg/day (P=0.028) in week 1 post‐amiloride, and by 488.28±99.75 mg/day (P=0.018) in week 2; 2) serum magnesium level increased by 1.63±0.05 mg/dL (P=0.005) in week 1 and by 1.96±0.06 mg/dL (P=0.005) in week 2; 3) serum potassium level increased by 4.45±0.15 mg/dL (P=0.032) in week 1, but not significantly changed in week 2. The mean hospital days for hypomagnesemia were 12.1±2.5 days, which were compared with 20.73±2.88 days in the control group (P=0.038).

**Conclusions**: Amiloride is safe and effective for reduction in magnesium supplementation in children with malignancy. Additionally, amiloride is considered a therapeutic option to decrease potassium and magnesium‐wasting in patients treated chemotherapy or HSCT.

### PO-289. Safety and Cost‐Effectiveness of Two Strategies of Antibiotic Treatment (Ambulatory versus Intravenous/Hospital) of Febrile Neutropenia in Children with Cancer {#pbc27455-sec-12580}

[M.M. Zapata Tarres]{.ul} ^1^, L.E. Juárez Villegas^2^, L. Velasco Hidalgo^3^, R. Cárdenas Cardos^3^, O.M. Francisco Javier^4^, P.G. Jose Gabriel^5^, V.A. Martha Margarita^6^, R.L. Alfonso^7^, A.R. Martha^8^

*^1^Instituto Nacional de Pediatria, Oncology, Mexico City, Mexico; ^2^Hospital Infantil de Mexico Federico Gomez, Oncology, Mexico City, Mexico; ^3^Instituto Nacional de Pediatría, Oncology, Mexico City, Mexico; ^4^Instituto Nacional de Pediatría, Infectology, Mexico City, Mexico; ^5^Hospital Juarez de Mexico, Oncology, Mexico City, Mexico; ^6^Hospital Juárez de México, Oncología, Mexico City, Mexico; ^7^Hospital Infantil de Mexico Federico Gómez, Economic research, Mexico City, Mexico; ^8^Hospital Infantil de Mexico Federico Gomez, Infectology, Mexico City, Mexico*

**Background/Objectives**: Febrile neutropenia is the main problem in children with cancer. There are different strategies for its ambulatory treatment. In our reality it has been difficult to implement these strategies because of medical resistance and patients\' social problems. This is the first clinical trial with an economic view done in our city.

**Design/Methods**: We measure the safety and effectiveness of two strategies of antibiotic treatment (oral and ambulatory versus intravenous in the hospital) in febrile neutropenia (FN) in children. The study was done in three hospitals with oncological departments. It was designed as a clinical trial, multicentric, with hypothesis of no inferiority, randomized in balanced blocks from july 2015 to october 2017. We included children from 1 to 18 yers old with low risk febrile neutropenia. Bivariated analysis and microscost was done (direct and indirect).

**Results**: 88 events of NF were registered, 46 ambulatory group (GA) (cefixima oral) y 46 hospitalary group (GH) (cefepima intravenous). GH had 90.9% of security (4 adverse events) VS 100% in GA (p=0.11). 100% of GA had succesful outcome. Median cost was for GH around \$1,100 (american dollars) VS \$120 (american dollars) GA (p\<0.01). Comparison of indirect costs were similar.

**Conclusions**: We observed no inferiority between GA and GH. There is a high economic saving with no adverse event. In our reality this can be very important because the overoccupancy of hospital in extreme. Ambulatory treatment with cefixime can be as safe and affective as the intravenous one. In the economic perspective of health it is a dominant strategy. The following step is the generalization of this strategy in our medical community.

Treatment and Care ‐ Palliative Care {#pbc27455-sec-12590}
------------------------------------

### PO-290. Identification of Palliative Care Needs on Children with Cancer Using Pediatric Palliative Screening (PaPaS Scale) Indonesia Version {#pbc27455-sec-12600}

W. Darpianur^1^, [A. Allenidekania]{.ul} ^1^, H. Hayati^1^

*^1^Faculty of Nursing‐ Universitas Indonesia, Pediatrict Nursing, Depok, Indonesia*

**Background/Objectives**: It is important to assess the needs of palliative care to children with advanced cancer. The purpose of this article is to test the Pediatric Palliative Screening Scale (PaPaS Scale) instrument on the practice of oncology child care as well as to identify the proper of palliative services.

**Design/Methods**: The quantitative design using descriptive analysis approached, applied to pilot the Pediatric Palliative Screening Scale (PaPaS Scale) instrument containing five domains of disease against daily activities, medication expectations and burden, psychological symptoms and pressure, patient choice, parent, or health team, and life expectancy estimate. It tested to 63 children with cancer who hospitalised in cancer children ward in one top referral hospital Jakarta. The instrument was translated into Indonesian language, followed by back translated to achieve the the similarity from the original instrument. Interrater reliability test between three researchers equal to r= 0.68. Validity test were r = 0.661 ‐ 0.907 for 5 domains, with Cronbach α = 0.711.

**Results**: Respondents were more boys (54%), age 12‐18 years old (38.1%). Medical diagnosis proportions were ALL vs Solid tumor 49.2% vs 50.8%, children suffered from anemia, leukositosis, trombocitopenia were 47.6%. Based on screening, there were identified 8 % children no need Palliative care, 33.3% children needs early palliative care, and 58,7% children needs delayed palliative care.

**Conclusions**: The PaPaS Scale instrument is well recommended to serve as a childcare assessment format with cancer to measure the scores of palliative care needs in children. Nurses as healthcare professionals can enhance their roles and competencies in identifying the needs of children with palliative care, so that it can improve quality nursing care.

### PO-291. Pain Assessment and Management of Pediatric Patients with Solid Tumors in a Tertiary Hospital {#pbc27455-sec-12610}

[S. Bravo]{.ul} ^1^, R. Sorrosa^1^

*^1^Southern Philippines Medical Center, Department of Family and Community Medicine‐ Section of Hospice and Palliative Medicine, Davao City, Philippines*

**Background/Objectives**: When a patient is diagnosed with cancer, especially advanced cases, more often than not, an accompanying severe and poorly‐controlled pain is observed. Pediatric age is different from adult patients, in which pain assessment is difficult hence, this symptom is often treated inadequately leading to a poor quality of life. The goal of the study was to describe the pain assessment and management admitted pediatric patients with malignant solid tumors in Southern Philippines Medical Center‐ Children\'s Cancer and Blood Disease Unit (CCBDU), Davao City.

**Design/Methods**: The study reviewed a total of 205 medical charts of admitted patients in Children\'s Cancer and Blood Disease Unit of Southern Philippines Medical Center from the year January 2012 to December 2014. The charts were reviewed for initial pain assessment, medical management of pain and nursing assessment and interventions. A cross‐sectional study design was utilized in this study.

**Results**: The review of medical charts showed no evidence of a complete and consistent recording of initial pain assessment at the time of admission as to identification of provocative and alleviating factors, description of the quality and radiation of the pain, severity and timing. Only 1 patient received an opioid as primary pain medication, but with lacking details of a complete pain evaluation. Nursing pain assessment and interventions were likewise not recorded upon admission. The primary and vital step in an effective pain management is assessment of pain, therefore, if it is not regularly done to pediatric patients with cancer then management of pain will definitely unlikely to happen.

**Conclusions**: The findings suggest that there is a deficiency in the routine evaluation, recording, management and monitoring of pediatric patients with malignant solid tumors.

### PO-292. Ethical Dilemmas Encountered by a Palliative Care Team at a Pediatric Cancer Center in Guatemala {#pbc27455-sec-12620}

[L.M. Bustamante Tuchez]{.ul} ^1^, S. Rivas^2^, G. Paz^1^, P. Valverde^3^, A. Zaidi^4^, P. Close^5^

*^1^Unidad Nacional de Oncologia Pediatrica, Palliative Care, Guatemala, Guatemala; ^2^Unidad Nacional de Oncologia Pediatrica, Medicina Integral, Guatemala, Guatemala; ^3^Unidad Nacional de Oncologia Pediatrica, Oncology, Guatemala, Guatemala; ^4^St. Jude\'s Research hospital, Oncology, Memphys, USA; ^5^My Child Matters Program, Grant mentor, California, USA*

**Background/Objectives**: Ethical dilemmas commonly occur around life threatening illness and are a source of distress for families and medical providers. Unidad Nacional de Oncologia Pediatrica (UNOP) is a large pediatric cancer center that treats over 500 new patients per year. A multidisciplinary palliative care team reviews all patients with ethical issues to provide consultation and support.

**Design/Methods**: A retrospective chart review was performed for patients evaluated between 2010 and 2017. Data was extracted from multidisciplinary team meeting notes. Common ethical themes were identified. Reviewer was a pediatric bioethics‐trained palliative physician.

**Results**: Of X cases reviewed, 207 patients with ethical dilemmas were identified by case notes. 40% (82/207) involved decisions about withdrawing or withholding treatment in Intensive Care (most patients discussed had cerebral death, refractory shock, or non‐response to cancer treatment). 25% (52/207) were decisions related to change in direction of therapy, typically de‐escalation of treatment intensity. 11% (23/207) involved treatment refusal, mostly declining mutilating surgery. 18% (37/207) ethical dilemmas related to beliefs ingrained in Mayan culture. Principles of justice, non‐maleficence, and patient autonomy were central to all discussions with patients. Treatment abandonment was found to have causal relationship with religious beliefs, culture, as well as poverty. Treatment modification decisions for 2 pregnant adolescents, 2 patients with substance abuse, and 6 patients who refused blood transfusions for religious reasons were noteworthy.

**Conclusions**: Ethical dilemmas are common in pediatric oncology patient care. Involvement of bioethics trained professionals in the multidisciplinary care teams helps patients, families, and care providers maintain alignment with sound bioethics principles while making culturally sensitive, difficult decisions about patient care.

### PO-293. Usefulness of Numbing Medication for Painful Procedures in Japan from the Viewpoint of Patients and Medical Professionals {#pbc27455-sec-12630}

[Y. Cho]{.ul} ^1^, A. Iguchi^1^, M. Sugiyama^1^, J. Okubo^1^

*^1^Hokkaido University Hospital, Pediatrics, Sapporo, Japan*

**Background/Objectives**: Children with cancer experience much pain from medical procedures. Many Japanese medical professionals, however, are not concerned about children\'s stress involving procedural pain, because most Japanese deem it a virtue to endure pain. In 2015, Lidocain/ Prilocain (EMLA) numbing cream received approval in Japan for painful procedures with needles. We analyzed the usefulness of this numbing medication from the point of view of both patients\' relief and medical professionals\' effort.

**Design/Methods**: EMLA cream was introduced to patients with cancer, ages 3 to 20 years in our hospital from April, 2016 to the present. By April, 2017, our staff were all trained and we began collecting data right after each procedure regarding: patient\'s receptiveness to EMLA cream use, type of procedure, patient\'s anxiety before procedure, pain reduction efficacy and side effects. We also surveyed patients, their caregivers, and our medical staff for their impressions of the numbing medication.

**Results**: From April, 2017 to March, 2018, 261 painful procedures were performed (117 venipunctures, 70 subcutaneous injections, 34 intramuscular injections, 17 bone marrow aspirations, 19 lumber punctures, 4 PICC line insertions) to 26 patients (17 males, 9 females) whose ages were from 3 to 16 (mean 10). Most of the patients requested EMLA cream regardless of the procedure. In 74% of the procedures, patient felt alleviation of pain. No serious side effects were observed. According to the survey, all patients and caregivers were satisfied with the numbing medication. Some medical staff remarked on the effort required to apply the numbing medication (even commenting that it was a waste of time ‐ delaying procedures) and nervousness about procedural success.

**Conclusions**: Even in Japan, numbing medication reduces the patients\' pain and anxiety, and increases caregivers' satisfaction. Staff\'s troubles can be resolved once they get used to the procedure. The advantage of numbing will soon surpass its inconvenience.

### PO-294. Treatment Refusal and Abandonment in Childhood Cancer at a Tertiary Care Center in North India {#pbc27455-sec-12640}

[H. Dhingra]{.ul} ^1^, A. Jadhav^1^, M. Kalra^1^, A. Mahajan^1^

*^1^Indraprastha Apollo Hospital, Pediatric hematology and oncology, delhi, India*

**Background/Objectives**: Abandonment is defined as failure either to begin or to continue the planned course or missing treatment for a sustained time period to an extent that impacts the ability to cure or definitively control the disease. This continues to be one of the most important reasons for treatment failure in low and middle‐income countries. At our center multipronged efforts are made to limit this. The aim of our study was to determine the magnitude and predictors of abandonment in childhood cancer at our center that caters to patients belonging to varying educational and socio‐economic backgrounds.

**Design/Methods**: Using an established database, a retrospective analysis was conducted on children aged 0--18 years, from Jan 2003 to June 2017. Abandonment rates and its risk factors were abstracted from the database and its correlation with diagnosis, distance, financial constraints, parental educational status and other factors was evaluated.

**Results**: A total of 1357 children were diagnosed with malignancy. Out of which 21.1% (286) are currently undergoing treatment. Of 1071 patients 3.7% refused treatment at diagnosis and 5.1% abandoned at some point during the course. Among abandoned patients, 35.8% suffered from leukemia/lymphoma, 13.7% had solid tumors and 13.7% had brain tumors. In multivariate analysis, financial constraints (aOR = 0.56 (95% \[CI\] 0.35‐0.7, p=0.006) and parental educational status (aOR = 0.5 (95% \[CI\] 0.3‐0.72, p=0.03) were associated with higher risk of abandonment. Other possible risk factors like gender, distance from the treating hospital, diagnosis, predicted outcomes of the cancer and length of treatment protocol were also analyzed, however these were not statistically significant.

**Conclusions**: We hereby report abandonment rates from a tertiary care center and these appear to be much lower than the previous reports from India. Financial constraints and educational status were the major predictors. Continuing efforts are being made to reduce abandonment even further.

### PO-295. Family Experiences and Viewpoints of Palliative and Supportive Care for Children with Cancer: Can We Do Better? {#pbc27455-sec-12650}

[J. Du Plessis]{.ul} ^1^, D. Stones^2^, M. Meiring^3^

*^1^University of the Free State, Paediatrics and Child Health, Bloemfontein, South Africa; ^2^Universtiy of the Free State, Paediatrics and Child Health, Bloemfontein, South Africa; ^3^University of Cape Town, Palliative Care, Cape Town, South Africa*

**Background/Objectives**: Palliative and supportive care needs of children with cancer and their families are unique and require special attention. Development of appropriate services sensitive to the needs of families and based on observed evidence has become more and more recognized. As an introduction to develop and improve supportive and palliative care services for children with cancer, families were questioned regarding their experiences and suggestions for improvements.

**Design/Methods**: In this exploratory, qualitative study using a grounded theory approach, sixteen family members of children with cancer and treated at Universitas Academic Hospital, Bloemfontein, South Africa were interviewed regarding their children\'s standard oncology and supportive/palliative care. Their responses were studied and repeating themes were identified.

**Results**: A number of areas of need were identified: erratic psychosocial support, minimal financial support, poor parental access to basic needs and food provision, preventable errors in procedures and lack of sibling support. Staff were also not always sufficiently equipped to attend to palliative care patients.

**Conclusions**: Supportive and palliative care for children with cancer need to be improved. Family members are a valuable resource and the interviews identified a number of themes, valuable to consider in the expansion of a supportive/palliative service. The intension of the study were to create the awareness that by making small and affordable changes the quality of care the children and families receive can be improved.

### PO-296. « Soi Même Comme Un Autre » ... in Africa {#pbc27455-sec-12660}

[C. Edan]{.ul} ^1^, S. Calmanti^2^, A. Gagnepain^3^, M.L. Viallard^4^, J.J. Atteby^5^, L. Hessissen^6^, M.S. Douçot^7^, C. Thinlot^1^, F. Aubier^1^, C. Patte^1^

*^1^GFAOP, Gustave Roussy, Villejuif, France; ^2^Association La Brise, Equipe Ressource Régionale des Soins Palliatifs Pédiatriques, Bretagne, France; ^3^Sanofi Espoir, My Child Matters Program, Paris, France; ^4^Hôpital Necker, UF Douleur & Médecine Palliative Périnatale, Paris, France; ^5^CHU Trechville, Paediatric Oncology, Abidjan, Ivory Coast\\r; ^6^Children Hospital, Paediatric Oncology, Rabat, Morocco; ^7^GFAOP, Institut Curie, Paris, France*

**Background/Objectives**: Driving a Pediatric palliative care (PPC) training programme in Africa within a curative approach: is it possible ? This abstract reports our experience within the My Child Matters Program, initiated by the Sanofi Espoir Fondation.

**Design/Methods**: In rich countries, programs are moving to embedding palliative care at the time of diagnosis of advanced cancer. It seems reasonable to transfer this knowledge to Africa where the majority of cancers are advanced, and a minority of children can access to cure. Integrating PPC into a curative approach, was therefore our main goal. 65 multidisciplinary trainees from 18 oncology pilot units (PU) and 15 French‐speaking African countries participated in three training sessions (Dakar, Abidjan, Rabat) providing basic knowledge of pediatric palliative care with special attention to pain. During these sessions, projects to improve their practice produced by each team were revised and realistically adjusted. We are currently conducting the in situ evaluation phase of this training.

**Results**: The most striking preliminary result so far: half of the visited units has not started the gait, while half really implemented the training concepts. This illustrates that barriers situate on a socio‐cultural nature rather than a cognitive one leading to differentiated ways to implement pain and PPC principles in each PU, different although African. However, we have to question ourselves: are we in a beneficiency framework ? Are we sure not to be maleficient? The concern of ethics, the question of legitimacy of action can be ignored, or not be regurlarly appreciated but this omission can lead to inefficient or counterproductive actions, and even to a general mistrust.

**Conclusions**: Training will be continued by adapting the offer to these preliminary results. Two different pedagogical formats, in‐depth training and practical training will be proposed depending on the local achievment, in order to improve actually the quallity of care.

### PO-297. The Voices of Cancer‐Bereaved Siblings: A Nation‐Wide Long‐Term Follow‐up {#pbc27455-sec-12670}

[M.E. Eilertsen]{.ul} ^1^, M. Lövgren^2^, A.E. Wallin^3^, U. kreicbergs^2^

*^1^NTNU ‐ Norwegian University of Technology and Science‐, Department of Public Health and Nursing‐, Trondheim, Norway; ^2^Ersta Sko¨ndal University College, The Department of Caring Sciences‐ Palliative Research Centre, Stockholm, Sweden; ^3^Dalarna University, School of Education‐ Health and Society, Stockholm, Sweden*

**Background/Objectives**: Siblings face many challenges and the aim of this paper is to explore bereaved siblings' memories and experiences of their brother\'s or sister\'s illness and death.

**Design/Methods**: In this nationwide Swedish study 174 of 240 (73 %) bereaved siblings participated and 70 % responded to two open‐ended questions on siblings' positive and negative memories and experiences of illness and death. The data were analyzed using systematic text condensation.

**Results**: The bereaved siblings' responses were categorized into four different themes: endurance vs. vulnerability; family cohesion vs. family conflicts; growth vs. stagnation; professional support vs. lack of professional support. Endurance was expressed as the influence that the ill siblings' willpower, good mood and stamina had on the healthy siblings, whereas vulnerability was expressed as the feeling of emptiness and loneliness. Family cohesion was expressed as the bonds being strengthened between family members, whereas family conflicts often led siblings to feel invisible and unacknowledged. In the third theme, most siblings expressed feeling that they grew as individuals in the process of their brother\'s or sister\'s illness and death, whereas others experienced stagnation because of the physical and mental distress they bore throughout this time, often feeling forgotten. In the last theme, most siblings perceived support by physicians and staff at the hospital as being warm, kind and honest, while some siblings had negative experiences.

**Conclusions**: Our study shows that bereaved siblings can have positive memories and experiences, even though the death of a sibling is a distressing situation. The significance of the positive buffering effect on the bereaved siblings' own endurance, personal growth, family cohesion and social support should be noted. The knowledge acquired by listening to the voices of bereaved siblings can be valuable in showing healthcare professionals the importance of supporting siblings of children with cancer throughout the cancer trajectory and afterwards into bereavement.

### PO-298. Factors Influencing Communication About Serious News in Pediatric Oncology {#pbc27455-sec-12680}

[L. Hrdlickova]{.ul} ^1,2,3^, M. Loucka^4,5^, K. Polakova^4^

*^1^University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic; ^2^Charles University, 1st Faculty of Medicine, Prague, Czech Republic; ^3^University Hospital Motol, Pediatric Palliative Care Team, Prague, Czech Republic; ^4^Center for Palliative Care, Center for Palliative Care, Prague, Czech Republic; ^5^Charles University, 3rd Faculty of Medicine, Prague, Czech Republic*

**Background/Objectives**: Delivering bad news is one of the biggest challenges for physicians in pediatric oncology. Evidence‐based guidelines for serious communication in pediatric oncology still remain an unmet need. The aim of this systematic review was to identify factors influencing serious communication in children and adolescents diagnosed with cancer, from the perspective of patients, their families and the care providing physicians.

**Design/Methods**: All qualitative and quantitative papers which had been produced since 1990 in English, French and Czech languages were included, if they reported primary data on children and adolescents with cancer up to 19 years of age, family members of children with cancer and care providing physicians. Only papers evaluating communication at crucial time points of initial diagnosis, relapse, the end of curative treatment and the impending death were included. Thematic analysis method was used to combine and analyze the results.

**Results**: The literature search resulted in total 1405 citations. After removing all duplicates and papers not meeting the eligible criteria, 36 full text articles remained. In total, 94 factors influencing delivering serious news were identified: 46 factors from the perspective of parents, 4 and 17 from the perspective of siblings and patients, respectively and 27 factors from the perspective of physicians. Six groups of factors were created by thematic analysis: setting, physician\'s approach, information exchange, parental aspects, illness related factors and age and mental development. Physician\'s empathy, parents\' protecting role and the amount of information given were identified as the most important factors which need to be taken into account when delivering bad news in pediatric oncology.

**Conclusions**: Communicating serious news in pediatric oncology is a complex task, influenced by many factors. Knowledge of these factors can serve as a foundation for standardized guidance for effective communication with pediatric cancer patients and their families.

### PO-299. A Photovoice Study on Life of Mothers after the Death of A Child from Cancer in Korea {#pbc27455-sec-12690}

[M.A. Kim]{.ul} ^1^, D. Jung^2^, J. Yi^3^

*^1^Myongji University, Department of Social Welfare, Seoul, Republic of Korea; ^2^Seoul National University Hospital, Department of Medical Social Work, Seoul, Republic of Korea; ^3^University of Utah, College of Social Work, Salt Lake City, USA*

**Background/Objectives**: Despite the increasing survival rate of childhood cancer, many parents face the death of a child from cancer. Mothers, as primary caregivers, often experience significant life challenges in adjusting to a world without their child. This study explored the understudied lives of mothers after losing a child to cancer in Korea.

**Design/Methods**: Seven sessions of Photovoice were conducted in 2018 with five mothers (M=45 years old) whose child died from cancer before age 19. The elapsed time since the death ranged from 29 to 80 months. The first session included an orientation with a discussion regarding the selection of themes for future sessions. In Sessions 2--6, participants were asked to bring several photos reflecting the themes and share their stories related to the photos. In the seventh session, they shared their photos with community stakeholders.

**Results**: Five themes were selected by the participants, and subthemes emerged through researchers' thematic analysis of the group discussions: (a) If I had one more day with my child (what I wanted to do for my child; showing my love to my child); (b) Memories with my child (being proud of my child; remembering happy moments; my child is still living in my heart); (c) Dreaming about my child\'s healthy future (realizing many of their dreams; becoming adults who help others; my child enjoying an ordinary life); (d) What gave me strength (my other children; other mothers from a support group; the hope of meeting my child in heaven); and (e) My life that my child would want (helping and energetic mom, forget me not, healthy and happy family).

**Conclusions**: The findings show that mothers who have lost a child to cancer need bereavement care to promote well‐being. This study helps pediatric oncology providers develop bereavement interventions that address parental grief and improve their long‐term quality of life.

### PO-300. Palliative Care Referral Patterns for Children with Cancer: A Three‐Year Retrospective Study {#pbc27455-sec-12700}

[M.S. Kim]{.ul} ^1^, C.H. Kim^1^, Y.J. Moon^1^, I.G. Song^2^, H.Y. Shin^1^

*^1^Seoul National University Hospital, Department of Pediatrics, Seoul, Republic of Korea; ^2^National Cancer Center, Hospice and Palliative Care Branch, Goyang, Republic of Korea*

**Background/Objectives**: Although pediatric palliative care (PPC) has developed worldwide with the increasing number of children with serious illness, the concept of pediatric palliative care is still unfamiliar in Asia. We report on pediatric cancer patient referral patterns to a new PPC team at a university‐affiliated children\'s hospital in Korea.

**Design/Methods**: We examined our PPC database and performed descriptive statistical analysis of patient referral from hemato‐oncology department.

**Results**: From April 2015 to March 2018, 142 patients were referred to PPC team from hemato‐oncology department. Ten patients (7.0%) were not seen in consultation by our team because of refusal of palliative care, referral to another hospital, or immediate death before consultation. Of 132 patients, eight patients were under 1 year‐old, 53 were ages 1 to 9 years, 54 were ages 10‐18 years, and 17 were older than 18. Most of our patients (72.0%) lived in distant region from our hospital and 76 patients (58%) were male. Diagnoses included solid tumor (35.6%), primary CNS (32.6%) and leukemia/lymphoma (29.5%). Significant number of patients were referred while in the pediatric ward (76.5%), and 18.2% and 5.3% were from outpatient clinic and intensive care unit, respectively. Lastly, 84 patients (63.6%) died during the observation period, and of those, 61 (72.6%) died in an inpatient setting, 13 (15.5%) died at home, 9 (10.7%) died at hospice facilities, and one (1.2%) died in the emergency department. At the time of death, most patients (95.2%) did not receive cardiopulmonary resuscitation (CPR) according to the end‐of‐life care plan, but 3 patients received CPR. The median age at death was 11.2 years.

**Conclusions**: We report the palliative care referral patterns of pediatric cancer patients in Korean children\'s hospital. To improve the quality of life of children with cancer, their palliative care needs should be identified and appropriate services be provided.

### PO-301. Palliative Care in Children with Cancer in a Developing Country. Report of the Cooperative Research Group on Pediatric Oncology, Sociedad Mexicana de Oncología {#pbc27455-sec-12710}

[N.A. Lopez‐Facundo]{.ul} ^1^, F. Arreguín^2^, O. Gonzalez‐R^3^, M. Zapata^4^, B. Almazán^2^, L. Velasco^4^, I. Tejocote^5^, C. Morales^5^, L. Vega^6^, N. Macias^7^, S. Chavez^8^, G. Escamilla^6^

*^1^Hospital Materno Infantil del Instituto de Seguridad Social del Estado de México y Municipios, Pediatric Oncology, Toluca, Mexico; ^2^Instituto de Seguridad Social al Servicio de Trabajadores del Estado, Pediatric Oncology, Ciudad de México, Mexico; ^3^Hospital Civil Dr Juan N Menchaca, Pediatric Oncology, Guadalajara, Mexico; ^4^Instituto Nacional de Pediatria, Pediatric Oncology, ciudad de México, Mexico; ^5^Instituto Materno Infantil del Estado de México, pediatric oncology, Toluca, Mexico; ^6^Hospital Infantil Teleton de Oncologia, pediatric Oncology, Queretaro, Mexico; ^7^Hospital Para el Niño de Saltillo, Pediatric Oncology, Saltillo, Mexico; ^8^Hospital Para el Niño de Morelia, Pediatric Oncology, Morelia, Mexico*

**Background/Objectives**: Introduction: In Mexico, the right to palliative care (PC) was established in 2012, and in most pediatric oncology units (OU) they are provided by the staff.

Objective: to report the PC that are provided to pediatric patients with cancer, in different OU units in Mexico

**Design/Methods**: We report a series of cases of patients who received PC in 7 OU units. We evaluated clinical‐demographic characteristics, oncological diagnosis, reason for admission, duration and type of specific PC provided as chemotherapy, radiotherapy, surgery and nonspecific as analgesia, nutritional support, reason and place of death.

**Results**: We included 414 patients, 40% adolescents, 53% male gender, 50% of parents with basic or no education. Residents of urban environment 57%. 80% profess the catholic religion. 59% with soft tissue and metastatic bone sarcomas at diagnosis, most with therapeutic failure in 2 or more schemes. Metronomic chemotherapy was the most used PC, pain control was achieved in 78%, nutritional support 40%, and 70% thanatological. PC duration 0‐40 months. 4. 5% left the CP. 57% of deaths happen at home

**Conclusions**: The PC in our country are an emerging field that must be applied according to international standards to grant dignity to the process of dying in our patients. Our main limitation is the poor infrastructure in human and economic resources, the ignorance of its benefits to the patient, the family, its environment and therefore to the health system.

### PO-302. Difficulties in Providing Palliative Care in Rural India (West Bengal): Experience of an NGO {#pbc27455-sec-12720}

[A. Manna]{.ul} ^1^, N. Mandal^1^

*^1^Narikeldaha Prayas, Palliative Care, East Medinipur, India*

**Background/Objectives**: As in any developing countries state of West Bengal in India has a huge burden of cancer patients in advanced stage coming from rural area where awareness regarding the usefulness of palliative care in rather poor. Our goal is to give a pain free good quality of life in these advanced stage cancer patients. Objective of this study is to identify the main difficulties in achieving the above goal in a rural village setting in India.

**Design/Methods**: Advanced cancer patients in need of palliative care in various villages in of rural India were selected for this study. Their symptoms and managements in that rural surroundings were evaluated by an NGO (under the guidance of a senior palliative care specialist) working in that area. An attempt was made to identify the main obstacles in getting proper palliative care in a rural setting.

**Results**: Pain, fatigue are the main symptoms effecting these patients. In most patients pain and other symptoms control were grossly inadequate due to lack of properly trained manpower in the rural India. However regular homecare visits by a group of social workers were of immense help in the last few months of life. NGO team was well guided by a palliative care specialist.

**Conclusions**: There is a wide gap of trained manpower in this filled in rural areas of India. Dedicated groups from rural area itself need encouragement and proper training, so that difficult symptoms can be managed locally along with necessary social and psychological support to these patients.

### PO-303. Alternate Method to Provide Palliative Care Where There is a Shortage of Caregivers {#pbc27455-sec-12730}

[A. Manna]{.ul} ^1^, N. Mandal^1^

*^1^Narikeldaha Prayas, Palliative Care, East Medinipur, India*

**Background/Objectives**: Due to financial incapability and absence of manpower poor families often fail to carry their advanced cancer patients to the nodal centres. This pilot study will explore whether communication by mobile phone can lessen this burden.

To identify and try to solve to the extent possible the main difficulties in giving palliative care to the terminal cancer patients of the area.

**Design/Methods**: Initially a plan was generated regarding management of an advanced cancer patient in a nodal centre at District Head Quarter. Subsequently every two week a trained social worker attached to nodal centre will follow up and give necessary advice and emotional support to the patients and their families through their registered mobile phone number. Patient\'s family were also encouraged to communicate with the team by phone in case of fresh complain and urgency in between.

**Results**: Since initiation cancer patients were contacted by mobile phone every two weeks to enquire about their difficulties. In 76% of the situation trained social workers could give necessary advice by phone regarding management of their physical symptoms. Moreover patient\'s family were really overwhelmed by the emotional support offered by the team over phone. Only 24% of cancer patients has to attend the nodal centre for expert advice from Palliative Care specialists.

**Conclusions**: This novel approach helped

\* In providing regular physical and emotional support to the patients and their families.

\* In significantly reducing the financial and manpower problems of carrying patients to the nodal units.

\* In improve the quality of life of patients by continuous guidance.

More and more team members can take help of this new strategy for better communication and uninterrupted care.

### PO-304. Pain Continues to be Significant in Children with Advanced Cancer: Using Patient Self‐Report to Measure Symptoms {#pbc27455-sec-12740}

[K. Montgomery]{.ul} ^1^, J. Raybin^2^, C. Balian^3^, E. Gilger^4^, J. Ward^3^

*^1^University of Wisconsin Health, American Family Children\'s Hospital, Madison, USA; ^2^Children\'s Hospital Colorado, Center for Cancer and Blood Disorders, Aurora, USA; ^3^Children\'s Hospital Los Angeles, Children\'s Center for Cancer and Blood Diseases, Los Angeles, USA; ^4^Cincinnati Children\'s Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, USA*

**Background/Objectives**: Children with advanced cancer may experience poorly controlled symptoms. Patient‐reported outcomes are used in symptom‐related research in pediatric oncology; however, the literature is primarily from retrospective chart reviews. The emerging field of patient self‐report allows better understanding of the child\'s experience. Electronic devices are an ideal way to collect this data in real time. The purpose of this study was to evaluate feasibility of prospective electronic data collection and to describe symptom frequency, severity, and level of distress in children with advanced cancer using patient self‐report and parent proxy.

**Design/Methods**: A prospective cohort design included 5 pediatric oncology institutions from across the United States. Eligibility included age between 7‐18 years, English‐speaking, and a diagnosis of advanced cancer (2‐week history of progressive, recurrent, or non‐responsive disease, or a decision not to pursue curative‐focused therapy). Disease and treatment information as well as a modified version of the Memorial Symptom Assessment Scale was used to measure symptom frequency, severity, and level of distress. Measures were collected electronically every 2 weeks. Data was analyzed using descriptive statistics and univariate logistic regression analysis.

**Results**: Forty‐seven dyads (patient and caregiver) participated. Median ages were 13 and 46 years for children and parents, respectively. Primary diagnoses of child participants included leukemia/lymphoma (n=11, 23%), solid tumor (n=21, 45%), and brain tumor (n=15, 32%). The most frequently reported symptoms were pain (n=195/562, 34.70%), lack of energy (n=186/561, 33.16%), and nausea (n=156/560, 27.86%). Presence of disease (P\<0.0001), recent disease progression (P=0.0002), and receiving cancer therapy (P=0.0004) were significant factors on the presence of pain. High intensity cancer therapy was a significant factor on pain frequency (P=0.0445) and pain level of distress (P=0.0224).

**Conclusions**: Electronic data collection is feasible and initial results confirm pain remains a significant symptom that is worsened during intensive treatment in children with advanced cancer.

### PO-305. Assessing Patient Waiting Time and Associated Factors on the Children\'s Out Patient Department of Uganda Cancer Institute {#pbc27455-sec-12750}

[I. Mulyowa]{.ul} ^1^, N. Rose^1^

*^1^Uganda Cancer Institute, Pediatric Oncology, Kampala, Uganda*

**Background/Objectives**: Excessive long waiting time in outpatient clinics in Africa is a constant challenge for patients and the health providers of these facilities. Prolonged waiting times are associated with poor adherence to treatment, missed appointment and failure or delay in initiation of necessary treatment. The time a patient spends at each service point before being attended to by a health provider and the overall total time a patient spends in a health facility from the arrival time to the departure time is a major factor towards the perception of the patient towards the care received.

**Design/Methods**: In this observational study, data collection was conducted on 50 outpatients over a period of 2 weeks. Simple random sampling was used to select respondents in a walk‐ in outpatient clinic set up

**Results**: The average patient waiting time was 55.3mins during the two week period. Majority of the respondents waited in the clinic for 60 minutes to receive the services they had sought. The longest average patient waiting was 13.1 minutes at the doctor\'s office. Most services sought for at the UCI are chemotherapy LAB, Radiology. Whilst most respondents at 69% felt the time they had spent at the clinic was acceptable, many at 52% suggested that improving availability of staff at their stations will help in reducing Patient waiting time at the clinic.

**Conclusions**: Identifying the area of delay and the actual mean waiting time at the clinic is the first step for iimplementing the needed changes in internal processes and practices at the clinic. Majority of the patients are spending an hour at the facility to be served. Most patients felt the overall time spent in the facility is acceptable but suggested that improving availability of health workers at their stations will reduce the patient waiting time and thus enhance service delivery at the clinic.

### PO-306. Care with Love: Parents' Experiences in Caring their Child with Cancer under Palliative Care {#pbc27455-sec-12760}

[M. Nafratilova]{.ul} ^1^, A. Allenidekania^1^, D. Wanda^1^

*^1^Pediatric Nursing, Department Faculty of Nursing Universitas Indonesia, Depok, Indonesia*

**Background/Objectives**: Bereaved parents during palliative care affects the quality of life of children and family. This research aims to explore parents' experiences caring children with cancer in palliative condition.

**Design/Methods**: The research applied descriptive qualitative phenomenology design. Data collection was conducted through an in‐depth interview involving ten parents as participants, while data analysis used was Colaizzi method

**Results**: The eight themes were identified as caring with love, continuity of fighting, mixed‐up feeling, changes of life, being a caregiver for a child, caring children not easy, trying to be normal parents, and seeking help. Parents took care of their children with love by making them comfortable, using love in caring their child, standing by their child, and caring by oriented on their child. The parents shown that they tried to be tough and to keep fighting in caring their child. Mixed‐up feelings were worry, uncertainty, sad, fear, fatigue, ignored feeling and isolated feeling, happy, calm, and touched described by the parents. Parents felt negative changes such as to change their daily activities and to limit the other activities. Their found difficulty to care and communicate with their child, financial problem, limitation of time, less support from their family, and jealousy from the sibling. But parents also give the best for their child, and tried to treated their child as normal as the other children.

**Conclusions**: Parents care their child with love even though they feel mixed feelings, difficulty, and changes in their life during palliative care. They need comprehensive support in playing roles as a primary care giver for their child caring with love. Nurses and all health care professionals involved are expected to be able to cooperate in providing palliative care that is comprehensive and continuous to the children and parents.

### PO-307. Integrating Palliative Care into the Care of Paediatric Patients at a Referral Hospital in Ghana {#pbc27455-sec-12770}

[V. Paintsil]{.ul} ^1^, B. Ossei‐Sekyere^1^, L. Osei‐Tutu^1^, C. Asiamah^1^

*^1^Komfo Anokye Teaching Hospital, Child Health, Kumasi, Ghana*

**Background/Objectives**: Caring for children with life threatening diseases can be difficult and also it could be compounded by insufficient training and competence in symptom management and communication skills by staff members. This affects the quality of care delivered to these patients. The objectives of this study was to determine if services delivered to patients with life threatening diseases could be improved by educating the healthcare providers.

**Design/Methods**: Twenty five doctors and nurses were selected from all the subspecialty wards of the Child Health Directorate of the Komfo Anokye Teaching Hospital ‐ Kumasi. Personnel selected were taken through a 2 day workshop in palliative care. They were educated on communication skills, pain assessment methods and management, symptom control, psychological support and ethical considerations in palliative care among others. Personnel were then divided into 4 groups with a group on each of the paediatric wards to help integrate palliative care services on the wards.

**Results**: About 90% of the healthcare personnel at the cancer ward who were part of the workshop attested to an improved knowledge about palliative care issues after the workshop. They were able to grade pain correctly and give analgesics appropriately to relieve pain. Symptom control for patients became better and healthcare workers became better at the psychosocial support. The different wards selected focal persons who supported patients who needed palliative care. This led to an improved care for patient with life threatening diseases. One healthcare worker who developed an interest in Palliative care later took up a fellowship programme afterwards,

**Conclusions**: In a Low Middle Income Country setting where formal paediatric palliative care programmes are non‐existent, informal education of healthcare personnel can lead to an improved palliative care delivery for children. Those personnel educated can also train the other members on the ward to deliver palliative care.

### PO-308. Palliative Care and Pain Relief Program Implementation for Children with Cancer in Latin‐American Countries {#pbc27455-sec-12780}

[C. Prieto]{.ul} ^1^

*^1^Fundación Nuestros Hijos, Research and Development, Santiago, Chile*

**Background/Objectives**: The objective of this Project was give theoretical and practical tools to physicians, nurses, multidisciplinary oncology teams, and parents, in order to favor the implementation of palliative care and pain relief program in children with cancer, to improve their quality of life, and decrease the socioeconomic burden on families from LA countries. The goal of this program was to implement it in four LA countries: Bolivia, Colombia, Paraguay and Perú, and to contribute to the creation of public policy directed to this issue. In order to do that, 11 professionals from 6 oncology units from these countries\* were invited to participate in a Program of training in palliative care in children with cancer in Chile After that, every unit formulated a palliative care and pain relief local program, which included collaboration between 3 sectors of population (state, private and civil society).

**Design/Methods**: This project involved 3 stages in 2 years: 1° human capital education in Chile (11 professionals; 2 from each medical center, with the exception of 'Hospital del niño' La Paz, Bolivia'), 2° Education to professionals in each country (multidisciplinary teams) and 3°, sensibilization of civil society through technical assistance in administration and money collection, among others. This project also included monitoring and evaluation of achievements and difficulties.

**Results**: Each stage created the following products: 1° The formulation of a pre‐program in palliative care; 2° Formulation of a Local Palliative Care Program, and 3° Implementation of a Palliative Care Program in 5 oncology units.

**Conclusions**: Collaborative actions should be considered in order to improve the management of palliative care in childhood cancer among Latin American (LA) countries, through collaborative actions between the Public health Service and civil society

### PO-309. "Medicina Integral": A Prognosis‐Stratified, Three‐Level, Model for the Delivery of Palliative Care in a Pediatric Oncology Center in Guatemala {#pbc27455-sec-12790}

[S. Rivas]{.ul} ^1^, P. Valverde^2^, M. Bustamante^3^, F. Antillon^2^, G. Paz^1^, A. Zaidi^4^, P. Close^5^

*^1^Unidad Nacional de Oncología Pediátrica, Palliative Care‐ Integral Medicine, Guatemal, Guatemala; ^2^Unidad Nacional de Oncología Pediátrica, Pediatric Oncology, Guatemala, Guatemala; ^3^Unidad Nacional de Oncología Pediátrica, Palliative Care‐ Integral Medicine, Guatemala, Guatemala; ^4^St. Jude Research Hospital, Department of Global Pediatric Medicine, Memphys, USA; ^5^Sanofi Spoir, My child matters program grand mentor, Los Angeles, USA*

**Background/Objectives**: Delivery of palliative care in high income countries has historically been provided in two models: a diagonal model that provides progressive attention as disease worsens, and a dichotomy model that distinguishes care as either "curative" or "palliative." Unidad Nacional de Oncologia Pediatrica (UNOP) is the largest pediatric cancer center in Guatemala. Many children present with advanced disease at diagnosis and healthcare resources are limited. The stratified model of palliative care provision helps allocate resources to the most needy, and Sanofi Espoir Foundation\'s My Child Matters Program helped train nurses and physicians to deliver care.

**Design/Methods**: In 2005 year the "Medicina Integral" multidisciplinary team (MIMDT) was developed as a palliative care service and evolved, in collaboration with pediatric oncology, as the care delivery model for all patients. This prognosis‐stratified model, groups patients into three levels based on chances of survival: Poor prognosis (\<25% chance of survival), Intermediate prognosis (\>25% but \<50%), and Good prognosis (\>50%).

**Results**: Of 550 new cancer diagnoses per year, approximately 10% have poor prognosis. Depending upon functional status, these children receive either possible life prolonging treatment with symptom management, or just symptomatic relief until end of life. 30% patients have intermediate prognosis, they receive need‐based palliative consultation for symptoms, and intention of cancer management is based on disease responsiveness. 60% of patients have good prognosis at diagnosis and receive treatment with curative intent, with MIMDT consultation for difficult symptoms only.

**Conclusions**: A stratified, three‐level model of palliative care provision helps prioritize scarce resources for improving quality of life for children with cancer at all stages of disease trajectory. All patients benefit from the services of MIMDT care, and degree of involvement is determined by the initial categorization into prognosis‐stratified level. Good collaboration and regular communication between MIMDT and the oncology team is crucial for success.

### PO-310. Impact of Pediatric Palliative Care Initiative at Tertiary Cancer Care Hospital of Nepal {#pbc27455-sec-12800}

[K.S. Sharma]{.ul} ^1^, S. Panthee^2^

*^1^B P Koirala Memorial Cancer Hospital‐ Bharatpur‐ Chitwan‐Nepal, Pediatric Oncology and palliative care, Bharatpur, Nepal; ^2^B P Koirala Memorial Cancer Hospital, Palliative care, Bharatpur, Nepal*

**Background/Objectives**: There are around 1400 new pediatrics malignancies each year are estimated and around 700 are registered in Hospital based cancer registry based on B P Koirala Memorial Cancer Hospital(BPKMCH). Nearly a half of diagnosed children with cancer are admitted for treatment and around 75% complete the recommended course. They usually lands to cancer hospital with advanced incurable state for comfort care towards the end of life. New initiative was taken at BPKMCH in 2015 to start palliative unit in pediatric. We want to know the impact of pediatric palliative care initiative in BPKMCH, frequency of admission, diagnosis, common presenting symptom and admission outcome in pediatric palliative care from March 2015 to February 2018.

**Design/Methods**: retrospective, single center case series of children to pediatric palliative care unit for study duration. All record of patients', admission and discharge records was collected and analyzed for age, major admitting symptoms and outcome

**Results**: There were 24, 18, and 36 children admitted respectively in 2015, 2016 & 2017. Children with age \<5 years are 13, 6 to 12 years were 28 and 13 to 19 years were 45 among 86 patients. Sarcomas group of tumors are 43 (50%) were commonest diagnosis. Hematological malignancies (20%) and brain tumor (10%) remain second and third commonest diagnosis among all. 46% of children present with pain 15% for wound care, 12% each for shortness of breath and supportive care, 7% each for Gastrointestinal symptoms and end of life care problems. 19% children were expired at hospice, 35% child brought back to home during end of life and 46% were discharged after making them comfortable after symptoms management.

**Conclusions**: Pediatric palliative care initiative increased the admission. Pain is the most common symptoms for seeking admission. pain management guideline help for management. Majorities' children were discharged with better quality of life.

### PO-311. Patient Reported Symptoms in Advanced Pediatric Malignancies: Effects on Quality of Life {#pbc27455-sec-12810}

[S. Szepetowski]{.ul} ^1^

*^1^Paediatric Trainee, Pediatric Oncology and Hematology Department, Marseille, France*

**Background/Objectives**: In High‐income countries, overall survival of childhood cancer exceeds 80%. For patients dying of cancer, development of Pediatric Palliative Oncology (PPO) is needed to allow the best level of care and quality of life (QOL). This should be supported by Patient Reported Outcomes (PRO) measurement. Our study aims to prospectively describe PRO in children with cancer and no‐realistic chance of cure.

**Design/Methods**: Prospective multicentric survey study of children with high‐risk malignancies. Symptoms were assessed by a questionnaire inspired from SSPedi and open question. Quality of life was assessed by PedQL 4.0 Generic version. Characteristics of patients, disease and treatment were reported as well as socio‐economic factors, physical activity and education.

**Results**: 26 patients were studied between December 2017 and February 2018: 42% had CNS tumor, 7% had acute leukemia and 50% had other solid tumor. Median time from diagnosis was 24.5 months (IQR25‐75: 11‐47.5), median number of treatment lines was 3 (IQR25‐75: 1.75‐4), 23% were included in clinical trial. Education was interrupted in 16 patients and 23 patients reported no physical activity. Median symptoms score was 9/60 and median number of symptom was 5.5. Fatigue and changes in appetite were the most frequent symptoms. Mean QOL score was 39/100 pointing moderate QOL. Factors associated with poorer QOL were: CNS tumor (*p*=0.08), intervention of specialized Pediatric Palliative Care team (*p*=0.001), interruption of education (*p*=0.02), participation to a clinical trial (*p*=0.019), progressive disease (*p*=0.012). After adjustment on confusion factors, QOL was associated to global symptoms score (*p*=0.005).

**Conclusions**: This is the first French study exploring PRO in advanced pediatric malignancies. Results suggest that active reporting and better treatment of symptoms can enhance quality of life in PPO.

### PO-312. Low Dose Metronomic Chemotherapy in Improving Quality of Life in Patients on Palliation {#pbc27455-sec-12820}

[K. V P]{.ul} ^1^, P. Kanvinde^1^, S. Patel^1^, S. Mudaliar^1^, A. Swami^1^, B. Agarwal^1^

*^1^Bai Jerbai Wadia Hospital for Children, Department of Pediatric Haemato‐Oncology, Mumbai, India*

**Background/Objectives**: Metronomic chemotherapy is the use of low dose chemotherapy drugs to target tumor cells directly and indirectly and their microenvironment.

**Design/Methods**: Here we present 6 children in whom metronomic therapy was started for palliation,which significantly improved the quality of life.

**Results**: 1.3 year old mch,case of Early Thymic Precursor‐Acute Lymphoblastic Leukemia(ALL),not on morphological remission mid‐consolidation;parents opted for palliation;put on oral 6‐Thioguanine,Etoposide(21 days) and Dexamethasone(7 days)per month and 6 weekly Vincristine,Cyclophospamide and triple Intrathecal(ITs);on treatment for 10 months; well on follow up.

2.16 year old mch, case of Pre‐B ALL;relapsed second time;parents opted for palliation;put on oral 6‐Thioguanine,Etoposide(21 days) and Dexamethasone(7 days) per month and 6 weekly Vincristine,Cyclophospamide and triple (ITs);on treatment for 12 months;well on follow up.

3.18 year old Fch, Downs with Pre‐B ALL; opted for palliation upfront; started on oral 6‐mercaptopurine, Methotrexate with 5days/month oral prednisolone; on treatment for 13 months; well on follow up.

4.14 year old Fch, Phladelphia chromosome positive Pre B ALL, had early CNS relapse; parents opted for palliation; put on oral 6‐Thioguanine, Etoposide(21 days) and Dexamethasone(7 days) per month and 6 weekly Vincristine, Cyclophospamide and triple ITs and palliative Cranial Radiotherapy; on treatment for 7 months; well on follow up.

5.16 year old McH, T‐ALL, had early combined medullary and CNS relapse; parents opted for palliation; put on oral 6‐Thioguanine, Etoposide(21 days) and Dexamethasone(7 days) per month and 6 weekly Vincristine, Cyclophospamide and triple Its and palliative Cranial Radiotherapy; expired after 5 months of therapy.

6.21/2 year old Mch, diagnosed with stage 4 neuroblastoma with metastasis in brain; parents opted for palliation; to decrease the discomfort, he was given 2 cycles of OJEC, palliative cranial radiotherapy and oral cis‐retinoic acid(14 days a month) and etoposide(21 days a month); on treatment for 12 months on last follow up; doing well on follow up.

**Conclusions**: Here we present the case report of 6 children on palliation on whom metronomic chemotherapy was used successfully to significantly improve quality of life and prolong survival.

### PO-313. Reflections on Acceptance. The Good Life or the Good Death? A Parent\'s Perspective on Palliative Care {#pbc27455-sec-12830}

[S. Waring]{.ul} ^1^

*^1^Royal Childrens Hospital Melbourne, Childrens Cancer Centre Parents Advisory Group, Melbourne, Australia*

**Background/Objectives**: To understand some of the key steps that help a family to build resilience and reach acceptance during a terminal illness and its aftermath, and the vital role Palliative Care professionals can play in assisting or hindering this journey of recovery.

**Design/Methods**: Oral presentation, drawing on stories and examples from three year terminal Neuroblastoma cancer journey of his son who died aged 4 years and two months.

**Results**: Reflecting on the three‐year cancer journey of his son Marmaduke, and in particular the final three months of his life under Palliative Care, Simon Waring addresses the key steps he believes allowed him to navigate the relentless stress and change of paediatric oncology and yet emerge from the loss with a degree of acceptance and gratitude. He draws parallels between these key steps and what he observed to be the successful strategies within the Palliative Care team.

**Conclusions**: The comfort and relief Palliative Care can provide to a paediatric patient has the ability to free a family to focus on the day‐to‐day care and celebration of their child\'s life. This not only impacts the quality of life of the patient, but potentially can allow family members to approach and emerge from the eventual trauma and grief of loss in a stronger and more resilient shape. Many key steps that can help a carer navigate the changes of a terminal illness are the same steps that Palliative Care professionals can employ to engage successfully with both patient and family.

### PO-314. Specialist Palliative Care Service for Children with Life‐Threatening Conditions in Japan: A Nationwide Survey of Resources and Utilization {#pbc27455-sec-12840}

[N. Yotani]{.ul} ^1^, Y. Kizawa^2^

*^1^National Center for Child Health and Development, Palliative Medicine, Tokyo, Japan; ^2^Kobe University Medical School, Palliative Medicine, Kobe, Japan*

**Background/Objectives**: To clarify the availability and utilization of specialist palliative care services among children with life‐threatening conditions in Japan.

**Design/Methods**: A questionnaire was administered to assess the availability of specialist palliative care services among children with life‐threatening conditions. All 427 certified regional cancer centers having hospital‐based adult palliative care teams, 15 certified children\'s cancer centers having pediatric palliative care teams, and 368 medical institutions having a certified palliative care unit, were surveyed.

**Results**: Fifteen percent of adult palliative care teams had experience providing palliative care to children with hematological cancer and 21% had experience with other cancers. More than 90% of pediatric palliative care teams had experience providing palliative care to children with cancer. In contrast, only 2%‐3% of adult palliative care teams and 15% of pediatric palliative care teams had experience providing care for the non‐cancer population. An estimated 12% of children with cancer in Japan used hospital‐based palliative care teams in 2015. Eight children used a palliative care unit in 2015 and of those, 7 (88%) had a solid tumor. An estimated 1.3% of children with cancer who died in Japan used a palliative care unit in 2015.

**Conclusions**: An estimated 12% of children with cancer in Japan used hospital‐based palliative care teams and an estimated 1.3% of children with cancer who died in Japan used a palliative care unit in 2015.

Treatment and Care ‐ Psychosocial (PPO) {#pbc27455-sec-12850}
---------------------------------------

### PO-315. Top 10 Research Priorities for Teenage and Young Adult Cancer in the United Kingdom: Prioritising Need for Psychosocial Research {#pbc27455-sec-12860}

[S. Aldiss]{.ul} ^1^, L.A. Fern^2^, B. Phillips^3,4^, F. Gibson^1,5^

*^1^University of Surrey, School of Health Sciences, Guildford, United Kingdom; ^2^University College London Hospitals NHS Foundation Trust, Division of Oncology, London, United Kingdom; ^3^University of York, Centre for Reviews and Dissemination, York, United Kingdom; ^4^Leeds Teaching Hospitals NHS Trust, Department of Paediatric Haematology and Oncology, Leeds, United Kingdom; ^5^Great Ormond Street Hospital for Children NHS Foundation Trust, Centre for Outcomes and Experience Research in Children\'s Health‐ Illness and Disability, London, United Kingdom*

**Background/Objectives**: The research agenda is frequently set by healthcare professionals and researchers. Young people with cancer, aged 13‐24, have unique physical, psychological and social responses to their diagnoses, with distinct outcomes. We aimed to engage young people, carers and professionals in a systematic method to identify and prioritise research questions relating to cancer in young people.

**Design/Methods**: We followed the James Lind Alliance process. A multidisciplinary steering group was established which included young people. Potential research questions were gathered via an online survey from young people, carers and professionals. Submitted questions were checked to ensure they were unanswered. Interim prioritisation was undertaken via a second survey to identify the highest priority questions. A final consensus meeting was held to reach agreement on the Top 10 research priorities.

**Results**: Eight hundred and fifty five potential questions were gathered from 292 respondents and refined into 208 unique questions. Seven were already answered and 16 were ongoing studies, therefore removed. One hundred and seventy four respondents completed the interim online survey prioritising 30 research questions. Prioritisation of the 30 questions was debated at a workshop attended by 25 young people, carers and professionals from a broad range of roles. The top research priority was, 'What psychological support package improves psychological well‐being, social functioning and mental health during and after treatment?' The Top 10 questions reflect the breadth of young people\'s experiences; recognising that cancer is not always curable, that young people are supported by a wide network of family and friends and future research should focus not only on drug trials but also on delivery of holistic care.

**Conclusions**: The Top 10 research priorities have been identified using a rigorous and person‐centred approach involving stakeholders who are typically not involved in setting the research agenda. These will inform the funding of future research.

### PO-316. Psychosocial Screening Implementation and Quality of Life Outcomes in the Patients, Caregivers and Siblings {#pbc27455-sec-12870}

[M. Barrera]{.ul} ^1^, K. Hancock^1^, J. Chung^2^, S. Alexander^3^, D. Mills^3^, W. Shama^4^, A. Solomon^1^

*^1^Hospital for Sick Children, Psychology, Toronto, Canada; ^2^BC Women and Children\'s, Psychology, Vancouver, Canada; ^3^Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^4^Hospital for Sick Children, Social Worker, Toronto, Canada*

**Background/Objectives**: Pediatric cancer diagnosis can negatively impact the whole family. The Psychosocial Assessment Tool (PAT) was developed to screen for psychosocial risk in newly diagnosed children with cancer and their families. This study evaluated whether providing psychosocial risk information (PAT summary profile) to the patient\'s treating team, improves quality of life (QOL) in patients, caregivers and siblings.

**Design/Methods**: Families were randomly allocated to an intervention (EG, PAT summary profile provided to patient treating team) or control group (CG, no summary provided) in two pediatric cancer centres. Parents (N = 122, mean age = 38 years) of children newly diagnosed with cancer, patients (n = 36, mean age = 12.81) and siblings (n = 25, mean age = 10.74) participated. At 2‐4 weeks post diagnosis (T1) parents completed the PAT, self‐reported (Caregiver Quality of Life Cancer, CQOLC), and proxy‐reported on QOL (Pediatric Quality of Life Inventory, PedsQL‐generic) for patient and sibling; children self‐reported on measures of PedsQL. Measures were completed again 6 months later (T2).

**Results**: At T1, 66% patients self‐ and 68% proxy‐reported total PedsQL scores below acceptable levels; only 16% and 17% of siblings self‐ or proxy‐ reported PedsQL scores below acceptable levels; 21% of caregivers reported total CQOLC scores below acceptable levels. At T2, 67% and 52% of patients and 14% and 19% of siblings self‐ or were reported to have scores below acceptable levels; 19% of caregivers reported scores below acceptable levels. Scores in the EG were not significantly different from the scores in CG for patients, siblings and caregivers, (ps \> 0.05).

**Conclusions**: Testing the benefits of psychosocial screening for patients and families is critical in determining screening validity for clinical implementation. Whether the treating team utilized the screening information to guide their services needs further investigation. Acknowledgements: The Canadian Cancer Society funded this research.

### PO-317. Psychosocial Screening Implementation and Mental Health Outcomes in the Patients, Caregivers and Siblings {#pbc27455-sec-12880}

[M. Barrera]{.ul} ^1^, A. Solomon^1^, J. Chung^2^, S. Alexander^3^, D. Mills^3^, W. Shama^4^, K. Hancock^1^

*^1^Hospital for Sick Children, Psychology, Toronto, Canada; ^2^BC Children and Women\'s Hospital, Psychology, Vancouver, Canada; ^3^Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^4^Hospital for Sick Children, Social Worker, Toronto, Canada*

**Background/Objectives**: Diagnosis of pediatric cancer and treatment can impact the mental health of the affected child and family. The Psychosocial Assessment Tool (PAT) screens for psychosocial risk in newly diagnosed children with cancer and their families. This study evaluated whether providing psychosocial risk information (PAT summary profile) to the patient\'s treating team improves mental health outcomes in patients, parents and siblings.

**Design/Methods**: We randomly allocated families to an intervention (EG, PAT profile provided to treating team) or control group (CG, no summary provided) in two Canadian pediatric cancer centres. Parents (N = 122, M = 38 years) of children newly diagnosed with cancer, patients (n = 36, M = 12.81 years) and siblings (n = 25, M = 10.74 years) participated. At 2‐4 weeks post diagnosis (T1) parents, patients, and siblings completed measures of anxiety and depression (Hospital Anxiety and Depression Scales; Pediatric Index of Emotional Distress); and parents completed the PAT. Measures were completed again 6 months later (T2).

**Results**: At T1, 22 % and 33% of patients, 20% and 36% of siblings and 42% and 28 % of parents were in the clinical range for anxiety and depression scores, respectively. At T2, 15 % and 37% of patients, 5% and 29% of siblings and 34% and 23% of the caregivers scored in the clinical range for anxiety and depression scores. Scores in the EG were not significantly different from those in the CG (p \> 0.05).

**Conclusions**: Sharing psychosocial risk results with the treating team did not result in improved mental health outcomes. It is important to further investigate the degree to which psychosocial screening results impact on provision of psychosocial services and whether additional screening for mental health is needed to improve outcomes. Acknowledgements: The Canadian Cancer Society funded this research.

### PO-318. To Study the Impact of Holistic Care Approach at St Jude India Childcare Centres (SJICC) Through Education, Counselling and Infection Control Programmes {#pbc27455-sec-12890}

[T. Bilgrami]{.ul} ^1^, P. Mainkar^2^, S. Chavan^2^, M. Marathe^3^, J. Banga^4^, V. Parte^5^, P. Kurkure^6^, U. Banerji^7^

*^1^St. Jude India ChildCare Centres, Development, Mumbai, India; ^2^St. Jude India ChildCare Centres, Development, Mumbai, India; ^3^St. Jude India ChildCare Centres, Counsellling, Mumbai, India; ^4^St. Jude India ChildCare Centres, Education, Mumbai, India; ^5^St. Jude India ChildCare Centres, Infection Control, Mumbai, India; ^6^SRCC Hospital‐ Tata Memorial Hospital, Paediatric Oncologist‐ Medical Officer, Mumbai, India; ^7^St. Jude India ChildCare Centres, Chief Executive Officer, Mumbai, India*

**Background/Objectives**: SJICC, established in 2006, provides free accommodation and holistic support for needy families travelling for their children\'s treatment to metropolitan hospitals. This study aims to assess the impact of our education, counselling and infection control programmes.

**Design/Methods**: We interviewed 86 families with children \>8 years having formal schooling, twice between June 2017‐Jan 2018 with structured questionnaires pertaining to accommodation, hygiene, nutrition & psycho‐social well‐being. Twenty‐five fresh admissions (stay\< 6wks), 21 had stayed for \>2 months and 40 were returnees at time of first interview. This forms Phase 1 of the study to be followed by a third interview and home visits in Phase 2.

**Results**: The education of parents markedly impacted their behaviour. Eighty‐eight percent of the parents having up to primary education, showed significant improvement while 99% parents with higher education understood & shared learning in the community. There was a significant increase in comprehending & preventing infection, understanding the importance of good nutrition and hygiene. Fifty‐eight of the 60 families followed the recommended diet, 53 continued to filter/boil water at home and 44 of them succeeded in maintaining similar cleanliness at home. The objective of children\'s education programme is to ensure they return to school after treatment. Of the 60 children who returned home 33 children re‐joined school immediately on returning home, 9 are home‐schooled, 4 will join in the next academic year. While distance(4) and non‐supportive schools(2) relapse of disease(3),medical advice(2) personal reasons(3) prevented the rest. All the families were counselled. Eighty‐eight percent perceived benefit to alleviate anxiety and better understanding of the treatment. All of those who received exit counselling found it helpful in coping when they returned home.

**Conclusions**: SJICC ensures an understanding of the proper care of the child and inculcates a positive attitude of families for better outcome.

### PO-319. Pediatric Cancer Families\' Participation in Whole Genome Sequencing Research in Denmark: Parent Perspectives {#pbc27455-sec-12900}

[A. Byrjalsen]{.ul} ^1^, U. Stoltze^2^, K. Wadt^3^, L.L. Hjalgrim^2^, A.M. Gerdes^3^, K. Schmiegelow^2^, A. Wahlberg^4^

*^1^Rigshospitalet, Department of Clinical Genetics and Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark; ^2^Rigshospitalet, Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark; ^3^Rigshospitalet, Department of Clinical Genetics, Copenhagen, Denmark; ^4^University of Copenhagen, Department of Anthropology, Copenhagen, Denmark*

**Background/Objectives**: We examined parent perspectives on participating in Whole Genome Sequencing (WGS) research in the weeks following a cancer diagnosis.

**Design/Methods**: As an embedded part of the project STAGING (Sequencing of Tumor And Germline DNA -- Implications for National Guidelines), a qualitative parent perspective study was conducted by a physician and an anthropologist to document the pragmatic, social, and ethical dilemmas faced by families when deciding on participation in pediatric WGS research. Following genetic counselling, systematic debriefings were held between the anthropologist and the physician. The anthropologist subsequently carried out semi‐structured, in‐depth parent interviews (N=30 parents to 15 patients). Interviews were transcribed verbatim. Debriefings and interviews were read and thematically analyzed by the anthropologist and physician separately, followed by meetings for consensus on key themes.

**Results**: Parents were approached 2‐28 days after diagnosis. The majority reported that an early approach had been acceptable for them, although one family stated it was too early. Participation in STAGING was explained in terms of altruism and a desire to learn why their child had developed cancer. Most parents requested full feedback on genomic findings, although some described being torn between wanting to receive cancer and other disease predisposition findings and worrying that they would become patients‐in‐waiting. A small minority wanted as little information returned as possible. Some parents openly disagreed about the amount of information they wanted reported back, but following family deliberations reached a consensus (a precondition for participation in STAGING).

**Conclusions**: Parents of newly diagnosed childhood cancer patients articulated numerous dilemmas arising from participation in WGS research. Enrollment at diagnosis is feasible however flexibility from researchers is essential. Notwithstanding high participation rates and a tendency to choose full disclosure, caution regarding parental views on participating in WGS research is warranted. Follow‐up studies after families have received WGS findings are necessary.

### PO-320. The Voices of the Siblings to Patients of Childhood Cancer: A Qualitative Study About the Social Consequences of Siblings to Childhood Cancer Patients {#pbc27455-sec-12910}

[L.T. Carlsen]{.ul} ^1,2,3^

*^1^The Danish Cancer Society, Patient Support and Community Activities, københavn, Denmark; ^2^The child cancer foundation, The child cancer foundation, Copenhagen, Denmark; ^3^Aalborg University, Department of Sociology and Social Work, Aalborg, Denmark*

**Background/Objectives**: During the latest decade, research indicates that siblings to childhood cancer patients are at risk of experiencing social challenges. This qualitative study aims to generate knowledge about the challenges and needs expressed by siblings to childhood cancer patients during the difficult time of their sibling\'s treatment. The study also includes the perspective of both the parents and the child diagnosed with cancers, perspective on the sibling\'s situation.

**Design/Methods**: The study is philosophically informed by a phenomenologically reference framework. A grounded theory approach is used to fulfill the aim of the thesis and to generate inductive new knowledge about social consequences of childhood cancer.

Data gathering was conducted through interviews and observational studies and included 42 childhood cancer patients (3‐17 years), 19 childhood cancer survivors (18‐39 year), 37 siblings to childhood cancer patients (5‐17 years), and 37 parents to childhood cancer patients from collectively 76 different families. The survivors and parents were also asked to give their own and their children\'s personal details, including disease history, in a written document, respectively.

**Results**: The qualitative data reveals four patterns of interaction between the parents and siblings: 1)receives help without asking, 2)receives help when asking, 3)strains and ask for help but the parents cannot meet the need, and 4)does not ask for help and the parents do not recognize or do not have the surplus to meet the needs. The patterns indicate a variety and each child can experience and exhibit different strategies of coping to handle the given situation and the absence of attention from the parents.

**Conclusions**: This study reveals four dynamic patterns of coping for siblings to childhood cancer patients in their relation to their parents. The patterns can help social and healthcare professionals to anticipate some of the consequences for the siblings.

### PO-321. Academic and Social Challenges Experienced by Patients of Childhood Cancer: A Qualitative Study about the Social Consequences of Childhood Cancer {#pbc27455-sec-12920}

[L.T. Carlsen]{.ul} ^1,2,3^

*^1^The Danish Cancer Society, Patient Support and Community Activities, københavn, Denmark; ^2^The child cancer foundation, The child cancer foundation, Copenhagen, Denmark; ^3^Aalborg University, Department of Sociology and Social Work‐ Aalborg, Aalborg, Denmark*

**Background/Objectives**: Over the last 20 years, an increased survival rate is seen in Danish childhood cancer patients as well as an intensified treatment protocol. As a result, there is an increasing number of both childhood cancer patients living with side effects, and children and young adults living with late effects of childhood cancer and.

The purpose of this qualitative study is to reduce the impact of childhood cancer at the everyday life in families with a diagnosed child.

**Design/Methods**: The study is philosophically informed by a phenomenologically reference framework. A grounded theory approach is used to fulfill the aim of the thesis and to generate inductive new knowledge about social consequences of childhood cancer.

Data gathering was conducted through interviews and observational studies and included 42 childhood cancer patients (3‐17 years), 19 childhood cancer survivors (18‐39 year), and 37 parents to childhood cancer patients. All subjects provided personal details, including disease history, in a written document.

**Results**: The qualitative data reveals academic and social challenges experienced patients of childhood cancer. The challenges are attributable to side effects and absence from school caused by hospitalizations. Patients of childhood cancer also experienced a deficient understanding of their situation from their classmates contribute to their experienced challenges, and the children with cancer often report that they feel more mature than their classmates. The study indicate, that the individual schools way of handling the situation, affects the way the child with cancers experiences both the academic and social challenges.

**Conclusions**: This study reveals academic and social challenges for both patients of childhood cancer patients. Overall, the data elaborate the importance of the professionals in the school as well as an engaged parents' group from the classmates.

### PO-322. The Family‐Pediatric Oncologist Relationship in the Age of Social Media {#pbc27455-sec-12930}

[A. Caruso Brown]{.ul} ^1^

*^1^SUNY Upstate Medical University, Pediatrics, New Hartford, USA*

**Background/Objectives**: Parents and families of children with cancer increasingly turn to social media to connect with families facing similar challenges. These multidirectional interactions are not only sources of psychosocial support but are frequently sources of medical information as well. These interactions have the potential to meaningfully change the dynamics of power, control and trust between families and pediatric oncologists.

**Design/Methods**: After surveying 80 pediatric oncology professionals regarding experiences with social media, key informant interviews were conducted with a subset of participants (n = 10) who agreed to discuss those experiences in more depth. Interviews were transcribed and iteratively coded for distinct ethical questions raised.

**Results**: Encounters in which families discussed information acquired from social media were particularly challenging when families posed questions that were outside providers' scope of practice and when the medical literature did not offer definite answers. They were also potentially time‐consuming, dominating encounters that pediatricians intended to use to address other issues. Ethical questions identified included: In these situations, whose priorities for a clinical encounter ought to take precedence? When, if ever, can decision‐making be ceded to families and their online sources? Is it ethical for pediatric oncologists to comment on the reliability of secondhand information, or should they be expected to evaluate online sources and verify claims themselves? What is the role of the pediatric oncologist, ultimately, in this interaction? When the confidentiality owed to one patient conflicts with another patient\'s right to accurate information, how should pediatric oncologists proceed?

**Conclusions**: It is possible to navigate these types of encounters in ways that maintain respect and build trust, but it requires openness on the part of pediatric oncologists and acknowledgment that cultural change is inevitable.

### PO-323. Arc Children\'s Centre: Lessons Learnt from Setting up a Community Care Centre for Children with Cancer {#pbc27455-sec-12940}

G. Lee^1^, R. Paul^2^, [M.Y. Chan]{.ul} ^3^

*^1^Arc Children\'s Centre Co Limited, Operations, Singapore, Singapore; ^2^Arc Children\'s Centre Co Limited, Nursing, Singapore, Singapore; ^3^Arc Children\'s Centre Co Limited, Board Vice‐Chairman, Singapore, Singapore*

**Background/Objectives**: Children on treatment for cancer are often not able to attend school. Arc Children\'s Centre (Arc) was set up to provide a safe environment for these children to socialise, learn and develop with fun and educational activities. At the same time, parents are given respite to rest and recuperate. This is the first such community care centre in Singapore.

**Design/Methods**: Arc opened in August 2011 with charity funding. Referrals to Arc are from the doctors. Patients and their siblings are transported to and fro the centre and if financially able, pay a nominal attendance fee of S\$10. They are provided education according to their level, and participate in creative and muscle strengthening activities like Zumba. Counselling services are also available for patients and their families.

**Results**: Since August 2011, 177 children and 64 siblings were referred from the hospitals. Diagnoses included brain tumour (30), leukaemia (98), neuroblastoma (14) and others (35). Other than helping to prepare for transition to normal school, Arc activities help children to be more confident and less withdrawn. Children from foreign countries who are often isolated are better adjusted and learning English. The sibling program helps to bridge the gap between the sick child and the healthy sibling. The parents have also benefitted as they form an informal support group for each other.

**Conclusions**: When given the chance, children have the strength and resilience to deal with their illness. They develop best when they are with children like themselves; they learn to share, comfort and forgive each other and learn about responsibility when they help to look after the little ones as well. However, they need boundaries and a healthy, loving environment to develop and Arc aims to provide that. Arc has since extended the program to include terminally ill children and children with other life‐threatening illnesses.

### PO-324. Quality of Life and Morbidities of Childhood Cancer Survivors in Hong Kong {#pbc27455-sec-12950}

[W. Chan]{.ul} ^1^, D. Cheuk^1^

*^1^Queen Mary Hospital, Paediatrics and Adolescent Medicine, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: With improvement in medical oncology and prolongs survival of childhood cancer patients, long‐term morbidity and quality of life (QoL) become increasingly important issues to address. Majority of QoL study were generated from Western developed countries while local data is lacking. This study is to provide a comprehensive systematic review of literatures studying local QoL, taking account into potential cultural differences and validity.

**Design/Methods**: Literature review was performed using PubMed, Ovid Medline, Cochrane Library and Google scholar using defined keywords 'QoL, 'cancer or malignancy or neoplasm or cancer survivor', 'child or adolescent or paediatric' and 'HK\'. Search was limited to publications written in English or Chinese with full text available published in the past 20 years since 1st January 1995.

**Results**: Cancer and its treatments have great impact on physical and psychosocial well‐being as well as overall QoL in HK Chinese childhood cancer survivors. Being female, older age, longer survival time, and specific cancer diagnoses were associated with poorer physical and mental adaptation. Health‐related quality of life was negatively correlated with psychological distress. Integrated adventure‐based training program is effective in promoting their physical activity level, self‐efficacy and quality of life.

**Conclusions**: This is the first literature review on local publications concerning QoL and morbidities of childhood cancer survivors in HK, which demonstrate compatible conclusions as in international studies that cancer and its treatments have long term effects on overall QoL in HK Chinese childhood cancer survivors. Further qualitative and quantitative researches are warranted for better understanding of the situation in local context. Early recognition of vulnerable disease groups, early identification and intervention of psychosocial risk factors in both patients and caretakers would improve quality of life in HK paediatric oncology patients in the long term.

### PO-325. Psychometric Properties of the Chinese Version of the Fatigue Scale for Children Surviving from Blood Cancer {#pbc27455-sec-12960}

[O.K. Chung]{.ul} ^1^

*^1^University of Hong Kong, School of Nursing, Hong Kong, China*

**Background/Objectives**: Cancer‐related fatigue is the most common physical concern reported by childhood cancer survivors. Previous studies indicate that up to 30% of survivors report feelings of fatigue. The fatigue can be distressing for children, as it may exacerbate other unpleasant symptoms such as nausea, dyspnoea and pain, substantially impairing their quality of life. It is vital, therefore, for healthcare professionals to develop and evaluate appropriate interventions that can help reduce fatigue among these population groups. First, however, the availability of a valid and reliable instrument that accurately documents the level of fatigue among childhood cancer survivors is crucial before any appropriate interventions can be appropriately planned and evaluated. This study aimed to test the psychometric properties of the Chinese version of the Fatigue Scale for Children

**Design/Methods**: The Fatigue Scale for Children was first translated from English into traditional Chinese. A cross‐sectional study was then conducted. Two hundred children who have survived blood cancer and attend medical follow‐up at the outpatient clinic of a public acute‐care hospital in Hong Kong were invited to participate. Participants were asked to respond to the Chinese version of the Fatigue Scale for Children, Center for Epidemiologic Studies Depression Scale for Children, and Pediatric Quality of Life Inventory. The internal consistency, content validity and construct validity and test--retest reliability of the Chinese version of the Fatigue Scale for Children were assessed. Exploratory and confirmatory factor analyses were conducted to test the construct\'s validity.

**Results**: The newly‐translated scale demonstrated adequate internal consistency, good content validity and appropriate convergent and discriminant validity. Exploratory and confirmatory factor analyses added further evidence of the construct validity of the scale.

**Conclusions**: Results suggest that the newly‐translated scale can be used as a self‐report assessment tool in assessing fatigue of Hong Kong Chinese children surviving from blood cancer.

### PO-326. Comparison of the Anxiety Levels in Children with Acute Lymphoblastic Leukemia and their Well Siblings using the Child Drawing: Hospital Manual {#pbc27455-sec-12970}

[E. Culminas]{.ul} ^1^

*^1^General Pediatrics‐ Philippine Children\'s Medical Center‐ Quezon City‐ Philippines, General Pediatrics, Quezon City, Philippines*

**Background/Objectives**: The study aims to determine and compare the anxiety of children with acute lymphoblastic leukemia and their well siblings based on Child drawing: Hospital manual and to identify factors associated with the level of anxiety.

**Design/Methods**: A prospective cross‐sectional study was done in the hematology‐oncology outpatient clinic and private clinics of hema‐oncology specialist in tertiary pediatric hospitals. The study included children five to eleven years old diagnosed with Acute Lymphoblastic Leukemia (ALL) and their well siblings.

**Results**: A total of forty dyads of participants were included in the study. ALL patients presented higher anxiety scores than their siblings. However, this was not statistically significant. There is a weak direct correlation between overall anxiety scores of ALL patients and their siblings (p = 0.017). There is insufficient evidence to demonstrate an association between select clinical factors with anxiety scores. The linear regression model showed 49.77% in the variation of the anxiety scores.

**Conclusions**: There is a direct correlation between overall anxiety scores of ALL patients and their siblings. There is a positive association with larger family size and child\'s response to sibling\'s illness. A larger families are likely to have a healthier environment. The study showed low to average anxiety levels among participants which may be related to quality of care and support given by the institution and inherent resiliency of the family.

### PO-327. Meeting the Social Needs of Young Children with Cancer: A Transdisciplinary Implementation of Research Results {#pbc27455-sec-12980}

[L. Darcy]{.ul} ^1^

*^1^University of Borås, Faculty of Health‐ Worklife and Welfare, Borås, Sweden*

**Background/Objectives**: Young children are increasingly surviving their cancer and their experiences of living with cancer are crucial to providing evidence based care. Their own experiences of everyday life with cancer were elicitated by interview shortly after diagnosis and six, 12, 18 and 36 months later (2011‐2015). Qualitative analyses of the results described the child living with cancer over a three year period as a child apart, striving to live an everyday life. A strong sense of loneliness, isolation, feeling left out and feeling different persisted throughout the study. Emerging issues of survivorship, such as the child\'s social needs, were revealed that need to be addressed as young children learn to live an everyday life with cancer and the effects of its treatment.

**Design/Methods**: The present paper aims to describe the actions taken by the Child Life Specialist Department at a paediatric hospital in the West of Sweden based on these results.

**Results**: Child Life Specialists (CLS) play an integral role on the oncology team. Guidelines and working practise were developed to meet the child\'s social needs. CLS are now present at visits made to preschool/schools together with the consultant oncology nurses and maintain contact with preschool/school personnel over time. Through brochures and meetings the CLS spreads information on the child\'s social needs to surrounding municipalities and other CLS teams in Sweden.

**Conclusions**: The results of studies with young children with cancer need to be implemented and evaluated in clinical care. Traditionally, studies within nursing are disseminated to and implemented by nursing staff. The present study shows how other disciplines can be involved in the dissemination and implementation of nursing study results‐ with the child and the child\'s needs as the guiding point.

### PO-328. A Follow‐up Program to Create Comfort and Security for Children Newly Diagnosed with Cancer and their Parents {#pbc27455-sec-12990}

[L. Dyrgaard]{.ul} ^1^, H. Hansson^1^, G. Petersen^1^

*^1^Copenhagen University Hospital Rigshospitalet‐, Pediatric Hematology Oncology Department, Copenhagen, Denmark*

**Background/Objectives**: Children with cancer are often discharged from the hospital shortly after being diagnosed. The treatment requires that both parents and child are trained to observe symptoms and handle necessary care tasks at home e.g. administration of medicine, central line care, and nasogastric tube feeding. Inadequate knowledge and training may affect both patient security, sense of security, and the overall quality of the treatment.

The aim of this study is to support parents to gain necessary knowledge and training to care for their child at home.

**Design/Methods**: We developed a systematic follow‐up program to ensure that parents gain necessary knowledge and skills to provide care tasks. Children in all ages and diagnoses and their parents are invited to participate. Shortly after the first discharge from the hospital, the family receive a follow‐up visit by a nurse at the family\'s home, or a follow‐up video call if they live more than 50 km from the hospital. The program is evaluated with a web‐based questionnaire measuring e.g. usability and sense of security, which the parents complete after the home visit.

**Results**: From June 2017 to February 2018 26 families received a follow‐up visit and 3 families declined to participate. 21 families returned the questionnaire. 17 parents reported "it was highly usable" and 3 "it was very usable". Prior to the follow‐up visit, 6 of the families reported to be "very secure" being at home, and after the follow‐up visit this number increased to 13. All families reported that their questions were adequate answered at the follow up visit. 12 of the parents would like a second follow‐up visit.

**Conclusions**: A follow‐up visit can enhance the parents' knowledge and training, and improve sense of security after the first discharge from the hospital.

### PO-329. Childhood Cancer: Should Parents Stop Living? {#pbc27455-sec-13000}

[J. Elhoudzi]{.ul} ^1^, M. elbouaychi^1^, M. elbaz^1^

*^1^University Hospital Mohammed VI‐, Pediatric Hematology and Oncology, Marrakesh, Morocco*

**Background/Objectives**: Having a child with cancer is the worst experience parents could have in their lives. in addition to take care of child and his or her disease, they have also to face their own fatigue,

anxiety, insomnia, and manage the hospitalization, travel, economic problems. This burdens heavy to bear, this chronic stress can lead to burnout.

**Objective**: To evaluate the impact of a child\'s cancer on the physical, emotional, mental, social and behavioral well‐being of parents.

**Design/Methods**: Parents of children followed for more than 6 months, in our center. were interviewed during 2 months

**Results**: 58 persons were questioned. 86% of our patients live outside Marrakech, 65% of parents were illiterate, 82% without insurance. and low income. 53% have already received medical education on warning signs and emergency care. 22% have already been hospitalized. 65% of the mothers felt that their husband was not supportive. 56% had conflicts with their husband and 5% divorced.13% moved to Marrakesh and 10% had to stop their professional activity. 84% of parents feel that their quality of life has been disturbed. 74% have sleep problems, 48% have eating disorders and they all have an anxiety disorder. Only 8% are followed by a psychologist and 84% would like to be. Reason of this anxiety was fear of death of the sick child in 65% of cases, economic problems (86%) and living far form center (56%). According to ZARIT score, burden was mild to moderate in 17% of cases, moderate to severe in 56% and severe in 15%. According to parents, their quality of life can be improved by facilitating access to care (65%), having more financial resources and having more help (48%).

**Conclusions**: Parents are often supposed to be the supporters of their children, so they forgot about themselves. Most of them had emotionnel and familial problems.

### PO-330. Psycho‐Oncology in Russia: Parent Psychological Distress and Sleep Outcomes on the Paediatric Oncology Ward {#pbc27455-sec-13010}

[S. Ellis]{.ul} ^1,2,3^, M. Burns^1,2^, C. Wakefield^1,2^, T. Egorkina^1^, M. Aralova^4^

*^1^Sydney Children\'s Hospital, Kids Cancer Centre, Sydney, Australia; ^2^University of New South Wales, School of Women\'s and Children\'s Health‐ UNSW Medicine, Sydney, Australia; ^3^The University of Sydney, School of Psychology, Sydney, Australia; ^4^Southern Federal University, Psychophysiology and Clinical Psychology Department, Rostov‐on‐Don, Russia*

**Background/Objectives**: Sleep quality is a robust predictor of parental quality of life during a child\'s cancer treatment. However, caring for a child with cancer may negatively impact sleep quality due to a range of complex psychological, physical and environmental factors. The experiences of families from post‐socialist countries, such as Russia, are largely underrepresented in international psycho‐oncology literature. Therefore, this study aimed to determine the prevalence of Russian parental psychological distress, as well as predictors of parental sleep when staying on the paediatric oncology ward.

**Design/Methods**: We recruited 74 parents of children completing chemotherapy and 74 parents of healthy children attending periodic health examinations at the Children\'s Regional Hospital of Rostov‐on‐Don, Russia. Parents completed a survey assessing demographic/clinical outcomes, sleep (St Mary\'s Sleep Quality Questionnaire), and psychological distress (DASS). We examined between‐group differences on demographic, sleep and psychological outcomes and conducted a multiple linear regression to identify predictors of parental sleep.

**Results**: Compared with controls, parents of childhood cancer patients had significantly more male children (*x*2(1) =11.92, p\< .001) and worked less hours of paid employment (*t*(124)=‐13.93, *p*\<.000). They also reported significantly lower sleep duration (*t*(143)=‐6.22, *p*=0.002), increased night‐time awakenings (*t*(135)=6.94, *p*\<.000), worse sleep quality (*x*2(1)=24.4, *p*\<0.000) and significantly higher scores on all DASS sub‐scales (depression t(145)=3.67, *p*\<.038; anxiety *t*(145)=5.89, *p*\<.000; stress *t*(145)=10.64, *p*\<.000). Significant predictors of sleep duration for parents of cancer patients included their overall health (*p*=.002), age (*p*=.018) and amount of sleep attained during the previous week (*p*=.012).

**Conclusions**: Russian parents sleeping on the paediatric oncology ward experience poor sleep and high rates of psychological distress. This may reflect challenges in the current oncological care system in Russia, including limited access to psychosocial support. Future research and clinical interventions targeting modifiable factors associated with sleep and distress may improve parents' quality of life and ability to care for their unwell child.

### PO-331. Identifying the Severity of Psychosocial Symptoms Among Parents of Children Diagnosed with Cancer {#pbc27455-sec-13020}

[A. Fatima]{.ul} ^1^, S.S.A. Zaidi^2^

*^1^SKMC & RC, Pediatric Onlcology, Lahore, Pakistan; ^2^wecare medical centre, medical centre, lahore, Pakistan*

**Background/Objectives**: Each year almost 18,000 children are diagnosed with cancer in Pakistan. Majority of these children are underprivileged and hence the cancer become the leading cause of death. The diagnosis and treatment of childhood cancer is a continuous emotional distress for both parents particularly mothers. We aim to identify the severity of depression, emotional distress, stress and mental fatigue among parents of children diagnosed with cancer.

**Design/Methods**: A cross sectional study was conducted in Shaukat Khanum Hospital, Lahore from March 2014 to April 2015. Exclusion and Inclusion criteria were made and One Hundred and fifty participants were enrolled in the study. Socio demographic characteristics were evaluated using Beck Depression Inventory and socio demographic form. Severity of depression was estimated by using Hamilton D (HAM‐D). Various variables were analysed including parent\'s age, level of education, socioeconomic status of family and gender and number of children.

**Results**: 68% of the participants exhibited severe range of depression. 27% showed moderate depression where as 5% participants were showing the mild range of depression. An inverse co relation was found between educational status, occupational status(paid or unpaid), their marital status, socioeconomic family status and depression. Mothers 71% were found be more depressed than fathers.

**Conclusions**: We concluded that majority of mothers suffer from psychosocial symptoms particularly depression and it is mainly associated with some factors. There is need to incorporate parents especially mothers into the diagnosis and treatment process so that we can over come the effects of parental depression on the health outcomes of children diagnosed with cancer.

### PO-332. Overcoming Barriers to Psychosocial Golden Standard Implementation in Paediatric Oncology: Catania Experience {#pbc27455-sec-13030}

[C. Favara‐Scacco]{.ul} ^1^, K. Maslak^1^, A. Di Cataldo^2^, E. Randazzo^3^, L. De Grandi^3^, M. Inzirillo^1^, C. Lo Giudice^1^, S. Cultrera^1^, G. Russo^2^

*^1^University Hospital Policlinico Vittorio‐Emanuele, Department of Pediatric Hematology and Oncology, Catania, Italy; ^2^University of Catania, Department of Pediatric Hematology and Oncology‐ Department of Clinical and Experimental Medicine‐, Catania, Italy; ^3^LAD Onlus, LAD Onlus, Catania, Italy*

**Background/Objectives**: Curing cancer while taking care of the child and his family is a golden standard of the paediatric cancer treatment, as the healing process goes far beyond the hospital. In 2016 our Center had a total of 1,131 admissions, curing children from Eastern Sicily. The growing number of patients challenges the community and local institution resources to create an environment sensible to the child\'s treatment and developmental needs from the time of diagnosis throughout survivorship.

**Design/Methods**: WonderLAD project follows the 'Cure&Care' approach to cancer treatment. It is composed of a structural and a functional part. The structural one consists of the edification of a 1,870 square meters facility, designed by a team of architects that won a dedicated international architecture competition. The functional part consists of a series of normal‐life activities guided and supported by a psychological team. Art and creativity are tools used to stimulate child\'s inner vitality to counterbalance an anguishing experience of cancer.

**Results**: Many non‐governative organizations believed in the project offering initial economic support. This year the Ministry of Labor and Social Policy offered remaining founds necessary to complete the construction. The Municipality of Catania has granted the right to use the ground of 17,500 square meters to erect the building. The facility is designed to offer spaces to perform daytime activities and night reception to six families. The project follows the principles of bio‐architecture to assure the young patients with impaired immune system a healthy environment. Opening ceremony will be on the 20th of November.

**Conclusions**: Conceived from a long‐term clinical experience and designed upon child and family\'s needs, WonderLAD fills the gap of a transitional space between the hospital care and every‐day life. It is the result of a coordinated effort where private initiative and public institution converge towards a single purpose.

### PO-333. Gabay Magulang: A Parent Empowerment Program {#pbc27455-sec-13040}

[A.S. Fernandez]{.ul} ^1^, N.N. Jose^1^

*^1^Kythe Foundation Inc, child life program department, Quezon city, Philippines*

**Background/Objectives**: Gabay Magulang or Parent Guide is a collaboration between Kythe Foundation Inc and selected medical students to provide support for and empower parents of children newly diagnosed with cancer. With the guide, parents would be better able to understand and care for their children. The program aims to develop and empower core Parent Leaders who will take the lead in educating and supporting other parents.

**Design/Methods**: Focus group discussions (FGDs) were conducted with parents of children with cancer to better understand their needs and how best they can be supported. With the information gathered, a draft of the guide was written by the medical students and forwarded first to Kythe staff and then to pediatric hematologists /oncologists for editing. Four pediatric hematologists/ oncologists edited the booklet before publishing. From the initial FGDs, a select group of core parents were invited to be Parent Leaders. Four training sessions on the use of the guide were conducted by Kythe. After the training, the Parent Leaders led learning sessions with parents of newly diagnosed children.

**Results**: Two programs are run every year with four months for each program. Monthly learning sessions are conducted in the four months by the Parent Leaders using Gabay Magulang. In these four sessions, Kythe staff are present to provide support, when needed, and a pediatric oncology fellow or consultant is on hand to either discuss a specific topic or provide answers to questions that arise.

**Conclusions**: Empowering parents to be active partners and advocates in the holistic healing of their children undergoing treatment for cancer is essential. The Gabay Magulang program has published a parent guide, trained Parent Leaders to lead learning sessions and has provided parents with opportunities for better understanding of their children\'s illness and treatment and answered questions through sessions with a pediatric oncology fellow or consultant.

### PO-334. Things that Matter: Adolescent and Young Adult Patients\' Priorities during Cancer Care {#pbc27455-sec-13050}

[D. Graetz]{.ul} ^1^, K. Fasciano^2^, S. Block^3^, J. Mack^4^

*^1^St. Jude Children\'s Research Hospital, Hematology/Oncology, Memphis, USA; ^2^Dana Farber Cancer Institute, Psychology, Boston, USA; ^3^Dana Farber Cancer Institute, Psychiatry, Boston, USA; ^4^Dana Farber Cancer Institute, Oncology, Boston, USA*

**Background/Objectives**: Adolescents and young adults (AYAs) experience cancer in the midst of emerging identity and life goals. We investigated AYAs' priorities during cancer treatment and the balance between psychosocial concerns, cure‐directed therapy, and potential late effects.

**Design/Methods**: We surveyed 203 AYA cancer patients (response rate 74%) aged 15‐29 treated at Dana‐Farber Cancer Institute, Boston, Massachusetts, and their oncologists. Patients were approached within 6 weeks of diagnosis and asked to rate the importance of aspects of cancer treatment, cancer outcomes, and life during treatment; 193 patients completed all relevant questions. For each attribute, response options were "extremely," "very," "somewhat," "a little important," or "not at all important". Ratings of "extremely" or "very important" were used as indicators of strong priorities.

**Results**: Patients' 3 most frequent priorities were cure (97%), being good to the people they care about (95%), and having supportive people around them (94%). Most also prioritized being with family (90%), returning to school/work (89%), maintaining relationships with friends (88%), and feeling normal (85%). While still important to many patients, fewer prioritized minimizing long term (78%) and acute side effects (68%) and fertility (59%). Older AYAs (\>22) were more likely to prioritize cure (P=0.02, Chi‐square), having romantic relationships (P\<0.001), and being around those who support them (P=0.01). Patients with poorer prognoses (\<50% chance of cure as reported by oncologists) were less likely to prioritize school or work during treatment (P=0.04) but no less likely to prioritize cure (P=0.38) when compared to patients with more favorable prognoses.

**Conclusions**: Nearly all AYA cancer patients prioritize having the best chance of cure, while maintaining relationships and a sense of normalcy. These priorities may influence decisions they make about medical aspects of treatment. Providers can help support AYA patients by recognizing and acknowledging these priorities from diagnosis.

### PO-335. Parental Vital Exhaustion in the Aftermath of a Child\'s Cancer Diagnosis {#pbc27455-sec-13060}

[E. Gudmundsdottir]{.ul} ^1^

*^1^Karolinska Institutet, Department of Women\'s and Children\'s Health, Stochholm, Sweden*

**Background/Objectives**: Assessment of further evidence about adverse reactions of parents of children diagnosed with cancer, focusing on mapping and analyzing levels of long‐term distress in terms of Vital Exhaustion (VE). Theoretically there could be a relationship between levels of Traumatic Stress Symptoms (TSS) and levels of VE, this study examined possible associations of levels of TSS and levels of VE symptoms with the purpose of possible early screening, sufficient intervention and prevention.

**Design/Methods**: Participants were 471 Swedish and Icelandic parents of CC patients diagnosed between the years 1986‐2007. Our reference group comprised of 174 parents of children without any known chronic or lethal disease. Parental Vital Exhaustion was assessed using the Maastricht Questionnaire (MQ‐21) and Traumatic stress symptoms assessed using the Impact of Events Scale‐Revised (IES‐R).

**Results**: Comparison of parents in the clinical (CG) and non‐clinical groups (NCG) revealed a significantly (p\<0.001) higher mean level of VE score in the CG. Comparing groups regarding the higher suggested clinical VE cut‐off score (≥20), results demonstrated that the number of parents being above the higher cut‐off score in the CG were significantly higher in this group than in the NCG (CG=45.4%; NCG=17.4%, p\<0.001). Analysis of MQ and IES‐R total scores in the clinical group demonstrated a strong relationship between VE and TSS (r.641 -- p\<0.001). Further analysis of subscales indicated a correlation between MQ total score and symptoms of Intrusion (r.536 -- p\<0.001), Avoidance (r.463 ‐ p\<0.001) and symptoms of Hyperarousal (r.692 -- p\<0.001).

**Conclusions**: Results of this study revealed that long‐term distress symptoms, in terms of Vital Exhaustion, were still significantly higher in the clinical group more than 9 years after a child\'s cancer diagnosis, compared to NCG. Results may therefore add to further understanding of the complexity and diversity of childhood cancer‐related parental burden over time that need attention in care and long‐term follow‐up.

### PO-336. The Features of Reproductive Behavior and Health in Families with Cancer Children: The Results of a Cohort Study {#pbc27455-sec-13070}

[M. Guseva]{.ul} ^1^, G. Tseytlin^1^, A. Antonov^2^, A. Karelin^3^

*^1^Dmitry Rogachev National Medical Research Center for Pediatric Hematology‐ Oncology and Immunology of the Ministry of Russia, Rehabilitation Center "Russkoe pole"‐ Social and Psychological Rehabilitation, Moscow, Russia; ^2^Moscow State University after M.V. Lomonosov, Sociology of Family and Demography, Moscow, Russia; ^3^Dmitry Rogachev National Medical Research Center for Pediatric Hematology‐ Oncology and Immunology of the Ministry of Russia, Deputy Director, Moscow, Russia*

**Background/Objectives**: Family stress associated with vitally dangerous and stigmatized disease in a child has a significant impact on all aspects of family life. Understanding the mechanisms to overcome stress and its consequences is very important for the organization of psychological and social assistance to these families. The goal was to study reproductive behavior and its special features in context of family stress in pediatric oncology.

**Design/Methods**: Data from the 98‐items questionnaires of 1085 mothers aged 25--49 (average 36.6) with a cancer child in remission were analyzed and compared with that of the Russian state statistics agency\'s demographic research. A range of relevant sociological and psychological theories were attracted to analyze the results of investigation. Statistical processing was carried out using the Chi squared test, for pairwise comparisons Bonferroni correction was applied.

**Results**: Reproductive attitudes (average desired number of children 2,59 vs 2,28 and average expected 2,05 vs 1,72, respectively) and birth rate (1,75 vs 1,28, respectively) in our cohort were considerably higher than in population and served as indicators of significant changes in the system of values and needs in these families. However stress had a considerable impact on common and reproductive health condition: 12,9% reported worsening of common health; 18,1% ‐ violation of reproductive function, 15,2% ‐ secondary infertility. The common and reproductive health conditions were the worst in a group of mothers with brain tumors (BT) children. The behavioral mechanisms to overcome family stress were revealed.

**Conclusions**: Emotionally determined need in caring about a sick child, formed in the context of life threatening circumstances, actualized self‐preservation needs in parents and their self‐concepts of "responsible" mothers and fathers, leading to deep emotional family binds and family activity (family education, holidays etc.), thus helping to overcome family stress and forming positive motivation for childbearing, and increasing the need in children.

### PO-337. Early Intervention for Functional and Nutritional Consequences of Childhood Cancer {#pbc27455-sec-13080}

A. Clarke^1^, J. Koo^2^, C.Y. Foo^3^, S. Chua^4^, M. Vellaichamy^4^, P. Sim^5^, K. Wong^6^, J. Xue^7^, M. Kwan^6^, S.L. Goh^5^, S. Sengupta^7^, [W.M. Han]{.ul} ^2^, L. Teo^1^, J. Tong^7^, M.Y. Chan^8^

*^1^KK Women\'s and Children\'s Hospital, Psychology Department, Singapore, Singapore; ^2^KK Women\'s and Children\'s Hospital, Nutrition & Dietetics Department, Singapore, Singapore; ^3^KK Women\'s and Children\'s Hospital, Occupational Therapy Service, Singapore, Singapore; ^4^KK Women\'s and Children\'s Hospital, Physiotherapy Department, Singapore, Singapore; ^5^KK Women\'s and Children\'s Hospital, Speech Language Therapy Service, Singapore, Singapore; ^6^KK Women\'s and Children\'s Hospital, Child Life‐ Art and Music Therapy Programmes, Singapore, Singapore; ^7^KK Women\'s and Children\'s Hospital, Allied Health Specialties, Singapore, Singapore; ^8^KK Women\'s and Children\'s Hospital, Haematology/ Oncology Service, Singapore, Singapore*

**Background/Objectives**: Children undergoing cancer treatment are at risk of malnutrition, with weight loss being associated with increased fever episodes and poorer survival rates (Brinksma 2015, Loeffen at al., 2015). They are less physically active, with decreased strength, balance, and cardiovascular health compared to peers (Gilliam, 2015). We evaluated the introduction of a pilot early intervention program involving nutritional intervention and functional rehabilitation sessions.

**Design/Methods**: Forty‐two children \[mean=8.6 years; range (2.3‐16)\] diagnosed with cancer in KK Women\'s and Children\'s Hospital, Singapore between March 2017 and February 2018 were involved. Weight was recorded at diagnosis and 3 months. Functional status was assessed using the WeeFIM (Functional Independence Measure for Children) at baseline and post‐rehabilitation intervention. Descriptive analysis, paired t‐test/Wilcoxon signed‐rank test and one‐way ANOVA were employed to evaluate the changes pre‐ and post‐intervention and among cancer types, with statistical significance defined as p \< 0.05..

**Results**: Cancer types included 39.0% blood cancer, 35.0% solid tumour and 26.0% brain tumour. Of this group, 29 were seen for nutritional intervention at 2 months and 23 had rehabilitation needs. With nutritional intervention, median weight of the cohort improved from 20.3 (IQR: 15.5 to 42.75) kg to 21.3 (IQR: 15.7 to 39.8) kg, although this did not reach statistical significance (p=0.054). This translated to a mean percentage weight change of 4.1±11.5% at 3 months. There was no association between percentage weight change at 3 months and cancer types (p=0.437). Scores on the WeeFim for all participants increased by 18.0% from baseline. Those diagnosed with brain tumours demonstrated a significant improvement between diagnosis (mean score=55.0±30.0) and post‐rehabilitation (mean score=84.0±44.0; p=0.002).

**Conclusions**: Our pilot early intervention programme with scheduled dietitian review shows promise in reducing the negative impact of cancer treatment on nutritional status. Early functional rehabilitation demonstrates effectiveness, particularly for children with brain tumours, in reducing the functional impact of cancer.

### PO-338. Brief Psychosocial Screening to Identify Patients in Need of a Mental Health Treatment Referral in a Childhood Cancer Survivorship Clinic {#pbc27455-sec-13090}

[S. Hardy]{.ul} ^1^, M. Connolly^1^, D. Footer^1^, A. Thompson^1^

*^1^Children\'s National Health System, Oncology, Washington‐ D.C., USA*

**Background/Objectives**: Annual psychosocial screening for survivors of childhood cancer is standard of care in pediatric oncology. However, not all institutions have sufficient resources to provide psychosocial assessments, and data on the utility of screening questionnaires in this context are limited. We examined the Strengths and Difficulties Questionnaire (SDQ) as a predictor of clinical decisions to provide psychology consultation and refer for outpatient psychotherapy during a survivorship clinic visit.

**Design/Methods**: Survivors of childhood cancer and parents completed the SDQ prior to a survivorship clinic visit. The SDQ, a publicly available 25‐item measure available in 86 languages, assesses Emotional Symptoms, Conduct Problems, Hyperactivity, Peer Problems, Prosocial Behavior, and Total Difficulties. A psychologist reviewed scores and decided whether to meet with patients. A chart review was conducted to determine if patients were referred for outpatient psychotherapy.

**Results**: Participants included 119 survivors aged 5‐17 years (M=12.37, SD=3.17). Few participants were identified as having Total Difficulties in the Borderline or Abnormal ranges, based on established cutoffs. Fifty‐three participants (45%) were seen by psychology for a consultation. Of those, 20 (43%) were referred for outpatient psychotherapy. Receiver Operating Characteristic (ROC) analyses showed that SDQ Total Difficulties scores were a fair discriminant of participants referred for outpatient psychotherapy (AUC=0.79, CI95=0.65‐0.93, p=0.001). A Total Difficulties cutoff of 11, while lower than established cutoffs, was the best discriminator of need for psychotherapy referral. Of participants with a Total Difficulties score of at least 11, 71% were referred for psychotherapy, while a psychotherapy referral was deemed unnecessary for 81% of participants with a score below 11.

**Conclusions**: The SDQ discriminates between survivors in need of a referral for outpatient psychotherapy; though, a lower than normal cutoff may be needed to identify patients needing treatment. Screening patients with the SDQ can help physicians identify survivors who should be referred for formal psychosocial evaluation and treatment.

### PO-339. A Systematic Review on the Use of the Emotion Thermometer in Individuals Diagnosed with Cancer {#pbc27455-sec-13100}

[E. Harju]{.ul} ^1^, K. Roser^1^, G. Michel^1^

*^1^University of Lucerne, Health Sciences and Health Policy, Lucerne, Switzerland*

**Background/Objectives**: A cancer diagnosis exerts profound psychological impact on the patient, even long after therapy has ended. Heightened distress has been associated with poorer survival in cancer patients and worse quality of life in patients and survivors. This consistent evidence promotes psychological distress screening. The emotion thermometer (ET) is a validated screening tool sensitive to the detection of psychological distress in cancer patients and reasonable in its length for use in acute and time constrained clinical settings. It consists of five dimensions (distress, anxiety, depression, anger and need‐for‐help). To determine the ET\'s integration into screening practice a systematic review and meta‐analysis were undertaken.

**Design/Methods**: Pubmed, Medline, PsychINFO, CINAHL, EMBASE and SCOPUS were systematically searched for studies using the ET in cancer patients and survivors.

**Results**: The search found 543 publications, of which we screened 47 full texts for inclusion. Finally, 16 studies were included in the review. Most studies were conducted in Europe (68.7%) and screened for distress (68.8%) using the ET\'s recommended cut‐off (≥4; 63.6%) in combination (72.7%) with other validated screening measures in females (61.5%). Mean age at study was \>50 years (83.3%) in patients (91.7%) and survivors (8.3%). Five studies validating the ET against other distress measures concluded that the ET has good criterion validity and its use is accepted in clinicians and patients while having no negative impact on clinic throughput time.

**Conclusions**: Despite the ET being a valid and feasible tool for distress screening that delivers prompt and accurate results, distress screening with the ET is scarce. We recommend the utility of the ET as part of a structured program for early distress screening in cancer care. Its application in younger populations still needs to be evaluated.

### PO-340. Art in Medicine: SAORI Weaving in a Pediatric Oncology Clinic {#pbc27455-sec-13110}

[R. Hawks]{.ul} ^1^, F. Heyman^2^, J. Garvin^3^

*^1^SAROI Arts NYC, Weaving Artist, New York, USA; ^2^Naomi Cohain Foundation, Artworks, Englewood‐ NJ, USA; ^3^Columbia University Medical Center, Department of Pediatrics, New York, USA*

**Background/Objectives**: Children with cancer face many challenges that impact growth, emotional and cognitive development, and quality of life. Art in Medicine programs have been introduced into a variety of pediatric medical settings to promote self‐expression and adjustment to illness and hospitalization, but experience in pediatric cancer patients is limited.

**Design/Methods**: SAORI is a holistic Japanese weaving method based on freestyle weaving with a highly adaptable stand‐alone loom compatible with physical disability. We hypothesized that introduction of a SAORI weaving intervention in a pediatric oncology outpatient clinic setting would be well received by patients and siblings.

**Results**: The SAORI weaving program was initiated on a weekly basis in March 2017, with supervision by a consistent teaching artist (a former pediatric oncology nurse). Participants were patients and siblings age 5 to 18 years, as well as parents or other caregivers. Many participants had multiple encounters, and logs of each encounter were maintained. A total of 55 encounters were documented over 12 months. We found that most participants reported or manifested improved well‐being, in realms of physical comfort, relaxation, self‐esteem, sibling insight, and parental pride. Formal assessment of QOL by standardized instruments was not pursued in this initial phase of the activity as tools for art intervention are difficult to administer and may interfere with the process itself. Illustrated case studies will be presented to introduce the activity.

**Conclusions**: As a form of art intervention in a pediatric oncology setting, SAORI weaving has broad accessibility, and provides subjective evidence of enhanced QOL among participants. A larger study is required with applicable QOL instruments to quantify outcomes of this novel intervention.

### PO-341. The Impact of Cancer and its Treatment on the Psychosocial Well‐Being Among Hong Kong Chinese Childhood Survivors of Solid Tumors: An Exploratory Study {#pbc27455-sec-13120}

[K.Y. Ho]{.ul} ^1^, L.L.K. Ho^1^, A.T. Cheung^1^, W.H.C. Li^1^

*^1^The University of Hong Kong, School of Nursing, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: Solid tumors account for approximately 30% of all pediatric cancers. The most common types of solid tumors in children include brain tumors, neuroblastoma, rhabdomyosarcoma, Wilms' tumor and osteosarcoma. When compared with treatments for other types of childhood malignancy, those for solid tumors are often more extensive and damaging. Childhood survivors of solid tumors thus require to face more severe treatment‐related sequelae, which in turn may create a substantial burden on their psychological health during the survivorship period. Nevertheless, evidence on the psychological well‐being of children surviving solid tumors remains relatively scant, especially in the Hong Kong Chinese context. This study aimed to address the gap in existing literature by exploring the impact of cancer and its treatment on the psychological well‐being of Hong Kong Chinese children who survived solid tumors.

**Design/Methods**: A cross‐sectional study design was employed. The subject recruitment was conducted in the pediatric oncology outpatient clinic of a public acute care hospital in Hong Kong. A total of 50 childhood survivors of solid tumors, aged 9‐16 were recruited. For the purpose of comparison, another similar age group of children who survived blood cancer (n=50) were recruited in the outpatient clinic. After we obtained the parental consent, all childhood survivors were assessed for self‐esteem, depressive symptoms and quality of life using self‐reported instruments.

**Results**: Childhood survivors of solid tumors reported a greater number of depressive symptoms (p\<.05), but lower levels of self‐esteem (p\<.05) and quality of life (p\<.05) than those who survived blood cancer by independent samples t‐test.

**Conclusions**: This study bridged the gap in existing literature by demonstrating the impact of cancer and its treatment on the psychological well‐being of children who survived solid tumors. Appropriate interventions should therefore be developed and implemented, thus optimizing their psychological well‐being and quality of life in the long run.

### PO-342. Technological Solution for Softening Social Isolation of the Patients Undergoing Bone Marrow Transplant/Stem Cells Transplant and their Accompanying Parents {#pbc27455-sec-13130}

[L. Hurajova]{.ul} ^1^

*^1^SMILE n.o., Organization of Parents and Patients, Trnava, Slovak Republic*

**Background/Objectives**: Bone marrow transplant (BMT) / Stem cells transplant (SCT) is a long lasting and demanding treatment which usually makes the patients and their accompanying parents stay 3 or more months at hospital, in this case to stay in one room without possibility to meet wider group of people they used to. This social isolation might have negative consequences on both patients\' and parents\' health condition. On the other hand, lowering the level of this isolation might assist to undergo the treatment better, a bit easier.

**Design/Methods**: Our community of parents whose children underwent BMT /SCT have decided to lower the isolation level using technology. We have prepared and just started to work on the project called "Digitalising sterile boxes". In the first phase of the project interactive computers were installed in all six sterile boxes in BMT Unit with several applications to provide entertaining, educational and social functions/features to patients and parents.

In 2016, we managed to design a room called "Living room" within the hospital where BMT unit is located. The "Living room" is utilised mainly for parents accompanying their children during oncological treatment or/and BMT/SCT process. We organised some events for them there (massages, art‐therapy, psychotherapy and some cultural events...).

The contribution deals with the system set up within the project "Digitalising sterile boxes" and its functions and consequences it might. have on patients\' and their parents\' stay in hospital during the treatment.

**Results**: The feedback of patients and their parents who have used the system will be presented. A new proposal for the phase II will be introduced.

**Conclusions**: To soften social isolation of the patients undergoing BMT/SCT and their parents can be lowered when technology is applied.

### PO-343. Health Related Quality of Life in Indonesian Pediatric Cancer {#pbc27455-sec-13140}

[B.W. Indraswari]{.ul} ^1^, S. Mostert^2^, S. Mulatsih^1^, M.N. Sitaresmi^1^, G. Kaspers^2^

*^1^Faculty of Medicine‐ Public Health and Nursing‐ Universitas Gadjah Mada/ Dr Sardjito Hospital‐ Yogyakarta‐ Indonesia, Pediatric Department, Yogyakarta, Indonesia; ^2^VU University Medical Center‐ Amsterdam‐ The Netherland, Pediatric Hematology Oncology, Amsterdam, The Netherlands*

**Background/Objectives**: Long‐term survival of childhood cancer patients has increased in the last decade. Measurement of HRQOL (Health Related Quality of Life) at certain times during the treatment process can recognize acute dysfunctions related to the disease or treatment. Characteristics of cancer, type, phase, intensity and duration of treatment are associated with patient\'s quality of life. This study aim was to identify the HRQOL of childhood cancer patients.

**Design/Methods**: A cross‐sectional study was conducted among all type of pediatric cancer in Dr. Sardjito Hospital, Indonesia from June 2016 to April 2017. The HRQOL data was obtained from patients and their guardians using the PedsQL™ 4.0 generic core scale and the PedsQL™ 3.0 Cancer Module for parents (Indonesian version).

**Results**: One hundred and forty patients aged 2‐18 years and 231 guardians were included in this study. Cronbach\'s alpha for this study were 0.73‐0.95 and Interclass Correlation Coefficient were 0.77‐0.92. Hematology malignancies group showed higher HRQOL than non‐hematology malignancies almost in all sub scales from patients and guardians reports. Patients and guardians of short treatment duration group reported lower scores than long treatment duration group for total score of PedsQL™ generic (67‐69 vs 76‐79) and cancer module (81‐83 vs 86). The subscales that impaired significantly were physic, school, and anxiety of procedure subscales (p=0.00) in short treatment compare to long treatment duration.

**Conclusions**: Maneuvers for reducing procedural anxiety and nausea is important to improve the quality of life in pediatric with cancer. Psychological support for parents will help them to search a good coping strategy in dealing with childhood cancer especially in the beginning of the cancer treatment.

### PO-344. Current Status and Effects of Training Workshop for Childhood Cancer Peer Supporters in Japan {#pbc27455-sec-13150}

[R. Inoue]{.ul} ^1^

*^1^Tokai University, School of Medicine, Isehara, Japan*

**Background/Objectives**: The "Cancer Control Act" was enacted in Japan in 2007, and "government‐designated core hospitals for pediatric cancer treatment" were subsequently established at fifteen locations across the nation. The government‐designated core hospitals provide places where survivors of childhood cancer and their families can interact, and they ensure that peer supporters are available.

**Design/Methods**: Therefore, for the purposes of teaching themselves peer support skills, members of a childhood cancer family group have been implementing a training workshop at government‐designated core hospitals for pediatric cancer treatment since 2013. To date, the training workshops have been held nine times, and have been attended by approximately 200 people. The content of the twelve‐hour/two‐day workshops consists of "medical knowledge about childhood cancer" and "counseling seminars."

**Results**: The majority of the participants are childhood cancer survivors and their families, followed by health professionals, healthcare volunteers, nursing students, and so on. The most common reasons for participation were interest and concern as well as improving counseling skills. As for the effects of the workshop, we found that the participants established a cancer family group, and the peer counselors became less distressed.

**Conclusions**: We believe that self‐help activities for patients who have experienced childhood cancer will play a large role in the future. Moreover, we believe that the activities will further contribute to healthcare by improving peer counseling skills.

### PO-345. Long‐Term Survivors of Childhood Acute Lymphoblastic Leukaemia (ALL): Does Parents' Emotional Well‐being Affect the Emotional Disposition of Their Survived Children? {#pbc27455-sec-13160}

G. Rampoldi^1^, [M. Jankovic]{.ul} ^2^, N. Masera^2^, F. Nichelli^2^, A. Biondi^2^, S. Ardenghi^3^, A. Plantulli^3^, S. Motta^2^, M.G. Strepparava^3^

*^1^University of Milano‐Bicocca, Department of Human Sciences for Education, Milano, Italy; ^2^Monza Brianza Foundation for Children and their Mothers MBBM, Department of Pediatrics, Monza, Italy; ^3^University of Milano‐Bicocca, Department of Medicine and Surgery, Monza, Italy*

**Background/Objectives**: The rate of long‐term survival for the Acute Lymphoblastic Leukaemia (ALL) increased during the years. Thus, in the literature the interest for the psychological long‐term effects of the treatment of ALL is progressively increased. Parental distress influences parents' perception of behavioural and emotional problems of their ALL long‐term survivors children. Nevertheless, it is unclear whether the parental emotional distress affects child\'s emotions and behaviour. The aim of this study is to investigate whether parents' emotional well‐being affects the emotional disposition of their ALL long‐term survivors children.

**Design/Methods**: A cohort of 70 Italian long‐term ALL childhood survivors and their parents were asked to complete respectively the children and the adult Italian version of the Positive and Negative Schedule (PANAS‐C; PANAS).

**Results**: Regression models showed that mothers' PANAS Positive Affect scale (PA) had a statistically significant effect (F4, 45 = 2.84; P = 0.035) on the PA of their ALL long‐term survivors children (PA‐C). Instead, fathers' PANAS scales did not have any effect on the PA‐C (F4, 33= 1.794; P = 0.154). These two results were controlled for children age, children gender and for, respectively, mothers' and fathers' PANAS Negative Affect scale (NA). Finally, parents' PA and NA did not significantly affect the Negative Affect scale of their ALL survived children (NA‐C).

**Conclusions**: In order to enhance the positive emotional disposition of ALL long‐term survivors children, this study suggests setting up a psychological intervention focused on their mothers' positive emotions.

### PO-346. Possibilities and Strains Regarding Fertility in Adult Childhood Cancer Survivors {#pbc27455-sec-13170}

[M. Jarfelt]{.ul} ^1^, S. Järvholm^2^, A. Thurin‐Kjellberg^2^

*^1^The Queen Silvia Children\'s Hospital, Pediatric Oncology, Gothenburg, Sweden; ^2^Sahlgrenska University Hospital, Department of Obstetrics and Gynecology, Gothenburg, Sweden*

**Background/Objectives**: For the increasing group of childhood cancer survivors the ability to become a parent is valued as one of the most important issues. Today, the first generation of childhood cancer survivors has reached the age where most people have established a family or decided not to have children. Our study investigated how questions about fertility and information or lack of information about fertility influence adult survivors.

**Design/Methods**: A cohort study of survivors of childhood cancer who were over 37 years of age in 2016 and identified from the Childhood cancer registry in the West region of Sweden, was performed. Twenty‐nine eligible patients treated for cancer at the median age of 14 (2.5‐17.5) were identified. Ten women and eight men participated in the study and were interviewed following a semi‐structured guide and filled out questionnaires about quality‐of‐life (SF‐36), mood (HADS), and sense of coherence (SoC).

**Results**: The interviews were analysed by thematic method. The theme, It is a long and winding road was seen as a master theme, affecting three underlying subthemes, which was labelled as follows: Pictures of fertility, Experience of fertility and Emotions and fertility. Women scored significantly higher on depression than men (4.2 vs 2.5, p=0021).The women\'s mean (7.7) for anxiety were above cut‐off (7) and on an individual level six women and two men score above the cut‐off of 7 indicating the need for clinical intervention.

**Conclusions**: There are unnecessary gaps of information and lack of support in questions about fertility even when the former childhood cancer survivors have reached adulthood. This may influence their psychological wellbeing.

### PO-347. A Social Network Intervention for Adolescents with Cancer and their Parents: Sharing Experiences Generates New Knowledge and Coping Strategies in the Individual Families {#pbc27455-sec-13180}

[L. Jensen]{.ul} ^1^, T. Brøner^1^, I.N. Christensen^1^

*^1^Aarhus University hospital, Department of Pediatrics, Aarhus, Denmark*

**Background/Objectives**: Cancer in adolescence affects no patient, but the whole family. The parents are an important resource for the young patient and they need support and knowledge to fulfil this role and support the young patient.

The evening will give the parents an increased understanding of the patterns of response in the young patient and an opportunity support them. The adolescent gets the opportunity to meet others in similar situations and can exchange experiences.

**Design/Methods**: The participant are young people aged 12‐20 with their parents. Three specialized nurses with knowledge of adolescents and the challenge the parents experience caused by the cancer attended.

The group is divided into two parts. The adolescents participate in a networking activity with one of the nurses. The adolescents will have the opportunity to get to know each other and talk about what is important to them. The parent group receives information from the nurses about the adolescents and the impact on the young people when they have cancer. The parents exchange experiences and sparring with the nurses as a facilitator.

The evenings are evaluated by a questionnaire to the parents and a subsequently oral evaluation with the adolescents.

**Results**: Three evenings with a total of 25 adolescents and 35 parents. 25 questionnaires completed and document a high level of satisfaction from parents. All the parents found it valuable to attend. 75 % of the parents gained useful knowledge and all the Parents were happy to share experiences with other parents. All the young people participating in the evening experiences a break from the disease and gain friendships with other young patients. They keep in touch with each other afterwards.

**Conclusions**: The study indicates, that the evenings are valuable for the interactions and understanding between adolescents with cancer and their parents.

### PO-348. Parenting Stress and Sibling Conflict: Temporal Relations Across the First Year of Pediatric Cancer Treatment {#pbc27455-sec-13190}

[L. Katz]{.ul} ^1^, K. Fladeboe^1^, K. King^1^, D. Friedman^2^, B. Compas^3^, L. Lengua^1^

*^1^University of Washington, Psychology, Seattle, USA; ^2^Vanderbilt University, Pediatrics, Nashville, USA; ^3^Vanderbilt University, Psychology, Nashville, USA*

**Background/Objectives**: When a child is diagnosed with cancer, parents experience a host of new stressors associated with parenting an ill child. Parenting stress during treatment may not only affect wellbeing of parents and children, but may also affect family relationships. Sibling relationships are in important source of life‐long social and instrumental support, yet little is known about how they are affected by cancer. We examine whether parenting strain longitudinally predicts elevations in sibling conflict across the first year of treatment. We hypothesize that parenting stress may be one way in which the cancer experience affects sibling relationships.

**Design/Methods**: Families (N=134) were recruited from two US children\'s hospitals at diagnosis. Children with cancer were 2‐17 years old (M~age~=5.4). Caregivers reported on illness‐related parenting stress and sibling conflict at 1‐, 6‐, and 12‐months post‐diagnosis. The parenting stress measure assessed stressors specific to parenting an ill child (i.e., communication, role strain). Subscales formed two scores: frequency and difficulty. Cross‐lagged models in SEM examined relations between parenting stress and sibling conflict. Models tested whether parenting stress predicted sibling conflict at the subsequent time point, controlling for previous conflict levels and potential bidirectional influence.

**Results**: Higher Month‐1 parenting stress frequency predicted higher sibling conflict at Month‐6, and higher Month‐6 parenting stress frequency predicted higher sibling conflict at Month‐12 (c2 (8)=9.94, p=0.27; CFI=0.99). Neither the reverse pattern (sibling conflict predicting later parenting stress) nor a bidirectional pattern were supported. Same pattern of results was observed for the model examining parenting stress difficulty (c2 (8)=11.76, p=0.16; CFI=0.98).

**Conclusions**: Illness‐related parenting stress may contribute to sibling conflict over time. To prevent problems in the sibling relationship, intervening with parents to help manage caregiving stress during treatment may be optimal.

### PO-349. Concordance Between Child Performance and Parent Report of Working Memory in Children with Cancer {#pbc27455-sec-13200}

[N. Kelly]{.ul} ^1^, C. Johansen^2^, N. Delgado^2^, S. Patel^2^

*^1^City of Hope, Supportive Care Medicine, Duarte, USA; ^2^City of Hope, Population Sciences, Duarte, USA*

**Background/Objectives**: Among survivors of childhood cancer, neuropsychological assessment is used to evaluate working memory deficits and other treatment‐related adverse cognitive late effects. However, neuropsychological evaluations are costly and time consuming. Increasingly, parent report of their child\'s functioning is used as an alternative, cost‐effective method to screen for neurocognitive late effects. In particular, the Parent‐Report Behavior Rating Inventory of Executive Function (BRIEF) is now part of the screening neurocognitive battery compiled by the Behavioral Science Committee of the Children\'s Oncology Group for use with childhood cancer survivors. The objective of this study was to examine concordance between the child\'s performance on objective tests of working memory and parent‐report of the child\'s working memory on the BRIEF.

**Design/Methods**: Participants were 44 parent‐child dyads who completed assessments. All children were at least 6 months post cancer treatment completion; mean age at testing was 11.92 years and mean age at diagnosis was 4.91 years. Majority (84%) were treated for leukemia. Child\'s performance was assessed using the WISC‐IV working memory index and parent report was assessed by the BRIEF working memory scale. Hierarchical regression analyses predicted parent report (dependent variable) using the child\'s performance scores (independent variable), controlled for child\'s age.

**Results**: Child performance on WISC‐IV working memory index was negatively associated with parent‐rated working memory on the BRIEF (β=‐0.298, t=‐2.06, p\<0.05) after controlling for age. The lower the child\'s performance, the higher the dysfunction reported by the parent. Exploratory analyses suggested that the child\'s performance on digit span was more highly associated with parent report of working memory than was performance on letter number sequencing.

**Conclusions**: Our analyses found good concordance between parent report and actual performance for child working memory skills, adding support to the utility of parent report as a screening tool in children with cancer. Results should be replicated with a larger sample size.

### PO-350. Mothers Retreats: A Therapeutical Approach to Peer Support for Parents Still Navigating Childhood Cancer {#pbc27455-sec-13210}

[R. Kiddle]{.ul} ^1^

*^1^Child Cancer Foundation, National Support Office, Auckland, New Zealand*

**Background/Objectives**: Child Cancer Foundation (NZ) employs 19 Family Support Coordinators who support children and their families on a one‐to‐one basis throughout New Zealand. While this is proactive approach to support is a point of difference in our sector we are also aware that parents benefit from peer support.

This year we piloted a programme of Mothers' Retreats. We have held two retreats -- one in the North Island and one in the South Island. They are of two‐day duration in a 'resort' style venue.

The objective of the retreat is to empower women to talk about their journey, connect with other parents and partake in some activities that will build their resilience and wellbeing.

**Design/Methods**: The weekend is a combination of relaxation and therapy led by an external facilitator, accompanied by one of our Family Support Coordinators, that explore the issues these parents are facing and provide a variety of coping mechanisms for the attendees.

Parents are selected according to criteria set out by the Family Support team. A detailed therapeutic programme of seven activities is put together. All costs associated with attendance at the Retreat are covered by Child Cancer Foundation.

**Results**: Feedback was through a confidential survey that covered the details of the retreat venue, planning, and the programme content. There were12 questions that are asked and, on average, the recipients spent 15 minutes giving feedback. The survey results show that the women value the opportunity to get away and would recommend this activity for other families. They were interested in more physical activities or a variety of options that suited their personal relaxation style and allowed them to engage with the other participants outside the formal programme that was put together.

**Conclusions**: This programme will be extended nationally next year and will be adjusted to meet the recommendations made by both pilot groups.

### PO-351. Transitioning Volunteer Groups from Traditional Formal Structure to Informal Support Groups: Getting Stakeholder Agreement {#pbc27455-sec-13220}

[R. Kiddle]{.ul} ^1^

*^1^Child Cancer Foundation, National Support Office, Auckland, New Zealand*

**Background/Objectives**: Child Cancer Foundation (NZ) relies on a network of volunteer groups to make social connection with families around New Zealand.

There are over 1,000 families that have indicated they are interested in connecting with other families through social occasions and smaller gatherings in their communities. There are currently 20 "branches" (groups of volunteers) but there is little oversight of the events they hold, the effectiveness and reach of the events.

With the decline in volunteer hours and the wish for volunteers to have impact but not participate in "Committees" we have embarked on a project to transition from the traditional branch model to a less formal and more impactful Connect group model.

**Design/Methods**: A Project Transition team was established that included all major facets of the organisation -- Family Support, Fundraising, Branch Representation and Regional Representatives from the National Board.

The project team discussed the core purpose of these groups, their composition, operational issues, financial accountability, communication tools and support mechanisms. Discussion papers were written and agreed and the proposed changes were presented at a Members Representative Forum where the majority of branches sent representatives. An external facilitator used the World Café model to discuss the six major topics and all Forum attendees participated in feedback workshops.

This concept allowed for 100% participation and consensus findings for all six areas.

**Results**: The Forum concluded that change was needed, agreed on the proposed changes with adaptation from the feedback workshops and felt more empowered by the ability to support families in their community with clarity and commitment.

**Conclusions**: The changes will be implemented over the next six months -- including rewriting of the Constitution ‐ in time for adoption at the Annual General Meeting in November.

### PO-352. Risky Health Behavior Related Deaths in Childhood Cancer Survivors: A Population‐based Register Study from Denmark, Finland, and Sweden {#pbc27455-sec-13230}

[L. Korhonen]{.ul} ^1,2^, M. Rantanen^1^, A. Bautz^3^, F. Erdmann^3^, J. Falck Winther^3^, M. Feychting^4^, N. Malila^1^, H. Mogensen^4^, M. Taskinen^2^, L.M. Madanat‐Harjuoja^1,2^

*^1^The Finnish Cancer Registry, The Finnish Cancer Registry, Helsinki, Finland; ^2^University of Helsinki and Helsinki University Hospital, Children\'s hospital, Helsinki, Finland; ^3^Danish Cancer Society Research Center, Survivorship Unit, Copenhagen, Denmark; ^4^Karolinska Institutet, Unit of Epidemiology‐ Institute of Environmental Medicine, Stockholm, Sweden*

**Background/Objectives**: Childhood cancer survivors have been reported to be particularly vulnerable to late psychiatric morbidities and risky health behavior. Suicides, accidents and violence as causes of death can be regarded as an extreme manifestation of risky health behavior.

We studied the risk for suicide and other risky health behavior related deaths (alcohol, drugs, accidents and violence) as independent outcomes among childhood cancer survivors in Denmark, Finland and Sweden.

**Design/Methods**: By linkage to national cancer, population and cause of death registers, we investigated the causes of death in 29,285 patients diagnosed with cancer under the age of 20 years between January 1^st^ 1971 and December 31^st^ 2008, compared with 146,282 age‐, sex‐ and country‐matched population controls. The follow‐up ended on December 31^st^ 2008 in Denmark and Sweden and on December 31^st^ 2012 in Finland. Rate ratios (RR) were estimated by using the Poisson regression model, adjusting for country and diagnostic period.

**Results**: The overall risk for dying of risky health behavior was increased among cancer patients (risky health behavior death N=114) as compared to controls (N=718) (RR 1.30 \[95%CI; 1.07‐1.59\]). The risk for dying of risky health behavior was highest among patients with central nervous system tumor (RR 1.84 \[1.30‐2.60\]), female patients (RR 1.65 \[1.12‐2.42\]) and patients diagnosed at 5‐9 years of age (RR 2.11 \[1.38 ‐ 3.22\]). The overall risk for suicide was not increased among cancer survivors (suicide N=53) when comparing with controls (N=337) (RR 1.28 \[95%CI; 0.96‐1.72\]). The cancer survivors' risk for dying of risky health behavior or suicide did not differ between countries (p=0.95; p=0.41, respectively) when comparing with their controls in corresponding countries.

**Conclusions**: We found childhood cancer survivors are more likely to die due to risky health behavior. Our results imply that emphasis in follow‐up care should be placed on the psychosocial screening and support of childhood cancer survivors.

### PO-353. Using Patient‐ and Parent‐Reported Outcomes to Predict Survival of Children with Brain Tumors {#pbc27455-sec-13240}

[J.S. Lai]{.ul} ^1^, J. Beaumont^1^, S. Goldman^2^

*^1^Northwestern University, Medical Social Sciences, Chicago, USA; ^2^Ann & Robert H. Lurie Children\'s Hospital of Chicago, Hematology‐Oncology‐ Neuro‐Oncology & Stem Cell transplantation, Chicago, USA*

**Background/Objectives**: The usefulness of patient‐ and parent‐reported outcomes (PRO) in understanding quality of life in children with brain tumor (BT) has now been recognized. Yet little is known on how PRO changes overtime and how it is related to clinical outcomes for BT. Using measures (Anxiety, Depressive Symptoms, Mobility, Upper Extremity Function, Fatigue, Peer Relationship, and Cognition) from Patient‐Reported Outcomes Information System, PROMIS, this study aimed to fill this gap by exploring the relationship between survival and PROMIS measures.

**Design/Methods**: Data from 468 participants (208 BT aged 8‐21yrs and 260 parents of patients aged 5‐21yrs) were used. Average age was 11.9yr and 43yr for patients (53.7% male) and parents (17.3% male), respectively. Most patients attended school (93%) but received an individualized education program (50.4%). 70.7% had surgery, 75.9% received chemotherapy and 57% received radiation for their tumors. Years since last treatment was 0.43 (SD=1.34). All participants completed PROMIS measures (self‐ or proxy‐reported versions). 224 (97 BT aged 8‐21yrs, 127 parents of patients aged 5‐21yrs) completed PROMIS measures at the 12‐month follow‐up. 25 patients died during the follow‐up period. All PROMIS measures were scored using T‐metric (mean=50, SD=10). Linear mixed model was used to evaluate scores over time. Cox proportional hazards models were used to evaluate whether PROMIS measures significantly predicted survival.

**Results**: Linear mixed model results indicated worsening patient‐reported cognition and parent‐reported anxiety (p\<0.05) over 12 months. Survival analysis indicated that patients who reported better mobility and upper extremity function had better survival. None of the proxy measures were significant. Longer time since diagnosis and higher performance rating were also predictive of survival.

**Conclusions**: This study provides preliminary evidence of using PROs to predict clinical outcomes, in this study, survival. With a small number of deaths, these results should be considered exploratory. Future studies are needed to confirm our conclusions.

### PO-354. Effectiveness of an Integrated Experiential Training Program with Coaching by Nursing Students in Reducing Fatigue Among Children with Cancer in Hong Kong {#pbc27455-sec-13250}

[K.W.K. Lam]{.ul} ^1^, H.C.W. Li^1^

*^1^The University of Hong Kong, School of Nursing, Hong Kong, Hong Kong S.A.R*.

**Background/Objectives**: The declining levels of physical activity in children with cancer warrens global attention. There is growing evidence supporting the benefits of exercising since cancer diagnosis to ameliorate fatigue and depressive symptoms, thus improving quality of life. Nevertheless, literature review shows that previous exercise interventions are unlikely to change behaviour. This study aimed to examine the effectiveness of an integrated experiential training program with coaching by nursing students in reducing fatigue, depressive symptoms and enhancing quality of life in children undergoing cancer treatment in Hong Kong.

**Design/Methods**: A randomized controlled trial, two‐group pre‐test and repeated post‐test, between‐subjects design was conducted in a total of 70 children with cancer who were receiving treatment. They were randomly allocated to the experimental (N=37) and control groups (N=33). The interventions in the experimental group consisted of 28 home visits by the nursing student coaches for a 6‐month period. The control group received the same amount of time and attention but not in a way to have specific effect on the outcome variables. Data about participants' levels of fatigue, physical activity, depressive symptoms, and quality of life was collected at the time of recruitment, 6 and 9 months after starting the intervention by questionnaires.

**Results**: Participants in the experimental group reported statistically lower levels of fatigue and depressive symptoms, higher levels of physical activity and quality of life than those in the control group. Statistically significant mean differences in fatigue, depressive symptoms, physical activity levels and quality of life were found among participants in the experimental group from baseline to 9 months after starting the intervention.

**Conclusions**: The integrated experiential training program with coaching by nursing students was effective in reducing fatigue, depressive symptoms, promoting physical activity and quality of life in children with cancer.

### PO-355. Relationship Status and Quality of the Partner Relationship in Parents of Long‐Term Childhood Cancer Survivors {#pbc27455-sec-13260}

[L. Mader]{.ul} ^1,2^, K. Roser^2^, J. Baenziger^2^, K. Scheinemann^3,4,5^, G. Michel^2^

*^1^Danish Cancer Society Research Center, Childhood Cancer, Copenhagen, Denmark; ^2^University of Lucerne, Department of Health Sciences and Health Policy, Lucerne, Switzerland; ^3^University Children\'s Hospital Basel, Division of Hematology/Oncology, Basel, Switzerland; ^4^Cantonal Hospital Aarau‐ Hospital for children and adolescents, Division of Hematology/Oncology, Aarau, Switzerland; ^5^McMaster Children\'s Hospital & McMaster University, Division of Hematology/Oncology, Hamilton, Canada*

**Background/Objectives**: The intensive and long‐lasting experience of childhood cancer may be a tremendous stressor for the parental relationship. We aimed to i) compare the relationship status of parents of long‐term childhood cancer survivors with control parents, ii) identify cancer‐related characteristics associated with being married, and iii) evaluate the quality of the parental relationship.

**Design/Methods**: We sent a questionnaire to parents of childhood cancer survivors, who were aged ≤16 years at diagnosis and ≥20 years at study. Control parents were derived from a random sample of the Swiss general population (≥1 child aged ≥20 years) and standardized on age, sex, and migration background according to parents of survivors. We used logistic regression to identify cancer‐related factors associated with marriage applying a multilevel modeling approach to account for family clustering. The quality of the partner relationship was evaluated using the relationship‐specific attachment scale for adults assessing the relationship‐specific dimensions "secure‐fearful" (scale 1) and "dependent‐independent" (scale 2).

**Results**: Our sample included 579 parents (58.2% mothers, mean age=62.1 years) of 376 survivors and 471 control parents. Compared to control parents, parents of survivors were more often in a partner relationship (84.8% vs. 91.3%, p=0.002) and married (75.2% vs. 85.2%, p\<0.001). No associations between marriage and cancer‐related characteristics were identified. Parents of survivors described their partner relationship as more secure (scale 1; 26.5 vs. 25.8, p=0.023) and indicated a higher dependency (scale 2; 24.4 vs. 23.3, p=0.003) than control parents. Among parents of survivors, no differences between mothers and fathers were observed for scale 1 or scale 2 (both p\>0.05).

**Conclusions**: Parenting a child with cancer did not adversely affect the parents' relationship status in the long‐term. The cancer experience rather appeared to have strengthened the security of and dependency within the partner relationship suggesting that parents manage their child\'s disease as a team.

### PO-356. Sexual Problems Reported by Patients with Testicular Cancer: Important to Screen and to Assess {#pbc27455-sec-13270}

[M.F. Marcusso Manhaes]{.ul} ^1^, R.N. Pedras^1^, G. Okuma^1^, C.D. Bergerot^1^

*^1^Federal University of Sao Paulo, Department of Clinical Oncology, São Paulo, Brazil*

**Background/Objectives**: Sexuality is an important issue faced by cancer patients, and rarely discussed between adolescents or young adults (AYA) patients and health care providers. In view of the challenges faced by patients with testicular cancer (TC), we sought to determine difference between sexual problems reported through well‐established scales.

**Design/Methods**: We identified consecutive Brazilian AYA patients, diagnosed with TC. Based on measures included in our screening program, patients' response to items on sexual problems were included: "sexual problem" (Distress Thermometer; DT), and "I am satisfied with my sex life" (Functional Assessment of Cancer Therapy‐General; FACT‐G). To in‐depth look at this specific need, eight specific items were included (Cancer Assessment for Young Adults‐Testicular; CAYA‐T). A qualitative and descriptive comparison were interrogated.

**Results**: A total of 28 patients (average age: 30; histology: 52% seminoma; surgery: 100% orchiectomy; chemotherapy: 59% bleomycin+etoposide+cisplatin) were assessed. Three patients reported sexual problems using the DT, and endorsed their non‐satisfaction with sex life in the FACT‐G. The CAYAT explored another opportunities for indicating specific concerns, such as: "I do not have adequate confidence about sex" (n=9), "I am not satisfied with my ability to have biological children" (n=8), "I am not satisfied with my ability to ejaculate" (n=7), "I am not satisfied with my ability to achieve orgasm" (n=7), and "I have been bothered by sex‐related concerns" (n=7).

**Conclusions**: A low proportion of patients reported sexual problems using general and briefest measures. It\'s seems that patients who used DT and FACT‐G to report sexual problems are even more suitable to indicate their specific needs in a comprehensive measure. However, a high proportion of patients just reported their needs when specifically inquired about their sexual functioning. Given these preliminary findings, the pro‐active rapid identification of key indicators should be followed by a more focused assessment to guide treatment decision when is appropriate.

### PO-357. The Child Chooses Medical Support During Invasive Procedures: Analysis of the Results {#pbc27455-sec-13280}

[K. Maslak]{.ul} ^1^, C. Favara‐Scacco^1^, M. Barchitta^2^, A. Agodi^2^, M. Astuto^3^, R. Scalisi^3^, S. Italia^1^, F. Bellia^1^, G. Bertuna^1^, S. D\'Amico^1^, M. La Spina^1^, M. Licciardello^1^, L. Lo Nigro^1^, P. Samperi^1^, V. Miraglia^1^, E. Cannata^1^, M. Meli^1^, F. Puglisi^1^, G. Russo^4^, A. Di Cataldo^4^

*^1^University Hospital Policlinico Vittorio‐Emanuele, Department of Pediatric Hematology and Oncology, Catania, Italy; ^2^University of Catania, Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", Catania, Italy; ^3^University Hospital Policlinico Vittorio‐Emanuele, Section of Anesthesia‐ Department of General Surgery and Medical Specialties, Catania, Italy; ^4^University of Catania, Department of Pediatric Hematology and Oncology‐ Department of Clinical and Experimental Medicine, Catania, Italy*

**Background/Objectives**: When cancer intrudes children\'s life, everyday equilibrium is destroyed. They suddenly find themselves in a totally new world where adults make all the important decisions. Children undergoing diagnostic and therapeutic treatment, experience an increasing level of anxiety with repeated invasive procedures and do not adapt to the discomfort. Bone marrow aspiration and lumbar puncture remain one of the most vivid memories even years after the treatment is finished. Professionals agree that children must receive developmentally appropriate preparatory information about invasive procedures, along with an adequate psychological support. Literature describes different support modalities, e.g. pharmacological, behavioural, sedative etc; however, there is no report on the possibility of asking children themselves about their preference for the medical support.

**Design/Methods**: The day of the procedure, each child was offered to choose the type of medical support among general anesthesia (GA), conscious sedation (CS) or nothing. Each child received also a psychological support, i.e. given by the psychologist before, during and after the procedure. An 'ad hoc' assessment tool was prepared in order to measure child discomfort before, during and after each procedure; also the caregiver adequacy was measured, based on a 4‐dimension evaluation. Both forms were filled in at every procedure by the attending psychologist.

**Results**: We monitored 247 consecutive invasive procedures in 85 children. We found that the choice of the type of medical support was different in the various age groups; elementary‐school age group showed significantly higher distress level than others; distress level diminished at succeeding procedures; caregiver behaviour influenced children\'s experience.

**Conclusions**: Offering children an opportunity to choose the medical support, during invasive procedures, is an effective modality to return active control to them; it is a way to truly strengthen the children\'s capacity to face the invasive procedures, limiting their emotionally traumatic content.

### PO-358. Development of Computer‐based Self‐Learning Tools for Childhood Cancer Survivors {#pbc27455-sec-13290}

[D. Masumoto]{.ul} ^1^, M. Nambu^2^, E. Nakagami‐Yamaguchi^3^, K. Kihira^4^, T. Deguchi^5^, M. Maeda^6^, H. Hori^1^

*^1^Mie University Graduate School of Medicine, Medical Education, Mie, Japan; ^2^Future University Hakodate, Media Architecture, Hokkaido, Japan; ^3^Osaka City University Graduate School of Medicine, Medical Quality and Safety Science, Osaka, Japan; ^4^Mie University, Pediatrics, Mie, Japan; ^5^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^6^Nippon Medical School, Pediatrics, Tokyo, Japan*

**Background/Objectives**: Late effects following anti‐cancer treatment as well as sequelae of the disease process have been emerging health problems for childhood cancer survivors (CCSs). To solve the problem, we have to improve their motivation in consulting their physicians through patient\'s education. In this study, we developed two digital tools (START LINE+ and FUN QUEST) to educate CCSs on late effects and long‐term health care as an activity of Japan Children\'s Cancer Group. We conducted this study to assess the effectiveness of and limitation in education using the age‐dependent computer‐based tools for CCSs.

**Design/Methods**: CCSs at Mie University Hospital over 10 years old were recruited between June 2016 and May 2017. They were given instructions on game operation and requested to play the game in a tablet‐type device and computer or laptop computer for the next one month at home. Their self‐esteem, health‐management awareness and knowledge of late effects and health promotion were evaluated at the end of 1‐month learning and at 6 and 12‐months from the baseline assessment.

**Results**: Eighty‐three survivors met eligibility criteria for the study. The median age at baseline was 19 years (range 10‐32 years); male slightly more prominent than female (55.4%). After playing game (1‐month), the score of self‐esteem, health‐management awareness and knowledge of late effects and health promotion became significantly higher than baseline. However, in adolescent and young adult survivors, these scores at 6‐months became significantly lower than 1‐months. Similarly, knowledge of late effects and health promotion in children also became significantly lower.

**Conclusions**: The results suggested that the digital tools which we developed for CCSs may be effective to learn knowledges on late effects and health and to increase the motivation for health management. To maintain the learning achievements, repeated learning‐opportunities may be recommended.

### PO-359. The Psychological Current Status of Siblings in Adolescent and Young Adult with Cancer Patients in Japan {#pbc27455-sec-13300}

[O. Miwa]{.ul} ^1^

*^1^Pediatrics, St.Luke\'s International hospital, Tokyo, Japan*

**Background/Objectives**: This study aimed to evaluate the psychological current status of siblings in adolescent and young adult (AYA) with AYA cancer patients in Japan.

**Design/Methods**: We conducted a nationwide survey of AYA cancer survivors, parents, siblings and healthy AYAs as a control group. We distributed questionnaires to AYA survivors via their doctors in 15 institutes and 31 patient advocacy groups from June to November in 2016. Two hundred healthy AYAs registered to a research company were recruited to a web‐based questionnaire. We analyzed the results from siblings compared from healthy AYAs.

**Results**: In total, there were 83 respondents (mean age at survey 23.0±10.9) among 213 participants. Forty two percent of them were male. Their patients were diagnosed leukemia (32.1%), brain tumor (12.3%), osteosarcoma (11.1%), malignant lymphoma (9.9%), breast cancer (8.6%) and others. Siblings showed lower self‐esteem (p=0.039) than healthy AYAs. And in one of 4 categories in posttraumatic growth was higher score (p=0.004) than healthy AYAs. That category was changed perception of self and feelings of gratitude for life. The common trouble of siblings aged 15‐29 years old is studies (48.1%), the future of own (45.0%) and future of their family (57.1%). In siblings aged 30‐39 years old, their common trouble is late effects and complications of the patient (54.5%), they also trouble in future of their family(45.5%) and work (36.4%).

**Conclusions**: Siblings of AYA with cancer patient have own trouble and lower self‐esteem than healthy AYAs. But they could experience posttraumatic growth with this struggling. They need a support to improving their self‐esteem.

### PO-360. National Survey of Long‐Term Childhood Cancer Survivors in Ireland: Identifying the Supportive Care Needs in the Irish Health System {#pbc27455-sec-13310}

[M. Molcho]{.ul} ^1^, M. Balfe^2^, L. Sharp^3^

*^1^National University of Ireland Galway, Children\'s Studies, Galway, Ireland; ^2^Ubiversity College Cork Ireland, Sociology, Cork, Ireland; ^3^Newcastle University, Institute of Health and Society, Newcastle upon Tyne, United Kingdom*

**Background/Objectives**: Childhood cancer survivors are known to suffer from long term effects, and have additional, or different, supportive care needs. This paper presents findings on the supportive care needs of childhood cancer survivors from the first ever national survey of survivors in Ireland.

**Design/Methods**: Data on all survivors that are over 19 years of age that were diagnosed with cancers between 1994 and 2012 were extracted from the National Cancer Registry Ireland. Eligible survivors were sent a questionnaire assessing their supportive care needs, mental health, and health‐related quality of life. Data were analyzed to identify current health problems, health care needs and supportive care needs, within the context of the Irish health system.

**Results**: Overall, 444 survivors met the eligibility criteria, of which 142 completed the questionnaire (32% response rate). The age of survivors ranges from 19‐39 (mean: 25.6; SD 5.3). The most prevalent medical problems were problems with vision (39%); dental problems (21%); and mental health issues (20%). Depression, anxiety and stress were commonly reported by survivors (60%, 57% and 47% respectively). The most common supportive care needs were psychological (uncertainty about the future -- 27%; need help in feeling in control ‐22%; need help with anxiety -- 21%), physical (lack of energy -- 22%), and health system related (access to counselling -- 14%; information on things that you can do yourself -- 11%). No gender or social class differences were demonstrated.

**Conclusions**: While previous research have highlighted the needs and concerns of childhood cancers survivors, this is the first time that these are mapped in Ireland, and one of the few studies that used a national survey to assess the health and needs of a large cohort of survivors in Ireland providing important information on the preferred care for survivors. The study was funded by the Irish Cancer Society.

### PO-361. Anxiety Associated with Clinic Visits for Children Undergoing Cancer Treatment: A Survey of Children and Parents {#pbc27455-sec-13320}

[A. Nageswara Rao]{.ul} ^1^, K. Davis^2^, D. Weinmann^2^, D. Warad^1^

*^1^Mayo Clinic, Division of Pediatric Hematology/Oncology, Rochester, USA; ^2^Mayo Clinic, Department of Nursing, Rochester, USA*

**Background/Objectives**: Cancer diagnosis and treatment is often a long process involving multiple clinic visits, procedures, treatments, and management of treatment‐related side effects. The study objective was to identify situations that may make children scared or nervous about clinic visits and activities/measures that may help alleviate their fear/anxiety.

**Design/Methods**: Cross‐sectional survey of children (aged 4‐14.99 years) diagnosed with cancer and undergoing radiation/chemotherapy at our institution and their parents.

**Results**: Forty‐nine (15 female; 34 male) patients were surveyed. Median age was 8.5 years (range; 4‐13.7 years). Diagnoses included leukemia/lymphoma (n=22), brain tumors (n=17), and other (n‐10). Top two situations children reported as feeling scared/ nervous "very often/always/a lot" were: having a needle poke/Port‐A‐Cath access (44.7%) and having a procedure without sedation (33.3%). Vast majority reported "never/rarely/not at all" feeling scared/ nervous when meeting the doctor (85.7%), receiving IV medications/infusions (74.5%), and coming to the clinic (63.3%). Almost half or more reported being less scared/nervous "very often/always/a lot" when they received candy or toys (67.5%), played with child‐life therapists/music therapy (54.5%), watched television (48.9%), played electronic games/listened to music (48.8%), and read/received books (47.9%).

No differences were noted between younger (4‐7.99 years; n=20) and older (8‐14.99 years; n=29) age groups in reported fear/nervousness around various clinic visits‐related situations. Children in the younger age group reported being less scared/nervous than the older age group when they read/received books (p=0.003), received toys (p=0.04), played with child‐life therapists/music therapy (p=0.016), and watched television (p=0.014).

Thirty‐nine parents (84.8%) "agreed/strongly agreed" that having interactive games and reward systems helps children overcome fear or nervousness. No differences were noted between parent and child report with various clinic visits‐related situations or activities/measures that may make children less nervous/scared.

**Conclusions**: Activities and reward systems may help ease fear/anxiety associated with clinic visits for pediatric oncology patients, especially younger children.

### PO-362. "Listening to the Soul": A Mindfulness Meditation Program for Children with Cancer and their Parents {#pbc27455-sec-13330}

[T. Natanzon‐Bracha]{.ul} ^1^, I. Schwartz‐Atias^1^, A. Klein^1^, M. Dayan^1^, I. Yaniv^1^, R. Tarrasch^2^

*^1^Schneider children\'s medicla center of Israel, Hematology Oncology, Petach Tikva, Israel; ^2^Tel Aviv University, School of education and the Sagol school of neurosceince, Tel Aviv, Israel*

**Background/Objectives**: Coping with childhood cancer is difficult. Academic studies support the use of mindfulness practice as a way of actively coping with challenging situations. Incorporating non‐conventional techniques such as meditation, may contribute to better management of the illness pathway thus achieving emotional and functional well‐being and alleviating symptoms while coping with a life‐threatening illness.

The purpose was to offer a program that incorporates mindfulness and self‐compassion with the goal of enriching existing treatment options for children with cancer and their parents.

**Design/Methods**: A program consisting of six meetings was held by professionals specializing in mindfulness, social workers and nurses. Two groups (children and parents) were held separately and parallel. Each meeting was attended by three to ten participants. The findings are based on observations and unstructured interviews.

**Results**: In the children\'s group, the meetings enabled open discussion and sharing of negative as well as positive aspects of their illness and treatments. Feelings of pain and loneliness related to the disease and the treatments, as well as the love and meaningful relationships that were forged with their close environment were raised. In the parent\'s group, calmness and serenity succeeded in bringing about openness, and raising complex and emotional issues. The parents found that the practice offered a refuge to their everyday physical and emotional difficulties.

**Conclusions**: The benefits of mindfulness practice were evident in both groups. The accessibility of this training to sick children and their parents may improve symptoms management, quality of life, subjective well‐being, and enhance the parent‐child relationships. The accessibility of this service within a structured framework expands the range of existing therapeutic tools available for staff to offer the patient and his/her family. The mindfulness and care approach provides an answer to emotional needs that are often unanswered in times of distress and crisis.

### PO-363. Adopting a Psychosocial Integrated Systemic Care Model in the Provision of Palliative and Bereavement Support for Children with Cancer and their Families {#pbc27455-sec-13340}

[S.S. Ng]{.ul} ^1^, C. Lee^1^

*^1^Children\'s Cancer Foundation, Social Work, Singapore, Singapore*

**Background/Objectives**: A diagnosis of childhood cancer and its treatment place multiple psychosocial challenges on children and their families. Whilst literature shows that the provision of psychosocial services mitigates the impact of childhood cancer on families, an anchoring framework is useful in guiding psychosocial assessments and interventions.

Recognising the diverse challenges and needs of clients at different phases of the illness trajectory, Children\'s Cancer Foundation, Singapore (CCF) has developed a comprehensive integrated systemic care model to offer a continuum of care that extends services beyond the acute setting to clients' homes and the community.

When treatment has poor outcome and cure is no longer possible,. CCF\'s Home Team provides holistic care towards the physical, emotional, mental, social and spiritual well‐being of children and their families through palliative and bereavement support.

While most families have the resilience and capacities to cope, those with more complex needs may exhibit higher levels of distress and require more specialised interventions and support. CCF\'s integrated systemic care model helps social workers conceptualise different levels of targeted interventions that are matched according to the intensity of clients' needs at the end of life and during bereavement.

This integrated systemic care model may serve as a reference for case management and service development for agencies and helping professionals providing psychosocial support to children with health issues and their families.

**Design/Methods**: NA

**Results**: NA

**Conclusions**: NA

### PO-364. The Difference Between the Transplant Group and non‐Transplant Group in Terms of Sexuality and Fertility in the Physical Self‐Concept of Childhood Cancer Survivors {#pbc27455-sec-13350}

[A. Nishio]{.ul} ^1^, S. Mizushima^2^, A. Mizushima^3^

*^1^Cancer Center, Juntendo Hospital, Bunkyo‐ku, Japan; ^2^Juntendo University, Anesthegiology, Tokyo, Japan; ^3^Juntendo University Graduate School of Medicine, Plliative Medicine, Tokyo, Japan*

**Background/Objectives**: In childhood cancer survivors (CCS), who developed pediatric cancer and completed treatment by 15 years of age, the aims to clarify the awareness and anguish regarding the physical self‐concept of the survivors after reaching adolescent and young adulthood (AYA) according to those who received bone marrow transplantation and those who did not. The study also aims to examine methods of support for CSS with psychological suffering.

**Design/Methods**: The present study included CCS aged from 20 to 30 years who were diagnosed with and received treatment between 6 and 15 years of age, and in whom at least 5 years had passed since completion of the treatment. We conducted subject interviews from 2014 to 2015.

**Results**: The subject sample consisted of 9 individuals (4 males, 5 females) in the transplant group(TTG), and 11 individuals (5 males, and 6 females) in the non‐TG. The diseases treated included hematological malignancy in the transplant group, with hematological malignancy, malignant lymphoma, rhabdomyosarcoma, and brain tumor in the non‐transplant group. Based on the interviews, we found the following codes regarding sexuality and fertility in the physical self‐concept of CCS. Codes extracted for sexuality included "hormones are supplemented by drugs" and "hesitation to be in a romantic relationship, or become intimate," while those for fertility included "implicating the inability to have children" only in TTG. The effect of treatment on fertility was only seen in the transplant group.

**Conclusions**: In 8 out of 9 CCS in TTG, received the explanation of possible loss of fertility due to treatment.

CCS in TTG had to sacrifice their fertility in exchange for curative treatment. Therefore, in "implicating the inability to have children," it can be said that CCS in TTG tried to sublimate their scarred physical self‐concept. We believe that having the opportunity to meet with fellow CCS will serve as support for CCS.

### PO-365. Caregivers of Children and Adolescents with Cancer: Emotional Burden and Quality of Life in Hospital Rebagliati of Lima, Peru from January 2012 to December 2016 {#pbc27455-sec-13360}

[M. Oscanoa Gutierrez]{.ul} ^1^

*^1^Hospital Rebagliati Martins, lima, Lima, Peru*

**Background/Objectives**: Cancer is a disease of high incidence among children/adolescents and patients are in need of a caregiver during their treatment.

Aim: to evaluate the emotional burden and quality of life (QOL) of caregivers during chemotherapy, relating them to each other and to the socio‐demographic data with the presence of a scale for depression.

**Design/Methods**: It is a cross‐sectional study, with 192 caregivers. Socio‐demographic, emotional burden (Caregiver Burden Scale) and QOL data (SF‐36) were collected.

**Results**: The results show that 87.5% of caregivers were mothers, total score of emotional burden 1.92±0.09 and most compromised score of the SF‐36: emotional aspects (59.3), vitality (60.0), pain (60.9). There was a significant correlation between emotional burden, mental health and vitality.

**Conclusions**: Caregivers who presented emotional burden and compromised aspects of QOL, need interventions that will promote social and emotional wellbeing to reduce the emotional burden, improve the quality of life QOL and consequently deliver better care for patients during chemotherapy.

### PO-366. Resilience as a Mediator of Well‐Being in Adolescents and Young Adults with Cancer {#pbc27455-sec-13370}

[C. Phillips]{.ul} ^1^, J. Haase^2^, T.S. Stump^3^

*^1^Indiana Univesity, School of Nursing, Indianapolis, USA; ^2^Indiana University, School of Nursing, Indianapolis, USA; ^3^Indiana University, Department of Biostatistics, Indianapolis, USA*

**Background/Objectives**: Adolescents and young adults with cancer (AYA) experience poor sense of well‐being during and after cancer treatment. Resilience is a positive health outcome known to enhance well‐being in people who face adversity. The Resilience in Illness Model (RIM) -- a theoretical model that guides interventions research for AYA ‐ explains predictor factors that enhance or hinder resilience. Exploratory and confirmatory analyses indicate the RIM risk and protective factors explain high levels of variance in resilience; what is unknown is how resilience influences well‐being. The study purposes were to: (1) examine the relationships between five RIM predictor variables (spiritual perspective, courageous coping, hope‐derived meaning, illness‐related distress, defensive coping) and well‐being; and (2) determine if resilience is a mediator between well‐being and RIM variables.

**Design/Methods**: Data from two studies of AYA ages 10‐26 (N=181) were used. Mediation models, using path modeling in Mplus, were used.

**Results**: Four RIM predictor variables indicated a significant influence on well‐being. Increasing levels of spirituality and hope led to greater well‐being (path coefficients=0.27, 0.45, respectively) while increasing levels of illness‐related distress and defensive coping resulted in worse well‐being (path coefficients= ‐ 0.28 & ‐ 0.40). Resilience was a significant mediator between four RIM factors (spirituality, defensive coping, courageous coping, and hope) and well‐being. Time‐since‐diagnosis played a significant role in explaining the variance in resilience in illness and index of well‐being. Increasing time‐since‐diagnosis resulted in lower resilience and lower well‐being.

**Conclusions**: Spirituality, hope, illness‐related distress, defensive coping significantly influence well‐being. Resilience is a significant mediator between well‐being and four variables (spirituality, hope, courageous coping, and defensive coping). These findings suggest that AYA well‐being can be enhanced by targeting RIM factors in future interventions.

### PO-367. A Systematic Review of the Lived Experience of Young People with Cancer, Specifically Bone Tumours {#pbc27455-sec-13380}

[H. Queen]{.ul} ^1^

*^1^Birmingham Childrens Hospital, Oncology/Palliative care, Birmingham, United Kingdom*

**Background/Objectives**: Aim:

Systematic review on the lived experiences of young people cancer

Based on patients' experiences, to identify factors that could be incorporated into an adolescent cancer care pathway with a specific focus on the needs of these adolescents.

**Design/Methods**: A modified qualitative systematic review with a descriptive qualitative research methodology. Using two critical appraisal tools 6 studies met the inclusion/exclusion criteria.

**Results**: Results: Thematic analysis was used to systematically organise the findings into four themes: social functioning; school; resilience; self‐perception and loss of normality and education; and communication. Results showed persistently lower scores and reduced coping strategies in maintaining physical, emotional and social resilience, reduced quality of life and loss of normality and social functioning, compared to healthy peers.

**Conclusions**: Physical, emotional, psychological and social resilience is greatly reduced, resulting in a sense of loss of control and normality leading to social isolation and a change in their sense of self perception and inability to maintain their basic needs and activities of daily living. The deficits in the literature highlights the need for further qualitative studies on the actual lived experience of the adolescents in order that achievements, social interaction, social acceptance, emotional and social resilience is comparable to their healthy peer group. Further research will assist health care professionals in providing a more comprehensive approach to care and lead to reintegration post treatment from a place of illness to health through on going parallel care planning from the outset of treatment throughout care and into long term follow up robust care pathways.

### PO-368. Prevalence of Parental Sleep Problems in Pediatric Oncology: An Opportunity to Improve Quality of Life? {#pbc27455-sec-13390}

[N. Rensen]{.ul} ^1,2^, L. Steur^1^, S. Schepers^2,3^, H. Merks^4^, A. Moll^5^, M. Grootenhuis^2^, G. Kaspers^1,2^, R. Van Litsenburg^1,2^

*^1^VU University Medical Center, Pediatric oncology‐hematology, Amsterdam, The Netherlands; ^2^Princess Máxima Center, Pediatric oncology, Utrecht, The Netherlands; ^3^Academic Medical Center, Psychosocial department, Amsterdam, The Netherlands; ^4^Academic Medical Center, Pediatric oncology‐hematology, Amsterdam, The Netherlands; ^5^VU University Medical Center, Ophthalmology, Amsterdam, The Netherlands*

**Background/Objectives**: Parents of children with cancer are at risk for impaired quality of life (QoL). An important determinant of QoL is sleep. However, the prevalence of parental sleep problems and associated risk factors are largely unknown. This study therefore aims at exploring sleep and the influence of distress, socio‐demographic and child characteristics on sleep.

**Design/Methods**: Parents of children with cancer completed questionnaires on their sleep (Medical Outcomes Study sleep scale), distress (Distress Thermometer for Parents) and socio‐demographics. Sleep scores were compared to population values of healthy adults by calculation of Z‐scores (\>1 SD above population mean was considered as clinically relevant). Risk factors for impaired sleep were assessed with multiple linear regression models, stratified by gender. Child\'s (clinical) variables were tested as predictors, as well as parents' sociodemographic variables and distress thermometer score. Significance was set at p \< 0.10 in the final model.

**Results**: Parents (n = 352, 58% mothers) of 231 children (hemato‐oncologic diagnosis 33.3%, brain tumor 21.2%, solid tumor 33.3%, retinoblastoma 12.1%) participated. Mean time since diagnosis was 3.3 ± 1.4 years. Compared to 16% (1SD) in the population, 36% of the parents reported clinically relevant overall sleep problems (45% of mothers versus 27% of fathers, p \< 0.001). Risk factors for sleep problems in both parents were higher distress and pre‐existent sleeping difficulties. Additionally, mothers of a child with retinoblastoma were at risk for impaired sleep. Risk factors explained 31% of the variance in fathers' sleep problems and 44% in mothers' sleep.

**Conclusions**: Even years after their child\'s cancer diagnosis, parents experience impaired sleep. Particularly at risk are parents with higher levels of distress. Targeting distress and sleep problems may inform future interventions that aim to improve parental QoL.

### PO-369. Enrolment in Early Phase Paediatric Oncology Early Phase Clinical Trials: The Healthcare Professionals' Perspective {#pbc27455-sec-13400}

[E. Robertson]{.ul} ^1,2^, R. Mitchell^1,2^, C. Wakefield^1,2^, P. Lewis^3^, N. Cousens^4^, G. Marshall^1,2^, S. Russell^1,2^, D. Ziegler^1,2^, A. Anazodo^1,2^, T. Trahair^1,2^, D. Barbaric^1,2^, R. Cohn^1,2^, F. Alvaro^5^, T. O\'Brien^1,2^

*^1^Sydney Children\'s Hospital, Kids Cancer Centre, Randwick, Australia; ^2^UNSW Sydney, School of Women\'s and Children\'s Health, Randwick, Australia; ^3^Western Sydney University, School of Nursing And Midwifery, Penrith, Australia; ^4^Prince of Wales Clinical School, UNSW Sydney, Randwick, Australia; ^5^John Hunter Children\'s Hospital, Oncology, Newcastle, Australia*

**Background/Objectives**: The process of enrolling a child with cancer in an early phase trial is complex. We examined the perspectives of healthcare professionals (HCPs) regarding obtaining informed consent for early phase trials in families of children with cancer.

**Design/Methods**: We collected data from 86 HCPs working in paediatric cancer centres across Australia/New Zealand. Our questionnaire addressed perceived benefits of early phase trials, barriers in obtaining consent, and information provision. We also examined HCPs' perceptions of parents' comprehension, preferences for information, and factors that influence their decision‐making.

**Results**: HCPs were on average 43 years (range=25‐74), with 15 years of experience in paediatric oncology (range=1‐40) (physician/fellow=43.7%; nurses=23.3%; other=12.6%; unknown=20.4%). Few HCPs (17.4%) received formal training for consent for early phase trials, however most were willing to attend training (77.9%). HCPs (61.6%) reported that they informed families about early phase trials without any attempt to influence their decision. Contradicting this, many (62.8%) also reported they were "slightly directive" in recommending the trial. HCPs' main obstacle in obtaining consent included their perception of parents' eagerness to "try anything" (52.3%) and feeling responsible for maintaining parents' hope (22.1%). On average, HCPs perceived that \<50% of parents understood concepts, such as 'dose escalation' or the likelihood of therapeutic benefit. HCPs reported that decision‐making was usually shared between the parent and treating team (44.7%) or the parents' decision (50.0%). HCPs believed that children should be involved in early phase trials discussions from 10 years (median; range=3‐16), and in the decision to enrol from 12 years (median; range=3‐18).

**Conclusions**: Early phase trials are an important part of improving paediatric cancer therapy. This study reports that HCPs may experience difficulty conducting early phase trial consultations and obtaining valid informed consent. Our study highlights the need for formal training for HCPs and additional patient education tools.

### PO-370. The Development of Delta: A Decision Aid to Help Parents Considering Enroling their Child in a Paediatric Oncology Clinical Trial {#pbc27455-sec-13410}

[E. Robertson]{.ul} ^1,2^, C. Wakefield^1,2^, R. Cohn^1,2^, J. Fardell^1,2^

*^1^Sydney Children\'s Hospital, Kids Cancer Centre, Randwick, Australia; ^2^UNSW Sydney, School of Women\'s and Children\'s Health, Randwick, Australia*

**Background/Objectives**: Families often find the decision to enrol in a clinical trial difficult. We developed Delta, a world‐first online decision‐aid to support families deciding on participation in a paediatric oncology clinical trial. Delta aims to improve clinical trial knowledge and decision satisfaction.

**Design/Methods**: To guide the development of Delta, we conducted semi‐structured interviews with 25 parents (mean age of child at diagnosis=6.9y) whose child had been diagnosed with cancer in the past 12‐months. Following the development of Delta, we conducted user‐testing, which included eye‐tracking and think‐aloud interviews with healthcare professionals (n=6) and parents (n=7).

**Results**: In our interviews, parents described feeling overwhelmed with information, yet still not having enough at the same time, highlighting a potential discrepancy between information provision and comprehension. Most parents (86.4%) accessed additional information to help make their decision, including online. Most parents (95.2%) preferred to be involved in the decision process, but often felt they "didn\'t have a choice". All parents emphasised the benefit of question‐asking. Based on the interviews, we developed the Delta website. In the user‐testing, participants (n=11/13) reported content was easy to read. Eye‐tracking showed participants read lines to completion, suggesting engagement with content. Participants reported minor navigational difficulties (n=7/13). Participants found the decision exercise useful (n=10/13), but eye‐tracking suggested a need to make the instructions more obvious. Overall, participants reported Delta had high acceptability (n=12/13) and good usability (n=8/13).

**Conclusions**: Families require clearer information provided in multiple modalities, more guidance to engage in decision‐making, and more emotional support throughout the decision process. Our interview findings contributed to the development of Delta, an innovative tool to provide accessible, balanced and evidence‐based information for families. User‐testing provided positive feedback, with requested changes now implemented. We are currently conducting a pilot of Delta. Early pilot data suggests Delta significantly improves parents' clinical trial knowledge.

### PO-371. Qualitative Review of Knowledge, Attitude and Practices of Caregivers of Pediatric Oncology Patients at a Tertiary Care Center in a Developing Country {#pbc27455-sec-13420}

[H. Saeed]{.ul} ^1^, S. Anjum^1^, R. Muhammad Wali^1^, S. Javed Khan^1^

*^1^Shaukat Khanum Memorial Cancer Hospital and Research Center, Pediatric Oncology, Lahore, Pakistan*

**Background/Objectives**: Knowledge, attitude and practices (KAP) about cancer is a key factor in success of cancer treatment. Approach to cancer and its treatment are determined by local beliefs and practices. The KAP of caregivers of pediatric cancer patients has not been studied in Pakistan. Thus, we conducted a qualitative review of KAP of caregivers of pediatric cancer patients.

**Design/Methods**: This study was done in a tertiary care cancer Hospital of Pakistan (Shaukat Khanum Hospital) between February and August 2016. A unique questionnaire was designed in accordance with the local cultural and religious beliefs and practices. Sampling was done opportunistically. Interviews were conducted in Urdu language. The interview lasted for 30‐60 minute. The interview tool content was analyzed and discussed between the authors to identify relevant categories.

**Results**: Sixty‐one caregivers were interviewed. 31 were caregivers of newly diagnosed patients. Parents were caregivers in 69% (n=42). When asked, "What is cancer?" 65% (n=40) replied "dangerous disease", 19.7% (n=12) did not know and the remaining considered it "worsening of wounds or infection" or "lump forming disease". When asked, "What causes cancer?" the majority (44.3%, n=27) did not know, eight (13%) considered the illness "fate, destiny or God\'s will". Majority of caregivers (93.4% n=57) consider cancer curable. 26.2% (n=16) consider cancer contagious. 51% (n=31) expressed fear for the rest of their family. 90 % (n=55) stated that they expect the patient to have a normal future. Majority of caregivers (68.9%, n=42) were using spiritual healers either prior to or during treatment. None were aware of screening for cancer.

**Conclusions**: This study has identified mutliple caregiver stressor and erroneous beliefs regarding food restriction and etiology of cancer. These finding can help target specific issues in counseling and education of caregivers. This can serve as a pilot study for designing interventions and further study of KAP in our region.

### PO-372. National Law on Child Rights in El Salvador: Implications for Cancer Control {#pbc27455-sec-13430}

S. Fuentes‐Alabi^1^, [C. Salaverria Castillo]{.ul} ^2^, R. Vasquez Zelaya^1^, C.G. Lam^3^

*^1^National Children Hospital Benjamin Bloom, Pediatric Hemato‐oncology, San Salvador, El Salvador; ^2^National Children Hospital Benjamin Bloom, Psychology, San Salvador, El Salvador; ^3^Memphis‐ Tennessee, USA*

**Background/Objectives**: In 2009, El Salvador established a national law for the comprehensive protection of children, known as LEPINA (Law for Integral Protection of Children and Adolescents). LEPINA includes stipulations that medical teams' instructions must be followed when a child requires treatment for a life‐threatening condition, with potential State/judicial enforcement. This policy analysis illustrates considerations for frontline providers and decision‐makers implementing national legal interventions with provisions for health rights in a lower‐middle‐income country, and implications for childhood cancer control.

**Design/Methods**: Data on processes and outcomes of LEPINA implementation was prospectively captured in an electronic patient tracking system and records at Hospital Benjamin Bloom (HBB), the only national pediatric referral hospital, and retrospectively analyzed. The Policy Triangle framework was utilized to consider central policy actors in relationship to the policy context, content and processes.

**Results**: The LEPINA Law was operationalized by a new, National Council on Children and Adolescents CONNA. Psychosocial team members were central in connecting with community‐based legal and State providers, and in co‐interpreting and communicating how LEPINA could apply and facilitate treatment completion for children with curable cancers. 1,321 children were diagnosed with cancer from 2011 to 2018. Starting on June 2, 2011, LEPINA became integrated in routine counseling for abandonment prevention. A subset of 43 children with curable cancers identified as at‐risk for treatment abandonment required counseling on potential application of LEPINA law. Twenty‐six patients required escalation with engagement involving legal authorities with 13 completing treatment successfully (disease‐free, follow‐up median 27 months). 30 of 43 patients still abandoned treatment, with however abandonment has been reduced from 13% to 2% in the last seven years.

**Conclusions**: Diverse actors affect effective policy implementation. While such a national law may be applied to facilitate timely treatment completion for cancer, additional work is warranted to characterize the implications and implementation needs of such legal interventions.

### PO-373. Cancer Charity House: Its Roles and Impact in Pediatric Cancer Treatment in Acute Lymphoblastic Leukemia {#pbc27455-sec-13440}

[N.M. Sari]{.ul} ^1^, N. Suryawan^1^, S. Susanah^1^, L. Reniarti^1^

*^1^Division of Hematology and Oncology, Child Health Department Dr. Hasan Sadikin Hospital/Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia*

**Background/Objectives**: Pediatric cancer treatment especially in limited income country faced many obstacles. Increasing number of patients is not accompanied by acceleration of pediatric oncology diagnostic nevertheless supportive care facilities. Thus result high rate of interrupted and abandonment treatments 21,3% and 41,5% respectively in our hospital. The community concern about pediatric cancer is bolted fast in the last 10 years characterized with establishment of cancer charity houses (CCH). The objectives of this study was to describe and understanding the impact of CCH on the abandonment treatment in acute lymphoblastic leukemia (ALL) patients.

**Design/Methods**: This was mixed method cross sectional study in Dr. Hasan Sadikin Hospital Bandung West Java Indonesia. Data were collected from observation and in depth interviewed using structured interview guide completed by 6 staff of CCH, 60 ALL parents, and 5 of pediatric oncology residents. Data from ALL parents were classified into interrupted and abandonment treatment group. All demographic patient data was extracted from Bandung Online Cancer Registry. The qualitative data was analysis by saturation methods and chi squre test for quantitative data.

**Results**: There were four CCHs located 800‐1000 m from Dr Hasan Sadikin Hospital namely: Rumah Kita, Rumah Cinta, Rumah Harapan and Rumah Teduh which have 10‐15 beds capacity initiated by parental supporting group and established a charity foundation each. They supported almost all the operational expenses. They did incidental program to obtain donations and used the social media to gain those. Activities of CCH include providing the home stay, meals, home schooling, transportation, drug donation and field trip. The prevalence of abandonment treatment was 1,53 times higher in patients who didn\'t use the CCH but statistically insignificant (RP 1,53;CI 95% 0,92‐2,56, p=0.021)

**Conclusions**: The role of charity house in pediatric cancer management is promising to decrease the abandonment treatment

### PO-374. Understanding the Impact of Having a Child with Cancer on Family Dynamics {#pbc27455-sec-13450}

[M. Sata]{.ul} ^1^

*^1^Kayula Childhood Cancer Foundation, Operations, Lusaka, Zambia*

**Background/Objectives**: In most African settings, extensive display of emotions is not encouraged. As we get through life\'s sometimes‐traumatic events, counselling is not available. One is expected to mourn a period and then move on with life as per usual. Keeping in line with the conference theme, we need to find new solutions of dealing with the trauma childhood cancer brings on the entire family. Seeking fresh ways of introducing/transforming the psychosocial care available we can achieve better results all round.

The main objectives of this abstract are to share and find long lasting solutions to a better quality life for the parent/ survivors and/or for the bereaved parents and siblings.

**Design/Methods**: A parent with a cancer riddled child exhibits various negative emotions that add to emotional de‐stress and fatigue; resulting in hypertension. Pressure from hospitalization and domestic responsibilities can be an additional strain financially. An expectant mother died of hypertension while nursing her child suffering with cancer.

Relationships experience severe strain during this time. Absence from partners lead to infidelity. Others end up exchanging sex for money. Pregnancies between single mothers and married men are cases in point. Cases of divorce are on the rise.

Siblings are deprived of family time resulting in them feeling neglected due to most of the attention being on the sick sibling. The siblings' education may be affected negatively. Various negative emotions may also play havoc on the sibling.

**Results**: As resources are stretched the family\'s way of life is adjusted, only necessities are considered.

**Conclusions**: The people involved in this journey go through various emotions and have to be supported in many ways through community intervention.

Employ a multi‐ sectoral approach by engaging various stakeholders, in our quest to mitigate childhood cancers and related blood disorders.

### PO-375. A New Kind of Language Barrier: Examining Disparities in Medical Teams' Referrals of Palliative Care Patients to Pediatric Psychology {#pbc27455-sec-13460}

[N. Schneider]{.ul} ^1^, D. Steinberg^2^, B. Karfunkle^3^

*^1^Baylor College of Medicine/Texas Children\'s Hospital, Pediatrics, Houston, USA; ^2^Columbia University Medical Center, Pediatrics‐ Psychiatry, New York, USA; ^3^Baylor College of Medicine, Emergency Medicine, Houston, USA*

**Background/Objectives**: As cancer care has improved, so has the understanding that children with cancer are at risk for psychological distress. The American Academy of Pediatrics has highlighted the importance of addressing these concerns. Our study aims to identify how cultural and language factors may influence whether psychology is involved in a patient and family\'s care. Preliminary literature in adult‐focused research suggests that a vast majority of those referred to psychology are English speaking.

**Design/Methods**: The medical records of pediatric patients who died from cancer or its complications over a consecutive 18 month‐period were examined via retrospective chart review. Patients' demographic information was collected, along with information about whether their medical team requested a psychology consultation. Details about consultations and subsequent intervention were collected.

**Results**: Eighty‐nine charts were reviewed. Patients ranged from age 3 months to 25 years. Data indicated that non‐English speaking families were referred to psychology at nearly half the rate of English‐speaking families (i.e., 16% of patients as compared to 31% of patients). There did not appear to be any statistically significant differences between the referred and non‐referred groups aside from the family\'s primary language. There was a wide range of when patients were referred (4‐3168 days before death).

**Conclusions**: Results indicate that, though the comprehensive biological‐psychological‐social care of children is widely recognized as important, there is a clear disparity in the services offered to families that speak languages other than English. Further research should be conducted to understand referral barriers and missed opportunities to utilize pediatric psychology, particularly as hospitals in the United States continue to diversify. Finally, offering providers education about how to identify common psychological concerns, particularly in those hailing from different cultural backgrounds, may be particularly valuable in closing the identified referral gap; our poster will make culturally‐informed recommendations for such a training.

### PO-376. Improving Quality of Sexual Life Among Paediatric Cancer Survivors in Developing Countries: Living Beyond the Disease {#pbc27455-sec-13470}

[D.S. Sharma]{.ul} ^1^, N. Somani^2^

*^1^SMS medical college and attached hospitals Jaipur, Radiotherapy, jaipur, India; ^2^BMCHRC Jaipur, medical oncology, Jaipur, India*

**Background/Objectives**: Cancer treatment is one of paediatric medicine\'s biggest success stories, chemotherapy, radiation and other therapies can do lasting damage to a child\'s developing body. It is incumbent upon oncologists to conceive of Paediatric malignancies as more than just a disease that begins with diagnosis and ends when the treatment protocol ends instead, it initiates a life‐long trajectory of survival having long‐term implications for quality of life.

**Design/Methods**: Emotional needs are deeply frustrated in children, due to long hospitalization, strong parental bonds that jeopardize the normal development of autonomy and independence, friends, painful tests, anxiety and anguish, hours of loneliness without tenderness, this critical suspension from normal life and shift to emergency survival further complicates attainment of satisfying sexual identity and disrupts basic psychosexual maturity process.

**Results**: Adolescent sexuality is very complex, and even more when serious adverse event like cancer affects the individual well‐being ‐ sexual and non‐sexual---in all its dimensions. Young survivors are significantly different in specific domains, they are less feminine in sexual identity have more restrictive and submissive images of sexuality, lower confidence with masturbation. They have less experience of intercourse. These effects can be better understood if put in perspectives with many changes and challenges young cancer survivors have to face and cope with in different emotional, affective, relational, cultural and existential domains. Cultural issues in our sexually polite Asian society, such as the myth that children are too young to be interested in sexuality and presumption that issues of survival overshadow sexuality, provide barriers to open communication about sexuality.

**Conclusions**: Sexual function and fertility should no longer be regarded by oncologists as frivolous or irrelevant issues, the very privileged relationship that oncologist have with their patients should permit them to assist children in their journey of cancer management.

### PO-377. Health‐Related Quality of Life in Adolescents with Cancer {#pbc27455-sec-13480}

[M.N. Sitaresmi]{.ul} ^1^, B.W. Indraswari^1^

*^1^Faculty of Medicine‐ Public Health and Nursing‐ Universitas Gadjah Mada/ DR. Sardjito Hospital, Paediatric Department, Yogyakarta, Indonesia*

**Background/Objectives**: Health‐related quality of life (HRQOL) of adolescents with cancer may be affected by the disease and treatment. The aims of this study are to assess profile HRQOL of adolescents with cancer and to assess the influence of demographic and medical characteristics on HRQOL score.

**Design/Methods**: Method: We conducted a cross sectional study of HRQOL in Dr. Sardjito General Hospital Yogyakarta, Indonesia from June to November 2017. Adolescents cancer patients (10‐18 years old) and their guardians in various phase of treatment were recruited. HRQOL was assessed using PedsQL ™ 4.0 generic module and PedsQL™ 3.0 cancer module Indonesian validated versions.

**Results**: Fifty‐eight adolescents and their guardians were recruited. The internal validity of both scales were good (Cronbach\'s Alpha Coefficient ranged from 0,81 to 0,98) as well as the internal correlation between self‐reports and proxy‐ reports (ICC was 0.84 to 0,95). Both patients and their guardians reported low scores on school function subscale (36 and 37). Compared to boys, female adolescents patients reported lower score in emotional function subscale (87 vs 76, p\<0.01). Late adolescents reported lower score than early adolescents especially in total score of both scales, emotional subscale and worry subscale. Guardians of non‐hematology malignancy patients reported lower score than hematology malignancies patients in physical function (83 vs 72, p 0.04), social function (94 vs 88, p 0.02) and pain‐hurt function (89 vs 77, p\<0.00).

**Conclusions**: Late adolescents had more problems both in generic and cancer scale. Psychosocial support should be provided by their families and peer group to facilitate their coping with the disease and treatment. School substitution should be offered to adolescents during their treatment.

### PO-378. Socio‐Psychological Aspects of the Professional Medical Team in Children\'s Department of Oncology/Hematology {#pbc27455-sec-13490}

[T. Stepanova]{.ul} ^1^, I. Balalaeva^1^, G. Trubnikova^2^, N. Yudina^2^, A. Shvirev^3^

*^1^N.N.Burdenko State Medical University, Pediatric oncology, Voronezh, Russia; ^2^Regional Children\'s Hospital, Pediatric oncology, Voronezh, Russia; ^3^N.N.Burdenko State Medical University, Pediatrics, Voronezh, Russia*

**Background/Objectives**: At the present time the problems of organization, management of professionals, ability to work in a team, are be coming of current interest. There fore, the research of psychosocial aspects of medical teams of the oncological/hematological medical care was carried out.

Purpose: Evaluation of the psychological parameters of the medical team and its readiness for a stable professional activity.

**Design/Methods**: The psychological features of the medical team of the children\'s oncohematological department of Voronezh regional hospital during the period from 1995 to 2016 have been studied. Sixteen physicians were examined: 8 women, 2 men aged 30 to 50 years (experience of joint work from 10 to 25 years); 6 women aged 26‐28 years with an experience of 2‐6 years. For the analysis of such psychological parameters as the formation of the medical team, standard maps‐schemes were used, as well as the test "Group roles" for assessing controllability and efficiency of work. The quantitative indicators were determined by the sum of the scores for each parameter.

**Results**: According to standard maps, the psychological parameters of the collective, such as the direction of activity, are studied; organizational unity; psychological unity with the aid of a map‐scheme. As our research has shown, the team is well developed all kinds of psychological unity: intellectual, emotional, strong willed. To assess the manageability and effectiveness of the team, a "Group role" test was conducted using a questionnaire with specific sections.

**Conclusions**: According to the research, the doctors of the children\'s oncohematological department represent a formed, socially‐mature collective with a single strategy, characterized by a high level of activity, psychological unity and organization. In the department, it is expedient to distribute all the roles that are performed by the members of the collective and complement each other. The revealed correlation of roles in collective promotes effective professional activity.

### PO-379. Improving Health Behaviors of Obese Pediatric Cancer Survivors: Measurement Considerations and Factors Affecting Participation and Adherence {#pbc27455-sec-13500}

[M. Stern]{.ul} ^1^, J. Bleck^1^, S. Mazzeo^2^

*^1^University of South Florida, Child and Family Studies, Tampa, USA; ^2^Virginia Commonwealth University, Psychology, Richmond, USA*

**Background/Objectives**: Obesity rates in pediatric cancer survivors (PCS) are alarmingly high. Results of our randomized control pilot trial aimed at improving healthy lifestyles, NOURISH‐T, found positive effects on parental and PCS BMI, dietary intake, and physical activity. As with all PCS‐focused interventions, participation and retention was a concern. This study explored potential factors associated with participation and retention in the context of our pilot findings.

**Design/Methods**: In total, 53 parents of eligible PCS were randomized to either the 6‐session NOURISH‐T intervention or a one‐time Enhanced Usual Care (EUC) session. An additional 14 provided baseline data but did not participate in either condition or post assessments (no contact group). Assessments were conducted at baseline, post‐intervention, and a 4‐month follow‐up.

**Results**: On average, PCS were 9.92 years old, 1.96 years off‐treatment, and 64.4% had ALL or lymphoma. Mean baseline child BMI%ile was 95.4. While there were no baseline differences, PCS BMI%ile at diagnosis was significantly higher among the no contact group (mean=93) than parents completing either NOURIST‐T or EUC (mean=72). Overall, 87.5% of NOURISH‐T parents attended at least 3/6 sessions. Generally speaking, lower annual income was associated with fewer completed sessions. Several factors were associated with completion of assessments. Families with an older parent, older PCS, and female PCS were more likely to continue participating through all assessements (p\<.05). However, time off‐treatment was not related to assessment completion. Higher child baseline BMI%ile was also related to lower assessment completion (p=.018). Mean child BMI%ile was 98.9 among the parents who only completed baseline assessment, 95.7 among parents who completed baseline and post assessments, and 93.9 among parents who completed all three assessments.

**Conclusions**: Results suggest that PCS gender, age, and BMI at diagnosis are key factors to be considered in designing behavioral interventions for PCS and their families. Implications for intervention strategies and measurement considerations are discussed.

### PO-380. Subjective but not Objective Increase in Sleep Problems During Dexamethasone Treatment in Pediatric Acute Lymphoblastic Leukemia {#pbc27455-sec-13510}

[L. Steur]{.ul} ^1^, M. Grootenhuis^2,3^, N. van Eijkelenburg^2^, I. van der Sluis^2,4^, N. Dors^2,5^, C. van den Bos^6^, W. Tissing^2,7^, G. Kaspers^1,2,8^, R. van Litsenburg^1,2^

*^1^VU University medical center, Department of pediatric oncology, Amsterdam, The Netherlands; ^2^Princess Máxima Center, Pediatric oncology, Utrecht, The Netherlands; ^3^Emma Children\'s Hospital Academic Medical Center, Psychosocial department, Amsterdam, The Netherlands; ^4^Erasmus Medical Center ‐ Sophia Children\'s Hospital, Department of pediatric haemato‐oncology, Rotterdam, The Netherlands; ^5^Amalia Children\'s Hospital Radboud University Medical Center, Department of pediatric oncology, Nijmegen, The Netherlands; ^6^Emma Children\'s Hospital Academic Medical Center, Department of pediatric oncology, Amsterdam, The Netherlands; ^7^University Medical Center Groningen, Department of pediatric oncology, Groningen, The Netherlands; ^8^Dutch Childhood Oncology Group, Pediatric oncology, The Hague, The Netherlands*

**Background/Objectives**: Sleep problems are common in childhood cancer and glucocorticoid treatment seems to be a risk factor. Current evidence is limited by small sample sizes and heterogeneous treatment groups. Additionally, most studies have not combined objective and subjective assessments although these provide valuable complementary information. This study evaluates the effect of dexamethasone treatment on objective and subjective sleep in a homogeneous cohort of children with acute lymphoblastic leukemia (ALL).

**Design/Methods**: The ALL11 SLEEP study is a national prospective study on sleep in children treated according to the Dutch Childhood Oncology Group ALL11 treatment guideline. At one year post‐diagnosis, children treated with cyclic dexamethasone (DEX) were assessed twice: on‐DEX and off‐DEX. Each measurement consisted of: 1) objective 7‐day sleep assessment with a wrist‐worn accelerometer (ActiGraph GTX3); 2) subjective sleep assessment with the parent‐reported Children\'s Sleep Habits Questionnaire (CSHQ). CSHQ Z‐scores were calculated based on Dutch norms as scores are age‐dependent. Differences on‐DEX and off‐DEX were evaluated using multilevel analysis. The effect of pre‐existent sleep problems, comorbidity, age, sex, and pain was evaluated.

**Results**: CSHQ scores were available in 68 patients, actigraphy in 47. Mean age was 5.9±2.5 years, 42% were girls. The prevalence of sleep problems was 55% on‐DEX and 48% off‐DEX, versus 16% in norms. Mean CSHQ Z‐score was significantly higher on‐DEX (1.19±1.40) compared to off‐DEX (1.00±1.39, p=0.009, 95%CI 0.12‐0.82). There were no significant differences in the objective sleep outcomes.

**Conclusions**: The prevalence of sleep problems is high during ALL maintenance treatment with cyclic dexamethasone. On‐DEX parent‐reported sleep problems are significantly higher than off‐DEX, but actigraph outcomes are similar. These results suggest that DEX treatment has a higher sleep problem burden as perceived by the parents, and stresses the importance of supporting families in coping with DEX effects. Future studies should include sleep self‐reports, to determine the burden experienced by the patients themselves.

### PO-381. Hope and Spirituality in Adolescent Cancer Patients {#pbc27455-sec-13520}

[C. Strahlendorf]{.ul} ^1^

*^1^BC Children\'s Hospital, Division Hem/Onc/BMT, Vancouver, Canada*

**Background/Objectives**: As pediatricians we recognize the importance of the social, emotional and developmental domains in the care and treatment of our patients. This study evokes a more humanistic approach facilitated by narratives and qualitative methodologies exploring the theme of spirituality, and hope as core enablers of resilience in adolescents undergoing cancer therapy, and how the diagnosis of cancer frames their meaning of life. Treatment of cancer results not only in loss of hair and body parts, but also of self‐control and dignity. So what do adolescents cling to in the midst of being treated for cancer and the consequent experience of uncertainty and loss?

**Design/Methods**: This qualitative study explored through narratives, how adolescents faced with cancer, find meaning in their lives and what factors facilitated their resilience in coping with treatment and the fear of death. Interpretive Description was used to analyse the data.

**Results**: Thirteen adolescent patients were interviewed and even though buffeted by illness all expressed a will to live and a hope to get better. Although there are many dimensions that contribute to resiliency this study focused primarily on the domains of hope and spirituality. Five domains were identified that highlighted both internal strengths and external supports that play important roles in the resilience of youth. The reality that adolescence is a stage of life during which the child evolves cognitively and morally and when self ‐identity is evolving was considered. Themes that emerged were redefined relationships with parents and friends, threatened social networks and arrested normal development, spirituality and optimism.

**Conclusions**: It is from our patients and their shared insights from their lives, illness and suffering that we as clinicians learn. This study helps us better understand, in adolescents, what illness takes away and how as health care providers we can holistically respond.

### PO-382. Effect of Virtual Reality Exergaming on Function in Children with Brain Tumors: 3 Months Follow Training in 5 Case Series {#pbc27455-sec-13530}

[M. Tanrıverdi]{.ul} ^1^, F. Mutluay^2^, F.B. Çakır^3^

*^1^Bezmialem Vakıf University, Faculty of Health Sciences‐ Department of Physiotherapy and Rehabilitation, İstanbul, Turkey; ^2^İstanbul Medipol University, Faculty of Health Sciences‐ Department of Physiotherapy and Rehabilitation, İstanbul, Turkey; ^3^Bezmialem Vakıf University, Faculty of Medicine‐ Department of Child Oncology, İstanbul, Turkey*

**Background/Objectives**: This pilot study focused a Nintendo Wii training for the children with brain tumors. This paper describes the virtual reality exercgaming of oncologic rehabilitation for function. The aim of study was investigated the effect of virtual reality exergaming on function in children with brain tumors.

**Design/Methods**: Children were Nintendo Wii training for 12 weeks X 2 days/week X 45 minutes/session. Traning included 5 different games; 1. Soccer Heading, 2. Ski Jumping, 3. Penguin Slide, 4. Ski Slalom, 5. Balance Bubble. Pre, and post measures were collected. Outcome measures were the dempgraphic characteristics, physical and clinical measurements, evaluations of function, and games scores recorded. Descriptive and correlation statistics were used.

**Results**: Five (3 girls, 2 boys) children were in the Nintendo Wii training. The mean age was 10.40±3.507 (min‐max=7‐14) years, height was 1.29±0.231 (min‐max=0.98‐1.51) meter, wieght was 31.40±12.239 (min‐max=18‐50) kg, the number of chemotherapy cure was 7.60±0.894 (min‐max=6‐8), the number of radiotherapy session was 35.20±6.534 (min‐max=30‐46), the surgeon age was 8.40±3.847 (min‐max=4‐13) years, and the number of Nintendo Wii training session was 18.20±5.495 (min‐max=12‐24). There was found a statisticially significant relationship between the number of Nintendo Wii sessions and age (r=‐0.973; p=0.005), height (r=‐0.975; p=0.005), surgery age (r=‐0.975; p=0.005). The scores of games were improved more than a hundred percent.

**Conclusions**: Children reported that the Nintendo Wii training compliance and consistently positive responses to motivation and feasibility questions. Therefore, Nintendo Wii training may be an effective home‐based rehabilitation strategy, and is worth exploring in a larger trial. Implications of Nintendo Wii training in the context of motivation theory are discussed. The long‐term goal of virtual exergaming rehabilitation is to provide support for a return to as normal and self‐determined a life as possible.

### PO-383. The Experiences of Childhood Cancer Survivors and Parents in Singapore: A Qualitative Study {#pbc27455-sec-13540}

A. Clarke^1^, [L. Teo Ling\'en]{.ul} ^1^

*^1^KK Women\'s and Children\'s Hospital, Psychology Service, Singapore, Singapore*

**Background/Objectives**: Over 150 children are diagnosed with cancer in Singapore each year, with an enormous impact on the family. Experiences of child survivors and parents are well documented in the Western literature, but much less well understood within the Asian context. This study sought to explore the experiences of Singaporean parents and child cancer survivors. This study is part of a larger project exploring the impact of childhood cancer in Singapore.

**Design/Methods**: Parents and survivors were invited to participate in a focus group discussion through a local childhood cancer charity. Time since diagnosis ranged from 2‐ 20 years. 5 parents (four mothers and one father) and two survivors (male) consented to participate. All identified their ethnicity as either Singaporean Chinese (n=5) or Singaporean Malay (n=2). The resultant discussion was transcribed verbatim, then coded and analysed using thematic analysis.

**Results**: Two major themes emerged for parents, financial strain and emotional impact, which contained two sub‐themes, managing uncertainty and trauma and loss. Two major themes were identified in both the parent and child discussions, importance of hope and education concerns.

**Conclusions**: This study found some commonalities of coping experience in both Western and Singaporean culture. It adds knowledge regarding the financial strain and education concerns within the Singaporean context and highlights the needs for practical and emotional support for parents and survivors.

### PO-384. Transition Age Youth Who are Nonadherent to Treatment Recommendations: Clinical, Legal, and Ethical Challenges {#pbc27455-sec-13550}

[A. Thompson]{.ul} ^1^, S. Hardy^1^

*^1^Children\'s National Health System, Center for Cancer and Blood Disorders, Washington DC, USA*

**Background/Objectives**: Nonadherence to treatment recommendations is a common problem among adolescents and young adults with cancer and can be frustrating for providers who understand the potential life‐threatening consequences of missed medications, procedures, and appointments. The challenge is exacerbated when patients reach the age of legal adulthood (age 18 in the US), gain responsibility for their care, and make treatment decisions that may negatively affect their health.

**Design/Methods**: A case study will be presented to illustrate the clinical, legal, and ethical challenges of young adults treated in pediatric facilities who are nonadherent to treatment recommendations. UR is a 19‐year‐old Hispanic male with a history of high‐risk acute myeloid leukemia s/p haploidentical bone marrow transplant. Although in remission, he requires ongoing monitoring and treatment for significant graft versus host disease and infections. UR\'s symptoms have been exacerbated by nonadherence to medication and other treatment recommendations, ongoing substance use, and failure to show for follow‐up as directed.

Unique perspectives will be offered to examine case dynamics. Clinical team\'s concerns include: patient\'s physical and emotional well‐being; fear that UR will stop treatment altogether if transitioned to an adult provider; personal emotional investment in this patient. Legally, concerns center on potential risk to the hospital if a patient who is unlikely to follow up is transitioned, when that lack of follow‐up could have life‐threatening implications. Ethical issues regarding the permissibility of recommending such a transition will also be discussed.

**Results**: After a number of attempted interventions with the patient, ongoing support of the medical team, and consultation with hospital resources, UR was transitioned to an adult facility.

**Conclusions**: Young adult patients in pediatric facilities present numerous unique challenges, especially if they are nonadherent to treatment recommendations. Multidisciplinary care and input is critical in evaluating the course of action that is most appropriate for the team, hospital, and patient.

### PO-385. Post‐Traumatic Stress Symptoms in Parents of Children with Leukemias at Day +33: Identifying the Early Predictors {#pbc27455-sec-13560}

[M. Tremolada]{.ul} ^1^, S. Bonichini^2^, L. Taverna^3^, M. Tumino^4^, G. Bisogno^4^, M.C. Putti^4^, G. Basso^4^, M. Pillon^4^

*^1^University of Padua, Department of Developmental and Social Psychology‐ Department of Child and Woman\'s Health‐ Oncology Hematology Division, Padua, Italy; ^2^University of Padua, Department of Developmental and Social Psychology, Padua, Italy; ^3^Free University of Bozen‐Bolzano, Faculty of Education, Brixen‐Bressanone, Italy; ^4^University of Padua, Department of Child and Woman\'s Health‐ Oncology Hematology Division, Padua, Italy*

**Background/Objectives**: Parents appear more at risk for post‐traumatic stress symptomatology (PTSS) (Tremolada et al., 2013) in the acute phase of leukemia treatment. Predictive risk factors for PTSS are: younger age and female gender (Rodriguez et al., 2012; Boman et al., 2013), lower economic condition (Jurbergs et al., 2009), difficult past life stress episodes (Cloitre at al., 2009), emotional coping (Barrera et al., 2004; Tremolada et al., 2012) and partner support unavailability (Sloper, 2000). The objectives of this study were: to screen PTSS severity and identify possible predictors of PTSS in parents.

**Design/Methods**: One‐hundred and seven Italian parents gave their consent to this study. They were mostly mothers (81.3%), with a mean age of 40.05 years (SD = 5.75). The children were 90, with a mean age of 7.66 years (SD = 4.11), mostly with a diagnosis of acute lymphoblastic leukemia (91%), followed by acute myeloid leukemia (9%). Parents were interviewed after one week from the diagnosis communication (EFI‐C, Tremolada et al., 2013), they filled in Ladder of life and socio‐demographic questionnaires and, at day +33, the PTSS checklist.

**Results**: Parents showed largely a marked severity of PTSS (88.8%; ³ 10 symptoms), followed by a moderate severity (8.4%; 6‐9 symptoms) and absence of evident symptomatology (2.8%; 0‐5 symptoms). A confirmative model of path‐analysis with good fit indexes (χ2 = 5.77, df = 7, p‐value = 0.57, RMSEA = 0.001) showed that: parenting had a direct effect on PTSS intrusion (effect = ‐0.18; p = 0.05) and on PTSS somatization (effect = ‐0.19; p = 0.05); couple connectedness predicted PTSS avoidance (effect = ‐0.32; p = 0.05) and future life perception influenced intrusion symptoms (effect= ‐0.27; p = 0.05).

**Conclusions**: A PTSS preventive screening and risk factors identification could allow to set up specific psychological interventions for parents to help them in their parenting activities.

### PO-386. Quality of Life in Children with Brain Tumors and their Parents after the Treatment {#pbc27455-sec-13570}

[G. Tseytlin]{.ul} ^1^, A. Rumyantsev^2^, A. Karelin^3^, T. Nikitina^4^, T. Ionova^5^

*^1^Dmitry Rogachev National Medical Research Center for Pediatric Hematology‐ Oncology and Immunology of the Ministry of Russia, Social and Psychological Rehabilitation, Moscow, Russia; ^2^Dmitry Rogachev National Medical Research Center for Pediatric Hematology‐ Oncology and Immunology of the Ministry of Russia, Director, Moscow, Russia; ^3^Dmitry Rogachev National Medical Research Center for Pediatric Hematology‐ Oncology and Immunology of the Ministry of Russia, Deputy Director, Moscow, Russia; ^4^Multinational Center for Quality of Life Research‐, Coordination of Scientific Programs in Oncology, Saint Petersburg, Russia; ^5^Multinational Center for Quality of Life Research‐, Chief, Saint Petersburg, Russia*

**Background/Objectives**: The goal of the family‐oriented rehabilitation in pediatric oncology is to improve the quality of life (QoL) of survivors and their parents. Therefore, it is important to carry out monitoring of QoL in both cancer children, and their parents. Our purpose was to assess QoL in children with brain tumors (BT) and their parents after treatment.

**Design/Methods**: 82 BT survivors of 6--17 y.o. (11.8±3.1 y.o.; 57% boys) and 82 parents (44.4±11.1 y.o., 85% mothers) were studied. Mean time after treatment (TAT) -- 26 months (1--123). Children filled out Pediatric Quality of Life Inventory -- PedsQL™ 4.0 (PedsQL), parents -- RAND SF‐36.

**Results**: QoL in BT survivors was significantly lower than that in healthy children (p\<0.001). The important finding of our investigation is QoL in BT survivors goes down with increasing TAT whereas in ALL survivors QoL positively correlated with TAT. According to parents' evaluation QoL in their children was lower than that reported by children themselves for all scales of the PedsQL except emotional functioning. Parents of BT survivors tend to exaggerate physical and social and underestimate emotional problems in their children. It is important that psycho‐social interventions would focus on the establishment of emotional contact in the child‐parent dyad. The other important finding of the investigation is QoL in parents of BT survivors was significantly lower than that in parents of ALL survivors. This finding shows a major distress in case of BT and requires early intervention to support.

**Conclusions**: QoL monitoring is important for psycho‐social support of children with BT and their parents in the process of treatment and follow‐up.

### PO-387. The Views and Experiences of Parents of Children Treated for Ewing Sarcoma or Rhabdomyosarcoma on the Surveillance Examinations after Completion of Therapy {#pbc27455-sec-13580}

[B. Vaarwerk]{.ul} ^1^, P. Limperg^2^, H. Merks^3^, M. Grootenhuis^4^

*^1^Emma Children\'s Hospital/Academic Medical Centre, Department of Paediatric Oncology, Amsterdam, The Netherlands; ^2^Emma Children\'s Hospital/Academic Medical Centre, Paediatric Psychosocial Department, Amsterdam, The Netherlands; ^3^Princess Máxima Centre for Paediatric Oncology, Solid tumour department, Utrecht, The Netherlands; ^4^Princess Máxima Centre for Paediatric Oncology, Psychosocial Research, Utrecht, The Netherlands*

**Background/Objectives**: Patients treated for Ewing sarcoma (ES) or Rhabdomyosarcoma (RMS) are subject to extensive surveillance after completion of therapy. The aim of this surveillance is to monitor treatment related adverse effects and detect relapse in an early phase to improve prognosis after relapse. While the clinical value of surveillance imaging in the detection of relapses is currently assessed in several studies, the experiences of parents during surveillance received less attention. Therefore, we assessed the views and experiences of parents of children treated for ES or RMS on the follow‐up examinations during surveillance.

**Design/Methods**: In this qualitative study we conducted 2 focus groups (FG) with parents of children treated for ES or RMS in Dutch paediatric oncology centres, who were invited via the Parent Childhood cancer Society. The children were all 0‐5 years after completion of therapy. In addition we conducted 4 semi‐structured telephone interviews with parents not participating in the FG meetings for personal or organizational reasons. The FG meetings and interviews were audio‐recorded and transcribed verbatim. Inductive thematic approach was used to analyse the data carried out by three of the authors.

**Results**: Twelve parents of 12 patients treated for ES (n=6) or RMS (n=6) shared their views on follow‐up examinations during surveillance. Most parents were well aware of the recommendations on follow‐up imaging described in the treatment protocol. The identified themes on the follow‐up examinations covered stress/anxiety (influenced by time since end‐of‐treatment, scheduled imaging and age of the child), search for hope/support (found in routine imaging and strict arrangements during visits and discussing of results), and family‐functioning (e.g. interaction with child/partner, interaction with siblings).

**Conclusions**: This study provides important insights in the experiences of parents during surveillance and could contribute to improvement in parental support during this period. The generalizability of our results should be assessed in comparable studies in other countries.

### PO-388. A Multiphase Project to Improve the Cancer Journey for Adolescents and Young Adults (AYA) in a Pediatric Setting {#pbc27455-sec-13590}

[D. Weidman]{.ul} ^1^, R. Fazelzad^2^, J. Bender^3^, A. Gupta^1^

*^1^The Hospital for Sick Children, Hematology/Oncology, Toronto, Canada; ^2^Princess Margaret Cancer Centre, UHN Library and Information Services, Toronto, Canada; ^3^Princess Margaret Cancer Center, ELLICSR‐ Department of Supportive Care, Toronto, Canada*

**Background/Objectives**: One third of new cancer diagnoses in pediatric hospitals occur in adolescents and young adults (AYA) ages 12 to 18 years. In this setting, the unique psychosocial needs of AYA with cancer (AYAWC) may not be consistently identified or adequately addressed, possibly impacting quality of life with long‐term sequelae. We have embarked on a multiphase project to approach improving care delivery and quality of life for AYAWC at our center.

**Design/Methods**: First, a quality improvement project was conducted to identify the needs of AYAWC. AYAWC (n=25) ages 12 to 18 years were interviewed and asked about their experience and what is lacking in the current system. Second, environmental scans were conducted of AYA cancer programs globally and of existing social media applications for AYAWC. Third, a scoping review of four electronic databases is currently underway using the Arksey and O\'Malley framework, to understand the utilization and impact of health related social media use by AYAWC. Fourth, once patient needs are understood, a social media tool will be developed and evaluated.

**Results**: The needs assessment revealed a unanimous desire to connect with other AYAWC. Some patients requested an online resource for social networking. Environmental scanning uncovered many support programs for AYAWC, majority within adult hospitals and targeting older AYA. Opportunities for AYAWC peer support at pediatric cancer centers in Canada are lacking. Only two peer support social media applications exist for AYAWC and one is inaccessible in Canada. Social media use among this population is nearly universal and has many benefits; however, this area is inadequately understood and deficient in evidence‐based information. Preliminary scoping review results demonstrate few relevant articles, with formal results pending.

**Conclusions**: Institutions may have specific needs for local populations. Before investing in a program, it is important to understand patient needs and systematically approach tool development and implementation.

### PO-389. Pediatric Lymphoma Patients in Malawi Present with Poor Health‐Related Quality of Life That Improves Throughout Treatment as Measured By the Promis‐25 Questionnaire {#pbc27455-sec-13600}

[K. Westmoreland]{.ul} ^1,2^, A. Tilly^3^, A. Amuquandoh^4^, T. van der Gronde^1^, S. Itimu^1^, A. Salima^1^, O. Manthalu^1^, P. Ward^1^, A. Mpasa^5^, S. Wachepa^6^, I. Mtete^5^, M. Butia^5^, P. Wasswa^5,7^, N. El‐Mallawany Kim^5,7^, S. Martin^5,7^, B. Reeve^8^, S. Gopal^9,10,11^

*^1^UNC Project Malawi, Cancer Program, Lilongwe, Malawi; ^2^University of North Carolina, Pediatric Hematology‐Oncology, Chapel HIll, USA; ^3^University of North Carolina, Internal Medicine & Pediatrics‐ Palliative Care, Chapel HIll, USA; ^4^University of North Carolina, School of Medicine, Chapel HIll, USA; ^5^Baylor College of Medicine Children\'s Foundation Malawi, Cancer Program, Lilongwe, Malawi; ^6^Baylor, Cancer Program, Lilongwe, Malawi; ^7^Texas Children\'s Hospital, Pediatric Hematology Oncology, Houston, USA; ^8^Duke University, Population Health Sciences, Durham, USA; ^9^UNC Project Malawi, Cancer Program Director, Lilongwe, Malawi; ^10^Malawi College of Medicine, Medical Oncology, Blantyre, Malawi; ^11^University of North Carolina, Medical Oncology & Infectious Diseases, Chapel Hill, USA*

**Background/Objectives**: The Patient‐Reported Outcomes Measurement Information System 25‐item (PROMIS‐25) pediatric questionnaire has been translated and validated for Malawi. We describe health‐related quality of life (HRQoL) for pediatric lymphoma patients at baseline and during treatment.

**Design/Methods**: The PROMIS‐25 questionnaire was administered to patients in Lilongwe. Participants reported on 6 HRQoL domains (mobility, anxiety, depression, fatigue, peer relationships, and pain interference) by answering 4 question items per domain using a 5‐point Likert scale. A single‐item pain intensity question was scored 0‐10. Each domain was transformed to a T‐score with a mean of 50 and standard deviation of 10 based on the PROMIS reference sample.

**Results**: Of the 148 PROMIS‐25 questionnaires, 85 were administered at diagnosis and 63 during active chemotherapy treatment (median days since diagnosis: 93, IQR: 65‐136). Median age was 10 years (IQR: 7‐12) and 104 (70%) male. At diagnosis, children reported poor HRQoL that improved during treatment. Very low levels of mobility (median: 33, IQR: 23‐38) improved to average (median: 49, IQR: 43‐57, p\<0.0001). High anxiety (median: 62, IQR: 52‐69) improved to average (median: 44, IQR: 38‐55, p\<0.0001). High depressive symptoms (median: 63, IQR: 55‐67) improved to average (median: 50, 44‐57, p\<0.0001). High fatigue (median: 61, IQR: 54‐67) improved to average (median 47, IQR: 43‐52, p\<0.0001). Average satisfaction with peer relationships (median: 52, IQR:47‐55) remained stable (median: 49, IQR: 39‐55, p=0.29). High pain interference (median: 57, IQR:49‐66) improved to average (median: 53, IQR: 43‐57, p\<0.0001). The highest score for pain intensity of 10 was given by 47/85 (55%) of patients at diagnosis and 2/63 (3%) subsequently during treatment.

**Conclusions**: HRQoL for pediatric lymphoma patients at diagnosis in Malawi is poor across various domains, and improves during treatment. Validated methods to assess HRQoL over time among children with cancer are essential in low‐resource settings to comprehensively understand effects of cancer and treatment on children\'s lives.

### PO-390. Courageous Conversations: Advance Care Planning and Family Communication {#pbc27455-sec-13610}

[L. Wiener]{.ul} ^1^, S. Zadeh Bedoya^1^, H. Battles^1^, S. Leonard^2^, K. Fasciano^3^, C. Heath^4^, M. Lyon^5^, K.A. Donovan^6^, M. Noronha Ferraz de Arruda Colli‐^1^, M. Pao^7^

*^1^National Cancer Institute‐ Center for Cancer Research‐ National Institutes of Health, Pediatric Oncology Branch, Bethesda, USA; ^2^CHOC Children\'s, Adolescent and Young Adult AYA Cancer Program, Irvine, USA; ^3^Dana Farber Cancer Institute, Adolescent and Young Adult AYA Cancer Program, Boston, USA; ^4^Cook Children\'s Medical Center, Adolescent and Young Adult Oncology Program, Fort Worth, USA; ^5^Children\'s National Medical Center, Center for Translational Science/Children\'s Research Institute, Washington‐ DC, USA; ^6^Moffitt Cancer Center, Supportive Care Medicine, Tampa, USA; ^7^National Institute of Mental Health‐ National Institutes of Health, Office of the Director, Bethesda, USA*

**Background/Objectives**: Discussing end‐of‐life (EoL) care is very challenging for adolescents and young adults (AYA) living with cancer. While many helpful documents exist to facilitate EoL conversations with adults, few resources exist to aid AYA in communicating their preferences for their care while they are living and how they want to be remembered after their death. Research completed at the National Cancer Institute, NIH led to the development of an advance care planning (ACP) guide, Voicing My CHOiCES™ (VMC). The objectives of this study are to determine 1) the perceived helpfulness of VMC; 2) whether further revisions are needed, and 3) whether engaging in ACP using VMC is associated with reduced anxiety and/or improved communication about ACP with family.

**Design/Methods**: AYA ages 18‐39 (NCI definition of AYA) complete a baseline assessment of anxiety and communication. Participants review VMC and rate the helpfulness, stressfulness and changes needed for each page and complete 3 pages of the document. Assessment of anxiety and communication is repeated 1 month later.

**Results**: Ninety AYA participated at baseline; 73 at follow up. Fifty‐five percent had not previously discussed their wishes/preferences for EoL care with their family at baseline. Of those, 50% shared what they wrote in VMC at follow‐up. For the 45% that had an initial conversation at baseline, 76% discussed what was written in the VMC. Among those who did not have the conversation, specific barriers were identified. Over 90% reported the VMC questions to be somewhat helpful/helpful/very helpful. Several changes were suggested, including remembrance on social media. Both general anxiety and anxiety around end of life planning decreased significantly (p\<.01) between baseline and follow up.

**Conclusions**: Introducing a developmentally appropriate ACP guide can facilitate EoL discussions with AYA family members. Our data suggests such discussions can lead to reduced generalized anxiety and anxiety specific to EoL planning.

### PO-391. Guided Internet‐Administered Self‐Help to Reduce Symptoms of Anxiety and Depression Among Adolescents and Young Adults Diagnosed with Cancer During Adolescence: Lessons Learned {#pbc27455-sec-13620}

[H. Wiman]{.ul} ^1^, M. Ander^1^, J. Woodford^1^, T. Hasselblad^1^, H. Grönqvist^1^, G. Ljungman^1^, A. Romppala^1^, A. Wikman^1^, L. von Essen^1^

*^1^Uppsala University, Women\'s and Children\'s Health, Uppsala, Sweden*

**Background/Objectives**: A subgroup of adolescents and young adults diagnosed with cancer during adolescence report elevated levels of anxiety and depressive symptoms and unmet needs for psychological support. Evidence‐based psychological treatments tailored for this population are lacking. This study examined the feasibility of a guided, internet‐administered self‐help programme (YoungCan) primarily targeting symptoms of anxiety and depression among young persons diagnosed with cancer during adolescence.

**Design/Methods**: The study is an uncontrolled feasibility trial with a pre‐post and 3‐month follow‐up design. Potential participants aged 15--25 years, diagnosed with cancer during adolescence, were identified via the Swedish Childhood Cancer Registry. Participants received YoungCan, a 12‐week therapist‐guided, internet‐administered, self‐help programme based primarily on cognitive behavioural therapy. Participants were individually assigned modules targeting depressive symptoms, worry and anxiety, body dissatisfaction, and post‐traumatic stress. Interactive peer support and psychoeducation functions were also available.

**Results**: A total of 409 potential participants were identified. Only six participants were allocated to the self‐help programme, resulting in an overall participation rate of 1.5%. In addition, the study experienced high levels of attrition.

**Conclusions**: Due to low recruitment and high attrition, it is not possible to deem the intervention and/or study procedures feasible. Potential reasons may be that young persons with lived experience of cancer during adolescence were not involved in developing the intervention and/or study procedures, that gender issues were not considered, and that appropriate recruitment procedures were not utilised.

### PO-392. Evaluation of Late‐Life Subjective Neurocognition using a Japanese Version of the Neurocognitive Questionnaire (NCQ) Among Childhood Atomic Bomb Survivors {#pbc27455-sec-13630}

[M. Yamada]{.ul} ^1^, R. Landes^2^, A. Hida^3^, K. Ishihara^1^, K. Krull^4^

*^1^Radiation Effects Research Foundation, Department of Clinical Studies, Hiroshima, Japan; ^2^University of Arkansas for Medical Sciences, Department of Biostatistics, Little Rock‐ Arkansas, USA; ^3^Radiation Effects Research Foundation, Department of Clinical Studies, Nagasaki, Japan; ^4^St. Jude Children\'s Hospital, Department of Epidemiology and Cancer Control‐, Memphis‐ Tennessee, USA*

**Background/Objectives**: The objective of this study was to examine the effects of atomic bomb radiation and demographic variables on late‐life subjective neurocognitive function using the Japanese version of the Neurocognitive Questionnaire (NCQ) among survivors exposed to the atomic bombings at 12 years old or younger. The NCQ is a self‐reported measure of subjective neurocognitive function developed to investigate effects of therapy, including radiotherapy, in the Childhood Cancer Survivor Study. The use of the NCQ in Asians has not been reported.

**Design/Methods**: The NCQ was administered in 2011 and 2013 as part of the Adult Health Study of the Radiation Effects Research Foundation to examine the long‐term radiation effects of atomic bombings. An exploratory factor analysis was conducted on NCQ items for participants (mean age 73.3 years old) who completed all 25 questions. The effects of radiation dose and demographic variables on the identified NCQ factors were examined among 402 survivors who were exposed to atomic bombings at age ≤12 years and on 348 controls, using linear mixed models.

**Results**: Four factors representing 20 of the 25 items were identified and labelled as metacognition, emotional regulation, motivation/organization, and processing speed. Linear deteriorations with age were observed in all factors. (P\<0.008) Lower education was suggested an association with more problems in metacognition and processing speed. Women showed more deterioration in motivation/organization and processing speed. (P\<0.02) A significant deteriorative effect from radiation was shown only in motivation/organization, after adjustment for demographic factors, (P=0.014) but the size of the effect was small.

**Conclusions**: The Japanese version of NCQ is sensitive to demographic variables known to impact report of subjective cognitive function. Exposure to environmental radiation is associated with more motivation/organization problems, though objective cognitive function is required to confirm validity of the NCQ.
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### PO-393. Development of a Competency‐Based Orientation Programme for Pediatric Oncology Nursing in Rural Cameroon {#pbc27455-sec-13650}

[G.M. Afungchwi]{.ul} ^1^, R. Hollis^2^

*^1^Banso Baptist Hospital, Pediatric Oncology, Kumbo, Cameroon; ^2^Leeds Children\'s Hospital, Pediatric Oncology, Leeds, United Kingdom*

**Background/Objectives**: The Cameroon Baptist Convention Health Services operates childhood cancer centers in three rural hospitals in Cameroon. The baseline standards of the SIOP PODC nursing group recommend formal nursing orientation programmes with both theory and skills training. The aim of this project is to establish a competency‐based pediatric oncology nursing induction programme which meets this standard.

**Design/Methods**: The programme was developed following a needs analysis undertaken with the local nursing team. It consists of two theory based workshops, each followed by 6 months of observed clinical skills acquisition. It is led by an expert nurse from Leeds Children\'s hospital and a local lead nurse. The first workshop covered: Cancer and its treatment; Supportive Care; and Professional Issues. The second workshop will cover: Outcomes of treatment (survivorship and palliative care) and further professional issues. Core competences have been developed with specific competencies for chemotherapy administration. A check list has been developed for validation of competency, through peer evaluation moderated by the lead pediatric oncology nurses.

**Results**: Fifteen nurses are currently in training. First workshop held in November 2017. Average rating of the workshop structure and content by participants was 4.5/5, likert scale. Graded assignments for submission in April 2018 include: a case study of a child with a commonly seen cancer; a presentation on a cancer and its treatment; and a policy for a nursing procedure. The second workshop will be held in May 2018. Graded assignments for submission in October 2018 will include a further case study, an "elevator" speech for nursing advocacy; and a research proposal on a nursing care related topic.

**Conclusions**: The SIOP PODC baseline standards recommend formal orientation programmes for pediatric oncology nurses. Twinning partnerships can facilitate the development of training programmes for nurses in Low and Middle Income Countries which respond to the local needs.

### PO-394. Fear and Coping During Treatment for Acute Lymphatic Leukemia -- from the Perspective of Children 5‐9 Years Old {#pbc27455-sec-13660}

[A. Anderzén Carlsson]{.ul} ^1^, I. Leibring^2^

*^1^Faculty of Medicine and Health‐ Örebro University, University Health Care Research Center, Örebro, Sweden; ^2^Karlstad University, Faculty of Health‐ Science and Technology‐ Department of Health Sciences‐ Nursing, Karlstad, Sweden*

**Background/Objectives**: The concept of fear can be defined as "an unpleasant often strong emotion caused by expectation of danger". It is reasonable to believe that fear and coping of fear, can vary during the course of treatment for ALL. The aim of the present study was to describe a longitudinal perspective on fear related to having ALL, based on children\'s perspective, as well as to describe the strategies these children use when experiencing fear.

**Design/Methods**: The study has a longitudinal descriptive qualitative design. Three girls and 10 boys, initially aged 5‐9 were interviewed once to three times during their treatment period (approximately two months after the diagnosis, after one year and at the end of the 2.5‐year long treatment). In total, 35 interviews were conducted. Data were analyzed using a matrix‐based qualitative analysis method.

**Results**: The children described fear of being subjected to needles and related to having a feeding tube, removing adhesive tape and taking tablets, as well as fear related to the bodily changes caused by the ALL. Existential fears were most frequently mentioned at the end of treatment. The children wanted to participate in their care. They used cognitive strategies, such as "thinking the right way" and emotional strategies, such as crying out loud and kicking. The fears changed over time, but the fear of being subjected to needles remained for half of the children, but was less intense at the end of treatment. The strategies developed, and became more sophisticated over the treatment period.

**Conclusions**: The fear changed throughout the course of treatment, and so did the strategies used. It is reasonable to believe that the need for support also vary, which is a topic for future research.

### PO-395. Distant Mentorship for Pediatric Oncology Nurses at the Indus Hospital, Pakistan {#pbc27455-sec-13670}

[S. Anwar Ali]{.ul} ^1^, R. Punjwani^1^, B. Khan^1^

*^1^The Indus Hospital, Pediatric Oncolgy Nursing Education, karachi, Pakistan*

**Background/Objectives**: Mentoring plays an important role in learning and career development. Mentoring is process that engages often elder and more experienced mentor and younger mentee in complex dynamic relationship of knowledge transfer based on predefined goals (Matovu JK et al, 2011). Since Pakistan is scarce in human resources, it is important for seniors to pass their years of experience to upcoming generation. The Indus Children Cancer Hospital, Karachi has taken initiative of establishing mentorship for distant sites of partnered organization of "My Child Matters Grant".

**Design/Methods**: Extensive literature review using words 'mentorship', 'distant', 'nurses', 'pediatric oncology' and 'effectiveness', suggestive effectiveness of distant mentorship for pediatric oncology nurses conducted. Mentoring was provided using multiple modes via face to face teaching, site visits, providing resource materials, structured observership programs, skype session, whatsapp groups and emails for partnered organization on My Child Matters Grant. Effectiveness shall be evaluated by qualitative (by asking nurses, assess progress) and quantitative approaches (clinical indicators).

**Results**: Evidence‐based nursing literature suggests integral connection between leadership, mentoring and professional career progression. Distant mentorship is proven as great modality based on needs communication, goals, expectations, planning time and methods for adequate connection. Project results will be evaluated by improvement in clinical objective indicators. Currently, we have visited partnered organizations, conducted baseline assessment, provided materials tools and direction to progress. After project completion, progress will be compared with baseline assessment.

**Conclusions**: Development of long‐distance mentorships programs are appreciated to improve knowledge transfer, career advancement and research. Mentorship programs should exist within defined framework and use measurable outcomes to evaluate effectiveness including achievement of goals, publications, career growth and development of mentee into a mentor for continuous cycle (Lawrence M and Lehana T, 2013). Formal mentorship relationships within low‐resource areas, of various medical disciplines is recommended to convey skills effectively, so benefits of mentoring relationships are gained.

### PO-396. Using Peripherally Inserted Central Catheter (PICC) in Pediatric Oncology Patients at a Private Hospital of São Paulo {#pbc27455-sec-13680}

[M. Barbosa]{.ul} ^1^, G. Bonfim^1^, S. Brandi^1^

*^1^HOspital Israelita Albert Einstein, Pediatric, São Paulo, Brazil*

**Background/Objectives**: The peripheral intravenous therapy is considered one of the most common procedures developed in onco‐hematologic Pediatric therapy. The treatment is prolonged and the chemotherapy drugs wear progressively the child venous system that has peculiar characteristics, either biological, emotional or cognitive. In this sense, the peripherally inserted central catheter (PICC), stands out as a safe intravenous device, which increasingly has been used in Oncology, remaining in patients along the proposed treatment, in accordance with the protocols used.

**Objective**: Describe the use of PICC in pediatric oncology patients, during one year, at a private hospital in São Paulo.

**Design/Methods**: A descriptive and retrospective study, about 12 pediatric patients with onco‐hematological disease in Pediatrics in a private hospital in São Paulo in use of PICC for treatment from January 2017 to April 2018.

**Results**: In the analysis of the data, the results showed that in 15 months were handled 12 children\'s oncological PICC during their chemotherapy treatment, with infection rate of 1.24; from 1 to 16 years, with a median of 5.5 years; 66.6% male predominance; diagnosis of Acute Lymphocytic Leukemia was the most prevalent (25.0%) followed by non‐Hodgkin\'s Lymphoma (25.0%). About 91.6% of patients follow in treatment and 8.3% removed the catheter due to injury on the skin by the device or the dressing. The most prevalent protocols used as therapeutic scheme were GBLTI‐09 (25.0%) and NHL‐2010 (25.0%).

**Conclusions**: PICC in Pediatric Oncology is a safe option for central access during chemotherapy treatment, primarily by allowing blood products and transfusions blood collection associated with the low rates of infections and complications and lower cost of procedure. Preserves the self‐image avoiding scars and reduces the stress from the punctures.

### PO-397. Ethics Case Refelction Sessions in Pediatric Oncology: Ethical Issues Raised and Quality Evaluation {#pbc27455-sec-13690}

[C. Bartholdson]{.ul} ^1^, B. Molewijk^2^, A. Castor^3^, P. Pernilla^1^

*^1^Karolinska Institutet, Department of Women and Children\'s Health, Stockholm, Sweden; ^2^VU Medical Center, Department of Medical Humanities, Amsterdam, Netherlands Antilles; ^3^Lund University, Department of Clinical Science, Lund, Sweden*

**Background/Objectives**: The intention of the NOPHO/NOBOS Working Group on Ethics (WGE) is to offer clinical ethics support in Nordic pediatric oncology. The WGE has offered healthcare professionals (HCP) a course in facilitating Ethics Case Reflection (ECR) sessions. During the course, ECR were implemented. The aim of this presentation is to describe results from Swedish pediatric oncology, including: the ethical issues raised and the trainees' evaluation of the quality of the ECR

**Design/Methods**: Nineteen HCP (physicians, nurses and social worker), representing all six pediatric oncology centres in Sweden, participated in the training. The trainees invited HCP at their centres to identify dilemmas in clinical cases and to participate in the ECR. After each session, the trainees completed a questionnaire with open ended questions about the case and the dilemma. Furthermore, the ECR was rated, on a 0‐10 scale, regarding: the benefit for the group, own performance and overall quality. Data was analysed with content analysis and descriptive statistics.

**Results**: Twenty‐four ECRs were performed and two main categories, representing the common pattern of the ethical cases raised, were identified. "The child\'s social situation" includes different examples of social vulnerability of the child/family. "Conflicts with parents", includes conflicts concerning truth‐telling, treatment levels and cultural practices. The benefit of the ECR for the group was rated high and also the facilitators' performance was relatively high. The mean‐value of the benefit for the group was 8.35, own performance 6.96 and overall quality 8.13.

**Conclusions**: Pediatric oncology includes complex medical and ethical issues but in the current cases the social complexity emerged as the core contributing factor for the moral dilemmas. The medical aspects were not the main issues, the cases rather needed to be reflected on with a comprehensive and holistic view of the situation in order to decide on the best ethical action.

### PO-398. Introduction of Chemotherapy Checklist Improves Administration Checking Process and Reduces Error {#pbc27455-sec-13700}

[H. Blundell]{.ul} ^1^, S. Chamberlain^1^, C. Fosbrook^1^, M. Day^1^, J. Gray^1^, J. Bate^1^

*^1^University Hospital Southampton, Paediatric Oncology, Southampton, United Kingdom*

**Background/Objectives**: The delivery of systemic anticancer therapy (SACT) to children and young people (CYP) with cancer is more complex with a greater potential for errors than in adults. The challenges include dose calculations with wide ranges, weight changes, unlicensed use in children, complex protocols and a wide spectrum of disease types. Therefore, it is imperative that pre‐chemotherapy treatment assessments are accurate, ensure detection of patient variability and meet requirements of the relevant chemotherapy. Nursing staff with the responsibility to administer SACT require confirmation that the pre‐chemotherapy assessment has been performed to a satisfactory standard. Our aim was to create and implement a chemotherapy checklist to ensure safe administration of chemotherapy, suitable chemotherapy pre‐assessment and reduce errors in the paediatric cancer unit at University Hospital Southampton ‐ one of 22 designated CYP primary treatment centres in the United Kingdom.

**Design/Methods**: Chemotherapy checklists were designed by SACT nurses within the unit to include verification of pre‐chemotherapy requirements, appropriate supportive care and anti‐emetic prescribing, awareness of drug interactions and protocol confirmation. Separate checklists were implemented for standard and high dose chemotherapy. All unit staff received education on the completion of the checklist. It was deemed mandatory that the checklist had to be fully complete before chemotherapy could be administered to the patient.

**Results**: Since the checklist implementation, no chemotherapy has been administered without a completed checklist with a reduction in medication errors. Nurses have reported they are now more empowered to raise queries if the checklist is incomplete or if there are discrepancies in pre‐chemotherapy requirements.

**Conclusions**: Implementation and full compliance of using a checklist for the administration of chemotherapy has resulted in a safer and more efficient process with reduced prescribing errors. Nursing staff feel more confident in challenging doctors as a result of this intervention.

### PO-399. Surgical Management of Pediatric Solid Tumors: A Single Surgical Unit Experience Over 1.5 Years {#pbc27455-sec-13710}

[A.K. Brar]{.ul} ^1^, N. Peters^1^, R. Samujh^1^

*^1^Post Graduate Institute of Medical Education and Research‐Chandigarh, Pediatric Surgery, Chandigarh, India*

**Background/Objectives**: We present our experience of the surgical management of pediatric solid tumors at a tertiary care center of a developing country.

**Design/Methods**: All patients of pediatric solid tumors who underwent surgery, between January 2017 and March 2018 were included in the study. This was a retrospective analysis which included presentation, neoadjuvant and adjuvant therapy along with outline of surgical management and perioperative mortality and morbidity.

**Results**: There were 39 boys and 23 girls between the ages from 7 days to 13 years. Geographical distribution included 67% (n=42) patients from adjoining states. Forty two (67%) patients had abdominal solid tumors, the commonest being Wilms\' Tumor (WT), which accounted for ∼ 30% of all cases. The other tumors predominantly included Neuroblastoma and ganglioneuroma (n=8), hepatoblastoma (n=3), teratoma (n=3), and germ cell tumors (n=5). The extra abdominal group included Chest Wall Ewings (CWT) (n=8) and Sacrococcygeal teratoma (n=3) amongst others. Patients underwent neoadjuvant chemotherapy as per standard protocols before surgical excision. Operative time ranged from 60 minutes to 335 minutes. Perioperative blood transfusion was given in ∼ 50% patients. Three patients one each of CWT, WT and neuroblastoma required post operative ventilation. Hospital stay ranged between 5 to 18 days. Relapse within 1 year was seen in 5 patients (8%), neuroblastoma (n=2), myofibroblastic tumor (n=1), Malignant nerve sheath tumor (n=1), CWT(n=1). The remaining are doing well. There was no immediate mortality in the series.

**Conclusions**: WT is the commonest tumor in our series. Perioperative management needs adequate planning in terms of protocolised approach, surgical expertise and surgical nursing care. Post operative critical care support may be required in extensive resections. Most pediatric solid tumors can be managed well in a multidisciplinary setting and have reasonably good outcomes.

### PO-400. A Possibility for Strengthening Family Life and Health: Family Members' Lived Experience When a Sick Child Recieves Home Care in Sweden {#pbc27455-sec-13720}

[C. Castor]{.ul} ^1^, H. Hansson^2^, K. Landgren^1^, I. Kristensson Hallström^1^

*^1^Lund Univesity, Health sciences, Lund, Sweden; ^2^Copenhagen University Hospital Rigshospitalet, Paediatrics and Adolescent Medicine‐, Copenhagen, Denmark*

**Background/Objectives**: Families often prefer home care to hospital care, and home‐care services for ill children are increasing worldwide with limited knowledge of families' needs during curative and palliative home care. The aim of this study was to elucidate family members' lived experience when a sick child received home care from county‐based healthcare services.

**Design/Methods**: A descriptive qualitative design was chosen. Twelve families including sick children receiving home care and their mothers, fathers and siblings in the south of Sweden were interviewed between December 2015 and January 2017. The transcribed interviews were analyzed using a hermeneutic phenomenological approach.

**Results**: The family members' lived experience was described in three essential themes. Strengthening family life relates to how home care induced freedom and luxury in a strained period of life and supported the families' everyday life. Usual social activities and relations were maintained as time and energy was saved when receiving home care. Promoting health relates to how the family members' burden of illness decreased as the child\'s signs of illness alleviated and the well‐being of the whole family increased when the child received care in the home. This provided a peaceful respite for family members' psychosocial recovery. The third theme, Creating alliances, relates to the importance of creating trustful alliances for communicating participation in care. If trustful alliances were not created, parents felt an overwhelming responsibility and family members became anxious.

**Conclusions**: The findings suggest that care in the family\'s home is a useful complement to hospital care when given with close attention to family members' needs, as positive effects of home care might be jeopardized when expectations are not successfully shared. The study was funded by the Swedish Childhood Cancer Foundation, The Swedish Research Council for Health, Working Life and Welfare, The Lions Research Foundation, and The Jonas Foundation.

### PO-401. Accessibility, Utilization and Acceptability of a County Based Home Care Service for Sick Children in Sweden {#pbc27455-sec-13730}

[C. Castor]{.ul} ^1^, I. Kristensson Hallström^1^, K. Landgren^1^, H. Hansson^2^

*^1^Lund University, Department of Health Sciences‐ Faculty of Medicine, Lund, Sweden; ^2^Copenhagen University Hospital Rigshospitalet, Paediatrics and Adolescent Medicine‐, Copenhagen, Denmark*

**Background/Objectives**: Home care service is a highly complex health care service which can be organized in various models. It can support family everyday life and is advocated nationally and internationally. Despite this, the accessibility and utilization may still be limited. The aim of this study was to determine characteristics in children and referrals of children to a county‐based home care service in Sweden and to assess the acceptability.

**Design/Methods**: A descriptive study report data from March 2015 to March 2018. Data on referrals were collected by retrospective review of medical journals of all children, 0‐17 years of age, referred to the home care service. Data on acceptability, in terms of satisfaction, safety and preference for care, was collected by an evaluation form completed by a sub‐group of 46 parents after each home care service visit. Descriptive and comparative statistics were used to analyze data.

**Results**: Preliminary results showed that 306 out of 344 referrals lead to home care. 194 sick children in different ages, with a wide range of diagnoses and conditions were referred to home care service, children with cancer composing the largest group, 29%. Administration of intravenous drugs, most often antibiotics, accounted for 70% of the care tasks. Ten percent of the children died during the study period of whom 50% were referred for palliative care. Duration of home care service varied highly, median 6, range 314, days. There was a trend towards uneven distribution of care throughout the county. Parents showed high rating of satisfaction and safety, and expressed a preference for home care service, with 96% of the home care service visits.

**Conclusions**: Children in all ages, suffering from cancer, can be provided county based home care service for various healthcare needs in all stages of illness including end‐of‐life‐care with high acceptability for care though usage may be unequally distributed.

### PO-402. Introduction of a Multi‐Disciplinary Safety Checklist in Elective Paediatric Oncology Theatre Lists within the Ward Environment {#pbc27455-sec-13740}

[S. Chamberlain]{.ul} ^1^, H. Blundell^1^

*^1^University Hospital Southampton, Piam Brown Ward, Southampton, United Kingdom*

**Background/Objectives**: University Hospital Southampton is one of 22 paediatric oncology Primary Treatment Centres (PTC) in the United Kingdom. Our unit is fortunate in having a dedicated theatre space where satellite anaesthetics are performed twice weekly for elective lumbar puncture, intra‐thecal and bone marrow lists. During participation in the SAFE (Situational Awareness For Everyone) project, a key area of perceived vulnerability during these lists was identified. Staff changes had created variability in practice when performing pre‐theatre checks. A baseline staff survey identified that improvement could be made in terms of the consistency of these pre‐theatre checks. Our objective was to reduce avoidable error and harm to children undergoing procedures under general anaesthetic within the ward environment.

**Design/Methods**: Nursing staff within the day unit created and implemented a pre‐theatre safety checklist specifically for paediatric oncology patients undergoing lumbar punctures and bone marrows for use within the ward environment.

**Results**: Consistent pre‐theatre checking of patients undergoing procedures under general anaesthetic within the ward environment. No errors in patients undergoing general anaesthetic in a satellite theatre environment.

**Conclusions**: The introduction of a new checklist has enabled us to tighten the process of pre‐theatre checking and reduce variation, therefore improving patient safety within our PTC oncology day‐ward setting. The new checklist is now embedded in our clinical practice and has been met with increased staff satisfaction. Ongoing improvement cycles will measure and modify the checklist as required.

### PO-403. Nursing Research Findings Paved a Road Toward An Integrated Multidisciplinary Care System for Children with Cancer Through Childhood Cancer Foundation in Taiwan {#pbc27455-sec-13750}

[Y.M. Chao‐Yu]{.ul} ^1^, D.T. Lin^1^, E.C. Fang^2^

*^1^Childhood Cancer Foundation of R.O.C.Taiwan, Board of Directors, Taipei, Taiwan R.O.C.; ^2^Childhood Cancer Foundation of R.O.C.Taiwan, Management, Taipei, Taiwan R.O.C*.

**Background/Objectives**: An international nursing study on the impact of childhood cancer on families was conducted in 1980 when there was no health insurance coverage to the health care for the children in Taiwan. Findings of the nursing study revealed that there was a need for a coordinated and concerted effort to help the families. Financial assistance needs to be found for more than one‐third of the families. The financial assistance should also be found to cover health care delivery system itself to respond to the challenge of childhood cancer. The objective of this paper was to reexamine our current health care delivery system and the quality of health care for children with cancer in Taiwan.

**Design/Methods**: A historical review approach was adopted for this study. Data sources included files, documents, annual report of the Childhood Cancer Foundation (CCF) and published research papers.

**Results**: After the establishment of the CCF in 1982, a coordinated and concerted care team of trained professionals has been gradually organized. More than 60 disease‐specific standardized treatment protocols have been tested and implemented in 21 medical centers and hospitals around the island since 1988. Financial assistance to the family has increased from limited chemotherapy drugs to include full treatment regimens, especially after national health insurance was introduced in 1995. As the over‐all survival rate of children with cancer has risen from 20% to 78% in 30 years, family financial assistance has expanded to include child normalization needs.

**Conclusions**: To meet the world mission of No Child Should Die Of Cancer, new efforts of cancer cure and care regimens will be incessantly exerted and implemented. Thus, impact and financial burden to the family having child with cancer will remain. As such, the accountability of the care professionals, government and the entire society will continue to be challenged.

### PO-404. Parental Treatment Decision Making and Quality of Life in Children with Cancer {#pbc27455-sec-13760}

[M.H. Chen]{.ul} ^1^, L.H. Huang^2^, W.Y. Hu^2^, Y.L. Lee^2^, K.P. Yao^3^, Y.C. Chang^4^

*^1^Tzu Chi University of Science and Technology, nursing, Hualien, Taiwan R.O.C.; ^2^National Taiwan University, nursing, Taipei, Taiwan R.O.C.; ^3^National Taiwan University, Psychology, Taipei, Taiwan R.O.C.; ^4^Tamkang University, Mathematics, Taipei, Taiwan R.O.C*.

**Background/Objectives**: This study purpose to explore the family's parental treatment decision making and quality of life of having a child diagnosed with cancer in the hospital.

**Design/Methods**: The institutional review board at the hospital approved all study procedures. Research design using a In depth interviews and focus group discussions approach in was parents of children diagnosed with cancer in the hospital. Using a participant observation study approach for data collection and themes were uncovered from each interview data set and rigorous methods to data analysis. Record the data with the process recording in interview and participant observation. Data analysis by authors and parent.

**Results**: The cancer treatment decisions made by the parents while their hospitalized children are being treated for cancer mainly include choosing the appropriate hospitals and treatment process. There are fourth themes of the quality of life: (1)Physiologically: Their sleep is disturbed due to the treatments of the children; They are more prone to feeling tired or catching a cold.(2) Psychologically: They are concerned about (a) the side effects of the treatments on the children, and (b) the children\'s emotional changes under the invasive treatments; Feeling guilty when the other children in the family are being neglected; Feeling difficult reconciling the demands of work and caring for the sick children.(3) The changes in everyday lives: The diets are mainly composed of self‐grown food; Timely isolations in the home environments; Living in one\'s tribe.(4) Using the support system: The mutual support among husbands, wives, siblings, and paramedical staff.

**Conclusions**: It was expected that findings of the study could provide family members and paramedical staff be the positive force supporting the healing of children.

### PO-405. Using Modified Pediatric Early Warning Scores and Staff Satisfaction at a Pediatric Oncology Ward {#pbc27455-sec-13770}

[J. Chidnog]{.ul} ^1^

*^1^Faculty of Medicine Ramathibodi Hospital‐ Mahidol University, Pediatric Oncology and Bone Marrow Transplantation Ward, Bangkok‐ 10400, Thailand*

**Background/Objectives**: Sepsis is a major cause of mortality, commonly found in oncologic patients. Clinical signs before severe sepsis is called systemic inflammation response syndrome (SIRs). SIRs can be defined by routine vital sign recording.

**Design/Methods**: We developed a chart record of vital signs for patients admitted to our ward. There were 3 different record forms for patients aged 1‐5, 5‐12, and ≥ 12 years. The measurement included systolic BP, heart rate, temperature, respiratory rate and conscious. The value of each measurement was graded from score 0 to 3. Each scores was summed into a total score. The total score of 0‐3 recognized as low risk, as we recorded vital sign as routine. The total score of 4 meaning moderate risk, we repeated vital signs in 1 hour. The total score of ≥ 5 or score 3 in any items meaning high risk, we notified physician to assess patient for appropriate treatment and recorded vital signs every 15 minutes.

**Results**: There were 81 patients admitted to oncology ward. Staffs gave the patient scores for 2,347 times. The scores were in low risk 2,312 times (98.51%), moderate risk 19 times (0.81%), and high risk 16 times (0.61%). Seventy eight patients (96.3%) with low or moderate risk were discharged home as plan. Two patients (2.5%) with high risk were transferred to intermediate ward for close observation and were discharged home safety later. Twenty Nursing staffs were asked to evaluate the satisfaction of recording early warning scores using a 10‐items questionnaires. The mean scores of satisfaction was 4.6 ± 0.5.

**Conclusions**: In conclusion, the early warning scores was an effective tool for recognizing children with early signs of sepsis.

### PO-406. The Development of a Nurse‐Led Program for Genetically Engineered Cellular Therapies {#pbc27455-sec-13780}

[C. Dansereau]{.ul} ^1^

*^1^Dana Farber Boston Childrens Cancer and Blood Disorders Center, Hematology/Oncology, BOSTON, USA*

**Background/Objectives**: The evolution of engineered cellular therapies,such as Chimeric Antigen Receptor (CAR) T cell therapy, has provided clinicians the ability to create patient specific treatments that offer the hope of cure for diseases that were previously thought of as life threatening or fatal. These therapies are complex both in clinical development and in the way that they are delivered to the patients. To safely and efficiently provide these novel therapies, a nurse led program was developed.

**Design/Methods**: The program is comprised of representatives from each step in this complex process; apheresis collection of the cells, transfer of cells to a manufacturing facility, coordination of inpatient admission for conditioning chemotherapy, the infusion of the genetically engineered product and arranging the required follow up visits. The nurse leader is responsible for orchestrating the sequential steps in preparation and delivery of this autologous cellular therapy. The team meets weekly to review patients in treatment as well as upcoming patients/ new referrals, create a schedule for each patient and review any operational or clinical issues that have been identified. The model provides for a central point of contact, the nurse leader, for physicians, nursing staff, ancillary staff, as well as patients and families. While the initial program team was small in composition, using a continuous quality improvement model, additional members were added to address new clinical or operational needs.

**Results**: While this program was initially developed to treat a single disease indication with novel engineered cell therapy, we have now successfully expanded this infrastructure model to treat over 10 diseases all led by the same nurse leader using the same systematic approach.

**Conclusions**: Creating an infrastructure that is treatment based but disease agnostic offers the institution the ability to be nimble, efficient and expeditious in getting these ground breaking, novel therapies to our patients.

### PO-407. Education Program to Parents of Children with Recently Diagnosis of Cancer and Their Impact in the Knowledge Level and Occurrence of Adverse Events {#pbc27455-sec-13790}

[V. De La Maza]{.ul} ^1^, P. Viveros^2^, M. Manriquez^3^, J.P. Torres^4^, M. Castro^5^, P. Erica^6^, M. Fernandez^2^, E. Vogel^6^

*^1^Universidad de Chile and Calvo Mackenna Hospital, Faculty of Medicine, Santiago, Chile; ^2^Calvo Makenna Hospital, Oncology, Santiago, Chile; ^3^Universidad de los Andes, Faculty of Medicine, Santiago, Chile; ^4^Universidad de Chile, Faculty of medicine, Santiago, Chile; ^5^Clinica Las Condes, Investigación, Santiago, Chile; ^6^Hospital Exequiel Gonzalez Cortés, Oncology, Santiago, Chile*

**Background/Objectives**: Parents of children with cancer must receive information related with their child disease. The aim of this study was to determinethe effect of a structured educational program to parents of children with cancer in the level of knowledge and occurrence of adverse events.

**Design/Methods**: Experimental and prospective study in parents with children recently diagnosed with cancer in two children\'s hospitals in Santiago, Chile. In one center, parents received an educational intervention (experimental group), while in the other, parents did not received intervention (control group). The knowledge level of child disease was evaluated at days 1, 10 and 90 and occurrence of adverse events during one year.

**Results**: A total of 102 parents were enrolled between June 2014--November 2015 (52/50 in each group). At day 1, both groups had the same knowledge level, however at day 10 and 90 the number of correct answers was increased in the experimental group (p \<0.001). Regarding the adverse events,the number of infections of central venous catheterwas significantly lower in the experimental group(5 vs 18) and there were no differences in the number of Emergency Room visits, but the number of episodes consulting because of fever (without neutropenia and not related with chemotherapy) was significantly lower in the experimental group (p\<0.0032).

**Conclusions**: Our results suggest that an educational program by the nurse to parents of children with cancer, increase the knowledge level about the disease and might lower the occurrence of adverse events of the patients. Due to the results from this study, the implementation of educational programs is being considered for Chilean public hospitals, along with the distribution of a book with 189 pages, created by local pediatric oncology specialists, called "Let\'s walk together: Orientation for parents of children with cancer", to prepare parents in the optimal care for their children.

### PO-408. The Education and Learning Program for (Pediatric Oncology) Nurses at the Prinses Maxima Centre {#pbc27455-sec-13800}

J. Flamand^1^, [A. Deege]{.ul} ^1^

*^1^nurses, Prinses maxima centrum for pediatric oncology, Utrecht, The Netherlands*

**Background/Objectives**: The Prinses Maxima centre for pediatric oncology (PMC) is an initiative for centralization of care made by a unique collaboration between health care professionals, researchers and parents of children with cancer. The first unit opened in October 2014 inside the Wilhelmina Children\'s Hospital Utrecht, The Netherlands. This unit started with 7 clinical patiënt beds and a small nursing staff.

The opening of the first unit was the beginning of a 4 year journey towards a new, independent, pediatric oncology hospital in The Netherlands.

To reach the adequate quantity of nurses, with sufficient pediatric oncology knowledge, a few challenges had to be overcome.

**Design/Methods**: In the Netherlands there was not yet a official certified nursing education program which contained the whole spectrum of pediatric oncology. In cooperation with the university medical center (UMC) Utrecht Academy, the Prinses Maxima Academy developed a one year program which leads to a certified pediatric oncology diploma.

To keep the learning vibe at a high level, workfloor theme weeks were developed, with several programs for quick learning sessions, bedside teaching and multidisciplinary presentations.

**Results**: In 4 years time the Prinses Maxima Centre for pediatric oncology has increased the health care workers from 35 to 452 expected at the end of 2018, an increase of 1291%.

From 2015 till 2018 a total of 85 nurses finished the pediatric oncology specializim and 82 nurses finished the pediatric specializim.

A theme week template was developed which allowed a recognisable workfloor learning method.

Theme weeks were successfully integrated, nurses are motivated, up‐to‐date and in an optimal learning position.

**Conclusions**: At the Prinses Maxima Centre, an official pediatric oncology program was created and more than one third of the nursing staff successfully finished the program.

With the development of the theme weeks, nursing education is a continuous workfloor process with a motivated and dedicated team.

### PO-409. Fertility‐Related Views and Life Priorities of Children Having Undergone Cancer Treatment and their Parents {#pbc27455-sec-13810}

M. Yılmaz^1^, [N. Demir]{.ul} ^2^, H. Yildirim Sari^1^, N. Cetingul^2^, E. Tavmergen^2^, M. Kantar^2^

*^1^Izmir Katip Celebi University, Nursing, Izmir, Turkey; ^2^Ege University, Pediatric Oncology, Izmir, Turkey*

**Background/Objectives**: The aim of this study is to determine the fertility‐related views and life priorities of children having undergone cancer treatment and their parents.

**Design/Methods**: The study was conducted in the Pediatric Oncology Outpatient Clinic. The study included 49 children aged 12 years and over who were followed during the aforementioned period after having been treated for cancer and their parents. A form questioning their fertility‐related opinions was used. Both the children and their parents were asked questions about their life priorities in eight areas, and were requested to rate their priorities ranging from "extremely important" (1) to "extremely unimportant" (8). Numbers and percentages were used in the analysis.

**Results**: The mean age of the children was 17.3 ± 2.3. Of the children, 29 were male. Thirty‐five fathers and 32 mothers stated that they heard about sperm / egg freezing method to have children in the future. Thirty‐one of the parents said that they were informed about child‐bearing in the future when the diagnosis was made. Eleven of the boys underwent sperm freezing process. Twenty‐one of the mothers and 15 of the fathers thought that their children were at high risk of not having children in the future due to the treatment they had. For both children and parents, life priorities in the first four places were to be healthy, to go to school, to have a job, and to start a family. Having a child was the last life priority for the mothers and children, but not for the fathers.

**Conclusions**: The study results indicated that approximately half of the male children with cancer underwent sperm freezing process in our clinic. Induction of ovum for girls was not recommended to families because it is not practical at the time of diagnosis. Of the life priorities, having children ranked the last for mothers and children.

### PO-410. Investigation of Quality of Life and Healthy Life Style Behaviors of Adolescents Having Undergone Cancer Treatment {#pbc27455-sec-13820}

[N. Demir]{.ul} ^1^, M. Yilmaz^2^, E. Acikel^1^, M. Kantar^1^, N. Cetingul^1^

*^1^Ege University, Pediatric Oncology Clinic, Izmir, Turkey; ^2^Izmir Katip Celebi University, Nursing Faculty, Izmir, Turkey*

**Background/Objectives**: The aim of this study was to investigate the quality of life and healthy life style behaviors of adolescents having undergone cancer treatment.

**Design/Methods**: This descriptive and relational study consisted of adolescents with cancer aged 12 years and over who were followed in the pediatric oncology polyclinic of a university hospital and whose active cancer treatment was completed at least 6 months ago. The study sample comprised 53 adolescents. Health behaviors of the adolescents were measured with the Adolescent Lifestyle Questionnaire (ALQ), and their quality of life was measured with the Kiddo‐KINDL. The higher the scores obtained from both scales were, the better the healthy lifestyle behaviors and perceived quality of life were.

**Results**: The mean age of the adolescents participating in the study was 17.1 ± 2.9 (min‐max: 13‐18). Of the participating adolescents, 35.8% (n = 19) were female. They all completed the course of treatment at least 8 months ago. Of the adolescents 26.4% had Hodgkin\'s lymphoma, 13.2% had ALL‐AML and 11.3% had Ewing\'s sarcoma. The ALQ mean score was 125.11 ± 12.99 (94‐158). The mean scores of the subscales were as follows: Health Responsibility 17.54 ± 2.88, Physical Activity 14.77 ± 3.82, Nutrition 19.45 ± 2.56, Positive Health 19.26 ± 2.6, Interpersonal Relations 19.47 ± 3.3, Stress 18.39 ± 2.88 and Spiritual Field 16.2 ± 3.6. The lowest mean scores were obtained from the school (49.6 ± 9.6) and family (61.08 ± 4.9) subscales of the quality of life scale. Gender did not affect ALQ and Kiddo‐KINDL scores. It was determined that the quality of life scale scores increased as the mean scores for the positive health (r=0.48, p=0.000) and spiritual health (r=0.36,p=0.007) subscale increased.

**Conclusions**: The adolescents' life style and quality of life levels were moderate and that they obtained the lowest scores from the physical activity and school subscales.

### PO-411. Reasons, Hopes, Risks and Expectations Expressed by Parents Consenting to Genomic Sequencing for their Child {#pbc27455-sec-13830}

[J. Gattuso]{.ul} ^1^, L.M. Johnson^2^, M. Pritchard^1^, B. Walker^1^, K. Hamilton^2^, J. Valdez^2^, B. Mandrell^1^, K. Nichols^2^

*^1^St. Jude Children\'s Research Hospital, Nursing Research, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Genomic sequencing is being incorporated into clinical care for patients with cancer. Little is known about why parents of children with cancer consent to sequencing and how they understand and weigh the risks, benefits, and uncertainty inherent in testing. This qualitative inquiry was part of a larger study of somatic and germline sequencing in a cohort of prospectively identified pediatric oncology patients treated at St. Jude Children\'s Research Hospital. The aims were to identify reasons for participation given by parents, risks, benefits, and what they expected or hoped to learn from participation.

**Design/Methods**: Grounded theory methodology guided this aspect of the research. A convenience sample of 31 parents of 31 patients from the total sample of 301 children and adolescents with cancer who agreed to be interviewed after enrollment in a genomic sequencing study were interviewed by 2 trained interviewers. Interviews were completed in person, recorded and transcribed. An open‐ended interview guide was used. The constant comparative method was used for data analysis. Codes were generated and analysis was completed jointly by 5 study team members.

**Results**: Altruism was the most common reason for participation and was the most frequently reported benefit of participation. Other benefits included gaining knowledge about the child\'s' cancer, determining if the cancer was hereditary (indicating risk for other family members) and contributing to research. The most frequent hopes or expectations for participation were determining if the cancer was hereditary followed by the desire to be proactive and begin treatment or surveillance as early as possible if needed. Most parents recalled risks such as the possibility of receiving positive results (and the implications) and concerns for insurance discrimination, however many perceived there to be no risk for their child.

**Conclusions**: Understanding the factors parents consider when consenting to genomic sequencing can assist nurses in providing more compassionate and informed care.

### PO-412. A Mixed Methods Approach to Understanding Hospital‐School‐Home Liaison Care for Children with Cancer in Taiwan {#pbc27455-sec-13840}

[B.S. Gau]{.ul} ^1^, H.Y. Huang^2^

*^1^National Taiwan University, School of Nursing‐ College of Medicine, Taipei, Taiwan R.O.C.; ^2^Childhood Cancer Foundation of R.O.C., Nursing Care Section, Taipei, Taiwan R.O.C*.

**Background/Objectives**: Children with cancer have rights of education and learning. However, the diagnosis and treatment of cancer affect children\'s learning status. Findings in our previous studies indicated that stable health status, available resources and accessible care were parents' major concerns of schooling arrangement for children. Levels of school nurses' involvement in the cancer child\'s school reentry significantly affect the learning adjustment for the child. The current study is aimed to explore the hospital‐school‐home liaison care issues for children with cancer.

**Design/Methods**: A mixed‐methods design was conducted. One thousand and forty‐one newly cancer diagnosed children were enrolled from 2016/1 to 2018/3, of whom 655 already attended kindergartens and even high schools. The questionnaire survey and telephone follow‐up were applied to collect the data. A semantic analysis was to explore schooling issues they stated.

**Results**: Changes in learning status, including dropout and homeschooling, each accounted for 6.72% (44/655) and 2.13% (14/655), with no difference between boys and girls. The logistic regression analysis indicates that Neuroblastoma is the most likely disease affecting the state of learning for children with solid tumors, with an increase in risk compared with leukemia (OR: 5.865, 95% CI: 1.574‐21.9861, p=0.008). Children living in the southern part of Taiwan obviously have fewer opportunities of school leave and home schooling than children in the north of the metropolitan area (OR=p.455, 95% CI: 0.212‐0,978, p=0.004). Promoting home education and admission system for weak students, empowering the children regain the peer identity at campus, and preparing parents to increase their resilience to reduce the sense of conflicts were reported by parents and children.

**Conclusions**: To provide good quality liaison care from hospital to school and home, the health professional needs to take efforts to integrate the resources including the bedside teacher, home education and Individual education program to support children being coexistence and learning with cancer.

### PO-413. Nursing Management of Patients with High Risk Neuroblastoma Receiving Outpatient Autologous Stem Cell Rescue {#pbc27455-sec-13850}

[R. Glincher]{.ul} ^1^, Y. Lin^1^, C. Durney^1^

*^1^Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA*

**Background/Objectives**: High‐risk neuroblastoma (HR‐NBL) patients require aggressive, high dose chemotherapy and radiation therapy for relapsed and/or refractory disease. Patients may require Autologous Stem Cell Rescue (ASCR) to ensure marrow recovery after these treatments. Due to profound pancytopenia and deconditioning of patients, excellent nursing care is essential.

**Design/Methods**: In the past 10 years, 72 HR‐NBL patients have received autologous stem cells outpatient at Memorial Sloan Kettering Cancer Center (MSKCC). Advanced Practice Nurses (APN) have the role of managing these complex patients. Standard care includes complete blood count and basic metabolic panel upon arrival, followed by PRBC and platelet transfusions as clinically indicated. Patients receive normal saline bolus of 20 mL/kg, acetaminophen, diphenhydramine, and ondansetron prior to ASCR. Stem Cells are administered by attending physician via intravenous push. The patient is closely monitored for acute reactions by the bedside Registered Nurse (RN). Following ASCR, hyper hydration is administered in clinic and via home infusion pump for 24 hours. Furosemide is administered 30 minutes post ASCR. Urinalysis is obtained every void to check for hemoglobinuria. Electrolytes are obtained after diuretic. Patients are observed for four hours post infusion and discharged home with hydration if clinically stable. All patients return for follow up the following day for a full assessment by Nurse Practitioner.

**Results**: Seventy‐two HR‐NBL patients have received ASCR outpatient over 10 years at MSKCC. The most common acute reactions were nausea, vomiting, and fever. All acute reactions were well managed by the clinical team including the RN, NP, and clinic attending. Patients who developed neutropenic fever were cared for outpatient until admission occurred.

**Conclusions**: ASCR can be safely administered in the outpatient setting with high quality nursing care. Outpatient administration of ASCR can increase quality of life for the patient and improve overall satisfaction. It can also eliminate unnecessary hospital days and decrease financial burdens.

### PO-414. The Need for Blood Return when Utilizing a Central Venous Catheter {#pbc27455-sec-13860}

[R. Glincher]{.ul} ^1^

*^1^Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA*

**Background/Objectives**: This case report presents a four year old female with history of neuroblastoma enrolled on clinical trial at Memorial Sloan Kettering Cancer Center who presented for routine evaluation. Her mediport was previously accessed and flushed one month prior to her arrival. At her scheduled visit her mediport was accessed per institutional guidelines using sterile technique without complications. Blood return was not obtained. Five milliliters Normal Saline was flushed with no swelling, tenderness, erythema noted. Blood return still unable to be obtained. Due to lack of blood return in a central venous catheter, alteplase was instilled. When blood return was still not present, a peripheral IV was placed. Chest x‐ray obtained to assess placement.

**Design/Methods**: Central lines including mediports are used in patients with cancer for administration of chemotherapy and bloodwork. Placement must be confirmed with radiographic imaging upon insertion. Subsequently, placement is confirmed on each use with blood return. Blood return is crucial prior to instilling any solution or medication in the line. This case highlights the necessity of evaluation when unable to obtain blood return.

**Results**: Chest X‐Ray showed "catheter from the port has migrated from its hub and is now located entirely within the right heart (crossing right atrium and right ventricle)." Patient was made NPO and Interventional Radiology was consulted. Using ultrasound guidance interventional radiology was able to successfully retrieve fractured catheter from the heart and place a new right chest wall Mediport.

**Conclusions**: Due to nursing vigilance and advocacy, the central venous catheter was not used for instillation of contrast as scheduled. The multidisciplinary team worked together closely for the maximum benefit of the patient. This case report highlights the necessity of always obtaining blood return whenever using a central line and the importance of imaging to confirm line placement when blood return is not able to be obtained.

### PO-415. Long‐Term Sustainability and Discontinuation of a Hospital‐based Home Care Service for Children with Cancer: Health Care Professionals' Narratives {#pbc27455-sec-13870}

[H. Hansson]{.ul} ^1^, I. Tiberg^2^, K. Hansson^3^

*^1^Copenhagen University Hospital Rigshospitalet, Department of Paediatrics and Adolescent Medicine/Research Unit Women\'s and Children\'s Health, Copenhagen, Denmark; ^2^Faculty of Medicine‐ Lund University, Department of Health Sciences‐, Lund, Sweden; ^3^Lund university, Department of Arts and Cultural Sciences, Lund, Sweden*

**Background/Objectives**: In 2008--2010, we developed and evaluated a hospital‐based home care (HBHC) intervention with an outreach service for children with cancer in a controlled trial in Denmark. The HBHC was successfully implemented as routine care immediately after the trial when the external funding ended. After five years, we conducted the present study to explore how health care professionals made sense of why the HBHC had been sustained, challenged and gradually discontinued. The aim was to identify important factors and processes that may enable or hinder the long‐term sustainability of the HBHC.

**Design/Methods**: We conducted a narrative analysis of data collected from individual and focus group interviews with 12 health care professionals from clinical staff and management working in different units at the department. We also used Greenhalgh\'s system‐dynamic framework of sustainability to analyse the data by means of how healthcare professionals explained what was driving and what was holding HBHC back.

**Results**: Two shared narrative themes emerged: meaningfulness for the children and their families as an enabling factor and the lack of resources to nurse staffing as a hindering factor in the continuation of the HBHC. But it differed in terms of how the health care professionals made sense of the decision to cancel the home visits despite the meaningfulness for the children and their families. This meant that clinical staff and management had conflicting understandings of priorities and responsibilities related to the continuation of the HBHC, according to their values and position.

**Conclusions**: The sustainability and discontinuation of the HBHC embodies a conflict between the psychosocial benefits for the children and their families and the role of resources. It may be used to anticipate challenges and illustrate the importance of a shared sense‐making process among health care professionals to support efforts in sustaining interventions in the long term.

### PO-416. Internet‐Based Information‐Seeking Practices Among the Parents of Children with Hematologic and Oncologic Diseases {#pbc27455-sec-13880}

[H. Hashimoto]{.ul} ^1^, H. Tani^1^, H. Watanabe^1^

*^1^Tokushima University Graduate School, Institute of Biomedical Sciences, Tokushima, Japan*

**Background/Objectives**: Parents of children with hematologic and oncologic diseases require diverse information for use in decision making and daily life care. Although the methods of obtaining such information have become more diversified and convenient, the large amount of information might cause parents anxiety and confusion. In this study, we examined how parents use the Internet for information seeking.

**Design/Methods**: We conducted a self‐administered questionnaire survey with parents of children with hematologic and oncologic diseases in the outpatient department, and analyzed the data obtained from 19 parents (response rate: 59.4%).

**Results**: Thirteen parents sought information from the Internet. Of these, 12 reported that the information was easy to understand. The most frequently used source was the website of the Japanese National Specialized Institutions, with 9 parents accessing it. Nine parents wanted to talk to health professionals about the information they obtained from the Internet, although only 5 actually consulted with such professionals. Eight parents needed health professionals' advice on seeking information from the Internet. Based on the results of Fisher\'s exact probability test and the Mann‐Whitney U‐test, no significant difference in parents' understanding of or satisfaction with information from health professionals was found between the participants who used the Internet and those who did not.

**Conclusions**: Parents require advice from health professionals about information from the Internet. However, some parents were unable to consult with such professionals. Besides verifying the needs of parents and giving advice on using the Internet, health professionals must carefully consider whether parents are asking questions about the information that they have collected from the Internet.

### PO-417. Management of Procedural Pain and Guidelines Implementation in a Pediatric Inpatient Cancer Center {#pbc27455-sec-13890}

[M. He]{.ul} ^1^, N. Shen^2^, F. Zhou^1^

*^1^Shanghai Children\'s Medical Center‐ affiliated with Shanghai Jiaotong University, Pediatric hematology and oncology, Shanghai, China; ^2^Shanghai Children\'s Medical Center‐ affiliated with Shanghai Jiaotong University, Nursing, Shanghai, China*

**Background/Objectives**: As a common negative experience, procedural pain was not well managed in a pediatric cancer department. There was a big gap between best evidence and clinical practice. The aim of this project was to implement the best available guideline on management of procedural pain into the nursing practice of a pediatric cancer department.

**Design/Methods**: A Plan, Do, Study, and Act (P‐D‐S‐A) QI framework was used. The intervention process included four steps: identify current deviations from best practice; assess barriers and supports; revise the related procedures and rules, and design the implementation protocol; and adopt the protocol and monitor the changes. Pain intensity, process measures of invasive procedure, patient/family education and satisfaction of procedural pain management, and professional training and knowledge of procedural pain management were assessed before and after interventions.

**Results**: Results from pre‐ and post‐ implementation audits showed increased compliance rates for preparation before procedure (93.02%), utilization of lidocaine before procedure (34.88%), attention distraction during procedure (79.07%), and family education (84.29%). The average procedural pain of pediatric patients with cancer also decreased from 5.74 ± 2.74 to 2.65 ± 1.75 (P\<0.01). The percentage of moderate or higher procedural pain (FACE or VAS ≥4) decreased from 75.0% to 25.6% (P\<0.01).

**Conclusions**: An effective way to continuously improve care is to integrate them into daily work. Performance feedback, and immediate positive outcomes of new practices promote compliance of both care staff and patient/family. Parents should be inspired to work cooperatively with healthcare professionals in management of procedural pain.

### PO-418. Relationship Between Nurse‐Reported Quality of Care and Nurse Practice Environment in Chinese Pediatric Hematology and Oncology Nurses {#pbc27455-sec-13900}

[M. He]{.ul} ^1^, H. Lu^1^

*^1^Shanghai Children\'s Medical Center‐ affiliated with Shanghai Jiaotong University, Pediatric hematology and oncology, Shanghai, China*

**Background/Objectives**: Nurses play an essential role in monitoring and reporting quality of healthcare in hospital. The disease acuity, treatment complexity, difficult decision‐makings and life‐threatening situations of pediatric patients with cancer always keep pediatric hematology and oncology nurses in such an environment of high‐risk and high intensity. However, there is no report on nurse reported quality of care, or nurse practice environment in Chinese pediatric hematology and oncology nurses. This study is to explore the current status of nurse reported quality of care and nurse practice environment in Chinese pediatric hematology and oncology nurses, and establish their relationships.

**Design/Methods**: This study was designed as a cross‐sectional investigation in all pediatric hematology and oncology nurses in all member institutions of Chinese Anti‐Cancer Association Pediatric Nursing Group. A questionnaire about demographic data, Nurse‐reported quality of care questions and Practice Environment Scale were used.

**Results**: The percentage of nurses considering "excellent quality of care on their unit", "their patients are able to manage their own care when discharged", "quality of care in their hospital has deteriorated in the past year" was 45.5%, 53.1% and 5.3% respectively. The score of nurse practice environment was 85.6±12.2. The lowest score was "Staffing and resource adequacy". The nurse‐reported quality of care and each dimension of nurse practice environment was all significantly correlated (r range 0.143∼0.454, P\<0.01).

**Conclusions**: Nurse‐reported quality of care in pediatric hematology and oncology was acceptable; the self‐management of patients and their family was below the average. Pediatric hematology and oncology nurses considered the "Staffing and resource adequacy" the most dissatisfied. There is significant relationship between nurse‐reported quality of care and nurse practice environment.

### PO-419. Challenges and Difficulties in Trans‐Disciplinary Team Approach Encountered by Nurses Involved in Care of Children with Cancer {#pbc27455-sec-13910}

[M. Hirata]{.ul} ^1^, M. Uchida^2^, N. Takenouchi^3^, F. Shirai^4^, Y. Ohara^5^

*^1^St. Luke\'s International University, Graduate School of Nursing Science, Tokyo, Japan; ^2^Tohto College of Health Science, Faculty of Makuhari Human Care, Chiba, Japan; ^3^Kanagawa Children\'s Medical Center, Cancer Center, Kanagawa, Japan; ^4^Nagano College of Nursing, School of Nursing, Nagano, Japan; ^5^Chiba Children\'s Hospital, Department of Nursing, Chiba, Japan*

**Background/Objectives**: The Japanese Society of Pediatric Oncology Nursing study group published a revised edition of "Nursing Care Guidelines for Children with Cancer and Families" in 2012 in order to improve quality of life for children with cancer and is currently reviewing the further revision. This study aims to examine challenges and difficulties encountered by nurses who engage in pediatric oncology nursing in trans‐disciplinary team and to consider educational support for nurses.

**Design/Methods**: We sent the questionnaire to 216 nurses with more than 5years pediatric oncology nursing experience at 108 hospitals nationwide and 71 were returned. Five experts in pediatric oncology nursing qualitatively analyzed the descriptive data with regard to challenges and difficulties in trans‐disciplinary team approach.

**Results**: As a result of coding the data regarding nurses' roles in the team, 10 codes and 5 categories were extracted. The five categories were: "Nurses do not express their own concerns", "The team is not functioning properly", "The burden on nurses is large as there are not many professionals", "The burden on a specific nurse is large as information sharing is not good enough", and "Nurses do not recognize their roles in the team". With regard to difficulties towards trans‐disciplinary team approach, 21 codes and 8 categories were extracted. The eight categories were: "Team meeting is not being held", "Difficulty to adjust the time for the meeting", "No nurses' participation in the meeting", "Doctor led", "Information sharing is difficult", "CNS intervention in complicated cases is insufficient", "Continuous team approach is not being done", and "There is no collaboration system".

**Conclusions**: It is important that nurses closely beside children 24 hours recognize the importance of their own roles, fulfill roles, and coordinate the team. We believe that educating nurses so that they could play such a role will help overcome challenges and difficulties in trans‐disciplinary team approach.

### PO-420. Retrospective Analysis of Factors Impacting Pediatric Cooperation with Radiation Therapy {#pbc27455-sec-13920}

[J. Holt]{.ul} ^1^, A. Reilly^2^, D. Crump^3^, R. Carson^1^

*^1^Sibley Memorial Hospital ‐ Johns Hopkins Health System, Radiation Oncology, Washington D.C., USA; ^2^Johns Hopkins Health System, Department of Child Life‐ Department of Radiation Oncology, Baltimore, USA; ^3^Johns Hopkins Health System, Department of Radiation Oncology, Baltimore, USA*

**Background/Objectives**: Radiation therapy (RT) is an essential treatment modality for many pediatric cancers. Treatment must be precisely delivered and execution relies heavily on a patient\'s ability to remain still during set up and delivery. Treatment length can vary between fifteen minutes up to an hour depending on the type of treatment and area of the body being treated. Many factors impact a child\'s ability to comply with the behavioral requirements of RT. The purpose of this analysis was to understand the socio‐developmental treatment factors that impact pediatric cooperation with RT to better predict which patients can be safely treated without intervention.

**Design/Methods**: Retrospective data from 94 patients was collected via electronic medical records at two collaborating radiation oncology departments from August 2016 to August 2017 for patients aged 18 years and younger who underwent RT. Data was collected on 11 categories thought to impact a child\'s behavior and cooperation during RT and then correlated with medical records or reports from healthcare providers.

**Results**: Six categories demonstrated statistical significance (p\<0.05) in their influence on behavioral cooperation during RT: Age category (specifically age \<7: Odds ratio \[OR\] 3.0, 95% Confidence Interval \[CI\] 1.0, 9.1), history of previous sedation for imaging studies (p\<0.001), parental belief of needing medication for successful treatment (p\<0.001), duration of treatment time, preferred language (p\<0.001), and undergoing total body irradiation (OR 3.1, 95% CI 1.1, 9.3).

**Conclusions**: Pediatric behavioral compliance with RT is complicated and multi‐factorial. Three domains comprise the most common variables that contribute to a patient\'s conformity during RT: Demographic, historical precedence, and radiation‐specific. Future research should focus on best practices to identify children in need of additional behavioral training or pharmacologic intervention in order to prevent unnecessary anxiety or emotional trauma from RT.

### PO-421. Improving the Physical Activity in Pediatric Oncology Inpatients Through the Child‐Friendly Program {#pbc27455-sec-13930}

[P.Y. Hsu]{.ul} ^1^, F.R. Lin^1^

*^1^National Taiwan University Children Hospital, Nursing, Taipei, Taiwan R.O.C*.

**Background/Objectives**: These treatment modalities are frequently accompanied by side effects, and the potential to a negative impact on physical activity and on psychosocial well‐being. There is evidence that exercise and physical activity programs can reduce fatigue, and enhance psychosocial health in the pediatric population. The purpose of this study was to develop a child‐friendly program for children with cancer and was to evaluate its effects in the behavioral responses during and after treatment.

**Design/Methods**: The setting of this study was about a 24‐bed pediatric oncology ward in Taiwan from May, 2017 to December, 2017. The first applied instruments was based on literatures review. Data collection started immediately before cancer treatment and the times of physical activity and quality of sleep were monitored and recorded in hospitalization. We worked out those methods:(1)Design child‐friendly program for children: with rewards card, children earn points with every exercise children make. Children should participate in muscle‐strengthening activities at least 60 minutes of physical activity, such as walking. (2) Kids' perceptions to set up to develop child‐friendly environments: we designed " kid gifts house" to motivate and stimulate children.

**Results**: The completion rate for physical activity in at least 60 minutes of physical activity per day, 3 days per week, were 100% and quality of sleep were increased from 2.31 points to 4.35 points after implementation of the program by 17 participants. Additional benefits were the satisfaction scores of caregivers, for child‐friendly program, were increased from 71 to 97.4 points before and after the program.

**Conclusions**: Based on our results, we found child‐friendly program what will help to reduce a child\'s negative psychological response to side effects of cancer treatment, minimizing fatigue, and will enhance muscle‐strengthening and the quality of sleep in pediatric patients undergoing cancer treatment for cancer.

### PO-422. Creative Designs for Port‐A Clinical Teaching Aids Improvement {#pbc27455-sec-13940}

[L.M. Hu]{.ul} ^1^, C.Y. Tseng^1^

*^1^National Taiwan University Hospital, Nursing, Taipei, Taiwan R.O.C*.

**Background/Objectives**: For children with pediatric hematological and oncological disorders, almost everyone have a port‐A device implanted. Port‐A care is an essential knowledge and skill for nurses at the pediatric hematology and oncology unit. An old port‐A angle needle practice model was used in our unit. However, due to the frequent practice and demonstration, its parts became falling off and worn out. In order to ensure every nurse is skilled with port‐A care and to reduce children\'s fear for port‐A angle needle puncture, an innovative model was designed.

**Design/Methods**: A pre and post quasi‐experimental design was conducted. In order to have the quasi‐realistic effect for clinical teaching, the new model is to use a puppet chest implanted a bottle with red dye as a substitution for blood. Sixteen nurses applied the new model to practice their skills from 2017/02 to 2017/03. Twenty‐three children received the new model demonstrations during 2017/04 to 2017/10.

**Results**: A 5‐point Likert scale was used to measure nurses' overall satisfaction for the new model. A significant improvement of satisfaction was from 2.4 points in old model to 4.8 in new one. Easy to operate and replace the supplies were reported by nurses. The puppet\'s soft texture and lovely appearance also let children become more familiar with port‐A care procedure. Most importantly, the new model relieved the level of anxiety and fear of needle puncture among children significantly.

**Conclusions**: The new model demonstrates three benefits for our clinical nursing practice: time effectiveness, economic benefits, and child friendliness. Based on this experiment, we found some new direction and function to develop with this new model. To provide better nurse in‐service education and childhood cancer care, we will keep working on it. Hope we can share more in a short future.

### PO-423. Coming Soon: Managing Pediatric Patients in the New "Archade/Cyclhad" Particle Therapy Program in Caen, France {#pbc27455-sec-13950}

[C. Huynh]{.ul} ^1^, A. Lecœur^1^, M. Micaud^1^, T. Tessonnier^1^, A. Vela^1^, D. Stefan^1^, P. Dutheil^1^, L. Guillemette^1^, T. Plouhinec^1^, J. Martin^1^, J.L. Habrand^1^

*^1^Centre François Baclesse, Radiation Oncology, Caen, France*

**Background/Objectives**: Particles therapy (i.e; protontherapy) is a highly sophisticated radiotherapeutical modality that aims mainly at limiting acute and long term sides‐effects in children. It is only available in selected advance centers worldwide. It requests a specific workflow that is detailed hereinafter.

**Design/Methods**: Treatment implementation has been divided in 4 steps following the ongoing physicians' guidelines: We provide children and family with specific information by written and video documentations (these patients are generally seen on an out‐patient basis)Treatment preparation including contention devices proton‐compatible and visit of the deported treatment siteDistractive or hypnotic approach can be used to manage the unusually increased treatment times (pediatric anesthesia is also easily available)Joint medical and para medical follow‐up during and after therapy.

For patients with special requirements, e.g. coming from abroad, we can arrange accommodation for the children and their families.

**Results**: Our group is opening shortly the proton "ARCHADE/CYCLHAD" program. It is estimated that a third of the patients treated will be children. Radiation must be delivered with a maximal accuracy and reproductibility. It imposes anticipated patients care pathway by a dedicated team and parental support.

**Conclusions**: Protontherapy is an increasingly popular radiotherapeutical modality requiring specific patient\'management, team training and quality assurance programs. In a not too far future, we may explore a new concept of light ions useful for highly radioresistant cases (carbon ions).

### PO-424. Developing a Provider to Patient (P2P) Care Delivery Model for an Oncology/Hematology/BMT Outpatient Clinic {#pbc27455-sec-13960}

[L. Jacques]{.ul} ^1^, G. Chan^1^, A. Perez^1^, N. Kennedy^1^

*^1^British Columbia Children\'s Hospital, Oncology/Hematology/BMT, Vancouver, Canada*

**Background/Objectives**: BC Children\'s Hospital\'s Oncology/Hematology/BMT Outpatient Clinic sees approximately 10,000 patient visits per year. In building a new acute care tower, our outpatient clinic expanded from 14 to 23 rooms. This provided an opportunity to implement a Provider to Patient (P2P) care delivery model wherein patients could be assigned a room for the duration of their visit and healthcare providers (HCPs) would move from room to room to see patients, rather than patients moving to providers. Anticipated outcomes of the P2P model were to improve patient experience and reduce appointment times without compromising workflow efficiency for HCPs.

**Design/Methods**: Research into the P2P model was conducted by way of literature reviews, benchmarking, and site visits. Meetings with stakeholders were held to understand workflows and develop an operational plan. Early implementation carried out prior to the move involved three trials using PDSA (Plan/Do/Study/Act) cycles and an evaluation strategy to assess quality and efficiency. Following implementation of P2P daily huddles involving all HCPs were carried out to obtain feedback on challenges and improvement opportunities. Observational timing studies and experience surveys were repeated to evaluate effectiveness of the P2P model.

**Results**: The P2P model was successfully implemented on opening day of the new outpatient clinic. While there continue to be opportunities for improvement to increase HCP satisfaction and efficiency, P2P has improved patient satisfaction and observational timing studies have demonstrated a decrease in length of stay.

**Conclusions**: The P2P model reflects a patient‐centered approach in providing families a private space, improving time spent with providers and reducing appointment times. Early implementation of PDSA cycles and staff engagement confirmed the proposed process would realize our goals of improved workflow efficiencies and initiated the "people‐side" of change management in a tangible way to ensure staff compliance and commitment to a new care delivery model.

### PO-425. To Explore Challenges Faced by Nurses Working in Pediatric Oncology Unit in Tertiary Cancer Center {#pbc27455-sec-13970}

[S. Joshi]{.ul} ^1^

*^1^Tata Memorial Hospital, Nursing Administration, Mumbai, India*

**Background/Objectives**: Pediatric nurses, who specialize in the care of children, face many challenges in their work. Some of these are problems common to all nurses. Exploring help managers to take decisions proactively to ensure quality output.

Objectives‐

1\. To identify various challenges faced by nurses.

2\. To find out personal and professional challenges.

3\. to identify potential stress nurses are at risk of.

**Design/Methods**: Methodology‐Exploitative survey

Samples‐staff nurses working in pediatric oncology department

Sampling technique‐purposive convenient sampling

Sample size‐50

Tool‐ /techniqque ‐Questionnair /structured interview.

Analysis‐Frequency and percentage.

**Results**: Findings and interpretations‐ Demographic‐ age‐60%‐ 31‐40 yrs. 20%‐21‐30 yrs 20%‐40 and above. Experience as nurse ‐30% more than 10 years, 45% 5‐10 years, 25% less than 5 years. Experience in onco pediatric‐60%‐more than 5 years 40% ‐less than 5 yearsSpecial training‐50% oncology trained, 40% specially trained in pediatric, Pediatric experience‐30%‐ by choice and interested, 60%‐ by rotation, Pediatric nursing learning ‐35%‐ only theory lectures,65%‐ only practical attended during in‐service programme. 45% of them spend about 2‐4 hours of hectic travelling from home to working place and back. 40% of nurses feel heavy workload always where as 55% answered some times. 5% of them felt never. Difficulty in completion of nursing responsibility ‐45% said always, 35% sometimes. where as 20% said never. All 100% of them felt shortages ‐sometimes (nurses, attendents, equipments). Risk of unsafe environment‐infection‐65%, Electric hazrds‐10%,physical stress‐90%,psychological stress‐85%. 42%‐moral distress, 37%‐risk of medication errors, 45% felt that they are at risk of potential occupational hazards. Almost 80% of them expressed no fear of handling medical gadgets. 20% felt uncomfortable to communicate to superiors. 92% expressed increased demand of services by parents. Non nursing assignments‐70% felt that they are busy with computers, 40% ‐ clerical work, 35% expressed busy in managing attendants job.

**Conclusions**: Suggestions to improve‐ quality induction programme, improve nurse:patient ratio, recognition, rewards appreciations,stress management programme,personality development programme,regular health checkups.

Conclusion: nurses in pediatric setup faces many challenges. we need empower oncology nurses to overcome these challenges.

### PO-426. Haematopoietic Stem Cell Donation by Parents for Children: Perspective and Experience {#pbc27455-sec-13980}

[B. Karayat]{.ul} ^1^, D. Thakkar^1^, A. Stephen^1^, S.P. Yadav^1^

*^1^Medanta ‐ The Medicity‐ Gurgaon, Paediatric Haematology Oncology and Bone Marrow Transplant, Gurgaon, India*

**Background/Objectives**: Recent advances in haematopoietic stem cell transplant (HSCT) techniques have made it possible for even half‐matched parents to become donors. While this has emerged as a boon to the child, the acknowledgement of donor\'s perceptions, experiences and concerns take a backseat in the entire process where the key focus is the cure of the child. Here we report perspective and experience of parents who were haploidentical donors for their children.

**Design/Methods**: A questionnaire was prepared comprising of questions addressing the concerns, comprehension and overall experience covering the peritransplant period of family haploidentical donors. Donors were interviewed telephonically and responses noted and analysed. The donors of deceased patients were not interviewed.

**Results**: Sixteen children underwent haploidentical HSCT at our centre from June\'16 to December\'17 for hemoglobinopathy‐3, bone‐marrow failure‐3, acute leukemia‐5, refractory solid tumors‐2 and others‐3. Of the stem cell donors, Male:Female ratio was 0.7:1 and the mean age was 35 (21‐46 years). Of the 11 donors available, only 6 responded. On being offered to become donor for their child, 4 felt anxious and 2 felt proud. All understood the procedure. During the GCSF administration, they reported bodyache‐2 and backpain‐2. On day of peripheral blood stem cell harvest, 4 donors reported anxiety, 5 had significant pain and 3 had discomfort. During the harvest, one donor had tingling and numbness whereas one had shivering. Post catheter removal, pain‐5, difficulty in walking‐3 and haematoma‐1 were reported. Two donors took the post harvest medications for a month and the others took them for 2 weeks. All the donors were proud to be donors and reported their experience to be satisfactory.

**Conclusions**: Where family donors face a moral responsibility and exceeding expectations, it is vital to address their physical and psychological concerns, alleviate their fears and facilitate their experience to make it worthy as a personal sense of achievement.

### PO-427. Trend in Research on Medication Management for Children Requiring Oral Medication Administration {#pbc27455-sec-13990}

[J. Kashiwase]{.ul} ^1^, S. Kanaizumi^1^, C. Akuzawa^2^, C. Aoyagi^3^, N. Matsuzaki^3^, H. Kubo^1^, A. Imai^4^, K. Sakou^1^

*^1^Gunma University, Graduate School of Health Sciences, Maebashi, Japan; ^2^Saitama Medical University, Faculty of Health and Medical Care, Hidaka, Japan; ^3^Takasaki University of Health and Welfare, Faculty of Health Care, Takasaki, Japan; ^4^Jobu University, Faculty of Nursing, Takasaki, Japan*

**Background/Objectives**: Oral medication administration is one of the important treatments for children with chronic diseases including cancers. Inappropriate administrations such as missing a dose or overdose have been reported, and improvement in oral medication management is needed. The aim of this study was to explore the trend in research in Japan on oral medication management for children requiring oral medications.

**Design/Methods**: Research articles published in the past 10 years were searched via key words "child" and "oral medication management", using an electronic database, Japan Centra Revuo Medicina Web Ver 5. Descriptive statistics were calculated for the number of research designs, subjects, targeted diseases and other data. The contents of the research were qualitatively, inductively analyzed.

**Results**: Of 69 articles retrieved, 19 articles meeting the study objective were analyzed. Approximately half were related to children with chronic diseases. Only one article clearly stated childhood cancer patients as the target of the study. Qualitative inductive analysis found eight categories delineating the research content: perceptions of children with chronic diseases toward taking oral medication and management condition; process regarding the child\'s will to take medication; mothers' behaviors in support of their child requiring oral medication administration; perceptions of the mothers of the child requiring oral medication administration; support and management of the nurses involved in oral medication administration; investigation of how children are taking oral medication; initiatives utilizing information technology for support of taking medication; and perceptions of the nurses on medication management of children with psychiatric disorders.

**Conclusions**: Few studies examined oral medication management regarding childhood cancer patients. More research is needed on this topic especially in the area of childhood cancers where both effects and side effects strongly influence the child\'s conditions.

### PO-428. Continuous Nursing Education Session and Certification for Pediatric Oncology Nurses of the Indus Hospital‐ Pediatric Complex, Pakistan {#pbc27455-sec-14000}

[B. Khan]{.ul} ^1^, S. Anwar^2^, R. Punjwani^2^

*^1^The Indus Hospital, Pediatric Oncology Nursing Education Service, Karachi, Pakistan; ^2^The Indus Hospital, Pediatric Oncology Nursing Education, Karachi, Pakistan*

**Background/Objectives**: Nurses are backbone of healthcare organization, providing care to patients on frontline. Many organizations seek enhance quality patient care by improving nursing knowledge and competency. It is nurses' duty to continue their education inorder to remain aware and updated with medical advancements and new researches. Continuing education and training to increase Pediatric Oncology nurses clinical skills and knowledge and a formalized Pediatric Oncology orientation program for new nurses require (SIOP PODC Baseline standards for pediatric oncology nursing care in LMIC 2014) is essential. Thus, The Indus Hospital, Pediatric complex, Nursing Education Service Karachi, Pakistan initiated various Continuous Nursing Educational (CNE) sessions and Certifications (e.g. Safe handling and administration of Chemotherapy, Basic Pediatric Oncology nursing, Medication Certification, Basic Infection prevention and Control, Resuscitation Skills, IV Cannulation, CAVD care and handling, Supplementary Potassium administration) inorder to attain primary goal of providing quality care and improving patients quality of life.

**Design/Methods**: Evidence based literature suggests strategies for enhancing professional skills and knowledge of nurses in hospitals of developed countries around world was observed and a comprehensive plan was made according to our domestic resources and circumstances. For which annual and monthly calendar are formulated.

**Results**: Due to different in‐service certification and CNE sessions nurses, improve their nursing knowledge and competency and increased Self‐confidence. By enhancing nursing skills and knowledge significant decrease in patient mortality and morbidity shall be observed E.g. Sepsis, Extravasation, Mucositis, Chemotherapy toxicities, Medication errors incidence, and unsuccessful code blue attempts.

**Conclusions**: Nursing education is an essential way of enhancing nurses\' professional skills and knowledge, effectiveness of CNEs/Certification Courses will reflect as quality patient care. CNE are anticipated to increase level of competency and confidence among pediatric oncology nurses to provide quality care and meet base line standard \#2 and \#3 of SIOP PODC Baseline standards for pediatric oncology nursing care in LMIC 2014.

### PO-429. "My Child Matters" by Sanofi Espoir Foundation Grant: Patients, Family and Healthcare Worker Education to Improve Infections Rate in Pediatric Oncology Center in Karachi Pakistan {#pbc27455-sec-14010}

[A. Khatoon]{.ul} ^1^, D.F. Siddiqui^1^, K. Qadir^1^

*^1^The Indus Hospital Network, Infection Control, Karachi, Pakistan*

**Background/Objectives**: Education is essential for the prevention of hospital‐ and community‐acquired infections. In Pakistan, infection control in pediatric oncology settings is challenging, and can lead to unnecessary morbidity and mortality. Infection Prevention Nursing Association (IPNA) received funding in 2017 from Sanofi Espoir Foundation, and created educational materials for reducing infection‐related issues of children with cancer.

**Design/Methods**: At Indus Hospital, in Karachi, six infection control nurses, two doctors, and three psyco‐oncology department members participated in the project. The team worked on finding the appropriate content relating to infection control for pediatric oncology patients. The material was then compiled into 5 videos for the health workers, and 1 video and book for patients and family. The head of the Infection Control department, a nurse, provided Urdu translation and a pediatric oncologist verified final drafts.

**Results**: Five healthcare professional educational videos (line care, 5‐moments of hand hygiene, ventilator‐associated pneumonia prevention, catheter‐associated urinary tract infection prevention, and aseptic cannula insertion) were made. The free videos were distributed through social media and hospitals targeting health workers. Patients and families were provided with a video on cancer care and a detailed book in Urdu on infection control practices. Approximately 250 books per month continue to be distributed amongst patients and their families across eight hospitals of Lahore, Islamabad, Multan and Karachi.

**Conclusions**: The video and books have been well received by patient families and educational videos by the healthcare professionals. We encourage other hospitals treating pediatric oncology patients in Karachi and across Pakistan to become more involved in infection control education. Awareness of infection control practices is the key to for reducing unnecessary infection‐related suffering and deaths in LMIC. We aim to improve patient care and survival rates, while reducing the burden of infections on Pakistani hospital caregivers and immunocompromised children.

### PO-430. Perception and Practice to Safety Management on Antineoplastic Agents Among Caregivers of Children with Cancer {#pbc27455-sec-14020}

[Y.S. Kim]{.ul} ^1^, H.J. Im^1^, J.J. Seo^1^, K.N. Koh^1^, J.Y. Park^2^

*^1^Asan Medical Center Children\'s Hospital, Pediatrics, Seoul, Republic of Korea; ^2^Clinical Nursing, University of Ulsan, Seoul, Republic of Korea*

**Background/Objectives**: Caregiver\'s knowledge and performance regarding care of their children with cancer is an essential issue. Thus, this study was conducted to investigate pediatric cancer caregiver\'s knowledge and performance for safety management of antineoplastic agents.

**Design/Methods**: This study was performed for 131 pediatric cancer caregivers using the questionnaire between November 9 to 30 2016 at Asan Medical Center. The measurement was developed by the researcher based on the 2006 American Society of Health‐System Pharmacists Guideline on Handling Hazardous Drugs, Safe Management of Chemotherapy in the Home established by Oncology Nursing Society and previous studies. It composed of each 15 questions for knowledge and performance of safety management of antineoplastic agents.

**Results**: The average score of knowledge of safety management of caregivers of pediatric cancer was 73.33% and the awareness of the metabolites of antineoplastic agents was higher than 90%. The lowest incorrect answer was the use of alcohol gel after exposed to antineoplastic agents on the skin. The average score of anticipated performance was 3.76 ± 0.59. The highest score of items is using hands to check without gloving when the antineoplastic agents are leaking while injection (4.54 ± 1.07). The lowest score of items is flushing two times of water during 48 hours after antineoplastic agents administrated (2.73 ± 1.55). There were significant correlations between pediatric cancer caregiver\'s knowledge and performance of safety management (r = 0.33, p \<.001).

**Conclusions**: This study showed that the level of knowledge and performance of pediatric cancer caregivers regarding safe handling of antineoplastic agents exceeded the average level in majority area. It implies that various and repeated education about safe handling of antineoplastic agents has improved their knowledge and performance. Our study suggests the repeated research through the standardized tools are warranted.

### PO-431. Health‐Related Quality of Life in Parents of Hospitalized Children with Cancer Focusing on Changes in Working Conditions and Parental Beliefs: A Cross‐Sectional Study {#pbc27455-sec-14030}

[A. Kobayashi]{.ul} ^1^, I. Sato^1^, S. Nakajima^1^, M. Hiwatari^2^, M. Seki^2^, Y. Mitani^2^, M. Hidaka^2^, K. Satake^3^, S. Shimosakon^3^, M. Yanagi^4^, Y. Yuza^5^, K. Koh^4^, J. Takita^2^, K. Kamibeppu^1^

*^1^The University of Tokyo, Department of Family Nursing, Tokyo, Japan; ^2^The University of Tokyo Hospital, Department of Pediatrics, Tokyo, Japan; ^3^The University of Tokyo Hospital, Department of Nursing, Tokyo, Japan; ^4^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^5^Tokyo Metropolitan Children\'s Medical Center, Department of Hematology/Oncology, Tokyo, Japan*

**Background/Objectives**: Parental life, especially the working conditions would be impacted by children\'s situation, such as diagnosis with cancer, hospitalization, and intensive and multidisciplinary treatments for several months or years. As the changes of working conditions would lead to lower parental health‐related quality of life (HRQOL), to understand parental beliefs would be beneficial to support these parents. The aim of this study is (1) to describe HRQOL in parents of hospitalized children with cancer in terms of changes in working conditions owing to children\'s cancer and (2) to clarify the relationship between HRQOL and beliefs related to changes in working conditions.

**Design/Methods**: A cross‐sectional study was employed from September 2017 to March 2018 at three hospitals in Japan. HRQOL was evaluated using by SF‐36v2 standard version. The changes in working conditions were assessed in terms of the changes in employment status, working hours, and/or work contents. Beliefs were evaluated using the original items. The mean scores of each summary score of SF‐36v2 were compared between four groups classified in terms of changes in working conditions ("quit/leave", "arranged", "continuing", "housewives"). Linear mixed model analysis was performed to calculate the coefficients for each summary score by beliefs.

**Results**: Data from 15 mothers and 11 fathers were analyzed. The "arranged" group had the lowest mean physical (PCS) and mental component summary scores (MCS), whereas the "quit/leave" group had the lowest role/social component summary scores (RCS). The belief "I can prioritize my work over caring for my child if necessary" item score and MCS were positively correlated.

**Conclusions**: The changes in working conditions may lower HRQOL in parents of hospitalized children with cancer. Beliefs were also related to parental HRQOL. To improve parental HRQOL, healthcare professionals should assess parental beliefs and if necessary encourage parents to maintain their working conditions.

### PO-432. Application of a Combined Pharmacological and Non‐Pharmacological Intervention Program on the First Lumber Puncture or Bone Biopsy of Childhood Cancer Patients {#pbc27455-sec-14040}

[Y. Le]{.ul} ^1^, F. Zhou^1^, M. He^1^

*^1^Shanghai Children\'s Medical Center‐ Affiliated with Shanghai Jiaotong University, Pediatric Hematology and Oncology, Shanghai, China*

**Background/Objectives**: Pediatric patients with cancer undergo repeated invasive painful medical procedures. Lumber puncture and bone biopsy are of the most painful and highly distressing ones. In resource‐limited environment, total anesthesia is not available for patients receiving lumber puncture or bone biopsy. This study evaluates the effect of a combined pharmacological and non‐pharmacological intervention program on the first time lumber puncture or bone biopsy of childhood cancer patients.

**Design/Methods**: In this clinical controlled trial, pediatric cancer patients (aged 3‐12 years) who received lumber puncture and bone biopsy for the first time in outpatient clinic were enrolled. 132 patients in the control group received routine care. 32 patients undergoing lumber puncture or bone biopsy were provided with a combined pharmacological and non‐pharmacological intervention program, including application of topical anesthetics and preparation using a children\'s comic book and audio about lumber puncture and bone biopsy. Procedural pain, fear and compliance were collected for both groups.

**Results**: The average pain in treatment group was 6.06±3.14, while 8.51±2.49 in control group, and there was a statistically significant difference (P\<0.01). The percentage of high‐level procedural fear in treatment group was 21.9%, while 43.2% in control group, and there was a statistically significant difference (P\<0.01). There was no difference in compliance between two groups.

**Conclusions**: A combined pharmacological and non‐pharmacological intervention program was effective in decreasing procedural pain and fear for the first time lumber puncture or bone biopsy of childhood cancer patients.

### PO-433. Work Related Burden in Pediatric Oncology Nurses: A Pilot Study {#pbc27455-sec-14050}

[M. Libura]{.ul} ^1^, K. Jankowska^2^

*^1^Uniwersity of Warmia and Mazury, Medical Training and Simulation Centre, Olsztyn, Poland; ^2^Ludwik Rydygier Collegium Medicum‐ Nicolaus Copernicus University, Paediatric Hematooncology and Oncology Department‐ Laboratory for Communication in Medcine, Bydgoszcz, Poland*

**Background/Objectives**: Working in paediatric oncology departments has been demonstrated to be related to a substantial level of emotional burden. Of all members of the oncology care team, nurses spend particularly high amount of time interacting directly with patients, which makes them more susceptible to stress. The purpose of the pilot study was to identify the primary sources of emotional burden in paediatric oncology nurses in Poland.

**Design/Methods**: A self‐constructed questionnaire based on literature review was distributed among paediatric oncology nurses working in University Hospital in Bydgoszcz. 15 out of 22 nurses returned competed questionnaires. The preliminary findings will serve as a basis for a larger multi‐centre study.

**Results**: Only one out of 15 participants of the study indicated that work in paediatric oncology department was a source of work satisfaction, while the remaining responders chose "rather" and "definitely not" answers. All participants evaluated work in their specialty as more emotionally burdensome in comparison with other hospital departments. Negotiating family life with work was not a major problem, contrary to expectations. The major sources of stress were: emotions related to the state of patients and their parents and relatively low wages. The majority also pointed to the challenging behaviours of parents as a burden, as well as to complicated interprofessional relations. Relations with other nurses were also pointed out as as sources of dissatisfaction. Interestingly, the lenght of shifts was not indicated as a problem.

**Conclusions**: The main sources of work related burden in paediatric oncology nurses were emotions related with interactions with patients and their families. This may signal the shortcomings in training in therms of competences and skills necessary for prevention of future burnout. Another major problematic area was renumeration, which is a wider problem in the national context in Poland. Training future health professionals in team work and communication skills is also crucial.

### PO-434. The Use of the PED‐MTNS in Detecting Chemotherapy Induced Peripheral Neuropathy in a Singapore Children\'s Hospital {#pbc27455-sec-14060}

[Y.Y. Lim]{.ul} ^1^

*^1^KK Women\'s and Children\'s Hospital, Paediatric Haematology and Oncology, Singapore, Singapore*

**Background/Objectives**: Chemotherapy Induced Peripheral Neuropathy (CIPN) as a long‐term complication is affecting more childhood cancer patients. This research addresses the need to ensure consistency of screening for CIPN. The primary aim of this study is to determine the inter‐rater reliability, between nurses and physiotherapists, in performing the CIPN assessment using the Pediatrics --modified Total Neuropathy Score (Ped‐mTNS). The secondary aim is to establish the relationship between the cumulative dose of vincristine and the Ped‐mTNS scores.

**Design/Methods**: This is a cohort study using physiological measurement with outcomes measure targeting participants between aged 5 to 18 years. The study will estimate the intraclass correlation coefficient (ICC) between nurses and physiotherapists conducting assessment of CIPN using Ped‐mTNS on 30 participants. The nonparametric Spearman correlation test will be used to estimate the correlation of cumulative dose of vincristine to the Ped‐mTNS scores.

**Results**: In the preliminary findings of 16 participants, the investigators observed a worsening of CIPN scores in all participants during the induction chemotherapy where vincristine is administered weekly. Most participants experienced mild to severe weakness of the lower extremities resulting in higher risk of falls during this phase. Progressive recovery overtime are prominent which may suggest no correlation between cumulative dose of vincristine and worsening of CIPN scores. However, as the results are still in its infancy, recruitment of participants to reach the target of 30 will continue as it is necessary for sufficient power in the data analysis.

**Conclusions**: Early detection of CIPN can lead to early interventions and supportive care, minimising the progression of symptoms, preventing patient\'s harm and alleviate the undesirable symptoms associated with CIPN. Thus, it is imperative to adopt a valid and reliable nursing assessment tool for early detection of CIPN to reduce such risks, potentially improving clinical outcomes and quality of life for the paediatric oncology patients.

### PO-435. Nursing Education Journey for Paediatric Haematopoietic Stem Cell Transplantation in a Singapore Children\'s Hospital {#pbc27455-sec-14070}

[Y.Y. Lim]{.ul} ^1^

*^1^KK Women\'s and Children\'s Hospital, Paediatric Haematology and Oncology, Singapore, Singapore*

**Background/Objectives**: The complexity and diversity of the haematopoietic stem cell transplant (HSCT) patients necessitate nurses to quickly integrate knowledge along with advanced set of clinical skills to ensure the provision of safe and effective care. Formerly, there was no training program for new HSCT nurses; they were trained on the job by experienced nurses that resulted in practice variations. Furthermore, nurses felt inadequately prepared to practice in this complex clinical environment.

**Design/Methods**: The Paediatric HSCT nursing course was designed to provide nurses with fundamental knowledge and skills to deliver a high standard of nursing care for HSCT patients. Course content outline are adopted from the Oncology Nursing Certification Corporation, parallel with the needs analysis conducted among HSCT nurses. The course comprises of didactic classes delivered by the multidisciplinary team, case discussion and experiential learning through clinical attachment with experienced nurses to translate the theoretical knowledge into clinical practice. Nurses are assessed through pre and post‐course multiple choice questions (MCQ), skills assessments and case presentation.

**Results**: All nurses were able to achieve at least 70% in post course MCQ on 1st attempt and scored a significantly higher percentage in the repeated pre‐course MCQ following the course. Core competency of skills such as stem cell infusion and patient education were assessed through competency checklist and direct observation of skill transfer to the nurses' practice setting. Post course evaluation had shown an increase rating of confidence level in all participants.

**Conclusions**: HSCT is a highly challenging area that is constantly evolving; nurses will continually be challenged to bridge advance technologies with complex care regimens involving the coordination of interdisciplinary care activities. Beyond the structured course curriculum, the future of HSCT nursing education can ameliorate on the benefits of interprofessional education to reflect on the most recent evidence and shape the successful collaborative teamwork in HSCT care.

### PO-436. An Interdisciplinary Care Model to Establishing Palliative Care for Children and Adolescents with Cancer {#pbc27455-sec-14080}

[F.R. Lin]{.ul} ^1^, P.Y. Hsu^1^

*^1^National Taiwan University Children Hospital, Nursing, Taipei, Taiwan R.O.C*.

**Background/Objectives**: Palliative care for pediatric cancer patients and their families includes the relief of symptom and improvement of quality of life at any and all stages of disease. There care are most effectively provided by an interdisciplinary team. The purpose of this study was to develop an interdisciplinary care model to establishing palliative care into end of life care for children and adolescents with cancer.

**Design/Methods**: The setting of this study was about a 24‐bed pediatric oncology ward in Taiwan from November 2015 to July 2017. We use "satisfaction with care at the end of life" to measure medical members satisfaction and the instruments was based on literature review. We worked out those methods:(1) Symptom management: scheduled education for symptom control and care of the end of life of patient, such as fatigue, pain, constipation, or dyspnea.(2.) To develop an interdisciplinary care model: we implemented case analysis of the end of life of patient and redesigned a new counseling mechanism. (3) To design implement for age‐appropriate: child life specialists are required to set and collected age‐appropriate toy from social worker.

**Results**: After our study, It have three aspects for satisfaction score: (1)"recognition of the problem by the medical team" were increased from 5.3 points to 8.1 points; (2)" an interdisciplinary care" were increased from 6.3 points to 9.1 points; (3)" age‐appropriate implement " were increased from 5.8 points to 9.7 points. Additional benefits for the rate of hospice‐palliative coverage, at the end of life in children and adolescents with cancer, were increased from 68% (2013/1/1∼2014/12/31) to 100% (2016/1/1∼2017/12/31).

**Conclusions**: We found that children and adolescents who died of cancer experienced substantial suffering in the last month of life. Based on our results, we established an interdisciplinary care model that it is most effectively and healthcare quality of palliative care can be improved.

### PO-437. Symptom Clusters in Children with Malignant Tumor During Induction Chemotherapy Period {#pbc27455-sec-14090}

[K. Liu]{.ul} ^1^, J. Liao^1^, X. Zhou^2^, X. Bu^1^, D. Tang^3^, M. Feng^3^

*^1^Sun Yat‐Sen University, School of Nursing, Guangzhou, China; ^2^Sun Yat‐Sen Memorial Hospital, Nursing Department, Guangzhou, China; ^3^Sun Yat‐Sen Memorial Hospital, Pediatric Oncology Department, Guangzhou, China*

**Background/Objectives**: Children with malignant tumors experience multiple, distressing and interrelated symptoms during chemotherapy, especially in induction period. Identifying which symptoms are co‐ocurrent and how they are interrelated with each other can guide symptom management in pediatric oncology department. The purpose of this study was to explore symptom characteristic and symptom clusters of children with malignant tumors during the induction chemotherapy period.

**Design/Methods**: A cross‐sectional design survey was conducted among 238 children with malignant tumors during induction chemotherapy period using the Chinese Version of Memorial Symptom Assessment Scale10‐18(Ch‐MSAS10‐18), then exploratory factor analysis was used to identify symptom clusters.

**Results**: The average age of 238 children was 6.40±3.63 years, and 60.9% of them were boys. The common symptoms of children with malignant tumor in the induction period were lack of energy, nervous, lack of appetite, nausea, irritable and vomiting. Seven clusters were identified from the data using exploratory factor analysis: upper gastrointestinal symptom cluster, irritable mood symptom cluster, depressive mood cluster, image impaired symptom cluster, nervous system symptom cluster, skin and mucosa symptom cluster, ingestion and excretion symptom cluster.

**Conclusions**: Children experienced multiple symptoms and underwent a variety of symptom clusters during induction chemotherapy period. In order to alleviate the overall symptom cluster distress, health care professionals should pay attention to the common symptoms bothered children during induction chemotherapy, find out and control the key symptoms of symptom clusters.

### PO-438. Patterns of Health Outcomes in Children with Cancer in China: Measuring with Pediatric Patient‐Reported Outcomes Measurement Information System (PROMIS) Short Forms {#pbc27455-sec-14100}

[Y. Liu]{.ul} ^1^, C. Yuan^2^, N. Shen^3^, P.S. Hinds^4,5^

*^1^Shanghai Jiaotong University, School of Nursing, Shanghai, China; ^2^Fudan University, School of Nursing, Shanghai, China; ^3^Shanghai Children\'s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Nursing Department, Shanghai, China; ^4^Children\'s National Health System, Department of Nursing Research and Quality Outcomes‐ and the Center for Translational Science, Washington.DC, USA; ^5^The George Washington University, School of Medicine, Washington.DC, USA*

**Background/Objectives**: Children with cancer experiences unpleasant symptoms and weakened body health due to their disease and treatment. The purpose of this study was to identify groups of patients who experience similar levels of symptoms and function by using latent profile analysis (LPA) and examine the predictors of profile membership in children with cancer in China.

**Design/Methods**: Children self‐reported health outcomes data were collected using the Chinese version of PROMIS Pediatric short forms (depressive symptoms, anger, anxiety, fatigue, pain interference, peer relationship, physical function‐mobility and physical function‐upper extremity). Children and adolescents with cancer who ages 8‐17 were recruited from three hospitals in China. LPA was used to identify and characterize groups of patients who reported similar levels of symptom suffering and body function. Multinomial logistic regression was used to test the relationship of the latent profile membership with individual characteristics.

**Results**: The analysis included 272 patients in treatment (72.1%, n=196) or in survivorship. More than half of them were diagnosed with leukemia (77.2 %, n=210), and few children had other health problem (5.7%, n=16).Three health outcomes profiles were identified (Entropy=0.825); currently receiving cancer treatment (Profile1:OR=5.09, P=0.026; Profile2:OR=9.93, P=0.003) and those hospitalized in the past seven days(Profile1:OR=2.15, P=0.032; Profile2:OR=2.48, P=0.030) were more likely to be members of the profile with the highest levels of symptom suffering and weakened body function. Age, gender, guardian\'s education level, tumor type, duration of the illness and other health problems were not associated with profile membership.

**Conclusions**: LPA was a useful cluster methodology to identify latent profiles of health status from observed symptoms and function in pediatric oncology, This made it possible to predict patients' risk of developing more severe symptoms and weaken function, allowing clinicians, parents and patient to better anticipate and prevent the multiple symptoms that occur during and after the cancer treatment.

### PO-439. Implantation of a Pioneer Naxitamab Administration Unit in a Pediatric Oncology European Hospital {#pbc27455-sec-14110}

[C. Llanos]{.ul} ^1^, S. López^1^, M.C. Molero^1^, M. Vallespí^1^

*^1^Institut de Recerca Sant Joan de Déu Research Foundation SJD, Clinical Trials Unit, Barcelona, Spain*

**Background/Objectives**: Anti‐GD2 immunotherapy has become standard of care for high‐risk neuroblastoma. Implementation of such novel therapies and the significant toxicities associated is a challenge for professionals but also for parents. The main objective here was to move from the current Dinutuximab based in‐patient treatments to Memorial Sloan Kettering Cancer Center (MSKCC) hu3F8 (Naxitamab) outpatient administrations.

The main three objectives to be achieved are: to empower patients and parents to be bio‐psycho‐socially prepared, second to train professionals on procedures and circuits and finally to customize a new protocol to avoid risks in patient caring.

**Design/Methods**: A training which consists on: eight days on‐site course at MSKCC by local nursing staff to learn the healthcare model to develop a local program and an on‐site supervision at Hospital Sant Joan de Déu by MSKCC nursing staff.

**Results**: The newly developed protocol for patients treated with hu3F8 includes: nursing visit with patient and parents prior to first infusion to focus on techniques and recommendations to deal with expected toxicities; skillful medical and nursing staff capable to face hu3F8 administrations with specific monitoring strategies; enrolment of supportive care professionals including child life, psychologist and anesthesiologist to increase patient well‐being before, during and after infusions. Specific monitoring registries have been elaborated to report on the whole experience by professionals, patient and parents. Weekly multidisciplinary staff meeting has been set to discuss single patient treatment and needs.

**Conclusions**: Adopting MSKCC hu3F8 treatment to our site has required an in‐depth analysis of all medications and procedures to the whole management of patients. Importantly, European legislative framework restricts some of the roles established at MSKCC for nurses requiring local adaptation. Increase in patient and family centered supportive care has improved significantly the intense psychological experience associated with Naxitamab treatment.

### PO-440. Preliminary Establishment of Quality Indicator System for Pediatric Hematology and Oncology Nursing in China {#pbc27455-sec-14120}

[H. Lu]{.ul} ^1^, M. He^1^

*^1^Shanghai Children\'s Medical Center‐ Affiliated with Shanghai Jiaotong University, Pediatric Hematology and Oncology, Shanghai, China*

**Background/Objectives**: Number of pediatric patients with cancer in low‐income and middle‐income countries is expanding rapidly, particularly in China. However, measurement of the quality or the impact of care provided, which is essential for improvement of nursing care, remains lacking. This study is to develop a quality indicator system for pediatric hematology and oncology nursing in China.

**Design/Methods**: Based on Donabedian\'s "structure‐process‐outcome" theory, literature review, semi‐structured interview, Delphi method and Analytic hierarchy process method were adopted to determine the nursing quality indicator system and indicators' weight, with the support of Chinese Anti‐Cancer Association and the Nursing Group.

**Results**: After three rounds of expert advisory, the effective response rates were 100%,93.3% and 100%; Cr coefficients were 0.93, 0.93, and 0.96; W coefficient were 0.209,0.166, and 0.332, and P values \<0.01. The indicator system consisted of 3 first level indicators, 8 second‐level indicators, and 29 third‐level indicators. Analytic hierarchy process was used to establish weight.

**Conclusions**: The constructed indicator system for pediatric hematology and oncology nursing are scientific, practical, and unique to this specialty, which could facilitate sustainable development of pediatric hematology and oncology.

### PO-441. A Critical Ethnographic View of Oncology Nurses {#pbc27455-sec-14130}

[P. Mahon]{.ul} ^1^

*^1^UBC, School of Nursing, Vancouver, Canada*

**Background/Objectives**: Paediatric Haematology/Oncological units (PHOUs) are highly paced, stressful environments and can be difficult areas to work. Thus, these units can present issues when it comes to both recruit and retain nurses. There is little research addressing how the environment of PHOU contribute to nurses desire to stay or leave this environment.

**Design/Methods**: To conduct this project a critical ethnographic approach was used. Critical Ethnography (CE) see the constructs of power and knowledge as interconnected, making mutual contributions to knowledge (Hardcastle et al., 2006). This adheres to the researchers beliefs. Critical ethnography is based on both critical social theory (CST) and ethnography: CE is one of the evolutionary paths of ethnography.

Carspeckens (1996) 5 stages of CE were followed. 21 (N=21) semi‐structured interviews were conducted. This sample represented approximately 1/3 of nursing staff.

**Results**: Developing long term relationships with children and families and being part of the "team" are sources of satisfaction.

The ability to have on‐going learning opportunities and teaching families was a satisfying aspect of their job. Thus, implying a power‐shift between staff and families. This is an unusual relationship in comparison to other hospital environments where staff tend to maintain more power over diagnosis and treatment,

The main frustration described pertained to administrative involvement in the everyday workings of PHOU.

**Conclusions**: Relationships with team members, children and families is a satisfier for nurses. However, difficult situations do arise and nurses do find them difficult to deal with but it might suggest that because these nurses work with children with cancer there is an unwritten rule or expectation that they should tolerate more bad behavior by families because of their 'understandable' level of stress. This warrants further investigation. The ability to learn in this evolving field is important to staff.

Administrative involvement in decisions surrounding every day workings of PHOU could cause attrition.

### PO-442. Change in Genetic Knowledge of Parents Consenting to Clinical Genomic Sequencing for Their Child with Cancer Following a Two‐Phase Consent {#pbc27455-sec-14140}

[B. Mandrell]{.ul} ^1^, A. Ouma^2^, L. Harrison^2^, E. Quinn^2^, R. McGee^2^, R. Nuccio^2^, S. Hines‐Dowell^2^, E. Gerhardt^2^, C. Kesserwan^2^, J. Valdez^2^, L. Johnson^2^, K. Nichols^2^

*^1^St. Jude Children\'s Research Hospital, Division of Nursing Research, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Little is known of the parental understanding and knowledge before and after the consenting process for genomic sequencing of their child\'s somatic and germline sample. The objective of this study aim was to evaluate change in parental genetic knowledge at the completion of a two‐phase consenting process.

**Design/Methods: Design**: Longitudinal study of parents consenting to clinical genomic sequencing for their child with cancer.

**Methods**: Parents interested in clinical genomic sequencing for their child with cancer participated in a two‐phase consent process. Prior to a study introductory visit (SIV) parents completed a 12‐item genetic knowledge test. The SIV was then conducted by a trained study nurse, providing genetic education and study summary. Approximately 1‐3 weeks later, parents returned for an informed consent conversation (ICC) conducted by the same trained study nurse. At the completion of the ICC, parents again completed the 12‐item genetic knowledge test.

**Results**: Results: 120 parents participated in both the SIV and ICC. Comparison between the answers provided on the two genetic knowledge tests revealed that parental genetic knowledge significantly improved on 10 of the 12 questions asked. The two questions without change were answered correctly by the majority of participants on the pre‐test. Despite a significant improvement in correct responses, only 36% and 41% of parents answered post‐ICC questions about the difference between germline and somatic testing correctly.

**Conclusions**: Conclusion: Parents consenting to clinical genomic sequencing for their child demonstrated improved knowledge following a two‐phase consent process. However, the concepts of germline and somatic mutations remain difficult to comprehend.

### PO-443. Improvement Processes of Skills Among a PHO Nursing Team {#pbc27455-sec-14150}

[A. Mannaerts]{.ul} ^1^, G. Laureys^1^, L. Willems^1^, F. Van Hoecke^2^, L. Steendam^1^, N. Herman^1^

*^1^UZ Gent, Pediatric Hemato‐Oncology, Gent, Belgium; ^2^Van Hoecke Consulting, Human Resources Consultant, Gent, Belgium*

**Background/Objectives**: During job evaluations at the pediatric hemato‐oncological ward (PHO) of the University Hospital Ghent some nurses expressed to be frustrated about some of their colleagues' lack of certain skills, without appreciating sufficiently their other talents. During these conversations three major qualities were defined: planning and organising well in a chaotic situation, working quickly and efficiently, and communicating self‐confidently about the nurses' own needs and those of the patients.

It was decided to organize a workshop in order to define skills a PHO‐nurse should have, evaluate colleagues in respect to these skills and to be able to give/receive feedback in a constructive manner.

**Design/Methods**: A workshop "talent scouting", spread over three sessions, was organised for all the nurses (47) in close collaboration with a consultant. First the skills an "ideal" nurse should have were decided in a group conversation. In small groups we discussed ways in which skills, individually and in a team, could best be used and developed, and how to give constructive feedback if irritations arise caused by individual weaknesses. Finally each nurse attributed the skills he/she thought to be most significant for each of their colleagues.

**Results**: Each nurse received a diagram of own skills as perceived by the colleagues. It will be used as a starting point in future job evaluations.

After this workshop a central study group drew up a "decision tree" to be hung out in the ward as a "charter". This "decision tree" decides upon the ways to react when irritated by behaviour of a colleague‐nurse.

**Conclusions**: This drawing‐up of an individual diagram of skills and of a "decision tree" can make frustrations a subject of discussion and can mean a start of more positive group dynamics, in which skills and not weaknesses are focussed upon. Further follow‐up and possibly other initiatives are necessary.

### PO-444. Challenges in Nursing Care for Children with Cancer: Report of Experience from Nigeria {#pbc27455-sec-14160}

[N. Mary]{.ul} ^1^

*^1^Paediatrics, Nursing, FCT, Nigeria*

**Background/Objectives**: Cancer is one the major causes of death in children and adolescents, accounting for about 4% of deaths in children below 5 years in Nigeria. The nursing care of these patients often does not receive adequate attention. This report highlights challenges in nursing care of these children in a low resource setting and is aimed at raising awareness to influence advocacy and action.

**Design/Methods**: A retrospective review of 38 children treated for cancers in an inpatient children\'s ward over a one‐year period (November 2015 -- November 2016). In the same period, a total of 992 children were admitted into the same ward. The nursing care of the patients has been reviewed. Design/Methods: A retrospective review of 38 children treated for cancers in an inpatient children\'s ward over a one‐year period (November 2015 -- November 2016). In the same period, a total of 992 children were admitted into the same ward. The nursing care of the patients has been reviewed.

**Results**: Children with cancers accounted for 3.8% of admissions on the ward. In addition to the nursing workload of these patients, several important challenges and limitations were encountered requiring attention and efforts of the nursing staff, including; financial burden on parents and their inability to cope with costs, psychological issues involving parents and patients (aggression, anxiety, depression, withdrawal) and difficulties with communicating disease course, treatment and complications of treatment. These challenges significantly increased the nursing burden of the patients, which were often not part of patient treatment plan.

**Conclusions**: It\'s important to include these identified challenges in the counseling and treatment plan of children with cancers, particularly in low resource settings where the burden of nursing care is enormous. Development and implementation of a careful multidisciplinary care plan should help in addressing these challenges.

### PO-445. Review of the Literature on Peer Support of Adolescent and Young Adult Cancer Patients {#pbc27455-sec-14170}

[N. Mashiko]{.ul} ^1^, Y. Kato^2^, M. Kobayashi^3^, A. Tsumura^4^, I. Fujimaki^5^, M. Ishigaki^2^, K. Toju^6^, Y. Wakiguchi^7^, R. Ohta^8^

*^1^Gunma Prefectural College of Health Science, School of Nursing, Maebashi, Japan; ^2^Shizuoka Children\'s Hospital, Nursing, Shizuoka, Japan; ^3^Kitasato University Graduate School of Nursing, Nursing, Sagamihara, Japan; ^4^Shizuoka Cancer Center Hospital, Nursing, Sunto‐gun, Japan; ^5^Jichi Medical University School of Nursing, Adult Nursing, Shimotsuke, Japan; ^6^National Cancer Center Hospital East, Nursing, Kashiwa, Japan; ^7^University of Hyogo College of Nursing Art and Science, Clinical Nursing, Hyogo, Japan; ^8^Osaka City General Hospital, Nursing, Osaka, Japan*

**Background/Objectives**: This study explored the context in which peer support is addressed in studies of adolescent and young adult (AYA) cancer patients in order to gain insight into how such support is utilized in clinical practice to improve the quality of life (QOL) of these patients.

**Design/Methods**: First, a literature search of the Japan medical abstracts society database was performed using the terms "peer support," "cancer," and "neoplasm" to obtain an overview of the research on peer support in Japan. A literature search of the PubMed database was then performed using the same terms in order to survey such research in other countries. Research that was found not to be consistent with the study\'s objectives was excluded based on the title of the article and its abstract. Thirteen articles from Japan and 22 from other countries were extracted based on the context in which peer support for AYA cancer patients was addressed.

**Results**: The articles on peer support of AYA cancer patients that were included in the analysis were analyzed for similarities in their descriptions of the context in which peer support was addressed. The articles were found to include 3 themes: 'peer support as a psychosocial need,' 'peer support as a strategy for facilitating support that improves QOL,' and 'devising ways to effectively implement peer support' for AYA cancer patients.

**Conclusions**: AYA cancer patients need connections with and support from peers. However, medical personnel cannot implement peer support as direct care. The findings suggested that acting to effectively provide a setting conducive to peer support and using such support strategically in clinical practice may be useful for facilitating other care intended to improve QOL.

### PO-446. Experience of a Parent Whose Children with Cancer Lost Friends During Hospitalization: The Narratives of 2 Mothers {#pbc27455-sec-14180}

[H. Megumi]{.ul} ^1^, A. Midori^1^

*^1^Department of Nursing, Nagoya University Graduate school of Medicine, Nagoya, Japan*

**Background/Objectives**: Children with cancer experience the death of close companions who too struggled against the disease. However, there is almost no domestic or international protocol, or assessment, of grief care for children and their families who continue treatment after having experienced the death of friends. Thus, it seems necessary to investigate the experience of parents of children with cancer and examine a method of support for children with cancer by providing nursing support to parents and establishing partnerships with parents.

**Design/Methods**: Study design: a qualitative inductive study. Data collection method: a semi‐structured interview. Inclusion criteria: being the parent of a child with cancer who continues to receive ambulatory treatment or has completed the course of treatment, after having lost a friend who had received inpatient care in the same hospital during the same period in the past 10 years.

**Results**: The subjects of the study were two mothers who were filled with sorrow over their child friend\'s death, as it was associated with the death of the surviving child, which brought on more personal anxiety. Their children were either in the higher grades of elementary or junior high school. The mothers did not hesitate to inform their child of the loss of the friend, possibly because of \[their desire that their child does not forget\] and the \[understanding of the futility of trying to conceal the death\]. However, the subjects did give due consideration to their child\'s physical and mental health when planning the timing of the disclosure of the loss to their children. After the disclosure, the subjects were unable to evaluate whether the decision they had made was correct, because of their children\'s initial lack of a reaction to the disclosure.

**Conclusions**: It is necessary to interventions that focus on understanding their confusion and having the attitude to support their decisions.

### PO-447. The Processes of Developing Independent Living and Compatibility Between Health Management and Social Life in Adolescent and Young Adult Childhood Cancer Survivors {#pbc27455-sec-14190}

[K. Miyagishima]{.ul} ^1^, K. Ichie^2^, K. Sakaguchi^3^, Y. Kato^4^

*^1^Hamamatsu University School of Medicine, Faculty of Nursing, Hamamatsu, Japan; ^2^Seirei Christopher University, School of Nursing, Hamamatsu, Japan; ^3^Hamamatsu University School of Medicine, Department of Pediatrics, Hamamatsu, Japan; ^4^Shizuoka Children Hospital, Nursing Department, Shizuoka, Japan*

**Background/Objectives**: This study aimed to elucidate the processes of how adolescent and young adult childhood cancer survivors develop independence and compatibility between health management and social life for long‐term support.

**Design/Methods**: We interviewed 20 childhood cancer survivors aged 16--25 years and performed analyses using the modified grounded theory approach.

**Results**: Forty‐two 'concepts', eight "sub‐categories", and six \[categories\] were generated. In health management, childhood cancer survivors \[overcame their disease by relying on their parents to make decisions and help\], which included "not completely accepting their disease", "enduring painful treatment by gaining help" and "attending healthcare visits with parents". As their development and treatment progressed, they \[managed their physical condithin based on their own judgment\], which included "physical condition management with awareness of their disease", "having consultations and obtaining imformation that does not pass through the parent" and "disease awareness fades along with recovery of physical condition". However, they also had \[concerns about the ongoing effects of cancer\]. The social lives of childhood cancer survivors were influenced by their health management. They experienced \[school life with coordination and mental conflict\], which included "adjusting to balancing school activities and treatment", 'gaining the cooperation of teachers and friends by explaining their disease carefully' and "worrying about being different from everyone else". Then, they \[had self‐confidence in being themselves\] with 'self‐confidence in doing same activities as everyone' and \[found the way to live on their own\] with 'motivation for performing activities and living by themselves', 'selecting life paths based on disease experience and work motivation', and 'consciousness to make a living on their own.

**Conclusions**: These findings suggest the necessity of supporting childhood cancer survivors in making cancer therapy compatible with school life and living independently in order to be themselves while being conscious of health management and the long‐term influences of childhood cancer.

### PO-448. Quality Program Targeting Extravasations in Pediatric Oncology Patients at Yangon Children\'s Hospital Demonstrates Success {#pbc27455-sec-14200}

[L. Morrissey]{.ul} ^1^, N.W. Kyi^2^, T.M. Hnin^3^

*^1^Boston Children\'s Hospital, Inpatient Hematology/Oncology Nursing, Walpole, USA; ^2^Yangon Children\'s Hospital, Hematology Oncology Unit, Yangon, Myanmar Burma; ^3^Yangon Childrens Hospital, Hematology/Oncology Unit, Yangon Childrens Hospital, Myanmar Burma*

**Background/Objectives**: Extravasation is a serious complication for pediatric oncology patients receiving chemotherapy via peripheral intravenous catheters. The leakage of vesicant chemotherapy from the venous pathway can cause injury ranging from blistering to necrosis of surrounding skin and tissue, leading to patient harm including pain, infection and loss of limb function. Children receiving cancer treatment in low resource settings where central venous access devices (CVAD\'s) are not available are especially vulnerable to extravasation risk.

**Design/Methods**: In 2015, the Hematology/Oncology Unit (HOU) at Yangon Children\'s Hospital (YCH) targeted extravasation prevention as a quality initiative. The initial components of the program included creation of a standardized guideline for chemotherapy administration, education of staff, and a monthly data collection program led by the HOU ward sister. The extravasation rate is calculated monthly by dividing the number of extravasations by the number of doses of vesicant chemotherapy and multiplying by one thousand. Number of days between extravasations is a new quality measure added in 2018.

**Results**: Since June 2015, the monthly average of vesicant chemotherapy doses administered has increased from 215 to 280. Concurrently, the 2018 extravasation rate to date has decreased to 1.04, compared to a rate of 6.89 in 2015. Between January and April, the HOU ward has gone 84 days and counting with no extravasations.

**Conclusions**: Although the number of patients receiving chemotherapy at YCH has increased, the HOU ward has successfully decreased the extravasation rate over a 32 month period. Development of standard guidelines, designation of on‐site leaders, education and ongoing surveillance has proven to be a successful strategy for reducing extravasations in a pediatric oncology program in a low resource setting where CVAD\'s are not available.

### PO-449. End of Life Care Experience at the Peadiatic Oncology Unit at the Uganda Cancer Institute: What Role Can Oncology Nurses Play? {#pbc27455-sec-14210}

[I. Mulyowa]{.ul} ^1^

*^1^Uganda Cancer Institute, Pediatric Oncology, Kampala, Uganda*

**Background/Objectives**: Although the majority of childhood cancers are curable, this is not yet true for low resource countries. In Uganda, cancer care is only done at the Uganda Cancer Institute.

Between Jan 1^st^ and Dec 31^st^, there were **4,321** new cancer cases registered and about **8%** were among children. The mortality rate is **70%** annually, that is every **3 in 5** children diagnosed with cancer will not survive past one year after cancer diagnosis. Here, we review the factors contributing to poor outcomes and potential solutions

objectives

**Design/Methods**: Experience

**Results**: Majority of the children (70%) present with advanced disease at cancer diagnosis, so the treatment intent is usually palliative. Family involvement in decisions regarding palliative chemotherapy at end of life is high in the pediatrics compared to the adult oncology. The concept of quality of life for patients with advanced cancer is not well perceived among caretakers. Nurses play an integral role, identifying symptoms, providing care coordination, because they are with the patients most of the time. Also ensuring clear communication with patients' and their caretakers. Nurses roles: While patients are admitted, they spend most of the time on the ward with the nurses, so nurses play a big role in: Identifying symptoms, providing care coordination, implementing doctor\'s written orders and also identifying a dying patient. Nurses also play a big role, continuing the canceling that was started by the doctors They play a role in reassuring the patient especially the adolescents and also reassuring the family.

**Conclusions**: Palliative Care Training for all the clinicians and other healthcare providers is essential, also educational initiatives for patients and their families regarding the type of cancer the child/patient has, treatment modalities should be emphasized. The oncology nurses play a key role in the multidisciplinary team approach to paediatric patients at end of life care.

### PO-450. Relationship Between Fatigue and Family Functioning in Children with Cancer Undergoing Treatment in the Hospital: A Cross--Sectional Study {#pbc27455-sec-14220}

[S. Murata]{.ul} ^1^, S. Suzuki^1^, T. Soejima^1^, M. Hiwatari^2^, M. Seki^2^, Y. Mitani^2^, M. Hidaka^2^, K. Satake^3^, S. Shimosakon^3^, J. Noguchi^4^, Y. Yuza^5^, J. Takita^2^, K. Koh^4^, K. Kamibeppu^1^

*^1^The University of Tokyo, Department of Family Nursing, Tokyo, Japan; ^2^The University of Tokyo Hospital, Department of Pediatrics, Tokyo, Japan; ^3^The University of Tokyo Hospital, Department of Nursing, Tokyo, Japan; ^4^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^5^Tokyo Metropolitan Children\'s Medical Center, Department of Hematology/Oncology, Tokyo, Japan*

**Background/Objectives**: Fatigue is the most common and a particularly problematic symptom among children with cancer undergoing treatment in the hospitals. Previous studies reported that good family functioning reduces problems related to cancer and its treatment. However, no study has evaluated how family functioning reduces fatigue among children with cancer. The aim of this study is to clarify the relationship between fatigue and family functioning among children with cancer undergoing treatment in the hospitals.

**Design/Methods**: This cross--sectional study included children with cancer who were treated in the hospitals and their families between September 2017 and March 2018. Data were collected from self--report questionnaires, medical records, and actigraphs. PedsQL Multidimensional Fatigue Scale (PedsQL--MFS) and Family Adaptability and Cohesion Evaluation Scale at Kwansei Gakuin IV--16 (FACESKG) were used to evaluate fatigue and family functioning, respectively. Spearman\'s rank correlation coefficients between PedsQL--MFS total score, subscale scores, and FACESKG cohesion and adaptability scores were calculated.

**Results**: Fifteen children with cancer and their families completed the questionnaires. Mean patient age was 10.2 years old, and the most common diagnosis was acute lymphoblastic leukemia (n = 9, 60%). The most common type of cohesion was enmeshed (n = 11, 73%), and the most common type of adaptability was flexible (n = 12, 80%). Correlation coefficients between FACESKG cohesion and PedsQL--MFS total scores (ρ = 0.35, p = 0.198), FACESKG cohesion and PedsQL--MFS cognitive fatigue scores (ρ = 0.46, p = 0.086), and FACESKG adaptability score and PedsQL--MFS sleep/rest fatigue score (ρ = --0.43, p = 0.110) indicated moderate effect size.

**Conclusions**: High family cohesion may reduce fatigue among children with cancer undergoing treatment in the hospitals. Nurses may need to support these patients to enhance emotional bonds with their families.

### PO-451. Support for Daily Activities in Social Rehabilitation of Children Undergoing Treatment for Cancer as Reported by Nurses {#pbc27455-sec-14230}

[M. Nagata]{.ul} ^1^, M. Iio^1^, Y. Hirose^2^, S. Hashiura^1^, M. Kobayashi^3^

*^1^Kanto Gakuin University, Nursing, Yokohama, Japan; ^2^Yokohama City University, Medicine, Yokohama, Japan; ^3^Seiryou Rehabilitarion College, Physical Therapy, Nagaoka, Japan*

**Background/Objectives**: Cancer rehabilitation is a medical care procedure aimed at improving vital functions and QOL of patients with cancer. Social rehabilitation is an approach for conditioning patients with cancer to facilitate return to normal life.

This study is aimed at clarifying the status of providing support for daily activities in social rehabilitation during hospitalization to maintain and improve the ability of patients with childhood cancer to return to normal life after discharge.

**Design/Methods**: We interviewed seven nurses who are engaged in social rehabilitation (basic daily activities, independent lifestyle, social participation) of children undergoing cancer treatment. We recorded the interview and transcribed the interview data, from which we extracted information regarding support for activities of daily living mentioned under the context of social rehabilitation of children undergoing cancer treatment, and conducted qualitative and inductive analysis. The study was approved by the Research Ethics Committee.

**Results**: Support activities reported by the nurses were divided into eight categories; (1) support for reestablishing daily life rhythms, (2) provision of environment for daily play and study, (3) coordination with teachers and volunteers of special support schools and classes to enable continuation of learning, (4) planning and hosting seasonal events and recreational activities, (5) training on activities to prevent infections and self‐management of CVC, (6) nutritional and oral healthcare based on immune state, (7) dietary education through cooking and meal sessions, and (8) situational safety education.

**Conclusions**: The study showed that (1) support for establishing daily rhythms, play, learning, and other daily activities in order to minimize the impact of prolonged hospitalization to daily life and (2) nutrition and health education in preparation for immunodeficiency resulting from treatment are important in providing support for activities of daily living as part of social rehabilitation of children undergoing cancer treatment. This study was supported by JSPS KAKENHI Grant Number JP16K12178.

### PO-452. A Prospective Study of Relationships Between Developmental Characteristics of Four‐ to Five‐Year‐Old Infants After Retinoblastoma Treatment and Parenting Stress {#pbc27455-sec-14240}

[M. Nagayoshi]{.ul} ^1^, Y. Hirose^2^

*^1^The Jikei University, School of Nursing, Tokyo, Japan; ^2^Yokohama City University, School of Nursing, Kanagawa, Japan*

**Background/Objectives**: Infants with retinoblastoma (RB) complete treatment in late infancy and attend kindergarten. This study aimed to clarify the developmental characteristics of RB infants in late infancy and to understand parenting stress experienced by mothers, and to explore the progress after treatment.

**Design/Methods**: Prospective study using the Strength and Difficulties Questionnaire (SDQ) and Parenting Stress Index (PSI) was conducted at a 6‐month interval on 20 Japanese mothers of 4‐ to 5‐year‐old RB infants. Cross‐sectional and longitudinal statistical analyses were performed using SPSS 23 (IBM).

**Results**: The subjects included 12 infants with unilateral RB (60.0%) and 8 with bilateral RB (40.0%). A single eye was enucleated in 19 infants (95.0%). Their median age was 49.0 (48--65) months and developmental quotients were 100 at time 1. The age at diagnosis was 10.5 (0--38) months and the treatment period was 9.0 (0.25--48) months. All infants entered kindergarten. No significant differences in PSI and SDQ scores were observed between time points. More mothers showed high‐risk scores on PSI\'s "Mood," which positively corelated with SDQ\'s "Conduct problems" at time 2 (p \< .001). "More problems/worries" scoreswere significantly higher than the normative means (p \< .05). Six infants (30.0%) at time 1 and four (20.0%) at time 2 showed a high need score on SDQ\'s "Prosocial." Its scores at time 2 negatively corelated to "More problems/worries" (p \< .01). "Total difficulties" corelated with "Child Domain Total" (p \< .001), "Hang around parents"(p \< .001), and "Depression"(p \< .01).

**Conclusions**: Although RB infants were not underdeveloped, their mothers frequently saw problems infants' behavior and social skills after joining kindergarten. They felt stress about their parenting roles, which may have exacerbated their mental depression. This suggests the need for advice and support tailored to different developmental stages. Acknowledgements: This study was funded partially by the Grants‐in‐Aid for Scientific Research in 2015.

### PO-453. Contents that Family Members of Long‐Term Hospitalized Pediatric Patients in the Oncology Unit Told a Certified Nurse Specialist About the Child\'s "Siblings" {#pbc27455-sec-14250}

[Y. Nagoya]{.ul} ^1^, W. Irie^2^, C. Irie^1^, K. Kimura^1^, Y. Yoshimoto^1^, M. Iwasaki^1^, H. Shiwaku^2^, A. Sato^3^

*^1^Miyagi Children\'s Hospital, Nursing Department, Miyagi, Japan; ^2^Tohoku University Graduate School of Medicine, Department of Child Health Nursing, Miyagi, Japan; ^3^Miyagi Children\'s Hospital, Department of Hematology and Oncology, Miyagi, Japan*

**Background/Objectives**: As part of family support, Miyagi Children\'s Hospital has a certified nurse specialist (CNS) visit the oncology unit once every two weeks for consultation with the family members of long‐term hospitalized pediatric patients. The aim of this study was to retrospectively elucidate what family members told CNS concerning "siblings" using medical records.

**Design/Methods**: Using medical records from July 2014 to July 2017, the narratives of 38 persons (289 recorded units) concerning "siblings\" were extracted and contents were analyzed.

**Results**: The narratives were categorized into 6 categories and 12 subcategories. The categories were as follows: changes in lifestyle of siblings, mental burden on siblings, provision of information to siblings, social interaction between patient and siblings, making time for siblings and parents to spend together, and awareness of growth of siblings. The subcategories were as follows: worries about changing lifestyle, adjustments and plans to minimize changes in life, worries creating mental burden, revelation of physical and behavioral problems, difficulty of finding words that take feelings into consideration, degree of understanding of disease and hesitation concerning method of explanation, confusion for siblings to be asked about disease of patient by surrounding people, both hoping for and status of social interaction through visiting and sleepover visits between patients and siblings, difficulty to care for patient and siblings during visiting and sleepover visits, consideration for creating memories during events and long vacations, and consideration for periodically making time for siblings and parents to spend together.

**Conclusions**: The results revealed that parents worry about and feel hesitation concerning the changes in lifestyle and accompanying burden on siblings, and need support related to siblings. CNS needs not only to listen to and give advice to parents concerning worries and hesitation related to siblings, but also to create a system that can directly provide support to siblings.

### PO-454. Active Participation for Oral Health Management By Parents Reduce the Frequencies of Oral Adverse Events of Pediatric Cancer Patients {#pbc27455-sec-14260}

[M. Nakamura]{.ul} ^1,2^, M. Matsuyama^3^, Y. Sone^4^, D. Hasegawa^5^, Y. Kosaka^5^

*^1^Kobe‐Tokiwa University, Department of Oral Health, Kobe, Japan; ^2^Tokushima University Graduate School, Department of Oral Health Care and Rehabilitation‐ Doctor\'s Course of Oral Health Science, Tokushima, Japan; ^3^Tokushima University Graduate School, Department of Oral Health Care and Rehabilitation‐ Institute of Biomedical Sciences‐, Tokushima, Japan; ^4^Hyogo prefectural Kobe Children\'s Hospital, Department of Pediatric Dentistry, Kobe, Japan; ^5^Hyogo Prefectural Kobe Children\'s Hospital, Department of Hematology and Oncology, Kobe, Japan*

**Background/Objectives**: Poor oral hygiene in patients undergoing chemotherapy often cause significant increase of treatment‐related morbidity. However, parents who have a child with cancer may be required to be in charge of their oral health management instead their children. We conducted the prospective observational study to clarify the relationship between parents' participation after comprehensive educational program for oral health management and oral adverse events of pediatric cancer patients.

**Design/Methods**: Between April 2012 and December 2016, 69 patients aged 3‐12 year‐old with childhood cancer in Kobe Children\'s Hospital was enrolled in this study. Before undergoing chemotherapy, all participants were provided the comprehensive educational program for oral health management. The degree of activities in participants for oral health management was assessed 3 months after their enrollment in the study and scored (0‐9) by a structured questionnaire obtained from participants, and categorized as active participation (≥8) and not‐active participation (≤7). Oral complications (stomatitis, xerostomia, gingivitis, and dental caries) were retrieved from medical records. Comparisons of categorical variables were performed using Fisher\'s exact test. This study was approved by the local institutional ethics committee, and written informed consent were obtained from all patients and/or parents.

**Results**: In preschool period (3‐6 yrs), the incidence of gingivitis and dental caries was notably increased in not‐active participation group compared with active participation group (p\<0.05), whereas it was not significant in school age period (7‐12 yrs).

**Conclusions**: Even if care‐givers help the patients doing oral health care to prevent oral complications in hospital, parents' participation level for oral health management may be associated with the oral adverse events of pediatric cancer patients. These results indicate that parents may play an important role in oral health management in their children undergoing chemotherapy.

### PO-455. Promoting Collaboration and Professional Development of Pediatric Oncology Nurses in Vietnam to Improve Pediatric Oncology Nursing Care {#pbc27455-sec-14270}

[N.T.T. Nhan]{.ul} ^1^, T. Hoang^2^, T. Quach^3^, S. Schroeder^4^, A. Dang^5^, K. Watanabe^6^, L. Abramovitz^7^

*^1^National Children\'s Hospital, Nursing Department, Hanoi, Vietnam; ^2^Hue Central Hospital, Nursing Department, Hue, Vietnam; ^3^Children\'s City Hospital, Nursing Department, Ho Chi Minh City, Vietnam; ^4^Shier Pharmaceuticals, Education, San Antonio‐ Texas, USA; ^5^UCSF Benioff Children\'s Hospital, Nursing Department, San Francisco‐ California, USA; ^6^Asian Children\'s Care League ACCL, Board, Tokyo, Japan; ^7^University of California‐ San Francisco, Department of Family Health Nursing and Global Cancer Program, San Francisco‐ California, USA*

**Background/Objectives**: New cases of childhood cancer in Vietnam have significantly increased as a result of efforts aimed towards early screening and referrals to the 12 pediatric cancer centers in Vietnam. In order to optimize care and improve outcomes for these patients, it is essential to support the emerging specialty of pediatric oncology nursing within Vietnam. Nurses from low‐and middle‐income countries (L&MIC) are often challenged by their education, lack of mentors, scope of professional practice and limited resources; therefore, efforts to promote professional activities and develop the specialty of pediatric oncology nursing in Vietnam is vital.

**Design/Methods**: Communication via email, conference calls, and in‐country visits between the Vietnam nursing leadership and twinning partners has generated several ongoing projects and educational programs. A mutually established mission statement and program objectives founded on the Baseline Nursing Standards have focused efforts on developing opportunities to foster education/training, promote collaboration and facilitate networking.

**Results**: Over the last year, Vietnamese nurses have attended approximately fifty educational offerings which includes web conferencing, didactic lectures and hands‐on skills training presented by international and local pediatric oncology nurses. The first Vietnam Pediatric Oncology Nursing Conference will be held in August. This two‐day program involves nursing sessions and joint programming with physicians and parents. In addition, a revision of the patient/parent educational handbook and development of a wallet size emergency card for patients/parents are examples of current collaborative national nursing projects. Awareness of the Baseline Nursing Standards has led to initiation of practice changes. Monthly conference calls between nurse leaders at key hospitals supports this ongoing collaboration.

**Conclusions**: Efforts to establish a professional collaborative environment nationally has led to the emergence of a competent, committed and empowered nursing workforce. As the pediatric oncology nursing specialty continues to develop in Vietnam, opportunities for other potential activities includes the establishment of a Pediatric Oncology Nursing organization.

### PO-456. Addressing Adolescents\' and Young Adults\' Needs for Support in Coping with Death when Living with Cancer {#pbc27455-sec-14280}

[S. Nilsson]{.ul} ^1^, P. Sand^2^, Y. Hård af Segerstad^3^

*^1^Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden; ^2^Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden; ^3^Divison of Learning Communication and IT, University of Gothenburg, Gothenburg, Sweden*

**Background/Objectives**: The age definition of adolescents and young adults (AYA) in this study is 16‐35 years. AYAs with cancer often lack fora where they can approach thoughts about death and dying, and healthcare professionals are not always able to support them. The aim was to investigate the needs that AYAs with cancer and people in close relation to them have for support in coping with death.

**Design/Methods**: A web‐based questionnaire investigating the needs of support was distributed to the members in the non‐profit organization Ung Cancer (Young Cancer) (Jan‐Feb, 2018).

**Results**: In total 148 members participated, of whom 13 were men. Eighty‐two were undergoing or off cancer treatment, and most of these had completed their cancer treatment (56/82; 68.3 %). Sixty‐six were in close relation to a person with cancer, among these 47/66 (71.2 %) were in close relation to a person who had died of cancer. Results indicated that 48 % (71/148) think about death every day. The reported need for support was in average 4.96 (ranging from *no need* (0) to *very* *much in need* (10)). The ranking order of persons who offered them support was; (1) partner (38/148; 25.7 %), (2) psychologist (22/148; 14.9 %), and (3) parent (21/148; 14.2 %). The three most common contexts where they talked about death were face‐to‐face at home (102/146; 69.9 %), on social media (57/146; 39 %), and face‐to‐face meetings at non‐profit organizations (53/146; 36.3 %).

**Conclusions**: Being diagnosed with cancer or living in close relation to a person with cancer, often pronounces a need to come to terms, or cope, with death. Opportunities to talk about death can improve management of negative stress and anxiety in the face of death. In this project, we will address needs for coping with death and develop platforms and contexts to support this.

### PO-457. Survey of Anticancer Drug Exposure to Attendant Families and Medical Staff in a Pediatric Medical Center {#pbc27455-sec-14290}

[Y. Noda]{.ul} ^1^, Y. Koga^2^, M. Miyazono^1^, T. Ueda^2^, H. Ono^2^, U. Oba^2^, K. Nakashima^2^, K. Okada^1^, K. Kubota^1^, S. Ohga^2^

*^1^Fukuoka Nursing College, Nursing, Fukuoka, Japan; ^2^Graduate School of Medical Sciences‐ Kyushu University, Department of Pediatrics, Fukuoka, Japan*

**Background/Objectives**: Occupational exposure to hazardous drugs (HDs) have been previously investigated and guidelines on HD exposure have been established. However, the status of HD exposure to attendant family members of pediatric cancer patients remains unknown.

**Design/Methods**: We analyzed cyclophosphamide exposure in the both the environment and urine of 6 attendant family members after administering this HD to pediatric cancer patients.

**Results**: Cyclophosphamide (CPM) of 320 ng/10ml (8.39--1510 ng/10ml) and 0 ng/10ml (0.0--58.4 ng/10ml) were detected in the urine of infant and adolescent patient families, respectively (p = 0.01). HD exposure to infant patient families was significantly greater than that of adolescent patient families. In addition, CPM was detected from the hot water used for bathing infants and from the underwear and sheets used by adolescents, and the exposure through the body fluid and excretion of infant and adolescent patients.

**Conclusions**: In the treatment of childhood cancer, measures to prevent HD exposure should be applied in accordance with the patient\'s age in order to minimize health risks to not only medical personnel, but also patient family members and other children in the presence of the patient. Nurses are recommended to educate the patients and their family members regarding the prevention of HD exposure in pediatric medical centers.

**Acknowledgements**: We would like to express our sincere gratitude to the patients' family and the ward staff for their cooperation in this research.

### PO-458. Validity and Reliabilty of the Instrument Constipation Assessment Scale (CAS) Indonesian Version in Pediatric Cancer {#pbc27455-sec-14300}

[N.S. Noviani Indah Sari]{.ul} ^1^, A. Allenidekania^2^, H. Hayati^2^

*^1^Dharmais National Cancer Centre, Pediatric Nursing, DKI Jakarta, Indonesia; ^2^Faculty of Nursing‐ Universitas Indonesia, Pediatric Nursing Departement, Depok, Indonesia*

**Background/Objectives**: Constipation is one of the problems that are often complained about and become a source of physical and psychological distress that affects the quality of life of cancer children if not handled properly. Constipation Assessment Scale (CAS) is one of an instrument of constipation assessment for pediatric cancer that have been validated in English version. However, Indonesia urge to use that instrument in Indonesian version. The purpose of this study were to test the validity and reliability of Constipation Assessment Scale in Indonesian version in pediatric cancer population and to identify the scope of constipation problem.

**Design/Methods**: CAS instrument translated into Indonesian language followed to back translation to get simililarity with the original instrument. CAS Indonesian version tested to 68 children (1 to 18 years old) with cancer whom undergoing chemoterapy and received opioid, pain therapy or both. The analysis used validity and reliability single test.

**Results**: CAS instrument has good validity r between 0.434 to 0.824 more than 0.361 (α = 0.05), and good reliability in Chronbach Alfa 0.851. CAS screening results majority of cancer patients have mild constipation (60.3%), with complaints of changes in bowel patterns, more hard stool and difficult bowel movements.

**Conclusions**: The CAS for pediatric instrument is a valid, reliable tool for screening constipation issues for Indonesian pediatric cancer.

### PO-459. The Actual Situation of Preventive Measures Against Exposure to Anticancer Drugs in Japan ‐ Focusing on Buttocks Skin Care for Children with Diapers {#pbc27455-sec-14310}

[J. Ogawa]{.ul} ^1^, M. Kudo^2^, M. Baba^3^, T. Watanabe^4^, K. Sakuta^5^, Y. Ohara^6^

*^1^Shukutoku University, Colleage of Nursing and Nutrition, Chiba, Japan; ^2^Chiba Children\'s Hospital, Outpatient ward, Chiba, Japan; ^3^Teikyo University Medical Center, Pediatric ward, Chiba, Japan; ^4^Chiba University Hospital, Pediatric ward, Chiba, Japan; ^5^Chiba Children\'s Hospital, Hematology and Oncology ward, Chiba, Japan; ^6^Chiba Children\'s Hospital, Intensive Care Unit, Chiba, Japan*

**Background/Objectives**: A guideline on preventing occupational exposure to anticancer drugs was published in 2016 in Japan. It is, however, insufficient to cover the pediatric oncology area. We researched how nurses thinks about occupational exposure focusing on buttock skin care for children.

**Design/Methods**: We mailed questionnaires regarding the preventing occupational exposure to nurses working for 104 childhood cancer treatment facilities (3 nurses from each hospital).

**Results**: Got 107 nurses (34.3%) responded including 86 nurses (80%) who reported they have hospital rules for occupational exposure. In addition, 80 nurses (75%) learned about preventive measures against exposure to anticancer drugs in their own facilities or the wards and 14 nurses (13%) have learned about it that outside of their hospitals. And found 78 nurses (73%) took some preventing measures for disposal of child excreta and 60 nurses of them educated family caregivers about preventing exposure.

Fifty‐nine nurses (55%) have changed children\'s diapers during chemotherapy every other 2 hours 26 (24%) changed every other 3 hours, and 3 have left the changing diapers to their families. And 55 nurses (51%) cleaned children at the time of urination. Forty‐two (39%) out of them which is almost all used wipes, but 10 nurses (9%) washed out with hot water. In the case of defecate 29 (27%) washed out with hot water. Ninteen nurses (18%) applied ointment for protecting buttocks skin from exposure as preventive manner. They used not only medicines such as Azulene, zinc oxide ointment, and Vaseline but also non‐medicinal water‐ shedding skin cream.

**Conclusions**: It\'s clear that preventing exposure to anticancer drugs in pediatric oncology ward is not sufficient, Each hospital made own rules and had own study meeting. It\'s an urgent need to develop the evidenced based guidelines specialized in childhood cancer treatment.

### PO-460. Parents' Concerns and Emotions About the Status of Peer Support‐Giving Among Children Receiving Treatment for Pediatric Cancers {#pbc27455-sec-14320}

[H. Ojiro]{.ul} ^1^, Y. Hayakawa^2^

*^1^Nara Medical University, Faculity of Nursing‐ School of Medicine, Nara, Japan; ^2^Nara Medical University Hospital, Children\'s Medical Center, Nara, Japan*

**Background/Objectives**: This study sheds light upon parents' concerns and emotions regarding peer support‐giving among children receiving treatment for pediatric cancers. When children with pediatric cancers experience extended hospitalizations, those who are more familiar with treatment may give advice to peers while at play or at study. We defined "peer support," as support received from fellow child cancer patients.

**Design/Methods**: Using a qualitative inductive method, we conducted interviews with 7 mothers of children formally diagnosed with pediatric cancers. Their responses were categorized according to Krippendorff\'s content analysis methodology. This study was conducted after receiving approval from the Nara Medical University Ethics Review Board.

**Results**: The mothers were between 39 and 46 years of age (mean 41.8 ± 2.71). The children were between 10 and 14 years of age (mean 12.0 ± 1.41) upon admission; 4 had been diagnosed with leukemia, 2 with brain tumors, and 1 with bone tumors. Analyses yielded 6 themes that parents' considered about peer support among children receiving treatment for pediatric cancer: "encouragement from seeing their child\'s positive attitudes," "encouragement from seeing their child having fun at the hospital school," "encouragement from seeing their child having fun with other children," "relief at seeing how their child copes in ways unique to children," "concern that treatment might interfere with socializing," and "concerns about peer support‐giving itself." The parents expressed relief that the peer support their children received from fellow child cancer patients had positive effects, encouraging them in their treatment. However, they also expressed concern that their children did not have time for socializing or that socializing might have a negative influence on their children.

**Conclusions**: Parents felt a mix of relief and anxiety about peer support‐giving among children receiving treatment for pediatric cancers, which must be addressed when providing nursing care to child cancer patients.

### PO-461. I Am Not Okay! -- Psychological Wellbeing in Adolescents and Young Adult Cancer Survivors {#pbc27455-sec-14330}

[M. Olsson]{.ul} ^1^

*^1^PhD student, CancerRehab‐ Oncology‐ Sahlgrenska Universityhospital, Göteborg, Sweden*

**Background/Objectives**: The purpose of this study is to explore psychological wellbeing in adolescent and young adult (AYA) cancer survivors.

**Design/Methods**: A study specific questionnaire has been developed from the results of the focus group interviews. The method used for question development includes expert validity from professionals and former AYA cancer patients (15‐29 years old). The areas in the questionnaire are; quality of life, psychological wellbeing, body image, sex & fertility, education, work and leisure. The questionnaire was web‐based, and sent to AYA cancer survivors and matched controls in Sweden in cooperation with four of the regional cancer centers. This study focus on variables of psychological wellbeing and the remaining results are will be analyzed elsewhere.

**Results**: AYA cancer survivors reported a higher incidence of self‐reported depression than controls χ²(1)=8.13, P=0.04. In a further analysis, female AYA survivors had a higher incidence of self‐reported depression than controls, χ²(1)=12.8, P\<0.001, while there were no differences in incidence of depression between male AYA survivors and controls. Additionally, female AYA cancer survivors reported stress in a higher degree, χ²(1)= 9.25(1), P\<0.01, and more difficulty falling asleep, χ²(1)=6.36(1), P=0.01, compare to female controls. Furthermore, female AYA cancer survivors expressed need for psychological counselling after treatment, in a higher frequency than males, χ²(1)=18.1(1), P\<0.001.

**Conclusions**: The result of this study shows that female AYA cancer survivors report lower mental wellbeing than controls. This observation indicated that we have an opportunity to improve the quality of life of young cancer survivors by screening for depression and then taking adequate psychological or medical measures. Overall, health care professionals need to address the need for psychosocial counselling in the aftermath of cancer treatment in AYA cancer survivors, especially female AYA cancer survivors.

### PO-462. Translating and Culturally Adapting the Shortened Version of the Hospital Ethical Climate Survey (HECS‐S) -- Developing a Multi‐Professional Version, Relevant for Paediatric Oncology {#pbc27455-sec-14340}

[P. Pergert]{.ul} ^1^, C. Bartholdson^1^, M. Wenemark^2^, K. Lützén^1^, M. af Sandeberg^1^

*^1^Karolinska Institutet, Women\'s and Children\'s Health, Stockholm, Sweden; ^2^Linköping University, Medicine and Health Sciences, Linköping, Sweden*

**Background/Objectives**: The ethical climate is the healthcare professionals' perceptions of the organization\'s atmosphere, which influences behaviours and attitudes. A positive correlation has been demonstrated between the ethical climate and nurses\' job satisfaction and ultimately the quality of patient care. To evaluate the ethical climate, a validated instrument appropriate for the setting in question is needed. The aim of this study was to describe the process of translating and culturally adapting the Hospital Ethical Climate Survey (HECS‐S) and to develop a Swedish multi‐professional version, relevant for paediatric oncology.

**Design/Methods**: The procedure of translating and culturally adapting the Swedish version followed the scientific structure of guidelines. Three focus group interviews and three cognitive interviews were performed with healthcare professionals. Furthermore, descriptive data were used from a previous study with healthcare professionals (n=89), using a modified Swedish HECS.

**Results**: The Swedish HECS‐S consists of 21 items: all 14 items from HECS‐S and items added to develop a multi‐professional version, relevant for paediatrics. For example, one item was added concerning parents' wishes, relevant to the paediatric setting. Linguistic adjustments were made to retain the intended meaning of the original items. The word 'respect' was used in HECS‐S with two different meanings and was replaced in one of these because participants were concerned that respecting patients' wishes implied always complying with them.

**Conclusions**: In the process of developing a Swedish HECS‐S, only minor adjustments were needed to achieve a good functional level and trustworthiness however, some items needed to be added to achieve a multi‐professional version, relevant for paediatric oncology, and also to better capture the ethical climate.

### PO-463. Road to Home Program: A Performance Improvement Initiative to Increase Family and Nurse Satisfaction with the Discharge Education Process for Newly Diagnosed Pediatric Oncology Patients {#pbc27455-sec-14350}

[M. Perry]{.ul} ^1^, M. Smith^2^, K. Sachse^3^

*^1^Children\'s National Health System, Hematology Oncology Care Unit, Washington‐ DC, USA; ^2^Children\'s National Health System, Clinical Resource Management, Washington‐ DC, USA; ^3^Shire‐ Inc., Oncology Education, Cambridge‐ MA, USA*

**Background/Objectives**: Families of children, adolescents and young adults (AYA) with a new oncology diagnosis must absorb knowledge and skills needed to care for their child at home during a period of emergent hospitalizations and intense medical interventions. Effective nurse led teaching and discharge planning begun at diagnosis can prepare families to safely care for their child following discharge and be a source of satisfaction. The objective of this performance improvement (PI) initiative was to increase family and nurse satisfaction with new diagnosis education and discharge.

**Design/Methods**: Using standard PI techniques, family and nursing stakeholder satisfaction with the current processes was assessed. Working from established best practice and literature review; The Road to Home was designed and implemented. This novel, comprehensive program includes a visual, interactive display of required education based on the Children\'s Oncology Group Family Handbook© and hospital specific discharge materials; standardized teaching, tools and documentation for nursing; and caregiver discharge tool kits. Stakeholder input guided improvement strategies throughout the phases of implementation.

**Results**: Sustained increases in family and nurse satisfaction resulted from each phase of project implementation. The "Road to Home" program is established for all families of newly diagnosed oncology patients and is meeting goals of increased family and nurse satisfaction with discharge education.

**Conclusions**: The Road to Home! Program has met our aim to develop interactive patient education methods to better engage nurses, clinical team members, parents and patients in new diagnosis cancer education processes. The improvements in communication, nursing resources and discharge tools incorporated within the RTH program have proven to impact sustained improvements in nursing and family satisfaction with the discharge education process.

**Acknowledgements**: The authors would like to thank members of the HOCU Education Committee and Dr. Viraj Mane, technical design consultant. We also acknowledge Phoenix Children\'s Hospital and their Journey Board for their inspiration.

### PO-464. Integrating Baseline Nursing Standards in Pakistani Pediatric Oncology Centers to Improve Overall Quality of Care {#pbc27455-sec-14360}

[R. Punjwani]{.ul} ^1^, S. Anwer Ali^1^

*^1^The Indus Hospital, Peads Complex, Karachi, Pakistan*

**Background/Objectives**: Lower‐ middle‐income countries, like Pakistan have a high cancer burden with survival often \<20% due to late diagnosis and inaccessible care. WHO recognizes nurses as frontline clinicians and vital for successful pediatric oncology programs. In 2014, the SIOP PODC nursing working group defined essential elements of pediatric oncology nursing care in low‐ and middle‐income countries as "Baseline Standards" to improve care.

**Design/Methods**: In 2016, a nurse‐mentoring project at Indus Cancer Hospital in Karachi was initiated with the support from a Sanofi Espoir Foundation My Child Matters grant to improve pediatric oncology in five centers across Pakistan. Achievement of all SIOP PODC Baseline Nursing Standards was one objective. Nursing strategies included training, mentorship, educational material development, human resource improvement and onsite evaluation visits.

**Results**: Although two centers experienced administrative challenges that slowed progress, after one year, nursing improvements according to Baseline Standards in three centers include:

1\. Safe staffing: Pediatric oncology nurse/patient ratio of 1:5; trained nurses do not rotate to other units.

2\. Orientation: \> 80% of oncology nurses trained in basic pediatric oncology nursing.

3: Continuing education: Identified and trained one nurse from each unit as pediatric oncology nursing trainer. All educational material and distant ongoing mentorship provided.

4: Multidisciplinary teamwork: Nurses now believe they have a better voice in patient care and are considered part of the team.

5: Resources for safe care: One unit has a biosafety cabinet. On‐going advocacy for pharmacists to prepare chemotherapy. PPE, hand sanitizer dispensers, and handwashing facilities available in the three units out of five.

6: Evidence‐driven practice: Developing evidence‐based policies to share across units.

**Conclusions**: Results of an initial survey across Pakistan showed multiple gaps in baseline nursing standards, but, after a year, changes are encouraging. Several standards have been achieved and continued efforts to address the rest are planned over the next years.

### PO-465. Empowering Nurses: A Viable Model to Improve Childhood Cancer Care in LMIC {#pbc27455-sec-14370}

[N. Radhakrishnan]{.ul} ^1^, D. Pal^1^, N. Prajapati^1^, C. Chouhan^1^, N. Kumari^1^, V. Rawat^1^, B. Malik^1^, S. Gupta^1^, J. Madan^1^

*^1^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Pediatric Hematology Oncology, Noida, India*

**Background/Objectives**: Even as pediatric cancer care continues to improve globally there is a gap in survival reported from low and middle income countries (LMIC). Lack of trained treatment providers is a major reason for this. The purpose of the study was to explore the challenges faced by oncology‐naïve nurses in providing childhood cancer care in a resource constrained center in India.

**Design/Methods**: A qualitative research on the difficulties faced in nursing care during the first 12 months (April 2017 to March 2018) of setting up of a pediatric hematology‐oncology department was done. Data was collected by interviewing of nurses during monthly meetings. Confidentiality of the nurse was maintained during the sessions.

**Results**: During the study period, the center catered to 2843 outpatients, 519 inpatients, 46 new oncology patients, 172 procedures and 636 day‐care admissions. The treating team consisted of 1 consultant with 6 dedicated nurses. The challenges faced were classified under manpower, skill and motivation. Poor nurse: patient ratio and lack of dedicated dietician, psychologist or social worker increased the burden on nurses. This was compensated for by focusing on the rest of the problems. Skill development was a major thrust area. All new nurses received induction to pediatric oncological care. Standard operating procedures, algorithmic approach to common and emergency situations, adaptation of treatment schedules etc. were developed. Social networking groups helped in faster remediation of problems. Motivation of nurses towards oncology was improved by constant discussions on handling success and failure, positive reinforcement, considering this as 'not‐just‐another‐job', making the workplace happy and other efforts for team building.

**Conclusions**: Nurses being closest to the family have been the backbone of patient care. In resource‐limited situations, empowering nurses as 'front‐line care providers' helped us establish care in the best possible manner. Dedicated pediatric oncology nursing is a sustainable solution to improving cancer care in LMIC.

### PO-466. Relationship‐Integration Nurse Doctor in Pediatric Palliative Patient Care in Latin American Countries {#pbc27455-sec-14380}

[S. Rivas]{.ul} ^1^

*^1^Unidad Nacional de Oncología Pediátrica, Paliative Care‐ Integral Medicine, Guatemal, Guatemala*

**Background/Objectives**: Validate the importance of collaborative work between doctor and nurse as a care strategy.

**Design/Methods**: A survey is presented to the nursing staff who trained in the National Pediatric Oncology Unit in Guatemala, to know their perception of the integration process in the collaborative work with the palliative doctor.

**Results**: The palliative care training program of the National Pediatric Oncology Unit of Guatemala, with the support of my child matters, began training nurses who did not have palliative pediatricians in their country to support their work. Subsequently, pediatricians were trained in palliative care. Currently, we proceeded to evaluate the integration of the pediatric‐nurse binomial in the collaborative work, through a survey that evaluates the nurse\'s perception regarding the participation that the doctor gives them in decision‐making and preparation of plans of patient and family care. The result of the survey shows that when both have the same knowledge in palliative care, they tend to be a fundamental support for each other, when developing care plans for each patient, as well as to evaluate and provide adequate management of symptoms, as well as for the correct calculation and use of opioids, for which nursing turned out to be very beneficial, sometimes taking the initiative to suggest the use, providing an adequate calculation and indication of them.

**Conclusions**: The sharing of knowledge, leadership in an adequate relationship and integration of nurses\' medical work, can result in an adequate palliative care strategy, because the nurse is empowered in the decision making and discussion of cases, which enriches the contribution for the best care of the patient in our countries where the nursing staff does not receive its fair value in the collaborative work.

### PO-467. Oncology Early Warning Score (OEWS) Improving the Outcome of Assessment and Prevention of Mortality and Clinical Deterioration Among Pediatric Oncology Patients {#pbc27455-sec-14390}

[S. Sadaruddin]{.ul} ^1^

*^1^The Indus Hospital, Nursing, Karachi, Pakistan*

**Background/Objectives: Background and Introduction**: Pediatric Oncology Patients are vulnerable for sudden clinical decline due to toxic and intensive nature of therapies. Multiple modalities of treatment and supportive care helps treat the primary disease but may also alter bodies response to timely react and respond It is an established fact that patients exhibits certain clinical features and signs before deterioration. To identify these signs healthcare facilities use tools like Warning Signs (EWS) which help the healthcare team in early recognition and timely implementation of care to reduce morbidity and mortality but standard PEWS or EWS are not specific for pediatric oncology patients. Hence, there is a need of specialized and effective quality measure that can help conduct the risk assessment for Pediatric oncology Population. The UK Oncology triage tool is one of the Early Warning assessment tool that is more specific to recognizing potential clinical signs in pediatric oncology patients.

**Objectives**: The aim of this paper is to examine the UK Oncology triage tool as Oncology Early warning Score (OEWS) and assess the role of this tool in prevention of pediatric oncology mortality and clinical deterioration among children and young adults.

**Design/Methods**: Several papers were reviewed using multiple database to understand the applicability of this tool. Three Article were shortlisted that covered essential knowledge and details about its implementation and effectiveness

**Results**: This paper concludes that OEWS serves as bedside instrument that may help trigger timely response in case of any clinical deterioration. Numeric values based on assessment indicates that may help generate timely response resulting in improved clinical outcomes by reducing incidences of cardiopulmonary resuscitation, septic shock and timely management of emergencies

**Conclusions**: Overall this paper is an attempt to understand the concept of OEWS and its potential use in pediatric oncology center to reduce sudden collapse thus early treatment can improve survival.

### PO-468. Employment Status and Termination Among Survivors of Pediatric Brain Tumors: A Cross‐Sectional Survey {#pbc27455-sec-14400}

[I. Sato]{.ul} ^1^, A. Higuchi^2^, T. Yanagisawa^3^, S. Murayama^1^, T. Kumabe^4^, K. Sugiyama^5^, A. Mukasa^6^, N. Saito^6^, Y. Sawamura^7^, M. Terasaki^8^, S. Shibui^9^, J. Takahashi^10^, R. Nishikawa^11^, Y. Ishida^12^, K. Kamibeppu^1^

*^1^The University of Tokyo, Department of Family Nursing, Tokyo, Japan; ^2^Children\'s Cancer Association of Japan, Children\'s Cancer Association of Japan, Tokyo, Japan; ^3^Jikei University School of Medicine, Department of Neurosurgery, Tokyo, Japan; ^4^Kitasato University School of Medicine, Department of Neurosurgery, Kanagawa, Japan; ^5^Cancer Treatment Center Hiroshima University Hospital, Department of Clinical Oncology & Neuro‐oncology Program, Hiroshima, Japan; ^6^The University of Tokyo, Department of Neurosurgery, Tokyo, Japan; ^7^Sawamura Neurosurgery Clinic, Sawamura Neurosurgery Clinic, Hokkaido, Japan; ^8^Kurume University School of Medicine, Department of Neurosurgery, Fukuoka, Japan; ^9^National Cancer Center Hospital, Department of Neurosurgery and Neuro‐Oncology, Tokyo, Japan; ^10^Uji Hospital Social Welfare Corporation, Department of Neurosurgery, Kyoto, Japan; ^11^Saitama Medical University International Medical Center, Department of Neuro‐Oncology/Neurosurgery, Saitama, Japan; ^12^Ehime Prefectural Central Hospital, Pediatric Medical Center, Ehime, Japan*

**Background/Objectives**: Some childhood cancer survivors experience employment difficulties. This study aimed to describe pediatric brain‐tumor survivors' employment status.

**Design/Methods**: A cross‐sectional, observational study was conducted, with questionnaires distributed to 101 pediatric brain‐tumor survivors (aged 15 years or older) and their attending physicians, from 9 institutions in Japan. We compared category and time‐series histories for participants' first‐time employment, using national census information. Factors related to delayed employment or early employment termination were examined using survival‐time analyses.

**Results**: Excluding students and homemakers, 38 brain‐tumor survivors (median age: 27 years, with 15 years since diagnosis) were of productive age. Of these, 12 (32%) were unemployed and 9 (24%) had never been employed. Brain‐tumor survivors' first‐time employment occurred later relative to that of the general population, particularly in those with lower educational levels. The number of brain‐tumor survivors whose first job was terminated within the first year was higher relative to that of the general population, particularly in male survivors and germ‐cell‐tumor survivors. Brain‐tumor survivors described their working patterns (irregular), job types (specialist or professional), reasons for early termination (unsuitable job), and thoughts about working (they wished to serve their communities but lacked confidence).

**Conclusions**: The results showed high unemployment rates and multiple unemployment‐related factors in cancer survivors. Education and welfare systems should identify individual methods of social participation for this group.

### PO-469. Survey on the Image about Cancer Among Junior High Students {#pbc27455-sec-14410}

[Y. Sato]{.ul} ^1^, A. Yoshimura^2^, N. Sumi^1^

*^1^Hokkaido University, Faculty of Health Sciences, Sapporo, Japan; ^2^Chiba University Hosptal, Dept. of Nursing, Chiba, Japan*

**Background/Objectives**: Parents often refrain from disclosing the name of the disease to children with cancer. However, it is necessary to improve children\'s ability to cope with their disease. Therefore, we examined children\'s image about cancer.

**Design/Methods**: An anonymous questionnaire survey was conducted with 12--15‐year‐old junior high students. The questionnaire comprised items on the characteristics of respondents and their consciousness regarding cancer. Data were analyzed using SPSS, and the analysis included the χ^2^, Mann‐Whitney, and Kruskal‐Wallis tests.

**Results**: We obtained effective responses from 197 students, of which, 71 were boys, 125 were girls, and one student had not mentioned their gender. Further, 56 students were first graders, 72 were second graders, and 69 were third graders. Regarding consciousness about cancer, 98.4% of the students reported that "It was a scary disease," 78.2% considered it as an "imminent disease," and 25.9% believed that one "could live a substantial life even if they contracted the disease." Further, 49.2% of the students believed that childhood cancer required long‐term hospitalization and 81.2% though that "the disease could be cured"; however, only 38.6% of the respondents knew about childhood cancer. The reason for expecting being informed about cancer was 45.9% that "could be opposite to a disease," 22.1% who ""wanted you to tell me without covering oneself," and 14.8% who "thought to get over treatment." Significant differences were observed in the desire to be informed about cancer in terms of school year (p=0.033) and person from whom the information should be received (p=0.005).

**Conclusions**: Junior high students were found to have a negative image of cancer. Therefore, medical personnel need to provide appropriate knowledge about cancer considering the developmental stage and the understanding level of the child.

### PO-470. Identifying Patterns of Symptom Clusters in Children with Leukemia Based on Latent Profile Analysis {#pbc27455-sec-14420}

[N. Shen]{.ul} ^1^, Y. Xu^2^, C. Yuan^3^, S. Liu^4^, M. He^5^, J. Sun^1^

*^1^Shanghai Children\'s Medical Center, Nursing Department, Shanghai, China; ^2^Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical School, Department of Hematology, Shanghai, China; ^3^Fudan University School of Nursing, School of Nursing, Shanghai, China; ^4^Shanghai Children\'s Medical Center, Department of Biobank‐Pediatric Translational Medicine Institute, Shanghai, China; ^5^Shanghai Children\'s Medical Center, Department of Hematology, Shanghai, China*

**Background/Objectives**: Children with leukemia experience multiple concurrent, interrelated symptoms which may influence the child\'s functional status and quality of life. Complex symptom clusters in this population although clinically important remain poorly understood and managed. Identifying subgroups of children based on symptom patterns provide valuable guidance for pediatric cancer care.

**Design/Methods**: In a cross‐sectional, single‐site design, children with leukemia aged 8‐17 were explored prospectively. Data was collected using a demographic questionnaire and the Chinese Version of Pediatric Patient Reported Outcomes Measurement Information System‐Child Version(C‐C‐Ped‐PROMIS), which included five symptom domains (depression, anger, anxiety, fatigue and pain interference) and three functional domains (peer relationships, physical function‐mobility and physical functional‐upper extremity). Latent profile analysis (LPA) was conducted to classify homogeneous subpopulation with respect to the C‐C‐Ped‐PROMIS symptom measures and then the functional impairments were compared across class designation.

**Results**: 218 children participated. The result of LPA indicate that the data best fit a three‐profile model. Posterior assignment probabilities for profiles were 91.5%, 97.0% and 96.8%. Given each profile\'s estimated mean symptom scores, we defined profile 1, profile 2, profile 3 as "Mild Symptom Group" (n=42,19.3%), "Less Severe Symptom Group"(n=110,50.5%) and "Severe Symptom Group"(n=66,30.3%), respectively. The mean standardized scores of three functioning short‐form measures significantly vary by profiles (P\<0.05 or P\<0.01). Further analysis found that children in "Severe Symptom Group" had on average worse physical functioning than those in other profiles (both P\<0.05), while children in "Mild Symptom Group" had on average better peer relationship than those in "Severe Symptom Group" (P\<0.05), conversely.

**Conclusions**: Children with leukemia undergoing multiple symptoms are empirically revealed to be a heterogeneous population. Three distinct profiles of children were identified with respect to patterns of these symptoms. There is a trend of functional impairments aggravate in children identified as experiencing higher symptom severity.

### PO-471. "I Don\'t Feel Good": Children\'s Accounts of Chemotherapy‐Induced Nausea {#pbc27455-sec-14430}

[L. Shipway]{.ul} ^1^, F. Gibson^1^

*^1^Great Ormond Street Hospital for Children NHS Foundation Trust, Haematology/Oncology, London, United Kingdom*

**Background/Objectives: Background**: Chemotherapy‐induced nausea and vomiting are two of the most distressing symptoms encountered by children with cancer receiving chemotherapy. Whilst collectively they are well documented, nausea on its own has received much less attention. How nausea is assessed and managed, and the need to assess the effectiveness of interventions to manage nausea, remain three key priorities in clinical practice.

**Objectives**: To explore the subjective experience of chemotherapy‐induced nausea in children in relation to (1) how they communicate about nausea and (2) the strategies they used to manage this symptom.

**Design/Methods**: This phenomenological study used creative, participatory methods to gain insight into the experience of nausea from children. It also sought to find out their perceptions of using a nausea assessment scale. Individual case reports and thematic data analysis built a picture of the experience of nausea.

**Results**: A convenience sample of seven children, aged 6‐12, with haematological/oncological malignancies, was recruited to this single‐site study. Four themes emerged from the data: 'It doesn\'t feel nice...' described the physical, emotional and social impact of nausea; 'Other things help...a lot' captured the strategies children found most helpful; 'Mum...I\'m going to be sick' described whom children looked to for help; and 'I wish I was told at the start...' highlighted children\'s information needs. Children adopted a number of non‐pharmacological approaches to manage this distressing symptom. Parents were an important source of support and comfort, and facilitated communication between their child and healthcare professionals. Children reported that a nausea scale would help them communicate about nausea, and highlighted information needs around identifying and managing nausea.

**Conclusions**: This study provided insight into non‐pharmacological nausea management, and how an assessment scale can facilitate communication. However further research to establish clinical utility of a nausea scale, and to explore non‐pharmacological strategies for nausea management is still needed.

### PO-472. Search for Improvement in Data Collection on Catheter Removal at a Pediatric Hemato‐Oncology (PHO) Ward {#pbc27455-sec-14440}

[L. Steendam]{.ul} ^1^, A. Mannaerts^1^, E. Willems^1^, E. Vandecruys^1^, L. Willems^1^, G. Laureys^1^, V. Van De Velde^1^

*^1^UZ Gent, Pediatric Hemato ‐ Oncology, Gent, Belgium*

**Background/Objectives**: Every year an average of 72 children at our PHO ward receive a central venous catheter(CVC) for long term intravenous medication such as chemotherapy, coagulation factors, total parental nutrition,... These CVC\'s ideally remain in place until the (intensive) therapy is finished, but sometimes catheter related problems require early removal or replacement. Since 2012 we use a "catheter passport" in the electronic patient file to record essential data (type, number of lumens, insertion date, removal date) and enable registration of all catheter related problems.

**Design/Methods**: A retrospective analysis was performed from the catheter passports (n=249) of patients in whom a catheter was placed in the period 2012‐2017 to determine the incidence of catheter related problems with focus on reason of catheter removal. Date of insertion and removal of catheter, reason of removal, presence of infection and occlusion problems were attempted to be collected.

**Results**: From the analysis it became obvious that essential data were missing or incompletely noted in the passport. Only 104 CVCs were reported as removed. 47/104 CVCs were removed without any report of reason. In 57/104 the reason of removal was given: end of (intensive) treatment in 30/104, infection in 9/104, occlusion in 9/104, accidental removal in 7/104 and rupture in 2/104. The main reason of underreporting is attributed to the electronic patient file, including the catheter passport, which is not user‐friendly and time consuming.

**Conclusions**: The results of this survey indicated that the previous "catheter passport" was poorly structured. As a consequence, the input of necessary data was time consuming for nurses, because of time pressure reporting of catheter related problems or essential information was incomplete. In 2018 the catheter passport was adapted, with a more logic structure and predetermined answers easy to check, hopefully enabling to get more complete data in the future.

### PO-473. Identification of Nursing Interventions Using Nursing Interventions Classification (NIC) in a Pediatric Allogenic Hematopoietic Stem Cell Transplantation Center {#pbc27455-sec-14450}

[O. Sunakozawa]{.ul} ^1^, C.P. Guimarães^1^, S.M. Oguita^1^, G.S. Tusani^1^, K.F.M. Mendonça^1^, S.C.A. Almeida^1^, J.L.V. SIlva^1^, L.P.M. Liano^1^, S.M. Berber^1^

*^1^Instituto da Criança HC FMUSP, Hematopoietic Stem Cell Transplantation Center, São Paulo, Brazil*

**Background/Objectives**: Given the scarcity of parameters that make it possible to know the nursing workload at the Hematopoietic Stem Cell Transplantation Center (HSCTC), in the development of nursing activities and the productive time of this team, it is essential to identify the interventions/activities performed by nursing staff, which is the first step towards more efficient human resources planning. The purpose of this research is to identify the nursing activities performed by the HSCTC nursing team in a tertiary pediatric hospital in São Paulo, Brazil, and classify them into interventions according to the Nursing Interventions Classification.

**Design/Methods**: We consulted the medical records of the patients diagnosed with leukemia hospitalized from June 2014 to June 2016, submitted to allogeneic stem cell transplantation. The activities identified were compared with those mapped in a validated instrument of Guimarães in a Pediatric Intensive Care Unit (PICU), the activities that were not included in the previous instrument were mapped and inserted according to the similarity between the definition of the intervention and the activities suggested in the NIC.

**Results**: 88 activities were surveyed in 20 medical records. We identified 61 interventions distributed in 21 Classes and six Domains.

**Conclusions**: In Brazil, in Hematopoietic Stem Cells Transplantation field, despite the large number and complexity of the nursing activities in the conditioning stage, on the day of infusion and post‐HSCT, which may contribute substantially to workload increase and affect quality of care and patient safety, there is still no formal system of nursing workload measurement. The instrument constructed with the interventions/activities will allow, in future studies, to correlate the time spent in the execution of these interventions and, thus, to propose parameters in the dimensioning of nursing staff in HSCTC.

### PO-474. Does Nutritional Status Influence the Demand of Nursing Care in a Pediatric Allogenic Hematopoietic Stem Cell Transplantation Center? {#pbc27455-sec-14460}

[O. Sunakozawa]{.ul} ^1^, K.H.C. Viani^1^, C.P. Guimarães^1^, G.S. Tusani^1^, J.L.V. Silva^1^

*^1^Instituto da Criança HC FMUSP, Hematopoietic Stem Cell Transplantation Center, São Paulo, Brazil*

**Background/Objectives**: Patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) are highly complex, which contributes substantially to nursing workload increase and affects quality of care and patient safety. They are also at high nutritional risk, which may exacerbate morbimortality. This study\'s goal was to identify whether nutritional status of children with cancer affects the demand of nursing care in a pediatric HSCT unit.

**Design/Methods**: This was a retrospective longitudinal study. Charts of patients with cancer who had allogeneic HSCT between January/2015 and March/2018 were reviewed on days ‐5, +10 and +25 HSCT in order to represent conditioning regimen, post cell infusion before and after neutrophil recovery. Patients were classified according to a validated Instrument of Classification of the Hospitalized Pediatric Patient (ICHPP). Malnutrition was defined as mid‐upper arm circumference (MUAC) below 5^th^ percentile, by Frisancho tables. Kruskal‐Wallis rank and chi‐square tests were used for comparisons, Spearman\'s rank for correlation.

**Results**: There were 33 patients with median age of 11 years, 45.4% female. The most frequent diagnosis was acute lymphoblastic leukemia (54.6%), followed by acute myeloid leukemia (33.3%). Transplants were 24.2% haploidentical, 57.6% non‐related donors (15% cord blood). ICHPP median scores went from 42 to 44 to 43 on the established time points (p\<0.05). On D+10, 97% patients were considered semi‐intensive or intensive. MUAC significantly decreased from D‐5 to D+25 (21 to 20 cm, p=0.0021) and D+10 to D+25 (20.5 to 20 cm, p=0.0013). Change in MUAC didn\'t correlate to ICHPP score. Malnourished patients on D+10 had a higher score on D+25 HSCT (0.0663).

**Conclusions**: Despite deterioration of nutritional status, there wasn\'t correlation to nursing workload, except when patients were malnourished on D+10 HSCT, which increased ICHPP score on D+25. This might be due to the known association of malnutrition and increased risk of infection and toxicity, which could be further explored by a large multicentric study.

### PO-475. The Factor of the Difficulty of Nurses Who are Taking Care of Children with Cancer {#pbc27455-sec-14470}

[N. Takenouchi]{.ul} ^1^, M. Uchida^2^, M. Hirata^3^, Y. Ohara^4^, F. Shirai^5^

*^1^Kanagawa Children\'s Medical Center, Cancer Center, Kanagawa, Japan; ^2^Tohto College of Health Sciences, Faculty of Makuhari Human care, Chiba, Japan; ^3^St. Lukes International University, Graduate School of Nursing Science, Tokyo, Japan; ^4^Chiba Children\'s Hospital, Nursing, Chiba, Japan; ^5^Nagano College of Nursing, School of Nursing, Nagano, Japan*

**Background/Objectives**: Japanese Society of Pediatric Oncology Nursing study group developed "Nursing Care Guidelines for Children with Cancer 2012". In our past researches we found that Care items of the guideline are valued as important. However, nurse felt difficulties in providing those care.

The aim of this study is to know the factor and reasons for having difficulties of nurses who are taking care of children with cancer, and to consider supporting nurses.

**Design/Methods**: We sent the original questionnaire to 108 facilities nationwide and asked one of the children\'s cancer nurses with more than 5 years experience to answer that. Five professional pediatric oncology nurses did content analysis of free description which is about why they think that the nursing care is difficult and challenging. The descriptive data was coded.

**Results**: There were 332 codes and 105 categories. From the codes, we found that nurses feel difficulties in "Home care at the terminal stages" "End of life care" "Support when explaining the disease and the treatment" "Building trust relationship" "Care when recurrence" "Relieve procedural pain" "Symptom management" "Care at stem Cell transplantation".

From the result of the categorization of codes, we found some features of factor. These are "Children\'s condition""Understanding Family\'s intention" "Lack of nursing skills, knowledge and experiences" "Collaboration with doctors and other medical staff" "Environmental factor of work and system".

**Conclusions**: From the result, pediatric oncology nurses in Japan needs more knowledge and skills to deal with complicated situation and also they needs communication skill and building trust relationship with patient and family continuously from the time of diagnosis. This result suggest that the additional educational system is required to support nurses and problems of environment and system surrounding children with cancer and their families should be clarified so that nurses could provide higher quality of care.

### PO-476. Developing a Paediatric Advanced Nurse Practitioner Led Telephone Clinic for Children with Acute Lymphoblastic Leukaemia {#pbc27455-sec-14480}

[J. Taylor]{.ul} ^1^, B. Gibson^1^, W. Taylor^1^, A. Clarkin^1^, C. Mitchell^1^, C. Barclay^1^, J. Baird^1^

*^1^RHC, Ward 2A, Glasgow, United Kingdom*

**Background/Objectives**: Children and young people on maintenance chemotherapy for acute lymphoblastic leukaemia traditionally attend hospital clinics weekly for medical review and management of chemotherapy. This significantly impacts on the quality of life of both child and family; children miss school and parents take time off work to attend hospital.

Working in collaboration with primary care and education this project aims to develop an improved method of delivering care which reduces hospital attendance and enriches quality of life for children and young people.

**Design/Methods**: The Advanced Nurse Practitioner (ANP) telephone clinic was introduced as a small‐scale pilot with the aim of extending this service to all patients on maintenance chemotherapy. Hospital attendance has reduced from weekly to monthly visits, when patients attend for review and receive a monthly chemotherapy supply. Out‐with these visits patients are managed at home by ANP and community nurses.

Patients have blood counts taken at home or school by an outreach nurse which normalises the procedure and reduces the impact on schooling. Blood counts are checked by the ANP, and chemotherapy prescribed by a Haematology consultant. The ANP confirms chemotherapy dose and follow up arrangements by phone and text to the parent or young person.

**Results**: Twelve of thirty‐one (36%) patients on maintenance chemotherapy are now managed on the ANP telephone clinic. This has reduced hospital attendance and improved quality of life for patients and families. The service has been evaluated through a patient and family survey which showed high levels of satisfaction. Children and young people reported that this service has improved their attendance at school and parents reported minimised disruption to work and family life.

**Conclusions**: Working collaboratively to change traditional outpatient care has delivered a patient and family‐centred approach to care in the community. The challenge is now to extend this service for all patients on maintenance chemotherapy.

### PO-477. Creating a Childhood Cancer Mobile Application -- What Information is Valuble for Patients and Their Families? {#pbc27455-sec-14490}

[A. Ternald]{.ul} ^1^

*^1^Sahlgrenska University Hospital‐ Queen Silvia Children\'s Hospital, Department of pediatric Oncology, Gothenburg, Sweden*

**Background/Objectives**: When a child is diagnosed and treated for cancer, the information given to the child and the family is of great importance. Information is provided by different healthcare professionals orally and written and it needs to be repeated and updated over time. A mobile application for children with cancer and their families to improve the flow of information and making it easily accessible is currently being developed. To ensure that the information is in line with the children and their families needs a survey to assess their demand was developed.

**Design/Methods**: A questionnaire was handed out to patients and families at the pediatric oncology closed ward, at the daycare unit and the region hospitals. The questionnaire focused on identifying what type of information the patients and their families would like to access in a mobile application. Four parents were then randomly selected for interviews.

**Results**: The children and their families reported great enthusiasm and appreciation of having an opportunity to access information in a mobile application. Three themes emerged (a) patient specific information including test results, appointment booking and treatment protocols; (b) communication platforms such as chat and message functions for direct contact with clinical staff from home; (c) care routines; for both ward and home based care and contact information.

**Conclusions**: The idea of a mobile application as a means to improve the flow of information and make it more efficient was welcomed and appreciated by the parents and children included in the study. The mobile application should include the specific areas of information and a means for real time communication to meet the needs of the patients and families.

### PO-478. Development of mini‐SSPedi for Children 4‐7 Years of Age Receiving Cancer Treatments {#pbc27455-sec-14500}

[D. Tomlinson]{.ul} ^1^, E. Stein^1^, E. Vettese^1^, S. Hyslop^1^, L.L. Dupuis^1^, B. Spiegler^1^, S. Kuczynski^2^, L. Sung^1^

*^1^Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Canada; ^2^Ontario Parents Advocating for Children with Cancer, Ontario Parents Advocating for Children with Cancer, Toronto, Canada*

**Background/Objectives**: The Symptom Screening in Pediatrics Tool (SSPedi) is valid for self‐report symptom screening in children aged 8‐18 years receiving cancer treatments. Our objective was to develop a new self‐report symptom screening tool for children receiving cancer treatments who are 4‐7 years old (mini‐SSPedi), based on SSPedi.

**Design/Methods**: Respondents were children aged 4‐7 years receiving cancer treatments. Using cognitive interviews, with iterative design, we developed mini‐SSPedi in three phases and made decisions based upon respondent understanding. Each phase was considered complete if at least 80% of respondents showed correct interpretation of a feature within the last group of 10 children interviewed. First, we determined questionnaire structure with respect to recall period, concept of bother and response option format. We tested understanding of "yesterday" and "today", understanding of "bother" and evaluated three different 3‐point Likert scales to measure degree of bother. Second, we examined wording of each symptom of the 15 SSPedi items. Third, we evaluated the entire mini‐SSPedi instrument for ease of completion. A second interviewer rated understanding of each component.

**Results**: Among the 100 enrolled participants, mean age (range) was 5.6 (4.0‐7.8) years. In developing questionnaire structure (n=30 respondents), a recall period of "today" and a faces‐based 3‐point Likert scale were well‐understood. With this structure, all participants understood the concept of "bother". In determining symptom wording (n=40 respondents), among the 15 SSPedi items, five required modification to achieve satisfactory understanding while ten symptoms did not. In evaluating mini‐SSPedi in its entirety (n=30 respondents), continued modifications resulted in the last 10 children understanding each mini‐SSPedi item; none thought mini‐SSPedi was hard to complete.

**Conclusions**: We developed a symptom screening tool for children aged 4‐7 years, receiving cancer treatments, that is understandable and easy to complete. Future work will evaluate the psychometric properties of mini‐SSPedi and develop an electronic version of the instrument.

### PO-479. Delayed Chemotherapy‐Induced Nausea and Vomiting in Pediatric Patient with Cancer: What the Nurse Can Do? {#pbc27455-sec-14510}

[K.Y. Triana]{.ul} ^1^, Z. Aprillia^1^, A. Allenidekania^1^

*^1^Faculty of Nursing‐ Universitas Indonesia‐ Depok‐ Indonesia Pediatric Nursing Department, Pediatric Nursing Department, Depok, Indonesia*

**Background/Objectives**: Chemotherapy‐Induced Nausea and Vomiting (CINV) is one of the most disturbing and frightening symptoms among patients with cancer whom experienced after receiving chemotherapy. This condition causes children at risk for physical and psychosocial problems, such as the risk of experiencing physic and psychosocial problems for instance anorexia, electrolyte imbalances, dehydration, weight loss, malnutrition, poor functional status, and anxiety. Chemotherapy programs may have an impact on subsequent treatment programs and quality of life degradation. The purpose of this literature review is to describe the mechanisms of delayed CINV in pediatric patients, epidemiology, etiology, possible assessment strategies and delayed CINV management in pediatric patients.

**Design/Methods**: The method used in this article was a literature review with summarize technique.

**Results**: Delayed CINV is the most common CINV symptom experienced by pediatric patients affected by the use of moderate to severe emetogenic chemotherapeutic agents. Therefore, effective management of delayed CINV is required, starting with the identification of the chemotherapy agents used, educate the parents about the side effect, such as CINV, the assessment of nausea and vomiting in children, followed by apply the guideline antiemetics combine with non‐pharmacologic therapy adapted to the age of child development, such as dietary regulation, distraction, active coping strategies, acupressure, social support, and psychosocial strategies.

**Conclusions**: Nurses have an important role both as care giver and educator in performing delayed CINV management in pediatric patients to optimize child growth and preventing stress in children by empowering their parents.

### PO-480. Analysis of Refusal of Recommended Treatment in Children with Cancer Through a 20‐Year Database {#pbc27455-sec-14520}

Y.L. Lee^1^, H. Hsiu‐E^2^, [J.L. Tsai]{.ul} ^3^

*^1^Fu Jen Catholic University Hospital/Childhood Cancer Foundation‐ ROC/National Taiwan University/Fu Jen Catholic University, Department of Nursing/Research & Statistics Sector/Department of Nursing/Department of Nursing, New Taipei/Taipei, Taiwan R.O.C.; ^2^Childhood Cancer Foundation‐ ROC, Research & Statistics Sector, Taipei, Taiwan R.O.C.; ^3^Chang Gung University/ National Taiwan University, School of Nursing/ School of Nursing, Taipei, Taiwan R.O.C*.

**Background/Objectives**: The outcomes of childhood cancer treatment have been improved greatly in three decades. The less dropout or refusal for the treatment, the more chances to be cured. The objective of current study is to understand the situations and changes of treatment refusal in children with cancer in Taiwan.

**Design/Methods**: A retrospective design is adopted for the study. The database was set‐up by the Taiwan Pediatric Oncology Group (TPOG), founded by Childhood Cancer Foundation, Republic of Taiwan in 1982. Two 10‐year cohorts are defined after the year of National Health Insurance implemented in 1995, cohort 1 (1995‐2004, n=6952) and cohort 2 (2005‐2014, n=5556), for the analysis. X^2^ and logistic regression are used to analyze the data.

**Results**: The number of recommended treatment refusal is significantly decreased in cohort 2 (5.6% vs 3.7%, p\<0.0001) with no difference in sex but in age at diagnosis, types of cancer and location of family residency in two cohorts. The children with age under 4 year‐old have significant high risks to reject recommended treatment than age greater than 5. Children with leukemia has high risks to reject recommended treatment in cohort 1 (p\<0.0001), however, children with retinoblastoma (OR=2.161, 95% CI:1.147‐4.071, p=0.0172) and soft tissue tumor (OR=2.198, 95% CI:1.069‐4.519, p=0.0323) have significant high risks to reject recommended treatment controlled by leukemia in cohort 2. The families reside in both central and southern areas of Taiwan have significant risks to reject recommended treatment in both cohorts (p=0.0136, 0.0052).

**Conclusions**: The reasons that those who are age at diagnosis under 4, diagnosed with retinoblastoma and soft tissue cancer and living in central and southern areas of Taiwan tend to reject recommended treatment need further study. The results will provide health care providers a direction for improving the quality of care.

### PO-481. Parental Smoking Behavior and the Related Factors Among the Family of a Child with Cancer in Taiwan {#pbc27455-sec-14530}

[J.L. Tsai]{.ul} ^1^, Y.L. Lee^2^

*^1^Chang Gung University/ National Taiwan University, School of Nursing/ School of Nursing, Tao‐Yuan City /Taipei, Taiwan R.O.C.; ^2^Fu Jen Catholic University Hospital/Childhood Cancer Foundation‐ ROC/National Taiwan University/Fu Jen Catholic University, Department of Nursing/Research & Statistics Sector/Department of Nursing/Department of Nursing, New Taipei /Taipei, Taiwan R.O.C*.

**Background/Objectives**: The effects of maternal smoking on the childhood cancer have been primarily focused on as the role of causes. It also has been reported that paternal smoking has positive association with the offspring\'s cancer. However, the results are still inconsistent and the relationship of paternal smoking behavior with the risk of childhood cancer has not been thoroughly studied and. We aim to investigate the parental smoking behavior and its related factors among the families with a cancer child in Taiwan.

**Design/Methods**: We conducted a survey method in Taiwan where the incidence of childhood cancer is around 550 per year. The study included 1041 cancer children enrolled last two years from 2016 to 2018. A questionnaire was designed for data collection when were newly diagnosed. The descriptive and chi‐squared test is used to analyze the data.

**Results**: In 1041 families, 44.1% of them have smoking behavior at home. The most frequent place for smoking is outdoors (73.2%). There is no difference regarding the factors of parental smoking behaviors such as the level of education of both parents and the paternal ethnicity. But the ethnicity of mothers is significantly related to the smoking behavior for the mothers of the indigenous peoples of Taiwan (p=0.0395). The family annual income with less than 40,000 US dollars significantly associated to have parental smoking (p\<0.0001).

**Conclusions**: In order to provide a non‐smoking environment for the cancer children, the health care providers may focus on the families with lower annual income and the ethnicity of mother to give them more education and attention.

### PO-482. Psychosocial Survivorship for Adolescents and Young Adults After Childhood Cancer: Findings from a Qualitative Research on Experiences of Survivors of Childhood Cancer and Their Parents {#pbc27455-sec-14540}

N. Belpame^1^, E. Deslypere^2^, M. Kars^3^, A. Van Hecke^1^, P. Rober^2^, [V. Van De Velde]{.ul} ^4^, S. Verhaeghe^1^

*^1^University Centre for Nursing and Midwifery‐ Ghent University, Department of Public Health‐ Faculty of Medicine and Health Sciences, Ghent, Belgium; ^2^University of Leuven, Institute for Family and Sexuality Studies, Leuven, Belgium; ^3^UMC Utrecht, Div. Julius Centrum, Utrecht, The Netherlands; ^4^University Hospital Ghent, Pediatric Hemato ‐ Oncology, Ghent, Belgium*

**Background/Objectives**: Adolescents and young adults (AYA) survivors of childhood cancer often experience long‐term consequences arising from their illness and its treatment. Understanding the meaning of a cancer experience in the survival phase can improve the development of psychosocial care for AYA survivors.

**Design/Methods**: In collaboration with University Hospital Ghent, University Hospital Leuven and University Leuven, University Centre for Nursing and Midwifery Ghent, Belgium, set up a qualitative research in which semi‐structured interviews were taken with 21 AYA survivors aged 14 to 25 years.

**Results**: Even many years after completing treatment, a cancer experience remains deeply ingrained in the lives of AYA survivors. The deployment of specific coping strategies helps AYA survivors to deal with the long‐term psychosocial consequences of the cancer experience with a view to ultimately leading a normal life. The ability to assume directorship of their life appears to be a driving force behind the existence and actions of AYA survivors.

**Conclusions**: Health care professionals could optimize the psychosocial care provided to AYA survivors by taking their experiences as a point of departure. Individual support should be brought in line with the way in which AYA survivors have integrated their cancer experience into their everyday lives. An e‐learning module for healthcare professionals was developed aiming to promote insight in the specific experiences and needs of the AYA survivors.

### PO-483. Affectionate Managers: A Qualitative Research on the Experiences of Care Giving Parents of Adolescents and Young Adults with Cancer and the Development of a Booklet {#pbc27455-sec-14550}

N. Belpame^1^, E. Decoene^1^, [V. Van De Velde]{.ul} ^2^, Q. Marijke^3^, S. Verhaeghe^4^

*^1^University Hospital Ghent, Cancer Centre, Ghent, Belgium; ^2^University Hospital Ghent, Pediatric Hemato ‐ Oncology, Ghent, Belgium; ^3^University Hospital Ghent, Hematology, Ghent, Belgium; ^4^University Centre for Nursing and Midwifery‐ Ghent University, Department of Public Health‐ Faculty of Medicine and Health Sciences, Ghent, Belgium*

**Background/Objectives**: Care giving parents of adolescents and young adults (AYAs) with cancer are very involved in the cancer trajectory of their child, both emotionally as practically. To offer parents adequate psychosocial care, insight in their experiences, needs and expectations is crucial.

**Design/Methods**: A qualitative research, based on principles of grounded theory, was conducted in the University Hospital of Ghent. Thirty one‐time only semi‐structured interviews were taken with parents of AYAs aged 15‐25 years at different times in the cancer trajectory, starting from the time of diagnosis until 5 years after the end of the treatment.

**Results**: Parents take different roles in the care for the AYA. They act as "affectionate managers" and take simultaneously the role of representative, gate‐keeper, advocate and loving parent of the AYA. Moreover, parents feel constantly challenged to find a balance in relation to the AYA, in relation to their partner and to possible other children, and in relation to their network (family, friends, colleagues, etc.). A majority of parents experience a lack of self‐care. Parents experience an important need to be involved in the cancer trajectory and care of the AYA. They want sufficient and useful information and understanding for their unique situation and for the challenges they face.

**Conclusions**: Most parents offer their AYA unconditional all‐round care but they face certain insecurities and fears. Adequate psychosocial care for parents requires acknowledgment of the different roles they take in the support of their child. Based on the findings of this research, a booklet was developed for parents of AYAs. This booklet describes the experiences of parents, using illustrative quotes of the interviewed parents. Worksheets are implemented, offering parents tools in expressing their feelings and thoughts and in communicating with the AYA and the people surrounding them.

### PO-484. Improving the Long Term Follow‐up Program for Childhood Cancer Survivors {#pbc27455-sec-14560}

[I. Van Den Bossche]{.ul} ^1^, C. Dhooge^1^, G. Laureys^1^, Y. Benoit^1^, E. Vandecruys^1^

*^1^Ghent University Hospital, Paediatrics Haematology/Oncology, Ghent, Belgium*

**Background/Objectives**: The increasing survival of patients with childhood cancer (CC) confronts us with late and long term effects (LLTE). A lifelong follow‐up (FU) is advised to improve the quality of life for CC survivors and to prevent illness and death from late effects.

**Design/Methods**: A nurse consultant was recruited to assist the paediatric oncologist in improving the long term follow‐up (LTFU) program for CC survivors in our hospital.

First, long term survivors (LTS) out of FU for several reasons but at high risk for LLTE (survivors from ALL diagnosed before 1984, from Hodgkin\'s lymphoma diagnosed before 2001, from bone and brain tumours diagnosed before 2012, all currently minimum 16 years old) were invited for a consultation to share oral and written (survivorship passport) information about the oncological history and appropriate LTFU.

Secondly, LTS at least 16 years old, in FU and ready for transition to adult services received in addition a nurse consultation focusing on quality of life and self‐management.

**Results**: Ninety‐seven (52.7%) of 184 invited LTS out of FU were seen at the consultation. Seventy‐one survivors in the process of transition received a nurse contributed transfer to the adult services.

Preparation of the survivorship passport took between 1 to 4 hours, consultation itself about 1 to 2 hours. The nurse was contacted afterwards in 24 cases (14.3%) concerning employment, insurance, health care and psychosocial matters. High risk survivors were referred to interdisciplinary partners we identified within the hospital. Survivors with a low risk of LLTE were referred to regional specialists/general practitioners.

**Conclusions**: There was and still is a need to improve our LTFU program. A nurse consultant can play an important role to achieve the goal of a step‐wise transition from paediatric to adult health care setting with several nurse contacts focusing on self‐management in LTFU, health promotion and social orientation.

### PO-485. Perceptions and Experiences of Stakeholders Regarding Clinical Education in a Nairobi School of Nursing {#pbc27455-sec-14570}

[F. Wambu]{.ul} ^1^

*^1^The Nairobi Hospital, Operating Theatre, Nairobi, Kenya*

**Background/Objectives**: Social accountability in professional education has been foregrounded; especially since the 2010 publication of the Lancet Commission which challenged the relevancy of health professional education in addressing current health challenges. The theory‐ practice gap in nursing education is such a concern as it impacts on the clinical competence of nurses and thus the health outcomes of patients (De Swardt et al 2012).Few studies have addressed the theory‐ practice gap and competency assessment phenomenon from key stakeholder viewpoints (Zannini et al 2010). This study explored how the stakeholders ((lecturers, charge nurses and clinical preceptors) worked collaboratively to achieve the stated clinical outcomes for the diploma in nursing curriculum.

**Design/Methods**: This qualitative study used semi‐ structured interviews and focus group discussions. Purposive sampling of stakeholders included the 3rd year student nurses, charge nurses, preceptors and nurse lecturers. Transcribed data was analysed for themes.

**Results**: Four themes emerged from nursing students. They perceived clinical education as offering student advocacy; peer reciprocity; opportunity for self‐directed learning; but found theory‐practice disparity. For preceptors it signified role overload; identification of teachable moments; and opportunities to build relationships. Nurse lecturers identified issues related to ownership of clinical learning; complexity of the clinical learning environment; and theory‐practice disparity. The charge nurses reported that clinical education functioned as a 'ward culture moderator'; offered opportunity for leadership and education; and partnering and collaboration.

Dynamic tools and assessment limitations were the themes that emerged from the question that explored the use of competency assessment tools. The stakeholders experienced limitations with the tools to measure students' achievement of skills, knowledge and learning outcomes in clinical education.

**Conclusions**: Stakeholders suggested some insightful ideas to improve clinical education. A suggestion was to have trained clinical instructors who would help the institution bridge the existing theory‐practice gap. Strategic reorganization of the current clinical education model at the hospital.

### PO-486. Effect of Inpatient Exercise Program During Hemopoietic Stem Cell Transplantation on Body Composition of Children {#pbc27455-sec-14580}

[B. Zhang]{.ul} ^1^, M. He^1^

*^1^Shanghai Children\'s Medical Center‐ Affiliated with Shanghai Jiaotong University, Pediatric hematology and oncology, Shanghai, China*

**Background/Objectives**: Exercise program in pediatric oncology are feasible and safe. However, scarce data are available with regard to the effect of exercise program on body composition. This explorative, prospective study was designed to evaluate the effects of an inpatient therapeutic exercise program.

**Design/Methods**: 44 HSCT children during January 2016 and March 2017 were enrolled as intervention group, and 43 HSCT children during January 2014 and December 2015 which were comparable with intervention group in terms of age, gender, diagnosis and matching. In addition to routine care, the children in intervention group underwent aerobic exercise and resistance exercise by a cycle ergometer(30min, 3 times per week). The body compositions, including height, body mass, BMI, FM, FFM, of both groups were tested before and 30‐day, 60‐day and 100‐day after transplantation. Difference between two groups were compared using variance analysis of repeated measurements.

**Results**: The main effects of body mass, standardized body mass and fat mass were statistically significant (P\<0.05); the time effect on body mass, standardized body mass, BMI and body muscle were statistically significant (P\<0.05); there were interaction effects between intervention and time on body mass(P\<0.05).

**Conclusions**: Exercise therapy shows a significant positive effect on the body mass and FM for inpatient children during HSCT, and slows down the FM accumulation. Children during HSCT should be instructed with aerobic exercise and resistance exercise of moderate or low intensity.

### PO-487. The Exploration of Multidisciplinary Cooperative Vaccination Management in Pediatric Cancer Survivors {#pbc27455-sec-14590}

[F. Zhou]{.ul} ^1^, Y. Gao^1^, H. Zhang^1^, M. He^1^

*^1^Shanghai Children\'s Medical Center‐ Affiliated with Shanghai Jiaotong University, Pediatric Hematology and Oncology, Shanghai, China*

**Background/Objectives**: Cancer survival rates of pediatric patients with cancer have significantly improved. For pediatric cancer survivors, sustained protection against infections should be emphasized. This is the first explorative study of the necessity and feasibility of multidisciplinary cooperative vaccination management in pediatric cancer survivors in China.

**Design/Methods**: Children 1‐18 groups old with chemotherapy completed for 1 year were eligible. We set up a multidisciplinary cooperative team. In vaccination consultation clinic of tertiary pediatric cancer center, every child received an individualized designed protocol of vaccination, after evaluation of humoral immunity and specific antibody. And qualified child was transferred to community health service center and got vaccines according to vaccination protocol. Then children returned to vaccination consultation clinic, and got evaluation of specific antibody and necessary readjustment of vaccination protocol.

**Results**: In total, 86 eligible patients visited the vaccination consultation clinic in tertiary pediatric cancer center. 79 Patients have received hepatitis B vaccination before chemotherapy, and protective antibody against hepatitis B were found in 12 cases (15.1%). 37 patients have received MMR before chemotherapy, and protective antibody levels against Measles, Mumps, Rubella were found in 9 cases (24.3%), 10 cases(27.0%), 8 cases(29.6%) respectively. 64 patients (74.4%) has started the post‐chemotherapy booster vaccines. 6 cases (9.4%) reported mild and self‐healing side effect, including redness and pain in injection site and slight fever. Parents of 63 cases (98.4%) demonstrated satisfaction on the multidisciplinary cooperative vaccination management.

**Conclusions**: A considerable number of pediatric cancer survivors lose immunity after chemotherapy. The multidisciplinary cooperative vaccination service was beneficial in terms of integration and coordination of resources of different healthcare institutions. As such, this study provides support for feasible vaccination management in pediatric cancer survivors, especially in resource‐limited countries and areas.

Treatment and Care ‐ Immunotherapy {#pbc27455-sec-14600}
----------------------------------

### PO-488. Mifamurtide: A Retrospective Multicentre Analysis of Its Indication, Safety and Efficacy in Osteosarcoma in Argentina. A Real World Evidence Experience {#pbc27455-sec-14610}

[M. Coirini]{.ul} ^1^, D. Morell^2^, G. Nalda^3^, M. Villamil^4^, G. Pallota^5^, J. Jotomliansky^1^, A. Schiffino^1^, P. Streitenberger^6^

*^1^Hospital de Niños Víctor J. Vilela, Pediatric Oncology, ROSARIO, Argentina; ^2^Hospital Infantil Municipal, Pediatric Hematology‐Oncology, Córdoba, Argentina; ^3^Hospital Pediátrico "Dr. Humberto J. Notti", Pediatric Oncology, Mendoza, Argentina; ^4^Hospital Italiano de San Justo, Pediatric Hematology‐Oncology, Buenos Aires, Argentina; ^5^Hospital Italiano Buenos Aires, Clinical Oncology, Buenos Aires, Argentina; ^6^Hospital Italiano Buenos Aires, Pediatric Hematology‐Oncology, Buenos Aires, Argentina*

**Background/Objectives**: According to our national registry (ROHA) there are 40 new pediatric osteosarcoma (OS) cases per year in Argentina. The aim of this study was to evaluate real world evidence of the use of mifamurtide in Argentina.

**Design/Methods**: We retrospectively analysed 14 pediatric patients with osteosarcoma without clinically detectable metastatic disease (9 with localized and 5 with relapsed OS in complete remission) who received mifamurtide between June 2016 and January 2018.

**Results**: We analysed 8 boys and 6 girls with OS, median age of 14 years old (r:5 ‐25) with a medium follow‐up of 12 months (3 ‐19). The most frequent localization was distal femur and proximal tibia (81%). Eight patients obtained more than 90% of necrosis. Patients received different combinations of chemotherapy based on platinum, doxorubicin, ifosfamide, high dose methotrexate, carboplatin, etoposide, docetaxel and gemcitabine. Five hundred thirty‐six doses of mifarmutida (2mg/m2) were given. Median time to mifamurtide initiation was 41 days post‐surgery (18‐64d) for all patients and 30 days in localized osteosarcoma patients. Adverse events were (in chemotherapy+mifamurtide pts): chills 10 patients, fever 8 patients, nausea 2 patients, myalgia 2 patients, palpitations 1 patient, hypokalemia 2 patients (one of them grade 4), leucopenia 7 patients (4 patients grade 3), anemia 7 patients (only 1 grade 3), thrombocytopenia 6 patients (4 patients grade 3). Ten patients received acetaminophen premedication. Ten patients with localized osteosarcoma are currently disease free, 5 are still on mifarmutide treatment. Four patients died due to progressive disease.

**Conclusions**: Mifamurtide therapy is safe, accessible and well tolerated in pediatric patients with osteosarcoma. Chills and fever were the major side effects. Longer follow‐up is needed to confirm efficacy.

### PO-489. Ligandome Analysis of AT/RTS Reveals Suitable Targets for Brain Tumor Immunotherapy {#pbc27455-sec-14620}

A. Marcu^1^, N. Trautwein^1^, S. Stevanovic^1^, P. Johann^2^, A. Technau^3^, J. Lager^3^, C.M. Monoranu^4^, L. Henkel^3^, J. Krauss^5^, M. Ebinger^6^, M. Schuhmann^7^, U. Thomale^8^, T. Pietsch^9^, M. Wölfl^3^, P.G. Schlegel^3^, M. Frühwald^10^, F. Oyen^11^, Y. Reisner^12^, H.G. Rammensee^1^, [M. Eyrich]{.ul} ^3^

*^1^University of Tübingen, Department of Immunology, Tübingen, Germany; ^2^DKFZ, Pediatric Neurooncology, Heidelberg, Germany; ^3^University Children\'s Hospital, Pediatric Hematology/Oncology, Wurzburg, Germany; ^4^University of Würzburg, Department of Neuropathology, Würzburg, Germany; ^5^University Medical Center, Department of Neurosurgery, Würzburg, Germany; ^6^University Medical Center, Children\'s Hospital, Tübingen, Germany; ^7^University Medical Center, Department of Neurosurgery, Tübingen, Germany; ^8^Charité, Department of Neurosurgery, Berlin, Germany; ^9^University of Bonn, Institute of Neuropathology‐DGNN Brain Tumor Reference Center, Bonn, Germany; ^10^Medical Center, Children\'s Hospital, Augsburg, Germany; ^11^University Medical Center, Children\'s Hospital, Hamburg Eppendorf, Germany; ^12^Weizmann Institute of Science, Department of Immunology, Rehovot, Israel*

**Background/Objectives**: Pediatric brain tumors are regarded as immunologically poorly recognized cancers, as they rank among malignancies with the lowest mutational load. However, this must not be correlated with poor immunogenicity, as tumor‐exclusive peptides bound in the tumor cell\'s MHC (=ligandome peptides) can represent attractive targets for immunotherapy.

**Design/Methods**: As a model disease with an extremely low mutational load, we investigated in AT/RTs, whether suitable targets for immunotherapy could be identified in ligandome versus neoantigen‐derived peptides.

**Results**: Upfront, we determined by IHC in a first set of n=17 AT/RTs that 1.8% of all cells within the tumors were T‐cells. MHC‐class‐I, class‐II, and PD‐L1 was expressed on 12.9%, 3%, and 5.1% of the tumor cells, respectively, indicating that AT/RTs were not immunologically cold. To decipher the AT/RT ligandome we then analyzed 23 centrally reviewed samples using LC‐MS and subsequent bioinformatical validation. Tumor‐specific MHC‐class‐I peptides could be identified in 61%, MHC‐class‐II peptides in 91% of the patients (range 2‐32 specific peptides per patient). In total, 59 MHC‐class‐I and 153 ‐class‐II tumor‐specific peptides could be found, of these, 47 and 109 peptides were exclusive for one tumor, demonstrating the high individuality of the ligandome. Representative examples of these ligandome peptides proved to be immunogenic in T‐cell assays, among these a MAGE‐B2 peptide which is also overexpressed in lymphomas and other brain tumors. Whole exome sequencing in n=9 so far analyzed AT/RTs revealed a median of 11 (range 1‐166) tumor‐specific mutations dispersed over the entire genome. In silico MHC‐binding prediction showed that these neoantigenic peptides had a similar binding affinity compared to their ligandome counterparts, thus questioning a superiority of neoantigen versus ligandome‐derived peptides.

**Conclusions**: Tumor‐exclusive ligandome peptides can be identified in the vast majority of AT/RTs. In silico and in vitro analyses qualify them as suitable candidates for personalized cancer vaccines.

### PO-490. Tumor Infiltrating Lymphocytes and Immunogenic Lipids in Pediatric Papillary Renal Cell Carcinoma {#pbc27455-sec-14630}

[N. Lehmann]{.ul} ^1^, C. Paret^1^, A. Russo^1^, K. El Malki^1^, M.A. Neu^1^, A. Wingerter^1^, F. Alt^1^, L. Seidmann^2^, S. Försch^2^, R. Sandhoff^3^, J. Faber^1^

*^1^Children\'s Hospital‐ University Medical Center of the Johannes Gutenberg University Mainz, Section of Pediatric Oncology, Mainz, Germany; ^2^University Medical Center of the Johannes Gutenberg University Mainz, Institute of Pathology, Mainz, Germany; ^3^German Cancer Research Center‐ Heidelberg‐ Germany, Division of Cellular and Molecular Pathology, Heidelberg, Germany*

**Background/Objectives**: Papillary renal cell carcinomas (RCC) rarely occur in children, which is why information about tumor biology and therapy is very limited. So far, the treatment of choice for pediatric papillary RCC is a complete surgical resection without any adjuvant therapy.

RCC is considered to be an immunogenic tumor but few information are available for pediatric entities. Tumor cells can be recognized and eliminated by conventional and nonconventional T cells such as invariant natural killer T cells (iNKT cells) and γδ T cells. Unlike conventional T cells, antigen recognition is independent of HLA haplotype in iNKT and γδ T cells and offers new options for cancer immunotherapies. These cells recognize lipids via CD1d molecules but so far, the nature of those lipids is largely unknown and α‐Galactosylceramide is used as a synthetic model antigen. Here, we aimed for the analysis of the infiltration of nonconventional and conventional T cells and the identification of endogenous lipid ligands.

**Design/Methods**: First, we isolated tumor infiltrating lymphocytes (TILs) from two pediatric papillary RCCs by percoll density centrifugation and analyzed the TILs via flow cytometry. The infiltration of immune cells was confirmed by immunohistochemistry. Furthermore, we fractionated tumor own lipids and tested the fractions for their ability to induce the proliferation of iNKT and Vδ1 cells, which are a subset of γδ T cells. Further characterization of these fractions by mass spectrometry is ongoing.

**Results**: In both samples, we detected infiltrations of nonconventional and conventional T cells. According to our first analysis, we found lipid fractions with the ability to induce the proliferation of iNKT and Vδ1 cells.

**Conclusions**: Our project is expected to provide new insights into the therapeutic utility of nonconventional T cell therapy and it helps to get new information about the biology of pediatric papillary RCCs.

### PO-491. Preclinical Rationale for Optimizing the Tumor Microenvironnement for Neuroblastoma Immunotherapy {#pbc27455-sec-14640}

M. Bahri^1^, S. Vermeulen^1^, M. Ben Mostafa Daho^1^, S. Faraj^1,2^, E. Thébaud^3^, S. Fougeray^1^, [B. Stephane]{.ul} ^1^

*^1^University of Nantes, CRCINA INSERM Université d\'Angers Université de Nantes, Nantes, France; ^2^CHU de Nantes, Service de Chirurgie Oncopédiatrique, Nantes, France; ^3^CHU de Nantes, Service d\'Oncopédiatrie, Nantes, France*

**Background/Objectives**: Immunotherapy targeting GD2 has emerged as a promising intervention for patients with neuroblastoma. However, a third of patients experiences immunotherapy failure. One reason is the tumor microenvironment, which potentially inhibits optimal anti‐tumor response. In this context, elucidation of the potential mechanisms of response merits consideration. As such, antibody‐dependant cell cytotoxicity (ADCC) induced by NK cells contributes to anti‐GD2 antibody therapeutic efficacy. Additionally, additive or synergistic treatment efficacy may be achieved by targeting other immune cells. However, tumor cells can escape ADCC by expressing immune checkpoint inhibitors. Here we evidence the immunomodulatory effects induced by isotretinoïn that can modulate immunotherapy potency.

**Design/Methods**: We evaluated the anti‐neuroblastoma response using isotretinoïn and anti‐O‐acetyl GD2 antibody 8B6 in the syngeneic NXS2 model. Mice were treated with isotretinoïn in combination with monoclonal antibody 8B6 and compared to controls. Next, we studied the immune modulation induced by isotretinoïn to the anti‐tumor potency evidenced in vivo. To this end, we studied the immune cell infiltrate composition and the immune checkpoint inhibitor PD1‐L and CD47 expression in NXS2 tumor in each treatment group by flow cytometry.

**Results**: Treatment with isotretinoïn + 8B6 antibody outperformed treatments with either isotretinoïn or antibody 8B6 used as monotherapy. This effect was correlated with an increased percentage of NK cells, macrophages, and neutrophils in the tumor compared to controls. Yet, isotretinoïn treatment induced a dose dependant up‐regulation of both PD1‐L and CD47 checkpoint inhibitors on the tumor cells.

**Conclusions**: In the isotretinoïn + 8B6 treated mice, tumor‐infiltrating macrophages and neutrophils could contribute with NK cells to potent 8B6 therapeutic efficacy. However, the antibody 8B6 enhanced lytic activity could be counteracted by the up‐regulation of checkpoint inhibitors PD1‐L and CD47. Better understanding of the cellular and the molecular changes following isotretinoïn is necessary to understand resistance mechanisms to anti‐GD2 immunotherapy in patients with neuroblastoma.
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### PO-492. Assessment of Genetic Assisted Neuroblastoma in Cambodia, Laos and Vietnam: Patient Knowledge, Attitudes, and Interest in Genetic Counseling {#pbc27455-sec-14660}

[B. Chi Bao]{.ul} ^1^, T. Diem Kieu^2^, S. Bong^3^, S. Sangkyunphan^4^, T. Khai^5^

*^1^City Children Hospital, Oncology genetics, hochiminh, Vietnam; ^2^University of medicine and pharmacy, Center for molecular biomedicine, Hochiminh, Vietnam; ^3^Angkor Hospital for Children, Oncology, Krong Siem Reap, Cambodia; ^4^Lao Friends Hospital for Children, Oncology, Luang Prabang, Lao PDR; ^5^Children hospital 2, Surgery and oncology, Hochiminh, Vietnam*

**Background/Objectives**: The most common genetic contributor to high‐risk Neuroblastoma (NB) is the amplification of MYCN gene. In order to effectively integrate MYCN genetic testing into clinical practice, a strategy tailored to the promoted area and population are investigated.

**Design/Methods**: In a prospective study involving 225 NB patients and their parent or guardians in three independent centers in Vietnam, Cambodia and Laos, the level of **knowledge** about **genetic** testing and patients\' attitudes towards such testing were evaluated using a standardized questionnaire.

**Results**: A greater number of NB patients and their parent or guardians reported a positive attitude towards the potential outcome benefits of genetic testing (85.4% vs. 42.2%, p\<0.005). Only a few participants had heard of any genetic tests for MYCN (19%) or ALK (1%). However, in the Laos and Cambodia cohort, multivariate analysis revealed that a high level of genetics knowledge was associated with a positive attitude response regarding the potential medical benefits of testing (p\<0.05), but a negative attitude towards compromises in healthcare and life insurance (87%, p\<0.03). These associations were not observed amongst Vietnamese subjects. The majority of participants thought it was likely they believed genetic testing for NB would be useful (86%), and were interested in genetic testing (59%) and genetic counseling (86%).

**Conclusions**: This study is the first to demonstrate an interest in genetic test and counseling among patients with NB. Our findings demonstrate a new approach for genetic counselors to support patients in clarifying gaps or misconceptions in knowledge about NB, particular for the low‐, middle‐income countries.

### PO-493. Whole Exome Sequencing Cell Free DNA Analysis Documents New Tumor Specific Alterations at Relapse of High Risk Pediatric Cancers {#pbc27455-sec-14670}

[M. Chicard]{.ul} ^1^, A. Danzon^1^, N. Clément^1^, I. Jiménez^1^, E. Lapouble^2^, G. Pierron^2^, A. Bellini^1^, N. Leprovost^1^, S. Baulande^3^, P. Fréneaux^4^, F. Doz^5^, J. Michon^5^, D. Orbach^5^, I. Aerts^5^, H. Pacquement^5^, F. Bourdeaut^1^, O. Delattre^6^, G. Schleiermacher^1^

*^1^Institut Curie, SiRIC RTOP « Recherche Translationelle en Oncologie Pédiatrique »‐ Translational Research Department‐ Research Center‐ PSL Research University, Paris, France; ^2^Institut Curie, Unité de Génétique Somatique, Paris, France; ^3^Institut Curie, Institut Curie Genomics of Excellence ICGex Platform‐ Research Center, Paris, France; ^4^Institut Curie, Département de Biologie des Tumeurs‐ Service d\'Anatomie Pathologique, Paris, France; ^5^Institut Curie, Departement of Pediatric Oncology‐ Hospital Group, Paris, France; ^6^Institut Curie, INSERM U830‐ Laboratoire de Génétique et Biologie des Cancers‐ Research Center‐ PSL Research University, Paris, France*

**Background/Objectives**: Pediatric cancers are in general characterized by few recurrent genetic alterations, but genetic heterogeneity and clonal evolution can play a role in tumor progression. Liquid biopsies now enable monitoring tumor‐specific genetic alterations in sequential samples based on the analysis of cell‐free DNA (cfDNA).

**Design/Methods**: We have subsequently enrolled 28 patients with high‐risk pediatric cancer (Neuroblastoma, Rhabdomyosarcoma, Ewing sarcoma, CNS tumors,other high‐risk cancers) with the aim to study clonal evolution based on sequential cfDNA analysis in the prospective trial NGSKids (<http://www.ClinicalTrials.gov> Identifier: NCT02546453). With a median follow up of 22 months (range 2‐36 months), 7 tumors have relapsed. Whole‐Exome‐Sequencing (WES) was performed on tumor and germline DNA as well as on cfDNA extracted from plasma at diagnosis, during treatment and follow up (2‐9 sequential cfDNA samples per patient). cfDNA analysis was performed using a modified in‐house procedure, with 20‐200 ng of cfDNA subjected to WES following modified library construction and capture approaches to account for small ctDNA molecules.

**Results**: At diagnosis, a mean of 9 tumor cell‐specific SNVs common to both primary tumor and corresponding cfDNA was observed (range 1‐57), with a mean of 11 and 6 SNVs specific to the primary and cfDNA respectively, indicating spatial heterogeneity. Whereas all cfDNA samples obtained at follow‐up in patients without evidence of disease revealed no or few tumor cell‐specific SNVs, interestingly, cfDNA samples obtained at relapse harbored additional, new relapse‐specific SNVs (mean: 10; range 2‐42) in all cases, targeting genes such MAPK and MLL4. Deep sequencing (5,000x) capture techniques with a panel encompassing all identified SNVs was applied to all sequential cfDNA samples, enabling to develop models of clonal evolution.

**Conclusions**: CfDNA WES proves to be an extremely powerful tool to study spatial and temporal heterogeneity in pediatric high risk cancers, providing further proof of the importance of clonal evolution in cancer progression.

### PO-494. Predisposing Mutations in Hippo Signaling Reveal an Actionable Target in Burkitt Lymphoma {#pbc27455-sec-14680}

[C. Derpoorter]{.ul} ^1^, K. Vandemeulebroecke^1^, T. Bauters^2^, J. Philippé^3,4^, G. Laureys^1,4^, T. Lammens^1,4^

*^1^Ghent University Hospital, Pediatric Hematology‐Oncology and Stem Cell Transplantation, Ghent, Belgium; ^2^Ghent University Hospital, Pharmacy, Ghent, Belgium; ^3^Ghent University Hospital, Clinical Chemistry‐ Microbiology and Immunology, Ghent, Belgium; ^4^Ghent University, Cancer Research Institute Ghent, Ghent, Belgium*

**Background/Objectives**: The proportion of childhood cancers attributable to germline genetic factors is most likely underestimated. Identification of predisposing aberrations significantly influences clinical decision making, impacts on early diagnosis and contributes to a better understanding of cancer development. Recently we performed whole genome sequencing on germline DNA of a family with 2 children affected by Burkitt lymphoma (BL). Interestingly, mutations in several regulators of Hippo signaling were identified. Here, we further validate these findings and address the impact of aberrant Hippo signaling in the context of BL.

**Design/Methods**: The impact of verteporfin treatment, a selective inhibitor of Yes‐associated protein 1 (YAP1), was evaluated in BL cell lines (DSMZ, n=7) using multiple concentrations (0.01‐50μM and Untreated Cells Control). Apoptosis, cytotoxicity and viability were assessed at different time points using the ApoTox‐Glo^TM^ Triplex assay (Promega).

**Results**: In order to further unravel the relevance of the Hippo signaling pathway in BL, we aimed to block the transcriptional read‐out of this program through inhibition of its nuclear effector YAP1. A concentration‐dependent decrease in viability after verteporfin treatment was measured for all investigated BL cell lines and the IC50 values ranged from 0.1‐0.5μM. Complete cell death was observed at concentrations of 5‐10μM.

**Conclusions**: Importantly, these results illustrate a potential role of Hippo signaling dysregulation in cancer development and genetic predisposition. Our preliminary functional experiments clearly show an important effect of verteporfin on the viability of BL cell lines. However, the effect of verteporfin treatment on gene expression of YAP1 transcriptional targets needs to be evaluated. In addition, preclinical data on efficacy and toxicity, with and without other chemotherapeutic/novel agents, in the context of BL treatment is being generated.

\*GL and TL are shared senior authors

### PO-495. Association Between Genetic Polymorphisms and Platinum‐Induced Ototoxicity in Children {#pbc27455-sec-14690}
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**Background/Objectives**: Platinum is widely used in the treatment of several childhood malignancies. However, ototoxicity is one of the most notable adverse effects especially in children. Several studies suggest that genetics may predict its occurrence. Here, the most common polymorphisms associated with platinum induced ototoxicity were selected from the literature and were investigated in a pediatric population treated with platinum‐based agents

**Design/Methods**: In this retrospective multicenter study, all patients treated with cisplatin and/or carboplatin were screened. The patients with pre‐ and post‐treatment audiogram (Brock criteria) available were included. We selected polymorphisms that have been previously associated with cisplatin ototoxicity with a minor allele frequency \>30%. Deletion of GSTM1 and GSTT1, rs1799735 (GSTM3), rs1695 (GSTP1), rs4880 (SOD), rs2228001 (XPC), rs1799793 (ERCC2) and rs4788863 (SLC16A5) were investigated.

**Results**: One hundred six children matching the eligible criteria were analyzed. Thirty‐three patients (31%) developed a moderate or severe ototoxicity (with a Brock grade ≥2). The probability of hearing loss increased significantly in patients carrying the null genotype for GSTT1 (P = 0.03), A/A genotype for rs1695 (P = 0.01), and C/C genotype for rs1799793 (P = 0.008). We also showed an association of the cumulative doses of carboplatin and cisplatin with a Brock grade ≥2 (P \<0.05).

**Conclusions**: Deletion in GSTT1, rs1695 in GSTP1 and rs1799793 in ERCC may constitute potential predictors of platinum induced ototoxicity.

### PO-496. Genotype‐Phenotype Variations and Spectrum of Malignancies in Patients with Noonan Syndrome: A Review of Literature {#pbc27455-sec-14700}

[S. Eissa]{.ul} ^1^, A. El Haddad^1,2^.

*^1^Children\'s Cancer Hospital‐Egypt 57357, Pediatric Oncology, Cairo, Egypt; ^2^National Cancer Institute, Pediatric Oncology, Cairo, Egypt*

**Background/Objectives**: Noonan syndrome (NS), the commonest RASopathy, is an autosomal dominant trait, characterized by short stature, craniofacial dysmorphism, congenital heart defects and susceptibility to cancer. Research suggests that there\'s a relationship between the underlying genotype and the apparent phenotype. The aim of this review is to examine NS\'s genotype‐phenotype variations and spectrum of malignancies.

**Design/Methods**: A review of previously published literature was conducted through PubMed database. Articles were chosen for review if they characterized NS, were available in English and were peer reviewed.

**Results**: Ninety three articles met the inclusion criteria. NS was described as the commonest of an inherited overlapping group of disorders collectively known as "RASopathies",including cardio‐facio‐cutaneous, Castello, LEOPARD and Legius syndromes‐in almost all articles. Heterozygous mutations in PTPN11, SOS1, KRAS, NRAS, BRAF, SHOC2, CBL and others were identified as leading etiologies in NS development through abnormal activation of the RAS‐MAPK signaling. Which is a pathway also incriminated in oncogenesis. Forty seven articles described abnormal myelopoiesis and Juvenile Myelo‐Monocytic Leukemia (JMML) in particular‐as the commonest malignancies. CNS tumors were the next most common. Solid tumors as neuroblastoma, chondroma and rhabdomyosarcoma were limited to case reports. The clinical features of NS were described in 21 articles and another 7 detailed its genotypic variations. Genotype‐phenotype variabilities were described by many authors. For example, germ line CBL mutations were characterized as having increased risk of neurological disorders, JMML but lowered risk for cardiac defects, growth retardation and cryptorchidism. NRAS positive NS was reported to be associated with hyperpigmentation. A genetically distinct subtype of NS patients "Neurofibromatosis‐Noonan (NFNS)" harbor both PTPN11 and neurofibromin mutations was also described.

**Conclusions**: Available research suggests that there\'s a relationship between the underlying genotype and the variably expressed phenotype. Mutations in the RAS‐MAPK pathway drive oncogenesis and should be identified utilizing molecular diagnostics in every patient. Such mutations are potential therapeutic targets.

### PO-497. Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children with High‐Risk Cancer {#pbc27455-sec-14710}

[P. Ekert]{.ul} ^1^, M. Wong^2^, Z.C.C. PRISM Omics Core^3^, Z.C.C. Preclinial Drug Testing Core^3^, E. Mould^3^, A. Gifford^3^, M. Norris^3^, M. Warby^4^, T. Trahair^5^, K. Tucker^4^, D. Ziegler^3^, G. Marshall^3^, T. O\'Brien^5^, M. Haber^3^, T. Vanessa^3^, M. Cowley^2^
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**Background/Objectives**: Identification of somatic and germline variants in paediatric cancer is a pathway to more accurate diagnosis and targeted treatment selection. The Zero Childhood Cancer (ZCC) PRISM trial aims to assess the feasibility of a precision medicine platform to identify targeted therapeutic agents for high‐risk paediatric malignancies (expected survival \<30%). We will report on the pilot feasibility study (TARGET) and the initial experience of the PRISM trial which opened in October of 2017.

**Design/Methods**: Combined whole genome sequencing (WGS), deep sequencing of a panel of cancer associated genes, and whole transcriptome (RNASeq), together with in vitro high‐throughput drug screening, and patient‐derived xenograft (PDX) drug efficacy testing, followed by assessment of and recommendations made by a national Multidisciplinary Tumour Board.

**Results**: 114 patients have been recruited to TARGET and PRISM. 34% of patients had CNS tumours; 23% sarcoma, 11% haematological cancers, 9% neuroblastoma and 23% other rare tumour type. In 91 curated cases, the complete molecular platform identified reportable somatic SNVs, fusions, and CNVs in more than 50% of patients. This included germline cancer predisposition variants, fusion oncogenes and other variants that indicated specific targeted treatments. We have developed a mature analytical pipeline to interrogate and cross‐validate the full range of variants and mutational signatures identified in paediatric cancers. The highest yield of reportable variants is derived from the combination of WGS and RNAseq. Twenty‐two xenografts models have been established on diverse tumour types. In vitro screening of 31samples has been possible. Overall, 57% of patients received a personalised medicine recommendation.

**Conclusions**: We have established a mature analytical pipeline to interrogate the full range of variants and mutational signatures identified in paediatric cancer. The ZCC PRISM study is combines comprehensive genomic analysis of tumours with unbiased in vitro and in vivo drug screening to generate treatment recommendations for children and adolescents with high‐risk cancer.

### PO-498. Personalized Medicine: Learning to Walk {#pbc27455-sec-14720}

[P. Gargallo]{.ul} ^1^, P. Berlanga^2^, I. Calabria^3^, M.J. Aparisi^3^, L. Pedrola^3^, M. Martínez^3^, J. Panadero^3^, Y. Yáñez^4^, M. Llavador^5^, Á. Zúñiga^6^, P. Escobar^7^, S. Dolz^8^, J. Font de Mora^8^, J. Cervera^6^, V. Castel^9^, A. Cañete^9^

*^1^Pediatrician, Oncology, Valencia, Spain; ^2^Gustave Roussy, oncology, Paris, France; ^3^La Fe, genomics, Valencia, Spain; ^4^La Fe, pediatric oncology, Valencia, Spain; ^5^La Fe, pathology, Valencia, Spain; ^6^La Fe, genetics, Valencia, Spain; ^7^La Fe, pharmacy, Valencia, Spain; ^8^La Fe, oncology group, valencia, Spain; ^9^La Fe, oncology, Valencia, Spain*

**Background/Objectives**: The study of pediatric solid tumors in relapse/progression through a precision medicine multidisciplinary board.

**Design/Methods**: Tumor samples from 70 patients were prospectively collected and studied using the Cancer Hotspot Panel (for embedded paraffin tissues; 40% of patients) and Cancer Comprehensive Panel (for fresh samples; 60% of cases).

RNAseq and CGH Array were also performed in 4% and 11% of patients, respectively. Genomic, immunohistochemical and clinical data were analyzed in the multidisciplinary personalized medicine committee for therapeutical recommendations.

**Results**: The most frequent tumor studied was Neuroblastoma (30%). Pathological mutations in cancer related genes were detected in 25% of cases. TP53 mutations were detected in 30% of cases. Pathological ALK mutations were found in 17% of patients, and 11% of patients presented ATM mutations. The cancer related pathways more frequently affected were PI3K‐AKT‐mTOR (11% of cases) and MAPK pathway (11%). Individualized therapeutic recommendations were proposed for 15% of cases. In 10% of cases, clinical recommendations were based on inmunohistochimical studies exclusively.

**Conclusions**: ‐It is possible to transfer genomic results from laboratory to clinical practice in pediatric oncology. ‐ Up to 25% of patients can benefit from new therapeutic strategies. Nevertheless, It is necessary to facilitate the access to new drugs in the pediatric age. ‐ CGH array can provide complementary information of interest.

### PO-499. Building Pediatric Cancer Data Commons {#pbc27455-sec-14730}

S. Volchenboum^1^, [D. Hawkins]{.ul} ^2^, L. Frazier^3^, M. Krailo^4^, Y. Xie^5^, B. Furner^6^, B. Ci^5^, S. Cohn^1^

*^1^University of Chicago, Pediatrics, Chicago, USA; ^2^University of Washington, Hematology Ongology, Seattle, USA; ^3^Dana‐Farber Cancer Institut, Pediatric oncology, Boston, USA; ^4^University Southern California, Preventive medicine, Monrovia, USA; ^5^UT Southwestern, Department of Clinical Science, Dallas, USA; ^6^University of Chicago, Center for Research Informatics, Chicago, USA*

**Background/Objectives**: To increase the number of children with cancer available for study, we formed international consortia for neuroblastoma, pediatric rhabdomyosarcoma, and germ cell tumors and worked to pool large amounts of patient data. We developed consensus standardized data dictionaries to facilitate data harmonization and prospective collection of interoperable data. We are now expanding these pediatric cancer data commons by adding more data, adding additional disease types, and linking to additional external data sources.

**Design/Methods**: Working with disease consortia, we created consensus data dictionaries based on standardized reference data in databases such as the NIH\'s EVS. Several international meetings and accompanying planning phone calls were required for each consortia to achieve consensus over data elements. A formal consensus data dictionary has been established for each disease group to cover a small (20‐30) base set of data elements. Data from prior trials have been transformed and for instantiation into a cohort discovery tool.

**Results**: The publicly‐available cohort discovery tools for germ cell tumors, neuroblastoma, and pediatric rhabdomyosarcoma are designed to allow anyone to determine cohort counts for sets of patients based on the baseline data elements. Furthermore, the patient cohort can be linked to external data sources, such as frozen tissue in the biopathology center as well as analyzed data in the TARGET database. An online system for requesting neuroblastoma data is in place to facilitate the review of projects and data fulfillment. Additional visualization and data manipulation tools are being developed.

**Conclusions**: We have built the world\'s first commons for neuroblastoma, rhabdomyosarcoma, and germ cell tumors, allowing. searching over common data elements and connections to external data sources. Furthermore, the clinical data in these commons can be linked via unique identifiers to available genomic data. Finally, the standardized data dictionaries developed through these efforts will inform the generation of future case report forms for data collection.

### PO-500. Germline DICER1 Mutation and Sarcoma of the Ovary {#pbc27455-sec-14740}

[R. Kebudi]{.ul} ^1^, K.A.P. Schultz^2^, R. Shah^3^, A.K. Harris^2^, M. Wilhelm^2^, B. Bilgic^4^, M. Warren^5^, E. Darendeliler^6^, D.A. Hill^7^, C.A. Arndt^8^

*^1^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^2^International Pleuropulmonary Blastoma/DICER1 Registry and Ovarian & Testicular Stromal Tumor Registies‐ Children\'s Hospitals and Clinics of Minnesota, Cancer and Blood Disorders Program, Minneapolis, USA; ^3^Children\'s Center for Cancer and Blood Diseases Children\'s Hospital of Los Angeles‐ Keck School of Medicine‐ University of Southern California, Division of Hematology‐ Oncology and Blood and Marrow Transplantation, Los Angeles, USA; ^4^Istanbul University‐ Istanbul School of Medicine, Pathology, Istanbul, Turkey; ^5^Children\'s Hospital of Los Angeles, Department of Pathology and Laboratory Medicine‐, Los Angeles, USA; ^6^Istanbul University Oncology Institute, Radiation Oncology, Istanbul, Turkey; ^7^Center for Cancer and Immunology Research Children\'s National Medical Center, Department of Pathology, Washington DC, USA; ^8^Mayo Clinic, Division of Pediatric Hematology/Oncology‐ Department of Pediatric and Adolescent Medicine, Rochester‐ Minnesota, USA*

**Background/Objectives**: Pathogenic germline DICER1 variants cause a hereditary cancer predisposition syndrome that increases risk of various benign and malignant conditions. Rarely, sarcomas of the genitourinary tract have been associated with DICER1. Herein, we present two children with germline DICER1‐associated ovarian sarcoma.

**Design/Methods**: Retrospective review and next generation sequencing (NGS).

**Results**: Patient \#1: A 4‐years old female presented with abdominal pain. Imaging identified a left adnexal mass complicated by ovarian torsion and preoperative rupture. She underwent a left oophorectomy and a second resection for residual abdominal tumor. Metastatic evaluation was negative. FIGO stage IIIC. Pathology revealed ovarian sarcoma with cartilaginous and rhabdomyoblastic differentiation. She received vincristine, actinomycin D, cyclophosphamide for a year and whole abdomen proton beam radiotherapy to 50.99Gy. NGS identified a monoallelic somatic DICER1 (D1709V) mutation. A germline loss of function DICER1 mutation (c.1870C\>T; p.Arg624Ter) was identified. Her father and sister were found to have the mutation as well.

Patient \#2: A 5‐years old female presented with acute onset abdominal pain. Imaging demonstrated a right adnexal mass complicated by ovarian torsion. She underwent a right salpingo‐oophorectomy. Intraoperative staging was FIGO stage IC2. Metastatic evaluation was negative. Pathology revealed a high‐grade sarcoma with heterologous mesenchymal differentiation with undifferentiated small round blue cells, poorly‐differentiated spindle cells, large highly‐pleomorphic cells, rhabdomyosarcoma‐like and chondrosarcoma‐like differentiation. She received 6‐cycles of ifosfamide in combination with 5‐cycles of doxorubicin. NGS demonstrated a biallelic somatic mutation: a frameshift mutation in DICER1(p.Ser742Thrfs\*16) and a missense mutation in DICER1(p.Gly1809Arg). Targeted mutation analysis confirmed a pathogenic germline variant in the DICER1 gene (c.2223_2230del (p.Ser742Thrfs\*16)). Parental testing is in progress. Both patients are in remission following completion of therapy.

**Conclusions**: Ovarian sarcoma may be associated with germline DICER1 mutation. Identification of a pathogenic DICER1 mutation has important surveillance implications for the individual and their family.

### PO-501. The Investigation of RB1 Promoter Methylation in Patients with Retinoblastoma {#pbc27455-sec-14750}

B. Çelik^1^, Ö. Şükrüoğlu^1^, Ş.B. Tunçer^1^, D. Akdeniz^1^, S. Kılıç^1^, S. Büyükkapı Bay^2^, S. Tuncer^3^, [R. Kebudi]{.ul} ^2^, H. Yazıcı^1^

*^1^Istanbul University‐ Oncology Institute, Department of cancer genetics, Istanbul, Turkey; ^2^Istanbul University Cerrahpasa Medical Faculty and Oncology Institute, Pediatric Hematology and Oncology, Istanbul, Turkey; ^3^Istanbul University Istanbul Medical Faculty, Department of Ophtalmology, Istanbul, Turkey*

**Background/Objectives**: Retinoblastoma (RB) is the most common malignant intraocular tumor of childhood. Retinoblastoma is known to arise due to two genetic events involving both alleles of RB1 and occurs in two forms, the hereditary and non‐hereditary. Mutation of both alleles of RB1 is required for tumor initiation. The RB1 gene shows a high degree of mutational heterogeneity in retinoblastoma. It is crucial to identify and distinguish RB1 gene mutations to predict the accurate risk in siblings and offsprings having a family history for retinoblastoma or other cancer. The RB1 gene may also be inactivated by the promoter methylation. This study aims to investigate the role of promoter methylation in retinoblastoma oncogenesis.

**Design/Methods**: Sixty patients with retinoblastoma having a family history for retinoblastoma or other cancer, who did not have RB1 mutation including large deletions and insertions and small indels mutations, and fifty two healthy controls who were matched for age and gender were recruited in this study. Methylation status was determined by Zymo Research The One Step qMethyl Kit using an Applied Biosystems 7500 Real Time PCR system. Mann Whitney U test was used to compare methylation levels between the group of patients and healthy controls.

**Results**: The mean levels of methylation in 60 patients with retinoblastoma and 52 healthy controls were 35.3% and 33.8%, respectively. There was no significant difference detected between two groups according to methylation status statistically (p = 0.882). The promoter methylation levels in RB1 gene was similar in both the group of patients and healthy controls.

**Conclusions**: The results suggest that promoter methylation of RB1 gene in patients who do not have the RB1 gene mutation may not be involved in the etiology of retinoblastoma and that there should be other genes involved in retinoblastoma oncogenesis.

This study was funded by the Istanbul University Research Fund (Grant TSA‐2017‐23070).

### PO-502. The Collagen Gel Droplet‐Embedded Culture Drug Sensitivity Test in Bone and Soft Tissue Tumors {#pbc27455-sec-14760}

[D. Keino]{.ul} ^1,2^, T. Yokosuka^1^, W. Nakamura^1^, N. Miyagawa^1^, F. Iwasaki^1^, S. Hamanoue^1^, M. Shiomi^1^, S. Goto^1^, N. Kitagawa^1^, M. Tanaka^1^, Y. Tanaka^1^, H. Goto^1^

*^1^Kanagawa Children\'s Medical Center, Childhood Cancer Center, Yokohama, Japan; ^2^St.marianna University school of Medicine Hospital, Department of Pediatrics, Kawasaki, Japan*

**Background/Objectives**: Multimodal therapeutic approach including chemotherapy is necessary for pediatric bone and soft tissue tumors. However, because of a rarity of the disease, it is difficult to develop new chemotherapy for patients who failed to respond to the standard chemotherapy. To exploit new therapies, the preclinical evaluation of sorafenib, everolimus, and eribulin was performed by the collagen‐gel droplet embedded culture drug sensitivity test (CD‐DST).

**Design/Methods**: In 12 patients with bone and soft tissue tumors, primary tumor, or lung metastatic tumors were surgically resected in Kanagawa Children\'s Medical Center between 2015 and 2017. The tumor tissues were tested for the sensitivity to the drugs by the CD‐DST. The tested drug concentrations were decided based on the clinically achievable serum concentration. Drug exposure time was 144h for all tested drugs. The study was approved by the institutional ethics board and the guardians' informed consent were obtained.

**Results**: The CD‐DST was successfully done in 8 out of 12 tumors. Four of 8 samples were OS, and the other was fibrosarcoma, malignant myoepithelioma, malignant rhabdoid tumor, or malignant perivascular epithelioid cell tumor (PEComa), respectively. The 50% growth inhibition was achieved by sorafenib in 6 of 8 samples at 2.5‐4.5 ug/ml, in 5 of 6 samples by everolimus at 10‐50 ng/ml, and in 6 of 6 samples by eribulin at 0.1‐10 ug/ml, respectively. Considering the results of CD‐DST, sorafenib was administered in 2 patients with OS and malignant myoepithelioma, and partial response or stable disease was obtained.

**Conclusions**: Sorafenib, everolimus and eribulin showed good activities in bone and soft tissue tumors, and sorafenib also showed clinical efficacies. The CD‐DST is a useful tool for preclinical drug evaluation which is necessary to develop the background of the clinical trials, especially in the recurrent or rare tumors.

### PO-503. Effect of ABCC3 Gene Polymorphism and Survival of Pediatric Rhabdomyosarcoma {#pbc27455-sec-14770}

[R. Labib]{.ul} ^1^, E. ElNadi^2^, D. Yassin^3^

*^1^Children\'s Cancer Hospital‐57357, Research, Cairo, Egypt; ^2^Children\'s Cancer Hospital‐57357, Pediatric Oncology, Cairo, Egypt; ^3^Children\'s Cancer Hospital‐57357, Clinical Pathology, Cairo, Egypt*

**Background/Objectives**: Rhabdomyosarcoma (RMS) is a small round blue cell tumor; representing 7% of all childhood malignancies. The standard treatment of RMS is composed of cyclophosphamide, actinomycin, and vincristine (VAC). Different drug transporters (e.g ABCC3 "MRP3") and drug metabolizing enzymes play a role in drug activation, metabolism and developing multi‐resistant of chemotherapeutic agent which can lead to failure of treatment.

**Design/Methods**: In a cohort of 75 pediatric RMS patients treated with cyclophosphamide based first line treatment, we genotyped CYP2B6 and ABCC3 by restriction fragment polymorphism (RFLP) and taqman pre‐designed assays. We then analyzed the association between those genotypes, response to treatment, and survival outcome of RMS.

**Results**: The frequencies of CYP2B6 rs2279343, rs3745274, and rs3211371 were 0.63, 0.45, and 0.05, respectively. The frequencies of ABCC3 rs4148412, rs4793665, and rs733392 were successfully detected. Carriers of at least one mutant allele CYP2B6 rs2279343 and ABCC3 had significantly longer event‐free survival.

**Conclusions**: Our results demonstrated that CYP2B6 and ABCC3 genotypes may predict EFS in pediatric RMS patients and be used to better stratify risk prior to treatment.

### PO-504. Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors {#pbc27455-sec-14780}

[J.W. Lee]{.ul} ^1^, B. Lee^2^, J.H. Shim^2^, J.G. Joung^2^, H.H. Koo^1^, K.W. Sung^1^, W.Y. Park^2^, H. Kook^3^, H.L. Jung^4^

*^1^Samsung Medical Center‐ Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, Republic of Korea; ^2^Samsung Medical Center, Samsung Genome Institute, Seoul, Republic of Korea; ^3^Chonnam National University College of Medicine, Department of Pediatrics, Gwangju, Republic of Korea; ^4^Kangbuk Samsung Hospital‐ Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: Relapsed/refractory pediatric cancers show poor prognosis; however, their genomic patterns remain unknown. To investigate the genetic mechanisms of tumor relapse and therapy resistance, we characterized genomic alterations in diagnostic and relapsed lesions in patients with relapsed/refractory pediatric solid tumors.

**Design/Methods**: Relapsed/refractory pediatric cancer patients who had both samples at diagnosis and relapse were included in this study. A targeted sequencing panel covering the exons of 381 cancer genes was used to characterize the paired diagnostic and relapsed samples.

**Results**: Nineteen patients with various diagnoses, including 5 rhabdomyosarcoma and 5 neuroblastoma were enrolled in this study. The mean coverage for all samples was 930.6× (SD = 213.8). Among the 381 genes, 173 single nucleotide variations (SNVs)/insertion‐deletions (InDels), 100 copy number alterations, and one structural variation were detected. Seventy‐two point six percent of SNVs in primary tumors were also found in recurrent lesions, and 27.2% of SNVs in recurrent tumors had newly occurred. Among SNVs/InDels detected only in recurrent lesions, 71% had a low variant allele fraction (VAF; \< 10%). Patients were classified into three categories based on the mutation patterns after cancer treatment. Patients whose relapsed tumor had fewer mutations than the diagnostic sample had longer progression‐free survival and achieved complete remission after relapse. Contrastingly, patients whose genetic profile only had concordant mutations without any change had the worst outcome.

**Conclusions**: We characterized genomic changes in recurrent pediatric solid tumors. These findings could help to understand the biology of relapsed childhood cancer and to develop personalized treatment based on their genetic profile.

### PO-505. Acute Leukaemia and Cancers Therapy Relevant Drug‐Drug Interaction (DDI) due to the Pharmacokinetic Factors {#pbc27455-sec-14790}

[F. Li]{.ul} ^1^, M. Ji^1^, X. Yang^1^, R. Wei^1^, Z. Liu^1^, Y. Zhang^1^, L. Zhang^1^

*^1^Qilu Children\'s Hospital of Shandong University, Department of Hematology and Oncology, JiNan, China*

**Background/Objectives**: Irinotecan and trametinib are two drugs utilized to treat acute leukaemia and other cancers in chlidren. This study aims to evaluate the drug‐drug interaction (DDI) between irinotecan and trametinib.

**Design/Methods**: To Determine the inhibitory effect of trametinib on the activity of UDP‐glucuronosyltransferase (UGT) 1A1. The inhibition type and kinetics were determined for the inhibition of trametinib towards UGT1A1.In vitro‐in vivo extrapolation (IVIVE) was performed using the following equation:AUC~i~/AUC = 1 + \[I\]~*in\ vivo*~/K~i.~

**Results**: (UGT)1A1 plays a key role in the metabolic elimination of irinotecan. 100 uM of trametinib inhibited more than 90% activity of UGT1A1. Furthermore, concentration‐dependent inhibition of trametinib towards UGT1A1 was demonstrated. Lineweaver‐Burk plot was drawn to determine the inhibition kinetic type of trametinib towards UGT1A1.The intersection point was located in the verticle axis, showing the competitive inhibition of trametinib towards UGT1A1. The second plot was furtherly drawn using the slopes of the lines in the Lineweaver‐Burk plot versus the concentrations of trametinib, and the fitting equation was y=138.2x+207.8. Using this equation, the inhibition kinetic parameter (Ki) was 1.5 uM. Based on in vitro‐in vivo extrapolation (IVIVE) equation and evaluation standard (0.1 \< \[I\]/Ki), the threshold value for inducing in vivo inhibition was calculated to be 0.15 uM.

**Conclusions**: This study demonstrated the inhibition of trametinib on the activity of UGT1A1, indicating potential trametinib‐irinotecan interaction.

### PO-506. CD8 Positive T Cell Number as Indicator of Prognosis in Children with Relapsed or Primarily Refractory Cancer {#pbc27455-sec-14800}

[V. Odone‐Filho]{.ul} ^1^, L.M. Cristofani^2^, R.A. Teixeira^2^, T.M. Gimenez^2^, A.R. Santos^2^, F.A. Marchi^3^, R.L. Lapa^4^, A.C. Krepischi^5^, E.M. Novak^6^, M. Brumatti^1^, P.L. Pereira^1^, A.M. Azambuja^1^, U. Doria‐Filho^2^, A.L. Cornachionni^2^, C.S. Vince^1^, N.H. Neves^1^

*^1^Sao Paulo University Medical School FMUSP‐ Sao Paulo‐ SP‐ Brazil and Albert Einstein Hospital HIAE‐ São Paulo‐ SP‐ Brazil, Pediatric Hematology‐Oncology Department at FMUSP ITACI and Hematology Division at HIAE, Sao Paulo, Brazil; ^2^Sao Paulo University Medical School FMUSP‐ Sao Paulo‐ SP‐ Brazil, Pediatric Hematology‐Oncology Department at FMUSP ITACI, Sao Paulo, Brazil; ^3^A.C.Camargo Cancer Center‐ São Paulo‐ SP‐ Brazil., Laboratory, São Paulo, Brazil; ^4^Faculty of Medicine‐ Sao Paulo State University ‐ UNESP‐ Botucatu‐ SP‐ Brazil., Laboratory, Botucatu, Brazil; ^5^Institute of Biosciences‐ University of São Paulo‐ São Paulo‐ SP‐ Brazil., Department of Genetics and Evolutionary Biology, São Paulo, Brazil; ^6^Sao Paulo University Medical School FMUSP‐ Sao Paulo‐ SP‐ Brazil and Fundação Pró‐Sangue Hemocentro de São Paulo‐ São Paulo‐ SP‐ Brazil, Division of Molecular Genetics, Sao Paulo, Brazil*

**Background/Objectives**: T‐cells play a role in cancer control, being also associated to responses in patients under chemotherapy and/or adoptive immunotherapy. The role of CD8+ T‐cells is particularly important due to their well‐known cytotoxic effects upon tumor cells. Primarily refractory/recurrent cancer patients had their CD4^+^ and CD8^+^ T‐cell absolute numbers (CD4 and CD8) as well as the CD4/CD8 ratio (CD4/8) retrospectively followed throughout their management. Periods of unresponsiveness (PU) were compared to periods of non‐progressive disease or complete remission (NPD‐CR) according to these indicators, to identify possible relationships.

**Design/Methods**: Twenty‐five children were enrolled: neuroblastoma‐5; acute leukemia, lymphocytic‐4 and myelocytic‐3; Hodgkin disease‐3; medulloblastomas‐2; peripheral neuroectodermal tumors‐3; diffuse pontine glioma‐1; rhabdomyosarcoma‐1; Wilms tumor‐1; non‐Hodgkin lymphoma‐1; post‐transplant lymphoproliferative disease‐1. All were either unresponsive following diagnosis (4) and/or had at least one documented episode of recurrence/progression (1‐7 episodes). 15/25(60%) are long‐term survivors, 12/15(80%) without any evidence of active disease, as of 30 March/2018. All had sequential counts of CD4, CD8 and CD4/8, measured by flow cytometry, done throughout all phases of their treatment. Comparisons were done between 1) CD4 and CD8 in PU and: 2) in NPD‐CR; 3) PU versus NPD‐CR CD4; 4) PU versus NPD‐CR CD8; 5) PU versus NPD‐CR CD4/8. Confidence interval (CI) of 95%.

**Results**: Individual analysis was obtained in 272 instances, 92 in PU and 180 in NPD‐CR. Significant differences were seen between CD4 and CD8 (median) in PU (174 versus 226.5, p:0,0015) and particularly in NPD‐CR (447 versus 717, p\<0.0001). Specific comparison between CD8 (median) in PU and NPD‐CR also strongly favors this last group (p\<0.0001). No significant difference was seen regarding CD4/8 (median) (0.76 versus 0.68, p:0.0907), despite CD8 predominance in both groups.

**Conclusions**: CD8 cell number was correlated to longer periods of absent progression of disease and sustained complete responses, what may represent the result of a more potent cytotoxic anti‐cancer activity.

### PO-507. The Validation of a Clinical Screening Instrument for Tumor Predisposition Syndromes in Children with Cancer (TUPS): A Prospective, Observational, Multi‐Center Study {#pbc27455-sec-14810}

[F. Postema]{.ul} ^1^, S. Hopman^1,2^, C. Aalfs^3^, J. Anninga^4^, L. Berger^5^, C. de Borgie^6^, C. Dommering^7^, N. van Eijkelenburg^8^, P. Hammond^9^, M. van den Heuvel‐Eibrink^8^, M. Jongmans^2,10^, W. Kors^11^, T. Letteboer^2^, J. Loeffen^12^, L. Meijer^13^, M. Olderode‐Berends^5^, A. Wagner^14^, R. Hennekam^15^, H. Merks^1,8^

*^1^Emma Children\'s Hospital‐ Academic Medical Center, Department of Pediatric Oncology, Amsterdam, The Netherlands; ^2^University Medical Center Utrecht, Department of Genetics, Utrecht, The Netherlands; ^3^Academic Medical Center, Department of Clinical Genetics, Amsterdam, The Netherlands; ^4^Amalia Children\'s Hospital‐ Radboud University Medical Center, Department of Pediatric Oncology, Nijmegen, The Netherlands; ^5^University of Groningen‐ University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands; ^6^Academic Medical Center, Clinical Research Unit, Amsterdam, The Netherlands; ^7^VU University Medical Center, Department of Clinical Genetics, Amsterdam, The Netherlands; ^8^Princess Máxima Center for Pediatric oncology, Department of Pediatric Oncology, Utrecht, The Netherlands; ^9^University of Oxford, Nuffield Department of Obstetrics and Gynaecology, Oxford, United Kingdom; ^10^Radboud University Medical Center, Department of Human Genetics, Nijmegen, The Netherlands; ^11^VU University Medical Center, Department of Pediatric Oncology, Amsterdam, The Netherlands; ^12^Sophia Children\'s Hospital‐ Erasmus Medical Center, Department of Pediatric Oncology, Rotterdam, The Netherlands; ^13^University of Groningen‐ University Medical Center Groningen, Department of Pediatric Oncology, Groningen, The Netherlands; ^14^Erasmus Medical Center, Department of Clinical Genetics, Rotterdam, The Netherlands; ^15^Academic Medical Center, Department of Pediatrics, Amsterdam, The Netherlands*

**Background/Objectives**: Up to 10% of the children with cancer has a tumor predisposition syndrome (TPS). Identification of a TPS in a child with cancer is of clinical relevance. Half of the TPSs are not recognized prior to or during the treatment of their cancer. To increase effectivity and decrease costs we developed a screening instrument, ensuring evaluation for a TPS in all children with cancer. Only children more likely of having a TPS will be referred to the clinical geneticist for full genetic counseling.

**Design/Methods**: The TuPS study is a prospective, observational, multi‐center study including all children in the Netherlands newly diagnosed with cancer. The screening instrument consists of a score form, 2D and 3D pictures and a digital assessment of these by two independent clinical geneticists. If a TPS is suspected by at least one of the clinical geneticists (positive assessment), the patient will be invited for full genetic consultation. The primary outcome measurement is the sensitivity of the instrument.

**Results**: Interim analysis of the first 150 patients show a positive assessment rate of 62% (93/150) (27% single positive, 36% double positive). The reason for a positive assessment was mainly based on the type of cancer, family history and 2D pictures, although the pictures are seemingly not a decisive factor. Fourteen children were referred as part of a negative control group. Seventy‐five patients have been evaluated by full genetic consultation thus far. Further genetic testing has been carried out in 38 of these patients. In two patients a TPS was diagnosed. In two other patients a germline mutation of non‐conclusive significance has been found.

**Conclusions**: Preliminary results indicate the screening instrument to be an easy‐to‐use tool in the care of children with cancer, ensuring evaluation of a TPS. Numbers are still too small to determine the sensitivity of the instrument.

### PO-508. Non‐Syndromic Presentations of Pediatric Cancer Syndromes {#pbc27455-sec-14820}

[B. Rivera]{.ul} ^1^, S. Fahiminiya^2^, A.S. Chong^3^, S. Rabinowicz^4^, A.K. Watters^5^, M. Levental^6^, M. Khanna^7^, D. Strother^8^, J. Priest^9^, S. Albrecht^10^, W. Foulkes^11^

*^1^McGill University, Oncology, Montreal, Canada; ^2^McGill University Health Centre, Cancer Research Program, Montreal, Canada; ^3^McGill University, Anatomy, Montreal, Canada; ^4^Imperial College London, Medicine, Londres, United Kingdom; ^5^McGill University Health Centre, Pathology, Montreal, Canada; ^6^Jewish General Hospital, Radiology, Montreal, Canada; ^7^Jewish General Hospital, Dermatology Oncology, Montreal, Canada; ^8^University of Calgary, Department of Oncology, Calgary, Canada; ^9^Minnessota, Minnessota, Minneapolis, USA; ^10^McGill University Health Centre, Pediatric Pathology, Montreal, Canada; ^11^McGill University, Oncology/ Human Genetics/ Medical Genetics, Montreal, Canada*

**Background/Objectives**: Key features of childhood cancer susceptibility syndromes are co‐occurrence of several tumors or congenital abnormalities accompanying tumor development. Recent advances indicate that an important proportion of childhood malignancies are due to germline or mosaic mutations. We used high sensitivity sequencing techniques to resolve 2 diagnosis conundrums.

**Design/Methods**: WES and digital droplet PCR (ddPCR) were used to study patients suspected to have a cancer predisposition condition and in which no germline mutations were previously found in candidate genes.

**Results**: 1) The co‐occurrence of a pleuropulmonary blastoma (PPB) and a choroid plexus papilloma (CPP) in a child was investigated. Fluidigm array sequencing and MLPA ruled out the presence of germline DICER1 mutations. Two somatic hits were identified in the PPB sample and a ddPCR assay ruled out DICER1 mosaicism in the CPP. Exome sequencing performed in the blood of the child focused on 114 cancer susceptibility genes identified no likely pathogenic mutation as the cause of his disease; thus, the nature of the CPP remains elusive. 2) An adult male attended our clinic with a diagnosis of a mosaic form of Gorlin syndrome. He was born with an eyelid closed, an iris coloboma, presented facial asymmetry by age 5 and molecular screening in blood and normal fibroblasts from the affected area ruled out the presence of PTCH1 germline or mosaic mutations. WES performed in his blood and 5 tumors revealed the presence of a SMO mutation in all five tumors and absent in the blood. ddPCR in several normal and tumor tissues confirmed the mosaic status of the mutation, suggesting a milder course of the pediatric condition known as Curry Jones syndrome as a more accurate diagnosis for his condition.

**Conclusions**: Multiple tumors do not always denote an underlying cancer susceptibility condition; in‐depth molecular studies are required in order to adjust clinical management accordingly.

### PO-509. The Fanconi Anemia DNA Damage Repair Pathway in Childhood Cancer Predisposition Syndromes {#pbc27455-sec-14830}

[A. Russo]{.ul} ^1^, M.A. Neu^1^, F. Alt^1^, N. Lehmann^1^, B. Kron^1^, A. Wingerter^1^, K. El Malki^1^, L. Roth^1^, N. Backes^1^, S. Stössel^1^, H. Otto^1^, N. Henninger^1^, C. Paret^1^, J. Faber^1^

*^1^University Medical Center Mainz, Department of Pediatric Hematology/Oncology/Hemostaseology, Mainz, Germany*

**Background/Objectives**: Fanconi anemia (FA) is the most common form of inherited bone marrow failure, developmental disorders and predisposition to leukemia and solid tumors. FA is caused by mutations in genes regulating DNA repair.

Fanconi anemia complementation group D1(*FANCD1*), better known as *BRCA2*, is a well‐described tumor suppressor. Mono‐allelic mutation of this gene is associated with adult onset cancer risks, particularly breast and ovarian cancer. In childhood cancer predisposition syndromes, *FANCD1* FA is caused by bi‐allelic inactivation of the *FANCD1/BRCA2* gene. Instead of bone marrow failure, *FANCD1* patients suffer from highly aggressive embryonal tumors in early childhood, generally medulloblastoma and nephroblastoma.

**Design/Methods**: We identified 2 families with *FANCD1/BRCA2* gene affection.

Family 1: A consanguineous family included 6 children. 3 of whom developed nephroblastoma at the median age of 24 months. One child died due to disease immediately after diagnosis, one from secondary glioblastoma at the age of 11 years. Only one affected brother is still alive, following multi‐organ failure due to severe toxicity during cancer treatment for nephroblastoma. All affected children revealed short stature, microcephaly and axillary freckling.

Family 2: Grandmother died of metastatic breast cancer at the age of 34 years. Her daughter suffered from medulloblastoma at the age of 9.5 years. She is still alive and mother of one son, who was diagnosed with nephroblastoma at the age of 25 months.

**Results**: Family1: Molecular analysis proved compound heterozygosity of the mutated FANCD1/BRCA2 alleles which appear to be associated with brain tumors respectively nephroblastoma.

Family2: Molecular analysis revealed the BRCA2 rs144848 polymorphism which has been associated with several cancer types, including breast and ovarian cancer.

**Conclusions**: The identification of BRCA2/FANCD1 gene affection is of particular interest in childhood cancer predisposition syndromes and their treatment options. Due to mutations in both BRCA2 alleles, overt treatment toxicity should be considered when choosing suitable therapies, e.g. PARP inhibitors.

### PO-510. High Prevalence of SMARCB1 Germline Abnormality in Rhabdoid Tumors {#pbc27455-sec-14840}

[R. Shirai]{.ul} ^1,2^, T. Osumi^1,3^, M. Uchiyama^1^, S. Tsujimoto^1,2^, M. Yoshida^1,2^, T. Uchiyama^4^, D. Tomizawa^3^, K. Watanabe^5^, Y. Shioda^3^, C. Kiyotani^3^, K. Terashima^3^, T. Yoshioka^6^, S. Ogawa^7^, K. Matsumoto^3^, M. Kato^1,3^

*^1^National Center for Child Health and Development, Pediatric Hematology and Oncology Research, Tokyo, Japan; ^2^Yokohama City University Graduate School of Medicine, Pediatrics, Kanagawa, Japan; ^3^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^4^National Research Institute for Child Health and Development, Human Genetics, Tokyo, Japan; ^5^Shizuoka Children\'s Hospital, Hematology and Oncology, Shizuoka, Japan; ^6^National Center for Child Health and Development, Pathology, Tokyo, Japan; ^7^Graduate School of Medicine‐ Kyoto University, Pathology and Tumor Biology, Kyoto, Japan*

**Background/Objectives**: Atypical teratoid/rhabdoid tumor (AT/RT) and malignant rhabdoid tumor (MRT) have common genomic feature, loss‐of‐function mutations and/or deletions in bi‐allelic *SMARCB1* gene on chromosome 22q11.2. Previous studies showed that a certain fraction of the "rhabdoid tumors" harbored germline mutation of *SMARCB1*, accounting for one‐third of the cases.

**Design/Methods**: Blood and tumor samples from the 14 cases of sporadic rhabdoid tumors, including CNS tumors (n =6), extracranial tumors (n = 6) and combined CNS and extracranial tumors (n=2), were analyzed to detect potential alterations in *SMARCB1* gene, using Sanger sequencing, SNP‐chip, and droplet digital PCR.

**Results**: Bi‐allelic alterations in *SMARCB1* were identified in 12 of the 14 cases. Our intensive genomic analyses demonstrated that the alterations arose from germline in eight of the 14 patients (57.1%), including 2 cases of low frequency of alteration considered as mosaicism. For the 8 cases with germline *SMARCB1* variants, CNS tumor cases (n = 4) had microdeletions (n = 3) and a missense variant (n = 1), MRT cases (n = 2) had missense variants (n = 2), and combined cases (n = 2) had a microdeletion (n = 1) and a missense variant (n = 1). Median age at diagnosis of the cases with germline variants was 5.5 months (range, 0‐154 months), while that of the cases without germline variants was 23.5 months (range, 17‐83 months).

**Conclusions**: We confirmed that alteration in *SMARCB1* is a genetic hallmark of AT/RT and MRT. Prevalence of germline alteration is higher than that of the previous reports, up to approximately half of the cases. Rhabdoid tumors associated with germline predisposition can be found at any age. Genetic counseling and surveillance of family members is essential for rhabdoid tumors.

### PO-511. Highlighting the CRISPR Cas9 Genome Editing Data for Chimeric Fusion Gene: The In Vitro BCR‐ABL1 Saga {#pbc27455-sec-14850}

[A. Singh]{.ul} ^1^, P. Bhatia^1^

*^1^Postgrauate Institute of Medical Education and Research, Paediatrics, Chandigarh, India*

**Background/Objectives**: *BCR‐ABL1* chimeric gene fusion product is the driving variation behind chronic myeloid leukaemia and certain forms of acute lymphoblastic leukaemia. The current study is an *in vitro* induction of fusion gene silencing using CRISPR‐Cas9 tool and hence has potential to translate into clinical cure. In addition, the study brings to light the issues faced in application of the above tool for *BCR‐ABL1* chimeric gene.

**Design/Methods**: CRISPR Cas9 guide RNA (sgRNA) was designed using multiple online platforms (*Deskgen, ChopChop* and *MIT‐CRISPR‐Tool*). CRISPR plasmid was generated after cloning the sgRNA into a blank CRISPR plasmid (Addgene \#79145) labelled with Green Fluorescent Protein (GFP). Sequencing was performed to verify successful cloning. The resulting plasmid was transfected into K562 cell line using lipid method. The selected cells were separated using Fluorescence‐activated cell sorting (FACS). Downstream gene quantification of phosphorylated *CRKL* (*pCRKL*) and phosphorylated *STAT5* (*pSTAT5*) was performed using flowcytometry.

**Results**: A single sgRNA with 69% activity and 78 points for on target activity (Deskgen) was selected for the p210 transcript. The same sgRNA was procured in form of oligonucleotides, T7 ligated and cloned in the CRISPR plasmid. Sequencing confirmed a successful insertion of the sgRNA at the designated site in the plasmid. Transfection showed an efficiency of 20%. pCRKL and pSTAT5 levels indicated low activity of the CRISPR plasmid.

**Conclusions**: Our results highlight that targeting chimeric fusion gene results into relatively lower on target activity due to the fact that the BCR‐ABL1 chimera at the DNA level is inconsistent in sequence as the breakpoints occur in the intronic region and hence the sgRNA can\'t bind all the chimeric forms. However, this issue can be circumvented by either designing multiple sgRNAs or targeting the chimeric gene at RNA transcript level using other modified formats of CRISPR.

### PO-512. Constitutional Mismatch Repair Deficiency Syndrome in an Indian Family ‐ Homozygous Germ Line 5' Splice Site Variation in Intron 12 of PMS2 Gene {#pbc27455-sec-14860}

[B. Thomas]{.ul} ^1^

*^1^MBBS‐ MD‐ DNB, Medical & Pediatric Oncology‐ Kims Cancer Centre, Thiruvananthapuram, India*

**Background/Objectives**: Biallelic germline *PMS2* mutations explain approximately 60% of constitutional mismatch repair deficiency (CMMRD) syndrome cases, an autosomal recessive disorder associated with a high risk of childhood cancer. CMMRD is characterized by highly penetrant childhood brain tumors, hematological malignancies, gastrointestinal cancer and other rare malignancies.

**Design/Methods**: We would like to present a case of two siblings who were affected with malignancies, but with absolutely no history of cancer in the family. The elder sibling was diagnosed and treated for glioblastoma multiforme. The younger sibling was diagnosed with acute lymphoblastic lymphoma (ALL) T‐cell. Their parents were third degree cousins. The couple was offered genetic counselling who then decided to go for genetic testing. Genetic testing was done at MedGenome Labs, Bangalore, India under MedGenome\'s Familial Genetic Disease Study project.

**Results**: Exome sequencing of the younger sibling detected a homozygous 5' splice site variation in intron 12 of the PMS2 gene (chr7:6022454C\>A; Depth: 24x) that affects the invariant GT donor splice site (c.2174+1G\>T; ENST00000265849). The *in silico* prediction of the variant was found to be damaging by MutationTaster2, and the variant was predicted to alter the donor site splicing by the *in silico* prediction tool human gene splice finder. The observed variant has previously been reported in one case, in a study with clinical phenotype of Lynch syndrome. The *PMS2* gene is a member of the mismatch repair (MMR) genes, and mutations in this gene have been associated with hereditary nonpolyposis colorectal cancer (HNPCC). On segregation analysis, the observed variant c.2174+1G\>T in *PMS2* gene was detected in homozygous state in the elder sibling, heterozygous state in the unaffected parents. Thus, the homozygous variant segregated with the affected individuals in this family.

**Conclusions**: This is the first time this variant has been associated with CMMRD and identified in an Indian family.

### PO-513. Oncokids, A Pan‐Pediatric Cancer‐Focused Next Generation Sequencing Panel {#pbc27455-sec-14870}

[T. Triche]{.ul} ^1^, G. Raca^1^, L. Mascarenhas^2^, J. Biegel^1^, M. Hiemenz^1^

*^1^Children\'s Hospital Los Angeles/University of Southern California, Pathology, Los Angeles, USA; ^2^Children\'s Hospital Los Angeles/University of Southern California, Pediatrics, Los Angeles, USA*

**Background/Objectives**: A next‐gen sequencing panel specifically for pediatric cancer has not heretofore been created. We sought to create such a panel capable of assessing important cancer gene mutations, copy number amplification, and gene fusions in one assay that could be performed on routine, FFPE tissue, frozen sections, white blood cells, or bone marrow, using as little as 20ng of extracted RNA and DNA. The goal was to incorporate all reasonably frequent, known genetic alterations reported in pediatric cancer of any type. This includes diagnostic and prognostic features, as well as 'actionable targets', or those features for which targeted therapeutics have been identified.

**Design/Methods**: The resulting panel, now offered at Children\'s Hospital Los Angeles as an LDT ('OncoKids') from the CAP/CLIA accredited Center for Personalized Medicine, is also available from our co‐developer, Thermo Fisher, as the Oncomine Childhood Cancer Research Assay. It consists of 187 genes, including 82 hotspot genes, 44 full length coding sequence genes, 24 genes for amplification, and 78 parent fusion gene partners with over 1,400 variants potentially detected. The assay was developed on the same Ion Torrent platform as Oncomine for the NCI MATCH program, using the same AmpliSeq target amplification technology.

**Results**: In the first six months of use on over 200 CHLA patients, 60% had at least one variant of strong clinical significance. In addition, 15% of patients had potential germline mutations, and half of those tested had inherited pathogenic variants. In at least two cases, novel gene fusions lead to clinically unsuspected targeted therapy options. In one case, an undiagnosed soft tissue sarcoma, a novel NTRK fusion led to successful use of an NTRK inhibitor, larotrectinib.

**Conclusions**: In our experience, a pediatric cancer focused gene panel has significantly improved diagnostic accuracy and led to targeted therapeutic alternatives that would otherwise have been missed.

### PO-514. Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1‐Syndrome {#pbc27455-sec-14880}

[K. Van Der Tuin]{.ul} ^1^, L. de Kock^2^, E.J. Kamping^3^, S.E. Hannema^4^, M.J.M. Pouwels^5^, M. Niedziela^6^, T. van Wezel^7^, F.J. Hes^1^, M.C. Jongmans^3,8,9^, W.D. Foulkes^2^, H. Morreau^7^

*^1^Leiden University Medical Centre, Clinical Genetics, Leiden, The Netherlands; ^2^McGill University, Human Genetics, Montreal, Canada; ^3^Radboud University Medical Centre, Clinical Genetics, Nijmegen, The Netherlands; ^4^Leiden University Medical Centre, Pediatrics, Leiden, The Netherlands; ^5^Medical Spectrum Twente, Endocrinology, Enschede, The Netherlands; ^6^Karol Jonscher\'s Clinical Hospital, Pediatrics, Poznan, Poland; ^7^Leiden University Medical Centre, Pathology, Leiden, The Netherlands; ^8^Princess Maxima Center for Pediatric Oncology, Genetics, Utrecht, The Netherlands; ^9^Utrecht University Medical Center, Medical Genetics, Utrecht, The Netherlands*

**Background/Objectives**: The DICER1 syndrome is a rare, autosomal dominant inherited disorder that predisposes to a variety of cancerous and noncancerous tumors of mostly pediatric‐ and adolescent‐onset, including differentiated thyroid carcinoma (DTC). DICER1‐related DTC has been hypothesized to arise secondary to the increased prevalence of pre‐malignant lesions, i.e. thyroid hyperplastic nodules. Limited data are available on the acquired genetic variants that induce malignant transformation.

**Design/Methods**: We performed somatic *DICER1* mutation analysis and extensive somatic DNA variant and gene fusion of ten patients with *DICER1* syndrome and young onset DTC.

**Results**: Median age at DTC diagnosis was 13.5 years and no patients developed recurrent or metastatic disease (median follow‐up 8 years). All thyroid specimens showed on re‐inspection diffuse nodular hyperplasia with at least one focus suspect for DTC, but without infiltrative growth, extra‐thyroidal extension, vascular invasion, or lymph node metastasis. Distinct somatic *DICER1* RNase IIIb domain variants were identified in most presumed‐malignant (and benign) nodules tested from each patient\'s tumor, suggestive of multiple distinct poly‐clonal tumors. Furthermore, 9 of 10 *DICER1*‐related DTC lacked well known oncogenic driver DNA variants and gene rearrangements.

**Conclusions**: On the basis of our clinical, histological and molecular data, we consider that DICER1‐related DTCs form a low‐risk subgroup. As these tumors may arise from one of many benign polyclonal nodules, right, left or total thyroidectomy may be often required, but radioiodine treatment may be unnecessary, given the patients age and their low propensity for metastases.

### PO-515. Proteomic Profiling of MYCN‐Associated Proteins in Neuroblastoma Revealed PKM2 as a Potential Therapeutic Target in MYCN Amplified Neuroblastoma {#pbc27455-sec-14890}

[Y. Wu]{.ul} ^1^, Z. Wu^1^

*^1^Xinhua Hospital, Pediatric Surgery, Shanghai, China*

**Background/Objectives**: MYCN‐amplified neuroblastoma is a subset of high‐risk neuroblastoma and is associated with advanced stages of disease, unfavorable biologic features, and a poor outcome. Even though the pathogenicity of MYCN in neuroblastoma is clear, its molecular pathogenic mechanism remains unclear and there is no effective therapeutic approach for the MYCN‐amplified neuroblastoma due to undruggable property of MYCN. To this end, we profiled the MYCN interactome by MS‐based proteomic to illustrate the potential molecular signaling pathways and the interacted proteins of MYCN, which could be alternatively developed as a drug target against MYCN.

**Design/Methods**: MYCN was amplified from 293T cells by PCR and cloned into the pBabe‐3×Flag retroviral vector. Stable expressed pBabe‐3 × Flag‐control and pBabe‐3 × Flag‐MYCN were constructs with SK‐N‐BE(2) cell line. Flag‐FMYCN or Flag and their interactors were then precipitated by anti‐Flag M2 resin and followed by subjecting to mass spectrometry analysis for protein identification.

**Results**: With this strategy, we in total identified 194 potential interacted proteins of MYCN including several known interactors, i.e. MAX, USP7, HUWE1, AURKA. In addition, plenty of the proteins were not reported as the interactors of MYCN thus far, such as PKM2, USP11. Bioinformatic analysis revealed seveal cancer relevant signaling pathways were significantly over‐represented by the MYCN interactors, including Mismatch repair, DNA replication, and also the metabolic pathways. PKM2, an glycolytic enzyme, was further validated as an bona fide interaction protein of MYCN. Targeting PKM2 with its specific small molecular inhibitor could significantly inhibt the MYCN amplified neuroblastoma cells line but not MYCN nonamplified cells.

**Conclusions**: Our data provide valuable information for the discovery of the interacting proteins of MYCN in neuroblastoma. Some of these interactors could be developed as an alternatively approach to interupt the MYCN signaling pathway, such as PKM2, which was further highlighted as a indirect target against MYCN in this study.

### PO-516. Proteomic Characterization of Human Neuroblastoma {#pbc27455-sec-14900}

[Z. Wu]{.ul} ^1^, K. Chen^1^

*^1^xinhua hospital, pediatric surgery, shanghai, China*

**Background/Objectives**: Neuroblastoma is a heterogeneous embryonic malignancy. The low frequency of genomic mutations has made genomic characterization of neuroblastoma less success as that in adult tumor. Only few genes have actually been shown to drive the disease at the molecular level thus far. Quantitative proteomics provides an althernative and more direct approach available for identifying diregulated signaling pathways and proteins that drive neuroblastoma

**Design/Methods**: Neuroblastoma tissues were evaulated by pathologist. Proteins were extracted and digested with trypsin and followed by TMT labeling to enable quantitative analysis. Resulted peptides were analyzed by nano‐LC coupled mass spectrometry. Protein identification and quantification were achieved by Maxquant.

**Results**: With this strategy, we quantitatively profiled of 95 neuroblastoma tissue samples and 5 cell lines. Primary data analysis showed that approximately 7000 proteins were identified from each sample and around 4000 proteins were identified and quantified across all the samples. Supervised analysis of the neuroblastoma, ganglioneuroblastoma and ganglioneuroma revealed different signaling pathways overrepresented in three groups. Particularly, several cancer relevant signaling pathways, i.e. Splicesome, DNA replication, Mismatch repair, were significantly enriched in neuroblastoma group but not ganglioneuroblastoma and ganglioneuroma group. Unsupervised analysis could clearly separate the samples into four subgroups either using the proteins with top standard deviations or proteins with top significant p values. Interestingly tow of the subgroups were clearly correlated to the clinical parameters, such as 2‐year overall survival rates, age at diagnosis and so on. Supervised cluster analysis of the samples with or without chemotherapy highlighted several chemotherapy related proteins, including the known drug resistant relevant proteins, i.e. TOP2A, also some unknown but potentially drug sensitivity correlated proteins, such as MCM2, CTCF and so on.

**Conclusions**: This straightforward proteome analysis provided an alternative strategy for molecular characterization of neuroblastoma and the primary findings have the potential to develop new diagnostic and therapeutic options for neuroblastoma patients.

### PO-517. Germline Genetic Predispositions to Secondary Malignant Neoplasms in Children {#pbc27455-sec-14910}

[M. Yoshida]{.ul} ^1,2^, K. Nakabayashi^3^, S.I. Tsujimoto^1,2^, T. Osumi^1,4^, R. Shirai^1,2^, T. Kawai^3^, Y. Yuza^5^, M. Takagi^6^, K. Koh^7^, H. Takahashi^8^, A. Kinoshita^9^, M. Hino^10^, A. Manabe^11^, T. Imamura^12^, A. Ohara^8^, D. Tomizawa^4^, N. Kiyokawa^1^, K. Hata^3^, M. Kato^1,4^

*^1^National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research, Tokyo, Japan; ^2^Yokohama City University, Department of Pediatrics‐ Graduate School of Medicine, Yokohama, Japan; ^3^National Research Institute for Child Health and Development, Department of Maternal‐Fetal Biology, Tokyo, Japan; ^4^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^5^Tokyo Metropolitan Children\'s Medical Center, Hematological Tumor Internal Medicine, Tokyo, Japan; ^6^Tokyo Medical Dental University, Department of Pediatrics, Tokyo, Japan; ^7^Saitama Children\'s Medical Center, Department of Hematology/Oncology, Saitama, Japan; ^8^Toho University, Pediatrics, Tokyo, Japan; ^9^St. Marianna University School of Medicine, Department of Pediatrics, Kawasaki, Japan; ^10^Chiba University Hospital, Department of Pediatrics, Chiba, Japan; ^11^St. Luke\'s International Hospital, Pediatric Department, Tokyo, Japan; ^12^Kyoto Prefectural University of Medicine, Department of Pediatrics, Kyoto, Japan*

**Background/Objectives**: Secondary malignant neoplasms (SMNs) are one of the most important late complication in the treatment of pediatric malignancies. Recently, higher prevalence of germline mutation in cancer‐predisposition genes in children who developed cancer compared to that in non‐cancer population have been reported. Here, we investigated the frequency of genetic mutation in cancer‐predisposition genes in children who suffered from SMNs after treatment of childhood cancer.

**Design/Methods**: Germline samples were obtained from 27 patients who developed SMNs after childhood cancer. Whole exome sequencing (WES) was performed to detect the germline mutations in 110 autosomal dominant (AD) cancer‐predisposition genes. Detected non‐silent coding variants were classified into five categories: pathogenic, probably pathogenic, uncertain significance, probably benign, or benign based on the common databases and *in‐silico* functional prediction algorithm calls. WES data from 105 control cohorts without known cancer history were also analyzed.

**Results**: Median ages at diagnoses of primary and secondary cancer were 4 and 11.5 years, respectively. Primary diseases were hematologic malignancy in 15 cases, whose SMNs were hematologic malignancy (n = 11) and solid tumor (n = 4), and solid tumor in 12 cases, whose SMNs were hematologic malignancy (n = 6) and solid tumor (n = 6). Mutations deemed to be pathogenic or probably pathogenic in the AD category were identified in 5 (18.5 %) of the 27 cases who developed SMNs, and the prevalence was significantly high compared to that of control cases, 3 (2.8 %) of the 105 cases (p \< 0.01). Mutated genes in AD category observed in the SMNs cohort were *TP53* (n = 2), *DICER1* (n = 1), *LZTR1* (n = 1), and *PTPN11* (n = 1).

**Conclusions**: Germline cancer predispositions affects susceptibility to SMNs in cases with pediatric cancer. Recognition of potential cancer predispositions may change treatment strategy, such as indication of radiation or alkylating agents.

Imaging {#pbc27455-sec-14920}
-------

### PO-518. Oncologic Treatment Effects in the Pediatric Spinal Cord Assessed by Diffusion Tensor Imaging {#pbc27455-sec-14930}

B. Reynolds^1^, S. By^1^, A. Witt^1^, Q. Weinberg^1^, B. Ramkorun^1^, B. Harrington^1^, J.M. Ndolo^1^, D. Pastakia^2^, A. Esbenshade^2^, J.C. Wellons^3^, S. Smith^1^, [A. Bhatia]{.ul} ^1^

*^1^Vanderbilt University Medical Center, Radiology, Nashville, USA; ^2^Vanderbilt University Medical Center, Oncology, Nashville, USA; ^3^Vanderbilt University Medical Center, Neurosurgery, Nashville, USA*

**Background/Objectives**: The purpose of the study is to evaluate treatment effects in the spinal cord (SC) in children using Diffusion Tensor Imaging (DTI). We performed and quantified DTI indices: mean diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD), and fractional anisotropy (FA) in control patients and oncologic patients.

**Design/Methods**: A retrospective analysis was performed on DTI acquired as part of clinical MRI SC protocol in the pediatric population at Vanderbilt Children\'s Hospital. Diffusion weighted images (15 directions, b=1000, slice thickness=5mm, nominal in‐plane resolution=1.0x1.0mm) were acquired on a 3T Philips Achieva in the SC. Each DTI acquisition included 14 axial slices, with placement varying between patients. Volumes of interest (VOI) were manually selected for each axial slice to include the entire cord and exclude CSF. Slices were identified as belonging to one of four SC levels: cervical (C1‐C8), upper thoracic (T1‐T6), thoracolumbar(T7‐L2), and conus. The mean DTI index was calculated across all voxels within the VOI, resulting in a single MD, AD, RD, and FA value for each level. These values were then compared between patients receiving oncologic treatment, including radiation and chemotherapy. Student\'s t‐tests were performed between patients with cancer and healthy controls for every SC level and DTI metric.

**Results**: 56 pediatric patients (PP) receiving a combination of chemotherapy and/or radiation were compared to 59 control patients (HC). There was no statistical significant difference in the DTI indices between PP and HC for cervical, thoracic, or thoracolumbar SC (p\>0.05). However, in the conus HC (n=38) had higher MD and AD than PP (n=35) (p=0.0319 and p=0.0174, respectively).

**Conclusions**: DTI of the SC provides an objective biomarker for analysis of oncologic treatment in children, primarily radiation the spine. Further studies will look to review radiation treatment based on dose to determine if there is a dose dependent change on the DTI indices.

### PO-519. Could the Unidentified Bright Objects in Children be Accepted as an Additional Diagnostic Criterion for Neurofibromatosis Type‐1? {#pbc27455-sec-14940}

[D. Ince]{.ul} ^1^, M. Erdem^1^, D. Kizmazoglu^1^, F.C. Sarioglu^2^, M.B. Ozdogar^3^, B. Baysal^1^, K. Mutafoglu^4^, A.S. Hiz^5^, H. Guleryuz^2^, N. Olgun^1^

*^1^Dokuz Eylul University Institute of Oncology, Pediatric Oncology, Izmir, Turkey; ^2^Dokuz Eylul University Faculty of Medicine, Radiodiagnostics, Izmir, Turkey; ^3^Dokuz Eylul University Faculty of Medicine, Pediatrics, Izmir, Turkey; ^4^Dokuz Eylul University Institute of Oncology, Pediatric Oncology‐ current adress: Izmir University of Economics Faculty of Medicine, Izmir, Turkey; ^5^Dokuz Eylul University Faculty of Medicine, Pediatric Neurology, Izmir, Turkey*

**Background/Objectives**: Neurofibromatosis type‐1(NF‐1) is the most common autosomal dominant neurocutaneous disorder affecting the central nervous system(CNS).The diagnostic criteria(DC) for NF‐1 were determined by Gutmann et al(JAMA.1997;278(1):51‐7).Many of these criteria can be described by clinical examination. Nowadays magnetic resonance imaging(MRI) is an available radiodiagnostic method and has revealed distinctive T2‐weighted hyperintense foci which termed as unidentified bright objects(UBOs) in NF‐1.In this study we aimed to determine the incidence of diagnostic criterion and the incidence and characteristics of UBOs in our patients with NF‐1.

**Design/Methods**: Medical reports of patients with NF‐1 were analized retrospectively. Clinical and laboratory characteristics,diagnostic criteria and CNS MRI findings of our patients with NF‐1 were evaluated retrospectively. The location,size and number of UBOs were examined. UBO locations were classified as basal ganglia,thalamus,brain stem,corpus callosum and cerebrum. We also analized patients who had been followed‐up with presumptive diagnosis of NF‐1.

**Results**: There were 131patients with definitive diagnosis of NF‐1 and 37patients with NF‐1 probability. Median age of diagnosis was 8years(2months‐17years),M/F ratio1.07.Fifty percent of patients had two DC,40%of patients had 3 DC,remaining had≥4DC. Frequencies of DC were cafe--au‐lait spots100%,neurofibromas26%,plexiform neurofibrom13%,freckling55%,optic glioma10%,Lisch nodules34%,bone lesion1%,relativity32%.Cranial MRI had performed in 104patients and MRI revealed UBOs in 77(74%)patients. Median age of UBOs detection was 10years(16months‐17years).Age groups,when UBOs were detected:≥10years49%,5--10years28%,\<5years24%.UBOs were located at basal ganglia in70%,thalamus in57%,brain stem in63%,cerebellum in68%,corpus callosum in14%,cerebrum in3%of 77patients. In 71%of patients(n:55) UBOs were detected in multiple locations. Median diameter of UBOs:9mm(3‐28mm).Malignant tumors occured in16%(n:21) of 131NF‐1 patients(15CNS tumors,6 had soft tissue sarcoma).There was 37patients who had been followed‐up with probability of NF‐1.36 of them had cafe‐au‐lait spots only,and one had 2neurofibromas. They didn\'t meet DC. However MRI revealed UBOs in7/37 patients.4/7cases were under 36months of age.

**Conclusions**: Three quarters of our patients with NF‐1 had UBOs. UBOs were detected in 19%of patients who had been followed up with presumptive diagnosis of highly probable NF‐1.We conclude that UBOs could be proposed as an additional DC for NF‐1.

### PO-520. Interventional Oncological Treatments in Pediatric Solid Tumors {#pbc27455-sec-14950}

[R. Shaikh]{.ul} ^1^

*^1^Boston Children\'s Hospital and Dana Farber Cancer Center, Interventional Radiology, Boston, USA*

**Background/Objectives**: While the use of interventional techniques to treat adult oncology patients is well established, the translation of these techniques to the pediatric realm continues to evolve. Interventional approaches provide a valuable alternative for disease treatment and symptom management. The pioneering use of interventional techniques to treat and palliate oncologic disease in pediatric patients is overdue. We evaluated pediatric patients who underwent different interventional procedures for cancer treatment or palliation at our institution.

**Design/Methods**: Pediatric patients with solid tumors who underwent interventional procedures e.g. cryoablation, radiofrequency ablation, microwave ablation, sclerotherapy and transarterial embolization at our institution were enrolled in a registry. Their medical records and imaging studies were reviewed. Patient and disease demographics, interventional procedures performed and outcomes were documented. Clinical and radiological changes were evaluated and compared pre procedure and post procedure.

**Results**: 50 pts (2‐26 yrs) underwent interventional oncological procedures for different indications. The outcome of these interventions was individually evaluated at procedural level. Clinical and radiological outcomes were measured.

**Conclusions**: Our experience demonstrates that interventional procedures are feasible and provide a safe and minimally invasive treatment and/ or palliative option in management of pediatric solid tumors and should be considered early or as adjuvant in management of such tumors.

### PO-521. Pulmonary Metastases of Neuroblastoma. CT Findings and Differential Diagnosis {#pbc27455-sec-14960}

[E. Ternovaya]{.ul} ^1^, G. Tereschenko^1^, D. Kachanov^2^, T. Shamanskaya^2^, S. Varfolomeeva^2^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Nuclear Medicine, Moscow, Russia; ^2^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Oncology, Moscow, Russia*

**Background/Objectives**: Neuroblastoma (NB) one of the most common extracranial solid tumor in children. Almost 50% of NB present with metastases at the initial diagnosis. Pulmonary metastases are rare. Presence of pulmonary metastases requires differential diagnosis with inflammatory and some nodal lung masses for correct staging.

Objective

Identification of radiological findings, typical features and incidence rate of pulmonary metastases in paediatric patients with NB. Comparison of plain radiography with computed tomography data.

**Design/Methods**: The retrospective study consisted of the 132 patients with INSS stage IV NB that were treated at Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology. The imaging data from plain radiography and computed tomography was analyzed. All patients have undergone CT with contrast enhancement performed by 16 slice Brightspeed, GE computed tomograph.

**Results**: Of the 132 patients with INSS stage IV neuroblastoma 10 (7,6%) were diagnosed with lung metastases at the diagnosis. 5/10 (50%) had bilateral distribution. 6/10 (60%) had multifocal lesions. Smallest size of the nodule was measured at 3х3mm, while the largest was measured at 29х38мм, in our cohort patients with middle and large calibre lesions predominated. All patients had different degree of pleural involvement. 5/10 (50%) showed involvement of mediastinal lymphatic nodules.1/10 (10%) had calcification in the lesion. 2/10 patients (20%) had tumor thrombosis from primary site of large vessels. 2/10 (20%) had nodal lung lesions visible on plain radiography at initial diagnosis.

**Conclusions**: Diagnostic criteria specific to the pulmonary metastases of NB were formulated ‐ foci of medium and large calibre, of rounded shape with even edges, homogeneous structure, presence of tumor thrombosis of large blood vessels, absence of calcification or "halo" sign, even enhancement after contrast agent administration, absence of cavitation during follow‐up imaging. Obtained data can help in differential diagnosis and chest CT should be considered as part of initial diagnostic process.

### PO-522. CT Findings of Air‐Leak Syndrome and Bronchiolitis Obliterans in Pediatric Patients as Late Onset Complications of Graft‐versus‐Host Disease Following Hematopoietic Stem Cell Transplantation {#pbc27455-sec-14970}

[E. Ternovaya]{.ul} ^1^, G. Tereschenko^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Nuclear Medicine, Moscow, Russia*

**Background/Objectives**: Chronic pulmonary graft‐versus‐host disease (cGVHD) remains major complication in patients surviving long‐term after allogenic stem cell transplantation (allo‐SCT). Bronchiolitis obliterans (BO) is considered as one of manifestation of cGVHD. BO can lead to another rare and potentialy lethal complication of cGVHD if not diagnosed early ‐ thoracic air‐leak syndrome (TALS). Diagnostic criteria for BO is not well defined and based on functional tests, which can be hard to obtain in pediatric patients, imaging data and lung biopsy. *Objective*: Establish diagnostic criteria specific to BO and study TALS as it\'s possible complication.

**Design/Methods**: Retrospectively surveyed 20 pediatric patients aged between 1 and 17 years old who received allo‐SCT and had radiological and clinical findings consistent with pulmonary cGVHD. Median time between onset of allo‐SCT and pulmonary complications was 213 days (interval 635‐152 days). All patients have undergone non‐enhanced chest computed tomography scan. The clinical data was reviewed and none of the patients had iatrogenic TALS that could occur due to transbronchial lung biopsy or mechanical ventilation.

**Results**: The CT findings of BO were mosaic perfusion 13/20 (65%), patchy peribronchial consolidation 3/20 (15%), air trapping 2/20 (10%),diffuse "ground glass opacities"4/20 (20%) and 3/20 (6%) demonstrated extra‐alveolar air collections. 1/3 patients with air‐leak syndrome was asymptomatic while the other 2 showed clinical symptoms. Their CT findings were consistent with pneumothorax ‐ 2/20 (10%) and combined pneumomediastinum with pneumothorax ‐ 1/20 (5%). All patients had follow up chest CT exams.

**Conclusions**: Extra‐alveolar air should be recognized as BO related complication. Clinical manifestation of spontaneous extra‐alveolar air varied from radiological findings alone in asymptomatic patients to severe respiratory insufficiency. Chest CT should be modality of choice for initial and follow up diagnostic of TALS in post transplant pediatric patients with the suspected BO or proven pulmonary cGVHD with acute onset of dyspnea and/or chest pain.

Epidemiology ‐ Pathways of Care {#pbc27455-sec-14980}
-------------------------------

### PO-523. Knowledge and Perception of Childhood Cancer Among the Population of Greater Accra Region of Ghana {#pbc27455-sec-14990}

[G. Achempim]{.ul} ^1^, J. Challinor^2^, L. Renner^3^

*^1^World Child Cancer, Programmes, Accra, Ghana; ^2^University of San Francisco, Nursing Department, San Francisco, USA; ^3^Korle Bu Teaching Hospital, Department of Child Health, Accra, Ghana*

**Background/Objectives**: With UK Aid funding, World Child Cancer implemented a 3‐year childhood cancer Twinning Programme (April 2014 ‐March 2017) in Accra and Kumasi, Ghana. One of the project objectives was to increase public/professional awareness about childhood cancer. Key project activities included rallies/awareness walks; radio and TV talk shows; posters, bumper stickers, branded T‐shirts and calendars distribution. Public education at churches and schools were conducted aside from social media campaigns. A community awareness survey was conducted to assess the programme\'s contributions towards public awareness raising in Accra.

**Design/Methods**: Assuming 28% childhood cancer awareness based on local programme activities and an anticipated increase to at least 35% (95% CI; 80% power), a total of 1380 participants was proposed based on ClinCal online Sample Calculation. Multi‐stage community sampling (simple random, purposive and systematic sampling) by oral individual interviews was performed over 6 weeks (May‐June 2017) in the Greater Accra Region. Data analysis used Microsoft Excel 2007; descriptive statistics and respondent comments were noted.

**Results**: Respondents aged 9‐65 years (mean age 29.24) were interviewed. Though 15% had no formal education, the rest had completed Basic school‐(38%), High School‐(36%), Bachelors‐(10%) or Masters‐(1%). Although 69% of the respondents had heard about childhood cancer, 27% said it is incurable, and 4% were uncertain. While only 0.3% had experienced childhood cancer, awareness information channels included radio/TV‐72.6%, churches‐7.10%, family/friends‐6.40%, social media‐6.3% and others‐7.3%. Free text comments and questions were documented and categorized by theme.

**Conclusions**: In a 2015 general cancer awareness study of 120 Accra respondents, none mentioned a childhood cancer. The relatively small, well‐managed budget (GBP15K for both sites) has had a significant impact in raising childhood cancer awareness to promote early detection, advocacy, and community support. The magnitude of effective awareness creation by this model programme supports media collaboration to raise and sustain childhood cancer awareness in LMICs.

### PO-524. Hematology Consultation Capture System -- Experience from a Pediatric Service {#pbc27455-sec-15000}

[M. Alsaleh]{.ul} ^1^, A. Ali^1^, A. AlKofide^1^, M. Ayas^1^, A. AlJefri^1^, A. AlSeraihy^1^, A. AlMusa^1^, S. Murtada^1^, M. ALMofareh^1^, A. Bin Hassan^1^, M. AlSaleh^1^, V. Mohammed^1^

*^1^King Faisal Specilaist Hospital & Research Centre, Pediatric Hematology / Oncology, Riyadh, Saudi Arabia*

**Background/Objectives**: Hematology services are known for providing prompt consultation in hematology and oncology, 7 days / week, 24 hours / day throughout the institution\'s inpatient and outpatient services; Pediatric Hematology / Oncology (PHO) department provides similar sub‐specialized consultation to pediatric patients at King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh.

**Design/Methods**: An online Consultation Capture System (CCS) using REDCap (Vanderbilt University) data management module was built to serve as a "Gateway" for Hematological Consultations for primary care physician access to the consultation services in real time to enable follow up, tracking, and endorsement processes.

**Results**: A total of 626 consultations were recorded in CCS provided to 420 patients as 33% (206) were consulted more than once during January' 2015 to March'2017. Consultative services requested from various hospital areas with more than half (53%) from inpatient wards, 18% consults from emergency room and intensive care units each and 7% from outpatient units while 4% from surgical units for pre‐procedural clearance. Majority (33%) of the consults were hematological complications related to cancer (solid tumors and neuro‐oncology,44%; leukemia,66%) therapy‐ and disease‐reoccurrence while histiocytosis observed in 3%; consults with hematological symptoms observed in 20% (anemia,11%; pancytopenia,4%; thrombocytopenia,3%; neutropenia,2%) while bleeding and thrombosis‐related consults accounted for 20%.; bone marrow transplantation‐related consults accounted for 11% and other reasons observed in 13% of the consults.

**Conclusions**: In our experience the virtual system facilitated data unique to pediatric hematology consultative service enabling us to catalogue our practice and identify "high‐demand areas" that led to consolidated disease‐specific consultative service at our center, proving to be an effective teaching for Hem‐Onc fellows. Further data analysis is underway to explore premise of national hematology e‐consultation module allowing sub‐specialized medical care accessible to every corner of the Kingdom.

### PO-525. The Paediatric Tumour Board: A Multidisciplinary Platform for Building a Comprehensive Paediatric Oncology Program {#pbc27455-sec-15010}

[J. Balagadde‐Kambugu]{.ul} ^1^, G. Fadhil^1^, J. Sekabira^1^, S. Nabadda^1^, S. Kalungi^1^, P. Wasswa^1^, I. Luutu^1^, N. Kakembo^1^, P. Kisa^1^, P. Nabbona^1^, R. Nassanga^1^, R. Namazzi^1^, B. Atwiine^1^, P. Kasirye^1^, D. Munube^1^, R. Kimutai^1^, V. Katasi^1^, L. Chirande^1^, J. Ssenyondwa^1^, J. Lubega^1^

*^1^Uganda Cancer Institute, Paediatric Oncology, Kampala, Uganda*

**Background/Objectives**: Paediatric tumour boards (PTBs) are a key element of paediatric oncology, providing a platform for timely multidisciplinary care and graduate/continuing medical education (CME). Upon establishment of a dedicated Pediatric Oncology Department at Uganda Cancer Institute (UCI) in 2012, we hypothesized that PTB was critical in this setting with socio‐economic and infrastructure limitations.

**Design/Methods**: Over the last four years we deliberately invested in creating and improving a PTB. We describe the key considerations in its creation, its evolution, and impact on the program.

**Results**: Critical specialties including radiotherapy, paediatric surgery, and pathology were hardly accessible at UCI in 2012, untimely, uncoordinated and, under‐appreciated each other. To address these challenges, we assembled a weekly, ninety‐minute, five‐member PTB with two paediatricians, a paediatric surgeon, a pathologist, and a radiation oncologist to discuss diagnostic challenges, and plans for tumour resections or radiotherapy. Initially, discussions were guided by medical notes but evolved to projection of case summaries, radiological and pathology images. With increasing caseload, the PTB was split into a solid tumour and haemato‐oncology PTB. Since establishment of the East Africa Pediatric Hematology and Oncology Fellowship at UCI in 2016, the PTB became an invaluable education platform; discussions emphasized evidence‐based approaches rather than improvised problem‐solving. Accreditation of the PTB for CME further attracted commitment from specialists. Subspecialties are now engaged in research and quality improvement initiatives through the PTB. The typical attendance at the PTB grew from five members in 2012 to fifty in 2018.

**Conclusions**: The PTB has been a key platform for the rapid growth of pediatric cancer care at UCI and, now supports the first pediatric oncology fellowship program in the region and highly organized research. We recommend that nascent pediatric cancer programs in developing countries, prioritise establishment and growth of PTBs.

### PO-526. Abdominal Malignant Tumor in Children: An Overwiew {#pbc27455-sec-15020}

[A. Borja]{.ul} ^1^, M.J. Pesantez^1^, D. Franco^2^

*^1^Hospital Axxis, Oncology and Hematology Pediatrics, Quito, Ecuador; ^2^Hospital Metropolitano, Pathology service, Quito, Ecuador*

**Background/Objectives**: Determinate the prevalence of abdominal tumors in children who were attended at Pediatrics Hospital, in Quito Ecuador, in the pathology area between 2007 to 2012.And compare results with another series outside the country.

International statistics estimated that 50% of all pediatric tumor are solid malignant tumor and 20% are located in the abdomen. In order of frequency,the tumors occurring in the abdomen are, Neuroblastoma, Nephroblastoma o Wilms Tumor, Hepatoblastoma and Germ cell tumor.

In our country approximately there are 600 news cases each year in children under 15 years old with out registration for studies.

**Design/Methods**: We performed an study retrospective, analityc and comparative of 69 pediatrics patients with diagnostic of abdominal tumor,with Histopathology samples for definitive diagnostics between January 2.007 and December 2.012 in an equatorian children hospital of Quito, capital of the country.

**Results**: Abdominal tumor were detected between 0,5 and 14 years old (main age 7,2), most frequent tumor at 3,4 years old, the gender distribution showed predominance in man with 36 cases (52,17%) versus 33 woman (47,8%), the classification by tumor type, the most common were Wilms Tumor 26 cases (37,7%), Germ cell tumor 14 (20,3%), Hepatoblastoma 10 cases(14,5%),Lymphoma 8 (8,5%), Neuroblastoma 8 (8,5%), and others as malignant Pancreas tumor and Angiosarcoma 2,4%. Most patients presented abdominal pain and palpable abdominal mass at diagnostics.

**Conclusions**: We observed that Wilms tumor was most frequent that Neuroblastoma compared with statistycs in USA,most of the abdominal malignant tumors were noted in children more than 5 years old and males are more common patients. We recommend to create a national program for statistical studies of children with cancer in my country, that will serve the health autorities to take correct decisions and developed programs in this field

### PO-527. National Review of Multidisciplinary Team Meetings in Children and Young People\'s Cancer Care in the UK {#pbc27455-sec-15030}

[S. Brown]{.ul} ^1^, R.M. Taylor^2^, R. Grundy^3^, J. Bate^1,4^

*^1^University Hospital Southampton, Paediatric Oncology, Southampton, United Kingdom; ^2^University College London Hospitals NHS Foundation Trust, Cancer Clinical Trials Unit, London, United Kingdom; ^3^University of Nottingham, Paediatric Neuro‐oncology and Cancer Biology, Nottingham, United Kingdom; ^4^University College London Hospitals NHS Foundation Trust, London Sarcoma Service, London, United Kingdom*

**Background/Objectives**: Multidisciplinary team meetings (MDTM) provide a regular forum for cancer teams to discuss patient care. In the UK, there has been a recent rise in the number of national advisory panels (NAP) for children and young people\'s cancer (CYP). These panels are distinct from local MDTMs and involve national experts for particular cancer types. Advice may be sought from these panels for individual patients. The aim of this study was to explore the opinions of healthcare professionals regarding CYP MDTMs and NAPs.

**Design/Methods**: Healthcare professionals involved in CYP cancer care were invited to complete an online survey through the Children\'s Cancer and Leukaemia Group (CCLG) and Teenage and Young Adults with Cancer (TYAC) membership lists from April‐July 2017.

**Results**: Fifty responses were received representing 13 UK principal treatment centres comprising doctors (36%), nurses (32%) and a further 32% from the range of professions within the MDT. Patient/family awareness of discussion at MDTM was reported by 76% of participants. Fifty percent felt it was the consultant\'s responsibility to inform patients of MDT decisions while 36% felt a combination of professionals could be responsible. The majority felt that patient and family views should always inform decision‐making in the MDTM and that these views should be presented by someone who has met them. Respondents did not agree with patients/families attending MDTs as it would be impractical. Approximately half (48%) of the respondents had accessed a NAP for their patients in the last 12 months; all had informed their patients of this process. The most common reason for referring to a NAP was to present an expert opinion to the family.

**Conclusions**: While patient‐centred care and communication are fundamental to the effectiveness of the MDTM and NAP, views are polarized as to how this is best achieved. Therefore, further evaluation is warranted.

### PO-528. Prevalence and Related Factors of Euthyroid Sick Syndrome in Children with Untreated Cancer {#pbc27455-sec-15040}

[C. Citak]{.ul} ^1^, A. Duyu^1^, E. Ak^1^, S. Kupeli^2^, B. Kupeli^3^, İ. Bayram^2^, G. Sezgin^2^

*^1^Mersin University Faculty of Medicine, Pediatric Oncology, Mersin, Turkey; ^2^Cukurova University Faculty of Medicine, Pediatric Oncology, Adana, Turkey; ^3^Ministry of Health Adana City Hospital, Pediatric Oncology, Adana, Turkey*

**Background/Objectives**: In this study, we evaluated the frequency of euthyroid sick syndrome (ESS) among patients with childhood cancer and its association with the stage of disease, nutritional parameters and cytokines levels.

**Design/Methods**: Eighty newly diagnosed children were included into study. ESS was diagnosed in two different ways: Group 1; fT3 was below the lower limit, fT4 was within the normal or low limits, TSH was in normal range and in group 2 all the levels were same as group 1 but moreover rT3 was performed and was higher than normal limits

**Results**: Three children have subclinical hypothyroidism and 2 children have subclinical hyperthyroidism. Out of 75 patients, ESS has been identified in 14 (17.3%) in group 1 and in 8 (10.6%) in group 2. In group 1, only fT3 levels were significantly different in ESS (+) and ESS (‐) group (p\<0.05). In group 2, both fT3 and rT3 levels were significantly different ESS (+) and ESS (‐) group (p\<0.05). Considering, the gender, age, stage of disease, and BMI of the patients, there was no statistically significant difference between the subjects with or without ESS in both groups (p\>0.05). In Group 1 and Group 2, a significantly negative correlation between IL‐6 and fT3 was found. TNF‐α was negatively correlated with fT3 levels only in Group 1. There were no correlation between IL‐1β and fT3, fT4, rT3 and TSH levels.

**Conclusions**: ESS may be seen in childhood cancer and thyroid function testing should be performed routinely when cancer diagnosed.

### PO-529. Characteristics of Pediatric Cancer Patients in the Emergence of a Pediatric Oncology Department at a Cancer Hospital {#pbc27455-sec-15050}

[M.O. Cunha]{.ul} ^1^, S. Ferman^1^, M. Grabois^1^, F. Ferreira da Silva^1^, M. Monteiro^1^

*^1^Instituto Nacional de Cancer HCI Brasil, Pediatric Oncology, Rio de Janeiro, Brazil*

**Background/Objectives**: Treatment of childhood cancer is associated with complications due to illness or treatment, requiring urgent or emergent medical care. The possibility of offering service 24 hours a day 7 days a week for patients with cancer is fundamental to improve cure rates. The aim of the study is to describe the reasons for emergency department visits, and factors associated with hospital admission.

**Design/Methods**: We conducted a retrospective cohort analysis through a database of the visits of pediatric patients with cancer with cancer to the pediatric emergency department within one year, from 01/01/2017 to 31/12/2017. Data collected were age, gender, tumor diagnosis, oncologic status, number of visits per patient, reason for emergency consultation and outcome.

**Results**: There were 3,557 visits in 757 pediatric patients with cancer over the study period. In 86% patients were solid tumors and in 14% patients were hematologic malignancies. The median age was 9 years (range 0.4 to 29.6 years). The three most common types of primary diagnosis by International Classification of Childhood Cancer 3 (ICCC‐3) were Central Nervous System Tumors (Group III), Lymphoma (Group II) and Wilms Tumor (Group VI) accounting for 38% of the visits. The most common cause of emergency visit was due to fever and neutropenia. Seventy percent of the patients were discharged home and 30% of patients were admitted to the hospital. Mortality rate at the emergency was very low, only one patient died due to terminal disease.

**Conclusions**: Knowledge of the most common reasons for emergency visits to pediatric patients with cancer is important for treatment planning and improvement of outcomes.

### PO-530. Outcomes in Shared Care Facilities for Pediatric Cancer Patients in a Resource Limited Setting {#pbc27455-sec-15060}

[M. Dolendo]{.ul} ^1^, K. Caranto^1^, C.L. Diez^1^, F.D. Go^2^, A. Tiongco^3^, M.C. Domingo^4^, C. Plete^5^, C. Uy^6^, C. Lam^7^, T. Eden^8^

*^1^Southern Philippines Medical Center, Department of Pediatrics Children\'s Cancer Institute, Davao City, Philippines; ^2^Northern Mindanao Medical Center, Department of Pediatrics, Cagayan de Oro City, Philippines; ^3^Davao Regional Medical Center, Department of Pediatrics, Tagum City, Philippines; ^4^Southern Philippines Medical Center, Department of Pediatrics, General Santos City, Philippines; ^5^Butuan City Medical Center, Department of Pediatrics, Butuan City, Philippines; ^6^La Vina General Hospital‐ Inc., Department of Pediatrics, Valencia City, Philippines; ^7^St Jude Children\'s Research Hospital, Global Pediatric Medicine Department, Memphis, USA; ^8^University of Manchester, Academic Unit of Paediatric and Adolescent Oncology, Manchester, United Kingdom*

**Background/Objectives**: Limited access to specialist care emphasizes the need to mitigate burden of care in large public tertiary centers. This study aims to describe the development of Mindanao Pediatric Cancer Care Network (MPCCN) shared care facilities with Southern Philippines Medical Center (SPMC), the hub referral center in Mindanao, Philippines.

**Design/Methods**: A retrospective review of shared care facilities chosen for strategic location to deliver acute care, awareness campaigns, prompt referral and follow up. MPCCN teams of pediatricians, nurses and support staff were trained at SPMC. Referrals were done through phone calls, text messages, emails and online conferences. Data collected include clinical profile, referral patterns and patient outcomes from January‐ December 2017 analyzed using Chi square and descriptive statistics.

**Results**: Six shared care facilities in Tagum, General Santos, Zamboanga, Cagayan de Oro, Butuan and Valencia were developed at different time points since 2010. From January to December 2017, five shared care facilities saw 110 patients: 16% (n=18) treated at SPMC, 18% (n=20) shared care and 66% (n=72) managed at the facilities. Majority had hematologic malignancies (n=68, 62%) particularly ALL (n=54, 79%). Retinoblastoma (n=10, 25%), osteosarcoma (n=7, 17%) and germ cell tumors (n=6, 14%) were common among patients with solid tumors. Outcomes for patients managed at shared care facilities show 47% (n=34) alive, 19% expired (n=14), 16% (n=12) abandoned, 11% (n=8) refused, 3% (n=2) no data or transferred to other facilities during the study period. Significantly greater number of patients were seen with hematologic malignancies in onsite settings (75%) compared to solid tumors (75%) in shared care (p value of 0.00013). In terms of outcomes the percentage of patients who were alive was significantly greater in shared care compared to onsite care (85% vs. 47%, p value of 0.008)

**Conclusions**: Optimizing communication and training teams caring for pediatric oncology patients enhance shared care facilities despite limited resources.

### PO-531. Incidence and Determinants of Barriers to Childhood Cancer Medication in a Developing Country {#pbc27455-sec-15070}

E. Grynzspancholc^1^, V. Pinto^2^, A. Ayoroa^3^, A. Armesto^4^, L. García^5^, [G. Dran]{.ul} ^6^

*^1^Natali Dafne Flexer Foundation, Presidency, Buenos Aires, Argentina; ^2^Natali Dafne Flexer Foundation, Department of Investigation, Buenos Aires, Argentina; ^3^Natali Dafne Flexer Foundation, Psychosocial Department, Buenos Aires, Argentina; ^4^Medicine School University of Buenos Aires, Pharmacology Department, Buenos Aires, Argentina; ^5^Natali Dafne Flexer, Strategy Department, Buenos Aires, Argentina; ^6^National Council of Scientific and Technological Investigation CONICET, Investigation Department, Buenos Aires, Argentina*

**Background/Objectives**: Barriers to adequate childhood cancer treatment are usual in developing countries, determining poor survival and QoL. The Natali Dafne Flexer Foundation (FNDF) provides assistance to children with cancer in Argentina. The aim of this study is to describe the incidence and determinants of barriers to medication (BtM) among families assisted by FNDF along a 5‐year period.

**Design/Methods**: Retrospective quantitative analysis of records of all consecutive children with cancer diagnosis at 0‐18 y.o., assisted by FNDF during 2011‐2015. Primary outcomes were the possibility of having BtM, and the possibility of undergoing ≥3 steps to obtain medication. Outcomes were compared among patients with different types of medication (cytostatic vs support), treatment center (public vs private), diagnoses (leukemia vs lymphoma/other solid tumors) and health coverage (public vs job vs private coverage). Chi^2^ or Fisher exact test were used.

**Results**: Five hundred ninety seven patients out of 4,925 assisted in the period (12.1%) faced BtM; 61% were boys and 93% Argentineans. A total of 1,003 steps were taken to obtain medication (mean number per patient= 3±2.3). The involved medication was support (51%), cytostatic (46%) and coadjuvant (1%). Barriers were due to institutional delay (58%), lack of pharmacy stock (24%), lack in the country/drug bank (12%), family delay (5%), or unauthorized medicine (1%). The proportion of patients who faced BtM was higher among those patients covered by job insurance than by public health (P\<0.0001) and private coverage (P=0.010). The proportion of patients who underwent ≥ 3 steps to get medication was higher among patients covered by job (P=0.03) or private (P=0.02) insurance than by public coverage. Both outcomes did not vary with diagnosis, type of treatment center or type of medication.

**Conclusions**: A substantial number of families experience barriers to cytostatic/ support medicines for cancer in Argentina, mostly related to institutional delays and inefficient job and private coverage.

### PO-532. Survival from Childhood Cancer in Sweden and Denmark: Is Survival Related to Birth Characteristics? {#pbc27455-sec-15080}

[F. Erdmann]{.ul} ^1,2^, L. Bouaoun^1^, G. Tettamanti^3^, M. Hargreave^4^, A. Krøyer^2^, J.F. Winther^2^, M. Feychting^3^, J. Schüz^1^

*^1^International Agency for Research on Cancer, Section of Environment and Radiation, Lyon, France; ^2^Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark; ^3^Karolinska Institutet, Unit of Epidemiology‐ Institute of Environmental Medicine, Stockholm, Sweden; ^4^Danish Cancer Society Research Center, Virus‐ Lifestyle and Genes, Copenhagen, Denmark*

**Background/Objectives**: Despite substantial advancements in survival from childhood cancer over the past decades, not all children benefit equally from these improvement. For some long‐term conditions in children there is evidence to suggest that factors acting prior to birth may influence disease trajectory including childhood cancer outcome. In this unique register‐based cohort of Swedish and Danish children we investigated the relationship between birth characteristics and survival from childhood cancer.

**Design/Methods**: All children born between 1978 and 2009 in Denmark and 2014 in Sweden and diagnosed with a primary cancer before the age of 15 years (N=11,376) were followed until 10 years from diagnosis. Multiple Cox proportional hazards models estimating hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the impact of birthweight, gestational age, number of siblings, parental age, mode of delivery and birth order on overall survival.

**Results**: Poorer survival was observed for children with low birthweight (\<1500 g) compared to children of a birthweight between 2500‐4000 g (HR adjusted for gestational age 1.64; CI 1.08, 2.51). Analyses of birthweight by gestational age did not point towards an association with survival. A slight tendency of inferior survival was found for children delivered by Caesarean section. Analyses for specific cancer types showed for children with acute lymphoblastic leukaemia a higher HR for the association with low birth weight (HR 2.42; CI 0.88, 6.64) and worse survival for children born small for gestational age (HR 1.50; CI 1.16, 194). For CNS tumours, no associations were observed. Associations with parental age were inconsistent between cancer types.

**Conclusions**: Overall, birth characteristics do not appear to strongly affect survival from childhood cancer. Since low birth weight is generally associated with increased mortality in infancy, relative survival will be calculated in additional analyses.

### PO-533. Exploring Barriers to Accessing Care for Childhood Cancers in India: A Qualitative Study (InNPOG‐ACC‐16‐03) {#pbc27455-sec-15090}

[N. Faruqui]{.ul} ^1^, R. Joshi^2^, J. Lowe^3^, R. Arora^4^, H. Anis^5^, M. Kalra^6^, S. Bakhshi^7^, A. Mishra^7^, A. Santa^8^, S. Sinha^9^, S. Rani^10^, R. Seth^11^, S. Bernays^1^, A. Martiniuk^12^

*^1^University of Sydney, School of Public Health, Sydney, Australia; ^2^The George Institute for Global Health, Office of the Chief Scientist, Sydney, Australia; ^3^Cankids NGO, Capacity Building, Delhi, India; ^4^Max Super Speciality Hospital, Paediatric Oncology, Delhi, India; ^5^Cankids NGO, Psycho‐oncology and Palliative Care Services, Delhi, India; ^6^Indraprastha Apollo Hospital, Institutes of Cancer, Delhi, India; ^7^All India Institute of Medical Sciences‐ Institute Rotary Cancer Hospital, Medical Oncology, Delhi, India; ^8^Basavatarakam Indo American Cancer Hospital, Medical Oncology, Hyderabad, India; ^9^MNJ Institute of Oncology, Medical Oncology, Hyderabad, India; ^10^Rainbow Children\'s Hospital, Pediatric Hematology‐Oncology, Hyderabad, India; ^11^All India Institute of Medical Sciences, Pediatric Oncology, Delhi, India; ^12^University of Sydney, Faculty of Medicine, Sydney, Australia*

**Background/Objectives**: The childhood cancer survival rate in India is estimated to be 40%. A primary reason behind these poor outcomes are challenges to accessing care at individual and health system levels. This qualitative study investigated barriers to accessing care from symptom onset to beginning of treatment from caregiver and healthcare professional perspectives.

**Design/Methods**: This study was conducted in 7 tertiary cancer centres across Delhi and Hyderabad. Caregivers of children (\< 18 years) and oncologists, senior residents, nurses, social workers, dieticians, psychologists and a radiologist were interviewed. Purposive sampling to saturation was used to ensure adequate representation of gender, age, cancer type, geographical location and socioeconomic status. Semi‐structured interviews were audio recorded after obtaining informed consent. Thematic content analysis was conducted and organised using NVivo 11 software.

**Results**: Thirty‐four caregivers and 27 healthcare professionals were recruited. Most caregivers, especially those from distant geographical areas had diverse and erratic referral pathways partly due to influence from family, friends and/or other stakeholders, lack of specialist doctors, paucity of diagnostic facilities in rural/regional areas and long travel times. Healthcare professionals interviewed reported similar complexities in patient journey as well as lack of adequate infrastructure, patient load in tertiary hospitals and inadequate support from government as barriers. Financial constraint was a recurring theme amongst low‐income families unable to support daily expenses throughout their journey. In comparison to private hospitals, some caregivers in public hospitals described a greater severity of barriers such as long waiting times, disorganised administrative support and overall difficulty in patient navigation. Barriers highlighted by healthcare professionals differed by health discipline.

**Conclusions**: There are various barriers to childhood cancer treatment in India, starting from symptom onset which are then exacerbated once treatment begins. This study can help inform policymakers of various system level barriers preventing appropriate access to care.

### PO-534. Public Health Actions on the Improvement of the Early Diagnosis of the Young Childhood Cancer in the West of Paraná‐ Brazil {#pbc27455-sec-15100}

[C. Fiori]{.ul} ^1^, A. Rosa^1^

*^1^Cancer Hospital of Cascavel‐UOPECCAN, Pediatric Oncology, Cascavel, Brazil*

**Background/Objectives**: Introduction: In Brazil, cancer in children and adolescents is considered a public health problem, due to high mortality rates and high financial costs. Being a rare disease, it represents the 2nd cause of death in the range of 05 to 19 years. On the other hand, the cure rate reaches above 70% if diagnosed early. The Cancer Hospital of Cascavel ‐ UOPECCAN in partnership with the Ronald McDonald Institute through the early diagnosis of cancer children and adolescents program, train professionals of health and pediatrics of the municipalities of Parana‐Brasil. Objective: Train professionals of health and pediatricians to contribute to the early identification of cancer in children and adolescents, reducing the time between the onset of signs and symptoms and diagnosis in a specialized center providing an increase of the probability of cure.

**Design/Methods**: Health professionals were trained from April /2008 to December /2017, received basic information about children cancer and adolescents(Epidemiology; signs and symptoms of suspicion; care to children and adolescents with cancer).

**Results**: 2203 professionals, 154 doctors, 243 nurses, 367 technicians / nursing assistants, 1006 community health agents, 217 upper level and 216 medium‐level professionals.

**Conclusions**: The preliminary analysis of the data allows us to observe that children and adolescents with cancer presented advanced disease at diagnosis. After 2014, we observed change in staging diagnosis of patients who are coming up with more localized disease. It is possible that this change may be related to the training activities through this program developed in Paraná, Brazil, since 2008. One goal of the campaign is to encourage educational and preventive actions, becoming known to more people about symptoms and signs of disease. Shortening the time between the suspicion of cancer and early diagnosis and treatment, will certainly contribute to the increasing expectations of cure in developing countries.

### PO-535. Modelling Sustainable, National, Regional and Local Healthcare Systems based on Childhood Cancer Shared‐Care Networks in LMICs {#pbc27455-sec-15110}

[P. Freccero]{.ul} ^1^, M. Collington^1^, L. Burns^1^, T. Eden^1^, L.A. Renner^2^, M. Dolendo^3^, V. Paintsil^4^, A.A. Khaing^5^, A. Islam^6^, J. Rosser^1^

*^1^World Child Cancer, Programmes, London, United Kingdom; ^2^University of Ghana Medical School, Department of Child Health, Accra, Ghana; ^3^Southern Philippines Medical Centre, Department of Pediatrics, Davao, Philippines; ^4^Komfo Anokye Teaching Hospital, Department of Child Health, Kumasi, Ghana; ^5^Yangon Children\'s Hospital, Haemato‐Oncology Unit, Yangon, Myanmar Burma; ^6^Bangabandhu Sheikh Mujib Medical University, Paediatric Haematology and Oncology, Dhaka, Bangladesh*

**Background/Objectives**: World Child Cancer (WCC) has been working in partnership with paediatric oncology programmes in low‐middle income countries (LMICs) to support improved services for children with cancer. Central to success is the development of effective shared‐care networks situated to match population centres. Literature on how to develop shared‐care networks in LMICs does not currently exist.

**Design/Methods**: The model was developed through learning from a 3 year UK Government (DFID) funded programme in Ghana and Bangladesh and lessons shared from WCC‐funded programmes in Myanmar and the Philippines. A workshop was held focussing on lessons learned from practitioners representing networks in different stages of development to identify key elements and steps necessary to build a shared‐care network.

**Results**: A successful shared‐care network must have a strong hub hospital at its centre which requires a doctor with training and experience in paediatric oncology, a committed multi‐disciplinary team, dedicated bed space, provision for training, patient data recorded and essential medicines available. A health partnership with a developed centre is beneficial. Support would ideally be available for patients and families. Each shared‐care centre requires a dedicated leader, a basic multi‐disciplinary team, ward space for oncology patients, a close relationship with the hub centre and services to replicate the hub as well as resources allow. Major challenges include obtaining support from the hospital administration, government policies and financing for such developments. Collaborative working and good communication are emphasised by using the same treatment protocols, developing two‐way referral systems and sharing learning. The over‐arching principle of sustainability requires availability of training within the system and funding.

**Conclusions**: This model can be shared to enable others in LMICs to access the information and inform their systems development. Whilst it is not exhaustive and requires further research, it represents an important first step including lessons learned from practitioners with experience.

### PO-536. Facilitators and Challenges in Operationalizing Global Health Partnerships: The Case of Dana‐Farber and Boston Children Hospital\'s Global Health Initiative {#pbc27455-sec-15120}

[E. Gold]{.ul} ^1^, I. Albanti^1^

*^1^Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center, Global Health Initiative, Boston, USA*

**Background/Objectives**: Since 2012, the Global Health Initiative (GHI) at Dana‐Farber/Boston Children\'s Hospital (DF/BC) has established partnerships with pediatric oncology hospitals in low‐ and middle‐income countries (LMIC). As the program enters its sixth year of operations, "GHI" sought to formally analyze lessons learned to determine what factors facilitate or hinder an impactful partnership, from the "DF/BC" perspective. The second phase of the study will be to interview international "GHI" partners to reflect and integrate their experiences.

**Design/Methods**: We conducted 15 in‐depth interviews with "DF/BC" physician, nursing, psychosocial, and administrative leadership. A structured interview guide was used to explore experiences and insights. Data was transcribed, manually coded in Excel, and tabulated to identify widely‐shared thematic elements of an effective global health program. IRB approval was obtained.

**Results**: Themes emerged around strategic and programmatic facilitators and challenges. Facilitators included 1) needs assessment (country and partner site); 2) mission‐alignment; 3) continuity and hands‐on work; and 4) impact measurement.

Challenges centered on 1) operational limitations in "LMIC" (e.g., staff turnover); 2) communication gaps; and 3) stakeholder engagement.

Respondents reported that the most productive partnerships are long‐term and have "GHI" staff who can formally allocate dedicated time and effort to work in‐country, for concentrated periods of time, with a specific international partner.

**Conclusions**: Findings from this study may assist the "GHI" and other global health programs to inform strategic decisions on future partnerships and how to maximize resources for a productive collaboration. Programmatic implications may include decision‐making around the requirements for starting a partnership. Next steps include completing the second phase of the study and developing an online, publicly available inquiry form to capture information from potential new partners to assess partner‐fit.

### PO-537. Socio‐Demographic Characteristics and Risk Factors that Influence the Delay in the Diagnosis of Cancer in Hospitals in Mexico {#pbc27455-sec-15130}

[E. Gonzalez]{.ul} ^1^, M. Zapata‐Tarres^1^, D. Arce^2^, D. Menendez^3^, C.S. Cruz Medina^4^, E. Chargoy^5^, R.S. Barajas^6^, O. Gonzalez Ramella^7^, M. Rivera Diaz^7^

*^1^Instituto Nacional de Pediatria, Oncology, Mexico City, Mexico; ^2^Hospital Infantil Teleton de Oncologia, Oncology, Queretaro, Mexico; ^3^Hospital Infantil de Mexico, Oncology, Ciudad de Mexico, Mexico; ^4^Hospital para el niño poblano, Oncology, Puebla, Mexico; ^5^Hospital Regional Presidente Juarez, Oncology, oaxaca, Mexico; ^6^Centro Medico Nacional 20 de Noviembre, Oncology, Ciudad de Mexico, Mexico; ^7^Hospital Civil de Guadalajara, Oncology, Guadalajara, Mexico*

**Background/Objectives**: In Mexico, cancer is the second cause of death in the population between 5 and 14 years old. It is considered that the main factors that determine in a general way the prognosis of the patients are the histology of the tumor and the stage at the time of the diagnosis. Objectives: determine risk factors, patient delay, medical delay and system delay.

**Design/Methods**: An observational, descriptive, prospective, multicenter study was conducted. A survey was applied with socio‐demographic and medical variables to the participants, 15 centers that offer pediatric oncology service participated, with a total of 270 patients.

**Results**: The following results were obtained: female 42%, male 58%, socioeconomic level low 61.7%, medium 36.9%, high 1.4%. Patient delay was: 7 days 59%, more than 120 days 4%. The number of doctors visited 2 or less 27.61%, of which the first action was give treatment in 54.8%, request image studies 22.7%, laboratories 25%, refer to another center 18.6%, hospitalize 6.5%, request a biopsy 5.22%. Medical delay was present in 44.60% of the cases, with a median of 42 days. Of the doctors visited, 33.58% had suspected cancer, 72.3% were general physicians, 20.3% were pediatrician, 33.95% prescribed antibiotics, NSAIDs were prescribed in 43.65% of the patients. According to the parents, 30.7% thought that the symptoms would resolve themselves, 23% had problems of economic resources, 14.8% had problems to miss work, 50.4% perceived mistakes in the diagnosis of the first doctors consulted. At the time of diagnosis 13.71% presented metastasis. Leukemia 59.09%, lymphoma 6.81%, solid tumors 34.09%.

**Conclusions**: There is a delay in the diagnostic of patients who are finally diagnosed with cancer at oncology hospitals in Mexico. These results may have an influence in health politics.

### PO-538. Knowledge, Attitude and Awareness of Childhood Cancer Among Practising Pediatricians: A Survey from Developing Country, India {#pbc27455-sec-15140}

[R. H N]{.ul} ^1^, V. Gunasekaran^1^, S. Sapkota^1^, A. Danewa^1^, A. Sachdeva^1^

*^1^Sir Ganga Ram Hospital, Pediatric hematology‐ oncology and BMT unit, New Delhi, India*

**Background/Objectives**: The presenting symptoms of childhood cancer are usually non‐specific. Pediatricians are usually the first point of contact for these children with health system.

**Design/Methods**: An online survey was conducted (August 1st ‐ 31st, 2017). A 26‐point questionnaire was sent to pediatricians all over India. Reponses from pediatric oncologists were excluded.

**Results**: There were 257 eligible responses (41% ‐ government institutions; 56.4% ‐ teaching institutions; 18.2% ‐ towns/villages). Out of 257, 69 had training in some pediatric subspeciality. Around 35% have \>5 years of pediatric practice and 91% have encountered pediatric cancer. There were 95% responses that childhood cancer is curable and 90% identified commonest malignancy as leukemia. However, 13% predicted 5‐year‐survival rate to be \<40%. Survival rates of Hodgkin lymphoma and Wilms tumour were underestimated by ∼50%. Around 80% appropriately responded that fever, abdominal mass, bicytopenia, leukocoria and bone pain could be manifestations of malignancy. Alarmingly, 25% presumed the minimum age to develop cancer to be \>2 years and 30% felt that steroid is not used in treating leukemia. However, 89% promptly responded that bone marrow evaluation is mandatory prior to initiating steroids in ITP and steroids can mask underlying malignancy. 26(10%) incorrectly responded that all leukemia patients need bone marrow transplantation for cure. 121(48%) erroneously responded that one\'s own cord blood can cure thalassemia/ leukemia in future. 120(48%) incorrectly responded that blood transfusion can change bone marrow findings in leukemia. 61(24%) responders did not have information about a nearby pediatric oncology centre for referral.

**Conclusions**: Pediatricians are aware about the presenting features and curable nature of childhood cancer. However, the awareness regarding age of onset, nature of treatment and limitations of utilizing one\'s own cord stem cells are highly lacking. Pediatric oncologists should ensure that the pediatricians are made aware of these aspects.

### PO-539. Improving Pediatric Oncology‐Hematology Care: Evaluation of Teleconference Between Indonesia and Netherlands {#pbc27455-sec-15150}

[K. Handayani]{.ul} ^1^, M. Veening^2^, A. Kors^2^, E. Supriyadi^3^, B. Indraswari^3^, E. Kelling^2^, A. Veerman^2^, G. Kaspers^2^, M. Sitaresmi^3^, S. Mostert^2^

*^1^Nyi Ageng Serang District Hospital, Paediatric, Yogyakarta, Indonesia; ^2^VU University Medical Centre, Paediatric Oncology‐Hematology, Amsterdam, Netherlands Antilles; ^3^Universitas Gadjah Mada, Paediatric, Yogyakarta, Indonesia*

**Background/Objectives**: Improving the quality of care through an outreach program is challenging. Teleconferencing is increasingly being used and considered a breakthrough in medical education. We evaluated adherence with childhood oncology‐hematology teleconferences between Indonesia and Netherlands.

**Design/Methods**: Teleconferences held between April 2014 and March 2015 in an Indonesian academic hospital were evaluated using a standardized form. Both adherence with diagnostic and treatment advices were explored in medical records.

**Results**: During 38 teleconferences, difficult cases of 53 children were discussed by Dutch pediatric oncologists and Indonesian residents. Dutch oncologists adviced diagnostic adjustments in 41 cases (77%). Most common diagnostic advices were: laboratory tests (68%), imaging (54%), physical examination (41%). Diagnostic advices were not adhered to in 12 children (30%). Common reasons for non‐adherence were: not applicable in middle‐income setting (25%), disagreement with Dutch advice (17%), CT scan is out of order (17%), patient died (17%). Dutch oncologists adviced treatment adjustments in 40 cases (75%). Most common treatment advices were: change of protocol (38%), nutrition (30%), prevention of tumor lysis syndrome (20%). Treatment advices were not adhered to in 9 children (22%). Common reasons for non‐adherence were: poor condition of child (44%), not applicable in middle‐income setting (22%), patient died (22%), disagreement with Dutch advice (11%). Twenty‐four children (45%) died after teleconference was held. Twenty‐nine children (55%) were alive. These children abandoned (38%), completed (31%) or were still under treatment (31%).

**Conclusions**: Through teleconferencing, knowledge between high and low or middle‐income countries can be shared to improve patient care. Locally applicable advices are required. Active participation by pediatric oncologists at both partner sites is essential and therefore recommended.

### PO-540. Managing Children\'s Malignancies with a Twinning Plan in China\'s Remote Minority Nationalities Areas {#pbc27455-sec-15160}

[K. He]{.ul} ^1^, Y. Liu^2^

*^1^Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Pediatric Hematology/Oncology, Shanghai, China; ^2^Shanghai Institute of Health Sciences, Department of Nursing, Shanghai, China*

**Background/Objectives**: The vast territory of China brings imbalanced distribution of medical resources between eastern costal and western inland areas. Children\'s malignancies in the remote areas where minority nationalities predominantly inhabited are always under‐diagnosed and poorly treated. We have been dedicated to a twinning plan to make the utmost of existing medical resources to help patients newly diagnosed with childhood and adolescent cancers.

**Design/Methods**: This twinning plan has been implemented with the supervision of a stationing pediatric oncologist working at Kashgar prefecture, which located in the western border of China with a population of about 4.5 million. Malignancies with favorable prognosis and involving less complicated treatment modalities would be treated locally. Critical and technique‐demanding diagnosis were performed with the aiding of its twinning partner, a tertiary pediatric cancer center in Shanghai. Intensive treatment phases and elaborate surgeries were also accomplished in Shanghai and then patients came back for subsequent treatment. This twinning plan was funded through a government‐supported medical aiding project.

**Results**: Over a 2‐year period, 45 children and adolescents were enrolled. With a median follow‐up of 24 months, 33 were alive among 37 patients sticking to the plan. The estimated 2‐year probability of survival (pSu) was 89%. According to the survey we conducted previously, this 2‐year pSu for leukemia and non‐CNS solid tumor in the same region were 46% and 66%, respectively. Lower rate of hematologic toxicity and severe infection after same chemotherapy regimens were observed among the patients predominant by Uygur and Khalkhas ethnic groups in Kashgar prefecture compared to Han nationality counterparts.

**Conclusions**: Owing to this twinning plan, outcome for these malignancies has significantly improved compared with historical data. This collaborative mode proves to be efficient and economic in China. Further education, communication, research and treatment refinements are needed to provide equally high‐quality care to all the patients throughout the country.

### PO-541. Pediatric Oncology Training Diploma for French‐Speaking African Countries: A Feasible Model for Addressing Human Resource Challenges in Countries with Limited Resources {#pbc27455-sec-15170}

[L. Hessissen]{.ul} ^1^, A. Kili^1^, M. ElKababri^1^, C. Coze^2^, M. Khattab^1^, O. Oberlin^3^, S. Howard^4^, A. Zaidi^5^, A. Gagnepain‐Lacheteau^6^, C. Patte^3^, H. Martelli^7^, M. Harif^8^

*^1^University Mohammed V of Rabat, Pediatric Oncology, Rabat, Morocco; ^2^Aix‐Marseille Univ‐ Assistance Publique Hôpitaux de Marseille APHM, Pediatric Oncology, Marseille, France; ^3^Gustave Roussy Institute, Pediatric Oncology, Villejuif, France; ^4^University of Tennessee Health Sciences Center, Health Sciences Center, Memphis‐ Tennessee, USA; ^5^St. Jude Children\'s Research Hospital, Department of Global Pediatric Medicine, Memphis‐ Tennessee, USA; ^6^Sanofi Espoir Foundation, Medical department, Paris, France; ^7^University Paris Sud ‐Villejuif hospital, Pediatric surgery, Villejuif, France; ^8^Ibnou rochd University hospital, Hematology and Pediatric oncology, Casablanca, Morocco*

**Background/Objectives**: Since the year 2000, theFrench African Group of Pediatric Oncology (GFAOP) has createdfifteenpediatric oncology units in French‐African countries. Producing skilled physicians is GFAOP\'s next challenge. In 2012, GFAOP received financial and intellectual support from the Sanofi Espoir Foundation\'s My Child Matters program and establishedthe African School of Pediatric Oncology. Pediatric oncology training diploma customized for African physicians is a one year intensive training program accredited by the University Mohammed‐V Rabat and the University Paris Sud. We present this experience as a model for countries facing similar challenges.

**Design/Methods**: A fourteen‐member committee of multidisciplinary experts from Morocco, France, and USA finalized a curriculum patterned on the French model "Diplôme Inter‐Universitaired\'OncologiePédiatrique". Teachings are multidisciplinary, and train 15‐25 candidates per year. Candidates must commit to serving their parent institutions. One year training includes didactic lectures by experts, both in‐person, and recorded for online delivery (e‐learning), an on‐site practicum, and a research project. Evaluation involves candidate evaluation, and feedback on effectiveness and quality of training.

**Results**: First cohort began October 2014. E‐learning modules became available to the third cohort in 2016. By October 2017, total 72 candidates had recruited in three cohorts. First two cohorts of 26 and 25 trainees respectively achieved 82.4% success rate (42 of 51), whilethird cohort of 21 trainees remains in session. Candidates were from 19 French African countries. Most of successful candidates have returned to their countries, and three new pediatric oncology units have established in Niger, Central African Republic and Gabon. E‐Learning is available at <http://www.e-gfaop.org>, with 66 users currently registered. Fifty of 51 fully trained participants have responded to program evaluation surveys with valuable feedback.

**Conclusions**: This model is feasible for implementation in other countries. The challenge is sustainability due to high time commitment for trainers.

### PO-542. National Registry‐based Incidence and Outcome Data on Rhabdomyosarcoma in Australian Children: Stable Incidence, Improving Survival, and High Risk of Second Primary Malignancy {#pbc27455-sec-15180}

[B. Jones]{.ul} ^1,2^, D. Youlden^3,4^, T. Cundy^5,6^, J. Karpelowsky^7,8^, J. Aitken^3^, C. McBride^1,2^

*^1^Children\'s Health Queensland, Department of Paediatric Surgery, South Brisbane, Australia; ^2^University of Queensland, Department of Paediatrics and Child Health, Brisbane, Australia; ^3^Cancer Council Queensland, Australian Childhood Cancer Registry, Fortitude Valley, Australia; ^4^Griffith University, Menzies Health Institute, Gold Coast, Australia; ^5^Women\'s and Children\'s Hospital, Department of Paediatric Surgery, Adelaide, Australia; ^6^University of Adelaide, Discipline of Surgery, Adelaide, Australia; ^7^Kids Research Institute, Children\'s Cancer Research Unit, Sydney, Australia; ^8^University of Sydney, Division of Child and Adolescent Health, Sydney, Australia*

**Background/Objectives**: To describe the incidence and survival of rhabdomyosarcoma in Australia using national data from the Australian Childhood Cancer Registry (ACCR). To investigate second primary malignancy (SPM) in children treated for rhabdomyosarcoma.

**Design/Methods**: All children (0‐14 years) diagnosed with rhabdomyosarcoma from 1983‐2014 inclusive were identified in the ACCR. Demographic, tumour characteristic, incidence, mortality and treatment data were extracted. Cause‐specific (CS) and event‐free (EFS) survival up to 20 years from diagnosis were estimated using the cohort method. Adjusted excess mortality hazard ratios (HR) were calculated using a multivariate flexible parametric survival model. Cumulative incidence, standardised incidence ratios (SIR), and mortality relating to SPMs were estimated relative to the general population.

**Results**: There were 600 children diagnosed with rhabdomyosarcoma during the study period. The incidence rate did not change significantly over the study period and was estimated at 4.9 per million children per year between 2010‐2014. CS was 70% and 66% at 5 and 20 years, respectively. Five‐year EFS was 59%. Five‐year CS improved over the study period; from 64% for those diagnosed 1983‐1992 to 75% for 2003‐2012 (p=0.007). Older age at diagnosis (10‐14 years) was associated with poorer survival compared to younger age groups (HR = 1.89 using baseline of 0‐4 years, p=0.001). Of 446 patients achieving remission, 30% relapsed with subsequent 5‐year CS of 34%. The cumulative incidence of SPM at 20 years was 9.9% (n=32). The overall SIR for SPM following rhabdomyosarcoma was 20.8. Girls were 2.6‐fold more likely than boys to be diagnosed with a SPM (p=0.01). Breast cancer accounts for some of the excess female risk. The most common SPMs were thyroid cancer, leukaemias, and osteosarcoma. Mortality was 37% within 5 years of SPM diagnosis.

**Conclusions**: Five‐year CS for rhabdomyosarcoma has improved over time in Australia. Survivors face a greatly increased risk of SPM and girls are disproportionately affected.

### PO-543. Increasing Incidence and Improved Survival for Neuroblastoma and Ganglioneuroblastoma in Australian Children: Data from the Australian Childhood Cancer Registry (1983‐2014) {#pbc27455-sec-15190}

[B. Jones]{.ul} ^1,2^, D. Youlden^3,4^, T. Cundy^5,6^, J. Karpelowsky^7,8^, J. Aitken^3^, C. McBride^1,2^

*^1^Children\'s Health Queensland, Department of Paediatric Surgery, South Brisbane, Australia; ^2^University of Queensland, Department of Paediatrics and Child Health, Brisbane, Australia; ^3^Cancer Council Queensland, Australian Childhood Cancer Registry, Fortitude Valley, Australia; ^4^Griffith University, Menzies Health Institute, Gold Coast, Australia; ^5^Women\'s and Children\'s Hospital, Department of Paediatric Surgery, Adelaide, Australia; ^6^University of Adelaide, Discipline of Surgery, Adelaide, Australia; ^7^Kids Research Institute, Children\'s Cancer Research Unit, Sydney, Australia; ^8^University of Sydney, Division of Child and Adolescent Health, Sydney, Australia*

**Background/Objectives**: To describe the incidence and outcomes, including second primary malignancy (SPM), for childhood neuroblastoma and ganglioneuroblastoma in Australia using national data from the Australian Childhood Cancer Registry (ACCR).

**Design/Methods**: All children (0‐14 years) diagnosed with neuroblastoma and ganglioneuroblastoma from 1983‐2014 inclusive were identified in the ACCR. Demographic, tumour characteristic, incidence, mortality, and treatment data were extracted. Cause‐specific (CS) and event‐free (EFS) survival up to 20 years from diagnosis were estimated using the cohort method. Adjusted excess mortality hazard ratios (HR) were calculated using a multivariate flexible parametric survival model. Cumulative incidence, standardised incidence ratios (SIR), and mortality relating to SPMs were estimated relative to the general population.

**Results**: A total of 1,227 children were diagnosed with neuroblastoma or ganglioneuroblastoma during the study period with an age‐standardised incidence rate of 9.9 per million children per year between 2010‐2014. Incidence rates increased by an estimated 15% from 1983 to 2014. The proportion of patients with non‐metastatic disease at diagnosis increased from 36% in 1983‐1994 to 53% in 2005‐2014 (p\<0.001). Cause‐specific survival was 66% and 64% at 5 and 20 years, respectively. The mortality risk due to neuroblastoma and ganglioneuroblastoma more than halved from 1983‐1992 to 2003‐2012 (HR = 0.48, p\<0.001). Five‐year EFS was 60%. Of patients achieving full remission, 28% relapsed with subsequent 5‐year CS of only 21%. Thirteen patients were diagnosed with a SPM (cumulative incidence at 20 years = 2.4%), giving an AER of 9.6 per 10,000 person‐years, and a SIR of 5.39. Leukaemias were the most common SPM (6 patients), and 54% of those with an SPM died within 5 years of the SPM diagnosis.

**Conclusions**: Diagnosis of non‐metastatic neuroblastoma and ganglioneuroblastoma, and cause‐specific survival, have substantially improved over time in Australia. Relapse portends a poor prognosis. SPMs are uncommon and carry a better prognosis than a relapse of the primary tumour.

### PO-544. Sleep Disturbances in Children with Cancer: A Descriptive Cross‐Sectional Study at a Tertiary Care Centre {#pbc27455-sec-15200}

[P. Kaushik]{.ul} ^1^, K. hegde^1^, V. Shah^1^, K. khurade^1^, I. Deshmukh^1^, N. shah^1^, P. kadakia^1^, S. Sharma^1^

*^1^Lokmanya tilak municipal general hospital, Division of pediatric hematology‐oncology‐ Pediatrics, mumbai, India*

**Background/Objectives**: Sleep disturbances are a common occurrence in pediatric population. Studies have reported prevalence of sleep problems in 74‐97% of children with cancer. Emotional and physical distress in children treated for cancer predispose to sleep disturbances in them.

Objective: To study the prevalence of sleep disorder in our children undergoing therapy for cancer. To assess the domains of sleep disoredr affected in our cohort.

**Design/Methods**: This study was a cross‐sectional descriptive study conducted at a tertiary care centre over a period of 30 days. Children with cancer, aged 3‐18 years, attending the outpatient department and inpatient care were included.

Details of patient demographics, sleep habits were collected according to a proforma. Sleep habits were assessed by using the BEARS screening tool and Childhood Sleep Habits Questionnaire(CHSQ). The various sleep domains included bedtime resistance, sleep anxiety, night awakening, parasomnias, sleep disordered breathing and daytime sleepiness. Data hence obtained was analysed.

The sample size was calculated to a relative precision of 15%.

**Results**: Total of 63 children were included in the study. Most of our patients were leukemics (56) constituting 88%. According to BEARS screening, tool most common domain affected was regularity of sleep(38%). CHSQ scores were above the cut off score in 44 children making the prevalence 69.8%. The most common domain affected was bedtime resistance (96%) followed by daytime sleepiness (66.6%) and parasomnias(49%). The least affected was sleep disordered breathing(9.5%). Preschool children had a higher mean of CHSQ scores(47.5) when compared to older children. The mean CHSQ scores were 45.5, 46.3 and 43.7 in children in intensive, maintainence and completed phases of therapy respectively. However age, gender, place of residence during treatment and phase of chemotherapy failed to show any statistically significant impact on sleep of our cohort.

**Conclusions**: A prevalence of 69.8 % of sleep disorders necessitates addressing these issues in children with cancer.

### PO-545. Diagnostic Timeliness in Children with Cancer in Chelyabinsk Region and its Influence to Early Mortality {#pbc27455-sec-15210}

[S. Kovalenko]{.ul} ^1^, I. Spitchak^1^, E. Basharova^1^, K. Volkova^1^

*^1^Chelyabinsk Regional Children Hospital, Pediatric oncology and hematology, Chelyabinsk, Russia*

**Background/Objectives**: The interval between onset of first symptoms of cancer and start of treatment suspected to be one of important factors of survival improvement. The aim of our study was to investigate diagnostic timeliness in various groups of cancer in children and to determine its influence to early mortality rate.

**Design/Methods**: The data of 537 patients for last 5 years (2013‐2017) from Chelyabinsk regional cancer registry was analyzed. We determined the interval between first onset of symptoms of cancer and time point of cancer diagnosis (diagnostic interval, DI). The early mortality was determined as death in first year of diagnosis. The Fisher\'s exact test was used for statistical analyses of relationship between DI and early mortality.

**Results**: The median DI in all patients was 36 days. No any significant deviations in DI was determined during study period. The minimal DI (18,7 days) was in leukemia subgroup, longest DI was in CNS tumors (49 days). In lymphoma subgroup DI was 43 days, in solid tumors -- 39,5 days. The one year mortality rate (MR) for all patients in our study was 11,8%. We used cut‐off 30 days to determine groups with appropriate and prolonged DI. In all patients with appropriate DI MR was 9,6%, in group with prolonged DI MR was 15,7% (p=0,04%). In patients with leukemia MR was 8,6% and 12,5%, with lymphoma 4,7% and 9,4%, with CNS‐tumors 12,8% and 19,6%, and with other solid tumors -- 12% and 15% respectively. The difference was statistically insignificant in all subgroups.

**Conclusions**: Our findings show the possibility of relationship between diagnostic timeliness and early mortality in children cancer. Reducing the diagnostic interval can improve the prognosis of cancer in children.

### PO-546. An Economical Analysis for the Care of Pediatric Cancer Patients {#pbc27455-sec-15220}

[M.T. Kutluk]{.ul} ^1^

*^1^Hacettepe University Faculty of Medicine and Oncology Hospital, Department of Pediatric Oncology, Ankara, Turkey*

**Background/Objectives**: Survival rates in childhood cancer improved significantly during recent years. However, cost of the treatment is a critical issue for the cancer care especially in low and middle‐income countries. The cost of diagnosis, treatment and follow‐up of children with pediatric cancers were investigated.

**Design/Methods**: Thirty‐six patients with leukemia, 27 with NHL\'s, 26 with Hodgkin\'s disease, 27 with medulloblastoma and 32 with osteosarcoma patients were included. All patients were younger than 19 years of age. Pediatric cancer cases were sequentially diagnosed in 2013 (leukemias), 2015 (lymphomas) 2013‐2015 (medulloblastoma) and 2009‐2014 (osteosarcoma) were included. The direct costs of ambulatory and inpatient care reimbursed from the social security system, starting from diagnosis to December 2017 were analyzed iincluding the costs of examination, imaging, laboratory, operation, pathology, medicines, medical supplies, hospital accommodation and other service costs both for inpatient and outpatient care.

**Results**: Total costs as USD for 148 patients were 3.706.796 including 496.934 outpatient & 3.209.862 for inpatient costs with an average cost of 25.045 per patient. The distribution of costs (as USD) to different groups for 148 patients were; operation 114.696 (%3.10), services 789.565 (%21.3), medicine 1.049.680 (%28.32), laboratory examinations 359.635 (%9.70), examination 71.404 (%1.93), pathology 6.610 (%0.18), supplies 876.327 (%23,64), imaging 189.172 (%5.10), hospital accommodation‐bed fees 249,702 (%6.74). Total cost per patients as USD for the defined period was 37.250 for leukemia; 22.471 for non‐Hodgkin\'s lymphoma, 4.980 for Hodgkin\'s disease, 12.132 for Medulloblastoma and 40.687 for osteosarcoma patients. Two‐year overall survival rate was 85.7% for leukemia, 81.3% for NHL\'s, 100% for Hodgkin\'s disease, 83.1% for medulloblastoma, 68.6% for osteosarcoma patients.

**Conclusions**: The cost of care in pediatric cancers for investment purposes are needed for the planning purposes. The average cost per patient were found reasonable for a middle‐income country. More detailed economic analysis are needed to overcome the problems faced on pediatric cancer control.

### PO-547. Implementation of a Pediatric Oncology Provider Education Program in Nairobi, Kenya {#pbc27455-sec-15230}

F. Okinyi^1^, A. Abubhakar^2^, D. Wata^3^, L. Miklavcic^4^, B. Bander^5^, F. Abdallah^1^, J. Githanga^1^, [J. Libes]{.ul} ^6^

*^1^University of Nairobi/Kenyatta National Hospital, Pathology, Nairobi, Kenya; ^2^Kenyatta National Hospital, Pediatric Oncology Unit, Nairobi, Kenya; ^3^Kenyatta National Hospital, Pharmacy, Nairobi, Kenya; ^4^Children\'s Hospital of Illinois at OSF Healthcare, Pharmacy, Peoria, Kenya; ^5^Children\'s Hospital of Illinois\@osfhealthcare.org, Pediatrics, Peoria, USA; ^6^University of Illinois College of Medicine at Peoria, Pediatrics, Peoria, USA*

**Background/Objectives**: Previous research estimates a 2 year‐overall survival (OS) of 36% for children diagnosed with Wilms Tumor (WT) between 2008‐2011 at four collaborating Kenyan Hospitals.\[1\] This dismal survival for a disease with over 90% OS in the U.S. is due to treatment abandonment and on‐therapy mortality. \[1, 2\] Twinning partnerships between low‐to‐middle‐income countries (LMICs) and higher‐income countries have been demonstrated to improve the quality of care and patient outcomes in LMICs.\[3, 4\] A needs assessment conducted in 2016 at a pediatric oncology referral center in Kenya revealed training of hospital staff and families as crucial requirements from a twinning partnership with a U.S. institution to improve pediatric cancer outcomes. We aimed to evaluate the impact of education about WT on provider knowledge and comfort levels when caring for patients with WT.

**Design/Methods**: After being piloted at a U.S. institution, pre‐ and post‐test surveys were completed by nurses and residents on the same days as a power‐point presentation in Nairobi, Kenya. Follow‐up surveys were requested 2 months later to assess retention of knowledge.

**Results**: In the U.S., the intervention was done during a regular work‐day and 20 nurses completed both pre‐ and post‐test surveys. An increase in knowledge was seen for nurses with less than 10 years of experience (p\<0.05), but not with more experienced nurses. The comfort level in caring for patients was unchanged. In Nairobi, 17 nurses completed pre‐and post‐test surveys. Both knowledge and comfort levels significantly increased (p\<0.05). Seven residents completed pre‐ and post‐tests. Although both knowledge and comfort levels increased, the differences were not statistically significant due to a small sample size. Response numbers were too small to assess retention.

**Conclusions**: The intervention was effective in increasing knowledge and comfort levels amongst Kenyan providers in the short‐term. Long‐term follow‐up to assess retention and impact on patient outcomes will be collected.

### PO-548. Setting up a Hospital Based Children and Adolescent Cancer Register in 12 French Speaking African Countries. On Behalf of the GFAOP (Groupe Franco‐Africain D\'Oncologie Pédiatrique) {#pbc27455-sec-15240}

[B. Mallon]{.ul} ^1^, R. Kaboré^2^, L. Couitchere^3^, R. Lukamba Diuop^4^, F.F. Ben Ayed^5^, G. Nyemb Mbog^6^, M. Rakotomahefa Narison^7^, F.F. Akonde^8^, A. Budiongo^9^, M.K. Guedenon^10^, A. Dakono^11^, M.A. Raquin^12^, C. Patte^12^

*^1^GFAOP Gustave ROUSSY, Pediatrie, Villejuif, France; ^2^Hôpital Yalgado Ouedraogo, Departement de pediatrie, Ouagadougou, Burkina Faso; ^3^CHU de Treichville, Pediatrie, Abidjan, Ivory Coast\\r; ^4^Cliniques Universitaires de Lubumbashi, Pediatrie, Lubumbashi, Congo; ^5^Hôpital d\'Enfants de Tunis, Service de Médecine Infantile C, Tunis, Tunisia; ^6^Centre Mère et Enfant CME‐FCB Fondation Chantal Biya, Oncologie, Yaounde, Cameroon; ^7^HJRA‐ Hôpital universitaire Joseph Ravoahangy Andrianavalona, Oncologie, Antananarivo, Madagascar; ^8^Hopital LE DANTEC, Unité d\'Oncologie Pédiatrique, Dakar, Senegal; ^9^Cliniques Universitaires de Kinshasa, Cliniques Universitaires de Kinshasa, Kinshasa, Congo; ^10^CHU Sylvanus Olympio, Pediatrie, Lome, Togo; ^11^Hôpital Gabriel Touré, Pediatrie, Bamako, Mali; ^12^GFAOP Gustave ROUSSY, Pediatrie, Villejuif, France*

**Background/Objectives**: Incidence of childhood cancer is unknown in Africa. The GFAOP, founded in 2000 is a medical association whose vision is that "African children with a cancer can and must be treated effectively in Africa by African teams". With time, the GFAOP enabled the opening of 20 hospital units specialized in pediatric oncology in 16 countries in Africa

From the outset, the GFAOP research program aimed at improving knowledge of pediatric cancers in participating centres, especially for 5 types of cancers sharing a high chance of remission when treated early enough: Wilms tumour (WT), retinoblastoma, Burkitt and Hodgkin lymphomas, acute lymphoblastic leukemia (ALL),

In January 2016, with the support of the "My child Matters" program from the Sanofi Espoir Foundation, the GFAOP set up a hospital based register with several aims: (1) to collect data in participating units, on cancer type, treatment, outcome and demography and socio‐economic status, 2) this data will in turn help identify: material, human resource and staff training needs locally and for the GFAOP (3) provide data to encourage consideration of pediatric cancer in the national and international cancer plan in participating countries.

**Design/Methods**: From January 2016 to December 2017, 1,758 cases of childhood cancer were registered in 12 cancer units. Data collection was progressively performed by trained research assistants using the online REDCAp platform.

**Results**: Median age was 5 years (0‐18 years), male/female sex ratio was 1.5. Most frequent diagnosis were WT (275), Burkitt lymphoma (272), retinoblastoma (265) and ALL (167). Diagnosis could not be achieved for 208 patients 208/1758 (8%) reasons included: dropout during initial workup, economic reasons, child death before diagnosis, impossibility to perform adequate biopsy in some centers.

**Conclusions**: In time, with the application of learned research skills this register will be an indispensable work tool helping our group evaluate progress.

### PO-549. Surgeries of Childhood Brain Tumors Need to be Integrated in Japan? ‐ An Analysis from National Administrative Database {#pbc27455-sec-15250}

[K. Matsumoto]{.ul} ^1^, S. Daisuke^2^, K. Terashima^1^, R. Nishikawa^3^, T. Takimoto^4^, T. Noguchi^2^, K. Fushimi^5^

*^1^National Center for Child Health and Development, Children\'s Cancer Center, Tokyo, Japan; ^2^National Center for Child Health and Development, Department of Information Technology and Management, Tokyo, Japan; ^3^Saitama Medical University International Medical Center, Department of Neuro‐Oncology/Neurosurgery, Saitama, Japan; ^4^National Center for Child Health and Development, Clinical Epidemiology Research Center for Pediatric Cancer, Tokyo, Japan; ^5^Tokyo Medical and Dental University Graduate School, Department of Health Policy and Informatics, Tokyo, Japan*

**Background/Objectives**: In Japan there exist about 200 hospitals that can care childhood cancer arising about 2500 patients yearly. In 2013, with the aim of further integration, the Ministry of Health, Labour and Welfare elected 15 core pediatric cancer hospitals in seven regional blocks. The aim of this study was to describe outcomes according to hospital surgical volume in pediatric patients who underwent brain tumor resection surgery in Japan.

**Design/Methods**: We retrospectively reviewed pediatric patients who underwent brain tumor resection surgery in less than 16 years old, using the Japanese Diagnosis Procedure Combination inpatient database between April 2012 and March 2016. We exclude patients with biopsies and those who stayed in the hospitals longer than 14 days before operations.

**Results**: We identified 1,354 pediatric patients who underwent brain tumor resection in 208 hospitals. Seventy‐five hospitals (36.1%) provided just one surgery during study period. The mean age of the patients was 8.2 years. Crude in‐hospital mortality rate (CMR) was 1.8% (24/1354). CMR in hospitals with lower surgical volume (1‐7 and 8‐14 cases /4 years) was 3.3% and 2.4%, respectively, which was significantly higher than 0.6% and 0.8% in higher surgical volume centers (15‐25 and \>25 cases /4 years respectively; p=0.021). A trend of surgical volume‐outcome association was also observed in the sub‐group analysis of patients aged 5 and younger (5.6%, 4.2%, 1.7% and 0.8% respectively in each surgical volume centers; p=0.120).

**Conclusions**: The present study implies the volume‐outcome relationship in pediatric resection surgery of brain tumors, although outcome analysis for this kind of surgery is complex due to its heterogeneity. We need to construct a sophisticated network system for pediatric brain tumors in Japan, through which patients can be referred for prompt surgical treatment to large centers with much experience of childhood brain tumors.

### PO-550. High Treatment Abandonment and Advanced Disease at Presentation are Major Hurdle for Cancer Care in a Newly Established Pediatric Oncology Setting: A Developing Country Experience {#pbc27455-sec-15260}

[S. Mohapatra]{.ul} ^1^, A. Panigrahi^1^, S. Padhi^2^

*^1^All India Institute of Medical Sci, Medical Oncology/Hematolo, Bhu, India; ^2^All India Institute of Medical Sci, Pathology and Lab Medicine, Bhu, India*

**Background/Objectives**: Therapeutic intervention is challenging for pediatric oncology patients in developing countries primarily due to limited financial resources, poor compliance and lack of social support system.

**Design/Methods**: This is a retrospective and descriptive study of children (0‐19 years) with cancer treated at a center in East India from July 2016 to March 2018. Treatment abandonment was defined as failure to start or complete curative cancer therapy. Children with stage ≥III in solid tumors and high risk leukemia/lymphoma at the time of therapy were considered as advanced stage disease.

**Results**: Out of 155 children, 65 (42%) were leukemia/lymphoma and rest 90 (58%) were solid tumors. The median age of children was 6.25 (interquartile range \[IQR\]: 3--13) years and male to female ratio was 2:1 with median follow up duration of 5.8 (interquartile range \[IQR\]: 2--11) months. Seventy six (49%) children had high risk/advanced stage disease. Treatment abandonment was observed in 41 (26.5%) children. Total 17 children (11%) died during treatment. Out of these, only 4 (23.5%) was treatment related/febrile neutropenia deaths, the rest 13 (76.5%) deaths was attributed to progressive disease.

**Conclusions**: Higher rate of treatment abandonment and delay in seeking treatment are risk factors for poor survival in developing countries. With advancement to reduce treatment related mortality in pediatric oncology patients in middle and low income countries, provision of financial and social support should be made feasible for childhood cancer patients who may be potentially curable with appropriate treatment.

### PO-551. Clinical Diagnosis of Chilhood Cancer, Epidemiological Analysis of the Population Attended At the Hospital Regional de Alta Especialidad de Ixtapaluca (Mexico) for 5 Years {#pbc27455-sec-15270}

[A. Mojica]{.ul} ^1^, A. Cruz Carrasco^2^, M. Mier Cabrera^2^

*^1^Hospital Regional de Alta Especilidad de Ixtapaluca, Pediatric, Ixtapaluca, Mexico; ^2^Hospital Regional de Alta Especilidad de Ixtapaluca, Pediatric Oncology, Ixtapaluca, Mexico*

**Background/Objectives: Introduction**: Childhood cancer is a growing health problem, currently the second cause of mortality in children between 5 and 15 years of age in México. There are multiple factors involved in the prognosis of this disease: social, cultural, economic, among others.

**Objective**: To analyse the epidemiological characteristics of the patients that are part of the pediatric oncology clinic of the Hospital Regional de Alta Especialidad de Ixtapaluca from it\'s conformation June 2013 to December 2017.

**Design/Methods: Methods**: Observational, descriptive, cross‐sectional and retrospective study; in patients from 0 to 18 years of age, from the Hospital Regional de Alta Especialidad de Ixtapaluca; diagnosed with cancer between June 2013 and December 2017; with base on the characteristics of the population: age, gender, place of origin, economic level, definitive diagnosis and current status of the disease.

**Results**: A total of 77 cases were included, of which 49% were female, the average age was 8 years; 79% are from the State of Mexico. The most frequent diagnosis was acute leukemia in 39% (ALL 26%, AML 13%), the second place was for SNC tumors (19%). Currently, 26% of patients are under treatment, 24% were referenced to other institutions for complete treatment, 30% were abandonment of the treatment, lost or deaths (27%) and 20% are under surveillance.

**Conclusions**: We now are a recent and young hospital with a great challenge ahead of us. In time, we will be a cancer reference center in Mexico and until now our survival rate is promising.

### PO-552. Global Prioritization of Workforce in National Cancer Control Plans {#pbc27455-sec-15280}

[D. Moreira]{.ul} ^1^, J. Ritter^1^, C. Lam^1^

*^1^St. Jude Children\'s Research Hospital, Global Pediatric Medicine, Memphis, USA*

**Background/Objectives**: National strategies addressing human resources for health (HRH) is crucial for effective care delivery. To assess the perceived importance of HRH in national pediatric cancer care, we sought to systematically review its inclusion in national cancer control plans (NCCPs).

**Design/Methods**: Publically available NCCPs, national health and noncommunicable disease plans were collated in the St. Jude National Policy CoreBank; plans available as of December 31, 2017 were analyzed. Documents were double‐coded in English, French, Spanish and German. After an initial screening of plans that included workforce elements, a systematic analysis utilizing the six components of the World Health Organization (WHO) HRH Action Framework was performed (22 plans).

**Results**: Of 222 plans analyzed from 150 countries and territories, 47 documents from 41 (27%) countries mentioned workforce elements for pediatric cancer care. These included 7 low‐income, 10 lower middle‐income, 8 upper middle‐income, and 16 high‐income countries. Of plans analyzed with the WHO HRH Action Framework, all described the current state of HRH, with 29% of countries specifying current numbers of pediatric oncologists nationally. All plans recognized the need for HRH, but 71% mentioned a scale up plan, 46% included measurable targets, and only 23% assigned a specified budget for HRH. Elements of workforce training for cancer management were included across plans, from targeted teaching in medical schools (59%) to continuing medical education of specialists (77%) and nursing training (83%). The other elements of the Action Framework were variably included: Partnership (86%), Leadership (86%), Policy (64%), HR Management (59%), and Finance (46%).

**Conclusions**: NCCPs do not consistently consider the workforce needed to care for children with cancer. Additionally, plans lack a clear strategy to address the scale‐up needs of HRH. A defined strategy to train, retain, equip and integrate increased workforce needs for children with cancer should be considered an essential component of national programmes and policies.

### PO-553. A 3 Year Review of a Cohort Turkish Paediatric Oncology Group (TURKPEDPGx) {#pbc27455-sec-15290}

Y. Baskın^1^, B. Uncu^2^, A. Leblebici^2^, G. Calibasi Kocal^1^, C. Citak^3^, E. Ak^3^, D. Ince^4^, D. Kizmazoglu^4^, B.B. Sevinir^5^, B. Kupeli^6^, M. Avci^7^, H. Oniz^8^, E. Cecen^9^, H. Ellidokuz^10^, [N. Olgun]{.ul} ^11^

*^1^Dokuz Eylul University, Institute of Oncology‐ Department of Basic Oncology, Izmir, Turkey; ^2^Dokuz Eylul University, Institute of Health Sciences‐ Department of Translational Oncology, Izmir, Turkey; ^3^Mersin University, School of Medicine‐ Department of Paediatric Oncology, Mersin, Turkey; ^4^Dokuz Eylul University, Faculty of Medicine‐ Department of Paediatric Oncology, Izmir, Turkey; ^5^Uludag University, Faculty of Medicine‐ Department of Paediatric Oncology, Bursa, Turkey; ^6^Adana Numune Training and Research Hospital, Department of Paediatric Oncology, Adana, Turkey; ^7^Sakarya University, Department Paediatric Oncology, Sakarya, Turkey; ^8^Izmir Tepecik Training and Research Hospital, Department of Paediatric Oncology, Izmir, Turkey; ^9^rececen\@adu.edu.tr, Adnan Menderes University, Aydın, Turkey; ^10^Dokuz Eylul University, Institute of Oncology‐ Department of Preventive Oncology, Izmir, Turkey; ^11^Dokuz Eylul University, Institute of Oncology, Izmir, Turkey*

**Background/Objectives**: Childhood cancer treatment protocols in standard regimens administered and toxicities observed. The aim of this study is to be able to distinguish the patients who will give a good response and will not give it and to provide personalized treatment for the person.

**Design/Methods**: In this context, Pharmacogenomics/Genetic of Childhood Cancers in a Cohort of Turkish Paediadric Oncology Group (TURKPEDPGx) has been initiated as a nationwide, prospective and observational cohort study between 2015 and 2020. The main outcome measure will be toxicity and therapeutic response throughout five year follow‐up.

**Results**: From March, 2015 to April, 2018; 205 patients have included to study. Leukemias, myeloproliferative diseases, and myelodysplastic diseases (n=11); Lymphomas and reticuloendothelial neoplasms (n=56), CNS and miscellaneous intracranial and intraspinal neoplasms (n=31), neuroblastoma and other peripheral nervous cell tumors (n=19), Malignant bone tumors (n=26), renal tumors (n=10), retinoblastoma (n=1), hepatic tumors (n=5), soft tissue and other extraosseous sarcomas (n=19), germ cell tumors (n=5), other malignant epithelial neoplasms (n=10) and unspecified malignant neoplasms (n=6) were observed. In this cohort study, 94.4% patients were alive, 75.87% had toxicity and 12.7% were relapsed.

**Conclusions**: Drug metabolizing enzyme polymorphisms are important in determining the phenotype of the treatment. Pharmacogenomics may predict treatment‐related toxicity risk and treatment response of pediatric cancer patients. In this context, population based cohort study is one of the most important points for defining the variations that can be used in the clinic.

**Acknowledgements**: Study was conducted with financial support of TPOG, DEU‐BAP (2014 KBSAG008), DEU BİFAGEM and Dokuz Eylul University Instute of Oncology.

### PO-554. Incidence and Time Trends of Childhood Cancer in Denmark, 1943‐2014 {#pbc27455-sec-15300}

[M. Ravn Grabas]{.ul} ^1^, S. Krüger Kjaer^2^, J. Falck Winther^3^, M. Hoffmann Frederiksen^4^, F. Erdmann^3^, C. Dehlendorff^4^, M. Hargreave^1^

*^1^Danish Cancer Society Research Center, Virus‐ Lifestyle and Genes, Copenhagen, Denmark; ^2^Danish Cancer Society Research Center and Rigshospitalet University Hospital, Virus‐ Lifestyle and Genes and Department of Gynecology, Copenhagen, Denmark; ^3^Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark; ^4^Danish Cancer Society Research Center, Statistics and Pharmacoepidemiology, Copenhagen, Denmark*

**Background/Objectives**: Surveillance of childhood cancer incidence can inform etiologic research and health policy. There are few nationwide population‐based cancer registries containing virtually complete data dating back more than seven decades.

**Design/Methods**: Incident childhood cancer cases (0‐19 years) were identified in the Danish Cancer Registry and used for calculating age‐standardized incidence rates (ASR) and annual percentage changes (APC) separately for 1943‐1976 (early period) and 1977‐2014 (recent period). Cases were classified according to Birch and Marsden\'s International Classification of Childhood Cancer.

**Results**: During 1943‐2014, there were 15,184 cases of childhood cancer. In the early period, the ASR for any cancer was 13.0 per 100,000 children with an increasing incidence for males (APC 0.69, 95% CI, 0.43‐0.96) and females (APC 0.37, 95% CI, ‐0.01‐0.75). In the recent period, the ASR was 17.7 per 100,000 children, with an increasing incidence for males (APC 0.96, 95% CI, 0.75‐1.17) and females (APC 1.41, 95% CI, 1.11‐1.72). The APC for central nervous system tumors (APC 1.19, 95% CI, 0.67‐1.70/APC 1.30, 95% CI, 0.91‐1.70) and gonadal neoplasms (APC 2.73, 95% CI, 1.59‐3.88/APC 1.53, 95% CI, 0.54‐2.52) increased in both periods, whereas the APC for sympathetic nervous system tumors (APC 4.41, 95% CI, 3.28‐5.57), retinoblastomas (APC 1.56, 95% CI, 0.18‐2.96) and renal tumors (APC 1.20, 95% CI, 0.21‐2.20) increased only in the early period. For leukemia (APC 0.41, 95% CI, 0.00‐0.82), lymphomas (APC 1.78, 95% CI, 1.34‐2.23), soft‐tissue sarcomas (APC 2.17, 95% CI, 1.37‐2.98), malignant epithelial tumors (APC 3.74, 95% CI, 3.06‐4.42) and other unspecified neoplasms (APC 5.87, 95% CI, 3.71‐8.08) the increasing incidence was observed only in the recent period.

**Conclusions**: The incidence of childhood cancer in Denmark has increased since the 1940s, with the most pronounced increase from 1977 onwards. It remains unclear whether the observed temporal trend might also reflect improvements in diagnosis or solely related to changes in exposure.

### PO-555. Continuous Renal Replacement Therapy in Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients: Epidemiology and Outcome {#pbc27455-sec-15310}

[P. Raymakers‐Janssen]{.ul} ^1^, M. Lilien^2^, D. Tibboel^3^, M. Kneyber^4^, J. Woensel^5^, J. Lemson^6^, K. Cransberg^7^, M. van den Heuvel‐Eibrink^8^, R. Wösten‐van Asperen^1^

*^1^University Medical Centre of Utrecht‐ Wilhelmina Children\'s Hospital, Pediatric Intensive Care Unit, Utrecht, The Netherlands; ^2^University Medical Centre of Utrecht‐ Wilhelmina Children\'s Hospital, Department of Pediatric Nephrology, Utrecht, The Netherlands; ^3^Erasmus Medical Center‐ Sophia Children\'s Hospital‐ Rotterdam, Intensive Care and Department of Paediatric Surgery, Rotterdam, The Netherlands; ^4^University Medical Centre of Groningen‐ Beatrix Children\'s Hospital, Pediatric Intensive Care, Groningen, The Netherlands; ^5^Academic Medical Centre Amsterdam, Pediatric Intensive Care, Amsterdam, The Netherlands; ^6^University Medical Centrum of Nijmegen‐ Radboud, Pediatric Intensive Care, Nijmegen, The Netherlands; ^7^Erasmus Medical Center‐ Sophia Children\'s Hospital‐ Rotterdam, Department of Pediatric Nephrology, Rotterdam, The Netherlands; ^8^Princess Máxima Center for Pediatric Oncology‐ Utrecht, Pediatric oncology, Utrecht, The Netherlands*

**Background/Objectives**: Acute kidney injury (AKI) is one of the serious treatment‐associated complications since the introduction of intensified treatment protocols and advanced supportive therapy in pediatric cancer and hematopoietic stem cell transplant (HSCT) patients. Continuous renal replacement therapy (CRRT) has become the most widely used renal support modality for use in these critically ill children. The purpose of this study was to assess epidemiology and outcome of pediatric cancer and HSCT patients who received CRRT in the pediatric intensive care unit (PICU).

**Design/Methods**: A nationwide, retrospective study of pediatric cancer and HSCT patients who received CRRT in 5 PICU\'s from January 2006 through July 2017 in the Netherlands. Our primary outcomes were PICU‐ and 3‐months mortality.

**Results**: In total 1927 patients with cancer were admitted to PICU. Sixty‐eight of them received CRRT (3.73%), which was far higher than in the general PICU population (0.4%). The majority of patients had leukemia/lymphoma or a solid tumor as underlying cancer diagnosis, with fluid overload due to renal failure as primary PICU admission reason. Interestingly, increasing body weight rather than the main criteria serum creatinine and oliguria, was the best predictor for early detection of development of AKI. PICU mortality was 37 of 68 (54.4%), after three months 43 of 68 (63.24%). After multivariable adjustment, fluid overload \> 10% \[Odds ratio 6.16 (95% CI 1.92‐19.75)\] and the need of vasoactive support \[Odds ratio 4.77 (95% CI 1.50‐15.18)\] were independent predictors of mortality.

**Conclusions**: Continuous renal replacement therapy in critically ill pediatric cancer and HSCT patients is associated with high mortality with fluid overload (especially \>10%) at the beginning of CRRT and the need for vasoactive support as independent risk factors of mortality. Serum creatinine and oliguria seem to be not sensitive markers for timely detection of AKI in this population.

### PO-556. Childhood Cancer Resource Use by Phase of Care: A Population‐Based Study in British Columbia and Ontario, Canada {#pbc27455-sec-15320}

M. Mcbride^1^, R. Duncan^2^, C. De Oliveira^3^, K. Bremner^4^, N. Liu^5^, [P. Rogers]{.ul} ^6^, P. Nathan^7^, M. Greenberg^8^, S. Peacock^1^, M. Krahn^9^

*^1^BC Cancer, Cancer Control Research, Vancouver, Canada; ^2^University of British Columbia, Pharmaceutical Sciences, Vancouver, Canada; ^3^Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, Canada; ^4^Toronto General Hospital Research Institute, Toronto Health Economics Technology Assessment Collaborative, Toronto, Canada; ^5^Institute of Clinical Evaluative Sciences, Analytic Services, Toronto, Canada; ^6^BC Children\'s Hospital, Hematology/Oncology/BMT, Vancouver, Canada; ^7^SickKids Hospital, Hematology/Oncology, Toronto, Canada; ^8^Pediatric Oncology Group of Ontario, Medical Director, Toronto, Canada; ^9^University of Toronto, Department of Medicine and Faculty of Pharmacy, Toronto, Canada*

**Background/Objectives**: Efficient use of health care resources is fundamental to cost‐effective care. This population‐based study estimates childhood cancer resource utilization by phase of care within a comprehensive, single‐payer health care system, and compares utilization between two Canadian provinces.

**Design/Methods**: Patients aged 0 to 14 years and diagnosed with cancer from 1995 to 2010 were identified from British Columbia (BC) and Ontario (ON) cancer registries. Resource‐specific health care utilization was estimated for all patients during pre‐diagnosis, initial treatment, continuing care, and final (for those who died) phases, using linked clinical and administrative health care databases. Phase lengths were 60 days for pre‐diagnosis, and 360 days for others. Documented resources included hospital‐based (inpatient, same‐day surgery, emergency) and outpatient (physician services, diagnostic tests and procedures, prescription drugs, home care) services.

**Results**: In the cohorts (number BC=1,503;number ON=4,606), (33BC, 36 ON)% of patients had leukemia, (22BC, 21 ON)% a CNS tumour, 10%(BC,ON) lymphoma, and (34BC, 33 ON)% other cancers; 93% survived \>=1 year. Utilization of physician services (95%‐100% of patients) and diagnostic tests (81%‐98% of patients) was similar in both provinces, across all phases of care. For all phases other than continuing care, inpatient hospitalization generally ranked as the third most‐used resource (43%‐97%). Relative utilization of other resources varied by province and phase of care. Compared to BC patients, \>5% more Ontario patients had documented: inpatient hospitalization, in all phases but the initial phase; home care, in all phases but the diagnosis phase; and emergency visits in the continuing care phase. In contrast, \>5% more BC patients had documented: same‐day surgery in initial and continuing care phases; emergency visits in the initial and final phases; radiation therapy in the initial phase; and chemotherapy in the final phase.

**Conclusions**: Differences in resource utilization patterns between comparable health care delivery systems may point to opportunities to provide more efficient care.

### PO-557. The First Register of Children with Cancer in the Russian Federation: Development and Implementation {#pbc27455-sec-15330}

[M. Rykov]{.ul} ^1^

*^1^N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia*

**Background/Objectives**: At present, there are no reliable statistical data (morbidity, mortality, one‐year mortality, etc.) that characterize the state of medical care for children with oncological diseases in the Russian Federation. With the purpose of elimination of existing defects, an electronic register of children with oncological diseases has been developed and introduced into clinical practice, which allows obtaining reliable statistical data.

**Design/Methods**: In the clinical practice of the "pilot" medical organizations ‐ oncology department of chemotherapy of tumors "Arkhangelsk Regional Children\'s Clinical Hospital named after PG Vyzhletsov" and children\'s oncology department of radiotherapy and complex methods of treatment "Russian Scientific Center of Roentgenology" ‐ electronic database of children with oncological diseases

**Results**: For 6 months (09.17 ‐ 02.18) the information on 318 patients with solid tumors and hemoblastoses treated in 2015 to date has been entered in the electronic database.

**Conclusions**: The electronic register is an independent development, where many possibilities are integrated, for example, the system of support for making medical decisions, based on protocols of treatment. Medical organizations were able to register patients with the diagnosis, the dates of the initial visit to the doctor and the verification of the diagnosis, follow‐up data, the analysis of the treatment received and the criteria for assessing its quality, the treatment plan, information on the availability of beds and the number of patients in other medical organizations, the ability to request and to receive consultations in medical organizations of the third level. Patients received access to a treatment plan, including a schedule of medication and routing capabilities. The introduction of an electronic database in all medical organizations that provide medical care to children with cancer will allow obtaining and analyzing reliable statistical data, monitoring the quality of medical care and routing patients. This will reduce the cost of budget funds and improve the survival of patients.

### PO-558. Increase in Early Detection of Malignant Tumors in Children {#pbc27455-sec-15340}

[M. Rykov]{.ul} ^1^

*^1^N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia*

**Background/Objectives**: In the Russian Federation, 70% of patients are identified in stages III or IV. This is explained by the absence of specific symptoms and low training of pediatricians in pediatric oncology

**Design/Methods**: A questionnaire designed and sent to all regions of the Russian Federation to be completed by pediatricians in the initial treatment of patients. The questionnaire contained the following questions:subfebrile fever more than 3 days without established causes; weight lossLethargy, fast fatigue; congenital malformations, syndromes; oncological diseases in the family; macrogematuria; pain syndrome; leucocoria; enlarged lymph nodes; symptoms of increased intracranial pressure (headache, vomiting, visual impairment); elevated serum alpha‐fetoprotein levels; elevated serum chorionic gonadotropin; levelIncreased serum lactate dehydrogenase; levelIncreased serum alkaline phosphatase; elevated serum level of aspartate aminotransferase; elevated serum levels of alanine aminotransferase; anemic syndromeLeukocytosis; palpable tumor formation; suspicious of tumor, according to instrumental methods of examination (ultrasound, X‐ray). With two or more answers, "Yes" in paragraphs No. 1 ‐ 5 or one or more "Yes" answers in paragraphs No. 6 ‐ 20 it is recommended to send the patient to a consultation with a pediatric oncologist. If there is one "Yes" answer in paragraphs No. 1‐5 are recommended for dynamic observation.

**Results**: Detection of malignant neoplasms in the period from 09.17 to 02.18 increased by 27% compared to the figures noted a year earlier.

**Conclusions**: Since malignant tumors in children are fairly rare diseases that do not have specific symptoms, the questionnaire allows to increase the oncological alertness of pediatricians.

### PO-559. Medical Care for Children with Cancer in the Central Federal District of the Russian Federation {#pbc27455-sec-15350}

[M. Rykov]{.ul} ^1^

*^1^N.N. Blockhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia*

**Background/Objectives**: Planning the organization of medical care for children with cancer, as well as analysis of the effectiveness of medical care is based on the analysis of statistical indicators.

**Design/Methods**: The operative reports for 2017 of the executive authorities in the sphere of health protection of 18 subjects of the Russian Federation that are part of the Central Federal District have been analyzed.

**Results**: The number of children was 6824049 people (0 ‐ 17 years), the number of child oncology departments ‐ 9, the number of children\'s oncological beds ‐ 464, the number of days of berth employment in the year ‐ 319.3. The number of doctors providing medical care to children with cancer was 91, 58 (64.5%) of them do not have a certificate of a pediatric oncologist. In 11 subjects of the department of pediatric oncology are absent, in 1 of them there are no children\'s oncological beds. The number of primary patients with malignant neoplasms is 821. The number of deceased patients is 156, including 66 out of those identified in 2017. The incidence of malignant tumors was 12 (per 100,000 for the 0‐17 age group), the mortality rate was 2, 3 (per 100 thousand for the age group 0 ‐ 17 years), one‐year mortality rate ‐ 8%. The average time taken to establish a diagnosis and that has elapsed since the diagnosis was verified before the start of treatment is unknown, since the reports do not contain precise information.

**Conclusions**: Most operational reports contain indicators that do not match. The incidence rates are significantly lower than those in countries with high statistical reliability. The percentage of patients identified actively remains extremely low. In order to eliminate these defects, it is necessary to introduce a single database of children with oncological diseases in the Russian Federation.

### PO-560. The Results of Using the Electronic Database of Children with Cancer in "Pilot" Medical Organisations in the Russian Federation {#pbc27455-sec-15360}

[M. Rykov]{.ul} ^1^

*^1^N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Institute of pediatric oncology, Moscow, Russia*

**Background/Objectives**: At present, there are no reliable statistical data (morbidity, mortality, one‐year mortality, etc.) that characterize the state of medical care for children with oncological diseases in the Russian Federation. This is due to the lack of a single electronic database of patients.

**Design/Methods**: In the clinical practice of two "pilot" medical organizations, an electronic database of children with oncological diseases has been introduced, which allows: keeping records of patients with a diagnosis; key dates; follow‐up data; to analyze the treatment received earlier and the criteria for assessing its quality; make a treatment plan; to obtain information on the availability of beds and the number of patients in various medical organizations; to conduct medical consultations with the involvement of specialists of medical organizations of the third level. For the patient (legal representatives of the patient), access to the "private cabinet", reflecting the treatment plan, including a schedule for taking medicines, as well as routing possibilities, is provided.

**Results**: For 6 months (09.17 ‐ 02.18) information was entered into the electronic database of 375 patients who received treatment from 2015 to the present.

**Conclusions**: The electronic database will allow obtaining reliable statistical data, monitoring the quality of medical care and routing patients. This will reduce the cost of budget funds and improve the survival of patients.

### PO-561. Congenital Anomaly Frequency in Pediatric Oncology Patients {#pbc27455-sec-15370}

[B. Sevinir]{.ul} ^1^, M. Demirkaya^1^, C. Turan^1^, M. Ertekin^1^, A. Temuroğlu^1^

*^1^Uludağ University Medical Faculty, Pediatric Oncology, Bursa, Turkey*

**Background/Objectives**: There is evidence of certain congenital abnormalities are associated with an increased risk of developing cancer. The aim of this study is to define the relationship between congenital anomalies and childhood malignancies.

**Design/Methods**: We evaluated the patients diagnosed as lymphoma and solid tumors between 2000 and 2016 years in the Pediatric Oncology Department of Uludag University Hospital. The control group consisted of children without any chronic disease. Congenital anomalies were defined according to ICD‐10(International Classification of Disease) version 2016 chapter 17.

**Results**: Total number of 506 patients with lymphoma or solid tumors and 513 healthy children at similar age and gender distrubition were analyzed. The most common cancer types were lymphomas (27%), central nervous system (CNS) tumors (13%), neuroblastoma (12%), soft tissue sarcoma and bone sarcomas (12%) germ cell tumor(12%) and renal tumors(11%). In the patient and control group the abort or stillbirth ratio was 20.4% and 12.8% respectively (p\<0.001). Cancer history of relatives was 28.1%in the patient group and 4.67% in the control group (p\<0.001). Consanguineous marriage ratio was 14.2 5 and 12.6 % respectively. Minor congenital anomaly ratio was 33.5% (n=170) in patients with cancer and 11.5%(n=59) in the control group (p\<0.001). The highest abnormality frequency was observed in children with the CNS tumors (61.5%,p\<0.001) The most common anomaly was eye, ear,face and neck anomalies(32%). The lowest abnormality ratio was observed in children with lymphomas(27%).

**Conclusions**: Congenital abnormalities in children with cancer was 2.9 fold compared the healhty population in this study. Minor anomalies are most commonly found in patients with CNS tumors and sarcomas. Further studies are necessary on genes involved in cancer development and congenital anomalies.

### PO-562. Barriers to Effective Financial Planning of Pediatric Oncology Services in Resource‐Limited Settings: Insights from Georgia and Guatemala {#pbc27455-sec-15380}

[N. Shrivastava]{.ul} ^1^, F. Antillón^2^, L. Baramidze^3^, H. Méndez^4^, I. Albanti^5^

*^1^Harvard T. H. Chan School of Public Health, Health Policy and Management, Boston, USA; ^2^Unidad Nacional de Oncología Pediátrica, Pediatric Oncology, Guatemala City, Guatemala; ^3^Tbilisi State Medical University, Public Health, Tbilisi, Georgia; ^4^Fundación Ayúdame a Vivir, Finance and Accounting, Guatemala City, Guatemala; ^5^Dana Farber/Boston Children\'s Cancer and Blood Disorders Center, Pediatric Oncology, Boston, USA*

**Background/Objectives**: While need for pediatric oncology services exists in low‐and‐middle‐income countries (LMICs), planners have limited access to free, user‐friendly resources to develop a comprehensive, evidence‐based financial plan for the establishment of these services. Lack of such information may negatively impact planning for construction, equipment procurement, and operations, and impede efficient resource allocation and long‐term financial sustainability. This qualitative study aimed to explore barriers to effective financial planning and examine past experiences of planners.

**Design/Methods**: Lean Six Sigma principles were used as the methodological framework. A literature review was performed within peer‐reviewed journals and open‐access web databases to assess existing financial planning resource availability. Key informant interviews using a structured interview guide were conducted with 23 stakeholders from not‐for‐profit hospitals, international not‐for‐profit organizations, and universities in Tbilisi, Georgia; Guatemala City, Guatemala; and Boston, USA. Budgets and financial reports provided by hospital administrators were reviewed and investigator observations were noted. Interviews were transcribed and analyzed using NVIVO for recurrent themes. IRB exemption was obtained.

**Results**: Recurring themes were organized into six categories following the Ishikawa diagram structure: people, environment, equipment, methods, materials, and other. Interviewees highlighted environmental factors that impede budgeting including insufficient reimbursement for treatment and fluctuating currency exchange rates. Data also revealed the lack of financial managers trained in accounting as a barrier to systematic and transparent financial planning. Key informants noted challenges specific to pediatric oncology, including the lack of national population‐based cancer registries, which prevents accurate incidence estimates and subsequent bed and staffing calculations.

**Conclusions**: The paucity of publicly‐accessible, easy‐to‐use financial planning resources leads to challenges in the feasibility and long‐term sustainability of pediatric cancer care in LMICs. The development of data‐driven financial planning tools may improve the ability of hospitals in LMICs to budget effectively, procure steady financing, promote transparency and accountability, and, ultimately, establish sustainable facilities for children with cancer.

### PO-563. Families of Children Newly Diagnosed with Cancer Incur Significant Out‐of‐Pocket Expenditure for Treatment -- Report of a Multi‐Site Prospective Longitudinal Study from India (InPOG‐ACC‐16‐01) {#pbc27455-sec-15390}

[R. Arora]{.ul} ^1^, R. Rahman^2^, W. Joe^3^, S. Bakhshi^4^, D. Dhawan^4^, V. Radhakrishnan^5^, M. Kalra^6^, G. Chinnaswamy^7^, A. Das^8^, S. Mudaliar^9^, S. Sangareddi^10^, S. Sharma^11^, R. Seth^12^, A. Singh^13^, S. De^14^, J. Scott^15^, R. Uppuluri^16^, A. Borker^17^, H. Sankaran^7^, P. Bagai^2^

*^1^Max Super Speciality Hospital‐ Saket, Medical Oncology, New Delhi, India; ^2^Cankids...Kidscan‐ New Delhi, Quality Care‐ Research and Impact, New Delhi, India; ^3^Delhi University, Institute of Economic Growth, New Delhi, India; ^4^All India Institute of Medical Sciences, Institute Rotary Cancer Hospital, New Delhi, India; ^5^Cancer Institute, Medical Oncology and Pediatric Oncology, Chennai, India; ^6^Indraprastha Apollo Hospital, Pediatric Hematology Oncology and BMT, New Delhi, India; ^7^Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; ^8^Tata Medical Centre, Pediatric Hematology Oncology, Kolkata, India; ^9^Bai Jerbai Wadia Hospital for Children, Pediatric Hematology Oncology, Mumbai, India; ^10^Institute of Child Health & Hospital, Pediatrics, Chennai, India; ^11^LokmanyaTilak Medical College and Hospital, Pediatric Hematology Oncology, Mumbai, India; ^12^All India Institute of Medical Sciences, Department of Pediatrics, New Delhi, India; ^13^Vardhman Mahavir Medical College & Safdarjung Hospital, Pediatrics, New Delhi, India; ^14^Saroj Gupta Cancer Centre & Research Institute, Haematology & Paediatric Oncology, Kolkata, India; ^15^Sri Ramachandra Medical College and Research Institute, Department of pediatrics, Chennai, India; ^16^Apollo Speciality Cancer Hospital, Pediatric Hematology Oncology, Chennai, India; ^17^Asian Cancer Institute, Medical Oncology, Mumbai, India*

**Background/Objectives**: Diagnosis of cancer in a child places considerable economic burden on families. The health expenditures are more catastrophic in resource‐limited countries like India where GDP spend on health is just over 1% and treatment financing usually out‐of‐pocket(OOP). The objective of this study is to describe the OOP expenditure incurred by families of children with cancer being treated in India prior to and during cancer directed treatment.

**Design/Methods**: A prospective cost of illness study from a family household perspective was conducted in 14 centres in 4 cities in India from 2016‐2018. Family demographic and socio‐economic data was collected followed by OOP expenditure incurred prior to start of treatment. Throughout child\'s treatment, a social worker contacted parents at regular intervals to record their expenditure on cancer directed treatment until completion/death/progression/relapse/abandonment/transfer. Data was described descriptively and a univariate/multivariate analysis using logistic regression was done to detect factors associated.

**Results**: 394 children (63% male, median age 5 years) with cancer were enrolled from public(45%), charitable trust(28%) and private(27%) sector hospitals. 88% were uninsured and 73% families had monthly income of \<Rs10,000(\<159US\$). Mean OOP expenditure was Rs209,500(3325US\$) which is 195% of per capita income (1706US\$) of India.

OOP expenditure from onset of symptoms to start of treatment ‐ Rs53,104(843US\$) of which 77% was medical (15% laboratory tests, 11% medicines, 9% hospital bed costs) and 23% non‐medical (12% travel, 6% food, 3% lodging).

OOP expenditure on cancer directed treatment ‐ Rs156,396(2482US\$) of which 64% was medical (9% hospital bed costs, 9% supportive care drugs, 8% laboratory tests) and 36% non‐medical (19% food, 9% travel, 6% lodging). Only insurance and type of treatment facility were found significantly associated with OOP expenditure on multivariate analysis.

**Conclusions**: Families of children with cancer incur significant OOP expenditure prior to and during treatment. Expenditure varied significantly by insurance and type of treatment facility.

### PO-564. Do New Zealand Children with Cancer Receive the Same High Quality of Care Regardless of Who They Are and Where They Live? {#pbc27455-sec-15400}

S. Macfarlane^1^, K. Ballantine^2^, L. Teague^1^, A. Lyver^2^, S. Cross^2^, P. Bradbeer^1^, S. Hunter^1^, [J. Skeen]{.ul} ^1^

*^1^Starship Children\'s Hospital, Starship Blood & Cancer Centre, Auckland, New Zealand; ^2^Christchurch Hospital, Children\'s Haematology Oncology Centre, Christchurch, New Zealand*

**Background/Objectives**: New Zealand\'s relatively small population necessitates centralised child cancer services. Since 2010 cancer treatment has been provided by two specialist centres ‐ located in Auckland and Christchurch ‐ and 14 shared care centres. We produced updated survival estimates to assess whether the National Child Cancer Network (NCCN) is meeting its overarching objective of ensuring that children receive the same high quality of care regardless of who they are and where they live.

**Design/Methods**: The New Zealand Children\'s Cancer Registry provided demographic and diagnostic data for 764 children aged 0‐14 years diagnosed between 1/1/2010 and 31/12/2014. Three‐year relative survival estimates were calculated according to age, sex, prioritised ethnicity, residence, and deprivation index.

**Results**: Overall three‐year child cancer survival was 85.5% (95% CI: 82.7‐87.8), an increase of 2.4% from the 2000‐2009 period. Comparable outcomes according to sex and age group were evident. Survival for children residing in the most deprived areas (83.2%) was comparable to survival for those in the least deprived (83.9%). According to ethnicity, survival was 82.3% for Maori (95% CI: 76.0‐87.1), 82.7% for Pacific Peoples (95% CI: 72.0‐89.6) and 87.0% for 'All Others' (95% CI: 83.7‐89.7). Three‐year survival was 86.4% for the 363 children who resided in Auckland or Christchurch and 84.6% for those 401 children who travelled outside their region for some of their cancer treatment. By specialist centre, there was no difference in survival for children referred to Auckland (85.6%) or Christchurch (85.4%).

**Conclusions**: Survival comparisons indicate that New Zealand is providing equitable and high‐quality cancer care. The NCCN\'s development of national guidelines to harmonise treatment across the country allows children to receive as much of their treatment as close to home as possible without impacting survival. Future initiatives should ensure equity of access to psychosocial and allied health services and the availability of culturally appropriate patient and family support.

### PO-565. Hepatoblastoma Incidence is Rising Rapidly Worldwide {#pbc27455-sec-15410}

A. Hubbard^1^, J. Poynter^1^, G. Fortuna^2^, E. Marcotte^1^, [L. Spector]{.ul} ^1^

*^1^University of Minnesota, Pediatrics, Minneapolis, USA; ^2^Faculdade de Ciências Médicas da Santa Casa São Paulo, Collective Health, Sao Paulo, Brazil*

**Background/Objectives**: Hepatoblastoma has had the largest average annual percent change (AAPC) of any childhood cancer under 5 years of age in the United States for nearly three decades. To determine if the same is true elsewhere we examined data in the Cancer Incidence of Five Continents system of the International Agency for Cancer Research (<http://www.ci5.iarc.fr>) from 1988‐2012.

**Design/Methods**: Rates of cancers frequently diagnosed at ages 0‐4 were extracted for each registry available during 1988‐1992, 1993‐1997, 1998‐2002, 2003‐2007, 2008‐2012. To overcome small numbers in individual registries, numerators and denominators were aggregated within regions corresponding to the United Nations geoscheme. Average annual percent change (AAPC) was calculated using Poisson regression to model counts with a log population offset. Robust standard errors were used in all models to correct for overdispersion in some regions or cancers. 95% Wald confidence intervals (CI\'s) and p‐values were reported. Within each region we ranked cancers by AAPC.

**Results**: Hepatoblastoma (HB) was the cancer with the fastest rising incidence in 11 of 15 regions, including Subsaharan Africa (AAPC: 4.85%), the Carribean (7.66%), Central America (14.25%), South America (5.55%), North America (2.56%), Northern Europe (3.82%), Western Europe (3.33%), Southern Europe (3.63%), Eastern Europe (6.51%), East Asia (3.63%), and Oceania (3.92%). In Southeast Asia HB was the second fastest rising cancer (4.9%), after ependymal tumors (5.86%), while in North Africa (1.92%) and Western Asia (3.63%) incidence rose but HB ranked below the top 3 AAPC\'s. Only in South Asia did HB incidence fall over the study period (‐2.23%).

**Conclusions**: Over a 25 year period in IARC\'s database of high‐quality, population‐based cancer registries hepatoblastoma was the cancer with the most rapidly rising incidence in children under 5 years of age in most areas of the world. The nearly worldwide, rapid rise in HB incidence implies an exogenous cause and invites explanation.

### PO-566. Singapore Childhood Cancer Registry: A 20‐Year Experience {#pbc27455-sec-15420}

[C.L.J. Teo]{.ul} ^1^, A.M. Tan^1^, G.S. Liew^1^, M.Y. Chan^1^, T.C. Quah^2^

*^1^KK Women\'s and Children\'s Hospital, Paediatric Subspecialties‐ Haematology/Oncology Service, Singapore, Singapore; ^2^National University Hospital, Division of Paediatric Haematology and Oncology, Singapore, Singapore*

**Background/Objectives**: The Singapore Childhood Cancer Registry (SCCR) was established in 1999 with the aim of studying the epidemiology of childhood cancers within a multi‐racial Asian population. SCCR has been systematically collecting information on malignant cancers and benign brain tumours in children and adolescents diagnosed and treated in Singapore since 1997. About 95% of the cancer cases registered in SCCR were notified by KK Women\'s and Children\'s Hospital and National University Hospital. This study aims to describe the epidemiological characteristics of childhood cancer patients registered in SCCR over a period of 20 years.

**Design/Methods**: The SCCR database was reviewed for local residents (Singapore Citizens and Permanent Residents), aged 0‐19 years, who were diagnosed with cancers between 1997 and 2016. The cancers were classified according to the International Classification of Childhood Cancer (ICCC).

**Results**: A total of 1,868 cases were registered in SCCR between 1997 and 2016. The annual number of new cases ranges from 77 to 120, with an average of 93.4 cases per year. The male to female ratio was 1.3:1. The common childhood cancers were leukaemia (37.8%), central nervous system tumours (17.3%), lymphomas (10.3%), followed by germ cell tumours (7.9%) and sympathetic nervous system tumours (5.9%). By age group stratification, 42.6% were 0‐4 years, 23.8% were 5‐9 years, 26.2% were 10‐14 years and 7.3% were 15‐19 years. Majority of the cases were Chinese (68.3%), followed by Malay (18.5%), Indian (9.3%) and other ethnicities (3.9%). This ethnic distribution pattern is similar to that of the national population.

**Conclusions**: SCCR provides epidemiology and clinical information of childhood cancers, which has offered a basis for various researches on these diseases in Singapore. In this study, variability is observed across different groups, such as cancer type, age group and gender. Further studies are warranted to understand these differences for effective treatment planning and improve outcomes.

### PO-567. Impact of Online Access to Rare Multidisciplinary Expertise in Pediatric Oncology: Prospective Analysis of an Online Expert Opinion Service from India {#pbc27455-sec-15430}

[T. Vora]{.ul} ^1^, V. Bhat^1^, M. Prasad^1^, N. Khanna^2^, A. Gulia^3^, G. Narula^1^, S. Laskar^2^, N. Ramarajan^4^, G. Srivastava^4^, S. Banavali^1^, C.S. Pramesh^4^

*^1^Tata Memorial Centre, Pediatric Medical Oncology, Mumbai, India; ^2^Tata Memorial Centre, Radiation Oncology, Mumbai, India; ^3^Tata Memorial Centre, Orthopedic Surgical Oncology, Mumbai, India; ^4^Tata Memorial Centre, National Cancer Grid, Mumbai, India*

**Background/Objectives**: Lack of access to evidence based multidisciplinary expertise is an under‐recognized cause of suboptimal outcomes in pediatric cancers in low middle income countries (LMIC) (unlike well recognized financial and psychosocial barriers). Imbalanced general oncologist:patient ratio (∼1600:1.8 Million,India, ∼23,000:15 Million,USA), are exacerbated in pediatric oncology. TMC NCG Navya Online ("Navya") is a multidisciplinary expert opinion service with a 24 hour turnaround based on a clinical informatics system validated in clinical trials(SABCS 2014, 2016, 2017;ASCO 2016, 2017).

**Design/Methods**: This is a prospective impact analysis of the use and reach of Navya for children (age \<15) over three years of the online service (April,2015 ‐ March,2018). Online opinion forms and medical reports of pediatric patients were analyzed. Adult data from the same dataset, and Globocan data were used as comparators.

**Results**: Of the 6804 patients analyzed, 77.50% received evidence based treatments recommended by Navya. Of these, 166(2.44%) were pediatric patients, comparable to global (1.16%) and Indian estimates (2.33%)(Globocan 2012). Pediatric patients were from seven countries (74.10%‐India), compared to adults from 37 countries (72.25%‐India). The prevalence of solid tumours:hemato‐lymphoid malignancies in the Globocan India estimates (28.32%:71.68%) is reversed in the Navya cohort (62.65%:37.35%). Demand for pediatric online expert opinions, as measured by size of the pediatric cohort (95% growth rate in 2017‐2018 compared to the initial baseline of 2015‐2016(78 from 40)), exceeded that of the adult cohort (83% growth rate, 2795 from 1524).

**Conclusions**: High percentage of pediatric solid tumors in this cohort, compared to hemato‐lymphoid, which have standardized treatment protocols, illustrates the impact and need of rapid, online access to expertise for uncommon cancers requiring complex, multidisciplinary treatment opinions. Increased demand for pediatric expertise is seen in the doubling of the pediatric cohort. Navya is highly utilized by patients to receive evidence based treatments. Scaling such access can improve outcomes for pediatric cancers worldwide.

### PO-568. Exploring Leadership Profiles and Strategic Decision‐Making in Pediatric Oncology: Insights from Hospital Infantil Teletón de Oncología and Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center {#pbc27455-sec-15440}

[K. Wachter]{.ul} ^1^, S. Popatia^2^, L. Vega‐Vega^3^, I. Albanti^4^

*^1^Harvard T.H. Chan School of Public Health, Global Health and Population, Boston, USA; ^2^Harvard T.H. Chan School of Public Health, Health Policy and Management, Boston, USA; ^3^Hospital Infantil Teletón de Oncología, Pediatric Oncology, Querétaro, Mexico; ^4^Global Health Initiative‐ Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center, Pediatric Oncology, Boston, USA*

**Background/Objectives**: Limited data exists on approaches to strategy and leadership at pediatric oncology units in Low‐ and Middle‐Income Countries. Understanding leadership traits and elements in decision‐making is essential for strong hospital governance, systematic strategic planning, and efficient resource allocation which can ultimately improve patient outcomes.

We developed a qualitative study to explore leadership profiles, examine decision‐making processes and priorities, assess strategy formulation, and obtain staff recommendations at Hospital Infantil Teletón de Oncología (HITO) in Querétaro, Mexico and Dana‐Farber/Boston Children\'s Cancer and Blood Disorders Center (DF/BC) in Boston, USA.

**Design/Methods**: We conducted 18 in‐depth interviews with senior clinical and administrative leaders at HITO and DF/BC, reviewed strategic planning materials, completed a systematic literature review, and facilitated group discussions and a strength‐finding exercise. Data was recorded, transcribed, and manually coded in Excel. IRB approval was obtained.

**Results**: Four themes emerged around training, priority‐setting, leadership styles, and organizational culture. All respondents learned management skills "on‐the‐job." Decisions at HITO were driven by strategic priorities including obtaining excellent survival rates, financial sustainability, and positive workplace environment; and at DF/BC by workforce development, cutting‐edge research, and partner engagement. Respondents emphasized the importance of people‐focused leaders who cultivated organizational culture. DF/BC respondents expressed loyalty and were motivated by pride for the mission and strong teaching environment. HITO prioritized efforts to define their culture as a four‐year‐old institution and expressed appreciation for its family‐like culture, while citing staff burnout and morale as focus areas.

**Conclusions**: Pediatric oncology leaders may have different training backgrounds and priorities, but share a commitment to establishing a strong workforce and organizational culture to strengthen staff engagement and promote systematic planning. Understanding culture and leadership, applying mission‐driven decision‐making, and aligning priorities may prepare organizations to effectively address changes, maximize resources, and improve cancer care delivery.

### PO-569. Racial Disparities in Outcomes of Adolescent and Young Adult Patients with Cancer Treated in Community Oncology Centers in the United States {#pbc27455-sec-15450}

[L. Wagner]{.ul} ^1^, S. Howard^2^

*^1^University of Kentucky, Pediatrics, Lexington, USA; ^2^University of Tennessee Health Science Center, College of Nursing, Memphis, USA*

**Background/Objectives**: Most adolescent and young adult (AYA) patients with cancer in the United States (US) are treated in community oncology centers rather than academic institutions, limiting the ability to track outcomes in the "real world" environment. Previous studies suggested race is often associated with outcome in this age group. Our objective was to investigate the demographic features and outcomes of a large group of AYA patients treated at community oncology centers and identify potential racial disparities in patients with higher‐risk cancers.

**Design/Methods**: To identify racial disparities in community oncology outcomes, we analyzed anonymized, de‐identified medical records from the Guardian Research Network (<http://www.GuardianResearch.org>), a non‐profit US clinical trials consortium of 101 hospitals.

**Results**: Of data from 10,619 patients aged 18‐39 years treated from 2009‐2018, we selected 7,087 patients (median age at diagnosis, 32 years) with higher‐risk cancers, of whom 73% were females, 77% Caucasian, 10% black, and 13% of other races. Diagnoses included breast cancer (29%), lymphoma (19%), gynecologic cancer (17%), head/neck cancer (11%), colorectal cancer (9%), leukemia (8%) and sarcoma (7%). The 5‐year overall survival for all patients was 92%. Survival for black patients was 89.6%, other non‐whites 88.2%, and whites 93.2%(p\<0.001). Within disease groups, significant differences were observed between races in all seven high‐risk tumor types, with log‐rank estimates ranging from p=0.04 for leukemia to p\<0.001 for breast cancer. Multivariable Cox analysis controlling for cancer type confirmed a relative risk of 1.8 (95% confidence interval 1.4‐2.3, p\<0.001) for black patients versus white, 2.4 for other races (1.9‐3.0, p\<0.001), and 1.7 for men versus women (1.4‐2.1, p\<0.001).

**Conclusions**: In this large survey of AYA patients with 7 index cancers treated at community oncology centers in the US, we identified a survival gap by race and gender, which can exist even in high‐income countries with large heath care expenditures.

Survivorship {#pbc27455-sec-15460}
------------

### PO-570. Creation of the First Clinic in Mexico City for Pediatric Survivors of Childhood and Adolescent Cancer. A Real Challenge for Pediatric Oncologists {#pbc27455-sec-15470}

[F. Arreguin]{.ul} ^1^, A. Benito^1^, E. Baños^1^, B. Almazan^1^, P. Loeza^2^, F. Acosta^3^, L. Ledesma^4^

*^1^Centro Medico Nacional 20 de Noviembre ISSSTE, Pediatric Oncology Department, Mexico, Mexico; ^2^Centro Medico Nacional 20 de Noviembre ISSSTE, Rehabilitation Department, Mexico, Mexico; ^3^Centro Medico Nacional 20 de Noviembre ISSSTE, Pediatric Department, Mexico, Mexico; ^4^Centro Medico Nacional 20 de Noviembre ISSSTE, Psychiatry Department, Mexico, Mexico*

**Background/Objectives**: Although pediatric cancer occurs in less than 5% of the annual incidence of cancer around the world, it remains as the most common cause of disease‐related mortality in this age group. Over the last 30 years, the survival rate in this disease has improved all around the world, but it is still a challenge in middle and low income countries. Currently, 8 of every 10 children will survive cancer, but they will have adverse healthrelated and quality of life outcomes as a sequelae. The ISSSTE (Institute of Security and Social Service for State Workers) is a third level institute in Mexico that takes care of 11% of Mexico\'s total population and the Medical National Center "20 de Noviembre" is the main reference hospital for ISSSTE\'s oncology patients. Our overall survival is around 66% and we created the first Survivorship Pediatric Cancer Clinic in Mexico.

**Design/Methods**: We implemented a risk based model based on the Childhood Cancer Survivor Study adjusted to our needs, and implemented a Program with 4 phases (1. Situational diagnosis, 2. Tailor‐made intervention 3.Health education 4. Transition Young‐Adulthood)

**Results**: We recluted 200 cancer survivors. Phase 1. Female predominance, adolescents most frequent group. Around 80% of survivors had sequelae. Most common late effects were endocrine (pituitary dysfunction, metabolic síndrome), musculoesqueletical and ovarian dysfunction. We detected social and psychologic impairment in 50%. There\'s a lack of information in our system during the patient cancer treatment.

**Conclusions**: It is a real challenge for oncologists to create a surveillance clinic, we need to improve our data basis when the patient is in treatment so we can have complete information. With these results, we can start our Phase 2 and work at the same time with our cancer patients in order to have all the information complete when they get cured.

### PO-571. My Middle Name is "Miracle" {#pbc27455-sec-15480}

[C. Audina]{.ul} ^1^

*^1^Indonesia Children Oncology Foundation YOAI, Survivor, Jakarta, Indonesia*

**Background/Objectives**: My name is Cindy Audina, I was born on September 4^th^ 1996. I was diagnosed with 2 types of cancer (Acute Lymphoblastic Leukemia and Lymphadenopathy) when I was 9 years old which is in October 2005 and finished my treatment in January 2009.

I am 21 years old now and active in Cancer Buster Community (CBC) since 2011. CBC is a survivor community under the umbrella of Indonesia Children Oncology Foundation (YOAI). CBC\'s activities mainly conducting a survivor cancer camp, roadshow throughout Indonesia to support patients of children with cancer by doing hospital visit.

Being a child with cancer is not an easy life.

There are so many myths about the disease that appears in the community that cancer is a threat and cannot be cured. Indonesia movie about cancer sells more sadness and that cancer patients will eventually died, thus made the cancer fighters broke their spirit.

As a cancer survivor who has been cured, I would like to give support and revive hope that childhood cancer is curable and cancer survivor can live as normal as a child in general.

**Design/Methods**: To installing hope to cancer patients and spread that miracle still exist, I wrote my success story in battling with cancer into a book with a title "Nama Tengahku "Mukjizat" "(My Middle Name is "Miracle")

**Results**: This book was launched on 04 July 2017. Lots of patients and their parents get inspired by my success story. They become more positive and eiger to do the protocol of their medication, also get supports from their family and their surroundings.

**Conclusions**: This book makes people more aware that childhood cancer is curable. In the end, this book can help me to reach my ultimate goal which is to improve the recovery rate of childhood cancer patients in Indonesia.

### PO-572. Ambulant Health Utilization Among Children of Childhood Cancer Survivors in Germany {#pbc27455-sec-15490}

[M. Balcerek]{.ul} ^1^, T. Schuster^1^, E. Korte^1^, S. Ralph^1^, H. Hölling^2^, A. Borgmann‐Staudt^1^

*^1^Charité ‐ Universitätsmedizin Berlin, Paediatric Oncology‐ Haematology and Stem Cell Transplantation, Berlin, Germany; ^2^Robert Koch Institute, FG26 Psychic Health, Berlin, Germany*

**Background/Objectives**: In a German‐wide questionnaire‐based health survey, ambulant health care utilization of childhood cancer survivors' offspring was compared to children of the general population.

**Design/Methods**: In total, 1299 childhood cancer survivors received a questionnaire for every known biological child in two survey periods, 2013/14 and 2015/16. For investigation of health care utilization, questions on frequencies and kind of ambulant medical services were chosen for bivariate, multivariate and matched pair analyses. Correlations between utilization and anxiety, diagnosis of the parent, pain or preterm birth of the child and social indicators were conducted. For comparison with the general population, data of 17,641 children and adolescents aged 0 to 17 years was used. These data were available from the KIGGS baseline study on the health of children and adolescents in Germany, conducted by the Robert Koch Institute.

**Results**: Overall 852 (65.6%) of the contacted 1299 survivors completed 1340 questionnaires on their children\'s health. Childhood cancer survivors' offspring showed a similar attendance of ambulant primary health care compared to the general population (pediatricians 83.1% vs. 82.1%). However, the majority of specialist physicians was visited significantly more often (e.g. dermatologist 10.5% vs. 6.2%) by childhood cancer survivors' offspring compared to children from the general population. Logistic regression showed that parental diagnosis of solid tumor and anxiety on children\'s health significantly influenced health care utilization.

**Conclusions**: Further improvement of after‐care for childhood cancer survivors by including topics on offspring seems necessary. Offspring\'s pediatricians should implement counselling and providing of information considering the special family anamnesis.

### PO-574. Hearing Impairment Among Long‐Term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS) {#pbc27455-sec-15500}

[A. Brown]{.ul} ^1^, K. Seidel^2^, S. Hayashi^3^, P. Lupo^1^, T. Henderson^4^, R. Howell^5^, K. Krull^6^, L. Robison^6^, W. Leisenring^2^, K. Oeffinger^7^, G. Armstrong^6^, R. Hayashi^8^

*^1^Baylor College of Medicine, Pediatrics, Houston‐ TX, USA; ^2^Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle‐ WA, USA; ^3^Children\'s Hospital St. Louis, Audiology, St. Louis‐ MO, USA; ^4^The University of Chicago, Pediatrics, Chicago‐ IL, USA; ^5^MD Anderson Cancer Center, Radiation Physics, Houston‐ TX, USA; ^6^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis‐ TN, USA; ^7^Duke University, Medicine, Durham‐ NC, USA; ^8^Washington University in St. Louis, Pediatric Hematology/Oncology, St. Louis‐ MO, USA*

**Background/Objectives**: Cisplatin, carboplatin, and cranial radiotherapy (CRT) ≥30 Gy are associated with ototoxicity; however, information on the magnitude of risk and latency associated with treatment combinations is limited.

**Design/Methods**: Presence or absence of hearing impairment (requiring a hearing aid or deafness) was reported by 24,306 ≥5 year childhood cancer survivors (mean years from diagnosis=24.1, standard deviation=8.9). Age‐ and sex‐adjusted prevalence ratios (PR) and hazard ratios (HR), with corresponding 95% confidence intervals (CI), were estimated for early‐onset (\<5 years post‐diagnosis) and late‐onset (≥5 years post‐diagnosis) hearing impairment, respectively.

**Results**: Among all survivors, the prevalence of hearing impairment was 3.1% (95% CI: 2.9‐3.4) at 5 years post‐diagnosis, and the 15‐year cumulative incidence was 4.8% (95% CI: 4.5‐5.1). Any cisplatin exposure was associated with early‐onset impairment, even at doses \<200 mg/m2 (PR\[95% CI\]=14.6 \[7.6‐28.0\]), while higher doses remained associated with late‐onset impairment (e.g., HR\[95% CI\]: 3.7 \[1.7‐8.0\] for 200‐300 mg/m2). In contrast, early‐onset impairment was associated with carboplatin doses ≥4.0 g/m2 (PR\[95% CI\]=8.6 \[4.1‐18.1\]), while doses \<4.0 g/m2 were associated with late‐onset impairment (e.g., HR\[95% CI\]: 4.6 \[1.1‐18.7\] for 0.1‐1.9 g/m2). Hearing impairment was more strongly associated with exposure to CRT≥30 Gy combined with platinum (PR\[95% CI\]: 49.5 \[36.5‐67.3\] for CRT≥30 Gy + 400‐599 mg/m2 cisplatin; 22.2 \[10.8‐45.7\] for CRT≥30 Gy + 2‐3.9 g/m2 carboplatin) than comparable doses of CRT (9.4 \[7.0‐12.6\]), cisplatin (19.2 \[12.9‐28.4\]), or carboplatin (2.0 \[0.3‐14.1\]) alone. Impairment occurred in 50.1% (95% CI: 45.3‐54.8) of survivors treated with CRT≥30 Gy and ≥200 mg/m2 cisplatin and 33.5% (95% CI: 22.5‐44.5) with CRT≥30 Gy and ≥2 g/m2 carboplatin by 15 years post‐diagnosis.

**Conclusions**: Hearing impairment in survivors of childhood cancer evolves over decades following treatment. Although the incidence is greatest in survivors exposed to multiple ototoxic therapies, survivors treated with platinum therapy, even at low doses, have a high likelihood of profound ototoxicity.

### PO-575. Social Consequences of Childhood Cancer Late Effects: A Qualitative Study of Survivors of Childhood Cancer Unique Knowlegde about Late Effects {#pbc27455-sec-15510}

[L.T. Carlsen]{.ul} ^1,2^

*^1^Danish Cancer Society, Patient Support and Community Activities, Copenhagen, Denmark; ^2^Aalborg University, Department of Sociology and Social Work, Aalborg, Denmark*

**Background/Objectives: Objective**

The last 20 years, an increased survival rate is seen in childhood cancer patients, with up to 80 percent cured in the Nordic countries. As a result, there is an increasing number of adults living with late effects of childhood cancer.

The purpose of this qualitative study is to generate new knowledge about the influence of late effects on the childhood cancer survivors' social life. The study includes patients' perspectives and is based on the unique knowledge provided by young adult childhood cancer survivors about both physical, mental, and social late effects.

**Design/Methods: Design** The qualitative study is based on phenomenology and the methodological analysis strategy is inspired by grounded theory. A total of 19 subjects (age 18 to 39) participated in this part of the study, including 25 semi‐structured interviews, three focus group interviews and observations in a group of childhood cancer survivors as the empirical basis. Besides attending the interviews, participants were asked to provide personal details including disease history.

**Results**: Different types of late effects may amplify and affect each other which may lead to new mental and social late effects with major consequences for daily life. Therefore, it is important to focus on the total sum of all the late effect complications to understand the overall daily consequence of life with late effects. The study explores that survivors of childhood cancer perceive that social consequences of late effects are not recognized. Hence, late effects can negatively influence four aspects of survivors\' social life: 1) education, job and economic opportunities, 2) participation in social life, 3) establishment of family, and 4) relationship to siblings and parents.

**Conclusions**: The study implies that survivors of childhood cancers late effects can influence the quality of social life in four aspects of their social life.

### PO-576. Survivors of Childhood Cancer Experience a Simultaneity of Thankfulness and Grief After Complete Medical Recovery: A Qualitative Study of Survivors Unique Knowlegde about Late Effects {#pbc27455-sec-15520}

[L.T. Carlsen]{.ul} ^1,2^

*^1^The Danish Cancer Society, Patient Support and Community Activities, københavn, Denmark; ^2^Aalborg University, Department of Sociology and Social Work, Aalborg, Denmark*

**Background/Objectives**: The last 20 years, an increased survival rate is seen in childhood cancer patients, with up to 80 percent cured in the Nordic countries. As a result, there is an increasing number of adults living with late effects of childhood cancer.

The purpose of this qualitative study is to generate new knowledge about the influence of late effects on the childhood cancer survivors' social life. The study includes patients' perspectives and is based on the unique knowledge provided by young adult childhood cancer survivors about both physical, mental, and social late effects.

**Design/Methods**: The qualitative study is based on phenomenology and the methodological analysis strategy is inspired by grounded theory. A total of 19 subjects (age 18 to 39) participated in this part of the study, including 25 semi‐structured interviews, three focus group interviews and observations in a group of childhood cancer survivors as the empirical basis. Besides attending the interviews, participants were asked to provide personal details including disease history.

**Results**: The survivors share that their survival can be characterized by many positives: 'fantastic', 'success', 'victory'. However, their experience has a shadow side: a life with late effects. They explain a simultaneity of happiness and grief. Delighted to survive but they are feeling grief for their lost opportunities and their changed life situation. Their comfortable, secure and familiar everyday life has changed, and the childhood cancer patient loses the opportunity to live a 'normal' childhood either periodic or permanent which the survivors themselves describe as a loss.

**Conclusions**: The study illustrates a simultaneity of thankfulness and grief in adult survivors of childhood cancer.

### PO-577. When Professional and Parental Priorities Differ: Understanding School Professionals' First‐time Experiences in Serving a Student with Langerhan\'s Cell Histiocytosis from Disadvantaged Family in Taiwan {#pbc27455-sec-15530}

[C.C. Cheng]{.ul} ^1^

*^1^National Kaohsiung Normal University, Special Education, Kaohsiung, Taiwan R.O.C*.

**Background/Objectives**: In 2015, 27 children were diagnosed with Langerhans\' cell histiocytosis (LCH) in Taiwan. Given the rarity of childhood LCH and a lack of school reentry protocol to prepare childhood cancer survivors for their return to school in Taiwan, how did school professionals fare when they encountered students with LCH from disadvantaged families for the first time? This study aimed to explore lessons learned from school personnel\'s experiences working among themselves and with parents to keep a middle school student with LCH in school.

**Design/Methods**: This is a qualitative study. The researcher conducted in‐depth interviews with five middle school professionals in 2017 on how they struggled to keep Weiheng (pseudonym) in school. Weiheng was diagnosed with LCH in Grade 2 at age 8 and left school for medical treatment. He only returned to middle school for Grade 7 at age 13 in 2016. The professionals interviewed were Weiheng\'s homeroom teacher, resource room teacher, counselor, social worker, and the administrator overseeing school\'s counseling and special education services.

**Results**: All participants agreed that working with Weiheng and his father the past school year was an arduous learning curve that took them through different stages of adaptation. As the professionals gained more knowledge about the seemingly dysfunctional family, they adjusted their expectations according to their changing understanding of what they could do in terms of their professional responsibilities. These stages started with teachers taking charge, on to seeking additional professional support and insight, and finally settling for the shared bottom line.

**Conclusions**: Differences among professional ideologies and conflicting professional‐parent perspectives initially rocked but eventually facilitated the implementation of this first‐time school reentry project for a student with LCH. With the shared goal of keeping Weiheng in school, professionals gradually started to appreciate the father\'s perspectives and change their expectations for Weiheng, which led to more effective collaboration.

### PO-578. Comparing Long‐Term Social, Cognitive, and Academic Outcomes after Treatment with Proton versus Photon Radiation Therapy for Pediatric Brain Tumors {#pbc27455-sec-15540}

[A. Child]{.ul} ^1,2^, E. Warren^1,2^, P. Cirino^1^, D. Grosshans^3^, A. Mahajan^4^, A. Paulino^3^, M. Chintagumpala^2,5^, F. Okcu^2,5^, M.D. Ris^2,6^, C. Minard^7^, A. Viana^1^, J. Bick^1^, S. Woods^1^, J. Orobio^2,6^, J. Xue^2,6^, L. Kahalley^2,6^

*^1^University of Houston, Department of Psychology, Houston‐ TX, USA; ^2^Baylor College of Medicine, Department of Pediatrics, Houston‐ TX, USA; ^3^The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston‐ TX, USA; ^4^Mayo Clinic, Department of Radiation Oncology, Rochester‐ MN, USA; ^5^Texas Children\'s Hospital, Cancer and Hematology Centers, Houston‐ TX, USA; ^6^Texas Children\'s Hospital, Psychology Service, Houston‐ TX, USA; ^7^Baylor College of Medicine, Department of Medicine, Houston‐ TX, USA*

**Background/Objectives**: Proton beam radiotherapy (PBRT) reduces exposure of healthy tissue to radiation, which may minimize late effects in patients with pediatric brain tumor. This study compared social, cognitive, and academic outcomes in children treated with PBRT versus photon radiotherapy (XRT).

**Design/Methods**: Survivors who were \>1 year post‐radiation (M=6.5, SD=3.27 years) completed cognitive (processing speed, working memory, language, attention, executive function, memory) and academic (reading, writing, math fluency) testing. Parents completed questionnaires assessing survivors' social functioning.

**Results**: XRT (n=29) and PBRT (n=54) groups did not differ on demographic/clinical variables (68.7% male, M age‐at‐treatment=7.8 years, 51.8% infratentorial tumor, 55.0% craniospinal RT, median RT dose to tumor=54.0 Gy), except for age‐at‐evaluation (PBRT M=13.23 years, XRT M=16.39 years; p=0.01) and follow‐up interval (PBRT M=5.05 years, XRT M=8.59 years; p\<0.01). Tumor types included: 21.7% glioma, 38.6% PNET/medulloblastoma, 13.3% ependymoma, 15.7% germ cell, 10.8% other. The PBRT group performed within normal limits (+/‐1SD) on most cognitive measures, while the XRT group performed \<‐1SD on measures of working memory, language, executive function, and memory. Both groups performed \<‐1SD on measures of processing speed and motor dexterity. On ANCOVA tests, controlling for group differences on age‐at‐evaluation and follow‐up interval, survivors treated with PBRT outperformed those treated with XRT on all cognitive (p\<0.001 to 0.032) and academic tasks (p\<0.001), except attention (p\>0.05). The PBRT group was also rated as having better social functioning (p\<0.05).

**Conclusions**: Findings suggest PBRT may provide a meaningful benefit over XRT for social, cognitive, and academic outcomes in pediatric brain tumor survivors.

### PO-579. Clinical Utility of Long‐Term Follow‐Up Program in Patients who Underwent Hematopoietic Stem Cell Transplantation in Childhood {#pbc27455-sec-15550}

[S. Doisaki]{.ul} ^1^, R. Maemura^1^, A. Yamamori^1^, Y. Nishikado^2^, H. Sakaguchi^1^, N. Yoshida^1^, T. Ando^3^, Y. Goto^4^, R. Hattori^5^, K. Kato^1^, A. Hama^1^

*^1^Japanese Red Cross Nagoya First Hospital, Department of Hematology and Oncology‐ Children\'s Medical Center, Nagoya, Japan; ^2^Japanese Red Cross Nagoya First Hospital, Department of Endocrinology‐ Children\'s Medical Center, Nagoya, Japan; ^3^Japanese Red Cross Nagoya First Hospital, Department of Obstetrics and Gynecology, Nagoya, Japan; ^4^Japanese Red Cross Nagoya First Hospital, Department of Breast and Endocrine Surgery, Nagoya, Japan; ^5^Japanese Red Cross Nagoya First Hospital, Department of Urology, Nagoya, Japan*

**Background/Objectives**: The patients, who receive hematopoietic stem cell transplantation (HSCT) in childhood, often have physical, psychological, and social problems due to complications after HSCT. The long‐term follow‐up (LTFU) program may play an important role to support them, however, it has not been well established in Japan.

**Design/Methods**: From April 1982 to March 2017, a total of 673 HSCT were performed for 625 patients at the median age of 7.9 years (range, 0.4‐20) in our institution. We started an LTFU program since April 2016, and evaluated the following physical conditions using the Common Terminology Criteria for Adverse Events (version 4.0); endocrinopathies, central nervous system complication, cardiopulmonary dysfunction, gastrointestinal and hepatic sequelae, renal dysfunction, iron overload, and secondary malignancies. Up to March 2018, 68 patients (male 35, female 33) visited the program. Underlying diseases were hematological malignancy in 45 patients, solid tumor in 14, and non‐malignancy in 9. The median age at initial visit to the LTFU and the time from HSCT was 15 years (range, 3.3‐41) and 7.3 years (range 1.1‐27), respectively. Out of 68 patients, 53 underwent allogeneic HSCT, and the conditioning regimen included ≥8 Gy of total body irradiation (TBI) for 35 patients.

**Results**: Ten patients developed moderate or severe chronic graft‐versus‐host disease. Through our program, grade 3 events were identified in 7 patients, all of whom were given ≥8 Gy of TBI; secondary malignancies (n=2, papillary thyroid cancer and renal cell carcinoma), iron overload (n=2), pulmonary dysfunction (n=1), cardiac disorder (n=1), and primary amenorrhea (n=1). Both of patients with secondary malignancies were diagnosed in early stage, and successfully treated with total resection of their tumors.

**Conclusions**: We found several life‐threatening complications including secondary malignancies through the LTFU program. The program is useful to detect latent problems and manage complications after HSCT.

### PO-580. Visual Working Memory State in Patients who Survived Posterior Fossa Tumors, Acute Lymphoblastic Leukemia, and Healthy Controls {#pbc27455-sec-15560}

A. Ryabova^1^, [A. Dreneva]{.ul} ^1^, V. Kasatkin^1^, A. Karelin^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Rehabilitation Research Center for Patients in Remission "Russkoye Pole", Moscow, Russia*

**Background/Objectives**: Posterior fossa tumors (PFT) and acute lymphoblastic leukemia (ALL) are frequently observed types of childhood malignancies. Current methods of treatment have provided notable increment in patients' survival rates. At the same time, the initial diagnosis combined with treatment effects can impair executive functioning, including working memory, sustained attention, inhibition, and shifting. Furthermore, the age of diagnosis and treatment does also matter.

**Design/Methods**: We performed the estimation of working memory state using the subtests for visual working memory of Cambridge Neuropsychological Test Automated Battery. The sample included three groups: 77 patients who survived PFT (32 females, mean age was 11.72 ±3.28), 49 patients after ALL (25 females, mean age was 11.05 ±3.58), and 34 healthy controls (18 females, mean age was 11.94 ±2.29). We used MANOVA for defining the effects of age and diagnosis on visual working memory state in all three groups.

**Results**: The findings demonstrate significant differences in working memory measures in three groups of the participants. The patients after PFT have the worst results, ALL survivors have shown better ones, even though they are worse than in healthy children. Furthermore, we have revealed age dynamics in performing working memory tasks: with aging, the amount of elements processed in working memory increases, whereas in contrast, the amount of mistakes decreases.

**Conclusions**: Children and adolescents who survived oncological diseases, show the deficiency in working memory processing as contrasted with healthy children. Notably, children with brain tumors are less successful in these tasks, than patients who survived blood malignancies. Moreover, the study indicates that executive control and the volume of working memory substantially increase with aging.

### PO-581. Introduction of Treatment Summaries and Holistic Needs Assessments for Teenagers and Young Adults after Cancer Treatment in Scotland: A National Feasibility Study {#pbc27455-sec-15570}

[A. Edgar]{.ul} ^1^, J. White^2^, S. Kumar^1^, N. Davison^1^, B. Wilkie^1^

*^1^Royal Hospital for Sick Children, Haematology and Oncology, Edinburgh, United Kingdom; ^2^Beatson West of Scotland Cancer Centre, Oncology, Glasgow, United Kingdom*

**Background/Objectives**: The Scottish Government recommends that all teenagers and young adults (TYA) treated for cancer, receive a Treatment Summary (TS) and Holistic Needs Assessment (HNA) to aid communication, education, self‐management and identify areas of concern.

The objectives of this study were: i) To determine the feasibility of implementing TS and HNA for Scottish TYA after cancer treatment; and ii) to share TS with health professionals to improve communication and engagement.

**Design/Methods**: Scottish TYA (16‐24 years) completing cancer treatment, between April 2016 ‐April 2017, were identified at the weekly National TYA Multidisciplinary Team (TYA MDT) meeting. Treatment Summaries and HNA were completed and distributed to patients and health professionals.

**Results**: Of 83 eligible patients, 51 were recruited (response rate 61%); 26 (51%) males, median (range) age 22 (16 -- 25) years. Among non‐recruits: 2 relocated, 1 relapsed, lead consultant deemed the process 'not relevant' (n=6), or did not respond (n=23). Cancer diagnoses: germ cell tumours (39%), lymphomas (27%) and bone tumours (14%) over represented; carcinoma (8%), melanoma (2%) and CNS tumours (2%) under‐represented.

**Conclusions**: Treatment Summaries and Holistic Needs Assessments were completed for almost two thirds of TYA identified after cancer treatment. Recruitment failure was due largely to consultant disengagement. Based on incidence data, current pathways do not allow identification of almost half of patients at the end of treatment. Completion of TS/HNA is labour intense and adequate time and training must be provided. By sharing Treatment Summaries we have improved communication and engagement with Primary Care and provided clear pathways for referral of patients to hospital when problems arise.

### PO-582. Holistic Needs Assessments for Teenagers and Young Adults after Cancer Treatment in Scotland Identified a Significant Burden of Unmet Needs {#pbc27455-sec-15580}

[A. Edgar]{.ul} ^1^, J. White^2^, S. Kumar^1^, N. Davison^1^, B. Wilkie^1^

*^1^Royal Hospital for Sick Children, Haematology and Oncology, Edinburgh, United Kingdom; ^2^Beatson West Of Scotland Cancer Centre, Oncology, Glasgow, United Kingdom*

**Background/Objectives**: Psychosocial issues are common amongst Teenagers and young adults (TYA) after cancer treatment and TYA report feeling unsupported.

The aim of this study was to determine the burden of needs amongst TYA after cancer treatment and evaluate whether these needs are being met.

**Design/Methods**: Scottish TYA (16‐24 years) completing cancer treatment, between April 2016‐April 2017, were identified. Treatment Summaries (TS) and Holistic Needs Assessment (HNA) were completed and distributed (TS only) to patients and health professionals. Qualitative analysis identified concerns.

**Results**: Fifty‐one of 83 eligible TYA were recruited (response rate 61%); 26 (51%) males, median (range) age 22 (16 -- 25) years with over‐representation of germ cell tumours (39%), lymphomas (27%), bone tumours (14%). TS data was available for 51 (100%) and raw HNA data for 26 patients (50%). 45 TYA (88%) reported concerns: 35 (69%) reported 1‐5 concerns; 2 (4%) reported 6‐10 concerns; 5 (10%) reporting 11‐15 concerns; 1 (2%) reported 1 concern and 2 (4%) reported \>20 concerns: general appearance, physical fitness and emotional issues, were the most numerous. One third of TYA were referred for psychological support; two‐thirds benefitted from third sector support programmes.

**Conclusions**: Almost 90% of TYA reported at least one concern after cancer treatment, with more than two‐thirds of patients reporting five to 10 concerns, and 10% reporting up to 15 concerns. While support services, largely provided by third sector, are in place for many patients, further evaluation of the Health Needs Assessments, exploring relationships to diagnoses, and identification of gaps in services, are required to inform future developments.

### PO-583. Using the Cumulative Illness Rating Scale to Characterize the Burden of Chronic Conditions Among Childhood Cancer Survivors and to Predict Mortality {#pbc27455-sec-15590}

[A. Esbenshade]{.ul} ^1^, D.L. Friedman^1^, L. Lu^2^, K.C. Oeffinger^3^, G.T. Armstrong^2^, K.R. Krull^2^, J.P. Neglia^4^, W. Leisenring^5^, M. Stovall^6^, L.L. Robison^2^, K.K. Ness^2^

*^1^Vanderbilt University Medical Center, Pediatric Hematology Oncology, Nashville, USA; ^2^Saint Jude Children\'s Research Hospital, Department of Epidemiology & Cancer Control, Memphis, USA; ^3^Duke Cancer Center, Medicine, Durham, USA; ^4^University of Minnesota, Pediatrics, Minneapolis, USA; ^5^Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA; ^6^University of Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA*

**Background/Objectives**: A uniform system of comorbidity classification in childhood cancer survivors is essential to enumerate and determine impact of disease burden on health outcomes, and permit comparisons across populations. We aimed to characterize burden of disease in adult childhood cancer survivors and siblings using the Cumulative Illness Rating Scale for Geriatrics (CIRS‐G), and determine associations between disease burden and incident mortality.

**Design/Methods**: Baseline questionnaires were completed by 14,355 CCSS participants (53.7% male, mean\[standard deviation\] age 23.1\[7.8\], age at diagnosis 7.8\[5.8\] years)and 4,022 siblings (48.2% male, age 26.2\[9.2\] years) and were used to determine CIRS‐G scores The CIRS‐G was summarizes disease burden across 14 organ‐systems, with items scored 0‐4 (no‐extremely severe problem). It has been used to characterize morbidity among elderly individuals without cancer and survivors of adult cancer, but not among childhood cancer survivors. CIRS‐G score outcomes were analyzed as total number of categories scored\>0, total score, total score/number of categories scored\>0 (severity index), number of grade 3, and number of grade 4 categories. Scores were compared between survivors/siblings with Chi‐squared statistics. Associations between disease burden and incident mortality were modeled with Cox Proportional Hazards Regression, adjusted for age and sex.

**Results**: Survivors had higher means for all score metrics than siblings (p\'s\<0.001) for total number of categories (3.48\[2.24\] vs. 2.84\[2.06\]), total score (6.67\[5.43\] vs. 4.26\[3.74\]), severity index (1.74\[0.97\] vs. 1.27\[0.69\]), number of grade 3 (0.51\[0.75\] vs. 0.18\[0.46\]), and number of grade 4 (0.14\[0.40\] vs. 0.04\[0.21\]) conditions. Risk of mortality increased by 7% (95%CI 6%‐8%) for each point increase in total score, 35% (95%CI 29%‐42%) for each point increase in severity index, and 44% (95%CI 38%‐51%) for each grade 3 or 4 condition.

**Conclusions**: Survivors have a greater burden of disease, characterized by higher summary scores on the CIRS‐G than siblings. Scores on the CIRS‐G are predictive of incident mortality.

### PO-584. Surviving Childhood Cancer: A Systematic Review on Risk and Determinants of Adverse Socioeconomic Outcomes {#pbc27455-sec-15600}

[L. Frederiksen]{.ul} ^1^, L. Mader^1^, M. Feychting^2^, H. Mogensen^2^, L. Madanat‐Harjuoja^3,4^, N. Malila^3^, A. Tolkkinen^3^, H. Hasle^5^, J.F. Winther^1,6^, F. Erdmann^1^

*^1^Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark; ^2^Institute of Environmental Medicine‐ Karolinska Institutet, Unit of Epidemiology, Stockholm, Sweden; ^3^Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland; ^4^University of Helsinki, Department of Pediatrics, Helsinki, Finland; ^5^Aarhus University Hospital, Department of Pediatrics, Aarhus, Denmark; ^6^Aarhus University‐ Faculty of Health, Department of Clinical Medicine, Aarhus, Denmark*

**Background/Objectives**: Substantial improvements in childhood cancer survival have resulted in a steadily increasing population of childhood cancer survivors. Whereas a large number of studies have investigated somatic late effects, less is known concerning the socioeconomic conditions in survivors of childhood cancer. This systematic review aimed to evaluate and summarize the evidence on socioeconomic conditions in survivors of childhood cancer and to identify survivors at particular risk of adverse socioeconomic outcomes.

**Design/Methods**: The systematic review was conducted according to the PRISMA guidelines. An extensive literature search for articles published between January 2000 and November 2017 was conducted by searching MEDLINE, EMBASE and PsycINFO. Of 419 articles identified, 52 met the inclusion criteria. All selected articles were quality appraised and findings were summarized by a narrative synthesis.

**Results**: Survivors of childhood cancer were at increased risk of adverse socioeconomic outcomes with regard to educational achievements, income, and uptake of social security benefits in comparison to the general population or a sibling comparison group. Findings on repeating a grade, employment status and occupational positions were inconsistent across studies that included survivors from all types of childhood cancers. Notably, survivors of central nervous system tumors, survivors treated with cranial radiotherapy and those diagnosed at younger age independent of cancer type, were at particular risk of adverse socioeconomic outcomes.

**Conclusions**: Some vulnerable groups of childhood cancer survivors face significant socioeconomic difficulties in their later life course. A better understanding of the underlying mechanism of the observed socioeconomic difficulties in some childhood cancer survivors is of high importance. Given the increasing population of childhood cancer survivors, targeted long‐term follow‐up interventions and support strategies addressing not only the somatic and psychiatric aspects of late effects, but also the socioeconomic difficulties is of high importance to reduce social inequity, and ensure a high quality of life after childhood cancer.

### PO-585. The Feasibility of a Comprehensive Medical Check‐Up in Adolescent and Young Adult Survivors of Childhood Cancer {#pbc27455-sec-15610}

[Y. Hosoya]{.ul} ^1^, M. Ozawa^1^, Y. Ishida^2^, K. Kobayashi^3^, K. Nagase^1^, M. Gunji^1^, K. Maeda^1^, Y. Yoshimoto^4^, D. Hasegawa^1^, A. Manabe^1^, R. Hosoya^1^

*^1^St. Luke\'s International Hospital, Pediatrics, Tokyo, Japan; ^2^Ehime Prefectural Central Hospital, Pediatrics, Ehime, Japan; ^3^Graduate School of Nursing Science‐ St. Luke\'s International University, Child Health Nursing, Tokyo, Japan; ^4^National Center Grobal Health and Medicine, Pediatrics, Tokyo, Japan*

**Background/Objectives**: In the previous report in Japan, the quality of life of childhood cancer survivors (CCSs) may have been underestimated because they were investigated with questionnaires. Thus, we made and operated a comprehensive clinical survey system for adolescent and young adult survivors of childhood cancer(AYA‐CCSs).

**Design/Methods**: \[Method\] AYA‐CCSs underwent medical examinations (ophthalmology, oral surgery, head MRI, heart ultrasonography, thyroid ultrasonography, and cognitive function tests) in preventive healthcare centers and a hospital.

\[Participants\] Study group: AYA‐CCSs 18 years of age or older who were in remission for \>5 years after the end of treatment and \>10 years after diagnosis. Control group: Siblings of AYA‐CCSs that were 18 years of age or older.

**Results**: \[Characteristics Study group\] M:F=23:17; age at consultation, 20∽42 years (median, 27 years); age of onset, 0∽16 years (6); period after the end of treatment, 9∽38 years (16.5); transplant:no transplant=5:35. Control group, M:F= 7:8; age, 18∽30 years (22).

\[Results\] (unit %) Lipidosis: study group, 33: control group, 3; fatty liver, 23:0; pulmonary dysfunction, 23:7; decrease in testicular size, 40:0; glaucoma doubt, 44:50; cataract, 3:0; decreased salivation, 19:20; lack of the tooth, 25:0; others: hydrocephalus, 1; bladder cancer, 1.

**Conclusions**: The comprehensive clinical survey for AYA‐CCSs was useful. In two of 40 people, this survey helped the diagnosis of a life‐threatening disease and symptoms. Fatty liver and lipidosis were more frequent in AYA‐CCSs than in their siblings, so it is necessary to educate AYA‐CCSs to take care of their own health. Male infertility of AYA‐CCSs may be more frequent than previously reported.

### PO-586. Impacts of Cognitive and Behavioral Deficits on Family Financial Hardship in Survivors of Pediatric Acute Lymphoblastic Leukemia (ALL) {#pbc27455-sec-15620}

[I.C. Huang]{.ul} ^1^, L. Mullins^2^, L. Robison^1^, C.H. Pui^3^, M. Hudson^3^, K. Krull^1^

*^1^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^2^Oklahoma State University, Psychology, Stillwater, USA; ^3^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Financial strain on families with children after the completion of anticancer therapies has been under‐reported. We aimed to investigate effects of cognitive and behavioral problems in pediatric ALL survivors on family financial strain and parental emotional distress, focusing on parental employment and income downturn as potential mechanisms.

**Design/Methods**: Pediatric ALL survivors (N=213; mean age=14.8 years; time since diagnosis=7.7 years) were assessed at \>5 years post‐diagnosis. Survivors completed standardized direct tests of cognitive function, including executive function and visual‐spatial processing. Behavioral outcomes were reported by parents using the Behavior Assessment System for Children, including externalizing and internalizing problems and adaptive skill domains. Parents self‐reported employment and economic challenges due to their child\'s health conditions (i.e. needing additional income to cover medical costs, missing‐work, and family financial strain), and emotional distress using the Brief Symptom Inventory‐18. Path analyses tested associations of cognitive and/or behavioral problems with family financial strain and parental emotional distress through influences of missing‐work and income shortage.

**Results**: Among parents, 24% and 20% had missed work and income shortage; 22% had family financial strain due to their child\'s health conditions. Risk of missing‐work increased with survivor impairment in executive function (odds ratio \[OR\]=1.2, p\<0.05), visual‐spatial processing (OR=1.3, p\<0.05), adaptive skills (OR=1.5, p\<0.001), and externalizing (OR=1.3, p\<0.05) or internalizing (OR=1.4, p\<0.05) behavioral problems. Parents who missed work had higher risk of income shortage and family financial strain (ORs=1.6 and 1.4, p\'s\<0.001). Income shortage was associated with family financial strain (OR=2.0; p\<0.001). Problems with executive function, visual‐spatial processing, adaptive skills, and externalizing behaviors significantly influence family finances through parent missing‐work and income shortage (ORs=1.0‐1.3; p\'s\<0.05). Parental emotional distress was not influenced by survivor cognitive/behavioral function and parental income shortage.

**Conclusions**: Vocational support for parents may reduce economic/financial burden in families of pediatric cancer survivors who develop cognitive or behavioral problems.

### PO-587. Persistent Bodily Pain and Use of Opioids and Marijuana: A Longitudinal Study Among Adult Survivors of Childhood Cancer in the St. Jude Lifetime Cohort (SJLIFE) {#pbc27455-sec-15630}

[I.C. Huang]{.ul} ^1^, M. Buckley^2^, L. Zhenghong^1^, M. Ehrhardt^3^, N. Alberts^4^, T. Brinkman^1^, J. Allen^4^, K. Krull^1^, J. Klosky^5^, W. Greene^6^, D.K. Srivastava^7^, L. Robison^1^, M. Hudson^3^, D. Anghelescu^8^

*^1^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^2^University of Tennessee, Pharmacy, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA; ^4^St. Jude Children\'s Research Hospital, Psychology, Memphis, USA; ^5^Children\'s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, USA; ^6^St. Jude Children\'s Research Hospital, Pharmaceutical Sciences, Memphis, USA; ^7^St. Jude Children\'s Research Hospital, Biostatistics, Memphis, USA; ^8^St. Jude Children\'s Research Hospital, Pediatric Medicine, Memphis, USA*

**Background/Objectives**: Increased attention has been placed on the use of controlled medical marijuana for pain management as a potential alternative to opioids. However, this topic has been understudied in cancer survivors, particularly among those with chronic pain. We investigated the patterns and determinants of opioid and marijuana use among adult survivors of childhood cancer experiencing chronic pain.

**Design/Methods**: Adult survivors of childhood cancer (n=1,995) participating in SJLIFE completed clinical evaluations and self‐reported surveys across two time points (T1 and T2: mean interval=4.2 years). Surveys contained the Medical Outcomes Study SF‐36\'s bodily pain scale (severe pain determined by a score of ≤40), opioid use, and marijuana use. Logistic regression identified the determinants (pain‐associated cancer treatments, sociodemographics, and psychological) of opioid and/or marijuana use at T2.

**Results**: The mean (range) age and time from diagnosis among survivors was 31.8 years (18‐65) and 24 years (10‐48), respectively. Among survivors having chronic severe/escalating pain over time, 16.5%, 11.7%, and 4.8% reported having used opioids, marijuana, or both, respectively, at T2. Chronic severe/escalating pain (vs. decreased severe/no pain) over time was associated with opioid (odds ratios \[OR\]: 9.2 (95%CI: 4.5‐18.8) but not marijuana use (OR: 1.3; 95%CI: 0.7‐2.4) at T2. Non‐Hispanic Caucasian, chronic severe/escalating anxiety, or lack of health insurance increased the likelihood of opioid use at T2 compared with other race/ethnicity, decreased severe/no anxiety, or having insurance coverage (ORs: 10.0, 2.7, and 2.2; p\'s\<0.05). Lack of health insurance, high school/some college education, or single/divorced marital status increased the likelihood of marijuana use at T2 compared with having insurance coverage, college/graduate education, or married status (ORs: 3.4, 2.3, and 1.6; p\'s\<0.05).

**Conclusions**: Chronic severe/escalating pain introduced opioid but not marijuana use later in cancer survivorship. Future research should focus on effectiveness and potential health impact of opioids and marijuana among childhood cancer survivors.

### PO-588. Secondary Cancer After a Childhood Cancer Diagnosis: Viewpoints Considering Primary Cancer {#pbc27455-sec-15640}

[Y. Ishida]{.ul} ^1^, M. Maeda^2^, S. Adachi^3^, H. Inada^4^, H. Kawaguchi^5^, H. Hori^6^, A. Ogawa^7^, K. Kudo^8^, C. Kiyotani^9^, H. Shichino^10^, T. Rikiishi^11^, R. Kobayashi^12^, M. Sato^13^, J. Okamura^14^, H. Goto^15^, A. Manabe^16^, S. Yoshinaga^17^, D. Qiu^18^, J. Fujimoto^19^, T. Kuroda^20^

*^1^Ehime Prefectural Central Hospital, Pediatric Medical Center, Matsuyama, Japan; ^2^Nippon Medical School, Department of Pediatrics, Tokyo, Japan; ^3^Kyoto University School of Medicine, Department of Human Health Sciences, Kyoto, Japan; ^4^Kurume University School of Medicine, Department of Pediatrics, Kurume, Japan; ^5^Hiroshima University Hospital, Department of Pediatrics, Hiroshima, Japan; ^6^Mie University Graduate School of Medicine‐, Department of Pediatrics, Mie, Japan; ^7^Niigata Cancer Center, Division of Pediatrics‐, Niigata, Japan; ^8^Shizuoka Children\'s Hospital, Division of Hematology and Oncology‐, Shizuoka, Japan; ^9^National Center for Child Health and Development, Children\'s Cancer Center‐, Tokyo, Japan; ^10^Nihon University School of Medicine, Department of Pediatrics and Child Health, Tokyo, Japan; ^11^Tohoku University School of Medicine, Department of Pediatrics, Sendai, Japan; ^12^Sapporo Hokuyu Hospital, Department of Pediatrics, Sapporo, Japan; ^13^Osaka Women\'s and Children\'s Hospital, Department of Hematology/Oncology, Osaka, Japan; ^14^National Kyushu Cancer Center, Department of Pediatrics, Fukuoka, Japan; ^15^Kanagawa Children\'s Medical Center, Division of Hematology‐oncology/Regenerative Medicine, Yokohama, Japan; ^16^St. Luke\'s International Hospital, Department of Pediatrics, Tokyo, Japan; ^17^National Institute of Radiological Sciences‐ National Institutes for Quantum and Radiological Science and Technology, Center for Radiation Protection Knowledge, Chiba, Japan; ^18^National Center of Neurology and Psychiatry‐ National Institute of Mental Health, Department of Drug Dependence Research, Tokyo, Japan; ^19^National Center for Child Health and Development, Epidemiology and Clinical Research Center for Children\'s Cancer, Tokyo, Japan; ^20^Keio University School of Medicine, Department of Pediatric Surgery, Tokyo, Japan*

**Background/Objectives**: Multidisciplinary therapy has increased the risk of subsequent late effects, but detailed analyses on secondary cancers in childhood cancer survivors (CCSs) are limited in Asian countries. This study aimed to evaluate the specific clinical characteristics of secondary cancers in CCSs using data from a previous nationwide survey in Japan.

**Design/Methods**: This was a retrospective cohort study comprising 10,069 CCSs who were diagnosed between 1980 and 2009 across 15 Japanese hospitals. We conducted secondary analyses to estimate the incidence of secondary cancer according to each primary malignancy and to elucidate the association between primary and secondary cancers. We also explored the risk factors for the development of secondary cancer in each independent primary malignancy.

**Results**: The cumulative incidence of secondary cancer at 20 years varied among primary cancers: hematological malignancy, 3.1% (95% CI: 2.2--4.3); retinoblastoma, 6.6% (95% CI: 1.5--16.8); pediatric solid tumor, 2.5% (95% CI: 1.3--4.2); brain tumors, 5.2% (95% CI: 1.7--11.8) bone/soft tissue sarcoma, 5.2% (95% CI, 2.3--10.1); and others, 3.3% (95% CI: 1.6--6.0) (p=0.015). Close association between the primary and secondary cancer diagnoses was found. The risk factors for secondary cancer development depended on the primary cancer. Multivariate Cox regression analysis showed that the significant risk factors for secondary cancers in ALL were surgery (HR: 3.30; 95% CI: 1.40--7.81) and allogeneic stem cell transplantation (SCT) (HR: 2.59; 95% CI: 1.22--5.48) and those in retinoblastoma were autologous SCT (HR: 73.8; 95% CI: 6.33--860) and radiation (HR: 13.4; 95% CI: 1.29--13.9).

**Conclusions**: The cumulative incidence of secondary cancer varied among primary cancers, with osteosarcoma and retinoblastoma having the highest risk for secondary cancers. The primary cancer was closely associated with the secondary cancer. but autologous/allogeneic SCT was a common risk factor for secondary cancers among CCSs.

### PO-589. Hospitalization Rate in Offspring of Cancer Survivors: A National Cohort Study {#pbc27455-sec-15650}

[J. Ji]{.ul} ^1^, J. Sundquist^1^

*^1^Lund University, Department of Medicine, MALMÖ, Sweden*

**Background/Objectives**: The number of childbirths among cancer survivors continues to increase, but it is still largely unknown whether the children of cancer survivors might experience adverse health outcomes during the process of growing up.

**Design/Methods**: We identified all individuals diagnosed with cancer between 1958 and 2015 from the Swedish Cancer Registar and linked to the Swedish Medical Birth Register to identify their offspring born between 1997 and 2015. Up to 10 children whose parents without a diagnosis of cancer were matched with the study population according to date of birth and gender.

**Results**: By linking with the Swedish Hospital Discharge Register, we found that the hospitalization rate was 15% higher in offspring of female cancer survivors, and 16% higher in offspring of male cancer survivors as compared to matched controls. The risk of hospitalization was stronger when parents were diagnosed with childhood cancer, whereas the risk was much weaker when parents diagnosed with cancer after age 30. Besides an increased risk of hospitalization due to neoplasms in childhood (RR=1.89), a significantly increased risk was found for hospitalization due to infectious and parasitic disease (RR=1.09), diseases of the blood and blood forming organs and certain disorders involving the immune mechanisms (RR=1.33), diseases of the circulatory system (RR=1.05), and diseases due to pregnancy, childbirth, and the puerperium (RR=1.85).

**Conclusions**: Our study suggests that children of cancer survivors might experience a moderately increased rate of hospitalization, which call for clinical attentions.

### PO-590. Impact of Long‐Term Follow‐Up Care (LTFU) on Adherence to Surveillance for Late‐Effects Among Survivors of Adolescent and Young Adult (AYA) Cancers: An Impact Cohort Study {#pbc27455-sec-15660}

[D. Kagramanov]{.ul} ^1^, R. Sutradhar^2^, Y. Zhan^2^, C. Lau^2^, S. Gupta^3^, N. Baxter^4^, P. Nathan^3^

*^1^Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Canada; ^2^Sunnybrook Health Sciences Centre, Institute For Clinical Evaluative Sciences, Toronto, Canada; ^3^Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^4^St. Michael\'s Hospital, General Surgery, Toronto, Canada*

**Background/Objectives**: Survivors of AYA cancer are at risk for developing therapy‐related adverse health outcomes and require life‐long risk‐adapted healthcare. We explored the predictors of LTFU care received by a population‐based cohort of survivors and the impact of care on adherence to recommended surveillance.

**Design/Methods**: We conducted a retrospective cohort study using administrative health databases in Ontario, Canada. Five‐year survivors were identified from the IMPACT cohort, a provincial database of all patients aged 15‐20.9 years at diagnosis of one of six common cancers between 1992‐2010. We defined four models of LTFU care: specialized survivor clinic (only available to those treated at a paediatric cancer centre); oncology clinic; primary care physician (PCP); no regular care. We assessed adherence to the Children\'s Oncology Group surveillance guidelines for cardiac disease and breast cancer. Poisson regression models examined attendance rates, while logistic regression models assessed guideline adherence.

**Results**: The cohort consisted of 1,574 survivors (1,066 treated at adult centres; 508 treated at paediatric centres). During a median follow‐up of 8.7 years (95% CI 4.3‐13.9), the highest level of care accessed was: survivor clinic (16.7%), oncology clinic (47.3%), PCP (9.3%), no regular care (26.7%). The risk of receiving no regular care was highest in males and increased 7% per year of follow‐up. Among those eligible for specialized survivor clinics, greater attendance was observed in females and those living closer to a clinic ‐ attendance decreased 8% with each year of follow‐up. Female survivors at risk for breast cancer were 2.9 times (95% CI 1.6‐5.3) more likely to receive annual mammograms if followed at a specialized survivor clinic. Specialized clinic attendance did not impact echocardiography adherence.

**Conclusions**: Most AYA survivors do not attend specialized clinics and almost one‐third receives no regular care. Identifying accessible care models that maximize surveillance adherence must be a key research focus.

### PO-591. Cardiac Outcomes in Childhood Cancer Survivors: A Population‐Based Study {#pbc27455-sec-15670}

[A. Khanna]{.ul} ^1,2^, P. Pequeno^3^, S. Gupta^4,5,6^, T. Dinesh^6,7^, D.S. Lee^3,6,7^, H. Abdel‐Qadir^3,6,8^, P.C. Nathan^4,5,6^

*^1^University of Toronto, Institute of Medical Science, Toronto, Canada; ^2^The Hospital for Sick Children, Child Health Evaluative Sciences Program, Toronto, Canada; ^3^Institute for Clinical Evaluative Sciences, ICES Central, Toronto, Canada; ^4^The Hospital for Sick Children, Haematology/Oncology, Toronto, Canada; ^5^University of Toronto, Institute of Health Policy‐ Management and Evaluation, Toronto, Canada; ^6^University of Toronto, Department of Medicine, Toronto, Canada; ^7^University Health Network, Division of Cardiology‐ Peter Munk Cardiac Centre, Toronto, Canada; ^8^Women\'s College Hospital, Division of Cardiology, Toronto, Canada*

**Background/Objectives**: Childhood cancer survivors (CCS) are at an elevated risk for various cardiovascular diseases (CVD); however, most studies have focused primarily on congestive heart failure (CHF). Cancer treatment‐related cardiac morbidities include CHF, arrhythmias, valve abnormalities, pericardial disease, and coronary artery disease (CAD). We conducted a population‐based retrospective cohort study to determine the incidence and predictors of all categories of CVD in survivors.

**Design/Methods**: Using a provincial pediatric cancer registry, we assembled a cohort of all 5‐year survivors diagnosed before age 18 years and treated in an Ontario pediatric cancer center between 1987‐2010. Patients were matched by age, sex, and geographic region to population controls and linked to health administrative databases for outcomes. We calculated the incidence of CVD and cardiac death and evaluated the diagnostic and treatment risk factors using survival analysis, accounting for competing risks of non‐cardiac death and adult cancer events.

**Results**: By age 30 years, the cumulative incidence of CVD in 7,342 CCS was 4.2% (95% confidence interval \[CI\] 3.5‐4.9%) compared to 1.4% (CI 1.2‐1.5%) in 36,586 controls. Survivors were at increased risk for CHF (hazard ratio \[HR\] 8.2; CI 6.0‐11.3), arrhythmias (HR 2.2; CI 1.7‐2.8), valve disease (HR 5.2; CI 3.1‐8.8), pericardial disease (HR 1.8; CI 1.2‐2.9), CAD (HR 2.8; CI 1.5‐5.2), and cardiac death (HR 7.7; CI 1.3‐45.9). Anthracycline dose \>250 mg/m2 (HR 1.9; CI 1.3‐2.8), age 15 to 17.9 years at cancer diagnosis (HR 1.8; CI 1.2‐2.8), childhood relapse (HR 1.7; CI 1.1‐2.6), and diabetes (HR 3.0; CI 1.6‐5.8) predicted increased risk of CVD in survivors.

**Conclusions**: CCS are at elevated risk for multiple types of CVD. Their absolute risk at 30 years of age is low, but significantly increased relative to the general population. Follow‐up care of CCS should assess and manage overall CVD risk rather than limiting solely to CHF.

### PO-592. Transfusion‐Related Iron Overload in Childhood Cancer Survivors {#pbc27455-sec-15680}

[O. Khattachan]{.ul} ^1^, K. Chiengthong^1^, S. Lauhasurayothin^1^, D. Sosothikul^1^, P. Techavichit.^1^

*^1^Division of hematology/oncology, Pediatrics, Bangkok, Thailand*

**Background/Objectives**: Anemia is a common complication of cancer and its therapy. Childhood cancer survivors who received red blood cells (RBCs) transfusion may have increased risk for vital organs iron deposition causing serious effects. However, the study of iron overload status is still limited in childhood cancer survivors. The objective of this study were to elucidate the prevalence and risk factors of transfusion related iron overload in childhood cancer survivors at King Chulalongkorn Memorial Hospital.

**Design/Methods**: Cross sectional descriptive study had been performed in cancer survivors, age 0‐15 year old at diagnosis time, who had histories of transfusion during cancer treatment. Serum ferritin was collected during outpatient visit from January 2016 to July 2017. The primary diagnosis, treatment, cumulative amount of RBCs transfusions were collected. Serum ferritin was measures in good health condition and was repeated in case of serum ferritin higher than 300 microgram/lite.

**Results**: Seventy‐two survivors (40 male, 32 female) with median of age 12 years (range 2‐21 years) were recruited in the study. The median episode of RBCs transfusions was 6.71 (range 1‐28 episodes), the adjusted cumulative RBCs volume/body weight 55.4 ml/kg (range 8‐328 ml/kg) and time since last transfusion was 32.5 months (range 3‐101 months). Twenty‐six survivors (36%) had serum ferritin level more than 300 mcg/L. The disease in high serum ferritin group were solid tumors in five, hematologic malignancies in eleven and post bone marrow transplantation in ten survivors.

**Conclusions**: There are significant correlation between transfusion with serum ferritin compound with number of transfusions, adjusted cumulative RBCs volume/body weight(ml/kg) and time since last transfusion(months).

Keywords: children, cancer, survivors, iron overload, serum ferritin, blood transfusion

This study was support by the Ratchadapiseksompotch Fund.

### PO-593. Changes in Marital Relationships After a Child\'s Cancer Diagnosis from the Perspectives of the Mother in Korea {#pbc27455-sec-15690}

J. Yi^1^, [M.A. Kim]{.ul} ^2^, S. Kim^3^, S. An^4^

*^1^University of Utah, College of Social Work, Salt lake city, USA; ^2^Myongji University, Department of Social Welfare, Seoul, Republic of Korea; ^3^Seoul National University Hospital, Department of Rehabilitation Medicine, Seoul, Republic of Korea; ^4^Severance Hospital, Social Service Team, Seoul, Republic of Korea*

**Background/Objectives**: As a child\'s journey with cancer progresses, parents often experience role changes, making it likely for spouses to experience increased conflict within the relationship. Although there has been research into the conflict between spouses and its effects on both the parents and child, there has been limited research on how such conflict is created, develops, and evolves. This study explored changes in marital relationships as reported by mothers of children with cancer in Korea.

**Design/Methods**: One‐hour, in‐depth interviews were conducted in Korean with 20 mothers of children who had been diagnosed with cancer within the last five years and before the age of 19. The mean age of participants was 39.1 years (SD = 3.55), with 75% not working or who were homemakers. Their children with cancer had a mean age of 8.3 years (SD = 2.58); 55% were boys, and 45% were girls. The mean age for cancer diagnosis was 5.7 years (SD = 2.79), and diagnoses included leukemia, malignant lymphoma, brain tumors, neuroblastoma, and osteosarcoma. The transcribed interviews were analyzed, using thematic analysis.

**Results**: The mothers perceived that their relationship with their spouse was significantly affected by their child\'s illness, and they tried to find ways to resolve the conflict. The two major themes that emerged from these mothers' interviews were conflict escalation (being physically and emotionally distant, having financial challenges, feeling resentful, experiencing a lack of understanding, not being reliable) and repercussions of conflict (explosion, a focus on the child, efforts to communicate better, husband\'s efforts).

**Conclusions**: The findings demonstrate the need for interventions to help the parents of a child with cancer to manage the emotional burdens that result from marital conflicts. Such an intervention can ultimately promote the child‐parent relationship as well as the psychosocial well‐being of the child with cancer.

### PO-594. Mortality in 1,948 Long‐Term Survivors of Retinoblastoma {#pbc27455-sec-15700}

[R. Kleinerman]{.ul} ^1^, M.A. Tucker^1^, B.S. Sigel^1^, D.H. Abramson^2^, J.M. Seddon^3^, L.M. Morton^1^

*^1^US National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, USA; ^2^Memorial Sloan Kettering Cancer Center, Ocular Oncology, New York, USA; ^3^Tufts‐New England Medical Center, Ophthalmic Epidemiology and Genetic Service, Boston, USA*

**Background/Objectives**: Retinoblastoma (RB) is one of the most curable childhood cancers when diagnosed early. However, survivors with hereditary RB (germline RB1 mutation) have a strikingly increased risk of subsequent malignant neoplasms, which are a major cause of mortality.

**Design/Methods**: Among 1,948 survivors of retinoblastoma diagnosed 1914‐2006 at two major US treatment centers and followed to 2016, we compared cause‐specific mortality in our cohort to that expected in the US general population using standardized mortality ratios (SMRs) and absolute excess risks (AERs). We also estimated cumulative mortality.

**Results**: Most of the 604 deaths in the cohort occurred in 1,094 survivors with hereditary RB (N=489 deaths, SMR=8.4, 95% confidence interval=7.7‐9.2). Of these, 257 were attributable to subsequent malignant neoplasms (SMR=26), with an AER of 7.1 deaths/1000 person‐years. SMRs for death due to subsequent malignant neoplasms were highest 15‐19 years following hereditary RB diagnosis (N=69, SMR=89) and declined through 60+ years following diagnosis (N=14, SMR=6.7). In contrast, AERs due to subsequent malignant neoplasms increased with time (31 versus 6.2 deaths per 1,000 person‐years at 60+ and 15‐29 years, respectively). Deaths due to bone cancer, soft tissue sarcomas and nasal cavity cancers were most common (N=141, SMR=507). For 854 survivors with non‐hereditary RB, we observed only a slightly increased risk of death compared with the general population, overall (N=115, SMR=1.8) and specifically for subsequent malignant neoplasms (N=25, SMR=1.9). SMRs for non‐cancer causes were similar to the general population for all survivors with RB. At 70 years after RB diagnosis, cumulative mortality for subsequent malignant neoplasms was 63% and 11% for survivors with hereditary and non‐hereditary RB, respectively.

**Conclusions**: Survivors with hereditary RB remain at risk for death from subsequent malignant neoplasms, especially sarcomas, up to 70 years after diagnosis. These results highlight the need to develop long‐term clinical management guidelines for retinoblastoma survivors.

### PO-595. Do Benign Ultrasound Findings Affect Quality of Life in Long Term Survivors After Cancer Treatment in Childhood? {#pbc27455-sec-15710}

[J. Kruseova]{.ul} ^1^, L. Hrivnova^1^, A. Lukš^1^, E. kabíčková^1^, M. Kyncl^2^, G. Calaminus^3^, V. Capek^4^, J. Byrne^5^, J. Stary^1^

*^1^Faculty Hospital Motol, Department of Paediatric Haematology and Oncology‐ 2nd Faculty of Medicine‐ Charles University‐ Prague‐ Czech Republic1, Prague, Czech Republic; ^2^Faculty Hospital Motol, Department of Radiology‐ 2nd Faculty of Medicine‐ Charles University‐ Prague‐ Czech Republic 2, Prague, Czech Republic; ^3^University Bonn, Department of of Paediatric Haematology and Oncology 4, Bonn, Germany; ^4^Faculty Hospital Motol, Bioinformatics Centre‐ 2nd Faculty of Medicine‐ Charles University‐ Prague‐ Czech Republic 4, Prague, Czech Republic; ^5^Boyne Research Institute, Boyne Research Institute5, Drogheda, Ireland*

**Background/Objectives**: Childhood cancer survivors have heterogeneous attitudes about their health related quality of life (HRQOL). When developing long‐term follow‐up guidelines much discussion centres on the frequency of follow‐up investigations and if knowledge of some incidental findings that do not need treatment may cause unnecessary anxiety and possibly affect HRQOL. This study seeks to determine if benign ultrasound findings influence survivors self perceived health.

**Design/Methods**: As a part of the PanCareLIFE\* study, 806 survivors from our Prague LTFU clinic completed SF‐36 HRQOL questionnaires. In the current study we included 355 survivors who were asked to participate during their regular long‐term follow‐up visit and had abdominal ultrasound. We compared HRQOL results to ultrasound findings, age, gender, education, smoking, alcohol and BMI. Of the 355 survivors 151 had at least one benign ultrasound finding and the remaining 204 had no abdominal ultrasound findings. The ultrasound findings included liver (N=92) (focal nodular hyperplasia, hemangioma, steatosis, cysts), kidney (N=38) (angiomyolipoma, cysts), gall bladder (N=28) (cholelithiasis, polyps) and other (N=34). Observed data were analysed using a linear model that controlled for age and other possible confounders. Analysis was performed using the R statistical package.

**Results**: There were no differences in HRQOL in patients with benign (median 2.2, IQR 1.8‐3.2, N=151) and normal (median 2.2, IQR 1.6‐3.0, N=204) ultrasound findings P=0.59 (F=0.86, power 0.27).

**Conclusions**: We did not confirm that benign ultrasound findings affect HRQOL. We can conclude that in guideline development medical testing with benign results may not generate a poorer health‐related quality of life.

\*This project has received funding from the EuropeanUnion\'s Seventh Framework Programme for Research, technological development and demonstration under grant agreement no 602030. This study has received funding from the Ministry of Education, Youth and Sport of the Czech Republic.

### PO-596. Influence of Cisplatin‐based Chemotherapy on Hearing Impairment, Neurological Outcome and Education in CNS Survivors {#pbc27455-sec-15720}

[J. Kruseova]{.ul} ^1^, I. Perníková^2^, J. Valvoda^3^, E. Císařová^1^, A.S. Kováčová^4^, D. Sumerauer^1^, A. Lukš^1^, V. Čapek^5^, T. Langer^6^, A. Zehnhoff‐Dinnesen^7^, M. Kynčl^4^, J. Starý^1^

*^1^Faculty Hospital Motol, Department of Paediatric Haematology and Oncology‐ Charles University‐ 2nd School of Medicine 1, Prague, Czech Republic; ^2^Faculty Hospital Motol, Department of Paediatric Neurology‐ Charles University‐ 2nd School of Medicine 2, Prague, Czech Republic; ^3^Faculty Hospital Motol, Department of Otorinolaryngology‐ Charles University‐ 2nd School of Medicine 3, Prague, Czech Republic; ^4^Faculty Hospital Motol, Department of radiology‐ Charles University‐ 2nd School of Medicine 4, Prague, Czech Republic; ^5^Faculty Hospital Motol, Bioinformatics Centre‐ Charles University‐ 2nd School of Medicine 5, Prague, Czech Republic; ^6^Universitätsklinikum Schleswig‐Holstein, Universitätsklinikum Schleswig‐Holstein 6, Lübeck, Germany; ^7^Universitätsklinikum‐ Münster, Department of Paediatric Oncology 7, Münster, Germany*

**Background/Objectives**: Patients treated with cisplatin‐based chemotherapy are known to be at risk of hearing loss. Cisplatin and cranial irradiation may also impact neurocognitive functions. We evaluate the effect of cisplatin on hearing changes, Karnovsky index and education in our CNS survivors.

**Design/Methods**: As a part of the PanCareLIFE\*study, 140 survivors had hearing and neurological examination. Treatments: study group: cisplatin and radiotherapy (N=51) (median age at dg 9.7yr, median follow up 11.9yr); control group I radiotherapy only (N=38)(age at dg 11.1yr, FUP 15yr); control group II operation only (N=51)(age at dg 9.8yr, FUP 11.8yr). For each we extracted indicators of hearing impairment, Karnovsky index, incidence of epilepsy and education. All correlations were made ≥ five years after the end of treatment. Data were analysed using a linear model with interactions.

**Results**: Hearing impairment: study group vs. control group I OR 5.4(1.8‐16.1) and vs control group II OR 41(5.2‐320). Education: study group vs. control group I P\<0.07, vs. control group II P\<0.001. Only for the study group we observed an effect of age at diagnosis on education P\<0.009. Karnovsky index: study group vs. control group I P=0.29, vs. control group II P\<0.07, control group I vs. II P\<0.002. Other factors were not statistically significant.

**Conclusions**: Cisplatin‐based chemotherapy not only has a greater detrimental effect on hearing but also on educational achievement. However, Karnovsky index was lower for radiotherapy only patients. This was probably due to longer follow‐up as the number of side effects of radiotherapy increases over time. For better understanding our results we want to look at MRI findings, initial tumour size and localisation and other possible influences.

\*This project has received funding from the European Union\'s Seventh Framework Programme for Research, technological development and demonstration under grant agreement no 602030 and from the Ministry of Education, Youth and Sport of the Czech Republic.

### PO-597. Current Status of Hospital School System for Children with Cancer in Korea: Parallel Class of Off‐Line and On‐Line System {#pbc27455-sec-15730}

Y.H. Lee^1^, [I. Gill]{.ul} ^1^, J. Chang^1^, M.O. Park^1^

*^1^Hanyang University Medical Center‐ Seoul‐ Korea, Department of Pediatrics, Seoul, Republic of Korea*

**Background/Objectives**: The continuity of education is needed for quality of life in childhood cancer survivors. Korean government has established an administrative and financial support for hospital schools since 2005. We will review the current status of hospital school system for children with cancer and look for future directions.

**Design/Methods**: This study was reviewed with the official data from the Ministry of Education as well as the internet homepages of hospital schools in Korea.

**Results**: As of 2018, there are 33 hospital schools nationwide, and the number of students currently enrolled in off‐line class is 456, and in online class 1,167. The off‐line class has been operated with 1‐2 full‐time teachers as well as volunteers in one or two classroom. The off‐line class schedules have been individualized in each hospital school and tailored to medical conditions of students. For the students who have difficulties for off‐line classes, internet real‐time interactive two‐way classes or video on demand (VOD)‐type classes have been performed during hospitalization or at home. There are 4 regional agencies operating on‐line classes. For the approval of attendance to their original school, elementary students must attend more than 1 hour of off‐line lessons a day or more than 1 lesson with 20 minutes a day of on‐line system in hospital school. In the case of junior and high school students, 2 hours of off‐line lessons or more than 2 lessons of each 20 minutes a day of on‐line system have been required. The students in hospital schools have to take the assessment tests in their original schools to promote their grades.

**Conclusions**: It seems desirable to combine the off‐line classes with on‐line classes for the children with cancer. Advances in class contents of hospital schools and alterations in management of academic performance would be considered.

### PO-598. Cardiac Magnetic Resonance Imaging in Screening Subclinical Late Anthracyclines Cardiomyopathy Among Childhood Cancer Survivors {#pbc27455-sec-15740}

[C.K. Loh]{.ul} ^1^, F. Mohd Zaki^2^, N. Abu Bakar^2^, M.B. Faleh Khries^1^, B.B.S. Abdul Aziz^1^, S.C. Lau^1^, H. Alias^1^

*^1^Universiti Kebangsaan Malaysia Medical Centre, Deparment of Paediatrics, Kuala Lumpur, Malaysia; ^2^Universiti Kebangsaan Malaysia Medical Centre, Department of Radiology, Kuala Lumpur, Malaysia*

**Background/Objectives**: Background: Anthracyclines are commonly used in the treatment of childhood cancer, but with the risk of myocardial damage. Echocardiography is the current method of choice for screening anthracycline‐related cardiomyopathy. Cardiac MRI (CMR) is more sensitive to measure the ventricle function with high detection of 50‐80% cases of subclinical cardiomyopathy.

Objective: We sought to compare between two dimensional (2D) echocardiography and CMR in screening of subclinical anthracyclines cardiomyopathy.

**Design/Methods**: We conducted a cross‐sectional study in 23 childhood cancer survivors who received treatment in a tertiary referral centre in Kuala Lumpur. The survivors had received anthracyclines and were off treatment for at least two years. All subjects had both CMR and trans‐thoracic 2D echocardiography done not more than two weeks apart to assess their cardiac function. Subclinical anthracyclines cardiomyopathy is defined as left ventricular ejection fraction (LVEF) of \< 55% and clinically asymptomatic.

**Results**: There were eight female and fifteen male survivors (ratio 1:2). Malay ethnicity comprised of 65%(n=15), Chinese 13%(n=3), Indian 17%(n=4) and one others. The median age of first exposure to anthracyclines was 5.6(IQR: 4.2‐9.1) years old. Median duration from the time of exposure was 7.9(IQR: 6.4‐9.6) years. There were 61%(n=14) standard risk acute lymphoblastic leukaemia(ALL), 22%(n=5) high risk ALL, 9% (n=2) relapsed ALL and 4% (n=1) each of acute myeloid leukaemia and non‐Hodgkin lymphoma. The prevalence of subclinical cardiomyopathy detected by CMR was 70% (n=16) compared to only 4% (n=1) by 2D echocardiography. The median LVEF was significantly lower in survivors with subclinical cardiomyopathy detected by CMR, in which the LVEF was 48% compare to 67% (p\<0.05) in those with normal cardiac function. There was no significant difference in LVEF between the two groups using 2D echocardiography.

**Conclusions**: We concluded that CMR has a high detection rate of subclinical anthracyclines cardiomyopathy among the childhood cancer survivors at our centre which was previously undiagnosed.

### PO-599. Serum Ferritin versus T2\*MRI for Estimation of Iron Overload in Children Treated for Hematological Malignancies {#pbc27455-sec-15750}

[V. Munikoty]{.ul} ^1^, D. Bansal^2^, K.S. Sodhi^3^, A. Bhatia^3^, P. Bhatia^2^, S.V. Attri^2^, M.K. Rohit^4^, A. Trehan^2^, N. Khandelwal^3^

*^1^DM Senior Resident fellow‐ Pediatric Hematology Oncology unit, Pediatrics‐ Advanced Pediatric centre‐ Post graduate Institute of Medical Education and Research, Chandigarh, India; ^2^Post graduate Institute of Medical Education and Research, Pediatrics, Chandigarh, India; ^3^Post graduate Institute of Medical Education and Research, Radiodiagnosis, Chandigarh, India; ^4^Post graduate Institute of Medical Education and Research, Cardiology, Chandigarh, India*

**Background/Objectives**: Indications for estimation of liver/myocardial iron concentration (LIC/MIC) by T2\* weighted magnetic resonance imaging (T2\*MRI) in cancer survivors are not described.

**Design/Methods**: The cross‐sectional study was performed in children treated for hematological‐malignancies. Patient\'s ≥6 months from therapy completion, who received ≥5 red cell transfusions were enrolled. Patients with relapsed disease, second‐malignancy or hematopoietic transplant were excluded. A T2\*MRI and serum ferritin were performed.

**Results**: Four‐hundred and thirty‐one patients treated for hematological‐malignancies were screened. Forty‐five patients, including, B‐ALL: 32(72%), T‐ALL: 5(11%), AML: 4(9%), T‐NHL: 3(7%) and MPAL: 1(2%) were enrolled. The median‐age at diagnosis and enrollment was 7 and 11 years, respectively. The median number of red‐cell units transfused was 8(IQR: 7,10). The mean ferritin was 581 ± 454ng/ml (range: 32‐2115) and was \>1000ng/ml in 5(11.4%) patients. LIC was elevated in 20/44(45.5%) patients. Eighteen (41%) patients had mild (2‐7 mg/g) and 2(4.5%) had a moderate(7‐15 mg/g) elevation in LIC. MIC was elevated in 2/44(4.5%) patients. All patients with a serum ferritin \>1000ng/ml had an elevated LIC. LIC correlated with ferritin(r=0.49, p\<0.001). MIC did not correlate with either ferritin or LIC. The number of red‐cell units transfused correlated with ferritin (p=0.001) and LIC (p=0.012). The duration since last transfusion negatively influenced serum ferritin (p=0.002) and LIC (p=0.005). A serum ferritin \>500ng/ml predicted an elevated LIC with sensitivity/specificity of 80%/79%, respectively. A cut‐off of 8‐units of red‐cell transfusions predicted an elevated LIC with sensitivity/specificity of 95%/49.8%, respectively.

**Conclusions**: The prevalence of an elevated LIC and MIC was 45.5% and 4.5%, respectively. No patient had a severe elevation of LIC/MIC. A screening by serum ferritin is suggested for patients who have received \>8 transfusions. If serum ferritin is between 500‐1000ng/ml, a T2\*MRI is useful for estimation of LIC. A T2\*MRI may be avoided in patients with serum ferritin \>1000ng/ml, as all the patients had an elevated LIC.

### PO-600. Difficulties and Coping Actions of Childhood Cancer Survivors in their Life After Returning to their School {#pbc27455-sec-15760}

[M. Nagayoshi]{.ul} ^1^, Y. Saito^2^, K. Adachi^3^, Y. Takahashi^4^, K. Tanigawa^5^

*^1^The Jikei University, School of Nursing, Tokyo, Japan; ^2^Tsuru University, Department of Teacher Education, Yamanashi, Japan; ^3^Japan Education for Special Health Care Needs Society, Secretariat, Tokyo, Japan; ^4^Tokyo Metropolitan Shikamoto Gakuen, Elementary school, Tokyo, Japan; ^5^Seinan Jo Gakuin University, Faculty of Health and Welfare, Hukuoka, Japan*

**Background/Objectives**: Children who underwent cancer treatment in childhood face many difficulties in their psychosocial development after returning to school.

**Design/Methods**: The purpose of this study was to understand the difficulties faced by children who have recovered from cancer, coping, and support in their development after leaving the hospital. A qualitative descriptive analysis was performed through 60‐minute semi‐structured interviews with 9 Japanese survivors of childhood cancer.

**Results**: Identified difficulties were "absenteeism from classroom because of decreased physical fitness after chemotherapy," "post‐therapy constraints on school activities because of decreased strength and motor dysfunction," "inability to join group activities because of decreased strength," "difficulty joining companions during the year," "lost confidence in physical condition and communication with their friends," "uncomfortable interacting with friends of the same age," "hesitation when concern for illness was shown by teachers and friends," "awareness of difference in themselves after re‐enrollment," "reduced academic ability due to absence of study and difficulty catching up with studies," "disadvantages for educational advancement caused by prolonged absence due to hospitalization," "difficulty continuing to attend school because of late effect of treatment," "chronic deconditioning into adulthood that causes low mood," and "feeling frustrated by physical stress and constraints in their work." These problems were related to school life or work. Nine categories were extracted for coping actions.

**Conclusions**: This study found that childhood cancer survivors are forced to have different activities and school life from their friends after re‐enrollment because of physical weaknesses and problems. They feel uncomfortable to communicate with their friends and teachers about their experience during hospitalization that they had a relationship with sick children and had few friends of the same age. Their personality have been built up also in adulthood with their experience of coping with those difficulties.

Acknowledgements: This study was funded in part by the Grants‐in‐Aid for Scientific Research in 2017.

### PO-601. Genetic Predisposition to Metabolic Syndrome in Pediatric Patients with Hematological Malignancies {#pbc27455-sec-15770}

[T. Nasedkina]{.ul} ^1,2^, T. Lisitsa^1,2^, A. Gavrilova^1^, E. Zhukovskaya^1^, V. Kasatkin^1^, A. Karelin^1^, A. Rumyantsev^1^

*^1^Dmitry Rogachev National Research Center of Pediatric Hematology‐ Oncology and Immunology, Clinical Rehabilitation Research Center for patients in remission "Russkoye pole", Moscow, Russia; ^2^Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Laboratory for Biological Microchips, Moscow, Russia*

**Background/Objectives**: The intensive chemotherapy often results in developing severe complications affecting different tissues and organs. One of such complications is metabolic syndrome (MetS), including obesity, insulin resistance, arterial hypertension and impaired fat metabolism. The genetic determinants of MetS in children after anticancer treatment are under investigation since the knowledge may be important for individualization of therapy.

**Design/Methods**: 54 children (26 male, average age 9.8 years) treated after hematological malignancies were studied. The glucose and insulin blood levels, body mass index (BMI) and blood pressure were analyzed. To estimate insulin resistance (IR) the Homeostasis Model Assessment of Insulin Resistance was used. The IR was found in 15 patients and obesity in 14 patients, the MetS was diagnosed in 7 patients. DNA was isolated from leukocytes of peripheral blood. In total, 32 SNPs in drug‐metabolizing enzyme genes, renin‐angiotensin system genes and immune response genes were genotyped. The next‐generation sequencing was performed in 15 patients using Inherited Disease Panel (Roche) for probe selection.

**Results**: The genotype and allele frequencies between different groups of patients were compared. It was found that the allele C (rs11091046) of AGTR2 and the allele G (rs4833095) of TLR1 were more frequent in patients with IR comparing with normal group (OR= 1.73, p=0.002, 95% CI=1.29‐2.34 and OR= 2.6, p=0.01, 95% CI=1.32‐5.14, correspondingly). Also, the polymorphic variant in AGTR2 was associated with MetS in pediatric patients (p=0.02). The allele A (rs1799930) of NAT2 was less frequent in patients with BMI \>95% percentile comparing with other patients (p=0.04), suggesting a protective effect.

**Conclusions**: Thus, polymorphisms rs11091046 in AGTR2 gene and rs4833095 in TLR1 gene were considered as genetic markers that may influence on risk of developing MetS in children with hematological malignancies undergoing anticancer therapy. Larger pharmacogenetic studies and exome sequencing are important to identify novel genetic markers predisposed to late effects of anticancer therapy.

### PO-602. Susceptibility‐Weighted Magnetic Resonance Imaging of Cerebrovascular Sequelae After Radiotherapy for Pediatric Brain Tumors {#pbc27455-sec-15780}

[M. Neu]{.ul} ^1^, Y. Tanyildizi^2^, A. Wingerter^1^, N. Henninger^1^, K. El Malki^1^, F. Alt^1^, B. Dörr^1^, H. Schmidberger^3^, M. Stockinger^3^, W. Wagner^4^, S. Keweloh^2^, M.A. Brockmann^2^, A. Russo^1^, J. Faber^1^
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**Background/Objectives**: Due to sensitive neuroimaging techniques, cerebrovascular complications such as cerebral microbleeds (CMB) and cerebral cavernous malformations (CCM) are increasingly recognized as considerable late effects after treatment for pediatric brain tumor. The aim of this study was to analyze CMB in a cohort of patients after cranial irradiation therapy for medulloblastoma or other pediatric brain tumors using susceptibility‐weighted magnetic resonance imaging (SWI).

**Design/Methods**: Forty former patients with pediatric brain tumor were enrolled in this prospective cross‐sectional study and examined by cranial MRI including SWI sequences. CMB, clinical symptoms and disability were evaluated. We assessed details of radiation therapy by medical record research. Furthermore, a detailed analysis of dose distribution and CMB distribution was performed in 16 patients. Both CMB and irradiated encephalon were identified and contoured manually. Dose‐volume histograms were generated for each individual to calculate median dose to the CMB volume (D50CMB) and to the whole encephalon (D50Enceph).

**Results**: Thirty‐six (90%) of the examined individuals (mean follow‐up age 22.2y; mean follow‐up time 13.5y) were affected by CMB. Thirteen patients (32.5%) presented with clinical symptoms. Individuals with CMB were more severely disabled than patients without CMB (p\<0.05). Longer follow‐up time and higher craniospinal irradiation doses correlated with higher total lesion count (p\<0.01). Individuals after whole brain radiotherapy plus boost presented with a significantly higher CMB count compared to focal irradiation (p\<0.05). Mean D50CMB was significantly higher than mean D50Enceph (p\<0.05) indicating a distinct tendency toward higher irradiation doses to the CMB volume compared to the encephalic volume.

**Conclusions**: Cerebrovascular sequelae occur frequently after treatment for pediatric brain tumor. In this study, a remarkable part of pediatric brain tumor patients presents with CMB. As a sign of vascular damage, they can cause clinical symptoms and may correspond to neurocognitive decline. Further studies are needed to standardize MRI protocols and to improve quality of long‐term follow‐up.

### PO-603. Sexual Function and Behavior in Male Childhood Cancer Survivors {#pbc27455-sec-15790}

[A. Nishimura]{.ul} ^1^, M. Ozawa^1^, S. Aiga^1^, Y. Ishida^2^, Y. Nagaoki^1^, Y. Yoshimoto^1^, S. Hirabayashi^1^, Y. Hosoya^1^, D. Hasegawa^1^, J. Ito^3^, R. Hosoya^1^, A. Manabe^1^
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**Background/Objectives**: While the proportion of childhood cancer survivors (CCS) has been increasing in general population because of improvement in treatment outcome of childhood cancers, adolescent and young adult (AYA) survivors have not received standardized medical screening examination. We developed a comprehensive clinical survey system in our institute, and male CCS were analyzed in order to study sexual function.

**Design/Methods**: CCS underwent medical examinations in preventive healthcare centers for adults of our hospital since 2015. Eighteen males out of 33 survivors aged 18 years old or older were examined in this study. We evaluated sexual hormone, testicular volume, Tanner developmental stage, and the age of first ejaculation.

**Results**: The median age at diagnosis of primary cancer and at enrollment of this study was 7.5 years old (range, 0‐16) and 26.5 years old (range, 21‐36), respectively. Primary cancers were as follows; acute lymphoblastic leukemia (n=10), neuroblastoma (n=3), brain tumor (n=2), and others (n=3). Two cases (11 %) were classified as below stage 5 of Tanner developmental stage. Six cases (30 %) had small testicular volume (\<10 mL) on both or either right and left side. Median age of first ejaculation was 13.5 years old (range, 11‐18). At the time of analysis, 17 cases (94 %) could ejaculate. In 6 cases who had small testicular volume, 2 cases (11 %) showed testosterone value less than 1 ng/mL while 4 cases (22 %) over 1 ng/mL.

**Conclusions**: Although most male survivors can ejaculate, 10‐30 % showed abnormalities in Tanner developmental stage, testicular volume or testosterone level. Spermatogenesis and sperm fertilizing ability in male CCS may be required for more comprehensive assessment of sexual function.

### PO-604. Somatic Late Effects in 5‐Year Survivors of Neuroblastoma: A Population‐Based Cohort Study Within the Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study {#pbc27455-sec-15800}
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**Background/Objectives**: Because of the rarity of neuroblastoma and poor survival until the 1990s, information on late effects in neuroblastoma survivors is sparse. We comprehensively reviewed the long‐term risk of neuroblastoma survivors for hospitalization for somatic disease.

**Design/Methods**: We identified 721 5‐year survivors of neuroblastoma in Nordic population‐based cancer registries dating back to the 1940s and identified late effects in national hospital registries covering the period 1977--2012. Treatment information was available from clinical registries for almost 50% of the survivors. The disease‐specific rates of hospitalization of survivors and of 152,231 randomly selected population comparisons for somatic diseases were used to calculate standardized hospitalization rate ratios (SHRRs) and absolute excess risks (AERs).

**Results**: During 5,500 person‐years of follow‐up, 501 5‐year survivors had a first hospital contact yielding a SHRR of 2.3 (95% CI 2.1--2.6) and a corresponding AER of 52 (95% CI 44--60) per 1,000 person‐years. The highest relative risks were those for diseases of blood and blood‐forming organs (SHRR 3.8; 95% CI 2.7--5.4), endocrine diseases (3.6 \[3.1--4.2\]), circulatory system diseases (3.1 \[2.5--3.8\]), and diseases of the nervous system (3.0 \[2.6--3.3\]). Approximately 60% of the excess new hospitalizations of survivors were for diseases of the nervous system, urinary system, endocrine system, and bone and soft tissue. The relative risks and AERs were highest for survivors who received intensive treatment.

**Conclusions**: Survivors of neuroblastoma have a highly increased long‐term risk for somatic late effects in all the main disease groups as compared with background levels. The increased risk was seen for all treatment groups but was most pronounced for the survivors most intensively treated. Our results should be useful for counseling survivors and should contribute to improving health care planning in post‐therapy clinics.

### PO-605. Osteoporotic Fractures in Childhood Cancer Survivors ‐ ALICCS Cohort Study {#pbc27455-sec-15810}
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**Background/Objectives**: Children and adolescents undergoing treatment for cancer are exposed to multiple factors that impact the development of peak bone mass and bone quality. The aims of this study were to examine the risks and cumulative incidence of osteoporotic fractures in childhood cancer survivors and identify subgroups at higher risk.

**Design/Methods**: In the national cancer registries of Denmark, Finland, Iceland and Sweden we identified patients diagnosed with cancer before 20 years of age from the start of registration in the 1940s and 1950s through 2008. We compared 26.334 one‐year survivors with a cohort of 162.372 age‐ and sex‐matched population comparison subjects selected from the national population registries. With data derived from national hospital registries we estimated the standardized hospitalization rate ratios (SHRR) and the mean cumulative count (MCC) of hospital admissions for osteoporotic fractures. To identify subgroups at risk we used Cox regression models to generate hazard ratios (HR) for osteoporotic fractures. Death and new cancer were treated as competing risks.

**Results**: The estimated SHRR for the first osteoporotic fracture was 1.41 (95% CI; 1.27‐1.58) but the MCC for recurrent osteoporotic fractures did not differ between the survivors and the comparison group. The SHRR for isolated hip fractures was 2.90 (2.32‐3.63). The adjusted HR for osteoporotic fracture as the first event was 1.53 (1.09‐2.16) if cancer was diagnosed 15‐19 years and 2.10 (1.48‐2.98) for long‐term survivors of CNS tumors. Survivors 15‐19 years at cancer diagnosis and long‐term survivors of CNS tumors were also at higher risk of experiencing a second fracture, HR 3.29 (1.65‐6.55) and HR 2.71 (1.45‐5.05), respectively.

**Conclusions**: Childhood cancer survivors are at higher risk of being hospitalized for osteoporotic fractures but the burden of recurrent fractures is not higher. For subgroups at risk, surveillance of bone health and measures to increase bone strength and prevent fractures should be encouraged.

### PO-606. School Experience of Childhood Cancer Survivors in Korea: A Multi‐Institutional Study on Behalf of the Korean Society of Pediatric Hematology and Oncology {#pbc27455-sec-15820}
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**Background/Objectives**: With the rapidly growing number of long‐term survivors, knowledge of the possible influences of the childhood cancer survivor\'s school life has been an increasingly important issue. Therefore, we investigated the school performance of childhood cancer survivors focusing on the child\'s functioning.

**Design/Methods**: We studied 241 children from 15 institutions in Korea between 2015 and 2016. The self‐reported paper‐and‐pencil questionnaires were used in this study.

**Results**: Approximately 80% of the survivors described themselves as satisfied with their school environment. After returning to school, 83.1% of the children reported that there were no differences in terms of peer relations. Children treated for brain tumors reported more trouble making friends compared to children with other tumors (35.0% vs. 14.8%, p=0.04). Bullying was reported by 30.2% of survivors. Survivors who returned to primary school reported a higher incidence of bullying compared to survivors who returned to middle or high school (p=0.03). The percentage of children who missed classes more than 4 days in a month was higher in survivors with brain tumors than those with other tumors (p=0.04). Approximately 41% of children reported learning difficulty. After returning to school, 52.7% of the patients reported that they had lower overall mark averages than they had before. Patients who returned to high school showed the highest rate of repeating a grade and the lowest rate of achieving high academic marks. The school marks in the Korean language (p=0.03), English (p=0.04), and physical education (p=0.04) were worse for the children with brain tumors than for the children with other tumors.

**Conclusions**: Our findings suggest that school‐organized educational support on returning to school was crucial, and that high school students with cancer have more difficulties in academic performance than younger children. Particular concern is needed to for patients with brain tumors with timely intervention to assist their school life and learning problem.

### PO-607. Associations Between Fitness and Neurocognitve Outcomes in Adult Survivors of Childhood Acute Lymphoblastic Leukemia in the St. Jude Lifetime Cohort Study {#pbc27455-sec-15830}

[N. Phillips]{.ul} ^1^, C. Howell^1^, M. Hudson^2^, L. Robison^1^, K. Krull^1^, K. Ness^1^

*^1^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^2^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for both exercise intolerance and neurocognitive deficits. Exercise capacity is associated with cognitive performance, and interventions to improve exercise capacity are associated with improved cognitive performance in other populations. Thus, the aim of this analysis was to determine if exercise intolerance is associated with neurocognitive impairment in ALL survivors.

**Design/Methods**: Submaximal (85% of predicted heart rate) cardiopulmonary exercise testing and neurocognitive performance were compared between 341 survivors of ALL (49% female; mean \[range\] age at diagnosis 5.1 \[0.6‐18.8\] years; age at evaluation 28.5 \[18.4‐44.6\] years) and 288 controls (49.3% female; age at evaluation 32.4 \[18.3‐44.8\] years). Within survivors, multivariable modeling tested associations between peak oxygen uptake (pkV0~2~) and neurocognitive domains, adjusted for sex, age at diagnosis, cranial radiation, anthracycline exposure and tobacco smoking status.

**Results**: Survivors had worse peak oxygen uptake (pkV02) (24.1 vs. 32.3 milliliters/kilogram/minute (ml/kg/min), p\<0.001), and performance (z‐scores) on verbal intelligence (‐0.35 vs. 0.92), verbal fluency (‐0.24 vs. 0.11), working memory (‐0.26 vs. 0.04), dominant/non‐dominant motor speed (‐0.92 vs. ‐0.11/‐0.81 vs. ‐0.04), visual ‐motor speed (‐0.22 vs 0.43), memory span (‐0.16 vs. 0.18), reading (‐0.30 vs. 0.002) and math (‐0.41 vs. ‐0.14) measures (all p\'s \< 0.001) than controls. In adjusted models, a 1 metabolic equivalent increase in exercise tolerance was associated with increases (in standard deviations) in performance of verbal intelligence (0.11, p=0.02), \[PN1\] verbal fluency (0.14, p\<0.001), working memory (0.07, p=0.03), dominant motor speed (0.14, p\<0.001), non‐dominant motor speed (0.18, p\<0.001), visual‐motor speed (0.98, p\<0.01), memory span (0.11, p\<0.01), reading academics (0.11, p\<0.01) and math academics (0.11, p\<0.01) in survivors.

**Conclusions**: This study demonstrates that fitness levels are significantly lower in survivors of childhood ALL than peers, with clear associations between fitness levels and neurocognitive outcomes in intelligence, executive function, processing speed, memory, and academic performance.

### PO-608. Health Utility‐based Quality of Life and Risk Factors in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort (SJLIFE) Study {#pbc27455-sec-15840}
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**Background/Objectives: Background**: Limited studies have evaluated health utility‐based quality of life, a form of health‐related quality of life measurement that considers societal preferences, for childhood cancer survivors. We aimed to compare health utility scores between adult survivors of childhood cancer and the general population, and to identify risk factors of decreased health utilities among survivors.

**Design/Methods: Methods**: Study participants included 2,811 SJLIFE study survivors who had detailed treatment exposures abstracted from medical records, 15 chronic conditions evaluated through comprehensive medical examinations and completed health surveys. Health utilities were estimated using the SF‐6D, and compared to normative data from the 2008‐2012 US Medical Expenditure Panel Survey. Treatment exposures included chemotherapy (corticosteroids, platinum, anthracyclines, alkylating agents, vincristine), radiotherapy (brain, chest, abdomen, pelvis) and invasive surgery. Symptom prevalence was measured by domains of sensation abnormality, movement problems, cardiac and pulmonary problems, pain, memory, anxiety, and depression. Survivors' health utilities were compared to normative data using t‐tests. Multiple linear regression was performed to test the effect of socio‐demographics, treatment, chronic conditions, and symptom prevalence on health utilities among survivors.

**Results**: Results: Survivors' mean age at survey was 31.8 years (SD=8.4) and mean time from diagnosis was 23.6 years (SD=8.1). Sex‐ and age‐adjusted health utility scores of survivors were lower than the norm by 0.033 (Cohen effect size: 0.32), indicating meaningful differences. Survivors of Hodgkin lymphoma, central nervous system malignancies, and sarcomas had worse health utilities than leukemia survivors (p\<0.05). Multivariable analyses indicated that being female (beta=‐0.025; p\<0.001), having no health insurance (beta=‐0.014; p\<0.05), and having peripheral neuropathy (beta=‐0.033; p\<0.001), skeletal disorders (beta=‐0.019; p\<0.001), or diabetes (beta=‐0.018; p\<0.05) were associated with lower health utilities. All symptom domains were associated with lower health utilities (betas=‐0.017 to ‐0.10; p\'s\<0.05).

**Conclusions**: Adult survivors of childhood cancer experience worse health utilities than population norms and are related to chronic symptoms and conditions.

### PO-609. Evaluating Content Validity of Patient‐Reported Outcome Measures Among Childhood Cancer Survivors and Caregivers for use in Pediatric Survivorship Care {#pbc27455-sec-15850}

[J. Pierzynski]{.ul} ^1^, J.L. Clegg^2^, B. Mandrell^3^, K.R. Krull^1^, C.B. Forrest^2^, M.M. Hudson^4^, L.L. Robison^1^, J. Baker^4^, I.C. Huang^1^

*^1^St. Jude Children\'s Research Hospital, Epidemiology and Cancer Control, Memphis, USA; ^2^Children\'s Hospital of Philadelphia, Division of General Pediatrics, Philadelphia, USA; ^3^St. Jude Children\'s Research Hospital, Department of Pediatric Medicine, Memphis, USA; ^4^St. Jude Children\'s Research Hospital, Oncology, Memphis, USA*

**Background/Objectives**: Background/Objectives: Few patient‐reported outcomes (PROs) measures have been validated for use in pediatric cancer survivor care. We aimed to test the content validity of four pediatric measures from the Patient‐Reported Outcomes Measurement Information System (PROMIS) among survivors of pediatric cancer and their caregivers.

**Design/Methods**: Design/Methods: The lived experience of four domains (fatigue, stress, positive affect, and pain interference) were elicited during semi‐structured interviews among 51 survivors (≥2 years off therapy, ≥ 5 years since diagnosis, and \<18 years of age) and 40 primary caregivers. Each transcribed interview was coded into "meaningful concepts" by two researchers. Tau‐b correlation coefficients were calculated based on the words/phrases used by survivors and caregivers, respectively, with positive correlation coefficients indicating more usage by survivors than caregivers, and negative coefficients otherwise. Linear semantic analysis and multidimensional scaling was conducted to test how meaningful concepts spatially clustered based on frequency of words/phrases used by survivors and caregivers.

**Results**: Results: For fatigue, stress, positive affect, and pain domains, the most common concepts reported by survivors were "needed to sleep during day", "felt worried", "felt happy", and "hurt a lot", respectively. The top words/phrases used by caregivers were "felt tired", "felt distressed", "felt happy", and "hurt a lot", respectively. Overall, 65% of words/phrases associated with fatigue, 60% with pain, 65% with stress, and 40% with positive affect were used more by children. Across domains, caregivers used the words/phrases with more objective contents (e.g., "Pain so bad had to take medicine" τB= ‐ 0.15) in contrast to survivors who used more subjective contents (e.g., "scared" τB= 0.17). Spatial analysis suggests a clear separation between meaningful concepts elicited by survivors and caregivers.

**Conclusions**: Conclusion: Important differences in the PRO themes were identified among survivors and caregivers for four symptom‐based domains. These findings help improve content validity of the PROMIS measures for pediatric cancer survivors.

### PO-610. Barriers to Long‐Term Followup in Adolescent/Young Adult Survivors of Childhood Cancer: What Survivors Say {#pbc27455-sec-15860}

[M. Prasad]{.ul} ^1^, H. Sankaran^1^, S. Goswami^2^, T. Vora^1^, G. Narula^1^, G. Chinnaswamy^1^, S. Banavali^1^, P. Kurkure^3^

*^1^TATA MEMORIAL HOSPITAL, Paediatric Oncology, Mumbai, India; ^2^Tata Memorial Hospital, Clinical Psychology, Mumbai, India; ^3^SRCC Hospital, Paediatric Oncology, Mumbai, India*

**Background/Objectives**: Survivors of childhood cancer(CCS)need lifelong follow‐up to detect late effects of treatment,many of which are known to develop in adulthood. Adherence to follow‐up is known to drop with time,especially in adolescent and young adult(AYA)CCS. Access to specialized clinics,out‐of‐pocket expenditure, low awareness and societal attitudes are barriers to survivorship care in resource‐limited settings. We attempted to prospectively identify reasons for delayed clinic attendance in our AYA CCS.

**Design/Methods**: All AYA CCS who attended our late effects clinic over the past one year(1st‐April 2017‐31st‐March 2018)after default of over one year from their scheduled follow‐up visit were interviewed about reasons for delay. Clinical and demographic information was extracted from the prospectively maintained database.

**Results**: Of 2100 5‐year CCS registered, 686(32%)have defaulted their scheduled follow‐up by over 1year; 72/686 defaulters attended over the past year; 61 were AYA. Median age at follow‐up 25‐years, median duration of follow‐up 19‐years, 43 male:18 female. Twenty‐four (39%) had grade 3‐4 late effects. Reasons for default included absence of symptoms (46%),lack of time due to school/work/family(50%), long distance(41%), expense of travel/stay(28%), expenses in hospital(15%), social issues(8%), medical issues(5%)and follow‐up elsewhere(5%).Amongst those married,5/6 females(but 0/13 males) did not come since spouse was unaware of cancer history. Reasons for return were medical concerns in 19 (31%),routine follow‐up in 26(42.6%)and response to tracking calls in 13(21%).

**Conclusions**: AYA CCS are often unaware of the importance of regular long‐term medical follow‐up,possibly because of the young age at diagnosis and current transition to independent living. Although our hospital is able to defray medical expenses, financial concerns hamper follow‐attendance in CCS, as do social,logistic and medical reasons. Educating CCS and their parents during treatment as well as repeatedly during subsequent visits is important. In the absence of a centralized health system, platforms such as social media,messaging services and peer support groups help to constantly update contact information and track defaulters.

### PO-611. Description of a Ten Year Single Centered Study Experience in Children\'s Splenectomy {#pbc27455-sec-15870}

[M. Quiros‐Mata]{.ul} ^1^, Y. Gamboa^2^, C. Araya^3^

*^1^Dr., Pediatrics, San Jose, Costa Rica; ^2^Caja Costarricense Seguro Social, Oncology, San Jose, Costa Rica; ^3^Caja Costarricense Seguro Social, Pediatrics, Alajuela, Costa Rica*

**Background/Objectives**: To describe the clinical characteristics and evolution of patients who underwent splenectomy in Costa Rica\'s National Children Hospital during 1996 and 2006.

**Design/Methods**: It\'s a chart review study of a 10 year period including children who underwent splenectomy in Costa Rica\'s National Children\'s Hospital. A hundred and seven children with ages between 0 and 13 years old were reviewed to obtain their clinical presentation and characteristics, indications for splenectomy, evolution in a 2 year period follow up, complications and mortality. Also the antibiotic prophylaxis and immunization schedule was analyzed based on international recommendations.

**Results**: A total of 107 patients were included. Our results showed that the mean age at which splenectomy was performed was 6.4 years. Most of the patients had their splenectomy due to hemoglobinophaties (59.8%). Mainly sepsis and hemorrhage were found as complications postsplenectomy. Overall mortality was 7.1%.

**Conclusions**: Splenectomy is an alternative for the treatment of patients with both medical and traumatic diseases. Overall, after the procedure patients in our country had satisfactory outcomes. Both vaccination and antibiotic prophylaxis recommendations were not followed in all our cases.

### PO-612. Second Primary Cancer After Childhood Cancer in Germany 1980‐2014 -- Incidence and Influcence of Radiotherapy {#pbc27455-sec-15880}

[P. Scholz‐Kreisel]{.ul} ^1^, P. Kaatsch^2^, C. Spix^2^, M. Blettner^1^

*^1^University Mainz Medical dept., Insitute for Biostatistics‐ Epidemiology and Medical Informatics, Mainz, Germany; ^2^University Mainz Medical dept., German Childhood Cancer Registry at the Insitute for Biostatistics Epidemiology and Medical Informatics, Mainz, Germany*

**Background/Objectives**: Due to the efforts to improve cancer therapy, more than 85 % of children with cancer survive at least five years. Late effects of cancer and cancer therapy, particularly second primary neoplasms (SPNs), have become more prevalent.

**Design/Methods**: Based on the data of the German Childhood Cancer Registry (GCCR), patients with a first neoplasm before the age of 15, who survived for at least 6 months and were first diagnosed between January 1st 1980 and December 31st 2014 were analyzed for the occurrence of second primary neoplasms. Cumulative incidence was estimated using the Aalen‐Johansen‐method and hazard ratios using Fine and Gray regression. For a subgroup basing on the period 1995‐2014 standardized incidence ratios (SIRs) compared to the general German population were calculated. To analyze the influence of radiotherapy on the risk of developing a SPN, a nested case‐control‐study was initiated.

**Results**: Among 47,650 childhood cancer survivors, 1,262 SPN cases were observed. The cumulative incidence until a maximum follow‐up of 35 years was 8.27% (95%‐confidence interval (CI)=7.51%‐9.03%). Hazard ratios (HR) showed a higher risk of developing a SPN for female patients (HR=1.29; CI=1.16--1.44) and patients with a systemic first neoplasm (HR=1.22; CI=1.09--1.36). The standardized incidence ratio (SIR) compared to the general German population for the period of 1995‐2014 was 7.08 (95%‐CI=6.42--7.9) for females and 5.83 (95%‐CI=5.27--6.42) for males. Therapy data for a subgroup of 2,845 patients were analyzed. 63 % of the patients received radiotherapy with a mean prescribed dose of 25,0 Gray.

**Conclusions**: SPN‐Risk keeps rising with rising age and survival‐time of the patients. Radiation therapy, chemotherapy, sex and age at exposure showed statistical significant influence on the SPN risk. Our further investigations are aiming at identifying individual biological risk factors which might determine the risk for secondary cancer in survivors of childhood malignancies.

### PO-613. The After‐Treatment Completion Card (ATCC): Medical Passport for a Child Cancer Survivor {#pbc27455-sec-15890}

[R. Seth]{.ul} ^1^, N. Pathak^2^, J. Meena^2^, A. Gupta^2^

*^1^Professor, Pediatrics, Delhi, India; ^2^AIIMS, Pediatrics, New Delhi, India*

**Background/Objectives**: The Childhood Cancer Survivor Study reported majority of survivors were receiving medical care, but only 31.5% reported care that focused on the prior cancer and only 18% reported survivor ‐ focused care that included advice about risk reduction and considering screening tests. Such a concept is not an area of focus in developing countries. We aimed to prepare and determine the utility of an A**fter Treatment Completion Card (ATCC)** for Childhood Cancer Survivors.

**Design/Methods**: The bilingual ATCC card was given to all pediatric cancer survivors. Details of treatment (chemotherapy /radiation/surgery/others), risk factors /stage of disease were noted. Possible late effects and modality of follow up assessment were determined. The card had messages to emphasise that the child is well, fit to go to school, his growth needs monitoring, vaccination must resume, but follow up is needed.

**Results**: 148 children received the ATCC card. Majority (87%) were coming for regular follow up at 16 months of follow up, 79% were going to school, 60% got vaccinated, growth monitoring was done for all. Late effects were monitored via the ATCC card. Growth retardation was found in 25% and behavioural problems were common in acute leukemia survivors. Cardiotoxicity was present in 4%. Retinoblastoma survivors had late effects related to chemotherapy, radiation and enucleation.

**Conclusions**: The ATCC was useful and adapted by other centres in India also. There is a need for sensitization of cancer survivors, their families and health professionals towards the existence and nature of late effects. The ATCC gives a comprehensive summary of cancer treatment received during childhood, the late effects that may occur and how they should be monitored. This card is a medical document which must be extremely valued and readily available for reference by the patient/ care giver.

### PO-614. The Indian Childhood Cancer Survivorship Study (C2S Study): After Treatment Completion Registry of Childhood Cancers ‐ Phase -- I. An InPOG‐LE‐16‐01 Study {#pbc27455-sec-15900}

[R. Seth]{.ul} ^1^, G. Kapoor^2^, R. Arora^3^, N. Verma^4^, A. Kumar^4^, A. Mahajan^5^, M. Kalra^5^, P. Mandal^6^, P. Kumari^7^, A. Das^8^, J. Ramamoorthy^9^

*^1^Professor, Pediatrics, Delhi, India; ^2^Rajiv Gandhi Cancer Institute & Research Centre, Oncology, New Delhi, India; ^3^Max Hospital Saket, Pediatrics Oncology, New Delhi, India; ^4^KGMU, Pediatrics, Lucknow, India; ^5^Apollo Hospital, Pediatric Oncology, New Delhi, India; ^6^LHMC & Kalawati Hospital, Pediatrics, New Delhi, India; ^7^RCC Trivandrum, Pediatric Oncology, Trivandrum, India; ^8^TMC Kolkata, Pediatric Oncology, Kolkata, India; ^9^Adyar, Pediatric Oncology, Chennai, India*

**Background/Objectives**: Advances in treatment for childhood cancers have resulted in a growing population of childhood cancer survivors. A priority area for the Pediatric oncology community is care of childhood cancer survivors and monitoring of late effects. This has hitherto been a neglected area in India with limited data on prevalence of late effects. Besides this no registry for childhood cancer survivors exists in India.

We proposed to establish a multicentre registry of children completing cancer treatment (phase ‐I), determine the spectrum of late effects in childhood cancer survivors and formulate recommendations/guidelines for long term follow up of Indian childhood cancer survivors (phase ‐II)

**Design/Methods**: All children completing treatment were enrolled into phase I of the study (registry). Demographic and treatment details with cumulative doses of chemotherapy/radiation were recorded. Follow up is planned at 3, 6, 12, 18 and 24 months by phone/teleconsultation/physical evaluation to document remission/relapse. At end of two years survivors will be eligible for phase --II wherein spectrum of late effects will be evaluated.

**Results**: We report data from Phase I (registry). Nine centres across India are participating and more centres are being recruited. Six hundred ninety‐seven patients have been enrolled, median age being 8.3 years (range 1‐26 years). Majority are males. Commonest malignancy was acute leukemia (40%) followed by lymphoma (18%) and retinoblastoma (9%). Majority belong to middle socio‐economic strata (modified Kuppuswamy scale). Period of follow up ranges from 0‐16 months (median 9 months). Majority (87%) are under follow up. Relapse was seen in 7%. Phase II will report on late effects.

**Conclusions**: The C2S Study should provide useful epidemiologic data on childhood cancer survivors. Long term follow up will demonstrate profile of late effects that occur in childhood cancer survivors. This will culminate in forming recommendations/guidelines for long term follow up of such children in India.

### PO-615. Re‐engage: A Nurse‐led eHealth Intervention to Promote Engagement and Empower Childhood Cancer Survivors {#pbc27455-sec-15910}

[C. Signorelli]{.ul} ^1^, C. Wakefield^2^, K. Johnston^2^, J. Fardell^1^, B. Mary‐Ellen^1^, E. Thornton‐Benko^3^, T. Foreman^1^, K. Webber^4^, W.H. Wallace^5^, R. Cohn^1^

*^1^Sydney Children\'s Hospital/UNSW Sydney, Kids Cancer Centre, Sydney, Australia; ^2^UNSW Sydney‐ Sydney Children\'s Hospital, Kids Cancer Centre, Randwick, Australia; ^3^Bondi Road Doctors/Wellac Lifestyle: Wellness After‐ And during Cancer, Bondi, Sydney, Australia; ^4^Prince of Wales Hospital/UNSW Sydney, Department of Medical Oncology/National Centre for Cancer Survivorship, Sydney, Australia; ^5^Royal Hospital for Sick Children, Department of Hematology/Oncology, Edinburgh, United Kingdom*

**Background/Objectives**: Many childhood cancer survivors are disengaged from long term follow‐up (LTFU) care despite the increasing importance of surveillance for second malignancies and late effects as they age. We assessed survivor/parent‐reported LTFU barriers and piloted a targeted intervention, called 'Re‐engage'.

**Design/Methods**: Australian and New Zealand survivors and parents (of survivors \<16years) completed surveys and optional interviews on LTFU barriers. We used survey results to design Re‐engage, currently being piloted with disengaged survivors (i.e. those who have not accessed cancer‐related care for \>2years).

**Results**: In total, 629 participants completed surveys: 404 survivors (mean age: 26.2years, mean time since diagnosis: 19.1years) and 225 parents (child\'s mean age: 12.5years, mean time since diagnosis: 9.7years). Survivors disengaged from LTFU (45%) reported significantly greater dissatisfaction with care received outside tertiary cancer centers, compared to engaged survivors (p\<0.001). Disengaged survivors endorsed more barriers to attending LTFU including costs (p\<0.001), distance to clinic (p\<0.001), or being unaware of LTFU (p\<0.001). Decreased clinic attendance was significantly more likely in older survivors (p=0.008) and in those who reported a higher total number of barriers to LTFU (p\<0.001). We designed 'Re‐engage' to address these barriers. Re‐engage is an eHealth, nurse‐led, intervention for disengaged survivors to improve health‐related self‐efficacy. To date, we have piloted Re‐engage with 22 survivors (53% male, mean age 29 years). Of these, 87% endorsed Re‐engage as beneficial and the remaining as 'a little bit' burdensome. More than half (54%) of disengaged survivors were at high‐risk of late effects and second malignancies. One‐month post‐intervention, early data show improvements in survivors' self‐efficacy.

**Conclusions**: Our data is unique in first identifying barriers and using these data to develop a targeted intervention. Re‐engage appears acceptable to survivors and may have potential in promoting self‐efficacy. The proportion of high‐risk survivors in our pilot sample highlights a critical need to engage survivors into appropriate follow‐up.

### PO-616. Developing a Survivor Passport for Childhood Cancer Survivors in India {#pbc27455-sec-15920}

C. Kumar^1^, [A.K. Singh]{.ul} ^1^, A. Kumar^1^, S. Sharma^1^, A. Mishra^1^, P. Bagai^1^

*^1^CanKids...KidsCan, Survivor Group, New Delhi, India*

**Background/Objectives**: Childhood Cancer Survivors face late and long‐term (LT) side effects psycho‐social, employment, and insurance issues and often lack consistent LT follow‐up care. At present in developing countries like India survivorship services are an underdeveloped area. KidsCan Konnect‐ Survivor group (KCK) of Cankids...Kidscan, strives to improve services available to survivors. In order to address the systemic service and knowledge gap experienced by our survivors, KCK has developed an innovative survivor passport program to educate survivors about late effects, and help them with proper documentation and the need for regular follow‐up.

**Design/Methods: Step 1 --** An educational and brainstorming stakeholder meeting between survivors, parents, reproductive medicine specialists and paediatric oncologist was held on 20th Dec 2016 in New Delhi.

**Step 2 --** Survivors treatment documents were collated in soft and hard copies and the project services options described to Survivors.

**Step 3‐** Existing methods/practice of information dissemination to survivors was discussed.

**Step 4**‐ Global and Indian practices in other centers was reviewed. The above provided information for discussion and deciding about survivor passport.

**Step 5‐** Subsequently we conducted Survivor Passport Clinic & Workshop, 4 times in Delhi, Kolkata and Ahmedabad focused on issues after childhood Cancer.

**Results**: Developed Survivor Passport -- As an After Treatment Completion Card for each survivor monitored in the study. It included information on demography, treatment summary and exposures, plan for follow up as well socio, economic and psychological issues. 77 survivors have attended the clinic and 71 passports have been issued. Out of 71, 50 hadn\'t known before about LT side effects & agreed for regular follow up after the workshops.

**Conclusions**: A purposeful start has been made by developing a passport to address the needs of CTYA survivors in India. Now We plan to provide full fledged service of this model and passport will be online for all KCK Members and other survivors.

### PO-617. "The Little Artisans Project" by Cancer Buster Community (CBC) Indonesia {#pbc27455-sec-15930}

[S. Tahir]{.ul} ^1^

*^1^Indonesia Childhood Cancer Foundation, Cancer Buster Community Survivors, Jakarta, Indonesia*

**Background/Objectives**: CBC is the biggest childhood cancer survivors' community in Indonesia, established under the umbrella of Yayasan Onkologi Anak Indonesia (**YOAI**). Every year, CBC, supported by YOAI, endeavor to develop new programs to promote encouragement to patients. This year, we decided to take on a new approach in celebrating the International Childhood Cancer Day through "The Little Artisans Project".

With our own past experiences as childhood cancer patients, we understand very well that being stress‐free is a key essential for one to be able to undergo such intense and onerous medical treatment. However, considering the condition of the patients, it is certainly not easy for them to always maintain their happiness. "The Little Artisans Project" was initiated to improve and preserve the contentment of patients through creativity and productivity.

**Design/Methods**: We engaged a renowned art community in Jakarta called "RuangRupa" to hold a workshop program that offered various arts and crafts activities. The patients got to choose one or more activities that they found interesting and the representatives from RuangRupa, assisted by members of CBC, taught and helped the patients to work on and complete their works.

**Results**: There were more than 80 patients participated in the workshop, including children and teenagers. They were all excited and enthusiastic. Not only they realized that they have the ability to produce artworks like other children, but they were also delighted to be able to meet and share new experiences with other patients and survivors. Many of the patients were very satisfied that they even requested another similar event to be held.

**Conclusions**: In order to motivate patients, we found it is more efficient and meaningful to encourage them to be engaged in activities that prove their productivity and ability. We also conclude that patients are most happy when they realize they are no different than other children.

### PO-618. The Early Experience of Implementing a Paediatric Cancer Survivorship Programme in Singapore {#pbc27455-sec-15940}

[A.M. Tan]{.ul} ^1^, C. Quek^1^, K. Lim^1^, M. Seng^1^

*^1^KK Women\'s and Children\'s Hospital, Paediatric Subspecialties ‐ Haematology/Oncology Service, Singapore, Singapore*

**Background/Objectives**: KKH is one of the two main children\'s cancer centres in Singapore which sees 100 new diagnoses a year. The survivorship programme was started with philanthropic funding from children\'s cancer foundation (CCF). The Paediatric Cancer Survivorship Programme was established in 2017. The multi‐disciplinary team consists of paediatric oncologists, a nurse coordinator, clinical psychologist and data manager. The aim of this report was to describe the early experience seen in the pilot cohort.

**Design/Methods**: Survivors were identified from the Singapore Childhood Cancer Registry, which captures epidemiology, treatment and outcomes for paediatric oncology patients seen in public hospitals since 1997. Patients were defined as all who were alive and in complete remission at 5 years from diagnosis. The pilot cohort seen in the clinic included patients aged 19 years and above. Cumulative treatment details and significant medical issues were entered into the Passport for Care (TM) portal, an internet based tool developed by Baylor College of Medicine with the COG to generate an individualised treatment summary and care plan.

**Results**: We have about 800 survivors in KKH with 50% lost to follow up. As of March 2018, the clinic has seen 17 survivors, of which, 14 cases had leukaemia and 3 had CNS tumours. The leukaemia survivors ranged from 19 to 37 years. 7/14 (50%) have a chronic health problem. The spectrum of late effects experienced ranged from asymptomatic low oestradiol level, osteopaenia to severe organ dysfunction including respiratory fibrosis and cataracts. All the leukaemia patients completed at least secondary school education. We see a fair number of defaulters at this clinic.

**Conclusions**: The early results showed many survivors have a chronic health condition. Utilizing an electronic tool has standardize practices. Survivor education is important in increasing attendance in the clinic as primary prevention and early intervention can help survivors maximise the quality of life.

### PO-619. Body Composition Nutritional Intake and Physical Activity in Childhood Leukemia Survivors {#pbc27455-sec-15950}

P. Mishra^1^, [A. Trehan]{.ul} ^2^, R. Jain^3^, D. Bansal^4^, N. Khandelwal^5^

*^1^Post Graduate Institute of Medical Education and Research‐, Department of Pediatrics‐, Chandigarh, India; ^2^Pediatric Hematology Oncology unit‐, Department of Pediatrics‐ Post Graduate Institute of Medical Education and Research‐, Chandigarh, India; ^3^Pediatric Hematology Oncology unit‐ Post Graduate Institute of Medical Education and Research‐, Department of Pediatrics, Chandigarh, India; ^4^Post Graduate Institute of Medical Education and Research‐, Pediatric Hematology Oncology unit‐Department of Pediatrics, Chandigarh, India; ^5^Post Graduate Institute of Medical Education and Research‐, Department of Radiology, Chandigarh, India*

**Background/Objectives**: Childhood cancer survivors (CCS) have some modifiable long term complications.. Altered body composition, physical activity and nutritional status are preventable long term effects which we analyzed in our CCS.

**Design/Methods**: Thirty adolescents and young adults treated for acute lymphoblastic leukemia, off therapy for≥ 5 years and 20 age matched controls were evaluated. Body composition was assessed by anthropometry and DEXA scan, physical activity gauged as per CDC criteria and nutritional intake calculated by a food frequency questionnaire.

**Results**: Thirty patients diagnosed at 5.9 yrs± 3.04years (22 boys & 8 girls) were evaluated 8.7±3.2 years after therapy. At diagnosis: 85.7% had normal weight, 14.3% underweight, 10% stunted, mean BMI being 14.39 ± 1.99 kg/m². At evaluation: 7(23.3%) underweight, 17(56.7%) with normal BMI, 5(16.7%): overweight and 1(3.3%) obese. Mean BMI increased significantly to 19.97±8.76 kg/m² (p =0.000). Cases and controls had similar BMI(p =0.807). Three fourth survivors had adequate carbohydrate & protein intake, fat intake being satisfactory in 46.7%. Calcium intake was sufficient in only 30% cases. Nutrition was similar in CCS and controls. Seventeen (56.7%) CCS had osteopenia with 16.7% having osteoporosis, with 70% cases with BMD abnormalities having inadequate calcium intake. Physical activity was better in controls (p = 0.029), 16.7% CCS doing moderate/vigorous and vigorous activities compared to 25% and 40% of controls doing moderate/vigorous and vigorous activities. Diet was not associated with BMI and physical inactivity. Association between BMI and fat mass/lean mass was significant (p value=0.000).

**Conclusions**: CCS and controls were noted to be deficient in nutrition, especially calcium. Physical activity was significantly less in CCS. Bone mineral density was low in 56.7% survivors. Our findings indicate the need for targeted interventions in CCS for a healthy future. The high prevalence of low BMD needs research.

### PO-620. Prediction of Low Bone Mineral Density Among Adult Survivors of Childhood Cancer {#pbc27455-sec-15960}

[J. Van Atteveld]{.ul} ^1^, S. Pluijm^1^, K. Ness^2^, M. Hudson^3^, W. Chemaitilly^4^, S. Kaste^5^, L. Robison^6^, S. Neggers^7^, M. van den Heuvel‐Eibrink^1^, C. Wilson^8^

*^1^Princess Máxima Center of Pediatric Oncology, Pediatric Oncology‐ Late Effects, Utrecht, The Netherlands; ^2^St. Jude Children\'s Research Hospital, Epidemiology/Cancer Control‐ Pediatric Medicine, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Oncology‐ Epidemiology/Cancer Control‐ Psychology‐ Cancer Control & Survivorship Program, Memphis, USA; ^4^St. Jude Children\'s Research Hospital, Pediatric Medicine‐ St. Jude Graduate School of Biomedical Science, Memphis, USA; ^5^St. Jude Children\'s Research Hospital, Diagnostic Imaging‐ Oncology, Memphis, USA; ^6^St. Jude Children\'s Research Hospital, Epidemiology/Cancer Control‐ Comprehensive Cancer Center‐ Cancer Control & Survivorship Program, Memphis, USA; ^7^Princess Máxima Center of Pediatric Oncology, Endocrinology‐ Late Effects, Utrecht, The Netherlands; ^8^St. Jude Children\'s Research Hospital, Epidemiology/Cancer Control, Memphis, USA*

**Background/Objectives**: Although low bone mineral density (BMD) is prevalent among adult survivors of childhood cancer, evidence‐based guidance for surveillance of low BMD among survivors by dual X‐ray absorptiometry (DXA) is limited. Therefore, we aimed to develop and validate a prediction model based on patient and treatment characteristics to identify adult survivors who require screening by DXA.

**Design/Methods**: Caucasian survivors (N=2412, median attained age, 30.9 \[range: 18.1‐65.9\] years) enrolled in the St. Jude Lifetime Cohort (SJLIFE, development) and survivors (validation) previously treated at the Erasmus Medical Center, the Netherlands (N=410, median age, 24.5 \[range: 18.0‐49.3\] years) were evaluated with DXA to determine lumbar spine (BMD~LS~) and total body (BMD~TB~) BMD, with low BMD defined as BMD~LS~ and/or BMD~TB~ Z‐score ≤‐1. Backward multivariable logistic regression was used to build a prediction model; performance was assessed using receiver operating characteristic curves. Diagnostic values were calculated at different probabilities. The formula P~lowBMD~=e\^(β~0~+β~1~\*x~1~+β~2~\*x~2~+...+β~n~\*x~n~)/(1+e\^(β~0~+β~1~\*x~1~+β~2~\*x~2~+...+β~n~\*x~n~)) was used to predict individual probability of low BMD (β~0~=intercept; β~n~=regression coefficient (β) of each predictor x~n~).

**Results**: Low BMD was prevalent among 52% and 44% of SJLIFE and Dutch participants. The model included male sex (β=0.50), height (β=‐0.05), weight (β=‐0.03), age at cancer diagnosis (β=‐0.02), current smoking (β=0.19) and cranial irradiation (β=0.31) as significant predictors. Areas under the curves were 0.72 (95%‐CI 0.70‐0.74) in SJLIFE and 0.70 (95%‐CI 0.65‐0.75) in the Dutch cohort. Sensitivity (69.6%), specificity (63.9%) and accuracy (66.9%) were optimized at a probability of 0.50, corresponding to positive and negative predictive values of 67.4% and 66.3%. At this point, 53.4% of survivors were predicted to have low BMD.

**Conclusions**: A validated model including sex, age at diagnosis, height, weight, smoking status and prior exposure to cranial radiation correctly identified BMD status in nearly 67% of Caucasian adult survivors through age 50 years. Clinical applicability can be warranted by our online calculator.

### PO-621. Pregnancy and Perinatal Risks in Female Cancer Survivors: A Population‐Based Analysis {#pbc27455-sec-15970}

[A.L. Van Der Kooi]{.ul} ^1,2^, D. Brewster^3^, R. Wood^3^, C. Fischbacher^4^, M. van den Heuvel‐Eibrink^2^, J. Laven^1^, H. Wallace^5^, R. Anderson^6^

*^1^Erasmus MC -- Sophia Children\'s Hospital, Obstetrics and Gynecology, Rotterdam, The Netherlands; ^2^Princess Máxima Center for Pediatric Oncology, Pediatric Oncology, Utrecht, The Netherlands; ^3^NHS National Services Scotland, Information Services Division, Edinburgh, United Kingdom; ^4^NHS National Services Scotland, Information Services Division and eDRIS, Edinburgh, United Kingdom; ^5^Royal Hospital for Sick Children, Department of Oncology and Haematology, Edinburgh, United Kingdom; ^6^University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, United Kingdom*

**Background/Objectives**: Advances in cancer management have resulted in improved survival rates. However, treatment may adversely affect reproductive outcomes among female survivors of cancer (FSC). We examined their risk of adverse pregnancy and perinatal outcomes compared to the general population.

**Design/Methods**: Pregnancy and perinatal complications were identified through linkage of the Scottish Cancer Registry with hospital discharge records based on the Community Health Index (CHI) database to identify all FSCs aged \<40 and nulliparous at cancer diagnosis between 1981 and 2014, and their first subsequent pregnancy. Three controls matched on age, year of cancer diagnosis and deprivation quintile were selected from the CHI. Relative risks and 95%‐confidence intervals of perinatal risks were calculated using log‐binomial regression.

**Results**: A total of 1,629 singleton first births in FSC were compared to 8,899 singleton births in control women. FSC were more likely to give birth before 37 weeks of gestation (RR 1.32,95%‐CI 1.10 -- 1.59). They were not at risk of delivering low birthweight offspring (\<2.5kg;RR 1.15, 0.94 -- 1.39), but had a decreased risk of delivering offspring small for gestational age (RR 0.81, 0.68 -- 0.98). Childhood cancer survivors (CCS), diagnosed aged 0‐14 years, were more than three times as likely to undergo an elective caesarean section (RR 3.15, 2.04 -- 4.88) and were at increased risk of postpartum haemorrhage (PPH) (RR 1.62,1.23 -- 2.13), but there were marked changes by period of diagnosis, with these risks normalizing with more recent diagnosis. The risk of congenital abnormalities was not increased (RR 1.01, 0.85 -- 1.20).

**Conclusions**: FSC are at risk for premature delivery, but not for small for gestational age or congenital abnormalities. CCS are at increased risk for PPH and elective caesarean section. While heightened alertness and careful management in FSC is appropriate, there has been a marked normalization of mode of delivery over recent decades.

### PO-622. Neurologic Morbidities, Emotional Distress, and Functional Independence in Adult Survivors of Childhood Cancer Treated with CNS‐Directed Therapies: A Report from the Childhood Cancer Survivor Study {#pbc27455-sec-15980}

[S. Vuotto]{.ul} ^1^, K. Krull^2^, C. Li^3^, F. Okcu^4^, D. Bowers^5^, N. Ullrich^6^, K. Srivastava^3^, R. Howell^7^, T. Gibson^2^, W. Leisenring^8^, K. Oeffinger^9^, L. Robison^2^, G. Armstrong^2^, T. Brinkman^2^

*^1^The College of Mount Saint Vincent, Department of Psychology, New York, USA; ^2^St. Jude Children\'s Research Hospital, Department of Epidemiology and Cancer Control, Memphis, USA; ^3^St. Jude Children\'s Research Hospital, Department of Biostatistics, Memphis, USA; ^4^Texas Children\'s Cancer Center‐ Texas Children\'s Hospital, Department of Pediatrics, Houston, USA; ^5^The University of Texas Southwestern Medical School, Department of Pediatrics, Dallas, USA; ^6^Boston Children\'s Hospital, Department of Neurology, Boston, USA; ^7^The University of Texas M. D. Anderson Cancer Center, Department of Radiation Physics, Houston, USA; ^8^Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, USA; ^9^Duke University Medical Center, Division of Medical Oncology‐ Departments of Medicine and Community and Family Medicine, Durham, USA*

**Background/Objectives**: Survivors of childhood cancer who received central nervous system (CNS)‐directed therapies are at risk for neurologic sequelae, which may adversely impact psychological functioning and independence in adulthood.

**Design/Methods**: Participants included 7,942 survivors of childhood cancer treated from 1970‐99 with cranial radiation, intrathecal methotrexate or cytarabine (59% leukemia; 27% CNS tumor; 11% non‐Hodgkin; 3% other; mean\[standard deviation\] age = 25.5\[5.8\] years, time since diagnosis = 17.7\[4.6\] years). Self‐reported neurologic conditions included stroke, seizure, sensory deficits, focal neurologic dysfunction, and severe headaches. Emotional distress symptoms (measured by BSI‐18) included anxiety, depression, and suicide ideation (SI). Functional independence was assessed using latent class analysis with six indicators (independent living, assistance with routine needs, assistance with personal care needs, ability to attend work/school, driver\'s license, marital status). Multivariable regression models, adjusted for age, sex, race, pain, and health status, estimated relative risks (RR) and odds ratios (OR) for associations of neurologic morbidity with emotional distress and functional independence.

**Results**: Prevalence of neurologic conditions was: 3% stroke; 11% seizure; 25% sensory deficits; 29% focal neurologic dysfunction; 31% severe headaches. In multivariable models, risk of emotional distress was associated with focal neurologic dysfunction (anxiety: RR=1.6; 95% Confidence Interval (CI)=1.3‐2.1; depression: RR=1.4; CI=1.2‐1.7), sensory deficits (anxiety: RR=1.3; CI=1.0‐1.6; depression: RR=1.3; CI=1.1‐1.5; SI: RR=1.3; CI=1.0‐1.6), and severe headaches (anxiety: RR=1.5; CI=1.2‐1.9; depression: RR=1.6; CI=1.4‐2.0; SI: RR=1.5; CI=1.2‐1.8). Stroke (OR=0.3, CI=0.2‐0.5), seizure (OR=0.2, CI=0.2‐0.3), and focal neurologic deficits (OR=0.26, CI=0.2‐0.3) were associated with decreased likelihood of functional independence.

**Conclusions**: Childhood cancer survivors who develop neurologic morbidities are at‐risk of emotional distress symptoms, including suicide ideation, and failure to attain independence in adulthood.

### PO-623. Changing Trends in Survival Outcomes for Infants Diagnosed with Tumours Under 1 Year of Age: A West of Scotland Retrospective Review {#pbc27455-sec-15990}

[C. Willis]{.ul} ^1^, M. Ronghe^1^, D. Murphy^1^, D. McIntosh^1^, J. Sastry^1^

*^1^Royal Hospital for Children, Paediatric oncology, Glasgow, United Kingdom*

**Background/Objectives**: Infantile tumours are rare. Tumour biology in infants differs to older children, therefore response to treatment and survival outcomes may also differ. The objectives of this review were to determine the number of infants diagnosed with tumours (benign and malignant, excluding haematological diagnosis) over a 15 year period. Survival outcomes between five year intervals were compared.

**Design/Methods**: A retrospective patient record review of all infants \< 1 year of age with a tumour diagnosis over a fifteen year period (Jan 2001‐2015) was performed. Using electronic patient records and databases, 92 patients were identified (54 boys: 38 girls). Data collated included benign/ solid or CNS groups, diagnosis, age at diagnosis, follow up time period and survival outcomes (relapse rate and overall survival). Comparisons were made between 2001‐2005, 2006‐2010, and 2011‐2015.

**Results**: Mean age at diagnosis was 146 days (1 day to 342days). Seventy four (80%) of patients had solid tumours. Of these, fifty four (58%) were malignant. Eighteen (20%) had CNS tumours. Fifteen (16%) patients had neuroblastoma, accounting for 28% of the malignant solid tumour. Overall relapse rate was 16 (17% of all infants). Relapse rate was highest in patients with neuroblastoma (31%). Of the relapsed patients, 5 (31%) survived. The overall mortality rate was 23 / 92 (25%) with 13 (56%) of patients having solid tumours (benign and malignant) and 10 (44%) of patients having CNS tumours. Between 2001‐2005, survival rates for all patients (benign and malignant) was 60%, 85% in 2006‐2010 and 76% in 2011‐2015. Follow up period ranges from 1 day to 18 years.

**Conclusions**: Solid tumours are more common than CNS tumours in infants. Neuroblastoma was the commonest tumour in infants and was associated with the highest relapse rates. Over the last decade, an improvement in overall survival for infants diagnosed with tumours has been reported.

Childhood Cancer International (CCI) {#pbc27455-sec-16000}
------------------------------------

### PO-624. Development and Delivery of a One‐Stop Multidisciplinary Clinic to Provide Comprehensive Palliative and Supportive Care for Children with Cancer {#pbc27455-sec-16010}

[H. Anis]{.ul} ^1^, A. Taluja^2^, T. Chuki^3^, L. Crack^4^, R. Arora^1^, P. Bagai^1^

*^1^Cankids...kidscan, Palliative Care & Psycho Oncology Department, New Delhi, India; ^2^Cankids...kidscan, Quality Care Research & Impact Department, New Delhi, India; ^3^Cankids...kidscan, Palliative Care, New Delhi, India; ^4^Cankids...kidscan, Palliative Care Department, New Delhi, India*

**Background/Objectives**: To address a service gap at the primary treating Center arising from patient overload and on holidays/weekends, Cankids Pediatric Palliative Care Center in Delhi was providing children with cancer inpatient admissions and ambulatory care IV antibiotics. Other Cankids Social Support services were generally not being offered. Objective of this service was to run a One‐ stop Social Support Clinic providing holistic care and strengthening Palliative Care Outpatient and Inpatient Services.

**Design/Methods**: Pilot phase of the Clinic (Mar‐Sep 2017) supplemented the ambulatory care service with additional access to Pain, Symptom, Wound Management, Psychological and Nutritional Counselling, Physiotherapy, Educational, Financial Support and Patient Navigation along with care giver education by trained professional team. The Clinic operated seven days a week, with 68 clinics, providing 11 services. Providers were trained for Patient Navigation and referrals, Standard Operational Procedures and Patient data management.

**Results**: Total 1,204 patients received 7,101 episodes of care. 195(16%) patients received Palliation of symptoms. Indication for inpatient admissions in 8 out of 64 were for end of life care. 23(62%) of 37 new inpatient admissions were from the Clinic. 261 (57%) of 456 patients who came for IV Ambulatory Care received other social support services including Pain, Symptom Management, Psychological, Nutritional, Hematological Support, Physiotherapy, Medical assistance and Investigations and Educational Scholarships. 25 Patient Care Training Sessions were attended by 347 caregivers. 62.6% participants were extremely satisfied and 37.6% satisfied with the services provided.

**Conclusions**: A well run Social Support One‐stop Clinic together with a Multi Disciplinary Team including Palliative Care Physicians, Nurses, Psychologists, Nutritionists,Physiotherapists and Patient Navigators at the Pediatric Palliative Care Center provides enhanced holistic care and a better understanding and acceptance of palliative care. It also provides a platform and the time for parent education on how to care for their child during treatment at home and in the hospital setting.

### PO-625. Registration of Childhood Cancer in Africa {#pbc27455-sec-16020}

[I. Cecile]{.ul} ^1^, L.C. Couitchéré^2^, J. Nsondé Malanda^3^, D.Y. Ye^4^, S. Perrier‐Bonnet^5^, D.M. Parkin^6^

*^1^African Cancer Registry Network, Research Assistant, Kigali, Rwanda; ^2^CHU de Treicheville, Service d\'Oncologie Pediatrique, Abidjan, Ivory Coast\\r; ^3^CHU de Brazzaville, Cancerologie Medicale, Brfazzaville, Congo; ^4^Université de Ouagadougou, Pédiatrie‐néonatologie, Ouagadougou, Burkina Faso; ^5^African Cancer Registry Network, Consultant/Project Manager, Monpellier, France; ^6^INCTR, African Cancer Registry Network, Oxford, United Kingdom*

**Background/Objectives**: Information on occurrence and survival of cancer at the population level can only be obtained through cancer registries. Studies of cancers in children in sub‐Saharan Africa are even more difficult than those of adults, because of their relative rarity (only 4.6% of cancers occur before age 15), and the fact that registries in sub Saharan Africa cover limited -- usually urban -- populations.

In partnership with the My Child Matters programme (Sanofi Foundation), the African Cancer Registry Network is piloting a project to enhance childhood cancer registration on the continent.

**Design/Methods**: In the first year, the registries of two countries (Cote d\'Ivoire and Republic of Congo) have expanded their scope to become national registries for paediatric cancer, and a new registry -- national paediatric registry of Burkina Faso, has been established.

The staff of all 3 registries were trained to record stage at diagnosis for childhood cancers, using the "Tier 1" classification of the Toronto consensus principles (as in TNM‐8) for which a special coding manual has been developed. Two long standing Anglophone registries (Harare and Kampala) were also trained in the staging of cancers, and follow‐up of patients registered was carried out in 4 centres, to estimate population‐level survival.

**Results**: The childhood cancer profile differed between the centres. Kaposi sarcoma remains a common childhood tumour in East Africa, Burkitt lymphoma is very common in Uganda and Cote d\'Ivoire, and while the most common solid tumour in West Africa was retinoblastoma, Wilms tumours were more common in East Africa. Survival is rather poor -- less than half of the cases were alive 3 years after diagnosis. The role of stage in determining these poor outcomes is being investigated.

**Conclusions**: Registration of childhood cancer in feasible in Africa, with proper training and support, and can provide valuable data on incidence, stage and survival.

### PO-626. To the World, a Network of Childhood Cancer Experienced People Shouting with Our Voices "Hee‐mahng Chun‐sa‐dan" {#pbc27455-sec-16030}

[J.M. Choe]{.ul} ^1^, J.M. Park^1^

*^1^KACLCKorean Association for Children with Leukemia & Cancer, Health Support Bureau, Seoul, Republic of Korea*

**Background/Objectives**: KACLC would like to present a case of "Hee‐mahng Chun‐sa‐dan" based on 'Emerging Trends in Survivorship Care and Re‐integration Programs', a sub‐theme of this year CCI conference.

As the cure‐rate and survivor‐rate of childhood cancer increased, the re‐integration of childhood cancer experienced has become a vital issue. While childhood cancer centered activity focused on building internal strength in the past, nowadays it puts more weight on how to take individual needs. Beyond overcoming individual treatment experiences, recent childhood‐cancer experienced wish to share and return their experience to the public value.

**Design/Methods**: "Hee‐mahng Chun‐sa‐dan" is a network of teenagers and young adult with childhood cancer experience between the ages of 17 and 29 in Korea. With the support of KACLC, the network holds a monthly meeting and recruits new member yearly. Under the vision of supporting the healthy social re‐integration of childhood cancer experienced, "Hee‐mahng Chun‐sa‐dan" set detailed directions and proceeded activities such as 'establishment of self‐identity', 'speaking own experience' and 'contribution to society'

**Results**: "Hee‐mahng Chun‐sa‐dan" has carried out variable activities such as volunteering for social rehabilitation for childhood cancer experienced people and children with cancer, internal and external mentoring, and public campaign for improving the awareness of childhood cancer. At the end of 2017, we took a reporting meeting between Korea and Japan to make known the public about the activities of the childhood cancer experience network in Korea and to share the results with those who have not been directly involved in the network.

**Conclusions**: Through the activities of "Hee‐mahng Chun‐sa‐dan", the members established their identity as a childhood cancer experienced and learned how to accept individual experiences in a sound way by building empathy and fellowship with one another. Furthermore, these social participation activities have laid the foundations for growth as an independent member of society.

### PO-627. Impact of Palliative Care Training and Capacity‐Building as Components of Pediatric Oncology Development Grants to Low and Middle Income Countries (LMICS) {#pbc27455-sec-16040}

[P. Close]{.ul} ^1^, A. Zaidi^2^, A. Gagnepain‐Lacheteau^3^

*^1^Sanofi Espoir Foundation, My Child Matters‐ grant mentor, Mendocino‐ California, USA; ^2^St.Jude Children\'s Research Hospital, Department of Pediatric Global Medicine, Memphis, USA; ^3^Sanofi Espoir Foundation, Medical Director, Paris, France*

**Background/Objectives**: Background: LMICs commonly have lower cure rates for pediatric cancer due to limitations in government funding, healthcare infrastructure, and access to specialty care in rural areas. Thus, the need to build capacity to effectively manage pain and other symptoms in children who may succumb to their cancers, and to provide culturally appropriate support for families throughout treatment, is compelling.

**Design/Methods**: Methods: The My Child Matters grant initiative to support improvements in pediatric cancer programs in LMICs has provided competitive funding to 55 grants in 42 countries since 2006. Grants have included an option to develop palliative care training and models for care delivery. Expert mentors are provided for support and leadership training. Each country, region, and/or institution is encouraged to develop culture and resource‐appropriate trainings and care models that include core palliative medicine knowledge and psychosocial and spiritual care skills development.

**Results**: Results: LMIC pediatric oncology grant recipients have demonstrated significant interest in developing palliative medicine capacity in parallel with other improvements of pediatric cancer care. A total of thirty‐nine pediatric oncology‐ trained professionals, including eight from Thailand, two from Bangladesh, four from Guatemala, one each from Nicaragua, Honduras, Haiti, Panama, Dominican Republic, and twenty‐three physician/nurse teams from fifteen Francophone countries in Africa have traveled to centers outside their countries for palliative medicine training. Additional documented impacts include establishment of national treatment guidelines for pediatric cancer‐ related palliative care, development of new palliative care units and teams in pediatric cancer centers, new medical school competencies, numerous nurse training courses, and enhanced availability and use of oral morphine for pediatric cancer patients at end of life. Language and culture‐specific publications for professionals and parents have been produced and local, national and international collaborations have expanded.

**Conclusions**: Philanthropic support for development of pediatric oncology palliative care in LMICs has demonstrated acceptance and beneficial impact.

### PO-628. The My Child Matters Programme: Improving Referrals of Children with Cancer by Using a Healthcare Systems Network in Paraguay {#pbc27455-sec-16050}

[D. Figueredo]{.ul} ^1^, I. Mattio^1^, J. Servin^1^, S. Aponte^1^, O. Zelada^1^, M. Caniza^2,3^, A. Gagnepain‐Lacheteau^4^, A. Samudio^1^

*^1^Facultad de Ciencias Médicas Universidad Nacional de Asunción, Hemato‐Oncología Pediátrica, San Lorenzo, Paraguay; ^2^St. Jude Children\'s Research Hospital, Department of Global Pediatric Medicine and Department of Infectious Diseases, Memphis, USA; ^3^University of Tennessee Health Science Center‐ College of Medicine, Department of Pediatrics, Memphis, USA; ^4^Sanofi Espoir Foundation, My Child Matters Program, Paris, France*

**Background/Objectives**: Paraguay is a lower middle‐income country. It has 6.802 million people. The under‐5 mortality rate is 21/1,000 live birth. Cancer is the second‐leading cause of death in children aged 5 to 19 years. The population living below the national poverty line are 23% and 30% has no access to healthcare. The health system are fragmented, almost nil coordination between health services, acting in isolation, without articulation. All pediatric cancer Centers were located close to the capital.

In 2009, a pediatric cancer network was implemented in Paraguay, the Childhood Cancer Care Network (ReNACI), under the auspice of Sanofi Espoir Foundation the My Child Matter Programme. The goal of this network was decentralizing care of children with cancer by establishing and sustain 4 regional pediatric satellite clinics for early cancer detection, referral, treatment, social assistance and follow‐up of pediatrics patients with cancer.

**Design/Methods**: Retrospective, descriptive study of transverse section. Using a hospital‐based registry of patients with childhood cancer from January 1, 2010 to December 31, 2017.

**Results**: The number of patients evaluated each year in satellite clinics increased from the beginning of the project from 273 to 906 in the year 2017. The total number of consultations increased 58.7%, from 6221 in 2010 to 9873 in 2017. The satellite clinics were responsible for 4.6% (273/5,948) of the attendances in 2010 and 9.2% in 2017 (906/9873). The total number of patients evaluated in the satellite clinics was 4,914, of these, 2,032 patients were referred to the central hospital with suspected oncological disease, confirming in 32.7% of patients.

**Conclusions**: The RENACI network improve access to medical care for pediatric patients with suspect of hematological or oncological disease by establishing a systems of referral satellite clinics. These clinics allowed medical and social support for the child and his family which are closer to home during the entire treatment period.

### PO-629. 12 Years Experience on Bereavement Families Approach in Argentina ‐ Lessons and Challenges {#pbc27455-sec-16060}

[E. Grynszpancholc]{.ul} ^1^, T. Mendez^2^, M. Capurro^2^

*^1^Fundación Natalí Dafne Flexer, Presidency, Buenos Aires, Argentina; ^2^Fundación Natalí Dafne Flexer, Psychology, Buenos Aires, Argentina*

**Background/Objectives**: Fundación Natalí Dafne Flexer (FNDF) provides direct servicies to more than a thousand families per month. 40% of them are coming to our City to receive Treatment. Emotional Support servicies are not enough at the biggest Hospitals in Argentina. When available, its not provided to the whole family. FNDF is located very close to each of the main Hospitals and at some locations in the Interior of the Country. Bereavement Parent Groups started since 2006. FNDF have records of the pathways of more than 10000 families affected Childhood cancer.

**Design/Methods**: The Proposal for families include 6 meetings for each Group, 2 hours long, every 15 days. Participating Parents are at various stage of Bereavement. Each Group has no more than 12 participants. Coordination by 2 Psychologists. A questionnaire is filled at start and end of the Group period by each participant.

**Results**: Meetings started in julio2006, 89 families have participated since then, 18 different groups, mainly mothers. Siblings Groups started for the last 2 years. GrandParents have their own meetings. Couples groups are also required. Starting whatsapp psychological support for those from the Interior of the Country. This Groups and the experienced mothers are able to support other mothers. Their participation in external congresses and meetings is frequent and required. Other Institutions receive orientation by our professionals.

**Conclusions**: This is a service needed by most of the families, after their lost. Other Bereavement Groups that are available, not focused on lost after Childhood Cancer Treatment are not desirable by those affected. Knowledge of the most frequent issues raised on the Meetings is a very useful information. New Technologies\' use are our next challenge, and need to be explored. The knowledge, experience and Records are the base to lead the change in Laws and promoting the availability of Services at Hospitals.

### PO-630. Integrated Services Across the Country for Children with Cancer and their Families {#pbc27455-sec-16070}

[S. Kamgar]{.ul} ^1^

*^1^MAHAK ‐ the Society to Support Children Suffering from Cancer, Public and International Relations Department, Tehran, Iran*

**Background/Objectives**: MAHAK is a non‐profit, non‐political and non‐governmental organization established with the goal of serving humanity by combatting pediatric cancer nationally and internationally through medical care, research and support services dependent exclusively on public support.

Over the past 27 years MAHAK\'s agenda has consisted of geographic and physical expansion; improving the quality and quantity of services; and human resource development which might best be summed up in two words: Sustainability and Development.

**Design/Methods**: We at MAHAK assess needs, to develop plans, and attract the support of the public, in order to address the concerns of more cancer‐stricken children and their families and improve the quality of their lives. In order to reach this point, providing integrated services across Iran, development of infrastructures according to international standards, expansion of digital communications and implementing joint research projects focusing on childhood cancer are some of MAHAK\'s main strategic plan for 2017‐2021.

**Results**: According to this five‐year strategic plan devised to reach the goal of "delivering integrated services across the country", MAHAK has undertaken various methods such as holding the 2nd International Congress on the Role of Supportive Bio‐Psycho‐Socio‐Spiritual Services in Multidisciplinary Treatment of Childhood Cancer on November 22‐23, 2017 with the presence of the Head of International Society of Pediatric Oncology (SIOP) along with different national and international speakers to explore the innovations and best practices in childhood cancer care. In line with the outcomes of this congress, MAHAK has planned some strategic projects to meet this goal by the end of 2021. Since the mentioned strategic plan has just been launched, MAHAK will deliver comprehensive reports on the outcomes of the implementation of this program.

**Conclusions**: MAHAK believes that the goals of its strategic plan will be met by close collaboration with all CCI members along with other alike organizations across the globe.

### PO-631. Campaign Improving Awareness of People Experienced Leukemic Childhood Cancer ('Hope! Talk about the World' National Pilgrimage Project) {#pbc27455-sec-16080}

[S.A. Kim]{.ul} ^1^

*^1^KFCCPO Korea Federation of Childhood Cancer Parent Organization, Family of Children with Cancer Bureau, Seoul, Republic of Korea*

**Background/Objectives**: \*CCI conference theme: Engaging and Mobilizing Stakeholders for Organizational Growth, Sustainability and Impact.

Our society has a prejudice against people who has experienced leukemia and childhood cancer treatment. Those experienced fought the disease and studied, and although the treatment was finished, the social prejudice hampers them in school, employment, and love.

**Design/Methods**: This campaign is a national pilgrimage that people treated with leukemic childhood cancer and their family marches from Jeju, the southernmost Island, to the northernmost Mt. Baekdu in Korea.

Every year, it will be held at the same time for a week before October 4^th^ (Angel day). Each year, they set a theme, dress in the same color and design, and walk around chanting slogans. And in the evening, they gather at a hotel to have a discussion to identify the issues of the experienced persons, the psychological state of siblings, and the difficulties of the caregiver who took care of them and consider solutions. These issues can also be the subject of the following year.

**Results**: The campaign has changed us and society in many ways. The participants opened their closed minds and started getting ready to go out into society. Someone fell in love, got a license, and came to have courage to challenge for their dreams. Broadcasting media and local communities were also interested in our movements. Our society was changing such as Pediatric ward was established in a place where there was no childhood cancer hospital, MOUs with the national public corporation, and conducting survey with social welfare service groups.

**Conclusions**: To bring awareness to the public that they are ready to do anything with healthy body and mind and to give hope and courage to the injured those experienced and their family, we will keep developing this campaign.

### PO-632. An Example of Our Actions to Improve the State Being Inactive in Supporting Parents with Children in Hospital {#pbc27455-sec-16090}

[K. Kimura]{.ul} ^1^

*^1^Children\'s Cancer Association of Japan, Niigata branch, Murakami, Japan*

**Background/Objectives**: CCAJ Niigata Branch, one of the regional chapters of Children\'s Cancer Association of Japan, provides support for children and their families placing Niigata Cancer Center Hospital as the core base of its activities.

However, our activities became so inactive due to the fixation of supporting members that we repeated discussions about the ways to revitalize our organization.

**Design/Methods**: Members having experiences with the treatment of childhood cancer discussed what requires most for the support during hospitalization, and created an action plan.

Specifically, we implemented a tea party once a month for the parents staying at the hospital in order to exercise a peer support.

Our staff took care of the children so that their parents could easily participate in the tea party.

**Results**: We were able to provide the parents with a pleasant time for relaxation and communication through the party, which contributed to the increase of parents who took their positive attitudes to medical treatment of their children.

The fact that we were able to refresh the parents' mind by listening to their concerns has given satisfaction and confidence to the supporters who participated in the tea party. Also, we could improve and enhance our skills of how we encourage parents with children suffering from cancer.

**Conclusions**: The stagnation of activities starts with members' immobilization and negative prospects.

With an atmosphere not to be afraid of failure, the important thing is to produce an active plan having supporting members feel accomplished.

A 24‐hour support from parents for long‐term hospitalized children is in need in Japan.

This brings about heavy burden on parents, which in some cases causes family breakdown.

Hospitalized children and their families are expecting our support. It is our role to meet their expectations, and we are required towards step up our activities continuously through carefully identifying the needs of patients.

### PO-633. Role of Family Group to Health Care and Treatment of Childhood Cancer: Collaborative Efforts in Development and Growth of Family Group in the Central Vietnam {#pbc27455-sec-16100}

[N. Le]{.ul} ^1^, C.V. Ha^2^, N.T. Kim Hoa^2^, W. Kazuyo^3^

*^1^Childhood Cancer Family Group in Central Vietnam, Hue, Hue, Vietnam; ^2^Hue Central Hospital, Pediatric Center, Hue, Vietnam; ^3^Asian Children\'s Care League, Founder, Tokyo, Japan*

**Background/Objectives**: To provide psycho‐social support and care to children and their families affected by cancer is vital to overcome the disease. Inspired, encouraged and supported by global organization (CCI), medical institution (Hue Central Hospital), NGO (ACCL), Childhood Cancer Family Group in Central Vietnam (CCFGCV), a first family group in Vietnam, was established in 2007, and a first free accommodation for patients/families was opened in 2017.

**Design/Methods**: Since the establishment of the family group, all patients/families treated at Hue Central Hospital were registered. Varieties of activities were carried out, and effectiveness was evaluated by collecting data of abandonment, death, accommodation usage and sponsors.

**Results**: Through hospitalization supports initiated by the family group such as monthly meeting in collaboration with medical staff to provide education, peer‐counseling and home‐visits, 100% of parents were educated, knowledge and conscious levels of parents to keep hygiene, avoid infection, deal with fever were higher, and core members were trained and experienced. Such programs had direct correlation to successful higher survival rate, lower abandonment rate (3.9%), delay of treatment to under 1‐week, and loss of follow‐up to 0%. The statistical usage of accommodation, a place to cook and to stay without cost showed satisfactory level specifically resulting to safe and nutritious foods leading to no patients died from food infection. Medical student volunteer group provided compassionate care for patients through ward activities, and number of local sponsors has increased.

**Conclusions**: Family group plays an important role to help patients/families during treatment in collaboration with stakeholders which leads to improvements of survival and abandonment rates. The activities of family group have convinced many local donors to support children. Continuous efforts to strengthen the organizational capacity in self‐sustainable ways and to promote this model to other regions in Vietnam bring further benefits to enhance the quality of life of children and their families nation‐wide.

### PO-634. NGO to War on Cancer in a Developing Country {#pbc27455-sec-16110}

[P. Manullang‐Panggabean]{.ul} ^1^

*^1^The Indonesian Anyo Foundation, YAI, Jakarta, Indonesia*

**Background/Objectives**: The Indonesian Anyo Foundation (YAI) an NGO for childhood cancer, plays an active role of educating people in early detection of childhood cancer and providing the shelter house for children with cancer. The Indonesian national health insurance (JKN), since 2014 has encouraged people to see medical treatments in primary health care as the government bears the medical treatment costs. Therefore, in addition to educating various communities on childhood cancer, YAI is also actively educating medical personnel at primary health care.

**Design/Methods**: This is a strategic measure for early detection of childhood cancer so that patients can be immediately referred to the hospital for further treatments. The number of pediatric oncologists in Indonesia is still limited, only about 70. Indonesia is a vast country with 34 provinces, 17,504 islands, and population of 270 million people. It is a big challenge for YAI to provide education on childhood cancer in all provinces with 10,000 primary health care facilities.

**Results**: In collaboration with local health authorities, step by step 10,000 copies of the guidebook on early detection of childhood cancer on the process distributed to 10,000 primary health care facilities throughout Indonesia. YAI also facilitates a grant of 1,000 opthalmoscopes that will be distributed to 1,000 primary health care to save children under five ages from retinoblastoma. It enables early detection so that we can save their lives, eyes and also vision. Most of retinoblastoma patients in Indonesia seek for medical treatment in hospital when the condition is advanced that make them losing their eyes and using the prosthesis.

**Conclusions**: Hopefully through 1,000 primary health care, it can be obtained data of suspected children with cancer, including retinoblastoma. And hopefully these efforts can also save the state expenditures for public health since the cost of cancer treatment is very expensive, especially in case of advanced conditions.

### PO-635. Reengineering of Resources and Outpatient Palliative Care for Children with Neoplastic Diseases in Honduras: Impact on Patients Care {#pbc27455-sec-16120}

[R. Martinez]{.ul} ^1^, V. Conter^2^, A. Zaidi^3^, A. Gagnepain‐Lacheteau^4^

*^1^Medical Doctor, Pediatric Oncology Department, San Pedro Sula, Honduras; ^2^Pediatric Hemato‐Oncology Center, Pediatric Hemato‐Oncology Center, Monza, Italy; ^3^Global Pediatric Medicine, St Jude Children\'s Research Hospital, Memphis, USA; ^4^Medical Director, Sanofi‐Espoir Foundation, Paris, France*

**Background/Objectives**: The Pediatric Hemato‐Oncology service (PHOS) at Mario Rivas Hospital is one of the two centers that care for children with cancer in Honduras. This center, with 16 hospital places and an outpatient clinic, receives 200 new cases of pediatric cancer every year, plus the other hematological diseases. Until 2017, palliative care (PC) was only provided in the Hospital. These limitations delayed the application of chemotherapy, and damaged the cure rate. A project of reorganization has been implemented with the support of the My Child Matters program (Sanofi Espoir Foundation), to improve efficiency of care delivery and provide PC ambulatory support.

**Design/Methods**: Elements of Industrial Engineering were incorporated to simplify the organization: monitoring activities, detecting bottleneck and creating a new workflow. Relevant hospital staff was trained. An audit of time gain was conducted. An Hospice was opened to offer 5 additional places for palliative patients. The entire team focused on finding solutions for PC outside the hospital whenever possible.

**Results**: The waiting time in the outpatient clinic fell from 6 to 2 hours, new patients can be seen in the 48 hours after referral. The Hospice received 37 children and released 568 days / bed. The delay in the administration of chemotherapy fell from 15 to 5 days.

**Conclusions**: Low‐income countries have a lot of children with cancer to care with limited resources. Improving the efficiency of care is vital. In this context the availability of an outpatient PC service allows reducing costs and improving the quality of life. The systematic reassessment of human and material resources is crucial.

### PO-636. Establishing a Nation Wide Forum/Group of Chilhood Cancer Survivors to Integrate and Enhance Survivors' Activities Across Japan {#pbc27455-sec-16130}

[D. Masumoto]{.ul} ^1,2,3^, K. Imoto^3,4^, T. Komatsu^3,5^

*^1^Mie University Graduate School of Medicine, Medical Education, Mie, Japan; ^2^Childhood Cancer Association in Japan, Tokai Branch, Aichi, Japan; ^3^SHAKE‐HANDS, Childhood Cancer Survivors Network in Japan, Fukuoka, Japan; ^4^Nicosumakyushu NPO, Secretariat director, Fukuoka, Japan; ^5^Fellow Tomorrow, Childhood Cancer Survivor, Tokyo, Japan*

**Background/Objectives**: Proportional to the improvement of the survival rate, the number of childhood cancer survivors increases rapidly and everlastingly. While the needs to support survivors become ever more important, the necessity of encouraging survivors to take initiatives of peer activities and to foster spirits of self‐reliance among survivors becomes also an issue.

**Design/Methods**: In 1993, Childhood Cancer Association of Japan (CCAJ) organized a childhood cancer survivors (CCSs) meeting, and in 1994 "Fellow Tomorrow" the first formal CCSs group was established. Since then many groups have been established and by 2017 there are 13 CCSs groups across Japan. CCAJ also sponsored leaders' meeting where leaders of CCS groups shared/discussed their activities and problems. Through the discussion of the leaders' meeting, a consensus was reached on organizing a national forum/group involving all survivors' groups and individuals in Japan.

**Results**: In 2014, "SHAKE‐HANDS", a national CCS forum/group was formed by survivors to enhance the bonds between survivors and between regional CCS groups. Meetings of "SHAKE‐HANDS" are held biannually, consists of three sessions, a lecture by leading pediatric oncologist, discussion on issues of survivors' life flowed by an informal convivial dinner. Many issues are discussed e.g. late‐effects, long‐term follow up, schools, employment, marriage, pregnancy. Activities of "SHAKE‐HANDS" is planned and organized wholly by survivors including raising funds to cover expenses. CCAJ remained as a strong supporter but its role is strictly advisory.

**Conclusions**: "SHAKE‐HANDS" has enabled CCS all over Japan to interact directly and its collective power enables participants to have access to better and wider information as well as variety of peer experiences. Besides the primary objectives having been met, there are other positive outcomes. An example of which is that raising funds by survivors themselves brings good opportunities to enlighten society at large including business sector of the facts concerning childhood cancer.

### PO-637. Information Technology and Gamification Applied on Camping Program Design for Children and Adolescents Under Cancer Treatment {#pbc27455-sec-16140}

[S. Mozzilli]{.ul} ^1^, E. Sassi^2^, A. Chibana^3^, F. Martins^4^, F. Francisco^5^, D. Gritti^6^

*^1^Beaba, Director ‐ President, São Paulo, Brazil; ^2^Beaba, Creative, Sao Paulo, Brazil; ^3^Fundação para Segurança do Paciente, Director ‐ Physicians, São Paulo, Brazil; ^4^Fundação para Segurança do Paciente, Director ‐ Nurses, São Paulo, Brazil; ^5^Beaba, Nurses, São Paulo, Brazil; ^6^Beaba, Director ‐ VP, São Paulo, Brazil*

**Background/Objectives**: The treatment of cancer causes children and adolescents to be constantly exposed to stressors.

Using Information Design and Gamification to educate about the disease and its treatment outside its original context enables young patients to learn and internalize knowledge.

Children and adolescents, between 6 and 18 years old, in different phases of treatment, from 3 cancer hospitals were invited to "Beaba Camping", a project that was run in August 2017.

**Design/Methods**: 1. Interdisciplinarity: combining the knowledge of physicians, nurses, psychologists, nutritionists, social workers, educators; professionals in communication, hospitality, safety; and most importantly of all: patients.

2\. Information Design: presenting cancer and treatment information in a way that fosters efficient and effective understanding by children and adolescents.

3\. Gamification: applying game mechanics to increase engagement and arouse users\' curiosity through rewards.

**Results**: Creation and production of a customizable lanyard with 12 badges, where each one symbolized important information or "missions" to be performed, such as hand hygiene, medication administration and even meditation. The tasks were set during the camping program, but were also of great importance during and after the cancer treatment.

The lanyards were used spontaneously by all participants and all of them had earned their badges by completing the missions. In addition to the immediate bonus stimulus after the completion of the missions, there was the larger goal of filling the lanyard.

**Conclusions**: Interdisciplinarity is essential for the success of projects like this, adding technical information and graphic design that appeals to children and adolescents, just as gamification is an effective tool for engaging and supporting outcomes related to health and well‐being.

The camping program will be held again in August 2018 and we will include the results of patient behavior in the respective hospitals after participating in the project.

\*To be presented in the SIOP, if we are selected;)

### PO-638. Childhood Cancer Early Detection Training Program for Primary Healthcare Providers {#pbc27455-sec-16150}

[J.C. Mutabazi]{.ul} ^1^, N. Blaise^2^

*^1^Rwanda Children\'s Cancer Relief, Executive Director, Kigali, Rwanda; ^2^Rwanda Children\'s Cancer Relief, Research, Kigali, Rwanda*

**Background/Objectives**: Over 250,000 new pediatric cancer cases are diagnosed yearly worldwide. Health care providers (mainly nurses) at Health Centers (HC) level are the children\'s first opportunity for correctly recognizing and responding to early signs and symptoms of childhood cancers by appropriately referring them to district hospitals but studies show that 83% of nurses did not receive training on pediatric cancers. Insufficient knowledge about the warning signs and symptoms of pediatric cancer usually leads to improper diagnosis or delay to diagnosis and hence loss of many lives of these children. Our efforts since 2017 has been concentrated on training primary healthcare providers to recognize early signs and symptoms of childhood cancers.

**Design/Methods**: The program is consisted of trainings in selected regions of Rwanda. The first step is a "train the trainer workshop" where volunteering medical students and doctors are trained to train the nurses and community health workers. A two days workshop is organized subsequently in each province bringing together at least with one nurse from each selected health center. These trained nurses go back with materials to train their colleagues. They are followed up every three months with a survey to assess how much they retain the learned knowledge and the impact made.

**Results**: The program was conducted in 4 health centers and around 90 healthcare providers were trained with more than 800 posters, 950 brochures and 300 flyers distributed. According to reports, after the training, the number of referrals from health centers increased and the post training showed how accurate nurses were in stating their differential diagnoses.

**Conclusions**: Childhood cancers are curable when detected and treated early, there is a need to build partnerships with private and public sectors to address the challenge of early detection and late presentation at the hospital because the program of training primary healthcare providers showed a good impact.

### PO-639. Personality Development Through Cultural Activities of Ugam: A Childhood Cancer Survivor\'s Support Group of Indian Cancer Society (ICS) {#pbc27455-sec-16160}

[A. Nikale]{.ul} ^1^, S.K. Jha^2^, F. Shaikh^1^, C. Behera^1^, S. Joshi^2^, V. Dhamankar^2^, P. Kurkure^2^, S. Nair^3^

*^1^Ugam‐ Indian Cancer Society, Cancer Survivorship, Mumbai, India; ^2^Indian Cancer Society, Cancer Survivorship, Mumbai, India; ^3^Indian Cance Society, Director General, Mumbai, India*

**Background/Objectives**: Ugam, is a childhood cancer survivors support group established under umbrella of Indian Cancer Society (ICS) in 2009. Its vision is to ensure that every childhood cancer survivor finds his/ her way to celebrate life after winning the battle with cancer. The empowerment of the young survivors, helping children with cancer undergoing treatment & creating social awareness and re‐bonding with society is Ugam\'s mission. The current study explores how Ugam through its various cultural activities has created social awareness & helped young survivors to develop their personality & increase their self‐esteem.

**Design/Methods**: Ugam has been conducting various cultural programs for either cancer awareness activities of ICS or when invited by social groups for interaction & re bonding with society. The cultural activities under Ugam would include various performing arts like dance, theatres etc. Those Ugam members who regularly participated in these events were interviewed and were further analyzed to study the desired impact.

**Results**: In 2017, Ugam organized/participated in 16 events creating awareness on cancer, and curability of childhood cancer. A total of 185 members participated in these events. It was observed that participation at cultural events enabled the young survivors to develop their creative and administrative abilities. It gave them a chance to develop social skills as well as create a sense of togetherness in the group. These events also gave them a chance to work on their self‐esteem. Being a part of these activities, lets them connect with the society at large and indirectly also helps spread the message of childhood cancer being curable.

**Conclusions**: Encouraging young survivors of childhood cancer to participate in cultural events and performing arts activities could help create a positive impact in shaping their overall personality.

### PO-640. Wishing Well, a Home‐based Pediatric Palliative Care Service for Childhood Cancer in Thailand {#pbc27455-sec-16170}

[I. Nuchprayoon]{.ul} ^1^, S. Chamnanprai^2^, T. Raksrithong^3^

*^1^Wishing well foundation, Secretary General, Bangkok, Thailand; ^2^King Chulalongkorn Memorial Hospital, Nursing, Bangkok, Thailand; ^3^Thammasat University Hospital, Nursing, Pathumthani, Thailand*

**Background/Objectives**: Thailand is an upper middle income country in Southeast Asia, with universal health care, including pediatric cancer treatment. While many children with cancer are curable, some are less fortunate. For children with limited hope for cure, palliative care (PC) is a preferred option for children. Wishing well foundation was established in 2005, with a mission to provide palliative care service for families with cancer children at home.

**Design/Methods**: The PC service starts with counseling parents and family at home. If the family choose palliative care, an individualized care plan was established to enhance quality of life. Children are asked about their wishes and efforts are made to have their wishes fulfilled. Children are invited to attend a cancer camp. Palliative care, including pain and symptom management, are provided at home, with a continuous communications on LINE® and by phone. Parents visit a palliative care clinic for morphine and other medications. Home visits are made as needed for children within 200‐km radius and families are supported through death and bereavement.

**Results**: Sixty‐five children with cancer were provided home palliative care (PC). The average age (+SD) was 10 (+5) years. Most children in this PC cohort (28, 43%) had brain tumors, followed by recurrent solid tumors (24, 37%), and relapsed leukemias/ lymphomas (13, 20%). The total follow‐up time was 75 patient‐years. The median survival was 4 months, with 14 (22%) children living \>1 year. Of 53 patients who had died, 29 (61%) died at home, 12 (23%) at a local hospital, and 12 (23%) at a cancer center. All families were satisfied.

**Conclusions**: Palliative care can be offered early through a strategic approach that emphasize quality living for children followed by home‐based provision of PC. Home palliative care has been expanded to include non‐cancer children, and to a network of cancer treatment centers.

### PO-641. The Role of Temankanker Application in Supporting Childhood Cancer Control in Indonesia {#pbc27455-sec-16180}

[K. Purwanto]{.ul} ^1^

*^1^Yayasan Onkologi Anak Indonesia, Public Relations, Jakarta, Indonesia*

**Background/Objectives**: Cases of childhood cancer are often found in advanced stages due to lack of information and knowledge of early symptons of cancer. Knowing the causes of cancer provides a basic understanding of early detection on childhood cancer. In this digital era, technology is playing an important role to build awareness in every aspect on our lives and create an easy way to provide information, such health. Almost everyone needs internet and is supported with the providers available which can be accessed through mobile phones. IBM Indonesia granted mobile application called TemanKanker or Friend of Cancer to the YOAI. It is a digital platform designed to provide access of information on cancer and for those who need detail knowledge. It is useful for patients, survivors, parents, medical practitioners, volunteers, citizens and other social communities. They can be interconnected with each other and get in depth information about cancer. The objective is to enhance public awareness about childhood cancer to all Indonesian people quickly and individually.

**Design/Methods**: This application contents various features, such as information, simptoms and types of cancer, prevention, treatment, hospital information and chatroom, read tips from doctors, inspirational survivors stories and the latest news related to cancer.

**Results**: Six months after the application was released, the application has been downloaded by 1300 people. We surveyed 20 people from various background and most of them used features of doctor\'s chat room, information, success stories and about survivors. Users view all features available.

**Conclusions**: This initiative is useful to increase the awareness of cancer and to take the prevention action to form a solid information for cancer supporters around the urbans as well as rurals area in Indonesia. Users are very enthusiastic to support and willing to provide useful input for the development of this application in future.

### PO-642. A Survey of Practice of Paediatric Surgical Oncology in Pakistan {#pbc27455-sec-16190}

[A. Qazi]{.ul} ^1^

*^1^National Hospital Medical Centre, Paediatric Surgery, Lahore, Pakistan*

**Background/Objectives**: Pakistan has about 45 percent population under 15 years. Healthcare services in the public sector have severe human resources and financial constraints. There are only a limited number of paediatric surgeons, working mostly in big cities, who have to offer a wide spectrum of subspeciality services including surgical oncology. A country wide survey has been conducted to palpate the current status of practices and perceptions in paediatric surgical oncology.

**Design/Methods**: A questionnaire was designed including questions to determine hospital setup, availability of paediatric oncology service, personal practice of individual surgeon and disease patterns. More than 200 questionnaires were sent out using survey monkey. Only 40 complete responses were received. All responses were charted and analysed.

**Results**: Responses when charted on geographical map of Pakistan, cover the entire country. Most respondents work in large teaching hospitals with more than 400 beds. About one third respondents work in children only facility. Majority of them have onsite pathologists and all of them have radiological services onsite. About sixty percent have paediatric oncology service available in the same hospital with already established tumour boards but only 10% surgeons managed to attend it regularly. About 50 percent respondents have experience one solid tumour per week and commonest tumour is wilms tumour. Similarly frequency of solid tumour surgery varied from less than one per months in about 50% to more than 5 solid tumours per months in about 20% respondents. Majority surgeons despite having more than 10 years as consultants, continued to perform routine operations like herniotomy along with major solid tumour surgery with a frequency ranging from 25 to 100 herniotomy per year.

**Conclusions**: Although the practices of paediatric surgical oncology in Pakistan are not comparable to the modern world, however this survey demonstrates that a country wide organized service can be established with minimal efforts.

### PO-643. Establishing a Pediatric Hematology‐Oncology Service in Government Sector; Challenges and Solutions {#pbc27455-sec-16200}

[N. Radhakrishnan]{.ul} ^1^, J. Madan^1^, S. Gupta^1^, S. Singh^2^, S. Dua^3^, S. Arora^3^, D. Singh^4^, P. Sharma^5^, D. Nath^2^

*^1^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Pediatric Hematology Oncology, Noida, India; ^2^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Pathology, Noida, India; ^3^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Transfusion Medicine, Noida, India; ^4^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Pediatric Medicine, Noida, India; ^5^Super Speciality Pediatric Hospital and PG Teaching Institute, Department of Pediatric Surgery, Noida, India*

**Background/Objectives**: Pediatric cancers are an important cause of death in developing countries as access to basic medical care has improved. Existing facilities in government sector are overburdened due to the lack of adequate manpower and facilities. We describe the challenges faced and solutions that emerged while establishing a pediatric hematology‐oncology service in government sector in India.

**Design/Methods**: An exploratory qualitative study on the challenges faced from the start of the department with no existing services to the solutions that emerged by the end of 12 months (April 2017 to March 2018) was done. Data was recorded prospectively under the following headings: clinical and laboratory services (manpower /skill/space/equipment), patient related (attitude, acceptance, concerns), treatment related (skill development, team building, collaborations) and logistics (governmental and non‐governmental support).

**Results**: During the study period, the department catered to 2843 outpatients, 519 inpatients, 46 new oncology patients, 172 procedures and 636 day‐care admissions. In clinical and laboratory services, manpower and equipment were the initial and major hurdles faced. Skill development of existing staff, part‐time employees, volunteers and inter‐institute collaboration helped us overcome this to an extent. Programs for raising awareness regarding curability of childhood cancer, reinforcement from survivors, normalizing the child\'s life by providing learning and play activities helped reduce abandonment and improve acceptance of the disease. Expenses incurred by the family till governmental aid arrives continues to be a major concern. Advancement of money from the hospital administration and involvement of donors has helped partially alleviate this concern. Positive attitude of care‐providers including doctors, nurses, technicians and support staff has been vital to the establishment of the service.

**Conclusions**: Establishing a high‐risk service such as cancer care in a center where none existed can be challenging. Support of administration and perseverance of the team has been crucial to developing solutions to improve childhood cancer care in the region.

### PO-644. National Stakeholder Programme Initiative, Improving the Outcomes of Retinoblastoma in India: Fight RB India {#pbc27455-sec-16210}

H. Gupta^1^, [B. Rathore]{.ul} ^1^, S. Honavar^2^, S. Das^3^, A. Mahajan^4^, P. Bagai^1^

*^1^CanKids...KidsCan, Medical Projects and Support Service Program, New Delhi, India; ^2^Centre For Sight Superspeciality Eye Hospital‐ Hyderabad, Ophthalmology, Hyderabad, India; ^3^Dr. Shroff\'s Charity Eye Hospital‐ Delhi, Ophthalmology, Delhi, India; ^4^Indraprastha Apollo Hospitals‐ New Delhi, Pediatrics Oncology and Hematology, Delhi, India*

**Background/Objectives**: Retinoblastoma is prevalent worldwide but, India bears 25% burden of this pediatric eye cancer. Survival rates of 20 to 50 percent reported in India are lower when compared to 90 to 95% in the developed countries.

**"Fight RB India"** is a partnership, stakeholder, awareness and advocacy program. CanKids, a social support organisation through FightRBIndia, aims to provide the best standards of care, improve hospital and manpower capacities, to achieve survival \>90%, ocular salvage of \> 75%, prosthesis coverage of 100% and limit abandonment to \<5%.

**Design/Methods**: Standard questionnaire was developed, to map the facilities for RB across the country. Primary interventions included awareness campaigns amongst parents and doctors, financing Continuing Medical Education(CME) and advocacy to the centres for best standards of care. Secondary intervention, includes financing drug and diagnostics support, equipment provision like Ret Cam, TTT and Cryosole and providing social workers and nurses to improve compliance. Tertiary intervention, provided support for surgical enucleation and prosthetic rehabilitation.

The initiative was launched in 2015, with target of **Vision 2020** plan authored by a leading internationally renowned ocular oncologist with the mandate to shift outcomes and improve the standards of care over a period of time.

**Results**: Thirty eight partnering ophthalmology‐oncology centres and 49 doctors were identified for collaboration. Awareness materials including Bruckner modules with helpline number and video were distributed in all Centres and 18 regional ophthalmology institutes during RB awareness week in May, each year. Six stakeholder meetings, five CME and 4 parent support group forums were funded and conducted. Research protocol INPOG‐RB‐17‐01 and microsite are under review. Under the secondary and tertiary interventions, we have supported 521, 348 and 525 cases respectively, from 2015 till 2018.

**Conclusions**: Stakeholder engagement program targets to improve the outcomes of RB by 2020. Support groups can be the anchor for such multidisciplinary efforts aimed at bringing change.

### PO-645. Love for Children with Cancer: A Campaign for Children with Cancer and their Families Produced by Japanese Survivors of Childhood Cancer {#pbc27455-sec-16220}

[S. Seto]{.ul} ^1^, M. Takahashi^2^

*^1^Tohoku University, International Research Institute of Disaster Science, Sendai, Japan; ^2^Nursery in Kyoto city, Nurse, Kyoto, Japan*

**Background/Objectives**: On the international childhood cancer day every year, people have expressed love for children with cancer and their families to the world. Some people know the day on SNS, sympathize with the significance of the day, and come to have the love for children with cancer and their families. However, if the love is not expressed in words or actions, that would not be conveyed to them. In order to improve the above situation, we held an activity to visualize love for them as a campaign for 2018 ICCD.

**Design/Methods**: We created the camera frame of "Love for Children with Cancer" by using the Camera Effects Platform provided by Facebook. This frame was published on Facebook to be used by any Facebook user. On February 10th, 2018, we announced this campaign on Facebook. In the post of the announcement, people find explanation of this campaign, the URL of the camera frame, and 3 hash tags as follows: \#L4CC, \#ICCD, and \#ChildhoodCancer. When the children or their families click the hashtags, they can obviously see and feel the love of the campaign participants.

**Results**: By February 15th, 2018, more than 160 people in the world used the camera effect and posted pictures. Some took selfies with the frame, and others posted pictures of beautiful views and messaged for them. Finally, by the end of February, more than 200 people participated in this campaign.

**Conclusions**: In order to visualize the love for the children with cancer and their families, we held the 2018 ICCD campaign with the frame (which we mentioned already). In the near future, we will cooperate with the survivors of childhood cancer to expand the range of this campaign around the world.

### PO-646. A Unique Model of Empowering Parents as Patient Navigators to Provide Better Care for Children with Cancer in India {#pbc27455-sec-16230}

C. Kumar^1^, [S. Sharma]{.ul} ^2^, P. Bagai^2^

*^1^CanKids...KidsCan, Survivor Group, New Delhi, India; ^2^CanKids...KidsCan, Parents Group, New Delhi, India*

**Background/Objectives**: Patient navigators (PN) are vital to help in facilitation care and are particularly relevant in Indian context, because of high illiteracy, poverty and overburdened healthcare infrastructure. There is a shortage of such trained individuals.

Parents of childhood cancer survivors and those who may have lost their child to cancer, are encouraged to join the Cankids Parents Support Group (CK PSG). They are trained and empowered to become PN. The majority are from lesser privileged backgrounds have never worked outside their homes and not been through high school.

**Design/Methods**: 1. At end of treatment -- willing parents join Cankids as CK PSG

2\. The six months training imparts required knowledge and skills in communication and providing effective emotional support. **They also get travel allowance during training period**

3\. On completion they become **PN and get stipend. After three years they can become employees**.

4.They hold the hand of families undergoing treatment and facilitate with **emotional support**, **direct care, financial facilitation, bereavement support, outings and celebrations, etc**. and Conduct Parents forum to bridge the gap between treating team and parents.

**Results**: The PSG was started in 2004 with two members. Today it has more than 650 members across India. In the last five years (2014‐2018) PSG has navigated 6,858 families and helped in facilitation of tests/medications to the tune of done the waiver of more than 1.4 Million rupees (21,000 USD). Provided counselling 44,858 times to these families and conducted 7,963 ward visits to interact with the patients and their families. The group has conducted 131 Parents support forums thereby fostering family engagement and participatory approach to their treating team.

**Conclusions**: Harnessing untapped resource of parents and skilling them as PN, CanKids has not only delivered holistic care to children with cancer and their families but also empowered these parents, giving them a source of income.

### PO-647. Development of Southern Childhood Cancer Network in Thailand {#pbc27455-sec-16240}

[P. Sripornsawan]{.ul} ^1^, T. Chotsampanchareon^1^, K. Lhekphet^2^, N. Yudhasompob^3^, R. Songnuy^4^, P. Close^5^, A. Zaidi^6^

*^1^Prince of Songkla University, Pediatrics, Hat Yai‐ Songkla, Thailand; ^2^Suratthanee Hospital, Pediatrics, Suratthanee, Thailand; ^3^Hat Yai Hospital, Pediatrics, Hat Yai, Thailand; ^4^Maharat Nakorn Srithammarat Hospital, Pediatrics, Nakorn Srithammarat, Thailand; ^5^University of Southern California, Palliative Medicine, Los Angeles, USA; ^6^St.Jude Children\'s Research Hospital, Hemato‐oncology, Memphis, USA*

**Background/Objectives: Background**: Cure rate for childhood cancer in developed world is around 90% of children but not for developing countries. Each year, about 100 newly diagnosed pediatric cancers were treated at our hospital. Many families could not access to healthcare services because they could not afford cost of living, transportation to the tertiary center. The diagnosis often delayed by lack of awareness about childhood cancer. Treatment abandoned often caused by socioeconomic problem.

**Objective**: To share our experience on building childhood cancer network in resource limited setting.

**Design/Methods: Methods**: In 2010, the Southern Childhood Cancer Network has been established under "My Childs Matters" program sponsored by Sanofi Espoir foundation collaborating with Union International Cancer Control (UICC) and Thai National Health Security Office (NHSO). The holistic care model comprising of medical treatments, psychosocial, socioeconomic support and palliative care.

**Results**: Results: A temporary building (14 beds) was arranged for children who could not afford a place to stay during treatment. This improved treatment adherence and decreased financial burden on families 20‐50 USD a night. The Network included 14 hospitals and 44 health care personnel. Pediatricians or trained nurses at local hospitals are able to give chemotherapy result in decreased admission visit at average 40 patients/year. Annual meeting and educational workshop were held to discuss treatment strategies & problems. Clinical practice guidelines for safe chemotherapy administration were developed and distributed. The patients visited local hospitals for chemotherapy on average 3 times per patient. Travel time decreased from 156 min to 37 min per visit and the travel cost decreased from an average of 37.9 USD to 10.2 USD per visit.

**Conclusions**: The networking program could decrease travel cost and time therefore improved treatment adherence and quality of life for children with cancer in southern Thailand. Acknowledgement: This work supported by funding from Sanofi Espoir foundation and NHSO.

### PO-648. The Current Standard of Paediatric Oncology in Lao PDR: A Descriptive Study {#pbc27455-sec-16250}

J. Cayrol^1^, [M. Sullivan]{.ul} ^1^, B. Sounvanlasy^2^, S. Sonephet^2^, T. Soosay Raj^1^

*^1^The Royal Children\'s Hospital, Oncology, Melbourne, Australia; ^2^The Children\'s Hospital, Oncology, Vientiane, Lao PDR*

**Background/Objectives**: Lao PDR is a low‐income country, where the care of paediatric oncology patients commenced at the Children\'s Hospital (CH), Vientiane in 2012. No report exists to date on the care of these patients.

Objectives: To describe a new twinning program between Australia and Lao PDR, and report on the current state of paediatric oncology at CH.

**Design/Methods**: An existing agreement between the Universities of Melbourne and Health Sciences, Laos, enabled a twinning relationship between the Royal Children\'s Hospital, Melbourne, and CH.

A retrospective data analysis was performed on a dataset created from 2012 to 2017.

Qualitative data was obtained using focused ethnography from 2017 to 2018. Field notes are being analysed using inductive qualitative content analysis. Approval from the Lao ethics committee was obtained.

**Results**: 128 children were diagnosed with cancer. 43 (34%) occurred in 2017. There were 97 haematological malignancies, of which 60 acute lymphoblastic leukaemias. All leukaemia patients were diagnosed using morphology. There were 31 solid tumours, 18 (58%) in 2017. 6 had a histopathological diagnosis. The majority were retinoblastomas(n=11).

The abandonment rate was 21% (n=27) and the overall mortality rate was 36% (n=47).

Two Thai‐trained paediatric oncologists have worked since 2016. Chemotherapy is donated by KOICA agency (Korea). The twinning relationship with Australia began with direct clinical support locally. Continuous support is provided through teleconferences with RCH. Preliminary results of the qualitative analysis include: lack of structure in care, difficult engagement for surgical procedures, difficult access to blood products, poor chemotherapy safety; with some improvements in 2017 with interventions including clinical support, use of standardised treatment regimens and education about supportive care.

**Conclusions**: The number of cancer diagnoses in Laos is increasing. Improvements have been demonstrated in human resources and supportive care. However, treatment affordability and abandonment remain a challenge. Enhanced diagnostic methods, improved documentation and data registries are needed.

### PO-649. Treatment of Acute Lymphoblastic Leukaemia (ALL) at Children\'s Hospital (CH), Vientiane, Lao PDR {#pbc27455-sec-16260}

B. Souvanlansy^1^, T. Soosay Raj^2^, S. Sonephet^1^, [M. Sullivan]{.ul} ^2^, J. Cayrol^3^

*^1^The Children\'s Hospital, Oncology, Vientiane, Lao PDR; ^2^The Royal Children\'s Hospital, Oncology, Melbourne, Lao PDR; ^3^The Royal Children\'s Hospital, Oncology, Melbourne, Australia*

**Background/Objectives**: The Children\'s Hospital (CH), Vientiane, is the only facility able to treat childhood cancer in Lao PDR, with support from Korean donors. The number of cancer patients has increased yearly. Induction mortality rate during ALL treatment is a quality benchmark of cancer care. We report the outcomes of ALL patients, and trends of induction deaths, to reflect the readiness of this facility to provide care for childhood leukaemia.

**Design/Methods**: Retrospective review of clinical data collected on a database from 2012 to 2017 at the CH.

**Results**: 128 children were diagnosed with cancer, of which 60 with ALL.

Amongst ALL patients, 41.7% are receiving treatment (n=25, including 1 relapse); 11.6% (n=7) are in complete remission (maximum 18 months). The rate of abandonment is 10% (n=6). The total mortality rate is 36.7% (n=22).

45% of deaths were not induction deaths (n=10). There were 2 deaths at presentation before treatment; 4 treatment‐related deaths (one during relapse treatment) and 4 from relapse (with no treatment). 55% of deaths occurred in induction (n=12, 5 infections, 7 haemorrhages), meaning an overall induction mortality rate of 20%.

Between 2012 and 2016, there were 45 new diagnoses and 17 deaths, of which 11 in induction. All patients received 3‐drug induction. The average induction mortality rate for that period was 24%.

During 2017, there were 15 new diagnoses and 2 relapsed patients. 4‐drug induction was first used in 6 patients. However, the induction death rate was 6.7%, with only 1 death (with 4‐drugs).

**Conclusions**: In 2017, patient number and complexity increased. However, induction death rate was the lowest. Several factors contributed to this: better human resources training, changes to workflow, improved supportive care, more reliable access to medication. However, challenges remain, such as the need for safer use of chemotherapy, enhanced diagnostic equipment, adaptation of disease protocols, and better approach to abandonment.

### PO-650. Siblings' Experiences of Living in a Family Where One Child is Diagnosed with Cancer: An Interpretative Phenomenological Analysis {#pbc27455-sec-16270}

[M. Van Schoors]{.ul} ^1^, J. De Mol^2^, L.L. Verhofstadt^1^, L. Goubert^1^, H. Van Parys^1^

*^1^Ghent University‐ Faculty of Psychology and Educational Sciences, Department of Experimental Clinical and Health Psychology, Ghent, Belgium; ^2^Université Catholic de Louvain, Department of Clinical Psychology, Louvain‐la‐Neuve, Belgium*

**Background/Objectives**: Childhood cancer presents many challenges to the life of the child diagnosed with cancer, the parents and siblings. Moreover, it also places considerable demands on the family\'s daily life. The aim of the current study was to gain a better understanding of siblings' daily experiences of living in a family where one child has been diagnosed with cancer.

**Design/Methods**: Ten siblings of children with blood cancer were interviewed. Interviews were semi‐structured and data were analyzed using Interpretative Phenomenological Analysis.

**Results**: Analysis of the data revealed two themes. (1) Overall, the siblings in our study experienced continuity in many aspects of their family life: they still experienced their family as an important source of support and information/communication, as warm and loving, and as a safe harbor where family members aimed to protect each other. (2) However, at the same time, the siblings also referred to the challenges they were confronted with due to the cancer diagnosis, expressing that some things felt unmistakably different. In specific, many felt that the family as a whole had been ripped apart post‐diagnosis, with a greater focus on the diagnosed child and changing responsibilities for each family member

**Conclusions**: This study informs parents and clinicians about the pediatric cancer experience from the siblings' perspective, one that is often overlooked. Siblings expressed the need for attentiveness to their feelings related to the cancer, as well as to other non‐cancer‐related feelings and experiences.

### PO-651. The Family Practice of Support Giving after a Pediatric Cancer Diagnosis: A Multi‐Family Member Interview Analysis {#pbc27455-sec-16280}

[M. Van Schoors]{.ul} ^1^, J. De Mol^2^, L.L. Verhofstadt^1^, L. Goubert^1^, H. Van Parys^1^

*^1^Ghent University‐ Faculty of Psychology and Educational Sciences, Department of Experimental Clinical and Health Psychology, Ghent, Belgium; ^2^Université Catholic de Louvain, Department of Clinical Psychology, Louvain‐la‐Neuve, Belgium*

**Background/Objectives**: Childhood cancer presents many challenges to the life of the child with cancer and his/her family. Among the studies investigating risk and protective factors of individual adjustment when facing a pediatric cancer diagnosis, social support has emerged as an important construct. However, little is currently known on how family members support each other in this particular context.

**Design/Methods**: Twelve one‐to‐one interviews with mothers, fathers or siblings were performed. Multi Family Member Interview Analysis was used as methodological framework to analyze the individual interviews, allowing a detailed and systematic analysis of shared family experiences.

**Results**: Analysis of the data revealed three themes: (1) Being together matters: the families identified the need of being physically together, both as a family and with the diagnosed child; (2) Finding support in (not) talking: this theme articulates the eagerness of the families to talk about the illness and its impact, as this was experienced as a relief. However, talking about emotions was sometimes also experienced as hard and some family members preferred not sharing their experiences. (3) Working together as a team: the families described they worked together as a team in order to get everything organized.

**Conclusions**: This study broadens our understanding of the interpersonal process of family support giving when facing pediatric cancer. In meeting with families, families should be invited as a whole in order to best capture family level constructs. Also, clinicians should be sensitive to the different needs with regard to cancer related family communication and make them subject of discussion within the family.

### PO-652. A Psyco‐Educational Model for the Utilisation of Play in Addressing Aggression in Children with a Haematology or Oncology Diagnosis in Order to Facilitate Resilience {#pbc27455-sec-16290}

[K. Van Zijl]{.ul} ^1^, C. Myburgh^2^, M. Poggenpoel^3^

*^1^The Organisation for Paediatric Support in South Africa OPSSA, Psychosocial Support Services, Pretoria, South Africa; ^2^University of Johannesburg, Educational Psychology, Johannesburg, South Africa; ^3^University of Johannesburg, Nursing, Johannesburg, South Africa*

**Background/Objectives**: Children with a haematology or oncology diagnosis face a plethora of stressors and difficulties related to their illness and treatment over an extended period of time. These adversities initiate an experience of stress and trauma in the children that may lead to aggressive behaviour. The children therefore need support to deal with their aggression and to overcome the adversities related to their illness.

The objective of the study was to explore and describe how play can be utilised in addressing aggression in children with a haematology or oncology diagnosis in order to facilitate resilience.

**Design/Methods**: A theory‐generative, qualitative, explorative, descriptive and contextual research design was utilised. Multiple case studies were utilised to generate empirical data.

**Results**: The utilisation of play assisted the participants to communicate and expressed their lived experience of the illness and the treatment as well as how their lived experience led to their exhibition of aggression. Content analysis was done on the transcribed content of the play therapy sessions in order to identify the main theme and sub‐themes of the lived experience of the participants. The main theme of feeling extradited was identified with sub‐themes of feeling depersonalised and feeling disempowered. These lived experiences launched an assault on their resilience. Play therapy was utilised to address these lived experiences of the participants in order to empower them and to facilitate resilience.

**Conclusions**: The lived experience of the children in dealing with their illness and treatment negatively impacted their resilience. The play process implemented during the play sessions facilitated the participants' experience of the core elements of resilience by means of awareness, expression and reformulation of their emotions, perceptions and lived experiences related to the illness and treatment.

Other {#pbc27455-sec-16300}
-----

### PO-653. Availability and Price of Essential Medicines for Treating Childhood Cancers in India {#pbc27455-sec-16310}
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*^1^University of Sydney, School of Public Health, Sydney, Australia; ^2^University of Sydney, Faculty of Medicine, Sydney, Australia; ^3^Boston University School of Public Health, Global Health, Boston, USA; ^4^Cankids NGO, Medical Projects, Delhi, India; ^5^Independent Researcher, Independent Researcher, Delhi, India; ^6^Max Super Speciality Hospital, Paediatric Oncology, Delhi, India; ^7^The George Institute for Global Health, Office of the Chief Scientist, Sydney, Australia*

**Background/Objectives**: Limited access to essential medicines (EMs) for treating chronic diseases is a major challenge, particularly in low‐ and middle‐income countries. Although India is the largest manufacturer of generic medicines, availability and affordable prices is not guaranteed. We assessed availability and prices of EMs for treating childhood cancers in Delhi, India.

**Design/Methods**: Using a modified WHO and Health Action International methodology, we collected data on availability and price of 24 anti‐neoplastic EMs (33 specific dosages) and 4 non‐cancer EMs as study control. Data were collected from pharmacies of 8 tertiary‐care 'survey anchor' hospitals (4 public and 4 private) that treat childhood cancers, and from a random sample of 32 retail pharmacies located near the survey anchors. Median Price Ratios (MPRs) were calculated by comparing consumer prices to 2015 International Reference Prices (IRPs).

**Results**: On average, 84% of 'survey anchor areas' (hospital plus retail pharmacies) had anti‐neoplastic EMs available in at least one dosage form, and 67% and 100% availability for dosage‐specific anti‐neoplastic EMs and control EMs, respectively. Vincristine‐5mg injection and Ifosfamide‐500mg injection were unavailable. Mean availability by facility type of dosage‐specific anti‐neoplastic EMs was 33% in retail pharmacies, 40% in public hospital‐pharmacies and 68% in private hospital‐pharmacies. All MPRs, except for Paclitaxel‐6mg/ml injection, were in line with WHO target that no consumer should pay more than 4 times IRPs. Estimated chemotherapy cost, based on consumer prices, for treating a 30kg child with standard‐risk leukaemia \[INR 27,577 (USD 438)\] and Hodgkin disease \[INR 17,500 (USD 278)\] is 26% and 16% of India\'s 2016 per‐capita income, respectively.

**Conclusions**: Most anti‐neoplastic EMs are found in survey anchor areas, however mean availability was less than control medicines; not meeting WHO target of 80% availability across all facilities. In local context, cost of chemotherapy medicines appear to be affordable however greater burden of costs may lie elsewhere.
